NCTId,BriefTitle,OfficialTitle,OverallStatus,StartDate,PrimaryCompletionDate,CompletionDate,LastUpdatePostDate,StudyFirstPostDate,StudyType,Phase,EnrollmentCount,EnrollmentType,LeadSponsorName,LeadSponsorClass,Collaborators,CollaboratorClasses,Conditions,Keywords,LocationCountry,LocationCity,LocationState,TotalLocations,InterventionNames,InterventionTypes,PrimaryOutcomeMeasures,SecondaryOutcomeMeasures,HasResults,ResultsFirstPostDate
NCT04019912,The Novel Use of Treadmill Plus Music in MS Patients Gate Rehabilitation,A Randomized Trial on the Novel Use of Treadmill Plus Music in Multiple Sclerosis Patients With Gate Impairnent,UNKNOWN,2019-10-01,2020-03-30,2020-05,2020-02-21,2019-07-15,INTERVENTIONAL,NA,40.0,ESTIMATED,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Interventional Study,Gait rehabilitation|Rhythmic auditory stimulation|GaitTrainer3|Multiple sclerosis,Italy,Messina,Sicily,1,Gait Training plus music|Traditional Gait Training,OTHER|OTHER,Ten-metre walking test|Timed up-and-go test,Gait Quality Index|Multiple Sclerosis Quality of Life-54,False,
NCT04490044,Under and Over Rehabilitation Study,Under & Over: A Controlled Study to Develop an Upper Limb Rehabilitation Tool for People With Multiple Sclerosis.,COMPLETED,2020-09-01,2022-04-01,2022-05-01,2022-11-18,2020-07-28,INTERVENTIONAL,NA,120.0,ACTUAL,Queen Mary University of London,OTHER,Roche Pharma AG|Barts & The London NHS Trust,INDUSTRY|OTHER,Multiple Sclerosis,rehabilitation|design,United Kingdom,London,,1,Under & Over rehabilitation tool,OTHER,Change in Cardboard 9 Hole Peg Test speed at 6 months.,,False,
NCT01743651,Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis,"A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis",COMPLETED,2012-11,2014-04,2014-04,2022-04-25,2012-12-06,INTERVENTIONAL,PHASE3,353.0,ACTUAL,"RVL Pharmaceuticals, Inc.",INDUSTRY,Osmotica Pharmaceutical US LLC,INDUSTRY,Spasticity|Multiple Sclerosis,spasticity|multiple sclerosis|arbaclofen,United States,Cullman,Alabama,48,arbaclofen|baclofen|Placebo,DRUG|DRUG|DRUG,Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb.|Clinical Global Impression of Change (CGIC) through end of treatment,Changes in the Multiple Sclerosis Spasticity Scale (MSSS-88)|Changes in the TNmAS for the most affected limb|Changes in the TNmAS for the sum of all limbs|Changes in Expanded Disability Status Score (EDSS)|Changes in the Lower Extremity Manual Muscle Testing (LEMMT) Scale|Changes in Epworth Sleepiness Scale (ESS)|Changes in the subject-recorded mean daily Drowsiness Numerical Rating Scale (DNRS)score for the day prior to each visit|Changes in the Urinary Symptom Profile (USP) Scale|Clinical Global Impression of Change (CGIC),False,
NCT05962177,Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic,Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic,RECRUITING,2023-09-11,2030-06,2030-06,2025-09-16,2023-07-27,INTERVENTIONAL,NA,400.0,ESTIMATED,"University Hospital, Montpellier",OTHER,,,Multiple Sclerosis,Multiple sclerosis|MRI|Longitudinal cohort|Real life|Biomarkers,France,Montpellier,,1,Magnetic Resonance Imaging|Blood withdrawal|Neuropsychological tests,OTHER|OTHER|OTHER,Total brain atrophy,Quantitative analysis: analysis of FLAIR hypersignals number|Quantitative analysis: analysis of FLAIR hypersignals volume|Qualitative analysis: analysis of central vein lesions|Qualitative analysis: analysis of peripheral rim lesion|Quantitative analysis: measurement of mean diffusivity|Quantitative analysis: measurement of anisotropy fraction|Quantitative analysis: measurement of cerebral blood flow (CBF)|Changes in serum light chain neurofilament values|Clinical assessment scale: relapses|Clinical assessment scale: Expanded Disability Status Scale (EDSS)|Clinical assessment scale: Computerized Speed Cognitive Test (CSCT)|Clinical assessment scale: Six-Minute Walk Test (6MWT)|Clinical assessment scale: 9-Hole Peg Test (9-HPT)|Clinical assessment scale: Timed 25-Foot Walk (T25-FW)|Quality of life scale: The 5-level EQ-5D questionnaire (EQ5D-5L)|Quality of life scale: The Brief Pain Inventory (BPI)|Quality of life scale: DN4|Fatigue scale: Chalder Fatigue Scale|Fatigue scale: Modified Fatigue Impact Scale (MFIS)|Sleep scale: Epworth Sleepiness Scale (ESS)|Depression scale: Beck Depression Inventory (BID)|Anxiety scale: Generalized Anxiety Disorder 7-Item Scale (GAD-7)|Headaches scale: ef-ID Migraine|Exploratory criteria:Serum Glial Fibrillary Acidic Protein (GFAP)|Exploratory criteria: Pittsburgh Sleep Quality Index (PSQI) questionnaire|Exploratory criteria: Idiopathic Hypersomnia Severity Hypersomnia Scale (IHSS)|Exploratory criteria: RU SATED score|Exploratory criteria: Insomnia Severity Index (ISI)|Exploratory criteria: Headaches Impact Test (HIT-6)|Exploratory criteria: Godin Leisure-Time Exercise Questionnaire (GLTEQ),False,
NCT02913209,Quantitative Fatigue and Muscle Performance in Multiple Sclerosis,Quantitative Fatigue and Muscle Performance in Multiple Sclerosis,UNKNOWN,2016-04,2018-10,2020-12,2020-02-17,2016-09-23,OBSERVATIONAL,,30.0,ACTUAL,Washington D.C. Veterans Affairs Medical Center,FED,,,Multiple Sclerosis|Fatigue,,,,,0,,,Fatigue Index|Maximal Volitional Contraction,The Adult Myopathy Assessment Tool|25 foot walk Test|Chair Stand Test|Modified Fatigue Impact Scale|Multiple Sclerosis Quality of Life|Adult Fatigue Bank|Ultrasound caliper measure of rectus femoris thickness|Ultrasound image post-processing of rectus femoris grayscale,False,
NCT02290587,Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients,Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients,COMPLETED,2015-11,2017-03,2017-03,2017-04-04,2014-11-14,INTERVENTIONAL,NA,35.0,ACTUAL,"University Hospital, Bordeaux",OTHER,La Ligue Française Contre la Sclérose en Plaques,OTHER,Multiple Sclerosis,social cognitive|theory of mind|cognitive impairment|functional MRI|brain activation network,France,Bordeaux,,1,Brain MRI - Clinical and cognitive evaluation|MRI,OTHER|DEVICE,Brain activation networks during MRI,Reduction of volume of deep brain structures and reduction of cortical thickness|White matter skeleton on Fractional Anisotropy (FA) maps established by voxel-based.,False,
NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,"A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2011-02,2012-07,2012-07,2016-11-18,2011-03-08,INTERVENTIONAL,PHASE4,447.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Multiple sclerosis|RRMS|relapsing-remitting|fingolimod|biomarkers,Germany,Ostfildern,Baden-Wurttemberg,61,Fingolimod,DRUG,Change from baseline of Cluster of Differentiation (CD)4+ naive T cells (C-C Chemokine Receptor Type 7+(CCR7+CD45RA+)|Change from baseline of CD8+ naïve T cells (CCR7+CD45RA+)|Change from baseline of CD4+ central memory T cells (CCR7+CD45RA-)|Change from baseline of CD8+ central memory T cells (CCR7+CD45RA-)|Change from baseline of CD8+ effector memory T-cells (CCR7-CD45RA-),Change from baseline of B-lymphocytes|Change from baseline of monocytes|Change from baseline of Natural Killer cells,False,
NCT00888277,Bayer/Cognitive Assessments With Multiple Sclerosis Subjects,Neuropsychological Assessments in the Multiple Sclerosis Clinic,COMPLETED,2009-05,2009-12,2010-01,2013-11-04,2009-04-27,OBSERVATIONAL,,74.0,ACTUAL,University of Louisville,OTHER,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INDUSTRY,"Multiple Sclerosis, Relapsing-remitting|Multiple Sclerosis, Secondary Progressive",,United States,Louisville,Kentucky,1,,,SDMT correlation with the findings on the Neuropsychological Battery. The Neuropsychological Battery will confirm that the SDMT is sensitive and specific in identifying MS patients with cognitive findings.,SDMT association with the BDI. The SDMT will be independent of depression.|Overlap of Depression with Cognitive Dysfunction. There will still be identified a high percentage of patients having both cognitive and depressive symptoms.|Lack of association of Cognitive Dysfunction with the Physical Scales of the EDSS.,False,
NCT05090709,MS Spinal Mobilisation Study,Analysis of a Spinal Mobilisation Intervention in People With Multiple Sclerosis,COMPLETED,2018-10-01,2019-04-01,2019-04-01,2024-01-05,2021-10-25,INTERVENTIONAL,NA,20.0,ACTUAL,Edinburgh Napier University,OTHER,Scottish Hospital Endowments Research Trust|Pacla Medical Ltd,OTHER|INDUSTRY,Multiple Sclerosis,multiple sclerosis|myometer|muscle stiffness|spinal mobilisations|body sway|fatigue,United Kingdom,Edinburgh,County,1,Spinal Mobilisation Intervention|General Massage,OTHER|OTHER,Participant Muscle Stiffness Measure|Participant Muscle Stiffness Measure|Participant Muscle Stiffness Measure|Participant Muscle Stiffness Measure|Participant Muscle Stiffness Measure|Participant Single Leg Stance Body Sway Path Length|Participant Single Leg Stance Body Sway Path Length|Participant Single Leg Stance Body Sway Path Length|Participant Single Leg Stance Body Sway Path Length|Participant Single Leg Stance Body Sway Path Length|Participant Sit-to-Stand Velocity|Participant Sit-to-Stand Velocity|Participant Sit-to-Stand Velocity|Participant Sit-to-Stand Velocity|Participant Sit-to-Stand Velocity|Participant Pain Score - Visual Analogue Scale (VAS)|Participant Pain Score - Visual Analogue Scale (VAS)|Participant Pain Score - Visual Analogue Scale (VAS)|Participant Pain Score - Visual Analogue Scale (VAS)|Participant Pain Score - Visual Analogue Scale (VAS)|Participant Fatigue Score - 5 Item Modified Fatigue Impact Scale.|Participant Fatigue Score - 5 Item Modified Fatigue Impact Scale.,Participant Muscle Tone Measure|Participant Muscle Tone Measure|Participant Muscle Tone Measure|Participant Muscle Tone Measure|Participant Muscle Tone Measure|Participant Muscle Elasticity Measure|Participant Muscle Elasticity Measure|Participant Muscle Elasticity Measure|Participant Muscle Elasticity Measure|Participant Muscle Elasticity Measure|Participant Single Leg Stance Body Sway Anterior-Posterior Path Length|Participant Single Leg Stance Body Sway Anterior-Posterior Path Length|Participant Single Leg Stance Body Sway Anterior-Posterior Path Length|Participant Single Leg Stance Body Sway Anterior-Posterior Path Length|Participant Single Leg Stance Body Sway Anterior-Posterior Path Length|Participant Single Leg Stance Body Sway Medial-Lateral Path Length|Participant Single Leg Stance Body Sway Medial-Lateral Path Length|Participant Single Leg Stance Body Sway Medial-Lateral Path Length|Participant Single Leg Stance Body Sway Medial-Lateral Path Length|Participant Single Leg Stance Body Sway Medial-Lateral Path Length|Participant Single Leg Stance Body Sway Velocity|Participant Single Leg Stance Body Sway Velocity|Participant Single Leg Stance Body Sway Velocity|Participant Single Leg Stance Body Sway Velocity|Participant Single Leg Stance Body Sway Velocity|Participant Sit-to-Stand Rising Index|Participant Sit-to-Stand Rising Index|Participant Sit-to-Stand Rising Index|Participant Sit-to-Stand Rising Index|Participant Sit-to-Stand Rising Index|Participant Sit-to-Stand Weight Transfer|Participant Sit-to-Stand Weight Transfer|Participant Sit-to-Stand Weight Transfer|Participant Sit-to-Stand Weight Transfer|Participant Sit-to-Stand Weight Transfer,True,2024-01-05
NCT05438693,"Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt","Factors Affecting Time Elapsed From First Symptom Till Complete Diagnosis of Multiple Sclerosis, Initiation of Disease Modifying Treatment and Drug Adherence in Upper Egypt",COMPLETED,2020-06-01,2022-04-30,2022-06-01,2022-06-30,2022-06-30,OBSERVATIONAL,,80.0,ACTUAL,doaa mokhtar mahmoud,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,Egypt,Qina,Qena Governorate,2,,,time to diagnosis of multiple sclerosis|time to disease modifying treatment initiation|rate of adherence to disease modifying treatment among MS patients,determine factors related to delayed diagnosis of MS|frequency of depression as a factor related to DMT adherence|frequency of fatigue as a factor related to DMT adherence|frequency of sleep disturbances as a factor related to DMT adherence|treatment satisfaction as a factor related to DMT adherence,False,
NCT04895202,Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study,Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study,TERMINATED,2021-11-19,2022-12-20,2022-12-20,2023-08-29,2021-05-20,OBSERVATIONAL,,8.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity,SPMS|secondary progressive multiple sclerosis|Siponimod|active disease|inflammatory disease activity|disability progression,Switzerland,Zug,Canton of Zug,6,Siponimod,OTHER,Change of expanded disability status scale (EDSS),Proportion of patients with six month confirmed disability progression (CDP) by expanded disability status scale (EDSS)|Proportion of patients with six month confirmed disease progression by symbol digit modalities test (SDMT)|Treatment effect of Siponimod on walking speed as measured by the timed 25 foot walk test (T25FWT)|Treatment effect of Siponimod on quality of life based on EQ-5D|Treatment effect of Siponimod on fatigue measured by Fatigue Scale for Motor and Cognitive Functions (FSMC)|Treatment effect of Siponimod on fatigue measured by Beck's depression inventory (BDI)|Treatment effect of Siponimod on fatigue measured by Epworth sleepiness scale (ESS) questionnaire,False,
NCT02628834,Acute Effect of Fascial Mobilization on Gait in Patients With Multiple Sclerosis,Investigating the Acute Effect of Fascial Mobilization on Dynamic Walking Parameters in Patients With Multiple Sclerosis: A Crossover Controlled Group Study,UNKNOWN,2015-12,2016-11,2016-12,2015-12-11,2015-12-11,INTERVENTIONAL,NA,20.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,Loading|Gait|Multiple Sclerosis|Manual Therapy,,,,0,Fascial mobilization|Stretching Exercise,OTHER|OTHER,Pedobarography for assessment of foot pressure while standing and walking.,Modified Ashworth Scale for evaluation of severity of involuntary muscle contraction,False,
NCT01817166,Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome,"Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.",COMPLETED,2013-07-16,2023-01-04,2023-01-04,2024-01-12,2013-03-22,INTERVENTIONAL,PHASE3,316.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis,cholecalciferol|vitamin D|immune disease|clinically isolated syndrome,France,Amiens,,33,Vitamin D|Placebo|Imaging|Lumbar puncture|Blood sampling|Urine samples,DRUG|DRUG|OTHER|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Conversion to MS yes/no,"Number of relapse episodes (number per year)|number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI|number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI|number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI|Number of new T1 lesions taking on Gadolinium highlighting|Number of new T1 lesions taking on Gadolinium highlighting|Number of new T1 lesions taking on Gadolinium highlighting|Number of hyposignal T1 lesions (black holes)|Number of hyposignal T1 lesions (black holes)|Number of hyposignal T1 lesions (black holes)|Lesional burden in mm^3 for each cerebral MRI|Lesional burden in mm^3 for each cerebral MRI|Lesional burden in mm^3 for each cerebral MRI|Total number of Gadolinium highlighted lesions on T1 images|Total number of Gadolinium highlighted lesions on T1 images|Total number of Gadolinium highlighted lesions on T1 images|Normalized cerebral volume (SIENAX) obtained from a T13D sequence|Normalized cerebral volume (SIENAX) obtained from a T13D sequence|Normalized cerebral volume (SIENAX) obtained from a T13D sequence|Change in global cerebral volume (mm^3)|EDSS score, including all subscores|EDSS score, including all subscores|EDSS score, including all subscores|EDSS score, including all subscores|EDSS score, including all subscores|score for the PASAT 3 seconds section of the MSFC score|score for the PASAT 3 seconds section of the MSFC score|score for the PASAT 3 seconds section of the MSFC score|score for the PASAT 3 seconds section of the MSFC score|score for the PASAT 3 seconds section of the MSFC score|EQ5D questionnaire|EQ5D questionnaire|EQ5D questionnaire|EQ5D questionnaire|SF36 questionnaire|SF36 questionnaire|SF36 questionnaire|SF36 questionnaire|FSMC fatigue scale|FSMC fatigue scale|FSMC fatigue scale|FSMC fatigue scale|TLS-QOL10 questionnaire|TLS-QOL10 questionnaire|TLS-QOL10 questionnaire|TLS-QOL10 questionnaire|TLS-Coping10 questionnaire|TLS-Coping10 questionnaire|TLS-Coping10 questionnaire|TLS-Coping10 questionnaire|HADS questionnaire|HADS questionnaire|HADS questionnaire|HADS questionnaire|Presence/absence of adverse events|Presence/absence of adverse events|Presence/absence of adverse events|Presence/absence of adverse events|Presence/absence of adverse events|Presence/absence of adverse events|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|25(OH)D2+D3 serum level (nmol/l)|Calciuria/creatinuria|Calciuria/creatinuria|Calciuria/creatinuria|Calciuria/creatinuria|Calciuria/creatinuria|Calciuria/creatinuria|Calciuria/creatinuria|Delay until conversion to MS",False,
NCT06083753,Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 As an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2023-11-06,2025-08,2025-09,2025-01-07,2023-10-16,INTERVENTIONAL,PHASE2,168.0,ESTIMATED,Contineum Therapeutics,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|PIPE 307|Multiple Sclerosis,United States,Phoenix,Arizona,21,PIPE-307 Dose A|PIPE-307 Dose B|Placebo,DRUG|DRUG|DRUG,Treatment-emergent adverse events (TEAE)|Change in binocular 2.5% low contrast letter acuity (LCLA),Percentage of subjects with >/=5-letter gain in binocular 2.5% LCLA|Change in monocular 2.5% LCLA|Number of subjects with at least a 15% change in disability with the Timed 25-Foot Walk Test (T25WT)|Number of subjects with at least a 15% change in disability with the Nine-Hole Peg Test (9HPT)|Number of subjects with at least a 15% change in disability with the Symbol Digital Modality Test (SDMT)|Change in magnetic resonance imaging (MRI) measures of myelination and MS disease activity|Change in serum neurofilament light chain (NfL)|Pharmacokinetics: Change in blood concentration levels of PIPE-307,False,
NCT04697407,IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis,BREGS - IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis,COMPLETED,2021-03-23,2023-05-23,2023-05-23,2023-05-24,2021-01-06,INTERVENTIONAL,NA,95.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,,France,Rennes,,1,Blood sampling|CSF sampling,BIOLOGICAL|BIOLOGICAL,Frequency of Bregs in blood of MS patients,"Frequency of Bregs in the CSF of MS patients|Comparison of IL-2, soluble IL2RA, IL-10, IL-21 and IL-5 protein concentrations|Comparison of the concentrations in Igs",False,
NCT06095271,MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC,"A Multicenter, Randomized Pragmatic Platform Trial Embedded Within the Swiss Multiple Sclerosis Cohort (SMSC) on Neurofilament Light Chain Monitoring Added to Usual Care to Inform Personalized Treatment Decisions in Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2023-02-05,2026-11,2027-05,2025-05-11,2023-10-23,INTERVENTIONAL,NA,920.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,Switzerland,Basel,Canton of Basel-City,8,serum Neurofilament Filament Light chain (sNfL) monitoring,DIAGNOSTIC_TEST,EDA3 (evidence of disease activity)|Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument,Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument|EDA3 (evidence of disease activity)|EQ-5D-5L|Short form 36 (SF-36)|relapses|disability worsening|New/enlarging T2w lesions|T1w contrast enhancing lesions|Amount of immunosuppressive/immunomodulatory drug treatment,False,
NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,"A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis",COMPLETED,2019-03-29,2020-01-02,2020-01-02,2025-09-17,2019-03-26,INTERVENTIONAL,PHASE2,130.0,ACTUAL,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Cullman,Alabama,48,SAR442168|Placebo|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI),DRUG|DRUG|DRUG,Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions,"Number of New or Enlarging T2 Lesions|Total Number of Gd-enhancing T1-hyperintense Lesions|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Weeks 1-4 Period|Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events: SAR442168 Treatment Period|Number of Participants With Individual Clinically Relevant Abnormalities in Laboratory Tests (Hematology, Chemistry, Urinalysis), Vital Signs, and Electrocardiograms (ECG)",True,2023-03-08
NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),"Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)",COMPLETED,2016-05-12,2016-11-14,2016-11-14,2019-02-08,2016-03-25,INTERVENTIONAL,PHASE4,133.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,fingolimod|Biomarker|Multiple sclerosis|Relapsing-remitting multiple sclerosis,Germany,Ostfildern,Baden-Wurttemberg,26,fingolimod,DRUG,Change in T Cells Status (Decrease or Increase) at Month 48 (FAS),"Percentage of Participants With Disability Progression as Measured by Expanded Disability Status Scale (EDSS) (FAS)|Change From Baseline in Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at Month 6 and Month 48 (FAS)|Change in Immune Status of B Cells, Monocytes and Natural Killer Cells (NK) Cells (FAS)",True,2019-02-08
NCT01615887,Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis,Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis,COMPLETED,2009-11,2011-08,2011-08,2022-09-16,2012-06-11,INTERVENTIONAL,PHASE2,63.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,lisdexamfetamine sulfate|placebo,DRUG|DRUG,Symbol Digit Modalities Test (SDMT)|Paced Auditory Serial Audition Test (PASAT),California Verbal Learning Test - 2nd Edition|Brief Visuospatial Memory Test - Revised|Vitals|Vitals (Diastolic Blood Pressure)|Vitals (Systolic Blood Pressure),True,2022-09-16
NCT01414816,Betaferon® Regulatory Post-Marketing Surveillance,Betaferon® Regulatory Post-Marketing Surveillance,COMPLETED,2008-04,2012-07,2012-07,2014-08-21,2011-08-11,OBSERVATIONAL,,355.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis|Clinically Isolated System,Multiple Sclerosis|Clinical Isolated Syndrome (CIS),South Korea,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Safety variables will be summarized using descriptive statistics based on adverse events.,The efficacy data regarding prevention of relapse due to MS will be estimated based on the number of relapse.|Progression or aggravation to Multiple sclerosis (MS) will be identified based on the change of Expanded Disability Status Scale (EDSS) and the Magnetic Resonance Imaging (MRI) outcome.,False,
NCT05088473,Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases,Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases,COMPLETED,2021-10-15,2021-10-31,2021-10-31,2021-11-09,2021-10-22,OBSERVATIONAL,,1500.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Central Nervous System Diseases|Multiple Sclerosis,multiple sclerosis|kappa free light chains|lambda free light chains,France,Clermont-Ferrand,,14,Biological collection,OTHER,Measurement of cerebrospinal fluid (CSF) and serum kappa and lambda free light chains (KFLC and LFLC)|Measurement of cerebrospinal fluid (CSF) and serum albumin|Evaluation of the diagnostic performances of KFLC and LFLC intrathecal synthesis biomarkers (K/L FLC index and K/L FLC intrathecal fraction (IF)) for multiple sclerosis|Comparison of diagnostic performances of K/L FLC intrathecal synthesis biomarkers to oligoclonal bands (OCB) for multiple sclerosis,Evaluation of clinical data that can alter KFLC and LFLC values,False,
NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),COMPLETED,2010-05-13,2017-08-11,2017-08-11,2019-11-01,2010-06-14,INTERVENTIONAL,PHASE1,48.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Daclizumab,United States,Bethesda,Maryland,1,DAC-HYP,BIOLOGICAL,Expansion of CD56bright NK cells.|Contraction of lymphoid tissue inducer cells (LTi) cells.|Expansion of double negative T cells.,Long-term safety and tolerability of DAC HYP in high-inflammatory multiple sclerosis (HI-MS) patients who were either previously successfully treated with Zenapax (registered trademark) or without any previous exposure to DC25-targeting therapie...|Secondary Outcome Measure: MRI outcomes Inhibition of the number of contrast-enhancing lesions. T2 lesion load and development of new MS lesions. Clinical/functional outcomesChange in EDSS. Change in Scripps NRS. Change in MSFC.Change in S...,False,
NCT02893683,Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients,Paris Visual Learning Test (PVLT): a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients,COMPLETED,2013-12-19,2017-05-15,2017-05-15,2018-02-12,2016-09-08,OBSERVATIONAL,,50.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,Paris Visual Learning Test|visual memory|criterion validity,France,Paris,,1,Paris Visual Learning Test,OTHER,test score,,False,
NCT05906992,"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis",RECRUITING,2024-01-11,2027-02,2029-01,2024-05-22,2023-06-18,INTERVENTIONAL,PHASE3,512.0,ESTIMATED,Celltrion,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,Poland,Poznan,,1,CT-P53|US-Ocrevus|EU-Ocrevus,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Area under the concentration-time curve in PK group|Total number of new GdE lesions on T1-weighted brain MRI in Main study group,Absoulte CD19+ B-cell counts for PD assessments|Area under the concentration-time curve in PK group|Total body clearance in PK group|Volume of distribution at steady state in PK group|Safety: Immunogenecity|Annualized Relapse Rate (ARR)|Change in Expanded Disability Status Score (EDSS)|Change in Multiple Sclerosis Functional Composite Score (MSFCS)|Total Number of Lesions on Brain Magnetic Resonance Imaging|Volume of Hypointense Lesions on T1-weighted Brain Magnetic Resonance Imaging|Brain Volume on Brain Magnetic Resonance Imaging|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,False,
NCT05182398,Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients,Investigation of Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients,WITHDRAWN,2022-05-15,2022-07-15,2022-08-15,2025-03-10,2022-01-10,OBSERVATIONAL,,0.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Multiple Sclerosis,Fall|Modified Four Square Step Test|Multiple sclerosis|Balance,,,,0,Assesment,OTHER,Modified Four Square Step Test|Modified Four Square Step Test,Berg Balance scale|Dynamic Gait Index|Activity-Specific Balance Confidence Scale,False,
NCT04236544,Patient Experiences of Multiple Sclerosis (PExMS),Impact of a Multimedia Website With Patient Experiences of Multiple Sclerosis (PExMS) on Immunotherapy Decision-making: a Pilot Randomised Controlled Trial in a Mixed-methods Design,NOT_YET_RECRUITING,2024-01-01,2025-12-31,2025-12-31,2023-02-08,2020-01-22,INTERVENTIONAL,NA,55.0,ESTIMATED,Universitätsklinikum Hamburg-Eppendorf,OTHER,"Marianne-Strauss-Klinik, Berg, Germany|Gesundheitszentrum St. Johannes Hospital, Bonn, Germany|University Hospital Cologne, Cologne, Germany|Rechts der Isar Hospital, Munich, Germany|University Medical Center Schleswig-Holstein, Kiel, Germany",UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Patient Engagement|Self Efficacy",multiple sclerosis|decision making|decision support|web-based experiential information|patient experiences|narrative information,,,,0,PExMS and DECIMS-Wiki|DECIMS-Wiki,BEHAVIORAL|BEHAVIORAL,Testing the feasibility of an intervention using patients' experiences as a supplement to evidence-based information in a pilot randomized controlled trial,Preparation for Decision Making|Decisional Conflict|Self-reported impact of eHealth on its users|Affective forecasting in regard to immunotherapies|Self-confidence in decision-making|Patients' beliefs about the necessity of their medication and their concerns about the current medication|Adherence,False,
NCT02004444,JC Virus Reactivation in Multiple Sclerosis,JC Virus Reactivation in Multiple Sclerosis,COMPLETED,2010-10,2016-01,2016-01,2016-01-29,2013-12-09,OBSERVATIONAL,,50.0,ACTUAL,Beth Israel Deaconess Medical Center,OTHER,National Multiple Sclerosis Society|Biogen,OTHER|INDUSTRY,Progressive Multifocal Leukoencephalopathy|Multiple Sclerosis,JC Virus|Natalizumab,United States,Boston,Massachusetts,1,,,"Molecular determinants of JCV reactivation in blood, urine, and CSF",Humoral and Cellular Immune Response to JCV,False,
NCT00947232,Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI,The Effectiveness of Physical Activity for Major Depression in People Aging With Multiple Sclerosis or Spinal Cord Injury,COMPLETED,2009-10,2012-12,2013-03,2017-05-05,2009-07-28,INTERVENTIONAL,NA,123.0,ACTUAL,University of Washington,OTHER,,,Multiple Sclerosis|Spinal Cord Injury,major depressive disorder|physical activity|aging with physical disability|motivational interviewing,United States,Seattle,Washington,1,Motivational interviewing|Education,BEHAVIORAL|BEHAVIORAL,HAM-D,International Physical Activity Questionnaire,False,
NCT05532163,A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),"A Prospective, Multicenter, Interventional, Open-Label, Single-arm Phase IV Study Over 24 Weeks to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous Natalizumab in Patients With Relapsing-Remitting Multiple Sclerosis (TYS-ON)",TERMINATED,2023-01-23,2023-10-09,2023-10-09,2024-06-21,2022-09-08,INTERVENTIONAL,PHASE4,1.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Germany,Bamberg,,2,Natalizumab,DRUG,Cumulative Number of Active Lesions (CUALs) Through Week 24,"Cumulative Number of CUALs Through Weeks 4, 8, and 12|Absolute Number of CUALs at Weeks 4, 8, 12, and 24|Mean Change From Baseline of CUALs at Weeks 4, 8, 12, and 24|Cumulative Number of New Gd-Enhancing Lesions Through Weeks 4, 8, 12, and 24|Absolute Number of New Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24|Absolute Number of Persisting Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24|Absolute Number of Any (New or Persisting) Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24|Change From Baseline of Any (New or Persisting) Gd-Enhancing Lesions at Weeks 4, 8, 12, and 24|Cumulative Number of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24|Absolute Number of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24|Change From Baseline of New or Enlarging T2 Lesions at Weeks 4, 8, 12, and 24|Annualized Relapse Rate|Time to First Relapse|Number of Participants With Expanded Disability Status Scale (EDSS) Improvement and Stable Disease and Worsening at Weeks 12, and 24|Trough Serum Natalizumab Concentration (Ctrough)|Trough alpha 4 (α4) Integrin Saturation|Change From Baseline in Lymphocyte Subsets Count|Change From Baseline in Anti-Natalizumab Antibodies|Persistence of Anti-Natalizumab Antibodies|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",False,
NCT04054050,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,ENROLLING_BY_INVITATION,2021-02-22,2025-01-30,2026-01-30,2025-02-03,2019-08-13,INTERVENTIONAL,NA,24.0,ESTIMATED,Johns Hopkins University,OTHER,National Institute on Minority Health and Health Disparities (NIMHD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH|NIH,Multiple Sclerosis,sleep disturbance|insomnia|fatigue,United States,Baltimore,Maryland,1,Light therapy,OTHER,Number of adverse events,Change in sleep quantity as assessed by the Pittsburgh Sleep Quality Index (PSQI)|Change in sleep efficiency as assessed by the Pittsburgh Sleep Quality Index (PSQI)|Change in overall sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)|Change in sleep efficiency as assessed by actigraphy|Change in total sleep time|Change in insomnia severity as assessed by the Insomnia Severity Index (ISI)|Change in daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS)|Change in fatigue severity as assessed by the Neuro-QoL fatigue questionnaire|Change in function of intrinsically photosensitive retinal ganglion cells,False,
NCT00240006,A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone,"An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center",COMPLETED,2006-01,2007-01,2007-09,2011-04-11,2005-10-17,INTERVENTIONAL,PHASE4,307.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Copaxone®|Shared Solutions®,,,,0,Shared Solutions® plus MS Center v. Shared Solutions®,PROCEDURE,Adherence rate of Copaxone therapy by procedural intervention,"Compliance of treatment, positive experience of treatment, levels of depression, proportion of time spent, self injection competency ratings, and the risk of non-adherence/non-compliance",False,
NCT02486640,Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon,BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence,COMPLETED,2015-09-08,2019-10-31,2020-01-16,2023-07-24,2015-07-01,OBSERVATIONAL,,162.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,"RRMS, CIS",Germany,Wermsdorf,Saxony,1,"Interferon beta-1b (Betaferon, BAY86-5046)|Betaconnect Autoinjector",DRUG|DEVICE,Compliance to therapy (%)|Persistence of therapy (Yes or No)|Overall adherence to therapy (Yes or No),"Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire|Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No)|Adherence to Betaferon treatment is associated with number of relapses (Yes or No)|Adherence to Betaferon treatment is associated with EDSS change (Yes or No)|Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ-5D quality of life questionnaire (Yes or No)",False,
NCT03750097,Validation of a Smartwatch in Persons With Multiple Sclerosis,Validation of a Commercially Available Smartwatch for Step Detection in Persons With Multiple Sclerosis,COMPLETED,2018-05-01,2018-12-15,2019-01-31,2019-04-12,2018-11-21,INTERVENTIONAL,NA,58.0,ACTUAL,University of Erlangen-Nürnberg,OTHER,Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen,UNKNOWN|OTHER,Multiple Sclerosis,Multiple Sclerosis|Motion sensors|Smartwatch|Steps|Walking|Validation,Germany,Erlangen,,1,Comfortable walking velocity (CWV)|Slow walking velocity (SWV: CWV - 20%)|Fast walking velocity (FWV: CWV + 20%),BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Step detection during comfortable walking,Step detection during slow walking|Step detection during fast walking,False,
NCT04356248,Training and Energy Management Education to Improve Quality of Life in Persons With Multiple Sclerosis,"High Intensity Training and Energy Management Education vs. Standard Training and Muscle Relaxation, to Improve Quality of Life in Persons With Multiple Sclerosis, a Randomized Controlled Superiority Trial With Six Months' Follow-up",COMPLETED,2020-07-13,2022-05-11,2022-05-11,2022-06-10,2020-04-22,INTERVENTIONAL,NA,106.0,ACTUAL,Klinik Valens,OTHER,"German Sport University, Cologne|University of Applied Sciences and Arts of Southern Switzerland",OTHER|OTHER,Multiple Sclerosis,,Switzerland,Valens,Canton of St. Gallen,1,Endurance Training|Education,BEHAVIORAL|BEHAVIORAL,Short-form 36 (SF-36),Indicators of inflammatory activity|Cardiorespiratory Fitness|Self-efficacy in performing energy conservation strategies (SEPECSA)|Self-perceived competence in activities of daily living (OSA)|Fatigue Scale of motor and cognitive function (FSMC)|Hospital Anxiety and Depression Scale (HADS),False,
NCT00288990,A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis,Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response.,COMPLETED,2006-01,,2007-08,2007-12-24,2006-02-09,OBSERVATIONAL,,300.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,MS,United States,Birmingham,Alabama,28,,,,,False,
NCT03257358,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,"A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]",COMPLETED,2017-09-19,2019-03-05,2019-06-28,2021-10-07,2017-08-22,INTERVENTIONAL,PHASE4,382.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|RMS|Relapsing Multiple Sclerosis (RMS)|Multiple Sclerosis|MS|Multiple Sclerosis (MS)|Fingolimod|FLUENT|Immune Phenotype|adult|FTY720,United States,Birmingham,Alabama,66,Fingolimod,DRUG,Change From Baseline to Month 6 in CD4+ Naive T Cells (CCR7+ CD45RA+)|Change From Baseline to Month 6 in CD4+ Central Memory T Cells (CCR7+CD45RA-CD45RO+)|Change From Baseline to Month 6 in CD4+ Effector Memory T Cells (CCR7-CD45RA-CD45RO+)|Change From Baseline to Month 6 in CD4+ Th1 Cells (CXCR3+)|Change From Baseline to Month 6 in CD4+ Th2 Cells (CCR4+)|Change From Baseline to Month 6 in CD4+ Th17 Cells (CCR6+)|Change From Baseline to Month 6 in CD8+ Naive T Cells (CCR7+CD45RA+)|Change From Baseline to Month 6 in CD8+ Central Memory T Cells (CCR7+CD45RA-CD45RO+)|Change From Baseline to Month 6 in CD8+ Effector Memory T Cells (CCR7-CD45RA-CD45RO+)|Change From Baseline to Month 6 in Naive B Lymphocytes (CD19+CD27-)|Change From Baseline to Month 6 in Memory B Lymphocytes (CD19+CD27+)|Change From Baseline to Month 6 in Regulatory B Lymphocytes (CD19+CD24+CD38+)|Change From Baseline to Month 6 in Monocytes (CD14+)|Change From Baseline to Month 6 in Neutrophils (CD16+)|Change From Baseline to Month 6 in NK Cells (CD56+)|Change From Baseline to Month 6 in Total CD4+ Absolute Cell Count|Change From Baseline to Month 6 in Total CD4+ Differential Cell Count|Change From Baseline to Month 6 in Total CD8+ Absolute Cell Count|Change From Baseline to Month 6 in Total CD8+ Differential Cell Counts (%)|Change From Baseline to Month 6 in Total CD19+ Absolute Cell Count|Change From Baseline to Month 6 in Total CD19+ Differential Cell Count (%),Change From Baseline to Month 12 in CD4+ Naive T Cells (CCR7+CD45RA+)|Change From Baseline to Month 12 in CD4+ Central Memory T Cells (CCR7+CD45RA-CD45RO+)|Change From Baseline to Month 12 in CD4+ Effector Memory T Cells (CCR7-CD45RA-CD45RO+)|Change From Baseline to Month 12 in CD4+ Th1 Cells (CXCR3+)|Change From Baseline to Month 12 in CD4+ Th2 Cells (CCR4+)|Change From Baseline to Month 12 in CD4+ Th17 Cells (CCR6+)|Change From Baseline to Month 12 in CD8+ Naive T Cells (CCR7+CD45RA+)|Change From Baseline to Month 12 in CD8+ Central Memory T Cells (CCR7+CD45RA-CD45RO+)|Change From Baseline to Month 12 in CD8+ Effector Memory T Cells (CCR7-CD45RA-CD45RO+)|Change From Baseline to Month 12 in Naive B Lymphocytes (CD19+CD27-)|Change From Baseline to Month 12 in Memory B Lymphocytes (CD19+CD27+)|Change From Baseline to Month 12 in Regulatory B Lymphocytes (CD19+CD24+CD38+)|Change From Baseline to Month 12 in Monocytes (CD14+)|Change From Baseline to Month 12 in Neutrophils (CD16+)|Change From Baseline to Month 12 in NK Cells (CD56+)|Change From Baseline to Month 12 in Total CD4+ Absolute Cell Count|Change From Baseline to Month 12 in Total CD4+ Differential Cell Count (%)|Change From Baseline to Month 12 in Total CD8+ Absolute Cell Count|Change From Baseline to Month 12 in Total CD8+ Differential Cell Counts (%)|Change From Baseline to Month 12 in Total CD19+ Absolute Cell Count|Change From Baseline to Month 12 in Total CD19+ Differential Cell Count (%)|Multiple Sclerosis (MS) Relapses During Treatment|Number of Participants Who Received Steroid Treatment for MS Relapses During Treatment|Change From Baseline in Patient Determined Disease Steps (PDDS)|Change From Baseline in T2 Lesion Burden|Change From Baseline for New Gd-Enhancing T1 Lesion Count|Change From Baseline to Months 6 and 12 in the Anti-JCV Antibody Index (Index/Value),True,2020-07-21
NCT02006160,Effects of Dalfampridine on Cognition in Multiple Sclerosis,Effects of Dalfampridine on Cognition in Multiple Sclerosis,COMPLETED,2011-12,2016-02,2016-02,2020-10-01,2013-12-10,INTERVENTIONAL,PHASE2|PHASE3,61.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,dalfampridine|placebo,DRUG|DRUG,Symbol Digit Modalities Test,,True,2019-05-07
NCT07037823,Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis,Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis: A Prospective Multi-Center Observational Comparative Study,NOT_YET_RECRUITING,2025-07-01,2026-10-31,2026-12-31,2025-06-26,2025-06-26,OBSERVATIONAL,,328.0,ESTIMATED,Ying Gao,OTHER,The Second Hospital of Hebei Medical University|First Affiliated Hospital of Jinan University|Chinese PLA General Hospital,OTHER|OTHER|OTHER,RRMS,,,,,0,Modified Yishen Daluo Yin formula,OTHER,The proportion of patients exhibiting no evidence of disease activity (NEDA) -3 at 48 weeks.,Annual Relapse Rate|Proportion of Patients Without Relapse|Changes in EDSS Compared to Baseline|The proportion of patients with confirmed disability progression within 3 months.|The proportion of patients with confirmed disability progression within 6 months.|Number of newly added gadolinium enhanced T1 lesions|Total number of gadolinium-enhanced T1 lesions|Changes in T1 lesion volume compared with baseline|Number of newly added or enlargement gadolinium enhanced T2 lesions.|Changes in T2 lesion volume compared with baseline|Proportion of patients with treatment interruption|Proportion of patients who terminated treatment|Proportion of patients who switch treatments,False,
NCT06812585,The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study,The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study,COMPLETED,2022-04-01,2023-05-30,2025-01-30,2025-02-06,2025-02-06,INTERVENTIONAL,PHASE2,30.0,ACTUAL,German University in Cairo,OTHER,,,Multiple Sclerosis (MS) - Relapsing-remitting,,Egypt,Cairo,Cairo Governorate,1,Metformin (Cidophage®)|Usual Care,DRUG|OTHER,Change in serum levels of neurofilament light chain in both arms,"Change in serum levels of nuclear factor kappa B in both arms|Degree of remyelination visualized by MRI, it depends on clinician's overview.|Degree of disability assessed by Expanded Disability Status Scale.",False,
NCT00988052,"A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course","A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS",TERMINATED,2009-11-10,2017-07-01,2017-07-01,2021-12-09,2009-10-01,INTERVENTIONAL,PHASE3,839.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,United States,Phoenix,Arizona,135,Laquinimod,DRUG,Participants With Treatment-Emergent Adverse Events (TEAEs),Participants With Potentially Clinically Significant Abnormal Vital Signs|Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study|Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study|Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study,True,2019-01-08
NCT06782490,"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)",RECRUITING,2025-06-05,2026-11-18,2027-01-27,2025-09-22,2025-01-20,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,Celgene,INDUSTRY,,,Multiple Sclerosis Spasticity,Spasticity|Multiple Sclerosis|BMS-986368,United States,Scottsdale,Arizona,51,BMS-986368|Placebo,DRUG|DRUG,Change from baseline in Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) score,Change from baseline on the Numeric Rating Scale Spasticity (NRS-S) score|Change from baseline on the MS Spasticity Scale (MSSS-88) total scores|Change from baseline on the Timed 25-Foot Walk (T25FW) score|Change from baseline on the Clinical Global Impression of Severity (CGI-S) score|Plasma concentrations of BMS-986368 at selected pre- and post-dose time points|Number of participants with Treatment-Emergent Adverse Events (TEAEs)|Serious adverse events (SAEs)|Adverse events (AEs) leading to treatment discontinuation|AEs leading to death|AEs leading to clinically significant lab abnormalities|Number of participants with suicidal ideation and behavior during BMS-986368 administration as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of participants with withdrawal symptoms following BMS-986368 administration as assessed by the Cannabis Withdrawal Scale (CWS),False,
NCT05789225,Evaluation of a Self-management Program to Prevent Falls in People With Multiple Sclerosis,Evaluation of a Self-management Program to Prevent Falls in Ambulatory and Non-ambulatory People With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2024-02-08,2025-12-31,2025-12-31,2025-02-27,2023-03-29,INTERVENTIONAL,NA,208.0,ESTIMATED,Karolinska Institutet,OTHER,,,Multiple Sclerosis,Self-management|Accidental Falls|Health Economics|Randomized Controlled Trial|Complex Intervention|Process Evaluation|Group-based|Online Intervention|Short Message Service,Sweden,Huddinge,,1,Fall prevention program|Brochure,BEHAVIORAL|OTHER,Falls incidence,Falls Control Scale|Measure of fear of falling|Falls Efficacy Scale-International|Spinal Cord Injury Fall Concern Scale|Revised version of the Short Falls Efficacy Scale-International|Activity curtailment|Multiple Sclerosis Impact Scale|EuroQol-5D-5L,False,
NCT01075880,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif,COMPLETED,2009-05,2013-06,2013-06,2013-09-06,2010-02-25,OBSERVATIONAL,,300.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck spol.s.r.o., Czech Republic",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Rebif|Interferon beta-1a",Czechia,Brno,,13,Rebif (Interferon beta-1a),DRUG,Percentage of subjects with decreased/increased/stable cognition status (PASAT),"Percentage of subjects with decreased/increased/stable fatigue (FDS)|Relationship between the cognition status, the fatigue status and the EDSS status|Relationship between the Rebif dosage used with cognition and fatigue status|Proportion of relapse-free subjects|Proportion of subjects with defined EDSS changes (decrease; no change; increase of 0.5 - 1.0; 1.5 - 2.0; 2.5 - 3.0; 3.0 or more points, respectively)|Proportion of subjects without either relapse, EDSS progression, cognition status decrease and fatigue increase|Number of Rebif doses not taken since the last study visit, and the reason of dose not taken|Proportion of subjects using the antidepressive or antifatigue medication",False,
NCT06949696,Effect of Dual-Task Training and Cognitive Rehabilitation in Individuals With Multiple Sclerosis.,"Effects of Dual-Task Training and Cognitive Rehabilitation on Gait, Balance, Fatigue and Cognitive Performance in Individuals With Multiple Sclerosis",RECRUITING,2025-04-20,2025-06-30,2026-06-01,2025-04-29,2025-04-29,INTERVENTIONAL,NA,30.0,ESTIMATED,Toros University,OTHER,,,Multiple Sclerosis,multiple sclerosis|balance|gait|dual task|fatigue,Turkey (Türkiye),Mersin,,1,Dual Task Training|Cognitive Rehabilitation|Conventionel Physiotherapy,OTHER|OTHER|OTHER,Dynamic Gait Index (DGI),Timed 25 Food Walk Test (T25FWT)|The 12-item MS Walking Scale (12-MSWS)|BICAMS (Brief International Cognitive Assessment for MS)|Trial Making Test (TMT)|Modified Fatigue Impact Scale (MFIS),False,
NCT03606668,Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders,Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders,COMPLETED,2018-06-20,2020-03-02,2020-03-02,2022-02-11,2018-07-31,INTERVENTIONAL,NA,20.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis|Chronic Pain|Neurological Disorder,,United States,New York,New York,1,HTC Vive Virtual Reality (VR) system,DEVICE,Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score,Change in Neuro-Quality of Life (Neuro-QOL) - Fatigue - Short Form Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Related Impairment Score|Change in PROMIS - Fatigue Score|Change in PROMIS - Fatigue Score,True,2022-02-11
NCT02784210,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study,RECRUITING,2016-10-05,2028-12-31,2028-12-31,2025-09-24,2016-05-27,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Centripetal Enhancement|MRI|7 Tesla|Gadolinium|MS,United States,Bethesda,Maryland,1,Methylprednisolone|Prednisone,DRUG|DRUG,the presence or absence of a hypointense phase rim around each lesion followed over time,"The change in normalized intralesional proton density-weighted and T1-weighted signal, as well as the R1 relaxation rate, from 3T scan.|The presence or absence of a 3T hypointense phase rim around each lesion|The presence or absence of a hypointense phase rim around each lesion followed over time.|Lesion volume and intralesional median R1 relaxation rate as determined from the 7T MP2RAGE scan,",False,
NCT03706118,Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging,Physiologic Interindividual Variability of Volume and Atrophy in Central Nervous System Structures With Focus on Spinal Cord as Measured by Quantitative Magnetic Resonance Imaging.,UNKNOWN,2018-03-15,2018-09-14,2021-11-01,2020-07-29,2018-10-15,INTERVENTIONAL,NA,102.0,ACTUAL,Dana Horakova,OTHER,,,Cognitive Change|Atrophy Brain|Atrophy; Spinal Cord|Multiple Sclerosis,Multiple Sclerosis|Spinal Cord Atrophy,Czechia,Prague,,1,Magnetic resonance imaging,OTHER,Measure Spinal Cord Volume Change at 12 months during 3 years follow-up in Healthy Controls|Measure Spinal Cord Atrophy Change at 12 months during 3 years follow-up in Healthy Controls,Measure Whole Brain Volume and Atrophy at 12 months during 3 years follow-up in Healthy Controls|Measure Regional Brain Volumes and Atrophies at 12 months during 3 years follow-up in Healthy Controls,False,
NCT03610139,Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients,Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial,UNKNOWN,2018-05-21,2022-12-31,2022-12-31,2021-08-30,2018-08-01,INTERVENTIONAL,NA,162.0,ESTIMATED,American University of Beirut Medical Center,OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome|Clinically Isolated Syndrome, CNS Demyelinating|Vitamin D3 Deficiency",cognitive performance|vitamin D3 replacement|Lebanon,Lebanon,Beirut,,1,Vitamin D3,DIETARY_SUPPLEMENT,Change from Baseline Brief Visuospatial Memory Test-Revised (BVMT-R) scores at 6 months|Change from Baseline Arabic Verbal Memory Test (VMAT) scores at 6 months|Change from Baseline Symbol Digit Modalities Test (SDMT) scores at 6 months|Change from Baseline Stroop test scores at 6 months|Change from Baseline Brief Visuospatial Memory Test-Revised (BVMT-R) scores at 12 months|Change from Baseline Arabic Verbal Memory Test (VMAT) scores at 12 months|Change from Baseline Symbol Digit Modalities Test (SDMT) scores at 12 months|Change from Baseline Stroop test scores at 12 months,Change from Baseline Magnetic Resonance Imaging Brain Markers of the Hippocampus volume at 12 months|Change from Baseline Magnetic Resonance Imaging Brain Markers of the frontal cortex volume at 12 months|Change from Baseline Magnetic Resonance Imaging Brain Markers of the brain parenchymal fraction at 12 months|Change from Baseline Magnetic Resonance Imaging Brain Markers of the Cerebellum at 12 months,False,
NCT01112345,An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters,"A Multicentre, Non Interventional, Non Randomized, Observational Study for the Assessment of Compliance and Persistence With Rebif® Therapy of Patients With Relapsing-Remitting Multiple Sclerosis as Well as for the Evaluation of Potential Factors Influencing These Parameters, in Real Life Clinical Practice",COMPLETED,2009-12,2012-09,2012-09,2014-07-16,2010-04-28,OBSERVATIONAL,,133.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck A.E., Greece",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Interferon-beta",Greece,Athens,,1,,,Assessment of subjects' compliance with physicians' instructions on the proper use of the treatment|Assessment of subjects' compliance with physicians' instructions on the proper use of the treatment after 6 months of therapy|Assessment of subjects' persistence to therapy,Assessment of the factors and their potential correlation with the defined subjects' compliance and persistence to therapy,False,
NCT05880745,The Effect of the Level of Hand Fatigability on Multiple Sclerosis on General Fatigue and Functionality,The Effect of the Level of Hand Fatigability on Multiple Sclerosis on General Fatigue and Functionality: A Controlled Study,COMPLETED,2018-12-08,2019-06-10,2019-12-09,2023-05-30,2023-05-30,INTERVENTIONAL,NA,2.0,ACTUAL,Pamukkale University,OTHER,,,Fatigue|Functionality|Multiple Sclerosis|Dexterity,multiple sclerosis|fatigue|hand fatigability|manuel dexterity,Turkey (Türkiye),Denizli,,1,Nine-Hole Peg Test (NHPT),DIAGNOSTIC_TEST,Expanded Disability Status Scale (EDSS)|Modified Ashworth Scale (MAS),"Ataxia Rating and Rating Scale (SARA)|Nine-Hole Peg Test (NHPT), and the Dexterity Questionnaire-24 (DextQ-24)|Beck Depression Scale|Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS)|Dynamic and Static Fatigue Index",False,
NCT05252195,Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS),Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2022-05-24,2027-03,2027-03,2025-04-27,2022-02-23,OBSERVATIONAL,,300.0,ACTUAL,University of Michigan,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Wayne State University|University of Washington,NIH|OTHER|OTHER,Multiple Sclerosis,Cognitive dysfunction,United States,Ann Arbor,Michigan,3,,,Change in Cognitive Function - Ambulatory measurement via Dot Memory Test|Change in Cognitive Function - Ambulatory measurement via Symbol Search Test|Change in Cognitive Function - clinic-based neurocognitive measurement via NIH Toolbox Cognitive Battery|Change in Cognitive Function - clinic-based neurocognitive measurement via Symbol Digit Modalities test|Change in Cognitive Function - clinic-based neurocognitive measurement via Paced Auditory Serial Addition Test|Change in Cognitive Function - clinic-based neurocognitive measurement via Rey Auditory Verbal Learning Test,,False,
NCT05970939,"Development, Reliability and Validity of the Telerehabilitation Usability Questionnaire- TrUQ","Development, Reliability and Validity of the Telerehabilitation Usability Questionnaire- TrUQ in Neurological Diseases",COMPLETED,2023-07-28,2024-10-28,2024-10-28,2024-11-14,2023-08-02,OBSERVATIONAL,,95.0,ACTUAL,Gazi University,OTHER,,,Neurological Disease,Multiple Sclerosis|Parkinson Disease|Stroke|Usability|Telerehabilitation,Turkey (Türkiye),Ankara,,1,Development of the Telerehabilitation Usability Questionnaire,OTHER,Telerehabilitation Usability Questionnaire in patients with Neurological disease|Telerehabilitation Usability Questionnaire in patients with Neurological disease-Second,,False,
NCT01134627,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS],"A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis",TERMINATED,2006-02,2011-04,2011-04,2013-12-27,2010-06-02,INTERVENTIONAL,PHASE2,305.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Interferon-β|Rebif®|Minocycline",Denmark,Copenhagen,,1,Minocycline|Placebo,DRUG|DRUG,Number of Participants Who Experienced First Documented Relapse,Number of Participants With Documented Relapses|Number of New or Enlarging Lesions on Time Constant 2 (T2) Weighted Magnetic Resonance Imaging (MRI)|Changes in Brain Volume Measured on Magnetic Resonance Imaging (MRI),True,2012-09-05
NCT06167642,Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab,Assessing the Modulation of Retinal Atrophy and Neurofilament Light Chain by Ofatumumab in Relapsing Multiple Sclerosis,ENROLLING_BY_INVITATION,2023-05-22,2027-03,2027-03,2025-06-06,2023-12-12,OBSERVATIONAL,,75.0,ESTIMATED,Johns Hopkins University,OTHER,Novartis,INDUSTRY,"Multiple Sclerosis|Tomography, Optical Coherence|Retinal Degeneration|Visual Acuity",,United States,Baltimore,Maryland,1,Ofatumumab,DRUG,"Ganglion cell inner plexiform (GCIP) atrophy in RMS relative to HCs, according to baseline sNfL levels",Inner nuclear layer (INL) atrophy in RMS relative to HCs|Outer nuclear layer (ONL) atrophy in RMS relative to HCs|Differences in the visual function scores|Differences in expanded disability status scale (EDSS) scores,False,
NCT00245622,Autologous T Cell Vaccine (TCV) for Multiple Sclerosis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS",COMPLETED,2006-05,2008-09,2008-09,2014-03-10,2005-10-28,INTERVENTIONAL,PHASE2,150.0,ACTUAL,"Opexa Therapeutics, Inc.",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Phase 2b Tovaxin|Clinically Isolated Syndrome (CIS)|Relapse-Remitting Multiple Sclerosis (RR-MS),United States,Cullman,Alabama,33,Tovaxin Autologous T cell vaccine|Placebo,BIOLOGICAL|BIOLOGICAL,"To evaluate the efficacy, safety, and tolerability of Tovaxin TCV in subjects with CIS or RR-MS",To evaluate biomarkers of efficacy of Tovaxin TCV and effects of Tovaxin TCV on epitope spreading,False,
NCT03740295,Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis,Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis,COMPLETED,2018-10-05,2019-01-05,2019-02-05,2019-10-31,2018-11-14,INTERVENTIONAL,PHASE2,60.0,ACTUAL,Fundación Universidad Católica de Valencia San Vicente Mártir,OTHER,Valencian Institute of Neurorehabilitation Foundation,UNKNOWN,Multiple Sclerosis,,Spain,Valencia,,1,Coconut oil and epigallocatechin gallate|Placebo,DIETARY_SUPPLEMENT|OTHER,Lipid peroxidation Malondialdehyde (MDA)|Tumor necrosis factor alfa (TNF-alpha)|Interleukin 6 (IL-6),Quantitative electroencephalogram (QEEG)|Betahydroxybutyrate|C-reactive protein|Haptoglobin|Field oxide (FOX)|Total antioxidants (TEAC)|Copper reduction capacity (CUPRAC)|Iron reduction capacity (FRAP)|Paraoxonase 1 (PON1)|Anxiety|Depression|Satiety|Sociodemographic|Berg|Exercise tolerance|Gait speed|Physical function and symptoms|Neurological impairment|Manual dexterity|Hand Grip Strength|Muscle power|Muscle Strength Assessment Dynamometer (NEDDFM/IBV )|Body diameters|Body perimeters|Skinfold calipe|Height|Weight,False,
NCT04095377,Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.,Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019 - A Retrospective Study,COMPLETED,2019-03-24,2022-02-14,2022-02-14,2022-02-16,2019-09-19,OBSERVATIONAL,,875.0,ACTUAL,QuantalX Neuroscience,INDUSTRY,,,"Healthy|CVA|Hemorrhage|TBI (Traumatic Brain Injury)|Concussion, Brain|Fibromyalgia|ABD|Adhd|Dementia|Mci|Cognitive Impairment|Cognitive Decline|MS (Multiple Sclerosis)",,Israel,Rishon LeZiyyon,,1,"No intervention, this is a retrospective study.",OTHER,"Defining Plasticity (the ratio between excitatory to inhibitory brain response) Means and STD in each cohort.|Defining Connectivity (dispersion of brain signal) Means and STD in each cohort.|Defining Plasticity (the ratio between excitatory to inhibitory brain response) standard error (SEM) in each cohort.|Defining Connectivity (dispersion of brain signal) standard error (SEM) in each cohort.|Defining Plasticity (excitation/inhibition brain response) coefficient of variation (CV%) in each cohort.|Defining Connectivity (dispersion of brain signal) coefficient of variation (CV%) in each cohort.|Defining Plasticity (excitation/inhibition brain response) minimum, median, maximum in each cohort.|Defining Connectivity (dispersion of brain signal) minimum, median, maximum in each cohort.|Defining Plasticity (excitation/inhibition brain response) 95% confidence interval in each cohort.|Defining Connectivity (dispersion of brain signal) 95% confidence interval in each cohort.",,False,
NCT01451723,Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II,Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS,TERMINATED,2011-07,2013-02,2013-02,2014-03-14,2011-10-14,INTERVENTIONAL,PHASE2,11.0,ACTUAL,Louisiana State University Health Sciences Center in New Orleans,OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis,Multiple Sclerosis|Polyphenon E|Green tea|EGCG|Epigallocatechin-galleate|Placebo|Randomized controlled trial,United States,New Orleans,Louisiana,1,Polyphenon E|Placebo,DRUG|OTHER,Rate of Change in NAA Levels Adjusted for Water Content.,Brain Atrophy,True,2014-03-14
NCT02524483,Influence of Exercise on the Mobility and Balance of Individuals With Multiple Sclerosis,Influence of Exercise on the Mobility and Balance of Individuals With Multiple Sclerosis Influence of High-Dosage Physical Therapy on the Balance and Mobility of Individuals With Multiple Sclerosis,COMPLETED,2014-10-01,2015-06-01,2015-06-01,2023-09-05,2015-08-14,INTERVENTIONAL,NA,32.0,ACTUAL,University of Nebraska,OTHER,,,Multiple Sclerosis,,United States,Omaha,Nebraska,1,Therapeutic Challenge Program|Therapeutic Exercise Program,BEHAVIORAL|BEHAVIORAL,"Changes in Balance Using the Sensory Organization Test|Changes in Walking Velocity, Step Lengths, Step Widths, and Cadence",Changes in Endurance using the 6-Minute Walk,False,
NCT06668324,Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation,Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS),COMPLETED,2024-11-15,2025-09-05,2025-09-05,2025-09-19,2024-10-31,OBSERVATIONAL,,134.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Proportion of patients reported local injection-related reaction post first injection,Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post first injection)|Proportion of patients reported local injection-related reaction post second injection|Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post second injection),False,
NCT04918251,"EEG and TMS-based Biomarkers of ALS, MS and FTD","Investigation of EEG and TMS-based Biomarkers of Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Frontotemporal Dementia",UNKNOWN,2012-09,2023-02,2023-04,2021-06-08,2021-06-08,OBSERVATIONAL,,400.0,ESTIMATED,"University of Dublin, Trinity College",OTHER,"Motor Neurone Disease Association, UK|Irish Research Council, IE|Health Research Board, IE|Research Motor Neurone, IE|Thierry Latran Foundation, FR|ALS Association, USA",UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Multiple Sclerosis,EEG|TMS|Neurodegeneration|Network|Electrophysiology|Biomarkers|Cognitive|Behavioural|Motor,Ireland,Dublin,Leinster,1,128 electrode electroencephalography (EEG)|Transcranial magnetic stimulation (TMS),PROCEDURE|PROCEDURE,Diagnosis-related difference in EEG or TMS measurements|Prognosis-related EEG or TMS measurements|Diagnosis-related changes in EEG or TMS measurements|Prognosis-related changes in EEG or TMS measurements,Diagnosis-specific changes in EEG or TMS measurements|Diagnosis-specific difference in EEG or TMS measurements,False,
NCT05359653,Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy,"A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",RECRUITING,2023-08-01,2025-06-01,2025-06-01,2024-07-01,2022-05-04,INTERVENTIONAL,PHASE1|PHASE2,74.0,ESTIMATED,"University of California, San Francisco",OTHER,United States Department of Defense,FED,"Multiple Sclerosis (MS)|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis Relapse|Multiple Sclerosis Brain Lesion|Multiple Sclerosis Benign",multiple sclerosis|mri|brain|spinal cord,United States,San Francisco,California,1,Clemastine Fumarate|Placebo,DRUG|DRUG,Corpus Callosum Myelin Water Fraction|Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months|Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months|Corpus Callosum T1 Relaxation Time|Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months|Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months|Corpus Callosum UTE Fraction|Change from Baseline in Corpus Callosum UTE Fraction at 3 Months|Change from Baseline in Corpus Callosum UTE Fraction at 6 Months,Optic Radiation Myelin Water Fraction|Change from Baseline in Optic Radiation Myelin Water Fraction at 3 Months|Change from Baseline in Optic Radiation Myelin Water Fraction at 6 Months|Corticospinal Tract Myelin Water Fraction|Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months|Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months|Optic Radiation T1 Relaxation time|Change from Baseline in Optic Radiation T1 Relaxation Time at 3 Months|Change from Baseline in Optic Radiation T1 Relaxation Time at 6 Months|Corticospinal Tract T1 Relaxation Time|Change from Baseline in Corticospinal T1 Relaxation Time at 3 Months|Change from Baseline in Corticospinal Tract T1 Relaxation Time at 6 Months|Optic radiation UTE Fraction|Change from Baseline in Optic radiation UTE Fraction at 3 Months|Change from Baseline in Optic radiation UTE Fraction at 6 Months|Corticospinal Tract UTE Fraction|Change from Baseline in Corticospinal Tract UTE Fraction at 3 Months|Change from Baseline in Corticospinal Tract UTE Fraction at 6 Months|Lesion of interest (LOI) MWF|Change from Baseline in LOI MWF at 3 Months|Change from Baseline in LOI MWF at 6 Months|LOI T1 Relaxation Time|Change from Baseline in LOI T1 Relaxation Time at 3 Months|Change from Baseline in LOI T1 Relaxation Time at 6 Months|LOI UTE Fraction|Change from Baseline in LOI UTE Fraction at 3 Months|Change from Baseline in LOI UTE Fraction at 6 Months|Whole Brain MWF|Change from Baseline in Whole Brain MWF at 3 Months|Change from Baseline in Whole Brain MWF at 6 Months|Whole Brain T1 Relaxation Time|Change from Baseline in Whole Brain T1 Relaxation Time at 3 Months|Change from Baseline in Whole Brain T1 Relaxation Time at 6 Months|Whole Brain UTE Fraction|Change from Baseline in Whole Brain UTE Values at 3 Months|Change from Baseline in Whole Brain UTE Values at 6 Months|Clemastine Tolerability|Change from Baseline in Clemastine Tolerability at 3 Months|Change from Baseline in Clemastine Tolerability at 6 Months|Informative Outcomes|Informative Outcomes at 3 Months|Informative Outcomes at 6 Months,False,
NCT03980145,G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis,G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis,COMPLETED,2017-05-02,2020-03-01,2020-03-01,2022-02-14,2019-06-10,INTERVENTIONAL,NA,15.0,ACTUAL,Indiana University,OTHER,University of Alabama at Birmingham|University of Ottawa,OTHER|OTHER,Progressive Multiple Sclerosis,Robotics|Gait Training,United States,Indianapolis,Indiana,1,"G-EO System (Reha Technology AG: Olten, Switzerland)|Conventional Physical Therapy",DEVICE|OTHER,Comfortable Walking Speed|Two Minute Walk Test|Modified Fatigue Impact Scale|Multiple Sclerosis Impact Scale-29|Fast Walking Speed,Hospital Anxiety and Depression Scale (HADS)|Short Form McGill Pain Questionnaire|Late-Life Disability Inventory (LLFDI)|Late-Life Function Inventory,True,2022-02-14
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,COMPLETED,2009-08,2016-02,2016-02,2017-05-15,2009-06-30,INTERVENTIONAL,PHASE3,1314.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,Bayer,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis,United States,Cullman,Alabama,176,alemtuzumab,BIOLOGICAL,Annualized Relapse Rate (ARR)|Annualized Relapse Rate (ARR) Before and After Receiving Alemtuzumab|Annualized Relapse Rate (ARR) Before and After Alemtuzumab Retreatment|Number of Participants With Sustained Accumulation of Disability (SAD)|Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year Comparison,"Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6|Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study|Change From Initial Study Baseline in EDSS Score at Year 3, 4, 5 and 6|Change From Initial Study Baseline in EDSS Score Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Retreatment Baseline in EDSS Score After Alemtuzumab Retreatment|Percentage of Participants Without New or Enlarging Magnetic Resonance Imaging (MRI)-T2-Hypertense Lesion Activity|Percentage of Participants Without New or Enlarging MRI-T2-Hypertense Lesion Activity Before and After Alemtuzumab Treatment|Percentage of Participants Without New or Enlarging MRI-T2-Hypertense Lesion Activity Before and After Alemtuzumab Retreatment|Percentage Change From Baseline in MRI-T2-Hypertense Lesion Volumes at Year 3, 4, 5, 6|Percentage of Participants Without New Gadolinium-enhancing MRI Lesion Activity|Percent Change From Baseline in Brain Parenchymal Fractions (BPF) at Year 3, 4, 5 and 6|Percentage of Relapse Free Participants|Change From Baseline in Physical Component Score (PCS) of Short Form-36 (SF-36) Health Survey at Year 3, 4, 5 and 6|Change From Baseline in Physical Component Score (PCS) of Short Form-36 (SF-36) Health Survey Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in Mental Component Score (MCS) of Short Form-36 (SF-36) at Year 3, 4, 5, and 6|Change From Baseline in Mental Component Score (MCS) of Short Form-36 (SF-36) Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in Self-reported Quality of Life as Assessed by Functional Assessment of Multiple Sclerosis (FAMS) Score at Year 3, 4, 5 and 6|Change From Baseline in Self-reported Quality of Life as Assessed by Functional Assessment of Multiple Sclerosis (FAMS) Score Before and After Alemtuzumab Treatment: 2 Year Comparison|Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Visual Analog Scale Score at Year 3, 4, 5 and 6|Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Visual Analog Scale Score Before and After Alemtuzumab Treatment: 2 Year Comparison",True,2017-05-15
NCT04539002,Aerobic Exercise for Remyelination in Multiple Sclerosis,Aerobic Exercise to Improve Mobility in Multiple Sclerosis: Optimizing Design and Execution for a Full-scale Multimodal Remyelination Clinical Trial,COMPLETED,2021-04-29,2025-03-27,2025-03-27,2025-07-31,2020-09-04,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,Oregon Health and Science University,OTHER,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Portland VA Medical Center|Oregon Clinical and Translational Research Institute|Myelin Repair Foundation|EMD Serono|Medical Research Foundation, Oregon",NIH|FED|OTHER|UNKNOWN|INDUSTRY|OTHER,"Multiple Sclerosis|Sclerosis|Demyelinating Diseases|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Exercise",Exercise|Aerobic Exercise|Remyelination|Neural Repair|Mobility,United States,Portland,Oregon,1,Aerobic exercise|Education Group Control,BEHAVIORAL|BEHAVIORAL,Somatosensory Evoked Potentials (SSEPs),6-Minute Timed Walk (6MTW)|Timed Up and Go (TUG)|Timed 25-Foot Walk (T25FW)|Fall frequency|9 Hole Peg Test|Multiple Sclerosis Functional Composite (MSFC)|Virtual aerobic exercise intervention adherence|Virtual education control group adherence|Average heart rate (HR) zone during exercise sessions|Brain Myelin Water Fraction (MWF)|Symbol Digit Modalities Test (SDMT)|VO2 max|7-site skinfold test|Modified Fatigue Impact Scale (MFIS)|Pain Effects Scale (PES)|Health-related quality of life (QoL)|International Physical Activity Questionnaire Short Form (IPAQ-SF),False,
NCT04129736,Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis,Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.,COMPLETED,2019-10-10,2021-03-31,2021-06-30,2022-12-12,2019-10-17,INTERVENTIONAL,PHASE4,12.0,ACTUAL,Jan Lycke,OTHER,,,"Multiple Sclerosis, Pharmacokinetics",,Sweden,Gothenburg,Västra Götaland County,1,Teriflunomide 14 MG,DRUG,Concentration of teriflunomide in cerebrospinal fluid,,False,
NCT05134441,"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)",RECRUITING,2021-11-18,2024-09,2032-09,2024-04-18,2021-11-26,INTERVENTIONAL,PHASE3,1050.0,ESTIMATED,Immunic AG,INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,86,IMU-838 tablets|Placebo matching IMU-838 tablets,DRUG|DRUG,To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse,Effect of IMU-838 versus placebo on volume of new T2 lesions|Effect of IMU-838 versus placebo on disability progression|Effect of IMU-838 versus placebo on cognitive performance|Effect of IMU-838 versus placebo on whole brain atrophy|Safety of IMU-838 versus placebo,False,
NCT03735654,Multi-joint Muscle Fatigability and Gait Performance in People With Multiple Sclerosis,Assessing the Impact of Muscle Strength and Fatigability on Gait Performance Using Single Joint and Multi-joint Assessments in People With Multiple Sclerosis,UNKNOWN,2018-11-15,2020-10-01,2021-10-01,2018-11-08,2018-11-08,OBSERVATIONAL,,35.0,ESTIMATED,Washington D.C. Veterans Affairs Medical Center,FED,,,"Multiple Sclerosis|Gait Disorders, Neurologic|Fatigue",,United States,Washington D.C.,District of Columbia,1,,,"Functional Ambulation Performance (FAP)|Hip, knee, and ankle fatigability|Hip, knee, and ankle maximal volitional contraction",Adult Myopathy Assessment Tool (AMAT)|5 times sit to stand test (5STS),False,
NCT05796037,An Observational Study of Patients Living With Chronic Neurological Diseases,An Observational Study of Patients Living With Chronic Neurological Diseases,NOT_YET_RECRUITING,2025-03-31,2038-12-31,2038-12-31,2024-11-20,2023-04-03,OBSERVATIONAL,,1500000.0,ESTIMATED,"Target PharmaSolutions, Inc.",INDUSTRY,,,Neurological Diseases or Conditions|Dementia of Alzheimer Type|Alzheimer Disease|Mild Cognitive Impairment|Parkinson Disease|Multiple Sclerosis,,,,,0,,,"To characterize the natural history of disease in patients living with chronic neurological diseases including ADRD, MCI, PD, or MS|To assess safety and effectiveness of disease treatments and treatments for complications of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for ADRD, MCI, PD, or MS.","To evaluate provider management practices in the treatment of patients living with ADRD, MCI, PD, or MS|To evaluate longitudinal and patient and care partner reported outcomes in patients with ADRD, MCI, PD, or MS, including care partner burden and quality of life.|3. To select and evaluate quality of care measures for patients living with ADRD, MCI, PD, or MS",False,
NCT01018537,NARCOMS Registry: a Multiple Sclerosis Registry,NARCOMS Global Multiple Sclerosis Registry: a Long-Term Study to Facilitate Research in Multiple Sclerosis,RECRUITING,1996-01,2050-12,2050-12,2024-11-13,2009-11-23,OBSERVATIONAL,,50000.0,ESTIMATED,University of Texas Southwestern Medical Center,OTHER,Consortium of Multiple Sclerosis Centers,OTHER,Multiple Sclerosis,Multiple Sclerosis|NARCOMS|Patient Registry|Registry,United States,Dallas,Texas,1,,,Disease progression over time of follow up,Contributing factors to change in MS disease status,False,
NCT06957145,Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation,Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation: A 1-Year Follow-up Study,RECRUITING,2025-06-30,2026-01-30,2026-12-30,2025-09-03,2025-05-04,OBSERVATIONAL,,60.0,ESTIMATED,Koç University,OTHER,,,"Multiple Sclerosis, MS",,Turkey (Türkiye),Istanbul,Istanbul,2,,,VISTA Protein Secretion,Functional Comparison of Immune Cell Subsets via Cytokine Profiling and VISTA Expression Analysis|Clinical and Radiological Correlation,False,
NCT05219201,Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis,Effectiveness of Partial-body Cryotherapy on the Fatigue of Patients With Multiple Sclerosis During Readaptation Stay,RECRUITING,2022-09-12,2023-03,2027-06,2022-09-19,2022-02-01,INTERVENTIONAL,NA,80.0,ESTIMATED,Fondation Ildys,OTHER,Lille Catholic University,OTHER,Multiple Sclerosis,cryotherapy|fatigue|quality of life|spasticity|quality of sleep|depression symptoms,France,Roscoff,,1,partial-body cryotherapy chamber session,DEVICE,Fatigue syndrome,spasticity symptom|quality of Life evaluation|pain evaluation|quality of sleep|depression symptoms|physician's global assessment-physical endurance|habit changes after rehabilitation stay|physician's global assessment-dynamic balance test|physician's global assessement-static balance test,False,
NCT06930339,Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis,Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2023-05-01,2026-04-30,2026-04-30,2025-04-16,2025-04-16,OBSERVATIONAL,,150.0,ESTIMATED,Helius Medical Inc,INDUSTRY,,,Multiple Sclerosis,"Gait deficit, PoNS",United States,Newtown,Pennsylvania,1,Portable Neuromodulation Stimulator (PoNS),DEVICE,Effectiveness of PoNS Therapy as measured by self-reported change in symptomatology,,False,
NCT03060759,Light Therapy as Treatment for Fatigue in Multiple Sclerosis,Light Therapy as Treatment for Fatigue in Multiple Sclerosis,COMPLETED,2017-04-01,2019-06-30,2019-11-04,2020-05-13,2017-02-23,INTERVENTIONAL,NA,35.0,ACTUAL,Massachusetts General Hospital,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Fatigue|Light Therapy,United States,Boston,Massachusetts,1,Light Therapy box,DEVICE,Change in Average Fatigue Severity Scale (FSS) Score,,True,2020-05-13
NCT03600779,Application of ihMT MRI in Multiple Sclerosis,"Application of the Inhomogeneous Magnetisation Transfer MRI (ihMT) Technique, a New Myelin-specific MRI Technique, in Multiple Sclerosis",RECRUITING,2018-06-14,2026-02-13,2027-02-13,2024-08-06,2018-07-26,INTERVENTIONAL,NA,85.0,ESTIMATED,Assistance Publique Hopitaux De Marseille,OTHER,,,"Sclerosis, Multiple",,France,Marseille,PACA,1,inhomogeneous Magnetisation Transfer (ihMT) sequence|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T,DEVICE|DEVICE,ihMTR ratio at 1.5TMRI|Magnetic transfert (MT) at 1.5TMRI|Myelin water fraction at 1.5TMRI,ihMTR ratio at 3TMRI|Evaluate the predictive value of ihMT,False,
NCT07149662,Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy,B-cells påverkan i Barn Till Kvinnor Med Multipel Skleros Och Rituximabbehandling före Eller Under Graviditeten (B-cell Effects in Children Born to Women With Multiple Sclerosis and Rituximab Treatment Before or During Pregnancy),NOT_YET_RECRUITING,2025-10,2027-10,2028-03,2025-09-02,2025-09-02,OBSERVATIONAL,,111.0,ESTIMATED,Region Stockholm,OTHER_GOV,The Swedish Research Council|Haukeland University Hospital|Karolinska Institutet,OTHER_GOV|OTHER|OTHER,Multiple Sclerosis|Pregnancy,Multiple Sclerosis|Rituximab|Ocrelizumab|Ofatumumab|monoclonal CD-20 antibodies|Pregnancy,Sweden,Stockholm,,1,monoclonal CD-20 antibodies|No Drug|Other treatment,DRUG|DRUG|DRUG,Effect on infant immune system|Effect on infant immune system|Effect on infant immune system|Effect on infant immune system,Drug level concentration infant,False,
NCT03284970,Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes,"Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review",COMPLETED,2017-08-23,2018-05-11,2018-05-11,2018-08-06,2017-09-15,OBSERVATIONAL,,34.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Relapsing-Remitting Multiple Sclerosis,Interferon beta-1a|Dimethyl fumarate|Rebif|Tecfidera|Relapsing-Remitting Multiple Sclerosis,United States,Foxborough,Massachusetts,1,,,Percentage of Subjects With One or More Infections,"Percentage of Subjects With One or More Serious Infections|Percentage of Subjects With One or More Opportunistic Infections|Number of Infections per Subject|Number of Serious Infections per Subject|Number of Opportunistic Infections per Subject|Total Lymphocyte Levels|Percentage of Subjects With Lymphopenia Grades I, II, III and IV|Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Counts|Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Ratio|Occurrence of Adverse Events (AEs) and Serious Adverse Events (SAEs)",False,
NCT01111656,"Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b","SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (""SWABIMS Follow Up-study"")",COMPLETED,2007-03,2010-04,2010-04,2011-09-07,2010-04-27,INTERVENTIONAL,PHASE2,28.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,"Viollier AG, Basel, Switzerland|PharmaPart",UNKNOWN|INDUSTRY,Relapsing-remitting Multiple Sclerosis,Multi-center|randomized|prospective|parallel-group|rater-blinded|RR-MS,Switzerland,Bern,Canton of Bern,1,Interferon beta-1b group|Interferon beta-1b/Atorvastatin group,DRUG|DRUG,Proportion of patients with new lesions on T2-weighted images after 12 months of treatment|Proportion of patients with new lesions on T2-weighted images after 12 months of treatment,"Gd-enhancing lesions on T1-weighted images after 12 months of treatment.|Total T2-hyperintense lesion volume (burden of disease, BOD) after 12 months of treatment.|Cortical atrophy (changes in brain volume, changes in grey matter and white matter) on magnetic resonance imaging (MRI) after 12 months of treatment|Clinical disease progression (Expanded Disability Status Scale [EDSS], Multiple Sclerosis Functional Composite [MSFC] )|Functional systems scores (of Expanded Disability Status Scale [EDSS] and Multiple Sclerosis Functional Composite [MSFC] )|Number of relapse-free patients after 12 months of treatment|Relapse rate after 12 months of treatment|Time to first relapse|Gd-enhancing lesions on T1-weighted images after 12 months of treatment.|Total T2-hyperintense lesion volume (burden of disease, BOD) after 12 months of treatment.|Cortical atrophy (changes in brain volume, changes in grey matter and white matter) on magnetic resonance imaging (MRI)after 12 months of treatment|Clinical disease progression (Expanded Disability Status Scale [EDSS] , Multiple Sclerosis Functional Composite [MSFC] )|Functional systems scores (of Expanded Disability Status Scale [EDSS] and Multiple Sclerosis Functional Composite [MSFC] )|Number of relapse-free patients after 12 months of treatment|Relapse rate after 12 months of treatment|Time of first relapse",False,
NCT07168772,The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis,"The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial",RECRUITING,2025-07-10,2027-12-31,2027-12-31,2025-09-23,2025-09-11,INTERVENTIONAL,NA,80.0,ESTIMATED,Hospital Universitari Vall d'Hebron Research Institute,OTHER,,,Multiple Sclerosis,,Spain,Barcelona,Barcelona,1,Lactibane Iki|Placebo,DIETARY_SUPPLEMENT|OTHER,Increase in the percentage of Treg cells,"Immunological profile (percentage of positive cells): Th1 cells; Th17cells; Breg cells; DCs|Serum levels of NfL, GFAP, cytokines and CRP|Serum and fecal levels of SCFAs|Microbiota composition analysis",False,
NCT02048358,"Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients","Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201",TERMINATED,2013-11,2015-01,2015-02,2015-02-06,2014-01-29,INTERVENTIONAL,PHASE1,47.0,ACTUAL,BBB-Therapeutics B.V.,INDUSTRY,,,Healthy Volunteers|Multiple Sclerosis,Healthy volunteers|first in human|2B3-201|methylprednisolone|CNS-targeting|liposomal|crossover|placebo controlled|active controlled|multiple sclerosis|multiple sclerosis relapse,Netherlands,Amsterdam,North Holland,2,2B3-201|Placebo|Methylprednisolone hemisuccinate,DRUG|DRUG|DRUG,"Number of subjects with adverse events as a measure of safety and tolerability of 2B3-201|Pharmacokinetics in plasma of intravenously administered 2B3-201 in terms of Cmax, Volume of distribution, half-life (T1/2), area under the plasma concentration-time curve (AUC), Clearance (CL)",Measure changes in central nervous system (CNS) functioning after intravenous administration of 2B3-201 by using the Neurocart test battery|Changes in levels of Hypothalamic-pituitary-adrenal (HPA) axis hormones as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;|Changes in levels of fasting blood glucose as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;|Changes in levels of osteocalcin concentrations as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;|Changes in levels of lymphocyte count as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;|Changes in levels of complement factors during infusion as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;,False,
NCT05503524,Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients,Extensive Clinical Trial Experiences of Multiple Sclerosis Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups,NOT_YET_RECRUITING,2024-09,2025-09,2026-09,2024-01-02,2022-08-16,OBSERVATIONAL,,500.0,ESTIMATED,Power Life Sciences Inc.,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Sclerosis,,,,0,,,Rate of patients who decide to enroll in a Multiple Sclerosis Clinical Trial|Number of patients who remain in Multiple Sclerosis clinical trial until completion,,False,
NCT01719159,Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis,Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis,COMPLETED,2009-11,2016-06,2016-06,2016-11-22,2012-11-01,INTERVENTIONAL,PHASE2,23.0,ACTUAL,Anders Svenningsson,OTHER,"Västerbotten County Council, Sweden",OTHER_GOV,Progressive Multiple Sclerosis,Progressive multiple sclerosis|Monoclonal antibodies|Mabthera|Intrathecal treatment,Sweden,Umeå,,2,Rituximab,DRUG,Number of participants with adverse events,Stabilisation of the neurological deterioration,False,
NCT04466150,Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset,Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset,ACTIVE_NOT_RECRUITING,2020-08-30,2026-12,2027-07,2025-01-08,2020-07-10,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,"University of California, San Francisco",OTHER,"Genentech, Inc.|Valhalla Foundation",INDUSTRY|OTHER,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,,United States,San Francisco,California,1,Ocrelizumab,DRUG,Comparison of intrathecal synthesis of gammaglobulins in treatment-naïve relapsing MS and clinically isolated syndrome participants before and after treatment with ocrelizumab,,False,
NCT06021561,Orofacial Pain in Multiple Sclerosis,Orofacial Pain in Multiple Sclerosis,WITHDRAWN,2023-09-04,2023-12-31,2023-12-31,2024-04-09,2023-09-01,OBSERVATIONAL,,0.0,ACTUAL,Varazdin General Hospital,OTHER,,,Multiple Sclerosis,facial pain|craniofacial pain|multiple sclerosis,Croatia,Varaždin,,1,Diagnosis of pain,DIAGNOSTIC_TEST,The frequency of orofacial pain in patients with multiple sclerosis|The location of orofacial pain in patients with multiple sclerosis|The duration of orofacial pain in patients with multiple sclerosis,MS therapy's influence to pain|MS orofacial pain and the duration of the disease|Pain and patients' characteristics|Other chronic diseases and orofacial pain|Pain and daily functioning,False,
NCT03134716,Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis,Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2016-04,2023-12,2026-12,2025-09-22,2017-05-01,OBSERVATIONAL,,35.0,ACTUAL,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,,,Correlation of microglial activation and MS progression,Correlation of 11C-TMSX radioligand binding and MS progression|Correlation of 11C-UCB-J-radioligand binding and cognition,False,
NCT04283071,Kinematic Assessment In Multiple Sclerosis,The Evaluation of Upper Limb Function in Multiple Sclerosis Using Kinematic Assessment,COMPLETED,2019-11-07,2021-10-30,2021-10-30,2022-03-07,2020-02-25,OBSERVATIONAL,,57.0,ACTUAL,The Leeds Teaching Hospitals NHS Trust,OTHER,University of Leeds,OTHER,Multiple Sclerosis,Upper limb function|Kinematic assessment,United Kingdom,Leeds,,1,Boxed infrared gross kinematic assessment tool,DEVICE,Change in upper limb kinematic function in patients with progressive multiple sclerosis,Change in 9-hole PEG test performance in patients with progressive multiple sclerosis|Change in EDSS in patients with progressive multiple sclerosis|Change in patient reported outcome measures in patients with progressive multiple sclerosis,False,
NCT01144052,Natalizumab De-escalation With Interferon Beta-1b,De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis,COMPLETED,2010-06,2011-11,2011-11,2014-04-17,2010-06-15,INTERVENTIONAL,PHASE4,19.0,ACTUAL,Claudio Gobbi,OTHER_GOV,"Ospedale Civico, Lugano",OTHER_GOV,Relapsing-remitting Multiple Sclerosis,Natalizumab|Interferon-beta 1b|De-escalation|Ticino,Switzerland,Lugano,Canton Ticino,1,interferon beta-1b|Natalizumab,DRUG|DRUG,Number of Days Until First On-study Relapse,Number of Participants With Relapses|Number of Relapses|Proportion of Relapse Free Patients|Severity of Relapses|MRI Parameters|Number of Patients With Adverse Events|Number of Infections,True,2014-04-17
NCT04147052,iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis,An Internet-delivered Cognitive Behavioral Intervention for Sleep Disturbance in Multiple Sclerosis,COMPLETED,2021-09-03,2022-04-20,2022-04-20,2022-05-09,2019-10-31,INTERVENTIONAL,NA,90.0,ACTUAL,Johns Hopkins University,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,,United States,Baltimore,Maryland,1,iSLEEPms,BEHAVIORAL,Change in the Pittsburgh Sleep Quality Index (PSQI) total score|Change in the Insomnia Severity Index (ISI) total score|Change in actigraphic total sleep time (TST)|Change in actigraphic sleep efficiency (SE)|Change in actigraphic sleep latency (SL)|Change in actigraphic wake after sleep onset (WASO),Change in the Modified Fatigue Impact Scale (MFIS) total score|Change in the Beck Depression Inventory - Fast Screen (BDI-FS) total score|Change in the MS Neuropsychological Screening Questionnaire (MSNQ) total score|Change in the TestMyBrain Memorizing Words (MW) score|Change in the TestMyBrain Memorizing Pictures (MP) score|Change in the TestMyBrain Matching Shapes and Numbers (MSN) score|Change in the TestMyBrain Fast Choices (FC) score|Treatment Satisfaction Scale (TSS) total score (iSLEEPms group only)|iSLEEPms treatment adherence (iSLEEPMS group only)|iSLEEPms treatment integrity (iSLEEPMS group only),False,
NCT01663649,Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders,Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms in Patients With Multiple Sclerosis and Epilepsy. A Randomized Controlled Trial,COMPLETED,2012-06,2013-12,2014-02,2015-03-25,2012-08-13,INTERVENTIONAL,NA,180.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,Epilepsy Centre Alsterdorf,UNKNOWN,Depression,Depression|Online-Therapy|Deprexis|Self-help,Germany,Hamburg,City state of Hamburg,2,Deprexis|Wait-list,BEHAVIORAL|BEHAVIORAL,Severity of depressive symptoms,quality of life,False,
NCT04367285,Sensor-based Technology for Upper Limb Rehabilitation,Sensor-based Technology for Upper Limb Rehabilitation in Subject With Multiple Sclerosis: a Randomized Controlled Trial,COMPLETED,2017-03-01,2019-11-04,2020-01-31,2020-04-29,2020-04-29,INTERVENTIONAL,NA,35.0,ACTUAL,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Multiple Sclerosis,,Italy,Rome,,1,Sensor-based Training|Upper limb motor training,OTHER|OTHER,Changes in functionality of the upper limb measured in 9 Hole Peg Test (9HPT) at 1 months,Fatigue Level at 1 month|Modified Barthel Index (MBI) at 1 month|Changes in Multiple Sclerosis Quality of Life-54 questionnaire (MSQOL-54)at 1 month|Changes of Medical Research Council scale (MRC) at 1 month,False,
NCT01808885,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,"A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.",COMPLETED,2013-04,2014-01,2014-01,2016-11-22,2013-03-11,INTERVENTIONAL,PHASE1,44.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,Hôpital de la Timone|SGS S.A.|STRAGEN Services,OTHER|INDUSTRY|UNKNOWN,Relapsing Remitting Multiple Sclerosis,safety|multiple sclerosis|olesoxime|double-blind|randomized,France,Marseille,,3,olesoxime (TRO19622)|placebo,DRUG|DRUG,Safety criteria,MRI Parameters,False,
NCT03705364,Fall Prevention Program for Non-ambulatory Wheeled Mobility Device Users Living With MS,Validation of a Fall Prevention Program Among Non-Ambulatory Wheeled Mobility Device Users With Multiple Sclerosis,UNKNOWN,2018-03-01,2020-01-01,2020-01-01,2019-04-04,2018-10-15,INTERVENTIONAL,NA,120.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,wheelchair|non-ambulatory,United States,Atlanta,Georgia,3,Fall Management program,OTHER,Reduction in fall incidence,Management of Fall|Prevention of Fall|Prevention and Management of Fall,False,
NCT00939549,High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,WITHDRAWN,2010-11,2010-11,2010-11,2018-09-26,2009-07-15,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Johns Hopkins University,OTHER,,,Relapsing Remitting Multiple Sclerosis,High dose cyclophosphamide,United States,Baltimore,Maryland,1,Cyclophosphamide/Glatiramer acetate,DRUG,Safety - Serious adverse events,"Radiologic - reduction in the number of gadolinium enhancing lesions, T2 plaque burden, and change in brain parenchymal fraction.|Clinical/Neurological - Change in disability|Immunological - change in immune profile",False,
NCT04934800,Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS),Oral CLADribine in Patients That Change From First-line Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety Study (CLAD CROSS),COMPLETED,2019-12-10,2024-05-20,2024-05-20,2025-06-24,2021-06-22,OBSERVATIONAL,,256.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany",UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Cladribine|MAVENCLAD ®,Austria,Eisenstadt,,61,Cladribine,DRUG,Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period (Baseline) and Over the 12 Months Period Before the End of Study Follow-Up (2 Years),"Change in ARR Between the Pre-Baseline 12-Month Period (Baseline) and Over the 12 Months Period After the Start of Cladribine (1 Year)|Percentage of Participants With 6-Month Disability Progression Measured With Expanded Disability Status Scale (EDSS)|Percentage of Participants With Overall 6-Month Disability Progression Measured With EDSS, Timed 25 Foot Walk (T25FW) or 9 Hole Peg Test (9HPT)|Percentage of Participants With 6-Month Disability Improvement Measured With EDSS|Percentage of Participants With Overall 6-Month Disability Improvement Measured With EDSS, Timed 25 Foot Walk (T25FW) or 9 Hole Peg Test(9HPT)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Quality of Life as Assessed by Multiple Sclerosis Impact Scale (MSIS-29) Score: Physical and Psychological Impact|Quality of Life as Assessed by EuroQol Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D-3L)|Treatment Satisfaction as Assessed by Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM v1.4) Scale|Number of Participants With Treatment Adherence",True,2025-06-24
NCT01766063,"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon","BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients",COMPLETED,2012-12-06,2017-01-09,2017-03-14,2018-02-19,2013-01-11,OBSERVATIONAL,,138.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Sleep|Quality of life|Observational study,Germany,Multiple Locations,,1,"Interferon beta-1b (Betaferon, BAY 86-5046)",DRUG,Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI)|Fatique assessed by the Modified Fatigue Impact Scale (MFIS)|Functional health status assessed by Short Form-36 (SF-36),Daytime sleepiness is measured with the Epworth Sleepiness Scale (ESS)|Depression and anxiety is measured with the Hospital anxiety and depression scale (HADS)|Pain is measured with the Hamburg Pain Adjective List (Hamburger Schmerz Adjektiv Liste (HSAL)|Severity of restless legs syndrome measured with the International Restless Legs Syndrome Study (IRLSS) group rating scale.,False,
NCT05165238,Impact Program for Multiple Sclerosis,Impact of a Four-Week Coaching Program on Dietary Habits in Adults With Multiple Sclerosis,COMPLETED,2022-01-10,2023-09-01,2023-09-01,2023-09-21,2021-12-21,INTERVENTIONAL,NA,30.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis,,United States,Birmingham,Alabama,1,Impact of four week coaching program on dietary habits,BEHAVIORAL,Diet quality|Diet quality,,False,
NCT02131285,Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis,Stabilometric Assessment of Context Dependent Balance Recovery in Persons With Multiple Sclerosis: a Randomized Controlled Study,COMPLETED,2005-01,2007-09,2007-09,2014-05-06,2014-05-06,INTERVENTIONAL,NA,53.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,"Rehabilitation,|Balance,|Sensory strategies,|Multiple Sclerosis,|Postural control",Italy,Milan,,1,Sensory training,OTHER,Change from baseline at three weeks (end of treatment) for the following variables: Length [mm]; Velocity[mm/s]; Sway[mm],Number of falls,False,
NCT00501943,Neuroprotection With Riluzole Patients With Early Multiple Sclerosis,Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis,COMPLETED,2006-07,2012-10,2012-10,2014-04-09,2007-07-16,INTERVENTIONAL,PHASE2,43.0,ACTUAL,"University of California, San Francisco",OTHER,National Multiple Sclerosis Society|Oregon Health and Science University,OTHER|OTHER,Multiple Sclerosis,,United States,San Francisco,California,1,Avonex (Interferon beta 1a)|Riluzole|Placebo,DRUG|DRUG|DRUG,MRI Parameter- Percent Brain Volume Change for 2 Years,Changes in Normalized White Matter Volumes (nWMV)|Changes in MS Functional Composite (MSFC)|Changes in Peripapillary Retinal Nerve Fiber Layer Thickness (RNFL)|Changes in Symbol Digit Modality Test (SDMT)|Changes in Normalized Grey Matter Volume,True,2014-04-09
NCT05351411,Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis,The Effect of Combined Progressive Functional Exercise on Contactin-1 and Contactin-2 Level in Mildly Disabled Persons With Multiple Sclerosis: A Randomized Controlled Trial,COMPLETED,2021-11-01,2022-01-03,2022-03-04,2022-04-28,2022-04-28,OBSERVATIONAL,,60.0,ACTUAL,Firat University,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|exercise|contactin 1|contactin 2,Turkey (Türkiye),Elâzığ,,1,,OTHER,Biomarker - Contactin 1|Biomarker - Contactin 2,Paced Auditory Serial Addition Test with 3-second stimulus (PASAT-3),False,
NCT01028209,Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions,,TERMINATED,2009-11,2010-09-22,2010-09-22,2019-04-03,2009-12-09,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,Institute for Neurodegenerative Disorders,OTHER,,,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,,United States,New Haven,Connecticut,1,[18F] PBR06,DRUG,"To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants.",,False,
NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,"A 3-year, Multi-center Study to Evaluate Optical Coherence Tomography as an Outcome Measure in Patients With Multiple Sclerosis",COMPLETED,2012-05-29,2017-07-24,2017-07-24,2017-11-17,2016-09-20,OBSERVATIONAL,,414.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|RRMS,"Multiple sclerosis,|MS,|Optical coherence tomography|OCT,|RRMS",United States,San Francisco,California,28,Observational,OTHER,Change in Retinal Nerve Fiber Layer Thickness (RNFL),Correlation of change in macular volume with change in brain volume|Assess reproducibility of RNFL thickness on optical coherence tomography|Change in macular volume over 36 months|Correlation of change in RNFL thickness with change in brain volume,False,
NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device,COMPLETED,2013-02-28,2016-02-29,2016-02-29,2017-08-24,2013-02-13,INTERVENTIONAL,PHASE4,93.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis|Relapsing-Remitting,Multiple Sclerosis|Relapsing-Remitting|Rebif|RebiSmart|Patient support program,Germany,Darmstadt,,14,Rebif®,DRUG,Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12,Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 6|Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Total Score at Month 6 and 12|Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Summary Score at Month 6 and 12|Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Visual Analogue Scale (VAS) Scale at Month 6 and 12|Percentage of Subjects With Treatment Adherence at Month 6 and 12|Change From Baseline in Fatigue Severity Scale (FSS) Score at Month 6 and 12|Change From Baseline in Modified Fatigue Impact Scale Score at Month 6 and 12|Change From Baseline in Modified Fatigue Impact Scale Index at Month 6 and 12|Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Month 6 and 12|Number of Subjects With Working Ability at Month 12|Percentage of Subjects With Adverse Events (AE) up to Month 12|Number of Subjects With Response Based on Lifestyle Questionnaire for (MinSupport Plus) at Month 6 and 12|Number of Subjects With Response Based on Subject Satisfaction Questionnaire at Month 12|Number of Subjects With Response Based on Health Care Personnel Satisfaction Questionnaire at Month 12|Number of Subjects With Lifestyle Goals for MinSupport Plus at Month 12,True,2017-07-12
NCT05877963,"Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab","Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )",RECRUITING,2023-06-13,2026-03-01,2026-03-01,2025-09-04,2023-05-26,INTERVENTIONAL,PHASE3,600.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Birmingham,Alabama,41,Ublituximab|Placebo,BIOLOGICAL|DRUG,Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48|Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab,Part A and Part B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)|Part A: Percentage of Participants Free of T1 Gd-Enhancing Lesions|Part A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores,False,
NCT03360487,Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:,"Effect of Photobiomodulation Treatment in the Sublingual Region and Along the Spinal Column in Individuals With Multiple Sclerosis: Protocol for a Randomized, Controlled, Double-blind, Clinical Trial",UNKNOWN,2018-01-01,2018-12-31,2019-02-28,2018-10-11,2017-12-04,INTERVENTIONAL,PHASE2,34.0,ESTIMATED,University of Nove de Julho,OTHER,,,Multiple Sclerosis,,Brazil,São Paulo,São Paulo,1,Photobiomodulation in the sublingual region|Photobiomodulation in the spinal cord|Photobiomodulation in the radial artery,RADIATION|RADIATION|RADIATION,Oxidative stress|Tumor Necrosis Factor Alpha|Interleukin-10,EDSS,False,
NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients,COMPLETED,2018-06-19,2022-04-28,2022-07-05,2023-05-03,2018-02-06,INTERVENTIONAL,PHASE1|PHASE2,59.0,ACTUAL,Johns Hopkins University,OTHER,,,Progressive Multiple Sclerosis,,United States,Baltimore,Maryland,1,Tauroursodeoxycholic Acid|Placebo oral capsule,DRUG|DRUG,Number of Participants With at Least One Treatment-related Adverse Event|Number of Total Treatment-related Adverse Events|Incidence of Treatment-related Adverse Events (AE),Change in Fasting Bile Acid Levels in Plasma|Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study|Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs)|Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument,True,2023-05-03
NCT04577404,Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS),"A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2020-10-29,2023-08-09,2023-08-09,2025-09-08,2020-10-06,INTERVENTIONAL,PHASE3,124.0,ACTUAL,Mitsubishi Tanabe Pharma America Inc.,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),,United States,Phoenix,Arizona,44,MT-1186,DRUG,"Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death|Number of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death",,True,2024-08-28
NCT05658484,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,"A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China",COMPLETED,2023-06-09,2025-03-27,2025-04-12,2025-05-16,2022-12-20,INTERVENTIONAL,PHASE4,60.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,China,Beijing,,15,Dimethyl fumarate,DRUG,Annualized Relapse Rate (ARR),"Change From Baseline in Number of Gadolinium-Enhancing (GdE) Lesions|Number of GdE Lesions|Percentage of Participants GdE-Lesion Free|Percentage of Participants Relapsed|Number of New T1 Hypo-Intense Lesions|Number of New/Newly Enlarging T2 Hyperintense Lesions|Total T2 Lesion Volume|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Change from Baseline in Clinical Laboratory Parameters, Electrocardiogram (ECG), and Vital Signs|Number of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Events",False,
NCT06005909,Current Exercise Approaches in Patients With Multiple Sclerosis,"Investigation of the Effects of Exercises With Mechanical Hippotherapy Device and Cawthorne-Cooksey Exercises on Balance, Dizziness, Fatigue and Quality of Life in Patients With Multiple Sclerosis.",COMPLETED,2022-02-01,2022-05-01,2023-04-30,2023-08-23,2023-08-23,INTERVENTIONAL,NA,50.0,ACTUAL,Uskudar University,OTHER,,,Multiple Sclerosis,Dizziness|Cawthorne-Cooksey|Hippotherapy simulator|Balance|Multiple sclerosis,Turkey (Türkiye),Üsküdar,Istanbul,1,Cawthorne-Cooksey Exercises|Mechanical Hippotherapy Exercises,OTHER|OTHER,Fatigue severity scale|Fatigue Impact Scale|Tinetti balance rating scale|Dizziness disability inventory|Ferrans&Powers quality of life index|Extended disability status scale,,False,
NCT05730738,Dalfampridine in Egyptian Patients With Multiple Sclerosis,"Effect of Dalfampridine on Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple Sclerosis",UNKNOWN,2021-06-01,2023-12-01,2024-12-01,2023-02-16,2023-02-16,INTERVENTIONAL,NA,100.0,ESTIMATED,Ain Shams University,OTHER,,,Multiple Sclerosis,"Multiple sclerosis,|Dalfampridine|Gait|cognition|Fatigue",Egypt,Cairo,,1,"Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|Placebo",DRUG|DRUG,gait|gait|Balance,cognition|fatigue|cognition|Cognition,False,
NCT05691192,Cognitive Reserve-building Activities in Multiple Sclerosis,Cognitive Reserve-building Activities in Multiple Sclerosis: a Randomized Controlled Trial of the Effect of Cognitive Leisure Activities on Objective and Subjective Measures of Cognition,COMPLETED,2022-12-01,2024-11-27,2025-02-12,2025-02-18,2023-01-19,INTERVENTIONAL,PHASE2,60.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,University of Copenhagen,OTHER,Multiple Sclerosis,Cognition|Multiple Sclerosis|Cognitive Rehabilitation|Cognitive Reserve|Cognitive Leisure Activities|Leisure Activities|Intellectual Enrichment|Relapsing-remitting multiple sclerosis|Secondary progressive multiple sclerosis|Progressive multiple sclerosis,Denmark,Glostrup Municipality,,1,Cognitive Leisure Activities,BEHAVIORAL,Change in score on the Symbol Digit Modality Test (SDMT)|Change in score on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ),Change in score on the California Verbal Learning Test II (CVLT II)|Change in score on the Brief Visuospatial Memory Test Revised (BVMT-R)|Change in score on the Word Fluency Test (phonological)|Change in score on the Five-point Test|Change in score on the Cognitive Leisure and Activity Scale (CLAS),False,
NCT04702763,Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography in Patients With Multiple Sclerosis,Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography Data in Patients With Multiple Sclerosis,COMPLETED,2020-10-08,2021-10-30,2021-10-30,2022-01-27,2021-01-11,OBSERVATIONAL,,30.0,ACTUAL,Association de Recherche Bibliographique pour les Neurosciences,OTHER,Centre Hospitalier Princesse Grace|Centre Hospitalier Universitaire de Nice,OTHER|OTHER,Multiple Sclerosis,Demyelinating disease|Multiple Sclerosis|Video-oculography|Eye-Tracking|Eye movements|Subclinical oculomotor abnormalities|Oculomotor disorders,Monaco,Monaco,,1,Eye-Tracker®T2 + e-VOG|e-VOG + Eye-Tracker®T2,OTHER|OTHER,Oculomotor profiles concordance,Latency during horizontal reflex saccades|Latency during vertical reflex saccades|Velocity during horizontal reflex saccades|Velocity during vertical reflex saccades|Inhibition capacity|Internuclear ophthalmoplegia (INO) detection|Fixations impairments detection|Impairment of horizontal smooth pursuit|Impairment of vertical smooth pursuit|Patient acceptability of the e-VOG digital assessment,False,
NCT06809192,Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue,Factorial Optimization Randomized Controlled Trial to Test The Effects of Cognitive Behavioral Therapy Components For Multiple Sclerosis Fatigue,RECRUITING,2025-01-10,2027-07-31,2027-07-31,2025-03-30,2025-02-05,INTERVENTIONAL,NA,112.0,ESTIMATED,University of Washington,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,Fatigue|Multiphase Optimization Strategy|Cognitive Behavioral Therapy|Relaxation|Behavioral Activation|Cognitive Therapy|Optimization|Factorial Trial,United States,Seattle,Washington,1,4-session Relaxation Training|4-session Behavioral Activation|4-session Cognitive Therapy,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Modified Fatigue Impact Scale|PROMIS Short Form - Ability to Participate in Social Roles and Activities,Perceived Stress Questionnaire - Tension scale|Behavioral Activation for Depression Scale Short Form|Fatigue Catastrophizing Scale|The Multiple Sclerosis-Fatigue Self Efficacy Scale|Perceived Stress Scale|Positive and Negative Affect Schedule|PROMIS Emotional Distress-Depression - Short Form 4a|EQ-5D-5L|Global Impression of Change Scale|Global Assessment of Treatment Satisfaction|Treatment Recommendation Question|PROMIS Emotional Distress- Anxiety Short Form 4a|PROMIS Pain Interference Short Form 4a|PROMIS Sleep Disturbance Short Form 4a|Ecological Momentary Assessment of Fatigue Severity and Interference,False,
NCT00376506,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,COMPLETED,2006-07,2010-09,2011-01,2012-10-26,2006-09-15,INTERVENTIONAL,PHASE2,10.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Chronic Dysphagia|Multiple Sclerosis|Parkinson Disease,Aspiration|Rehabilitation|Swallowing Disorders|Stroke|Parkinson's Disease|Dysphagia|Parkinson Disease|PD,United States,Bethesda,Maryland,1,Neurostimulation device for dysphagia|External vibrotactile device,DEVICE|DEVICE,Swallowing Safety for 10 ml of Thin Liquid|Swallowing Safety for 5 ml of Pudding,Penetration-Aspiration Scale for 10 ml Thin Liquid|Penetration-Aspiration Scale for 5 ml Pudding|Functional Oral Intake Scale (FOIS) for Dysphagia|Quality of Life Patient Questionnaire,True,2012-10-26
NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,"A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2010-10,2014-12,2014-12,2016-01-14,2011-08-12,INTERVENTIONAL,PHASE2,97.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,,Japan,Chiba,Chiba,22,natalizumab,DRUG,"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs|Number of Participants With Serum Antibodies to Natalizumab",Adjusted Annualized Relapse Rate|Mean Change From Baseline in the Assessment of Expanded Disability Status Scale (EDSS) up to Week 192,True,2016-01-14
NCT01465087,Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples,"Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples",COMPLETED,2011-12,2014-02,2015-01,2016-06-28,2011-11-04,INTERVENTIONAL,NA,314.0,ACTUAL,Carmel Medical Center,OTHER,"Technion, Israel Institute of Technology",OTHER,Multiple Sclerosis,Multiple Sclerosis|Breath|Diagnosis|Discrimination MS/healthy subj. via exhaled breath samples|Discrimination MS/other neurological and autoimmune diseases,Israel,Haifa,,1,NA-NOSE artificial olfactory system,OTHER,Volatile organic compounds in the exhaled breath,Markers in exhaled breath,False,
NCT06634758,The Effect of the Human Care Model on Patients With Multiple Sclerosis,The Effect Of Nursing Care Based On Watson's Human Care Model On Quality Of Life Of Patients iıth Multıple Sclerosis,ACTIVE_NOT_RECRUITING,2022-05-01,2024-10-28,2024-11-28,2024-10-10,2024-10-10,INTERVENTIONAL,NA,74.0,ACTUAL,Saglik Bilimleri Universitesi,OTHER,,,Nursing Caries,Nursing Care|Multiple Sclerosis|Quality of Life|Watson human care model,Turkey (Türkiye),Ankara,Keçiören,1,Nursing interventions based on the Watson Human Caring Model,BEHAVIORAL,Multiple Sclerosis Quality of Life (MSQOL)-54 scale,,False,
NCT04753411,The 3-Meter Backward Walk Test in Individuals With Multiple Sclerosis,Validity and Reliability of The 3-Meter Backward Walk Test in Individuals With Multiple Sclerosis,UNKNOWN,2021-02-05,2021-04-04,2021-05-04,2021-02-15,2021-02-15,OBSERVATIONAL,,50.0,ESTIMATED,Firat University,OTHER,,,Reliability and Validity,Multiple Sclerosis|Balance|Backward,,,,0,,,3 Meter Backward Walking Test|Berg Balance Scale|Timed Get Up and Go Test|4-Square Step Test,,False,
NCT03878836,Follow-up of Persons With Multiple Sclerosis,"Follow-up of Physical, Psychosocial and Cognitive Influences in Persons With Multiple Sclerosis: a Prospective Cohort Study",UNKNOWN,2016-10-01,2021-08-01,2021-08-01,2019-03-18,2019-03-18,OBSERVATIONAL,,118.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Routine assessments,OTHER,Expanded Disability Status Scale,Timed 25-Foot Walk|Timed Up and Go test|Single Leg Stance Test|6-Minute Walk Test|12-Item Multiple sclerosis walking scale|Modified Fatigue Impact Scale|Epworth Sleepiness Scale|Symbol Digit Modalities Test|California Verbal Learning Test-II|Revised Brief Visuospatial Memory Test|Godin Leisure Time Exercise Questionnaire|Multiple Sclerosis International Quality of Life questionnaire|Beck Depression Inventory|Nine-Hole Peg Test|Nordic Musculoskeletal Questionnaire|painDETECT Questionnaire|International Restless Legs Syndrome Study Group rating scale for restless legs syndrome,False,
NCT01975298,A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).",WITHDRAWN,2014-01,2014-03,2014-03,2021-11-09,2013-11-04,INTERVENTIONAL,PHASE3,0.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,RRMS,,,,0,Laquinimod|Avonex®,DRUG|DRUG,Brain Atrophyas observed by Magnetic Resonance Imaging (MRI),The cumulative number of reported influenza-like symptoms|Cumulative number of new T2 lesions observed by Magnetic Resonance Imaging (MRI) between the 2 laquinimod doses|Summary of Participant with Adverse Events,False,
NCT04975685,Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial,Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial,RECRUITING,2022-02-07,2024-04-30,2024-04-30,2023-12-05,2021-07-23,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Lincoln,OTHER,"University of Exeter|Nottinghamshire Healthcare NHS Trust|National University of Ireland, Maynooth|University of Nottingham",OTHER|OTHER_GOV|OTHER|OTHER,Multiple Sclerosis,,United Kingdom,Nottingham,,1,SMART|Sham brain training (Sudoku),BEHAVIORAL|BEHAVIORAL,Recruitment and retention rates|Completion rates of outcome measures|Intervention drop-out rate,,False,
NCT06429085,"Rex Robot Assisted Rehabilitation to Enhance Balance and Mobility for People With Multiple Sclerosis, Clinical and Biomarker Study - RAPPER IV","Rex Robot Assisted Rehabilitation to Enhance Balance and Mobility for People With Multiple Sclerosis, Clinical and Biomarker Study - RAPPER IV",COMPLETED,2018-12-18,2020-03-31,2020-03-31,2024-05-24,2024-05-24,INTERVENTIONAL,PHASE1,20.0,ACTUAL,East Kent Hospitals University NHS Foundation Trust,OTHER_GOV,Rex Bionics,UNKNOWN,Multiple Sclerosis,Balance|Core stability|Mobility|Powered exoskeleton|Neuro-rehabilitation,United Kingdom,Canterbury,Kent,1,Rex robotic assisted balance exercises,DEVICE,Timed transfer into the Rex device|Completion of sit to stand and stand to sit within the Rex device|Completion of 1 Rex robotic assisted balance rehabilitation exercise session|Screening loss analysis,Timed up and Go|Berg Balance Scale|Visual Analog Scale (Pain)|Modified Falls Efficacy Scale|Activities-specific Balance Confidence scale|Spasticity Impact Scale|EQ-5D-5L|MSIS-29|Joint range of movement|Goal Attainment Scale|Modified Ashworth Scale,False,
NCT06389968,Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis,Lichtstimulation Zur Verbesserung Der Sehleistung Bei Patientinnen Und Patienten Mit Multipler Sklerose Nach Sehnerventzündung,RECRUITING,2024-08-01,2026-12-31,2026-12-31,2024-11-22,2024-04-29,INTERVENTIONAL,NA,50.0,ESTIMATED,Technical University of Munich,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Optic Neuritis",,Germany,Munich,Bavaria,1,Light stimulation|Sham light stimulation,DEVICE|DEVICE,High contrast visual sensitivity,Low contrast visual sensitivity|Visually evoked potentials|Optical coherence tomography|Optical coherence tomographic angiography|Color contrast,False,
NCT00473213,Optimizing IFN Beta - 1B Dose,Optimizing IFN Beta - 1B Dose,COMPLETED,1999-09,,2004-02,2007-05-14,2007-05-14,INTERVENTIONAL,PHASE3,217.0,ACTUAL,"University of Turin, Italy",OTHER,Dimensione Ricerca s.r.l.,OTHER,Multiple Sclerosis,Multiple Sclerosis|Interferon|Magnetic Resonance,,,,0,Interferon Beta 1,DRUG,"the effects of BetaferonR on MRI enhancing lesion frequency are detectable very early.Differently from clinical effects on relapse rate, BetaferonR administration results in an almost immediate reduction of enhancing lesion frequency at MRI.","Monitoring MRI effects (evaluating the number of total active lesions, areas of gadolinium-enhancing, T1 hypointense, and T2 hyperintense lesions)Monitoring clinical effects (relapse frequency and severity, changes in EDSS)",False,
NCT05639517,The Effect of Augmented Reality Based Telerehabilitation Application on Neuromuscular and Sensorimotor Parameters in Multiple Sclerosis Patients,The Effect of Augmented Reality Based Telerehabilitation Application on Neuromuscular and Sensorimotor Parameters in Multiple Sclerosis Patients,UNKNOWN,2023-01-30,2024-09-30,2024-12-15,2023-02-10,2022-12-06,INTERVENTIONAL,NA,30.0,ESTIMATED,Ankara Yildirim Beyazıt University,OTHER,,,Multiple Sclerosis,,,,,0,Augmented Reality Based Telerehabilitation Application|Training face-to-face,OTHER|OTHER,Balance,Muscle Activity|Core Muscle Endurance-Trunk Flexor|Core Muscle Endurance- Trunk Extansor|Core Muscle Endurance- Side Bridge|Trunk Position Sense|Spinal mobility|Fatique-Fatigue Severity Scale|Fatigue- Fatigue Impact Scale,False,
NCT05660187,VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS),Virtual Versus Usual In-office Care for Multiple Sclerosis: A Randomized Trial (VIRTUAL-MS),RECRUITING,2023-03-31,2027-12-31,2027-12-31,2025-04-17,2022-12-21,INTERVENTIONAL,NA,120.0,ESTIMATED,The Cleveland Clinic,OTHER,"University of California, San Francisco|University of Washington",OTHER|OTHER,Multiple Sclerosis,Multiple sclerosis|MS|telehealth|healthcare delivery,United States,San Francisco,California,2,Multiple Sclerosis Clinical Care Delivery via telehealth|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits,OTHER|OTHER,Proportion of patients with disability progression,Change in Patient Satisfaction Questionnaire Short Form (PSQ-18)|Compare major healthcare costs,False,
NCT02318576,Computerized Cognition Testing and Cognitive Motor Interference in MS,Computerized Cognition Testing and Cognitive Motor Interference in MS,COMPLETED,2015-03,2016-03,2016-03,2016-10-26,2014-12-17,INTERVENTIONAL,NA,29.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,Multiple Sclerosis,United States,Urbana,Illinois,1,Cognitive Training,OTHER,Cognitive motor interference meausred by the percent change in walking velocity from single (walking only) to dual task (walking while thinking).,Cognitive Function,False,
NCT00087529,A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis,"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis",COMPLETED,2004-06,2007-10,,2015-09-09,2004-07-13,INTERVENTIONAL,PHASE2|PHASE3,439.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,Multiple Sclerosis,PPMS|Primary progressive MS|Primary progressive multiple sclerosis|Rituxan|MS,,,,0,placebo|rituximab,DRUG|DRUG,Time to Confirmed Disease Progression (CDP)|Percentage of Participants With CDP,Change From Baseline to Week 96 in Total Volume of Transverse Relaxation Time (T2) Brain Lesions on Magnetic Resonance Imaging (MRI) Scan|Change From Baseline to Week 96 in Brain Volume on MRI Scan,True,2015-09-09
NCT03766698,Muscle Architecture of Lower Extremity In Multiple Sclerosis,Muscle Architecture of Lower Extremity In Multiple Sclerosis,COMPLETED,2018-12-18,2020-01-18,2020-02-15,2020-03-18,2018-12-06,OBSERVATIONAL,,35.0,ACTUAL,Sanko University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Muscle Architecture|Lower extremity,Turkey (Türkiye),Gaziantep,,1,,,Muscle Architecture Pennation Angle|Muscle Architecture Muscle Fiber Lengh|Muscle Architecture Muscle Thickness,Muscle Strength|Circumference Measurement of Thigh|Circumference Measurement of shin,False,
NCT02596633,A RCT of Telephone-supported ACT in MS,A Feasibility Randomized Control Trial (RCT) of Telephone-supported Acceptance and Commitment Therapy (ACT) for Low Mood in Multiple Sclerosis (MS),UNKNOWN,2015-01,2016-03,2016-04,2016-02-18,2015-11-04,INTERVENTIONAL,PHASE3,30.0,ACTUAL,University of Nottingham,OTHER,,,Multiple Sclerosis,,,,,0,Telephone-support Acceptance and Commitment Therapy (ACT),BEHAVIORAL,"Feasibility of recruitment, measured with telephone-interviews.|Feasibility of randomisation, measured with telephone-interviews.|Feasibility of psychometric assessment, measured with telephone-interviews.|Feasibility of the self-help book, measured with telephone-interviews.|Feasibility of the telephone-support calls, measured with telephone-interviews.","Effectiveness in reducing anxiety, as measured using online psycho-metrics.|Effectiveness in reducing depression, as measured using online psycho-metrics.|Effectiveness in reducing physical health problems, as measured using online psycho-metrics.|Effectiveness in increasing quality of life, as measured using online psycho-metrics.",False,
NCT06001138,Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study,"FutureMS-2: Clinical, Laboratory, and Genomic Predictors of Disease Activity in People Diagnosed With Relapsing Onset Multiple Sclerosis: an Observational Cohort and Scottish Precision Medicine Study",ENROLLING_BY_INVITATION,2021-10-07,2029-09,2029-09,2025-05-11,2023-08-21,OBSERVATIONAL,,440.0,ESTIMATED,University of Edinburgh,OTHER,NHS Lothian,OTHER_GOV,Multiple Sclerosis,,United Kingdom,Aberdeen,,5,,,Disease activity defined by new or enlarging T2 hyperintense lesion count on MR brain imaging at 5 years and 10 years of diagnosis with relapsing-remitting MS,Disease activity defined by the composite endpoint of new or enlarging T2 hyperintense lesions on MR brain imagingneurodegeneration and regenerative markers of disease activity|clinical relapse at 5 and 10 years of diagnosis with relapsing-remitting MS,False,
NCT01198132,A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly,"A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly",COMPLETED,2009-11,2015-03,2015-11,2017-12-14,2010-09-09,INTERVENTIONAL,PHASE2,129.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono S.A.S, France",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis Relapsing-Remitting|Relapsing Multiple Sclerosis (RMS)|Rebif|Vitamin D3|Cholecalciferol,France,Montpellier,,1,Cholecalciferol (Vitamin D3)|Placebo|Rebif,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DRUG,Annualized Relapse Rate,"Time to First Documented Relapse|Mean Number of Relapses Per Subject|Number of Relapse-Free (Documented) Subjects|Cumulative Probability of Progression of Disability (Kaplan-Meier Curves)|Number of New or Extended Lesions by T1- and T2-Weighted Magnetic Resonance Imaging (MRI)|Changes From Baseline in Measured Lesion Load (T2)|Change From Baseline in Measurement and Evaluation of Cognitive Ability by Paced Auditory Serial Addition Task (PASAT) Total Score At Week 96|Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L)|Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Abnormal Clinical Laboratory",True,2017-12-14
NCT06004518,The Effect of Sexual Counseling With the PLISSIT Model on Sexual Function and Sexual Quality of Life in Women With Multiple Sclerosis: A Randomized Controlled Study,The Effect of Sexual Counseling With the PLISSIT Model on Sexual Function and Sexual Quality of Life in Women With Multiple Sclerosis: A Randomized Controlled Study,UNKNOWN,2023-08-01,2024-10-01,2024-12-01,2023-08-22,2023-08-22,INTERVENTIONAL,NA,86.0,ESTIMATED,Istanbul University,OTHER,,,Multiple Sclerosis|Female Sexual Dysfunction,,Turkey (Türkiye),Istanbul,,1,sexual counselling with PLISSIT model,OTHER,sexual function,sexual quality of life,False,
NCT03335618,Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study,"A First-in-Kind Randomized, Controlled Pilot Clinical Trial Testing Proactive vs Reactive Management of a Symptom Triad in Multiple Sclerosis",COMPLETED,2017-10-01,2019-08-01,2020-03-23,2020-08-20,2017-11-08,INTERVENTIONAL,NA,30.0,ACTUAL,"University of California, San Francisco",OTHER,,,Multiple Sclerosis,Activity|Mood,United States,San Francisco,California,1,Activity Monitoring and Symptom Coaching|Passive Activity Monitoring,OTHER|OTHER,Feasibility of an active symptom monitoring and intervention protocol,Improvement in ambulation symptoms in MS participants|Improvement in mood symptoms in MS participants.|Improvement in bladder symptoms in MS participants.,False,
NCT04988880,Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program,Territorial Implementation and Evaluation of an Expert Patient Program to Improve the Empowerment and Quality of Life of People With Multiple Sclerosis,COMPLETED,2021-11-01,2023-12-31,2024-07-31,2025-05-16,2021-08-04,INTERVENTIONAL,NA,152.0,ACTUAL,Hospital Universitari Vall d'Hebron Research Institute,OTHER,,,Multiple Sclerosis|Quality of Life|Patient Empowerment|Patient Activation|Fatigue|Peer Group,Peer Group|Multiple sclerosis|Patient Empowerment|Quality of life|Patient Activation|Fatigue,Spain,Badalona,Barcelona,6,Multiple Sclerosis Expert Patient Program of Catalonia,OTHER,Number of groups constituted in each unit compared to the number of groups planned.,Change in Quality of life measured by the Multiple Sclerosis Quality of Life 54 items (MSQOL54) from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in emotional impact measured by the Hospital Anxiety and Depression Scale (HADS) from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in fatigue management measured by the Fatigue Severity Scale (FSS) from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in patient activation and engagement measured by the 13-item Patient Activation Measure (PAM-13) from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in patient knowledge measured by the PPEC specific questionnaire about the MS knowledge from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in individuals habits and lifestyles measured by the PPEC specific questionnaire about the habits and lifestyles from beginning of the intervention to end of intervention (9 weeks) and compared to 6 and 12 months after the end of the intervention.|Change in the use of the care services from 1 year pre-intervention to end of intervention (9 weeks) compared to end of intervention (9 weeks) and 12 months after the end of the intervention.|Change in Patient Reported Experience measured from the end of intervention (9 weeks) to 12 months after the end of the intervention.,False,
NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),"A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2009-02-03,2019-11-08,2019-11-08,2020-12-31,2009-02-04,INTERVENTIONAL,PHASE3,1736.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,relapsing|multiple sclerosis|remitting|oral,United States,Birmingham,Alabama,246,dimethyl fumarate|Placebo,DRUG|DRUG,Number of Participants With Treatment-Emergent Adverse Events (AEs),Percentage of Participants Who Had Relapses|Annualized Relapse Rate (ARR)|Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384|Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)|Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)|Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)|Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)|Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)|Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)|Percent Change From Baseline in Brain Atrophy|Percent Change From Baseline in Magnetization Transfer Ratio (MTR)|Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384|Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384|Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384|Change From Baseline in Visual Function Test Scores at Week 384,True,2020-12-31
NCT07087873,Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases,Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases,RECRUITING,2025-05-30,2027-10-31,2027-10-31,2025-07-28,2025-07-28,INTERVENTIONAL,NA,128.0,ESTIMATED,"Xuanwu Hospital, Beijing",OTHER,,,Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System|MS (Multiple Sclerosis)|NMOSD|Acute Disseminated Encephalomyelitis|Transcranial Alternating Current Stimulation,,China,Beijing,Beijing Municipality,1,Neuroelectrical modulation group|Pseudo-neuromodulation group,DEVICE|DEVICE,"Expanded Disability Status Scale, EDSS score|Symbol Digit Modalities Test (SDMT) scale|Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog)",Mini-mental State Examination（MMSE）|Montreal-Cognitive Assessment（MoCA）|Stroop Color-Word Test score|Hamilton Depression Scale，HAMD|Hamilton Anxiety Scale，HAMA|a subjective questionnaire，adverse effects,False,
NCT05482542,Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis,Optimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantation of Relapsing Remitting Multiple Sclerosis,WITHDRAWN,2023-01-01,2027-07-01,2027-07-01,2023-11-09,2022-08-01,INTERVENTIONAL,NA,0.0,ACTUAL,Scripps Health,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Autologous Hematopoietic Stem Cell Transplant,United States,La Jolla,California,1,Autologous hematopoietic stem cell transplantation|Cyclophosphamide/ATG|Cyclophosphamide/Rituximab,OTHER|DRUG|DRUG,Durability of remission between two arms,Neurologic Disability,False,
NCT02234713,Adherence in Pediatric Multiple Sclerosis,Treatment Adherence in Pediatric Multiple Sclerosis,COMPLETED,2013-01,2016-07,2016-09,2020-01-18,2014-09-09,INTERVENTIONAL,NA,71.0,ACTUAL,The Hospital for Sick Children,OTHER,"National Multiple Sclerosis Society|Loma Linda University|University of Pittsburgh|Children's Hospital of Philadelphia|Boston Children's Hospital|Baylor College of Medicine|University of Alabama at Birmingham|Mayo Clinic|University of Colorado, Denver|University of California, San Francisco|Washington University School of Medicine|Alberta Children's Hospital|The Cleveland Clinic|DeltaQuest Foundation",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN,Multiple Sclerosis,,United States,Birmingham,Alabama,13,Motivational Interview|Video Attention Control,BEHAVIORAL|OTHER,Change in Level of Adherence in Subjects (Objective Measure)|Change in Level of Adherence in Subjects (Parent- and Patient-Reported): MSTAQ|Change in Level of Adherence in Subjects (Parent- and Patient-Reported): Morisky|Change in Level of Adherence in Subjects (Parent- and Patient-Reported): Parental Involvement,Quality of Life and Psychosocial Outcomes (Parent- and Patient-Reported): PedsQL|Quality of Life and Psychosocial Outcomes (Parent- and Patient-Reported): MSNQ,True,2020-01-18
NCT06170970,Solriamfetol for the Treatment of Multiple Sclerosis Fatigue,Solriamfetol for the Treatment of Fatigue in Patients With Multiple Sclerosis and Excessive Daytime Sleepiness,RECRUITING,2024-06-01,2026-12-01,2027-03-01,2025-06-11,2023-12-14,INTERVENTIONAL,PHASE2,46.0,ESTIMATED,Johns Hopkins University,OTHER,"National Multiple Sclerosis Society|Axsome Therapeutics, Inc.",OTHER|INDUSTRY,Multiple Sclerosis|Multiple Sclerosis Fatigue,multiple sclerosis|fatigue|daytime sleepiness,United States,Baltimore,Maryland,1,Solriamfetol|Placebo,DRUG|DRUG,Modified Fatigue Impact Scale (MFIS) Score,Fatigue Severity Scale (FSS) Score|Epworth Sleepiness Scale (ESS) Score,False,
NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,"A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.",WITHDRAWN,2007-10,,,2016-08-24,2005-02-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,Bulgaria,Sofia,,39,A4I Antagonist,DRUG,Cumulative number of new gadolinium-enhancing MRI lesions during double-blind treatment period,No. of new active MRI lesions; no. of patients with >=1 objective/subjective MS attack; total no. of MS attacks; no. of patients requiring systemic corticosteroids; change from baseline to wk 12 in EDSS,False,
NCT00668343,Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo,,COMPLETED,2005-04,2008-03,2009-03,2010-07-30,2008-04-29,INTERVENTIONAL,PHASE3,80.0,ESTIMATED,Tehran University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,edss attack,Iran,Tehran,,1,simvastatin|placebo,DRUG|DRUG,attack number,,False,
NCT03101735,Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece,"A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study",COMPLETED,2016-09-23,2020-04-23,2020-04-23,2021-07-28,2017-04-05,OBSERVATIONAL,,455.0,ACTUAL,Genesis Pharma CNS & Specialty,INDUSTRY,,,RRMS,,Greece,Thessaloniki,,1,Dimethyl Fumarate (DMF),DRUG,Total Cost,,False,
NCT03603691,Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With MS,"A Single-centre, Prospective, Cross-sectional Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With Multiple Sclerosis) (MS)",COMPLETED,2018-08-01,2018-12-15,2019-01-29,2019-01-30,2018-07-27,INTERVENTIONAL,NA,28.0,ACTUAL,Nanco van der Maas,OTHER,"University Hospital, Basel, Switzerland|Physiotherapie Langmatten Binningen, Switzerland|Clinical Trial Unit, University Hospital Basel, Switzerland",OTHER|UNKNOWN|OTHER,Multiple Sclerosis,,Switzerland,Basel,,1,Modified Manual Muscle Test|BMRC manual muscle test|MicroFET2 handhold dynamometer|Modified Tardieu Scale|Fatigue Scale for Motor and Cognitive Functions|numeric rating scale Fatigue,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Inter-rater reliability Modified Manual Muscle Test,Intra-rater reliability Modified Manual Muscle Test|Validity of the Modified Manual Muscle Test|Modified Tardieu Scale level,False,
NCT01981161,Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis,"Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques",COMPLETED,2013-11-19,2018-06-20,2018-11-30,2020-08-25,2013-11-11,OBSERVATIONAL,,307.0,ACTUAL,"University Hospital, Toulouse",OTHER,European Commission,OTHER,Multiple Sclerosis,progressive multifocal leucoencephalopathy|JC virus|Zoster infection,France,Besançon,,12,biological samples and clinical data,PROCEDURE,Disease free patients,comparing the efficacy of Natalizumab with that of Fingolimod with regard to the annual incidence rate (comparison against the annual incidence rate criterion after 1 year,False,
NCT04496531,Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis,Examining the Efficacy of Non-invasive Neuromodulation in Reducing Symptoms of Multiple Sclerosis - a Pilot Study,COMPLETED,2014-12,2016-08,2016-08,2020-08-05,2020-08-03,INTERVENTIONAL,NA,14.0,ACTUAL,Helius Medical Inc,INDUSTRY,McGill University,OTHER,Multiple Sclerosis,,,,,0,Portable Neuromodulation Stimulator,DEVICE,Dynamic Gait Index,,False,
NCT03840928,PatientSpot Formerly Known as ArthritisPower,,RECRUITING,2015-04-01,2025-03-01,2025-03-01,2023-12-13,2019-02-15,OBSERVATIONAL,,40000.0,ESTIMATED,Global Healthy Living Foundation,OTHER,University of Alabama at Birmingham,OTHER,Rheumatoid Arthritis|Ankylosing Spondylitis|Fibromyalgia|Gout|Crohn Disease|Juvenile Idiopathic Arthritis|Lupus Erythematosus|Myositis|Osteoarthritis|Osteoporosis|Psoriasis|Psoriatic Arthritis|Scleroderma|Dermatomyositis|Inflammatory Bowel Diseases|Polymyositis|Axial Spondyloarthritis|Diffuse Idiopathic Skeletal Hyperostosis|Polymyalgia Rheumatica|Giant Cell Arteritis|Temporal Arteritis|Wegener|Relapsing Polychondritis|Undifferentiated Connective Tissue Disease|Spinal Cord Injuries|Alzheimer Disease|Amyotrophic Lateral Sclerosis|Ataxia|Bell Palsy|Brain Tumor|Cerebral Aneurysm|Epilepsy|Guillain-Barre Syndrome|Headache|Head Injury|Hydrocephalus|Lumbar Disc Disease|Meningitis|Multiple Sclerosis|Muscular Dystrophy|Neurocutaneous Syndromes|Parkinson Disease|Stroke|Cluster Headache|Tension-Type Headache|Chronic Obstructive Pulmonary Disease|Asthma|Lung Cancer|Cystic Fibrosis|Sleep Apnea|Eczema|Alopecia|Chronic Inflammation|Unstable Angina|Heart Attack|Heart Failure|Arrythmia|Valve Heart Disease|High Blood Pressure|Congenital Heart Disease|Peripheral Arterial Disease|Diabetes|Chronic Liver Disease|Obesity,,United States,Upper Nyack,New York,1,,,Pain Interference (PROMIS)|Fatigue (PROMIS)|Sleep Disturbance (PROMIS)|Physical Function (PROMIS)|RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),,False,
NCT04777539,Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis,Assessing the Safety and Benefit of Home-hospitalization Program in the Management of Natalizumab (Tysabri®) Medication in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-06-14,2024-11-15,2025-05-15,2024-03-19,2021-03-02,OBSERVATIONAL,,279.0,ACTUAL,Nantes University Hospital,OTHER,Rennes University Hospital,OTHER,Multiple Sclerosis (MS),At-home hospitalization (HAD)|Natalizumab|Safety|Medico-economic data|Multiple sclerosis,France,Strasbourg,Bas-Rhin,24,At-home natalizumab treated MS patient,OTHER,Number of serious Adverse events (SAE) and selected adverse events (AEs) of grade 2,Annualized Relapse Rate|Change from baseline in T2 lesion load as assessed by MRI|Change from baseline in gadolinium positive lesion as assessed by MRI|Multiple Sclerosis International quality of Life (MusiQoL)|EuroQol-5Dimension 5Level (EQ-5D-5L)|Musicare|Patient experience|Clinical Global impressions of improvement (CGI-I)|The average cost per patient,False,
NCT01281657,Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program,"A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program",COMPLETED,2011-02,2012-07,2012-07,2012-09-06,2011-01-24,OBSERVATIONAL,,64.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,Fingolimod|FTY720|Relapsing forms of multiple sclerosis|Multiple sclerosis|MS|Safety|Efficacy,United States,Cullman,Alabama,58,fingolimod,DRUG,Long-term safety data in patients with relapsing forms of multiple sclerosis who have participated in clinical trials with fingolimod and who are now taking prescribed fingolimod under the conditions of routine medical practice,"Long-term effectiveness data, particularly including clinical disease and patient outcome related parameters such as relapse and disability",False,
NCT04031469,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease,SUSPENDED,2019-07-11,2030-07-10,2030-12-10,2025-07-31,2019-07-24,OBSERVATIONAL,,1000.0,ESTIMATED,ProgenaBiome,OTHER,,,"Gut Microbiome|Gastrointestinal Microbiome|Autism|Autism Spectrum Disorder|Autism Spectrum Disorder High-Functioning|Alzheimer Disease|Alzheimer Dementia (AD)|Alzheimer Dementia|Alzheimer Disease (AD)|Crohn|Crohn Colitis|Crohn Disease (CD)|Crohn Disease Colon|Myalgic Encephalomyelitis|ME/CFS|Myalgic Encephalomyelitis (ME)|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|Psoriasis|Psoriasis Annularis|Psoriasis Chronic|Chronic Urinary Tract Infection|Ulcerative Colitis (Disorder)|Ulcerative Colitis (UC)|Ulcerative Colitis Acute|Ulcerative Colitis Chronic|Multiple Sclerosis|Multiple Sclerosis (MS) - Relapsing-remitting|Multiple Sclerosis (MS) Primary Progressive|Constipation Chronic Idiopathic|Constipation|Celiac|Celiac Disease|Celiac Sprue|Lyme Arthritis|Lyme Borreliosis, Nervous System|Lyme Disease, Chronic|Cholesterol|Cholesterol Level, High|Cancer|Colon Cancer|Amyotrophic Lateral Sclerosis (ALS)|Amyotrophic Lateral Sclerosis|Rheumatoid Arthritis (RA)|Rheumatoid Arthritis - Rheumatism|Chronic Fatigue Syndrome (CFS)|PARKINSON DISEASE (Disorder)|Parkinson Disease|Parkinson Disease (PD)|Depression|Major Depressive Disorder (MDD)|Depression Disorder|Depression in Adults|Anxiety|Anxiety Disorder Generalized|Obsessive Compulsive Disorder (OCD)|Obsessive Compulsive Disorder OCD|Obsessive - Compulsive Disorder|Bipolar|Bipolar 1 Disorder|Bipolar Disorder (BD)|Bipolar Disorder I and II|Bipolar and Related Disorders|Migraine|Migraine Disorder|Diabetes (DM)|Diabetes|Lupus|Lupus Erythematosus|Epidermolysis Bullosa (EB)|Mesothelioma|Mesothelioma Malignant|IBS (Irritable Bowel Syndrome)|Irritable Bowel|IBS - Irritable Bowel Syndrome|Irritable Bowel Syndrome (IBS)|Eczema|Eczema Atopic Dermatitis|Acne|Myasthaenia Gravis|Gout",Microbiome|autism|ASD|Myalgic encephalomyelitis|ME/CFS|Psoriasis|Chronic UTI|Chronic Urinary Tract Infection|Ulcerative Colitis|UC|Multiple Sclerosis|MS|Chronic Constipation|Constipation|Celiac disease|Celic Sprue|Lyme disease|Elevated Cholesterol|Colorectal Cancer|Cancer|Amyotrophic Lateral Sclerosis|ALS|Rheumatoid Arthritis|RA|Chronic Fatigue|Alzheimer disease|Chrohns colitis|Crohn|Alzheimer|Parkinson|depression|major depressive disorder|OCD|Obsessive-Compulsive disorder|Biopolar|Bipolar disorder|Migraine|Migraine headache|Diabetes|DM|Diabetes DM|Lupus|Lupus eruthematosus|Epidermolysis Bullosa|Mesothelioma|IBS|Irritable Bowel Syndrome|Eczema|Acne|Myasthenia Gravis|Gout,United States,Ventura,California,1,There is no intervention in this study,OTHER,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,Validation of Sequencing Methods,False,
NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis","A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.",COMPLETED,2008-12,2010-03,2010-03,2016-02-26,2008-12-19,INTERVENTIONAL,PHASE2,405.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis,United States,Bridgewater,New Jersey,7,Nerispirdine|placebo,DRUG|DRUG,Responder criterion based on consistency of improved response in walking speed on the Timed 25-Foot Walk (T25-FWT),Change from baseline to endpoint in the 12-item MS Walking Scale (MSWS-12),False,
NCT03108573,Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters,Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters,COMPLETED,2012-12-12,2013-07-31,2013-07-31,2017-04-11,2017-04-11,OBSERVATIONAL,,27.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,,,,0,,,Number of detectable lesions,localisation of lesions,False,
NCT01195857,Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration,Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration,COMPLETED,2009-01,2009-09,2009-09,2014-02-04,2010-09-06,OBSERVATIONAL,,100.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono Limited, UK",INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Rebif|Interferon beta-1a,,,,0,,,Percentage of subjects who correctly use the Rebiject II injection device based on reaching all correct injection steps as assessed by a nurse,Most common 3 steps for error with the Rebiject II injection device out of the ten step checklist|Correlation with recent training within the last 6 months|Correlation with disease control (relapse rate)|Length of time on treatment|Presence of injection site reactions|Cognitive impairment,False,
NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,"A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy",COMPLETED,2011-05,2015-09,2015-09,2017-03-21,2011-04-12,INTERVENTIONAL,PHASE4,151.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|cognitive symptoms|relapsing-remitting multiple sclerosis (RRMS)|fingolimod|Magnetic resonance imaging (MRI),Germany,Alzenau in Unterfranken,,26,Fingolimod|Interferon beta 1b,DRUG|DRUG,"Change From Screening in Selective Reminding Test - Long-Term Storage (SRT-LTS) Raw Score|Change From Screening in Selective Reminding Test - Consistent Long Term Retrieval (SRT-CLTR) Raw Score|Change From Screening in Spatial Recall Test (SPART) Raw Score|Change From Screening in Symbol Digit Modalities Test (SDMT) Raw Score|Change From Screening in Paced Auditory Serial Addition Test - 3 Seconds (PASAT 3) Raw Score|Change From Screening in Paced Auditory Serial Addition Test - 2 (PASAT 2) Raw Score|Change From Screening in Selective Reminding Test - Delayed Recall (SRT-D) Raw Score|Change From Screening in Spatial Recall Test - Delayed Recall (SPART-D)|Change From Screening in Word List Generation (WLG)|Change From Screening in Delis-Kaplan Executive Function System (DKEFS) Condition 1: Free Sorting, Confirmed Correct Sort- Card Set 1+2|Change From Screening in DKEFS Condition 1: Free Sorting, Free Sorting, Description Score, Card Set 1+2|Change From Screening in DKEFS Condition 2: Sort Recognition, Sort Recognition Description Score- Card Set 1+2","Change From Screening in the Volume of Total T2 Lesions|Change From Screening in Montgomery-Asberg Depression Rating Scale (MADRS)|Changes in Quality of Life, by Means of the Multiple Sclerosis Quality of Life (MSQoL-54)|Changes From Baseline in Fatigue Impact Scale (mFIS, Total Score and Scores of the 3 Individual Domains).|Change From Screening in the Number of New T2 Lesions|Change From Screening in the Volume of Total T1 Hypointense Lesions|Change From Screening in the Number of T1 Gd+ Enhancing Lesions|Change From Screening in the Percentage of Brain Volume Change|Changes in the Environmental Status Scale Score (ESS)",True,2017-03-21
NCT00168701,Efficacy and Safety of BG00012 in MS,"Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2004-10-01,2006-03-31,2006-03-31,2023-08-28,2005-09-15,INTERVENTIONAL,PHASE2,260.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MRI,Czechia,Bmo,,42,BG00012,DRUG,"The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.","The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12 weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.",False,
NCT04856345,Running Title: Walking to Music and in Silence on a Treadmill,"The Effect of a 4 Week Auditory-motor Coupling Intervention on Walking, Information Processing Speed and Fatigue in Persons With Multiple Sclerosis: Three Armed Pilot Intervention",COMPLETED,2021-01-22,2023-12-31,2023-12-31,2024-04-25,2021-04-23,INTERVENTIONAL,NA,5.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt,OTHER,Multiple Sclerosis,,Belgium,Overpelt,,1,Walking with music with synchronisation|Walking with music without synchronisation|walking without music,OTHER|OTHER|OTHER,12- item multiple sclerosis walking scale|12- item multiple sclerosis walking scale|6 minutes walking test to calculate the distance walking Index|6 minutes walking test to calculate the distance walking Index|12 minute walking with sensors|12 minute walking with sensors,"Paced auditory serial addition test and symbol digit modality test|Paced auditory serial addition test and symbol digit modality test|Motricity Index of dorsi flexors, knee extensors and hip flexors|Motricity Index of dorsi flexors, knee extensors and hip flexors|Modified Aschowrth scale Hamstrings, Tricepts Surae, Quadricepts|Modified Aschowrth scale Hamstrings, Tricepts Surae, Quadricepts|Scale for the assessment and rating of ataxia|Scale for the assessment and rating of ataxia|Dynamic gait index|Dynamic gait index|Time up and Go test|Time up and Go test|Modified fatigue impact scale|Modified fatigue impact scale|Barcelona music reward questionnaire|Barcelona music reward questionnaire|Hospital anxiety and depression questionnaire|Hospital anxiety and depression questionnaire|Activities-specific balance confidence scale|Activities-specific balance confidence scale|Stroke rehabilitation motivation scale|Stroke rehabilitation motivation scale|the Brunnel Music Rating Inventory-2|the Brunnel Music Rating Inventory-2|credibility and expectations questionnaire|Pre and Post training sessions, 2x a week, 20 minutes for 4 weeks",False,
NCT05835622,Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.,Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients With Gait Disorders.,RECRUITING,2024-02-01,2026-10,2026-10-02,2025-04-09,2023-04-28,INTERVENTIONAL,NA,28.0,ESTIMATED,Pôle Saint Hélier,OTHER,,,Multiple Sclerosis,,France,Saint-Genis-Laval,Auvergne-Rhône-Alpes,6,Keeogo|adviced home practice,DEVICE|OTHER,"Evolution of the quality of life assessed with the ""Functional Assessment Of Multiple Sclerosis"" questionnaire (change between two time points)","Walking and balancing performance with the Keeogo exoskeleton (1)|Walking and balancing performance with the Keeogo exoskeleton (2)|Walking and balancing performance with the Keeogo exoskeleton (3)|Walking and balancing performance with the Keeogo exoskeleton (4)|Walking and balancing performance with the Keeogo exoskeleton (5)|Walking and balancing performance with the Keeogo exoskeleton (6)|Spasticity of the quadriceps, hamstrings and abductors muscles|Sense of self-efficacy|The average daily distance travelled|Fatigue|Anxiety and depression|Satisfaction with this new home technical aid|Projection in use|Walking and balancing performance without exoskeleton (1)|Walking and balancing performance without exoskeleton (2)|Walking and balancing performance without exoskeleton (3)|Walking and balancing performance without exoskeleton (4)|Walking and balancing performance without exoskeleton (5)|Walking and balancing performance without exoskeleton (6)",False,
NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®,COMPLETED,2014-10-20,2016-07-19,2016-11-08,2017-11-07,2014-09-25,OBSERVATIONAL,,498.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing Remitting",,Austria,Many Locations,,11,"Interferon beta-1b (Betaferon®, BAY 86-5046)|BETACONNECT",DRUG|DEVICE,Adherence to therapy at the final visit.,Satisfaction with and evaluation of the BETACONNECT auto-injector|Injection site pain and prophylactic analgesic use|Health related quality of life|Anxiety|Depression|Fatigue|Cognition|Local skin reactions|Injection-related specifics,False,
NCT04793087,Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON),Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis in Patients Presenting With Acute Visual Loss and Otherwise Normal Ophthalmological Examination,COMPLETED,2018-01-01,2018-01-01,2020-08-30,2021-03-15,2021-03-11,OBSERVATIONAL,,1200.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Optic Neuritis|Multiple Sclerosis,,France,Paris,Île-de-France Region,1,Magnetic Resonance Imaging,DIAGNOSTIC_TEST,Detection of optic neuropathies using MRI,,False,
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2007-08,2011-04,2011-04,2014-11-24,2007-09-17,INTERVENTIONAL,PHASE3,581.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,Bayer,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis,United States,Cullman,Alabama,101,Alemtuzumab|Interferon beta-1a,BIOLOGICAL|BIOLOGICAL,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate,Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,True,2014-11-24
NCT04338022,Study of Evobrutinib in Participants With RMS (evolutionRMS 1),"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1)",TERMINATED,2020-06-12,2023-10-02,2024-03-08,2025-06-12,2020-04-08,INTERVENTIONAL,PHASE3,1124.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,Relapsing Multiple Sclerosis,Evobrutinib|Teriflunomide|Aubagio®|Relapsing Multiple Sclerosis,United States,Mobile,Alabama,279,Teriflunomide|Evobrutinib,DRUG|DRUG,Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)|Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEs,"DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156|DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156|DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions|DBTP and DBE Period: New or Enlarging T2 Lesions Rate|DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12|DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)|DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity|DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure|DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate|DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate|DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight|DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature|DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate|DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameters: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate|DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine|DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine|DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels|DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels|OLE Period: Annualized Relapse Rate (ARR)|OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)|OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)|OLE Period: Symbol Digit Modalities Test (SDMT)|OLE Period: Change From Baseline in PROMISnq Physical Function (PF) Multiple Sclerosis (MS) 15a at Week 52|OLE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue (MS) 8a Score at Week 52|OLE Period: Number of Participants With Abnormalities in Laboratory Parameters|OLE Period: Number of Participants With Abnormalities in Vital Signs|OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings|OLE Period: Number of New or Enlarging T2 Lesions|OLE Period: Change From Baseline in T2 Lesion Volume",True,2025-06-12
NCT01219647,Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis,Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis,COMPLETED,2010-07,2014-08,2014-08,2014-12-09,2010-10-13,INTERVENTIONAL,PHASE1|PHASE2,35.0,ACTUAL,"University of California, Los Angeles",OTHER,"California State University, Northridge",OTHER,Multiple Sclerosis,Multiple Sclerosis|Exercise|Cognition,United States,Los Angeles,California,2,exercise|stretching,BEHAVIORAL|BEHAVIORAL,Paced Auditory Serial Addition Test (PASAT),Symbol Digit Modalities Test (SDMT)|VO2 max|Long latency cognitive event related potentials ( LLCERP),False,
NCT05446285,Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE,Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE,UNKNOWN,2022-02-07,2023-08,2023-08,2022-07-25,2022-07-06,OBSERVATIONAL,,245.0,ESTIMATED,NHS Greater Glasgow and Clyde,OTHER,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,United Kingdom,Glasgow,,1,Clinical assessment,OTHER,Mean Expanded Disability Status Scale (EDSS) score at prospective assessment.,"Proportion experiencing (serious) adverse events in first 9-10 years after diagnosis|Proportion attaining Expanded Disability Status Scale (EDSS) 3.0, 4.0 and 6.0|Mean change in Expanded Disability Status Scale (EDSS) between treatment groups|Mean scores on patient reported outcome measure Multiple Sclerosis Impact Scale -29 (MSIS-29) at prospective assessment|Mean Brief International Cognitive Assessment for MS (BICAMS) score at prospective assessment|Mean 9-Hole Peg Test (9-HPT) at prospective assessment",False,
NCT05732285,A Pilot Randomized Controlled Trial: CoINTEGRATE,A Pilot Randomized Controlled Trial of A Comprehensive Cognitive and Affective Intervention for Neurocognitive Disorders (CoINTEGRATE),RECRUITING,2023-09-01,2025-09-01,2026-03-30,2025-06-15,2023-02-17,INTERVENTIONAL,NA,56.0,ESTIMATED,University of Michigan,OTHER,,,Neurocognitive Disorders|Cognitive Dysfunction|Traumatic Brain Injury|Multiple Sclerosis|Mild Cognitive Impairment,Affective Dysfunction|Cognitive Behavioral Therapy|Modifiable lifestyle factors|Cognitive Rehabilitation Therapy|Long COVID (coronavirus disease),United States,Ann Arbor,Michigan,1,CRT|CBT|Modifiable lifestyle factors|Usual care Psychoeducation,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Number of patients that complete the study|Average number of sessions completed|Overall experience based qualitative semi-structured interview,The Community Integration Questionnaire (CIQ) Score|The Short Form Health Survey (SF-36)|Montreal Cognitive Assessment (MoCA)|The Symbol Digit Modalities Test Score (SDMT-5 minutes)|Brief Visuospatial Memory test (BVMT-R-25 minutes)|California Verbal Learning Test-Third Edition (CVLT-3-60 minutes)|The Memory Complaint Scale (MCS-2 minute) score,False,
NCT02649985,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease,UNKNOWN,2016-05-02,2021-12-31,2021-12-31,2020-12-11,2016-01-08,INTERVENTIONAL,PHASE1|PHASE2,105.0,ESTIMATED,Brigham and Women's Hospital,OTHER,,,Multiple Sclerosis|Alzheimer's Disease,,United States,Boston,Massachusetts,1,[F-18]PBR06|[C-11]PBR28,DRUG|DRUG,Tissue Volume of Distribution,Standardized uptake values (SUV)/Standardized uptake value Ratios (SUVR),False,
NCT00381576,Multiple Sclerosis and Heavy Progressive Resistance Training,Multiple Sclerosis and Muscle Function - Effects of Heavy Progressive Resistance Training,COMPLETED,2006-11,2008-03,2008-06,2008-08-12,2006-09-28,INTERVENTIONAL,NA,36.0,ESTIMATED,University of Aarhus,OTHER,Sonderborg Hospital|The Danish Multiple Sclerosis Society,OTHER_GOV|UNKNOWN,Multiple Sclerosis,Resistance training|Strength training|Training adaptations|CNS,Denmark,Aarhus,,2,Resistance training,BEHAVIORAL,Muscle strength (isokinetic testing),"Functional capacity (Six minute walk test, 10m walk test, chair rise, stair climbing)|Muscle biopsies from m. vastus lateralis|% Fat (skinfold)|Blood samples (immunologic parameters)|Fatigue (Fatigue Severity Scale - FSS, Modified Fatigue Inventory - MFI-20)|HRQOL: SF36|Depression: Major Depression Inventory (MDI)|Surface EMG from m. vastus lateralis during MVC",False,
NCT05131984,Ocrelizumab Access by Socio-Economic Status,"Ocrelizumab Treatment Access and Outcomes by Gender, Race, and Socio-economic Status in Multiple Sclerosis Patients: Real World Investigation",UNKNOWN,2021-11-15,2022-07-01,2022-10-01,2021-11-23,2021-11-23,OBSERVATIONAL,,600.0,ESTIMATED,Brigham and Women's Hospital,OTHER,"Genentech, Inc.|Boston Medical Center",INDUSTRY|OTHER,Multiple Sclerosis,,United States,Boston,Massachusetts,1,Ocrelizumab,DRUG,Time to treatment initiation,Annualized relapse rate|MRI Changes,False,
NCT05544448,"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","n Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases",UNKNOWN,2022-10-15,2023-04-15,2023-04-15,2022-09-16,2022-09-16,INTERVENTIONAL,NA,90.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Autoimmune Diseases|Inflammatory Disease|Acquired Bone Marrow Aplasia|Systemic Lupus Erythematosus|Multiple Sclerosis|Gvhd|Rheumatoid Arthritis|Autoimmune Thyroiditis|Vitiligo|Alopecia|Atopic Dermatitis,"Autoimmune Diseases|Inflammation|Graft vs Host Disease|T-lymphocytes, Regulatory|Interleukin-2",,,,0,Blood sample taken at a single time point,OTHER,the percentage of phosphorylated STAT5 in LTresg compared to LTconv after incubation with IL-2 muteins,,False,
NCT06459232,"Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies","Baseline Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With FDA-approved Disease-Modifying Therapies",COMPLETED,2020-11-19,2021-12-17,2021-12-17,2024-06-14,2024-06-14,OBSERVATIONAL,,143.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Number of Patients with a Minimum of 6 Months Follow-up by Disease-Modifying Therapy (DMT) Use|Number of Patients with a Minimum of 12 Months Follow-up by DMT Use,Mean Age|Number of Patients with a Minimum of 6 Months Follow-up by Age Group|Number of Patients with a Minimum of 12 Months Follow-up by Age Group|Number of Patients with a Minimum of 6 months Follow-up by Gender|Number of Patients with a Minimum of 12 months Follow-up by Gender|Number of Patients with a Minimum of 6 Months Follow-up by Geographical Region|Number of Patients with a Minimum of 12 Months Follow-up by Geographical Region|Number of Patients with a Minimum of 6 Months Follow-up by Insurance Plan Type|Number of Patients with a Minimum of 12 Months Follow-up by Insurance Plan Type|Number of Patients with a Minimum of 6 Months Follow-up by Health Plan Type|Number of Patients with a Minimum of 12 Months Follow-up by Health Plan Type|Percentage of Patients with MS Relapses|Mean Charlson Comorbidity Index (CCI) Score|Percentage of Patients with a Minimum of 6 Months Follow-up by Disability Level|Percentage of Patients with a Minimum of 12 Months Follow-up by Disability Level|Percentage of Patients with a Minimum of 6 Months Follow-up by Most Observed Comorbidities|Percentage of Patients with a Minimum of 12 Months Follow-up by Most Observed Comorbidities|Number of Patients with a Minimum of 6 Months Follow-up by Type of Prior Disease-Modifying Therapy (DMT)|Number of Patients with a Minimum of 12 Months Follow-up by Type of Prior DMT|Mean Proportion of Days Covered (Adherence) for Patients with a Minimum of 6 Months Follow-up|Mean Proportion of Days Covered (Adherence) for Patients with a Minimum of 12 Months Follow-up,False,
NCT03783585,Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis,Assessment of the Feasibility of a Web-based CBT-I Intervention to Improve Sleep Quality and Fatigue in Individuals With Multiple Sclerosis,COMPLETED,2018-10-01,2019-08-20,2019-08-20,2019-08-28,2018-12-21,INTERVENTIONAL,NA,44.0,ACTUAL,University of Kansas Medical Center,OTHER,,,Multiple Sclerosis,,United States,Kansas City,Kansas,1,Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia + biweekly support,BEHAVIORAL|BEHAVIORAL,change in Insomnia Severity Index (ISI),change in Pittsburgh Sleep Quality Index (PSQI)|change in Modified Fatigue Impact Scale (MFIS)|change in Fatigue Severity Scale (FSS)|change in Multiple Sclerosis Impact Scale (MSIS),False,
NCT02833714,Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.,Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.,TERMINATED,2016-01,2016-12-21,2016-12-21,2017-09-15,2016-07-14,OBSERVATIONAL,,26.0,ACTUAL,"University of North Carolina, Chapel Hill",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,RELAPSING REMITTING MULTIPLE SCLEROSIS,,United States,Chapel Hill,North Carolina,1,,,Percent Inhibition of activated/memory B-cells derived from RRMS patients.,Change in Cytokine Secretion Profile of T-cells stimulated by teriflunomide treatment|Measure the effect of oral teriflunomide on the cytokine secretion as measured in the ex-vivo obtained longitudinal samples from the treated patients.|Measure the effect of oral teriflunomide on the B cell activation as measured in the ex-vivo obtained longitudinal samples from the treated patients.,False,
NCT03944538,Physical Activity Intervention for Improving Vascular Comorbidity Risk in Multiple Sclerosis,Physical Activity Intervention for Improving Vascular Comorbidity Risk in Multiple Sclerosis,TERMINATED,2019-07-21,2020-10-20,2020-10-20,2023-05-30,2019-05-09,INTERVENTIONAL,NA,5.0,ACTUAL,University of Ottawa,OTHER,University of Illinois at Chicago|National Multiple Sclerosis Society,OTHER|OTHER,Multiple Sclerosis,Exercise|Fitness|Co-morbidity,Canada,Ottawa,Ontario,1,Lifestyle Physical Activity|General Wellness,BEHAVIORAL|BEHAVIORAL,Change in Cardiorespiratory Fitness,Change in Blood Pressure|Change in Body Composition|Change in Blood Glucose|Change in Insulin Resistance|Change in Triglycerides and Cholesterols,False,
NCT03806387,Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment,Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study,COMPLETED,2017-03-01,2020-07-30,2021-06-30,2023-09-06,2019-01-16,OBSERVATIONAL,,17.0,ACTUAL,University of Aarhus,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,,Denmark,Aarhus,Jutland,1,Alemtuzumab,DRUG,Six minute walking test (6MWT),Six minute walking test (6MWT)|Timed 25 foot walk (T25FWT)|5 times sit to stand test (5STS)|Timed Up and Go (TUG)|Stair Climbing test|Six Spot Step Test (SSST)|Maximal oxygen uptake (VO2 max)|Maximal muscle strength|Neuromuscular activation|Body composition - limb lean mass|Body composition - limb fat mass|Body composition - whole body lean mass|Body composition - whole body fat mass|Selective Reminding Test (SRT)|Symbol Digit Modalities Test (SDMT)|Physical activity|Clinical Severity of Disease|Relapse frequency|12-item Multiple Sclerosis Walking Scale (MSWS-12)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Impact Scale (MSIS-29)|Hospital Anxiety and Depression Scale (HADS),False,
NCT01080014,Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina,The Multiple Sclerosis Functional Composite (MSFC) in the Follow-up of MS Patients: Correlation With the Expanded Disability Status Scale (EDSS) Among Different Clinical Forms in Argentina,COMPLETED,2008-08,2013-04,2013-04,2013-10-16,2010-03-03,OBSERVATIONAL,,252.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Relapsing-remitting multiple sclerosis (RRMS)|primary progressive multiple sclerosis (PPMS)|secondary progressive multiple sclerosis (SPMS)|Multiple Sclerosis Functional Composite (MSFC)|Expanded Disability Status Scale (EDSS),Argentina,Buenos Aires,,1,,,- Evaluation of correlations between changes over time,To evaluate the predictive validity of MSFC score of a subsequent EDSS change in a subgroup of MS patients,False,
NCT01456416,Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities,Pilot Study for Evaluation of Glatiramer Acetate in RRMS Patients With Comorbid Autoimmune Conditions,COMPLETED,2011-09,2013-04,2013-04,2013-04-04,2011-10-20,OBSERVATIONAL,,10.0,ACTUAL,University of Southern California,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Relapsing Remitting Multiple Sclerosis,RRMS|Multiple Sclerosis|Glatiramer Acetate|Autoimmune Comorbidities|Psoriasis|Autoimmune Thyroiditis|Vasculitis|Rheumatoid Arthritis,United States,Los Angeles,California,1,,,Change from Baseline in Clinical Global Impression Scale (CGI-1).,Secondary objectives include Visual Analog Scale (VAS).|Secondary objectives include Expanded Disability Status Scale (EDSS)|Secondary objectives include concomitant medication review.,False,
NCT05718947,Ultra-high-field Brain MRI in Multiple Sclerosis,Multiple Sclerosis Lesion Characterization on Ultra-high-field MRI: Comparative Pilot Study of 9.4 Vs 7 Vs 3 Tesla,COMPLETED,2023-09-12,2024-06-17,2024-06-17,2024-09-19,2023-02-08,OBSERVATIONAL,,10.0,ACTUAL,Zuyderland Medisch Centrum,OTHER,Scannexus,UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|MRI|Ultra-high field,Netherlands,Geleen,Limburg,1,"Brain MRI (3T, 7T, 9.4T)",DIAGNOSTIC_TEST,Detected white- and grey-matter lesions,Image quality parameters (signal-to-noise and contrast-to-noise ratios),False,
NCT04300816,Coping and Adjusting to Living With Multiple Sclerosis,Efficacy of a Psychosocial Intervention to Improve Ability to Cope With Uncertainty in MS,COMPLETED,2019-10-30,2022-11-11,2022-11-11,2023-06-23,2020-03-09,INTERVENTIONAL,NA,242.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Seattle,Washington,1,CBT for Uncertainty Tolerance|Traditional CBT,BEHAVIORAL|BEHAVIORAL,"Questionnaire: Level of MS Acceptance as measured by the Acceptance of Chronic Health Conditions, MS Version Questionnaire.|Questionnaire: Level of anxiety as measured by the Global Anxiety Disorder-7 scale (GAD-7).|Questionnaire: Level of depression as measured by the Patient Health Questionnaire (PHQ-9).",Demographic: MS Progression Type. Measured by self-reported type of MS.|Demographic: Biological Sex. Measured by self-report.,False,
NCT01201343,Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients,Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients,COMPLETED,2005-01,2010-07,2010-07,2013-12-27,2010-09-14,INTERVENTIONAL,PHASE4,79.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono S.A.S, France",INDUSTRY,"Multiple Sclerosis, Relapsing, Remitting","Multiple sclerosis, relapsing, remitting|Interferon-beta",,,,0,Interferon beta-1a,DRUG,Change From Baseline in Emotional Dyscontrol Sub-score of the Depressive Mood Scale (Echelle d'Humeur Depressive [EHD]) Scale at Month 12|Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18|Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24,"Change From Baseline in Emotional Abrasion Sub-score of the EHD Scale at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24|Change From Baseline in State-trait Anxiety Inventory (STAI State) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24|Change From Baseline in Center for Epidemiologic Studies Depression (CES-D) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24|Change From Baseline in Center for State-trait Anger Expression Inventory 2 (STAXI-state) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24|Change From Baseline in Fatigue Score at Months 1, 2, 3, 6, 12 and 24",True,2012-04-11
NCT06166043,The Effect of the Nurses Support Program on Fatigue in MS Patient,Evaluation of the Efficiency of the Nurse Follow-up Program Supported With Web Based Education in Managing Fatigue in Patient With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2023-01-30,2023-12,2024-03,2023-12-12,2023-12-12,INTERVENTIONAL,NA,30.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis|Fatigue|Sleep Hygiene|Quality of Life,,Turkey (Türkiye),Istanbul,,1,NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION,BEHAVIORAL,Fatigue levels,sleep quality levels|quality of life levels,False,
NCT02373098,Fingolimod Effect on Cytokine and Chemokine Levels,Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients,COMPLETED,2015-03-31,2017-01-18,2017-01-18,2019-09-30,2015-02-26,INTERVENTIONAL,PHASE4,126.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,"Fingolimod,cytokine,chemokine,RRMS",Turkey (Türkiye),Mecidiyeköy,Istanbul,3,Fingolimod 0.5 mg,DRUG,Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA|Baseline Flow Cytometry Analyses for Blood Cytokines and Chemokines in Healthy Controls and RRMS Patients|Percent Blood Cytokines and Chemokines Via Flow Cytometry Analyses of Healthy Controls and RRMS Patients at Baseline,Serum Cytokine and Chemokine Levels inRRMS Patients Between Visits|Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients|Absolute Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients|Percent of Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients,True,2019-09-30
NCT01330498,"Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical","Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort",COMPLETED,2011-04,2011-08,2011-08,2012-01-06,2011-04-07,OBSERVATIONAL,,229.0,ACTUAL,"John F. Foley, MD",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Longitudinal assessment of biomarkers|duration of natalizumab|stratification of risk for PML,United States,Salt Lake City,Utah,1,,,Duration Effect of natalizumab,Stability of cell trafficking inhibition,False,
NCT06546033,Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis,"Determination of the Effects of Intermittent Fasting and Mediterranean Diet on Quality of Life, Circadian Rhythm and Appetite Markers in Patient With Multiple Sclerosis",RECRUITING,2024-05-02,2026-09-02,2026-12-02,2024-08-09,2024-08-09,INTERVENTIONAL,NA,34.0,ESTIMATED,Nigde Omer Halisdemir University,OTHER,Acibadem University,OTHER,Multiple Sclerosis|Intermittent Fasting,Multiple sclerosis|circadian rhythm|mediterranean diet|Intermittent Fasting,Turkey (Türkiye),Niğde,Bor,1,application of different types of diet,OTHER,Biochemical parameter,The Morning and Evening Questionnaire|Pittsburgh Sleep Quality Index|Multiple Sclerosis Quality of Life-MuSiQoL,False,
NCT05644522,Nomad P-KAFO Study,"Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis",RECRUITING,2024-03-01,2027-12,2027-12,2025-04-06,2022-12-09,INTERVENTIONAL,NA,36.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,,,Cerebrovascular Accident|Post-polio Syndrome|Spinal Cord Injuries|Multiple Sclerosis|Muscular Dystrophy|Paralysis,,United States,Chicago,Illinois,1,"Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)",DEVICE,Change in 10 Meter Walk Test speed,Six Minute Walk Test|Berg Balance Test|Functional Gait Assessment|Hill Assessment Index|Stair Assessment Index|Timed Up and Go|Activities Specific Balance Confidence Scale|Modified Falls Efficacy Scale|Orthotics and Prosthetics User Survey|World Health Organization Quality of Life|EQ5D-5L|Numeric Pain Rating Scale|Borg Rate of Perceived Exertion|Manual Muscle Test|Range of Motion (both passive and active)|Six Minute Push Test,False,
NCT04356339,US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector,US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBETAapp™ in Patients With Multiple Sclerosis Treated With BETASERON® Using BETACONNECT™ Autoinjector,COMPLETED,2020-11-24,2021-08-29,2021-11-11,2023-07-24,2020-04-22,OBSERVATIONAL,,100.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,MS,United States,Whippany,New Jersey,1,"Interferon-beta-1b (BETASERON, BAY 86-5046)",DRUG,Compliance to therapy|Persistence of therapy|Adherence to therapy,Change in patient-reported health-related quality of life (HRQOL)|Patient satisfaction with the myBETAapp|Change in health status evaluated by EQ-5D-5L descriptive system|Change in EQ-Visual Analog Score (EQ-VAS)|Change in prescription and non-prescription medication usage|Number of relapses|Number of participants with treatment with corticosteroids due to relapses|Number of emergency room visits due to relapse|Number of hospitalizations due to relapse|Patient self-assessment|Change in dose of BETASERON prescription|Change in frequency of BETASERON prescription|Patient satisfaction with the BETACONNECT autoinjector,False,
NCT00220428,T-Cell Vaccination in Multiple Sclerosis (MS),The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial,UNKNOWN,1998-07,,2007-12,2007-01-24,2005-09-22,INTERVENTIONAL,PHASE1|PHASE2,20.0,,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,T cell,Israel,Ramat Gan,,1,T-Cell Vaccination,BIOLOGICAL,safety assessment of T-cell vaccination in nonresponding MS patients,,False,
NCT02994121,Prospective Investigation of Multiple Sclerosis in the Three Rivers Region,Prospective Investigation of Multiple Sclerosis in the Three Rivers Region,RECRUITING,2016-12,2047-01,2047-01,2025-01-03,2016-12-15,OBSERVATIONAL,,7500.0,ESTIMATED,University of Pittsburgh,OTHER,,,Multiple Sclerosis,,United States,Pittsburgh,Pennsylvania,1,,,Establish a prospective cohort of well-characterized MS patients and controls|Investigate the predictors of the variations in disease trajectory and treatment response,,False,
NCT00451204,A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS),A Combination Trial of Copaxone Plus Estriol in RRMS,COMPLETED,2007-03,2014-07,2014-07,2016-06-16,2007-03-23,INTERVENTIONAL,PHASE2,158.0,ACTUAL,"University of California, Los Angeles",OTHER,"Washington University School of Medicine|University of Texas Southwestern Medical Center|Ohio State University|University of Medicine and Dentistry of New Jersey|University of Chicago|University of Utah|Johns Hopkins University|University of Kansas Medical Center|University of Minnesota|Mayo Clinic|University of Colorado, Denver|University of New Mexico|University of Pennsylvania|Dartmouth-Hitchcock Medical Center|National Multiple Sclerosis Society|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|NIH|NIH,Relapsing Remitting Multiple Sclerosis,Multiple sclerosis|estrogen|estriol|progesterone,United States,Scottsdale,Arizona,16,Estriol|Placebo|Copaxone,DRUG|DRUG|DRUG,"Confirmed Relapse, Annualized Relapse Rate","Relapse Event, Annualized Relapse Rate|Confirmed Relapse, Probability of First Relapse|Relapse Event, Probability of First Relapse Event",True,2016-06-16
NCT02493049,Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS),"Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis",COMPLETED,2015-08,2019-02,2019-02,2019-10-08,2015-07-09,INTERVENTIONAL,PHASE2,17.0,ACTUAL,University of Calgary,OTHER,Alberta Innovates Health Solutions,OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Domperidone|Relapsing-Remitting MS|Demyelinating disease|Remyelination,Canada,Calgary,Alberta,1,Domperidone,DRUG,Measures of repair within enhancing T1 MRI lesions,Number and type of adverse events over the 16 week treatment period.|Serum Prolactin Levels at both 6 and 16 weeks,False,
NCT01572714,Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis,"Examining the Effects of Physical Activity Promotion, Fatigue Management Education, and Social Support Using a Telehealth Intervention Approach Among Adults With Multiple Sclerosis",COMPLETED,2011-07,2017-02,2017-02,2022-01-06,2012-04-06,INTERVENTIONAL,NA,208.0,ACTUAL,Case Western Reserve University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Exercise|Self Care|Fatigue,United States,Cleveland,Ohio,1,Social Support Program|Physical Activity Program|Physical Activity Plus Fatigue Management Education Program,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Changes from baseline in physical activity levels,Changes from baseline in fatigue levels|Changes from baseline in quality of life,False,
NCT05929638,Aromatherapy With Lavender Essential Oil in Patients With Multiple Sclerosis,The Effect of Aromatherapy With Lavender Essential Oil on the Sleep and Fatigue Level of Patients With Multiple Sclerosis: A Randomized Controlled Trial,UNKNOWN,2023-01-15,2023-05-15,2023-07-15,2023-07-03,2023-07-03,INTERVENTIONAL,NA,70.0,ESTIMATED,Ataturk University,OTHER,,,Aromatherapy|Randomized Controlled Trial|Multiple Sclerosis,,Turkey (Türkiye),Erzurum,,1,lavender oil,BEHAVIORAL,Fatigue Severity Scale -FSS|Pittsburgh Sleep Quality Index (PUKI),,False,
NCT03114293,Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS,Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS,UNKNOWN,2016-04-01,2017-05-30,2017-05-30,2017-05-03,2017-04-14,INTERVENTIONAL,NA,40.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,"Multiple Sclerosis, Chronic Progressive",Physical activity|Mobility,,,,0,Smartphone App,BEHAVIORAL,Rate of responders,"Physical activity: total activity|Physical activity: distance per day|Physical activity: number of steps per day|Questionnaires on quality of life (QoL, HAQUAMS)|Questionnaires on activities of daily living (ADL)|Questionnaires on physical activity",False,
NCT03647904,The SEMS Project: Staying Employed With MS,The SEMS Project: Staying Employed With MS,UNKNOWN,2017-10-01,2018-10,2018-10,2018-08-27,2018-08-27,INTERVENTIONAL,NA,16.0,ESTIMATED,Kessler Foundation,OTHER,,,Multiple Sclerosis,Employment|Self efficacy,United States,East Hanover,New Jersey,1,SEMS Project,BEHAVIORAL,Change in Work Commitment|Change in adjustment to MS|Change in self-efficacy,Change in mood|Change in anxiety|Change in psychological well-being|Changes in stress,False,
NCT02587715,A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,"An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",UNKNOWN,2015-02,2017-02,2017-02,2015-10-28,2015-10-27,INTERVENTIONAL,PHASE1|PHASE2,69.0,ESTIMATED,Novo Cellular Medicine Institute LLP,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",RRMS,Trinidad and Tobago,San Fernando,Trinidad,1,Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Liberation therapy,BIOLOGICAL|OTHER,Proportion of patients with clinical improvement in EDSS score compared to baseline,Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with clinical improvement in MSFC score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease,False,
NCT02273635,"Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS","Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis",UNKNOWN,2014-09,2016-11,2017-04,2014-10-27,2014-10-24,INTERVENTIONAL,PHASE1|PHASE2,68.0,ESTIMATED,Innobioscience SpA,INDUSTRY,Pontificia Universidad Catolica de Chile|University of Chile|Universidad Austral de Chile,OTHER|OTHER|OTHER,"Primary Progressive Multiple Sclerosis|Multiple Sclerosis, Secondary Progressive",,Chile,Santiago,Santiago Metropolitan,1,Andrographolides|placebo,DRUG|DRUG,Brain atrophy in patients with progressive forms of MS,Expanded Disability Status Scale (EDSS)|Paced Auditory Serial Addition Test (PASAT)|Quality of life Multiple Sclerosis Impact Scale (MSIS 29)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Number of new T2 lesions|New hypointense lesions in T1|Optical Coherence Tomography (OCT)|Record of adverse effects in daily symptoms and programmed interviews.|Multiple Sclerosis Functional Composite (MSFC)|Symbol Digit Modalities Test (SDMT)|Depression by Beck scale|Fatigue by Krupp scale|Number of new gadolinium enhancement lesions in T1 by MR|Visual field|Volume of new T2 lesions,False,
NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.","An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™.",COMPLETED,2011-09,2013-09,2013-09,2014-09-09,2011-07-29,OBSERVATIONAL,,270.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Denmark,Glostrup Municipality,,64,AVONEX PEN,OTHER,Persistence with Avonex PEN therapy at Month 12/End of Study as measured by the percentage of patients remaining on therapy at Month 12/End of Study as reported by a physician.,Tolerability of Avonex PEN as measured by Injection Site Pain|Patient Quality of Life as measured by the EuroQol 5 domain (EQ-5D) Questionnaire|Clarity of directions for use of the Avonex PEN as measured by the Avonex PEN Instruction Grading Scale|Ease of use and patient's assessment of the injection procedure with the Avonex PEN as measured by Ease of Use Grading Scale|Patient reported adherence as measured by number of doses missed|Physician reported persistence as measured by number of patients still on therapy|Patient reported satisfaction with the Avonex PEN as measured by the Patient Satisfaction Questionnaire|Patient reported fear of injection using the Fear of Injection Scale|Percent of patients switching from caregiver to self-injection|Tolerability of Avonex PEN as measured by Injection Site Reaction|Ease of use and patient's assessment of the injection procedure with the Avonex PEN as measured by Patient Assessment of Injection Procedure,False,
NCT01563900,Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA),Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea,WITHDRAWN,2012-02,2015-02,2016-02,2013-04-18,2012-03-27,INTERVENTIONAL,NA,0.0,ACTUAL,Northwestern University,OTHER,,,Fatigue|Multiple Sclerosis|Sleep Apnea,fatigue|multiple sclerosis|sleep apnea|CPAP,United States,Chicago,Illinois,1,Auto-titration CPAP|Sham-CPAP,DEVICE|DEVICE,10 point change in Modified Fatigue Impact Scale (MFIS),Improvement in the Epworth sleeping scale (ESS).,False,
NCT01962571,"Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial","Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial",COMPLETED,2014-11-25,2018-06-20,2019-11-26,2019-12-02,2013-10-14,INTERVENTIONAL,PHASE3,108.0,ACTUAL,"University Eye Hospital, Freiburg",OTHER,German Federal Ministry of Education and Research,OTHER_GOV,Optic Neuritis,Optic neuritis|Multiple Sclerosis|Clinically isolated syndrome|Erythropoietin,Germany,Freiburg im Breisgau,Baden-Wurttemberg,11,Erythropoietin alfa|Placebo,DRUG|DRUG,Global retinal nerve fibre layer thickness (RNFLT-G)|Low contrast visual acuity (LCVA),Absolute values of the global retinal nerve fibre layer thickness|Retinal nerve fibre layer thickness in the papillomacular bundle|Retinal nerve fibre layer thickness in the temporal quadrant|Total macular volume|Visual acuity|Contrast sensitivity|Mean visual field defect|Latency [ms] and amplitude [µV] of visual evoked potentials (VEP)|Expanded Disability Status Scale (EDSS) score|Quality of life|Safety,False,
NCT04837352,Therapeutic Adherence of Multiple Sclerosis Patients,Obstacles and Levers of the Therapeutic Adherence of Multiple Sclerosis Patients,RECRUITING,2022-01-18,2025-01-18,2025-10-18,2024-03-26,2021-04-08,OBSERVATIONAL,,153.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis,Theory of Planned Behaviour|Therapeutic adherence|Sociocognitive and interpersonal factors,France,Bordeaux,,4,Study of the role of sociocognitive factors,OTHER,Therapeutic adherence evaluated by a Likert scale,Perceived threat measured with a self-assessment form|Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP)|Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS)|Illness duration in days|Handicap will be evaluated by the Expanded Disability Status Scale (EDSS)|Relapses number|Fatigue perceived through the FSS (Fatigue Severity Scale)|Cognitive disorders through the SDMT (Symbol Digit Modalities Test)|Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS)|Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR),False,
NCT02896933,Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis,,COMPLETED,,2015-01,,2016-09-12,2016-09-12,OBSERVATIONAL,,64.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,,,,0,,,Variation coefficient of gait cadence,,False,
NCT01627938,Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination,A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro),UNKNOWN,2012-04,2015-04,2016-04,2014-11-05,2012-06-26,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,PD Dr. Andrew Chan,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|Mitoxantrone|Dexrazoxane|Cardioxane|cardiotoxicity|cardiac toxicity|cardiotoxic side effects|cardiac MRI|cranial MRI|LVEF|neurological outcome,Germany,Bochum,,1,Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Placebo plus Mitoxantrone (MX),DRUG|DRUG,Changes in LVEF in the different treatment arms by cardiac MRI,"Changes in LVEF by transthoracic echocardiography and determination of cardiac side effects by ECG and by measurement of CK-MB, Troponin and BNP in mitoxantrone plus dexrazoxane versus mitoxantrone plus placebo treatment arms|Determination of EDSS and relapse rate in mitoxantrone plus dexrazoxane treatment arm versus mitoxantrone plus placebo treatment arm|Cumulative number of active lesions by cMRI|LVEF in 3D-echocardiography vs. LVEF in cardiac MRI|Clinical efficacy of DRZ+MX vs. MX monotherapy by MSFC|Quality of Life by SF-36 questionnaire|Changes in magnetic evoked potentials: prolongation of TMCT+CMCT, potential configuration|Annual brain atrophy rates in cMRI|Changes in transcranial sonography (abnormal iron deposition AID). AID in cMRI. Comparison of both methods|Analysis of ABD transporter gene polymorphisms as predictor of therapy response and side effect profile via TaqMan PCR",False,
NCT02638038,This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years,"A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2015-02,2016-12-12,2016-12-12,2018-02-28,2015-12-22,INTERVENTIONAL,PHASE2,228.0,ACTUAL,"InteKrin Therapeutics, Inc.",INDUSTRY,,,"Multiple Sclerosis, Relapsing Remitting",,,,,0,INT131,DRUG,The number of new gadolinium CE T1 weighted lesions,,False,
NCT02166021,Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis,"Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis",COMPLETED,2015-01-29,2018-06-15,2018-12-24,2019-08-01,2014-06-18,INTERVENTIONAL,PHASE2,48.0,ACTUAL,Dimitrios Karussis,OTHER,,,Multiple Sclerosis (MS),Multiple Sclerosis (MS)|Stem Cells,Israel,Jerusalem,,1,Mesenchymal stem cells,BIOLOGICAL,Safety Assessment|Neurological efficacy,EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology,False,
NCT05364021,Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies,"Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies",COMPLETED,2022-03-03,2023-11-16,2023-11-20,2024-11-08,2022-05-06,INTERVENTIONAL,PHASE1|PHASE2,52.0,ACTUAL,Longboard Pharmaceuticals,INDUSTRY,,,Developmental and Epileptic Encephalopathy|Dravet Syndrome|Lennox Gastaut Syndrome,CDKL5 deficiency disorder|developmental and epileptic encephalopathy|Dravet Syndrome|epilepsy|Lennox-Gastaut Syndrome|treatment resistant epilepsy|tuberous sclerosis complex,United States,Tucson,Arizona,34,LP352|Placebo,DRUG|DRUG,Treatment-emergent Adverse Events|Columbia-Suicide Severity Rating Scale (C-SSRS) Response|Patient Health Questionnaire-9 Total Score and Question 9 Score|Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Treatment Period|Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Maintenance Period,Observed Plasma Concentrations of LP352 by Time and Dose|Modeled Estimate of Average Plasma Concentration|Modeled Estimate of Observed Plasma Concentration Just Prior to Dosing|Correlation of Plasma Concentration with Incidence of Treatment-emergent Adverse Events|Correlation of Plasma Concentration with Seizure Frequency|Observed and Change from Baseline Prolactin Concentration During the Treatment Period,False,
NCT02810314,Default Mode Network in Multiple Sclerosis,Study of Default Mode Network (DMN) on Patients With Multiple Sclerosis (MS),UNKNOWN,2017-05-01,2021-10,2021-12,2021-02-10,2016-06-22,INTERVENTIONAL,NA,64.0,ESTIMATED,Hospital General Universitario Gregorio Marañon,OTHER,,,Multiple Sclerosis,,Spain,Madrid,,1,neuropsychological battery|resting state functional magnetic resonance image (rs-fMRI),BEHAVIORAL|OTHER,Change of functional connectivity of default mode network (DMN),Correlate grey matter indexes and cognitive functioning indexes|Correlate grey matter indexes and emotional/behavioural indexes,False,
NCT05275049,Neuromodulation in MS Using Translingual Stimulation,Translingual Stimulation Combined With Physiotherapy to Improve Walking and Balance in Multiple Sclerosis: an RCT,UNKNOWN,2021-07-05,2022-07-05,2022-12-01,2022-03-11,2022-03-11,INTERVENTIONAL,NA,52.0,ESTIMATED,University of Saskatchewan,OTHER,Memorial University of Newfoundland,OTHER,Multiple Sclerosis,physiotherapy|walking and balance|neurorehabilitation|non-invasive cranial nerve neuromodulation,Canada,St. John's,Newfoundland and Labrador,2,PT plus translingual stimulation device|PT plus translingual stimulation control device,COMBINATION_PRODUCT|COMBINATION_PRODUCT,Timed 25 foot walk test (T25FWT)|Dynamic Gait Index (DGI),Multiple Sclerosis Impact Scale (MSIS-29)|Fatigue Scale for Motor and Cognitive Functions|Short From 36 Health Survey Questionnaire (SF-36)|Multiple sclerosis walking scale - 12 item (MSWS-12),False,
NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.,COMPLETED,2015-02-28,2016-05-02,2016-05-02,2017-06-02,2014-03-27,INTERVENTIONAL,PHASE2,71.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,vaccine|pneumococcal|meningococcal|tetanus diphtheria|immune response,United States,Gilbert,Arizona,14,dimethyl fumarate|tetanus diphtheria toxoids vaccine|23-valent pneumococcal polysaccharide vaccine|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|non-pegylated interferon,DRUG|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|DRUG,Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level,Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level|Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level|Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level|Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level|Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level|Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level|Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level|Ratio of Serum Tetanus Level at Day 28 to Prevaccination|Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination|Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination|Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination|Number of Participants Experiencing Vaccination-Emergent Adverse Events (AEs) and Serious AEs|Number of Participants With Shifts From Baseline in Hematology|Number of Participants With Shifts From Baseline in Blood Chemistry|Number of Participants With Abnormalities in Vital Signs,True,2017-06-02
NCT03177785,Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS),Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS),COMPLETED,2016-08-04,2016-12-31,2016-12-31,2017-06-06,2017-06-06,INTERVENTIONAL,NA,31.0,ACTUAL,University of Washington,OTHER,,,Multiple Sclerosis,,,,,0,EverydayMatters,BEHAVIORAL,Change in Resilience using Connor Davidson Resilience Scale (brief),Change in positive affect and well being using the Quality of Life in Neurological Disorders (NeuroQoL) Positive Affect and Well-Being Short Form|Change in Patient Reported Outcomes Measurement Information System (PROMIS) Satisfaction with Social Roles Short Form|Change in disease-management self-efficacy using the University of Washington Self-Efficacy Scale,False,
NCT00315367,A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties,"A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function",COMPLETED,2004-09,,2007-10,2007-10-16,2006-04-18,INTERVENTIONAL,PHASE4,26.0,ESTIMATED,Neurognostics,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Memory impairment,United States,Milwaukee,Wisconsin,1,Donepezil HCI (drug),DRUG,"Anatomic relationships during cognitive activity, and how these relationships change as a function of drug",fMRI as a surrogate marker for drug efficacy,False,
NCT03477500,"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for Patients With Relapsing Remitting Multiple Sclerosis (RAM-MS)",ACTIVE_NOT_RECRUITING,2018-03-21,2026-11-21,2028-03-21,2025-06-25,2018-03-26,INTERVENTIONAL,PHASE3,100.0,ESTIMATED,Haukeland University Hospital,OTHER,,,Multiple Sclerosis,"multiple sclerosis,|HSCT|alemtuzumab|RCT",Denmark,Copenhagen,,8,Cyclophosphamide and ATG|Alemtuzumab|Cladribine Pill|Ocrelizumab,DRUG|DRUG|DRUG|DRUG,"Proportion of patients with no evidence of disease activity (NEDA, as defined per protocol).","NEDA-4|Pre-planned study extension:|Time to first protocol-defined disease activity event|Change in Expanded Disability Status scale (EDSS) from baseline (Visit 4.1) to Weeks 96 and 240|The proportion of patients who, at Week 96, have protocol-defined Confirmed Disability Improvement (CDI) , confirmed stable EDSS or Confirmed Disability Progression (CDP) compared to baseline|Annualized rate of protocol-defined relapses during 96 weeks|Time to onset of first protocol-defined relapse|Change in MRI T2-weighted hyperintense lesion volume from baseline to weeks 96 (and 240)|Change in MRI T1-weighted hypointense lesion volume from baseline to weeks 96 (and 240)|Change in brain volume from baseline to week 96 (and week 240)|Time to detection of a new MRI T2 lesion|Total number of MRI T1-weighted Gd-enhanced lesions|Proportion of patients free from T1 Gd-enhancing lesions|Change in Nine-hole-peg test (9-HPT) score from baseline to week 96 (and 240)|Change in Timed 25 Foot Walk (T25FW) score from baseline to week 48, 96 (and 240)|Change in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) score from baseline to week 96 (and 240)",False,
NCT01977287,Walking With FES or AFO in People With MS With Foot Drop,A Pilot Study to Assess the Effects of Using FES or AFO as an Assistive Mobility for Period of 12 Weeks for People With Multiple Sclerosis With Foot Drop,COMPLETED,2011-06,2016-03,2016-03,2016-04-04,2013-11-06,OBSERVATIONAL,,18.0,ACTUAL,Queen Margaret University,OTHER,Multiple Sclerosis Society UK|NHS Lothian,UNKNOWN|OTHER_GOV,Multiple Sclerosis|Foot Drop,Multiple Sclerosis|Functional Electrical Stimulation|Ankle Foot Orthosis|Walking performance|gait analysis|fatigue|activity monitoring,United Kingdom,Musselburgh,East Lothian,1,Functional Electrical Stimulation|Ankle Foot Orthosis,DEVICE|DEVICE,Change in time taken for 10 meter walk test,Change in ankle dorsiflexion angle at initial contact,False,
NCT05562414,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis: A Pilot Study.,UNKNOWN,2022-10-01,2023-04-01,2023-04-01,2022-10-14,2022-09-30,INTERVENTIONAL,NA,30.0,ESTIMATED,Klinik Valens,OTHER,,,"Multiple Sclerosis, Chronic Progressive|High-Intensity Interval Training|Motor Symptoms","Multiple Sclerosis, Chronic Progressive|Physical Conditioning, Human|Paraparesis|Gait|Dexterity",Switzerland,Valens,Canton of St. Gallen,1,HIIT|MCT,BEHAVIORAL|BEHAVIORAL,Functional mobility,Spasticity (objective)|Spasticity (subjective)|Gait pattern|Dexterity,False,
NCT04530955,Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS),"Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS): A Randomized, Controlled, Multi-center, Prospective Study Evaluating Dose Reduction in ITB Patients.",UNKNOWN,2020-09-24,2022-12,2023-06,2020-09-28,2020-08-28,INTERVENTIONAL,NA,92.0,ESTIMATED,Culicchia Neurological Clinic,OTHER,Flowonix Medical,INDUSTRY,"Injuries, Spinal Cord|CVA (Cerebrovascular Accident)|Traumatic Brain Injury|MS (Multiple Sclerosis)|Muscle Spasticity|Cerebral Palsy, Spastic",Spasticity,United States,Marrero,Louisiana,1,Prometra II Programmable Pump - Flowonix Medical,DEVICE,Comparison of spasticity control with Synchromed II versus Prometra II,Comparison of patient report of spasm frequency with Synchromed II versus Prometra II,False,
NCT01396343,Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis,Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis,COMPLETED,2011-10,2018-04,2018-04,2018-10-18,2011-07-18,OBSERVATIONAL,,1276.0,ACTUAL,"University of California, San Francisco",OTHER,New York University|Massachusetts General Hospital|State University of New York at Buffalo|University of Alabama at Birmingham|Mayo Clinic|Children's Hospital of Philadelphia|Boston Children's Hospital|Baylor College of Medicine|Loma Linda University|Children's Hospital Colorado|University of Texas|Ann & Robert H Lurie Children's Hospital of Chicago|Washington University School of Medicine|Children's National Med Center|Primary Children's Hospital|The Cleveland Clinic,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER,Pediatric Multiple Sclerosis,Pediatric Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Clinically Isolated Syndrome|Demyelinating Disease,United States,Birmingham,Alabama,17,,,Identify risk factors and their respective contribution to developing pediatric multiple sclerosis,,False,
NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis",COMPLETED,2019-08-12,2025-06-03,2025-06-03,2025-07-08,2019-06-03,INTERVENTIONAL,PHASE1,134.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis (MS),,United States,Aurora,Colorado,18,Ocrelizumab|Ocrelizumab|rHuPH20,DRUG|DRUG|DRUG,Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following subcutaneous (SC) administration|Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following single IV (intravenous Infusion)administration|Percentage of participants with adverse events|Percentage of participants with change from baseline in Marked Abnormality in Electrocardiogram (ECG) Parameters|Incidence of local pain at site of injection assessed using Visual Analog Scale (VAS|Incidence of local-injection reaction (ISR) assessed using Local Injection-Site Symptom Assessment (LISSA),Percentage of Participants with Anti-Drug Antibodies (ADAs) to ocrelizumab|Percentage of Participants with Anti-Drug Antibodies (ADAs) to rHuPH20,False,
NCT01420055,Fingolimod -Response According to Coping - Evaluation,"A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France",COMPLETED,2011-08,2013-06,2013-06,2016-11-18,2011-08-19,INTERVENTIONAL,PHASE4,189.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|Fingolimod|Coping|Anxiety|France|Treatment Satisfaction Questionnaire for Medication-9 items (TSQM 9)|Active,France,Angers,France,47,fingolimod,DRUG,"To assess the mean change in Hospital Anxiety Depression Scale (HADS) anxiety sub-score between baseline and Month 4 in RRMS fingolimod treated patient total population, and according to coping profile (task, emotion or avoidance oriented).","To assess patient Clinical Global Impression (CGI) and clinician CGI at M4 in total population, and according to coping profile.|To evaluate the safety and tolerability of fingolimod 0.5 mg/day (especially initial cardiac effects, liver function and macular edema onset)|To explore treatment satisfaction with fingolimod in patients with RRMS either naive (rapidly evolving severe RRMS) or who transitioned from previous treatment with Disease Modifying Therapy using the TSQM 9 and according to coping profile",False,
NCT07135752,Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination,Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination,NOT_YET_RECRUITING,2025-09-01,2027-09-01,2027-09-01,2025-08-22,2025-08-22,INTERVENTIONAL,NA,150.0,ESTIMATED,Centre Hospitalier Universitaire de Nice,OTHER,,,Radiologically Isolated Syndromes; Multiple Sclerosis,,France,Nice,,1,Precision assessment,OTHER,Comparaison of digital biomarkers performance,Comparaison of standard MRI biomarkers|Comparaison of unconventional MRI biomarkers,False,
NCT07138833,A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS),"A Multicenter, Open-label, Single Group, Phase 4 Study to Evaluate Dimethyl Fumarate Enteric-coated Capsules in Relapsing Multiple Sclerosis (RMS)",NOT_YET_RECRUITING,2025-09,2028-04,2028-08,2025-08-24,2025-08-24,INTERVENTIONAL,PHASE4,50.0,ESTIMATED,"Qilu Pharmaceutical (Hainan) Co., Ltd.",INDUSTRY,,,Relapsing Multiple Sclerosis,,,,,0,Dimethyl Fumarate Enteric-coated Capsules,DRUG,Annualized Relapse Rate at Week 48,,False,
NCT03471338,Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme,Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme,COMPLETED,2017-10-31,2023-05-31,2024-05-31,2025-07-25,2018-03-20,INTERVENTIONAL,NA,40.0,ACTUAL,"University Hospital, Caen",OTHER,,,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,multiple sclerosis|cognition|neuropsychology|cognitive rehabilitation,France,Caen,Calvados,1,Cognitive rehabilitation|Standard Psychological care,BEHAVIORAL|BEHAVIORAL,Efficacy of cognitive rehabilitation on quality of life at short term.|Efficacy of cognitive rehabilitation on quality of life at long term.,Efficacy of cognitive rehabilitation on self-esteem at short term.|Efficacy of cognitive rehabilitation on self-esteem long term.|Efficacy of cognitive rehabilitation on depression at short term.|Efficacy of cognitive rehabilitation on depression at long term.|Efficacy of cognitive rehabilitation on cognition at short term.|Efficacy of cognitive rehabilitation on cognition at long term.|Efficacy of cognitive rehabilitation on metacognition at short term.|Efficacy of cognitive rehabilitation on metacognition at long term.|Efficacy of cognitive rehabilitation on fatigue at short term|Efficacy of cognitive rehabilitation on fatigue at long term|Efficacy of cognitive rehabilitation on sleep at short term|Efficacy of cognitive rehabilitation on sleep at long term|Efficacy of cognitive rehabilitation on anxiety at short term.|Efficacy of cognitive rehabilitation on anxiety at long term.,False,
NCT01250678,Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab,Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab,UNKNOWN,2011-01,2014-01,2014-06,2010-12-01,2010-12-01,OBSERVATIONAL,,50.0,ESTIMATED,Cantonal Hospital of St. Gallen,OTHER,Biogen,INDUSTRY,Multiple Sclerosis|Cognitive Impairment,multiple sclerosis|cognitive impairment|natalizumab|SDMT,Switzerland,Sankt Gallen,,1,,,The Symbol Digit Modalities Test (SDMT),Multiple Sclerosis Inventory Cognition (MUSIC)|TAP subtest Alertness|Composite neurocognitive index,False,
NCT06485115,Telerehabilitation in Progressive Multiple Sclerosis,"The Effectiveness of Combining a Home-based Digital Motor Telerehabilitation Program With Conventional Therapy in Progressive Multiple Sclerosis: a Multicentre, Randomized Controlled Trial",NOT_YET_RECRUITING,2024-06-30,2026-06-30,2026-06-30,2024-07-03,2024-07-03,INTERVENTIONAL,NA,78.0,ESTIMATED,Universita di Verona,OTHER,Università degli Studi di Ferrara,OTHER,Progressive Multiple Sclerosis,Balance|Dual Task|Cognitive Function|Digital Telemedicine|Wearables,Italy,Verona,,1,Digital Telerehabilitation (Euleria Home)|Conventional therapy,DEVICE|OTHER,Change in the Timed Up and Go test,Change in the Multiple Sclerosis Functional Composite (MSFC)|Mental workload through Electroencephalography (EEG) during Multiple Sclerosis Functional Composite Score|Vigilance state through Electroencephalography (EEG) during Multiple Sclerosis Functional Composite Score|Surface electromyography (EMG) during the performance of the Nine Hole Peg test part of the Multiple Sclerosis Functional Composite (MSFC).|Inertial Measurement Unit (IMU) system during the performance of the Nine Hole Peg test part of the Multiple Sclerosis Functional Composite (MSFC).|Change in the Fatigue Severity Scale (FSS)|Change in the Activities-specific balance confidence (ABC)|Change in the Manual Ability Measure-36 (MAM-36)|The number of falls in the previous month|Timed Up and Go (TUG) test - Cognitive|Electroencephalography (EEG) during the Timed Up and Go (TUG) test - Cognitive|Timed Up and Go (TUG) test - Manual|Electroencephalography (EEG) during the Timed Up and Go (TUG) test - Manual|Change in the gait speed (cm/s)|Change in the cadence (step/min)|Change in the stride length (cm)|Change in the length of the centre of pressure (CoP)|Change in the trajectory (mm)|Change in the sway area (mm2)|Change in the Brief Pain Inventory (BPI)|Change in the Hospital Anxiety and Depression Scale|Change in the Hospital Anxiety and Depression Scale - Anxiety (HADS-A)|Change in the Hospital Anxiety and Depression Scale - Depression (HADS-D)|Change in the Modified Asworth Scale|Change in the Modified Tardieu Scale|Change in the the Multiple Sclerosis Quality Of Life-54 (MSQOL-54)|The EuroQol five domains (EQ-5D)|The volumes of health services|The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS)|The TheiTA Productivity Cost Questionnaire|Change in the Clinical Global Impression (CGI)|Changes in effective brain connectivity through Electroencephalography (EEG)|Change in the Brief Illness Perception Questionnaire (B-IPQ)|Change in the Multidimensional Psychological Flexibility Inventory (MPFI)|Change in the Self-Efficacy for Multiple Sclerosis Scale (SEMS)|Tele-healthcare Satisfaction Questionnaire-Wearable Technology|Patients' In-home Digital Telerehabilitation training experience questionnaire|Activity levels through Technology-based Objective Measures (TOMS)|Number of steps through Technology-based Objective Measures (TOMS)|Distance traveled through Technology-based Objective Measures (TOMS)|Risk of fall assessment|Adverse Events|Number of patients who accept/refuse the treatment|Number of dropouts,False,
NCT06502015,Biomarkers in Autoimmune Disease of Nervous System,Biomarkers of Neurological Autoimmune Diseases,RECRUITING,2024-07-31,2027-07,2027-07,2024-11-20,2024-07-15,OBSERVATIONAL,,50000.0,ESTIMATED,Tongji Hospital,OTHER,,,Autoimmune Diseases of the Nervous System|Neuromyelitis Optica Spectrum Disorder|Multiple Sclerosis|Guillain-Barre Syndrome|Acute Disseminated Encephalomyelitis|Autoimmune Encephalitis|Stiff-Person Syndrome|Myasthenia Gravis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Idiopathic Inflammatory Myopathies|Autoimmune Diseases,Biomarker|Autoimmune Diseases of the Nervous System|Immune cell,China,Wuhan,,1,biomaker levels,DIAGNOSTIC_TEST,All-cause mortality,Autoimmune disease of any kind,False,
NCT02149706,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis","A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination",UNKNOWN,2020-03-09,2022-03-09,2022-03-09,2020-03-11,2014-05-29,INTERVENTIONAL,PHASE2,150.0,ESTIMATED,"Immune Response BioPharma, Inc.",INDUSTRY,cro,AMBIG,Multiple Sclerosis,Secondary Progress Multiple Sclerosis|SPMS|Multiple Sclerosis|NeuroVax,United States,San Diego,California,1,NeuroVax|IFA Incomplete Freund's Adjuvant,BIOLOGICAL|BIOLOGICAL,The primary objective is to compare between treatment groups the Measures of neurologic disability EDSS score,Secondary measurements objectives immunologic evaluations,False,
NCT04711148,A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity",ACTIVE_NOT_RECRUITING,2021-03-01,2026-02-25,2026-03-01,2023-04-21,2021-01-15,INTERVENTIONAL,PHASE2,160.0,ESTIMATED,"Beijing InnoCare Pharma Tech Co., Ltd.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United States,Ormond Beach,Florida,42,placebo|orelabrutinib,OTHER|DRUG,The cumulative number of new GdE T1 MRI brain lesions,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability ]|ARR[efficacy],False,
NCT01411514,Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis,Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort,TERMINATED,2011-08,2015-01,2015-01,2015-12-18,2011-08-08,INTERVENTIONAL,PHASE4,27.0,ACTUAL,Claudio Gobbi,OTHER_GOV,"Ente Ospedaliero Cantonale, Ticino, Switzerland",OTHER,Multiple Sclerosis,Relapsing remittent multipse sclerosis|Secondary progressive multiple sclerosis|Clinically isolated syndrome|Primary progressive multiple sclerosis,Switzerland,Lugano,Canton Ticino,1,Prednisone|Placebo,DRUG|DRUG,Expanded Disability Status Scale (EDSS),Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Functional Composite Score (MSFC)|Gd-enhancing lesions on T1-weighted images|number of new T2-hyperintense lesions|mental status (MUSIC)|Euroqol-5D (EQ-5D|Functional Assessment Multiple Sclerosis (FAMS)|Beck Depression Inventory Second edition (BDI-II)|Fatigue Scale for Motor and Cognitive functions (FSMC)|Expanded Disability Status Scale (EDSS)|Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Functional Composite Score (MSFC)|Multiple Sclerosis Functional Composite Score (MSFC)|Multiple Sclerosis Functional Composite Score (MSFC)|Gd-enhancing lesions on T1-weighted images|Gd-enhancing lesions on T1-weighted images|number of new T2-hyperintense lesions|number of new T2-hyperintense lesions|mental status (MUSIC)|mental status (MUSIC)|Euroqol-5D (EQ-5D|Euroqol-5D (EQ-5D|Functional Assessment Multiple Sclerosis (FAMS)|Functional Assessment Multiple Sclerosis (FAMS)|Beck Depression Inventory Second edition (BDI-II)|Beck Depression Inventory Second edition (BDI-II)|Fatigue Scale for Motor and Cognitive functions (FSMC)|Fatigue Scale for Motor and Cognitive functions (FSMC),False,
NCT01257958,Vitamin D Pilot Study in Patients With Multiple Sclerosis,Vitamin D Pilot Study in Patients With Multiple Sclerosis,COMPLETED,1998-02,2000-02,2000-06,2015-10-05,2010-12-10,INTERVENTIONAL,PHASE1,,,"University of Wisconsin, Madison",OTHER,,,Relapsing Remitting Multiple Sclerosis,"Vitamin D, 19 nor Vitamin D, Multiple Sclerosis",United States,Madison,Wisconsin,1,19 nor vitamin d,DRUG,"MRI Measure of new active lesions, observation vs. treatment",,False,
NCT04857489,Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis,Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis,UNKNOWN,2020-06-01,2023-06,2023-06,2022-06-15,2021-04-23,OBSERVATIONAL,,80.0,ESTIMATED,Thomas Jefferson University,OTHER,,,Relapse Remitting Multiple Sclerosis,,United States,Philadelphia,Pennsylvania,1,,,Characterize natural (n) Tregs' functional deficit in RRMS|Identify the role of inducible (i) Treg cells in maintaining the immunological tolerance in RRMS,Identify the phenotype changes in CD4+CD25+CD127 nTregs in RRMS patients|Characterize functional deficits of nTregs in RRMS|Determine the effects of hemostatic cytokines on the nTregs' suppressive function in RRMS|Determine the phenotype of iTreg cells in RRMS|Identify the mechanisms of deficient nTreg induction of iTregs in RRMS|Characterize the effect of the iTreg-produced immunoregulatory cytokines on the reconstitution of immune tolerance,False,
NCT01142518,An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone,A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment,COMPLETED,2005-07,2009-03,2009-03,2014-03-18,2010-06-11,OBSERVATIONAL,,86.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Interferon beta-1a|Multiple Sclerosis,,,,0,Interferon beta 1a,DRUG,Stabilization of the course of the disease in MS subjects previously treated with mitoxantrone,Safety and tolerance of the treatment,False,
NCT04186910,In Clinic Physical Activity in Persons With Multiple Sclerosis,Increasing Physical Activity in Recovered Persons With Multiple Sclerosis Through Daily Sensor Based Feedback and Weekly Focus Group Meetings: A Feasibility and Pilot II Study,UNKNOWN,2019-07-01,2020-07,2020-09,2019-12-05,2019-12-05,INTERVENTIONAL,NA,20.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Rehabilitation|Multiple Sclerosis,Multiple Sclerosis|Physical activity|Mobility|Self efficacy,Italy,Milan,,1,Control group|Feedback group,BEHAVIORAL|BEHAVIORAL,Number of passes with Fitbit wristband|The 2 minute walking test|The Self-Efficacy in Multiple Sclerosis Scale,The 10 meters walking scale|The Short Form-12 questionnaire|The EQ-5D visual analogue scale|The Twelve Item MS Walking Scale|The Fatigue severity Scale|The Physical Activity Disability Survey-Revised questionnaire,False,
NCT04667013,"A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN","A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TBN in Healthy Subjects",NOT_YET_RECRUITING,2025-09-01,2026-03-31,2026-08-30,2025-03-19,2020-12-14,INTERVENTIONAL,PHASE1,16.0,ESTIMATED,"Guangzhou Magpie Pharmaceuticals Co., Ltd.",INDUSTRY,,,Healthy,Phase 1|Amyotrophic lateral sclerosis|TBN,,,,0,Tetramethylpyrazine nitrone (TBN) tablet / Placebo,DRUG,Number of participants with Adverse Events (AEs)|Assessment of physical examination.|Assessment of vital signs.|Assessment of 12 lead-ECG.|Assessment of urine pregnancy.|Assessment of Clinical Laboratory Tests.,Maximum observed concentration (Cmax) of TBN and its metabolite.|Time of occurrence of Cmax (Tmax) of TBN and its metabolite.|Area under the concentration-time curve from time zero to time 12 hours (AUC0-12) of TBN and its metabolite.|Lowest concentration before the next dose is administered (Ctrough) of TBN and its metabolite.|Area under the concentration-time curve for one dosing interval (12 hours) at steady-state (AUC0-tau) of TBN and its metabolite.|Average drug concentration calculated at AUC0-tau/tau (Caverage) of TBN and its metabolite.|Minimum observed concentration at steady-state (Cmin_ss) of TBN and its metabolite.|Area under the concentration-time curve from time zero to the 24 hours concentration (AUC0-24) of TBN and its metabolite.|Maximum observed concentration at steady-state (Cmax_ss) of TBN and its metabolite.|Time of observed Cmax_ss (Tmax_ss) of TBN and its metabolite.|Area under the concentration-time curve from time zero to infinity (AUC0-inf) of TBN and its metabolite.,False,
NCT00591721,Teleconference Fatigue Management for People With Multiple Sclerosis,Effectiveness of a Teleconference Delivered Fatigue Management Program for People With Multiple Sclerosis,COMPLETED,2007-11,2010-02,2010-02,2013-02-28,2008-01-11,INTERVENTIONAL,NA,190.0,ACTUAL,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,energy conservation education|occupational therapy intervention|fatigue management|psychoeducation,United States,Chicago,Illinois,1,Energy conservation education,BEHAVIORAL,Change From Baseline in Subscale Scores of the Fatigue Impact Scale,,True,2013-02-28
NCT04997343,Neurophysiological Assessment in Patients With Multiple Sclerosis,Neurophysiological Estimates of Cortical Grey and White Matters Damage in Patients With Multiple Sclerosis,UNKNOWN,2021-10,2023-07-01,2023-09-01,2021-08-09,2021-08-09,INTERVENTIONAL,NA,128.0,ESTIMATED,University of Roma La Sapienza,OTHER,,,Multiple Sclerosis|Demyelinating Disease|Inflammatory Disease,neurophysiology|TMS-EEG|multiple sclerosis,,,,0,Neurophysiological assessment|clinical assessment,OTHER|OTHER,Changes of Global cortico-cortical myelination|Changes of the Cortical-cortical coherence|Changes of the Local cortical-cortical myelination (motor)|Changes of the Trans-callosal axonal myelination|Changes of Interhemispheric signal propagation (iSP)|Changes of TMS-EEG measurement of the functional integrity of the grey matter:|Changes of TMS-EMG measurement of the functional integrity of the grey matter:|Changes of clinical outcome measures|Changes of the Multiple Sclerosis Functional Composite (MSFC)|Changes of radiological outcome measures|Changes of magnetic resonance imaging (MRI) number of lesions in T2,,False,
NCT03110315,A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia,"A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia",COMPLETED,2017-03-28,2022-03-21,2022-03-21,2025-02-03,2017-04-12,INTERVENTIONAL,PHASE4,36.0,ACTUAL,"Theodore R. Brown, MD MPH",OTHER,Merck Sharp & Dohme LLC,INDUSTRY,Multiple Sclerosis|Fatigue|Insomnia,Multiple Sclerosis|Fatigue|Insomnia|Suvorexant|Belsomra|Sleep disorder|Sleep,United States,Kirkland,Washington,1,Suvorexant|Placebo,DRUG|DRUG,Change in Insomnia Severity Index (ISI) Score,Change in Modified Fatigue Index Scale (MFIS) Score|Patient Global Impression of Change|Fatigue Visual Analog Scale,True,2025-02-03
NCT02208050,A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS,"A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis",COMPLETED,2014-02-21,2016-02-16,2016-02-16,2021-07-09,2014-08-04,INTERVENTIONAL,PHASE4,64.0,ACTUAL,University College Dublin,OTHER,,,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Multiple Sclerosis|Upper limb function|Mobility|Fampridine|DASH|AMSQ|MSWS-12|MSIS-29|SF-36|9HPT|25FTW|JTT,Ireland,Dublin,Dublin 4,2,Fampridine|Placebo,DRUG|DRUG,Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT),Number of Participants Defined as Upper Limb Responders on the Jebsen Taylor Hand Function Test (JTT)|The Number of Mobility Responders to Fampridine as Measured by an Improvement in the 25 Foot Timed Walk (T25FW)|Mean Scores in DASH - Fampridine and Placebo.|Mean Scores in Multiple Sclerosis Walking Scale (MSWS-12) - Fampridine and Placebo.|Mean Scores in the Disabilities in Arm Function in Multiple Sclerosis Questionnaire (AMSQ) Score Between Fampridine and Placebo.|Mean Scores of MSIS-29 - Fampridine and Placebo,True,2021-07-09
NCT04562376,High-intensity Resistance Training in People With Multiple Sclerosis Experiencing Fatigue,"High-intensity Resistance Training in People With Multiple Sclerosis Experiencing Fatigue - Effects on Functioning, Wellbeing and Inflammatory Biological Markers",COMPLETED,2020-08-20,2021-06-28,2022-06-30,2022-08-16,2020-09-24,INTERVENTIONAL,NA,73.0,ACTUAL,Karolinska Institutet,OTHER,Neuro+,INDUSTRY,Multiple Sclerosis|Fatigue|Exercise Therapy|Resistance Training|Cytokines,,Sweden,Stockholm,,1,High-intensity resistance training|Low frequency of high-intensity resistance training,OTHER|OTHER,Fatigue Scale for Motor and Cognitive Functions,Fatigue Severity Scale|Hospital Anxiety and Depression Scale|Occupational Gaps Questionnaire|Multiple Sclerosis Impact Scale-29|Euroqool five dimension five level|Euroqool visual analogue scale|Multiplex proteomic immunoassay and enzyme-linked immunosorbent assay,False,
NCT02846558,A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS),A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis,COMPLETED,2016-08,2017-06,2017-07,2018-06-15,2016-07-27,INTERVENTIONAL,NA,54.0,ACTUAL,Johns Hopkins University,OTHER,,,Multiple Sclerosis,calorie restriction|weight loss,,,,0,Frequent Patient Interaction|Timing Restriction|LoseIt! Smartphone Application,OTHER|BEHAVIORAL|DEVICE,Adherence,Body Mass Index (BMI)|Weight Change|Weight Change Among Adherent Participants|Functional Assessment in MS Score|Fatigue|Sleep Quality|Self-esteem,True,2018-06-15
NCT00436826,A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD),"A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease",COMPLETED,2006-11-30,2011-09-30,2012-03-31,2020-10-12,2007-02-19,INTERVENTIONAL,PHASE2,172.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing forms|Interferon-beta therapy,United States,Cullman,Alabama,39,Cladribine|Placebo|Interferon-beta (IFN-beta),DRUG|DRUG|DRUG,"Double Blind Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity|Double Blind Period: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) in Infections and Infestations System Organ Class (SOC)|Double Blind Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs|Double Blind Period: Time to First Grade 3 or 4 Hematological Toxicity or Liver Toxicity|Double Blind Period: Time to Recovery From Grade 3 or 4 Hematological Toxicity|Double Blind Period: Mean Changes in Lymphocytes, White Blood Cells (WBC), Neutrophils and Platelets Values From Baseline to Week 96|Double Blind Period: Maximum Corrected QT Interval (QTc)|Double Blind Period: Mean Change From Baseline in Vital Signs- Systolic and Diastolic Blood Pressure|Double Blind Period: Mean Change From Baseline in Vital Signs- Pulse Rate|Double Blind Period: Mean Change From Baseline in Vital Signs- Weight|Double Blind Period: Mean Change From Baseline in Vital Signs- Temperature|Double Blind Period: Mean Change From Baseline in Electrocardiogram (ECG) Parameters- Heart Rate|Double Blind Period: Mean Change From Baseline in Electrocardiogram (ECG) Parameters- PR, RR, QRS and OT Interval|Double Blind Period: Mean Changes From Baseline in Hemoglobin Level to Week 96|Double Blind Period: Mean Changes From Baseline in CD4+ Count, CD8+ Count, and CD19+ to Week 96|Double Blind Period: Mean Changes From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to Week 96|Open Label Extension Period: Maximum Corrected QT Interval (Qtc)|Open Label Extension Period: Mean Change From Baseline in Vital Signs- Systolic and Diastolic Blood Pressure|Open Label Extension Period: Mean Change From Baseline in Vital Signs- Pulse Rate|Open Label Extension Period: Mean Change From Baseline in Vital Signs- Weight|Open Label Extension Period: Mean Change From Baseline in Vital Signs- Temperature|Open Label Extension Period: Mean Change From Baseline in Electrocardiogram (ECG) Parameters- Heart Rate|Open Label Extension Period: Mean Change From Baseline in Electrocardiogram (ECG) Parameters- PR, RR, QRS and OT Interval|OLE and Safety Follow-up Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity|OLE and Safety Follow-up Period: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) in Infections and Infestations System Organ Class (SOC)|OLE and Safety Follow-up Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs|Open Label Extension Period: Time to First Grade 3 or 4 Hematological Toxicity or Liver Toxicity","Double Blind Period: Number of Combined Unique Active (CUA) Lesions, Active Time Constant 2 (T2) Lesions, and Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan|Double Blind Period: Mean Number of T1 Hypointense Lesions Per Participant Per Scan at Week 96|Double Blind Period: Percentage of Participants With no Active T2 Lesions at Week 96|Double Blind Period: Percentage of Participants With no Active T1 Gd-Enhanced Lesions at Week 96|Double Blind Period: Mean Change in T2 Lesion Volume From Baseline to Week 96|Double Blind Period: Percent Change in Normalized Brain Volume From Baseline to Week 96|Double Blind Period: Mean Change in T1 Hypointense Lesion Volume From Baseline to Week 96|Double Blind Period: Annualized Qualifying Relapse Rate|Double Blind Period: Percentage of Participants Qualifying Relapse-free|Double Blind Period and OLE Period: Time to 3-Month Sustained Expanded Disability Status Scale (EDSS) Progression|Double Blind Period and OLE Period: Time to First Qualifying Relapse|Double Blind Period: Mean Change in New T1 Gd+ Lesions From Baseline to Week 96",True,2013-07-01
NCT05090033,Characterizing the Use of Ofatumumab in a Real World Setting,"Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS)",ACTIVE_NOT_RECRUITING,2022-12-08,2025-12-31,2025-12-31,2025-01-14,2021-10-22,OBSERVATIONAL,,103.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,ofatumumab|NIS|RMS,Australia,Concord,New South Wales,7,ofatumumab,OTHER,Part I and II: Proportion of doses not completed within three days of the expected date|Part I and II: Proportion of doses not completed within 3 days of the expected date,Part I: Proportion of doses not completed within three days of the expected date|Part I: Proportion of doses not completed within 14 days of the expected date|Part I: Proportion of participants with a treatment interruption of more than six months during maintenance|Part I: Proportion of participants discontinued within three months of the intial dose|Part I: Proportion of participants discontinued within 12 months of the intial dose.|Part I: Proportion of doses not completed within three days of the expected date for individual patient sub-groups|Part II: Proportion of doses not completed within 14 days of the expected date|Part II: proportion of participants discontinued within 18 months of the intial dose|Part II: Change in work productivity measured by the Work Productivity and Activity Impairment (WPAI) questionnaire|Part II: Change in generic health status as measured by the EQ5D|Part II: Change in fatigue as measured by the Fatigue Scale for Motor and Cognitive Function (FSMC).|Part II: Assessment of treatment satisfaction as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM1.4)|Part II: Proportion of self administration|Part II: Proportion of patients initiating ofatumumab who are treatment naïve|Part II: Change in Expanded Disability Status Scale (EDSS)|Part II: Annualized relapse rate|Part II: Number of T1 Gd-enhancing lesions per MRI scan|Part II: Number of new or enlarging T2 lesions on MRI|Percentage brain volume change,False,
NCT06121648,Effect of Hydrotherapy on Multiple Sclerosis,Effect of Hydrotherapy on the Balance and Fatigue of Multiple Sclerosis Patients,ACTIVE_NOT_RECRUITING,2023-09-01,2023-11-26,2023-12-15,2023-11-21,2023-11-08,INTERVENTIONAL,NA,26.0,ACTUAL,University of Thessaly,OTHER,,,Multiple Sclerosis,,Greece,Lamía,Central Macedonia,1,hydrotherapy|neurological physiotherapy,OTHER|OTHER,BBS scale|MFIS scale,,False,
NCT01667497,Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?,Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study,COMPLETED,2012-09,2015-07,2015-08,2015-09-02,2012-08-17,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,London Health Sciences Centre,OTHER,,,Cognitive Fatigue,Cognitive fatigue|multiple sclerosis,Canada,London,Ontario,1,Fampridine SR|Placebo,DRUG|DRUG,Change in Paced Auditory Serial Addition Test (PASAT) Cognitive Fatigue scores,,False,
NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,"A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients With Spasticity Due to Multiple Sclerosis",TERMINATED,2020-10-01,2023-02-10,2023-02-28,2024-05-08,2019-12-18,INTERVENTIONAL,PHASE3,139.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis (MS),Spasticity,United States,Birmingham,Alabama,37,Nabiximols|Placebo,DRUG|DRUG,Change in Average Daily Spasm Count From Baseline to Week 12 By 4-Week Period During the 12-Week Randomized Period,Change in Multiple Sclerosis Spasticity Scale (MSSS-88) Total Score|Number of Patients Reporting Any Treatment-emergent Adverse Events|Change From Baseline in Clinical Laboratory Test Values|Change From Baseline in Erythrocytes|Change From Baseline in Hemoglobin|Change From Baseline in Hematocrit Ratio|Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin|Change From Baseline in Blood Pressure|Change From Baseline in Heart Rate|Change From Baseline in Electrocardiogram Parameters|Change From Baseline in Electrocardiogram Pulse Rate|Change From Baseline in Weight|Change in Body Mass Index|Number of Patients With Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS),True,2024-05-08
NCT02193906,Neuropsychological Profile of a Patient's Group With Multiple Sclerosis and Effect of a Cognitive Rehabilitation Program,Neuropsychological Profile of a Portuguese Patient's Group With Multiple Sclerosis and Results of a Cognitive Rehabilitation Program,UNKNOWN,2012-12,2013-06,2014-12,2014-07-18,2014-07-18,INTERVENTIONAL,NA,75.0,ESTIMATED,Aveiro University,OTHER,,,Cognitive Dysfunction,Cognitive training|Multiple sclerosis|Cognitive deficits,,,,0,Cognitive training|Placebo task,OTHER|OTHER,Effect of an intensive cognitive rehabilitation program in neuropsychological performance of a population of patients with multiple sclerosis or clinical isolated syndrome.,Neuropsychological profile of a population of patients with multiple sclerosis or clinical isolated syndrome.|Percentage of patients with Cognitive Dysfunction|Relation between Expended Disability Status Scale score and cognitive dysfunction.|Impact of depression on neuropsychological performance.|Relation between cognitive dysfunction and the 9-hole peg test.|Relation between cognitive dysfunction and the 25-foot walk test.,False,
NCT03570268,Preventing Falls and Participation Restrictions in Neurological Diseases,Educational and Exercise Intervention to Prevent Falls and Participation Restrictions in Subjects With Neurological Diseases,COMPLETED,2015-01-01,2016-12-30,2017-01-15,2018-06-26,2018-06-26,INTERVENTIONAL,NA,90.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis|Parkinson Disease|Stroke,Falls prevention|Education|Neurological disease,Italy,Milan,,1,Experimental Group: Education|Control Group: Usual care,OTHER|OTHER,Change of Percentage of fallers,Change of Participation level,False,
NCT05811949,Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.,Effects of Dimethyl Fumarate on Cognitive Performances and Gray Matter and Thalamic Pathology in Multiple Sclerosis: a Correlation Study.,COMPLETED,2021-02-24,2022-10-11,2023-06-07,2024-10-15,2023-04-13,OBSERVATIONAL,,52.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Multiple Sclerosis,,Italy,Messina,,1,Dimethyl Fumarate 240 MG [Tecfidera],DRUG,Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Change in subjects' cognitive performance|Changes brain MRI parameters|Changes brain MRI parameters|Changes brain MRI parameters|Changes brain MRI parameters,Correlation between scores of cognitive battery and brain MRI parameters,False,
NCT00913250,A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers,"A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process",COMPLETED,2003-08,,2003-10,2009-06-04,2009-06-04,INTERVENTIONAL,PHASE1,96.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Interferon beta-1a,,,,0,Serum containing Avonex|Serum Free Avonex,DRUG|DRUG,To demonstrate the bioequivalence of a serum-free Avonex and a serum-containing AVONEX® when given intramuscularly (IM) to healthy volunteers.,,False,
NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,"A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients",COMPLETED,2013-06,2015-11,2015-11,2016-12-06,2013-07-10,INTERVENTIONAL,PHASE4,1001.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,169,Teriflunomide,DRUG,Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 - Assessment of Global Satisfaction Subscale Score With Teriflunomide Treatment at Week 48,"Change From Baseline in TSQM Scores in Participants Switching From Another Disease Modifying Therapy (DMT) at Week 4 and Week 48|Change From Week 4 in TSQM Scores in Naïve Participants to Week 48|Change From Baseline in Disease Progression Using Patient Determined Disease Steps (PDDS) Score at Week 48|Change From Baseline in Multiple Sclerosis Performance Scale (MSPS) Score at Week 24 and Week 48|Annualized Treated Relapse Rate|Time to Relapse: Kaplan-Meier Estimates of the Probability of Treated Relapse at Week 4, Week 24 and Week 48|Change From Baseline in Cognition Measured by Symbol Digit Modalities Test (SDMT) Score at Week 48|Overview of Adverse Events (AEs)|Percentage of Participants With Treatment Compliance of ≥80% During the Study Treatment Period|Duration of Teriflunomide Treatment Exposure|Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQoL) Score at Week 48|Change From Baseline in Stern Leisure Activity Scale at Week 48|Expanded Disability Status Scale (EDSS) Score at Baseline and Week 48",True,2016-12-06
NCT02457091,Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS,COMPLETED,2013-10,2014-09,2014-12,2015-12-03,2015-05-29,INTERVENTIONAL,PHASE2,32.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,multiple sclerosis|exercise|home-based|training|fitness,United States,Urbana-Champaign,Illinois,1,Resistance exercise|Stretching exercise,BEHAVIORAL|BEHAVIORAL,Physical fitness (aerobic and muscular)|Walking and physical function|Cognition|Physical activity|Patient-rated outcomes,Body composition|OCT Eye imaging|Cardiovascular function|Blood biomarkers,False,
NCT07142291,Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS,"A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)",NOT_YET_RECRUITING,2025-09,2027-09,2028-03,2025-09-18,2025-08-26,INTERVENTIONAL,PHASE2,105.0,ESTIMATED,"PhenoNet, Inc.",INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),Amyotrophic Lateral Sclerosis|Lou Gehrigs Disease|ALS,,,,0,Riluzole 50 MG,DRUG,Absolute change in ALSFRS-R total score from baseline to Week 24|Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs),"Mean rank for CAFS at Week 24|Time to event requiring full-time or nearly full-time respiratory support|Mean change in percent predicted forced vital capacity (%FVC) from baseline to Week 24|Mean change in peak inspiratory flow rate (PIFR) from baseline to Week 24|Absolute Values and Changes From Baseline in Vital Signs From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects With Abnormal Clinical Laboratory Values and Changes From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects With Abnormal Physical Examination Findings From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects With Abnormal Neurological Examination Findings From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects With Abnormal Electrocardiogram (ECG) Findings From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects With Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 24 by Treatment Arm|Number and Percentage of Subjects Who Discontinue Study Participation Due to Adverse Events From Baseline to Week 24",False,
NCT03655223,Early Check: Expanded Screening in Newborns,Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns,ENROLLING_BY_INVITATION,2018-10-15,2025-11-30,2025-12-31,2025-04-04,2018-08-31,OBSERVATIONAL,,30000.0,ESTIMATED,RTI International,OTHER,"University of North Carolina, Chapel Hill|The John Merck Fund|Duke University|Wake Forest University|North Carolina Department of Health and Human Services|National Center for Advancing Translational Sciences (NCATS)|Cure SMA|The National Fragile X Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Asuragen, Inc.|Sarepta Therapeutics, Inc.|Muscular Dystrophy Association|The Leona M. and Harry B. Helmsley Charitable Trust|Juvenile Diabetes Research Foundation|Janssen Pharmaceuticals|GeneDx|Illumina, Inc.",OTHER|UNKNOWN|OTHER|OTHER|OTHER_GOV|NIH|OTHER|OTHER|NIH|UNKNOWN|INDUSTRY|OTHER|OTHER|OTHER|INDUSTRY|UNKNOWN|INDUSTRY,"Spinal Muscular Atrophy|Fragile X Syndrome|Fragile X - Premutation|Duchenne Muscular Dystrophy|Hyperinsulinemic Hypoglycemia, Familial 1|Diabetes Mellitus|Adrenoleukodystrophy, Neonatal|Medium-chain Acyl-CoA Dehydrogenase Deficiency|Very Long Chain Acyl Coa Dehydrogenase Deficiency|Beta-ketothiolase Deficiency|Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency|Primary Hyperoxaluria Type 1|Congenital Bile Acid Synthesis Defect Type 2|Pyridoxine-Dependent Epilepsy|Hereditary Fructose Intolerance|Hypophosphatasia|Hyperargininemia|Mucopolysaccharidosis Type 6|Argininosuccinic Aciduria|Citrullinemia, Type I|Wilson Disease|Maple Syrup Urine Disease, Type 1A|Maple Syrup Urine Disease, Type 1B|Biotinidase Deficiency|Neonatal Severe Primary Hyperparathyroidism|Intrinsic Factor Deficiency|Usher Syndrome Type 1D/F Digenic (Diagnosis)|Cystic Fibrosis|Stickler Syndrome Type 2|Stickler Syndrome Type 1|Alport Syndrome, Autosomal Recessive|Alport Syndrome, X-Linked|Carbamoyl Phosphate Synthetase I Deficiency Disease|Carnitine Palmitoyl Transferase 1A Deficiency|Carnitine Palmitoyltransferase II Deficiency|Cystinosis|Chronic Granulomatous Disease|Cerebrotendinous Xanthomatoses|Maple Syrup Urine Disease, Type 2|Severe Combined Immunodeficiency Due to DCLRE1C Deficiency|Thyroid Dyshormonogenesis 6|Thyroid Dyshormonogenesis 5|Supravalvar Aortic Stenosis|Factor X Deficiency|Hemophilia A|Hemophilia B|Tyrosinemia, Type I|Fructose 1,6 Bisphosphatase Deficiency|Glycogen Storage Disease Type I|G6PD Deficiency|Glycogen Storage Disease II|Galactokinase Deficiency|Mucopolysaccharidosis Type IV A|Galactosemias|Guanidinoacetate Methyltransferase Deficiency|Agat Deficiency|Glutaryl-CoA Dehydrogenase Deficiency|Gtp Cyclohydrolase I Deficiency|Hyperinsulinism-Hyperammonemia Syndrome|Primary Hyperoxaluria Type 2|3-Hydroxyacyl-CoA Dehydrogenase Deficiency|Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency|Mitochondrial Trifunctional Protein Deficiency|Sickle Cell Disease|Beta-Thalassemia|Holocarboxylase Synthetase Deficiency|3-Hydroxy-3-Methylglutaric Aciduria|Primary Hyperoxaluria Type 3|Hermansky-Pudlak Syndrome 1|Hermansky-Pudlak Syndrome 4|Apparent Mineralocorticoid Excess|HSDB|CBAS1|Mucopolysaccharidosis Type 2|Mucopolysaccharidosis Type 1|Severe Combined Immunodeficiency, X Linked|Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency|Diabetes Mellitus, Permanent Neonatal|Isovaleric Acidemia|Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder)|Jervell and Lange-Nielsen Syndrome 2|Hyperinsulinemic Hypoglycemia, Familial, 2|Diabetes Mellitus, Permanent Neonatal, With Neurologic Features|Jervell and Lange-Nielsen Syndrome 1|Lysosomal Acid Lipase Deficiency|CblF|3-Methylcrotonyl CoA Carboxylase 1 Deficiency|3-Methylcrotonyl CoA Carboxylase 2 Deficiency|Waardenburg Syndrome Type 2A|Methylmalonic Aciduria cblA Type|Methylmalonic Aciduria cblB Type|Methylmalonic Aciduria and Homocystinuria Type cblC|MAHCD|Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency|Congenital Disorder of Glycosylation Type 1B|Mthfr Deficiency|Methylcobalamin Deficiency Type Cbl G (Disorder)|Methylcobalamin Deficiency Type cblE|Usher Syndrome, Type 1B|N-acetylglutamate Synthase Deficiency|Ornithine Transcarbamylase Deficiency|Phenylketonurias|Waardenburg Syndrome Type 1|Congenital Hypothyroidism|Propionic Acidemia|Usher Syndrome, Type 1F|Pancreatic Agenesis 1|Hereditary Hypophosphatemic Rickets|Glycogen Storage Disease IXB|Glycogen Storage Disease IXC|MOWS|Epilepsy, Early-Onset, Vitamin B6-Dependent|Pyridoxal Phosphate-Responsive Seizures|Pituitary Hormone Deficiency, Combined, 1|Ptsd|Dihydropteridine Reductase Deficiency|Severe Combined Immunodeficiency Due to RAG1 Deficiency|Severe Combined Immunodeficiency Due to RAG2 Deficiency|Retinoblastoma|Multiple Endocrine Neoplasia Type 2B|Pseudohypoaldosteronism, Type I|Liddle Syndrome|Biotin-Responsive Basal Ganglia Disease|SCD|DIAR1|GSD1C|Acrodermatitis Enteropathica|Thyroid Dyshormonogenesis 1|Riboflavin Transporter Deficiency|Waardenburg Syndrome, Type 2E|SRD|Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency|Barth Syndrome|Adrenocorticotropic Hormone Deficiency|Transcobalamin II Deficiency|Thyroid Dyshormonogenesis 3|Segawa Syndrome, Autosomal Recessive|Autosomal Recessive Nonsyndromic Hearing Loss|Thyroid Dyshormonogenesis 2A|Congenital Isolated Thyroid Stimulating Hormone Deficiency|Hypothyroidism Due to TSH Receptor Mutations|Usher Syndrome Type 1C|Usher Syndrome Type 1G (Diagnosis)|Von Willebrand Disease, Type 3|Combined Immunodeficiency Due to ZAP70 Deficiency|Adenine Phosphoribosyltransferase Deficiency|Metachromatic Leukodystrophy|Canavan Disease|Menkes Disease|Carbonic Anhydrase VA Deficiency|Developmental and Epileptic Encephalopathy 2|17 Alpha-Hydroxylase Deficiency|Smith-Lemli-Opitz Syndrome|Krabbe Disease|Glutathione Synthetase Deficiency|Mucopolysaccharidosis Type 7|Rett Syndrome|Molybdenum Cofactor Deficiency, Type A|Niemann-Pick Disease, Type C1|Niemann-Pick Disease Type C2|Ornithine Aminotransferase Deficiency|3-Phosphoglycerate Dehydrogenase Deficiency|Leber Congenital Amaurosis 2|Dravet Syndrome|Mucopolysaccharidosis Type 3 A|Ornithine Translocase Deficiency|Carnitine-acylcarnitine Translocase Deficiency|Glucose Transporter Type 1 Deficiency Syndrome|Creatine Transporter Deficiency|Niemann-Pick Disease Type A|Pitt Hopkins Syndrome|Tuberous Sclerosis 1|Tuberous Sclerosis 2|Ataxia With Isolated Vitamin E Deficiency|Angelman Syndrome|Prader-Willi Syndrome|Homocystinuria|Permanent Neonatal Diabetes Mellitus|Transient Neonatal Diabetes Mellitus|Factor VII Deficiency|Glycogen Storage Disease Type IXA1|Glycogen Storage Disease, Type IXA2|Glycogen Storage Disease IC|Glycogen Storage Disease Type IB|Central Hypoventilation Syndrome With or Without Hirschsprung Disease",Newborn Screening|Rare Disorders|Genetic Counseling|Families|Development|Risk|Genetic Sequencing,United States,Research Triangle Park,North Carolina,1,Confirmatory Testing,DIAGNOSTIC_TEST,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,False,
NCT02296346,Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis,"A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)",TERMINATED,2014-10,2017-06-13,2018-05-10,2019-08-14,2014-11-20,INTERVENTIONAL,NA,13.0,ACTUAL,University of Utah,OTHER,Mallinckrodt,INDUSTRY,Secondary Progressive Multiple Sclerosis,,United States,Ann Arbor,Michigan,1,SoluMedrol|Extracorporeal Photopheresis,DRUG|DEVICE,Multiple Sclerosis Functional Composite (MSFC) Z-score and Expanded Disability Status Scale (EDSS),Immunological Parameters in Relation to SPMS,True,2019-08-14
NCT05057676,Autoimmune Intervention Mastery Course Study,Evaluation of an Online Course Designed to Support the Adoption of Healthier Diet and Self-Care Routines in Multiple Sclerosis Patients,RECRUITING,2021-12-01,2026-12-01,2026-12-01,2024-07-24,2021-09-27,INTERVENTIONAL,NA,80.0,ESTIMATED,Terry L. Wahls,OTHER,,,Multiple Sclerosis|Clinically Isolated Syndrome|Fibromyalgia|Post Acute Sequelae of COVID-19|Cancer in Remission With Persisting Fatigue,diet|self care,United States,Iowa City,Iowa,1,Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate Question and Answer sessions. (AIM Q and A sessions)|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed AIM Question and Answer sessions,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)|Short form 36 (SF 36)|Short form 36 (SF 36)|The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-FS):|The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-FS):,Modified Fatigue Impact Scale|Modified Fatigue Impact Scale|vegetable and fruit intake|vegetable and fruit intake|added sugar intake|added sugar intake|calcium intake|calcium intake|Servings of whole grains consumed|Servings of whole grains consumed|Fibromyalgia Impact Questionnaire Revised|Fibromyalgia Impact Questionnaire Revised|Brief Pain Inventory|Brief Pain Inventory|FM Disease activity (FIQR)|FM Disease activity (FIQR)|Pain scale|Pain catastrophizing scale|Functional Assessment of Cancer Therapy - General (FACT-G)|Functional Assessment of Cancer Therapy - General (FACT-G),False,
NCT04082468,VALIDATE: Factor VIII Trending for MS Relapse,Observational Trial Evaluating Whether Elevated Factor VIII Activity During Multiple Sclerosis Relapses Serves as a Marker for Solumedrol-Resistance and Incomplete Relapse Recovery,WITHDRAWN,2019-08-13,2021-12-01,2022-03-01,2021-09-21,2019-09-09,OBSERVATIONAL,,0.0,ACTUAL,"St. Joseph's Hospital and Medical Center, Phoenix",OTHER,,,Multiple Sclerosis,Relapsing remitting Multiple Sclerosis,United States,Phoenix,Arizona,1,Blood sample collection for coagulation profile,DIAGNOSTIC_TEST,Correlation of MS relapse recovery time with elevated lab values.,,False,
NCT05051618,Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis,Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis,RECRUITING,2023-04-01,2026-03-31,2026-03-31,2025-06-11,2021-09-21,INTERVENTIONAL,NA,146.0,ESTIMATED,University of Illinois at Chicago,OTHER,Congressionally Directed Medical Research Programs,FED,Multiple Sclerosis|Major Depressive Disorder,Multiple Sclerosis|MS|Depression|MDD|Exercise|Physical Activity|Intervention|Behavior,United States,Chicago,Illinois,1,POWER-MS|FLEX-MS,BEHAVIORAL|BEHAVIORAL,Change in Depression Severity (self-report)|Change in Depression Severity (observer-rated),Change in Perception of Fatigue Severity|Change in Cognitive Performance|Change in Quality of Life,False,
NCT00915460,Open-Label Safety Extension Study of Avonex,"An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830",COMPLETED,1999-09,2003-06,2003-07,2009-06-08,2009-06-08,INTERVENTIONAL,PHASE4,408.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Avonex|Interferon beta-1a|patients at high risk to develop multiple sclerosis,,,,0,Interferon beta-1a (Avonex),DRUG,The primary objective of this study is to collect data on serious adverse events which occur during extended treatment with AVONEX in subjects at high risk for developing MS and in subjects with secondary progressive MS.,To monitor the occurrence of diagnosed clinically definite multiple sclerosis (CDMS) in subjects who enter this study at high risk for developing MS following an initial demyelinating event.,False,
NCT04125823,Video Game-based Physical Activity Training in People With Multiple Sclerosis During Relapse Treatment,Effects of Video Game-based Physical Activity Training in People With Multiple Sclerosis in the Inpatient Period During Relapse Treatment: a Pilot Randomized Controlled Trial,COMPLETED,2019-10-23,2022-01-15,2022-02-15,2022-06-01,2019-10-14,INTERVENTIONAL,NA,30.0,ACTUAL,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Video game-based physical activity training|Conventional physiotherapy program,BEHAVIORAL|BEHAVIORAL,"Feasibility - Recruitment process: Number of people referred from physician and eligible for screening. Number of people attending interview with researcher.|Acceptability - Prospective acceptability: Barriers (screening interview).|Acceptability - Intervention coherence and adherence: Number of sessions attended.|Acceptability - Experience (satisfaction, perceptions): Qualitative interview",Timed 25-Foot Walk|12-Item Multiple Sclerosis Walking Scale|Modified Fatigue Impact Scale|2-Minute Walk Test|Six-Spot Step Test|Nine-Hole Peg Test|Manual Ability Measure-36|Epworth Sleepiness Scale|Multiple Sclerosis International Quality of Life Questionnaire|Hospital Anxiety and Depression Scale - Anxiety|Hospital Anxiety and Depression Scale - Depression|Symbol Digit Modalities Test|California Verbal Learning Test-II|Revised Brief Visuospatial Memory Test|Paced Auditory Serial Addition Test,False,
NCT04006613,Effects of a Circuit Training on Balance in Persons With Multiple Sclerosis,Effects of a Circuit Training on Balance Management in a State of Fatigue in Persons With Multiple Sclerosis,COMPLETED,2019-02-26,2025-05-01,2025-05-01,2025-07-08,2019-07-05,INTERVENTIONAL,NA,52.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,Fatigue|Balance|Aerobic training,Italy,Milan,,1,Circuit Training|Usual Care,OTHER|OTHER,Change from Baseline Modified Fatigue Impact Scale at 6-8 weeks,Change from Baseline Modified Dynamic Gait Index at 6-8 weeks|Change from Baseline 6 Minutes Walking Test at 6-8 weeks|Change from Baseline 10 Meter Walking Test at 6-8 weeks|Change from Baseline 5-Time-Sit-To-Stand at 6-8 weeks|Change from Baseline 12 item Multiple Sclerosis Walking Scale at 6-8 weeks|Change from Baseline Hospital Anxiety and Depression Scale at 6-8 weeks,False,
NCT01202227,An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain,"An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)",COMPLETED,2010-09,2012-03,2012-03,2021-01-28,2010-09-15,INTERVENTIONAL,PHASE3,104.0,ACTUAL,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,,,Spinal Cord Diseases|Spinal Cord Injuries|Neuralgia|Pain,Central Nervous System Diseases|Therapeutic Uses|Wounds and Injuries|Trauma|Nervous System|pregabalin,Japan,Nagoya,Aichi-ken,26,pregabalin,DRUG,Number of Participants With Peripheral Edema|Number of Participants With Facial/Periorbital Edema|Number of Participants With Generalized or Abdominal Edema|Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)|Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)|Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)|Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)|Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)|Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)|Number of Participants With Visual Field Deteriorated|Number of Participants With Deterioration in Neurological Examination Findings|Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS),Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores|Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores|Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores|Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score,True,2013-05-17
NCT05017038,The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis,The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis - Longitudinal Observational Study - INESEP,UNKNOWN,2021-03-03,2023-03-03,2023-06-30,2021-08-23,2021-08-23,OBSERVATIONAL,,2000.0,ESTIMATED,"Central Hospital, Nancy, France",OTHER,,,Multiple Sclerosis|Social and Territorial Inequalities,,France,Bordeaux,,5,,,"The endpoint will be the time from disease onset to treatment, and the co-variates of the multivariate model will be all socio-demographic and clinical characteristics at disease onset.",Delay before first treatment|Time to reach an EDSS of more than 4|Difference in disposable income between the start of the illness and the point date.,False,
NCT01387217,GSK2018682 FTIH in Healthy Volunteers,"A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers",COMPLETED,2010-05-21,2010-12-20,2010-12-20,2017-06-09,2011-07-04,INTERVENTIONAL,PHASE1,27.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,GSK2018682|First Time in Human|Healthy Volunteer,Australia,Randwick,New South Wales,2,GSK2018682|Placebo,DRUG|DRUG,To investigate the safety and tolerability of single escalating oral doses of GSK2018682|To investigate effects of GSK2018682 on heart rate and blood pressure|To investigate the pharmacokinetics of single doses of GSK2018682|Evaluate the effect of single escalating oral doses of GSK2018682 on lymphocytes (totals plus subsets),,False,
NCT01610310,Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers,"A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) Delivered by Pre-filled Syringe (PFS) or Autoinjector in Healthy Volunteers",COMPLETED,2012-06,2012-10,2012-10,2014-06-13,2012-06-04,INTERVENTIONAL,PHASE1,55.0,ACTUAL,Biogen,INDUSTRY,,,Healthy|Multiple Sclerosis,SC|PEG|Inteferon|PK|Subcutaneous|PEGylated|Autoinjector|Injectable|MS,United States,Saint Paul,Minnesota,1,BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|BIIB017 (peginterferon beta-1a) Autoinjector,DEVICE|DEVICE,Area under the time-concentration curve for serum concentrations of peginterferon beta-1a from time zero to infinity post dose (AUC0-∞),Maximum Serum Concentration (Cmax) of peginterferon beta-1a|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Changes in clinical laboratory assessments|Vital sign changes|Physical exam changes|Electrocardiogram changes|Clinician injection site assessment,False,
NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2020-12-03,2025-06-30,2027-09-08,2025-09-08,2020-09-16,INTERVENTIONAL,PHASE3,769.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,"Primary Progressive Multiple Sclerosis; Higher Dose of CD20 Antibody Ocrelizumab; Efficacy, Safety and Pharmacokinetics",United States,Homewood,Alabama,149,Ocrelizumab|Ocrelizumab|Antihistamine|Methylprednisolone,DRUG|DRUG|DRUG|DRUG,Time to Onset of Composite Confirmed Disability Progression (cCDP) Sustained for at least 12 Weeks,Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) Independent of Protocol-defined Relapses (PDR)|Time to Onset of 12-week Confirmed Disability Progression (CDP12)|Time to ≥ 20% Increase in 12-week Confirmed by T25FWT|Change in Neurofilament Light (NfL) at Week 96|Time to 12-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS12)|Annual Rate of Percent Change From Baseline in Total Brain Volume|Annual Rate of Percent Change From Baseline in Thalamic Volume|Time to 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)|Change in NfL (i.e. Ratio to Baseline) at Week 96 for Participants in the Approved Dose Ocrelizumab Group|Change in NfL (i.e. Ratio to Baseline) at Week 96 for Participants in the Higher Dose Ocrelizumab Group|Time to Onset of 24-week Composite Confirmed Disability Progression (cCDP24) Independent of PDR|Percentage of Participants With Adverse Events (AEs)|Serum Concentrations of Ocrelizumab at Specified Timepoints|Change in B-cell Levels in Blood|Percentage of Participants Achieving 5 or Less B-cells per Microliter of Blood|Change From Baseline in the Anti-drug Antibody (ADA) Levels,False,
NCT05090371,A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation,"A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)",RECRUITING,2022-03-02,2026-12-31,2026-12-31,2025-08-19,2021-10-22,INTERVENTIONAL,PHASE4,150.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Ofatumumab|Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|adult|OMB157|RRMS|MS|secondary progressive MS|relapse,United States,Birmingham,Alabama,43,Ofatumumab|Disease modifying treatment (DMT),DRUG|DRUG,Percentage of participants achieving NEDA-3 (No Evidence of Disease Activity-3),Percentage of participants with a single baseline NfL≥10pg/ml and NfL<10pg/ml achieving NEDA-3 (No Evidence of Disease Activity-3)|Annualized relapse rate in Months 3 to 15|Percentage of participants without a worsening of their disability|Percentage of participants with NEDA (No Evidence of Disease Activity) - Clinical|Percentage of participants with NEDA (No Evidence of Disease Activity) - Radiological|Mean change in The Symbol-Digit Modality Test|Mean change in the Time 25 Foot Walk|Mean change in the 9 Hole Peg Test|Mean change in Gd+ lesion count|Mean change in Gd+ lesion volume|Mean change in T2 lesion count|Mean change in T2 lesion volume|Mean change from Baseline in T1|Mean change in MSQOL-54|Mean whole brain and regional volume loss from Baseline|Percentage of participants reporting treatment emergent adverse events (TEAEs) and serious adverse events,False,
NCT05313204,Exercise and Pregnancy in People With Multiple Sclerosis,Physiological Responses to Exercise During Pregnancy in People With Multiple Sclerosis,COMPLETED,2020-09-01,2023-08-01,2023-08-01,2023-10-06,2022-04-06,OBSERVATIONAL,,29.0,ACTUAL,University of Alberta,OTHER,,,Multiple Sclerosis|Pregnancy,,Canada,Edmonton,Alberta,1,Moderate-intensity cardiovascular exercise,OTHER,Heart rate|Fatigue|Physical activity and sedentary behaviour,Glucose,False,
NCT00037947,Auditory Function in Patients With and Without Multiple Sclerosis,Auditory Function in Patients With and Without Multiple Sclerosis,COMPLETED,2001-10,2007-12,2007-12,2008-06-04,2002-05-27,INTERVENTIONAL,PHASE2,300.0,ESTIMATED,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Multiple Sclerosis|MS|Hearing,United States,Portland,Oregon,1,Hearing in Multiple Sclerosis,PROCEDURE,,,False,
NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,"Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase",COMPLETED,2003-05,2011-04,2011-04,2017-09-15,2006-06-02,INTERVENTIONAL,PHASE2,281.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,FTY720|MS|Multiple Sclerosis|RRMS,Canada,Montreal,,26,FTY720|Placebo,DRUG|DRUG,Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)|Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12|Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60|Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study,Percentage of Participants Free of T1-weighted Lesions|Percentage of Patients Free of Gd-enhanced T1-weighted and New T2- Weighted Lesions by Visit|Mean Number of New T2-weighted Lesions|Volume of T2-weighted Lesions|Change From Baseline in Volume of Total T2-weighted Lesions|Time to Event Analysis: Kaplan Meier Estimates of Percentage of Relapse-free Patients|Mean Trough Blood Concentrations of FTY720,True,2012-10-30
NCT00278655,Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis,Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial,TERMINATED,2003-06,2011-12,2012-05,2014-05-01,2006-01-18,INTERVENTIONAL,PHASE1|PHASE2,21.0,ACTUAL,Northwestern University,OTHER,,,Multiple Sclerosis,,,,,0,Hematopoietic stem cell transplantation,BIOLOGICAL,Disease Progression,Survival,True,2014-05-01
NCT04744207,A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis,"A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)",COMPLETED,2020-12-29,2022-06-15,2022-06-15,2024-08-09,2021-02-08,INTERVENTIONAL,PHASE2,94.0,ACTUAL,Gesynta Pharma AB,INDUSTRY,Ergomed,INDUSTRY,Systemic Sclerosis,,Belgium,Ghent,,12,GS-248|Placebo,DRUG|DRUG,Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week.,Mean Change From Baseline to Week 4 in the Raynaud's Condition Score.|Mean Change From Baseline to Week 4 in Pain Experienced During Raynaud Attacks.|Mean Change From Baseline to Week 4 in the Mean Duration of Raynaud's Attacks|Mean Change From Baseline to Week 4 in the Cumulative Duration of Raynaud Attacks.,True,2024-08-09
NCT03092544,Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients,Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients,UNKNOWN,2015-02,2018-12,2018-12,2018-03-22,2017-03-28,INTERVENTIONAL,PHASE4,57.0,ACTUAL,Multiple Sclerosis Center of Northeastern New York,OTHER,Icahn School of Medicine at Mount Sinai|Biogen,OTHER|INDUSTRY,Multiple Sclerosis,,United States,Latham,New York,1,dimethyl fumarate,DRUG,Change in plasma samples collected from stable RRMS patients on dimethyl fumarate for their ability to induce changes in neuronal bioenergetics|Change in cerebrospinal (CSF) samples collected from stable RRMS patients on dimethyl fumarate for their ability to induce changes in neuronal bioenergetics|change in levels of neurofilament( NFL) in RRMS patients|change in levels of ceramide sphyngosine and other lipid species in samples collected from patients before and after therapy in CSF samples in RRMS patients|changes in microbiota composition consequent to dimethyl fumarate treatment.,,False,
NCT06947434,Laughter Yoga for Improving Sexual Function and Psychosocial Outcomes in Multiple Sclerosis,"Effects of Laughter Yoga on Sexual Functioning, Anxiety, Depression, Fatigue, and Quality of Life in Patients With Multiple Sclerosis: A Quasi-Experimental Study",COMPLETED,2022-03-01,2023-03-01,2024-03-01,2025-04-30,2025-04-27,INTERVENTIONAL,NA,26.0,ACTUAL,Istanbul University,OTHER,,,Multiple Sclerosis|Sexual Dysfunction,multiple sclerosis|sexual life|anxiety|depression|quality of life|laughter yoga,Turkey (Türkiye),Istanbul,,1,Laughter Yoga,OTHER,Change in Sexual Functioning (MSISQ-19 Total Score),Change in Anxiety Level (HADS-A Score)|Change in Fatigue Level (Fatigue Severity Scale Score),False,
NCT04239521,"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata",COMPLETED,2020-10-01,2022-03-31,2022-11-28,2022-12-15,2020-01-27,OBSERVATIONAL,,51955.0,ACTUAL,Momentum Data,INDUSTRY,Pfizer|University of Surrey|University of Oxford,INDUSTRY|OTHER|OTHER,Alopecia Areata|Depressive Episode|Recurrent Depressive Disorder|Anxiety Disorders|Atopic Dermatitis|Allergic Rhinitis|Asthma|Crohn Disease|Ulcerative Colitis|Pernicious Anemia|Type 1 Diabetes|Hashimoto Thyroiditis|Graves Disease|Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Systemic Lupus Erythematosus|Polymyalgia Rheumatica|Sjogren's Syndrome|Psoriasis|Vitiligo|Multiple Sclerosis|Celiac Disease|Upper Respiratory Tract Infection|Influenza|Lower Resp Tract Infection|Acute Bronchitis|Pneumonia|Gastrointestinal Infection|Skin Infection|Urinary Tract Infections|Genital Infection|Herpes Zoster|Herpes Simplex|Infection|Infection Viral,Alopecia areata|Common mental health conditions|Depression|Anxiety|Autoimmune disease|Atopic conditions|Epidemiology|Incidence|Prevalence|Infection,United Kingdom,London,,1,Exposure of interest (studies 2 & 3).,OTHER,Study 1: The incidence of Alopecia Areata|Study 1: The incidence of Alopecia Areata stratified by sociodemographic factors|Study 1:The annual rate of primary care visits for people with Alopecia Areata.|Study 1: Secondary care dermatology service utilisation|Study 2: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis|Study 2: Describe the incidence of common mental health conditions in adult patients with Alopecia Areata|Study 2: Describe the mental health medication treatment burden of adult patients diagnosed with Alopecia Areata.|Study 2: Number of patients diagnosed with Alopecia Areata receiving mental health psychological intervention.|Study 3: Describe the prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis|Study 3: Describe the incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata.|Study 4: The incidence of a composite of common infections in adult patients with Alopecia Areata|Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata,"Study 1: Adjusted incidence rate ratios of Alopecia Areata within England by geographic region.|Study 2: Prevalence (percentage) of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder), by socio-demographic factors, in adult patients diagnosed with Alopecia Areata.|Study 2: Describe the burden of 'sick days' in adult patients diagnosed with Alopecia Areata relating to mental health conditions.|Study 2: Describe the prevalence of unemployment in adult patients diagnosed with Alopecia Areata.|Study 4: The incidence of upper respiratory tract infection in adult patients with Alopecia Areata|Study 4: The incidence of lower respiratory tract infection in adult patients with Alopecia Areata|Study 4: The incidence of influenza infection in adult patients with Alopecia Areata|Study 4: The incidence of acute bronchitis in adult patients with Alopecia Areata|Study 4: The incidence of pneumonia in adult patients with Alopecia Areata|Study 4: The incidence of gastrointestinal infection in adult patients with Alopecia Areata|Study 4: The incidence of stool confirmed gastrointestinal infection in adult patients with Alopecia Areata|Study 4: The incidence of skin infection in adult patients with Alopecia Areata|Study 4: The incidence of urinary tract infection in adult patients with Alopecia Areata|Study 4: The incidence of genital infection in adult patients with Alopecia Areata|Study 4: The incidence of herpes zoster infection in adult patients with Alopecia Areata|Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata",False,
NCT05362006,"Exopulse Mollii Suit, Spasticity & Tissue Oxygenation",The Effects of a TENS System (Transcutaneous Electric Nerve Stimulation) on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis (ENNOX Study),COMPLETED,2022-03-01,2023-04-18,2023-05-30,2025-06-26,2022-05-05,INTERVENTIONAL,NA,28.0,ACTUAL,Institut De La Colonne Vertebrale Et Des Neurosciences,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Oxygenation|Muscles|Spasticity,France,Créteil,,1,Exopulse Mollii Suit|Exopulse Mollii suit (sham),DEVICE|DEVICE,Changes in oxyhemoglobin level at baseline and at week 2.|Changes in deoxyhemoglobin level at baseline and at week 2.|Changes in tissue oxygenation index at baseline and at week 2.|Change in total hemoglobin level at baseline and at week 2.,Modified Ashworth Scale (MAS)|Numerical Rating Scale of spasticity (NRS)|Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL)|Changes in oxyhemoglobin level at week 4 and week 8.|Changes in deoxyhemoglobin level at week 4 and week 8.|Changes in tissue oxygenation index at week 4 and week 8.|Changes in total hemoglobin level at week 4 and week 8.|Visual Analog Scale (VAS) pain|Mobility will be assessed using the MSWS-12 (Multiple Sclerosis Walking Scale - 12)|Mobility will be assessed using the FES-I (Falls Efficacy Scale-International scale),False,
NCT03933215,A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS),Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Injectable DMDs for RMS (CLICK-MS),COMPLETED,2019-05-21,2024-03-30,2024-03-30,2025-04-29,2019-05-01,OBSERVATIONAL,,100.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Cladribine Tablets|Observational|Mavenclad,United States,Little Rock,Arkansas,18,Cladribine,DRUG,Annualized Relapse Rate (ARR),"Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Score at Month 6, 12 and 24|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score at Month 6, 12 and 24|Change From Baseline in Modified Fatigue Impact Scale - 5-item Version (MFIS-5) Total Score at Month 6, 12 and 24|Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24|Change From Baseline in Percent Work Time Missed Assessed by 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Score at Month 6, 12 and 24|Change From Baseline in Percent Impairment While Working Assessed by 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Score at Month 6, 12 and 24|Change From Baseline in Percent Overall Work Impairment Assessed by 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Score at Month 6, 12 and 24|Change From Baseline in Percent Activity Impairment Assessed by 6-Item Work Productivity Activity Impairment- Multiple Sclerosis (WPAI-MS) Score at Month 6, 12 and 24|Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24|Number of Participants With Adherence to Cladribine as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)|Percentage of Participants Who Experienced Relapse at Months 12 and 24|Annualized Relapse Rate (ARR) at Month 12|Percentage of Participants Who Experienced Relapse Associated With Hospitalization|Annualized Relapse Rate (ARR) Associated With Hospitalization at Months 12 and 24|Percentage of Participants Who Experienced Relapse Associated With Glucocorticoid Use|Annualized Relapse Rate (ARR) Associated With Glucocorticoid Use at Months 12 and 24|Number of Previous Disease-Modifying Drugs (DMD) Received for Multiple Sclerosis (MS) at Baseline|Number of Participants Who Received At Least One Concomitant Medication|Percentage of Participants Who Discontinued Cladribine Tablets|Elapsed Time to Discontinuation After First Dose of Cladribine Tablets|Number of Doses Received by Participants as Per United States Prescribing Information|Percentage of Participants With Treatment Compliance as Per United States Prescribing Information|Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs) and Adverse Events of Special Interest (AESIs)",True,2025-04-29
NCT05456464,Fatigue and Sleep Quality in Multiple Sclerosis Patients,Fatigue and Sleep Quality in Multiple Sclerosis Patients: Does Reiki Application Affect?,COMPLETED,2022-06-01,2022-08-08,2022-09-30,2023-08-31,2022-07-13,INTERVENTIONAL,NA,60.0,ACTUAL,Istanbul Sabahattin Zaim University,OTHER,,,Multiple Sclerosis,Reiki|Fatigue|Sleep quality|Nursing,Turkey (Türkiye),Istanbul,Güneydoğu Anadolu Bölgesi,1,Reiki,OTHER,The Piper Fatigue Scale|The Piper Fatigue Scale|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI),,False,
NCT03655093,Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis,Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis,COMPLETED,2017-04-25,2017-07-03,2017-07-03,2018-08-31,2018-08-31,OBSERVATIONAL,,200.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Self-questionnaire|Measurement tools,France,Rennes,,1,Validation of AMSQ questionnaire,OTHER,Validate the French version of the AMSQ self-questionnaire in a population of MS patients,,False,
NCT00704626,Serum Auto-Antibodies in Neurological Diseases,CCRC: Serum Auto-Antibodies in Neurological Disease,ENROLLING_BY_INVITATION,2002-01,2031-03,2031-03,2025-05-15,2008-06-25,OBSERVATIONAL,,120.0,ESTIMATED,"University of California, Davis",OTHER,,,Multiple Sclerosis|Myasthenia Gravis|Transverse Myelitis,Multiple Sclerosis|Autoimmune disease|Inflammatory disease|Myasthenia Gravis|Transverse Myelitis,United States,Sacramento,California,1,Blood Draw|Cheek swab,OTHER|OTHER,"If the serum is positive for specific antibody binding, additional serum samples may be obtained and retested up to 8 more times approximately 3 months apart.",,False,
NCT06648499,Five Times Sit-To-Stand Test for Patients with Pediatric-Onset Multiple Sclerosis,Five Times Sit-To-Stand Test for Patients with Pediatric-Onset Multiple Sclerosis: Performance and Explanatory Factors,NOT_YET_RECRUITING,2024-10-28,2024-11-18,2024-12-16,2024-10-22,2024-10-18,OBSERVATIONAL,,46.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,,,Pediatric-Onset Multiple Sclerosis (POMS),lower extremity muscle strength|pediatric-onset multiple sclerosis|five times sit-to-stand test|physiotherapy,,,,0,"Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls",OTHER|OTHER,Five Times Sit-To-Stand Test performance,Pediatric Quality of Life Inventory|PedsQL Multidimensional Fatigue Scale|The Godin Leisure Time Exercise Questionnaire|2-Minute Walk Test|Timed Up and Go Test,False,
NCT05367947,In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis,Investigation of In-phase Bilateral Exercise Effects on Corticospinal Plasticity in Relapsing Remitting Multiple Sclerosis: a Registered Report Single-case Concurrent Multiple Baseline Design Across Five Subjects,COMPLETED,2023-03-10,2023-10-06,2023-10-13,2024-02-07,2022-05-10,INTERVENTIONAL,NA,5.0,ACTUAL,Cyprus University of Technology,OTHER,The Cyprus Foundation for Muscular Dystrophy Research,OTHER,Multiple Sclerosis,transcranial magnetic stimulation|multiple sclerosis|exercise,Cyprus,Limassol,,1,In-phase Bilateral Exercises of the upper limbs,BEHAVIORAL,Corticospinal Plasticity,Mini Balance Evaluation Systems Test|Six Spot Step Test|Action Research Arm Test|Isometric Dynamometer|Symbol Digit Modalities Test|Modified Fatigue Impact Scale,False,
NCT04532944,The Energetic Origin of Neurodegeneration in MS,"Exploring in Vivo the Energetic Origin of Neurodegeneration in Multiple Sclerosis: a Ultra-high Field Sodium Imaging, Phosphorus Spectroscopy and Diffusion-weighted Spectroscopy Study.",UNKNOWN,2020-09-15,2022-09-15,2024-03-15,2020-08-31,2020-08-31,INTERVENTIONAL,NA,55.0,ESTIMATED,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,,,Multiple Sclerosis,energy dysfunction|neurodegeneration|7 T MRI|sodium imaging|phosphorus spectroscopy|diffusion-weighted spectroscopy,,,,0,imaging of energy dysfunction,DIAGNOSTIC_TEST,Energy dysregulation in the whole brain with sodium imaging|Energy dysregulation in the motor-sensory region (MSR) with phosphorus spectroscopy|Energy dysregulation in the motor-sensory region with diffusion-weighted spectroscopy|Neurodegeneration in the MSR after 24 months,Patient-specific profiles of energy dysregulation|cortical demyelination and remyelination|neuro-axonal damage over time|functional changes in brain connectivity|serum markers of tissue damage|physical and cognitive dysfunction|physical and cognitive dysfunction|physical and cognitive dysfunction,False,
NCT06179134,Cognitive Rehabilitation for People With Multiple Sclerosis,Cognitive Rehabilitation Training for People With Multiple Sclerosis: a Randomized Controlled Trial,NOT_YET_RECRUITING,2024-06-03,2024-12-31,2025-01-31,2024-04-16,2023-12-21,INTERVENTIONAL,NA,50.0,ESTIMATED,Sunnybrook Health Sciences Centre,OTHER,,,Multiple Sclerosis,Cognitive rehabilitation|Goal Management Training,Canada,Toronto,Ontario,1,Goal Management Training,BEHAVIORAL,Number of participants with improved Information processing speed,Number of participants with improved learning and memory|Number of participants with improved executive function,False,
NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,"A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)",COMPLETED,2011-05,2014-06,2014-06,2015-06-22,2011-03-16,INTERVENTIONAL,PHASE4,61.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple sclerosis|Fingolimod|Disease Modifying Therapy|TSQM-9,Italy,Ancona,AN,17,Fingolimod|Standard MS DMT,DRUG|DRUG,Change From Baseline in Patient-reported Treatment Satisfaction,Change From Baseline in Patient-reported Activities of Daily Living (ADL)|Change From Baseline in Patient-reported Fatigue|Change From Baseline in Patient-Reported Effectiveness and Convenience|Change From Baseline in Patient-reported Depression|Change From Baseline in Patient-reported Health Related Quality of Life (QOL)|Physician-reported Clinical Global Impression of Improvement (CGI-I),True,2015-06-22
NCT00794352,Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System,Comprehensive Multimodal Analysis of Patients With Neuroimmunological Diseases of the CNS,RECRUITING,2008-10-01,,,2025-09-24,2008-11-20,OBSERVATIONAL,,2400.0,ESTIMATED,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,Central Nervous System Disease|Multiple Sclerosis,Inflammation|Multiple Sclerosis|Neuroimmunology|Immune Disorder|Neuroimaging|Natural History|Central Nervous System Disease|Healthy Volunteers|HV,United States,Bethesda,Maryland,1,,,Disease progression as assessed by clinical and MRI criteria.|Definite diagnosis of MS or another disorder.,MRI measures of lesion load and CNS tissue destruction|Immunological biomarkers|Clinical measures of disability|Changes in MRI measure of lesion load and CNS tissue destruction from baseline|Changes in clinical measures of disability from baseline,False,
NCT05010902,Pregnancy Cohort in Multiple Sclerosis (MS),Pregnancy Cohort in Multiple Sclerosis (MS),RECRUITING,2013-01-01,2025-12-31,2026-12-31,2024-07-05,2021-08-18,OBSERVATIONAL,,100.0,ESTIMATED,"Charite University, Berlin, Germany",OTHER,,,Multiple Sclerosis (MS)|Clinically Isolated Syndrome (CIS),Pregnancy,Germany,Berlin,,1,,,Time until relapse,Number of T2 lesions|Number of gadolinium enhancing lesions|Volume of T2 lesions|Volume of gadolinium enhancing lesions|Change in immune cell phenotypes|Galectin-1|Galectin-3|Galectin-9|Neurofilament (NfL)|Pro-inflammatory interleukin-17|Anti-inflammatory interleukin-10|Autoantibody profiling|Fecal microbiome composition|Thickness of the retinal nerve fibre layer|Total macular volume (TMV)|Mini-International Neuropsychiatric Interview (M.I.N.I.) German Version 5.0.0 Module A-C|Montgomery-Asberg Depression Rating Scale (MADRS)|Beck Depression Inventory (BDI-II)|Edinburgh Postpartum Depression Scale (EPDS)|Modified Fatigue Inventory Scale (MFIS)|Fatigue Severity Scale (FSS)|Visual Fatigue Analogue Scale (VFAS)|Short-Form Health Survey (SF-36),False,
NCT01710228,Alternative Treatment Paradigm for Natalizumab Trial,Alternative Treatment Paradigm for Natalizumab Trial,WITHDRAWN,2013-07,2013-12,2013-12,2016-12-29,2012-10-19,INTERVENTIONAL,PHASE2,0.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,"Teva Branded Pharmaceutical Products R&D, Inc.|The University of Texas Health Science Center, Houston|University of Alabama at Birmingham|Charite University, Berlin, Germany",INDUSTRY|OTHER|OTHER|OTHER,Multiple Sclerosis (MS),MS|Natalizumab|copaxone,United States,Dallas,Texas,1,methylprednisolone,DRUG,annualized relapse rate,"restoration of immune homeostasis - evaluated by regular brain MRI with contrast at baseline, month6 and month 12 of the study",False,
NCT05776511,Diagnostic Value of eVOG,Diagnostic Value of Digital Video Oculography in Patients With White Matter Lesions,RECRUITING,2023-04-07,2025-04-01,2026-04-01,2024-04-17,2023-03-20,INTERVENTIONAL,NA,150.0,ESTIMATED,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis|Radiologically Isolated Syndrome|White Matter Lesions,,France,Nice,,1,eVOG,PROCEDURE,interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions. (square wave jerks)|interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions. (Horizontal saccades abnormalities)|interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions. (Vertical saccades abnormalities)|interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions. (Smooth pursuit abnormality)|interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions. (Antisaccade abnormality)|interest of digital VOG at the diagnostic stage in patients referred to a tertiary center for discovery on MRI of white matter lesions,"Correlations between the presence of EMA and the diffuse damage to brain tissue measured by MRI.(In the subgroup of patients with RIS, CIS or MS, to study)|association between the number or type of EMA at inclusion and the occurrence of a clinical conversion to multiple sclerosis (EDSS)|association between the number or type of EMA at inclusion and the occurrence of a clinical conversion to multiple sclerosis (second line treatment)|association between the number or type of EMA at inclusion and the occurrence of a clinical conversion to multiple sclerosis (secondary progressive form)|type of EMA between patients and controls|number of EMA between patients and controls",False,
NCT03160898,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)","A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2017-07-24,2019-03-07,2019-03-07,2020-09-11,2017-05-19,INTERVENTIONAL,PHASE2,458.0,ACTUAL,Cytokinetics,INDUSTRY,Astellas Pharma Inc,INDUSTRY,Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis|ALS|CK-2127107|Reldesemtiv,United States,Phoenix,Arizona,64,Reldesemtiv|Placebo,DRUG|DRUG,Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC),Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score|Slope of Muscle Strength Mega-score From Baseline to Week 12,True,2020-09-11
NCT05562453,Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain,"A Double-blind, Randomized, Controlled, Parallel Design 4-week Investigation, Followed by an Open 6-month Investigation, to Evaluate the Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis",UNKNOWN,2022-10-04,2023-07-15,2023-08-15,2023-06-29,2022-09-30,INTERVENTIONAL,NA,56.0,ACTUAL,Otivio AS,INDUSTRY,,,"Multiple Sclerosis|Spasticity, Muscle|Pain, Chronic",,Sweden,Stockholm,,1,FlowOx 2.0|FlowOx2.0 (Sham),DEVICE|DEVICE,Change in self-reported spasticity using Numeric Rating Scale (NRS),Change in self-reported pain using NRS for subjects with a baseline NRS ≥4.|Frequency of adverse events|Change in timed 25-foot walk (T25-FW)|Change in 2-minute walking tests|Change in health-related quality of life measured by Multiple sclerosis impact scale (MSIS-29)|Change in health-related quality of life measured by EQ-5D-5L|Change in Hospital Anxiety and Depression Scale (HADS),False,
NCT04990219,A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis,"Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis",TERMINATED,2021-09-27,2023-01-19,2023-01-31,2023-02-03,2021-08-04,INTERVENTIONAL,PHASE1,37.0,ACTUAL,H. Lundbeck A/S,INDUSTRY,,,Multiple Sclerosis,,United States,Denver,Colorado,7,Lu AG06466|Placebo,DRUG|DRUG,Number of Participants with Spasticity Response|Change from Baseline to Week 5 in Spasticity NRS Score,,False,
NCT05181215,Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects,"A Single-Dose, Randomized, Open-Label, Two-Way Crossover, Bioequivalence Study of Bafiertam (Monomethyl Fumarate) 190 mg and Vumerity® (Diroximel Fumarate) 462 mg Delayed-Release Capsules in Fasting Healthy Male and Female Subjects",COMPLETED,2021-05-14,2021-08-27,2021-08-27,2022-01-06,2022-01-06,INTERVENTIONAL,PHASE1,46.0,ACTUAL,Banner Life Sciences LLC,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United States,St Louis,Missouri,1,Monomethyl Fumarate 190 Mg|Diroximel Fumarate 462 mg,DRUG|DRUG,The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments|The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments,,False,
NCT03493841,Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis,Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial,COMPLETED,2018-06-08,2019-01-25,2019-01-25,2019-03-22,2018-04-11,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Rebecca Spain,OTHER,,,Multiple Sclerosis|Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,,United States,Portland,Oregon,1,Alpha Lipoic Acid,DRUG,Comparison of oral tolerance between R-LA and racemic LA|Comparison of serum bioavailability as measured by Area Under the Curve (0-infinity) between R-LA and racemic LA,,False,
NCT04578639,Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease,Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing,ACTIVE_NOT_RECRUITING,2020-11-02,2025-08-14,2025-09-14,2025-06-27,2020-10-08,INTERVENTIONAL,PHASE3,214.0,ACTUAL,Haukeland University Hospital,OTHER,"University Hospital, Akershus|Oslo University Hospital|Helse Stavanger HF|St. Olavs Hospital|University Hospital of North Norway",OTHER|OTHER|OTHER_GOV|OTHER|OTHER,Relapsing Remitting Multiple Sclerosis,RRMS|MS,Norway,Bergen,,12,Rituximab|Ocrelizumab,DRUG|DRUG,Proportion without new MRI activity,Proportion of patients with 6-months confirmed disability progression (6M-CDP)|Proportion of patients with 6-months confirmed disability improvement (6M-CDI)|Annual relapse rate|Proportion of patients without relapses|Proportion of patients with 6M-CDP in T25FW|Proportion of patients with 6M-CDP in 9-HPT|Proportion of patients with 6M-CDP in SDMT|Proportion of patients with no new or enlarging T2-weighted brain MRI lesions|Proportion of patients without new gadolinium enhancing T1-weighted brain MRI lesions|Change in brain volumes|Frequency of SAE/SAR and AESI during 24 months of treatment|The frequency of immediate and delayed infusion reactions|Frequency of infections|The frequency any malignancies|Change in the quality of life (MSIS-29)|Change in Health related Anxiety and Depression as measured by HADS|Change in the fatigue (FSMC)|Change in EQ-5D score|Change in employment status|The frequency of anti-drug-antibodies,False,
NCT03155334,Understanding Evaluation of Patient Information Sheets by User Testing Method,"Understanding Evaluation of Patient Information Sheets of Two Multiple Sclerosis Studies Through User Testing Method in a Randomized, Open Label, Crossover Design",UNKNOWN,2017-01-31,2018-02-20,2018-12-30,2018-01-16,2017-05-16,INTERVENTIONAL,NA,100.0,ESTIMATED,Fondazione Italiana Sclerosi Multipla,OTHER,"Opera CRO, a TIGERMED Group Company",OTHER,MS (Multiple Sclerosis),Multiple Sclerosis; Patient Information Sheet; User Testing,Italy,Genoa,Liguria,2,PIS User Testing,OTHER,percentage of found and understood-if-found items,understanding of the text expressed by subject,False,
NCT00915577,Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe,"An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects",COMPLETED,2005-08,2006-04,2006-04,2009-06-08,2009-06-08,INTERVENTIONAL,PHASE3,74.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|interferon beta-1a|Avonex|liquid Avonex,,,,0,Interferon beta-1a|Single-use autoinjector,DRUG|DEVICE,The primary objective of the study is to determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled AVONEX® syringe,,False,
NCT03117881,Tele-Exercise and Multiple Sclerosis,Comparative Effectiveness Trial Between a Clinic- and Home-Based Complementary and Alternative Medicine Telerehabilitation Intervention for Adults With Multiple Sclerosis (MS),COMPLETED,2018-01-08,2021-10-30,2022-10-30,2024-12-11,2017-04-18,INTERVENTIONAL,NA,911.0,ACTUAL,University of Alabama at Birmingham,OTHER,"Patient-Centered Outcomes Research Institute|Alabama Neurology Associates, PC|Lakeshore Foundation",OTHER|OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Yoga|Pilates|Telerehabilitation|Physical activity,United States,Athens,Alabama,40,DirectCAM|TeleCAM|rDirectCAM,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in Pain|Change in Fatigue|Change in Quality of Life (Physical Component)|Change in Quality of Life (Mental Component)|Change in Physical Activity,Change in Balance (Berg Balance Scale)|Change in Balance (Five Times Site to Stand)|Change in Endurance|Change in Gait (Timed Up and Go)|Change in Gait (Timed 25-Foot Walk)|Change in Grip Strength,True,2024-12-11
NCT02141022,Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya,A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya,COMPLETED,2013-08,2014-09,2015-09,2016-05-10,2014-05-16,INTERVENTIONAL,NA,20.0,ACTUAL,Stony Brook University,OTHER,Novartis,INDUSTRY,Multiple Sclerosis|Cognitive Deficits|Gilenya Modifying Therapy for MS,Multiple Sclerosis|Cognition|Cognitive Remediation|Gilenya|Computerized Cognitive Exercise,United States,Stony Brook,New York,1,plasticity-based computerized cognitive remediation program|Gileyna,OTHER|DRUG,Change from Baseline in Neuropsychological Test Results at 12weeks,Evaluate the feasibility of PACR for adults with MS on Gilenya therapy who have cognitive impairment based on Participant Adherence to Study Protocol,False,
NCT02346734,Physical Telerehabilitation in Veterans With Multiple Sclerosis,Physical Telerehabilitation in Veterans With Multiple Sclerosis,COMPLETED,2012-07,2017-04-06,2017-04-06,2017-05-05,2015-01-27,INTERVENTIONAL,NA,74.0,ACTUAL,University of Maryland,OTHER,Baltimore VA Medical Center,FED,Multiple Sclerosis,Multiple Sclerosis|Telerehablitation,United States,Baltimore,Maryland,1,Multiple Sclerosis Home Automated Telemanagement (MS HAT) system,DEVICE,The Berg Balance Scale (BBS),Expanded Disability Status Scale (EDSS)|9-Hole Peg Test|Paced Auditory Serial Addition Test|Patient Determined Disease Steps (PDDS)|Range of motion|Lower extremities manual muscle test (LE-MMT)|Functional Mobility|Balance|Gait|Spasticity Scale (Modified Ashworth Scale)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Walking Scale (MSWS-12)|MS Self-efficacy (MSSE)|The Timed 25-Foot Walk (T25-FW)|The Six Minute Walk Test (6MWT),False,
NCT04719494,Dynamic Balance Training in Multiple Sclerosis,Dynamic Balance Training in Multiple Sclerosis,COMPLETED,2017-01-01,2019-05-31,2020-08-31,2021-01-22,2021-01-22,INTERVENTIONAL,NA,20.0,ACTUAL,Marquette University,OTHER,Greater Milwaukee Foundation,UNKNOWN,Multiple Sclerosis,,,,,0,Dynamic balance walking training,OTHER,Change in Functional Gait Assessment|Change in Dynamic Stability|Change in Step Width,Change in Step Length|Change in Step Frequency|Change in 10-Meter Walk Test,False,
NCT02744222,"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis","An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2017-08-10,2018-11-23,2020-07-06,2021-09-08,2016-04-20,INTERVENTIONAL,PHASE2|PHASE3,399.0,ACTUAL,Biocad,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Russia,Nizhny Novgorod,,1,BCD-054 180 mcg|Avonex®|BCD-054 240 mcg|Placebo,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|OTHER,Time to first relapse after 52 weeks of blinded treatment with BCD-054 or Avonex,"CUA|Proportion of patients without contrast-enhancing lesions|Number of new or enlarging T2-weighted lesions|Proportion of patients without new or enlarging T2-weighted lesions|Changes in T2-weighted lesion volume|Changes in hypointense T1-weighted lesion volume|Annual average frequency of relapses|Proportion of relapse-free patients|Proportion of patients with sustained disability progression|Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk|9-Hole Peg Test (9 HPT)|Symbol Digit Modalities Test (SDMT)|The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-054 or Avonex®|The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-054 or Avonex®|The proportion of patients, in each group, who discontinued the study due to AEs/SAEs|The proportion of BAb- and NAb-positive patients|AUC (0-168 hours)|AUC (0-336 hours)|AUCss (0-168 hours, 0-336 hours)|AUECss (0-168 hours, 0-336 hours)|AUEC (0-168 hours)|AUEC (0-336 hours)",False,
NCT03603457,OFSEP High Definition Cohort,OFSEP High Definition Cohort,ACTIVE_NOT_RECRUITING,2018-07-10,2026-12,2026-12,2024-09-26,2018-07-27,OBSERVATIONAL,,2842.0,ACTUAL,EDMUS Foundation,OTHER,,,Multiple Sclerosis,Epidemiology|Prognostic factors|Stratified medicine|Quality of life|Economic assessment,France,Besançon,,25,,,Time to reach irreversible Expanded Disability Status Scale (EDSS) scores of 6|Activity of disease|Change in T2 lesion load evaluated by analysis of raw MRI|Change in quality of life evaluated by EQ-5D-5L scale|Change in quality of life evaluated by SF-12 scale|Change in quality of life evaluated by MusiQoL scale,,False,
NCT04823000,Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis,Long Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cells (MSC) Injections in Patients With Progressive Forms of Multiple Sclerosis (MS),COMPLETED,2013-01-01,2016-12-01,2020-04-01,2021-03-30,2021-03-30,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Mesenchymal Stem Cells,,,,0,Mesenchymal Stem Cells (MSC),BIOLOGICAL,"Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)","Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment",False,
NCT00276341,Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis,"Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.",COMPLETED,2003-08-26,,2005-12-08,2024-03-07,2006-01-13,INTERVENTIONAL,PHASE3,47.0,ACTUAL,Ipsen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",cognitive impairment,France,Aix-en-Provence,,30,EGb 761® (Tanakan®),DRUG,Evolution of Paced Auditory Serial Addition Test 3 and 2 seconds between baseline and week 24,"Evolution of the following tests between baseline and week 24:|Multiple Sclerosis Functional Composite Test|Selective Reminding Test|10/36 Visual-Spatial Recall Test|Symbol Digit Modalities Test|Trail Making Test A and B|Verbal Fluency Test|Empan Test|Evolution of the following scales between baseline and week 24:|Cognitive Deficit Interview based screen|Anxiety Brief Scale|Beck Depression Inventory Scale|Modified Fatigue Impact Scale|Evolution of Quality of Life|Evolution of the following between baseline, week 12, and week 24: Kurtzke Extended Disability Status Scale, and Clinician Interview Based Impression of Change",False,
NCT05012241,The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis,The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-09-01,2022-02-28,2024-12-31,2024-04-30,2021-08-19,OBSERVATIONAL,,33.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Motor Activity,occupational therapy|fine motor skills|Nine Hole Peg Test|inter-rater reliability|variability|multiple sclerosis,Czechia,Prague,,2,Nine Hole Peg Test,DIAGNOSTIC_TEST,results from the Nine Hole Peg Test,,False,
NCT06261541,Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting,Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting,COMPLETED,2024-04-08,2024-07-30,2024-07-30,2024-07-31,2024-02-15,INTERVENTIONAL,NA,33.0,ACTUAL,ABLE Human Motion S.L.,INDUSTRY,Fundación Esclerosis Múltiple Madrid (FEMM),UNKNOWN,Multiple Sclerosis,Lower-limb exoskeleton|Gait training,Spain,Madrid,,1,ABLE Exoskeleton,DEVICE,Number and type of device-related Adverse Events|Level of Assistance (LoA) to don/doff the device|Time taken to don/doff the device|Level of Assistance (LoA) to complete therapy activity tasks|Time spent upright and time spent walking|Number of steps walked|Distance walked,Timed 25-Feet Walk test (T25FW)|Ambulation Index (AI)|6-Minute Walk Test (6MWT)|Timed Up-and-Go test (TUG)|Trunk Impairment Scale (TIS)|Lower extremity muscle strenght|Modified Ashworth Scale (MAS)|Borg Rating of Perceived Exertion|Barthel Index (BI) score|Modified Fatigue Impact Scale (MFIS) score|Multiple Sclerosis Quality of Life-54 (MSQoL-54)|Psychosocial Impact of Assistive Devices Scale (PIADS) score|Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score,False,
NCT02890641,Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies,,RECRUITING,2015-12-12,2030-12,2030-12,2023-12-13,2016-09-07,OBSERVATIONAL,,450.0,ESTIMATED,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Refractory Focal Epilepsy|Focal Cortical Dysplasia|Hemimegalencephaly|Tuberous Sclerosis|Mild Malformation of Cortical Development With Oligodendroglial Hyperplasia in Epilepsy (MOGHE),Refratory Focal Epilepsy|Focal Cortical Dysplasia|Cortical Malformation|Hemimegalencephaly|Tuberous sclerosis|Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE),France,Paris,,1,"Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)",GENETIC,qualitative genetic analysis,,False,
NCT04157283,Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities,Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities,UNKNOWN,2019-11-05,2020-05-05,2020-06-01,2019-11-08,2019-11-08,OBSERVATIONAL,,120.0,ESTIMATED,Mansoura University Hospital,OTHER,,,Multiple Sclerosis|Sexual Dysfunction,,Egypt,Al Mansurah,Dakahlia Governorate,1,"MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)",DIAGNOSTIC_TEST,The Sexual Quality of Life-Male (SQOL-M)|The Sexual Quality of Life-Female (SQOL-F)|The international index of erectile function (IIEF),Beck's Depression Inventory|Fatigue symptoms,False,
NCT00262314,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients","Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",COMPLETED,2000-10,2008-01,2008-09,2013-11-14,2005-12-06,OBSERVATIONAL,,509.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,,United States,Lexington,Kentucky,1,,,"Congestive Heart Failure (Treatment Phase)|Congestive Heart Failure (Annual Follow-Up Phase)|Left Ventricular Ejection Fraction (Treatment Phase)|Left Ventricular Ejection Fraction (Annual Follow-Up Phase)|Serious Infections (Treatment Phase)|Serious Infections (Annual Follow-Up Phase)|IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)|IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)|Severe Neutropenia (Treatment Phase)|Severe Neutropenia (Annual Follow-Up Phase)|Clinical Relapses (Treatment Phase)|Clinical Relapses (Annual Follow-Up Phase)|Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses",,True,2010-06-23
NCT04548206,Effect of Pilates Training in Patients With Multiple Sclerosis,"Effect of Pilates Training on Sensory, Muscle Strength, Balance, and Gait in Patients With Multiple Sclerosis",COMPLETED,2020-09-14,2022-07-29,2022-07-29,2022-08-05,2020-09-14,INTERVENTIONAL,NA,34.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|sensation|gait|Pilates,Turkey (Türkiye),Ankara,,1,Pilates training|control,OTHER|OTHER,Gait|Balance|Light touch-pressure sensation|Vibration sensation|Two-point discrimination|Position sensation of knee joint|Knee proprioception|Position sensation of trunk|Knee strength,,False,
NCT00137904,Sleep Disorders in Patients With Multiple Sclerosis,Study of Sleep Disorders and Fatigue in Patients With Multiple Sclerosis,UNKNOWN,,,,2006-02-09,2005-08-30,OBSERVATIONAL,,51.0,,Groupe Hospitalier Pitie-Salpetriere,OTHER,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,Multiple Sclerosis,multiple sclerosis|fatigue|sleep disorders,France,Paris,,1,,,,,False,
NCT00126672,RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS,A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients,COMPLETED,2005-12-20,2010-04,2010-04,2022-04-25,2005-08-04,INTERVENTIONAL,PHASE2,36.0,ACTUAL,Dana-Farber Cancer Institute,OTHER,National Cancer Institute (NCI)|Wyeth is now a wholly owned subsidiary of Pfizer|Tuberous Sclerosis Alliance,NIH|INDUSTRY|OTHER,Nonmalignant Neoplasm|Tuberous Sclerosis|Lymphangioleimyomatosis|Kidney Angiomyolipoma,angiomyolipoma,United States,Loma Linda,California,7,Rapamycin,DRUG,Objective Response Rate,Number of Participants With Grade 3 or More Treatment-Related Lymphopenia|Number of Participants With no Change Are Observed Changes That Occur in Other TSC Lesions,True,2022-04-25
NCT06802328,Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients,"An Intermediate-Size Patient Population Expanded Access Treatment Protocol Evaluating the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Non-Active Secondary Progressive MS Patients Foralumab Nasal",AVAILABLE,,,,2025-06-06,2025-01-31,EXPANDED_ACCESS,,,,Tiziana Life Sciences LTD,INDUSTRY,,,Non-Active Secondary Progressive Multiple Sclerosis,multiple sclerosis|non-active secondary progressive multiple sclerosis|MS|expanded access|anti-cd3 monoclonal antibody|foralumab|nasal,United States,Boston,Massachusetts,1,Foralumab TZLS-401 50 µg,DRUG,,,False,
NCT02499900,Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®,"CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily",COMPLETED,2015-08-10,2017-01-10,2017-06-02,2021-12-09,2015-07-16,INTERVENTIONAL,PHASE4,861.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Cullman,Alabama,97,Copaxone®,DRUG,Change From Baseline in the Medication Satisfaction Questionnaire (MSQ) to Month 6 Using a Repeated Measures ANCOVA,Change From Baseline in the Treatment Satisfaction Questionnaire for Medication 9-item Version (TSQM-9) Convenience Score to Month 6 Using a Repeated Measures ANCOVA|Change From Baseline in the Modified Fatigue Impact Scale (MFIS) Total Score and Subscales to Month 6 Using a Repeated Measures ANCOVA|Change From Baseline in the Mental Health Index (MHI) Total Score and Subscales to Month 6 Using a Repeated Measures ANCOVA|Change From Baseline in the Beck Depression Inventory II (BDI-II) Total Score to Month 6 Using a Repeated Measures ANCOVA|Participants With Treatment-Emergent Adverse Events (TEAEs) During Both the Core Period and Extension Periods,True,2018-08-20
NCT04066244,Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients,"An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28",TERMINATED,2019-12-30,2024-02-01,2024-02-01,2025-03-19,2019-08-26,INTERVENTIONAL,PHASE2,28.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Amyotrophic Lateral Sclerosis,PET|ALS|Microglia|CSF,United States,New Haven,Connecticut,4,BLZ945,DRUG,Cohorts 1-4 : Change From Baseline in Volume of Distribution (Vt) in Different Brain Regions for [11C]-PBR28 PET Scan|Cohort 5 (PET Sub-study): Change From Baseline in Volume of Distribution (Vt) in Different Brain Regions for [11C]-PBR28 PET Scan|Cohort 5: Change From Baseline in Esophageal Wall Thickness|Cohort 5: Cardiac Valve Thickness at Day 84 Compared to Baseline|Cohort 5: Cardiac Valve Stenosis at Day 84 Compared to Baseline|Cohort 5: Cardiac Valve Regurgitation Severity at Day 84 Compared to Baseline|Cohort 5: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Cohort 5: Adverse Events Related to Extracellular Matrix (ECM) Accumulation,Cohorts 1-5: Plasma Pharmacokinetics (PK) of BLZ945 - Cmax|Cohorts 1-5: Plasma Pharmacokinetics (PK) of BLZ945 - Tmax|Cohorts 1-5: Plasma Pharmacokinetics (PK) of BLZ945 - AUC|Cohorts 1-4: Plasma Pharmacokinetics (PK) of BLZ945 - T1/2|Cohorts 1-4: Renal Clearance (CLR) of BLZ945|Cohorts 1-5: Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs),True,2025-03-19
NCT06589999,Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis,Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis,RECRUITING,2024-07-31,2026-07,2026-07,2024-10-16,2024-09-19,OBSERVATIONAL,,196.0,ESTIMATED,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Paris,,1,MP2RAGE sequence,DIAGNOSTIC_TEST,"In patients with inflammatory neuraxial disease, estimate the number of cervical lesions detected with the MP2RAGE sequence that were not detected with the recommended standard set.",,False,
NCT04185792,"Polish Translation and Validation of NBSS, Qualiveen and SF-Qualiveen","Polish Translation and Validation of the Neurogenic Bladder Symptom Score (NBSS), Qualiveen and Short Form Qualiveen (SF-Qualiveen) Questionnaires",COMPLETED,2020-01-01,2020-09-18,2020-09-18,2022-07-06,2019-12-04,OBSERVATIONAL,,200.0,ACTUAL,Jagiellonian University,OTHER,"Piotr Chlosta, Full-time Professor, University Hospital, Cracow, Poland",UNKNOWN,Spinal Cord Injuries|Multiple Sclerosis,,Poland,Krakow,Malopolska,1,"NBSS, Qualiveen and SF-Qualiveen",DIAGNOSTIC_TEST,ICIQ-SF|Neurogenic Bladder Symptom Score Questionnaire (NBSS)|Qualiveen|Short Form Qualiveen (SF-Qualiveen)|The King's Health Questionnaire (KHQ),,False,
NCT01628393,Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients,"A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients",COMPLETED,2012-09-18,2014-04-13,2016-05-11,2021-02-11,2012-06-26,INTERVENTIONAL,PHASE2|PHASE3,258.0,ACTUAL,Celgene,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Berkeley,California,58,Ozanimod|Placebo,DRUG|DRUG,Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24,The Number of Gadolinium-Enhancing Lesions on Brain MRI Scan at Week 24|The Total Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions From Week 12 to Week 24|Adjusted Annualized Relapse Rate (ARR) at Week 24|Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Treatment Period|Number of Participants With Treatment Emergent Adverse Events (TEAE) During Ozanimod Exposure,True,2021-02-11
NCT02996084,MS PATHS Normative Sub-Study,Longitudinal Brain Volume Change (and Correlates) in Healthy Control Subjects: A Normative Sub-Study of Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS),COMPLETED,2017-12-12,2022-12-31,2022-12-31,2023-02-24,2016-12-19,OBSERVATIONAL,,246.0,ACTUAL,Biogen,INDUSTRY,,,Healthy Volunteer,Imaging research,United States,Baltimore,Maryland,6,,,Brain volume|Brain volume change,"Development of models to calibrate brain volume measurements between centers, if necessary",False,
NCT06965881,Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults,"A Phase 1, Open-label, 2-part Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of a CYP3A4 Inducer (Carbamazepine) or Inhibitor (Itraconazole), With Radiprodil in Healthy Adult Participants",RECRUITING,2025-05-08,2025-08,2025-09-30,2025-05-22,2025-05-11,INTERVENTIONAL,PHASE1,36.0,ESTIMATED,"GRIN Therapeutics, Inc.",INDUSTRY,Avance Clinical Pty Ltd.,INDUSTRY,Tuberous Sclerosis Complex (TSC)|Focal Cortical Dysplasia|Other Neurological Disorders,healthy adults|tuberous sclerosis|focal cortical dysplasia,Australia,Brisbane,Queensland,2,Radiprodil with Carbamazepine|Radiprodil with Itraconazole,DRUG|DRUG,Part A: To assess the effect of oral carbamazepine on the maximum observed plasma concentration (Cmax) of oral dosing of radiprodil|Part B: To assess the effect of oral itraconazole on the maximum plasma concentration (Cmax) of oral dosing of radiprodil|Part A: To asses the effect of oral carbamazepine on radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)|Part B: To asses the effect of oral itraconazole on the radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)|Part A: To assess the effect of oral oral carbamazepine on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil|Part B: To assess the effect of oral itraconazole on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil,"Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), TEAEs Leading to Discontinuation and Severity of TEAEs|Part A: To assess the area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil|Part B: To assess the area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil|Part B: To assess the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil|Part A: To assess the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil|Part A: To assess the time to maximum observed plasma concentration (Tmax) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil|Part B: To assess the time to maximum observed plasma concentration (Tmax) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil|Part B: To assess the maximum observed plasma concentration (Cmax) of itraconazole following oral dosing of itraconazole alone and in the presence of radiprodil|Part A: To assess the maximum observed plasma concentration (Cmax) of carbamazepine and carbamazepine metabolites following oral dosing of carbamazepine alone and in the presence of radiprodil|Number of participants with abnormal laboratory test results|To assess the Columbia-Suicide Severity Rating Scale (C-SSRS) scores|12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS interval",False,
NCT05808101,Gut Microbiome and Depression,Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects,TERMINATED,2022-01-27,2024-10-29,2024-10-29,2024-12-13,2023-04-11,OBSERVATIONAL,,51.0,ACTUAL,Washington University School of Medicine,OTHER,University of Connecticut|University of Texas,OTHER|OTHER,Multiple Sclerosis|Depression,Multiple Sclerosis|Depression|Microbiome,United States,St Louis,Missouri,1,Neuro-QoL T-score determination,OTHER,"Gut microbiome, gut-derived metabolites and peripheral blood immune profiles|GABA levels in whole stool, specific stool bacteria isolates and blood",,False,
NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,"A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate the Efficacy of Vigantol® Oil as Add on Therapy in Subjects With Relapsing Remitting Multiple Sclerosis Receiving Treatment With 44mg Tiw of Rebif®",COMPLETED,2011-02,2015-04,2015-05,2016-11-28,2011-01-28,INTERVENTIONAL,PHASE2,260.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Rebif|VigantOL® oil|Vitamin D|Add-on treatment,Austria,Vienna,,38,VigantOL oil plus interferon beta-1a (Rebif)|Placebo plus interferon beta-1a (Rebif)|Interferon beta-1a (Rebif®) alone,DRUG|DRUG|BIOLOGICAL,Percentage of Subjects With Disease Activity Free Status up to Week 48,Percentage of Relapse-free Subjects at Week 48|Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48|Number od Subjects With Confirmed EDSS Progression|Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48|Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48|Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 48|Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)|Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48|Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48|Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions|Number of Subjects With Relapse|Annualized Relapse Rate at Week 48|Total Number of Reported Relapses at All Time Points up to 48 Weeks|Percentage of Subjects Treated With Glucocorticoids Due to Relapses|Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48,True,2016-07-11
NCT03887507,Vojta Therapy in Multiple Sclerosis.,The Implementation of a Reflex Locomotion Program According to Vojta Produces Short-term Automatic Postural Control Changes in Patients With Multiple Sclerosis.,COMPLETED,2019-01-21,2019-03-28,2019-05-12,2019-05-21,2019-03-25,INTERVENTIONAL,NA,21.0,ACTUAL,NUMEN Foundation,OTHER,Multiple Sclerosis Foundation of Madrid|Fisiovillalba Clinical center,UNKNOWN|UNKNOWN,Multiple Sclerosis|Physical Therapy,Vojta therapy|core stability|postural balance,Spain,Madrid,España,1,Vojta Therapy|Standard Program,OTHER|OTHER,Berg Balance Scale|10 metres walk,Tandem 6 metres test,False,
NCT03536299,Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis,Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis,UNKNOWN,2018-05-31,2020-05-31,2020-05-31,2019-09-18,2018-05-24,INTERVENTIONAL,NA,80.0,ESTIMATED,Texas Woman's University,OTHER,"TIRR Memorial Hermann|The University of Texas Health Science Center, Houston",OTHER|OTHER,"Multiple Sclerosis|Gait Disorders, Neurologic|Cognitive Impairment",Physical therapy|Gait training|Cognitive-motor interference|Rehabilitation,United States,Houston,Texas,2,Dual-task gait|Single-task gait,OTHER|OTHER,Change in Walking and Remembering Test,Change in 2-Minute Walk Test|Change in 12-Item Multiple Sclerosis Walking Scale|Change in Fatigue Scale for Motor and Cognitive Functions|Change in Gait Speed|Change in Gait Cadence|Change in Step Length,False,
NCT02011204,Study of Electrical Impedance Myography (EIM) in ALS,Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance,COMPLETED,2013-11,2016-03,2016-03,2016-05-11,2013-12-13,OBSERVATIONAL,,106.0,ACTUAL,"Skulpt, Inc.",INDUSTRY,,,Amyotrophic Lateral Sclerosis|Motor Neuron Disease|Charcot-Marie-Tooth Disease|Multiple Sclerosis,,United States,Phoenix,Arizona,6,Electrical impedance myography (EIM),DEVICE,Discrimination between Groups,Tracking Progression|Correlation with Outcome Measures,False,
NCT02290444,Effects of Acthar on Recovery From Cognitive Relapses in MS,Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis,COMPLETED,2013-08,2018-11-01,2018-11-01,2020-04-06,2014-11-14,INTERVENTIONAL,PHASE3,64.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,"Acute Relapsing Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive",United States,Buffalo,New York,1,Adrenocorticotropic Hormone,DRUG,"Change From Baseline on the Symbol Digit Modalities Test (SDMT)|Timed 25-foot Walk|Change From Baseline on the Paced Auditory Serial Addition Test (PASAT)|Change From Baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R)|Change From Baseline on the California Verbal Learning Test, Second Edition (CVLT-II)",Change From Baseline on the Expanded Disability Status Scale (EDSS).|Change From Baseline on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)|Change From Baseline on the Beck Depression Inventory-Fast Screen (BDI-FS)|Change From Baseline on the Fatigue Severity Scale (FSS),True,2020-04-06
NCT04145284,Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS,Performance and Feasibility of Quantitative MRI Metrics in Routine Radiology Practice: A Sub-Study of MS PATHS,COMPLETED,2019-04-30,2020-04-30,2020-04-30,2021-03-24,2019-10-30,OBSERVATIONAL,,6.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Cleveland,Ohio,2,,,Radiologist Assessment of the Performance of the MS MRI Metrics Software Prototype by the Number of Approve or Reject Decision|Radiologist Assessment of the Performance of the MS MRI Metrics Software Prototype by the Number of False-Positive and False-Negative Lesions,,False,
NCT04746807,Barriers to Physical Activity in People With MS,Barriers to Physical Activity in People With MS (Barrieren für körperliche Aktivität Bei MS-Betroffenen - BarKA-MS) - A Longitudinal Observational Study,COMPLETED,2021-01-08,2021-11-14,2021-11-14,2021-11-19,2021-02-10,OBSERVATIONAL,,45.0,ACTUAL,University of Zurich,OTHER,"Dr. Roman Gonzenbach, Kliniken Valens",UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|physical acitivity|digital mobility measurements|real-life assessments,Switzerland,Valens,,1,,,Step count (Fitbit)|Step count (Accelerometer)|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|Perceived Barriers to Physical Activity,Health status and Health-Related Quality of Life (EQ-5D-5L)|Patient Health Questionnaire depression scale (PHQ-8)|Generalized Self Efficacy Scale (GSE)|Fatigue Scale for Motor and Cognitive Functions (FSMC)|Valens in-house pain scale|MS Walking Scale-12 (MSWS-12)|Timed Up and Go (TUG)|10 Meter Walk Test (10mWT)|6 Minute Walk Test (6MWT)|Weekly diary,False,
NCT06455332,Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome,"Evaluation of the Predictive Value of the Optic Nerve Involvement at the Stage of Clinically Isolated Syndrome, for the Diagnosis of Clinically Definite Multiple Sclerosis and the Delay of Second Relapses' Occurrence",RECRUITING,2025-07-17,2028-07-01,2028-07-01,2025-08-24,2024-06-12,INTERVENTIONAL,NA,200.0,ESTIMATED,"University Hospital, Lille",OTHER,"Région Nord-Pas de Calais, France|Amiens University Hospital|Boulogne sur Mer Hospital Center|Centre Hospitalier VALENCIENNES|Centre Hospitalier de Roubaix|Centre Hospitalier de Lens",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Clinically Isolated Syndrome|Multiple Sclerosis,Clinically isolated syndrome|Multiple sclerosis|MRI|Optical coherence tomography|Optic nerve|Diagnostic criteria,France,Lille,,1,Optic nerve MRI sequence,OTHER,"Optic nerve involvement defined by occurrence of a recent clinical episode of ON|Asymptomatic optic nerve involvement defined by MRI (detection of an optic nerve T2 hypersignal)|Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a second MS clinical relapse|Asymptomatic optic nerve involvement defined by OCT (GCIPL-IETD,3pm)|Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a CDMS","Asymptomatic optic nerve involvement will be defined by: - asymptomatic optic nerve T2 hypersignal detected on one or both optic nerve(s) - or by GCIPL-IETD,3pm measured by OCT - or by GCIPL-IETD≥3µm measured by OCT|Time to the second clinical relapse occurrence will be assessed every 6 months during 24 months at each neurological examination",False,
NCT01742052,Dose-finding Study of MT-1303,"A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis",COMPLETED,2013-01,2014-07,2014-10,2016-09-14,2012-12-05,INTERVENTIONAL,PHASE2,415.0,ACTUAL,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,relapsing-remitting multiple sclerosis|RRMS,Belgium,Brussels,,18,MT-1303-Low|MT-1303-Middle|MT-1303-High|Placebo,DRUG|DRUG|DRUG|DRUG,The total number of MRI Gd-enhanced T1-weighted lesions,,False,
NCT03091400,Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS),Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis,COMPLETED,2017-03-16,2018-06-11,2018-06-11,2020-03-13,2017-03-27,INTERVENTIONAL,PHASE2,11.0,ACTUAL,Icahn School of Medicine at Mount Sinai,OTHER,,,Memory Disorders|Multiple Sclerosis,Memory Disorders|Multiple Sclerosis|Atomoxetine Hydrochloride,United States,New York,New York,1,Atomoxetine|Placebo,DRUG|DRUG,Change in Memory Change,Change in Patient-Reported Memory Change|Change in CANTAB Paired Associate Learning|Change in NIH Toolbox Picture Sequence Memory Test|Change in Perceived Deficits Questionnaire (PDQ)|Change in Symbol Digit Modalities Test,True,2020-03-13
NCT01084798,A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years,A Retrospective Study On The Management of Multiple Sclerosis (MS) Over The Last 10 Years,COMPLETED,2008-08,2008-12,2009-11,2014-07-31,2010-03-11,OBSERVATIONAL,,123.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Expanded Disability Status Scale|Sclerosis,Taiwan,Taoyuan,,1,,,"Distribution of locations (medical centre, regional hospital, general practitioners) where subjects were treated for the first episode of attack prior to multiple sclerosis diagnosis",Duration from first attack to confirmation of MS|Distribution of MS diagnosis criteria and treatment regimens|Annual relapse rate before and after MS treatment|Changes in Expanded Disability Status Scale (EDSS) before and after treatment|Changes in VEP before and after treatment|Association between baseline demographics/disease characteristics and MS,False,
NCT06505421,Eccentric Exercise and Fatigue in Multiple Sclerosis,The Effect of Lower Extremity Eccentric Resistance Training on Fatigue in Multiple Sclerosis,RECRUITING,2024-07-01,2025-12-30,2026-12-30,2024-07-17,2024-07-17,OBSERVATIONAL,,30.0,ESTIMATED,Hunter College of City University of New York,OTHER,,,Multiple Sclerosis|Fatigue,Exercise|resistance training,United States,New York,New York,1,Resistance training,BEHAVIORAL,6-Minute walk test,Visual analog scale of fatigue,False,
NCT04287244,Transcutaneous Direct Current Stimulation of the Spinal Cord for Treatment of Spasticity in Multiple Sclerosis,Transcutaneous Direct Current Stimulation of the Spinal Cord for Treatment of Spasticity in Multiple Sclerosis,UNKNOWN,2020-03,2022-02,2022-05,2020-03-04,2020-02-27,INTERVENTIONAL,NA,40.0,ESTIMATED,Lebanese American University,OTHER,,,Spastic Parapareses,,,,,0,Transcutaneous Spinal Direct Current Stimulation,DEVICE,Gait improvement,Spasticity Assessment|Multiple Sclerosis Walking Assessment|Quality of Life Measures|Disability Measure,False,
NCT02474134,Comparison Study of PF530 and Betaferon in Healthy Subjects,"A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers",COMPLETED,2015-03,2015-10,2015-10,2015-11-16,2015-06-17,INTERVENTIONAL,PHASE1,12.0,ACTUAL,"Pfenex, Inc",INDUSTRY,,,Multiple Sclerosis,,Australia,Adelaide,South Australia,1,"Interferon beta-1b (PF530, Betaferon)",DRUG,Adverse event (AE) and serious adverse event (SAE) incidence,Serum area-under-the-curve (AUC) of PF530 and Betaferon|Serum maximum concentration (Tmax) of PF530 and Betaferon|Serum half-life (t1/2) of PF530 and Betaferon|Serum neopterin|Serum myxovirus resistance protein A,False,
NCT03066752,Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes,Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes,COMPLETED,2017-03-27,2017-11-24,2017-11-24,2020-01-07,2017-02-28,OBSERVATIONAL,,20.0,ACTUAL,The Hospital for Sick Children,OTHER,,,Pediatric Multiple Sclerosis,,Canada,Toronto,Ontario,1,,,"Neuronal responses during simple and choice reaction time tasks|MRI scans of the brain, including Diffusion Tensor Imagine (DTI)|Neurocognitive Testing|Neurological Exam - Standard physical exam performed by the neurologist to determine the Expanded Disability Status Scale (EDSS) score.|Clinical Interview",,False,
NCT04758494,Quality of Life Assessment Between Stroke and Multiple Sclerosis Patients of the Same Age Range,A Study to Assess Quality of Life in Stroke and Multiple Sclerosis Patients of the Same Age Range,COMPLETED,2019-11-11,2020-11-10,2020-11-10,2021-02-17,2021-02-17,OBSERVATIONAL,,172.0,ACTUAL,Hellenic Red Cross Hospital,OTHER,G.Gennimatas General Hospital,OTHER,Stroke|Multiple Sclerosis|Quality of Life|Depression|Mental Health Disorder,stroke|multiple sclerosis|quality of life|mental health|depression|anxiety|well-being|wellness|neurological disorder,Greece,Athens,,1,Questionnaire,OTHER,Barthel score|PHQ-9 score|SF12-physical component summary (PCS) score|SF12-mental component summary (MCS) score|Depression severity level|Dependency category,,False,
NCT03847545,Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique,Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking,COMPLETED,2018-12-12,2021-10-15,2021-10-15,2022-04-05,2019-02-20,INTERVENTIONAL,NA,48.0,ACTUAL,University of Southern Denmark,OTHER,"Odense University Hospital|Sygehus Lillebaelt|Region of Southern Denmark|The Augustinus Foundation, Denmark.|Lounkær Fonden|Fonden for scleroseramte på Fyn|The Danish Multiple Sclerosis Society|TH MAIGAARDS EFTF. FRU LILY BENTHINE LUNDS FOND AF 1. JUNI 1978|Fonden til Lægevidenskabens Fremme|Overlægeråds forskningsfond",OTHER|OTHER|OTHER|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|OTHER|UNKNOWN,Multiple Sclerosis,Speckle tracking ultrasonography|Muscle strain|Fampridine|Multiple Sclerosis|Neurological diseases|Biomarkers|muscle contractility,Denmark,Odense C,,1,Fampridine,DRUG,Gait Profile Score (GPS) - (subgroup of 30 allocated to 3D gait analysis),"Gait Variable Scores (GVS) - (subgroup of 30 allocated to 3D gait analysis)|Functional test - 6 Spot Step Test (SSST)|Functional test - Timed 25 Footwalk (T25-FW)|Functional test - 2-minute Walk Test (2MWT)|Walking speed - (subgroup of 30 allocated to 3D gait analysis)|Step length - (subgroup of 30 allocated to 3D gait analysis)|Step width - (subgroup of 30 allocated to 3D gait analysis)|Stride length - (subgroup of 30 allocated to 3D gait analysis)|Cadence - (subgroup of 30 allocated to 3D gait analysis)|Questionnaire - 12-Item Multiple Sclerosis Walking Scale (MSWS-12), Danish version",False,
NCT01865357,Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI,"Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI:""SCI-COG"" Study",COMPLETED,2012-08-24,2016-12-01,2016-12-01,2018-10-03,2013-05-30,INTERVENTIONAL,NA,117.0,ACTUAL,"University Hospital, Bordeaux",OTHER,TEVA laboratories,UNKNOWN,Clinically Isolated Demyelinating Syndromes|Multiple Sclerosis|Cognitive Deficiencies|Brain MRI,,France,Bordeaux,,1,Brain MRI - Clinical and cognitive evaluation|Eye movement,OTHER|OTHER,Correlation between fractional anisotropy (FA) value and cognitive z scores or cognitive impairment indexes for each domains,"Comparison of skeleton of FA between CIS patients and healthy subjects|Comparison of cognitive scores at each test between CIS patients and controls|Proportion of patients with cognitive impairment (≥ 3 tests impaired) and correlations with anxiety, depressive syndrome and fatigue|Comparison of statistical maps of FA|Correlations between cognitive scores and mean cortical thickness and deep grey nuclei volumes in CIS patients|Comparison of cognitive scores at each test and eye movements scores",False,
NCT05098600,"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Cross-sectional and Cohort Study",COMPLETED,2021-10-15,2022-10-14,2022-12-20,2024-12-03,2021-10-28,OBSERVATIONAL,,123.0,ACTUAL,Faculty Hospital Kralovske Vinohrady,OTHER_GOV,,,"Alopecia Areata|Alopecia Totalis|Alopecia Universalis|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|Diabetes Mellitus, Type 1|Ulcerative Colitis|Inflammatory Bowel Diseases|Crohn Disease|Rheumatoid Arthritis|Down Syndrome|Atopic Dermatitis|Atopic Asthma|Atopic Rhinitis|Vitiligo|Psoriasis|Ankylosing Spondylitis|Multiple Sclerosis|Lupus Erythematosus|COVID-19 Pandemic|Vaccine Reaction|Infections|Anemia, Pernicious",,Czechia,Prague,,1,Exposure of interest,OTHER,The epidemiology of Alopecia areata|The epidemiology of Alopecia areata|Prevalence of atopic and autoimmune conditions in patients with Alopecia Areata|Treatments for alopecia areata|Safety and efficacy of treatments in alopecia areata|Measurement of Thyroid stimulating hormone (TSH)|Measurement of free Thyroxine (fT4)|Measurement of free Triodothyronine (fT3)|Measurement of Thyroid peroxidase autoantibodies (TPOAbs)|Measurement of thyreoglobulin autoantibodies (TgAbs)|Measurement of anti TSH receptor antibodies (TRAbs)|Measurement of Vitamin D levels,Prevalence of atopic and autoimmune conditions in the family history of patients with Alopecia Areata|Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata,False,
NCT00978536,"A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).","A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).",TERMINATED,2009-02,2011-11,2011-11,2013-09-30,2009-09-17,INTERVENTIONAL,NA,29.0,ACTUAL,Nantes University Hospital,OTHER,,,Disseminated Sclerosis,Multiple sclerosis|cognitive deterioration|biomarkers|cerebrospinal fluid|Alzheimer disease,France,Nantes,,1,Cognitive impairment of multiple sclerosis,OTHER,"The aim of this pilot study is to measure the level of total tau, phosphorylated tau and amyloid peptide in the CSF in order to establish correlations between a profile ofCSF biomarkers and a type of cognitive impairment, cortical or subcortical.","To compare each biomarker individually between the three groups.|To define clinical and paraclinical characteristics of MS patients with cortical cognitive dysfunction by a clinical and neuropsychological evaluation, a morphological (cerebral MRI) and a functional exam (cerebral scintigraphy).",False,
NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,"A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab",COMPLETED,2021-09-16,2024-03-29,2025-01-13,2025-08-21,2021-08-10,INTERVENTIONAL,PHASE4,26.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,"PPD Development, LP|Laboratory Corporation of America|Illingworth Research Group",INDUSTRY|INDUSTRY|UNKNOWN,Multiple Sclerosis|Clinically Isolated Syndrome,"ocrelizumab, OCREVUS, breastmilk transfer, breast milk transfer, lactation",United States,San Francisco,California,8,Ocrelizumab,DRUG,Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion|Estimated Average Oral Daily Infant Dosage (ADID),"Absolute CD19+ B Cell Count in the Infant|Percentage of CD19+ B Cell in the Infant|Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk|Average Concentration of Ocrelizumab in Breastmilk (Cmean)|Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk|Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk|Estimated Maximum Oral Daily Infant Dosage (MDID)|Average Relative Infant Dose (RID)|Serum Concentration of Ocrelizumab in the Infant at Day 30|Percentage of Mothers With Adverse Events (AEs)|Percentage of Infants With AEs|Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Mumps, and Rubella (MMR) Vaccination|Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination|Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination|Percentage of Infants With Positive Humoral Response to MMR Vaccination|Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine|Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine|Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine|Percentage of Infants With Positive Humoral Response to DTP Vaccine|Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine|Percentage of Infants With Positive Humoral Response to Hib Vaccine|Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine|Percentage of Infants With Positive Humoral Response to HBV Vaccine|Mean Titers of Pneumococcal Capsular Polysaccharide, Serotypes, IgG Antibody in Response to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)|Percentage of Infants With Positive Humoral Response to PCV-13",True,2025-04-16
NCT01891071,Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis,Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis,UNKNOWN,2013-07,2017-04,2017-04,2016-03-31,2013-07-02,INTERVENTIONAL,NA,35.0,ESTIMATED,Ottawa Hospital Research Institute,OTHER,The Ottawa Hospital,OTHER,Multiple Sclerosis,Multiple sclerosis|Lung volume recruitment|Pulmonary function impairment|Cough impairment,Canada,Ottawa,Ontario,2,Lung volume recruitment,PROCEDURE,Rate of decline of FVC (forced vital capacity),"Rate of decline of peak cough flow|Change from baseline in FVC at 2, 4, 6 and 9 months|Change from baseline in peak cough flow at 2, 4, 6 and 9 months",False,
NCT06329453,Intestinal Immunity in Neurologic Disease,Intestinal Immunity in Neurologic Disease,RECRUITING,2022-08-02,2027-08-31,2027-08-31,2025-04-11,2024-03-26,OBSERVATIONAL,,100.0,ESTIMATED,Yale University,OTHER,,,Multiple Sclerosis|Parkinson Disease|REM Sleep Behavior Disorder,,United States,North Haven,Connecticut,1,Colon Tissue Biopsy,PROCEDURE,Characterization of immune cells from the gastrointestinal mucosa,Evaluate spatial transcriptomics of intestinal tissue|Characterize the microbiome at different anatomic sites within the gastrointestinal tract,False,
NCT05029700,The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis,The Effect of Trunk Stabilization Training Combined With Aerobic Training on Neuromuscular Parameters and Functional Exercise Capacity in Patients With Multiple Sclerosis,COMPLETED,2019-06-01,2020-12-01,2021-02-01,2021-08-31,2021-08-31,INTERVENTIONAL,NA,20.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Physical Therapy,balance|strength|endurance|stability|exercise,Turkey (Türkiye),Ankara,,1,Combined exercise training|Aerobic training,OTHER|OTHER,Static balance|Static balance|Static balance|Dynamic balance,Lower extremity muscle strength|Lower extremity muscle strength|Lower extremity muscle endurance|Lower extremity muscle endurance,False,
NCT00784836,Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients,"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis",TERMINATED,2008-10,2009-02,2009-02,2014-05-07,2008-11-04,INTERVENTIONAL,PHASE3,3.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis - Relapsing,United States,Detroit,Michigan,2,BG9418 (interferon beta 1-a),DRUG,Number of Participants Who Developed Neutralizing Antibodies (NAbs) to Interferon-beta (IFN-beta),Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),True,2014-05-07
NCT03186612,Virtual Reality and Manual Dexterity in in Patients With Multiple Sclerosis,Effects of a Game-based Virtual Reality Video Capture Training Program Plus Occupational Therapy on Manual Dexterity in Patients With Multiple Sclerosis: a Randomizaed Controlled Trial,UNKNOWN,2016-03-02,2017-12-02,2017-12-31,2017-06-16,2017-06-14,INTERVENTIONAL,NA,26.0,ESTIMATED,Universidad Rey Juan Carlos,OTHER,,,Multiple Sclerosis|Physical Activity|Upper Limb|Virtual Reality|Dexterity,"Video games; Virtual reality; Occupational therapy, Manual dexterity; Multiple sclerosis.",Spain,Alcorcón,Madrid,1,OT+VR intervention with videogames for the upper limb (dexterity),BEHAVIORAL,"Manual dexterity, gross dexterity and coordination|Hand´s functional capacity|Manipulative dexterity",,False,
NCT02716701,Exercise in Multiple Sclerosis,Effects of Exercise on Brain Structure and Function in Multiple Sclerosis,TERMINATED,2016-01,2020-08-12,2020-08-13,2020-08-25,2016-03-23,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Minnesota,OTHER,,,Multiple Sclerosis,Exercise,United States,Minneapolis,Minnesota,1,Exercise Group|Control Group|wristband activity tracker,BEHAVIORAL|OTHER|OTHER,Change from baseline in brain structure as measured by magnetic resonance imaging scans at 7 months|Change from baseline in brain structure as measured by magnetoencephalography (MEG) scans at 7 months,,False,
NCT06966128,Transcranial Electrical Stimulation in Multiple Sclerosis,The Effect of Transcranial Direct Current Stimulation on Cerebral Blood Flow in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-06-01,2029-01-01,2029-01-01,2025-05-29,2025-05-11,INTERVENTIONAL,NA,100.0,ESTIMATED,Universitair Ziekenhuis Brussel,OTHER,"Fund for Scientific Research, Flanders, Belgium|Vrije Universiteit Brussel",OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Cerebral hemodynamics|Cerebral circulation|Cerebral hypoperfusion|Transcranial Direct Current Stimulation|Electrical stimulation,Belgium,Brussels,,2,transcranial Direct Current Stimulation,DEVICE,Cerebral blood flow (CBF),Symbol Digit Modalities Test (SDMT)|California Verbal Learning Test (CVLT-II)|Controlled Oral Word Association Test (COWAT)|Brief visuospatial Memory Test (BVMT-R)|Fatigue Scale for Motor and Cognitive Function (FSMC)|Beck's depression inventory (BDI)|MRI T1 scan|MRI T2 FLAIR scan,False,
NCT05984095,Multiple Sclerosis Pelvic Floor Telerehabilitation,Pelvic Floor Rehabilitation in Females With Multiple Sclerosis: Comparison of Two Telerehabilitation Protocols,COMPLETED,2023-09-15,2023-11-15,2023-11-25,2023-11-28,2023-08-09,INTERVENTIONAL,NA,28.0,ACTUAL,University of Trieste,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Pelvic Floor|Telerehabilitation|Exercise,Italy,Trieste,,1,Telerehabilitation,OTHER,Pain perception|Depression symptoms|Perceived quality of life|Sexual health|Urinary incontinence symptoms,,False,
NCT01198977,Telehealth-Based Exercise Program to Treat Fatigue in MS,Telehealth-Based Exercise Program to Treat Fatigue in MS,COMPLETED,2009-10,2015-09,2016-12,2019-10-09,2010-09-10,INTERVENTIONAL,NA,64.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis,multiple sclerosis|Fatigue|exercise|telemedicine|motivational interviewing|counseling|depression|physical activity,United States,Seattle,Washington,1,Brief telephone-based counseling|Education counseling,BEHAVIORAL|OTHER,Fatigue,Depression,True,2016-08-12
NCT03451175,Reproductibility of Cystometry in Multiple Sclerosis Patient,Reproductibility of Cystometry in Multiple Sclerosis Patient,COMPLETED,2017-07-02,2017-11-01,2018-01-01,2018-03-01,2018-03-01,OBSERVATIONAL,,31.0,ACTUAL,Pierre and Marie Curie University,OTHER,,,Lower Urinary Tract Symptoms|Cystometry|Multiple Sclerosis|Overactive Bladder|Overactive Detrusor,Overactive Detrusor|Multiple Sclerosis|Reproductibility|Cystometry,France,Paris,,1,,,Reproductibility of urodynamic Capacity Cystometric Maximum (CCM)|Reproductibility of urodynamic : Pressure maximum|Reproductibility of urodynamic : Pressure of the first involuntary detrusor contraction (IDC)|Reproductibility of urodynamic : volume of filling for the first IDC,Comparaison of urodynamic parameters between naive treatment patient and non naive treatment patients,False,
NCT04225312,Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis,Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis,UNKNOWN,2020-02-03,2025-03-01,2025-03-01,2023-04-27,2020-01-13,INTERVENTIONAL,PHASE4,300.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,Stichting MS Research|Innovatiefonds Zorgverzekeraars|Stichting Treatmeds,UNKNOWN|OTHER|UNKNOWN,Relapsing Remitting Multiple Sclerosis,Natalizumab|Extended interval dosing,Netherlands,'s-Hertogenbosch,,24,Personalized extended interval dosing of natalizumab|Standard interval dosing,DRUG|DRUG,Change of T2 lesions on brain MRI,Annualized relapse rate|Disability progression during follow-up|Cost analysis|JC virus conversion|Course JC virus index|Natalizumab wearing-off effect|Stability of natalizumab trough concentration|Patient preference|Quality of life: MSIS-29|Satisfaction of treatment: TSQM|Progressive multifocal leukoencephalopathy|Brain atrophy|Serum neurofilament light levels,False,
NCT06219291,Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part A,Preventing the Progression of Physical Disability and Promoting Brain Functional Adaptation in People With Multiple Sclerosis: Integration of Early Rehabilitative Treatment and Multimodal Clinical and Instrumental Assessment - Part A,ENROLLING_BY_INVITATION,2022-07-01,2024-07-07,2025-12,2024-01-23,2024-01-23,OBSERVATIONAL,,80.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,IRCCS San Raffaele|Azienda Sanitaria Locale di Cagliari,OTHER|OTHER,Multiple Sclerosis,early phase|non-disabled,Italy,Cagliari,,3,Observational,OTHER,Six Minute Walk test (SMWT),Concentration of oxygenated hemoglobin (Delta oxyHb)|Expanded Disability Status Scale (EDSS)|Regularity of gait,False,
NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,"Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS",COMPLETED,2007-08-01,2010-07-31,2010-07-31,2023-08-22,2007-04-20,OBSERVATIONAL,,89.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Multiple Sclerosis,fatigue|Tysabri|cognition,United States,Phoenix,Arizona,31,,,Visual Analog Scale for Fatigue (VAS-F),,False,
NCT05432713,A Study of LP-168 in Healthy Volunteers,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LP-168 Following Single and Multiple Oral Administration to Healthy Volunteers",COMPLETED,2022-05-14,2022-11-20,2022-12-28,2023-02-24,2022-06-27,INTERVENTIONAL,PHASE1,70.0,ACTUAL,Guangzhou Lupeng Pharmaceutical Company LTD.,INDUSTRY,,,Multiple Sclerosis|NMO Spectrum Disorder,,China,Hangzhou,Zhejiang,1,LP-168 tablet|LP-168 Placebo tablet,DRUG|DRUG,Number of Participants With Treatment Emergent Adverse Events as determined by CTCAE v5.0|Severity of Treatment Emergent Adverse Events as determined by CTCAE v5.0|Pharmacokinetics (PK) As Assessed By Maximum Observed Plasma Concentration (Cmax) of LP-168|PK As Assessed By Area Under The Plasma Concentration Time Curve From Time 0 To The Time of The Last Quantifiable Concentration (AUC0-t) Of LP-168|PK As Assessed By Time To Maximum Observed Plasma Concentration (Tmax) of LP-168|PK As Assessed By Terminal Half-life (t1/2) of LP-168|PK As Assessed By Terminal Vd/F of LP-168|PK As Assessed By Terminal CL/F of LP-168,PD as Assessed by elisa analysis the proportion of LP-168 occupied kinase at scheduled timepoints pre-dose and post-dose,False,
NCT02386566,Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab,"A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab",COMPLETED,2015-03-20,2018-01-28,2018-01-28,2018-09-13,2015-03-12,OBSERVATIONAL,,48.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Switzerland,Aarau,,7,natalizumab,DRUG,Compare EDSS change categories with changes in MusiQoL,Cumulative probabilities of sustained improvement and progression in neurological disability|Compare clinical disease-free status (no sustained EDSS increase of 1.0 and no relapse) with MusiQoL|Compare EDSS change categories with EQ-5D|Compare FSMC score with EQ-5D|Compare MSISQ-19 scores with EQ-5D|Comparison of BDI-FS with EQ-5D|Compare SDMT scores with EQ-5D|Rates of clinical relapses and relapses requiring steroid treatment|Changes in the WPAI questionnaire|Change in kind and percentage of occupation due to MS|Change in the percentage of disability pension|Incidence and number of SAEs and SUSARs,False,
NCT05541965,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,COMPLETED,2020-05-01,2022-09-30,2022-09-30,2025-08-01,2022-09-15,INTERVENTIONAL,NA,15.0,ACTUAL,Ondokuz Mayıs University,OTHER,,,Multiple Sclerosis|Reflexology|Urinary Incontinence,Multiple sclerosis|Nurses|Complementary Therapies|Urinary Incontinence|Reflexology,Turkey (Türkiye),Samsun,,1,Reflexology and kegel exercises,OTHER,Index of severity incontinence (ISI)|nternational Consultation on Incontinence Questionnaire Short Form(ICIQ-SF)|Incontinence quality of life (IQOL),,False,
NCT00649792,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",COMPLETED,2007-08,2011-01,2011-04,2012-02-28,2008-04-01,INTERVENTIONAL,PHASE3,214.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|MS|walking|leg strength|demyelination,United States,Phoenix,Arizona,42,Fampridine-SR,DRUG,Summary of Treatment Emergent Adverse Events (TEAE).,Timed 25-Foot Walk (T25FW)|Subject Global Impression (SGI)|Clinician's Global Impression (CGI)|Expanded Disability Status Scale (EDSS),True,2012-02-27
NCT03744351,B Cell Differentiation in MS,Analysis of B Cell Differentiation in Multiple Sclerosis,COMPLETED,2019-02-25,2023-05-30,2023-05-30,2024-04-10,2018-11-16,INTERVENTIONAL,NA,136.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,Follicular helper T cells|B cells|Differentiation,France,Rennes,,1,Biological Samples|Biological Samples|Biological Samples|Biological Samples,OTHER|OTHER|OTHER|OTHER,Plasmablasts frequency,,False,
NCT06528665,Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects,"A Pharmacokinetic, Safety and Tolerability Formulation Screening Comparing Corplex Ozanimod TDS to Oral Ozanimod Capsules in Healthy Adults Subjects",RECRUITING,2025-02-10,2025-03-16,2025-04-16,2025-02-11,2024-07-30,OBSERVATIONAL,,24.0,ESTIMATED,"Corium Innovations, Inc.",INDUSTRY,,,Multiple Sclerosis|Ulcerative Colitis,Ozanimod; Transdermal Delivery system; Pharmacokinetics,Malaysia,Ampang,Selangor,1,"ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults",DRUG,"Plasma Pharmacokinetic- AUC 0-t (Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic- AUC 0-∞ (Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic- Cmax (Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic- Tmax (Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic- T 1/2 (Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic- MTR(Ozanimod, CC112273, CC1084037)|Plasma Pharmacokinetic-Lambda z(λz) (Ozanimod, CC112273, CC1084037)",,False,
NCT05388331,RIS International Cohort,The Radiologically Isolated Syndrome International Cohort,RECRUITING,2022-04-15,2023-04-15,2029-04-15,2022-05-24,2022-05-24,OBSERVATIONAL,,1000.0,ESTIMATED,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis|Radiologically Isolated Syndrome,,France,Nice,,1,No intervention,OTHER,Identification of lesions T2-weighted sequence at the index scan|Identification of lesions T2-weighted sequence at the index scan|Identification of lesions T1 sequence with and without Gd at the index scan.|Identification of lesions T1 sequence with and without Gd at the index scan.|Radiological progression : new T2 lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Brain atrophy|Brain atrophy|Brain atrophy|Brain atrophy|Brain atrophy|Brain atrophy|Radiological progression : new T2 lesions|Radiological progression : new T2 lesions|Radiological progression : new T2 lesions|Radiological progression : new T2 lesions|Radiological progression : new T2 lesions|Radiological progression : new T2 lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions|Radiological progression : new contrast enhancing lesions,Collect biological data|Collect biological data|Collect digital markers|Collect digital markers|Collect digital markers|Collect digital markers|Collect digital markers|Collect digital markers|Collect digital markers,False,
NCT06526000,Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies,Retrospective EMR Study to Assess Changes in Immunoglobulins in Patients With Relapsing Forms of Multiple Sclerosis Treated With Anti-CD20 Monoclonal Antibodies,COMPLETED,2022-10-11,2024-02-28,2024-02-28,2024-07-29,2024-07-29,OBSERVATIONAL,,326.0,ACTUAL,Novartis,INDUSTRY,,,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome|Relapsing-remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Percentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab,Percentage of Patients Newly Treated with Ocrelizumab With Low Immunoglobulin Values|Percentage Change per Year in Immunoglobulin M (IgM) Levels in Patients Receiving Ocrelizumab|Percentage Change per Year in IgG Levels Associated With Risk Factors in Patients Treated With Ocrelizumab,False,
NCT03870048,tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis,Transcranial Direct Current Stimulation to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis,COMPLETED,2019-04-15,2020-03-30,2020-03-30,2022-08-25,2019-03-11,INTERVENTIONAL,NA,6.0,ACTUAL,University of Iowa,OTHER,"jkamholz|Workman, Craig D., PhD",UNKNOWN|INDIV,Multiple Sclerosis,,United States,Iowa City,Iowa,1,transcranial direct current stimulation,DEVICE,Neuropathic Pain Questionnaire (NPQ) Contains 12 Items.,Fatigue Severity Scale (FSS) Contains Nine Statements That Attempt to Explore Severity of Fatigue Symptoms.,True,2022-08-25
NCT02274935,Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis,Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis,COMPLETED,2014-10,2016-07,2016-09,2016-10-26,2014-10-24,INTERVENTIONAL,NA,20.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,,United States,Urbana,Illinois,1,Exercise,OTHER,Cognitive Motor interference,,False,
NCT02408380,Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720),"Analysis of a Biomarker Signature, Consisting of Toll-like Receptor 2 (TLR2), TLR4 and CCR1, by Flow Cytometry in Patients With MS Treated With Gilenya (FTY720)",UNKNOWN,2014-09,2015-09,2015-12,2015-04-03,2015-04-03,OBSERVATIONAL,,216.0,ESTIMATED,McGill University,OTHER,Novartis Pharmaceuticals,INDUSTRY,Multiple Sclerosis,biomarker|disease progression,Canada,Montreal,Quebec,1,,,Change in expression of a biomarker signature,,False,
NCT01337427,Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis,"Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",WITHDRAWN,2010-08,2013-08,2013-08,2014-09-15,2011-04-18,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Johns Hopkins University,OTHER,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis,multiple sclerosis|relapsing|MS|injectable|subcutaneous|SC|PEGylated|interferon|PEG|OCT|Optical Coherence Tomography,,,,0,BIIB017,DRUG,To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 12 in the BIIB-17 vs. placebo arms.|To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 24 in the BIIB-17 vs. placebo arms.,Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 12 in the BIIB-17 vs. placebo arms.|Analysis of decrease between baseline scans and 3 month scan (to examine for pseudoatrophy) in this study population.|Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (12 months) in this study population.|Analysis of macular volume decreases from baseline or 3 months to follow up scans at 12 months in this study population.|Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 12 months in this study population.|Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.|Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 24 in the BIIB-17 vs. placebo arms.|Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (24 months) in this study population.|Analysis of macular volume decreases from baseline or 3 months to follow up scans at 24 months in this study population.|Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 24 months in this study population.|Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.,False,
NCT06973018,Internet Delivered Cognitive Rehabilitation for Mild Cognitive Impairments,Internetförmedlad Kognitiv Rehabilitering Vid Lindrig Kognitiv störning,ENROLLING_BY_INVITATION,2021-05-02,2025-07-01,2027-12-31,2025-05-15,2025-05-15,INTERVENTIONAL,NA,64.0,ESTIMATED,Aniko Bartfai,OTHER,Region Stockholm,OTHER_GOV,Traumatic Brain Injury|Stroke|Multiple Sclerosis|Parkinsons Disease (PD)|Post-COVID-19 Condition,brain injury|cognitive rehabilitation|nervous system disorders|eHealth|self assessment,Sweden,Stockholm,Stockholm County,1,eRehabCog|CogMed QM,BEHAVIORAL|BEHAVIORAL,"Mayo Portland Adaptability Inventory - fourth edition (MPAI-4), Participation subscale",MPAI-4 Adaptability subscale|MPAI-4 Abilities subscale|MPAI-4 Total score|Hospital Anxiety and Depression Scale|Life Satisfaction Questionnaire (LiSat-11)|Community Integration Questionnaire - Revised (CIQ-R),False,
NCT03322761,Early Exercise Efforts in Multiple Sclerosis,Exercise as a Supplemental Treatment Strategy Early in the Disease Course of Multiple Sclerosis,COMPLETED,2018-04-01,2021-12-31,2021-12-31,2022-11-03,2017-10-26,INTERVENTIONAL,NA,84.0,ACTUAL,University of Aarhus,OTHER,University of Southern Denmark|Region of Southern Denmark,OTHER|OTHER,Multiple Sclerosis,Multiple sclerosis|Exercise|Disease-modifying treatment|Early treatment,Denmark,Aarhus,,1,Systematic exercise training|Educational program,COMBINATION_PRODUCT|BEHAVIORAL,Change in Annual Relapse Rate (ARR)|Percentage brain volume change,Multiple Sclerosis Functional Composite (MSFC)|Expanded Disability Status Scale (EDSS) score,False,
NCT01303770,Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis,Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis,UNKNOWN,2011-02,2014-12,2014-12,2013-12-25,2011-02-25,INTERVENTIONAL,NA,50.0,ESTIMATED,Tel Aviv University,OTHER,,,Multiple Sclerosis|Cognitive Impairment,Multiple Sclerosis|Cognitive impairment|Self-management programs|Occupational Therapy|Rehabilitation,Israel,Petah Tikva,,1,Self-management cognitive rehabilitation group intervention|Control intervention,BEHAVIORAL|BEHAVIORAL,Cognitive strategy use,Cognitive self-efficacy,False,
NCT00790582,A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,2008-05,2010-03,2010-03,2020-10-30,2008-11-13,INTERVENTIONAL,PHASE2,109.0,ACTUAL,Forbes Norris MDA/ALS Research Center,OTHER,Muscular Dystrophy Association,OTHER,Amyotrophic Lateral Sclerosis,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Lithium|Lithium Carbonate,United States,Scottsdale,Arizona,10,lithium carbonate,DRUG,Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised),Vital Capacity,True,2020-10-30
NCT04688788,Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis,Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-04-28,2026-05-05,2029-05-05,2025-07-28,2020-12-30,INTERVENTIONAL,PHASE3,600.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,"Odense University Hospital|Aarhus University Hospital|Aalborg University Hospital|Herlev Hospital|Hillerod Hospital, Denmark|Kolding Sygehus|Gødstrup Hospital|Hvidovre University Hospital|Hospital of South West Jutland, Esbjerg, Denmark|GCP unit, Copenhagen University Hospital|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|Hospital of Southern Jutland, Sønderborg, Denmark|Hospital of Central Denmark Region, Viborg, Denmark|Danske Regioner|Hospital of Southern Jutland, Aabenraa, Denmark|Sanquin Research & Blood Bank Divisions",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|OTHER|UNKNOWN|OTHER,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Magnetic resonance imaging|Rituximab|Ocrelizumab,Denmark,Glostrup Municipality,Copenhagen,11,Rituximab|Ocrelizumab|Fexofenadine|Paracetamol|Methylprednisolone,DRUG|DRUG|DRUG|DRUG|DRUG,Percentage of patients without new or enlarging T2 white matter lesions on brain MRI scans,Percentage of patients with 6-month confirmed disability progression (CDP) in Expanded Disability Status Scale (EDSS)|Annualised relapse rate based on cumulative number of confirmed relapses from baseline to months 24|Percentage of patients with 6-months CDP in Timed 25 Foot Walk (T25FW)|Percentage of patients with 6-months CDP in 9-Hole-Peg Test (9HPT)|Percentage of patients with 6-months CDP in Symbol Digit Modalities Test (SDMT)|Change in Multiple Sclerosis Impact Scale (MSIS-29)|Change in Fatigue Scale for Motor and Cognitive Functions (FSMC)|EuroQol- 5 Dimension (EQ-5D)|Percentage of patients without gadolinium-enhancing lesions (GdEL)|Change in T2 white matter lesion volume|Change in T1 white matter lesion volume|Percentage brain volume change (PBVC) from month 6 to month 24|Change in serum neurofilament light chain level|Blood levels of cluster of differentiation antigen 19 (CD19)+ B cells,False,
NCT04593927,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis),COMPLETED,2020-10-28,2023-08-30,2023-08-30,2024-02-12,2020-10-20,OBSERVATIONAL,,451.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis (SPMS),Secondary Progressive Multiple Sclerosis|SPMS|Mayzent|Siponimod|Japan,Japan,Anjo,Aichi-ken,174,Mayzent,DRUG,"Incidence of Adverse Events (AE), Serious Adverse Events (SAE) and Adverse Reactions",Physician's Global Assessment (PGA) of disease activity|Changes over time in Expanded Disability Status Scale (EDSS) score|Time to confirmed disability progression continuing for ≥ 3 months from the start of administration as assessed by the EDSS|Time to confirmed disability progression continuing for ≥ 6 months from the start of administration as assessed by the EDSS|Annual relapse rate,False,
NCT04996186,Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q,Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q (STAR Questionnaire): Validation of a New Tool to Better Explore and Manage Bowel Dysfunction.,COMPLETED,2019-06-01,2020-07-01,2021-04-30,2021-08-27,2021-08-09,OBSERVATIONAL,,200.0,ACTUAL,Pierre and Marie Curie University,OTHER,,,Multiple Sclerosis|Constipation|Fecal Incontinence,multiple sclerosis|constipation|fecal incontinence|questionnaire|evaluation|quality of life,France,Paris,,1,Clinical interviews,OTHER,Reproductibility of STAR-Q|Acceptability and comprehension of STAR-Q,,False,
NCT01610713,An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,"Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension",COMPLETED,2001-05,2002-07,2002-07,2023-01-10,2012-06-04,INTERVENTIONAL,PHASE3,154.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United Kingdom,Oxford,,1,GW-1000-02,DRUG,Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total),Change From Mean Part A Guy's Neurological Disability Scale Score at the End of Open-label Treatment|Change From Mean Part A Care-Giver Strain Index Score at the End of Open-label Treatment|Change From Mean Part A Reading Visual Acuity Test Score at the End of Open-label Treatment|Change From Mean Part A Ashworth Scale Score at the End of Open-label Treatment|Change From Mean Part A Short Orientation Memory Concentration Score at the End of Open-label Treatment|Change From Mean Part A Barthel Activities for Daily Living Score at the End of Open-label Treatment|Change From Mean Part A Total Adult Memory and Information Processing Battery Score at the End of Open-label Treatment|Change From Mean Part A Beck's Depression Inventory (BDI-II) Score at the End of Open-label Treatment|Change From Mean Part A Fatigue Severity Scale Questionnaire Score at the End of Open-label Treatment|Change From Mean Part A Rivermead Mobility Index Score at the End of Open-label Treatment|Change From Mean Part A Total 28-item General Health Questionnaire Score at the End of Open-label Treatment|Change From Mean Part A Nine Hole Peg Test Score at the End of Open-label Treatment|Change From Mean Part A Total Bladder Control Questionnaire Score at the End of Open-label Treatment|Change From Mean Part A Tremor Activities of Daily Living Score at the End of Open-label Treatment|Change From Mean Part A Sleep Quality 100 mm Visual Analogue Scale Score at the End of Open-label Treatment|Incidence of Adverse Events as a Measure of Patient Safety|Change From Part A Mean Sleep Amount 100 mm Visual Analogue Scale Score at the End of Open-label Treatment|Change From Part A Mean Feeling Upon Wakening 100 mm Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Spasticity Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Pain Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Muscle Spasm Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Tremor Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Bladder Problems Visual Analogue Scale Score at the End of Open-Label Treatment|Change From Part A Mean Ten-metre Mobility Score at the End of Open-Label Treatment|Subject Global Opinion of Effect on Multiple Sclerosis at the End of Open-label Treatment,True,2012-09-19
NCT02782858,Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS,"An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2016-04,2017-08,2017-12,2020-10-20,2016-05-25,INTERVENTIONAL,PHASE2,270.0,ACTUAL,GeNeuro SA,INDUSTRY,Les Laboratoires Servier (LLS)|Institut de Recherches Internationales Servier|Worldwide Clinical Trials,UNKNOWN|OTHER|OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Multiple Sclerosis Relapsing-Remitting|GNbAC1|MRI|Monoclonal antibody|Multiple Sclerosis associated retrovirus MSRV|MS|RRMS|HERV-W|Temelimab,Bulgaria,Sofia,,12,GNbAC1|Placebo,DRUG|DRUG,Cumulative number of Gd-enhancing T1 lesions in brain MRI,,False,
NCT06463743,Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS),"Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS): Randomized, Placebo-controlled Pilot Study.",NOT_YET_RECRUITING,2025-08-01,2027-01-01,2027-06-01,2025-06-27,2024-06-18,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,State University of New York at Buffalo,OTHER,National Center for Advancing Translational Sciences (NCATS),NIH,Multiple Sclerosis,metformin,,,,0,metformin|Placebo,DRUG|DRUG,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.|Percent change in N-Acetyl Aspartate (NAA) in the cortex over 9 months,Disability progression as measured with Expanded Disability Status Scale (EDSS)|Symbol Digit Modality Test (SDMT)|Brief Visuospatial Memory Test ( BVMT)|California Verbal Learning Test (CVLT)|Conventional MRI outcomes|Timed 25-foot walk test (T25FWT)|9-hole peg test (9HPT)|Myelin water fraction (MWF),False,
NCT01947582,The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS),The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS),COMPLETED,2013-10,2014-12,2014-12,2016-03-07,2013-09-20,INTERVENTIONAL,NA,2.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,,,Multiple Sclerosis,multiple sclerosis|gait|ankle foot orthosis (AFO),United States,Dallas,Texas,1,Ankle foot orthosis,DEVICE,Change in Walking Distance During 6-Minute Walk Test,Change in Impact of MS on Fatigue Using the 12-Item Walk Scale|Change in Step Length Using the GAITRite Computerized Gait Analysis System|Number of Persons With Change in Muscle Activity Using Surface Electromyography (EMG),True,2015-06-01
NCT01808482,"A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis",TERMINATED,2013-03-13,2013-08-06,2013-08-06,2017-06-07,2013-03-11,INTERVENTIONAL,PHASE1,16.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",monoclonal antibody|Multiple Sclerosis|Interleukin-7 Receptor,United Kingdom,Cambridge,,1,Part A: 100 mg/mL GSK2618960|Part A: matching placebo|Part B: Dose of GSK2618960 decided from Part A|Part B: matching placebo|Part C: Dose of GSK2618960 decided from Part A and B,DRUG|DRUG|DRUG|DRUG|DRUG,"Safety and tolerability of GSK2618960 as assessed by changes in: vital signs, ECG monitoring, haematology, clinical chemistry, urinalysis, and monitoring of AEs in healthy volunteers and MS patients|Safety and tolerability of GSK2618960 as assessed by changes in MS relapses: Number, duration, severity in MS patients","Composite of PK parameters of GSK2618960|Receptor occupancy by GSK2618960 - Blinding of fluorophore-conjugated competing and non-competing antibody of GSK2618960 following the single and repeat IV doses|Relationship between dose and duration of >95% RO of GSK2618960 following single and repeat IV doses in healthy volunteers|To characterize the effect of GSK2618960 on IL-7 downstream signalling - Phosphorylation level of stat5 protein upon ex vivo stimulation of IL-7 cytokine, normalized by baseline, maximum receptor blocking controls and unstimulated controls|Presence of antibodies to GSK2618960|Changes in numbers and relevant ratios of lymphocyte subsets|Markers of serum inflammatory mediators in blood.|Cumulative number of new brain lesions",False,
NCT00666224,Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome,"A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS)",COMPLETED,2004-01,2007-10,2010-06,2012-06-25,2008-04-24,INTERVENTIONAL,PHASE3,481.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,Clinically Definite Multiple Sclerosis|Clinically Isolated Syndrome|Multiple Sclerosis,,,,0,Glatiramer Acetate (DB)|Placebo|Glatiramer Acetate (OL),DRUG|DRUG|DRUG,Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion|Twenty-fifth Percentile (25%) Kaplan-Meier Estimates for Time From Randomization to Conversion to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period,Number of New T2 Brain Lesions Observed at the Last Observed Value (LOV) in the Double-blind Period|Change From Baseline to Last Observed Value (LOV) in T2 Brain Lesion Volume in the Double-blind Period|Percentage Change in Brain Volume From Baseline to the Last Observed Value (LOV) During the Double-blind Period Using the Structural Image Evaluation of Normalized Atrophy (SIENA) Technique|Percentage of Participants Who Converted to Clinically Definite Multiple Sclerosis (CDMS) During the Double-blind Period,True,2012-06-13
NCT06341023,Functional Balance Intervention in Multiple Sclerosis,Functional Balance Intervention (FBI) for Physical and Cognitive Symptoms of Multiple Sclerosis,RECRUITING,2025-01-21,2026-01-09,2027-01-09,2025-03-12,2024-04-02,INTERVENTIONAL,NA,120.0,ESTIMATED,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,Functional Balance|Cognition|Dual task|Physical function|Muscular strength|Spasticity|Sensorimotor dysfunction|Fall prevention|Vestibular,United States,Chicago,Illinois,1,Functional Balance Intervention|Stretching,BEHAVIORAL|BEHAVIORAL,Change in physical function|Change in cognitive function|Change in dual task balance performance|Change in dual task gait performance|Change in measured community mobility|Change in self-reported community mobility|Change in self-reported quality of Life,Change in walking performance|Change in walking speed|Change in balance confidence|Change in functional independence,False,
NCT04377555,Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab,"An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab",ACTIVE_NOT_RECRUITING,2020-07-30,2025-12-29,2025-12-29,2025-07-30,2020-05-06,INTERVENTIONAL,PHASE4,179.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,"Multiple Sclerosis, Relapsing",,United States,Phoenix,Arizona,32,Ocrelizumab,DRUG,Proportion of Participants Free of Any Protocol-defined Events During a 48-week Period on Treatment,Time to onset of 24 weeks confirmed disability progression (CDP) at week 48|Time to protocol-defined event|Annualized relapse rate at week 48,False,
NCT01378676,A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS),"A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2011-06,2012-03,2012-03,2019-05-07,2011-06-22,INTERVENTIONAL,PHASE2,49.0,ACTUAL,Cytokinetics,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,San Francisco,California,9,Placebo (Part A)|CK-2017357 (Part A)|CK-2017357 (Part A)|CK-2017357 (Part A)|Riluzole 50 MG (Part B)|Placebo (Part B)|CK-2017357 (Part B)|CK-2017357 (Part B)|CK-2017357 (Part B),DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Measurement of Grip Strength and Handgrip Fatigue|Measurement of muscle strength|Measurement of Slow Vital Capacity (SVC)|Measurement of Sniff Nasal Inspiratory Pressure (SNIP)|Measurement of Maximum Voluntary Ventilation (MVV)|Patient global assessment|Investigator global assessment,False,
NCT01065090,"A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis","A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis",COMPLETED,2010-06,2014-01,2014-01,2015-04-13,2010-02-09,OBSERVATIONAL,,38.0,ACTUAL,Biogen,INDUSTRY,Biogen Idec A/S,UNKNOWN,Exercise,Capacity for Work Questionnaire|exercise|AVONEX|SDMT: Symbol Digit Modalities Test|FSMC: Fatigue Scale for Motor and Cognitive functions|effects of exercise|EDSS: Expanded Disability Status Scale,Australia,NSW,,14,,,Change of muscle strength,Changes of speed of walking,False,
NCT02490982,Teriflunomide Observational Effectiveness Study,Teriflunomide Observational Effectiveness Study,COMPLETED,2015-11,2018-12,2021-06-28,2021-08-18,2015-07-07,OBSERVATIONAL,,106.0,ACTUAL,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,"Genzyme, a Sanofi Company|Montreal Neurological Institute and Hospital",INDUSTRY|OTHER,Relapsing Remitting Multiple Sclerosis,,Canada,Montreal,Quebec,1,Teriflunomide,DRUG,Patient-reported outcome (PRO) scores,Disease activity - Composite measure,False,
NCT02217982,Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation,A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration,TERMINATED,2014-07,2015-06,2015-06,2017-03-23,2014-08-15,INTERVENTIONAL,PHASE4,5.0,ACTUAL,"Rocky Mountain MS Research Group, LLC",OTHER,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,United States,Salt Lake City,Utah,1,Simethicone|Loperamide|Peanut Butter,DRUG|DRUG|OTHER,Reported GI Symptoms,Diarrhea Reduction,True,2017-01-06
NCT00441103,A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis,"A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis",COMPLETED,2006-12,2008-11,2009-02,2014-07-09,2007-02-28,INTERVENTIONAL,PHASE3,180.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Subjects with relapsing remitting multiple sclerosis,,,,0,"Rebif® New Formulation (IFN-beta-1a, RNF)|Placebo|Rebif® New Formulation (IFN-beta-1a, RNF)",DRUG|DRUG|DRUG,Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),"Mean Number of CU Lesions Per Scan Between the Initial 16 Weeks of Placebo Treatment and 24 Weeks of RNF Treatment in the Same Participants, Originally Randomized to Placebo.|Number of CU Active MRI Lesions",True,2010-07-05
NCT05017142,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),Swiss Pediatric Inflammatory Bain Disease Cohort Study,RECRUITING,2020-04-14,2071-01-01,2071-01-01,2024-12-16,2021-08-23,OBSERVATIONAL,,500.0,ESTIMATED,University of Bern,OTHER,"Schweizerische Multiple Sklerose Gesellschaft|Insel Gruppe AG, University Hospital Bern|Novartis|Anna Mueller Grocholski-Stiftung|Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel|Biogen|Roche Pharma (Switzerland) Ltd|Fondation Johanna Dürmüller-Bol|Kantonsspital Aarau|University Children's Hospital Basel|Ente Ospedaliero Cantonale, Bellinzona|Kantonsspital Graubünden|University Hospital, Geneva|Centre Hospitalier Universitaire Vaudois|Ostschweizer Kinderspital|Kantonsspital Winterthur KSW|Sanofi|Hôpital Fribourgeois|University Children's Hospital, Zurich|Luzerner Kantonsspital",OTHER|OTHER|INDUSTRY|UNKNOWN|OTHER|INDUSTRY|UNKNOWN|UNKNOWN|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|INDUSTRY|OTHER|OTHER|OTHER,"Optic Neuritis|Transverse Myelitis|Acute Disseminated Encephalomyelitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Anti-NMDAR Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Hashimoto Encephalitis|CNS Vasculitis|CNS Sarcoidosis|CNS Lupus|Rasmussen Encephalitis|Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",,Switzerland,Aarau,Canton of Aargau,13,,,Personal data|Diagnosis|Age at diagnosis|First symptoms|Age at first symptoms|Diagnostic delay|Hospitalization|Rehabilitation|Death date|Death cause|Change in EDSS|Change in Neurostatus|Change in medication|Change in Education|Change in MRI data|Change in MRI data|Change in laboratory test data|Electrophysiological testing,Future questionnaires,False,
NCT02493491,Neurogenic Dysphonia/Dysphagia Registry,Neurogenic Dysphonia/Dysphagia Registry,TERMINATED,2015-06,2016-08,2016-09,2016-09-09,2015-07-09,OBSERVATIONAL,,146.0,ACTUAL,"Merz North America, Inc.",INDUSTRY,Carelon Research|Cmed Clinical Services,OTHER|OTHER,Neurogenic Dysphonia|Neurogenic Dysphagia,dysphonia|dysphagia|neurogenic|vocal fold augmentation|VFA|vocal fold insufficiency|Prolaryn|Radiesse|Coaptite|voice|Parkinson's Disease|Multiple Sclerosis|Amyotrophic Lateral Sclerosis|ALS|MS|calcium hydroxylapatite|hyaluronic acid,United States,La Jolla,California,12,,,"Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.|Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment","Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection|Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA|Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection|Collect characteristics, management, and outcomes of patients who receive CaHA implants and thryoplasty",False,
NCT02509897,Normobaric Hypoxic Training and Multiple Sclerosis,"Cardiorespiratory, Metabolic and Immunoregulatory Response to Hypoxia in Multiple Sclerosis Patients: A Pilot Study",COMPLETED,2015-07,2017-12,2018-07,2022-07-11,2015-07-28,INTERVENTIONAL,NA,39.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,,,Multiple Sclerosis,Hypoxia training|Activity energy expenditure|Immunoregulation|Energy Metabolism|Exercise,Germany,Berlin,,1,Hypoxic training|Normoxic training,OTHER|OTHER,Activity energy expenditure measured by indirect calorimetry (respiratory chamber),,False,
NCT02044510,Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients,"A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients",TERMINATED,2014-07,2018-01,2018-02,2019-02-05,2014-01-24,INTERVENTIONAL,PHASE2|PHASE3,32.0,ACTUAL,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,,,"Urinary Bladder, Neurogenic",Multiple Sclerosis|Spinal Cord Injuries|mirabegron|Urodynamics,Canada,Winnipeg,Manitoba,5,Mirabegron|Placebo,DRUG|DRUG,Bladder Capacity,3 Day Voiding Diary|24hr Urinary Pad Weights|Quality of Life (Bladder Specific)|Quality of Life (Incontinence)|Patient Reported Outcome Measure-NBSS|Patient Perception of Bladder Condition|Adverse Events|Secondary Urodynamic Characteristics: Maximum Detrusor Pressure|Secondary Urodynamic Characteristics: Volume at Maximum Detrusor Pressure|Secondary Urodynamic Characteristics: Bladder Sensation|Secondary Urodynamic Characteristics: Bladder Compliance|Secondary Urodynamic Characteristics: Volume at First Detrusor Overactivity,True,2019-01-07
NCT03658668,Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis,Study of the Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis,COMPLETED,2018-10-03,2021-06-10,2021-06-10,2023-08-16,2018-09-05,INTERVENTIONAL,NA,23.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,active tDCS|sham tDCS|Physical Activity (PA),DEVICE|DEVICE|OTHER,Change in Gait Velocity|Change in Stride Length,Percent of tDCS Sessions Completed|Change in 12-item Multiple Sclerosis Walking Scale Score|Change 21-item Modified Fatigue Impact Scale Score,True,2023-08-16
NCT05418010,"Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)","AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation",SUSPENDED,2022-12-01,2028-01-31,2028-01-31,2025-03-19,2022-06-14,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,Queen Mary University of London,OTHER,Biogen|UCL Queen Square Institute of Neurology|Moorfields Eye Hospital NHS Foundation Trust|Barts & The London NHS Trust,INDUSTRY|OTHER|OTHER|OTHER,Multiple Sclerosis|Clinically Isolated Syndrome of Demyelination,Multiple Sclerosis|Magnetic Resonance Imaging (MRI)|Neurofilament light chain|Demyelinating Diseases|Immunologic Factors|Immune System Diseases|Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Tysabri,United Kingdom,London,,1,Tysabri Injectable Product|Placebo,DRUG|DRUG,"To establish whether there is efficacy superiority of Tysabri® over placebo at 12 weeks in facilitating remyelination of previously demyelinated CNS lesions, as measured by MRI lesion magnetization transfer ratio (MTR).",To establish whether there is a difference between participants receiving Tysabri® or placebo at 24 weeks in P100 latency measured using visually evoked potentials (VEP).|To establish whether there is a difference between participants receiving Tysabri® or placebo at 24 weeks in number and occurrence of adverse events.|To establish whether there is a difference between participants receiving Tysabri® or placebo at 24 weeks in facilitating remyelination of previously demyelinated CNS lesions using Magnetisation transfer ratio (MTR).|To establish whether there is a difference between participants receiving Tysabri® or placebo at 24 weeks in protecting limb function.|To establish whether there is a difference between participants receiving Tysabri® or placebo at 24 weeks in Retinal nerve fibre layer and ganglion cell + inner plexiform (GCIP) layer thickness measured using optical coherence tomography (OCT).,False,
NCT06638775,Functional Electrostimulation on the Upper Lip in Multiple Sclerosis,RESEARCH PROJECT on the APPLICATION of FUNCTIONAL ELECTROSTIMULATION on the UPPER LIMB in MULTIPLE SCLEROSIS,NOT_YET_RECRUITING,2025-01-20,2025-06-20,2025-09-20,2024-10-15,2024-10-15,INTERVENTIONAL,NA,30.0,ESTIMATED,Universidad de Burgos,OTHER,,,Electrode Site Reaction|Therapy|Directly Observed Therapy,fesia grasp|multiple sclerosis|multicampe|therapy,,,,0,Fesia Grasp|GLOBUS ELITE,OTHER|OTHER,"Nine Hole Peg Test|Box and Block|Jamar hand-held dynamometer|Movement imagery Questionnaire, revisado (MIQ-RS)|Chronometry",,False,
NCT05650281,Silent Progression Activity Monitoring - SPAM Study,"Silent Progression Monitoring in Extreme Phenotypes. SP-MS, Despite an Effective Early Highly Active Treatment as a Paradigm SPAM Study (Silent Progression Activity Monitoring)",COMPLETED,2023-01-01,2023-03-31,2023-03-31,2023-07-21,2022-12-14,OBSERVATIONAL,,2230.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,,France,Nice,,1,NO INTERVENTION,OTHER,"Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline clinical markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.|Determination of baseline MRI markers associated with SPMS diagnosis despite an early, practical, Highly Active Treatment.","To determine re-baseline clinical markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline clinical markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline clinical markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|To determine re-baseline clinical and MRI markers associated with SPMS diagnosis despite an early, practical, HAT.|Detremination of the impact of different definition of SPMS according to the clinician|Dertermination of the impact of different definition of SPMS according to Lublin.|Dertermination of the impact of different definition of SPMS according to Lorscheider.|Analyze of the influence of NEDA (No Evidence of Disease activity)|Analyze of the influence of MEDA (Mild Evidence of Disease Activity)|To find a composite score usable at baseline when prescribing early HAT in clinical practice to predict early SPMS",False,
NCT02695394,Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study,,COMPLETED,2016-02,2016-12,2016-12,2020-07-17,2016-03-01,OBSERVATIONAL,,60.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"NeuroCure Clinical Research Center, Charite, Berlin",OTHER,Multiple Sclerosis (MS)|Clinically Isolated Syndrome (CIS),,Germany,Berlin,,1,,,Emotional modulation of motor response time|Emotional memory performance|Emotional experience,BOLD-fMRI brain responses during emotional processing|Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Functional Composite (MSFC)|Short Form Health Survey (SF-36)|Satisfaction With Life Scale (SWLS)|Paced Auditory Serial Addition Test (PASAT)|Serial Reaction Time (SRT) Task|Symbol Digit Modalities Test (SDMT)|Beck depression inventory BDI-2|Positive and Negative Affect Schedule (PANAS),False,
NCT01933802,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis,"Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis",COMPLETED,2014-04,2016-12,2017-03,2018-03-19,2013-09-02,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Tisch Multiple Sclerosis Research Center of New York,OTHER,,,Multiple Sclerosis,mesenchymal stem cells|neural progenitors|autologous|bone marrow|multiple sclerosis,United States,New York,New York,1,intrathecal administration of autologous MSC-NP,BIOLOGICAL,Number of participants with adverse events|Number of participants with adverse events .,Preliminary evaluation of efficacy,False,
NCT06248281,Be Cool: An Innovative and Holistic Psychoeducational Program for Multiple Sclerosis Individuals,"Be Cool: An Innovative and Holistic Psychoeducational Program to Improve and Promote Care, Education and Quality of Life for Multiple Sclerosis Individuals",COMPLETED,2023-06-01,2023-07-01,2024-02-28,2024-05-08,2024-02-08,OBSERVATIONAL,,30.0,ACTUAL,University of Thessaly,OTHER,Greek Multiple Sclerosis Society|European Committee for Treatment and Research in Multiple Sclerosis,UNKNOWN|UNKNOWN,Multiple Sclerosis,symptom management|hybrid program|rehabilitation|quality of life|psychoeducational program,Greece,Thessaloniki,Central Macedonia,1,combination of different rehabilitation strategies,OTHER,"anxiety and depression|Overall quality of life, namely satisfaction with their life|Perception of stress|Cognitive fusion which refers to the degree to which an individual's thoughts and feelings are intertwined with their sense of self, often leading to an inability to separate from, or 'defuse' from, these internal experiences.|The value of living|Psychological flexibility which is the ability to be in the present moment with full awareness and openness to experiences, and to take action guided by one's values.|The resilience which is defined as the ability to cope with and bounce back from adversity.|Aerobic capacity and ability to walk|Lower body strength and functional mobility|Static and dynamic balance ability|Mobility and walking speed","Finger dexterity and arm-hand coordination|Core temperature|Skin temperature|Nutritional status, how balance is their nutrition",False,
NCT04403594,Functional Intermuscular Reduction of Spasticity,Functional Intermuscular Reduction of SpasTicity in MS (MS-FIRST),COMPLETED,2019-08-19,2021-04-01,2021-04-18,2021-09-29,2020-05-27,OBSERVATIONAL,,16.0,ACTUAL,University of Oklahoma,OTHER,Oklahoma Medical Research Foundation,OTHER,Multiple Sclerosis,,United States,Oklahoma City,Oklahoma,1,dry needling,OTHER,6 minute walk test|25-foot walk|Berg Balance Scale|Modified Fatigue Impact Scale|Toe taps on force plate|EMG data of both lower extremities,,False,
NCT01895439,Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis,Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment,COMPLETED,2012-10,2016-02,2016-02,2017-05-02,2013-07-10,INTERVENTIONAL,PHASE1|PHASE2,13.0,ACTUAL,University of Jordan,OTHER,,,Multiple Sclerosis,Bone marrow derived Mesenchymal Stem Cells|Multiple Sclerosis|Oligodendrocytes|Neuroimmunology|Autoimmune disease,Jordan,Amman,,1,Autologous Mesenchymal Stem Cells,BIOLOGICAL,The number of patients with any relevant side effects observed,Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.,False,
NCT03164031,Feasibility and Acceptability of Orthotic Shorts for People With Multiple Sclerosis,A Clinical Trial Evaluating the Feasibility and Acceptability of Orthotic Shorts for Walking Function in People With Multiple Sclerosis.,COMPLETED,2018-01-10,2019-05-30,2019-05-30,2021-10-04,2017-05-23,INTERVENTIONAL,NA,16.0,ACTUAL,Sheffield Hallam University,OTHER,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,Multiple Sclerosis,,United Kingdom,Sheffield,South Yorkshire,1,Close-fitting orthotic shorts|Looser fitting shorts,DEVICE|DEVICE,Adherence to wear protocol,Cadence|Step length|Proportion of gait cycle in double support|Width of base of support|Variability of step length|Variability of stride time|Variability of stride width|Trunk stability in walking|Walking speed|Cognitive demand of walking|Participant rated perception of effect|Self-perceived walking ability|Balance confidence|Frequency of falls,False,
NCT02495766,Autologous Mesenchymal Stromal Cells for Multiple Sclerosis,Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis,COMPLETED,2015-05-11,2017-11-27,2018-11-15,2020-01-21,2015-07-13,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,Banc de Sang i Teixits,OTHER,Vall d'Hebron Research Institute (VHIR),UNKNOWN,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Multiple sclerosis|Bone marrow mesenchymal stromal cells|Stem cells|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases,Spain,Barcelona,,1,XCEL-MC-ALPHA|Placebo,DRUG|DRUG,Adverse events,Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence,False,
NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab,COMPLETED,2015-12-31,2016-08-18,2016-08-18,2019-01-04,2016-02-09,OBSERVATIONAL,,277.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,RRMS|MRI,Belgium,Brussels,,4,natalizumab,DRUG,Change over time in the number of participants free of new or enlarging FLAIR lesions,Annualized brain volume change rate as assessed by % change in brain parenchymal fraction [BPF]|Annualized brain volume change rate as assessed by percent brain volume change [PBVC]|Annualized brain volume change rate as assessed by white matter [WM] and gray matter [GM] atrophy)|Cumulative number of new ≥6-month confirmed T1-hypointense lesions|Annualized T1-hypointense and FLAIR lesion volume change|Cumulative percent change in T1-hypointense and FLAIR lesion volume|Cumulative number of ≥6-month-confirmed T1-hypointense lesions arising from new on- treatment Gadolinium (Gd+)-enhancing lesions|Number of total participants and 4-year completers with NEDA as measured by clinical measures|Number of total participants and 4-year completers with NEDA as measured by radiological measures|Number of participants with brain volume loss ≤0.2% and ≤0.4%,False,
NCT01954875,Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases,WITHDRAWN,2009-12-02,2016-12-30,2019-07-02,2022-04-26,2013-10-07,OBSERVATIONAL,,0.0,ACTUAL,Wake Forest University Health Sciences,OTHER,,,Neurodegenerative Diseases|Amyotrophic Lateral Sclerosis|Multiple Sclerosis|Parkinson Disease,neurodegenerative diseases|amyotrophic lateral sclerosis|multiple sclerosis|Parkinson's Disease,United States,Charlotte,North Carolina,1,,,Creation of a bank of fecal and blood samples to study the mirobial etiology of neurodegenerative diseases,,False,
NCT03121105,Pathologic-MRI Findings in Atypical IIDD,A Pathologic-MRI Reappraisal of Patients With Atypical Idiopathic Inflammatory Demyelinating Disorders,COMPLETED,2017-01-01,2017-12-01,2017-12-31,2018-05-07,2017-04-19,OBSERVATIONAL,,25.0,ACTUAL,"University Hospital, Montpellier",OTHER,"University Hospital, Strasbourg, France|Rennes University Hospital|University Hospital, Bordeaux|University Hospital, Limoges|Hospices Civils de Lyon|Centre Hospitalier Universitaire de Nīmes|Colmar Hospital|Centre hospitalier de Perpignan",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER,Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System,Idiopathic Inflammatory demyelinating disorders of the central nervous system|Multiple Sclerosis|Neuromyelitis Optica|MRI|pahtological,,,,0,,,pathological,MRI (magnetic resonnance Imaging),False,
NCT05516537,"Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.",Promotion of Exercise Behavior Among Rural-Residing African-Americans With Multiple Sclerosis,RECRUITING,2022-09-02,2025-12,2026-08,2025-09-22,2022-08-25,INTERVENTIONAL,NA,100.0,ESTIMATED,University of Illinois at Chicago,OTHER,University of Alabama at Birmingham|Bristol-Myers Squibb,OTHER|INDUSTRY,Multiple Sclerosis,Rural|Walking dysfunction|Health-Related Quality of Life|African-American,United States,Chicago,Illinois,1,Guidelines for Exercise in Multiple Sclerosis (GEMS)|FLEX Stretching and Toning Program,BEHAVIORAL|BEHAVIORAL,Walking Dysfunction,Disability|Fatigue Severity|Depressive Symptoms|Anxiety|Health-related Quality of Life (HRQOL),False,
NCT00228397,Study Evaluating CCI-779 in Relapsing Multiple Sclerosis,"A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.",COMPLETED,2003-11,2005-11,2005-11,2013-02-13,2005-09-28,INTERVENTIONAL,PHASE2,221.0,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis,,,,0,CCI-779,DRUG,"Long-term safety.|Listing and summary tables of AE and TEAEs, vital signs, laboratory evaluations, and ECG data will be generated.","Preliminary efficacy of long-term treatment.|Lesions observed on MRI scans, clinical measures such as the EDSS scale, the 9-Hole Peg Test, the Paced Auditory Serial Addition Test and the Timed Ambulation 25-Foot Test, occurrence of relapse, will be analyzed at end -point (12 or 16 months).|Only descriptive statistics will be performed.",False,
NCT05641532,Physical Activity in Persons Newly Diagnosed With Multiple Sclerosis,Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis,COMPLETED,2023-01-17,2023-08-08,2023-08-08,2023-08-16,2022-12-07,INTERVENTIONAL,NA,16.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis (MS),Physical activity|Newly diagnosed with MS|Behavior change|Multiple sclerosis,United States,Birmingham,Alabama,1,Physical activity behavioral intervention in persons newly diagnosed with MS,BEHAVIORAL,Feasibility metric: Process|Feasibility metric: Resource|Feasibility metric: Management|Feasibility metric: Overall safety|Change of Physical Activity levels through Accelerometry from baseline and 12 weeks|Change of Physical Activity levels through the Godin Leisure-Time Exercise Questionnaire from baseline and 12 weeks|Change of Physical Activity levels through the Abbreviated International Physical Activity Questionnaire from baseline and 12 weeks,Change of self-report measures of Fatigue through the Fatigue Severity Scale from baseline and 12 weeks|Changes of self-report measures of quality of life through the Multiple Sclerosis Impact Scale-29 at baseline and 12 weeks|Formative evaluation,False,
NCT00358293,Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity,"A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients",COMPLETED,2006-12,,2007-02,2009-01-21,2006-07-31,INTERVENTIONAL,PHASE1|PHASE2,20.0,,Teva GTC,INDUSTRY,,,Muscle Spasticity,Multiple Sclerosis|Spasticity|Sublingual Tizanidine|Ashworth Scores|Spasticity in Multiple Sclerosis Patients,Israel,Tel Aviv,,1,Tizanidine (sublingual or oral),DRUG,"Clinical efficacy - improvement in next-day spasticity (Ashworth scores)|Safety - no increase in next-day somnolence (measured objectively using PVT psychomotor vigilance task monitoring) and subjectively, using Epworth Sleepiness Scale (ESS) and Fatigue Severity Scale (FSS) questionnaires",Secondary clinical efficacy - objective measure of sleep (actigraphy measures),False,
NCT03345199,Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis,Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis,COMPLETED,2017-10-28,2018-12-31,2019-04-01,2019-05-01,2017-11-17,INTERVENTIONAL,NA,38.0,ACTUAL,University of Michigan,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,"Multiple Sclerosis, Inspiratory Muscle Training",United States,Boston,Massachusetts,2,Inspiratory Muscle Trainer (IMT),OTHER,Change in Maximal inspiratory Pressure (MIP)|Change in Maximal Expiratory Pressure (MEP),Change in Fatigue|Change in Activity Participation|Change in Respiratory Infection Incidents,False,
NCT01632293,Evaluating Intervention Responsiveness in People With Multiple Sclerosis,Evaluating Intervention Responsiveness in People With Multiple Sclerosis,COMPLETED,2012-04,2015-09,2015-09,2016-02-23,2012-07-02,INTERVENTIONAL,NA,60.0,ACTUAL,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Baltimore,Maryland,1,progressive resistance training,BEHAVIORAL,Change in maximal voluntary contraction of the hip flexors from baseline to end of training and to post-training,,False,
NCT01271699,Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis,Multiple Sclerosis and Fabry Disease: Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis - an Epidemiological Study,COMPLETED,2011-01,2019-12-01,2019-12-01,2021-04-09,2011-01-07,OBSERVATIONAL,,250.0,ACTUAL,CENTOGENE GmbH Rostock,INDUSTRY,,,Multiple Sclerosis,Fabry Disease|Fabry´s Disease|Anderson-Fabry Disease|Multiple Sclerosis,,,,0,,,Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis,,False,
NCT03243721,Gilenya's Impact on Cognitive Function and Thalamic Volumes,Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis,COMPLETED,2017-10-20,2019-11-12,2019-11-12,2021-09-05,2017-08-09,INTERVENTIONAL,NA,20.0,ACTUAL,The Cleveland Clinic,OTHER,Novartis Pharmaceuticals,INDUSTRY,Multiple Sclerosis,multiple sclerosis|thalamus|high field MRI|cognition,United States,Cleveland,Ohio,1,7T MRI|Neurocognitive testing,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Thalamic volume to cognitive performance,Thalamic volume to other MRI metrics|Thalamic nuclei to cognitive performance|Thalamic myelin density to cognitive performance|Thalamic axon density to cognitive performance|Changes in MRI metrics in Gilenya treated patients vs. controls|Changes in cognitive performance in Gilenya treated patients vs controls|Thalamic volume to cognitive performance,False,
NCT07021716,"COVID-19 Knowledge, Attitudes, Practices and Perceived Risk: Cross Sectional Mixed Methods","COVID-19 Knowledge, Attitudes, Practices and Perceived Risk: Cross Sectional Mixed Methods",COMPLETED,2020-04-01,2020-09-01,2020-12-30,2025-06-15,2025-06-15,OBSERVATIONAL,,148.0,ACTUAL,Hunter College of City University of New York,OTHER,,,COVID - 19|Multiple Sclerosis,COVID|Knowledge|Attitudes|Practices,United States,New York,New York,1,No Interventions,OTHER,Knowledge|Perceived Risk|Attitudes|Practices,,False,
NCT06595212,Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach,Genetics and Environment iNtersection In the Amyotrophic Lateral Sclerosis - FrontoTemporal Dementia Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach,RECRUITING,2024-01-29,2026-01-29,2026-01-30,2025-02-04,2024-09-19,OBSERVATIONAL,,45.0,ESTIMATED,Azienda Ospedaliero-Universitaria di Modena,OTHER,A.O.U. Città della Salute e della Scienza - Molinette Hospital|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo|University of Modena and Reggio Emilia|Azienda Ospedaliero-Universitaria Careggi,OTHER|OTHER|OTHER|OTHER,ALS|FTD,ALS|FTD|twin|cohort,Italy,Modena,Italy,3,multiomic profile to assess genetic and environmental risk factiors,OTHER,Environmental/genetic risk/protective factors involved in driving discordance in monozygotic (MZ) twins,,False,
NCT01783665,The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis,The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis,COMPLETED,2012-08,2015-12,2015-12,2019-08-28,2013-02-05,INTERVENTIONAL,NA,28.0,ACTUAL,"Catherine Siengsukon, PT, PhD",OTHER,,,Multiple Sclerosis,,United States,Kansas City,Kansas,1,aerobic exercise|home exercise program,OTHER|OTHER,Change in Cognitive Function,Change in Sleep Quality,False,
NCT01917019,A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension",COMPLETED,2013-08,2015-10,2017-03,2017-03-21,2013-08-06,INTERVENTIONAL,PHASE3,101.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Remittent Progressive|Multiple Sclerosis, Primary Progressive|Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Multiple Sclerosis",Japan,Japan,Bunkyō City,,19,Placebo|BIIB041 (fampridine),DRUG|DRUG,The proportion of participants who show a consistent improvement in walking speed|Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),False,
NCT00001975,Study of Skin Tumors in Tuberous Sclerosis,Cutaneous Tumorigenesis in Patients With Tuberous Sclerosis,RECRUITING,2000-01-26,,,2025-09-18,2000-01-21,OBSERVATIONAL,,400.0,ESTIMATED,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,Uniformed Services University of the Health Sciences,FED,Tuberous Sclerosis,Skin Biopsy|Familial Tumor Syndrome|Cell Growth|Loss of Heterozygosity|Cytokines|Natural History|Tuberous Sclerosis,United States,Bethesda,Maryland,1,,,1.Identify the tumor cells in cutaneous and mucosal tumors in patients with TSC through LOH studies on microdissected cell populations,,False,
NCT03308994,Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration,Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration,COMPLETED,2017-11-01,2019-12-31,2019-12-31,2020-10-22,2017-10-13,OBSERVATIONAL,,650.0,ACTUAL,"University Hospital, Caen",OTHER,"Genzyme, a Sanofi Company|Ligue contre le cancer, France",INDUSTRY|OTHER,C10.114.375.500,Multiple sclerosis|Epidemiology|Oral disease modifying treatments|Therapeutical delays|Socio-Economic Status,France,Lille,Hauts-de-France,4,Delay between MS onset and introduction of first line DMT|EDI,OTHER|OTHER,Date of MS onset|Date of introduction of first line DMT|Residence location,,False,
NCT04625153,RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial,"RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial",RECRUITING,2021-05-13,2025-10,2025-12,2024-03-18,2020-11-12,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,"RemeGen Co., Ltd.",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,China,Guangzhou,Guangdong,1,RC18 160mg|RC18 240mg,BIOLOGICAL|BIOLOGICAL,48-week annual recurrence rate (ARR),"24 weeks confirmed disability progression|12 weeks confirmed disability progression|12 weeks confirmed disability improvement|Changes in EDSS scores from baseline at weeks 12, 24, 36 and 48|Number of new low-signaling T1 lesions in the brain|Number of new/new large T2 lesions in the brain|Proportion of patients without recurrence at weeks 0 to 48",False,
NCT03595631,Neurodynamic Interventions for Multiple Sclerosis,Effects of Neurodynamic Interventions to Multimodal Physical Therapy in Patients With Multiple Sclerosis,COMPLETED,2018-07-26,2018-09-15,2018-10-04,2018-10-22,2018-07-23,INTERVENTIONAL,NA,32.0,ACTUAL,Universidad Rey Juan Carlos,OTHER,,,Multiple Sclerosis,neurodynamics|pain,Spain,Alcorcón,Madrid,1,Physical Therapy|Physical Therapy plus Neurodynamic,OTHER|OTHER,Changes in pressure pain sensitivity,Changes in upper extremity pain intensity before and after the intervention|Changes in light touch detection threshold|Changes in manual dexterity,False,
NCT05805839,A Study of Imaging in Demyelinating Diseases,Advanced MR and PET Imaging in Inflammatory Demyelinating Diseases of the Central Nervous System,ENROLLING_BY_INVITATION,2023-07-10,2028-05,2028-05,2025-08-29,2023-04-10,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,Mayo Clinic,OTHER,,,Multiple Sclerosis|Inflammatory Demyelinating Disease,,United States,Rochester,Minnesota,1,C-11 ER176 Radiotracer|C11 Pittsburgh Compound B|PET/CT scan|MRI,DRUG|DRUG|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin|Uptake of C-11 ER176 Radiotracer,Number of subjects with adverse events,False,
NCT05374031,Multiple Sclerosis Intimacy and Sexuality Questionnaire,The Multiple Sclerosis Intimacy and Sexuality Questionnaire-15 (MSISQ-15): Validation of the Turkish Version in Patients With Multiple Sclerosis,COMPLETED,2021-08-12,2021-12-10,2022-03-10,2022-05-13,2022-05-13,OBSERVATIONAL,,130.0,ACTUAL,Bozok University,OTHER,,,Multiple Sclerosis|Sexual Dysfunction|Questionnaires,Multiple sclerosis|questionnaires|sexual dysfunction|self-report,Turkey (Türkiye),Yozgat,,1,descriptive study,OTHER,Questionnaire|Questionnaire|Questionnaire|Questionnaire|Questionnaire,,False,
NCT00781872,Mesenchymal Stem Cells for the Treatment of MS,Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS),COMPLETED,2006-10,2009-12,2009-12,2021-03-29,2008-10-29,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,multiple sclerosis (MS)|bone marrow stromal cells|stem cells,,,,0,Injection of autologous bone marrow derived mesenchymal stem cells,BIOLOGICAL,Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis,Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS,False,
NCT00077584,Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma,"A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis",COMPLETED,2003-10,2005-03,2005-05,2025-02-03,2004-02-11,INTERVENTIONAL,PHASE3,188.0,ACTUAL,Actelion,INDUSTRY,,,Digital Ulcers|Systemic Sclerosis,Scleroderma|Finger Ulcers|Digital Ulcers|Systemic Sclerosis,,,,0,Bosentan 62.5 mg|Bosentan 125 mg|Placebo,DRUG|DRUG|DRUG,Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeks|Total number of new digital ulcers per patient up to Week 24,Change from baseline to Week 24 in hand pain|Change from baseline to Week 24 in hand disability|Proportion of subjects with treatment-emergent adverse events|Proportion of subjects with liver function abnormalities,False,
NCT06949449,Upper Limb Function in Mental Health Disorders,Upper Limb Functional Capacity in Individuals Diagnosed With Mental Disorders: A Cross-Sectional Study,COMPLETED,2024-10-01,2025-01-25,2025-03-25,2025-04-29,2025-04-29,OBSERVATIONAL,,38.0,ACTUAL,Universidad de Burgos,OTHER,,,Mental Health|Multiple Sclerosis,mental disorders|upper extremity|hand strength|motor skills|hand,Spain,Burgos,Burgos,1,,,Nine Hole Peg Test (NHPT)|Box and Block Test (BBT)|Digital Hand Dynamometer|Semmes-Weinstein Monofilament Test|Two-Point Discrimination Test (Touch-Test)|QuickDASH Questionnaire,,False,
NCT02543788,CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS,CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?,COMPLETED,2014-09,2016-08,2016-08,2025-09-03,2015-09-07,INTERVENTIONAL,NA,39.0,ACTUAL,Hospices Civils de Lyon,OTHER,Fondation pour la Recherche Médicale,OTHER,Chronic Optic Neuropathy in Multiple Sclerosis,optic neuritis|vision|quality of life|pathophysiology,France,France,BRON,1,"• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG",PROCEDURE,Change from Day0 15' P100 VEP latency at one year,"Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure)|Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure)|change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure)|Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure)|Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure)|MRI presence or absence of optic nerve inflammatory signs on diameter of the optic nerve",False,
NCT02019927,Electric Stimulation of the Eye to Improve Vision After Trauma,Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma,COMPLETED,2013-07,2017-09,2017-09,2020-01-18,2013-12-24,INTERVENTIONAL,NA,97.0,ACTUAL,Wills Eye,OTHER,United States Department of Defense,FED,Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Trauma|Multiple Sclerosis (MS),NAION|Decreased vision|Eye trauma|TES|Electrical stimulation|Multiple Sclerosis|Optic Neuritis,United States,Philadelphia,Pennsylvania,1,Transcorneal Electrical Stimulation|Sham,DEVICE|DEVICE,Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity,"Intra-Ocular Pressure (IOP)|Visual Field Mean Deviation|Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Superior Quadrant|Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Nasal Quadrant|Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Inferior Quadrant|Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Temporal Quadrant|Ocular Coherent Tomography, Retinal Nerve Fiber Layer Thickness in Center Quadrant|National Eye Institute's Visual Functioning Questionnaire - 25|Symbol Digit Modality Testing",True,2020-01-18
NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis",TERMINATED,2015-05,2016-01,2016-01,2017-04-26,2015-04-30,INTERVENTIONAL,PHASE3,58.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Secondary Progressive",INSPIRE|SPMS|Tecfidera|BG00012,United States,Long Beach,California,18,dimethyl fumarate|Placebo,DRUG|OTHER,Time to Disability Progression Independent of Relapse,Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)|Change From Baseline to Week 108 in ABILHAND Questionnaire Score|Percentage Change From Baseline to Week 108 in Whole Brain Volume|Change From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT),True,2017-03-27
NCT02737904,Effect of Active-Passive Trainer Cycling on Multiple Sclerosis,"The Effect of Cycling Using Active-passive Trainers on Spasticity, Cardiovascular Fitness, Function and Quality of Life in People With Multiple Sclerosis",COMPLETED,2016-08-01,2017-07-31,2017-07-31,2017-08-22,2016-04-14,INTERVENTIONAL,NA,24.0,ACTUAL,NHS Greater Glasgow and Clyde,OTHER,University of Glasgow,OTHER,Multiple Sclerosis,Muscle spasticity,United Kingdom,Glasgow,,1,APT|Usual care,OTHER|OTHER,Effect of spasticity on daily life scored on Multiple Sclerosis Spasticity Scale (MSSS-88),Spasticity scored on Modified Ashworth Scale (MAS)|Cardiovascular fitness calculated using Oxygen Uptake Efficiency Slope (OUES)|Function - FIM|Function - T25FW|Quality of Life (MSQOL)-54 scale|APT cycling performance - symmetry|APT cycling performance - distance|APT cycling performance - power,False,
NCT03122652,"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome","Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study",COMPLETED,2017-09-25,2019-02-05,2022-10-04,2023-03-17,2017-04-21,INTERVENTIONAL,PHASE3,125.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,Radiologically Isolated Syndrome,France,Bordeaux,,23,Teriflunomide 14 MG Oral Tablet [Aubagio]|Placebo Oral Tablet,DRUG|DRUG,Time to the first acute or progressive neurological event resulting from CNS demyelination.,New or enlarging T2 lesions|New or enlarging T2 lesions|New contrast enhancing lesions|New contrast enhancing lesions|New T2-lesion volumes|New T2-lesion volumes|Brain atrophy,False,
NCT03797378,"Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study","The M2M LEADERS Project: Lakeshore Examination of Activity, Disability, and Exercise Response Study (LEADERS)",ACTIVE_NOT_RECRUITING,2019-08-09,2023-05-25,2025-09-29,2025-08-17,2019-01-09,INTERVENTIONAL,NA,108.0,ESTIMATED,University of Alabama at Birmingham,OTHER,Lakeshore Foundation|YMCA of Greater Birmingham,OTHER|UNKNOWN,Spinal Cord Injuries|Traumatic Brain Injury|Spina Bifida|Cerebral Palsy|Stroke|Parkinson Disease|Multiple Sclerosis,,United States,Birmingham,Alabama,1,eM2M,OTHER,Change from baseline cardiorespiratory fitness at 3 months|Change from baseline muscle strength at 3 months,Change from baseline lower extremity function at 3 months|Change from baseline lower extremity function at 3 months|Change from baseline health-related quality of life at 3 months|Change from baseline social participation at 3 months|Change from baseline physical activity at 3 months,False,
NCT02815878,Enhance Wellness for Individuals With Long-Term Physical Disabilities,Project Enhance for Adults Aging With Long-Term Physical Disability,COMPLETED,2014-05-12,2017-11,2017-11,2018-04-03,2016-06-28,INTERVENTIONAL,NA,240.0,ACTUAL,University of Washington,OTHER,,,Multiple Sclerosis|Muscular Dystrophy|Post-polio Syndrome|Spinal Cord Injury,,United States,Seattle,Washington,1,Enhance Wellness,BEHAVIORAL,Questionnaire: Level of reported self-efficacy as measured by the University of Washington Self-Efficacy Scale Questionnaire|Questionnaire: Patient Reported Outcome Measurement Information System (PROMIS) Pain Interference Short Form|Questionnaire: Patient Reported Outcome Measurement Information System (PROMIS) Depression Short Form,,False,
NCT07012135,Deciphering Preserved Autonomic Function After Multiple Sclerosis,Deciphering Preserved Autonomic Function After Multiple Sclerosis,RECRUITING,2025-07-31,2026-01-31,2026-01-31,2025-07-11,2025-06-10,INTERVENTIONAL,NA,13.0,ESTIMATED,Mayo Clinic,OTHER,,,Multiple Sclerosis|Control Subjects|Autonomic Dysreflexia,,United States,Rochester,Minnesota,1,Tests of sympathetic inhibition|Tests of sympathetic activation|Testing of autonomic dysreflexia,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Valsalva Maneuver Phase II,Beat-to-beat heart rate|Beat-to-beat blood pressure|Quantify autonomic dysreflexia and orthostatic hypotension|Quantify secondary autonomic complications|Serum Catecholamines|Serum Cortisol|T-Cell Exhaustion Markers,False,
NCT00525668,Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),COMPLETED,2007-09,2012-11,2012-11,2021-07-29,2007-09-06,INTERVENTIONAL,PHASE1|PHASE2,120.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,,,Relapsing-remitting Multiple Sclerosis,multiple sclerosis|inflammation|neurodegeneration|neuroprotection,Germany,Berlin,,2,epigallocatechin-gallate (Sunphenon)|placebo,DRUG|DRUG,number of new T2 lesions on brain MRI performed after 18 months of Sunphenon treatment compared to baseline MRI in the verum arm versus placebo,development of brain atrophy under treatment with EGCG vs. placebo|Safety and tolerability,False,
NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients,COMPLETED,2010-07,2011-07,2011-07,2015-05-15,2010-09-23,OBSERVATIONAL,,307.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,"Interferon beta 1a|Autoimmune Diseases|Demyelinating Diseases|Immune System Diseases|Immunologic Factors|Nervous System Diseases|Physiological Effects of Drugs|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Retrospective Cohort Study",United States,Birmingham,Alabama,18,Rebif®,DRUG,"Number of Participants With Pre-specified Medical Events|Number of Participants With Serious Medical Events, and Non-serious Medical Events (Reported by the Investigator as Related to Rebif®)|Number of Participants With Abnormal Laboratory Parameters",Annualized Medically Confirmed Clinical Relapses Rate Prior to Rebif® Initiation and During Rebif® Treatment|Time to First Medically Confirmed Clinical Relapse Post-Rebif® Initiation,True,2013-05-30
NCT02885233,Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis,Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis,COMPLETED,2017-02-15,2018-01-25,2018-01-25,2018-04-09,2016-08-31,INTERVENTIONAL,NA,30.0,ACTUAL,Oregon Health and Science University,OTHER,University of Alabama at Birmingham,OTHER,Multiple Sclerosis,Fall Prevention|Multiple Sclerosis|Web-based education|Self-efficacy,United States,Portland,Oregon,1,Free From Falls Online|Waitlist Control,BEHAVIORAL|BEHAVIORAL,Difference in mean change in total falls between intervention and control arms,"Difference in patient reported outcomes including physical function, fatigue, self efficacy, psychosocial illness impact, social participation and satisfaction, and perception of global health between intervention and control arms.|Quantitative assessment of the web-based program|Qualitative assessment of the web-based program",False,
NCT06094855,Effect of Cooling on Balance Performance in Multiple Sclerosis,Effect of Cooling on Balance Performance in Persons With Multiple Sclerosis,RECRUITING,2023-11-02,2025-12-31,2026-12-31,2023-11-15,2023-10-23,OBSERVATIONAL,,30.0,ESTIMATED,Hunter College of City University of New York,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest,OTHER,Mini Balance Systems Evaluation Test,Visual Analog Scale of Fatigue,False,
NCT06956326,Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation,Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation,RECRUITING,2025-05-01,2027-12-31,2027-12-31,2025-05-04,2025-05-04,INTERVENTIONAL,PHASE2,64.0,ESTIMATED,Lars Hvid,OTHER,,,Multiple Sclerosis,Neurorehabilitation,Denmark,Haslev,,2,Intensive rehab|Usual care,BEHAVIORAL|BEHAVIORAL,Expanded Disability Status Scale (EDSS)|MS Functional Composite (MSFC) Score,MS Functional Composite (MSFC) Score|Handgrip strength|Six spot step test (SSST)|Five times sit to stand chair rise test (5STS)|Five times sit to stand chair rise test muscle power (5STS_power)|Patient determined disease steps (PDDS)|MS Walking Scale (MSWS)|Falls Efficacy Scale International (short FES-I)|Functional Assessment of MS (FAMS)|Modified Fatigue Impact Scale (MFIS)|Manual Ability Measurement (MAM36)|Treatment Satisfactory Questionnaire (TSQ)|Multiple Sclerosis Cognitive Scale (MSCS),False,
NCT06986278,tdCS Combined With Treadmill Training in Patients With Multiple Sclerosis,Transcranial Direct Current Stimulation Combined With Treadmill Training With Partial Body Weight Support in Patients With Multiple Sclerosis,RECRUITING,2025-05-26,2025-08-31,2025-12-31,2025-05-29,2025-05-22,INTERVENTIONAL,NA,78.0,ESTIMATED,University of Castilla-La Mancha,OTHER,"Asociación Esclerosis Múltiple de Toledo, España",UNKNOWN,tDCS|Sham tDCS,tdcs|gait|multiple sclerosis|gait training,Spain,Toledo,Toledo,2,tDCS|shamtDCS,DEVICE|DEVICE,TUG|Timed 25-Foot Walk,MSWS-12|FSS,False,
NCT04201691,"Effect of Manuel Therapy on Tonus, Proprioseption and Balance in Multiple Sclerosis","The Effect of Cervical Mobilization on Tonus, Position Sense and Balance in Multiple Sclerosis Patients",COMPLETED,2020-01-07,2020-11-02,2020-12-30,2021-08-10,2019-12-17,INTERVENTIONAL,NA,16.0,ACTUAL,Tuba Maden,OTHER,,,Postural Balance|Multiple Sclerosis|Cervical Region Disorder Nos|Muscle Tonus|Proprioception,,Turkey (Türkiye),Gaziantep,,1,classic rehabilitation|classic rehabilitation+mobilization,OTHER|OTHER,Change Modified ashworth scale|Change Berg Balance Test|Change Dynamic Gait Index|MyotonPRO|Change The timed 25-foot walk|Change Functional Reach Test|Change Sharpened Romberg|Change Single Leg Stance Test- Right|Change Single Leg Stance Test- Left|Change Joint of position sense,,False,
NCT04027491,Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,Innovative Low-cost Solutions Based on Virtual Reality for Upper Limb Home-based Rehabilitation in Multiple Sclerosis,UNKNOWN,2019-04-23,2021-06-03,2022-06-03,2019-07-22,2019-07-22,INTERVENTIONAL,NA,24.0,ESTIMATED,University of Cagliari,OTHER,Italian Multiple Sclerosis Foundation|Fondazione Don Carlo Gnocchi Onlus|Azienda Sanitaria Locale di Cagliari,OTHER|OTHER|OTHER,Multiple Sclerosis,Rehabilitation|Upper limbs|Virtual Reality,Italy,Monserrato,Cagliari,1,Virtual Reality,BEHAVIORAL,Change in box and block score,Change in Nine-Hole Peg score,False,
NCT00103974,Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,COMPLETED,2004-07,,2007-03,2008-04-07,2005-02-18,INTERVENTIONAL,PHASE1,30.0,,Bayhill Therapeutics,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|relapsing-remitting|secondary progressive,United States,Phoenix,Arizona,4,BHT-3009-01,BIOLOGICAL,Evaluate safety of BHT-3009 alone and when combined with atorvastatin in patients with multiple sclerosis.|Determine dose of BHT-3009 and regimen for phase II testing.,Describe effect of treatment on antibody and T cell responses to myelin basic protein (MBP).|Describe clinical course of treated patients.|Explore biomarkers of MS activity,False,
NCT02200718,"A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis","A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis",UNKNOWN,2020-12-31,2024-11-09,2024-11-09,2020-03-31,2014-07-25,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,"Immune Response BioPharma, Inc.",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis Pediatric MS NeuroVax Vaccine Therapeutic,United States,San Diego,California,1,NeuroVax|IFA Incomplete Freund's Adjuvant,BIOLOGICAL|BIOLOGICAL,The primary clinical endpoints are comparisons of MRI & WBC measurements between the treatment groups,A Secondary clinical endpoint is the measurement of FOXP3+ expression|A Secondary clinical endpoint is the measurment of EDSS scores|A Secondary clinical endpoint is the measurement of clinical relapses,False,
NCT01776060,Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study,Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study,COMPLETED,2013-01,2020-09-21,2020-09-21,2024-05-21,2013-01-25,OBSERVATIONAL,,28.0,ACTUAL,Duke University,OTHER,,,Primary Progressive Multiple Sclerosis,Primary Progressive Multiple Sclerosis|Multiple Sclerosis|biomarker|'omic|progression,United States,Concord,North Carolina,3,generation of 'omic markers of disease progression,OTHER,Generation of 'omic markers of disease progression,,False,
NCT02523703,Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study,,COMPLETED,2007-09-10,2012-02-15,2015-02-23,2020-09-02,2015-08-14,INTERVENTIONAL,NA,36.0,ACTUAL,"University Hospital, Caen",OTHER,,,Multiple Sclerosis,,,,,0,glutamate and aspartate,BIOLOGICAL,glutamate concentration (in nM),,False,
NCT06712342,Effects of Upper Extremity-Focused Neuromuscular Training in People With Multiple Sclerosis,Effects of Upper Extremity-Focused Neuromuscular Exercise Training on Physical and Cognitive Functions in People With Multiple Sclerosis (NExTUp),NOT_YET_RECRUITING,2024-11-30,2025-11-01,2025-12-29,2024-12-04,2024-12-02,INTERVENTIONAL,NA,72.0,ESTIMATED,Istanbul Aydın University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|exercise|function|upper extremity|neuromuscular exercise training|manual dexterity,,,,0,Neuromuscular Exercise Training|Conventional Exercise Training,OTHER|OTHER,Nine Hole Peg Test|Minnesota Manual Dexterity Test|Manual Ability Measure-36|Timed 25-Foot Walk|Symbol Digit Modalities Test|Hand Dynamometer,Hand Held Dynamometer|Biodex Balance System|Laser-pointer Assisted Angle Reproduction Test|Finger Tapping Test|Fatigue Severity Scale|Plank|Curl-up,False,
NCT03541226,"Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)","Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome",UNKNOWN,2014-09,2021-09,2021-09,2020-09-11,2018-05-30,OBSERVATIONAL,,134.0,ESTIMATED,"University Hospital, Lille",OTHER,,,Clinically Isolated Syndrome|Multiple Sclerosis,,France,Lille,,1,,,severity of the disease defined by Expanded Disability Status Scale (EDSS) ≥ 2.0,Occurrence of a second push|Occurrence of progression of the EDSS (Expanded Disability Status Scale) score|Occurrence of a handicap objectified by the Multiple Sclerosis Functional Composite(MSFC)|variation of parameters measuring axonal pain / degeneration in MRI|variation of parameters measuring axonal pain / degeneration in OCT,False,
NCT00605215,BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),"A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design",COMPLETED,2008-04-24,2011-06-10,2011-06-10,2022-04-21,2008-01-30,INTERVENTIONAL,PHASE3,1331.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,170,Laquinimod|Placebo|Avonex®,DRUG|DRUG|DRUG,Annualized Rate of Confirmed Relapses,Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score|Percent Change From Baseline in Brain Volume|Accumulation of Physical Disability Measured by the Number of Participants With Confirmed Progression of EDSS,True,2022-04-21
NCT01364246,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica,Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica,UNKNOWN,2010-01,2013-03,2014-12,2012-11-28,2011-06-02,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,"Shenzhen Beike Bio-Technology Co., Ltd.",INDUSTRY,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Nanjing Medical University|Nanjing University Medical College Affiliated Wuxi Second Hospital|Xuzhou Medical University|The Second Hospital of Nanjing Medical University,OTHER|OTHER|UNKNOWN|OTHER|OTHER,Progressive Multiple Sclerosis|Neuromyelitis Optica.,Progressive Multiple Sclerosis|neuromyelitis optica|Umbilical Cord Mesenchymal Stem Cell,China,Nanjing,Jiangsu,1,human umbilical cord mesenchymal stem cells,BIOLOGICAL,Score of Expanded Disability Status Scale (EDSS),Visual Evoked Potential (VEP)|Brainstem Auditory Evoked Potential (BAEP)|Somatosensory Evoked Potential(SEP)|Brain Magnetic Resonance Imaging （MRI） Scan,False,
NCT05232825,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",COMPLETED,2022-05-03,2023-03-10,2025-06-06,2025-08-06,2022-02-10,INTERVENTIONAL,PHASE3,236.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis|Primary Progressive Multiple Sclerosis,,United States,Maitland,Florida,37,Ocrelizumab IV|Ocrelizumab SC|Methylprednisolone IV|Diphenhydramine IV|Dexamethasone given orally|Desloratadine given orally,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Serum ocrelizumab area under the concentration-time curve (AUCW1-12),Maximum serum concentration (Cmax) of ocrelizumab SC in patients with MS|Total number of T1Gd+ lesions as detected by brain MRI|Total number of new or enlarging T2 lesions as detected by brain MRI|Percentage of participants with Adverse Events|Incidence of treatment-emergent antidrug antibodies to ocrelizumab after SC or IV administration|Incidence of treatment-emergent antibodies to rHuPH20|Proportion of participants achieving CD19+ B cell level ≤5 cells/uL,False,
NCT06384976,"KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis","KYSA-7: A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-09-20,2027-04,2029-01,2025-01-13,2024-04-25,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,Kyverna Therapeutics,INDUSTRY,,,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis|MS",KYV-101|multiple sclerosis|autoimmune disease|anti-CD19 CAR-T therapy|cellular therapy|MS,United States,Palo Alto,California,1,KYV-101|Standard lymphodepletion regimen|Anti-CD20 mAB,BIOLOGICAL|DRUG|DRUG,To evaluate efficacy of KYV-101,To characterize the safety and tolerability of KYV-101|To characterize the safety and tolerability of KYV-101|To characterize the safety and tolerability of KYV-101|To evaluate efficacy of KYV-101|To characterize the pharmacokinetics (PK)|To characterize the pharmacokinetics (PK)|To characterize the Pharmacodynamics (PD)|To characterize the Pharmacodynamics (PD)|To evaluate the immunogenicity (humoral response) of KYV-101,False,
NCT01225289,Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients,The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis,COMPLETED,2009-10,2013-12,2014-01,2014-03-14,2010-10-21,INTERVENTIONAL,PHASE4,36.0,ACTUAL,Tehran University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Vitamin A|CD4-Positive T-Lymphocytes|Th1 Cells|Th2 Cells,Iran,Tehran,Tehran Province,2,Vitamin A|Placebo,DIETARY_SUPPLEMENT|DRUG,"Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation","Difference of IL-4 Levels in Supernatant of Peripheral Blood Mononucleated Cells (PBMCs) Stimulated With Phytohemagglutinin (PHA), Before and After of Supplementation|Difference of Retinol Binding Protein (RBP) / Transthyretin (TTR) Ratio, (Difference of RBP/ TTR Ratio), Before and After of Supplementation|Peripheral Blood Mononucleated Cells (PBMCs) Proliferation Assay (BrdU Colorimetric)",True,2014-03-14
NCT06428201,The Efficacy of Tele Rehabilitation- Based Task-Specific Training for Cognitive Function Improvement,The Efficacy of Tele Rehabilitation- Based Task-Specific Training for Cognitive Function Improvement in Multiple Sclerosis (MS) Patients,ACTIVE_NOT_RECRUITING,2023-09-01,2024-04-01,2024-09-01,2024-05-24,2024-05-24,INTERVENTIONAL,NA,52.0,ACTUAL,Superior University,OTHER,,,"Sclerosis, Multiple",,Pakistan,Lahore,Punjab Province,1,Control Group|Experimental Group,DIAGNOSTIC_TEST|COMBINATION_PRODUCT,Montreal Cognitive Assessment (MoCA) scale,,False,
NCT04016844,tDCS and Glucose Uptake in Leg Muscles,Transcranial Direct Current Stimulation to Reduce Asymmetric Glucose Uptake in Leg Muscles of Persons With Multiple Sclerosis,COMPLETED,2019-12-06,2020-10-01,2020-10-01,2023-01-25,2019-07-12,INTERVENTIONAL,NA,4.0,ACTUAL,University of Iowa,OTHER,,,Multiple Sclerosis,Multiple Scerosis|PET|tDCS,United States,Iowa City,Iowa,1,transcranial direct current stimulation or SHAM,DEVICE,Glucose Uptake in Leg Muscles,Ratings of Perceived Exertion (RPE),True,2023-01-25
NCT04892134,"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis","Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis - MarkMS",RECRUITING,2019-10-03,2024-10-31,2025-10-31,2023-10-19,2021-05-19,OBSERVATIONAL,,500.0,ESTIMATED,Medical University of Graz,OTHER,,,Multiple Sclerosis,biomarker|progression|MRI|cognition,Austria,Graz,Styria,1,blood sample,OTHER,Prediction of EDSS ( Expanded Disability Status Scale) progression by combined markers of the disease,"Prediction of clinical relapses|Conversion from CIS (Clinically Isolated Syndrome) to MS (Multiple Sclerosis) defined by MRI and clinical criteria|Time of transition to progressive form of MS|Neuropsychological progression (decrease in SDMT performance)|Increase in morphological damage (lesion load, atrophy)",False,
NCT00754832,American Ginseng Treatment for Multiple Sclerosis Related Fatigue,"A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue",COMPLETED,2005-09,2008-09,2011-03,2012-01-24,2008-09-18,INTERVENTIONAL,PHASE2,56.0,ACTUAL,Oregon Health and Science University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Multiple sclerosis|fatigue|ginseng,United States,Portland,Oregon,1,American ginseng extract HT-1001|placebo,DRUG|DRUG,Fatigue Severity Scale,Modified Fatigue Impact Scale|Realtime Digital Fatigue Score,True,2012-01-24
NCT01943526,Ireland Natalizumab (TYSABRI) Observational Program,Ireland Natalizumab (TYSABRI®) Observational Program (iTOP),COMPLETED,2011-11-30,2017-12-31,2017-12-31,2018-05-04,2013-09-17,OBSERVATIONAL,,191.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Ireland|Natalizumab,Ireland,Cork,County Cork,5,natalizumab,BIOLOGICAL,Number of participants experiencing Serious Adverse Events (SAEs),Disability progression as determined by Expanded Disability Status Scale (EDSS)|MS disease activity as determined by annualized relapse rate (ARR)|MS disease activity as determined by distribution of the total number of relapses during the study|MS disease activity as determined by time to first relapse|MS disease activity as determined by number of participants with relapse|MS disability progression and MS disease activity summarized for subpopulations according to baseline characteristics|MS disease activity as determined by MRI parameters|Evaluation of short-term disease outcomes as assessed by EDSS progression|Evaluation of short-term disease outcomes as assessed by occurrence of relapses,False,
NCT07175792,Accuracy of Motor Performance Perception in Multiple Sclerosis,Assessment of Perceptive Accuracy for Motor Performance in Persons With Multiple Sclerosis,RECRUITING,2024-12-09,2025-10-16,2025-12-09,2025-09-16,2025-09-16,OBSERVATIONAL,,88.0,ESTIMATED,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,OTHER|OTHER,Multiple Sclerosis,Motor Performance|Task-specific|Perception|Multiple Sclerosis|Walking|Sit-to-stand|Inteoception,Belgium,Diepenbeek,,3,,,Perceptive Sensitivity|Detection Accuracy|Correspondence Accuracy,Confidence Rating|Perceptive Awareness|Interoceptive Sensibility|Proprioceptive Sensibility|Interoceptive Sensitivity and Attention Questionnaire (ISAQ)|6 minutes walking test,False,
NCT05064436,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis","A Phase 1, Open-label, Multi-part Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution, and CNS Signal of the Positron Emission Tomography Ligand 11C-BMS-986196 in Healthy Participants After Intravenous Administration and to Evaluate the Safety, Tolerability, Kinetics, and CNS Signal Repeatability of 11C-BMS-986196 After Repeat Intravenous Administration in Participants With Multiple Sclerosis",TERMINATED,2021-12-10,2023-12-18,2023-12-18,2025-04-24,2021-10-01,INTERVENTIONAL,PHASE1,10.0,ACTUAL,Bristol-Myers Squibb,INDUSTRY,,,Multiple Sclerosis (MS),Multiple Sclerosis (MS)|Healthy Participants|11C-BMS-986196|PET tracer,United States,Ann Arbor,Michigan,2,11C-BMS-986196,DRUG,Number of Participants With Adverse Events Based on Severity.|Number of Participants With Clinically Significant Changes in Electrocardiograms.|Number of Participants With Clinically Significant Changes in Vital Signs.|Number of Participants With Clinically Significant Changes in Laboratory Values.|Number of Participants With Clinically Significant Changes in Phsyical Examinations.|Number of Participants With Clinically Significant Changes in C-SSRS.|Radiation Dosimetry Calculated From PET-CT Images in Healthy Participants|Image Acquisition Window After Tracer Administration|Percentage of Participants With Test Repeatablity Based on SUV.|Percentage of Participants With Test Repeatablity Based on VT.|Percentage of Free Brain BTK Relative to Baseline|Mean Standardized Uptake Value (SUV) in the Brain|Mean Volume of Distribution (VT) in the Brain,,True,2025-04-24
NCT02876536,Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients,Effect of Transcutaneous Electrical Nerve Stimulation on Cognitive Disorders in Multiple Sclerosis Patients,UNKNOWN,2016-06,2016-08,2016-09,2016-08-23,2016-08-23,INTERVENTIONAL,NA,20.0,ESTIMATED,Isfahan University of Medical Sciences,OTHER,,,Multiple Sclerosis|Cognitive Disorders,,Iran,Isfahan,,1,TENS,DEVICE,change in the level of cognition measured by Addenbrooke's cognitive examination,,False,
NCT04317716,A Self-management Program to Prevent Falls in People With Multiple Sclerosis,A Self-management Program to Prevent Falls in Ambulatory and Non-ambulatory Community Dwelling People With Multiple Sclerosis,COMPLETED,2022-02-11,2022-08-17,2022-08-17,2025-02-28,2020-03-23,INTERVENTIONAL,NA,45.0,ACTUAL,Karolinska Institutet,OTHER,Forte|The Swedish Research Council,INDUSTRY|OTHER_GOV,Multiple Sclerosis,Feasibility Studies|Accidental Falls|Self-management|Complex Intervention|Group-based|Online Intervention|Short Message Service,Sweden,Stockholm,,2,fall prevention program|Brochure about falls and fall risk factors,BEHAVIORAL|OTHER,Fall Prevention Strategy Survey|Fall Prevention Strategy Survey,Falls incidence|Measure of fear of falling|Falls Efficacy Scale -International|Spinal Cord Injury Fall Concern Scale|Multiple Sclerosis Impact Scale|Frenchay Activities Index,False,
NCT02496416,Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis,Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis: A Randomized Clinical Trial,UNKNOWN,2016-08,2022-12,2022-12,2022-12-05,2015-07-14,INTERVENTIONAL,NA,30.0,ESTIMATED,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,Aquatic Exercise Program|Stretching Program,BEHAVIORAL|BEHAVIORAL,Cognition measured by results of standardized neuropsychological tests,Fatigue measured by self-report questionnaires|Quality of Life measured by self report questionnaires,False,
NCT05188937,Validity and Reliability of the Dual-task Questionnaire,Validity and Reliability of the Dual-task Questionnaire in Multiple Sclerosis Patients,COMPLETED,2021-02-01,2021-10-01,2022-05-05,2022-05-27,2022-01-12,INTERVENTIONAL,NA,50.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Dual-Task|Validity|Reliability,Turkey (Türkiye),Ankara,,1,validity and reliability study,PROCEDURE,Validity and reliability of Dual-Task Questionnaire in patients with MS,,False,
NCT06871072,Telerehabilitation for Multiple Sclerosis,Telerehabilitation for Multiple Sclerosis: Artificial Intelligence vs. Conventional Approaches in Strength Training. A Sin-gle-Blinded Randomized Clinical Trial,COMPLETED,2025-04-01,2025-08-15,2025-08-31,2025-09-19,2025-03-11,INTERVENTIONAL,NA,58.0,ACTUAL,University of Cadiz,OTHER,,,Multiple Sclerosis,artificial intelligence|exercise|multiple sclerosis|physical therapy|strength|telerehabilitation,Spain,Seville,,1,Telerehabilitation|Exercise program,OTHER|OTHER,Maximal Strength,Maximal Strength.|Maximal Strength.|Strength endurance.|Endurance capacity.|Strength endurance.|Strength endurance.|Endurance capacity.|Endurance capacity.,False,
NCT07087106,Glucose Consumption in MS Using [F-18]FDG-PET,Novel Assessment of Glucose Consumption in Multiple Sclerosis Utilizing [F-18]FDG-PET,NOT_YET_RECRUITING,2025-07,2025-12-31,2026-05-31,2025-07-25,2025-07-25,INTERVENTIONAL,PHASE4,50.0,ESTIMATED,Brigham and Women's Hospital,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|MS|FDG|Positron Emission Tomography|PET,United States,Boston,Massachusetts,1,[F-18]FDG,DRUG,Standardized Uptake Value (SUV),SUV Ratio (SUVR)|Brain Parenchymal Volume (BPV)|MRI lesion volume|Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk (T25FW)|Modified Fatigue Impact Scale (MFIS)|Brief Repeatable Battery of Neuropsychological Tests in MS (BRB),False,
NCT00367484,Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis,"Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis",COMPLETED,2004-05,2006-01,2006-01,2014-02-27,2006-08-23,INTERVENTIONAL,PHASE4,460.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,Rebif® (clone 484-39),BIOLOGICAL,Number of Participants Testing Positive for Neutralising Antibody (NAb),,True,2010-08-27
NCT06039007,A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis,A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple Sclerosis (FAST-MS),ACTIVE_NOT_RECRUITING,2019-12-16,2023-07-31,2024-03-30,2023-10-04,2023-09-15,INTERVENTIONAL,EARLY_PHASE1,24.0,ACTUAL,Ospedale Policlinico San Martino,OTHER,,,Multiple Sclerosis,fasting mimicking diet|multiple sclerosis,Italy,Genova,,1,7-day Fasting-Mimicking Diet (7-DAY FMD),DIETARY_SUPPLEMENT,Safety and tolerability of 7-day FMD,Percentage of patients able to achieve the designated diet regimen|Changes in the Expanded Disability Status Scale (EDSS)|Changes in Body Mass Index (BMI)|Changes in the serum light chain neurofilaments concentration|White Blood Cells|Efficacy of the FMD in terms of nutritional state,False,
NCT03784898,Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada,Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment,COMPLETED,2019-02-08,2019-12-11,2019-12-11,2022-03-28,2018-12-24,INTERVENTIONAL,PHASE4,13.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Multiple Sclerosis,,United States,Los Angeles,California,1,Blood draw for future biomarker analysis,OTHER,Number of Participants Who Provided Whole Blood Samples for DNA Extraction and Analysis,,True,2020-07-20
NCT03825055,Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis,Behaviour and Well-Being: A Bio-Psycho-Social Model of Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis,COMPLETED,2019-02-26,2022-03-31,2022-03-31,2022-11-15,2019-01-31,OBSERVATIONAL,,51.0,ACTUAL,Universita di Verona,OTHER,Azienda Ospedaliera Universitaria Integrata Verona|Fondazione Italiana Sclerosi Multipla|Federico II University,OTHER|OTHER|OTHER,Multiple Sclerosis,disease-specific variables|biopsychosocial characteristics|resilience|adjustment|quality of life|well-being|young adults,Italy,Verona,Veneto,1,,,Level of resilience,Level of quality of life,False,
NCT00151801,Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients,Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis,UNKNOWN,2002-05,,2008-12,2005-09-09,2005-09-09,INTERVENTIONAL,PHASE2,200.0,,S. Andrea Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|estroprogestins|interferon-beta|sex hormones|MRI,Italy,Rome,Rome,1,estroprogestins|interferon-beta 1a,DRUG|DRUG,"Safety assessment at 6, 12, 18 and 24 months, including adverse events, physical examination and laboratory parameters|Relapse rate at 6, 12, 18 and 24 months,|EDSS progression at 12 and 24 months,|MS functional composite score at 12 and 24 months,","Number and volume of new gad-enhancing lesions at 12 and 24 months|Number of new T1 and T2 lesions at 12 and 24 months|Brain volume changes at 12 and 24 months|Neuropsychological examination at 0, 12, 24 months|Hamilton scale for depression score at 0, 12, 24 months|MS Quality of Life scale score(MSQOL54)at 0, 12, 24 months|Fatigue Severity Scale score at 0, 12, 24 months",False,
NCT04322149,Multiple Doses of AT-1501-A201 in Adults With ALS,"A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS",COMPLETED,2020-10-16,2022-03-24,2022-03-24,2023-06-28,2020-03-26,INTERVENTIONAL,PHASE2,54.0,ACTUAL,"Anelixis Therapeutics, LLC",INDUSTRY,,,Amyotrophic Lateral Sclerosis,ALS|Lou Gehrig's Disease|motor neuron disease|motor neuron degeneration|AT-1501|humanized blocking antibody to CD40LG|CD40L inhibitor|monoclonal antibody,United States,Phoenix,Arizona,13,AT-1501,DRUG,Safety and Tolerability|Safety and Tolerability,,True,2023-06-28
NCT04498039,Reducing Symptoms of Multiple Sclerosis Using Non-invasive Neuromodulation,Reducing Symptoms of Multiple Sclerosis Using Non-invasive Neuromodulation,COMPLETED,2009-11,2011-05,2011-05,2020-08-07,2020-08-04,INTERVENTIONAL,NA,20.0,ACTUAL,"University of Wisconsin, Madison",OTHER,,,Multiple Sclerosis,,,,,0,Portable Neuromodulation Stimulator,DEVICE,Dynamic Gait Index DGI,,False,
NCT05347875,Implementation of an App-based Walking Aid Skills Training Program,Exploring the Influence of a Novel Application for Training and Evaluating Walking Implementation of an App-based Walking Aid Skills Training Program Aid Skills in Walking Aid Users: A Protocol for a Pragmatic Single-blind Randomized Controlled Trial,ACTIVE_NOT_RECRUITING,2024-06-01,2026-05-01,2026-06-01,2025-08-14,2022-04-26,INTERVENTIONAL,NA,52.0,ESTIMATED,University of Calgary,OTHER,Alberta Health services|Laval University|CIRISS,OTHER|OTHER|UNKNOWN,Lower Limb; Sprain (Strain)|Lower Limb Fracture|Stroke|Multiple Sclerosis,Gait aid|Walking aid|Cane|Crutch|Walker,Canada,Calgary,Alberta,2,Walking aid skills app|Breathing skills app,OTHER|OTHER,Activities-specific Balance Confidence (ABC),2-minute walk test|Berg Balance Scale|Timed Up and Go|Walking Aid Skills Measurement Test,False,
NCT04344626,Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery,Use of a Tonometer to Identify Focal Cortical Dysplasia and Tuberous Sclerosis Complex During Pediatric Epilepsy Surgery,WITHDRAWN,2018-07-16,2023-03,2023-03,2023-10-10,2020-04-14,INTERVENTIONAL,NA,0.0,ACTUAL,"University of California, Los Angeles",OTHER,Université de Montréal,OTHER,"Epilepsy|Focal Cortical Dysplasia|Tuberous Sclerosis|Hemimegalencephaly|Polymicrogyria|Rasmussen Encephalitis|Sturge-Weber Syndrome|Gliosis|Stroke|Tumor, Brain",Pediatric|Epilepsy|Tonometer|Focal cortical dysplasia|Tuberous sclerosis|Polymicrogyria|Rasmussen encephalitis|Sturge-Weber syndrome|Gliosis|Stroke|Developmental brain tumor,United States,Los Angeles,California,2,Intra-operative brain tonometry,DEVICE,"Brain tissue stiffness measurements in mmHg as assessed by intraoperative use of a digital tonometer on presumed normal cerebral cortex|Brain tissue stiffness measurements in mmHg as assessed by intraoperative use of a digital tonometer on presumed pathological cerebral cortex|Correlation between brain tissue stiffness measurements in mmHg as assessed by novel intraoperative use of a digital tonometer and results of standard perioperative evaluations, using a 3D model of each brain","Surgical complications as assessed clinically on standard postoperative follow-up through study completion, up to 36 months|Seizure freedom as assessed clinically on standard postoperative follow-up through study completion, up to 36 months",False,
NCT01080053,"Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)",Observational Study to Determine the Relationship Between the Degree of Disability and the Presence of Sexual Dysfunction and Between Sexual Dysfunction and the Quality of Life in Patients With Multiple Sclerosis (RRMS),COMPLETED,2008-11,2013-05,2013-05,2013-10-16,2010-03-03,OBSERVATIONAL,,306.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Merck Quimica Argentina S.A.I.C,INDUSTRY,"Multiple Sclerosis, Relapsing Remitting","Multiple Sclerosis, Relapsing Remitting|Sexual dysfunction",Argentina,Buenos Aires,,1,,,"The correlation between the degree of disability and sexual dysfunction, and between the sexual dysfunction and the QoL of subjects",,False,
NCT05171972,Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment,Assessing Reduced Oligodendrocyte-specific Cytotoxicity of Peripheral Blood Leukocytes in Patients With Multiple Sclerosis Following Treatment With Ofatumumab,ACTIVE_NOT_RECRUITING,2022-01-29,2025-06-30,2025-06-30,2025-04-11,2021-12-29,OBSERVATIONAL,,40.0,ESTIMATED,University of Southern California,OTHER,Novartis Pharmaceuticals,INDUSTRY,Relapsing Remitting Multiple Sclerosis,Kesimpta|Ofatumumab,United States,Los Angeles,California,1,Ofatumumab,DRUG,"Assessment of oligodendrocyte death and mitochondrial dysfunction comparing supernatant samples from patients after 6 months treatment (M06) to pre-treatment, drug naïve supernatants (M00) and to supernatants collected from healthy control subjects",Identify factor(s) associated with oligodendrocyte and OPC stress/death,False,
NCT05435404,Qualitative Study Patient & Physician Experiences Botox COVID-19,"A Qualitative Research Study Into Patient, Carer and Physician Experiences of Spasticity Management Via Botulinum Toxin Treatment During and Post COVID-19 Pandemic. Perceptions, Opportunities and Barriers",COMPLETED,2021-10-08,2022-04-30,2022-04-30,2022-06-28,2022-06-28,OBSERVATIONAL,,11.0,ACTUAL,East Kent Hospitals University NHS Foundation Trust,OTHER_GOV,,,Chronic Brain Injury|Cerebral Stroke|MS (Multiple Sclerosis),spasticity|botulinum toxin|qualitative research|rehabilitation,United Kingdom,Canterbury,Kent,1,,,Interview with participant,,False,
NCT04565431,Examining Effects of Tysabri on Cognitive Fatigue Using fMRI,Biomarker for Cognitive Fatigue Using Functional Imaging in Multiple Sclerosis,RECRUITING,2021-03-19,2024-12,2024-12,2024-02-15,2020-09-25,OBSERVATIONAL,,25.0,ESTIMATED,Kessler Foundation,OTHER,St. Barnabas Medical Center,OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Cognitive Fatigue,United States,West Orange,New Jersey,1,Tysabri,DRUG,Brain activation (BOLD signal),Fatigue onset (SDMT)|Fatigue onset,False,
NCT01555684,Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients,"The Effect of Percutaneous Venoplasty on Muscular Function, Mobility and Fatigue of Multiple Sclerosis (MS) Patients With Chronic Cerebrospinal Venous Insufficiency (CCSVI).",WITHDRAWN,2012-04,2012-11,2012-12,2015-12-02,2012-03-15,INTERVENTIONAL,NA,0.0,ACTUAL,University of Stirling,OTHER,,,Multiple Sclerosis|Chronic Cerebrospinal Venous Insufficiency,MS|CCSVI,United Kingdom,Stirling,,1,percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency,PROCEDURE,Neuromuscular function,Free living activity,False,
NCT04619953,Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis,Neuropsychological Changes After Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis,COMPLETED,2020-11-09,2022-05-01,2022-10-01,2023-07-13,2020-11-06,INTERVENTIONAL,NA,42.0,ACTUAL,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Multiple Sclerosis|Cognitive Impairment|Motor Disorders,,Italy,Roma,,1,Dynamic Postural Stability Training|Cognitive-Motor Training|Conventional Therapy,OTHER|OTHER|OTHER,Balance Evaluation System Test (Mini-BESTest),Modified Barthel Index (MBI)|Tinetti Balance and Gait Scale (TBG)|10 Meter Walk Test (10MWT)|Inertial sensors-based assessment|2 Minute Walking Test (2MWT)|2 Minute Walking Test (2MWT) associated with Cognitive Task,False,
NCT02421744,A Task-oriented Circuit Training in Multiple Sclerosis,A Task-oriented Circuit Training in Multiple Sclerosis: a Multicentric Randomized Controlled Trial,COMPLETED,2015-03,2018-10,2018-10,2018-11-29,2015-04-21,INTERVENTIONAL,NA,35.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,rehabilitation|Multiple Sclerosis|mobility|gait|task-oriented training,Italy,Ferrara,,2,Task Oriented Circuit Training|Delayed Onset TOCT,BEHAVIORAL|BEHAVIORAL,Six-Minute Walking Test,"Timed 25-Foot walk (25FWT)|Time Up and Go Test|Dynamic Gait Index (DGI)|Modified fatigue impact scale (MFIS)|Multiple Sclerosis Walking Scale - 12 (MSWS-12)|Multiple Sclerosis Impact Scale- 29 (MSIS-29)|Functional Assessment of Multiple Sclerosis (FAMS)|Metabolic cerebral measurements by Near infrared spectroscopy|Postural sway (Center of pressure (COP) trajectories)|Force and EMG signal (perform an isometric extension of the knees on an isokinetic dynamometer (PrimusRS BTETM Technology), achieving their own Maximum Voluntary Contraction (MVC)|Mechanical and electrical fatigue assessment (evaluated measuring sustained contractions in isometric tasks in lower limbs on an isokinetic dynamometer (PrimusRS BTETM Technology)|Brain plasticity and connectivity (High density EEG and vertical electrooculogram (EOG) will be recorded with a standard bipolar 64-channels montage and a DC-coupled amplifier (Micromed SD MRI, System Plus acquisition software)|Metabolic muscular measurements by Near infrared spectroscopy",False,
NCT01547234,Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis,Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis,COMPLETED,2013-02,2014-12,2014-12,2016-06-28,2012-03-07,OBSERVATIONAL,,47.0,ACTUAL,Carmel Medical Center,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|ambulation|manual function|Fampridine,Israel,Haifa,,1,,,Score of hand function tests,Improvement in daily function|Correlation between improvement in manual function and ambulation,False,
NCT03671499,A Study for Testing Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior,"A Pilot Study for Testing the Feasibility and Efficacy of Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior (Sit Less, Move More)",COMPLETED,2018-03-27,2019-06-05,2019-10-25,2019-11-29,2018-09-14,INTERVENTIONAL,NA,30.0,ACTUAL,University of Alabama at Birmingham,OTHER,Consortium of Multiple Sclerosis Centers,OTHER,Multiple Sclerosis,sedentary behavior|physical activity,United States,Birmingham,Alabama,1,Social Cognitive Theory based text messages,BEHAVIORAL,Change in sedentary behavior evaluated with activity monitors|Change in sedentary behavior evaluated with activity monitors|Change in sedentary behavior evaluated with activity monitors|Change in physical activity evaluated with activity monitors|Change in physical activity evaluated with activity monitors|Change in physical activity evaluated with activity monitors,Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).|Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).|Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).,False,
NCT00202384,Gene Expression in MS Patients Before and During Treatment With Interferon-beta,Gene Expression in MS Patients Before and During Treatment With High-dose Interferon Beta: Prospective Study for the Identification of Predicting Factors of Therapeutic Response.,TERMINATED,2004-11,2011-01,2011-01,2018-04-19,2005-09-20,OBSERVATIONAL,,600.0,ACTUAL,S. Andrea Hospital,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|microarrays,Italy,Rome,,1,,,Gene Expression in MS Patients,,False,
NCT02977533,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,"A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis",COMPLETED,2016-12-01,2018-05-16,2018-05-16,2022-04-25,2016-11-30,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Sanofi,INDUSTRY,,,Progressive Multiple Sclerosis,,Germany,Berlin,,1,GZ402668|Placebo|Acyclovir,DRUG|DRUG|DRUG,Number of participants with treatment emergent adverse events,Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: area under curve (AUC)|Number of participants with lymphocyte depletion|Number of participants with anti-drug antibodies|Number of participants with injection site reactions,False,
NCT05301907,Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials,Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent,COMPLETED,2021-12-02,2025-05-16,2025-05-16,2025-07-09,2022-03-31,OBSERVATIONAL,,335.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|NIS|survey,Switzerland,Basel,,1,,,Percentage of HCPs and patients/caregivers who report receive and reading of the educational materials.|Knowledge and understanding of the HCPs as per detailed in the educational information provided|Knowledge and understanding of the patient/caregivers' as per detailed in the educational information provided,,False,
NCT02234869,Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy,"Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)",WITHDRAWN,2014-10,2017-02,2018-03,2014-11-17,2014-09-09,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,Peginterferon Beta-1a|Relapsing Multiple Sclerosis|RMS|flu-like symptoms,,,,0,Interferon Beta|BIIB017 (Peginterferon beta-1a),DRUG|DRUG,"Combined Counts of adverse events (AEs) of flu-like symptoms, injection site reactions or injection site reaction pain","Change from Baseline in treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication-9 Items (TSQM-9)|Change from Baseline in adapted Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ) total score|Change from Baseline in the adapted MSTCQ Side Effects Score|Percentage of participants pain-free|Change from Baseline in mean change in VAS pain score from pre-injection to 30 minutes post-injection|Change from Baseline in mean McGill Pain Questionnaire Short Form (SF-MPQ) VAS pain score|Change from Baseline in the Multiple Sclerosis Impact Scale-29 items (MSIS-29) score|Change from Baseline in the Modified Fatigue Impact Scale-5 Item (MFIS-5) score|Change from Baseline in the EuroQol-5-dimension 3-level version (EQ-5D-3L) index|Change from Baseline in the Health-Related Productivity Questionnaire (HRPQ) score|Change from Baseline in the Beck Depression Inventory, second edition (BDI-II) score|Percentage of participants with changes in Clinical Status assessed using the Expanded Disability Status Scale (EDSS)|Annualized relapse rate (ARR)|Percentage of participants with relapse|Adherence to study treatment measured by returned autoinjectors/syringes|Adherence to study treatment measured by the treatment adherence questionnaire|Number of participants with adverse events (AEs), serious adverse events (SAEs), and discontinuations of study treatment due to an AE|Number of participants with IFN β-1a and IFN β-1b binding and neutralizing antibodies, and poly(ethylene glycol) (PEG)-binding antibodies",False,
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy",COMPLETED,2007-10,2011-09,2011-09,2017-04-17,2007-10-24,INTERVENTIONAL,PHASE3,840.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,Bayer,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis,United States,Cullman,Alabama,191,Alemtuzumab 12 mg|Alemtuzumab 24 mg|Interferon beta-1a,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate,Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,True,2015-01-08
NCT05323370,"Lymphangioleiomyomatosis, a Study on Cathepsin K","Study of New Potential Biomarkers of Lymphangioleiomyomatosis: Determination of Cathepsin K, Cystatin C, Collagen Telopeptides and Chondroitin Sulfates",COMPLETED,2022-05-31,2022-10-30,2022-10-30,2023-03-29,2022-04-12,OBSERVATIONAL,,19.0,ACTUAL,"University Hospital, Tours",OTHER,,,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,urine,France,Tours,,1,24h urine|urine sample,OTHER|OTHER,urine cathepsin K proteins levels|urine cathepsin K activity,urinary quantity of cystatin C|urinary quantity C and N-telopeptides of type 1 collagen|serum level of chondroitin sulphates|renal angiolipomas|FEV1 measurement|VEGF-D measurement|T-score measurement,False,
NCT03262870,Gut Microbiota and Multiple Sclerosis,Gut Microbiota and Multiple Sclerosis,UNKNOWN,2018-01-04,2019-01-04,2020-01-04,2017-08-29,2017-08-25,OBSERVATIONAL,,40.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,,,Understanding the role of gut microbiota in the modification of the disease course of MS .,,False,
NCT05142111,Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life,Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life,RECRUITING,2021-04-01,2025-03-31,2025-03-31,2023-10-04,2021-12-02,INTERVENTIONAL,NA,60.0,ESTIMATED,"IRCCS San Camillo, Venezia, Italy",OTHER,,,Multiple Sclerosis|Spinal Cord Injuries,sexuality,Italy,Venice,,1,Therapy,BEHAVIORAL,Changes in quality of actual and perceived sexual health for females|Changes in quality of actual and perceived sexual health for males|Changes in erectile function|Changes in intimacy and sexuality,Changes in brain spectral power after viewing neutral and erotic videos|Changes in Mutual Information between brain regions after viewing neutral and erotic videos|Psychological Well-Being|Anxiety|Changes in the assessment of the emotional response after viewing neutral and erotic videos,False,
NCT06581341,Enhancing Pelvic Floor Function With Transcranial Magnetic and Tibial Nerve Stimulation for Neurogenic Bladder in MS,Improvement of Pelvic Floor Function Using Repetitive Transcranial Magnetic Stimulation and Posterior Tibial Nerve Stimulation in Treating Neurogenic Overactive Bladder in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-01,2025-01-27,2025-09-22,2024-09-03,2024-09-03,INTERVENTIONAL,NA,60.0,ESTIMATED,Sierra Varona SL,OTHER,Universidad Complutense de Madrid,OTHER,Neurogenic Overactive Bladder|Multiple Sclerosis,Múltiple Sclerosis|Neurogenic Overactive Bladder|Posterior Tibial Nerve Meuromodulation|Repetitive Transcranial Magnetic Stimulation.,,,,0,Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation|Repetitive Transcranial Magnetic Stimulation|Percutaneous Tibial Nerve Stimulation,DEVICE|DEVICE|DEVICE,Reduction in Frequency of Urinary Urgency Episodes,Frequency of Urination|Urinary Incontinence|Expanded Disability Status Scale (EDSS)|The Multiple Sclerosis Quality of Life-54 (MSQoL-54) Questionnaire|The semi-open question to assess the impact of overactive bladder on daily life.,False,
NCT03362294,Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS,"A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)",ACTIVE_NOT_RECRUITING,2017-12-11,2026-08,2026-09,2024-12-05,2017-12-05,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,Mapi Pharma Ltd.,INDUSTRY,,,Primary Progressive Multiple Sclerosis,,Israel,Haifa,,7,GA Depot 40mg once monthly|GA Depot 25mg once monthly,DRUG|DRUG,Safety (Adverse Events and Injection Site Reactions),Efficacy (Confirmed Disease Progression)|Efficacy (Whole brain volume change)|Efficacy (Cortical volume change),False,
NCT05715268,Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study,Moving MS Bladder Dysfunction Into the 21st Century: Developing Novel and Accessible Ways to Treat Dysfunction in the Home - a Three Month Single Arm Open Label Feasibility Pilot With Waitlist Control,ACTIVE_NOT_RECRUITING,2023-03-15,2025-09-10,2025-09-25,2025-03-10,2023-02-06,INTERVENTIONAL,NA,20.0,ESTIMATED,"University of California, San Francisco",OTHER,National Multiple Sclerosis Society,OTHER,"Multiple Sclerosis|Urinary Bladder, Overactive",multiple sclerosis|remote|wearables|overactive bladder|pelvic floor physical therapy,United States,San Francisco,California,1,WeB|Standard pelvic floor physical therapy,DEVICE|OTHER,Net Promoter Score|Health Information Technology Usability Evaluation Scale (Health-ITUES) - Ease of use|Health Information Technology Usability Evaluation Scale (Health-ITUES) - Perceived usefulness|System usability scale|Adherence as measured by percent usage,Change in Overactive bladder symptom scale; OABSS|Change in Overactive bladder symptom scale; OABSS|Change in the number of daily leakage episodes|Change in the number of daily leakage episodes|Change in the frequency of daily voiding episodes|Change in the frequency of daily voiding episodes|Change in the 29 item- multiple sclerosis quality of life survey (MSQOL-29)|Change in the SymptoMScreen survey|Satisfaction with using WeB devices,False,
NCT04878211,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,TERMINATED,2021-06-10,2023-04-14,2023-04-14,2025-05-16,2021-05-07,INTERVENTIONAL,PHASE4,24.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),Multiple Sclerosis|Relapsing Multiple Sclerosis|COVID|COVID-19|Vaccine|Coronavirus|adult|OMB157,United States,Phoenix,Arizona,7,Ofatumumab|mRNA COVID-19 vaccine|interferon or glatiramer acetate,DRUG|BIOLOGICAL|DRUG,"Percentage of Participants With Response by SARS-CoV-2 Qualitative IgG Antibody Assay at 14 Days Post-vaccination by Cohort Group and Overall, Non-response Imputation Approach (Safety Analysis Set)","Percentage of Patients With an Immune Response by SARS-CoV-2 Qualitative IgG Antibody Assay by Time Point, Cohort Group and Overall, Non-response Imputation Approach (Safety Analysis Set)|Percentage of Participants Achieving Immune Conversion by Individual Cohort Group and Overall, Non-response Imputation Approach (Safety Analysis Set)",True,2024-06-20
NCT05182411,Validity and Reliability of Turkish Version Leg Activity Measure,Validity and Reliability of Turkish Version Leg Activity Measure,COMPLETED,2022-06-30,2022-07-30,2022-08-05,2022-08-30,2022-01-10,OBSERVATIONAL,,50.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Spinal Cord Injuries|Multiple Sclerosis|Stroke,activity|participation|spasticity|passive function|active function,Turkey (Türkiye),Kahramanmaraş,,1,assessment,OTHER,Turkish version of Leg Activity Measure|Turkish version of Leg Activity Measure,The Rivermead Mobility Index|Nottingham Health Profile (NHP)|The Functional Independence Measure (FIM),False,
NCT06042244,Multimodal Exercise Training to Reduce Frailty in People With Multiple Sclerosis,Multimodal Exercise Training to Reduce Frailty in People With Multiple Sclerosis,COMPLETED,2023-11-20,2025-02-23,2025-02-23,2025-06-15,2023-09-18,INTERVENTIONAL,NA,16.0,ACTUAL,University of Kansas Medical Center,OTHER,,,Multiple Sclerosis|Frailty,,United States,Kansas City,Kansas,1,Multimodal Exercise Group|Waitlist,OTHER|OTHER,Primary Outcome,,False,
NCT04355611,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Cohort Study Evaluating the Epidemiological Characteristics of Coronavirus Infection (SARS-CoV-2) in Patients With MS or NMO,COMPLETED,2020-04-17,2022-06-30,2022-06-30,2024-02-05,2020-04-21,OBSERVATIONAL,,2465.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis|NMO Spectrum Disorder|COVID-19,Factors,France,Paris,,1,Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2),OTHER,Clinical severity,EDSS (Expanded Disability Status Scale),False,
NCT06709768,Pilot of the Virtual Memory Attention and Problem Solving Skills Intervention for Persons With Multiple Sclerosis (MS),Virtual Memory Attention and Problem Solving Skills for Persons With MS (MAPSS-MS) Pilot,NOT_YET_RECRUITING,2024-12,2025-05,2025-11,2024-11-29,2024-11-29,INTERVENTIONAL,NA,34.0,ESTIMATED,University of Texas at Austin,OTHER,,,Multiple Sclerosis (MS),cognitive rehabilitation,,,,0,"Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)",BEHAVIORAL,Neurocognitive Function -Objective|Perceived Cognitive Function PROMIS v2.0 - Cognitive Function-Abilities Short Form 8a,Self-Efficacy for Cognitive Tasks|Depressive Symptoms - CES-D 10|Compensatory Strategies|Perceived Stress|Pain Symptoms|Fatigue|Sleep,False,
NCT06110468,"Physical Function, Health and Employment for People With Multiple Sclerosis","Tailored Follow-up for Persons With Multiple Sclerosis to Optimize Physical Functions, Health and Employment: a Prospective Single-blinded Randomized Controlled Trial",ACTIVE_NOT_RECRUITING,2024-03-04,2024-12,2035-12,2024-11-21,2023-10-31,INTERVENTIONAL,NA,114.0,ESTIMATED,Nordlandssykehuset HF,OTHER,The Royal Norwegian Ministry of Health|University Hospital of North Norway|Nord University|UiT The Arctic University of Norway|Helgeland Hospital Trust|University of Tasmania|Norwegian Labour and Welfare Administration,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,Physiotherapy|Employment|Physical activity|Health related quality of life|Cost-benefit,Norway,Bodø,Nordland,1,CoreDISTParticipation,OTHER,Multiple Sclerosis Work Difficulties Questionnaire -23 Norwegian version|Levels of physical activity measured using ActiGraph wGT3x-BT monitors,6 meter walk test|Step count using ActiGraph wGT3x-BT monitors|Fatigue Severity Scale -Norwegian version|Multiple Sclerosis Walking Scale-12|Mini Balance Evaluation Systems Test (MiniBESTest)|Trunk Impairment Scale-modified Norwegian version (TISmodNV)|Postural control measured by AccuGait Optimized force platforms|European Quality of Life 5-Dimension (EQ-5D-5L) + Complementary questions|Multiple Sclerosis Impact Scale 29-Norwegian version|Patient Global Impression of Change - physical activity and balance,False,
NCT04314076,Rhythmic Auditory Stimulation & Gait Training,A Pilot Single-blind Randomized Controlled Trial to Evaluate the Safety and Feasibility of Rhythmic Auditory Stimulation for Gait Training in Persons With Multiple Sclerosis,COMPLETED,2020-06-08,2022-11-07,2022-11-07,2023-02-09,2020-03-18,INTERVENTIONAL,NA,24.0,ACTUAL,The Cleveland Clinic,OTHER,"Consortium of Multiple Sclerosis Centers|MedRhythms, Inc.",OTHER|INDUSTRY,"Multiple Sclerosis|Gait Disorders, Neurologic",Gait analysis|Music therapy|Multiple sclerosis,United States,Cleveland,Ohio,1,Rhythmic auditory stimulation|Gait Training,OTHER|OTHER,Number of patients with adverse events|Percentage of training sessions missed.,Timed 25 Foot Walk|6-Minute Walk|Spatiotemporal gait parameters|MS Walking Scale - 12,False,
NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,COMPLETED,2015-06,2020-07,2020-11,2021-10-26,2015-04-17,INTERVENTIONAL,PHASE4,15.0,ACTUAL,University Hospital Muenster,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,Germany,Münster,,1,Alemtuzumab,DRUG,Absolute change from baseline in naïve CD4 positive T cell counts in peripheral blood|Relative change from baseline in naïve CD4 positive T cell counts in peripheral blood|Relative change from baseline in naïve CD8 positive T cell counts in peripheral blood|Absolute change from baseline in naïve CD8 positive T cell counts in peripheral blood|Absolute change from baseline in CD4 positive T effector cell counts in peripheral blood|Relative change from baseline in CD4 positive T effector cell counts in peripheral blood|Absolute change from baseline in CD8 positive T effector cell counts in peripheral blood|Absolute change from baseline in CD4 positive T memory cell counts in peripheral blood|Relative change from baseline in CD4 positive T memory cell counts in peripheral blood|Absolute change from baseline in CD8 positive T memory cell counts peripheral blood|Relative change from baseline in CD8 positive T memory cell counts in peripheral blood|Absolute change from baseline in CD4 positive regulatory T cell counts in peripheral blood|Relative change from baseline in CD4 positive regulatory T cell counts in peripheral blood|Absolute change from baseline in CD8 positive regulatory T cell counts in peripheral blood|Relative change from baseline in CD8 positive regulatory T cell counts in peripheral blood|Absolute change from baseline in Th1 T-helper cell counts in peripheral blood|Relative change from baseline in Th1 T-helper cell counts in peripheral blood|Absolute change from baseline in Th2 T-helper cell counts in peripheral blood|Relative change from baseline in Th2 T-helper cell counts in peripheral blood|Absolute change from baseline in Th17 T-helper cell counts in peripheral blood|Relative change from baseline in Th17 T-helper cell counts in peripheral blood|Absolute change from baseline in recent bone marrow emigrant B cell counts peripheral blood|Relative change from baseline in recent bone marrow emigrant B cell counts in peripheral blood|Absolute change from baseline in mature naïve B cell counts in peripheral blood|Relative change from baseline in mature naïve B cell counts in peripheral blood|Absolute change from baseline in memory B cell counts in peripheral blood|Relative change from baseline in memory B cell counts in peripheral blood|Absolute change from baseline in plasma cell counts in peripheral blood|Relative change from baseline in plasma cell counts in peripheral blood|Absolute change from baseline in CD56bright natural killer cell counts in peripheral blood|Relative change from baseline in CD56bright natural killer cell counts in peripheral blood|Absolute change from baseline in CD56dim natural killer cell counts in peripheral blood|Relative change from baseline in CD56dim natural killer cell counts in peripheral blood|Absolute change from baseline in natural killer T cell counts in peripheral blood|Relative change from baseline in natural killer T cell counts in peripheral blood|Absolute change from baseline in CD303+ plasmacytoid dendritic cell counts in peripheral blood|Relative change from baseline in CD303+ plasmacytoid dendritic cell counts in peripheral blood|Absolute change from baseline in CD11c+ myeloid dendritic cell counts in peripheral blood|Relative change from baseline in CD11c+ myeloid dendritic cell counts in peripheral blood|Absolute change from baseline in CD141+ myeloid dendritic cell counts in peripheral blood|Relative change from baseline in CD141+ myeloid dendritic cell counts in peripheral blood|Absolute change from baseline in monocyte counts in peripheral blood|Relative change from baseline in monocyte counts in peripheral blood|Absolute change from baseline in macrophage counts in peripheral blood|Relative change from baseline in macrophage counts in peripheral blood|Absolute change from baseline in myeloid-derived suppressor cell counts in peripheral blood|Relative change from baseline in myeloid-derived suppressor cell counts in peripheral blood,"Absolute change from baseline in naïve CD4 positive T cell counts in cerebrospinal fluid|Relative change from baseline in naïve CD4 positive T cell counts in cerebrospinal fluid|Absolute change from baseline in naïve CD8 positive T cell counts in cerebrospinal fluid|Relative change from baseline in naïve CD8 positive T cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive T effector cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive T effector cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive T effector cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive T effector cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive T memory cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive T memory cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive T memory cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive T memory cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive regulatory T cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive regulatory T cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive regulatory T cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive regulatory T cell counts in cerebrospinal fluid|Absolute change from baseline in Th1 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th1 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in Th2 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th2 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in Th17 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th17 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in recent bone marrow emigrant B cell counts in cerebrospinal fluid|Relative change from baseline in recent bone marrow emigrant B cell counts in cerebrospinal fluid|Absolute change from baseline in mature naïve B cell counts in cerebrospinal fluid|Relative change from baseline in mature naïve B cell counts in cerebrospinal fluid|Absolute change from baseline in memory B cell counts in cerebrospinal fluid|Relative change from baseline in memory B cell counts in cerebrospinal fluid|Absolute change from baseline in plasma cell counts in cerebrospinal fluid|Relative change from baseline in plasma cell counts in cerebrospinal fluid|Absolute change from baseline in CD56bright natural killer cell counts in cerebrospinal fluid|Relative change from baseline in CD56bright natural killer cell counts in cerebrospinal fluid|Absolute change from baseline in CD56dim natural killer cell counts in cerebrospinal fluid|Relative change from baseline in CD56dim natural killer cell counts in cerebrospinal fluid|Absolute change from baseline in natural killer T cell counts in cerebrospinal fluid|Relative change from baseline in natural killer T cell counts in cerebrospinal fluid|Absolute change from baseline in CD303+ plasmacytoid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD303+ plasmacytoid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in CD11c+ myeloid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD11c+ myeloid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in CD141+ myeloid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD141+ myeloid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in monocyte counts in cerebrospinal fluid|Relative change from baseline in monocyte counts in cerebrospinal fluid|Absolute change from baseline in macrophage counts in cerebrospinal fluid|Relative change from baseline in macrophage counts in cerebrospinal fluid|Absolute change from baseline in myeloid-derived suppressor cell counts in cerebrospinal fluid|Relative change from baseline in myeloid-derived suppressor cell counts in cerebrospinal fluid|Activation status of cell surface receptors on T cells fom peripheral blood as assessed by flow cytometry|Activation status of cell surface receptors on T cells from cerebrospinal fluid as assessed by flow cytometry|Expression of co-inhibitory molecules by T cells from peripheral blood as assessed by flow cytometry|Expression of co-inhibitory molecules by T cells from cerebrospinal fluid as assessed by flow cytometry|Effector functions of CD4 and CD8 positive T cells from peripheral blood|Effector functions of CD4 and CD8 positive T cells from cerebrospinal fluid|Migrational capacity of T cells from peripheral blood|Migrational capacity of T cells from cerebrospinal fluid|Spectratyping of the T cell repertoire of T cells from peripheral blood concerning the expansion of distinct clones|Spectratyping of the T cell repertoire of T cells from cerebrospinal fluid concerning the expansion of distinct clones|Regulatory T-cell function in peripheral blood|Regulatory T-cell function in cerebrospinal fluid|Relative and absolute change from baseline in the concentration of markers in the cerebrospinal fluid|Relative and absolute change from baseline in neuronal activity, action potential generation and cellular integrity by obtained human CSF supernatant samples using multi-electrode arrays|Relative and absolute change from baseline in the concentration of neurotrophic factors in the peripheral blood|Relative and absolute change from baseline in the concentration of neurotrophic factors in cerebrospinal fluid|Percent change from Baseline in the following MRI findings which are defined as markers for neurodegeneration: MRI-T1-measured cerebral volume, MRI-T1-measured number of black holes|Relative and absolute change from baseline in retinal nerve fiber layer thickness (assessment by optical coherence tomography)|Data on Adverse Events",False,
NCT06387043,Effects of Balance Exercises Performed With Different Visual Stimuli,Comparison of the Effects of Balance Exercises Performed With Different Visual Stimuli in Individuals With Multiple Sclerosis,NOT_YET_RECRUITING,2024-12-01,2025-03-01,2026-12-01,2024-04-26,2024-04-26,INTERVENTIONAL,NA,40.0,ESTIMATED,Halic University,OTHER,Fenerbahce University|Biruni University|Istanbul University - Cerrahpasa,OTHER|OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|visual stimulus|balance|virtual reality|stroboscopic glasses|metaphoric imaginary,Turkey (Türkiye),Istanbul,Eyüpsultan,1,Balance exercises with Virtual Reality Glasses|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Visual-Based Metaphor Training|Traditional Balance Exercises,OTHER|OTHER|OTHER|OTHER,Functional Near Infrared Ray Spectroscopy (fNIRS)|Timed Up and Go Test|Functional Reach Test|Berg Balance Scale|Timed 25 Step Walking Test,Lower Extremity Motor Coordination Test|Fatigue Severity Scale|Quality of Life in Multiple Sclerosis Patients,False,
NCT06663189,Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis),"Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over: A Multicentric, Randomized, Controlled, Open-label Clinical Trial (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",NOT_YET_RECRUITING,2025-01,2027-01,2029-06,2025-01-03,2024-10-29,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,"Ministry of Health, France",OTHER_GOV,Relapsing-remitting Multiple Sclerosis (RRMS),,France,Bordeaux,,22,treatment withdrawal|Usual DMT continuation|MRI|Quality of Life questionnaires|Disability evaluation tests,DRUG|DRUG|OTHER|BEHAVIORAL|OTHER,Time to first clinical and/or radiological disease activity during a period of 2 years.,,False,
NCT06306768,Remote Therapeutic Monitoring Exercise Tracking,Remote Therapeutic Monitoring for Longitudinal Exercise and Self-Efficacy Tracking in Persons With Parkinson's Disease and Multiple Sclerosis.,RECRUITING,2024-04-01,2028-03,2028-03,2025-05-15,2024-03-12,INTERVENTIONAL,NA,200.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,,,Parkinson Disease|Multiple Sclerosis,physical activity|exercise tracking|remote therapeutic monitoring|quality of life|self-efficacy,United States,Chicago,Illinois,1,Activity Monitoring,DEVICE,Physical Activity Metric 1|Physical Activity Metric 2,Exercise Self Efficacy|Quality of Life from PROMIS 10-b|Quality of Life from PROMIS-29,False,
NCT04032171,Study of Evobrutinib in Participants With RMS,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With RMS to Evaluate Efficacy and Safety",TERMINATED,2019-09-10,2020-05-20,2020-05-20,2021-08-05,2019-07-25,INTERVENTIONAL,PHASE3,1.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Relapsing-remitting Multiple Sclerosis,Evobrutinib|Avonex®|Interferon-beta 1a|Relapsing Multiple Sclerosis,United States,Rockland,Massachusetts,2,Evobrutinib|Avonex®|Avonex® matched Placebo|Evobrutinib matched Placebo,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),"Time to First Occurrence of 12-Week Confirmed Expanded Disability Status Scale (EDSS) Progression|Time to First Occurrence of 24-Week Confirmed Expanded Disability Status Scale (EDSS) Progression|Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Short Form Score at Week 96|Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form Score at Week 96|Total Number of Gadolinium-Enhancing (Gd+) Time Constant 1 (T1) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96|Total Number of New or Enlarging Time Constant 2 (T2) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)|Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Vital Signs: Pulse Rate|Vital Signs: Respiratory Rate|Vital Signs: Temperature|Vital Signs: Weight|Number of Participants With Abnormal Lab Values|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Absolute Concentrations of Immunoglobulin (Ig) A Level|Absolute Concentrations of Immunoglobulin (Ig) G Level|Absolute Concentrations of Immunoglobulin (Ig) M Level|Absolute Concentrations of Immunoglobulin (Ig) E Level|Change From Baseline in Immunoglobulin (Ig) A Level|Change From Baseline in Immunoglobulin (Ig) E Level|Change From Baseline in Immunoglobulin (Ig) G Level|Change From Baseline in Immunoglobulin (Ig) M Level",True,2021-08-05
NCT01578330,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720","A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine",COMPLETED,2012-10,2015-04,2015-04,2016-06-07,2012-04-16,INTERVENTIONAL,PHASE4,42.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Relapsing-Remitting,Relapsing remitting multiple sclerosis|Fingolimod|FTY720,Turkey (Türkiye),Ankara,Turkey,11,Fingolimod,DRUG,Mean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9),Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).|Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).|Mean Patient-reported Health-related Quality-of-life With Fingolimod (Short Form Health Survey: SF-36).,True,2016-06-07
NCT04595799,Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.,MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2020-11-09,2025-11-09,2025-11-09,2024-05-17,2020-10-22,OBSERVATIONAL,,240.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,,France,Lille,,10,,,speed test in MMST results|agility test in MMST results|synchronization test in MMST results|visual test in MMST results|Cognitive test in MMST results,,False,
NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.",COMPLETED,2012-12-20,2016-04-29,2023-03-31,2024-06-05,2012-08-15,INTERVENTIONAL,PHASE3,1651.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis,United States,Phoenix,Arizona,290,BAF312|Placebo,DRUG|DRUG,Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS),Percentage of Participants With 3-month Confirmed Worsening in T25W of at Least 20% From Baseline|Change From Baseline in T2 Lesion Volume|Percentage of Participants With 6-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)|Annualized Relapse Rate (ARR) for Confirmed Relapses|Percentage of Participants With First Relapse Events as Measured by Time to First Confirmed Relapse|Percentage of Patients With Relapse (Confirmed Relapse and Any Relapse)|Change From Baseline in MSWS-12 Converted Score|Number of T1 Gd-enhancing Lesions Per Patient Per Scan|Number of New or Enlarging T2 Lesions Per Patient Per Year|Percent Brain Volume Change (PBVC) Relative to Baseline|Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of SPMS Patients With/Without Superimposed Relapses|Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of Rapidly and Not Rapidly Evolving Patients|Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of Patients With and Without Moderate/Severe Disease Course,True,2018-10-31
NCT02142764,Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients,Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).,COMPLETED,2014-11,2016-02,2016-02,2016-12-07,2014-05-20,INTERVENTIONAL,NA,30.0,ESTIMATED,"University Hospital, Bordeaux",OTHER,Merck Serono International SA|ADERA,INDUSTRY|UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|CD8+ T-cells|Class I Major Histocompatibility Complex (MHC)|pentamers,France,Bordeaux,Bordeaux,1,Blood samples|Blood samples,BIOLOGICAL|BIOLOGICAL,"Analysis of pentamers (> 0,1 % of the CD3 + CD8 + T-cells) will be statistically compared between the 3 groups of patients.",The results will be correlated with the patients clinical|The results will be correlated with the patients MRI data|Description of lymphocyte immunophenotyping and dosage of immunoglobulins in patients treated with Natalizumab,False,
NCT00674934,Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS),Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.,UNKNOWN,2008-05,2010-05,2010-06,2009-01-05,2008-05-08,INTERVENTIONAL,PHASE1,5.0,ESTIMATED,GAAD Medical Research Institute Inc.,OTHER,,,Multiple Sclerosis,"MS (Multiple Sclerosis)|Multiple Sclerosis, Acute Fulminating|Sclerosis, Disseminated",Canada,Toronto,Ontario,1,Far Infrared Radiation (5μm to 20μm wavelength),RADIATION,Treatment of MS,Rehabilitation of MS Patients,False,
NCT04091464,TRAIN-BW: Backward Walking Training in Multiple Sclerosis,TRAIN-BW: Backward Walking Training in Multiple Sclerosis,RECRUITING,2020-01-01,2025-08-31,2026-02-28,2025-07-18,2019-09-16,INTERVENTIONAL,NA,90.0,ESTIMATED,Wayne State University,OTHER,,,"Multiple Sclerosis|Gait Disorders, Neurologic|Accidental Fall",Backward Walking|Neurorehabilitation,United States,Detroit,Michigan,1,Backward Walking Training|Forward Walking Training,BEHAVIORAL|BEHAVIORAL,Sway during quiet stance|Stepping latency on push-and-release test,Client Satisfaction Questionnaire (CSQ-8)|Patient Global Impression of Change|Number of Active Minutes|Number of Falls|Forward and Backward Velocity and Double Support Time|ABC Scale,False,
NCT03339817,Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose En Plaques (SEP) Sévère,Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose En Plaques (SEP) Sévère,COMPLETED,2018-01-11,2020-11-06,2020-11-06,2025-03-05,2017-11-13,INTERVENTIONAL,NA,70.0,ACTUAL,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,,,Multiple Sclerosis|Respiration Disorders,,France,Paris,Paris,1,Polysomnography,DIAGNOSTIC_TEST,Polysomnography,Respiratory function testing|Respiratory function testing|Respiratory function testing|Respiratory function testing|Respiratory function testing|Cerebral and cervical spine MRI|Expanded Disability Status Scale (EDSS)|BICAMS,False,
NCT05626634,"Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy","A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks",COMPLETED,2022-11-08,2024-12-20,2024-12-20,2025-01-27,2022-11-25,INTERVENTIONAL,PHASE2,41.0,ACTUAL,Longboard Pharmaceuticals,INDUSTRY,,,Developmental and Epileptic Encephalopathy|Dravet Syndrome|Lennox-Gastaut Syndrome,CDKL5 deficiency disorder|developmental and epileptic encephalopathy|Dravet Syndrome|epilepsy|Lennox-Gastaut Syndrome|treatment resistant epilepsy|tuberous sclerosis complex,United States,Little Rock,Arkansas,28,"LP352, bexicaserin",DRUG,Treatment-emergent Adverse Events|Columbia-Suicide Severity Rating Scale (C-SSRS) Response|Patient Health Questionnaire-9 Total Score and Question 9 Score,Percent Change from Baseline in Observed Countable Motor Seizure Frequency During the Treatment Period|Proportion of Subjects with > 50% Reduction in Total Seizures During the Treatment Period|Percent Reduction in Individual Seizure Type During the Treatment Period|Proportion of Subjects Requiring Rescue Medication During the Treatment Period|Percent Change from Baseline in the Number of Episodes of Status Epilepticus During the Treatment Period|Percent of Subjects with Countable Motor Seizure-free Days During the Treatment Period|Percentage Change from Baseline in Non-motor and Difficult to Count Seizures|LGS: Percentage Change from Baseline in the Frequency of Observed Drop Seizures Over the Treatment Period,False,
NCT02688231,Task-oriented Upper Limb Training in MS,Intensity Dependent Clinical Effects of a Task-oriented Upper Limb Training in Multiple Sclerosis,COMPLETED,2016-01,2018-03,2018-03,2019-05-06,2016-02-23,INTERVENTIONAL,NA,21.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Upper limb rehabilitation,Belgium,Overpelt,Limburg,2,Task-oriented upper limb training|Control intervention,OTHER|OTHER,Nine Hole peg test|Manual Ability Measure-36|Isometric hand grip|Training tolerance|pinch grip strength,Motricity Index|Muscle fatigue indices|Tactile sensitivity in the fingers Semmens-Weinstein monofilaments|Rydel Seiffer Tuning fork|Symbol digit modalities test|Box and block test|Action Research Arm Test|Test d'Évaluation des Membres Supérieurs des Personnes Âgées (TEMPA)|Virtual Peg Insertion Test|Accelerometers (Actigraph),False,
NCT03993171,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.,"A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis.",ACTIVE_NOT_RECRUITING,2019-12-19,2025-04,2025-06,2025-01-29,2019-06-20,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,Clene Nanomedicine,INDUSTRY,University of Texas Southwestern Medical Center,OTHER,Multiple Sclerosis,neurodegeneration|gold|nanoparticle|NAD+|redox|31P-MRS|multiple sclerosis|magnetic resonance spectroscopy|nanocrystal|NADH|primary progressive multiple sclerosis|relapsing multiple sclerosis,United States,Dallas,Texas,1,gold nanocrystals,DRUG,"The change from baseline to week 12 in CNS metabolic changes, based on 31P-MRS Redox Ratio.",,False,
NCT05234671,Exercise in People With Systemic Sclerosis,Exploring the Effects of a Combined Exercise Programme on Pain and Fatigue Outcomes in People With Systemic Sclerosis: A Large Multi-centre Randomised Controlled Trial,COMPLETED,2021-09-01,2023-09-30,2024-02-28,2024-10-15,2022-02-10,INTERVENTIONAL,NA,170.0,ACTUAL,Sheffield Hallam University,OTHER,Leiden University|Rikshospitalet University Hospital|Karolinska Institutet|Aristotle University Of Thessaloniki|University of Campania Luigi Vanvitelli,OTHER|OTHER|OTHER|OTHER|OTHER,Systemic Sclerosis,,United Kingdom,Sheffield,,1,Exercise programme,OTHER,Pain Assessment (Overall Pain)|Pain Assessment (Overall Pain)|Pain Assessment (Digital Pain)|Pain Assessment (Digital Pain)|Fatigue Assessment|Fatigue Assessment,Quality of life questionnaire|Quality of life questionnaire|Depression scale questionnaire|Depression scale questionnaire|Microvascular assessment|Microvascular assessment|Peak oxygen uptake test on an arm crank ergometer|Peak oxygen uptake test on an arm crank ergometer|Handgrip strength test|Handgrip strength test|Biceps curl endurance test|Biceps curl endurance test,False,
NCT00704834,Gene Expression Profiles in Multiple Sclerosis (MS),Gene Expression Profiles in Patients With Multiple Sclerosis,COMPLETED,2006-03,2017-07-05,2017-07-05,2020-02-21,2008-06-25,OBSERVATIONAL,,46.0,ACTUAL,"University of California, Davis",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Chronic Progressive Multiple Sclerosis|Clinically Isolated Syndrome|Normal Controls|Blood Draw,United States,Sacramento,California,1,Blood Draw,OTHER,Determine MS-specific peripheral blood gene expression patterns|Determine differences in peripheral blood gene expression patterns between subgroups of MS patients|Determine whether there are specific SNPs correlated with altered gene expression profiles in multiple sclerosis|Determine MS-specific peripheral blood inflammatory marker profiles,,False,
NCT06901687,Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS),Home-Based tDCS for Depression in Multiple Sclerosis: A Randomized Sham-Controlled Trial,RECRUITING,2025-08-11,2028-01-01,2028-06-01,2025-08-14,2025-03-30,INTERVENTIONAL,PHASE2,170.0,ESTIMATED,NYU Langone Health,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Depression,Multiple Sclerosis|Depression|Neuromodulation|Home-Based|transcranial direct current stimulation,United States,New York,New York,1,Active tDCS|Sham tDCS,DEVICE|DEVICE,Change in Hamilton Depression Rating Scale (HDRS-17)|Change in Hamilton Depression Rating Scale (HDRS-17),Change in SymptoMScreen Score|Change in SymptoMScreen Score|Change in Cognitive Processing Speed (SDMT)|Change in Cognitive Processing Speed (SDMT)|Change in Quality of Life in Neurological Disorders (Neuro-QOL) Scale v1.0 - Communication Score|Change in Quality of Life in Neurological Disorders (Neuro-QOL) Scale v1.0 - Communication Score|Proportion of Participant who Achieve Clinical Response per HDRS-17 at End of Intervention|Proportion of Participant who Achieve Clinical Response per HDRS-17 at Month 3 Follow-Up|Proportion of Participant who Achieve Remission per HDRS-17 at End of Intervention|Proportion of Participant who Achieve Remission per HDRS-17 at Month 3 Follow-Up,False,
NCT06816004,Noninvasive Vagal Nerve Stimulation,Noninvasive Vagal Nerve Stimulation for the Management of Symptoms Experienced in Multiple Sclerosis (VANISH-MS): An Open-Label Home-Based Study of taVNS and tcVNS Compared to tDCS,RECRUITING,2025-08-20,2026-02-05,2026-05-05,2025-08-26,2025-02-10,INTERVENTIONAL,NA,30.0,ESTIMATED,NYU Langone Health,OTHER,,,Multiple Sclerosis,VNS|tDCS|Vagus Nerve Stimulation|Neuromodulation|Multiple Sclerosis|Home-Based,United States,New York,New York,1,Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)|Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)|Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS),DEVICE|DEVICE|DEVICE,Percentage of Participants who Complete Home-Based taVNS or tcVNS Sessions,Change in SymptoMScreen Score|Change in Multiple Sclerosis Impact Scale (MSIS-29) Score|Change in Memorial Symptom Assessment Scale (MSAS) Score|Change in Kessler Psychological Distress Scale (K10) Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form Score|Change in PROMIS Fatigue - Short Form 7a Score|Change in PROMIS Pain Intensity - Short Form 3a Score|Change in General Anxiety Disorder (GAD-7) Score|Change in Composite Autonomic Symptom Score-31 (COMPASS-31) Score|Change in Patient Health Questionnaire (PHQ-9) Score|Change in Nine-Hole Peg Test (9HPT) Score|Change in Heart Rate Variability (HRV),False,
NCT03650452,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies",COMPLETED,2018-08-08,2020-06-09,2020-07-20,2021-02-18,2018-08-28,INTERVENTIONAL,PHASE2,141.0,ACTUAL,Takeda,INDUSTRY,Healx AI,INDUSTRY,Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome,Drug Therapy|Brain Diseases|Central Nervous System Diseases|Tuberous Sclerosis|CDKL5 deficiency disorder|Dup15Q syndrome|Anoxic brain injury|Infantile spams|West syndrome|Cortical dysplasia|SCN1A|OV-935|Cholesterol 24S-hydroxylase inhibitor|Seizure|Anti-epileptic drug|Anticonvulsants|Nervous System Diseases|Drop seizure|Atonic seizure,United States,Phoenix,Arizona,44,TAK-935|Placebo,DRUG|DRUG,Percent Change From Baseline in Seizure Frequency Per 28 Days During the Maintenance Period,Percent Change From Baseline in Seizure Frequency Per 28 Days During the Treatment Period|Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days in Participants With Dravet Syndrome Stratum During the Maintenance Period|Percent Change From Baseline in Drop Seizure Frequency Per 28 Days in Participants With the Lennox-Gastaut Syndrome (LGS) Stratum During the Maintenance Period|Percentage of Participants With LGS Stratum Considered Treatment Responders Throughout the Maintenance Period|Percentage of Participants With Dravet Syndrome Stratum Considered Treatment Responders Throughout the Maintenance Period|Change From Baseline in Clinician's Clinical Global Impression of Severity (CGI-S) Responses of Investigator Reported Impression of Efficacy and Tolerability of Study Drug|Percentage of Participants With Clinical Global Impression of Change (CGI-C) Responses as Per the Investigator Reported Impression of Efficacy and Tolerability TAK-935|Percentage of Participants With Caregiver Global Impression of Change (Care GI-C) Responses as Per the Parent/Family Reported Impression of Efficacy and Tolerability of TAK-935|Change From Baseline in Plasma 24S-Hydroxycholesterol (24HC) Levels in Participants Treated With TAK-935 as an Adjunctive Therapy|Change From Baseline in Seizure Frequency in Participants Treated With TAK-935 as an Adjunctive Therapy,True,2021-02-18
NCT03302806,Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis,Observational Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis,COMPLETED,2016-06-29,2017-10-04,2018-10-24,2021-09-21,2017-10-05,OBSERVATIONAL,,103.0,ACTUAL,Nantes University Hospital,OTHER,,,Progressive Multiple Sclerosis,disability|EDSS,France,Nantes,,1,Non interventional Study,OTHER,Evolution of post-treatment disability,CGI-t scale|Functional disability : Multiple sclerosis Functional composite|Ambulation|Quality of life|adverse effect (adverse drug reaction),False,
NCT07101653,Exercise-Induced Irisin and Brain Changes,"From Muscle to Brain: Exercise Induces Structural Brain Changes, Irisin Elevation, and Functional Recovery in Multiple Sclerosis - Exploring the Interrelationships",COMPLETED,2024-10-15,2024-11-15,2025-06-15,2025-08-03,2025-08-03,INTERVENTIONAL,NA,21.0,ACTUAL,Firat University,OTHER,,,Multiple Sclerosis,Exercise|Irisin|Brain Volume,Turkey (Türkiye),Elâzığ,,1,Exercise,OTHER,MRI Acquisition and Volumetric Analysis|Serum irisin hormone measurement,Multiple Sclerosis Functional Composite,False,
NCT00641537,CLARITY Extension Study,"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)",COMPLETED,2008-02-29,2011-12-31,2011-12-31,2020-12-07,2008-03-24,INTERVENTIONAL,PHASE3,867.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Boulder,Colorado,116,Cladribine|Placebo|Cladribine|Cladribine|Placebo,DRUG|DRUG|DRUG|DRUG|DRUG,"Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity|Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120|Safety Population: Mean Change From Baseline in Hemoglobin at Week 120|Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120|Safety Population: Mean Change From Baseline in Bilirubin at Week 120|Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs|SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs|Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies|SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies|Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver Toxicity|Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic Toxicity|Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver Toxicity|Safety Population: Median Time to Nadir of Absolute Lymphocyte Count|Safety Population: Mean Time to Nadir of Absolute Lymphocyte Count|Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal Value|Safety Population: Mean Change in Corrected QT (QTc) Interval From Baseline",,True,2013-12-02
NCT02269436,A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS,"A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis",TERMINATED,2015-01,2015-10,2015-10,2016-01-27,2014-10-21,INTERVENTIONAL,PHASE1,11.0,ACTUAL,Newron Sweden AB,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,Belgium,Leuven,,2,sNN0029 infusion solution,DRUG,Number Patients with Adverse Events as a measure of Safety and Tolerability,,False,
NCT05688436,A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate,Pregnancy Outcomes in Women Exposed to Diroximel Fumarate,RECRUITING,2021-09-24,2031-01-17,2031-01-17,2025-01-30,2023-01-18,OBSERVATIONAL,,1178.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,Pregnancy|Relapsing forms of Multiple Sclerosis (MS),United States,Eden Prairie,Minnesota,1,Diroximel Fumarate|Alemtuzumab|Fingolimod|Glatiramer acetate|Interferon beta|Natalizumab|Ocrelizumab|Ofatumumab|Ozanimod|Peginterferon beta-1a|Ponesimod|Siponimod,DRUG|BIOLOGICAL|DRUG|DRUG|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|DRUG|BIOLOGICAL|DRUG|DRUG,Number of Major Congenital Malformations (MCMs),Number of Spontaneous Abortions|Number of Preterm Births|Number of Stillbirths|Number of Small for Gestational Age (SGA),False,
NCT02253264,A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients,A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement,COMPLETED,2014-11,2017-08,2017-08,2017-08-30,2014-10-01,INTERVENTIONAL,PHASE1,8.0,ACTUAL,Johns Hopkins University,OTHER,,,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,United States,Baltimore,Maryland,1,Rituximab,DRUG,"Number of serious adverse events over the course of the study at least possibly related to intrathecal rituximab therapy, as determined by the principal investigator.",,False,
NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,"Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers",COMPLETED,2009-01,2009-12,2009-12,2014-04-02,2009-12-14,INTERVENTIONAL,PHASE1,16.0,ACTUAL,Bayer,INDUSTRY,,,Positron-Emission Tomography|Multiple Sclerosis,Multiple sclerosis|Diagnostic imaging|Neuroinflammation|PET diagnosis|PET tracer,Australia,Heidelberg,Victoria,2,F-18 FEDAA1106 (BAY85-8101)|F-18 FEDAA1106 (BAY85-8101),DRUG|DRUG,Standard quantification variables derived from 3D PET imaging and brain modeling.|Visual analysis/description of the uptake and description of brain PET scans.,Standard Safety Parameter: Adverse Event Collection|Standard Safety Parameter: Electrocardiogram|Standard Safety Parameter: Safety laboratory|Standard Safety Parameter: Vital signs,False,
NCT00490906,Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis,Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study,COMPLETED,2007-06,2009-02,2012-12,2014-01-22,2007-06-25,OBSERVATIONAL,,60.0,ACTUAL,"Nancy Hammond, MD",OTHER,"Kansas City Area Life Sciences Institute, Inc.",OTHER,Multiple Sclerosis|Low Bone Density,MS (Multiple Sclerosis),United States,Kansas City,Kansas,2,Copaxone|Interferon-beta 1a|Interferon-beta 1b,DRUG|DRUG|DRUG,,,False,
NCT06617793,"An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis","An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Participants With Relapsing Multiple Sclerosis With Breakthrough Disease Activity During Previous Treatment With a Highly Efficacious Therapy",RECRUITING,2025-02-24,2030-10-22,2030-10-22,2025-08-19,2024-09-27,INTERVENTIONAL,PHASE1|PHASE2,28.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Chimeric Antigen Receptor T cells|CAR-T|YTB323|Multiple Sclerosis|MS|Relapsing Multiple Sclerosis|RMS|breakthrough disease activity during previous treatment with a highly efficacious therapy|BD-HET,Australia,Darlinghurst,New South Wales,15,rapcabtagene autoleucel (YTB323),BIOLOGICAL,Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),"Measure of Disability: Expanded Disability Status Scale (EDSS).|Measure of Disability: Short Form Health Survey (SF-36 v2)|Measure of Disability: Timed 25 Foot Walk (T25FW)|Measure of Disability: 9 Hole Peg Test (9HPT)|Measure of Disability: Symbol Digit Modalities Test (SDMT)|Measure of Disability: Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS)|Number of new and enlarging T2 lesions and Gd-enhancing T1 Lesions|Plasma Pharmacokinetics (PK) of YTB323 - CMAX|Plasma Pharmacokinetics (PK) of YTB323 - AUC|Plasma Pharmacokinetics (PK) of YTB323 - Tmax|Plasma Pharmacokinetics (PK) of YTB323 - Clast|Plasma Pharmacokinetics (PK) of YTB323 - Tlast|Safety data including dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) from each dose level|Humoral Immunogenicity of YTB323|Cellular Immunogenicity of YTB323",False,
NCT04123353,Scan-Rescan Sub-Study of MS PATHS,Reproducibility of Brain Volume and Lesion Measurements in Multiple Sclerosis: a Scan-Rescan Sub-Study of Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS),COMPLETED,2017-02-11,2017-05-09,2017-05-09,2019-10-10,2019-10-10,OBSERVATIONAL,,30.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Baltimore,Maryland,3,,,Overall Reproducibility of Brain Volume|Overall Reproducibility of Lesions|Intrascanner Reproducibility of Brain Volume|Intrascanner Reproducibility of Lesions|Interscanner Reproducibility of Brain Volume|Interscanner Reproducibility of Lesions|Intra-class Correlation Coefficients (ICCs) Across Repeated Magnetic Resonance Imaging (MRI) for Brain Lesions|Kappa Coefficients Across Expert Manual Segmentation for Brain Lesions|Sensitivity and Specificity for Lesion Detection,Correlation Coefficients of Equation Parameters for Models to Map Brain Volume and Lesion Measurements between Scanners,False,
NCT00398528,An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis,An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-β-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-β-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter Study of Patients With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy.,TERMINATED,2006-09,,2007-11,2007-12-05,2006-11-10,OBSERVATIONAL,,48.0,ESTIMATED,Neurognostics,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Disease Modifying Therapy,United States,Los Angeles,California,5,"Glatiramer acetate, (Copaxone®)|IFN-β-1a, (Avonex®)",DRUG|DRUG,Examine the change in task-activated fMRI response as a function of disease modifying therapies assigned to MS.|Secondary: fMRI as a surrogate marker for drug efficacy,fMRI as a surrogate marker for drug efficacy.,False,
NCT01954693,A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis,"TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous Sclerosis",UNKNOWN,2012-06,2018-08-06,2018-08-06,2018-01-30,2013-10-07,INTERVENTIONAL,PHASE2,48.0,ESTIMATED,Cardiff University,OTHER,Novartis,INDUSTRY,Tuberous Sclerosis,Tuberous Sclerosis|Everolimus|Neurocognitive functioning,United Kingdom,Cardiff,,1,Placebo|Everolimus (RAD001),DRUG|DRUG,List Learning test (from the BIRT Memory and Information Processing Battery)|Complex Figure test (from the BIRT Memory and Information Processing Battery)|CANTAB - Stockings of Cambridge (SOC)|CANTAB - Spatial Working Memory (SWM)|Telephone search dual task (from the Test of Everyday Attention),CANTAB - Rapid Visual Information Processing Battery (RVIP)|CANTAB - Spatial Span (SSP)|CANTAB - Attentional Set-shifting (IDED)|Verbal Fluency /Controlled Oral Word Association Test (COWAT)|Cancellation task|Symptom Checklist 90R (SCL-90R)|Quality of Life in Epilepsy (QOLIE)|Liverpool Seizure Severity Scale (LSSS)|Vineland Adaptive Behavior Scales-II (VABS-II) (survey form)|Social Responsiveness Scale - Adult version (SRS-A)|Social communication questionnaire (SCQ)|National Adult Reading Test (NART),False,
NCT04125628,Exercise on Multiple Sclerosis Patients,Effects of Head and Neck Cooling on Functional Ability and Fatigue of Multiple Sclerosis,COMPLETED,2019-06-01,2019-06-25,2019-06-25,2019-10-14,2019-10-14,INTERVENTIONAL,NA,10.0,ACTUAL,Petros Dinas,OTHER,,,Multiple Sclerosis,Uthoff's phenomenon|Thermosensitivity|Functional capacity|Exercise intolerance,Greece,Trikala,Thessaly,1,Exercise with cooling|Exercise without cooling,BEHAVIORAL|BEHAVIORAL,Core Temperature|Functional ability test Handgrip|Functional ability test 2-minute walk|Functional ability test 25-Foot Walk (T25-FW)|Functional ability test five times sit-to-stand test (STS)|Functional ability test Berg Balance Scale (BBS)|Functional ability test level of fatigue severity (FSS)|Functional ability test Cognitive function|Functional ability test level of fatigue impact|Functional ability test level of fatigue inventory|Functional ability test level of physical fatigue,,False,
NCT06195644,Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients,Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients,RECRUITING,2023-09-03,2024-12,2025-12,2024-01-08,2024-01-08,INTERVENTIONAL,PHASE1,40.0,ESTIMATED,Cairo University,OTHER,,,Cortical Excitability|Multiple Sclerosis,Galvanic Vestibular Stimulation|Hand Dexterity|Multiple Sclerosis|Transcranial magnetic Stimulation|Cortical excitability,Egypt,Cairo,,1,Galvanic vestibular stimulation|MovAlyzeR® software from Neuroscript|BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer),DEVICE|DEVICE|DEVICE,Cortical changes|Upper Limb motor dexterity,Advanced dexterity (Handwriting analysis) by MovAlyzeR® software|Balance|Fatigue,False,
NCT00381264,Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis,A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis,COMPLETED,2006-09,2007-10,2007-10,2008-02-15,2006-09-27,INTERVENTIONAL,PHASE4,23.0,ESTIMATED,"NEMA Research, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Aventura,Florida,4,Cesamet™ (nabilone),DRUG,The Average Pain Score at target site.,The Worst Pain Score at target site.|The Pain at Night Score at target site.|Quality of Life measures.|Patient satisfaction with treatment.|Safety will be assessed through the collection of AEs and vital signs.,False,
NCT07114809,Impact of Anodal tDCS and Virtual Reality on Cognitive Dysfunction in Patients With Multiple Sclerosis,"Impact of Anodal tDCS and Virtual Reality on Cognitive Dysfunction in Patients With Multiple Sclerosis: a Protocol of a Double Blind, Randomized, Prospective, Controlled Study.",RECRUITING,2024-09-02,2026-01,2026-01,2025-08-11,2025-08-11,INTERVENTIONAL,NA,80.0,ESTIMATED,Ospedale Policlinico San Martino,OTHER,Italian Multiple Sclerosis Foundation,OTHER,Cognitive Impairment|Multiple Sclerosis,Cognitive impairment|Multiple Sclerosis|Exergaiming|Virtual Reality|tDCS,Italy,Genova,Italy,3,Experimental group (EG) performing Anodal-tDCS (A-tDCS) and VR|Sham Comparator: Control group (CG) performing sham-tDCS (S-tCDS) and VR,DEVICE|DEVICE,"Revised Brief Visuo-Spatial Memory test (BVMT-R)|Symbol digit modalities test (SDMT)|California Verbal Learning test II edition (CVLT-II)|Paced Auditory Serial Addition Task 3"" and 2"" intervals (PASAT)",Multiple Sclerosis Quality of life (MSQoL)|Beck depression inventory scale (BDI)|Fatigue Severity Scale (FSS),False,
NCT02010398,Effects of the Cross-Training in Patients With Multiple Sclerosis,"Neurophysiological, Dynamometric, Functional and Clinical Assessment of the Cross-Training Effect in Patients With Multiple Sclerosis",COMPLETED,2013-07,2017-03-27,2017-03-27,2017-03-29,2013-12-12,INTERVENTIONAL,NA,45.0,ACTUAL,Università degli Studi di Sassari,OTHER,,,Multiple Sclerosis|Weakness|Fatigue,"Resistance training/methods|contralateral strength training|ipsilateral strength training|Isokinetic contraction|Adaptation, Physiological/physiology|Electromyography/methods|Transcranial Magnetic Stimulation/methods|Evoked Potentials, Motor",Italy,Sassari,Sassari (SS),3,Cross-Training healthy subjects|Cross-Training multiple sclerosis|Standard-training multiple sclerosis,OTHER|OTHER|OTHER,Muscular strength,Neural adaptations to Cross Training,False,
NCT05029830,Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis,Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis,COMPLETED,2021-09-01,2022-09-01,2022-10-30,2023-02-06,2021-09-01,OBSERVATIONAL,,70.0,ACTUAL,Assiut University,OTHER,,,Multiple Sclerosis Acute and Progressive,,Egypt,Asyut,,1,investigations like MRI..,COMBINATION_PRODUCT,Measurement affection quality of life in patient's with MS,Measure psychiatric comorbidity in patients with MS,False,
NCT02511028,"In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging","In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",COMPLETED,2015-11-27,2018-08-01,2019-01-29,2025-09-19,2015-07-29,INTERVENTIONAL,PHASE1,14.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,National Institutes of Health Clinical Center (CC),NIH,Multiple Sclerosis,MRI|Multiple Sclerosis|Healthy Volunteer,United States,Bethesda,Maryland,1,Ferumoxytol,DRUG,"change in gradient-echo T2*-weighted signal in an iron-rich brain structure, the globus pallidus",,False,
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),"A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)",COMPLETED,2009-08,2011-03,2014-10,2016-02-03,2008-11-13,INTERVENTIONAL,PHASE3,117.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,SEGA|Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma|mTOR|RAD001|Mamalian Target Rapamycin|Everolimus|TSC,United States,Birmingham,Alabama,24,Everolimus|Placebo,DRUG|DRUG,Percentage of Participants With Best Overall Subependymal Giant Cell Astrocytomas (SEGA) Response,Change From Baseline in Frequency of Total Seizure Events Per 24 Hours at Week 24 in Both Core and Extension Period|Time to SEGA Progression|Time to SEGA Response|Duration of SEGA Response|Time to SEGA Worsening|Percentage of Participants With Skin Lesions Assessed Using Physician's Global Assessement Overall Score|Duration of Skin Lesion Response in Everolimus Treated Participants|Everolimus Blood Concentration (C2h) at 2 Hours Post Dose|Everolimus Trough Concentrations (Cmin) at 24 Hours After Last Dose|Percentage of Participants With Renal Impairment During Core Period,True,2012-05-01
NCT01106365,Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis,Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis - A Pilot Study to Evaluate Safety and Efficacy of Deep rTMS on Fatigue and Depressivity in Patients With Multiple Sclerosis,COMPLETED,2010-02,2012-12,2012-12,2021-07-29,2010-04-19,INTERVENTIONAL,NA,36.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,Brainsway,INDUSTRY,Multiple Sclerosis,multiple sclerosis|fatigue|depressivity|repetitive deep transcranial magnetic stimulation,Germany,Berlin,,1,H-coil (Repetitive deep transcranial magnetic stimulation),DEVICE,Safety,Fatigue|Depressivity,False,
NCT02012439,Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain,The Efficacy and Mechanisms of Cognitive Therapy Compared to Mindfulness-Based Cognitive Therapy in Multiple Sclerosis (MS) Pain,COMPLETED,2013-10,2015-04,2016-12,2019-09-16,2013-12-16,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,multiple sclerosis|chronic pain|treatment|nonpharmacological|mindfulness|cognitive therapy,United States,Seattle,Washington,1,Mindfulness Based Cognitive Therapy|Cognitive Therapy,BEHAVIORAL|BEHAVIORAL,pain intensity,,False,
NCT05124600,An Individualized-health eLibrary App for People With Multiple Sclerosis,An Individualized-health eLibrary App for People With Multiple Sclerosis: Testing Feasibility and Effectiveness of a Brief Education Intervention,RECRUITING,2021-10-25,2026-12-31,2026-12-31,2025-08-24,2021-11-18,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,eHealth|mHealth,United States,Champaign,Illinois,1,SavvyHealth,DEVICE,MS Self-management Scale,,False,
NCT06282081,Serum Neurofilament Light in Multiple Sclerosis,Serum Neurofilament Light As a Clinical Tool in Relapsing Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2024-04-09,2026-03-01,2027-03-01,2025-02-14,2024-02-28,OBSERVATIONAL,,42.0,ESTIMATED,Dent Neuroscience Research Center,OTHER,"Genentech, Inc., a subsidiary of F. Hoffman-La Roche AG|Monogram Biosciences (LabCorp Specialty Testing Group)",UNKNOWN|UNKNOWN,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis,,United States,Amherst,New York,1,Serum Neurofilament Light,DIAGNOSTIC_TEST,Evaluate the utility of sNfL levels to aid with clinical decision-making by examining clinicians' understanding of patient's clinical status before sNfL results are received vs. after sNfL results are received|Evaluate the utility of sNfL levels to aid with clinical decision-making by examining clinicians' opinion as to how sNfL results could guide clinical practice|Describe the optimal sNfL sampling frequency by capturing frequency of unscheduled clinician-ordered sNfL measurements.|Describe the optimal sNfL sampling frequency by capturing reason for unscheduled clinician-ordered sNfL measurements.|Describe the optimal sNfL sampling frequency by capturing usefulness of scheduled and unscheduled sNfL measurements based on a visual analog scale.|Describe the optimal sNfL sampling frequency by capturing usefulness of scheduled and unscheduled sNfL measurements based on a visual analog scale.,Describe patient demographics|Describe patient comorbidities|Describe patient concomitant medications|Describe patient MS medications|Describe patient reasons for MS medication changes|Describe patient MS relapses including date of relapse|Describe patient MS relapses including clinical findings|Describe patient MS relapses including radiologic findings|Describe patient MS relapses including severity|Explore patient attitudes towards sNfL measurements by capturing patients' perceptions of undergoing sNfL measurements vs. receiving an MRI based on a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patients' perceptions of undergoing sNfL measurements vs. receiving an MRI based on a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patients' perceptions of undergoing sNfL measurements vs. receiving an MRI based on a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patients' perceptions of undergoing sNfL measurements vs. receiving an MRI based on a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patients' perceptions of undergoing sNfL measurements vs. receiving an MRI based on a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patients' understanding of their disease before sNfL results are received vs. after sNfL results are received via a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patient attitudes towards sNfL sampling via a structured questionnaire.|Explore patient attitudes towards sNfL measurements by capturing patient attitudes towards sNfL sampling via a structured questionnaire.|Compare sNfL levels after initiation of a new MS disease-modifying therapy (DMT; when patient is treated with a DMT) vs. prior to MS DMT initiation (when patient is not treated with any DMT) where available.|Compare sNfL levels at scheduled sampling time points between patients initiating any new MS DMT vs. patients who do not change MS DMT where available.|Compare sNfL levels in patients who have a clinical or radiologic relapse during the study vs. patients who do not.|Describe changes in sNfL levels with Expanded Disability Status Scale (EDSS) where available.|Describe changes in sNfL levels with Symbol Digit Modalities Test (SDMT) where available.|Describe changes in sNfL levels with Patient Health Questionnaire-9 (PHQ-9) where available.|Describe changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) physical health summary score where available.|Describe changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) mental health summary score where available.|Describe changes in sNfL levels with magnetic resonance imaging disease activity where available.|Describe changes in sNfL levels with changes to multiple sclerosis disease-modifying therapy where available.|Compare changes in sNfL levels with Expanded Disability Status Scale (EDSS) where available.|Compare changes in sNfL levels with Symbol Digit Modalities Test (SDMT) where available.|Compare changes in sNfL levels with Patient Health Questionnaire-9 (PHQ-9) where available.|Compare changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) physical health summary score where available.|Compare changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) mental health summary score where available.|Compare changes in sNfL levels with magnetic resonance imaging disease activity where available.|Compare changes in sNfL levels with changes to multiple sclerosis disease-modifying therapy where available.|Correlate changes in sNfL levels with Expanded Disability Status Scale (EDSS) where available.|Correlate changes in sNfL levels with Symbol Digit Modalities Test (SDMT) where available.|Correlate changes in sNfL levels with Patient Health Questionnaire-9 (PHQ-9) where available.|Correlate changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) physical health summary score where available.|Correlate changes in sNfL levels with Multiple Sclerosis Quality of Life - 54 (MSQOL-54) mental health summary score where available.|Correlate changes in sNfL levels with magnetic resonance imaging disease activity where available.|Correlate changes in sNfL levels with changes to multiple sclerosis disease-modifying therapy where available.,False,
NCT04369092,Myotonometer Analyses of Muscles in Multiple Sclerosis Patients With Dysphagia,Myotonometric Assessment of Muscles in Multiple Sclerosis Patients With Dysphagia,COMPLETED,2019-10-02,2019-12-28,2020-01-30,2020-04-30,2020-04-30,INTERVENTIONAL,NA,28.0,ACTUAL,Tuba Maden,OTHER,,,Multiple Sclerosis|Dysphagia|Swallowing Disorder|Deglutition Disorders|Muscle Tonus,,Turkey (Türkiye),Gaziantep,,1,DYMUS,OTHER,Myotonometric Measurement,Eating Assessment Tool,False,
NCT03032601,Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis,Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis,ENROLLING_BY_INVITATION,2017-01-05,2027-07-08,2027-07-08,2025-09-17,2017-01-26,INTERVENTIONAL,NA,55.0,ESTIMATED,Thomas Jefferson University,OTHER,,,Multiple Sclerosis,MS (Multiple Sclerosis)|Acute Fulminating|Sclerosis|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose|18F Fluorodeoxyglucose 2-Fluoro-2-deoxy-D-glucose (18 FDG)|Fludeoxyglucose F 18|Fluorine-18-fluorodeoxyglucose|Positron Emission Tomography (PET)|Magnetic Resonance Imaging (MRI)|PET MRI|Acetylcysteine|N-acetyl cysteine (NAC)|Oral supplements|functional magnetic resonance imaging (fMRI)|FDG positron emission tomography (FDG PET),United States,Philadelphia,Pennsylvania,1,N-acetyl Cysteine,DIETARY_SUPPLEMENT,"Changes in the metabolic activity in the brain, and improved parameters with regard to the inflammation associated with the active lesions based on both MRI and PET findings.",Mini-Mental Status examination (MMSE)|Multiple Sclerosis Quality of Life Inventory (MSQLI)|Health Status Questionnaire (SF-36) standard form|Modified Fatigue Impact Scale (MFIS) standard form|MOS Pain Effects Scale (PES)|Bladder Control Scale (BLCS)|Bowel Control Scale (BWCS)|Impact of Visual Impairment Scale (IVIS)|Perceived Deficits Questionnaire (PDQ) standard form|Mental Health Inventory (MHI) standard form|MOS Modified Social Support Survey (MSSS) standard form|Sexual Satisfaction Scale (SSS)|Kurtzke Expanded Disability Status Scale (EDSS),False,
NCT04496830,SPINCOMS Biomarker Study,Cerebrospinal Fluid-biomarkers-based Diagnostic and Prognostic Models for Multiple Sclerosis,COMPLETED,2020-06-15,2023-11-24,2023-11-24,2025-09-11,2020-08-03,OBSERVATIONAL,,161.0,ACTUAL,Washington University School of Medicine,OTHER,"National Institute of Allergy and Infectious Diseases (NIAID)|University of Colorado, Denver|University of Ottawa|Montana State University",NIH|OTHER|OTHER|OTHER,Multiple Sclerosis,,United States,St Louis,Missouri,1,,,Biomarker Predicted Outcomes against NeurEx-based outcomes|MS Severity Model Analyses,,False,
NCT06982742,Effect of a Mobile Health App on Pain and Quality of Life in Patients With Neuropathic Pain in Multiple Sclerosis,Development of a Mobile Health Application for Patients With Neuropathic Pain in Multiple Sclerosis and the Effect of the Application on Pain Intensity and Quality of Life,NOT_YET_RECRUITING,2025-07-01,2025-10-01,2025-12-15,2025-05-25,2025-05-21,INTERVENTIONAL,NA,52.0,ESTIMATED,Meryem Kocaslan Toran,OTHER,Uskudar University|The Scientific and Technological Research Council of Turkey,OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|neuroparthic pain|quality opf life|mobile health aplication,Turkey (Türkiye),Istanbul,,1,Mobile Health App for Neuropathic Pain Management in MS,OTHER,Reduction in Neuropathic Pain Intensity Measured by Visual Analog Scale (VAS),Improvement in Quality of Life Measured by Multiple Sclerosis Quality of Life-54 (MSQOL-54),False,
NCT00270816,Interferon ß-1b Treatment by Cyclical Administration,Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.,COMPLETED,2005-11,2010-08,2011-01,2018-12-19,2005-12-28,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,S. Andrea Hospital,OTHER,Italian Multiple Sclerosis Foundation,OTHER,Multiple Sclerosis,Multiple Sclerosis|Interferon-ß-1b|Therapy,Italy,Rome,,1,Interferon-ß-1b|Interferon ß-1b,DRUG|DRUG,number of gad-enhancing lesions (CELs) in T1,number of new and enlarging T2 lesions|volume of T1 lesions (black holes)|relapse rate,False,
NCT02887352,French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis,French Adaptation of the CCST (California Card Sorting Task). Comparison of 3 Packages to CCST With Multiple Sclerosis (MS) Patients,COMPLETED,2014-03,2020-01,2020-01,2021-06-14,2016-09-02,OBSERVATIONAL,,48.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Paris,,1,assessment of problem-solving ability,OTHER,CCST Test score,,False,
NCT05888727,Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis,Feasibility and Initial Efficacy of a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis,COMPLETED,2024-01-17,2025-05-30,2025-05-30,2025-06-19,2023-06-05,INTERVENTIONAL,NA,24.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,University of Illinois at Chicago|Craig Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),OTHER|OTHER|NIH,Multiple Sclerosis,,United States,Houston,Texas,1,"Seated Physical activity INtervention for persons with MS, ""SPIN"" program- Intervention Condition|WEllness for Longevity Living with MS (WELL)- Control Condition",BEHAVIORAL|BEHAVIORAL,Study Feasibility: Number of Participants Recruited|Study Feasibility: Number of Participants Retained|Study Feasibility: Incidence of Adverse Events,Acceptability: Semi-structured interview|Acceptability: Survey,False,
NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301",TERMINATED,2013-02-15,2018-09-24,2018-09-24,2019-12-04,2013-02-25,INTERVENTIONAL,PHASE3,1501.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,,United States,Phoenix,Arizona,222,BIIB019 (Daclizumab),DRUG,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),"Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period|ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period|Number of Participants With Relapse in the 205MS303 Treatment Period|Number of Participants With Relapse in the 205MS301-303 Combined Study Period|Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period|Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period|Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period|Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period|Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period|Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period|Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period|Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period|Percent Change in Brain Volume From the 205MS303 Baseline|Percent Change in Brain Volume From 205MS301 Baseline|Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period|Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period|Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period|Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period|Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period|Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period|Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period|Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period|Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period|Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period|Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period|Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period|HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period|HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period|HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period|HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period|HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period|HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period|HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period|Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period|Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS|Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories|Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period|Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period|Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period|Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period|Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period|Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period",True,2019-12-04
NCT01507636,Occupational Therapy in Patients With Multiple Sclerosis,Apraxia-specific Occupational Therapy in Patients With Multiple Sclerosis,COMPLETED,2012-01,2012-12,2012-12,2013-05-15,2012-01-11,INTERVENTIONAL,NA,40.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,,,Multiple Sclerosis|Apraxia,apraxia|occupational therapy|multiple sclerosis|manual dexterity,Switzerland,Bern,,1,Occupational Therapy|Physical therapy,OTHER|OTHER,Change in apraxia score as measured by TULIA,Change in manual dexterity|Change in activities of daily living|Change in quality of life|Change in fatigue,False,
NCT06733922,ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS,Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS),RECRUITING,2024-11-27,2027-11-22,2027-11-30,2025-07-22,2024-12-13,INTERVENTIONAL,PHASE4,224.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS),"Ofatumumab|Eye Movement Biomarkers (EMB)|Patient-Reported Outcomes (PRO)|Active Relapsing-Remitting MS (RRMS)|Real-World, Neurofilament Light Chain (NfL)|Digital, Eye-Tracking",Canada,Halifax,Nova Scotia,5,ETNATM-ProgMS,DEVICE,1- Change Eye Movement Biomarkers (EMB),"1a. Change in EMB|1b. Change in EMB trajectories|2a. Change in Annual Relapse Rate (ARR)|2b. Change in patient disability measured by Expanded Disability Status Scale EDSS|2b. Change in patient disability measured by Timed 25-foot walk test (T25-FW)|2b. Change in patient disability measured by the 9-hole peg test (9-HPT)|2c. Change in objective measures of cognitive impairment as measured by the Symbol Digit Modalities Test (SDMT)|2c. Change in objective measures of cognitive impairment as measured by the Brief Visuospatial Memory Test (BVMT-R)|2c. Change in objective measures of cognitive impairment as measured by the Rey Auditory Verbal Learning Test (RAVLT)|3a. Association between EMB and annual relapse rate (AAR)|3b. Association of EMBs and objective measures of disability - EDSS, T25-FW, and 9-HPT|3c. Association of EMBs and objective measures of cognitive impairment - SDMT|3c. Association of EMBs and objective measures of cognitive impairment - BVMT-R, and RAVLT|4. Change in serum Neurofilament light Chain (sNfL)|5a. Change in patient-reported physical and psychological impact of MS disease as measured by the Multiple Sclerosis impact scale-29 version 2 (MSIS-29v2)|5b. Baseline assessment and change in patient-reported depression as measured by the Beck depression inventory-II (BDI-II)|5c. Change in patient-reported cognitive impairment as measured by the MS neuropsychology questionnaire (MSNQ)|5d. Change in patient-reported mobility as measured by the MS walking scale-12 version 1 (MSWS-12v1)|6. Incidence of treatment emergent adverse events and serious adverse events",False,
NCT01723631,Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis,"Study Multicenter, Controlled, Prospective, Non-randomized Test to Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis",TERMINATED,2012-04,2014-12,2015-10,2017-05-16,2012-11-08,INTERVENTIONAL,NA,189.0,ACTUAL,Nantes University Hospital,OTHER,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,Multiple Sclerosis,Multiple sclerosis|TRAP|TRAP-Myéline,France,Bordeaux,,11,Trap Myelin Test,DEVICE,Evaluate the diagnostic performance of myelin-TRAP assay for Multiple Sclerosis,Determine the best cut-off rate of myelin-Trap and evaluate the sensitivity and specificity associated,False,
NCT02889419,Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization,"Benefits Evaluation of Selfia® Adapted Underwear for Multiple Sclerosis Patients With Severe to Moderate Handicap Performing Self-catheterization : a Multicenter, Prospective, Uncontrolled and Before/After Study.",WITHDRAWN,2017-01,2020-06,2020-06,2018-08-22,2016-09-05,INTERVENTIONAL,NA,0.0,ACTUAL,Lille Catholic University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Disability|Underwear|Urinary catheter|Self-catheterisation,France,Lomme,Hauts-de-France,6,Evaluation of underwear Selfia®,DEVICE,"Average time spend for the realization of a self-catheterisation, from undressing to dressing, measured by a chronometer provided to the patient",Measure of the quality of life|Measure of fatigue for every SC|Comfort linked to SC|Consequences from SC complications|Number of documented urinary infections|Number of self-catheterisation or hetero-catheterisation per day|Opinion of the patient (favorable/non favorable) on the use of underwear Selfia ®|Re-use (yes/no) of underwear with or without purchase (yes/no),False,
NCT06702137,"EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis",The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP Study),COMPLETED,2022-06-01,2024-04-02,2024-05-14,2025-06-18,2024-11-22,INTERVENTIONAL,NA,34.0,ACTUAL,Institut De La Colonne Vertebrale Et Des Neurosciences,OTHER,,,Multiple Sclerosis,Spasticity|Motor Functions|Quality of life,France,Créteil,VAL DE MARNE,1,EXOPULSE MOLLII SUIT (active)|EXOPULSE MOLLII SUIT (sham),DEVICE|DEVICE,Improvement in balance using the BBS (Berg Balance Scale) ),Assessment of the cumulative effects of EXOPULSE Mollii suit on balance using the BBS (Berg Balance Scale) after 4 weeks of using Exopulse Molii Suit|Assessment of the spasticity using the MAS (Modified Ashworth Scale)|Assessment of the spasticity using the VAS spasticity (Visual Analogue Scale)|Mobility will be assessed using the TUG (Time Up and Go)|Mobility will be assessed using the FES-I (Falls Efficacy Scale-International scale)|Mobility will be assessed using the MSWS-12 (Multiple Sclerosis Walking Scale - 12)|Quality of life will be measured using the MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire)|Pain will be assessed using a VAS (Visual Analogue Scale)|Fatigue will be assessed using a VAS (Visual Analogue Scale)|Evaluation of overall improvement using the CGI (Clinical Global Impression)|Evaluation of patient's blinding to the type of stimulation in the crossover trial,False,
NCT05974839,Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical),"Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study",COMPLETED,2023-10-01,2024-02-28,2024-02-28,2024-09-26,2023-08-03,OBSERVATIONAL,,732.0,ACTUAL,State University of New York at Buffalo,OTHER,"Genentech, Inc.",INDUSTRY,Primary Progressive Multiple Sclerosis,,United States,Buffalo,New York,1,Ocrelizumab,OTHER,Cortical lesion number accumulation,Cortical lesion number accumulation and disability.,False,
NCT01272128,Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study,"A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated",COMPLETED,2012-12,2014-09,2015-09,2015-10-20,2011-01-07,OBSERVATIONAL,,100.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Belgium,Bonheiden,Antwerp,17,Interferon beta-1a,DRUG,Change from Baseline in EuroQol 5D (EQ-5D) Visual Analog Scale (VAS) at 12 months,"Change from Baseline in EQ-5D VAS at 6, 18 and 24 months|Change from Baseline in the Multiple Sclerosis Impact Scale-29 (MSIS-29) score|Change from Baseline in EQ-5D Summary Score|Convenience|Correlation between VAS and MSIS29|Correlation between VAS and Convenience questionnaire",False,
NCT01228396,AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis,"A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis",UNKNOWN,2009-05,2011-05,2012-03,2011-08-18,2010-10-26,INTERVENTIONAL,PHASE2,20.0,ACTUAL,Daval International Limited,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,bladder|optic neuritis|secondary progressive multiple sclerosis|AIMSPRO|hyperimmune caprine serum|hyperimmune goat serum,United Kingdom,London,,1,Hyperimmune caprine serum against HIV lysate,DRUG,Change in average voided volume,Change in average 24-hour frequency|Change in visual acuity and colour vision|Change in average 24-hour incontinence|Change in urgency score|Change in I-QOL score|Change in Whittington Urgency Score|Change in Kurtzke EDS|Change in MSIS-29|Change in MS FC|Change in MS WS,False,
NCT07066137,Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices,"Motor Planning, Execution, and Modulation in Healthy Individuals and Patients With Movement Disorders or Neuromuscular Diseases Using Traditional Physical Activity or Advanced Devices to Enhance Motor Learning and Sensorimotor Processing",ACTIVE_NOT_RECRUITING,2024-05-05,2026-05-05,2026-12-31,2025-07-15,2025-07-15,INTERVENTIONAL,NA,150.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Healthy Individuals (Controls)|Parkinson Disease|Multiple Sclerosis|Alzheimer Disease|Dementia|Stroke,Virtual Reality|motor rehabilitation|cognitive rehabilitation|Functional Recovery,Italy,Messina,Italy/Me,1,CAREN|Control group,DEVICE|OTHER,Amplitude of Motor-Related Event-Related Potentials (ERPs) During Gesture Execution Assessed by EEG.,Respiratory Exchange Ratio (RER) During Submaximal Exercis|Change in Global Cognitive Function as Measured by MoCA Total Score,False,
NCT04114994,Longitudinal Cognitive Assessment by BoCA,Longitudinal Cognitive Assessment by BoCA,RECRUITING,2019-10-01,2029-10-01,2029-10-01,2024-08-01,2019-10-03,OBSERVATIONAL,,10000.0,ESTIMATED,Alzheimer's Light LLC,INDUSTRY,,,Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia|Frontotemporal Dementia|Parkinson Disease|Multiple Sclerosis|TBI,,United States,Miami,Florida,1,Boston Cognitive Assessment (BoCA),DIAGNOSTIC_TEST,Boston Cognitive Assessment (BoCA),,False,
NCT02529839,Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS),Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis,UNKNOWN,2015-10,2017-10,2017-10,2015-08-20,2015-08-20,INTERVENTIONAL,NA,20.0,ESTIMATED,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,MS|BMT,,,,0,Autologous bone marrow transplantation|Fludarabine|Cyclophosphamide|Alemtuzumab,PROCEDURE|DRUG|DRUG|DRUG,Engraftment parameters of Neutrophils and Platelets|Transplant related mortality by Day 100,"Changes in the Expanded Disability Status Scale (EDSS score, as compared to baseline)|Overall survival (OS) at 1 year|Progression-free survival (PFS) at 1 year|Changes in MRI activity|Changes in MRI activity",False,
NCT02746705,Pilot Study of Transcranial Direct Current Stimulation (tDCS),Pilot Study of Transcranial Direct Current Stimulation (tDCS),COMPLETED,2016-04,2018-09-30,2018-09-30,2020-05-08,2016-04-21,INTERVENTIONAL,NA,31.0,ACTUAL,NYU Langone Health,OTHER,Stony Brook University,OTHER,Multiple Sclerosis,,United States,New York,New York,1,Transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation|Cognitive Training Program,DEVICE|DEVICE|BEHAVIORAL,The Number of Participants Completing at Least 80% of the Targeted Sessions.|Change in Total Score of the Brief International Assessment of Cognition in MS (BICAMS),Change in Score on Modified Fatigue Impact Scale (MFIS)|Change in Score of CogState Brief Battery (CBB),True,2020-05-08
NCT05882695,Study of SPG302 in Healthy Volunteers and ALS Participants,"A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Single and Multiple Dose Escalation Study in Healthy Volunteers and an Expansion Cohort in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302",COMPLETED,2023-07-03,2025-06-27,2025-06-27,2025-06-29,2023-05-31,INTERVENTIONAL,PHASE1,88.0,ACTUAL,Spinogenix,INDUSTRY,Novotech (Australia) Pty Limited,INDUSTRY,Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis|regenerative|synapse,Australia,North Ryde,New South Wales,4,SPG302|Placebo,DRUG|DRUG,Safety and tolerability in healthy volunteers (SAD cohort)|Safety and tolerability in healthy volunteers (SAD food effect cohort)|Safety and tolerability in healthy volunteers (MAD cohort)|Safety and tolerability in participants with ALS,Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD cohort)|Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD food effect cohort)|Plasma pharmacokinetics of SPG302 in healthy volunteers (MAD cohort)|Plasma pharmacokinetics of SPG302 in participants with ALS|Clinical outcomes of multiple oral doses of SPG302 in participants with ALS|Clinical efficacy measures of SPG302 in participants with ALS,False,
NCT04657666,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis",COMPLETED,2020-12-21,2022-05-04,2022-05-10,2023-07-20,2020-12-08,INTERVENTIONAL,PHASE3,68.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Spasticity in Participants With Multiple Sclerosis,spasticity|multiple sclerosis|nabiximols|adjunctive therapy|velocity-dependent muscle tone,Czechia,Choceň,,16,Nabiximols|Placebo,DRUG|DRUG,Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6),"Change From Baseline in Lower Limb Muscle Tone-4 (LLMT-4)|Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in Blood Pressure|Change From Baseline in Heart Rate|Change From Baseline in Weight|Change From Baseline in Body Mass Index|Change From Baseline in Clinical Laboratory Test Values|Change From Baseline in Erythrocytes|Change From Baseline in Hemoglobin|Change From Baseline in Hematocrit Ratio|Change From Baseline in Erythrocyte Mean Corpuscular Volume|Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin|Change From Baseline in Electrocardiogram Parameters|Change From Baseline in Electrocardiogram Pulse Rate|Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (CSSRS)|Plasma Concentrations for Δ9-tetrahydrocannabinol (THC)|Plasma Concentrations for Relevant Metabolites, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-carboxy-Δ9-tetrahydrocannabinol (11-COOH-THC), for Δ9-tetrahydrocannabinol (THC)|Plasma Concentrations for Cannabidiol (CBD)|Plasma Concentrations for Relevant Metabolites, 7-hydroxy-cannabidiol (7-OH-CBD) and 7-carboxy-cannabidiol (7-COOH-CBD), for Cannabidiol (CBD)",True,2023-07-20
NCT05119569,A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS),"A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-03-01,2023-03-29,2026-12-30,2025-08-11,2021-11-15,INTERVENTIONAL,PHASE2,109.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Fullerton,California,17,Fenebrutinib|Placebo,DRUG|DRUG,DBT Phase: New Gadolinium (Gd) - Enhancing T1 Lesion Rate Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain Over 12 Weeks,DBT Phase: New or Enlarging T2 - Weighted Lesion Rate Observed on MRI Scans of the Brain Over 12 Weeks|DBT Phase: Proportion of Participants Free From Any New Gd - Enhancing T1 Lesions and New or Enlarging T2 - Weighted Lesions Observed on MRI Scans of the Brain Over 12 Weeks|DBT Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|OLE Phase: Number of Participants With AEs and SAEs|Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)|Plasma Concentrations of Fenebrutinib at Specified Timepoints,True,2024-06-12
NCT06198972,Pelvic Proprioceptive Neuromuscular Facilitation (PNF) Exercises in Multiple Sclerosis Patients,"The Effect of Pelvic Proprioceptive Neuromuscular Facilitation (PNF) Exercises on Strength, Balance and Walking Skills in Multiple Sclerosis Patients.",COMPLETED,2024-01-01,2024-03-01,2024-03-15,2025-04-17,2024-01-10,INTERVENTIONAL,NA,30.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Multiple Sclerosis,PNF|Pelvic exercise|strength,Turkey (Türkiye),Gaziantep,,1,Pelvic Pnf exercises|Strength exercises,OTHER|OTHER,Muscle Strength:|Figure of 8 walk test|12 ıtem walk test,,False,
NCT01328379,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,"Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis",COMPLETED,2011-03,2012-04,2012-07,2013-09-05,2011-04-04,INTERVENTIONAL,PHASE3,430.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,,United States,Cullman,Alabama,70,Dalfampridine-ER 5mg|Dalfampridine-ER 10mg|Placebo,DRUG|DRUG|OTHER,"Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).","Change From Baseline in Walking Speed Near Minimum Plasma Concentration at Steady State (CminSS) of Placebo, Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).|Change From Baseline in 12-item MS Walking Scale (MSWS-12) at Visit 3|Change From Baseline in MSWS-12 at Visit 2|Change From Baseline in Six-Minute Walk Distance at Visit 2|Change From Baseline in EuroQol Group 5 Dimensions (EQ-5D) Scores at Visit 3.|Change From Baseline in EQ-5D Visual Analogue Self-rating (VAS) Score at Visit 3.",True,2013-08-13
NCT04153773,OCT and Early Cognitive Impairment in Multiple Sclerosis,Retinal Thickness as a Potential Biomarker of Neurodegeneration and Early Cognitive Impairment in Patients With Multiple Sclerosis,COMPLETED,2018-08-01,2019-06-01,2019-09-01,2019-11-13,2019-11-06,OBSERVATIONAL,,90.0,ACTUAL,Mansoura University Hospital,OTHER,,,Multiple Sclerosis,,Egypt,Al Mansurah,Dakahlia Governorate,1,OCT,DIAGNOSTIC_TEST,Optical coherence tomography,Cognitive assessment|Expanded Disability Status Scale (EDSS),False,
NCT03276195,Studies in Patients With Tuberous Sclerosis Complex,"Studies in Patients With Rett Syndrome, Tuberous Sclerosis Complex, Neurofibromatoses, and Other Neurodevelopmental Disorders",COMPLETED,2016-05-01,2023-11-27,2023-11-27,2023-11-29,2017-09-08,OBSERVATIONAL,,32.0,ACTUAL,Translational Genomics Research Institute,OTHER,United States Department of Defense,FED,Tuberous Sclerosis Complex,Neurodevelopmental Disorder|Genomics|Genetics,United States,Phoenix,Arizona,1,,,Next Generation Sequencing to Measure Phenotypic Variability,,False,
NCT00276172,Open-Label Natalizumab Safety Extension Study,"An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803",COMPLETED,2003-12,2005-10,2006-01,2009-06-22,2006-01-13,INTERVENTIONAL,PHASE3,1615.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Cambridge,Massachusetts,1,Natalizumab,DRUG,"The safety endpoints under consideration will be the incidence of adverse events, changes in laboratory evaluations, vital signs, and physical examinations. The incidence of development of antibodies to natalizumab will also be assessed.",EDSS scores and assessments of relapse.,False,
NCT04550650,Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients,Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients,COMPLETED,2018-04-06,2020-04-06,2020-09-01,2022-04-05,2020-09-16,INTERVENTIONAL,NA,4.0,ACTUAL,Somogy Megyei Kaposi Mór Teaching Hospital,OTHER,,,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Primary Progressive",multiple sclerosis|posture|neurorehabilitation|balance,Hungary,Kaposvár,Somogy County,1,Training groupe|PNF|Spinning grp|Balance,OTHER|OTHER|OTHER|OTHER,Postural instability|EQ-5D quality of life|balance test|mobility test|depression scale|MSIS-29,,False,
NCT00468182,Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis,Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis,COMPLETED,2007-04,2011-12,2011-12,2015-05-07,2007-05-02,OBSERVATIONAL,,24.0,ACTUAL,"Rutgers, The State University of New Jersey",OTHER,Bayer,INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Interferon beta|plasmacytoid dendritic cells,United States,New Brunswick,New Jersey,1,Interferon-beta 1b (Betaseron),DRUG,Relative gene expression in plasmacytoid dendritic cells (pDCs),,False,
NCT05395624,"Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers","A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers",RECRUITING,2023-02-02,2026-01-01,2026-05-01,2025-05-02,2022-05-27,INTERVENTIONAL,PHASE1|PHASE2,65.0,ESTIMATED,"Ashvattha Therapeutics, Inc.",INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS)|Parkinson Disease (PD)|Alzheimer Disease (AD)|Multiple Sclerosis (MS),,United States,San Francisco,California,3,18F-OP-801,DRUG,The number of participants with treatment emergent adverse events (Safety and Tolerability),"Measurement of biodistribution of 18F-OP-801 for each participant|Measurement of clearance of 18F-OP-801 for each participant|Assess ability of 18F-OP-801 to detect regions of neuroinflammation in ALS, AD, MS, and PD participants|Assess test/retest imaging repeatability|Correlation between plasma NfL levels and degree of 18F-OP-801 uptake in each participant|Correlation between relevant clinical scales and degree of 18F-OP-801 uptake in each participant",False,
NCT04904016,Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity,"A Single Center, Open, Non-controlled Pilot Investigation to Evaluate FLowOx2.0™ for Experimental Treatment of Spasticity With Concomitant Pain in Multiple Sclerosis, Using Intermittent Negative Pressure Affecting Arteriovenous Reflex",UNKNOWN,2021-05-28,2021-12,2021-12,2021-05-27,2021-05-27,INTERVENTIONAL,NA,10.0,ESTIMATED,Otivio AS,INDUSTRY,Haukeland University Hospital,OTHER,"Multiple Sclerosis|Spasticity, Muscle|Pain",Blood flow|FlowOx™|Stiffness,Norway,Bergen,,1,FlowOx™,DEVICE,"Self-Reported Spasticity, using Numerical Rating Scale:","Desire to continue treatment|Self-Reported Spasticity, using Numerical Rating Scale|Spasticity - modified Ashworth Scale|Self-reported pain using Numerical Rating Scale|T25-FW|Expanded Disability Status Scale|Self-reported sleep (NRS)|Hospital Anxiety and Depression Scale|Fatigue Scale for Motor and Cognitive Functions|Multiple Sclerosis Impact Scale (MSIS-29)|SDMT|Change in medication|Compliance|Safety- Incidence of device related adverse and serious adverse events",False,
NCT02100020,Implementing Physical Activity Guidelines for Adults With MS,A Community-based Randomized Controlled Trial Testing Implementation of the New Canadian Physical Activity Guidelines for Adults With Multiple Sclerosis.,COMPLETED,2014-05,2018-03-31,2018-03-31,2018-05-31,2014-03-31,INTERVENTIONAL,NA,94.0,ACTUAL,McMaster University,OTHER,,,Multiple Sclerosis,physical activity|exercise guidelines|multiple sclerosis,Canada,Hamilton,Ontario,2,Direct Referral to physical activity,OTHER,Adherence to the Physical Activity Guidelines,Physical Fitness|Perceived Quality of Life|Fatigue|Mobility|Blood markers of cardiovascular disease risk,False,
NCT03480854,The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative,Improving Quality and Value of Multiple Sclerosis Care at the Microsystem Level: The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative,COMPLETED,2017-07-01,2020-06-30,2020-12-31,2021-05-07,2018-03-29,INTERVENTIONAL,NA,694.0,ACTUAL,Dartmouth-Hitchcock Medical Center,OTHER,MGH Multiple Sclerosis Clinic|University of Vermont|Neurology Associates Multiple Sclerosis Center of Greater Orlando|Concord Hospital,UNKNOWN|OTHER|UNKNOWN|OTHER,Multiple Sclerosis,,United States,Maitland,Florida,4,Quality Improvement,OTHER,Disease modifying therapy utilization,Clinical outcome for Depression|Clinic Outcome for Anxiety|Clinic Outcomes on Cognitive Function|Clinic Outcomes on mobility|Clinic Outcomes on fine motor skills and activities of daily living|Clinic Outcomes on stigma associated with MS|Clinic Outcomes on ability to participate in social roles and activities|Clinic Outcomes on satisfaction with social roles and activities|Clinic Outcomes for sleep disturbance|Clinic Outcomes for communication|Clinic Outcomes for Vitamin D levels in MS patients|Clinic Outcomes for fatigue|Clinic Outcomes for assesment of patient health status|Clinic Outcomes for satisfaction of treatment by medication|Clinic Outcomes for the effects of MS on the patient|Clinic Outcomes for the presence of a MS relapse|Clinic Outcomes reporting of MS patient daily symptoms|Medical History|Hospitalization|Demographic information|Medication|MRI utilization|Exercise|System level measure the patient experience for ambulatory care.|System level measure of Health Care Quality,False,
NCT02282878,The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis,The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis,COMPLETED,2014-09,2018-12-19,2019-12-08,2021-04-19,2014-11-05,INTERVENTIONAL,NA,14.0,ACTUAL,Yale University,OTHER,,,Multiple Sclerosis,High Sodium Diet|Low Sodium Diet|MS,United States,New Haven,Connecticut,1,High/Low Sodium Diet,DIETARY_SUPPLEMENT,Number of Th17 cells,Regulatory T cell function,False,
NCT01628276,Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study,,COMPLETED,2012-07,2013-09,2013-10,2014-09-12,2012-06-26,INTERVENTIONAL,NA,45.0,ACTUAL,"Sina Hospital, Iran",OTHER,,,MS (Multiple Sclerosis),Multiple Sclerosis|MRI Scans,Iran,Tehran,Tehran Province,1,Cog Rehab,BEHAVIORAL,functional connectivity,,False,
NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,"A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2006-01,2009-07,2009-07,2012-04-11,2006-02-10,INTERVENTIONAL,PHASE3,1272.0,ACTUAL,Novartis,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis|FTY720|Fingolimod,Australia,Woodville South,South Australia,115,Fingolimod 1.25 mg|Fingolimod 0.5 mg|Placebo,DRUG|DRUG|DRUG,Estimated Annualized Aggregate Relapse Rate (ARR),Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)|Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline,True,2011-03-16
NCT03205280,Clinical Decision Support System (CADIMS) for MS Diagnostic,Assessment of a Clinical Decision Support System (CADIMS) for Improving Multiple Sclerosis Diagnostic Accuracy,COMPLETED,2017-10-11,2022-12-07,2022-12-07,2023-04-12,2017-07-02,OBSERVATIONAL,,200.0,ACTUAL,Rennes University Hospital,OTHER,Association Neuro-Bretagne|Institut National de Recherche en Informatique et en Automatique|Groupement de Coopération Sanitaire e-Santé Bretagne|Institut de Recherche Technologique b<>com,UNKNOWN|OTHER|UNKNOWN|UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting, Computer-Assisted Diagnosis, MRI, Diagnosis, Treatment Efficacy",France,Lorient,,5,,,"Concordance among the number of new T2 lesions, the total number of T2 lesions and the number of gadolinium enhanced lesions on brain MRIs identified by the CADIMS tool and by the expert consensus",,False,
NCT03568760,Finding the Right Words in Neurogenic Communication Disorders,"Finding the Right Words in Neurogenic Communication Disorders: Naming of Objects and Actions, Communicative Strategies in Conversation and Effects of Training",COMPLETED,2016-01-01,2021-12-31,2021-12-31,2022-03-16,2018-06-26,INTERVENTIONAL,NA,17.0,ACTUAL,Göteborg University,OTHER,The Swedish Research Council|Swedish Council for Working Life and Social Research,OTHER_GOV|OTHER,Anomia|Stroke|Aphasia|Parkinson Disease|Multiple Sclerosis,Anomia,Sweden,Gothenburg,Västra Göraland,1,Semantic feature analysis|Comprehension training,BEHAVIORAL|BEHAVIORAL,Naming ability in the Object & Action Naming Battery,Sustained change in naming ability in the Object & Action Naming Battery|Naming of 20 individually chosen training words|Sustained change in naming of 20 individually chosen training words|The Communication Outcome After Stroke (COAST) scale|Sustained change in the Communication Outcome After Stroke (COAST) scale|The Stroke Aphasia Quality of Life (SAQOL-39)|Sustained change in the Stroke Aphasia Quality of Life (SAQOL-39)|The Communicative Participation Item Bank (CPIB)|Sustained change in the Communicative Participation Item Bank (CPIB)|Retelling of events in video clips|Sustained change in retelling of events in video clips,False,
NCT06136923,"An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer","An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer",COMPLETED,2023-10-19,2024-04-18,2024-05-06,2024-05-13,2023-11-18,INTERVENTIONAL,NA,194.0,ACTUAL,"Click Therapeutics, Inc.",INDUSTRY,,,Multiple Sclerosis|Lung Cancer|Breast Cancer,Prescription digital therapeutic (PDT)|Software as a Medical Device (SaMD)|Smartphone app|Attention Biases|Cognition|Multiple Sclerosis|Lung Cancer|Breast Cancer,United States,New York,New York,1,CT-100-D-004-A|CT-100-D-004-B,DEVICE|DEVICE,Change in Patient Reported Outcomes,Change in Pain Severity and Pain Interference|Change in Pain Catastrophizing Scale|Change in indication-specific measures MS|Change in indication-specific measures Cancer|Proportion of participants with an improvement|Engagement with Study App,False,
NCT02798055,Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis,"A National, Observational, Multi-center Registry to Examine the Characteristics of Patients With Systematic Sclerosis Digital Ulcers and Assess Bosentan Treatment.",COMPLETED,2016-09-30,2019-06-30,2019-06-30,2019-07-05,2016-06-14,OBSERVATIONAL,,148.0,ACTUAL,Elpen Pharmaceutical Co. Inc.,INDUSTRY,,,Systematic Sclerosis|Digital Ulcer|Scleroderma,,Greece,Athens,,1,Bosentan group,DRUG,Reynaud Severity Scale|Number of Ulcers|Modified Rodnan Skin Score - MRSS|Complications of systems,Adverse Events,False,
NCT05950308,Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies,Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies,COMPLETED,2022-01-05,2022-07-14,2022-07-14,2023-07-18,2023-07-18,OBSERVATIONAL,,61.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Percentage of participants achieving humoral response (i.e. immune response) to an FDA-authorized COVID 19 vaccine in ofatumumab treated participants|Percentage of participants achieving T-cell response (i.e. immune response) to an FDA-authorized COVID 19 vaccine in ofatumumab treated participants,,False,
NCT04380220,Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis,Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis,UNKNOWN,2017-09-07,2020-08-31,2020-12-31,2020-05-21,2020-05-08,OBSERVATIONAL,,80.0,ACTUAL,Regina Elena Cancer Institute,OTHER,University of Roma La Sapienza|Icahn School of Medicine at Mount Sinai,OTHER|OTHER,Multiple Sclerosis|Relapse,multiple sclerosis|relapse|coagulation|complement|cerebral blood flow,United States,New York,New York,3,Blood samples and processing,DIAGNOSTIC_TEST,plasma concentration of coagulation factor|plasma concentration of coagulation factor|plasma concentration of coagulation factor|plasma concentration of coagulation factor|plasma concentration of coagulation factor|plasma concentration of coagulation factor|plasma concentration of coagulation factor,Brain MRI hemodynamic changes at DSC 3.0-T MRI|Brain MRI hemodynamic changes at DSC 3.0-T MRI|Brain MRI hemodynamic changes at DSC 3.0-T MRI,False,
NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS,ACTIVE_NOT_RECRUITING,2021-07-23,2025-11-11,2026-02-13,2025-08-19,2021-03-09,INTERVENTIONAL,PHASE3,185.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Ofatumumab|relapsing multiple sclerosis|relapsing-remitting MS|MS therapy|RMS|Relapsing MS|Glatiramer acetate|IFNβ-1b|IFNβ-1a|peg-IFNβ-1a|Teriflunomide|Dimethyl fumarate|Diroximel fumarate|OMB157|adult,France,Bayonne,Bayonne Cedex,41,Ofatumumab|First line DMT,DRUG|DRUG,Number of participants with no evidence of disease activity (NEDA-3),"Number of relapses|Annual relapse rate|Percentage of relapse-free patients and proportion of relapse free patients with MRI activity free|Time to 3 month Confirmed Disability Worsening (CDW) and time to 6-month Confirmed Disability Worsening (CDW)|Change in expanded disability status scale (EDSS)|Percentage of disability-progression free patients|Number of Gd+ T1 lesions of brain|The number and percentage of patients with Treatment emergent adverse events (TEAE) or adverse events reports|Volume of Gd+ T1 lesions of brain|Number of new/enlarging T2 lesions of brain|Volume of new enlarging T2 lesions of brain|Mean time to first relapse|Percentage of SAEs, and SAEs with hospitalizations|Percentage of treatment compliance of participants|Percentage of patient with AEs|Percentage of withdrawn patients|Percentage of treatment discontinuation or interruptions",False,
NCT04937725,Reading Problems Associated With Central Nervous System (CNS) Pathologies.,Reading Problems Associated With Central Nervous System Pathologies,COMPLETED,2021-06-01,2022-11-01,2022-11-30,2023-02-02,2021-06-24,OBSERVATIONAL,,75.0,ACTUAL,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA,OTHER,Hospital Clínico Universitario de Valladolid|Hospital del Rio Hortega,OTHER|OTHER,"Injury Brain|Eye Abnormalities|Multiple Sclerosis|Parkinson Disease|Ataxia, Cerebellar",eye tracking,Spain,Valladolid,,1,eye tracking,DIAGNOSTIC_TEST,Reading performance,Reading performance,False,
NCT07160218,Effects of tDCS and Cognitive Rehabilitation on Cognition and Neural Plasticity in MS Patients,The Effect of Trans-cranial Direct Current Stimulation and Cognitive Rehabilitation on Cognitive Functions and Neuronal Plasticity inPatients With Multiple Sclerosis: A Randomized Controlled Trial,COMPLETED,2024-01-02,2025-08-01,2025-08-15,2025-09-08,2025-09-08,INTERVENTIONAL,NA,45.0,ACTUAL,Shahid Beheshti University of Medical Sciences,OTHER,,,Multiple Sclerosis,,Iran,Tehran,,1,tDCS|Cognitive Rehabilitation|Sham tDCS,DEVICE|DEVICE|DEVICE,Change in verbal memory performance measured by California Verbal Learning Test-II (CVLT-II)|Change in attention performance measured by Integrated Visual and Auditory Continuous Performance Test (IVA-2)|Change in visuospatial memory performance measured by Rey-Osterrieth Complex Figure Test|Change in serum BDNF levels (ng/mL)|Change in white matter integrity measured by Diffusion Tensor Imaging (DTI)|Change in acetylcholinesterase (AChE) activity in blood (U/mL),,False,
NCT06056960,Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part B,Preventing the Progression of Physical Disability and Promoting Brain Functional Adaptation in People With Multiple Sclerosis: Integration of Early Rehabilitative Treatment and Multimodal Clinical and Instrumental Assessment - Part B,UNKNOWN,2024-07-15,2025-01-30,2025-01-30,2023-09-28,2023-09-28,INTERVENTIONAL,NA,80.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,IRCCS San Raffaele|Azienda Sanitaria Locale di Cagliari,OTHER|OTHER,Multiple Sclerosis,early phase|non-disabled,Italy,Cagliari,,3,Tailored Physical Activity,OTHER,Fatigue Severity Scale (FSS),Differences in oxygenated hemoglobin (Delta oxyHb)|Six Minute walking test (6MWT)|Number of steps/day|Endurance walking capacity,False,
NCT00424359,Ambulation Study in Multiple Sclerosis,A Prospective Study of Clinical Indices as Predictors of Ambulatory Effectiveness in Multiple Sclerosis,COMPLETED,2005-04,,2009-01,2011-05-16,2007-01-19,OBSERVATIONAL,,40.0,ESTIMATED,"Brown, Theodore R., M.D., MPH",INDIV,,,Multiple Sclerosis,Mulitple Sclerosis|Ambulation,,,,0,,,,,False,
NCT03787446,PET Study in Multiple Sclerosis,Positron Emission Tomography (PET) Imaging Study in Relapsing-Remitting and Primary-Progressive Multiple Sclerosis (MS): Correlations With Advanced MRI in MS,UNKNOWN,2019-03-26,2020-03,2020-09,2019-04-22,2018-12-26,OBSERVATIONAL,,9.0,ESTIMATED,University of British Columbia,OTHER,Hoffmann-La Roche,INDUSTRY,Multiple Sclerosis,,Canada,Vancouver,British Columbia,1,,,Whole Brain PBR28 binding,Myelin Water Imaging by MRI|Optical Coherence Tomography|MS Spectroscopy,False,
NCT06877273,Improving Cognitive Recovery in Multiple Sclerosis,CIRCuiTS MS: Improving Cognitive Recovery in Multiple Sclerosis,RECRUITING,2025-07-17,2026-09-15,2026-09-15,2025-07-22,2025-03-14,INTERVENTIONAL,NA,24.0,ESTIMATED,King's College London,OTHER,King's College Hospital NHS Trust,OTHER,Multiple Sclerosis,Cognitive rehabilitation|cognitive training|cognitive remediation|thinking skills|randomised controlled trial|feasibility|acceptability|metacognition|cognitive remediation therapy|cognitive dysfunction|cognitive function,United Kingdom,London,East of England,1,CIRCuiTS-MS,BEHAVIORAL,Recruitment rate|Ethnic enrolment diversity|Gender enrolment diversity|Completion rate|Midpoint retention|Dropout|Serious adverse events|Manageability of adverse events|Data completeness|Specific measure completeness|Operational feasibility|Adherence: Therapy|Adherence: Independent sessions|Specific measure acceptability|Program acceptability,Goal Attainment Scale|Measure of Insight into Cognition|Brief International Cognitive Assessment for Multiple Sclerosis|Digit Span|Controlled Oral Word Association Test|Patient Health Questionnaire-9|Generalised Anxiety Disorder Scale|Fatigue Severity Scale|Work and Social Adjustment Scale,False,
NCT01453868,The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis,The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis,UNKNOWN,2011-10,2012-03,2012-06,2011-10-18,2011-10-18,INTERVENTIONAL,EARLY_PHASE1,60.0,ESTIMATED,Nelson Mandela Metropolitan University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|non impact aerobics,United States,Gaylord,Michigan,1,Non Impact Aerobics|Passive : lecture series,OTHER|OTHER,Biodex Scale Balance score: Automated,Pre and post intervention questionaire,False,
NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis,COMPLETED,2015-08-11,2017-04-24,2018-04-23,2019-06-27,2015-08-18,INTERVENTIONAL,PHASE3,218.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Tecfidera|DMF|dimethyl fumarate,United States,Gilbert,Arizona,34,dimethyl fumarate,DRUG,"Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK)|Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cells Subsets|Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: B-Cell Subsets|Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Myeloid and Natural Killer (NK) Cells|Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cell Cytokines|Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Very Late Antigen-4 (VLA-4/Lymphocyte Function-Associated Antigen-1 (LFA-1) Antigen",Change From Baseline in Immunoglobulin A (IgA) up to 48 Weeks|Change From Baseline in Immunoglobulin M (IgM) up to 48 Weeks|Change From Baseline in Immunoglobulin G (IgG) up to 48 Weeks|Change From Baseline in Immunoglobulin G (IgG) Subclasses up to 48 Weeks,True,2019-06-27
NCT02549703,Mitochondrial Dysfunction and Disease Progression,Mitochondrial Dysfunction and Disease Progression,COMPLETED,2015-09,2018-09-27,2018-09-27,2019-02-20,2015-09-15,OBSERVATIONAL,,47.0,ACTUAL,Icahn School of Medicine at Mount Sinai,OTHER,Columbia University|New York Stem Cell Foundation Research Institute,OTHER|OTHER,Clinically Isolated Syndrome|Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,multiple sclerosis|progressive multiple sclerosis|mitochondria|neurodegeneration,United States,New York,New York,1,,,Spare respiratory capacity|Oxygen consumption rate,Multiple Sclerosis Functional Composite (MSFC) Score|Multiple Sclerosis Functional Composite (MSFC) Score|Expanded Disability Status Scale|MS Impact Scale-29 (MSIS-29),False,
NCT01428505,[18F]PBR111 and Microglial Activation in Multiple Sclerosis,A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis,TERMINATED,2011-07,2013-03,2013-03,2016-02-08,2011-09-05,INTERVENTIONAL,PHASE2,50.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,,United Kingdom,London,London,1,[18F]PBR111,RADIATION,VT of [18F]PBR111,Test-retest variability of regional [18F]PBR111|regional [18F]PBR111 VT|White matter lesion load and distribution|Cortical grey matter lesion load and distribution|Genetic polymorphisms related to the TSPO gene,False,
NCT05697523,Multiple Sclerosis and Respiratory and Functional Capacity,"Comparison of Respiratory, Physical Activity and Functional Capacities of Patients wıth Mild Relapsing Remitting Multiple Sclerosis and Healthy Controls",COMPLETED,2020-01-01,2021-01-01,2021-01-01,2023-01-26,2023-01-26,OBSERVATIONAL,,80.0,ACTUAL,Nigde Omer Halisdemir University,OTHER,Pamukkale University,OTHER,Multiple Sclerosis,Multiple Sclerosis|functional capacity|physical activity|respiratory system|Relapsing-Remitting,Turkey (Türkiye),Denizli,,1,"Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test",OTHER,Pulmonary Function Tests- FEV1/FVC|Pulmonary Function Tests- FVC|Pulmonary Function Tests- FEV1|Pulmonary Function Tests- PEF|Pulmonary Function Tests- MVV|Functional Capacity|International Physical Activity Questionnaire - Short Form,Expanded Disability Status Scale,False,
NCT04062331,Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis,Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis,UNKNOWN,2019-10-01,2021-10-01,2022-10-01,2019-08-21,2019-08-20,INTERVENTIONAL,PHASE1|PHASE2,90.0,ESTIMATED,Maimónides Biomedical Research Institute of Córdoba,OTHER,Isaac Tunez-Fiñana|Eduardo Agüera-Morales,UNKNOWN|UNKNOWN,Multiple Sclerosis,clinical trial|multiple sclerosis|neurodegenerative diseases|transcranial magnetic stimulation|deep brain stimulation|neurochemistry,,,,0,Transcranial Magnetic Stimulation (TMS)|Placebos,DEVICE|DRUG,Clinical activity of the disease|Comprehensive clinical assessment of the disease|Cognitive function,Assessment of fatigue|Depression assessment|Image analysis|Lipoperoxidation molecules|Carbonylated proteins|Complete blood count|glucose|Routine serum lipids|Routine serum proteins|Transaminases|creatine kinase (CK)|lactate dehydrogenase,False,
NCT01492023,The Effects of Attention Retraining in MS,"The Effects of Attention Retraining on Cognitive Performance, QoL and Perceived Cognitive Impairment in MS - a Single Blind, Randomized, Controlled Study",COMPLETED,2010-11,2012-04,2012-05,2013-03-11,2011-12-14,OBSERVATIONAL,,97.0,ACTUAL,Finnish MS Society,OTHER,"Social Insurance Institution, Finland|Tampere University Hospital|Seinajoki Central Hospital",OTHER|OTHER|OTHER,Multiple Sclerosis,neuropsychological|rehabilitation|multiple sclerosis|RCT study,Finland,Masku,,3,neuropsychological rehabilitation,BEHAVIORAL,Objective cognitive performance|Subjective cognitive performance|Goal achievement,Quality of life|Objective cognitive performance|Mood|Fatigue|Subjective cognitive performance|The impact of the disease,False,
NCT01074346,Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis,"A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif®) Therapy for Korean Patients With Multiple Sclerosis",COMPLETED,2008-08,2011-11,2011-11,2014-02-19,2010-02-24,OBSERVATIONAL,,60.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Interferon-beta 1-a,South Korea,"Seoul, 50 Ilwon-dong, Gangnam-gu",,1,Interferon-β-1a,DRUG,"Proportion of subjects with moderate to severe (grade 3-5) injection site reactions based on pain, bruising and/or transient (<24 hours) erythema; inflammation alone and with induration; necrosis at injection site; plastic surgery required for necrosis",Annual relapse rate|Change in EDSS|Change in MSTCQ|Time to first relapse|Incidence of side effects associated with Rebif therapy,False,
NCT00039988,Treatment of Multiple Sclerosis With Copaxone and Albuterol,Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol,COMPLETED,2001-11,2006-03,2007-11,2016-09-22,2002-06-20,INTERVENTIONAL,NA,40.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Autoimmunity Centers of Excellence,OTHER,Autoimmune Diseases|Multiple Sclerosis,Treatment Outcome|Multiple Sclerosis|Albuterol|Copolymer 1,United States,Boston,Massachusetts,1,Glatiramer acetate|Albuterol|Albuterol placebo,DRUG|DRUG|DRUG,"Change in each participant's disease status, as measured by the Multiple Sclerosis Functional Composite score (MSFC)|Glatiramer acetate-specific cytokine secretion of IL-13 cytokine secretion and IFN-gamma secretion by glatiramer acetate-reactive T-cell lines","Change in IL-5 secretion in the supernatants of lines stimulated with glatiramer acetate|Change in percentage of IL-12-producing monocytes by intracytoplasmic staining|Time to first exacerbation|Number and severity of exacerbations|MRI evidence as measured by T2 lesion volume, number of enhancing lesions on T1 weighted images, and measurements of atrophy (brain parenchymal fraction, atrophy index)|Expanded Disability Status Scale (EDSS), Ambulation Index (AI), and Disease Steps (DS) scores",False,
NCT05558683,Effect of the Vojta Therapy in Patients Multiple Sclerosis,Effect of the Vojta Therapy on Lipid Biomarkers Related to Myelin in Subjects With Multiple Sclerosis.,UNKNOWN,2022-12-01,2023-06-01,2023-12-01,2022-09-28,2022-09-28,INTERVENTIONAL,NA,25.0,ESTIMATED,Aymara Abreu Corrales,OTHER,University of Salamanca,OTHER,Multiple Sclerosis,Vojta Therapy|Bobath Therapy,,,,0,Randomized clinical trial.,OTHER,Respiratory function|Spasticity|Balance|Age|Time reaction,Myelin,False,
NCT02659956,Pathological Basis of MRI Signal Changes in Multiple Sclerosis,The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study,RECRUITING,2016-04-07,2080-02-26,2080-02-26,2025-08-01,2016-01-21,OBSERVATIONAL,,250.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Longitudinal Prospective Follow-Up|Natural History,United States,Bethesda,Maryland,1,,,"Correlation among in vivo imaging, postmortem imaging, and pathological characteristics of individual areas of tissue damage (""lesions"") in the brain, spinal cord, and retinas.",,False,
NCT01547351,Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire,Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire - A Phase 4 Pilot Study,COMPLETED,2011-12,2012-09,2012-09,2016-10-19,2012-03-07,OBSERVATIONAL,,103.0,ACTUAL,Mallinckrodt,INDUSTRY,,,Multiple Sclerosis,Relapse in multiple sclerosis|Psychometric properties of the patient self-report questionnaire|Evaluation of ARMS questionnaire,United States,Birmingham,Alabama,5,ARMS Questionnaire,OTHER,Total Composite Score (TCS),,False,
NCT05321927,TENS in Persons With MS,Transcutaneous Electrical Nerve Stimulation in Persons With MS,COMPLETED,2023-01-05,2024-03-15,2024-03-15,2025-04-10,2022-04-11,INTERVENTIONAL,NA,80.0,ACTUAL,University Medical Center Groningen,OTHER,,,Multiple Sclerosis,,Netherlands,Groningen,Provincie Groningen,1,Trancutaneous Electrical Nerve Stimulation|Strength training|Sham stimulation,DEVICE|OTHER|DEVICE,6-minute walk test|chair-stand test|Fatigue Severity Scale (FSS)|Modified Fatigue Impact Scale (MFIS)|12-item MS walking scale (MSWS-12),Elbow flexor muscle force (maximal and submaximal levels)|Knee extensor muscle force (maximal and submaximal levels)|Handgrip force|Effort during submaximal contractions with elbow flexors|Effort during submaximal contractions with knee extensors,False,
NCT02275741,Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis,Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis,COMPLETED,2009-10,2015-09,2016-11,2018-11-27,2014-10-27,OBSERVATIONAL,,226.0,ACTUAL,Dr. med. Micha Loebermann,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Vaccine|Antibody response|relaps rate|expanded disability status scale,Germany,Rostock,,1,"prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)",BIOLOGICAL,Specific antibody response to vaccination,MS relapse rate,False,
NCT03668990,"Feasability, Validty and Reliability of Inertial Sensors","Feasibility, Validity and Reliability Kinematic Movement Analysis of Upper Limb Movements in Stroke and MS Patients Using Inertial Sensors",COMPLETED,2017-10-01,2018-05-31,2018-05-31,2018-12-11,2018-09-13,INTERVENTIONAL,NA,18.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|Jessa Hospital,OTHER|OTHER,Multiple Sclerosis|CVA,,Belgium,Hasselt,,2,"IMUs (Xsens, MVN Studio)",OTHER,kinematic parameter|kinematic parameter,The Brunnström Fugl Meyer (BFM)|Action Research arm test|Trunk Impairment Scale|Manual Ability Measure-36 (questionnaire),False,
NCT03826056,Neurology Inpatient Clinical Education Trial,Neurology Inpatient Clinical Education Trial,COMPLETED,2019-02-01,2021-12-07,2021-12-07,2022-01-11,2019-02-01,INTERVENTIONAL,NA,50.0,ACTUAL,Dartmouth-Hitchcock Medical Center,OTHER,,,Myasthenia Gravis|Guillain-Barre Syndrome|Multiple Sclerosis|Seizures|Parkinsonism|Meningitis|Encephalitis|Headache|Vestibular Disorder|Spondylosis|Normal Pressure Hydrocephalus,clinical education,United States,Lebanon,New Hampshire,1,Current standard discharge educational intervention|Personalized discharge educational intervention,BEHAVIORAL|BEHAVIORAL,Patient satisfaction scores,,False,
NCT04441229,Mobile Attentional Bias Modification Training in Pediatric MS,"A Prospective, Observational Study of Mobile Attentional Bias Modification Training (ABMT) in the Pediatric Multiple Sclerosis (MS) Population",COMPLETED,2020-06-12,2021-03-25,2021-03-26,2022-03-04,2020-06-22,INTERVENTIONAL,NA,37.0,ACTUAL,NYU Langone Health,OTHER,,,Pediatric Multiple Sclerosis,,United States,New York,New York,1,ABMT mobile application,BEHAVIORAL,"Proportion of ""compliant"" participants",Preliminary efficacy composite score,False,
NCT02519413,Tecfidera Lymphocyte Chart Review,"A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)",COMPLETED,2015-07,2016-02,2016-02,2016-08-26,2015-08-10,OBSERVATIONAL,,483.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,lymphocyte|serious infections|opportunistic infections|Relapsing Forms,United States,Homewood,Alabama,10,dimethyl fumarate,DRUG,Estimated absolute lymphocyte count (ALC) change from baseline following Tecfidera initiation|Estimated CD4+ count change from baseline following Tecfidera initiation|Estimated CD8+ count change from baseline following Tecfidera initiation,"Raw absolute counts for leukocyte, lymphocyte, CD4+/CD8+ ratio following Tecfidera initiation|Raw absolute counts for additional lymphocyte subsets (other than CD4+ and CD8+)|Change from baseline for leukocyte, lymphocyte, CD4+/CD8+ ratio following Tecfidera initiation|Change from baseline for additional lymphocyte subsets (other than CD4+and CD8+) following Tecfidera initiation|Percentage change from baseline for leukocyte, lymphocyte, CD4+/CD8+ ratio following Tecfidera initiation|Percentage change from baseline for additional lymphocyte subsets (other than CD4+and CD8+) following Tecfidera initiation|Time to pre-determined lymphocyte counts following Tecfidera initiation|Potential predictors of low lymphocyte counts following Tecfidera initiation",False,
NCT06746896,Retrospective Study on the Role of SCFA Modulation in Multiple Sclerosis,A Retrospective Study on the Role of Short-chain Fatty Acids Modulation in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-11-17,2022-11-24,2025-09-30,2024-12-30,2024-12-24,OBSERVATIONAL,,40.0,ACTUAL,Prof. Massimo Filippi,OTHER,Università Vita-Salute San Raffaele,OTHER,Multiple Sclerosis,Gut-brain axis|SCFA|Microbiota,Italy,Milan,Italy,1,,,Modulation of SCFAs levels in MS patients versus healthy controls.,Gut microbial composition in MS patients versus healthy controls,False,
NCT04285346,Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B),A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B),COMPLETED,2020-04-08,2021-06-25,2022-08-30,2023-04-04,2020-02-26,INTERVENTIONAL,PHASE2,23.0,ACTUAL,Marinus Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis,,United States,Los Angeles,California,7,Ganaxolone,DRUG,Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period,Percentage of Participants Experiencing a >=50 Percent Reduction in 28-day Primary Seizure Frequency Through the End of the 12-week Treatment Period Compared to the Baseline Period,True,2023-04-04
NCT04267926,MitoQ for Fatigue in Multiple Sclerosis (MS),MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial,ACTIVE_NOT_RECRUITING,2020-04-01,2024-10-15,2026-03-31,2025-04-06,2020-02-13,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis|Fatigue,Multiple Sclerosis|Fatigue|Mitochondrial,United States,Portland,Oregon,1,20 mg MitoQ|Placebo|40mg of MitoQ,DRUG|DRUG|DRUG,Modified Fatigue Inventory Scale (MFIS),Symbol Digit Modalities Test (SDMT)|Expanded Disability Status Scale (EDSS)|Beck's Depression Inventory (BDI),False,
NCT03464448,Mechanistic Studies of Teriflunomide in RRMS,Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS,COMPLETED,2018-04-17,2021-10-13,2021-10-13,2022-12-27,2018-03-14,OBSERVATIONAL,,30.0,ACTUAL,University of Michigan,OTHER,,,Relapsing Remitting Multiple Sclerosis,Teriflunomide|B cell|T cell|cytokines,United States,Ann Arbor,Michigan,1,Teriflunomide,DRUG,Changes in frequency of regulatory and effector B cell subset,"Change in frequency of CD4+ Th17, Th1, Th2, and Treg cells|Change in chemokine levels|Change in cytokine levels",False,
NCT04902690,The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients,An Observation Monocentric Study to Analyse the Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients,UNKNOWN,2021-05-31,2024-07-31,2024-07-31,2021-05-26,2021-05-26,OBSERVATIONAL,,21.0,ESTIMATED,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",OTHER,,,Multiple Sclerosis Relapse,Neuroprotective effect|Ocrelizumab|Multiple sclerosis|Vascular Endothelial Growth Factor,,,,0,,,VEGF protein levels,VEGF protein levels|VEGF mRNA levels|PKCβ protein levels|PKCβ mRNA levels|Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Severity Score (MSSS),False,
NCT01424462,Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.,"An Open Label, Randomised Healthy Volunteer Study to Assess the Single Dose Safety and Pharmacokinetics of Three Modified Release Dosage Forms of Firategrast",COMPLETED,2010-04-19,2010-07-06,2010-07-06,2017-06-20,2011-08-29,INTERVENTIONAL,PHASE1,20.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",healthy volunteers|firategrast|Pharmacokinetics|modified release,Australia,Randwick,New South Wales,1,A|B|C|D,DRUG|DRUG|DRUG|DRUG,Systemic concentration & AUC of study drug,"Adverse events|Systemic concentration & AUC of study drug metabolite|Vital signs|12-lead Electrocardiogram|Heamatology, clinical chemistry and Uninalysis",False,
NCT06141486,Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis,"A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis",RECRUITING,2023-12-27,2026-12-23,2028-03-24,2025-08-24,2023-11-21,INTERVENTIONAL,PHASE3,900.0,ESTIMATED,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Homewood,Alabama,321,Frexalimab|Placebo|MRI contrast-enhancing agents,DRUG|DRUG|DRUG,Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period,"Time to onset of composite cCDP confirmed over 3 months in the double-blind treatment period|Time to onset of individual components of the composite, confirmed over 3-months or 6 months in the double-blind treatment period|Time to onset of confirmed disability improvement (CDI) in the double-blind treatment period|Number of new and/or enlarging T2hyperintense lesions per scan as detected by MRI, and number of new and/or enlarging T2-hyperintense lesions per scan as detected by MRI|Percent change in brain volume loss as detected by MRI scans at the end of double-blind treatment period compared to Month 6|Change in cognitive function at the end of double-blind treatment period compared to baseline as assessed by symbol digit modalities test (SDMT)|Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time in the double-blind treatment period|Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue multiple sclerosis (MS)-8a over time in the double-blind treatment period|Annualized relapse rate during the double-blind treatment period assessed by protocol defined adjudicated relapses|Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation and AE of special interests (AESIs)|Number of participants with potentially clinically significant abnormalities (PCSAs) in laboratory tests, ECG, and vital signs during the study period|Number of participants with antibody over time|Change from baseline in serum Ig levels over time|Change from baseline in plasma neurofilament light chain (NfL) levels over time in the double-blind treatment period|Frexalimab plasma concentration over time in the double-blind treatment period",False,
NCT02010554,Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS,Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS,COMPLETED,2013-12,2015-03,2015-09,2015-12-02,2013-12-12,INTERVENTIONAL,NA,40.0,ACTUAL,"University of Missouri, Kansas City",OTHER,,,Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis|Disease modifying medication|Relapsing-Remitting MS|Motivational Interviewing|Telephone Counseling,United States,Kansas City,Missouri,2,Brief Education|Motivational Interviewing-Cognitive Behavioral Therapy,BEHAVIORAL|BEHAVIORAL,Adherence Treatment Survey,Adherence Treatment Survey|Adherence Treatment Survey|Adherence Treatment Survey,False,
NCT00913666,Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers,"A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects",COMPLETED,2002-11,,2004-11,2009-06-04,2009-06-04,INTERVENTIONAL,PHASE4,121.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis,,,,0,Interferon beta-1a (Avonex),DRUG,Changes in bioanalytical measures after receiving therapy for 3 to 6 months,,False,
NCT06845722,Combined Effects of Balance and Cognitive Training in Patients With Multiple Sclerosis,"Combined Effects of Balance and Cognitive Training on Executive Functions, Balance and Quality of Life in Patients With Multiple Sclerosis",RECRUITING,2024-10-01,2025-02-20,2025-05-02,2025-02-25,2025-02-25,INTERVENTIONAL,NA,42.0,ESTIMATED,Riphah International University,OTHER,,,Multiple Sclerosis,balance|cognitive training|executive function|quality of life|multiple sclerosis,Pakistan,Lahore,,1,Balance training|Cognitive Rehabilitation:,OTHER|OTHER,I. Montreal Cognitive Assessment for Cognitive Impairment:|II. Berg Balance Scale for balance assessment:,III. Short form of SF 36-Item health survey for Quality of life:,False,
NCT07183683,Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction,"Electrical Versus Manual Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction - A Pragmatic, Exploratory, Three-Arm, Randomized Controlled Trial Using a Mixed Methods Approach",RECRUITING,2025-09,2026-12-30,2027-04-30,2025-09-19,2025-09-19,INTERVENTIONAL,NA,150.0,ESTIMATED,"Charite University, Berlin, Germany",OTHER,,,Neurogenic Bladder Dysfunction,multiple sclerosis|urinary bladder dysfunction|electrical stimulation|acupressure|acupuncture|posterior tibial nerve,Germany,Berlin,State of Berlin,1,group 1: electrical stimulation of acupuncture points plus routine care|group 2: acupressure plus routine care,DEVICE|OTHER,Incontinence Questionnaire Overactive Bladder (ICIQ-OAB),Incontinence Quality of Life Measure (I-QoL)|Patient's Global Impression of Change (PGIC)|3-day voiding diary|100mm Visual Analogue pain Scale (VAS) for last menstruation,False,
NCT03135327,Clinical Applications of Advanced Ophthalmic Imaging,Clinical Applications of Advanced Ophthalmic Imaging,RECRUITING,2007-01-01,2029-12-31,2029-12-31,2025-08-12,2017-05-01,INTERVENTIONAL,NA,5000.0,ESTIMATED,University of Miami,OTHER,,,Multiple Sclerosis|Dry Eye Syndromes|Diabetic Retinopathy|Presbyopia|Myopia|Dementia,,United States,Miami,Florida,1,Ocufolin,DIETARY_SUPPLEMENT,Retinal microstructure using OCT.|Retinal vasculature by optical coherence tomography angiography (OCTA)|Conjunctival vasculature by functional slit-lamp (FSLB)|Corneal epithelial thickness|Tear film thickness,Retinal blood flow velocity by retinal function imager (RFI)|Conjunctival blood flow velocity by functional slit-lamp (FSLB),False,
NCT05870254,Exergaming With Immersive Virtual Reality For People With Multiple Sclerosis (ExeRVIEM),Exergaming With Immersive Virtual Reality to Improve Functional Abilities in People With Multiple Sclerosis,COMPLETED,2024-01-29,2024-03-25,2024-03-29,2025-06-26,2023-05-23,INTERVENTIONAL,NA,18.0,ACTUAL,University of Vigo,OTHER,Asociación Viguesa de Esclerosis Múltiple de Pontevedra,UNKNOWN,Multiple Sclerosis|Physical Therapy|Exercise|Virtual Reality Exposure Therapy|Rehabilitation,,Spain,Pontevedra,Galicia,2,ExeRVIEM Program|Usual center program,OTHER|OTHER,"Balance, gait and risk of falling|Balance, gait and risk of falling|Balance, gait and risk of falling|functional autonomy|functional autonomy|functional autonomy|functional and cognitive autonomy|functional and cognitive autonomy|functional and cognitive autonomy|functional mobility and lower limb strength|functional mobility and lower limb strength|functional mobility and lower limb strength|Reaction Time|Reaction Time|Reaction Time|Fatigue|Fatigue|Fatigue",Safety of the IVR intervention|Usability of the IVR intervention|Satisfaction and experiences post IVR intervention,False,
NCT03046251,Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis,Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis,COMPLETED,2015-08,2023-12,2023-12,2025-01-24,2017-02-08,INTERVENTIONAL,PHASE4,30.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,Natalizumab,DRUG,Relapses Post Partum,Expanded Disability Status Scale (EDSS) Worsening|Difference in Mean Expanded Disability Status Scale (EDSS) Scores Between Persons With MS (pwMS) Treated With Natalizumab Versus Other Disease-modifying Therapies (DMT)|Change in MRI|Percent of Relapse Free Patients,True,2025-01-22
NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2020-11-26,2024-12-19,2028-08-31,2025-07-24,2020-09-10,INTERVENTIONAL,PHASE3,864.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,"Relapsing Remitting Multiple Sclerosis; Higher Dose of CD20 Antibody Ocrelizumab; Efficacy, Safety and Pharmacokinetics",United States,Cullman,Alabama,122,Ocrelizumab|Ocrelizumab|Antihistamine|Methylprednisolone,DRUG|DRUG|DRUG|DRUG,Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12),Time to Onset of 24-week cCDP (cCDP24)|Time to Onset of 48-week cCDP (cCDP48)|Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR)|Time to Onset of 12-week Confirmed Disability Progression (CDP12)|Time to ≥ 20% Increase in 12-week Confirmed by T25FWT|Annual Rate of Percent Change From Baseline in Total Brain Volume|Time to 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)|Time to 12-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS-12)|Change in Neurofilament Light (NfL) at Week 48 for Participants Assigned to the Higher Dose Ocrelizumab Group|Change in NfL at Week 48 for Participants Assigned to the Approved Dose Ocrelizumab Group|Percentage of Participants With Adverse Events (AEs)|Serum Concentration of Ocrelizumab at Specified Time Points|B-cell Levels in Blood|Percentage of Participants Achieving 5 or Less B-cells per Microliter of Blood|Change From Baseline in the Anti-drug Antibody (ADA) Levels,False,
NCT02442557,Safety and Dose-finding Study of DC-TAB in Healthy Subjects,"A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers",COMPLETED,2009-12,2010-10,2011-07,2015-05-13,2015-05-13,INTERVENTIONAL,PHASE1,76.0,ACTUAL,Delta Crystallon BV,INDUSTRY,,,Multiple Sclerosis,alpha B-crystallin|immune tolerance,Netherlands,Utrecht,,1,recombinant human alpha B-crystallin|placebo comparator,BIOLOGICAL|OTHER,Safety (adverse events),Antigen-specific T-cell response|Pharmacokinetics (serum levels of DC-TAB)|Local tolerability (Injection site abnormalities)|Antibody responses,False,
NCT03856801,Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia in Multiple Sclerosis Patients,Acute Effects of Whole-body Vibration Training in Hypoxia and Normoxia Condition on Neuromuscular Performance and Mobility in Patients With Multiple Sclerosis,COMPLETED,2018-06-15,2018-07-30,2018-08-30,2019-02-27,2019-02-27,INTERVENTIONAL,NA,13.0,ACTUAL,Universidad Católica San Antonio de Murcia,OTHER,,,Multiple Sclerosis,neuromuscular disease|whole-body vibration|hypoxia|strength,Spain,Murcia,,1,Exercise,OTHER,Maximal Voluntary Isometric Contraction of Knee Extension|Maximal Voluntary Isometric Contraction of Knee Extension|Rate of Force Development|Rate of Force Development|Central Activation Ratio|Central Activation Ratio|Biomechanical study of the walk by video recording|Biomechanical study of the walk by video recording|Biomechanical study of the walk by video recording|Biomechanical study of the walk by video recording|Spasticity|Spasticity,Rate of Perceived Exertion|Rate of Perceived Exertion|Walking speed|Walking speed|Static balance|Static balance|Muscle oxygenation in soleus|Muscle oxygenation in soleus,False,
NCT01274702,Visual Reconstitution Therapy After Optic Neuritis,Visual Reconstitution Therapy After Optic Neuritis,COMPLETED,2010-05,2013-03,2013-03,2021-07-29,2011-01-11,INTERVENTIONAL,PHASE2,25.0,ACTUAL,Friedemann Paul,OTHER,"Beuth Hochschule für Technik Berlin|NovaVision AG, Zentrum für Sehtherapie",UNKNOWN|UNKNOWN,Optic Neuritis|Multiple Sclerosis,History of|Patients|acute,Germany,Berlin,,1,Visual Reconstitutions Therapy|Saccadic Eye Movement Training,OTHER|OTHER,Visual field,structural retinal changes|Quality of Life,False,
NCT00001781,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)","Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark",COMPLETED,1998-02,,2002-03,2008-03-04,1999-11-04,INTERVENTIONAL,PHASE2,25.0,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Immunology|Treatment,United States,Bethesda,Maryland,1,CGP 77116,DRUG,,,False,
NCT03757819,Transcranial Direct Current Stimulation and Walking in Multiple Sclerosis,Can Transcranial Direct Stimulation Improve Walking in Multiple Sclerosis?,COMPLETED,2019-02-25,2019-07-07,2019-07-07,2022-12-21,2018-11-29,INTERVENTIONAL,NA,12.0,ACTUAL,Thorsten Rudroff,OTHER,,,Transcranial Direct Current Stimulation,Multiple Scerosis,United States,Iowa City,Iowa,1,tDCS|SHAM,DEVICE|DEVICE,Distance Walked on a Treadmill With tDCS|Distance Walked on a Treadmill With SHAM,,True,2022-12-21
NCT01392872,Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant,Evaluation of Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scleroses and Treat With Immunosuppressant,COMPLETED,2009-11,2016-01,2016-01,2016-07-29,2011-07-13,INTERVENTIONAL,NA,48.0,ACTUAL,"University Hospital, Clermont-Ferrand",OTHER,"University Hospital, Bordeaux|University Hospital, Caen|University Hospital, Marseille|Dr Remy MORELLO - CHU de Caen",OTHER|OTHER|OTHER|UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",Immunosuppressant|Quality of life|Cognitive function|Relapsing Multiple Sclerosis,France,Clermont-Ferrand,,1,Neuropsychological assessment,OTHER,Evolution of the quality of life of patients diagnosed with relapsing MS and starting a treatment with immunosuppressant,"Analysis of variance for repeated measurement|Selective Reminding Test (SRT)|Delayed recall of SRT|Visuo-spatial span|Digit span|Reverse span|Stroop test|• Tiredness (EMIF SEP scale): Analysis of variance for repeated measurement|• Physical function (9HPT, 8 meter walk) : Analysis of variance for repeated measurement|Disability (EDSS) : Analysis of variance for repeated measurement|• Psychological disorder (Beck depression inventory, COVI scale, Depressive scale) : Analysis of variance for repeated measurement",False,
NCT05347277,CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders,CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders Taking Oligoclonal Banding Via Isoelectric Focusing Electrophoresis as Gold Standard: A Laboratory Study,COMPLETED,2021-06-01,2021-08-31,2021-08-31,2022-04-26,2022-04-26,OBSERVATIONAL,,60.0,ACTUAL,Aga Khan University,OTHER,,,Multiple Sclerosis,,Pakistan,Karachi,Sindh,1,Kappa Free Light Chain (K-FLC),DIAGNOSTIC_TEST,Kappa Free Light Chain (KFLC) levels greater than 1 mg/L|Kappa Free Light Chain (KFLC) levels less than 1 mg/L,,False,
NCT02388334,Impact of Multiple Sclerosis From the Viewpoint of the Caregivers,Impact of Multiple Sclerosis From the Viewpoint of the Caregivers : Exploring Their Quality Of Life and Their Expectations Concerning the Quality of Professional Management,UNKNOWN,2015-03,2015-12,2017-06,2015-03-17,2015-03-17,OBSERVATIONAL,,730.0,ESTIMATED,Rennes University Hospital,OTHER,"Ministry of Health, France|Nantes University Hospital|University Hospital, Angers|Central Hospital, Nancy, France|University Hospital, Strasbourg|University Hospital, Marseille|University Hospital, Clermont-Ferrand",OTHER_GOV|OTHER|OTHER_GOV|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,Caregivers|Quality of life|Quality of care,,,,0,to develop a standardized questionnaire,OTHER,Validation phase of the questionnaire,,False,
NCT06016309,"The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis","The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis",RECRUITING,2023-07-20,2027-07-20,2027-12-31,2025-03-30,2023-08-29,OBSERVATIONAL,,500.0,ESTIMATED,University Medical Center Groningen,OTHER,University of Groningen,OTHER,Multiple Sclerosis,,Netherlands,Groningen,Provincie Groningen,1,There is no intervention.,OTHER,Cognition|Energy|Behaviour|Affect,Level of societal participation|Subjective burden|Demographic information,False,
NCT01979081,Detecting and Addressing Preclinical Disability,Detecting and Addressing Preclinical Disability,COMPLETED,2013-01,2017-06,2017-12,2018-04-09,2013-11-08,OBSERVATIONAL,,148.0,ACTUAL,McMaster University,OTHER,,,Back Pain|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Diabetes|Hypertension|Multiple Sclerosis|Osteoporosis|Osteoarthritis|Rheumatoid Arthritis|Stroke,,Canada,Hamilton,Ontario,1,Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal,OTHER,Physical Functioning Inventory,Mobility Survey|The Rapid Assessment of Physical Activity (RAPA)|Patient Specific Functional Scale (PSFS),False,
NCT06683612,PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF,"A Phase 1b, Open-label Study of PIPE-791 to Determine Brain and Lung Lysophosphatidic Acid Receptor 1 (LPA1) Occupancy, by [18F] PIPE-497 PET Imaging in Healthy Volunteers, Volunteers With Progressive Multiple Sclerosis, and Volunteers With Idiopathic Pulmonary Fibrosis",COMPLETED,2024-12-09,2025-06-04,2025-06-12,2025-08-06,2024-11-12,INTERVENTIONAL,PHASE1,16.0,ACTUAL,Contineum Therapeutics,INDUSTRY,,,"Idiopathic Pulmonary Fibrosis (IPF)|Idiopathic Pulmonary Fibrosis|Multiple Sclerosis|Multiple Sclerosis, MS|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Progressive|Multiple Sclerosis, Secondary Progressive|Healthy|Healthy Volunteers","remyelination|MS|multiple sclerosis|PrMS|PPMS|SPMS|primary progressive MS|primary progressive multiple sclerosis|secondary progressive multiple sclerosis|secondary progressive MS|LPA1|PMS|idiopathic pulmonary fibrosis|IPF|neuroinflammation|PIPE-791|demyelinating diseases|autoimmune diseases|pathologic processes|demyelinating autoimmune diseases, CNS|autoimmune diseases of the nervous system|nervous system diseases|immune diseases|sclerosis",United Kingdom,London,,1,PIPE-791,DRUG,LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan.|LPA1 occupancy as determined by regional total volume of distribution (VT) at each lung scan.,"The relationship between PIPE-791 plasma concentration and brain and lung LPA1 occupancy.|The PIPE-791 EC50 (i.e., the plasma concentration of PIPE-791 associated with 50% occupancy of LPA1) in the brain and lungs.|Pharmacokinetics (PK): blood concentration levels of PIPE-791|Safety and tolerability: Treatment-Emergent Adverse Events (TEAE)",False,
NCT02743312,Long-Term Effects of Torso-Weighting,Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study,COMPLETED,2015-11,2016-05,2016-06,2018-11-06,2016-04-19,INTERVENTIONAL,NA,5.0,ACTUAL,San Francisco State University,OTHER,Samuel Merritt University,OTHER,Multiple Sclerosis,Balance-Based Torso-Weighting|Physical Activity|Neurorehabilitation,United States,Oakland,California,1,Torso Weights|Sham Weights|Fitbit Flex,DEVICE|DEVICE|DEVICE,Steps Per Day,"Sensory Organization Test|Gait Velocity|Movement Ability Measure, Computer Adaptive Test Version (MAM-CAT)|Activities-Specific Balance Confidence Scale|Multiple Sclerosis Impact Scale 29|Multiple Sclerosis Walking Scale 12|Six-Minute Walk Test|Stride Length|Percent of Gait Cycle in Single Limb Support|Step Width|Electromyography to Assess Muscle Activation|Number of Falls Recorded in 2 Weeks of Wear Time.",True,2018-11-06
NCT05225012,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2,COMPLETED,2022-08-12,2023-04-28,2023-06-30,2024-11-15,2022-02-04,INTERVENTIONAL,NA,5.0,ACTUAL,University of Nottingham,OTHER,,,Multiple Sclerosis,Acceptance and Commitment Therapy,United Kingdom,Nottingham,,1,Acceptance and Commitment Therapy,OTHER,Perceived psychological impact of MS|Patient Health Questionnaire - 9 (PHQ-9)|Generalised Anxiety Disorder - 7 (GAD-7)|Visual Analogue Scales,Health-related quality of life|Perceived levels of stress|Self efficacy in the context of MS|Levels of fatigue,False,
NCT05503628,A Measurement Study of TIS-modNV and AccuGait Force Platform in People With MS,The Validity and Reliability of the Trunk Impairment Scale-modNV and the AMTI AccuGait Optimized Force Platform Across Mild and Moderate Disability Levels in the MS Population,UNKNOWN,2022-08-15,2023-01-01,2023-01-01,2022-08-19,2022-08-16,OBSERVATIONAL,,60.0,ESTIMATED,Nordlandssykehuset HF,OTHER,Nord University|Helse Nord,OTHER|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Trunk control|Balance|Outcome measure,Norway,Bodø,,1,,,"The modified Trunk Impairment Scale - Norwegian version (TIS-modNV)|AMTI AccuGait OptimizedTM (Advanced Mechanical technology, Inc., Watertown, USA) multi-axis force plate system",,False,
NCT02425644,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,"Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2015-06-04,2019-05-16,2019-05-16,2025-03-30,2015-04-24,INTERVENTIONAL,PHASE3,1133.0,ACTUAL,Actelion,INDUSTRY,,,Multiple Sclerosis,relapsing multiple sclerosis,United States,Carlsbad,California,162,ponesimod|teriflunomide,DRUG|DRUG,Annualized Confirmed Relapse Rate,Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108|Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108|12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS|24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS,True,2021-06-11
NCT04302870,Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial,Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial,RECRUITING,2020-02-27,2030-12,2030-12,2025-06-12,2020-03-10,INTERVENTIONAL,PHASE2|PHASE3,1150.0,ESTIMATED,University of Edinburgh,OTHER,"University College, London|University of Warwick|NHS Lothian",OTHER|OTHER|OTHER_GOV,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis",,United Kingdom,Portadown,County Armagh,22,Memantine Hydrochloride Oral Solution|Trazodone Hydrochloride oral solution|Placebo oral solution|Amantadine Hydrochloride Oral Solution|Tacrolimus 1Mg Cap|Placebo capsule,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Change in decline of ALS-FRS(R) over 18months|Survival,Cognition and behaviour|Respiratory function - Forced vital capacity|King's ALS Clinical stage|Changes in anxiety and depression|Changes in Quality of Life|Safety and tolerability of IMPs,False,
NCT03244696,Behavior and Activity Monitoring in MS,Behavior and Activity Monitoring in Multiple Sclerosis,COMPLETED,2017-11-02,2021-06-28,2021-06-28,2023-03-24,2017-08-09,INTERVENTIONAL,NA,87.0,ACTUAL,Ohio State University,OTHER,National Multiple Sclerosis Society,OTHER,Relapsing-Remitting Multiple Sclerosis,"Multiple Sclerosis|Sclerosis|Demyelinating Autoimmune Diseases, Central Nervous System|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Immune System Diseases|Physical Activity|Walking|Hydration|Lifestyle Intervention|Health Behavior Tracking|Inflammatory Biomarkers|Neurodegenerative Disease",United States,Columbus,Ohio,1,Step Tracking|Water Tracking,BEHAVIORAL|BEHAVIORAL,Change in Cognitive Performance on a Latent Measure of Working Memory/Processing Speed,Changes in the Functional Architecture of the MS Brain during Working Memory|Changes in the Functional Architecture of the MS Brain during Processing Speed|Changes on a Self-Report Measure of Depression|Changes on a Self-Report Measure of Anxiety|Changes on a Self-Report Measure of Perceived Stress|Changes on a Self-Report Measure of Quality of Life|Changes on a Self-Report Measure of Sleep Quality|Changes on a Self-Report Measure of Fatigue,False,
NCT02403570,Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis,Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis,COMPLETED,2015-02,2016-12-31,2016-12-31,2021-03-03,2015-03-31,OBSERVATIONAL,,21.0,ACTUAL,Turku University Hospital,OTHER_GOV,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis, MRI, rotating frame",Finland,Turku,,1,Brain MRI,OTHER,MR relaxation values 0|MR relaxation values 1,MR relaxation values and clinical markers 0|MR relaxation values and clinical markers 1,False,
NCT06647069,DR-0201 in Subjects With Autoimmune Diseases,"A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients With Select Autoimmune Rheumatic Diseases",RECRUITING,2025-03-27,2026-12,2026-12,2025-09-19,2024-10-17,INTERVENTIONAL,PHASE1,36.0,ESTIMATED,Dren Bio,INDUSTRY,,,"SLE|SLE (Systemic Lupus)|CLE|Cutaneous Lupus|Sjogren's Syndrome|Primary Sjögren Syndrome|Dermatomyositis|Polymyositis|Scleroderma|SSc, Diffuse Sclerosis|dcSSc|Diffuse Cutaneous Systemic Sclerosis",,Australia,Coorparoo,Queensland,8,DR-0201,DRUG,Incidence and severity of adverse events as assessed by CTCAE v5.0.(Safety and Tolerability),,False,
NCT05663853,An Observational Biomarker Study in Multiple Sclerosis (MS) Patients,A Multicenter Observational Study for Ex-vivo Evaluation of the Likelihood of Response to an Experimental Tolerance Restoration Therapy in Subjects Diagnosed With Multiple Sclerosis (MS),COMPLETED,2023-03-28,2024-04-30,2024-04-30,2024-06-11,2022-12-23,OBSERVATIONAL,,137.0,ACTUAL,LAPIX Therapeutics Inc.,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",,United States,Baltimore,Maryland,4,,,Collect clinical information pertaining to MS disease|Collect radiographical data|Collect patient demographic data|Evaluate factors affecting the pharmacological response to LAPIX's lead immune-tolerance restoration molecule ex-vivo.,,False,
NCT05516303,Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod,Pharmacogenetic Investigation of Susceptibility to Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod,UNKNOWN,2022-06-07,2022-10-31,2022-10-31,2022-08-25,2022-08-25,OBSERVATIONAL,,65.0,ESTIMATED,"University Hospital, Caen",OTHER,,,Multiple Sclerosis,Fingolimod|hepatic adverse events|polymorphism,France,Caen,,1,Genetic polymorphism|Measurement of fingolimod and fingolimod-phosphate concentrations,GENETIC|DIAGNOSTIC_TEST,CYP4F2 polymorphism frequency in case and control groups,Fingolimod concentrations in case and control groups|Fingolimod-phosphate concentrations in case and control groups,False,
NCT03935529,Behavioural Activation for Low Mood in Multiple Sclerosis,Behavioural Activation for Low Mood in Multiple Sclerosis,COMPLETED,2019-03-04,2019-06-30,2019-06-30,2020-06-11,2019-05-02,INTERVENTIONAL,NA,10.0,ACTUAL,University of Lincoln,OTHER,Nottingham University Hospitals NHS Trust,OTHER,Depression|Secondary-progressive Multiple Sclerosis,,United Kingdom,Nottingham,,1,Behavioural Activation,BEHAVIORAL,"Change in depression: Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983","Changes to fatigue: Modified Fatigue Impact Scale; Vickrey et al., 1995|Changes to quality of life: Health Status Questionnaire Short form version 2. SF-12v2; Ware, Kosinski, & Keller, 1996|Changes in behaviour associated with depression: The Behavioural Activation for Depression Scale Short Form",False,
NCT05777902,Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.,Multidimensional Integrated Assessment of Neurological and Immunological Patterns to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.,TERMINATED,2023-01-31,2024-04-11,2024-04-11,2025-01-15,2023-03-21,INTERVENTIONAL,PHASE4,30.0,ACTUAL,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Multiple Sclerosis,,Italy,Roma,RM,1,Ozanimod Oral Capsule,DRUG,verify the therapeutical activity of Ozanimod on the inflammatory mediated neurodegeneration.,,False,
NCT06460077,Exploring Pathology Related to Slowly Expanding Lesions Using Advanced Imaging,Exploring Pathology Related to Slowly Expanding Lesions Using Advanced Imaging,ENROLLING_BY_INVITATION,2024-10-03,2028-06,2028-12,2025-04-16,2024-06-14,OBSERVATIONAL,,15.0,ESTIMATED,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,,,Number of lesions|Co-localization of lesions,Correlation of PET imaging and clinical variables|Correlation of magnetic resonance imaging and clinical variables|Correlation of quality of life questionnaires and clinical variables|Correlation of neuropsychological evaluation and clinical variables,False,
NCT01024777,Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis,A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis,COMPLETED,2010-03,2013-01,2013-01,2013-02-06,2009-12-03,INTERVENTIONAL,PHASE1,40.0,ACTUAL,Johns Hopkins University,OTHER,,,Multiple Sclerosis|Vitamin D Deficiency,cholecalciferol|multiple sclerosis|vitamin D|D3,United States,Baltimore,Maryland,1,Cholecalciferol|Cholecalciferol,DRUG|DRUG,Assess safety of high dose cholecalciferol in patients with multiple sclerosis|Assess the effects of cholecalciferol supplementation on serum immune markers in patients with multiple sclerosis,Assess clinical effects of cholecalciferol supplementation in patients with multiple sclerosis,False,
NCT03193086,The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients,The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis,UNKNOWN,2017-01-01,2020-03-31,2020-03-31,2017-06-20,2017-06-20,OBSERVATIONAL,,35.0,ESTIMATED,"Glostrup University Hospital, Copenhagen",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Blood-Brain-Barrier|Treatment response|Metabolism|Alemtuzumab|Perfusion|Oxygen consumption,Denmark,Glostrup Municipality,Copenhagen Capital Region,1,Alemtuzumab,DRUG,Blood-Brain-Barrier Permeability,Oxygen Consumption|Cerebral perfusion|Diffusion Tensor MRI parameters and MR spectroscopy metabolite concentrations|Brain atrophy|Clinical Severity of Disease|Relapse frequency|Plasma markers of Blood-Brain-Barrier breakdown|Plasma markers of neuronal damage|Urinary markers of inflammation,False,
NCT03652805,A Study of IPL344 in the Treatment of ALS Patients,"Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)",SUSPENDED,2018-08-01,2026-01,2026-02,2025-01-10,2018-08-29,INTERVENTIONAL,PHASE1|PHASE2,15.0,ESTIMATED,Immunity Pharma Ltd.,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,Israel,Jerusalem,,1,IPL344,DRUG,Adverse Events (AEs) and serious adverse events (SAEs) Reporting|Maximum Tolerated Dose (MTD),Pharmacokinetic (PK) profile - Maximum Plasma Concentration (Cmax)|Pharmacokinetic (PK) profile - Area Under the Curve (AUC)|Pharmacokinetic (PK) profile - time to reach maximum plasma concentration (Tmax)|Pharmacokinetic (PK) profile - apparent terminal exponential half-life (T1/2),False,
NCT00292266,A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS),"An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis",COMPLETED,1999-11,2002-06,2002-06,2013-08-05,2006-02-15,INTERVENTIONAL,PHASE3,677.0,ACTUAL,EMD Serono,INDUSTRY,Merck Serono International SA,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Relapsing-remitting Multiple Sclerosis|Rebif®|Avonex®|interferon-beta-1a,,,,0,Rebif®|Avonex®,DRUG|DRUG,Percentage of exacerbation-free subjects|Percentage of exacerbation-free subjects|Percentage of exacerbation-free subjects,Mean number of combined unique (CU) active lesions per subject per scan|Total exacerbation count per subject|Mean Number of Time constant 2 (T2) active lesions per subject per scan,False,
NCT02082002,Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino,Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino,COMPLETED,2013-11,2018-12-21,2018-12-21,2019-03-21,2014-03-07,OBSERVATIONAL,,93.0,ACTUAL,Claudio Gobbi,OTHER_GOV,Swiss Multiple Sclerosis Society,UNKNOWN,Multiple Sclerosis,Multiple scerlosis|Fatigue|Sleep|Somnolence|Depression|Cognitive disorders,Switzerland,Lugano,Canton Ticino,1,,,Fatigue Severity Scale,Modified Fatigue Impact Scale|Fatigue Scale for Motor and Cognitive functions|Visual analogue scale for fatigue|Maintenance of wakefulness test|Epworth Sleepiness Scale|Visual analogue scale for somnolence|Beck depression inventory II|Mongomery Asberg Depression Rating Scale|Symbol Digit Modalities Test|Paced Auditory Serial Addition Test|Stroop Test,False,
NCT04035720,Decision Making in Multiple Sclerosis Care Under Uncertainty,Decision Making in Multiple Sclerosis Care Under Uncertainty,UNKNOWN,2019-07-06,2021-07-21,2021-12-22,2019-07-29,2019-07-29,INTERVENTIONAL,NA,450.0,ESTIMATED,Unity Health Toronto,OTHER,Hoffmann-La Roche|University of Toronto,INDUSTRY|OTHER,Multiple Sclerosis,decision making|therapeutic|disease modifying agents|monoclonal antobodies|physicians|neurologists|uncertainty|neuroeconomics,Canada,Toronto,Ontario,1,Quantitative risk,OTHER,Therapeutic inertia score|Accuracy of treatment decisions,Therapeutic decisions under fatigue|Prevalence of therapeutic inertia (TI)|Factors associated with therapeutic decisions,False,
NCT02651545,Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis,"Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.",COMPLETED,2014-02,2020-11-30,2020-11-30,2021-09-24,2016-01-11,OBSERVATIONAL,,60.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,,,Expanded Disability Status Scale Score (EDSS)|Timed 25-foot Walk.|Nine-hole Peg Test|California Verbal Learning Test 2nd Edition Total Learning Score|Brief Visuospatial Memory Test Revised Total Learning Score|Symbol Digit Modalities Test Total Correct,Change in Vocational Status,True,2021-09-24
NCT03826095,"Respiratory Functions, Trunk Control and Mobility Evaluation in Multiple Sclerosis",Investigation of the Effects of Respiratory Functions and Trunk Control on Functional Mobility in Individuals With Multiple Sclerosis,COMPLETED,2019-02-04,2019-07-26,2019-08-02,2019-08-06,2019-02-01,OBSERVATIONAL,,60.0,ACTUAL,Hacettepe University,OTHER,KARMUTLU|MATUNCER|EÇKÜTÜKÇÜ,UNKNOWN|UNKNOWN|UNKNOWN,Physical Therapy,Multiple Sclerosis|Respiratory function|Respiratory muscle strength|Trunk control|Functional mobility,Turkey (Türkiye),Ankara,,1,,,2 Minutes Walking Test|Timed Up and Go Test,Respiratory Functions Test|Respiratory Muscle Strength|Trunk Impairment Scale|Side Bridge Test (core muscles endurance)|Modified Biering-Sorensen test (core muscles endurance)|Trunk Flexion Test (core muscles endurance)|Prone bridge test (core muscles endurance)|Sit-ups Test (core muscles power)|Modified Push-ups Test (core muscles power)|Lumbopelvic Stability Test,False,
NCT02521545,Single-Dose Study of a New Formulation of BIIB061,A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061,COMPLETED,2015-07,2015-08,2015-08,2015-09-07,2015-08-13,INTERVENTIONAL,PHASE1,8.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Oral Remyelination,United States,Madison,Wisconsin,1,BIIB061,DRUG,PK parameter - area under the concentration-time curve from time 0 to infinity (AUCinf)|PK parameter - AUC from time 0 to time of the last measurable concentration (AUClast)|PK parameter - maximum observed concentration (Cmax),PK parameter - Time to reach maximum observed concentration (Tmax)|PK parameter - half-life (t1/2)|Incidence of adverse events (AEs) and serious adverse events (SAEs)|Assessment of changes from baseline in Clinical laboratory parameters|Assessment of clinically relevant abnormalities in Vital signs|Assessment of physical examinations,False,
NCT00638196,Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS,Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis,TERMINATED,2008-03,2012-09,2012-09,2015-08-11,2008-03-18,INTERVENTIONAL,PHASE1,9.0,ACTUAL,University of Rochester,OTHER,,,Multiple Sclerosis,relapsing multiple sclerosis|polyunsaturated fatty acids|omega-6 fatty acids,United States,Rochester,New York,1,Linoleic Acid/Oleic Acid,DRUG,Within patient change in the sum of gadolinium-enhancing lesions on brain MRIs obtained during the treatment period compared to pre-treatment.,"Annualized relapse rate|Changes in depression and fatigue symptoms on standardized questionnaires (Beck Depression Scale and Modified Fatigue Impact Scale).|Changes in T2 lesion counts/volume, change in T1 hypointense lesion counts/volume, white matter volume and gray matter volume",False,
NCT03735524,Exercise-based Therapy for Multiple Sclerosis Patients,The Inflammatory Synaptopathy as a Target of Exercise Therapy in the Fight Against Multiple Sclerosis,UNKNOWN,2019-05,2020-11,2021-05,2018-11-08,2018-11-08,INTERVENTIONAL,NA,35.0,ESTIMATED,Neuromed IRCCS,OTHER,,,Multiple Sclerosis,"exercise, synaptopathy, inflammation",Italy,Pozzilli,Isernia,1,Exercise,OTHER,Changes in clinical disability (EDSS)|Changes in clinical disability: Multiple Sclerosis Functional Composite (MSFC)|Changes in clinical disability (VA),Changes in Mood-depressive trait|Changes in Mood-anxiety trait|Neurophysiological assessment|Changes in autonomic function|Changes in peripheral cytokine levels,False,
NCT00501696,"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone","A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)",COMPLETED,2007-02,2007-11,2007-11,2008-05-19,2007-07-16,INTERVENTIONAL,PHASE3,80.0,ACTUAL,"University of California, San Francisco",OTHER,,,Multiple Sclerosis,,United States,San Francisco,California,1,4.5 mg Naltrexone|Naltrexone,DRUG|DRUG,"comparison of the mean score between treated and placebo groups, adjusting for differences in the baseline score between the two groups; comparison of each of the 10 scales of the MSQLI54 between treated and placebo groups",,False,
NCT01026272,Novel Immune Markers in Patients With Multiple Sclerosis,Quantification of Novel Immune Markers in Human Serum of Patients With MS,UNKNOWN,2010-01,2011-01,2011-05,2010-07-13,2009-12-04,OBSERVATIONAL,,120.0,ESTIMATED,University of Washington,OTHER,,,Multiple Sclerosis,Endocannabinoid|Fish Oil|Multiple Sclerosis|Monocyte Migration,United States,Seattle,Washington,2,,,Quantification of endogenous cannabinoids,Monocyte migration,False,
NCT05177523,Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis,INsIDER: Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis,RECRUITING,2018-09-04,2028-12,2028-12,2024-12-16,2022-01-04,OBSERVATIONAL,,300.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,Swiss National Science Foundation,OTHER,Multiple Sclerosis (MS)|Relapsing-remitting Multiple Sclerosis (RRMS)|Secondary-progressive Multiple Sclerosis (SPMS)|Primary Progressive Multiple Sclerosis (PPMS),"axonal damage|axonal demyelination|axonal degeneration|axonal loss|axonal disorganization|axonal repair|axonal remyelination|axonal reorganization|Advanced MRI (aMRI)|Neurite Orientation Dispersion and Density Imaging (NODDI)|Diffusion Kurtosis (DK)|Magnetization Transfer Imaging (MTI)|Multi-echo Susceptibility-Based imaging (SBI)|Myelin Water Imaging (MWI)|T1 relaxometry (quantitative T1, qT1)|machine learning technique",Switzerland,Basel,,1,MRI|Neurocognitive examination for healthy subjects|blood sampling,DIAGNOSTIC_TEST|OTHER|OTHER,"MRI- change in axonal integrity and organization over 2 years in aMS, naPMS and HC, by using machine learning techniques",Change in MUSIC Test|Change in auditory verbal learning and memory test/ Verbaler Lern- und Merkfähigkeitstest (VLMT)|Change in Symbol Digital Modalities Test (SDMT)|Change in Brief Visuospatial Memory Test (BVMT)|Change in Hospital Anxiety and Depression Scale (HADS),False,
NCT05031403,Development and Application of Tele-Neuro Rehabilitation System,Development and Application of Tele-Neuro Rehabilitation System: An Example of Digital Transformation in Health,UNKNOWN,2021-04-01,2022-09-01,2022-10-01,2021-09-01,2021-09-01,INTERVENTIONAL,NA,114.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,The Scientific and Technological Research Council of Turkey,OTHER,Stroke|Multiple Sclerosis|Parkinson Disease,E-Health|Web Based Systems|Neurologic Rehabilitation|Neurorehabilitation|Physical Therapy and Rehabilitation|Stroke Rehabilitation|Multiple Sclerosis|Parkinson's Disease|Data Storage|Stroke,Turkey (Türkiye),Istanbul,,1,Telerehabilitaton|Home Exercise,OTHER|OTHER,Independent Standing Test (The change between the initial value and the value after 2 months will be evaluated).|Romberg Test (The change between the initial value and the value after 2 months will be evaluated).|One-Legged Standing Test (The change between the initial value and the value after 2 months will be evaluated).|5 Times Sit and Stand Test (The change between the initial value and the value after 2 months will be evaluated).|KATZ Independence Index in Activities of Daily Living (The change between the initial value and the value after 2 months will be evaluated).,Modified Fall Efficiency Scale (The change between the initial value and the value after 2 months will be evaluated).|World Health Organization Quality of Life Scale Short Form Turkish Version (WHOQOL-BREF-TR) (The change between the initial value and the value after 2 months will be evaluated).|Fatigue Severity Scale (The change between the initial value and the value after 2 months will be evaluated).|System Usability Scale (The change between the initial value and the value after 2 months will be evaluated).|Global Change Scale (The change between the initial value and the value after 2 months will be evaluated).,False,
NCT01431937,Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers,"A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers",COMPLETED,2010-10-10,2011-03-29,2011-03-29,2017-07-07,2011-09-12,INTERVENTIONAL,PHASE1,40.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Pharmacodynamics|Pharmacokinetics,Australia,Randwick,New South Wales,3,GSK2018682|Placebo,DRUG|DRUG,To investigate the safety and tolerability of repeat oral doses of GSK2018682 in healthy volunteers (males and females of non-childbearing potential)|To investigate effects of repeat oral doses of GSK2018682 on heart rate and blood pressure in healthy volunteers|To investigate effects of repeat oral doses of GSK2018682 on lung function in healthy volunteers|To investigate the pharmacokinetics of repeat oral doses of GSK2018682 in healthy volunteers|To characterize the metabolism of GSK2018682|Evaluate the effect of repeat oral doses of GSK2018682 on lymphocytes in healthy volunteers|To explore the PK/PD relationship between blood concentrations and changes in vital signs and ECG parameters|To explore the PK/PD relationship between blood concentrations of GSK2018682 and reduction in lymphocyte counts,,False,
NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,"An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2020-01-09,2023-10-05,2029-12-01,2025-09-09,2019-08-30,INTERVENTIONAL,PHASE2,23.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,United States,Aurora,Colorado,12,Ocrelizumab,DRUG,Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab|Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab|Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood,"Number of Participants With Adverse Events (AEs)|Dose Exploration Period: Level of Circulating T Cells and Natural Killer (NK) Cells|OOE Period: Level of Circulating T Cells and NK Cells|Dose Exploration Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte|OOE Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte|Developmental Milestones - Growth Velocity: Change in Height|Developmental Milestones: Bone Age Assessment by Wrist/Hand Radiographs|Developmental Milestones: Male and Female Puberty Assessed by Tanner Staging|Developmental Milestones: Age at Menarche, Related With the Female Reproductive Status|Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)|OOE Period: Number of Participants With Shift From Baseline in Non-MS CNS Pathology as Measured by Brain MRI|Dose Exploration Period: Levels of Blood Immunoglobulins|OOE Period: Levels of Blood Immunoglobulins|Dose Exploration Period: Number of Participants With Antibody Titers Against Standard Vaccines|OOE Period: Number of Participants With Antibody Titers Against Standard Vaccines|Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab|OOE Period: Number of Participants With ADAs to Ocrelizumab",True,2024-11-08
NCT05124522,A Health Action Process Approach Online Intervention for People With Multiple Sclerosis,Developing A Person-centered Internet-based Health Action Process Approach to Promoting Physical Activity in People With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-10-25,2026-04-30,2026-12-31,2025-08-24,2021-11-18,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,Physical Activity|Internet-Based Intervention,United States,Champaign,Illinois,1,MSPA eClass,BEHAVIORAL,The Health Action Process Approach Battery,,False,
NCT03797937,Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II,Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II,COMPLETED,2018-11-01,2021-11-01,2022-05-01,2022-05-11,2019-01-09,INTERVENTIONAL,NA,250.0,ACTUAL,National MS Center Melsbroek,OTHER,,,Multiple Sclerosis,,Belgium,Jette,Brussels Capital,2,Magnetic resonance imaging (MRI),OTHER,Clinical evidence for active disease,Radiological evidence for active disease,False,
NCT00382629,BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis,BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis,COMPLETED,2006-02,,2007-06,2008-02-11,2006-09-29,INTERVENTIONAL,PHASE2,252.0,,Bayhill Therapeutics,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple sclerosis|MS|Bayhill|BHT-3009|immunotherapy,,,,0,BHT-3009 0.5 mg|BHT-3009 1.5 mg|Placebo,DRUG|DRUG|DRUG,Evaluate the effect of BHT-3009 on the mean four-week rate of occurrence of new gadolinium (Gd) enhancing MRI lesions in relapsing remitting MS.,Evaluate the safety and tolerability of intramuscular injections of BHT-3009 given for a total of one year.|Evaluate the effect of BHT-3009 on other cranial MRI measures.|Describe the effect of BHT-3009 therapy on relapse rate.|Describe the effect of BHT-3009 on subject disability scores.,False,
NCT02471222,Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment,COMPLETED,2015-05,2016-06,2016-06,2017-08-08,2015-06-15,INTERVENTIONAL,PHASE2,60.0,ACTUAL,"Adamas Pharmaceuticals, Inc.",INDUSTRY,,,Walking Impairment|Multiple Sclerosis,,United States,Phoenix,Arizona,15,ADS-5102|Placebo,DRUG|OTHER,"Safety of ADS-5102 assessed by adverse events, safety-related study drug discontinuations, vital signs, and safety laboratory test",Timed 25 Foot Walk|Timed Up and go|2 Minute Walk Test|MS Walking Scale-12,False,
NCT00095329,"Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor","A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis",TERMINATED,2003-05,2005-03,2005-03,2016-09-22,2004-11-03,INTERVENTIONAL,PHASE1|PHASE2,14.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Autoimmunity Centers of Excellence,OTHER,Multiple Sclerosis (MS) - Relapsing-remitting,relapsing-remitting MS|nonresponsive to standard of care MS|sirolimus,United States,Boston,Massachusetts,1,sirolimus,BIOLOGICAL,"Safety of sirolimus, including number of lesions detected by brain MRI|Tolerability of sirolimus|Mean number of new and overall total number of gadolinium-enhancing lesions reported on sequential brain MRIs","Efficacy, as measured by change in the mean number of new and overall total number of gadolinium-enhancing lesions on pre-treatment brain MRIs, compared to post-treatment|Effect of sirolimus therapy on the immune function of patients with relapsing-remitting multiple sclerosis (RRMS)",False,
NCT00638027,Memantine for Spasticity in MS Patients,Memantine for Spasticity in MS Patients,COMPLETED,2006-07,2009-02,2009-02,2015-12-07,2008-03-18,INTERVENTIONAL,PHASE4,21.0,ACTUAL,University of Rochester,OTHER,Forest Laboratories,INDUSTRY,Multiple Sclerosis,multiple sclerosis,United States,Rochester,New York,1,placebo|memantine,DRUG|DRUG,Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks,Difference in the Multiple Sclerosis Spacticy Scale (MSSS-88) Between Baseline and 12 Weeks|Change in Multiple Sclerosis Functional Composite (MSFC) Score Between Baseline and Week 12,True,2015-12-07
NCT01863069,"Avonex®: Safety, Blood Levels and Effects","A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers",COMPLETED,2001-01,2001-10,2001-10,2013-05-27,2013-05-27,INTERVENTIONAL,PHASE1,77.0,ACTUAL,Trio Medicines Ltd.,INDUSTRY,Biogen,INDUSTRY,Multiple Sclerosis (MS),inhaled|interferon beta-1a|healthy subjects,United Kingdom,London,,1,Interferon beta 1a|(IM) AVONEX®,DRUG|DRUG,Pharmacokinetic parameter|Pharmacodynamic parameter|Number of adverse events|Clinically relevant changes from baseline in safety assessments|Pharmacodynamic paramter,,False,
NCT04573673,Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.,Efficacy and Safety of Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis Patients.,UNKNOWN,2021-12-01,2024-04,2024-04,2022-03-29,2020-10-05,INTERVENTIONAL,NA,68.0,ESTIMATED,"University Hospital, Lille",OTHER,,,Multiple Sclerosis|Lower Urinary Tract Symptoms,Multiple sclerosis|Voiding dysfunction|Bladder-sphincter dyssinergia|Tibial neuro-stimulation,France,Lille,,1,PTNS de verum|PTNS placebo,DEVICE|DEVICE,BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume,Maximal flow rate (mL/s) on multi-channel urodynamic study|Post-void residual volume (mL) on multi-channel urodynamic study|Maximal detrusor pressure during micturition (cmH2O) on multi-channel urodynamic study|Mean voided volume (mL) on a three-day ambulatory measure|Mean maximal flow rate (mL/s) on a three-day ambulatory measure|Mean post-void residual volume (mL) on a three-day ambulatory measure|Frequency of patients who were able to stop clean intermittent self-catheterization (PVR < 100 mL)|Urinary symptoms self-reported questionnaire (USP)|Quality of life self-reported questionnaire (Qualiveen)|Difficulty to perform CISC self-reported questionnaire (ICDQ)|Digestive symptoms self-reported questionnaire (NBD)|Digestive symptoms self-reported questionnaire (Wexner)|Sexual symptoms self-reported questionnaire (FSFI)|Sexual symptoms self-reported questionnaire ( MSHQ)|Frequency of patients with detrusor overactivity on multi-channel urodynamic study|Filling volume (mL) at first detrusor unhibited contraction on multi-channel urodynamic study - If detrusor overactivity.|Maximal detrusor pressure (cmH2O) on multi-channel urodynamic study - If detrusor overactivity.|Maximal cystomanometric capacity (cmH2O) on multi-channel urodynamic study|Frequency of adverse events occurring during the 12-week follow-up,False,
NCT07174973,Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis,"Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis: Evaluating the Combined Effects of Transcutaneous Spinal Cord Stimulation, Functional Electrical Stimulation, and Visual Feedback Balance Training",NOT_YET_RECRUITING,2025-10-30,2028-09-30,2028-12-30,2025-09-16,2025-09-16,INTERVENTIONAL,NA,24.0,ESTIMATED,"University Health Network, Toronto",OTHER,Direct MS Canada,UNKNOWN,Multiple Sclerosis|Mobility Limitation|Balance; Distorted|Gait,balance|neuromodulation|neuroplasticity|multiple sclerosis|mobility,Canada,Toronto,Ontario,1,Balance training with FES|Balance training wiith combined neuromodulation (TSCS+FES)|Balance training only,OTHER|OTHER|OTHER,Timed Up and Go (TUG)|10-Meter Walk Test (10MWT)|Berg Balance Scale (BBS):|Static & Dynamic balance tests|MS Walking Scale-12 (MSWS-12)|Falls Efficacy Scale-International (FES-I)|Activities-Specific Balance Confidence (ABC) Scale|Technology Acceptance Model (TAM) questionnaire,Neurophysiological assessment:corticospinal excitability,False,
NCT04762342,Power Training in Older Multiple Sclerosis Patients,Power Training in Older Multiple Sclerosis Patients,UNKNOWN,2020-12-07,2024-08-28,2024-08-28,2023-06-23,2021-02-21,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Aarhus,OTHER,University of Southern Denmark|University of Copenhagen,OTHER|OTHER,"Multiple Sclerosis|Sclerosis|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Demyelinating Diseases|Healthy Aging|Aging",Multiple Sclerosis|Healthy aging|Exercise|Neuroprotection,Denmark,Aarhus C,,1,Power training,OTHER,Percentage brain volume change.,,False,
NCT02142205,"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).",COMPLETED,2012-05,2013-12,2013-12,2014-05-20,2014-05-20,INTERVENTIONAL,PHASE4,100.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,Russia,Belgorod,,11,BG00002,BIOLOGICAL,Number of participants that experience Serious Adverse Events (SAEs) and adverse events (AEs),Annualized relapse rate (ARR)|Time course to first relapse|Severity of relapse as measured by the Number of relapses requiring hospitalization and the Number of relapses requiring steroid treatment|Number of participants that do not experience a relapse|Change in EDSS scores|Duration of time to progression as measured by EDSS score|Number of participants that do not experience a progression in EDSS score|Percentage of participants with improvement in EDSS scores|Changes from baseline in nine hole peg test (9HPT)|Changes in Timed 25 foot walk from baseline|Changes in cognition as assessed by the Symbol digit modalities test (SDMT)|Changes from baseline in visual function test (VFT)|Impact on participants quality of life using SF-36 and MSIS-29 self-assessment questionnaires|Percentage of participants that do not experience a relapse or progression in EDSS score|Number of T1 gadolinium (Gd) enhancing lesions|Number of new T2 hyper intense lesions|Number of newly enlarging T2 hyper intense lesions|Number of new hypo intense T1 lesions (black holes)|Number of conversion of Gd lesions into black holes|Percentage of participants that do not experience a relapse as measured by an EDSS score that is not indicative of progression|Percentage of participants that do not develop new GD+ and new or newly enlarging T2 hyper intense lesions|Proportion of participants free of disease activity: no clinical & no MRI activity|Number of participates that are Anti JCV antibody positive at baseline,False,
NCT05491031,MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis,Evaluation of MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis,RECRUITING,2023-04-25,2028-01-01,2028-05-01,2023-09-14,2022-08-08,INTERVENTIONAL,NA,250.0,ESTIMATED,Poitiers University Hospital,OTHER,,,Multiple Sclerosis|Magnetic Resonance Spectroscopy,Multiple sclerosis|ultra-high field 7T magnetic resonance spectroscopy|sodium imaging|predictive MR biomarker of MS,France,Poitiers,,1,magnetic resonance spectroscopy,OTHER,Identify imaging biomarkers at inclusion predictive of disability progression.,"Determine the correlation between brain MRI and the concentration of imaging biomarkers (mmols) at 6, 12, 18 and 24 months.|Develop realistic mathematical models of disease progression associated with clinical assessment of disability through dynamics, by the EDSS-plus score (EDSS scale from 0 to 10, T25FW in seconds, 9HPT in seconds).|Develop an artificial intelligence algorithm to identify predictive markers for disability. The artificial intelligence algorithm utilizes patients' clinical (EDSSS-Plus Scale) and radiological (brain MRI) characteristics.",False,
NCT06270641,Increasing Physical Activity for Adults With Multiple Sclerosis (MS),Increasing Physical Activity Via Provider Prescription and Engagement: Efficacy of ExerciseRx for Adults With Multiple Sclerosis (MS),RECRUITING,2024-02-16,2025-04-30,2026-09-30,2024-02-22,2024-02-21,INTERVENTIONAL,NA,106.0,ESTIMATED,University of Washington,OTHER,,,Multiple Sclerosis (MS)|Fatigue|Physical Inactivity,,United States,Seattle,Washington,1,ExerciseRx intervention,OTHER,Physical activity: daily average step count,Activity volume|Minutes/week of moderate intensity aerobic activity|Fatigue - PROMIS Fatigue-MS Short Form 8a|Pain intensity - PROMIS Pain Intensity Short Form 3a|Depressive symptom severity - PROMIS Depression Short Form 8a|Sleep disturbance - PROMIS Sleep Disturbance Short Form 6a|Physical functioning - PROMIS Physical Function 10a|Pain interference - PROMIS Pain Interference Scale Short Form 6a|Social participation - PROMIS Satisfaction with Social Roles and Activities Short Form 8a|Social participation - PROMIS Ability to Participate in Social Roles and Activities Short Form 8a,False,
NCT06322342,"Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent","A Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients",RECRUITING,2024-08-15,2025-12,2025-12,2025-08-14,2024-03-21,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,Reveal Pharmaceuticals Inc.,INDUSTRY,National Cancer Institute (NCI),NIH,"Central Nervous System (CNS) Lesions|Brain Metastases|Brain Neoplasms|Brain Neoplasms, Benign|Brain Tumor, Primary|Brain Tumor, Recurrent|Brain Tumors|Brain Cancer|Brain Tumor|Brain Neoplasm, Primary|Multiple Sclerosis|Multiple Sclerosis Brain Lesion|Neurofibroma|Acoustic Neuroma|CNS Tumor|CNS Lesion|CNS Metastases|CNS Cancer|CNS Lymphoma|Von Hippel Lindau|Meningioma|Glioma|Schwannomas|Neuroinflammation|Neoplasia",,United States,New Haven,Connecticut,5,RVP-001,DRUG,Adverse Events|Lesion visualization criteria for RVP-001 enhanced MRI compared to unenhanced MRI|Lesion visualization criteria for RVP-001 compared to gadolinium-based contrast agent (GBCA),,False,
NCT04291456,Minocycline in MS: Confirmation of Benefit,Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit,TERMINATED,2020-01-31,2022-12-16,2022-12-31,2023-03-24,2020-03-02,INTERVENTIONAL,PHASE3,9.0,ACTUAL,University of Calgary,OTHER,"Hotchkiss Brain Institute, University of Calgary|Multiple Sclerosis Society of Canada",OTHER|OTHER,Multiple Sclerosis|Clinically Isolated Syndrome,Multiple Sclerosis|Clinically Isolated syndrome|Minocycline,Canada,Calgary,Alberta,1,Minocycline 100mg,DRUG,proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria,Proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria|The proportion of participants with no evidence of disease activity (NEDA),False,
NCT02367222,"A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada","An Observational Retrospective Database Analysis to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada",COMPLETED,2014-08,2015-08,2015-12,2016-05-12,2015-02-20,OBSERVATIONAL,,1.0,ESTIMATED,University of Manitoba,OTHER,GlaxoSmithKline,INDUSTRY,Multiple Sclerosis,,,,,0,Exposed to Arepanrix™ Cohort|Unexposed to Arepanrix™ Cohort,OTHER|OTHER,Occurrence of MS,Occurrence of MS|Occurrence of demyelinating events which do not ultimately lead to a diagnosis of MS|Occurrence of demyelinating events which do not ultimately lead to a diagnosis of MS,False,
NCT03290131,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,"A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis",COMPLETED,2018-01-28,2018-12-03,2019-01-02,2022-07-15,2017-09-21,INTERVENTIONAL,PHASE3,536.0,ACTUAL,"RVL Pharmaceuticals, Inc.",INDUSTRY,Osmotica Pharmaceutical US LLC,INDUSTRY,"Multiple Sclerosis|Spasticity, Muscle",,Belarus,Grodno,,30,Arbaclofen|Placebo,DRUG|DRUG,Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL)|Clinical Global Impression of Change (CGIC),,True,2022-07-15
NCT05859802,Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis,Effects of Physical Therapy and Dalfampridine on Functional Mobility and Lower Extremity Strength in Non Ambulatory Persons With Multiple Sclerosis,COMPLETED,2011-07-13,2015-03-03,2016-01-09,2023-05-16,2023-05-16,INTERVENTIONAL,PHASE2|PHASE3,35.0,ACTUAL,D'Youville College,OTHER,Acorda Therapeutics|University at Buffalo,INDUSTRY|OTHER,Multiple Sclerosis,Dalfampridine|Functional Mobility|Non ambulatory|Cognition|Quality of Life,,,,0,Dalfampridine Pill|Placebo,DRUG|DRUG,MSQOL -54|MSQOL -54|MSQOL -54|Five time Sit to Stand|Five time Sit to Stand|Five time Sit to Stand,Symbol Digit Modalities Test|Symbol Digit Modalities Test|Symbol Digit Modalities Test|Wheel chair to Mat transfers - Functional Independence Measure|Wheel chair to Mat transfers - Functional Independence Measure|Wheel chair to Mat transfers - Functional Independence Measure|Standing Tolerance|Standing Tolerance|Standing Tolerance|9 Hole Peg Test|9 Hole Peg Test|9 Hole Peg Test,False,
NCT01871337,Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS),A Clinical Trial for the Efficacy of Paula Method ( Circular Muscle Exercise) in Women With Multiple Sclerosis Who Suffer From Urinary Incontinence,COMPLETED,2014-02,2015-09,2015-09,2015-09-22,2013-06-06,INTERVENTIONAL,NA,12.0,ACTUAL,Hadassah Medical Organization,OTHER,,,Urinary Incontinence;|Multiple Sclerosis,Multiple Sclerosis|urinary incontinence,Israel,Jerusalem,,2,Paula method,BEHAVIORAL,"Urinary Incontinence ,measured by The ICIQ-SF Short Form questionnaire","quality of life, sexual function and mobility",False,
NCT02123537,Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation,Functional Electrical Stimulation to Treat Foot Drop in People With Multiple Sclerosis,COMPLETED,2014-06,2016-07,2016-07,2016-09-07,2014-04-25,INTERVENTIONAL,NA,10.0,ACTUAL,University of Manitoba,OTHER,Riverview Health Centre Foundation,OTHER,Multiple Sclerosis|Foot Drop,Bioness L300 Foot Drop System|Functional electrical stimulation,Canada,Winnipeg,Manitoba,1,Bioness L300 Foot Drop System,DEVICE,Speed during the 10-metre straight line walking test,Distance travelled during the 4-minute figure-8 walking test|Speed during the 10-metre straight line walking test|Speed during the 10-metre straight line walking test|Distance travelled during the 4-minute figure-8 walking test|Distance travelled during the 4-minute figure-8 walking test|Physiological cost index during walking tests|Physiological cost index during walking tests|Physiological cost index during walking tests|Participant satisfaction questionnaire score|Treadmill Gait Assessment,False,
NCT00725985,Oral Cladribine in Early Multiple Sclerosis (MS),"A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS",COMPLETED,2008-12-31,2011-07-31,2012-04-30,2021-03-22,2008-07-31,INTERVENTIONAL,PHASE3,617.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,,,Multiple Sclerosis,Clinically Isolated Syndrome (CIS)|Early MS|Multiple Sclerosis,United States,Phoenix,Arizona,158,Cladribine|Placebo|Rebif® new formulation (RNF),DRUG|DRUG|DRUG,ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS,"ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS|ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan|OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria|ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria|ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)|ITP: Number of New or Persisting Gd-enhanced Lesions|OLMP: Number of New or Persisting Gd-enhanced Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions|ITP: Number of New or Enlarging T2 Lesions|OLMP: Number of New or Enlarging T2 Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions|ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions|OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions|ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions|OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions|ITP: Changes From Baseline in Volume of T2 Lesions|OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions|ITP: Number of T1 Hypointense Lesions|OLMP: Number of T1 Hypointense Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions|ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions|OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions|ITP: Percentage of Participants With no New or Enlarging T2 Lesions|OLMP: Percentage of Participants With no New or Enlarging T2 Lesions|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions|ITP: Percent Change From Baseline in Brain Volume|OLMP: Percent Change From Baseline in Brain Volume|OLMP: Number of Relapses|LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses|LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses|OLMP: Annualized Relapse Rate|OLMP: Percentage of Relapse-Free Participants|ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs",True,2013-10-10
NCT01587690,Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells,Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells,COMPLETED,2011-11,2013-01,2013-01,2013-11-20,2012-04-30,OBSERVATIONAL,,24.0,ACTUAL,"Rutgers, The State University of New Jersey",OTHER,,,Multiple Sclerosis,,United States,New Brunswick,New Jersey,1,,,Relative MicroRNA expression in B cells,,False,
NCT06394310,Dry Needling in Multiple Sclerosis,The Effectiveness of Dry Needling on Reducing Spasticity and Promoting Mobility and Balance in People With Multiple Sclerosis,RECRUITING,2024-05-01,2025-07-02,2025-08-01,2025-06-11,2024-05-01,INTERVENTIONAL,NA,24.0,ESTIMATED,University of Kansas Medical Center,OTHER,,,Multiple Sclerosis|Spasticity,multiple sclerosis|Dry needling|Spasticity|Mobility|Balance,United States,Kansas City,Kansas,1,Dry needling|Sham dry needling,DEVICE|DEVICE,Spasticity,,False,
NCT05762003,Czech Pharmaco-epidemiological Study on Disease Modifying Drugs,Czech Pharmaco-epidemiological Real World Data Study Focused on Effectiveness of Different Disease Modifying Drugs,COMPLETED,2019-01-01,2021-12-31,2021-12-31,2023-03-09,2023-03-09,OBSERVATIONAL,,17478.0,ACTUAL,IMPULS Endowment Fund,OTHER,,,Multiple Sclerosis,,Czechia,Prague,,1,"interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab",DRUG,Effectiveness in relapses|Effectiveness EDSS,Description of baseline characteristics of patients treated by different DMDs at the time of DMT initiation|Description of termination of different DMDs treatment,False,
NCT02740361,Online Program to Reduce Depression in MS,International Deprexis Trial in Multiple Sclerosis (IDEMS) - a Multicenter Randomized Controlled Trial,COMPLETED,2017-02-15,2021-01-30,2021-05-01,2025-05-20,2016-04-15,INTERVENTIONAL,NA,279.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"National Multiple Sclerosis Society|Universitätsklinikum Hamburg-Eppendorf|Cedars-Sinai Medical Center|University of Missouri, Kansas City|Penn State University|King's College London|University Medical Center Goettingen|NeuroCure Clinical Research Center, Charite, Berlin",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,,United States,Los Angeles,California,5,"Deprexis, DeprexisPlus",BEHAVIORAL,Beck Depression Inventory-II,WHO Quality of Life scale (WHO-QOL BREF)|Multiple Sclerosis Impact Scale (MSIS)|Fatigue Scale for Motor and Cognitive Functions (FSMC)|Chalder Fatigue Scale,False,
NCT02259361,Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS,Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study,UNKNOWN,2014-11,2014-11,2014-11,2014-10-08,2014-10-08,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,,Israel,Tel Litwinsky,Ramat-gan,1,Sustained-release oral dalfampridine|Placebo,DRUG|DRUG,Nine-Hole Peg Test|Nine-Hole Peg Test|Nine-Hole Peg Test,"Box and Block test|Box and Block test|Box and Block test|Isometric grip force and motor fatigue|Isometric grip force and motor fatigue|Isometric grip force and motor fatigue|Sensory evaluation|Sensory evaluation|Sensory evaluation|Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)|Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)|Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)",False,
NCT02016222,Tear Analysis in the Diagnosis of Multiple Sclerosis,Tear Analysis in the Diagnosis of Primary Progressive Forms of Multiple Sclerosis,COMPLETED,2011-04,2016-03,2016-03,2016-09-20,2013-12-19,INTERVENTIONAL,NA,80.0,ACTUAL,Lille Catholic University,OTHER,Bayer,INDUSTRY,Primary Progressive Multiple Sclerosis,primary progressive multiple sclerosis|diagnosis|tears|isoelectric focusing|oligoclonal bands,France,Nice,Alpes Maritimes,13,tears sampling,PROCEDURE,Concordance between the quantification of oligoclonal IgG bands by isoelectric focusing in tears and in the cerebrospinal fluid in patients with primary progressive multiple sclerosis,Isoelectrophoretic profile of tears|Isoelectrophoretic profiles of tears by digital recording and analysis of images,False,
NCT04746976,Study of Diroximel Fumarate in the Real-World Setting,"A Prospective, Observational Study Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World Setting (EXPERIENCE-US Study)",TERMINATED,2021-03-01,2023-04-14,2023-04-14,2023-05-26,2021-02-10,OBSERVATIONAL,,75.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of MS,Clinically isolated syndrome|Multiple Sclerosis|Relapsing forms of Multiple Sclerosis|Active secondary progressive disease,United States,West Hollywood,California,18,Diroximel Fumarate,DRUG,Percentage of Participants on Treatment with DRF at 1 Year,"Percentage of Participants on Treatment with DRF at 3 Months|Percentage of Participants on Treatment with DRF at 2 Years|Annualized Relapse Rate (ARR) with DRF|Percentage of Participants Relapsed|Change in Processing Speed Test (PST) Score from Baseline|Change in Score for Each Domain of Quality of Life in Neurological Disorders (Neuro- QoL™) Questionnaire|Change in Disability, as Measured by Patient Determined Disease Steps (PDDS)|Change in Work Productivity and Activity Impairment Due to Multiple Sclerosis (WPAI- MS) Scores from Baseline|Number of Participants with Gastrointestinal (GI) Adverse Events (AEs)|Number of Participants with AEs Leading to Treatment Discontinuation|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants categorized by the types of actions taken to mitigate GI AEs|Median Absolute Lymphocyte Count (ALC) Over Time|Percent Change in Median ALC from Baseline|Number of Participants with Lymphopenia According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE)Severity Grading",False,
NCT05092191,Cannabis as a Complementary Treatment in Multiple Sclerosis,Efficacy of Cannabinoids to the Current Standard Treatments on Symptom Relief in Persons With Multiple Sclerosis: Randomized Controlled Trial,RECRUITING,2022-11-10,2025-04-10,2025-05-10,2024-12-13,2021-10-25,INTERVENTIONAL,PHASE2,250.0,ESTIMATED,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,Canadian Institutes of Health Research (CIHR)|Multiple Sclerosis Society of Canada,OTHER_GOV|OTHER,Multiple Sclerosis,,Canada,Montreal,Quebec,1,Cannabis oil vs placebo,DRUG,Spasticity patient reported change assessment,,False,
NCT00621374,Management of Pain in Persons With Multiple Sclerosis,Pilot Study of CBT and Self-hypnosis Training for Pain in Persons With Multiple Sclerosis,COMPLETED,2008-02,2009-06,2009-06,2013-01-16,2008-02-22,INTERVENTIONAL,NA,22.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Pain,Pain Management|Cognitive Behavior Therapy|Hypnosis,United States,Seattle,Washington,1,Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|Cognitive Behavioral Therapy (CBT)|Self-Hypnosis Training (HYP)|Education Control (CONT),BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,A composite of average daily pain intensity measured using a 0-10 NRS via four phone interviews performed on different days by research staff.,"Sleep quality- Medical Outcomes Sleep Study Measure (Hays et al., 2005)|Depression- (CMDI; Nyenhuis et al., 1998)|Catastrophizing cognitions- (PCS; Sullivan et al. 1995)|Adaptive cognitions (CPAQ; McCracken et al., 2004)|Distinguishing neuropathic vs. non-neuropathic pain (S-LANSS; Bennett et al., 2005)|Pain Interference-(Brief Pain Inventory, Cleeland et al., 1994)|Impact of Fatigue (FIS; Fisk et al. 1993)|Fatigue Severity (FSS; Krupp et al., 1989)|Health Status (SF-36; Ware et al., 1992)",False,
NCT00959218,Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis,"Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain",COMPLETED,2007-06,2010-03,2010-04,2012-02-03,2009-08-14,INTERVENTIONAL,PHASE3,240.0,ACTUAL,Bionorica Research GmbH,INDUSTRY,,,Central Neuropathic Pain in Multiple Sclerosis,Dronabinol|(-)trans-delta9-tetrahydrocannabinol|central neuropathic pain|multiple sclerosis|analgesic|Central neuropathic pain related to multiple sclerosis,Germany,Lüdenscheid,,1,Dronabinol|Placebo,DRUG|DRUG,Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary,Likert Numerical Rating Scale pain relief|Pain-related sleep interference|SF-36 (QoL-questionnaire)|Intake of rescue medication,False,
NCT06849882,Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis,Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis,RECRUITING,2025-02-10,2025-03,2025-05,2025-03-03,2025-02-27,OBSERVATIONAL,,33.0,ESTIMATED,Inonu University,OTHER,Kayseri Erciyes University Faculty of Medicine,UNKNOWN,MS (Multiple Sclerosis),Multiple Sclerosis|Dubousset Functional Test|Validity|Reliability,Turkey (Türkiye),Kayseri,Kayseri,1,,,Dubousset Functional Testing in Individuals with MS,TUG (Timed Up and Go) Test|Dual Task TUG (Additional Cognitive Task)|Tinetti POMA|Berg Balance Scale (BBS)|3 Meter Backward Walking Test (3MBWT)|Functional Reach Test (FRT),False,
NCT02772666,Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect,New Automatic Portable Ophthalmology Device,COMPLETED,2015-12,2016-05,2016-06,2016-12-29,2016-05-13,INTERVENTIONAL,NA,44.0,ACTUAL,Mashhad University of Medical Sciences,OTHER,,,Multiple Sclerosis|Glaucoma,Relative afferent pupillary defect (RAPD)|Multiple sclerosis|Glaucoma,,,,0,O-Glass|Swinging Flashlight Test,DEVICE|OTHER,Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD),,True,2016-11-01
NCT07178431,MB-CART2019.1 in Refractory Multiple Sclerosis,"An Open Label Phase I/IIa, Multicenter, Interventional Single-arm Trial of MB-CART 2019.1 in Patients With Refractory Multiple Sclerosis (MS)",NOT_YET_RECRUITING,2025-10-30,2030-02-28,2030-12-30,2025-09-17,2025-09-17,INTERVENTIONAL,PHASE1|PHASE2,26.0,ESTIMATED,Miltenyi Biomedicine GmbH,INDUSTRY,,,Multiple Sclerosis|CAR T Cell Therapy,,Germany,Berlin,,1,MB-CART2019.1,BIOLOGICAL,Primary endpoints Phase I|Primary endpoints Phase IIa,Secondary endpoints Phase I only (primary in phase IIa),False,
NCT05442112,Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes,A Randomized Control Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes,COMPLETED,2023-06-11,2024-05-11,2024-05-11,2024-05-17,2022-07-01,INTERVENTIONAL,NA,51.0,ACTUAL,Johns Hopkins University,OTHER,,,Multiple Sclerosis,,United States,Baltimore,Maryland,1,Wellness Patient Message,BEHAVIORAL,Change in self-efficacy as assessed by the MS Self-Efficacy Scale (MSSE),Change in Sleep Disturbance the Neuro-Quality of Life Sleep disturbance short form|Change in Diet behavior Scores as assessed by the Mediterranean-DASH Intervention for Neurodegenerative Delay score (MIND Diet score)|Change in Reported physical activity as assessed by the Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Change in Reported physical activity as assessed by the International Physical Activity Questionnaire (IPAQ) short form,False,
NCT01970410,MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV,MAIN STUDY: Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? SUB-STUDY: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide,COMPLETED,2013-10,2021-04-30,2022-02-14,2023-01-30,2013-10-28,INTERVENTIONAL,PHASE4,55.0,ACTUAL,Providence Health & Services,OTHER,Multiple Sclerosis Center of Northeastern New York,OTHER,Multiple Sclerosis,teriflunomide|natalizumab|relapsing multiple sclerosis,United States,Phoenix,Arizona,3,teriflunomide,DRUG,MAIN STUDY: Number of Participants Relapse Free at 24 Months,"MAIN STUDY: Time to Return of Radiological Evidence of Multiple Sclerosis Activity With New Gadolinium ""Enhancing"" (Gd+) Lesions on Cranial MRI.|MAIN STUDY: Expanded Disability Status Scale (EDSS) Sustained Progression for 3 Months as Measured by at Least 0.5 Increase From Baseline or 1 in Any EDSS Set Score|MAIN STUDY: Mean Time to New T2 or Enlarging T2 Hyperintensities on Monthly Sentinel Brain MRIs",True,2022-10-20
NCT07183020,Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS),"Prospective, Multicentric, Real-world Investigation of Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)",ENROLLING_BY_INVITATION,2022-10-27,2026-07-31,2026-12-31,2025-09-19,2025-09-19,OBSERVATIONAL,,1142.0,ESTIMATED,"Skripuletz, Thomas Prof. Dr.",OTHER,,,Multiple Sclerosis|Clinically Isolated Syndrome (CIS),multiple sclerosis|clinically isolated syndrome|cerebrospinal fluid|kappa free light chains|oligoclonal bands|biomarker|diagnosis,Germany,Hanover,Lower Saxony,1,Oligoclonal bands and kappa free light chains (KFLC),DIAGNOSTIC_TEST,Non-inferiority of diagnostic sensitivity of cerebrospinal fluid (CSF) kappa free light chains (KFLC) in multiple sclerosis (MS) and clinically isolated syndrome (CIS) compared to oligoclonal bands,Superiority of Reiber´s diagram for kappa free light chains (KFLC) compared to KFLC index of 6.1 to assess for an intrathecal KFLC synthesis in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients,False,
NCT07159789,Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis,Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis,RECRUITING,2025-10-01,2027-10,2028-03,2025-09-12,2025-09-08,INTERVENTIONAL,NA,60.0,ESTIMATED,Clinique Neuro-Outaouais,OTHER,University of Ottawa,OTHER,Multiple Sclerosis,rTMS|Neuromodulation|MS Induced Spastic Paraparesis|Spastic paresis|neural synchrony|neuroplasticity,Canada,Gatineau,Quebec,1,Repetitive Transcranial Magnetic Stimulation,DEVICE,Improvement of T25FWT (Timed 25-Foot Walk Test),6MWT (Six minute Walk Test)|MSQoL (Multiple Sclerosis Quality of Life),False,
NCT07155642,Yoga in Multiple Sclerosis Patients,"Effects of Yoga and Conventional Physiotherapy Programs on Fatigue, Balance, Walking and Quality of Life in Multiple Sclerosis Patients.",COMPLETED,2019-03-04,2019-04-20,2019-06-07,2025-09-04,2025-09-04,INTERVENTIONAL,NA,20.0,ACTUAL,Istanbul Rumeli University,OTHER,,,Multiple Sclerosis,multiple sclerosis|yoga|fatigue|balance|quality of life,Turkey (Türkiye),Ataşehir,Istanbul,1,yoga|conventional physiotheraphy,OTHER|OTHER,MS Walking Scale (MSWS-12)|MS Quality of Life-54 (MSQOL-54),Fatigue Severity Scale (FSS)|Berg Balance Scale (BBS),False,
NCT02391961,Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis,Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis,COMPLETED,2015-04-01,2019-01-31,2019-03-31,2020-09-04,2015-03-18,INTERVENTIONAL,PHASE2,23.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis|Internuclear Ophthalmoplegia|Fatigue,,United States,Cleveland,Ohio,1,Dalfampridine|Placebo,DRUG|DRUG,Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity.|Pulse Time Delay (PTD): Time Difference Between Onset of the Saccade in the Adducting Eye and Onset of the Saccade in the Abducting Eye.,Reading Acuity (RA)|Maximum Reading Speed (MRS)|Gait Assessment|National Eye Institute (NEI) Visual Function Questionnaire 25 (VFQ-25)|10-Item Neuro-Ophthalmic Supplement (NOS),True,2020-09-04
NCT00881205,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,"A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase",TERMINATED,2009-04,2011-01,2011-01,2012-03-12,2009-04-15,INTERVENTIONAL,PHASE4,86.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Cognitive Impairment,Multiple Sclerosis|Cognition|Rivastigmine|Patch,Germany,Aachen,,49,Rivastigmine transdermal patch|Placebo,DRUG|DRUG,Change From Baseline to Week 16 in Total Recall on the Selective Reminding Test (SRT) in the Intent to Treat (ITT) Population,,True,2012-02-24
NCT03429062,Comparison of Two Community Based Exercise Protocols in People With Multiple Sclerosis,The Comparison of Community Based Personal Training to Whole Body Vibration on Balance and Gait Parameters in People With Multiple Sclerosis,WITHDRAWN,2018-02-13,2019-02-13,2019-02-13,2019-09-17,2018-02-12,OBSERVATIONAL,,0.0,ACTUAL,Texas Woman's University,OTHER,,,Multiple Sclerosis,balance|gait|Multiple Sclerosis,United States,Fort Worth,Texas,1,Personal training exercises,OTHER,Mini Balance Evaluations Systems Test (MiniBEST Test),Activities Specific Balance Scale|Fatigue Severity Scale|Multiple Sclerosis Impact Scale|Dynamic Gait Index|5 Times Sit to Stand Test|2 Minute Walk test,False,
NCT05623254,Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.,Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers: a Pilot Study (KMPO Project),UNKNOWN,2023-01-02,2023-12-31,2023-12-31,2023-03-02,2022-11-21,INTERVENTIONAL,NA,1.0,ESTIMATED,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,OTHER,,,Chronic Migraine; Multiple Sclerosis; Motoneuron Disease,,Italy,Milan,,1,no comparator - TAU (Treatment-as-usual),OTHER,MINDFULNESS,,False,
NCT06433765,A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS),BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®,RECRUITING,2024-06-01,2035-03-31,2035-03-31,2025-08-29,2024-05-30,OBSERVATIONAL,,728.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Wilmington,North Carolina,1,No intervention,OTHER,Percentage of Participants with Major Congenital Malformations (MCMs),,False,
NCT01371071,Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis,"Clinically Isolated Syndrome and Newly Diagnosed Multiple Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational Study (Berlin CIS-COHORT)",UNKNOWN,2011-01,2017-12,2017-12,2011-06-10,2011-06-10,OBSERVATIONAL,,200.0,ESTIMATED,"Charite University, Berlin, Germany",OTHER,,,"Multiple Sclerosis, MS|Clinically Isolated Syndrome",Clinically isolated syndrome (CIS)|Multiple sclerosis (MS)|Immunomodulatory therapy|Prognostic markers|MRI|OCT,Germany,Berlin,,2,,,time (in days) until relapse during the observation period of four years,"MRI - parameters: number and volume of T2 and gadolinium enhancing lesions, analysis of lesion patterns (spinal und cerebral MRI)|biomarkers: RNA, microRNA, DNA, proteins, enzymes, autoantibodies, antiviral antibodies, virus DNA, Vitamin D and lipids in serum, plasma, peripheral cells, urine, saliva and CSF|Optical Coherence Tomography (OCT): thickness of the retinal nerve fibre layer (RNFL) or total macular volume (TMV)",False,
NCT06951919,HOBSCOTCH-MS-Efficacy Trial,HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS) - Efficacy Trial,RECRUITING,2025-09-09,2028-05,2028-12,2025-09-12,2025-04-30,INTERVENTIONAL,NA,125.0,ESTIMATED,Dartmouth-Hitchcock Medical Center,OTHER,,,Multiple Sclerosis|Cognitive Dysfunction|Memory Disorders|Memory Impairment|Memory Dysfunction,Cognition|Self-Management|Cognitive Remediation|Cognitive Training|Memory Disorders|Caregivers|Caregiver Burden|Mindfulness,United States,Lebanon,New Hampshire,1,Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS),BEHAVIORAL,Change in quality of life in MS participants as measured by comparing PROMIS-10 Global Health scores at baseline and at 3 months post-intervention.|Change in subjective cognitive function in MS participants as measured by comparing scores on the Cognitive Function Sub-Scale (Item Bank 2.0) of the Neuro-QOL at baseline and at 3 months post-intervention.|Change in Caregiver participants caregiver burden as measured by comparing Zarit Burden Interview scores at baseline and at 3 months post-intervention.,Changes in MS and Caregiver participants' knowledge of relationship between the condition of MS and cognition and memory as measured by comparing scores on the HOBSCOTCH-MS Knowledge Questionnaire at baseline and at 6 months (end of study).|Change in MS participants quality of life as measured by comparing FAMS-Functional Assessment of Multiple Sclerosis v4.0 scores at base line and at 3 months post-HOBSCOTCH-MS intervention.|Change in MS participants objective cognitive processing speed as measured by comparing Symbol-Digit Modalities Test scores (orally) at base line and at 3 months post-HOBSCOTCH-MS intervention.|Change in MS participants verbal learning and memory as measured by comparing California Verbal Learning Test-III scores at baseline and 3 months post-HOBSCOTCH-MS intervention|Change in MS participants visuospatial learning and memory as measured by comparting Brief Visuospatial Memory Test-Revised (BVMT-R) scores at baseline and 3 months post-HOBSCOTCH-MS intervention|Changes in MS participants executive function as measured by comparing scores on the self-reported Behavior Inventory of Executive Function-Adult Version (BRIEF-A) at baseline and 3-months post intervention.|Changes in MS participants self-efficacy as measured by comparing scores on the PROMIS (Patient-Reported Outcomes Measurement Information System) Item Bank v1.0 General Self-Efficacy assessment at baseline and 3-months post-intervention.|Changes in MS participants and Caregiver participants mood as measured by comparing scores on the Patient Health Questionnaire (PHQ-9) at baseline and at 3 months post- intervention.|Changes in MS participants and Caregiver participants anxiety as measured by comparing score on the Generalized Anxiety Disorder-7 (GAD-7) at baseline and at 3-months post-intervention.|Changes in MS participants' symptom frequency as measured by a daily self-reported diary compared at baseline and at 3 months post-intervention.|Changes in MS participants' medication adherence as measured by a daily self-reported diary of compared at baseline and at 3 months post-intervention.|Changes in MS participants' use of memory strategies as measured by a daily self-reported diary compared at baseline and 3 months post-intervention.|Changes in Caregiver participants use of quick relaxation strategies as measured by a daily self-reported diary compared at baseline and 3 months post-intervention.|Changes in MS participants and MS Caregiver participants self-reports of wellbeing as measured by comparing daily reports of well-being in a diary at baseline and at 3 months post-intervention.|Engagement and Satisfaction for MS participants as measured by analyzing study attrition and a Participant Satisfaction Survey at the end of the study.|Engagement and Satisfaction for MS Participants as measured by CollaboRATE post-study completion.|HOBSCOTCH-MS fidelity as measured by MS participant's compliance with weekly homework assignments.|Changes in MS Caregiver participants self-reported health status as measured by comparing scores on the Short-Form Health Survey 36 (SF-36) at baseline and 3 months-post HOBSCOTCH MS intervention.|Feasibility of HOBSCOTCH-MS program for Caregivers as measured by study attrition and a Participant Satisfaction Survey.|Sustainability of improvement on primary outcome measure of quality of life for Group 1 MS Participants by comparing scores on the PROMIS 10-Global Health at 3 months and 6 months post-intervention.|Sustainability of improvement on primary outcome measure of quality of life for Group 1 MS Participants by comparing scores on the Neuro-QOL at 3 months and 6 months post-intervention.|Sustainability of improvement on primary outcome measures for Group 1 Caregiver Participants by comparing scores on the Zarit Caregiver Burden at 3 months and 6 months post-intervention.,False,
NCT06485232,Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.,An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System,NOT_YET_RECRUITING,2025-02-28,2026-12-31,2027-12-31,2025-01-01,2024-07-03,INTERVENTIONAL,EARLY_PHASE1,25.0,ESTIMATED,"Xuanwu Hospital, Beijing",OTHER,Bioray Laboratories,INDUSTRY,"Neuromyelitis Optica Spectrum Disorders|Myasthenia Gravis, Generalized|Multiple Sclerosis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy",universal CAR-T|Neuromyelitis Optica Spectrum Disorders|Myasthenia Gravis|Multiple Sclerosis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy,China,Beijing,Beijing Municipality,1,Universal BCMA CAR-T|Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T,DRUG|DRUG|DRUG,Incidence of dose-limiting toxicities(DLTs)|Incidence of adverse events(AEs) and severe adverse,Concentrations of UCAR-T cells|B cell levels in peripheral blood|Changes of pathogenic antibody titers after infusion|NMOSD: Annualized relapse rate|gMG: Changes of Myasthenia Gravis Activities if Daily Living (MG-ADL) Score|CIDP:Changes of Inflammatory Neuropathy Cause and Treatment (INCAT) Score after infusion.|MS: Changes of the number of Gd-enhancing T1 Lesions|MS: Changes of the number of Number of New or Enlarging T2 Lesions,False,
NCT03808545,Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS,Comprehensive Lifestyle Intervention for Reducing Cardiometabolic Risk and Symptom Burden in Adults With Multiple Sclerosis,TERMINATED,2019-02-26,2020-03-19,2020-03-19,2022-11-18,2019-01-17,INTERVENTIONAL,NA,11.0,ACTUAL,University of Alabama at Birmingham,OTHER,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,Multiple Sclerosis,,United States,Birmingham,Alabama,1,Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|BIPAMS + Diet,BEHAVIORAL|BEHAVIORAL,BMI Change|Waist Circumference Change|Fat Mass Change,Diastolic Blood Pressure Change|Systolic Blood Pressure Change|Glucose Change|Insulin Change|Triglycerides Change|LDL-C Change|HDL-C Change|Total Cholesterol Change|Change in Fatigue Severity Scale|Change in Modified Fatigue Impact Scale|Change in Depression Symptoms|Change in Anxiety,True,2022-11-18
NCT06900244,Metabolic Imaging of Neurological Disease,Probing Metabolic Dysregulation and Altered Substrate Metabolism in the Healthy and Disrupted Brain Using Hyperpolarised 13C Labelled Substrates.,ENROLLING_BY_INVITATION,2021-07-01,2027-06,2027-06,2025-03-28,2025-03-28,OBSERVATIONAL,,250.0,ESTIMATED,University of Oxford,OTHER,,,Multiple Sclerosis,,United Kingdom,Oxford,,1,,,"To detect 13C metabolism in healthy participants and MS, CIS, and Stroke patients.",,False,
NCT04567264,"Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",Prospective Single Centre Trial of Percutaneous Tibial Nerve Stimulation With the Implantable StimRouter Neuromodulation System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,COMPLETED,2020-08-26,2022-06-30,2022-06-30,2023-09-07,2020-09-28,INTERVENTIONAL,NA,23.0,ACTUAL,Chiara Zecca,OTHER,ABREOC,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",overactive bladder|posterior tibial nerve stimulation|lower urinary tract symptoms,Switzerland,Lugano,Canton Ticino,1,"StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).",DEVICE,Change in bladder volume,Cystometric capacity (mL)|Compliance (ml/cmH20)|Maximum detrusor pressure (cmH20) during storage phase|Maximum detrusor pressure (cmH20) during voiding phase|Voided volume (mL)|Maximum flow rate (mL/s)|Post void residual|Pelvic floor electromyographic activity (normal/detrusor sphincter dyssynergia/non-relaxing pelvic floor)|Number of voids/day|Volume voided/void|Number of leaks per day|Degree of urgency prior to void|Number of CISC through the day|Residual urine volume|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Over active bladder questionnaire (OAB),False,
NCT05199571,Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China,"A 12-month, Open-label, Prospective, Multicenter, Interventional, Single-arm Study Assessing the Efficacy and Safety of Ofatumumab 20 mg Subcutaneous (s.c.) Injection in Relapsing Multiple Sclerosis (RMS) Patients in China",COMPLETED,2022-07-22,2025-02-13,2025-02-13,2025-03-10,2022-01-20,INTERVENTIONAL,PHASE4,99.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing multiple sclerosis|open-label|interventional|efficacy and safety|ofatumumab|China|adult|OMB157,China,Lanzhou,Gansu,18,Ofatumumab,BIOLOGICAL,Annualized relapse rate (ARR),Number of adverse events and serious adverse events|Number of gadolinium (Gd)-enhancing T1 lesions per MRI scan|Annualized rate of new or enlarging T2 lesion|Percent change in T2 lesion volume relative to baseline,False,
NCT01171209,REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients,REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients,COMPLETED,2010-07,2011-06,2011-08,2012-11-30,2010-07-28,INTERVENTIONAL,PHASE2,10.0,ACTUAL,Melinda Magyari,OTHER,University of Copenhagen,OTHER,Multiple Sclerosis,MS,,,,0,Interferon-beta and human leukocyte Interferon-α,DRUG,In vivo mRNA MxA response,Determining response marker: IL10|Determining response marker:TRAIL|Determining response marker IFI27|Determining response marker:CXCL10 at mRNA level|Changes i Neutralizing antibodies Nabs,False,
NCT05460299,Closed Kinetic Chain Exercises for Balance and Gait Rehabilitation for People With MS,Effects of Closed Kinetic Chain Exercises on Balance and Gait in People With Multiple Sclerosis: A Randomized Controlled Trial,UNKNOWN,2023-07-04,2023-08-16,2023-08-20,2023-06-13,2022-07-15,INTERVENTIONAL,NA,24.0,ESTIMATED,Anas Radi Hassan Alashram,OTHER,,,Multiple Sclerosis,,Jordan,Amman,,1,Telko plus conventional physical therapy (CPT),COMBINATION_PRODUCT,6-minute walk test (6-MWT)|Berg Balance Scale (BBS),Timed-Up and Go (TUG),False,
NCT04626921,"A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis","VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis",COMPLETED,2020-10-22,2023-05-29,2023-09-06,2023-12-08,2020-11-13,INTERVENTIONAL,PHASE2|PHASE3,55.0,ACTUAL,Clene Nanomedicine,INDUSTRY,George Clinical,UNKNOWN,Relapsing Multiple Sclerosis,MS|RMS|Multiple Sclerosis|Demyelination|Remyelination|Optic Neuropathy|Optic Neuritis|Gold|Nanocrystal|Multifocal VEP|Full Field VEP|Low contrast letter acuity,Australia,Camperdown,New South Wales,5,CNM-Au8,DRUG,Change in Best-Corrected Low-Contrast Letter Acuity score.|Incidence of treatment-emergent AEs throughout the study.,Measure of neurological function assessed by a functional composite responder analysis.,False,
NCT01684761,Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis,"A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis",COMPLETED,2012-08,2016-10,2016-10,2017-01-10,2012-09-13,INTERVENTIONAL,PHASE2,183.0,ACTUAL,"Opexa Therapeutics, Inc.",INDUSTRY,,,Autoimmune Diseases of the Nervous System|Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Disease Progression|Brain Atrophy,Multicenter Study|Randomized Controlled Trial|Individualized Medicine|Immunotherapy|Myelin Proteins|Biological Agents,United States,Phoenix,Arizona,36,Tcelna|Placebo,BIOLOGICAL|BIOLOGICAL,Brain Atrophy,Disease Progression,False,
NCT01906866,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",COMPLETED,2013-10,2018-03-27,2018-03-27,2024-04-23,2013-07-24,INTERVENTIONAL,PHASE3,125.0,ACTUAL,Neurim Pharmaceuticals Ltd.,INDUSTRY,,,Sleep Disorders,Sleep disturbance|Circadian|Prolong release melatonin|Autism Spectrum Disorder|Smith-Magenis Syndrome|Angelman Syndrome|tuberous sclerosis,United States,Phoenix,Arizona,28,Circadin 2/5/10 mg|Placebo,DRUG|DRUG,Total Sleep Time (TST),Sleep Latency (Mins)|Duration of Wake After Sleep|Number of Awakenings Per Night|Longest Sleep Period|Social Functioning - Children Global Assessment Scale (CGAS)|Behavior at Home and in School - Strengths and Difficulties Questionnaire (SDQ)|Number of Dropouts|Assessment of Sleep Parameters by Actigraphy|Safety and Tolerability - Treatment Emergent Signs and Symptoms (TESS) Summary.|Safety and Tolerability - Blood Pressure (mmHg)|Safety and Tolerability - Pulse (Beats Per Minute)|Safety and Tolerability - Respiratory Rate (Bpm)|Safety and Tolerability - Body Temperature (°C),True,2018-10-30
NCT03619642,"Reliability, Validity and Clinical Utility of a Robotic Assessment for Proprioception","Reliability, Validity and Clinical Utility of a Robotic Assessment of Finger Proprioception in Neurological Subjects",COMPLETED,2017-12-15,2018-05-31,2018-05-31,2018-09-13,2018-08-08,INTERVENTIONAL,NA,50.0,ACTUAL,Hasselt University,OTHER,Jessa Hospital|Revalidatie & MS Centrum Overpelt,OTHER|OTHER,Neurological Diseases or Conditions|Sensory Disorders|Multiple Sclerosis|Stroke,,Belgium,Hasselt,,2,Robotic assessment of finger proprioception,OTHER,Error|Error,sex|Age|medication use|the modified Ashworth scale|Edinburgh Handedness Inventory|Nine Hole Peg test|Box and block test|Manual Ability Measure-36 (questionnaire)|Symbol digit modalities test|25 foot walk test|Semmens-Weinstein monofilaments|Semmens-Weinstein monofilaments|Semmens-Weinstein monofilaments|Rydel Seiffer Tuning fork|Rydel Seiffer Tuning fork|Rydel Seiffer Tuning fork|The Erasmus MC modification of the Nottingham Sensory Assessment (EmNSA)|The Erasmus MC modification of the Nottingham Sensory Assessment (EmNSA)|The Erasmus MC modification of the Nottingham Sensory Assessment (EmNSA)|The System Usability Scale (SUS)|The System Usability Scale (SUS),False,
NCT00799942,Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus,"Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus",TERMINATED,2009-05,,,2010-07-01,2008-12-01,INTERVENTIONAL,PHASE2,48.0,ESTIMATED,Merz Pharmaceuticals GmbH,INDUSTRY,,,"Nystagmus, Congenital|Nystagmus, Acquired|Multiple Sclerosis","Nystagmus, congenital idiopathic",United Kingdom,Leicester,,1,Neramexane mesylate,DRUG,"Long-term safety, Visual acuity",,False,
NCT05212805,Promoting Aerobic Training in Multiple Sclerosis,Aerobic Training as Substrate for Neural Plastic Changes in Multiple Sclerosis: a Putative Disease-modifying Treatment?,UNKNOWN,2018-01-01,2023-06-24,2023-12-25,2022-01-28,2022-01-28,INTERVENTIONAL,NA,62.0,ESTIMATED,Fondazione Italiana Sclerosi Multipla,OTHER,Universita degli Studi di Genova|University Grenoble Alps,OTHER|OTHER,Multiple Sclerosis,Aerobic exercise|Sports activity|Motor performance|Neural plasticity|Participation|Upper limb,Italy,Genoa,GE,1,Aerobic exercise|Task-oriented upper-limb training|Sport events participation,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in the 6 minute walk test (6mWT) performance,Change in the Timed 25-Foot Walk test (T25FW) performance|Change in the Nine Hole Peg Test (NHPT) performance|Change in the Modified Fatigue Impact Scale (MFIS) score|Change in the Short Form Health Survey (SF-36) score|Structural and functional plasticity of the Central Nervous System (CNS)|Interview|Change in the Hand Grip Strength Test (HGST) performance|Change in the Pinch Strength Test (PST) performance|Change in the Timed Up and Go (TUG) performance|Change in the Timed Up and Go cognitive (TUG-cog) performance|Change in the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) score|Change in the 12-Item MS Walking Scale (MSWS-12) score|Change in the Dual-task Impact of Daily Activities Questionnaire (DIDA-Q) score|Change in the Brief Illness Perception Questionnaire (Brief IPQ) score|Continuous monitoring of the time of activity|Continuous monitoring of calories expenditure|Questionnaire on acceptability,False,
NCT06854094,Consolidation Therapy with Cladribine in Relapsing Multiple Sclerosis Patients,Consolidation Therapy with Immune Reconstitution Therapy (cladribine) in Relapsing Multiple Sclerosis Patients Following a Treatment with Anti-CD20 Compounds: a Pivotal Study,RECRUITING,2024-10-03,2026-12,2028-12,2025-03-03,2025-03-03,OBSERVATIONAL,,70.0,ESTIMATED,"Ente Ospedaliero Cantonale, Bellinzona",OTHER,3B Biotech Research,OTHER,Multiple Sclerosis,Switch to Cladribine,Switzerland,Lugano,Canton Ticino,1,,,"changes in IgG serum concentrations 6, 12, 24 months after switching to cladribine following a treatment with anti-CD20 therapies compared to the last 12 months of antiCD20 therapy, and to patients continuing anti-CD20.",,False,
NCT03193866,COMparison Between All immunoTherapies for Multiple Sclerosis.,"COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis",COMPLETED,2017-06-02,2022-03-31,2022-03-31,2025-04-20,2017-06-21,OBSERVATIONAL,,3526.0,ACTUAL,Karolinska Institutet,OTHER,Patient-Centered Outcomes Research Institute|Kaiser Foundation Research Institute,OTHER|OTHER,Relapsing-remitting Multiple Sclerosis,Immunomodulating treatment|Cohort study|Dimethyl fumarate|Fingolimod|Interferon-beta|Natalizumab|Rituximab|Glatiramer acetate,Sweden,Stockholm,,1,Rituximab,DRUG,"Confirmed Disease Progression in Patients With Expanded Disability Status Scale (EDSS) <2.5 at Baseline|Confirmed Disease Progression in Patients With EDSS ≥2.5 at Baseline|Disease-related Impact on Daily Life, Physical|Disease-related Impact on Daily Life, Psychological",Annualized Relapse Rate|Remaining on Drug|Increase in EDSS|Proportion of Patients With at Least 1 Step Increase in EDSS|Proportion of Patients With No Evidence of Disease Activity (NEDA) -2|Proportion of Patients With NEDA-3|Quality of Life Assessments|Fatigue|Treatment Satisfaction|Rate of Serious Infections|Rate of Major Adverse Cardiovascular Events (MACE)|Rate of Invasive Cancer,True,2025-04-20
NCT00001156,Assessment of Patients With Multiple Sclerosis (MS),"Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS)",COMPLETED,1976-01-23,,2010-02-01,2017-07-02,1999-11-04,OBSERVATIONAL,,1388.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Herpesviridae Infection|HTLV-I Infection|Multiple Sclerosis|Tropical Spastic Paraparesis|Vasculitis,Immunogenetics|Tropical Spastic Paraplegia|Twins|Epstein-Barr Virus|HTLV-I|Vasculitis|Cerebrospinal Fluid|Immunity to Viruses|Multiple Sclerosis|Magnetic Resonance Imaging,United States,Bethesda,Maryland,1,,,,,False,
NCT04379193,Physical Therapy and Neuroactive Steroids Therapy Does Not Modulate Serum Level of Neuroactive Steroids,Ambulatory Neuroproprioceptive Facilitation and Inhibition Physical Therapy Does Not Modulate Serum Level of Neuroactive Steroids,COMPLETED,2015-05-20,2017-05-20,2019-09-01,2020-05-07,2020-05-07,INTERVENTIONAL,NA,63.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Multiple Sclerosis,neuroactive steroids|physical therapy|dehydroepiandrosterone|cortisol|multiple sclerosis,,,,0,Neuroproprioceptive facilitation and inhibition physical therapy,BEHAVIORAL,serum level of neuroactive steroids,"Berg Balance Scale, BBS outcomes|Paced Auditory Serial Addition Test|the 29-item Multiple Sclerosis Impact Scale, MSIS -29|Modified Fatigue Impact Scale",False,
NCT04510350,Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO),Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO),COMPLETED,2020-02-19,2022-03-02,2022-03-02,2022-03-03,2020-08-12,OBSERVATIONAL,,90.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,,France,Rennes,,1,Biomarkers analysis,OTHER,Frequency of immune subpopulations,Frequency of immune subpopulations correlated to EDSS score|Frequency of immune subpopulations correlated to disease progression delay|Frequency of immune subpopulations correlated to disease progression events|Frequency of immune subpopulations correlated to spinal lesions|Profiles of CIS+ patients,False,
NCT03710655,Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients",UNKNOWN,2019-04,2019-08,2019-11,2018-10-18,2018-10-18,INTERVENTIONAL,PHASE3,468.0,ESTIMATED,"Apimeds, Inc.",INDUSTRY,,,Multiple Sclerosis,QOL and pain,,,,0,Apitox - pure honeybee toxin|Placebo,DRUG|DRUG,Expanded Disability Status Scale (EDSS)|MS Functional Composite (MSFC),Quality of life questionnaire (MSQoL-54)|Functional System Scores (FSS)|Pain Intensity Numerical Rating Scale (PI-NRS)|Patient Global Impression of Change (PGIC)|Patient Global Assessment (PGA)|Physician's Global Assessment (PhGA),False,
NCT03283826,Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis,"A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis",TERMINATED,2017-10-19,2023-11-09,2024-01-17,2024-02-23,2017-09-14,INTERVENTIONAL,PHASE1|PHASE2,134.0,ACTUAL,Atara Biotherapeutics,INDUSTRY,,,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Multiple Sclerosis (MS)|Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Epstein-Barr Virus (EBV)|EBV-associated Multiple Sclerosis|Inflammation|Central Nervous System|Autoimmune Disease|Autoimmunity|Demyelination|Cell Therapy|T-cell|Allogeneic|EBV viremia|Off-the-shelf (T cells),United States,La Jolla,California,31,ATA188|Placebo,BIOLOGICAL|DRUG,"Part 1: Incidence of adverse events|Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signs|Part 1: Recommended Part 2 dose of ATA188 monotherapy|Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 months","Part 1: Change from baseline in EDSS score|Part 2: Percentage of participants with confirmed EDSS improvement at 15 months|Part 2: Percentage of participants with sustained disability improvement (SDI; ie, confirmed EDSS improvement or 20% decrease in timed 25-foot walk [T25W]) at 12 months|Part 2: Percentage of participants with SDI at 15 months|Part 2: Change from baseline in immunoglobulin G (IgG) index",False,
NCT05596526,Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients,Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric Study,RECRUITING,2022-12-01,2024-12-31,2025-12-31,2024-04-10,2022-10-27,INTERVENTIONAL,PHASE4,100.0,ESTIMATED,Prof Patrice Lalive,OTHER,,,Shingles|Zoster,RZV vaccine|Multiple Sclerosis|Immune response|Safety,Switzerland,Geneva,,1,recombinant zoster vaccine,BIOLOGICAL,Geometric mean titer (GMT) of glycoprotein E (gE)-specific total IgG,"Vaccine safety - AESI 7 days|Vaccine safety - SAE 360 days|Vaccine safety -pIMDs|Vaccine safety-relapse in MS patients|Vaccine immunogenicity - CD4+ T cells per million of T cells, measured at D90",False,
NCT03353974,Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.,The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.,COMPLETED,2017-12-01,2022-10-01,2022-10-01,2023-11-22,2017-11-27,INTERVENTIONAL,NA,48.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Video game therapy|Balance|Cognitive functions|Dual tasking,Italy,Ferrara,Emilia-Romagna,2,Video game therapy|Balance platform therapy,DEVICE|DEVICE,Timed Up and Go (TUG) test,Four Square Step Test (FSST)|Functional Reach Test (FRT)|Dynamic Gait Index (DGI)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Walking Scale-12 (MSWS-12)|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Beck Depression Inventory-Second Edition (BDI-II)|State Trait Anxiety Inventory (STAI-Y)|Go-No Go - Test of Attentional Performance T.A.P.|Test of Attentional Performance T.A.P.|Stroop Color-Word Test (SCWT)|Symbol Digit Modalities Test (SDMT)|Instrumented Basic Balance Evaluation (IBBE)|Instrumented Dual Task (IDT),False,
NCT07167680,Fall Prevention Among People With Spinal Cord Injury and Multiple Sclerosis Who Use Wheelchairs and Scooters,Development and Validation of a mHealth Fall Management Program - Phase III,NOT_YET_RECRUITING,2025-09-01,2026-08-01,2027-12-01,2025-09-11,2025-09-11,INTERVENTIONAL,NA,120.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,University of Illinois at Chicago,OTHER,Spinal Cord Injuries (SCI)|Multiple Sclerosis,wheelchair|fall prevention|mobile application|spinal cord injury|multiple sclerosis|education,United States,Urbana,Illinois,1,"Individualized reduction of falls (iROLL)|Stopping Elderly Accidents, Deaths & Injuries (STEADI)",PROCEDURE|PROCEDURE,"Functional Assessment of Currently Employed Technology Scale|Fall Concerns Scale for Wheelchair and Scooter Users|Falls Prevention Strategies Survey|The Fall Management Scale|Fall Prevention and Management Questionnaire|Community Participation Indicators Questionnaire|Transfer Assessment Instrument Questionnaire|Wheelchair Skills Test - Questionnaire|System Usability Scale|Usefulness, Satisfaction, and Ease of Use Questionnaire|Mobile App Rating Scale",,False,
NCT05671055,CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis,CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis,COMPLETED,2023-01-07,2023-12-06,2023-12-06,2023-12-07,2023-01-04,OBSERVATIONAL,,300.0,ACTUAL,icometrix,INDUSTRY,Bristol-Myers Squibb,INDUSTRY,Multiple Sclerosis,Cognition,United States,Aurora,Colorado,10,Custom study version of icompanion app,OTHER,Neuro-QoL cognitive|icognition Symbol test score|icognition Dot test score|icognition Digit test score,prEDSS|Neuro-QoL fatigue|Beck's depression inventory|MRI volumetric variables|System usability score (cognitive smartphone-based tests)|Preference icognition vs. paper-based assessments|SymptoMScreen,False,
NCT06870968,FIT-ATOMIC Exercise Feasibility Trial,An Exercise Training Intervention for Depressive Symptoms in Youth With MS: A Randomized Controlled Feasibility Trial,NOT_YET_RECRUITING,2025-06,2026-09-30,2026-09-30,2025-05-21,2025-03-11,INTERVENTIONAL,NA,40.0,ESTIMATED,The Hospital for Sick Children,OTHER,"National Multiple Sclerosis Society|Multiple Sclerosis Society of Canada|University of California, San Diego|Children's Hospital of Philadelphia|Alberta Health Services, Calgary|Queen's University|University of Illinois at Chicago|Unity Health Toronto",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Neuroinflammatory Diseases|Multiple Sclerosis,multiple sclerosis|physical activity|depression|exercise intervention|biomarkers|irisin|brain-derived neurotrophic factor BDNF|randomized controlled trial|feasibility study|home-based exercise|youth|children|pediatric|brain and mental health,United States,La Jolla,California,4,Exercise Training|Mobility and Flexibility Training,BEHAVIORAL|BEHAVIORAL,Participant accrual rate|Fidelity of delivering the intervention|Participant drop-out rate|Adverse event rate|Completion rate of study measures,,False,
NCT02466074,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis,TERMINATED,2016-08-17,2022-02-07,2022-02-07,2023-04-27,2015-06-09,INTERVENTIONAL,PHASE2,5.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,,,Multiple Sclerosis,Acetazolamide|Lesions|Neurodegeneration|Repair,United States,Houston,Texas,1,Acetazolamide|Placebo,DRUG|DRUG,Percent Change in Global Cerebral Blood Flow,Percent Change in Tissue Integrity in White Matter (Mean Diffusivity)|Percent Change in Tissue Integrity in White Matter (Fractional Anisotropy),True,2023-03-01
NCT06515782,Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS),Effect of Fasting Mimicking Diet on Measures of Inflammatory Disease in Relapsing Multiple Sclerosis (RMS) Patients Treated With Standard Disease Modifying Therapies,RECRUITING,2023-10-20,2025-10-20,2025-10-20,2024-07-23,2024-07-23,INTERVENTIONAL,NA,50.0,ESTIMATED,University of Southern California,OTHER,,,Multiple Sclerosis,fasting|Mediterranean diet|body composition|quality of life,United States,Los Angeles,California,1,Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.,OTHER,Health-related Quality of Life (HRQOL),"Assessing Safety and Tolerability of a FMD in MS: Compliance and Serious Adverse Events|To evaluate the effect on clinical measures of neurological status: Annualized relapse rate|To evaluate the effect on clinical measures of neurological status: EDSS|To evaluate the effect on clinical measures of neurological status: depression, anxiety|To evaluate body composition|To evaluate IGF-1 changes|To estimate changes in measures of disease activity in the central nervous system (CNS)|To estimate changes in measures of disease activity in the central nervous system (CNS)|To evaluate alterations in immune function by assessing changes in cell counts, serum cytokines and secretion patterns, with a focus on pro-inflammatory cytokines IL-2, interferon-gamma (IFNγ), and IL-17A, and the regulatory cytokine, IL-10. Units: pg/mL|To evaluate changes following the FMD in the composition and function of the gut microbiota which influences immune function in the T and B cells compartment in the blood.",False,
NCT04515355,Preventing Job Loss Using Acceptance and Commitment Therapy in Vocational Rehabilitation,Preventing Job Loss Using Acceptance and Commitment Therapy in Vocational Rehabilitation,UNKNOWN,2020-08-13,2022-08-30,2022-08-30,2020-08-17,2020-08-17,INTERVENTIONAL,NA,92.0,ESTIMATED,The Leeds Teaching Hospitals NHS Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Leeds,West Yorkshire,1,Ready for MS,BEHAVIORAL,Completing the Ready for MS programme,,False,
NCT03963310,Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis,Evaluation and Follow-up of Optic Neuritis Not Related to Multiple Sclerosis,COMPLETED,2020-09-14,2024-05-23,2024-05-23,2025-06-25,2019-05-24,OBSERVATIONAL,,38.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Optic Neuritis,,France,Paris,,1,,,"Visual acuity (ETDRS scale)|Thickness of the layers of the retina with Optical Coherent Tomography(OCT),|Standard Humphrey Visual Field Test",,False,
NCT00190268,"Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis","Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis",COMPLETED,2005-02,2008-06,2008-06,2011-02-21,2005-09-19,INTERVENTIONAL,PHASE3,126.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,"multiple sclerosis|fatigue|3,4-diaminopyridine",France,Créteil,,4,"3,4-diaminopyridine",DRUG,improvement of fatigue measured by a decrease of EMIF-SEP score compared to placebo group.,evaluation of safety|quality of life impact,False,
NCT02797015,Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS,"A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis",COMPLETED,2016-06-23,2017-10-20,2017-10-20,2018-03-27,2016-06-13,INTERVENTIONAL,PHASE1,22.0,ACTUAL,Celgene,INDUSTRY,,,Multiple Sclerosis,MS|RMS|Multiple Sclerosis|Relapsing Multiple Sclerosis,United States,Long Beach,California,6,RPC1063,DRUG,Maximum plasma concentration (Cmax)|Area under the plasma concentration-time curve (AUC),Adverse Events|EDSS (Expanded Disability Status Scale)|Pharmacodynamic response measured in change from baseline in Absolute Lymphocyte Count,False,
NCT02284568,"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo","A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)",COMPLETED,2015-01-12,2017-05-04,2017-10-01,2022-03-10,2014-11-06,INTERVENTIONAL,PHASE2,374.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Primary Progressive Multiple Sclerosis,multiple sclerosis|primary progressive multiple sclerosis|oral immunomodulator,United States,Phoenix,Arizona,99,Placebo|Laquinimod|Placebo,DRUG|DRUG|DRUG,Percent Brain Volume Change (PBVC) From Baseline to Week 48 Using a Repeated Measures ANCOVA Model|Percent Brain Volume Change (PBVC) From Baseline to Weeks 24 and 48,"Percentage of Participants With 12-Week Confirmed Disability Progression (CDP) As Measured by Expanded Disability Status Scale (EDSS) up to Week 48|Percentage of Participants With 12-Week Confirmed Disability Progression (CDP) As Measured by Expanded Disability Status Scale (EDSS) or the Timed 25-foot Walk (T25FW) Test up to Week 48|Change From Baseline for the Timed 25-foot Walk (T25FW) Score at Weeks 12, 24, 36 and 48|Number of New T2 Brain Lesions at Week 48|Participants With Treatment-Emergent Adverse Events (TEAEs)",True,2018-11-02
NCT01804660,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population,A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Normal Population as Assessed by PCR and ELISA in Blood,COMPLETED,2012-10,2013-11,2013-12,2020-10-20,2013-03-05,OBSERVATIONAL,,25.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis (MS)|Multiple Sclerosis associated RetroVirus (MSRV)|MSRV envelop protein (MSRV-Env)|Temelimab,France,Annemasse,,1,No study treatments administered,OTHER,Establish a control value for the levels of MSRV expression in the normal population over time,Inflammatory markers and reverse transcriptase activity in blood.,False,
NCT03561155,Robot-assisted Arm Training in Multiple Sclerosis,Effects of High-intensity Robot-assisted Training in Hand Function Recovery and ADL Independence in Individuals With Multiple Sclerosis: a Randomized Controlled Single-blinded Trial,COMPLETED,2014-11,2017-09-01,2018-05-01,2018-06-19,2018-06-19,INTERVENTIONAL,NA,60.0,ACTUAL,Universita di Verona,OTHER,,,Multiple Sclerosis|Rehabilitation,Upper Extremity|Recovery,Italy,Verona,,1,Robot assisted treatment (Amadeo®)|Conventional treatment,DEVICE|OTHER,Action Research Arm test,Fugl-Meyer Assessment Motor Scale - Arm Section|Motor Activity Log|Tremor Severity Scale|Nine Hole Peg Test|Motricity Index|Amadeo® hand muscle strength (Newton)|Visual anolgue Scale for tiredness and fatigue|Multiple Sclerosis Quality of Life-54|Assessment of Life Habits|UL electromyographic analysis of muscle activation,False,
NCT01235455,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",Portuguese BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis (MS) After Conversion to Betaferon by Using Elements of the BetaPlus Program,COMPLETED,2007-08,,2011-05,2012-11-01,2010-11-05,OBSERVATIONAL,,10.0,ACTUAL,Bayer,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS)|Secondary Progressive Multiple Sclerosis (SPMS),Multiple Sclerosis|Adherence|Interferon beta-1b|Coping styles,Portugal,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,"Identification of reasons why patients are switched from other disease modifying drugs to Betaferon due to perceived lack of efficacy, adverse events, poor compliance, and others.|Assessment of factors predictive of non-adherence to disease modifying drugs such as demographic data, course of disease, drug history, patients characteristics, history of poor compliance to prior therapy or others.","Assessment of impact of supportive elements of the BetaPlus Program like nurse support, auto-injector, website, etc on treatment adherence.|Evaluation of impact of Betaferon treatment on health related quality of life using the Functional Assessment of Multiple Sclerosis Questionnaire - FAMS.|Assessment of coping processes by applying the Ways of Coping Questionnaire.|Measurement of safety of Betaferon by assessing the number of participants with adverse events and severe adverse events. Classification by MedDRA category.",False,
NCT03574610,Brain Targets in Patients With Bladder Emptying Difficulties,Supraspinal Mechanisms Involved in Voiding Dysfunction.,COMPLETED,2018-07-01,2021-07-31,2022-07-31,2023-10-05,2018-07-02,INTERVENTIONAL,NA,11.0,ACTUAL,The Methodist Hospital Research Institute,OTHER,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,Neurogenic Bladder|Multiple Sclerosis|Voiding Dysfunction,Neurogenic bladder|Functional Neuroimaging|Transcranial Rotating Permanent Magnet Stimulator (TRPMS),United States,Houston,Texas,1,Transcranial Rotating Permanent Magnet Stimulator (TRPMS),DEVICE,Changes in Brain Activity After Treatment Measured Using Functional MRI,"Changes in Objective Clinical Outcomes Following Treatment|Changes in %Post-Void Residual/Bladder Capacity (PVR/BC) Following Treatment|Changes in Non-instrumented Uroflow Variable Qmax Following Treatment|Changes in Liverpool Nomogram Following Treatment|Changes in Subjective Clinical Outcomes Following Treatment - Urinary Distress Inventory, Short Form (UDI-6) Questionnaire|Changes in Subjective Clinical Outcomes Following Treatment - American Urological Association Symptom Score (AUASS) Questionnaire|Changes in Subjective Clinical Outcomes Following Treatment - Neurogenic Bladder Symptom Score (NBSS) Questionnaire",True,2023-10-05
NCT04355663,"Neuroproprioceptive ""Facilitation, Inhibition"" and Brain Plasticity",Neuroproprioceptive Facilitation and Inhibition Physical Therapy Activates Adaptive and Plastic Changes in the Central Nervous System,COMPLETED,2015-05-20,2017-05-20,2019-08-01,2020-07-17,2020-04-21,INTERVENTIONAL,NA,92.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Multiple Sclerosis,"multiple sclerosis|physical therapy|white matter integrity|neuroproprioceptive ""facilitation, inhibition""|functional recovery|network reorganization|neurohormones|dehydroepiandrosterone",,,,0,Motor program activating therapy|Vojta's reflex locomotion|Functional electric stimulation,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,White Matter Integrity,"Berg Balance Scale, BBS|Timed up and go Test, TUG|the 12-item Multiple Sclerosis Walking Scale, MSWS - 12|the 29-item Multiple Sclerosis Impact Scale, MSIS -29",True,2020-07-17
NCT05561621,Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers,Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers,COMPLETED,2022-07-15,2022-12-20,2022-12-20,2023-06-15,2022-09-30,OBSERVATIONAL,,70.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,Audeering GMBH|Biogen,INDUSTRY|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Digital Biomarker|Non-Motor symptoms|Fatigue|Cognition|Depression|Voice Analysis,Switzerland,Bern,,1,Voice analysis,OTHER,Identification of a voice signature that separates between pwMS with and without fatigue,Identification of a voice signature that separates between pwMS with and without cognitive impairment|Identification of a voice signature that separates between pwMS with and without depression,False,
NCT01070719,"Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort","Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort",COMPLETED,2010-02,2010-05,2010-05,2012-03-01,2010-02-18,OBSERVATIONAL,,270.0,ACTUAL,"John F. Foley, MD",OTHER,Biogen,INDUSTRY,Multiple Sclerosis|Relapse,"Multiple Sclerosis, relapsing forms",United States,Salt Lake City,Utah,1,,,,,False,
NCT06607900,hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases,"A Multi-center, Open, Single-arm, Basket-design Clinical Trial to Evaluate the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles hUC-MSC-sEV-001 Nasal Drops for the Treatment of Multiple Neurodegenerative Diseases",NOT_YET_RECRUITING,2025-07-01,2027-08-31,2028-08-31,2025-07-08,2024-09-23,INTERVENTIONAL,PHASE1,120.0,ESTIMATED,"Xuanwu Hospital, Beijing",OTHER,,,Alzheimer Disease|Parkinson Disease|Lewy Body Dementia|Multiple System Atrophy|Fronto-temporal Dementia|Amyotrophic Lateral Sclerosis,,China,Beijing,Beijing Municipality,1,hUC-MSC-sEV-001 nasal drops,DRUG,Alzheimer's disease: Change in Alzheimer's disease assessment scale-cognitive section（ADAS-cog）|Parkinson's disease: Change in MDS Unified-Parkinson Disease Rating Scale(MDS-UPDRS)|multiple system atrophy: Unified Multiple System Atrophy Rating Scale（Part I and Part II）|lewy body dementia: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)|frontotemporal dementia: CDR Dementia Staging Instrument PLUS National Alzheimer's Coordinating Center Behavior and Language Domains（CDR+NACC FTLD）|Amyotrophic lateral sclerosis: Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R),Barthel index|mini mental status exam(MMSE)|EQ-5D-5L|Alzheimer's disease: sum of boxes of the CDR（CDR-SB）|Alzheimer's disease: Alzheimer's Disease Cooperative Study - Activities of Daily Living （ADCS-ADL）|multiple system atrophy: Composite Autonomic Symptom Score|Clinical Global Impression|lewy body dementia: MDS-UPRDS|Lewy body dementia：Neuropsychiatric Inventory（NPI）|frontotemporal dementia: NPI|frontotemporal dementia: ADAS-cog|Amyotrophic lateral sclerosis: Change in forced vital capacity to predicted value ratio (FVC% pred)|Amyotrophic lateral sclerosis: Change in the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40).|Amyotrophic lateral sclerosis: Change in the Edinburgh Cognitive and Behavioral ALS Screen (ECAS).|Amyotrophic lateral sclerosis: Change in the Neurophysiological Index (NI) and Compound Muscle Action Potential (CMAP) score.|Amyotrophic lateral sclersis: Change in the Rasch Overall ALS Disability Scale (ROADS).|Adverse effects,False,
NCT06999434,Exploring the Utility of [18F]3F4AP for Demyelination Imaging,Exploring the Utility of [18F]3F4AP for Demyelination Imaging,RECRUITING,2025-05-05,2030-05-05,2030-05-05,2025-05-31,2025-05-31,INTERVENTIONAL,PHASE1,105.0,ESTIMATED,Yale University,OTHER,National Institute for Biomedical Imaging and Bioengineering (NIBIB)|National Institute on Aging (NIA),NIH|NIH,Demyelinating Disorders|MCI|Alzheimer's Disease (AD)|MS (Multiple Sclerosis)|SCI - Spinal Cord Injury|Spinal Radiculopathy,3F4AP|Demyelinating Disorders|MS|SCI|AD,United States,New Haven,Connecticut,1,[ 18F]3F4AP|[18F]MK6240|[11C]PIB,DRUG|DRUG|DRUG,Tracers volume of distribution (VT)|Distribution volume ratio (DVR)|Binding potential (BPND)|Demyelination|Tau burden|Amyloid burden|Tracer rate constant|Associations between imaging modalities and biomarkers.,Measure of brain atrophy|Measure of cerebrovascular burden|Measure of White matter lesions (WML)|MR/MRSI images,False,
NCT03368664,"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)",ACTIVE_NOT_RECRUITING,2017-10-24,2021-05-04,2025-12,2025-07-11,2017-12-11,INTERVENTIONAL,PHASE3,16.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Multiple Sclerosis,,Austria,Vienna,,21,Alemtuzumab GZ402673|Glatiramer acetate|Beta-Interferon|Methylprednisolone|Ranitidine|Ceterizine|Dexchlorpheniramine|Paracetamol|Acyclovir|Prednisolone|Diphenydramine|Other H1 antagonist|Other H1 antagonist,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan,Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Participants With New or Enlarged T2 Lesions Per MRI Scan|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Months 4 and 8|Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAE)|Annualized Relapse Rate (ARR)|Change From Baseline in Cognition Test Scores of Brief Visuospatial Memory Test - Revised (BVMT-R)|Change From Baseline in Cognition Test Scores of Symbol Digit Modality Test (SDMT)|Change From Baseline in Quality of Life (QoL) Measures of Pediatric Quality of Life (PedsQL) Questionnaire Score|Change From Baseline in Pediatric Quality of Life in Neurological Disorders (NeuroQoL) Questionnaire Score|Serum Concentrations of Alemtuzumab Over Time|Maximum Serum Concentration Observed (Cmax) of Alemtuzumab|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alemtuzumab|Area Under the Plasma Concentration-Time Curve (AUC) of Alemtuzumab|Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Alemtuzumab|Terminal Half-life (T1/2z) of Alemtuzumab|Assessment of Lymphocyte Phenotyping|Percentage of Participants With Incidence of Antidrug Antibodies (ADA),True,2022-07-12
NCT00457964,RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM,RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis,COMPLETED,2005-08,2013-07,2013-07,2013-09-25,2007-04-09,INTERVENTIONAL,PHASE1|PHASE2,36.0,ACTUAL,"Children's Hospital Medical Center, Cincinnati",OTHER,Novartis Pharmaceuticals,INDUSTRY,Tuberous Sclerosis|Lymphangioleiomyomatosis,Tuberous Sclerosis Complex (TSC)|Lymyphangioleiomyomatosis|Mammalian Target of Rapamycin (mTOR)|RAD001|Angiomyolipmas,United States,Cincinnati,Ohio,1,RAD001,DRUG,Patients will be considered responders if their angiomyolipoma volume decreases by thirty percent or more from baseline,,False,
NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment,COMPLETED,2016-09-09,2019-10-25,2020-12-15,2022-01-27,2016-08-10,INTERVENTIONAL,PHASE3,681.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Australia,"Kogarah, New South Wales",New South Wales,163,Ocrelizumab,BIOLOGICAL,Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period,"Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period|Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period|Time to First Protocol-Defined Event of Disease Activity|Change From Baseline to Week 96 in Expanded Disability Status Scale (EDSS)|Absolute Change From Baseline in EDSS Category at Week 96|Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96|Annualized Protocol-defined Relapse Rate at Week 96|Time to Onset of 24-week Confirmed Disability Progression|Time to Onset of First Protocol-Defined Relapse|Time to Onset of First New and/or Enlarging T2 Lesion|Mean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96|Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From|Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI|Volume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96|Mean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan|Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume|Percentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume|Adjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume|Adjusted Mean Percentage Change From Baseline in Brain Volume|Adjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume|Adjusted Mean Percentage Change From Baseline in White Matter Volume|Mean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score|Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score|Percentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score|Percentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",True,2021-02-03
NCT03508284,Dual-Task Performance in Patients With Multiple Sclerosis,Factors Associated With Dual-Task Performance in Patients With Multiple Sclerosis,COMPLETED,2018-06-18,2019-05-16,2019-05-18,2019-07-31,2018-04-25,OBSERVATIONAL,,60.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Dual-task|Balance|Mobility|Cognition,Turkey (Türkiye),Ankara,,1,,,Timed Up and Go Test|Modified Sensory Organization Test|upper extremity function,Sleep Quality: PSQI|Fatigue Severity|Balance Confidence|Mood|Visual attention and task switching|selective attention|cognitive function,False,
NCT01931644,"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives,COMPLETED,2013-07,2024-04,2024-04,2024-04-18,2013-08-29,OBSERVATIONAL,,17667.0,ACTUAL,Sanguine Biosciences,INDUSTRY,,,All Diagnosed Health Conditions|ADD/ADHD|Alopecia Areata|Ankylosing Spondylitis|Asthma|Atopic Dermatitis Eczema|Beta Thalassemia|Bipolar Disorder|Breast Cancer|Celiac Disease|Cervical Cancer|Chronic Inflammatory Demyelinating Polyneuropathy|Chronic Kidney Diseases|Chronic Obstructive Pulmonary Disease|Colon Cancer|Colorectal Cancer|Crohn's Disease|Cystic Fibrosis|Depression|Diabetes Mellitus|Duchenne Muscular Dystrophy|Endometriosis|Epilepsy|Facioscapulohumeral Muscular Dystrophy|G6PD Deficiency|General Anxiety Disorder|Hepatitis B|Hereditary Hemorrhagic Telangiectasia|HIV/AIDS|Human Papilloma Virus|Huntington's Disease|Idiopathic Thrombocytopenic Purpura|Insomnia|Kidney Cancer|Leukemia|Lung Cancer|Lupus Nephritis|Lymphoma|Melanoma|Multiple Myeloma|Multiple Sclerosis|Myositis|Myotonic Dystrophy|Ovarian Cancer|Pancreatic Cancer|Parkinson's Disease|Polycystic Kidney Diseases|Prostate Cancer|Psoriasis|Psoriatic Arthritis|Rosacea|Scleroderma|Sickle Cell Anemia|Sickle Cell Trait|Sjogren's Syndrome|Skin Cancer|Spinal Muscular Atrophy|Systemic Lupus Erythematosus|Thrombotic Thrombocytopenic Purpura|Trisomy 21|Ulcerative Colitis,ADD/ADHD|Alopecia Areata|Ankylosing Spondylitis|Asthma|Atopic Dermatitis Eczema|Beta Thalassemia|Bipolar Disorder|Breast Cancer|Celiac Disease|Cervical Cancer|Chronic Inflammatory Demyelinating Polyneuropathy|Chronic Kidney Diseases|Chronic Obstructive Pulmonary Disease|Colon Cancer|Colorectal Cancer|Crohn's Disease|Cystic Fibrosis|Depression|Diabete Mellitus|Duchenne Muscular Dystrophy|Endometriosis|Epilepsy|Facioscapulohumeral Muscular Dystrophy|G6PD Deficiency|General Anxiety Disorder|Hepatitis B|Hereditary Hemorrhagic Telangiectasia|HIV/AIDS|Human Papilloma Virus|Huntington's Disease|Idiopathic Thrombocytopenic Purpura|Insomnia|Kidney Cancer|Leukemia|Lung Cancer|Lupus Nephritis|Lymphoma|Melanoma|Multiple Myeloma|Multiple Sclerosis|Myositis|Myotonic Dystrophy|Ovarian Cancer|Pancreatic Cancer|Parkinson's Disease|Polycystic Kidney Diseases|Prostate Cancer|Psoriasis|Psoriatic Arthritis|Rosacea|Scleroderma|Sickle Cell Anemia|Sickle Cell Disease|Sickle Cell Trait|Sjogren's Syndrome|Skin Cancer|Spinal Muscular Atrophy|Systemic Lupus Erythematosus|Thrombotic Thrombocytopenic Purpura|Trisomy 21|Ulcerative Colitis,United States,Los Angeles,California,1,,,Biospecimen & Clinical Data Collection,,False,
NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation",TERMINATED,2006-03,2014-04,2014-04,2016-07-15,2006-02-28,INTERVENTIONAL,PHASE3,1094.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|MS,Australia,Camperdown,,112,Natalizumab,DRUG,Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) Progression|Time to 48-week Confirmed EDSS Progression|Time to 24-week Confirmed EDSS Improvement Where Baseline ≥ 2.0,,True,2015-05-29
NCT04749667,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-08-09,2024-10-04,2025-01-04,2023-09-11,2021-02-11,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,Haukeland University Hospital,OTHER,"University of Bergen|University Hospital Ulm|University Hospital, Akershus|St. Olavs Hospital|University Hospital of North Norway",OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis|Progressive Multiple Sclerosis,Mesenchymal stem cells|Multiple sclerosis,Norway,Lørenskog,Akershus,4,MSCs|Saline,OTHER|DRUG,Neurophysiological parameters - Combined evoked potentials,Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events,False,
NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis",TERMINATED,2019-03-19,2022-07-21,2022-07-21,2023-06-15,2019-03-12,INTERVENTIONAL,PHASE3,11.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Pediatric, Multiple Sclerosis",United States,Raleigh,North Carolina,23,Dimethyl Fumarate|Peginterferon Beta-1a|Placebo,DRUG|DRUG|DRUG,Time to First Relapse,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 48 and 96|Number of Galdolinium (Gd)-Enhancing Lesions at Weeks 48 and 96|Annualized Relapse Rate,True,2023-05-16
NCT05767736,A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS),An Observational Study Utilising Data From Big MS Data Registries to Evaluate the Long-Term Safety of Vumerity and Tecfidera,ACTIVE_NOT_RECRUITING,2024-06-08,2032-12-01,2032-12-01,2024-09-27,2023-03-14,OBSERVATIONAL,,10500.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Cambridge,Massachusetts,1,Diroximel Fumarate|Dimethyl Fumarate|Disease-Modifying Therapies (DMTs),DRUG|DRUG|DRUG,"Number of Participants With Confirmed Serious Adverse Events (SAEs) in the Vumerity, Tecfidera, Other Selected DMTs (Teriflunomide, Beta-interferons, or Glatiramer Acetate), or Vumerity/Tecfidera Switch Cohorts","Hazard Ratio of Confirmed SAEs in Vumerity, Tecfidera, or Vumerity/Tecfidera Switch Cohorts Versus Other Selected DMTs (Teriflunomide, Beta-interferons, or Glatiramer acetate) Cohort",False,
NCT06153264,Neural Mobilization on Multiple Sclerosis,"Effect of Neurodynamic Mobilization Exercises on Pain, Muscle Strength and Manual Dexterity in Multiple Sclerosis Patients",COMPLETED,2023-09-15,2024-06-15,2024-07-15,2024-08-21,2023-12-01,INTERVENTIONAL,NA,40.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Strength|Neuro mobilization|pain,Turkey (Türkiye),Kahramanmaraş,,1,neurodynamic mobilization exercise|strengthening exercises,OTHER|OTHER,Visual Analog Scale|Leeds Assessment of Neuropathic Symptoms and Signs Scale,Muscle strength|Manual Ability Measure-36|Nine hole peg test,False,
NCT02146534,Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients,"Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study.",COMPLETED,2013-12,2016-01,2016-01,2019-03-06,2014-05-26,INTERVENTIONAL,PHASE4,44.0,ACTUAL,Clinique Neuro-Outaouais,OTHER,CogState Ltd.,INDUSTRY,Multiple Sclerosis,,Canada,Gatineau,Quebec,1,extended release fampridine|Placebo,DRUG|DRUG,change in mobility,change in quality of life,False,
NCT00043264,Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis,Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis,COMPLETED,,,,2005-06-24,2002-08-08,INTERVENTIONAL,PHASE2,40.0,,National Center for Research Resources (NCRR),NIH,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Houston,Texas,1,Rifampin|Azithromycin,DRUG|DRUG,,,False,
NCT01324232,Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis,"A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis",COMPLETED,2011-09-08,2013-09-26,2013-09-26,2021-11-22,2011-03-28,INTERVENTIONAL,PHASE2,209.0,ACTUAL,Avanir Pharmaceuticals,INDUSTRY,,,Central Neuropathic Pain|Multiple Sclerosis,,United States,Cullman,Alabama,72,AVP-923-45|AVP-923-30|AVP-923-20|Placebo,DRUG|DRUG|DRUG|DRUG,Association Between the Dextromethorphan Plasma Concentration and the Change From Baseline Pain Rating Scale (PRS) Score to the Average Pain Rating Scale Score During Days 57 Through 84|Average Logarithms of Dextromethorphan (DM) Plasma Concentrations (Cmax) on Days 22 and 50,"Comparison of the Adjusted Mean Change From Baseline PRS Score to the Average PRS Score During Days 57 Through 84|Mean Change From Baseline in Fatigue Severity Scale (FSS) Scores at Days 57 Through 84|Mean Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Days 22 and 85|Mean Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Scores at Day 85|Mean Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Scores at Day 85|Mean Change From Baseline in MS Neuropsychological Screening Questionnaire (MSNQ) Scores at Day 85|Mean Change From Baseline in Beck Depression Inventory (BDI-II) Scores at Day 85|Mean Change From Baseline in Symbol Digit Modalities Test (SDMT) Scores at Day 85|Mean Numerical Rating Scale (NRS) Scores at Days 22, 50, and 85|Mean Overall Patient Global Impression of Change (PGIC) Scores at Day 85",True,2021-11-22
NCT04354519,The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,The UK MS Regsiter COVID-19 Substudy,UNKNOWN,2020-03-14,2022-07-14,2022-07-14,2021-08-17,2020-04-21,OBSERVATIONAL,,3000.0,ESTIMATED,Swansea University,OTHER,,,Multiple Sclerosis|COVID-19,,United Kingdom,Swansea,,1,,,Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality,Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l),False,
NCT03679806,Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis,Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis: Halliwick Versus Aquatic Plyometric Exercises,COMPLETED,2016-05,2016-07,2016-09,2018-09-20,2018-09-20,INTERVENTIONAL,NA,30.0,ACTUAL,Dokuz Eylul University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",aquatic therapy|Limits of stability|Halliwick|aquatic plyometric exercises,Turkey (Türkiye),Izmir,,1,Halliwick|Aquatic Plyometric Exercises,OTHER|OTHER,Change in limits of stability|Change in Nine hole peg Test,,False,
NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2,COMPLETED,2010-03,2015-11,2015-11,2016-09-29,2010-02-18,OBSERVATIONAL,,35895.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,JCV|Sample Collection|PML|Antibody,United States,Birmingham,Alabama,478,natalizumab,DRUG,Demonstrate that the incidence of PML in natalizumab-treated participants who do not have detectable antibodies to JC virus (JCV) (antibody negative) is lower than in patents who have detectable antibodies to JCV (antibody positive),"Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources|Define the prevalence of anti-JCV antibody in relapsing MS participants receiving natalizumab within the TOUCH Prescribing Program|Determine changes in anti-JCV antibody status over time",False,
NCT03369171,Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients,Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients,COMPLETED,2018-01-23,2020-02-28,2020-02-28,2020-05-19,2017-12-11,INTERVENTIONAL,NA,64.0,ACTUAL,Nantes University Hospital,OTHER,,,Multiple Sclerosis,,France,Nantes,,1,"Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)",DEVICE,Discrimination of walking disorder status,Foot tapping test|Finger tapping test|Heel-knee test|Romberg test|Finger to nose test|Timed 25 foot walk test result|Nine holes peg test|Expanded disability status scores (EDSS)|Patient-reported disability using self-report questionnaire|Twelve items Multiple Sclerosis Walking Scale Assessment (MSWS-12) scale|12-item version of World Health Organization Disability Assessment Schedule (WHODAS 2.0)|Disability as measured with EDSS score|Disability as measured with Functional systems score (FS)|Dysfunction assessed by walking disorder status|Dysfunction assessed by foot tapping test|Dysfunction assessed by finger tapping test|Dysfunction assessed by heel-knee test|Dysfunction assessed by Romberg test|Dysfunction assessed by finger to nose test|Dysfunction assessed by timed 25 foot walk test result|Dysfunction assessed by nine holes peg test,False,
NCT02277964,Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod,"An Observational Study to Evaluate Disease Control, Safety and Immunological Changes in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Transferred From Previous Treatment With Natalizumab to Fingolimod.",COMPLETED,2012-03,2016-08,2016-08,2016-09-14,2014-10-29,OBSERVATIONAL,,25.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,Novartis,INDUSTRY,Relapsing Remitting Multiple Sclerosis,RRMS|Natalizumab|Fingolimod|Treatment Change|Disease Activity,Switzerland,Basel,,1,,,Relapse rate|New or newly enlarging lesions/Gadolinium enhancing lesions,Immunological markers,False,
NCT04650321,Home Based Infusions for Ocrelizumab,"Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions",RECRUITING,2021-03-01,2021-08-31,2021-08-31,2021-06-10,2020-12-02,INTERVENTIONAL,PHASE4,110.0,ESTIMATED,"University of Colorado, Denver",OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,,United States,Centennial,Colorado,1,Ocrelizumab at home,DRUG,Severe infusion reactions|Infusion reactions,Severe infusion reactions compared to historic controls.|Infusion reactions compared to historic controls.|Validated Patient Reported Outcomes (PROs) - PROMIS 10 Physical|Validated Patient Reported Outcomes (PROs) - PROMIS 10 Mental|Validated Patient Reported Outcomes (PROs) - Neuro-QOL Anxiety|Validated Patient Reported Outcomes (PROs) - Neuro-QOL Depression|Validated Patient Reported Outcomes (PROs) - Patient Determined Disease Steps (PDDS)|Adverse events,False,
NCT01250665,Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis,Cohort Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Early and Remitting Relapsing Multiple Sclerosis,UNKNOWN,2011-01,2011-06,2011-06,2010-12-01,2010-12-01,OBSERVATIONAL,,65.0,ESTIMATED,Cantonal Hospital of St. Gallen,OTHER,Bayer,INDUSTRY,Multiple Sclerosis|Cognitive Impairment,multiple sclerosis|cognitive impairment|interferon-beta 1b|corpus callosum index,Switzerland,Sankt Gallen,,1,,,Multiple Sclerosis Inventory Cognition (MUSIC)|Annual Corpus Callosum Index decrease,Corpus callosum Index at baseline|Time to clinically definite MS|The Symbol Digit Modalities Test (SDMT)|Ratio treatment duration to disease duration,False,
NCT06675864,"Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)","An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)",RECRUITING,2024-12-12,2030-06-13,2030-06-13,2025-08-15,2024-11-05,INTERVENTIONAL,PHASE1|PHASE2,28.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Progressive Multiple Sclerosis,Chimeric Antigen Receptor T cells|CAR-T|YTB323|Multiple Sclerosis|MS|Progressive Multiple Sclerosis|PMS|rapcabtagene autoleucel,Australia,Darlinghurst,New South Wales,15,rapcabtagene autoleucel (YTB323),BIOLOGICAL,"Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs)","Measure of Disability: Expanded Disability Status Scale (EDSS).|Measure of Disability: Short Form Health Survey (SF-36 v2)|Measure of Disability: Timed 25 Foot Walk (T25FW)|Measure of Disability: 9 Hole Peg Test (9HPT)|Measure of Disability: Symbol Digit Modalities Test (SDMT)|Modified Fatigue Impact Scale (MFIS)|Whole Blood Pharmacokinetics (PK) of YTB323 - CMAX|Whole Blood Pharmacokinetics (PK) of YTB323 - AUC|Whole Blood Pharmacokinetics (PK) of YTB323 - Tmax|Whole Blood Pharmacokinetics (PK) of YTB323 - Clast|Whole Blood Pharmacokinetics (PK) of YTB323 - Tlast|Humoral Immunogenicity of YTB323|Cellular Immunogenicity of YTB323|Safety data including dose limiting toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) from each dose level",False,
NCT05352971,Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients,Multi-Site Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients,COMPLETED,2022-09-15,2023-09-30,2023-09-30,2023-10-10,2022-04-29,OBSERVATIONAL,,664.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis,,France,Clermont-Ferrand,,10,Biomarker quantification,OTHER,Inter-laboratory reproducibility of neurofilament-light chain level measurements|Inter-laboratory repeatability of neurofilament-light chain level measurements|Inter-laboratory reproducibility and repeatability of glial fibrillary acidic protein level measurements|Inter-laboratory repeatability of glial fibrillary acidic protein level measurements,"compare the GFAP values obtained using the ELLA and SIMOA platforms in MS patients|to build a ""global disease activity score""|to build a ""global disability score""",False,
NCT00715598,Cognitive Testing for the Pain Quality Assessment Scale (PQAS),Cognitive Testing for the Pain Quality Assessment Scale (PQAS),COMPLETED,2008-06,2010-06,2010-08,2012-05-09,2008-07-15,OBSERVATIONAL,,213.0,ACTUAL,University of Washington,OTHER,Merck Sharp & Dohme LLC,INDUSTRY,Pain|Spinal Cord Injuries|Multiple Sclerosis,Pain Assessment|Measurement,United States,Seattle,Washington,1,,,Pain Quality Assessment Scale (PQAS),,False,
NCT01743664,The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis,The Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Post Traumatic Stress Disorder in Multiple Sclerosis. A Randomized Controlled Trial.,UNKNOWN,2010-05,2013-03,2014-02,2012-12-07,2012-12-06,INTERVENTIONAL,PHASE3,60.0,ESTIMATED,San Luigi Gonzaga Hospital,OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,Posttraumatic Stress Disorders|Multiple Sclerosis,Posttraumatic Stress Disorders|Multiple Sclerosis|Eye Movement Desensitization Reprocessing|Psychotherapy|Anxiety|Depression|Quality of Life,Italy,Orbassano,Torino,1,EMDR|Relaxation,BEHAVIORAL|BEHAVIORAL,Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group after the treatment.,Reduction in the IES scores after the treatment.|Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group at the follow up.|Reduction in the IES scores at the follow-up.,False,
NCT04390009,Entire-body PET Scans for Multiple Sclerosis,Exploratory Study of Entire-body PET Scans for Multiple Sclerosis,RECRUITING,2024-09-30,2025-09-30,2025-12-30,2025-01-07,2020-05-15,INTERVENTIONAL,EARLY_PHASE1,20.0,ESTIMATED,Brain Health Alliance,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Entire-body PET imaging,United States,Ladera Ranch,California,1,Entire-body PET-CT scans|Amyvid radiopharmaceutical,DIAGNOSTIC_TEST|DRUG,Entire-body PET imaging of demyelination of peripheral and central nervous system|Psychometric questionnaire for monitoring psychological health,,False,
NCT01932593,Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis,Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (SIAMMS-II),COMPLETED,2014-01-31,2017-09-01,2018-08-20,2018-08-23,2013-08-30,INTERVENTIONAL,NA,4.0,ACTUAL,North Bristol NHS Trust,OTHER,Sir Halley Stewart Trust,UNKNOWN,Multiple Sclerosis,multiple sclerosis|bone marrow|stem cell therapy,United Kingdom,Bristol,Avon,1,Infusion of autologous bone marrow,PROCEDURE,Adverse events,Global evoked potential|MRI brain|Expanded disability status scale (EDSS)|Multiple sclerosis functional composite (MSFC)|Multiple sclerosis impact scale (MSIS-29),False,
NCT01906684,Comprehensive Analysis of Relapse in Multiple Sclerosis,Comprehensive Analysis of Relapse in Multiple Sclerosis,UNKNOWN,2013-08,2014-01,2015-01,2013-08-01,2013-07-24,INTERVENTIONAL,NA,20.0,ESTIMATED,Tanner Foundation for Multiple Sclerosis,OTHER,Mallinckrodt|Auburn University MRI Research Center|iReportoire Inc,INDUSTRY|UNKNOWN|UNKNOWN,Multiple Sclerosis,Acthar Gel|MS relapse|7T MRI imaging|Quality of Life,United States,Birmingham,Alabama,1,Acthar Gel,DRUG,"Changes in immunorepertoire, MRI imaging, clinical outcomes and patient reported quality of life",,False,
NCT01395316,Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis,Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis,COMPLETED,2011-06,2015-10,2017-07,2018-12-07,2011-07-15,INTERVENTIONAL,PHASE4,8.0,ACTUAL,University of Chicago,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,,,,,0,Alemtuzumab,DRUG,Diffusion and Myelin Fraction Water Changes on Magnetic Resonance Imaging (MRI),,True,2018-12-07
NCT05000216,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01),TERMINATED,2021-08-13,2023-06-22,2024-03-28,2025-08-22,2021-08-11,INTERVENTIONAL,PHASE2,258.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc.",OTHER|INDUSTRY,Rheumatoid Arthritis (RA)|Systemic Lupus Erythematosus (SLE)|Pemphigus Vulgaris|Multiple Sclerosis (MS)|Systemic Sclerosis (SSc)|Pediatric SLE|Juvenile Idiopathic Arthritis (JIA)|Juvenile Dermatomyositis (JDM)|Pediatric-Onset Multiple Sclerosis (POMS),SARS-CoV-2 Infection|COVID-19|autoimmune disease|non-responders to COVID-19 vaccination|suboptimal response to COVID-19 vaccination|COVID-19 booster vaccine|booster effects with autoimmune treatments,United States,Los Angeles,California,29,"Moderna mRNA-1273|BNT162b2|Ad26.COV2.S|Continue IS (MMF or MPA)|Continue IS (MTX)|Continue IS (B cell depletion therapy)|Monovalent [B.1.351] CoV2 preS dTM-AS03|Withhold IS (MMF or MPA)|Withhold IS (MTX)|Withhold IS (B cell depletion therapy)|Moderna mRNA-1273, Bivalent|BNT162b2, Bivalent",BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|DRUG|DRUG|BIOLOGICAL|BIOLOGICAL|DRUG|DRUG|DRUG|BIOLOGICAL|BIOLOGICAL,Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4|Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4|Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4,Percentage of Stage 1 Adult Participants Who Seroconverted|Percentage of Stage 2 Adult Participants Who Seroconverted|Fold Increase in Stage 1 Adult Anti-COVID-19 Antibody Levels|Fold Increase in Stage 2 Adult Anti-COVID-19 Antibody Levels|Change in Stage 1 Adult Anti-COVID-19 Antibody Response|Change in Stage 2 Adult Anti-COVID-19 Antibody Response|Fold Inhibition of ACE2 Binding to SARS-CoV-2 Variant Antigens by Stage 1 Adult Samples|Fold Inhibition of ACE2 Binding to SARS-CoV-2 Variant Antigens by Stage 2 Adult Samples|Change in Stage 1 Adult Disease Activity as Measured by the Clinical Global Impression of Change (CGI-C)|Change in Stage 2 Adult Disease Activity After Receipt of Additional Doses of COVID-19 Vaccine as Measured by the Clinical Global Impression of Change (CGI-C)|Change in Adult Stage 1 Disease Activity as Measured by the Physician's Global Assessment|Change in Adult Stage 2 Disease Activity After Receipt of Additional Doses of COVID-19 Vaccine as Measured by the Physician's Global Assessment|Change in Disease Activity in Stage 1 Adult Participants With Systemic Lupus Erythematosus (SLE) as Measured by Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI)|Change in Disease Activity in Stage 2 Adult Participants With Systemic Lupus Erythematosus (SLE) as Measured by Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI)|Change in Disease Activity in Stage 1 Adult Participants With Systemic Lupus Erythematosus (SLE) as Measured by the Thanou Modified SELENA-SLEDAI Flare Index|Change in Disease Activity in Stage 2 Adult Participants With Systemic Lupus Erythematosus (SLE) as Measured by the Thanou Modified SELENA-SLEDAI Flare Index|Change in Disease Activity in Stage 1 Adult Participants With Rheumatoid Arthritis (RA) as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)|Change in Disease Activity in Stage 2 Adult Participants With Rheumatoid Arthritis (RA) as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)|Change in Disease Activity in Stage 1 Adult Participants With Systemic Sclerosis (SSc) as Measured by Disease Flare Activity|Change in Disease Activity in Stage 2 Adult Participants With Systemic Sclerosis (SSc) as Measured by Disease Flare Activity|Change in Disease Activity in Stage 1 Adult Participants With Pemphigus as Measured by Disease Area Index (PDAI) for Pemphigus|Change in Disease Activity in Stage 2 Adult Participants With Pemphigus as Measured by Disease Area Index (PDAI) for Pemphigus|Change in Disease Activity in Stage 1 Adult Participants With Multiple Sclerosis (MS) as Measured by Physician Assessed Relapse for MS|Change in Disease Activity in Stage 2 Adult Participants With Multiple Sclerosis (MS) as Measured by Physician Assessed Relapse for MS|Change in Disease Activity in Stage 2 Pediatric Participants With Juvenile Idiopathic Arthritis (JIA) as Measured by the Juvenile Arthritis Disease Activity Score 10 (JADAS10)|Change in Adult Stage 1 Disease Activity as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS-29)|Change in Adult Stage 2 Disease Activity as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS-29)|Change in Adult Stage 1 Disease Activity as Measured by the Patient Global Assessment|Change in Adult Stage 2 Disease Activity as Measured by the Patient Global Assessment|Change in Stage 1 Adult Disease Activity as Measured by the Patient Global Impression of Change (PGI-C)|Change in Stage 2 Adult Disease Activity as Measured by the Patient Global Impression of Change (PGI-C)|Percent of Stage 1 Adult Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine|Percent of Stage 2 Adult Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine|Percent of Stage 1 Adult Participants Who Experience Any Serious Adverse Events (SAEs)|Percent of Stage 2 Adult Participants Who Experience Any Serious Adverse Events (SAEs)|Percent of Stage 1 Adult Participants Who Experience Any Medically Attended Adverse Events (MAAEs)|Percent of Stage 2 Adult Participants Who Experience Any Medically Attended Adverse Events (MAAEs)|Percent of Stage 1 Adult Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs)|Percent of Stage 2 Adult Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs)|Percent of Stage 1 Adult Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection|Percent of Stage 2 Adult Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection|Percentage of Stage 2 Pediatric Participants Who Seroconverted|Fold Increase in Stage 2 Pediatric Anti-COVID-19 Antibody Levels|Change in Stage 2 Pediatric Anti-COVID-19 Antibody Response|Fold Inhibition of ACE2 Binding to SARS-CoV-2 Variant Antigens by Stage 2 Pediatric Samples|Change in Stage 2 Pediatric Disease Activity After Receipt of Additional Doses of COVID-19 Vaccine as Measured by the Clinical Global Impression of Change (CGI-C)|Change in Pediatric Stage 2 Disease Activity After Receipt of Additional Doses of COVID-19 Vaccine as Measured by the Physician's Global Assessment|Change in Disease Activity in Stage 2 Pediatric Participants With Systemic Lupus Erythematosus (SLE) as Measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K|Change in Pediatric Stage 2 Disease Activity as Measured by the Patient Global Assessment|Change in Stage 2 Pediatric Disease Activity as Measured by the Patient Global Impression of Change (PGI-C)|Percent of Stage 2 Pediatric Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine|Percent of Stage 2 Pediatric Participants Who Experience Any Serious Adverse Events (SAEs)|Percent of Stage 2 Pediatric Participants Who Experience Any Medically Attended Adverse Events (MAAEs)|Percent of Stage 2 Pediatric Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs)|Percent of Stage 2 Pediatric Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection,True,2025-08-22
NCT02521311,Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER),"A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis",RECRUITING,2017-02-28,2026-08,2026-08,2024-07-01,2015-08-13,INTERVENTIONAL,PHASE2,90.0,ESTIMATED,"University of California, San Francisco",OTHER,Moorfields Eye Hospital NHS Foundation Trust,OTHER,Optic Neuritis,multiple sclerosis|eye pain|vision loss,United States,San Francisco,California,1,Clemastine|Placebo,DRUG|DRUG,Change in P100 latency on full-field visual evoked potential|Change in low contrast visual acuity,Change in retinal nerve fiber layer thickness on optical coherence tomography|Radiological outcomes assessed by magnetic resonance imaging|Expanded Disability Status Scale score,False,
NCT06053749,An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden,INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden,ACTIVE_NOT_RECRUITING,2024-03-20,2026-03-31,2026-03-31,2025-09-08,2023-09-26,OBSERVATIONAL,,4.0,ACTUAL,Bayer,INDUSTRY,Biogen Netherlands B.V|Novartis Europharm Limited|Merck Europe B.V.,UNKNOWN|UNKNOWN|UNKNOWN,Multiple Sclerosis (MS),,Finland,Multiple Locations,,2,"Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Rebif (IFNβ-1-a, Merck Europe B.V.)|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|MS disease modifying drugs (MSDMDs)",DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,"The number of pregnancies of women with MS, not allowing exposure to other MS Disease Modifying Drugs (MSDMDs)|The level of precision for the risk of pre-defined adverse pregnancy outcomes in late pregnancy that can be obtained with the available number of exposed and unexposed pregnancies|The annual number of pregnancies of women with MS in the exposure groups","The number of pregnancies of women with MS in Finland and Sweden in exposure groups allowing exposure to other MSDMDs|The annual number of women with MS in childbearing age, and with dispensed IFNB",False,
NCT02209467,Balance and Falls in Multiple Sclerosis,Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins,COMPLETED,2014-08,2015-03,2015-08,2015-10-29,2014-08-06,INTERVENTIONAL,NA,52.0,ACTUAL,Örebro County Council,OTHER_GOV,,,Multiple Sclerosis,walking|postural balance|falls,Sweden,Eskilstuna,,7,Group balance training,OTHER,Change from baseline in Berg Balance Scale at 8 weeks,Change from baseline in 10 repetitions Sit to stand test at 15 weeks|Change from baseline in Trunk Impairment scale at 8 weeks|Change from baseline in the Trunk Impairment Scale at 15 weeks|Change from baseline in the 10 repetition Si to stand test at 8 weeks|Change from baseline in the Berg Balance scale at 15 weeks|Change from baseline on the Timed Up and Go test at 8 weeks|Change from baseline on the Timed Up and Go test at 15 weeks|Change from baseline on the10 meter walking test at 8 weeks|Change from baseline on the 10 meter walking test at 15 weks|Change from baseline on the 2 minutes walking test at 8 weeks|Change from baseline on the 2 minutes walking test at 15 weeks|Change from baseline in postural sway at 8 weeks|Change from baseline in postural sway at 15 weeks|Change from baseline on the Falls-Efficacy scale at 8 weeks|Change from baseline on the Falls Efficacy scale at 15 weeks|Change from baseline on the Fatigue Scale for Motor and Cognitive functions at 8 weeks|Change from baseline on the Fatigue Scale for Motor and Cognitive functions at 15 weeks|Change from baseline on the MS Walking Scale-12 at 8 weeks|Change from baseline on the MS Walking scale-12 at 15 weeks|The number of falls and accidental falls,False,
NCT02519244,Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis,Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis,COMPLETED,2015-05,2017-02-06,2017-02-06,2019-05-29,2015-08-10,INTERVENTIONAL,NA,11.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,National Multiple Sclerosis Society|Texas Woman's University,OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Ambulation|Rehabilitation|Wearable Robotic Devices,United States,Houston,Texas,1,Ekso® (Wearable lower limb exoskeleton),DEVICE,Speed in the Timed 25 Feet Walk Test at Self-selected Speed (Without Exoskeleton)|Speed in the Timed 25 Feet Walk Test at Self-selected Speed (Without Exoskeleton)|Speed in the Timed 25 Feet Walk Test at Self-selected Speed (With Exoskeleton)|Speed in the Timed 25 Feet Walk Test at Fast Speed (Without Exoskeleton)|Speed in the Timed 25 Feet Walk Test at Fast Speed (Without Exoskeleton)|Speed in the Timed 25 Feet Walk Test at Fast Speed (With Exoskeleton)|Distance Walked During the Six-minute Walk Test (Without Exoskeleton)|Distance Walked During the Six-minute Walk Test (Without Exoskeleton)|Distance Walked During the Six-minute Walk Test (With Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Self-selected Speed (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Self-selected Speed (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Self-selected Speed (With Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Fast Speed (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Fast Speed (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Timed 25 Feet Walk Test at Fast Speed (With Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Six-Minute Walk Test (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Six-Minute Walk Test (Without Exoskeleton)|Physical Demands as Assessed by Energy Expenditure (Which is Indicated by VO2-max as Measured by the Cosmed K4b2) During the Six-Minute Walk Test (With Exoskeleton),Cognitive Demands as Indicated by Reaction Time in Dual Task Paradigm (Without Exoskeleton)|Cognitive Demands as Indicated by Reaction Time in Dual Task Paradigm (With Exoskeleton)|Amount of Time Taken to Complete the Time Up and Go Test (Without Exoskeleton)|Amount of Time Taken to Complete the Time Up and Go Test (Without Exoskeleton)|Quality of Life as Assessed by the Multiple Sclerosis Quality of Life-54 (MSQOL-54) Questionnaire - Physical Health Composite Score|Quality of Life as Assessed by the Multiple Sclerosis Quality of Life-54 (MSQOL-54) Questionnaire - Physical Health Composite Score|Quality of Life as Assessed by the Multiple Sclerosis Quality of Life-54 (MSQOL-54) Questionnaire - Mental Health Composite Score|Quality of Life as Assessed by the Multiple Sclerosis Quality of Life-54 (MSQOL-54) Questionnaire - Mental Health Composite Score,True,2019-05-29
NCT06782464,Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing with Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment,Ultrasound Guided Cryoneurolysis to Treat Shoulder Pain and Functional Problems Related to Upper Limb Spasticity,RECRUITING,2024-12-12,2026-12-12,2027-12-12,2025-01-17,2025-01-17,INTERVENTIONAL,NA,50.0,ESTIMATED,Centre National de Rééducation Fonctionnelle et de Réadaptation,OTHER,,,Hemiplegia|Spasticity|Shoulder Spasticity|Shoulder Stiffness|Stroke|Multiple Sclerosis|Traumatic Brain Injury|Spinal Cord Injury,cryoneurolysis|spasticity|pain|stroke|traumatic brain injury|spinal cord injury,Luxembourg,Luxembourg,,1,Treatment,PROCEDURE,Change in active Range of motion shoulder|Change in passive range of motion of shoulder,Change in muscle tone muscles controlling the shoulder|Change in nociceptive pain: Visual analogue scale|Upper limb fonction - Fugl-Meyer Assessment (FMA)|Quality of Life|Tardieu Modified scale|Change in neuropathic pain - Douleur Neuropathique 4 (DN4)|Change in upper limb function - Box and Block Test,False,
NCT00618267,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow®"" Assay.","Single Center, Pilot Study to Measure ATP Expression in Lymphocytes of MS Patients Undergoing Various Therapies by Means of Using the ""ImmuKnow®"" Test",COMPLETED,2008-03,2008-12,2008-12,2010-03-05,2008-02-20,OBSERVATIONAL,,100.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Multiple Sclerosis,,United States,Brookline,Massachusetts,1,,,The primary objective of this study is to determine the effects of various therapies (immunomodulatory as well as immunosuppressive) on ATP levels in CD4+ cells.,Secondary objective is to correlate the expression of ATP in CD4+ cells with CD4+ cell count.,False,
NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,"International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)",COMPLETED,2008-07,2009-01,,2013-11-14,2008-08-14,INTERVENTIONAL,PHASE3,106.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis,United States,Rockland,Massachusetts,6,Rebif® New Formulation (RNF) using RebiSmartTM,DRUG,The Number of Subjects Rating the Suitability of RebiSmart at the End of 12-week Treatment Period for Self-injecting Rebif® New Formulation (RNF).,"Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 12|The Incidence of Predefined Injection Site Reactions, MSTCQ Scores, Side Effects, McGill Pain Questionnaire, Visual Analog Scale, and Rating of Pain Regarding Injection Pain Following RNF Administration With RebiSmart at 12-week Treatment Period.",True,2010-08-11
NCT05433103,Blood Flow Restriction And Veterans With MS,Low-Load Resistance Training With Blood Flow Restriction in People With Multiple Sclerosis and Advanced Disability: A Randomized Control Trial,RECRUITING,2023-01-01,2027-12-31,2027-12-31,2025-03-14,2022-06-27,INTERVENTIONAL,NA,58.0,ESTIMATED,VA Office of Research and Development,FED,,,Multiple Sclerosis,Multiple Sclerosis|Blood Flow Restriction|Exercise|Low-load resistance training,United States,Aurora,Colorado,1,Low-Load Exercise with Blood Flow Restriction|Low-Load Exercise Control Group,OTHER|OTHER,Quadriceps muscle strength,Muscle morphology|30-second sit to stand|Modified Fatigue Impact Scale,False,
NCT00220922,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.,"An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone®",COMPLETED,2004-08,2005-10,2006-02,2011-04-08,2005-09-22,INTERVENTIONAL,PHASE4,50.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,Copaxone,,,,0,Alcohol Wipes vs. No Alcohol Wipes,PROCEDURE,Total number of local injection site reactions (LISRs) noted at 5-minutes post-injection,The total number of LISRs noted at 2-minutes post-injection The total number of LISRs noted immediately after injection,False,
NCT04917705,Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies,Search for Diagnostic and Prognostic Biomarkers (Molecular Signatures) in Systemic Sclerosis and Inflammatory Myopathies by a Multi-OMIC Strategy Integrating a Single Cell Analysis Approach,RECRUITING,2021-11-25,2023-06,2028-06,2021-12-15,2021-06-08,INTERVENTIONAL,NA,55.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,,,Systemic Sclerosis|Inflammatory Myopathies,Scleroderma|Myopathy|Multi-OMICS|Biomarkers|Single-cell,France,Strasbourg,Bas-Rhin,1,Collection of biological samples,OTHER,"Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of systemic sclerosis during 5 years.|Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of systemic sclerosis during 5 years.|Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of systemic sclerosis during 5 years.|Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of inflammatory myopathies during 5 years.|Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of inflammatory myopathies during 5 years.|Evolution of the molecular profiles (i.e., genomic [New Generation Sequencing], transcriptomic [RNA chip], proteomic [mass spectrometry] and identification of cell population [single cell RNA sequencing]) of inflammatory myopathies during 5 years.|Comparison of the molecular profiles between systemic sclerosis and inflammatory myopathies at disease early stage.|Comparison of the molecular profiles between systemic sclerosis and inflammatory myopathies at one year and versus disease early stage.|Comparison of the molecular profiles between systemic sclerosis and inflammatory myopathies at 5 years and versus disease early stage.","Identification of molecular profiles specific to the evolution of clinical and biological characteristics of systemic sclerosis and inflammatory myopathies|Identification of molecular profiles specific to the impact of the implementation of targeted treatments in systemic sclerosis and inflammatory myopathies|Assessment of the presence of discriminating molecular profiles in different tissues (blood, skin, muscle) in systemic sclerosis and inflammatory myopathies|Assessment of the presence of discriminating molecular profiles in different cell subpopulations within these tissues (blood, skin, muscle) in systemic sclerosis and inflammatory myopathies",False,
NCT05635266,Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,RECRUITING,2021-10-26,2025-10,2025-10,2024-05-07,2022-12-02,OBSERVATIONAL,,20000.0,ESTIMATED,Sanguine Biosciences,INDUSTRY,,,Age-Related Macular Degeneration|Allergies|Alpha-Gal Syndrome|Alzheimer Disease|Amyloidosis|Ankylosing Spondylitis|Arthritis|Alopecia Areata|Asthma|Atopic Dermatitis|Autism|Autoimmune Hepatitis|Behcet's Disease|Beta-Thalassemia|Cancer|Celiac Disease|Kidney Diseases|COPD|Crohn Disease|Cystic Fibrosis|Diabetes|Dravet Syndrome|DMD|Fibromyalgia|Graves Disease|Thyroid Diseases|Hepatitis|Hidradenitis Suppurativa|ITP|Leukemia|ALS|Lupus or SLE|Lymphoma|Multiple Sclerosis|Myasthenia Gravis|Heart Diseases|Parkinson Disease|Pemphigus Vulgaris|Cirrhosis|Psoriasis|Schizophrenia|Scleroderma|Sickle Cell Disease|Stroke|Ulcerative Colitis|Vasculitis|Vitiligo,,United States,Waltham,Massachusetts,1,Specimen sample,DIAGNOSTIC_TEST,Biospecimen & Clinical Data Collection,,False,
NCT06937723,Smart Monitoring Assessing Spasticity-related Health,Smart Monitoring Assessing Spasticity-related Health - A Prospective Multiple Sclerosis Study With Wearables,RECRUITING,2023-10-19,2025-07,2025-09,2025-04-22,2025-04-22,OBSERVATIONAL,,46.0,ESTIMATED,"Heinrich-Heine University, Duesseldorf",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Spasticity|Smartwatch|Wearables|Digital health tools,Germany,Düsseldorf,North Rhine-Westphalia,1,Device: Smartwatch (Withings Scanwatch),OTHER,"Wearing time of smartwatch (daily)|Longitudinal development of activity parameter: step count|Longitudinal development of activity parameter: approximate distance traveled (meter)|Longitudinal development of activity parameter: duration of soft activity (seconds) defined by Withings Description: Examples for soft activity: Sleeping, Sitting quietly, Walking slowly, Typing on a computer keyboard while seated, Watching television|Longitudinal development of activity parameter: duration of moderate activity (seconds) defined by Withings Description: Examples for moderate activity: Walking fast, Cleaning (vacuuming, washing windows, etc.), Playing doubles tennis or badminton|Longitudinal development of activity parameter: duration of intense activity (seconds) defined by Withings Description: Examples for intense activity: Hiking, Running, Carrying heavy loads, Riding a bike, Playing football, baseball, or tennis (singles)|Longitudinal development of activity parameter: sum of all active time (seconds)|Longitudinal development of activity parameter: approximate calories burned Time|Longitudinal development of sleep parameter: time awake (seconds)|Longitudinal development of sleep parameter: number of times user woke up|Longitudinal development of sleep parameter: time to sleep (seconds)|Longitudinal development of sleep parameter: total time in bed (seconds)|Longitudinal development of sleep parameter: total time asleep (seconds)|Longitudinal development of sleep parameter: ratio of sleep/time in bed|Longitudinal development of sleep parameter: time spent in bed before falling asleep (seconds)|Longitudinal development of sleep parameter: time awake after first falling asleep (seconds)|Longitudinal development of sleep parameter: Withings Sleep score Description: Defined by Withings as follows: It measures every night's sleep and provides a score out of 100 points|Longitudinal development of cardiovascular parameter: average heartrate|Longitudinal development of cardiovascular parameter: maximal heartrate|Longitudinal development of cardiovascular parameter: minimum heartrate|Longitudinal development of cardiovascular parameter: time in light heartrate zone (seconds) Description: Light heartrate zone is defined by Withings as follows: from 0% inclusive to 50% exclusive of maximum heart rate.|Longitudinal development of cardiovascular parameter: time in moderate heartrate zone (seconds) Description: Moderate heartrate zone is defined by Withings as follows: from 50% included to 70% excluded of maximal heart rate.|Longitudinal development of cardiovascular parameter: time in intense heartrate zone (seconds) Description: Intense heartrate zone is defined by Withings as follows: from 70% included to 90% excluded of maximal heart rate.|Longitudinal development of cardiovascular parameter: time in maximal heartrate zone (seconds) Description: Maximal heartrate zone is defined by Withings as follows: from 90% included to 100% included of maximal heart rate|The Modified Ashworth Scale (MAS)",WHOQoL-BREF (World Health Organization Quality of Life Questionnaire Brief Version)|The Expanded Disability Status Scale (EDSS)|Smartwatch Questionnaire|End of Dose Questionnaire (EOD)|McCorkle and Young Symptom Distress Scale|The Multiple Sclerosis Impact Scale 29 (MSIS-29)|The Numeric Rating Scale (NRS)|The Montgomery-Asberg Depression Rating Scale (MADRS)|The Edmonton Symptom Assessment Scale (ESAS)|Sleep-Questionnaire|EQ-5D-5L,False,
NCT07028879,Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis,"Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis: a Non-randomized, Open-label, Controlled Clinical Trial",ACTIVE_NOT_RECRUITING,2025-03-13,2026-03-14,2026-09-13,2025-06-19,2025-06-19,INTERVENTIONAL,NA,24.0,ACTUAL,Hospital Clinic of Barcelona,OTHER,,,Multiple Sclerosis,,Spain,Barcelona,Spain,1,Fatigue management program,PROCEDURE,To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in reducing the severity of perceived fatigue by the Modified Fatigue Impact Scale (MFIS).,To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in improving self-efficacy by the 4-item Spanish chronic disease self - efficacy.|To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in improving incidental and planned exercise by the International Physical Activity Questionnaire (IPAQ)|To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in improving sleep quality by the Pittsburgh Sleep Quality Index (PSQI).|To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in Reducing anxiety and depression levels by the Hospital Anxiety and Depression Scale (HADS).|To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in reducing the impact of fatigue on health status by the EQ-5D-5L.|To determine the effectiveness of this program after completion (12 months after the start of the program) and at mid-term follow-up (18 months) in improving quality of life by the SF-36 questionnaire.,False,
NCT06280573,COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS),COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS),ACTIVE_NOT_RECRUITING,2022-09-01,2025-12-01,2025-12-01,2024-03-19,2024-02-28,INTERVENTIONAL,NA,50.0,ESTIMATED,Comenius University,OTHER,,,Multiple Sclerosis,,Slovakia,Bratislava,,1,Wim Hoff method,COMBINATION_PRODUCT,concentration of pro-inflammatory cytokines|concentration of markers of oxidative stress|concentration of NfL|concentration of GFAP|concentration of ecDNA,Expanded Disability Status Scale|Timed 25-Foot Walk|Nine-Hole Peg Test|Symbol Digit Modalities Test|Fatigue Scale for Motor and Cognitive Functions|General Anxiety Disorder-7|Patient Health Questionnaire-9,False,
NCT04178980,Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis,"Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis",UNKNOWN,2020-01-01,2022-01-01,2022-03-01,2019-11-29,2019-11-26,INTERVENTIONAL,PHASE1,60.0,ESTIMATED,Assiut University,OTHER,,,Simvastatin Multiple Sclerosis,,,,,0,Simvastatin in relapsing remitting multiple sclerosis,DRUG,EDSS,Response rate on the patient reported outcome form Multiple Sclerosis Walking Scale-12 version 2|Change in time taken to complete 25-Foot Timed Walk|Change in time taken to complete 9 hole peg test|modified Rankin scale|Change in frontal lobe function based on Frontal Assessment Battery (FAB) scores,False,
NCT04405479,Resting Postural Tremor in Multiple Sclerosis,Spectral Analyses of Resting Postural Tremor Measured by Accelerometer and Gyroscope as a Predictive Tool of Multiple Sclerosis,RECRUITING,2021-05-01,2024-10-28,2024-12-30,2024-02-06,2020-05-28,OBSERVATIONAL,,30.0,ESTIMATED,"Charles University, Czech Republic",OTHER,,,Multiple Sclerosis,Tremor|Accelerometer,Czechia,Prague,,3,Examination of tremor and upper hand functions,BEHAVIORAL,Tremor,Hand grip strength|Hand and arm function|Psychomotor processing speed,False,
NCT00241254,Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis,"A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study",COMPLETED,2005-12,2010-03,2012-03,2012-03-15,2005-10-18,INTERVENTIONAL,PHASE3,138.0,ACTUAL,"University Hospital, Bordeaux",OTHER,"Ministry of Health, France",OTHER_GOV,"Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis, Chronic Progressive|Cyclophosphamide|Methylprednisolone|Randomized Controlled Trials|Double-Blind Study",France,Bayonne,,26,Cyclophosphamide (drug)|Methylprednisolone (drug),DRUG|DRUG,"Delay to disability deterioration as assessed by the Expanded Disability Status Scale (EDSS: 0.5 or 1 point increase, depending on baseline score)","Proportion of patients with disability deterioration (EDSS: 0.5 or 1 point increase, depending on baseline score)|Multiple Sclerosis Functional Composite (MSFC) and the Z scores of MSFC three components|Number of MS relapses|Proportion of patients with adverse events and delay of occurrence of adverse events|Quality of life questionnaires|Disability self-assessment questionnaires",False,
NCT03621761,"Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue","A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis",COMPLETED,2018-11-15,2021-08-24,2021-11-30,2022-12-27,2018-08-08,INTERVENTIONAL,PHASE4,343.0,ACTUAL,University of Michigan,OTHER,University of Washington|Patient-Centered Outcomes Research Institute|National Multiple Sclerosis Society,OTHER|OTHER|OTHER,Multiple Sclerosis,cognitive behavioral therapy|modafinil|Provigil|fatigue|MS,United States,Ann Arbor,Michigan,2,Telephone-based Cognitive Behavioral Therapy|Modafinil,BEHAVIORAL|DRUG,Change in the Modified Fatigue Impact Scale (MFIS) Score,Change in Fatigue Intensity as Assessed by Self-reported Numerical Rating Scale (NRS) Score.|Change in Fatigue Interference as Assessed by Self-reported Numerical Rating Scale (NRS) Score|Change in Fatigability as Assessed by the Self-reported Fatigue Intensity Numerical Rating Scale (NRS) Score and Physical Activity Level,True,2022-12-27
NCT01854294,GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS),COMPLETED,2013-08,2014-04,2014-07,2021-04-27,2013-05-15,INTERVENTIONAL,PHASE2,12.0,ACTUAL,"Genervon Biopharmaceuticals, LLC",INDUSTRY,Columbia University|Massachusetts General Hospital,OTHER|OTHER,Amyotrophic Lateral Sclerosis,ALS|motorneuron disease|Central Nervous System (CNS) disease|neurodegeneration|neuroprotective|mechanisms of action|pathways|biomarkers|Cerebral Spinal Fluid (CSF)|blood biomarkers|multi-factorial|multisystem|single target|pathogenic mechanisms|Protein Bands Selection by Function|in silico analysis|active site|protein|peptide|embryonic stage|endogenous|master regulators|fetal development|embryonic development|common pathways|Blood Brain Barrier (BBB)|anti-inflammatory|anti-apoptotic|anti-oxidative|regenerative|distress signals|neurotrophin|Motoneuronotrophic factor (MNTF)|ALS model|life span|disease onset|grip strength|protein expression|DNA microarray|differential expression|Phase 1 clinical trial|rare disease|common underlying pathogenic mechanisms|neurological deficits|gene mutation|misfolded proteins|inadvertent errors|modulation of genes|master regulator peptide drug|ALS related genes|mitochondria dysfunction|excitotoxicity|axonal transport|oxidative stress|protein aggregation|pathogenesis|target biomarkers|efficacy biomarkers,United States,Boston,Massachusetts,2,GM604|Placebo comparator,DRUG|DRUG,"Efficacy by percent change in biomarker in th CSF at week 12 from baseline|Safety by measuring 1. adverse event frequency and severity, changes in vital signs, clinical laboratory values. 2. Serious adverse event frequency|Tolerability by measuring the ability to complete the first 2 weeks of active treatment in the study",ALSFRS-R (Amyotrophic Laeral Sclerosis Functional Rating Scale - Revised)|Forced Vital Capacity (FVC)|Time Up and Go (TUG)|muscle strength|Biomarker in blood|Mortality rate,False,
NCT05755061,WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis,Long-Term Aerobic Walking Exercise for Restoring Cognition and Brain in People With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2023-02-01,2025-02-28,2026-01-31,2025-08-28,2023-03-06,INTERVENTIONAL,PHASE1,31.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis,Exercise|Cognition|Brain|Rehabilitation|Remote,United States,West Orange,New Jersey,1,GEMS Plus|GEMS,BEHAVIORAL|BEHAVIORAL,Change in cognitive processing speed|Change in resting-state functional connectivity,Change in thalamic volume,False,
NCT04764383,Histaminergic Basis of Fatigue in Multiple Sclerosis,Histaminergic Basis of Fatigue in Multiple Sclerosis,WITHDRAWN,2022-01-01,2022-10-30,2022-10-30,2021-07-29,2021-02-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,University of Miami,OTHER,,,Multiple Sclerosis,Fatigue|Histamine,United States,Miami,Florida,1,L-Histidine|Placebo|Lodosyn,DRUG|DRUG|DRUG,Incidence of Adverse Events,Efficacy as measured by FSS scores|Efficacy as measured by MFIS Scores|Efficacy as measured by the VAS scores|Efficacy as measured by the MSQOL Scores,False,
NCT05663541,Validity and Reliability of Lower Extremity Position Test in Patients with Multiple Sclerosis,Validity and Reliability of Lower Extremity Position Test in Patients with Multiple Sclerosis,COMPLETED,2022-10-24,2023-05-06,2023-07-24,2024-12-05,2022-12-23,OBSERVATIONAL,,90.0,ACTUAL,Pamukkale University,OTHER,,,Multiple Sclerosis|Sensory Impairments|Proprioceptive Disorders|Validity|Reliability,,Turkey (Türkiye),Bursa,,1,Lower extremity position test,DIAGNOSTIC_TEST,Sensorial Assessment-1|Sensorial Assessment-2|Balance Assessment-1|Balance Assessment-2|Walking Speed Assessment,Demographic Assessment|Expanded Disability Status Scale (EDSS),False,
NCT05973929,Movement Disorders in Multiple Sclerosis Patients,Clinical and Radiological Evaluation of Movement Disorders in Multiple Sclerosis Patients.,UNKNOWN,2022-09-22,2024-03-21,2024-05-01,2023-08-14,2023-08-03,OBSERVATIONAL,,57.0,ESTIMATED,Al-Azhar University,OTHER,,,Multiple Sclerosis|Movement Disorders,Multiple sclerosis|Movement Disorders,Egypt,Cairo,Select A State Or Province,1,Screen for movement disorder and correlates it with MRI findings.,OTHER,Determine the prevalence of movement disorders in MS patients.|know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.|find the correlation between the movement disorder and the different types of MS.,,False,
NCT05450237,Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation,Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation,ENROLLING_BY_INVITATION,2022-07-01,2025-07-01,2026-06-01,2024-10-16,2022-07-08,OBSERVATIONAL,,500.0,ESTIMATED,Neuromed IRCCS,OTHER,,,Multiple Sclerosis|Epilepsy|Parkinson Disease|Dementia|Stroke,,Italy,Pozzilli,Isernia,1,Psychometric Evaluations,BEHAVIORAL,"500 patients will be enrolled in the study. The aim is to monitor over time items such as lifestyle indicators, cognitive, functional, emotional abilities and anxiety in patients with various types of neurological damage through use of evaluation scales.",,False,
NCT03381170,An Extension of the TG1101-RMS201 Trial,"An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis",COMPLETED,2017-06-01,2022-11-11,2022-11-11,2022-12-21,2017-12-21,INTERVENTIONAL,PHASE2,48.0,ACTUAL,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Multiple Sclerosis,United States,Pasadena,California,8,Ublituximab,BIOLOGICAL,Number of participants with treatment-related events as assessed by CTCAE V4.0,Evaluate the % of participants with relapses,False,
NCT00492570,GER-009-06-AVX Early Therapy in Multiple Sclerosis,GER-009-06-AVX Early Therapy in Multiple Sclerosis,COMPLETED,2006-04,2007-10,2008-12,2009-06-16,2007-06-27,OBSERVATIONAL,,230.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Cognitive Dysfunction in Multiple sclerosis|early treatment|Avonex|interferon beta 1a|Cognitive Dysfunction,,,,0,,,,,False,
NCT04002102,Open-Label Placebos to Treat Fatigue in Multiple Sclerosis,Open-Label Placebos to Treat Fatigue in Multiple Sclerosis,COMPLETED,2020-02-17,2022-01-19,2022-01-19,2022-02-01,2019-06-28,INTERVENTIONAL,NA,48.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis|Fatigue,Placebo|Open-Label,United States,Birmingham,Alabama,2,OLP treatment|Usual care|Expectancy Group,OTHER|OTHER|OTHER,Change from baseline fatigue at 21 days using the Fatigue Severity Scale (FSS).|Change from baseline impact of fatigue at 21 days using the Modified Fatigue Impact Scale (MFIS).|Change from baseline quality of life at 21 days using the 36-item Short Form survey (SF-36).,Change from baseline sleepiness at 21 days using the Epworth Sleepiness Scale (ESS).|Change from baseline neurological functioning at 21 days using the Perceived Deficit Questionnaire 5-Item Version (PDQ-5).|Godin Leisure-Time Exercise Questionnaire,False,
NCT06145737,HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS),HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS),ACTIVE_NOT_RECRUITING,2024-01-02,2025-09-01,2025-12-01,2025-05-21,2023-11-24,INTERVENTIONAL,NA,11.0,ACTUAL,Dartmouth-Hitchcock Medical Center,OTHER,,,Multiple Sclerosis|Cognitive Dysfunction|Memory Disorders,Multiple Sclerosis|Memory Disorders|Cognition|Self-Management,United States,Lebanon,New Hampshire,1,HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH),BEHAVIORAL,Change in quality of life as measured by comparing FAMS-Functional Assessment of Multiple Sclerosis v4.0 scores pre- and post-HOBSCOTCH-MS intervention.|Change in subjective cognition as measured by comparing Neuro-QOL Item Bank v2.0 Cognitive Function scores pre- and post-HOBSCOTCH-MS intervention.,Change in objective cognition as measured by comparing Symbol-Digit Modalities Test scores pre- and post-HOBSCOTCH-MS intervention.|Change in objective cognition as measured by comparing California Verbal Learning Test-III scores pre- and post-HOBSCOTCH-MS intervention.,False,
NCT01737372,A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis,A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis,COMPLETED,2012-11,2016-10,2016-10,2016-11-09,2012-11-29,OBSERVATIONAL,,49.0,ACTUAL,"John F. Foley, MD",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Clinically Isolated Syndrome,Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Clinically Isolated Syndrome,United States,Salt Lake City,Utah,1,,,To characterize differences in microRNA profile and cell product patterns between early and later stage multiple sclerosis.,Correlate microRNA profiles with clinical and CSF inflammation indexes,False,
NCT02508961,WEB-Based Physiotherapy for People With Multiple Sclerosis,WEB-Based Physiotherapy for People With Multiple Sclerosis,COMPLETED,2015-01,2016-12,2016-12,2017-06-01,2015-07-27,INTERVENTIONAL,NA,90.0,ACTUAL,University of Glasgow,OTHER,National Heatlh Service Ayrshire and Arran|NHS Lothian|University of Plymouth|University Hospital Plymouth NHS Trust,OTHER_GOV|OTHER_GOV|OTHER|OTHER,Multiple Sclerosis,Physical Activity|Exercise|Physiotherapy,United Kingdom,Edinburgh,,3,Exercise,BEHAVIORAL,Compliance to the exercise programme|Two Minute Walk Test,Timed 25 Foot Walk|Timed Up and Go|Berg Balance Scale|Physical Activity|MS-Related Symptom Checklist|Multiple Sclerosis Impact Scale|Hospital Anxiety and Depression Scale|Health related quality of life,False,
NCT05104983,Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study,Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study,RECRUITING,2021-10-13,2025-12-31,2027-06-30,2025-01-20,2021-11-03,INTERVENTIONAL,PHASE2,64.0,ESTIMATED,Darcy Krueger,OTHER,,,Tuberous Sclerosis Complex|Epilepsy,Tuberous Sclerosis Complex|TSC|epilepsy|prevention|mTOR|sirolimus|infant,United States,Birmingham,Alabama,11,Sirolimus|Placebo,DRUG|DRUG,Efficacy -- time to seizure onset|Safety -- adverse events,Neurodevelopmental Outcomes|Quality of Life Outcomes|EEG Biomarkers|MRI Biomarkers|Sirolimus Precision Dosing,False,
NCT06308042,Remote Evaluation in Patients With Multiple Sclerosis,Remote Reliability Of 30 Seconds Sit And Stand Test In Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2024-03-11,2024-06-24,2024-06-29,2024-03-13,2024-03-13,OBSERVATIONAL,,10.0,ESTIMATED,Inonu University,OTHER,,,Multiple Sclerosis,30 SECONDS SIT AND STAND TEST|REMOTE RELIABILITY,,,,0,30 second sit and stand test,OTHER,30 second sit and stand test,,False,
NCT01780441,Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC),Longitudinal Study to Identify Early Biomarkers of Autism Spectrum Disorder (ASD) in Infants With Tuberous Sclerosis Complex (TSC),COMPLETED,2013-01,2019-12,2020-12,2021-02-04,2013-01-31,OBSERVATIONAL,,166.0,ACTUAL,Boston Children's Hospital,OTHER,National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance,NIH|OTHER,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex|TSC|Autism|ASD|Biomarkers|Infants,United States,Birmingham,Alabama,5,,,ADOS evaluation score at the 36 month visit|MRI biomarkers|EEG biomarkers,,False,
NCT03968172,Interactive Web Platform for EmPOWERment in Early Multiple Sclerosis,Development and Evaluation of a Web-based Lifestyle Intervention for EmPOWERment in Early Multiple Sclerosis (POWER@MS1) - a Randomized Controlled Trial and Mixed-methods Process Evaluation,COMPLETED,2019-07-01,2023-04-05,2023-04-05,2023-09-13,2019-05-30,INTERVENTIONAL,NA,234.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,"Charite University, Berlin, Germany|University of Cologne|University Medical Center Goettingen|Heinrich-Heine University, Duesseldorf|Gaia AG|BKK Dachverband e.V.|Deutsche Multiple Sklerose Gesellschaft (DMSG)",OTHER|OTHER|OTHER|OTHER|INDUSTRY|UNKNOWN|UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Complex Intervention|Lifestyle Intervention|Randomized Controlled Trial|Evidence-based Medicine,Germany,Hamburg,,1,EBBC programme|Control group programme,BEHAVIORAL|BEHAVIORAL,Occurrence of new lesions on T2-weighted images on MRI scans|Time to a second relapse,"Risk Knowledge (RiKno10)|Control Preference Scale (CPS)|Immunotherapy Decision Satisfaction Questionnaire|Immunotherapy Status Questionnaire|Patient Activation Measure (PAM)|Coping self-efficacy (CSE) scale|Changes in Perceived Empowerment Questionnaire|Credibility/Expectancy Questionnaire|Readiness to Change (stage assessment) based on the Health Action Process Approach (HAPA)|Impairment in the Expanded Disability Status Scale (EDSS)|Hamburg Quality of life in MS Scale (HAQUAMS)|EQ-5D|Hospital anxiety and distress scale (HADS)|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Physical Activity, Exercise, and Sport Questionnaire (Bewegungs- und Sportaktivität Fragebogen (BSA-F))|Questionnaire of Healthy Diet (QHOD2), adapted version of the Mediterranean Diet Screener (aMDS)|24-h dietary recall myfood24|Health Economic Evaluation",False,
NCT00142402,Modafinil in Multiple Sclerosis,Modafinil for Improving New Learning and Memory in Multiple Sclerosis,COMPLETED,2003-06,2006-09,2006-09,2013-09-26,2005-09-02,INTERVENTIONAL,NA,20.0,,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Multiple Sclerosis|Memory|New Learning|Fatigue,United States,West Orange,New Jersey,1,Modafinil,DRUG,Scores on memory tests at 3 weeks and 6 weeks,Scores on fatigue measures at 3 weeks and 6 weeks|Scores on emotional measures at 3 weeks and 6 weeks,False,
NCT00344253,"Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis","A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)",COMPLETED,2006-03,2011-03,2012-01,2012-12-03,2006-06-26,INTERVENTIONAL,PHASE3,19.0,ACTUAL,Heidelberg University,OTHER,Serono GmbH,UNKNOWN,"Uveitis, Intermediate|Macular Edema|Multiple Sclerosis",Uveitis|Macular Edema|Interferon|Multiple Sclerosis|Encephalomyelitis disseminata (ED),Germany,Heidelberg,,1,Interferon beta|Methotrexate,DRUG|DRUG,"Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12","Reduction of macular edema (OCT)|Reduction intraocular inflammation (2 step change, SUN classification)|Increase in retinal light sensitivity (fundus controlled perimetry)",False,
NCT01080027,"Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)","An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings",COMPLETED,2008-10,2011-06,2011-06,2014-07-31,2010-03-03,OBSERVATIONAL,,254.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck A.E., Greece|Merck OY, Finland|Merck B.V., Netherlands|Merck A.B., Sweden|Merck, S.A., Portugal",INDUSTRY|INDUSTRY|INDUSTRY|INDUSTRY|INDUSTRY,"Multiple Sclerosis, Relapsing Remitting",Multiple sclerosis|Relapsing remitting|Rebif,Greece,Thessaloniki,,1,Rebif® New Formulation,DRUG,Proportion of subjects with injection site reactions (ISRs),"proportion of subjects with AEs and with specific categories of AEs; proportion and reasons of missed injections, annual relapse rate, proportion of relapse-free subjects from baseline, time to first relapse",False,
NCT01377805,Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life,Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life -- a Retrospective Analysis,WITHDRAWN,2011-06,2011-11,2011-11,2024-02-14,2011-06-21,OBSERVATIONAL,,0.0,ACTUAL,Genetic Disease Investigators,OTHER,,,Multiple Sclerosis,Multiple Sclerosis hydrocephalus,United States,Colleyville,Texas,1,,,Measurement of Head Circumference in Multiple Sclerosis patients (retrospectively),,False,
NCT06090305,Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex),Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex): Randomized Controlled Trial,COMPLETED,2023-11-20,2024-12-06,2024-12-06,2025-01-30,2023-10-19,INTERVENTIONAL,NA,470.0,ACTUAL,Gaia AG,INDUSTRY,University Hospital Schleswig-Holstein|Universität Duisburg-Essen,OTHER|OTHER,Multiple Sclerosis,,Germany,Hamburg,,1,levidex|Control|treatment as usual (TAU),BEHAVIORAL|BEHAVIORAL|OTHER,Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HALEMS),Patient Health Questionnaire (PHQ-9)|Work and Social Assessment Scale (WSAS)|Global index score of the Multiple Sclerosis International Quality of Life (MuSiQoL)|Generalized Anxiety Disorder Scale-7 (GAD-7)|Frenchay Activities Index (FAI)|Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HALEMS),False,
NCT03191669,Vaccine Exposure in Patients With MS,Vaccine Exposure in Patients With Multiple Sclerosis in the Auvergne-Rhone-Alpes Region,COMPLETED,2017-06-26,2017-07-07,2017-07-07,2018-04-13,2017-06-19,OBSERVATIONAL,,335.0,ACTUAL,Hospices Civils de Lyon,OTHER,,,Multiple Sclerosis,,France,Bron,,6,Auto-questionnaire,OTHER,Percentage of patients exposed to seasonal flu vaccine in 2016-2017,,False,
NCT01006941,Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study,Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study,COMPLETED,2010-05,2011-01,2011-09,2011-11-10,2009-11-03,INTERVENTIONAL,PHASE2,10.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,"University of Copenhagen|Statens Serum Institut|Copenhagen University Hospital, Hvidovre|OvaMed GmbH",OTHER|OTHER|OTHER|INDUSTRY,Relapsing Multiple Sclerosis,Multiple sclerosis|safety|MRI|immunological|Helminths|Trichuris suis,Denmark,Copenhagen,Copenhagen,1,Trichuris suis ova,BIOLOGICAL,"MRI activity judged by the number of new or enlarging T2 lesions, number of Gd enhancing lesions and volume of T2 lesions",,False,
NCT07081594,Investigating the Impact of Sex Hormones in Multiple Sclerosis,"Investigating the Impact of Sex Hormones on Corticospinal Excitability, Motor Learning, and Fatigue in Females With Multiple Sclerosis",NOT_YET_RECRUITING,2025-09-01,2027-03,2029-03,2025-07-23,2025-07-23,OBSERVATIONAL,,14.0,ESTIMATED,Milap Sandhu,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Sex hormones|menstrual cycle,,,,0,,,Corticospinal excitability|Blood Draw,strength|Fatigue|Motor Learning,False,
NCT06599866,Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Individuals With Multiple Sclerosis,Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Patients With Multiple Sclerosis,COMPLETED,2024-05-15,2025-01-15,2025-03-26,2025-09-05,2024-09-19,OBSERVATIONAL,,71.0,ACTUAL,Kutahya Health Sciences University,OTHER,,,Lower Urinary Track Symptoms|Multiple Sclerosis,lower urinary tract symptoms|multiple sclerosis|reliability|validity,Turkey (Türkiye),Kütahya,Center,1,,,Core Lower Urinary Tract Symptoms Score,Overactive Bladder Questionnaire-V8,False,
NCT01272596,Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis,Evaluation of Low Contrast Sloan Visual Charts as Method for the Assessment of Disease Progression in Multiple Sclerosis,COMPLETED,2009-12,2013-11,2013-11,2021-07-29,2011-01-10,OBSERVATIONAL,,100.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,Novartis Germany GmbH,UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Visual Contrast Acuity|Visual Contrast Sensitivity|Sloan Charts,Germany,Berlin,,1,,,Visual Contrast Acuity,Structural and Functional Changes of Optic Pathway|Clinical Neurological Assessment|Quality of Life|Contrast Sensitivity,False,
NCT06868342,Nerve Root Block in Spasticity,Determination of Feasibility of Reversible Conduction Block Generated Using Peripheral Nerve Stimulator in Treatment of Focal Spasticity and the Stimulation Parameters for the Same.,COMPLETED,2024-01-15,2024-12-09,2024-12-09,2025-03-17,2025-03-10,INTERVENTIONAL,NA,4.0,ACTUAL,Walton Centre NHS Foundation Trust,OTHER,Nevro Corp,INDUSTRY,Spasticity|Spasticity in Participants With Multiple Sclerosis|Spasticity Post Stroke|Spasticity Related to Any Cause Except Cerebral Palsy,Spasticity|High-Frequency Stimulation|Electrical Nerve Block|Conduction Block,United Kingdom,Liverpool,,1,High-frequency nerve conduction block,PROCEDURE,EMG - Nerve conduction block|EMG - The reversibility of nerve conduction block|EMG - Comparative analysis of the effects of nerve block vs. neurectomy.,,False,
NCT00001869,Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM),Lymphangioleiomyomatosis (LAM) Registry,COMPLETED,1998-12,,2003-04,2008-03-04,1999-11-04,OBSERVATIONAL,,400.0,,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,,,Leiomyomatosis,Progesterone|Pulmonary Function Tests|Pneumothorax|Oopherectomy|High Resolution CT|Tuberous Sclerosis Complex|Lymphangioleiomyomatosis (LAM),United States,Bethesda,Maryland,1,,,,,False,
NCT05141669,Impact of Fingolimod Adherence on Outcomes,Impact of Fingolimod Adherence on Outcomes,COMPLETED,2020-05-18,2020-11-20,2020-11-20,2021-12-16,2021-12-02,OBSERVATIONAL,,694.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,Fingolimod,DRUG,Number of Multiple Sclerosis (MS) relapses,Number of Multiple Sclerosis-related inpatient admission|Number of Multiple Sclerosis-related Emergency Room (ER) visits|All-cause total (medical plus pharmacy) health care costs|All-cause medical health care costs|All-cause total (medical plus pharmacy) health care costs excluding fingolimod,False,
NCT00122954,Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis,Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis,COMPLETED,2005-07,2009-06,2009-06,2017-06-08,2005-07-22,INTERVENTIONAL,PHASE1|PHASE2,39.0,ACTUAL,Oregon Health and Science University,OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis|Depression,"Fatty Acids, Omega-3|Fish Oils|Complementary Therapies",United States,Portland,Oregon,1,Fish oil concentrate|Placebo,DRUG|DRUG,Montgomery-Asberg Depression Rating Scale (MADRS),Quality of Life (SF-36),True,2014-01-14
NCT03782246,MBCT and CBT for Chronic Pain in Multiple Sclerosis,Mindfulness-based Cognitive Therapy and Cognitive Behavioral Therapy for Chronic Pain in Multiple Sclerosis,UNKNOWN,2018-11-28,2022-08-01,2022-08-01,2022-04-18,2018-12-20,INTERVENTIONAL,NA,273.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,chronic pain|multiple sclerosis|pain|mindfulness|cognitive behavioral therapy,United States,Seattle,Washington,1,MBCT|CBT,BEHAVIORAL|BEHAVIORAL,Change in average pain intensity,Pain interference|Average pain intensity - maintenance|Depressive symptom severity|Patient ratings of global improvement & satisfaction|Fatigue severity|Sleep disturbance|Self-efficacy|Physical Function|Global Quality of LIfe,False,
NCT03356769,Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex,A Placebo-controlled Study of Efficacy & Safety of Aspirin as an add-on Treatment in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Seizures,UNKNOWN,2017-11-20,2021-11-20,2021-11-20,2020-06-09,2017-11-29,INTERVENTIONAL,PHASE2,98.0,ESTIMATED,Peking Union Medical College Hospital,OTHER,Shijiazhuang Yiling Pharmaceutical Co. Ltd,INDUSTRY,Tuberous Sclerosis Complex|Aspirin|Epilepsy|Cognitive Decline|Skin Lesions,refractory seizure|cognitive impairment|electroencephalography improvement|seizure reduction|seizure free|aspirin,China,Beijing,Beijing Municipality,1,Aspirin|AED|Placebo,DRUG|DRUG|DRUG,Percentage of reduction in seizure frequency,Total days of seizure free|A mild reduction in seizure frequency|Changes of epileptic discharges in electroencephalogram|Improvement of facial angiofibromas|Changes of cognitive condition|Subjective evaluation of treatment-response condition,False,
NCT02452996,Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers,"A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers",COMPLETED,2015-04,2015-08,2015-08,2020-10-20,2015-05-25,INTERVENTIONAL,PHASE1,21.0,ESTIMATED,GeNeuro Innovation SAS,INDUSTRY,,,Healthy Volunteers,GNbAC1|Multiple Sclerosis|Multiple Sclerosis Associated Retrovirus (MSRV)|MSRV-Envelope protein|Monoclonal antibody|Temelimab,Germany,Berlin,,1,GNbAC1,DRUG,safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects,PK characteristics: GNbAC1 serum concentrations|immunogenicity in terms of antibodies against GNbAC1 (anti-drug antibodies)|ratio of serum to CSF GNbAC1 concentration,False,
NCT00112723,Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma,TERMINATED,2005-12,2011-02,2015-11,2016-08-08,2005-06-03,INTERVENTIONAL,PHASE1|PHASE2,46.0,ACTUAL,National Cancer Institute (NCI),NIH,,,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Waldenström Macroglobulinemia,,United States,Columbus,Ohio,1,alvocidib,DRUG,Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I)|Maximum Tolerated Dose (MTD)|Complete and Partial Response Rate (Phase II)|Qualitative and Quantitative Toxicities in Regard to Organ Specificity|Lymphoid/Plasma Cell Malignancies,"Pharmacokinetics (Area Under the Curve; AUC) of Flavopiridol|Number of Patients Reporting Acute Infusion Toxicity (e.g., Fever, Hypotension, Tumor Pain, and Dyspnea)|Induced Response in Patients Independent of p53 Mutational Status|Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).|Pharmacokinetics (Cmax) of Flavopiridol",True,2016-08-08
NCT06280742,Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET),Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study,NOT_YET_RECRUITING,2025-09,2027-11,2027-11,2025-09-04,2024-02-28,INTERVENTIONAL,NA,41.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|PET-MRI,France,Lyon,,7,PET-MRI with [18F]-DPA-714,RADIATION,"To quantify the smoldering component of white matter lesions in people with MS, as compared with [18F]-DPA-714 binding in the white matter of HC who underwent a PET a acquisition with the same camera camera than patients in each center.","To quantify for each patient the regional neuroinflammatory load, measured as [18F]-DPA-714 DVR, in specific regions of interest: total brain, normal appearing white matter, cortex, thalami, deep grey matter.|The MRI signatures of each lesional subtypes, and correlation between MRI metrics and [18F]-DPA-714 DVR in each region of interest.",False,
NCT01864941,Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients,Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients,COMPLETED,2013-05,2017-08-01,2017-08-01,2018-04-17,2013-05-30,INTERVENTIONAL,PHASE1|PHASE2,104.0,ACTUAL,University of British Columbia,OTHER,Canadian Institutes of Health Research (CIHR)|Multiple Sclerosis Society of Canada,OTHER_GOV|OTHER,Multiple Sclerosis,Multiple Sclerosis|MS|CCSVI|Zamboni|catheter venography|balloon angioplasty,Canada,Vancouver,British Columbia,4,Catheter venography with balloon venoplasty|Catheter venography with balloon venoplasty and balloon,PROCEDURE|DEVICE,Adverse Events,Clinical Outcome|Clinical Outcome|Clinical Outcome|Clinical Outcome,False,
NCT05062083,PET Imaging of Cyclooxygenase in Multiple Sclerosis,PET Imaging of Cyclooxygenases in Multiple Sclerosis,TERMINATED,2022-06-07,2023-09-05,2024-01-30,2024-06-27,2021-09-30,INTERVENTIONAL,PHASE2,7.0,ACTUAL,National Institute of Mental Health (NIMH),NIH,University of Maryland,OTHER,Multiple Sclerosis,PET Imaging|Multiple Sclerosis|Neuroinflammation|Neurological Symptoms|Cyclooxygenases,United States,Bethesda,Maryland,1,11C-MC1|11C-PS13|Ketoprofen|Celecoxib,DRUG|DRUG|DRUG|DRUG,Standard Uptake Value Ratio (SUVR) of Lesions With Injection of [11C]PS13|Standard Uptake Value Ratio (SUVR) of Lesions With Injection of [11C]MC1|Standard Uptake Value Ratio (SUVR) of Lesions With Injection of [11C]PS13 After Blockade With Ketoprofen|Standard Uptake Value Ratio (SUVR) of Lesions With Injection of [11C]MC1 After Blockade With Celecoxib,Standard Uptake Value Ratio (SUVR) of Chronic Active Lesions With Injection of [11C]PS13|Standard Uptake Value Ratio (SUVR) of Chronic Active Lesions With Injection of [11C]MC1,True,2024-06-27
NCT00246324,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS),COMPLETED,2003-12,2009-08,2009-10,2022-11-08,2005-10-31,INTERVENTIONAL,PHASE4,16.0,ACTUAL,Louisiana State University Health Sciences Center Shreveport,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Shreveport,Louisiana,1,"Interferon beta 1a, oral doxycycline",DRUG,Gadolinium-enhancing (Gd+)Lesion Number Change.,"Relapse Rates, Serum Matrix Metalloproteinase 9 Levels, Transendothelial Migration of Monocytes",True,2011-11-17
NCT02236624,Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?,Can Aerobic Exercise Reduce Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?,COMPLETED,2014-03,2016-02,2016-04,2016-04-19,2014-09-10,INTERVENTIONAL,NA,20.0,ESTIMATED,University of Aarhus,OTHER,Aarhus University Hospital|MS-Clinic of Southern Jutland|MS-Clinic Viborg|MS-Clinic Odense|Biogen,OTHER|UNKNOWN|UNKNOWN|UNKNOWN|INDUSTRY,Multiple Sclerosis,,Denmark,Aarhus,Aarhus C,1,Aerobic exercise,BEHAVIORAL,Flu-like symptoms assessment,Bloodbourne biomarkers,False,
NCT06847724,An Efficacy and Safety Study With Integrated Pharmacokinetics (PK) and Pharmacodynamic (PD) Assessment to Compare the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (RMS),"A Randomized, Double-blind, Parallel-group Study to Compare the Pharmacokinetics, Efficacy, Pharmacodynamics, Safety, and Immunogenicity of CYB704 (Proposed Ocrelizumab Biosimilar) and Ocrevus® (EU-authorized and US-licensed) in Participants With Relapsing Multiple Sclerosis (RMS)",RECRUITING,2025-06-10,2027-05-14,2029-10-14,2025-09-05,2025-02-26,INTERVENTIONAL,PHASE3,518.0,ESTIMATED,Sandoz,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Maitland,Florida,17,CYB704|Ocrevus-EU|Ocrevus-US,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Area under the concentration time curve in cohort 1|Total number of T1-weighted Gadolinium enhancing (GdE) lesions on brain MRI scans,Area under the plasma concentration versus time curve (AUC) in cohort 1|Peak Plasma Concentration (Cmax) in cohort 1|CD19+ B-cell count|Total number of new/enlarging T2 lesions|Total number of new T1 GdE lesions|Annualized Relapse Rate|Treatment emergent Adverse Events and Serious Adverse Events|Rate of patients with anti-drug antibodies,False,
NCT02939859,"Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions","Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.",WITHDRAWN,2018-12-15,2022-10,2023-10,2021-02-16,2016-10-20,INTERVENTIONAL,PHASE1,0.0,ACTUAL,Healeon Medical Inc,INDUSTRY,Global Alliance for Regenerative Medicine,OTHER,Multiple Sclerosis|Autoimmune,Multiple Sclerosis|Demyelinating Diseases|Nervous System Diseases|Autoimmune Disorders,United States,Stevensville,Montana,2,Microcannula Harvest Adipose|Centricyte 1000|Sterile Normal Saline IV deployment AD-cSVF,PROCEDURE|DEVICE|PROCEDURE,Number of participants with adverse events [Time Frame: Outcome measures evaluated at baseline and reviewed at 6 month intervals for average time frame of 5 years],Neurologic Functioning|Quality of Life Questionnairre|Fatigue|Cognitive Problems|Brain Lesions,False,
NCT02032589,Testing the Efficacy of Self-Generation Treatment Protocol,Exploring the Effects of a Memory Intervention on Memory and Everyday Life Activities With Persons With MS,UNKNOWN,2014-01,2014-12,2014-12,2014-01-10,2014-01-10,INTERVENTIONAL,NA,40.0,ESTIMATED,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,West Orange,New Jersey,1,Self-generation treatment,BEHAVIORAL,Neuropsychological Assessment,Assessment of Global Functioning,False,
NCT01259388,A Pilot Study of Lithium in Progressive Multiple Sclerosis,A Pilot Trial of Lithium in Progressive Multiple Sclerosis,COMPLETED,2011-05,2015-08,2015-12,2019-09-10,2010-12-14,INTERVENTIONAL,PHASE1|PHASE2,23.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis,Multiple sclerosis|Lithium,United States,Birmingham,Alabama,2,Lithium Carbonate,DRUG,Rate of Change in Brain Parenchymal Fraction,Total Relapses|Change in Expanded Disability Status Scale Score,True,2019-09-10
NCT03703180,Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS,Vision Assessment With the qCSF Method in Healthy Controls and MS: Investigating the Association Between Optical Coherence Tomography (OCT) and qCSF Dynamics Over Two Years and Set-up of a Representative Normative Data-set,UNKNOWN,2018-01-29,2021-02,2021-02,2018-10-22,2018-10-11,OBSERVATIONAL,,200.0,ESTIMATED,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,Multiple Sclerosis,,Germany,Hamburg,,1,,,Correlation between ganglion cell / inner plexiform layer (GCIPL) thickness loss and area under the log CSF curve change over two years,Correlation between retinal nerve fibre layer (RNFL) thickness loss and area under the log CSF curve change over two years|Longitudinal correlation between visual quality of life and contrast vision,False,
NCT04294979,Exercise Therapy in Multiple Sclerosis,"Study on the Interaction Between Immune, Autonomic and Central Nervous Systems as a Target of Exercise Therapy in Multiple Sclerosis",COMPLETED,2020-02-01,2023-12-01,2024-04-01,2025-05-13,2020-03-04,INTERVENTIONAL,NA,44.0,ACTUAL,IRCCS San Raffaele Roma,OTHER,Neuromed IRCCS,OTHER,Multiple Sclerosis,Rehabilitation|exercise|Multiple sclerosis|Physical therapy,Italy,Roma,RM,1,Physical Therapy,OTHER,Changes in clinical disability (EDSS)|Changes in clinical disability: Multiple Sclerosis Functional Composite (MSFC)|Changes in visual disability,Changes in Mood-depressive trait|Changes in Mood-anxiety trait|Neurophysiological assessment|Changes in autonomic function|Changes in T cell function|Electrophysiological evaluation,False,
NCT06318923,Social and Moral Cognition in Multiple Sclerosis,Social and Moral Cognition in Multiple Sclerosis,RECRUITING,2023-12-19,2025-04-30,2025-10-30,2024-03-20,2024-03-19,INTERVENTIONAL,NA,90.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis,France,Lille,,2,"Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|MS questionnaire|MONTREAL COGNITIVE ASSESSMENT (MoCA) test",OTHER|OTHER|OTHER,Moral dilemma judgments,Explicit time perspective inventory test|Implicit time perspective inventory test|Dot Probe Task|Level of moral permissibility|Level of emotional reactivity|Moral relativity level|Brief International Cognitive Assessment for Multiple Sclerosis|The Beck Depression Inventory|State-Trait Anxiety Inventory|Toronto Alexithymia Scale (TAS)-20|Empathy quotient-8 (EQ-8)|Electrodermal response,False,
NCT01790269,Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod,"Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial",TERMINATED,2013-09,2018-08,2018-08,2021-07-29,2013-02-13,OBSERVATIONAL,,21.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,Dr. Carmen Infante-Duarte,UNKNOWN,Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting Multiple Sclerosis|NK cells|Fingolimod,Germany,Berlin,,1,,,Status of NK cell maturation,NK cell frequency|Percentage immature NK cells/total NK cells|NK cell activation|NK cell maturation and activation|NK cell cytotoxicity and the cytokine production,False,
NCT04891341,Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis,Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis,COMPLETED,2021-02-16,2022-07-16,2022-07-17,2022-07-19,2021-05-18,INTERVENTIONAL,NA,34.0,ACTUAL,Hacettepe University,OTHER,,,Multiple Sclerosis,Virtual Reality|Telerehabilitation|Task-oriented Circuit Therapy|Kinematics|Kinematic Analysis,Turkey (Türkiye),Ankara,Altındağ,1,Technology Supported Task-Oriented Circuit Training|Home-based Telerehabilitation,OTHER|OTHER,Berg Balance Scale|Multiple Sclerosis Quality of Life Scale (MSSQL-54),Trunk Impairment Scale|Timed Up and Go Test|Goal Assesment Scale|ABILHAND-Stroke|Minnesota Manual Dexterity Test|Twelve Item MS Walking Scale|Kinematic Analysis During Functional Activities|International Cooperative Ataxia Rating Scale,False,
NCT00289159,Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up,Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).,UNKNOWN,,,,2006-02-09,2006-02-09,OBSERVATIONAL,,,,Groupe Hospitalier Pitie-Salpetriere,OTHER,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,Multiple Sclerosis,aged 18-50|remitting evolution|less than two years of evolution|MS patients,,,,0,,,,,False,
NCT01089686,Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients,Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study (Liberation Study),TERMINATED,2010-08,2012-10,2012-10,2012-03-07,2010-03-18,INTERVENTIONAL,NA,2.0,ACTUAL,"Manish Mehta, MD",OTHER,"Center for Vascular Awareness, Albany, New York",OTHER,Multiple Sclerosis,Chronic Cerebrospinal Venous Insufficiency,United States,Albany,New York,1,Venoplasty|Sham procedure (non-treatment),PROCEDURE|PROCEDURE,"Incidence of major adverse events|Neurological assessment of MS|MRI/MRA evaluation of MS lesions, recommended",Mortality|Major adverse events|Identification of central venous stenosis,False,
NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,"A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2012-02,2014-04,2014-04,2015-03-19,2011-12-22,INTERVENTIONAL,PHASE3,162.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing-Remitting,Argentina,Caba,Buenos Aires,29,Fingolimod,DRUG,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,"Number (%) of Patients With AE of Special Interest Including Bradyarrhythmia, BP Increase, Liver Transaminase Elevations, Infections , Macula Oedema.",True,2015-03-19
NCT01982942,"Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis",COMPLETED,2013-11,2017-05,2017-12,2020-07-28,2013-11-13,INTERVENTIONAL,PHASE2,255.0,ACTUAL,MediciNova,INDUSTRY,National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|National Multiple Sclerosis Society,NIH|NIH|OTHER,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",,United States,Birmingham,Alabama,28,ibudilast|Placebo oral capsule,DRUG|DRUG,Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).|Percentage of Participants With Adverse Events.,Diffusion Tensor Imaging (DTI) in Descending Pyramidal White Matter Tracts|Magnetization Transfer Ratio (MTR) Imaging in Normal-appearing Brain Tissue|Retinal Nerve Fiber Layer as Measured by Optical Coherence Tomography (OCT).,True,2020-07-28
NCT05620940,"A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.","A PHASE 1, OPEN-LABEL, EXPLORATORY, FIXED-SEQUENCE, PHARMACOKINETIC SINGLE ASCENDING DOSE STUDY OF IVL3004 VERSUS VIVITROL® (NALTREXONE) LONG-ACTING INJECTABLE (LAI) AND IVL4002 IN HEALTHY SUBJECTS",RECRUITING,2024-09-11,2025-12-30,2025-12-30,2025-09-15,2022-11-17,INTERVENTIONAL,PHASE1,40.0,ESTIMATED,"Inventage Lab., Inc.",INDUSTRY,,,Opioid Dependence|Alcohol Dependence|Multiple Sclerosis,,Australia,Herston,Queensland,1,Vivitrol Injectable Product|IVL3004|IVL4002,DRUG|DRUG|DRUG,AUC0-240|Cmax|AUC240-672|AUC0-672|AUC0-inf,,False,
NCT01578785,"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)","A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection",TERMINATED,2012-03,2012-10,2012-11,2014-04-02,2012-04-17,INTERVENTIONAL,PHASE3,178.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Cullman,Alabama,169,Glatiramer Acetate|Placebo,DRUG|DRUG,The Annualized Relapse Rate During the Placebo Controlled Period,The Cumulative Number of New or Enlarging T2 Lesions Measured at Months 6 and 12 (End of Placebo Controlled Period)|The Cumulative Number of Gadolinium-enhancing Lesions on T1-weighted Images Measured at Months 6 and 12 (End of Placebo Controlled Period)|Percent Change From Baseline to Month 12 (End of Placebo Controlled Period) in Brain Volume,True,2014-04-02
NCT06117020,Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals,"A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study of MTR-601 in Healthy Volunteers.",COMPLETED,2023-09-11,2024-10-16,2024-10-16,2025-03-12,2023-11-03,INTERVENTIONAL,PHASE1,89.0,ACTUAL,Motric Bio,INDUSTRY,,,"Muscle Spasticity|Hypertonia, Muscle|Cerebral Palsy|Multiple Sclerosis|Stroke|Hereditary Spastic Paraplegia|Dystonia|Spinal Cord Injuries",Fast twitch type 2 myosin ATPase,United States,San Antonio,Texas,1,MTR-601,DRUG,"Incidence, severity and relatedness of Treatment-emergent adverse events (TEAEs). TEAE severity will be measured as mild, moderate or severe, and relatedness will be either related or not related.",Maximum plasma concentration (Cmax) of MTR-601|Time to maximum plasma concentration (Tmax) of MTR-601|Plasma area under the curve (AUC) concentration of MTR-601|Plasma half-life (T1/2) of MTR-601|Urine concentration of MTR-601|Pharmacodynamic of MTR-601-Grip strength by dynamometry|Pharmacodynamic of MTR-601-Forearm extension and flexion strength by dynamometry|Pharmacodynamic of MTR-601-Knee extension and flexion strength by dynamometry|Pharmacodynamic of MTR-601-Lower-extremity magnetic stimulated contraction,False,
NCT01333358,Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients,"Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints",UNKNOWN,2011-05,2013-12,2014-03,2011-04-25,2011-04-12,INTERVENTIONAL,PHASE3,30.0,ESTIMATED,Central Texas Neurology Consultants,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,Relapsing|remitting,,,,0,Alemtuzumab,DRUG,The primary study objective is to demonstrate whether treatment with alemtuzumab is effective in stabilizing overall neurocognitive functioning in relapsing-remitting multiple sclerosis over time.,,False,
NCT01149525,Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis,"A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis",COMPLETED,2010-06,2013-03,2013-07,2017-05-08,2010-06-23,INTERVENTIONAL,PHASE3,59.0,ACTUAL,"University Hospital, Bordeaux",OTHER,,,Multiple Sclerosis,Multiple Sclerosis/complications|Fatigue Syndrome|Chronic/drug therapy,France,Bordeaux,,6,L-Carnitine|Placebo,DRUG|DRUG,"Global score on the 21 item Modified Fatigue Impact Scale (MFIS, translated and validated in French).",Fatigue Severity Scale (FSS)|Fatigue Visual Analogic Scale (VAS)|physical dimension scale of MFIS|SEP59 scale of quality of life (Multiple Sclerosis Quality Of Life scale validated in french),False,
NCT05355389,Cognitive-motor Telerehabilitation in MS,Cognitive-motor Telerehabilitation in Multiple Sclerosis,RECRUITING,2022-09-01,2027-05-31,2027-05-31,2025-04-02,2022-05-02,INTERVENTIONAL,NA,90.0,ESTIMATED,Universitair Ziekenhuis Brussel,OTHER,National MS Center Melsbroek|Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek),OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|cognitive rehabilitation|cognitive-motor rehabilitation|telerehabilitation,Belgium,Brussels,,2,Cognitive training|Motor training,BEHAVIORAL|BEHAVIORAL,Change in Digit span backwards,Change in Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|Change in Corsi backwards|Change in Expanded Disability Status Scale (EDSS)|Change in 6-Minute Walk Test (6MWT)|Change in 25-Foot Walk Test (25FWT)|Change in 9-Hole Peg Test (9HPT)|MRI T1 3D BRAVO scan|MRI T2 FLAIR 3D Cube scan|Diffusion weighted image (DWI)|Synthetic MRI|resting-state EEG|task-related EEG - auditory oddball paradigm|task-related EEG - adjusted SDMT paradigm|task-related EEG - n-back paradigm,False,
NCT01606176,A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin,"A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function.",COMPLETED,2002-03,2002-08,2002-08,2023-01-10,2012-05-25,INTERVENTIONAL,PHASE3,70.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Pain|Multiple Sclerosis,,United Kingdom,Norfolk,,1,GW-1000-02|Placebo,DRUG|DRUG,Change From Baseline in Mean Pain Box Scale-11 Score at 3 Weeks.,Use of Analgesic Escape Medication.|Change From Baseline in Mean Sleep Disturbance Score at 3 Weeks.|Change From Baseline in Mean Total Pain Disability Index Score at 3 Weeks.|Change From Baseline in Mean Total Brief Pain Inventory (Short Form) Score at 3 Weeks.|Change From Baseline in Mean Spitzer Quality of Life Index Scores at 3 Weeks.|Patient Global Impression of Change at the End of 3 Weeks of Treatment.|Change From Baseline in Mean Pain Box Scale-11 Scores (Multiple Sclerosis Subset) at 3 Weeks.|Use of Analgesic Escape Medication - Multiple Sclerosis Subset.|Change From Baseline in Mean Sleep Disturbance Scores (Multiple Sclerosis Subset) at 3 Weeks.|Change From Baseline in Mean Pain Disability Index Scores at 3 Weeks.|Change From Baseline in Mean Brief Pain Inventory (Short Form) Scores (Multiple Sclerosis Subset) at 3 Weeks.|Change From Baseline in Mean Spitzer Quality of Life Index Scores (Multiple Sclerosis Subset) at 3 Weeks.|Patient Global Impression of Change - Multiple Sclerosis Subset.|Incidence of Adverse Events as a Measure of Patient Safety.,True,2012-08-24
NCT01866878,Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.,Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.,COMPLETED,2013-07-30,2015-07-28,2015-07-28,2018-03-12,2013-06-03,INTERVENTIONAL,NA,10.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,"transcutaneous electrical nerve stimulation, sensitivity, multiple sclerosis,Reeducation through labor tactile discrimination",France,Nice,,1,equipment rehabilitation stereognosis|TENS,DEVICE|DEVICE,Compare quality of life between baseline and procedure,Compare the performance during functional tests between baseline and procedure|Compare the improvement clinically sensitive target from baseline procedure,False,
NCT02858778,Timing of Acute Palliative Care Consultation in Critically Ill Patients,A Randomized Allocation of Palliative Care Consultation in the Emergency Department Compared to Usual Practice,UNKNOWN,2016-06,2017-01,,2016-08-08,2016-08-08,INTERVENTIONAL,NA,120.0,ESTIMATED,Wayne State University,OTHER,Blue Cross Blue Shield of Michigan Foundation,OTHER,Multiple Organ Failure|End Stage Cardiac Failure|End Stage Chronic Obstructive Airways Disease|Chronic Kidney Disease Stage 5|Hepatic Encephalopathy|Sepsis|Dementia|Multiple Sclerosis|Parkinson's Disease|In-Hospital Cardiac Arrest|Solid Organ Cancer,Palliative Care|Emergency Department,United States,Detroit,Michigan,2,Early order of palliative care consultation,OTHER,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,The proportion of billed CMS ACP-CPT codes in Ig vs. Cg|Matches of care received to patient-specific preferences in Ig vs. Cg|Patient/family satisfaction with care in Ig vs. Cg|Amount of hospice referrals in Ig vs. Cg|Hospital total direct costs for the index visit in Ig vs. Cg|Hospital and ICU length of stay in Ig vs. Cg|Average days in hospice in Ig vs. Cg|Hospital margin contribution for the index visit in Ig vs. Cg|Time to consultation in Ig vs. Cg groups,False,
NCT00525343,Avonex 15 Year Long Term Follow-up Study,"Avonex® Fifteen Year Long Term Follow Up of Patients With Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs",COMPLETED,2007-03,,2008-09,2010-03-08,2007-09-05,OBSERVATIONAL,,122.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Avonex pivotal trial|Avonex|Avonex long term follow-up|Avonex outcomes,United States,Washington D.C.,District of Columbia,4,,,To determine the impact of early versus delayed initiation of treatment on the long-term disability status of patients with relapsing forms of multiple sclerosis (MS) measured by the self-reported EDSS.,"To determine the impact of early versus delayed initiation of treatment on patients' mortality, living independence, and quality of life.",False,
NCT00812474,Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis,Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis,COMPLETED,2008-12,2009-06,2015-11,2015-11-18,2008-12-22,OBSERVATIONAL,,60.0,ACTUAL,Sunnybrook Health Sciences Centre,OTHER,Unity Health Toronto|The Physicians' Services Incorporated Foundation,OTHER|OTHER,Multiple Sclerosis,cerebral blood flow,,,,0,,,Cognitive Impairment,,False,
NCT05301335,"Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE ""CONTINENCE"" Clinical Study",Spinal Cord Neuromodulator by SpineX and Scone to Treat Neurogenic Bladder,COMPLETED,2022-05-25,2024-05-01,2024-05-01,2025-02-17,2022-03-29,INTERVENTIONAL,NA,126.0,ACTUAL,SpineX Inc.,INDUSTRY,"Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|Atrium Health, Charlotte, North Carolina, United States|MedStar National Rehabilitation Network, Washington, District of Columbia, United States|University of California, San Diego, California United States|Craig Hospital, Englewood, Colorado, United States|Columbia University, New York City, New York, United States|Institute of Brain and Spine (IBS Hospital), New Delhi, India|International Collaboration On Repair Discoveries (ICORD), Vancouver, British Columbia, Canada|University of Miami, Miami, United States|Mayo Clinic, Rochester, Minnesota, United States|Shepherd Center, Atlanta, Georgia, United States|Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States",UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Neurogenic Bladder|Spinal Cord Injuries (Complete and Incomplete)|Stroke|Multiple Sclerosis,,United States,Downey,California,12,SCONE,DEVICE,Neurogenic Bladder Symptom Score (NBSS),Urge Urinary Incontinence Episodes|Patient Global Improvement Index (PGI-I),False,
NCT07189325,A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis,A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis,NOT_YET_RECRUITING,2025-09,2030-09,2030-09,2025-09-23,2025-09-23,INTERVENTIONAL,PHASE3,250.0,ESTIMATED,"University Hospital, Montpellier",OTHER,,,Relapsing-Remitting Multiple Sclerosis (RRMS)|Anti-CD20 Therapy,Multiple Sclerosis|High efficacy therapies|de-escalation|adverse events|relapses|escalation,France,Montpellier,,1,"Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)|Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)",DRUG|DRUG,Relapse|New/enlarged MRI lesions,"Relapse|Expanded Disability Status Scale (EDSS)|Brain MRI (T2/FLAIR Lesions)|Number of adverse events and severe adverse events|Number of infections and serious infections|B-cell count (CD19/CD20 B cells)|Serum immunoglobulin (IgG, IgA, IgM) levels",False,
NCT00914290,A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis,A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis,COMPLETED,2009-04,2010-01,2010-02,2019-11-06,2009-06-04,INTERVENTIONAL,PHASE2,23.0,ACTUAL,"Impax Laboratories, LLC",INDUSTRY,,,Spasticity|Multiple Sclerosis,,United States,Tucson,Arizona,11,IPX056|Baclofen IR|Placebo IPX056|Placebo IR,DRUG|DRUG|DRUG|DRUG,Morning Stiffness Score,,False,
NCT04963335,Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS,Effects of a User-centered Exergame Training on Motor and Cognitive Functions in Persons With Multiple Sclerosis: A Pilot Quasi-Randomized Controlled Trial,UNKNOWN,2021-03-28,2021-07-31,2021-07-31,2021-07-15,2021-07-15,INTERVENTIONAL,NA,30.0,ESTIMATED,Eling DeBruin,OTHER,,,Multiple Sclerosis,Exergame|Multiple Sclerosis|Feasibility|Motor functions|Cognitive functions,Switzerland,Zurich,,1,Exergame Training,BEHAVIORAL,"Feasibility assessed by recruitment rate|Feasibility assessed by adherence rate|Feasibility assessed by attrition rate|Feasibility assessed by a safety protocol|System Usability|Feasibility, usability and training experience - Semi-structured interview",Changes in balance and mobility|Changes in spatio-temporal gait parameters|Changes in information processing speed|Changes in executive functions - inhibition|Changes in executive functions - flexibility|Training experience - Physical Activity Enjoyment Scale|Training experience - Flow Short Scale,False,
NCT02325440,Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya,"A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod)",UNKNOWN,2014-03,2016-04,2016-04,2014-12-25,2014-12-25,INTERVENTIONAL,PHASE4,15.0,ESTIMATED,University Hospital Muenster,OTHER,Novartis,INDUSTRY,Relapsing Remitting Multiple Sclerosis,RRMS (relapsing remitting multiple sclerosis)|Cluster of differentiation 49d (CD49d)|immune function|disease activity,Germany,Münster,,1,Fingolimod|Natalizumab,DRUG|DRUG,Temporal changes in the expression of CD49d|Migratory capacity of immune cells,"MRI disease activity over time by GD+, T2w and DTI|MRI disease activity over time by T1w / FLAIR",False,
NCT02030197,"Impact of CRISP on Self-Efficacy, Loneliness, and Depression",Effects of an Educational Socialization Program Designed to Improve Self-Efficacy and Subsequent Effects on Decreasing Loneliness and Depression Among People With Multiple Sclerosis,COMPLETED,2014-02,2014-12,2014-12,2014-12-02,2014-01-08,INTERVENTIONAL,NA,118.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,CRISP Program|Control Group,BEHAVIORAL|OTHER,Multiple Sclerosis Self-Efficacy Scale (MSSS),UCLA Revised Loneliness Scale|Chicago Multiscale Depression Inventory (CMDI)|Performance Scales (PS)|Community Integration Questionnaire (CIQ),False,
NCT04510220,9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis,"Open-label, Observational, Prospective, 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis",RECRUITING,2020-09-21,2021-12-31,2021-12-31,2021-07-27,2020-08-12,INTERVENTIONAL,PHASE3,10.0,ESTIMATED,Brigham and Women's Hospital,OTHER,Novartis,INDUSTRY,Relapsing Multiple Sclerosis,,United States,Boston,Massachusetts,1,Ofatumumab|[F-18]PBR06,DRUG|DRUG,Effect of Ofatumumab on microglial activity,Relationship between changes in Microglial activity and CD19 counts|Relationship between changes in Microglial activity and glial fibrillary acid protein (GFAP)|Relationship between changes in Microglial activity and neurofilament light chain|Relationship between changes in Microglial activity and MRI-based brain atrophy changes|Relationship between changes in Microglial activity and physical disability|Relationship between changes in Microglial activity and cognitive disability,False,
NCT04416243,Feasibility of a High-intensity Interval Training Program in Persons With Multiple Sclerosis Who Have Walking Disability,"A Single-group, Feasibility, and Initial Efficacy Study of a High-intensity Interval Training Program Using Adaptive Equipment in Persons With Multiple Sclerosis Who Have Walking Disability",COMPLETED,2019-12-19,2022-12-14,2022-12-14,2023-04-19,2020-06-04,INTERVENTIONAL,NA,17.0,ACTUAL,"University of North Texas, Denton, TX",OTHER,University of Alabama at Birmingham|Berry College,OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|adaptive equipment|rehabilitation|recumbent stepping|high-intensity interval training,United States,Denton,Texas,1,"Recumbent Stepping, High-Intensity Interval Training",BEHAVIORAL,"Recruitment, Retention, and Adherence Rates|Time Needs|Monetary Needs|Data Management and Safety Reporting|Participant Burden Reporting|Safety Reporting","Change in Aerobic Capacity|Change in 6-Minute Walk Distance|Change in 25-Foot Walk Speed|Change in Sedentary, Light, and Moderate-to-Vigorous Counts of Physical Activity|Change in the Brief International Cognitive Assessment in MS Scores|Change in 9-Hole Peg Test Score|Change in Fatigue Scores|Change in Depressive Symptoms Scores",False,
NCT01044576,Patient Research Cohort: Rapidly Evolving Multiple Sclerosis,Patient Research Cohort: Rapidly Evolving Multiple Sclerosis Opening the Window of Therapeutic Opportunity,COMPLETED,2010-01,2012-11,2012-11,2021-03-08,2010-01-08,OBSERVATIONAL,,200.0,ACTUAL,Imperial College London,OTHER,"Medical Research Council|Imperial College Healthcare NHS Trust|University College, London|Queen Mary University of London|GlaxoSmithKline|University of Cambridge",OTHER_GOV|OTHER|OTHER|OTHER|INDUSTRY|OTHER,Relapsing-remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Multiple Sclerosis,United Kingdom,London,,1,,,Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy.,Access and Utilization of Cohort Data|Development of Biomarkers|Development of Clinical Prognostic Markers.,True,2021-03-08
NCT05735691,"High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis","High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis",RECRUITING,2023-01-01,2027-06-30,2027-06-30,2024-06-05,2023-02-21,INTERVENTIONAL,NA,150.0,ESTIMATED,Marquette University,OTHER,Indiana University|Medical College of Wisconsin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),OTHER|OTHER|NIH,Multiple Sclerosis,Walking|Balance|Treadmill|Exercise,United States,Indianapolis,Indiana,2,High-Intensity Treadmill Training|Treadmill Training with Perturbations|Standard Treadmill Training,PROCEDURE|PROCEDURE|PROCEDURE,Changes in Timed 25-foot walk test|Changes in 6-minute walk test|Changes in Functional Gait Assessment (FGA)|Changes in Daily stepping activity,Changes in Peak treadmill speed and cardiorespiratory fitness|Changes in Berg Balance Scale|Changes in Falls incidence|Changes in Kinematic Response to unexpected perturbations|Changes in Activities-specific Balance Confidence (ABC) score|Changes in Medical Outcomes Short-Form 36 (SF-36) Version 2|Changes in Peak Stepping Rate|Changes in Total Bouts of Stepping|Changes in Average Duration of Stepping Bouts,False,
NCT01592474,Evaluation of Brain Atrophy in CIS Patients on Avonex,Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNβ-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy),COMPLETED,2005-10,2011-08,2012-06,2014-07-09,2012-05-07,OBSERVATIONAL,,180.0,ACTUAL,University at Buffalo,OTHER,"Biogen|Jacobs Neurological Institute|Charles University, Czech Republic",INDUSTRY|OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Avonex|Brain atrophy|MRI|Interferon-beta 1a|IFN Beta 1-a|Clinically isolated syndrome|CIS,,,,0,,,Can Avonex delay development of clinically definite MS?,Can Avonex delay disability progression?,False,
NCT06865274,"Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.","Multicenter Prospective Interventional Study to Evaluate the Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody Disease, and Multiple Sclerosis.",RECRUITING,2025-02-20,2026-02-28,2027-02-28,2025-03-07,2025-03-07,INTERVENTIONAL,NA,50.0,ESTIMATED,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,Neuromyelitis Optica Spectrum Disorders|MOGAD|Multiple Sclerosis,NMOSD|MOGAD|MS|polymorphysm|FCG3A,Italy,Roma,Roma,1,Blood draw for the laboratory assessment,PROCEDURE,FCGR3A gene polymorphism frequency in a cohort of Italian patients affected by NMOSD and MOGAD.,Clinical characteristics of NMOSD and MOGAD patients who express the polymorphism|Clinical characteristics of NMOSD and MOGAD patients who express the polymorphism,False,
NCT03322748,Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis,"Efficacy of Isometric Contraction Exercises of Lower Limbs Muscles, in Modulating Neurological Control of Bladder Function in Patients With Multiple Sclerosis",UNKNOWN,2018-02,2020-02,2020-02,2018-01-10,2017-10-26,INTERVENTIONAL,NA,30.0,ESTIMATED,IRCCS San Raffaele,OTHER,,,Overactive Bladder Syndrome|Multiple Sclerosis|Muscle Strain,,Italy,Milan,MI,1,Usual physical therapy+ strengthening of lower limbs muscles|Usual physical therapy,OTHER|OTHER,Change of Urinary frequency|Change of Urge score|Change of total score of OAB-q ( Overact Bladder questionnaire) long form,"Change of Urine volume|Change of episodes of urinary incontinence|Change of episodes of nocturia|Change of Postvoid Residual Volume|Change of Pad-test 24 Hours|PGI (Patient global impression of improvement)|Change of value at Uroflussimetry|Change of value at ""H REFLEX"" test|Change of EDSS (Expanded Disability Status Scale)|Change of Barthel Index Score|Change of MAS (Modified Ashworth Scale )",False,
NCT00156676,Restoration of Walking in Multiple Sclerosis Using Treadmill Training.,Pilot Study on Gait & Motor Function in MS Using BWS Treadmill Training,COMPLETED,2004-09,2007-09,2007-09,2013-09-20,2005-09-12,INTERVENTIONAL,NA,30.0,ESTIMATED,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Disability|Gait|Multiple Sclerosis|Rehabilitation|Robot,United States,Providence,Rhode Island,1,Body-weight supported treadmill|Lokomat|Body-weight supported treadmill|Lokomat,DEVICE|DEVICE|DEVICE|DEVICE,"Mean changes and variances in ambulation, motor, fatigue and quality of life",,False,
NCT00513448,Promoting Physical Activity for Persons With Multiple Sclerosis,Comparing Individualized Rehabilitation to a Group Wellness Intervention for Persons With Multiple Sclerosis,COMPLETED,2005-04,,2005-11,2007-08-08,2007-08-08,INTERVENTIONAL,NA,50.0,ACTUAL,University of Minnesota,OTHER,Agency for Healthcare Research and Quality (AHRQ),FED,Multiple Sclerosis,Chronic Disabling Condition|Comparative Evaluation|Physical Activity|Physical Therapy|Rehabilitation,United States,Minneapolis,Minnesota,1,Group wellness intervention|Individualized physical rehabilitation,OTHER|OTHER,Modified Fatigue Impact Scale SF-36 Mental Health Inventory,Physical assessments,False,
NCT02937285,"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis","National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Beta-1a (REBIF 44mg 3 Times / Week) Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis",COMPLETED,2010-12-06,2020-05-28,2020-05-28,2023-03-29,2016-10-18,INTERVENTIONAL,PHASE3,35.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,,France,Rennes,,1,Interferon beta 1a|Mitoxantrone,DRUG|DRUG,Treatment efficacy,Time to first relapse|Frequency of relapses in 2 years|Frequency of relapses in 4 years|Changes in the level of disability in 2 years|Changes in the level of disability in 4 years|Patients in progression|Disease activity on MRI at 6 months|Patients without disease activity on MRI at 12 months|Patients without disease activity on MRI at 24 months|Patients without disease activity on MRI at 48 months|Number of visible lesions on MRI at 6 months|Number of visible lesions on MRI at 12 months|Number of visible lesions on MRI at 24 months|Number of visible lesions on MRI at 48 months|Lesion load on evaluated T2 weighted MRI at 12 months|Lesion load on evaluated T2 weighted MRI at 24 months|Lesion load on evaluated T2 weighted MRI at 48 months|Brain atrophy,False,
NCT05797740,Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA),Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA),ACTIVE_NOT_RECRUITING,2023-08-03,2029-01-31,2029-01-31,2025-08-11,2023-04-04,OBSERVATIONAL,,367.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing Multiple Sclerosis|Mavenclad|Cladribine Tablets,Belgium,Brussels,,30,Mavenclad,DRUG,Time to Discontinuation of Treatment with Cladribine tablets,"Percentage of participants Receiving Each of The Possible Number of Annual Treatment Courses with Cladribine Tablets|Cumulative Cladribine Dose|Number of Relapses|Proportion of Severe Relapses|Percentage of Participants Free From Relapse|Time From Onset of Relapse to Recovery|Annualized Relapse Rate (ARR)|Percentage of Participants Free From Magnetic Resonance Imaging (MRI) Activity|Percentage of Participants with Minimal MRI Activity (=< 2 New T2 Lesions)|Timed 25-Foot Walk (T25FW) Score|Percentage of Participants with an Increase and Decrease in Timed 25-Foot Walk (T25FW) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4|9-Hole Peg Test (9HPT) Score|Percentage of Participants with an Increase and Decrease in 9-Hole Peg Test (9HPT) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4|Percentage of Participants With Progressed, Improved, or Stable Disability as Assessed by Expanded Disability Status Scale (EDSS) Confirmed Over 6 Months|Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by T25FW Score|Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by 9HPT Score|Percentage of Participants With Minimal Evidence of Disease Activity (MEDA)|Percentage of Participants With No Evidence of Disease Activity (NEDA-3)|Multiple Sclerosis Impact Scale (MSIS-29) Physical Domain Score, Psychological Domain Score and Total Score|EuroQol 5-Dimensions (EQ-5D-5L) Score|Global Satisfaction, Effectiveness, Side Effects, and Convenience Domain Scores of Treatment Satisfaction Questionnaire for Medication (TSQM)|Treatment Cost of Disease-Modifying Treatment (DMTs)|EuroQol Visual Analog Scale (EQ-VAS) Score",False,
NCT03492606,Lipid Mediators in Multiple Sclerosis,Specialized Pro-resolving Lipid Mediators in the Resolution of Multiple Sclerosis,COMPLETED,2019-03-01,2020-09-09,2021-01-09,2022-11-29,2018-04-10,OBSERVATIONAL,,150.0,ACTUAL,Neuromed IRCCS,OTHER,,,Multiple Sclerosis,,Italy,Pozzilli,Isernia,1,Samples,PROCEDURE,SPMs in plasma|T cells|EAE,,False,
NCT03804047,KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis,KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis,UNKNOWN,2019-01-01,2021-12-25,2021-12-31,2021-03-03,2019-01-15,INTERVENTIONAL,NA,24.0,ESTIMATED,Northern Illinois University,OTHER,,,Multiple Sclerosis,Kinesio Tape|Physical functioning|Disability,United States,DeKalb,Illinois,1,kinesio tape,OTHER,Static Balance Performance|Timed and Up and Go|Timed 25-foot Walk|Six-minute Walking Test|Six-spot Step Test|The Short Physical Performance Battery,,False,
NCT01110993,An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF),"Prospective, Non-interventional, Multicenter Study to Evaluate QoL and Influence of Cognitive Status on QoL in Patients With RRMS During 2 Years Treatment With RNF",COMPLETED,2010-11,2013-09,2013-09,2014-02-03,2010-04-27,OBSERVATIONAL,,65.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Interferon-beta 1-a",Poland,Lublin,,1,,,Quality of Life,"Assessment of Cognitive Status|Influence of cognitive impairment on QoL in subjects with RRMS|Assessment of Expanded Disability Status Scale|Assessment of number of relapses|Assessment of results of Evoked Potentials (visual, auditory, somatosensory/ if they are routinely done)|Assessment of Magnetic Resonance Imaging results",False,
NCT00484536,"Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323","Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.",TERMINATED,2007-05,2009-11,2010-07,2011-09-12,2007-06-11,INTERVENTIONAL,PHASE2,232.0,ACTUAL,UCB Pharma,INDUSTRY,Biogen,INDUSTRY,Multiple Sclerosis,CDP323|Relapsing Multiple Sclerosis|Magnetic Resonance Imaging|Oral Compound|MS,United States,Cullman,Alabama,71,CDP323|placebo|CDP323,DRUG|DRUG|DRUG,The cumulative number of newly active lesions on standardized brain MRI scans after 24 weeks of treatment (Week 28).,Occurrence of any treatment emergent adverse event.,False,
NCT06430671,Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis,"Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients With Relapsing Remitting Multiple Sclerosis - RED4MS Trial",ACTIVE_NOT_RECRUITING,2024-06-18,2025-12,2025-12,2025-07-03,2024-05-28,INTERVENTIONAL,PHASE1,11.0,ACTUAL,Cellerys AG,INDUSTRY,Novartis|Scope International AG|Tetec AG|Jung Diagnostics GmbH,INDUSTRY|INDUSTRY|INDUSTRY|INDUSTRY,Relapsing-remitting Multiple Sclerosis (RRMS),,Czechia,Prague,,8,CLS12311 low|CLS12311 medium|CLS12311 high|uncoupled RBCs,DRUG|DRUG|DRUG|DRUG,Incidence of treatment-related adverse events as assessed by CTCAE v4.0 and worsening of MS [Safety of CLS12311],Incidence of treatment-related adverse events as assessed by CTCAE v4.0 in each dose group [Safety of CLS12311]|Incidence of patients experiencing worsening of MS in each dose group [Safety of CLS12311]|Incidence of patients experiencing worsening of EDSS in each dose group [Safety of CLS12311]|Incidence of patients experiencing worsening of T25-FW in each dose group [Safety of CLS12311]|Incidence of patients experiencing worsening of 9-HPT in each dose group [Safety of CLS12311]|Incidence of patients experiencing worsening of SDMT in each dose group [Safety of CLS12311],False,
NCT06665607,Foot Muscles Training in Sclerosis,Effects of Intrinsic Foot Muscles Training in Improving Stability in Multiple Sclerosis Patients,RECRUITING,2024-11-04,2025-06-30,2025-07-15,2024-11-01,2024-10-30,INTERVENTIONAL,NA,34.0,ESTIMATED,Inés Llamas-Ramos,OTHER,,,"Multiple Sclerosis|Muscle Weakness|Training Group, Sensitivity",,Spain,Valladolid,,1,Intrinsic Mucle Training,PROCEDURE,Four Square Step Test (FSST): dynamic stability assessment test.|Six Spot Step Test (SSST): test that quantitatively assesses lower limb function|The Frailty and Injuries: Cooperative Studies of Intervention Tecnhiques (FICSIT-4 test): Test of static balance|Activities-specific Balance Confidence scale (AsBC),,False,
NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya®,COMPLETED,2012-08-20,2019-02-18,2019-02-18,2020-03-02,2012-10-12,INTERVENTIONAL,PHASE4,87.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis RRMS,Multiple sclerosis (MS)|MS,Germany,Bochum,,10,Fingolimod,DRUG,Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT),"Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)|Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT)|Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV)|Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP)|Number of Participants With Adverse Events",True,2020-03-02
NCT06873464,Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial,Evaluation of the Efficacy of Transcranial Direct Current Stimulation in Reducing Fatigue and Improving Quality of Life in Patients With Multiple Sclerosis: A Randomized Clinical Trial,ENROLLING_BY_INVITATION,2025-02-20,2025-07-31,2025-08-31,2025-03-12,2025-03-12,INTERVENTIONAL,NA,24.0,ESTIMATED,European University of Madrid,OTHER,,,"Multiple Sclerosis, MS",Transcranial Direct-Current Stimulation|fatigue|multiple sclerosis,Spain,Madrid,,1,Three cycles of tDCS combined with motor tasks|Two cycles of tDCS combined with motor tasks,OTHER|OTHER,Fatigue Impact,Multiple Sclerosis Quality of Life assessment|Balance,False,
NCT02297932,Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes,Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes,COMPLETED,2014-11,2016-06,2016-06,2017-08-18,2014-11-21,INTERVENTIONAL,NA,18.0,ACTUAL,Kessler Foundation,OTHER,University of Illinois at Urbana-Champaign,OTHER,Multiple Sclerosis,Exercise,United States,West Orange,New Jersey,1,Strength training|Stretching,BEHAVIORAL|BEHAVIORAL,Change from baseline in fatigue after 4-month exercise intervention (Questionnaires and fMRI)|Change from baseline in cognition after 4-month exercise intervention (Questionnaires and neuropsychological testing)|Change from baseline in participation in activities of daily living (ADLs) after 4-month exercise intervention (Questionnaire; The Neistadt and Crepeau Activities of Daily Living test; Timed Instrumental Activities of Daily Living (TIADL) test,,False,
NCT00325988,Biomarkers in Multiple Sclerosis,NINDS Biomarkers in Multiple Sclerosis Study (BioMS),COMPLETED,2004-12-17,,2014-02-03,2019-12-17,2006-05-15,OBSERVATIONAL,,858.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Neuroimmunology|Demyelinating Disease|Genetics|Proteins,United States,Bethesda,Maryland,1,,,,,False,
NCT06728956,Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis,Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis,RECRUITING,2024-06-14,2027-07-01,2027-07-01,2024-12-11,2024-12-11,INTERVENTIONAL,NA,300.0,ESTIMATED,The Leeds Teaching Hospitals NHS Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Leeds,,1,READY for MS UK digital programme,OTHER,Multiple Sclerosis Work Instability Scale (MS-WIS)|Psychological Flexibility -Multi-dimensional Psychological Flexibility Inventory (MPFI)|Resilience Connor-Davidson Resilience Scale (CD-RISC 10)|Self-efficacy -Unidimensional Self-efficacy scale for Multiple Sclerosis (USE-MS),,False,
NCT02950454,The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.,The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.,COMPLETED,2017-01,2017-09,2017-09,2017-10-25,2016-11-01,INTERVENTIONAL,NA,12.0,ACTUAL,University of Glasgow,OTHER,NHS Ayrshire and Arran|AKM,OTHER|OTHER,"Multiple Sclerosis, Progressive",Progressive Multiple Sclerosis|Rehabilitation|Exercise,United Kingdom,Glasgow,,1,High intensity interval training|Continuous moderate exercise,OTHER|OTHER,heart rate max,Resting blood pressure|Resting heart rate|Brain derived neurotrophic factor|Lactate|Lipoprotein profile|MSIS-29 version 2|Hospital anxiety and depression scale|Timed 25 foot walk test|Symbol digit modalities test|Fatigue severity scale,False,
NCT06395662,Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.,Improving the Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid. The ProBioRIS Study,ACTIVE_NOT_RECRUITING,2024-04-15,2024-12,2025-07,2024-11-01,2024-05-02,OBSERVATIONAL,,320.0,ESTIMATED,Centre Hospitalier Universitaire de Nīmes,OTHER,"International Center of Research in Infectiology, Lyon University|Universite Cote d'Azur|The University of Texas at Dallas",UNKNOWN|OTHER|OTHER,Radiologically Isolated Syndrome|Multiple Sclerosis,Radiologically Isolated Syndrome|Multiple Sclerosis|Biomarkers,United States,Dallas,Texas,3,Observational,OTHER,Aim 1a : Association between Serum Neurofilament Light chain (sNfL) and RIS in all groups of patients|Aim 1a : Association between Serum Neurofilament Light chain (sNfL) and RIS in all groups of patients|Aim 1a : Association between Serum Glial Fibrillary Astrocytic Protein (sGFAP) and RIS in all groups of patients|Aim 1a : Association between Serum Glial Fibrillary Astrocytic Protein (sGFAP) and RIS in all groups of patients|Aim 1b: Association between Serum Neurofilament Light chain (sNfL) and RIS in placebo-treated patients|Aim 1b: Association between Serum Neurofilament Light chain (sNfL) and RIS in placebo-treated patients|Aim 1b : Association between Serum Glial Fibrillary Astrocytic Protein (sGFAP)and RIS in placebo-treated patients|Aim 1b: Association between Serum Glial Fibrillary Astrocytic Protein (sGFAP)and RIS in placebo-treated patients,"Aim 2a: Kappa free light chain (KFLC) index in RIS patients in the SFSEP, OFSEP and ARISE cohorts, n=121|Aim 2a: Kappa free light chain (KFLC) index in RIS patients in the SFSEP, OFSEP and ARISE cohorts, n=121|Aim 2a: Cerebrospinal fluid neurofilament light chain as a potential biomarker of RIS.|Aim 2a: Cerebrospinal fluid neurofilament light chain as a potential biomarker of RIS.|Aim 2a: Chitinase-3-like protein 1 as a potential biomarker of RIS.|Aim 2a: Chitinase-3-like protein 1 as a potential biomarker of RIS.|Aim 2a: Oligoclonal bands as a potential biomarker of RIS.|Aim 2a: Oligoclonal bands as a potential biomarker of RIS.|Aim 2b: Validation of cerebrospinal fluid neurofilament light chain as a potential biomarker of RIS.|Aim 2b: Validation of cerebrospinal fluid neurofilament light chain as a potential biomarker of RIS.|Aim 2b: Validation of chitinase-3-like protein 1 as a potential biomarker of RIS.|Aim 2b: Validation of chitinase-3-like protein 1 as a potential biomarker of RIS.|Aim 2b: Validation of oligoclonal bands as a potential biomarker of RIS.|Aim 2b: Validation of oligoclonal bands as a potential biomarker of RIS.|Aim 3: Improving prediction of clinical disease activity of RIS|Aim 3: Improving prediction of clinical disease activity of RIS",False,
NCT00109161,"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis","A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis",COMPLETED,2005-04,,2006-10,2008-08-05,2005-04-25,INTERVENTIONAL,PHASE2,270.0,,"PDL BioPharma, Inc.",INDUSTRY,,,Multiple Sclerosis,"Multiple Sclerosis, MS, CNS, Daclizumab",United States,Phoenix,Arizona,36,Daclizumab (Anti-CD25 Humanized Monoclonal Antibody),DRUG,Number of new or enlarged gadolinium contrast enhancing lesions (Gd-CELs) on monthly brain MRIs collected between Weeks 8 to 24 in daclizumab- vs. placebo-treated patients,Pharmacokinetics|Immunogenicity|Clinical improvement,False,
NCT03977922,A Pilot Nutrition Program for Spinal Cord Injury and MS,"A Pilot Nutrition Program for Spinal Cord Injury and MS: Effects on Inflammation, Cardiometabolic Health and Psychosocial Well-being",COMPLETED,2022-02-28,2022-02-28,2022-02-28,2023-02-08,2019-06-06,INTERVENTIONAL,NA,6.0,ACTUAL,Brock University,OTHER,,,Spinal Cord Injuries|Multiple Sclerosis,,Canada,St. Catharines,Ontario,1,Diet group,OTHER,Change from baseline body composition at 12 weeks|Change from baseline inflammation at 12 weeks|Change from baseline neuropathic pain at 12 weeks|Change from baseline depression at 12 weeks|Change from baseline perceived quality of Life at 12 weeks|Change from baseline blood lipids at 12 weeks|Change from baseline glucose tolerance at 12 weeks,Dietary intake,False,
NCT07116070,Sarcopenia and Related Factors in Patients With Multiple Sclerosis,Sarcopenia and Related Factors in Patients With Multiple Sclerosis,RECRUITING,2025-06-01,2026-01-20,2026-03-20,2025-08-11,2025-08-11,OBSERVATIONAL,,90.0,ESTIMATED,Selcuk University,OTHER,,,Multiple Sclerosis|Sarcopenia,multiple sclerosis|sarcopenia|muscle strength|physical performance|nutrition,Turkey (Türkiye),Konya,Selcuklu,1,Clinical Assessments,OTHER,Body composition|Handgrip Strength|6-Minute Walk Test|Mini Nutritional Assessment Form (MNA),Demographic data and personal characteristics|Godin Leisure Time Exercise Questionnaire|Expanded Disability Status Scale (EDSS)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life Scale-54,False,
NCT03979456,RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS,RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis,UNKNOWN,2018-07-04,2024-12-20,2025-06-01,2021-04-19,2019-06-07,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,Karolinska Institutet,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|Relapsing-Remitting|Dosing protocols|Randomized trial,Sweden,Danderyd,Stockholm County,17,Rituximab,DRUG,No evidence of disease activity (NEDA),No evidence of disease activity (NEDA) in subgroups|Time to first relapse|Freedom of new or enlarged lesions on MRI|Development of brain atrophy|Development of confirmed sustained disability|Mean progression of disability|Neurodegeneration|Dose persistence|Development of hypogammaglobulinaemia|Development of neutropenia|Development of infections,False,
NCT06412003,Home-based Balance Training in Adults With Multiple Sclerosis,Home-based Balance Training With Family Member Support in Adults With Multiple Sclerosis: A Feasibility Single-group Pretest-posttest Design,NOT_YET_RECRUITING,2024-07-01,2025-03-31,2025-05-31,2024-05-16,2024-05-14,INTERVENTIONAL,NA,30.0,ESTIMATED,University of Vermont,OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, MS",balance training|Home-based exercise,,,,0,Home-based balance training,BEHAVIORAL,Feasibility outcome: Process|Feasibility outcome: Resources|Feasibility outcome: Management|Feasibility outcome: Participant burden/satisfaction|Feasibility outcome: Adverse event|Feasibility outcome: Intervention acceptability|Feasibility outcome: exercise intensity acceptability/compliance,Changes in balance as measured by Timed Up and Go/Dual-task Timed Up and Go|Changes in functional mobility as measured by 5-time sit-to-stand|Changes in static balance as measured by4-stage static balance tests|Changes in cognitive function as measured by Brief International Cognitive Assessments for MS (BICAMS)|Changes in community mobility perception as measured by Environmental Analysis of Mobility Questionnaire (EAMQ)|Changes in fear of falling as measured by Fall Efficacy Scale-International (FES-I)|Changes in self-reported walking disability as measured by Multiple Sclerosis Walking Scale-12v2 (MSWS-12v2)|Changes in self-reported dual-tasking difficulty as measured by Dual-task Impact on Daily-Living Activities Questionnaire (DIDA-Q)|Changes in self-reported fatigue as measured by Fatigue Scale for Motor and Cognitive Functions (FSMC)|Changes in Real-world ambulation metrics as measured by tri-axial accelerometer|Changes in exercise intention,False,
NCT06157086,Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France,"This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.",RECRUITING,2023-12-21,2026-07-31,2026-07-31,2025-01-14,2023-12-05,OBSERVATIONAL,,294.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis (MS),MS|Multiple sclerosis|NIS|ofatumumab|Kesimpta|QoL|PRO,France,Agen,,43,ofatumumab,OTHER,Quality of life - MUSIQoL questionnaire,Treatment satisfaction of patients treated with ofatumumab using TSQM 9 questionnaire|Impact of MS on professional activity using the 6-item WPAI questionnaire|Neurologist's decision criteria for initiating ofatumumab and patient involvement in the treatment choice|Clinical evolution of Multiple sclerosis - EDSS score|Clinical evolution of Multiple sclerosis - Number of patients with relapses|Number of patient adherent to ofatumumab from patient and practitioner perspectives|Ofatumumab discontinuation|Persistence on ofatumumab,False,
NCT02364505,A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers,Improving the Quality of Life of People With Multiple Sclerosis and Their Caregivers With a Telemedicine Mindfulness-Based Intervention,COMPLETED,2014-09,2016-11,2016-12,2017-08-03,2015-02-18,INTERVENTIONAL,NA,156.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,Catholic University of the Sacred Heart,OTHER,Multiple Sclerosis,caregivers,Italy,Milan,Mi,1,Telemedicine mindfulness-based intervention|Psycho-education intervention,BEHAVIORAL|BEHAVIORAL,Evidence of an improved quality of life in patients with multiple sclerosis as measured by The Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Evidence of an improved quality of life in caregivers as measured by the Short-Form-36 (SF-36)|Evidence of a decrease of anxiety and depression in patients with multiple sclerosis and in caregivers as measured by the Hospital Anxiety and Depression Scale (HADS),Evidence of an attained mindfulness level in patients with multiple sclerosis and in caregivers as measured by the Langer Mindfulness Scale (LMS)|Evidence of a decrease of sleep disturbance and better quality of sleep in patients with multiple sclerosis and in caregivers as measured by the Medical Outcomes Study Sleep Measure (MOSssm)|Evidence of a decrease of sleep disturbance and fatigue and a better quality of sleep in patients with multiple sclerosis as measured by actigraphy unit|Evidence of a decrease in fatigue in patients with multiple sclerosis and in caregivers as measured by the Modified Fatigue Impact Scale (MFIS)|Evidence of a decrease in caregiver burden as measured by the Zarit Burden Interview (ZBI),False,
NCT01881191,Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months,"Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study",COMPLETED,2013-06,2015-10,2015-10,2016-02-12,2013-06-19,OBSERVATIONAL,,50.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,multiple sclerosis|relapsing remitting|MRI|teriflunomide|aubagio|gray matter atrophy|gray matter pathology,United States,Buffalo,New York,1,MRI,OTHER,The primary aim of this study is to define the effect of teriflunomide (Aubagio®) on the development of gray matter (GM) atrophy in patients with relapsing multiple sclerosis (MS) using MRI.,The secondary objective of this study is to define the effect of teriflunomide on subcortical deep gray matter (SDGM) pathology using MRI over 12 months.,False,
NCT03822858,Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,"Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally",AVAILABLE,,,,2025-08-17,2019-01-30,EXPANDED_ACCESS,,,,Tisch Multiple Sclerosis Research Center of New York,OTHER,,,Multiple Sclerosis,Mesenchymal Stem Cells|Neural Progenitors|Autologous|Bone Marrow|Multiple Sclerosis,United States,New York,New York,1,Intrathecal MSC-NP injection,DRUG,,,False,
NCT04950933,The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules,"A Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase Ⅱ Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome)",UNKNOWN,2020-06-01,2021-12-31,2022-12-31,2021-07-08,2021-07-06,INTERVENTIONAL,PHASE2|PHASE3,144.0,ESTIMATED,Peking University Third Hospital,OTHER,The Second Hospital of Hebei Medical University,OTHER,Amyotrophic Lateral Sclerosis,,China,Beijin,,1,Huolingshengji Granules|Riluzole tablet,DRUG|DRUG,ALSFRS-R scores,FVC%,False,
NCT02992847,Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/),Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/),UNKNOWN,2017-01,2017-07,2017-07,2016-12-14,2016-12-14,OBSERVATIONAL,,160.0,ESTIMATED,Hospices Civils de Lyon,OTHER,Guerbet,INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Gadolinium based contrast agent|MRI|Dentate nucleus,,,,0,Unenhanced MRI,OTHER,"Mean signal intensity in the dentate nucleus, pons, globus pallidus, and thalamus on unenhanced T1-weighted images after unenhanced MRI (magnetic resonance imaging), (no measurement unit)",EDSS (Expanded Disability Status Scale) score,False,
NCT03784547,Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM,Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America,UNKNOWN,2019-02-01,2019-08-01,2019-09-01,2019-08-09,2018-12-24,OBSERVATIONAL,,100.0,ESTIMATED,Hospital Italiano de Buenos Aires,OTHER,,,Multiple Sclerosis,multiple sclerosis|Latin america,Argentina,Buenos Aires,,4,Ocrelizumab,DRUG,Proportion of patients discontinuing the treatment with ocrelizumab in the last 12 months after inclusion|Multiple sclerosis phenotype,Gender|Age at study entry,False,
NCT02254304,Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™,Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™,COMPLETED,2014-12-31,2016-08-20,2016-08-20,2018-03-30,2014-10-01,INTERVENTIONAL,PHASE4,106.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany",UNKNOWN,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,Relapsing multiple sclerosis|Clinically isolated syndrome|RMS|CIS|RebiSmart™|Rebif®|Interferon beta-1a,Germany,Darmstadt,,1,Rebif,DRUG,Percentage of Relapse-free RMS Subjects|Time to the First Relapse for CIS Subjects,"Percentage of Subjects With Treatment Adherence|Percentage of Subjects With Relapse by Adherence Category|Percentage of Subjects Who Prematurely Terminated Treatment and Reasons|Percentage of Subjects Free From Clinical Disease Activity|Percentage of Subjects Free From Disability Progression|Mean Number of Relapses in RMS Subjects|Number of Subjects With Reasons of Missed Injections|Overall Evaluation of RebiSmart Use as Assessed by Investigator|Healthcare Resource Utilization Questionnaire - Number of Visits to Clinic by Subjects Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Subjects Visiting Different Types of Doctors During Their Clinical Visit|Healthcare Resource Utilization Questionnaire - Number of Visits by Healthcare Professional to Subjects' Home|Healthcare Resource Utilization Questionnaire - Number of Times Subjects Visited Emergency Room Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Days Subjects Hospitalized Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire -Number of Subjects Who Paid Someone to Assist Them Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Days Per Week Assistant Worked For Subject Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Assistant Worked for Subject Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Subjects Whose Relatives or Friends Missed Work Due to Subjects' Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Working Days Missed by Relative or Friend Due to Subjects' Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Full Days From Work Due to Multiple Sclerosis (MS).|Healthcare Resource Utilization Questionnaire - Number of Full Days Missed From Work by Subjects|Healthcare Resource Utilization Questionnaire - Number of Subjects Who Missed Any Partial Days From Work Due to Multiple Sclerosis (MS).|Healthcare Resource Utilization Questionnaire - Number of Hours Per Day Missed From Work by Subjects|Healthcare Resource Utilization Questionnaire - Number of Subjects Accomplished Less Work Due to Multiple Sclerosis (MS)|Healthcare Resource Utilization Questionnaire - Number of Subjects With Percentage of Work Completed Despite of Multiple Sclerosis (MS)|Number of Subjects With Medication Adherence Based on Morisky Medication Adherence Score|Number of Subjects With Adverse Event or Adverse Drug Reaction (AE/ADR), Serious AE/ADR, AE/ADR Leading to Death and AE/ADR Leading to Early Termination|Expanded Disability Status Scale (EDSS) Score|Body Mass Index (BMI)",True,2018-03-30
NCT04667130,Preventive Program in Multiple Sclerosis,Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis,COMPLETED,2017-10-01,2019-10-01,2019-10-01,2021-02-01,2020-12-14,INTERVENTIONAL,NA,17.0,ACTUAL,Kamila Řasová,OTHER,,,Multiple Sclerosis,Preventive program|Multiple Sclerosis|Rehabilitation,Czechia,Prague,,1,Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis,BEHAVIORAL,Questionnaires - The Fatigue scale for motor and cognitive functions|Questionnaires - The Satisfaction With Life Scale|Questionnaires - Multiple Sclerosis Acceptance Questionnaire|Questionnaires - Beck Depression Inventory Score,Ventilation capacity|Metabolic utilization|Maximal oxygen uptake|Maximal oxygen pulse|Relative ventilation|Cortisol|Cortizone|Dehydroepiandrosterone (DHEA)|7β-hydroxydehydroepiandrosterone (7β-OH-DHEA )|7-oxo dehydroepiandrosterone (7-oxo-DHEA ),False,
NCT02468765,Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis,Depression and Reconnaissance of Emotions in Multiple Sclerosis Patients,COMPLETED,2015-04-24,2016-05-30,2016-05-30,2025-09-04,2015-06-11,OBSERVATIONAL,,38.0,ACTUAL,Lille Catholic University,OTHER,,,Multiple Sclerosis|Depression,,France,Lille,Hauts-de-France,1,Neuropsychological and emotional evaluation with monitoring,OTHER,"Rate of correct answers to recognition tasks of emotional facial expressions (categorization by anger, joy or neutral)",Correlation between facial identity recognition abilities and physiological index measured by electroencephalography|Correlation between facial identity recognition abilities and morphological index measured by magnetic resonance imaging|Correlation between facial identity recognition abilities and cognitive functions evaluated by different tests,False,
NCT05587101,Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,Optimal Diagnostic Algorithm for Neurogenic Lower Urinary Tract Symptoms in Patients With MS,UNKNOWN,2021-10-19,2024-01-01,2024-06-01,2022-10-19,2022-10-19,OBSERVATIONAL,,30.0,ESTIMATED,Koç University,OTHER,,,Multiple Sclerosis|Neurogenic Bladder,,Turkey (Türkiye),Istanbul,,1,Urodynamic Study (Filling cystometry and pressure-flow study)|Questionnaires|Uroflowmetry,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Changes in Questionnaire Scores|Changes in Urodynamics,,False,
NCT03718819,Effects of Exercises in MS on Postural Control With Dual Task,Effects of Combined Exercises on Postural Control With and Without Dual Task in Patients With Multiple Sclerosis,UNKNOWN,2018-03-01,2018-11-30,2018-11-30,2018-10-29,2018-10-24,INTERVENTIONAL,NA,13.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,multiple sclerosis|pilates|aquatherapy|postural control|dual task,Turkey (Türkiye),Izmir,Balçova,1,exercise,OTHER,Change in limits of stability parameter with Biodex Balance System|Change in limits of stability parameter with cognitive task by Biodex Balance System,Change in Nine hole peg Test|Change in timed up and go test|Change in 5-Repetititon Sit-To-Stand Test|Change in timed 25 step walking test|Handgrip strength test,False,
NCT04183751,"The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in MS Patients","The Relationship Between Kinesiophobia, Physical Activity, Balance and Fear of Fall in Multiple Sclerosis Patients",UNKNOWN,2019-04-21,2020-12-21,2021-07,2020-09-04,2019-12-03,OBSERVATIONAL,,40.0,ESTIMATED,Marmara University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Kinesiophobia|Balance,Turkey (Türkiye),Istanbul,,1,scale study,OTHER,Tampa Kinesiophobia Scale (TSK)|International Physical Activity Questionnaire Short Form (IPAQ-SF)|Berg Balance Scale (BBS)|Fall Efficacy Scale (FES),,False,
NCT00355095,Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis,"Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT)",COMPLETED,2006-08,2011-02,2011-07,2012-09-13,2006-07-21,INTERVENTIONAL,PHASE2,40.0,ACTUAL,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,OTHER,,,Optic Neuritis,multiple sclerosis|add-on Therapy|erythropoietin|methylprednisolone|autoimmune optic neuritis,Germany,Hamburg,City state of Hamburg,3,Erythropoietin,DRUG,"nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.","Visual acuity and visual field perception determined at weeks 1, 4, 8, 16 compared to baseline (week 0). MRI measurements of optic nerve atrophy performed at weeks 4, 8 and 16 compared to baseline (week 0)",False,
NCT04639401,Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions,Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Percieved Fatigue in Persons With Multiple Sclerosis With Cerebellar Lesions,COMPLETED,2020-11-09,2025-01-01,2025-02-21,2025-02-27,2020-11-20,INTERVENTIONAL,NA,8.0,ACTUAL,Hasselt University,OTHER,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,OTHER|OTHER,Multiple Sclerosis|Cerebral Lesion,,Belgium,Melsbroek,,2,motor entrainment to auditory cues and music during walking on quality of movement,OTHER,Resultant Vector Length|Resultant Vector Length|Resultant Vector Length|Relative phase angle|Relative phase angle|Relative phase angle|Perceptual tempo and rhythm judgements|Asynchrony|EEG|Muscle weakness|Spasticity|Ataxia|Dynamic gait index|Time up and Go test|6 minute walking test|Brief repeatable battery of Rao|Symbol digit mobility test|Stroop test 0|MS walking scale -12|Activities-specific balance confidence scale|Modified fatigue impact scale|Hospital Anxiety and Depression Scale|Dual task questionnaire,Cadence|Cadence|Cadence|Stride length|Stride length|Stride length|speed|speed|speed|Double Support|Double Support|Double Support|Perceived cognitive and physical fatigue|Perceived cognitive and physical fatigue|Perceived cognitive and physical fatigue|Perceived motivation|Perceived motivation|Perceived motivation|Perceived walking speed|Perceived walking speed|Perceived walking speed,False,
NCT02559765,"Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.","Current Access to, Use and Perceived Efficacy of Physiotherapy and Rehabilitation Services by People With Progressive Multiple Sclerosis: a Survey of People With Progressive Multiple Sclerosis Via the UK MS Register.",COMPLETED,2015-08,2015-11,2015-11,2016-05-13,2015-09-24,OBSERVATIONAL,,1298.0,ACTUAL,University of Glasgow,OTHER,NHS Ayrshire and Arran|AKM,OTHER|OTHER,Progressive Multiple Sclerosis,physiotherapy|progressive multiple sclerosis|rehabilitation|rehabilitation services,United Kingdom,Glasgow,,1,,,Number of participants with access to physiotherapy for their MS. Questionnaire|Number of participants that use physiotherapy for their MS. Questionnaire|What is the participants' perceived efficacy of physiotherapy for their MS? Questionnaire,Most common referral process. Questionnaire|Most common provider of physiotherapy to the participant. Questionnaire|Most common physiotherapy intervention received for participant's MS. Questionnaire|Most common pattern of physiotherapy appointments. Questionnaire|Most common expected waiting time from referral to receiving physiotherapy appointment. Questionnaire|Most common frequency of appointments. Questionnaire|Most common length of physiotherapy sessions. Questionnaire|Most common number of people present at physiotherapy sessions. Questionnaire.|Most common setting of receipt of physiotherapy. Questionnaire|Number of participants who think they need more physiotherapy than they currently receive. Questionnaire|Most common desired pattern of delivery of physiotherapy. Questionnaire|Most common desired frequency of appointments. Questionnaire|Most common desired length of physiotherapy appointments. Questionnaire|Most common desired setting for receiving physiotherapy. Questionnaire|Most common desired number of people present at physiotherapy sessions. Questionnaire.|Most common barriers to receiving physiotherapy. Questionnaire.|Number of participants who have access to MS specialist services. Questionnaire|Number of participants who are able to access MS specialist services as their needs change. Questionnaire|Most common health professional available as part of MS specialist services. Questionnaire|Most commonly used health professional available as part of MS specialist services. Questionnaire|Number of participants who are offered a regular review for their MS. Questionnaire|Most common frequency of review. Questionnaire|Most common health professional who carries out review. Questionnaire|Most common setting of review. Questionnaire|Most common disease modifying therapy taken in past. Questionnaire|Most common disease modifying therapy being taken. Questionnaire|Most commonly used complimentary therapy used for MS. Questionnaire,False,
NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,"A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis",COMPLETED,2007-04,2009-10,2009-10,2012-11-06,2007-05-21,INTERVENTIONAL,PHASE2,123.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,MS|glatiramer acetate|adjunctive therapy|relapses,United States,Bridgewater,New Jersey,6,Teriflunomide|Placebo (for teriflunomide)|Glatiramer Acetate (GA),DRUG|DRUG|DRUG,Overview of Adverse Events (AE]|Overview of AE With Potential Risk of Occurrence|Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA),Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)|Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)|Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan|Annualized Relapse Rate [ARR]: Poisson Regression Estimates|Pharmacokinetic [PK]: Teriflunomide Plasma Concentration,True,2012-11-02
NCT04047628,Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS),A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI),RECRUITING,2019-12-19,2026-10,2029-10,2025-08-29,2019-08-07,INTERVENTIONAL,PHASE3,156.0,ESTIMATED,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Immune Tolerance Network (ITN)|Blood and Marrow Transplant Clinical Trials Network|PPD Development, LP|Rho Federal Systems Division, Inc.",NETWORK|NETWORK|INDUSTRY|INDUSTRY,Relapsing Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Treatment-Resistant Relapsing Multiple Sclerosis (MS)|Autologous Hematopoietic Stem Cell Transplantation (AHSCT)|Autologous Peripheral Blood Stem Cells (PBMCs) Graft|Best Available Therapy (BAT)|Disease-Modifying Therapy (DMT)|BAT DMT,United States,Palo Alto,California,20,Autologous Hematopoietic Stem Cell Transplantation|Best Available Therapy (BAT),PROCEDURE|BIOLOGICAL,Multiple Sclerosis (MS) Relapse-Free Survival,Number of Multiple Sclerosis (MS) Relapses Per Year|The Occurrence of Any Evidence of Multiple Sclerosis (MS) Disease Activity or Death From Any Cause|The Occurence of Confirmed Disability Worsening by the Kurtz Expanded Disability Status Scale (EDSS)|The Occurrence of Confirmed Disability Improvement by the Kurtz Expanded Disability Status Scale (EDSS)|Whole Brain Volume Change from Pre-Randomization Visit to the follow-up evaluations|Change in Serum Neurofilament Light Chain (NfL) Concentration|The Occurrence of Death From Any Cause: All-Cause Mortality|Proportion of Participants who Experience a Serious Adverse Event (SAE)|Proportion of Participants with a Grade 3 or Higher Infection|Proportion of Participants with Progressive Multifocal Leukoencephalopathy (PML)|Time to Neutrophil Engraftment Among Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Recipients|Proportion of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Recipients Who Experience Primary or Secondary Graft Failure,False,
NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS),"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)",ACTIVE_NOT_RECRUITING,2020-08-13,2025-11-14,2025-11-14,2025-08-17,2020-07-07,INTERVENTIONAL,PHASE3,767.0,ACTUAL,Sanofi,INDUSTRY,,,Primary Progressive Multiple Sclerosis,,United States,La Jolla,California,277,Tolebrutinib|Placebo,DRUG|DRUG,6-month composite Confirmed Disability Progression (cCDP),6-month Confirmed Disability Progression (CDP)|3-month composite Confirmed Disability Progression (cCDP)|Change in T2 hyperintense lesions by MRI|Time to onset of confirmed disability improvement (CDI)|Percent change in Brain volume (BV)|Change in cognitive function as assessed by SDMT|Change in cognitive function as assessed by CVLT-II|Change in Multiple Sclerosis Quality of Life|Safety and Tolerability|Population pharmacokinetics|Change in plasma neurofilament light chain (NfL)|Change in lymphocyte phenotype subsets|Changes in serum Immunoglobulin level|Change in serum chitinase-3 like protein 1 (Chi3L1),False,
NCT05742152,Reliability and Validity of Outcome Measures for Pain in Multiple Sclerosis,Between-day Reliability and Concurrent Validity of Outcome Measures for Pain in Multiple Sclerosis,COMPLETED,2023-04-01,2024-04-23,2024-05-01,2024-07-12,2023-02-23,OBSERVATIONAL,,60.0,ACTUAL,Hasselt University,OTHER,,,Pain,"Pain, outcome measure, assessment, multiple sclerosis, reliability, validity",Belgium,Melsbroek,Brabant,4,,,Douleur Neuropathique 4 (DN4) Questionnaire,PainDETECT Questionnaire,False,
NCT00997438,Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis,Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis,COMPLETED,2010-08,2013-12,2013-12,2017-01-26,2009-10-19,INTERVENTIONAL,PHASE1,69.0,ACTUAL,Portland VA Medical Center,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,,United States,Portland,Oregon,2,Lipoic Acid,DIETARY_SUPPLEMENT,Lipoic Acid Levels|Lipoic Acid Levels|Lipoic Acid Levels|Lipoic Acid Levels|Lipoic Acid Levels|Lipoic Acid Levels|cAMP Levels|cAMP Levels,RANTES Levels|RANTES Levels,True,2017-01-26
NCT00771043,A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a,Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a,WITHDRAWN,2008-11-01,2009-08-01,2010-06-01,2024-06-03,2008-10-10,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,,,,0,TYSABRI and AVONEX,DRUG,Changes in average RNFL thickness as measured by OCT of affected eyes across treatment groups.,Changes in average RNFL thickness of affected eyes (corrected by fellow eyes) across treatment groups.,False,
NCT05236777,TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants,Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections Among Patients Treated With Natalizumab,COMPLETED,2019-01-01,2025-04-30,2025-04-30,2025-05-13,2022-02-11,OBSERVATIONAL,,675.0,ACTUAL,Biogen,INDUSTRY,ReMuS Registry,UNKNOWN,Multiple Sclerosis,Progressive Multifocal Leukoencephalopathy (PML),Czechia,Brno,,15,Natalizumab,DRUG,Number of Participants With Progressive Multifocal Leukoencephalopathy (PML) who are Taking Natalizumab|Number of Participants with Serious Adverse Events (SAEs) of Other Opportunistic Infections (OIs) who are Taking Natalizumab,Number of Participants With SAEs|Number of Participants With SAEs Among Participant Subgroups Defined by Demographic and Clinical Factors|Number of Participants With Malignancies who are Taking Natalizumab|Number of Participants With Hypersensitivity Reactions who are Taking Natalizumab|Number of Participants who are John Cunningham Virus (JCV) Positive and Taking Natalizumab|Number of Pregnant and Breastfeeding Participants who Were Previously Exposed to Natalizumab,False,
NCT05156281,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS),"A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",RECRUITING,2021-12-13,2026-04-30,2030-10-30,2025-08-19,2021-12-14,INTERVENTIONAL,PHASE3,800.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,MS|RMS|RRMS|active secondary progressive multiple sclerosis SPMS|remibrutinib|LOU064|teriflunomide|adult|relapse|Expanded Disability Status Scale|T2 lesions|T1 lesions|GD- enhancing MRI|Neurofilament light chain|McDonald diagnostic criteria,United States,Phoenix,Arizona,241,Remibrutinib|Teriflunomide,DRUG|DRUG,Annualized relapse rate (ARR) of confirmed relapses [Core Part],Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)|Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)|Annualized rate of new or enlarging T2 lesion [Core Part]|Neurofilament light chain (Nfl) [Core Part]|Number of Gd-enhancing T1 lesions per MRI scan [Core Part]|Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)|Time to first confirmed relapse [Core Part]|Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)|Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)|Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)|Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)|Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)|Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)|Change from Baseline in T2 lesion volume [Core Part]|Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]|Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]|Pharmacokinetics of remibrutinib [Core Part]|Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]|Annualized relapse rate (ARR) of confirmed relapses [Extension Part]|Annualized rate of new or enlarging T2 lesion [Extension Part]|Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]|Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]|Neurofilament light chain (NfL) [Extension Part]|Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part],False,
NCT07100119,A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis,"A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis",NOT_YET_RECRUITING,2025-09,2027-08,2027-09,2025-08-07,2025-08-03,INTERVENTIONAL,PHASE1,32.0,ESTIMATED,Eli Lilly and Company,INDUSTRY,,,ALS (Amyotrophic Lateral Sclerosis),,Belgium,Leuven,Vlaams-Brabant,10,LY4256984|Placebo,DRUG|DRUG,"Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration",Pharmacokinetics (PK): Plasma Area Under the Concentration Versus Time Curve (AUC) of LY4256984|PK: Plasma Maximum Concentration (Cmax) of LY4256984|PK: Cerebrospinal Fluid Concentrations (CSF) of LY4256984,False,
NCT00616733,12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients,"An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis",COMPLETED,2008-03,2010-09,2010-09,2011-03-10,2008-02-15,INTERVENTIONAL,PHASE1,25.0,ACTUAL,Daiichi Sankyo,INDUSTRY,,,Multiple Sclerosis,"Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI",United States,Denver,Colorado,5,CS-0777 tablets|CS-0777 tablets|CS-0777 tablets,DRUG|DRUG|DRUG,Safety and tolerability.,Pharmacodynamic response (lymphocyte counts Pharmacokinetics Exploratory efficacy based on brain MRI lesions),False,
NCT01874145,Safety and Tolerability of Glatiramer Acetate,"An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2013-06,2014-04,2014-05,2016-01-14,2013-06-10,INTERVENTIONAL,PHASE3,209.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Glatiramer Acetate|Glatiramer,United States,Cullman,Alabama,35,GA 20 mg/mL|GA 40 mg/mL,DRUG|DRUG,Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period|Injection-Related Adverse Event Rate Per Year in the Extension Period|Injection-Related Adverse Events in the Extension Period,Adjusted Mean Estimates for Injection Site Reaction Event Rate Per Year in the Core Period|Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Impact on Physical Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO) in the Core Period|Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Impact on Psychological Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO) in the Core Period|Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Convenience Score in the Core Period|Change From Baseline to Month 4 in in the Adjusted Mean Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Satisfaction Score in the Core Period|Injection Site Reaction Event Rate Per Year in the Extension Period|Injection Site Reaction Events in the Extension Period|Change From Start of Extension Period (Month 4) to Month 8 (and to Endpoint Visit) in the Participant-Reported Impact on Physical Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO)|Change From Start of Extension Period (Month 4) to Month 8 (and to Endpoint Visit) in the Participant-Reported Impact on Psychological Wellbeing Using Multiple Sclerosis Impact Scale (MSIS-29 PRO)|Change From Start of Extension Period to Month 8 (and to Endpoint Visit) in in the Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Convenience Score|Change From Start of Extension Period to Month 8 (and to Endpoint Visit) in in the Participant-Reported Treatment Satisfaction Questionnaire for Medication (TSQM-9) Satisfaction Score,True,2016-01-14
NCT04191772,The Impact of Training on Sitting Time and Brain Volumes in Multiple Sclerosis.,"The Impact of Structured Exercise on Physical Fitness, Sedentary Time, Brain Volume, Cognitive, Health-related and Immunological Parameters in Multiple Sclerosis.",COMPLETED,2020-01-15,2021-06-30,2021-06-30,2021-08-31,2019-12-10,INTERVENTIONAL,NA,156.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,Sedentary time|Exercise|Brain volume|Health-related variables|Immunological variables|Multiple Sclerosis,Belgium,Diepenbeek,Limburg,1,"Periodized, home-based running program",OTHER,Number of steps per day|Number of steps per day|Number of steps per day|Number of steps per day|Number of steps per day|Sitting time|Sitting time|Sitting time|Sitting time|Sitting time|Standing time|Standing time|Standing time|Standing time|Standing time|Stepping time|Stepping time|Stepping time|Stepping time|Stepping time,Blood pressure|Blood pressure|Resting heart rate|Resting heart rate|Total calorie intake|Total calorie intake|Total calorie intake|Total calorie intake|Total calorie intake|Macronutrient content|Macronutrient content|Macronutrient content|Macronutrient content|Macronutrient content|Participation - Ghent Participation Scale (GPS)|Participation - Ghent Participation Scale (GPS)|Mobility - MS walking scale (MSWS-12)|Mobility - MS walking scale (MSWS-12)|Fatigue - Modified Fatigue Impact scale (MFIS)|Fatigue - Modified Fatigue Impact scale (MFIS)|Fatigue - Modified Fatigue Impact scale (MFIS)|Fatigue - Modified Fatigue Impact scale (MFIS)|Fatigue - Modified Fatigue Impact scale (MFIS)|Fatigue - Modified Fatigue Impact scale (MFIS)|Cognition - Spatial Recall test (SPART)|Cognition - Spatial Recall test (SPART)|Cognition - Symbol Digit Modalities Test (SDMT)|Cognition - Symbol Digit Modalities Test (SDMT)|Body weight|Body weight|Height|Height|DEXA (Dual Energy X-Ray)|DEXA (Dual Energy X-Ray)|Coordination - timed tandem walk (TTW)|Coordination - timed tandem walk (TTW)|Oxygen uptake (VO2)|Oxygen uptake (VO2)|Carbon dioxide output (VCO2)|Carbon dioxide output (VCO2)|Minute ventilation (VE)|Minute ventilation (VE)|Equivalents for oxygen uptake (VE/VO2)|Equivalents for oxygen uptake (VE/VO2)|Equivalents for carbon dioxide production (VE/VCO2)|Equivalents for carbon dioxide production (VE/VCO2)|Tidal volume (Vt)|Tidal volume (Vt)|Breathing frequency (BF)|Breathing frequency (BF)|Respiratory gas exchange ratio (RER)|Respiratory gas exchange ratio (RER)|Cardiorespiratory fitness (CRF)|Cardiorespiratory fitness (CRF)|Lipidomic profile|Lipidomic profile|Brain volumes|Brain volumes|PBMC subset parameters|PBMC subset parameters|serum cytokines|serum cytokines,False,
NCT03268187,Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.,Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.,COMPLETED,2017-07-17,2018-06-09,2018-10-18,2019-04-11,2017-08-31,INTERVENTIONAL,NA,61.0,ACTUAL,Rehazentrum Wilhelmshaven,OTHER,,,Fatigue|Multiple Sclerosis,Cognitive Fatigue|Multiple Sclerosis|Biofeedback|Self-Alert Training|Vigilance|Autonomic potentials,Germany,Wilhelmshaven,Lower Saxony,1,Biofeedback|Self-Alert Training|Relaxation Training,DEVICE|BEHAVIORAL|BEHAVIORAL,Reaction Time of Vigilance Task (TAP)|Subjective Fatigue (VAS),Omissions and errors of Vigilance Task (TAP),False,
NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,"A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects",TERMINATED,2014-11-30,2016-05-18,2016-05-18,2017-06-09,2015-01-21,INTERVENTIONAL,PHASE4,111.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Aurora,Colorado,42,natalizumab|fingolimod,DRUG|DRUG,Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions,Cumulative Number of New T1-Gd+ Lesions|Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24|Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52|Cumulative Number of New or Enlarging T2 Lesions|Proportion of Participants With No Evidence of Disease Activity (NEDA)|Time to First Relapse|Cumulative Risk of Relapse|Time to Complete Recovery From First Relapse|Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24|Change From Baseline in SDMT at Week 52,True,2017-06-09
NCT04032158,Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS),"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety",TERMINATED,2019-08-26,2020-04-16,2020-04-16,2021-08-05,2019-07-25,INTERVENTIONAL,PHASE3,3.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Relapsing-remitting Multiple Sclerosis,Evobrutinib|Avonex®|Interferon-beta 1a|Relapsing Multiple Sclerosis,United States,Rockland,Massachusetts,2,Evobrutinib|Avonex®|Avonex® matched Placebo|Evobrutinib matched Placebo,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),"Time to First Occurrence of 12-Week Confirmed Expanded Disability Status Scale (EDSS) Progression|Time to First Occurrence of 24-Week Confirmed Expanded Disability Status Scale (EDSS) Progression|Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Short Form Score at Week 96|Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Fatigue Score at Week 96|Total Number of Gadolinium-Enhancing (Gd+) Time Constant 1 (T1) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96|Total Number of New or Enlarging Time Constant 2 (T2) Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans at Week 24, 48, and 96|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)|Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Vital Signs: Pulse Rate|Vital Signs: Respiratory Rate|Vital Signs: Temperature|Vital Signs: Weight|Number of Participants With Abnormal Lab Values|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Absolute Concentrations of Immunoglobulin (Ig) A Level|Absolute Concentrations of Immunoglobulin (Ig) E Level|Absolute Concentrations of Immunoglobulin (Ig) G Level|Absolute Concentrations of Immunoglobulin (Ig) M Level|Change From Baseline in Immunoglobulin (Ig) A Level|Change From Baseline in Immunoglobulin (Ig) E Level|Change From Baseline in Immunoglobulin (Ig) G Level|Change From Baseline in Immunoglobulin (Ig) M Level",True,2021-08-05
NCT00647348,Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis,"A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.",COMPLETED,2008-01,2011-11,2011-11,2019-12-12,2008-03-31,INTERVENTIONAL,PHASE2,140.0,ACTUAL,Imperial College London,OTHER,,,Secondary Progressive Multiple Sclerosis,Secondary progressive Multiple Sclerosis|Simvastatin|MRI,United Kingdom,Chalfont Saint Peter,Buckinghamshire,3,Simvastatin|Placebo,DRUG|DRUG,Percentage Change in Whole Brain Volume,Evaluation of Disability (EDSS).|Evaluation of Disability (MSFC Z Score).|Evaluation of Disability (MSFC Walk).|Evaluation of Disability (MSFC Peg Test).|Evaluation of Disability (MSFC PASAT).|Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Total Score)|Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Physical Score)|Disease Impact Specific to the Disease and Rated by the Patient (MSIS-29 Questionnaire Psychological Score),True,2019-12-12
NCT05462678,Memory Rehabilitation Strategies in Patients With Multiple Sclerosis,Strategies and Techniques for the Rehabilitation of Memory Deficits in Patients With Multiple Sclerosis,COMPLETED,2018-09-01,2021-04-20,2021-11-20,2022-07-18,2022-07-18,INTERVENTIONAL,NA,60.0,ACTUAL,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Multiple Sclerosis,Cognitive Rehabilitation|Motor Rehabilitation|Cognitive Impairment,Italy,Roma,Rm,2,Cognitive Rehabilitation|Combined Rehabilitation|Motor Rehabilitation,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Pre- and Post treatment and long term cognitive efficiency,Pre- and Post-treatment and long term motor efficiency,False,
NCT05840653,The Effect of Hope Placement Program on Dıagnosed Wıth MS,The Effect Of Posıtıve Psychotherapy-Based Hope Placement Program On The Level Of Determınatıon Of Hope And Lıve Goals In Indıvıduals Dıagnosed Wıth Multıple Sclerosıs,UNKNOWN,2023-05-01,2023-06-01,2023-12-01,2023-05-03,2023-05-03,INTERVENTIONAL,NA,80.0,ESTIMATED,Ondokuz Mayıs University,OTHER,,,Multiple Sclerosis,multiple sclerosis|hope|life purpose|Psychiatric Nursing|positive psychotherapy,Turkey (Türkiye),Samsun,,1,psychotherapeutic intervention,OTHER,experiment 1 and experiment 2 group level of determination of life purpose|experiment 1 and experiment 2 group hopelessness is to decrease.|control1 and control 2 group hopelessness is to decrease.,,False,
NCT03166800,MitoQ for Fatigue in Multiple Sclerosis,MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial,TERMINATED,2018-09-15,2019-01-10,2019-01-10,2023-04-05,2017-05-25,INTERVENTIONAL,PHASE1|PHASE2,9.0,ACTUAL,Oregon Health and Science University,OTHER,MitoQ Limited|National Multiple Sclerosis Society,UNKNOWN|OTHER,Multiple Sclerosis|Fatigue,mitoquinone|Fatigue|Multiple Sclerosis,United States,Portland,Oregon,1,Mitoquinone|Mitoquinone|Placebo,DRUG|DRUG|DRUG,Fatigue measured by Modified Fatigue Impact Scale (MFIS) Score at 12 weeks post study drug initiation,,False,
NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)","A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis",TERMINATED,2013-10,2015-03,2015-03,2016-05-11,2013-10-16,INTERVENTIONAL,PHASE2,255.0,ACTUAL,EMD Serono,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting|Plovamer acetate|Copaxone,United States,Redding,California,118,Plovamer acetate 0.5 milligram (mg)|Copaxone 20 mg|Plovamer acetate 3 mg|Plovamer acetate 10 mg|Plovamer acetate 20 mg,DRUG|DRUG|DRUG|DRUG|DRUG,Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan,"Mean Annualized Relapse Rate (ARR)|Percentage of Subjects Remaining Relapse-Free|Mean Number of New T1 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan|Mean Number of New or Enlarging Time Constant 2 (T2) Lesions Per Subject and Scan|Mean Number of New, Unenhancing T1 Lesions (Black Holes) Per Subject and Scan|Mean Change From Baseline in Volume of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan|Mean Change From Baseline in Volume of T2 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan|Time to First Relapse|Mean Change From Baseline in Brain Volume Per Subject",True,2016-05-11
NCT00323271,Cognitive-behavior Therapy for MS-Related Chronic Pain,Cognitive-behavior Therapy for MS-Related Chronic Pain,COMPLETED,2006-07,2011-03,2011-03,2015-09-25,2006-05-09,INTERVENTIONAL,NA,26.0,ACTUAL,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Chronic pain|Cognitive behavioral therapy|Multiple sclerosis|Randomized controlled trial,United States,West Haven,Connecticut,2,Cognitive-behavior therapy|Interventional,BEHAVIORAL|OTHER,Pain Intensity|Pain Intensity,,True,2015-09-25
NCT01056471,Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis,"Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment",COMPLETED,2010-01,2012-06,2015-06,2015-08-07,2010-01-26,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,OTHER,Carlos III Health Institute,OTHER_GOV,"Autoimmune Diseases|Immune System Diseases|Demyelinating Diseases|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System",Multiple Sclerosis|Mesenchymal Stem Cells|Autologous,Spain,Málaga,Málaga,2,Autologous mesenchymal stem cells from adipose tissue.|Autologous mesenchymal stem cells from adipose tissue.,OTHER|OTHER,To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells,"To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.",False,
NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,"A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",COMPLETED,2006-05,2011-07,2011-07,2017-09-21,2006-06-21,INTERVENTIONAL,PHASE3,1292.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,FTY720|Interferon|RRMS|Multiple Sclerosis|Efficacy,United States,Cullman,Alabama,170,Fingolimod 1.25 mg|Fingolimod 0.5 mg|Interferon β-1a 30 µg,DRUG|DRUG|DRUG,Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study,Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study|Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study|Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study|Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study|Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study,True,2011-05-16
NCT02291107,Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods,Robot-assisted Gait Training in Patients Affected by Multiple Sclerosis: Rehabilitative Efficacy Evaluation and Comparison With Traditional Methods,UNKNOWN,2014-06,2015-12,2016-06,2015-08-21,2014-11-14,INTERVENTIONAL,NA,17.0,ESTIMATED,"Habilita, Ospedale di Sarnico",OTHER,,,Multiple Sclerosis,Gait orthosis|Lokomat|Robotic Rehabilitation,Italy,Zingonia Di Ciserano,Bergamo,1,"Lokomat (Hocoma, Zurich, Switzerland)|Conventional Physiotherapy",DEVICE|OTHER,Timed 25 Foot Walk (25FW),Timed 10 meter walking test (TWT)|6 minute walking test (6MWT)|Tinetti Test (TT)|Functional Ambulation Categories (FAC)|Modified Ashworth scale for lower limbs|Modified Motricity Index for lower limbs|Knee extensor strength (KES)|Double Time Support (DST)|Step Length Ratio (SLR)|Expanded Disability Status Scale (EDSS)|Functional Independence Measure (FIM)|Quality of Life Index (QL Index - SF36)|Numeric Rating Scale (NRS),False,
NCT05385744,"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis","An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",COMPLETED,2021-04-05,2022-09-09,2023-09-29,2024-11-25,2022-05-23,INTERVENTIONAL,PHASE3,336.0,ACTUAL,Biocad,INDUSTRY,,,Multiple Sclerosis,,Russia,Moscow,,1,BCD-132|Teriflunomide,BIOLOGICAL|DRUG,Annualized relapse rate,Proportion of patients with persistent progression|Total number of T1 Gd+ lesions|CUA|Proportion of patients without contrast-enhancing lesions|Number of new or enlarged T2 lesions|Proportion of patients without new or enlarged T2 lesions|Changes in the neurologic deficit according to EDSS score|Annualized relapse rate|Proportion of patients with adverse reactions|Proportion of patients with serious adverse reactions,False,
NCT02440516,Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis,Standardized Comprehensive Two-month Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis: a Randomized-controlled Trial,COMPLETED,2016-02,2019-02-26,2019-02-26,2019-03-01,2015-05-12,INTERVENTIONAL,NA,65.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,,,Multiple Sclerosis,Standardized|Physical therapy|occupational therapy|quality of life|disability|activities of daily living|ambulatory therapy|multiple sclerosis,Switzerland,Bern,,2,Early treatment group|Late treatment group,OTHER|OTHER,Change from baseline in Multiple Sclerosis Impact Scale 29 (MSIS-29),Change from baseline in Coin Rotation Task (Heldner et al. 2014)|Change from baseline in Timed Up and Go (TUG) (Nilsagard et al. 2007)|Change from baseline in Nine-hole-Peg Test (NHPT) (Gookin et al. 1988)|Change from baseline in 25-Foot Walk Test (25-FWT) (Cohen et al. 2014)|Change from baseline in EDSS|Change from baseline in Rand 36|Change from baseline in Fatigue Severity Scale,False,
NCT06171152,Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues,Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity,RECRUITING,2024-01-26,2026-06-01,2026-10-01,2024-07-31,2023-12-14,INTERVENTIONAL,EARLY_PHASE1,30.0,ESTIMATED,University of Chicago,OTHER,,,"Multiple Sclerosis|Long COVID|Long Covid19|Obese|Obesity|Obesity, Morbid|Acute Leukemia in Remission",,United States,Chicago,Illinois,1,Liraglutide Pen Injector [Saxenda]|Medication Diary,DRUG|OTHER,Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 8 Weeks,Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 4 Weeks|Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 12 Weeks|Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 21 Weeks,False,
NCT01448252,T Cell Vaccination in Patients With Progressive Multiple Sclerosis,Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis,COMPLETED,2002-05,2008-09,2009-03,2011-10-07,2011-10-07,INTERVENTIONAL,PHASE1|PHASE2,30.0,ESTIMATED,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,T cell vaccination|Immunotherapy|Tolerance|safety|clinical efficacy,Israel,Jerusalem,,1,multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|T cell vaccination,BIOLOGICAL|BIOLOGICAL,EDSS changes|Relapse rate of MS|PASAT test|Nine hole PEG test|timed ten meter walking,Quantitative MRI evaluation,False,
NCT02398149,Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis,Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis,COMPLETED,2013-10,2016-10,2016-10,2017-08-30,2015-03-25,OBSERVATIONAL,,267.0,ACTUAL,Mount Sinai Rehabilitation Hospital,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Hartford,Connecticut,1,,,Prevalance of Impairment in the Upper Extremity,,False,
NCT00342381,Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation,Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation,COMPLETED,2006-06,,2007-12,2007-12-17,2006-06-21,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,University of Aarhus,OTHER,The Danish Multiple Sclerosis Society,UNKNOWN,Multiple Sclerosis|Fatigue,Motor fatigue|Cognitive fatigue,Denmark,Aarhus,,1,"3,4-diaminopyridine|Placebo",DRUG|DRUG,"Subjective fatigue (FSS)|Maximal voluntary isometric contraction, central activation before and after exercise|Digit Symbol-Coding scores|Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters)|Cortical atrophy|Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine)","Subjective fatigue (MFI-20, Danish version)|Rapid voluntary twitches|6 minute walk test|9-hole peg test|WAIS/WMS tests|WHO-5 Questionnaire|Major Depression Inventory|Lesion load|Whole brain atrophy|Subjective fatigue (VAS)",False,
NCT02575365,Effect of Fingolimod on Neurodegeneration,"Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients",TERMINATED,2016-02-16,2017-01-27,2017-01-27,2019-02-27,2015-10-14,INTERVENTIONAL,PHASE4,4.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Cognition|Brain Volume Loss,"RRMS,|Cognition,|brain,|Fingolimod,|Multiple Sclerosis,|neurodegeneration,|Brain atrophy,|gray matter atrophy,|thalamic atrophy,|biomarkers,|BICAMS Battery,",Turkey (Türkiye),Bursa,,3,"0,5 mg Fingolimod",DRUG,Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 12 Months|Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 24 Months,"Change From Baseline in PASAT Test|Change From Baseline in Stroop Test|Change From Baseline in Brain Gray Matter Atrophy and Thalamic Atrophy|Change From Baseline in Serum Levels of 24S-hydroxycholesterol (24OHC) , Osteopontin and Matrix Metalloproteinases (and Also MMPI's)|the Correlation Between Effect of Fingolimod on Cognitive Performances and Brain Atrophy (Gray Matter Atrophy and Thalamic Atrophy) by Comparing Baseline and Month 24.",True,2019-02-27
NCT01037907,A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS,TERMINATED,2009-11,2011-12,2011-12,2022-06-03,2009-12-23,INTERVENTIONAL,PHASE2,173.0,ACTUAL,Boston Scientific Corporation,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Oral treatment for MS|Oral drug for multiple sclerosis|Oral RRMS|Oral relapsing remitting multiple sclerosis|Gamma Linolenic Acid|GLA|Fatty acid|Triglyceride|Structured lipid|MRI|Magnetic resonance imaging|gadolinium enhancing lesions|expanded disability status scale|EDSS|Demyelination|Remyelination|TGFB1|Transforming growth factor beta 1|cytokines|disease modifying therapy|immunomodulator|Anti inflammatory|Pro inflammatory|TNF alpha|interleukin 1 beta|interferon gamma|Fayaz Master|Omega 6|Polyunsaturated fatty acid|Cytokine balance|Pleneva TM|BGC20-0134|RRMS,Belgium,Ghent,,35,Pleneva TM BGC20-0134|Placebo,DRUG|DRUG,"The cumulative number of new gadolinium-enhanced (GdE) T1 weighted lesions developing while on treatment (specifically the sum of new GdE T1 lesions seen on MRI at weeks 12, 16, 20 and 24).","Cumulative number of total GdE T1 weighted lesions developing while on treatment|Cumulative number of new T2 weighted lesions|Patients free of GdE (T1-weighted) lesions|Change in volume of GdE T1 weighted lesions|Change in volume of T2 lesions|Brain atrophy|Cumulative number of new T1 hypointense lesions (black holes)|Disease burden, T1 and T2 lesion activity at week 48.|Number of clinical relapses from baseline during the first 24 weeks.|Change on the Expanded Disability Status Scale (EDSS) during the first 24 weeks|Number of patients receiving methylprednisolone treatment for a relapse during the first 24 weeks.|Serum levels of cytokines during the first 24 weeks.|Quality of life (MSQOL-54) assessment|PK for determination of circulating levels of BGC20-0134 and plasma concentrations of dihomo-gamma linolenic acid (DHGLA) during the first 24 weeks.|Overall safety of BGC20-0134",False,
NCT01201707,Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis,The Effectiveness of Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis,TERMINATED,2010-08,2013-09,2013-09,2013-11-26,2010-09-15,INTERVENTIONAL,NA,18.0,ACTUAL,"Community Care Physicians, P.C.",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Angioplasty|Vein,United States,Albany,New York,2,Angioplasty|Observation,PROCEDURE|OTHER,Impact of CCSVI treatment on quality of life in patients with MS|Impact of CCSVI treatment on quality of life in patients with MS|Impact of CCSVI treatment on quality of life in patients with MS|Impact of CCSVI treatment on quality of life in patients with MS|Impact of CCSVI treatment on quality of life in patients with MS|Impact of CCSVI treatment on quality of life in patients with MS,Clinical significance of CCSVI in MS patients|Superiority of angioplasty to observation for treatment of CCSVI|Incidence of CCSVI in patients with MS|Safety of endovascular treatment of CCSVI|Target vessel primary and secondary patency|Clinical significance of CCSVI in MS patients|Clinical significance of CCSVI in MS patients|Clinical significance of CCSVI in MS patients|Clinical significance of CCSVI in MS patients|Superiority of angioplasty to observation for treatment of CCSVI|Superiority of angioplasty to observation for treatment of CCSVI|Superiority of angioplasty to observation for treatment of CCSVI|Superiority of angioplasty to observation for treatment of CCSVI|Safety of endovascular treatment of CCSVI|Safety of endovascular treatment of CCSVI|Safety of endovascular treatment of CCSVI|Safety of endovascular treatment of CCSVI|Safety of endovascular treatment of CCSVI|Target vessel primary and secondary patency|Target vessel primary and secondary patency|Target vessel primary and secondary patency|Target vessel primary and secondary patency|Target vessel primary and secondary patency,False,
NCT02133664,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,COMPLETED,2014-06,2016-05,2016-05,2017-06-02,2014-05-08,INTERVENTIONAL,PHASE1|PHASE2,54.0,ACTUAL,Oregon Health and Science University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Cognition,multiple sclerosis|cognition|clinical trial|thiotic acid|Omega-3 fatty acids,United States,Portland,Oregon,1,lipoic acid and omega-3 fatty acids|Placebo,DRUG|DRUG,Paced Auditory Serial Addition Task (PASAT)|Stroop Color-Word Test|California Verbal Learning Test-II (CVLT-II)|Controlled Oral Word Association Test (COWAT),,True,2017-05-03
NCT00430599,The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis,,COMPLETED,2007-02,,2009-09,2015-10-12,2007-02-02,OBSERVATIONAL,,20.0,ACTUAL,Newcastle-upon-Tyne Hospitals NHS Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Newcastle,Tyne and Wear,1,,,,,False,
NCT03375177,Multiple Sclerosis Registry in Argentina (RelevarEM),Multiple Sclerosis Registry in Argentina (RelevarEM),UNKNOWN,2018-03-25,2021-07-16,2024-06-23,2019-08-06,2017-12-15,OBSERVATIONAL,,4000.0,ESTIMATED,Hospital Italiano de Buenos Aires,OTHER,,,Multiple Sclerosis,multiple sclerosis|Argentina|epidemiology|registry,Argentina,Buenos Aires,,1,Natural history of disease,OTHER,Demographic outcomes,,False,
NCT01142557,An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis,Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®),COMPLETED,2004-06,2005-11,2005-11,2014-07-11,2010-06-11,OBSERVATIONAL,,522.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Gesellschaft für Therapieforschung mbH,INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Rebif|Interferon-beta,Germany,Darmstadt,,1,Interferon beta-1a (Rebif),DRUG,Assessment of the effectiveness and compatibility of Rebif 44 or 22 µg,Side effects occurring in the initial phase of therapy|Satisfaction of the subject as well as the treating doctor,False,
NCT06769763,MHealth Effect on Multiple Sclerosis Patients' Quality of Life and Self-care Practices,Arabic Mobile Application for Multiple Sclerosis (MS) Patients and Its Effect on Their Quality of Life and Self-care Practices,RECRUITING,2025-01-14,2025-03-10,2025-06-15,2025-02-18,2025-01-10,INTERVENTIONAL,NA,74.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Quality of life|Self-care|mHealth|Arabic Application,Egypt,Giza,,1,My Journey with MS application,OTHER,The effect of mHealth on the self-care practices of multiple sclerosis patients|The effect of mHealth on the quality of life of multiple sclerosis patients,The usability of the developed application,False,
NCT05391906,Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis,Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2023-01-30,2026-12-20,2026-12-30,2025-03-12,2022-05-26,INTERVENTIONAL,NA,50.0,ACTUAL,Chinese University of Hong Kong,OTHER,,,Multiple Sclerosis,,Hong Kong,Hong Kong,,1,Diffusion-weighted magnetic resonance imaging,OTHER,"IVIM parameters (including ADC,D,D*,f) in Multiple Sclerosis brain regions.",,False,
NCT01941004,Safety and Efficacy of Fingolimod in MS Patients in China,"A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis",WITHDRAWN,2014-06,2017-05,2017-05,2017-04-21,2013-09-12,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis (Relapsing Remitting),multiple sclerosis (MS)|relapsing remitting multiple sclerosis (RRMS)|fingolimod,,,,0,fingolimod|Placebo (6mos) + open label fingolimod (6 mos),DRUG|DRUG,number of new/newly enlarged T2 MRI lesions over 6 months,annualized relapse rate (ARR)|number of Gd-enhancing T1 lesions|Safety and tolerability of fingolimod 0.5 mg compared to placebo,False,
NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,"24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",COMPLETED,2006-06,2011-06,2011-08,2012-08-07,2006-07-21,INTERVENTIONAL,PHASE3,1083.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,fingolimod|FTY720|relapsing-remitting multiple sclerosis|MS|RRMS,United States,Birmingham,Alabama,112,Fingolimod|Placebo,DRUG|DRUG,Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24,Aggregate Annualized Relapse Rate (ARR) Estimate up to End of Study|Percent Change From Baseline in Brain Volume|Number of New or Newly Enlarged T2 Lesions|Number of Gadolinium-enhanced T1 Lesions|Change From Baseline in Lesion Volume at Month 24 (Core Phase)|Percentage of Participants Free of 3-month Confirmed Disability Progression at Month 24 and End of Study|Percentage of Participants Free of 6-month Confirmed Disability Progression at Month 24 and End of Study|Percentage of Participants Relapse-free up to Month 24|Percentage of Participants Relapse-free up to End of Study|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Z-score,True,2012-06-26
NCT00232193,Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS,Steroid Adjunctive Treatment at Initiation of Avonex Therapy for Patients With Mono-Symptomatic or Relapsing-Remitting Multiple Sclerosis,COMPLETED,2003-12,2008-12,2010-08,2011-07-22,2005-10-04,OBSERVATIONAL,,40.0,ACTUAL,Providence Multiple Sclerosis Center,OTHER,Biogen,INDUSTRY,Relapsing-remitting Multiple Sclerosis|Clinically Isolated Syndrome,Multiple Sclerosis|Interferon Beta 1-a|Pulsed steroids,United States,Portland,Oregon,1,,,,,False,
NCT06226831,Onset of Lower Urinary Tract Symptoms in Multiple Sclerosis Patients,Onset of Lower Urinary Tract Symptoms in Multiple Sclerosis Patients,RECRUITING,2020-06-01,2025-12,2025-12,2024-01-26,2024-01-26,OBSERVATIONAL,,1500.0,ESTIMATED,University Hospital Ostrava,OTHER,,,Lower Urinary Tract Symptoms|Multiple Sclerosis,Multiple Sclerosis|Lower-Urinary Tract Symptoms|Urinary Urgency|Cerebellar and/or Pyramidal Symptoms,Czechia,Ostrava,Moravian-Silesian Region,1,Structured interview,OTHER,LUTS onset,Course of disease (clinical examination)|Course of disease (EDSS scale),False,
NCT05534672,Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex,"Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With TSC",RECRUITING,2023-01-23,2027-06,2027-06,2023-08-08,2022-09-09,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,Katarzyna Kotulska,OTHER,,,Tuberous Sclerosis Complex,"tuberous sclerosis complex, epilepsy, rapamycin, drug resistant epilepsy",Poland,Lodz,,2,Rapamycin|Placebo,OTHER|OTHER,comparison of the number of patients with at least 50% reduction of seizures per week in the last month of the core blinded phase in comparison to screening phase in the rapamycin vs placebo group|number of adverse events (according to CTCAE classification) in the rapamycin vs placebo group during the double-blind core phase,"comparison of the number of seizures per week and the number of days free of seizures in the rapamycin vs placebo group, during 12-week treatment in double-blind core phase|severity of adverse events (according to CTCAE) and the number of patients withdrawn from the study due to adverse events in the rapamycin vs placebo group",False,
NCT03161028,Lipoic Acid for Progressive Multiple Sclerosis (MS),Lipoic Acid for the Treatment of Progressive Multiple Sclerosis,COMPLETED,2018-08-17,2023-12-31,2024-06-30,2025-03-03,2017-05-19,INTERVENTIONAL,PHASE2,115.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis,multiple sclerosis|magnetic resonance imaging|gait|neuroprotective agents|thioctic acid|alpha-lipoic acid|mobility|chronic progressive multiple sclerosis,United States,Birmingham,Alabama,11,Lipoic acid|Placebo,DRUG|DRUG,Change in Mobility: Timed 25 Foot Walk,Change in Mobility: 2-minute Timed Walk|Mobility: Fall Count|Brain Atrophy by MRI,True,2025-03-03
NCT05735067,The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients,The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients,ACTIVE_NOT_RECRUITING,2022-02-01,2023-05-01,2025-07-30,2023-12-19,2023-02-21,OBSERVATIONAL,,138.0,ACTUAL,German University in Cairo,OTHER,,,Multiple Sclerosis,"Multiple Sclerosis, IFB 1a",Egypt,Cairo,,1,Blood sample collection,OTHER,Correlation between IL17 levels and patients' response to interferon beta 1a as measured by ELISA,"Correlation between IL 22 levels and patients' response to interferon beta 1a, measured by ELISA|Correlation between Expanded Disability Status Scale and patients' response to interferon beta 1a|Correlation between malondialdehyde levels and patients' response to interferon beta 1a|Correlation between MRI load and Patients' response to interferon beta 1a|Correlation between body mass index and patients' response to interferon beta 1 a",False,
NCT01413100,Scleroderma Treatment With Autologous Transplant (STAT) Study,A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis,COMPLETED,2011-09-15,2023-09-15,2024-09-11,2025-01-07,2011-08-10,INTERVENTIONAL,PHASE2,21.0,ACTUAL,Fred Hutchinson Cancer Center,OTHER,National Cancer Institute (NCI),NIH,Systemic Scleroderma,,United States,Duarte,California,12,Anti-Thymocyte Globulin|Autologous Hematopoietic Stem Cell Transplantation|Cyclophosphamide|Filgrastim|Laboratory Biomarker Analysis|Mycophenolate Mofetil|Peripheral Blood Stem Cell Transplantation|Plerixafor|Quality-of-Life Assessment|Questionnaire Administration,BIOLOGICAL|PROCEDURE|DRUG|BIOLOGICAL|OTHER|DRUG|PROCEDURE|DRUG|OTHER|OTHER,EFS of Patients Undergoing Transplant,All-cause Mortality|The Number of Participants With Stable or Improved LVEF|Number of Participants Requiring Dialysis|The Number of Participants With Disease Progression|The Number of Participants Who Completed ALL Health Care Utilization as Assessed by UCSD Healthcare Utilization Surveys|The Median SHAQ Score|The Number of Participants With Improvement in Pulmonary Function|The Number of Participants With Significant Infectious Complications|The Number of Participants With Non-progression Mortality|The Number of Participants Who Survived|The Number of Participants Who Had Regimen-related Toxicities|The Median Time of Initiation of Disease-modifying Antirheumatic Drugs (DMARDS) for Relapse After Transplant|Median Time to Treatment Failure|The Number of Participants With Treatment-related Mortality|The Number of Participants Who Completed ALL Work Productivity Survey (WPS),True,2025-01-07
NCT05326711,Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis,Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis,COMPLETED,2022-04-11,2022-11-21,2022-11-21,2023-07-11,2022-04-13,INTERVENTIONAL,NA,32.0,ACTUAL,Dokuz Eylul University,OTHER,Izmir Katip Celebi University,OTHER,Multiple Sclerosis|Pain,multiple sclerosis|motor imagery|pain|telerehabilitation,Turkey (Türkiye),Izmir,Inciralti,2,Telerehabilitation-based motor imagery training,BEHAVIORAL,Change in Visual Analog Scale (VAS) Score,Expanded Disability Status Scale|Change in Patient-Determined Disease Steps Scale Score|Change in Numeric Rating Scale Score|Change in PainDETECT Questionnaire Score|Change in Nordic Musculoskeletal Questionnaire Score|Change in Kinesthetic and Visual Imagery Questionnaire- 20 Score|Change in Modified Fatigue Impact Scale Score|Change in Multiple Sclerosis İnternational Quality of Life Questionnaire Score|Change in Pittsburgh Sleep Quality Index Score|Change in Epworth Sleepiness Scale Score|Change in Hospital Anxiety and Depression Scale (HADS) Score|Change in Mental Chronometer Time Ratio for Timed Up and Go Test Score|Change in California Verbal Learning Test-II Score|Change in Revised Brief Visuospatial Memory Test Score|Change in Symbol Digit Modalities Test Test Score,False,
NCT05286632,KidneYou - Innovative Digital Therapy,"Evaluation of Performance and Safety of App KidneYou, an Innovative Digital Therapy, in Improving Health of Patients with Chronic Kidney Disease (CKD) by Increasing Their Adherence to Dietary, Exercise Regimens or Mindfulness Program",COMPLETED,2022-07-18,2024-06-28,2024-07-31,2024-11-06,2022-03-18,INTERVENTIONAL,NA,210.0,ACTUAL,Advice Pharma Group srl,INDUSTRY,,,Chronic Kidney Diseases|Diabetes|Arterial Hypertension|Chronic Glomerulonephritis|Cystic Kidney Diseases|Polycystic Kidney|Nephronophthisis|Cortical Cystic Disease|Cystic Diseases|Tuberous Sclerosis|Albuminuria|Treatment Adherence|Treatment Adherence and Compliance,Digital Therapeutics|Digital Medicine|Adherence|Software|Software Medical Device|Quality of life|Digital Therapy,Italy,Bari,Bari,1,KidneYou APP,DEVICE,Evaluation of changes in azoturia|Evaluation of changes in distance covered|Evaluation of changes in Perceived Stress,,False,
NCT04667221,Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis,Cognitive Improvement Through Transcranial Direct Current Stimulation for Patients With Multiple Sclerosis,UNKNOWN,2020-12-08,2023-12-31,2023-12-31,2023-05-15,2020-12-14,INTERVENTIONAL,NA,30.0,ESTIMATED,University Medicine Greifswald,OTHER,,,Multiple Sclerosis,,Germany,Greifswald,,1,Active transcranial direct current stimulation|Sham transcranial direct current stimulation,DEVICE|DEVICE,Reaction Times in symbol-digit modalities test.,Hit Rate in symbol-digit modalities test.|Baseline performance in symbol-digit modalities test.,False,
NCT01156298,Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance,"Phase IV, Multi-center, Non-treatment, Observational, Registry Study to Determine Long Term Effects of AVONEX® Therapy on EDSS, MRI, QoL, and Cognition.",TERMINATED,2010-06,2016-12,2017-03,2012-08-03,2010-07-02,OBSERVATIONAL,,383.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Buffalo,New York,1,,,EDSS|MRI,Quality of Life|Symbol Digit Modality Test,False,
NCT04369898,Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential Diagnosis,A Multi-centric Study of the Combined Sensitivity and Specificity of Cortical Lesions and Central Vein Sign for MS Diagnosis and Differential Diagnosis,COMPLETED,2010-06-01,2022-12,2023-09,2024-01-22,2020-04-30,OBSERVATIONAL,,1051.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis),cortical lesions|leuco-cortical lesions|central vein sign,Switzerland,Basel,,1,Image analysis/ Central vein detection|Image analysis/ Automatic cortical lesion detection,OTHER|OTHER,differentiation between patients with MS and clinically isolated syndrome and patients without MS (specificity)|differentiation between patients with MS and clinically isolated syndrome and patients without MS ((specificity)|specificity of the combination of CLs/ LCLs compared to the one of the current diagnostic criteria for MS diagnosis|sensitivity of the combination of CLs/ LCLs compared to the one of the current diagnostic criteria for MS diagnosis,,False,
NCT03949387,Functional Electrical Stimulation Cycling for Managing Mobility Disability in People with Multiple Sclerosis,Functional Electrical Stimulation Cycling for Managing Mobility Disability in People with Multiple Sclerosis,COMPLETED,2019-10-16,2024-10-28,2024-10-28,2024-12-24,2019-05-14,INTERVENTIONAL,NA,10.0,ACTUAL,University of Ottawa,OTHER,The Ottawa Hospital|Multiple Sclerosis Society of Canada,OTHER|OTHER,Multiple Sclerosis,exercise|multiple sclerosis|mobility,Canada,Ottawa,Ontario,1,FES Cycling Exercise|Passive Leg Cycling,OTHER|OTHER,Change in Walking Speed,Change in Walking Endurance|Change in Agility|Change in Patient-rated Mobility Impairment|Change in Cognitive Performance: Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery|Change in Cognitive Performance: Paced Auditory Serial Addition Test (PASAT)|Change in Fatigue Impact|Change in Fatigue Severity|Change in Pain|Change in Symptoms of Anxiety and Depression|Change in Health-related Quality of Life|Change in Activities of Daily Living,False,
NCT06800404,"""HB-adMSCs for the Treatment of Patients With Multiple Sclerosis""","""A Phase 2, Open Label, Efficacy and Safety Study of Autologous HB-adMSCs for the Treatment of Patients With Multiple Sclerosis""",ENROLLING_BY_INVITATION,2025-05-02,2027-01,2027-01,2025-06-29,2025-01-30,INTERVENTIONAL,PHASE2,10.0,ESTIMATED,Hope Biosciences Research Foundation,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS)|Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Stem Cells|Hope Biosciences|MS|RRMS,United States,Sugar Land,Texas,1,Autologous HB-adMSCs,DRUG,Change from Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument scores,Change from Baseline in Expanded Disability Status Scale (EDSS) scores|Change from Baseline in Patient Health Questionnaire (PHQ-9) scores|Incidence of treatment-emergent Adverse Event (TEAEs)|Incidence of serious Adverse Events (SAEs)|Incidence of AEs of special interest (serious or nonserious)|Clinically significant changes in laboratory value results|Clinically significant changes in vital signs|Clinically significant changes in weight|Clinically significant changes in physical examination results|Clinically significant changes in Multiple Sclerosis concomitant medications,False,
NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2013-03-28,2015-06-16,2018-09-04,2018-11-20,2013-04-24,INTERVENTIONAL,PHASE3,225.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,,Czechia,Brno,,54,Placebo|dimethyl fumarate,DRUG|DRUG,"Total number of new Gadolinium-enhancing lesions over 4 scans at Weeks 12, 16, 20, and 24.|Incidence of treatment-emergent adverse events and serious adverse events",Cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24|Number of new or newly enlarging T2 hyperintense lesions at Week 24 compared with Baseline,False,
NCT06780150,A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS),SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis,RECRUITING,2024-09-26,2026-11-30,2026-11-30,2025-09-02,2025-01-17,OBSERVATIONAL,,349.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,Germany,Aachen,,60,Ocrelizumab,DRUG,Number of Participants Their Level of by Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC,"Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC|Change From Baseline in NfL Protein Levels in Serum|Concentration of NfL Protein Levels in Serum|Correlation Between NfL Protein Levels in Serum With MS Relapse|Correlation Between NfL Protein Levels in Serum With Expanded Disability Status Scale (EDSS)|Correlation Between NfL Protein Levels in Serum With Previous MS Disease Modifying Therapy (DMT)|Correlation Between NfL Protein Levels in Serum With NfL Confounder - Serum Creatinine|Correlation Between NfL Protein Levels in Serum With NfL Confounder - Co-morbidities|Correlation Between NfL Protein Levels in Serum With NfL Confounder - Age|Correlation Between NfL Protein Levels in Serum With NfL Confounder - Body Mass Index [BMI]|Correlation Between NfL Protein Levels in Serum With Magnetic Resonance Imaging (MRI) Lesion Count|Correlation Between NfL Protein Levels in Serum With Glial Fibrillary Acidic Protein (GFAP) Levels|Correlation Between NfL Protein Levels in Serum With No Evidence of Disease Activity-3 (NEDA-3)|Change From Baseline in Participant Satisfaction With Ocrelizumab SC Assessed Using Treatment Satisfaction Questionnaire for Medication (TSQM) 1.4|Number of Participants by Their Level of Satisfaction With Ocrelizumab SC Assessed by Physician Survey|Annualized Relapse Rate|Percentage of Participants With Progression Independent of Relapse Activity (PIRA)|Number of Participants With Non-serious Adverse Events (nsAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)",False,
NCT03029897,E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis,Impact of E-reporting by Patients With Relapsing-remitting Multiple Sclerosis on the Reporting of Adverse Drug Reactions in France: a Randomized Controlled Trial.,COMPLETED,2017-05-05,2019-04-24,2019-04-24,2019-07-02,2017-01-24,INTERVENTIONAL,NA,161.0,ACTUAL,"University Hospital, Caen",OTHER,,,Multiple Sclerosis,,France,Caen,,1,My eReport France,OTHER,number of reports of adverse drug reactions,,False,
NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,COMPLETED,2021-05-11,2021-10-21,2021-10-21,2022-10-24,2020-12-21,OBSERVATIONAL,,2.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,Relapsing forms of Multiple Sclerosis|RMS|Ocrelizumab|Ofatumumab|TIMIOS,United States,Lutherville,Maryland,2,Ocrelizumab|Ofatumumab,DRUG|DRUG,"Time spent by Healthcare Providers (staff) in the preparation, administration and post-treatment observation of Ocrelizumab and Ofatumumab","Healthcare resources used, in terms of consumables in the treatment preparation and administration of Ocrelizumab and Ofatumumab|Cost of staff and consumables used in the treatment preparation, administration and post-treatment observation of Ocrelizumab and Ofatumumab|Healthcare resources used, in terms of staff time in managing the adverse events occurred during the administration and post treatment observation of Ocrelizumab and Ofatumumab|Healthcare resources used, in terms of consumables in managing the adverse events occurred during the administration and post treatment observation of Ocrelizumab and Ofatumumab|Indirect cost as assessed by the Work Productivity and Activity Impairment Questionnaire: Multiple sclerosis (WPAI:MS|Indirect cost as assessed by the Work Productivity and Activity Impairment Questionnaire: Caregiver (WPAI:CG)",False,
NCT07139743,Obe-cel in Refractory Progressive Forms of Multiple Sclerosis,"A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis",RECRUITING,2025-08-04,2029-08-15,2029-08-15,2025-09-04,2025-08-24,INTERVENTIONAL,PHASE1,18.0,ESTIMATED,Autolus Limited,INDUSTRY,,,Progressive Multiple Sclerosis,Multiple sclerosis|Refractory multiple sclerosis|Progressive multiple sclerosis|Obecabtagene autoleucel|Obe-cel,United Kingdom,London,,1,Obecabtagene autoleucel (obe-cel),BIOLOGICAL,To evaluate the tolerability of obe cel in participants with refractory forms of progressive multiple sclerosis (PMS)|To evaluate the safety of obe-cel in participants with refractory forms of progressive multiple sclerosis (PMS),To evaluate the preliminary efficacy of obe-cel in participants with refractory forms of PMS using Expanded Disability Status Scale (EDSS) - Change from baseline in EDSS|To evaluate the preliminary efficacy of obe-cel in participants with refractory forms of PMS using Timed 25-foot Walk Test (T25FWT).|To evaluate the preliminary efficacy of obe-cel in participants with refractory forms of PMS using 9-hole Peg Test (9-HPT)|To evaluate the preliminary efficacy of obe-cel in participants with refractory forms of PMS using Symbol Digit Modalities Test (SDMT),False,
NCT04530318,Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis,Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis,RECRUITING,2020-01-27,2025-06,2025-06,2024-03-27,2020-08-28,INTERVENTIONAL,PHASE2,45.0,ESTIMATED,Judit Pich,OTHER,,,Relapsing-Remitting Multiple Sclerosis,,Spain,L'Hospitalet de Llobregat,Barcelona,5,Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|Placebo,OTHER|OTHER,"Changes from baseline in the number of CUA lesion (mean number of the sum at week 12, 18 and 24).|Proportion of patients with any Grade 3 -4 adverse events related to product administration during the study period.|Proportion of patients with any Grade 3 -4 adverse events related to study product.","Proportion of patients with any Grade 3 -4 adverse events related to study product.|Proportion of patients with any SAE events related to study product.|Proportion of patients with at least one MS relapse during the study period.|Total number of MS relapse at 24 weeks.|Time to first MS relapse during the study period.|Changes from baseline in the disability progression by Expanded Disability Status Scale (EDSS) at week 24.|Changes from baseline in the disability progression by Multiple Sclerosis Functional Composite (MSFC) at week 24.|Changes from baseline in the number of CUA lesion at week 24.|Proportion of patients free from CUA lesion, gadolinium-enhancing lesions on T1 MRI and new or enlarged lesions on T2-MRI thought the 24 weeks of study.|Changes from baseline in the number of Gd-enhancing T1 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24.|Changes from baseline in number of new or enlarging T2 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24.|Changes from baseline in brain global, white and gray matter volume and cervical cord volume on MRI at 24 weeks.|Changes from baseline in the number of cortical lesions on MRI at 24 weeks.|Changes from baseline in MR measurements of diffuse damage of brain tissue by MTR at 24 weeks|Changes from baseline in MR measurements of relaxation times of T1 and T2 by MTR at 24 weeks.|Changes in DTI measures as mean diffusivity (MD), fractional anisotropy (FA), radial diffusivity (Dr) and axial diffusivity (Da) at 24 weeks.|Changes from baseline in cytokine production (including IFNgamma, IL-17, IL-4 and IL-10) in response to specific peptide stimulation in peripheral blood mononuclear cells (PBMCs) culture supernatants at 12 and 24 weeks.|Changes from baseline in T cell proliferation to immunogenic peptides at 12 and 24 weeks.|Changes from baseline in immune cell subsets in PBMCs including PBMC subtypes, T lymphocytes subpopulations and Treg subsets, CD4 and CD8 GM-CSF 'encephalitogenic' T cells and T cell subtypes by activation memory phenotype at 12 and 24 weeks.",False,
NCT02461459,Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC),Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC),ACTIVE_NOT_RECRUITING,2015-05,2025-12,2026-12,2024-10-26,2015-06-03,OBSERVATIONAL,,205.0,ACTUAL,Boston Children's Hospital,OTHER,National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance|National Center for Advancing Translational Sciences (NCATS)|Office of Rare Diseases (ORD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH|NIH|OTHER|NIH|NIH|NIH,Tuberous Sclerosis|Autism Disorder|Intellectual Disability,Tuberous Sclerosis Complex|TSC|Autism|ASD|Intellectual Disability|ID|MRI|EEG,United States,Birmingham,Alabama,6,,,Change in ADOS-2 scores at end of study|Change in SBIS-5 scores or Mullen Scales of Early Learning (MSEL) at end of study|Change in Fractional anisotropy (FA) at 12 months|Change in fractional anisotropy (FA) at 24 months|Change in radial diffusivity (RD) at 12 months|Change in radial diffusivity (RD) at 24 months|Change in mean diffusivity (MD) of cerebellar fascicles at 12 months|Change in mean diffusivity (MD) of cerebellar fascicles at 24 months|Change in axial diffusivity (AD) at 12 months|Change in axial diffusivity (AD) at 24 months,,False,
NCT04217564,Nutritional Counselling for Patients at Kasr AlAiny Multiple Sclerosis Clinic: an Intervention Study,Nutritional Counselling for Patients at Kasr AlAiny Multiple Sclerosis Clinic: an Intervention Study,COMPLETED,2020-01-01,2020-03-18,2020-06-30,2020-07-22,2020-01-03,INTERVENTIONAL,NA,120.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,,Egypt,Cairo,,1,Nutritional counselling,BEHAVIORAL,Change of quality of life of MS patients: 36-SF|Change of nutritional status of MS patients,Change of the disease progression.,False,
NCT00870155,A Study for Patients With Multiple Sclerosis,An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis,TERMINATED,2007-02,2009-09,2009-09,2010-09-09,2009-03-27,INTERVENTIONAL,PHASE2|PHASE3,546.0,ESTIMATED,Eli Lilly and Company,INDUSTRY,BioMS Technology Corp.,INDUSTRY,Secondary Progressive Multiple Sclerosis,,Canada,Toronto,Ontario,10,dirucotide,DRUG,"To assess clinically significant effects of MBP8298 synthetic peptide in all subjects by collecting adverse event, ECG, laboratory, and physical exam outcomes",Degree of change in Kurtzke Expended Disability Status (EDSS)|Brain atrophy by MRI|Activity analysis of T2 and Gadolinium enhancing lesions|Lesion burden|Degree of change in MS Functional Composite Index (MSFC)|Relapse rates|Quality of life as measured by Short Form 36 (SF-36) or MSQoL54,False,
NCT01023074,Effects of Training on Central Auditory Function in Multiple Sclerosis,Effects of Training on Central Auditory Function in Multiple Sclerosis,COMPLETED,2007-10,2011-06,2011-06,2018-10-09,2009-12-02,INTERVENTIONAL,NA,52.0,ACTUAL,VA Office of Research and Development,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,MS|CAP,United States,Portland,Oregon,1,Auditory training|MS: Control Activity,BEHAVIORAL|OTHER,Electrophysiological Auditory Test,Neural Magnetic Resonance Imaging (MRI)|SCAN-A: Competing Words Test,True,2015-03-17
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,"An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects",COMPLETED,2009-01,2010-07,2010-10,2014-06-03,2009-01-23,INTERVENTIONAL,PHASE3,95.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Gilbert,Arizona,16,single-use autoinjector with a prefilled liquid Avonex syringe|Avonex prefilled syringe via manual IM injection|BG9418 (interferon beta-1a),DEVICE|DEVICE|DRUG,Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector,,True,2011-08-09
NCT01718678,Effect of Melatonin on Multiple Sclerosis Related Fatigue,Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis,COMPLETED,2012-05,2012-10,2012-10,2012-10-31,2012-10-31,INTERVENTIONAL,PHASE2,44.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,,,Fatigue,Multiple sclerosis|Melatonin|Fatigue|Quality of life,Iran,Isfahan,Isfahan,1,Melatonin|Placebo,DRUG|DRUG,Fatigue,Quality Of Life,False,
NCT04100525,Intervention for Employed Women With Multiple Sclerosis,Neuropsychological Feedback Style and Case Management to Improve Intervention Outcome for Employed Women With Multiple Sclerosis: a Randomized Clinical Trial,UNKNOWN,2016-04,2020-02,2022-01,2021-02-18,2019-09-24,INTERVENTIONAL,NA,89.0,ACTUAL,"Holy Name Medical Center, Inc.",OTHER,Women United in Philanthropy (WUIP),UNKNOWN,Multiple Sclerosis,Employment|Vocational Rehabilitation,,,,0,Neuropsychological testing intervention plus follow up,BEHAVIORAL,Employment,Adherence to Recommendations,False,
NCT00656825,Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers,"Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers.",COMPLETED,2007-03,2007-06,2007-06,2008-11-05,2008-04-11,INTERVENTIONAL,PHASE1,36.0,ACTUAL,ISDIN,INDUSTRY,Digna Biotech S.L.,INDUSTRY,Healthy,P144|TGF-β1|Healthy volunteers|Cutaneous tolerability|Skin fibrosis|systemic scleroderma|systemic sclerosis|Safety,Spain,Madrid,Madrid,2,P144 cream|P144 cream|P144 cream|Placebo,DRUG|DRUG|DRUG|DRUG,Tolerability evaluation was performed through the specific cutaneous tolerability visual scale of Frosch and Kligman.,"Safety assessment was carried out by studying vital signs, physical examination, by performing laboratory tests, electrocardiogram and reporting any adverse events experienced. Bioavailability of P 144 in serum.",False,
NCT03679468,Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation,"Improving Cognition in People With Progressive Multiple Sclerosis: A Multi-Arm, Randomized, Blinded, Sham-Controlled Trial of Cognitive Rehabilitation and Aerobic Exercise.",COMPLETED,2019-03-18,2022-10-30,2023-02-03,2023-11-08,2018-09-20,INTERVENTIONAL,NA,309.0,ACTUAL,Sunnybrook Health Sciences Centre,OTHER,"University of Florence|Fondazione Italiana Sclerosi Multipla|University College, London|Kessler Foundation|University of Alabama at Birmingham|University of Southern Denmark|Hasselt University|University of Plymouth|Universita degli Studi di Genova|Unity Health Toronto|Ospedale San Raffaele",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,"Multiple Sclerosis, Primary Progressive|Cognitive Impairment",,Canada,Toronto,Ontario,1,Cognitive Rehabilitation|Sham Exercise|Sham Cognitive Rehabilitation|Aerobic Exercise,OTHER|OTHER|OTHER|OTHER,Change from baseline cognitive Information processing speed at 12 weeks and 6 months,"Change from baseline cognitive verbal memory at 12 weeks and 6 months|Change from baseline cognitive visual memory at 12 weeks and 6 months|Change from baseline anxiety & depression, at 12 weeks and 6 months|Change from baseline depression, at 12 weeks and 6 months|Change from baseline fatigue, at 12 weeks and 6 months|Change from baseline perceived deficits, at 12 weeks and 6 months|Change from baseline subjective impact of walking, at 12 weeks and 6 months|Change from baseline impact of Multiple Sclerosis, at 12 weeks and 6 months|Change from baseline quality of life, at 12 weeks and 6 months|Change from baseline global function, at 12 weeks and 6 months",False,
NCT03569618,Digital Cognition in Multiple Sclerosis,Effect of a Digital Therapeutic on Processing Speed in Adults With Multiple Sclerosis,COMPLETED,2018-04-01,2018-11-01,2019-01-15,2020-10-26,2018-06-26,INTERVENTIONAL,NA,44.0,ACTUAL,"University of California, San Francisco",OTHER,"Akili Interactive Labs, Inc.",INDUSTRY,Multiple Sclerosis|Cognitive Decline,,United States,San Francisco,California,1,Tablet-based Game,DEVICE,"Change in Processing Speed After 6 Weeks of Treatment With a Digital Therapeutic 'Game 1', vs. 'Game 2'.",Number of Participants With at Least 4-point Increase in SDMT Above Their Baseline Value 8 Weeks After Treatment,True,2020-10-26
NCT05991297,Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis,Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis,UNKNOWN,2023-06-01,2024-02-01,2024-06-01,2023-08-14,2023-08-14,INTERVENTIONAL,NA,40.0,ACTUAL,Nermin Çalışır,OTHER,Bursa Sevket Yilmaz Training and Research Hospital,OTHER_GOV,MS (Multiple Sclerosis),deep sensory assisted rehabilitation|MS gait and balance|deep sensory walkway,Turkey (Türkiye),Bursa,Yildirim,2,Deep sensory assisted rehabilitation|classical rehabilitation,OTHER|OTHER,Multipl sclerosis quality of life-54(MSQOL-54)|Multipl sclerosis quality of life-54(MSQOL-54)|MiniBest test|MiniBest test|10 meter walking time|10 meter walking time|Nottingham Extended Activities of Daily Living Scale|Nottingham Extended Activities of Daily Living Scale|Functional Ambulation Classification|Functional Ambulation Classification|Fatigue Severity Score|Fatigue Severity Score|DN4(Douleur Neuropathique 4 Questions)|DN4(Douleur Neuropathique 4 Questions)|MSWS-12( MS walking scale-12)|MSWS-12( MS walking scale-12)|FES-1: (Falls Efficay Scale-1)|FES-1: (Falls Efficay Scale-1),,False,
NCT05162638,Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation,Analysis of Lymphatic Fluid From the Thoracic Duct of Healthy People and People With Multiple Sclerosis (MS) Before and After Ofatumumab Treatment,ENROLLING_BY_INVITATION,2022-04-19,2025-12,2027-01,2025-08-19,2021-12-17,INTERVENTIONAL,NA,24.0,ESTIMATED,University of Pennsylvania,OTHER,Novartis Pharmaceuticals|Novartis Institutes for BioMedical Research,INDUSTRY|OTHER,Multiple Sclerosis|Healthy,multiple sclerosis|thoracic duct,United States,Philadelphia,Pennsylvania,1,thoracic duct cannulation,PROCEDURE,Safety and Tolerability|B Cells,Immune cell profiles (MS and healthy controls)|Immune cell profiles (ofatumumab),False,
NCT01097538,Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS),Total Body Recumbent Stepper Training in Progressive MS: An Alternative Training Therapy for Patients With Impaired Mobility,COMPLETED,2010-04,2011-06,2011-08,2011-08-12,2010-04-01,INTERVENTIONAL,NA,10.0,ACTUAL,"Hicks, Audrey, Ph.D.",INDIV,,,Multiple Sclerosis,exercise|rehabilitation|progressive multiple sclerosis|functional ability|fatigue|quality of life,Canada,Hamilton,Ontario,1,Body-weight supported treadmill training|Total body recumbent stepper training,OTHER|OTHER,Safety,Expanded Disability Status Scale (EDSS) -neurologic function|Multiple Sclerosis Functional Composite (MSFC)-functional ability|Modified Fatigue Impact Scale (MFIS) -fatigue|Multiple Sclerosis Quality of Life-54 -quality of life questionnaire|Multiple Sclerosis Self-Efficacy Scale (MSSE) -ability to manage MS symptoms|Participant Satisfaction with Equipment,False,
NCT05123443,Longitudinal Assessment of Iron Rims in MS Lesions,Longitudinal Assessment of Iron Rims in White Matter MS Lesions as a Marker of Disability,UNKNOWN,2022-01-01,2022-06-30,2022-09-30,2021-11-17,2021-11-17,OBSERVATIONAL,,100.0,ESTIMATED,Nottingham University Hospitals NHS Trust,OTHER,Johns Hopkins University,OTHER,Multiple Sclerosis,,,,,0,Blood sample provided|7-T MRI scan,BIOLOGICAL|DIAGNOSTIC_TEST,Cross-sectional: To identify gene variants or genetic network predictors of chronic perilesional inflammation in patients classified by the presence of rim lesions on brain MRI.|Longitudinal: To assess whether the presence and frequency of iron rim lesions in MS patients is associated with a more severe disability or disease course by comparing clinical and cognitive outcomes.,Cross-sectional: To integrate genetic risk variant information.|Longitudinal: To assess long-term evolution of iron rim presence and frequency from T2* MRI scans of MS patients.,False,
NCT00137176,EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,COMPLETED,2004-10,2007-10,2008-10,2009-06-23,2005-08-29,INTERVENTIONAL,NA,30.0,ESTIMATED,"University of North Carolina, Chapel Hill",OTHER,,,Multiple Sclerosis,Clinically Isolated Syndrome,United States,Chapel Hill,North Carolina,1,Rebif,DRUG,To determine the effects of IFNb-1a plus atorvastatin versus IFNb-1a plus placebo on the gene expression in peripheral blood mononuclear cells (PBMCs) derived from patients with isolated clinical syndrome suggestive of MS|To identify markers of therapeutic response and to predict patients' clinical response based on their in vitro response to this combination therapy measured by the gene expression levels in activated PBMCs,evaluate safety and efficacy of combination therapy with Rebif and Lipitor in patients with clinicayy isolated syndrome suggestive of MS.,False,
NCT05747040,Pain in Neurorehabilitation Through Wearable Devices: an Exploratory Study,Pain Assessment in Neurorehabilitation Through Physiological Signals Recorded by Wearable Devices in Real-world Context: an Exploratory Study,UNKNOWN,2023-02-01,2023-10-01,2023-10-01,2023-02-28,2023-02-28,INTERVENTIONAL,NA,15.0,ESTIMATED,Azienda Usl di Bologna,OTHER_GOV,,,Pain|Multiple Sclerosis,Pain assessment|physiological signals|wearable sensors|artificial intelligence|machine learning,Italy,Bologna,,1,monitoring,DIAGNOSTIC_TEST,Number of registrations,regression model - intensity of pain,False,
NCT04843774,Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),COMPLETED,2021-04-20,2023-04-18,2023-04-18,2023-11-08,2021-04-14,OBSERVATIONAL,,64.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,SARS-CoV-2 Vaccine|Ocrelizumab,United States,Denver,Colorado,2,SARS-COV-2 mRNA Vaccine,DRUG,Anti-SARS-CoV-2 S Titer Levels|Anti-SARS-CoV-2 S Titer Levels|Anti-SARS-CoV-2 S Titer Levels|Number of participants with a fold rise of serum anti-SARS-CoV-2 S titers|Number of participants with a fold rise of serum anti-SARS-CoV-2 S titers|Number of participants with a fold rise of serum anti-SARS-CoV-2 S titers|T-Cell Response|T-Cell Response|T-Cell Response,SARS-CoV-2 anti-S1 and anti-Receptor Binding Domain (RBD) binding antibody levels|SARS-CoV-2 anti-S1 and anti-Receptor Binding Domain (RBD) binding antibody levels,False,
NCT04602390,Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis,A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis,COMPLETED,2020-11-06,2024-04-23,2024-04-23,2025-05-31,2020-10-26,INTERVENTIONAL,PHASE1,34.0,ACTUAL,Anokion SA,INDUSTRY,,,Multiple Sclerosis (MS)|Relapsing Remitting Multiple Sclerosis,Autoimmune|Multiple Sclerosis (MS)|Relapsing Remitting MS,United States,Cullman,Alabama,15,ANK-700|Placebo,DRUG|DRUG,Number of Participants With Treatment-emergent Adverse Events (TEAEs),CMAX|AUC Last,True,2025-05-31
NCT00477113,TYSABRI Global Observational Program in Safety,TYGRIS: TYSABRI® Global Observational Program in Safety,COMPLETED,2007-01,2015-05,2015-05,2015-06-22,2007-05-22,OBSERVATIONAL,,2207.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,natalizumab|MS|Tysabri|Multiple Sclerosis|TYGRIS,United States,Kansas City,Missouri,1,,,"Number of participants with serious infections, malignancies, and other SAEs",,False,
NCT04452760,"Effects of Ten-Weeks Progressive Resistance Training on Neuromuscular Performance, Mobility, Heart Rate Variability and Sleep Quality in Persons With Multiple Sclerosis","Effects of Ten-Weeks Progressive Resistance Training on Neuromuscular Performance, Mobility, Heart Rate Variability and Sleep Quality in Persons With Multiple Sclerosis",COMPLETED,2020-07-15,2020-10-01,2020-10-05,2020-10-08,2020-06-30,INTERVENTIONAL,NA,36.0,ACTUAL,Universidad Católica San Antonio de Murcia,OTHER,,,Multiple Sclerosis,neurological disorders|resistance training|strength training|sleep quality|neuromuscular performance|functional capacity,Spain,Murcia,,1,Physical exercise|Testing sessions,OTHER|OTHER,Maximal Voluntary Isometric Contraction of Knee Extension|Maximal Voluntary Isometric Contraction of Knee Extension|Rate of Force Development|Rate of Force Development|Central Activation Ratio|Central Activation Ratio|Spasticity|Spasticity,Walking speed|Walking speed|Static Balance|Static Balance|Functional capacity|Functional capacity|Heart Rate Variability|Heart Rate Variability|Sleep Quality|Sleep Quality,False,
NCT02671682,Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis,Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome,COMPLETED,2016-02-26,2019-01-03,2019-01-25,2019-09-11,2016-02-02,INTERVENTIONAL,NA,61.0,ACTUAL,"Albert Christian Ludolph, Prof.",OTHER,,,Multiple Sclerosis|Clinically Isolated Syndrome,Immunoadsorption|Plasmapheresis,Germany,Ulm,Baden-Wurttemberg,1,Immunoadsorption|Plasmapheresis,PROCEDURE|PROCEDURE,Multiple Sclerosis Functional Composite (MSFC),"Expanded Disability Status Scale (EDSS)|EuroQol (EQ5D-5L)|Response Rate|Vision|Visually Evoked Potentials (VEP; P100 latency)|Somatosensory Evoked Potentials (SEP; Medianus and Tibialis; N20-, P40-latency)|Thickness of Retinal Nerve Fiber Layer (RNFL) in Optical Coherence Tomography (OCT)|Verbaler Lern- und Merkfähigkeitstest (VLMT) score|MSFC|Thickness of Ganglion Cell Layer (GCL) in OCT|Symbol Digit Modalities Test (SDMT) score",False,
NCT03254680,Turmeric as Treatment in Epilepsy,Turmeric as Treatment in Epilepsy,WITHDRAWN,2018-03,2018-11,2018-11,2018-04-30,2017-08-18,INTERVENTIONAL,NA,0.0,ACTUAL,NYU Langone Health,OTHER,,,Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome|Tuberous Sclerosis|Focal Seizures,Turmeric Oil|antiseizure medications|ar-turmerone,United States,New York,New York,1,Turmeric,DIETARY_SUPPLEMENT,Number of epilepsy patients enrolled in study,Number of epilepsy seizures post epilepsy treatment with turmeric,False,
NCT04042363,Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis,Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis,UNKNOWN,2019-07-10,2021-07,2022-07,2019-08-28,2019-08-01,INTERVENTIONAL,NA,45.0,ESTIMATED,Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,OTHER,Fondation ARSEP|APHP,UNKNOWN|OTHER,Multiple Sclerosis|Optic Neuritis,multiple sclerosis|optic neuritis|transorbital stimulation|remyelination|nervous system disease|peripheral nervous system disease|optic nerve disease|adaptive optic,France,Paris,,2,Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation,DEVICE|DEVICE,P100 latency (VEP) after treatment,Change of P100 amplitude (VEP) after treatment|Change of P100 latency and amplitude (VEP) after treatment|Evolution of macular volume after treatment|Change of mean and temporal Retinal Nerve Fiber Layer (RNFL) thickness and average thickness of macular ganglion cell layer after treatment|Change of average thickness of macular ganglion cell layer after treatment|Change of mean deflection of visual field 24-2 after treatment|Occurrence of adverse events related or not to the stimulation,False,
NCT01335633,Psychometric Validation of Cognitive Endpoints,Psychometric Validation of Cognitive Endpoints,COMPLETED,2011-03,2011-08,2011-08,2012-05-03,2011-04-14,OBSERVATIONAL,,60.0,ACTUAL,Kessler Foundation,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,MS|Neuropsychological tests,United States,Teaneck,New Jersey,4,,,,,False,
NCT02310048,Comparative Oral Bioavailability Study of MT-1303,"A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects",COMPLETED,2014-11,2015-03,2015-03,2015-03-17,2014-12-05,INTERVENTIONAL,PHASE1,34.0,ACTUAL,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,United Kingdom,Leeds,,1,MT-1303-FormA|MT-1303-FormB,DRUG|DRUG,Area under the concentration-time curve(AUC) .,Peak drug concentration (Cmax) of MT-1303|Time to reach peak concentration (Tmax) of MT-1303|Half-life(t1/2.) of MT-1303,False,
NCT06705608,Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study,Fingolimod and Risk of Skin Cancer Among Individuals with Multiple Sclerosis: a Population-based Cohort Study,COMPLETED,2003-01-01,2020-12-31,2020-12-31,2024-11-26,2024-11-26,OBSERVATIONAL,,4000.0,ESTIMATED,University of British Columbia,OTHER,,,"Multiple Sclerosis|Skin Cancer|Skin Cancer Melanoma|Skin Cancers - Basal Cell Carcinoma|Skin Cancer, Squamous Cell|Multiple Sclerosis (MS) - Relapsing-remitting",multiple sclerosis and skin cancer|fingolimod|disease modifying therapy|FTY720|fingolimod and skin cancer,,,,0,Fingolimod|Natalizumab|Dimethyl fumarate (DMF)|Alemtuzumab|Teriflunomide,DRUG|DRUG|DRUG|DRUG|DRUG,Number of participants who developed skin cancer|Time to development of skin cancer,,False,
NCT04171908,Semi-inmersive Virtual Reality on Upper Limb in Multiple Sclerosis,"Effects of a Semi-inmersive Virtual Reality Training Program on Muscle Strength, Coordination, Fatigue, Functionality and Quality of Life in Patients With Multiple Sclerosis",COMPLETED,2019-11-12,2023-03-11,2023-04-11,2023-06-23,2019-11-21,INTERVENTIONAL,NA,30.0,ACTUAL,Universidad Rey Juan Carlos,OTHER,,,Multiple Sclerosis|Treatment Adherence|Upper Extremity Paresis,,Spain,Alcorcón,Madrid,1,Conventional therapy|semi-inversive tech,OTHER|OTHER,Jamar|Box and blocks|The Purdue Pegboard Test|Nine Hole Peg Test,The Client Satisfaction Questionnaire|Adherence,False,
NCT06122740,Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36,Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36 (MAM-36),COMPLETED,2016-07-15,2017-01-25,2017-06-30,2024-02-06,2023-11-08,OBSERVATIONAL,,250.0,ACTUAL,Istanbul Medeniyet University,OTHER,,,Parkinson Disease|Multiple Sclerosis|Stroke|Upper Extremity Problem,,,,,0,Turkish Validity and Reliability of The MAM-36 Scale,OTHER,Manual Ability Measure-36|Disability of Arm Shoulder and Hand,,False,
NCT01649050,Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis,"A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis",WITHDRAWN,2016-10,2018-03,2018-03,2017-04-20,2012-07-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Muscle Spasticity Due to Multiple Sclerosis,Spasticity|Multiple Sclerosis,,,,0,BGG492|Placebo,DRUG|DRUG,Change in spasticity NRS score from baseline to 5 weeks|PGIC score at 5 weeks,Change from baseline to 5 weeks in Ashworth spasticity score|Safety and tolerability,False,
NCT03979391,Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome,"Detecting Oligoclonal Bands Through Isoelectric Focusing of Tears in Children With Radiologically Isolated Syndrome or Clinically Isolated Syndrome: a Diagnostic, Prospective, Multicentric Study With a 2-year Longitudinal Follow-up",RECRUITING,2019-09-26,2024-11-26,2024-11-26,2023-09-13,2019-06-07,INTERVENTIONAL,NA,20.0,ESTIMATED,Lille Catholic University,OTHER,,,Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Multiple Sclerosis in Children,Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Multiple Sclerosis|Children|Tear analysis,France,Lomme,,1,Tear collection and lumbar punction,DIAGNOSTIC_TEST,Sensitivity of tears analysis compared to lumbar punction analysis for the diagnosis of CIS and RIS|Specificity of tears analysis compared to lumbar punction analysis for the diagnosis of CIS and RIS|Positive predictive value of tears analysis compared to lumbar punction analysis for the diagnosis of CIS and RIS|Negative predictive value of tears analysis compared to lumbar punction analysis for the diagnosis of CIS and RIS,Proportion of patients with OCBs in tears,False,
NCT01371760,BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis),Randomized Multi-centered Study for Evaluating the Efficacy and Safety of Angioplastic Surgery of the Extracranial Veins in the Treatment of Multiple Sclerosis. Studio Randomizzato Multicentrico Per la Valutazione Dell'Efficacia e Sicurezza Dell'Intervento di Disostruzione Delle Vene Extracraniche Nel Trattamento Della Sclerosi Multipla,COMPLETED,2012-08,2014-12,2015-12,2015-12-17,2011-06-13,INTERVENTIONAL,NA,212.0,ACTUAL,S. Anna Hospital,OTHER,Regione Emilia-Romagna,OTHER,Multiple Sclerosis|Venous Insufficiency,Multiple sclerosis|Chronic cerebrospinal venous insufficiency|Percutaneous Transluminal Angioplasty (PTA)|Internal jugular vein|Azygous vein,Italy,Ferrara,Fe,2,Venous PTA|Catheter Venography,PROCEDURE|OTHER,Clinical parameters in an integrated functional score|MRI outcome measures: T1Gad active lesion.T2 lesion volume MRI evaluation.,EDSS|Chronic fatigue|Cognitive function|Annualized relapse rate|Patency rate|Emotional status|Memory and cognition|Overactive Bladder,False,
NCT00097760,Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis,Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA),COMPLETED,2003-06,2004-03,2004-03,2009-06-18,2004-12-01,INTERVENTIONAL,PHASE2,110.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|MS,,,,0,Natalizumab|Natalizumab|Placebo,DRUG|DRUG|DRUG,Rate of development of new active lesions on MRI scans.,Incidence and severity of adverse events.,False,
NCT00097331,Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis,"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2004-09,2006-07,2006-07,2015-04-13,2004-11-23,INTERVENTIONAL,PHASE2,261.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|relapsing|remitting|Relapsing-Remitting MS (RRMS),Belgium,Brussels,,11,SB683699,DRUG,Number of new gadolinium-enhancing lesions on monthly MRI scans,"Number of other lesion types on MRI|Number of relapses during treatment|Expanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC)|Circulating lymphocyte and neutrophil counts|Health Outcomes: MSIS-29, Employment status",False,
NCT01490502,Vitamin D Supplementation in Multiple Sclerosis,A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis,COMPLETED,2012-03,2021-05-15,2021-05-15,2022-09-28,2011-12-13,INTERVENTIONAL,PHASE3,172.0,ACTUAL,Johns Hopkins University,OTHER,"Oregon Health and Science University|University of California, San Francisco|Washington University School of Medicine|Icahn School of Medicine at Mount Sinai|University of Pennsylvania|Yale University|The Cleveland Clinic|University of Rochester|Stanford University|University of Virginia|Swedish Medical Center|Anne Arundel Health System Research Institute|Columbia University|University of Massachusetts, Worcester|Dignity Health",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Relapsing Remitting Multiple Sclerosis,,United States,Carmichael,California,16,Vitamin D3,DRUG,Proportion of Subjects That Experience a Relapse,Annualized Relapse Rate|Number of Relapses Requiring Treatment|Number of New or Enlarging T2 Lesions|Proportion of Participants With Sustained Disability Progression|Change in Multiple Sclerosis Functional Composite (MSFC) Score|Change in Low-contrast Acuity|Change in Health-related Quality of Life|Change in Brain Parenchymal Volume|Change in Normalized Gray Matter Volume|Change in Cortical Thickness|Development of Hypercalcemia|Development of Nephrolithiasis,True,2022-09-28
NCT03006900,Multiple Sclerosis and Pilates,Determining the Impact of a Pilates Program in Multiple Sclerosis,COMPLETED,2016-12,2017-12,2017-12,2018-06-28,2016-12-30,INTERVENTIONAL,NA,30.0,ACTUAL,University of Saskatchewan,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,,Canada,Saskatoon,Saskatchewan,1,Pilates|Massage,OTHER|OTHER,Change from baseline in distance during the 6-minute walk test,Change from baseline in balance score for the Fullerton Advanced Balance Scale|Change in sit and reach test score for flexibility|Change from baseline in timed up and go test score|Change from baseline in physical activity level|Change from baseline in maximal isometric knee extension strength|Change from baseline in ability to recruit motor units|Change from baseline in ability to recruit motor units in a fatigued state|Change from baseline in trunk muscular endurance|Change from baseline in lean tissue mass|Change from baseline in fat mass|Change from baseline for score from the MS International Quality of Life questionnaire|Change from baseline in adverse events,False,
NCT02137707,Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya,"An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years",COMPLETED,2012-11,2017-11,2018-10-30,2018-11-09,2014-05-14,OBSERVATIONAL,,135.0,ACTUAL,McGill University,OTHER,Novartis,INDUSTRY,Multiple Sclerosis-Relapsing-Remitting,"Multiple Sclerosis, Relapsing-Remitting|Gilenya|Fingolimod",Canada,Vancouver,British Columbia,6,Gilenya,DRUG,Determination of disease progression of subjects treated with Gilenya over 2 years,Change in cognitive function in patients treated with Gilenya|Changes in biologic measures in patients treated with Gilenya|Safety and tolerability of Gilenya therapy will be assessed,False,
NCT06600971,The Effect of Self Acupressure in Patients With Multiple Sclerosis,The Effect of Self Acupressure on Fatigue and Sleep Quality in Patients With Multiple Sclerosis,COMPLETED,2024-03-18,2024-07-18,2024-09-03,2024-10-16,2024-09-19,INTERVENTIONAL,NA,40.0,ACTUAL,Yuzuncu Yıl University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Acupressure|Fatigue|Sleep Quality,Turkey (Türkiye),Van,,1,acupressure application,OTHER,Fatigue Severity Scale|Richard-Campbell Sleep Scale,,False,
NCT01453764,Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis,"An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis",WITHDRAWN,2016-04,2018-12,2019-04,2017-09-01,2011-10-18,INTERVENTIONAL,NA,0.0,ACTUAL,Ageless Regenerative Institute,INDUSTRY,,,Multiple Sclerosis|Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Nervous System Diseases,,United States,Aventura,Florida,1,Harvesting and Implantation of SVF,PROCEDURE,Clinical improvement in disability score compared to baseline|Number of patients with adverse events|Clinical improvement in disability score compared to baseline,MS disease activity measured by the number of Gd-enhancing brain MRI lesions|Reduced number of relapses or freedom from progression of disease|Reduced number of relapses or freedom from progression of disease|MS disease activity measured by the number of Gd-enhancing brain MRI lesions,False,
NCT01079975,To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis,Predicting Factors for Depression in Patients With MS in Argentina,COMPLETED,2008-08,2010-10,2012-07,2014-07-31,2010-03-03,OBSERVATIONAL,,301.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Depression,Argentina,Capital Federal,Buenos Aires,1,,,Apparition and/or modification of depression symptoms through the agreed assessments,Proportion of subjects that developed depression symptoms during the study compared to the total population of subjects enrolled in the study,False,
NCT03319732,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005),COMPLETED,2018-04-03,2020-01-27,2020-06-11,2022-08-09,2017-10-24,INTERVENTIONAL,PHASE3,323.0,ACTUAL,"RVL Pharmaceuticals, Inc.",INDUSTRY,Osmotica Pharmaceutical US LLC,INDUSTRY,"Multiple Sclerosis|Spasticity, Muscle",,United States,Fresno,California,1,Arbaclofen,DRUG,"Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results",Patient Global Impression of Change (PGIC)|Total Numeric-transformed Modified Ashworth Scale Score or the Most Affected Limb (TNmAS-MAL)|Expanded Disability Status Scale (EDSS),True,2022-07-15
NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,"A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period",COMPLETED,2009-04,2011-09,2015-05,2016-06-13,2009-04-17,INTERVENTIONAL,PHASE3,324.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,Relapsing-remitting multiple sclerosis,Belgium,Brussels,,54,Interferon β-1a|Teriflunomide,DRUG|DRUG,Core Treatment Period: Overview of Failures|Core Treatment Period: Time to Failure: Kaplan-Meier Estimates of the Rate of Failure at Timepoints,Core Treatment Period: Annualized Relapse Rate [ARR] - Poisson Regression Estimates|Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score|Core Treatment Period: Treatment Satisfaction Questionnaire for Medication [TSQM] Scores|Core Treatment Period: Overview of Adverse Events [AE]|Extension Treatment Period: Overview of AEs|Extension Treatment Period: ARR Poisson Regression Estimates,True,2012-11-06
NCT06699095,Home Rehabilitation As Continuity of Care in MS,"""Tele-riabilitazione in Sclerosi Multipla: Continuità Terapeutica Domiciliare Dopo Trattamento Di Neuro-riabilitazione Intensiva, Studio Randomizzato Controllato Con Piattaforma Integrata Per La Riabilitazione Del Disequilibrio""",RECRUITING,2024-11-06,2025-11-06,2025-11-15,2024-11-21,2024-11-21,INTERVENTIONAL,NA,20.0,ESTIMATED,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,OTHER,Istituto Auxologico Italiano|Fondazione Don Carlo Gnocchi Onlus,OTHER|OTHER,Multiple Sclerosis,Balance rehabilitation|Telemedicine|Home rehabilitation,Italy,Milan,MI,3,Telerehabilitation,DEVICE,Feasibility,Telehealthcare Satisfaction Questionnaire (TSQ)|Telehealthcare Usability Questionnaire (TUQ)|Timed Up and Go test (TUG)|Timed 10-Meter Walk Test|Equiscale test|12-Item Multiple Sclerosis Walking Scale|Multiple Sclerosis Quality of Life Questionnaire-54 (MSQoL-54)|Modified Fatigue Impact Scale (M-FIS)|Patient Health Engagement scale (PHE scale),False,
NCT01099930,Autologous Stem Cell Transplant for Multiple Sclerosis,Targeting Multiple Sclerosis as an Autoimmune Disease With Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients With a Predicted Poor Prognosis,COMPLETED,2001-08,2012-11,2016-06,2016-09-28,2010-04-08,INTERVENTIONAL,PHASE2,24.0,ACTUAL,Ottawa Hospital Research Institute,OTHER,Multiple Sclerosis Scientific Research Foundation,UNKNOWN,Multiple Sclerosis,immunoablation|stem cell transplantation,Canada,Ottawa,Ontario,1,"immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|Standard Therapy",OTHER|OTHER,3 year MS activity free survival,Transplant related morbidity|Transplant related mortality|Time to MS treatment failure|rate of immune reconstitution following treatment,False,
NCT03846336,"Upper Extremity Function, Shoulder Position Sense and Disability Level İn Patients With Multiple Sclerosis","An Investigation of Upper Extremity Function in Patients With Multiple Sclerosis, and Its Relation With Shoulder Position Sense and Disability Level",COMPLETED,2018-06-01,2018-07-01,2018-09-01,2019-02-19,2019-02-19,INTERVENTIONAL,NA,41.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Physical Therapy|Upper Extremity Function|Position Sense,Multiple Sclerosis|Upper Extremity Function|Position Sense,Turkey (Türkiye),Ankara,Esenboğa,1,Upper extremity function|Shoulder position sense,OTHER|OTHER,Upper extremity function,Shoulder position sense,False,
NCT06474520,Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD),An Open Label Clinical Trial to Evaluate the Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease,RECRUITING,2024-08-08,2029-07,2029-12,2024-09-20,2024-06-25,INTERVENTIONAL,NA,250.0,ESTIMATED,Tongji Hospital,OTHER,"Jianmin Pharmaceutical Group Co., LTD.",INDUSTRY,Idiopathic Inflammatory Demyelinating Disease|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Acute Disseminated Encephalomyelitis,,China,Wuhan,Hubei,1,Calculus bovis sativus (CBS),DRUG,The Modified Rankin Scale (mRS)|Expanded Disability Status Scale (EDSS)|Incidence and Severity of Adverse Effects (AEs) and Severe Adverse Effects (SAEs),The number of newly increased inflammatory lesions on T2 flair weighted imaging at week 12 compared with baseline (visit 1) and control group.|The number of newly increased inflammatory lesions on gadolinium-enhanced T1 weighted imaging at week 12 compared with baseline (visit 1) and control group.|The score of Mini-mental State Examination (MMSE) at week 12 compared with baseline (visit 1) and control group.|Quantitative and qualitative changes in Montreal cognitive assessment scale (MoCA) at week 12 compared with baseline (visit 1) and control group.|The score of Montreal cognitive assessment scale (MoCA) at week 12 compared with baseline (visit 1) and control group.|The score of Hamilton Anxiety Scale at week 12 compared with baseline (visit 1) and control group.|The score of Hamilton Depression Scale at week 12 compared with baseline (visit 1) and control group.|The score of 36-item Short-Form (SF-36) at week 12 compared with baseline (visit 1) and control group.|The incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) events at week 14 compared with baseline (visit 1) and control group.,False,
NCT05083923,A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS),"An Open-Label, Single-Arm, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability, and Pharmacokinetics of Diroximel Fumarate (BIIB098) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis",COMPLETED,2021-11-18,2024-09-11,2024-09-11,2024-09-19,2021-10-19,INTERVENTIONAL,PHASE3,102.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,,China,Hefei,Anhui,52,Diroximel fumarate,DRUG,Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1: Number of Participants with Potentially Clinically Serious (PCS) Change from Baseline in Clinical Laboratory Parameters|Part 1: Number of Participants with PCS Change from Baseline in 12-Lead Electrocardiogram (ECG) Parameters|Part 1: Number of Participants with PCS Change from Baseline in Vital Sign Parameters|Part 1: Number of Participants with Columbia Suicide Severity Rating Scale (C-SSRS) Events|Part 2: Number of Participants with AEs and SAEs|Part 2: Number of Participants with PCS Change from Baseline in Clinical Laboratory Parameters|Part 2: Number of Participants with PCS Change from Baseline in 12-Lead ECG Parameters|Part 2: Number of Participants with PCS Change from Baseline in Vital Sign Parameters|Part 2: Number of Participants with C-SSRS Events,Part 1: Plasma Concentrations of MMF and HES|Part 1: Maximum Observed Concentration (Cmax) of MMF and HES|Part 1: Area Under the Concentration-Time Curve from Time Zero to Time of Last Measurable Concentration (AUClast) of MMF and HES|Part 1: Time to Reach Cmax (Tmax) of MMF and HES|Part 1: Elimination Half-Life (t½) of MMF,False,
NCT03217396,Biomarkers of Synaptic Damage in Multiple Sclerosis,Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage,RECRUITING,2017-11-22,2026-09-01,2027-09-30,2022-10-28,2017-07-14,OBSERVATIONAL,,300.0,ESTIMATED,Neuromed IRCCS,OTHER,IRCCS Multimedica,OTHER,Multiple Sclerosis|Parkinson Disease|Amyotrophic Lateral Sclerosis|Alzheimer Disease,synaptic plasticity|neuroinflammation|neurodegeneration,Italy,Pozzilli,Isernia,1,lumbar puncture,PROCEDURE,Identification of predictive biomarkers of SM using an ex vivo chimeric model,Identification of new therapeutic targets in MS.,False,
NCT02021162,Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis,"Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.",COMPLETED,2013-11,2018-09,2018-10,2019-04-17,2013-12-27,OBSERVATIONAL,,50.0,ACTUAL,University at Buffalo,OTHER,Novartis,INDUSTRY,Multiple Sclerosis|Healthy,Multiple sclerosis|Gilenya|Healthy controls|Thalamic atrophy|MRI,United States,Buffalo,New York,1,,,Thalamic atrophy,Thalamic pathology|Cognitive impairment|Thalamic volume and accumulation of iron in response to herpes viruses,False,
NCT05218317,Evaluation of Relapse Presence in Multiple Sclerosis,Evaluation of Relapse Presence in Multiple Sclerosis Patients by Cross-Sectional In-Vivo Corneal Confocal Microscopy,COMPLETED,2021-01-01,2021-10-01,2022-01-01,2022-02-01,2022-02-01,OBSERVATIONAL,,87.0,ACTUAL,Marmara University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis Relapse","multiple sclerosis, in-vivo corneal confocal microscopy, relapse, inflammation, neurodegeneration, neuroregeneration",Turkey (Türkiye),Istanbul,,1,in-vivo Corneal Confocal Microscopy,DIAGNOSTIC_TEST,Corneal nerve fiber density (CNFD)|Corneal nerve fiber density (CNFD)|Corneal nerve branch density (CNBD)|Corneal nerve branch density (CNBD)|Corneal nerve fiber length (CNFL)|Corneal nerve fiber length (CNFL),Dendritic Cells|Dendritic Cells,False,
NCT06128668,"The Effect of Yoga on Sleep Quality, Fatigue and Physical Activity Level of Multiple Sclerosis","The Effect of Yoga on Sleep Quality, Fatigue and Physical Activity Level of Multiple Sclerosis Patients: A Randomized Controlled Study",COMPLETED,2023-11-25,2024-03-25,2024-07-25,2024-12-13,2023-11-13,INTERVENTIONAL,NA,60.0,ACTUAL,Ataturk University,OTHER,,,Multiple Sclerosis,Fatigue|Sleep Quality|Yoga,Turkey (Türkiye),Elâzığ,,1,Yoga,BEHAVIORAL,"Pittsburgh Sleep Quality Index|Fatigue Severity Scale:|Expanded Disability Status Scale (EDSS, ExpandedDisabilityStatusScala):|International Physical Activity Questionnaire (IPAQ):",,False,
NCT06998810,Cerebellar High-Frequency rTMS in Balance of Multiple Sclerosis Patients,Effect of Cerebellar High-Frequency rTMS in Improving Balance Performance in Multiple Sclerosis Patients,COMPLETED,2023-02-25,2024-12-25,2025-03-25,2025-05-31,2025-05-31,INTERVENTIONAL,NA,40.0,ACTUAL,Ain Shams University,OTHER,,,Multiple Sclerosis,"multiple sclerosis, cerebellar rTMS, balance in Multiple sclerosis,",Egypt,Cairo,Other,1,cerebellar rTMS,DEVICE,Static posturography|International Cooperative Ataxia Rating Scale (ICARS)|Expanded Disability Status Scale (EDSS),10-Meter Walk Test (10MWT),False,
NCT05633459,A Study Evaluating the Safety and Tolerability of QRL-201 in ALS,"A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis",ACTIVE_NOT_RECRUITING,2022-12-16,2026-10-08,2026-10-08,2025-08-29,2022-12-01,INTERVENTIONAL,PHASE1,64.0,ESTIMATED,QurAlis Corporation,INDUSTRY,,,Amyotrophic Lateral Sclerosis,"ALS, Stathmin-2, STMN2, ASO, Antisense Oligonucleotide",Belgium,Leuven,,15,Multiple ascending doses of QRL-201|Multiple ascending doses of Placebo|QRL-201|Placebo,DRUG|DRUG|DRUG|DRUG,Number of participants with one or more treatment emergent adverse events and serious adverse events,Pharmacokinetics (plasma): Maximum observed concentration of QRL-201 (Cmax)|Pharmacokinetics (plasma): Area under the concentration time curve from zero to infinity (AUCinf) of QRL-201|Pharmacokinetics (plasma): Time of maximum concentration (Tmax) of QRL-201,False,
NCT03268096,"Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination","Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination",COMPLETED,2017-05-03,2021-11-03,2021-11-03,2022-04-22,2017-08-31,OBSERVATIONAL,,182.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,"Multiple Sclerosis|Pathologic Processes|Tomography, Optical Coherence|Magnetic Resonance Imaging|Prognosis",,France,Paris,,1,Cerebral MRI and Optical Coherence Tomography,DEVICE,Disability assessed with EDSS (Expanded Disability Status Scale),,False,
NCT00242268,A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis,,UNKNOWN,2005-10,,,2005-12-07,2005-10-20,INTERVENTIONAL,PHASE3,30.0,,"Alabama Neurology Associates, PC",OTHER,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,United States,Birmingham,Alabama,1,Simvastatin,DRUG,"1. To evaluate the safety of combining Avonex with Zocor for a period of fourteen months in patients with RRMS|2. To evaluate the effect of treatment on MRI, specifically new or enlarging T2 lesions burden",1. To evaluate the effect on Relapse Rates|2. To evaluate the effect on disease progression as measured with EDSS and MSFC,False,
NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,"A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules",COMPLETED,2014-05,2015-02,2015-11,2016-12-28,2014-03-18,INTERVENTIONAL,PHASE4,241.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,multiple sclerosis|flushing|aspirin,Ireland,Cork,,21,dimethyl fumarate|acetylsalicylic acid|ASA-Placebo,DRUG|DRUG|DRUG,"Percentage of Participants Reporting Overall Flushing Events During the First 4 Weeks of Treatment, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)|Percentage of Participants Reporting Overall Flushing Events During the First 4 Weeks of Treatment, as Assessed by the Modified Flushing Severity Scale (MFSS)|Worst Severity Scores of Overall Flushing During the First 4 Weeks of Treatment, as Assessed by MGFSS|Worst Severity Scores of Overall Flushing During the First 4 Weeks of Treatment, as Assessed by MFSS","Percentage of Participants Reporting Overall Flushing Events During Weeks 5-8 and Weeks 9-12 of Treatment, as Assessed by MGFSS|Percentage of Participants Reporting Overall Flushing Events During Weeks 5-8 and Weeks 9-12 of Treatment, as Assessed by MFSS|Worst Severity Scores of Overall Flushing During Weeks 5-8 and Weeks 9-12 of the Study, as Assessed by MGFSS|Worst Severity Scores of Overall Flushing During Weeks 5-8 and Weeks 9-12 of the Study, as Assessed by MFSS|Duration of Flushing Episodes During Weeks 1-4, 5-8 and 9-12 of the Study, as Assessed by MGFSS|Duration of Flushing Episodes During Weeks 1-4, 5-8 and 9-12 of the Study, as Assessed by MFSS|Number of Participants With Self-Reported Flushing Events During Weeks 13 to 48|Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs in the First 12 Weeks|Number of Participants Experiencing Treatment-Emergent AEs, SAEs, and Discontinuations Due to AEs in Weeks 13 to 48|Number of Participants Discontinuing Treatment and Discontinuing the Study Due to Treatment-emergent Flushing AEs in the First 12 Weeks|Number of Participants Discontinuing Treatment and Discontinuing the Study Due to Treatment-Emergent Flushing AEs in Weeks 13 to 48|Change From Baseline at Weeks 24 and 48 in Quality of Life Measurements as Assessed by Short Form-36 (SF-36) Questionnaire: Physical Component Summary (PCS)|Change From Baseline at Weeks 24 and 48 in Quality of Life Measurements as Assessed by Short Form-36 (SF-36) Questionnaire: Mental Component Summary (MCS)|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the European Quality of Life 5-Dimensions Questionnaire (EQ-5D-5L) Questionnaire: Mobility|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the EQ-5D-5L Questionnaire: Self-Care|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the EQ-5D-5L Questionnaire: Usual Activities|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the EQ-5D-5L Questionnaire: Pain/Discomfort|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the EQ-5D-5L Questionnaire: Anxiety/Depression|Change From Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the EQ-VAS",True,2016-12-28
NCT03933020,Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-Onset Multiple Sclerosis (POMS),Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-onset Multiple Sclerosis,TERMINATED,2019-05-10,2019-05-31,2019-05-31,2022-05-19,2019-05-01,INTERVENTIONAL,NA,2.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,Microsoft Corporation,INDUSTRY,Pediatric Onset Multiple Sclerosis (POMS),Multiple Sclerosis|Cognitive Impairment|Physical activity,United States,Houston,Texas,1,VR active video game intervention|Educational session|Standard Management of Physical Activity,DEVICE|BEHAVIORAL|BEHAVIORAL,Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Symbol Digit Modalities Test (SDMT)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Symbol Digit Modalities Test (SDMT)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Symbol Digit Modalities Test (SDMT)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - California Verbal Learning Test - II (CVLT-II)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - California Verbal Learning Test - II (CVLT-II)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - California Verbal Learning Test - II (CVLT-II)|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Brief Visuospatial Memory Test (BVMT) - Revised|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Brief Visuospatial Memory Test (BVMT) - Revised|Cognitive Disability as Assessed by the Brief International Cognitive Assessment for MS (BICAMS) - Brief Visuospatial Memory Test (BVMT) - Revised,"Physical and Psychological Impact of MS as Assessed by the Multiple Sclerosis Impact Scale-29 (MSIS-29)|Physical and Psychological Impact of MS as Assessed by the Multiple Sclerosis Impact Scale-29 (MSIS-29)|Physical and Psychological Impact of MS as Assessed by the Multiple Sclerosis Impact Scale-29 (MSIS-29)|Fatigue as Assessed by the Modified Fatigue Impact Scale (MFIS)|Fatigue as Assessed by the Modified Fatigue Impact Scale (MFIS)|Fatigue as Assessed by the Modified Fatigue Impact Scale (MFIS)|Anxiety and Depression as Assessed by the Hospital Anxiety and Depression Scale (HADS)|Anxiety and Depression as Assessed by the Hospital Anxiety and Depression Scale (HADS)|Anxiety and Depression as Assessed by the Hospital Anxiety and Depression Scale (HADS)|Distance Walked as Assessed by the Six Minute Walk Test (6MWT)|Distance Walked as Assessed by the Six Minute Walk Test (6MWT)|Number of Clinical Relapses|New Activity on MRI (T2 Lesions, Gd+)|Safety of Implementing a VR Active Video Game Program at Home as Assessed by the Number of Self-reported Incidents That Occur During the Exercise Sessions, Including Falls or Physical Injuries.|Safety of Implementing a VR Active Video Game Program at Home as Assessed by the Number of Self-reported Incidents That Occur During the Exercise Sessions, Including Falls or Physical Injuries.|Safety of Implementing a VR Active Video Game Program at Home as Assessed by the Number of Self-reported Incidents That Occur During the Exercise Sessions, Including Falls or Physical Injuries.|Degree of Incorporation of Physical Activity Into Daily Life as Assessed by a Self Report Questionnaire|Degree of Incorporation of Physical Activity Into Daily Life as Assessed by a Self Report Questionnaire",True,2022-05-19
NCT06838624,RedCord in Neurogenic Bowel Dysfunction in Multiple Sclerosis,Effectiveness of Treatment With RedCord in Neurogenic Bowel Dysfunction in People With Multiple Sclerosis,NOT_YET_RECRUITING,2025-09-01,2026-09-30,2026-12-15,2025-02-24,2025-02-20,INTERVENTIONAL,NA,76.0,ESTIMATED,University of Castilla-La Mancha,OTHER,,,Multiple Sclerosis|Pelvic Floor Disorder,Multiple Sclerosis|Constipation|Faecal Incontinence|Pelvic Floor|Abdominal Muscles,Spain,Toledo,Toledo,1,Redcord|Control (Standard treatment),DEVICE|OTHER,Neurogenic Bowel Dysfunction score (NBDS),Electromyography: Root mean square,False,
NCT01092208,Studies of Autistic Patients: Gene Networks and Clinical Subtypes,Studies of Autistic Patients: Gene Networks and Clinical Subtypes,TERMINATED,2010-03-17,,2013-09-24,2019-12-17,2010-03-24,OBSERVATIONAL,,11.0,ACTUAL,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,,,Autism|Tuberous Sclerosis,Autism|iPS Cells|Fibroblasts|Gene Networks|Tuberous Sclerosis|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,,,,,False,
NCT04497025,Conventional Vestibular Training Versus Immersive Virtual Reality- Based Vestibular in Multiple Sclerosis,"Feasibility and Safety of an Immersive Virtual Reality-based Vestibular Rehabilitation Program for Dizziness, Balance and Fatigue Improvement in People With Multiple Sclerosis: Protocol for a Pilot Randomised Controlled Study",NOT_YET_RECRUITING,2026-01,2028-12,2029-12,2024-06-03,2020-08-04,INTERVENTIONAL,NA,30.0,ESTIMATED,Maria Jesus Casuso-Holgado,OTHER,,,Multiple Sclerosis|Vestibular Disease|Dizziness|Balance Disorders|Fatigue|Quality of Life|Usability|Cybersickness,,Spain,Seville,,1,Immersive Virtual-based vestibular rehabilitation|Conventional vestibular rehabilitation protocol,OTHER|OTHER,Feasibility of virtual reality-based vestibular rehabilitation|Safety of virtual reality-based vestibular rehabilitation,Change from baseline dizziness symptoms at 7 weeks|Change from baseline static balance at 7 weeks|Change from baseline fatigue at 7 weeks|Change from baseline quality of life at 7 weeks,False,
NCT01992679,Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis,Body Weight Supported Treadmill Training in Advanced Multiple Sclerosis,COMPLETED,2013-10,2014-09,2014-09,2014-12-12,2013-11-25,INTERVENTIONAL,PHASE1|PHASE2,24.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,,United States,Urbana-Champaign,Illinois,1,Exercise group,BEHAVIORAL,Clinical Disability|Quality of Life,Walking function|Balance|Cardiorespiratory fitness,False,
NCT03492450,Unraveling Early Walking Dysfunction in Non-disabled MS People: Assessment and Potential Therapeutic Interventions,Unraveling Early Walking Dysfunction in Non-disabled MS People: Clinical and Instrumental Assessment of Disease Progression and Potential Therapeutic Interventions,UNKNOWN,2018-05-12,2019-12,2020-06,2019-07-08,2018-04-10,INTERVENTIONAL,NA,40.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,Treadmill training|Instrumented assessment|Disease progression,Italy,Milan,,1,Treadmill training,OTHER,Change in Six Minutes Walking Test|Change in Instrumented variables,the Twelve-Item Walking Scale|the Twentyfive-foot walking test|The Fatigue Severity Scale|the Nine hole peg test,False,
NCT01112657,An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period,"A Prospective, Observational Study On The Progression Of Clinically Isolated Syndrome (CIS) To Multiple Sclerosis Over A 2-year Period",COMPLETED,2008-11,2014-10,2014-10,2014-11-13,2010-04-28,OBSERVATIONAL,,154.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Clinical isolated syndrome|Demyelination,Taiwan,Kaohsiung City,,6,,,"Proportion of subjects who convert to multiple sclerosis (MS), defined by McDonald criteria (Version 2005), over 2 years from the first episode of Clinically Isolated Syndrome (CIS)",Duration between first episode of neurological event and diagnosis of MS|Proportion of subjects with conventional MS and optic-spinal MS (OSMS)|Proportion of subjects with anti-AQP4 IgG antibody|Association between baseline demographics/disease characteristics and progression to MS,False,
NCT05821257,Arm Swing During Walking in Early Multiple Sclerosis,Arm Swing During Walking in Early Multiple Sclerosis,COMPLETED,2021-12-01,2023-05-31,2023-06-30,2023-07-27,2023-04-20,OBSERVATIONAL,,28.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,"Multiple Sclerosis|Upper Extremity Problem|Gait Disorders, Neurologic","arm swing, multiple sclerosis, gait, foot pressure analysis",Turkey (Türkiye),Istanbul,,1,Evaluation of the arm swing during gait|Functional Tests,OTHER|OTHER,Arm swing amplitude-shoulder degrees in flexion-extension direction|Arm swing amplitude-elbow degrees in flexion-extension direction|Arm swing amplitude-overall degrees in flexion-extension direction|Step-speed|Two Minute Walk Test (2MWT)|Timed Up and Go (TUG)|Timed 25Foot Walk Test (T25FW),,False,
NCT06199219,Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction,Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction in Women With Multiple Sclerosis: A Randomized Controlled Study,COMPLETED,2023-05-10,2023-08-30,2023-09-30,2024-01-10,2024-01-10,INTERVENTIONAL,NA,40.0,ACTUAL,Necmettin Erbakan University,OTHER,,,MS (Multiple Sclerosis)|Sexual Dysfunctions|Counseling,,Turkey (Türkiye),Konya,,1,"Sexual counseling, based on the extended (EX-PLISSIT)",OTHER,The Female Sexual Function Index (FSFI) Score,New Sexual Satisfaction Scale (NSSS) Score,False,
NCT04906928,Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research,Evaluation of the Performance of a 3D FGAPSIR Sequence by MRI in the Detection and Characterization of Spinal Cord Injuries in Patients With Multiple Sclerosis,RECRUITING,2023-10-01,2024-06,2024-08,2023-12-13,2021-05-28,OBSERVATIONAL,,200.0,ESTIMATED,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Spinal Cord Injuries,,France,Paris,,1,MRI,DEVICE,estimate the number of lesions detected with the 3D FGAPSIR sequence and not detected with the 3D PSIR sequence.,,False,
NCT05533905,DECISIve - DiagnosE Using the Central veIn SIgn v1.0,DECISIve - DiagnosE Using the Central veIn SIgn. A Prospective Diagnostic Superiority Study Comparing T2*MRI and Lumbar Puncture in Patients Presenting With Possible Multiple Sclerosis.,COMPLETED,2019-12-09,2023-11-06,2023-11-06,2024-03-29,2022-09-09,OBSERVATIONAL,,113.0,ACTUAL,Nottingham University Hospitals NHS Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Nottingham,,1,Lumbar puncture|MRI,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Is T2* MRI scan more sensitive than lumbar puncture with oligoclonal band testing for diagnosing MS at the time of first clinical presentation?,Is there a significant difference between the specificity of each diagnostic test in this cohort?|Is there a significant difference between the sensitivity and specificity of the 'rule of six' proposed in Mistry et al. 2016 and lumbar puncture with oligoclonal bands?,False,
NCT04821596,Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis,Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis,UNKNOWN,2020-07-13,2021-08-13,2021-12-31,2021-03-29,2021-03-29,INTERVENTIONAL,NA,75.0,ESTIMATED,"University Hospital, Rouen",OTHER,,,Multiple Sclerosis,,France,Rouen,,1,biological collection,OTHER,Description of cladribine's effects on immune system of multiple sclerosis patients,,False,
NCT02315872,ACTH for Fatigue in Multiple Sclerosis Patients,The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.,COMPLETED,2015-05-22,2017-06-20,2018-12-13,2019-09-09,2014-12-12,INTERVENTIONAL,PHASE3,8.0,ACTUAL,Providence Health & Services,OTHER,Mallinckrodt,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Acthar Gel|ACTH|Fatigue,United States,Cullman,Alabama,5,ACTH|Placebo,DRUG|DRUG,Fatigue at 28 Weeks,Depression at 28 Weeks|Sleepiness at 28 Weeks|Quality of Life at 28 Weeks,True,2019-08-13
NCT06064539,Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects,"A Phase 1, Single-center, Open-label, Two-cohort, Two-period, One-sequence, Two Treatment, Drug-drug Interaction Study of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Subjects",COMPLETED,2020-05-18,2020-07-08,2020-07-08,2025-09-17,2023-10-03,INTERVENTIONAL,PHASE1,30.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Saint Paul,Minnesota,1,Tolebrutinib|gemfibrozil|rifampicin,DRUG|DRUG|DRUG,Pharmacokinetics: AUClast of SAR442168|Pharmacokinetics: AUC of SAR442168,Pharmacokinetics: Maximum plasma concentration observed (Cmax) of SAR442168|Pharmacokinetics: Cmax of SAR442168 metabolite(s)|Pharmacokinetics: AUC of SAR442168 metabolite(s)|Pharmacokinetics: Time to reach Cmax (tmax) of SAR442168|Pharmacokinetics: tmax of SAR442168 metabolite(s)|Pharmacokinetics: Cmax of gemfibrozil|Pharmacokinetics: Cmax of gemfibrozil 1-O-glucuronide|Pharmacokinetics: tmax of gemfibrozil|Pharmacokinetics: tmax of gemfibrozil 1-O-glucuronide|Pharmacokinetics: Cmax of rifampicin|Pharmacokinetics: tmax of rifampicin|Numbers of participants with adverse events (AEs),False,
NCT03594357,Cognitive Functions in Patients With Multiple Sclerosis,The Relationship of Cognitive Functions to Physical and Personal Factors in Patients With Multiple Sclerosis,COMPLETED,2018-09-03,2018-12-21,2018-12-24,2019-01-30,2018-07-20,OBSERVATIONAL,,137.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Balance|Cognition|Functional exercise capacity|Fatigue|Sleep quality,Turkey (Türkiye),Ankara,,1,,,cognitive function,Balance|Functional exercise capacity.|Fatigue|Mood|Sleep Quality,False,
NCT04568707,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19,COMPLETED,2020-10-23,2022-12-14,2022-12-14,2024-02-02,2020-09-29,INTERVENTIONAL,NA,238.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,Paris Brain Institute (ICM),OTHER,Covid19|Neurologic Manifestations|Psychiatric Manifestations,"COVID-19|neurological disease|Multiple Sclerosis|psychiatric disease|biology,|biocollection,|biomarkers,|DNA,|Parkinson's Disease",France,Paris,,1,blood sample,OTHER,dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients,Serum neurofilaments,False,
NCT06782958,"Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of FHND1002 Granules After Single and Multiple Doses in Healthy Adult Volunteers",ENROLLING_BY_INVITATION,2024-07-05,2025-03-03,2025-06-05,2025-01-20,2025-01-20,INTERVENTIONAL,PHASE1,72.0,ESTIMATED,"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.",INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),FHND1002|Amyotrophic Lateral Sclerosis(ALS),China,Lanzhou,Gansu,1,50mg FHND1002|100mg FHND1002|150 mg FHND1002|200 mg FHND1002（fasting）|250mg FHND1002|200mg FHND1002(postprandial),DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Peak Plasma Concentration (Cmax)|Time to Peak Plasma Concentration (Tmax)|Area Under the Curve from 0 to the Last Quantifiable Time Point (AUClast)|Area Under the Curve Over the Dosing Interval (AUCτ)|Trough Concentration (Cmin)|Average Plasma Concentration (Cavg)|Accumulation Ratio (Rac)|Elimination Half-life (t1/2)|Area Under the Curve from 0 to Infinity (AUC0-inf)|Incidence of Adverse Events(AEs)|Incidence of Adverse Drug Reactions (ADRs),Coefficient of Variation (DF) of Pharmacokinetic Parameter|Apparent Clearance (CL/F)|Apparent Volume of Distribution (Vz/F),False,
NCT00480181,Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis,"A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS)",COMPLETED,2007-06,2012-07,2012-07,2012-07-27,2007-05-30,INTERVENTIONAL,PHASE4,50.0,ESTIMATED,University of Manitoba,OTHER,"Bausch Health Americas, Inc.",INDUSTRY,Neuropathic Pain|Multiple Sclerosis,Neuropathic pain|Multiple Sclerosis|Nabilone|Gabapentin,Canada,Winnipeg,Manitoba,1,nabilone|placebo,DRUG|OTHER,VAS,SF MPQ|SF-36|PGIC,False,
NCT06795230,Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM),Effects of a Low-intensity Muscle Strengthening Protocol in Combination With Blood Flow Restriction Training on Upper Limb Impairment in People With Multiple Sclerosis. A Randomized Controlled Trial,RECRUITING,2025-03-01,2025-12-31,2026-01-31,2025-03-30,2025-01-28,INTERVENTIONAL,NA,20.0,ESTIMATED,Universidad Rey Juan Carlos,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Upper limb|Rehabilitation|Blood Flow Restriction Training,Spain,Alcorcón,Madrid,1,Muscle strengthening (BFRT)|Conventional physical therapy,OTHER|OTHER,Isometric prehensile hand strength (Kg),Isometric pincer force (Kg)|Gross coordination for the upper limb (Block and Box; number of cubes)|Fine coordination for the upper limb (NHPT; time in seconds)|Functional status of the upper limb (ABILHAND)|Quality of life (MSIS-29)|Satisfaction (CSQ8),False,
NCT06680037,A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders,"A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders",RECRUITING,2025-05-06,2026-12-01,2029-01-01,2025-09-10,2024-11-08,INTERVENTIONAL,PHASE1,32.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,B-cell Mediated Autoimmune Disorders,Progressive forms of multiple sclerosis (PMS)|Primary Progressive MS (PPMS)|Secondary Progressive MS (SPMS),United States,La Jolla,California,5,Azercabtagene zapreleucel (azer-cel),DRUG,Number of Participants with Dose-Limiting Toxicities (DLTs),"Number of Participants with Treatment Emergent Adverse Events (TEAEs), Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)|Change From Baseline in CAR T-cell Toxicities|Pharmacokinetics (PK) Plasma Concentrations of Azer-cel|Pharmacodynamics (PD) Plasma Concentrations of Azer-cel|Time to Confirmed Disability Progression (CDP)|Time to Confirmed Disability Improvement (CDI)|Change From Baseline in Brain MRI Gadolinium Enhancing T1, New or Enlarging Hyperintense T2|Change From Baseline in Whole Brain Atrophy",False,
NCT07123337,Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis,Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis: A Cross-Sectional Study From the Mediterranean Epidemiological Frontier,COMPLETED,2023-08-01,2025-02-15,2025-04-08,2025-08-19,2025-08-14,OBSERVATIONAL,,369.0,ACTUAL,University of Zintan,OTHER,,,Multiple Sclerosis,EDSS|MS,Libya,Tripoli,Tripoli,1,,,EDSS|Serum 25-Hydroxyvitamin D,,False,
NCT02676739,Adderall XR and Cognitive Impairment in MS,"A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS",ACTIVE_NOT_RECRUITING,2016-05-20,2024-11,2024-12,2024-10-17,2016-02-08,INTERVENTIONAL,PHASE2|PHASE3,180.0,ESTIMATED,Sarah Morrow,OTHER,,,Multiple Sclerosis,,Canada,Edmonton,Alberta,3,Adderall XR,DRUG,Symbol Digit Modalities Test (SDMT),Brief Visuospatial Memory Test Revised - immediate recall|California Verbal Learning Test 2nd edition - immediate recall|Multiple Sclerosis Neuropsychological Screening Questionnaire|Perceived Deficits Questionnaire|36-Item Short Form Survey|The Modified Fatigue Impact Scale|Hospital Anxiety and Depression Scale,False,
NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),"Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension",COMPLETED,2014-08-28,2025-07-08,2025-07-08,2025-07-20,2014-11-05,INTERVENTIONAL,PHASE3,156.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Pediatrics,United States,Boston,Massachusetts,62,dimethyl fumarate|Interferon β-1a,DRUG|DRUG,Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans|Number of Participants That Experience Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants Who Discontinue Study Treatment due to an AE,"The Number of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans|Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans|Proportion of Participants Free of New MRI Activity as measured by Brain MRI Scans|Time to First Relapse|Proportion of Participants Who Do Not Experience Relapse|Annualized Relapse Rate|Number of Participants That Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)|Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale Scores|Quality of Life as measured by the PedsQL|Change from Baseline to Week 96 in the Expanded Disability Status Scale (EDSS) Score|Vital Signs, Electrocardiograms (ECGs) and Changes in Clinical Laboratory Data, including Monitoring of Liver Function, Renal Function, Hematologic, and Coagulation Parameters|Annualized Relapse Rate|Change from Baseline in EDSS Score|Change from Baseline in Symbol Digit Modalities Test (SDMT) Score|Change from Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score|Change from Baseline in School Progression Query|Number of Participants with Incidences of Clinically Relevant Vital Signs Abnormalities|Number of Participants with Incidences of Clinically Relevant ECG Abnormalities|Number of Participants with Incidences of Clinically Relevant Laboratory Assessment Abnormalities|Change from Baseline in Height|Change from Baseline in Weight|Change from Baseline in Bone Age|Tanner Stage",False,
NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,"A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase",ACTIVE_NOT_RECRUITING,2013-07-26,2017-07-14,2030-02-18,2025-07-23,2013-07-04,INTERVENTIONAL,PHASE3,240.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,pediatric|multiple sclerosis|fingolimod|pre-pubertal|low weight|children|adolescent|MS|core phase|extension phase|younger cohort,United States,Birmingham,Alabama,73,Interferon beta-1a|Fingolimod|Placebo capsule|Placebo i.m. injection,DRUG|DRUG|DRUG|DRUG,Frequency of Relapses in Patients Treated for up to 24 Months,New/Newly Enlarged T2 Lesions|Time to First Relapse|Proportion of Patients Relapse-free|T1 Gd- Enhancing Lesions|Pharmacokinetics (Cavg) of Fingolimod-P|Pharmacokinetic/Pharmacodynamic Relationship for Fingolimod-P to Lymphocyte Levels,True,2018-09-19
NCT01228266,Mesenchymal Stem Cell Transplantation in MS,"Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study",TERMINATED,2010-12,2013-06,2013-12,2014-02-13,2010-10-26,INTERVENTIONAL,PHASE2,9.0,ACTUAL,Albert Saiz,OTHER,Instituto de Salud Carlos III,OTHER_GOV,Multiple Sclerosis,Multiple Sclerosis,Spain,Barcelona,Barcelona,1,autologous mesenchymal stem cells,BIOLOGICAL,"To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study","To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales",False,
NCT00965497,Escitalopram (Lexapro) for Depression MS or ALS,"An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis",COMPLETED,2009-07,2010-03,2010-03,2019-05-01,2009-08-25,INTERVENTIONAL,PHASE3,13.0,ACTUAL,University of South Carolina,OTHER,,,Major Depression|Multiple Sclerosis|Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis|ALS|Multiple Sclerosis|MS|Major Depression|Depression|Major Depressive Disorder|antidepressants|Escitalopram|Lexapro,United States,Columbia,South Carolina,1,escitalopram,DRUG,Hamilton Depression Scale (HAM-D 17).,McGill Quality of Life Scale (MQOL),True,2011-09-07
NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II","An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)",TERMINATED,2009-03,2009-09,2011-02,2017-03-20,2009-03-02,INTERVENTIONAL,PHASE2,74.0,ACTUAL,EMD Serono,INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Relapsing Multiple Sclerosis,,United States,Phoenix,Arizona,47,Atacicept 25 mg|Atacicept 75 mg|Atacicept 150 mg|Atacicept 150 mg,DRUG|DRUG|DRUG|DRUG,"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity|Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Vital Signs: Pulse Rate|Change From Baseline in Vital Signs: Temperature|Change From Baseline in Electrocardiogram (ECGs)|Number of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels|Number of Subjects With Positive Neutralizing Antibody (NAb)",Number of Subjects With Clinical Attacks/Relapses|Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12|Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12|Magnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject|Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject|Concentrations of Free and Total Atacicept|Free B-Lymphocyte Stimulator (BLyS) and Free A Proliferation-Inducing Ligand (APRIL) Serum Concentrations.|Pharmacogenetics/Pharmacogenomics Analysis,True,2016-05-24
NCT01883661,Safety and Efficacy of BMMNC in Multiple Sclerosis (MS),Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial,UNKNOWN,2014-06,2016-11,2016-12,2014-09-17,2013-06-21,INTERVENTIONAL,PHASE1|PHASE2,15.0,ESTIMATED,"Chaitanya Hospital, Pune",OTHER,,,Multiple Sclerosis,stem cell|Multiple Sclerosis|BMMNC,India,Pune,Maharashtra,1,BMMNC,BIOLOGICAL,analysis of patients symptoms,changes in Expanded Kurtzke Disability Status Score scale|changes in clinical variables|Quality Of life questionnaire|changes in MRI scan report|changes in cerebrospinal fluid tests|Changes in analysis of visual evoked potential test,False,
NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,"A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression",TERMINATED,2011-11,2013-09,2013-09,2014-09-25,2011-09-20,INTERVENTIONAL,PHASE4,54.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Depression|Relapsing-remitting Multiple Sclerosis,Depression|Multiple Sclerosis|Fingolimod|Venlafaxine|Fluoxetine,Germany,Altenholz-Stift,Germany,25,Venlafaxine|Fluoxetine|Citalopram|Fingolimod,DRUG|DRUG|DRUG|DRUG,"Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death",,True,2014-09-25
NCT02571335,Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS,Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial,COMPLETED,2015-09,2016-08,2016-08,2016-08-30,2015-10-08,INTERVENTIONAL,NA,65.0,ACTUAL,Klinik Valens,OTHER,"German Sport University, Cologne",OTHER,Multiple Sclerosis,,Switzerland,Valens,Canton of St. Gallen,1,Intensive Training|Normal Training,BEHAVIORAL|BEHAVIORAL,Neurotrophic Factor BDNF,Maximum Oxygen consumption (VO2peak)|Maximum heart rate (HRmax)|Maximum workload (Loadmax)|Fatigue|Health-related Quality of life|Cognitive Functions,False,
NCT02845635,MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis,MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis,COMPLETED,2017-09-29,2021-07-28,2021-07-28,2022-04-20,2016-07-27,OBSERVATIONAL,,2200.0,ACTUAL,Duke University,OTHER,,,Multiple Sclerosis,,United States,Durham,North Carolina,1,Personal history of multiple sclerosis,OTHER,Change in perceived fatigue severity (self-report) as recorded by symptom diary|Change in perceived cognitive impairment (self-report) as recorded by symptom diary|Change in perceived depression or anxiety severity (self-report) as recorded by symptom diary,Change in perceived walking instability (self-report) as recorded by symptom diary|Change in perceived vision difficulties (self-report) as recorded by symptom diary|Change in perceived Bowel/Bladder dysfunction (self-report) as recorded by symptom diary|Change in perceived sensory disturbance (self-report) as recorded by symptom diary|Change in perceived vertigo severity (self-report) as recorded by symptom diary|Change in perceived dysarthria severity (self-report) as recorded by symptom diary|Change in pain (self-report) as recorded by symptom diary|Change in sleep quality as recorded by app-linked wearable device|Change in medication adherence (self-report) as recorded by medication diary|Change in self-efficacy (self-report) as determined by the Multiple Sclerosis self-efficacy scale (survey instrument)|Change in Multiple Sclerosis Quality of Life Inventory,False,
NCT06159712,Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis,Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis,RECRUITING,2023-11-27,2024-11,2025-11,2023-12-07,2023-12-07,INTERVENTIONAL,NA,200.0,ESTIMATED,University of Aarhus,OTHER,"Aarhus University Hospital|Gødstrup Hospital|Regionshospitalet Viborg, Skive|Sorbonne University",OTHER|OTHER|OTHER|OTHER,Relapsing Remitting Multiple Sclerosis,,Denmark,Aarhus,,1,Blood samples,OTHER,Changes in B cell populations,,False,
NCT01569451,Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate,"A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2012-02,2015-05,2015-05,2018-06-08,2012-04-03,INTERVENTIONAL,PHASE2,53.0,ACTUAL,"University of Colorado, Denver",OTHER,"Rocky Mountain MS Research Group, LLC",OTHER,Multiple Sclerosis,Multiple Sclerosis|Glatiramer Acetate|Rituximab|Relapsing forms of Multiple Sclerosis|Relapsing Multiple Sclerosis,United States,Aurora,Colorado,1,Rituximab|Glatiramer Acetate|Placebo,DRUG|DRUG|OTHER,Number of Disease-free Patients,Time to Treatment Failure|Number of Subjects That Fail Treatment|Number of Relapse-free Subjects|Number of Patients Treated for Relapse With Corticosteroid|Number of Subjects Who Experience Multiple Relapses|Number of Patients That Develop Sustained Accumulation of Disability|Change From Baseline to 24 Months on the Multiple Sclerosis Functional Composite (MSFC) Z-score|Percentage of Subjects Worsening One Point or More on the Patient Determined Disease Steps (PDDS) Questionnaire|Change in Mean Score on Performance Scales (Baseline to 24 Months),True,2018-06-07
NCT04796272,Role of Individualized Versus Traditional Exercise in Combating Fatigue,Role of Individualized Versus Traditional Exercise in Combating Fatigue in Fatigued Multiple Sclerosis Patients,TERMINATED,2021-04-02,2022-02-23,2022-06-30,2023-11-02,2021-03-12,INTERVENTIONAL,NA,30.0,ACTUAL,Centre Hospitalier Universitaire de Saint Etienne,OTHER,,,Multiple Sclerosis,multiple sclerosis|individual exercise|fatigue|traditional exercise,France,Saint-Etienne,,1,Adapted and individualized physical training program|traditional training program,OTHER|OTHER,Chronic fatigue score,cardiorespiratory fitness|Hematological parameters|Inflammatory parameters|quality of sleep|cortical activation level|cortico-spinal excitability|neuromuscular fatigue of peripheral function|Analysis overall quality of life : Fatigue questionnaire|Analysis overall quality of life :Quality of Life|Analysis overall quality of life :Depression|Analysis overall quality of life : Sleep Quality|Analysis overall quality of life : Physical Activity,False,
NCT06292312,Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis.,"Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis: A Randomized Controlled, Single-Blind Study",RECRUITING,2024-02-27,2025-04-15,2025-05-15,2024-07-30,2024-03-05,INTERVENTIONAL,NA,32.0,ESTIMATED,Ankara Yildirim Beyazıt University,OTHER,Lokman Hekim University,OTHER_GOV,Multiple Sclerosis,multiple sclerosis|craniosacral therapy,Turkey (Türkiye),Ankara,,1,Craniosacral therapy|Conventional physiotherapy,OTHER|OTHER,Dynamic posturography|Heart rate variability|Number of participants,Pain level|Central sensitization|Fatigue|Sleep quality|Life quality,False,
NCT06136728,Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis,Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis,RECRUITING,2024-06-12,2026-01,2026-06,2024-12-19,2023-11-18,INTERVENTIONAL,PHASE4,48.0,ESTIMATED,MGH Institute of Health Professions,OTHER,,,Multiple Sclerosis,,United States,Boston,Massachusetts,1,Dalfampridine 10 MG [Ampyra]|Physical therapy|Dalfampridine plus physical therapy,DRUG|BEHAVIORAL|OTHER,Change in Timed 25-Foot Walk (T25FW),,False,
NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,"Long-term Extension of the Multinational, Double-blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses",COMPLETED,2007-10,2010-04,2010-04,2012-12-31,2008-12-19,INTERVENTIONAL,PHASE2,182.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Bridgewater,New Jersey,7,Teriflunomide|Placebo (for teriflunomide)|Interferon-β [IFN-β]|Glatiramer Acetate [GA],DRUG|DRUG|DRUG|DRUG,Overview of Adverse Events [AE]|Overview of AE With Potential Risk of Occurence|Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities [PCSA],Annualized Relapse Rate [ARR]: Poisson Regression Estimates|Overview of 12-week Sustained Disability Progression|Time to 12-week Sustained Disability Progression: Kaplan-Meier Estimates of the Rate of Disability Progression at Timepoints|Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)|Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)|Cerebral MRI Assessment: Total Volume of Gd-enhancing T1-lesions Per Scan,True,2012-12-31
NCT00079495,Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis",COMPLETED,2003-07,,2005-04,2008-03-21,2004-03-10,INTERVENTIONAL,PHASE2,150.0,,Neurocrine Biosciences,INDUSTRY,Immune Tolerance Network (ITN),NETWORK,Multiple Sclerosis,MS|Autoimmune disease|relapsing|progressive|Myelin|Myelin Basic Protein|MBP|acute fulminating|chronic progressive|Altered Peptide Ligand|APL|Neurocrine|NBI-5788|Relapse,,,,0,NBI-5788,DRUG,,,False,
NCT01706107,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients,TERMINATED,2012-11-07,2015-10-02,2015-10-02,2024-06-03,2012-10-15,OBSERVATIONAL,,73.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Quality of life,Canada,Victoria,British Columbia,11,,,Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29),Change from Baseline in Annualized Relapse Rate|Change from Baseline in Expanded Disability Status Scale (EDSS)|Change from Baseline in Work Productivity and Activity Impairment|Change from Baseline in EuroQol 5-Dimension (EQ-5D)|Change from Baseline in Patient Global Assessment of Wellbeing Visual Analog Scale|Percentage of participants with Clinical Disease-Free Status,False,
NCT00988988,The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections,The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate,WITHDRAWN,2010-02,2012-08-03,2012-08-03,2023-08-23,2009-10-02,INTERVENTIONAL,PHASE4,0.0,ACTUAL,University of Nebraska,OTHER,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|AGEE|histamine response,,,,0,AGEE cream|1% Steroid Cream|topical placebo cream with no active ingredients,DRUG|DRUG|DRUG,Histamine response after ethyl-α-guanida-methyl ethanoate (AGEE) and subcutaneous injection of glatiramer acetate,,False,
NCT01805986,Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner,Investigation of Grey Matter Pathology Using Ultra High Field (7T) MRI Scanner,UNKNOWN,2013-03,2014-02,2015-02,2013-05-17,2013-03-06,OBSERVATIONAL,,100.0,ESTIMATED,University of Nottingham,OTHER,,,Multiple Sclerosis,"Multiple Sclerosis, other neurological conditions",,,,0,,,The number of Gray Matter lesions detected using different sequences.,"Comparison of MRI sequencies|To determine the relationship between cortical thickness as measured on T1 weighted images and GM and WM lesion load.|Regional variation in the brain|To detect cortical variations in MT inside and outside GM lesions, in a longitudinal pilot study, reflecting possible cortical remyelination.",False,
NCT04838886,The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients,The Effect of Telerehabilitation Based Pilates Training on Physical Performance and Quality of Life in Multiple Sclerosis Patients,COMPLETED,2021-04-15,2022-05-15,2022-05-25,2022-05-27,2021-04-09,INTERVENTIONAL,NA,30.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Pilates|Exercise|Telerehabilitation|Physical performance|Balance|Gait|Fatigue,Turkey (Türkiye),Ankara,,1,Telerehabilitation-based Pilates Exercise,OTHER,Dynamic Balance- Baseline|Dynamic Balance-Post intervention|Static Balance- Baseline|Static Balance- Post intervention|An individual's confidence in performing activities- Baseline|An individual's confidence in performing activities- Post intervention|Exercise capacity- Baseline|Exercise capacity- Post intervention|Gait parameters- Baseline|Gait parameters- Post intervention|Functional mobility- Baseline|Functional mobility- Post intervention|Core endurance- Baseline|Core endurance- Post intervention|Core strength- Baseline|Core strength-Post intervention|Muscle Strength outcomes- Baseline|Muscle Strength outcomes- Post intervention,Physical activity level- Baseline|Physical activity level- Post intervention|Fatigue severity- Baseline|Fatigue severity- Post intervention|Impact of fatigue on activities- Baseline|Impact of fatigue on activities- Post intervention|Health related quality of life- Baseline|Health related quality of life- Post intervention- Post intervention,False,
NCT02308670,Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis,"An Open-label, Prospective, Observational, Single-blinded, Longitudinal, Cross-over Study to Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week on Thalamic Pathology in Subjects With Relapsing-remitting Multiple Sclerosis",COMPLETED,2014-07,2016-10,2016-10,2016-10-25,2014-12-04,OBSERVATIONAL,,150.0,ACTUAL,University at Buffalo,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Multiple Sclerosis,,United States,Buffalo,New York,1,,,Absolute and percent change in thalamus pathology as measured by axial and radial diffusivity using diffusion tensor imaging tract-based spatial statistics,Absolute and percent changes in normal-appearing white and grey matter as measured by fractional anisotropy and mean diffusivity using diffusion tensor imaging tract-based spatial statistics.,False,
NCT04674280,Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation,Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation,UNKNOWN,2021-01,2025-01,2025-01,2020-12-21,2020-12-19,OBSERVATIONAL,,50.0,ESTIMATED,European Society for Blood and Marrow Transplantation,NETWORK,,,Multiple Sclerosis,,,,,0,aHSCT,PROCEDURE,Time to NEDA-3 failure,Overall survival|Transplant related mortality,False,
NCT03981003,Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis,Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis,RECRUITING,2019-05-22,2028-06,2028-06,2024-05-14,2019-06-10,OBSERVATIONAL,,1150.0,ESTIMATED,Centre Hospitalier Universitaire de Nīmes,OTHER,Hospices Civils de Lyon,OTHER,Multiple Sclerosis,Neurofilament-light chain|Glial fibrillary Acidic Protein (GFAP),France,Amiens,,28,Blood sample,DIAGNOSTIC_TEST,Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease|GFAP level in patients with evolving disease compared to those with stable disease,"Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.|Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients|GFAP level in patients with relapse compared to stable patients|Serum Neurofilament Light Chain level in patients with relapse compared to stable patients|GFAP level in patients with relapse compared to stable patients|Serum Neurofilament Light Chain level in patients with relapse compared to stable patients|GFAP level in patients with relapse compared to stable patients|Serum Neurofilament Light Chain level in patients with relapse compared to stable patients|GFAP level in patients with relapse compared to stable patients|Serum Neurofilament Light Chain level in patients with relapse compared to stable patients|GFAP level in patients with relapse compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients|GFAP level in patients with isolated MRI activity compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients|GFAP level in patients with isolated MRI activity compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients|Serum GFAP level in patients with isolated MRI activity compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients|Serum GFAP level in patients with isolated MRI activity compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients|Serum GFAP level in patients with isolated MRI activity compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients|Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort|Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease|Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)|Serum GFAP level in patients with disease activity (relapse or MRI activity)|Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)|Serum GFAP level in patients with disease activity (relapse, or MRI activity)|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)|Serum GFAP level in patients with disease activity (relapse or MRI activity)|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)|Serum GFAP level in patients with disease activity (relapse or MRI activity)|Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)|Serum GFAP level in patients with disease activity (relapse or MRI activity)|Serum Neurofilament Light Chain level in patients with relapses|Serum GFAP level in patients with relapses|Serum Neurofilament Light Chain level in patients with relapses|Serum GFAP level in patients with relapses|Serum Neurofilament Light Chain level in patients with relapses|Serum GFAP level in patients with relapses|Serum Neurofilament Light Chain level in patients with relapses|Serum GFAP level in patients with relapses|Serum Neurofilament Light Chain level in patients with relapses|Serum GFAP level in patients with relapses|Serum Neurofilament Light Chain level in patients with MRI activity|Serum GFAP level in patients with MRI activity|Serum Neurofilament Light Chain level in patients with MRI activity|Serum GFAP level in patients with MRI activity|Serum Neurofilament Light Chain level in patients with MRI activity|Serum GFAP level in patients with MRI activity|Serum Neurofilament Light Chain level in patients with MRI activity|Serum GFAP level in patients with MRI activity|Serum Neurofilament Light Chain level in patients with MRI activity|Serum GFAP level in patients with MRI activity|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement|Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement|Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement|Level of disability|Level of disability|Severity of multiple sclerosis|Severity of multiple sclerosis|Generic health status|Generic health status|Generic health status|Generic health status|Use of Disease Modifying Drugs|Use of Disease Modifying Drugs|Use of Disease Modifying Drugs|Use of Disease Modifying Drugs|Use of Disease Modifying Drugs|Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients|Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients|Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients|Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients|Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion|Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion|Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion|Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion|Create biobank|Create biobank|Create biobank|Create biobank|Create biobank",False,
NCT04389970,Time Restricted Eating Outcomes in Multiple Sclerosis,Time Restricted Eating Outcomes in Multiple Sclerosis,COMPLETED,2020-10-01,2021-07-30,2021-07-30,2024-03-27,2020-05-15,INTERVENTIONAL,NA,12.0,ACTUAL,University of Alabama at Birmingham,OTHER,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,"Multiple Sclerosis|Diet, Healthy",,United States,Birmingham,Alabama,1,Time Restricted Feeding,BEHAVIORAL,Timed 25-foot Walk Speed,Short Form McGill Pain Questionnaire|Modified Fatigue Impact Scale|Fatigue Severity Scale|Pittsburgh Sleep Quality Index|Percent Lean Mass|9 Hole Peg Test Speed|Symbol Digit Modalities Test (SDMT)|Percent Fat Mass,True,2024-03-27
NCT02198599,Mobility Enhancing Nursing Intervention,Effects of Mobility-Enhancing Nursing Intervention in Patients With MS and Stroke: Randomised Controlled Trial,COMPLETED,2011-03,2013-04,2013-04,2014-07-24,2014-07-23,INTERVENTIONAL,NA,140.0,ACTUAL,Zurich University of Applied Sciences,OTHER,Swiss National Science Foundation,OTHER,Stroke|Multiple Sclerosis,Multiple sclerosis|Stroke|Nursing|Mobility|Rehabilitation,Switzerland,Winterthur,Canton of Zurich,1,Mobility-enhancing-nursing intervention,PROCEDURE,Change in Extended Barthel Index (EBI) between admission and discharge,Change in Quality of life between admission and discharge|Change in Fall Efficacy Scale between admission and discharge,False,
NCT05634993,Disability Level and Trunk Control in Individuals With Multiple Sclerosis,The Relationship Between Disability Level and Trunk Control in Individuals With Multiple Sclerosis,COMPLETED,2022-06-01,2023-06-01,2023-09-01,2025-02-07,2022-12-02,OBSERVATIONAL,,102.0,ACTUAL,Hacettepe University,OTHER,Bandırma Onyedi Eylül University,OTHER,Multiple Sclerosis,multiple sclerosis|disability level|trunk control,Turkey (Türkiye),Bandırma,Balıkesir,1,Assessment,OTHER,"Expanded Disability Status Scale|Trunk Impairment Scale|""Sit-ups"" test|Modified ""Push-ups"" test|Lateral bridge test|Modified ""Biering-Sorensen"" trunk extension test|Trunk flexion test|""Prone Bridge"" test",,False,
NCT01435993,Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis,"A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.",TERMINATED,2011-09-08,2012-01-23,2012-01-23,2020-11-24,2011-09-19,INTERVENTIONAL,PHASE1,3.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Secondary-Progressive with relapses",Italy,Verona,Veneto,2,GSK1223249|Saline placebo,DRUG|OTHER,Safety,Cmax values and AUC(0-∞)|Immunogenicity of GSK1223249 in MS patients|Pharmacokinetics of GSK1223249 in cerebro-spinal fluid (CSF) in MS patients,False,
NCT06671236,Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases,"An Open, Single-Arm, Multi-Center Clinical Study to Evaluate the Safety and Tolerability of Regulatory T Cells (Tregs) In the Treatment of Neurodegenerative Diseases",RECRUITING,2024-11-21,2026-12,2027-12,2025-09-25,2024-11-04,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,Novabio Therapeutics,INDUSTRY,The First Affiliated Hospital of Zhengzhou University,OTHER,Amyotrophic Lateral Sclerosis (ALS),Treg|regulatory T cells|neurodegenerative diseases|Amyotrophic Lateral Sclerosis,China,Zhengzhou,Henan,1,Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection),BIOLOGICAL,Incidence of Treatment Related adverse events (AEs)|Identification of Maximum Tolerated Dose (MTD),Amyotrophic lateral sclerosis functional rating scale- revised (ALSFRS-R)|Rasch Overall ALS Disability Scale (ROADS),False,
NCT01564511,Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis,"Effects of Electromechanical Gait Trainer on Endurance, Fatigue and Daily Life Autonomy in Patients With Multiple Sclerosis: a Randomized Control Trial",COMPLETED,2011-11,2012-02,2012-12,2016-09-12,2012-03-27,INTERVENTIONAL,NA,50.0,ACTUAL,Universita di Verona,OTHER,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Robotic Rahabilitation|Fatigue|Gait disorder,Italy,Verona,Verona,1,Gait trainer treatment|Conventional treatment,DEVICE|OTHER,6-minute Walking Test,10-meter Walking Test|Falls efficacy scale score|Spatio-temporal gait analysis|Static balance assessment|Measure of energy cost|Hamilton Rating Scale for Depression,False,
NCT04748302,Impaired Glucose Tolerance and Cognition in MS,Impaired Glucose Tolerance and Cognition in MS,TERMINATED,2020-01-06,2020-04-01,2020-04-01,2021-02-10,2021-02-10,OBSERVATIONAL,,7.0,ACTUAL,University of Virginia,OTHER,,,Multiple Sclerosis,,United States,Charlottesville,Virginia,1,,,Assessment of glucose intolerance on clinical outcome measure of disability.,,False,
NCT04877457,Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.,"A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Ocrelizumab in Patients With Radiologically Isolated Syndrome",TERMINATED,2022-02-15,2023-06-12,2023-06-12,2024-10-09,2021-05-07,INTERVENTIONAL,PHASE4,3.0,ACTUAL,Yale University,OTHER,"Genentech, Inc.",INDUSTRY,Radiologically Isolated Syndrome|Multiple Sclerosis,,United States,North Haven,Connecticut,4,Ocrelizumab|Placebo,DRUG|OTHER,Time to Development of First New Radiologic or Clinical Evidence of MS,Cumulative Number of New or Enlarging T2 Lesions|Change in T2-lesion Volume|Cumulative Number of New T1 Gadolinium-enhancing Lesions|Change in Total Brain Volume|Change in Total Spinal Cord Volume|Change in Serum NfL (sNfL),True,2024-10-09
NCT03401307,Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis,Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis,COMPLETED,2017-08-01,2020-06-20,2020-12-01,2021-10-14,2018-01-17,OBSERVATIONAL,,49.0,ACTUAL,University of Southern Denmark,OTHER,Region of Southern Denmark,OTHER,Multiple Sclerosis|Neurodegeneration|Central Nervous System Lesion|Peripheral Nervous System Problem|Neurologic Deficits|Drug Effect|Genetic Disease|Neurophysiologic Abnormality,,Denmark,Sønderborg,Jylland,1,,,Timed 25-Foot Walk Test (T25FW),Twelve Item MS Walking Scale (MSWS-12)|Guys Neurological Disability Scale (GNDS)|5-Times-Sit-to-Stand Test (5-STS)|The Six Spot Step Test (SSST)|Antibodies|9-Hole Peg Test (9-HPT)|Symbol Digit Modalities Test (SDMT)|MRI of the brain|Neurophysiologic examinations,False,
NCT00630383,Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.,Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.,WITHDRAWN,2008-02,2008-05,2008-05,2012-06-14,2008-03-07,INTERVENTIONAL,PHASE2,0.0,ACTUAL,University of Nottingham,OTHER,,,Multiple Sclerosis,Parasite|Necator|immune regulation|regulatory T cells|foxp3|cytokines|multiple sclerosis|hygiene hypothesis,United Kingdom,Nottingham,Nottinghamshire,1,Live Hookworm Larvae|Histamine,BIOLOGICAL|OTHER,Primary outcome measure is an increase in the percentage from total CD4+ T cells of CD4+CD25+foxp3+ cells.,The expression of foxp3 mRNA from peripheral blood mononuclear cells (PBMC).|The percentage from total PBMC of NK and NKT cells (CD3-CD56+ and CD3+CD56+ respectively).|The percentage from total CD3+ T cells of Tr1 cells (CD3+IL10+ T cells).|The percentage from total PBMC of B regulatory cells (CD20+IL-10+).,False,
NCT05752630,"Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis","The Relation Between Physical Activity, Sedentary Behaviour, and Cardiometabolic Health in Multiple Sclerosis",UNKNOWN,2023-01-30,2024-01-20,2024-01-20,2023-03-02,2023-03-02,OBSERVATIONAL,,50.0,ESTIMATED,Hasselt University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Physical activity|Sedentary behaviour|Cardiometabolic health|Comorbidities,Belgium,Diepenbeek,Limburg,1,,,Body weight|Height|DEXA (Dual Energy X-Ray)|Waist circumference|Hip circumference|Concentration of glucose|Concentration of Insulin|Concentration of total cholesterol|Concentration of high density lipoprotein cholesterol (HDL-cholesterol|Concentration of low density lipoprotein cholesterol (LDL-cholesterol)|Concentration of triglyceride|Concentration of inflammatory markers|Reactive hyperaemia index (RHI)|Homeostatic model assessment for insulin resistance (HOMA-IR)|Insulinogenic index|Area under the curve of glucose and insulin concentrations|Cardiac autonomic function|Systolic and Diastolic blood pressure|metabolic syndrome (MetS) risk score|Oxygen uptake (VO2)|Respiratory gas exchange ratio (RER)|Heart rate (HR)|Arterial stiffness|Whole-body insulin sensitivity (WBISI),Steps per day|Sitting time|Standing time|Walking time|Sleeping time|Exercise information|Total calorie intake|Macronutrient content|12-Item Multiple Sclerosis Walking Scale (MSWS-12) questionnaire|RAND-36 Item Health Survey (RAND-36) questionnaire|Modified fatigue impact scale (MFIS) questionnaire|Perceived stress scale (PSS) questionnaire,False,
NCT05147532,Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation,Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation,RECRUITING,2022-01-24,2023-10,2024-05,2023-09-13,2021-12-07,INTERVENTIONAL,NA,80.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis|Inflammatory Disease,Multiple sclerosis|Remyelination|Combination of magnetic resonance imaging (MRI) and positron emission tomography (PET),France,Paris,,1,PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714,PROCEDURE,Proportion of lesional demyelinated voxels at baseline that are classified as remyelinating at month 6 of multiple sclerosis patients during the relapsing and the progressive phases of the disease,"the percentage of voxels classified as significantly activated compared to control white matter, and the number/proportion of MS lesions classified as activated based on [18F]-DPA-714 PET|Proportion of each lymphocyte cluster identified from the single cell sequencing of T lymphocytes over the total T lymphocyte population for each patient|Remyelination level in rodents demyelinated by lysolecithin and grafted with single patient's lymphocytes quantified at week 3 post-graft|Proportion of lesions that persist as chronic active at month 3 post graft over the total number of lesions induced in the rodent demyelinating models by grafting patients' lymphocytes",False,
NCT02647502,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,COMPLETED,2015-12,2017-06,2017-06,2017-11-17,2016-01-06,INTERVENTIONAL,NA,36.0,ACTUAL,Johns Hopkins University,OTHER,,,Relapsing Remitting Multiple Sclerosis,,United States,Baltimore,Maryland,1,Diet,OTHER,Adverse events,Adherence to Calories Assigned|Adherence to Calories Assigned|Adverse Events|Quality of Life Questionnaire|NIH Patient-Reported-Outcomes Measurement Information System (PROMIS )Fatigue Questionnaire|Change in metabolite ratios|Immune cell subsets/cytokines|Change in concentration of measures of metabolism|Change in serum lipid concentration|Change in serum brain-derived neurotrophic factor concentration (BDNF)|Change in levels of oxidative stress biomarkers,False,
NCT04468165,"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region","Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region",COMPLETED,2021-02-23,2023-07-20,2023-07-20,2023-09-22,2020-07-13,OBSERVATIONAL,,160.0,ACTUAL,Hikma Pharmaceuticals LLC,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Dimethyl Fumarate|Generic Dimethyl Fumarate|Delayed-Release Dimethyl Fumarate|Disease Modifying Treatments|Nervous System|Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Cohort Study|Observational Study|Effectiveness|Safety|Health Related Quality of life,Algeria,Blida,,6,Dimethyl Fumarate (DMF),DRUG,The primary endpoint of the study is ARR (Annualized Relapse Rate) at 12 month.,Proportion of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) (including laboratory abnormalities)|Proportion of patients with AEs and SAEs (including laboratory abnormalities) leading to treatment discontinuation will be assessed|Proportion of patients experiencing a relapse over the 12 months period from Initiation of Hikma DMF|Time to First Relapse|Proportion of patients with disability progression as measured by the EDSS over time|Change in Multiple Sclerosis Impact Scale-29 Items (MSIS-29) scores over time,False,
NCT05783934,Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT,Evaluation of the Degree of Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Positron Emission Tomography With Amyloid Markers (PET-CT 18F-Florbetaben) and Comparison With MRI Findings,COMPLETED,2021-07-27,2023-11-15,2024-01-09,2025-05-30,2023-03-24,INTERVENTIONAL,NA,6.0,ACTUAL,Istituti Clinici Scientifici Maugeri SpA,OTHER,,,Multiple Sclerosis,MRI|18F-Florbetaben PET/CT,Italy,Pavia,PV,1,18F-florbetaben PET/CT,DIAGNOSTIC_TEST,PET outcome,correlation between PET data and MRI images and degree of disability,False,
NCT00142714,Effects of Spinal Cord Injury on Female Sexual Response,Effects of SCI on Female Sexual Response,UNKNOWN,2003-08,,2005-06,2006-10-16,2005-09-02,INTERVENTIONAL,NA,70.0,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,,,Female Sexual Dysfunction|Multiple Sclerosis|Spinal Cord Injury,sexual response|sexual dysfunction in females|spinal cord injury,United States,Birmingham,Alabama,1,Sympathetic manipulation on sexual arousal in women,PROCEDURE,"Our central hypothesis are:|1) In females the SNS regulates psychogenic genital vasocongestion 2) In females the orgasmic reflex requires the presence of an intact sacral spinal cord, 3) In females a pattern generator is responsible for the orgasmic reflex.",,False,
NCT00317941,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,"The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®).",COMPLETED,2006-03,2008-04,2008-04,2013-10-21,2006-04-25,INTERVENTIONAL,PHASE4,220.0,ACTUAL,Bayer,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis|RRMS,France,Aix-en-Provence,,59,Betaferon/Betaseron|Rebif|Betaferon/Betaseron,DRUG|DRUG|DRUG,Percentage of the Sites Developing a Injection Site Reaction (ISR) Reported by Participants 24 Hours After Each Injection|Percentage of Sites Developing a Injection Site Reaction (ISR) Reported by Participants 48 Hours After Each Injection|Mean Scores of Reaction After Injection Reported by Participants,Percentage of Injection Sites With Pain Reported by Physicians|Percentage of Injection Sites Per Participant With Reaction Reported by Physicians|Percentage of Participants Without ISR Reported by Participants|Percentage of Sites Developing a Severe Reaction 24 Hours After Injection|Percentage of Sites Developing a Severe Reaction 48 Hours After Injection|Percentage of Participants Without Pain Reported by Participants|Percentage of Injection Sites Without Pain Reported by Physicians|Percentage of Injection Sites Without Pain Reported by Participants|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants Immediately After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 30 Minutes After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 1 Hour After Injection|Mean Pain Assessment Using Visual Analogue Scale (VAS) Reported by Participants 24 Hours After Injection|Percentage of Sites Without Reaction 24 Hours After Injection Reported by Participants|Percentage of Sites Without Reaction 48 Hours After Injection Reported by Participants,True,2013-10-21
NCT00753792,Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse,"Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse",COMPLETED,2008-11,2010-11,2011-01,2011-06-02,2008-09-17,INTERVENTIONAL,PHASE4,49.0,ACTUAL,Germans Trias i Pujol Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|relapse|methylprednisolone,Spain,Badalona,Barcelona,7,methylprednisolone|methylprednisolone|Placebo,DRUG|DRUG|DRUG,"Change in the punctuation of diana functional system score corresponding to in relapse of optic neuritis, trunk's syndrome and myelitis|Change in EDSS in patients who present a relapse from different type or unknown topography","Change in the punctuation in each group|Percentage of patients who improve, get worse and keep stable",False,
NCT05902429,Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients,Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients,ACTIVE_NOT_RECRUITING,2021-04-28,2024-08,2024-08,2024-01-08,2023-06-15,INTERVENTIONAL,PHASE4,10.0,ACTUAL,Pontificia Universidade Católica do Rio Grande do Sul,OTHER,"Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany",UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|cladribine tablets|remyelination,Brazil,Porto Alegre,Rio Grande do Sul,1,Cladribine 10 mg oral tablet,DRUG,Proportion of remyelinated lesions (as assessed by neuroradiologist) in q-Space myelin map,"Median ""lesion ratio"" (i.e., myelin index: lesion signal / normal appearing white matter signal) in q-Space myelin map|Mean signal intensity of lesions in q-Space myelin map|Correlation between lymphocyte profile and remyelination parameters in q-Space myelin map|Correlation between cytokine profile and remyelination parameters in q-Space myelin map|Correlation between remyelination parameters in q-Space myelin map and evolution of clinical scores (annualized relapse rate, EDSS, MSFC and their subtests)|Correlation between remyelination parameters in q-Space myelin map and evolution of neuropsychological scores (BICAMS and MFIS subtests)",False,
NCT04126772,Multimodal Imaging of MS Reveals the Smoldering Inflammation,Multimodal Imaging of MS Reveals the Smoldering Inflammation,ACTIVE_NOT_RECRUITING,2019-02-27,2025-12,2025-12,2025-01-15,2019-10-15,OBSERVATIONAL,,40.0,ESTIMATED,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,,,11C-PK11195 binding in MS patient brain|11C-SMW139 binding in MS patient brain|QSM-signal in MS patient brain,11C-PK11195 binding in healthy control brain|11C-SMW139 binding in healthy control brain|QSM-signal in healthy control brain|MRI metrics|EDSS|MSFC|Fatigue severity scale|Modified Fatigue Impact Scale,False,
NCT01986998,Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse,"Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.",COMPLETED,2013-10,2016-02,2016-03,2016-06-03,2013-11-19,INTERVENTIONAL,PHASE4,49.0,ACTUAL,Germans Trias i Pujol Hospital,OTHER,,,Multiple Sclerosis,Multiple sclerosis relapse|oral methylprednisolone|EDSS|gadolinium,Spain,Badalona,Barcelona,8,Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 625 mg/24h x3 days,DRUG|DRUG,Disability scale of Kurtzke EDSS score,"Adverse events / tolerability|Disability scale of Kurtzke EDSS score|The number and volume of active lesions (measured by the T2 or gadolinium enhancement), the number of new active lesions and the percentage of active lesions at baseline that becomes black holes|Adverse events / tolerability|Questionnaire MSQOL-54|Questionnaire MSQOL-54",False,
NCT01039103,Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS),"A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)",TERMINATED,2009-12,2011-11,2011-11,2016-10-06,2009-12-24,INTERVENTIONAL,PHASE2,15.0,ACTUAL,Galapagos NV,INDUSTRY,,,Acute Exacerbation of Remitting Relapsing Multiple Sclerosis|Clinically Isolated Syndrome,PEG-liposomal prednisolone sodium phosphate,Belgium,Bruges,,8,PEG-liposomal prednisolone sodium phosphate|Methylprednisolone,DRUG|DRUG,Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 8.,Change in gadolinium-enhanced T1-weighted lesions according to the McDonald criteria (2005) from Day 8 to Week 4.|Quality of life measured by changes in MSIS-29|Clinical response measured by changes in MSFC|Plasma levels of free prednisolone and prednisolone phosphate|Occurrence of adverse events,False,
NCT02048072,Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS,"Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose",COMPLETED,2013-07,2015-06,2015-06,2016-04-29,2014-01-29,INTERVENTIONAL,PHASE4,33.0,ACTUAL,Jochen Vehoff,OTHER,,,Multiple Sclerosis|Autonomic Nervous System Dysfunction,relapsing remitting|multiple sclerosis|fingolimod|Gilenya|autonomic nervous system,Switzerland,Sankt Gallen,Canton of St. Gallen,1,Gilenya,DRUG,RMSSD Normal Breathing,,True,2016-04-29
NCT03186664,The Role of SAtivex® in Robotic-Rehabilitation,The Role of SAtivex® Associated With Robotic-Rehabilitation in Improving the Motor Performances of Multiple Sclerosis Patients (SARR),COMPLETED,2016-12-28,2017-12,2018-06,2019-07-26,2017-06-14,INTERVENTIONAL,NA,40.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Rehabilitation,,Italy,Messina,Sicily,1,Lokomat training|Sativex,DEVICE|DRUG,Functional Independence Measure|10m walking test,,False,
NCT02017808,Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months,"A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months",COMPLETED,2014-02,2014-12,2014-12,2014-12-03,2013-12-23,OBSERVATIONAL,,100.0,ACTUAL,University at Buffalo,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Multiple Sclerosis,OCT|Copaxone|Multiple sclerosis|relapsing-remitting,United States,Buffalo,New York,1,,,Retinal health in multiple sclerosis patients prescribed copaxone,Measuring disability progression,False,
NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1),"A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis",COMPLETED,2020-06-30,2024-07-15,2024-07-15,2025-07-02,2020-06-01,INTERVENTIONAL,PHASE3,974.0,ACTUAL,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Birmingham,Alabama,179,Tolebrutinib|Teriflunomide|Placebo to match Tolebrutinib|Placebo to match Teriflunomide,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses,"Time to Onset of 6-Month Confirmed Disability Worsening as Assessed by Expanded Disability Status Scale|Time to Onset of 3-Month Confirmed Disability Worsening as Assessed by Expanded Disability Status Scale|Mean Number of New and/or Enlarging T2-Hyperintense Lesions Per Year|Mean Number of New Gadolinium-Enhancing T1-Hyperintense Lesions Per Scan|Change From Baseline in Cognitive Function as Assessed by the Symbol Digit Modalities Test (SDMT) at EOS|Change From Baseline in Cognitive Function as Assessed by the California Verbal Learning Test Second Edition (CVLT-II) at EOS|Time to Onset of 6-Month Confirmed Disability Improvement (CDI) as Assessed by Expanded Disability Status Scale|Percent Change in Brain Volume Loss at EOS Compared to Month 6|Change From Baseline in Multiple Sclerosis Quality of Life 54 (MSQoL-54) Questionnaire Score at EOS|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), TEAEs Leading to Permanent Study Intervention Discontinuation and Treatment-emergent Adverse Events of Special Interest (AESIs)|Maximum Observed Plasma Concentration (Cmax) of Tolebrutinib and M2 Metabolite|Time to Maximum Observed Plasma Concentration (Tmax) of Tolebrutinib and M2 Metabolite|Area Under the Plasma Concentration-time Curve Over the Last 24-hours Dosing Interval (AUC0-24) of Tolebrutinib and M2 Metabolite|Change From Baseline in Plasma Neurofilament Light Chain (NfL) and Serum Chitinase-3 Like Protein-1 (Chi3L1) Levels at EOS|Change From Baseline in Cluster of Differentiation (CD)19+ B Cells at EOS|Change From Baseline in Serum Immunoglobulin (Ig) Levels at EOS",True,2025-06-18
NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,"Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses",COMPLETED,2006-10,2015-12,2015-12,2017-01-30,2008-12-05,INTERVENTIONAL,PHASE3,742.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Oral treatment,United States,Maitland,Florida,116,Teriflunomide (HMR1726),DRUG,Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs),Time to 12 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP|Time to 24 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP|Percentage of Participants Free of Sustained Disability Progression (DP)|Annualized MS Relapse Rate (ARR): Poisson Regression Estimates|Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Volume of Abnormal Lesions (Burden of Disease [BOD]) at Week 192 Since LTS6050 Randomization,True,2017-01-30
NCT02966808,Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis,Retrospective Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis,UNKNOWN,2016-12,2021-12,2021-12,2021-02-10,2016-11-17,OBSERVATIONAL,,50.0,ESTIMATED,Hospital General Universitario Gregorio Marañon,OTHER,,,Multiple Sclerosis,,Spain,Madrid,,1,cognitive and behavioural questionnaires,BEHAVIORAL,Change in speed of processing|change in attention|change in walking ability|change in perception of walking ability,change in fatigue|change in quality of life,False,
NCT01070316,Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC),Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex,COMPLETED,2010-01,2016-04,2016-04,2017-03-13,2010-02-18,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,"Children's Hospital Medical Center, Cincinnati",OTHER,Novartis,INDUSTRY,Epilepsy|Tuberous Sclerosis Complex,Epilepsy|Tuberous Sclerosis Complex|Everolimus|RAD001|Mammalian Target of Rapamycin (MTOR),United States,Cincinnati,Ohio,2,Everolimus,DRUG,Reduction in Seizure Frequency|Number of Participants Continuing Study Medication Over Time,,True,2016-09-23
NCT00532532,Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis,"AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis",TERMINATED,2007-09,2008-09,2008-11,2008-11-04,2007-09-20,INTERVENTIONAL,PHASE2,150.0,ESTIMATED,Avigen,INDUSTRY,,,Muscle Spasticity,Multiple sclerosis,Czechia,Brno,,28,tolperisone HCl|tolperisone HCl|tolperisone HCl,DRUG|DRUG|DRUG,To determine the long-term safety and tolerability of AV650 (tolperisone HCl) in subjects with spasticity associated with MS,To determine preliminary efficacy of AV650 as compared to placebo in subjects with spasticity associated with MS; and to determine the pharmacokinetic (PK) profile of AV650 at two dose levels,False,
NCT04413032,DreaMS - Digital Biomarkers for Multiple Sclerosis,DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Feasibility Study,COMPLETED,2020-10-05,2021-02-26,2021-02-26,2021-03-02,2020-06-02,INTERVENTIONAL,NA,62.0,ACTUAL,Research Center for Clinical Neuroimmunology and Neuroscience Basel,OTHER,,,Multiple Sclerosis,,Switzerland,Basel,,1,DreaMS,DEVICE,Test Reliability of digital biomarkers measured by Intra Class Correlation|Test Reliability of digital biomarkers measured by Coefficient of variation|Determination of user acceptance of each digital biomarker with regards to acceptance based on a questionnaire using a likert scale,,False,
NCT03653585,Cortical Lesions in Patients With Multiple Sclerosis,Cortical Lesions in the Primary Sensorimotor Hand Area and Their Impact on Dexterity in Multiple Sclerosis: a 7T MRI Study,COMPLETED,2018-09-04,2020-09-03,2020-09-03,2021-04-08,2018-08-31,OBSERVATIONAL,,80.0,ACTUAL,Danish Research Centre for Magnetic Resonance,OTHER,Scleroseforeningen|Danish Multiple Sclerosis Center,UNKNOWN|UNKNOWN,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",Multiple Sclerosis|Magnetic Resonance Imaging|Magnetic Resonance Spectroscopy|Transcranial Magnetic Stimulation|Functional Neuroimaging|Cortical Lesion|Sensorimotor cortex|7T|7 Tesla,Denmark,Hvidovre,,1,,,Number of cortical lesions in the primary sensorimotor cortex (SM1)|Unimanual motor function,Functional brain activation pattern as revealed by task related blood oxygenation level dependent (BOLD) signal changes.|Unimanual sensory acuity|Intra-cortical inhibition and facilitation (Exploratory outcome measure)|Regional NAA concentration of the SM1|Cortical lesion subtype (Exploratory outcome measure)|Expanded Disability status scale (EDSS) score|Motor fatigue|Volume of cortical lesions in the primary sensorimotor cortex (SM1),False,
NCT03520517,"Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS","Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis",COMPLETED,2018-02-02,2018-10-08,2018-10-08,2022-10-06,2018-05-09,INTERVENTIONAL,PHASE1,22.0,ACTUAL,"Biohaven Pharmaceuticals, Inc.",INDUSTRY,Cognitive Research Corporation,INDUSTRY,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Amyotrophic Lateral Sclerosis|ALS|Biohaven|Motor Neuron Disease, Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Lou-Gehrigs Disease|Lou Gehrig Disease|Riluzole|Rilutek®|Neuroprotective Agents|Administration, Sublingual|Administration, Oral|Biological Availability",United States,Fort Lauderdale,Florida,5,BHV-0223,DRUG,Incidence of Treatment Emergent Adverse Events (Safety and Tolerability),"BHV-0223 Concentrations in Blood at Days 1, 29 and 57",False,
NCT01780792,Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis,"Examining the Effects of Dance, Dance Revolution on Mobility, Brain Plasticity and Cognition in Individuals With Multiple Sclerosis",COMPLETED,2011-08,2015-08,2016-12,2017-04-07,2013-01-31,INTERVENTIONAL,NA,30.0,ACTUAL,Ohio State University,OTHER,,,Multiple Sclerosis,multiple sclerosis|mobility|cognition|neuroplasticity|videogame play,United States,Columbus,Ohio,1,Dance Dance Revolution video game play,OTHER,Berg Balance Scale|PASAT,4 square step test|The Activities Specific Balance Confidence Scale|GAITRite|6 minute walk test|physical activity|multiple sclerosis quality of life inventory|fMRI,False,
NCT06641271,Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery,Vagus Nerve Stimulation to Promote Remyelination in Multiple Sclerosis,RECRUITING,2025-01-21,2027-11,2027-11,2025-03-14,2024-10-15,INTERVENTIONAL,NA,70.0,ESTIMATED,"University of Colorado, Denver",OTHER,,,Multiple Sclerosis (MS) - Relapsing-remitting|Multiple Sclerosis,,United States,Aurora,Colorado,1,Closed Loop Trans-Auricular Vagus Nerve Stimulation System|Placebo,DEVICE|DEVICE,Change from baseline in time to complete the grooved peg test|Change from baseline of score of the upper extremity portion of the Fugl-Meyer Assessment|Change from baseline score of the Expanded Disability Status Scale|Change in time from baseline to complete the timed 25 foot walk test|Change from baseline in composite disability metric|Change from baseline in patient reported outcomes from the multiple sclerosis impact scale 29,,False,
NCT00202397,Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia,Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia,COMPLETED,2005-06,2008-06,2008-08,2024-12-02,2005-09-20,INTERVENTIONAL,PHASE2,40.0,ACTUAL,S. Andrea Hospital,OTHER,,,Hereditary Ataxia|Multiple Sclerosis|Cerebellar Ataxia,cerebellar ataxia|deep cerebellar nuclei (DCN)|small-conductance calcium-activated potassium(SK)channels|riluzole|Sporadic ataxia|Multiple system atrophy type C,Italy,Rome,,1,Riluzole|placebo,DRUG|OTHER,"The International Cooperative Ataxia Rating Scale (ICARS) total scores and subscores (oculomotor, kinetic, postural, speech), comparing the three time points in the treated versus placebo group",,False,
NCT03975413,Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis,"Single-Arm, Non-Randomized, Time Series, Single-Subject Study: Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis",COMPLETED,2018-09-25,2020-04-01,2020-05-01,2020-10-08,2019-06-05,OBSERVATIONAL,,1.0,ACTUAL,Rush University Medical Center,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",FMT|Microbiome|Gait|Longitudinal|Multiple Sclerosis,United States,Chicago,Illinois,1,Fecal Microbiota Transplantation (FMT),OTHER,"Fecal microbial community structure and functional changes over six time frames for phylum, genus and species taxonomic level bacteria, virus, fungi, and archaea.|Walking and balance changes over four time frames for stride time (seconds).|Walking and balance changes over four time frames for stride distance (meters).|Walking and balance changes over four time frames for cadence (total number of steps per minute).|Walking and balance changes over four time frames for step width (meters).|Walking and balance changes over four time frames for average pelvis forward velocity (meters per second).|Walking and balance changes over four time frames for pelvis smoothness (pelvis horizontal speed).","Fecal targeted short-chain-fatty-acid metabolomics concentration changes over six time frames for acetate (mM/kg), propionate (mM/kg), butyrate (mM/kg), and total SCFA (mM/kg).|Measurement of blood serum biomarker brain-derived neurotrophic factor (BDNF) (ng/ml) changes over six time frames.|Sleep changes over six time frames.|Food timing changes over six time frames.|Gastrointestinal symptoms changes over six time frames (t-scores, mean, standard deviations).|Walking changes over six time frames.|Lesions changes over three time frames.|Food and frequency of consumption changes over six time frames.|Single day food recall changes over six time frames.|Diet changes over six time frames.|Measurement of blood serum biomarker Interleukin-6 (IL-6) (pg/ml) changes over six time frames.|Measurement of blood serum biomarker Interleukin-* (IL-8) (pg/ml) changes over six time frames.|Measurement of blood serum biomarker Tumor necrosis factor alpha (TNFα) (pg/ml) changes over six time frames.",False,
NCT05523466,Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis,Effect of Acupuncture on Heart Rate Variability in Individuals With Multiple Sclerosis,UNKNOWN,2022-12,2023-07,2023-12,2022-08-31,2022-08-31,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Sao Paulo,OTHER,,,Multiple Sclerosis,,,,,0,Acupuncture Active|Acupuncture Sham,OTHER|OTHER,Changes in the Heart Rate Variability after intervention,,False,
NCT03638739,Exercise and Brain Health in MS,Exercise and Brain Health in Multiple Sclerosis: A Pilot Study,COMPLETED,2018-08-01,2019-06-30,2019-09-01,2021-03-05,2018-08-20,INTERVENTIONAL,NA,10.0,ACTUAL,McMaster University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,Canada,Hamilton,Ontario,1,Twice-weekly exercise,OTHER,Change in Perceived Fatigue|Change in Inflammatory Markers|Change in Depression|Change in Cognition,Change in Aerobic Capacity|Change in Muscle Strength|Change in Perceived Quality of Life (QOL),False,
NCT05849467,Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy,Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy: A Pilot Study,RECRUITING,2023-10-19,2026-06-30,2026-06-30,2025-09-15,2023-05-09,INTERVENTIONAL,PHASE1,15.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis|Progressive Multifocal Leukoencephalopathy,89 Zr-Df-crefmirlimab|PET Imaging,United States,Bethesda,Maryland,1,89 Zr-Df-crefmirlimab,DRUG,Infiltration of CD8+ T cells in the CNS of adults with MS and PML via PET-CT scans using a minibody with high affinity for CD8+ T cells.,"For the PML cohort with longitudinal evaluation, effects of immune reconstitution, either spontaneous or facilitated, on 89Zr-Dfcrefmirlimab uptake.|Safety of 89Zr-Dfcrefmirlimab in the participants with CNS disease.|To determine whether 89Zr-Df-crefmirlimab uptake profile in MS and PML is disease-specific.",False,
NCT02936037,Effect of MD1003 in Progressive Multiple Sclerosis (SPI2),Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study,TERMINATED,2016-12,2019-11-15,2020-04-23,2020-11-23,2016-10-18,INTERVENTIONAL,PHASE3,642.0,ACTUAL,MedDay Pharmaceuticals SA,INDUSTRY,,,Multiple Sclerosis,progressive multiple sclerosis|MS|EDSS|TW25|multiple sclerosis,United States,Phoenix,Arizona,92,MD1003 100mg capsule|PLACEBO,DRUG|DRUG,Proportion of Patients Improved on Either Expanded Disability Status Scale (EDSS) or Time to Walk 25 Feet (TW25),"Time to 12-Weeks Confirmed EDSS Progression|CGI-I Score (Clinical Global Impression of Change - Improvement), Evaluated Both by the Patient (SGI) and by the Evaluating Physician (CGI)|Mean Change in TW25 Between M0 and M15",True,2020-11-23
NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,"A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2011-04,2015-10,2015-10,2017-01-13,2011-04-08,INTERVENTIONAL,PHASE3,1077.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,Subcutaneous|Extension|Interferon|MS|PEGylated|Injectable|SC|PEG|peginterferon beta-1a|Relapsing,United States,Atlanta,Georgia,151,peginterferon beta-1a,DRUG,"Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs|Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities|Number of Participants With Shifts From Baseline: Liver Function Laboratory Values|Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry|Number of Participants With Shifts From Baseline: Urinalysis","Annualized Relapse Rate (ARR)|Percentage of Participants Who Relapsed|Number of New or Newly Enlarging T2 Hyperintense Lesions|Number of New Active Lesions|Number of New T1 Hypointense Lesions|Number of Gd-Enhancing Lesions|Volume of T2 Hyperintense Lesions|Volume of T1 Hypointense Lesions|Volume of Gd-Enhancing Lesions|Percentage Change of Whole Brain Volume|Change From Baseline in Expanded Disability Status Scale (EDSS)|Time to Sustained Disability Progression|Change From Baseline in Symbol Digit Modalities Test (SDMT)|Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score|Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)|Change From Baseline in SF-12 Physical Component Score (PCS)|Change From Baseline in Euro Quality of Life (EQ-5D) Index Score|Change From Baseline in EQ-5D Visual Analogue Scale (VAS)|Number of Relapses Requiring IV Steroid Use|Number of MS-Related Hospitalizations|Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?|Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?|Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?|Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?|Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?|Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?|Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.|Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.|Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.|Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.|Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.|Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.|Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?|Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections",True,2017-01-13
NCT00037102,Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis,An Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple Sclerosis,COMPLETED,2001-07,2003-12,2003-12,2018-04-12,2002-05-17,INTERVENTIONAL,PHASE4,16.0,ACTUAL,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,OTHER,Consultants in Neurology|Biogen,INDUSTRY|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Relapsing|Methotrexate|AVONEX|interferon beta 1a|demyelinating|autoimmune,,,,0,interferon beta 1a|methotrexate,DRUG|DRUG,,,False,
NCT04472975,Prescription Drug Safety and Effectiveness in Multiple Sclerosis,Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS],COMPLETED,1996-01-01,2018-03-31,2018-03-31,2024-05-16,2020-07-16,OBSERVATIONAL,,35000.0,ACTUAL,University of British Columbia,OTHER,University of Manitoba|Dalhousie University|University of Saskatchewan|Alberta Health services|University of Alberta,OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,disease-modifying drugs|health administrative data|population-based|Canada|cohort studies,,,,0,Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS,DRUG,Study 1: All-cause hospitalizations|Study 2: All-cause mortality|Study 3: Change in disability (Expanded Disability Status Scale [EDSS]) over time,"Study 1: Physician consultation rates (overall and by physician specialty)|Study 3: MS disability, measured using the Expanded Disability Status Scale (EDSS) and assessed as time to sustained EDSS 6|Study 3: Sustained EDSS 4|Study 4: Explore the modifying effects|Study 5: Potential incident adverse events|Study 6: Characteristics associated with risk of adverse events",False,
NCT03521557,Gaze and Postural Stability in Multiple Sclerosis,Gaze and Postural Stability in People With MS: Characterizing Deficits and Response to Treatment,COMPLETED,2018-05-29,2020-06-30,2020-09-30,2021-10-06,2018-05-11,INTERVENTIONAL,NA,42.0,ACTUAL,University of Utah,OTHER,National Multiple Sclerosis Society|Arizona State University|Johns Hopkins University,OTHER|OTHER|OTHER,Multiple Sclerosis|Vertigo|Dizziness|Falls Injury,,United States,Salt Lake City,Utah,1,Gaze and Postural Stability|Standard Care Control,BEHAVIORAL|BEHAVIORAL,Dizziness Handicap Inventory,Dizziness Handicap Inventory Follow-up|Activity Specific Balance Confidence Scale|Functional Gait Assessment|Mini-BEST test|Dynamic Visual Acuity|Passive Angular Vestibulo-ocular Reflex Gain|Compensatory Saccade Frequency|Compensatory Saccade Latency|Gaze Position Error|Margin of stability|Step Latency|Postural Sway,False,
NCT01968902,Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients,"A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis",COMPLETED,2013-11,2016-01-27,2016-12-31,2017-03-22,2013-10-24,INTERVENTIONAL,PHASE4,27.0,ACTUAL,Multiple Sclerosis Center of Northeastern New York,OTHER,"Merz North America, Inc.",INDUSTRY,Muscle Spasticity|Multiple Sclerosis,spasticity|lower limb|multiple sclerosis|toxin,United States,Latham,New York,1,incabotulinumtoxinA|Placebo,BIOLOGICAL|BIOLOGICAL,Mean change from injection visit to week 6 in the Modified Ashworth score between Xeomin vs placebo group,Mean change from injection visit to week 6 in Multiple Sclerosis Walking Scale (MSWS-12) between Xeomin vs placebo group|Change in Patient Global impression of change between Xeomin vs placebo group|Mean change from injection visit to week 6 in Multiple Sclerosis Impact Scale (MSIS-29) physical and psychological scores between Xeomin vs placebo group|Mean change from injection visit to week 6 in Timed 25 Foot Walk (T25FW) between Xeomin vs placebo group|Clinical Global impression of change between Xeomin vs placebo group|Mean change from injection visit to week 6 in Likert Pain Scale between Xeomin vs placebo group,False,
NCT05227092,3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME),3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME),RECRUITING,2023-08-02,2026-05-01,2026-05-01,2025-06-29,2022-02-07,INTERVENTIONAL,NA,60.0,ESTIMATED,"University Hospital, Bordeaux",OTHER,,,Multiple Sclerosis,MS|MRI|CIS|RRMS|PPMS|MPRAGE,France,Bordeaux,,1,3D OPTIMIZED WMN MPRAGE,DEVICE,lesions at the cervical level,lesions at the thoracic level|sensitivity of the 3D optimised WMN MPRAGE sequence|positive predictive value of the 3D optimized WMN MPRAGE sequence|Intraclass corelation coefficient|pathogenicity of the lesions|presence of artefacts|volume of lesion|contrast-to-noise ratio|patient's disability,False,
NCT06197841,Neurofilament Light Chain as Diagnostic and Prognostic Marker in naïve Multiple Sclerosis Patients,Neurofilament Light Chain and Cognitive Impairment as Diagnostic and Prognostic Markers in naïve Multiple Sclerosis Patients,ENROLLING_BY_INVITATION,2023-12-01,2024-12-01,2024-12,2024-01-09,2024-01-09,OBSERVATIONAL,,85.0,ESTIMATED,Assiut University,OTHER,Al-Azhar University,OTHER,Role of Neurofilment in Diagnosis of Multiple Sclerosis,Naïve multiple sclerosis patients|cognitive impairment|Neurofilment light chain|Chitinase|diagnosis and predictor for outcome,Egypt,Asyut,,1,,,The primary outcome is the detection of neurofilament light chain as diagnostic and prognostic inflammatory markers in newly diagnosed MS patients.,Assessment of the incidence of cognitive impairment among naive multiple sclerosis patients and their correlation with neurofilment light chain,False,
NCT01728922,Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome,Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.,COMPLETED,2012-11-06,2015-06-05,2016-06-05,2017-05-03,2012-11-20,INTERVENTIONAL,PHASE1|PHASE2,64.0,ACTUAL,University College Dublin,OTHER,"University of Dublin, Trinity College|St Vincent's University Hospital, Ireland",OTHER|OTHER,Clinically Isolated Syndrome|Multiple Sclerosis,Clinically isolated syndrome|Multiple sclerosis|Vitamin D|Immune response|CD4 T cell subsets|Cytokine,Ireland,Dublin,Dublin 4,1,5000IU vitamin D|10000IU vitamin D|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|OTHER,The effects of two doses of vitamin D and placebo therapy on the change in the frequency of CD4 T cell subsets and cytokine responses of PBMC over 24 weeks of therapy from baseline.,"The number of new T2 and gadolinium enhancing lesions compared to baseline amongst the study group.|Relapse occurrence in the CIS patients during 24 weeks of the trial|The percentage of CIS patients in each treatment arm free from any evidence of disease activity (No relapses, no new T2 lesions, no gadolinium enhancing lesions).",False,
NCT02011451,Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis,Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis,WITHDRAWN,2015-12,2017-03,2017-12,2016-09-26,2013-12-13,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Louisiana State University Health Sciences Center in New Orleans,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Multiple Sclerosis|Green Tea|ECGC|Theaphenon|Randomized placebo controlled trial|NAA|Spectroscopy|Brain Atrophy|SIENA,United States,New Orleans,Louisiana,1,95% Pure ECGC capsules 200mg|Placebo Comparator:,DRUG|DRUG,Rate of change in NAA levels adjusted for water content.,Brain Atrophy,False,
NCT03157830,Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab,Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab,COMPLETED,2017-06-01,2022-01-28,2022-06-06,2024-09-19,2017-05-17,OBSERVATIONAL,,43.0,ACTUAL,Providence Health & Services,OTHER,"Genentech, Inc.",INDUSTRY,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|MS|ocrelizumab|OCREVUS|Natalizumab|Tysabri,United States,Livingston,New Jersey,5,,,Relapse Free Survival at Month 12,"Relapse Rate at Months 3, 6, and 9|MRI Evidence of MS Disease Activity at Months 3, 6, and 12|New or Enlarging T2 Lesions at 3, 6, and 12 Months|New Gd+ Lesions Detected at Months 3, 6, and 12|Change in the EDSS Score From Baseline to Month 12|Change in MSIS-29 From Baseline to Months 6 and 12|Proportion of Patients That Discontinued OCR",True,2024-09-19
NCT01585766,"Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis,COMPLETED,2012-04-24,2015-01-02,2016-06-20,2018-10-29,2012-04-26,INTERVENTIONAL,PHASE1,56.0,ACTUAL,MedImmune LLC,INDUSTRY,,,"Multiple Sclerosis, Relapsing Forms","MAb, B cell, depletion, RMS",United States,Scottsdale,Arizona,16,MEDI-551 30 MG-IV|MEDI-551 60 MG-SC|PLACEBO-IV-SC|MEDI-551 100 MG-IV|MEDI-551 300 MG-SC|MEDI-551 600 MG-IV,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs|Number of Participants With Vital Sign Abnormalities Reported as TEAEs,Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551|Maximum Observed Serum Concentration (Cmax) of MEDI-551|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551|Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551|Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551|Clearance of MEDI-551|Terminal Elimination Half-life (t1/2) of MEDI-551|Absolute Subcutaneous Bioavailability (F%) of MEDI-551|Absolute CD20 B-cell Count at Baseline|Time to 90 Percent (%) CD20 B-cell Depletion|Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count|Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU|Number of Participants Positive for Anti-Drug Antibodies to MEDI-551,True,2018-10-29
NCT07085507,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients","A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208",RECRUITING,2025-08-01,2026-10-30,2027-12-31,2025-09-03,2025-07-25,INTERVENTIONAL,PHASE1|PHASE2,100.0,ESTIMATED,Vidya Therapeutics Inc,INDUSTRY,Vidya Therapeutics Australia Pty Ltd,UNKNOWN,Multiple Sclerosis,pharmacokinetics|healthy volunteers|pharmacodynamics|central nervous system,Australia,Adelaide,South Australia,1,VT7208|Placebo,DRUG|DRUG,"Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of VT7208 in healthy volunteers and patients with MS",Part 1: Pharmacokinetics of a single dose of VT7208 in healthy adults|Part 1: Pharmacodynamics (PD) of a single dose of VT7208 in healthy adults|Part 1: Pharmacokinetics of multiple doses of VT7208 in healthy adults and in patients with MS|Part 1: Pharmacodynamics (PD) of multiple doses of VT7208 in healthy adults and in patients with MS|Part 2: Pharmacokinetics of VT7208 in healthy adults fed and fasted|Part 2: Pharmacodynamics (PD) of VT7208 in healthy adults fed and fasted|Characterize the ability of VT7208 to cross the blood brain barrier in healthy adults and in patients with MS,False,
NCT00220506,Fatigue Treatment Using Provigil,Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis,UNKNOWN,2005-09,,2006-12,2006-02-17,2005-09-22,INTERVENTIONAL,NA,50.0,,Sheba Medical Center,OTHER_GOV,,,All Multiple Sclerosis Patients,provigil|fatigue|Multiple Sclerosis|cognition,Israel,Tel Litwinsky,,1,Provigil,DRUG,To determine fatigue impact scale,to determine cognition measurements,False,
NCT04063852,PTNS on Urinary and Global Quality of Life in MS Patients,Impact of Percutaneous Posterior Tibial Nerve Stimulation on Urinary and Global Quality of Life in Multiple Sclerosis Patients,COMPLETED,2019-02-27,2022-11-27,2022-11-27,2023-02-14,2019-08-21,OBSERVATIONAL,,23.0,ACTUAL,University of Michigan,OTHER,"Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction",OTHER,Multiple Sclerosis|Lower Urinary Tract Symptoms|Neurogenic Bladder|Overactive Bladder|Urinary Incontinence|Urinary Urge Incontinence,,United States,Ann Arbor,Michigan,1,,,Urinary Frequency and/or Urinary Incontinence Episodes on 3 day voiding diary,,False,
NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,"An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis",COMPLETED,2012-02,2013-07,2013-08,2017-03-21,2011-11-28,INTERVENTIONAL,PHASE4,901.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Quality of Life|Multiple Sclerosis,Australia,Concord,New South Wales,59,Fampridine,DRUG,"Change From Baseline in the Physical Component Scale (PCS) of the Short Form 36 Health Status Questionnaire (SF-36) At Months 3, 6, 9, and 12: Responders","Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12: Responders Versus Non-responders|Change From Baseline in the MCS of the SF-36 At Months 3, 6, 9, and 12|Change From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Score at Months 3, 6, 9, and 12|Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12|Change From Baseline in the Activities Limitation Scale of the Patient-Reported Indices for Multiple Sclerosis (PRIMUS) at Months 3, 6, 9, and 12|Change From Baseline in the Current Health State of EuroQoL Descriptive System of Health-related Quality of Life States Consisting of 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Months 3, 6, 9, And 12|Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12|Change From Baseline in Percent Work Time Missed Due to MS, by the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) Questionnaire at Months 3, 6, 9, and 12|Change From Baseline in Percent Impairment While Working Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12|Change From Baseline in Percent Overall Work Impairment Due to MS, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12|Change From Baseline in Regular Activity Productivity Loss, by the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12|Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in the MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in the Activity Limitation Scale (ALS) of PRIMUS Score at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in Current Health State of the EQ-5D VAS at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in EQ-5D Index Scores at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by MS Disease Type: Responders|Change From Baseline in the PCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in the MCS of the SF-36 at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in the MSIS-29 Physical Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in MSIS-29 Psychological Score at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in the Activities Limitation Scale of the PRIMUS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in the Current Health State of EQ-5D VAS at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in the Index Scores of EQ-5D at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in Percent Work Time Missed Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in Percent Impairment While Working Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in Percent Overall Work Impairment Due to MS on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Change From Baseline in Regular Activity Productivity Loss on the WPAI-SHP Questionnaire at Months 3, 6, 9, and 12 by Whether Taking Additional MS Therapy|Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)",True,2016-11-04
NCT03873389,Ocrelizumab Effects on the Metabolome in MS,Evaluating the Effects of Ocrelizumab on the Circulating Metabolome in Multiple Sclerosis (MS),COMPLETED,2019-06-12,2023-06-22,2023-12-05,2023-12-12,2019-03-13,OBSERVATIONAL,,25.0,ACTUAL,Johns Hopkins University,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,,United States,Baltimore,Maryland,1,Ocrelizumab,DRUG,Change in Global metabolomic profile,Change in Expanded Disability Status Scale|Change in Multiple Sclerosis Functional Composite score|Change in Modified Fatigue Impact Scale score|Change in Multiple Sclerosis Quality of Life score,False,
NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,"A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)",COMPLETED,2014-09,2016-02,2016-02,2017-03-27,2014-08-19,INTERVENTIONAL,PHASE3,646.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Fampridine,United States,Cullman,Alabama,87,fampridine|Placebo,DRUG|DRUG,Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks,Proportion of Participants Achieving a Mean Improvement From Baseline of ≥ 15% in Timed Up and Go (TUG) Speed Over 24 Weeks|Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Physical Score Over 24 Weeks|Change From Baseline in Berg Balance Scale (BBS) Over 24 Weeks|Change From Baseline in ABILHAND Score Over 24 Weeks,True,2017-03-27
NCT01730547,Mesenchymal Stem Cells for Multiple Sclerosis,Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,COMPLETED,2013-02,2019-05-09,2021-11-20,2023-06-01,2012-11-21,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,Karolinska Institutet,OTHER,,,Multiple Sclerosis,Mesenchymal stem cells|Multiple Sclerosis|Autoimmune diseases,Sweden,Stockholm,,1,Autologous mesenchymal stem cells,BIOLOGICAL,To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.,To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).,False,
NCT03915028,Thermal Cures in the Treatment of Multiple Sclerosis,Thermal Cures in the Treatment of Multiple Sclerosis: Effectiveness on the Quality of Life,UNKNOWN,2019-05-23,2021-05,2021-08,2019-07-10,2019-04-16,INTERVENTIONAL,NA,200.0,ESTIMATED,Association Francaise pour la Recherche Thermale,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Spa treatment|Crenotherapy|Balneotherapy|Physical exercise,France,Montpellier,,1,Spa therapy,OTHER,Benefit of spa treatment on quality of life assessed by the scale SEP-59,Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter|Benefit of a thermal cure based on treatment consumption of hospital and ambulatory care|Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale|Benefit of a thermal cure based on tiredness assesed by the fatigue impact scale|Benefit of a thermal cure regarding pain assessed by the scale DN 4,False,
NCT01914016,Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop,Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop:Feasibility of Instrumented Gait Analysis in Clinical Practice.,COMPLETED,2013-09,2015-10,2015-11,2016-09-28,2013-08-01,INTERVENTIONAL,NA,15.0,ACTUAL,Queen Margaret University,OTHER,NHS Lothian,OTHER_GOV,Multiple Sclerosis,,United Kingdom,Edinburgh,,1,prolonged walk,OTHER,Peak dorsiflexion angle during the swing phase without FES,Rate of perceived exertion (RPE)|Peak dorsiflexion angle during swing phase (with FES)|Rates of perceived Exertion (RPE) with FES,False,
NCT06102148,The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson in Patients With Multiple Sclerosis,"The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson Pain, Motor Functions, Fatique and Health Related Quality of Life in Patients With Multiple Sclerosis: A Randomized, Single-blind Study.",COMPLETED,2021-11-01,2022-11-01,2022-11-01,2023-10-26,2023-10-26,INTERVENTIONAL,NA,44.0,ACTUAL,Nilay Comuk Balci,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Proprioceptive Neuromuscular Facilitation|Pain|Motor Function|Fatigue|Quality of Life,Turkey (Türkiye),Samsun,,1,PNF Group|Control Group,OTHER|OTHER,Visual Analogue Scale (VAS)|Multiple Sclerosis Quality of Life-54 (MSQoL-54)|Fatigue Severity Scale and Fatigue Impact Scale (FIS)|Timed Up and Go (TUG)|The Six-Minute Walk Test (6-MWT)|Hand Dexterity,,False,
NCT06201026,Effects of Individualized Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis,"Effects of Individualized, Home-based, Mobile App-guided Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis: a Randomized Controlled Trial.",RECRUITING,2023-09-12,2025-07-01,2025-09-15,2024-10-23,2024-01-11,INTERVENTIONAL,NA,96.0,ESTIMATED,Centre Hospitalier Universitaire de Saint Etienne,OTHER,,,Sclerosis|Fatigue,Fatigue|Neuromuscular function|Muscle characteristics|Physical capacity,France,Saint-Etienne,,1,Traditional exercise|Individualized exercise,OTHER|OTHER,Fatigue Severity Scale (FSS),cross sectional area (µm2) of type IIA fibers from the vastus lateralis muscle biopsies|Muscle enzymatic activity (UI)|Maximal oxygen uptake (VO2max) (ml/min)|Percentage of voluntary activation (%)|C-reactive protein (CRP) (mg/l)|Maximal voluntary contraction (MVC) of the knee extensor muscle measurement|Maximal voluntary contraction (MVC) of the hand grip measurement|Balance test (s)|Quality of life questionnaire (SEP-59)|Epworth score|Pittsburgh Sleep Quality Index (PSQI)|Hospital Anxiety and Depression scale (HAD),False,
NCT06992115,A Study of the MIND Diet for Persons With Multiple Sclerosis,Randomized Controlled Trial of MIND Diet for Neuroprotection and Symptom Management in MS,NOT_YET_RECRUITING,2025-05,2029-04-30,2029-04-30,2025-05-28,2025-05-28,INTERVENTIONAL,NA,100.0,ESTIMATED,Icahn School of Medicine at Mount Sinai,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Diet,United States,New York,New York,1,Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet|Small Group,BEHAVIORAL|BEHAVIORAL,Changes in plasma neurofilament light chain (NfL),Neurological Fatigue Index-MS (NFI-MS)|The Expanded Disability Status Scale (EDSS)|The Symbol-Digit Modalities Test (SDMT)|California Verbal Learning Test (CVLT-II)|Brief Visuospatial Memory Test (BVMT-R)|The 9-Hole Peg Test (9HPT)|Timed 25-Foot Walk (T25FW)|The 2-Minute Walk Test|Multiple Sclerosis Impact Scale (MSIS-29)|Multiple Sclerosis Cognitive Scale (MSCS)|MIND Diet Score|MIND Diet Adherence Score|The Diet History Questionnaire (DHQ)|The Insomnia Severity Index (ISI)|The Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Glial fibrillary acidic protein (GFAP) level|Lipid panel|Apolipoproteins level|Hemoglobin A1C Test|The NHANES biological aging index (BAI)|Leukocyte telomere length (LTL),False,
NCT00467584,Aspirin for Treatment of Multiple Sclerosis-Related Fatigue,Aspirin for Treatment of Multiple Sclerosis-Related Fatigue,TERMINATED,2007-07,2013-09,2013-09,2014-05-20,2007-04-30,INTERVENTIONAL,PHASE3,62.0,ACTUAL,Mayo Clinic,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Fatigue,,United States,Scottsdale,Arizona,1,High Dose Aspirin (1300 mg/day)|Low Dose Aspirin (162 mg/day)|Placebo,DRUG|DRUG|DRUG,Modified Fatigue Impact Scale Score,,True,2014-05-16
NCT06478784,Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial.,Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial. ACTIVE (Physical Activity and Its Impact on Patients With Multiple Sclerosis.),RECRUITING,2024-01-01,2024-12-31,2025-01-30,2024-06-27,2024-06-27,INTERVENTIONAL,NA,50.0,ESTIMATED,Hospital Clínico Universitario de Valladolid,OTHER,European University Miguel de Cervantes,OTHER,Multiple Sclerosis,physical exercise|resistance training|neurofilaments|GFAP,Spain,Valladolid,,1,Resistance training|Low aerobic training,OTHER|OTHER,Comparison of plasma light chain neurofilaments (Nfl) level,Comparison of plasma Glial fibrillary acidic protein (GFAP) level,False,
NCT00257855,A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis,"A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial",COMPLETED,2005-11,2009-01,2009-02,2010-02-08,2005-11-23,INTERVENTIONAL,PHASE2,120.0,,University College London Hospitals,OTHER,,,Secondary Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis|Neuroprotection|Axonal loss|Brain atrophy|MRI|Lamotrigine|Sodium Channel Blockers,United Kingdom,London,,1,Lamotrigine,DRUG,Change in central brain volume on MRI using the 'Loseff method',Change in whole brain volume on MRI using Brain Boundary Shift Integral|Number and volume of new T2 high intensity lesion volume on T2 weighted MRI|Number and volume of new T1 low signal lesion volume on T1 weighted MRI|Ratio of new T1 to new T2 lesions on MRI|Change in magnetisation transfer ratio in normal MRI normal appearing white matter and normal appearing grey matter.|Change in upper cervical cord cross sectional area using the 'Loseff method' on MRI|Change in Kurtzke's Extended Disability Scaling Score.|Change in Multiple Sclerosis Functional Composite.|Change in Multiple Sclerosis Impact Scale.,False,
NCT00127075,POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis,POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis,UNKNOWN,2005-06,2012-04,2012-04,2011-12-30,2005-08-05,INTERVENTIONAL,PHASE3,300.0,ESTIMATED,Hospices Civils de Lyon,OTHER,,,Multiple Sclerosis,Multiple sclerosis. Relapses. Post partum. Pregnancy. Delivery. Hormones. Progesterone. Estradiol. Clinical trial. Prevention.,France,Bron,,1,nomegestrol acetate|estradiol|placebo,DRUG|DRUG|DRUG,"To compare the rate of relapses during the first 12 weeks after delivery, between the treated and placebo groups","Percentage of patients who remain relapse-free during the 12-week period after delivery|Rate of relapses, percentage of patients who remain relapse-free during the 24-week period after delivery|Rate of relapses, percentage of patients who remain relapse-free during the 12- to 24-week period after delivery",False,
NCT01125475,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study,COMPLETED,2010-08,2012-03,,2014-07-16,2010-05-18,OBSERVATIONAL,,61.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Merck Serono Norway|Smerud Medical Research International AS,INDUSTRY|OTHER,Relapsing Remitting Multiple Sclerosis (RRMS),Relapsing Remitting Multiple Sclerosis|RebiSmart|Rebif|Adherence,Norway,Sandvika,Sandviksveien 178,1,RebiSmart,DEVICE,Adherence assessment,,False,
NCT01744444,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis,,COMPLETED,2012-11,2013-07,2013-07,2025-09-03,2012-12-06,INTERVENTIONAL,PHASE2,10.0,ACTUAL,Hospices Civils de Lyon,OTHER,,,Pendular Nystagmus Patients With Multiple Sclerosis,,France,Bron,,1,Memantine|Gabapentin,DRUG|DRUG,Velocity using eye movement recording|Velocity using eye movement recording|Velocity using eye movement recording|Velocity using eye movement recording,Functional score on questioning|Subjective measure of oscillopsia|Far visual acuity,False,
NCT00000147,Longitudinal Optic Neuritis Study (LONS),,UNKNOWN,1988-07,,,2006-05-29,1999-09-24,INTERVENTIONAL,NA,,,National Eye Institute (NEI),NIH,,,Multiple Sclerosis|Optic Neuritis,,United States,Little Rock,Arkansas,15,Methylprednisolone|Prednisone,DRUG|DRUG,,,False,
NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),Betaferon Treatment and Exercise Data Gathering IN Early MS,COMPLETED,2006-08,2011-03,2011-03,2012-05-30,2009-04-16,OBSERVATIONAL,,1739.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Physical Activity|Fatigue|RRMS|CIS,Australia,Many Locations,,33,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Physical Activity and Fatigue,Health-related Quality of Life|Depression,False,
NCT04480853,Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis,"A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)",RECRUITING,2020-10-12,2026-01-27,2026-01-27,2024-12-27,2020-07-21,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Fingolimod|Multiple sclerosis|Relapsing-remitting multiple sclerosis|Relapsing-remitting|Post-authorization study|Adult|MS,Taiwan,Kaohsiung City,,6,Fingolimod,DRUG,Number of Adverse Events of Special Interest(AESI)|Number of Adverse Events of Special Interest (AESI),Annualized relapse reate (ARR)|Change from baseline of Pulse (beats/min)|Change from baseline of blood pressure (mmHg),False,
NCT00004814,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis",,COMPLETED,1991-10,,,2005-06-24,2000-02-25,INTERVENTIONAL,PHASE3,250.0,,National Center for Research Resources (NCRR),NIH,University of Maryland,OTHER,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,,,,0,copolymer 1,DRUG,,,False,
NCT00403104,Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS),"A Multi-centre, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Investigate Efficacy and Safety of ONO-2506PO Compared to Placebo, in the Presence of Riluzole, to Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS), Who Have Had Onset of Muscle Weakness Within 14 Months of Randomization",COMPLETED,2006-11,2008-12,2008-12,2012-06-13,2006-11-23,INTERVENTIONAL,PHASE2,420.0,ACTUAL,Ono Pharmaceutical Co. Ltd,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),ONO-2506PO|Amyotrophic Lateral Sclerosis|ALS,Austria,Vienna,,26,ONO-2506PO|ONO-2506PO,DRUG|DRUG,Rate of decline of respiratory function determined as SVC over the 12 month treatment period,Survival|Functional Assessment (ALSFRS-R)|Muscle Strength (MRC muscle score)|Quality of Life,False,
NCT05787704,Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis,Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis,COMPLETED,2023-04-21,2024-05-14,2024-05-22,2024-10-24,2023-03-28,OBSERVATIONAL,,41.0,ACTUAL,Karolinska Institutet,OTHER,Karolinska University Hospital,OTHER,"Multiple Sclerosis|Gait Disorders, Neurologic|Neuro-Degenerative Disease|Aging",functional near infrared spectrometry|gait|physical activity|cognition|brain activity,Sweden,Stockholm,Solna,1,No intervention,OTHER,Functional near infrared spectrometry (fNIRS)|Gait performance during all conditions|Dual-task performance-reaction time,Cognitive function- composite score|Cognitive function - verbal fluency|Cognitive function - Attention and psychomotor processing speed|Cognitive function - Episodic memory|Cognitive function - Cognitive processing speed|Cognitive function - Inhibition & task-set switching|Self-reported level of physical activity|Physical activity level and intensity|Overall MS-disability|Balance performance|Anxiety and depression|Walking ability|Dual-task performance -errors|Disability|Impact of Fatigue|Impact of MS on health,False,
NCT00291148,Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain,"A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine",COMPLETED,2006-03,2012-07,2012-07,2012-07-27,2006-02-13,INTERVENTIONAL,PHASE3,75.0,ESTIMATED,University of Manitoba,OTHER,,,Neuropathic Pain|Multiple Sclerosis,Neuropathic pain|Multiple Sclerosis|pregabalin|paroxetine,Canada,Winnipeg,Manitoba,1,paroxetine|pregabalin,DRUG|DRUG,Pain levels (as determined by weekly Visual Analogue Scale for pain),Short-Form 36 health outcomes survey (SF-36)|Short-form McGill Pain Questionnaire (SF MPQ)|Patient-rated Global Impression of Change (PGIC),False,
NCT05201638,"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)",RECRUITING,2022-01-12,2024-10,2032-10,2024-04-18,2022-01-21,INTERVENTIONAL,PHASE3,1050.0,ESTIMATED,Immunic AG,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Scottsdale,Arizona,91,IMU-838 tablets|Placebo matching IMU-838 tablets,DRUG|DRUG,To evaluate efficacy of IMU-838 versus placebo based on time to first relapse,Effect of IMU-838 versus placebo on volume of new T2 lesions|Effect of IMU-838 versus placebo on disability progression|Effect of IMU-838 versus placebo on cognitive performance|Effect of IMU-838 versus placebo on whole brain atrophy|Safety of IMU-838 versus placebo,False,
NCT05787795,Identifying and Characterizing Preclinical MS,Identifying and Characterizing Preclinical MS,RECRUITING,2022-06-21,2032-06-30,2033-06-30,2025-02-14,2023-03-28,OBSERVATIONAL,,1000.0,ESTIMATED,Yale University,OTHER,Roche-Genentech,INDUSTRY,Multiple Sclerosis,,United States,North Haven,Connecticut,1,biological samples,OTHER,To build a machine learning model of risk prediction,Individual data types collected,False,
NCT03399981,Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries,An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri,COMPLETED,2017-06-01,2023-12-31,2023-12-31,2024-03-19,2018-01-17,OBSERVATIONAL,,80327.0,ACTUAL,Biogen,INDUSTRY,,,Progressive Multifocal Leukoencephalopathy,,United States,Cambridge,Massachusetts,1,Tysabri,BIOLOGICAL,Prospective and Retrospective Analyses: Number of Participants with Confirmed Progressive Multifocal Leukoencephalopathy (PML)|Prospective and Retrospective Analyses: Number of Participants with Serious Adverse Events of Other Serious Opportunistic Infections (OIs),,False,
NCT01851434,Natural History of Optic Neuritis,Natural History of Optic Neuritis,TERMINATED,2013-03-20,2014-09-05,2017-10-26,2022-09-29,2013-05-10,OBSERVATIONAL,,8.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,National Eye Institute (NEI),NIH,Multiple Sclerosis,OCT|Multiple Sclerosis|Optic Neuritis|Magnetic Resonance Imaging (MRI)|Natural History,United States,Bethesda,Maryland,3,,,The primary outcome measure is the RNFL thickness in the affected eye 12 months after optic neuritis,,False,
NCT00220493,Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients,Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients,UNKNOWN,2003-06,,2005-06,2007-01-05,2005-09-22,INTERVENTIONAL,PHASE1,80.0,,Sheba Medical Center,OTHER_GOV,,,"Relapsing Remitting Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive",MS|RITALIN|PASAT|COGNITION|ATTENTION|Relapsing remitting|Secondary progressive|Primary progressive,Israel,Ramat Gan,,1,Ritalin,DRUG,Score on the Paced Auditory Serial Addition Test (PASAT) one hour after taking the drug/placebo,,False,
NCT04550455,A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets,A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets,RECRUITING,2020-09-16,2024-12,2025-12,2022-01-13,2020-09-16,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,"Keith Edwards, M.D.",OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis,,United States,Latham,New York,1,Cladribine Tablets,DRUG,Time to achieve no evidence of disease activity (NEDA) -4 compared to baseline|Decrease of serum/CSF NfL,Change in upper body function|Change in Cognitive Function,False,
NCT00598455,Tuberous Sclerosis Complex Natural History Study: Renal Manifestations,Tuberous Sclerosis Complex Natural History Study: Renal Manifestations,COMPLETED,2008-02,2013-09,2013-09,2017-05-04,2008-01-22,OBSERVATIONAL,,450.0,ESTIMATED,"Children's Hospital Medical Center, Cincinnati",OTHER,"Loma Linda University|Massachusetts General Hospital|Boston Children's Hospital|University of Alabama at Birmingham|University of Pennsylvania|Connecticut Children's Medical Center|The University of Texas Health Science Center, Houston",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Tuberous Sclerosis Complex,angiomyolipomata|tuberous sclerosis complex,United States,Cincinnati,Ohio,1,,,,,False,
NCT06415552,Implementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis,Implementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis,NOT_YET_RECRUITING,2025-01-01,2026-12-31,2027-05-31,2024-12-06,2024-05-16,INTERVENTIONAL,NA,120.0,ESTIMATED,Robert Simpson,OTHER,,,Multiple Sclerosis,Mindfulness,Canada,Toronto,,1,Mindfulness-Based Stress Reduction,BEHAVIORAL,Recruitment|Retention|Adherence|Follow-up rates,Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29)|Quality of Life using the EuroQol (EQ-5D-5L)|Anxiety|Depression|Health services use|Emotion regulation|Self-compassion|Mindfulness|Climate|Therapeutic alliance|Sleep|Pain Effects|Fatigue|Cognitive function,False,
NCT07008378,"A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis","A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis",RECRUITING,2025-09-30,2032-08-31,2032-08-31,2025-09-16,2025-06-06,INTERVENTIONAL,PHASE1,60.0,ESTIMATED,"Genentech, Inc.",INDUSTRY,"Poseida Therapeutics, Inc., a member of the Roche Group",UNKNOWN,Multiple Sclerosis,,United States,St Louis,Missouri,1,P-CD19CD20-ALLO1 Cells|Cyclophosphamide|Fludarabine,BIOLOGICAL|DRUG|DRUG,Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1|Number of Participants With Adverse Events (AEs),Number of Chimeric Antigen Receptor (CAR) Transgene Copies in Blood Assessed by Droplet Digital Polymerase Chain Reaction (ddPCR)|B-cell Levels in the Blood|Number of Participants With Anti-CAR T Antibodies,False,
NCT01428726,A Phase IIa Study of NT-KO-003 for Multiple Sclerosis,A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis,COMPLETED,2011-06,2014-01,2014-01,2014-03-18,2011-09-05,INTERVENTIONAL,PHASE2,99.0,ESTIMATED,Neurotec Pharma,INDUSTRY,"Advancell - Advanced In Vitro Cell Technologies, S.A.",INDUSTRY,Relapsing Remitting Multiple Sclerosis,NT-KO-003|RRMS|efficacy|safety|Phase IIa,Germany,Berlin,,17,NT-KO-003,DRUG,Efficacy of NT-KO-003 in patients with relapsing remitting MS patients,Efficacy of NT-KO-003 in relapsing remitting MS patients|Clinical efficacy of NT-KO-003 in relapsing remitting MS patients|Safety of NT-KO-003 in patients with relapsing remitting MS patients,False,
NCT01081782,A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis,"A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2010-03,2011-12,2011-12,2013-12-25,2010-03-05,INTERVENTIONAL,PHASE2,407.0,ACTUAL,Ono Pharma USA Inc,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|ONO-4641,United States,Tucson,Arizona,86,ONO-4641|ONO-4641|ONO-4641|ONO-4641 placebo,DRUG|DRUG|DRUG|DRUG,Total number of T-1-weighted Gd-enhanced lesions obtained with MRI at 4-week intervals for 26 weeks.,Total volume of Gd-enhanced lesions,False,
NCT04593082,Obesity and Pediatric Multiple Sclerosis,Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.,RECRUITING,2021-06-03,2025-06-01,2025-06-01,2024-12-09,2020-10-19,OBSERVATIONAL,,116.0,ESTIMATED,University of Virginia,OTHER,Children's Hospital of Philadelphia,OTHER,Multiple Sclerosis,Pediatric|Obesity|Neurodegeneration|Inflammation,United States,Philadelphia,Pennsylvania,2,,,Whole brain volumes and focal demyelinating lesion volumes,Adipo-cytokine profiles|Adipo-cytokines correlation with brain volume loss and neuroaxonal injury,False,
NCT01667484,Adderall XR and Processing Speed in Multiple Sclerosis (MS),Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?,COMPLETED,2012-09,2013-02,2015-02,2015-05-12,2012-08-17,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,London Health Sciences Centre,OTHER,,,Impaired Processing Speed|Cognitive Impairment|Multiple Sclerosis,Cognitive Impairment|Multiple Sclerosis|Processing Speed|Treatment,Canada,London,Ontario,1,Adderall XR 5mg|Adderall XR 10 mg|Placebo,DRUG|DRUG|DRUG,Change in score of Paced Auditory Serial Addition Test (PASAT)|Change in Score of Symbol Digit Modalities Test (SDMT),,False,
NCT05297474,Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study,Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study,UNKNOWN,2021-07-01,2022-07-01,2022-12-01,2022-03-29,2022-03-28,OBSERVATIONAL,,95.0,ESTIMATED,Tsinghua University,OTHER,Peking Union Medical College Hospital,OTHER,Systemic Sclerosis|Multisystem Disorder,,China,Beijing,,2,MRI,OTHER,"The incidence of structural and functional disorders of heart, brain and kidney in SSc patients.",,False,
NCT06869785,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab","An Open-label, Randomized, Parallel Group, Non-inferiority Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab, Followed by Extended Treatment in Participants With Relapsing Multiple Sclerosis",RECRUITING,2025-03-13,2026-12-24,2031-05-26,2025-08-19,2025-03-11,INTERVENTIONAL,PHASE3,180.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),Relapsing Multiple Sclerosis,United States,Birmingham,Alabama,53,Ofatumumab approved dose|Ofatumumab new dose,BIOLOGICAL|BIOLOGICAL,Ofatumumab plasma pharmacokinetics - area under the curve,Ofatumumab plasma pharmacokinetics - minimum observed plasma concentration|Ofatumumab plasma pharmacokinetics - maximum observed plasma concentration|Incidence of Adverse events (AE) and Serious adverse events (SAE)|Proportion of participants with anti-drug antibodies|Participant B cell counts,False,
NCT03339908,Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis,Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis,COMPLETED,2017-10-23,2021-01-20,2023-04-04,2023-04-06,2017-11-13,INTERVENTIONAL,NA,7.0,ACTUAL,Assistance Publique Hopitaux De Marseille,OTHER,,,Multiple Sclerosis,,France,Marseille,,1,Thalamotomy by gamma Knife radiosurgery,DEVICE,Scale evaluation Tremor and Coordination Scale (TACS)|Scale evaluation Tremor and Coordination Scale (TACS),,False,
NCT06843239,Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE),"A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis",RECRUITING,2025-02-06,2026-12,2027-05,2025-09-11,2025-02-24,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,Zura Bio Inc,INDUSTRY,,,Systemic Sclerosis (SSc)|Scleroderma,Scleroderma|Systemic Sclerosis (SSc)|Tibulizumab|Cutaneous|Interstitial lung disease (ILD)|Autoimmune diseases|Immune system diseases|Systemic Sclerosis interstitial lung disease (SSC-ILD)|Skin Diseases,United States,Plantation,Florida,15,Tibulizumab|Placebo,BIOLOGICAL|OTHER,[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks|[Period 2] Safety and tolerability of tibulizumab,[Period 1] Change from baseline in quantitative interstitial lung disease (QILD) obtained with high-resolution quantitative tomography (HRCT) in the whole lung in participants with SSc-interstitial lung disease (ILD)|[Period 1] Change from baseline in forced vital capacity (FVC)|[Period 1] Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)|[Period 1] Safety and tolerability of tibulizumab|[Period 2] Change from baseline in mRSS|[Period 2] Change from baseline in QILD obtained with HRCT in the whole lung in participants with SSc-ILD,False,
NCT03096977,Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity,Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity,COMPLETED,2017-03-15,2019-01-30,2019-01-30,2019-04-17,2017-03-31,INTERVENTIONAL,NA,30.0,ACTUAL,Brugmann University Hospital,OTHER,,,Multiple Sclerosis,Hand dexterity|Multiple sclerosis|Nine Holes Peg,Belgium,Brussels,,1,Scale for the assessment and rating of ataxia (SARA)|JAMAR hand dynamometer|Vibratory sensibility testing|Sermes and Weinstein test|Weber test,DIAGNOSTIC_TEST|DEVICE|DEVICE|DEVICE|DEVICE,Scale for the assessment and rating of ataxia (SARA)|Prehension force|Tuned fork result|Sermes and Weinstein test|Weber test,,False,
NCT00432900,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [(11)C]PBR28 in Patients With Multiple Sclerosis (MS),COMPLETED,2007-02-05,2013-05-23,2013-05-29,2019-12-12,2007-02-08,INTERVENTIONAL,PHASE1,21.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Inflammation|Neuroimmunology|Multiple Sclerosis|MS|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,[(11)C]PBR28,RADIATION,Correspondence between increased PBR expression measured by [11C]PBR28 PET and gadolinium-enhancing lesions on MRI.|Correspondence between increased PBR expression and previously and/or persistently gadolinium-enhancing lesions on MRI.,Correspondence between PBR expression and other MRI defined pathology including T2-weighted hyperintense and T1-weighted hypointense lesions.|Correspondence between PBR expression and normal appearing white and gray matter on MRI.,False,
NCT05795907,Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants,"A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of SAR443820 in Healthy Adult Participants.",COMPLETED,2020-11-30,2021-07-20,2021-07-20,2023-04-03,2023-04-03,INTERVENTIONAL,PHASE1,84.0,ACTUAL,Sanofi,INDUSTRY,,,Amyotrophic Lateral Sclerosis (Healthy Volunteers),,United States,Saint Paul,Minnesota,1,SAR443820|Placebo,DRUG|DRUG,Parts 1a and 1b: Number of participants with adverse events|Part 2: Number of participants with adverse events,Parts 1a and 1b: Assessment of pharmacokinetic parameter of SAR443820: Cmax in plasma|Parts 1a and 1b: Assessment of pharmacokinetic parameter of SAR443820: tmax in plasma|Parts 1a and 1b : Assessment of pharmacokinetic parameter of SAR443820: AUC in plasma|Parts 1a and 1b : Assessment of pharmacokinetic parameter of SAR443820: t1/2z in plasma|Part1b: SAR443820 concentrations in cerebrospinal fluid (CSF) samples|Part 2: Assessment of pharmacokinetic parameter of SAR443820: Cmax in plasma|Part 2: Assessment of pharmacokinetic parameter of SAR443820: tmax in plasma|Part 2: Assessment of pharmacokinetic parameter of SAR443820: AUC tau in plasma|Part 2 Assessment of pharmacokinetic parameter of SAR443820: t1/2z in plasma|Part 2: Day14/Day1 of 4β-hydroxycholesterol ratio in plasma,False,
NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2009-06,2012-10,2013-10,2014-09-19,2009-05-21,INTERVENTIONAL,PHASE3,1516.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,interferon|injectable|MS|SC|PEGylated|Interferon beta-1a|relapsing|PEG|multiple sclerosis|subcutaneous,United States,Phoenix,Arizona,178,BIIB017 (peginterferon beta-1a)|Placebo,DRUG|DRUG,Annualized Relapse Rate (ARR) at 1 Year,Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year|Proportion of Participants Relapsed at 1 Year|Estimated Proportion of Participants With Sustained Disability Progression at 1 Year,True,2014-09-19
NCT05420532,Designing Virtual Reality-based Software for People With Multiple Sclerosis,Designing Virtual Reality-based Testing and Rehabilitation for Upper Extremity Software for People With Multiple Sclerosis,UNKNOWN,2022-01-30,2023-07-15,2023-08-30,2022-06-15,2022-06-15,INTERVENTIONAL,NA,15.0,ESTIMATED,Yuzuncu Yıl University,OTHER,Dokuz Eylul University,OTHER,Multiple Sclerosis,multiple sclerosis|virtual reality|exergaming,Turkey (Türkiye),Izmir,,1,Exergaming,OTHER,Nine-Hole Peg Test,Jamar Hand Dynamometer|Arm Function in Multiple Sclerosis Questionnaire|The User Satisfaction Evaluation Questionnaire,False,
NCT00902135,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH),COMPLETED,2009-05,2013-12,2014-08,2015-07-17,2009-05-14,OBSERVATIONAL,,702.0,ACTUAL,Bayer,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Interferon beta-1b,Germany,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaseron, BAY86-5046)",DRUG|DRUG|DRUG,Drop out rate over 2 years,Disability status|Grade of depressiveness|Grade of fatigue|Quality of life|Cognitive status|Injection regularity,False,
NCT06028776,"Effects of MS Ballroom Fitness on Balance, Walking Capacity, and Well-being in Multiple Sclerosis","MS Ballroom Fitness - Benefits of a Personalized Dance-based Concept on Balance, Walking Capacity, and Well-being in Multiple Sclerosis",COMPLETED,2023-07-01,2024-06-30,2024-09-10,2025-03-19,2023-09-08,INTERVENTIONAL,NA,95.0,ACTUAL,University of Aarhus,OTHER,The Danish MS Society,UNKNOWN,Multiple Sclerosis,,Denmark,Aarhus C,Jutland,1,MS Ballroom Fitness,BEHAVIORAL,Six spot step test (SSST)|WHO5 wellbeing index,Static balance|Functional reach test|Modified functional reach test|Four square step test (FSST)|6-minute walk test|Trunk Impairment Scale 2.0|Patient determined disease steps|Multiple Sclerosis Walking Scale|Health-related quality of life visual analogue scale (HR-QoL VAS)|Modified fatigue impact scale|Falls-efficacy scale - international|Falls,False,
NCT06500039,Positive Psychological Interventions for Patients With Multiple Sclerosis,The Effect of Positive Psychological Interventions on Quality of Life and Well-Being in Patients With Multiple Sclerosis,ENROLLING_BY_INVITATION,2024-07-15,2024-08-30,2025-01-01,2024-08-22,2024-07-15,INTERVENTIONAL,NA,30.0,ESTIMATED,Abant Izzet Baysal University,OTHER,,,Multiple Sclerosis,"Multiple sclerosis, Quality of Life, Well-Being",Turkey (Türkiye),Bolu,,1,Positive Psychological Intervention Program|Writing Daily Routines,OTHER|OTHER,Multiple Sclerosis Quality of Life Scale (MSQOL)-54|PERMA Measuring Tool,Positive and Negative Mood Scale (PNDS),False,
NCT05357781,Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?,Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? - A Prospective Observational Fatigue Trial,RECRUITING,2022-07-01,2026-12-30,2026-12-30,2025-03-30,2022-05-03,OBSERVATIONAL,,106.0,ESTIMATED,"Insel Gruppe AG, University Hospital Bern",OTHER,,,Hypogammaglobulinemia|Multiple Sclerosis|Fatigue,Fatigue|Hypogammaglobulinemia,Switzerland,Bern,Canton of Bern,1,Laboratory test,DIAGNOSTIC_TEST,Number of patients with fatigue and hypogammaglobulinemia|Number of patients with fatigue without hypogammaglobulinemia,Fatigue and infections,False,
NCT03826628,Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex,"A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over",COMPLETED,2019-07-28,2022-09-01,2022-09-01,2023-09-08,2019-02-01,INTERVENTIONAL,PHASE2|PHASE3,107.0,ACTUAL,Dermatology Specialties Limited Partnership,INDUSTRY,,,Facial Angiofibroma|Tuberous Sclerosis,,United States,Phoenix,Arizona,17,rapamycin|placebo,DRUG|DRUG,Percentage of Participants Obtaining Successful Treatment,Time to Treatment Success|Change From Baseline in Investigator's Global Assessment|Change From Baseline in Facial Angiofibroma Severity Index (FASI)|Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale|Objective (Clinician) Percentage Change Rating Scale|Categorical Change in Facial Angiofibroma,True,2023-08-14
NCT01356134,Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI),Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency),COMPLETED,2011-05,2015-04,2015-04,2015-04-03,2011-05-19,OBSERVATIONAL,,60.0,ACTUAL,Genetic Disease Investigators,OTHER,"Optos, PLC",INDUSTRY,Ehlers-Danlos Syndrome|Multiple Sclerosis,multiple sclerosis|ehlers danlos syndrome|CCSVI|chronic cerebrospinal venous insufficiency|fundus|retina,United States,Colleyville,Texas,1,,,Fundus: venous engorgement/beading,,False,
NCT03094364,Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis,Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis,COMPLETED,2015-11,2018-10-31,2018-10-31,2019-04-18,2017-03-29,INTERVENTIONAL,NA,31.0,ACTUAL,"University of Massachusetts, Lowell",OTHER,Ohio State University,OTHER,Primary Progressive Multiple Sclerosis|Hemiparesis,Constraint-induced movement therapy|video game|virtual reality|upper extremity|CI therapy|rehabilitation|hemiparesis|MS|multiple sclerosis|progressive multiple sclerosis|primary progressive multiple sclerosis|secondary progressive multiple sclerosis|motor|physical therapy|physiotherapy|occupational therapy|arm|hand,United States,Columbus,Ohio,1,Gaming CI Therapy,BEHAVIORAL,Bilateral Activity Monitors (Accelerometers)|Wolf Motor Function Test,Biomechanical Measures|Multiple Sclerosis Impact Scale (MSIS-29)|Short form-36 Health Survey|Neuro-QOL|Patient Health Questionnaire (PHQ-9)|Montreal Cognitive Assessment (MoCA),False,
NCT04875832,EMDR for Depressed People With Multiple Sclerosis,Eye Movement Desensitization and Reprocessing for Depressed People With Multiple Sclerosis: A Pilot Study,UNKNOWN,2021-05,2022-08,2022-11,2021-05-06,2021-05-06,INTERVENTIONAL,NA,15.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,EMDR Europe|Catholic University of the Sacred Heart,INDUSTRY|OTHER,Multiple Sclerosis|Depression,Multiple Sclerosis|Depression|EMDR|Qualiti of life|MRI,,,,0,Eye Movement Desensitization and Reprocessing - EMDR,BEHAVIORAL,Hamilton Depression Rating Scale (HDRS)|Hospital Anxiety and Depression Scale (HADS),"Multiple Scleroris Quality of Life - 54, MSQoL-54|Brain MRI|Expanded Disability Status Scale - EDSS Scale",False,
NCT00623415,Flupirtine as Oral Treatment in Multiple Sclerosis,"Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-β1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis",TERMINATED,2007-12,2012-11,2012-11,2018-03-20,2008-02-26,INTERVENTIONAL,PHASE2,30.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,Bayer,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,Germany,Berlin,,4,Flupirtine|Placebo,DRUG|DRUG,Cumulative number of new T2-hypertensive lesions on cranial magnetic resonance imaging (MRI),"Cerebral atrophy (brain parenchymal fraction)|Number of new and total gadolinium(Gd)-enhancing lesions|Disease progression (measured by Expanded Disability Status (EDSS), Multiple Sclerosis Functional Composite (MSFC))|Retinal nerve fiber layer thickness, assessed by Optical coherence tomography",False,
NCT00835835,Lokomat Treadmill Training Effects on MS Gait,Lokomat Treadmill Training Effects on MS Gait,COMPLETED,2008-02,2011-10,2013-06,2015-11-11,2009-02-04,INTERVENTIONAL,NA,8.0,ACTUAL,Mount Sinai Rehabilitation Hospital,OTHER,,,"Gait, Unsteady|Multiple Sclerosis",Multiple Sclerosis|gait|falls|lokomat|body-weight support treadmill training,United States,Hartford,Connecticut,1,Body-weight supported treadmill training +/- Lokomat assistance|Usual Care - no active intervention,OTHER|OTHER,Gait Parameters,,False,
NCT01299025,Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit,Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit,COMPLETED,2010-09,2011-06,2011-06,2015-04-24,2011-02-18,INTERVENTIONAL,NA,84.0,ACTUAL,Örebro County Council,OTHER_GOV,Uppsala-Örebro Regional Research Council|Norrbacka-Eugenia Foundation,OTHER|OTHER,Multiple Sclerosis,balance|walking,Sweden,Eskilstuna,,4,Training using Nintendo Wii Fit,OTHER,Change in Timed Up and Go Test From Day 1 to Day 42,Change in Score on the Dynamic Gait Index From Day 1 to Day 42|Change in the Activities-specific Balance Confidence (ABC) Scalefrom Day 1 to Day 42|Change in the 12 Item Walking Scale From Day 1 to Day 42,True,2015-04-24
NCT04847609,GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders,Multicentric Observational Study of Pain When Using the GentleCath™ Air Catheter in Female Patients Followed at Home With Neurological Vesico-sphincter Disorders With Urinary Self-catheterization as a Bladder Emptying Method,WITHDRAWN,2021-05-31,2021-09-01,2021-10-01,2022-10-07,2021-04-19,OBSERVATIONAL,,0.0,ACTUAL,ConvaTec Inc.,INDUSTRY,ClinSearch,OTHER,Spinal Cord Injuries|Multiple Sclerosis|Parkinsonian Disorders|Allodynia,Neurogenic Bladder|Intermittent Urethral Catheterization|Pain|Tolerance,,,,0,GentleCath™ Air catheter,DEVICE,Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway|Pain assessment score during the insertion and removal of the GentleCath™ Air urinary catheter in female patients with confirmed neurological pathway,Assessment of patients' satisfaction of self-catheterisation|Assessment of patients' satisfaction of self-catheterisation|Patient compliance|Patient compliance|Measurement of the post-voiding residue on inclusion|Measurement of the post-voiding residue on inclusion|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self--catheterization - number of catheterizations|Assessment of compliance with the self-cathetization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - number of catheterizations|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Assessment of compliance with the self-catheterization - Volume measurements|Description of the tolerance of the GentleCath™ Air catheter|Measurement of the overall satisfaction on Gentle Cath Air,False,
NCT03753698,"Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With MS","A Prospective, Single Arm, Interventional, Self-controlled Pilot Study to Assess the Performance and Safety of the New Generation, Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",WITHDRAWN,2020-07-01,2022-12-31,2022-12-31,2021-02-04,2018-11-27,INTERVENTIONAL,NA,0.0,ACTUAL,Chiara Zecca,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Lower Urinary Tract Symptoms|Posterior tibial nerve stimulation|Neuromodulation,Switzerland,Lugano,Canton Ticino,1,eCoin,DEVICE,Change from baseline in bladder volume (mL)|Change from baseline of detrusor pressure amplitude (cmH2O),"Change from baseline of cystometric capacity (mL)|Change from baseline of bladder compliance (mL/cmH2O)|Change from baseline of maximum detrusor pressure (cmH20) during storage phase|Change from baseline of maximum detrusor pressure (cmH20) during voiding phase|Change from baseline of voided urine volume (mL)|Change from baseline of maximum urine flow rate (mL/s)|Change from baseline of post void residual urine (mL)|Change from baseline of pelvic floor electromyographic activity|Change from baseline of vesico-uretero-renal reflux|Change from baseline to 4, 12, and 24 weeks of bladder voiding assessed by means of a 3-day voiding diary|Change from baseline to 4, 12, and 24 weeks of overactive bladder symptoms scores using the short form of the overactive bladder questionnaire OAB-q|Change from baseline to 4, 12, and 24 weeks of MSQOL54 scores.|Treatment satisfaction, as measured on a composite visual analogue scale (VAS) score ranging from 0-100|Incidence of adverse events",False,
NCT07067463,A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis,"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis",NOT_YET_RECRUITING,2025-09,2030-06,2030-07,2025-07-16,2025-07-16,INTERVENTIONAL,PHASE3,705.0,ESTIMATED,"Beijing InnoCare Pharma Tech Co., Ltd.",INDUSTRY,,,Multiple Sclerosis (MS) Primary Progressive,,,,,0,Orelabrutinib|Placebo,DRUG|DRUG,"Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 12 weeks (12-week cCDP)","Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 24 weeks (24-week cCDP)|Time to onset of confirmed disability progression (CDP) , confirmed over at least 24 weeks (24-week CDP)|MRI T2 lesion|12-week CDP|Time to onset of CDP defined as ≥ 20% increase on 9-hole Peg Test (9HPT) from baseline, confirmed over at least 12 weeks (12-week CDP-9HPT)|Time to onset of CDP defined as ≥ 20% increase on Timed 25-Foot Walk Test (T25FWT) from baseline, confirmed over at least 12 weeks (12-week CDP-T25FWT)|24-week cCDI|24-week CDI-9HPT|24-week CDI|24-week CDI-T25FWT|SDMT|AEs",False,
NCT04858763,MS Relapses During COVID-19 Pandemic,The Impact of the COVID-19 Pandemic on the Reporting and Management of Multiple Sclerosis Relapses,UNKNOWN,2021-05-01,2021-08-01,2021-12-01,2021-04-26,2021-04-26,OBSERVATIONAL,,340.0,ESTIMATED,Nottingham University Hospitals NHS Trust,OTHER,,,Multiple Sclerosis|Covid19|Relapsing Remitting Multiple Sclerosis,,,,,0,No Intervention,OTHER,Compare the number of MS relapses during the first wave of the Covid-19 pandemic to the same period in 2019.,1. To compare decisions made about administration of DMDs (starting or switching to a DMD) when a patient with MS has a relapse during the Covid-19 pandemic and in the same period in 2019.|2. To compare decisions around treating an MS relapse with steroids during the Covid-19 pandemic and the same period in 2019.,False,
NCT03001284,Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction,,UNKNOWN,2012-10,2016-12,2016-12,2016-12-23,2016-12-23,OBSERVATIONAL,,103.0,ACTUAL,Carol Davila University of Medicine and Pharmacy,OTHER,,,Multiple Sclerosis,,,,,0,NO intervention,OTHER,Left ventricle systolic dysfunction - by echocardiography|Right ventricle systolic dysfunction- by echocardiography|Left ventricular diastolic function - by echocardiography|arterial function - by vascular echography,,False,
NCT06998147,Postural Control and Psychosocial Measures Associations in Multiple Sclerosis,"Investigating Predictive Associations Among Postural Balance, Functional Mobility, Cognitive Function and Psychological Well-being in Patients With Multiple Sclerosis: A Cross-Sectional Study",COMPLETED,2025-03-18,2025-04-25,2025-04-29,2025-07-24,2025-05-31,OBSERVATIONAL,,64.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,Balance|Cognitive function|Depression|Multiple Sclerosis,Egypt,Dokki,,1,correlation and regression analyses,OTHER,Berg Balance Scale (BBS) scores,TUG test scores.|Montreal Cognitive Assessment (MoCA) scores|HADS scores|CIQ scores,False,
NCT05326048,Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis,Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis,COMPLETED,2022-03-09,2022-09-09,2022-09-09,2023-03-29,2022-04-13,OBSERVATIONAL,,60.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,,France,Rennes,,1,cytof analysis,OTHER,Differences in Immune profile,,False,
NCT05890885,MS Fatigue and tDCS on Fatigue in Multiple Sclerosis,The Effect of Home-Based Transcranial Direct Current Stimulation on Fatigue in Multiple Sclerosis,UNKNOWN,2022-09-01,2023-06-15,2023-08-15,2023-06-06,2023-06-06,INTERVENTIONAL,NA,30.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Fatigue in Multiple Sclerosis,Fatigue|Multiple sclerosis|Anodal tDCS|Prefrontal cortex,France,Créteil,,1,Real left prefrontal tDCS - sham|Sham - Real left prefrontal tDCS,PROCEDURE|PROCEDURE,Tiredness,Depression|Anxiety|Alexithymia|MSQOL scale|Cognitive functions,False,
NCT03692975,MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis,Hippocampal Microstructure Assessed by a New MRI Sequence and Episodic Memory at the Early Stage of Multiple Sclerosis: Comparison Between Patients After a Clinically Isolated Syndrome (CIS) and Controls,COMPLETED,2019-02-12,2023-02-24,2023-02-24,2023-03-08,2018-10-02,INTERVENTIONAL,NA,84.0,ACTUAL,"University Hospital, Bordeaux",OTHER,,,Multiple Sclerosis,Clinically Isolated Syndrome|NODDI|Hippocampus|episodic memory function|dentate gyrus|MRI,France,Bordeaux,,1,Clinical assessment|Neuropsychological evaluation|Psychological evaluation|MRI Evaluation,OTHER|OTHER|OTHER|DEVICE,Index of orientation-dispersion (IOD)|Index of Neurite density (ND),Diffusion parameters : Index of orientation-dispersion|Diffusion parameters : Neurite density|Diffusion parameters : Fractional Anisotropy|Diffusion parameters : Mean diffusivity|Atrophy parameters|Lesion volume|Inflammatory activity|Connectivity|Verbal episodic memory test|Visual episodic memory score|Information processing speed and attention score|Working memory score,False,
NCT05630547,A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis,"A Phase 2 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effect of SAR443820 on Serum Neurofilament Levels in Participants With Multiple Sclerosis, Followed by an Open-label Long-term Extension Period",TERMINATED,2022-12-19,2024-11-21,2024-11-21,2024-12-13,2022-11-29,INTERVENTIONAL,PHASE2,174.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,Belgium,Brussels,,35,SAR443820|Placebo,DRUG|OTHER,Part A: Week 48 sNfL levels relative to baseline|Part B: Week 96 sNfL levels relative to baseline,"Part A: Cumulative number of new gadolinium (Gd)-enhancing T1 hyperintense lesions as detected by magnetic resonance imaging (MRI)|Part A: Cumulative number of new and/or enlarging T2 hyperintense lesions as detected by MRI|Part A: Time to onset of 12 weeks confirmed disability progression (CDP) from baseline as assessed by the Expanded Disability Status Scale (EDSS) score|Part A: Time to onset of sustained 20% increase in 9-Hole Peg Test (9-HPT) confirmed over at least 12 weeks|Part A: Time to onset of sustained 20% increase in timed 25-foot walk test (T25-FW) confirmed over at least 12 weeks|Part A: Change from baseline in EDSS Plus|Part A: Annualized relapse rate (ARR) of RMS population (relapsing SPMS and RRMS)|Part A: Percent change from baseline in brain volume loss (BVL) as detected by brain MRI|Part A: Change from baseline in the volume of slowly expanding lesions (SELs)|Part A: Change from baseline in the number of SELs|Part A: Change from baseline in the intensity (T1) of SELs|Part A: Change from baseline in the normalized T1 intensity in lesions|Part A: Change from baseline in the total number of non-enhancing lesions|Part A: Change from baseline in the volume of non-enhancing lesions|Part A: Change from baseline in the number of phase rim lesions (PRL) will be conducted at 3 Tesla (3T) capable sites|Part A: Incidence of adverse event (AE)|Part A: Incidence of serious adverse event (SAE)|Part A: Incidence of treatment emergent adverse event (TEAE)|Part A: Incidence of potentially clinically significant abnormality (PCSA) in laboratory tests|Part A: Plasma concentration of SAR443820|Part B: Percent change from baseline in BVL as detected by brain MRI|Part B: Change from baseline in the volume of slowly expanding lesions (SELs)|Part B: Change from baseline in the number of SELs|Part B: Change from baseline in the intensity (T1) of SELs|Part B: Change from baseline in the normalized T1 intensity in lesions|Part B: Change from baseline in the total number of non-enhancing lesions|Part B: Change from baseline in the volume of non-enhancing lesions|Part B: Change from baseline in the number of PRLs (same participants/centers from Part A with 3T capability)|Part B: Incidence of AE|Part B: Incidence of SAE|Part B: Incidence of TEAE|Part B: Incidence of potentially clinically significant abnormality (PCSA) in laboratory tests|Part B: Incidence of PCSA in ECG|Part B: Incidence of PCSA in vital signs|Part B: Cumulative number of new Gd-enhancing lesions as detected by T1-weighted MRI|Part B: number of new or enlarging T2-hyperintense lesions on MRI|Part B: ARR of RMS population (relapsing SPMS and RRMS)|Part B: Time to onset of composite CDP (CCDP), confirmed over at least 12 weeks (3-month CCDP), by the EDSS Plus composite (EDSS score increase, OR 20% increase in the T25-FW test, OR 20% increase in the 9-HPT)|Part B: Time to onset of 12 weeks CDP as assessed by the EDSS score|Part B: Time to onset of sustained 20% increase in 9-HPT confirmed over at least 12 weeks|Part B: Time to onset of sustained 20% increase T25-FW test confirmed over at least 12 weeks|Part B: Change from baseline in EDSS Plus|Part B: Change in Multiple Sclerosis Impact Scale -29 version 2 (MSIS-29v2) physical and psychological domains scoring|Part B: Change in Multiple Sclerosis Walking Scale 12 items (MSWS-12",False,
NCT04267185,A Dyadic Approach for Promoting Physical Activity Among People with MS and Their Support Partners,Physical Activity Together for MS (PAT-MS): Pilot Study of a Dyadic Rehabilitation Intervention for People with Moderate-to-Severe Multiple Sclerosis Disability and Their Family Caregivers,COMPLETED,2020-02-04,2022-06-12,2022-10-04,2024-12-12,2020-02-12,INTERVENTIONAL,NA,22.0,ACTUAL,University of Ottawa,OTHER,The Ottawa Hospital|Consortium of Multiple Sclerosis Centers|Queen's University,OTHER|OTHER|OTHER,Multiple Sclerosis,Exercise|Caregiver|Physical Activity,Canada,Ottawa,Ontario,1,Physical Activity Together for PwMS and their CGs (PAT-MS),BEHAVIORAL,Safety of the PAT-MS intervention|Feasibility: Participant recruitment rate|Feasibility: Participant compliance rate|Feasibility: Participant attrition rate|Feasibility: Monetary cost of research|Feasibility: Staff time|Feasibility: Research ethics procedures|Feasibility: Data collection at T1|Feasibility: Data collection at T2|Change in Self-Reported Physical Activity - Primary Efficacy Outcome,Change in Accelerometer-measured Physical Activity - steps/day|Change in Accelerometer-measured Physical Activity - minutes of PA|Change in Walking Speed|Change in Walking Endurance|Change in Agility|Change in Physical Functional Limitations and Disability|Change in MS Self-Efficacy|Change in Quality of Life in PwMS|Change in Dyadic Relationship Quality|Change in Perceptions of Social Support|Change in Resilience|Change in Coping|Change in Quality of Life in Caregivers,False,
NCT01610687,A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,"A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension",COMPLETED,2001-07,2005-02,2005-02,2023-01-10,2012-06-04,INTERVENTIONAL,PHASE3,137.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Spasticity,,United Kingdom,Oxford,,1,GW-1000-02,DRUG,Incidence of Adverse Events as a Measure of Patient Safety,Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment|Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.|Investigator Assessed Global Severity Score at Week 18|Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18|Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18|Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18|Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18,True,2012-08-17
NCT03424733,Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects,A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a,UNKNOWN,2017-09-25,2020-05-01,2020-05-31,2019-08-15,2018-02-07,INTERVENTIONAL,PHASE4,50.0,ESTIMATED,"Holy Name Medical Center, Inc.",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,demyelination|relapse rate|Pegylated interferon beta-1a|side effects|flu-like symptoms|injection site reactions|prednisone,United States,Teaneck,New Jersey,1,Plegridy|Prednisone|Tylenol Pill,DRUG|DRUG|DRUG,Flu-like symptoms,Injection site reactions,False,
NCT01868048,"Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.",A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.,WITHDRAWN,,2017-06,,2016-08-11,2013-06-04,INTERVENTIONAL,PHASE3,0.0,ACTUAL,GW Research Ltd,INDUSTRY,,,Spasticity|Multiple Sclerosis,Spasticity|Multiple Sclerosis,,,,0,Sativex|Placebo,DRUG|DRUG,Physician Global Impression of Change (PGIC) questionnaire|Change in mean Modified Ashworth Scale score from baseline to the end of treatment period.,Change in mean sleep disruption (0-10 NRS) score from baseline to the end of treatment (Part B)|Change in mean spasm frequency (number of spasms per day) from baseline to the end of treatment (Part B).|Subject global impression of change (SGIC) questionnaire|Carer Global Impression of Change Questionnaire,False,
NCT02912897,Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis,"An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis",RECRUITING,2021-01-26,2028-11,2028-11,2025-02-19,2016-09-23,INTERVENTIONAL,PHASE1,7.0,ESTIMATED,Nantes University Hospital,OTHER,,,Multiple Sclerosis,EBV-CTL|Multiple sclerosis|cellular therapy,France,Nantes,,1,Cellular therapy with EBV specific autologous CTL infusion,BIOLOGICAL,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE,,False,
NCT01071512,Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis,Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis,COMPLETED,2010-04,2016-01,2016-01,2017-10-25,2010-02-19,INTERVENTIONAL,NA,20.0,ACTUAL,University of Chicago,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,MRI|OCT|Tysabri|Multiple Sclerosis|cognition,United States,Chicago,Illinois,1,Tysabri,DRUG,Change in Cognitive Function Over Time,Change Over Time in Retinal Nerve Fiber Layer Thickness|Change Over Time in Brain Parenchymal Fraction|Change Over Time in Normalized Thalamic Volume|Change Over Time in Normalized Hippocampal Volume,True,2017-09-06
NCT05265728,"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Via a Subcutaneous Route of Administration",TERMINATED,2022-04-26,2024-01-18,2024-05-27,2025-01-23,2022-03-03,INTERVENTIONAL,PHASE3,21.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Japan,Bunkyō City,,12,Natalizumab,DRUG,Cumulative Number of New Active Lesions on Week 24 Brain Magnetic Resonance Imaging (MRI) Scans,"Cumulative Number of New Active Lesions on Week 48 Brain Magnetic Resonance Imaging (MRI) Scans|Percentage of Participants With Any New Active Lesions on Week 24 Brain Magnetic Resonance Imaging (MRI) Scans|Percentage of Participants With Any New Active Lesions on Week 48 Brain Magnetic Resonance Imaging (MRI) Scans|Change from Baseline in Number of Gadolinium-Enhancing Lesions at Week 24 and Week 48|Number of Nonenhancing New or Newly Enlarging T2 Hyperintense Lesions at Week 24 and Week 48|Number of New T1 Hypointense Lesions at Week 24 and Week 48|Annualized Relapse Rate (ARR) at Week 24, Week 48 and Week 52|Percentage of Relapse-Free Participants at Week 24 and Week 52|Visual Analog Scale (VAS) Score at Week 24 and Week 48|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Anti-John Cunningham Virus (Anti-JCV) Antibodies|Number of Participants With Injection Site Reactions and Injection Reactions|Number of Participants With Anti-Natalizumab Antibodies|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 24 and Week 48|Serum Trough Concentration (Ctrough) of Natalizumab|Serum Concentration of Natalizumab Between Day 6 and Day 8|Alpha-4 (α4)-Integrin Saturation|Serum Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) Concentrations",False,
NCT03778333,Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden,Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden,COMPLETED,2012-12-01,2016-12,2016-12-31,2023-06-01,2018-12-19,INTERVENTIONAL,PHASE1,7.0,ACTUAL,Karolinska Institutet,OTHER,,,Autologous Mesenchymal Stem Cells|Multiple Sclerosis,Mesenchymal Stem Cells|Multiple Sclerosis,Sweden,Stockholm,,2,Autologous mesenchymal stem cells,BIOLOGICAL,To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.,To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.,False,
NCT01836055,Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist,Comparing Lesion Contrast With Both Magnevist and Gadavist and Understanding the Cerebral Perfusion Patterns of Patients With Multiple Sclerosis (MS) Using Magnetic Resonance Imaging (MRI),TERMINATED,2012-01,2014-01,2014-02,2014-12-09,2013-04-19,OBSERVATIONAL,,19.0,ACTUAL,Wayne State University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|White Matter Lesions|Contrast Agent|Magnetic Resonance Imaging,United States,Detroit,Michigan,1,,,Lesion detection and quantification in Multiple Sclerosis Patients,MR cerebral blood flow Quantification,False,
NCT00873340,Physical Disability in Patients Treated With Betaferon,Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice,COMPLETED,2007-10,2011-01,2011-01,2014-06-26,2009-04-01,OBSERVATIONAL,,83.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,MS|Multiple Sclerosis|Betaferon|Colombia,Colombia,Many Locations,,1,"Interferon-1beta (Betaseron, BAY86-5046)",DRUG,To collect observational local data about effectivity related to physical disability progression on the daily routine basis in patients treated with Betaferon,To evaluate Betaferon safety on the daily routine basis|To evaluate patient adherence to Betaferon treatment,False,
NCT01181089,Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS),"A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis",WITHDRAWN,2010-09,,,2013-09-16,2010-08-13,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,Biogen,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,,,,,0,Placebo|Baminercept,BIOLOGICAL|BIOLOGICAL,Measure: Change in cerebrospinal fluid levels of secondary lymphoid organs chemokines from baseline with baminercept relative to placebo,Number of subjects experiencing Serious Adverse Event (SAE) and Adverse Event (AE) with baminercept relative to placebo,False,
NCT03817073,Assessing Fatiguability of Tongue Muscles in MS,Assessing Fatiguability of Tongue Muscles and the Effect on Tongue Strength and Swallowing Pressures in Patients With Multiple Sclerosis,UNKNOWN,2019-03-01,2021-07-01,2021-07-01,2019-01-25,2019-01-25,INTERVENTIONAL,NA,60.0,ESTIMATED,Thomas More Kempen,OTHER,Revalidatie & MS Centrum Overpelt,OTHER,Muscle Weakness|Fatigue|Multiple Sclerosis|Deglutition Disorders|Exertion; Excess,,Belgium,Antwerp,Antwerpen,1,Iowa Oral Performance Instrument (IOPI),DEVICE,Number of successful repetitions|Evolution of MIP during subsequent repetitions,Baseline MIP as predictor for number of repetitions,False,
NCT04530669,The Effect of High Tone Power Therapy on Fatigue and Functional Outcomes in Multiple Sclerosis,The Effect of High Tone Power Therapy on Fatigue and Functional Outcomes in Multiple Sclerosis,COMPLETED,2020-09-01,2020-10-15,2020-12-30,2021-07-13,2020-08-28,INTERVENTIONAL,NA,40.0,ACTUAL,Lama Saad El-Din Mahmoud,OTHER,,,Multiple Sclerosis,High Tone Power Therapy|fatigue|functional outcomes,Egypt,Al Jīzah,Select State,1,High Tone Power Therapy|exercise program,DEVICE|OTHER,"Expanded Disability Status Scale (EDSS)|Functional Systems Score (FSS),",,False,
NCT01359566,Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis,"A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis",COMPLETED,2011-05,2013-02,2013-02,2021-02-21,2011-05-24,INTERVENTIONAL,PHASE3,228.0,ACTUAL,"XenoPort, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,28,Arbaclofen placarbil 15 mg BID|Placebo|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil 45 mg BID,DRUG|DRUG|DRUG|DRUG,Change from Baseline in Maximum Ashworth Scale score (6 hour post-dose time point)|Patient Global Impression of Change (PGIC) score,Change in the overall Modified PRISM score|Change in weekly average severity of pain score associated with muscle spasm.|Change in weekly average VAS score of sleep quality,False,
NCT00229502,Cognitive Effects of Immunomodulatory Drugs in MS,Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study,COMPLETED,2005-09,2011-09,2011-12,2012-03-23,2005-09-29,OBSERVATIONAL,,96.0,ACTUAL,"Sharon Lynch, MD",OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis,,United States,Kansas City,Kansas,1,,,,,False,
NCT05247372,The Effect of Iyengar Yoga Practice on Patients with Multiple Sclerosis,The Effect of Iyengar Yoga Practice on Patients with Multiple Sclerosis,COMPLETED,2021-06-25,2022-06-30,2022-06-30,2024-09-19,2022-02-18,INTERVENTIONAL,NA,5.0,ACTUAL,"University Hospital, Motol",OTHER,,,"Multiple Sclerosis, Iyenagar Yoga, Yoga, EDSS",,Czechia,Prague,Czech Republic,1,The effect of Iyengar yoga practice on patients with multiple sclerosis,OTHER,Hypothesis 1|Hypothesis 2|Hypothesis 3|Hypothesis 4|Hypothesis 5,,False,
NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),"A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)",COMPLETED,2016-05,2016-12,2016-12,2017-03-23,2016-05-18,OBSERVATIONAL,,2978.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,"Tecfidera, DMF, dimethyl fumarate, Fingolimod, Glatiramer acetate, Teriflunomide, Gilenya, Copaxone, Aubagio",United States,Homewood,Alabama,121,,,Proportion of participants relapsed at 12 months in participants treated with DMF,Proportion of participants relapsed at 12 months treated with index therapy in the overall population as well as the subgroup of MS participants who were naïve to DMTs and were diagnosed with MS within 3 years of starting the index therapy|ARR at 12 months in participants treated with index therapy in the overall population as well as in the matched cohorts|Proportion of relapsed participants with one or more MS-related hospitalizations during the 12 months following treatment initiation in participants treated with index therapy in the overall population and the matched cohorts|Proportion of relapsed participants requiring treatment with intravenous corticosteroids during the 12 months following treatment initiation in participants treated with index therapy in the overall participant population and the matched cohorts,False,
NCT06256731,ETNA-MS Device Validation Study,ETNA-MS Device Validation Study,RECRUITING,2023-12-12,2024-06-12,2024-06-12,2024-02-13,2024-02-13,OBSERVATIONAL,,60.0,ESTIMATED,Innodem Neurosciences,INDUSTRY,Syneos Health,OTHER,Multiple Sclerosis,,United States,Phoenix,Arizona,5,Eye-Tracking,DEVICE,Validate the effectiveness of the ETNA-MS device to estimate MS disease severity/status as estimated by the EDSS.,Validate that the ETNA-MS device has good test-retest reliability for estimating the EDSS.|Validate the effectiveness of the ETNA-MS device to estimate the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Validate the effectiveness of the ETNA-MS device to estimate the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Validate the effectiveness of the ETNA-MS device to estimate the Rey Auditory Verbal Learning Test (RAVLT) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Validate the effectiveness of the ETNA-MS device to estimate the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC).|Validate the effectiveness of the ETNA-MS device to estimate the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC).,False,
NCT01305837,Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,COMPLETED,2011-04,2013-07,2013-07,2013-07-11,2011-03-01,INTERVENTIONAL,PHASE2,30.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,,,Progressive Multiple Sclerosis,multiple sclerosis|methylprednisolone|osteopontin|inflammation|demyelinating,Denmark,Copenhagen,,1,methylprednisolone,DRUG,CSF osteopontin,aims for clinical progression|aims for demyelination and disease activity|aims of intrathecal inflammation|safety,False,
NCT06591429,Smoldering Inflammation in MS,Investigation of Smoldering Inflammation in Multiple Sclerosis,RECRUITING,2024-06-19,2027-06-30,2027-06-30,2025-04-03,2024-09-19,OBSERVATIONAL,,25.0,ESTIMATED,Washington University School of Medicine,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Imaging|Inflammation,United States,St Louis,Missouri,1,Radiotracer [11C]-CS1P1|Radiotracer [11C]-DPA-713|anti-CD20 MS treatment|Radiotracer [12F]-FDG,RADIATION|RADIATION|DRUG|RADIATION,Volume of Distribution (Vt) of DPA-713 and CS1P1 and Cerebral metabolic rate of glucose (CMRglc) in white matter lesions and normal appearing white matter before and after treatment.|Changes in scRNAseq measures of inflammatory cell types in the CSF before and after treatment,Correlation between changes in Vt or CMRglc compared to changes in cell type numbers from scRNAseq,False,
NCT05978531,Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice,"A Prospective, Observational Study of Bafiertam Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness in Routine Clinical Practice.",TERMINATED,2023-08-17,2025-02-24,2025-02-24,2025-03-06,2023-08-07,OBSERVATIONAL,,25.0,ACTUAL,Banner Life Sciences LLC,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United States,Gilbert,Arizona,10,Monomethyl Fumarate,DRUG,Percentage of participants on treatment with Bafiertam at 1 Year.,Percentage of Participants on Treatment with Bafiertam at 6 months|Treatment Satisfaction Questionnaire for Medication (TSQM-9)|Number of Participants with Adverse Events (AEs) Leading to Treatment Discontinuation.,False,
NCT01755871,Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis,The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis,TERMINATED,2013-01,2016-01,2016-02,2016-06-09,2012-12-24,INTERVENTIONAL,PHASE4,8.0,ACTUAL,"Heinrich-Heine University, Duesseldorf",OTHER,Novartis Pharmaceuticals,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,Germany,Düsseldorf,Nord-Rhein Westfahlen,1,Fingolimod,DRUG,"Reduction of CD4+ and CD8+ naïve T cells (CCR7+ CD45RA+) and central memory T cells (CCR7+CD45RA-), and an elevation of effector memory T cells (CCR7- CD45RA-) by examining the blood","To investigate changes from baseline in B Lymphocytes, monocytes and NK cells in the blood after treatment with fingolimod",False,
NCT03535298,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS,Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2019-01-03,2027-07-30,2027-07-30,2025-08-28,2018-05-24,INTERVENTIONAL,PHASE4,800.0,ESTIMATED,The Cleveland Clinic,OTHER,University of Nottingham,OTHER,"Multiple Sclerosis, Relapsing-Remitting",,United States,Aurora,Colorado,30,Early Highly Effective Therapies Group|Escalation Therapies Group,DRUG|DRUG,"Brain volume loss, baseline to month 36|EDSS+, month 48 to month 108","Brain volume loss, month 6 to month 36|Proportion of participants with progression|Change in MSIS-29, baseline to 36 months|Change in Neuro-QOL, baseline to 36 months|Time to reach SPMS, month 48 to month 108|Efficacy difference between EHT and ESC, month 48 to month 108|Safety difference between EHT and ESC, month 48 to month 108",False,
NCT04033133,Cerebral Blood Flow and tDCS,Cerebral Blood Flow in People With Multiple Sclerosis During Transcranial Direct Current Stimulation,COMPLETED,2019-12-20,2020-08-15,2020-08-15,2021-09-28,2019-07-25,INTERVENTIONAL,NA,3.0,ACTUAL,University of Iowa,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|tDCS|Cerebral Blood Flow,United States,Iowa City,Iowa,1,tDCS,DEVICE,Cerebral Blood Flow,,False,
NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,Outcomes Mandate National Integration With Cannabis as Medicine,RECRUITING,2018-12-01,2025-12-31,2025-12-31,2022-06-02,2019-05-09,INTERVENTIONAL,PHASE2,200000.0,ESTIMATED,"OMNI Medical Services, LLC",NETWORK,OMNI Medical Services Inc,UNKNOWN,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus,,United States,Boca Raton,Florida,17,"Cannabis, Medical|RYAH-Medtech Inhaler",DRUG|DEVICE,Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms,Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events,False,
NCT04807738,Virtual Reality in Physical Therapy in Multiple Sclerosis,"Effect of Neuroproprioceptive ""Facilitation, Inhibition"" Physical Therapy Using Virtual Reality on Upper Limb Mobility and Postural Stability in Multiple Sclerosis",COMPLETED,2021-04-01,2025-01-02,2025-02-01,2025-03-07,2021-03-19,INTERVENTIONAL,NA,71.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Multiple Sclerosis,"multiple sclerosis|virtual reality|hand dexterity|postural stability|physical therapy|coordination|upper limb fine motor skills|motor programme activating therapy|neuroproprioceptive ""facilitation, inhibition""|postural control|functional recovery|Demyelinating Autoimmune Disease|Autoimmune Diseases of the Nervous System",Czechia,Prague,,2,"Neuroproprioceptive ""facilitation and inhibition"" in virtual reality|Neuroproprioceptive ""facilitation and inhibition""",DEVICE|OTHER,Nine Hole Peg Test (9HPT) - change pre/post intervention|Box and Block Test (BNB) - change pre/post intervention|Hand Grip Strength (HGS) -change pre/post intervention|Tremor; Frequency for which the smoothed power spectral density is maximal (fMAX)|Tremor; Power of the signal in band from f1 to f2 (Pf1-f2)|Five times Sit to Stand test (5STS) -change pre/post intervention,Multiple Sclerosis Impact Scale (MSIS-29) - change pre/post intervention|EQ-5D-3L-health questionnaire - change pre/post intervention,False,
NCT05044819,Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution,A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution,ACTIVE_NOT_RECRUITING,2021-07-07,2027-08-01,2028-03-31,2025-08-26,2021-09-16,INTERVENTIONAL,PHASE4,154.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,Jazz Pharmaceuticals Research UK Limited,INDUSTRY,Lennox Gastaut Syndrome|Dravet Syndrome|Tuberous Sclerosis Complex,Liver injury|Liver fibrosis|Epidiolex|Cannabidiol,United States,Little Rock,Arkansas,20,Cannabidiol,DRUG,Number of Participants With Liver Fibrosis and Evaluable Fibrotic Changes as Determined and Assessed by an Independent Adjudication Committee,Change From Baseline in Aspartate Aminotransferase (AST) to Platelet Ratio Index|Change from Baseline in the Enhanced Liver Fibrosis Score|Change From Baseline in Fibrosis-4|Change From Baseline in FibroScan Scoring (FibroScan subset only)|Number of Participants With Potential Drug-Induced Liver Injury (DILI)|Number of Participants with Severe Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Clinical Laboratory Findings|Number of Participants With Clinically Significant Physical Examinations,False,
NCT07011914,Care in Multiple Sclerosis (MS),CARE in MS: Childhood Adversity Research Effort in MS,NOT_YET_RECRUITING,2025-09-01,2029-06-30,2029-06-30,2025-06-10,2025-06-10,OBSERVATIONAL,,386.0,ESTIMATED,NYU Langone Health,OTHER,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Multiple Sclerosis,,United States,Birmingham,Alabama,6,,,Severity of MS,Age of MS Onset,False,
NCT00552604,MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study,"Randomised, Double-blind, Placebo-controlled Phase III Trial to Determine the Efficacy and Safety of a Standardised Oral Extract of Cannabis Sativa for the Symptomatic Relief of Muscle Stiffness and Pain in Multiple Sclerosis.",TERMINATED,2006-06,2008-11,2008-11,2015-03-25,2007-11-02,INTERVENTIONAL,PHASE3,279.0,ACTUAL,"Institut fur Klinische Forschung, Germany",OTHER,Weleda AG,INDUSTRY,Muscle Spasticity,multiple sclerosis|muscle stiffness|spasticity|pain|treatment|cannabinoids,United Kingdom,Plymouth,Plymouth,1,standardized cannabis extract|Placebo,DRUG|DRUG,Change in muscle stiffness: 11-point numerical Likert scale,Change in pain: 11-point numerical Likert scale,False,
NCT04495556,Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis,Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2020-06-11,2025-06,2025-06,2024-09-20,2020-08-03,OBSERVATIONAL,,420.0,ACTUAL,The Cleveland Clinic,OTHER,National Institute of Neurological Disorders and Stroke (NINDS)|University of Pennsylvania|Cedars-Sinai Medical Center|National Institutes of Health (NIH),NIH|OTHER|OTHER|NIH,Multiple Sclerosis,Multiple Sclerosis|MS|MRI|Central Vein Sign|CVS|Diagnostic Biomarker|Autoimmune disease,United States,Los Angeles,California,11,MRI,DIAGNOSTIC_TEST,MRI Outcomes,"Clinical Outcomes - McDonald Criteria 2017|Clinical Outcomes - Relapses|Clinical Outcomes - Lab results - Cerebrospinal Fluid Testing|Lab results - Neuromyelitis Optica Antibodies (NMO-IgG)|Lab results - Myelin oligodendrocyte glycoprotein (MOG) testing.|Patient reported Outcomes - Change in Neuro-QoL (Quality of Life in Neurological disorders) using Neuro-QoL short forms to assess Physical Domains, from baseline to month 24.|Change in Neuro-QoL using Neuro-QoL short forms to assess Mental Domains, from baseline to month 24|Change in Neuro-QoL using Neuro-QoL short forms to assess Social Domains, from baseline to month 24|Patient reported Outcomes - PDDS (patient determined disease steps)",False,
NCT02760056,Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study,Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study,COMPLETED,2016-06-06,2017-01-10,2017-01-10,2018-11-19,2016-05-03,INTERVENTIONAL,PHASE1,15.0,ACTUAL,Oregon Health and Science University,OTHER,,,Multiple Sclerosis,Thyroid hormone|Remyelination,United States,Portland,Oregon,1,Liothyronine sodium|Placebo,DRUG|DRUG,Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS,Reliability of Visual Evoked Potential (VEP) Testing (ICC),True,2018-11-19
NCT06928194,Reliability of Kinovea in Gait Assessment in Multiple Sclerosis: a Pilot Study.,Reliability of the Kinovea System in the Study of Spatiotemporal Gait Parameters in Multiple Sclerosis: a Pilot Study.,COMPLETED,2025-03-10,2025-04-02,2025-04-02,2025-04-18,2025-04-15,OBSERVATIONAL,,24.0,ACTUAL,University of Cadiz,OTHER,Hospital Universitario Virgen Macarena,OTHER,"Multiple Sclerosis|Gait Disorders, Neurologic","Multiple Sclerosis|Gait Disorders, Neurologic|Kinovea|GAITRite",Spain,Seville,Sevilla,1,,,Step length (cm)|Stride length (cm)|Support base (cm)|Cadence (steps/min)|Walking speed (cm/s),,False,
NCT06265922,Cerebellar RTMS in Patients with Multiple Sclerosis,Effect of Cerebellar Repetitive Transcranial Magnetic Stimulation on Coordination in Patients with Multiple Sclerosis,COMPLETED,2024-02-18,2024-07-17,2024-08-05,2025-02-19,2024-02-20,INTERVENTIONAL,NA,30.0,ACTUAL,Cairo University,OTHER,,,Patients with Multiple Sclerosis,Patients with Multiple Sclerosis|Coordination|Transcranial magnetic stimulation,Egypt,Giza,Dokki,1,High frequency repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation,DEVICE|DEVICE,Biodex balance system,Berg balance scale|Nine-Hole Peg Test (9-HPT)|Four square step test (FSST),False,
NCT05380856,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction","Sacral Neuromodulation for Patients With Multiple Sclerosis With Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial.",RECRUITING,2023-09-26,2027-03-01,2027-03-01,2025-03-20,2022-05-19,INTERVENTIONAL,NA,60.0,ESTIMATED,Odense University Hospital,OTHER,University of Copenhagen|Université de Nantes|University of Ostrava,OTHER|OTHER|OTHER,Neurogenic Dysfunction of the Urinary Bladder|Multiple Sclerosis|Sacral Neuromodulation|Bowel Dysfunction|Sexual Dysfunction|Quality of Life,,Denmark,Odense,Fyn,1,Turning ON the neuromodulator|Turning OFF the neuromodulator,DEVICE|DEVICE,Success of SNM for neurogenic lower urinary tract dysfunction|Male bladder function|Female bladder function,Changes in bladder volume|Changes in bladder sensation Mangler|Bowel function|Male sexual function|Female sexual function|Quality of life by standard questionnaire EQ-5D-5L,False,
NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,"A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2003-01,2008-11,2008-11,2013-09-16,2005-09-15,INTERVENTIONAL,PHASE4,345.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Combination therapy for multiple sclerosis,Belgium,Brussels,,9,Interferon-beta-1a (Avonex) plus methylprednisolone,DRUG,To estimate the effect interferon-beta-1a in combination with methylprednisolone vs interferon-beta-1a in combination with placebo on the time to onset of disability progression sustained over at least 6 months based on change from randomization in EDSS,,False,
NCT01226654,Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis,Quantitative MR Imaging and Proton Spectroscopy in MS,TERMINATED,1991-08,2016-04,2016-04,2017-08-01,2010-10-22,INTERVENTIONAL,NA,69.0,ACTUAL,NYU Langone Health,OTHER,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Multiple Sclerosis,Quantitative Imaging of Multiple Sclerosis,United States,New York,New York,1,Magnetic Resonance Imaging,DEVICE,Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume,Quantitative analysis of whole brain N-acetylaspartate (WBNAA),False,
NCT04977622,Gray Matter Demyelination in Primary Progressive MS at 7T,Investigating Cortical Gray Matter Demyelination in Primary Progressive Multiple Sclerosis at 7 Tesla,RECRUITING,2021-11-30,2024-06,2024-12,2024-01-29,2021-07-27,OBSERVATIONAL,,60.0,ESTIMATED,Danish Research Centre for Magnetic Resonance,OTHER,Scleroseforeningen|Danish Multiple Sclerosis Center,UNKNOWN|UNKNOWN,Primary Progressive Multiple Sclerosis,Magnetic Resonance Imaging|Ultra-high field MRI|Cortex|Multiple Sclerosis|Sensorimotor Function|Myelin|7T|Magnetic Resonance Spectroscopy,Denmark,Hvidovre,,1,,,"Distribution of cortical lesions in PPMS|Volume of cortical lesions in PPMS|Identify central veins and the presence of paramagnetic rims for cortical lesions|Quantitative assessment of myelin density in cortical lesions, perilesional gray and white matter, and normal appearing cortex using myelin water imaging|Quantitative assessment of magnetization transfer in cortical lesions, perilesional gray and white matter, and normal appearing cortex|Quantitative assessment of fractional anisotropy in cortical lesions, perilesional gray and white matter, and normal appearing cortex using diffusion tensor imaging data",Number of cortical lesions in the primary sensorimotor cortex (SM1)|Cortical lesion volume in the primary sensorimotor cortex (SM1)|Motor function|Sensory acuity|Regional metabolite concentration of the SM1|Functional MRI data for the assessment of temporal synchronization|Cognitive performance and relationship to MRI measures (Exploratory),False,
NCT06083194,"Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).",Non-invasive Evaluation of Muscle Oxidative Capacity. Study of Its Relationship With Muscular Endurance and Fatigue in Patients With Multiple Sclerosis,RECRUITING,2024-01-14,2025-05,2025-06,2024-01-17,2023-10-13,OBSERVATIONAL,,30.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Near infrared spectroscopy (NIRS)|Physical capacities|Fatigue|Muscle oxidative capacity|Skeletal muscle mitochondrial capacity|Muscle oxygen consumption|Single-Leg Heel Raise Test|Endurance,France,Clermont-Ferrand,,1,,,Maximal muscle oxidative capacity (mVO2)|Muscular endurance of the gastrocnemius muscles,"Expanded Disability Status Scale (EDSS)|Weight (Kg)|Height (cm)|Waist circumference (cm)|Hip circumference (cm)|Body Mass Index (Kg/m²)|Body composition|Thickness of subcutaneous adipose tissue of the gastrocnemius muscles (mm)|Functional capacity|Gastrocnemius muscle endurance (number of repetitions and time(sec))|Energy expenditure level (MET/minute/week)|Functional Assessment of Chronic Illness Therapy Fatigue Scale|VO2max (maximal oxygen consumption) (mL/Kg/min)|Maximum power (Watts)|Threshold power (Watts)|Maximum heart rate (bpm)|Threshold heart rate (bpm)|Forced vital Capacity (L and % of the theoretical value)|Forced Expiratory volume (L and % of the theoretical value)|Tiffeneau ratio (%)|Ventilatory reserve (%)|Tissue saturation index (kNIRS, min-1)",False,
NCT04379661,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,COMPLETED,2020-05-07,2020-07-07,2020-08-31,2021-01-08,2020-05-07,INTERVENTIONAL,NA,32.0,ACTUAL,Columbia University,OTHER,,,MS (Multiple Sclerosis)|COVID-19|Support Groups,,United States,New York,New York,1,Online support Group,BEHAVIORAL,Rate of completion|Rate of adherence,Score on the State Trait Anxiety Inventory (STAI),False,
NCT01971294,Lower Urinary Tract Symptoms in Systemic Sclerosis,Lower Urinary Tract Symptoms in Patients Suffering From Systemic Sclerosis: a Multi-centric Longitudinal Study,COMPLETED,2013-10,2015-10,2022-10,2023-05-16,2013-10-29,OBSERVATIONAL,,334.0,ACTUAL,"University Hospital, Geneva",OTHER,"University Hospital, Paris|Azienda Ospedaliera di Padova|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",OTHER|OTHER|OTHER,Urinary Symptoms|Systemic Sclerosis,Urinary symptoms|Systemic sclerosis|Severity index|Urinary tract infection|mortality|Quality of life,France,Paris,,4,,,Prevalence/incidence of urinary symptoms in scleroderma,Short Form 36 Health Survey (SF-36)|Mortality|Urinary tract infection|Incontinence Quality of Life (IQol),False,
NCT02493166,Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis,Cognitive Motor Interference During Dual Tasking With Movements of the Upper Limb in Persons With Multiple Sclerosis,COMPLETED,2016-03,2016-03,2016-06,2016-06-14,2015-07-09,INTERVENTIONAL,NA,68.0,ACTUAL,Hasselt University,OTHER,"AZ Klina|University Hospital, Antwerp|private practice physician De Barsy",OTHER|OTHER|UNKNOWN,Multiple Sclerosis,,Belgium,Brasschaat,,4,dual task cost (cognitive-motor interference),OTHER,single motor task cost|Dual motor task cost|single cognitive task cost|Dual cognitive task cost,,False,
NCT02738775,Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis,"A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.",COMPLETED,2016-05-27,2017-09-27,2018-08-13,2021-07-15,2016-04-14,INTERVENTIONAL,PHASE2,49.0,ACTUAL,"TG Therapeutics, Inc.",INDUSTRY,,,Multiple Sclerosis,multiple sclerosis,United States,Phoenix,Arizona,12,Ublituximab|Placebo,BIOLOGICAL|DRUG,Responder Rate of B-Cell Depletion at Week 4,"Number of New Gadolinium (Gd)-Enhancing T1 Lesions at Weeks 24 and 48|Number of New or Enlarging T2 Lesions at Weeks 24 and 48|Annualized Relapse Rate (ARR)|Relapse Rate Reduction (RRR)|Percentage of Relapse Free Participants|Change From Baseline in B Cells (CD19+), Memory (CD19+CD27+) and Naïve (CD19+CD27-[Negative]) B Cells|Change From Baseline in Sustained B Cell|Additional Immune Profiling-CD4+ (Cluster of Differentiation 4 Positive)|Additional Immune Profiling-CD8+ (Cluster of Differentiation 8 Positive)|Additional Immune Profiling-Interleukin 10 (IL10)|Additional Immune Profiling-Natural Killer (NK) Cells|Pharmacokinetic Parameter: Plasma Concentration of Ublituximab",True,2021-07-15
NCT06210581,The Effects of Internet-Based and Supervised Exercise Programs in People With Multiple Sclerosis,Comparison of the Effects of Internet-Based and Supervised Exercise Programs in People With Multiple Sclerosis,RECRUITING,2023-05-29,2024-05-29,2024-10-29,2024-01-18,2024-01-18,INTERVENTIONAL,NA,40.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Balance|Multiple Sclerosis|Exercise,Turkey (Türkiye),Istanbul,,1,Supervised Exercise Program Group|Internet Based Exercise Program Group,OTHER|OTHER,2 Minutes Walk Test (2MWT) (The change between the initial value and the value after 2 months will be evaluated).,Fatigue Severity Scale (FSS) (The change between the initial value and the value after 2 months will be evaluated).|12 Item MS Walking Scale (MSWS- 12) (The change between the initial value and the value after 2 months will be evaluated).|Modified Falls Efficacy Scale (MFES) (The change between the initial value and the value after 2 months will be evaluated).|Canadian Occupational Performance Measure (COPM) (The change between the initial value and the value after 2 months will be evaluated).|Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) (The change between the initial value and the value after 2 months will be evaluated).|The Multiple Sclerosis Impact Scale (MSIS- 29) (The change between the initial value and the value after 2 months will be evaluated).|Berg Balance Scale (BBS) (The change between the initial value and the value after 2 months will be evaluated).|5 Times Sit to Stand Test (5TSTS) (The change between the initial value and the value after 2 months will be evaluated).|Timed 25- Foot Walk (T25- FW) (The change between the initial value and the value after 2 months will be evaluated).|Timed Get up and Go Test (TUG) (The change between the initial value and the value after 2 months will be evaluated).,False,
NCT06599307,The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis,The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis: a Randomized Controlled Trial,RECRUITING,2024-08-01,2026-05,2026-05,2024-09-19,2024-09-19,INTERVENTIONAL,PHASE2,46.0,ESTIMATED,Cairo University,OTHER,,,Secondary Progressive Multiple Sclerosis (SPMS),Rituximab|Cognitive functions|Hand functions|Secondary Progressive Multiple Sclerosis,Egypt,Giza,Giza Governorate,1,"Rituximab|Saline (NaCl 0,9 %) (placebo)",DRUG|OTHER,The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test|The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised|The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II|The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test,The effect of rituximab on quality of life|The effect of rituximab on EDSS,False,
NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,"Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.",COMPLETED,2002-08,2008-05,2008-05,2013-12-30,2005-09-16,INTERVENTIONAL,PHASE3,468.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,Austria,Graz,,94,"Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaseron, BAY86-5046)",DRUG|DRUG,Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time|Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time|Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60,Relapse-based Efficacy Domain: Time to Multiple Sclerosis (MS) According to McDonald Criteria|Relapse-based Efficacy Domain: Hazard Ratio for Recurrent Relapses|Relapse-based Efficacy Domain (Supportive): Annualized Relapse Rate|Disability-based Efficacy Domain: Multiple Sclerosis Functional Composite (MSFC) at Month 60|MRI (Magnet-Resonance Imaging)-Based Efficacy Domain: Cumulative Number of Newly Active Lesions at Month 60|MRI-based Efficacy Domain: Absolute Change of T2 Lesion Volume From Screening MRI to Month 60|MRI-based Efficacy Domain: Absolute Change of Volume of Black Holes From Screening MRI to Month 60|MRI-based Efficacy Domain: Percentage Change of Brain Volume From Screening MRI to Month 60,True,2010-11-30
NCT04720898,LUNA-EMG to Enhance Motor Functions in Multiple Sclerosis,LUNA-EMG to Enhance Lower Limb Motor Functions in Multiple Sclerosis,COMPLETED,2021-03-01,2024-06-01,2024-06-01,2025-08-05,2021-01-22,INTERVENTIONAL,NA,42.0,ACTUAL,University of Liege,OTHER,,,Multiple Sclerosis,,Belgium,Tinlot,Liege,1,LUNA-EMG,DEVICE,Muscle strength in mV,"Timed 25-Foot Walk, seconds|Timed Up and Go, seconds|Proprioception",False,
NCT05529498,High Intensity Interval Gait Training in Multiple Sclerosis,Effect of High Intensity Interval Gait Training on Ambulation in MS,UNKNOWN,2022-09-02,2023-12-31,2023-12-31,2022-09-07,2022-09-07,INTERVENTIONAL,NA,30.0,ESTIMATED,City University of New York,OTHER,,,"Multiple Sclerosis,Gait, Exercise",,United States,New York,New York,1,Moderate paced continuous gait training|High Intensity Interval gait training,BEHAVIORAL|BEHAVIORAL,6 minute walk test,Finctional gait assessment,False,
NCT03967106,"RIPC on Activity, Fatigue and Gait in MS","Role of Remote Ischaemic Preconditioning on Activity, Fatigue and Gait in People With Multiple Sclerosis.",COMPLETED,2019-08-19,2023-03-31,2023-03-31,2024-01-05,2019-05-30,INTERVENTIONAL,NA,92.0,ACTUAL,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,JP Moulton Charitable Foundation,OTHER,Multiple Sclerosis,remote ischaemic preconditioning|gait analysis|activity|fatigue,United Kingdom,Sheffield,South Yorkshire,1,Ischaemic Preconditioning|Sham,OTHER|OTHER,Change from baseline in speed of walking over a one week period|Change from baseline in number of steps taken over a one week period|Change from baseline in length of stride over a one week period|Change from baseline in speed of walking during the 6 minute walk test|Change from baseline in Modified Fatigue Impact Scale (MFIS) Score|Change from baseline in Multiple Sclerosis Walking Scale 12 (MSWS-12) score|Change from baseline in Borgs rating of perceived exertion scale score,,False,
NCT05837949,Multiple Sclerosis Falls Insight Track,Multiple Sclerosis Falls Insight Track: A Personal Health Library to Reduce Falls in Patients With Multiple Sclerosis,RECRUITING,2023-04-12,2026-04-12,2026-04-12,2024-06-21,2023-05-01,INTERVENTIONAL,NA,100.0,ESTIMATED,"University of California, San Francisco",OTHER,National Institutes of Health (NIH)|National Library of Medicine (NLM),NIH|NIH,Multiple Sclerosis,Multiple Sclerosis|MS|Falls|Falling|Closed-loop|Digital health|Falls tracking|Falls prevention|FitBit|Wearables,United States,San Francisco,California,1,MS FIT: Falls Insight Track,BEHAVIORAL,Percentage of patients initially use the tool (Adoption)|Percentage of patient-clinician encounters initially use the tool (Adoption)|Percentage of patients who continue to use the tool (Engagement)|Percentage of patient-clinician encounters use the tool during the 12-month visit (Engagement)|Percentage of patients who respond to fall prompts (Adherence),,False,
NCT03277248,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS),Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY),COMPLETED,2017-08-25,2020-08-04,2020-11-12,2021-12-06,2017-09-11,INTERVENTIONAL,PHASE3,545.0,ACTUAL,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),,United States,Phoenix,Arizona,13,Ublituximab|Teriflunomide|Oral Placebo|IV Placebo,BIOLOGICAL|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),Total Number of Gadolinium (Gd)-Enhancing T1-Lesions Per Magnetic Resonance Imaging (MRI) Scan Per Participant|Total Number of New and Enlarging T2 Hyperintense Lesions (NELs) Per MRI Scan Per Participant|Time to Confirmed Disability Progression (CDP) for at Least 12 Weeks|Percentage of Participants With No Evidence of Disease Activity (NEDA)|Percentage of Participants With Impaired Symbol Digit Modalities Test (SDMT)|Percent Change From Baseline in Brain Volume|Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),True,2021-12-06
NCT05834855,Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS,Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing Multiple Sclerosis,RECRUITING,2023-04,2027-05,2027-05,2023-04-28,2023-04-28,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,Stichting Treatmeds,UNKNOWN,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases",ocrelizumab|rituximab|non-inferiority,Netherlands,Amsterdam,,1,Rituximab,DRUG,Proportion of patients free of inflammatory disease activity,Presence and number of clinical relapses|Contrast enhancing lesions|Average number of T2 lesions on brain MRI|Disability progression during follow-up|Disability progression during follow-up|Disability progression during follow-up|Disability progression during follow-up,False,
NCT06629428,Effects of Ublituximab on Motor Functions in Multiple Sclerosis,Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People with Relapsing Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-01,2026-06-30,2026-12-31,2024-10-08,2024-10-08,INTERVENTIONAL,EARLY_PHASE1,25.0,ESTIMATED,Georgia State University,OTHER,Atlanta Neuroscience Institute,UNKNOWN,Multiple Sclerosis (MS) - Relapsing-remitting,ublituximab|gait function|disease progression|perturbed walking|Cognition,United States,Atlanta,Georgia,2,Ublituximab,DRUG,slip-fall|Dynamic gait stability during slip,Dynamic gait stability during walking|Spatiotemporal gait parameters during walking|Leg muscle strength|Leg Muscle Activities|Sway index|Stability index|Extended Disability Status Scale|MSFC|Prospective falls|Serum neurofilament light chain,False,
NCT05029609,Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS,"A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS",WITHDRAWN,2021-10,2022-11,2022-12,2022-03-03,2021-08-31,INTERVENTIONAL,PHASE1,0.0,ACTUAL,Tiziana Life Sciences LTD,INDUSTRY,,,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Multiple Sclerosis,,,,,0,Intranasal Foralumab Solution|Placebo,DRUG|DRUG,To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive days,Change in Expanded Disability Status Scale (EDSS) at Day 45,False,
NCT02040116,Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases,Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases,COMPLETED,2013-02,2014-08,2014-08,2018-09-07,2014-01-20,INTERVENTIONAL,PHASE4,19.0,ACTUAL,Wake Forest University Health Sciences,OTHER,,,Multiple Sclerosis,Rapid Infusion Rituximab,United States,Winston-Salem,North Carolina,1,Rituximab Infusion,DRUG,Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported|Grade of Infusion Related Reactions With Rapid Infusion Will be Reported,Change in Chair Time With Rapid Infusion Will be Reported,True,2017-09-20
NCT06337903,Self-compassion for People with Multiple Sclerosis: an Exploratory Feasibility Study,Self-compassion for People with Multiple Sclerosis: an Exploratory Feasibility Study,NOT_YET_RECRUITING,2025-01-01,2025-04-30,2025-04-30,2024-12-06,2024-03-29,INTERVENTIONAL,NA,45.0,ESTIMATED,Robert Simpson,OTHER,,,Multiple Sclerosis|Self-Compassion,Mindfulness,Canada,Toronto,,1,Self-compassion intervention (the Mindful Self-Compassion course),BEHAVIORAL,Recruitment|Retention|Adherence|Follow-up rates,Stress|Anxiety|Depression|Self-compassion|Emotion Regulation|Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29)|Participant Experiences and Perspectives|Adjustment,False,
NCT04837365,Impact of Neuropsychological Disorders in Multiple Sclerosis,"Impact of Neuropsychological Disorders on Visual Exploration, Walking Initiation and Walking in Multiple Sclerosis",RECRUITING,2021-05-21,2025-11-21,2026-05,2025-09-04,2021-04-08,INTERVENTIONAL,NA,20.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis,,France,Lille,,3,Three dimensional gait analysis with eyetracking,OTHER,Cadence of walking (in cycles.min-1)|Step length (in m)|Walking speed (in m.s-1)|Range of motion in the lower limbs in degrees,Ocular fixation time (measured in ms)|Muscle contractions determined by the electromyogram (EMG) (mV)|Displacements (in mm) during walking|Acceleration (in mm.s-2) during walking|Joint angles,False,
NCT01156311,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,"An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)",COMPLETED,2010-06,2012-03,2012-03,2017-03-21,2010-07-02,INTERVENTIONAL,PHASE2,108.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,BG00012|MS|RRMS,United States,Gilbert,Arizona,16,dimethyl fumarate,DRUG,Summary of Treatment-emergent Adverse Events (TEAEs) Occurring Post-BG00012 Dosing (Add-on Therapy Period)|Potentially Clinically Significant Hematology Laboratory Abnormalities for Combination Therapy|Maximum Post-Baseline Values: Liver Enzymes for Combination Therapy|Worst Post-Baseline Values for Selected Urinalysis Parameters That Require Further Evaluation for Combination Therapy,,True,2015-06-09
NCT06454162,Effect of Adding Modified Ketogenic Diet to Exercise Program in Treating Obese Patient With Multiple Sclerosis: A Randomized Controlled Trial,Effect of Adding Modified Ketogenic Diet to Exercise Program in Treating Obese Patient With Multiple Sclerosis: A Randomized Controlled Trial,NOT_YET_RECRUITING,2024-06-15,2024-12-30,2024-12-30,2024-06-12,2024-06-12,INTERVENTIONAL,NA,64.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,Modified Ketogenic Diet|Multiple Sclerosis,,,,0,Modified Ketogenic Diet|exercise program,OTHER|OTHER,VO2 max,exercise capacity|fatigue|life disability|Oxygen Consumption|Carbon Dioxide Production|Anaerobic Threshold|Ventilatory Equivalent for Carbon Dioxide|Ventilatory Equivalent for Oxygen,False,
NCT03853746,Short-term B-cell Depletion in Relapsing Multiple Sclerosis,Evaluating the Effects of Short-term B-cell Depletion on Long-term Disease Activity and Immune Tolerance in Relapsing Multiple Sclerosis,COMPLETED,2019-04-01,2024-03-01,2024-07-01,2025-02-05,2019-02-26,INTERVENTIONAL,PHASE4,10.0,ACTUAL,Johns Hopkins University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Baltimore,Maryland,1,Ocrelizumab,DRUG,Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion,Change in Disability as Assessed by Expanded Disability Status Scale (EDSS)|Change in a Quality of Life Measure as Assessed by Neuro-QoL Computer Adaptive Test (CAT) Fatigue Test,True,2025-02-05
NCT04855617,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,COMPLETED,2020-10-26,2022-10-01,2022-10-01,2023-06-15,2021-04-22,OBSERVATIONAL,,122.0,ACTUAL,NYU Langone Health,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,,United States,Wellesley,Massachusetts,2,Ocrelizumab,DRUG,Change in Quality of Life in Neurologic Disorders (NeuroQoL) Scores,Change in SymptoMScreen (SyMS) Scores|Change in Work Productivity and Activity Impairment Questionnaire: MS (WPAI:MS) Scores,False,
NCT04122989,Validation of a Shared Decision-Making Tool for Multiple Sclerosis,"Validation of a Shared Decision-Making Tool, MS-SUPPORT, to Improve Decisions About Disease Modifying Therapies (DMT) for Multiple Sclerosis",COMPLETED,2019-11-12,2020-10-26,2021-12-23,2022-05-09,2019-10-10,INTERVENTIONAL,NA,501.0,ACTUAL,Shared Decision Making Resources,OTHER,EMD Serono|Multiple Sclerosis Association of America,INDUSTRY|UNKNOWN,Multiple Sclerosis,,United States,Georgetown,Maine,1,MS-SUPPORT,OTHER,Start/Switch DMT,Patient-provider communication|Adherence to DMT|Decision Quality|Quality of Life--Healthy Days Core Module|CAHPS Quality of Care|Decision Conflict,False,
NCT00461396,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron","Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months",COMPLETED,2007-05,2009-06,2009-11,2011-04-08,2007-04-18,OBSERVATIONAL,,104.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Relapsing-Remitting Multiple Sclerosis|First demyelinating event|MRI features consistent with MS,United States,Many Locations,Alabama,19,"Interferon-1beta (Betaseron, BAY86-5046)",DRUG,"Evaluate the impact of titration, analgesics and 12-month BETA nurse follow-up on adherence to Betaseron treatment",Extended Disability Status Scale (EDSS)|Functional Assessment in Multiple Sclerosis (FAMS)|Cytokine and neurotrophic factor production|Visual function assessed by OCT and NEI-VFQ-25 (25-Item National Eye Institute Visual Functioning Questionnaire),False,
NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE),TERMINATED,2018-03-26,2019-01-11,2019-01-11,2020-02-10,2017-12-29,INTERVENTIONAL,PHASE2,7.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing remitting multiple sclerosis|D-Aspartate|interferon beta-1a,Italy,Cagliari,,17,D-aspartate|Placebo|IFN beta-1a|Methylprednisolone,DIETARY_SUPPLEMENT|DRUG|BIOLOGICAL|DRUG,Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8,"Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24|25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment|9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment|Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment|Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment|Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24|Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24|Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)|Number of Treated Participants With Immune-metabolic Response of Lymphocytes",True,2020-02-10
NCT03369470,App Based Dexterity Training in Multiple Sclerosis,A New App Home Based Dexterity Training in Multiple Sclerosis: a Randomized Controlled Trial,COMPLETED,2017-12-01,2021-08-01,2021-08-30,2021-09-01,2017-12-12,INTERVENTIONAL,NA,50.0,ACTUAL,Luzerner Kantonsspital,OTHER,"Insel Gruppe AG, University Hospital Bern",OTHER,Multiple Sclerosis,,Switzerland,Lucerne,,1,App Dexterity|Theraband,BEHAVIORAL|BEHAVIORAL,"AMSQ, Arm Function in Multiple Sclerosis Questionnaire (AMSQ)",Nine Hole Peg Test (9HPT)|Multiple Sclerosis Impact Scale 29 (MSIS 29)|Coin Rotation Task (Kamm et al. 2012),False,
NCT06381440,Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability,Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability: Study Protocol for a the PROGR-EX Randomized-controlled Trial,RECRUITING,2023-11-15,2024-11-30,2024-11-30,2024-04-24,2024-04-24,INTERVENTIONAL,NA,24.0,ESTIMATED,University Hospital of Ferrara,OTHER,Universita di Verona|Università degli Studi di Ferrara,OTHER|OTHER,Multiple Sclerosis,Robot Assisted Gait Training|Mobility|Biomarkers,Italy,Ferrara,Emilia-Romagna,1,"Lokomat device (Hocoma AG, Volketswil, Switzerland).|Conventional walking training",DEVICE|OTHER,Walking function,Mobility|Walking endurance|Balance|Spasticity|Perceived quality of life|Perceived walking ability|Fatigue|Anxiety|Depression|Kinesiophobia|Adaptation to medical condition|Coping strategies|Muscle oxygen consumption|Hemodynamic cortical activation|Electrical brain activity|miRNA expression|Acceptability of robot intervention,False,
NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,"A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis",COMPLETED,2016-09-20,2019-07-05,2020-07-20,2021-10-01,2016-06-07,INTERVENTIONAL,PHASE3,930.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing multiple sclerosis|Ofatumumab|adult|OMB157|multiple sclerosis|T1 lesions|T2 lesions|relapse|GD-enhancing MRI|McDonald criteria|RRMS|SPMS,United States,Phoenix,Arizona,166,Ofatumumab subcutaneous injection|Teriflunomide-matching placebo capsules|Teriflunomide capsule|Matching placebo of ofatumumab subcutaneous injections,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2301|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2301|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2301|Number of Gd-enhancing T1 Lesions Per MRI Scan|Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate)|Neurofilament Light Chain (NfL) Concentration in Serum|Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline|Percentage of Participants With Confirmed Relapse|Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data|Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data|6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data|Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS)|Percent Change in T2 Lesion Volume Relative to Baseline|No Evidence of Disease Activity (NEDA-4)|Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline|Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline|Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data|Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data|Annual Rate of Percent Change in Brain Volume Loss by NfL High-low Subgroups - Pooled Data|Pharmacokinetic (PK) Concentrations of Ofatumumab,True,2020-10-19
NCT02882724,"Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training",Effect Aquatic Exercise Training on Patients With Multiple Sclerosis,COMPLETED,2016-01,2016-04,,2016-08-30,2016-08-30,INTERVENTIONAL,PHASE1,32.0,ACTUAL,University of Isfahan,OTHER,,,Multiple Sclerosis|Aquatic|Exercise,,,,,0,Exercise|Control,BEHAVIORAL|BEHAVIORAL,Effect of exercise on balance was surveyed with using of Berg analyze,Effect of exercise on speed was measured by walking test|Effect of exercise on endurance was measured by walking test,False,
NCT01285479,The Gilenya Pregnancy Registry,The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis,COMPLETED,2011-10-15,2024-05-29,2024-05-29,2025-01-22,2011-01-28,OBSERVATIONAL,,312.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Fingolimod|FTY720|Gilenya|Multiple sclerosis|MS|Safety|Pregnancy|Pregnancy outcomes,United States,Fort Lauderdale,Florida,61,Fingolimod,DRUG,Frequency of major malformations associated with exposure to fingolimod during pregnancy|Frequency of minor congenital malformations associated to fingolimod during pregnancy,"Frequency of specific types of major and minor congenital malformations associated with exposure to fingolimod during pregnancy|Number of spontaneous abortions, stillbirths and elective terminations;|Number of occurrence of physical developmental delays as well as adverse effects on immune system development in infants around one year of age",False,
NCT04261790,Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,Evaluating the Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,COMPLETED,2020-08-01,2024-10-31,2024-11-01,2025-02-17,2020-02-10,INTERVENTIONAL,PHASE4,10.0,ACTUAL,Johns Hopkins University,OTHER,"Genentech, Inc.",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,United States,Baltimore,Maryland,1,Ocrelizumab,DRUG,Change in Peripheral B-cell Tolerance Checkpoints in People With MS Before and After Ocrelizumab Therapy.|Change in B-cell Subpopulations|Change in Frequency of T-cell Phenotypes|Change in the Production of Pro Inflammatory Cytokines Produced by Activated T-cells|Change in the Production of Anti-inflammatory Cytokines Produced by Activated T-cells,Patients With Return of Disease Activity|Change in Disability as Assessed by Expanded Disability Status Scale (EDSS)|Change in Quality of Life as Assessed by Neuro-QoL Fatigue T-score,True,2025-02-17
NCT04660227,Exercise Training in Pediatric-Onset Multiple Sclerosis Patients,Effectiveness of Exercise Training in Pediatric-Onset Multiple Sclerosis Patients,COMPLETED,2020-11-23,2021-11-25,2022-01-01,2023-05-19,2020-12-09,INTERVENTIONAL,NA,20.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Pediatric Multiple Sclerosis,Physical Activity|Physiotherapy|Degenerative diseases|Exercise,Turkey (Türkiye),Bakırköy,Istanbul,1,Exercise Trainning|Control Group,PROCEDURE|OTHER,The Leisure-Time Exercise Questionnaire (The change between the initial value and the value after 2 months will be evaluated).|One-Week Step Count Measurement with Pedometer for Physical Activity Assessment (The change between the initial value and the value after 2 months will be evaluated).,Evaluation of Isokinetic Muscle Strength of Quadriceps and Hamstring Muscles with Biodex Multi-Joint System (The change between the initial value and the value after 2 months will be evaluated).|Knee Joint Proprioception Assessment with Biodex Multi-Joint System (The change between the initial value and the value after 2 months will be evaluated).|Static and Dynamic Postural Stability Assessment with Biodex Balance System (The change between the initial value and the value after 2 months will be evaluated).|6 Minute Walk Test (The change between the initial value and the value after 2 months will be evaluated).|Timed 25-Foot Walk (The change between the initial value and the value after 2 months will be evaluated).|Timed Up and Go (The change between the initial value and the value after 2 months will be evaluated).|The Pediatric Quality of Life Inventory 4.0 (The change between the initial value and the value after 2 months will be evaluated).|Fatigue Severity Scale (The change between the initial value and the value after 2 months will be evaluated).,False,
NCT02398461,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse,"A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse",COMPLETED,2015-04,2017-09,2017-09-21,2018-08-22,2015-03-25,INTERVENTIONAL,PHASE1,27.0,ACTUAL,Acorda Therapeutics,INDUSTRY,PRA Health Sciences,INDUSTRY,"Multiple Sclerosis, Acute Relapsing",,United States,Long Beach,California,12,rHIgM22|Placebo,DRUG|DRUG,Safety and tolerability of single ascending doses of rHIgM22 in patients with MS immediately following a relapse as measured by the number of patients with Adverse Events (AEs),Maximum measured plasma concentration (Cmax) of single ascending doses of rHIgM22|Time to maximum plasma concentration (Tmax) of single ascending doses of rHIgM22|Half-life (T1/2) of single ascending doses of rHIgM22|Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of single ascending doses of rHIgM22|Immunogenicity profile of single ascending doses of rHIgM22|The Expanded Disability Status Scale (EDSS),False,
NCT00548769,Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients,"An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic Profiles of Tablets From Three Batches of Firategrast With Different Surface Areas and Two Different Tablet Formulations Containing the Same Batch of Firategrast, Given as Single 900mg Doses to Male and Female Subjects With a Diagnosis of Multiple Sclerosis",COMPLETED,2007-04-21,2007-11-26,2007-11-26,2017-08-01,2007-10-24,INTERVENTIONAL,PHASE1,37.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,"PK,|SB-683699,|multiple sclerosis|firategrast,|surface area,",Czechia,Prague,,4,Formulation A|Formulation B|Formulation C|Formulation D,DRUG|DRUG|DRUG|DRUG,The AUC(0-24) for firategrast following administration of tablets made from three different batches of drug with different surface areas.,"Cmax and Tmax. The AUC(0-24) Cmax and Tmax of of SB683699 metabolite GW786375X.|AEs, vital signs and clinical laboratory data during the course of the study.|SB-683699 and GW786375X plasma concentration to derive pharmacokinetic parameters.",False,
NCT06879665,TANDem-2: Closing the Gap to Interventions for TAND,TANDem-2: Closing the Gap to Interventions for TAND,ENROLLING_BY_INVITATION,2025-07-15,2026-12-31,2027-07-15,2025-09-22,2025-03-17,INTERVENTIONAL,NA,30.0,ESTIMATED,Vrije Universiteit Brussel,OTHER,University of Cape Town|United States Department of Defense,OTHER|FED,Adult Caregivers of Individuals With TSC|Tuberous Sclerosis Complex (TSC),Caregiver well-being|Psychological flexibility|Acceptance and Commitment Therapy (ACT)|Tuberous sclerosis complex (TSC)|TSC-Associated Neuropsychiatric Disorders (TAND),United States,Silver Spring,Maryland,2,Well-Beans for Caregivers Program,BEHAVIORAL,"Attendance rates to assess feasibility|Feasibility Feedback Forms for caregivers, facilitators and observers|Acceptability Feedback Forms for caregivers, facilitators and observers",Change in psychological flexibility on the Psy-Flex measure|Change in depression on the Patient Health Questionnaire-9 (PHQ-9)|Change in anxiety on the Generalized Anxiety Disorder-7 Scale (GAD-7)|Change in general wellbeing scores on the World Health Organization Wellbeing Index (WHO-5)|Change in resilience as measured on the Brief Resilience Scale,False,
NCT05269888,Covid-19 Vaccine Immune Response in Multiple Sclerosis,"An Observational Study to Evaluate Immune Response to Covid-19 Vaccines, Infections and Immune Treatments in People With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-02-16,2024-12-30,2025-12-30,2025-02-04,2022-03-08,OBSERVATIONAL,,240.0,ESTIMATED,University Hospitals of North Midlands NHS Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Stoke-on-Trent,,1,Blood Test 1|Blood Test 2,OTHER|OTHER,Blood titres of Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche in MS patients compared with healthy volunteers 12 months from date of first dose of Covid-19 vaccine|Blood titres of Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche in MS patients compared with healthy volunteers 18 months from date of first dose of Covid-19 vaccine|T-SPOT® COVID SARS-CoV-2 test status in MS patients compared with healthy volunteers 12 months from date of first dose of Covid-19 vaccine|T-SPOT® COVID SARS-CoV-2 test status in MS patients compared with healthy volunteers 18 months from date of first dose of Covid-19 vaccine,Type and timing of DMT in MS patients|Type and timing of DMT in MS patients|Type and timing of Covid-19 vaccine in MS patients compared with healthy volunteers|Type and timing of Covid-19 vaccine in MS patients compared with healthy volunteers|Participant-reported PCR positive Covid-19 infection/s in MS patients compared with healthy volunteers|Participant-reported PCR positive Covid-19 infection/s in MS patients compared with healthy volunteers|Covid-19 vaccine-related serious adverse events in MS patients compared with healthy volunteers|Covid-19 vaccine-related serious adverse events in MS patients compared with healthy volunteers|Demographics of MS patients compared with healthy volunteers|Demographics of MS patients compared with healthy volunteers|Co-morbidity status of MS patients compared with healthy volunteers|Co-morbidity status of MS patients compared with healthy volunteers,False,
NCT04754542,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study,COMPLETED,2021-05-18,2022-11-30,2022-11-30,2024-09-25,2021-02-15,OBSERVATIONAL,,76.0,ACTUAL,"University of Colorado, Denver",OTHER,EMD Serono|National Multiple Sclerosis Society,INDUSTRY|OTHER,Multiple Sclerosis,Discontinuation|MS|DMT|Medication|Extension,United States,Aurora,Colorado,10,,,Number of Participants Off Drug That Have New Inflammatory Disease Compared to Those on Drug.,Compare the Change in Disability Using the EDSS Over the Duration of the Trial in Those Who Were Able to Maintain Their Treatment Assignment Without Inflammatory Activity.,True,2024-09-25
NCT04215354,Association Between Fatigue and Balance in Patients With Multiple Sclerosis,Association Between Fatigue and Balance in Patients With Multiple Sclerosis,COMPLETED,2014-09,2016-01,2016-05,2020-01-06,2020-01-02,INTERVENTIONAL,NA,95.0,ACTUAL,Imam Abdulrahman Bin Faisal University,OTHER,King AbdulAziz City for Science and Technology,OTHER,Multiple Sclerosis,MULTIPLE SCLEROSIS|FATIGUE|BALANCE,Saudi Arabia,Dammam,Eastern Province,1,Magnetic field|Virtual reality,DEVICE|DEVICE,"Modified Fatigue Impact Scale|Balance|balance confidence|Depression (Beck depression inventory ii (BDI-II))|Static balance using posturography,",Quality of life measurement (Short Form 36 (SF-36),False,
NCT04880577,Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis,Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis,WITHDRAWN,2022-09-15,2024-02-14,2025-02-14,2022-11-15,2021-05-10,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Massachusetts General Hospital,OTHER,Gilead Sciences,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting|Fatigue",,United States,Boston,Massachusetts,1,TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|Placebo,DRUG|DRUG,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Modified Fatigue Impact Scale|serum concentrations of neurofilament light chains (NfL),Multiple Sclerosis Impact Scale-29|Short Form 36 Health Survey Questionnaire|Beck Depression Inventory|Perceived Deficits Questionnaire|Annualized relapse rate|Expanded Disability Status Scale|Symbol Digit Modality Test|Timed 25 Foot Walk|9-Hole Peg Test|Number of new MRI lesions|EBV viral load|EBV titers,False,
NCT06897657,A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients,"Retrospective, Non-interventional Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients",COMPLETED,2023-11-06,2024-07-25,2024-07-25,2025-03-27,2025-03-27,OBSERVATIONAL,,155.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Disease modifying therapy|Medication adherence|Ofatumumab,United States,East Hanover,New Jersey,1,,,Medical Possession Ratio (MPR)|Number of Patients by MPR Category,Number of Patients by Demographic Category|Time From MS Diagnosis to Ofatumumab Initiation|Number of Patients by Comorbidity|Number of Patients who Received at Least one DMT Prior to Ofatumumab Initiation|Number of Prior DMTs Reported|Number of Patients by Prior DMT Category|Number of Patients by Reason for Switch from Other DMT to Ofatumumab|Individual Annualized Relapse Rate (ARR) Before Ofatumumab Initiation|Total ARR Before Ofatumumab Initiation|Individual ARR After Ofatumumab Initiation|Total ARR After Ofatumumab Initiation|Average Expanded Disability Status Scale (EDSS) Score Before Ofatumumab Initiation|Average EDSS Score After Ofatumumab Initiation|Absolute Change in Average EDSS Score|Average Number of T1 and T2 Lesions Before Ofatumumab Initiation|Average Number of T1 and T2 Lesions After Ofatumumab Initiation|Individual ARR After Ofatumumab Initiation by MPR Category|Total ARR After Ofatumumab Initiation by MPR Category|Average EDSS Score Before Ofatumumab Initiation by MPR Category|Average EDSS Score After Ofatumumab Initiation by MPR Category|Absolute Change in Average EDSS Score by MPR Category|Number of Patients per MPR Category by Type of KC PSP Services Received|Number of Medical Visits After Ofatumumab Initiation|Annualized Medical Visit Rate After Ofatumumab Initiation|Number of MS-related Medical Visits After Ofatumumab Initiation|Annualized MS-related Medical Visit Rate After Ofatumumab Initiation|Number of Patients With Medically Reported Adherence (MRA) After Ofatumumab Initiation|Number of Patients by Reason for Discontinuation of Ofatumumab|Number of Patients who Switched From Ofatumumab to an Alternative DMT,False,
NCT04633967,Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.,Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.,COMPLETED,2016-05-15,2020-12-30,2021-02-28,2024-03-13,2020-11-18,OBSERVATIONAL,,30.0,ACTUAL,Maritime Neurology,NETWORK,,,Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis,,Canada,Halifax,Nova Scotia,1,Alemtuzumab Injection,DRUG,Number and type of adverse events in Novel versus standard infusion protocol,,False,
NCT00050232,Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients,,COMPLETED,2002-12,2004-06,2004-06,2016-07-14,2002-12-03,INTERVENTIONAL,PHASE3,96.0,,Avanir Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Pseudobulbar Affect|Uncontrolled|Laughing|Crying,United States,Phoenix,Arizona,20,AVP-923,DRUG,emotional control,,False,
NCT02459821,Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects,The Effects of an Innovative Gait Robot for the Repetitive Practice of Floor Walking and Stair Climbing up and Down in Patients Suffered From Multiple Sclerosis: a Randomized Control Trial,UNKNOWN,2015-05,2016-09,2016-12,2016-09-12,2015-06-02,INTERVENTIONAL,NA,40.0,ACTUAL,Universita di Verona,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Gait rehabilitation|Quality of life|Stair climbing|Robotic,Italy,Verona,"Italy, Verona",2,GE-O SYSTEM|Conventional training,OTHER|OTHER,6-Minute Walking Test (meters),10-Metre Walking Test (seconds)|Berg Balance Scale|Activities-specific Balance Confidence Scale|Fatigue Severity Scale|Stair Climbing Test (seconds)|Multiple Sclerosis Quality Of Life-54|Gait Analysis|Stabilometric assessment,False,
NCT05462522,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis","A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Participants With Systemic Sclerosis",COMPLETED,2023-01-16,2025-07-11,2025-07-11,2025-07-20,2022-07-18,INTERVENTIONAL,PHASE1,56.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,Systemic Sclerosis,,United States,Palo Alto,California,25,RO7303509|Placebo,DRUG|DRUG,Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Test Results|Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters,MAD Stage: Maximum Serum Concentration (Cmax) of RO7303509|MAD Stage: Area Under the Concentration vs Time Curve (AUC) of RO7303509|MAD Stage: Time to Maximum Concentration (Tmax) of RO7303509|MAD Stage: Total Clearance (CL) of RO7303509|MAD Stage: Volume of Distribution (V) of RO7303509|MAD Stage: Half-Life (t1/2) of RO7303509|MAD and OSE Stage: Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7303509,False,
NCT03816345,"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer",A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO),RECRUITING,2019-07-16,2026-09-30,2026-09-30,2025-09-23,2019-01-25,INTERVENTIONAL,PHASE1,300.0,ESTIMATED,National Cancer Institute (NCI),NIH,,,Autoimmune Disease|Crohn Disease|Dermatomyositis|Hematopoietic and Lymphoid Cell Neoplasm|Inflammatory Bowel Disease|Malignant Solid Neoplasm|Multiple Sclerosis|Psoriasis|Psoriatic Arthritis|Rheumatoid Arthritis|Sjogren Syndrome|Systemic Lupus Erythematosus|Systemic Scleroderma|Ulcerative Colitis,,United States,Birmingham,Alabama,52,Biospecimen Collection|Nivolumab,PROCEDURE|BIOLOGICAL,Incidence of adverse events|Change in disease assessments|Overall response rate|Changes in serum chemokines and circulating immune cells over time|Gene expression in normal tissues|Clinical measures of interest,,False,
NCT05981339,Acute Effect of Osteopathic Visceral Mobilization Techniques,"Acute Effect of Osteopathic Visceral Mobilization Techniques on Adductor Spasticity, Incontinence and Constipation in Multiple Sclerosis Patients",UNKNOWN,2023-08-07,2023-09-15,2023-09-30,2023-08-08,2023-08-08,INTERVENTIONAL,NA,20.0,ESTIMATED,University of Gaziantep,OTHER,,,Multiple Sclerosis|Pelvic Floor Disorders|Urinary Incontinence|Visceral Mobilization|Osteopathic Manipulative Treatment,,Turkey (Türkiye),Gaziantep,,1,breathing exercises|osteopathic manual therapy techniques,OTHER|OTHER,Spasticity Assessment|Evaluation of Pelvic Floor Muscle Activity|International Consultation on Incontinence Questionnaire Short Form ICIQ-SF|Constipation Quality of Life Scale: Constipation Quality of Life Scale (CIQS),,False,
NCT05378100,Ketamine for Multiple Sclerosis Fatigue,Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS),RECRUITING,2023-01-01,2025-12-01,2026-03-01,2025-01-10,2022-05-18,INTERVENTIONAL,PHASE2,110.0,ESTIMATED,Johns Hopkins University,OTHER,United States Department of Defense,FED,Multiple Sclerosis Fatigue,,United States,Baltimore,Maryland,1,Ketamine|Midazolam,DRUG|DRUG,Modified Fatigue Impact Scale (MFIS) Score,Fatigue Severity Scale (FSS)|Epworth Sleepiness Scale (ESS)|Beck Depression Inventory-II (BDI-II),False,
NCT05409599,The Effects of Vestibular Exercise and Cervical Stabilization Exercise Training on Balance and Gait in MS Patients,Comparison of the Effects of Vestibular Exercise and Cervical Stabilization Exercise Training on Balance and Gait in Multiple Sclerosis Patients,UNKNOWN,2021-10-01,2023-01-25,2023-02-01,2023-01-23,2022-06-08,INTERVENTIONAL,NA,36.0,ESTIMATED,Sanko University,OTHER,,,Multiple Sclerosis|Vestibular|Exercises,Multiple Sclerosis|vestibular exercises|cervical stabilization|gait,Turkey (Türkiye),Gaziantep,Şehitkamil,1,Exercises,OTHER,Static Balance|Gait speed|Dizziness|Dinamic Balance|Dinamic Balance|Endurance|Coordination|Postural swing|Walkiing difficulty,Fatigue|Depression|MSQ54 İnventory,False,
NCT04081714,Intermediate Expanded Access Protocol CNMAu8.EAP03,Intermediate Expanded Access Protocol With CNM-Au8 for Multiple Sclerosis,AVAILABLE,,,,2025-01-29,2019-09-09,EXPANDED_ACCESS,,,,Clene Nanomedicine,INDUSTRY,"University of Texas, Southwestern Medical Center at Dallas",OTHER,Multiple Sclerosis,MS|Gold|Nanoparticle|Expanded access|Au8|CNMAu8,United States,Dallas,Texas,1,CNM-Au8,DRUG,,,False,
NCT05242133,Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis,"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) Versus CinnoVex® (CinnaGen) in Reducing the Annualized Relapse Rate in Participants With Relapsing Remitting Multiple Sclerosis: A Phase III, Randomized, Parallel, Noninferiority Study",COMPLETED,2017-12-20,2022-04-27,2022-04-27,2022-10-18,2022-02-16,INTERVENTIONAL,PHASE3,168.0,ACTUAL,Cinnagen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS),,Iran,Tehran,,1,Pegylated interferon beta-1a|Interferon Beta-1A Prefilled Syringe,DRUG|DRUG,Annualized Relapse Rate,Proportion of patients with 12 weeks of sustained disability progression|Total number of new or newly enlarging T2-hyperintense lesions as detected by brain MRI|Total number of gadolinium enhancing lesions as detected by brain MRI|Total number of new or newly enlarging T1 hypointense lesions as detected by brain MRI|Total number of new active lesions as detected by brain MRI|Volume of new or newly enlarging T2 hyperintense lesions as detected by brain MRI|Volume of gadolinium enhancing lesions as detected by brain MRI|Volume of new or newly enlarging T1 hypointense lesions as detected by brain MRI|Brain atrophy,False,
NCT06441617,Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis,Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis,ENROLLING_BY_INVITATION,2024-12-05,2027-02-15,2027-09-14,2025-07-28,2024-06-04,INTERVENTIONAL,NA,2000.0,ESTIMATED,Accelerated Cure Project for Multiple Sclerosis,OTHER,"Congressionally Directed Medical Research Programs|United States Department of Defense|Charite University, Berlin, Germany|University Medical Center Goettingen|US Department of Veterans Affairs",FED|FED|OTHER|OTHER|FED,Multiple Sclerosis|Fatigue,,United States,Washington D.C.,District of Columbia,6,Online Program for Fatigue,DEVICE,Chalder Fatigue Scale,PROMIS FatigueMS-8a|PROMIS MS Health|SymptoMScreen|Frenchay Activities Index,False,
NCT04640818,Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy,Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study,UNKNOWN,2020-12-17,2022-10-31,2022-10-31,2022-03-23,2020-11-23,OBSERVATIONAL,,45.0,ESTIMATED,Claudio Gobbi,OTHER_GOV,Merck AG Switzerland,UNKNOWN,Multiple Sclerosis,anti CD20 therapy|cladribine,Switzerland,Lugano,Canton Ticino,1,Cladribine Oral Tablet|Rituximab|Ocrelizumab,DRUG|DRUG|DRUG,Changes in IgG serum concentrations in Cald-Group|Changes in IgM serum concentrations in Cald-Group|Changes in IgG serum concentrations in Clad-Group|Changes in IgM serum concentrations in Clad-Group,"Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies|Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies|Changes in IgG serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies|Changes in IgM serum concentrations after switching to cladribine, as compared to continued anti CD20 therapies|Proportion of patients reaching NEDA -3|Annualized relapse rate (ARR) over 12 months after switching to cladribine as compared to patients continuing anti CD20 therapies|Proportion of patients with disability progression|Proportion of patients with disability progression|Number/volume of cumulative new T2/ enlarging lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies|Number/volume of cumulative Gd enhancing lesions at brain and spinal MRI over 12 months after switching to cladribine, as compared to patients continuing anti CD20 therapies|Changes in serum neurofilament light chain concentration",False,
NCT03974997,Multiple Sclerosis,"TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis",UNKNOWN,2019-09-01,2020-09-01,2021-09-01,2019-06-05,2019-06-05,INTERVENTIONAL,NA,50.0,ESTIMATED,Assistance Publique Hopitaux De Marseille,OTHER,,,Multiple Sclerosis,,France,Marseille,,1,Determination of the circulating serum concentration of cytoquine TWEAK,DIAGNOSTIC_TEST,The serum concentration of soluble TWEAK,,False,
NCT06783413,"Effects of Laughter Yoga on Fatigue, Sleep Quality and Psychological Well-Being in Patients With Multiple Sclerosis: A Randomized Controlled Trial","Effects of Laughter Yoga on Fatigue, Sleep Quality and Psychological Well-Being in Patients With Multiple Sclerosis: A Randomized Controlled Trial",NOT_YET_RECRUITING,2025-04-15,2025-05-30,2025-05-30,2025-04-10,2025-01-20,INTERVENTIONAL,NA,40.0,ESTIMATED,Tokat Gaziosmanpasa University,OTHER,Ataturk University,OTHER,Multiple Sclerosis|Fatigue|Sleep Quality|Psychological Well-being,Multiple Sclerosis|Laughter Yoga|Fatigue|Sleep Quality|Psychological Well-Being|Nursing,,,,0,Intervention group (Laughter Yoga)|Control group,BEHAVIORAL|OTHER,Fatigue,Sleep Quality,False,
NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate,COMPLETED,2017-03-15,2019-06-27,2019-06-27,2020-07-14,2017-03-28,INTERVENTIONAL,PHASE3,506.0,ACTUAL,Biogen,INDUSTRY,"Alkermes, Inc.",INDUSTRY,Relapsing Remitting Multiple Sclerosis,RRMS|Multiple Sclerosis|MS|Alkermes|ALKS 8700|Dimethyl Fumarate|DMF|Tecfidera,United States,Cullman,Alabama,67,ALKS 8700|Dimethyl Fumarate,DRUG|DRUG,Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B,Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B|Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B|Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B|Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B|Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B|Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B|Worst IGISIS Individual Symptom Intensity Score During the 5-Week Treatment Period in Parts A and B|Number of Participants With Adverse Events (AEs),True,2020-07-14
NCT01070823,JC-Virus (JCV) Antibody Program,JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1,COMPLETED,2010-03,2012-06,2012-06,2016-10-05,2010-02-18,OBSERVATIONAL,,1096.0,ACTUAL,Biogen,INDUSTRY,"United BioSource, LLC|Elan Pharmaceuticals",INDUSTRY|INDUSTRY,Multiple Sclerosis,Sample Collection|JCV|PML,United States,Aurora,Colorado,11,Tysabri® (natalizumab),DRUG,Prevalence of serum anti-JC virus (JCV) antibody|Number of participants with a false negative test,Changes in JCV antibody status over time,False,
NCT04936555,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,COMPLETED,2021-05-01,2021-06-01,2021-07-15,2021-07-22,2021-06-23,INTERVENTIONAL,NA,60.0,ACTUAL,Istanbul Sabahattin Zaim University,OTHER,,,Multiple Sclerosis,Self-Acupressure|Functional composite|Quality of life,Turkey (Türkiye),Istanbul,State,1,Self-Acupressure,OTHER,Multiple Sclerosis Functional Composite (MSFC)|Multiple Sclerosis Functional Composite (MSFC)|Multiple Sclerosis Quality of Life Scale-54|Multiple Sclerosis Quality of Life Scale-54,,False,
NCT02553525,Effects of Stimulation Patterns of Deep Brain Stimulation,Effects of Stimulation Patterns of Deep Brain Stimulation,ENROLLING_BY_INVITATION,2016-06-02,2026-09,2026-09,2025-04-15,2015-09-17,INTERVENTIONAL,NA,180.0,ESTIMATED,Duke University,OTHER,National Institute of Neurological Disorders and Stroke (NINDS)|Emory University|University of Florida|Boston Scientific Corporation,NIH|OTHER|OTHER|INDUSTRY,Parkinson Disease|Essential Tremor|Multiple Sclerosis|Dystonia,Deep Brain Stimulation|Movement Disorders|Parkinson Disease|Essential Tremor|Subthalamic Nucleus|Globus Pallidus|Thalamus|Tremor|Bradykinesia|Temporal Pattern|Electrical Stimulation|Neuromodulation|PD|ET|MS|STN|GPi|DBS|Nervous System Diseases|Neurodegenerative Diseases,United States,Gainesville,Florida,3,Therapeutic Stimulation Patterns|Symptogenic Stimulation Patterns,PROCEDURE|PROCEDURE,Tremor Accelerometry|Bradykinesia Finger Tapping|Neural Activity,Electrode Location,False,
NCT02266121,Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis,Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques,TERMINATED,2014-10,2023-05-08,2023-05-08,2023-05-09,2014-10-16,INTERVENTIONAL,NA,100.0,ESTIMATED,University Hospital of Mont-Godinne,OTHER,Université Catholique de Louvain|Teva Pharmaceuticals USA,OTHER|INDUSTRY,Relapsing Remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Cognitive Deficits|Motor Deficits,Multiple Sclerosis|MS|Cognitive deficits|Motor deficits|Fatigue|Nervous System Diseases|Brain Diseases|Brain stimulation|Working memory|Motor learning|Central Nervous System Diseases|Neuropsychological rehabilitation,Belgium,Yvoir,Namur,1,tDCS,DEVICE,Enhancement of Cognitive aptitudes with tDCS,Enhancement of Motor skills with tDCS|Impact on Fatigue and Enhancement of Cognitive performances with tDCS,False,
NCT04202055,Immunologic Biomarker Profile of Cerebrospinal Fluid,Immunologic Biomarker Profile of Cerebrospinal Fluid,COMPLETED,2018-01-02,2019-08-31,2019-08-31,2019-12-17,2019-12-17,OBSERVATIONAL,,165.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica,,France,Nîmes,,1,Biomarker analysis,OTHER,Level of glial fibrillar acidic protein in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of chitinase-3-like protein 1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of neurofilament in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Interleukin-6 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Interleukin-8 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Matrix metalloproteinase-9 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Soluble CD27 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Interleukin 10 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Interleukin 17A in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of Interleukin 1B in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein|Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein,Level of glial fibrillar acidic protein in cerebrospinal fluid in each group|Level of chitinase-3-like protein 1 in cerebrospinal fluid in each group|Level of neurofilament in cerebrospinal fluid in each group|Level of Interleukin-6 in cerebrospinal fluid in each group|Level of Interleukin-8 in cerebrospinal fluid in each group|Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in each group|Level of Matrix metalloproteinase-9 in cerebrospinal fluid in each group|Level of Soluble CD27 in cerebrospinal fluid in each group|Level of Interleukin 10 in cerebrospinal fluid in each group|Level of Interleukin 17A in cerebrospinal fluid in each group|Level of Interleukin 1B in cerebrospinal fluid in each group|Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in each group|Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in each group|Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in each group,False,
NCT02688985,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),"An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis",COMPLETED,2016-04-29,2023-04-11,2023-04-11,2024-06-04,2016-02-23,INTERVENTIONAL,PHASE3,131.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,"Relapsing Multiple Sclerorsis|Multiple Sclerosis, Primary Progressive",,United States,Palo Alto,California,17,Ocrelizumab|Lumbar Puncture|Methyloprednisolone|Antihistamine,DRUG|PROCEDURE|DRUG|DRUG,Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab|Change in Number of CD19+ B Cells in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab|Change From Baseline in Number of CD3+ T-Cells in CSF Post-Treatment With Ocrelizumab,,True,2024-06-04
NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,"Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2008-02,2011-05,2011-08,2016-07-11,2006-10-19,INTERVENTIONAL,PHASE2,621.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis,MS|multiple sclerosis,Czechia,Brno,,56,BIIB019 (Daclizumab High Yield Process)|Placebo,BIOLOGICAL|DRUG,Adjusted Annualized Relapse Rate Between Baseline and Week 52,Adjusted Mean Number of New Gadolinium (Gd)-Enhancing Lesions Between Week 8 and Week 24|Adjusted Mean Number of New or Newly-enlarging T2 Hyperintense Lesions at Week 52|Proportion of Participants Who Relapsed at Week 52|Mean Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Impact Score at Week 52,True,2016-07-11
NCT01235221,Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.,Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials,COMPLETED,2010-12,2012-06,2012-06,2014-07-04,2010-11-05,INTERVENTIONAL,PHASE3,38.0,ACTUAL,Biogen,INDUSTRY,Acorda Therapeutics,INDUSTRY,Multiple Sclerosis,,Canada,Calgary,Alberta,5,BIIB041 (Fampridine-SR),DRUG,Adverse events (AEs) and serious adverse events (SAEs) as well as Changes in vital signs and clinical laboratory assessments,,False,
NCT04100343,Detection of Pattern of Some Unusual Signs and Symptoms of Multiple Sclerosis,Detection of Pattern of Unusual Signs and Symptoms of Multiple Sclerosis,UNKNOWN,2019-11-01,2021-12-01,2021-12-01,2019-10-04,2019-09-24,OBSERVATIONAL,,100.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,,,Fatigue severity scale,,False,
NCT03453125,Improving Learning in Hispanics With TBI or MS,Improving Learning in Hispanics With TBI or MS: A Pilot Trial,UNKNOWN,2013-09-25,2022-09-30,2022-09-30,2022-01-12,2018-03-05,INTERVENTIONAL,NA,40.0,ESTIMATED,Kessler Foundation,OTHER,"Instituto Vocacional Enrique Díaz de León A.C., Guadalajara, Mexico",UNKNOWN,TBI (Traumatic Brain Injury) or MS (Multiple Sclerosis),cognitive rehabilitation|memory,United States,East Hanover,New Jersey,2,Spanish modified Story Memory Technique (mSMT),BEHAVIORAL,Total learning post-treatment (covarying for baseline performance),,False,
NCT03490240,Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis,Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2018-03-01,2023-03-01,2025-12-31,2025-02-04,2018-04-06,INTERVENTIONAL,NA,280.0,ESTIMATED,University of Alabama at Birmingham,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Birmingham,Alabama,1,BIPAMS|WELLMS,BEHAVIORAL|BEHAVIORAL,Change of Physical Activity levels through Accelerometery from baseline at 6 and 12 months.|Change of Physical Activity levels through the Godin Leisure-Time Exercise Questionnaire from baseline at 6 and 12 months.|Change of Physical Activity levels through the Abbreviated International Physical Activity Questionnaire from baseline at 6 and 12 months.,Change of self-report measures of walking through the Multiple Sclerosis Walking Scale - 12 from baseline at 6 and 12 months|Change of self-report measures of Walking through the Patient Determined Disease Steps Scale from baseline at 6 and 12 months.|Change of self-report measures of Cognition through the Perceived Deficits Questionnaire from baseline at 6 and 12 months.|Change of self-report measures of Cognition through the Multiple Sclerosis Neuropsychological Questionnaire from baseline at 6 and 12 months.|Change of self-report measures of Fatigue through the Fatigue Severity Scale from baseline at 6 and 12 months.|Change of self-report measures of Fatigue through the Modified Fatigue Impact Scale at 6 and 12 months from baseline.|Change of self-report measures of Anxiety and Depression through the Hospital Anxiety and Depression Scale at 6 months and 12 months from baseline.|Change of self-report measures of Pain through the Short-form of McGill Pain Questionnaire at 6 and 12 months from baseline.|Changes of self-report measures of sleep through the Pittsburgh Sleep Quality Index at 6 and 12 months from baseline.|Changes of self-report measures of quality of life through the Medical Outcomes Study Short Form-36 at 6 and 12 months from baseline.|Changes of self-report measures of quality of life through the Multiple Sclerosis Impact Scale-29 at 6 and 12 months from baseline.,False,
NCT04964700,Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab,Analysis of Multiple Sclerosis Patients Who Have Had Greater Than 60 Infusions of Natalizumab: Safety and Efficacy,UNKNOWN,2021-05-06,2022-04-01,2022-06-01,2022-03-24,2021-07-16,OBSERVATIONAL,,42.0,ACTUAL,Multiple Sclerosis Center of Northeastern New York,OTHER,,,Multiple Sclerosis,Natalizumab|Tysabri,United States,Latham,New York,1,Natalizumab,DRUG,Number of reported cases of PML ( progressive multifocal leukoencephalopathy)|Number of documented exacerbations|Change in EDSS Score|Number of new MRI lesions,Change in JCV Ab index value|Number of reported clinically significant changes on MRI that may indicate other opportunistic infections.|Number of clinically significant lab values as measured CMP ( Comprehensive Metabolic Panel)|Number of clinically significant lab values as measured by the CBC (Complete Blood Count),False,
NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2001-11,2004-11,2005-01,2017-01-09,2001-12-03,INTERVENTIONAL,PHASE3,900.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Relapsing Remitting Multiple Sclerosis,United States,Scottsdale,Arizona,53,Natalizumab|Placebo,DRUG|DRUG,"The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years.",Reduction in MRI changes and clinical relapses,False,
NCT01707992,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",COMPLETED,2013-02-20,2015-04-13,2017-07-04,2021-11-09,2012-10-16,INTERVENTIONAL,PHASE3,2199.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Cullman,Alabama,284,Laquinimod|Placebo,DRUG|DRUG,Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months),Placebo-Controlled Phase: Percent Change From Baseline in Brain Volume at Month 15|Placebo-Controlled Phase: Time to First Confirmed Relapse (Number of Participants With Confirmed Relapse)|Placebo-Controlled Phase: Time to CDP Confirmed After At Least 6 Months (Number of Participants With CDP After At Least 6 Months)|Placebo-Controlled Phase: Time to CDP Confirmed After At Least 9 Months (Number of Participants With Confirmed Relapse After At Least 9 Months),True,2019-03-13
NCT04289909,Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS),Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics,COMPLETED,2020-12-01,2024-06-26,2024-07-17,2025-04-04,2020-02-28,INTERVENTIONAL,NA,50.0,ACTUAL,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis|Optic Neuritis|Eye Diseases|Optic Nerve Diseases|Nervous System Diseases|Multiple Sclerosis,relapsing remitting Multiple sclerosis|Progressive Multiple Sclerosis|Optic neuritis|multiple sclerosis|adaptive optics|eye disease|peripheral nervous system disease,France,Paris,,1,Adaptive Optics Ophthalmoscopy (AOO),OTHER,Quantification of retinal perivascular cuff width across MS phenotypes,Variation of size of perivascular sheathing|Clinical disability measure with EDSS|Clinical disability measured with MSFC|Number of relapses|Presence of disc oedema measured at Optical Coherence Tomography (OCT) measurements|RNLF thickness measured at Optical Coherence Tomography (OCT) measurements|parenchymal T2 lesion volume at MRI|gadolinium enhanced T1 lesion at MRI|optic nerve cross-sectional area at MRI|Hyperintensity on the optic nerve at MRI,False,
NCT02106052,Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients,The Effect of Aerobic Exercise on Cognition in Multiple Sclerosis (MS Exercise Study),UNKNOWN,2014-03,2020-05,2020-05,2020-05-05,2014-04-07,INTERVENTIONAL,NA,117.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,cognitive function|cognitive impairment|cognitive intervention|cognitive improvement|information processing speed|exercise training program|aerobic exercise|stretching and toning|Multiple sclerosis|executive function,United States,Seattle,Washington,1,Aerobic exercise|Stretching and toning exercise,OTHER|OTHER,"Composite score of the Paced Auditory Serial Addition Test-3 (PASAT-3"") and the oral version of the Symbol-Digit Modalities Test (SDMT)","Delis Kaplan Executive Function System Sorting Test (DKEFS)|California Verbal Learning Test, second edition (CVLT2)|Brief Visuospatial Memory Test Revised (BVMTR)|The Controlled Oral Word Association Test (COWAT)",False,
NCT03662347,Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP),Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP),UNKNOWN,2020-03-19,2022-03,2022-03,2020-07-08,2018-09-07,OBSERVATIONAL,,2100.0,ESTIMATED,"Central Hospital, Nancy, France",OTHER,,,Multiple Sclerosis,,France,Vandœuvre-lès-Nancy,,1,,,Fatigue score: EMIF-SEP scale,"The quality of life: SF-36|The quality of life: MuSIQoL|Nutritional behaviors (physical activity and sedentary lifestyle)|Psychological state (optimism, anxiety, depression)",False,
NCT05077956,Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis,Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis,WITHDRAWN,2021-10-19,2023-10-25,2023-10-25,2023-08-07,2021-10-14,OBSERVATIONAL,,0.0,ACTUAL,Providence Health & Services,OTHER,Milton S. Hershey Medical Center|Bristol-Myers Squibb,OTHER|INDUSTRY,Relapsing Multiple Sclerosis|Multiple Sclerosis,multiple sclerosis|relapsing multiple sclerosis|semaphorin 4A|sema4a|disease modifying therapy|biomarker,United States,Portland,Oregon,1,Cerebrospinal and Blood Serum Semaphorin 4A Levels,DIAGNOSTIC_TEST,Blood Serum Semaphorin 4A Levels|Cerebrospinal Fluid Semaphorin 4A Levels,Correlation between Semaphorin 4A levels and Demyelination and Axonal Degeneration,False,
NCT03829267,eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS,eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With Multiple Sclerosis,COMPLETED,2019-04-26,2020-04-13,2020-04-13,2020-11-04,2019-02-04,INTERVENTIONAL,NA,44.0,ACTUAL,Columbia University,OTHER,,,Multiple Sclerosis,exercise|physical activity,United States,New York,New York,1,eFIT Intervention|eJournal Intervention|Treatment as usual,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Adherence rate: Percentage of weekly eFIT group meetings that participants attend|Completion rate: Percentage of enrolled participants who complete follow-up questionnaires,Change in International Physical Activity Questionnaire (IPAQ) total score (self-reported physical activity level)|Patient Health Questionnaire-9 (PHQ-9)|UCLA Loneliness Scale,False,
NCT01928134,"The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis","The Efficacy of Vitamin K2 on Human Osteoporosis, Blood-vessel Calcification and Sclerosis",COMPLETED,2011-04,2011-11,2012-02,2013-08-23,2013-08-23,INTERVENTIONAL,NA,60.0,ACTUAL,Changhua Christian Hospital,OTHER,,,Healthy,Vitamin K2|Vitamin D3|Bioavailability of calcium|volunteers|Men|non-pregnant women|twenty years of age,Taiwan,Changhua,Taiwan,1,Vit K2+ Vit D3+ calcium carbonate (CaCO3)|Vit K2+CaCO3,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Change from baseline in Serum Calcium,Change from baseline in urine calcium/creatinine ratio,False,
NCT01930799,Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns,,COMPLETED,2013-08,2015-03,2015-03,2016-05-27,2013-08-29,INTERVENTIONAL,PHASE4,120.0,ACTUAL,Allergan,INDUSTRY,,,Multiple Sclerosis|Urinary Bladder Diseases,,United States,Fresno,California,1,Systematic Screening and Education Regimen,BEHAVIORAL,Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores,Percentage of Patients Who Agree/Completely Agree With Each Question on the Patient Post-Video Questionnaire,True,2016-05-27
NCT01815632,Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS),Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS),UNKNOWN,2014-01,2019-10,2019-10,2018-06-27,2013-03-21,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,North Bristol NHS Trust,OTHER,Bristol Royal Hospital for Children|University of Bristol|University of Nottingham|NHS Blood and Transplant|Kenneth and Claudia Silverman Family Foundation|Multiple Sclerosis Trust|Medical Research Council|Rosetrees Trust|Catholic Bishops of England and Wales|Friends of Frenchay,OTHER|OTHER|OTHER|OTHER_GOV|OTHER|UNKNOWN|OTHER_GOV|OTHER|UNKNOWN|UNKNOWN,Progressive Multiple Sclerosis,multiple sclerosis|progressive MS|stem cell|cell therapy|neurodegeneration|CNS repair,United Kingdom,Bristol,,1,Early infusion of autologous marrow|Late infusion of autologous marrow,OTHER|OTHER,Global evoked potential (GEP): mean change from time of marrow infusion to end of study,Safety|Expanded disability status scale|Multiple sclerosis impact scale (MSIS-29)|Multiple sclerosis functional composite (MSFC)|MRI head and cord|Optical coherence tomography,False,
NCT04237337,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,UNKNOWN,2020-01,2020-02,2020-03,2020-01-23,2020-01-23,OBSERVATIONAL,,200000.0,ESTIMATED,"University Hospital, Caen",OTHER,,,Multiple Sclerosis|Malignant Tumor,pharmacovigilance,,,,0,Exposure to MS drugs,OTHER,Risk of reporting cancer overall specific cancers [ Time Frame: Reported in the World Health Organization (WHO) database of individual safety case reports from 2000 to 12/31/2019 ] performing a disproportionality analysis,Risk of reporting cancer specific cancers [ Time Frame: Reported in the World Health Organization (WHO) database of individual safety case reports from 2000 to 12/31/2019 ] performing a disproportionality analysis,False,
NCT06723444,Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis,Testing the Efficacy of a Memory Training Program to Improve New Learning and Memory in Portuguese Patients With Multiple Sclerosis: A Randomized Clinical Trial,RECRUITING,2024-12-05,2026-12,2028-08,2025-02-12,2024-12-09,INTERVENTIONAL,NA,80.0,ESTIMATED,"Centro Hospitalar De São João, E.P.E.",OTHER,Instituto de Saude Publica da Universidade do Porto|Center of Psychology at University of Porto,OTHER|UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Memory|Cognitive Rehabilitation|Randomized Controlled Trial,Portugal,Porto,,1,Learning and Memory Training|Placebo Comparator,BEHAVIORAL|BEHAVIORAL,Verbal memory|Verbal memory,Self-reported Questionnaires|Self-reported Questionnaires,False,
NCT06827834,Spinal Cord Monitoring in Multiple Sclerosis,A Prospective Longitudinal Study of Spinal Cord Lesions in Multiple Sclerosis: MRI Monitoring and Prognostic Factors for Active Disease,RECRUITING,2024-08-06,2028-06-01,2028-06-01,2025-02-14,2025-02-14,OBSERVATIONAL,,155.0,ESTIMATED,Zuyderland Medisch Centrum,OTHER,,,Multiple Sclerosis,spinal cord|mri|biomarkers|multiple sclerosis,Netherlands,Arnhem,Gelderland,5,,,Spinal cord lesion count,Brain MRI acitivity|Expanded disability status scale (EDSS)|Timed 25 foot walk test|Nine hole peg test|No evidence of disease activity|Biomarkers neuronal damage|Lower urinary tract symptoms,False,
NCT07137624,Motor Imagery and Action Observation for Gait Function in MS,Effects of Motor Imagery and Action Observation on Gait Initiation and Spatiotemporal Gait Parameters in Multiple Sclerosis,NOT_YET_RECRUITING,2025-09-15,2025-10,2025-10,2025-09-16,2025-08-22,INTERVENTIONAL,NA,20.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,Motor imagery|Action Observation,Turkey (Türkiye),Ankara,,1,Action Observation + Motor Imagery|Nature Video,BEHAVIORAL|BEHAVIORAL,Change in Tibialis Anterior and Gastrocnemius Medialis Muscle Activity Amplitude|Change in Tibialis Anterior and Gastrocnemius Medialis Muscle Activity Onset Latency|Change in Step Length|Change in Step Time|Change in Step Width|Change in Double Support Period|Change in Gait Velocity|Change in Cadence,Motor Imagery Vividness|Mental Chronometry Ratio|Limb Laterality Recognition Performance|Cognitive Status|Fatigue Level|Anxiety and Depression|Disability Level|Visual Acuity,False,
NCT01854359,Idebenone for Primary Progressive Multiple Sclerosis,Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis,COMPLETED,2013-03-12,2018-10-31,2018-10-31,2021-05-19,2013-05-15,INTERVENTIONAL,PHASE1|PHASE2,61.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Multiple Sclerosis|Extension Trial,United States,Bethesda,Maryland,1,Idebenone,DRUG,Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE),Slopes of 25 Foot Walk (25FW) Time|Slopes of 9 Hole Peg Test (9HPT) Time|Slopes of Expanded Disability Status Scale (EDSS) Score|Change in Slopes of Scripps Neurological Rating Scale (SNRS) Score,True,2021-05-19
NCT06572059,Upper Extremity Motor Imagery Functional Skills and Quality of Life in Patients With Multiple Sclerosis,"The Relationship Between Upper Extremity Motor Imagery Ability, Upper Extremity Functional Skills and Quality of Life in Patients With Multiple Sclerosis",COMPLETED,2023-07-07,2023-10-30,2023-10-30,2024-08-29,2024-08-26,OBSERVATIONAL,,100.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,Ege University,OTHER,"Multiple Sclerosis|Upper Extremity Problem|Quality of Life|Image, Body|Motor Activity",,Turkey (Türkiye),Kahramanmaraş,Onikisubat,1,assesments for once,OTHER,The Kinesthetic and Visual Imagery Questionnaire (KVIQ)|Mental Stopwatch|Nine Hole Peg Test (NHPT)|Jebson-Taylor Hand Function Test (JTHFT)|Manual Ability Measure-36 (MAM-36)|multiple sclerosis impact scale-29,Expanded disability status scale (EDSS)|Mini-Mental State Examination (MMSE)|Fatigue Severity Scale (FSS)|Beck Depression Inventory (BDI),False,
NCT02096133,Vitamin D3 and the Stress-axis in MS,"Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study",TERMINATED,2014-10-13,2016-11-07,2016-11-07,2017-01-25,2014-03-26,INTERVENTIONAL,PHASE2,54.0,ACTUAL,Academic MS Center Limburg,OTHER,,,Multiple Sclerosis,"Multiple sclerosis, vitamin D, HPA-axis, cortisol",Netherlands,Nijmegen,,2,Cholecalciferol|Placebo comparator,DRUG|OTHER,The area under the curve (AUC) of the cortisol day curve,The slope of the cortisol day-curve|The cortisol awakening response|Clinical outcomes on depression|Efficacy of supplementation|Side effects,False,
NCT07161258,"A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)","An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis",RECRUITING,2025-10-03,2027-06-08,2029-02-13,2025-09-22,2025-09-08,INTERVENTIONAL,PHASE2,12.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,Pediatric multiple sclerosis|Pediatric MS|Children MS|Children multiple sclerosis|Adolescent multiple sclerosis|Pediatric fenebrutinib,Argentina,San Miguel de Tucumán,,5,Fenebrutinib,DRUG,Plasma Concentration of Fenebrutinib|Total Number of New T1 Gadolinium (Gd)-Enhancing Lesions on Brain Observed Through Magnetic Resonance Imaging (MRI) Scans,"Number of Participants With Adverse Events (AEs)|Percentage of Participants With Suicidal Ideation (SI) or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Baseline in Vital Signs - Pulse Rate|Change From Baseline in Vital Signs - Blood Pressure|Change From Baseline in Single 12-lead Electrocardiogram (ECG) Parameter - QTc Interval|Change From Baseline in Single 12-lead ECG Parameter - PR Interval|Change from Baseline in Clinical Laboratory Test Results - Alanine Aminotransferase (ALT)|Change from Baseline in Clinical Laboratory Test Results - Aspartate Aminotransferase (AST)",False,
NCT06875908,Reliability and Validity of the Turkish Version of General Sleep Disturbance Scale (GSDS-T) in Multiple Sclerosis,Reliability and Validity of the Turkish Version of General Sleep Disturbance Scale (GSDS-T) in Multiple Sclerosis,RECRUITING,2025-04-15,2025-07-20,2025-08-10,2025-06-17,2025-03-13,OBSERVATIONAL,,126.0,ESTIMATED,Istanbul Medeniyet University,OTHER,,,Multiple Sclerosis|Sleep Disturbance,Multiple sclerosis|Sleep disturbances,Turkey (Türkiye),Bağcılar,Istanbul,1,Turkish Validity and Reliability of The GSDS-T in patients with multiple sclerosis,OTHER,Sleep disturbances|Sleep quality,,False,
NCT06327789,Trunk Control and Disability in Persons With Multiple Sclerosis,The Relationship Between Trunk Control and Disability in Persons With Early Relapsing Multiple Sclerosis,COMPLETED,2021-12-21,2021-12-25,2022-02-21,2024-03-25,2024-03-25,OBSERVATIONAL,,23.0,ACTUAL,Zonguldak Bulent Ecevit University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Zonguldak,,1,,,"Expanded Disability Status Scale (EDSS)|Trunk Impairment Scale (TIS)|Biodex Balance System (BBS) (MedicalSystems, Shirley, NY, USA)|Step Length (cm)|Stride Length (cm)|Step Width (cm)|Cadence (steps/min)|Velocity (m/s)|Step time (s)|Stride time (s)|Timed 25-Foot Walk Test (T25FW)|Nine-Hole Peg Test (9HPT)",,False,
NCT03783416,SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis,"Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.",RECRUITING,2020-06-15,2026-07-31,2026-07-31,2025-09-04,2018-12-21,INTERVENTIONAL,PHASE1,72.0,ESTIMATED,Queen Mary University of London,OTHER,"Takeda Pharmaceuticals International, Inc.",INDUSTRY,Relapsing Remitting Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,United Kingdom,London,Greater London,1,Ixazomib (NINLARO®) capsules / Matching placebo capsules,DRUG,Safety - Adverse events (AE) will be compared between active and placebo arm|Efficacy - the proportion of OCB IgG negative subjects will be compared between active and placebo arm,Magnetic Resonance Imaging (MRI)|Change In Expanded Disability Status Scale (EDSS) with Ixazomib versus placebo arm at 24 months. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist,False,
NCT05945784,Exploring Accessible Beauty for Individuals With Upper Extremity Deficits,Exploring Accessible Beauty: A Study on Enhancing Beauty Product Accessibility for Individuals With Upper Extremity Deficits,COMPLETED,2023-07-21,2023-09-15,2023-09-29,2023-12-06,2023-07-14,OBSERVATIONAL,,57.0,ACTUAL,Casa Colina Hospital and Centers for Healthcare,OTHER,,,"Stroke, Ischemic|Stroke Hemorrhagic|Stroke (CVA) or TIA|Stroke, Acute|Traumatic Brain Injury|SCI - Spinal Cord Injury|Ehlers-Danlos Syndromes (EDS)|Lupus Erythematosus|Guillain-Barre Syndrome|Multiple Sclerosis|Myasthenia Gravis|Amyotrophic Lateral Sclerosis|Graves Disease|Muscular Dystrophies",upper extremity disabilities|limited mobility|dexterity impairments|muscle weakness,United States,Pomona,California,1,Use of Rare Beauty makeup products,OTHER,Likert Scale|Likert Scale|Pre-test Questionnaire|Accessibility Evaluation|Accessibility Evaluation|Post-test Questionnaire,,False,
NCT00497952,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis,WITHDRAWN,2007-07,2024-12,2024-12,2023-10-12,2007-07-09,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,Talaris Therapeutics Inc.,INDUSTRY,,,Multiple Sclerosis,Relapsing-remitting multiple sclerosis|Marrow/Stem cell transplant,,,,0,hematopoetic stem cell infusion,BIOLOGICAL,Stem cell engraftment,Disease remission,False,
NCT02201849,"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults","A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults",COMPLETED,2014-07,2014-12,2014-12,2019-11-26,2014-07-28,INTERVENTIONAL,PHASE1,104.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Alkermes|ALKS 8700,United States,Austin,Texas,1,Study Drug|Active Control|Placebo,DRUG|DRUG|DRUG,Safety and tolerability will be measured by incidence of adverse events,Maximum plasma concentration (Cmax)|Time to attain Cmax (Tmax)|Area under the concentration-time curve from 0 to the last quantifiable time interval (AUClast)|Area under the concentration-time curve from time 0 to infinity (AUCinf),False,
NCT04303143,Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms,Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms,UNKNOWN,2021-03,2021-05,2021-07,2020-07-29,2020-03-10,OBSERVATIONAL,,20.0,ESTIMATED,Inner Group Inc.,INDUSTRY,,,"Restless Legs Syndrome|Multiple Sclerosis|Trauma, Psychological|Chronic Disease|Trauma",hypnosis|trauma|chronic disease,,,,0,Self-Hypnosis|Direct Autonomic Experience Control,BEHAVIORAL|BEHAVIORAL,SUDS,DAX Control of SUDS Change|Professional Control of SUDS change,False,
NCT05204459,MS-ResearchBiomarkerS,"Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders",RECRUITING,2021-11-11,2041-11-11,2041-11-11,2024-02-06,2022-01-24,OBSERVATIONAL,,1000.0,ESTIMATED,Cedars-Sinai Medical Center,OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive|Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Neuromyelitis Optica Spectrum Disorders|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Neurologic Autoimmune Disease|Neurologic Disorder|Healthy Aging","Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive|Clinically Isolated Syndrome|Radiologically Isolated Syndrome|Neuromyelitis Optica Spectrum Disorders|Myelin oligodendrocyte glycoprotein antibody-associated disease|Neurologic Autoimmune Disease|Neurologic Disorder|Healthy Aging",United States,Los Angeles,California,1,,,Identifying risk factors for disability progression,"Effect of disease modifying therapy|Identify factors associated with visual disability and optic neuropathy in multiple sclerosis and related disorders|Identify serum, genetic, and stem cell-derived biomarkers influencing disability risks",False,
NCT03138525,Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis,Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis,COMPLETED,2017-06-20,2019-12-20,2019-12-20,2021-01-27,2017-05-03,OBSERVATIONAL,,161.0,ACTUAL,Brigham and Women's Hospital,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis|Healthy,,United States,Boston,Massachusetts,1,Blood sampling (MS)|Blood sampling (controls),OTHER|OTHER,Monocyte Transcriptome Profiling|Antigen microarrays|Serum microRNA profiles,,False,
NCT00411723,Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis,Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis,UNKNOWN,2006-12,2009-02,2009-05,2009-02-20,2006-12-14,INTERVENTIONAL,PHASE1,34.0,ACTUAL,Artielle ImmunoTherapeutics,INDUSTRY,,,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting","multiple sclerosis, chronic-progressive, relapsing-remitting",United States,New Haven,Connecticut,6,RTL1000 (recombinant T cell receptor ligand)|RTL1000 Placebo,DRUG|DRUG,"Adverse events, safety, laboratory parameters, vital signs, ECG and physical exam results. Disease parameters (neurologic exam, EDSS, 25 foot timed walk, 9-hole PEG test, MRI). Antibodies to drug.",,False,
NCT03401879,Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis,Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis,RECRUITING,2018-02-01,2026-03,2026-03,2025-05-23,2018-01-17,INTERVENTIONAL,NA,50.0,ESTIMATED,Medical University of Vienna,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Optic Neuritis",,Austria,Vienna,Austria,1,Dynamic Vessel Analyzer (DVA)|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Optical coherence tomography (OCT)|Optical coherence tomography angiography (OCTA),DEVICE|DEVICE|DEVICE|DEVICE,Flicker induced increase in retinal blood flow,Retinal vessel diameters|Retinal oxygen saturation|Retinal nerve fiber layer thickness|Layer specific flow signal,False,
NCT04979546,Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis,Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial,COMPLETED,2021-11-04,2024-04-03,2024-04-03,2024-09-19,2021-07-28,INTERVENTIONAL,NA,237.0,ACTUAL,University of Alberta,OTHER,University Hospital Foundation,OTHER,Multiple Sclerosis|Anxiety|Depression|Patient Satisfaction,"patient reported outcome measures, consultant satisfaction shared decision-making",Canada,Edmonton,Alberta,1,Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist,OTHER|OTHER,Difference in Change in Depression score in the Hospital Anxiety and Depression Scale (HADS-D) scores|Difference in Change in Anxiety score in the Hospital Anxiety and Depression Scale (HADS-A) scores,Difference in Change in the Euro Quality of Life Measurement (EQ5D)|Difference in Change in the Modified Fatigue Impact Scale (MFIS) score|Scores on Qualitative Consultant Satisfaction Questionnaire (CSQ)|The Patient Determined Disease Steps (PDDS) Stability of Score|Difference in Change in the Patient Health Questionnaire-9 (PHQ-9)|Difference in change in the CollaboRATE shared decision-making survey,False,
NCT01199640,Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis,A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis,COMPLETED,2005-05,2007-07,2007-10,2010-09-13,2010-09-13,INTERVENTIONAL,PHASE2,50.0,ACTUAL,"Millennium Pharmaceuticals, Inc.",INDUSTRY,,,Multiple Sclerosis,,,,,0,MLN1202,DRUG,To determine the safety and tolerability of MLN1202 in patients with relapsing-remitting multiple sclerosis (RRMS)|To determine the efficacy of MLN1202 in patients with RRMS,,False,
NCT02466191,Treatment of Pendular Nystagmus in OPT,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study,COMPLETED,2015-06,2016-01,2016-01,2025-09-03,2015-06-09,INTERVENTIONAL,PHASE4,7.0,ACTUAL,Hospices Civils de Lyon,OTHER,,,Pendular Nystagmus|Oculopalatal Tremor,nystagmus|pharmacological trial|multiple sclerosis|oscillopsia,France,Lyon,,1,Memantine|Gabapentin,DRUG|DRUG,"Velocity, amplitude and frequency of nystagmus using eye movement recording|Velocity, amplitude and frequency of nystagmus using eye movement recording|Velocity, amplitude and frequency of nystagmus using eye movement recording|Velocity, amplitude and frequency of nystagmus using eye movement recording","Functional score on questioning as measured by the 25-Item National Eye Institute Visual Function Questionnaire|Functional score on questioning as measured by the 25-Item National Eye Institute Visual Function Questionnaire|Functional score on questioning as measured by the 25-Item National Eye Institute Visual Function Questionnaire|Functional score on questioning as measured by the 25-Item National Eye Institute Visual Function Questionnaire|subjective measure of oscillopsia|subjective measure of oscillopsia|subjective measure of oscillopsia|subjective measure of oscillopsia|far visual acuity as measured by monocularly and binocularly direction and amplitude (measures in degrees) of their oscillopsia while viewing, with best correction, a stationary target at far (5 m) and near (57 cm) location.|far visual acuity as measured by monocularly and binocularly direction and amplitude (measures in degrees) of their oscillopsia while viewing, with best correction, a stationary target at far (5 m) and near (57 cm) location.|far visual acuity as measured by monocularly and binocularly direction and amplitude (measures in degrees) of their oscillopsia while viewing, with best correction, a stationary target at far (5 m) and near (57 cm) location.|far visual acuity as measured by monocularly and binocularly direction and amplitude (measures in degrees) of their oscillopsia while viewing, with best correction, a stationary target at far (5 m) and near (57 cm) location.",False,
NCT05466682,RELAXaHEAD for Headache Patients (Phase II),RELAXaHEAD for Headache Patients (Phase II): RELAXaHEAD for Migraine and Sleep,COMPLETED,2022-06-09,2022-12-19,2023-06-19,2024-01-10,2022-07-20,INTERVENTIONAL,NA,48.0,ACTUAL,NYU Langone Health,OTHER,"Center for Advancing Point of Care Technologies|National Heart, Lung, and Blood Institute (NHLBI)",OTHER|NIH,Migraine|Headache|Multiple Sclerosis|Insomnia,Progressive Muscle Relaxation Therapy|Migraine|Insomnia,United States,New York,New York,1,Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Monitored Usual Care (MUC),BEHAVIORAL|BEHAVIORAL,Number of Patients Enrolled in the Study|Daily Diary Satisfaction Scores|Daily Diary Satisfaction Scores|Daily Diary Satisfaction Scores|Daily Diary Satisfaction Scores|Daily Diary Satisfaction Scores|Progressive Muscle Relaxation Therapy (PMR) Satisfaction Scores Among RELAX Arm Participants|Progressive Muscle Relaxation Therapy (PMR) Satisfaction Scores Among RELAX Arm Participants|Progressive Muscle Relaxation Therapy (PMR) Satisfaction Scores Among RELAX Arm Participants|Progressive Muscle Relaxation Therapy (PMR) Satisfaction Scores Among RELAX Arm Participants|Progressive Muscle Relaxation Therapy (PMR) Satisfaction Scores Among RELAX Arm Participants|Number of Days RELAX Arm Participants Performed Progressive Muscle Relaxation Therapy (PMR) at Least 5 Minutes/Day|Number of Days Participants Used Diary,,True,2024-01-10
NCT03779724,Isokinetic Exercises in Patients With Multiple Sclerosis,"The Effects of Isokinetic Exercises on Muscle Strength, Joint Position Sense, and Kinesiophobia in Patients With Multiple Sclerosis: a Randomized Controlled Trial",COMPLETED,2015-07-29,2016-07-29,2016-07-29,2019-07-24,2018-12-19,INTERVENTIONAL,NA,50.0,ACTUAL,Aksaray University Training and Research Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|isokinetic|exercises|joint position sense|kinesiophobia,Turkey (Türkiye),Aksaray,,2,exercises,OTHER,"Isokinetic Muscle Strength Test of the More and Less Affected Knees|Joint Position Sense of the More and Less Affected Knees|Tampa Scale of Kinesiophobia|Multiple Sclerosis Quality of Life-54 Total Score, Physical and Emotional Composite Scores, and Pain Subscale Score|Visual Analog Scale",,True,2019-07-24
NCT05776888,Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years,Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years- A Non-interventional Observational Study,ACTIVE_NOT_RECRUITING,2023-07-10,2027-03-31,2027-03-31,2025-08-15,2023-03-20,OBSERVATIONAL,,106.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,relapsing multiple sclerosis|RMS|Ofatumumab|NIS,Austria,Linz,Austria,14,Ofatumumab,OTHER,Proportion of patients demonstrating NEDA-3,"Proportion of patients displaying NEDA-3, as well as individual NEDA components|Proportion of patients permanently discontinuing Ofatumumab during the study",False,
NCT05080270,Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis,Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis,COMPLETED,2020-09-21,2021-06-08,2021-06-08,2021-10-22,2021-10-15,INTERVENTIONAL,EARLY_PHASE1,5.0,ACTUAL,FibroBiologics,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",MS|Cell Therapy|Fibroblasts|Fibrobiologics|Stem cells|regenerative medicine|tissue regeneration|Immune modulation,Mexico,Tijuana,Estado de Baja California,1,Tolerogenic Fibroblasts,BIOLOGICAL,Safety: Adverse even monitoring of subjects for 4 hours after infusion|Safety: Complete Blood Count to monitor inflammation markers|Safety: Serum chemistry to monitor impact on serum chemistry|Safety: 12-lead Electrocardiogram (ECG) to monitor cardiovascular health,Efficacy: Expanded Disability Status Scale (EDSS) to quantify disability scale and monitors changes|Efficacy: Paced Auditory Serial Addition Test (PASAT) to measure cognitive function and processing speed|Efficacy: Nine-Hole Peg Test to measure and quantify upper extermity function|Efficacy: Timed 25-Foot Walk Test to quantify mobility and leg function|Efficacy: Gadolinium Enhanced MRI to detect demyelinated areas of the nerves,False,
NCT02949908,MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS),"A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment",TERMINATED,2017-02-09,2017-08-25,2017-08-25,2019-01-18,2016-10-31,OBSERVATIONAL,,2.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck B.V., Netherlands",INDUSTRY,Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|Rebif|Treatment Satisfaction Questionnaire for Medication Version II|Multiple Sclerosis International Quality of Life Questionnaire,Germany,Darmstadt,,1,Rebif,DRUG,Treatment Satisfaction Score Determined With Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II)|Treatment Satisfaction Determined With Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II),Annualized Relapse Rate (ARR)|Number of Participants With Adherence to Treatment|Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) Score at Month 6 and 12|Number of Participants Discontinued From Initial MS Treatment (Oral or Injectable) by Reason for Discontinuation|Correlation Between Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) and Annualized Relapse Rate (ARR)|Correlation Between Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) and Adherence|Correlation Between Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) and Reason for Discontinuation|Correlation Between Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Annualized Relapse Rate (ARR)|Correlation Between Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Adherence|Correlation Between Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Reason for Discontinuation|Correlation Between Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) Subscales and Adherence|Correlation Between Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) Subscales and Reasons for Discontinuation|Change From Baseline in Treatment Satisfaction Questionnaire for Medication Version II (TSQM v II) Subscale Score at Month 6 and Month 12|Change From Baseline in Annualized Relapse Rate (ARR) at Month 12|Correlation Between Annualized Relapse Rate (ARR) and Treatment Adherence,True,2019-01-18
NCT07175324,Oct-A and Perimetry in Multiple Sclerosis,Correlation Between Optical Coherence Tomography Angiography and Visual Field Changes in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-09,2026-09,2026-10,2025-09-16,2025-09-16,OBSERVATIONAL,,32.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,MS|OctA,,,,0,optical coherence tomography angiography|Visual Field Perimetry,DEVICE|DEVICE,1-To evaluate the correlation between OCTA-derived microvascular metrics {Structural measure} and visual field defects{Functional measure} in patients with multiple sclerosis (MS),,False,
NCT03222596,The Impact of Exercise Training on Living Quality in Multiple Sclerosis Individuals,The Impact of 4-weeks Mild Exercise Training on Living Quality in Ambulatory and Non-ambulatory Multiple Sclerosis Individuals (EDSS From 0-8) in Motivational and Social Supporting Environment: a Randomized Controlled Trial,COMPLETED,2017-07-14,2017-08-28,2017-08-28,2019-01-02,2017-07-19,INTERVENTIONAL,NA,40.0,ACTUAL,University of Rijeka,OTHER,,,Multiple Sclerosis|Fatigue|Mental Status Change|Physical Disability|Physical Activity|Mental Impairment|Quality of Life|Disabilities Psychological|Disability Physical|Pain|Energy Supply; Deficiency|Motivation,Quality of Life|Fatigue|Physical Disability|Disabilities Psychological|Pain|Motivation|Multiple sclerosis,Croatia,Rijeka,Primorje-Gorski Kotar County,1,Exercise training,BEHAVIORAL,Change of fatigue intensity|Change of pain intensity|Motivation.|Change of physical abilities and limitations.|Change of mental abilities and limitations.|Change of quality of life.|Change of grip strength.,,False,
NCT05116540,Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis,"A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis",COMPLETED,2021-11-24,2024-06-04,2024-06-04,2025-05-07,2021-11-11,INTERVENTIONAL,PHASE2,24.0,ACTUAL,Hope Biosciences Stem Cell Research Foundation,OTHER,,,Multiple Sclerosis,Mesenchymal Stem Cells|MS|RRMS|stem cells|MSCs|Relapsing|Remitting,United States,Sugar Land,Texas,1,HB-adMSCs|Placebo,BIOLOGICAL|DRUG,Change From Baseline in Physical Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument|Change From Baseline in Mental Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Cognitive Function Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Emotional Well-Being Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Health Distress Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in RL/Emotional Problems Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Overall Quality of Life Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Energy/Fatigue Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Health Perception Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Physical Function Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in RL/Physical Problems Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Pain Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Social Function Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Change From Baseline in Sexual Function Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|Analysis of Covariance (ANCOVA) Model - Physical Health Composite Score Change From Baseline Multiple Sclerosis Quality of Life (MSQOL)-54|Analysis of Covariance (ANCOVA) Model - Mental Health Composite Score Change From Baseline Multiple Sclerosis Quality of Life (MSQOL)-54 Composite Score|Bayesian Statistical Analysis - Analysis of Covariance (ANCOVA) Model - Physical Health Composite Score Change From Baseline Multiple Sclerosis Quality of Life (MSQOL)-54|Bayesian Statistical Analysis - Analysis of Covariance (ANCOVA) Model - Mental Health Composite Score Change From Baseline - Multiple Sclerosis Quality of Life (MSQOL)-54,Analysis of Covariance (ANCOVA) Model - Total Expanded Disability Status Scale (EDSS) Scores Through Week 52 - Change From Baseline - Efficacy Analysis Set|Analysis of Covariance (ANCOVA) Model - Change From Baseline Barthel Index Scores Through Week 52 - Efficacy Analysis Set|ANCOVA Model - Change From Baseline 9-Hole Peg Test Scores - Dominant Hand Avg Time Through Week 52|Analysis of Covariance (ANCOVA) Model - Change From Baseline 9-Hole Peg Test Scores - Non-Dominant Hand Avg Time Through Week 52|Analysis of Covariance (ANCOVA) Model - Change in Patient Health Questionnaire (PHQ-9) Test Scores|Baseline Vitals Values - Height|Change From Baseline Vitals Values - Weight|Change From Baseline Vitals Values - Body Mass Index|Change From Baseline Vitals Values - Respiratory Rate|Change From Baseline Vitals Values - Temperature|Change From Baseline Vitals Values - Systolic Blood Pressure|Change From Baseline Vitals Values - Diastolic Blood Pressure|Change From Baseline Vitals Values - Pulse Rate|Change From Baseline Vitals Values - Oxygen Saturation|Change From Baseline Physical Examination Results - Abdomen|Change From Baseline Physical Examination Results - Cardiovascular|Change From Baseline Physical Examination Results - HEENT|Change From Baseline Physical Examination Results - Lymph Node|Change From Baseline Physical Examination Results - Musculoskeletal|Change From Baseline Physical Examination Results - Neurological|Change From Baseline Physical Examination Results - Respiratory|Change From Baseline Physical Examination Results - Skin|Laboratory Values - CBC (x10^3 Cells/uL)|Laboratory Values - CBC (% of WBC)|Laboratory Values - CBC (% of Total Blood Cell Count)|Laboratory Values - CBC (g/dL)|Laboratory Values - CBC (pg)|Laboratory Values - CBC (fL)|Laboratory Values - CBC (x10^6 Cells/uL)|Laboratory Values - CBC (RDW)|Laboratory Values - CMP (g/dL)|Laboratory Values - CMP (Ratio: Albumin (g/dL) to Calc. Globulin (g/dL))|Laboratory Values - CMP (U/L)|Laboratory Values - CMP (mg/dL)|Laboratory Values - CMP (mEq/L)|Laboratory Values - CMP (mL/Min/1.73m^2)|Laboratory Values - CMP (Ratio: Urea Nitrogen (mg/dL) to Creatinine (mg/dL))|Laboratory Values - Coagulation Panel (Seconds)|Laboratory Values. Coagulation Panel (Ratio: Prothrombin Time (Seconds) / Mean Normal Prothrombin Time (Seconds)),True,2025-05-07
NCT04014413,Safety and Efficacy of Fecal Microbiota Transplantation,Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study,RECRUITING,2019-07-15,2030-10-31,2030-10-31,2024-08-22,2019-07-10,INTERVENTIONAL,NA,450.0,ESTIMATED,Chinese University of Hong Kong,OTHER,,,Crohn Disease|Ulcerative Colitis|Celiac Disease|Irritable Bowel Syndrome|Functional Dysphonia|Constipation|Clostridium Difficile Infection|Diabetes Mellitus|Obesity|Multidrug -Resistant Infection|Hepatic Encephalopathy|Multiple Sclerosis|Pseudo-Obstruction|Carbapenem-Resistant Enterobacteriaceae Infection|Vancomycin Resistant Enterococci Infection|Multiple Organ Dysfunction Syndrome|Dysbiotic Bowel Syndrome|MRSA Enteritis|Pseudomembranous Enterocolitis|Alopecia|Autism|Graft-versus-host Disease|Idiopathic Thrombocytopenic Purpura|Atopy or Allergy|Liver Disease|Alcohol Dependence|Psoriatic Arthropathy,,Hong Kong,Hong Kong,Shatin,1,Fecal Microbiota Transplantation,PROCEDURE,The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome),Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,False,
NCT01517282,Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis,"A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis",COMPLETED,2012-01,2014-01,2014-02,2014-11-21,2012-01-25,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,MorphoSys AG,INDUSTRY,,,Multiple Sclerosis,,Germany,Berlin,,5,MOR103|Placebo,BIOLOGICAL|OTHER,Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs),Percentages of Patients Negative for Anti-MOR103 Antibodies in Serum Samples|Mean Serum Concentration of MOR103 Over Time|Mean Maximum MOR103 Concentration (Cmax) After the First and Last MOR103 Doses|Mean Time to Maximum MOR103 Concentration (Tmax) After the First and Last MOR103 Doses|Accumulation Ratio for Area Under the MOR103 Serum Concentration Versus Time Curve (AUC) Over One Dosing Interval: Ratio of Week 10 (Last Dose) AUC to Week 0 (First Dose) AUC|Number of New T1 Gadolinium-enhancing Lesions|Number of New or Enlarging T2 Lesions,True,2014-10-13
NCT02442570,A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis,"A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis",COMPLETED,2012-09,2014-06,2015-02,2015-08-27,2015-05-13,INTERVENTIONAL,PHASE2,32.0,ACTUAL,Delta Crystallon BV,INDUSTRY,,,Multiple Sclerosis,alpha B-crystallin|immune tolerance,Bulgaria,Sofia,,5,recombinant human alpha B-crystallin|Placebo comparator,BIOLOGICAL|OTHER,Safety (adverse events),Tolerability (Injection site abnormalities)|Clinical efficacy (Number of Gadolinium-enhancing MRI lesions)|Pharmacokinetics (serum levels of DC-TAB)|Antigen-specific T-cell response|Antibody response,False,
NCT01592097,Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS,"A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms",COMPLETED,2012-06,2018-04,2018-04,2018-05-03,2012-05-07,OBSERVATIONAL,,51.0,ACTUAL,University of Southern California,OTHER,Novartis Pharmaceuticals,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|MS|Autoimmune,United States,Los Angeles,California,1,,,,,False,
NCT05102682,Robotics for Mobility Rehabilitation in MS,"Rex Robot Assisted Rehabilitation Exercise to Enhance Balance, Mobility and Upper Limb Function in People With Multiple Sclerosis",COMPLETED,2017-03-10,2017-09-12,2017-09-12,2024-02-22,2021-11-01,INTERVENTIONAL,PHASE1,11.0,ACTUAL,East Kent Hospitals University NHS Foundation Trust,OTHER_GOV,,,Multiple Sclerosis|MS,Neurorehabilitation|Feasibility|exoskeleton,United Kingdom,Canterbury,Kent,1,Balance exercise program using exoskeleton device,OTHER,Completion and time taken for participant transfer into Rex device|Completion of sit to stand in Rex device by participant|Completion of 1 timed 3 metre walk in device (Timed Up & Go Test)|Completion of trial sessions,,False,
NCT00989742,Doxycycline In Lymphangioleiomyomatosis (LAM),"A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.",COMPLETED,2009-07,2013-01,2013-01,2015-12-02,2009-10-05,INTERVENTIONAL,PHASE4,24.0,ACTUAL,University of Nottingham,OTHER,,,Lymphangioleiomyomatosis|Tuberous Sclerosis,lymphangioleiomatosis|LAM|tuberous sclerosis|doxycycline|matrix metalloproteinases|MMP,United Kingdom,Nottingham,Nottingham,1,Doxycycline|Placebo,DRUG|DRUG,Mean rate of change of FEV1 over 24 months on doxycycline compared with placebo.,Rate change FVC over 24 months Change DLCO at 12 & 24 mths Change in shuttle walk distance at 12 & 24 mths Change in QOL at 12 & 24 mths Time to composite safety endpoint Number complications Number respiratory infections Adverse effects,False,
NCT00069186,Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis,"A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis",UNKNOWN,2003-06,,2005-04,2005-06-24,2003-09-23,INTERVENTIONAL,PHASE3,107.0,,The Avicena Group,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),Amyotrophic Lateral Sclerosis|ALS|Creatine|Creatine Monohydrate|Muscle Strength,United States,San Francisco,California,8,Creatine Monohydrate,DRUG,Change in upper extremity motor function after 3 weeks|Change in upper extremity motor function after 9 months,Acute changes in muscle strength|Chronic changes in muscle strength|ALS functioning|Quality of life|Pulmonary function|Muscle fatigue.,False,
NCT02504840,Natural History of Multiple Sclerosis and Its Mimickers,Thematic Studies of Multiple Sclerosis and Related Diseases,COMPLETED,2015-07-23,2020-03-05,2020-03-05,2022-10-14,2015-07-22,OBSERVATIONAL,,104.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Neurologic Disorders|Healthy Volunteers|Multiple Sclerosis,Multiple Sclerosis|Clinically Isolated Syndrome|CNS Inflammatory Demyelination|Radiologically Isolated Syndrome|Natural History,United States,Bethesda,Maryland,1,,,Association between clinical status and research data,,False,
NCT04169750,Home-based EXergames To impRove cognitivE Function in MUltiple Sclerosis,"Home-based EXergames To impRove cognitivE Function in MUltiple Sclerosis: the EXTREMUS Study. A Multicenter, Randomized, Single-blind Non-inferiority Trial",UNKNOWN,2020-03-01,2022-06-30,2022-09-30,2021-10-01,2019-11-20,INTERVENTIONAL,NA,135.0,ESTIMATED,"San Camillo Hospital, Rome",OTHER,"Fondazione Don Carlo Gnocchi Onlus|Fondazione Italiana Sclerosi Multipla|Rehabilitation Unit 'Mons. L. Novarese' Hospital, Moncrivello (VC), IT|University of Chieti",OTHER|OTHER|UNKNOWN|OTHER,Multiple Sclerosis,Rehabilitation|Cognitive impairment|Exergames|Neuroplasticity|Clinical Trial,Italy,Genova,GE,4,Exergames|Adaptive COGNI-TRAcK|Sham COGNI-TRAcK,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Symbol Digit Modalities Test,Brief International Cognitive Assessment for Multiple Sclerosis|Stroop Color-Word Test,False,
NCT06501950,Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach,Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach,RECRUITING,2024-06-20,2027-10,2027-12,2024-07-15,2024-07-15,OBSERVATIONAL,,77.0,ESTIMATED,"Heinrich-Heine University, Duesseldorf",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Follow-Up|Observational study|PIRA|RRMS|PPMS,Germany,Düsseldorf,North Rhine-Westphalia,1,,,Percentage of Progression independent from relapse (PIRA )at month 24,EDSS: Change From Baseline in Expanded Disability Status Scale (EDSS) Score|Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Score|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component Paced Auditory Serial Addition Test|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component 9-hole peg test|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component Timed 25-foot walk (T25FW)|Change in Pittsburgh Sleep Quality Index (PSQI)|Change From Baseline in Fatigue Severity Scale (FSS)|Change in blood-based serum filament lightchain (sNFL) levels|Change in blood-based glial fibrillary acidic protein(GFAP) levels|Change in proteomic signatures|Questionnaire about smartwatch usage (System Usability Score)|Changes in fine motor skills composite as calculated by Neurokeys|Changes in cognition composite as calculated by Neurokeys|Wearing time of smartwatch (daily)|Longitudinal development of activity parameter: step count|Longitudinal development of activity parameter: approximate distance traveled (meter)|Longitudinal development of activity parameter: duration of soft activity (seconds) defined by Withings|Longitudinal development of activity parameter: duration of moderate activity (seconds) defined by Withings|Longitudinal development of activity parameter: duration of intense activity (seconds) defined by Withings|Longitudinal development of activity parameter: sum of all active time (seconds)|Longitudinal development of sleep parameter: time awake (seconds)|Longitudinal development of activity parameter: approximate calories burned|Longitudinal development of sleep parameter: number of times user woke up|Longitudinal development of sleep parameter: time to sleep (seconds)|Longitudinal development of sleep parameter: heart rate variability (ms)|Longitudinal development of sleep parameter: total time asleep (seconds)|Longitudinal development of sleep parameter: total time in bed (seconds)|Longitudinal development of sleep parameter: ratio of sleep/time in bed|Longitudinal development of sleep parameter: time spent in bed before falling asleep (seconds|Longitudinal development of sleep parameter: time awake after first falling asleep (seconds)|Longitudinal development of sleep parameter: Withings Sleep score|Longitudinal development of cardiovascular parameter: maximal heartrate|Longitudinal development of cardiovascular parameter: minimum heartrate|Longitudinal development of cardiovascular parameter: time in light heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in moderate heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in intense heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in maximal heartrate zone (seconds),False,
NCT03164018,"Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis","Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis",COMPLETED,2017-03-07,2018-12-15,2018-12-15,2019-02-15,2017-05-23,OBSERVATIONAL,,111.0,ACTUAL,Genesis Pharma CNS & Specialty,INDUSTRY,,,Multiple Sclerosis,,Greece,Athens,Attica,1,Fampridine,DRUG,Changes in cognition measured with PASAT scale|Changes in depression measured with BDI-II scale|Changes in fatigue measured with MFIS scale|Changes in Quality of Life measured with MusiQoL scale|Changes in Quality of Life measured with MSIS-29 scale,,False,
NCT04930380,Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis,Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis,UNKNOWN,2021-04-01,2023-02-28,2023-03-30,2022-11-16,2021-06-18,OBSERVATIONAL,,1250.0,ESTIMATED,University of Siena,OTHER,,,Multiple Sclerosis,preventive medicine,Italy,Ferrara,FE,12,phone interview,OTHER,questionnaire,,False,
NCT07070388,Robotic -Assisted Rehabilitation for Multiple Sclerosis: An Adaptive Approach for Individualized Therapy,Robotic -Assisted Rehabilitation for Multiple Sclerosis: An Adaptive Approach for Individualized Therapy,COMPLETED,2023-01-01,2023-08-31,2025-06-27,2025-07-17,2025-07-17,INTERVENTIONAL,NA,9.0,ACTUAL,Michael Holmes,OTHER,,,Multiple Sclerosis,Rehabilitation|Upper Limb|Robot|Multiple Sclerosis,Canada,St. Catharines,Ontario,1,end-effector robotic training,DEVICE,maximum grip force|Maximum isometric wrist force,Wrist tracking task|wrist range of motion|Wolf Motor Function Test,False,
NCT04185688,The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis,The Reliability and Validity of the Functional Reach Test in Patients With Multiple Sclerosis,COMPLETED,2019-12-06,2020-02-07,2020-02-07,2020-05-04,2019-12-04,OBSERVATIONAL,,79.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Functional reach test|Reliability|Validity,Turkey (Türkiye),Ankara,,1,Functional Reach Test,OTHER,Functional Reach Test,Biodex Balance System|Berg Balance Scale|Four Square Step Test|Timed Up and Go Test,False,
NCT01184833,Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis,Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis,COMPLETED,2008-09,,2011-08,2013-06-25,2010-08-19,OBSERVATIONAL,,852.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Interferon beta-1b|Compliance to treatment|Premature treatment discontinuation,Poland,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Rate of discontinuation of Betaferon,Number of missed doses of Betaferon|Depression score as measured by CES-D questionnaire|Neurological disability score as measured by EDSS scale|Overall tolerability of treatment as measured by rate of adverse events,False,
NCT06551649,Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation,Contrasting Chronic Inflammation and Neurodegeneration Using the Human Amniotic Mesenchymal Cell Secretome as an Innovative Therapeutic Strategy,RECRUITING,2025-01-17,2026-03-31,2026-09-30,2025-08-14,2024-08-13,INTERVENTIONAL,NA,60.0,ESTIMATED,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,Amyotrophic Lateral Sclerosis|Multiple Sclerosis,,Italy,Roma,,2,Venous blood draw and skin biopsy,OTHER,Neurite length measurement in a three-dimensional cellular model of amyotrophic lateral sclerosis.|Percentage of apoptotic cells in a three-dimensional cellular model of amyotrophic lateral sclerosis.|Area measurement of damaged myelin in a three-dimensional cellular model of multiple sclerosis.|Number of inflamed microglial cells in a three-dimensional cellular model of multiple sclerosis.|Neurite length measurement in amyotrophic lateral sclerosis organoids after treatment with human amniotic mesenchymal stromal cell secretome.|Percentage of apoptotic cells in amyotrophic lateral sclerosis organoids after treatment with human amniotic mesenchymal stromal cell secretome.|Area measurement of damaged myelin in multiple sclerosis organoids after treatment with human amniotic mesenchymal stromal cell secretome.|Number of immunoregulatory microglial cells in multiple sclerosis organoids after treatment with human amniotic mesenchymal stromal cell secretome.,Percentage of altered immune phenotypic markers in amyotrophic lateral sclerosis and multiple sclerosis patients,False,
NCT06843915,Aerobic Exercise for Urinary Incontinence in Multiple Sclerosis,Aerobic Exercise as a Therapeutic Approach for Urinary Incon-tinence in Multiple Sclerosis: Insights From a Pilot Randomized Controlled Trial,COMPLETED,2018-11-01,2019-12-01,2020-05-01,2025-02-25,2025-02-25,INTERVENTIONAL,NA,40.0,ACTUAL,University of Sharjah,OTHER,,,Multiple Sclerosis|Urinary Incontinence,,Jordan,Irbid,,1,Moderate intensity aerobic exercise|Home Exercise Program,OTHER|OTHER,Incontinence Questionnaire short-form ques-tionnaire (ICIQ-UI SF),Plasma Cortisol level,False,
NCT04175418,The Effects of Two Different Types of Exercise Programs to Increase Physical Activity in Patients With MS,The Effects of a Supervised Exercise Program Versus Online Education Program to Increase Physical Activity in Patients With Multiple Sclerosis,COMPLETED,2019-11-01,2020-01-08,2021-02-01,2023-06-22,2019-11-25,INTERVENTIONAL,NA,21.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,"Prof.Dr.Mazhar Osman Mental Health and Psychiatric Diseases Education, Research Hospital",UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Rehabilitation|Physical Activity|Exercise,Turkey (Türkiye),Istanbul,,1,Supervised Exercise Program|Online Education Program,OTHER|OTHER,The Leisure-Time Exercise Questionnaire|Pedometer,6 Minute Walk Test|Multiple Sclerosis Walking Scale-12|Fatigue Severity Scale|Multiple Sclerosis International Quality of Life Questionnaire|Brief International Cognitive Assessment for MS|Bioelectrical Impedance Analysis|Muscle Strength Test,False,
NCT04387110,Ocrelizumab in Breastmilk,Monoclonal Antibodies in Mothers' Milk and Infants: Ocrelizumab in Breastmilk,COMPLETED,2020-08-07,2022-03-01,2022-03-01,2022-12-16,2020-05-13,OBSERVATIONAL,,30.0,ACTUAL,"University of California, San Francisco",OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis|Clinically Isolated Syndrome,,United States,San Francisco,California,1,Ocrelizumab,DRUG,Determine levels of ocrelizumab in the breastmilk of women with MS|Determine time to peak levels of ocrelizumab in the breastmilk of women with MS.|Determine predictors of ocrelizumab levels in breastmilk.,Obtain information on newborn adjusted length until 12 months of life.|Obtain information on newborn weight until 12 months of life.|Obtain information on newborn head circumference until 12 months of life.|Obtain information on newborn infections until 12 months of life.|Obtain information on newborn vaccines until 12 months of life.|Obtain information on newborn developmental milestones until 12 months of life.,False,
NCT05701423,A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants,End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients,TERMINATED,2023-02-08,2024-07-31,2024-07-31,2024-09-19,2023-01-27,OBSERVATIONAL,,34.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Germany,Düsseldorf,,1,Natalizumab,DRUG,Percentage of Participants who Develop End of Dose Symptoms (EOD) Under NTZ,Change From Baseline in Expanded Disability Status Scale (EDSS) Score|Change From Baseline in Fatigue Scale for Motor and Cognitive Functions (FSMC)|Change From Baseline in Fatigue Severity Scale (FSS)|Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Score|Change From Baseline in Brief Fatigue Inventory (BFI) Score|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score,False,
NCT02654340,Biomarkers for Tuberous Sclerosis Complex (BioTuScCom),Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol,TERMINATED,2018-08-01,2022-12-30,2022-12-30,2023-02-10,2016-01-13,OBSERVATIONAL,,20.0,ACTUAL,CENTOGENE GmbH Rostock,INDUSTRY,,,Hypomelanotic Macules|Facial Angiofibroma|Shagreen Patches|Ungual Fibromas|Cortical Dysplasia|Cardiac Rhabdomyoma|Lymphangioleiomyomatosis|Renal Angiomyolipoma|Subependymal Giant Cell Astrocytoma,Tuberous sclerosis complex|Biomarker,Albania,Tirana,,8,,,Identification of TSC biomarker/s,"Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s",False,
NCT01366040,Avonex PEN Satisfaction and Patients Experience Clinical Trial,"An Open-Label, Survey-Based, Multicenter Study to Determine Patient Satisfaction With Single-Use Prefilled Avonex® PEN Autoinjector in Multiple Sclerosis Patients",COMPLETED,2011-06,2012-05,2012-05,2013-09-16,2011-06-03,OBSERVATIONAL,,89.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Patient Satisfaction|Multiple Sclerosis|Autoinjector|Avonex,Canada,Calgary,Alberta,10,,,Patient satisfaction,Ease of use grading scale|Autoinjector instructions grading scale,False,
NCT05112289,A Study to Evaluate White Matter Hyperintensities in Migraine,White Matter Hyperintensities in Migraine: A Multi-modal Imaging Project to Classify Disease Pathology,ACTIVE_NOT_RECRUITING,2021-08-16,2026-08,2026-08,2025-09-05,2021-11-08,INTERVENTIONAL,NA,50.0,ESTIMATED,Mayo Clinic,OTHER,,,Migraine|Small Vessel Ischemic Disease|Multiple Sclerosis,,United States,Phoenix,Arizona,1,Brain Neuroimaging,DIAGNOSTIC_TEST,WMH imaging disease parameters,,False,
NCT05285891,Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis,"Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)",RECRUITING,2023-01-12,2030-05-01,2030-11-01,2025-08-11,2022-03-18,INTERVENTIONAL,PHASE4,123.0,ESTIMATED,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"Autoimmunity Centers of Excellence (ACE)|Rho Federal Systems Division, Inc.|Genentech, Inc.",UNKNOWN|INDUSTRY|INDUSTRY,Multiple Sclerosis,Ocrelizumab|Multiple sclerosis|Relapse,United States,New Haven,Connecticut,11,Ocrelizumab|Placebo for Ocrelizumab,DRUG|DRUG,Absence of clinical relapse,"The change in Expanded Disability Status Scale (EDSS) score|Proportion of participants with a serious adverse event (SAE)|Proportion of participants who experience at least one Grade 3 or higher adverse event|Proportion of participants with infections, Grade 3 or higher|Proportion of participants with malignancies|Proportion of participants experiencing infusion related reactions|The ratio of granulocyte-macrophage colony-stimulating factor (GM-CSF) expressing B-Cells to Interleukin 10 (IL-10) expressing B cells at Month 48 in participants who do versus do not exhibit durable disease remission",False,
NCT02660359,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",TERMINATED,2016-07-08,2018-11-09,2019-07-04,2022-09-28,2016-01-21,INTERVENTIONAL,PHASE3,258.0,ACTUAL,Ipsen,INDUSTRY,,,Urinary Incontinence|Overactive Bladder,,Argentina,Buenos Aires,,82,Botulinum toxin type A|Botulinum toxin type A|Placebo|Placebo,BIOLOGICAL|BIOLOGICAL|DRUG|DRUG,Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC Cycle,"Percentage of Subjects With No Episodes of UI at Week 6 of DBPC Cycle|Percentage of Subjects With a UI Response at Improvement Levels ≥30%, ≥50%, and ≥75% at Week 6 of the DBPC Cycle|Median Time Between Treatments|Mean Change From Baseline in Volume Per Void at Week 6 of DBPC Cycle|Mean Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 6 of DBPC Cycle|Mean Change From Baseline in Maximum Detrusor Pressure (MDP) During Storage at Week 6 of DBPC Cycle|Mean Change From Baseline in Volume at First Involuntary Detrusor Contraction (Vol@1stIDC) at Week 6 of DBPC Cycle|Percentage of Subjects With No Involuntary Detrusor Contraction (IDCs) During Storage at Week 6 of DBPC Cycle",True,2021-06-16
NCT02749396,EPID Multiple Sclerosis Pregnancy Study,Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon β - a Register-based Study in the Nordic Countries,COMPLETED,2016-05-02,2018-08-14,2018-08-14,2019-08-14,2016-04-25,OBSERVATIONAL,,2089.0,ACTUAL,Bayer,INDUSTRY,EPID Research|Biogen|Merck Serono Europe Ltd|Novartis Pharmaceuticals,UNKNOWN|INDUSTRY|UNKNOWN|INDUSTRY,Multiple Sclerosis,,Finland,Multiple Locations,,1,"Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Extavia (interferon beta-1b), Novartis Pharma AG|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Avonex (interferon beta-1a), Biogen Idec Ltd|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|No MSDMDs therapy (control)",DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|OTHER,"Serious adverse pregnancy outcome due to different regimes of IFN-β exposure defined as a composite endpoint including presence of elective Termination of Pregnancy due to Foetal Anomaly (TOPFA), Major Congenital Anomaly (MCA) or stillbirth|Elective TOPFA for other reasons than IFN-β exposure|Elective termination for other reasonsthan IFN-β exposure|Stillbirth due to different regimes of IFN-β exposure|Live birth while different regimes of IFN-β exposure|MCA due to different regimes of IFN-β exposure|Comparison of the prevalence of serious adverse pregnancy outcome due to different regimes of IFN-β exposure defined as a composite endpoint including elective TOPFA, MCA or stillbirth|Comparison of the prevalence of elective termination for other reasons than due to different regimes of IFN-β exposure|Comparison of the prevalence of stillbirth due to different regimes of IFN-β exposure|Comparison of the prevalence of live birth due to different regimes of IFN-β exposure|Comparison of the prevalence of MCA due to different regimes of IFN-β exposure|Comparison of the prevalence of Elective TOPFA due to different regimes of IFN-β exposure",Comparison of the prevalence of ectopic pregnancies due to different regimes of IFN-β exposure|Comparison of the prevalence of spontaneous abortions due to different regimes of IFN-β exposure|Prevalence of elective TOPFA stratified by specific patient characteristics|Prevalence of stillbirth stratified by specific patient characteristics|Prevalence of live birth stratified by specific patient characteristics|Prevalence of MCA stratified by specific patient characteristics|Comparison of the prevalence of ectopic pregnancies due to different regimes of IFN-β exposure,False,
NCT06955962,Examining the Effect of Mandala Art Therapy on Symptoms and Quality of Life in Multiple Sclerosis Patients,Examining the Effect of Mandala Art Therapy on Symptoms and Quality of Life in Multiple Sclerosis Patients,ENROLLING_BY_INVITATION,2025-05-10,2025-07-10,2025-08-30,2025-05-09,2025-05-02,INTERVENTIONAL,NA,70.0,ESTIMATED,Karadeniz Technical University,OTHER,,,Multiple Sclerosis,multiple sclerosis|mandala art therapy|quality of life,Turkey (Türkiye),Trabzon,,1,Mandala Art Therapy,OTHER,Quality of life of patient with MS,Symptom evaluation of patient with MS,False,
NCT00457808,Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM,Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis,COMPLETED,2002-12,,2006-03,2007-04-09,2007-04-09,INTERVENTIONAL,PHASE2,25.0,,"Children's Hospital Medical Center, Cincinnati",OTHER,The LAM Foundation|Tuberous Sclerosis Alliance,OTHER|OTHER,Tuberous Sclerosis|Lymphangioleiomyomatosis,TSC and LAM|Tuberous Sclerosis Complex and sporadic LAM,United States,Cincinnati,Ohio,1,"Rapamycin, sirolimus",DRUG,Volume of Angiomyolipomata,,False,
NCT05377476,Investigation of the Effects of Motor Imagery and Action Observation in People With Multiple Sclerosis,"Investigation of the Effects of Motor Imagery and Action Observation on Walking, Fatigue, and Muscle Oxygenation in People With Multiple Sclerosis",COMPLETED,2022-06-01,2023-12-29,2024-07-01,2025-03-26,2022-05-17,INTERVENTIONAL,NA,48.0,ACTUAL,Hacettepe University,OTHER,Bandırma Onyedi Eylül University,OTHER,Multiple Sclerosis,Multiple Sclerosis|Motor Imagery|Action Observation|Walking|Fatigue|Muscle Oxygenation,Turkey (Türkiye),Ankara,,1,Motor Imagery training|Action Observation training|standard rehabilitation,OTHER|OTHER|OTHER,6 Min Walking Test,"Timed Up and Go Test|Multiple Sclerosis Walking Scale-12|RehaGait® (Hasomed, Magdeburg, Germany) Gait Analysis|Fatigue Severity Scale|Measurement of Muscle Oxygenation",False,
NCT02369224,Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics,Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics,COMPLETED,2015-01,2016-02,2016-02,2017-02-01,2015-02-23,OBSERVATIONAL,,27.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Kirkland,Washington,1,,,To assess the intra-rater and inter-rater reliability of a hand-held dynamometer (HHD) in the assessment of lower extremity strength in patients with multiple sclerosis,,False,
NCT04390126,COVID-19 Related Lockdown Effects On Chronic Diseases,COVID-19 Related Lockdown Effects On Chronic Diseases,UNKNOWN,2020-04-20,2021-05-07,2021-11-07,2021-01-20,2020-05-15,OBSERVATIONAL,,1200.0,ACTUAL,Centre Hospitalier Universitaire Dijon,OTHER,,,Chronic Coronary Syndrome|Heart Failure|AMD and Macular Edema|Chronic Respiratory Failure|Hemophilia|Malignant Hemopathy|Multiple Sclerosis|Horton's Disease,,France,Dijon,,1,life questionnaires|questionnaire,OTHER|OTHER,% adherence to each pharmacological class|number of occurrence of medical events at 1 year,"Expressed in %: Non-pharmacological treatment/lifestyle:|Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication|Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)",False,
NCT02869425,To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS,"A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis",WITHDRAWN,2016-07,2018-10,2019-01,2022-04-27,2016-08-17,INTERVENTIONAL,PHASE3,0.0,ACTUAL,"RVL Pharmaceuticals, Inc.",INDUSTRY,Osmotica Pharmaceutical US LLC,INDUSTRY,Multiple Sclerosis|Sperm,,United States,Miami,Florida,2,arbaclofen ER Tablets|Placebo for arbaclofen ER tablets,DRUG|DRUG,Measure of sperm concentration according to WHO guidelines,"Measure of sperm motility according to the WHO guidelines|Measure of Plasma levels of FSH, LH, and total testosterone values and their respective change from baseline values will be summarized by visit|Measure of Semen volume per ejaculate according to the WHO guidelines|Measure of total sperm count per ejaculate according to the WHO guidelines|Measure of Sperm morphology according to the WHO guidelines|The recovery of subjects with 50% decrease in sperm parameters 90 days after the discontinuation of IP",False,
NCT06524089,Pilates Versus Eccentric Exercises on Multiple Sclerosis,Pilates Versus Eccentric Exercises in Chronic Low Back Pain With Multiple Sclerosis,COMPLETED,2024-07-30,2025-03-02,2025-03-02,2025-03-06,2024-07-29,INTERVENTIONAL,NA,30.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,Pilates|eccentric|multiple sclerosis|low back pain,Egypt,Giza,,1,Pilate training|eccentric training,OTHER|OTHER,pain intensity|Function,back muscle strength,False,
NCT02098759,"Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex","Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex",UNKNOWN,2013-11,2018-10,2018-10,2014-04-04,2014-03-28,INTERVENTIONAL,NA,100.0,ESTIMATED,Sergiusz Jozwiak,OTHER,"University of Rome Tor Vergata|Institut National de la Santé Et de la Recherche Médicale, France|Vrije Universiteit Brussel|General University Hospital, Prague|Charite University, Berlin, Germany|KU Leuven|Medical University of Vienna|Rudolf Magnus Institute - University of Utrecht|Brigham and Women's Hospital",OTHER|OTHER_GOV|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,TSC|Tuberous Sclerosis Complex|Epilepsy,TSC|tuberous sclerosis complex|epilepsy,Austria,Vienna,,9,epilepsy early diagnosis protocol,DEVICE,number of patients with epilepsy,,False,
NCT06975605,"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","Phase 1, Open-label, 3-period Study to Evaluate Drug-Drug Interaction Potential of Radiprodil With Cocktail Probes Representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP in Healthy Adult Subjects",ACTIVE_NOT_RECRUITING,2025-05-20,2025-07-30,2025-08-30,2025-06-05,2025-05-16,INTERVENTIONAL,PHASE1,18.0,ESTIMATED,"GRIN Therapeutics, Inc.",INDUSTRY,Avance Clinical Pty Ltd.,INDUSTRY,Tuberous Sclerosis Complex (TSC)|Focal Cortical Dysplasia|Other Neurological Disorders,healthy adults|tuberous sclerosis|focal cortical dysplasia,Australia,Melbourne,Victoria,1,Radiprodil + co-administered drugs,DRUG,To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of warfarin following repeated oral doses of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of warfarin following repeated oral dosing of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of midazolam following repeated oral doses of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of midazolam following repeated oral dosing of radiprodil|To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of digoxin following repeated oral doses of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of digoxin following repeated oral dosing of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of rosuvastatin following repeated oral doses of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of rosuvastatin following repeated oral dosing of radiprodil|To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of omeprazole following repeated oral doses of radiprodil.|To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of omeprazole following repeated oral dosing of radiprodil.,To assess the safety of oral dosing of radiprodil co-administered with midazolam.|To assess the safety of oral dosing of radiprodil co-administered with digoxin|To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin.|To assess the safety of oral dosing of radiprodil co-administered with omeprazole|To assess the safety of oral dosing of radiprodil co-administered with oral warfarin.|12-lead ECG - Mean change in QT interval from baseline to end of treatment (oral dosing of radiprodil co-administered with midazolam)|12-lead ECG - Mean change in QT interval from baseline to end of treatment (oral radiprodil co-administered with digoxin)|12-lead ECG- Mean change from Baseline to End-of-Treatment in QT interval(oral dosing of radiprodil co-administered with rosuvastatin)|12-lead ECG- Mean change from Baseline to End-of-Treatment in QT interval (oral dosing of radiprodil co-administered with omeprazole)|To assess the safety of oral dosing of radiprodil co-administered with oral warfarin|To assess the safety of oral dosing of radiprodil co-administered with midazolam|To assess the safety of oral dosing of radiprodil co-administered with digoxin|To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin|To assess the safety of oral dosing of radiprodil co-administered with omeprazole|To assess the safety of oral dosing of radiprodil co-administered with oral warfarin.|To assess the safety of oral dosing of radiprodil co-administered with midazolam|To assess the safety of oral dosing of radiprodil co-administered with digoxin.|To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin|To assess the safety of oral dosing of radiprodil co-administered with omeprazole,False,
NCT00445367,Biobank For MS And Other Demyelinating Diseases,"Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases",ACTIVE_NOT_RECRUITING,2006-05,2026-10,2036-10,2024-04-19,2007-03-09,OBSERVATIONAL,,3226.0,ACTUAL,Accelerated Cure Project for Multiple Sclerosis,OTHER,,,Multiple Sclerosis|Transverse Myelitis|Neuromyelitis Optica|Acute Disseminated Encephalomyelitis|Optic Neuritis,Multiple Sclerosis|Clinically Isolated Syndrome|Transverse Myelitis|Neuromyelitis Optica|Acute Disseminated Encephalomyelitis|Optic Neuritis|Repository|Biobank,United States,Phoenix,Arizona,10,,,,,False,
NCT00765544,Targeted Lower Extremity Joint Training,Robot-assisted Ankle Rehabilitation for Multiple Sclerosis (Anklebot),TERMINATED,2008-09,2008-09,2008-09,2013-09-23,2008-10-03,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,MS|Rehabilitation|Treadmill|Robot|Foot-drop,United States,Providence,Rhode Island,1,Anklebot|Lokomat,DEVICE|DEVICE,Strength and Gait,,False,
NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),"Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION)",COMPLETED,2008-12,2011-08,2013-09,2017-03-08,2008-12-23,INTERVENTIONAL,PHASE3,402.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis|Clinically Isolated Syndrome,Interferon 1-beta|Clinical Definite Multiple Sclerosis,Argentina,Mendoza,,57,RNF|RNF|RNF|Placebo,DRUG|DRUG|DRUG|DRUG,Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to 36 Months,"Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 36 Months|Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, New Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Lesions Per Participant Per Scan at Month 36|Change From Baseline in Time Constant 1 (T1) Hypointense Lesion Volume and Time Constant 2 (T2) Lesion Volume at Month 36|Percent Change From Baseline in Brain Volume at Month 36|Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) up to 36 Months|Change From Baseline in Paced Auditory Serial Addition Test 3 (PASAT-3) Score at Month 36|Percentage of Relapse-Free Participants at Month 36|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 36|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Month 36|Numbers of Participants With Binding Antibodies (BAb) and Neutralizing Antibody (NAb) at Month 36|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation|Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to Month 60|Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 60 Months|Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, New Gadolinium Enhanced (Gd+) Lesions and New T1 Lesions Per Participant Per Scan at Month 60|Change From Baseline in Time Constant 1 (T1) Hypointense Volume, and Time Constant 2 (T2) Lesion Volume at Month 60|Percent Change From Baseline in Brain Volume at Month 60|Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) at Month 60|Change From Baseline in Paced Auditory Serial Addition Test 3 (PASAT-3) Score at Month 60|Percentage of Relapse-Free Participants at Month 60|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 60|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Month 60|Numbers of Participants With Binding Antibodies (BAb) and Neutralizing Antibody (NAb) at Month 60|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation",True,2013-10-28
NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012,COMPLETED,2014-04-30,2016-12-21,2016-12-21,2017-04-27,2015-10-20,INTERVENTIONAL,PHASE3,221.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Cognition|Tecfidera|RRMS|BG00012,Italy,Bari,,18,dimethyl fumarate,DRUG,Proportion of patients with worsening in cognitive improvement over 2 years.,"Change in cognitive impairment index score (CII) over two years|Annualized relapse rate at year 1.|Annualized relapse rate at year 2.|Time to relapse over 2 years.|Proportion of patients with 6-month sustained progression of disability as measured by at least a 1.0 point increase from a baseline EDSS>1.0 or at least a 1.5 point increase from a baseline EDSS=0).|Assessment of baseline demographic, disease characteristics and related patient reported outcomes that predict CI at two years.|Change from baseline in a self rating version of the Montgomery and Asberg Depression Rating Scale (MADRS)|Change from baseline in fatigue as measured by the Modified Fatigue Impact Scale (MFIS)|Change from baseline in Quality of life (QOL) as measured by the EQ-5D Health Survey|Change from baseline in the Environmental Status Scale (ESS)",False,
NCT07030036,Screening for Cognitive Disorders in Multiple Sclerosis,Screening for Cognitive Disorders in Multiple Sclerosis,NOT_YET_RECRUITING,2025-07-15,2025-11-15,2025-11-15,2025-06-19,2025-06-19,OBSERVATIONAL,,60.0,ESTIMATED,Centre Hospitalier de Gonesse,OTHER,,,Multiple Sclerosis|Cognitive Dysfunction|Neuropsychological Tests|Quality of Life,,France,Gonesse,France,1,,,"Prevalence of cognitive impairment in patients with multiple sclerosis, assessed by validated cognitive tests (CSCT, RL/RI-16, Figure de REY, HAD scale, SF-12).",,False,
NCT02710214,A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis,Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.,COMPLETED,2016-02,2019-04-24,2019-04-24,2020-07-15,2016-03-16,INTERVENTIONAL,PHASE2,24.0,ACTUAL,"University of California, San Francisco",OTHER,National Multiple Sclerosis Society,OTHER,Menopause|Multiple Sclerosis,Hot flash|Estrogen|Women,United States,San Francisco,California,1,Tissue Selective Estrogen Complex|Placebo,DRUG|DRUG,Hot Flash Related Daily Interference Scale (HFRDIS) Score|Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks|Change in Average Hot Flashes Per Day From Baseline to 8 Weeks|Number of Participants Reporting Side Effects on the Treatment Satisfaction Questionnaire for Medication (TSQM)|Change in the Expanded Disability Status Scale (EDSS),Change in the MS Quality of Life 54 (MSQOL-54)|Change in the Bladder Control Scale (BLCS)|Change in the Multiple Sclerosis Rating Scale (MSRS)|Change in the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)|Change in the Symbol Digit Modalities Test (SDMT) Raw Score|Change in SDMT Z-score|Change in Letter Number Sequencing (LNS) Performance|Number of Participants With New or Enhancing Lesions on MRI|Number of Missed Doses,True,2020-06-29
NCT01804647,Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease,A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Multiple Sclerosis Patients (RRMS - SPMS - PPMS - CIS) as Assessed by PCR and ELISA in Blood,COMPLETED,2012-11,2015-02,2015-02,2020-10-20,2013-03-05,OBSERVATIONAL,,58.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis (MS)|Relapsing-Remitting MS|Primary Progressive MS|Secondary Progressive MS|Clinically Isolated Syndrome (CIS),Multiple sclerosis (MS)|Relapsing-Remitting MS|Primary progressive MS|Secondary progressive MS|Clinically Isolated Syndrome (CIS)|Multiple Sclerosis associated RetroVirus (MSRV)|MSRV envelop protein (MSRV-Env)|Temelimab,France,Bron,,4,No study treatments administered - blood draws only,OTHER,"Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS)",Associate the levels of MSRV-Env protein and transcripts|Associate the levels of MSRV-Env as assessed with the 3 approaches with MS relapses/exacerbations and/or clinical evolution (EDSS score) and /or treatment|Associate the levels of MSRV-Env as assessed with the 3 approaches with levels of inflammatory markers and reverse transcriptase activity|Compare levels of MSRV-Env of MS patients to those obtained in a parallel study in Healthy Controls,False,
NCT01626248,Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control,Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in a Natalizumab Treated Population With Active Control Assessment,COMPLETED,2012-07,2013-03,2013-04,2013-06-14,2012-06-22,OBSERVATIONAL,,164.0,ACTUAL,"John F. Foley, MD",OTHER,Biogen|Elan Pharmaceuticals,INDUSTRY|INDUSTRY,Multiple Sclerosis,Immunological|biomarkers|observational|RRMS|Relapsing|Remitting Multiple Sclerosis,United States,Salt Lake City,Utah,1,,,Quantitative Assessment of CD62L in MS Patients on Immunomodulatory Agents,,False,
NCT02087631,Safety and Tolerability of Quetiapine in Multiple Sclerosis,"A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis",COMPLETED,2014-12,2019-07,2019-07,2019-10-09,2014-03-14,INTERVENTIONAL,PHASE1|PHASE2,14.0,ACTUAL,University of Calgary,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,multiple sclerosis|quetiapine|remyelination,Canada,Calgary,Alberta,1,Extended-release quetiapine fumarate,DRUG,Dose-limiting toxicity,Adverse events,False,
NCT06280131,The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients:,The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients: Clinical and Neurophysiology Study.,NOT_YET_RECRUITING,2024-03-01,2025-03-01,2025-04-01,2024-02-28,2024-02-28,OBSERVATIONAL,,30.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|pulse therapy,,,,0,,,to evaluate efficacy of a pulse therapy on clinical outcome,clinical correlation between clinical scales scores and neurophysiological changes(visual evoked potional|clinical correlation between clinical scales scores and neurophysiological changes( cortical exitability parameters),False,
NCT01864707,Acupuncture or MBSR for Patients With Fatigue and MS,Randomized Controlled Trial on the Efficacy of Acupuncture and the Efficacy of Mindfulness-Based Stress Reduction (MBSR) in Patients With Multiple Sclerosis Suffering From Fatigue,COMPLETED,2013-04,2015-06,2015-10,2016-01-29,2013-05-30,INTERVENTIONAL,NA,104.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,,,Fatigue|Multiple Sclerosis,"multiple sclerosis, fatigue",Germany,Berlin,State of Berlin,1,Usual care + acupuncture|usual care+mbsr|usual care,OTHER|OTHER|OTHER,fatigue severity scale,fatigue severity scale|modified fatigue impact scale|therapy response rates|expanded disability status scale|multipe sclerosis functional composite scale|beck depression inventory II|Body efficacy expectation|SF-12|HAQUAMS|Costs|overall treatment effect|immune parameters|number of serious adverse events|number of suspected adverse reactions,False,
NCT01086371,Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients,Rhythmic Auditory Stimulation and Walking Performance in MS Patients,WITHDRAWN,2012-01,2012-01,2012-01,2022-06-27,2010-03-15,INTERVENTIONAL,PHASE2,0.0,ACTUAL,The Cleveland Clinic,OTHER,National Institutes of Health (NIH),NIH,Gait Disturbance in Multiple Sclerosis Patients,Multiple Sclerosis|gait,United States,Cleveland,Ohio,1,Rhythmic auditory stimulation|Walking exercise,OTHER|OTHER,Stride Length,25 foot walk time,False,
NCT07057999,Investigation of the Effect of the MIND Diet on Disease Symptoms in Patients With MS,"Effects of the MIND Diet on Fatigue, Quality of Life, and Brain Fog in Patients With Multiple Sclerosis: A Randomized Controlled Trial",ACTIVE_NOT_RECRUITING,2025-06-16,2025-11-27,2025-12-27,2025-09-03,2025-07-10,INTERVENTIONAL,NA,62.0,ESTIMATED,Betul Uner,OTHER,,,"Multiple Sclerosis|Diet Therapy|Body Composition|Randomised Controlled Trial|Brain Fog|Fatigue Syndrome, Chronic|Quality of Life (QOL)",,Turkey (Türkiye),Muğla,Mentese,1,MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay)|Traditional healthy nutrition program specific to Turkey,BEHAVIORAL|BEHAVIORAL,The Effect of the MIND Diet on Quality of Life|Effect of the MIND diet on fatigue in MS patients|The effect of the MIND diet on brain fog in MS patients,The effect of the MIND diet on blood parameters|Effect of the applied MIND diet on body composition,False,
NCT04121221,"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS","A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo",COMPLETED,2019-09-19,2023-06-13,2023-06-13,2023-12-01,2019-10-09,INTERVENTIONAL,PHASE3,1016.0,ACTUAL,Mapi Pharma Ltd.,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis|RMS|GA Depot|Multiple Sclerosis, Relapsing-Remitting",United States,Birmingham,Alabama,112,GA Depot|Placebo,DRUG|OTHER,Annualized Relapse Rate (ARR),Changes in brain MRI (number of T1 lesions)|Changes in brain MRI (number of T2 lesions)|Hyperintense T2-lesion volume change|Enhancing T1-lesion volume change,False,
NCT05269004,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,"A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-05-03,2029-12-31,2029-12-31,2025-09-25,2022-03-07,INTERVENTIONAL,PHASE3,1300.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,235,Ocrelizumab,DRUG,"Incidence and severity of adverse events, with severity determined according to the NCI CTCAE v5.0",Change in Expanded Disability Status Scale (EDSS) score over time|Change in 9-Hole Peg Test (9HPT) over time|Change in Timed 25-Foot Walk Test (T25FWT) over time|The number of T1 lesions and number of new or enlarging T2 lesions|The change in total volume of T2 lesions and in total non-enhancing T1 lesion volume,False,
NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,"Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2010-05,2014-03,2014-07,2016-07-11,2010-02-08,INTERVENTIONAL,PHASE3,1841.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis,,United States,Gilbert,Arizona,228,BIIB019 (Daclizumab High Yield Process)|Interferon beta-1a Placebo|Interferon beta-1a|Daclizumab High Yield Process Placebo,BIOLOGICAL|DRUG|BIOLOGICAL|DRUG,Adjusted Annualized Relapse Rate (ARR),Adjusted Mean Number of New or Newly Enlarging T2 Hyperintense Lesions up to Week 96|Proportion of Participants With Sustained Disability Progression at 144 Weeks|Proportion of Participants Relapse-free at Week 144|Percentage of Participants With a ≥ 7.5 Point Worsening From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score at 96 Weeks,True,2016-07-11
NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,"A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)",TERMINATED,2017-04-18,2018-09-12,2018-09-12,2019-09-27,2016-08-29,INTERVENTIONAL,PHASE3,41.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis (RRMS),Multiple Sclerosis|Daclizumab|Tysabri-Switch,United States,Tampa,Florida,11,Daclizumab,DRUG,Percentage of Participants Relapse-free at Month 6,Percentage of Participants Relapse-free at Month 12|Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12|Annualized Relapse Rate (ARR) at Month 12|Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12|Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12|Permanent Discontinuation Rate of Daclizumab at Month 12|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Relevant Shifts in Laboratory Assessments,True,2019-09-24
NCT00360906,Omega-3 Fatty Acid Treatment in Multiple Sclerosis,Omega-3 Fatty Acid Treatment in Multiple Sclerosis,COMPLETED,2004-12,,2008-07,2006-08-07,2006-08-07,INTERVENTIONAL,PHASE2|PHASE3,100.0,,Haukeland University Hospital,OTHER,The Multiple Sclerosis National Competence Centre|The Norwegian Multiple sclerosis Society|Pronova BioPharma|Serono Nordic|Amersham Health,UNKNOWN|UNKNOWN|INDUSTRY|UNKNOWN|INDUSTRY,Relapsing-Remitting Multiple Sclerosis,RRMS|Omega-3|Treatment,Norway,Bergen,,1,Triomar™ (omega-3 fatty acids),DRUG,MRI disease activity measured by the number of new T1-enhancing lesions during the six months of treatment.|MRI disease activity measured by the number of new T1-hypo-intensive lesions (black holes) after 24 months of treatment.,"MRI disease activity measured by the number of new T1-enhancing lesions during the first 9 months and the whole study period of 24 months.|Brain atrophy measured by total MRI brain volume at month 6 and month 24|The number of relapses during the first six months and the whole study period of 24 months.|The increase in disability as measured by Expanded Disability Status Scale (EDSS) during the first six months and the whole study period of 24 months.|Changes in the Multiple Sclerosis Functional Composite (MSFC) score during the first six months and the whole study period of 24 months.|MRI disease activity as measured by the number of new or enlarging T2 lesions and enhancing T1 lesions during the first six months and the whole study period of 24 months.|Changes in serum concentrations of mono-unsaturated fatty acids, saturated fatty acids, omega-3- and omega-6 fatty acids during the study.|Changes in immune responses during the first six months and the whole study period of 24 months.|The occurrence of adverse events during the first six months and the whole study period of 24 months.|The occurrence of adverse events during the first three months of interferon-beta 1a (Rebif®) treatment.|The occurrence of neutralising antibodies against interferon-beta 1a (Rebif®) during the study.",False,
NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),"A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course",TERMINATED,2008-04,2009-09,2009-09,2016-05-24,2008-03-25,INTERVENTIONAL,PHASE2,255.0,ACTUAL,EMD Serono,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|Atacicept,United States,Phoenix,Arizona,50,Atacicept|Atacicept|Atacicept|Placebo matched to atacicept,DRUG|DRUG|DRUG|DRUG,Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan,Number of New T1 Gd-enhancing Lesions Per Participant|Percentage of Participants Free From Relapses|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs,True,2016-05-24
NCT01705457,Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis,Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients,UNKNOWN,2010-02,2013-02,2013-08,2012-10-12,2012-10-12,INTERVENTIONAL,PHASE4,20.0,ESTIMATED,Tehran University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,multiple sclerosis|Vitamin A|retinoic acid receptor|retinoic x receptor,Iran,Tehran,,1,Dietary Supplement: vitamin A|placebo,DRUG|DRUG,Gene expression of RAR(Relative quantification),,False,
NCT04228328,Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis,Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis,COMPLETED,2020-03-03,2020-11-05,2020-11-05,2020-12-21,2020-01-14,OBSERVATIONAL,,21.0,ACTUAL,Haute Ecole de Santé Vaud,OTHER,University of Applied Sciences of Western Switzerland,OTHER,Multiple Sclerosis,,Switzerland,Lausanne,Canton of Vaud,1,The 6-minutes Walk Test,DIAGNOSTIC_TEST,The 6- minutes Walk Test,360 Degree Turn Test,False,
NCT02045732,A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS),"A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)",TERMINATED,2014-09,2015-10,2015-10,2017-01-16,2014-01-27,INTERVENTIONAL,PHASE1,4.0,ACTUAL,Pfizer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MRI,United States,Albany,New York,8,PF-06342674 0.25 mg/kg|Placebo|PF-06342674 1.5 mg/kg|PF-06342674 6.0 mg/kg,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,"Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs|Number of Treatment-Emergent AEs and SAEs by Severity|Number of Participants With Clinical Laboratory Abnormalities|Number of Participants With Clinically Significant Changes in Vital Signs|Number of Participants With Abnormal Electrocardiogram (ECG)|Number of Participants With Confirmed Positive Anti-Drug Antibodies (ADAs)",Concentration of PF-06342674,True,2017-01-16
NCT04306939,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,SUSPENDED,2014-11-01,2025-12-01,2025-12-01,2025-06-27,2020-03-13,OBSERVATIONAL,,120000.0,ESTIMATED,University of Pittsburgh,OTHER,,,Chronic Pancreatitis|Inflammatory Bowel Diseases|Hepatitis|NASH - Nonalcoholic Steatohepatitis|Acute Pancreatitis|Rheumatoid Arthritis|Diabetes Mellitus|Dyslipidemias|Multiple Sclerosis|Irritable Bowel Syndrome|Chronic Pain|Chronic Disease|Chronic Kidney Diseases|Crohn Disease|Celiac Disease|Biliary Cirrhosis|Bile Acid Synthesis Defect|Gastritis|Cholecystitis|Cholelithiases|IPMN|Cyst Pancreas|Cystic Fibrosis|Pancreatic Exocrine Insufficiency|Diarrhea Chronic|Constipation - Functional|Constipation Chronic Idiopathic,fibrosis|chronic inflammation,United States,Pittsburgh,Pennsylvania,1,venipuncture|Questionnaires|Additional Sample Collections,OTHER|BEHAVIORAL|OTHER,"Define the molecular disorders contributing to clinicopathological disease definitions for common complex disorders|Define risk factors for disease progression, severity, complications and poor quality of life.|Common disease mechanisms and repurposing of medications.",Pain profile|Patient Reported Global Health Assessment,False,
NCT06129019,"the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis","Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2023-06-01,2024-04-01,2024-06-01,2025-01-07,2023-11-13,INTERVENTIONAL,NA,60.0,ACTUAL,Ataturk University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",reiki|anxiety|physical activity,Turkey (Türkiye),Elâzığ,,1,Reiki,BEHAVIORAL,Beck Depression Scale|Beck Anxiety Scale|International Physical Activity Survey,,False,
NCT03552211,Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis,Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis,UNKNOWN,2018-05-30,2019-02-01,2019-04-30,2018-06-11,2018-06-11,OBSERVATIONAL,,3000.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,OFSEP (Observatoire Français de la Sclérose en Plaques)|SFSEP (Société Francophone de la Sclérose en Plaques)|MedDay Pharmaceuticals SA,UNKNOWN|UNKNOWN|INDUSTRY,Progressive Multiple Sclerosis,Multiple Sclerosis|Progressive Multiple Sclerosis|Biotin|Relapse,France,Clermont-Ferrand,,1,biotin|propensity score,DRUG|OTHER,Relapses with biotin,Clinical characteristics of the relapses with biotin|Characteristics of patients with relapse with biotin,False,
NCT01236534,Lubiprostone in Patients With Multiple Sclerosis Associated Constipation,"Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation",COMPLETED,2010-11,2012-01,2012-04,2015-12-10,2010-11-08,INTERVENTIONAL,PHASE4,21.0,ACTUAL,University of Rochester,OTHER,Takeda,INDUSTRY,Multiple Sclerosis|Constipation,Multiple Sclerosis|Constipation|Multiple Sclerosis Associated Constipation,United States,Rochester,New York,1,Lubiprostone|Placebo,DRUG|DRUG,Number of Spontaneous Bowel Movements in Patients With Multiple Sclerosis (MS)-Associated Constipation Per Day.,Number of Participants With Diarrheic Events.,True,2015-12-10
NCT04048577,A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab,"The Impact of a Planned 12-week Dosing Interruption of Natalizumab on Immune Cell Trafficking, Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters, and Multiple Sclerosis (MS) Disease Stability.",UNKNOWN,2019-07-03,2021-11-01,2021-12-01,2021-07-22,2019-08-07,INTERVENTIONAL,PHASE4,10.0,ESTIMATED,"Berkovich, Regina MD, PhD Inc.",OTHER,Biogen|Cedars-Sinai Medical Center,INDUSTRY|OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Natalizumab|Drug Holiday|Alternative Dosing|Extended Dosing,United States,West Hollywood,California,1,Dosing Interruption of Natalizumab,DRUG,"Leukocyte Type and Quantity in CSF|MS Activity through CSF, Blood, and MRI",Natalizumab Concentrations in Blood|immunoglobulin G4 Levels in Blood|Soluble Vascular Cell Adhesion Molecules and Soluble Mucosal Vascular Addressin Cell Adhesion Molecule Levels (sVCAM sMAdCAM) in Blood|John Cunningham Virus Extracellular Vesicle Antibody Levels in CSF,False,
NCT01585298,STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START),"A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2012-04-29,2016-12-12,2016-12-12,2019-09-23,2012-04-25,INTERVENTIONAL,PHASE4,6998.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|Fingolimod|Gilenya|ECG|Bradyarrythmia|conduction abnormalities|first dose observation,Germany,Ostfildern,Baden-Wurttemberg,258,FTY720,DRUG,Participants With 2nd or 3rd Degree Atrioventricular (AV) Block|Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM),Number of Participants With Prolonged QTc Interval (Friderica)|Number of Participants With Bradyarrhythmic Electrocardiogram (ECG) Events|Number of Patients With Cardiac Adverse Events,True,2019-09-23
NCT05385731,MUSCLE - Nordic Walking in MUltiple SCLErosis,"MUSCLE - Nordic and Free Walking in People With Multiple Sclerosis: Clinical-functional, Motor Control, and Gait Analysis Findings: a Randomized Controlled Multicentre Clinical Trials",UNKNOWN,2022-08-02,2022-12-30,2024-12-30,2022-05-23,2022-05-23,INTERVENTIONAL,NA,60.0,ESTIMATED,Leonardo A. Peyré-Tartaruga,OTHER,Aline Nogueira Haas|Flávia Gomes Martinez,UNKNOWN|UNKNOWN,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",Mobility|Functionality|Movement disorders|Rehabilitation|Locomotion|Gait kinematics|Electromyographic activity|Quality of life,Brazil,Porto Alegre,Rio Grande do Sul,1,Nordic Walking (NWG)|Free Walking (FWG)|Health Education (HEG),OTHER|OTHER|OTHER,Test Timed Up and Go|Locomotor Rehabilitation Index|Self-selected walking speed,Optimal Walking Speed (OPT)|Quality of life (QoL)|Cognitive function|Depressive symptoms|Expanded Disability Status Scale,False,
NCT05563402,"""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis""","""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis""",COMPLETED,2022-09-20,2022-12-20,2023-03-30,2023-06-15,2022-10-03,INTERVENTIONAL,NA,15.0,ACTUAL,Multiple Sclerosis Center of Catalonia,OTHER,,,Multiple Sclerosis|Ataxia|Paraplegia,exoskeletons|bioengineering|biomechanics;|biomechatronics;|rehabilitation robotics|Atalante,Spain,Barcelona,,1,Atalante,DEVICE,To describe usability of Robotic-Assisted Gait therapy (RAGT) using the Atalante self-balance exoskeleton for persons with multiple sclerosis (PwMS) and explore patient characteristics related to this feature.,"To describe safety and occurrence of adverse effect of Robotic-Assisted Gait therapy (RAGT) using the Atalante self-balance exoskeleton for persons with multiple sclerosis (PwMS).|To describe safety of Robotic-Assisted Gait therapy (RAGT) using the Atalante self-balance exoskeleton for persons with multiple sclerosis (PwMS), measured by the occurrence of pressure ulcers|To describe the effect at the functional level of RAGT using the Atalante self-balance exoskeleton for improving Balance outcome.|To describe the effect at the functional level of RAGT using the Atalante self-balance exoskeleton for improving Walking speed, quality of life, depression.|To describe the effect at the functional level of RAGT using the Atalante self-balance. Physiological Changes at Bowel Dysfunction|To describe the effect at the self-perception and psychological level of RAGT using the Atalante self-balancing exoskeleton to improve quality of life.|To describe the effect at the self-perception and psychological level of RAGT using the Atalante self-balancing exoskeleton to improve quality of life and depression.",False,
NCT03370965,Optic Neuritis Differential Diagnosis Study,Optic Neuritis Differential Diagnosis Study (ONDDS),UNKNOWN,2019-06-07,2024-06,2025-06,2022-02-24,2017-12-13,INTERVENTIONAL,NA,150.0,ESTIMATED,University Hospital Center of Martinique,OTHER,University Hospital Center of Guadeloupe|Hospital Center of Cayenne (French Guyana),UNKNOWN|UNKNOWN,Optic Neuritis|Neuromyelitis Optica|Multiple Sclerosis,optic neuritis|neuromyelitis optica|multiple sclerosis|emergent treatment of optic neuritis|optic neuritis disease modifying therapy|optic neuritis treatment trial|plasma exchange,France,Fort-de-France,,1,Neuro-ophtalmology examination,DIAGNOSTIC_TEST,"Final diagnosis using MS (McDonald, 2010) - Spatial dissemination|Final diagnosis using MS (McDonald, 2010) - Time dissemination|NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with positive anti-AQP4 Antibody|NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with anti-AQP4 negative antibody",,False,
NCT06009770,Telerehabilitation Protocols With Digital and Robotic Tools for People With Chronic Neurological Disorders,"Development and Implementation of Telerehabilitation Protocols With Digital and Robotic Tools for the Continuity of Care of People With Chronic Neurological Disorders - TELENEURO@REHAB""",UNKNOWN,2023-09-01,2024-05-29,2025-01-01,2023-08-24,2023-08-24,INTERVENTIONAL,NA,90.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,Fondazione Ico Falck,UNKNOWN,Post-stroke|Parkinson Disease|Multiple Sclerosis,Telerehabilitation|Digital medicine|Robotics|Chronic Neurological conditions,,,,0,"medical device ""Homing"" (TecnoBody); medical device ""Icone"" (Heaxel)|Usual Care",DEVICE|BEHAVIORAL,"Change in the perceived level of disability as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0, Federici et al., 2017)","Change in global cognitive functioning as measured by the Montreal Cognitive Assessment (MoCA test, Conti et al., 2015) in PD, MS, and post-stroke groups|Change in visuoperceptual and attentional abilities as measured by the Trail Making Test (TMT part A and B, Giovagnoli et al., 1996) in PD, MS, and post-stroke groups|Change in visuoperceptual and attentional abilities as measured by the and the Symbol Digit Modalities Test (SDMT; Smith A., 1973; Nocentini U., 2006) in PD, MS, and post-stroke groups|Change in depressive symptoms as measured by the Beck Depression Inventory for Primary Care (BDI-PC, Steer et al., 1999) in PD, MS, and post-stroke groups|Change in anxiety level as measured by the State-Trait Anxiety Inventory - Form Y (STAI - Y2; Spielberger, 1983; Pedrabissi & Santinello, 1989) in PD, MS, and post-stroke groups|Change in gross manual dexterity as measured by the Box and Block Test (BBT; Desrosiers et al., 1994) in PD, MS, and post-stroke groups|Change in finger dexterity as measured by the Nine Hole Peg Test (Feys et al., 2017) in PD and MS groups|Change in dynamic balance as measured by the modified Dynamic Gait Index (mDGI; Anastasi et al., 2019) in PD and MS groups|Change in static and dynamic balance as measured by the Mini-Best Test (Franchignoni et al., 2010) in PD and MS groups|Change in perceived stability during activities of daily living as measured by the Activities Balance Confidence scale (ABC; Cattaneo et al., 2006; Franchignoni et al., 2014) in PD and MS groups|Change in motor functionality as measured by the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS; Goetz et al., 2008) part III only in the PD group|Change in the level of disability as measured by the EDSS (Kurtzke, 1983) only in the MS group|Change in sensory-motor function of the upper limb as measured by the Fugl-Meyer Assessment - Upper Extremity (Fugl Meyer et al. 1975) only in post-stroke group|Change in motor function of the upper limb as measured by the Action Research Arm Test (ARAT; Lyle, 1981) only in post-stroke group",False,
NCT06421753,Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients,Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients,COMPLETED,2024-05-16,2024-12-31,2024-12-31,2025-09-19,2024-05-20,INTERVENTIONAL,NA,10.0,ACTUAL,UGECAM Rhône-Alpes,OTHER,,,Upper Motor Neuron Disease,functional electrical stimulation|muscle fatigue|rehabilitation|spinal cord injury|stroke|multiple sclerosis,France,Saint-Didier-au-Mont-d'Or,France,1,SDSS|Standard Electrical Stimulation During Functional Electrical Stimulation,DEVICE|DEVICE,Average quadriceps power output (watts) measured during 3 minutes of FES cycling,Evaluate the comfort of dry and hydrogel based functional electrical stimulation electrodes,False,
NCT00613171,Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis,"A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis",COMPLETED,2008-01-02,2010-01-13,2010-01-13,2021-07-07,2008-02-12,INTERVENTIONAL,PHASE2,27.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,"Systemic Sclerosis, Scleroderma","Systemic sclerosis, scleroderma, fibrosis, STI571, imatinib",United States,Chicago,Illinois,7,STI571,DRUG,Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis|Number of Participants With Adverse Events (AE's) and Serious Adverse Events (SAE's),"Number of Participants With Non-response, Partial Response, Complete Response, and Remission Assessed by MRSS Values",True,2021-05-21
NCT00852722,Low Fat Diet and Multiple Sclerosis,"A Randomized, Controlled Study of Diet and Multiple Sclerosis",COMPLETED,2009-02,2014-07,2014-07,2015-02-04,2009-02-27,INTERVENTIONAL,PHASE1,61.0,ACTUAL,Oregon Health and Science University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Diet,United States,Portland,Oregon,1,Low fat study diet,OTHER,Number of new MS T2 lesion formation on brain MRI in those randomized to the low fat study diet with that of subjects randomized to follow their regular diet.,"To assess effects of the low fat study diet on clinical activity of MS as by relapse rate and disability progression and on fatigue, depression and quality of life.|To study the effects of the Low Fat Study Diet on serum markers of inflammation|To assess safety and tolerability of the low fat study diet upon 12 months of administration",False,
NCT02609607,Treating Anorectal Dysfunction in MS,Treating Anorectal Dysfunction Associated With Multiple Sclerosis,TERMINATED,2016-06,2018-11,2018-12,2020-01-22,2015-11-20,INTERVENTIONAL,PHASE2,11.0,ACTUAL,David Levinthal,OTHER,Consortium of Multiple Sclerosis Centers,OTHER,Constipation|Fecal Incontinence|Multiple Sclerosis,,United States,Pittsburgh,Pennsylvania,1,Bisacodyl|Placebo,DRUG|OTHER,Number of Participants With 30% Improvement From Baseline in Bowel Symptoms at 4 Weeks,Change From Baseline in Mean PAC-SYM Subscale Scores at 4 Weeks|Change From Baseline in Fecal Incontinence Severity Index (FISI) Score at 4 Weeks|Change From Baseline in Fecal Incontinence Quality of Life (FIQL) Score at 4 Weeks|Change From Baseline in PAC-QOL Scores at 4 Weeks|Change From Baseline in SF-36 Scores at 4 Weeks|Change From Baseline In Percent of Subjects With Normal Average Stool Form at 4 Weeks|Change From Baseline In Average Number of Daily Bowel Movements at 4 Weeks|Change From Baseline In Average Number of Fecal Incontinence Episodes at 4 Weeks,True,2020-01-22
NCT04635436,Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication,Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication,RECRUITING,2020-02-05,2024-12-31,2024-12-31,2024-10-08,2020-11-19,INTERVENTIONAL,NA,20.0,ESTIMATED,Istituto Auxologico Italiano,OTHER,,,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Amputation|Knee Impairment,walking|split-belt treadmill|motor adaptation|after-effect|dynamic symmetry|rehabilitation,Italy,Milan,MI,1,Split-belt treadmill walking.,OTHER,Ankle Joint Power,Step Length|Single Stance Time|Double Stance Time|Parameters of the center of mass motion,False,
NCT07178834,Impact of a Tele-rehabilitation Program on People With Multiple Sclerosis,"Impact of a Tele-rehabilitation Program on People With Multiple Sclerosis: A Multicenter, Randomized, Single-blind Study.",ACTIVE_NOT_RECRUITING,2025-02-10,2025-09-30,2025-09-30,2025-09-17,2025-09-17,INTERVENTIONAL,NA,75.0,ACTUAL,Multiple Sclerosis Center of Catalonia,OTHER,,,Multiple Sclerosis,Telerehabilitation|Rehabilitatiton|Patient-Reported Outcome Measures,Spain,Barcelona,,1,Telerehab,BEHAVIORAL,Adverse events,Multiple Sclerosis Quality of Life 54|10 meters walking test|6 minute walking test|Berg Balance Scale,False,
NCT04524039,iTBS Study for Depression in Patients With Multiple Sclerosis,Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Depression in Patients With Multiple Sclerosis: a Randomized Controlled Study,UNKNOWN,2020-12-01,2022-09-01,2022-12-31,2020-11-24,2020-08-24,INTERVENTIONAL,NA,30.0,ESTIMATED,"Third Affiliated Hospital, Sun Yat-Sen University",OTHER,,,"Multiple Sclerosis|Depression, Anxiety",Multiple Sclerosis|Depression|Transcranial Magnetic Stimulation,,,,0,intermittent theta burst stimulation using a MagPro X100|sham intermittent theta burst stimulation using a MagPro X100,DEVICE|DEVICE,Change in Montgomery-Asberg Depression Rating Scale (MADRS),Presence and changes in severity of side effects|Change in Beck Depressive Inventory (BDI)|Change in 21-item Beck's Anxiety Inventory (BAI)|Change in Fatigue Severity Scale (FSS)|Change in Pittsburgh Sleep Quality Index (PSQI)|Change in Expand Disability Status Scale (EDSS)|Change in Cortical silent period (CSP) duration|Change in short-interval intracortical inhibition (SICI)|Change in intracortical facilitation (ICF)|Changes in long-interval intracortical inhibition (LICI)|Change in slow-wave/fast-wave (theta/beta) ratio from resting-state electroencephalograph (EEG) recording|Serum biomarker,False,
NCT02117375,EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients,EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients,UNKNOWN,2014-01,2022-04,2022-07,2020-06-11,2014-04-17,INTERVENTIONAL,NA,115.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|spinal cord|MRI|longitudinal study|disability,France,Rennes,,1,spinal cord MRI follow-up|clinical follow-up|brain MRI follow-up,DEVICE|OTHER|OTHER,Progressive neurological disability,Progressive ambulatory disability|Progressive disability in the upper limbs|Progressive urinary disability|Progressive difficulty walking,False,
NCT06228781,Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis,Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis,NOT_YET_RECRUITING,2026-12-01,2029-01-01,2029-01-01,2025-05-30,2024-01-29,INTERVENTIONAL,NA,20.0,ESTIMATED,Tianjin Medical University General Hospital,OTHER,,,Multiple Sclerosis,,,,,0,Autologous haemopoietic stem cell transplantation,PROCEDURE,3 year MS activity free survival,Time to MS treatment failure|Transplant related morbidity|Transplant related mortality|Immune reconstitution following transplant|Hematopoietic reconstitution following transplant|Imaging changes associated with the disease activity,False,
NCT01639300,Safety Study of GNbAC1 in Multiple Sclerosis Patients,Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1,COMPLETED,2012-07,2014-04,2014-04,2021-02-08,2012-07-12,INTERVENTIONAL,PHASE2,10.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis|Progressive Forms of Multiple Sclerosis|GNbAC1|Monoclonal antibody|Multiple Sclerosis Associated Retrovirus (MSRV)|Temelimab,Switzerland,Basel,,2,GNbAC1|GNbAC1 placebo,BIOLOGICAL|BIOLOGICAL,"To assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.","To determine the pharmacokinetics (PK) characteristics following administration of single ascending doses, as well as of repeated administrations, of GNbAC1 in MS patients|To determine pharmacodynamic markers of MS disease activity in patients including measurement of MSRV-Env markers and magnetic resonance imaging (MRI)|To assess the immunogenicity of GNbAC1.",False,
NCT01280539,The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis,,COMPLETED,2011-01,2012-01,2012-06,2012-09-05,2011-01-20,INTERVENTIONAL,NA,20.0,ESTIMATED,Hasselt University,OTHER,Provinciale Hogeschool Limburg,OTHER,Multiple Sclerosis,Multiple Sclerosis|Transcutaneous electrical nerve stimulation|Cortical Excitability,Belgium,Diepenbeek,Limburg,1,Transcutaneous electrical nerve stimulation,DEVICE,Change in cortical excitability,,False,
NCT04486209,Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis,Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis,COMPLETED,2017-12-27,2020-07-02,2020-07-02,2023-10-19,2020-07-24,INTERVENTIONAL,EARLY_PHASE1,15.0,ACTUAL,Medical University of Vienna,OTHER,"Neurological Center, Otto Wagner Hospital",UNKNOWN,Multiple Sclerosis,neuromodulation|spinal cord stimulation|walking function|spasticity,Austria,Vienna,,1,transcutaneous spinal cord stimulation,DEVICE,Modified Ashworth Scale,10-m walk test|2-min walk test|Timed up an go test,False,
NCT07186998,Validity and Reliability of the L Test in Single and Dual Task Conditions in Multiple Sclerosis,The Application of the L Test's Validity and Reliability in Single and Dual Task Conditions in Patients With Multiple Sclerosis,COMPLETED,2024-12-15,2025-04-15,2025-08-15,2025-09-22,2025-09-22,OBSERVATIONAL,,50.0,ACTUAL,Sanko University,OTHER,,,Multiple Sclerosis|Walking|Validity During Daily Activities,multiple skleroz|yürüme|geçerlilik|güvenirlilik,Turkey (Türkiye),Gaziantep,,1,,,The timed up-and-go test:|L test:|Timed 25-step walking test,,False,
NCT05342025,Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis,"Investigation Of The Effects Of Proprioceptive Neuromuscular Facilitation Techniques For Upper Extremity And Trunk, Combined With Respiration, On Respiratory Capacity And Swallowing In Individuals With Multiple Sclerosis",COMPLETED,2022-05-01,2022-11-15,2023-04-01,2023-05-12,2022-04-22,INTERVENTIONAL,NA,34.0,ACTUAL,Biruni University,OTHER,,,Multiple Sclerosis,respiratory function|swallowing|proprioceptive neuromuscular facilitation,Turkey (Türkiye),Istanbul,,1,PNF|Breathing exercises,OTHER|OTHER,Forced expiratory volume 1st second|Peak cough flow|Respiratory muscle strength|Forced vital capacity,2 Minutes Walking Test|Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL)|Eating Assessment Tool (EAT-10)|Fatigue Severity Scale (Fatigue Severity Scale)|Dysphagia Rating Scale in Multiple Sclerosis (DYMUS),False,
NCT03608527,Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis,The Impact of Motor Rehabilitation on the Dynamic Properties of the Brain: Towards the Individual Tailoring of Therapeutic Interventions in Multiple Sclerosis Patients,COMPLETED,2013-09-09,2014-12-22,2015-03-04,2018-08-01,2018-08-01,INTERVENTIONAL,NA,30.0,ACTUAL,Fondazione Italiana Sclerosi Multipla,OTHER,Universita degli Studi di Genova,OTHER,Multiple Sclerosis,Upper limb motor rehabilitation|Voluntary movements|functional magnetic resonance imaging,,,,0,Voluntary-based upper limb motor rehabilitation|Passive upper limb mobilization,BEHAVIORAL|BEHAVIORAL,Change in the time to perform the Nine Hole Peg Test (NHPT),Score obtained at the Action Research Arm Test (ARAT)|Grip and pinch strength|Brain activity (blood-oxygenation-level dependent signal),False,
NCT01337986,Ampyra for Optic Neuritis in Multiple Sclerosis,Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis,COMPLETED,2011-05,2013-12,2013-12,2020-01-30,2011-04-19,INTERVENTIONAL,PHASE2|PHASE3,53.0,ACTUAL,Washington University School of Medicine,OTHER,Acorda Therapeutics,INDUSTRY,Multiple Sclerosis|Optic Neuritis,Multiple Sclerosis|Optic Neuritis|Ampyra|Dalfampridine|Fampridine|Remote Optic Neuritis|Contrast Sensitivity|Treatment,United States,St Louis,Missouri,1,Dalfampridine/Placebo|Placebo/Dalfampridine,DRUG|DRUG,Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores|Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity|Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1|Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity,Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart|Percentage of Eyes That Improved by One-line (5 Letters)|Visual Evoked Potential P100 Latency Per Treatment Arm|Odds Ratio Quartile of Visual Field Index|Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).|Dalfampridine Effect on Quality of Life Change From Baseline.|Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1,True,2020-01-30
NCT04201470,Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis,Serum Neurofilaments Light Chain and GFAP (Glial Fibrillary Acidic Protein) in Atypical Idiopathic Inflammatory Demyelinating Disorders,COMPLETED,2019-12-09,2022-05-23,2022-05-23,2023-02-17,2019-12-17,INTERVENTIONAL,NA,58.0,ACTUAL,"University Hospital, Montpellier",OTHER,,,Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis|Controls|Multiple Sclerosis,Atypical multiple sclerosis|Cavitary multiple sclerosis|Myelocortical multiple sclerosis,France,Montpellier,,1,Blood withdrawal|MRI|Neurologic / neuropsychologic tests - Patients|Neurologic / neuropsychologic tests - Controls,OTHER|OTHER|OTHER|OTHER,Serum neurofilaments light chain,Serum GFAP,False,
NCT05451069,"Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis","Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients",UNKNOWN,2022-10-01,2024-07-25,2025-07-27,2022-10-12,2022-07-11,OBSERVATIONAL,,42.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,"Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells",DIAGNOSTIC_TEST,Levels of different markers in MS diagnosis,Different samples levels in MS diagnosis,False,
NCT03091569,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY),COMPLETED,2017-03-10,2018-01-27,2018-01-27,2018-04-05,2017-03-27,INTERVENTIONAL,PHASE4,23.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,Italy,Napoli,,1,Vitamin K Cream|Placebo Cream,OTHER|OTHER,Change in Clinician's Erythema Assessment (CEA) scale from pre-application of topical cream to 24 hours post-application|Change in Participants Erythema Self-Assessment (PSA) scale from pre-application of topical cream to 24 hours post-application,Change in Visual Analogue Scale (VAS) score from pre-application of topical cream to 24 hours post-application|Change in Adapted Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ) from pre-application of topical cream to 24 hours post-application|Change in the longest diameter of erythema from pre-application of topical cream to 24 hours post-application,False,
NCT05161494,Gait in Rare Diseases,"Identification of Gait Disorders in Children, Adolescents and Young Adults With Rare Genetic Diseases",ACTIVE_NOT_RECRUITING,2022-01-25,2025-07-01,2026-01-30,2025-08-29,2021-12-17,OBSERVATIONAL,,70.0,ESTIMATED,Universiteit Antwerpen,OTHER,"University Hospital, Antwerp",OTHER,Tuberous Sclerosis|STXBP1 Encephalopathy With Epilepsy,gait|movement disorders|biomechanics|kinematics,Belgium,Antwerp,,1,,,Gait Profile Score (degrees),Lower limb kinematics during walking (degrees)|Functional Mobility Scale|Mobility Questionnaire 28,False,
NCT04242056,To Study the Pathophysiological Features of Multiple Sclerosis,To Study the Pathophysiological Features of Multiple Sclerosis: Combined Multi-modalities of Amyloid and Tau Images Associated With Serum Neurofilament Light Chain Levels,UNKNOWN,2020-02-20,2020-09-30,2020-09-30,2020-01-27,2020-01-27,INTERVENTIONAL,PHASE1|PHASE2,38.0,ESTIMATED,Chang Gung Memorial Hospital,OTHER,,,Multiple Sclerosis|Neurofilament Light Chain|Glial Fibrillary Acidic Protein,,,,,0,18F-PM-PBB3,DRUG,Correlation between hyperintensity lesions in FLAIR MRI and demyelination in amyloid PET image,Correlation between clinical parameters (EDSS) and hyperintensity lesions in FLAIR MRI and hyperintensity region of tau PET image light chain and GFAP levels.|Correlation between clinical parameters (EDSS) and serum NfL levels,False,
NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,"Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years",COMPLETED,2015-09-30,2016-09-23,2016-09-23,2017-10-23,2015-04-07,INTERVENTIONAL,PHASE2,22.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Pediatrics,United States,San Bernardino,California,12,dimethyl fumarate,DRUG,Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period,Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Clearance (CL/F)|Apparent Volume of Distribution (V/F)|Half-Life Lambda z|Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)|Number of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),True,2017-04-28
NCT01207856,Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis,Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis and Assessment by Neuroimaging,COMPLETED,2011-05,2015-07,2016-02,2016-02-09,2010-09-23,INTERVENTIONAL,NA,65.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Merck Serono International SA|ARSEP foundation,INDUSTRY|UNKNOWN,Multiple Sclerosis|Cognitive Rehabilitation,Multiple sclerosis|functional MRI|cognitive rehabilitation|ecological evaluation|neuroplasticity,France,Bordeaux,,1,specific cognitive rehabilitation|non specific cognitive rehabilitation|no intervention,BEHAVIORAL|BEHAVIORAL|OTHER,Comparison between groups concerning the z cognitive global executive z score .,Comparison of brain activation in the treated group versus control group at the fourth condition.|Comparison between groups concerning the z score of the SDMT|Comparison between groups of the daily-life cognitive questionnaire scores|Comparison between groups concerning the z cognitive global executive z score|Clinical Global impression of patients,False,
NCT04066972,Vigorous Cool Room Treadmill Training,Intensive Aerobic and Task-specific Training to Restore Walking and Boost Neuroplasticity Among People With MS-related Walking Disability: a Proof of Principle Trial,COMPLETED,2018-07-10,2019-07-09,2019-07-09,2019-08-28,2019-08-26,INTERVENTIONAL,NA,10.0,ACTUAL,Memorial University of Newfoundland,OTHER,,,"Multiple Sclerosis|Rehabilitation|Gait Disorders, Neurologic|Neuronal Plasticity",,Canada,St. John's,Newfoundland and Labrador,1,Body-weight supported treadmill training in a room cooled to 16°C,OTHER,Feasibility of conducting vigorous cool room treadmill training|Feasibility of conducting vigorous cool room treadmill training|Feasibility of conducting vigorous cool room treadmill training|Feasibility of conducting vigorous cool room treadmill training,Timed 25 foot walk test|Spatiotemporal parameters of gait measured while walking at fast and self-selected pace|Fatigue severity scale|Modified fatigue impact scale|Maximal oxygen consumption during graded exercise test|Health-related quality of life assessed using 36-Item Short-Form Health Survey|Serum brain derived neurotrophic factor|Serum interleukin-6|Montreal cognitive assessment|Corticospinal excitability measured using transcranial magnetic stimulation|Body composition measured using dual energy x-ray absorptiometry|Magnetization transfer ratio measured using magnetic resonance imaging|Aerobic cost of walking|Step counts,False,
NCT01142583,A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis,Canadian Assessment of the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis,COMPLETED,2006-07,2009-08,2009-08,2014-03-18,2010-06-11,OBSERVATIONAL,,192.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple sclerosis|Expanded Disability Status Scale|Multiple Sclerosis, Relapsing-Remitting",,,,0,,,Assessment of history or current status of Expanded Disability Status Score (EDSS)|Assessment of history or current relapse status|Assessment of history or current magnetic resonance imaging (MRI) status|Assessment of history or current cognitive status|Assessment of history or current status of neutralizing antibodies (NAb),Treatment Optimization Recommendation Questionnaire,False,
NCT03326505,Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment,The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.,COMPLETED,2017-09-25,2020-01-25,2020-02-20,2020-03-04,2017-10-31,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,University of Jordan,OTHER,,,Multiple Sclerosis,Umbilical Cord Mesenchymal Stem Cells|Multiple Sclerosis|Neuroimmunology|Autoimmune disease|Physical therapy,Jordan,Amman,,2,Umbilical cord derived Mesenchymal Stem Cells|Supervised physical therapy,BIOLOGICAL|OTHER,Isolation and Expansion of Mesenchymal Stem Cells,Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments,False,
NCT06330077,Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis,A Phase 2 Trial Assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis,NOT_YET_RECRUITING,2024-03,2027-03,2027-06,2024-03-26,2024-03-26,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis|Remitting Relapsing Multiple Sclerosis,Multiple Sclerosis|Ifenprofil|Combination of magnetic resonance imaging (MRI) and positron emission tomography (PET)|18f-Florbetaben|Remyelination,France,Bron,,2,Ifenprodil|Placebo,DRUG|DRUG,Change in P100 latency according to visual evoked potential.,Proportion of voxels within white matter lesions classified as remyelinating|Proportion of remyelinating voxels extracted in cortical regions from magnetization transfer imaging (MTR) acquisitions|Change in amplitude of P100 on to visual evoked potential|Change in retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thickness on OCT|Change in blood concentration of NfL fragments|Change in the brain atrophy rate|The correlation between the change in the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions|The comparison of the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions|Incidence of adverse drug reactions,False,
NCT04279912,MR-Guided Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,A Feasibility and Safety Clinical Trial of the Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,UNKNOWN,2020-01-16,2021-03,2021-07,2020-02-21,2020-02-21,INTERVENTIONAL,NA,6.0,ESTIMATED,Sunnybrook Health Sciences Centre,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,Tremor|Multiple Sclerosis|MR-guided Focused Ultrasound,Canada,Toronto,Ontario,1,Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis,DEVICE,Composite safety outcome of MRgFUS thalamotomy,Incidence and severity of adverse events related to MRgFUS thalamotomy|Incidence and severity of adverse events related to MS disease relapse or progression|Changes from baseline in the EDSS (Expanded Disability Status Scale) scores|Changes from baseline in the SARA (Scale for Assessment and Rating of Ataxia) scores|Changes from baseline in the speech intelligibility (percentage of intelligible words recorded during standardized passage reading)|Changes from baseline in QUEST (Quality of Life in Essential Tremor Questionnaire) scores|Change from baseline in the CRST (Clinical Rating Scale for Tremors)|Composite safety outcome of MRgFUS thalamotomy,False,
NCT03785483,Implementation Intention for Physical Activity in Multiple Sclerosis,Controlled Trial Testing the Effectiveness of Motivational Support on Physical Activity and Fatigue of Patients With Multiple Sclerosis,UNKNOWN,2018-12-30,2019-06-15,2019-06-30,2018-12-26,2018-12-24,INTERVENTIONAL,NA,45.0,ESTIMATED,University of Paris 5 - Rene Descartes,OTHER,CeRSM|COMUE|Poissy-Saint Germain Hospital|Hôpital Raymond Poincaré|Paris West University Nanterre La Défense|Cite Sep,UNKNOWN|UNKNOWN|OTHER|OTHER|OTHER|OTHER,Motivation|Mindfulness,Physical activity|Multiple sclerosis|Motivation|Intention|Mindfulness,France,Garches,,2,Motivation,BEHAVIORAL,Change in physical activity,Change in self-reported anxiety and depression (HADS)|Change in self-reported mindfulness skills (FFMQ)|Change in self-reported motivational regulation toward exercise (BREQ)|Change in self-reported beliefs toward physical activity (TPB).,False,
NCT04819737,Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences,Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study,RECRUITING,2022-07-18,2025-12,2025-12,2025-03-12,2021-03-29,INTERVENTIONAL,NA,10.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,Freie Akademische Gesellschaft Basel,UNKNOWN,Multiple Sclerosis (MS),spinal cord (SC) pathology|demyelinating lesions|Spinal cord MRI|Averaged magnetization inversion recovery acquisitions (AMIRA) sequence|Swiss MS Cohort (SMSC),Switzerland,Basel,,1,SC MRI|patient questionnaire,PROCEDURE|OTHER,Number of SC lesions|Inter-observer agreement on SC lesion count|Presence of ongoing inflammation (acute or chronic) in the SC,,False,
NCT03691077,Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714,A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714,RECRUITING,2018-11-11,2024-05,2024-09,2023-09-06,2018-10-01,INTERVENTIONAL,PHASE3,51.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,Roche Pharma AG|Institut du Cerveau et de la Moelle épinière,INDUSTRY|UNKNOWN,Multiple Sclerosis|Relapse|Primary Progressive Multiple Sclerosis,Multiple Sclerosis|Ocrelizumab|Microglial cells Activation|PET-IRM|18F-DPA714,France,Paris,,1,Ocrelizumab,DRUG,Determine if ocrelizumab treatment is associated with a decrease in the extent of brain white matter microglial activation.,Decrease of microglial activation as measured by [18F]DPA-714 PET in normal appearing white matter|decrease of microglial activation as measured by [18F]DPA-714 PET in the total white matter|decrease of microglial activation as measured by [18F]DPA-714 PET in white matter lesions|decrease of microglial activation as measured by [18F]DPA-714 PET in white matter perilesional areas|decrease of microglial activation as measured by [18F]DPA-714 PET in in number of plaques classified as chronic active|decrease of microglial activation as measured by [18F]DPA-714 PET in number of plaques classified as smoldering plaques|decrease of microglial activation as measured by [18F]DPA-714 PET in deep grey matter|decrease of microglial activation as measured by [18F]DPA-714 PET in cortical grey matter,False,
NCT00640328,Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients,"A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients",COMPLETED,2008-05,2010-05,2011-10,2017-04-11,2008-03-21,INTERVENTIONAL,PHASE2,38.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,relapsing forms of multiple sclerosis|ofatumumab|multiple sclerosis,,,,0,Ofatumumab 100|Ofatumumab 300|Ofatumumab 700|Placebo,DRUG|DRUG|DRUG|DRUG,"Number of Participants With Any Adverse Event|Number of Participants With the Indicated Critical Adverse Events (CAEs)|Number of Participants With Negative or Unconfirmed Human Anti-human Antibodies (HAHA) in Which Concentrations of Ofa Were Below 500 Nanograms Per Milliliter (ng/ml)|Number of Participants With Abnormal Physical Examination Findings|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelet Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Erythrocyte Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hematocrit at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Hemoglobin Count at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Albumin at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Alkaline Phosphatase, Aspartate Aminotransferase (AST), and Alanine Transaminase (ALT) at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Bicarbonate, Glucose, Potassium, Sodium, and Urea at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP,Week 24 for the STP, and Week 0 for the IFUP) in Bilirubin and Creatinine at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP, Week 24 for the STP, and Week 0 for the IFUP) in Immunoglobins at Week 24 (FTP), Week 48 (STP), and Week 104 (IFUP)|Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Blood Pressure (BP) at Week 24 (FTP) and Week 48 (STP)|Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Pulse Rate at Week 24 (FTP) and Week 48 (STP)|Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Temperature at Week 24 (FTP) and Week 48 (STP)|Change From Baseline (Week 0 for the FTP and Week 24 for the STP) in Complement Activation (CH50) at Week 24 (FTP) and Week 48 (STP)","Number of the Indicated Types of Lesions (Ls) Assessed Per Magnetic Resonance Imaging (MRI)|Total Volume of T2 Lesions at Week 24 and Week 48|Ofa Drug Concentration After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) Intravenous (i.v.) Infusions|The Maximum Observed Plasma Concentration (Cmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions|The Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point (AUC(0-t)) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions|Time to Reach Cmax (Tmax) After the First (Visit 3), Second (Visit 4), Third (Visit 10), and Fourth (Visit 11) i.v. Infusions|Clearance of Ofa Over the Course of Weeks 0-2 and 24-26|The Volume of Distribution at Steady State (Vss) of Ofatumumab Over the Course of Weeks 0-2 and 24-26|Half Life (t1/2) of Ofatumumab in the Terminal Elimination Phase Over the Course of Weeks 0-2 and 24-26",True,2012-12-04
NCT04782466,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,"Physical Activity, Quality of Life and Disease Outcomes in Youth With Multiple Sclerosis: the ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program",ACTIVE_NOT_RECRUITING,2020-12-01,2025-09,2025-09,2025-09-23,2021-03-04,INTERVENTIONAL,NA,56.0,ESTIMATED,The Hospital for Sick Children,OTHER,Children's Hospital of Philadelphia|University of Alabama at Birmingham|Queen's University|National Multiple Sclerosis Society,OTHER|OTHER|OTHER|OTHER,Pediatric Multiple Sclerosis,Physical Activity|Exercise|Multiple Sclerosis|Demyelinating Disorders|Pediatric|Neurology|Children,United States,Birmingham,Alabama,3,Physical Activity (PA) Intervention|Waitlist attention-control,BEHAVIORAL|BEHAVIORAL,Physical Activity Level,Aerobic Capacity|Self-Reported PA Outcomes|Social Cognitive Theory Based Mediators of Physical Activity,False,
NCT05772637,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,UNKNOWN,2024-02-14,2025-02-14,2025-02-14,2024-02-20,2023-03-16,INTERVENTIONAL,NA,113.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Overactive Bladder,overactive bladder|multiple sclerosis|bladder sensations,France,Paris,Choisir Une Région,1,Repeated cystometries with bladder sensations assessment,PROCEDURE,bladder sensation ( area under the sensation-capacity curve (AUC)),bladder sensitivity,False,
NCT01532037,Self Help for Fatigue in Multiple Sclerosis,A Randomised Controlled Trial of Cognitive Behavioural Therapy Based Self Help for Fatigue in Multiple Sclerosis,COMPLETED,2012-06,2014-05,2014-05,2021-06-23,2012-02-13,INTERVENTIONAL,NA,73.0,ACTUAL,University of Edinburgh,OTHER,,,Multiple Sclerosis|Fatigue,Randomised controlled trial|Multiple Sclerosis|Fatigue|Cognitive Behavioural Therapy|Self Help,United Kingdom,Leven,Scotland,2,Cognitive behavioural therapy based self help|Treatment as usual,OTHER|OTHER,"Change from baseline on ratings of the Modified Fatigue Impact Scale at post measure, 3, 6 & 12 months follow up.","Change from baseline on the 36-Item Short Form Survey Instrument at post measure, 3, 6 and 12 months follow up.|Change from baseline on the Hospital Anxiety and Depression Scale at post measure, 3, 6 and 12 months follow up.|Change from baseline on the Self-Efficacy for managing chronic Disease 6 Item Scale at post measure, 3, 6 and 12 months follow up.",False,
NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMPLETED,2008-08,2012-04,2015-08,2016-07-07,2008-09-12,INTERVENTIONAL,PHASE3,1169.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,relapsing multiple sclerosis,United States,Phoenix,Arizona,193,Placebo|Teriflunomide,DRUG|DRUG,Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate,Core Treatment Period: Time to Disability Progression|Core Treatment Period: Time Without Relapse|Core Treatment Period: Change From Baseline to Week 48 in EDSS Total Score|Core Treatment Period: Change From Baseline to Week 48 in Fatigue Impact Scale (FIS) Total Score|Core Treatment Period: Change From Baseline to Last Visit in Fatigue Impact Scale (FIS) Total Score|Core Treatment Period: Change From Baseline to Week 48 in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores|Core Treatment Period: Change From Baseline to Last Visit in Short Form Generic Health Survey - 36 Items (SF-36) Summary Scores|Core Treatment Period: Overview of Adverse Events|Extension Treatment Period: Overview of Treatment Emergent Adverse Events (TEAE)|Extension Treatment Period: Time to Disability Progression|Extension Treatment Period: ARR: Poisson Regression Estimate,True,2013-06-26
NCT00813969,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,"A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2011-03,2014-01,2014-05,2016-03-30,2008-12-23,INTERVENTIONAL,PHASE1,24.0,ACTUAL,The Cleveland Clinic,OTHER,University Hospitals Cleveland Medical Center,OTHER,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,Mesenchymal Stem Cell|MSC|Autologous|Multiple Sclerosis,United States,Cleveland,Ohio,1,Autologous mesenchymal stem cell transplantation,BIOLOGICAL,"To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS",To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months,False,
NCT02230969,Plegridy Observational Program,Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program,COMPLETED,2014-11-12,2022-01-20,2022-01-20,2022-09-26,2014-09-03,OBSERVATIONAL,,1208.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,peginterferon|relapsing|pegylated|Subcutaneous|Injectable|Multiple Sclerosis,United States,Homewood,Alabama,152,peginterferon beta-1a,DRUG,Safety as measured by the incidence proportion of SAEs|Safety as measured by the incidence rate of SAEs|Clinical no evidence of disease activity (NEDA) as measured by the proportion of participants with no relapses|Clinical NEDA as measured by the proportion of participants with no disability progression,"Prescription and utilization patterns as measured by prescribed dosing frequency|Prescription and utilization patterns as measured by duration of Plegridy use|Prescription and utilization patterns as measured by the primary reason for discontinuation of Plegridy|Relapse activity as measured by annualized relapse rate (ARR)|Relapse activity as measured by time to first relapse|Relapse activity as measured by the proportion of participants with relapse|Relapse activity as measured by the distribution of the number of relapses|Disability progression as measured by the proportion of participants with sustained progression for at least six months|Disability progression as measured by the time to sustained disability progression for at least six months|Incidence proportion of non-serious AEs leading to treatment discontinuation|Incidence rate of non-serious AEs leading to treatment discontinuation|Impact of the severity of FLS on the ability to successfully manage symptoms via prophylaxis as measured by the participant-reported FLS-VAS|Changes in FLS assessment and FLS-VAS over time|Changes in EuroQoL EQ-5D, 3-level (EQ-5D-3L) score over time|Treatment adherence as measured by changes in adherence over time as reported in the treatment adherence questionnaires|Frequency of MS-related and non-MS-related physician visits, specialists' visits, use of physiotherapy, hospitalizations and lengths of stay, and emergency room/department visits",False,
NCT01384825,Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases,Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases,COMPLETED,2010-12,2012-09,2012-10,2018-01-16,2011-06-29,OBSERVATIONAL,,200.0,ACTUAL,Fondazione Italiana Sclerosi Multipla,OTHER,"Opera CRO, a TIGERMED Group Company",OTHER,Multiple Sclerosis|Neurodegenerative Diseases,Multiple Sclerosis|Other Neurodegenerative Diseases|Chronic CerebroSpinal Venous Insufficiency|Prevalence|Case-control,Italy,Ancona,,43,,,Prevalence of CCSVI,,False,
NCT00006060,Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis,,UNKNOWN,1999-04,,,2009-03-12,2000-07-06,OBSERVATIONAL,,100.0,,National Center for Research Resources (NCRR),NIH,University of Pennsylvania,OTHER,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,United States,New York,New York,1,standard gadolinium contrast,DRUG,,,False,
NCT00618527,Combination Therapy Using Cellcept and Rebif in RRMS,Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis,COMPLETED,2006-08,2012-05,2012-05,2012-11-15,2008-02-20,INTERVENTIONAL,EARLY_PHASE1,31.0,ACTUAL,Aaron Boster,OTHER,EMD Serono|Pfizer,INDUSTRY|INDUSTRY,Multiple Sclerosis,relapsing remitting multiple sclerosis|multiple sclerosis,United States,Columbus,Ohio,1,mycophenolate mofetil (Cellcept)|human interferon beta 1a (Rebif),DRUG|DRUG,mRNA for MxA gene levels,,False,
NCT04292717,Deficit-specific Training in Spinal Disorders,Precision Medicine in the Rehabilitation of Locomotor Function: Individual Gait Profiles for Deficit-specific Training Strategies in Spinal Disorders,RECRUITING,2021-01-01,2025-12-31,2025-12-31,2025-08-06,2020-03-03,INTERVENTIONAL,NA,56.0,ESTIMATED,University of Zurich,OTHER,Swiss National Science Foundation,OTHER,"Spinal Cord Injuries|Multiple Sclerosis|Gait Disorders, Neurologic|Training|Neurorehabilitation",,Switzerland,Zurich,,1,Gait training,BEHAVIORAL,Six minute walk test (6MWT),MS-patients: Expanded disability status scale (EDSS)|SCI-patients: ISNCSCI by the American Spinal Injury Association (ASIA protocol)|SCI-patients: Walking index for Spinal Cord Injury (WISCI II)|MS-/ SCI-patients: Six-minute walk test (6MWT)|MS-patients. Timed 25-foot walk (T25FW)|SCI-patients: Timed 10-meter walk test (10MWT)|MS-/ SCI-patients: Timed up and go test (TUG)|MS-/ SCI-patients: Kinematic measures on treadmill|MS-/ SCI-patients: Kinetic measures|MS-/ SCI-patients: Electromyographic measures|MS-/ SCI-patients: 12-item WS for walking function (questionnaire)|MS-/ SCI-patients: Time to swim 10m|MS-/ SCI-patients: Kinematic parameters of leg movements during swimming (activity sensors)|MS-/SCI-patients: Spinal Cord Independence Measure (SCIM-III)|MS-/ SCI-patients: Magnetic resonance imaging (MRI)|MS-/ SCI-patients: Magnetic resonance spectroscopy (MRS)|MS-/ SCI-patients: over ground gait kinematics during clinical walking tests (activity sensors),False,
NCT04926818,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,"A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension",ACTIVE_NOT_RECRUITING,2021-10-05,2027-03-02,2031-11-18,2025-07-08,2021-06-15,INTERVENTIONAL,PHASE3,129.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis (MS),relapsing multiple sclerosis|pediatric|relapse|EDSS|ofatumumab|siponimod|fingolimod|RMS|MS,United States,Little Rock,Arkansas,52,Fingolimod|Ofatumumab|Siponimod|Fingolimod placebo|Siponimod placebo|Ofatumumab placebo,DRUG|DRUG|DRUG|OTHER|OTHER|OTHER,Annualized relapse rate (ARR) in target pediatric participants,Annualized relapse rate (ARR) as compared to historical interferon β-1a data|Annualized T2 lesion rate|Neurofilament light chain (NfL) concentrations|Plasma Concentrations of ofatumumab|Plasma Concentrations of siponimod|Plasma Concentrations of siponimod metabolite (M17)|Percentage of participants with anti-ofatumumab antibodies|Number of adverse events and serious adverse events,False,
NCT05864846,A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex,"A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex",ACTIVE_NOT_RECRUITING,2023-06-29,2026-03-26,2026-03-26,2025-09-18,2023-05-18,INTERVENTIONAL,PHASE4,79.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex Associated Neuropsychiatric Disease,Seizures|Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND)|Epidiolex|Epidyolex|GWP42003-P|JZP926|TSC Associated Neuropsychiatric Disorders|Cannabidiol|Behavior,United States,Aurora,Colorado,19,Cannabidiol Oral Solution [Epidiolex],DRUG,"Change in the most problematic behavior Numerical Rating Score (NRS) score within the TAND-SQ|Change in Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders Self-report, Quantified Checklist (TAND-SQ) score|Change in Aberrant Behavior Checklist (ABC) score|Change in Child Behavior Checklist (CBCL) score|Change in Adult Behavior Checklist (ABCL) score|Change in Adult Self-Report (ASR) score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) domains score|Change in sleep characteristics using the Children's Sleep Habits Questionnaire (CSHQ)|Change in sleep characteristics using the Pittsburgh Sleep Quality Index (PSQI)|Change in executive function using Behavior Rating Inventory of Executive Function (BRIEF)|Change in caregiver-reported assessment of Quality of Life (QOL) using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM)|Change in caregiver-reported assessment of family functioning using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM)|Change in assessment of QOL using Pediatric Quality of Life Inventory (PedsQL)|Change in caregiver impression of overall severity of symptoms (behavior and seizure control) using the Caregiver Global Impression of Severity (CareGI-S)|Change in participant impression of overall severity of symptoms (behavior and seizure control) using the Patient Global Impression of Severity (PGI-S)|Change in clinician impression of overall severity of symptoms (behavior and seizure control) using the Clinician Global Impression of Severity (CGI-S)|Retention Rate|Number of participants considered treatment responders|Change in number of seizure-free days|Number of participants experiencing a worsening, no change, or improvement in seizure frequency|Change in ideation score per the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change in number of suicide attempts per the C-SSRS|Change in ideation score per the Children's C-SSRS|Change in number of suicide attempts per the Children's C-SSRS|Number of participant inpatient hospitalizations due to epilepsy|Number of withdrawals due to Treatment Emergent Adverse Events (TEAEs)",,False,
NCT04863586,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,Prevalence of Coronavirus Disease 2019 in People With Multiple Sclerosis Taking Disease Modifying Therapies in England,UNKNOWN,2021-04-01,2021-10-31,2022-05-31,2021-04-28,2021-04-28,OBSERVATIONAL,,14240.0,ESTIMATED,Nottingham University Hospitals NHS Trust,OTHER,,,Covid19|Multiple Sclerosis,Covid19|Multiple sclerosis|Disease modifying therapies,United Kingdom,Nottingham,Nottinghamshire,1,,,Prevalence of testing positive for SARS-CoV-2 in people with MS taking DMTs,Clinical outcomes of COVID-19 among people with MS taking DMTs|Risk of contracting COVID-19 associated with individual DMTs/other clinical and paraclinical factors|Association between clinical outcomes of COVID-19 and individual DMTs/other clinical and paraclinical factors,False,
NCT02141386,Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis,"Plasticity-based, Adaptive, Computerized Cognitive Remediation Treatment (PACR) for Adults With Multiple Sclerosis (MS)",UNKNOWN,2013-09,2015-09,,2015-11-20,2014-05-19,INTERVENTIONAL,NA,136.0,ESTIMATED,Stony Brook University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,"Multiple Sclerosis|Cognitive remediation|Plasticity-based, adaptive, computerized cognitive remediation|Cognitive impairment",United States,Stony Brook,New York,1,"PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)",OTHER,A composite derived from a standardized battery of neuropsychological tests,A timed measure based on direct observation of functional performance,False,
NCT02099370,Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients,A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.,COMPLETED,2014-03,2016-01,2016-01,2020-04-03,2014-03-28,OBSERVATIONAL,,34.0,ACTUAL,University of South Florida,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Tecfidera(R)|Oral medication|Adherence,United States,Tampa,Florida,1,,,adherence rates to Tecfidera,,False,
NCT01080573,Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis,A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes,COMPLETED,2007-01,2011-04,2011-04,2014-07-31,2010-03-04,OBSERVATIONAL,,1257.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Rebif|Interferon beta-1a,United Kingdom,Harlow,Essex,1,,,Discontinuation of Rebif treatment (yes or no),,False,
NCT03134794,Medical Education for Better Multiple Sclerosis Outcomes,Decision Making Under Uncertainty in MS Care: an Innovative Educational Intervention Applying Concepts From Neuroeconomics,COMPLETED,2017-03-22,2018-10-30,2018-10-30,2020-10-19,2017-05-01,INTERVENTIONAL,NA,90.0,ACTUAL,Unity Health Toronto,OTHER,Roche Pharma AG,INDUSTRY,Multiple Sclerosis,neuroeconomics|multiple sclerosis|educational intervention|traffic light system|aversion to ambiguity|risk|outcomes|knowledge|action|gaps|disease modifying agents,Argentina,Buenos Aires,Buenos Aires F.D.,4,Educational intervention applying the traffic light system (TLS),BEHAVIORAL,Feasibility of the educational intervention|The proportion of participants who exhibit therapeutic inertia|Pupil dilation from baseline (Primary outcome of the study conducted in Canada),Efficacy of the educational intervention|Scale (based on the experiment on ambiguity aversion)|Scale (physician reaction to uncertainty),False,
NCT01377870,Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis,Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis,COMPLETED,2011-12,2014-03,2014-04,2018-03-07,2011-06-21,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,Royan Institute,OTHER_GOV,,,Multiple Sclerosis,multiple sclerosis mesenchymal stem cell intravenous injection,Iran,Tehran,,1,intravenous injection of mesenchymal stem cells|injection of cell free media,BIOLOGICAL|BIOLOGICAL,MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC,quality of life|RAO Test|intravenous cell transplantation,False,
NCT06164483,Auditory Functions in Patients With Multiple Sclerosis,Electrophysiological Studies of Auditory Functions and CSF Analyses in Patients With Multiple Sclerosis,RECRUITING,2023-10-01,2024-12-30,2025-12-30,2024-05-08,2023-12-11,OBSERVATIONAL,,30.0,ESTIMATED,University of Catania,OTHER,Hannover Medical School,OTHER,Multiple Sclerosis|Hearing Disorders,,Italy,Catania,Sicily,1,Auditory test|CSF sampling,DIAGNOSTIC_TEST|OTHER,Auditory functions and correlation with CSF findings,,False,
NCT04607174,Voluntary Activation During Isokinetic Contractions in Subjects with Neuromotor Disorders,Measuring Voluntary Activation of the Quadriceps Femoris During Isokinetic Concentric Contractions with the Interpolated Twitch Technique (ITT) in Subjects with Neuromotor Disorders,RECRUITING,2020-10-07,2024-12-31,2024-12-31,2024-10-24,2020-10-29,INTERVENTIONAL,NA,20.0,ESTIMATED,Istituto Auxologico Italiano,OTHER,,,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Knee Impairment,voluntary activation|lower limb|interpolated twitch technique|rehabilitation,Italy,Milan,MI,1,Pathologic group,OTHER,Voluntary Activation,,False,
NCT05654818,Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects,"Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects: Randomized, Single-center, Double-blind Trial",COMPLETED,2023-04-13,2023-10-10,2023-10-10,2024-05-14,2022-12-16,INTERVENTIONAL,NA,56.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Vitamin d Deficiency,Multiple sclerosis|Immunomodulation|lymphocyte subset,France,Nîmes,,1,Vitamin D|Placebo,DRUG|DRUG,Change in Lymphocyte T CD4+ cells since baseline|Change in T helper1 (Th1) Lymphocyte T CD4+ cells since baseline|Change in Th1*Lymphocyte T CD4+ cells since baseline|Change in naive Lymphocyte T CD4+ cells since baseline|Change in effector memory Lymphocyte T CD4+ cells since baseline|Change in central memory Lymphocyte T CD4+ cells since baseline|Change in Teffector memory RA+ Lymphocyte T CD4+ cells since baseline|Change in FOXP3 Treg / Treg Lymphocyte T CD4+ cells since baseline|Change in naive Treg Lymphocyte T CD4+ cells since baseline|Change in memory Treg Lymphocyte T CD4+ cells since baseline|Change in Tr1 Lymphocyte T cells CD4+ since baseline|Change in Lymphocyte T CD8+ cells since baseline|Change in naive Lymphocyte T CD8+ cells since baseline|Change in effector memory Lymphocyte T CD8+ cells since baseline|Change in central memory Lymphocyte T CD8+ cells since baseline|Change in Teffector memory RA+ Lymphocyte T CD8+ cells since baseline|Change in Tc1 Lymphocyte T CD8+ cells since baseline|Change in Tc1* Lymphocyte T CD8+ cells since baseline|Change in Tc2 Lymphocyte T CD8+ cells since baseline|Change in Tc17 Lymphocyte T CD8+ cells since baseline|Change in CD8 Tcreg / TcReg Lymphocyte T CD8+ cells since baseline|Change in naive Tcreg Lymphocyte T CD8+ cells since baseline|Change in memory Tcreg Lymphocyte T CD8+ cells since baseline|Change in Lymphocyte B cells since baseline,lymphocyte subpopulations change in CD6 phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CD162 phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CD226 phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CD46 phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CD11a phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CD49d phenotype after 3 months of high dose vitamin D treatment or placebo|lymphocyte subpopulations change in CLA phenotype after 3 months of high dose vitamin D treatment or placebo|Change in production of cytokine IL-10 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo|Change in production of cytokine IFNg in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo|Change in production of cytokine IL-17 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo|Change in plasma Vitamin D levels 3 months after baseline of high dose Vitamin D treatment versus placebo|Change in 16sRNA levels 3 months after baseline of high dose Vitamin D treatment versus placebo|Nature of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo|Nature of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo|Percentage of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo|Percentage of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo|Diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo|Diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo|Beta diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo|Beta diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo|Describing the genetic determinants of vitamin D response using a Single Nucleotide Polymorphism (SNP) database,False,
NCT01116427,A Cooperative Clinical Study of Abatacept in Multiple Sclerosis,"A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis",COMPLETED,2010-09,2014-06,2015-02,2016-09-15,2010-05-05,INTERVENTIONAL,PHASE2,65.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Immune Tolerance Network (ITN),NETWORK,"Multiple Sclerosis, Relapsing-Remitting",MS|multiple sclerosis|relapsing-remitting multiple sclerosis|RRMS,United States,Phonix,Arizona,21,abatacept|Placebo,BIOLOGICAL|DRUG,Mean Number of New Inflammatory MRI Lesions Per Monthly Scans,Absolute Number of New Inflammatory MRI Lesions on Monthly Scans|Lesion Volume Accumulation on T2-weighted MRI Scans Over 24 Weeks|Percent Brain Volume Change|Mean Number of New Inflammatory Lesions in 8-week Intervals|Number of Participants Progressing on the EDSS Scale by at Least 1 Point|Annualized Relapse Rate|Mean Change in the MSFC Over 24 Weeks of Treatment|Mean Number of New Inflammatory MRI Lesions Per Scan During the Extension Phase|Lesion Volume Accumulation on T2-Weighted MRI Scans Between 24 Weeks and 52 Weeks|Percent Brain Volume Change Between 24 Weeks and 52 Weeks|Number of Participants Progressing on the EDSS Scale by at Least 1 Point|Annualized Relapse in Extension Phase|Mean Change in the MSFC in Extension Phase,True,2016-04-08
NCT04578262,Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo,Epley Manoeuvre for Posterior Semi-circular Canal Benign Paroxysmal Positional Vertigo in People With Multiple Sclerosis: Protocol of a Randomized Controlled Trial,UNKNOWN,2020-11-01,2022-02,2022-03,2020-10-08,2020-10-08,INTERVENTIONAL,NA,80.0,ESTIMATED,University of Seville,OTHER,,,Benign Paroxysmal Positional Vertigo|Multiple Sclerosis,Multiple Sclerosis|Benign Paroxysmal Positional Vertigo|Epley Manoeuvre|Vertigo|Dizziness,,,,0,Epley Manoeuvre|Sham Manoeuvre,PROCEDURE|PROCEDURE,Changes in the conversion of a positive to a negative Dix Hallpike Test,Impact of dizziness in the quality of life in participants with Multiple Sclerosis. Dizziness Handicap Inventory (DHI).|Independency in activities of daily living measure by Vestibular Disorders Activities of Daily Living Scale (VADL).,False,
NCT03691766,Photobiomodulation Therapy in Persons With Multiple Sclerosis,Effect of Photobiomodulation Therapy on Muscle Function and Inflammation in Persons With Multiple Sclerosis,COMPLETED,2018-04-30,2019-09-23,2019-09-23,2021-02-26,2018-10-02,INTERVENTIONAL,NA,21.0,ACTUAL,Marquette University,OTHER,"University of Wisconsin, Milwaukee",OTHER,"Multiple Sclerosis, Relapsing-Remitting",,United States,Milwaukee,Wisconsin,1,Photobiomodulation Therapy|Placebo,OTHER|OTHER,Muscle Fatigue,Systemic Inflammation,False,
NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project,COMPLETED,2013-04-25,2023-06-13,2023-06-13,2023-08-28,2017-06-26,OBSERVATIONAL,,220.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,San Diego,California,2,Teriflunomide (HMR1726),DRUG,Rate of major structural defects in live born infants,"Proportion of major structural defects in all pregnancies|Specific pattern of 3 or more minor structural defects in live born infants receiving the exam|Rate of spontaneous abortion|Rate of preterm delivery|Proportion of infants who are small for gestational age (less than or equal to the 10th percentile for gestational age and sex) on weight, length, or head circumference|Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation",False,
NCT02517788,Phase I BP Interferon (IFN) Beta-004,Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects,COMPLETED,2006-05,2006-07,2006-07,2015-08-10,2015-08-07,INTERVENTIONAL,PHASE1,24.0,ACTUAL,Centre Hospitalier Universitaire Vaudois,OTHER,BioPartners GmbH,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,,,,0,Interferon beta-1a HSA-free biosimilar|Interferon beta-1a HSA+ biosimilar|Interferon beta-1a original,DRUG|DRUG|DRUG,Composite of interferon beta-1a PK parameters,Serum concentration of neopterin (PD marker)|Number of participants with adverse events (AE)/serious adverse event (SAE) as a measure of safety and tolerability|Composite of local reactions as a measure of local tolerance|Composite of clinical laboratory tests as a measure of safety and tolerability|Composite of vital signs as a measure of safety and tolerability|Sickness behavior assessment|Electrocardiogram (ECG) as a measure of safety and tolerability,False,
NCT05344469,A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis,"A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) in Patients With Relapsing Multiple Sclerosis [AIOLOS]",ACTIVE_NOT_RECRUITING,2022-05-10,2026-12-31,2026-12-31,2025-01-14,2022-04-25,OBSERVATIONAL,,564.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|RMS|NIS|ofatumumab,Germany,Hettingen,Baden-Wurttemberg,90,ofatumumab|glatiramer acetate|interferon β1,OTHER|OTHER|OTHER,Proportion of patients who continue to receive their first-line treatment,Proportion of patients who continue to receive their first-line treatment|Impact of first-line treatment on health economy|Fatigue Symptoms and Impact Questionnaire-RMS|Patient Health Questionnaire 8 [PHQ-8]|Generalized Anxiety Disorder Scale 7 [GAD-7]|MS Treatment Concerns Questionnaire [MSTCQ]|Expanded disability status scale (EDSS)|Time to onset of confirmed disability progression (CDP)|Proportion of patients with confirmed disability progression (CDP)|Time to onset of confirmed disability improvement (CDI)|Proportion of patients with CDI|T1 Gd-enhancing lesions per brain|Annualized T2 lesion rate|Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator.|Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs|Annualized relapse rate|Time to first relapse|Proportion of relapse free patients|Number of patients and reasons for discontinuation of treatment|Proportion of patients who continue to receive their subsequent treatment|Reasons for and number of treatment interruptions per patient|Duration of treatment interruptions per patient|Number of patients with treatment interruptions|Proportion of drug-related adverse events (AEs)|Persistence of drug-related adverse events (AEs)|Specific safety assessment of injection related AEs|Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons|Presence of spinal cord lesions,False,
NCT07037966,Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI,Truly Portable MRI for Extremity and Brain Imaging Anywhere & Everywhere,NOT_YET_RECRUITING,2025-10,2026-09,2026-09,2025-09-23,2025-06-26,INTERVENTIONAL,NA,50.0,ESTIMATED,Instituto de Investigacion Sanitaria La Fe,OTHER,"National Research Council, Spain",OTHER_GOV,Multiple Sclerosis,multiple sclerosis|MRI|Brain Imaging,Spain,Valencia,Valencia,1,MRI|MRI,DEVICE|DEVICE,Radiological reports to Evaluate NextMRI prototype performance,Patient Comfort and Satisfaction Questionnaire to Evaluate the New NextMRI Prototype Compared to the Standard MRI Scanner|User Comfort and Satisfaction Questionnaire Evaluate the New NextMRI Prototype Compared to the Standard MRI Scanner,False,
NCT05546424,EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis,EMRESERVA A Program to Enhace Cognitive Reserve in Patients With Multiple Scleorisis,COMPLETED,2022-05-19,2023-11-30,2023-11-30,2024-02-07,2022-09-19,OBSERVATIONAL,,58.0,ACTUAL,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,OTHER,,,Cognitive Change,,Spain,Seville,Andalusia,1,EMRESERVA,BEHAVIORAL,Change in Symbol Digit modality test,Change in Trail Making Test form A and B|Change in BRB-N subtest|Change in Wechsler Intelligence Scale Vocabulary subtest (WAIS IV) mean scores at 6 and Change in Wechsler Intelligence Scale Vocabulary subtest (WAIS IV) mean scores at 6 and Change in Wechsler Intelligence Scale Vocabulary subtest|Change in Work memory index (WAIS)|Change in Tower of London test|Change in Phonetic and semantic fluencies|Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire|Change in Beck depression/anxiety questionnaires|Change in MFIS-5|Change in Perceived Deficit Questionnaire (PDQ-5),False,
NCT00348296,Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis,"A Randomized, Double-blind, Placebo-controlled Multi-center Study of GB-0998 for Treatment of Systemic Sclerosis",COMPLETED,2006-07,2009-07,2009-07,2010-07-30,2006-07-04,INTERVENTIONAL,PHASE3,60.0,ESTIMATED,Benesis Corporation,INDUSTRY,,,"Scleroderma, Systemic","Scleroderma, Systemic",Japan,Nagasaki,Nagasaki,1,High-dose intravenous immunoglobulin (Venoglobulin-IH),DRUG,Changes in TSS at 12 weeks,"Changes in joint motion, oral aperture, active hand spread, fingertip-to-palm distance, health assessment questionnaire, histological analysis of dermal section at 12 weeks.; Adverse events and laboratory test.",False,
NCT02980042,Safety of Switching From Rituximab to Ocrelizumab in MS Patients,Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis,COMPLETED,2017-01-01,2019-03-06,2019-03-06,2021-07-21,2016-12-02,INTERVENTIONAL,PHASE3,200.0,ACTUAL,"University of Colorado, Denver",OTHER,,,Multiple Sclerosis,,United States,Aurora,Colorado,1,Ocrelizumab|Rituximab,DRUG|DRUG,Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups|Difference in the Total Number of IRRs After Each Infusion of Ocrelizumab Compared to Rituximab Infusions in the Comparator Group.|Severity of IRRs Following the Day 1 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions|Severity of IRRs Following the Day 15 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions|Severity of IRRs Following the Week 24 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions|Proportion of Patients With an IRR at Day 1 Versus Day 15 and Week 24 Infusions,Presence of Ocrelizumab Anti-drug Anti-bodies|Presence of Rituximab Anti-drug Anti-bodies|B Cell Depletion (CD19)|B Cell Depletion (CD20)|Cytokine: Eotaxin - Pre-Post Infusion - Day 1|Cytokine: IFN-gamma - Pre-Post Infusion - Day 1|Cytokine: IL-10 - Pre-Post Infusion - Day 1|Cytokine: IL-12/IL-23p40 - Pre-Post Infusion - Day 1|Cytokine: IL-16 - Pre-Post Infusion - Day 1|Cytokine: IL-1RA - Pre-Post Infusion - Day 1|Cytokine: IL-27 - Pre-Post Infusion - Day 1|Cytokine: IL-6 - Pre-Post Infusion - Day 1|Cytokine: IL-7 - Pre-Post Infusion - Day 1|Cytokine: IL-8(HA) - Pre-Post Infusion - Day 1|Cytokine: MCP-1 - Pre-Post Infusion - Day 1|Cytokine: MDC - Pre-Post Infusion - Day 1|Cytokine: MIP-1alpha - Pre-Post Infusion - Day 1|Cytokine: MIP-1beta - Pre-Post Infusion - Day 1|Cytokine: MIP-3alpha - Pre-Post Infusion - Day 1|Cytokine: TARC - Pre-Post Infusion - Day 1|Cytokine: TNF-alpha - Pre-Post Infusion - Day 1|Cytokine: Exotaxin - Pre-Post Infusion - Day 15|Cytokine: IFN-gamma - Pre-Post Infusion - Day 15|Cytokine: IL-10 - Pre-Post Infusion - Day 15|Cytokine: IL-12/IL-23p40 - Pre-Post Infusion - Day 15|Cytokine: IL-16 - Pre-Post Infusion - Day 15|Cytokine: IL-1beta - Pre-Post Infusion - Day 15|Cytokine: IL-7 - Pre-Post Infusion - Day 15|Cytokine: IL-8 - Pre-Post Infusion - Day 15|Cytokine: MCP-1 - Pre-Post Infusion - Day 15|Cytokine: MCP-4 - Pre-Post Infusion - Day 15|Cytokine: MDC - Pre-Post Infusion - Day 15|Cytokine: MIP-1beta - Pre-Post Infusion - Day 15|Cytokine: MIP-3alpha - Pre-Post Infusion - Day 15|Cytokine: TNF-alpha - Pre-Post Infusion - Day 15,True,2020-01-14
NCT05266469,Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf,Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region,COMPLETED,2022-07-26,2024-11-11,2024-11-11,2025-07-09,2022-03-04,OBSERVATIONAL,,168.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|RMS|NIS|Gulf Region|Ofatumumab|Ocrelizumab,United Arab Emirates,Al Ain Abu Dhabi,United Arab Emirates,6,Ofatumumab|Ocrelizumab,OTHER|OTHER,Expanded Disability Status Scale (EDSS)|Magnetic Resonance Imaging (MRI) activity|Volume of T2 lesions|Number of relapses in the past 12 months|Baseline ARR (Annualized Relapse Rates)|Time since MS diagnosis|Time since first MS symptom|Percentage of participants with previous DMTs|Time from diagnosis to start of treatment|Number of previous DMT treatment|Line of previous DMT treatment|Type of previous DMT|Percentage of participants with comorbidities|Percentage of participants by number of comorbidities|Percentage of smoking participants|Percentage of alcohol intake participants|Percentage of patients by employment status|Percentage of participants by monthly income|Percentage of participants by educational level|Percentage of participants by ethnicity|Percentage of patients by frequency preference|Percentage of patients by route of administration|Percentage of participants by type of coverage,Treatment Satisfaction Questionnaire for Medicines (TSQM)|Total number of visits|Number of visits to clinics|Reason for out patient department (OPD) visit|Number and reason of ER visits|Number and reason of hospitalizations|Length of hospital stay|proxy costs for each visit,False,
NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,"A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2010-09-13,2018-10-19,2018-10-19,2021-04-21,2010-09-14,INTERVENTIONAL,PHASE3,4125.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,Fingolimod|FTY720|Relapsing forms of MS|Multiple Sclerosis|Efficacy,United States,Cullman,Alabama,458,Fingolimod,DRUG,"Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death",Part I: Aggregate Annualized Relapse Rates (ARR) From First Dose of Fingolimod|Part I: Number of Participants With Relapses (Confirmed and Unconfirmed) From First Dose of Fingolimod|Part I: Annualized Rates of New or Newly Enlarging T2 Lesions (ARneT2) Compared With First Dose of Fingolimod|Part I: Change From First Dose of Fingolimod in Total T2 Lesions Volume|Part I: Change From First Dose of Fingolimod in Total T1 Hypointense Lesions Volume|Part I: Percent Brain Volume Change (PBVC) Relative to First Dose of Fingolimod|Part I: Annualized Rate of Brain Atrophy (ARBA) Relative to First Dose of Fingolimod|Part I: Number of Participants With Confirmed 6-month Disability Progression After First Dose of Fingolimod|Part I: Number of Participants With Categorized Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS) Overall Score|Part I: Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS),True,2019-11-07
NCT03025269,Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis,"Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis",COMPLETED,2017-11-15,2022-01-08,2022-01-08,2022-03-11,2017-01-19,OBSERVATIONAL,,30.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,Ocrelizumab,DRUG,Absolute cortical atrophy 12|Percent change cortical atrophy 12|Absolute cortical atrophy 24|Percent cortical atrophy 24|Absolute thalamic atrophy 12|Percent thalamic atrophy 12|Absolute thalamic atrophy 24|Percent thalamic atrophy 24|Inflammation foci 12|Inflammation foci 24,SDMT score 12|SDMT 24|Memory 12|Memory 24|Verbal learning 12|Verbal learning 24,False,
NCT01067573,The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment,The Role of Leptin Levels in Multiple Sclerosis,COMPLETED,2009-12,,2011-07,2012-06-18,2010-02-11,OBSERVATIONAL,,20.0,ACTUAL,University of South Florida,OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis,MS|Serum Leptin Levels during relapse|Multiple sclerosis|relapse,United States,Tampa,Florida,1,,,Fasting leptin and nitric oxide testing,,False,
NCT07083856,Effects of Reiki and Self-Acupressure Applications,Comparison of the Effects of Reiki and Self-Acupressure Applications on Functionality and Quality of Life in Patients With Multiple Sclerosis: A Randomized Controlled Trial,RECRUITING,2025-04-20,2025-07-20,2025-09-20,2025-07-24,2025-07-24,INTERVENTIONAL,NA,50.0,ESTIMATED,Firat University,OTHER,,,Multiple Sclerosis,Reiki|Self-Acupressure|Functionality|Quality of Life,Turkey (Türkiye),Muğla,Fethi̇ye,1,Reiki|Self-Acupressure,BEHAVIORAL|BEHAVIORAL,The Multiple Sclerosis Quality of Life|The Multiple Sclerosis Functional Composite,,False,
NCT02433028,Swiss Multiple Sclerosis Cohort-Study,Swiss Multiple Sclerosis Cohort-Study: A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options,RECRUITING,2012-06,2042-01,2042-01,2025-04-14,2015-05-04,OBSERVATIONAL,,1200.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,"Cantonal Hospital of Aarau, Switzerland|Cantonal Hospital of St. Gallen|Insel Gruppe AG, University Hospital Bern|Regional Hospital Lugano (EOC), Switzerland|University Hospital, Geneva|University of Lausanne Hospitals|National Multiple Sclerosis Society",OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER|OTHER,Multiple Sclerosis,MS key phases of disease evolution|MS New Treatment Options,Switzerland,Aarau,Canton of Aargau,8,,,"Assessment of Expanded Disability Status Scale (EDSS)|Assessment of the quality of life|Collection of serum and plasma (and, optional) cerebrospinal fluid samples|(Optional) Assessment of finger dexterity|(Optional) Electrophysiological assessment|(Optional) Laboratory tests|(Optional) Magnetic resonance imaging",,False,
NCT03850301,Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target,An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis,RECRUITING,2018-01-01,2025-01-31,2025-01-31,2024-10-15,2019-02-21,INTERVENTIONAL,NA,44.0,ESTIMATED,Imperial College London,OTHER,,,Multiple Sclerosis,,United Kingdom,London,England,1,XBD173|Etifoxine,DRUG|DRUG,Monocyte phenotye - Tissue necrosis factor-α|Monocyte phenotye - Interferon-γ|Monocyte phenotype - Interleukins- 1β|Monocyte phenotype - Interleukins- 16|Monocyte phenotype - Interleukins- 17|Monocyte phenotype - Interleukins- 23|Immunomodulatory factor -Transforming growth factor-β|Immunomodulatory factor - Interleukins -4|Immunomodulatory factor - Interleukins - 10|Relative proportions of WBC subsets,Monocyte phenotype - 'omic analyses|Neurofilament,False,
NCT03951181,Life-Style Exercise and Activity Package for People Living With Progressive MS,A Single-Arm Feasibility Study of the Life-Style Exercise and Activity Package for People Living With Progressive Multiple Sclerosis,COMPLETED,2020-08-13,2021-04-19,2021-04-19,2021-07-02,2019-05-15,INTERVENTIONAL,NA,21.0,ACTUAL,Cardiff University,OTHER,,,Multiple Sclerosis,,United Kingdom,Cardiff,,1,LEAP-MS,BEHAVIORAL,Recruitment rate|Retention rate|Intervention uptake|Costs associated with intervention delivery|Incidence of Treatment-Emergent Adverse Events|Acceptability assessment (process evaluation)|Fidelity of intervention delivery,,False,
NCT03836300,Parent and Infant Inter(X)Action Intervention (PIXI),Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,ENROLLING_BY_INVITATION,2018-11-30,2026-06-30,2026-12-31,2025-07-31,2019-02-11,INTERVENTIONAL,NA,120.0,ESTIMATED,RTI International,OTHER,"University of North Carolina, Chapel Hill",OTHER,Fragile X Syndrome|Angelman Syndrome|Prader-Willi Syndrome|Dup15Q Syndrome|Duchenne Muscular Dystrophy|Phelan-McDermid Syndrome|Rett Syndrome|Smith Magenis Syndrome|Williams Syndrome|Turner Syndrome|Klinefelter Syndrome|Chromosome 22q11.2 Deletion Syndrome|Tuberous Sclerosis|Down Syndrome,Early intervention|Parent-Child interaction|Rare Neurogenetic Conditions|Intellectual and Developmental Disabilities,United States,Research Triangle Park,North Carolina,1,Parent-Infant Inter(X)action Intervention (PIXI),BEHAVIORAL,Social Validity and Acceptability|Social Validity and Acceptability|Fidelity|Fidelity,Parent Implementation and Engagement|Early Developmental Outcomes|Autism Symptoms|Autism Symptoms|Autism Symptoms|Autism Symptoms|Autism Symptoms,False,
NCT07166809,The Effect of DNS-Based Training Combined With PFMT on LUTS and Pelvic Floor Functions in Women With MS,The Effect of Dynamic Neuromuscular Stabilization-Based Training Combined With Pelvic Floor Muscle Training on Lower Urinary Tract Symptoms and Pelvic Floor Functions in Women With Multiple Sclerosis,COMPLETED,2023-09-01,2024-09-27,2025-08-27,2025-09-10,2025-09-10,INTERVENTIONAL,NA,24.0,ACTUAL,Ondokuz Mayıs University,OTHER,The Scientific and Technological Research Council of Turkey,OTHER,Women With Multiple Sclerosis|Multiple Sclerosis|Lower Urinary Track Symptoms|Pelvic Floor Disorder,Multiple sclerosis|Lower urinary tract symptoms|Pelvic floor muscle training|stabilization|Dynamic neuromuscular stabilization,Turkey (Türkiye),Samsun,Samsun,1,Pelvic Floor Muscle Training (PFMT)|Pelvic Floor Muscle Training combined with Dynamic Neuromuscular Stabilization (PFMT+DNS),OTHER|OTHER,Lower urinary tract symptoms (LUTS) severity|Urinary incontinence severity and impact on quality of life|Overactive bladder symptoms|Objective urinary flow parameters|Pelvic Floor Muscle Function - Vaginal Palpation|Pelvic floor muscle function - Electromyography (EMG),Diaphragm Function - Magnetic Resonance Imaging (MRI)|Perceived level of improvement - Global Perceived Effect Scale (GPE)|Treatment adherence - Visual Analog Scale (VAS),False,
NCT00202995,Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS,"A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients",TERMINATED,2004-07,2007-10,2007-10,2010-10-18,2005-09-20,INTERVENTIONAL,PHASE4,91.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,Glatiramer Acetate|Betaseron|Rebif,DRUG|DRUG|DRUG,The primary objective of the study is to compare the total number of confirmed relapses experienced by patients randomized to maintain treatment on high dose IFN therapy compared to those who were switched to Copaxone® treatment.,,False,
NCT04964336,An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis,Decoding the B Cell Response in Multiple Sclerosis,UNKNOWN,2018-02-05,2024-12,2024-12,2021-07-16,2021-07-16,OBSERVATIONAL,,40.0,ESTIMATED,University of Oslo,OTHER,,,Multiple Sclerosis,,Norway,Lørenskog,,2,Analysis of B cells,OTHER,The transcriptome of B cells from blood and cerebrospinal fluid|The immunglobulin receptors of B cells from blood and cerebrospinal fluid,,False,
NCT06415864,Oral Cladribine B-cell Study,Oral Cladribine B-cell Study,COMPLETED,2019-07-01,2024-01-31,2024-01-31,2024-05-16,2024-05-16,OBSERVATIONAL,,10.0,ACTUAL,Queen Mary University of London,OTHER,,,Multiple Sclerosis,MS,United Kingdom,London,,1,,,To study B cells subsets changes,Changes in OCBs and free immunoglobulin kappa and lambda light chain levels (FLC)|Measure of CXCL-13 and urine markers of inflammation (neopterin)|Measure of Neurofilament light chain (NFL)|Measure of soluble CD138|Measure of cytokines and chemokines,False,
NCT06955832,Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI,Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI: A Cross-sectional Study,RECRUITING,2025-06,2025-06,2025-10,2025-05-18,2025-05-02,OBSERVATIONAL,,30.0,ESTIMATED,Benha University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cortical lesions|MRI|Early diagnosis|McDonald criteria,Egypt,Banhā,Qalyubia Governorate,3,,,Number and classification of cortical lesions,,False,
NCT03363763,Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex,Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label,TERMINATED,2017-04-12,2023-03-24,2023-03-24,2023-03-30,2017-12-06,INTERVENTIONAL,PHASE2,24.0,ACTUAL,"Aucta Pharmaceuticals, Inc",INDUSTRY,,,Angiofibroma of Face|Tuberous Sclerosis,rash|fibroma|skin|facial|face|bumps|redness|erythema|lesions|papules|blood vessel|cheeks,United States,Phoenix,Arizona,8,Sirolimus 0.2%|Sirolimus 0.4%|Placebo ointment,DRUG|DRUG|DRUG,The proportion of subjects with a clinical response of treatment success.,The proportion of subjects with at least 30% improvement at Week 12 as compared to Baseline in the Facial Angiofibromas Severity Index (FASI) score.|The time to reach at least 30% improvement from Baseline in the Facial Angiofibromas Severity Index (FASI) score|The proportion of subjects with at least 2-grade improvement as compared to Baseline in categorical lesion counts|The proportion of subjects with at least 2-grade improvement as compared to Baseline in lesion elevation score|The proportion of subjects with at least 2-grade improvement as compared to Baseline in the subject self-assessment survey|The proportion of subjects with an investigator assessed IGA score of clear or almost clear with at least a 2-grade improvement on the Week 12 IGA of the facial skin lesions|Overall response of angiofibroma assessed by the investigator at Week 12 as compared to baseline based on Modified Nobel Scoring System|Overall response of angiofibroma assessed by the IRC at Week 12 compared to baseline based on Modified Nobel Scoring System|The proportion of subjects with at least Moderate Improvement on Modified Nobel Scoring System assessed by the investigator at Week 12|The proportion of subjects with at least Moderate Improvement on Modified Nobel Scoring System assessed by the IRC at Week 12|The proportion of subjects with at least a 2-grade improvement on the Week 12 Investigator Global Assessment (IGA) of the facial skin lesions assessed by the IRC,False,
NCT05414487,Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases,Exploring the Effects of B Cell Depletion With Ofatumumab on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases - a Prospective Observational Study,UNKNOWN,2022-10-15,2023-12-01,2024-06-01,2022-10-20,2022-06-10,OBSERVATIONAL,,34.0,ESTIMATED,Tianjin Medical University General Hospital,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Demyelinating Diseases of the Central Nervous System,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Demyelinating Diseases|Ofatumumab|Meningeal Lymphatic Drainage,China,Tianjin,Tianjin Municipality,1,Ofatumumab,DRUG,Change from baseline in Time to Peak (TTP) of the meningeal lymphatic vessels in superior sagittal sinus (mLVs-SSS) to the end of study.,Immune cells landscape over time|Adjudicated On-trial Annualized Relapse Rate (ARR)|Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score From Baseline to the end of study|Percentage of participants with new lesions by MRI assessments from baseline to the end of study,False,
NCT01424423,NOGO-A in Multiple Sclerosis FTIH,"A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy",TERMINATED,2010-02-11,2010-08-26,2010-08-26,2017-09-20,2011-08-29,INTERVENTIONAL,PHASE1,3.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,Safety|GSK1223249|Pharmacokinetics|Single dose escalation|anti-GSK1223249 antibodies|Multiple Sclerosis,Australia,Heidelberg,Victoria,1,Placebo|GSK1223249,DRUG|DRUG,The preliminary safety and tolerability of single doses of GSK1223249,Single dose pharmacokinetics.,False,
NCT01621269,ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon,"A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta",WITHDRAWN,2013-06,2014-06,2014-06,2017-04-20,2012-06-18,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|Fingolimod|Gilenya|Neutralizing Antibodies|NAb,,,,0,Fingolimod,DRUG,Number of patients with active MRI lesions,Number of patients with adverse events,False,
NCT05387395,COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort,Impact of COVID 19 Vaccination or Infection on Disease Activity in Radiologically Isolated Syndrome Cohort: the VaxiRIS Study,COMPLETED,2022-05-31,2022-07-01,2022-07-01,2022-08-01,2022-05-24,OBSERVATIONAL,,217.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis|COVID-19,,France,Nice,,1,NO intervention,OTHER,COVID 19 vaccination and clinical conversion to multiple sclerosis risk,COVID 19 vaccination and evidence disease activity risk|multiple sclerosis evolution and history of COVID 19 infection,False,
NCT00493077,Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy,"A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy",COMPLETED,2004-05,2006-05,2006-05,2008-01-30,2007-06-27,INTERVENTIONAL,PHASE4,3.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Neutralizing antibodies|Safety|Low immunogenicity|interferon|interferon-beta-1a,Sweden,Gothenburg,,5,low immunogenic interferon-beta-1a,DRUG,neutralizing antibody levels will be followed,Proportion of patients with NAb positive titre > 20.|Relative change from baseline (screening) of NAb titre|Change in the annualised relapse rate and number of relapse-free (total and documented relapses) patients|The percentage of patients with a loss of disability of 1.0 (or more) score on the EDSS.,False,
NCT01774201,Respiratory Function and Walking Capacity in Multiple Sclerosis,Respiratory Function and Walking Capacity in Multiple Sclerosis,COMPLETED,2012-09,2014-12,2014-12,2017-01-18,2013-01-23,INTERVENTIONAL,NA,50.0,ACTUAL,Region Örebro County,OTHER,Örebro County Council,OTHER_GOV,"Multiple Sclerosis|Respiratory; Disorder, Functional, Impaired|Difficulty Walking",Multiple sclerosis|Self-assessment|Physical endurance|Respiratory function|Fatigue,,,,0,Breathing exercises,OTHER,Respiratory muscle strength,,False,
NCT01289912,Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC),Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex,COMPLETED,2011-01,2014-12,2014-12,2018-01-25,2011-02-04,INTERVENTIONAL,PHASE2,52.0,ACTUAL,Mustafa Sahin,OTHER,Tuberous Sclerosis Alliance|Autism Speaks|Novartis Pharmaceuticals|Seizure Tracker LLC,OTHER|OTHER|INDUSTRY|UNKNOWN,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex|Autism|Neurocognition|RAD001|Everolimus|Afinitor|TSC,United States,Boston,Massachusetts,2,RAD001|Placebo,DRUG|DRUG,Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC.|Evaluation of the Efficacy of RAD001 on Neurocognition in Patients With TSC Compared With Placebo.|Evaluation of the Efficacy of RAD001 on Neurocognition (Cambridge Neuropsychological Test Automated Battery) in Patients With TSC Compared With Placebo.,Comparison of Absolute Change From Baseline in Frequency of Epileptiform Events Between Patients Taking RAD001 vs. Placebo|Comparison of Sleep Disturbances Between Patients Taking RAD001 vs. Placebo|Comparison of Autism Spectrum Disorders Features Between Patients Taking RAD001 vs. Placebo|Comparison of Academic Skills Between Patients Taking RAD001 vs. Placebo|Comparison of Behavioral Problems Between Patients Taking RAD001 vs Placebo,True,2018-01-25
NCT06900192,A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis,"A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood",NOT_YET_RECRUITING,2025-03,2029-08,2029-08,2025-03-28,2025-03-28,INTERVENTIONAL,PHASE1,10.0,ESTIMATED,Stanford University,OTHER,"Orca Biosystems, Inc.",INDUSTRY,"Primary Progressive Multiple Sclerosis|Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",,,,,0,Orca-Q|myeloablative regimen,BIOLOGICAL|DRUG,Severe acute Graft-versus-Host-Disease-free survival,Evaluate treatment response|Evaluate safety of treatment,False,
NCT04260711,Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).,The Safety and Cost-effectiveness of Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS): a Randomized Rater-blinded Multicenter Trial.,UNKNOWN,2020-07-01,2023-08-01,2024-01-01,2020-10-19,2020-02-07,INTERVENTIONAL,NA,130.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",multiple sclerosis|disease modifying therapy,Netherlands,Amsterdam,,1,DMT,DRUG,Clinical relapses|New lesions on MRI-brain,EDSS (Expanded Disability Status Scale)|9-hole peg test|Timed 25-Foot Walk|Symbol Digits Modalities Test|MRI-parameter: T1 post-contrast lesion number|MRI-parameter: T2 post-contrast lesion number|Multiple Sclerosis Impact Scale (MSIS-29)|Short Form health survey (SF-36)|Checklist Individual Strength (CIS20r)|Treatment Satisfaction Questionnaire for Medication (TSQM)|EuroQol 5 dimensions questionnaire (EQ-5D-5L)|Medical consumption questionnaire (iMCQ)|Productivity costs questionnaire (iPCQ)|Neurofilament light level in serum,False,
NCT06685744,TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial,Effectiveness of TeleNEUROrehabilitation Systems for Timely and Personalized Interventions and Vigilant Care in Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial,RECRUITING,2024-10-23,2026-05-30,2026-06-30,2025-03-03,2024-11-12,INTERVENTIONAL,NA,300.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,"Fondazione Don Carlo Gnocchi Onlus, IRCCS Milano|Fondazione Don Carlo Gnocchi Onlus, Centro S Maria della Provvidenza, Roma|Fondazione Mondino|Istituti Clinici Scientifici Maugeri SpA, IRCCS Bari|Istituti Clinici Scientifici Maugeri SpA, IRCCS Pavia|Istituti Clinici Scientifici Maugeri SpA, IRCCS Milano|Istituti Clinici Scientifici Maugeri SpA, IRCCS Montescano|Istituti Clinici Scientifici Maugeri SpA, IRCCS Telese|IRCCS Azienda Ospedaliera Universitaria San Martino - Genova|University of Modena and Reggio Emilia|Centro Riabilitativo Villa Beretta",UNKNOWN|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|OTHER|UNKNOWN,"Parkinson Disease|Multiple Sclerosis|Neurologic Diseases, General",Telerehabilitation|Digital Medicine|Chronic Neurological diseases|Rehabilitation|Telemedicine|Parkinson&#39;s Disease|Multiple Sclerosis|ehealth,Italy,Bari,,6,Telerehabilitation_TRsA|Educational treatment|Telerehabilitation_TRcA,DEVICE|BEHAVIORAL|DEVICE,Change in static and dynamic balance as measured by the Mini-Best Test,"Change in dynamic and static balance measured by the Fullerton Advanced Balance Scale - FAB|Change in dynamic balance as measured by the modified Dynamic Gait Index - mDGI|Change in perceived stability during activities of daily living as measured by the Activities Balance Confidence scale - ABC|Change in perceived fatigue during activities of daily living measured by the Fatigue Severity Scale - FSS|Change in functional lower limbs strength as measured by the Five Times Sit to Stand Test - 5xSTS|Change in mobility and leg function performance as measured by the Timed 25 Foot Walk - T25FW|Change in aerobic capacity and endurance as measured by the 6-Minute Walk Test - 6MWT|Change in global cognitive functioning as measured by the Montreal Cognitive Assessment test - MoCA|Change in visuoperceptual and attentional abilities as measured by the Trail Making Test - TMT parti A e B|Change in visuoperceptual and attentional abilities as measured by the Symbol Digit Modalities Test - SDMT, Smith A., 1973; Nocentini U., 2006|Change in the perceived level of disability as measured by the World Health Organization disability assessment schedule 2.0 - WHODAS 2.0|Change in depressive symptoms as measured by the Beck Depression Inventory - BDI-II",False,
NCT02986893,Pilot Diet Study for Multiple Sclerosis,Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS),COMPLETED,2016-11,2018-08-31,2018-08-31,2018-10-03,2016-12-08,INTERVENTIONAL,NA,36.0,ACTUAL,Icahn School of Medicine at Mount Sinai,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Diet|Clinical Trial,United States,New York,New York,1,Dietary Intervention|Non-dietary Intervention Arm,BEHAVIORAL|BEHAVIORAL,Food Frequency Questionnaire|Carotenoids level|Pooled fatty acids level|Urinary sodium level,Change in Blood pressure|Change in body mass index|Change in lipid profile|Change in fasting glucose level|Change in hemoglobin a1c level|Change in Multiple Sclerosis Impact Scale-29 (MSIS-29)|Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Change in the Minimum Assessment of Cognitive Function in MS (MACFIMS)|Neurological Fatigue Index-MS,False,
NCT02835677,Integrating Caregiver Support Into MS Care,Integrating Caregiver Support Into MS Care,COMPLETED,2016-09-07,2018-04-09,2018-06-30,2019-07-24,2016-07-18,INTERVENTIONAL,NA,25.0,ACTUAL,VA Office of Research and Development,FED,Memphis VA Medical Center,FED,Multiple Sclerosis,Caregivers|Activities of Daily Living,United States,Memphis,Tennessee,1,Behavioral,BEHAVIORAL,Depression Measured With the Patient Health Questionnaire 9 (PHQ-9) Scale|Burden Measured With the Zarit Burden Inventory|Anxiety Measured With the Generalized Anxiety Disorders 7 Scale|Number of Patient MS Problems|Bother With Patient MS Problems,,True,2019-07-24
NCT00223301,Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis,"A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis",COMPLETED,2004-07,2007-03,2007-03,2013-04-22,2005-09-22,INTERVENTIONAL,PHASE2|PHASE3,24.0,,University of Texas Southwestern Medical Center,OTHER,Roche Pharma AG|Biogen,INDUSTRY|INDUSTRY,Multiple Sclerosis,,United States,Dallas,Texas,1,Mycophenolate Mofetil (cellcept),DRUG,The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when used in combination with weekly intramuscular Avonex in early MS. Early MS for this study is defined at a definite diagnosis of less,"To document changes in exacerbation frequency|To document the incidence of mild, moderate, and severe exacerbations in the treated groups.|To document changes in the level of sustained disability as measured by the expanded disability status score (EDSS) and ambulation index (AI) as assessed by the Kaplan-Meier methodology.|To document changes in quality of life measures (MSQOL-54, SF-36, and Beck's Depression Index).|To assess fatigue with the validated fatigue assessment inventory|Neuroimmunological studies:At baseline, 6 and 12 months after treatment.|Pharmacodynamics.|Genetic Studies.",False,
NCT04707144,Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T,Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T in the Detection and Characterization of Spinal Cord Injuries in Patients With Multiple Sclerosis,COMPLETED,2021-05-06,2023-06-06,2023-06-28,2023-12-13,2021-01-13,OBSERVATIONAL,,106.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Bordeaux,,6,MRI 1.5 tesla,DEVICE,"Estimate the number of spinal cord injuries detected with the set of standard sequences (T1, T2 and STIR) that are not detected with the 3D PSIR sequence|Estimate the number of active lesions taking the contrast after injection of gadolinium, with the 3D PSIR sequence which is not detected in the set of standard sequences (T1, T2 and STIR)|Compare the diagnostic confidence expressed by the radiologist for the detection of spinal cord injuries with the 3D PSIR sequence compared to the set of standard sequences (T1, T2 and STIR)|Describe the quality of the images in terms of artifacts for each of the sequences used (T1, T2, STIR and PSIR)|Measure the signal-to-noise ratio of each of the sequences used (T1, T2, STIR and PSIR)|Measure the inter-observer agreement on the number of lesions detected with the 3D PSIR sequence|Measure the intra-observer agreement on the number of lesions detected with the 3D PSIR sequence",,False,
NCT05439902,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,RECRUITING,2022-10-05,2026-03,2026-03,2024-06-25,2022-06-30,INTERVENTIONAL,NA,60.0,ESTIMATED,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis|Dysuria|Lower Urinary Tract Symptoms|Voiding Dysfunction|Urinary Retention,,France,Nîmes,,1,Tamsulosin|Placebo,DRUG|DRUG,Urinary symptoms between groups|Urinary symptoms between groups|Urinary symptoms between groups|Urinary symptoms between groups,Urinary symptoms between groups|Urinary symptoms between groups|Urinary symptoms between groups|Urinary symptoms between groups|Post-mictional residue between groups|Post-mictional residue between groups|Post-mictional residue between groups|Post-mictional residue between groups|Maximum urine flow rate between groups|Maximum urine flow rate between groups|Maximum urine flow rate between groups|Maximum urine flow rate between groups|Quality of life linked to urinary dysfunction between groups|Quality of life linked to urinary dysfunction between groups|Quality of life linked to urinary dysfunction between groups|Quality of life linked to urinary dysfunction between groups|Quality of life between groups|Quality of life between groups|Quality of life between groups|Quality of life between groups|Fatigue between groups|Fatigue between groups|Fatigue between groups|Fatigue between groups|Drug safety|Drug safety,False,
NCT06921551,Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis,Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis,RECRUITING,2025-04-07,2026-05-07,2026-05-07,2025-05-31,2025-04-10,INTERVENTIONAL,NA,20.0,ESTIMATED,ABLE Human Motion S.L.,INDUSTRY,Fundación Esclerosis Múltiple Madrid (FEMM),UNKNOWN,Multiple Sclerosis,Gait training|Wearable exoskeleton|Multiple Sclerosis,Spain,Madrid,Madrid,1,ABLE Exoskeleton,DEVICE,Number of therapeutic objectives achieved|Lower extremity muscle strenght|Modified Ashworth Scale (MAS)|Location and level of pain|Timed 25-Feet Walk test (T25FW)|6-Minute Walk Test (6MWT)|Borg Rating of Perceived Exertion|Trunk Impairment Scale (TIS)|Barthel Index (BI) score|Modified Fatigue Impact Scale (MFIS) score|Multiple Sclerosis Quality of Life-54 (MSQoL-54) scores|Self-perceived impact on general health status|Level of motivation|Psychosocial Impact of Assistive Devices Scale (PIADS) score|Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score,Time spent upright and time spent walking|Number of steps walked|Distance walked,False,
NCT05283551,Famciclovir in Multiple Sclerosis,A Phase 2 Open Label Clinical Trial to Determine the Effect of Famciclovir on Epstein-Barr Virus Activity as Measured by EBV Shedding in Saliva of Patients With Multiple Sclerosis.,UNKNOWN,2020-11-25,2023-11-25,2023-11-25,2022-03-17,2022-03-17,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,Queen Mary University of London,OTHER,,,Multiple Sclerosis,,United Kingdom,London,,1,Famciclovir,DRUG,Effect of famciclovir on Epstein-Barr virus (EBV) shedding,,False,
NCT01879202,Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis,Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.,UNKNOWN,2012-12,2017-02,2017-02,2015-05-12,2013-06-17,INTERVENTIONAL,PHASE2,96.0,ESTIMATED,Medical University of Vienna,OTHER,,,Multiple Sclerosis|Fatigue,multiple sclerosis|fatigue|fatigue severity scale|fatigue impact scale|quality of life,Austria,Vienna,Vienna,1,Methylphenidate modified release|Maltodextrin,DRUG|DRUG,Change of Fatigue as measured by Fatigue Severity Scale,Change of Fatigue as measured by Modified Fatigue Impact Scale (MFIS),False,
NCT05098145,A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis,"A Single-arm, Multi-center, Open-label Proof of Concept Safety and Efficacy Study of FCR001 Cell-based Therapy in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis at Risk for Organ Failure",WITHDRAWN,2021-11-24,2026-11,2027-02,2023-10-12,2021-10-28,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,Talaris Therapeutics Inc.,INDUSTRY,,,Diffuse Cutaneous Systemic Sclerosis,Stem cell therapy|Scleroderma|Severe scleroderma|Allogeneic|Transplant,United States,Ann Arbor,Michigan,1,FCR001,BIOLOGICAL,Incidence of recipient adverse events (AEs)|Incidence of recipient serious adverse events (SAEs)|Occurrence of Graft versus Host Disease (GvHD)|Time to neutrophil recovery|Time to platelet recovery,Percent donor whole blood chimerism|Percentage of donor T-cell chimerism|Incidence of donor AEs|Incidence of donor SAEs,False,
NCT01419301,Mindfulness Based Stress Reduction in Multiple Sclerosis (MS),Mindfulness Based Stress Reduction in MS,COMPLETED,2011-05,2013-04,2014-11,2014-11-20,2011-08-18,INTERVENTIONAL,NA,31.0,ACTUAL,Stony Brook University,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Multiple Sclerosis,multiple sclerosis|glatiramer acetate|stress reduction|medication adherence,United States,Stony Brook,New York,1,Mindfulness based stress reduction (MBSR),BEHAVIORAL,Electronic measure of needle disposals (MEMS TrackCaps),Perceived Stress Scale-10|Holmes and Rahe Social Readjustment Rating Scale (SRRS|Chicago Multiscale Depression Inventory (CMDI)|State Trait Anxiety Inventory (STAI)|Positive and Negative Affect Scale (PANAS)|Fatigue Severity Scale (FSS)|MACFIMS neuropsychological battery|Expanded Disability Status Scale (EDSS)|Physiologic Markers of Stress|Physiologic Maker of Stress,False,
NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension",TERMINATED,2011-09-13,2015-07-28,2016-04-13,2017-09-11,2011-08-12,INTERVENTIONAL,PHASE3,889.0,ACTUAL,Biogen,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,Natalizumab|secondary|multiple sclerosis|MS|SPMS|Tysabri,United States,Phoenix,Arizona,161,natalizumab|Placebo,DRUG|DRUG,"Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",Part 1: Percentage of Participants With a T25FW Response|Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)|Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire|Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score|Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96|Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores|Part 2: Percentage of Participants With Disability Worsening at 156 Weeks|Part 2: Absolute Change From Baseline (Part 1) in T25FW|Part 2: Percentage Change From Baseline (Part 1) in T25FW|Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)|Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)|Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)|Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)|Part 2: Absolute Change From Baseline (Part 1) in EDSS|Part 2: Percentage Change From Baseline (Part 1) in EDSS|Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)|Part 2: Percentage Change From Baseline (Part 1) in the 6MWT|Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score|Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score|Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)|Part 2: Percentage Change From Baseline (Part 1) in the SDMT|Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire|Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire|Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume|Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume|Part 2: Summary of New/Enlarging T2 Lesion Counts|Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions,True,2017-06-27
NCT06267781,RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies,Biomarkers of Disease PROgression and Myeloid Profiling in Patients With Relapsing Remitting Multiple Sclerosis Treated With Autologous Hematopoietic Stem Cell TRANSPLANTation and Second Line Therapies.,RECRUITING,2022-09-02,2027-09-02,2027-09-02,2024-02-20,2024-02-20,OBSERVATIONAL,,30.0,ESTIMATED,IRCCS San Raffaele,OTHER,,,Multiple Sclerosis,,Italy,Milan,,1,,,Number of fading/disappearing paramagnetic rim lesions (PRLs),Surrogate biomarkers of disease progression (MSFC)|Surrogate biomarkers of disease progression (sNfL)|Surrogate biomarkers of disease progression (RNFL)|Surrogate biomarkers of disease progression (cortical lesions)|Surrogate biomarkers of disease progression (atrophy)|Changes in myeloid landscape,False,
NCT06300619,Pilates+4MS: Pilates Intervention for Multiple Sclerosis,Evaluating the Impact of Introducing the 4-quadrant Stability Model Into Pilates Instruction: Effects on Function Among Adults With Multiple Sclerosis,COMPLETED,2022-04-05,2022-08-25,2022-08-25,2024-03-08,2024-03-08,INTERVENTIONAL,NA,22.0,ACTUAL,"University of Colorado, Colorado Springs",OTHER,University of Illinois at Urbana-Champaign,OTHER,Multiple Sclerosis,,United States,Colorado Springs,Colorado,1,Pilates+4|Pilates,BEHAVIORAL|BEHAVIORAL,Timed 25 Foot Walk|Timed Up and Go|Berg Balance Scale,"Triaxial Accelerometer (FitBit) Physical Activity Data (minutes of wear time in sedentary time and light, moderate and vigorous physical activity)|The Godin-Shepherd Leisure Time Exercise Questionnaire|Late-Life Function and Disability Instrument Short Form|Leeds Multiple Sclerosis Quality of Life Scale|Modified Fatigue Impact Scale|Multiple Sclerosis Impact Scale",False,
NCT02634567,Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training,,COMPLETED,2016-04,2018-11,2018-12,2019-08-13,2015-12-18,INTERVENTIONAL,NA,31.0,ACTUAL,London Health Sciences Centre,OTHER,,,Multiple Sclerosis,,Canada,London,Ontario,1,Cogmed Working Memory Training (CWMT),BEHAVIORAL,Paced Auditory Serial Addition Test|Symbol Digit Modalities Test|Stroop colour word test,Judgement of Line Orientation|Controlled Oral Word Association Test|California Verbal Learning Test|Brief Visual Memory Test|Delis-Kaplan Executive Function System Sorting Test|Beck Depression Inventory - Fast Screen|Hospital Anxiety and Depression Scale|Fatigue Severity Scale|Short Form Health Survey|Dysexecutive Questionnaire|Cognitive Failures Questionnaire|BRIEF Cope|Social Stress and Support Interview|Multiple Sclerosis Neuropsychological Screening Questionnaire|Perceived Deficits Questionnaire|Visual Spatial Span Board Assessment|Digit Span|Arithmetic|Letter-Number Sequencing,False,
NCT05598736,"Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain","An Open 6-month Investigation, to Evaluate the Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis (Optional Continuation From NCT05562453)",UNKNOWN,2022-11-04,2023-06-30,2023-12-31,2023-02-23,2022-10-28,INTERVENTIONAL,NA,60.0,ESTIMATED,Otivio AS,INDUSTRY,,,"Multiple Sclerosis|Spasticity, Muscle|Pain",,Norway,Bergen,,1,FlowOx 2.0,DEVICE,Change in self-reported spasticity using Numeric Rating Scale (NRS),Change in self-reported pain using NRS for subjects with a baseline NRS ≥4.|Frequency of adverse events|Change in timed 25-foot walk (T25-FW)|Change in 2-minute walking tests|Change in health-related quality of life measured by Multiple sclerosis impact scale (MSIS-29)|Change in health-related quality of life measured by EQ-5D-5L|Change in Hospital Anxiety and Depression Scale (HADS),False,
NCT06197685,A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis,A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis,RECRUITING,2024-02-12,2026-06-30,2026-06-30,2025-09-02,2024-01-09,INTERVENTIONAL,NA,78.0,ESTIMATED,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Multiple Sclerosis|Aerobic exercise|Virtual Reality|Leg cycling|Mobility disability,United States,East Hanover,New Jersey,1,The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|Stretching and Toning (S/T),BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in objective new learning and memory (NLM).|Change in everyday memory,Change in hippocampal volume|Change in hippocampal function,False,
NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis,COMPLETED,2016-02-22,2018-09-24,2018-09-24,2019-11-22,2015-09-21,INTERVENTIONAL,PHASE3,20.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Pediatrics,United States,Loma Linda,California,12,dimethyl fumarate,DRUG,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants Discontinuing Treatment Due to an Adverse Event,Total Number of New or Newly Enlarging T2 Hyperintense Lesions From Week 16 to Week 24|Total Number of New or Newly Enlarging T2 Hyperintense Lesions From Week 64 to Week 72|Average Annualized Relapse Rate (ARR)|Percentage of Participants Experiencing One or More Relapses|Change From Baseline in the Degree of Disability|Number of Participants Experiencing Disability Progression,True,2019-11-22
NCT04893590,Adapting MHealth Technology to Improve Patient Activation,Adapting MHealth Technology to Improve Patient Activation and Overall Wellness for Persons with Disabilities,COMPLETED,2021-05-14,2022-02-28,2022-02-28,2025-03-28,2021-05-19,INTERVENTIONAL,NA,27.0,ACTUAL,Washington University School of Medicine,OTHER,The Foundation for Barnes-Jewish Hospital,OTHER,Spinal Cord Injuries|Stroke|Multiple Sclerosis,Fatigue|Persons with disabilities|Patient activation|Mobile health,United States,St Louis,Missouri,1,Fatigue self-management SMS intervention,BEHAVIORAL,"Patient Activation - change in knowledge, skill and confidence for self-management",The Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue Short Form 8a|The Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Short Form 8a,False,
NCT00337779,Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).,"A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)",COMPLETED,2006-08,2008-10,2008-10,2011-10-10,2006-06-16,INTERVENTIONAL,PHASE3,1155.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,Glatiramer Acetate (GA) 40 mg|glatiramer acetate 20 mg,DRUG|DRUG,The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).,"The Number of New T2 Lesions at Month 12 as Compared to the Baseline Scan.|The Cumulative Number of T1-Gd Enhancing Lesions at Months 3, 6, 9 and 12 (in the Frequent MRI Cohort-described Below).",True,2010-05-14
NCT01767493,Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients,"An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2012-11,2013-11,2013-11,2021-08-30,2013-01-14,INTERVENTIONAL,PHASE4,19.0,ACTUAL,Institute for Neurodegenerative Disorders,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis,United States,New Haven,Connecticut,1,[18F]Florbetapir PET imaging,DRUG,Total Number of Lesions Detected by [18F]Florbetapir PET,,True,2021-08-27
NCT00239993,A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®,"An Open-Label, Randomized, Single Cross-over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®.",COMPLETED,2005-08,2005-12,2006-02,2017-02-06,2005-10-17,INTERVENTIONAL,PHASE4,50.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Fullerton,California,6,glatiramer acetate|Warm compress prior to injection of glatiramer acetate,DRUG|PROCEDURE,The number of local injection site reactions (LISRs) noted at 5-minutes post-injection,The total and partial number of LISRs noted at 2-minutes post-injection The total and partial number of LISRs noted immediately after injection,False,
NCT02702804,High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study,High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study,COMPLETED,2016-04-21,2017-11,2017-11-08,2019-11-14,2016-03-09,INTERVENTIONAL,NA,11.0,ACTUAL,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,Sheffield Hallam University,OTHER,Multiple Sclerosis,,United Kingdom,Sheffield,South Yorkshire,2,High Intensity Interval Training,OTHER,Number of participants recruited to the study who adhere to high intensity interval training intervention|Number of participants with treatment related adverse events as recorded by the research team,Physical fitness|Impact of treatment intervention on multiple sclerosis|Impact of treatment intervention on multiple sclerosis,False,
NCT01873417,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,"A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules",COMPLETED,2013-05,2013-11,2013-11,2017-03-21,2013-06-10,INTERVENTIONAL,PHASE4,237.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,,United States,Cullman,Alabama,37,BG00012 (DMF),DRUG,"Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)|Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale|Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy|Duration of GI-related Episodes in DMF-treated Participants","Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy|Participants' Use of Symptomatic Therapy, by Type and Category|Summary of Use and Days on Symptomatic Therapy, by Category|Number of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy",True,2014-11-11
NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,"A 6-month, Multicenter, Randomized, Controlled Parallel Group Study to Evaluate the Effect of Physical Training on Fatigue in Patients With Relapsing-remitting Multiple Sclerosis Treated With Fingolimod, Followed by a 6 Month Optional Extension Phase",TERMINATED,2011-11,2014-07,2014-07,2016-05-12,2011-12-13,INTERVENTIONAL,PHASE4,178.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Fatigue in Multiple Sclerosis,Fatigue|MS|Multiple Sclerosis|Exercise|Physical activity|Physical training|Fingolimod,Germany,Dortmund,Germany,32,Physical exercise,OTHER,Change From Baseline in Fatigue as Measured by the Modified Fatigue Impact Scale (mFIS ).,Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Sit-to-stand Test|Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Change in Leg Strength and Trunk Strength|Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Leg Strength Endurance|Change From Baseline in Quality of Life as Measured by the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS)|Change From Baseline in Fatigue as Measured by the WEIMuS (Würzburg Fatigue Inventory for MS)|Change From Baseline in Depression as Measured by the Beck Depression Inventory Second Edition (BDI-II)|Change From Baseline in Aerobic Capacity (VO2max) as Measured by a Physical Endurance Spiroergometry on a Treadmill|Change From Baseline in Peak Expiratory Flow as Measured by a Physical Endurance Spiroergometry on a Treadmill,True,2016-05-12
NCT04882891,Holter of Movement in Patients with Multiple Sclerosis in Uncontrolled Environment.,Holter of Movement in Patients with Multiple Sclerosis. Acti-SEP Study: Uncontrolled Environment.,ACTIVE_NOT_RECRUITING,2021-03-09,2026-02-15,2026-02-15,2025-02-12,2021-05-12,INTERVENTIONAL,NA,80.0,ESTIMATED,Centre Hospitalier Universitaire de Liege,OTHER,SYSNAV|Centre Hospitalier Régional de la Citadelle,INDUSTRY|OTHER,Multiple Sclerosis,Actimyo|Accelerometry|Home monitoring,Belgium,Liège,Liège,7,Actimyo,DEVICE,95th centile of stride velocity|50th centile of stride velocity|95th centile of stride length|50th centile of stride length|Stance phase time,,False,
NCT03653390,A Community Wellness Program for Adults Living With Long-term Physical Disability,Efficacy and Mechanism of a Community Wellness Promotion Program for Middle-aged Adults Living With Long-term Physical Disability,COMPLETED,2019-01-31,2022-11-14,2022-11-14,2023-11-21,2018-08-31,INTERVENTIONAL,NA,516.0,ACTUAL,University of Washington,OTHER,National Institute of Nursing Research (NINR),NIH,Physical Disability,health promotion intervention|community participation|quality of life|middle age|multiple sclerosis|spinal cord injury|muscular dystrophy|post-polio syndrome,United States,Seattle,Washington,1,EnhanceWellness for Disability (EW-D)|Wellness Education,BEHAVIORAL|BEHAVIORAL,Change in Self-reported Ability to Participate in Community Activities From Baseline to 6 Months,"Change in Self-report of Confidence in Managing One's Chronic Illness (Disease Management Self-efficacy) From Baseline to 3 Months|Change in Self-reported Interference Due to Pain From Baseline to 3 Months|Change in Self-reported Interference Due to Fatigue From Baseline to 3 Months|Change in Psychological Resilience From Baseline to 3 Months|Change in Number of Trips Outside the Home From Baseline to 12 Months|Change in Radius of Gyration From Baseline to 12 Months|Change in Number of Trips Outside the Home Containing ""Social"" Elements From Baseline to 12 Months|Change in Time Spent in Activities Outside the Home Containing Social Elements From Baseline to 12 Months|Change in Self-reported Ability to Participate in Community Activities From Baseline to 12 Months",True,2023-11-21
NCT02533882,Lakeshore Examination of Activity and Disability Exercise Response Study,Dose-Response Effects of Transformative Exercise in Improving Health and Function in Adults With Spinal Cord Injury and Multiple Sclerosis,COMPLETED,2014-12,2019-07-15,2019-08-30,2019-10-15,2015-08-27,INTERVENTIONAL,NA,180.0,ACTUAL,University of Alabama at Birmingham,OTHER,Lakeshore Foundation,OTHER,Multiple Sclerosis|Stroke,,United States,Birmingham,Alabama,1,Movement to Music|Adapted Yoga,BEHAVIORAL|BEHAVIORAL,Cardiorespiratory Fitness as measured by sub-maximal VO2|Pain as measured by PROMIS Pain Interference Short Form 8a|Fatigue as measured by PROMIS Fatigue Short Form 8a|Loneliness as measured by the Three-Item Loneliness Scale|Grip Strength as measured by hand grip dynamometer|Strength as measured by Biodex System 3 Multijoint dynamometer|Balance as measured by the Timed Up and Go|Balance as measured by Biodex Limits of Stability|Balance as measured by Repeated Chair Stands,"Health Biomarkers as measured by blood analysis (insulin)|Health Biomarkers as measured by blood analysis (lipids)|Health Biomarkers as measured by blood analysis (fasting glucose)|Blood pressure|Anthropometric measurements (weight)|Circumference measurements to be reported as composite ratios (waist circumference, hip circumference, neck circumference)|Physical Function with Mobility Aid as measured by PROMIS Physical Function with Mobility Aid 455b|Anxiety as measured by PROMIS Emotional Distress-Anxiety Short Form 8a|Depression as measured by PROMIS Emotional Distress-Depression Short Form 8a|Sleep Disturbance as measured by PROMIS Sleep Disturbance Short Form 8a|Ability to participate in social roles and activities as measured by PROMIS Ability to Participate in Social Roles and Activities Short Form 8a|Nutrition Self-Efficacy as measured by the Nutrition Self-Efficacy Scale|Physical Exercise Self-Efficacy as measured by the Physical Exercise Self Efficacy Scale|PROMIS Pain Intensity Short Form",False,
NCT02775110,Natalizumab Temporary Discontinuation Study,Natalizumab Temporary Discontinuation Study,COMPLETED,2012-11,2014-03,2014-03,2016-05-17,2016-05-17,INTERVENTIONAL,PHASE4,50.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,2,Natalizumab discontinuation,OTHER,Number of recorded infections including viral opportunistic infection|Saturation percentage of α4β1integrin receptors on the surface of lymphocytes|Number gadolinium-enhancing lesions|Absolute changes in gadolinium-enhancing and T2-weighted lesion volume between timepoints|Sum of new and enlarging T2-weighted lesions,Number of clinical relapses|Expanded Disability Status Scale (EDSS) score,False,
NCT01206023,Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples,Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis by Respiratory Samples,COMPLETED,2010-11,2011-11,2012-11,2017-02-23,2010-09-21,OBSERVATIONAL,,71.0,ACTUAL,Carmel Medical Center,OTHER,"Technion, Israel Institute of Technology",OTHER,Multiple Sclerosis,Multiple Sclerosis|Breath|Diagnosis|Discrimination MS/healthy subj. via exhaled breath samples,Israel,Haifa,,2,NA-NOSE artificial olfactory system,OTHER,Successful discrimination between healthy and MS,,False,
NCT00776048,Validation of an Obstacle Course Used in Patients With Muscle Tightness,The Validation of a New Method to Evaluate the Effects of Chemoneurolytic Intervention on Balance and Community Ambulation in Spastic Hemiplegic Patients,UNKNOWN,2007-01,2009-12,2009-12,2010-06-24,2008-10-20,OBSERVATIONAL,,40.0,ESTIMATED,Kessler Foundation,OTHER,,,Stroke|Traumatic Brain Injury|Multiple Sclerosis|Spasticity|Healthy Controls,,United States,West Orange,New Jersey,1,,,To demonstrate the objective utility of the use of pedobarography to differentiate normal controls from people with spastic gait as well as having utility in objectification of treatment effect on level surfaces and on a ADA based obstacle course.,,False,
NCT05893225,Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration,MACSiMiSE-BRAIN: Metformin add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination and Neurodegeneration: a Phase II Placebo-controlled Randomized Clinical Trial,ACTIVE_NOT_RECRUITING,2023-11-23,2027-02-28,2027-02-28,2025-06-24,2023-06-07,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,"University Hospital, Antwerp",OTHER,"University Hospital, Ghent|Hasselt University|AZ Sint-Jan AV|Noorderhart Pelt|National MS Center Melsbroek",OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Secondary-progressive Multiple Sclerosis,"Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Sclerosis|Metformin|Pathologic Processes|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Brain Remyelination|Neurodegeneration",Belgium,Bruges,,5,Metformin Hydrochloride 850 mg Oral Tablet|Placebo,DRUG|DRUG,Change in walking speed,Change in cognitive function|Change in hand function|Change in EDSS|Change in brain volume|Change in T2 lesion volume|Change in T1 lesion volume|Change in brain magnetic resonance imaging diffusion tensor imaging (MRI-DTI) metrics,False,
NCT04874597,Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS,The Effect of Ocrelizumab on the Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in Patients with Multiple Sclerosis Previously Treated with Disease Modifying Therapy - a Prospective Exploratory Observational Study,ACTIVE_NOT_RECRUITING,2021-11-15,2025-04-10,2025-04-15,2024-10-15,2021-05-05,OBSERVATIONAL,,30.0,ACTUAL,Dr Recai Turkoglu,OTHER,Haydarpasa Numune Training and Research Hospital,OTHER,Multiple Sclerosis,Ocrelizumab|Disease modifying therapy|T cell|B cell,Turkey (Türkiye),Istanbul,Uskudar,1,Ocrelizumab,DRUG,Change from baseline in T cell capacity achieved by eliminating B cells as measured by flow cytometry.|Change from baseline in T cell function achieved by eliminating B cells as measured by flow cytometry.,Correlation between changes in T and B cell capacity and function during course of ocrelizumab therapy.|Clinical improvement|Changes in T cells in case of relapse or infection after vaccination during ocrelizumab treatment by flow cytometry.|Changes in B cells in case of relapse or infection after vaccination during ocrelizumab treatment by flow cytometry.,False,
NCT04281160,Patient Centered Outcomes Analysis for MS Using a Mobile Application,Patient Centered Outcomes Analysis for MS Using a Mobile Application,UNKNOWN,2020-02-19,2023-09-01,2023-09-01,2022-12-23,2020-02-24,OBSERVATIONAL,,60.0,ESTIMATED,BeCare Link LLC,INDUSTRY,Weill Medical College of Cornell University,OTHER,Multiple Sclerosis,mobile app|TUG test|25 foot walk|six minute walk|working memory test|Contrast Sensitivity|Coded Message Cognitive Test|Fine motor function|Digit Modality test,United States,New York,New York,1,BeCare Mobile App,DEVICE,Compare the App-based TUG with the clinically derived TUG results,Fine motor function/rapid finger movements (FMF)|Upper extremity coordination|Auditory-Comprehension-Typing (ACT) test|Timed 25-foot walk|Coded Message Cognitive Test|Six minute walk|Contrast Sensitivity|Arm Swing Test|Birds in a box working memory test,False,
NCT02481882,Baseline Cortical Haemodynamics in MS,Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis,UNKNOWN,2017-01,2019-10,2019-10,2018-10-12,2015-06-25,INTERVENTIONAL,NA,80.0,ESTIMATED,University of Nottingham,OTHER,,,Multiple Sclerosis,,United Kingdom,Nottingham,Nottinghamshire,1,Magnetic Resonance Imaging|Prohance (Gadoteridol),DEVICE|DRUG,Cerebral Blood Flow,Arterial Cerebral Blood Volume|Arterial Transit Time,False,
NCT03869879,"Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation",Mobility Rehab: A Feedback System for Mobility Rehabilitation for Older Adults,UNKNOWN,2019-07-24,2021-05-30,2021-05-30,2020-05-11,2019-03-11,INTERVENTIONAL,NA,300.0,ESTIMATED,Oregon Health and Science University,OTHER,NorthWest Rehabilitations Associates|APDM,UNKNOWN|UNKNOWN,"Parkinson Disease|Stroke|Multiple Sclerosis|Gait Disorders, Neurologic|Gait Disorder, Sensorimotor|Gait, Unsteady|Gait Ataxia|Gait, Stumbling|Gait, Shuffling",gait|balance|falls|mobility|feedback,United States,Salem,Oregon,1,Feedback-assisted physical therapy|Traditional physical therapy,OTHER|OTHER,Activities-Specific Balance Confidence (ABC) Scale,Gait speed,False,
NCT02019550,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,"A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week",COMPLETED,2014-03,2016-01,2016-01,2017-03-07,2013-12-24,INTERVENTIONAL,PHASE4,97.0,ACTUAL,EMD Serono,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Rebif®Rebidose®|Rebiject II®",United States,Cullman,Alabama,21,Rebif Rebidose|Rebiject II,DEVICE|DEVICE,"Percentage of Subjects Rating Each Device as ""Easy/Very Easy to Use"" Based on User Trial Questionnaire (UTQ) at Week 4|Percentage of Subjects Rating Each Device as ""Easy/Very Easy to Use"" Based on User Trial Questionnaire (UTQ) at Week 8|Percentage of Subjects Rating Each Device as ""Easy/Very Easy to Use"" Based on User Trial Questionnaire (UTQ) up to Week 8",Number of Subjects Rating Each Device on Level of Satisfaction With Using the Device While Traveling Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Amount of Time Needed to Complete the Injection Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Number of Steps Involved in Completing the Injection Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Ease of Holding Based on User Trial Questionnaire (UTQ)|Number of Subjects Rating Each Device on Level of Satisfaction With Using the Device Away From Home Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Level of Convenience of Using the Device Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Level of Convenience of Storing the Device Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Minimization of Safety Hazards Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Amount of Needle Anxiety While Using the Device Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Level of Satisfaction With Information Provided by the Trainer Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Likelihood of Recommending the Device to Others Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Overall Satisfaction With the Injection Device Based on User Trial Questionnaire (UTQ)|Percentage of Subjects Rating Each Device on Ease of Use Based on User Trial Questionnaire (UTQ)|Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQoL) Scores to Week 8,True,2017-03-07
NCT06223074,Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration,"Towards the Improvement of the Treatment of Acute Relapses in Multiple Sclerosis: A Randomized Double-blind, Non-inferiority Controlled Trial Comparing Intranasal Versus Intravenous Methylprednisolone",ENROLLING_BY_INVITATION,2023-01-09,2026-02-25,2026-07-05,2025-04-03,2024-01-25,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,Universidad Nacional Autonoma de Mexico,OTHER,Instituto Nacional de Neurología y Neurocirugía,UNKNOWN,Multiple Sclerosis Relapsing Remitting|Treatment,methylprednisolone|intranasal administration|Multiple Sclerosis Relapsing Remitting,Mexico,Mexico City,,1,IV Methylprednisolone administration|Nasal Methylprednisolone (MT),OTHER|DRUG,Patients' score on the Expanded Disability Status Scale (EDSS) before and after treatment to assess clinical efficacy of treatments,"Concentration of inflammatory cytokines and chemokines in peripheral blood before, during, and after treatment",False,
NCT01440062,Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS),Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis,TERMINATED,2011-12,2017-06,2017-06,2021-07-29,2011-09-26,INTERVENTIONAL,PHASE2,55.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"NeuroCure Clinical Research Center, Charite, Berlin",OTHER,Multiple Sclerosis,,Germany,Teupitz,Brandenburg,6,Verum arm receiving Vitamin D oil|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day,DRUG|DRUG,Efficacy parameters,Safety & tolerability parameters,False,
NCT05003388,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis,RECRUITING,2021-06-26,2025-10,2025-10,2025-04-08,2021-08-12,INTERVENTIONAL,PHASE1,15.0,ESTIMATED,The Foundation for Orthopaedics and Regenerative Medicine,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|stem cell treatment,Antigua and Barbuda,St John's,,2,AlloRx,BIOLOGICAL,Safety (adverse events),Efficacy: Kurtzke Expanded Disability Status Scale (EDSS),False,
NCT01450488,Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis,"A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis",COMPLETED,2005-06,2007-07,2010-01,2018-12-11,2011-10-12,INTERVENTIONAL,PHASE2,35.0,ACTUAL,AB Science,INDUSTRY,,,Multiple Sclerosis,primary progressive multiple sclerosis|relapse-free secondary progressive multiple sclerosis,,,,0,masitinib|masitinib,DRUG|DRUG,change in MSFC,MSFC subcategories|Expanded Disability Status Scale (EDSS)|MFSC subcategories|MFSC subcategories,False,
NCT05934968,"Mad Dog Cooking Class Series: Effects on Dietary Self-efficacy, Eating Behaviors and Health Outcomes","The Effects of the 6-week Mad Dog Anti-inflammatory Cooking Class Series on Dietary Self-efficacy, Eating Behaviors and Health Outcomes in People With Neurological Disability",UNKNOWN,2023-09,2024-06,2024-08,2023-07-07,2023-07-07,INTERVENTIONAL,NA,14.0,ESTIMATED,Brock University,OTHER,,,"Spinal Cord Injuries|Multiple Sclerosis|Diet, Healthy|Inflammation|Depression|Adherence, Treatment",,Canada,St. Catharines,Ontario,1,Mad Dog cooking class series,OTHER,Custom-designed task self-efficacy questionnaire|Custom-designed task self-efficacy questionnaire|Custom-designed task self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Adherence to the anti-inflammatory diet|Adherence to the anti-inflammatory diet|Adherence to the anti-inflammatory diet|Custom-designed consumer satisfaction questionnaire,Depression as determined by the Centre for Epidemiological Studies depression (CES-D)|Depression as determined by the Centre for Epidemiological Studies depression (CES-D)|Depression as determined by the Centre for Epidemiological Studies depression (CES-D),False,
NCT05778474,Mechanical Determinants of Upper Limbs Oscillation During Gait,Mechanical Determinants of Upper Limbs Oscillation During Gait,RECRUITING,2020-05-27,2024-12,2024-12,2024-03-18,2023-03-21,OBSERVATIONAL,,25.0,ESTIMATED,Istituto Auxologico Italiano,OTHER,,,Multiple Sclerosis|Poststroke/CVA Hemiparesis|Parkinson Disease|Cerebral Palsy|Amputation,Walking|Upper limb oscillations|Treadmill|Center of Mass|Rehabilitation,Italy,Milan,,1,Healthy subjects|Pathologic group,OTHER|OTHER,Ankle joint power,Spatio parameter|Shoulder and elbow joint angles on the sagittal plane|Energy of the center of mass,False,
NCT03403413,Muscle Vibration in MS to Improve Walking,Cyclical Muscle Vibration in MS to Improve Walking,TERMINATED,2017-01-01,2018-12-31,2018-12-31,2020-05-08,2018-01-18,INTERVENTIONAL,NA,5.0,ACTUAL,VA Office of Research and Development,FED,,,Multiple Sclerosis,,United States,Cleveland,Ohio,1,muscle vibration during walking,DEVICE,10MWT|Kinematics|Toe Clearance|Walking Distance,,True,2020-05-08
NCT02576717,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients",COMPLETED,2015-10-16,2023-01-05,2023-01-05,2024-01-30,2015-10-15,INTERVENTIONAL,PHASE3,2494.0,ACTUAL,Celgene,INDUSTRY,,,Multiple Sclerosis,MS|RMS|Multiple Sclerosis|Relapsing Multiple Sclerosis,United States,Phoenix,Arizona,175,RPC1063,DRUG,Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Experiencing Serious Adverse Events (SAEs)|Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation|Number of Participants Experiencing Adverse Events (AEs) Leading to Withdrawal|Number of Participants Experiencing Adverse Events (AEs) of Special Interest|Number of Participants With Abnormalities in Blood Absolute Lymphocyte Count (ALC)|Number of Participants With Abnormalities in White Blood Cell Count (WBC)|Number of Participants With Abnormalities in Blood Absolute Neutrophil Count (ANC)|Number of Participants With Abnormalities in Specific Liver Function Tests|Number of Participants With Electrocardiogram (ECG) Result Abnormalities|Number of Participants With Clinically Relevant Abnormalities in Vital Signs|Number of Participants With Physical Examination Abnormalities|Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of Participants With Changes in Suicidality From Last Day on Treatment Per the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change in Physician's Withdrawal Checklist (PWC-20) Total Score From Last Day on Treatment|Change in Hospital Anxiety and Depression Scale (HADS) Score From Last Day on Treatment|Changes in Epworth Sleepiness Scale (ESS) Score From Last Day on Treatment|Changes in Vital Sign Values From Last Day on Treatment,Annualized Relapse Rate (ARR)|Time to First Relapse (TFR)|Number of Participants Who Were Relapse Free|Average Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions Per Scan at Each Visit|Average Number of Gadolinium-Enhanced (GdE) Brain MRI Lesions Per Scan at Each Visit|Time to Onset of Disability Progression as Defined by a Sustained Worsening in Expanded Disability Status Scale (EDSS)|Number of Participants Free of Gadolinium-Enhanced (GdE) Brain Lesions at Each Visit|Number of Participants Free of New or Enlarging T2 Lesions at Each Visit|Percent Change in Normalized Brain Volume (Atrophy) on Brain MRI Scans From Baseline at Each Visit|Change in Multiple Sclerosis Functional Composite (MSFC) Score From Baseline at Each Applicable Visit|Change in Multiple Sclerosis Quality of Life 54 Score From Baseline at Each Applicable Visit|Change From Baseline in Volume of Gadolinium Enhanced T1 Lesions|Change From Baseline in Volume of T2 Lesions|Change From Baseline in Volume of Unenhancing T1 Lesions|Cumulative Number of New Unenhancing T1 Lesions,True,2024-01-30
NCT00000146,Optic Neuritis Treatment Trial (ONTT),,UNKNOWN,1988-07,,,2006-06-05,1999-09-24,INTERVENTIONAL,PHASE3,,,National Eye Institute (NEI),NIH,,,Multiple Sclerosis|Optic Neuritis,,United States,Little Rock,Arkansas,15,Methylprednisolone|Prednisone,DRUG|DRUG,,,False,
NCT02423083,Oral Guanabenz for Multiple Sclerosis,Phase I Study of Oral Guanabenz for Multiple Sclerosis,TERMINATED,2015-04-21,2017-10-30,2017-10-30,2019-12-12,2015-04-22,INTERVENTIONAL,PHASE1,2.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Neuroprotection|Multiple Sclerosis|Clinical Trial|Safety and Tolerability,United States,Bethesda,Maryland,1,Guanabenz,DRUG,Maximum tolerated dose (MTD),Pharmacokinetics of guanabenz in MS patients,False,
NCT01158183,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,"Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis",COMPLETED,2007-07,2009-09,2009-09,2010-07-08,2010-07-08,OBSERVATIONAL,,226.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Outcomes|real world and web tool|electronic data capture,United States,Many Locations,Alabama,27,BAY86-5046_Interferon-beta-1b,DRUG,Key Objective: To collect patient reported outcomes and clinical assessments via the same web-based data capture tool in a real world setting in relapse-remitting multiple sclerosis patients,,False,
NCT06506929,Task Specific Training for Advanced Multiple Sclerosis,The Effect of Task Specific Physical Therapy for Persons With Advanced Multiple Sclerosis,RECRUITING,2024-07-10,2025-12,2026-01,2024-07-19,2024-07-18,INTERVENTIONAL,NA,15.0,ESTIMATED,Hunter College of City University of New York,OTHER,Multiple Sclerosis Foundation,UNKNOWN,Multiple Sclerosis,,United States,New York,New York,1,Task specific physical therapy,OTHER,Multiple Sclerosis Physical Frailty Functional Assessment (MSPFFA),Multiple Sclerosis Impact Scale-29 (MSIS29),False,
NCT00702468,Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis,"A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.",COMPLETED,2007-11,2009-01,2009-01,2023-05-06,2008-06-20,INTERVENTIONAL,PHASE3,36.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Spasticity|Multiple Sclerosis,Spasticity|Multiple Sclerosis,United Kingdom,Gorleston-on-Sea,Norfolk,1,Sativex|Placebo,DRUG|DRUG,Number of Subjects Who Experience Treatment Failure.,Change in Mean Daily Spasticity Severity as Measured on a Spasticity Severity 0-10 Numerical Rating Scale (NRS).|Change in Modified Ashworth Scale.|Change in Motricity Index|Timed 10-metre Walk.|Daily Sleep Disruption NRS|Subject Global Impressions of Change.|Carer Global Impressions of Change for Functional Ability|Carer Global Impressions of Change for Ease of Transfer,True,2011-06-17
NCT04933110,Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis,Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis in the Very Early Stage.,UNKNOWN,2021-07-05,2021-09-06,2021-09-20,2021-06-25,2021-06-21,OBSERVATIONAL,,90.0,ESTIMATED,Uğur OVACIK,OTHER,Istanbul University - Cerrahpasa,OTHER,Multiple Sclerosis,multiple sclerosis|upper limb function|activity|participation,,,,0,,,Nine Hole Peg Test|Minnesota Manual Dexterity Test|ABILHAND|Motor Activity Log-28|Community Integration Questionnaire,Hand Held Dynamometer|Hand Dynamometer|Pinchmeter|Tuning fork|Aesthesiometer|Fatigue Severity Scale|Symbol Digit Modalities Test|Hospital Anxiety and Depression Scale,False,
NCT03872583,Understanding Magnetic Resonance Imaging in Multiple Sclerosis,"Understanding Magnetic Resonance Imaging in Multiple Sclerosis - a Randomized, Controlled, Double Blind Trial",COMPLETED,2019-03-15,2022-12-01,2022-12-01,2024-01-03,2019-03-13,INTERVENTIONAL,NA,120.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,Sanofi,INDUSTRY,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome",Patient education|Disease-specific knowledge|Shared decision making,Germany,Hamburg,,1,Understanding MRI in MS (website)|Control website,OTHER|OTHER,Magnetic resonance imaging risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0),Emotions and attitude towards magnetic resonance imaging (MRI-EMA)|Control preference scale (CPS)|Threat by MS|Hospital Anxiety and Depression Scale (HADS)|Multifocal Approach to Sharing in Shared Decision Making (MAPPIN'SDM),False,
NCT01952483,Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients,Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients,COMPLETED,2012-08,2017-05-01,2017-06-30,2018-01-11,2013-09-30,OBSERVATIONAL,,108.0,ACTUAL,American University of Beirut Medical Center,OTHER,,,Multiple Sclerosis (MS),Multiple Sclerosis (MS),Lebanon,Beirut,Riad El Solh,1,,,Is there evidence of immune activation in MS patients deficient in Vitamin D and does Vitamin D supplementation reverse the immune activation?,Does Vitamin D deficiency result in lower cognitive performance in MS patients and does Vitamin D supplementation reverse the cognitive impairment?,False,
NCT00238654,A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy,"A Multicenter, Open-Label, Two-Arm Prospective Study to Evaluate the Impact of Patient Readiness to Self-Inject on Outcomes When Using the Copaxone® Prefilled Syringes [The ""READY"" Trial]",COMPLETED,2003-05,2008-07,2008-07,2011-04-12,2005-10-13,OBSERVATIONAL,,257.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,,,,,0,,,Adherence of self-injection assessed by self-report at each follow-up visit,,False,
NCT01302431,Nurse-Led Manualized Telephone Support Intervention,"An Exploratory Randomized Controlled Trial of a Manualized, Nurse-led, Telephone Intervention Support Service for Support Persons of People With Multiple Sclerosis",COMPLETED,2011-04,2013-10,2014-03,2014-12-03,2011-02-24,INTERVENTIONAL,NA,71.0,ACTUAL,"University of Dublin, Trinity College",OTHER,,,Multiple Sclerosis,experimental|intervention|nurse-led|nurse specialist|multiple sclerosis|support of caregivers,Ireland,Dublin,,2,Manualised nurse-led telephone support,OTHER,Support person/caregiver Self-efficacy,Support person/caregiver preparedness to care,False,
NCT03067025,"Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis","Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis",COMPLETED,2018-03-07,2019-09-16,2019-09-16,2019-11-20,2017-03-01,OBSERVATIONAL,,50.0,ACTUAL,The Hospital for Sick Children,OTHER,University of Alabama at Birmingham|Queen's University,OTHER|OTHER,Pediatric Multiple Sclerosis,,Canada,Toronto,Ontario,1,Actigraphy,DEVICE,"Sleep quality, duration and timing",,False,
NCT02086188,Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis,Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR),COMPLETED,2014-05,2019-04,2019-06,2023-10-18,2014-03-13,INTERVENTIONAL,PHASE4,28.0,ACTUAL,"Theodore R. Brown, MD MPH",OTHER,Astellas Pharma Inc,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Overactive Bladder|Incontinence|Voiding|Bladder Urgency|Pelvic Floor Exercises,United States,Kirkland,Washington,1,Mirabegron|Placebo,DRUG|DRUG,Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Final Visit,Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Titration Visit|Mean # of Micturitions/Day Based on Voiding Diaries|Mean # of Incontinence Episodes/Day|Mean Volume Voided/Micturition|Qualiveen Questionnaire|Subject Global Impression (Single Question),True,2023-10-18
NCT06218927,The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients,The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related Quality of Life in Multiple Sclerosis Patients,RECRUITING,2023-11-01,2026-12,2026-12,2024-01-23,2024-01-23,OBSERVATIONAL,,40.0,ESTIMATED,University Hospital Ostrava,OTHER,,,Multiple Sclerosis|Lower Urinary Tract Symptoms,Multiple Sclerosis|Lower Urinary Tract Symptoms|Autologous Hematopoietic Stem Cell Transplantation|Disease-Modifying Therapy|Quality of Life,Czechia,Ostrava,Moravian-Silesian Region,1,QoL monitoring,OTHER,QoL changes associated with MS treatment,Neurogenic Bladder Symptom Score (NBSS)|Patient satisfaction (PGI-I),False,
NCT07032246,Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study,Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study,NOT_YET_RECRUITING,2025-09-01,2028-08-31,2028-12-31,2025-06-22,2025-06-22,INTERVENTIONAL,NA,750.0,ESTIMATED,icometrix,INDUSTRY,"Ruhr University of Bochum|Technische Universität Dresden|Casa di Cura IGEA|General University Hospital, Prague|Charite University, Berlin, Germany",OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis|Radiologically Isolated Syndrome|Clinically Isolated Syndrome,Multiple Sclerosis|Quantitative Brain MRI|icobrain mr|Neurodegeneration|Disease activity|Disease worsening,Czechia,Prague,Prague,6,quantitative brain MRI (icobrain mr)|Standard of Care (SOC),DEVICE|OTHER,Impact of using icobrain mr on detecting (inflammatory or smouldering) disease activity|Impact of using icobrain mr on the clinical outcome,"Proportion of patients who switch treatment|Objective of each treatment switch|Role of disease activity on MRI in the decision to make a treatment switch|Role of quantitative brain MRI in the decision to make a treatment switch|Neurologist confidence in the clinical decision-making process (Likert scale: 1 - not confident, 2 - slightly confident, 3 - somewhat confident, 4 - fairly confident, 5 - very confident)|Neurologist confidence in confirming the diagnosis of MS (Likert scale: 1 - not confident, 2 - slightly confident, 3 - somewhat confident, 4 - fairly confident, 5 - very confident)|Neurologist confidence in confirming the conversion to SPMS (Likert scale: 1 - not confident, 2 - slightly confident, 3 - somewhat confident, 4 - fairly confident, 5 - very confident)|Proportion of patients with detected smouldering or inflammatory disease components|Reported MRI findings at baseline|Proportion of patients with relapse associated worsening (RAW)|Proportion of patients with smouldering associated worsening (SAW)|Proportion of relapse-free participants between month 12 and month 24|Relapse rate between month 12 and month 24|Proportion of participants with EDSS progression between month 12 and 24|Change in clinical score Nine Hole Peg Test (9HPT) between month 12 and 24|Change in clinical score Timed 25-Foot Walk (T25WT) between month 12 and 24|Change in clinical score Symbol Digit Modalities Test (SDMT) between month 12 and 24|MRI findings as assessed by icobrain mr in combination with the radiologist at month 24",False,
NCT04115488,Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®,Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),COMPLETED,2019-10-01,2021-08-23,2022-02-07,2023-07-03,2019-10-04,INTERVENTIONAL,PHASE3,265.0,ACTUAL,Polpharma Biologics S.A.,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis (RRMS),,Belarus,Grodno,,48,Intravenous (IV) infusions,BIOLOGICAL,Cumulative Number of New Active Lesions Over 24 Weeks,"Cumulative Number of New Active Lesions Over 48 Weeks|Cumulative Number of New GdE T1-weighted Lesions Over 24 Weeks|Cumulative Number of New GdE T1-weighted Lesions Over 48 Weeks|Number of Patients Without New GdE T1-weighted Lesions Over 24 Weeks|Number of Patients Without New GdE T1-weighted Lesions Over 48 Weeks|Cumulative Number of New/Enlarging T2-weighted Lesions Over 24 Weeks|Cumulative Number of New/Enlarging T2-weighted Lesions Over 48 Weeks|Number of Persistent Lesions After 24 Weeks|Number of Persistent Lesions After 48 Weeks|Annualized Relapse Rate After 24 Weeks|Annualized Relapse Rate After 48 Weeks|Change From Baseline in Expanded Disability Status Scale (EDSS) After 24 Weeks|Change From Baseline in Expanded Disability Status Scale (EDSS) After 48 Weeks|Percentage of Subjects With Anti-drug (Natalizumab) Antibodies (ADA) and Persistent Antibodies After 24 Weeks|Percentage of Subjects With Anti-drug (Natalizumab) Antibodies (ADA) and Persistent Antibodies After 48 Weeks|Percentage of Subjects With Neutralizing Antibodies After 24 Weeks|Percentage of Subjects With Neutralizing Antibodies After 48 Weeks|Number of Subjects With Any Treatment-Emergent Adverse Event (TEAE) or Any Treatment-Emergent Serious Adverse Event (SAE) After 24 Weeks|Number of Subjects With Any Treatment-Emergent Adverse Event (TEAE) or Any Treatment-Emergent Serious Adverse Event (SAE) After 48 Weeks|Natalizumab Trough Concentration (Ctrough) Over Time, Week 8|Natalizumab Trough Concentration (Ctrough) Over Time, Week 16|Natalizumab Trough Concentration (Ctrough) Over Time, Week 24|Natalizumab Trough Concentration (Ctrough) Over Time, Week 32|Natalizumab Trough Concentration (Ctrough) Over Time, Week 48|Number of Patients Without New/Enlarging T2-weighted Lesions Over 24 Weeks|Number of Patients Without New/Enlarging T2-weighted Lesions Over 48 Weeks|Number of Patients With Abnormal Clinical Laboratory Tests at Week 24|Number of Patients With Abnormal Clinical Laboratory Tests at Week 48|Number of Patients With Abnormal Findings in Physical Examination at Week 24|Number of Patients With Abnormal Findings in Physical Examination at Week 48|Change From Baseline in Blood Pressure at Week 24|Change From Baseline in Blood Pressure at Week 48|Change From Baseline in Heart Rate at Week 24|Change From Baseline in Heart Rate at Week 48",True,2023-07-03
NCT06063850,AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy,"A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)",RECRUITING,2024-06-12,2026-11-30,2031-12,2025-09-04,2023-10-03,INTERVENTIONAL,PHASE1|PHASE2,12.0,ESTIMATED,UniQure Biopharma B.V.,INDUSTRY,,,Mesial Temporal Lobe Epilepsy,Epilepsy|Temporal Lobe|Hippocampal Sclerosis|Epileptic Syndromes,United States,Birmingham,Alabama,18,AAV9-hSyn1-miGRIK2,GENETIC,To evaluate the safety and tolerability of AMT-260 in adults with unilateral refractory MTLE.,To evaluate first signs of efficacy of AMT-260.|To evaluate the biodistribution properties of AMT-260.,False,
NCT04142008,Walk With Me: a Mobile Application to Improve Walking in Persons With MS,Walk With Me: a Mobile Application to Improve Walking in Persons With MS,COMPLETED,2018-09-01,2019-08-31,2019-12-31,2020-05-21,2019-10-29,INTERVENTIONAL,NA,19.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,,Belgium,Hasselt,,1,Walk with Me app,DEVICE,VAS score pre 6-minute walk test (6 MWT) indoor|VAS score pre 6-minute walk test (6 MWT) outdoor|VAS score pre 6-minute walk test (6 MWT) indoor|VAS score pre 6-minute walk test (6 MWT) outdoor|VAS score pre 6-minute walk test (6 MWT) indoor|VAS score pre 6-minute walk test (6 MWT) outdoor|Distance walked index during the 6MWT indoor|Distance walked index during the 6MWT outdoor|Distance walked index during the 6MWT indoor|Distance walked index during the 6MWT outdoor|MSWS-12 score|MSWS-12 score|the Paced Auditory Serial Addition Test (PASAT) (Cognitive Fatigability)|the Paced Auditory Serial Addition Test (PASAT) (Cognitive Fatigability)|the Symbol Digit Modality Test (SDMT) (Cognitive fatigability)|the Symbol Digit Modality Test (SDMT) (Cognitive fatigability),5 times sit to stand (5xSTS) (Motor Function test)|5 times sit to stand (5xSTS) (Motor Function test)|Timed 25 Foot Walk (T25FW) (Motor Function)|Timed 25 Foot Walk (T25FW) (Motor Function)|Nine Hole Peg Test (NHPT)|Nine Hole Peg Test (NHPT)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Fatigue severity scale (FSS)|Fatigue severity scale (FSS)|Multiple Sclerosis Impact Scale (MSIS-29)|Multiple Sclerosis Impact Scale (MSIS-29)|Health-related quality of life (SF-36)|Health-related quality of life (SF-36)|International Physical Activity Questionnaire (IPAQ)|International Physical Activity Questionnaire (IPAQ),False,
NCT01925690,Development of a Motivational Intervention to Improve Treatment Adherence in MS,Development of a Motivational Intervention to Improve Treatment Adherence in MS,COMPLETED,2013-02,2015-04,2015-09,2015-12-02,2013-08-20,INTERVENTIONAL,NA,80.0,ACTUAL,"University of Missouri, Kansas City",OTHER,National Multiple Sclerosis Society,OTHER,Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis|Disease modifying medication|Relapsing-Remitting MS|Motivational Interviewing|Telephone Counseling,United States,Kansas City,Missouri,2,Motivational Interviewing-Cognitive Behavioral Therapy|Brief Education,BEHAVIORAL|BEHAVIORAL,Adherence Treatment Survey,Adherence Treatment Survey|Adherence Treatment Survey|Adherence Treatment Survey,False,
NCT03302442,Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis,Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis,COMPLETED,2017-05-01,2017-08-01,2017-10-01,2017-10-05,2017-10-05,OBSERVATIONAL,,3000.0,ACTUAL,Nantes University Hospital,OTHER,,,Relapsing-remitting Multiple Sclerosis,,France,Nantes,,1,Non interventional study,OTHER,Relapse within first year of treatment,Occurrence of clinical event at Two years|Progression of disability|Radiological disease activity|Adverse drug reaction,False,
NCT03539094,Intermittent Fasting in Multiple Sclerosis,Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis,COMPLETED,2018-01-01,2022-01-20,2022-01-20,2024-01-16,2018-05-29,INTERVENTIONAL,NA,61.0,ACTUAL,Washington University School of Medicine,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Intermittent fasting|western diet|microbiome,United States,St Louis,Missouri,1,Intermittent fasting,OTHER,Leptin,Peripheral metabolic and inflammatory profiling|Anthropometric measure|Anthropometric measure|Gut microbiota,False,
NCT03150966,The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients,The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients,COMPLETED,2016-06-08,2017-08-10,2017-11-07,2018-09-17,2017-05-12,INTERVENTIONAL,PHASE2,41.0,ACTUAL,Tabriz University of Medical Sciences,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Nanocurcumin|MicroRNAs|Th17 cells|Treg cells,Iran,Tabriz,,1,Nanocurcumin|Placebo,DRUG|DRUG,EDSS measurment,Treg cells frequency|Th17 cells frequency|IL-17 and RORγt expression|IL-17 secretion levels|microRNAs (miRNA-326) expression|TGF-β and FoxP3 expression|TGF-β secretion levels|microRNAs (miRNA-106b and miRNA-25) expression,False,
NCT00207727,A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis,"A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis",COMPLETED,2004-07,2006-03,2006-08,2012-04-23,2005-09-21,INTERVENTIONAL,PHASE2,249.0,ACTUAL,"Centocor, Inc.",INDUSTRY,Centocor BV,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis,,,,0,CNTO 1275,DRUG,The Cumulative Number of Newly Gadolinium-enhancing T1-weighted Lesions on Cranial Magnetic Resonance Imaging (MRI)s Through Week 23.,Relapses of Multiple Sclerosis (MS) Through Week 23|Change From Baseline in Expanded Disability Status Scale (EDSS),True,2009-12-02
NCT03122873,Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis,Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis,COMPLETED,2016-02-01,2017-06-30,2017-06-30,2017-08-30,2017-04-21,OBSERVATIONAL,,125.0,ACTUAL,Mayo Clinic,OTHER,,,Multiple Sclerosis,,United States,Rochester,Minnesota,1,,,Difference in quantitative measure of strength between extended positions of the neck and fully flexed position of the neck (McArdle's sign),Relative sensitivity of clinical versus instrument-based detection of McArdle's sign.,False,
NCT00612872,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects,Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects,TERMINATED,2008-01,2009-11-01,2009-11-01,2019-04-03,2008-02-12,INTERVENTIONAL,PHASE1,46.0,ACTUAL,Institute for Neurodegenerative Disorders,OTHER,,,Parkinson Disease|Alzheimer Disease|Healthy Controls|Multiple Sclerosis,,United States,New Haven,Connecticut,1,[123I]CLINDE,DRUG,"To assess the dynamic uptake and washout of 123-I CLINDE, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD).",,False,
NCT00818038,A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function,"Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function",COMPLETED,2009-03,2011-03,2011-03,2014-06-27,2009-01-07,OBSERVATIONAL,,30.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,RRMS|Relapsing Remitting|MS,,,,0,BG0002 (natalizumab),DRUG,Change in bladder function as measured by UDI-6 compared to baseline over 6 months of TYSABRI treatment.,Change from baseline over 6 months of TYSABRI treatment in the number of urinary incontinence episodes per participant per week.|Change from baseline over 6 months of TYSABRI treatment in the number of micturitions per participant per day.|Change in NARCOMS PSB scores from baseline over 6 months of TYSABRI treatment.|Change in IIQ-7 scores from baseline over 6 months of TYSABRI treatment.,False,
NCT06832293,My MS and My Menstrual Cycle,Measuring MS Symptoms in Relation to Menstrual Cycles: Exploring How MS Symptoms May be Affected at Different Times During a Menstrual Cycle in Females Living With Multiple Sclerosis,RECRUITING,2025-02-19,2027-01-31,2027-01-31,2025-03-26,2025-02-18,OBSERVATIONAL,,300.0,ESTIMATED,University of Alberta,OTHER,,,Multiple Sclerosis|Menstrual Cycle,Multiple Sclerosis|Menstrual Cycle|MS Symptoms|Fatigue|Cognition,Canada,Calgary,Alberta,2,,,Difference in the Modified Fatigue Impact Scale-5 (MFIS-5) Score Across Menstrual Cycle Phases Over Six Months,Qualitative Self-Reported Differences in Self-Perceived Cognitive Function Across Menstrual Cycle Phases|Qualitative Self-Reported Differences in Hospital Anxiety and Depression Scale (HADS) Scores|Qualitative Self-Reported Difference in Mini-COPE Scores Across Menstrual Cycle Phases|Qualitative Self-Reported Difference in MFC (Motivation for Cognition) Scores Across Menstrual Cycle Phases|Qualitative Self-Reported Difference in SymptoMScreen Scores Across Menstrual Cycle Phases|Qualitative Self-Reported MSNQ (Multiple Sclerosis Neuropsychological Screening Questionnaire) Scores,False,
NCT01720849,"Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis",,UNKNOWN,2012-12,2016-05,,2015-06-30,2012-11-02,OBSERVATIONAL,,50.0,ESTIMATED,Vestre Viken Hospital Trust,OTHER,,,Multiple Sclerosis|EDSS 4-7,,Norway,Drammen,,1,Fampyra,DRUG,change from baseline in visual evoked potential after 2 weeks and 3 months,,False,
NCT01144117,The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis,"Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis",UNKNOWN,2009-11,2012-12,2013-04,2011-08-08,2010-06-15,INTERVENTIONAL,PHASE2,56.0,ESTIMATED,"Rigshospitalet, Denmark",OTHER,Danish Research Centre for Magnetic Resonance,OTHER,Multiple Sclerosis (Primary or Secondary Progressive Phase).,Progressive Multiple Sclerosis,Denmark,Copenhagen,Oesterbro,1,Erythropoietin,DRUG,"The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the EPO-treatment group.",Comparisons between the placebo-and the EPO-group regarding:difference in maximum gait distance between baseline and week 24.|Comparisons between the placebo-and the EPO-group regarding:difference in 9-hole peg test|Comparisons between the placebo-and the EPO-group regarding:difference in TRAIL making B,False,
NCT06310343,ADAs to Alemtuzumab,A Study of a New Assay to Detect Anti-drug Antibodies to Alemtuzumab and Their Potential Impact in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2022-07-12,2025-11-30,2025-11-30,2025-03-17,2024-03-15,OBSERVATIONAL,,15.0,ACTUAL,Queen Mary University of London,OTHER,,,Multiple Sclerosis,,United Kingdom,London,Second Floor Neurophys Dept,1,Alemtuzumab,DRUG,To quantify the longitudinal changes in alemtuzumab ADAs,"1. Relative occurrence of infusion-related reactions based on high alemtuzumab ADA levels prior to course 2.|2. Relative change in lymphocyte counts after the second infusion of alemtuzumab in ADA positive patients to assess the health economic impact of infusion-related reactions.|3. Relative change in relapses or EDSS score based on alemtuzumab ADA levels to assess the health economic impact of disease activity.|4. Relative change in relapses or EDSS score based on alemtuzumab ADA levels|5. Relative change in T2 lesion number or Gd-enhancing lesions, and serum NfL based on alemtuzumab ADA levels to assess the health economic impact of disease activity.",False,
NCT01181115,Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS),An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis,COMPLETED,2010-04,2011-10,2011-10,2013-09-16,2010-08-13,INTERVENTIONAL,PHASE3,60.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Chinese Patients|Relapsing MS|Safety|Avonex|Tolerability|Gadolinium|Interferon Beta 1a,China,Baotou,,10,Avonex,DRUG,The number and proportion of subjects with adverse events (AEs)|Assessment of clinical laboratory parameters|Assessment of vital signs and physical examinations|Assessment of electrocardiogram (ECG)|Assessment of immunogenicity|Incidence of depression|Incidence of flu-like symptoms|Subject assessment of injection site pain|Clinical assessment of the injection site,Assess safety of Avonex by evaluating changes in the Expanded Disability Status Scale (EDSS) score over time|Number of Gd-enhancing lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment|Number of new or newly enlarging T2-weighted lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment|Volume of T2-weighted lesions on brain MRI scans taken after 6 months following initiation of Avonex treatment|Assess pharmacodynamic response to Avonex by evaluating the change from baseline in serum levels of neopterin,False,
NCT05635890,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,COMPLETED,2022-05-06,2022-08-10,2022-09-20,2022-12-02,2022-12-02,INTERVENTIONAL,NA,30.0,ACTUAL,October 6 University,OTHER,,,Vestibular Rehabilitation in MS,"Trunk kinetic and kinematic parameters, Vestibular rehabilitation, Multiple Sclerosis.",Egypt,El-Sheikh Zayed City,Giza Governorate,1,Cawthorne Cooksey exercise protocol|conventional vestibular rehabilitation,OTHER|OTHER,Isokinetic dynamometer (average power)|Isokinetic dynamometer (acceleration time)|Isokinetic dynamometer (deceleration time),,False,
NCT01656148,FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra,Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra,COMPLETED,2012-06,2014-05,2014-05,2018-08-23,2012-08-02,INTERVENTIONAL,PHASE4,108.0,ACTUAL,University of Southern Denmark,OTHER,Region of Southern Denmark|Biogen,OTHER|INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Walking disablility|Mobility|Six Spot Step Test|Outcome measures|Fampridine-SR|Fampyra,Denmark,Esbjerg,,4,Fampridine-SR,DRUG,The mean change in SSST,"Mean change in T25FW|Mean change in hip flexion, knee flexion and knee extension force|Mean change on Chair Rise Test|Mean change on 9-Hole Peg Test (9HPT)|Mean change on Symbol Digit Modalitites Test (SDMT)",False,
NCT01294176,Lipoic Acid as a Treatment for Acute Optic Neuritis,Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study,COMPLETED,2011-01,2016-11,2016-11,2019-04-26,2011-02-11,INTERVENTIONAL,PHASE1,31.0,ACTUAL,Oregon Health and Science University,OTHER,,,Optic Neuritis,Optic Neuritis|Lipoic Acid|Multiple Sclerosis|Antioxidant|OCT|Acute,United States,Portland,Oregon,1,Lipoic Acid,DRUG,"The primary outcome measure will be the difference from baseline in retinal nerve fiber layer (RNFL) thickness of the affected optic nerve, as determined by OCT, at 12 and 24weeks post LA treatment.","Secondary outcome measures to assess optic nerve injury will be changes from baseline in the RNFL thickness at week 24, and changes from baseline in low- and high-contrast visual acuity, contrast sensitivity, and visual field changes at weeks 12 and 24.",False,
NCT04548310,Muscle Fatigue in Patients With Multiple Sclerosis,"Effect of Muscle Fatigue on Strength, Joint Position Sensation, and Walking in Patients With Multiple Sclerosis",COMPLETED,2020-09-14,2022-05-27,2022-05-27,2022-08-05,2020-09-14,OBSERVATIONAL,,36.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|gait|sensation|fatigue,Turkey (Türkiye),Ankara,,1,Muscles Fatigue,OTHER,Knee proprioception|Knee strength|Gait|Perceived Exertion,,False,
NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis,COMPLETED,2019-09-23,2024-11-26,2024-11-26,2024-12-27,2019-06-24,INTERVENTIONAL,PHASE2,125.0,ACTUAL,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Cullman,Alabama,37,Tolebrutinib,DRUG,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Potentially Clinically Significant Abnormalities,Number of new gadolinium (Gd)-enhancing T1 hyperintense lesions|Number of new or enlarging T2 lesions|Total number of Gd-enhancing T1-hyperintense lesions|Number of participants wih relapse (Annualized Relapse rate)|Change in Expanded Disability Status Scale (EDSS) from baseline over time,False,
NCT06718920,Adverse Childhood Experiences in Patients With MS: Impact on Quality of Life and on Coping Strategies Towards the Disease and Its Treatment,"Single-center Observational Study to Characterize Adverse Childhood Experiences (ACE) in Patients With Multiple Sclerosis and Their Impact on Quality of Life, Disease Coping Strategies, and Adherence to Disease Course-modifying Therapies",RECRUITING,2024-01-13,2025-12,2025-12,2025-02-26,2024-12-05,OBSERVATIONAL,,500.0,ESTIMATED,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,Multiple Sclerosis,ACE|multiple sclerosis|treatment adherence|adverse childhood experiences|quality of life,Italy,Rome,RM,1,,,To assess the prevalence of ACE in a cohort of patients with relapsing-remitting multiple sclerosis|To assess the prevalence of ACE in a cohort of patients with relapsing-remitting multiple sclerosis,To correlate the impact of ACE on quality of life and general distress|To correlate the impact of ACE on how the patient perceives and copes with the disease|To correlate the impact of ACE on treatment adherence|To correlate the impact of ACE on disease treatment,False,
NCT03424538,"The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients","The Effect of Variable Intensity Work on Postural Instability, Motion Performance and Quality of Life in Multiple Sclerosis Patients",COMPLETED,2018-02-05,2018-04-16,2018-06-10,2020-04-28,2018-02-07,INTERVENTIONAL,NA,2.0,ACTUAL,Somogy Megyei Kaposi Mór Teaching Hospital,OTHER,University Medical Center Groningen,OTHER,"Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Primary Progressive",multiple sclerosis|posture|neurorehabilitation|balance,Hungary,Kaposvár,Somogy County,1,Neurorehabilitation|Physiotherapy,OTHER|OTHER,Postural instability|quality of life|balance test|mobility test,depression scale,False,
NCT04465448,Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping),Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping),TERMINATED,2020-12-17,2022-06-16,2022-06-16,2023-12-18,2020-07-10,OBSERVATIONAL,,18.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,White Matter Hyperintensity|Multiple Sclerosis,,France,Paris,,1,MRI,OTHER,"QSM signal difference at two acquisition times in white matter, on an individual scale",,False,
NCT02686684,Tecfidera Diffusion Tensor Imaging,"An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2015-11,2016-10,2016-10,2016-10-26,2016-02-19,OBSERVATIONAL,,115.0,ACTUAL,University at Buffalo,OTHER,,,"Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging",,,,,0,Dimethyl fumarate,DRUG,Change in thalamus pathology as measured by FIRST analysis,Change in normal appearing white matter (NAWM) pathology as measured by SIENAX v2.6,False,
NCT03215433,Study of Biomarkers of the Response to Biotine,"Single-centre, Observational Study, Concerning Blood-lipid Biomarkers of the Response to Treatment With Biotine, Prescribed in the Context of a Nominative TAU (Temporary Authorized Use) in Patients With an Inactive Progressive Form of Multiple Sclerosis (MS).",COMPLETED,2016-12-08,2019-01-23,2019-01-23,2019-09-18,2017-07-12,OBSERVATIONAL,,25.0,ACTUAL,Centre Hospitalier Universitaire Dijon,OTHER,,,Multiple Sclerosis|Biotine,,France,Dijon,,1,,,validated disability scale (EDSS)|Walking test|Evolution of blood lipid biomarkers,,False,
NCT04042415,Calorie Restriction in Multiple Sclerosis,Calorie Restriction as a Novel Therapeutic Tool to Manipulate Immunity and Improve Therapeutic Potential of First Line Drug Treatments During Relapsing Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2020-07-14,2025-09,2025-09,2024-08-20,2019-08-02,INTERVENTIONAL,NA,93.0,ACTUAL,Federico II University,OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,"Multiple Sclerosis, Relapsing-Remitting|Caloric Restriction",Multiple Sclerosis|Immuno-metabolism|Calorie restriction|Treg cells|Inflammation,Italy,Pozzilli,IS,1,Caloric restriction|Caloric restriction without cow's milk and gluten,OTHER|OTHER,"Change of the ""no evident disease activity"" (NEDA) from baseline clinical status of MS patients at 6, 12, and 24 months","Percentage of different immune cells populations (circulating immune cells, regulatory T cells, conventional T cells, etc.)|Mitotic cell divisions of conventional T cells|Glycolytic metabolism of T cells (mpH/min)|Oxidative metabolism of T cells (pMol/min)|Circulating adipokines (pg/ml)|Change in the expression level of molecules involved in the signalling pathway of T-cell receptor (TCR)|Change in the composition of the gut microbiota",False,
NCT02665221,"Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY","Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.",TERMINATED,2015-07,2016-09,2016-09,2018-01-18,2016-01-27,INTERVENTIONAL,PHASE4,30.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|erythema,United States,New York,New York,1,No Treatment Arm|Topical Preparation H arm,OTHER|DRUG,Patient Erythema Self-Assessment (PSA) Score 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline PSA Score of Injection Site Erythema at Least 2 Hours After PLEGRIDY Injection.,"Width of Injection Site Erythema in Millimeters 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline Width of Injection Site Erythema at Least 2 Hours After Injection.|Number of Patients Experiencing Injection Site Reaction Erythema, Itching and Pain.",True,2018-01-18
NCT06643390,A Study of MK-2225 in Healthy Participants (MK-2225-003),"A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2225 in Healthy Participants",COMPLETED,2023-11-21,2025-07-14,2025-07-14,2025-07-29,2024-10-16,INTERVENTIONAL,PHASE1,32.0,ACTUAL,Merck Sharp & Dohme LLC,INDUSTRY,,,Systemic Sclerosis,,United States,Miami,Florida,2,MK-2225|Placebo,DRUG|OTHER,Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinue Study Treatment Due to an AE,Maximum Plasma Concentration (Cmax) of MK-2225|Lowest Plasma Concentration (Ctrough) of MK-2225|Time to Maximum Plasma Concentration (Tmax) of MK-2225|Area Under the Concentration-Time Curve from Time 0 to Tau (AUC0-τ) of MK-2225|Apparent Terminal Half-life (t1/2) of MK-2225|Mean Accumulation Ratio of MK-2225,False,
NCT00843128,The Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Multiple Sclerosis Patients,Phase II Study of the Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Acute Stroke Patients: A Randomized Controlled Trial.,COMPLETED,2009-03,2010-08,2010-08,2011-04-08,2009-02-13,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,,Israel,Jerusalem,,1,robot-assisted gait training (RAGT)|conventional walking training (CWT),DEVICE|DEVICE,Functional Ambulatory Capacity (FAC) scale and the 6-minutes walking distance,"Time up & Go (TUG) test, 10 Meter Walking test, Berg balance test, EDSS score, FIM score and SF36 questioner for quality of life.",False,
NCT02305264,Imaging of Intracerebral Inflammation in MS,Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis,COMPLETED,2012-03-19,2018-09-10,2018-09-10,2022-09-16,2014-12-02,INTERVENTIONAL,NA,61.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",,France,Paris,,2,18F-DPA-714 and 18F-FDG,DRUG,Whole brain Binding Potential (BP) of 18F-DPA-714,Binding potential of 18F-DPA-714 in segmented brain regions|Binding potential of 18F-DPA-714 in subgroups of MS patients|Predictive value of PET 18F-DPA-714 BP on neurological clinical metrics|Predictive value of PET 18F-DPA-714 BP on MRI metrics,False,
NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,"A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability",COMPLETED,2003-10,2009-12,2009-12,2013-09-16,2007-06-27,INTERVENTIONAL,PHASE4,20.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,recovery of efficacy|MxA protein|neutralizing antibodies|Multiple sclerosis,Australia,NSW,,2,Interferon-beta-1a|methylprednisolone,DRUG|DRUG,return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA,Proportion of patients becoming neutralizing antibody negative|proportion of patients becoming neutralizing antibody positive after treatment with AVONEX|proportion of patents relapse free|total relapses|proportion of patients with an increase in EDSS of 1 point|Brain atrophy and cumulative number of enlarging T2 lesions on MRI,False,
NCT03927092,Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire,Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire,COMPLETED,2016-05,2016-05,2016-05,2019-04-29,2019-04-25,OBSERVATIONAL,,58.0,ACTUAL,Ege University,OTHER,,,Multiple Sclerosis,multiple sclerosis|surveys and questionnaires|diagnostic self evaluation,,,,0,Multiple Sclerosis Knowledge Questionnaire,OTHER,reliability of the questionnaire,Number of correct answers,False,
NCT04032431,Upper Limb Telerehabilitation With Virtual Reality in Multiple Sclerosis,The Effect of a Telerehabilitation Virtual Reality Intervention on Functional Upper Limb Activities in People With Multiple Sclerosis,UNKNOWN,2020-12-01,2021-09-01,2022-09-01,2020-03-24,2019-07-25,INTERVENTIONAL,NA,24.0,ESTIMATED,University of Cagliari,OTHER,Azienda Sanitaria Locale di Cagliari|Tel Aviv University,OTHER|OTHER,Multiple Sclerosis,Rehabilitation|Virtual Reality|Upper limb|Neurorehabilitation,Israel,Tel Litwinsky,,2,Telerehab VR intervention,BEHAVIORAL,Change in Nine Hole Peg Test (9HPT),"Action Research Arm Test (ARAT)|Manual Ability Measure-36 (MAM-36)|Value of ""Impression of change"" parameter",False,
NCT01888354,Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations,Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations,COMPLETED,2013-04,2014-08,2014-08,2014-09-16,2013-06-27,INTERVENTIONAL,PHASE4,25.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,,,Multiple Sclerosis (MS),MS|Multiple Sclerosis,United States,Oceanside,California,2,H.P. Acthar Gel (repository corticotropin injection),DRUG,Comparison of EDSS Mean Recovery between 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups,Comparison of ambulation between the 5-day vs.14-day SQ 80 IU ACTHar Gel therapy groups|Comparison of upper extremity function between the 5-day vs.14-day SQ 80 IU ACTHar Gel therapy groups|Comparison of subjective impressions of effectiveness between the 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups|Compare visual function between 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups|Comparison of cognitive function between the 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups,False,
NCT01768039,Vitamine D in Multiple Sclerosis,Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis,UNKNOWN,2013-03,2014-08,2014-10,2013-01-15,2013-01-15,INTERVENTIONAL,PHASE3,240.0,ESTIMATED,Mazandaran University of Medical Sciences,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Vitamin D|EDSS|ARR,Iran,Sari,Mazandaran,1,Vitamin D|Placebo,DRUG|DRUG,Expanded disability state scale score (EDSS),Annual relapse rate(ARR),False,
NCT00228228,TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis,T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis,UNKNOWN,2002-05,,2006-12,2006-08-29,2005-09-28,INTERVENTIONAL,PHASE3,80.0,,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,Multiple Sclerosis|T-cell vaccination|Autoreactive T cells,Israel,Ramat Gan,,1,T cell vaccination,BIOLOGICAL,The rate of progression to definite MS (second attack) during the study|Time to progression to definite MS (second attack),Change in the count of new gadolinium (GD) enhancing lesions from two baseline (B) MRIs to the final (F) MRIs|Change in total volume of new GD enhancing lesions from two baseline MRIs (B) to the final MRIs (F)|The change in neurological disability as measured by the Expanded Disability Status Scale (EDSS),False,
NCT05615207,The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis,The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis,UNKNOWN,2023-01-01,2023-11-01,2023-11-01,2023-02-08,2022-11-14,INTERVENTIONAL,NA,10.0,ESTIMATED,Dominican University New York,OTHER,,,Falls|Motor Imagery|Multiple Sclerosis|Balance|Fatigue,,United States,Orangeburg,New York,1,Motor Imagery as compared to physical practice for balance tasks,OTHER,Berg Balance Test,MS Impact Scale-29 (MSIS29)|Fatigue Severity Scale (FSS)|Activities-Specific Balance Confidence scale (ABC),False,
NCT04634994,Novel Assessment of Synaptic Density in Progressive MS,Novel Assessment of Synaptic Density in Progressive MS,UNKNOWN,2021-08,2022-08,2022-08,2021-07-21,2020-11-18,INTERVENTIONAL,EARLY_PHASE1,30.0,ESTIMATED,Brigham and Women's Hospital,OTHER,Massachusetts General Hospital,OTHER,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Relapsing Multiple Sclerosis|Multiple Sclerosis,multiple sclerosis|MS|PPMS|SPMS|RRMS|Synaptic Density|PET,United States,Boston,Massachusetts,1,[F-18]SDM-8,DRUG,Tissue volume of Distribution (Vt),Standardized uptake values (SUV),False,
NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMPLETED,2018-09-11,2019-08-26,2020-05-05,2021-10-08,2018-06-18,INTERVENTIONAL,PHASE2,284.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Relapsing Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis|Secondary progressive Multiple Sclerosis|Bioequivalence|Pharmacokinetics|Neurofilament light chain|Pre-filled Syringe|Auto-injector|adult|AI|PFS|OMB157,United States,Fullerton,California,41,ofatumumab with PRF|ofatumumab with AI,COMBINATION_PRODUCT|COMBINATION_PRODUCT,Bioequivalence of 20 mg Ofatumumab Injected by Pre-filled Syringe (PFS) vs Autoinjector (AI) to Abdomen as Measured by AUCtau|Bioequivalence of 20 mg Ofatumumab Injected by Pre-filled Syringe (PFS) vs Autoinjector (AI) to Abdomen as Measured by Cmax,Pharmacokinetics of the Study Drug as Measured by AUCtau for PFS and AI Devices When Administered to Abdomen or Thigh|Pharmacokinetics of the Study Drug as Measured by Cmax for PFS and AI Devices When Administered to Abdomen or Thigh|Plasma Concentrations of the Study Drug for PFS and AI Devices When Administered to Abdomen or Thigh|Percentage of Patients With Anti-ofatumumab Antibodies,True,2020-10-09
NCT02286557,Testing the Effects of Methylphenidate on Multiple Sclerosis,"Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial",COMPLETED,2014-10,2025-02-28,2025-03-04,2025-09-02,2014-11-10,INTERVENTIONAL,PHASE2,36.0,ESTIMATED,Kessler Foundation,OTHER,,,Fatigue in Multiple Sclerosis,Methylphenidate|Multiple Sclerosis|Cognitive Fatigue,United States,East Hanover,New Jersey,1,Methelphenidate|Placebo,DRUG|DRUG,Fatigue - Modified Fatigue Impact Scale,Processing Speed - Symbol Digit Modalities Test,False,
NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis","A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis",TERMINATED,2010-03,2012-04,2012-04,2014-09-03,2010-01-28,INTERVENTIONAL,PHASE3,84.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Relapsing Remitting Multiple Sclerosis,MS,United States,Cullman,Alabama,42,BG00002 (natalizumab)|interferon beta-1a|glatiramer acetate,DRUG|DRUG|DRUG,Incidence of Treatment-emergent Serious Adverse Events (SAEs),,True,2014-08-13
NCT03803800,Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis,Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis,COMPLETED,2019-01-09,2019-12-01,2019-12-09,2020-02-13,2019-01-15,INTERVENTIONAL,NA,31.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,Rehabilitation|Periodized exercise therapy|Ergogenic supplementation,Belgium,Diepenbeek,Limburg,1,"Classic, progressive endurance training|Periodized exercise training|beta-alanine",OTHER|OTHER|DIETARY_SUPPLEMENT,Exercise capacity|Serum lactate|Body composition|Body mass index|Strength measurement|Muscle carnosine concentration,,False,
NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®,COMPLETED,2012-04-30,2016-12-22,2017-04-05,2018-04-05,2011-12-13,OBSERVATIONAL,,1085.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Cognition|Physical Activity|Relapsing Remitting Multiple Sclerosis,Albania,Multiple Locations,,17,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Cognitive performance as measured by SDMT (Symbol Digit Modalities Test)|Physical activity as measured by the Baecke questionnaire,Disability as measured by EDSS (Expanded Disability Status Scale)|Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions)|Depression as measured by the CES-D (Center for Epidemiologic Studies Depression)|Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life),False,
NCT03860675,Assessment of Walking-related Fatigability in Patients With Multiple Sclerosis.,"Clinical Profiling, Manifestation and Assessment of Walking-related Performance Fatigability in Patients With Multiple Sclerosis: a Cross Sectional Study",COMPLETED,2017-12-01,2018-05-31,2018-05-31,2019-03-04,2019-03-04,INTERVENTIONAL,NA,85.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,OTHER|OTHER,Multiple Sclerosis,,Belgium,Diepenbeek,,3,Assessment of walking-related fatigability,DIAGNOSTIC_TEST,Deceleration index,Symptom Inventory Questionnaire|Symptom Inventory Questionnaire|spasticity|spasticity|Strength|Strength|Balance|Balance|VAS fatigue|VAS fatigue|heart rate|heart rate|gait parameter|gait parameter|Cognitive fatigability,False,
NCT04979819,The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis,The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis,UNKNOWN,2021-07-01,2021-10-31,2021-10-31,2021-07-28,2021-07-28,INTERVENTIONAL,NA,20.0,ESTIMATED,Marmara University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Istanbul,,1,Upper extremity endurance test (UULEX),OTHER,Upper extremity endurance testing,,False,
NCT04815967,Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity,"Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC",UNKNOWN,2021-11-16,2023-07-01,2024-07-01,2023-03-07,2021-03-25,INTERVENTIONAL,PHASE2|PHASE3,272.0,ESTIMATED,"Supernus Pharmaceuticals, Inc.",INDUSTRY,Solstice Neurosciences,INDUSTRY,Spasticity|Cerebrovascular Accident|Multiple Sclerosis|Traumatic Brain Injury|Cervical Spinal Cord Injury|Cerebral Palsy,Stroke|Traumatic Brain Injury|Monoplegia|Hemiplegia|Upper limb|Multiple Sclerosis|Cerebral Palsy|Cervical Spinal Cord Injury,United States,Downey,California,9,Phase 2; Low Dose MYOBLOC|Phase 2; High Dose MYOBLOC|Phase 2; Placebo|Phase 3; MYOBLOC|Phase 3; Placebo,DRUG|DRUG|DRUG|DRUG|DRUG,Effect of MYOBLOC on the Modified Ashworth Scale (MAS) for tone of the Primary Target Muscle Group (PTMG) [Phase 2 and Phase 3]|Effect of MYOBLOC on Clinical Global Impression of Change (CGI-C) Scale [Phase 2 and Phase 3],Effect of MYOBLOC on the Modified Ashworth Scale (MAS) for tone in each muscle group selected for treatment [Phase 2 and Phase 3]|Effect of MYOBLOC on the Patient Global Impression of Change (PGI-C) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Caregiver Global Impression of Change (GGI-C) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Pain Numeric Rating Scale (Pain-NRS) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Modified Barthel Index (MBI) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Modified Ashworth Scale (MAS) Responder Rate for the Primary Target Muscle Group (PTMG) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Modified Ashworth Scale (MAS) for tone in the Primary Target Muscle Group (PTMG) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Modified Ashworth Scale (MAS) for tone in each muscle group selected for treatment [Phase 2 and Phase 3]|Effect of MYOBLOC on Clinical Global Impression of Change (CGI-C) Scale [Phase 2 and Phase 3]|Effect of MYOBLOC on the Clinical Global Impression of Severity (CGI-S) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Patient Global Impression of Change (PGI-C) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Patient Global Impression of Severity (PGI-S) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Caregiver Global Impression of Change (GGI-C) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Caregiver Global Impression of Severity (GGI-S) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Pain Numeric Rating Scale (Pain-NRS) [Phase 2 and Phase 3]|Effect of MYOBLOC on the Modified Barthel Index (MBI) [Phase 2 and Phase 3],False,
NCT03436927,Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis,Comparison of the Effects of Two Different Virtual Reality Treatment Methods in Patients With Multiple Sclerosis: A Randomized Controlled Trial,COMPLETED,2016-07-15,2017-07-15,2017-07-15,2018-02-19,2018-02-19,INTERVENTIONAL,NA,51.0,ACTUAL,Biruni University,OTHER,Istanbul University,OTHER,Multiple Sclerosis,Multiple Sclerosis|rehabilitation|postural balance|exercise,,,,0,Nintendo Wii Fit Balance exercises|Balance Trainer Balance Exercises,OTHER|OTHER,Berg Balance Scale,Timed Up and Go Test|Six Minutes Walk Test|Fatigue Severity Scale,False,
NCT05828901,Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM),Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM),RECRUITING,2023-03-27,2026-03,2027-03,2024-11-14,2023-04-25,OBSERVATIONAL,,60.0,ESTIMATED,"Insel Gruppe AG, University Hospital Bern",OTHER,,,Multiple Sclerosis,,Switzerland,Bern,,1,S1PR analysis on immune cells,OTHER,"""On treatment"" MRI disease activity|""Off treatment"" MRI disease activity","""On treatment"" Relapse rate|""Off treatment"" Relapse rate and severity|""On treatment"" Disability progression|""Off treatment"" Severity",False,
NCT02317263,A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis,,WITHDRAWN,,2099-01,2099-01,2016-08-04,2014-12-15,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"University of California, Los Angeles",OTHER,,,Multiple Sclerosis,MS,,,,0,testosterone|placebo gel,DRUG|DRUG,Whole Brain Atrophy,,False,
NCT03508414,Nutritional Approaches in Multiple Sclerosis,Nutritional Approaches in Multiple Sclerosis,UNKNOWN,2017-04-11,2021-12-01,2021-12-01,2021-07-29,2018-04-25,INTERVENTIONAL,NA,111.0,ESTIMATED,"Charite University, Berlin, Germany",OTHER,,,Multiple Sclerosis,Relapse-remitting Multiple Sclerosis,Germany,Berlin,,1,ketogenic diet|Intermittent therapeutical fasting|Active comparator,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in cerebral T2 lesions from Baseline at 18 months,Change in neurological-functional disability: physical and cognitive function|Change in neurological-functional disability : physical function|annual relapse rate|progress of brain atrophy,False,
NCT06068582,Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis,Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis,RECRUITING,2023-04-16,2026-09,2026-09,2025-04-03,2023-10-05,INTERVENTIONAL,NA,270.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,"Universiteit Leiden|Personal Fitness Nederland|MS Vereniging Nederland|Merck BV|Genzyme, a Sanofi Company|MS Sherpa",OTHER|UNKNOWN|UNKNOWN|UNKNOWN|INDUSTRY|UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Cognition|Exercise|Employment|Prevention|Health-related Quality of Life,Netherlands,Amsterdam,,1,Strenghtening the brain|Strengthening the mind,BEHAVIORAL|BEHAVIORAL,Quality of Life,"Information processing speed|Information processing speed|Verbal fluency|Spatial Processing|Verbal New Learning and Memory|Visual New Learning and Memory|Executive Function|Self-Reported Cognitive Functioning|Work Participation and Productivity|Work Difficulties|Capability to carry out Work Activities|Quality of Working Life|Grey Matter Volume of the Brain|White Matter Volume of the Brain|Total Brain Volume|Volumes of Deep Grey Matter Structures|Cortical Thickness|White Matter Integrity|Functional Connectivity|Regional Functional Activation|Fatigue|Mood and Anxiety|Resilience|Perceived Level of Stress|Social Mindfulness|Social Participation|MS-related disability|Balance|Walking Speed|Endurance|Grip Strength|Upper Limb Dexterity|Lost Productivity Costs|Societal Costs including Healthcare, Patient, and family|Quality Adjusted Life Years",False,
NCT02804594,A Study of Oxidative Pathways in MS Fatigue,"A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis",COMPLETED,2016-10-01,2018-06-01,2018-06-01,2025-07-11,2016-06-17,INTERVENTIONAL,PHASE2,15.0,ACTUAL,"University of California, San Francisco",OTHER,,,Progressive Multiple Sclerosis|Fatigue,,United States,San Francisco,California,1,N-acetyl cysteine|Placebo,DRUG|DRUG,Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine.,Change in Fatigue Score on Questionnaires From Baseline|Change in Level of Blood Markers From Baseline,True,2020-02-18
NCT03591809,Combined Exercise Training in Patients With Multiple Sclerosis,The Effect of Combined Exercise Training on Cognitive Functions in Patients With Multiple Sclerosis,COMPLETED,2018-09-03,2019-10-18,2019-10-21,2019-10-22,2018-07-19,INTERVENTIONAL,NA,17.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,cognitive function|fatigue|quality of life|Functional exercise capacity,Turkey (Türkiye),Ankara,,1,combined exercise training,OTHER,cognitive function,functional exercise capacity|Fatigue|Multiple Sclerosis Quality of Life-54,False,
NCT01847287,A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years,"A Prospective, Observational, Single-blinded, Longitudinal Study of Natalizumab Effect on Brain Atrophy and Disability in Multiple Sclerosis Patients Over 5 Years.",COMPLETED,2012-05,2013-02,2013-02,2013-05-07,2013-05-06,OBSERVATIONAL,,60.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Tysabri|MRI|Natalizumab,United States,Buffalo,New York,1,,,The primary aim of this study is to define the effect of the number of natalizumab cycles on development of brain atrophy and progression of disability in originally treated patients with natalizumab in relapsing multiple sclerosis (MS).,The secondary objective of this study is to define the effect of the number of natalizumab cycles on accumulation of T2-LV and T1-LV and their VW-MTR changes over 5 years.,False,
NCT05269628,Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype,Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype,RECRUITING,2022-03-25,2027-08-30,2027-08-30,2025-07-25,2022-03-08,INTERVENTIONAL,PHASE2,166.0,ESTIMATED,"Tiffany J. Braley, MD, MS",OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis|Sleep|Pain,Cannabidiol,United States,Ann Arbor,Michigan,1,Cannabidiol (CBD)|Tetrahydrocannabinol (THC)|Placebo CBD|Placebo THC,DRUG|DRUG|DRUG|DRUG,Mean change in sleep bout length|Change in Walsh Spectral Entropy|Change in Transition Entropy|Change of center of activity|Change in sleep rhythmicity|Change in sleep regularity|Change in sleep continuity and duration,,False,
NCT02525367,"Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy","Clinical Pilot Study in the Feasibility and Effect of Online Cognitive Training on Cognitive Functions in Patients With Parkinson's Disease, Multiple Sclerosis and Depressive Patients Treated With Electroconvulsive Therapy",TERMINATED,2016-03,2017-06,2017-07-07,2017-08-28,2015-08-17,INTERVENTIONAL,NA,28.0,ACTUAL,"Amsterdam UMC, location VUmc",OTHER,Parnassia Bavo Groep|GGZ inGeest,UNKNOWN|OTHER,Idiopathic Parkinson's Disease|Multiple Sclerosis|Elderly Post Electric Convulsive Therapy,Parkinson's disease|Multiple Sclerosis|Depressed Elderly|Cognitive Dysfunction|Online Cognitive Training,Netherlands,Amsterdam,North Holland,1,Online cognitive training|Active control condition,BEHAVIORAL|BEHAVIORAL,Feasibility,Trail Making Task|Cognitive functioning (subjectively measured)|Feasibility|Stroop Color Word Task|Letter Fluency|Rey Auditory Verbal Learning Test|Location Learning Test,False,
NCT01690871,A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa,A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa,WITHDRAWN,2012-09,2015-01,2015-01,2013-08-02,2012-09-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Malignant PEComa (Perivascular Epithelioid Cell Tumors),Malignant PEComa|Angiomyolipoma|Tuberous Sclerosis Complex|Pi3kinase /m-tor inhibitors,Spain,Barcelona,Catalonia,1,BEZ235,DRUG,Proportion of Patients with best Objective Response Rate (ORR),Progression Free Survival rate|Duration of response|Time to response|Time to disease progression|Overall survival|Number of Adverse Events as a Measure of Safety and Tolerability,False,
NCT06330298,Improving Social Cognition and Social Behaviour in Various Brain Disorders,Improving Social Cognition and Social Behaviour in Various Brain Disorders.,RECRUITING,2021-05-31,2025-01-31,2025-01-31,2024-04-16,2024-03-26,INTERVENTIONAL,NA,84.0,ESTIMATED,University Medical Center Groningen,OTHER,,,Stroke|Multiple Sclerosis|Brain Tumor,Neuropsychology|Treatment|Social cognitive disorders|Emotion recognition|Theory of Mind|Social behaviour|Neurological disorders|Stroke|Brain tumour|Mulitple Sclerosis,Netherlands,Deventer,Overijssel,2,Treatment social cognition and emotion regulation (T-ScEmo),BEHAVIORAL,Change in social behaviour examined by proxy,Social cognition: Emotion recognition as assessed using the Eckman-60 faces test|Social cognition: Theory of Mind as assessed using the Happé cartoons test|Social cognition: Theory of Mind as assessed using the Faux Pas test|Social cognition: assessed using the Hailing Sentence Completion Test|Demographic information|Self-rated social behaviour as assessed using the Dysexecutive questionnaire Social Scales.|Self-rated social behaviour as assessed using the Interpersonal Reactivity Index|Self-rated social behaviour as assessed using The Dutch version of the BAFQ social scales|Proxy-rated social behaviour as assessed using the Interpersonal Reactivity Index|Proxy-rated social behaviour as assessed using the Socioemotional Dysfunction Scale|Proxy-rated social behaviour as assessed using the Dutch version of the BAFQ social scales|Alexithymia|Life satisfaction|(Social) participation as assessed using the Utrecht Scale for Evaluation of Rehabilitation|(Social) participation as assessed using the Impact on Participation and Autonomy scale|Mood and anxiety|Caregiving burden|Goal attainment,False,
NCT00616187,Atorvastatin in Relapsing-Remitting Multiple Sclerosis,Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis,COMPLETED,2003-10,2007-06,,2018-03-20,2008-02-15,INTERVENTIONAL,PHASE2,41.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,German Research Foundation|German Federal Ministry of Education and Research|Pfizer,OTHER|OTHER_GOV|INDUSTRY,Relapsing Remitting Multiple Sclerosis,,,,,0,interferon beta treatment to add-on atorvastatin treatment|untreated to atorvastatin treatment,DRUG|DRUG,number of MRI contrast enhancing lesions,"other MRI-based parameters (CEL volume, T2-lesion load, T1-hypointense lesion volume, whole brain magnetization transfer ratio, and apparent diffusion coefficient of normal appearing white matter)",False,
NCT03319771,Exercise and Learning and Memory in Multiple Sclerosis,Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis,TERMINATED,2018-12-01,2020-03-16,2021-01-03,2021-10-11,2017-10-24,INTERVENTIONAL,NA,14.0,ACTUAL,University of Alabama at Birmingham,OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis|Physical Activity|Memory Impairment|Cognitive Change,exercise|neuroimaging|walking|multiple sclerosis,United States,Birmingham,Alabama,1,Treadmill Walking Exercise Training|Stretching-and-toning Exercise Training,BEHAVIORAL|BEHAVIORAL,Composite Learning and Memory Performance,Hippocampal Volume,False,
NCT05895734,Effectiveness of Powerball System in People With Multiple Sclerosis,Effectiveness of Upper Limb Rehabilitation Using the Powerball System in People With Multiple Sclerosis,COMPLETED,2023-01-10,2023-07-10,2023-07-10,2023-07-14,2023-06-09,INTERVENTIONAL,NA,25.0,ACTUAL,Universidad Rey Juan Carlos,OTHER,,,Neurologic Disorder|Multiple Sclerosis,,Spain,Alcorcón,Madrid,1,"NDS-Powerball®,|Conventional treatment",DEVICE|OTHER,Isometric hand strength:|Isometric pincer force,Box and Block Test (BBT)|Nine Hole Peg Test (NHPT)|Abilhand test|Fatigue Severity Scale (FSS)|Multiple Sclerosis Impact Scale (MSIS-29)|Customer Satisfaction Questionnaire (CSQ8)|Likert satisfaction questionnaire for the experimental group,False,
NCT00411619,Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex,Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex,COMPLETED,2007-01,2014-01,2014-01,2014-10-20,2006-12-14,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,"Children's Hospital Medical Center, Cincinnati",OTHER,Novartis,INDUSTRY,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Tuberous Sclerosis Complex (TSC)|Subendymal Giant Cell Astrocytomas (SEGA'S)|Mammalian Target of Rapamycin (mTOR)|Everolimus (RAD001)|Tuberous Sclerosis with Subependymal Giant Cell Astrocytomas,United States,Cincinnati,Ohio,1,Everolimus,DRUG,Number With Observed Adverse Side Effects,Overall Reduction in SEGA Tumor Volume.,True,2014-10-20
NCT01036165,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study","A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)",COMPLETED,2010-01,2010-08,2010-08,2013-08-08,2009-12-21,INTERVENTIONAL,PHASE3,103.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,,United States,Rockland,Massachusetts,1,RebiSmart™,DEVICE,The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire.,"Multiple Secondary Endpoints Will be Assessed, Based on Questions From the User Trial Questionnaire Related to the RebiSmart™ Autoinjector Use-related Outcomes.",True,2010-12-22
NCT06072703,Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS,"A Randomized, Sham-Controlled Clinical Trial Evaluating Individualized Neuromodulation of Cortical Regions Involved in Neurogenic Overactive Bladder in Multiple Sclerosis",RECRUITING,2023-10-30,2027-12-31,2027-12-31,2025-02-14,2023-10-10,INTERVENTIONAL,NA,29.0,ESTIMATED,The Methodist Hospital Research Institute,OTHER,,,Neurogenic Bladder|Multiple Sclerosis|Overactive Bladder,Neurogenic bladder|Functional Neuroimaging|repetitive Transcranial Magnetic Stimulation (rTMS)|Neuromodulation,United States,Houston,Texas,1,Magstim Rapid2 System,DEVICE,Changes in subjective clinical outcomes following treatment - Neurogenic Bladder Symptom Score (NBSS) Questionnaire|Changes on patient reported outcomes following treatment - 2 day bladder diary,Changes in brain activation patterns following rTMS treatment - functional MRI imaging|Changes in objective clinical outcomes following treatment - Bladder Capacity|Changes in %Post-Void Residual/Bladder Capacity (PVR/BC) following treatment,False,
NCT01903681,Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances,"Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances",COMPLETED,2013-03,2014-02,2014-04,2014-04-04,2013-07-19,INTERVENTIONAL,PHASE1,16.0,ACTUAL,Neurim Pharmaceuticals Ltd.,INDUSTRY,,,Sleep Problems,"Sleep problems, autism spectrum disorder, prolonged-release melatonin, Circadin, endogenous saliva melatonin|Smith-Magenis syndrome, Angelman syndrome, Tuberous Sclerosis",Netherlands,Leiden,,1,Circadin 2 mg|Circadin 10 mg,DRUG|DRUG,baseline profile of endogenous saliva melatonin concentrations and urine 6-SMT excretion|concentration-time profile of saliva melatonin concentrations and 24 hour 6-SMT urine excretion after 2 and 10 mg Circadin® mini-tablets single dose administration|adverse event profile after a single dose of 2 or 10 mg Circadin® mini-tablets,,False,
NCT02687919,Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis,Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study,COMPLETED,2012-10,2014-09,2014-10,2019-08-12,2016-02-22,INTERVENTIONAL,NA,31.0,ACTUAL,Amanda Irish,OTHER,,,"Multiple Sclerosis, Relapsing-remitting",diet (gluten-free)|diet therapy|quality of life,United States,Iowa City,Iowa,1,Modified Paleo diet,OTHER,Change in Fatigue Severity Scale (FSS)-9 Score|Change in Paced Auditory Serial Addition Test (PASAT) Score|Change in 6-minute Walk (6-MW) Distance|Change in (25-FW) 25-ft Walk Time,Quality of Life (MSQOL-54)|Quality of Life (Vitamin B-1 Blood Serum Measures)|Quality of Life (Vitamin B-9 Blood Serum Measures)|Quality of Life (Vitamins B-12 and K Blood Serum Measures)|Quality of Life (Homocysteine Blood Serum Measures)|Quality of Life (C-reactive Protein Blood Serum Measures)|Quality of Life (9-HPT)|Quality of Life (VSAQ),True,2019-08-12
NCT06715436,Multiple Sclerosis and the Effects of Ketogenic Diet Therapy,The Effects of Ketogenic Diet Therapy Versus the Mediterranean Diet on Quality of Life in a Group of Patients With Multiple Sclerosis - the KETOMED-MS Study,RECRUITING,2024-03-15,2025-03-15,2025-09-15,2024-12-20,2024-12-04,INTERVENTIONAL,NA,111.0,ESTIMATED,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",OTHER,University of Pavia,OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Ketogenic Dietary Therapy|Mediterranean diet,Italy,Pavia,,1,Mediterranean Diet|Ketogenic Diet|Control group,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,The CPH subscale of the Multiple Sclerosis Quality of Life-54 (MSQoL -54),Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Functional Composite (MSFC)|Modified Fatigue Impact Scale (MFIS)|The Pittsburgh Sleep Quality Index|The Beck Depression Inventory,False,
NCT02952911,Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study,,COMPLETED,2016-11-28,2018-05-04,2018-05-04,2019-02-22,2016-11-02,INTERVENTIONAL,NA,100.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,United States,San Francisco,California,2,Smartphone and Smartwatch,DEVICE,Compliance Level: Number of Active and Passive Tests Conducted by MS Participants and Healthy Controls in 12 Weeks|Compliance Level: Number of Active and Passive Tests Conducted by MS Participants and Healthy Controls in 24 Weeks|Satisfaction Questionnaire Score at Week 12: Assessment of MS Participants' and Healthy Volunteers' Experience Regarding Smartphone and Smartwatch Use and its Impact on Their Daily Activities|Satisfaction Questionnaire Score at Week 24: Assessment of MS Participants' and Healthy Volunteers' Experience Regarding Smartphone and Smartwatch Use and its Impact on Their Daily Activities,,False,
NCT04538872,Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis,Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis,COMPLETED,2020-09-01,2021-04-30,2021-04-30,2021-09-02,2020-09-04,INTERVENTIONAL,NA,37.0,ACTUAL,Hasselt University,OTHER,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,OTHER|OTHER,Multiple Sclerosis,,Belgium,Overpelt,,2,StraDiMS implicit|StraDiMs explicit,BEHAVIORAL|BEHAVIORAL,Dual task (STEP + substraction sevens)|Dual task (STEP + substraction sevens)|Dual task (STEP + phonetic word list generation)|Dual task (STEP + phonetic word list generation)|Dual task (STEP + Auditory vigilance)|Dual task (STEP + Auditory vigilance)|Dual Task (WALK + Subtraction sevens)|Dual Task (WALK + Subtraction sevens)|Dual Task (WALK + Word list generation (phonetic)|Dual Task (WALK + Word list generation (phonetic)|Dual Task (WALK + Auditory vigilance)|Dual Task (WALK + Auditory vigilance)|learning measure|fNIRS measure (functional near-infrared spectroscopy),Age|height|weight|educational level questionnaire|date of diagnosis questionnaire|type of MS questionnaire|EDSS|Digit span forwards visually|Brief Visuospatial Memory Test (BVMT)|10/36 Spatial Recall test (SPART)|Symbol Digit Modalities Test (SDMT)|Paced Auditory Serial Addition Test (PASAT)-3 seconds|Digit Span backwards auditory|6 minute walking test (6MWT)|Timed-Up and Go (TUG)|Timed 25 Foot Walk (T25FW)|4 square stepping test (FSST)|Berg Balance Scale (BBS)|Tandem Walk 3m|Motricity Index|Movement specific reinvestment scale (MSRS)|MS Neuropsychological screening questionnaire (MSNQ)|Multiple Sclerosis Walking Scale (MSWS-12)|Modified fatigue impact scale (MFIS)|Activities-specific Balance Confidence scale (ABC)|Dual Task Questionnaire (DTQ),False,
NCT06450977,Remote Evaluation of MIND Diet,Remote Evaluation of MIND Diet,RECRUITING,2024-06-07,2026-01-01,2026-12-31,2024-06-27,2024-06-10,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,"Multiple Sclerosis|Cognitive Change|Nutrition, Healthy",Executive Function|MIND|Dietary Pattern|Telehealth,United States,Urbana,Illinois,1,MIND Diet|Control Diet,OTHER|OTHER,Information Processing|Visual Processing|Processing Speed|Learning|Memory|MIND Scores,Recruitment Rates|Refusal Rates|Retention rates|Attrition rates|Adherence/Compliance Rates|Participant Experience and Burden,False,
NCT05496894,A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,WITHDRAWN,2022-08,2022-11-08,2022-11-08,2022-12-15,2022-08-11,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.",INDUSTRY,,,Relapsing Multiple Sclerosis,,China,Beijing,Beijing Municipality,1,Mitoxantrone Hydrochloride Liposome Injection,DRUG,The cumulative number of new Gadolinium (Gd)-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.,Annualized Relapse Rate (ARR)|Number of Relapses|Time to Onset of Confirmed Disability Progression for at least 6 Months|Time to Onset of Confirmed Disability Progression for at least 3 Months|Proportion of participants with ≥ 20% improvement from baseline in T25FW walking speed.|Change from baseline to Week 48 in T25FW walking speed.|Number of new or enlarged T2 lesions.|Change from baseline in brain MRI Gd-enhancing T1 lesion volume at Weeks 12、24、36、48.|Change from baseline in brain MRI T2 lesion volume at Weeks 12、24、36、48.|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Plasma concentration of Mitoxantrone Hydrochloride Liposome Injection.|Descriptive analysis of the rate of change in the number or proportion of B cells from baseline to different time points in different dose groups.|Descriptive analysis of the rate of change in the number or proportion of T cells from baseline to different time points in different dose groups.|Descriptive analysis of the rate of change in the number or proportion of NK cells from baseline to different time points in different dose groups.,False,
NCT06410261,Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device,Randomized Pilot Study Evaluating the Effect of a 6-Month Exercise Rehabilitation Program on Physical and Cognitive Function in Persons With MS Who Use Wheelchairs as a Primary Mobility Device,RECRUITING,2024-04-29,2026-07-31,2027-07-31,2024-09-20,2024-05-13,INTERVENTIONAL,NA,24.0,ESTIMATED,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,Exercise|Rehabilitation|Physical function|Cognition,United States,Chicago,Illinois,1,Exercise rehabilitation program,BEHAVIORAL,Physical Function|Walking Speed|Lower-Extremity Function|Walking Endurance,Cognitive Function|Cognitive Function|Fatigue Severity|Fatigue Impact|Depressive Symptoms|Anxiety|Health-Related Quality of Life|Exercise Behavior|Usual Pattern of Mobility in Various Life-Space Levels,False,
NCT01929642,Rapalogues for Autism Phenotype in TSC: A Feasibility Study,Rapalogues for Autism Phenotype in TSC: A Feasibility Study,COMPLETED,2013-07,2016-07,2016-08,2021-03-29,2013-08-28,INTERVENTIONAL,PHASE2,3.0,ACTUAL,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",OTHER,,,Tuberous Sclerosis Complex|Self-injury|Autism,Tuberous Sclerosis Complex (TSC)|self-injury|Autism,United States,Baltimore,Maryland,1,Sirolimus|Everolimus,DRUG|DRUG,Number of Participants With Compliance to the Treatment Protocol.|Caregiver Burden|Feasibility Measurements of Parental Stress,Total Number of Aggressions or Self-injuries|Cognitive Function as Assessed by the Capute Scale|Repetitive Behavior|Self-Injury Trauma Scale--SIT Scale|Frequency of Seizures Assessed by Total Number of Seizures,True,2021-03-29
NCT05374473,An Online Lifestyle Modification Course for People With Multiple Sclerosis,An Online Lifestyle Modification Course for People With MS: a Randomised Controlled Trial of Course Effectiveness,ACTIVE_NOT_RECRUITING,2022-06-24,2024-12,2024-12,2023-12-12,2022-05-16,INTERVENTIONAL,NA,945.0,ACTUAL,University of Melbourne,OTHER,,,Multiple Sclerosis,Randomised controlled trial|Lifestyle modification|Online intervention,Australia,Melbourne,Victoria,1,Lifestyle modification|Standard-care,BEHAVIORAL|BEHAVIORAL,Change in physical health-related quality of life from baseline to 6- 12- and 30-month follow-up|Change in mental health-related quality of life from baseline to 6- 12- and 30-month follow-up,Change in depression|Change in anxiety|Change in fatigue|Change in disability|Change in self-efficacy,False,
NCT06805331,The Effect of Health Belief Model-Based Pelvic Floor Muscle Exercise Training on Urinary Incontinence and Quality of Life in Female Patients With Multiple Sclerosis,The Effect of Health Belief Model-Based Pelvic Floor Muscle Exercise Training on Urinary Incontinence and Quality of Life in Female Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-04-09,2025-06-01,2025-06-13,2025-04-10,2025-02-03,INTERVENTIONAL,NA,46.0,ESTIMATED,Nurgül KAPLAN,OTHER,,,Multiple Sclerosis|Urinary Incontinence,Exercise training|Multiple Sclerosis|Pelvic Floor Muscle Exercise|Health Belief Model|Urinary Incontinence|Quality of Life,Turkey (Türkiye),Tokat Province,,1,Intervention group(Pelvic Floor Muscle Exercise Training)|control group,BEHAVIORAL|OTHER,Urinary Incontinence,Quality of life in Women with Multiple Sclerosis,False,
NCT05270239,Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).,Neurorehabilitation and Functional Recovery in Multiple Sclerosis: Assessing Two Therapeutic Strategies Using Functional Magnetic Resonance Imaging.,COMPLETED,2022-05-27,2023-07-31,2023-07-31,2024-07-26,2022-03-08,INTERVENTIONAL,NA,94.0,ACTUAL,Universitat Jaume I,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Magnetic Resonance Imaging|Neuroplasticity|Cognitive Impairment|Virtual Reality,Spain,Castellon,Castellón,1,N-back Cognitive Training|Virtual Reality Motor and Cognitive Training,BEHAVIORAL|BEHAVIORAL,Change from baseline in Correct Responses|Change from baseline in Reaction Time|Change from baseline in Omissions|Change from baseline in Errors|Change from baseline in Functional Connectivity in resting state|Change from baseline in Functional Connectivity in task performance|Change from baseline in SRT-S: Selective Reminding Test (Storing)|Change from baseline in SRT-R: Selective Reminding Test (Retrieval)|Change from baseline in SRT-D: Selective Reminding Test (Delayed)|Change from baseline in SPART: Spatial Recall Test|Change from baseline in SPART-D: Spatial Recall Test (Delayed)|Change from baseline in SDMT: Symbol Digit Modalities Test|Change from baseline in PASAT: Paced Auditory Serial Addition Task|Change from baseline in Phonemic Fluency|Change from baseline in Semantic Fluency|Change from baseline in Digit Span Forward|Change from baseline in Digit Span Backward|Change from baseline in Letters and Numbers,Total Intracranial Volume (TIV)|Brain Parenchymal Fraction (BPF)|Lesion Volume in white matter tissue|Cortical Lesions|Cortical Thickness,False,
NCT03052595,Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance,Multiple Sclerosis: The Role of Mitochondrial Dysfunction in Insulin Resistance,COMPLETED,2017-02-01,2023-03-31,2023-03-31,2023-04-12,2017-02-14,OBSERVATIONAL,,70.0,ACTUAL,Slovak Academy of Sciences,OTHER_GOV,Comenius University,OTHER,Multiple Sclerosis|Mitochondrial Alteration,,Slovakia,Bratislava,,1,Oral glucose tolerance test|Testing of autonomous nervous system function|Stroop test,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Insulin sensitivity,Expanded Disability Status Scale (EDSS),False,
NCT04521439,Accurate Diagnosis of Multiple Sclerosis Using PET/MR,Hybrid PET/MR Imaging to Assess Demyelination and Axonal Injury in Multiple Sclerosis,COMPLETED,2020-02-01,2022-03-30,2022-07-30,2022-10-25,2020-08-20,INTERVENTIONAL,NA,49.0,ACTUAL,Ruijin Hospital,OTHER,,,Multiple Sclerosis,,China,Shanghai,,1,18F-florbetapir PET+MRSI,DIAGNOSTIC_TEST,Distribution Volume Ratio (DVR)|Change from Baseline DVR at 6 months|Change from Baseline DVR at 1 year|Standardized Uptake Value Ratio (SUVR)|Change from Baseline SUVR at 6 months|Change from Baseline SUVR at 1 year|N-acetyl aspartate (NAA) quantification|Change from Baseline NAA at 6 months|Change from Baseline NAA at 1 year,,False,
NCT06309173,Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2,Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2,NOT_YET_RECRUITING,2026-01,2028-02,2028-02,2025-09-04,2024-03-13,OBSERVATIONAL,,600.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,Digital Biomarkers,United States,San Francisco,California,3,,,Correlation of the digital features with the respective measurements of the clinical reference tests|The ability of measurements of the changes in the digital biomarkers over the two-year follow-up to predict worsening in the clinical reference test over the same period expressed as binary variables,"The ability of the digital biomarker to detect worsening in other relevant reference test results creating converging evidence|The ability of the digital biomarker to detect worsening in standard assessments used for treatment of PwMS (clinical, imaging, body fluids)|The ability of the digital biomarker to detect change of Patient Reported Outcomes|The ability of the digital biomarker to detect occurrence of clinical and other meaningful events (relapses, PIRA, serious adverse events, hospitalizations, working capacity)|The relationship of the digital biomarkers with imaging and body fluid markers|The relationship of the digital biomarkers with Patient Reported Outcomes",False,
NCT04847596,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Single-arm Pilot Study to Assess Immune Response to COVID-19 Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,COMPLETED,2021-05-21,2022-02-18,2022-02-18,2023-01-25,2021-04-19,OBSERVATIONAL,,25.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,COVID-19|vaccine|ofatumumab|SARS-coV2|antibody|open-label,United States,Phoenix,Arizona,5,Ofatumumab|Covid-19 vaccine,OTHER|OTHER,Proportion of participants achieving immune response - immune assay No. 1,Proportion of participants achieving immune response - immune assay No. 2|Adverse events/serious adverse events,False,
NCT04545372,Aerobic Exercises for Multiple Sclerosis,Effect of Aerobic Exercises on Immune System in Patients With Multiple Sclerosis,COMPLETED,2015-02-02,2018-08-04,2020-08-06,2020-09-11,2020-09-11,INTERVENTIONAL,NA,30.0,ACTUAL,South Valley University,OTHER,,,"Multiple Sclerosis, Primary Progressive",Multiple Sclerosis|Aerobic exercises|cytokine IL-10|cytokine IL-17,Egypt,Qina,,1,aerobic exercise,OTHER,blood analysis|blood analysis|blood analysis|blood analysis,,False,
NCT02874677,A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients,Effects of an Endurance Training Program at Ventilatory Threshold on the Walking Distance of Ambulatory Patients With Multiple Sclerosis,TERMINATED,2017-12-07,2022-01-14,2022-01-14,2024-03-26,2016-08-22,INTERVENTIONAL,NA,46.0,ACTUAL,Lille Catholic University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Ventilatory threshold|Effort Reeducation,France,Amiens,Hauts-de-France,4,Effort reeducation program,OTHER,Distance estimated by the 6 minutes Walk Test,Walking speed measured by the timed 25-ft walk test (T25FWT)|Heart rate estimation at the end of the 6 minutes walk test|Walking perception measured by the Twelve Item MS Walking Scale (MSWS-12) scale|Effort test for the estimation of the maximal consumption of oxygen (O2max)|Multiple sclerosis-59 French scale for the estimation of the quality of life|Fatigue Impact Scale (EMIF-SEP)|Effort test for the estimation of the ventilatory threshold (VT1),False,
NCT06838975,"Virtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders","Effectiveness of Virtual Reality Rehabilitation to Improve Cognitive, Emotional, Relational, and Motor Domains in Patients With Neurological and Neurodegenerative Disorders",ACTIVE_NOT_RECRUITING,2025-01-16,2027-09-29,2028-01-31,2025-02-21,2025-02-21,INTERVENTIONAL,NA,328.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Acquired Brain Injuries|Spinal Cord Injury|Multiple Sclerosis|Parkinson Disease,Neurorehabilitation|Virtual Reality|Cognitive and motor recovery|cognitive rehabilitation|neurological disorders,Italy,Messina,Italy/Me,2,VR Training|traditional cognitive and motor rehabilitation following standard clinical practices,DEVICE|OTHER,Improvement in Cognitive Function|Improvement in Motor Function,Neurophysiological Changes Associated with Rehabilitation|Effectiveness of Telerehabilitation,False,
NCT01212094,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),TERMINATED,2010-09,2015-12,2015-12,2016-03-28,2010-09-30,INTERVENTIONAL,PHASE1|PHASE2,44.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Rituximab|Multiple Sclerosis|Intrathecal|MS|Secondary-Progressive Multiple Sclerosis|SP-MS,United States,Bethesda,Maryland,1,Rituximab|normal saline,DRUG|OTHER,Analysis of Changes in CSF CXCL13 Induced by Active Treatment (Rituximab) Measured 3 Months After 1st Drug Administration|Analysis of Changes in CSF BAFF Induced by Active Treatment (Rituximab) Measured 3 Months After 1st Drug Administration,Analysis of Changes in CSF B Cell Numbers Between Rituximab and Placebo|Expanded Disability Status Scale (EDSS)|Scripps Neurological Rating Scale (NRS)|Timed 25 Foot Walk|9-Hole Peg Test|Multiple Sclerosis Functional Composite (MSFC)|EDSS|Scripps Neurological Rating Scale (NRS)|Timed 25 Foot Walk|9-Hole Peg Test|Multiple Sclerosis Functional Composite (MSFC),True,2016-03-28
NCT03647722,Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).,Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).,TERMINATED,2018-11-02,2020-11-01,2020-11-30,2020-12-17,2018-08-27,OBSERVATIONAL,,97.0,ACTUAL,University of Southern California,OTHER,,,Multiple Sclerosis,,United States,Los Angeles,California,1,Assessment of leukocyte function.,OTHER,Assess changes in the circulating regulatory B-cell population.,,False,
NCT06586177,Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies,Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies,RECRUITING,2021-10-27,2028-12-31,2028-12-31,2025-09-18,2024-09-19,OBSERVATIONAL,,100.0,ESTIMATED,"Heinrich-Heine University, Duesseldorf",OTHER,Novartis,INDUSTRY,Relapsing-remitting Multiple Sclerosis,,Germany,Düsseldorf,,1,Anti-CD20 antibody,DRUG,Change from baseline in the peripheral immune cell profile|Change from baseline in protein profile of the peripheral blood|Change from baseline in TCR/BCR profile,Change from baseline in Expanded Disability Status Scale (EDSS) Score|Change from baseline in Short Form Health Survey (SF-36)|Change from baseline on Magnetic Resonance Imaging (MRI)|Change from baseline in Retinal Nerve Fiber Layer thickness (RNFL)|Change from baseline in visual acuity (HCV and LCV)|Change from baseline in Fatigue Scale for Motor and Cognitive Functions (FSMC)|Change from baseline in Multiple Sclerosis Functional Composite (MSFC) Score|Change from baseline in Symbol Digit Modalities Test (SDMT)|Change from baseline in Verbal Memory Learning Test (VMLT)|Change from baseline in Brief Visuospatial Memory Test (BVMT)|Change from baseline in Montreal Cognitive Assessment (MoCA)|Change from baseline in BDI-FS/BDI II,False,
NCT03034317,NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS),"Multi-Center, Concurrent-Controlled, On-Label Study of the NeuRx Diaphragm Pacing System (DPS) in Participants With Amyotrophic Lateral Sclerosis (ALS)",WITHDRAWN,2017-02-02,2018-02-08,2018-02-12,2020-03-26,2017-01-27,INTERVENTIONAL,NA,0.0,ACTUAL,Synapse Biomedical,INDUSTRY,,,Amyotrophic Lateral Sclerosis,Diaphragm Pacing,,,,0,NeuRx DPS,DEVICE,Survival,Relationship between survival time and clinical features of ALS|Relationship between survival time and ALS assessment scores|Relationship between survival time and onset of weakness from ALS to treatment|Relationship between survival time and ALS treatment interventions|Relationship between survival time and intraoperative strength of contraction|Characterize change in overall and respiratory function|Characterize change in respiratory function|Types device and procedure-related adverse events|Frequency of device and procedure-related adverse events|Types of respiratory serious adverse events|Frequency of respiratory adverse events,False,
NCT02652091,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,COMPLETED,2016-02-05,2017-08-11,2017-09-13,2018-09-06,2016-01-11,OBSERVATIONAL,,146.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Adherence|Persistence|Patient satisfaction,United States,Cullman,Alabama,23,"Interferon beta-1b (Betaseron, BAY86-5046)|BETACONNECT device",DRUG|DEVICE,Number of BETASERON injections as captured by the BETACONNECT device|Time (days) between BETASERON injections as captured by BETACONNECT device,Patient reported satisfaction by a questionnaire,False,
NCT03255460,The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis,Investigation of the Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis,COMPLETED,2017-03-27,2018-07-04,2018-07-04,2021-04-02,2017-08-21,OBSERVATIONAL,,70.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Fatigue|Physical Activity|Exercise,Turkey (Türkiye),Ankara,,1,,,Fatigue severity|Fatigue|Physical activity behavior|Physical activity,Functional exercise capacity|Balance|Functional Mobility|Muscle strength,False,
NCT00744679,A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State,An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions,COMPLETED,2008-11,2008-12,2008-12,2015-02-10,2008-09-01,INTERVENTIONAL,PHASE4,20.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Multiple Sclerosis,MS|Multiple Sclerosis,United States,Latham,New York,1,Natalizumab,DRUG,Pharmacokinetic (PK) Profile of Natalizumab,Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC).,False,
NCT03049046,CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS,Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS,UNKNOWN,2017-04-07,2018-01-30,2018-03-30,2017-08-03,2017-02-09,INTERVENTIONAL,PHASE1,21.0,ESTIMATED,"Chemigen, LLC",INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,Indianapolis,Indiana,1,CC100|Placebos,DRUG|DRUG,"Safety and Tolerability: Adverse events, safety labs, vital signs, and ECGs",Pharmacokinetics (PK)--Peak plasma concentration (Cmax)|Pharmacokinetics (PK)--Area under the plasma concentration versus time curve (AUC)|Pharmacokinetics (PK)--Half life (T 1/2)|Pharmacodynamics (PD)--Monocyte chemotactic protein 1 (MCP-1)|Pharmacodynamics (PD)--Excitotoxicity/oxidative stress biomarkers,False,
NCT02228213,Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis,"A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis",COMPLETED,2014-10,2017-05,2017-06,2017-07-14,2014-08-28,INTERVENTIONAL,PHASE2,93.0,ACTUAL,Innate Immunotherapeutics,INDUSTRY,Syneos Health,OTHER,Secondary Progressive Multiple Sclerosis,multiple sclerosis|SPMS,Australia,Brisbane,Queensland,7,MIS416|Saline,BIOLOGICAL|DRUG,Change from baseline of neuromuscular function at 12 months|Proportion of Participants with Serious and Non-Serious Adverse Events,Change from baseline of disability and health status at 12 months|Change from baseline of neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers at 12 months|Change from baseline of activity of immune biomarkers in serum|Change from baseline of activity of immune biomarkers in cerebrospinal fluid (CSF)|Change from baseline in Peripheral Blood Mononuclear Cell (PBMC) immune biomarkers,False,
NCT04192786,Local Vibration in Multiple Sclerosis Patients,The Effect of Local Vibration Applied to Spastic Gastrocnemius on Muscle Architecture and Functional Properties in Multiple Sclerosis Patients,UNKNOWN,2019-12-15,2020-11,2020-12,2020-06-30,2019-12-10,INTERVENTIONAL,NA,30.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Spasticity|Local Vibration|Muscle Architecture|Functionality,Turkey (Türkiye),Ankara,Altındağ,1,Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program,OTHER|OTHER|OTHER,Evaluation of Muscle Thickness and Fascicle Length with Ultrasonography|Evaluation of Pennation Angle with Ultrasonography,Assessment of spasticity|Assessment of viscoelastic properties of muscle|Assessment of ankle proprioception|Assessment of single leg balance|Assessment of balance|Assessment of gait characterictics,False,
NCT05063708,Neuromuscular Electrostimulation in Multiple Sclerosis People With Dysphagia,To Evaluate the Activity and the Efficacy of Traditional Swallowing Therapy (TST) Plus Neuromuscular Electrostimulation (NMES) vs TST Plus Sham- NMES in Multiple Sclerosis People With Dysphagia,COMPLETED,2022-01-21,2023-04-15,2024-04-15,2025-09-25,2021-10-01,INTERVENTIONAL,NA,136.0,ACTUAL,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Deglutition Disorders|Multiple Sclerosis,Neuromuscular electrostimulation Multiple Sclerosis,Italy,Roma,,1,Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation,DEVICE|DEVICE,change from American Speech-Language Hearing Association (ASHA) score baseline at 12 weeks,Change from Dysphagia in Multiple Sclerosis (DYMUS) scale at 12 weeks|Change from Fiber-optic endoscopic evaluation of swallowing /Dysphagia at Outcome Severity Scale (FESS/DOSS score) at 12 weeks|Change from Mini Nutritional Assessment at 12 weeks|Change from the Swallowing Quality of life questionnaire at 12 weeks|Change from Penetration and Aspiration Score at 12 weeks|Change from Pooling score at 12 weeks,False,
NCT00678496,Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis,Computerised Cognitive Behavioural Therapy for Treatment of Depression in MS (CoSMoS): Clinical Trial Pilot Study,COMPLETED,2008-10,2010-01-31,2010-01-31,2021-03-17,2008-05-15,INTERVENTIONAL,NA,24.0,ACTUAL,University of Sheffield,OTHER,Sheffield Teaching Hospitals NHS Foundation Trust|Walton Centre NHS Foundation Trust,OTHER|OTHER,Depression|Multiple Sclerosis,"CBT-software|Computerised Cognitive Behavioural Therapy|CCBT|Cognitive Therapy|Therapy, Computer-Assisted|Depression|Multiple Sclerosis",United Kingdom,Sheffield,South Yorkshire,1,CBT Software|Treatment as usual,OTHER|OTHER,"Change in Self-reported Symptoms of Depression, as Measured by Total BDI-II Score","Change in Disease-specific Quality of Life, Measured on the Multiple Sclerosis Impact Scale-29 Item (MSIS-29)",True,2021-03-17
NCT03586986,Risk Factors in Early Multiple Sclerosis,Risk Factors in Early Multiple Sclerosis,UNKNOWN,2018-07-26,2024-05,2024-05,2023-02-06,2018-07-16,OBSERVATIONAL,,300.0,ESTIMATED,"University of Colorado, Denver",OTHER,Colorado School of Public Health,OTHER,Multiple Sclerosis|Magnetic Resonance Imaging|Biomarkers|Clinically Isolated Syndrome|Radiologically Isolated Syndrome,First degree relative,United States,Aurora,Colorado,1,Brain MRI,DIAGNOSTIC_TEST,Discovery of Lesions disseminated in space on brain MRI,Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS|Define risk stratification algorithm for prediction of MS,False,
NCT00856518,Expiratory Muscle Training for Persons With Neurodegenerative Disease,Expiratory Muscle Training for Persons With Neurodegenerative Disease,COMPLETED,2009-03,2014-08,2014-08,2017-02-10,2009-03-05,INTERVENTIONAL,PHASE2|PHASE3,42.0,ACTUAL,VA Office of Research and Development,FED,University of Florida,OTHER,Parkinson's Disease|Multiple Sclerosis,Multiple Sclerosis|Parkinson's disease|Dysphagia,United States,Gainesville,Florida,1,EMST|Sham,DEVICE|DEVICE,Maximum Expiratory Pressure (MEP)|Penetration-Aspiration Scale Score|Swallow-related Quality of Life (SWAL-QOL),,True,2016-11-29
NCT04681586,Bright Light Therapy as Possible Treatment Option for MS-Fatigue,Bright Light Therapy as Possible Treatment Option for Fatigue in Multiple Sclerosis Patients - A Randomised Controlled Trial,UNKNOWN,2019-12-01,2021-09,2022-01,2020-12-23,2020-12-23,INTERVENTIONAL,NA,36.0,ESTIMATED,Medical University of Vienna,OTHER,National Bank of Austria,OTHER_GOV,Multiple Sclerosis|Fatigue,bright light therapy|MS-Fatigue,Austria,Vienna,,1,bright light therapy|dim red light,DEVICE|DEVICE,Change in fatigue levels|Change in fatigue levels,,False,
NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,"A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)",COMPLETED,2009-02,2012-05,2012-10,2016-08-30,2009-03-27,INTERVENTIONAL,PHASE2,517.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis,MS|Multiple Sclerosis,Czechia,Brno,,58,BIIB019 (Daclizumab High Yield Process)|Placebo,BIOLOGICAL|DRUG,Number of Participants With Treatment-emergent Adverse Events (AEs)|Number of Participants With Abnormalities in Vital Signs|Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities|Number of Participants With Abnormalities in Blood Chemistry Laboratory Data|Number of Participants With Development of Anti-DAC Antibodies (ADAb) and Neutralizing Antibodies (NAb) Post-baseline,Adjusted Annualized Relapse Rate|Estimated Proportion of Participants With a Relapse|Mean Number of New Gadolinium-enhancing Lesions|Mean Number of New or Newly-enlarging T2 Hyperintense Lesions|Mean Volume of New T1 Hypointense Lesions|Mean Percentage Change From Baseline in Total Lesion Volume of T2 Hyperintense Lesions|Mean Percentage Change From Baseline in Total Volume of Non-gadolinium (Gd)-Enhancing T1 Hypointense Lesions|Rate of Percentage Change From Baseline in Mean Total Brain Volume,True,2016-08-30
NCT03045380,Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis,"Effect of Video Game Based Physical Activity Training on Upper Extremity Functions, Walking, Balance and Cognitive Functions in Persons With Multiple Sclerosis",COMPLETED,2016-11,2017-06,2017-06,2017-11-20,2017-02-07,INTERVENTIONAL,NA,60.0,ACTUAL,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Game based physical activity training|Conventional physiotherapy,OTHER|OTHER,Nine-Hole Peg Test,Expanded Disability Status Scale|12-Item Multiple Sclerosis Walking Scale|Timed 25-Foot Walk|Six-Spot Step Test|Five Times Sit to Stand Test|Sit-Up Test|Activities-specific Balance Confidence Scale|Manual Ability Measure-36|Beck Depression Inventory|Modified Fatigue Impact Scale|Multiple Sclerosis International Quality of Life Questionnaire|Brief International Cognitive Assessment for Multiple Sclerosis,False,
NCT02361697,DTI in Children With Multiple Sclerosis,Monitoring of Neurodegenerative Processes in Children With Multiple Sclerosis by Diffusion-weighed Magnetic Resonance Imaging (DTI),UNKNOWN,2014-12,2016-12,2017-12,2016-05-19,2015-02-12,INTERVENTIONAL,NA,15.0,ESTIMATED,University Hospital Muenster,OTHER,,,"Multiple Sclerosis - Relapsing Remitting|Clinically Isolated Syndrome, CNS Demyelinating",pediatric multiple sclerosis|clinically isolated syndrome in children|biomarker|magnetic resonance imaging|diffusion weighted imaging,Germany,Münster,,1,DTI-MRI,OTHER,change from baseline fractional anisotropy (FA) at 36 months measured by cerebral MRI and special DTI sequences|change from baseline apparent diffusion coefficient (ADC) at 36 months measured by cerebral MRI and special DTI sequences,"Disease activity (relapse rate, lesion load)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|EDSS (Expanded disability status scale, Values between 0-10)|spinal lesion load measured by spinal MRI (which is performed in each participant every 12 months)|VEP-Score|SSEP somatosensory evoked potentials, records of amplitudes and latency|Medication particular medication of each patient|neurocognitive deficits neuropsychological test battery",False,
NCT06121635,The Effects of Two Types of t-DCS Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis,The Effects of Transcranial Direct Current Stimulation and Transcutaneous Spinal Direct Current Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2023-12-20,2024-05-15,2024-07-30,2024-05-20,2023-11-08,INTERVENTIONAL,NA,36.0,ACTUAL,Istanbul Medeniyet University,OTHER,,,Multiple Sclerosis|Transcranial Direct Current Stimulation,,Turkey (Türkiye),Istanbul,Kadıköy,1,Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|Sham ts-DCS and sham t-DCS,COMBINATION_PRODUCT|COMBINATION_PRODUCT,Timed 25-Foot Walk (T25-FW)|Time Up and Go (TUG)|Multiple Sclerosis Walking Scale-12 (MSWS-12)|Gait Speed Assessment,Fatigue Severity Scale (FSS)|Fatigue Impact Scale (FIS),False,
NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)",COMPLETED,2006-11,2010-08,2011-07,2014-01-24,2006-11-28,INTERVENTIONAL,PHASE3,517.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Rebif New Formulation|Clinical Isolated Syndrome|Multiple Sclerosis,Argentina,Mendoza,,67,RNF|RNF|Placebo,DRUG|DRUG|DRUG,Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)|Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005),"Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score|Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score|Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan|Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36|Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36",True,2012-09-24
NCT04053374,Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis,Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis,UNKNOWN,2018-09-01,2020-06,2020-06,2020-04-24,2019-08-12,OBSERVATIONAL,,275.0,ESTIMATED,"University College, London",OTHER,University College London Hospitals,OTHER,Multiple Sclerosis,,United Kingdom,London,,2,Blood sampling,OTHER,Lipid Phenotyping (1)|Lipid Phenotyping (2)|Analysis of immune cell function|Analysis of cytokine|Analysis of immune cell function (1)|Analysis of immune cell function (2)|Analysis of serum,,False,
NCT02524093,The Impact of Positive Mental Training in Multiple Sclerosis,The Efficacy of Positive Mental Training in Patients With Multiple Sclerosis Experiencing Psychological Distress: A Pilot Randomised Controlled Trial,COMPLETED,2016-01,2017-07,2017-07,2018-04-05,2015-08-14,INTERVENTIONAL,NA,60.0,ACTUAL,University of Edinburgh,OTHER,NHS Lothian,OTHER_GOV,Multiple Sclerosis|Psychological Distress,,United Kingdom,Edinburgh,Scotland,1,Positive Mental Training|treatment as usual,BEHAVIORAL|OTHER,Hospital Anxiety and Depression Scale (HADS)|Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS),Assessment of health-related quality of life - EuroQol health related quality of life - 5 dimensions - 5 levels (EuroQol-5D-5L),False,
NCT06065852,National Registry of Rare Kidney Diseases,National Registry of Rare Kidney Diseases (RaDaR),RECRUITING,2009-11-06,2039-12-31,2039-12-31,2023-10-04,2023-10-04,OBSERVATIONAL,,35000.0,ESTIMATED,UK Kidney Association,OTHER,,,"Adenine Phosphoribosyltransferase Deficiency|AH Amyloidosis|AHL Amyloidosis|AL Amyloidosis|Alport Syndrome|Atypical Hemolytic Uremic Syndrome|Autoimmune Distal Renal Tubular Acidosis|Autosomal Recessive Proximal Renal Tubular Acidosis|Autosomal Recessive Distal Renal Tubular Acidosis|Autosomal Dominant Polycystic Kidney Disease|Autosomal Recessive Polycystic Kidney Disease|Bartter Syndrome|BK Nephropathy|C3 Glomerulopathy With Monoclonal Gammopathy|C3 Glomerulopathy|Calciphylaxis|Crystalglobulinaemia|Crystal-storing Histiocytosis|Cystinosis|Cystinuria|Dense Deposit Disease|Dent Disease|Denys-Drash Syndrome|Dominant Hypophosphataemia With Nephrolithiasis and/or Osteoporosis|Drug Induced Fanconi Syndrome|Drug-Induced Hypomagnesemia|Drug-Induced Nephrogenic Diabetes Insipidus|Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy|Fabry Disease|Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis|Familial Primary Hypomagnesemia With Hypocalcuria|Familial Primary Hypomagnesaemia With Normocalciuria|Familial Renal Glucosuria|Fanconi Renotubular Syndrome 1|Fanconi Renotubular Syndrome 2|Fanconi Renotubular Syndrome 3|Fibrillary Glomerulonephritis|Fibromuscular Dysplasia|Focal Segmental Glomerulosclerosis|Generalised Pseudohypoaldosteronism Type 1|Gitelman Syndrome|Heavy-Metal-Induced Fanconi Syndrome|Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes|Hereditary Renal Hypouricemia|Hereditary Hypophosphatemic Rickets With Hypercalciuria|Hyperuricaemic Nephropathy|IgA Nephropathy|Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits|Inherited Renal Cancer Syndromes|Intracapillary Monoclonal IgM Without Cryoglobulin|Intraglomerular/Capillary Lymphoma/Leukaemia|Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type|Liddle Syndrome|Light Chain Cast Nephropathy|Light Chain Proximal Tubulopathy Without Crystals|Light Chain Proximal Tubulopathy With Crystals|Lowe Syndrome|Membranous Nephropathy|Membranoproliferative Glomerulonephritis|Medullary Cystic Kidney Disease|Minimal Change Nephropathy|Mitochondrial Disease Of The Kidney|Monoclonal Immunoglobulin Deposition Disease|Nail Patella Syndrome|Nephrogenic Diabetes Insipidus|Nephrogenic Syndrome of Inappropriate Antidiuresis|Nephronophthisis|Primary Hypomagnesemia With Secondary Hypocalcemia|Primary Hyperoxaluria|Proliferative Glomerulonephritis With Monoclonal IgG Deposits|Proximal Tubulopathy Without Crystals|Pseudohypoaldosteronism Type 1, 2A-2E|Pure Red Cell Aplasia|Retroperitoneal Fibrosis|Sickle Cell Nephropathy|Shiga Toxin Associated Haemolytic Uraemic Syndrome|Steroid Resistant Nephrotic Syndrome|Steroid-Sensitive Nephrotic Syndrome|Thin Basement Membrane Nephropathy|Thrombotic Microangiopathy With Monoclonal Gammopathy|Type 1 Cryoglobulinaemic Glomerulonephritis|Tuberous Sclerosis|Unclassified Monoclonal Gammopathy Of Renal Significance|Vasculitis",,United Kingdom,Bristol,South West,1,,,Facilitate translational and epidemiological research,,False,
NCT04625049,Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients,Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients,ENROLLING_BY_INVITATION,2021-04-01,2030-11,2031-11,2025-09-22,2020-11-12,OBSERVATIONAL,,100.0,ESTIMATED,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,,,Correlation of the lesion volume changes to the microglial activity at the initial positron emission tomography imaging,magnetic resonance imaging metrics|Multiple Sclerosis Composite Score,False,
NCT07086950,"Neurorehabilitation of Cognitive Deficits in Multiple Sclerosis Using an Adaptive Cognitive Exergame - Randomized, Controlled, Multi-center Clinical Trial","Neurorehabilitation of Cognitive Deficits in Multiple Sclerosis Using an Adaptive Cognitive Exergame - Randomized, Controlled, Multi-center Clinical Trial",NOT_YET_RECRUITING,2025-09-01,2028-06-30,2028-06-30,2025-07-25,2025-07-25,INTERVENTIONAL,EARLY_PHASE1,190.0,ESTIMATED,"Prof. Arseny Sokolov, MD, PhD",OTHER,,,Multiple Sclerosis|Neurorehabilitation,,,,,0,Body Brain Trainer software|RehaCom software,DEVICE|DEVICE,PDQ-20,,False,
NCT03499314,A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS),A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS),COMPLETED,2018-04-15,2020-11-30,2020-11-30,2022-03-09,2018-04-17,INTERVENTIONAL,NA,65.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,Anodal transcranial stimulation (tDCS),United States,New York,New York,1,Active RS-tDCS +At-Home Manual Dexterity Training|Sham RS-tDCS +At-Home Manual Dexterity Training|Manual dexterity training,DEVICE|DEVICE|OTHER,Mean Preload Phase Duration (PLD),,True,2022-03-09
NCT04756687,Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera,A Retrospective Analysis in Real World on Lymphocyte Reconstitution After Lymphopenia in Patients Treated by Tecfidera and Description of Management Strategies in France,COMPLETED,2021-03-10,2021-06-15,2021-06-15,2023-10-23,2021-02-16,OBSERVATIONAL,,1507.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",,France,Amiens,,32,Dimethyl fumarate,DRUG,Time to ALC Reconstitution After DMF Discontinuation,Time From DMF Initiation to Lymphopenia Initiation Assessed in Participants With and Without DMF Discontinuation|Time From DMF Initiation to Lymphopenia Assessed at Time of DMF Discontinuation|Percent Change in ALC Over Time From DMF Initiation to DMF Discontinuation or End of Study|Time From DMF Initiation to DMF Discontinuation|Percentage of Participants with Discontinuation of DMF Treatment|Time to DMF Discontinuation to the First Relapses and/or an EDSS Progression|Percentage of Participants With Serious or Opportunistic Infections in Overall and According to DMF On-going or not and in Lymphopenic Population|Percentage of Participants With Serious and Opportunistic Infections in Overall and in Lymphopenic Population|Time to Occurrence of Lymphopenia During DMF Treatment Assessed in Association Between Demographic and Clinical Characteristics|Time to Lymphocyte Reconstitution After DMF Discontinuation Assessed in Association Between Demographic and Clinical Characteristics|Percent Change from Baseline in Absolute CD4+ Count|Percent Change from Baseline in Absolute CD8+ Count|Percent Change from Baseline in Absolute CD4+/CD8+ Ratio,False,
NCT06072287,The Living With a Long-Term Condition Study,Testing the Reliability and Validity of a New Measure for Illness-related Distress.,RECRUITING,2023-06-28,2023-12-31,2024-01-10,2023-10-12,2023-10-10,OBSERVATIONAL,,600.0,ESTIMATED,King's College London,OTHER,,,Asthma|Atrial Fibrillation|Cancer|Cerebrovascular Disorders|Stroke|CKD|Copd|Fibromyalgia|Pain|Heart Diseases|Heart Disease Chronic|Dementia|Diabetes|Epilepsy|Heart Failure|High Blood Pressure|Hypertension|Hiv|AIDS|IBD|IBS|Liver Diseases|Long COVID|Lupus Erythematosus|Multiple Sclerosis|Obesity|Osteoarthritis|Arthritis|Rheumatoid Arthritis|Osteoporosis|Parkinson Disease|Sickle Cell Disease|Hepatitis|Endometriosis|PCOS|Neurological Disorder|POTS - Postural Orthostatic Tachycardia Syndrome|MND (Motor Neurone DIsease)|Cystic Fibrosis|Migraine|Spondylitis|Celiac Disease|Hidradenitis Suppurativa|Eczema|ME/CFS,mental health|depression|anxiety|chronic illness,United Kingdom,London,,1,Living with LTC Questionnaire,DIAGNOSTIC_TEST,Illness-related distress,Depression|Anxiety|Functional impairment|Diabetes Related Distress Scale|IBD Distress Scale|Cognitive and Behavioural Responses to Symptoms,False,
NCT05543915,Cognitive Markers in Prodromal MS,Intra-Individual Variability in Cognitive Performance as a Marker of Prodromal Disability in MS,COMPLETED,2022-02-09,2024-06-20,2024-06-20,2025-07-14,2022-09-16,INTERVENTIONAL,NA,60.0,ACTUAL,NYU Langone Health,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,New York,New York,1,Active tDCS,DEVICE,Cerebral Metabolic Rate of Oxygen (CMRO2)|Intra-Individual Variability (IIV) as Measured by Cogstate Brief Battery (CBB),Brief International Cognitive Assessment for MS (BICAMS) Symbol Digit Modalities Test (SDMT) Z-Score|BICAMS Rey Auditory Verbal Learning Test (RAVLT) Z-Score|BICAMS Brief Visuospatial Memory Test Revised (BVMT-R) Z-Score,True,2025-07-14
NCT05422625,PTNS for Female Patients Suffering From Multiple Sclerosis,Percutaneous Tibial Nerve Stimulation (PTNS) Therapy for Female Patients Suffering From Multiple Sclerosis,TERMINATED,2023-01-09,2023-04-10,2023-08-03,2024-10-09,2022-06-16,INTERVENTIONAL,NA,2.0,ACTUAL,William Beaumont Hospitals,OTHER,,,Multiple Sclerosis|Overactive Bladder,Multiple Sclerosis|MS|Overactive bladder|OAB,United States,Royal Oak,Michigan,1,PTNS Treatment|Sham PTNS Treatment,DEVICE|DEVICE,The Overall Patient Reported Change of Bladder Overactivity (OAB) Symptoms in MS Patients as Reported on the Patient Global Impression of Improvement (PGI-I) Questionnaire,Change in Urinary Voids in Response to the Treatment Using a 3-day Voiding Diary|Change in Urinary Incontinence Episodes in Response to the Treatment Using a 3-day Voiding Diary|Change in Urinary Urgency Episodes in Response to the Treatment Using a 3-day Voiding Diary|Change in Overactive Bladder Symptoms in Response to the Treatment Using the Overactive Bladder Quality of Life Short Form Questionnaire.,True,2024-10-09
NCT01185717,JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS),Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients,COMPLETED,2010-09,2012-05,2012-06,2014-06-02,2010-08-20,OBSERVATIONAL,,7726.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,,,,0,,,Prevalence of anti-JCV antibodies,,False,
NCT01964547,A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients,"A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis",COMPLETED,2012-01,2013-05,2013-05,2023-01-12,2013-10-17,INTERVENTIONAL,PHASE4,121.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Spasticity,Cognition|Mood,Czechia,Prague,,1,Sativex|Placebo,DRUG|DRUG,Change From Baseline to the End of Treatment in Paced Auditory Serial Addition Test (PASAT) Total Score.,Change From Baseline to the End of Treatment in Beck Depression Inventory-II (BDI-II) Total Score.|Subject Global Impression of Change (SGIC) in the Severity of Their Spasticity at the End of Treatment.|Caregiver's Global Impression of Change (CGIC) in the Severity of the Patient's Spasticity at the End of Treatment.|Physician's Global Impression of Change (PGIC) in the Severity of the Patient's Spasticity at the End of Treatment.|Change From Baseline to End of Treatment in Modified Ashworth Scale Total Score.|Change From Baseline to End of Treatment in Number of Visits to a Healthcare Professional.|The Number of Patients With a Treatment-emergent Flag Using the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Course of the Study.|Change From Baseline to End of Treatment in Timed 10-meter Walk Times.|Incidence of Adverse Events as a Measure of Patient Safety.,True,2014-05-02
NCT00772525,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,"A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis",COMPLETED,2008-09,2009-06,2009-06,2016-02-26,2008-10-15,INTERVENTIONAL,PHASE2,31.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis|Optic Nerve|Neuritis,Visual acuity|Contrast sensitivity|Visual Evoked Potentials|Optical Coherence Tomography,United States,Bridgewater,New Jersey,1,Nerispirdine|Placebo,DRUG|DRUG,Visual Evoked Potential (P100) latency,Pelli-Robson Contrast Sensitivity Score|Early Treatment Diabetic Retinopathy Study (EDTRS) visual acuity score|Visual Evoked Potential (VEP) amplitude,False,
NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,"A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis",TERMINATED,2013-06,2014-04,2014-04,2015-06-01,2013-06-11,INTERVENTIONAL,PHASE2,28.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing Multiple Sclerosis|AIN457|Secukinumab|Magnetic Resonance Imaging|Relapsing Remitting Multiple Sclerosis|Autoimmune Diseases|Nervous System Diseases|Immune System Diseases|Demyelinating Diseases,Belgium,Bruges,,13,Placebo|AIN457,DRUG|DRUG,Cumulative Number of New Gadolinium [Gd]-Enhancing T1-weighted Lesions,Annualized Relapse Rate|Combined Unique Active Lesions (CUAL)|Change in Total Volume of T2-weighted Lesions|Number of Particpants With Adverse Events as a Measure of Safety and Tolerability,True,2015-06-01
NCT02769767,"Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.","Association of Polymorphisms of the Interleukin-7 Receptor-α (IL-7R), Glypican 5 (GPC5), Interleukin-2 Receptor-α (IL2-RA) , Human Leukocyte Antigen Class II Beta Chain (HLA-DRB1) Genes and Treatment Response in Multiple Sclerosis (MS).",UNKNOWN,2012-08,2016-12,2016-12,2016-05-12,2016-05-12,OBSERVATIONAL,,500.0,ESTIMATED,Instituto Jalisciense de Cancerologia,OTHER_GOV,Instituto Mexicano del Seguro Social|University of Guadalajara,OTHER_GOV|OTHER,"Multiple Sclerosis, Relapsing-Remitting",,Mexico,Guadalajara,Jalisco,1,"Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.",GENETIC,"Treatment response evaluated by relapses per year, evaluated during two years after recruitment.|Treatment response evaluated by Expanded Disability Status Scale (EDSS) during two years after recruitment.","Multiple Sclerosis Risk Conferred by Single Nucleotide Polymorphisms (SNPs) of Interleukins, Glypican, and Human Leukocyte Antigen Genes.",False,
NCT03207464,Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis,Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis,UNKNOWN,2017-10-10,2021-12-31,2021-12-31,2020-12-11,2017-07-02,INTERVENTIONAL,PHASE1|PHASE2,19.0,ESTIMATED,Brigham and Women's Hospital,OTHER,,,Multiple Sclerosis,,United States,Boston,Massachusetts,1,[C-11]Methylreboxetine,DRUG,Tissue Volume of Distribution,,False,
NCT05809414,Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis,"Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis: Phase III Study, Controlled, Randomized, Crossed Over and Double Blind.",RECRUITING,2022-11-28,2024-07-15,2025-02-28,2023-12-11,2023-04-12,INTERVENTIONAL,PHASE3,144.0,ESTIMATED,"Hospital San Carlos, Madrid",OTHER,,,Multiple Sclerosis|Fatigue,Amantadine|Multiple Sclerosis|Fatigue|Transcranial Magnetic Stimulation (TMS)|Modified Fatigue Impact Scale (MFIS),Spain,Cadiz,,4,Transcranial Magnetic Stimulation|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule,DEVICE|DRUG,To assess the fatigue severity,To assess the cognitive condition|To assess the depression condition|To assess the quality of life|Safety assessment|Cost-effectivity assessment,False,
NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,"Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis",COMPLETED,2004-02-16,2006-11-28,2006-11-28,2018-06-27,2004-02-26,INTERVENTIONAL,PHASE4,764.0,ACTUAL,EMD Serono,INDUSTRY,Pfizer,INDUSTRY,Relapsing-remitting Multiple Sclerosis,,United States,Birmingham,Alabama,80,Rebif®|Copaxone®,DRUG|DRUG,Time to First Relapse,,True,2018-06-27
NCT05013463,Hydroxychloroquine and Indapamide in SPMS,"Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS)",UNKNOWN,2021-10-01,2023-09-01,2024-09-01,2022-05-18,2021-08-19,INTERVENTIONAL,PHASE2,35.0,ESTIMATED,University of Calgary,OTHER,,,"Multiple Sclerosis, Secondary Progressive",,Canada,Calgary,Alberta,1,Hydroxychloroquine Pill|Indapamide Pill,DRUG|DRUG,Timed 25-Foot Walk (T25FW),9-Hole Peg Test|Symbol Digit Modalities Test|Functional Systems and Expanded Disability Status Scale (EDSS)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life Scale 54 item version,False,
NCT00203021,Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness,Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone,COMPLETED,1994-03-26,2018-02-28,2018-02-28,2020-02-18,2005-09-20,INTERVENTIONAL,PHASE4,208.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Los Angeles,California,11,Glatiramer acetate,DRUG,Number of Participants With Adverse Events (AEs)|Change From Baseline in Kurtzke Expanded Disability Status Scale (EDSS) Score at Month 288,,True,2019-07-18
NCT00837785,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis,COMPLETED,2009-02-28,2009-10-31,2009-10-31,2018-02-15,2009-02-05,INTERVENTIONAL,PHASE1,48.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,Germany,Berlin,,1,BG00012|BG00012,DRUG|DRUG,To establish a PK profile of MMF during a 24-hour BG00012 dosing period in subjects with RRMS,To explore the relationship of differences in baseline demographics and dosing factors in the disposition of BG00012,False,
NCT02418897,Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis,Does Abnormal Neuromuscular Junction Function Play a Role in the Pathogenesis of Motor Fatigue in Women With Multiple Sclerosis?,COMPLETED,2015-04,2016-11,2016-11,2016-11-16,2015-04-16,OBSERVATIONAL,,40.0,ACTUAL,Texas Tech University Health Sciences Center,OTHER,,,Multiple Sclerosis,Fatigue|multiple sclerosis|neuromuscular junction|SFEMG,United States,Lubbock,Texas,1,,,Number of patients with abnormal Jitter.,Score of fatigue (Fatigue severity scale (FSS) and modified fatigue impact scale (MFIS)),False,
NCT02580435,Deciphering the Role of the Gut Microbiota in Multiple Sclerosis,Deciphering the Role of the Gut Microbiota in Multiple Sclerosis,UNKNOWN,2015-12,2020-12,2021-12,2015-10-29,2015-10-20,OBSERVATIONAL,,520.0,ESTIMATED,Sheba Medical Center,OTHER_GOV,Weizmann Institute of Science,OTHER,Multiple Sclerosis,multiple sclerosis|microbiome|prediction|outcome,,,,0,,,1. Change in expression of intestinal microbiome composition between MS patients and healthy controls.|Change in microbiome expression intestinal microbiome composition between MS patients phenotypes.,,False,
NCT00581997,QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis,"A Randomized, Double-blinded, Placebo Controlled, Multiple-dose, Multi-center Pilot Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients With Pulmonary Fibrosis Secondary to System Sclerosis",TERMINATED,2007-12,2009-04,,2020-12-19,2007-12-28,INTERVENTIONAL,PHASE2,8.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Pulmonary Fibrosis Secondary to Systemic Sclerosis,"Pulmonary fibrosis, systemic sclerosis",,,,0,QAX576|Placebo,DRUG|DRUG,"- Safety assessments including vital Signs, ECG's, Echocardiograms and blood draws. - The pharmacokinetics and pharmacodynamics of multiple doses of the drug will be assessed by blood draws at the 3 dosing visits. A blood sample will also be collected.","- The effect of the drug on biomarkers of pulmonary fibrosis and systemic sclerosis. - Pulmonary function tests. - Disease specific measurements, active hand extension, oral aperture, MRSS.",False,
NCT03999788,miR-142-3p as Potential Biomarker of Synaptopathy in MS,Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis,RECRUITING,2019-12-10,2024-12-28,2025-12-28,2024-03-29,2019-06-27,INTERVENTIONAL,NA,1000.0,ESTIMATED,Neuromed IRCCS,OTHER,,,Multiple Sclerosis|Spasticity,microRNA|Multiple Sclerosis|synaptopathy|lower limb spasticity|transcranial magnetic stimulation|repetitive TMS stimulation protocol|GLAST/EAAT1|single nucleotide polymorphisms|Intermittent theta burst stimulation (iTBS),Italy,Pozzilli,Isernia,1,lumbar puncture and blood withdrawal|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity,PROCEDURE|PROCEDURE,CSF concentration of miR-142-3p|CSF concentration of soluble molecules|Clinical disability assessment by Progression Index calculation for correlation analysis with CSF-miR-142-3p levels|Clinical disability assessment by MSFC calculation for correlation analysis with CSF-miR-142-3p levels|Neuroradiological assessment for correlation analysis with CSF-miR-142-3p levels|Neurophysiological assessments for correlation analysis with CSF-miR-142-3p levels|Statistical correlation of miR-142-3p levels in MS CSF with disease and neurophysiological parameters,Statistical correlation of miR-142-3p levels in MS CSF with patient's responsiveness to disease modifying therapies (DMTs).|Genotyping of SNPs in SLC1A3 and MIR-142 genes for correlation analysis with disease parameters|Lower limb spasticity assessment by H/M amplitude ratio for the therapeutic TMS substudy|Lower limb spasticity assessment by MAS score for the therapeutic TMS substudy|Statistical correlation of response to iTBS treatment with MS-significant SNPs of both SLC1A3 and MIR-142.,False,
NCT00338741,Rebif® Pregnancy Registry,Rebif® Pregnancy Registry,COMPLETED,2002-12,2007-10,2008-02,2013-08-05,2006-06-20,OBSERVATIONAL,,36.0,ACTUAL,EMD Serono,INDUSTRY,Pfizer,INDUSTRY,Multiple Sclerosis,,United States,Rockland,Massachusetts,1,,,Spontaneous Abortion,Fetal Death/Stillbirth,True,2010-06-02
NCT02694666,Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis,Effects of Controlled Whole-body Vibration Training on Preventing Falls Among Healthy Population and Ambulatory People With Multiple Sclerosis,TERMINATED,2016-04,2023-04-10,2023-04-10,2023-11-18,2016-02-29,INTERVENTIONAL,NA,58.0,ACTUAL,Georgia State University,OTHER,,,Falls Prevention,,United States,Atlanta,Georgia,1,Controlled whole-body vibration training,OTHER,Real life falls,Berg Balance Scale test|Slip-related falls on treadmill|Functional mobility|Sensation|Muscle strength|Range of motion|Bone density|Multiple Sclerosis Functional Composite score|Equiscale balance test|Symbol Digit Modalities test|Selective Reminding test|Behavior Rating Inventory of Executive Function,False,
NCT04833673,"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial","The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial",COMPLETED,2020-06-22,2020-12-30,2021-03-15,2021-04-06,2021-04-06,INTERVENTIONAL,NA,80.0,ACTUAL,Hacettepe University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Pain, Chronic|Fatigue Syndrome, Chronic|Kinesiophobia",multiple sclerosis|pain|fatigue|kinesiophobia|relaxation techniques|muscle relaxation,Turkey (Türkiye),Ankara,None Selected,1,PMR: Progressive Muscle Relaxation|BRT:Benson Relaxation Technique,BEHAVIORAL|BEHAVIORAL,Fatigue,Chronic Pain|Kinesiophobia,False,
NCT03597451,The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis,"The Effects of Extremity and ""Core"" Muscles Strength on Walking and Sit-to-Stand Performance in Patients With Multiple Sclerosis",COMPLETED,2018-08-13,2020-02-28,2020-03-06,2020-04-09,2018-07-24,OBSERVATIONAL,,87.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,strength|walking|sit-to-stand,Turkey (Türkiye),Ankara,,1,,,strength of extremity muscles,6 minutes walking test|timed up and go test|sit-to-stand test|Side Bridge Test (core muscles endurance)|Modified Biering-Sorensen test (core muscles endurance)|Trunk Flexion Test (core muscles endurance)|Prone bridge test (core muscles endurance),False,
NCT05777629,"Determination of Compliance to Mediterranean Diet, Impacts on Walking and Quality of Life in Multiple Sclerosis","Determination of Compliance to Mediterranean Diet, Impacts on Walking and Quality of Life in Multiple Sclerosis",UNKNOWN,2021-02-28,2023-05-30,2023-06-01,2023-03-21,2023-03-21,OBSERVATIONAL,,103.0,ACTUAL,University of Gaziantep,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Mediterranean Diet|Quality of Life|Walking,Turkey (Türkiye),Gaziantep,,1,,,Mediterranean Diet Compliance Status|Quality of Life Of Multiple Sclerosis Patients|Impacts on Walking|Expanded Disability Status Scale,,False,
NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,"Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy",COMPLETED,2011-08-01,2020-07-10,2020-07-10,2022-01-14,2011-09-28,OBSERVATIONAL,,3076.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|fingolimod|observational study,United States,Birmingham,Alabama,238,other disease-modifying therapy|Fingolimod,DRUG|DRUG,"For each of the selected safety outcomes, number of patients with a reported event since study start","Number of patients SAEs since study start|PRIMUS activities, comparison of mean change between the 2 cohorts|TSQM-9, comparison between the 2 cohorts|WPAI-GH, comparison of mean change between the 2 cohorts|MSIS-29, comparison of mean change between the 2 cohorts",False,
NCT02601131,Post-transfusion Platelet Count,Post-transfusion Platelet Count,COMPLETED,2016-02,2016-09,2016-09,2016-11-29,2015-11-10,OBSERVATIONAL,,80.0,ACTUAL,Region Skane,OTHER,,,Leukemia|Multiple Sclerosis,platelet count|platelet transfusion|complement factors|endothelial markers|stem cell transplantation,Sweden,Lund,,1,Platelet transfusion,BIOLOGICAL,Change in platelet count after platelet transfusion,Change in concentrations of complement factors in plasma after platelet transfusion|Change in concentrations of endothelial markers in plasma after platelet transfusion|Change in concentrations of complement factors in platelet rich plasma after platelet transfusion|Analysis of platelets in platelet transfusions given to patients included in the study,False,
NCT05451251,Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion,Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion: a Pilot Study,RECRUITING,2024-10-15,2025-10-15,2026-10,2024-12-12,2022-07-11,INTERVENTIONAL,PHASE1,6.0,ESTIMATED,Université de Sherbrooke,OTHER,,,Trigeminal Neuralgia,Multiple sclerosis|Deep brain stimulation|Pontine lesion,Canada,Sherbrooke,Quebec,1,Deep brain stimulation,DEVICE,Demonstrating the feasibility of the intervention by assessing protocol completion without deviation,Lead implantation accuracy|Pain evolution|Facial numbness|Complications|Quality of life progression|Patient acceptability of the procedure|Patient global impression of change,False,
NCT04009005,Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis,Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2020-05-01,2022-08-01,2027-09-01,2025-03-25,2019-07-05,INTERVENTIONAL,NA,44.0,ACTUAL,Terry L. Wahls,OTHER,,,Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis,,United States,Iowa City,Iowa,1,Therapeutic diet and lifestyle,BEHAVIORAL,MS 54 Quality of Life scale physical health score|MS 54 Quality of Life scale mental health score,Anxiety Score -Hospital Anxiety and Depression Survey|Depression score -Hospital Anxiety and Depression Survey|Magnetic Resonance Imaging of CNS|Magnetic Resonance Imaging of CNS|Magnetic Resonance Imaging of CNS|Magnetic Resonance Imaging of CNS|MS Clinical symptoms over time|MS Clinical symptoms over time|MS Clinical symptoms over time|MS Clinical symptoms over time|Dietary intake,False,
NCT04705870,Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis,Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis,UNKNOWN,2021-06-02,2023-05-24,2024-03-02,2023-07-27,2021-01-12,OBSERVATIONAL,,60.0,ESTIMATED,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Paris,,1,cerebral MRI,DEVICE,percentage of lesions showing the central vein sign with the SWI EPI sequence that also show the central vein sign with the candidate sequence|percentage of lesions which do not present the sign of the central vein with the SWI EPI sequence but which present it with the candidate sequence,,False,
NCT02583386,Comprehensive Fall Prevention and Detection in Multiple Sclerosis,Comprehensive Fall Prevention and Detection in Multiple Sclerosis,COMPLETED,2016-04,2019-10,2019-10,2021-03-11,2015-10-22,INTERVENTIONAL,NA,96.0,ACTUAL,Portland VA Medical Center,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,mobility|falls|fall prevention|gait and balance|automatic fall detector,United States,Portland,Oregon,1,Free From Falls fall prevention program|Electronic Fall Detector,BEHAVIORAL|OTHER,"Change from Baseline in Self-Reported Falls and Fall-Related Injuries at Completion of Program and the Following Six Months|Change from Baseline in Balance Confidence|Change from Baseline in Satisfaction with Participation in Social Roles|Change from Baseline in Ability to Participate in Social Roles and Activities|Change from Baseline in Quality of Life|Accuracy and Impact of Fall Detection and Localization by the MobileRF Fall Detection System, Compared to Paper Fall Calendars",Change from Baseline in Mobility and Balance (TUG score) at Completion of Program and the Following Six Months|Change from Baseline in Mobility and Balance (FSST score) at Completion of Program and the Following Six Months|Change from Baseline in Level of Physical Activity at Completion of Program and the Following Six Months|Change from Baseline in Fall Prevention Strategy at Completion of Program and the Following Six Months|Change from Baseline in Fatigue at Completion of Program and the Following Six Months|Change from Baseline in Mobility at Completion of Program and the Following Six Months|Change from Baseline in Psychosocial Function at Completion of Program and the Following Six Months|Change from Baseline in Knowledge and Confidence Regarding Fall Prevention at Completion of Program and the Following Six Months,False,
NCT06395909,A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis,"A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2023-04-23,2023-08-31,2023-08-31,2024-05-02,2024-05-02,OBSERVATIONAL,,113.0,ACTUAL,Novartis,INDUSTRY,,,Relapsing Multiple Sclerosis|Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Annualized Relapse Rate (ARR),"Proportion of Patients Relapse-free at 12 Months after Index Date|Proportion of Patients Free of Magnetic Resonance Imaging (MRI) Activity at 12 Months after Index Date|Proportion of Patients with Treatment-emergent Adverse Events (TEAEs), per Category|Proportion of Patients with Selected Notable Abnormal Laboratory Data",False,
NCT05482906,Common and Specific Information From Neuroimaging and Smartphone,Individual Gait Pattern and MRI Lesion Load to Quantify Gait Impairment in MS: A Cross Sectional Study.,UNKNOWN,2023-04-03,2025-04-01,2025-04-01,2023-04-07,2022-08-01,OBSERVATIONAL,,100.0,ESTIMATED,Nantes University Hospital,OTHER,Rennes University Hospital,OTHER,Multiple Sclerosis,Wearable sensor|Gait|MRI,France,Nantes,Loire-Atlantique,1,eGait,OTHER,Clustering analyze based on IGP|Clustering analyze based on EDSS score|Clustering analyze based on MRI lesion load,Correlation with disability|Correlation with MRI lesion load|Building a predictive model for lesion load involving in walk ability from IGP|Building a predictive model for group belonging from group established in main outcome based on IGP,False,
NCT01800604,Power Over Pain (POP) Study,Psychological Treatment of Disability-Related Pain: Efficacy and Mechanisms,COMPLETED,2013-02,2018-01,2018-01,2018-10-17,2013-02-27,INTERVENTIONAL,NA,177.0,ACTUAL,University of Washington,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH),NIH|NIH,Multiple Sclerosis|Spinal Cord Injury|Chronic Pain|Other and Unspecified Amputation Stump Complications|Muscular Dystrophies|Low Back Pain,,United States,Seattle,Washington,1,Pain Self-Management Intervention #1|Pain Self-Management Intervention #2|Pain Self-Management Intervention #3|Pain Self-Management Intervention #4,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in average pain intensity pre-treatment to post-treatment,,False,
NCT01167426,Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients,"An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.",COMPLETED,2010-07,2010-11,2010-12,2013-10-17,2010-07-22,INTERVENTIONAL,PHASE3,148.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|RRMS|Clinically Isolated Syndrome|CIS|Copaxone|glatiramer acetate|Autoject 2,,,,0,Glatiramer Acetate 20 mg/0.5 mL|Glatiramer acetate 20 mg/0.5 mL,DRUG|DRUG,Change From Week 2 to Week 6 in Composite Score of Patient Satisfaction With Injection Experience,Patient Injection Experience Preference,True,2013-10-17
NCT04838015,Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS,Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS,UNKNOWN,2020-11-13,2021-11-13,2021-11-13,2021-04-13,2021-04-08,OBSERVATIONAL,,250.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,,,Multiple Sclerosis,MS-RR|Ocrelizumab|Switch,France,Strasbourg,,1,,,Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis,,False,
NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),"An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017",COMPLETED,2013-11,2015-10,2015-11,2017-01-25,2013-09-11,INTERVENTIONAL,PHASE3,251.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,flu-like symptoms,United States,Gilbert,Arizona,38,BIIB017|naproxen,DRUG|DRUG,Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall Population,"Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Between FLS Management Arms|Percentage of Participants With Any FLS in the 4-Week Run-In Period, During the First 8 Weeks of Treatment, and During 48 Weeks of Treatment|Shift in Percentage of Participants With Any FLS From 4-Week Run-In Period to the First 8 Weeks|Shift in Percentage of Participants With Any FLS From 4-Week Run-In Period to 48 Weeks|Summary of Severity of FLS (Per FLS-S) in the First 8 Weeks Compared to 4-Week Run-In Period Between Arms|Summary of Severity of FLS (Per FLS-S) in the 48 Weeks of Treatment Compared to 4-Week Run-In Period Between Arms|Summary of Average Duration of FLS in the First 8 Weeks of Treatment|Summary of Average Duration of FLS in the 48 Weeks of Treatment|Summary of FLS-Visual Analogue Scale (VAS) During the First 8 Weeks of Treatment Compared to 4-Week Run-In Period: Effectiveness of FLS Treatment|Summary of FLS-VAS During the First 8 Weeks of Treatment Compared to 4-Week Run-In Period: Satisfaction With FLS Treatment|Summary of FLS-VAS During the 48 Weeks of Treatment Compared to 4-Week Run-In Period: Effectiveness of FLS Treatment|Summary of FLS-VAS During the 48 Weeks of Treatment Compared to 4-Week Run-In Period: Satisfaction With FLS Treatment|Percentage of Participants Requiring Additional FLS Management Regimen to Relieve BIIB017-related FLS|Mean Change From 4-Week Run-In Period at Each Visit for Treatment Satisfaction Questionnaire for Medication (TSQM), Effectiveness Scale Factor: Overall Population|Mean Change From 4-Week Run-In Period at Each Visit for TSQM, Side-Effects Scale Factor: Overall Population|Mean Change From 4-Week Run-In Period at Each Visit for TSQM, Convenience Scale Factor: Overall Population|Mean Change From 4-Week Run-In Period at Each Visit for TSQM, Global Satisfaction Scale Factor: Overall Population|Mean Change From 4-Week Run-In Period at Week 4 for TSQM, Effectiveness Scale Factor: Between FLS Management Arms|Mean Change From 4-Week Run-In Period at Week 4 for TSQM, Side Effects Scale Factor: Between FLS Management Arms|Mean Change From 4-Week Run-In Period at Week 4 for TSQM, Convenience Scale Factor: Between FLS Management Arms|Mean Change From 4-Week Run-In Period at Week 4 for TSQM, Global Satisfaction Scale Factor: Between FLS Management Arms|Mean Change From Screening at Each Visit in Absenteeism Questionnaire, Usual Work Days Per Week: Overall Population|Mean Change From Screening at Each Visit in Absenteeism Questionnaire, Days Missed in 2 Weeks From MS Symptoms: Overall Population|Mean Change From Screening at Each Visit in Absenteeism Questionnaire, Days Missed in 2 Weeks From MS Treatment: Overall Population|Change From Baseline Visit (Day 1) to Week 48 in Walking Disability Status as Measured by Patient Determined Disease Steps (PDDS): Overall Population|Summary of Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs|Summary of Average Duration of FLS Within the Last 4 Weeks of the BIIB017 Treatment Period Compared With the Duration of FLS in the 4-Week Run-In Period|Antibody Data in the Overall Population: IFN β-1a Antibody Screening|Antibody Data in the Overall Population: IFN β-1a Anti-Pegylated (PEG) Antibody Testing|Antibody Data in the Overall Population: IFN β-1a Neutralizing Antibodies (Nabs) Testing",True,2017-01-25
NCT01081275,Improving Hand Use in Multiple Sclerosis,Rehabilitating Extremity Use After Multiple Sclerosis,UNKNOWN,2010-02,2016-02,2016-03,2015-04-15,2010-03-05,INTERVENTIONAL,PHASE2,66.0,ESTIMATED,National Multiple Sclerosis Society,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|CI Therapy|CIMT|Constraint-Induced Movement Therapy|Complementary and Alternative Medicine|CAM|Physical Therapy|Occupational Therapy|Relaxation|Exercise|Massage|Yoga|Pool Therapy|Aquatherapy|Aquatic Therapy,United States,Birmingham,Alabama,1,CI Therapy|CAM treatments,BEHAVIORAL|BEHAVIORAL,Motor Activity Log (MAL),Wolf Motor Function Test (WMFT)|MSFC (Multiple Sclerosis Composite Measure)|SARA (Scale for the Assessment and Rating of Ataxia)|EDSS (Expanded Disability Status Scale)|Fatigue Severity Scale (FSS)|MSIS-29 (Multiple Sclerosis Impact Scale)|MSSS-88 (Multiple Sclerosis Spasticity Scale)|Baecke Activity Questionnaire,False,
NCT00317564,Betaseron Pregnancy Registry,Betaseron Pregnancy Registry,COMPLETED,2006-04,2012-04,2012-06,2018-12-12,2006-04-25,OBSERVATIONAL,,113.0,ACTUAL,Syneos Health,OTHER,Bayer,INDUSTRY,Birth Defects|Pregnancy Complications|Multiple Sclerosis,Birth Defects|High Risk Pregnancy|Multiple Sclerosis,United States,Wilmington,North Carolina,1,,,,,False,
NCT05177718,Natalizumab and Chronic Inflammation,Assessing the Effect of Natalizumab of Magnetic Resonance Imaging Measures of Blood Brain Barrier Permeability and Myelin Integrity,TERMINATED,2022-09-16,2023-04-05,2023-04-05,2024-04-18,2022-01-05,INTERVENTIONAL,PHASE4,1.0,ACTUAL,Vanderbilt University Medical Center,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,"multiple sclerosis, MRI, blood brain barrier, myelin",United States,Nashville,Tennessee,1,Natalizumab 300 MG in 15 ML Injection,DRUG,Effect of Natalizumab on Magnetic Resonance Imaging Measures of Blood Brain Barrier Permeability: K-trans,Effect of Natalizumab on Magnetic Resonance Imaging Measures of Myelin Integrity: Pool Saturation Ratio (PSR),True,2024-04-18
NCT06513546,"A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients","A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of ALS",RECRUITING,2025-04-08,2026-10-15,2026-12-15,2025-07-23,2024-07-22,INTERVENTIONAL,PHASE1|PHASE2,153.0,ESTIMATED,PLL TX AUSTRALIA PTY LTD,INDUSTRY,,,Amyotrophic Lateral Sclerosis|ALS,,Australia,Liverpool,New South Wales,10,PLL001 or placebo daily subcutaneous injections,DRUG,"Part 1: safety|Part 2: efficacy of PLL001 compared to placebo after 8, 16, and 24 weeks of once daily (QD) treatment|Part 2: survival after 8, 16, and 24 weeks of QD treatment for PLL001 compared to placebo",Part 2: safety|Part 2: efficacy over 24 weeks,False,
NCT05779449,Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS,Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in Multiple Sclerosis,RECRUITING,2023-07-26,2024-11-02,2026-05-01,2023-08-14,2023-03-22,INTERVENTIONAL,NA,100.0,ESTIMATED,Neuromed IRCCS,OTHER,I.R.C.C.S. Fondazione Santa Lucia,OTHER,Patient Participation,gut microbiota|dysbiosis|multiple sclerosis|glutamate-mediated excitotoxicity|synaptopathy,Italy,Pozzilli,Isernia,1,Prebiotics and Probiotics supplementation|Placebo supplementation|peripheral blood withdrawal|Transcranial Magnetic Stimulation (TMS),DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|PROCEDURE|PROCEDURE,Changes in gut microbiota diversity or composition|Changes in microbiota metabolites - indican|Changes in microbiota metabolites - skatole|Changes in serum glutamate|Changes in serum synaptotoxic miRNAs|Changes in plasma inflammatory molecules|Changes in immunophenotype|Changes in T cell metabolic asset,Changes in neurophysiological response|Changes in clinical disability|Changes in lower extremity function|Changes in upper extremity function|Changes in quality of life|Assessment of mild to moderate dysfunctions|Changes in global cognitive disability|Assessment of attention and information processing speed|Changes in phonemic verbal fluency|Changes in verbal memory performance|Changes in measure visuospatial memory|Changes in depressive symptoms|Changes in anxious symptoms|Changes in disease progression index (PI)|Changes in the Annualized Relapse Rate (ARR)|Changes in radiological activity|Changes in brain atrophy,False,
NCT04150549,FMT for MS Patients,"Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Double-blinded, Randomized Trial",UNKNOWN,2023-06,2025-05,2025-08,2022-10-25,2019-11-04,INTERVENTIONAL,PHASE2,34.0,ESTIMATED,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,,,Multiple Sclerosis,,,,,0,Fecal Microbial Transplants|Fecal Microbial Transplants,BIOLOGICAL|BIOLOGICAL,Changes in T2 Lesions - MRI,Blood Brain Barrier - MRI|Neurofilament Light Serum Levels|Intestinal Permeability|IgA Microbiota|Stool Microbiome|Metabolomics|Metabolomics,False,
NCT01018485,The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor,"Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis",COMPLETED,2008-10,2010-02,2010-06,2015-05-12,2009-11-23,INTERVENTIONAL,PHASE3,30.0,ESTIMATED,Melbourne Health,OTHER,Eastern Health,OTHER,Multiple Sclerosis|Tremor,,Australia,Melbourne,Victoria,1,Botulinum Toxin Type A,DRUG,A decrease in tremor,The safety profile of Botulinum Toxin in MS patients,False,
NCT02506751,Open-label Study of Liothyronine in MS,"A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS",COMPLETED,2015-07,2017-09-18,2017-09-18,2018-02-12,2015-07-23,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Johns Hopkins University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",,United States,Baltimore,Maryland,1,liothyronine,DRUG,The incidence rate of adverse events,,False,
NCT06737419,"Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice","Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice",COMPLETED,2021-06-09,2024-02-05,2024-02-05,2024-12-17,2024-12-17,OBSERVATIONAL,,175.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Clinically Isolated Syndrome|Relapsing-remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,United States,East Hanover,New Jersey,1,,,Number of Patients Categorized by Number of Relapses|Change in Relapse Rate From Baseline to Month 6 and Month 12 After Initiating OMB Treatment,Age|Number of Patients per Demographic Category|Mean Duration of Disease|Number of Patients by Most Recent Disease Course|Number of Patients by Patient Determined Disease Steps (PDDS) Score|Number of Patients Categorized by Comorbidity|Number of Patients With no Prior Exposure to Disease Modifying Therapies (DMTs)|Number of Prior DMTs|Number of Patients who Switched From a DMT to OMB|Duration of Time Between Prior DMT and Initiating OMB Treatment|Number of Patients by Most Recent Prior DMT|Number of Patients who Discontinued DMT Prior to OMB Treatment by Reason for Discontinuation|Number of Patients by Number of New Brain T2 Lesions|Number of Patients by Number of New Brain Gadolinium Enhancing (GdE) Lesions|Change in Number of New Brain T2 Lesions From Baseline to Month 6 and Month 12 After Initiating OMB Treatment|Change in Number of New Brain GdE Lesions From Baseline to Month 6 and Month 12 After Initiating OMB Treatment|Change in PDDS Scores From Baseline to Month 6 and Month 12 After Initiating OMB Treatment|Change in Neuro-performance Tests From Baseline to Month 6 and Month 12 After Initiating OMB Treatment|Change in No Evidence of Disease Activity (NEDA) From Baseline to Month 6 and Month 12 After Initiating OMB Treatment|Median Change of PDDS From Baseline to Month 6 and Month 12 After Initiation of OMB Treatment|Number of Patients With 20% or Greater Worsening of Neuro-performance Test Scores After Initiating OMB Treatment|Number of Patients With 20% or Greater Worsening of PDDS Scores After Initiating OMB Treatment,False,
NCT02592265,Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden,Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden and Social Participation.,COMPLETED,2012-10,2015-08,2016-06,2024-09-19,2015-10-30,OBSERVATIONAL,,233.0,ACTUAL,Lille Catholic University,OTHER,"Université de Lille|Région Nord-Pas de Calais, France|La Ligue Française Contre la Sclérose en Plaques|Novartis",OTHER|OTHER|OTHER|INDUSTRY,Multiple Sclerosis|Physical Disability|Economic Burden|Social Interaction|Capability|Quality of Life,,,,,0,,,Annual average total health care cost of the Multiple Sclerosis by patient,Score of social participation|Validity of life quality measurement EQ-5D|Utilities measured by the Short Form-6D (SF-6D)|QALY,False,
NCT04120207,"An Eight-week RCT of Home-based Pilates for Symptoms of Anxiety, Depression, and Fatigue Among People With MS","An Eight-week Randomised Controlled Trial of Home-based Pilates for Symptoms of Anxiety, Depression, and Fatigue Among People With MS With Minimal-to-mild Mobility Disability: Study Protocol",COMPLETED,2019-01-01,2019-08-28,2019-08-28,2019-10-09,2019-10-09,INTERVENTIONAL,NA,63.0,ACTUAL,University of Limerick,OTHER,,,Multiple Sclerosis,Pilates|Home-based|Anxiety|Depression|Fatigue,Ireland,Limerick,,1,Home-based Pilates|Delayed-start Pilates,BEHAVIORAL|OTHER,Profile of Mood States - Brief Form (POMS-B)|Profile of Mood States - Brief Form (POMS-B)|Profile of Mood States - Brief Form (POMS-B)|Profile of Mood States - Brief Form (POMS-B)|Profile of Mood States - Brief Form (POMS-B)|State Trait Anxiety Inventory (STAI-Y1)|State Trait Anxiety Inventory (STAI-Y1)|State Trait Anxiety Inventory (STAI-Y1)|State Trait Anxiety Inventory (STAI-Y1)|State Trait Anxiety Inventory (STAI-Y1)|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS)|Quick Inventory of Depressive Symptomatology (QIDS)|Quick Inventory of Depressive Symptomatology (QIDS)|Quick Inventory of Depressive Symptomatology (QIDS)|Quick Inventory of Depressive Symptomatology (QIDS)|Quick Inventory of Depressive Symptomatology (QIDS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS),Seven-day Physical Activity Recall Scale (7d-PAR)|Seven-day Physical Activity Recall Scale (7d-PAR)|Seven-day Physical Activity Recall Scale (7d-PAR)|Seven-day Physical Activity Recall Scale (7d-PAR)|Seven-day Physical Activity Recall Scale (7d-PAR)|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|Godin Leisure-Time Exercise Questionnaire (GLTEQ),False,
NCT01647321,Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis,Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis,COMPLETED,2012-07,2019-10,2019-10,2020-03-19,2012-07-23,INTERVENTIONAL,NA,16.0,ACTUAL,Johns Hopkins University,OTHER,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",OTHER,Secondary Progressive Multiple Sclerosis,SPMS,United States,Baltimore,Maryland,1,Active cycling|Passive cycling,BEHAVIORAL|BEHAVIORAL,Change in timed 25 foot walk from baseline to end of training,,False,
NCT04667949,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,"A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China",COMPLETED,2021-02-20,2025-03-25,2025-03-25,2025-08-29,2020-12-16,INTERVENTIONAL,PHASE4,98.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),Relapsing Multiple Sclerosis (RMS)|Fingolimod|Adult|Pediatric|China,China,Beijing,Beijing Municipality,13,Fingolimod 0.5mg,DRUG,Adjusted Annualized Relapse Rate (ARR) in Adult Group,Number of Participants With Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE)|Annualized Rate of the Number of New or Newly Enlarged T2 Lesions|Change From Baseline in Number of New or Newly Enlarged T2 Lesions|Change From Baseline in T2 Lesion Volume|Number of Gd-enhancing T1 Lesions Per Scan in Adult Group|Number of Gd-enhancing T1 Lesions|Change From Baseline in Gd-enhancing T1 Lesion Volume|Number of T1 Hypo-intense Lesions|Change From Baseline in T1 Hypo-intense Lesion Volume,True,2025-08-29
NCT01307332,Advanced MRI Measures of Repair in Alemtuzumab Treated Patients,Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients,COMPLETED,2011-03,2018-09-28,2018-09-28,2018-10-16,2011-03-02,INTERVENTIONAL,PHASE3,27.0,ACTUAL,University of British Columbia,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Relapsing Remitting Multiple Sclerosis,"Multiple Sclerosis|MS|Relapsing Remitting Multiple Sclerosis|RRMS|Alemtuzumab|Demyelination|Remyelination|Tolerogenic|T cells|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases|Immune System Diseases",Canada,Vancouver,British Columbia,1,MabCampath-1h,DRUG,Changes in normal appearing white matter from baseline through month 24.,To identify specific changes in T cell subsets and functions in Relapsing Remitting Multiple Sclerosis from baseline through month 48.,False,
NCT03768648,Cognition and MRI Markers in MS Patients With Aubagio® Treatment,Everyday Life Cognition and Non-conventional Magnetic Resonance Markers in RRMS Patients Treated With Aubagio® in a Real-life Setting,COMPLETED,2019-05-21,2023-02-23,2023-02-23,2023-03-08,2018-12-07,INTERVENTIONAL,NA,75.0,ACTUAL,"University Hospital, Bordeaux",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Autoimmune Diseases of the Nervous System|Demyelinating Autoimmune Diseases, CNS|Demyelinating Diseases|Immune System Diseases|Nervous System Diseases|Pathologic Processes|cognitive impairment|ecological assessment|brain MRI",France,Bordeaux,,1,Clinical assessment|Ecological evaluation|Neuropsychological evaluation|Psychological evaluation|MRI Evaluation,OTHER|OTHER|OTHER|OTHER|DEVICE,Change of composite z ecological score based on individual ecological scores.,Change of composite z cognitive score based on individual neuropsychological scores|Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity,False,
NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,"A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex",COMPLETED,2003-03,,2005-10,2014-12-31,2005-09-21,INTERVENTIONAL,PHASE4,271.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Tucson,Arizona,53,Betaferon/Betaseron|Betaferon/Betaseron,DRUG|DRUG,Time to onset of first relapse,Number of patients relapse free at week 104,False,
NCT00587691,Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis,"An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis",COMPLETED,2002-07,2007-06,2008-12,2017-01-11,2008-01-07,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,"Opexa Therapeutics, Inc.",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",Tovaxin|TCV|Autologous,United States,Bellaire,Texas,2,Tovaxin Autologous T Cell Vaccine,BIOLOGICAL,Evaluation of safety and tolerability,To assess changes in EDSS Scores|To assess changes in the myelin-reactive profile in the blood|To assess changes in the frequency of MS relapses,False,
NCT04759391,Effects of Digital Pelvic Floor Muscle Training in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms,Effects of Digital Pelvic Floor Muscle Training and Lifestyle Recommendations in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms,UNKNOWN,2021-02,2021-06,2021-07,2021-02-18,2021-02-18,INTERVENTIONAL,NA,30.0,ESTIMATED,Ataturk Training and Research Hospital,OTHER,,,Lower Urinary Tract Symptoms,Lower Urinary Tract Symptoms|Multiple Sclerosis|Pelvic Floor Muscle Training,Turkey (Türkiye),Ankara,,1,Exercise|Lifestyle recommendations,OTHER|OTHER,Incontinence symtoms|Overactive bladder symptoms,bladder functions|Quality of life level|subjective perception of improvement|patient satisfaction,False,
NCT00944190,TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS),"Telephone Delivered Self-management Intervention for People With Multiple Sclerosis Addressing Pain, Fatigue, Depression, and Cognitive Difficulties",COMPLETED,2009-10,2012-12,2013-09,2015-04-07,2009-07-23,INTERVENTIONAL,NA,166.0,ACTUAL,University of Washington,OTHER,,,Multiple Sclerosis,pain|fatigue|depression|cognitive difficulties|self-management,United States,Seattle,Washington,1,Self-management intervention|Education,BEHAVIORAL|BEHAVIORAL,PHQ 9|Brief Pain Inventory|Modified Fatigue Impact Scale,PROMIS Depression Short Form|PROMIS Pain Impact Short Form|PROMIS Fatigue Short Form,False,
NCT00510523,Whole Body Vibration Therapy in Participants With MS Related Balance Deficits,Whole Body Vibration Therapy in Participants With MS Related Balance Deficits,COMPLETED,2006-10,,2007-11,2013-05-03,2007-08-02,INTERVENTIONAL,NA,80.0,ESTIMATED,Logan College of Chiropractic,OTHER,,,Multiple Sclerosis,MS|Balance|Multiple Sclerosis,United States,Chesterfield,Missouri,2,Whole Body Vibration machine,DEVICE,NeuroCom Balance Master|SF-EMG Nerve conduction velocity test|Berg balance score,,False,
NCT06025968,Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis,Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis: A Randomised Controlled Trial,NOT_YET_RECRUITING,2023-09,2024-01,2025-09,2023-09-06,2023-09-06,INTERVENTIONAL,NA,69.0,ESTIMATED,Uppsala University,OTHER,,,Multiple Sclerosis|Insomnia,,Sweden,Uppsala,Uppland,1,i-CBT|Applied relaxation,BEHAVIORAL|BEHAVIORAL,Sleep diary - Total Wake Time (TWT),Insomnia Severity Index (ISI)|Patient Health Questionnaire (PHQ-9)|The Generalized Anxiety Disorder (GAD-7)|Fatigue Severity Scale (FSS)|The Brunnsviken Brief Quality of Life Scale (BBQ)|Negative effects|Sleep diary- Sleep onset latensy (SOL)|Sleep diary- wake after sleep onset (WASO)|Sleep diary. early morning awakening (EMA)|Multiple Sclerosis Impact Scale (MSIS-29)|Client Satisfaction Questionnaire-8 (CSQ-8),False,
NCT06107023,Action Observation Training With 3D Virtual Reality in Patients With Multiple Sclerosis,Investigation of the Effect of Action Observation Training With 3D Virtual Reality on Upper Extremity Functions in Patients With Multiple Sclerosis With Attacks,COMPLETED,2023-11-15,2025-02-02,2025-03-02,2025-07-22,2023-10-30,INTERVENTIONAL,NA,36.0,ACTUAL,Abant Izzet Baysal University,OTHER,,,Multiple Sclerosis,multiple sclerosis|motor learning|action observation training|virtual reality|upper extremity function,Turkey (Türkiye),Bolu,Center,1,Action observation training|sham action observation training,BEHAVIORAL|BEHAVIORAL,Box and Block Test|nine hole peg test|hand dynamometer,Fatigue severity scale|Paced Auditory Serial Addition Test|The Arm Function in Multiple Sclerosis Questionnaire|Multiple Sclerosis Quality of Life-54,False,
NCT01601080,"An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device","REbiSmart™ Retrospective ADherencE Review (READER) An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device",COMPLETED,2012-04,2012-10,,2014-02-04,2012-05-17,OBSERVATIONAL,,230.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono Limited, UK",INDUSTRY,Relapsing Multiple Sclerosis,Adherence|Multiple Sclerosis,United Kingdom,Merck KGaA Communication Center For Recruiting Locations,,1,,,Patient Adherence,Patient Adherence|Patient Adherence|Patient Adherence|Patient Adherence|Difference in patient adherence over time|Medication Possession Ratio|Medication Possession Ratio|Adherence of patient subgroups|Adherence of patient subgroups|Patient Adherence in the UK versus Ireland|Patient Adherence in the UK versus Ireland|Device Comfort Settings,False,
NCT03004079,Clinical Importance of Glucose Regulation in Relapsing MS,Assessment of the Clinical Importance of Insulin Resistance & Steroid-Associated Hyperglycemia in Relapsing Multiple Sclerosis,UNKNOWN,2016-10,2020-09,2020-09,2018-11-07,2016-12-28,OBSERVATIONAL,,160.0,ESTIMATED,University of Virginia,OTHER,National Multiple Sclerosis Society,OTHER,Relapsing Remitting Multiple Sclerosis|Clinically Isolated Syndrome,,United States,Charlottesville,Virginia,1,,,Relapse Recovery & Hyperglycemia|Insulin Resistance & Relapse Severity,,False,
NCT05819008,Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries,Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries,RECRUITING,2023-03-10,2025-12-31,2025-12-31,2024-05-09,2023-04-19,OBSERVATIONAL,,350.0,ESTIMATED,Umeå University,OTHER,"Västerbotten County Council, Sweden",OTHER_GOV,Traumatic Brain Injury|Stroke|Multiple Sclerosis|Parkinson Disease|Epilepsy|Brain Tumor,Neuropsychological assessment,Sweden,Umeå,,1,Neuropsychological Assessment,DIAGNOSTIC_TEST,Validity of Rey Auditory Verbal Learning Test in Mindmore|Validity of Symbol Digit Processing Test in Mindmore|Validity of Corsi Block Test in Mindmore|Validity of Trail Making Test - Click in Mindmore|Validity of Stroop in Mindmore|Validity of FAS in Mindmore,,False,
NCT01339676,Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS,UNKNOWN,2008-03,2011-05,2011-06,2011-05-19,2011-04-21,INTERVENTIONAL,PHASE4,70.0,ACTUAL,University of Turku,OTHER,,,Multiple Sclerosis,Vitamin D|Multiple Sclerosis|MRI|Randomised Trial|Finland,Finland,Turku,,1,Colecalciferol|Placebo capsules,DRUG|DRUG,Measure: the proportion of patients with P-PTH< 20 ng/l and S-OH(D)2 > 85 nmol/l at 6 and 12 months,Number of Gadolinium-enhancing lesions on T1 and /or new enlarging lesions on Measure: T2/PD based on MRI done 12 months following randomisation compared with the MRI done at the time of randomisation,False,
NCT01500408,Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers,"A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of Interferon Beta-1a Manufactured by Two Different Processes",COMPLETED,2012-01,2012-04,2012-04,2012-11-19,2011-12-28,INTERVENTIONAL,PHASE1,110.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Saint Paul,Minnesota,1,"Interferon beta-1a (current approved manufacturing process invloving FBS)|Interferon beta-1a (new process, manufactured without FBS)",DRUG|DRUG,Area under the serum concentration-time curve (AUC) as a measure of PK.,The observed maximum (peak) serum Interferon beta-1a concentration (Cmax),False,
NCT01433497,Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis,"A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis",COMPLETED,2011-08,2019-09,2020-02,2020-04-08,2011-09-14,INTERVENTIONAL,PHASE3,656.0,ACTUAL,AB Science,INDUSTRY,,,"Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Relapse Free",multiple sclerosis|primary progressive|relapse-free|secondary progressive,Bulgaria,Sofia,,8,Masitinib|Placebo,DRUG|DRUG,EDSS,MSQOL-54|MSFC,False,
NCT05792176,Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study,A Randomized Controlled Trial of Ukulele Playing Compared to Music Listening to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study,COMPLETED,2023-03-27,2024-10-01,2024-10-01,2025-03-13,2023-03-31,INTERVENTIONAL,NA,29.0,ACTUAL,University of Texas at Austin,OTHER,,,"Multiple Sclerosis|Pathologic Processes|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases|Immune System Diseases",cognitive rehabilitation,United States,Austin,Texas,1,Music Training Intervention|Music Listening,BEHAVIORAL|BEHAVIORAL,Intervention Feasibility|Intervention Feasibility|Intervention Feasibility|Intervention Acceptability,Mean Change from Baseline in Anxiety Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Depression Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Stress Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Self-Efficacy Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Quality of Life Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Sleep Disturbance Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Attention Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Memory Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Executive Functioning Scores at 12 weeks and 16 weeks|Mean Change from Baseline in Executive Functioning Scores at 12 weeks and 16 weeks,False,
NCT05901259,The Exopulse Mollii Suit Study - a Database for Routine Follow-up of Clinical Outcomes,The Exopulse Mollii Suit Study - a Database for Routine Follow-up of Clinical Outcomes,NOT_YET_RECRUITING,2024-08-01,2027-08-01,2027-12-31,2023-09-13,2023-06-13,OBSERVATIONAL,,200.0,ESTIMATED,Exoneural Network AB,INDUSTRY,,,Cerebral Palsy|Multiple Sclerosis|Stroke|Spinal Cord Injuries|Neurologic Disorder,,Sweden,Bergshamra,Stockholm County,1,Exopulse Mollii Suit,DEVICE,Berg's Balance Scale,"Timed Up and Go (TUG), if applicable for the patient|10 m Walk Test, if applicable for the patient|Wolf Motor Function Test, if applicable for the patient|Numeric Rating Scale (NRS), if applicable for the patient|EQ-5D-5L, if applicable for the patient|Fibromyalgia Impact Questionnaire (FIQ), if applicable for the patient|Quebec Back Pain Disability Scale, if applicable for the patient|Near Infrared Spectroscopy (NIRS), if applicable for the patient",False,
NCT04948645,A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of Fosigotifator in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension",TERMINATED,2021-09-22,2025-07-15,2025-07-15,2025-08-01,2021-07-02,INTERVENTIONAL,PHASE1,31.0,ACTUAL,AbbVie,INDUSTRY,Calico Life Sciences LLC,INDUSTRY,ALS|Amyotrophic Lateral Sclerosis,Fosigotifator|ABBV-CLS-7262,United States,Irvine,California,14,Fosigotifator|Placebo,DRUG|DRUG,Safety and Tolerability|Pharmacokinetics|Pharmacokinetics,CSF Pharmacokinetics|Safety and Tolerability,False,
NCT03993275,Exergames Balance Program in Neurorehabilitation,Exergames Balance Program in Neurorehabilitation,COMPLETED,2018-10-10,2020-01-15,2020-01-15,2020-05-13,2019-06-20,OBSERVATIONAL,,84.0,ACTUAL,Klinik Valens,OTHER,Mindmaze SA|KU Leuven,INDUSTRY|OTHER,Stroke|Multiple Sclerosis|Balance Disorders,Trunk Control|Exergames,Switzerland,Valens,Canton of St. Gallen,1,MindMotion GO,DEVICE,Game score of performed MindMotion GO Exergames|Change in Balance (Berg Balance Scale)|Change in trunk control and sitting Balance (Trunk Impairment Scale)|Change in mobility|Change in dynamic balance during gait|Change in the perceived Walking ability|Subjective difficulty of performed MindMotion GO Exerames,Change in Intrinsic Motivation during the treatment phase|Montreal cognitive assessment,False,
NCT04768777,Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis,Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis,NOT_YET_RECRUITING,2025-12-01,2026-12-01,2026-12-30,2024-12-24,2021-02-24,INTERVENTIONAL,NA,30.0,ESTIMATED,University of Alabama at Birmingham,OTHER,National Multiple Sclerosis Society,OTHER,"Multiple Sclerosis, Relapsing-Remitting|Sexual Dysfunction",physical activity|sexual behaviour,United States,Birmingham,Alabama,1,Behavioural intervention for physical activity for multiple sclerosis (BIPAMS),BEHAVIORAL,Change from baseline Sexual Dysfunction at 16 weeks,Change from baseline Sexual Dysfunction in MS at 16 weeks|Change from baseline Physical activity at 16 weeks|Change from baseline physical activity duration at 16 weeks,False,
NCT04289675,Multiple Sclerosis: Chi3L1 and Treatment Efficacy,Chi3L1: A Marker of Efficacy of Platform Treatments in Relapsing-onset Multiple Sclerosis: A Prognostic Study on Existing Clinical Data and Biological Samples,COMPLETED,2012-01-01,2019-12-01,2019-12-01,2020-03-09,2020-02-28,OBSERVATIONAL,,63.0,ACTUAL,"Central Hospital, Nancy, France",OTHER,,,Multiple Sclerosis,,,,,0,Interferon-Beta,DRUG,"Statistical association between the baseline chitinase 3-like 1 serum level and being ""responder"" at year one","Threshold chitinase 3-like 1 serum level at baseline to distinguish responders from non-responders|Statistical association between the baseline chitinase 3-like 1 cerebrospinal fluid level and being ""responder"" at year one|Statistical association between the baseline neurofilaments light chains cerebrospinal fluid level and being ""responder"" at year one|Statistical association between the baseline interleukin 6 cerebrospinal fluid level and being ""responder"" at year one",False,
NCT05296161,B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis,"Efficacy, Safety and Cost-effectiveness of B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis: a Randomized Controlled Trial",RECRUITING,2022-04-20,2024-04,2026-03,2022-04-28,2022-03-25,INTERVENTIONAL,PHASE4,296.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",ocrevus|ocrelizumab|personalised dosing,Netherlands,Amsterdam,North Holland,1,Ocrelizumab,DRUG,Confirmed relapse-free patients|Change of T2 lesions on brain MR,Annualized relapse rate|Total number of active (new and/or enlarging) T2 lesions on brain MRI|Disability progression during follow-up|Disability progression during follow-up|Brain atrophy|NEDA (no evidence of disease activity)|Change of neurofilament light|Change of quality of life|Change of burden of treatment|Ocrelizumab wearing-off effect|IgG levels|Cost analysis|Disability progression: decrease of hand mobility|Disability progression: two minute walking distance|Disability progression: cognitive impairment,False,
NCT03906370,Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS,The Association Between Capillary Dysfunction and CD46 Phenotype in Early Diagnosed MS Patients,COMPLETED,2018-12-01,2021-05-01,2021-05-01,2023-05-11,2019-04-08,OBSERVATIONAL,,83.0,ACTUAL,University of Aarhus,OTHER,,,Multiple Sclerosis,,Denmark,Aarhus,,1,Diagnostic criteria for MS,DIAGNOSTIC_TEST,Capillary dysfunction|CD46 dysfunction,,False,
NCT06156683,Kesimpta Pregnancy and Infant Safety Study Using Real World Data,Kesimpta (Ofatumumab) Pregnancy and Infant Safety Study Using Real World Data,RECRUITING,2024-06-30,2028-02-01,2028-02-01,2024-08-01,2023-12-05,OBSERVATIONAL,,1500.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Kesimpta|ofatumumab|real world data,Switzerland,Basel,,1,Multiple sclerosis disease modifying drug,OTHER,Number of major congenital malformations (MCM) among live births,Number of participants with spontaneous abortions|Number of participants with elective termination of pregnancy|Number of participants with stillbirths|Number of participants with preterm births|Number of participants with preeclampsia|Number of participants with eclampsia|Number of participants small for gestational age (SGA),False,
NCT04906057,The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis,The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis,COMPLETED,2021-07-06,2022-11-29,2022-11-29,2025-03-06,2021-05-28,INTERVENTIONAL,NA,22.0,ACTUAL,The Cleveland Clinic,OTHER,,,Multiple Sclerosis,aerobic exercise|gait,United States,Cleveland,Ohio,2,Forced Aerobic Exercise (FE)|Voluntary Aerobic Exercise (VE),BEHAVIORAL|BEHAVIORAL,Exercise Duration|Aerobic Intensity|Exercise Cadence|Six Minute Walk Test|Gait Velocity|PROMIS-29|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Manual Dexterity Test|Processing Speed Test,To Investigate the Role of Klotho in Promoting Neuroprotection.,True,2025-02-11
NCT00336557,Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy,"A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in High-Dose Interferon Treated Patients",COMPLETED,2006-07,2009-04,2009-07,2013-10-30,2006-06-13,OBSERVATIONAL,,1230.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,High-Dose Interferon|Neutralizing Antibodies,United States,Phoenix,Arizona,49,NAbs testing,PROCEDURE,Proportion of subjects whose high dose IFN therapy had changed in the regularly scheduled NAbs testing arm versus the Usual Care Arm,The nature of any therapy/management change in each arm|Reason for change in therapy/management,False,
NCT06341673,"Impact of TTNS on Bladder Symptoms Among People With MS, A RCT","Impact of Transcutaneous Tibial Nerve Stimulation on Bladder Storage Symptoms and Quality of Life in People With Multiple Sclerosis- A Randomised Controlled Trial""",RECRUITING,2024-03-15,2024-04-28,2024-06-30,2024-04-02,2024-04-02,INTERVENTIONAL,NA,72.0,ESTIMATED,Hawra Al-Dandan,OTHER,,,Overactive Bladder Syndrome,Multiple Sclerosis|Overactive bladder|Bladder storage symptoms|Incontinence|Tibial nerve stimulation|Stimulation,Saudi Arabia,Khobar,Eastern Providence,1,Active Transcutaneous Electrical Nerve Stimulation (TENS)|Sham Transcutaneous Electrical Nerve Stimulation (TENS),DEVICE|DEVICE,The International Consultation of Incontinence Questionnaire- Overactive Bladder (ICIQ- OAB)|3- day Bladder diary|Urinary sensation scale.,"The International Consultation of incontinence Questionnaire, Lower Urinary Tract Symptoms, Quality of life (ICIQ - LUTS,Qol)|Pittsburgh Sleep Quality Index (PSQI)-item 6|Global Perceived Effect (GPE) Scale",False,
NCT02207075,Measuring Active Microglia in Progressive Multiple Sclerosis,Measuring Active Microglia in Progressive Multiple Sclerosis,COMPLETED,2014-07,2020-12,2020-12,2022-01-18,2014-08-01,OBSERVATIONAL,,50.0,ACTUAL,Weill Medical College of Cornell University,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Secondary Progressive Multiple Sclerosis,SPMS|Myelin Water Fraction|activated microglia,United States,New York,New York,1,[C11]PK-1195 PET scan,DRUG,"Measure the level of baseline and change of whole brain uptake of [11C]PK-11195 at 6, 12 and 24 months in SPMS subjects.","To correlate the change in T2-hyperintense lesion volume at 6,12 and 24 months of with whole brain uptake of [11C]PK-11195 on PET (at the 6,12 and 24 months) in SPMS subjects.|To correlate the change of conventional MRI measures of neuronal integrity (Gray Matter Fraction, White Matter Fraction, whole brain volume, T1-hypointense lesion volume) at 6,12 and 24 months with whole brain PET uptake of [11C]PK-11195 (at the 6,12 and|To correlate the change in whole brain PET uptake of [11C]PK-11195 (at the 6,12 and 24 months) and level in disability, as measured by a change in EDSS at 6, 12, and 24 months in SPMS subjects.",False,
NCT04182269,Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients,Reliability and Validity of the Glittre Activities of Daily Living Test in Multiple Sclerosis Patients,COMPLETED,2018-10-01,2019-10-15,2020-08-04,2021-02-12,2019-12-02,OBSERVATIONAL,,51.0,ACTUAL,Hacettepe University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Glittre ADL test|Functional capacity assesment,Turkey (Türkiye),Ankara,,1,Measurement of functional exercise capacity,OTHER,Glittre Activities of Dailiy Living Test,6 minute walk test (6MWT)|Nottingham Extended Daily Living Activities Index (NGGYAI)|Extended Disability Status Scale (EDSS)|Fatigue Severity Scale|Multiple Sclerosis Quality of Life İnstrument - 54 (MSQOL-54)|Mini-BEST Test (Balance Assessment Systems Test)|The 5-repetition sit-to-stand test,False,
NCT03458169,LEAP a New Overground Body Weight Support Robot: Usability Trial,Usability of a New Overground Body Weight Support Rehabilitation Robot LEAP: A Monocentric Consideration-of-concept Trial,COMPLETED,2018-01-01,2018-04-30,2018-04-30,2019-01-30,2018-03-08,INTERVENTIONAL,NA,43.0,ACTUAL,Clinique Romande de Readaptation,NETWORK,,,Spinal Cord Injuries|Cerebral Palsy|Parkinson Disease|Multiple Sclerosis|Stroke|People With Impaired Lower Extremity Function,,Switzerland,Sion,Valais,1,Therapist LEAP session feedback|Participant LEAP session feedback|LEAP risk control validation,DEVICE|DEVICE|DEVICE,Usability of the robot - Fixation|Usability of the robot - Applicability|Usability of the robot - Robot support|Usability of the robot - User interface|Usability of the robot - Interaction|Risk control validation - Observer|Risk control validation - User|Participant feeling of safety/comfort - Fixation|Participant feeling of safety/comfort - Robot training|Participant feeling of safety/comfort - Robot support,Robot Measurement - Patient position|Robot Measurement - Walking speed|Robot Measurement - Occurred errors|Robot Measurement - Support forces|Robot Measurement - Fall detection|Robot Measurement - Walked distance|EMG system|Patient characteristics - Testing date|Patient characteristics - Identification number|Patient characteristics - Body height|Patient characteristics - Body weight|Patient characteristics - Waist size|Patient characteristics - Tight circumference|Patient characteristics - Chest size|Patient characteristics - Age|Patient characteristics - Stationary or ambulant|Patient characteristics - Dominant side|Patient characteristics - Walking aid|Patient characteristics - Six minute walking test|Patient characteristics - BAECKE score|Patient characteristics - Fugl-Meyer score,False,
NCT04371575,Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients,"Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - Clinical Characteristics, Neuroanatomical Abnormalities and Treatment Efficacy",COMPLETED,2012-09-01,2019-12-31,2019-12-31,2020-05-01,2020-05-01,OBSERVATIONAL,,60.0,ACTUAL,"Stine Maarbjerg, MD PhD",OTHER,,,"Trigeminal Neuralgia|Multiple Sclerosis|Pain, Neuropathic",,,,,0,Carbamazepine,DRUG,Demyelinating brainstem plaques and neurovascular contact,,False,
NCT03736902,Views on Physical Activity Following a Relapse in People With Multiple Sclerosis,"Attitudes, Barriers and Facilitators to Physical Activity in People With Multiple Sclerosis Following a Relapse",COMPLETED,2018-11-13,2019-05-14,2019-09-30,2019-12-18,2018-11-09,OBSERVATIONAL,,15.0,ACTUAL,"City, University of London",OTHER,University College London Hospitals,OTHER,Multiple Sclerosis,Physical activity|Exercise|Relapse|Exacerbation|Attack,United Kingdom,London,Greater London,1,Qualitative semi structured interview,OTHER,Analysis of interview transcripts,,False,
NCT05937802,Osmotin Plant Protein for Progressive Multiple Sclerosis,"Exploratory Trial of Forza™️, a Novel Nutraceutical From Actinidia Deliciosa Plants Bioengineered to Bio-encapsulate the Osmotin Plant Protein as Adjuvant for the Treatment of Progressive Multiple Sclerosis",UNKNOWN,2023-01-02,2024-01-02,2025-01-02,2023-07-10,2023-07-10,INTERVENTIONAL,NA,50.0,ESTIMATED,Ospedale Policlinico San Martino,OTHER,Italian Multiple Sclerosis Foundation|S. Andrea Hospital,OTHER|OTHER,Progressive Multiple Sclerosis,Osmotin,Italy,Genova,,2,Osmotin,DIETARY_SUPPLEMENT,Incidence and severity of treatment-related adverse events after 1 month of therapy.|Incidence and severity of treatment-related adverse events after 6 months of therapy.,"Change in Expanded Disability Status Scale (EDSS).|Change in Timed 25 Foot Walk (T25FW).|Change in 12-item Multiple Sclerosis Walking Scale (MSWS12).|Change in Nine-Hole Peg Test (9HPT).|Change in Montreal Cognitive Assessment (MOCA).|Change in Symbol Digit Modalities Test (SDMT).|Change in patient self-evaluation of depression and anxiety recorded with Hospital Anxiety Depression Scale (HADS).|Change in bladder domain function recorded with Overactive Bladder (OAB) questionnaire.|The impact of Forza™️ on neurophysiology in PMS.|The impact of Forza™️ on retinal atrophy in PMS.|Change in serum neurofilament Light Chain (NfL) levels to verify the neuroprotective action of Forza™️ in PMS.|Change in brain metabolism as concentration of glutamate, N-acetylaspartate, creatine and choline.|Change in brain microstructure.",False,
NCT01111435,A Prospective Study of Spasticity in Individuals With Multiple Sclerosis,A Prospective Study of Spasticity in Individuals With Multiple Sclerosis in Transition From Interferon to Glatiramer Acetate (Copaxone®),UNKNOWN,2010-04,2012-09,2012-12,2012-03-05,2010-04-27,OBSERVATIONAL,,110.0,ESTIMATED,"Fraser, Cira, Ph.D., RN, ACNS-BC",INDIV,,,Spasticity,,United States,Kansas City,Missouri,1,,,Multiple Sclerosis Spasticity Scale,Performance Scales (Measure of Disability),False,
NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis","An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2012-02,2014-06,2014-06,2016-03-14,2011-09-13,INTERVENTIONAL,PHASE2,39.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,"Multiple Sclerosis,|demyelinating autoimmune diseases,|interleukin-17,|monoclonal human antibody",Czechia,Hradec Králové,Czech Republic,14,AIN457|AIN457,DRUG|DRUG,"Measure: Number of Subjects With Adverse Events, Number of Abnormalities in Safety Assessments",Distribution of Patients With Relapses to End of Study (EOS) (All Subjects)|Number Lesions Measured in the Brain by Magnetic Resonance Imaging. T1 Weighted MRI|Number Lesions Measured in the Brain by Magnetic Resonance Imaging. T2 Weighted MRI|Change in Brain Volume at End of Study.|Measure of Disability: Expanded Disability Status Scale (EDSS).,True,2016-03-14
NCT01601119,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients,COMPLETED,2012-01,2014-07,2014-07,2015-05-29,2012-05-17,OBSERVATIONAL,,545.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono Limited, UK",INDUSTRY,Relapsing Multiple Sclerosis,Multiple Sclerosis|Patient reported outcome|Patient reported experience,United Kingdom,Merck KGaA Communication Center For Locations,,1,Rebif|Other: Disease modifying therapies (DMT),DRUG|OTHER,Treatment Satisfaction,Work Productivity|Health Related Quality of Life|Health Related Quality of Life EuroQoL (EQ-5D)-5L Questionnaire|Device satisfaction|Evaluation of support services,False,
NCT02727907,Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis,"International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2015-02-12,2016-11-21,2017-08-11,2023-02-17,2016-04-05,INTERVENTIONAL,PHASE2|PHASE3,163.0,ACTUAL,Biocad,INDUSTRY,,,Multiple Sclerosis,,Russia,Moscow,,1,BCD-033 (interferon beta 1a)|Rebif (interferon beta 1a)|Placebo,DRUG|DRUG|DRUG,Number of Combined Unique Active Lesions,Annual Relapse Rate|Proportion of Subjects Without Confirmed Relapse|Relapse Free Time|Number of Combined Unique Active Lesions|Annual Relapse Rate|Relapse Free Time|Number of Combined Unique Active Lesions,True,2023-02-17
NCT03077971,Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis,Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis: A Feasibility Randomised Controlled Trial,UNKNOWN,2016-12-01,2018-01,2018-06,2017-11-27,2017-03-13,INTERVENTIONAL,NA,24.0,ACTUAL,University of Nottingham,OTHER,,,Carer Stress Syndrome,Carers of People with Multiple Sclerosis|Carer Strain|Acceptance and Commitment Therapy,United Kingdom,Nottingham,Nottinghamshire,1,ACT Self-Help|ACT Self-Help with Telephone Support,BEHAVIORAL|BEHAVIORAL,ZBI,ZBI|MCSI|CAREQOL-MS|AAQ-II|CompACT|Service Use Questionnaire,False,
NCT06435962,Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple,Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple,NOT_YET_RECRUITING,2024-08-01,2026-01-01,2026-03-01,2024-06-04,2024-05-30,OBSERVATIONAL,,100.0,ESTIMATED,Assiut University,OTHER,,,Relapsing Remitting Multiple Sclerosis,,,,,0,sonography,DEVICE,optic nerve measurement and correlation with axonal affection in RRMS,2.Correlation of ultrasonography and visual evoked potential (change in p100 latency) with physical disability and cognitive score and fatigue by Multiple Sclerosis Functional Composite,False,
NCT04953689,Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis,Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis,COMPLETED,2021-10-19,2024-06-01,2024-10-28,2024-10-30,2021-07-08,INTERVENTIONAL,NA,60.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,neuropsychology|multiple sclerosis|conscientiousness|mobile application|smartphone application|employment|quality of life,United States,Buffalo,New York,1,Conscientiousness Coach,BEHAVIORAL,Self -Reflection and Insight Scale (SRIS): change from baseline to 12 weeks and from baseline to 24 weeks|Buffalo Vocational Monitoring Survey (BVMS): change from baseline to 12 weeks and from baseline to 24 weeks|The Valued Living Questionnaire (VLQ): change from baseline to 12 weeks and from baseline to 24 weeks,NEO Five Factor Inventory (NEOFFI): change from baseline to 12 weeks and from baseline to 24 weeks|Quality of Life in Neurological Disorders (NeuroQol): change from baseline to 12 weeks and from baseline to 24 weeks|Beck Depression Inventory 2nd Edition (BDI-II): change from baseline to 12 weeks and from baseline to 24 weeks|Beck Anxiety Inventory (BAI): change from baseline to 12 weeks and from baseline to 24 weeks|Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23): change from baseline to 12 weeks and from baseline to 24 weeks|The Symbol Digit Modalities Test (SDMT)|The California Verbal Learning Test Second Edition (CVLT2)|The Brief Visuospatial Memory Test Revised (BVMTR),False,
NCT04633759,Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis,Feasibility of Low-load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis and Marked Mobility Restriction,COMPLETED,2021-02-19,2022-10-05,2022-10-05,2022-10-20,2020-11-18,INTERVENTIONAL,NA,15.0,ACTUAL,"University of Colorado, Denver",OTHER,Consortium of Multiple Sclerosis Centers,OTHER,Multiple Sclerosis,Multiple Sclerosis|Blood Flow Restriction|Resistance Training,United States,Aurora,Colorado,1,Blood Flow Restriction Exercise,OTHER,Change in knee extension muscle strength|Change in hip abduction muscle strength|Change in ankle plantarflexion muscle strength,Change in 30-second sit-to-stand completions|Change in Berg Balance Scale|Change in timed 25-foot walk|Change in activity level|Change in 12-Item MS Walking Scale|Change in Modified Fatigue Impact Scale|Change in MS Impact Scale-29|Change in MS Patient-Specific Function Scale,False,
NCT06732674,Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases,"A 54-week, Multi-centre, 2-arm, Randomised Controlled Trial to Assess Home Monitoring for Lung Function and Patient Reported Outcome Measurements Vs. Usual Care in RheuMatic Disease-associated Interstitial Lung Disease: the RMD-mILDer Trial",RECRUITING,2024-12-16,2026-10-01,2028-02-28,2024-12-19,2024-12-13,INTERVENTIONAL,NA,218.0,ESTIMATED,Oslo University Hospital,OTHER,Carol Davila University of Medicine and Pharmacy|University of Zurich,OTHER|OTHER,Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere|Systemic Sclerosis Pulmonary|Dermatomyositis|Rheumatoid Arthritis|Sjogren Syndrome with Lung Involvement|Connective Tissue Diseases,home monitoring|remote monitoring|interstitial lung disease|rheumatic disease|lung fibrosis|Systemic sclerosis|Dermatomyositis|Sjøgren,Norway,Oslo,,1,A home monitoring strategy with event driven management,DIAGNOSTIC_TEST,Assess whether home monitoring identifies disease progression earlier than monitoring by fixed-interval hospital visits.,Estimate effects of home monitoring compared to fixed-interval hospital visits on change in FVC|Estimate effects of home monitoring compared to fixed-interval hospital visits on FVC decline >10% events.|Estimate effects of home monitoring compared to fixed-interval hospital visits on patient reported respiratory symptoms|Estimate effects of home monitoring compared to fixed hospital visits on progressive pulmonary fibrosis events.,False,
NCT02870023,How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?,How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?,COMPLETED,2016-06,2018-12,2018-12,2019-02-19,2016-08-17,INTERVENTIONAL,NA,71.0,ACTUAL,University of Aarhus,OTHER,"VIA University College|TrygFonden, Denmark|Fondazione Don Carlo Gnocchi Onlus",OTHER|INDUSTRY|OTHER,Multiple Sclerosis,,Denmark,Aarhus,,1,Balance training|Strength training,OTHER|OTHER,"Change in gait speed measured by ""Six Spot Step Test""|Change in gait speed measured by ""Timed 25 Foot Walk""",Fatigue|Endurance|Self-evaluated gait function|Temporospatial measures|Balance - static|Balance - functional|Balance - confidence|Strength,False,
NCT05121662,COVID-19 Vaccine Biomarker Study in Multiple Sclerosis,Immunogenicity of COVID-19 Vaccines in MS Patients on B-cell Depleting Therapy,COMPLETED,2021-07-29,2025-02-13,2025-02-13,2025-05-12,2021-11-16,OBSERVATIONAL,,154.0,ACTUAL,Columbia University,OTHER,Novartis,INDUSTRY,Multiple Sclerosis|COVID-19,Vaccine,United States,New York,New York,1,,,Level of Receptor Binding Domain (RBD),Level of SARS-CoV-2 Neutralizing Antibodies|T-Cell Profile,False,
NCT02339688,Psychometric Properties Mobility Measures MS,"Psychometric Properties of Mobility, Beyond Walking Speed, in Multiple Sclerosis: a Multi-center Study.",COMPLETED,2014-10,2015-12,2016-06,2016-06-14,2015-01-15,INTERVENTIONAL,NA,254.0,ACTUAL,Hasselt University,OTHER,"Dept Neurological Rehabilitation Reha Zentrum Münster Gröben|National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt|De Mick|Charles University, Czech Republic|Danish MS Hospitals, Haslev and Ry|Masku Neurological Rehabilitation Center|Quellenhof|Fondazione Don Carlo Gnocchi Onlus|Italian Multiple Sclerosis Foundation|Sheba Medical Center|MS-Senteret Hakadal|Haukeland University Hospital|MS Rehabilitation Center Borne Sulinowo|Clinical center Belgrado|Eugenia Epalza Rehabilitation Center, Bilbao, Spain|Cleveland Mellen MS Center|University of Colorado, Denver|Queen's University|Shepherd Center Atlanta|St. Louis University",UNKNOWN|OTHER|OTHER|UNKNOWN|OTHER|OTHER|UNKNOWN|UNKNOWN|OTHER|OTHER|OTHER_GOV|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|OTHER|UNKNOWN|OTHER|OTHER|UNKNOWN|OTHER,Multiple Sclerosis,,Belgium,Diepenbeek,,1,conventional MS rehabilitation,OTHER,"Timed 25-Foot Walk test (T25FW)|Timed up and go (TUG), TUGcognitive|Two minute walk test (2MWT)|Four Square Step Test (FSST)|5 repetition sit-to-stand test (5STS-test)|Modified 5 repetition sit-to-stand test (mod 5STS-test)|Rivermead Mobility Index (RMI)|Multiple Sclerosis Walking Scale-12 (MSWS-12)|Performance Scale mobility (PS-mob)","Timed Up and Go, manual|Berg Balance Scale (BBS)|Dynamic Gait index (DGI)|Activities-specific Balance Confidence Scale (ABC)|Trunk Impairment Scale, modified Norwegian version (TIS-modNV)|International Physical Activity Questionnaire (IPAQ)",False,
NCT00529581,A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment",COMPLETED,2006-11,2008-03,2008-04,2008-05-28,2007-09-14,INTERVENTIONAL,PHASE2,150.0,ESTIMATED,"Cognition Pharmaceuticals, LLC",INDUSTRY,,,Cognition Disorders|Multiple Sclerosis,multiple sclerosis|cognitive impairment|cognitive dysfunction|Cognitive Dysfunction associated with Multiple Sclerosis,United States,Phoenix,Arizona,30,C105,DRUG,"Symbol Digit Modalities Test, Oral Version (SDMT) - Total # Correct|Subject's Global Assessment of Cognitive Change",,False,
NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment","A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",COMPLETED,2007-11,2010-10,2010-10,2014-06-17,2008-06-20,OBSERVATIONAL,,599.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis Quality of life,United States,Phoenix,Arizona,30,,,MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Score,,False,
NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis,COMPLETED,2015-12-10,2021-06-01,2021-11-11,2022-07-26,2015-12-18,INTERVENTIONAL,PHASE3,1057.0,ACTUAL,Biogen,INDUSTRY,"Alkermes, Inc.",INDUSTRY,Multiple Sclerosis,MS|Relapsing Remitting Multiple Sclerosis|RRMS|dimethyl fumarate|DMF,United States,Cullman,Alabama,115,ALKS 8700,DRUG,Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities|Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities|Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline Visit|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities,,True,2022-06-24
NCT06110936,Effects of Transcutaneous Spinal Direct Current Stimulation on Mobility in Cases With Multiple Sclerosis,Effects of Transcutaneous Spinal Direct Current Stimulation on Mobility in Cases With Multiple Sclerosis,COMPLETED,2023-11-27,2024-03-30,2024-03-30,2024-04-18,2023-11-01,INTERVENTIONAL,NA,22.0,ACTUAL,Istanbul Medeniyet University,OTHER,,,Multiple Sclerosis|Transcranial Direct Current Stimulation,,Turkey (Türkiye),Istanbul,Kadıköy,1,Transcutaneous Spinal Direct Current Stimulation,DEVICE,Timed 25-Foot Walk (T25-FW)|Time Up and Go (TUG)|Multiple Sclerosis Walking Scale-12 (MSWS-12)|Gait Speed Assessment,Fatigue Severity Scale (FSS)|Fatigue Impact Scale (FIS),False,
NCT06436131,The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis,"The Effects of In-phase Bilateral Exercise on Cognitive and Motor Outcome Measures, in Patients with Progressive Multiple Sclerosis, a Randomized Control Trial.",COMPLETED,2023-10-02,2023-12-22,2023-12-22,2024-09-19,2024-05-30,INTERVENTIONAL,NA,20.0,ACTUAL,Cyprus University of Technology,OTHER,Cyprus Institute of Neurology and Genetics,OTHER,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",In-phase Bilateral|exercise|cognitive processing|multiple sclerosis|manual dexterity,Cyprus,Limassol,,1,In-phase Bilateral Exercise|Conservative exercises,BEHAVIORAL|BEHAVIORAL,Symbol Digit Modalities Test,Medical Outcomes Study Short Form 36|Modified Fatigue Impact Scale|Trail Making Test|Purdue Pegboard Test|Timed 25-Foot Walk|Six Spot Step Test,False,
NCT00947895,Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone,Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study,TERMINATED,2009-10,2011-01,2011-01,2016-03-22,2009-07-28,INTERVENTIONAL,PHASE2|PHASE3,30.0,ACTUAL,"Neurologique Foundation, Inc.",OTHER,Mallinckrodt,INDUSTRY,Multiple Sclerosis,ACTH|Acthar gel|adrenocorticotropin|methylprednisolone|solumedrol|MS|multiple|sclerosis|relapse|exacerbation|sub-responsive|IV,United States,Ponte Vedra,Florida,1,Methylprednisolone|ACTH|IV placebo|IM placebo,DRUG|DRUG|OTHER|OTHER,Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).,Improvement in MSFC (Multiple Sclerosis Functional Composite)18 and its three individual components.|Safety and tolerability of ACTH and MP in patients with an acute relapse of multiple sclerosis after sub-response to an initial course of intravenous methylprednisolone.,False,
NCT01718392,"Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity",,COMPLETED,2011-03,2013-03,2013-09,2016-11-25,2012-10-31,INTERVENTIONAL,NA,45.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,combined training|insulin resistance,Belgium,Diepenbeek,,1,Training,BEHAVIORAL,insulin sensitivity (insulin profile),aerobic capacity|aerobic capacity - lactate concentrations|cytokine profile|walking performance|Self-reported measures|body composition|muscle strength of knee flexor|muscle strength of knee extensor|muscle strength of elbow flexor|muscle strength of elbow extensor,False,
NCT04468919,Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit,Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit,COMPLETED,2022-07-15,2025-05-05,2025-05-05,2025-05-16,2020-07-13,INTERVENTIONAL,NA,55.0,ACTUAL,Oregon Health and Science University,OTHER,,,Amyotrophic Lateral Sclerosis|Brainstem Stroke|Muscular Dystrophies|Parkinson's Disease and Parkinsonism|Multiple System Atrophy|Brain Tumor Adult|Spinal Cord Injuries|Locked-in Syndrome,brain-computer interface,United States,Portland,Oregon,1,BCI-FIT multi-modal access|BCI-FIT adaptive signal modeling|BCI-FIT active querying|BCI-FIT language modeling,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Typing Accuracy|Typing Speed|Information transfer rate|User experience,,False,
NCT03373344,Remediation of Emotional Processing Deficits in MS,Remediation of Emotional Processing Deficits in MS: A Randomized Clinical Trial,COMPLETED,2016-11,2020-03,2020-03,2020-07-10,2017-12-14,INTERVENTIONAL,NA,39.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis,emotional processing|multiple sclerosis|cognition,United States,East Hanover,New Jersey,1,Emotional Processing Training|Placebo control exercises,BEHAVIORAL|BEHAVIORAL,Emotional Processing,Emotional Function|Self report of Quality of Life,False,
NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,"An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period",COMPLETED,2008-02,2012-12,2016-02,2017-03-13,2008-02-25,INTERVENTIONAL,PHASE3,618.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,MS|Clinically Isolated Syndrome|CIS|CDMS|relapses,United States,Cullman,Alabama,131,Teriflunomide|Placebo,DRUG|DRUG,Core Treatment Period: Time to Conversion to Clinically Deﬁnite Multiple Sclerosis (CDMS),Core Treatment Period: Time to Conversion to Definite Multiple Sclerosis (DMS)|Core Treatment Period: Annualized Relapse Rate (ARR)|Core Treatment Period: Brain Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Lesion Volume at Week 108|Core Treatment Period: Brain MRI Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan (Poisson Regression Estimates)|Core Treatment Period: Brain MRI Assessment: Volume of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan|Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of Hypointense Post-Gadolinium T1 Lesion Component|Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of T2 Lesion Component|Core Treatment Period: Brain MRI Assessment: Percent Change From Baseline in Atrophy|Core Treatment Period: Time to 12-Week Sustained Disability Progression|Core Treatment Period: Change From Baseline in EDSS at Week 108|Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 108|Core Treatment Period: Overview of Adverse Events (AEs)|Extension Treatment Period: Time to Conversion to Clinically Deﬁnite Multiple Sclerosis (CDMS)|Extension Treatment Period: Overview of Adverse Events (AEs),True,2014-12-19
NCT04694534,"Remediation Program Via a ""Serious Game"" for the Cognitive Functions of Multiple Sclerosis Patients","e-SEP Cognition: Effectiveness of a Remediation Program Via a ""Serious Game"" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial",RECRUITING,2021-10-08,2026-04-04,2027-03-01,2025-09-04,2021-01-05,INTERVENTIONAL,NA,150.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis|Memory|Learning,Multiple sclerosis|Serious game|Episodic memory learning capacities|Information processing speed capacities,France,Arras,Hauts-de-France,6,Serious game|Usual HAS care,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Change in the California Verbal Learning Test (CVLT)|Change in the Brief Visuo-spatial Memory Test (BVMT)|Change in the Symbol Digit Modalities Test (SDMT),Change in the Auditory-verbal spans in direct or reverse order|Change in the Stroop Color-Word Test|Change in the Trail Making Test|Change in the Categorical and phonemic verbal fluency test|Change in the Tower of London test|Change in the Commission test|Change in the Concentrated Attention Test|Change in the Paced Auditory Serial Addition Task (PASAT)|Change in the Mac Nair Scale|Change in the IPA (Participation and Autonomy Impact) Form|Change in the BDI-II Scale (Beck Depression Inventory II)|Change in the State-Trait Anxiety Inventory (STAI Y)|Change in the Visual Analogue Scale for Fatigue|Change in the Apparent validity|Change in the EDSS score (Expanded disability status scale)|Frequency of game play per Week (in days)|Game session lenght|Time spent gaming|Game performance : tests number per exercise|Game performance : difficulty levels,False,
NCT06854341,A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data,A Canadian Retrospective Analysis of Persistence on Ofatumumab Using Patient Support Program Data,COMPLETED,2024-02-09,2024-08-27,2024-08-27,2025-03-25,2025-03-03,OBSERVATIONAL,,5448.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Patient Support Program|Ofatumumab|Persistence,United States,East Hanover,New Jersey,1,,,Percentage of Patients who Discontinued Ofatumumab per Patient Characteristic,Number of Patients per Demographic Category|Number of Patients per Clinical History Characteristic|Cox Proportional Hazard Ratio for the Association Between Discontinuation of Ofatumumab and Patient Characteristics|Number of Patients by Reason for Discontinuation of Ofatumumab Treatment|Number of Patients by Reason for Leaving the Kesimpta Go Program,False,
NCT01005095,The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients,"A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis",TERMINATED,2010-10,2012-04,2012-04,2012-09-05,2009-10-30,INTERVENTIONAL,PHASE4,45.0,ACTUAL,Carmel Medical Center,OTHER,,,MULTIPLE SCLEROSIS,,Israel,Haifa,Israel,1,Vitamin D3|Vitamin D3,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Occurrence and severity of Interferon beta related Flu Like Symptoms and Injection Site Reactions.,Expanded Disability Status Scale (EDSS) progression|Relapse rate|Quality of life|Change in serum levels of cytokines and proteins involved in MS pathogenesis|Immune cells subsets|Night time Urine levels of 6-sulphatoxy-melatonin|Percent rise of IL6 and TRAIL levels following IFN-beta injection,False,
NCT02849457,Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex,"Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC",COMPLETED,2016-12,2023-04-26,2023-05-05,2024-08-19,2016-07-29,INTERVENTIONAL,PHASE2,84.0,ACTUAL,Martina Bebin,OTHER,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Tuberous Sclerosis Complex,,United States,Birmingham,Alabama,13,Early Vigabatrin|Delayed Vigabatrin (Placebo),DRUG|DRUG,Cognitive Assessment Scores and Developmental Impact,Number of Subjects That Develop Seizures When Treated With Study Drug During the Randomized Phase of the Study.|Time to the Subject's First Clinical Seizure From Randomization|Count of Participants With Drug Resistant Epilepsy at 24 Months of Age.|Evaluate Vineland II ABC Scores and Impact of Early Versus Late Treatment|Evaluate Autism Diagnostic Observation Schedule 2nd Edition (ADOS2) Scores and Impact of Early Versus Late Treatment|Number of Subjects With Vigabatrin Related Adverse Events and Severe Adverse Events|EEG Biomarker for Developing Epilepsy,True,2024-08-19
NCT00682929,Cannabis for Spasticity in Multiple Sclerosis,Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study,TERMINATED,2004-04-14,2011-08-17,2011-08-17,2018-05-18,2008-05-23,INTERVENTIONAL,PHASE1|PHASE2,41.0,ACTUAL,"University of California, Davis",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,cannabis|marijuana|Multiple Sclerosis|spasticity,United States,Sacramento,California,1,Inhaled Cannabis|Oral THC|Oral Placebo|Inhaled placebo,DRUG|DRUG|DRUG|DRUG,"Change From Week 0 to Week 3 in the Rate of Torque Increase, Flexion|Change From Week 0 to Week 3 in the Rate of Torque Increase, Extension|Change From Week 0 to Week 7 in the Rate of Torque Increase, Flexion|LIDO Machine Score - Rate of Torque Increase, Extension",Change From Week 0 to Week 3 in Modified Ashworth Score (MAS)|Change From Week 0 to Week 7 in Modified Ashworth Score|Change From Week 0 to Week 3 in Ambulation Index (AI) Score|Change From Week 0 to Week 7 in Ambulation Index (AI) Score|Change From Week 0 to Week 3 in 25 Foot Walk Time|Change From Week 0 to Week 7 in 25 Foot Walk Time|Change From Week 0 to Week 3 in 9 Hole Peg Test (Dominant Hand) Time|Change From Week 0 to Week 7 in 9 Hole Peg Test (Dominant Hand) Time|Change From Week 0 to Week 3 in 9 Hole Peg Test (Non- Dominant Hand) Time|Change From Week 0 to Week 7 in 9 Hole Peg Test (Non- Dominant Hand) Time|Change From Week 0 to Week 3 in Paced Auditory Serial Addition Test (PASAT) Score|Change From Week 0 to Week 7 in Paced Auditory Serial Addition Test (PASAT) Score|Change From Week 0 to Week 3 in Functional System Score - Vision|Change From Week 0 to Week 7 in Functional System Score - Vision|Change From Week 0 to Week 3 in Functional System Score - Brainstem|Change From Week 0 to Week 7 in Functional System Score - Brainstem|Change From Week 0 to Week 3 in Functional System Score - Pyramidal|Change From Week 0 to Week 7 in Functional System Score - Pyramidal|Change From Week 0 to Week 3 in Functional System Score - Cerebellar|Change From Week 0 to Week 7 in Functional System Score - Cerebellar|Change From Week 0 to Week 3 in Functional System Score - Sensory|Change From Week 0 to Week 7 in Functional System Score - Sensory|Change From Week 0 to Week 3 in Functional System Score - Bowel and Bladder|Change From Week 0 to Week 7 in Functional System Score - Bowel and Bladder|Change From Week 0 to Week 3 in Functional System Score - Cerebral|Change From Week 0 to Week 7 in Functional System Score - Cerebral|Change From Week 0 to Week 3 in Expanded Disability Status Score (EDSS)|Change From Week 0 to Week 7 in Expanded Disability Status Score (EDSS)|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component|Change From Week 0 to Week3 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score|Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score|Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score,True,2018-05-18
NCT00011375,Rolipram to Treat Multiple Sclerosis,"Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure",COMPLETED,2001-02,,2004-04,2008-03-04,2001-02-19,INTERVENTIONAL,PHASE2,52.0,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Phosphodiesterase Inhibitor|Immunology|Immunomodulation|Antidepressant|Therapy|Multiple Sclerosis|Immunotherapy,United States,Bethesda,Maryland,1,Rolipram,DRUG,,,False,
NCT06595394,Effect of Combined Exercise Training in Patients With Multiple Sclerosis,Investigation of the Effect of Exercise Training in Patient With Sarcopenic Multiple Sclerosis,NOT_YET_RECRUITING,2024-10,2025-01,2025-02,2024-09-19,2024-09-19,INTERVENTIONAL,NA,30.0,ESTIMATED,Uskudar University,OTHER,,,Multiple Sclerosis,Sarcopenia|Exercise,,,,0,Exercise|Home program,OTHER|OTHER,Muscle thickness,SARC -F|Hand grip strength measurement|Bioelectrical impedance analysis|Timed Up and Go (TUG)|Berg Balance Scale (BBS)|Fatigue Severity Scale (FSS)|6 Minute Walk Test,False,
NCT04112537,Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship,Dermatologic Clinical Patterns Study of Tuberous Sclerosis Complex Patients Related With Their Somatic Mutation,UNKNOWN,2019-03-01,2019-12-30,2020-12-30,2020-03-10,2019-10-02,OBSERVATIONAL,,90.0,ACTUAL,"University Hospital, Montpellier",OTHER,,,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex|MTOR associated protein|Neurocutaneous Syndromes|High-Throughput Nucleotide Sequencing,France,Montpellier,,1,,,Phenotype,Genotype,False,
NCT06715605,A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS,A Controlled Phase II Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for Multiple Sclerosis,WITHDRAWN,2025-04-30,2025-04-30,2027-10-29,2025-08-17,2024-12-04,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"University Hospital, Antwerp",OTHER,Hospital Germans Tríes i Pujol de Badalona,UNKNOWN,Multiple Sclerosis,patient safety|tolerogenic dendritic cells|tolDC|phase II|MS|Multiple sclerosis,Belgium,Edegem,,1,tolerogenic dendritic cells (tolDC)|Standard-of-care,BIOLOGICAL|BIOLOGICAL,Efficacy (Number of new and/or enlarging T2 lesions on MRI)|Safety (Occurrence and severity of adverse events will be recorded),Expanded disability status scale (EDSS)|9 Hole Peg Test (9HPT)|25 Foot walk test (T25FW)|Symbol Digit Modalities test (SDMT)|Non-clinical outcome measure (T2 lesion volume on MRI)|Non-clinical outcome measure (atrophy rate on MRI)|Non-clinical outcome measure (total brain volume on MRI)|Non-clinical outcome measure (fractional anisotropy on MRI),False,
NCT05061953,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,RECRUITING,2021-10-18,2027-10-18,2027-10-18,2023-03-03,2021-09-30,OBSERVATIONAL,,168.0,ESTIMATED,Innodem Neurosciences,INDUSTRY,Novartis Pharmaceuticals,INDUSTRY,Multiple Sclerosis,,Canada,Montreal,Quebec,2,Eye-Tracking,DEVICE,Change from Baseline in Symbol Digit Modalities Test (SDMT) score at Month 48,Change from Baseline in the Expanded Disability Status Scale (EDSS) score at Month 48|Change from Baseline in the Brief International Cognitive Assessment for MS (BICAMS) scores at Month 48|Change from Baseline in the Multiple sclerosis functional composite (MSFC) scores at Month 48,False,
NCT06403631,Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis,Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis: the Role of Flow Experience and Mindfulness,RECRUITING,2023-11-06,2025-11-25,2026-02-28,2024-07-25,2024-05-08,OBSERVATIONAL,,123.0,ESTIMATED,Marta Bassi,OTHER,Italian Multiple Sclerosis Foundation|Università Vita-Salute San Raffaele|Azienda Ospedaliera Sant'Anna|San Luigi Gonzaga Hospital|University of Florence|University of Bari|University of Cagliari|Azienda Ospedaliera San Camillo Forlanini|University of Catania,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,,Italy,Bari,,8,observational,OTHER,Positive mental health (Mental Health Continuum Short Form)|Anxiety (subscale of the Hospital Anxiety and Depression Scale)|Depression (subscale of the Hospital Anxiety and Depression Scale),Flow-related activities (Flow Questionnaire)|Flow occurrence (Flow Questionnaire),False,
NCT03723356,Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS),Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis,TERMINATED,2018-07-01,2021-01-09,2021-01-09,2021-03-26,2018-10-29,OBSERVATIONAL,,6.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis|Cognition Disorders,,United States,New York,New York,1,Siemens Biograph mMR (molecular MR)|fMRI|Diffusion Spectrum Imaging (DSI),DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT)|intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT)|intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT)|intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT)|intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT),,False,
NCT06160310,Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry),Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry,RECRUITING,2023-07-01,2028-07-01,2029-07-01,2025-01-15,2023-12-07,OBSERVATIONAL,,300.0,ESTIMATED,David M. Ritter,OTHER,,,Tuberous Sclerosis Complex|Lymphangioleiomyomatosis,Tuberous Sclerosis Complex|TSC|Lymphangioleiomyomatosis|LAM,United States,Cincinnati,Ohio,1,,,Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor adherence|Safety of mTOR inhibitor in Pregnancy -- mTOR inhibitor dosing|Safety of mTOR inhibitor in Pregnancy -- side effects|Maternal-Fetal Complications in TSC|Maternal Post-Partum Behavioral Health|Maternal Post-Partum Mental Health|Optimum Time of Fetal Imaging for TSC,,False,
NCT01485003,Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants,"A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients",COMPLETED,2012-02-07,2018-11-26,2018-11-26,2019-02-12,2011-12-05,OBSERVATIONAL,,231.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Homewood,Alabama,44,natalizumab,BIOLOGICAL,Proportion of Participants who are overall disease activity-free at Months 12 and 24|Proportion of participants who are clinical disease activity-free at Months 36 and 48,Identification of baseline prognostic factors that predict overall disease-free status|Identification of yearly overall disease-free response factors that predict overall disease-free status|Number of Participants with Clinical Disease-Free Status Measured by Relapses|Identification of baseline prognostic factors that predict clinical disease-free status|Identification of yearly clinical disease-free response factors that predict clinical disease-free status|Annualized Relapse Rate|Percentage of participants with Sustained EDSS progression|Sustained EDSS improvement|Change form baseline in number of new or newly enlarging T2 hyperintense lesions as assessed by MRI|Change from baseline in number of new T1 hypointense lesions as assessed by MRI|Change form baseline in number of T1 lesions with Gd-enhancing lesions as assessed by MRI|MRI brain atrophy as assessed by MRI|Change from baseline in retinal nerve fiber layer (RNFL) thickness as assessed by OCT|Change from baseline in low contrast visual acuity|Change from baseline in high contrast visual acuity|Cognitive impairment as assessed by change from baseline in SDMT|Capacity for work as assessed by change from baseline in WPAI questionnaire|Quality of Life as measured by MSIS-29|Number of Participants with Clinical Disease-Free Status Measured by EDSS,False,
NCT05426980,Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study,Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study,COMPLETED,2021-12-13,2023-09-30,2023-09-30,2023-12-05,2022-06-22,OBSERVATIONAL,,654.0,ACTUAL,University of Ljubljana,OTHER,Novartis|General and Teaching Hospital Celje|University Medical Centre Ljubljana|University Medical Centre Maribor|Izola General Hospital,INDUSTRY|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis|Multiple Sclerosis Lesion|Multiple Sclerosis Brain Lesion,Artificial intelligence|Prediction model|Magnetic resonance imaging|Computer-assisted image analysis,Slovenia,Ljubljana,Osrednjeslovenska,4,,,Atrophied lesion volume derived from MRI predicts confirmed EDSS disability progression,Atrophied lesion volume derived from MRI predicts conversion to secondary progressive multiple sclerosis,False,
NCT02851342,GTA-MEG as a Biomarker for Cognition in MS,Graph-theoretical Analysis of Magnetoencephalographic Recordings as a Biomarker for Cognitive Deterioration in Multiple Sclerosis,COMPLETED,2016-04,2018-01,2019-01,2020-11-10,2016-08-01,OBSERVATIONAL,,159.0,ACTUAL,Universitair Ziekenhuis Brussel,OTHER,,,Multiple Sclerosis,Cognition|MEG,Belgium,Melsbroek,Vlaams Brabant,1,,,MEG Contrasts of parameter estimates (COPE),,False,
NCT07168694,A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia,"Retrospective, Multicenter, Non-interventional (Observational) Study With the Aim to Describe the Impact of Siponimod Treatment in a Real-world SPMS Population in Russia",COMPLETED,2024-04-16,2024-09-26,2024-09-26,2025-09-11,2025-09-11,OBSERVATIONAL,,606.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,Siponimod|Treatment of multiple sclerosis|Real-world clinical data,United States,East Hanover,New Jersey,1,,,Demographics: Number of Patients by Age|Demographics: Number of Patients by Gender|Time Between MS Diagnosis and Treatment Initiation|Time Between SPMS Diagnosis and Treatment Initiation|Time Between First Symptoms and Treatment Initiation|Number of Patients by Clinical Characteristic Category|Number of Patients Categorized by Type of Treatment Received Before Initiation of Siponimod|Number of Patients by DMT Received Before Initiation of Siponimod|Duration of the Washout Period After Other DMTs and Before Initiation of Siponimod|Number of Patients by Reason for Switching From Other DMTs to Siponimod|Duration of Siponimod Therapy,"Change From Baseline in Expanded Disability Status Scale (EDSS) Score|Percentage of Patients With Confirmed Disability Progression Over 6 Months (6m-CDP) Based on the EDSS Score|Number of Patients With MS Relapses|Annualized Relapse Rate (ARR)|Change in ARR From 1 Year Before Siponimod Initiation to 6, 12, 18, and 24 Months After Siponimod Treatment|Number of Patients With MRI Signs of MS After Siponimod Treatment|Number of Patients by Reason for Stopping Siponimod Treatment|Number of Patients With Siponimod-related Adverse Events|Number of Patients With Siponimod-related Serious Adverse Events",False,
NCT06360861,Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis,"An Open-label, Non-randomized, Phase I Study of Allogeneic Placenta Derived Mesenchymal Stem Cells in Patients With Secondary-Progressive Multiple Sclerosis (SPMS),",COMPLETED,2019-07-23,2024-03-04,2024-03-06,2024-04-11,2024-04-11,INTERVENTIONAL,PHASE1,5.0,ACTUAL,Tehran University of Medical Sciences,OTHER,,,Multiple Sclerosis|Secondary-Progressive Multiple Sclerosis|Mesenchymal Stem Cells,Mesenchymal Stem cells|Multiple Sclerosis|Placenta derived Mesenchymal Stem Cells|Stem Cell therapy|Neuroimmunology|Autoimmune Disease,Iran,Tehran,,1,Allogenic placenta derived mesenchymal stem cells,BIOLOGICAL,Number of participants with Treatment-Emergent Adverse Events [Safety and Tolerability].,"Number of participants with a change in disability as measured by Expanded Disability Status Scale .|Number of participants with a change in cognitive function as measured by the Paced Auditory Serial Addition Test .|Number of participants with a change in cognitive performance as measured by Persian version of minimal assessment of cognitive function in MS battery.|Number of participants with a change in brain connectivity as measured by Functional magnetic resonance imaging .|Number of participants with a change in white matter integrity as measured by quantitative diffusion tensor imaging .|Number of participants with a change in processing and motor speed as assessed by the Symbol Digit Modalities Test .|Number of participants with evaluation of verbal learning and memory deficits as measured by the California Verbal Learning Test second edition .|Proportion of patients with change in CD20 / CD19 B cells surface markers|Biological Assessments including IL-10, IL-6, IL-17, and TNFα levels of cytokines.|Proportion of patients with change in T2 lesion volume on brain MRI.|Proportion of patients with change in brain volume on MRI.|Proportion of patients for assessment of visuospatial learning as measured by the Brief Visuospatial Memory Test-Revised .|Proportion of patients for assessment of visuospatial ability as measured by Judgment of Line Orientation Test .|Proportion of patients for evaluation of executive functions as measured by the Delis-Kaplan Executive Function System Sorting and descriptive tests.|Proportion of patients for measuring verbal fluency as measured by the Controlled Oral Word Association Test .|Proportion of patients for psychological assessment as measured by the validated Persian version of Symptom Checklist-90-Revised .|Proportion of patients for evaluation of fatigue as measured by was examined by the Persian version of Fatigue Severity Scale .|Proportion of patients for assessment of visuospatial ability as measured by the brief visuospatial memory test-revised test.|Proportion of patients for assessment of visuospatial ability as measured by the California Verbal Learning Test Second Edition test.",False,
NCT02170779,Developing and Testing a Comprehensive MS Spasticity Management Program,Developing and Testing a Comprehensive MS Spasticity Management Program,COMPLETED,2015-10,2016-05,2016-06,2017-03-28,2014-06-23,INTERVENTIONAL,PHASE2,40.0,ACTUAL,VA Office of Research and Development,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis|Spasticity,multiple sclerosis|spasticity|stretching|exercise|rehabilitation,United States,Portland,Oregon,1,Spasticity: Take Control|Usual care,BEHAVIORAL|OTHER,MS Walking Scale-12 (MSWS-12),Timed 25 Foot Walk|Timed up and go Test|2 Minute Walk Test|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Impact Scale (MSIS-29)|Spasticity Measured by the Modified Ashworth Scale|Multiple Sclerosis Spasticity Scale - 88 (MSSS-88)|Beck Depression Inventory II (BDI II),True,2017-03-28
NCT03219073,Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis,Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis: a Mechanistic FDG-PET Study,TERMINATED,2018-02-01,2018-06-16,2018-07-01,2022-11-29,2017-07-17,INTERVENTIONAL,NA,1.0,ACTUAL,Thorsten Rudroff,OTHER,,,Multiple Sclerosis|Neuropathic Pain,multiple sclerosis|neuropathic pain|[18F] FDG-PET CT|tDCS|transcranial direct current stimulation,United States,Aurora,Colorado,1,Active tDCS using tDCS device|SHAM tDCS using tDCS device,DEVICE|DEVICE,Cerebral Glucose Uptake in Patients With Multiple Sclerosis With Neuropathic Pain,Change in Neuropathic Pain as Recorded on a Visual Analog Scale (VAS).|Change in Neuropathic Symptom Inventory,True,2022-11-29
NCT02736279,Impact of Tecfidera on Gut Microbiota,Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation?,UNKNOWN,2015-05,2020-06,2020-12,2016-11-04,2016-04-13,OBSERVATIONAL,,25.0,ESTIMATED,Virginia Simnad,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Kirkland,Washington,1,Dimethyl fumarate,DRUG,Measure change in the diversity and relative abundance of bacterial and archaeal species in the gut microbiota following the start of DMF therapy.,Measure change in anxiety level within the first 6 months following the start of dimethyl fumarate therapy.|Measure change in depression level within the first 6 months following the start of dimethyl fumarate therapy.|Define pre-existing functional bowel disturbance as a predictor of GI symptoms development and severity following the start of dimethyl fumarate treatment.,False,
NCT03315923,Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients,"Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate",COMPLETED,2017-12-01,2019-02-01,2019-03-01,2019-05-23,2017-10-20,INTERVENTIONAL,PHASE2|PHASE3,84.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,,,Secondary Progressive Multiple Sclerosis,Active secondary progressive Multiple Sclerosis|Glatiramer acetate|Rituximab|Comparative study|Disability|Randomized clinical trial|Annualized relapse rate,Iran,Isfahan,,1,Rituximab|Glatiramer Acetate,DRUG|DRUG,Disability measured by Expanded Disability Status Scale,Adverse Drug Reactions|number of Gadolinium-enhanced brain lesions and neuroimaging findings|Annualized relapse rate,False,
NCT04304027,Exercise to Manage Fatigue in Progressive Multiple Sclerosis,Feasibility Evaluation of a Tailored Exercise Intervention to Manage Fatigue in Progressive Multiple Sclerosis,UNKNOWN,2019-12-10,2020-06,2020-06,2020-03-12,2020-03-11,INTERVENTIONAL,NA,45.0,ESTIMATED,Glasgow Caledonian University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Exercise|Fatigue,United Kingdom,Falkirk,,1,Tailored exercise intervention|Standard exercise intervention,OTHER|OTHER,Intervention tolerance|Intervention adherence|Intervention acceptability,Fatigue Severity Scale|Modified Fatigue Impact Scale|Aerobic capacity|Multiple Sclerosis Impact Scale|Hospital Anxiety and Depression Scale|Pittsburgh Sleep Quality Index|Symbol Digits Modalities Test|Six Minute Walk Test|Energy Cost of Walking,False,
NCT06065670,Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy,"A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy",NOT_YET_RECRUITING,2024-09-15,2026-10-30,2026-10-30,2024-09-19,2023-10-04,INTERVENTIONAL,PHASE1|PHASE2,44.0,ESTIMATED,"University of California, San Francisco",OTHER,,,"Demyelinating Diseases|Demyelination; Corpus Callosum|Multiple Sclerosis Brain Lesion|Multiple Sclerosis Acute and Progressive|Clinically Isolated Syndrome, CNS Demyelinating",acute brain lesions|mri|brain|demyelinating lesions|spinal cord,United States,San Francisco,California,1,Clemastine Fumarate|Placebo,DRUG|DRUG,Corpus Callosum Myelin Water Fraction|Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months|Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months|Corpus Callosum T1 Relaxation Time|Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months|Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months|Corpus Callosum UTE Fraction|Change from Baseline in Corpus Callosum UTE Fraction at 3 Months|Change from Baseline in Corpus Callosum UTE Fraction at 6 Months,Optic Radiation Myelin Water Fraction|Change from Baseline in Optic Radiation Myelin Water Fraction at 3 Months|Change from Baseline in Optic Radiation Myelin Water Fraction at 6 Months|Corticospinal Tract Myelin Water Fraction|Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months|Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months|Optic Radiation T1 Relaxation time|Change from Baseline in Optic Radiation T1 Relaxation time at 3 Months|Change from Baseline in Optic Radiation T1 Relaxation time at 6 Months|Corticospinal Tract T1 Relaxation Time|Change from Baseline in Corticospinal Tract T1 Relaxation Time at 3 Months|Change from Baseline in Corticospinal Tract T1 Relaxation Time at 6 Months|Optic radiation UTE Fraction|Change from Baseline in Optic radiation UTE Fraction at 3 Months|Change from Baseline in Optic radiation UTE Fraction at 6 Months|Corticospinal Tract UTE Fraction|Change from Baseline in Corticospinal Tract UTE Fraction at 3 Months|Change from Baseline in Corticospinal Tract UTE Fraction at 6 Months|Lesion of interest (LOI) MWF|Change from Baseline in Lesion of interest (LOI) MWF at 3 Months|Change from Baseline in Lesion of interest (LOI) MWF at 6 Months|LOI T1 Relaxation Time|Change from Baseline in LOI T1 Relaxation Time at 3 Months|Change from Baseline in LOI T1 Relaxation Time at 6 Months|LOI UTE Fraction|Change from Baseline in LOI UTE Fraction at 3 Months|Change from Baseline in LOI UTE Fraction at 6 Months|Whole Brain MWF|Change from Baseline in Whole Brain MWF at 3 Months|Change from Baseline in Whole Brain MWF at 6 Months|Whole Brain T1 Relaxation Time|Change from Baseline in Whole Brain T1 Relaxation Time at 3 Months|Change from Baseline in Whole Brain T1 Relaxation Time at 6 Months|Whole Brain UTE Fraction|Change from Baseline in Whole Brain UTE Fraction at 3 Months|Change from Baseline in Whole Brain UTE Fraction at 6 Months|Clemastine Tolerability|Change from Baseline in Clemastine Tolerability at 3 Months|Change from Baseline in Clemastine Tolerability at 6 Months,False,
NCT01786005,Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity,Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity,UNKNOWN,2013-02,2015-09,2015-12,2014-11-07,2013-02-07,INTERVENTIONAL,PHASE4,60.0,ESTIMATED,Russian Academy of Medical Sciences,OTHER,,,"Spasticity, Multiple Sclerosis, Stroke, Trauma",,Russia,"Moscow, Volokolamskoe Shosse, 80",,1,Transcranial magnetic stimulation,DEVICE,Stroke|Epileptic seizure,The patient is discharged from clinic,False,
NCT03134573,Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study,PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study,COMPLETED,2017-09-15,2018-05-09,2018-05-09,2019-03-26,2017-05-01,OBSERVATIONAL,,96.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,"Relapsing Remitting Multiple Sclerosis (RRMS),|Clinically isolated Syndrome (CIS),|Secondary Progressive Multiple Sclerosis (SPMS)",Germany,Multiple Locations,,1,"Interferon beta-1b (Betaferon, BAY86-5046)|Betaconnect auto-injector|myBETAapp",DRUG|DEVICE|DEVICE,"Compliance to therapy (%)|Persistence of therapy (yes, no)|Adherence to therapy (yes, no)","Proportion of patients consenting to participate in this study among those using the myBETAapp|Proportion of patients volunteering to record wellness related data in each of the following categories on the ""Wellness chart"" on the myBETAapp",False,
NCT03183869,Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients,Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients,TERMINATED,2017-08-24,2018-11-19,2019-01-25,2019-12-02,2017-06-12,INTERVENTIONAL,PHASE2,14.0,ACTUAL,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,,,Autoimmune Diseases|Relapsing Multiple Sclerosis,microbiome|multiple sclerosis|microbiota|gut,Canada,London,Ontario,1,Fecal microbiota,DRUG,Effect of Fecal Microbial Transplantation in Peripheral Blood Cytokines Within Relapsing Multiple Sclerosis Patients,Evaluate Effect of Fecal Microbial Transplantation in Gut Microbiome|Evaluate Effect of Fecal Microbial Transplantation in Gut Permeability|Evaluate Treatment Clinical Safety: Neurological Exam Using the Expanded Disability Status Scale|Evaluate Treatment Safety: MRI to Access Subclinical Disease Activity,True,2019-12-02
NCT02545959,Intrathecal Rituximab in Progressive Multiple Sclerosis,Intrathecal Rituximab in Progressive Multiple Sclerosis,COMPLETED,2015-11-30,2019-02-22,2019-09-02,2019-10-03,2015-09-10,INTERVENTIONAL,PHASE2,10.0,ACTUAL,Centre Hospitalier de PAU,OTHER,"University Hospital, Bordeaux",OTHER,"Multiple Sclerosis, Chronic Progressive|Nervous System Diseases",Intrathecal Rituximab|intrathecal chemotherapy|cerebrospinal fluid|lumbar puncture|Physiological Effects of Drugs|Rituximab,France,Pau,,1,Rituximab IT|methylprednisolone IV|Rituximab IV,DRUG|DRUG|DRUG,Change in osteopontin level in CSF,Change in Tumor Necrosis Factor alpha level in CSF|Change in IgG synthesis in CSF|Change in neurofilament level in CSF,False,
NCT04952246,Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis,Clinical Isolated Spinal Cord Syndrome Was Identified as Multiple Sclerosis Associated Risk Factor Analysis,UNKNOWN,2010-01-01,2020-11-30,2023-11-30,2021-07-07,2021-07-07,OBSERVATIONAL,,150.0,ESTIMATED,Peking University Third Hospital,OTHER,,,Clinical Isolation Syndrome of Spinal Cord|Multiple Sclerosis,,China,Beijin,,1,,,Progressed to multiple sclerosis,,False,
NCT05075642,Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis,A Multicentre Observational Study for the Evaluation in Clinical Practice of the Initial Diagnostic-therapeutic Path of Urinary Disorders in Multiple Sclerosis,UNKNOWN,2021-11,2023-05,2023-07,2021-10-13,2021-10-13,OBSERVATIONAL,,214.0,ESTIMATED,ASP 7 Ragusa,OTHER,,,"Multiple Sclerosis|Urinary Bladder, Neurogenic",Patient global impression of improvement|management|treatment|low urinary tract symptoms|diagnostic tools|prevalence,Italy,Vittoria,Ragusa,1,Initial management of the urinary disorder/s identified during the screening phase,OTHER,Patient global impression of Improvement (PGI-I) questionnaire,Qualiveen-Short Form (SF) questionnaire|Post-void residual volume (PVR) assessment|Micturitions' frequency and episodes of urgency/incontinence at three days frequency/volume chart,False,
NCT05704361,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis","A Multiple-center, Non-randomized, Open-label, Adaptive, Single-ascending Dose (Part 1 and Part 2) Multiple-ascending Dose (Part 3), and Long-term Safety (Part 4), Parallel, Phase IB Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 Following Intravenous (Parts 1 and 4) and Subcutaneous (Parts 2, 3 and 4) Administration in Participants With Multiple Sclerosis",RECRUITING,2021-08-11,2027-04-28,2027-04-28,2025-09-18,2023-01-30,INTERVENTIONAL,PHASE1,165.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,United States,Stanford,California,32,RO7121932 IV|RO7121932 SC,DRUG|DRUG,"Parts 1, 2, 3 and 4: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) With Severity of AEs Measured According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE V5)|Part 1, 2, 3 and 4: Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)|Parts 2 and 3: Percentage of Participants With Local Pain at the Site of Injection Assessed Using the Visual Analog Scale (VAS)|Parts 2 and 3: Percentage of Participants With Local Injection-site Reaction Using Local Injection-site Symptom Assessment (LISSA)|Part 4: Percentage of Participants With Local Injection-site Reactions","Parts 1, 2 and 3 (Week 1 and Week 4): Time to Maximum Observed Concentration (Tmax) of RO7121932|Parts 1, 2 and 3 (Week 1 and Week 4): Maximum Observed Serum Concentration (Cmax) of RO7121932|Parts 1, 2 and 3 (Week 1 and Week 4): Area Under the Serum Concentration-time Curve From Time 0 to 168 Hours (h) (AUC0-168h) Postdose|Parts 1 and 2: Area Under the Serum Concentration-time Curve up to the Last Measurable Concentration (AUClast)|Parts 1 and 2: AUC From Time 0 to Infinity (AUCinf)|Part 1: Total Body Clearance (CL) Of RO7121932|Parts 2 and 3 (Week 4): Apparent Clearance (CL/F) of RO7121932|Parts 1, 2 and 3: Terminal Rate Constant of RO7121932|Parts 1, 2 and 3: Apparent Terminal Half-Life (T1/2) of RO7121932|Part 3: Trough Concentrations (Ctrough) of RO7121932|Part 3 (Week 1 and Week 4): Area Under the Concentration-time Curve Over One Dosing Interval (AUCtau) of RO7121932|Part 4: Serum Concentration of RO7121932|Parts 1, 3 and 4: Cerebrospinal Fluid (CSF) Concentration of RO7121932|Parts 1, 2, 3 and 4: Percentage of Participants With Anti-RO7121932 Antibodies|Parts 1, 2, 3 and 4: Time Course of B-cell Frequencies in Blood|Parts 1 and 4: Time Course of B-cell Frequencies in CSF|Parts 1, 2, 3 and 4: Change From Baseline in B-cell Frequencies in Blood|Parts 1, 3 and 4: Change From Baseline in B-cell Frequencies in CSF",False,
NCT04969562,"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis","The Effect of Emotional Freedom Technique on Depressive Symptom, Anxiety and Psychological Distress of Individuals With New Diagnosis Multiple Sclerosis: A Randomized Controlled Study",COMPLETED,2020-08-01,2021-10-30,2021-10-30,2022-03-23,2021-07-20,INTERVENTIONAL,NA,36.0,ACTUAL,Dokuz Eylul University,OTHER,,,Multiple Sclerosis|Anxiety|Depressive Symptoms|Psychiatric Nursing,"Multiple Sclerosis, anxiety, depression, pschological distress, emotional freedom technique",Turkey (Türkiye),Izmir,,1,Emotional Freedom Technique,BEHAVIORAL,Change from baseline anxiety levels at 6 weeks assessed by anxiety subscale of Hospital Anxiety Depression Scale (HADS)|Change from baseline depressive symptoms levels at 6 weeks assessed by depressive symptoms subscale of Hospital Anxiety Depression Scale (HADS)|Change from baseline psychological distress symptoms levels at 6 weeks assessed by Subjective Units of Distress Scale (SUDS).,,False,
NCT05123703,A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS),"A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-05-19,2025-06-09,2029-09-17,2025-09-22,2021-11-17,INTERVENTIONAL,PHASE3,188.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,"PPD Development, LP",INDUSTRY,Relapsing-Remitting Multiple Sclerosis,pediatric Multiple Sclerosis|pediatric MS|children MS|children Multiple Sclerosis|pediatric ocrelizumab,United States,La Jolla,California,105,Ocrelizumab|Ocrelizumab Placebo|Fingolimod|Fingolimod Placebo,DRUG|OTHER|DRUG|OTHER,Annualized Relapse Rate (ARR),"Number of New or Enlarging T2-hyperintense Lesions (T2 lesions) as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-blind Period|Number of New or Enlarging T2 Lesions by Week 96|ARR by Week 96|Number of T1 Gadolinium (Gd) Lesions at Week 12|Incidence and Severity of Adverse Events (AEs), With Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)|Prevalence of Anti-drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study",False,
NCT00574041,How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose,An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY),TERMINATED,2007-06,2008-02,2008-02,2008-09-04,2007-12-14,INTERVENTIONAL,PHASE4,19.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Avonex|side effects|flu like symptoms,Australia,Malvern,Victoria,1,Interferon beta-1a,DRUG,To assess the mean severity of episodes of FLS during the 4 week titration phase,To assess the mean severity and duration of FLS episodes in post-titration phase,False,
NCT02364986,Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis,Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis,UNKNOWN,2015-01,2017-01,2017-01,2016-06-03,2015-02-18,INTERVENTIONAL,PHASE1,50.0,ESTIMATED,PD Dr. Marcus Müller,OTHER,"BfARM, Bonn|DZNE, Bonn",UNKNOWN|UNKNOWN,Relapsing-remitting Multiple Sclerosis,,Germany,Bonn,,2,Rebif®|Avonex,DRUG|DRUG,"Change of mRNA (IFN-b, CXCL10, IL-6, MxA and 5'-3'OAS) and protein expression (IFN-b, CXCL10, IL-6) in peripheral blood mononuclear cells/ serum","Change of mRNA and miRNA expression in peripheral blood mononuclear cells and serum in healthy volunteers as well as in patients with RRMS|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Correlation of Rebif/Avonex side effects in patients with RRMS and healthy volunteers with changes in IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA expression pattern and functional immune tests|Psychometric testing: correlation between Rebif/Avonex administration and scores in depression and anxiety scales|MRI: Changes in regional cerebral blood flow at rest (arterial spin labeling) and their correlation with psychometric outcome variables and with transcriptome data|Changes in functional neuroimaging endophenotypes in the limbic system or prefrontal cortex that constitute possible markers of anxiety and depression and their correlation with psychometric outcome variables|Changes of IFN-b, CXCL10, MxA, 5'-3'OAS, IL-6 serum levels, gene- and miRNA-expression pattern and functional immune tests between healthy volunteers, RRMS-patients naïve to IFN-b and RRMS-patients with established IFN-b treatment",False,
NCT00424788,A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),COMPLETED,2007-01,2007-10,2007-10,2009-09-04,2007-01-22,INTERVENTIONAL,EARLY_PHASE1,12.0,ESTIMATED,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,multiple sclerosis (MS),United States,Cleveland,Ohio,2,Plasma exchange|natalizumab treatment,PROCEDURE|DRUG,,,False,
NCT01464905,Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS),"A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis",UNKNOWN,2011-10,2013-12,2014-12,2013-09-23,2011-11-04,INTERVENTIONAL,PHASE3,500.0,ESTIMATED,Nuron Biotech Inc.,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,RRMS,Belarus,Minsk,,12,NU100|Placebo|rhIFN beta-1b,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,New CALs after 4 months of treatment based on the MRI outcomes obtained at 4 and 12 months,Incidence of annualized relapse rates,False,
NCT01034579,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,"A Multinational, Multicenter, Single Blood Sampling Exploratory Pharmacogenetic Study of the REGARD (the REbif® vs Glatiramer Acetate in Relapsing MS Disease) Trial",COMPLETED,2010-02,2010-11,2010-11,2014-03-10,2009-12-17,INTERVENTIONAL,PHASE4,324.0,ACTUAL,EMD Serono,INDUSTRY,,,Relapsing Multiple Sclerosis,Biomarkers|Genetic markers,United States,Rockland,Massachusetts,1,Blood sampling|Blood sampling,OTHER|OTHER,Percentage of Responders as Defined by Single Nucleotide Polymorphism (SNP) Markers,Number of Participants With Confirmed Expanded Disability Status Scale (EDSS) Progression as Defined by SNP2 Marker|Change in Time Constant 1 Gadolinium (T1 Gd) Enhancing Lesion Volume as Defined by SNP3 and SNP4 Markers|Change in Brain Volume as Defined by SNP2 Marker|Mean Number of Time Constant 2 (T2) Active Lesions Per Subject Per Scan as Defined by SNP5 Marker,True,2014-03-10
NCT06596746,Neurodegenerative Diseases Progression Markers (MARKERS-NDD),Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study,RECRUITING,2024-09-09,2034-09-09,2034-09-09,2024-09-19,2024-09-19,OBSERVATIONAL,,600.0,ESTIMATED,Casa di Cura San Raffaele Cassino,NETWORK,"IRCCS San Raffaele Roma|San Raffaele Telematic University|University of Urbino ""Carlo Bo""|University of Cassino and Southern Lazio|University of Roma La Sapienza|Politecnico di Milano",OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER,"Neurodegenerative Diseases|Parkinson Disease|Synucleinopathies|Lewy Body Disease|Multiple System Atrophy|Tauopathies|Alzheimer Disease|Corticobasal Degeneration|Supranuclear Palsy, Progressive|Atypical Parkinsonism|TDP-43 Proteinopathies|Amyotrophic Lateral Sclerosis|Frontotemporal Lobar Degeneration|Movement Disorders|Cognitive Impairment|Dementia|Iron Overload|Neurodegeneration With Brain Iron Accumulation (NBIA)",Neurodegenerative Diseases|Markers|Gait analysis|Wearable inertial sensors|IMU|Artificial intelligence|AI-Video gait analysis|Handwriting analysis|Voice-based artificial intelligence systems|imaging|multimodal analysis|electroencephalogram|cortical activity|gut microbiota|laboratory blood chemistry parameters,Italy,Cassino,Frosinone,1,Observation,OTHER,To monitor and predict the course of neurodegenerative diseases through the study of clinical markers and the creation of AI-models,To predict the risk to develop neurodegenerative diseases through the study of clinical markers and the creation of AI-models,False,
NCT07098273,Improving Hand Movement and Coordination in People With Multiple Sclerosis Using Transcranial Magnetic Stimulation (TMS) and Muscle Electrostimulation (FES) To Support Manual Dexterity and Daily Function,Restoring Manual Dexterity in Multiple Sclerosis: A Feasibility Study Combining Muscle Electrostimulation and Transcranial Magnetic Stimulation To Enhance Neuroplasticity,NOT_YET_RECRUITING,2025-10,2026-12,2027-05,2025-08-12,2025-08-01,INTERVENTIONAL,NA,50.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,Multiple Sclerosis,Multiple Sclerosis|Hand Dexterity|Technology-based Rehabilitation|Functional Electrical Stimulation|Transcranial Magnetic Stimulation,Italy,Genova,Italy,2,TMS and FES- based rehabilitation|FES-based rehabilitation,DEVICE|DEVICE,9-Hole Peg Test (9HPT),Box and Block Test (BBT)|Arm Function in Multiple Sclerosis Questionnaire (AMSQ)|Symbol Digit Modalities Test (SDMT)|12-Item Short Form Survey (SF-12)|Fatigue Scale of Motor and Cognitive Functions (FSMC)|Intrinsic Motivation Inventory (IMI)|System Usability Scale (SUS),False,
NCT02486562,IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis,,RECRUITING,2014-11,2030-10,2036-10,2025-02-18,2015-07-01,OBSERVATIONAL,,20000.0,ESTIMATED,Accelerated Cure Project for Multiple Sclerosis,OTHER,Patient-Centered Outcomes Research Institute|Ogilvy|Arizona State University,OTHER|UNKNOWN|OTHER,Multiple Sclerosis,Multiple Sclerosis|MS,United States,Waltham,Massachusetts,1,,,Number of people with multiple sclerosis who experience health-related quality-of-life changes,,False,
NCT06468241,The Effect of Music and Progressive Relaxation Exercise on Fatigue and Sleep in Multiple Sclerosis,The Effect of Listening to Music and Progressive Relaxation Exercise on Fatigue and Sleep in Multiple Sclerosis: A Randomized Controlled Study,COMPLETED,2023-08-15,2023-12-15,2024-04-15,2024-07-16,2024-06-21,INTERVENTIONAL,NA,30.0,ACTUAL,Ondokuz Mayıs University,OTHER,,,Multiple Sclerosis|Fatigue|Sleep,Multiple Sclerosis|Progressive relaxation exercise|listening to music|sleep|fatigue,Turkey (Türkiye),Samsun,,1,Progressive relaxation exercise|Listening to music,OTHER|OTHER,The effect of progressive relaxation exercise and listening to music on sleep quality|The effect of progressive relaxation exercise and listening to music on fatigue|The effect of progressive relaxation exercise and listening to music on fatigue effect|The effect of progressive relaxation exercise and listening to music on sleep,,False,
NCT02777060,Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures,Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures,UNKNOWN,2014-09,2016-12,2017-08,2016-05-19,2016-05-19,INTERVENTIONAL,NA,200.0,ESTIMATED,University of Arizona,OTHER,,,Diabetes|Cancer|Multiple Sclerosis|Arthritis|Parkinson's Disease|Cognitive Disorders|Brain Injury|Stroke,virtual reality|sensor-based balance training|gait|balance,United States,Tucson,Arizona,1,Exergame|Home based balance training,PROCEDURE|PROCEDURE,Change in Balance,Change in gait Speed|Change in Stride length|Change in Stride time|Change in number of walking steps per day|Change in average of walking bout|Change in average of standing bout|Change in average of longest walking bout,False,
NCT04000373,Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis,Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis,COMPLETED,2019-07-23,2020-01-09,2020-01-09,2022-06-27,2019-06-27,INTERVENTIONAL,NA,5.0,ACTUAL,The Cleveland Clinic,OTHER,,,"Multiple Sclerosis|Gait Disorders, Neurologic",,United States,Cleveland,Ohio,1,Ekso GT™ exoskeleton,DEVICE,Dropout Rate|Adverse Events,Timed 25 Foot Walk,True,2020-04-07
NCT02485223,Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis,"Single Test to ARrive at MS Diagnosis. A Prospective, Longitudinal, Investigator Blinded, Pilot Study Assessing the Accuracy of a Single 3 Tesla MRI Scan in Predicting Multiple Sclerosis in Cases of Diagnostic Uncertainty",UNKNOWN,2015-05,2016-05,2017-05,2015-12-02,2015-06-30,OBSERVATIONAL,,60.0,ESTIMATED,University of Nottingham,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|Diagnostic test|Central veins|MRI,United Kingdom,Nottingham,Nottinghamshire,1,,,Difference in the proportion of central veins:lesions in patients with MS and non-MS.,Sensitivity of using a proportion of central veins:lesions in diagnosing MS.|Specificity of using a proportion of central veins:lesions in diagnosing MS.|Positive predictive value of the central vein:lesion MRI test.|Negative predictive value of the central vein:lesion MRI test.|Optimal proportion of central veins:lesions to make a diagnosis of MS.|Rate of patient recruitment.|Cohen's kappa inter-rater agreement for the diagnosis of MS using the MRI test.,False,
NCT01846234,Sodium Intake in Multiple Sclerosis,Effect of Sodium Intake in Multiple Sclerosis Disease Activity,COMPLETED,2010-11,2013-07,2013-07,2013-10-22,2013-05-03,OBSERVATIONAL,,132.0,ACTUAL,Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Salt,Argentina,Buenos Aires,,1,,,Exacerbation rate,Radiological activity,False,
NCT04431323,Intervention for Young Adults With Multiple Sclerosis,ESPRIMO: A Bio-psycho-social Co-created Intervention for Young Adults With Multiple Sclerosis: Study Protocol for a Feasibility Study,COMPLETED,2020-05-13,2022-07-30,2022-10-30,2023-02-02,2020-06-16,INTERVENTIONAL,NA,53.0,ACTUAL,Azienda Ospedaliera Universitaria Integrata Verona,OTHER,,,Multiple Sclerosis,quality of life|young adults|biopsychosocial intervention,Italy,Verona,Veneto,1,ESPRIMO,BEHAVIORAL,Change from Baseline Health-related Quality of Life up to 1 week post-intervention|Acceptance and Satisfaction with the Intervention assessed by an ad hoc questionnaire,"Change from Baseline Resilience Features up to 1 week post-intervention|Change from Baseline Well-being up to 1 week post-intervention|Change from Baseline Mindfulness Traits up to 1 week post-intervention|Change from Baseline Self-efficacy in MS up to 1 week post-intervention assessed by the ""Self-Efficacy in Multiple Sclerosis Scale"" (SEMS)|Change from Baseline Perceived Social Support up to 1 week post-intervention|Change from Baseline Levels of Anxiety and Depression up to 1 week post-intervention|Change from Baseline Illness Representations up to 1 week post-intervention|Change from Baseline Committed Action up to 1 week post-intervention|Change from Baseline Levels of (Motor and Cognitive) Fatigue up to 1 week post-intervention|Change from Baseline Perceived Autonomy Support up to 1 week post-intervention|Change from Baseline Autonomous Motivation up to 1 week post-intervention|Change from Baseline Attitudes up to 1 week post-intervention|Change from Baseline Subjective Norms up to 1 week post-intervention|Change from Baseline Perceived Behavioral Control up to 1 week post-intervention|Change from baseline number of steps/day to 5 days post-intervention|Change from baseline km traveled/day to 5 days post-intervention|Change from baseline number of active hours/day to 5 days post-intervention|Change from baseline number of inactive hours/day to 5 days post-intervention|Change from Baseline number of hours of sleep/day to 5 days post-intervention|Change from baseline heart rate to 5 days post-intervention|Change from baseline heart rate variability to 5 days post-intervention|Change from estimated kilocalories consumed/day at baseline to 5 days post-intervention|Number of Drop Outs|Exact Time of Dropping Out|Underlying Reasons for Dropping Out assessed by an ad hoc questionnaire with open questions",False,
NCT06486779,Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study,A Non-interventional multiCenter Observational Study to Evaluate tHe Effectiveness and Patient-Reported Outcomes of Ofatumumab (Kesimpta®) in patieNts With Relapsing Multiple sclerOsis Treated in Routine Care Settings in Greece (CHRONOS),RECRUITING,2024-12-10,2028-12-30,2028-12-30,2025-07-09,2024-07-05,OBSERVATIONAL,,160.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),Relapsing Multiple Sclerosis (RMS)|RMS|NIS|Greece|Ofatumumab|Kesimpta,Greece,Chaïdári,Attica,13,Ofatumumab,OTHER,Proportion of patients with no evidence of disease activity (NEDA-3) compared to SoC arm of STHENOS,Proportion of patients achieving NEDA-3 status compared to Ofatumumab arm of STHENOS|Proportion of patients achieving each individual component of NEDA-3 compared to Ofatumumab arm of STHENOS|Proportion of patients achieving NEDA-3 status (no comparator)|Proportion of patients achieving each individual component of NEDA-3 (no comparator)|Proportion of patients free of 6m-RAW and 6m-PIRA - no comparator|Change in MSIS-29 impact score from enrollment.|Persistence and treatment discontinuation|Time from the start of ofatumumab to all-cause treatment discontinuation,False,
NCT02686788,TMP001 in Relapsing-remitting Multiple Sclerosis,"TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial",COMPLETED,2015-08,2018-04,2018-04,2018-11-21,2016-02-22,INTERVENTIONAL,PHASE2,9.0,ACTUAL,Dr. Frank Behrens,OTHER,SocraMetrics GmbH,INDUSTRY,Remitting-Relapsing Multiple Sclerosis,multiple sclerosis|relapsing remitting|nonsteroidal anti-inflammatory drug|contrast enhancing lesions,Germany,Tübingen,Baden-Würtemberg,5,TMP001,DRUG,Comparison of average total number of contrast enhancing lesions,Comparison of average total volume of contrast enhancing lesions|Comparison of T2- hyperintense lesions as assessed in MRI|Comparison of T1-hypointense lesions as assessed in MRI|relapse rate|Expanded disability status scale (EDSS)|Assessment of Lipid profile at different time points|TMP001-concentrations|Pain questionnaire,False,
NCT05671588,"Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression",Cardiovascular Fitness and the Influence of a Controlled Combined Exercise Program on Fatigue and Depression of Newly Diagnosed Patients With Multiple Sclerosis,RECRUITING,2022-05-01,2025-06-30,2025-12-31,2024-01-16,2023-01-04,INTERVENTIONAL,NA,70.0,ESTIMATED,University Hospital Ostrava,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Controlled combined exercise|Cardiovascular fitness|Fatigue|Depression,Czechia,Ostrava,Moravian-Silesian Region,1,Controlled combined exercise group|Conventional rehabilitation,PROCEDURE|PROCEDURE,Maximal aerobic capacity (VO2max.kg-1)|Power to weight ratio (W.kg-1),Modified Fatigue Impact Scale (MFIS)|Symptom-Checklist-90-Standard (SCL-90-S)|Beck Depression Inventory Score II (BDI II)|36-Item Short Form Survey (SF-36)|Maximal heart rate (bpm)|Heart rate variability (ms)|Body composition analysis %),False,
NCT05941975,Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression,Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression,RECRUITING,2023-02-14,2025-12-31,2025-12-31,2023-07-12,2023-07-12,INTERVENTIONAL,NA,60.0,ESTIMATED,Brugmann University Hospital,OTHER,,,Multiple Sclerosis,,Belgium,Brussels,,1,Visual Evoked Potential (VEP)|Somatosensory evoked potential (SSEP)|Transcranial magnetic motor evoked potentials (TCmMEP)|Tesla Brain MRI|Blood test - Neurofilament light chain (NfL)|Blood test - EBV serology,DEVICE|DEVICE|DEVICE|DEVICE|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Visual Evoked Potential (VEP)|Somatosensory evoked potential (SSEP)|Transcranial magnetic motor evoked potentials (TCmMEP)|Tesla Brain MRI|Neurofilament light chain (NfL) serum levels|Neurofilament light chain (NfL) serum levels|Neurofilament light chain (NfL) serum levels|Epstein-Barr virus (EBV) serology (VCA IgG)|Epstein-Barr virus (EBV) serology (VCA IgG)|Epstein-Barr virus (EBV) serology (VCA IgG),,False,
NCT01753375,Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis,Role of Vitamin D on the Relapse Rate of Multiple Sclerosis,UNKNOWN,2013-01,2014-07,2014-10,2012-12-20,2012-12-20,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,"AlJohara M AlQuaiz, M.D.",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing rate|Expanded disability status scale|Vitamin D3,Saudi Arabia,Riyadh,,1,Vitamin D3|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Relapse rate in patients with Multiple Sclerosis,Improvement in the expanded disability status scores after receiving vitamin D3,False,
NCT04546698,5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis,5-HTSEP: Serotonin 5-HT7 Receptor Implication in the Inflammatory Mechanisms in Multiple Sclerosis,COMPLETED,2020-09-07,2021-07-19,2021-07-19,2022-02-17,2020-09-14,OBSERVATIONAL,,78.0,ACTUAL,Centre Hospitalier Régional d'Orléans,OTHER,National Scientific Research Centre,UNKNOWN,"Multiple Sclerosis, Acute Relapsing|Multiple Sclerosis",Multiple sclerosis|serotonin|5-HT7 receptor|inflammation|lymphocytes|cytokines,France,Orléans,,1,blood sampling,OTHER,5HT7 Serotonin receptor expression on circulating leukocyte cells|5-HT7 Serotonin receptor mRNA quantity|Immunological context on blood samples|5-HT7 receptor role on lymphocyte functions in vitro|5-HT7 receptor isoforms 5-HT7 receptor isoforms,,False,
NCT06569550,Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis,Neuromodulation of the Left Premotor Cortex with Transcranial Magnetic Stimulation to Alleviate Fatigue in Multiple Sclerosis - a Randomised Controlled Clinical Trial,RECRUITING,2024-08-14,2026-01-01,2026-02-01,2025-01-23,2024-08-26,INTERVENTIONAL,NA,60.0,ESTIMATED,Danish Research Centre for Magnetic Resonance,OTHER,Danish Multiple Sclerosis Center|Scleroseforeningen|Independent Research Fund Denmark,UNKNOWN|UNKNOWN|INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting|Fatigue","Transcranial Magnetic Stimulation, Repetitive|Magnetic Resonance Imaging|Magnetic Resonance Imaging, Spectroscopy",Denmark,Hvidovre,Capital Region,1,Real Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation,DEVICE|DEVICE,"Change from baseline in patient reported fatigue severity, measured by the Fatigue Scale for Motor and Cognitive Symptoms (FSMC) from baseline to +6 days","Change from baseline in regional brain tissue concentration of glutamate/glutamine in the stimulated premotor cortex, measured by single-voxel Magnetic Resonance Spectroscopy|Change from baseline in Brain tissue concentration of GABA in the stimulated premotor cortex, measured by single-voxel Magnetic Resonance Spectroscopy|Change from baseline in patient reported fatigue severity, measured by the Fatigue Scale for Motor and Cognitive Symptoms (FSMC)|Change from baseline in objective fatiguability, measured by the Fatiguability Index (FI)|Change from baseline in patient-reported fatiguability, measured by the Pittsburgh Fatiguability Score (PFS)",False,
NCT01188811,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),Lipoic Acid for Neuroprotection in Secondary Progressive MS,COMPLETED,2010-10,2015-08,2015-08,2017-02-02,2010-08-26,INTERVENTIONAL,PHASE2|PHASE3,54.0,ACTUAL,VA Office of Research and Development,FED,Oregon Health and Science University,OTHER,"Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis|Multiple sclerosis, chronic progressive|Neuroprotective agents|Magnetic resonance imaging|Optical coherence tomography|Gait|Thioctic acid|Alpha-lipoic acid",United States,Portland,Oregon,1,lipoic acid|Placebo,DRUG|DRUG,Brain Atrophy by MRI,Disability Measures: Mobility|Safety Measure: Adverse Events,True,2017-02-02
NCT03269071,Neural Stem Cell Transplantation in Multiple Sclerosis Patients,Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study,COMPLETED,2017-05-17,2021-07-31,2021-07-31,2021-09-05,2017-08-31,INTERVENTIONAL,PHASE1,4.0,ACTUAL,IRCCS San Raffaele,OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,Progressive Multiple Sclerosis,Multiple Sclerosis|Cell Therapy|Human Neural Stem Cells,Italy,Milan,MI,1,human fetal-derived Neural Stem Cells (hNSCs),DRUG,SHORT TERM (0-24 hours) Overall survival|SHORT TERM (0-24 hours) Overall safety and tolerability measured by Adverse Event (AE) recording|SHORT TERM (0-24 hours) Changes in neurological conditions not related to disease|SHORT TERM (0-24 hours) Proportion of successful intrathecal administration procedure (feasibility)|MID TERM (day 1- day 14) Overall survival|MID TERM (day 1- day 14) Overall safety and tolerability measured by AE recording|MID TERM (day 1- day 14) Changes in neurological conditions not related to disease|LONG TERM (day 15 - week 96) Overall survival|LONG TERM (day 15 - week 96) Overall safety and tolerability measured by AE recording|Long term incidence of malignancies|Evaluation of changes in quality of life measures|LONG TERM (day 15 - week 96) Changes in neurological conditions not related to the disease,,False,
NCT02747914,Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients,Repetitive Transcranial Magnetic Stimulation Boosted Exercise Therapy for Lower Limb Spasticity in Multiple Sclerosis Patients,SUSPENDED,2021-01-25,2025-12,2025-12,2024-05-09,2016-04-22,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Belgrade,OTHER,,,Multiple Sclerosis,,Serbia,Belgrade,,1,Transcranial magnetic stimulation|Conventional exercise,DEVICE|OTHER,muscle tone measured by Modified Ashworth Scale (MAS),impact of leg spasticity on daily activities measured by Multiple Sclerosis Spasticity Scale 88 (MSSS-88)|Activities of daily living measured by Barthel Index|Walking mobility measured by Timed 25 Foot Walk test|Quality of life measured by Multiple Sclerosis Quality of Life 54 (MSQoL54).,False,
NCT03033355,Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder,A Prospective Study of Higher Neural Control Changes Following Intra-detrusor Injection of Onabotulinumtoxin-A in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms.,COMPLETED,2014-02,2019-03,2019-03,2025-08-05,2017-01-26,OBSERVATIONAL,,12.0,ACTUAL,The Methodist Hospital Research Institute,OTHER,,,"Multiple Sclerosis|Lower Urinary Tract Symptoms|Neurogenic Bladder|Detrusor, Overactive|Urge Incontinence","Neurogenic Bladder, Detrusor Overactivity, Botox, fMRI",United States,Houston,Texas,1,Intra-detrusor injection of Onabotulinumtoxin-A,DRUG,Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment,"Changes in Urodynamic (UDS) Parameters Following OnabotA Treatment|Number of Participants Presenting With Neurogenic Detrusor Overactivity (NDO) Events During Urodynamic Studies (UDS) Before and After OnabotA Treatment|Changes in Subjective Clinical Outcomes Following Treatment - Urogenital Distress Inventory, Short Form (UDI-6)|Changes in Subjective Clinical Outcomes Following Treatment - Incontinence Impact Questionnaire Short Form (IIQ-7)|Changes in Voiding Diary Metrics - Urge Urinary Incontinence (UUI) Events Per Day|Changes in Voiding Diary Metrics - Number of Participants Requiring Clean Intermittent Catheterization(CIC)",True,2025-08-05
NCT02152085,Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis,Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis,COMPLETED,2014-05,2017-12-31,2017-12-31,2021-05-07,2014-06-02,INTERVENTIONAL,NA,29.0,ACTUAL,"University of Colorado, Boulder",OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,Walking|Mobility|Neuromuscular electrical stimulation|Multiple sclerosis,United States,Boulder,Colorado,1,Narrow pulse|Wide pulse,DEVICE|DEVICE,Walking Endurance|Modified Fatigue Impact Scale,Maximal Walking Speed,True,2021-05-07
NCT05196425,Expression of PARP-1 in Multiple Sclerosis Patients,Expression of PARP-1 in Optic Neuritis of Multiple Sclerosis Patients,COMPLETED,2021-08-01,2022-03-30,2022-04-30,2025-05-02,2022-01-19,INTERVENTIONAL,NA,80.0,ACTUAL,Sohag University,OTHER,,,Multiple Sclerosis,Optic neuritis-Multiple sclerosis-PARP-1,Egypt,Sohag,,1,Blood sampling,GENETIC,measure PARP-1 mRNA,"Optic nerve, RNFL and GCC layer affection by MS",False,
NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference,COMPLETED,2011-09,2012-01,2012-01,2016-02-18,2011-07-27,INTERVENTIONAL,PHASE2,128.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,Austria,Vienna,,14,teriflunomide|Interferon-β-1|Influenza vaccine,DRUG|DRUG|BIOLOGICAL,Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination,Percentage of Participants With 2 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination|Percentage of Participants With 4 Fold or More Increase in Antibody Titer at 28 Days Post Vaccination|Geometric Mean of Titers (GMT) Ratio Post/Pre Vaccination|Immunoglobulin Levels,True,2013-02-26
NCT06143397,Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.,Effect of Transcutaneous Posterior Tibial Nerve Stimulation and Parasacral Transcutaneous Electrical Stimulation on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.,RECRUITING,2023-11-20,2025-10-20,2025-10-30,2025-07-09,2023-11-22,INTERVENTIONAL,NA,42.0,ESTIMATED,Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization,OTHER,Marmara University,OTHER,Multiple Sclerosis|Overactive Bladder Syndrome,,Turkey (Türkiye),Istanbul,,1,TTNS (Transcutaneous tibial nerve stimulation)|PNS (Parasacral nerve stimulation)|Sham stimulation|Behavioral treatment,DEVICE|DEVICE|DEVICE|BEHAVIORAL,Uroflowmetry|Uroflowmetry|Post voiding residue (PVR)|Post voiding residue (PVR),Overactive bladder form (OAB-v8)|Three-day bladder diary (BD)|King's Quality of Life Questionnaire (KHQ)|Incontinence Severity Index (ISI)|Neurogenic Bladder Symptom Score (NBSS)|Overactive bladder form (OAB-v8)|Three-day bladder diary (BD)|King's Quality of Life Questionnaire (KHQ)|Incontinence Severity Index (ISI)|Neurogenic Bladder Symptom Score (NBSS),False,
NCT07063810,"NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.","NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.",NOT_YET_RECRUITING,2025-07-10,2025-10-31,2025-12-31,2025-07-14,2025-07-14,INTERVENTIONAL,NA,120.0,ESTIMATED,Slb Pharma,OTHER,"Université de Caen Normandie|NeoXpériences, Carpiquet, France",OTHER|UNKNOWN,Neurological Conditions|Brain Diseases|Cerebral Palsy|Parkinson Disease (PD)|Multiple Sclerosis|Head Trauma|Ischemic Stroke|Cerebral Anoxia,Mixed Reality|Neurological Conditions|Motor Rehabilitation|Postural Stability|Upper Limb|Locomotion,France,Aunay-sur-Odon,Normandy,5,Mixed Reality Rehabilitation,DEVICE,Change in postural stability measured by the Mini-BesTest (or Kids Mini-BesTest) for children.,"Change in postural stability measured by the Functional Reach Test.|Change in locomotor ability measured by the 6-minute walk test (6MWT) and the 10-meter walk test (10MWT).|Change in limb mobility measured by goniometry and a specific task implemented in the Mixed reality system.|Change in quality of life measured by the MHAVIE questionnaire (measure of life habits).|Change in pain, fatigue and motivation during the rehabilitation|Change in cinematic parameters of upper limb movements and locomotion during the virtual activities (experimental group only).|Progression in difficulty levels of the virtual activities (experimental group only).|User experience measures as perceived by the care providers involved in the mixed reality rehabilitation protocol, using the AttrakDiff, UEQ and meCUE questionnaires.",False,
NCT06365216,ALS Phase II Study of NX210c,"A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c",RECRUITING,2024-10-25,2026-02-01,2026-02-01,2025-02-05,2024-04-15,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,Axoltis Pharma,INDUSTRY,ACT4ALS network,UNKNOWN,Amyotrophic Lateral Sclerosis,ALS,France,Angers,,12,NX210c|Placebo,DRUG|DRUG,The effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity.,,False,
NCT01097668,ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis,SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).,COMPLETED,2010-03,2013-07,2013-07,2015-02-16,2010-04-02,INTERVENTIONAL,PHASE1,43.0,ACTUAL,Apitope Technology (Bristol) Ltd.,INDUSTRY,"Aptiv Solutions|ClinStar, LLC",INDUSTRY|INDUSTRY,Relapsing Remitting Multiple Sclerosis,Multiple sclerosis|Immunomodulation|Phase 1,Russia,Chelyabinsk,,16,ATX-MS-1467,BIOLOGICAL,Safety and Tolerability,The Effect of ATX-MS-1467 on Brain Magnetic Resonance Imaging (MRI).,True,2015-02-16
NCT01127750,Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients,"A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2010-05,2011-10,2011-10,2017-02-23,2010-05-21,INTERVENTIONAL,PHASE3,2417.0,ACTUAL,Novartis,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing multiple sclerosis|MS|safety|tolerability|health outcomes,Australia,Box Hill,,289,FTY720,DRUG,Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MS,"Incidence of macular edema|Incidence of bradyarrhythmic electrocardiograms (ECGs)|Patient reported outcomes indices in multiple sclerosis (PRIMUS), short form health survey-12, and treatment satisfaction questionnaire for medication (TSQM-9)",False,
NCT04257071,Out of Pocket Cost Communication in Multiple Sclerosis Patients,Pilot Feasibility Study of Out-of-Pocket Cost Communication and Supportive Financial Services for Reducing Financial Toxicity Among Multiple Sclerosis Patients,COMPLETED,2020-03-03,2021-12-31,2021-12-31,2022-02-18,2020-02-05,INTERVENTIONAL,NA,61.0,ACTUAL,Emory University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Financial toxicity|Financial burden|Financial distress|Medical expense|Out of Pocket cost|Cost communication|Cost optimization|Price transparency|Financial navigation,United States,Atlanta,Georgia,1,Usual Care|OOP Cost Communication and Optimization,BEHAVIORAL|BEHAVIORAL,Patient Satisfaction Questionnaire,Percentage of Patients Participating in Cost Conversations|Minutes of Patient Engagement in Cost Conversations|Patient Adherence to Cost Optimization Program|Change in Utilization of Financial Supportive Services|Accuracy of OOP Cost Estimates,False,
NCT01994109,Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects,"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects",COMPLETED,2013-11,2016-01,2017-01,2021-07-13,2013-11-25,INTERVENTIONAL,PHASE3,187.0,ACTUAL,"Supernus Pharmaceuticals, Inc.",INDUSTRY,,,Sialorrhea,Sialorrhea|Parkinson's disease|Amyotrophic lateral sclerosis (ALS)|stroke|neuroleptics,United States,Loma Linda,California,34,MYOBLOC|PLACEBO,DRUG|OTHER,Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)|Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A),,True,2019-08-15
NCT00854750,Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis,Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis,TERMINATED,2009-05,2010-05,2010-07,2013-04-22,2009-03-03,INTERVENTIONAL,PHASE4,1.0,ACTUAL,Elliot Frohman,OTHER,Mallinckrodt,INDUSTRY,Multiple Sclerosis,"Multiple Sclerosis, hx of unilateral ON, evidence of thermal sensitivity, and no evidence of an ocular motor syndrome|Multiple Sclerosis, no evidence of ON, and evidence of thermal sensitivity|Healthy age/gender matched controls",United States,Dallas,Texas,1,ACTHAR|ACTHAR|ACTHAR|ACTHAR,DRUG|DRUG|DRUG|DRUG,"To determine if preemptive cooling provides protection against worsening of INO and its effect on reading, with body heating.",To determine whether changes in core body temperature has an impact on patient reported measures of vision (high and low contrast acuity) and reading acuity and speed.,False,
NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),"An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis",TERMINATED,2017-03-24,2023-04-27,2023-04-27,2025-01-15,2017-03-21,INTERVENTIONAL,PHASE3,1225.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Irvine,California,193,Ocrelizumab,DRUG,"Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)|Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS|Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS|Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS|Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS|Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS|Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS|Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS|Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS|Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS|Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS|Mean Change From Baseline in EDSS Score at Week 24|Mean Change From Baseline in EDSS Score at Week 48|Mean Change From Baseline in EDSS Score at Week 72|Mean Change From Baseline in EDSS Score at Week 96|Mean Change From Baseline in EDSS Score at Week 120|Mean Change From Baseline in EDSS Score at Week 144|Mean Change From Baseline in EDSS Score at Week 168|Mean Change From Baseline in EDSS Score at Week 192|Percentage of Participants Without Protocol-Defined Event of Disease Activity|Percentage of Participants Without Relapse|Annualized Relapse Rate|Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy",Percentage of Participants Who Are Relapse Free|Percentage of Participants With No Evidence of Protocol Defined Disease Activity|Percentage of Participants Without Protocol-defined Event of Evidence of Progression (NEP)|Percentage of Participants With no Evidence of Progression Sustained for At Least 24 Weeks and no Active Disease (NEPAD)|Secondary: Change From Baseline in Multiple Sclerosis Functional Composite Score (MSFC) Total|Change From Baseline in MSFC Composite Timed 25 Foot Walk Test (T25FW) Score.|Change From Baseline in MSFC Composite 9 Hole Peg Test (9HPT) Score|Change From Baseline in MSFC Composite (Paced Auditory Serial Addition Test [PASAT]) Score|Change From Baseline in Cognitive Performance as Measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Symbol Digits Modalities Test (SDMT)|Change From Baseline in Cognitive Performance as Measured by BICAMS -California Verbal Learning Test-II (CVLT-II)|Change From Baseline in Cognitive Performance as Measured by BICAMS - Brief Visuospatial Memory Test-Revised (BVMT-R)|Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI|Total Number of New and/or Enlarging T2 Lesion as Detected by Brain MRI|Change From Baseline in Total T1 Hypointense Lesion Volume as Detected by Brain MRI|Total Number of Fluid-Attenuated Inversion-Recovery (FLAIR) Lesion as Detected by Brain MRI|Change From Baseline in Brain Volume as Detected by Brain MRI|Percentage of Participants Without Treatment Discontinuation|Employment Status: Work Productivity and Activity Impairment Questionnaire (WAPI) Score|SymptoMScreen Composite Score|Quality of Life: Multiple Sclerosis Impact Scale (MSIS)-29 Questionnaire Score|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Substudy: Number of Participants With IRR Overall and by Dose at Randomization|Substudy: Severity of IRRs|Substudy: Number of IRR Symptoms|Substudy: IRRs Leading to Treatment Discontinuation,True,2025-01-15
NCT06461481,Strategies for Adaptive Follow-up and Evaluation - Guiding Use of Indicators for De-Escalation in Multiple Sclerosis,Strategies for Adaptive Follow-up and Evaluation - Guiding Use of Indicators for De-Escalation in Multiple Sclerosis,RECRUITING,2024-06-15,2026-10-30,2026-12-31,2024-07-03,2024-06-17,OBSERVATIONAL,,150.0,ESTIMATED,"Heinrich-Heine University, Duesseldorf",OTHER,,,Multiple Sclerosis,"Multiple Sclerosis, Follow-Up",Germany,Düsseldorf,,1,Withings Scanwatch,DEVICE,"Percentage of disease activity, measured by loss of NEDA at month 24","EDSS: Change From Baseline in Expanded Disability Status Scale (EDSS) Score|Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Score|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component Paced Auditory Serial Addition Test|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component 9-hole peg test|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score - Component Timed 25-foot walk (T25FW)|Change in Pittsburgh Sleep Quality Index (PSQI)|Change From Baseline in Fatigue Severity Scale (FSS)|Change in Blood analysis (levels of sNfl, GFAP, serum proteomics)|Questionnaire about smartwatch usage (System Usability Score)|Wearing time of smartwatch (daily)|Longitudinal development of activity parameter: step count|Longitudinal development of activity parameter: approximate distance traveled (meter)|Longitudinal development of activity parameter: duration of soft activity (seconds) defined by Withings|Longitudinal development of activity parameter: duration of moderate activity (seconds) defined by Withings|Longitudinal development of activity parameter: duration of intense activity (seconds) defined by Withings|Longitudinal development of activity parameter: sum of all active time (seconds)|Longitudinal development of sleep parameter: time awake (seconds)|Longitudinal development of activity parameter: approximate calories burned|Longitudinal development of sleep parameter: number of times user woke up|Longitudinal development of sleep parameter: time to sleep (seconds)|Longitudinal development of sleep parameter: heart rate variability (ms)|Longitudinal development of sleep parameter: total time asleep (seconds)|Longitudinal development of sleep parameter: total time in bed (seconds)|Longitudinal development of sleep parameter: ratio of sleep/time in bed|Longitudinal development of sleep parameter: time spent in bed before falling asleep (seconds)|Longitudinal development of sleep parameter: time awake after first falling asleep (seconds)|Longitudinal development of sleep parameter: Withings Sleep score|Longitudinal development of cardiovascular parameter: average heartrate|Longitudinal development of cardiovascular parameter: maximal heartrate|Longitudinal development of cardiovascular parameter: minimum heartrate|Longitudinal development of cardiovascular parameter: time in light heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in moderate heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in intense heartrate zone (seconds)|Longitudinal development of cardiovascular parameter: time in maximal heartrate zone (seconds)",False,
NCT02330965,Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis,Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04),COMPLETED,2014-12,2017-07-12,2017-07-12,2020-11-09,2015-01-05,OBSERVATIONAL,,36.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Autoimmunity Centers of Excellence|Novartis Pharmaceuticals,OTHER|INDUSTRY,Secondary Progressive Multiple Sclerosis,autoimmunity|clinical research|mechanistic studies|blood draw|cerebrospinal fluid (CSF) by lumbar puncture (optional),United States,Berkeley,California,13,Blood Draw|CSF collection by lumbar puncture (Optional),PROCEDURE|PROCEDURE,Change in frequency of MBP-reactive Th17 cells,"Change in frequency of polyclonal CD4+ Th17, Th1, Th2, and Treg cells|Change in chemokine and cytokines levels|Change in Regulatory B Cells|Changes of clinical status and lymphocyte subgroups",False,
NCT01451593,Neuroprotection With Phenytoin in Optic Neuritis,"A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis",COMPLETED,2011-11,2014-12,2015-03,2015-09-09,2011-10-13,INTERVENTIONAL,PHASE2,92.0,ACTUAL,"University College, London",OTHER,National Multiple Sclerosis Society|Multiple Sclerosis Society of Great Britain and Northern Ireland,OTHER|UNKNOWN,Optic Neuritis|Multiple Sclerosis,Optic neuritis|Multiple sclerosis|Retinal nerve fibre layer|Axonal loss|Neuroprotection|Phenytoin|MRI|Optical coherence tomography|Sodium Channel Blockers,United Kingdom,London,,2,Phenytoin|Placebo,DRUG|DRUG,Mean Retinal nerve fibre layer thickness,Visual function|Visual evoked potentials|Optic nerve and brain MRI,False,
NCT02065284,Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis,Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis.,COMPLETED,2014-02,2015-09,2015-11,2022-06-21,2014-02-19,INTERVENTIONAL,NA,32.0,ACTUAL,The Cleveland Clinic,OTHER,The Kelvin and Eleanor Smith Foundation,UNKNOWN,Multiple Sclerosis|Ambulation Difficulty,MS|Ambulation,United States,Cleveland,Ohio,1,Rhythmic Auditory Stimulation (RAS),OTHER,Improved gait pattern on gait analysis,Improved walk time on the timed 25 foot walk test|Improved distance on the 2 minute walk test,False,
NCT02896647,3D Phase Sensitive Inversion Recuperation MRI to Detect and Characterize Multiple Sclerosis Spinal Cord Lesions,,TERMINATED,2016-12-14,2018-09,2018-09,2021-09-13,2016-09-12,OBSERVATIONAL,,60.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Paris,,1,,,number of spinal cord lesions,,False,
NCT02975349,A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.",TERMINATED,2017-03-07,2018-01-24,2024-04-02,2025-05-14,2016-11-29,INTERVENTIONAL,PHASE2,267.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Relapsing-remitting Multiple Sclerosis,M2951|Relapsing Multiple Sclerosis|Bruton's Tyrosine Kinase inhibitor,Bulgaria,Blagoevgrad,,56,Evobrutinib|Evobrutinib|Evobrutinib|Placebo|Tecfidera,DRUG|DRUG|DRUG|DRUG|DRUG,Total Number of Gadolinium-Enhancing T1 Lesions,"Annualized Relapse Rate (ARR) at Week 24|Qualified Relapse-Free Status at Week 24|Change From Baseline in Expanded Disability Status Scale (EDSS) at Week 24|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death|Number of Participants With Clinically Significant Changes From Baseline in Vital Signs and Electrocardiograms (ECGs)|Number of Participants With Grade 3 or Higher Hematology, Biochemistry and Urinalysis Values|Absolute Concentrations of Immunoglobulin (Ig) Levels (Active Treatment Period)|Absolute Concentrations of Immunoglobulin (Ig) Levels (Blinded Extension Period)|Change From Baseline in Immunoglobulin (Ig) Levels (Active Treatment Period)|Change From Baseline in Immunoglobulin (Ig) Levels (Blinded Extension Period)|Absolute Concentration of B Cells (Active Treatment Period)|Absolute Concentration of B Cells (Blinded Extension Period)|Change From Baseline in Absolute B Cells (Active Treatment Period)|Change From Baseline in Absolute B Cells (Blinded Extension Period)|Total Number of New Gadolinium-positive (Gd+) T1 Lesions|Mean Per-scan Number of Gadolinium-positive (Gd+) T1 Lesions|Total Number of New or Enlarging T2 Lesions|Change From Baseline in Volume of T2 Lesions at Week 24|Change From Baseline in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 24|Number of Gadolinium-positive (Gd+) T1 Lesions at Week 48|Number of New Gadolinium-positive (Gd+) T1 Lesions at Week 48|Annualized Relapse Rate (ARR)|Qualified Relapse-free Status|Change From Week 24 in Expanded Disability Status Scale (EDSS) at Week 48|Total Number of New or Enlarging T2 Lesions at Week 48 Relative to Week 24|Change From Week 24 in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 48|Change From Week 24 in Volume of T2 Lesions at Week 48|OLE Period: Total Number of Gadolinium-Enhancing T1 Lesions|OLE Period: Annualized Relapse Rate (ARR)|OLE Period: Percentage of Participants With Qualified Relapse-Free Status|OLE Period: Change From Baseline in Expanded Disability Status Scale (EDSS) at Week 96, 144, 192, 240, 288 and 336|OLE Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)|OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs|OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters|OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECGs)|OLE Period: Absolute Concentrations of Immunoglobulin (Ig) Levels|OLE Period: Change From Baseline in Immunoglobulin (Ig) Levels",True,2021-02-05
NCT02418325,A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,"An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",TERMINATED,2015-02,2017-02,2017-02,2015-11-04,2015-04-16,INTERVENTIONAL,PHASE1|PHASE2,69.0,ESTIMATED,Genesis Limited,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",RRMS,Trinidad and Tobago,San Fernando,Trinidad,1,Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Liberation therapy,BIOLOGICAL|OTHER,Proportion of patients with clinical improvement in EDSS score compared to baseline,Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with clinical improvement in MSFC score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease,False,
NCT00755807,Duloxetine for Multiple Sclerosis Pain,Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.,COMPLETED,2008-10,2010-08,2010-11,2011-12-09,2008-09-19,INTERVENTIONAL,PHASE3,239.0,ACTUAL,Eli Lilly and Company,INDUSTRY,,,Multiple Sclerosis,Central Neuropathic Pain|Multiple Sclerosis,United States,Birmingham,Alabama,22,Duloxetine Hydrochloride (HCI)|Placebo,DRUG|DRUG,Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase),"Change From Baseline in the Weekly 24-Hour Average Pain Scores up to Week 6 (Acute Phase)|Patient Global Impressions of Improvement Scale (PGI-I) at 6 Weeks|Change From Baseline in the Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 6 (Acute Phase)|Change From Baseline in the Clinical Global Impression of Severity Scale (CGI-S) at 6 Weeks (Acute Phase)|Change From Baseline in the Multiple Sclerosis Quality of Life-54 Instrument (MS-QOL-54) at 6 Weeks (Acute Phase)|Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 6|Change From Baseline in the Weekly Mean of Night Pain Scores at Week 6 (Acute Phase)|Change From Baseline in the Beck Depression Inventory II (BDI-II) Question #9 at Week 6 (Acute Phase)|Number of Participants Who Discontinued During the Acute Phase (by Week 6)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Acute Phase|Number of Participants With Adverse Events (AEs) Resulting in Discontinuation From Baseline During the Acute Phase|Change From Baseline in Blood Pressure at Week 6 (Acute Phase)|Change From Baseline in Pulse Rate at Week 6 (Acute Phase)|Change From Baseline in Weight at Week 6 (Acute Phase)|Patient Global Impressions of Improvement Scale (PGI-I) Score at 18 Weeks|Change From Baseline in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) at Week 18|Change From Baseline in the Clinical Global Impression of Severity Scale (CGI-S) Score at Week 18 (Open-label Extension Phase)|Change From Baseline in Multiple Sclerosis Quality of Life-54 Instrument (MS-QOL-54) at Week 18 (Open-label Extension Phase)|Number of Participants With Suicidal Behaviors, Ideations, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 18|Change in the Weekly Mean of the Night Pain Scores From Week 6 Through Week 18 (Open-label Extension Phase)|Change From Baseline in Beck Depression Inventory II (BDI-II), Question #9 at Week 18 (Open-label Extension Phase)|Number of Participants Who Discontinued During the Open-label Extension Phase (by Week 18)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Open-label Extension Phase|Number of Participants With Adverse Events (AEs) Resulting in Discontinuation During the Open-label Extension Phase|Change From Baseline in Blood Pressure at Week 18 (Open-label Extension Phase)|Change From Baseline in Pulse Rate at Week 18 (Open-label Extension Phase)|Change From Baseline in Weight at Week 18 (Open-label Extension Phase)",True,2011-12-09
NCT04244214,Pilot Study for the Evaluation of the More Stamina in Persons With Multiple Sclerosis,Pilot Study for the Evaluation of the More Stamina Mobile Application for Fatigue Management in Persons With Multiple Sclerosis,COMPLETED,2023-01-01,2023-03-31,2023-03-31,2025-01-09,2020-01-28,OBSERVATIONAL,,20.0,ACTUAL,Hospital Italiano de Buenos Aires,OTHER,"Oulu University Hospital|University of Oulu, Finland",OTHER|UNKNOWN,"Multiple Sclerosis|Fatigue|Chronic Conditions, Multiple",eHealth|mHealth|gamification,Finland,Oulu,,1,More Stamina,OTHER,App Engagement Patterns|Qualitative Insights into Usability and Barriers,Association Between User Categories and Fatigue Severity Scores|Association Between User Categories and Health-Related Quality of Life Scores,False,
NCT03900221,French Registry for Monitoring Pregnancies for Multiple Sclerosis,French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort,RECRUITING,2019-08-12,2036-08-12,2036-08-12,2025-03-12,2019-04-02,OBSERVATIONAL,,1500.0,ESTIMATED,Hospices Civils de Lyon,OTHER,,,"Sclerosis, Multiple|Neuromyelitis Optica Spectrum Disorder|Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders|Pregnancy Abnormal",Multiple sclerosis|pregnancy|disease modifying drugs|breastfeeding|loco-regional analgesia,France,Amiens,,46,No intervention,OTHER,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 during pregnancy period|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 during post-partum period,,False,
NCT05867576,Acceptance and Commitment Therapy in Tuberous Sclerosis Complex,Randomised Controlled Trial of Acceptance and Commitment Therapy in Tuberous Sclerosis Complex,ACTIVE_NOT_RECRUITING,2021-08-12,2024-03-30,2024-03-30,2024-02-14,2023-05-22,INTERVENTIONAL,NA,15.0,ESTIMATED,University Hospitals Bristol and Weston NHS Foundation Trust,OTHER,"The Tuberous Sclerosis Association|University College, London",OTHER|OTHER,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex|Acceptance and Commitment Therapy|Mental Health|Psychology|Paediatrics|Neurology|Remote therapy|TAND,United Kingdom,Bristol,,1,Acceptance and Commitment Therapy (ACT),BEHAVIORAL,Treatment completion rate|Treatment completion rate|Session attendance rate|Session attendance rate|The credibility/expectancy questionnaire|The credibility/expectancy questionnaire|The experience of service questionnaire|The experience of service questionnaire,Acceptance and Action Questionnaire II|Avoidance and Fusion Questionnaire for Youth 8-items|World Health Organisation wellbeing index 5-items|Generalised Anxiety Disorder assessment 7-items|Patient Health Questionnaire 9-items|Client Service Receipt Inventory|TAND - TSC Associated Neuropsychiatric Disorders|Pediatric Quality of Life Inventory (PedsQL)|Experiential interviews,False,
NCT03389217,Efficacy of tDCS on Pain in Multiple Sclerosis,Efficacy of tDCS on Pain Experience in People With Multiple Sclerosis: A Pilot Randomized Control Trial,UNKNOWN,2017-12-01,2022-12-01,2023-05-01,2022-05-25,2018-01-03,INTERVENTIONAL,NA,30.0,ESTIMATED,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Pain|Transcranial Direct Current Stimulation|tDCS,Italy,Ferrara,,1,Real-tDCS + rehabilitation programme|Sham-tDCS + rehabilitation programme,DEVICE|DEVICE,Numeric Rating Scale (NRS),Short Form McGill Pain Questionnaire (SF-MPQ)|Brief Pain Inventory (BPI)|Pain Catastrophizing Scale (PCS)|Coping Strategies Questionnaire (CSQ)|Beck Depression Inventory II (BDI-II)|MS Quality of Life - 54 (MSQOL-54)|Fatigue Severity Scale (FSS)|Go/No-go Task|Patient Global Impression of Change (PGIC)|Pressure Pain Threshold (PPT)|Electroencephalography (EEG) recordings,False,
NCT05054140,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2021-09-30,2025-01-07,2025-01-07,2024-04-29,2021-09-23,INTERVENTIONAL,PHASE2,450.0,ESTIMATED,Immunic AG,INDUSTRY,,,Multiple Sclerosis,Progressive Multiple Sclerosis,United States,Coral Springs,Florida,73,IMU-838|Placebo matching IMU-838,DRUG|DRUG,Efficacy of IMU-838 versus placebo,Efficacy of IMU-838 versus placebo|Efficacy of IMU-838 versus placebo in terms of disability worsening,False,
NCT02280876,Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS),"Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).",COMPLETED,2012-01,2015-02,2015-05,2016-06-23,2014-11-03,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,Universidad Austral de Chile,OTHER,Comisión Nacional de Investigación Científica y Tecnológica|University of Chile,OTHER_GOV|OTHER,"Multiple Sclerosis, Relapsing-Remitting",MS|Demyelinating Autoimmune Diseases|CNS|Nervous System Diseases,Chile,Valdivia,Los Ríos Region,1,1 - Andrographis paniculata p/st extract|2 - Excipients,DRUG|DRUG,"Clinical inflammatory (stamina) and disability score parameters (sensorial, neurosensitive, neuromotor and cognitive function) in patients with RRMS, treated with ApE and placebo administered over beta interferon.","Safety, tolerability and efficacy of ApE and placebo administered over beta interferon in RRMS treated patients (adverse symptoms, general clinical laboratory and comparative statistical parameters)",False,
NCT03500289,Ketamine for Treatment of MS Fatigue,Ketamine for Treatment of Multiple Sclerosis-related Fatigue,COMPLETED,2018-08-10,2019-08-30,2019-08-30,2020-08-18,2018-04-18,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,Johns Hopkins University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Fatigue,,United States,Baltimore,Maryland,1,Ketamine|Midazolam,DRUG|DRUG,Change in Daily Fatigue Severity Score,Change in Quality of Life in Neurological Disorders (NeuroQol) Fatigue Item Bank Score|Change in Modified Fatigue Impact Scale (MFIS) Score|Change in Epworth Sleepiness Scale Score|Change in Beck Depression Inventory (BDI) Score|Change in Fatigue Severity Scale (FSS) Score,True,2020-08-04
NCT03660618,"LSFG-SKIN, Laser Speckle Flowgraphy","LSFG-SKIN, Laser Speckle Flowgraphy",TERMINATED,2017-05-23,2019-03-02,2019-03-02,2023-05-10,2018-09-06,INTERVENTIONAL,NA,1.0,ACTUAL,Randy Kardon,OTHER,,,Hypertension|Heart Failure|Vascular Ischemia|Burns|Chemotherapy Effect|Radiation Injuries|Uveitis|Scleritis|Multiple Sclerosis|Autonomic Neuropathy|Stroke|Intracranial Hemorrhages|TIA|Migraine|Headache|Pain,perfusion|inflammatory|ischemia|lesions|neuropathy|burns|cancer|stroke,United States,Iowa City,Iowa,1,laser speckle flowgraphy,DEVICE,Imaging Blood Flow,,True,2023-05-10
NCT02419638,Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS,,WITHDRAWN,2015-05,2015-12,2016-02,2016-02-29,2015-04-17,OBSERVATIONAL,,0.0,ACTUAL,Brigham and Women's Hospital,OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis,relapsing-remitting MS|lesions|treatment,United States,Brookline,Massachusetts,1,Rebif (IFN β-1a subcutaneous three times per week)|Tecifdera (dimethyl fumarate),DRUG|DRUG,T2 lesion load: Rebif v. Tecfidera,Reducing lesion load and MRI characteristics: Rebif v. Tecfidera,False,
NCT01538225,Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity,Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis,COMPLETED,2012-04,2013-11,2013-11,2014-01-20,2012-02-24,INTERVENTIONAL,PHASE3,45.0,ACTUAL,"Almirall, S.A.",INDUSTRY,,,Multiple Sclerosis,Spasticity,Italy,Milan,,1,Sativex®|Placebo,DRUG|DRUG,H/M reflex ratio,"Neurophysiology ·H/M ratio ·Transcranial Magnetic Stimulation a) MEP Motor threshold, upper limb b) MEPs amplitudes c) Intracortical facilitation/inhibition (ICI/ICF), upper limb|Adverse Events recording|Spasticity: ·0-10 11-point numerical spasticity rating scale (NRS) ·Mean modified Ashworth scale (MAS)|Function: ·Timed 25 feet and 10 meters walk ·Hand dexterity measured with 9-HPT|Other MS Symptoms: ·Sleep Quality NRS ·Pain NRS and Spasm frequency ·Fatigue Severity Scale (FSS)",False,
NCT04367389,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis,COMPLETED,2019-10-01,2020-07-30,2020-07-30,2021-04-28,2020-04-29,INTERVENTIONAL,NA,62.0,ACTUAL,University of Erlangen-Nürnberg,OTHER,"Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen|Medi train - Zentrum für Gesundheitssport, Sport- und Physiotherapie|proMX GmbH Nürnberg|motionNET systems Limited|Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg (AMSEL) e.V.|Klinikum Würzburg Mitte GmbH",UNKNOWN|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|physical activity|exercise|behavior change|internet-based intervention|physical literacy|self-determination theory,Germany,Bad Wildbad,,9,Physical activity promotion|Exercise,BEHAVIORAL|BEHAVIORAL,Changes in objectively measures physical activity,Changes in subjectively measured physical activity: BSA-Questionnaire|Würzburger Fatigue Inventory for MS (WEIMuS)|Allgemeine Depressionsskala (ADS-L)|Multiple Sclerosis Walking Scale-12|Multiple Sclerosis Impact Scale (MSIS-29)|Timed 25-Foot Walk Test (T25FW)|Two-minute Walk Test (2MWT)|Selbstkonkordanz-Skala (SSK-Scale)|Physical activity-related health competence questionnaire|German psychological need satisfaction in exercise scale|Usability and usefulness of the mobile application (meCue 2.0 questionnaire)|Usability and usefulness of the intervention,False,
NCT05781113,A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition,A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Disease Condition Through Home Monitoring of MS Patients,RECRUITING,2023-07-01,2025-12-01,2026-03-01,2025-03-25,2023-03-23,OBSERVATIONAL,,90.0,ESTIMATED,Celestra Health Systems,INDUSTRY,University of Ottawa|Barts & The London NHS Trust|The Ottawa Hospital|Brigham and Women's Hospital,OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,,United States,Boston,Massachusetts,3,,,Participant Adherence|Clinician Acceptance,Gait Quality Measurement|Correlation between AI Gait Algorithms and Patience Perceptions|AI-based Identification of Gait Phenotypes,False,
NCT04255953,Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS,Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS,COMPLETED,2020-08-01,2022-10-20,2023-09-20,2023-11-30,2020-02-05,INTERVENTIONAL,NA,70.0,ACTUAL,Jared Bruce,OTHER,National Multiple Sclerosis Society|University of Kansas Medical Center|Children's Mercy Hospital Kansas City,OTHER|OTHER|OTHER,Multiple Sclerosis|Obesity,,United States,Kansas City,Missouri,1,behavioral telehealth|Treatment as Usual,BEHAVIORAL|OTHER,Weight Loss,modified fatigue Impact scale|Hospital Anxiety and Depression Scale|MS Quality of Life Inventory|6 Minute Walk,False,
NCT03136744,Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?,Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?,COMPLETED,2018-02-03,2019-06-12,2019-12-31,2024-09-19,2017-05-02,INTERVENTIONAL,NA,40.0,ACTUAL,University of Alberta,OTHER,Alberta Innovates Health Solutions,OTHER,Multiple Sclerosis,Sedentary behaviour|Co-morbidity|Intervention,Canada,Edmonton,Alberta,1,Sit Less with MS,BEHAVIORAL,Number of sedentary interruptions per day|Average sedentary time per day,Patient Determined Disease Steps (PDDS)|Fatigue Severity Scale (FSS)|Modified Fatigue Impact Scale|Symbol Digit Modality Test|Hospital Anxiety and Depression Scale|Short Form McGill Pain Questionnaire|Pittsburgh Sleep Quality Questionnaire|Godin-Shephard Leisure-Time Physical Activity Questionnaire|6-minute Walk Test|10-meter Walk test|Short Physical Performance Battery|Quality of Life (SF-36) Questionnaire,False,
NCT02121444,"BAY86-5046 (Betaseron), Non Interventional Studies",BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®,COMPLETED,2014-06-23,2016-03-09,2016-06-01,2017-10-18,2014-04-23,OBSERVATIONAL,,151.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,RRMS|CIS,Germany,Many Locations,,1,"Interferon beta-1b (Betaferon, BAY 86-5046)|BETACONNECT auto-injector.",DRUG|DEVICE,Adherence measure to Betaferon therapy based on the real BETACONNECT injections,"Satisfaction with and evaluation of the BETACONNECT auto-injector recorded by patient questionnaire|Evaluation of health related quality of life,measured with the self-administered Functional Assessment of Multiple Sclerosis (FAMS) questionnaire|Evaluation of Anxiety measured with the self-administered Hospital Anxiety and Depression Scale (HADS)|Evaluation of Depression measured with the self-administered Center for Epidemiologic Studies Depression Scale (CES-D)|Evaluation of Fatigue measured with the self-administered Fatigue Scale for Motor and Cognitive functions (FSMC)|Evaluation of Cognition will be measured by the HCP with the Symbol Digit Modalities Test (SDMT)|Local skin reactions recorded by Health Care Provider (HCP) evaluation|Evaluation of injection-related specifics such as injection date, time, and speed will be recorded by the BETACONNECT device|Number of Treatment-emergent Adverse Events (TEAE)",False,
NCT01709149,"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)","A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)",COMPLETED,2012-10,2014-03,2014-03,2020-03-31,2012-10-18,INTERVENTIONAL,PHASE2,711.0,ACTUAL,Cytokinetics,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,Phoenix,Arizona,75,CK-2017357|Placebo tablets|Riluzole,DRUG|OTHER|DRUG,The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment,Change From Baseline in Maximum Voluntary Ventilation (MVV) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment|Change From Baseline in Sniff Nasal Inspiratory Pressure (SNIP) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment|Change From Baseline in Slow Vital Capacity (SVC) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment|Change From Baseline in Maximum Handgrip Strength in the Weaker Hand to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment|Change From Baseline in Handgrip Fatigability (at 60% of Target in the Weaker Hand) to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment|Change From Baseline in Muscle Strength Mega-Score Based on Percent Change in Muscle Strength Measurements to the Average at the End of Weeks 8 and 12 of Double-blind Treatment,True,2020-03-31
NCT01436838,"China Betaferon Adherence, Coping and Nurse Support Study","Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis",COMPLETED,2012-03,2015-09,2015-12,2016-09-05,2011-09-20,OBSERVATIONAL,,110.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Chronic Progressive",Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,China,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment,Ways of Coping Questionnaire (WCQ)|Hospital Anxiety and Depression Scale (HAD),False,
NCT02814487,MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.,"A Pilot Validation Study Comparing ""DAM"" a Smartphone Application With the Composite MSFC Score Intra-individually Among Multiple Sclerosis Patients",COMPLETED,2015-12,2016-09,2016-09,2016-09-12,2016-06-27,OBSERVATIONAL,,30.0,ACTUAL,Ad scientiam,OTHER,Roche Pharma AG,INDUSTRY,Multiple Sclerosis,DAM|multiple sclerosis|MSFC|application|smartphone,,,,0,,,correlation between the MSFC score and the DAM score,correlation between the DAM score|correlation between the DAM score|correlation between the the MSFC and the DAM score,False,
NCT00211887,Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx,"A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)",COMPLETED,2005-01,2012-04,2013-03,2014-04-03,2005-09-21,INTERVENTIONAL,PHASE3,1008.0,ACTUAL,Fred Lublin,OTHER,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Clinical trial|treatment trial|autoimmune disease|Relapsing Remitting|MS Treatment|interferon beta-1a|glatiramer acetate,United States,Birmingham,Alabama,71,Interferon beta 1-a|glatiramer acetate|placebo,DRUG|DRUG|OTHER,ARR - PDEs,Confirmed Progression on the Expanded Disability Status Scale|Change in the Multiple Sclerosis Functional Composite|Change in MRI Composite Score,True,2014-04-03
NCT06428006,Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis,Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms and Fatigue in Individuals With Multiple Sclerosis,RECRUITING,2024-07-30,2027-05-31,2027-05-31,2025-07-20,2024-05-24,INTERVENTIONAL,PHASE2,70.0,ESTIMATED,University of Kansas Medical Center,OTHER,,,Multiple Sclerosis|Insomnia,Cognitive behavioral therapy for insomnia|CBT-I,United States,Kansas City,Kansas,1,Cognitive behavioral therapy for insomnia|Sleep and lifestyle education,BEHAVIORAL|BEHAVIORAL,Insomnia Severity Index (ISI),Pittsburgh Sleep Quality Index (PSQI)|Epworth Sleepiness Scale (ESS)|Dysfunctional Beliefs About Sleep|Positive Affect and Negative Affect Schedule (PANAS)|Sleep Self-Efficacy Scale (SESS)|Actigraphy|Modified Fatigue Impact Scale (MFIS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Impact Scale (MSIS-29)|Cognitive Failures Questionnaire (CFQ),False,
NCT06592352,MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis,"MODAFIMS: An Open-label, Single-center Clinical Trial to Evaluate Predictors of Response to MODAFinil in the Treatment of Cognitive Deficits in Patients With Multiple Sclerosis",RECRUITING,2024-08-27,2026-06,2026-09,2025-08-13,2024-09-19,INTERVENTIONAL,PHASE2,64.0,ESTIMATED,Clinical Academic Center (2CA-Braga),OTHER,,,Multiple Sclerosis|Cognitive Impairment,multiple sclerosis|cognitive impairment|functional MRI,Portugal,Braga,,1,Modafinil Generis 100 mg,DRUG,Acute changes in brain fuction and connectivity measured using resting state fMRI.|Long-term changes in brain function and connectivity measured using resting state fMRI.,Acute changes in brain function and connectivity measured using a Go/no-Go task fMRI.|Long-term changes in brain function and connectivity measured using a Go/no-Go task fMRI.|SDMT score|Stroop test|MS-QoL-54 total score|WPAI:MS total score|MFIS total score|PDQ total score,False,
NCT05279755,A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants With Amyotrophic Lateral Sclerosis (ALS) With an Optional Open-Label Extended Treatment Period for ALS Participants Who Complete 14 Days of Blinded Treatment",RECRUITING,2022-02-26,2026-06-30,2026-10-31,2025-04-08,2022-03-15,INTERVENTIONAL,PHASE1,72.0,ESTIMATED,ProJenX,INDUSTRY,Congressionally Directed Medical Research Programs,FED,Amyotrophic Lateral Sclerosis,ALS|Amyotrophic lateral sclerosis|MAP4K|prosetin,United States,Boston,Massachusetts,4,prosetin|placebo,DRUG|DRUG,"Parts A, B, C, D: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Parts A, B, C, D: Number of Participants with Clinically Significant Laboratory Test Abnormalities|Parts A, B, C, D: Number of Participants with Clinically Significant Vital Signs Abnormalities|Parts A, B, C, and D: Number of Participants with Clinically Significant Electrocardiogram (ECG) Abnormalities|Parts A, B, C, and D: Number of Participants with Clinically Significant Physical Examination Abnormalities|Parts A, B, C, and D: Number of Participants with Clinically Significant Neurological Examination Abnormalities|Parts A, B, C, and D: Number of Participants with Clinically Significant Ophthalmic Examination Abnormalities|Parts C and D: Number of Participants with Clinically Significant Electroencephalogram (EEG) Abnormalities","Parts A, B, C, and D: Maximum Observed Concentration (Cmax) of Prosetin in Plasma|Parts A, B, C, and D: Time to Reach Maximum Observed Concentration (Tmax) of Prosetin in Plasma|Parts A, B, C, and D: Area Under the Concentration-Time Curve (AUC) of Prosetin in Plasma|Parts A, B, C, and D: Apparent Terminal Elimination Half-life (t1/2) of Prosetin in Plasma|Parts A and D: Measure of Concentration of Prosetin in CSF",False,
NCT05604092,"Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS","White Matter Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2022-03-01,2022-08-31,2022-09-30,2022-11-03,2022-11-03,OBSERVATIONAL,,63.0,ACTUAL,Assiut University,OTHER,,,Relapsing Remitting Multiple Sclerosis,,Egypt,Asyut,,1,"VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)",DIAGNOSTIC_TEST|OTHER,"The relation of white matter lesion load, location and parameters of cognitive function measured by BICAMS|The relation of white matter lesion load, location and Fatigue in patients with relapsing remitting multiple sclerosis","the relation of white matter lesion load, location and atrophy parameters to physical disability in patients with relapsing remitting multiple sclerosis",False,
NCT04239664,Acceptance Based Telephone Support When Transitioning to SPMS,Acceptance Based Telephone Support Around the Time of Transition to Secondary Progressive Multiple Sclerosis: A Feasibility Randomised Controlled Trial,COMPLETED,2019-09-09,2020-03-20,2020-03-20,2020-09-25,2020-01-27,INTERVENTIONAL,NA,14.0,ACTUAL,University of Nottingham,OTHER,Nottingham University Hospitals NHS Trust,OTHER,Secondary Progressive Multiple Sclerosis,,United Kingdom,Nottingham,Nottinghamshire,1,Acceptance Based Telephone Support (ABS+UC),OTHER,"The administrative burden of the trial for participants and for investigators, measured through feedback interviews and hours per week necessary to facilitate the trial|The appropriateness of the overall eligibility criteria, such as the total number, and ratio, of participants being included/excluded by each criteria.|The ease and success of the randomisation protocol, measured through the amount and frequency of any errors (see description) during the randomisation process.|Acceptability of audio recording of sessions: number who accept, decline|Success of recruitment/ recruitment rates|Retention rates|Completion rates of outcome measures","Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)|Multiple Sclerosis Impact Scale-29 (MSIS-29) (Riazi, Thompson, Lamping, Hobart, & Fitzpatrick, 2001)|Multiple Sclerosis Self-Efficacy Scale (Rigby et al., 2003)|EQ-5D-5L (Herdman et al., 2011)|Comprehensive Assessment of Acceptance and Commitment Therapy processes (CompACT) (Francis, Dawson, & Golijani-Moghaddam, 2016)",False,
NCT05783999,Muscle Vibration and Fatigue in Patients With MS,Role of Muscle Vibration in Improving the Sense of Fatigue in Patients With Multiple Sclerosis,UNKNOWN,2021-10-28,2024-06-30,2024-06-30,2023-04-07,2023-03-24,INTERVENTIONAL,NA,20.0,ESTIMATED,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Multiple Sclerosis,,Italy,Messina,Sicily,1,vibra plus,DEVICE,mobility|postural control|postural control,fatigue|fatigue|fatigue|fatigue|fatigue|quality of life|quality of life,False,
NCT04944784,A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),"A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,2021-08-16,2023-07-18,2023-07-18,2024-12-05,2021-06-30,INTERVENTIONAL,PHASE3,489.0,ACTUAL,Cytokinetics,INDUSTRY,,,Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis|ALS|CK-2127107|Reldesemtiv|COURAGE-ALS,United States,Phoenix,Arizona,84,Reldesemtiv|Placebo,DRUG|DRUG,Effect of Reldesemtiv Versus Placebo on Functional Outcomes in Amyotrophic Lateral Sclerosis (ALS),Effect of Reldesemtiv Versus Placebo on Combined Functional and Survival Outcomes in Amyotrophic Lateral Sclerosis (ALS)|Effect of Reldesemtiv Versus Placebo on Ventilatory Function|Effect of Reldesemtiv Versus Placebo on Quality of Life|Effect of Reldesemtiv Versus Placebo on Handgrip Strength,True,2024-12-05
NCT00377949,"Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients",The Natural History and Outcome of Patients With Scleroderma at High Risk for or With Early Pulmonary Hypertension,COMPLETED,2005-02,2016-01,,2016-05-03,2006-09-19,OBSERVATIONAL,,602.0,ACTUAL,Georgetown University,OTHER,Gilead Sciences,INDUSTRY,Systemic Sclerosis|Scleroderma|Pulmonary Hypertension|Pulmonary Arterial Hypertension,Systemic Sclerosis|Scleroderma|Pulmonary Hypertension|PHAROS|PHROS|Exercise Echocardiogram|Pulmonary Functional Tests|Six minute walk tests|6 minute walk tests|Right heart catheterization,United States,Los Angeles,California,25,,,Pulmonary Hypertension Progression,,False,
NCT05706220,Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis,Visual Processing Speed and Objective Analysis of Supranuclear Ocular Movements Control in Multiple Sclerosis Patients and Its Relationship With OCT and Reading Difficulties,ENROLLING_BY_INVITATION,2022-06-13,2025-12-31,2025-12-31,2025-05-16,2023-01-31,OBSERVATIONAL,,120.0,ESTIMATED,Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA,OTHER,Fundación Eugenio Rodríguez Pascual|Hospital del Rio Hortega,UNKNOWN|OTHER,Multiple Sclerosis|Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis,ocular motility disorders|eye movement|eye tracking|microperimetry|fixational eye movements|visual processing speed|optical coherence tomography,Spain,Valladolid,Valladolid,1,Eye tracking|Microperimetry|Optical coherence tomography (OCT)|Visual processing speed test,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Eye Tracking Data|Values for Visual Processing Speed (VPS)|Retinal sensitivity assessed by microperimetry|Values for OCT neuroretinal and peripapillary parameters,Fixations recorded with the eye tracker system|Saccades recorded with the eye tracker system|Fixation assessment with microperimetry|Bivariate Contour Ellipse Area (BCEA) analysis with microperimetry|Preferred Retinal Locus (PRL) analysis with microperimetry|Analysis of the macular integrity (MI) with microperimetry|Ganglion Cell Layer measurement (GCL: Macular OCT)|Retinal Nerve Fiber Layer measurement (RNFL: peri-papillary OCT)|Macular ganglion cell-inner plexiform layer thickness measurement (GCIPL),False,
NCT02394782,Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL),"A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart®2.0 + MSdialog™, Assessing Quality of Life (ADHERQOL)",TERMINATED,2015-02,2015-11,2016-03,2016-04-25,2015-03-20,OBSERVATIONAL,,8.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-remitting","Multiple sclerosis, relapsing-remitting|Rebif|Interferon beta-1a|RebiSmart®2.0|MSdialog™",Germany,Darmstadt,,1,RebiSmart®2.0|MSdialog™,DEVICE|DEVICE,Percentage of Relapse-free Subjects,Annualized Relapse Rate|Multiple Sclerosis International Quality of Life (MusiQoL) and Multiple Sclerosis Quality of Life Inventory (MSQLI) Subscale Scores for MSdialog™,False,
NCT01774123,Optical Coherence Tomography in Multiple Sclerosis Patients,Optical Coherence Tomography in Multiple Sclerosis Patients,COMPLETED,2012-08,2013-06,2013-06,2014-06-03,2013-01-23,OBSERVATIONAL,,78.0,ACTUAL,The Cleveland Clinic,OTHER,,,Multiple Sclerosis|Optic Neuritis,,United States,Cleveland,Ohio,1,,,Thickness of retinal layer,Iris area,False,
NCT05543213,The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.,The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.,RECRUITING,2023-01-01,2024-07-01,2024-10-01,2023-12-07,2022-09-16,INTERVENTIONAL,NA,28.0,ESTIMATED,Shiraz University of Medical Sciences,OTHER,,,Multiple Sclerosis,Action Observation|gait|Balance,Iran,Shiraz,Fars,1,Action Observation Therapy,BEHAVIORAL,Berg Balance Scale|Barthel Index|Functional Independence Measure (FIM),Fatigue Assessment Scale (FAS),False,
NCT05009160,DreaMS - Validation Study 1,DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Validation Study 1,RECRUITING,2022-03-30,2026-12,2027-03,2025-04-02,2021-08-17,OBSERVATIONAL,,300.0,ESTIMATED,Research Center for Clinical Neuroimmunology and Neuroscience Basel,OTHER,"University Hospital, Basel, Switzerland|University of Basel|Innosuisse - Swiss Innovation Agency|Novartis Pharmaceuticals|Hoffmann-La Roche|Indivi AG",OTHER|OTHER|OTHER|INDUSTRY|INDUSTRY|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Digital Biomarker,Switzerland,Aarau,Switzerland,6,dreaMS App R2.1,DEVICE,Correlation of the digital features with the respective measurements of the clinical reference tests|The ability of measurements of the changes in the digital biomarkers over the two-year follow-up to predict worsening in the clinical reference test over the same period expressed as binary variables,,False,
NCT02607020,Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis,Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial,UNKNOWN,2015-12,2018-12,2020-01,2016-12-08,2015-11-17,INTERVENTIONAL,NA,100.0,ESTIMATED,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,Hôpital Raymond Poincaré|CHU de Reims,OTHER|OTHER,Multiple Sclerosis,,Belgium,Brussels,,1,Physical exercises in an self-management setting|Relaxation,OTHER|OTHER,Fatigue|Change in fatigue,Safety (Number of patients with adverse events related to treatment).|Change in MS-specific health related quality of life|Change in MS-specific health related quality of life|Change in walking capacity|Change in plasmatic cytokines: IFNg|Change in plasmatic cytokines: TNFa|Adherence|Adherence|Amount of physical activity performed|Change in Cardiorespiratory fitness|Change in Cardiorespiratory fitness|Change in Lower limbs spasticity|Change in objective walking endurance|Change in static and dynamic balance|Change in Neurological Disability,False,
NCT03179423,Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years,"Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years",COMPLETED,2017-06-14,2018-09-01,2019-05-07,2020-10-20,2017-06-07,INTERVENTIONAL,PHASE2,64.0,ACTUAL,GeNeuro Australia PTY Ltd,INDUSTRY,Southern Star Research,INDUSTRY,Diabetes Mellitus Type 1,"Diabetes Mellitus, Type 1|T1D|Monoclonal antibody|Multiple Sclerosis associated retrovirus MSRV|Human Endogenous Retrovirus Type W (HERV-W)|GNbAC1|Temelimab",Australia,Macquarie University,New South Wales,13,GNbAC1|Placebo,DRUG|DRUG,Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE),,False,
NCT02750982,"Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.","A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.",COMPLETED,2016-07,2018-08,2018-08,2018-09-26,2016-04-26,INTERVENTIONAL,NA,24.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,,,Alzheimer's Disease|Amyotrophic Lateral Sclerosis|Brain Injury|Huntington's Disease|Multiple Sclerosis|Parkinson's Disease|Stroke|Spinal Cord Injury,,United States,Kirkland,Washington,1,Laughter Therapy,OTHER,"Patient Health Questionnaire (PHQ-9, for depression)|Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety)",The General Self-Efficacy Scale (GSE),False,
NCT01470521,Worms for Immune Regulation of Multiple Sclerosis,Worms for Immune Regulation of Multiple Sclerosis (WIRMS),COMPLETED,2011-12,2016-01,2016-01,2016-01-29,2011-11-11,INTERVENTIONAL,PHASE2,72.0,ACTUAL,University of Nottingham,OTHER,National Multiple Sclerosis Society,OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|Hookworm larvae|Necator americanus|Treg cells,United Kingdom,Nottingham,Nottinghamshire,1,Hookworm larvae|Placebo,BIOLOGICAL|BIOLOGICAL,The cumulative number of new or enlarging Gd+ lesions at month 9,"Percentage of cells positive simultaneously for CD4, CD25, foxp3|Cumulative number of newly active lesions (new GD+ T1; new and enlarging T2) at month 9|Change in expanded disability status scale (EDSS) at month 9",False,
NCT06826638,Unraveling Active Ingredients of Neurorehabilitation: Investigating Cortical Activity During Task-oriented Exercises,Investigate Neuro-rehabilitation Active Ingredients of Specific Task-oriented Training In People With Multiple Sclerosis With Different Challenging Conditions and Extrinsic Feedbacks,RECRUITING,2023-09-01,2025-07-31,2025-07-31,2025-02-14,2025-02-14,OBSERVATIONAL,,40.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,Università degli Studi of Genova|University of Milan,UNKNOWN|OTHER,Multiple Sclerosis|Healthy Volunteer,rehabilitation|multiple sclerosis|motor control|cortical plasticity,Italy,Genova,,3,,,Head and trunk movements quantified with Inertial Measurement Units (IMU)|Cortical activation with Functional Infrared Spettroscopy (fNIRS),10 Meters walking test|Twelve-Item Multiple Sclerosis Walking Scale (MSWS_12)|Modified Fatigue Impact Scale (MFIS)|Beck Depression Inventory (BDI-II),False,
NCT05834335,Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment,Protection Against Severe Coronavirus Disease 2019 Following in Patients With Multiple Sclerosis Statified According to Disease Modifying Treatment,COMPLETED,2020-03-01,2022-12-01,2023-04-01,2023-11-18,2023-04-28,OBSERVATIONAL,,400.0,ACTUAL,National MS Center Melsbroek,OTHER,,,Multiple Sclerosis,,Belgium,Melsbroek,Vlaams Brabant,1,,,For each DMT category the proportion of patients with a worse COVID-19 outcome will be compared between those 'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection.,,False,
NCT01356940,A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis,A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis,COMPLETED,2010-11,2013-04,2013-04,2018-10-31,2011-05-20,INTERVENTIONAL,PHASE4,43.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,Acorda Therapeutics,INDUSTRY,Multiple Sclerosis,Ambulation,United States,Kirkland,Washington,1,dalfampridine ER|placebo,DRUG|DRUG,Peak Activity Index,Stepcount,True,2015-04-09
NCT04966338,Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis,"A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active-controlled Clinical Trial to Evaluate Equivalency of the Efficacy and Safety of Ocrelizumab (CinnaGen, Iran) in Comparison to Reference Product, Ocrevus® (Roche, Switzerland) in Patients With Relapsing Multiple Sclerosis",COMPLETED,2019-08-19,2020-11-09,2021-10-01,2022-10-18,2021-07-19,INTERVENTIONAL,PHASE3,170.0,ACTUAL,Cinnagen,INDUSTRY,,,Multiple Sclerosis|Relapsing-Remitting,RRMS|Annualized Relapse Rate|Monoclonal|Humanized|Ocrelizumab,Iran,Rasht,Gilan Province,15,"Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (Roche, Switzerland)",BIOLOGICAL|BIOLOGICAL,Annualized Relapse Rate at 48 weeks,"Time to onset of sustained disability progression for at least 12 weeks|Time to onset of sustained disability progression for at least 24 weeks|Proportion of relapse-free patients by 96 weeks|Total number of new Gadolinium (Gd)-enhancing lesions as detected by brain MRI|Total number of new, and/or enlarging T2 hyperintense lesions as detected by brain MRI|Change in total T2 lesion volume as detected by brain MRI from baseline to week 96|Number of Participants With Adverse Events (AEs)|Number of Participants With Infusion Related Reactions (IRRs)|Immunogenicity Assessment",False,
NCT01264848,Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI),Endovascular Correction of Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Evaluation of Influence of These Treatments on the Symptoms of Multiple Sclerosis,COMPLETED,2010-03,2010-10,2012-12,2015-02-10,2010-12-22,INTERVENTIONAL,PHASE1|PHASE2,100.0,ACTUAL,"Euromedic Specialist Clinics, Poland",OTHER,,,Multiple Sclerosis,multiple sclerosis|venous insufficiency,Poland,Katowice,,1,balloon angioplasty and/or stenting|balloon angioplasty and/or stenting,PROCEDURE|PROCEDURE,"Change in clinical symptoms of multiple sclerosis measured by Extended Disability Severity Score (EDSS), Multiple Sclerosis Impact Scale-29 (MSIS-29), Fatigue Severity Scale (FSS) and heat intolerance",,False,
NCT06652308,Mood Disorders in Multiple Sclerosis Patients,Frequency of Unipolar and Bipolar Mood Disorders in Patients with Multiple Sclerosis: a Retrospective Cohort Study,COMPLETED,2024-07-01,2024-08-30,2024-09-30,2024-10-22,2024-10-22,OBSERVATIONAL,,85.0,ACTUAL,"Islamic Azad University, Sanandaj",OTHER,,,Multiple Sclerosis (MS)|Unipolar Depression|Bipolar Disorder|Mood Disorders,Multiple Sclerosis|Mood Disorders|Unipolar Depression|Mental Health,China,Jinan,,1,,,6-year Frequency of Mood Disorders,,False,
NCT05072691,Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis,Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis,UNKNOWN,2020-07-14,2024-01-01,2024-01-01,2021-10-11,2021-10-11,OBSERVATIONAL,,100.0,ESTIMATED,Francis Corazza,OTHER,,,Multiple Sclerosis,,Belgium,Brussels,,1,CSF immunoglobulin (Ig) free light chains (FLC) dosage,DIAGNOSTIC_TEST,Expanded Disability Status Scale (EDSS)|Fatigue Severity Scale (FSS)|Hospital Anxiety and Depression Scale (HADS)|Symbol-Digit Modalities Test (SDMT)|Nine Hole Peg Test (NHPT)|Timed 25-Foot Walk (T25FW)|Six Spot Step Test (SSST)|Ambulation Score (AS)|Annualized relapse rate (ARR)|MRI data: T2 lesions|MRI data : gadolinium enhancing lesions|P100 latency (VEP)|Visual acuity|Visual field|Color discrimination|GCL thickness (OCT)|RNFL thickness (OCT)|immunoglobulin (Ig) free light chains (FLC),,False,
NCT03951974,A Social Emotion Regulation Intervention in MS,A Social Emotion Regulation Intervention in MS,UNKNOWN,2019-07-09,2021-07-09,2021-07-09,2021-05-07,2019-05-16,INTERVENTIONAL,NA,42.0,ESTIMATED,Kessler Foundation,OTHER,,,Multiple Sclerosis|Emotional Disturbances,emotion regulation|social regulation of emotion,United States,East Hanover,New Jersey,1,Social Emotion Regulation Strategy Development|Control,BEHAVIORAL|BEHAVIORAL,Well-being: Depression|Well-being: Stress|Well-being: Quality of life,Perceived social support,False,
NCT07152015,"Multiple Sclerosis, Sarcopenia and Respiration",Examination of Sarcopenia and Respiratory Functions in Multiple Sclerosis,NOT_YET_RECRUITING,2025-09-05,2025-09-15,2025-09-20,2025-09-03,2025-09-03,OBSERVATIONAL,,40.0,ESTIMATED,Uskudar University,OTHER,,,Multiple Sclerosis,multiple sclerosis|sarcopenia|inspiratory muscle strength,,,,0,,,Forced Vital Capacity|Forced Expiratory Volume in 1 second (FEV1)|FEV1/FVC Ratio (%)|Maximal Inspiratory Pressure|Maximal Expiratory Pressure,"and grip strength measurement|Skeletal Muscle Index (SMI, kg/m²)",False,
NCT04391023,Cerebellar tDCS and Balance Training in PwMS,The Effects of 2 mA and 4 mA Cerebellar Transcranial Direct Current Stimulation and Balance Training to Reduce Fall Risk in People With Multiple Sclerosis,COMPLETED,2022-09-26,2023-07-16,2023-07-16,2024-06-18,2020-05-18,INTERVENTIONAL,NA,18.0,ACTUAL,University of Iowa,OTHER,,,Multiple Sclerosis,Brain Stimulation|Balance Training,United States,Iowa City,Iowa,1,Sham Transcranial Direct Current Stimulation (tDCS)|Balance Training|2 mA Transcranial Direct Current Stimulation|4 mA Transcranial Direct Current Stimulation,DEVICE|BEHAVIORAL|DEVICE|DEVICE,Score on the Berg Balance Scale|Time to Complete the Timed Up and Go Test (TUG),Time to Complete the Six Minute Walk Test (6MWT)|Score on the Fatigue Severity Scale (FSS),True,2024-06-18
NCT03889327,Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis,Intervention to Reduce Distress from Perceived Cognitive Impairment in Multiple Sclerosis,COMPLETED,2018-03-26,2019-08-15,2019-09-01,2024-12-06,2019-03-26,INTERVENTIONAL,NA,51.0,ACTUAL,"University of Missouri, Kansas City",OTHER,University of Kansas,OTHER,Multiple Sclerosis,Perceived Cognitive Impairment|Neuropsychology,United States,Kansas City,Kansas,1,Neuropsychological Feedback & Psychoeducation (Cognition)|Psychoeducation (Health),BEHAVIORAL|BEHAVIORAL,Feasibility and Acceptability Questionnaire,Cognition Quiz|Perceived Cognitive Impairment-Distress (PCI-D),False,
NCT00986960,Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS),"Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study",WITHDRAWN,2009-12,2010-09,2010-12,2021-01-05,2009-09-30,INTERVENTIONAL,PHASE2,0.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,multiple sclerosis|relapsing remitting|RRMS,United States,Buffalo,New York,1,repository corticotropin injection|Saline,DRUG|DRUG,To define the effect of add-on pulsed IM ACTH vs. placebo to IFNβ-1a I.M. on a voxel-wise MTR dynamic mapping of the lesions and NABT in patients with RRMS,"To define the effect of add-on pulsed IM ACTH vs. placebo to IFNβ-1a I.M. in RRMS on anterior optic pathway pathology, as measured by OCT and LCLA in patients with RRMS.",False,
NCT04413682,Telerehabilitation vs Supervised Exercises in MS,Effectiveness of Structured Exercise Program on Quality of Life and Activities of Daily Living in Persons With Multiple Sclerosis: Telerehabilitation vs Supervised Program,COMPLETED,2019-02-01,2020-02-10,2020-05-30,2020-06-04,2020-06-04,INTERVENTIONAL,NA,30.0,ACTUAL,Istanbul University,OTHER,Istanbul University - Cerrahpasa|Medipol University,OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Telerehabilitation|Supervised exercises|Structured exercise|Quality of Life|Activities of Daily Living,Turkey (Türkiye),Istanbul,,1,Structured Supervised Exercise|Structured telerehabilitation,BEHAVIORAL|BEHAVIORAL,"Functional Independence Measure (FIM)|Nottingham Health Profile, First section (NHP-I)|Quality of life scale (QoLS)",,False,
NCT04776213,Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension),"A 2-year Follow-up Study to Assess Cognition and Health-related Quality of Life in Participants With Highly-active Relapsing Multiple Sclerosis, Having Participated in the CLARIFY MS Trial (CLARIFY MS Extension)",COMPLETED,2021-02-23,2023-06-20,2023-06-20,2024-05-28,2021-03-01,INTERVENTIONAL,PHASE4,280.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Health related quality of life|Mavenclad®|Relapsing Multiple Sclerosis|Cladribine|Cognitive impairment cognition|Fatigue,Austria,Vienna,,60,Mavenclad®,DRUG,"Percentage of Participants With No or Minimal Decline in Cognitive Function, Defined As an Improved or Stable Symbol Digit Modalities Test (SDMT) Score or a Decline of 4 Points or Less in the SDMT Score, From Baseline of Parent Study to Month 48",Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by Multiple Sclerosis Quality of Life 54 Questionnaire (MSQoL-54) Physical and Mental Health Composite Summary Scores at 4 Years|Change From Month 24 in Health Related Quality of Life (HRQoL) as Measured by Multiple Sclerosis Quality of Life 54 Questionnaire (MSQoL-54) Physical and Mental Health Composite Summary Scores at 4 Years,True,2024-05-28
NCT04211740,Phase II Clinical Trial of OCH-NCNP1,Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis,COMPLETED,2019-12-06,2023-05-31,2023-05-31,2023-11-09,2019-12-26,INTERVENTIONAL,PHASE2,30.0,ACTUAL,"National Center of Neurology and Psychiatry, Japan",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",,Japan,Tokyo,,1,OCH-NCNP1|Placebo,DRUG|DRUG,The rate of the patients who identified new or enlarging T2 lesions on MRI scans compared to baseline,annual relapse rate|Detection of asymptomatic|Expanded Disability Status Scale (EDSS) / Functional Scale (FS)|Duration of sustained reduction in disability (SRD)|Change of MRI|Change of No evidence of disease activity (NEDA),False,
NCT02913157,Hydroxychloroquine in Primary Progressive Multiple Sclerosis,"Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)",COMPLETED,2016-11,2021-06,2021-06,2021-07-30,2016-09-23,INTERVENTIONAL,PHASE2,35.0,ACTUAL,University of Calgary,OTHER,,,"Multiple Sclerosis, Primary Progressive",,Canada,Calgary,Alberta,1,Hydroxychloroquine,DRUG,Timed 25-Foot Walk (T25FW),9-Hole Peg Test|Symbol Digit Modalities Test|Functional Systems and Expanded Disability Status Scale (EDSS)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life Scale 54 item version,False,
NCT05319093,Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients,Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients,UNKNOWN,2022-04,2023-07,2023-12,2022-04-22,2022-04-08,OBSERVATIONAL,,40.0,ESTIMATED,Brigham and Women's Hospital,OTHER,Bristol-Myers Squibb,INDUSTRY,Fatigue|Multiple Sclerosis,fatigue|multiple sclerosis|brain|ozanimod|diffusion MRI,,,,0,Ozanimod,DRUG,Three-months change in Modified Fatigue Impact Scale (MFIS) score,Three-months change in Chalder Fatigue Scale (CFS) score|Three-months change in Fatigue Severity Scale (FSS) score|Three-months change in NeuroQOL-fatigue questionnaire score|Visual Analog Scale (VAS) for fatigue score|Three-months change in NeuroQOL-cognitive function questionnaire score,False,
NCT00954421,Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor,Use of Two DBS Electrodes to Treat Post-Traumatic Tremor,COMPLETED,2006-11,2012-06,2013-12,2014-07-25,2009-08-07,INTERVENTIONAL,NA,16.0,ACTUAL,University of Florida,OTHER,National Institute of Neurological Disorders and Stroke (NINDS)|Medtronic,NIH|INDUSTRY,Multiple Sclerosis,,United States,Gainesville,Florida,1,Deep Brain Stimulation,DEVICE,Fain-Tolosa-Marin Tremor Rating Scale (TRS) Change Score for Both VIM and VO ON (Baseline Minus 6 Months Post-implant),"Fain-Tolosa-Marin Tremor Rating Scale (TRS) Change Score for Either VIM or VO On, and for Both VIM and VO Off (Baseline Minus 6 Months Post-implant)",True,2014-06-27
NCT06121349,WOE of Anti-CD20 Therapies,The Wearing-off Effect of Anti-CD20 Therapies in Patients With Multiple Sclerosis,COMPLETED,2023-12-04,2025-06-13,2025-06-13,2025-07-11,2023-11-07,OBSERVATIONAL,,157.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,NIS|Anti-CD20 Therapies|Multiple Sclerosis|OCR|Ocrevus|OMB|KESIMPTA,United States,East Hanover,New Jersey,1,ocrelizumab|ofatumumab,DRUG|DRUG,"Proportion of patients who experience wearing-off effect|Proportion of patients with worsening ≥1 category for PROMIS physical health NRS|Proportion of patients with worsening ≥ 1 category for PROMIS mental health NRS|Proportion of patients with worsening ≥ 1 category for PROMIS fatigue NRS|Proportion of patients with worsening ≥1 category for PROMIS pain NRS|Median score change for the physical health, mental health, fatigue and pain domains of PROMIS NRS|Proportion of patients with worsening ≥ 1 category for Neuro-QoL fatigue scale|Median score change for Neuro-QoL fatigue scale|Proportion of patients with worsening ≥ Minimal Clinically Important Difference (MCID) for Fatigue Severity Scale (FSS)|Mean score change for Fatigue Severity Scale (FSS)|Proportion of patients with worsening ≥ significant individual difference (SID) for Neuro-QoL mobility scale|Proportion of patients with worsening ≥ SID for Neuro-QoL depression scale|Proportion of patients with worsening ≥ SID for Neuro-QoL cognition scale|Mean score change for Neuro-QoL mobility, depression and cognition domains",Mean score change for both domains (physical impact and psychological impact) of Multiple Sclerosis Impact Scale (MSIS-29)|Proportion of patients with worsening ≥ MCID for the MSIS-29|Mean score change for each of the 4 domains of the Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS),False,
NCT01582126,Group Balance Training for People With Multiple Sclerosis,Group Balance Training for People With Multiple Sclerosis,COMPLETED,2012-08,2013-07,2013-07,2015-03-27,2012-04-20,INTERVENTIONAL,NA,87.0,ACTUAL,Örebro County Council,OTHER_GOV,Uppsala-Örebro Regional Research Council|Norrbacka-Eugenia Foundation,OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|physical therapy|postural control,Sweden,Eskilstuna,,7,Group balance training,OTHER,Change from Baseline in Bergs balance scale,Change from Baseline in Four Square step test|Change from baseline in Timed chair stands test|Change from baseline in Timed Up and Go test|Change from baseline in Functional Gait Assessment|Change from baseline in Postural sway|Change from baseline in Activities-specific Balance scale|Change from baseline in 12-item Multiple Sclerosis Walking scale|Change from Baseline in Bergs balance scale|Change from Baseline in Four Square step test|Change from baseline in Times Chair stands test|Change from baseline in Timed Up and Go test|Change from baseline in Functional Gait Assessment|Change from baseline in postoral sway|Change from baseline in Activities-specific Balance scale|Change from baseline in 12-item Multiple Sclerosis Walking scale,False,
NCT04503187,Motor Skill Acquisition Between Individuals With Neurological Disorders and Healthy Individuals,Comparison of Motor Skill Acquisition Between Individuals With Neurological Disorders,UNKNOWN,2013-04-04,2023-12-31,2024-12-31,2020-08-07,2020-08-07,OBSERVATIONAL,,130.0,ESTIMATED,Texas Woman's University,OTHER,,,Stroke|Multiple Sclerosis,,United States,Houston,Texas,1,Visuomotor leg reaching task,BEHAVIORAL,Changes in movement errors|Peripheral nerve activity,Walking performance|Mini-mental State Examination|Fugl-Meyer Lower Extremity Function Assessment,False,
NCT06588387,A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis,Observational Retrospective Study to Assess the Use of Siponimod (Mayzent) on Patients With Secondary Progressive Multiple Sclerosis in Clinical Practice in Spain - RESYZE Study,COMPLETED,2022-11-03,2023-09-08,2023-09-08,2024-09-19,2024-09-19,OBSERVATIONAL,,210.0,ACTUAL,Novartis,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Number of Patients by Education Status|Number of Patients by Working Status|Body Mass Index (BMI)|Number of Patients by Smoking Habit|Number of Patients by Alcohol Consumption|Number of Patients by Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) Genotype|Time Since Multiple Sclerosis (MS) Diagnosis|Time Since Secondary Progressive Multiple Sclerosis (SPMS) Diagnosis|Number of Patients by Number of Relapses in the 12 Months Before Starting Siponimod Treatment|Number of Patients by Number of Relapses in the 24 Months Before Starting Siponimod Treatment|Number of Patients by Number of Gadolinium T1 (Gd-T1) Lesions 24 Months Before Starting Siponimod Treatment|Baseline Expanded Disability Status Scale (EDSS) Score at the Start of Siponimod Treatment|Number of Patients With Cognitive Decline Diagnosis|EDSS Cognitive Subscale Score in Patients With Cognitive Decline|Number of Patients by Comorbidity,Number of Patients who Discontinued Siponimod Treatment|Number of Patients by Type of Siponimod Treatment Discontinuation|Number of Patients by Reason for Temporal Discontinuation of Siponimod Treatment|Number of Patients by Reason for Permanent Discontinuation of Siponimod Treatment|Number of Patients Who Started a New Disease Modifying Treatment After Permanent Discontinuation of Siponimod Treatment|Number of Patients by New Disease Modifying Treatment After Permanent Discontinuation of Siponimod Treatment|Number of Patients Who Received Concomitant Treatment for Symptomatic Treatment of MS|Number of Patients by Type of Concomitant Treatment Received for Symptomatic Treatment of MS|Number of Patients by Maintenance Siponimod Dose|Number of Patients who Needed a Siponimod Dose Modification|Number of Patients by Reason for Siponimod Dose Modification|Number of Patients who Needed First Dose Observation|Number of Patients who Reported an Adverse Event During First Dose Observation|Number of Patients who Reported an Adverse Event During Treatment With Siponimod|Number of Patients who Reported an Adverse Event of Special Interest During Treatment With Siponimod|Number of Patients who Reported a Serious Adverse Event During Treatment With Siponimod|Number of Patients With Adverse Events Which Led to Permanent Discontinuation of Siponimod Treatment|Number of Patients With Adverse Events Which Led to Temporary Discontinuation or Dose Adjustment of Siponimod Treatment|Number of Patients With Serious Adverse Events Which Led to Permanent Discontinuation of Siponimod Treatment|Number of Patients With Serious Adverse Events Which Led to Temporary Discontinuation or Dose Adjustment of Siponimod Treatment|Number of Patients Who Died During Treatment With Siponimod|Number of Patients by Lymphopenia Grade During Treatment With Siponimod|Number of Patients With Confirmed Disability Progression During Treatment With Siponimod|Time to First Relapse|Number of Patients Free From Relapses During the 12 Months of Treatment With Siponimod|Number of Patients With Radiologically Detected MS Disease Activity During Treatment With Siponimod|Number of Patients With New Gd-T1 Lesions Detected After Treatment With Siponimod|Number of Patients With New or Enhanced T2 Lesions Detected After Treatment With Siponimod|Number of Patients With COVID-19 During the Study|Number of Patients by COVID-19 Vaccination Status at the Moment of COVID-19 Infection|Number of Patients who Required Hospitalization due to COVID-19 Infection During the Study,False,
NCT06017726,Insulin Resistance in Egyptian Patients With Multiple Sclerosis,"Insulin Resistance in Non-diabetic Multiple Sclerosis Patients: Prevalence, Pre and Post-treatment Effect on Clinical, Cognitive Profile, Laboratory, and Radiological Markers",NOT_YET_RECRUITING,2024-12,2026-12,2027-06,2024-07-30,2023-08-30,OBSERVATIONAL,,100.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis|Insulin Resistance,,,,,0,treatment of insulin resistance with appropriate modality according to each patient,OTHER,prevalence of insulin resistance among Egyptians with multiple sclerosis,effect of insulin resistance on Multiple sclerosis disease activity|effect of insulin resistance on Multiple sclerosis disease progression|effect of treating insulin resistance on Multiple sclerosis disease activity|effect of treating insulin resistance on Multiple sclerosis disease progression,False,
NCT03686826,Feasibility and Reliability of Multimodal Evoked Potentials,Feasibility and Reliability of Multimodal Evoked Potentials,COMPLETED,2016-09-06,2017-09-15,2018-12-31,2019-01-23,2018-09-27,OBSERVATIONAL,,40.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,evoked potentials (EP)|motor evoked potentials (MEP)|Somato-sensory evoked potentials (SSEP)|multimodal evoked potentials (mmEP),Switzerland,Basel,,1,Acquisition of MEP und SSEP,PROCEDURE,intraclass correlation coefficient (ICC) of MEP and SSEP,,False,
NCT05106465,A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage,Konect-MF: A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and MRI Measures of Brain Tissue Damage,COMPLETED,2021-12-15,2024-04-03,2024-04-03,2024-05-17,2021-11-03,OBSERVATIONAL,,200.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis (MS),,Germany,Dresden,,1,Konectom platform,DEVICE,Correlation Between Konectom Tests and MRI Measures of Brain Tissue Damage,Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From Fluid-attenuated Inversion Recovery (FLAIR) Hyperintense MS Lesions Using 3D-T1 and 3D FLAIR Data|Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From the Normal Appearing White Matter Using 3D-T1 and 3D FLAIR Data|Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From the Cortex Using 3D-T1 and 3D FLAIR Data|Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From Deep Grey Matter Using 3D-T1 and 3D FLAIR Data,False,
NCT05634967,Kesimpta (Ofatumumab) Pregnancy Registry,Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated With Kesimpta (Ofatumumab) Using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry,RECRUITING,2023-01-05,2033-02-28,2033-02-28,2025-01-14,2022-12-02,OBSERVATIONAL,,725.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Pregnancy,PASS|Kesimpta|ofatumumab|Pregnancy|Multiple Sclerosis,United States,La Jolla,California,1,Kesimpta,OTHER,Number of participants with major structural defects,Number of participants with spontaneous abortion/miscarriage|Number of stillbirth cases|Number of elective termination cases|Number of preterm delivery cases|Number of preeclampsia / eclampsia cases|Number of cases with pattern of 3 or more minor structural defects|Number of participants small for gestational age|Number of participants with postnatal growth small for age at one year of age|Developmental performance at approximately one year of age: Michaelis developmental milestones questionnaires|Developmental performance at approximately one year of age: Denver developmental screening test|Number of serious or opportunistic infections in the first year of life.,False,
NCT03087136,A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil,A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil,ACTIVE_NOT_RECRUITING,2017-03-01,2025-03-31,2025-03-31,2024-01-08,2017-03-22,OBSERVATIONAL,,100.0,ESTIMATED,Pontificia Universidade Católica do Rio Grande do Sul,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Multiple Sclerosis,multiple sclerosis|pediatric,Brazil,Uberlândia,Minas Gerais,8,anti-aquaporin-4 antibody|anti-myelin oligodendrocyte glycoprotein,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Convertion rate to MS,Clinical features|epidemiology|autoantibodies|treatments,False,
NCT04948606,Exploring Diroximel Fumarate Real-world Experience in Canada and Israel,"A Prospective, Observational Study Evaluating Persistence on Treatment, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World Setting (EXPERIENCE-CA+IL Study)",TERMINATED,2021-12-09,2023-04-14,2023-04-14,2023-05-10,2021-07-02,OBSERVATIONAL,,64.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of MS,Clinically isolated syndrome|Multiple Sclerosis|Relapsing forms of Multiple Sclerosis|Active secondary progressive disease,Israel,Haifa,,6,Diroximel Fumarate,DRUG,Percentage of Participants on Treatment with DRF,"Percentage of Participants on Treatment with DRF|Percentage of Participants on Treatment with DRF|Annualized Relapse Rate (ARR) with DRF|Percentage of Participants Relapsed|Change in Cognitive Processing Speed Test (CPST) Score|Change in Score for Each Domain of Quality of Life in Neurological Disorders (Neuro- QoL™) Questionnaire|Change in Disability, as Measured by Expanded Disability Status Scale (EDSS)|Mean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Score|Number of Participants with Gastrointestinal (GI) Adverse Events (AEs)|Number of Participants with AEs Leading to Treatment Discontinuation|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Relevant Concomitant Medication Use|Number of Participants Categorized by the Types of Actions Taken Due to GI AEs|Median Absolute Lymphocyte Count (ALC) Over Time|Percent Change from Baseline in Median ALC|Number of Participants with Lymphopenia According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) Severity Grading",False,
NCT03759522,Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.,Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.,RECRUITING,2019-02-03,2026-04-10,2026-04-10,2024-12-18,2018-11-30,INTERVENTIONAL,PHASE1,120.0,ESTIMATED,University of Alabama at Birmingham,OTHER,,,Fibromyalgia|Chronic Fatigue Syndrome|Multiple Sclerosis|Healthy,,United States,Birmingham,Alabama,1,DPA-714 PET/MRI,DRUG,"Neuroinflammation will be measured in healthy volunteers and compared to neuroinflammation in individuals with pain and fatigue, as measured with [F-18]DPA-714-PET/MRI.",,False,
NCT00035529,A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis,"A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis",TERMINATED,2001-11,2003-12,2003-12,2010-12-06,2002-05-06,INTERVENTIONAL,PHASE2,,,Bristol-Myers Squibb,INDUSTRY,,,Multiple Sclerosis,MS,United States,New Haven,Connecticut,10,Placebo|BMS 188667 (Abatacept)|BMS 188667 (Abatacept),DRUG|DRUG|DRUG,Preliminary efficacy- Reduction in cumulative nr of new or recurrent Gd-enhancing lesions.,Preliminary efficacy: 1) Decrease in annualized relapse rate and 2) Reduction in cumulative nr of new or enlarging T2-weighted MRI lesions.,False,
NCT02454465,Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions,"""Time to ACT"": Multi-site Evaluation of an Acceptance and Commitment Therapy Group Intervention for Adjustment Difficulties in Neurological Conditions",COMPLETED,2015-07,2016-02,2016-09,2021-09-05,2015-05-27,INTERVENTIONAL,NA,26.0,ACTUAL,University of Hertfordshire,OTHER,,,Brain Injuries|Multiple Sclerosis|Parkinson Disease|Stroke,,United Kingdom,Abbots Langley,,1,Acceptance and Commitment Therapy group,OTHER,"Change in Psychological Flexibility on the Acceptance and Action Questionnaire between baseline, 6 weeks and 10 weeks.","Change in Low mood on the Patient Health Questionnaire -9 between baseline, 6 weeks and 10 weeks.|Anxiety on the Generalised Anxiety Disorder Questionnaire -7 between baseline, 6 weeks and 10 weeks.|Severity of individual difficulties on a Visual Analog Scale between baseline, 6 weeks and 10 weeks.",False,
NCT00498199,"Visual Impairment, Oscillopsia and Multiple Sclerosis","Visual Impairment, Oscillopsia and Multiple Sclerosis",TERMINATED,2007-04,,,2010-09-30,2007-07-09,OBSERVATIONAL,,100.0,ESTIMATED,Hospices Civils de Lyon,OTHER,,,Multiple Sclerosis,Multiples sclerosis|oscillopsia|eye movements|motion detection|retinal slip|nystagmus,France,Lyon,,1,visual tests,PROCEDURE,,,False,
NCT07161999,Study of COYA 302 for the Treatment of ALS,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)",NOT_YET_RECRUITING,2025-10-01,2027-01,2027-07,2025-09-16,2025-09-09,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,Coya Therapeutics,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),,United States,Lincoln,Nebraska,2,COYA 302|Placebo,DRUG|DRUG,The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R),Serum neurofilament light chain (NfL)|Maximal Inspiratory Pressure (MIP)|Combined Assessment of Function and Survival (CAFS)|Slow Vital Capacity (SVC),False,
NCT04691102,Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation,Dynamic Postural Stability Assessment in Neurorehabilitation,UNKNOWN,2021-05-01,2023-06-30,2023-10-01,2023-04-18,2020-12-31,OBSERVATIONAL,,120.0,ESTIMATED,I.R.C.C.S. Fondazione Santa Lucia,OTHER,,,Stroke|Brain Injuries|Mild Cognitive Impairment|Parkinson Disease|Multiple Sclerosis,,Italy,Roma,Rm,1,,,Inertial sensors-based assessment,Berg Balance Scale (BBS)|Dynamic Gait Index (DGI)|Balance Evaluation System Test (Mini-BESTest)|Electroencephalography (EEG),False,
NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod),COMPLETED,2021-04-19,2021-09-06,2022-08-15,2024-06-20,2021-03-11,INTERVENTIONAL,PHASE4,41.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,COVID-19|SARS-CoV-2 mRNA vaccine|Siponimod|Secondary Progressive Multiple Sclerosis|SPMS|adult|MS,Germany,Mittweida,Saxony,10,BAF312|Baseline disease modifying therapies (DMTs)|BNT162|mRNA-1273,DRUG|DRUG|BIOLOGICAL|BIOLOGICAL,Percentage of Participants Achieving Seroconversion One Week After Receiving Second Vaccine (EAS),SARS-CoV-2 Functional Antibodies (% Inhibition) by Visits (SAF/EAS)|Number of Patients Reactive to INFg or IL-2 SARS-CoV-2 by Visit SAF/EAS,True,2024-05-17
NCT02239393,Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study,MEsenchymal Stem Cell Therapy for CAnadian MS Patients,COMPLETED,2015-06,2019-12,2019-12,2020-03-04,2014-09-12,INTERVENTIONAL,PHASE2,31.0,ACTUAL,Ottawa Hospital Research Institute,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Mesenchymal Stem Cells|MSC,Canada,Winnipeg,Manitoba,2,Mesenchymal Stem Cells,BIOLOGICAL,Safety|Efficacy,Efficacy|Efficacy|Efficacy|Efficacy|Efficacy,False,
NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2018-12-28,2027-12-30,2028-09-30,2025-08-15,2018-08-28,INTERVENTIONAL,PHASE3,1882.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,ofatumumab|relapsing multiple sclerosis,United States,Birmingham,Alabama,296,"Ofatumumab|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|13-valent pneumococcal conjugate vaccine (13-PCV)|23-valent pneumococcal polysaccharide vaccine (23-PPV)|Seasonal Quadrivalent influenza vaccine|Keyhole limpet hemocyanin (KLH) neo-antigen",BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,"Number of patients that experience an adverse event or abnormal laboratory, vital and/or ECG results and positive suicidiality outcomes","Number of relapse rates per year|Patients with confirmed 3 and 6 month disability worsening|Patients with confirmed 6, 12, and 24 month disability improvement and improvement during the first 5 years of the study.|Patients with changes in Expanded Disability Status Scale (EDSS) scores|Changes in and time to 6 month confirmed worsening of Symbol Digit Modalities Test Scores|Changes in the Magnetic Resonance Image (MRI) related to brain volume loss|Changes in the Magnetic Resonance Image (MRI) related to T2 lesions|Changes in the Magnetic Resonance Image (MRI) related to Gd-enhancing lesions|Changes in neurofilament light change serum concentration",False,
NCT04735406,The MS-LINK™ Outcomes Study,The MS-LINK™ Outcomes Study: A Comprehensive Prospective Longitudinal Assessment of Patient and Clinical Reported Outcomes in Multiple Sclerosis Patients Across North America,COMPLETED,2021-03-24,2024-01-31,2024-05-31,2024-08-22,2021-02-03,OBSERVATIONAL,,2182.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,,,Multiple Sclerosis,Expanded Disability Status Scale|Multiple Sclerosis|Patient Reported Outcomes Measurement Information System,United States,Birmingham,Alabama,9,,,Patient-determined Disease Steps (PDDS) Scale Score|Patient Reported Outcomes Measurement Information System (PROMIS) Multiple Sclerosis (MS) Fatigue Score|Patient Reported Outcomes Measurement Information System (PROMIS) Multiple Sclerosis (MS) Physical Function Score|Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Score|Patient Reported Outcomes Measurement Information System (PROMIS) MS Cognitive Function Score|Patient Health Questionnaire 9-Item (PHQ9) Score|Wasson Health Confidence Scale Score|Health-related Quality of Life Assessed by Centers for Disease Control and Prevention Health-Related Quality of Life Measure (CDC HRQoL-14)|Work Productivity and Activity Impairment Questionnaire-Multiple Sclerosis (WPAI-MS) Score|Number of Participants with Reasons for Discontinued Disease-Modifying Therapies (DMT)|Number of Participants with Current Use of Disease-Modifying Therapies (DMT)|Duration of Disease-Modifying Therapies (DMT) use|Number of Participants With Adherence to Treatment as Assessed by Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)|Occurrence of Relapses|Occurrence of Multiple Sclerosis (MS) Symptoms|Number of Utilization of Healthcare Resources by Participants|Well-being of Participant Assessed by Physical Activity Diary|Number of Participants with Response to Health Priorities and Goals|Expanded Disability Status Scale (EDSS) Score|Multiple Sclerosis Functional Composite (MSFC) Score|Timed 25-Foot Walk Test|9-Hole Peg Test (9HPT) Score|Paced Auditory Serial Addition Test (PASAT) Score|Symbol Digit Modalities Test (SDMT)|Processing Speed Test (PST)|Number of Participants with Magnetic resonance imaging (MRI) History|Number of Participants with History of Fall|Number of Participants with Adverse Events of Interest|Number of Participants with Symptoms of Coronavirus (COVID),,False,
NCT05648292,"The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis","The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis",RECRUITING,2022-12-07,2024-12-07,2025-06-07,2023-09-06,2022-12-13,OBSERVATIONAL,,90.0,ESTIMATED,Centre d'Investigation Clinique et Technologique 805,OTHER,University Paris 8 Vincennes Saint Denis|ARSEP foundation,OTHER|UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting|Healthy Controls",,France,Garches,Hauts De Seine,1,Neuropsychological tests and psychological questionnaires,BEHAVIORAL,"Relationships between personal identity, autobiographical memory and future thinking","Relationships between personal identity, psychological functioning and clinical characteristics",False,
NCT03637699,A Positive Psychology Intervention for Patients With Multiple Sclerosis,A Phase I Randomized Controlled Trial of a Positive Psychology Intervention for Patients With Multiple Sclerosis,COMPLETED,2018-03-12,2019-04-09,2019-04-09,2021-08-16,2018-08-20,INTERVENTIONAL,NA,30.0,ACTUAL,Brigham and Women's Hospital,OTHER,Consortium of Multiple Sclerosis Centers|Massachusetts General Hospital,OTHER|OTHER,Multiple Sclerosis,Positive Psychology|Positive Affect,United States,Boston,Massachusetts,1,Positive Psychology,BEHAVIORAL,Percentage of PP Exercises Completed by Subjects,Subject Ratings of Ease of Completion of PP Exercises|Changes in Affect|Change in Trait Optimism|Change in Depression|Change in Anxiety|Changes in Health-related Quality of Life|Change in Work Productivity|Change in Perceived Stress|Change in Resilience,True,2021-08-16
NCT07074587,Effects of Spinal Stabilization on the Pelvic Floor in Women With Multiple Sclerosis,"Investigation of the Effects of Spinal Stabilization Exercises Focusing on the Pelvic Floor on Core Stability, Urinary Symptoms, and Pelvic Floor Muscle Function in Women With Multiple Sclerosis and Lower Urinary Tract Symptoms",ENROLLING_BY_INVITATION,2025-06-30,2027-10-15,2027-12-15,2025-07-20,2025-07-20,INTERVENTIONAL,NA,36.0,ESTIMATED,Abant Izzet Baysal University,OTHER,,,Multiple Sclerosis|Urinary Incontinence|Lower Urinary Tract Symptoms,Multiple Sclerosis|Lower Urinary Tract Symptoms|Urinary Incontinence|Core Stability|Spinal Stabilization,Turkey (Türkiye),Merkez,Bolu,1,Pelvic floor muscle exercises|Spinal stabilization exercises focusing on the pelvic floor + Pelvic floor muscle exercises,BEHAVIORAL|BEHAVIORAL,Evaluation of Urinary Symptoms|Evaluation of Bladder Functions,Evaluation of the degree of urinary symptoms|Evaluation of Pelvic Floor Muscle Function|Evaluation of pelvic floor muscle strength|Evaluation of the endurance of the lateral core muscles|Evaluation of the endurance of the anterior core muscles|Evaluation of endurance of the posterior core muscles|Evaluation of Deep Lumbar Muscular Strength|Evaluation of Quality of Life|Evaluation of Subjective Perception of Recovery|Evaluation of Perceived Health Problem|Evaluation of Compliance with Training,False,
NCT01432704,Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),Phase IV Study of Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS,COMPLETED,2008-03,2011-05,2011-08,2011-09-13,2011-09-13,INTERVENTIONAL,PHASE2|PHASE3,70.0,ACTUAL,University of Turku,OTHER,Bayer,INDUSTRY,Multiple Sclerosis,MS|vitamin D|environment,,,,0,colecalciferol,DRUG,To evaluate the safety and tolerability of add-on -treatment with colecalciferol of MS patients treated with interferon beta-1b and|To estimate the effect of interferon-beta-1b with an add-on of colecalciferol versus interferon-beta-1b with an add-on of placebo on MRI T2 BOD at 12 months in comparison with MRI T2 BOD at baseline,Number of Gadolinium-enhancing lesions on T1 and /or new enlarging lesions on T2/PD based on MRI done 12 months following randomisation compared with the MRI done at the time of randomisation,False,
NCT00064909,MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis,Using MR Perfusion Imaging and Hypercapnia to Study Angiogenesis in Multiple Sclerosis Patients,COMPLETED,2003-07,,2006-03,2008-03-04,2003-07-15,OBSERVATIONAL,,50.0,,National Institutes of Health Clinical Center (CC),NIH,,,Multiple Sclerosis,Multiple Sclerosis|MRI|Perfusion|Imaging|Cerebral Blood Flow|Cerebral Blood Volume|CO2 Inhalation|Contrast Agent|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,,,,,False,
NCT00588393,FolateScan in Autoimmune Disease,Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases,COMPLETED,2006-09,2007-12,2007-12,2010-04-16,2008-01-08,INTERVENTIONAL,PHASE2,75.0,ACTUAL,Mayo Clinic,OTHER,Endocyte,INDUSTRY,Rheumatoid Arthritis|Osteoarthritis|Multiple Sclerosis|Crohn's Disease|Systemic Lupus Erythematosus,,United States,Rochester,Minnesota,1,FolateScan (Technetium Tc 99mEC20),DRUG,detection of joint inflammation due to active rheumatoid arthritis,detection of systemic organ inflammation due to rheumatoid arthritis,False,
NCT02880553,"Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis",,COMPLETED,2016-08-23,2017-03-09,2017-03-09,2017-07-28,2016-08-26,OBSERVATIONAL,,150.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,Italy,San Pellegrino,,1,,,statistical association between perceived social support and quality of life,,False,
NCT03562975,Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus,A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™,COMPLETED,2018-07-23,2023-01-11,2023-01-11,2024-12-10,2018-06-20,OBSERVATIONAL,,18.0,ACTUAL,University of South Florida,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis|Pathologic Processes|Demyelinating Diseases|Nervous System Diseases|Autoimmune Diseases|Immune System Diseases|Primary Progressive Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis,,United States,Tampa,Florida,1,Ocrelizumab,DRUG,"Stabilization of Scores Using the Test d'Evaluation de la Performance Des Membres Supérieurs Des Personnes Agées (TEMPA) -Translasted in English to Mean ""Performance Evaluation Test for the Elderly""",Stabilization of the Upper Extremity Functional Index (UEFI)|Stabilization of 9-Hole Peg Test Scores,True,2024-10-28
NCT05962281,Investigation The Effect of Conventional Vs. Individualized tDCS Intensity to Achieve Uniform E-Fields,Investigation The Effect of Conventional Vs. Individualized Transcranial Direct Current Stimulation Intensity to Achieve Uniform E-Fields,UNKNOWN,2024-03-01,2024-12-31,2025-07-31,2023-07-27,2023-07-27,INTERVENTIONAL,NA,30.0,ESTIMATED,Koen Cuypers,OTHER,BOF-BILA,UNKNOWN,Multiple Sclerosis|Neurophysiologic Abnormality,Multiple Sclerosis|Brain Stimulation|Non-invasive Brain Stimulation,,,,0,Transcranial direct current stimulation (tDCS),DEVICE,Transcranial Magnetic Stimulation (TMS) Assessment,Behavioral Assessment,False,
NCT06495593,Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis,Identifying Ocrelizumab-resistant Lymphocytes in Lymphoid Tissue in Multiple Sclerosis,RECRUITING,2025-02-04,2025-12-31,2025-12-31,2025-02-12,2024-07-10,INTERVENTIONAL,PHASE4,5.0,ESTIMATED,"University of California, San Francisco",OTHER,"Genentech, Inc.",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Ocrelizumab|Lymph node|Lymphocyte,United States,San Francisco,California,1,Ocrelizumab,DRUG,Lymphocyte analysis,,False,
NCT02307877,"Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate","Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis",COMPLETED,2014-09,2018-05,2018-05,2022-03-08,2014-12-04,OBSERVATIONAL,,157.0,ACTUAL,"University of Colorado, Denver",OTHER,,,Multiple Sclerosis,,United States,Aurora,Colorado,1,,,Whole Brain Atrophy (Rate of whole brain atrophy (T2 - T0): Two-time point percentage brain volume change (PBVC),,False,
NCT06125301,Multiple Sclerosis Self Monitoring Study,"The Multiple Sclerosis Self Monitoring Study: An Intervention Study on the Effect of Digital Self-monitoring-based Management of Relapsing and Remitting Multiple Sclerosis on Self-efficacy, Clinical Outcomes and Cost-effectiveness",RECRUITING,2022-08-15,2024-08-15,2024-08-15,2023-11-09,2023-11-09,INTERVENTIONAL,NA,225.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,,,Multiple Sclerosis,,Netherlands,Amsterdam,,1,MS Sherpa,DEVICE,the Multiple Sclerosis Self-Efficacy Control scale (MSSE-C),Decision making process - caregiver|Decision making process - patient,False,
NCT01407211,"Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient",The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients,UNKNOWN,2011-04,2013-04,2013-09,2012-07-18,2011-08-02,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,Tehran University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,multiple sclerosis|Myelin Oligodendrocyte Glycoprotein(MOG)|Vitamin A|CD4-Positive T-Lymphocytes|gene expression|Th1 Cells|Th2 Cells,Iran,Tehran,,1,vitamin A,DIETARY_SUPPLEMENT,serum Total cholesterol|serum HDL cholesterol|serum triglycerides level|RBP/ TTR ratio|PBMC's prolifration(BrdU colorimetric)|complete blood count (CBC)|serum SGOT concentration|serum SGPT concentration,"gene expression of T-bet, INF-gamma, IL-4, GATA3, IL-17, RORc, IL-10, FOXP3 (Relative quantification)",False,
NCT07136311,The Effect of Obesity on Contralateral Suppression in Patients With Multiple Sclerosis,Otoacoustics Emissions Contralateral Supression Test,COMPLETED,2022-06-01,2024-06-03,2025-06-30,2025-08-22,2025-08-22,INTERVENTIONAL,NA,49.0,ACTUAL,Ondokuz Mayıs University,OTHER,,,Multiple Sclerosis|Obesity|Hearing Loss,,Turkey (Türkiye),Samsun,,1,DPOAE with Contralateral Suppression,DIAGNOSTIC_TEST,Contralateral supression,DPOAE Amplitude Levels,False,
NCT00094172,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)",COMPLETED,2005-05,2009-05,2009-05,2017-04-28,2004-10-15,INTERVENTIONAL,PHASE2,82.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Immune Tolerance Network (ITN),NETWORK,Multiple Sclerosis,Early Multiple Sclerosis|MS|Clinically Isolated Syndrome,United States,Phoenix,Arizona,14,Atorvastatin|Placebo,DRUG|DRUG,The Occurrence of ≥ 3 New T2 Lesions With or Without Gd+ Enhancement or Clinical Exacerbation Through 12 Months.,Proportion of Participants Who Are Diagnosed With Multiple Sclerosis According to the McDonald Criteria|Proportion of Participants Diagnosed With Multiple Sclerosis According to the McDonald Criteria,True,2011-11-03
NCT03887065,Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients,Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide,UNKNOWN,2019-06-15,2019-12-15,2020-03-15,2019-05-07,2019-03-22,INTERVENTIONAL,EARLY_PHASE1,15.0,ESTIMATED,"Cook, Stuart, MD",OTHER,,,Multiple Sclerosis,,,,,0,JM-4,DRUG,Number of patients with treatment-related adverse events|Change in GAD(+) brain lesions measured via MRI scan,Changes in the ability of patients to complete a timed 25-foot walk|Treatment-induced changes in Expanded Disability Status Score in patients|Changes in neurological exam,False,
NCT01723709,The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort,The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort,COMPLETED,2010-06,2017-05,2017-05,2017-07-21,2012-11-08,OBSERVATIONAL,,973.0,ACTUAL,Duke University,OTHER,,,Multiple Sclerosis,multiple sclerosis|immune response|genetic|progression|relapse|biomarkers|disease|proteomics|genome|gene,United States,Concord,North Carolina,5,,,Serum-based proteomic biomarkers associated with disease initiation and progression in MS,,False,
NCT03551665,Protective Stepping in People With MS,Effects of Protective Step Training in People With Multiple Sclerosis,COMPLETED,2019-02-22,2024-07-24,2024-08-01,2025-06-24,2018-06-11,INTERVENTIONAL,NA,57.0,ACTUAL,VA Office of Research and Development,FED,Arizona State University,OTHER,Multiple Sclerosis,Multiple Sclerosis|Falls|Posture|Rehabilitation|Cognition|Neuroimaging,United States,Phoenix,Arizona,1,Protective step training,BEHAVIORAL,Training-related Change in Margin of Stability|Symbol Digit Modality Test,Training-related Changes in Reactive Step Length|Training-related Change in Reactive Step Latency,True,2025-06-10
NCT06764563,The Effect of a Mediterranean Diet on Quality of Life in Multiple Sclerosis Patients,The Effect of a Mediterranean Diet on Quality of Life in Multiple Sclerosis Patients,RECRUITING,2025-02-01,2027-01-01,2028-01-01,2025-02-25,2025-01-08,INTERVENTIONAL,NA,140.0,ESTIMATED,Tel-Aviv Sourasky Medical Center,OTHER_GOV,Ariel University,OTHER,Multiple Sclerosis,multiple sclerosis|mediterranean diet|quality of life,Israel,Tel Aviv,Israel,1,Mediterranean Medical Nutrition Therapy (counselling),BEHAVIORAL,MS QOL score,Disease Disability score|Chronic fatigue levels|Depression levels|Carotenoid plasma concentration.|Neurofilament light chain (NfL).|Cognitive function,False,
NCT05571826,Effectiveness of Telerehabilitation Interventions in Multiple Sclerosis,Effectiveness of Telerehabilitation Interventions in Persons With Multiple Sclerosis: Patient Perspective,UNKNOWN,2022-10-01,2023-10-01,2023-11-01,2022-10-07,2022-10-07,OBSERVATIONAL,,30.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,multiple sclerosis|upper extremity|telerehabilitation|patient perspective,Turkey (Türkiye),Izmir,,1,telerehabilitation,BEHAVIORAL,Telehealth Usability Questionnaire|Telemedicine Satisfaction Questionnaire,Expanded Disability Status Scale,False,
NCT02488343,Profile of Adherence to Therapy and Interventions to Promote Adherence in MS,Personal Profile of Adherence to Therapy and Tailored Interventions to Promote Adherence in Multiple Sclerosis Patients,UNKNOWN,2015-08,2024-06,2024-06,2022-08-02,2015-07-02,INTERVENTIONAL,NA,400.0,ESTIMATED,Carmel Medical Center,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Adherence|Therapies|Psychological Intervention,Israel,Haifa,,1,Behavioral Intervention,BEHAVIORAL,Adherence to therapy by assessment of remaining pills/medication claims electronic records|Adherence to therapy according to ProMas|Adherence to therapy according to MS-TAQ,Improvement in quality of life,False,
NCT05002764,Thalamic Nuclei Volumes in Multiple Sclerosis,Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis,UNKNOWN,2021-07-01,2023-07-01,2023-07-01,2021-08-12,2021-08-12,OBSERVATIONAL,,2000.0,ESTIMATED,"University Hospital, Bordeaux",OTHER,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,Multiple Sclerosis,Multiple sclerosis|Thalamus|Nuclei|Atrophy,France,Bordeaux,,1,,,Volume of thalamic nuclei,,False,
NCT02314585,Fall Risk Reduction in Multiple Sclerosis (FIRMS),Fall Risk Reduction in Multiple Sclerosis: Exercise Intervention vs. Attention Control Modification,UNKNOWN,2014-12,2018-01,2018-01,2015-08-26,2014-12-11,INTERVENTIONAL,NA,100.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,,United States,Urbana,Illinois,1,Exercise|Education,OTHER|OTHER,Chagne in Fall Risk,Identification of Fall Risk Factors,False,
NCT05155644,Safety of Therapeutic Step-down in Neuromyelitis Optica,Safety of Therapeutic Step-down in Neuromyelitis Optica,COMPLETED,2020-08-01,2021-11-30,2021-12-31,2022-01-21,2021-12-13,OBSERVATIONAL,,947.0,ACTUAL,"University Hospital, Strasbourg, France",OTHER,,,Neuromyelitis Optica,Neuromyelitis Optica|NMO|multiple sclerosis (MS)|Iatrogeny.|Autoimmune diseases,France,Strasbourg,,1,,,Retrospective evaluation of the risk of rebound during therapeutic escalations in neuromyelitis optica (NMO),,False,
NCT02137109,Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri,Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis,COMPLETED,2014-03,2015-10,2015-10,2015-10-20,2014-05-13,OBSERVATIONAL,,400.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Pediatric,,,,0,natalizumab,DRUG,Incidence of all serious adverse events (SAEs),,False,
NCT03436199,Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment,"A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment",COMPLETED,2018-03-29,2019-12-10,2019-12-10,2021-12-21,2018-02-19,INTERVENTIONAL,PHASE3,558.0,ACTUAL,"Adamas Pharmaceuticals, Inc.",INDUSTRY,,,Walking Impairment|Multiple Sclerosis,,United States,Cullman,Alabama,84,"ADS-5102, 137 mg|ADS-5102, 274 mg|Placebo",DRUG|DRUG|OTHER,"Timed 25 Foot Walk (T25FW, Feet/Second): the Proportion of Subjects With a ≥ 20% Increase in Walking Speed (Measured by T25FW) From Baseline at Week 16 (Responder Analysis)",Timed 25 Foot Walk: Change From Baseline at Week 16|Timed Up and Go (TUG): Change From Baseline at Week 16|2-Minute Walk Test (2MWT): Change From Baseline at Week 16,True,2021-12-21
NCT00630721,Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells,Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells,COMPLETED,2007-09,2010-05-15,2011-03-15,2018-10-18,2008-03-07,INTERVENTIONAL,NA,56.0,ACTUAL,"University of North Carolina, Chapel Hill",OTHER,,,Multiple Sclerosis,,United States,Chapel Hill,North Carolina,1,IFNbeta-1b,OTHER,Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs' on their maturation and the capacity to present,Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription.,False,
NCT01600716,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),,COMPLETED,2012-06-13,2014-04-04,2015-03-27,2019-04-30,2012-05-17,INTERVENTIONAL,PHASE3,144.0,ACTUAL,Allergan,INDUSTRY,,,Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder,,United States,Mountlake Terrace,Washington,10,OnabotulinumtoxinA|Placebo (Normal Saline),BIOLOGICAL|DRUG,Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes,Change From Baseline in Maximum Cystometric Capacity (MCC)|Change From Baseline in Maximum Detrusor Pressure During the First Involuntary Detrusor Contraction (IDC)|Change From Baseline in Incontinence Quality of Life Instrument (I-QOL) Total Summary Score,True,2016-03-22
NCT02264704,Exercise Intensity and Immune Function in Multiple Sclerosis,Exercise Intensity and Immune Function in Multiple Sclerosis,UNKNOWN,2014-11,2015-07,2015-07,2014-10-15,2014-10-15,INTERVENTIONAL,NA,63.0,ESTIMATED,University of the West of Scotland,OTHER,National Heatlh Service Ayrshire and Arran,OTHER_GOV,Multiple Sclerosis,MS|Exercise|Training|Multiple sclerosis|Immune response|Neurotrophin|Cytokine|Fatigue,United Kingdom,Irvine,Ayrshire,1,High intensity exericse|Moderate intensity exericse,OTHER|OTHER,Change in serum brain-derived neurotrophic factor (BDNF) level,Change in serum nerve growth factor (NGF) level|Change in serum interleukin-4 (IL-4) level|Change in serum interferon gamma (IFN-γ) level|Change in mobility|Change in exercise capacity|Change in fatigue|Change in health-related quality of life|Change in cognitive ability|Number of sessions attended|Change in cardiorespiratory fitness|Change in mood,False,
NCT02301247,Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),COMPLETED,2014-11,2017-04-02,2017-04-02,2017-07-02,2014-11-25,INTERVENTIONAL,NA,32.0,ACTUAL,Kessler Foundation,OTHER,International Progressive MS Alliance,UNKNOWN,"Multiple Sclerosis, Progressive|Cognition - Other|Memory Impairment","Multiple Sclerosis, Progressive|cognition|memory|treatment",United States,West Orange,New Jersey,1,Memory retraining exercises|Placebo control memory exercises,BEHAVIORAL|BEHAVIORAL,Change in scores on standardized neuropsychological tests of memory,"Change in scores on self-report of emotional functioning, measured via questionnaire|Change in scores on self-report of memory functioning, measured via questionnaire|Change in scores on self-report of quality of life, measured via questionnaire",False,
NCT04096443,Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis,A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2019-10-28,2023-09-21,2024-12-30,2024-10-18,2019-09-19,INTERVENTIONAL,EARLY_PHASE1,9.0,ACTUAL,Griffin Hospital,OTHER,Yale-Griffin Prevention Research Center,OTHER,Multiple Sclerosis,Fecal microbial transplant|FMT|Pilot study,United States,Derby,Connecticut,1,Fecal microbial transplant (FMT),BIOLOGICAL,Change in engraftment of donor microbiome in stool samples,Change in immune markers in blood samples assessed using assays of lymphocyte phenotyping and intracellular cytokines|Change in neurological status using Kurtzke Functional Systems Scale (FSS)|Change in neurological status using Kurtzke Expanded Disability Status Scale (EDSS)|Change in self-reported health-related quality of life assessed using the Health Status Questionnaire Short-Form 36 (SF-36)|Change in self-reported mental health status assessed using Mental Health Inventory (MHI)|Change in self-reported levels of fatigue assessed using Modified Fatigue Impact Scale (MFIS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],False,
NCT01749943,Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis,Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics,COMPLETED,2012-07,2013-07,2013-07,2013-08-22,2012-12-17,OBSERVATIONAL,,21.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Kirkland,Washington,1,,,Assessment of HHD,Validation of a Hand-held dynamometer for assessment of lower limb muscle strength.,False,
NCT06345157,"ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients","An ITAlian Observational, Multicenter, 12-month, Single-arm Study to Evaluate the Effectiveness and Safety of Treatment With Ofatumumab (Kesimpta®) in a pOpulation of RRMS Patients in a Real-world Setting - the ITAKOS Study",RECRUITING,2024-07-30,2026-06-30,2026-06-30,2025-01-14,2024-04-03,OBSERVATIONAL,,300.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis,|Relapsing-Remitting,|RRMS,|ofatumumab",Italy,Ancona,AN,27,Ofatumumab,DRUG,Annualized relapse rate (ARR),Proportion of patients with an improvement in SDMT (Symbol Digit Modality Test)|Fatigue Severity Scale [FSS]|Quality of life parameters assessed by EQ-5D-3L|Treatment satisfaction assessed by TSQM-9|Expanded Disability Status Scale (EDSS)|Variation of NfL in plasma|Adverse Events (AEs)|Discontinuation rates due to AE and/or other reasons,False,
NCT00086671,Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS),"A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase",COMPLETED,2004-04,2006-11,2006-11,2013-01-04,2004-07-09,INTERVENTIONAL,PHASE2,215.0,ACTUAL,"AbbVie (prior sponsor, Abbott)",INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,44,ABT-874/Human monoclonal antibody against IL-12|Placebo,DRUG|DRUG,Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase|Safety and clinical laboratory parameters|vital signs,Magnetic Resonance Imaging endpoints|Magnetic Resonance Imaging endpoints|Magnetic Resonance Imaging endpoints|Magnetic Resonance Imaging endpoints|Magnetic Resonance Imaging endpoints,False,
NCT04940065,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis),COMPLETED,2021-06-30,2024-12-12,2024-12-12,2025-08-11,2021-06-25,OBSERVATIONAL,,368.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis|Active Secondary Progressive Multiple Sclerosis,Kesimpta|multiple sclerosis|Japan,Japan,Ichinomiya,Aichi-ken,104,Kesimpta,OTHER,Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of adverse reactions,Physician's Global Assessment|Confirmed disability worsening on Expanded Disability Status Scale (EDSS)|Confirmed improvement on Expanded Disability Status Scale (EDSS)|Number of gadolinium (Gd)-enhancing lesions on Magnetic Resonance Imaging (MRI)|Annual relapse rate|No Evidence of Disease Activity (NEDA-3),False,
NCT00230204,Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis,Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.,UNKNOWN,2005-09,,2006-04,2006-02-16,2005-09-30,INTERVENTIONAL,PHASE1,100.0,,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,Multiple sclerosis|Antibodies|Serum|Infectious agents|Immunoglobulin G|Immunoglobulin M,Israel,Ramat Gan,,1,Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits,PROCEDURE,"Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis",Assess correlation between antibody levels to various infectious agents with clinical disease variables,False,
NCT04496804,Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis,BIPAMS-Brain:Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis,COMPLETED,2020-11-02,2021-11-03,2021-11-03,2022-02-04,2020-08-03,INTERVENTIONAL,NA,24.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis,physical activity,United States,Birmingham,Alabama,1,Behavioral Intervention for Physical Activity in MS (BIPAMS)|Wellness for MS (WellMS),BEHAVIORAL|BEHAVIORAL,Minutes of moderate to vigorous physical activity - Baseline|Minutes of moderate to vigorous physical activity - Post intervention,cardiorespiratory fitness; oxygen consumption during exercise - baseline|cardiorespiratory fitness; oxygen consumption during exercise - post intervention|distance walked - baseline|distance walked - post-intervention|information processing speed; cognitive function - baseline|information processing speed; cognitive function - post intervention|volume of subcortical grey matter brain structures - baseline|volume of subcortical grey matter brain structures - post intervention|resting state functional brain connectivity - baseline|resting state functional brain connectivity - post intervention,False,
NCT05053984,Ultrasound-Guided Percutaneous Neuromodulation in Spasticity,Ultrasound-Guided Percutaneous Neuromodulation in Spasticity,UNKNOWN,2021-11-02,2022-01-31,2022-06-30,2021-09-23,2021-09-23,INTERVENTIONAL,NA,30.0,ESTIMATED,Hospital Universitario de Canarias,OTHER,,,Multiple Sclerosis,,Spain,San Cristóbal de La Laguna,S/C de Tenerife,1,Percutaneous Echoguided Neuromodulation,PROCEDURE,Spasticity|Patient's quality of life|Patient Functionality|9 hole peg test|Muscle strength|Range of Motion|Satisfaction Scale,,False,
NCT06612138,"Pilates, Yoga and Tai Chi Exercises' Effect on Balance and Gait in Patients With Multiple Sclerosis","Pilates, Yoga and Tai Chi Exercises' Effect on Balance and Gait in Patients With Multiple Sclerosis",NOT_YET_RECRUITING,2024-10-10,2025-07-30,2025-07-30,2024-09-25,2024-09-25,INTERVENTIONAL,NA,120.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,pilates|yoga|tai chi|multiple scelerosis,,,,0,pilates exercises|yoga exercises|tai chi exercises|tradional physical therapy,OTHER|OTHER|OTHER|OTHER,balance|gait assessment|exercise capacity,functional mobility|fatigue|life disability,False,
NCT02714036,A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS),"A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)",COMPLETED,2016-05-06,2019-12-31,2020-06-30,2024-09-24,2016-03-21,INTERVENTIONAL,PHASE1|PHASE2,35.0,ACTUAL,MediciNova,INDUSTRY,Massachusetts General Hospital|South Shore Neurologic Associates,OTHER|INDUSTRY,Amyotrophic Lateral Sclerosis,ALS,United States,Boston,Massachusetts,2,ibudilast|Ibudilast,DRUG|DRUG,Impact of MN-166 on [11C]-PBR28 Uptake in the Motor Cortices and Brain Stem Measured by Positron Emission Tomography (PET) Imaging at 12 - 24 Weeks|Impact of MN-166 on Several Markers of Neuro-inflammation Measured by Blood Biomarkers at Week 36,Safety and Tolerability of MN-166 Over 36 Weeks|Evaluate the Effect of MN-166 on ALS Clinical Outcomes (ALS Functional Rating Scale-revised [ALSFRS-R]) Over 36 Weeks.|Mean Change From Baseline in Slow Vital Capacity (Percent Predicted) Normal Volume at Week 36|Mean Change From Baseline in Isometric Strength as Measured by Hand-held Dynamometry (HHD) at Week 36.,True,2024-09-24
NCT00004744,"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis",,COMPLETED,1993-02,1998-09,,2008-09-09,2000-02-25,INTERVENTIONAL,PHASE3,76.0,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Mayo Clinic,OTHER,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,,,,0,immune globulin,DRUG,,,False,
NCT05112484,Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis,Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis,NOT_YET_RECRUITING,2024-06,2025-11,2026-05,2024-01-18,2021-11-09,OBSERVATIONAL,,600.0,ESTIMATED,University Hospital Ostrava,OTHER,University of Ostrava,OTHER,Multiple Sclerosis,Multiple Sclerosis|Therapeutic Drug Monitoring|Concentrations|Disease-Modifying Drugs,Czechia,Ostrava,Moravian-Silesian Region,2,Measurement of concentrations of orally-used DMDs|Genetic testing|Parameters for routine use of DMDs|Side effects of orally used DMDs,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|OTHER,"Correlation of measured concentrations of orally used ""DMDs"" with the clinical condition of patients with MS|Objectification of adherence to treatment in individual ""DMDs""|The percentage of patients with ""DMDs"" in whom therapeutic monitoring is used","Analysis of the relationship between the measured concentrations of orally used ""DMDs"" and the concentrations of other biomarkers of MS|Analysis of the relationship between the measured concentrations of orally used ""DMDs"" with the results of genetic examination of drug transporters of the P-gp (ABCB1) and BCRP (ABCG2) type",False,
NCT06796504,The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study,The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study,NOT_YET_RECRUITING,2025-09-30,2027-03-30,2030-09-30,2025-01-28,2025-01-28,INTERVENTIONAL,NA,60.0,ESTIMATED,SetPoint Medical Corporation,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,Procedure/Surgery: Implant Procedure|Disease-Modifying Therapies (DMTs)|Device: Active stimulation|Device: Non-active stimulation,PROCEDURE|DRUG|DEVICE|DEVICE,Incidence of adverse events,,False,
NCT00428584,RNF and Betaseron® Tolerability Study,"A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension",COMPLETED,2006-12,2007-11,2009-09,2013-08-07,2007-01-30,INTERVENTIONAL,PHASE3,129.0,ACTUAL,EMD Serono,INDUSTRY,Pfizer,INDUSTRY,Relapsing Remitting Multiple Sclerosis (RRMS),,United States,Rockland,Massachusetts,1,New Formulation of rebif - human interferon beta-1a|Interferon beta -1b,DRUG|DRUG,Visual Analog Scale (VAS) of Patient Reported Pain: Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 30 Minutes Post-injection Timepoints,Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and Immediately After Injection Timepoints|Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 10 Minutes Post-injection Timepoints|Number of Pain Free Patients at 30 Minutes Post-injection|Diameter of Injection Site Redness,True,2010-03-04
NCT05993819,Impact of Adding Cognitive Behaviour Therapy to Supervised Pilates-based Core Stability Training in Patients With Multiple Sclerosis,Impact of Adding Cognitive Behaviour Therapy to Supervised Pilates-based Core Stability Training on Balance and Walking in Patients With Multiple Sclerosis,UNKNOWN,2023-08-15,2023-12-30,2023-12-30,2023-08-15,2023-08-15,INTERVENTIONAL,NA,50.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,cognitive behaviour therapy|Pilates exercise|palance|walking,,,,0,pilates based core stability training and congnitive therapy|Pilates based core stability training,OTHER|OTHER,walking assessment|balance,fatigue|life disability,False,
NCT06281314,The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment,VESPA 2.0 - Virtual Environment for a Superior Neuropsychiatry Second Generation,COMPLETED,2021-03-01,2022-12-27,2023-12-31,2024-03-08,2024-02-28,INTERVENTIONAL,NA,60.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Neurodegenerative Diseases|Cognitive Decline|Parkinson Disease Dementia|Alzheimer Disease|Multiple Sclerosis,,Italy,Messina,Sicily,1,Vespa software,DEVICE,Montreal cognitive assessment (MoCA),,False,
NCT06551519,A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis,A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (FILAXOS),RECRUITING,2024-10-23,2027-09-16,2027-09-16,2025-01-14,2024-08-13,OBSERVATIONAL,,900.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|MS|Ofatumumab|NIS|Germany,Germany,Bamberg,Bavaria,26,ofatumumab|DMT category 1,OTHER|OTHER,Proportion of patients with high serum neurofilament light (sNfL) levels,"sNfL use as a biomarker for Multiple Sclerosis disease activity in clinical practice|Proportion of patients demonstrating radiological and / or clinical activity|Proportion of patients with no evidence of disease activity (NEDA)|Proportion of patients demonstrating NEDA 3 and its individual components at 24 months as compared to Baseline|Proportion of patients perceived as clinically stable depending on sNfL level|Multiple sclerosis impact scale 29 (MSIS-29)|Fatigue questionnaire: Fatigue Scale for Motor and Cognitive Functions (FSMC)|EuroQol- 5 Dimension (EQ-5D) score|Number of participants using Ekiva MS App|Treatment Satisfaction Questionnaire for Medication (TSQM) score|Reasons for and proportion of patients switching from current DMTs to ofatumumab|Proportion of missed ofatumumab doses within one year,|Proportion of patients who continue to receive their initial treatment|Reasons for, number of and duration of treatment interruptions and discontinuations.|Duration of treatment interruptions and discontinuations.|Characterization of patient subgroups with and without 100% adherence",False,
NCT05956119,Effectiveness of Dry Needling for Improving Gait in the Patient With Multiple Sclerosis,Analysis of the Effectiveness of Dry Needling for Improving Gait in the Patient With Multiple Sclerosis: a Randomized Single-blind Clinical Trial,COMPLETED,2023-07-03,2023-11-02,2023-11-28,2023-11-29,2023-07-21,INTERVENTIONAL,NA,18.0,ACTUAL,Hospital Universitario de Canarias,OTHER,,,Multiple Sclerosis,,Spain,San Cristóbal de La Laguna,Santa Cruz De Tenerife,1,dry needling + physiotherapy (standard/usual care)|sham dry needling + physiotherapy (standard/usual care),DEVICE|OTHER,Change in Timed 25-Foot Walk (T25FW),Change in Multiple Sclerosis Walking Scale (MSWS-12)|Change in The Time up and go test (TUG)|Change in The Multiple Sclerosis International QoL (Musiqol-54)|Change in analog scale of quality of life,False,
NCT06390930,Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS,Investigating the Effects of Acute Intermittent Hypoxia on Neuroplasticity in Persons With Multiple Sclerosis,NOT_YET_RECRUITING,2024-07,2026-07,2027-07,2024-04-30,2024-04-30,INTERVENTIONAL,NA,22.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,National Multiple Sclerosis Society,OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",multiple sclerosis|plasticity|neuroplasticity|motoneuron|aih|hypoxia|Acute Intermittent Hypoxia|arm|upper extremity,United States,Chicago,Illinois,1,Acute Intermittent Hypoxia|Sham Acute Intermittent Hypoxia,OTHER|OTHER,Motor Evoked Potentials (MEPs) in First Dorsal Interosseous (FDI)|Changes in Spinal Reflex Threshold|Threshold For Detecting Passive Joint Movement|Accuracy of Direction Estimation of Passive Joint Movement,Grip Strength|Pinch Strength|Index Finger Abduction Force|Nine-Hole Peg Test|Symbol Digit Modalities Test|Box and Block Test|Modified Ashworth Scale|Ipsilateral Joint Position Matching Task|Visual Analog Pain Scale,False,
NCT06220409,"Gut Microbiota Composition, Cognitive Function, and Physical Fitness in Multiple Sclerosis Patients","Effect of Dance Classes on Gut Microbiota Composition, Cognitive Function, and Physical Fitness in Multiple Sclerosis Patients",COMPLETED,2022-03-01,2023-08-30,2023-12-15,2024-01-24,2024-01-24,INTERVENTIONAL,NA,29.0,ACTUAL,Comenius University,OTHER,,,"Sclerosis, Multiple",Physical Activity|Gut Microbiome|Dance,Slovakia,Bratislava,,1,Dance classes,OTHER,The shift in the mean gut microbiota diversity|Change from baseline in the mean quantitative mobility and leg function performance|Change from baseline in the mean quantitative upper extremity function performance|Differences in the mean quantitative maximal oxygen consumption,,False,
NCT04528784,Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis,Transcutaneous Tibial Nerve Stimulation for the Treatment of Bladder Storage Symptoms in People With Multiple Sclerosis: Protocol of a Single-arm Feasibility Study,COMPLETED,2020-10-14,2021-03-12,2021-03-12,2021-04-28,2020-08-27,INTERVENTIONAL,NA,23.0,ACTUAL,University of Limerick,OTHER,,,"Bladder Dysfunction|Neurogenic Bladder Dysfunction|Urinary Incontinence|Urinary Bladder, Overactive|Urinary Incontinence, Urge|Nocturia|Urinary Frequency More Than Once at Night|Lower Urinary Tract Symptoms|Multiple Sclerosis|Urinary Bladder, Neurogenic",Multiple sclerosis|Neurogenic bladder|Feasibility study|Tibial nerve stimulation,Ireland,Limerick,LK,1,Transcutaneous tibial nerve stimulation,DEVICE,Recruitment rate/ retention rate|Adherence rate|Adverse events|Acceptability of using TTNS: proportion of participants with MS reporting that TTNS is acceptable,International Consultation of Incontinence Questionnaire-Overactive bladder (ICIQ-OAB)|Kings Health Questionnaire|3- day bladder diary|Patient Perception of Intensity of Urgency Scale,False,
NCT02634931,Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex,"A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex",COMPLETED,2015-12,2018-10,2018-10,2019-02-20,2015-12-18,INTERVENTIONAL,PHASE3,94.0,ACTUAL,Nobelpharma,INDUSTRY,,,Tuberous Sclerosis|Angiofibroma|Hypomelanotic Macule|Plaque,Sirolimus|Skin lesions|TSC|Tuberous Sclerosis Complex|NPC-12G|Angiofibroma|Hypomelanotic Macule|Plaque,Japan,"Suita, Osaka",,1,NPC-12G gel,DRUG,The discontinuation rate due to adverse events,"Adverse events and adverse events related to the test drug|Adverse events related to the test drug leading to the discontinuation permanently|Serious adverse events and serious adverse events related to the test drug|Adverse events and adverse events related to the test drug leading to modification of dosage and administration|Significant adverse events and significant adverse events related to the test drug|Laboratory tests, vital signs|Blood level of sirolimus|Improvements in angiofibroma|Improvements in sizes of angiofibroma|Improvements in redness of angiofibroma|Improvements in white macule and plaque upper neck|The rate of patients evaluated ''improvement'' or more (improvement rate) in above the efficacy measures.|Change in total score of DLQI and CDLQI from baseline|Degree of patient's satisfaction",False,
NCT05199402,Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases,Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases,COMPLETED,2021-07-01,2022-03-31,2023-10-01,2025-01-15,2022-01-20,OBSERVATIONAL,,10.0,ACTUAL,Imagine Institute,OTHER,RWTH Aachen University|Ruhr University of Bochum|Medical University of Warsaw,OTHER|OTHER|OTHER,Tuberous Sclerosis|Epilepsy,,France,Paris,,1,,,Time between birth and onset of seizures,The duration of active epilepsy|The number of individuals with active epilepsy at 2 years old|The number of individuals with drug-resistant epilepsy at 2 years old|The number of individuals with EEG abnormalities at 2 years old|The psychomotor development at 24 months|The number of individuals with hypsarrhythmia at 24 months on EEG|The number of individuals with West syndrome before 24 months of age|The number of individuals with autism spectrum disorders (ASD),False,
NCT01606137,A Study of the Long-term Safety of Sativex Use,"A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.",COMPLETED,2002-02,2004-12,2004-12,2023-05-06,2012-05-25,INTERVENTIONAL,PHASE3,507.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Spasticity|Pain,,United Kingdom,Glasgow,,1,GW-1000-02,DRUG,Incidence of Adverse Events as a Measure of Subject Safety.,Change From Parent Study Baseline in Spasticity 0-10 Numerical Rating Scale Score After 52 Weeks of Treatment.|Change From Parent Study Baseline in Central Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.|Change From Parent Study Baseline in Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment in Multiple Sclerosis Subjects.|Change From Parent Study Baseline in Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.|Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.|Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.|Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.|Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.|Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.|Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.|Subject Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.|Investigator Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.|Investigator Global Assessment at the Last Study Visit in Subjects With Neuropathic Pain Due to Multiple Sclerosis.|Investigator Global Assessment at the Last Study Visit in Subjects With Central Neuropathic Pain.|Investigator Global Assessment at the Last Study Visit in Subjects With Pain.|Investigator Global Assessment at the Last Study Visit in Subjects With Multiple Sclerosis.,True,2012-08-23
NCT01740830,The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis,,COMPLETED,2012-06,2012-10,2012-10,2013-06-04,2012-12-04,INTERVENTIONAL,NA,31.0,ACTUAL,Hasselt University,OTHER,,,Anodal tDCS|Recruitment Curves,,,,,0,Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator),DEVICE,Motor performance on a unimanual sequence learning task,,False,
NCT02137044,Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study,Improving the Quality of Care for Pain and Depression in Persons With Multiple Sclerosis,COMPLETED,2014-07,2017-04,2017-04,2017-12-06,2014-05-13,INTERVENTIONAL,NA,195.0,ACTUAL,University of Washington,OTHER,Patient-Centered Outcomes Research Institute,OTHER,Multiple Sclerosis|Pain|Depression,multiple sclerosis|pain|depression,United States,Seattle,Washington,3,Collaborative Care (CC),BEHAVIORAL,Change in Control of Pain|Change in Control Of Depression,Change in Depression Severity|Change in Quality of Depression Care|Change in Pain Severity|Change in Disability|Change in Health-Related Quality of Life|Improvement and Satisfaction with Care,False,
NCT06777134,Relationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients,"Relationship Between Pelvic Floor Dysfunctions and Core Endurance, Hip Rotation Muscle Strength, Tibialis Anterior and Tibialis Posterior Muscle Activation in Patients with Multiple Sclerosis",ENROLLING_BY_INVITATION,2025-01-01,2025-09-10,2026-01-10,2025-01-16,2025-01-15,OBSERVATIONAL,,73.0,ESTIMATED,Berivan Beril Kılıç,OTHER,,,Multiple Sclerosis|Pelvic Floor Dysfunction,pelvic floor|multiple sclerosis|core endurance|tibialis anterior|tibialis posterior|electromyography,Turkey (Türkiye),Istanbul,,1,Assessment of pelvic floor dysfunction|The Quality of Life Assessment|Core endurance assessment|Hip strength assessment|Tibialis posterior muscle activation|Tibialis anterior muscle activation,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Pelvic floor muscle dysfunction,Qualitf of life|Core endurance -trunk flexor endurance|Core endurance -trunk extansor endurance|Core endurance - lateral flexor endurance|Hip strength|tibialis posterior muscle activation - peak torque|tibialis posterior muscle activation - work avarage|tibialis posterior muscle activation - percentage of maximal voluntary contractions|tibialis posterior muscle activation - rest tone|tibialis anterior muscle activation - peak torque|tibialis anterior muscle activation - work avarage|tibialis anterior muscle activation - percentage of maximal voluntarily contractions|tibialis anterior muscle activation - rest tone,False,
NCT04024085,Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis,Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition for Patients With Multiple Sclerosis,COMPLETED,2019-03-13,2019-07-31,2019-07-31,2022-02-18,2019-07-18,OBSERVATIONAL,,70.0,ACTUAL,Gérard Amarenco,OTHER,,,"Gait Disorders, Neurologic|Urinary Incontinence, Urge|Multiple Sclerosis",,France,Paris,,1,completion of the test created Time to be Ready to Void,OTHER,Total time for TRV,"Time for the first stage: ""mobility"" stage|Time for the second stage: ""settled"" stage",False,
NCT01837017,Project FARMS: Fall Risk Reduction in Multiple Sclerosis,Project FARMS: Fall Risk Reduction in Multiple Sclerosis,COMPLETED,2012-06,2012-12,2013-03,2014-11-25,2013-04-22,INTERVENTIONAL,PHASE1,33.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,"Falls,|Balance,|Gait,|Older adults",United States,Urbana,Illinois,1,Home-based Exercise,BEHAVIORAL,Physiological Fall risk,Mobility|Balance|Spasticity,False,
NCT00321568,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,An Exploratory Study on Detection of Cortical and White Matter Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging at 7 Tesla,COMPLETED,2006-05-01,,2011-04-19,2017-07-02,2006-05-04,OBSERVATIONAL,,60.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Magnetic Resonance|MRI|Magnetic Field|MS,United States,Bethesda,Maryland,1,,,,,False,
NCT02463318,The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects,,COMPLETED,2012-09,2015-06,2015-09,2017-05-02,2015-06-04,INTERVENTIONAL,NA,34.0,ACTUAL,Tehran University of Medical Sciences,OTHER,,,Multiple Sclerosis|Oxidative Stress,Multiple sclerosis|SIRT1|MnSOD|Catalase|Oxidative stress|Antioxidant enzyme,Iran,Tehran,,1,Melatonin|Hydrogen peroxide,DRUG|OTHER,Relative gene expression by real-time PCR (polymerase chain reaction),MnSOD enzyme activity assay|Catalse enzyme activity assay|SIRT1 enzyme activity assay,False,
NCT06567197,Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands,Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A Long-term Prospective Observational Study in the Netherlands,RECRUITING,2023-08-25,2028-09-01,2028-09-01,2024-08-22,2024-08-22,OBSERVATIONAL,,24.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,St. Antonius Hospital,OTHER,"Multiple Sclerosis, Relapsing-Remitting",,Netherlands,Amsterdam,,2,,,Treatment efficacy,Annual relapse rate|Time to first relapse|Confirmed disability progression (CDP)|Confirmed disability improvement (CDI)|Progression independent of relapse activity (PIRA)|Changes on the multiple sclerosis functional composite (MSFC)|Brain/spinal cord MRI|Optical coherence tomography (OCT)|Side-effects and toxicity|Multiple Sclerosis Impact Scale-29 (MSIS-29)|EuroQoL 5D (EQ-5D-5L)|Modified Fatigue Impact Scale (MFIS-5)|Hospital Anxiety and Depression Scale (HADS)|iMTA Medical Cost Questionnaire (iMCQ)|iMTA Productivity Cost Questionnaire (iPCQ)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Biomarkers|Proteomics|Immune phenotyping|Genetic analysis,False,
NCT04819360,Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis,Injections of Botulinum Toxin a or Anticholinergic Treatment As First Line Therapy to Treat Neurogenic Overactive Bladder in Patients with Multiple Sclerosis,TERMINATED,2021-06-01,2022-03-09,2024-04-21,2024-09-27,2021-03-26,INTERVENTIONAL,PHASE4,1.0,ACTUAL,Brigitte Schürch,OTHER,Centre Hospitalier Universitaire Vaudois,OTHER,"Urinary Bladder, Neurogenic|Multiple Sclerosis",Botulinum toxin|Neurogenic bladder|Multiple sclerosis|Anticholinergic drugs,Switzerland,Lausanne,,1,VESIcare 10Mg Tablet|Botox 100 UNT Injection,DRUG|DRUG,Magnitude of effect - Number of micturitions per 24h,Other parameters of effects - Number of urgent urinations per 24h|Other parameters of effects - Number of urgency urinary incontinence episodes per 24h|Other parameters of effects - Number of nocturnal micturition episodes per 24h|Other parameters of effects - Number of 100% dry patients|Other parameters of effects - Urodynamic parameter : cystomanometric capacity|Other parameters of effects - Urodynamic parameter : reflex volume at first contraction|Other parameters of effects - Urodynamic parameter : bladder compliance|Other parameters of effects - Urodynamic parameter : maximum detrusor pressure|Other parameters of effects - Urodynamic parameter : post-void residual after flowmetry,False,
NCT03983720,Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?,Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?,TERMINATED,2020-01-21,2021-06-16,2021-07-31,2023-11-02,2019-06-12,INTERVENTIONAL,PHASE2,67.0,ACTUAL,Centre Hospitalier Universitaire de Saint Etienne,OTHER,,,"Sclerosis, Multiple",Sleep assessment|Neuromuscular Fatigability|Multiple sclerosis|Chronic fatigue,France,Saint-Etienne,,1,Evaluation of degree chronic fatigue.|Questionnaires|Blood sample|Cardiopulmonary evaluation|Capacity of muscular oxygen extraction|Sleep assessment|Metabolic fatigue|Neuromuscular evaluation,OTHER|OTHER|BIOLOGICAL|OTHER|DEVICE|DEVICE|DEVICE|OTHER,Voluntary maximum contraction,Neuromuscular function during the dynamic strenuous exercise|Muscle oxygen extraction capacity|Anemia|Inflammation|VO2 max|Heart rate|Cognitive fatigue|Perceived fatigue|Thermoregulation|Sleep quality|Muscle volume|Metabolic fatigue,False,
NCT02760082,Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers,Identifying Motivational Factors for Registering Nutrition and Lifestyle Factors Among Patients With Multiple Sclerosis,UNKNOWN,2016-02,2017-04,2017-04,2016-05-03,2016-05-03,OBSERVATIONAL,,500.0,ESTIMATED,University of Copenhagen,OTHER,Danish Multiple Sclerosis Society,UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Qualitative study|Motivation,Denmark,Copenhagen,,1,Qualitative evaluation,OTHER,Analysis of qualitative interviews and measurement of eHealth literacy (eHealth literacy questionnaire)|Evaluation of motivational factors based on questionnaire survey|Analysis of focus group interviews on motivational factors for registering nutrition and lifestyle factors among patients with multiple sclerosis,,False,
NCT04334031,Deployment o the Multidisciplinary Prospective Cohort Imminent,Deployment o the Multidisciplinary Prospective Cohort Imminent,RECRUITING,2020-07-20,2031-07,2031-07,2022-05-23,2020-04-03,INTERVENTIONAL,NA,2200.0,ESTIMATED,"University Hospital, Lille",OTHER,FHU IMMINeNT|FHU PRECISE: Projet Fédératif Hospitalo-Universitaire PREcision health in Complex Immune-mediated inflammatory diseaSEs|Fond de dotation de la Société Française de Dermatologie (SFD),UNKNOWN|UNKNOWN|UNKNOWN,Chronic Inflammatory Disease|Angioedema|Severe Asthma|Lupus|Atopic Dermatitis|Psoriatic Arthritis|Multiple Sclerosis|Systemic Sclerosis|Behçet Disease,Immune Mediated Inflammatory Diseases (IMIDs)|biomarker|cohort study|quality of life|disease severity,France,Lille,,1,Biobanking with genetic analysis|SF-12 questionnaire,GENETIC|OTHER,Change of SLEDAI for lupus|Change of Medsger score|Change of EDSS for multiple sclerosis|Change of BASDAI for psoriatic arthristis|Change of Longhurst criteria for hereditary angioedema|Change of number of flares for atopic dermatitis|Change of number of exacerbations for severe asthma|Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale|number of participant with severe infectious events,,False,
NCT06220201,"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)","A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).",RECRUITING,2024-03-28,2027-07-15,2027-07-15,2025-08-20,2024-01-23,INTERVENTIONAL,PHASE1,120.0,ESTIMATED,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",INDUSTRY,Celgene Corporation,INDUSTRY,Multiple Sclerosis|Myasthenia Gravis,CC-97540|CAR T|CART|NEX T|NEXT|BMS-986353|RMS|PMS|Multiple sclerosis|RRMS|aSPMS|PPMS|iSPMS|MG|gMG|refractory myasthenia gravis|general myasthenia gravis|CD19,United States,Birmingham,Alabama,35,CC-97540|Fludarabine|Cyclophosphamide,DRUG|DRUG|DRUG,Number of participants with adverse events (AEs)|Number of participants with serious adverse events (SAEs)|Number of participants with adverse events of special interest (AESIs)|Number of participants with laboratory test result abnormalities|Number of participants with imaging abnormalities|Number of participants with dose-limiting toxicities (DLTs)|Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period,Number of participants meeting no evidence of disease activity (NEDA) criteria|Number of participants with confirmed disability progression per Expanded Disability Status Scale (EDSS)|Annualized relapse rate|Change from baseline in magnetic resonance imaging (MRI) metrics|Number of participants with disability improvement confirmed per EDSS|Maximum observed blood concentration (Cmax)|Time of maximum observed blood concentration (Tmax)|Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))|Time to last measurable chimeric antigen receptor (CAR T) concentrations (Tlast)|Number of participants with at least 2 points improvement for at least 4 weeks in Myasthenia Gravis activities of daily living (MG-ADL) score|Number of participants with at least 3 point improvement in Myasthenia Gravis composite (MG-C) score|Number of participants with at least 3 point improvement in quantitative Myasthenia Gravis (QMG) score,False,
NCT03166007,Abdominal Massage for Bowel Dysfunction,Abdominal Massage for Neurogenic Bowel Dysfunction in People With Multiple Sclerosis (AMBER Abdominal Massage for Bowel Dysfunction Effectiveness Research).,COMPLETED,2014-06,2017-01,2017-03,2017-05-24,2017-05-24,INTERVENTIONAL,NA,191.0,ACTUAL,Glasgow Caledonian University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Neurogenic Bowel Dysfunction|Abdominal massage,United Kingdom,Glasgow,Glasgow City of,1,Abdominal massage|Optimised bowel care,BEHAVIORAL|BEHAVIORAL,Change from Baseline to 24 weeks Neurogenic Bowel Dysfunction Score (NBDs),"Neurogenic Bowel Dysfunction Questionnaire (NBD PROM) - change in Score from Baseline to 24 weeks|Constipation Symptoms (Constipation Scoring System (CSS)) - change in Score from Baseline to 24 weeks|Bowel Symptoms (7 day diary) - change in Score from Baseline to 24 weeks|Radio Opaque Marker transit tests - change in Score from Baseline to 24 weeks|Adherence to massage schedule (7 day diary) - change in Score from Baseline to 24 weeks|Bladder Function (Qualiveen Questionnaire Short Form) - change in Score from Baseline to 24 weeks|Health Status (EQ-5D-5L Health Questionnaire) - change in Score from Baseline to 24 weeks|Change of medication (Concomitant Medication Form)|Patient Resource Questionnaire - cost and use of NHS services (£)|Patient Resource Questionnaire - cost to the patients and their families/carers (£)|Patient Resource Questionnaire - incremental costs, QALYs and incremental cost per QALY derived by the economic model (£)",False,
NCT05539729,Vancomycin Study in Multiple Sclerosis (MS),Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis,RECRUITING,2023-01-31,2026-03,2026-09,2025-09-10,2022-09-14,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,Icahn School of Medicine at Mount Sinai,OTHER,Doris Duke Charitable Foundation,OTHER,Multiple Sclerosis,gut microbiome|peripheral immune function|neuroinflammation|gut-brain axis,United States,New York,New York,1,Vancomycin|Placebo,DRUG|DRUG,Changes in abundance of butyrate producing bacteria|Changes in Serum Butyrate levels|Changes in number of peripheral T cells,Changes in abundance of short chain fatty acids (SCFAs)-producing bacteria|Change in stool SCFAs levels|Change in serum SCFAs levels|Change in number of gadolium enhancing brain lesions|Change in volume of gadolium enhancing brain lesions|Change in number of new brain lesions|Change in volume of new brain lesions|Change in number of total brain lesions|Change in volume of total brain lesions|Changes in number of paramagnetic rim lesions|Changes in volume of paramagnetic rim lesions|Changes in thalamic brain volumes|Changes in cortical brain volumes|Changes in total brain volumes,False,
NCT04564495,Home Based Tele-exercise for People With Chronic Neurological Impairments,Home Based Tele-exercise for People With Chronic Neurological Impairments,ACTIVE_NOT_RECRUITING,2021-01-22,2023-12-31,2025-05-31,2025-02-05,2020-09-25,INTERVENTIONAL,NA,60.0,ESTIMATED,Burke Medical Research Institute,OTHER,,,"Neurologic Disorder|Stroke|Spinal Cord Injuries|Cerebral Palsy|Hemiplegia|Hemiparesis|Multiple Sclerosis|Parkinson Disease|Trauma, Brain|Transverse Myelitis|Friedreich Ataxia",,United States,White Plains,New York,1,Seated exercise,BEHAVIORAL,Change in heart rate,Perceived Wellness Survey|Physical Activity Enjoyment Scale|Short Form-36 Health Survey|Numerical pain rating|Borg's Rating Scale of Perceived Exertion|Reason for exercise inventory,False,
NCT00242177,Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability,Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability,COMPLETED,2003-10,,2005-10,2019-07-22,2005-10-19,INTERVENTIONAL,PHASE1,30.0,,University of Illinois at Chicago,OTHER,"Takeda Pharmaceuticals North America, Inc.",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis|Relapsing, Remitting|Autoimmune disease",United States,Chicago,Illinois,1,ACTOS (Pioglitazone),DRUG,"MRI with GD enhancement at visit 2, 5, 8|Blood test (CBC, Liver enzymes)at each visit|EDSS at each visit|MSFC at each visit",,False,
NCT02889965,The French Multiple Sclerosis Registry,The French Multiple Sclerosis Registry,UNKNOWN,2011-01,2019-12,2019-12,2016-09-07,2016-09-07,OBSERVATIONAL,,54000.0,ESTIMATED,Hospices Civils de Lyon,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders,Multiple sclerosis|Pharmacoepidemiology|Disease modifying drugs|Neuro-myelitis optica,France,Bron,,1,,,Number of cases of MS included|number of patients|demographic characteristics|geographical distribution|disease characteristics|simple disease-modifying treatment description,,False,
NCT06583967,"The Effect of Aerobic Exercise on an Elliptical Trainer Versus a Treadmill, in People with Multiple Sclerosis","The Effect of Aerobic Exercise on an Elliptical Trainer Versus a Treadmill, on Gait and Walking Abilities, Expressed in Dynamic Stability, Balance and Walking Speed, in People with Multiple Sclerosis (MS)",RECRUITING,2024-06-01,2025-02-28,2025-06-30,2024-09-04,2024-09-04,INTERVENTIONAL,NA,30.0,ESTIMATED,Soroka University Medical Center,OTHER,,,Multiple Sclerosis (MS),Aerobic|Exercise|Elliptical trainer|Treadmill|6 Minute Walk Test (6MWT)|Timed Up & Go (TUG)|Berg Balance Scale (BBS)|10 Meter Walk Test (10MWT)|Informed Consent Form (ICF),Israel,Beersheba,Israel,2,Physical Training,OTHER,Quality of life outcomes,6 Minute Walk Test (6MWT)|Timed Up &amp; Go (TUG)|Berg Balance Scale (BBS)|10 Meter Walk Test (10MWT),False,
NCT00151294,The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis,"A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis",TERMINATED,2004-11,,2006-10,2006-09-14,2005-09-08,INTERVENTIONAL,PHASE4,20.0,,Weill Medical College of Cornell University,OTHER,Forest Laboratories,INDUSTRY,Depression|Multiple Sclerosis,Depression (mild to moderate)|Affective symptoms|Emotional lability|Multiple Sclerosis,United States,White Plains,New York,1,escitalopram oxalate antidepressant,DRUG,Escitalopram-treated MS patients will have greater reductions in their depressive symptom scores than patients randomized to placebo|Adverse events for both groups will be similar,Escitalopram-treated emotionally labile patients with MS will have a greater reduction in emotional lability scores than those randomized to placebo.,False,
NCT00210301,Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS,Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS,UNKNOWN,2003-01,,,2006-09-07,2005-09-21,INTERVENTIONAL,NA,60.0,,Institute for Clinical Research,OTHER,,,Relapsing-Remitting Multiple Sclerosis,MS|cognition|attention|fatigue,United States,Washington D.C.,District of Columbia,1,Provigil (modafinil),DRUG,Comparison of AE's and SAE's to determine safety of combination,Full neuropsychological test battery (including fatigue measures) to assess effect on fatigue and cognition.,False,
NCT03983681,Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS,Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS,ACTIVE_NOT_RECRUITING,2019-09-26,2025-09-15,2025-09-30,2025-05-07,2019-06-12,INTERVENTIONAL,NA,120.0,ESTIMATED,Kessler Foundation,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|Relapsing-Remitting MS|Progressive MS|RRMS|PPMS|SPMS|Primary Progressive|Secondary Progressive,United States,East Hanover,New Jersey,2,Strategy-Based Training to Enhance Memory (STEM)|Placebo control exercises,BEHAVIORAL|BEHAVIORAL,Changes in scores on self-report measure of everyday cognition (subjective)|Changes in scores on self-report measure of everyday cognition (objective),Changes in auditory processing speed|Changes in information processing speed|Changes in episodic verbal memory and learning|Changes in visuospatial memory|Changes in ability in spontaneous production of words|Changes in visual perception|Changes in executive function,False,
NCT04132037,An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients,An Observational Study on Intermittent Self Catheterisation Discontinuation Factors in Multiple Sclerosis Patients,UNKNOWN,2019-06-26,2021-12,2022-12,2019-10-18,2019-10-18,OBSERVATIONAL,,225.0,ESTIMATED,"University Hospital, Toulouse",OTHER,French Association for Research on Multiple Sclerosis,UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Urinary disorders|Intermittent Self Catheterisation,France,Toulouse,,1,data record,OTHER,intermittent self catheterisation discontinuation at 2 years after the start of learning.,"intermittent self catheterisation discontinuation at 6 weeks, after the start of learning.|intermittent self catheterisation discontinuation 6 months after the start of learning.|intermittent self catheterisation discontinuation at 1 year after the start of learning.",False,
NCT04447937,Immunodeficiency in MS,Analysis of Medical Therapy and History as Risks of Immunodeficiency in Multiple Sclerosis Patients,UNKNOWN,2020-06-29,2021-01-30,2021-07-30,2020-06-25,2020-06-25,OBSERVATIONAL,,1500.0,ESTIMATED,Advanced Neurosciences Institute,OTHER,Novel Pharmaceutics Institute,UNKNOWN,"Multiple Sclerosis|Hypogammaglobulinemia|Immunodeficiency|Infection, Bacterial",,United States,Franklin,Tennessee,1,No Interventions,OTHER,Immunoglobulin Levels,Infections|Immune-mediated conditions|Malignant and pre-malignant conditions,False,
NCT00217295,A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis,A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.,UNKNOWN,2004-04,,2007-12,2005-09-22,2005-09-22,INTERVENTIONAL,PHASE2,30.0,,Multiple Sclerosis Institute,OTHER,,,Multiple Sclerosis,Relapsing-remitting multiple sclerosis|Brain atrophy|Disease progression,United States,Philadelphia,Pennsylvania,1,Avonex and Topamax,DRUG,Safety and tolerability,Brain atrophy on nMRI|Disease progression on EDSS and MSFC|Relapse rate,False,
NCT05078177,Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis,Trial of the Efficacy and Safety of Pathogenetic Therapy of Multiple Sclerosis and Other Autoimmune Diseases Using Intrathecal Rituximab,UNKNOWN,2020-12-21,2022-12-21,2024-12-21,2021-10-14,2021-10-14,INTERVENTIONAL,PHASE1,40.0,ESTIMATED,St. Petersburg State Pavlov Medical University,OTHER,,,Multiple Sclerosis,Autoimmune Diseases|Rituximab,Russia,Saint Petersburg,,1,Rituximab,DRUG,Multiple sclerosis progression free survival,Overall survival|To evaluate adverse effects after intrathecal Rituximab|Quality of life status 1|Quality of life status 2|Quality of life status 3|Quality of life status 4|Neurological status 1|Evaluation of Immune system reconstitution after AHSCT 1|Evaluation of Immune system reconstitution after AHSCT 2|Impact of autoHSCT+intrathecal Rituximab on brain structure anatomy,False,
NCT04941781,PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers,"A Phase 1, Open-label Study of PIPE-307 to Determine Muscarinic Type I Receptor (M1AChR) Occupancy Parameters by [11C] PIPE-307 PET Imaging in Healthy Volunteers",COMPLETED,2021-09-01,2021-11-10,2021-11-10,2022-10-05,2021-06-28,INTERVENTIONAL,PHASE1,6.0,ACTUAL,Contineum Therapeutics,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis,United Kingdom,London,,1,PIPE-307,DRUG,M1AChR receptor occupancy as determined by regional total volume of distribution (VT) of [11C] PIPE-307 at 24 hours,,False,
NCT03735056,The PrEliMS Feasibility Trial,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis (PrEliMS): A Feasibility Randomised Controlled Trial,COMPLETED,2018-11-30,2020-10-31,2020-10-31,2020-11-09,2018-11-08,INTERVENTIONAL,NA,40.0,ACTUAL,University of Nottingham,OTHER,Multiple Sclerosis Society UK|Swansea University,UNKNOWN|OTHER,Multiple Sclerosis,Diagnosis|Emotional support|Peer support,United Kingdom,Nottingham,,1,MS Nurse Support|Peer Support,OTHER|OTHER,Feasibility of trial procedures|Acceptability of trial procedures|Feasibility of randomisation protocol|Feasibility of recruitment|Estimating sample size needed for a Phase III RCT|Appropriateness of measures|Feasibility of self-report data collection|Feasibility of audio recording support sessions|Acceptability of interventions (Support 1 and Support 2)|Feasibility of delivering Support 1 intervention|Feasibility of delivering Support 2 intervention|Credibility of interventions|Fidelity of intervention|Documentation of usual care|Feasibility of collecting data for an economic evaluation using a bespoke service use questionnaire,,False,
NCT05427045,A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis,A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis and Back Pain,TERMINATED,2022-05-01,2023-05-05,2023-05-05,2024-11-07,2022-06-22,INTERVENTIONAL,NA,7.0,ACTUAL,University of Arkansas,OTHER,,,Multiple Sclerosis|Back Pain,,United States,Little Rock,Arkansas,1,home - exercise program,OTHER,Study the Compliance of a Home-exercise Program in Patients With MS,Qualify the Multifidus Dysfunction in Patients With MS - Ultrasound|Qualify the Multifidus Dysfunction in Patients With MS - Physical Exam|Correlation Between Compliance and Plain and Size of Muscle,True,2024-11-07
NCT07064239,Effect of Cooling Vest in Multiple Sclerosis Patients,Effect of Cooling Vest on Fatigue and Spatiotemporal Gait Parameters in Multiple Sclerosis Patients,ACTIVE_NOT_RECRUITING,2025-05-20,2025-07-03,2025-07-08,2025-07-14,2025-07-14,INTERVENTIONAL,NA,30.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,,Egypt,Giza,,1,cooling vest|Aerobic exercises,DEVICE|OTHER,fatigue|gait parameter (Gait Speed)|gait parameters: Stride Length and Stride Length|gait parameter (Double Support),functional capacity,False,
NCT03185065,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis","Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",COMPLETED,2017-10-04,2019-11-21,2019-11-21,2020-10-20,2017-06-14,INTERVENTIONAL,PHASE3,141.0,ACTUAL,Johns Hopkins University,OTHER,Patient-Centered Outcomes Research Institute,OTHER,Fatigue in Multiple Sclerosis,,United States,San Francisco,California,2,Amantadine|Modafinil|Methylphenidate|Placebos,DRUG|DRUG|DRUG|DRUG,Modified Fatigue Impact Scale (MFIS) Score,Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score|Epworth Sleepiness Scale (ESS) Score,True,2020-10-19
NCT03945006,"Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence","An Investigation of Balance, Trunk Impairment, and Fear of Falling in Multiple Sclerosis Patients With Incontinence",COMPLETED,2019-03-25,2019-04-20,2019-04-30,2019-05-10,2019-05-10,OBSERVATIONAL,,36.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Multiple Sclerosis|Physical Therapy|Incontinence,Multiple Sclerosis|Balance|Trunk impairment|Fear of falling|Incontinence,Turkey (Türkiye),Ankara,Esenboğa,1,Incontinence Severity|Balance|Trunk impairment|Fear of falling,OTHER|OTHER|OTHER|OTHER,Assessment of the Severity of Incontinence,Static Balance Assessment|Trunk Impairment Assesment|Fear of Falling,False,
NCT02410278,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,"A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules",COMPLETED,2015-03-12,2017-02-16,2017-04-27,2020-03-31,2015-04-07,INTERVENTIONAL,PHASE4,102.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Jonesboro,Arkansas,50,dimethyl fumarate|montelukast|Placebo,DRUG|DRUG|DRUG,Percentage of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the GSRS From Day 0 to Day 10,Average Change From Baseline in GSRS Overall Score at Day 1 to Day 10|Average Change From Baseline in GSRS Overall Score at Day 1 to Week 10|Time to First Worsening From Baseline in GSRS Overall Score at Day 1 to Day 10|Time to Recovery to Baseline GSRS Score From Last Occurrence of Worst GSRS Score at Day 1 to Week 8|Average Change From Baseline in GSRS Overall Score at Day 1 to Weeks 1 to 8|Average Change From Baseline in GSRS Overall Score at Day 0 to 72 Hours From the Initiation of Randomized Study Treatment|Percentage of Participants Who Required GI Symptomatic Therapy During the Study|Percentage of Participants Who Discontinued DMF Therapy Due to GI-Related Adverse Events (AEs) From Day 0 to Week 10|Percentage of Participants Who Experienced AEs Related to Flushing,True,2018-07-24
NCT04707976,Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis,A Randomized Controlled Trial Comparing the Efficacy of Transanal Irrigation With Navina Smart Versus Standard Bowel Care in Patients With Multiple Sclerosis,RECRUITING,2020-12-01,2024-12,2025-02,2024-07-11,2021-01-13,INTERVENTIONAL,NA,92.0,ESTIMATED,Wellspect HealthCare,INDUSTRY,,,Neurogenic Bowel (Disorder)|Fecal Constipation|Fecal Incontinence|Multiple Sclerosis,,Denmark,Aarhus,,9,Navina Smart|Standard Bowel Care,DEVICE|OTHER,Change in fecal incontinence score.|Change in fecal constipation score,Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Efficacy of TAI with Navina Smart vs. SBC|Change in perception of impact of bowel symptoms on QoL|Change in NBD symptoms|Change in bladder specific QoL|Study therapy adherence|Frequency of UTI|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation APP/irrigation parameters|Navina Smart: Correlation anorectal APP/irrigation parameters between responders/non-responders|Navina Smart: Correlation anorectal APP/irrigation parameters between responders/non-responders|Navina Smart: Correlation anorectal APP/irrigation parameters between responders/non-responders,False,
NCT02696590,High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients,Isfahan University of Medical Sciences,COMPLETED,2015-07,2015-11,2015-12,2016-03-02,2016-03-02,INTERVENTIONAL,NA,200.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,,Iran,Isfahan,Isfahan,1,Vitamin D3,DIETARY_SUPPLEMENT,Serum concentration of 25(OH)D,,False,
NCT00203047,Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate,"A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA)",TERMINATED,2005-01,2009-05,2009-05,2014-01-06,2005-09-20,INTERVENTIONAL,PHASE4,414.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|brain atrophy|Glatiramer Acetate|Copaxone|Steroids|Prednisone,,,,0,Glatiramer Acetate|Placebo|Prednisone,DRUG|DRUG|DRUG,Percent Change From Baseline to Termination in Normalized Brain Volume Measured According to the SIENA (Structural Imaging Evaluation Using Normalization of Atrophy) Method,"Cumulative Number of Enhancing Lesions at Months 12, 24 and 36|Change From Baseline to Month 36 or Early Termination Visit in Volume of T2-Lesions|Change From Baseline to Month 36 or Early Termination Visit in Volume of Hypointense Lesions",True,2014-01-06
NCT06887426,Cladribine Tablets as an Exit Therapy Strategy,Cladribine Tablets as an Exit Therapy Strategy: Alternative to Continuing Treatment and Plain Treatment Discontinuation in Ageing Stable RMS Patients,NOT_YET_RECRUITING,2025-06,2025-12,2025-12,2025-06-02,2025-03-20,OBSERVATIONAL,,450.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,,,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,France,Strasbourg,,1,Cladribine,DRUG,To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT,"To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and stopping current DMT|To evaluate the clinical activity during the 3 years of follow-up in patients switching to cladribine and continuing current DMT|To evaluate the radiological activity during the follow-up in patients switching to cladribine, continuing current DMT and stopping DMT|To evaluate the disability during the follow-up in patients switching to cladribine, continuing current DMT and stopping DMT|To evaluate the risk of serious adverse events in patients switching to cladribine and continuing current DMT",False,
NCT04325074,Mental Practice and Manipulative Skills Training in Multiple Sclerosis,Mental Practice and Manipulative Skills Training in Multiple Sclerosis: a Pilot Study,COMPLETED,2015-09-15,2015-11,2016-06,2020-03-27,2020-03-27,INTERVENTIONAL,NA,40.0,ACTUAL,Cristina García-Bravo,OTHER,,,Multiple Sclerosis,,,,,0,Mental practice|Mental practice + skill training|Control group,OTHER|OTHER|OTHER,Nine Hole Peg Test (NHPT). Pre-treatment|Box and Block Test (BBT). Pre-treatment|The ABILHAND questionnaire. Pre-treatment|The Canadian Occupational Performance Measure (COPM). Pre-treatment,Nine Hole Peg Test (NHPT). Post-treatment|Box and Block Test (BBT). Post-treatment|The ABILHAND questionnaire. Post-treatment|The Canadian Occupational Performance Measure (COPM). Post-treatment,False,
NCT01652352,Experimental Evaluation of Wheelchair-Mounted Robotic Arms,HRI: Maximizing Manipulation of Persons With Disabilities Using a Smart Wheelchair-Mounted Robotic System,COMPLETED,2010-08,2011-07,2011-07,2012-07-30,2012-07-30,OBSERVATIONAL,,20.0,ACTUAL,University of South Florida,OTHER,U.S. National Science Foundation,FED,Spinal Cord Injury|Cerebral Palsy|Multiple Sclerosis,Disabled|Disability|Power wheelchair|Wheelchair|Wheelchair mounted robotic arm|WMRA|Assistive|Assistive robot|Assistive robotics|Rehabilitation robot|Rehabilitation engineering|Rehabilitation robotics,United States,Tampa,Florida,1,,,Efficacy - Ease of Use,Time of Completion,False,
NCT06649955,Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study,Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study,RECRUITING,2025-02-10,2026-06,2026-11,2025-09-19,2024-10-21,INTERVENTIONAL,NA,15.0,ESTIMATED,PathMaker Neurosystems Inc.,INDUSTRY,Beth Israel Deaconess Medical Center|United States Department of Defense,OTHER|FED,ALS - Amyotrophic Lateral Sclerosis,ALS|Lou Gehrig's disease|Non-invasive|Multi-site direct current stimulation (multi-site DCS),United States,Boston,Massachusetts,1,Multi-site direct current stimulation (DCS),DEVICE,Feasibility of treating ALS patients using multi-site DCS|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],ALS Functional Rating Scale (ALSFRS-R)|Rasch Overall ALS Disability Scale (ROADS)|ALS Assessment Questionnaire (ALSAQ-40)|Accurate Test of Limb Isometric Strength (ATLIS)|Threshold tracking nerve conduction studies (TTNCS)|Measurement of cortical motor neuron excitabiity using Trans-cranial magnetic stimulation (TMS)|Slow Vital Capacity (SVC),False,
NCT06700343,Comparison Between ABP 692 and Ocrevus® (Ocrelizumab),"A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis",RECRUITING,2025-01-13,2027-01-15,2027-12-17,2025-09-25,2024-11-22,INTERVENTIONAL,PHASE3,444.0,ESTIMATED,Amgen,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis (RRMS),Neuroscience|Neurology|Neuroimmunology|Immunosuppressants|Ocrelizumab|ABP 692,United States,Mobile,Alabama,34,Ocrelizumab (US)|Ocrelizumab (EU)|ABP 692,DRUG|DRUG|DRUG,Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day 15 (AUC0-d15) Following Infusion 1 of the Initial Dose of Investigational Product (IP)|AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of the Entire Initial Dose of IP|Total Number of New Gadolinium Enhanced (GdE) T1-weighted Lesions per Brain MRI,"Maximum Concentration (Cmax) Following Infusion 1 of the Initial Dose of IP at Day 1 (Cmax, d1)|Cmax Following Infusion 2 of the Initial Dose of IP at Day 15 (Cmax, d15)|AUC of the Initial Dose From Time 0 to Week 16 (AUC0-wk16) of IP|AUC of Infusion 2 of IP From Day 15 to Week 16 (AUCd15-wk16)|Time at Which Cmax, d1 (Tmax, d1) of IP is Observed|Time at Which Cmax, d15 (Tmax, d15) of IP is Observed|Trough Concentration (Ctrough) of IP at Day 15|Clearance (CL) of IP|Volume of Distribution (Vd) of IP|Terminal Elimination Half-life (T1/2) of IP|Mean Residence Time (MRT) of IP|Total Number of New or Enlarging T2 Hyperintense Lesions per Brain MRI|Total Number of New or Enlarging T2 Hyperintense Lesions per Brain MRI at Week 48|Total Number of GdE T1-weighted Lesions per Brain MRI|Total Number of GdE T1-weighted Lesions per Brain MRI at Week 48|Total Number of Combined Unique Active (CUA) Lesions per Brain MRI|Total Number of CUA Lesions per Brain MRI at Week 48|Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 24|Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 24|Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 48|Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 48|Percentage of Participants who are Relapse-free at Week 24|Percentage of Participants who are Relapse-free at Week 48|Percentage of Participants with Anti-drug Antibodies (ADAs)|Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)|Number of Participants Experiencing Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants Experiencing Treatment-emergent Events of Interest (EOIs)",False,
NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,"A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2009-12,2012-04,2012-04,2015-02-27,2010-01-20,INTERVENTIONAL,PHASE2,73.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis|RRMS,relapsing-remitting multiple sclerosis|RRMS,Czechia,Hradec Králové,Czech Republic,16,AIN457|Placebo,DRUG|DRUG,Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment,Raw Number of Cumulative New Gd-T1 Lesions|Raw Number of Cumulative New Gd-T2 Lesions,True,2015-02-27
NCT03636789,Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome,Evaluation of the Prevalence of Oculomotor Disorders in Patients With Radiologically Isolated Syndrome,COMPLETED,2018-10-26,2021-10-21,2021-11-05,2022-04-18,2018-08-17,INTERVENTIONAL,NA,61.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Radiologically Isolated Syndrome (RIS)|Multiple Sclerosis,,France,Bron,,6,Neurological consultation,OTHER,Evaluation of the occurrence of oculomotor disorders,To establish the prevalence of each of the different types of oculomotor abnormalities that constitute the oculomotor disorder|To identify a correlation between oculomotor disorders and MRI abnormalities.|To identify a correlation between oculomotor disorders and the cognitive impairment test (Symbol Digit Modalities Test),False,
NCT02383550,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension,COMPLETED,2014-12,2017-08-30,2017-08-30,2017-11-06,2015-03-09,OBSERVATIONAL,,46.0,ACTUAL,Clinique Neuro-Outaouais,OTHER,CogState Ltd.,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Cognition,Canada,Gatineau,Quebec,1,Observational Cognitive assessments,OTHER,SDMT|Cogstate Battery,,False,
NCT02283671,Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B,,COMPLETED,2015-09,2019-07-10,2019-07-10,2020-02-27,2014-11-05,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Sara Varea,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica,,Spain,Barcelona,,1,Tolerogenic Dendritic cells loaded with myelin peptides,BIOLOGICAL,number of patients with adverse events,Multiple Sclerosis Functional Composite scale|Multiple Sclerosis Spasticity Scale|Expanded Disability Status Scale|SF36 Health Status questionnaire|EuroQol5D|Changes in immunological profile|number of disease outbreaks,False,
NCT05168384,Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis,"Randomized, Controlled, Open-label Study Evaluating the Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2022-03-26,2025-09,2025-12,2025-02-20,2021-12-23,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,Abu Dhabi Stem Cells Center,OTHER_GOV,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",Extracorporeal Photopheresis|Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,United Arab Emirates,Abu Dhabi,Abu Dhabi Emirate,1,Extracorporeal Photopheresis|MS standard of care,COMBINATION_PRODUCT|COMBINATION_PRODUCT,"Tolerability to ECP procedures (Group A patients)|Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)|Tolerability to TEAEs, AESIs, and SAEs|Clinical improvement (25-foot walk)|Clinical improvement (9-hole peg test)|Clinical improvement (36-Item Short Form Survey)|Clinical improvement (EDSS baseline low score)|Clinical improvement (EDSS baseline high score)|Occurrence of clinical relapse at any point in the study",Immune response profile (cellular)|Immune response profile (humoral),False,
NCT01730131,Natural History Study of Progressive Multifocal Leukoencephalopathy (PML),Natural History Study of Progressive Multifocal Leukoencephalopathy (PML),RECRUITING,2012-11-08,2052-01-01,,2025-09-18,2012-11-21,OBSERVATIONAL,,700.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Progressive Multifocal Leukoencephalopathy,Encephalitis|Immune Reconstitution Syndrome|Human Immunodeficiency Virus|Multiple Sclerosis|Natural History,United States,Bethesda,Maryland,1,,,"To characterize the baseline presentation of patients with JCV infection and/or PML with regard to clinical, radiological, immunological, genetic and viral features.","To longitudinally follow patients with JCV infection and/or PML with thorough characterization of their clinical course, imaging correlates, immunological markers, and viral studies",False,
NCT02252666,Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS),Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS),COMPLETED,2014-03,2017-01,2017-06-28,2019-07-09,2014-09-30,INTERVENTIONAL,NA,6.0,ACTUAL,"University of Wisconsin, Madison",OTHER,,,Multiple Sclerosis,MS|balance|standing|control|movement,United States,Madison,Wisconsin,1,Neuromodulation Rehabilitation,DEVICE,Trunk Impairment Scale (TIS),Static Standing Balance Test|Impact of Visual Impairment Scale (IVIS)|Medical Outcomes Study (MOS) Pain Effects Scale (PES)|Bladder Control Scale (BLCS)|Bowel Control Scale (BWCS)|Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Walking Distance|Walking Speed|12-item MS Walking Scale (MSWS-12)|Box & Blocks (B&B) Assessment - Right|Box & Blocks (B&B) Assessment - Left|Multiple Sclerosis Impact Scale (MSIS-29) - Physical|Multiple Sclerosis Impact Scale (MSIS-29) - Psychological|Modified Fatigue Impact Scale (MFIS)|Gross Motor Function Measure (GMFM)|Slump Test|Modified Rivermead Mobility Index,True,2019-06-28
NCT01776034,Health Promotion and Wellness Program for Adults With Disabling Conditions,Examining the Efficacy of a SystemCHANGE™ Weight Management Intervention in Stroke Survivors and Persons With Chronic Inflammatory Autoimmune/Immune-mediated Diseases,COMPLETED,2013-01,2016-12,2016-12,2022-01-24,2013-01-25,INTERVENTIONAL,NA,66.0,ACTUAL,Case Western Reserve University,OTHER,American Heart Association|National Institutes of Health (NIH),OTHER|NIH,Stroke|Multiple Sclerosis|Rheumatoid Arthritis,Self Care|Exercise|Weight management,United States,Cleveland,Ohio,1,SystemCHANGE Group Lifestyle counseling|Phone Lifestyle Counseling,BEHAVIORAL|BEHAVIORAL,Changes from baseline in body weight.,Changes from baseline in cardiovascular risk biomarkers.|Changes from baseline in Walking Test.|Changes from baseline in 1-minute sit to stand test|Changes from baseline Physical Activity|Changes from baseline Self-efficacy for weight management|Changes from baseline social support for physical activity from family|Changes from baseline in emotional well-being,False,
NCT00866112,A Randomized Exercise Trial for Wheelchair Users,A Randomized Exercise Trial for Wheelchair Users,COMPLETED,2008-05,2011-02,2012-06,2012-06-15,2009-03-20,INTERVENTIONAL,NA,135.0,ACTUAL,University of Kansas,OTHER,,,Spinal Cord Injury|Multiple Sclerosis|Muscular Dystrophy|Cerebral Palsy|Spina Bifida|Amputation|Arthritis|Stroke,Wheelchair use|Spinal cord injury|Multiple sclerosis|Muscular dystrophy|Cerebral palsy|Spina bifida|Amputation|Arthritis|Stroke,United States,Lawrence,Kansas,1,Educational session to promote physical activity|Minimal contact,OTHER|OTHER,Weekly minutes spent in aerobic and strengthening activity,,False,
NCT03856619,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,COMPLETED,2019-03-27,2022-05-13,2022-05-13,2023-04-19,2019-02-27,INTERVENTIONAL,PHASE4,121.0,ACTUAL,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis,,India,Ahmedabad,,14,TERIFLUNOMIDE HMR1726,DRUG,Adverse events (AEs),Annualized relapse rate|First relapse|Relapse free|Neurological impairment/disability|Disability progression|Drug compliance,False,
NCT04742400,"Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis","A Phase 2 Clinical Trial of Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2021-04-15,2023-06-15,2025-12-31,2024-08-13,2021-02-08,INTERVENTIONAL,PHASE2,12.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,MS|BTK Inhibitor,United States,Bethesda,Maryland,1,tolebrutinib 60mg|tolebrutinib 120mg,DRUG|DRUG,Disappearance of Paramagnetic Rim Lesions at 48 Weeks of 60 mg of Tolebrutinib.,Safety and Tolerability of Tolebrutinib.|Repair of Chronically Inflamed White Matter Lesions,True,2024-08-13
NCT03057652,Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training,Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training,UNKNOWN,2016-03,2023-12,2023-12,2022-05-23,2017-02-20,INTERVENTIONAL,NA,75.0,ESTIMATED,"The University of Texas Health Science Center, Houston",OTHER,,,Complete Spinal Cord Injury|Incomplete Spinal Cord Injury|Acquired Brain Injury|Multiple Sclerosis,,United States,Houston,Texas,1,ReWalk|EKSO|REX,DEVICE|DEVICE|DEVICE,Change in over ground gait speed as assessed by the 10 Meter Walk Test without WRE|Change in walking endurance as assessed by the 6 Minute Walk Test without WRE|Change in muscle activity as assessed by electromyography (EMG) during 10MWT without WRE|Change in muscle activity as assessed by electromyography (EMG) during 6MWT without WRE|Change in energy expenditure as assessed by oxygen consumption during 10MWT without WRE|Change in energy expenditure as assessed by oxygen consumption during 6MWT without WRE|Change in gait kinematics as assessed by lower extremity joint excursion without WRE|Change in gait kinematics as assessed by lower extremity joint angular velocities without WRE,Bone mineral density as assessed by whole body scan|Cognitive impairment as assessed by Folstein Mini Mental State Examination|Lower Extremity Muscle Strength as assessed by using a force gauge such as a handheld dynamometer|Spasticity as assessed by the Modified Ashworth Scale (MAS)|Range of motion for lower extremity joints as assessed by manual examination|Stability during the maximum distance an individual can reach forward from a seated position as assessed by Modified Functional Reach (MFR)|Walking ability in ambulatory individuals with SC as assessed by Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI):|Amount of physical assistance needed for walking following paralysis resulted from SCI as assessed by Walking Index of Spinal Cord Injury (WISCI-II)|Motor recovery after stroke as assessed by Fugl-Meyer Assessment|Confidence in performing various ambulatory activities as assessed by Activities-Specific Balance Confidence Scale|User feedback as assessed by a questionnaire|Over ground gait speed as assessed by the 10 Meter Walk Test while wearing WRE|Change in walking endurance as assessed by the 6 Minute Walk Test while wearing WRE|Change in muscle activity as assessed by electromyography (EMG) during 10MWT while wearing WRE|Change in muscle activity as assessed by electromyography (EMG) during 6MWT while wearing WRE|Change in energy expenditure as assessed by oxygen consumption during 10MWT while wearing WRE|Change in energy expenditure as assessed by oxygen consumption during 6MWT while wearing WRE|Change in gait kinematics as assessed by lower extremity joint excursion while wearing WRE|Change in gait kinematics as assessed by lower extremity joint angular velocities while wearing WRE|Change in H-reflex of soleus muscle as assessed by electromyography (EMG),False,
NCT06615947,Conventional Multidisciplinary Gait Rehabilitation VR Robotic Self-balancing Based Gait Rehabilitation,Clinical Trial to Compare Conventional Multidisciplinary Gait Rehabilitation With the Atalante Self-balancing Walking System in Patients With Multiple Sclerosis,ENROLLING_BY_INVITATION,2023-02-28,2025-03-30,2025-03-30,2024-09-27,2024-09-27,INTERVENTIONAL,NA,60.0,ESTIMATED,Multiple Sclerosis Center of Catalonia,OTHER,,,"Multiple Sclerosis|Gait Disorders, Neurologic",,Spain,Barcelona,,1,Robotic gait training|tRHB,DEVICE|OTHER,"Timed 10-meters walk test (10-MWT),",,False,
NCT04022564,"Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis","Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis",UNKNOWN,2019-07-15,2020-05-20,2020-05-20,2019-07-17,2019-07-17,OBSERVATIONAL,,2000.0,ESTIMATED,Chun-Ming Liao,OTHER,,,Neurologic Signs and Symptoms,multiple sclerosis|Survival Analysis|cause of death|medical resources,Taiwan,Taichung,,1,,,"Incidence, and SurvivalMedical Expenditure of Patients with Multiple Sclerosis",,False,
NCT03774407,Vaginal Estriol in Multiple Sclerosis,Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS),COMPLETED,2019-06-20,2020-11-10,2020-11-29,2022-09-21,2018-12-13,INTERVENTIONAL,PHASE2|PHASE3,21.0,ACTUAL,Texas Tech University Health Sciences Center,OTHER,,,Multiple Sclerosis|Neurogenic Bladder,remyelination|urogenital health|multiple sclerosis,United States,Lubbock,Texas,1,vaginal estriol,DRUG,Change in Bladder Control Scale (BLCS)|Change in Visual Evoked Potential and Ocular Tomography Results From Baseline to 9 Months of Both Eyes|Change in MS Quality of Life Questionnaire at Baseline and 9 Months. (Physical Score),,True,2022-09-21
NCT04834401,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,Evaluating the Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in People With Multiple Sclerosis,COMPLETED,2021-03-22,2022-05-17,2022-05-17,2022-08-18,2021-04-08,OBSERVATIONAL,,45.0,ACTUAL,St. Barnabas Medical Center,OTHER,,,Multiple Sclerosis|Covid19,mRNA vaccine|Ocrelizumab|Natalizumab|Dimethyl Fumarate|Diroximel Fumarate|Interferon Beta|SARS-CoV-2,United States,Livingston,New Jersey,1,,,Geometric mean titers (GMT) of anti-SARS-CoV-2 spike IgG for each treatment at 8 weeks from initial vaccination dose,Proportion of participants with >4 fold increase in anti-SARS-CoV-2 spike IgG between baseline and 8 weeks|Proportion of participants with >2 fold increase in anti-SARS-CoV-2 spike IgG between baseline and 8 weeks|Median time from peak to complete absence of anti-SARS-CoV-2 IgG for each treatment arm|Proportion of spike-specific T-cells/Total T cells,False,
NCT02201212,Everolimus for Cancer With TSC1 or TSC2 Mutation,A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations,COMPLETED,2014-09,2019-06,2019-06,2020-09-16,2014-07-28,INTERVENTIONAL,PHASE2,30.0,ACTUAL,Dana-Farber Cancer Institute,OTHER,Novartis Pharmaceuticals,INDUSTRY,TSC1|TSC2|Tuberous Sclerosis Complex|MTOR,TSC1|TSC2|Tuberous Sclerosis Complex|MTOR,United States,Boston,Massachusetts,2,Everolimus,DRUG,Objective Response Rate,Duration of Response|Progression-free Survival|Overall Survival|Toxicity Rate,True,2020-09-16
NCT03846219,MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS),"Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)",ACTIVE_NOT_RECRUITING,2019-01-28,2020-04-24,2029-12,2024-04-24,2019-02-19,INTERVENTIONAL,PHASE2,210.0,ACTUAL,Immunic AG,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis (RRMS),RRMS|Multiple Sclerosis (MS),Bulgaria,Blagoevgrad,,38,IMU-838 (30 mg/day)|IMU-838 (45 mg/day)|Placebo|IMU-838 (10 mg/day),DRUG|DRUG|DRUG|DRUG,Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI Lesions,"Difference Between 30 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI Lesions|Difference Between 45 mg/Day IMU-838 and 30 mg/Day IMU-838 in the Cumulative Number of Combined Unique Active (CUA) MRI Lesions|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Mean Number of CUA Lesions Per Patient Per Scan at Weeks 6, 12, 18 and 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Cumulative Number of CUA MRI Lesions up to Weeks 6, 12, and 18|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Volume Changes of T2 Lesions at Weeks 6, 12, 18 and 24 Compared to Baseline|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the T2-lesion Load at Weeks 6, 12, 18 and 24 Compared to Baseline|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the T1-lesion Load at Weeks 6, 12, 18 and 24 Compared to Baseline|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Cumulative Number of New Gd+ Lesions up to Weeks 6, 12, 18 and 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Cumulative Number of New T2 Lesions up to Weeks 6, 12, 18 and 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Cumulative Number of New T1 Lesions up to Weeks 6, 12, 18 and 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Number of Patients Without New Gd+ Lesions Over 24 Weeks|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Number of Patients Without New or Enlarging T2-weighted Lesions Over 24 Weeks|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Number of Patients With CUA Lesions at Week 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Number of Patients With Gd+ Lesions at Week 24|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for the Number of Patients With T2 Lesions at Week 24|Differences Between Individual Treatments and Between the Pooled 30 mg/Day and 45 mg/Day Groups and Placebo in the Relapse-related Clinical Endpoints: Mean Annualized Relapse Rate (During Main and Extended Treatment Period)|Differences Between Individual Treatments and Between the Pooled 30 mg/Day and 45 mg/Day Groups and Placebo in the Relapse-related Clinical Endpoints: Proportion of Relapse-free Patients up to Week 24 and at Extended Periods Thereafter|Differences Between Individual Treatments and Between the Pooled 30 mg/Day and 45 mg/Day Groups and Placebo in the Relapse-related Clinical Endpoints: Time to Relapse at Time of Final Analysis of Main Part|Differences Between Treatments in Changes of Disease Activity as Measured by the Mean Change in the Expanded Disability Status Scale (EDSS) as Compared to Baseline During the Main and Extended Period (Every 12 Weeks Starting at Week 12)|Differences Between Treatments in Changes of Disease Activity as Measured by the Number of Patients With EDSS Progression During the Main and Extended Period (Every 12 Weeks Starting at Week 12, and Cumulatively)|Correlation of MRI-based Assessments With Quartiles of IMU-838 Trough Levels|Number of Participants With AEs|Number of Participants With Serious AEs|Number of Participants With Clinically Significant Laboratory Abnormalities (as Assessed by the Investigator)|Number of Participants With AEs of Special Interest: Red Blood Cell Urine Positive, at Least of Moderate Intensity|Number of Participants With AEs of Special Interest: Hematuria|Number of Participants With AEs of Special Interest: Retroperitoneal Colicky Pain With Suspected or Confirmed Nephrolithiasis|Number of Patients Treated With 30 mg/Day or 45 mg/Day IMU-838 as Compared to Placebo Who Experienced at Least One of the Following AEs:|12-lead Electrocardiogram (ECG): Heart Rate|12-lead Electrocardiogram (ECG): PQ-interval|12-lead Electrocardiogram (ECG): QRS-interval|12-lead Electrocardiogram (ECG): QT-interval|12-lead Electrocardiogram (ECG): Heart Rate-corrected QTc Interval (According to Bazett's Formula)|Physical Examination|Vital Signs: Height|Vital Signs: Weight (Absolute Change From Baseline at Week 24)|Vital Signs: Body Temperature (ºC) (Absolute Change From Baseline at Week 24)|Vital Signs: Respiratory Rate (Absolute Change From Baseline at Week 24)|Vital Signs: Pulse Rates (Absolute Change From Baseline at Week 24)|Vital Signs: Systolic and Diastolic Blood Pressures (Absolute Change From Baseline at Week 24)|Micro Ribonucleic Acid (miR)-122 Expression|Presence of John Cunningham Virus (JCV) Deoxyribonucleic Acid (DNA) in Urine in Patients With Detectable JCV-DNA in Urine|Time to Treatment Discontinuation for Any Reason|Rate of Treatment Discontinuations up to Week 24|Population Pharmacokinetics: Minimum IMU-838 Plasma Concentration Over the Dosing Interval (Cmin)|Population Pharmacokinetics: Maximum IMU-838 Plasma Concentration Over the Dosing Interval (Cmax)|Population Pharmacokinetics: Area Under the IMU-838 Plasma Concentration-time Curve Over the Dosing Interval (AUC0-τ)|Population Pharmacokinetics: IMU-838 Apparent Clearance Following Oral Dosing (CL/F)|Population Pharmacokinetics: IMU-838 Apparent Volume of Distribution (V/F)|Plasma Trough Levels of IMU-838|Changes From Baseline in Th1 Lymphocyte Subset as Measured by Flow Cytometry|Changes From Baseline in Th17 Lymphocyte Subset as Measured by Flow Cytometry|Changes From Baseline in Treg Lymphocyte Subset as Measured by Flow Cytometry|Changes From Baseline in Serum Neurofilament|Treatment Satisfaction Questionnaire for Medication (TSQM)|Difference Between 30 mg/Day IMU-838 and Placebo, 45 mg/Day IMU-838 and Placebo, and 30 mg/Day and 45 mg/Day IMU-838 for Brain Atrophy.",True,2021-07-23
NCT05366036,A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis,Post Marketing Surveillance Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Patients With Relapsing-Remitting Multiple Sclerosis,COMPLETED,2017-06-14,2022-01-14,2022-01-14,2022-05-09,2022-05-09,OBSERVATIONAL,,172.0,ACTUAL,Eisai Korea Inc.,INDUSTRY,,,"Multiple Sclerosis, Relapsing-remitting",MS0008|Dimethyl Fumarate|Multiple sclerosis|Tecfidera|Korean participants,South Korea,Cheonan,Chungcheongnam-do,20,No Intervention,OTHER,Number of Participants With Adverse Events (AEs)|Number of Participants With Adverse Drug Reactions (ADRs)|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants With Serious Adverse Drug Reactions (SADRs)|Number of Participants With Unexpected AEs|Number of Participants With Unexpected ADRs,Annualized Relapse Rate|Percentage of Relapsing Participants|Number of Gadolinium (Gd) Enhancing Lesions|Change from Baseline in Participant's Global Efficacy Assessment by the Treating Physician,False,
NCT06576947,Virtual Reality in the Treatment of Pelvic Floor Dysfunction in Women With Multiple Sclerosis,Effects of Virtual Reality in the Treatment of Pelvic Floor Dysfunction in Women With Multiple Sclerosis: A Randomized Clinical Trial,NOT_YET_RECRUITING,2024-09-01,2025-07-01,2025-12-01,2024-08-29,2024-08-29,INTERVENTIONAL,NA,45.0,ESTIMATED,Universidad de Almeria,OTHER,,,Multiple Sclerosis,virtual reality|multiple sclerosis|pelvic floor|randomized controlled trial,,,,0,Virtual reality|Neuromodulation of the tibialis posterior nerve|Pelvic floor muscle training,OTHER|OTHER|OTHER,Pelvic floor strength,Australian pelvic floor questionnaire:|Multiple Sclerosis Quality of Life-54 (MSQOL-54):|Euroqol|SF12,False,
NCT00099307,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,An Exploratory Study on Detection of Cortical Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging,COMPLETED,2004-12-08,,2011-09-28,2017-07-02,2004-12-10,OBSERVATIONAL,,94.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,White Matter|Grey Matter|Brain|Disability|Lesions|Multiple Sclerosis|MS|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,,,,,False,
NCT04386863,Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study,Taxonomy of Neurorehabilitation Treatments and Outcome Measures: a Multicentre Italian Study,COMPLETED,2018-06-22,2022-07-07,2022-07-22,2022-11-15,2020-05-13,OBSERVATIONAL,,204.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,"IRCCS San Camillo, Venezia, Italy|Universita degli Studi di Genova|AIAS di Milano Onlus|Ospedale San Carlo Borromeo|Azienda Universitaria Integrata Giuliano Isontina, Trieste, Italy|Presidio Ospedaliero San Camillo di Torino|Ospedali Riuniti Ancona|Istituto Don Orione, Pescara, Italy",OTHER|OTHER|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|OTHER|UNKNOWN,Multiple Sclerosis|Stroke|Parkinson Disease,Multiple Sclerosis|Stroke|Parkinson|Taxonomy|Rehabilitation|Outcome measures,Italy,Genova,,7,,,Change in Two minute walking test|Change in Box and Blocks test,Change in Reaching Performance Scale|Change in Activities-specific Balance Confidence scale|Change in Cognitive dual-task Timed-Up-and-Go test|Change in Manual Ability Measurement|Change in modified Dynamic Gait Index|Modified Barthel Index,False,
NCT07146087,Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis,Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis,SUSPENDED,2020-07-01,2023-06-30,2027-12-31,2025-08-28,2025-08-28,INTERVENTIONAL,EARLY_PHASE1,20.0,ESTIMATED,Biocells Medical,INDUSTRY,,,Multiple Sclerosis,sclerosis|multiple sclerosis|MSC,Poland,Warsaw,,1,MSC-Derived Exosomes|Placebo (Normal Saline),BIOLOGICAL|BIOLOGICAL,Change in Expanded Disability Status Scale (EDSS) score,Change in T2 lesion load and brain atrophy|Change in neurocognitive performance,False,
NCT04009187,A Wheelchair Propulsion Training Program,Efficacy of a Wheelchair Propulsion Training Program for Manual Wheelchair Users: a Pilot Study,COMPLETED,2018-03-27,2019-10-22,2019-10-22,2025-03-28,2019-07-05,INTERVENTIONAL,NA,20.0,ACTUAL,Washington University School of Medicine,OTHER,,,Spinal Cord Injuries|Multiple Sclerosis|Amputation|Spina Bifida,manual wheelchair|wheelchair propulsion|motor learning,United States,St Louis,Missouri,1,In-person wheelchair propulsion training program|30-minute education session,BEHAVIORAL|BEHAVIORAL,Motion capture - changes in push angle|Motion capture - changes in hand-axle distance|Wheelchair Propulsion Test (WPT) - changes in effectiveness|Wheelchair Propulsion Test (WPT) - changes in cadence|Wheelchair Propulsion Test (WPT) - changes in propulsion pattern|Outdoor propulsion - ratio of efficient propulsion pattern,,False,
NCT00845338,Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",TERMINATED,2007-02,2007-10,2007-10,2014-12-02,2009-02-18,INTERVENTIONAL,PHASE2,7.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis|Overactive Detrusor,Darifenacin|Multiple Sclerosis|Open Label Study,Germany,Emmendingen,Baden-Wurttemberg,15,Darifenacin (BAY79-4998),DRUG,Change from baseline in volume at first detrusor contraction as determined by urodynamics,Detrusor pressure at first contraction|Volume at first detectable leakage|Volume at 10/20/30/40 cm H2O|Compliance|Maximum cystometric bladder capacity|7-day micturition diary: Micturitions|7-day micturition diary: Urgency episodes|7-day micturition diary: Urge urinary incontinence episodes,False,
NCT06256471,The Impact of Parasitic Infection on Multiple Sclerosis and Nephrotic Syndrome,The Impact of Parasitic Infection on the Course of Multiple Sclerosis and Nephrotic Syndrome,NOT_YET_RECRUITING,2024-06-01,2025-06-01,2025-08-01,2024-02-13,2024-02-13,OBSERVATIONAL,,200.0,ESTIMATED,Assiut University,OTHER,,,Parasitic Disease,,,,,0,Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months,OTHER,The impact of parasitic infection on multiple sclerosis and nephrotic syndrome,,False,
NCT00594087,Eszopiclone for Improving Sleep in Multiple Sclerosis (MS),Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue,COMPLETED,2006-12,2008-05,2008-06,2009-01-05,2008-01-15,INTERVENTIONAL,NA,30.0,ACTUAL,University of Vermont,OTHER,,,Relapsing Remitting Multiple Sclerosis|Sleep Initiation and Maintenance Disorders|Fatigue,,United States,Burlington,Vermont,1,eszopiclone|placebo,DRUG|OTHER,Fatigue,Sleep continuity|Neurocognitive function,False,
NCT02792231,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.,"A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.",COMPLETED,2016-08-26,2019-07-10,2020-10-22,2021-11-22,2016-06-07,INTERVENTIONAL,PHASE3,955.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Scelrosis,Relapsing multiple sclerosis|Ofatumumab|adult|OMB157|multiple sclerosis|T1 lesions|T2 lesions|relapse|GD-enhancing MRI|McDonald criteria|RRMS|SPMS,United States,Birmingham,Alabama,178,Ofatumumab subcutaneous injection|Teriflunomide-matching placebo capsules|Teriflunomide capsule|Matching placebo of ofatumumab subcutaneous injections,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2302|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2302|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2302|Number of Gadolinium-enhancing T1 Lesions Per MRI Scan|Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate)|Neurofilament Light Chain (NfL) Concentration in Serum|Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline|Participants With Confirmed Relapse|Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data|Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data|6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data|Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS)|Percent Change in T2 Lesion Volume Relative to Baseline|No Evidence of Disease Activity (NEDA-4)|Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline|Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline|Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data|Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data|Brain Volume Loss by NfL High-low Subgroups - Pooled Data|Pharmacokinetic (PK) Concentrations of Ofatumumab,True,2020-10-19
NCT01539395,A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis,A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis,WITHDRAWN,2012-01,2012-04,2012-07,2020-09-02,2012-02-27,OBSERVATIONAL,,0.0,ACTUAL,"MSDx, Inc.",INDUSTRY,,,Multiple Sclerosis,Relapsing Remitting|MS,United States,Tucson,Arizona,1,MSDx Complex-1 Biomarker Test,OTHER,Biomarker Differential,Biomarker reduction with steroid therapy,False,
NCT05930821,"Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis","Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2023-07-05,2025-02-11,2025-03-31,2025-02-27,2023-07-05,INTERVENTIONAL,NA,51.0,ACTUAL,University of Illinois at Chicago,OTHER,,,Older Adults|Multiple Sclerosis|Cognitive Impairment|Walking Impairment,Cognition|Walking|Exercise|Physical Activity,United States,Chicago,Illinois,1,Aerobic and Resistance Exercise Program (GEMS program)|Flexibility and Stretching Program (FLEX-MS program),BEHAVIORAL|BEHAVIORAL,Cognitive Function|Cognitive Function|Physical Function|Lower-extremity Function|Functional Mobility|Walking Endurance|Walking Speed,Physical Activity Level|Physical Activity Level|Exercise Behavior|Vascular Function|Vascular Function|Vascular Function,False,
NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,"A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2015-09-03,2017-03-09,2017-09-27,2020-09-09,2015-07-14,INTERVENTIONAL,PHASE3,744.0,ACTUAL,Cytokinetics,INDUSTRY,,,Amyotrophic Lateral Sclerosis,fast skeletal troponin activator|tirasemtiv|CK-2017357|double-blind|randomized|placebo-controlled,United States,Phoenix,Arizona,81,Tirasemtiv|Placebo tablets,DRUG|DRUG,"Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)","Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment|Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment|Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment|Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment|Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment|Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment",True,2020-06-19
NCT04480307,Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis,"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis (RMS)",COMPLETED,2020-06-17,2022-01-24,2022-01-24,2024-11-07,2020-07-21,INTERVENTIONAL,PHASE2,41.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis|GNbAC1|Human Endogenous Retrovirus Type W|HERV-W|Temelimab,Sweden,Stockholm,,1,temelimab 18 mg/kg|temelimab 36 mg/kg|temelimab 54 mg/kg|Placebo,DRUG|DRUG|DRUG|DRUG,Safety and Tolerability,Neuroimaging|Neuroimaging|Neuroimaging|Neuroimaging|Neuroimaging,True,2024-11-07
NCT04987463,Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants,"Randomized, Placebo-controlled, Double-blind and Double-dummy Clinical Trial Comparing the Safety, Tolerability, and Efficacy of Vigabatrin and Rapamycin in a Preventive Treatment of Infants With Tuberous Sclerosis Complex",RECRUITING,2021-05-07,2026-03,2026-03,2024-02-08,2021-08-03,INTERVENTIONAL,PHASE2|PHASE3,60.0,ESTIMATED,Katarzyna Kotulska,OTHER,,,Tuberous Sclerosis Complex,"tuberous sclerosis complex, epilepsy, rapamycin, vigabatrin, tumors, prevention",Poland,Warsaw,,2,Vigabatrin|Rapamycin|Placebo|Placebo,DRUG|DRUG|DRUG|DRUG,"Occurrence of clinical seizures in the blinded phase of the study,|Summarized volume of TSC-associated tumors ≥ 125% of initial value within the blinded phase of the study","Total volume of TSC-associated tumors within the blinded phase and the whole study|The risk for high risk of autism assessed with psychological test at 6, 12, 18, 24 months|The risk for low developmental quotient (< 70 points in Bayley Scales of Infant Development, measured at the end of the blinded phase and at the end of the entire study) at the end of the study|The risk of drug-resistant epilepsy at any point of the study|Occurrence of adverse events within the blinded phase of the study|Number of adverse events across the whole study|Parameters of physical development (weight gain history) across the whole study|Parameters of physical development (height gain history) across the whole study",False,
NCT04786821,Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis,Feasibility Study for a Randomised Control Trial for the Acceptability of Exoskeleton Assisted Walking Compared to Standard Exercise Training for Persons With Mobility Issues Due to Multiple Sclerosis,RECRUITING,2022-06-23,2024-10-30,2024-10-30,2024-05-29,2021-03-08,INTERVENTIONAL,NA,24.0,ESTIMATED,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,,,"Multiple Sclerosis|Pathologic Processes|Sclerosis|Autoimmune Diseases of the Nervous System|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases",Exoskeleton Device|Exercise Programme,United Kingdom,Sheffield,South Yorkshire,1,Standard Exercise Training|Phoenix Exoskeleton suit,BEHAVIORAL|DEVICE,Recruitment rate estimation|Retention rate estimation|Acceptability of the intervention - VAS|Acceptability of the intervention - Patient perception questionnaire,Number of participants achieving target heart rate|Aerobic Fitness (arm cranking)|Waist to hip ratio|Body fat percentages|10 metre walking gait test wearing inertial sensors|Multiple Sclerosis Impact Scale (MSIS-29)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis walking scale (MSWS-12)|The Borg rating of perceived exertion scale|Quality of life questionnaire (EQ-5D-5L & VAS),False,
NCT02421731,Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis Patients,Effectiveness of Robot-assisted Gait Training Versus Conventional Therapy on Mobility in Severely Disabled Multiple Sclerosis Patients,COMPLETED,2014-02,2018-02,2018-02,2023-02-08,2015-04-21,INTERVENTIONAL,NA,72.0,ACTUAL,University Hospital of Ferrara,OTHER,Regione Emilia-Romagna|Università degli Studi di Ferrara,OTHER|OTHER,Multiple Sclerosis,Rehabilitation|Gait,Italy,Ferrara,,1,Robot-assisted gait training|Conventional therapy,DEVICE|OTHER,Timed 25 Foot Walk,Six-Minute Walking Test|Berg Balance Scale|Up and Go Test|Fatigue Severity Scale|Modified Ashworth Scale|Short-Form 36|Haemodynamic measurements|Metabolic measurements by Near infrared spectroscopy|Circulating biomarkers,False,
NCT03655431,Home Exercise Telerehabiliation for MS,Telerehabilitation Using Kinect-based VR to Improve Mobility and Fatigue in Veterans With MS,COMPLETED,2016-10-01,2019-10-01,2021-01-01,2021-04-08,2018-08-31,INTERVENTIONAL,NA,10.0,ACTUAL,Shane.Chanpimol,FED,,,Multiple Sclerosis,multiple sclerosis|rehabilitation|telerehabilitation|telehealth|veteran health|physical therapy,United States,Washington D.C.,District of Columbia,1,Telerehabilitation|Standard treatment,OTHER|OTHER,Multiple Sclerosis Walking Scale-12 (MSWS-12),Short Physical Performance Battery (SPPB)|25-Foot Walk Test (25FWT)|Modified Fatigue Impact Scale (MFIS)|Veteran Rand 12 Quality of Life Measure (VR-12),False,
NCT01532154,Fampridine Pregnancy Exposure Registry,Fampridine Pregnancy Exposure Registry,TERMINATED,2015-08,2016-02,2016-02,2016-10-18,2012-02-14,OBSERVATIONAL,,1.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis|Pregnancy,,France,Paris,,1,Fampridine,DRUG,Spontaneous abortions|Elective or therapeutic terminations|Ectopic pregnancy|Fetal death including still births|Live born infants|Premature births|Maternal death|Neonatal death|Birth Defects,,False,
NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,"A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)",TERMINATED,2014-09-30,2016-05-02,2016-05-02,2017-06-05,2014-09-16,INTERVENTIONAL,PHASE4,47.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Fullerton,California,11,natalizumab,DRUG,Proportion of Participants With No Evidence of Disease Activity (NEDA) From Reset Baseline (Week 8) to Week 56,Change in T1 Unenhancing Lesion Volume and T2 Lesion Volume From Baseline (Day -1) to Reset Baseline (Week 8)|Proportion of Participants With NEDA From Week 8 (Reset Baseline) to Week 104|Pre- and Post-Natalizumab Infusion Annualized Relapse Rate (ARR) Comparison at Month 12|Change in MSIS-29 Physical Impact Scores From Baseline (Day -1) to Reset Baseline (Week 8),True,2017-06-05
NCT05712408,"Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis","Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis",COMPLETED,2023-01-01,2023-04-19,2023-04-19,2023-08-14,2023-02-03,INTERVENTIONAL,NA,16.0,ACTUAL,"University of North Texas, Denton, TX",OTHER,,,Multiple Sclerosis,,United States,Denton,Texas,1,800g Challenge,BEHAVIORAL,Metabolic Health|Body Weight|Body Fat,6-Minute Walk|25-Foot Walk|Cognitive Assessments|Fatigue|Health-Related Quality of Life,False,
NCT01853423,Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream,Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream,COMPLETED,2013-10,2016-05,2016-07,2016-08-19,2013-05-15,INTERVENTIONAL,PHASE1,11.0,ACTUAL,Le Bonheur Children's Hospital,OTHER,Pfizer|University of Tennessee,INDUSTRY|OTHER,Facial Angiofibroma,Rapamune|Topical|Pediatric|Safety|Efficiency|Angiofibroma|Skin Cream,United States,Memphis,Tennessee,1,Rapamune,DRUG,Reduction of facial angiofibroma with use of rapamune facial skin cream,,False,
NCT06127095,A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments,New perSEPtion. New Patient's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based RRMS Treatments.,COMPLETED,2023-11-24,2024-11-28,2024-11-28,2024-12-18,2023-11-13,OBSERVATIONAL,,474.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Cambridge,Massachusetts,1,,,Number of Participants who Perceived the Treatment Added Value of Natalizumab Assessed by Likert's Scale,Number of Participants who Perceived Burden of Treatment Assessed by Closed and Open-ended Questions|Number of Participants With Perceived Decision-making Process Assessed by Likert's Scale|Number of Participants With Perceived Decision-making Process Assessed by Open-ended Questions on Quality of Life (QOL)|Number of Participants Characterized by Multiple Sclerosis (MS) Types|Number of Participants Characterized by MS Duration|Number of Participants Characterized by Current Disease Modifying Treatment (DMT)|Mean Multiple Sclerosis International Quality of Life Questionnaire (MusiQol) Score|Mean Fatigue Severity Scale (FSS) Score,False,
NCT05724901,At-Home Gait Assessment,A Wearable Remote Data Capture Solution for Home-Based Gait Assessment in Multiple Sclerosis,COMPLETED,2023-01-11,2024-01-04,2024-01-04,2024-01-17,2023-02-13,OBSERVATIONAL,,30.0,ACTUAL,NYU Langone Health,OTHER,United States Department of Defense,FED,Multiple Sclerosis,Gait Analysis|telehealth|sensor-based gait analysis|home-based,United States,New York,New York,1,,,Mean Gait Velocity,Mean Stride Length|Mean Double Support Duration|Mean Stance Duration|Mean Cadence,False,
NCT01526356,Topical Rapamycin to Erase Angiofibromas in TSC,Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy,COMPLETED,2012-05,2014-08,2014-08,2020-10-26,2012-02-03,INTERVENTIONAL,PHASE2,179.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,,,Angiofibromas|Tuberous Sclerosis,Angiofibroma|Tuberous Sclerosis|Rapamycin|Sirolimus|mTOR,United States,Birmingham,Alabama,10,Placebo|Rapamycin|Rapamycin,DRUG|DRUG|DRUG,Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score,"Photo Readers' Rating (Better, Same, or Worse) of Paired Baseline and End-of-trial (EOT) Photographs for Each Patient|Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Dermatology Life Quality Index (DLQI)|Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Children's Dermatology Life Quality Index (CDLQI)|Change in Quality of Life (QOL) Questionnaire Scores as Assessed by the Family Dermatology Life Quality Index (FDLQI)",True,2020-10-26
NCT06401928,Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis,Electrical Brain Stimulation for Improving Mental Health and Cognitive Functioning in Patients With Multiple Sclerosis,COMPLETED,2023-02-28,2023-12-15,2024-01-31,2024-05-08,2024-05-07,INTERVENTIONAL,NA,53.0,ACTUAL,The National Brain Mapping Laboratory (NBML),OTHER,Mohaghegh Ardabili University,UNKNOWN,Multiple Sclerosis,,Iran,Rasht,Giulan,1,transcranial direct current stimulation|transcranial direct current stimulation combined with cognitive training|transcranial direct current stimulation,DEVICE|DEVICE|DEVICE,Multiple Sclerosis Impact Scale (MSIS-29)|and Depression Anxiety Stress Scale-21 (DASS-21)|Mini sleep questionnaire (MSQ),psychomotor speed task|attention / vigilance task,False,
NCT03796611,Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS),Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS),UNKNOWN,2020-12,2022-10,2022-10,2020-09-16,2019-01-08,OBSERVATIONAL,,172.0,ESTIMATED,"University Hospital, Lille",OTHER,,,Multiple Sclerosis,immunology|B cells,,,,0,,,the percentage of 4 BL cells in blood between MS patients and healthy controls,the percentage of 4 BL cells in blood between MS patients and patients with inflammatory and non inflammatory neurological disease|the percentage of 4 BL cells in CSF between MS patients and patients with inflammatory and non inflammatory neurological disease|to analyse over time the evolution of 4BL percentages in blood in MS patients,False,
NCT00695084,Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS),Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis,COMPLETED,2007-03,2008-04,2008-04,2008-06-11,2008-06-11,INTERVENTIONAL,PHASE1,7.0,ACTUAL,National Multiple Sclerosis Society,OTHER,,,Multiple Sclerosis,multiple sclerosis,United States,Birmingham,Alabama,1,Constraint-Induced Movement Therapy,BEHAVIORAL,Improvement on the Motor Activity Log,Improvement on the Wolf Motor Function Test,False,
NCT06249438,A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy,An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)/Anti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy,RECRUITING,2024-03-20,2027-03,2040-03,2025-07-25,2024-02-08,INTERVENTIONAL,PHASE1,30.0,ESTIMATED,RenJi Hospital,OTHER,AbelZeta Pharma Inc.,UNKNOWN,Systemic Lupus Erythematosus (SLE)|Immune-mediated Necrotizing Myopathy (IMNM)|Neuromyelitis Optica Spectrum Disorders (NMOSD)|Multiple Sclerosis (MS)|Myasthenia Gravis|Systemic Sclerosis (SSc),CD20/BCMA-directed CAR-T cells,China,Shanghai,Shanghai Municipality,1,CD20/BCMA-directed CAR-T cells,BIOLOGICAL,Incidence of Adverse Events [Safety and Tolerability]|The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapy,The proportion of subjects who achieved remission at 6 months (6M)|The proportion of subjects who achieved remission during the main study period|The proportion of subjects who experienced relapse during the main study period|Time to response (TTR)|Progression-free survival (PFS)|The proportion of subjects who achieved glucocorticoids/immunosuppressant free and subjects who achieved low-dose glucocorticoids application during the main study period|Maximal plasma concentration (Cmax)|Time to reach the maximal plasma concentration (Tmax)|Duration in peripheral blood (Tlast)|Area under curve (AUC)|The clearance of peripheral blood B cell|The decline of serum immunoglobulin|The elevation of peripheral blood complement|The decline of autoantibodies or other disease specific biomarkers,False,
NCT05357950,"A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS","A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS",COMPLETED,2022-05-31,2023-11-02,2024-11-04,2025-09-05,2022-05-03,INTERVENTIONAL,PHASE2,69.0,ACTUAL,NeuroSense Therapeutics Ltd.,INDUSTRY,,,Amyotrophic Lateral Sclerosis|ALS,,Canada,London,Ontario,4,PrimeC|Placebo,DRUG|DRUG,Incidence and severity of treatment-emergent adverse events (TEAEs)|Number of subjects who discontinued treatment prematurely|Number of patients who discontinued treatment prematurely due to adverse events|Number of patients with clinically significant abnormal laboratory values|The mean difference between PrimeC and Placebo in serum concentration of NDE TDP-43 at month 6|The mean difference between PrimeC and placebo in serum concentration of NDE PgJ2 at month 6,Change from baseline to 6 months in ALS functional rating scale - revised (ALSFRS-R)|Change from baseline to 6 months in slow vital capacity (SVC)|Change from baseline to 6 months in quality of life ALSSQOL-SF|Change from baseline to 6 months in PROMIS-10 quality of life questionnaire|Survival at 6 months of treatment|Composite survival at 6 months of treatment|Composite survival at 6 months of treatment|Joint Assessment of Function and Survival after 6 months of treatment,False,
NCT02081508,Consolidation & Interference in Multiple Sclerosis,Consolidation & Interference in Multiple Sclerosis,COMPLETED,2014-03,2015-05,2015-05,2016-08-01,2014-03-07,INTERVENTIONAL,NA,39.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis,Memory,United States,West Orange,New Jersey,1,Interference onset,BEHAVIORAL,Recall Proportion,,False,
NCT03283397,"A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS","A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",TERMINATED,2019-03-26,2023-07-01,2023-07-01,2024-08-13,2017-09-14,INTERVENTIONAL,PHASE3,301.0,ACTUAL,Bosnalijek D.D,INDUSTRY,MonitorCRO,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,Turkey (Türkiye),Kocaeli,,1,EK-12|INF beta-1a,DRUG|DRUG,Superiority of efficacy of EK-12 to interferon beta-1a in patients with RRMS,EDSS score|clinical attacks|T2 lesions|T1 lesions,False,
NCT02869360,Correlation Between PET and Advanced MRI in Multiple Sclerosis,Pilot Study of Positron Emission Tomography (PET) Imaging: Correlations With Advanced Magnetic Resonance Imaging in Multiple Sclerosis,COMPLETED,2016-10,2019-10-02,2019-10-02,2019-10-03,2016-08-16,OBSERVATIONAL,,14.0,ACTUAL,University of British Columbia,OTHER,Teva Pharmaceuticals USA,INDUSTRY,Multiple Sclerosis,,Canada,Vancouver,British Columbia,1,,,Whole Brain PBR28 binding,"Lesional PiB binding|Myelin Water Imaging|MR Spectroscopy (Total NAA, NAA/Cr, mI)|Optical Coherence Tomography (RNFL thickness)",False,
NCT01489748,Canadian Avonex PEN Productivity Study,"An Open-Label, Observational, Multicenter Study to Evaluate the Impact of AVONEX PEN Autoinjector Therapy on Work Capacity of Multiple Sclerosis Patients in Canada",COMPLETED,2012-03,2014-10,2014-12,2015-02-20,2011-12-12,OBSERVATIONAL,,111.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Canada,Burlington,Ontario,1,,,Change from Baseline in work capacity,Number of participants with hospital and emergency episodes of care|Number of missed injections|Number of participants who discontinued treatment|Change from Baseline in Global Quality of life score|Change from Baseline in participants' satisfaction with the device|Change from Baseline in ease of use of the device|Number of participants with injection site reactions (ISRs),False,
NCT00752778,Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri,MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri,TERMINATED,2008-12,2011-03,2011-03,2012-11-12,2008-09-15,INTERVENTIONAL,PHASE4,8.0,ACTUAL,"University Hospital, Strasbourg, France",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,"MRI, PET scan",France,Strasbourg,,3,pet-scan FDG-F18,OTHER,Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).,Correlation with relapses.,False,
NCT06256159,Validity and Reliability of the 12-item Multiple Sclerosis Walking Scale (12-WS) in Subjects With Spinal Cord Injury,Validity and Reliability of the 12-item Multiple Sclerosis Walking Scale (12-WS) in Subjects With Spinal Cord Injury,COMPLETED,2024-03-22,2025-03-05,2025-03-05,2025-05-29,2024-02-13,INTERVENTIONAL,NA,67.0,ACTUAL,University of Zurich,OTHER,"Swiss National Science Foundation|Swiss Paraplegic Research, Nottwil",OTHER|NETWORK,"Spinal Cord Injuries|Gait Disorders, Neurologic",,Switzerland,Nottwil,,2,12 MSWS questionnaire,OTHER,Re-test reliability of the subjective perceived limitations in ambulation of the 12-item Multiple Sclerosis Walking Scale (12-WS) in subjects with incomplete SCI.|Validity of the 12-item Multiple Sclerosis Walking Scale (12-WS) in subjects with incomplete SCI.,"Clinical examination (a neurological examination including the ASIA score (categoric outcome grade A-E) - International Standards for Neurological Classification of Spinal Cord Injury|Walking impairment (numeric value from 0-20) - WISCI II|Walking distance (m) and number of rests - 6MWT|Walking speed (m/s) - 10-meter walkint test (10MWT)|Walking speed including sit-stand transfer (s) - Timed Up and Go-test (TUG)|Functional independence (numeric value from 0-40) - Spinal Cord Independence Measure III (SCIM III), Items 9-17|Dynamic balance (numeric value from 0-30) - Functional Gait Assessment (FGA)|Change in impairment level (nominal outcome Yes - No) - Follow up questions in telephone interview",False,
NCT02451696,A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD,A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD,COMPLETED,2014-01,2017-12-08,2017-12-28,2021-09-01,2015-05-22,INTERVENTIONAL,PHASE2,15.0,ACTUAL,NYU Langone Health,OTHER,,,Epilepsy|Tuberous Sclerosis Complex|Focal Cortical Dysplasia,,United States,New York,New York,1,Everolimus,DRUG,Number of Patients With Adverse Events,Blood Everolimus Levels|Blood Total VEGF Levels (Not Only VEGF-D)|mTOR Brain Tissue-S6 Phosphate by Western Blot|HMGB1 Expression in Brain Tissue,True,2021-09-01
NCT06640660,Investigating Visuo-spatial Abilities and Psychological Effects in West Nile and Multiple Sclerosis Patients with a Focus on a Possible Rehabilitation Protocol,Investigating Visuo-spatial Abilities and Psychological Effects in West Nile and Multiple Sclerosis Patients with a Focus on a Possible Rehabilitation Protocol,RECRUITING,2022-09-21,2024-12-30,2024-12-30,2024-10-15,2024-10-15,INTERVENTIONAL,NA,50.0,ESTIMATED,"IRCCS San Camillo, Venezia, Italy",OTHER,,,Multiple Sclerosis|West Nile Virus,neurological patients|cognitive training|neuropsychology,Italy,Lido,Venezia,1,Mindlenses Professional|Conventional rehabilitation,DEVICE|BEHAVIORAL,Measure of changes in cognitive performance after the treatment,Measure of changes in psychological aspects after the treatment,False,
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)",COMPLETED,2007-12,2009-06,2009-09,2017-04-12,2007-12-14,INTERVENTIONAL,PHASE3,326.0,ACTUAL,Avanir Pharmaceuticals,INDUSTRY,Syneos Health,OTHER,Pseudobulbar Affect (PBA),"Amyotrophic Lateral Sclerosis (Lou Gehrig's disease, ALS)|Multiple Sclerosis (MS)",United States,Phoenix,Arizona,62,dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Placebo,DRUG|DRUG|DRUG,"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted",Mean Change From Baseline in CNS-LS Total Score by Visit|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)|Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)|Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category|Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score|Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects,True,2013-07-10
NCT00676715,A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS",COMPLETED,2008-07-17,2012-03-09,2023-11-08,2024-12-31,2008-05-13,INTERVENTIONAL,PHASE2,220.0,ACTUAL,"Genentech, Inc.",INDUSTRY,Roche Pharma AG,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,United States,Phoenix,Arizona,84,Placebo|Ocrelizumab|Avonex,DRUG|DRUG|DRUG,Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain,Annualized Protocol Defined Relapse Rate at Week 24|Percentage of Participants Who Remained Relapse Free at Week 24|Change From Baseline in Total Volume of T2 Lesions on MRI Scans of the Brain at Week 24|Total Number of New Gadolinium-Enhancing T1 Lesions Observed by MRI Scans of the Brain|Total Number of Gadolinium-Enhancing T1 Lesions,True,2017-05-11
NCT00536120,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,"A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis",COMPLETED,2008-01,2009-11,2009-12,2017-02-15,2007-09-27,INTERVENTIONAL,PHASE4,60.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,MS|Multiple sclerosis|Relapsing forms of Multiple Sclerosis,United States,Fullerton,California,10,BG00002 (natalizumab)|keyhole limpet hemocyanin (KLH)|tetanus diphtheria toxoid vaccine (Td),BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Percentage of Keyhole Limpet Hemocyanin (KLH) Responders at Day 28 Post-Vaccination|Percentage of Tetanus Diphtheria Toxoid (Td) Responders at Day 28 Post-Vaccination,"Mean Percentage Change From Baseline in Circulating Lymphocyte Subsets CD3+, CD4+, CD8+, CD19+, and CD56+ at Month 3 of Tysabri Therapy|Mean Percentage Change From Baseline in Circulating Lymphocyte Subsets CD3+, CD4+, CD8+, CD19+, and CD56+ at Month 6 of Tysabri Therapy|Mean Alpha4-Integrin Saturation at Baseline, Month 3, and Month 6|Mean Alpha4-Integrin Expression at Baseline, Month 3, and Month 6",True,2011-07-29
NCT02047097,Dimethyl Fumarate (DMF) Observational Study,"A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)",COMPLETED,2013-11-19,2022-10-31,2022-10-31,2023-05-24,2014-01-28,OBSERVATIONAL,,5487.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,468,dimethyl fumarate,DRUG,The number of participants that experience Adverse Events (AEs) that lead to discontinuation of dimethyl fumarate (DMF)|The number of participants that experience Serious Adverse Events (SAEs),"Duration of dimethyl fumarate (DMF) use|dimethyl fumarate (DMF) dosing frequency|Primary reasons for discontinuation of dimethyl fumarate (DMF) use|Frequency of relapses over time|Disease progression as measured by Expanded Disability Status Scale (EDSS) over time|Multiple Sclerosis Impact Scale-29 Items (MSIS-29) physical multiple sclerosis (MS) impact score|Multiple Sclerosis Impact Scale-29 Items (MSIS-29) psychological multiple sclerosis (MS) impact score|EuroQol-5 Dimensions (5 Level) (EQ-5D-5L) index score|EuroQol Visual Analogue Scale (EQ VAS) (0-100 scale)|Modified Fatigue Impact Scale-5 (MFIS-5) total score|Work Productivity and Activity Impairment questionnaire: Multiple Sclerosis, Version 2.0 (WPAI-MS) impairment percentages|Health Care Resource Consumption Questionnaire",False,
NCT04705610,"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography","EYE-SEP : Study of Social Cognition in Patients With Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography.",COMPLETED,2017-05-23,2019-06-26,2019-06-26,2021-01-22,2021-01-12,INTERVENTIONAL,NA,76.0,ACTUAL,Association de Recherche Bibliographique pour les Neurosciences,OTHER,Centre Hospitalier Universitaire de Nice|Centre Hospitalier Princesse Grace,OTHER|OTHER,Multiple Sclerosis (MS)|Multiple Sclerosis (MS) Relapsing Remitting|Multiple Sclerosis (MS) Primary Progressive|Multiple Sclerosis (MS) Secondary Progressive|Radiologically Isolated Syndrome|Clinically Isolated Syndrome|Healthy,Demyelinating disease|Video-oculography|Eye-Tracking|Visual exploration strategies|Oculomotor behaviors|Oculomotor disorders|Emotions recognition|Social behavioral disorders|Social cognition|brain MRI,Monaco,Monaco,,1,Video-oculography / Social cognition tasks / Neuropsychological evaluations,OTHER,Prevalence of Oculomotor disorders (OMD)|Eye gaze strategies during Emotion recognition: Affective Theory of Mind (ToM)|Eye gaze strategies during Emotion recognition assessment: Facial emotion recognition (FER),T2 MRI lesion location: Posterior fossa lesions|T2 MRI lesion location: Spinal cord lesions|T2 MRI lesion location: T2 lesions load|Oculomotor paradigms raw performance - Horizontal saccades|Oculomotor paradigms raw performance - Vertical saccades|Disease Disability|Disease Duration|Correlations between visual exploration strategies and behavioral disorders.|Correlations between visual exploration strategies and social cognition impairment: Facial emotion recognition.|Correlations between visual exploration strategies and social cognition impairment: Affective ToM.|Correlations between Facial emotion recognition and behavioral disorders.|Correlations between Emotion recognition and behavioral disorders.|Correlations between Facial emotion recognition and disability level.|Correlations between Emotion recognition and disability level.|Correlations between Cognitive Theory of mind and disability level.|Correlations between Affective empathy and disability level.|Eye gaze strategies during exploration of a specific artwork,False,
NCT04239820,Effect of Cladribine Treatment on Microglial Activation in the CNS,Effect of Cladribine Treatment on Microglial Activation in the CNS,ACTIVE_NOT_RECRUITING,2020-01-10,2024-02-15,2025-12,2025-01-15,2020-01-27,OBSERVATIONAL,,15.0,ACTUAL,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,Imaging,RADIATION,11C-PK11195 binding in MS patient brain,MRI metrics|Expanded Disability Status Scale|Multiple Sclerosis Composite Score|Blood biomarkers|11C-PK11195 difference in RRMS and historical healthy controls|QSM-signal in MS patient brain,False,
NCT00298662,Combination Therapy of Betaseron-Prograf in Multiple Sclerosis,A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents,UNKNOWN,2003-02,,2006-09,2006-03-03,2006-03-03,INTERVENTIONAL,PHASE2,30.0,,Clinique de sclérose en plaques et neuromusculaire de l'Outaouais,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Betaseron-Prograf|patients of Multiple Sclerosis|Secondary Progressive type|Relapsing-Remitting type,Canada,Gatineau,Quebec,1,Interferon beta-1b and Tacrolimus,DRUG,safety and tolerability|relapse rate|number of T2 godolinium enhencing lesions on MRI|expanded disease severity score (EDSS)|multiple sclerosis functional composite(MSFC),,False,
NCT02057159,"A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis","A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis",UNKNOWN,2020-03-09,2023-03-09,2023-03-09,2020-03-11,2014-02-06,INTERVENTIONAL,PHASE2|PHASE3,200.0,ESTIMATED,"Immune Response BioPharma, Inc.",INDUSTRY,cro,AMBIG,Secondary Progress Multiple Sclerosis|Multiple Sclerosis,Secondary Progress Multiple Sclerosis|SPMS|Multiple Sclerosis|NeuroVax,United States,San Diego,California,1,NeuroVax|IFA Placebo,BIOLOGICAL|BIOLOGICAL,The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at up to 48 weeks in subjects with secondary progressive MS,"Secondary MRI measurements objectives include additional MRI measurements, analyses of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.|Analyses of clinical relapses|Measures of neurologic disability EDSS score|Immunologic evaluations|Safety Evaluation",False,
NCT02427997,VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis,Virtual Reality-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis,COMPLETED,2015-06,2022-03-31,2022-03-31,2022-04-08,2015-04-28,INTERVENTIONAL,NA,139.0,ACTUAL,Tel-Aviv Sourasky Medical Center,OTHER_GOV,,,Multiple Sclerosis,Virtual Reality|Treadmill|Multiple Sclerosis,United States,Urbana,Illinois,2,Treadmill training with Virtual Reality|Treadmill training,BEHAVIORAL|BEHAVIORAL,Immediate change in gait speed|Number of correct answers in the oral version of the Symbol Digit Modalities Test,The 25 feet walk test (25FWT),False,
NCT01191996,Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis,"A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis",COMPLETED,2010-08,2012-06,2012-11,2012-12-07,2010-08-31,INTERVENTIONAL,PHASE1|PHASE2,34.0,ACTUAL,Innate Immunotherapeutics,INDUSTRY,Primorus Clinical Trials|National Multiple Sclerosis Society,UNKNOWN|OTHER,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,SPMS|PPMS|MS|Multiple Sclerosis,New Zealand,Christchurch,Canterbury,1,MIS416,BIOLOGICAL,"Safety profile, including maximum tolerated dose",Pharmacodynamic assessments|MRI assessments|Clinical status,False,
NCT04651725,Effectiveness of Hippotherapy Simulator in PwMS,Effectiveness of Hippotherapy Simulator on Balance and Knee Strength in People With Multiple Sclerosis: a Randomized Controlled Trial,COMPLETED,2020-11-01,2022-04-15,2022-04-15,2022-04-18,2020-12-03,INTERVENTIONAL,NA,40.0,ACTUAL,Uşak University,OTHER,,,Multiple Sclerosis|Exercise,hippotherapy|multiple sclerosis|balance|strength|exercise,Turkey (Türkiye),Uşak,,1,Exercises,OTHER,Balance dysfunction in Multiple Sclerosis|Muscle Strength,Disability associated with Multiple Sclerosis,False,
NCT02047734,Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis,"A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients",COMPLETED,2013-12-03,2017-03-27,2017-04-13,2021-02-11,2014-01-28,INTERVENTIONAL,PHASE3,1320.0,ACTUAL,Celgene,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Phoenix,Arizona,299,Ozanimod|Ozanimod placebo|Interferon beta-1a|Interferon beta-1a placebo,DRUG|DRUG|DRUG|DRUG,Adjusted Annualized Relapse Rate (ARR) at the End of Month 24,Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 24 Months|Adjusted Mean Number of Gadolinium Enhancing Brain Lesions at Month 24|Time to Onset of Disability Progression Confirmed After 3 Months|Time to Onset of Disability Progression Confirmed After 6 Months|Percentage of Participants Who Were Gadolinium Enhancing (GdE) Lesion-Free at Month 24|Percentage of Participants Who Were New or Enlarging T2 Lesion-Free at Month 24|Percent Change From Baseline in Normalized Brain Volume to Month 24|Change From Baseline to Month 24 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test|Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores|Number of Participants With Treatment Emergent Adverse Events,True,2021-02-11
NCT01738347,"Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).","Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)",COMPLETED,2013-04,2016-05,2016-05,2017-02-24,2012-11-30,INTERVENTIONAL,PHASE1,30.0,ESTIMATED,GE Healthcare,INDUSTRY,Centre for Probe Development and Commercialization,OTHER,Relapsing-remitting Multiple Sclerosis (rrMS),,Canada,Hamilton,Ontario,1,Arm 1 - GEH120714 (18F) Injection,DRUG,Recording the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.,"Blood samples collected multiple periods post injection; and urine samples at periods post injection to count radioactivity to determine bio-distribution, internal radiation dosimetry and Effective Dose (E) in healthy volunteers (HV).",False,
NCT05983809,Technological Balance and Gait Rehabilitation in Patients With Multiple Sclerosis.,"Technological Balance and Gait Rehabilitation in Patients With Multiple Sclerosis: Effects on Functional, Motor and Cognitive Outcomes (ROAR-MS).",RECRUITING,2023-09-15,2024-03-31,2026-05,2025-07-14,2023-08-09,INTERVENTIONAL,NA,24.0,ESTIMATED,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,Multiple Sclerosis|Balance|Cognitive Impairment,Rehabilitation|Multiple Sclerosis|Technology|Balance|Cognitive Impairment,Italy,Roma,RM,1,Technological rehabilitation,DEVICE,Berg Balance Scale,Modified Fatigue Impact Scale (MFIS)|Fatigue Scale for Motor and Cognitive Function (FSMC)|Timed Up and Go test (TUG)|Ambulation Index (AI)|Walking handicap scale (WHS)|Functional Ambulation Classification (FAC)|10 Meter Walk Test (10mWT)|Six-minute walk test (6MWT)|Multiple Sclerosis Walking Scale (MSWS-12)|Modified Barthel Index (mBI)|Multiple Sclerosis Impact Scale (MSIS-29)|Beck Depression Inventory-II (BDI-II)|State-Trait Anxiety Inventory (STAI-Y1 and Y2)|Stroop Colour Word Test (SCWT)|Symbol Digit Modalities Test (SDMT),False,
NCT05999604,"Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial","Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial",RECRUITING,2023-11-09,2027-11,2027-11,2023-11-28,2023-08-21,INTERVENTIONAL,PHASE3,244.0,ESTIMATED,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Multiple Sclerosis,,France,Paris,,1,Ocrelizumab Injection [Ocrevus]|Ocrelizumab Injection [Ocrevus],DRUG|DRUG,Absence of radiological disease activity at 2 years,,False,
NCT06644638,Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis,Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis,COMPLETED,2023-02-15,2023-10-30,2023-10-30,2024-10-16,2024-10-16,OBSERVATIONAL,,3632.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Number of Patients Persistent on Ofatumumab and Self-injectable Disease-modifying Therapies (DMTs),,False,
NCT06841068,Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis,A Phase I/II Trial of Intrathecal Delivery of Amniotic Fluid Stem Cells for Primary and Secondary Progressive Multiple Sclerosis,NOT_YET_RECRUITING,2026-02-01,2026-08-01,2026-11-01,2025-03-17,2025-02-24,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,Wake Forest University Health Sciences,OTHER,,,"Multiple Sclerosis, Progressive",,United States,Charlotte,North Carolina,1,Amniotic fluid or placental CD117 stem cells,BIOLOGICAL,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),The Multiple Sclerosis Functional Composite (MSFC) score|The Six-minute Walk Test|The Expanded Disability Status Scale (EDSS)|The Multiple Sclerosis Quality of Life-54 (MSQoL-54),False,
NCT02143167,Resistance Training and Amino Pyridine in Multiple Sclerosis,"RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis",COMPLETED,2014-05,2015-01,2015-01,2018-08-23,2014-05-20,INTERVENTIONAL,PHASE4,40.0,ACTUAL,University of Southern Denmark,OTHER,Region of Southern Denmark|Biogen,OTHER|INDUSTRY,Multiple Sclerosis,,Denmark,Esbjerg,,4,SR-fampridine|Placebo,DRUG|DRUG,Muscle power in the lower limbs,Activity|Walking capacity|Walking speed|Functional capacity in the lower limbs|Self rated walking capacity,False,
NCT04699747,Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects,Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects,RECRUITING,2021-03-25,2026-11-30,2026-11-30,2025-02-27,2021-01-07,INTERVENTIONAL,PHASE1,60.0,ESTIMATED,Massachusetts General Hospital,OTHER,,,Multiple Sclerosis,Demyelination|Brain imaging|Positron Emission Tomography|Radiopharmaceutical,United States,Boston,Massachusetts,1,F-18 3F4AP,DRUG,Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects|Number of participants with adverse events related to tracer administration as assessed by CTCAE v4.0,Binding of 18-F 3F4AP in brain lesions of multiple sclerosis subjects|Within-subject variability in healthy controls and multiple sclerosis subjects,False,
NCT05627609,Sunlight-mediated Inter-organ Leukocyte Exchange,Sunlight-mediated Inter-organ Leukocyte Exchange,COMPLETED,2022-11-21,2023-04-14,2023-04-14,2023-05-09,2022-11-25,INTERVENTIONAL,NA,18.0,ACTUAL,University Hospital Muenster,OTHER,,,Multiple Sclerosis,UVB|scRNAseq,Germany,Münster,North Rhine-Westphalia,1,311 nm narrowband UVB irradiation,DEVICE,Vitamin D3 serum concentration (ng/mL),single-cell RNA sequencing,False,
NCT00391352,fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls,"A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.",COMPLETED,2008-02,2012-08,2012-08,2014-06-04,2006-10-23,OBSERVATIONAL,,21.0,ACTUAL,Waukesha Memorial Hospital,OTHER,The Cleveland Clinic,OTHER,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Disease Modifying Therapy,United States,Waukesha,Wisconsin,1,IFN-β-1a (Rebif®),DRUG,Primary: Examine the change in task-activated fMRI response as a function of disease modifying therapy assigned to MS as compared to controls,Neuropsychological and Neurological outcome measures.,False,
NCT06105463,"Multiple Sclerosis, Menstrual Cycle and Physical Acivity",Response to Physical Activity in Women with Multiple Sclerosis Throughout the Menstrual Cycle (EMMA Project),COMPLETED,2024-05-06,2024-11-30,2024-12-30,2025-02-24,2023-10-27,INTERVENTIONAL,NA,30.0,ACTUAL,Universidad de Almeria,OTHER,,,Multiple Sclerosis,strength training|High-Intensity Interval Training|Physical activity satisfaction|quality of life,Spain,Almería,Almeria,1,Strength training sessions and High-interval intensity training sessions,OTHER,Satisfaction with physical activity|Satisfaction with physical activity|Satisfaction with physical activity|Satisfaction with physical activity|Satisfaction with physical activity|Visual analog scale of fatigue (VAS-F)|Visual analog scale of fatigue (VAS-F)|Visual analog scale of fatigue (VAS-F)|Visual analog scale of fatigue (VAS-F)|Visual analog scale of fatigue (VAS-F),Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Sleep Quality Measured by Actigraphy|Sleep Quality Measured by Actigraphy|Sleep Quality Measured by Actigraphy|Sleep Quality Measured by Actigraphy|Sleep Quality Measured by Actigraphy|Heart Rate Variability|Heart Rate Variability|Heart Rate Variability|Heart Rate Variability|Heart Rate Variability|Heart Rate Variability|Muscle oxygen saturation|Lactate|Maximum oxygen consumption|Body composition|Body composition|Hormonal profile|Hormonal profile|Inflammatory profile|Inflammatory profile|Cognitive function|Cognitive function|Rate of force development|Rate of force development|Maximal Voluntary Activation|Maximal Voluntary Activation|Contractile properties of muscle|Contractile properties of muscle|Central activation ratio|Central activation ratio|Maximal upper limb strength|Maximal upper limb strength|Spasticity|Spasticity|Gait speed|Gait speed|Balance|Balance|Sit-to-Stand Test (STS)|Sit-to-Stand Test (STS)|Timed Up and Go Test (TUG)|Timed Up and Go Test (TUG)|Rating of Perceived Exertion (RPE)|Rating of Perceived Exertion (RPE)|Delayed-Onset Muscle Soreness (DOMS)|Delayed-Onset Muscle Soreness (DOMS)|Muscle pain sensitivity|Muscle pain sensitivity|Fat mass|Muscle mass|Bone mass|Dietary and nutritional monitoring|Physical activity levels|Physical activity levels|Walking endurance|Physical self-perception|Catastrophizing Pain Scale|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life-54 (MSQoL-54)|State anxiety and trait anxiety (STAI)|Body temperature,False,
NCT04080687,Effect of Ankle-foot Orthoses on Balance Confidence,Effect of Ankle-foot Orthoses on Patients' Confidence in Balance-related Activities,COMPLETED,2020-02-06,2021-02-12,2021-02-12,2021-02-15,2019-09-06,OBSERVATIONAL,,150.0,ACTUAL,"University Rehabilitation Institute, Republic of Slovenia",OTHER,,,Peripheral Nerve Disease|Peripheral Nerve Injury Lower Limb|Poliomyelitis|Cerebral Palsy|Multiple Sclerosis,ankle-foot orthoses|lower limbs|rehabilitation outpatients|balance confidence|falls,Slovenia,Ljubljana,,1,Ankle-foot orthosis,DEVICE,ABC Scale,,False,
NCT04110171,Relationship Between the Nutritional Habits and Relapsing and Disability Rates in Patient With Multiple Sclerosis.,Relationship Between the Nutritional Habits and Relapsing and Disability Rates in Patient With,UNKNOWN,2019-11-01,2021-12-01,2021-12-01,2019-10-01,2019-10-01,OBSERVATIONAL,,100.0,ESTIMATED,Assiut University,OTHER,,,Nutrition Habits in Multiple Sclerosis,,,,,0,,,measurement of the body mass index and so assessment of obesity of the patient and multiple sclerosis . also assessment of nutrition habits by dietary habits questionnaire in theses patient .|assessment of disability rates of the patient of multiple sclerosis.,,False,
NCT05312138,Multiple Sclerosis and Overactive Bladder Treatment,The Effect of Different Neuromodulation Techniques in the Treatment of Multiple Sclerosis Patients With Neurogenic Bladder Dysfunction,COMPLETED,2021-06-08,2022-10-08,2022-12-07,2025-05-02,2022-04-05,INTERVENTIONAL,NA,16.0,ACTUAL,Istanbul Medipol University Hospital,OTHER,,,Neurogenic Bladder Dysfunction,Multiple Sclerosis|Overactive Bladder|Neurogenic Bladder|Electrical stimulation,Turkey (Türkiye),Istanbul,,1,Repetitive Transcranial Magnetic Stimulation|Transcutaneous Posterior Tibial Nerve Stimulation,DEVICE|DEVICE,Urodynamics Test|Extended Disability Status Scale (EDSS)|Overactive Bladder Questionnaire-V8 (OAB-V8)|Incontinence Quality of Life -I-QOL|Voiding Diary|Incontinence Severity Index (ISI),,False,
NCT06675955,An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment,"An Open-Label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients With Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and Without Access to a Post-Trial Access Program",RECRUITING,2024-12-13,2029-12-31,2029-12-31,2025-09-11,2024-11-06,INTERVENTIONAL,PHASE3,500.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,Ocrelizumab,France,Amiens Cedex1,,21,Ocrelizumab,DRUG,Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders-Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a)|Number of Eligible Participants who Have Received Access to Ocrelizumab in the Study,Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Adverse Events (AEs) Leading to Discontinuation|Number of Participants with Adverse Events of Special Interest (AESIs),False,
NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,Effect of a Training Regime Featuring the I-TRAVLE System on Arm Function and Skill Performance in Persons With Multiple Sclerosis and Chronic Stroke Patients: a Single Arm Trial,UNKNOWN,2013-07,2014-06,2014-09,2013-08-08,2013-08-08,INTERVENTIONAL,NA,30.0,ESTIMATED,Hasselt University,OTHER,,,Multiple Sclerosis|Paralytic Stroke,,Belgium,Overpelt,Limburg,2,Haptic Master,DEVICE,change from baseline Wolf Motor Function Test at 8 weeks and 3 months.,change from baseline motricity index at 8 weeks and 3 months|change from baseline plate tapping tasks at 8 weeks and 3 months|change from baseline active Range of Motion at 8 weeks and 3 months|change from baseline perceived strength & fatigue at 8 weeks and 3 months,False,
NCT06869278,A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases,"An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases",RECRUITING,2025-06-17,2026-06-30,2029-12-31,2025-06-11,2025-03-11,INTERVENTIONAL,PHASE1,37.0,ESTIMATED,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,Nanjing Legend Biotech Co.,INDUSTRY,Multiple Sclerosis (MS)|Neuromyelitis Optica Spectrum Disease (NMOSD)|Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD)|Myasthenia Gravis,Relapsed/Refractory Multiple Sclerosis (r/r MS)|Relapsed/Refractory Neuromyelitis Optica Spectrum Disease (r/r NMOSD)|Relapsed/Refractory Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (r/r MOGAD)|Relapsed/Refractory Myasthenia Gravis (r/r MG),China,Fuzhou,,3,LCAR-AIO T cells,BIOLOGICAL,"Incidence, severity, and type of treatment-emergent adverse events (TEAEs)|Incidence of dose-limiting toxicity (DLT)|Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration|Recommended Phase 2 Dose (RP2D) regimen finding|Transgene Levels of LCAR-AIO CAR-T Cells",Annua Relapse Rate (ARR)|Change in Expanded Disability Status Scale (EDSS) scores from baseline up to 104 weeks|Changes in Visual Acuity from baseline up to 104 weeks|Changes in Visual analogue scale (VAS) pain score from baseline up to 104 weeks|Changes in MSE proportion from baseline up to 104 weeks|Changes in Quantitative Myasthenia Gravis Score (QMGS) from baseline up to 104 weeks|Changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline up to 104 weeks,False,
NCT01101776,Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.,Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting,COMPLETED,2010-01,2013-04,2013-04,2014-08-13,2010-04-12,OBSERVATIONAL,,49.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Merck Serono Australia Pty Ltd,INDUSTRY,Multiple Sclerosis,"Multiple Sclerosis, relapsing|Rebif New Formulation|Interferon beta-1a",Australia,Bruce,Australian Capital Territory,16,Interferon beta-1a (Rebif),DRUG,Incidence and type of injection site reactions (ISRs),"Number of missed injections of Rebif New Formulation since the previous visit|Reasons for missed injections of Rebif New Formulation since the previous visit|Changes in quality of life (MusiQoL)|Number and type (telephone, face-to-face, written) of interactions with nurse support|Relapse rate|Proportion of subjects with dose reductions to 22 mcg as a result of tolerability",False,
NCT00139789,"A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis","A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis",COMPLETED,2005-01,2005-04,2005-04,2013-08-30,2005-08-31,INTERVENTIONAL,PHASE3,60.0,ACTUAL,UCB Pharma,INDUSTRY,,,Multiple Sclerosis,,United States,Milwaukee,Wisconsin,1,Kemstro,DRUG,,,False,
NCT03047460,Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting,Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting,COMPLETED,2016-04,2018-01,2018-01,2019-03-06,2017-02-09,OBSERVATIONAL,,14.0,ACTUAL,Clinique Neuro-Outaouais,OTHER,,,Multiple Sclerosis,motor evoked potential|somatosensory evoked potentials|biomarker,Canada,Gatineau,Quebec,1,multimodal evoked potentials,OTHER,Intraclass correlation coefficient (ICC) of the multi modal evoked potential parameters in order to determine the validity of the compound measures,,False,
NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,"A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.",COMPLETED,2011-12-24,2015-12-26,2015-12-26,2019-01-25,2011-12-26,INTERVENTIONAL,PHASE4,347.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Fingolimod|Early multiple sclerosis|Naive patients,Australia,East Gosford,New South Wales,47,Fingolimod (FTY720),DRUG,Annual Relapse Rate (ARR),"Time to First Relapse|Change From Baseline in Expanded Disability Status Scale (EDSS) Score|Change From Baseline in Cerebral Volume|Percentage of Participants With Mild, Moderate or Severe Relapse|Percentage of Relapse-free Participants|Mean Number of T2 Active Lesions",True,2019-01-25
NCT04783935,Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension),COMPLETED,2021-03-10,2023-09-21,2023-09-21,2025-01-22,2021-03-05,INTERVENTIONAL,PHASE4,219.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Mavenclad ®|Cladribine|Relapsing Multiple Sclerosis|Immune cell kinetics,Australia,Liverpool,,46,Mavenclad®,DRUG,Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) During Year 3 to 4,Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) at Year 3 and at Year 4|Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) After the Start of Study Medication During the Parent Study Until the End of Year 3 and Year 4|Percentage of Participants Remaining Three Parameter No Evidence of Disease Activity (NEDA-3) During Year 3 or 4 Among Those With NEDA-3 During Year 1 or 2|Time to First Disease Activity During Extension Study Period|Time to First Disease Activity During up to Parent and Extension Study Period (4 Years)|Time to First New or Enlarging T2 Lesion During Extension Study Period|Time to First New T1 Gadolinium Enhancing (Gd+) Lesion During Parent and Extension Study Period|Time to First Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS) During Parent and Extension Study Period|Time to First Qualifying Relapse During Parent and Extension Study Period|Time to Recurrent Qualifying Relapse During Parent and Extension Study Period|Time to Treatment Start With Other Disease Modifying Drugs (DMDs) During Parent and Extension Study Period|Time to First New or Enlarging T2 Lesion During Extension Study Period|Time to First New T1 Gadolinium Enhancing (Gd+) Lesion During Extension Study Period|Time to First Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS) During Extension Study Period|Time to First Qualifying Relapse During Extension Study Period|Time to Recurrent Qualifying Relapse During Extension Study Period|Time to Treatment Start With Other Disease Modifying Drugs (DMDs) During Extension Study Period|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),True,2025-01-22
NCT02440126,Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk,Longitudinal Meta-Analysis and Further Sample Collection To Evaluate Potential Host Markers for PML Risk,COMPLETED,2014-10,2017-03,2020-07,2021-02-21,2015-05-12,OBSERVATIONAL,,196.0,ACTUAL,"Rocky Mountain MS Research Group, LLC",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|immunological|biomarkers|observational|Relapsing|Remitting Multiple Sclerosis,United States,Salt Lake City,Utah,1,,,Pharmacokinetic (PK) Changes over Time|Pharmacodynamic (PD) Changes over Time,,False,
NCT06330350,Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling,Investigating Perspectives of Patients With Genodermatosis and Healthcare Professionals on Reproductive Counselling,RECRUITING,2024-01-01,2025-08-31,2025-12-31,2025-05-18,2024-03-26,OBSERVATIONAL,,25.0,ESTIMATED,Maastricht University Medical Center,OTHER,,,Quality of Life|Ichthyosis|Palmoplantar Keratoses|Epidermolysis Bullosa|Ectodermal Dysplasia|Basal Cell Nevus Syndrome|Birt-Hogg-Dube Syndrome|Tuberous Sclerosis|Cutis Laxa|Albinism,,Netherlands,Maastricht,Limburg,1,Qualitative interview,OTHER,Assessment of perspectives of affected patients + partners and of healthcare professionals concerning reproductive decision-making,,False,
NCT05526287,Effects of Dual-Task Training in People With Multiple Sclerosis,"Effects of Dual-Task Training on Balance, Gait, Dual-Task Performance, Cognitive Function, Fatigue in People With Multiple Sclerosis",UNKNOWN,2022-11-01,2023-04-01,2023-08-15,2023-03-02,2022-09-02,INTERVENTIONAL,NA,26.0,ESTIMATED,Ege University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Balance|Gait|Dual-Task|Cognitive Function|Functional Mobility|Activities of Daily Living,Turkey (Türkiye),Izmir,Karsıyaka,1,Dual-Task Training|Home Exercise Program,OTHER|OTHER,"Berg Balance Scale(BBS)|Timed Up And Go Test (TUG)|Tetrax((Sunlight Medical Ltd, Israel),Computerized Static Posturography Device",MS Walking Scale-12(MSWS-12)|Fatigue Severity Index(FSI)|Brief International Cognitive Assesment for MS(BICAMS)|10 Meter Walking Test(10MWT)|Dual-Task Performance|Dual-Task Questionnaire(DTQ),False,
NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)","A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis",WITHDRAWN,,,,2015-03-10,2006-04-12,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Early secondary progressive Multiple Sclerosis,Denmark,Ask Contact,,7,"Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)",DRUG|DRUG,Magnetic Resonance Imaging (MRI): T2-lesions,Further Magnetic Resonance Imaging (MRI) parameters|Relapses|Changes in Expanded Disability Status Score (EDSS) and Multiple Sclerosis Impact Scale (MSIS)|Hospitalizations|Neutralizing antibodies|Adverse events,False,
NCT03108950,From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings,Dose-Response Effects of Transformative Exercise in Improving Health and Function in Adults With Spinal Cord Injury and Multiple Sclerosis,COMPLETED,2017-02-01,2019-05-31,2019-05-31,2019-08-05,2017-04-11,INTERVENTIONAL,NA,27.0,ACTUAL,University of Alabama at Birmingham,OTHER,Lakeshore Foundation,OTHER,Multiple Sclerosis|Stroke,,United States,Birmingham,Alabama,1,Movement to Music,BEHAVIORAL,Cardiorespiratory Fitness as measured by sub-maximal VO2|Pain as measured by PROMIS Pain Interference Short Form 8a|Fatigue as measured by PROMIS Fatigue Short Form 8a|Grip Strength as measured by hand grip dynamometer|Strength as measured by Biodex System 3 Multijoint dynamometer|Balance as measured by the Timed Up and Go|Balance as measured by Biodex Limits of Stability|Balance as measured by Repeated Chair Stands|Walking velocity as measured by the GaitRite,"Health Biomarkers as measured by blood analysis (insulin)|Health Biomarkers as measured by blood analysis (lipids)|Health Biomarkers as measured by blood analysis (fasting glucose)|Anthropometric measurements (BMI)|Circumference measurements to be reported as composite ratios (waist circumference, hip circumference, neck circumference)|Physical Function with Mobility Aid as measured by PROMIS Physical Function with Mobility Aid 455b|Anxiety as measured by PROMIS Emotional Distress-Anxiety Short Form 8a|Depression as measured by PROMIS Emotional Distress-Depression Short Form 8a|Sleep Disturbance as measured by PROMIS Sleep Disturbance Short Form 8a|Ability to participate in social roles and activities as measured by PROMIS Ability to Participate in Social Roles and Activities Short Form 8a|Nutrition Self-Efficacy as measured by the Nutrition Self-Efficacy Scale|Physical Exercise Self-Efficacy as measured by the Physical Exercise Self Efficacy Scale|Pain intensity is measured by the PROMIS Pain Intensity Short Form|Body Composition as measured using a DEXA scan|Loneliness as measured by the Three-item loneliness scale",False,
NCT02635789,Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC),"A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex",COMPLETED,2015-12,2016-10,2016-10,2017-02-02,2015-12-21,INTERVENTIONAL,PHASE3,62.0,ACTUAL,Nobelpharma,INDUSTRY,,,Tuberous Sclerosis|Angiofibroma|Hypomelanotic Macule|Plaque,Sirolimus|Skin lesions|TSC|Tuberous Sclerosis Complex|NPC-12G|Angiofibroma|Hypomelanotic macule|Plaque,Japan,"Suita, Osaka",,1,NPC-12G gel|Placebo gel,DRUG|DRUG,Improvements in angiofibroma,Improvements in angiofibroma|Improvements in angiofibroma|Improvements in redness of angiofibroma|Improvements in hypomelanotic macule and plaque of upper neck|The rate of patients who are evaluated as ''improvement'' or more (improvement rate) in primary outcome measure and in secondary outcome measures above outcome 1 to 5|Change in total score from baseline for DLQI and CDLQI|Adverse events|Serious adverse events|Laboratory findings|Vital sign|Sirolimus blood concentration,False,
NCT05493514,Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System,Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System: an Observational Longitudinal Study,RECRUITING,2022-05-13,2027-04-01,2027-04-01,2022-08-09,2022-08-09,OBSERVATIONAL,,260.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis|Stroke|Parkinson Disease|Acquired Brain Injury,Multiple Sclerosis|Stroke|Parkinson Disease|Acquired Brain Injury|Robotic|End-effector,Italy,Milan,,1,Robotic Assisted Gait Training with G-EO system,DEVICE,Change in gait speed,Trunk control|Mobility|Strength|Walking Endurance|Walking ability|Activities of daily living|Cognitive function|Balance confidence|Community integration|Gait symmetry (Instrumental index)|Gait regularity (Instrumental index),False,
NCT00644904,Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis,A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis,COMPLETED,2006-07,2008-02,2008-02,2008-03-28,2008-03-27,INTERVENTIONAL,PHASE1|PHASE2,49.0,ACTUAL,University of Toronto,OTHER,Direct MS-Proactive Charity|Multiple Sclerosis Society of Canada,UNKNOWN|OTHER,Multiple Sclerosis,Multiple Sclerosis|Vitamin D|Safety,Canada,Toronto,Ontario,1,Vitamin D3|Vitamin D3,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Serum calcium,Serum 25(OH)D|EDSS|N-telopeptide (bone marker)|ALP/AST/ALT|Creatinine/urea|EKG|Renal ultrasound|Cytokine profile/MMP/lymphocyte response assay|Annualized relapse rate|PTH,False,
NCT05292690,An Assistive Powered Wheelchair: Stage 2 Trial,An Assistive Powered Wheelchair: Stage 2 Trial - Powered Wheelchair User Evaluation of an Obstacle Alerting System. A Non-interventional Study,COMPLETED,2021-03-29,2021-04-01,2021-08-31,2022-08-01,2022-03-23,OBSERVATIONAL,,17.0,ACTUAL,East Kent Hospitals University NHS Foundation Trust,OTHER_GOV,University of Kent|Sussex Community NHS Foundation Trust|KU Leuven|l'Institut supérieur de l'électronique et du numérique (ISEN) Lille,OTHER|OTHER|OTHER|UNKNOWN,Multiple Sclerosis|Stroke|Cystic Fibrosis|Motor Neurone Disease|Craniocerebral Trauma|Guillain-Barre Syndrome,,United Kingdom,Canterbury,Kent,1,Powered Wheelchair Obstacle Alerting System,DEVICE,Pre-trial Participant Evaluation of the possible Value of an Obstacle Alerting System|Post-trial Participant Evaluation of the possible Value of the Obstacle Alerting System|Joystick range of movement patterns with and without the Obstacle alerting System Active|Smoothness of joystick movement with and without the Obstacle alerting System Active|Joystick path length with and without the Obstacle alerting System Active|Time to complete the course with and without the Obstacle alerting System Active,,False,
NCT02904876,Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis,Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis,TERMINATED,2015-03,2019-12,2020-05,2020-07-27,2016-09-19,INTERVENTIONAL,PHASE4,70.0,ACTUAL,"University Hospital, Strasbourg, France",OTHER,,,Multiple Sclerosis,,France,Strasbourg,Alsace,1,Diffusion Magnetic Resonance Imaging at 6 months,RADIATION,Comparaison of diffusion Magnetic Resonance Imaging before and after the initiation of treatment with Tysabri using fractional anisotropy (FA).,Comparison of different Magnetic Resonance Imaging criteria before and after treatment,False,
NCT01266291,Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients,"Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study",TERMINATED,2010-08,2013-02,2013-12,2017-07-12,2010-12-24,INTERVENTIONAL,PHASE4,1.0,ACTUAL,University of Pennsylvania,OTHER,H. Lundbeck A/S,INDUSTRY,Complex Partial Seizures,Tuberous sclerosis|TS|Seizures,United States,Philadelphia,Pennsylvania,1,vigabatrin,DRUG,Number of Participants Safely Tolerating Sabril,Number of Patients Who Become Seizure Free While Taking Sabril,True,2017-07-12
NCT06994026,Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis,Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-06-15,2025-08-15,2025-08-15,2025-05-29,2025-05-29,OBSERVATIONAL,,10.0,ESTIMATED,Centre Hospitalier de Gonesse,OTHER,,,Multiple Sclerosis|Disease Management|Feasibility Studies,,France,Gonesse,France,1,,,"Effectiveness of the relapse investigation questionnaire completed by the MS care coordinator nurse (IDEC) in guiding the patient's care pathway during a suspected relapse, according to the local task-sharing protocol.",,False,
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,"A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)",COMPLETED,2007-04,2009-02,2009-11,2013-08-07,2007-05-14,INTERVENTIONAL,PHASE3,232.0,ACTUAL,EMD Serono,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Rockland,Massachusetts,1,Rebif New Formulation Non Titrated|Rebif New Formulation Titrated,DRUG|DRUG,Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ),Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12|Tolerability in Pain Using Visual Analog Scale (VAS)|Tolerability - Redness at Injection Site,True,2009-09-02
NCT04074629,Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis,Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis,COMPLETED,2019-12-16,2022-05-23,2022-08-02,2022-12-07,2019-08-30,INTERVENTIONAL,NA,107.0,ACTUAL,Carmel Medical Center,OTHER,"Technion, Israel Institute of Technology",OTHER,Multiple Sclerosis,Multiple Sclerosis|Skin volatile organic compounds (VOCs),Israel,Haifa,,1,"Diagnosis, skin volatile organic compounds (VOCs)",DIAGNOSTIC_TEST,Volatile organic compounds (VOCs) in skin,Volatile biomarkers for disease monitoring,False,
NCT01701856,Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis,"Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis: A Swiss Multicenter Study Prospective, Controlled, Single-arm, Open-label, Multi-centre, Phase IV Study",TERMINATED,2012-09,2013-10,2013-10,2014-01-22,2012-10-05,INTERVENTIONAL,PHASE4,5.0,ACTUAL,Claudio Gobbi,OTHER_GOV,Bayer,INDUSTRY,Relapsing-remitting Multiple Sclerosis,relapsing-remitting multiple sclerosis|natalizumab|de-escalation|interferon beta-1b,Switzerland,Lugano,Canton Ticino,1,Interferon beta-1b,DRUG,Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12)|Annualized relapse rate on study compared to annualized relapse rate in the year prior to natalizumab initiation on first line disease modifying treatment (month -24 to -12),Severity of relapses|Severity of relapses|Severity of relapses|Severity of relapses|Severity of relapses|Severity of relapses|Severity of relapses|Severity of relapses|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|Proportion of relapse free patients|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|3-month confirmed EDSS progression|MSFC|MSFC|MSFC|MSFC|MSFC|MSFC|MSFC|Change of EDSS score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of EDSS score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of EDSS score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of EDSS score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of MSFC score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of MSFC score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of MSFC score compared to change in the year prior to natalizumab treatment (month -24 to-12|Change of MSFC score compared to change in the year prior to natalizumab treatment (month -24 to-12|Number of new/enlarging T2-hyperintense lesions|Number of new/enlarging T2-hyperintense lesions|Number of new/enlarging T2-hyperintense lesions|Number of Gd-enhancing lesions|Number of Gd-enhancing lesions|Number of Gd-enhancing lesions|EQ-5D|EQ-5D|EQ-5D|FAMS|FAMS|MSFC|EQ-5D|FAMS|FAMS,False,
NCT02587065,Plegridy Satisfaction Study in Participants,Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM),COMPLETED,2016-02-03,2017-10-02,2017-12-21,2023-08-31,2015-10-27,INTERVENTIONAL,PHASE4,193.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis (RRMS),,Italy,Arezzo,,30,peginterferon beta-1a,DRUG,Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12,Change From Baseline in the Score of All Domains of TSQM-9 at Week 24|Change From Baseline in Number of Participants With Adherence to Study Treatment at Weeks 12 and 24|Change From Baseline in Fatigue Status Scale (FSS) Score at Weeks 12 and 24|Change From Baseline in Adapted Sclerosis Treatment Concerns Questionnaire (MSTCQ) Score at Weeks 12 and 24|Change From Baseline in Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) Score at Week 12 and 24|Change From Baseline in Annualized Relapse Rate (ARR) at Week 24|Percent Change in Relapse-Free Participants at Week 24|Number of Participants With Adverse Events (AE)|Number of Participants With AE Stratified by Severity|Number of Participants With Clinical Abnormal Laboratory Values,True,2020-01-13
NCT01034644,Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15),"A Multinational, Multicenter, Single Visit, Exploratory Pharmacogenetic Trial and Long-term Follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Trial",COMPLETED,2010-03,2010-11,2011-01,2014-07-31,2009-12-17,OBSERVATIONAL,,290.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Biomarkers|Genetic markers,Switzerland,Geneva,,1,,,The proportion of responders by group as defined by SNP (Single Nucleotide Polymorphism) markers,Current course of MS: RRMS or SPMS|Current EDSS score|Change in EDSS since randomization|Immunogenicity assessment,False,
NCT02746744,RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.,RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.,COMPLETED,2016-05,2021-07,2021-08,2021-10-12,2016-04-21,INTERVENTIONAL,PHASE3,200.0,ACTUAL,Anders Svenningsson,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,Sweden,Borås,,17,Rituximab|Dimethyl fumarate|Sodium Chloride solution,DRUG|DRUG|DRUG,Freedom of relapse,,False,
NCT06062693,New Interactive Sensor-home-based Hand Training to Improve Dexterity,New Interactive Sensor-home-based Hand Training to Improve Dexterity,RECRUITING,2023-06-01,2027-08-30,2027-08-30,2023-10-02,2023-10-02,INTERVENTIONAL,NA,160.0,ESTIMATED,Luzerner Kantonsspital,OTHER,,,Stroke|Multiple Sclerosis|Parkinson Disease,dexterity|training,Switzerland,Lucerne,,1,smart sensor egg training,DEVICE,hand dexterity,fine finger movements|grip strength|cognition|executive function|executive function|self-reported dexterity related problems in daily living for PD|self-reported arm and hand function related problems in patients with MS|Arm and hand function in stroke patients,False,
NCT06334094,Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS,Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS,WITHDRAWN,2024-06-01,2028-03-31,2028-05-31,2024-08-09,2024-03-27,INTERVENTIONAL,PHASE4,0.0,ACTUAL,The University of Texas at Dallas,OTHER,Texas Institute for Neurological Disorders,UNKNOWN,Multiple Sclerosis,Zeposia|Ozanimod,United States,Dallas,Texas,1,Ozanimod,DRUG,Change in Processing Speed/Symbol-Digit Modality Test (SDMT) Performance,Change in Volumetric Blood-Oxygen-Level-Dependent (BOLD) signal as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI)|Change in Cerebral Blood Flow (CBF) as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI)|Change in Cerebral Metabolic Rate of Oxygen (CMRO2) as Measured by Dual Echo Functional Magnetic Resonance Imaging (fMRI)|Change in Whole Brain Volume as Measured By Structural Magnetic Resonance Imaging|Differences in Diffusion parameters of ozanimod-responders to non-responders as Measured By a Diffusion Kurtosis Resonance Imaging (DKI),False,
NCT07097402,Examination of a Self-Compassion Course for Healthcare Providers Working With People With Multiple Sclerosis,Examination of a Self-Compassion Course for Healthcare Providers Working With People With Multiple Sclerosis,NOT_YET_RECRUITING,2025-09-01,2026-02-28,2026-07-31,2025-07-31,2025-07-31,INTERVENTIONAL,NA,40.0,ESTIMATED,Robert Simpson,OTHER,,,Burnout|Compassion,,Canada,Toronto,Ontario,1,Self-compassion intervention (Self-Compassion for Healthcare Communities course),BEHAVIORAL,Recruitment|Retention|Adherence|Follow-up rates,Professional Quality of Life Scale (ProQOL) Version 5|Self-Compassion Scale - Short Form|Relational Compassion Scale|Perceived Stress Scale-10|Difficulties in Emotion Regulation Scale - Short Form|Dispositional Joy Scale,False,
NCT03567057,A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,"A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment",COMPLETED,2018-07-18,2020-11-17,2021-04-18,2022-01-18,2018-06-25,INTERVENTIONAL,PHASE3,424.0,ACTUAL,"Adamas Pharmaceuticals, Inc.",INDUSTRY,,,Multiple Sclerosis|Walking Impairment,,United States,Cullman,Alabama,92,"ADS-5102, 274 mg",DRUG,Number of Patients With Adverse Events,Timed 25-Foot Walk (Feet/Second) (Baseline Value)|Timed 25-Foot Walk (Feet/Second) (Week 24 Value)|Timed 25-Foot Walk (Feet/Second) (Week 52 Value)|Timed up and go (Baseline Value)|Timed up and go (Week 24 Value)|Timed up and go (Week 52 Value)|2-Minute Walk Test (Baseline Value)|2-Minute Walk Test (Week 24 Value)|2-Minute Walk Test (Week 52 Value),True,2022-01-18
NCT01435694,Robot-assisted Gait Training in Multiple Sclerosis Subjects,The Effects of Robot-assisted Gait Training on Locomotor Function and Motor Unit Firing in Multiple Sclerosis Subjects With Severe Gait Impairments. A Randomized Control Trial,COMPLETED,2011-04,2013-06,2013-06,2014-01-16,2011-09-19,INTERVENTIONAL,NA,60.0,ACTUAL,University Hospital of Ferrara,OTHER,"Azienda Ospedaliero, Universitaria Pisana",OTHER,Multiple Sclerosis,multiple sclerosis|gait rehabilitation,Italy,Ferrara,Ferrara,1,"Lokomat (Hocoma, Switzerland)|Conventional Therapy",BEHAVIORAL|BEHAVIORAL,motor unit firing rate characteristics,walking endurance|mobility|balance|gait speed|Fatigue|quality of life|depression,False,
NCT06264336,"Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis","Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis",RECRUITING,2024-03-01,2025-12-31,2025-12-31,2025-05-31,2024-02-16,INTERVENTIONAL,NA,20.0,ESTIMATED,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,,United States,Chicago,Illinois,1,treadmill training,BEHAVIORAL,Symptomatic fatigue|Walking speed|Corticomotor excitability,Fatigue impact|Walking endurance|Aerobic capacity|Visual processing speed|Verbal learning and memory,False,
NCT00076934,Safety of RG2077 in Patients With Multiple Sclerosis,A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis,COMPLETED,2003-01,,2006-02,2017-03-27,2004-02-09,INTERVENTIONAL,PHASE1,20.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Immune Tolerance Network (ITN)|Repligen Corporation,NETWORK|INDUSTRY,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Ataxia|MRI|MS|CTLA4-IgG4m|Costimulatory Signals|Autoimmune Disorders,United States,Boston,Massachusetts,1,RG2077 (CTLA4-IgG4m),DRUG,"Safety assessment including a MRI, neurological and physical examinations",Number of gadolinium (GD) enhancing lesions and T2 lesion volume on MRI,False,
NCT04266444,Functional Exercise in Virtual Environment for Persons With Multiple Sclerosis or Parkinson's Disease,"Motivation, Neuropsychological Testing and Functional Exercise in Virtual Environment for Persons With Multiple Sclerosis or Parkinson's Disease",COMPLETED,2020-02-06,2021-09-29,2021-09-29,2021-09-30,2020-02-12,INTERVENTIONAL,NA,108.0,ACTUAL,"University Rehabilitation Institute, Republic of Slovenia",OTHER,,,Parkinson Disease|Multiple Sclerosis,exergaming|virtual reality|neuropsychological tests|motivation,Slovenia,Ljubljana,,1,Exergaming in virtual environment,DEVICE,Change in Box & Blocks Test from baseline|Change in Frontal Assessment Battery (FAB) score from baseline|Intrinsic Motivation Inventory (IMI) scores,Change in Delis-Kaplan Executive Function System (D-KEFS) scores from baseline|Change in Judgment of Line Orientation (JLO),False,
NCT06434571,"Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection","Comparing Telehealth-Delivered Cognitive Behavioral Therapy for Insomnia to Web-Based to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection",RECRUITING,2024-10-11,2028-07-31,2028-07-31,2024-10-17,2024-05-30,INTERVENTIONAL,PHASE2,90.0,ESTIMATED,University of Kansas Medical Center,OTHER,,,Multiple Sclerosis|Insomnia,Cognitive behavioral therapy for insomnia|CBT-I,United States,Kansas City,Kansas,1,Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Treatment as usual (TAU),BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Insomnia Severity Index (ISI),Pittsburgh Sleep Quality Index (PSQI)|Epworth Sleepiness Scale (ESS)|Dysfunctional Beliefs About Sleep|Positive Affect and Negative Affect Schedule (PANAS)|Sleep Self-Efficacy Scale (SESS)|Actigraphy|Modified Fatigue Impact Scale (MFIS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Impact Scale (MSIS-29)|Cognitive Failures Questionnaire (CFQ)|plasma neurofilament light (NfL),False,
NCT03555253,Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis,A Pilot Single-Center Study of a Manualized Resilience-Based Telehealth Program for Support Partners of Persons With Multiple Sclerosis,COMPLETED,2018-05-23,2019-03-31,2019-03-31,2019-04-10,2018-06-13,INTERVENTIONAL,NA,62.0,ACTUAL,Healios Inc.,INDUSTRY,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,Resilience|Telehealth|Well-being|Support|Caregiving,United States,Flemington,New Jersey,1,Resilience-Based Program for Support Partners of PwMS,BEHAVIORAL,Feasibility: Recruitment (i.e. willingness to participate in program)|Feasibility: Participation rates and attrition|Feasibility: Participant satisfaction of the program.,Change from Baseline: Sense of Competence Questionnaire (Support Partner)|Change from Baseline: Connor-Davidson Resilience Scale (Support Partner)|Change from Baseline: Zarit Burden Interview (Support Partner)|Change from Baseline: Perceived Stress (Support Partner)|Change from Baseline: Knowledge Questionnaire (Support Partner)|Change from Baseline: Positive and Negative Affect Schedule (Support Partner)|Change from Baseline: Burns Relationship Satisfaction Scale (Support Partner)|Change from Baseline: Relationship Assessment Scale (Support Partner)|Change from Baseline: Modified Social Support Survey (Person with Multiple Sclerosis)|Change from Baseline: Burns Relationship Satisfaction Scale (Person with Multiple Sclerosis)|Change from Baseline: Relationship Assessment Scale (Person with Multiple Sclerosis),False,
NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration",COMPLETED,2018-11-27,2023-01-31,2023-07-24,2024-06-12,2018-10-01,INTERVENTIONAL,PHASE3,585.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Cullman,Alabama,107,Natalizumab|Natalizumab,DRUG|DRUG,Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72|Part 2: Percentage of Participants Indicating a Preference for Natalizumab SC Administration at the End of Crossover Period of Part 2,"Part 1: Time to First Relapse as Adjudicated by an Independent Neurology Evaluation Committee (INEC)|Part 1: Annualized Relapse Rate at Week 72|Part 1: Time to Expanded Disability Status Scale (EDSS) Worsening|Part 1: Mean Number of New T1 Hypointense Lesions at Weeks 24, 48, and 72|Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Weeks 24 and 48|Part 1: Mean Number of New Gadolinium (Gd) Enhancing Lesions at Weeks 24, 48, and 72|Part 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Part 2: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Scores During the Crossover Period|Part 2: Mean Time for Drug Preparation and Drug Administration During the Crossover Period|Part 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part 2: Percentage of Participants With Anti-Natalizumab Antibodies During the Crossover Period|Part 2: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions During the Crossover Period|Part 2: Time to First Relapse During the Crossover Period|Part 2: Annualized Relapse Rate During the Crossover Period|Part 2: Change From Baseline in EDSS Score During the Crossover Period|Part 2: Mean Number of New Gd Enhancing Lesions During the Crossover Period|Part 2: Mean Number of New T1 Hypointense Lesions During the Crossover Period|Part 2: Mean Percentage Change From Baseline in Brain Volume During the Crossover Period|Part 2: Change From Baseline in Cortical and Thalamic Brain Region Volume During the Crossover Period|Part 2: Trough Serum Concentration of Natalizumab (Ctrough) During the Crossover Period|Part 2: Mean Trough α4 Integrin Saturation During the Crossover Period",True,2024-06-12
NCT00439257,"Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)","Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)",COMPLETED,,,2000-06,2015-04-07,2007-02-23,OBSERVATIONAL,,124.0,ESTIMATED,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,,United States,West Haven,Connecticut,1,,,,,False,
NCT05341895,Kinesiotape on Balance in With Multiple Sclerosis,The Effect of Kinesiotape Applied on Paraspinal Muscles on Balance in Individuals With Multiple Sclerosis,UNKNOWN,2021-11-22,2022-04-22,2022-05-06,2022-04-22,2022-04-22,INTERVENTIONAL,NA,60.0,ESTIMATED,Firat University,OTHER,,,Individuals With Multiple Sclerosis|With Ataxia Symptoms|No Secondary Disease Affecting Balance,Multiple Sclerosis|Balance|Ataxia|Kinesiotape,Turkey (Türkiye),Elâzığ,,2,Kinesiotape,OTHER,Timed Up and Go Test|Win-Track Analysis|3-meter Backward walk Test,Functional Reach Test|Timed 25-Foot Walk,False,
NCT02339675,Psychometric Properties Upper Limb Function Measures Multiple Sclerosis,"Psychometric Properties of Outcome Measures for Upper Limb Function, in Multiple Sclerosis: a Multi-center Study",COMPLETED,2014-10,2016-02,2016-06,2020-05-22,2015-01-15,INTERVENTIONAL,NA,136.0,ACTUAL,Hasselt University,OTHER,"Revalidatie & MS Centrum Overpelt|Charles University, Czech Republic|Danish MS Hospitals, Haslev and Ry|Fondazione Don Carlo Gnocchi Onlus|Italian Multiple Sclerosis Foundation|centrisclerosimultipla|Sheba Medical Center|Haukeland University Hospital|MS Rehabilitation Center Borne Sulinowo|University of Ljubljana|Eugenia Epalza Rehabilitation Center, Bilbao, Spain|Day General Hospital.|Shepherd Center, Atlanta GA|Queen's University|St. Louis University|De Mick|MS center Hakadal AS",OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER_GOV|OTHER|UNKNOWN|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|UNKNOWN,Multiple Sclerosis,,Belgium,Diepenbeek,,1,conventional MS rehabilitation,OTHER,Pinch strength|Nine Hole Peg Test (NHPT)|Box and Block Test (BBT)|Coin rotation task (CRT)|Spasticity 0-10 numeric rating scale (NRS/VAS)|Visual Analogue Scale muscle weakness|Visual Analogue Scale sensory|Visual Analogue Scale coordination|Visual Analogue Scale fatigability|Manual Ability Measurement (MAM-36)|ABILHAND scale|Performance Scale hand function (PS hand)|Upper Extremity Motor Activity Log (EU-MAL),Hand grip strength (JAMAR)|Fatigability: plate tapping test|Trunk Impairment Scale modified Norwegian version (TIS-modNV)|Action Research Arm test (ARAT) for patients with NHPT ≤0.27 peg/s (33.3 sec)|International Physical Activity Questionnaire (IPAQ),False,
NCT02883335,Lorraine Registry of Multiple Sclerosis,Lorraine Registry of Multiple Sclerosis,RECRUITING,2003-05,2030-01,2030-01,2023-02-08,2016-08-30,OBSERVATIONAL,,6000.0,ESTIMATED,"Central Hospital, Nancy, France",OTHER,"Institut National de la Santé Et de la Recherche Médicale, France|University of Lorraine",OTHER_GOV|OTHER,Multiple Sclerosis,,France,Nancy,,1,Observational registry,OTHER,case occurence of multiple sclerosis,EDSS score,False,
NCT03109288,"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)",RECRUITING,2017-08-11,2026-01-01,2029-01-01,2025-07-10,2017-04-12,INTERVENTIONAL,PHASE1|PHASE2,250.0,ESTIMATED,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,Multiple Sclerosis,Targeted Therapy|Multiple Sclerosis|Biomarkers|Combination Therapy|Progressive Multiple Sclerosis,United States,Bethesda,Maryland,1,Pioglitazone|clemastine fumarate|Dantrolene|Pirfenidone,DRUG|DRUG|DRUG|DRUG,Primary outcome will be change in CombiWISE progression rate at the end of monotherapy plus combination therapy period in comparison to projected baseline disability progression.,"Change in CombiWISE progression rates between baseline and monotherapy phase, monotherapy and combination therapy phase and between different drugs.|Safety and tolerability of individual drugs and their combinations|Change in the rate of ventricular atrophy between baseline, monotherapy and combination therapy periods, measured by linear regression slopes of greater than or equal to 3 time-points for each period|Correlations between change(s) in CSF biomarkers and clinical efficacy (systems biology approach analyzing drugs/combinations separately and combining all drugs/combinations to a single larger cohort; exploratory analysis)|Development of new CSF (combinatorial) biomarkers, new clinical scales, new MRI outcomes will be included in exploratory analyses",False,
NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis",COMPLETED,2006-11,2008-09,2008-09,2015-10-29,2006-08-30,INTERVENTIONAL,PHASE3,39.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,MS,China,Beijing,,3,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly Active Lesions During 3-month Pre-treatment,"Difference Between the Number of New Gadolinium (Gd)-Enhancing Lesions Per 3 Months During the 6-month Treatment Period and the Number of New Gd-enhancing Lesions During 3-month Pre-treatment|Difference Between the Number of New or Enlarging T2 Lesions Per 3 Months During the 6-month Treatment Period and the Number of New or Enlarging T2 Lesions During 3-month Pre-treatment|Volume of Gadolinium-enhancing Lesions at Baseline, Weeks 12 and 24|Number of New Gadolinium (T1)-Enhancing Lesions at Baseline, Weeks 12 and 24|Number of T2 Lesions at Baseline, Weeks 12 and 24|Assessment of Relapses: Relapse Rate|Assessment of Relapses: Number of Relapses|Assessment of Relapses: Percentage of Relapse-free Subjects After 24 Weeks|Assessment of Relapses: Relapse Severity|Expanded Disability Status Scale (EDSS)|Percentage of Subjects Without EDSS Progression",True,2010-02-10
NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,"A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS",COMPLETED,2019-01-17,2022-09-02,2022-09-16,2024-03-15,2018-11-19,INTERVENTIONAL,PHASE1,28.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),Multiple Sclerosis|Cladribine|Microgynon®,Germany,Bochum,,7,Cladribine|Placebo|Microgynon®,DRUG|DRUG|DRUG,"Area Under the Plasma Concentration-Time Curve From Zero to Tau at Steady State (AUCt,ss) of Ethinyl Estradiol and Levonorgestrel|Maximum Observed Plasma Concentration in Steady State (Cmax,ss) of Ethinyl Estradiol And Levonorgestrel|Minimum Observed Plasma Concentration in Steady State (Cmin,ss) of Ethinyl Estradiol and Levonorgestrel|Plasma Concentration at End of Dosing Interval at Steady State (Ctrough) of Ethinyl Estradiol and Levonorgestrel|Time to Reach the Maximum Observed Plasma Concentration At Steady State (Tmax,ss) of Ethinyl Estradiol and Levonorgestrel|Average Plasma Concentration at Steady State (Cav,ss) of Ethinyl Estradiol and Levonorgestrel|Peak-to-Trough Fluctuation Over One Complete Dosing Interval At Steady State (PTF%)",Number of Participants With Treatment -Emergent Adverse Events (TEAEs)|Number of Participants With Clinically Relevant Change From Baseline in Laboratory Values|Number of Participants With Clinically Relevant Change From Baseline in Electrocardiogram (ECG)|Number of Participants With Clinically Relevant Change From Baseline in Vital Signs|Maximum Plasma Concentration (Cmax) of Cladribine|Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Cladribine,True,2024-03-15
NCT04887051,The Effects of Respiratory-based Telerehabilitaion in Patients With MS,The Effects of Respiratory-based Telerehabilitation on Physical Performance and Factors Affecting Compliance in Patients With Multiple Sclerosis,UNKNOWN,2021-04-16,2021-06-30,2021-08-30,2021-05-14,2021-05-14,INTERVENTIONAL,NA,100.0,ESTIMATED,Dr. Anıl Tosun,OTHER,Trakya University,OTHER,"Multiple Sclerosis|Telerehabilitation|Compliance, Patient","Telerehabilitation, Multiple Sclerosis",Turkey (Türkiye),Istanbul,,1,pulmonory based home exercises,OTHER,Barthell Scale|Functional Ambulatation Categories|Fatigue Severity Scale,,False,
NCT06290453,The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis,The Regulatory Role of miRNA 27 and Follistatin Like Protein-1 Gene in the Pathophysiology of Multiple Sclerosis Patients.,NOT_YET_RECRUITING,2024-03,2025-03,2026-03,2024-03-04,2024-03-04,OBSERVATIONAL,,60.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,micro RNA 27- FLP1 gene expression|The Expanded Disability Status Scale (EDSS)|Electrophysiological assessment:|MRI examination MRI brain:,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,• To measure the levels of miR-27 expression and its target gene (FSTL1) in progressive MS and relapsing-remitting multiple sclerosis (RRMS) patients.,To correlate the levels of expression of miR-27 expression and its target gene (FSTL1) relative to the severity of symptoms of MD patients.,False,
NCT04756700,Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis,"Validation of DigiCog (BCCAMS App) and Konectom™ Tools, for Supporting Digitalized Clinical Assessment of Cognitive and Motor Functions in Patients With Multiple Sclerosis. DigiToms Study",COMPLETED,2020-10-12,2022-07-26,2022-07-26,2023-04-18,2021-02-16,INTERVENTIONAL,NA,158.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,France,Bordeaux,,1,DigiCog (BCCAMS app)|Konectom Application,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,"Raw Score of the Computerized Speed Cognitive Test (CSCT) using DigiCog (BCCAMS app)|Raw Score of the Computerized Episodic Visual Memory Test (CEVMT) using DigiCog (BCCAMS app)|Raw Score of the French Learning Test (FLT), using DigiCog (BCCAMS app)",Sensitivity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the Brief International Cognitive Assessment for MS (BICAMS)|Specificity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS|Accuracy of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS|Relationship between Depressive Symptoms with BDI FAST and Cognitive Performance ((BICAMS/DigiCog)|Relationship Between Subjective Perception of CI with DailyCog and Cognitive Performance (BICAMS/DigiCog)|Reliability of Konectom Digital Outcome Assessment (DOA) in HS and PwMS: Intraclass Correlation Coefficient (ICC) of the score for Cognitive Processing Speed test (CPS)|Reliability of Konectom DOA in HS and PwMS: ICC of the score for Pinching Test|Reliability of Konectom DOA HS and PwMS: ICC of the score for Drawing Test|Reliability of Konectom DOA HS and PwMS: ICC of the score for Grip Force Tests|Reliability of Konectom DOA in HS and PwMS: ICC of the score for 6-minute Walk Test (6MWT)|Reliability of Konectom DOA in HS and PwMS: ICC of the score for U-turn Test (UTT)|Reliability of Konectom DOA in HS and PwMS: ICC of the score for Static Balance test (SBT)|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: CPS Versus Symbol Digit Modalities Test (SDMT) in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Pinching Versus 9-Hole Peg Test (9HPT) in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Drawing Versus 9HPT in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Grip Force Test Versus 9HPT in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: SBT Versus Timed 25-foot Walk Test (T25FW) in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: UTT Versus T25FW in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: 6MWT Versus T25FW in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Passive Mobility Versus T25FW in PwMS|Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Konectom™ overall disability Versus Expanded Disability Status Scale (EDSS) and its Subscores in PwMS|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: CPS Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Pinching Test Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Drawing Test Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Grip Force Test Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: 6MWT Score|DDifference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: UTT Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: SBT Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mobility Behavior Score|Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mood Scale Question (MSQ)|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: CPS Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Pinching Test Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Drawing Test Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Grip Force Test Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: 6MWT Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: UTT Score|Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: SBT Score|Difference in Konectom DOA Between In-clinic Supervised Administration Versus Self-assessments in Free-living Environment in HS and PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive Sub-Scores of the Fatigue Scale for Motor and Cognitive Functions (FSMC) in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive/Psychological Items of the Multiple Sclerosis Impact Scale 29 (MSIS-29) in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Daily Cog in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with ABILHAND-56 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with early MS manual ability questionnaires|Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with ABILHAND-56 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with early MS manual ability questionnaires|Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with ABILHAND-56 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with Early MS Manual Ability Questionnaires|Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Multiple Sclerosis Walking Scale 12 items (MSWS-12) in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Early MS Walking Ability-gait Questionnaires in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Ambulation-related Items of the MSIS-29 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with PDDS in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with MSWS-12 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Early MS Walking Ability-gait Questionnaires in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Ambulation-related Items of the MSIS-29 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with PDDS in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with MSWS-12 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Early MS Walking Ability-gait Questionnaires in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Ambulation-related Items of the MSIS-29 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with PDDS in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with MSWS-12 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Early MS Walking Ability-gait Questionnaires in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Ambulation-related Items of the MSIS-29 in PwMS|Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with PDDS in PwMS,False,
NCT03886753,Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products,Pharmacokinetic and Pharmacodynamic Study of Ilera Medical Marijuana Products,TERMINATED,2019-05-15,2020-06-30,2020-06-30,2020-07-30,2019-03-22,OBSERVATIONAL,,10.0,ACTUAL,Children's Hospital of Philadelphia,OTHER,Ilera Healthcare,UNKNOWN,"ALS|Autism Spectrum Disorder|Cancer|Spasticity, Muscle|Dyskinetic Syndrome|Epilepsy|Glaucoma|Huntington Disease|Inflammatory Bowel Disease (IBD)|Multiple Sclerosis|Neuropathy|Opioid Use|Parkinson Disease|HIV/AIDS|Ptsd|Intractable Pain|Sickle Cell Disease|Terminal Illness",,United States,Philadelphia,Pennsylvania,1,Registry|PK microsampling of blood,OTHER|OTHER,Change in symptoms,Description and incidence of patient or caregiver reported side effects|Changes in drug concentrations|Rate of bioavailabilty|Volume of distribution|Report area under the plasma concentration versus time curve (AUC)|Report half-life|Assess therapeutic range,False,
NCT04931953,Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS,A Feasibility Trial of Neuromodulation With Connectivity-Guided Intermittent Theta Burst Stimulation for Cognitive Impairment in Multiple Sclerosis,UNKNOWN,2022-06-01,2023-08,2023-12,2023-06-12,2021-06-18,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Nottingham,OTHER,,,Multiple Sclerosis|Cognitive Impairment,,United Kingdom,Nottingham,Nottinghamshire,1,Intermittent theta burst stimulation (iTBS)|Sham Intermittent theta burst stimulation (iTBS),OTHER|OTHER,Feasibility of Trial Procedures,Feasibility of recruitment|The Brief Visuospatial Memory Test Revised (BVMT-R) Trials 1-3.|The Brief Visuospatial Memory Test Revised (BVMT-R) Total learning|The Brief Visuospatial Memory Test Revised (BVMT-R) Learning|The Brief Visuospatial Memory Test Revised (BVMT-R) Delayed recall|The Brief Visuospatial Memory Test Revised (BVMT-R) Percent retained|The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition hits|The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition false alarms|The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition discrimination index|The Brief Visuospatial Memory Test Revised (BVMT-R) Recognition response bias|The California Verbal Learning Test-II (CVLT-II)|The Symbol Digit Modalities Test (SDMT)|Digit Span Forwards (from WAIS-IV)|Digit Span Backwards (from WAIS-IV)|Patient Health Questionnaire - Depression|General Anxiety Disorder Scale|Perceived Deficits Questionnaire (PDQ)|The Modified Fatigue Impact Scale (MFIS)|The Edinburgh Handedness Inventory (EHI)|Change in effective connectivity between left dorsolateral prefrontal cortex and left caudate nucleus|Change in cerebral blood flow in the left dorsolateral prefrontal cortex and in the left caudate nucleus (normalised to whole brain cerebral blood flow)|Safety outcomes of iTBS|Undesired effects of iTBS|iTBS Experience Questionnaire - Tolerability|iTBS Experience Questionnaire - Acceptability|iTBS Experience Questionnaire - Blinding|Interviews - Tolerability|Interviews - Acceptability|Interviews - perceived differences|Interviews - Improvements|Post-participation workshop,False,
NCT03976128,Endurance and Walking Training by Nordic Walking in Multiple Sclerosis,Effect of Nordic Walking Training Compared With Conventional Endurance Training in Walking Capacity in People With Multiple Sclerosis: a Simple Blinded Randomized Controlled Trial,COMPLETED,2016-09,2019-06,2020-03,2022-09-16,2019-06-05,INTERVENTIONAL,NA,66.0,ACTUAL,Multiple Sclerosis Center of Catalonia,OTHER,,,Multiple Sclerosis,endurance training|nordic walking|walking ability|fatigue,Spain,Barcelona,,1,Nordic Walking Training|Conventional endurance training,BEHAVIORAL|BEHAVIORAL,6 Minute Walk Test (6MWT)|Change from baseline 6 Minute Walk Test (6MWT) to 6 months,Timed 25 Foot Walk Test|Change from baseline Timed 25 Foot Walk Test to 6 months|Multiple Sclerosis Walking Scale 12|Change from baseline Multiple Sclerosis Walking Scale 12 to 6 months|Timed Up and Go Test|Change from baseline Timed Up and Go Test to 6 months|Berg Balance Scale|Change from baseline Berg Balance Scale to 6 months|Activities Specific Balance Confidence Scale|Change from baseline Activities Specific Balance Confidence Scale to 6 months|Modified Fatigue Impact Scale|Change from baseline Modified Fatigue Impact Scale to 6 months|Multiple Sclerosis Quality of Life 54|Change from baseline Multiple Sclerosis Quality of Life 54 to 6 months,False,
NCT06494228,"Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis","Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis",RECRUITING,2024-01-19,2025-01,2025-01-19,2024-07-10,2024-07-10,OBSERVATIONAL,,60.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,,,Multiple Sclerosis|Demyelinating Diseases,Multiple Sclerosis|Demyelinating Diseases,France,Strasbourg,Les Hôpitaux Universitaires de Strasbourg,1,,,"Comparison of the radiologist's degree of diagnostic confidence based on the three sequences (3D FLAIR, 3D DIR and 3D PSIR sequences).",,False,
NCT03154801,Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX),Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors,UNKNOWN,2017-07-26,2022-01-26,2022-07-26,2022-02-18,2017-05-16,INTERVENTIONAL,NA,54.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Low Grade Glioma of Brain|Multiple Sclerosis|Sexual Dysfunctions,,France,Paris,,1,Paramedical care,OTHER,Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire),Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)|Change of HAD scale (Hospital Anxiety and Depression)|Change of HAD scale (Hospital Anxiety and Depression)|Change of Rosenberg's Self-esteem Scale|Change of Rosenberg's Self-esteem Scale|Change of Quality of life scale|Change of Quality of life scale|Change of QLQ-C30/BM20 scale (Quality of Life Questionnaire - Core Questionnaire / Brain Module)|Change of QLQ-C30/BM20 scale (Quality of Life Questionnaire - Core Questionnaire / Brain Module)|Change of SEP59 scale (Sclérose En Plaques)|Change of SEP59 scale (Sclérose En Plaques)|Program satisfaction scale|Program satisfaction scale,False,
NCT03256851,Telephone-Delivered Exercise for Multiple Sclerosis Fatigue,Telephone-Delivered Interventions to Target Multiple Sclerosis Fatigue,COMPLETED,2017-06-01,2018-05-31,2018-07-31,2019-10-30,2017-08-22,INTERVENTIONAL,NA,20.0,ACTUAL,Wayne State University,OTHER,National Multiple Sclerosis Society|University of Michigan,OTHER|OTHER,Multiple Sclerosis|Fatigue|Physical Activity,,United States,Detroit,Michigan,1,Telephone-Delivered Exercise Therapy|In-Person Delivered Exercise Therapy,BEHAVIORAL|BEHAVIORAL,Daily Average Fatigue Intensity Score|Daily Average Fatigue Interference Score,,True,2019-10-30
NCT03566251,"Core Stability, Trunk Position Sense, Balance and Functional Mobility in Patients With Multiple Sclerosis",The Investigation of the Relationship Between Core Stability and Trunk Position Sense With Balance and Functional Mobility in Patients With Multiple Sclerosis,COMPLETED,2016-05-01,2017-01-01,2017-02-01,2021-07-14,2018-06-25,INTERVENTIONAL,NA,74.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Physical Therapy,Multiple Sclerosis|Balance|Core Stability|Proprioception|Functional Mobility,Turkey (Türkiye),Ankara,,1,Balance|Functional mobility|Core stability|Trunk position sense,OTHER|OTHER|OTHER|OTHER,Balance|Balance|Balance,,False,
NCT02636829,Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis,Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis,COMPLETED,2016-03,2016-08,2016-08,2016-09-15,2015-12-22,INTERVENTIONAL,NA,100.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis|Rheumatoid Arthritis,,France,Nîmes,,1,QALCIMUM questionnaire|Determination of calcium intake by a dietician interview,OTHER|OTHER,Calcium intake (mg/day)|The QALCIMUM questionnaire,Patient diet (qualitative)|QALCIMUM questionnaire administration time (minutes)|The GRIO questionnaire|The FRAX questionnaire|Quality of Life questionnaire: MSIS29 (MS Impact Scale)|Quality of Life questionnaire: TLSQOL10|Quality of Life questionnaire: TLS Coping|The Vitamin D questionnaire,False,
NCT03626012,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis","A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",COMPLETED,2018-09-10,2021-11-17,2021-11-17,2022-01-14,2018-08-10,INTERVENTIONAL,PHASE1,106.0,ACTUAL,Biogen,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,La Jolla,California,21,BIIB078|Placebo,DRUG|DRUG,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),Serum BIIB078 Concentration|Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf)|AUC from Time 0 to Time of the Last Measurable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time to Reach Cmax (Tmax)|Terminal Elimination Half-Life (t 1/2)|Change from Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Scores|Change from Baseline in Percent of Predicted Slow Vital Capacity (SVC)|Change from Baseline in Muscle Strength|Change from Baseline in Bulbar Strength,False,
NCT04956744,"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis","A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Single Dose of IV IMS001 in Subjects With Multiple Sclerosis and Treatment Failure to Prior Disease Modifying Treatments (DMTs)",RECRUITING,2021-08-31,2027-12,2027-12,2023-09-28,2021-07-09,INTERVENTIONAL,PHASE1,30.0,ESTIMATED,ImStem Biotechnology,INDUSTRY,"Rho, Inc.",INDUSTRY,Multiple Sclerosis,,United States,Atlanta,Georgia,3,IMS001,BIOLOGICAL,Safety and tolerability|Safety and tolerability,,False,
NCT02027025,Study of SPARC1103 in Subjects With Spasticity,,COMPLETED,2014-04-21,2017-04-28,2017-04-28,2019-05-03,2014-01-03,INTERVENTIONAL,PHASE2,142.0,ACTUAL,Sun Pharma Advanced Research Company Limited,INDUSTRY,,,Spasticity,"Spasticity, Multiple sclerosis",United States,Long Beach,California,23,SPARC1103 low dose|SPARC1103 high dose|SPARC Placebo,DRUG|DRUG|DRUG,Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score,Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Night Time Awakening Score|Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Spasm Frequency|Clinical Global Impression of Change Results at 24 Hours Post Dose on Day 24|Subject Global Impression of Severity of Spasticity,True,2019-01-15
NCT04035889,Melatonin for Sleep in MS,"A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)",COMPLETED,2019-09-23,2020-11-17,2020-11-17,2021-01-19,2019-07-29,INTERVENTIONAL,NA,30.0,ACTUAL,"University of California, San Francisco",OTHER,,,Multiple Sclerosis,Sleep|Melatonin|Sleep disturbance,United States,San Francisco,California,1,Melatonin|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Sleep time|Sleep quality,Sleep efficiency,False,
NCT03624296,Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study,Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study,UNKNOWN,2018-10,2019-10,2020-03,2018-08-10,2018-08-10,INTERVENTIONAL,NA,30.0,ESTIMATED,Assistance Publique Hopitaux De Marseille,OTHER,,,Multiple Sclerosis (MS),,France,Marseille,,1,MRI 7T|TEST EDSS|TEST MSFC,DEVICE|OTHER|OTHER,visualization of cortical lesions,measure of physical disability|cognitive impairment index,False,
NCT03755167,A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV,"An Open-Label, Multi-Center, Follow up Study to Protocol 101/2 - Continued Treatment by Intravenously Administered IPL344 to Amyotrophic Lateral Sclerosis (ALS) Patients",SUSPENDED,2018-12-09,2027-01,2027-02,2025-01-10,2018-11-27,INTERVENTIONAL,PHASE2,15.0,ESTIMATED,Immunity Pharma Ltd.,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),,Israel,Jerusalem,,2,IPL344,DRUG,Adverse Events (AEs) and Serious Adverse Events (SAEs) Reporting,Changes from baseline in ALS disease progression,False,
NCT06320444,"Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease",Developing Novel Non-invasive Electrophysiological Biomarkers of Dysfunction in Spinal and Cortical Pathways and Sensorimotor Impairments in Motor Neurone Disease,RECRUITING,2023-06-15,2024-12-15,2025-07-15,2024-03-20,2024-03-20,OBSERVATIONAL,,240.0,ESTIMATED,"University of Dublin, Trinity College",OTHER,"Motor Neurone Disease Association, UK|Irish Research Council, IE|Health Research Board, IE|Research Motor Neurone, IE|Thierry Latran Foundation, FR|ALS Association, USA",UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis|Motor Neuron Disease Progressive Spinal Muscle Atrophy|Primary Lateral Sclerosis|Multiple Sclerosis|Postpoliomyelitis Syndrome",Electroencephalography (EEG)|Peripheral Nerve Stimulation|Vibration-Induced Stimulation|Neurodegeneration|Electrophysiology|Biomarkers|Neuromuscular Physiology|Spinal Connectivity,Ireland,Dublin,Leinster,1,232 Electrode Electrophysiology (EEG-ECG-EMG-EXG),PROCEDURE,Biomarker of sensorimotor integration|Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALS|Non-invasive recording of the SC functional neuro-electric activity,,False,
NCT03039400,Physiotherapist-guided Home Exercise in Moderate to Severe MS,Physiotherapist-guided Home Exercise in Moderate to Severe Multiple Sclerosis,COMPLETED,2017-03-06,2018-10-11,2018-10-11,2021-04-13,2017-02-01,INTERVENTIONAL,NA,48.0,ACTUAL,University of Saskatchewan,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,,Canada,Saskatoon,Saskatchewan,1,Physiotherapist-guided home exercise with web-based support|Physiotherapist-guided home exercise with standard support,BEHAVIORAL|BEHAVIORAL,Adherence to prescribed exercise program,Injury or fall|Multiple Sclerosis Impact Scale (MSIS29 v.2)|Godin Leisure Time Exercise Questionnaire (GLTEQ)|Grip strength measured on hand dynamometer|Timed 25-Foot Walk Test|Timed Up and Go|FIM (R) instrument|Hospital Anxiety and Depression Scale,False,
NCT05081700,A Systems Approach to Understanding Disease Processes in Multiple Sclerosis,A Systems Approach to Understanding Disease Processes in Multiple Sclerosis,COMPLETED,2020-05-11,2023-06-27,2023-11-03,2024-10-02,2021-10-18,OBSERVATIONAL,,14.0,ACTUAL,Providence Health & Services,OTHER,"Institute for Systems Biology|Genentech, Inc.",OTHER|INDUSTRY,Multiple Sclerosis,multi-omic factors,United States,Portland,Oregon,2,All patients in the study will be treated with ocrelizumab,DRUG,Proportion of relapse free patients,Annualized relapse rate (ARR)|Correlates of T2 lesions on-study MRI activity|Correlates of gadolinium enhancing lesions on-study MRI activity|Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk (T25FW)|9-Hole Peg Test (9HPT)|Low Contrast Visual Acuity (LCVA)|Symbol digit modality test (SDMT)|Modified Fatigue Impact Scale (MFIS)|Beck Depression Inventory (BDI-2),False,
NCT05881122,Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability,"The Effects of an Anti-inflammatory Dietary Consultation on Self-efficacy, Adherence and Selected Health Outcomes: A Randomized Control Trial",COMPLETED,2021-11-01,2022-04-30,2022-05-30,2023-05-31,2023-05-31,INTERVENTIONAL,NA,11.0,ACTUAL,Brock University,OTHER,,,Inflammation|Spinal Cord Injuries|Multiple Sclerosis|Muscular Dystrophies|Diet Habit,,Canada,St. Catharines,Ontario,1,Mad Dog Dietary Consultation,BEHAVIORAL,Custom-designed task self-efficacy questionnaire|Custom-designed task self-efficacy questionnaire|Custom-designed task self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Custom-designed barrier self-efficacy questionnaire|Adherence to the anti-inflammatory diet|Adherence to the anti-inflammatory diet,Neuropathic pain questionnaire (NPQ)|Neuropathic pain questionnaire (NPQ)|Depression as determined by the Centre for Epidemiological Studies depression (CES-D) questionnaire|Depression as determined by the Centre for Epidemiological Studies depression (CES-D) questionnaire,False,
NCT03422367,JASPER Early Intervention for Tuberous Sclerosis,Mechanisms of Change With Early Intervention in Tuberous Sclerosis,UNKNOWN,2017-10-24,2022-06-15,2022-06-15,2020-11-06,2018-02-05,INTERVENTIONAL,NA,64.0,ESTIMATED,"University of California, Los Angeles",OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Boston Children's Hospital|Massachusetts General Hospital,NIH|OTHER|OTHER,Tuberous Sclerosis,autism|epilepsy|asd|TSC|UCLA|Los Angeles|JASPER|intervention|Boston|BCH|MGH,United States,Los Angeles,California,2,JASPER,BEHAVIORAL,ESCS (Early Social Communication Scales) Assessment.|ESCS (Early Social Communication Scales) Assessment.|Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine.|Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine.|Structured Play Assessment (SPA)|SPA|Mullen Scales of Early Learning (MSEL)|Mullen|Social communication|Social communication,,False,
NCT04837651,Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab,"A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab",COMPLETED,2021-03-02,2021-07-01,2021-07-01,2021-08-02,2021-04-08,OBSERVATIONAL,,48.0,ACTUAL,"Dragonfly Research, LLC",OTHER,,,"Multiple Sclerosis|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Demyelinating Diseases|Autoimmune Diseases|Immune System Diseases|Pathologic Processes",COVID-19|Natalizumab|Ocrelizumab|Ocrevus|Tysabri|Antibody|Coronavirus|Vaccine,United States,Wellesley,Massachusetts,1,Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|T-Detect COVID T-cell blood test,DEVICE|DEVICE,SARS-CoV-2 B-cell response|SARS-CoV-2 T-cell response,,False,
NCT04130256,Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis,Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis,COMPLETED,2019-11-15,2021-01-26,2021-01-26,2021-07-30,2019-10-17,INTERVENTIONAL,NA,85.0,ACTUAL,Massachusetts General Hospital,OTHER,"National Multiple Sclerosis Society|Pillsy, Inc.",OTHER|UNKNOWN,Multiple Sclerosis,Medication adherence,United States,Boston,Massachusetts,1,Electronic Pill Bottle,DEVICE,Rate of perfect adherence,Participant satisfaction,False,
NCT05913219,Smart Wearable Device (gaitQ): Walk Better Project,Smart Wearable Device (gaitQ) That Helps People With Long-term Conditions Affecting Movement: Walk Better,RECRUITING,2023-09-15,2025-07-30,2025-07-30,2025-03-17,2023-06-22,OBSERVATIONAL,,150.0,ESTIMATED,University of Exeter,OTHER,GaitQ company,UNKNOWN,Parkinson Disease|Stroke|Multiple Sclerosis|Osteoporosis|Arthritis,"Parkinson, MS, osteoporosis, arthritis, Stroke",United Kingdom,Exeter,,1,,,Freezing and festinating events|Step length|Step rate|Step length symmetry index|Walking speed|Acceptability of the gaitQ device|Safety of the gaitQ device|Usability of the gaitQ device|Timed Up and Go,,False,
NCT03502772,Clinical Pilates Training for Persons With Multiple Sclerosis,"The Effects of Clinical Pilates Training on Walking, Balance, Fall Risk, Respiratory and Cognitive Functions in Persons With Multiple Sclerosis: A Randomized Controlled Trial",COMPLETED,2017-04-03,2017-12-29,2017-12-29,2018-04-19,2018-04-19,INTERVENTIONAL,NA,42.0,ACTUAL,Dokuz Eylul University,OTHER,Izmir Katip Celebi University,OTHER,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Pilates exercises|Home exercise program,OTHER|OTHER,12-Item MS Walking Scale,Six-Minute Walk Test|Timed 25-Foot Walk|Timed-Up and Go|Limits of Stability Test|Postural Stability Test|Fall Risk Index|Falls Efficacy Scale-International|Activities-Specific Balance Confidence Scale|Curl-up Test|Maximum Inspiratory Pressure|Maximum Expiratory Pressure|Symbol Digit Modalities Test|California Verbal Learning Test-II|Brief Visuospatial Memory Test Revised|Expanded Disability Status Scale,False,
NCT01157728,Early Cognitive Impairment in Multiple Sclerosis,Early Cognitive Impairment in Multiple Sclerosis: a Multimodal MRI Study Evaluating the Relative Contribution of Cortical and White Matter Tract Injury,COMPLETED,2008-05,2010-12,2010-12,2012-07-31,2010-07-07,OBSERVATIONAL,,69.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,ARSEP (Association pour la Recherche sur la Sclerose en Plaques)|JNLF (Journées de Neurologie de Langue Française),UNKNOWN|UNKNOWN,Multiple Sclerosis|Cognitive Impairment,Multiple sclerosis|Cognitive impairment,France,Paris,,1,,,,,False,
NCT07096700,VR and Orthoses for Rehabilitation in Multiple Sclerosis,Virtual Reality for Gait Training in Multiple Sclerosis (VIRTUE): an Interventional Feasibility Study,NOT_YET_RECRUITING,2025-10,2026-02,2026-05,2025-07-31,2025-07-31,INTERVENTIONAL,NA,12.0,ESTIMATED,Azienda Usl di Bologna,OTHER_GOV,,,Multiple Sclerosis,Multiple sclerosis|Neurorehabilitation|Gait impairments|Virtual Reality|Wearable technology|Sensor-based monitoring|Inertial sensors|Physiological signals|Walking braces|Remote monitoring,Italy,Bologna,Bologna,1,VR and walking brace-based gait rehabilitation,OTHER,Score of the standardized tests and gait parameters,NASA-TLX (NASA Task Load Index) questionnaire score|MSAQ (Motion Sickness Assessment Questionnaire) questionnaire score|IPQ (iGroupPresence Questionnaire) questionnaire score|MusiQoL (Multiple Sclerosis International Quality of Life) questionnaire score|BBS (Berg Balance Scale) questionnaire score|EDSS (Expanded Disability Status Scale) questionnaire score|MFIS (Modified Fatigue Impact Scale) questionnaire score|MSWS-12 (Twelve-Item Multiple Sclerosis Walking Scale) questionnaire score|Timed 25-Foot Walk Test (T25FW) test score|2MWT (2-Minute Walk Test) test score|TAM (Technology Acceptance Model) questionnaire score|TLSQ-WT (Tele-healthcare Satisfaction Questionnaire - Wearable Technology) questionnaire score|Timed Up and Go (TUG) test score,False,
NCT05338450,Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis,Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis,RECRUITING,2022-08-30,2027-12-31,2027-12-31,2024-11-15,2022-04-21,INTERVENTIONAL,PHASE3,80.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,,,Multiple Sclerosis|Internuclear Ophthalmoplegia,clemastine|fampridine|remyelination|eye-tracking|infrared oculography,Netherlands,Amsterdam,,1,Clemastine Fumarate|Placebo,DRUG|DRUG,Versional Dysconjugacy Index (VDI) - Area Under the Curve (VDI-AUC) (6 months)|Versional Dysconjugacy Index (VDI) - Area Under the Curve (VDI-AUC) (36 months),Other Versional Dysconjugacy Index (VDI) measures - Peak Velocity (VDI-pV + VDI-pV/Am)|Versional Dysconjugacy Index (VDI) - Response to Fampridine|Other infrared oculography parameters - Saccadic Latency|Other infrared oculography parameters - Proportion of errors in an anti-saccadic task|Other infrared oculography parameters - Proportion of correct double-step saccades|Other infrared oculography parameters - Error of the final eye position in double-step saccades|Symbol Digit Modalities Test (SDMT)|Expanded Disability Status Scale (EDSS)|High and Low Contrast Visual Acuity (HCVA and LCVA)|Subjective visual functioning (NEI-VFQ-25)|Visual complaints (NOV-AU)|Quality of life (EQ5D-5L)|Fatigue - CIS20R|Fatigue - NFI-MS,False,
NCT05957913,Effects of Antiviral Therapies on Epstein-Barr Virus Replication,Effects of Antiviral Therapies on Epstein-Barr Virus Replication,ENROLLING_BY_INVITATION,2023-06-05,2025-06-04,2025-12-31,2024-11-22,2023-07-24,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,Massachusetts General Hospital,OTHER,Solving MS,UNKNOWN,Multiple Sclerosis,,United States,Boston,Massachusetts,1,Truvada (tenofovir/emtricitabine),DRUG,Epstein Barr virus (EBV) viral load,Tolerability of Truvada (tenofovir/emtricitabine)|Fatigue,False,
NCT03233646,Retinal Imaging in Neurodegenerative Disease,Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study,RECRUITING,2017-07-20,2025-12-31,2025-12-31,2025-01-27,2017-07-28,OBSERVATIONAL,,2000.0,ESTIMATED,Duke University,OTHER,University of Edinburgh in Scotland|Tan Tock Seng Hospital in Singapore|Queens University of Belfast United Kingdom,UNKNOWN|UNKNOWN|UNKNOWN,Alzheimer's Disease|Mild Cognitive Impairment|Parkinson's Disease|Multiple Sclerosis|Huntington Disease|Lewy Body Dementia|Frontotemporal Dementia|Amyotrophic Lateral Sclerosis (ALS)|APOE-4 Positive|Traumatic Brain Injury|Concussion|Post-Traumatic Stress Disorder|Down Syndrome|Neuro-Degenerative Disease|Normal Cognition,OCT angiography (OCTA)|Optical Coherence Tomography (OCT)|Vessel Density|Superficial Capillary Plexus|Retinal microvasculature|Scanning Laser Ophthalmoscopy|Ultra-widefield (UWF) Imaging|Perfusion Density|Retinal Nerve Fiber Layer|Ganglion Cell Inner Plexiform Layer|Choroidal Vascularity Index,United States,Durham,North Carolina,1,Retinal and Choroidal Imaging,DEVICE,Change in ganglion cell-inner plexiform layer (GCIPL) thickness|Change in retinal nerve fiber layer (RNFL) thickness|Change in central subfield thickness (CST)|Change in choroidal vascularity index (CVI)|Change in foveal avascular zone (FAZ) area|Change in average perfusion density (PD)|Change in average vessel density (VD)|Change in average capillary perfusion density (CPD)|Change in average capillary flux index (CFI),Change in retinal vessel tortuosity|Change in retinal vessel width gradient|Change in retinal vessel fractal dimension,False,
NCT00248378,Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis,Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis,COMPLETED,2001-09,,2005-03,2006-06-23,2005-11-04,INTERVENTIONAL,PHASE1|PHASE2,30.0,,Center for Medicinal Cannabis Research,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cannabis|Spasticity|Tolerability,United States,San Diego,California,1,Smoked Cannabis,DRUG,"Reduction in spasticity as indicated by the: Ashworth Spasticity Scale, Timed 25-ft Walk, and Grooved Pegboard Test","Tolerability of study drug as determined by the Brief Symptom Inventory, Subjective Ratings of High and Sedation-Revised, and UKU Side Effect Rating Scale|Effect of study drug on global functioning and quality of life as indicated by the Multiple Sclerosis Quality of Life Inventory",False,
NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,"A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting",COMPLETED,2013-10-31,2016-03-31,2020-01-09,2020-03-19,2013-08-29,INTERVENTIONAL,PHASE4,1114.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,BG-12,Austria,Innsbruck,,90,dimethyl fumarate,DRUG,Annualized Relapse Rate (ARR),"Change from Baseline in Multiple Sclerosis Impact Scale (MSIS-29) score|Change from Baseline in Modified Fatigue Impact Scale-5 Item (MFIS-5) score|Change from Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) score|Change from Baseline in EQ-5D 5 level version (EQ-5D-5L) index|Change from Baseline in participants-Reported Indices for Multiple Sclerosis-Activity Limitations (PRIMUS-Activity Limitations) score|Change from Baseline in Work Productivity and Activity Impairment-Multiple Sclerosis version (WPAI-MS) score|Change from Baseline in Beck Depression Inventory-Fast Screen (BDI-Fast Screen) score|Proportion of participants with confirmed (24-week) Expanded Disability Status Scale (EDSS) progression|Annualized Relapse Rate (ARR) at Baseline (i.e., over the 12 months prior to enrollment) and at Month 6|The proportion of participants relapsed|Number of participants who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS|Proportion of participants who are hospitalized/have emergency room visits due to MS relapses or have relapses requiring intravenous (IV) steroid treatment during the study, or who make visits to neurologists/other specialists due to MS|Proportion of participants who report taking the prescribed DMF dose|Percentage of participants who report taking the prescribed DMF dose|Reasons reported by participants for not taking prescribed DMF dose|Change from baseline in EQ Visual Analog Scale (EQVAS) score",False,
NCT06968676,Mixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS),"Effects of Mixed Reality on Manipulative Skills, Functionality and Quality of Life in People With Multiple Sclerosis. A Randomized Controlled Trial (VIRTUAL-DOMUS)",NOT_YET_RECRUITING,2025-09-01,2026-12-31,2027-12-31,2025-05-16,2025-05-13,INTERVENTIONAL,NA,30.0,ESTIMATED,Universidad Rey Juan Carlos,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Mixed reality|Upper limb|Rehabilitation|Manipulative skills|Functionality|Quality of life,,,,0,Conventional Upper Limb Treatment|Experimental intervention with mixed reality,OTHER|OTHER,Isometric prehensile hand strength (Kg),Isometric pincer force (Kg)|Gross coordination for the upper limb (Block and Box; number of cubes)|Fine coordination for the upper limb (NHPT; time in seconds)|Functional status of the upper limb (ABILHAND)|Quality of life (MSIS-29)|Satisfaction (CSQ8),False,
NCT03917589,Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS),Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS,COMPLETED,2019-06-20,2020-05-18,2020-05-18,2020-11-10,2019-04-17,OBSERVATIONAL,,350.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,post-partum|corticosteroids|relapse|disease modifying drugs (DMD),France,Saint-Herblain,Nantes,5,,,Difference of the proportion of patients with >= 1 relapse between the two groups,Difference of the proportion of patients with >= 1 relapse|Difference of the annualized relapse rate|Difference of the annualized relapse rate|Difference of the annualized relapse rate|Difference of the time to first relapse|Difference of the disability progression|Difference of the disability progression|Difference of the disability progression|Difference of percentage of with Gadolinium enhancing lesions|Difference of the number of Gadolinium enhancing lesions,False,
NCT03756142,Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients,"Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients : Determination of Indicators of the Premature Degradation of the Orthostatic Posture, Gait Initiation and Walking",COMPLETED,2018-11-19,2020-01-07,2020-01-07,2024-03-06,2018-11-28,OBSERVATIONAL,,40.0,ACTUAL,Lille Catholic University,OTHER,"Laboratoire d'Automatique, de Mécanique et d'Informatique Industrielles et Humaines",UNKNOWN,Multiple Sclerosis,3D analysis|Biomarkers|Rehabilition|Locomotion,France,Lomme,,1,Motion Analysis,DIAGNOSTIC_TEST,Kinematics of lower limbs articulations,,False,
NCT01074827,Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking?,Strength Training or Treadmill Walking? A Randomized Control Study on the Effect on Gait in Multiple Sclerosis,COMPLETED,2010-03,2011-04,2011-04,2015-07-08,2010-02-24,INTERVENTIONAL,NA,28.0,ACTUAL,St. Olavs Hospital,OTHER,Norwegian University of Science and Technology|Helse Midt-Norge,OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Walking ability|Strength|Balance|Treadmill walking,Norway,Trondheim,,1,Strength training and treadmill training,OTHER,Walking ability,Strength|Work economy O2|Balance,False,
NCT05290688,Cellular microRNA Signatures in Multiple Sclerosis,Cellular microRNA Signatures in Multiple Sclerosis,UNKNOWN,2022-09-15,2024-09-15,2024-09-15,2022-08-17,2022-03-22,INTERVENTIONAL,NA,20.0,ESTIMATED,Institut Pasteur,INDUSTRY,Höpital La Pitié-Salpêtrière,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",Inflammation|IFN-beta|Autoimmunity|Gene regulation,France,Paris,,1,50 ml blodd sampling,GENETIC,microRNA expression profiles in immune cell populations from RRMS patients,microRNA expression profiles in unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients|microRNA expression profiles in monocytes from RRMS patients,False,
NCT00785473,Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis,"Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study",COMPLETED,2008-01,2010-04,2010-04,2011-09-05,2008-11-05,INTERVENTIONAL,PHASE4,80.0,ESTIMATED,University Hospital of North Norway,OTHER,,,"Multiple Sclerosis, Osteoporosis",,Norway,Tromsø,,1,cholecalciferol|calcium carbonate,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Changes in BMD over the 2 year study period comparing treatment and placebo groups,"Cytokine expression following vitamin D supplementation|Contribution of vitamin D from different sources (generation in the skin, diet and supplements) to serum 25(OH) vitamin D (vitamin D status)|Changes in parameters of lower extremity function over the 2 year study period|The number of relapses, the time to first relapse, the number of relapse-free patients|The number of patients without progression of disability judged by EDSS and|Reported infections|Ratings on a fatigue scale",False,
NCT05469373,ESIS in Pediatric DRE,Electrical Stimulation for Seizure Induction in Pediatric Drug-Refractory Epilepsy (ESIS in Pedriatric DRE).,RECRUITING,2022-02-17,2025-06-30,2027-12-31,2025-01-15,2022-07-21,OBSERVATIONAL,,86.0,ESTIMATED,Sarah Katie Ihnen,OTHER,Network for Excellence in Neuroscience Clinical Trials|Child Neurologist Career Development Program,UNKNOWN|UNKNOWN,Epilepsy,"epilepsy surgery, drug-resistant epilepsy, tuberous sclerosis",United States,Cincinnati,Ohio,1,,,"Safety -- Occurrence of generalized, convulsive and prolonged seizures|Tolerability -- Quantify study withdrawal and patient/caregiver experience|Yield -- Rate of induction of habitual seizures|Clinical Validity|Predictors",,False,
NCT03113162,Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis,Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis,UNKNOWN,2015-05-29,2020-05-29,2022-05-29,2017-05-05,2017-04-13,INTERVENTIONAL,PHASE1,15.0,ESTIMATED,Makati Medical Center,OTHER,,,Multiple Sclerosis,multiple sclerosis|HSCT,Philippines,Makati,,1,Autologous Hematopoietic Stem Cell|BEAM Regimen,BIOLOGICAL|DRUG,Safety: Adverse Events,Efficacy: EDSS Score|Efficacy: RAND-36 Score,False,
NCT04022473,Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers,"A Randomized, Double-Blind Study to Compare Gastrointestinal Tolerability Following Oral Administration of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) to Healthy Male and Female Volunteers",COMPLETED,2019-07-07,2019-10-19,2019-10-19,2020-01-18,2019-07-17,INTERVENTIONAL,PHASE1,210.0,ACTUAL,Banner Life Sciences LLC,INDUSTRY,,,Multiple Sclerosis,Gastrointestinal,United States,Columbia,Missouri,1,Bafiertam|Tecfidera,DRUG|DRUG,Area Under the Curve (AUC) in each of the individual symptoms over the treatment period.,"Comparison of the Modified Overall Gastrointestinal Symptom Scale (MOGISS) composite score|The number of days that a subject experiences at least one GI symptom.|AUC in the MOGISS total score within in each subject over the treatment period|Frequency, severity, and duration of overall GI events using the MOGISS.|Safety and tolerability outcomes: incidence rates of all non GI-adverse events",False,
NCT05122559,Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis,Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis,RECRUITING,2022-02-16,2027-02,2027-02,2025-06-06,2021-11-16,INTERVENTIONAL,PHASE2,98.0,ESTIMATED,"Emmanuelle Waubant, MD PhD",OTHER,United States Department of Defense,FED,"Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",,United States,San Francisco,California,1,N-acetyl cysteine|Placebo,DRUG|DRUG,"Safety and tolerability|Effect of NAC on on progression of brain, thalamic and cervical cord atrophy",Clinical effects of NAC,False,
NCT00203073,A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.,"A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis.",COMPLETED,2003-06,2005-01,2005-04,2011-04-14,2005-09-20,INTERVENTIONAL,PHASE2,40.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,"glatiramer acetate 20 mg|glatiramer acetate 20 mg, with mitoxantrone",DRUG|DRUG,Determine if short-term immunosuppression with mitoxantrone (Novantrone®) followed by chronic treatment with Glatiramer Acetate (GA) in comparison to treatment with GA for the same period of time but without immunosuppression is well-tolerated and safe,,False,
NCT04885894,An Examination of Cognitive Fatigue Using Functional Neuroimaging,An Examination of Cognitive Fatigue Using Functional Neuroimaging,RECRUITING,2022-01-01,2024-12,2024-12,2024-03-01,2021-05-13,OBSERVATIONAL,,60.0,ESTIMATED,Kessler Foundation,OTHER,Celgene|Hackensack Meridian Health|St. Barnabas Medical Center,INDUSTRY|OTHER|OTHER,"Multiple Sclerosis, Relapsing-Remitting",,United States,West Orange,New Jersey,1,Zeposia,DRUG,Brain activation (BOLD signal),Fatigue Onset,False,
NCT01318421,A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,"An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis",TERMINATED,2010-12,2012-12,,2015-12-14,2011-03-18,INTERVENTIONAL,PHASE1,12.0,ACTUAL,Elan Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS),,,,0,ELND002,DRUG,To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT).,To evaluate the PK/PD/BM measurement of ELND002 in patients with MS.,False,
NCT03051646,Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis,A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis,COMPLETED,2017-01-13,2017-05-10,2017-05-10,2018-11-20,2017-02-14,INTERVENTIONAL,EARLY_PHASE1,12.0,ACTUAL,Columbia University,OTHER,National Multiple Sclerosis Society,OTHER,Fatigue|Overheating,Exercise|Time to Exhaustion,United States,New York,New York,1,"Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit",DRUG|DRUG,Change in Time to Exhaustion,Exercise-induced Body Temperature Increase,True,2018-11-20
NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis",COMPLETED,2012-08,2013-08,2013-08,2017-01-09,2012-05-14,INTERVENTIONAL,PHASE2,132.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Belgium,Ath,,23,BIIB041 (PR Fampridine)|Placebo,DRUG|OTHER,Change from baseline in self-assessed walking disability as reported on the Multiple Sclerosis Walking Scale-12 (MSWS-12)|Change from baseline in static balance as assessed by Berg Balance Scale (BBS)|Change from baseline in dynamic balance as assessed by the Timed Up and Go (TUG) scale)|Change from baseline in subjective impression of well-being measured by Multiple Sclerosis Impact Scale-29 (MSIS-29)|Change from baseline in subjective impression of well-being measured by Euro Quality of Life-5D (EQ-5D)|Participant's global impression of change in walking as reported on the Patient Global Impression of Change Scale (PGIC)|Summary of Participants with adverse events (AEs) and serious adverse events (SAEs),,False,
NCT00220779,"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2002-12,2005-02,2005-02,2016-04-27,2005-09-22,INTERVENTIONAL,PHASE2,128.0,ACTUAL,Grifols Therapeutics LLC,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Phoenix,Arizona,37,"Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|Albumin (Human) 25%, United States Pharmacopeia (USP)",DRUG|DRUG,Percentage of Relapse Free Subjects (no Relapse),Effect on the Combined Unique Lesion Activity on Magnetic Resonance Imaging (MRI),True,2014-04-11
NCT01765361,Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG),Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG),COMPLETED,2012-09,2015-01,2017-01,2017-02-01,2013-01-10,OBSERVATIONAL,,16.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,,Switzerland,Basel,,1,,,dΣ-EP,d#-EP,False,
NCT06402487,Propionic Acid in Multiple Sclerosis,Propionic Acid in Multiple Sclerosis - a Placebo-controlled Randomized Double-blinded Clinical Trial,COMPLETED,2024-05-01,2024-09-15,2024-10-09,2024-10-15,2024-05-07,INTERVENTIONAL,PHASE2|PHASE3,101.0,ACTUAL,Salzburger Landeskliniken,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Propionic Acid|Progression|Disability|Fatigue,Austria,Salzburg,Salzburg,1,Propionic acid 1000 mg capsule|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Serum neurofilament light chain (NfL)|Serum glial fibrillary acid protein (GFAP),"Fatigue Scale for Motor and Cognitive Functions (FSMC)|Walking test, 10 meters distance|cerebral MRI|36-Item Short Form Health Survey (SF-36)|Magnetoencephalography (MEG)|9-hole peg test",False,
NCT06920524,Interest of a Musical Intervention on Stress Induced During Botulinum Toxin Injections in Spasticity (MUSIBOT),Interest of a Musical Intervention on Stress Induced During Botulinum Toxin Injections in Spasticity,RECRUITING,2025-04-25,2027-10-30,2027-10-30,2025-05-23,2025-04-09,INTERVENTIONAL,NA,80.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,,,Stroke|Multiple Sclerosis|Spinal Cord Injury|Head Trauma Injury,Musical intervention|Pain Management|stress|Botulinum toxin,France,Clermont-Ferrand,,1,Intervention group IM-IM,DEVICE,Stress|Stress,Stress|Intensity of pain|Variation of anxiety|Measurement of perception of session time|Patient satisfaction with the procedure|Quality of the conditions under which botulinum toxin injections,False,
NCT03526224,Teriflunomide Tecfidera LMCE,Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study,COMPLETED,2018-06-14,2019-07-10,2019-07-10,2021-01-06,2018-05-16,OBSERVATIONAL,,120.0,ACTUAL,University at Buffalo,OTHER,,,Tecfidera|Teriflunomide,,United States,Buffalo,New York,1,Dimethyl Fumarate|Teriflunomide,DRUG|DRUG,Percent change in CGM between teriflunomide and dimethyl fumarate|LM CE lesions at 24 months|CGM atrophy and LM inflammation,,False,
NCT00711646,A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.,"A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.",COMPLETED,2002-06,2004-03,2004-03,2023-05-06,2008-07-09,INTERVENTIONAL,PHASE3,189.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Spasticity|Multiple Sclerosis,Spasticity|Multiple Sclerosis,United Kingdom,Reading,Oxfordshire,1,Sativex®|Placebo,DRUG|DRUG,Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score.,Change From Baseline in Mean Ashworth Scale Score at the End of Treatment|Change From Baseline in Mean Spasm Frequency Score at the End of Treatment|Change From Baseline in Mean Motricity Index Score for the Arms|Patient's Global Impression of Change in Condition at the End of Treatment|Incidence of Adverse Events as a Measure of Subject Safety|Change From Baseline in Mean Motricity Index Score for the Legs,True,2012-09-14
NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®),COMPLETED,1999-11,,2004-02,2007-12-13,2007-09-24,INTERVENTIONAL,PHASE4,284.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Avonex|Interferon beta-1a,Belgium,Sijsele-Damme,,3,Interferon beta-1a,DRUG,The primary objective of this study is to evaluate the correlation between the MS Functional Composite Index and two Quality of Life scales (MS Quality of Life 54 and AMS Quality of Life) in patients treated with interferon beta-1a (AVONEX®).,Reproducibility of Quality of Life scales per language version|Reliability of the Quality of Life scales per language version|EDSS score throughout the study,False,
NCT04552561,My MS Toolkit + Coaching: A Guided Web-based Symptom Self-Management Program for People With MS,My MS Toolkit + Coaching: A Guided Web-based Symptom Self-Management Program for People With MS,COMPLETED,2020-10-19,2021-01-18,2021-01-18,2021-09-27,2020-09-17,INTERVENTIONAL,NA,5.0,ACTUAL,University of Michigan,OTHER,,,Multiple Sclerosis,Self-management|Web-based program,United States,Ann Arbor,Michigan,1,My MS Toolkit,BEHAVIORAL,Acceptability/Feasibility of the the coached version of My MS Toolkit,Impact of My MS Toolkit: Change in fatigue|Impact My MS Toolkit: Change in pain interference as measured by The Brief Pain Inventory Short Form|Impact My MS Toolkit: Change in depressive symptoms as measured by the Patient Health Questionnaire depression scale|Change in self-efficacy for managing symptoms as measured by the University of Washington Self-Efficacy Scale|Participant perception of change,False,
NCT05369741,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program","Feasibility and Potential Benefits of a Virtually Delivered, Community-based, Task-oriented Exercise Program (TIME™ at Home) for People With Balance and Mobility Limitations",COMPLETED,2022-01-22,2022-07-31,2022-07-31,2023-05-18,2022-05-11,INTERVENTIONAL,NA,20.0,ACTUAL,University of Toronto,OTHER,"March of Dimes, Canada",OTHER,Mobility Limitation|Balance Impairment,Community-based exercise program|Stroke|Multiple Sclerosis|Age-related mobility changes|Brain injury|Virtual exercise program,Canada,Halifax,Nova Scotia,2,TIME™ at Home,OTHER,Change in Subjective Index of Physical and Social Outcome for exercise participants,Change in Activities-Specific Balance Confidence scale for exercise participants|Change in EuroQuol Visual Analogue Scale for exercise participants|Change in Center for Epidemiological Studies Depression scale for caregiver|Change in 30-second sit to stand test (30STS) for exercise participants|Change in Timed Up and Go (TUG) test for exercise participants|Change in Center for Epidemiological Studies Depression scale for exercise participants|Feasibility outcome: adverse events|Feasibility outcome: acceptability of the facilitator|Feasibility outcome: acceptability of the social component|Feasibility outcome: acceptability of the healthcare partner|Feasibility outcome: acceptability of the Level 2 video|Feasibility: intervention fidelity|Feasibility: Healthcare partner feedback questionnaire|Feasibility outcome: attendance,False,
NCT03277261,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ),Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY),COMPLETED,2017-09-19,2020-07-23,2020-11-06,2021-12-06,2017-09-11,INTERVENTIONAL,PHASE3,549.0,ACTUAL,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),,United States,Carlsbad,California,14,Ublituximab|Teriflunomide|Oral Placebo|IV Placebo,BIOLOGICAL|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),Total Number of Gadolinium (Gd)-Enhancing T1-Lesions Per Magnetic Resonance Imaging (MRI) Scan Per Participant|Total Number of New and Enlarging T2 Hyperintense Lesions (NELs) Per MRI Scan Per Participant|Time to Confirmed Disability Progression (CDP) for at Least 12 Weeks|Percentage of Participants With No Evidence of Disease Activity (NEDA)|Percentage of Participants With Impaired Symbol Digit Modalities Test (SDMT)|Percent Change From Baseline in Brain Volume|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs),True,2021-12-06
NCT00001669,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,COMPLETED,1997-07,,2000-04,2008-03-04,2002-12-10,INTERVENTIONAL,PHASE2,15.0,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,EAE|EDSS|MRI|SNRS|Multiple Sclerosis,United States,Bethesda,Maryland,1,rhIGF-1 (CEP-151),DRUG,,,False,
NCT00872053,Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis,Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis,COMPLETED,2009-02,2009-12,2010-01,2013-09-20,2009-03-31,INTERVENTIONAL,PHASE1|PHASE2,18.0,ESTIMATED,US Department of Veterans Affairs,FED,,,MS (Multiple Sclerosis),robot|treadmill|foot drop|rehabilitation|gait,United States,Providence,Rhode Island,1,Anklebot|Lokomat,DEVICE|DEVICE,Ankle accuracy and stiffness,"Gait assessments (e.g., 6-Minute Walk, Timed 25-Foot Walk)|Functional assessments (EDSS, MS Functional Composite)",False,
NCT00678795,A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis,"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.",COMPLETED,2002-08,2005-10,2005-10,2023-05-03,2008-05-16,INTERVENTIONAL,PHASE3,135.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Detrusor Overactivity|Multiple Sclerosis,Detrusor overactivity|Multiple Sclerosis,United Kingdom,Nottingham,Notts,1,Sativex®|Placebo,DRUG|DRUG,Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment,Change From Baseline in the Mean Daily Episodes of Urgency at the End of Treatment|Change From Baseline in the Mean Daily Episodes of Nocturia at the End of Treatment|Change From Baseline in the Mean Daily Number of Incontinence Pads Used at the End of Treatment|Change From Baseline in Mean Total Incontinence Quality of Life (I-QOL) Questionnaire Score at the End of Treatment (Completion or Withdrawal)|Change From Baseline in Mean Overall Bladder Condition 0-10 Numerical Rating Scale Score at the End of Treatment|Patient's Global Impression of Change|Change From Baseline in the Mean Number of Daily Voids at the End of Treatment,True,2012-09-21
NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES),"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis",COMPLETED,2020-09-24,2024-08-29,2024-08-29,2025-07-02,2020-06-02,INTERVENTIONAL,PHASE3,1131.0,ACTUAL,Sanofi,INDUSTRY,,,Non-relapsing Secondary Progressive Multiple Sclerosis,,United States,Birmingham,Alabama,306,Tolebrutinib|Placebo to match Tolebrutinib,DRUG|DRUG,Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS),"Time to Onset of 3-month Confirmed Disability Progression as Assessed by Expanded Disability Status Scale|Mean Number of New and/or Enlarging T2-hyperintense Lesions Per Year|Time to Onset of Sustained 20% Increase in the 9-hole Peg Test (HPT) for at Least 3 Months|Time to Onset of Sustained 20% Increase in the Timed 25-foot Walk (T25-FW) for at Least 3 Months|Time to Onset of 6-month Confirmed Disability Improvement (CDI) as Assessed by Expanded Disability Status Scale|Percent Change in Brain Volume at EOS Compared to Month 6|Change From Baseline in Cognitive Function as Assessed by Symbol Digit Modalities Test (SDMT) at EOS|Change From Baseline in Cognitive Function as Assessed by California Verbal Learning Test Second Edition (CVLT-II) at EOS|Change From Baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) Questionnaire Score at EOS|Number of Participants With Treatment-emergent Adverse Events (AEs), Treatment-emergent Serious AEs, Treatment-emergent AEs Leading to Permanent Study Intervention Discontinuation, and Treatment-emergent Adverse Events of Special Interest (AESIs)|Maximum Observed Plasma Concentration (Cmax) of Tolebrutinib and M2 Metabolite|Time to Maximum Observed Plasma Concentration (Tmax) of Tolebrutinib and M2 Metabolite|Area Under the Plasma Concentration-time Curve Over the Last 24-hours Dosing Interval (AUC0-24) of Tolebrutinib and M2 Metabolite|Change From Baseline in Plasma Neurofilament Light Chain (NfL) and Serum Chitinase-3 Like Protein-1 (Chi3L1) Levels at EOS|Change From Baseline in Cluster of Differentiation (CD)19+ B Cells at EOS|Change From Baseline in Serum Immunoglobulin (Ig) Levels at EOS",True,2025-06-18
NCT02580669,Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis,Study by Magnetic Resonance Imaging of the Modifications of the Vasoreactivity and Cerebral Connectivity in the Progressive Forms of Multiple Sclerosis,TERMINATED,2014-06-16,2017-02-13,2017-02-13,2021-05-18,2015-10-20,INTERVENTIONAL,NA,70.0,ACTUAL,"University Hospital, Montpellier",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,"Progressive Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",,France,Montpellier,,1,Neuropsychological assessment|Neurologic consultation|MRIs (with vasoreactivity testing),OTHER|OTHER|OTHER,Cerebral vasoreactivity measured by diffusion imaging MRI (quantitative variable) :parameter which allow us to estimate the organization of the white matter tracts,Comparison of fonctional connective cards at Resting state|Cognitive disorders,False,
NCT00922831,Progression of Cognitive and Physical Symptoms in Multiple Sclerosis,"Progression of Cognitive, Affective, and Physical Symptoms in Multiple Sclerosis.",WITHDRAWN,2008-08,2013-08,2013-08,2018-04-12,2009-06-17,OBSERVATIONAL,,0.0,ACTUAL,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,OTHER,"University of Missouri, Kansas City",OTHER,Multiple Sclerosis,"Cognition, Affective MS symptoms",,,,0,,,,,False,
NCT06413602,The Synergistic Effects of AIH and FES in Persons With MS,Exploring the Synergistic Effects of AIH and FES in Persons With MS,NOT_YET_RECRUITING,2024-08,2026-08,2027-08,2024-06-21,2024-05-14,INTERVENTIONAL,NA,20.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,Northwestern University,OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",multiple sclerosis|plasticity|electrical stimulation|NMES|modalities|neuroplasticity|motoneuron|aih|hypoxia|acute intermittent hypoxia,United States,Chicago,Illinois,1,Acute Intermittent Hypoxia|Neuromuscular Electrical Stimulation,OTHER|OTHER,Motor Evoked Potentials (MEPs) in Ankle Dorsiflexors,Ankle Dorsiflexion Torque|Ankle Dorsiflexion EMG|Symbol Digit Modalities Test,False,
NCT04175054,Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis,Training to Restore Walking and Promote Nervous System Repair in Multiple Sclerosis: RCT to Determine the Importance of Intensity,WITHDRAWN,2030-01,2030-02,2030-02,2024-11-27,2019-11-22,INTERVENTIONAL,NA,0.0,ACTUAL,Memorial University of Newfoundland,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis|Neurological Rehabilitation|Exercise|Neuronal Plasticity|Cooling,,Canada,St. John's,Newfoundland and Labrador,1,Body-weight supported treadmill training in a room cooled to 16°C,OTHER,Fast walking speed,Spatiotemporal parameters of gait measured while walking at self-selected pace|Maximal oxygen consumption during graded exercise test|Multiple Sclerosis Impact Scale-29|Fatigue Severity Scale|Hospital Anxiety and Depression Scale|Montreal Cognitive Assessment|Symbol Digit Modality Test|Transcranial Magnetic Stimulation|Serum Insulin-like growth factor-1 (IGF-1)|Structural and functional brain changes on Magnetic Resonance Imaging (MRI),False,
NCT00296205,Phase II High-Dose Cyclophosphamide for Multiple Sclerosis,Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis,WITHDRAWN,2003-10,,2006-02,2009-07-22,2006-02-24,INTERVENTIONAL,PHASE2,25.0,ESTIMATED,Stony Brook University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cyclophosphamide|autoimmune,United States,Stony Brook,New York,1,Cyclophosphamide,DRUG,The primary endpoint of this study is to evaluate the response rate of MS patients after high-dose cyclophosphamide therapy as determined by a sustained (greater than 6 months) decrease of greater than or equal to 1.0 in their EDSS score.,The secondary endpoint of this study is to evaluate time to EDSS score progression.,False,
NCT00405353,Testosterone Treatment for Multiple Sclerosis,Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial,COMPLETED,2002-04,2007-03,2007-03,2019-11-22,2006-11-30,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,"University of California, Los Angeles",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,multiple sclerosis|testosterone,United States,Los Angeles,California,1,Androgel 10 grams of gel containing 100 mg of testosterone,DRUG,Whole Brain Atrophy Rate,,True,2019-11-22
NCT03632473,Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis,Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC),COMPLETED,2014-08-28,2020-06-26,2020-06-26,2024-09-19,2018-08-15,OBSERVATIONAL,,29.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,Multimodal Evoked potentials|Visual evoked potentials|Somato-sensory evoked potentials|Motor evoked potentials|Expanded Disability Status Scale (EDSS),Switzerland,Basel,,3,multimodal evoked potentials (mmEP),DIAGNOSTIC_TEST,correlation of EP-sum-score (Σ-EP) and the Expanded Disability Status Scale (EDSS),,False,
NCT02331654,Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis,Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment and Evaluation of Endocannabinoid System Activity,UNKNOWN,2013-11,2015-06,2016-02,2015-01-06,2015-01-06,INTERVENTIONAL,NA,60.0,ESTIMATED,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",OTHER,,,Multiple Sclerosis,Chronic pain|Direct Current Stimulation,Italy,Pavia,Pavia,1,Experimental treatment|Placebo treatment,OTHER|OTHER,sDCS efficacy in pain as determined by NPSI and NRS scale,Central endocannabinoid level as determined by Activity of Fatty Acid Amide Hydrolase (FAAH) in platelets|Spasticity as determined by Ashworth Scale,False,
NCT04570670,Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects,"A Single-Dose, Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of BLS-11 (Monomethyl Fumarate) 190 mg and Tecfidera (Dimethyl Fumarate) 240 mg in Healthy Male and Female Subjects Under Fasting Conditions",COMPLETED,2017-01-06,2017-02-17,2017-02-17,2022-12-30,2020-09-30,INTERVENTIONAL,PHASE1,50.0,ACTUAL,Banner Life Sciences LLC,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,monomethyl fumarate 190 mg|dimethyl fumarate 240 mg,DRUG|DRUG,The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments|The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments,,True,2021-07-28
NCT00617383,AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS,Determine if the Presence of Characteristic MS-like Lesion(s) on Baseline MRI Predisposes to CIS/MS in Female MZ Twins Discordant for CIS/MS.,COMPLETED,2008-02,2010-12,2010-12,2017-04-04,2008-02-18,OBSERVATIONAL,,3.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Clinically Isolated Syndrome,demyelinating disease|multiple sclerosis|female monozygotic identical twins|MS|non-concordant|clinically isolated syndrome - CIS|brain MRI|proteomics,United States,Houston,Texas,1,,,Determine if the presence of characteristic MS-like lesion(s) on baseline MRI predisposes to CIS/MS in female MZ twins discordant for CIS/MS.,Define the protein and microarray gene expression profile predictive of conversion to MS/CIS in female MZ twins discordant for CIS/MS.,False,
NCT00648908,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial","Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial",COMPLETED,2006-06,2011-01,2011-04,2012-02-27,2008-04-01,INTERVENTIONAL,PHASE3,269.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|MS|walking|leg strength|demyelination,United States,Phoenix,Arizona,32,Fampridine-SR,DRUG,Summary of Treatment Emergent Adverse Events (TEAE).,Timed 25 Foot Walk (T25FW)|Subject Global Impression (SGI)|Clinician Global Impression of Change (CGIC)|Expanded Disability Status Scale (EDSS),True,2012-02-27
NCT04888689,Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.,Holter of Movement in Patients with Multiple Sclerosis. Acti-SEP Study: Controlled Environment.,COMPLETED,2021-02-04,2021-09-30,2021-09-30,2025-02-12,2021-05-17,INTERVENTIONAL,NA,21.0,ACTUAL,Laurent Servais,OTHER,SYSNAV|Centre Hospitalier Régional de la Citadelle,INDUSTRY|OTHER,Multiple Sclerosis,Actimyo|Accelerometry|Motion laboratory,Belgium,Liège,Liège,1,Actimyo°|IMU,DEVICE|DEVICE,95th centile of stride velocity|50th centile of stride velocity|95th centile of stride length|50th centile of stride length|Stance phase time,,False,
NCT04758468,Effects of Telerehabilitation-Based Pelvic Floor Muscle Training in People With Multiple Sclerosis,"Effects of Telerehabilitation-Based Pelvic Floor Muscle Training on Urinary Incontinence, Sexual Function and Quality of Life in People With Multiple Sclerosis",COMPLETED,2021-02-18,2021-11-15,2021-11-15,2022-03-29,2021-02-17,INTERVENTIONAL,NA,45.0,ACTUAL,Dokuz Eylul University,OTHER,Izmir Katip Celebi University,OTHER,Multiple Sclerosis|Urinary Incontinence,Multiple Sclerosis|Urinary Incontinence|Pelvic Floor Muscle Training|Sexual Function,Turkey (Türkiye),Izmir,Inciralti,1,Telerehabilitation-based pelvic floor muscle training|Home-based pelvic floor muscle training,BEHAVIORAL|BEHAVIORAL,Feasibility of the methods-minimum recruitment rate|Feasibility of the methods-minimum retention rate|Feasibility of the methods-minimum adherence rate|Feasibility of the methods-adverse events|Change in Leakage Episodes,Expanded Disability Status Scale (EDSS)|Change in Patient-Determined Disease Steps Scale (PDDS) Score|Change in Brief International Cognitive Assessment for MS-Symbol Digit Modalities Test Score|Change in Brief International Cognitive Assessment for MS-California Verbal Learning Test-Second Edition Score|Change in Brief International Cognitive Assessment for MS-Brief Visuospatial Memory Test-Revised Score|Change in Pad Usage|Change in International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form Score|Change in Overactive Bladder-Validated 8-Question (OAB-V8) Score|Change in EuroQOL 5-Dimension 3-Level Questionnaire Score|Change in Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19) Score|Change in Hospital Anxiety and Depression Scale (HADS) Score|Change in the number of falls due to a sense of urgency,False,
NCT06084182,Cognitive Function in Multiple Sclerosis,"The Relationship Between Cognitive Function and Functional Capacity, Cognitive Reserve, Reaction Time in Patients With Multiple Sclerosis",COMPLETED,2021-11-15,2022-07-15,2022-11-15,2023-10-16,2023-10-16,INTERVENTIONAL,NA,76.0,ACTUAL,Inonu University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|cognitive function|cognitive reserve|functional capacity,Turkey (Türkiye),Malatya,,1,"Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment",OTHER,Functional capacity assessment|Functional capacity assessment|Cognitive function|Visiospatial perception|Cognitive Reserve Index Questionnaire,Hand grip strength|Nottingham Health Profile.|Beck Depression Inventory|Fatigue Severity Scale.|Reaction time,False,
NCT03322982,Low Fat Diet for Fatigue in MS,"A Randomized, Controlled Trial of Low-fat Diet for Fatigue in Multiple Sclerosis",UNKNOWN,2018-08-15,2021-09-30,2022-03-31,2021-03-01,2017-10-26,INTERVENTIONAL,NA,108.0,ESTIMATED,Oregon Health and Science University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,"diet, low-fat",United States,Portland,Oregon,1,Low-fat diet,BEHAVIORAL,Fatigue,Fatigue|Disability,False,
NCT01489254,Efficacy and Safety of GTR in Comparison to Copaxone®,"Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects",COMPLETED,2011-10,2015-01,2015-01,2016-12-29,2011-12-09,INTERVENTIONAL,PHASE3,794.0,ACTUAL,Synthon BV,INDUSTRY,,,Multiple Sclerosis,"Multiple Sclerosis,|Relapsing-Remitting Multiple Sclerosis,|glatiramer acetate,|MRI,|lesions,|MS relapse rate,|Copaxone",United States,Irvine,California,133,Glatiramer Acetate (GTR)|Glatiramer Acetate (Copaxone®)|Placebo,DRUG|DRUG|DRUG,The Number of T1-Gadolinium Enhancing Lesions During Months 7-9,,True,2016-10-31
NCT02538094,tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis,Transcranial Direct Current Stimulation and Cognition in Adults With Multiple Sclerosis or Encephalitis,COMPLETED,2014-09,2019-06-30,2019-06-30,2020-04-06,2015-09-02,INTERVENTIONAL,NA,7.0,ACTUAL,Johns Hopkins University,OTHER,,,Multiple Sclerosis|Encephalitis,Cognitive Enhancement|tDCS|stimulation|MS|Multiple Sclerosis|Encephalitis,United States,Baltimore,Maryland,1,Sham Transcranial direct current stimulation|Anodal Transcranial direct current stimulation,DEVICE|DEVICE,Change in Cognition as Assessed by Change in Paced Auditory Serial Addition Test Scores,Change in Fatigue as Assessed by Multidimensional Fatigue Symptom Inventory 30-item Short Form (MFSI-SF) Total Scores,True,2020-04-06
NCT04210960,Correlation of Serum Lactate and Activity of Multiple Sclerosis,Correlation of Serum Lactate and Activity of Multiple Sclerosis,UNKNOWN,2019-12-23,2020-05-01,2020-06-01,2019-12-27,2019-12-26,OBSERVATIONAL,,80.0,ESTIMATED,Mansoura University Hospital,OTHER,,,Multiple Sclerosis,"Multiple sclerosis, serum lactate and MRS",Egypt,Al Mansurah,Dakahlia Governorate,1,Magentic resonanace imaging|Magentic resonanace spectroscopy,RADIATION|RADIATION,Biochemical testing,,False,
NCT06940323,"Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)","Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA): Pregnancy Registry for Women With Chronic Conditions",RECRUITING,2017-03-21,2030-06,2035-06,2025-05-04,2025-04-23,OBSERVATIONAL,,250.0,ESTIMATED,"University of California, San Francisco",OTHER,,,Multiple Sclerosis|Clinically Isolated Syndrome|NMOSD|Myasthenia Gravis,,United States,San Francisco,California,1,,,Maternal Disease Activity During Pregnancy and Postpartum Assessed by Expanded Disability Status Scale (EDSS)|Maternal Disease Activity During Pregnancy and Postpartum Assessed by MRI Findings|Maternal Disease Treatment Course During Pregnancy and Postpartum Assessed by Disease Modifying Therapy (DMT) Use|Maternal Disease Activity During Pregnancy and Postpartum Assessed by Clinical Relapse Rates,Infant Growth and Development Outcomes Assessed by Chart Review and ASQ-3|Detection and Concentration of Monoclonal Antibodies in Breastmilk|Concentration of Monoclonal Antibodies and Disease-Related Biomarkers in Maternal Blood|Maternal Fatigue During Pregnancy and Postpartum Assessed by Modified Fatigue Impact Scale (MFIS)|Maternal Sleep Quality During Pregnancy and Postpartum Assessed by Medical Outcomes Study Sleep Scale (MOS-SS)|Maternal Sleep Quality During Pregnancy and Postpartum Assessed by Epworth-Sleepiness Scale (ESS)|Maternal Cognitive Function During Pregnancy and Postpartum Assessed by Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)|Social Support During Pregnancy and Postpartum Assessed by Medical Outcomes Study Social Support Survey (19-Item Version)|Maternal Per-partum Depression Status During Pregnancy and Postpartum Assessed by Hospital Anxiety and Depression Scale (HADS)|Maternal Per-partum Depression Status During Pregnancy and Postpartum Assessed by Edinburgh Postnatal Depression Scale (EPDS)|Maternal Per-partum Depression Status During Pregnancy and Postpartum Assessed by Mini International Neuropsychiatric Interview (MINI)|Maternal Per-partum Depression Status During Pregnancy and Postpartum Assessed by Structured Clinical Interview for DSM-5 (SCID)|Maternal Bonding with Infant Assessed by Mother-to-Infant Bonding Scale (MIBS)|Infant Feeding Practices Assessed by Breastfeeding Questionnaire,False,
NCT06251986,A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice,A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice: the CRONOS-MS Study.,COMPLETED,2024-02-26,2024-12-16,2024-12-16,2025-02-07,2024-02-09,OBSERVATIONAL,,311.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,RMS|NIS|Spain|ofatumumab,Spain,Córdoba,Andalusia,32,ofatumumab,OTHER,Reductions in the Annualized relapse rate (ARR),Reductions in the ARR in naïve vs previously treated patients|Reductions in the ARR in previously treated with high-efficacy Disease-modifying treatments (DMT) vs previously treated with moderate-efficacy DMT|Number of days from ofatumumab treatment initiation to first relapse|Proportion of relapse-free patients|Change in EDSS score|Number of participants with radiological disease activity on the cranial MRI|Percentage of participants reporting injection site reactions (ISR)|Percentage of patients with AEs leading to temporal or permanent discontinuation|Number of pregnancies and pregnancy outcome|Proportion of participants with non-adherence|Proportion of patients who discontinue ofatumumab during the observation period|Scores on the Work Productivity and Activity Impairment (WPAI) questionnaire|Scores on the SDMT|Scores on the Modified Fatigue Impact Scale-5 (MFIS-5)|Scores on the EuroQol-5 dimension (EQ-5D)-5L|Scores on the Patients' Global Impression of Change (PGIC) scale completed by patients|Scores on the Clinical Global Impressions (CGI) scale completed by physicians|Scores on the Treatment Satisfaction Questionnaire for Medication (TSQM-9),False,
NCT07150520,VR-Based Optokinetic Stimulation in Multiple Sclerosis,Acute Effects of Virtual Reality-Based Optokinetic Stimulation in Individuals With Multiple Sclerosis: Does Central Vestibular Dysfunction Alter These Effects?,NOT_YET_RECRUITING,2025-09-15,2025-10,2025-10,2025-09-09,2025-09-02,INTERVENTIONAL,NA,30.0,ESTIMATED,Avrasya University,OTHER,Hacettepe University,OTHER,Multiple Sclerosis,multiple sclerosis|vestibular dysfunction|optokinetic stimulation|virtual reality,,,,0,Virtual Reality-Based Optokinetic Stimulation (OKS),DEVICE,Postural Sway,,False,
NCT01953523,"Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions","Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.",COMPLETED,2013-09-02,2016-12-31,2017-01-01,2018-09-25,2013-10-01,INTERVENTIONAL,NA,3000.0,ACTUAL,Elliot Lander,INDUSTRY,,,Neurodegenerative Diseases|Osteoarthritis|Erectile Dysfunction|Autoimmune Diseases|Cardiomyopathies|Emphysema,erectile dysfunction|peyronies|interstitial cystitis|cardiomyopathy|emphysema|copd|arthritis|multiple sclerosis|parkinson's,United States,Rancho Mirage,California,1,Administration of autologous adipose derived SVF,PROCEDURE,Number of participants with adverse events,Changes in the Oswestry Disability Index|Changes in the Neck Disability Index|Changes in Koos Physical Function Shortform|Changes in Hoos Physical Function Shortform|Changes in the DASH questionnaire|Changes in the Visual Analog Pain Score|Changes in the Aqol-4|Changes in the O'leary-Sant IC Questionnaire|Changes in PUF Symptom Scale|Changes in the IIEF Questionnaire|EHGS Grading Score measuring change in hardness score,False,
NCT04818008,The Use of Arabic Otago Exercise Program in People With Multiple Sclerosis,Measuring the Effect of Using the Arabic Otago Exercise Program on Falls and Falls-related Factors in People With Multiple Sclerosis,COMPLETED,2022-04-01,2023-06-30,2023-06-30,2023-07-10,2021-03-26,INTERVENTIONAL,NA,73.0,ACTUAL,University of Jordan,OTHER,,,Multiple Sclerosis,Otago Exercise Program|Falls,Jordan,Amman,,1,Otago Exercise Program,OTHER,Incidence of falls|Incidence of falls|Incidence of falls,Fear of Falling (using the Falls Efficacy Scale-International )|Balance (using Chair balance test and Four test balance scale)|Mobility (using Timed-Up and go)|Quadriceps strength (using a dynamometer)|The severity of fatigue (using Modified Fatigue Impact Scale)|the Quality of sleep (Using Pittsburgh Sleep Quality Index)|the severity of Anxiety and Depression (using Hospital Anxiety and Depression Scale)|The Quality of Life (using Medical Outcomes Study Short Form 12)|Cognitive ability (using Montreal Cognitive Assessment),False,
NCT05147220,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS),"A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",RECRUITING,2021-12-16,2026-04-30,2030-10-30,2025-06-04,2021-12-07,INTERVENTIONAL,PHASE3,800.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,MS|RMS|RRMS|active secondary progressive multiple sclerosis SPMS|remibrutinib|LOU064|teriflunomide|adult|relapse|Expanded Disability Status Scale|T2 lesions|T1 lesions|GD- enhancing MRI|Neurofilament light chain|McDonald diagnostic criteria,United States,Phoenix,Arizona,244,Remibrutinib|Teriflunomide,DRUG|DRUG,Annualized relapse rate (ARR) of confirmed relapses [Core Part],Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)|Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)|Annualized rate of new or enlarging T2 lesion [Core Part]|Neurofilament light chain (Nfl) [Core Part]|Number of Gd-enhancing T1 lesions per MRI scan [Core Part]|Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)|Time to first confirmed relapse [Core Part]|Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)|Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)|Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)|Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)|Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)|Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)|Change from Baseline in T2 lesion volume [Core Part]|Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]|Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]|Pharmacokinetics of remibrutinib [Core Part]|Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]|Annualized relapse rate (ARR) of confirmed relapses [Extension Part]|Annualized rate of new or enlarging T2 lesion [Extension Part]|Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]|Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]|Neurofilament light chain (NfL) [Extension Part]|Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part],False,
NCT04699370,The Added Value of Cognition-targeted Exercise Versus Symptom-targeted Exercise for Multiple Sclerosis Fatigue,The Added Value of Cognition-targeted Exercise Versus Symptom-targeted Exercise for Multiple Sclerosis Fatigue: Randomized Controlled Trial,COMPLETED,2021-01-01,2021-02-20,2021-06-04,2021-06-08,2021-01-07,INTERVENTIONAL,NA,60.0,ACTUAL,Cairo University,OTHER,,,Physical and Rehabilitation Medicine,Randomized controlled trial|Multiple Sclerosis|Fatigue|Cognitive Behavioral Therapy|exercise,Egypt,Giza,,1,cognition-targeted exercise|Cognitive behavioral therapy|Standardized physical therapy,OTHER|BEHAVIORAL|OTHER,Change in Modified Fatigue Impact Scale,Change in Work and Social Adjustment Scale|Change in Hospital Anxiety and Depression Scale|Change in Perceived Stress Scale,False,
NCT01973517,High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases,7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases,WITHDRAWN,2014-04,2018-09,2018-09,2018-09-10,2013-10-31,OBSERVATIONAL,,0.0,ACTUAL,Stanford University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|MRI|USPIO|Ferumoxytol|Feraheme,United States,Stanford,California,2,Feraheme|Gadolinium-based contrast,DRUG|DRUG,Number and location of enhancing brain lesions seen on 7 tesla MRI following Feraheme administration.,Number and location of enhancing brain lesions seen on 7 tesla MRI following gadolinium-based contrast administration.,False,
NCT03693118,Influence of Cognitive Function Software Therapy on the Improvement of Manual Skills in Multiple Sclerosis Patients,Influence of Cognitive Function Software Therapy on the Improvement of Manual Skills in Multiple Sclerosis Patients,TERMINATED,2018-01-13,2018-04-20,2018-05-30,2018-10-02,2018-10-02,INTERVENTIONAL,NA,86.0,ACTUAL,Pomeranian Medical University Szczecin,OTHER,,,Multiple Sclerosis,manual therapy; multiple sclerosis; rehabilitation; motor cortex; neuroplasticity,Poland,Szczecin,Unii Lubelskiej,1,"Reh1,Reh2",BEHAVIORAL,Hand therapy using cognitive functions in patients with MS,,False,
NCT03050268,Familial Investigations of Childhood Cancer Predisposition,Familial Investigations of Childhood Cancer Predisposition,RECRUITING,2017-04-06,2037-03-31,2037-03-31,2025-04-15,2017-02-10,OBSERVATIONAL,,3000.0,ESTIMATED,St. Jude Children's Research Hospital,OTHER,,,Acute Leukemia|Adenomatous Polyposis|Adrenocortical Carcinoma|AML|BAP1 Tumor Predisposition Syndrome|Carney Complex|Choroid Plexus Carcinoma|Constitutional Mismatch Repair Deficiency Syndrome|Diamond-Blackfan Anemia|DICER1 Syndrome|Dyskeratosis Congenita|Emberger Syndrome|Familial Acute Myeloid Leukemia|Familial Adenomatous Polyposis|Fanconi Anemia|Familial Cancer|Familial Wilms Tumor|Familial Neuroblastoma|GIST|Hereditary Breast and Ovarian Cancer|Hereditary Paraganglioma-Pheochromocytoma Syndrome|Hodgkin Lymphoma|Juvenile Polyposis|Li-Fraumeni Syndrome|Lynch Syndrome|MDS|Melanoma Syndrome|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Neuroblastoma|Neurofibromatosis Type 1|Neurofibromatosis Type II|Nevoid Basal Cell Carcinoma Syndrome|Non Hodgkin Lymphoma|Noonan Syndrome and Other Rasopathy|Overgrowth Syndromes|Pancreatic Cancer|Peutz-Jeghers Syndrome|Pheochromocytoma/Paraganglioma|PTEN Hamartoma Tumor Syndrome|Retinoblastoma|Rhabdoid Tumor Predisposition Syndrome|Rhabdomyosarcoma|Rothmund-Thomson Syndrome|Tuberous Sclerosis|Von Hippel-Lindau Disease,Familial cancer|Genetic predisposition|Heritable disease|Cancer risk|Genome analysis|Genetic modifiers|Next generation sequencing (NGS)|Genetic counseling|DNA,United States,Memphis,Tennessee,1,,,Identification of novel cancer predisposing genes,,False,
NCT01455220,The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis,The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis,COMPLETED,2011-01,2014-10,2014-10,2017-03-31,2011-10-19,INTERVENTIONAL,NA,45.0,ACTUAL,University of South Florida,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Sexual Dysfunction|Quality of Life,United States,Tampa,Florida,1,Tysabri ® (Natalizumab),DRUG,Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ),Sexual Function (as Measured by the Multiple Sclerosis Quality of Life (MSQOL-54))|Health Related Quality of Life (as Measured by the Functional Assessment of MS (FAMS))|Quality of Life (as Measured by the Multiple Sclerosis Quality of Life (MSQOL-54)),True,2017-03-31
NCT03183791,RELAXaHEAD for Headache Patients (Phase I),RELAXaHEAD for Headache Patients (Phase I),COMPLETED,2017-11-01,2019-05-25,2019-05-25,2022-07-11,2017-06-12,INTERVENTIONAL,NA,402.0,ACTUAL,NYU Langone Health,OTHER,National Multiple Sclerosis Society,OTHER,Headache|Migraine|Multiple Sclerosis,,United States,New York,New York,1,RELAXaHEAD app|Monitored Usual Care (MUC),BEHAVIORAL|BEHAVIORAL,"Number of days spent logging headache data as determined by entries into the RELAXaHEAD app|Number of days spent doing PMR as determined with the backend analytics in the RELAXaHEAD app backend analytics in the RELAXaHEAD app|Minutes/day spent doing PMR as determined with the backend analytics in the RELAXaHEAD app|Satisfaction using Likert scale questions on RELAXaHEAD usability, content, and functionality",,False,
NCT04459988,Mechanistic Study of Ocrevus,Enhanced Regulatory Functions of Bregs With Ocrelizumab in Multiple Sclerosis,COMPLETED,2020-07-01,2022-10-25,2022-10-25,2024-05-31,2020-07-07,OBSERVATIONAL,,35.0,ACTUAL,University of Michigan,OTHER,,,Multiple Sclerosis,Ocrevus|B cell|T cell|cytokines,United States,Ann Arbor,Michigan,1,Ocrelizumab,DRUG,Change in frequency of regulatory B cells,Change in frequency of T cell subtypes,False,
NCT00300716,Trial of Memantine for Cognitive Impairment in Multiple Sclerosis,Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis,COMPLETED,2004-04,2009-01,2009-01,2019-10-15,2006-03-09,INTERVENTIONAL,PHASE2|PHASE3,82.0,ACTUAL,Oregon Health and Science University,OTHER,Forest Laboratories|University of Southern California|University of Texas Southwestern Medical Center|MS-Hub Seattle,INDUSTRY|OTHER|OTHER|UNKNOWN,Multiple Sclerosis|Cognition Disorders,Multiple Sclerosis|Cognitive impairment|Memantine|Placebo|Neuropsychological tests|Quality of life|Fatigue,United States,Los Angeles,California,4,Memantine,DRUG,Change in the Paced Auditory Serial Addition Test and the California Verbal Learning Test II (multivariate end-point) after 15 weeks of treatment.,Controlled Oral Word Association Test|Stroop Color and Word Test|Symbol Digit Modalities Test|Delis-Kaplan Executive Function System|Perceived Deficit Questionnaire|Multiple Sclerosis Screening Neuropsychological Questionnaire|Modified Neuropsychiatric Inventory|Fatigue Severity Scale|Modified Fatigue Impact Scale|MS Quality of Life Inventory|Beck Depression Inventory,False,
NCT06529406,Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod,Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial),RECRUITING,2024-07-29,2028-08-01,2029-08-01,2025-09-18,2024-07-31,INTERVENTIONAL,PHASE4,100.0,ESTIMATED,"University of Colorado, Denver",OTHER,,,Relapsing Multiple Sclerosis,,United States,Aurora,Colorado,3,Ozanimod,DRUG,New T2 lesions count|Serious infections,Relapses|IgG and IgM levels|Infections|No Evidence of Disease Activity (NEDA-3)|Neurofilament light (NfL) and Glial Fibrillary Acid Protein (GFAP)|Brain parenchymal and thalamic volume loss|Adverse Events,False,
NCT04465084,Assessment of Language Disorders in Multiple Sclerosis Patients,Assessment of Language Disorders in Multiple Sclerosis Patients,COMPLETED,2020-08-17,2020-08-17,2022-07-08,2023-02-15,2020-07-09,INTERVENTIONAL,NA,142.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,Groupe Hospitalier Pitie-Salpetriere|Saint Antoine University Hospital,OTHER|OTHER,Sclerosis|Language Disorders,,France,Paris,,1,Case|Withness,OTHER|OTHER,proportion de patient with language disorders in patients with RRMS or MS,,False,
NCT02136485,Mindfulness-based Stress Reduction in Multiple Sclerosis,Mindfulness-based Stress Reduction in Multiple Sclerosis - a Randomised Controlled Trial,COMPLETED,2014-06-02,2016-08-31,2016-08-31,2019-03-01,2014-05-13,INTERVENTIONAL,NA,50.0,ACTUAL,NHS Greater Glasgow and Clyde,OTHER,University of Glasgow,OTHER,Multiple Sclerosis,,United Kingdom,Glasgow,,1,Mindfulness-based stress reduction (MBSR)|waiting list control,BEHAVIORAL|OTHER,"Feasibility, accessibility, and acceptability of MBSR in people with MS",Perceived stress symptoms (PSS)|Health related Quality of Life|Multiple Sclerosis Quality of Life Inventory (MSQLI),False,
NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),"A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)",COMPLETED,2016-06-30,2020-07-27,2020-07-27,2022-04-04,2016-09-30,OBSERVATIONAL,,594.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Merck Serono Middle East FZ LLC,INDUSTRY,Relapsing Multiple Sclerosis (RMS),Relapsing Multiple Sclerosis|Interferon beta-1a|Rebif®|Morisky Green Levine Medication Adherence Scale,Algeria,Algiers,,41,Rebif (Interferon beta-1a),DRUG,"Percentage adherence of subjects on Rebif, using the Morisky Green Levine Medication Adherence Scale (MGLS) Score",Percentage of subjects on Rebif who discontinued the treatment|Time to treatment discontinuation|Reason for treatment discontinuation|Percentage of relapse-free subjects|Percentage of subjects with expanded disability status scale (EDSS) progression|Number of subjects with suspected adverse drug reactions (ADRs) related to Rebif treatment and concomitant therapy over the 24 months of the study|Percentage of relapse-free subjects based on MGLS Score,False,
NCT04662008,Offering Support and Electronic Resources for Care Partners of Those With Multiple Sclerosis,CLOSER_MS: Communicating With Local or Distance Caregivers Offering Support and Electronic Resources,COMPLETED,2021-03-10,2022-03-07,2022-03-07,2022-03-31,2020-12-10,INTERVENTIONAL,NA,151.0,ACTUAL,Case Western Reserve University,OTHER,,,Multiple Sclerosis|Caregivers,,United States,Cleveland,Ohio,1,Tele-coaching|Website,BEHAVIORAL|BEHAVIORAL,"anxiety, depression, and stress (DASS-42)",COVID specific anxiety (CAS scale),False,
NCT03718026,"The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis","The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test Test in Patients With Multiple Sclerosis",COMPLETED,2018-10-24,2018-11-16,2018-11-19,2018-11-21,2018-10-24,OBSERVATIONAL,,95.0,ACTUAL,Gazi University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",The timed 360° turn test|Multiple sclerosis|reliability|validity,Turkey (Türkiye),Ankara,,1,The timed 360° turn test,OTHER,The timed 360° turn test,Berg Balance Scale|Timed Up and Go test|Functional Reach Test|Four Square Step Test|One Leg Stance Test,False,
NCT05438147,Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms,A Randomized Exploratory Basket Study to Evaluate the Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms in Adult Participants With a Primary Non-DSM-5 Diagnosis,COMPLETED,2022-05-13,2022-09-06,2022-09-06,2023-04-26,2022-06-29,INTERVENTIONAL,NA,114.0,ACTUAL,"Click Therapeutics, Inc.",INDUSTRY,,,Multiple Sclerosis|Mild Cognitive Impairment|Cancer,Digital therapeutics|Phone app|Virtual study,United States,New York,New York,1,CT-100 DiNaMo|Care-as-Usual,OTHER|OTHER,PROMIS Item Bank v2.0 - Cognitive Function - Short Form 8a (PROMIS-CF),Patient-reported Quality-of-Life (QoL) as measured by the PROMIS-29 in the Study App intervention group compared to a Care-As-Usual control group|Global Rating of Change (GRC-Cognition and GRC-Mood)|Changes in indication-specific measures of Symbol Digit Modalities Test (SDMT) in Multiple Sclerosis (only)|Changes in indication-specific measures of Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) in Cancer (Breast/Lung; only).,False,
NCT01884935,PK and PD Study of Natalizumab in Pediatric Subjects With RRMS,"A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)",COMPLETED,2013-07,2014-09,2014-09,2016-06-23,2013-06-24,INTERVENTIONAL,PHASE1,13.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Pediatric,Italy,Cefalù,,5,Natalizumab,BIOLOGICAL,predose (trough) concentrations from multiple dosing (Cpredose)|maximum plasma concentration (Cmax)|time to maximum plasma concentration (Tmax)|area under the plasma concentration curve from time of first dose to infinity (AUCinf)|apparent clearance (Cl/F)|volume of distribution|elimination half-life (t1/2),"the average and minimum saturation values of α4 integrin over the dosing interval|incidence of serious adverse events (SAEs), infusion and hypersensitivity reactions, and other AEs|the presence of anti-natalizumab antibodies",False,
NCT02769689,Methylprednisolone During the Switch Between Natalizumab and Fingolimod,"Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)",UNKNOWN,2019-06-12,2024-06-20,2024-07-20,2023-01-09,2016-05-12,INTERVENTIONAL,PHASE4,56.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,,,Multiple Sclerosis,Multiple sclerosis|Natalizumab|Fingolimod|Methylprednisolone,France,Clermont-Ferrand,,1,Methylprednisolone|Placebo|natalizumab (NTZ)|fingolimob (FTY),DRUG|DRUG|DRUG|DRUG,efficacy of high dose methylprednisolone compared to that of a placebo,"comparison of the number of new T2 or gadolinium enhanced lesions on MRI in the 2 treatment groups|comparison of the number of MS relapses during the 6 months after natalizumab discontinuation, in the 2 treatment groups|potential correlations between previous MS activity and the risk of relapse or inflammatory rebound on MRI after natalizumab discontinuation|adverse effects of high dose oral prednisolone|use of methylprednisolone once every 4 weeks during the switch between natalizumab and fingolimod in patients with MS",False,
NCT02660138,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",TERMINATED,2016-03,2018-11-09,2019-02-14,2022-09-28,2016-01-21,INTERVENTIONAL,PHASE3,227.0,ACTUAL,Ipsen,INDUSTRY,,,Urinary Incontinence|Overactive Bladder,,United States,Birmingham,Alabama,81,Botulinum toxin type A|Botulinum toxin type A|Placebo|Placebo,BIOLOGICAL|BIOLOGICAL|DRUG|DRUG,Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC Cycle,"Mean Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 6 of DBPC Cycle|Mean Change From Baseline in Maximum Detrusor Pressure (MDP) at Week 6 of DBPC Cycle|Mean Change From Baseline in Volume at First Involuntary Detrusor Contraction (Vol@1stIDC) at Week 6 of DBPC Cycle|Number of Subjects With No Episodes of UI at Week 6 of DBPC Cycle|Number of Subjects With No IDCs During Storage at Week 6 of DBPC Cycle|Mean Change From Baseline in Incontinence Quality of Life (I-QoL) Questionnaire Total Summary Score at Week 6 of DBPC Cycle|Number of Subjects With a UI Response at Improvement Levels ≥30%, ≥50%, and ≥75% at Week 6 of the DBPC Cycle|Mean Change From Baseline in Volume Per Void at Week 6 of DBPC Cycle|Median Time Between Treatments",True,2021-06-16
NCT01413243,Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome,"Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial",TERMINATED,2012-09,2016-12,2017-06,2016-05-06,2011-08-10,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,"Charite University, Berlin, Germany",OTHER,,,Multiple Sclerosis,"Multipe sclerosis, Trichuris suis ova",Germany,Berlin,State of Berlin,1,Trichuris suis ova,DRUG,Cumulative number of new T2 hyperintensive in cerebral magnetic resonance imaging (MRI),"reduction NAA/Cr-ratio in MR-spectroscopy|Number of new Gadolinium lesions in magnetic resonance imaging (MRI) cerebral magnetic resonance imaging (MRI)|Volume of new T2 hyperintensive in cerebral magnetic resonance imaging (MRI)|Number of relapes, proression of diability measured in EDSS (Expanded Disability Status Scale) and MSFC (Multiple Sclerosis Functional Composite),|Number of Participants with Adverse Events",False,
NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,"A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2011-11,2016-01,2016-01,2017-03-14,2011-10-31,INTERVENTIONAL,PHASE3,133.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Pre-filled syringe|Pharmacokinetic|Daclizumab High Yield Process|immunogenicity,United States,Centennial,Colorado,19,Midazolam|Caffeine|S-warfarin|Vitamin K|Omeprazole|Dextromethorphan|BIIB019 (Daclizumab),DRUG|OTHER|DRUG|OTHER|DRUG|DRUG|BIOLOGICAL,Number of Participants With Anti-DAC HYP Binding Antibodies (ADAbs): Electrochemiluminescent (ECL) Anti-Drug Antibody (ADA) Assay|Number of Participants With Anti-DAC HYP Neutralizing Antibodies (NAbs): ECL ADA Assay|TP-DI Sub-study: Area-Under-the-Curve From Zero to Infinity (AUCinf) of Each Probe Drug|TP-DI Sub-study: Dextromethorphan to Dextrorphan Urine Concentration Ratio,Intensive PK Sub-study: Cmax of DAC HYP|Intensive PK Sub-study: Time to Reach Maximum Concentration (Tmax) of DAC HYP|Intensive PK Sub-study: Area-Under-the-Curve From Start to End of the Dosing Interval (AUCtau) of DAC HYP|Intensive PK Sub-study: Minimum Concentrations (Cmin) of DAC HYP|Intensive PK Sub-study: Apparent Volume of Distribution (V/F) of DAC HYP|Intensive PK Sub-study: Elimination Half-life (t½) of DAC HYP|Intensive PK Sub-study: Apparent Clearance (CL/F) of DAC HYP|TP-DI Sub-study: Cmax of Each Probe Drug|TP-DI Sub-study: CL/F of Each Probe Drug|TP-DI Sub-study: Omeprazole/Hydroxyomeprazole Concentration Ratio at 2 Hours Post-omeprazole Dosing,True,2017-03-14
NCT00914758,Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS),Comparison of Alemtuzumab (Campath®) and High Dose Interferon Beta-1a (Rebif®) Treatment on Cognition in Subjects With Relapsing Forms of MS,UNKNOWN,2009-03,2011-10,2011-12,2009-06-05,2009-06-05,OBSERVATIONAL,,1.0,ACTUAL,Washington Neuropsychology Research Group,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Relapsing Remitting Multiple Sclerosis,multiple sclerosis|cognition|cognitive functioning|Campath|Rebif|alemtuzumab|interferon,United States,Berkely,California,7,,,Paced Auditory Serial Addition Test|Stroop Test|Symbol Digit Modalities Test|Lexical and Categorical Associative Fluency Tests|Automated Neuropsychological Assessment Metrics|MS Quality of Life Instrument-54|Fatigue Severity Scale|Epworth Sleepiness Scale|MS Fatigue Impact Scale,MRI data,False,
NCT06215755,A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS),"A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment",ACTIVE_NOT_RECRUITING,2024-01-15,2026-06,2026-06,2024-12-12,2024-01-22,INTERVENTIONAL,PHASE1,54.0,ACTUAL,Verge Genomics,INDUSTRY,,,Amyotrophic Lateral Sclerosis,VRG50635|Familial Amyotrophic Lateral Sclerosis|Sporadic Amyotrophic Lateral Sclerosis|ALS,Belgium,Leuven,Flemish Brabant,7,VRG50635,DRUG,Number of Participants with Treatment-emergent Adverse Events (TEAEs)|Number of Participants with Clinical Laboratory Evaluation Abnormalities|Number of Participants with Vital Sign Abnormalities|Number of Participants with Electrocardiogram (ECG) Abnormalities|Number of Participants with Physical Examination Abnormalities|Number of Participants with Neurological Examination Abnormalities,Maximum Observed Concentration (Cmax)|Area Under the Concentration-time Curve (AUC)|Time to Maximum Observed Concentration (tmax)|Change from Baseline in Plasma Levels of Neurofilament Light Chain (NfL) as Measured by Immunoassay|Time to Disease Progression|Change in Harmonized ALS Functional Rating Scale-Revised (ALS-FRS-R) Score,False,
NCT04408274,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury: A Piolt Study,COMPLETED,2013-05,2017-08,2017-08,2020-05-29,2020-05-29,INTERVENTIONAL,NA,29.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis|Traumatic Brain Injury,Processing Speed|Intervention|Multiple Sclerosis|Traumatic Brain Injury|Cognition,United States,East Hanover,New Jersey,1,Emotional Processing Training|Placebo Control,BEHAVIORAL|BEHAVIORAL,Change in scores on Facial Expression Identification Task (FEIT),Change in scores on Emotion Regulation Questionnaire (ERQ)|Change in scores on Satisfaction with Life Scale (SWLS),False,
NCT01711255,Evaluation of Coagulation in Multiple Sclerosis,A Cross-Sectional Study of Coagulation in Multiple Sclerosis,COMPLETED,2012-10,2016-05,2016-05,2017-07-28,2012-10-22,OBSERVATIONAL,,69.0,ACTUAL,Bastyr University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Coagulation|Alternative Medicine|Clotting|Complementary Medicine|Inflammation,United States,Kenmore,Washington,1,,,Sonoclot Coagulation Spectrum (Sonoclot Signature),ASA24 omega-3 fatty acid intake,False,
NCT06794008,BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases,"An Open, Single-Arm, Single-Center Clinical Study Assessing the Safety and Efficacy of BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell Therapy in Multiple Refractory Autoimmune Diseases",RECRUITING,2024-12-26,2027-12-30,2027-12-31,2025-04-02,2025-01-27,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,Peking University People's Hospital,OTHER,,,Systemic Lupus Erythematosus|Inflammatory Myopathy|Systemic Sclerosis (SSc)|ANCA-associated Vasculitis|IgG4-Related Diseases|Antiphospholipid Syndrome|Acquired Thrombotic Thrombocytopenic Purpura|Behcet Disease|Sjogren Syndrome,CAR-T|CD19|BCMA,China,Beijing,Beijing Municipality,1,BCMA-CD19 CAR-T therapy,DRUG,Systemic Lupus Erythematosus primary outcome|Sjogren syndrome primary outcome|Inflammatory Myopathy primary outcome|Systemic Sclerosis primary outcome|Behçet's Disease primary outcome|ANCA associated Vasculitis primary outcome|Antiphospholipid Syndrome primary outcome|Acquired Thrombotic Thrombocytopenic Purpura primary outcome|IgG4-related Disease primary outcome,Systemic Lupus Erythematosus primary secondary Outcome|Sjogren syndrome secondary outcome|Inflammatory Myopathy secondary outcome|Systemic Sclerosis secondary outcome|Behçet's Disease secondary outcome|ANCA associated Vasculitis secondary outcome|Antiphospholipid Syndrome secondary outcome|Acquired Thrombotic Thrombocytopenic Purpura secondary outcome|IgG4-related Disease secondary outcome,False,
NCT03709290,Cerebrovascular Changes in Multiple Sclerosis Patients,Cerebrovascular Changes in Multiple Sclerosis Patients,UNKNOWN,2020-10-01,2020-12-01,2021-12-31,2020-07-27,2018-10-17,OBSERVATIONAL,,50.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,mri,RADIATION,"evaluate cerebrovascular changes in patients with MS byTCD, which is an easy applicable and non-invasivebedside technique",,False,
NCT04369976,Short Arm Human Centrifuge Therapeutic Training and Rehabilitation (GRACER1),Estimating the Optimal G Level for Training and Rehabilitation on a Short Arm Human Centrifuge,ACTIVE_NOT_RECRUITING,2020-02-01,2021-03-01,2025-12-01,2025-03-11,2020-04-30,INTERVENTIONAL,NA,105.0,ESTIMATED,Greek Aerospace Medical Association and Space Research,OTHER,,,"Multiple Sclerosis|Stroke|Pulmonary Disease, Chronic Obstructive|Aged",,Greece,Thessaloniki,FW,1,ARTIFICIAL GRAVITY COMBINED WITH EXERCISE,DEVICE,"Cardiovascular physiological parameter 1 cardiac output (CO) 1-standing|Cardiovascular physiological parameter 1 cardiac output (CO) 2-lying|Cardiovascular physiological parameter 1 cardiac output (CO) 3-mild intensity|Cardiovascular physiological parameter 1 cardiac output (CO) 4-medium intensity|Cardiovascular physiological parameter 1 cardiac output (CO) 5-high intensity|Cardiovascular physiological parameter 2, Stroke volume (SV) 1-standing|Cardiovascular physiological parameter 2, Stroke volume (SV) 2-lying|Cardiovascular physiological parameter 2, Stroke volume (SV) 3-mild intensity|Cardiovascular physiological parameter 2, Stroke volume (SV) 4-medium intensity|Cardiovascular physiological parameter 2, Stroke volume (SV) 5-high intensity|Cardiovascular physiological parameter 3, mean arterial pressure (MAP) 1-standing|Cardiovascular physiological parameter 3, mean arterial pressure (MAP) 2-lying|Cardiovascular physiological parameter 3, mean arterial pressure (MAP) 3-mild intensity|Cardiovascular physiological parameter 3, mean arterial pressure (MAP) 4-medium intensity|Cardiovascular physiological parameter 3, mean arterial pressure (MAP) 5-high intensity|Cardiovascular physiological parameter 4, diastolic blood pressure (DBP) 1-standing|Cardiovascular physiological parameter 4, diastolic blood pressure (DBP) 2-lying|Cardiovascular physiological parameter 4, diastolic blood pressure (DBP) 3-low intensity|Cardiovascular physiological parameter 4, diastolic blood pressure (DBP) 4-medium intensity|Cardiovascular physiological parameter 4, diastolic blood pressure (DBP) 5-high intensity|Cardiovascular physiological parameter 5, systolic blood pressure (SBP) 1-standing|Cardiovascular physiological parameter 5, systolic blood pressure (SBP) 2;lying|Cardiovascular physiological parameter 5, systolic blood pressure (SBP) 3-mild intensity|Cardiovascular physiological parameter 5, systolic blood pressure (SBP) 4-medium intensity|Cardiovascular physiological parameter 5, systolic blood pressure (SBP) 5-high intensity|Cardiovascular physiological parameter 6, heart rate (HR) 1-standing|Cardiovascular physiological parameter 6, heart rate (HR) 2-lying|Cardiovascular physiological parameter 6, heart rate (HR) 3-mild intensity|Cardiovascular physiological parameter 6, heart rate (HR) 4-medium intensity|Cardiovascular physiological parameter 6, heart rate (HR) 5-high intensity|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 1|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 2|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 3|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 4|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 5|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 6|Electrical activity of the brain in alpha band, Electroencephalography (EEG)(μV) 7|The Short Physical Performance Battery assessment score|The Functional Gait Assessment (FGA)|Gastrocnemius muscle oxygenation|Biological samples 1: CATECHOLAMINES|Biological samples 2: ADIPONECTINE|Biological samples 3:BDNF|Biological samples 4:MELATONINE|Biological samples 5:ADENOSINE|Biological samples 5:TNF-α|Biological samples 6:IL-1β|Biological samples 7:High-sensitivity C-reactive Protein (hs-CRP)|Biological samples 8:Total leucocyte number:|Biological samples 9:sTNF-RII|Biological samples 10:D-creatinine|Biological samples 11:alpha-amylase|Biological samples 12:secretory immunoglobulin A (sIgA)|Biological samples 13: cortisol (SC) mg/dL|Biological samples 14: Glucose|Biological samples 15: ACTH|Biological samples 16: Transcortin (mg/liter)|Biological samples 17: Total antioxidant capacity (TAC)|weight in kilograms, height in meters), as appropriate, or to clarify how multiple measurements will be aggregated to arrive at one reported value (e.g., weight|Height|Body Mass Index",,False,
NCT02282826,"A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis","A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis",COMPLETED,2014-10,2016-03,2016-03,2016-04-13,2014-11-04,INTERVENTIONAL,PHASE1,48.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Progressive Multiple Sclerosis,,Germany,Berlin,,1,GZ402668|placebo|GZ402668|placebo|acyclovir,DRUG|DRUG|DRUG|DRUG|DRUG,Number of participants with treatment emergent adverse events,maximum concentration (Cmax)|area under curve (AUC)|Number of participants with lymphocyte depletion|Number of participants with anti-drug antibodies|Number of participants with injection site reactions|Number of participants with corrected QT interval (QTcF) prolongation,False,
NCT04248725,Telehealth Pain Self-Management for Employed Adults,Efficacy of a Telehealth Pain Self-Management Intervention in Employed Adults With Physical Disability: A Randomized Controlled Trial,COMPLETED,2020-03-02,2023-09-30,2024-03-01,2025-01-24,2020-01-30,INTERVENTIONAL,NA,220.0,ACTUAL,University of Washington,OTHER,"National Institute on Disability, Independent Living, and Rehabilitation Research",FED,"Chronic Pain|Brain Injuries, Traumatic|Multiple Sclerosis|Spinal Cord Injuries|Amputation",chronic pain|cognitive therapy|mindfulness meditation|activation skills|pain|employment|telehealth,United States,Seattle,Washington,1,E-TIPS,BEHAVIORAL,Change in Pain Interference,Change in Pain Self-efficacy|Change in Average Pain Intensity,True,2025-01-24
NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)","A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis",COMPLETED,2011-08,2014-04,2014-10,2015-08-21,2011-07-29,INTERVENTIONAL,PHASE2,290.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,Belgium,Brasschaat,,64,natalizumab IV|natalizumab SC|IV Placebo|SC Placebo,DRUG|DRUG|DRUG|DRUG,Cumulative Number of Combined Unique Active Lesions,,True,2015-07-29
NCT01166178,Zoledronic Acid in MS-patients With Osteoporosis,"A 1-year, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Zoledronic Acid 5 mg (Aclasta®) on Bone Mineral Density in Patients With Multiple Sclerosis Followed by a 1-year Open-label Treatment Phase",TERMINATED,2010-10,2012-06,2012-06,2013-11-26,2010-07-20,INTERVENTIONAL,PHASE3,29.0,ACTUAL,Novartis,INDUSTRY,,,Osteoporosis|Multiple Sclerosis,Multiple Sclerosis|Osteoporosis|Zoledronic Acid,Germany,Bamberg,,15,Zoledronic Acid|Placebo|Calcium and Vitamin D combination,DRUG|DRUG|DIETARY_SUPPLEMENT,Change in Bone Mineral Density of the Lumbar Spine at 12 Months|Change in Bone Mineral Density of the Total Hip Region at 12 Months,Change in Bone Mineral Density of the Lumbar Spine at 6 Months|Change in Bone Mineral Density of the Femoral Neck at 6 Months|Change in Bone Mineral Density of the Total Hip at 6 Months|Change in Bone Mineral Density of the Femoral Neck at 12 Months|Change in Bone Mineral Density of the Lumbar Spine at 24 Months|Change in Bone Mineral Density of the Total Hip Region at 24 Months|Change in Bone Mineral Density of the Femoral Neck at 24 Months|Course of Disease in Multiple Sclerosis Patients|Adverse Events and Serious Adverse Events Comparison of Treatment Groups,True,2013-11-26
NCT04918225,Motor Asymmetry in Progressive Multiple Sclerosis Patients,Motor Asymmetry in Progressive Multiple Sclerosis Patients,RECRUITING,2021-11-03,2026-05,2026-05,2023-04-26,2021-06-08,OBSERVATIONAL,,60.0,ESTIMATED,Rennes University Hospital,OTHER,,,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive","motor disability, Magnetic Resonance Imaging",France,Marseille,,2,Magnetic Resonance Imaging|Neurological examination|Multiple Sclerosis Functional Composite|Physiotherapist examination,RADIATION|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,link between focal and diffuse damage in motor tract,"Link between the asymmetry of functional motor impairment and the asymmetry of structural damage on the motor pathways|prognostic value of motor tract focal and diffuse damage on clinical scores variations|link between fatigability, fatigue and analytical disorders|link between fatigue and fatigability and the focal and diffuse impairment of the motor pathways",False,
NCT03548974,Internet-based MOTOmed Exercise to Reduce Spasticity and Improve Physical Function in Persons With Multiple Sclerosis,Internet-based Physical Activity Promotion Using the MOTOmed Movement Trainer to Reduce Spasticity and Improve Physical Function in Moderately to Severely Affected Persons With Multiple Sclerosis,COMPLETED,2015-01,2015-10,2015-10,2018-06-07,2018-06-07,INTERVENTIONAL,NA,57.0,ACTUAL,University of Erlangen-Nürnberg,OTHER,Fa. Reck MOTOmed,UNKNOWN,Multiple Sclerosis,Multiple Sclerosis|Spasticity|MOTOmed training|internet,,,,0,Treatment group 1|Treatment group 2,BEHAVIORAL|BEHAVIORAL,Change in spasticity: MSSS-88|Change in sSpasticity: Modified Tardieu scale,Change in function: 5-Chair-Rise|Change in function: 25foot-walk-test|Change in function: 2min-walk,False,
NCT05853835,"First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641","A Phase I First in Human, Randomized, Double-blind, Placebo- Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 After Single and Multiple Oral Doses.",COMPLETED,2023-10-30,2024-08-15,2024-11-01,2025-01-23,2023-05-11,INTERVENTIONAL,PHASE1,72.0,ACTUAL,LAPIX Therapeutics Inc.,INDUSTRY,,,Autoimmune Diseases|Multiple Sclerosis,,United States,Dilworth,Minnesota,2,LPX-TI641,DRUG,To evaluate the safety and tolerability after single ascending oral doses of LPX-TI641 in healthy adult volunteers.|To evaluate the safety and tolerability after multiple ascending oral doses of LPX-TI641 in healthy adult volunteers.,To evaluate the plasma pharmacokinetics after single ascending oral doses of LPX-TI641 in healthy adult volunteers.|To evaluate the plasma pharmacokinetics after multiple ascending oral doses of LPXTI641 in healthy adult volunteers.,False,
NCT04300868,Immunisation Status and Safety of Vaccines in Italian MS Patients,"Immunisation Status Against Major Communicable Diseases Preventable With Vaccines, and Safety of Vaccines, in a Cohort of MS Patients. An Italian Multicenter Study",UNKNOWN,2019-03-20,2023-01-31,2023-03-31,2022-11-16,2020-03-09,OBSERVATIONAL,,3000.0,ESTIMATED,Monica Ulivelli,OTHER,"Fondazione Italiana Sclerosi Multipla|San Luigi Gonzaga Hospital|University of Roma La Sapienza|Universita degli Studi di Catania|Universita degli Studi di Genova|San Camillo Hospital, Rome|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|University of Florence|Istituto Neurologico Mediterraneo Neuromed S. R. L|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Maggiore Bellaria Hospital, Bologna|Federico II University|Ospedale San Donato|Ospedale San Giuseppe di Empoli|Ospedale Livorno|Ospedale Misericordia e Dolce|Ospedale della Misericordia|Ospedale San Jacopo|Ospedale Felice Lotti di Pontedera|Campus Bio-Medico University|Università degli Studi di Ferrara",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER|OTHER,Multiple Sclerosis,immunisation status|vaccine safety|vaccination,Italy,Siena,SI,1,,,prevalence of MS patients susceptible to infections,safety of vaccination in MS patients,False,
NCT06450418,Digital App for Speech & Health Monitoring,Digital App for Speech & Health Monitoring in Neurodegenerative Disorders,RECRUITING,2024-07-12,2026-06,2026-06,2025-09-18,2024-06-10,OBSERVATIONAL,,150.0,ESTIMATED,University of Edinburgh,OTHER,NHS Lothian,OTHER_GOV,Dementia|Motor Neuron Disease|Multiple Sclerosis|Parkinson Disease,,United Kingdom,Edinburgh,,1,,,Primary outcome measures,Secondary outcome measure|Secondary outcome measure,False,
NCT03888924,Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS),RECRUITING,2019-06-17,2026-07-01,2026-10-01,2024-11-29,2019-03-25,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,S. Andrea Hospital,OTHER,,,Multiple Sclerosis,BCG Vaccine|Radiologically Isolated Syndrome,Italy,Rome,,1,Bacille Calmette-Guerin vaccine|Placebo,DRUG|DRUG,cumulative number of CUAL (new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on MRI scans over 1 year.,Time to the first clinical event.,False,
NCT01829776,Pilot Study of Free From Falls Program in Multiple Sclerosis,Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis,COMPLETED,2013-04,2014-09,2014-09,2014-11-04,2013-04-11,INTERVENTIONAL,NA,13.0,ACTUAL,Oregon Health and Science University,OTHER,,,Multiple Sclerosis,Accidental falls|Multiple Sclerosis|Education|Exercise|Postural balance,United States,Portland,Oregon,1,Educational intervention,BEHAVIORAL,Change in fall frequency per month (30 days),Relationship between paper and electronic fall calendars,False,
NCT00094068,The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients,A Pilot Study to Detect the Effect of Sildenafil Citrate on Cerebral Blood Perfusion in Multiple Sclerosis Patients by Perfusion MRI,COMPLETED,2004-10,,2006-05,2008-03-04,2004-10-11,OBSERVATIONAL,,76.0,,National Institutes of Health Clinical Center (CC),NIH,,,Multiple Sclerosis,Gray Matter|White Matter|Cerebral Blood Flow|Cerebral Blood Volume|Lesion|MRI|Multiple Sclerosis|Perfusion|Imaging|Sildenafil|MS|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,,,,,False,
NCT06954597,Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis,"Local and Systemic Safety and Tolerability of Ascending Doses of TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor, Administered Topically, on Wounds in Patients With Digital Ulcers (DU) in Systemic Sclerosis (SSc) in an Open-label, Vehicle-controlled, Phase 2a, Multi-center Clinical Trial",RECRUITING,2025-02-04,2025-08-04,2025-08-04,2025-05-01,2025-05-01,INTERVENTIONAL,PHASE2,15.0,ESTIMATED,Topadur Pharma AG,INDUSTRY,Bioskin GmbH,INDUSTRY,Digital Ulcers in Systemic Sclerosis,digital ulcer|systemic sclerosis|safety|PDE5 inhibitor,France,La Tronche,,2,TOP-N53|Sildenafil|TOP-N53 vehicle,DRUG|DRUG|DRUG,Local treatment emergent adverse events (TEAEs)|Investigator-solicited digital ulcer (DU)-related patient reported outcome (DU-PRO) - Pain,"Clinical digital ulcer (DU) assessment (CDUA) endpoint - erythema at the peri ulcer area of the cardinal DU|Clinical digital ulcer (DU) assessment (CDUA) endpoint - bruising at the peri-ulcer area of the cardinal DU or beyond|Clinical digital ulcer (DU) assessment (CDUA) endpoint - hemorrhage in the cardinal DU|Clinical digital ulcer (DU) assessment (CDUA) endpoint - perilesional newly emerging, wound related edema at the cardinal DU|Clinical digital ulcer (DU) assessment (CDUA) endpoint - clinical infection at the cardinal DU|Investigator-solicited digital ulcer (DU)-related patient reported outcome (DU-PRO) - Itching|Further investigator-solicited digital ulcer (DU) patient reported outcome (DU-PRO)|Systemic TEAEs",False,
NCT01117090,Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery,Feasibility of Measuring Cerebrospinal Fluid (CSF) Signatures in Subjects With Intrathecal Catheter-Related Problems,COMPLETED,2010-06,2012-09,2012-12,2017-05-30,2010-05-05,OBSERVATIONAL,,47.0,ACTUAL,MedtronicNeuro,INDUSTRY,,,Cerebral Palsy|Multiple Sclerosis|Traumatic Brain Injury|Spinal Cord Injury,Feasibility|SynchroMed II|Intrathecal catheter|Baclofen,United States,Indianapolis,Indiana,2,,,Classification of Catheter Function by CSF Signatures vs. Physician's Standard Trouble-shooting Diagnosis,The Relationship Between Catheter Flow Resistance Check Data and Physician's Standard Trouble-shooting Diagnosis|The Relationship Between CSF Pressure Data and Physician's Standard Trouble-shooting Diagnosis During Physical Task Protocol: Cough|The Relationship Between CSF Pressure Data and Physician's Standard Trouble-shooting Diagnosis During Physical Task Protocol: Valsalva,True,2013-11-18
NCT03995810,Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis,"Oral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple Sclerosis",COMPLETED,2019-06-15,2019-11-01,2019-12-01,2020-03-24,2019-06-24,INTERVENTIONAL,NA,3.0,ACTUAL,"University of Novi Sad, Faculty of Sport and Physical Education",OTHER,CarnoMed,UNKNOWN,Multiple Sclerosis,,Serbia,Novi Sad,Vojvodina,1,"Carnosine, capsulle, 2 g/day, 8 weeks",DIETARY_SUPPLEMENT,Brain carnosine change,Health-related quality of life with SF36 Questionnaire change|Change in neuromuscular performance for autonomic dysfunction (Ewing)|Change in multidimensional fatigue|Change in blood clinical chemistry panel,False,
NCT01556685,"MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia","Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",COMPLETED,2011-03,2011-10,,2013-09-16,2012-03-16,INTERVENTIONAL,PHASE4,180.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Colombia,Bogotá,,2,clinical and neurological evaluation|Blood Sample|Blood Sample,OTHER|OTHER|GENETIC,Neutralizing antibodies to Interferon beta 1a IM (Avonex) or IFN beta 1a IM biosimilar|Percentage of patients with interferon induced Nabs measured in luciferase test|neutralizing antibodies to IFN beta 1a IM (Avonex) or IFN beta 1a IM biosimilar formulation (Jumtab)|Percent of patients with interferon induced neutralizing antibodies measured in a luciferase test,Rate and duration of corticosteroid use for relapse|Need and duration of hospitalization for relapse|Genetic profile of patients with relation to their predisposition to Nab development|The interferon activity will be tested by neopterin protein activation (level before IFNbeta1a IM injection and 48 hours after the injection)|Genetic profile of population with relation to predisposition to Nab generation|Rate/ duration of corticosteroid use for relapse|Need/ duration of hospitalization for relapse|Genetic profile of patients with relation to the predisposition to Nab development|Interferon activity will be tested by neopterin protein activation before and after injection,False,
NCT00927108,Rajavtihi Neuronal Adult Stem Cells Project,Adult Neuronal Progenitor Stem Cell Project,WITHDRAWN,2009-07,2011-12,2011-12,2020-10-19,2009-06-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Department of Medical Services Ministry of Public Health of Thailand,OTHER_GOV,Rajavithi Biomolecular Research Center,OTHER,Alzheimer's Disease|Parkinson's Disease|Multiple Sclerosis,Adult Progenitor Stem cells|Alzheimer's disease|Parkinson's disease|Multiple sclerosis,Thailand,Bangkok,,1,Progenitor Stem Cell Culture,OTHER,,,False,
NCT02759211,Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis,Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis,UNKNOWN,2016-04,2018-02,2018-02,2017-08-30,2016-05-03,INTERVENTIONAL,NA,16.0,ESTIMATED,Mount Sinai Rehabilitation Hospital,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Hartford,Connecticut,1,Backwards Walking|Forwards Walking,OTHER|OTHER,Spatiotemporal Walking Parameters from Gaitrite Mat|Gait Speed (Timed 25 Foot Walk)|Single Leg Stance (SLS),Timed-up and Go|Activities-Specific Balance Confidence Scale (ABC),False,
NCT03999034,XO as a Screening Test of Cognitive Impairment in Multiple Sclerosis,Evaluation of a New Screening Test of Cognitive Impairment Among Multiple Sclerosis Patients,UNKNOWN,2019-07-08,2020-09-08,2020-10-08,2019-10-01,2019-06-26,INTERVENTIONAL,NA,540.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,Merck Santé SAS,UNKNOWN,"Sclerosis, Multiple|Cognitive Dysfunction",screening test|XO test,France,Clermont-Ferrand,,1,questionnaire completion,DIAGNOSTIC_TEST,Score of XO test,Score of anxiety|Score of depression|Score of asthenia|Score of pain,False,
NCT06704464,Investigation of Validity and Reliability of the Minnesota Manual Dexterity Test in Patients With Multiple Sclerosis,Investigation of Validity and Reliability of the Minnesota Manual Dexterity Test in Patients With Multiple Sclerosis,COMPLETED,2024-11-28,2025-01-25,2025-01-25,2025-03-18,2024-11-26,OBSERVATIONAL,,60.0,ACTUAL,Gazi University,OTHER,Cumhuriyet University,OTHER,Multiple Sclerosis,Minnesota manual dexterity|reliability|validity|multiple sclerosis|hand function,Turkey (Türkiye),Sivas,,1,Manual Dexterity|Manual Dexterity (only MMDT)|disability level,OTHER|OTHER|OTHER,Minnesota Manual Dexterity Test|Minnesota Manual Dexterity Test-second,9-Hole Peg Test|ABILHAND|The Jebsen Hand Function Test|The Expanded Disability Status Scale,False,
NCT06143514,A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk,A Post-marketing Study Evaluating the Presence and Concentration of BRIUMVI™ in Breast Milk (PROVIDE),RECRUITING,2024-03-26,2026-06-30,2026-06-30,2025-09-05,2023-11-22,OBSERVATIONAL,,16.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis,Multiple Sclerosis,United States,San Francisco,California,2,No intervention,OTHER,Area Under the Milk Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of BRIUMVI™|Area Under the Milk Concentration-time Curve from Time 0 to the Last Measurable Observed Concentration (AUC0-last) of BRIUMVI™|Area Under the Milk Concentration-Time Curve from Time 0 to 24 Hours Post-Dose (AUC0-24) of BRIUMVI™|Maximum Observed Milk Concentration of BRIUMVI™ (Cmax)|Observed Milk Concentration of BRIUMVI™ at End of Dosing Interval (Ctrough) of BRIUMVI™|Time of Cmax (Tmax) of BRIUMVI™ in Milk,Amount Excreted (Ae) of BRIUMVI™ in Milk|Fraction of Dose Excreted (Fe) in Milk of BRIUMVI™|Infant Dose (ID) of BRIUMVI™|Relative Infant Dose (RID) of BRIUMVI™|Number of Infants with Adverse Events,False,
NCT03372187,Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS,Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS,COMPLETED,2018-03-09,2019-06-30,2019-12-31,2020-03-23,2017-12-13,INTERVENTIONAL,NA,20.0,ACTUAL,University of Alabama at Birmingham,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,diet|MS|Telehealth,United States,Birmingham,Alabama,1,DIET-MS,BEHAVIORAL,Dietary adherence|Physical activity adherence,Feasibility of intervention implementation,False,
NCT03326765,Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC),Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC),UNKNOWN,2017-09-27,2019-11-01,2019-11-30,2018-10-17,2017-10-31,INTERVENTIONAL,NA,60.0,ESTIMATED,Universitair Ziekenhuis Brussel,OTHER,,,Sleep Disorder,tuberous sclerosis complex (TSC)|Children|Adults,Belgium,Jette,Vlaams Brabant,1,Questionnaires|electroencephalogram (EEG)|polysomnography|Actigraphy,OTHER|PROCEDURE|PROCEDURE|PROCEDURE,characterize the sleep phenotype of TSC in children and adults without epilepsy,,False,
NCT05820334,Multiple Sclerosis and Fatigue Assessment,"Fatigue in Multiple Sclerosis Patients; Subjective, Objective and Cognitive Analysis",RECRUITING,2023-04-01,2024-12-01,2024-12-01,2024-09-03,2023-04-19,OBSERVATIONAL,,54.0,ESTIMATED,Asli Demirtaş,OTHER,Gazi University,OTHER,Multiple Sclerosis,Multiple sclerosis|Fatigue|Assessment|Objective|Cognitive,Turkey (Türkiye),Ankara,Ankara,1,,,Fatigue Severity|Fatigue Impact|Fatigue Assessment|Cognitive Fatigue Assessment|Lower extremity functions|Upper extremity functions|Hand grip-fatigue assessment|Muscle strength-fatigue assessment|Balance-fatigue assessment,Extended Disability Status Scale (EDSS)|Standardized Mini Mental Test|Subjective fatigue assessment,False,
NCT05684016,"Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM","Assessment of Deep Gray Matter Anatomic Changes in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With Gilenya® (Fingolimod) With and Without Cognitive Impairment Over a 2 Year Period Using 3 Dimensional Volumetric MRI Studies (NeuroQuant, NeuroQuarc) and Automated Neuropsychological Assessment Matrices (ANAM)",COMPLETED,2013-12,2016-09,2016-12,2023-01-13,2023-01-13,INTERVENTIONAL,NA,75.0,ACTUAL,George Washington University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing Remitting Multiple Sclerosis|RRMS|Gilenya|Fingolimod|MRI|NeuroQuant|NeuroQuarc|Automated Neuropsychological Assessment Matrices|ANAM,United States,Washington D.C.,District of Columbia,1,NeuroQuant|Automated Neuropsychological Assessment Matrices|EDSS|Physical Examination,OTHER|OTHER|OTHER|OTHER,Changes in size of brain region by cm3 over a 2 year period in RRMS patients with and without cognitive impairment compared to healthy age matched controls,"Determine in patients with RRMS treated with Gilenya®, the changes on various gray matter volume as assessed by serial NeuroQuant/NeuroQuarc 3 dimensional volumetric analysis over a 2 year period.|Compare Neuropsychological Evaluations using ANAM to address cognitive changes in patients treated with Gilenya over time as compared to healthy aged matched control patients.",False,
NCT06426316,The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.,"Immune System, Inflammation, Migraine - The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology",RECRUITING,2025-06-02,2027-04-30,2027-04-30,2025-07-08,2024-05-23,INTERVENTIONAL,NA,396.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,,,Migraine Disorders|Pain|Autoimmune Diseases|Multiple Sclerosis|Endometriosis|Rheumatoid Arthritis|Crohn Disease|Lupus Erythematosus,Migraine Disorders|Pain|Cytokines|Regulatory T cell,France,Clermont-Ferrand,AURA,1,Blood test,BIOLOGICAL,"Treg cell levels in cell/microliter (cell/µL)|Treg cell levels in percentage (%) of white blood cells|Age in years|Weight in kilograms (kg)|Score on the Hospital Anxiety and Depression Scale|Score on the Headache Impact Test|Migraine diagnostic criteria from the International Classification of Headache Disorders 3rd edition (ICHD-3)|Number of headache days per month in days/month|White blood cell count in giga/liter (G/L)|Sex (female, male)|Date of last menstrual period as a date in the form: day/month/year|Human chorionic gonadotropin subunit beta level in milli-international units per milliliter (mIU/mL)|Height in meters (m)|Body mass index (BMI) in kilogram per square meter (kg/m2)",Cytokine levels in picogram per milliliter (pg/mL)|Progesterone in nanogram per milliliter (ng/mL)|Estrogen in picogram per milliliter (pg/mL)|Follicle stimulating hormone (FSH) in milli-international units per milliliter (mIU/mL)|Luteinizing hormone in international units per liter (IU/L)|Levels of C-reactive protein (CRP) in milligram per liter (mg/L)|Fasting blood glucose concentration in gram per liter (g/L)|Insulin levels in milligram per deciliter (mg/dL)|Prolactin levels in nanogram per milliliter (ng/mL)|Calcitonin gene-related peptide (CGRP) in picogram per milliliter (pg/mL)|Vasoactive intestinal polypeptide (VIP) in picogram per milliliter (pg/mL)|Pituitary adenylate cyclase-activating polypeptide (PACAP) levels in nanogram per milliliter (ng/mL),False,
NCT02390830,Falls Prevention and Balance Rehabilitation in Multiple Sclerosis,Falls Prevention and Balance Rehabilitation in Multiple Sclerosis: a Bi-centre Randomized Control Trial,COMPLETED,2011-03,2013-10,2013-10,2015-03-18,2015-03-18,INTERVENTIONAL,NA,119.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,,,,,0,Falls Prevention|Reduction of limitations at body function and activity levels,OTHER|OTHER,Change from Baseline in Frequency of fallers at 2 and 4 months,,False,
NCT03757065,Cell Surface Marker Expression in Autoimmune Diseases,A Cross-Sectional Study of Cell Surface Marker Expression in Participants With Autoimmune or Inflammatory Diseases,COMPLETED,2019-06-12,2019-10-25,2019-10-25,2020-08-27,2018-11-28,OBSERVATIONAL,,14.0,ACTUAL,"Alpine Immune Sciences, Inc.",INDUSTRY,,,Systemic Lupus Erythematosus|Sjogren's Syndrome|Multiple Sclerosis|Systemic Sclerosis|Crohn's Disease|Ulcerative Colitis|Inflammatory Myositis,,Canada,Vancouver,British Columbia,2,,,CD28 Expression|ICOS Expression,,False,
NCT05029206,Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden,Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden - a Register-based Retrospective Observational Study,COMPLETED,2021-05-05,2022-09-30,2022-09-30,2023-11-22,2021-08-31,OBSERVATIONAL,,174.0,ACTUAL,Uppsala University,OTHER,"Karolinska University Hospital|Sahlgrenska University Hospital|Uppsala University Hospital|Skane University Hospital|University Hospital, Linkoeping|University Hospital, Umeå|Region Örebro County",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Autologous hematopoietic stem cell transplantation|Chemotherapy|Cyclophosphamide|Etoposide|Carmustine|Cytarabine|Melphalan|Antilymphocyte serum,Sweden,Gothenburg,,8,Autologous hematopoietic stem cell transplantation,PROCEDURE,No evidence of disease activity (NEDA)|Treatment related mortality (TRM),No evidence of disease activity (NEDA)|MRI event free survival|Relapse free survival|Progression free survival|Annualized relapse rate (ARR)|Proportion of patients with clinical improvement|EDSS change|Grade 3 serious adverse events the first 100 days|Grade 4 serious adverse events the first 100 days,False,
NCT02005237,Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity,Randomized Controlled Trial Investigating the Effects of a Standardized Aerobic Exercise Intervention on Cognitive Function and Brain Connectivity in Relapsing-remitting Multiple Sclerosis,COMPLETED,2013-12,2016-05,2016-11,2017-06-26,2013-12-09,INTERVENTIONAL,NA,68.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,German Federal Ministry of Education and Research,OTHER_GOV,Multiple Sclerosis,Exercise|Cognition|Neuroimaging|Rehabilitation|Connectivity,Germany,Hamburg,,1,Aerobic Exercise,BEHAVIORAL,Change in Verbal Learning and Memory,Change in Functional Connectivity|Change in Structural Connectivity|Change in Neuropsychological Function,False,
NCT04121637,To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.,To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals With Multiple Sclerosis.,UNKNOWN,2019-10-21,2020-01-01,2020-06-01,2019-10-10,2019-10-10,INTERVENTIONAL,NA,22.0,ESTIMATED,Firat University,OTHER,Pamukkale University,OTHER,"Multiple Sclerosis, Relapsing-Remitting|FNDC5|Irisin Hormone|Aerobic Exercise|EMG: Axonal Abnormality",,,,,0,Aerobic Exercise|Frenkel coordination exercises,OTHER|OTHER,Physiological - Irisin Hormone|Neurophysiological - EMG|VO2 Max,Multiple Sclerosis Functional Composites (MSFC)|Ataxia Scale (SARA)|Leeds Multiple Sclerosis Quality of Life Scale (LMSQoL),False,
NCT03847753,Exploring the Comorbidity Between Mental Disorders and General Medical Conditions,Exploring the Comorbidity Between Mental Disorders and General Medical Conditions Among a Danish National Population,COMPLETED,2000-01-01,2016-12-31,2020-01-31,2020-05-22,2019-02-20,OBSERVATIONAL,,5940299.0,ACTUAL,University of Aarhus,OTHER,,,"Organic, Including Symptomatic, Mental Disorders|Substance Use|Schizophrenia|Mood [Affective] Disorders|Neurotic, Stress-related and Somatoform Disorders|Eating Disorder|Disorders of Adult Personality and Behavior|Mental Retardation|Disorder of Psychological Development|Behavioural Disorder|Hypertension|Dyslipidemias|Ischemic Heart Disease|Atrial Fibrillation|Heart Failure|Peripheral Occlusive Disease|Stroke|Diabetes Mellitus|Thyroid Disorder|Gout|Chronic Pulmonary Disease|Allergy|Chronic Gastritis|Chronic Liver Disease|Inflammatory Bowel Diseases|Diverticular Disease of Large Intestine|Chronic Kidney Diseases|Prostate Disorders|Connective Tissue Disorder|Osteoporosis|Pain|HIV/AIDS|Anemia|Cancer|Vision Disorders|Hearing Disorders|Migraine|Epilepsy|Parkinson Disease|Multiple Sclerosis|Neuropathy",Comorbidity,,,,0,Organic Disorders|Substance Use Disorders|Schizophrenia Disorders|Mood disorders|Neurotic disorders|Eating Disorders|Personality Disorders|Intellectual Disorders|Developmental Disorders|Behavioral Disorders,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Risk of circulatory system general medical conditions|Risk of Endocrine System general medical conditions|Risk of Pulmonary System general medical conditions|Risk of Gastrointestinal System general medical conditions|Risk of Urogenital System general medical conditions|Musculoskeletal System general medical conditions|Risk of Neurological System general medical conditions|Risk of Hematological System general medical conditions|Risk of Cancers,,False,
NCT04142853,"Underlying Causes and Related Factors, and Rehabilitation Approaches",Walking-related Performance Fatigabitity in People With Multiple Sclerosis: Clinical Profile o,COMPLETED,2019-03-01,2019-12-31,2019-12-31,2020-06-01,2019-10-29,INTERVENTIONAL,NA,40.0,ACTUAL,Hasselt University,OTHER,University of Liege,OTHER,Multiple Sclerosis,,Belgium,Hasselt,,2,Training intervention + Dance intervention,OTHER,the Coordination test|TST (Triple Stimulation Technique)|TMS (Transcranial Magnetic Stimulation)|the Voluntary Drive test|the Fatigability Index Legs|Analysis of a Muscle Biopsy|the Digit Span|the Digit Span|the Stroop test|the Stroop test|the Paced Auditory Serial Addition Test (PASAT)|the Paced Auditory Serial Addition Test (PASAT)|the Symbol Digit Modality Test (SDMT) (Cognitive fatigability)|the Symbol Digit Modality Test (SDMT) (Cognitive fatigability)|Motor function test (lower limb muscle strength)|Motor function test (lower limb muscle strength)|25 Foot Walk (T25FW) test|25 Foot Walk (T25FW) test|Nine Hole Peg Test (NHPT)|Nine Hole Peg Test (NHPT)|Fatigability Index Hand|Fatigability Index Hand|Activity tracker|Glycocheck|Six minute walking test,Fatigue severity scale (FSS)|Fatigue severity scale (FSS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Fatigue Scale of Motor and Cognitive Functions (FSMC)|Fatigue Scale of Motor and Cognitive Functions (FSMC)|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS)|The Sleep Condition Indicator (SCI)|The Sleep Condition Indicator (SCI)|Social Role Participation Questionnaire (SRPQ)|Social Role Participation Questionnaire (SRPQ)|pre-interventionMSWS-12 score|post-interventionMSWS-12 score|pre-interventionMSWS-12 score|post-interventionMSWS-12 score|Multiple Sclerosis Impact Scale (MSIS-29)|Multiple Sclerosis Impact Scale (MSIS-29)|Short Form Health survey (SF-36)|Short Form Health survey (SF-36),False,
NCT03954600,"A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Single and Multiple Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT520-34 in Healthy Subjects",COMPLETED,2019-05-05,2019-10-02,2019-10-09,2020-01-13,2019-05-17,INTERVENTIONAL,PHASE1,49.0,ACTUAL,Neuropore Therapies Inc.,INDUSTRY,Celerion,INDUSTRY,Healthy Volunteers,Phase 1|Safety|Tolerability|Pharmacokinetics|Parkinson's Disease|Amyotrophic Lateral Sclerosis,United States,Tempe,Arizona,1,NPT520-34 (125 mg)|Placebos (125 mg),DRUG|DRUG,"Safety/Tolerability of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Maximum observed plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Time to maximum plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable plasma concentration of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Area under the plasma concentration-time curve extrapolated to infinity of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Apparent oral clearance of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Apparent oral volume of distribution during the terminal phase of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Mean residence time of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Terminal elimination half-life of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Safety/Tolerability as measures of hematology, clinical chemistry, FSH, coagulation and urinalysis of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of vital signs and physical examination of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of continuous telemetry of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measures of suicidal ideation, 12-lead ECG, adverse events and serious adverse events of multiple ascending doses (250 mg and 500 mg)|Safety/Tolerability as measure of continuous ECG of Multiple Ascending Doses (250 mg and 500 mg)|Maximum observed plasma concentration (Cmax) after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|Maximum observed concentration at steady-state after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Concentration observed at the end of the dosing interval of Multiple Ascending Doses (250 mg, 500 mg)|Time to max. plasma concentration after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|Time to reach Cmax,ss of Multiple Ascending Doses (250 mg, 500 mg)|Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable plasma concentration of Multiple Ascending Doses (250 mg, 500 mg)|Area under the plasma concentration-time curve extrapolated to infinity after dosing of Multiple Ascending Doses (250 mg, 500 mg)|Area under the concentration time curve from 0-24 hours after dosing on Day 1 of Multiple Ascending Doses (250 mg, 500 mg)|The area under the concentration time curve during a dosing interval (tau) at steady state after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Apparent oral clearance of Multiple Ascending Doses (250 mg, 500 mg)|Apparent total plasma clearance after oral administration, calculated as Dose/AUCtau after dosing on Day 14 of Multiple Ascending Doses (250 mg, 500 mg)|Apparent oral volume of distribution during the terminal phase of Multiple Ascending Doses (250 mg, 500 mg)|Mean residence time of Multiple Ascending Doses (250 mg, 500 mg)|Terminal elimination half-life of Multiple Ascending Doses (250 mg, 500 mg)","Maximum Tolerated Dose of Single Ascending Doses (125 mg, 250 mg, 500 mg and 1000 mg)|Maximum Tolerated Dose of Multiple Ascending Doses (250 mg and 500 mg)",False,
NCT03198598,Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach,Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach,ACTIVE_NOT_RECRUITING,2017-06-19,2026-12-26,2026-12-26,2024-02-28,2017-06-26,INTERVENTIONAL,NA,130.0,ESTIMATED,Hospital Israelita Albert Einstein,OTHER,,,Multiple Sclerosis,,Brazil,São Paulo,,1,Iyengar Yoga|Yoga app,BEHAVIORAL|BEHAVIORAL,Improvement of overall MS impact in patients life|Cognition in MS|Fatigue in MS|Self-efficacy in MS,Cyytokine levels|Correlation between gait and hemodynamic response|Motor agility|Awareness and attention|Lymphocyte B activity|Walking speed|Ability to stand up and walk|Hands strenght|Self-compassion|Affects,False,
NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months,COMPLETED,2009-03-23,2011-06-30,2011-06-30,2018-11-08,2009-04-20,OBSERVATIONAL,,195.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Fatigue,,Austria,Graz,,27,Natalizumab,OTHER,To investigate the MS related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months.,"Changes in fatigue after initiation of Tysabri treatment|Change in capacity for work (capacity for work questionnaire (CWQ)) at different points after initiation of Tysabri treatment|Change in health-related-quality of life (HRQ0L) (short form-12 questions (SF-12)) at different points after initiation of Tysabri treatment|Change in Sleepiness (Epworth sleepiness scale (ESS)) at different points after initiation of Tysabri treatment|Change in cognitive impairment (the paced auditory serial addition test (PASAT) and symbol digit modalities test (SDMT)) at different points after initiation of Tysabri treatment|Change in depression (Center for epidemiologic studies depression scale (CES-D)) at different points after initiation of Tysabri treatment|Change in Physical activity induced exhaustion (Borg scale CR10 (BS-CR10)) at different points after initiation of Tysabri treatment|Change in speed of walking (6MWT) at different points after initiation of Tysabri treatment|Change in status of MS disease progression (expanded disability status scale (EDSS)) at different points after initiation of Tysabri treatment|Change in amount of walking (step counter) at different points after initiation of Tysabri treatment|To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression|To document any changes in fatigue related medication",False,
NCT02644044,Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study,Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study,UNKNOWN,2016-01,2017-12,2018-01,2015-12-31,2015-12-31,INTERVENTIONAL,EARLY_PHASE1,30.0,ESTIMATED,Tel-Aviv Sourasky Medical Center,OTHER_GOV,,,To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS,Progressive multiple sclerosis|methotrexate,,,,0,Intrathecal methotrexate,DRUG,The change in disability ( Multiple Sclerosis Functional Composite (MSFC)|Safety and tolerability (adverse events),Changes in brain MRI measurements|Laboratory measurements,False,
NCT06171334,Remote Ischemic Conditioning in PPMS,"Open-label, Single-center, Single-arm Futility Trial Evaluating Daily Remote Ischemic Conditioning for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)",NOT_YET_RECRUITING,2024-07-01,2026-03-01,2026-12-01,2024-05-09,2023-12-14,INTERVENTIONAL,NA,45.0,ESTIMATED,University of Calgary,OTHER,,,Multiple Sclerosis,,Canada,Calgary,,1,Remote ischemic conditioning,DEVICE,Timed 25-foot walk,Nine Hole Peg Test|MRI measure of remyelination|SDMT (Single digit modalities test),False,
NCT02454907,The Use of Technology to Improve MS Clinical Trials and Patient Care,The Use of Technology to Improve MS Clinical Trials and Patient Care,ACTIVE_NOT_RECRUITING,2018-07-31,2025-10-31,2025-10-31,2024-10-08,2015-05-27,INTERVENTIONAL,NA,150.0,ACTUAL,Johns Hopkins University,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Baltimore,Maryland,1,Communication with the clinic,OTHER,Blinded,,False,
NCT05243407,Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M),Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M) - an Observational Study,COMPLETED,2022-02-21,2022-08-30,2022-08-30,2023-04-12,2022-02-17,OBSERVATIONAL,,23.0,ACTUAL,University of Zurich,OTHER,Kliniken Valens,UNKNOWN,Disease With a Risk for Chronicity,chronic disease|multiple sclerosis|cardiovascular disease|physical activity|activity tracker,Switzerland,Valens,,1,,,"Active zone minutes (Fitbit)|Step count (Fitbit)|Minutes spent in activity intensity levels (high, moderate, low; Fitbit)|Heart rate (Fitbit)|Answers to open questions for program participants and therapists regarding the implementation of the 'Stay with it'-program as well as their experience with the Fitbit",Patient-Reported Outcomes Measurement Information System - Global 10 (PROMIS-10)|International Physical Activity Questionnaire-Short Form (IPAQ-SF),False,
NCT02790307,Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,Single Centre Randomised Pilot Study of Two Regimens (30mins Daily or Weekly for 12 Weeks) of Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,COMPLETED,2013-01,2013-09,2013-12,2016-06-03,2016-06-03,INTERVENTIONAL,PHASE2,48.0,ACTUAL,"University College, London",OTHER,,,Overactive Bladder|Multiple Sclerosis,multiple sclerosis|overactive bladder|urinary incontinence|tibial nerve stimulation,United Kingdom,London,,1,The Geko,DEVICE,Number of participants reporting adverse events as recorded using a customised diary,Improvement in overactive bladder symptoms as evaluated using a Global Response Assessment (GRA) scale,False,
NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis","An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension",ACTIVE_NOT_RECRUITING,2019-10-18,2027-05-20,2027-05-20,2025-09-11,2019-05-22,INTERVENTIONAL,PHASE3,152.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,La Jolla,California,65,BIIB017 (peginterferon beta-1a)|Interferon beta type 1a,DRUG|DRUG,"Part 1: Annualized Relapse Rate (ARR) at Week 48|Part 2: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Treatment Discontinuation","Part 1: ARR at Week 96|Part 1: Percentage of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans at Weeks 24, 48, and 96|Part 1: Percentage of Participants Free of New MRI Activity in the Brain (Free of Gadolinium [Gd]-Enhancing Lesions and New or Newly Enlarging T2 Hyperintense Lesions) at Weeks 24, 48, and 96|Part 1: Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans at Weeks 24, 48, and 96|Part 1: Number of Gd-Enhancing Lesions on Brain MRI Scans at Weeks 24, 48, and 96|Part 1: Time to First Relapse|Part 1: Percentage of Participants Free of Relapse at Weeks 48 and 96|Part 1: Change from Baseline in Cognition at Weeks 24, 48, 72, and 96 as Measured by the Symbol Digit Modality Test (SDMT)|Part 1: Change from Baseline in the Expanded Disability Status Scale (EDSS) Score at Weeks 48 and 96|Part 1: Change from Baseline in the Quality of Life as Measured by the Pediatric Quality of Life Inventory (PedsQL) at Weeks 24, 48, 72 and 96|Part 1: Area Under the Plasma Concentration-Time Curve from Time Zero to End of Dosing Interval (AUCtau) for BIIB017|Part 1: Maximum Observed Plasma Concentration (Cmax) at Steady State for BIIB017|Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State for BIIB017|Part 1: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Treatment Discontinuation|Part 1: Change from Baseline in Height at Weeks 24, 48, 72, 96, and 100|Part 1: Change from Baseline in Weight at Weeks 24, 48, 72, 96, and 100|Part 1: Change from Baseline in Tanner Score at Weeks 24, 48, 72, 96, and 100|Part 1: Number of Participants With Binding and Neutralizing Antibodies to Interferon Beta Type 1a (IFN β-1a) [All Participants]|Part 1: Number of Participants With Binding Antibodies to Peginterferon (PEG) [BIIB017-Treated Participants]|Part 1: Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 12, 24, 36, 48, 60, 72, 84, 96, and 100|Part 1: Change from Baseline in Blood Pressure at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100|Part 1: Change from Baseline in Pulse Rate at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100|Part 1: Change from Baseline in Body Temperature at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100|Part 1: Change from Baseline in Respiratory Rate at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 100|Part 1: Change from Baseline in 12-Lead Electrocardiogram (ECG) Parameters at Weeks 48, 96, and 100|Part 1: Percentage of Participants with Changes Over Time in Clinical Laboratory Values|Part 2: ARR at Weeks 144 and 192|Part 2: Change from Baseline in EDSS Score at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in Height at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in Weight at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in Tanner Score at Weeks 120, 144, 168, 192, and 196|Part 2: Number of Participants With Binding and Neutralizing Antibodies to IFN β-1a (All Participants)|Part 2: Number of Participants With Binding Antibodies to PEG (BIIB017-Treated Participants)|Part 2: Change from Baseline in Blood Pressure at Weeks 120,144,168, 192, and 196|Part 2: Change from Baseline in Pulse Rate at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in Body Temperature at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in Respiratory Rate at Weeks 120, 144, 168, 192, and 196|Part 2: Change from Baseline in 12-Lead ECG Parameters at Weeks 144, 192, and 196|Part 2: Change from Baseline in Depression as Assessed by Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Weeks 108, 120, 132, 144,156, 168, 180, 192, and 196|Part 2: Percentage of Participants with Changes Over Time in Clinical Laboratory Values",False,
NCT03920995,Multi-center Database Registry to Study Thalamus Changes Using AI in MS,Creation of a Multi-center Database Registry to Study Real World Thalamus Volume Changes by Use of Artificial Intelligence in Patients With Multiple Sclerosis (MS),COMPLETED,2020-04-01,2023-10-31,2023-10-31,2024-03-06,2019-04-19,OBSERVATIONAL,,1000.0,ACTUAL,University at Buffalo,OTHER,Celgene,INDUSTRY,Multiple Sclerosis,,United States,Buffalo,New York,1,,,Multi-center registry of MRI scans,,False,
NCT05658601,A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),"SWITCH - ITA A Multicentre, Single Country, Prospective Non Interventional Observational Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod, in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated According to Clinical Practice.",RECRUITING,2023-07-14,2027-01-31,2027-01-31,2024-01-11,2022-12-21,OBSERVATIONAL,,180.0,ESTIMATED,Bristol-Myers Squibb,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Ozanimod,Italy,Isernia,,1,,,Reason for switching treatment|Mode of switching treatment,Expanded Disability Status Score (EDSS)|MRI|TSQM|Lymphocyte sub populations|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs),False,
NCT04115930,"Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients","Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients",COMPLETED,2018-05-16,2019-06-13,2019-06-13,2019-10-04,2019-10-04,OBSERVATIONAL,,61.0,ACTUAL,University of Eastern Finland,OTHER,,,Relapsing Remitting Multiple Sclerosis|Fatigue|Quality of Life|Physical Activity,,Finland,Joensuu,,4,Physical Activity measurement:,DEVICE,"Correlation between daily physical activity and quality of life to disability.|Correlation between fatigue and cognition to daily physical activity and disability.|Correlation between fatigue, cognition, quality of life and daily physical activity.|Disability level EDSS|Disability level MSFC|9-Hole Peg Test|The Timed 25-Foot Walk test|Daily physical activity|Quality of life 15-D|Quality of life RAND-36|Cognition level SDMT|Cognition level PASAT|Fatigue level FSS|Fatigue level MFIS|General condition (endurance)",Body Composition Weight|Body Composition Height|Body Composition Weist|Body Composition BMI|Equilibrioception (balance)|Abs strength,False,
NCT02606630,[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis,A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis,TERMINATED,2015-10,2015-12,2015-12,2017-02-08,2015-11-17,INTERVENTIONAL,PHASE1,4.0,ACTUAL,AbbVie,INDUSTRY,,,Multiple Sclerosis,Relapsing multiple sclerosis,United Kingdom,London,,2,ABT-555,DRUG,Change in translocator protein expression,,False,
NCT01354665,Depression and Fatigue in MS Patients Treated With Betaferon.,The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.,COMPLETED,2010-05,2013-06,2013-06,2015-01-21,2011-05-17,OBSERVATIONAL,,567.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Interferon beta-1b|Fatigue|Depression,Poland,Many Locations,,1,"Interferon beta-1b (Betaferon, BAY86-5046)",BIOLOGICAL,Changes of fatigue score over time,Changes of depression score over time|Treatment adherence|Clinical course of the disease|Overall treatment tolerability as measured by rate of adverse events,False,
NCT03486665,Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.,Characterization and Quantitative Analysis of White Blood Cells in the Blood and Cerebrospinal Fluid of MS Patients,UNKNOWN,2018-04-24,2018-09,2020-03,2018-07-19,2018-04-03,OBSERVATIONAL,,60.0,ESTIMATED,Bioimmunate,INDUSTRY,,,Multiple Sclerosis,,Israel,Jerusalem,,1,Blood Sampling|CSF Sampling,OTHER|OTHER,Quantification of disease related white blood cells from blood and/ or CSF,,False,
NCT04876339,Sonification Techniques for Gait Training,Sonification Techniques for Gait Training: a Pilot Multicentric Randomized Controlled Trial,RECRUITING,2021-01-18,2025-12-31,2026-06-30,2025-05-11,2021-05-06,INTERVENTIONAL,NA,120.0,ESTIMATED,Istituti Clinici Scientifici Maugeri SpA,OTHER,,,Parkinson Disease|Stroke|Multiple Sclerosis,,Italy,Pavia,,1,"Gait rehabilitation with ""sonification""|Standard gait rehabilitation (without sonification)",DEVICE|OTHER,Change in the Six Minutes Walking Test,Mini BesTest|Dynamic Gait Index|Timed Up & Go,False,
NCT06587828,A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease,A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease,RECRUITING,2023-01-03,2025-01,2025-06,2024-09-19,2024-09-19,OBSERVATIONAL,,300.0,ESTIMATED,"TScan Therapeutics, Inc.",INDUSTRY,,,Autoimmune Diseases|Ulcerative Colitis|Multiple Sclerosis|Scleroderma|Ankylosing Spondylitis|Celiac Disease|Non-radiographic Axial Spondyloarthritis (nr-axSpA)|Crohn&amp;#39;s Disease|Birdshot Chorioretinitis,Autoimmune Diseases|Multiple Sclerosis|Systemic Sclerosis|Ankylosing Spondylitis|Scleroderma|Inflammatory Bowel Disease|Crohn&amp;#39;s Disease|Non-radiographic axial spondyloarthritis (nr-axSpA)|Birdshot Chorioretinitis,United States,Phoenix,Arizona,22,Companion blood samples with procedure,PROCEDURE,Identify peptide targets together with their associated TCRs in patients with autoimmune diseases under study.,,False,
NCT02301572,Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course,Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course,COMPLETED,2014-08,2016-07,2016-08,2023-05-03,2014-11-26,OBSERVATIONAL,,750.0,ACTUAL,Weill Medical College of Cornell University,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,,United States,New York,New York,1,,,Disability outcome will be determined based on EDDS.,,False,
NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,COMPLETED,2017-09-29,2018-05-24,2018-05-24,2019-05-16,2017-08-31,INTERVENTIONAL,PHASE4,261.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Clinically Isolated Syndrome suggestive of Multiple Sclerosis or Multiple Sclerosis,Austria,Graz,Styria,61,Brain MRI|Blood sampling,OTHER|OTHER,Number of subjects with diagnosis of multiple sclerosis within fifteen years after Clinically-Isolated Syndrome (CIS) according to McDonald 2001 and 2010 criteria|Disease course since start of BENEFIT as assessed at the time of BENEFIT 15|Time to first relapse|Time to recurrent relapse|Annualized relapse rate|Time to conversion to Clinically-Definite Multiple Sclerosis (CDMS)|Time to conversion to Secondary Progressive Multiple Sclerosis (SPMS)|Expanded Disability Status Scale these scores (EDSS score) for disability assessed by the investigator during the neurological examination|Number of subjects with confirmed and sustained 1-point EDSS progression (Disability progression)|Number of subjects with confirmed 2.5-point EDSS progression (Disability progression)|Multiple Sclerosis Functional Composite (MSFC) score (Neurological status)|Paced Auditory Serial Addition Test (PASAT-3) score (Cognitive function)|Time to use of ambulatory device|Time to dependence on ambulatory device|Time to use of wheelchair|Employment status (Standardized questions)|Multiple sclerosis impact on employment|Resource use assessment questions: Help from family/regular ambulatory services|Resource use assessment questions: Additional ambulatory services during relapse|Resource use assessment questions: Adaptions (past 6 months),Symbol Digit Modalities Test score (SDMT score)|Relation of SDMT and FSMC (Fatigue Scale for Motor and Cognitive Functions)|Relation of mental processing speed and MRI parameters|European Quality of life - 5 Dimensions Health-related Quality of life (EQ-5D HRQoL) score|European Quality of Life-5 Dimensions Visual Analog Scale (EQ-5D VAS) score|Functional Assessment of Multiple Sclerosis (FAMS score)|Fatigue Scale for Motor and Cognitive Functions (FSMC score)|Center of Epidemiological Studies for Depression (CES-D) score|Time to second line therapy|Time to first disease-modifying therapies (DMT) other than IFNB-1b,False,
NCT04787497,The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis,The Neuropsychological Effects of Extra-Virgin Olive Oil in People With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2022-05-01,2024-05,2024-09,2023-11-02,2021-03-08,INTERVENTIONAL,NA,46.0,ACTUAL,University of Cyprus,OTHER,"World Olive Center for Health|Ellis-Farm, Eliama Daily Value",UNKNOWN|UNKNOWN,Multiple Sclerosis,,Greece,Thessaloniki,,1,High Phenolic Extra Virgin Olive Oil,DIETARY_SUPPLEMENT,Symbol Digits Modalities Test (SDMT)|California Verbal Learning Test-Second Edition (CVLT-II)|Brief Visuospatial Memory Test-Revised (BVMT-R)|Wisconsin Card Sorting Test (WCST)|Trail Making Test (TMT)|The Vocabulary and Block Design from the Wechsler Adult Intelligence Scale (WAIS)|The Digit Span Test (DST) from WAIS|Word List Generation (WLG) Test|Faux Pas Recognition (FPR) Test|Hospital Anxiety and Depression Scale (HADS)|Health Status Questionnaire (SF-36)|Modified Fatigue Impact Scale (MFIS),,False,
NCT06292923,A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients,"A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients",RECRUITING,2023-11-15,2025-11,2025-11,2025-08-28,2024-03-05,INTERVENTIONAL,PHASE2,54.0,ESTIMATED,Tiziana Life Sciences LTD,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,Secondary Multiple Sclerosis|Progressive|Non-active|Double-blind|Nasal Foralumab|Placeb-controlled|Randomized|Phase 2a|Anti-CD3 monoclonal antibody,United States,North Haven,Connecticut,7,Foralumab|Placebo,DRUG|OTHER,The number of patients with adverse event (AE) reports.|Changes in the Total Nasal Symptom Score (TNSS).|Change from baseline for [18F]PBR06-positron emission tomography (PET) scans for microglial activation after 12 weeks (3 months) of study treatment.,Changes in the Expanded Disability Status Scale (EDSS).|Changes in the Multiple Sclerosis Functional Composite-4 (MSFC-4).|Changes in the Modified Fatigue Impact Scale (MFIS).,False,
NCT02377323,Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif,"Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study",COMPLETED,2014-01,2015-05,2016-12,2017-05-24,2015-03-03,INTERVENTIONAL,NA,296.0,ACTUAL,Centre hospitalier de l'Université de Montréal (CHUM),OTHER,EMD Serono Canada Inc.,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Patient-reported outcomes|Employment status|Quality of Life|Cognition|Rebif,Canada,Montreal,Quebec,1,MACFIMS|MSQoL-54,OTHER|OTHER,Employment status,Quality of life|Cognitive function,False,
NCT00202423,Use of Cannabinoids in Patients With Multiple Sclerosis,fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis,UNKNOWN,2005-07,,,2005-11-29,2005-09-20,INTERVENTIONAL,PHASE2,20.0,,S. Andrea Hospital,OTHER,University of Roma La Sapienza,OTHER,Multiple Sclerosis,Multiple sclerosis|Cannabinoids|Spasticity|fMRI|TMS,Italy,Rome,,1,Sativex,DRUG,To evaluate the effect of Sativex on: a)patterns of brain activation associated with movement(fMRI); b) changes in level of spasticity (H-reflex); c)changes in intracortical excitability and on synaptic intracortical network of the motor areas(TMS).,,False,
NCT07006259,Effect of Bobath Therapy on Balance Alterations in Patients With Multiple Sclerosis,Effect of Bobath Therapy on Balance Alterations in Patients With Multiple Sclerosis,COMPLETED,2024-09-26,2025-01-26,2025-03-26,2025-06-05,2025-06-05,INTERVENTIONAL,NA,45.0,ACTUAL,Universidad Rey Juan Carlos,OTHER,,,Bobath Therapy|Postural Control|Virtual Reality|Home Exercise Program,,Spain,Alcorcón,Madrid,1,Bobath Therapy|Bobath therapy plus virtual reality|Home exercises,OTHER|OTHER|OTHER,Balance Evaluation Systems Test (Mini BESTest).,Timed Up and Go Test,False,
NCT01746342,Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial,"A Randomized, Controlled, Clinical Trial of Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Multiple Sclerosis",COMPLETED,2013-02,2018-11-30,2018-11-30,2019-01-11,2012-12-10,INTERVENTIONAL,NA,49.0,ACTUAL,McGill University,OTHER,Multiple Sclerosis Society of Canada (Primary funding agency)|Centre hospitalier de l'Université de Montréal (CHUM)|Philips Respironics|VitalAire Incorporated (Respiratory Therapist time),UNKNOWN|OTHER|INDUSTRY|UNKNOWN,Obstructive Sleep Apnea-hypopnea in Multiple Sclerosis Patients,,Canada,Montreal,Quebec,1,Effective continuous positive airway pressure (CPAP)|Sham continuous positive airway pressure (CPAP),DEVICE|DEVICE,Fatigue Severity Scale,Fatigue Scale for Motor and Cognitive Functions|Epworth Sleepiness Scale|Pittsburgh Sleep Quality Index|Pain visual analog scale|Multiple Sclerosis-specific quality of life measure-54 (MSQOL-54)|Fatigue Severity Scale|Expanded Disability Status Scale|Center for Epidemiological Studies-Depression Scale|Cognitive evaluation|Polysomnographic variables|Objective CPAP compliance,False,
NCT01366027,PRISM Registry: Pseudobulbar Affect Registry Series,PRISM Registry: Pseudobulbar Affect Registry Series,COMPLETED,2011-05,2012-09,2012-09,2014-04-16,2011-06-03,OBSERVATIONAL,,5290.0,ACTUAL,Avanir Pharmaceuticals,INDUSTRY,,,Alzheimer's Disease|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson's Disease|Stroke|Traumatic Brain Injury,pseudobulbar affect,United States,Aliso Viejo,California,1,,,Prevalence of PBA (using CNS-LS),,False,
NCT06961383,Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis,"A Double Blind, Randomized, Placebo Controlled Phase 2b Study to Evaluate the Safety and Clinical Efficacy of Treatment With the Autologous Cell Therapy Product, NG01, in Patients With Secondary Progressive Multiple Sclerosis",NOT_YET_RECRUITING,2025-10-01,2027-10-01,2028-03-01,2025-05-07,2025-05-07,INTERVENTIONAL,PHASE2,45.0,ESTIMATED,NeuroGenesis Ltd.,INDUSTRY,,,Secondary Progressive Multiple Sclerosis (SPMS),Secondary progressive multiple sclerosis|Multiple sclerosis|Autologous cell therapy,United States,Miami,Florida,2,NG01 - Autologous bone marrow derived human stromal cells|Sodium Chloride 0.9%,BIOLOGICAL|OTHER,Walking Ability|Incidence of Treatment-Emergent Adverse Events (AEs),Walking Speed|Neuroimaging Parameters - Change in T2-hyperintense Lesion|Neuroimaging Parameters - Change in T1-hypointense Lesion|Neuroimaging Parameters - Change in Brain and Thalamus|Efficacy - Finger Dexterity|Quality of Life (QoL)|Fatigue|Walking ability|Efficacy - Congnition|Change in Disability,False,
NCT04860791,Validation of the French Adaptation of the MSWDQ-23 Questionnaire,"Validation Study of the French Adaptation of the MSWDQ-23 Questionnaire, a Tool Assessing the Work Difficulties of Patients With Multiple Sclerosis.",COMPLETED,2021-05-10,2023-05-31,2023-05-31,2024-02-05,2021-04-27,OBSERVATIONAL,,206.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,,France,Besançon,,16,questionnaires,OTHER,MSWDQ-23 score,,False,
NCT01954823,Use of an Electronic Diary by People With Multiple Sclerosis,Randomized Controlled Trial for the Evaluation of the Use of an Electronic Diary by People With Multiple Sclerosis,UNKNOWN,2015-09,2016-10,2016-12,2015-08-04,2013-10-07,INTERVENTIONAL,NA,100.0,ESTIMATED,Carmel Medical Center,OTHER,,,Multiple Sclerosis,"Multiple sclerosis, Patient-reported outcomes, patient diary",Israel,Haifa,,1,e-diary,DEVICE,Change in Adherence to therapy,,False,
NCT04844489,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,COMPLETED,2021-04-16,2022-11-24,2022-12-31,2023-02-06,2021-04-14,INTERVENTIONAL,NA,377.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Autoimmune or Autoinflammatory Diseases|HIV|Multiple Sclerosis|Solid Tumors or Cancers|Solid Organ Transplant,Covid-19|Vaccination|Variants|Neutralizing antibodies|Cellular immunity,France,Paris,,1,Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19,OTHER,"Proportion of patients with a neutralizing antibody titer greater than 1/10 towards the wild strain and the English VOC 202012/01, South African 501Y.V2 variants and any other variants that may emerge","Proportion of patients with a positive serology by detection of IgG anti-receptor-binding domain (RBD) antibodies to the Spike protein of SARS-CoV-2 measured by the SARS-CoV technique -2 IgG II Quant assay (Abbott)|Proportion of patients with a positive serology by detection of the anti-Spike protein IgG antibodies of SARS-CoV-2 measured by the Euroimmun technique|Proportion of patients with positive anti-RBD IgG serology on D0|Anti-RBD IgG level|Antibody neutralization title|Neutralization title for antibodies against the wild strain and to the English VOC 202012/01, South African 501Y.V2 variants and any other variants that could be introduced to emerge.|Supervised and unsupervised analyzes of deep immunophenotyping of T and B lymphocytes|Cytometric measurement of intracellular cytokines (IFN, TNF, IL-2, IL4, IL10, IL-17) after stimulation of T lymphocytes by pools of SARS-CoV-2, CMV, EBV and influenza peptides|Structure and specificity of the TCR (T-cells Receptors) repertoire of blood cells",False,
NCT06776224,Visual (Path)Ways in Multiple Sclerosis - Part II,Evaluation of Neuroaxonal Loss Outside of Any Inflammation in Multiple Sclerosis by a Multimodal Study of the Visual Pathways Model,RECRUITING,2025-01-24,2026-04-24,2026-04-24,2025-01-31,2025-01-15,INTERVENTIONAL,NA,64.0,ESTIMATED,"University Hospital, Lille",OTHER,,,"Multiple Sclerosis, Optic Neuritis, Demyelinating Disease","Multiple sclerosis, cognition, OCT, MRI, visual impairment",France,Lille,,1,Measurement of retinal vascular density and visual cognition,OTHER,Quantifying progressive retinal axonal loss in the absence of inflammation,,False,
NCT05415579,Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM),Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM),NOT_YET_RECRUITING,2022-06-20,2029-10-31,2030-05-31,2022-06-13,2022-06-13,OBSERVATIONAL,,2000.0,ESTIMATED,"Dongzhimen Hospital, Beijing",OTHER,,,Demyelinating Diseases of the Central Nervous System (DDC),Demyelinating Diseases of the Central Nervous System|Multiple sclerosis|Neuromyelitis optica spectrum disorder|Myelin oligodendrocyte glycoprotein associated disorder,,,,0,Traditional Chinese medicine (TCM),OTHER,Annualized Aggregate Relapse Rate (ARR),Total Number of Adverse Events During Evaluation|Percentage of Participants With Adverse Events|Time to 3-month Sustained Disability Progression|Time to 6-month Sustained Disability Progression|Number of New or Newly Enlarging T2 hyperintense lesions as Measured by Magnetic Resonance Imaging (MRI)|Number of Gadolinium-enhancing T1-weighted Lesions as Measured by Magnetic Resonance Imaging (MRI)|Percent Change in Brain Volume Measured by Magnetic Resonance Imaging (MRI)|Change in Multiple Sclerosis Functional Composite (MSFC) score|Change in Symbol Digit Modalities Test (SDMT) score|Chance in fatigue severity scale (FSS) score|Change in EuroQol- 5 Dimension (EQ-5D) score|Change from Multiple Sclerosis impact scale (MSIS) score,False,
NCT03564496,Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI,Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI,COMPLETED,2018-07-09,2021-09-29,2021-09-29,2024-01-17,2018-06-20,INTERVENTIONAL,NA,73.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,Anodal transcranial stimulation (tDCS),United States,New York,New York,1,tDCS Administration during MRI|Remotely-supervised Daily tDCS Administration|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA,DEVICE|DEVICE|DEVICE,Cerebral Metabolic Rate of Oxygen (CMRO2)|Cerebral Metabolic Rate of Oxygen (CMRO2)|Neuronal Reactivity (NR)|Neuronal Reactivity (NR),Quality of Life in Neurological Disorders (Neuro-QOL) Score|Quality of Life in Neurological Disorders (Neuro-QOL) Score|Quality of Life in Neurological Disorders (Neuro-QOL) Score,True,2024-01-17
NCT06922942,MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience,MS-FLOWER: MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience,RECRUITING,2025-08-12,2026-03-01,2026-03-01,2025-09-15,2025-04-11,INTERVENTIONAL,NA,60.0,ESTIMATED,Ad scientiam,OTHER,,,Multiple Sclerosis,,United States,New Orleans,Louisiana,5,MSCopilot Flower mobile application,DEVICE,To assess the ease of integrating the MSCopilot dashboard into clinical workflows for neurologists and the ease of use at home for patients with multiple sclerosis.,"To assess the integration of MSCopilot dashboard and application into routine clinical practice as well as perceived value for both HCPs and patients.|To assess patients' ability to use MSCopilot at home without supervision.|To assess patients' ability to use MSCopilot at home without supervision.|To assess the need for patient support when using MSCopilot at home|To assess patient adherence to MSCopilot use in routine clinical practice.|To assess user behavior based on usage analytics data from the MSCopilot mobile app and the dashboard.|To assess the effectiveness of HCPs onboarding/training in ensuring successful patient onboarding.|To assess the effectiveness of HCPs onboarding/training in ensuring successful patient onboarding.|To assess the adequacy of the onboarding/training process for HCPs, including neurologists, nurses, and medical assistants, focusing on clarity, satisfaction, and confidence in using MSCopilot|To assess the variances in user behavior and adherence to MSCopilot use according to socio-demographic factors and EDSS scores.|To assess the variances in user behavior and adherence to MSCopilot use according to socio-demographic factors and EDSS scores.",False,
NCT00972062,Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis,Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis,COMPLETED,2009-06,2009-12,2010-03,2012-03-07,2009-09-04,INTERVENTIONAL,NA,60.0,ACTUAL,"University of North Carolina, Charlotte",OTHER,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,Multiple Sclerosis,Subcutaneous injections|Skin abnormalities,United States,Charlotte,North Carolina,1,Bach's Rescue Remedy Cream|Placebo Cream,OTHER|OTHER,Significant decrease in time and size of redness based on daily measure of skin site reactions using herbal cream compared to placebo cream.,Participants will indicate how the herbal cream has made a difference to their quality of life based on a qualitative description of effects of skin site reactions before herbal cream and following use of herbal cream,False,
NCT05705986,Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS),Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS),UNKNOWN,2021-02-26,2024-05,2024-05,2023-01-31,2023-01-31,OBSERVATIONAL,,40.0,ESTIMATED,Thomas Jefferson University,OTHER,,,Relapse Remitting Multiple Sclerosis,,United States,Philadelphia,Pennsylvania,1,Blood Draw,OTHER,Characterize cGAMP MP-induced tolerogenic DCs from RRMS patients.|Determine the capacity of cGAMP MP-treated DCs to induce iTreg expansion in human in-vitro cultures,Determine the transcriptome of cGAMP MP IL-27- and IL-10-induced Tregs.|Determine the in-vitro reconstitution of iTreg suppressive function in RRMS patients after coculture with cGAMP MP-treated DCs.|Induction of antigen-specific immune tolerance after co-administer DR2-aAPMs with the cGAMP MPs to DCs.,False,
NCT06592703,Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis,Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis: an Open-label Phase I Clinical Trial.,RECRUITING,2025-03-06,2029-12,2029-12,2025-03-18,2024-09-19,INTERVENTIONAL,PHASE1,10.0,ESTIMATED,Rennes University Hospital,OTHER,Etablissement Français du Sang,OTHER,Multiple Sclerosis,,France,Créteil,,2,Adipose tissue-derived Mesenchymal Stromal Cells,DRUG,Percentage of patients experiencing at least one adverse effect,Description of Adverse events related to experimental product|Clinical disease evolution at Week24 and Week48 after treatment : Confirmed Disability Progression using Expanded Disability Status Scale score|Clinical disease evolution at Week24 and Week48 after treatment : Expanded Disability Status Scale score|Clinical disease evolution at Week24 and Week48 after treatment : Expanded Disability Status Scale score|Clinical disease evolution at Week24 and Week48 after treatment : no evidence progression using 9HPT test|Clinical disease evolution at Week24 and Week48 after treatment : no evidence progression using T25-FW|Clinical disease evolution at Week24 and Week48 after treatment : MSFC mean changes|Quality of life disease evolution at Week24 and Week48 after treatment : Multiple Sclerosis International Quality Of Life (MusiQoL) questionnaire|Immunophenotyping|Detection of donor specific anti-HLA antibodies in the blood|MRI parameters : gadolinium (Gd) enhancing lesions|MRI parameters : new T2 lesions|MRI parameters : change in brain volume|MRI parameters : change in spinal cord volume,False,
NCT00818103,Characteristic Study on Chinese Patients With Multiple Sclerosis,Characteristic Study on Chinese Patients With Multiple Sclerosis,UNKNOWN,2006-01,2015-01,2016-01,2009-09-29,2009-01-07,INTERVENTIONAL,NA,600.0,ESTIMATED,Sun Yat-sen University,OTHER,"Third Affiliated Hospital, Sun Yat-Sen University",OTHER,Multiple Sclerosis,"Multiple Sclerosis,Genetics,Pathogenesis,Pathology,Therapy",China,Guangzhou,Guangdong,1,atorvastatin|β-interferon|EPO,DRUG|DRUG|DRUG,The recurrence of NMO or MS,"EDSS scores, active lesion detected by MRI",False,
NCT01534182,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),"A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)",COMPLETED,2012-01,2013-06,2013-06,2014-08-08,2012-02-16,INTERVENTIONAL,PHASE4,298.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis (RRMS)|Fingolimod|Disease Modifying Therapy (DMT)|TSQM-9,Russia,Arkhangelsk,Russia,26,Fingolimod|Interferon beta - 1a (IFN)|Glatiramer acetate (GA),DRUG|DRUG|DRUG,Change in Patient-reported Treatment Satisfaction,"Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death|Changes in Patient-reported Effectiveness, Side Effects and Convenience|Change in Patient-reported Depression|Change in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute)",True,2014-08-08
NCT03250169,Neurofilaments for NEDA Assessing in MS,Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study,TERMINATED,2017-08-01,2022-01-28,2022-01-28,2022-02-25,2017-08-15,OBSERVATIONAL,,21.0,ACTUAL,Queen Mary University of London,OTHER,,,Multiple Sclerosis,,United Kingdom,London,England,1,Alemtuzumab,DRUG,Blood and CSF neurofilaments in Alemtuzumab patients over 24months,Overall clinical response based on neurofilament response|Neurofilament status and association with clinical and MRI markers of disease activity.|Longitudinal assessment of other biomarkers of inflammation & plasticity,False,
NCT01745783,"Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis","Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis",COMPLETED,2013-01,2020-06-30,2020-06-30,2022-04-06,2012-12-10,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,OTHER,Iniciativa Andaluza en Terapias Avanzadas,OTHER,Multiple Sclerosis,,Spain,Córdoba,,3,Bone marrow mesenchymal stem cells autologous|Placebo comparator,OTHER|OTHER,Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image,Differences the results obtained in the two groups of patients due to determined parameters.,False,
NCT03758820,Behavior Cognitive Therapy on Fatigue Impact in MS Patients,"Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)",COMPLETED,2017-05-31,2020-10-15,2020-10-15,2021-03-16,2018-11-29,INTERVENTIONAL,NA,105.0,ACTUAL,Réseau Sep Idf Ouest,OTHER,,,Relapsing Remitting Multiple Sclerosis|Fatigue|Cognitive Therapy,,France,Poissy,,1,Behavorial Cognitive Therapy (BCT),BEHAVIORAL,"Change assessment from Baseline measure of Fatigue Impact to month 6, 12 and 18",Change assessment from Baseline of Anxiety and depression|Change assessment from Baseline of Fatigue severity|Change assessment from Baseline of Quality of sleep: Pittsburgh Sleep Quality scale|Change assessment from Baseline of Quality of sleep: Epworth Sleepiness Scale|Change assessment from Baseline of Cognitive disorders|Change assessment from Baseline of Cognitive disorders|Change assessment from Baseline of Quality of life: MSIS-29|Change assessment from Baseline of Quality of life: EQ5D-3L|Change assessment from Baseline of Medical care consumption and professional impact|Change assessment from Baseline of professional impact,False,
NCT06196866,Effectiveness of Exergaming in Adittion to Conventional Treatment for Physical Therapy in People with Multiple Sclerosis,"Effectiveness of Two Different Exergaming Systems in Addition to Conventional Treatment for Physical Therapy in Patients with Multiple Sclerosis: a Study Protocol for a Multicenter, Assessor-blind, 24-week, Randomized Controlled Trial",ACTIVE_NOT_RECRUITING,2023-09-01,2024-10-31,2025-06-01,2025-03-07,2024-01-09,INTERVENTIONAL,NA,36.0,ACTUAL,Universidad de Córdoba,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Exergaming|Nintendo Wii Fit|Nintendo Ring Fit Adventure|Physical therapy|Randomized controlled trial|Neurological rehabilitation,Spain,Córdoba,Cordoba,1,Conventional Therapy|Nintendo Ring Fit Adventure + Conventional Therapy|Nintendo Wii Fit + Conventional Therapy,OTHER|DEVICE|DEVICE,Physical Functional Capacity (6MWT)|Quality Of Life (MSQOL-54)|Balance (Tinetti Balance Scale)|Strength in Lower Limbs (Handheld dynamometer)|Spasticity in Lower Limbs (Modified Ashworth Scale),,False,
NCT02740296,Depression and Immune Function in Multiple Sclerosis (MS),Depression and Immune Function in Multiple Sclerosis (MS),COMPLETED,2015-11,2017-06,2017-06,2021-07-29,2016-04-15,OBSERVATIONAL,,104.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"National Multiple Sclerosis Society|Universitätsklinikum Hamburg-Eppendorf|NeuroCure Clinical Research Center, Charite, Berlin",OTHER|OTHER|OTHER,"Multiple Sclerosis|Depressive Disorder, Major",,Germany,Berlin,,1,No intervention,OTHER,Beck Depression Inventory - II,,False,
NCT07074886,A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS),"A Phase II, Randomized, Open-label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients With Multiple Sclerosis",NOT_YET_RECRUITING,2025-11-01,2027-01-31,2030-10-30,2025-09-25,2025-07-20,INTERVENTIONAL,PHASE2,182.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,,,,0,Ocrelizumab Test Formulation|Ocrelizumab Reference Formulation,DRUG|DRUG,Area Under the Serum Concentration-time Curve (AUC) of Ocrelizumab|Maximum Serum Concentration (Cmax) of Ocrelizumab,Number of Participants With Adverse Events (AEs),False,
NCT05049161,A Long-term Extension of Study GNC-401,A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab,TERMINATED,2021-08-27,2022-05-18,2022-05-18,2022-07-07,2021-09-17,INTERVENTIONAL,PHASE2,33.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis|GNbAC1|Human Endogenous Retrovirus Type W|HERV-W|Temelimab,Sweden,Stockholm,,1,Temelimab 18 mg/kg|Temelimab 36mg/kg|Temelimab 54 mg/kg,DRUG|DRUG|DRUG,safety and tolerability:adverse event,Neuroimaging|Neuroimaging|Neuroimaging|Neuroimaging|Neuroimaging,False,
NCT05003375,Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS),Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS): a Feasibility Study,UNKNOWN,2020-10-15,2021-08-30,2021-09-01,2021-08-12,2021-08-12,OBSERVATIONAL,,40.0,ESTIMATED,KU Leuven,OTHER,National MS Center Melsbroek,OTHER,Multiple Sclerosis|Fatigue|Stress,fatigability|cognitive fatigue|cognitive fatigability,Belgium,Leuven,,2,High-challenging cognitive protocol to provoke stress and (cognitive) fatigue,BEHAVIORAL,Change in heart rate variability (time-domain)|Change in heart rate variability (frequency-domain),"Change in Visual Analogue Scale (VAS) Momentary fatigue|Change in Visual Analogue Scale (VAS) Momentary pain|Usefulness, Satisfaction, and ease of use Questionnaire (USE)|NASA Task Load Index (NASA-TLX)|Galvanic Skin Response (GSR)|Galvanic Skin Response (GSR)|Galvanic Skin Response (GSR)|Brain activity|Brain activity|Brain activity|Respiration|Respiration|Respiration|Decline in Symbol Digit Modalities Test|Decline in N-Back Task",False,
NCT01220830,Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis,Efficacy of Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) Based Tissue Engineering in the Treatment of Multiple Sclerosis,UNKNOWN,2010-09,2011-12,2011-12,2011-09-19,2010-10-14,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,"The Centre for Advanced Research & Development, India",OTHER,,,Multiple Sclerosis,Multiple sclerosis|RFQMR|Cytotron|EDSS|QOL assessment with FAMS,India,Bangalore,Karnataka,1,Cytotron,DEVICE,Effect of RFQMR therapy on MS lesion confirmed by Magnetic Resonance Imaging (MRI),Effect of RFQMR therapy on disability status and quality of life of MS patients.,False,
NCT00666887,Minocycline in Clinically Isolated Syndromes (CIS),"A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)",COMPLETED,2009-01,2014-12,2015-07,2017-02-27,2008-04-25,INTERVENTIONAL,PHASE3,142.0,ACTUAL,Dr. Luanne Metz,OTHER,Multiple Sclerosis Society of Canada,OTHER,Clinically Isolated Syndromes|Early Single Relapse of Multiple Sclerosis,Multiple Sclerosis|Clinically Isolated Syndrome|Minocycline|Placebo,Canada,Calgary,Alberta,12,Minocycline|Placebo,DRUG|DRUG,"To demonstrate that 100 mg of oral minocycline twice daily reduces the conversion of CIS to McDonald Criteria MS (McDMS) by an absolute 25% as compared to placebo, over a 6 month follow-up period.","To confirm that this early treatment benefit is maintained at two years.|Change in T2 lesion volume|Cumulative number of enhancing T1 lesions|cumulative combined unique lesions (new enhancing T1-weighted lesions plus new and enlarging T2 lesions, without lesion double counting)",False,
NCT03585569,""" Treating MS Patients With Lower Extremity Spasticity Using Dysport""","A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport",UNKNOWN,2018-05-01,2019-05,2020-05,2018-07-13,2018-07-13,INTERVENTIONAL,PHASE3,30.0,ESTIMATED,Neurology Center of New England P.C.,OTHER,Ipsen,INDUSTRY,"Multiple Sclerosis|Spasticity, Muscle",,United States,Foxborough,Massachusetts,1,Abobotulinumtoxin A,BIOLOGICAL,Using Dysport to treat lower extremity spasticty in patients diagnosed with Multiple Sclerosis. Improved walking ability and quality of life in 28 patients based on quality of life assessments and patient reported outcomes.,Mean change from baseline in Modified Ashworth Scale (MAS),False,
NCT02008669,Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis,Evaluation of the Nutritional Status of Patients With Multiple Sclerosis and Relationship With Fatigue,COMPLETED,2013-11,2017-06-09,2017-06-09,2018-08-21,2013-12-11,OBSERVATIONAL,,360.0,ACTUAL,Lille Catholic University,OTHER,,,Multiple Sclerosis,"Multiple Sclerosis, Fatigue, Nutritional Status, Disability.",France,Caen,Basse-Normandie,12,Blood sampling|Gustatory sensitivity test using Taste strips|Questionnaires,PROCEDURE|OTHER|OTHER,"Correlation between the score of fatigue EMIF-SEP and the dosage of nutrients in blood (vitamins, minerals, proteins) adjusted by the EDSS status",Presence or absence of sociodemographic variables|Presence or absence of clinical manifestations|Level of physical activity and daily energy expenditure|Assessment of dysphagia according to the score of the Dymus Test|Score of the taste sensibility test|Score of the Beck depression inventory test|Score of the visual analog scale for the evaluation of sleep quality|Score of the Nutrition and Eating Habits Questionnaire,False,
NCT05496881,Exercise Effects in Multiple Sclerosis,Evaluating Task-Oriented Exercise Effects on Walking Function and the Central Nervous System in People With Multiple Sclerosis,RECRUITING,2022-06-15,2024-10-31,2025-04-30,2024-02-15,2022-08-11,INTERVENTIONAL,NA,69.0,ESTIMATED,University of Regina,OTHER,First Steps Wellness Centre|Saskatchewan Health Research Foundation|University of Saskatchewan,UNKNOWN|OTHER|OTHER,"Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis",Progressive Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Central Nervous System|Motor Learning|Transcranial Magnetic Stimulation|Mobility Limitation,Canada,Regina,Saskatchewan,1,Exercise Group 1|Exercise Group 2|Exercise Group 3,OTHER|OTHER|OTHER,Timed 25-Foot Walk Test,Motor Evoked Potential Amplitude,False,
NCT03769636,Changes in Physical Activity in All Day Life in People With MS Before and After Rehabilitation,"Changes in Physical Activity in All Day Life (Steps, Distance, Periods, Max. Speed) in People With MS Before and After the Rehabilitation - A Prospective Observational Study",UNKNOWN,2018-01-01,2019-06,2019-10,2018-12-07,2018-12-07,OBSERVATIONAL,,30.0,ESTIMATED,Klinik Valens,OTHER,,,Rehabilitation,Multiple Sclerosis|In-patient rehabilitation|All day life activities|Walking capacity|Fatigue|Quality of life,Switzerland,Valens,St.Gallen,1,GaitUp Physilog 5,DEVICE,Changes in physical activity: Locomotion|Changes in physical activity: Non-locomotion|Changes in physical activity: Level walking|Changes in physical activity: Up walking|Changes in physical activity: Down walking|Changes in physical activity: Maximum steps|Changes in physical activity: Steps per hour,Changes in self-rated fatigue|Changes in self-rated health-related quality of life: EQ-5D|Changes in self-rated walking capacity,False,
NCT04387734,Effects of Ocrevus in Relapsing Multiple Sclerosis,Effects and Mechanisms of Ocrevus on Ambulatory Functions in People With Relapsing Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2021-02-05,2025-02-17,2025-09,2025-04-04,2020-05-14,INTERVENTIONAL,PHASE4,60.0,ACTUAL,Georgia State University,OTHER,Multiple Sclerosis Center of Atlanta,OTHER,Relapsing Multiple Sclerosis,Mobility; Fall risk; Balance; Multiple sclerosis; T2LV,United States,Atlanta,Georgia,2,Ocrelizumab|Platform,DRUG|DRUG,Dynamic Gait Stability,Gait speed|Step length|Step width|Step time|Cadence|Stability index|Swing index|Lower limb muscle strength|Lower limb muscle activity|Multiple Sclerosis Functional Composite|Expanded Disability Status Scale|Total cerebral T2 lesion volume|Prospective falls,False,
NCT00010998,Yoga: Effect on Attention in Aging & Multiple Sclerosis,Yoga: Effect on Attention in Aging & Multiple Sclerosis,COMPLETED,1999-09,,2004-12,2006-08-18,2001-02-05,INTERVENTIONAL,PHASE2,,,National Center for Complementary and Integrative Health (NCCIH),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Yoga,United States,Portland,Oregon,1,Yoga,PROCEDURE,,,False,
NCT01416363,Healthy Volunteer Study Using 3 Different Formulations of Firategrast,"A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers",COMPLETED,2011-05-20,2011-09-17,2011-09-17,2017-07-07,2011-08-15,INTERVENTIONAL,PHASE1,38.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","firategrast|pharmacokinetics, modified release, firategrast,|simulated gastro-retentive|pharmacokinetics|healthy volunteers, simulated gastro-retentive|healthy volunteers|modified release",Australia,Randwick,New South Wales,1,Firategrast immediate release tablet|Firategrast modified release tablet|Firategrast gastro-retentive solution,DRUG|DRUG|DRUG,Pharmacokinetic measures for single and repeat dose|PK measures for single and repeat dose|Pharmacokinetic measurements for single and repeat dose,Safety & Tolerability in single and repeat doses|CD34 positive cell count,False,
NCT04518657,Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis,Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis,RECRUITING,2023-03-01,2025-10-31,2026-07-31,2024-11-13,2020-08-19,INTERVENTIONAL,NA,280.0,ESTIMATED,University of Illinois at Chicago,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,Physical Activity|Cognition,United States,Chicago,Illinois,1,Behavioral Intervention for Physical Activity in MS (BIPAMS)|Wellness for MS (WellMS),BEHAVIORAL|BEHAVIORAL,Cognition,Fatigue Severity|Fatigue Impact|Depressive Symptoms|Anxiety|Quality of Life (QOL),False,
NCT05245344,Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study,Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study,UNKNOWN,2022-04-01,2023-06-30,2023-10-31,2022-02-17,2022-02-17,OBSERVATIONAL,,154.0,ESTIMATED,Neuromed IRCCS,OTHER,University of Rome Tor Vergata,OTHER,Relapsing-Remitting Multiple Sclerosis (RRMS)|Neuromyelitis Optica|Healthy,in vitro ozanimod treatment|T cells|Treg cells|NK cells|B cells|T-cell-mediated synaptotoxicy|cytokine-mediated breakdown of the Blood Brain Barrier|Epstein-Barr virus (EBV) infected B cells,Italy,Pozzilli,Isernia,3,Peripheral blood withdrawal,PROCEDURE,"To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological kinetics in the MS chimeric model|To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological frequency in the MS chimeric model|To evaluate the potential anti-synaptotoxic effect of ozanimod on electrophysiological amplitude in the MS chimeric model|To asses the ability of ozanimod to reduce the breakdown of the ex vivo model of BBB (BBB integrity).|To asses the ability of ozanimod to reduce the cytokine-mediated permeability of the ex vivo model of BBB.|To evaluate the migration properties of B cells, spLCLs (with 1.2 and with 1.3 viral alleles) and B95.8LCLs isolated from peripheral blood of (untreated) RRMS and HD.|To evaluate the effect of ozanimod on the proliferation of Treg cells|To evaluate the effect of ozanimod on metabolic asset of Treg cells.|To evaluate the effect of ozanimod on the function of Treg cells.",,False,
NCT06665165,AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis,"Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis",RECRUITING,2025-04-07,2027-02,2027-10,2025-09-08,2024-10-30,INTERVENTIONAL,PHASE1,48.0,ESTIMATED,Amylyx Pharmaceuticals Inc.,INDUSTRY,,,ALS,Amyotrophic Lateral Sclerosis|Sporadic ALS|Motor Neuron Disease|Antisense oligonucleotide|ASO|Calpain-2,United States,La Jolla,California,13,AMX0114|Placebo,DRUG|OTHER,Evaluate the safety and tolerability of AMX0114 in adult participants living with ALS,Evaluate the PK of AMX0114,False,
NCT05961644,Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).,"Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.",RECRUITING,2022-10-03,2027-06-30,2027-10-30,2023-07-28,2023-07-27,INTERVENTIONAL,PHASE2|PHASE3,188.0,ESTIMATED,"Institute of Psychiatry and Neurology, Warsaw",OTHER,"Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences|Mossakowski Medical Research Centre Polish Academy of Sciences|Poznan University of Medical Sciences|Military Institute of Aviation Medicine",OTHER|OTHER|OTHER|OTHER_GOV,"Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis",Cladribine|Multiple Sclerosis Secondary Progressive|Brain Volume|Quantitative Susceptibility Mapping|Magnetic Resonance Imaging|Cognitive assessment,Poland,Warsaw,Masovian Voivodeship,1,Cladribine Subcutaneous Injection|0.9% Chloride Injection Sodium,DRUG|DRUG,Percent brain volume|Percent brain volume,24 weeks confirmed composite progression of disability|Symbol-Digit Modality Test|Symbol-Digit Modality Test|California Verbal Learning Test|California Verbal Learning Test|Multiple Sclerosis Quality of Life Questionnaire 54 [MSQOL-54]|Multiple Sclerosis Quality of Life Questionnaire 54 [MSQOL-54]|Assessment of disease activity in MRI|Assesment of chronic inflammation in MRI|Volume change of cervical spine|Laboratory measures -neurofilament light chain serum level|Laboratory measures|Laboratory measures - pro-inflammatory cytokines|Oligoclonal bands (OCB),False,
NCT01717664,Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS),A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis,COMPLETED,2013-06,2015-12,2016-07,2016-07-28,2012-10-30,INTERVENTIONAL,PHASE2,18.0,ACTUAL,RedHill Biopharma Limited,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|MAP|antibiotic|Interferon beta 1-a|MS|MRI|EDSS|relapse rate,Israel,Tel Aviv,,2,RHB-104,DRUG,Combined Unique Active lesions,,False,
NCT00166283,Improving New Learning and Memory in Multiple Sclerosis,Improving New Learning in Multiple Sclerosis: A Randomized Clinical Trial,COMPLETED,2005-02,2011-12,2011-12,2013-06-11,2005-09-14,INTERVENTIONAL,NA,88.0,ACTUAL,Kessler Foundation,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,memory|learning|Multiple Sclerosis|Cognition|treatment|therapy,United States,West Orange,New Jersey,1,memory retraining exercises|placebo control memory exercises,BEHAVIORAL|BEHAVIORAL,Scores on memory tests,"Reports of emotional functioning, memory functioning, quality of life and neuroimaging.",False,
NCT03190902,Cognitive Impairment in Pediatric Onset Multiple Sclerosis,Cognitive Impairment in Pediatric Onset Multiple Sclerosis: Research of Biomarkers Predictive of Cognitive Impairment Progression,COMPLETED,2015-09-15,2016-04-30,2016-04-30,2017-06-19,2017-06-19,INTERVENTIONAL,NA,36.0,ACTUAL,Pietro Iaffaldano,OTHER,,,Pediatric Onset Multiple Sclerosis|ADHD Predominantly Inattentive Type,,,,,0,Attention Processing Training program (APT)|nonspecific computer training (n-ST),BEHAVIORAL|BEHAVIORAL,to evaluate the effect of the cognitive training on neuropsychological performances.,,False,
NCT01709812,Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS,"A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis",WITHDRAWN,2013-07,2013-07,2013-07,2014-09-30,2012-10-18,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,,,,0,individualized patient support program|Standard care,OTHER|OTHER,change in treatment satisfaction (TSQM-9) from baseline to month 6,change in Modified Morisky Scale score from baseline to month 6|quantification of therapy adherence (pill-count) over 6 months|change in mFIS score from baseline to month 6|change in BDI from baseline to month 6,False,
NCT03652519,High-intensity Training and Its Effects on Neuroplasticity,"Influence of Different Rehabilitative Aerobic Exercise Programs on (Anti-) Inflammatory Immune Signalling, Cognitive Performance and Processing Skills in Persons With MS - A Randomized Controlled Trial",COMPLETED,2018-11-21,2019-11-11,2019-11-11,2019-11-13,2018-08-29,INTERVENTIONAL,NA,72.0,ACTUAL,Klinik Valens,OTHER,"German Sport University, Cologne",OTHER,Multiple Sclerosis,Exercise|Immune Signalling|Cognition|Health-related Quality of Life,Switzerland,Valens,Canton of St. Gallen,1,Exercise Training,BEHAVIORAL,Tregs,"Immune status|Soluble factors (cytokines, tryptophan metabolites, blood brain barrier markers)|Migratory Potential of peripheral mononuclear cells (PBMC)|Endurance capacity|Assessment of Motor and Processing Skills (AMPS)|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|Fatigue Scale of Motor and cognitive function (FSMC)|Hospital Anxiety and Depression Scale (HADS)|Patient-Reported Outcome Measurement Information System (PROMIS)|Test battery of attention (TAP)",False,
NCT02335892,PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod,Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE),COMPLETED,2014-11-11,2017-02-01,2017-02-01,2019-04-01,2015-01-12,OBSERVATIONAL,,114.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United Kingdom,Truro,Cornwall,14,,,Changes from baseline after 12 months treatment with Gilenya as measured by the MSIS-29 (physical and psychological domains),"MSIS-29 and utility scores measured by EQ-5D-5L and any correlation between them|Treatment Satisfaction Questionnaire for Medication (TSQM) and changes at 3 , 6 and 12mths after Gilenya treatment|Morisky questionnaire and changes at 3 , 6 and 12 mths after treament with Gilenya|Changes from baseline after 3 and 6 months treatment with Gilenya as measured by MSIS-29|Changes from Baseline after 3, 6 and 12 months of treatment with Gilenya as measured by EQ-5D-5L",False,
NCT00836719,Safety of Polyphenon E in Multiple Sclerosis Pilot Study,Safety and Neuroprotective Effects of Polyphenon E in Multiple Sclerosis,COMPLETED,2009-02,2010-11,2010-11,2013-06-27,2009-02-04,INTERVENTIONAL,PHASE1,10.0,ACTUAL,Louisiana State University Health Sciences Center in New Orleans,OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis,Multiple sclerosis|safety|open label|Polyphenon E|EGCG|NAA|N-acetyl-aspartate|MRI,United States,New Orleans,Louisiana,1,Polyphenon E,DRUG,Number of Participants Experiencing Serious Adverse Events,Change in Brain NAA Level as Measured by MR Spectroscopy,True,2013-06-27
NCT00364936,Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS),Proposal to Create a Flagship Neurology and Palliative Care Service for South London,COMPLETED,2004-03,,2006-12,2009-06-11,2006-08-16,INTERVENTIONAL,PHASE1|PHASE2,52.0,ACTUAL,King's College London,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,palliative care|hospice|end-of-life|symptom control|evaluation|effectiveness,United Kingdom,London,London,1,Palliative care service,PROCEDURE,Palliative Care Outcome Scale - Symptoms,Self-reported quality of life|Impact of MS|Psychosocial palliative care outcomes|use of health and social services|Experience of hospital services|Carer burden and satisfaction|Costs (formal and informal),False,
NCT02220244,Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis,Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study,UNKNOWN,2013-10,2015-12,2018-01,2017-03-27,2014-08-19,INTERVENTIONAL,PHASE3,105.0,ESTIMATED,MedDay Pharmaceuticals SA,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis (MS)|optic neuritis|visual defect|visual loss|relapsing remitting multiple sclerosis (RRMS)|primary progressive multiple sclerosis (PPMS)|secondary progressive multiple sclerosis (SPMS),France,Bordeaux,,20,MD1003 100mg capsule,DRUG,Change from baseline of the best corrected visual acuity at 100% contrast,Visual field mean deviation change from baseline|Reappearance or improvement of the P00 wave on Visual Evoked Potential|Optical Coherence Tomography,False,
NCT05839977,The Effect of Telerehabilitation on Balance in People With Multiple Sclerosis,Possibilities of Using Telerehabilitation for the Therapy of Balance and Walking Disorders in Patients With Multiple Sclerosis in Clinical Practice,RECRUITING,2023-03-01,2025-10,2025-12,2023-05-03,2023-05-03,INTERVENTIONAL,NA,60.0,ESTIMATED,"Charles University, Czech Republic",OTHER,,,Telerehabilitation,multiple sclerosis|telerehabilitation|remote rehabilitation|exergaming|balance,Czechia,Prague,Karlovo Náměstí 32,2,Individual telerehabilitation|Home exercises based on videos,OTHER|OTHER,Change in balance (Berg Balance Scale)|Change in functional mobility (Timed Up and Go)|Change in functional mobility (Timed Up and Go Cognitive)|Change in balance (One leg stance),Change in balance (Activity Balance Scale)|Change in balance (Falls Efficacy Scale-I)|Change in walk (Multiple Sclerosis Walking Scale 12)|Change in fatigue (Modified Fatigue Impact Scale),False,
NCT04929145,The Gut Microbiome in Adult Multiple Sclerosis,Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis I,COMPLETED,2013-10-02,2019-09-16,2020-04,2021-07-23,2021-06-18,OBSERVATIONAL,,152.0,ACTUAL,National MS Center Melsbroek,OTHER,,,Multiple Sclerosis,gut microbiome,Belgium,Jette,Brussel-Hoofdstedelijk-Gewest,2,,,Sustained disability worsening,Clinical evidence for active disease,False,
NCT04695080,ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis,"ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?",ACTIVE_NOT_RECRUITING,2021-06-25,2027-12-31,2027-12-31,2025-09-08,2021-01-05,INTERVENTIONAL,PHASE2|PHASE3,204.0,ACTUAL,Queen Mary University of London,OTHER,"National Institute for Health Research, United Kingdom|Merck Serono Limited, UK|Multiple Sclerosis Society of Great Britain & Northern Ireland|National Multiple Sclerosis Society|Barts & The London NHS Trust",OTHER_GOV|INDUSTRY|UNKNOWN|OTHER|OTHER,Advanced Multiple Sclerosis|Progressive Multiple Sclerosis,Multiple Sclerosis|Progressive multiple sclerosis|Advanced multiple sclerosis|Upper limb function|Cladribine|Quality of life|Cognition|Health Economics|Biomarkers|Neurofilament light chain|B cells|Lymphocytes|Magnetic Resonance Imaging (MRI),United Kingdom,Belfast,,22,Cladribine (MAVENCLAD®)|Placebo,DRUG|DRUG,The 9-HPT peg speed (tasks/second) at 24 months|9-HPT proportion of patients who do not deteriorate at 24 months,"Change over 24 months of the study in clinical outcome measure: EDSS|Change over 24 months of the study in clinical outcome measure: ARAT|Change over 24 months of the study in clinical outcome measure: ABILHAND|Change over 24 months of the study in clinical outcome measure: T25ftWT|Change over 24 months of the study in clinical outcome measure: SLCVA|Change over 24 months of the study in clinical outcome measure: MSIS-29v2|Change over 24 months of the study in clinical outcome measure: SDMT|Change over 24 months of the study in clinical outcome measure: NFI-MS|Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L|Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L|Change over 24 months of the study in clinical outcome measure: EuroQoL EQ-5D-5L|Change over 24 months of the study in clinical outcome measure: WPAI-GH|Safety/occurrence of adverse events|Preventing loss of brain volume|Preventing loss of brain volume|Preventing loss of spinal cord cross sectional area|Preventing new focal demyelinating lesions and T2 burden of disease increase.|Preventing new hypo-intense lesions (""black holes"") on T1 weighted MRI|Degree of unblinding",False,
NCT00716066,Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases,"High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases",ACTIVE_NOT_RECRUITING,2008-06,2025-12-30,2030-01-31,2025-07-16,2008-07-16,INTERVENTIONAL,PHASE2,53.0,ACTUAL,Fred Hutchinson Cancer Center,OTHER,,,Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis,neurologic autoimmune disease|autologous transplant autoimmune|multiple sclerosis transplant|MS stem cell transplant|multiple sclerosis stem cell transplant|Stiff Person Syndrome|HCT for neurologic autoimmune disorders|CIDP transplant|myasthenia gravis transplant,United States,Denver,Colorado,3,Anti-Thymocyte Globulin|Autologous Hematopoietic Stem Cell Transplantation|Carmustine|Cytarabine|Etoposide|Laboratory Biomarker Analysis|Melphalan|Peripheral Blood Stem Cell Transplantation|Prednisone|Syngeneic Bone Marrow Transplantation,BIOLOGICAL|PROCEDURE|DRUG|DRUG|DRUG|OTHER|DRUG|PROCEDURE|DRUG|PROCEDURE,Incidence of grades 4-5 regimen-related toxicity,"Transplant-related mortality|Disease responses|Engraftment kinetics|Number of subjects achieving greater than or equal to 4.0 x 10^6 CD34+ cells/kg, after up to two peripheral blood stem cell mobilizations|Number of subjects with an exacerbation of autoimmune disease symptoms secondary to G-CSF (filgrastim) during peripheral blood stem cell mobilization",False,
NCT03385356,Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis,Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis,COMPLETED,2017-12-19,2018-04-30,2018-04-30,2019-03-20,2017-12-28,INTERVENTIONAL,PHASE4,89.0,ACTUAL,University Medical Centre Maribor,OTHER,Medical Faculty Maribor,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting|Vitamin D Deficiency",,Slovenia,Maribor,,1,Vitamin D,DRUG,Vitamin D supplementation dose response,,False,
NCT00799890,Sunphenon in Progressive Forms of Multiple Sclerosis,"Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis",COMPLETED,2009-05,2016-03,2016-03,2021-07-29,2008-12-01,INTERVENTIONAL,PHASE2|PHASE3,61.0,ACTUAL,Friedemann Paul,OTHER,TAIYO EUROPE,UNKNOWN,Multiple Sclerosis,primary or secondary chronic-progressive|sunphenon egcg|brain atrophy|T2 lesions,Germany,Berlin,,1,Sunphenon EGCG|Placebo,DRUG|DRUG,brain atrophy,new T2 lesions|reduction of the NAA/Cr-ratio in MR-spectroscopy|progression of disability such as cognitive disorders|number of AEs,False,
NCT00202982,"A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose","A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients",COMPLETED,2003-08,2005-09,2005-09,2010-01-14,2005-09-20,INTERVENTIONAL,PHASE2,90.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapse-Remitting Multiple Sclerosis,,United States,La Jolla,California,20,glatiramer acetate 20 mg|glatiramer acetate 40 mg,DRUG|DRUG,"The total number of T1 Gd-enhancing lesions in T1-weighted images, as measured at months 7, 8 and 9",,False,
NCT04478591,The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis,The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis,COMPLETED,2020-05-12,2021-04-01,2021-05-01,2021-09-28,2020-07-20,OBSERVATIONAL,,117.0,ACTUAL,"Amsterdam UMC, location VUmc",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Ocrelizumab|Wearing-off effect|Neurofilament Light|Extended dosing,Netherlands,Amsterdam,North Holland,1,Questionnaires,OTHER,Wearing-off symptoms,% of wearing-off symptoms (yes/no assessed on questionnaires) in correlation to the % of patients with extended dosing versus standard dosing with ocrelizumab.|Neurofilament light levels in patients with wearing-off symptoms.|Absolute B-cells count in blood in correlation to the presence of wearing-off symptoms (yes/no assessed on questionnaires)|Type of multiple sclerosis (either RRMS or PPMS) in correlation to % of patients with wearing-off symptoms (yes/no assessed on questionnaires).|Treatment satisfaction score measured by the treatment satisfaction questionnaire in correlation to the % of patients with wearing-off symptoms (yes/no assessed on questionnaires)|Self-reported disability (MSIS-29 questionnaire) compared before and after ocrelizumab infusion in patients with wearing-off symptoms|Self-reported disability (MSIS-29 questionnaire) after ocrelizumab infusion in patients without wearing-off symptoms|Change of wearing-off symptoms after ocrelizumab infusion in patients with wearing-off symptoms|Post-dose symptoms after ocrelizumab infusion,False,
NCT03126760,Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS),"A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of Acthar® in Subjects With Relapsing-remitting Multiple Sclerosis",TERMINATED,2017-05-22,2020-07-14,2020-07-14,2021-07-12,2017-04-24,INTERVENTIONAL,PHASE4,35.0,ACTUAL,Mallinckrodt ARD LLC,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Relapsing, Remitting Multiple Sclerosis|RRMS",United States,Palo Alto,California,22,Acthar Gel|Placebo,DRUG|DRUG,Score on the Expanded Disability Status Scale (EDSS) at Baseline and Day 42,,True,2021-06-03
NCT00654927,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis","Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",COMPLETED,2003-11,2011-01,2011-04,2012-03-02,2008-04-09,INTERVENTIONAL,PHASE3,177.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|MS|walking|leg strength|demyelination,United States,Phoenix,Arizona,22,Fampridine-SR b.i.d. (Twice Daily),DRUG,Summary of Treatment Emergent Adverse Events (TEAE).,Timed 25 Foot Walk (T25FW)|Subject Global Impression (SGI)|Clinician Global Impression of Change (CGIC)|Expanded Disability Status Scale (EDSS),True,2012-02-29
NCT06523582,Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients,Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients,RECRUITING,2022-08-03,2037-03-01,2037-03-01,2024-07-26,2024-07-26,OBSERVATIONAL,,750.0,ESTIMATED,Universidad Nacional Autonoma de Mexico,OTHER,Instituto Mexicano del Seguro Social|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,OTHER_GOV|OTHER,Neuroendocrine Neoplasm|Neuroendocrine Neoplasm of Gastrointestinal Tract|Neuroendocrine Neoplasm of Lung|Thymic Neuroendocrine Neoplasm|Neuroendocrine Tumor of Pancreas|Gastrointestinal Stromal Tumors|Medullary Thyroid Cancer|Paraganglioma|Pheochromocytoma|Primary Hyperparathyroidism|Pituitary Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Multiple Endocrine Neoplasia Type 4|Carney Complex|Carney Stratakis Dyad|Carney Triad|Cowden Syndrome|DICER1 Syndrome|Li-Fraumeni Syndrome|Lynch Syndrome|Von Hippel-Lindau Disease|Familial Isolated Pituitary Adenoma|X-Linked Acrogigantism|Neurofibromatosis 1|Tuberous Sclerosis,,Mexico,Mexico City,Mexico City,3,,,Detection of a germline or somatic genetic defect of interest.,,False,
NCT04240379,Metacognition Assessment in Patient With Multiple Sclerosis,Metacognition Assessment in Patient With Multiple Sclerosis,COMPLETED,2020-06-11,2022-04-08,2022-04-08,2022-06-01,2020-01-27,OBSERVATIONAL,,80.0,ACTUAL,"University Hospital, Grenoble",OTHER,University Grenoble Alps,OTHER,Multiple Sclerosis,Multiple Sclerosis|Multiple Sclerosis Functional Composite (MSFC)|Metacognition,France,Grenoble,,1,,,Metacognitive precision,,False,
NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study,COMPLETED,2016-06-13,2019-10-11,2020-06-15,2020-11-09,2015-04-23,INTERVENTIONAL,PHASE2,30.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,Fondation ARSEP/AFM,UNKNOWN,Relapsing Remitting Multiple Sclerosis,"Interleukin 2, IL2|Relapsing Remitting Multiple Sclerosis|Autoimmune diseases|Regulatory T cells, Tregs",France,Paris,,3,IL2|Placebo,DRUG|DRUG,"Treg response to low dose IL2 induction course period, expressed as % of total CD4 cells","Change in Treg percentage on D15 after induction (D1-D5) compared to baseline|Change in Treg percentage from D15 to M6 compared to baseline|The cumulative number of new lesions enhanced by Gd+ (Sum of Gd + lesions on T1 MRI on M2, M4 and M6)|Frequency of patients free of Gd+ lesions at M6|The cumulative number of new T2 lesions|Annual relapse rate (number of relapses observed over a 6 month period)|% of patients with flare|% of disease free patient i.e % of patient with no clinical symptoms and no activity on MRI",False,
NCT06143930,Blood Flow Restriction Training in Multiple Sclerosis,(Effect of Blood Flow Restriction Training on Muscle Strength and Gait Performance in Multiple Sclerosis Patients).,RECRUITING,2023-07-01,2024-04,2024-07,2023-11-22,2023-11-22,INTERVENTIONAL,NA,48.0,ESTIMATED,Cairo University,OTHER,,,MS,,Egypt,Giza,,1,strengthening ex with BFR training|strengthening ex,OTHER|OTHER,muscle strength,gait performance by Two-dimensional (2D) Motion Analysis system,False,
NCT05740722,Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis,Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study,RECRUITING,2023-05-03,2027-08-01,2027-12-30,2024-01-11,2023-02-23,INTERVENTIONAL,PHASE2,300.0,ESTIMATED,Haukeland University Hospital,OTHER,,,Multiple Sclerosis|Progressive Multiple Sclerosis,nicotinamid riboside,Norway,Bergen,,1,Nicotinamid riboside|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Proportion of patients with sustained disability progression over the treatment period,"To determine the efficacy of NR compared with placebo, as reflected by EDSS|To determine the efficacy of NR compared with placebo, as reflected by 25-footwalk|To determine the efficacy of NR compared with placebo, as reflected by 9-Hole Peg test|To determine the efficacy of NR compared with placebo, as reflected by total volume of T2 lesions on MRI scans of the brain|To determine the efficacy of NR compared with placebo, as reflected by formation of lesions|Changes in brain atrophy in NR-treated patients with primary progressive multiple sclerosis as compared with placebo|Time to onset of sustained disability progression over the treatment period",False,
NCT00861172,"Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy","Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy",COMPLETED,2009-02,2012-07,2012-07,2013-06-21,2009-03-13,INTERVENTIONAL,NA,6.0,ACTUAL,Hospices Civils de Lyon,OTHER,,,Lesions|Multiple Sclerosis,Multiple sclerosis|Active plaque|Multimodal analysis|3T MRI|Weekly follow-up|Physiopathology|Physiopathology of active lesions formation in Multiple Sclerosis using multimodal MR sequences,France,Bron,,1,3T MR scanner,PROCEDURE,Modification of MR parameters before and after the blood brain barrier disruption observed in newly enhancing lesion in MS.,"Predictive scorers of plaque transformation in ""black-holes"", which correspond with a pejorative evolution of accurate lesions, also defined by a focal destruction of cerebral tissue.|Relation between plaques development and cerebral venous structures.",False,
NCT06396039,A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis,"A Phase 4, Multicenter, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Oral Ozanimod for Relapsing Multiple Sclerosis (RMS) in Chinese Participants",ACTIVE_NOT_RECRUITING,2024-05-15,2028-12-29,2029-03-30,2025-04-16,2024-05-02,INTERVENTIONAL,PHASE4,84.0,ESTIMATED,Bristol-Myers Squibb,INDUSTRY,,,Relapsing Multiple Sclerosis,,China,Beijing,Beijing Municipality,25,BMS-986374,DRUG,Annualized relapse rate (ARR) over 36 months,"Annualized relapse rate (ARR) over 12 months and 24 months|The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions at Months 12, 24, and 36|The cumulative number of GdE brain MRI lesions at Months 12, 24, and 36|Proportion of participants who are new or enlarging hyperintense T2 lesion free at Months 12, 24, and 36|Proportion of participants who are GdE lesion-free at Months 12, 24, and 36|Proportion of participants with adverse events (AEs)|Proportion of participants with serious adverse events (SAEs)|Proportion of participants with AEs leading to discontinuation of study treatment|Proportion of participants with laboratory abnormalities|Proportion of participants with vital sign abnormalities|Proportion of participants with electrocardiogram (ECG) abnormalities|Proportion of participants with physical examination abnormalities|Proportion of participants with serious or opportunistic infections|Proportion of participants with malignancy|Proportion of participants with bradycardia and heart condition abnormalities|Proportion of participants with pulmonary toxicity|Proportion of participants with macular edema|Proportion of participants with hepatotoxicity|Proportion of participants with posterior reversible encephalopathy syndrome|Proportion of participants with progressive multifocal leukoencephalopathy",False,
NCT01651520,Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis,Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.,UNKNOWN,2013-06,2019-06,2019-06,2017-08-16,2012-07-27,INTERVENTIONAL,NA,60.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,Neurodegeneration|Disability|Cognition|Prognosis,France,Paris,,1,PET with 11C-Flumazenil,DRUG,neuronal imaging,,False,
NCT06191380,Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS),Effects of a Single Bout of Moderate Intensity Aerobic Cycling Exercise Combined With Virtual Reality on Processing Speed in Persons With Multiple Sclerosis and Mobility Disability,RECRUITING,2024-02-12,2025-09-30,2025-09-30,2025-09-02,2024-01-05,INTERVENTIONAL,NA,24.0,ESTIMATED,Kessler Foundation,OTHER,Consortium of Multiple Sclerosis Centers,OTHER,Multiple Sclerosis,Multiple Sclerosis|Leg Cycling|Virtual Reality|Mobility Disability|Processing Speed,United States,East Hanover,New Jersey,1,PACE-MS,BEHAVIORAL,Modified Flanker Task (MFT),Baseline mobility disability|Baseline Symbol Digit Modalities Test (SDMT),False,
NCT03069170,Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.,Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.,UNKNOWN,2016-07,2020-09,2021-01,2020-03-17,2017-03-03,INTERVENTIONAL,PHASE1,50.0,ESTIMATED,Stem Cells Arabia,OTHER,,,Multiple Sclerosis,,Jordan,Amman,,1,Stem Cell Transplantation,BIOLOGICAL,"Effectiveness assessment by MRI|Safety assessment by physical examination, vital signs, analytical results, electrocardiograph monitoring, and Expanded Disability Status Scale (EDSS)","Change in Quality of life by Multiple Sclerosis Quality of Life (MSQOL-54)|Axonal effect by Optical coherence tomography (OCT)|Immunology: Dosing of G, A and M immunoglobulins, and complement factors C3 and C4",False,
NCT00937157,Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA),Comparison of Standard 1.5 Versus 3T Optimized Protocols in Patients Treated With Glatiramer Acetate. A Conventional and Non-conventional MRI Study,COMPLETED,2007-09,2010-07,2011-04,2021-03-19,2009-07-10,INTERVENTIONAL,NA,12.0,ACTUAL,University at Buffalo,OTHER,"Teva Neuroscience, Inc.",INDUSTRY,Multiple Sclerosis,Inflammation|Multiple Sclerosis|Glatiramer Acetate|Gd enhancing lesions|1.5T protocol|3T protocol|Magnetization transfer imaging (MTI)|Lesion activity analysis|Copaxone,United States,Buffalo,New York,1,Copaxone,DRUG,A Change in the Cumulative Number of Gd Enhancing Lesions Using a 3T Protocol.,,True,2014-12-09
NCT06295601,Telerehabilitation Based Motor Imagery and Action Observation Training in Multiple Sclerosis,Effect of Telerehabilitation-Based Motor Imagery and Action Observation Training on Balance and Functional Mobility in Multiple Sclerosis: Randomized Controlled Study,NOT_YET_RECRUITING,2024-03-20,2025-02-15,2025-08-15,2024-03-06,2024-03-06,INTERVENTIONAL,NA,10.0,ESTIMATED,Inonu University,OTHER,,,Multiple Sclerosis,motor imagery|telerehabilitation|action observation therapy,,,,0,Traditional rehabilitation|Action observation therapy and motor imagery,OTHER|OTHER,Berg Balance Scale|Berg Balance Scale|Muscle strength and functional mobility|Muscle strength and functional mobility,Fatigue Severity Scale|Fatigue Severity Scale|Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire|Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire,False,
NCT02637856,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment,COMPLETED,2016-02-11,2019-05-03,2019-05-03,2020-05-26,2015-12-22,INTERVENTIONAL,PHASE3,608.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Cullman,Alabama,82,Ocrelizumab|Ocrelizumab,DRUG|DRUG,Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period|Percentage of Participants With Infusion Related Reactions (IRRs) in Optional Substudy,Percentage of Participants Without Any Protocol-Defined Events During 24-Week and 48-Week Period|Time to Protocol-Defined Event|Total Number of Protocol-Defined Relapses Per Participant Year During 96-week Period|Time to Onset of First Protocol-Defined Relapse|Time to Onset of First T1 Gd-Enhanced Lesion as Detected by Brain MRI|Time to Onset of First New and/or Enlarging T2 Lesion as Detected by Brain MRI|Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks According to Expanded Disability Status Scale (EDSS) Score|Total Number of T1 Gd-Enhancing Lesions as Detected by Brain MRI|Change From Baseline in Total T2 Lesion Volume as Detected by Brain MRI|Total Number of New and/or Enlarging T2 Lesions as Detected by Brain MRI|Percentage of Participants With Adverse Events,True,2020-05-26
NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis,TERMINATED,2010-10,2015-01,2015-01,2016-07-12,2010-10-22,INTERVENTIONAL,PHASE2,340.0,ACTUAL,EMD Serono,INDUSTRY,"Merck KGaA, Darmstadt, Germany|Ono Pharmaceutical Co. Ltd",INDUSTRY|INDUSTRY,Multiple Sclerosis,Multiple sclerosis|ONO-4641|MSC2430913A|Efficacy,United States,Tucson,Arizona,70,ONO-4641|ONO-4641|ONO-4641|ONO-4641|ONO-4641|ONO-4641,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,"Number of Subjects With Clinically Significant Abnormal Vital Signs|Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Percent (%) Predicted Value)|Change From Baseline in Forced Vital Capacity (FVC)|Change From Baseline in Diffusing Capacity of Lung for Carbon Monoxide (DLCO)|Number of Subjects With Clinically Significant Abnormal Electrocardiogram (ECG) Measures|Number of Subjects With Clinically Significant Abnormal Ophthalmologic Examination|Number of Subjects With Clinically Significant Abnormalities in Dermatological Examination|Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation",Number of Gadolinium (Gd)-Enhanced Lesions|Change From Baseline in Lesion Volume at the End of the Treatment (EoT)|Percent Brain Volume Change (PBVC) From Baseline at the End of Treatment,True,2016-07-12
NCT06890923,Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis,"An Open Label, Multicenter Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients",RECRUITING,2025-03-04,2026-04-30,2026-08-30,2025-06-06,2025-03-24,INTERVENTIONAL,PHASE2,55.0,ESTIMATED,Tiziana Life Sciences LTD,INDUSTRY,,,Non-Active Secondary Progressive Multiple Sclerosis,Non-Active Secondary Progressive Multiple Sclerosis|Multiple Sclerosis|Foralumab|phase 2,United States,Boston,Massachusetts,1,Foralumab TZLS-401 100 µg,DRUG,Safety and Tolerability|Change in Baseline|Safety and Tolerability|Safety and Tolerability|Safety and Tolerability|Safety and Tolerability,Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue|Baseline Neurostatus Expanded Disability Status Scale (EDSS)|Baseline Multiple Sclerosis Functional Composite (MSFC-4),False,
NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,"A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis",COMPLETED,2005-01,2007-04,2007-04,2015-07-15,2005-05-09,INTERVENTIONAL,PHASE3,260.0,ACTUAL,EMD Serono,INDUSTRY,Pfizer,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Relapsing forms of multiple sclerosis,United States,Rockland,Massachusetts,1,Interferon-beta-1a FBS-free/HSA-free,BIOLOGICAL,Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit.,Number of Participants Who Were Neutralising Antibody (NAb) Positive at Anytime During the Study|Number of Participants With Binding Antibodies (BAb) at Week 96,True,2010-07-09
NCT01399957,Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients,Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes,COMPLETED,2010-08,2014-09,2015-09,2015-11-10,2011-07-22,OBSERVATIONAL,,52.0,ACTUAL,Mount Sinai Rehabilitation Hospital,OTHER,Brown University|Acorda Therapeutics,OTHER|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Dalfampridine-ER|Walking speed,United States,Hartford,Connecticut,1,,,Change in 25ft walk time|Change in 6 minute walk distance,Change of Upper extremity dexterity with 9hole peg test,False,
NCT04252053,The Effects of Pilates-Based Core Stabilization Training in Multiple Sclerosis,The Effects of Pilates-Based Core Stabilization Training on Isokinetic Knee Strength and Postural Sway in People With Multiple Sclerosis,COMPLETED,2020-02-06,2021-01-03,2021-01-03,2021-01-07,2020-02-05,INTERVENTIONAL,NA,50.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Pilates|Core stability|Isokinetic strength|Postural sway,Turkey (Türkiye),Istanbul,,1,Pilates Based Core Stabilization Training|Home based exercise,OTHER|OTHER,Isokinetic strength|Postural sways,Core strength|Core endurance|Balance|Mobility|Fatigue|Quality of life|Fall risk,False,
NCT06139172,Web Intervention for Parents of Youth With Genetic Syndromes (WINGS),Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities,RECRUITING,2023-09-15,2025-12,2026-12,2025-01-31,2023-11-18,INTERVENTIONAL,NA,92.0,ESTIMATED,Rush University Medical Center,OTHER,Emory University,OTHER,"Telomeric 22Q13 Monosomy Syndrome|Tuberous Sclerosis|Hamartoma Syndrome, Multiple|Fragile X Syndrome|Angelman Syndrome|Rett Syndrome|Chromosome 15Q, Partial Deletion|Creatine Deficiency, X-linked",,United States,Chicago,Illinois,1,Functional Behavioral Training (FBT)|Positive Parenting Strategies-Treatment as Usual,BEHAVIORAL|OTHER,Clinical Global Impression,"Parent Target Problems (PTP) Inventory|Aberrant Behavior Checklist, Second Edition (ABC-2)|Adverse Event Monitoring",False,
NCT05958381,Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation,Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation,RECRUITING,2023-10-18,2026-06-29,2027-06-30,2025-08-14,2023-07-24,INTERVENTIONAL,NA,100.0,ESTIMATED,The University of Texas at Dallas,OTHER,University of Texas Southwestern Medical Center,OTHER,"Multiple Sclerosis, Relapsing-Remitting",transcranial direct current stimulation (tDCS)|multiple sclerosis|electroencephalography (EEG),United States,Richardson,Texas,1,Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation,DEVICE|DEVICE,Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency|Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency|Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT|Treatment group differences in change from Baseline to 2-months Post-Treatment on COWAT,Treatment group differences in change from Baseline to 1-week Post-Treatment on the Trail Making Test (Part A)|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Trail Making Test (Part B)|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Delis Kaplan Color Word Interference Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on on the Digit Span Forward|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Digit Span Backward|Treatment group differences in change from Baseline to 1-week Post-Treatment on on the the Rey-Osterrieth Complex Figure Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Digit Symbol Substitution Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Grooved Pegboard Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Object Retrieval Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Boston Naming Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Auditory Verbal Learning Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Trail Making Test (Part A)|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Trail Making Test (Part B)|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Delis Kaplan Color Word Interference Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Digit Span Forward|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Digit Span Backward|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Rey-Osterrieth Complex Figure Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Digit Symbol Substitution Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Grooved Pegboard Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Semantic Object Retrieval Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Boston Naming Test|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Auditory Verbal Learning Test|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Inhibition Task EEG spectral power|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Semantic Inhibition Task EEG spectral power|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Inhibition Task EEG Event-Related Potential (N2/P3)|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Semantic Inhibition Task EEG Event-Related Potential (N2/P3)|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Object Retrieval EEG spectral power|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Semantic Object Retrieval EEG spectral power|Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Object Retrieval EEG event-related potential|Treatment group differences in change from Baseline to 2-months Post-Treatment on the Semantic Object Retrieval EEG event-related potential,False,
NCT02293967,Mass Balance Study of MT-1303,"An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.",COMPLETED,2014-09,2014-12,2014-12,2015-03-17,2014-11-19,INTERVENTIONAL,PHASE1,8.0,ACTUAL,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,United Kingdom,Ruddington,Nottingham,1,MT-1303,DRUG,Total radioactivity in urine and faeces,PK of total radioactivity in plasma,False,
NCT06534177,Digital Diagnostics and Intervention Services for Parkinson's Disease,Development of Digital Diagnostics and Intervention Services for Parkinson's Disease,NOT_YET_RECRUITING,2024-10-15,2025-07-31,2026-03-01,2024-08-09,2024-08-02,OBSERVATIONAL,,80.0,ESTIMATED,University of Exeter,OTHER,GaitQ company,UNKNOWN,"Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Joint Diseases|Musculoskeletal Diseases|Parkinson Disease|Basal Ganglia Diseases|Movement Disorders|Synucleinopathies|Neuro-Degenerative Disease|Demyelinating Disease, Autoimmune, CNS|Demyelinating Disease|Autoimmune Diseases|Immune System Diseases|Bone Diseases, Metabolic|Bone Diseases|Arthritis|Osteoporosis|Multiple Sclerosis",parkinson's disease|osteoarthritis|stroke|MS|osteoporosis,,,,0,,,Lab validation of MachineMD opthalamic device vs UPDRS|Reliability testing of GaitQ wearable device|Home/community validation|Home/community validation|Reliability data collection for determining minimally important differnce|Determine intervention potential,,False,
NCT03355365,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,"Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally",COMPLETED,2018-09-21,2023-02-09,2023-04-17,2025-06-11,2017-11-28,INTERVENTIONAL,PHASE2,54.0,ACTUAL,Tisch Multiple Sclerosis Research Center of New York,OTHER,,,Multiple Sclerosis,Mesenchymal Stem Cells|Neural Progenitors|Autologous|Bone Marrow|Multiple Sclerosis,United States,New York,New York,1,Intrathecal MSC-NP injection|Intrathecal saline injection,BIOLOGICAL|OTHER,Expanded Disability Status Scale (EDSS) Plus,Change in Multiple Sclerosis Functional Composite (MSFC) Z-Score From Baseline|Change in EDSS From Baseline|Percent Change in T25FW (Timed 25 Foot Walk) From Baseline|Percent Change in 6MWT (6 Minute Walk Test) From Baseline|Percent Change in 9HPT-D (9 Hole Peg Test in Dominant Hand) From Baseline|Percent Change in 9HPT-ND (9 Hole Peg Test in Non-Dominant Hand) From Baseline|Change in MSWS-12 (12 Item MS Walking Scale) Score From Baseline|Change in PASAT (Paced Auditory Serial Addition Test) Score From Baseline,True,2025-06-11
NCT06450600,Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education,Enhancing Quality of Life in Multiple Sclerosis: a Study Protocol to Evaluate the Impact of a Therapeutic Education Program,NOT_YET_RECRUITING,2024-10-05,2025-04-05,2025-06-05,2024-06-10,2024-06-10,INTERVENTIONAL,NA,50.0,ESTIMATED,Akhrif Iman,OTHER_GOV,,,Multiple Sclerosis (MS),Multiple Sclerosis|therapeutic education program|bladder dysfunction,,,,0,Multiple Sclerosis Therapeutic Education Program,BEHAVIORAL,Multiple Sclerosis Quality of Life-54 (MSQOL-54),Measure of Urinary Handicap scale (M.H.U),False,
NCT03574428,Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers,"A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers",COMPLETED,2018-05-08,2018-11-02,2018-11-02,2020-10-20,2018-07-02,INTERVENTIONAL,PHASE1,24.0,ACTUAL,GeNeuro Australia PTY Ltd,INDUSTRY,,,Multiple Sclerosis,Temelimab,Australia,Sydney,New South Wales,1,GNbAC1|GNbAC1 Placebo,DRUG|OTHER,"Safety and tolerability of single ascending doses of GNbAC1 (Serious Adverse Events, Adverse Events)",Pharmacokinetic (PK): GNbAC1 serum concentrations over time|Immunogenicity: Antibodies against GNbAC1 (ADA),False,
NCT01802931,GSK239512 DDI Study,An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512,COMPLETED,2013-01-07,2013-04-15,2013-04-15,2017-07-26,2013-03-04,INTERVENTIONAL,PHASE1,22.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,GSK239512|H3 receptor antagonist|drug-drug interaction|pharmacokinetics|ketoconazole,Australia,Randwick,New South Wales,1,GSK239512|ketoconazole,DRUG|DRUG,AUC of GSK239512|Cmax of GSK239512,Number of participants with adverse events as a measure of safety and tolerability,False,
NCT00338637,Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit,,UNKNOWN,2006-04,,2006-10,2006-06-20,2006-06-20,INTERVENTIONAL,PHASE2,30.0,,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis|Balance|Cerebelar Impairment,,Israel,Ramat Gan,,1,APOS shoe kit,DEVICE,functional tests,gait analysis,False,
NCT04448977,Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI,A Biomarker for Cognitive Fatigue Using Functional Imaging in MS,RECRUITING,2021-05-06,2024-12,2024-12,2024-02-14,2020-06-26,OBSERVATIONAL,,60.0,ESTIMATED,Kessler Foundation,OTHER,Hackensack Meridian Health,OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|cognitive fatigue,United States,West Orange,New Jersey,1,Ocrevus,DRUG,Brain activation (BOLD signal),Fatigue onset,False,
NCT04873492,From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis,From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis,UNKNOWN,2022-01-24,2023-07-24,2025-07-24,2023-01-30,2021-05-05,INTERVENTIONAL,NA,130.0,ESTIMATED,Nantes University Hospital,OTHER,,,Multiple Sclerosis,,France,Nantes,Loire-Atlantique,1,Biological sample collection,OTHER,Bulk RNA-sequencing,Single RNA sequencing|Association of genetic sequence variation from whole genome sequencing with gene expression profile via Bulk RNA-seq|Association of transcriptomic variation with DNA methylation|OMIC integration,False,
NCT05633875,Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis,Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis: Long Term Predictive Value (IMAGIN-DEAL in MS),RECRUITING,2023-03-23,2025-04-25,2025-04-25,2024-01-09,2022-12-01,OBSERVATIONAL,,80.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis (MS),Multiple sclerosis (MS)|MRI|RRMS|long term predictive value|PET-MRI,France,Paris,,1,MRI,OTHER,EDSS (Expanded Disability Status Scale) score,"MSFC (Component of the Multiple Sclerosis Functional Score) score for neurological disability: 9-Hole Peg Test (9HPG)|SDMT(Symbol Digit Modalities Test) for speed processing|T25FW (Timed 25 Foot Walk test)|MSFC (component of the Multiple Sclerosis Functional Score) score for neurological disability: PASAT (Paced Auditory Serial Addition Test) 3 sec for speed processing. Scale: min=0 ;max=60|10/36 Spatial Recall tests|RL/RI-16 memory test|Backward and forward verbal digit span test|Stroop test|Deno 80 test|White matter lesion load on MRI|Whole brain, white matter, deep grey matter and cortical atrophy on MRI",False,
NCT00017628,Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis,,COMPLETED,2001-04,,,2005-06-24,2001-06-06,INTERVENTIONAL,PHASE1,20.0,,Northwestern Memorial Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,United States,Chicago,Illinois,2,cyclophosphamide|filgrastim|methylprednisolone|Autologous Stem Cell Transplantation,DRUG|DRUG|DRUG|PROCEDURE,,,False,
NCT04543448,Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis,Investigation the Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis Patients: A Randomized Crossover Controlled Study,COMPLETED,2019-10-02,2020-05-31,2020-08-20,2021-01-22,2020-09-10,INTERVENTIONAL,NA,12.0,ACTUAL,Hasan Kalyoncu University,OTHER,,,Multiple Sclerosis|Muscle Spasticity|Pressure Area|Cervical Region Disorder Nos,cervical region|multiple sclerosis|muscle spasticity|manual therapy|cervical spine|Plantar pressure,Turkey (Türkiye),Gaziantep,,1,Traditional Rehabilitation for multiple sclerosis|Cervical mobilization for multiple sclerosis,OTHER|OTHER,Change Plantar Pressure Distribution|Change Balance,Change Modified ashworth scale,False,
NCT03357887,Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome,Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome,COMPLETED,2018-07-01,2018-12-31,2018-12-31,2020-12-10,2017-11-30,OBSERVATIONAL,,100.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis|Radiologically Isolated Syndrome,,France,Nîmes,,1,Analysis of cerebrospinal fluid and serum,OTHER,Level of tumour necrosis factor receptor in cerebrospinal fluid|Level of Neurofilament in cerebrospinal fluid|Level of GFAP in cerebrospinal fluid|Level of secreted glycoprotein in cerebrospinal fluid,"Level of tumour necrosis factor receptor in serum|Level of Neurofilament in serum|Level of GFAP in serum|Level of secreted glycoprotein in serum|Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients|Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis).|Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls)",False,
NCT04618978,Periodic Leg Movements' Diagnosis in Spinal Cord Injury: Actigraphy as an Alternative for Polysomnography?,Periodic Leg Movement's Diagnosis in Spinal Cord Injury: Actigraphy as an Alternative for Polysomnography?,COMPLETED,2021-02-25,2024-07-04,2025-01-17,2025-02-11,2020-11-06,INTERVENTIONAL,NA,160.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Spinal Cord Injuries|Periodic Limb Movement Disorder,spinal cord injury|multiple sclerosis|periodic leg movements|spasticity|periodic limb movement disorder,France,Garches,,1,PSG and actigraphy recording,PROCEDURE,The Receiver Operating Characteristic (ROC) analysis,Predictive values estimation|Threshold of PLMs Index|Lower limb nocturnal movements evaluation|PLMs diagnosis based on the actigraphy|Kappa coefficient|Actigraphy diagnostic performance|Installation time|Interpretation time,False,
NCT02084121,Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use),Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use),NO_LONGER_AVAILABLE,,,,2022-07-18,2014-03-11,EXPANDED_ACCESS,,,,Talaris Therapeutics Inc.,INDUSTRY,Duke University,OTHER,Metachromatic Leukodystrophy,metachromatic leukodystrophy,United States,Durham,North Carolina,1,Enriched Hematopoetic Stem Cell Infusion,BIOLOGICAL,,,False,
NCT01915433,Wahls Paleo Diet and Progressive Multiple Sclerosis,Wahls Paleo Diet and Progressive Multiple Sclerosis,COMPLETED,2013-07,2014-02,2016-11,2018-06-26,2013-08-02,INTERVENTIONAL,NA,15.0,ACTUAL,Terry L. Wahls,OTHER,,,Multiple Sclerosis,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Relapsing progressive multiple sclerosis|relapsing remitting multiple sclerosis|Fatigue|Quality of life|Paleo|Nutrition|Ketogenic,United States,Iowa City,Iowa,2,Wahls Paleo Plus|Wahls Diet,OTHER|OTHER,Perceived Fatigue,"Biomarkers|Biomarkers - glucose and ketones|24 hr food recalls.|Daily Food logs|MS functional composite score.|6 minute walk test|Medical symptoms quest. (MSQ)|Life spaces score|Medication audit|Physical examination|Health questions|MS Quality of Life (MSQoli 54)|MS Quality of life inventory (MSQLI)|Demographic data|Functional Medicine assessment summary|Veteran Specific Activity Quest.|MS Function Scale|Satiety scale|Harvard Food Frequency Quest.|Brachial artery dilation (FMD)and endothelium-dependent dilation, EDD) and endothelium-independent dilation|Expanded disability status score",False,
NCT04283747,Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis,Hypogammaglobulinemia and Immunization Responses to Measles in Rituximab-treated Multiple Sclerosis Patients,UNKNOWN,2020-02-28,2022-10,2022-12,2020-07-10,2020-02-25,OBSERVATIONAL,,170.0,ESTIMATED,Mazandaran University of Medical Sciences,OTHER,,,Multiple Sclerosis|Hypogammaglobulinemia,Rituximab|Varicella Zoster|Hypogammaglobulinemia,Iran,Sari,,1,Serum immunoglobulin titer,DIAGNOSTIC_TEST,Rate of hypogammaglobinemia,severity of hypogammaglobinemia|immunization response to VZV vaccination|Rate of infection|type of infection|severity of infection events,False,
NCT04445116,Endeavor™ in Pediatric MS,"A Study of Endeavor™, a Video-Game Based Cognitive Remediation, in the Pediatric Multiple Sclerosis (MS) Population",WITHDRAWN,2023-01,2023-02-23,2023-02-23,2023-05-06,2020-06-24,INTERVENTIONAL,NA,0.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,Action Video Game Treatment,DEVICE,Percent compliance for total at-home sessions,Change in Fatigue in Adult participants|Change in Fatigue in Pediatric participants|Change in Depression in Participants|Change in Quality of life in Participants|Change in behaviors in pediatric participants.,False,
NCT04635033,Intermittent Hypoxia Intervention in MS Patients,Safety and Tolerance of an Intermittent Intervention in MS Patients,COMPLETED,2018-09-19,2019-10-10,2019-10-10,2020-11-18,2020-11-18,OBSERVATIONAL,,12.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,Multiple Sclerosis,,Germany,Hamburg,,1,,,Lake Louise Score (LLS),Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk (T25-FW)|6 minute walking test (6MWT)|9-Hole-Peg-Test (9 HPT)|Verbal learning and memory test (VLMT)|Symbol Digit Modalities Test (SDMT)|Brief Visuospatial Memory Test-Revised (BVMT-R)|Frenchay Activities Index (FAI)|Fatigue Scale Motor Cognition (FSMC)|Beck Depression Inventory (BDI)|MRI Lesions|Brain atrophy|Immune cell subsets|Heart rate|Blood pressure|Heart rate|Oxygen saturation|Blood sugar|Blood count|Erythropoetin|Liver enzymes|Kidney enzyme|NFL,False,
NCT01900093,Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses,An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone,UNKNOWN,2013-07,2018-03,2018-03,2017-09-06,2013-07-16,INTERVENTIONAL,NA,10.0,ESTIMATED,Aaron Miller,OTHER,Mallinckrodt,INDUSTRY,Multiple Sclerosis,,United States,New York,New York,1,Acthar Gel,DRUG,Improvement in Functional System Score appropriate to the Targeted Neurological Deficit,Improvement in Expanded Disability Status Scale,False,
NCT00071838,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System,COMPLETED,2003-10-30,2007-10-04,2011-08-16,2017-07-02,2003-11-03,INTERVENTIONAL,PHASE2,16.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,"Multiple Sclerosis, Relapsing-Remitting",Neuroimmunology|Therapy|Demyelinating Disease|Immunological Mechanism|MRI|Multiple Sclerosis|MS,United States,Bethesda,Maryland,1,Daclizumab,DRUG,Reduction in mean number of new gaolinium-enhancing lesions in the treatment phase (Weeks 18 to 30) versus baseline (Weeks -12 to 0).,Mean change in the MS functional composite from completion of treatment. Reduction of mean number of new gaolinium-enhancing lesions at the completion of treatment. Mean change in Multiple Sclerosis Quality of Life Inventory from completion of t...,False,
NCT04682548,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,"Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls",COMPLETED,2021-01-05,2022-09-15,2022-09-15,2022-11-03,2020-12-23,OBSERVATIONAL,,920.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis|Covid19,Disease-Modifying Therapy,United States,New York,New York,1,,,Seropositivie Rate Against SARS-CoV-2,T Cell Response,False,
NCT00423111,Correlation Between Cognitive Functions and MRI in Multiple Sclerosis,,UNKNOWN,2007-02,,2009-02,2007-09-21,2007-01-17,OBSERVATIONAL,,100.0,ESTIMATED,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,Multiple sclerosis|Memory|Cognitive deficits|MRI|Hippocampus|Prefrontal cortex,Israel,Ramat Gan,,1,,,,,False,
NCT00101959,Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects,"An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy",WITHDRAWN,2004-11,,,2013-08-06,2005-01-19,INTERVENTIONAL,PHASE4,0.0,ACTUAL,EMD Serono,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,,,,0,Rebif,DRUG,,,False,
NCT00537082,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS),"A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",COMPLETED,2007-09,2010-02,,2011-04-21,2007-09-28,INTERVENTIONAL,PHASE2,171.0,ACTUAL,Novartis,INDUSTRY,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,Multiple Sclerosis,"FTY720,|MS",Japan,Sapporo,Hokkaido,18,FTY720|Placebo,DRUG|DRUG,Number of Patients Free of Gadolinium-enhanced T1-Weighted Magnetic Resonance Imaging (MRI) Lesions at Both Month 3 and Month 6,Number of Patients Free of MS Relapse up to Month 6 (Confirmed Relapse Only)|Number of Patients Free of New or Newly Enlarged T2 Lesions|Annualized Relapse Rate (ARR) at 6 Months,True,2011-03-23
NCT02967380,"Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases",Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions,TERMINATED,2011-12-14,2014-10-14,2015-10-14,2017-03-27,2016-11-18,INTERVENTIONAL,NA,14.0,ACTUAL,University of Southern California,OTHER,National Cancer Institute (NCI),NIH,Adult Anaplastic (Malignant) Meningioma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Neoplasm|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Primary Melanocytic Lesion of Meninges|Adult Supratentorial Primitive Neuroectodermal Tumor|Malignant Adult Intracranial Hemangiopericytoma|Metastatic Malignant Neoplasm in the Brain|Multiple Sclerosis|Recurrent Adult Brain Neoplasm,,United States,Los Angeles,California,1,Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Gadobenate Dimeglumine|Gadobutrol|Gadopentetate Dimeglumine,PROCEDURE|DRUG|DRUG|RADIATION,Agreement of using Magnevist® or Multihance versus Gadavist® on glioma grading,,False,
NCT03387670,Multiple Sclerosis-Simvastatin Trial 2,"A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability",COMPLETED,2018-03-28,2024-07-26,2024-08-25,2024-09-19,2018-01-02,INTERVENTIONAL,PHASE3,964.0,ACTUAL,"University College, London",OTHER,University of Edinburgh|Queen Mary University of London|London School of Hygiene and Tropical Medicine|University of Leeds|The Leeds Teaching Hospitals NHS Trust|Imperial College Healthcare NHS Trust,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Secondary Progressive Multiple Sclerosis (SPMS),,United Kingdom,Belfast,,31,Simvastatin|Placebo,DRUG|DRUG,Time to confirmed disability progression between simvastatin and placebo arm based on change in EDSS scores compared to baseline.,Response rate on the patient reported outcome form Multiple Sclerosis Walking Scale-12 version 2 (MSWS-12v2)|Response rate on the patient reported outcome form Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29v2)|Cost effectiveness of intervention|Evaluating change in degree of disability based on the modified Rankin scale (mRS)|Change in visual function based on the Sloan Low Contrast Visual Acuity (SLCVA)|Difference in patient reported quality of life based on the EuroQoL Health Related Quality of Life - 5 Dimensions - 5 Levels (EQ-5D 5L) scores|Change in a modified Multiple Sclerosis Functional Composite scores|Change in cognitive performance as measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|Change in cognitive impairment based on Symbol Digit Modalities Test (SDMT) scores|Change in fatigue as measured by the Chalder Fatigue Scale|Change in rates of service utilisation as measured by the Client Service Receipt Inventory (CSRI) questionnaire|Change in time taken to complete 25-Foot Timed Walk (T25FW)|Difference in the number and severity of multiple sclerosis related relapse events between treatment groups|Evaluating the time to disability progression based on a secondary composite progression outcome measure|Change in time taken to complete 9 hole peg test (9HPT),False,
NCT02789670,Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients,Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients,COMPLETED,2014-07,2021-04,2021-04,2022-10-14,2016-06-03,OBSERVATIONAL,,137.0,ACTUAL,"University Hospital, Lille",OTHER,,,Multiple Sclerosis|Systemic Sclerosis,,France,Lille,,1,Blood sample collection,OTHER,Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at inclusion time point,Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at the different time points of the study|Comparison of the production of IL-10 and IL-6 by B cells in the MS patient subgroups at the inclusion time point|Comparison of the production of IL-10 and IL-6 by B cells in the MS patient subgroups at the different time points of the study|Comparison B cell subset distribution in MS patients and the control group|Comparison B cell subset distribution|Comparison B cell subset distribution in MS patients versus the control group at the different time points of the study|Comparison B cell subset distribution in MS patients versus the control group at the different time points of the study,False,
NCT01020370,Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies,An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies,COMPLETED,,,,2009-11-25,2009-11-25,OBSERVATIONAL,,,,Wayne State University,OTHER,,,Multiple Sclerosis,Patients with RRMS who are participating in the CARE MS I and CARE MS II,,,,0,,,Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies,Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes,False,
NCT03347370,A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis,Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting,COMPLETED,2017-11-27,2019-07-31,2019-07-31,2019-09-25,2017-11-20,OBSERVATIONAL,,626.0,ACTUAL,Biogen,INDUSTRY,AMS Advanced Medical Services GmbH,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",subcutaneous interferon beta therapy multiple sclerosis (MS)|injection site reactions (ISR)|flu-like symptoms (FLS)|non-interventional study (NIS)|SC Peginterferon beta-1a|SC interferon beta-1a|SC interferon beta-1b|Plegridy®|Betaferon®|Extavia®|Rebif®,Germany,Göttingen,,1,SC Peginterferon beta-1a|SC interferon beta-1a|SC interferon beta-1b,DRUG|DRUG|DRUG,Percentage of Participants with at Least one Injection Site Reaction (ISR) as Reported by the Participants|Percentage of Participants with at Least one Flu-like Symptoms (FLS) as Reported by the Participants,"Percentage of Participants with at Least one ISR (FLS) as Reported by the Nurse|Percentage of Participants with at Least one ISR (FLS) as Reported by the Physician|Percentage of Participants with Types of ISR (FLS) Reported by Participants, Nurses, and Physician|Duration of ISR (FLS) Reported by Participants, Nurses, and Physician|Usual Time of Occurrence of ISR (FLS) as Reported by the Participants, Nurses and Physicians|Interference Score of ISR (FLS) With Participant's Daily Activities|Number of Participants Taking Treatments/Actions to Relieve the ISR (FLS) Assessed by Participants, Nurses and Physicians|Percentage of Participants With at Least one Self-administered Treatment/Action Resulting in Disappearance or Relief of ISR/FLS|Percentage of Participants With Reducing or Increasing Frequency of ISR/FLS Compared to Previous Therapy|Percentage of Participants With Reducing or Increasing Intensity of ISR/FLS Compared to Previous Therapy",False,
NCT02436746,The Cognitive Variability in NF1 and TSC Monozygotic Twins,The Cognitive Variability in Neurofibromatosis Type I and Tuberous Sclerosis Complex Monozygotic Twins,UNKNOWN,2015-04,2017-04,2017-04,2015-05-07,2015-05-07,OBSERVATIONAL,,116.0,ESTIMATED,Erasmus Medical Center,OTHER,,,Neurofibromatosis Type I|Tuberous Sclerosis Complex,Von Recklinghausen's disease|Bourneville's disease|Cognitive variability|Loss of heterozygosity,Netherlands,Rotterdam,,1,,,Correlation of full intelligence quotient,Correlation of word reading ability|Correlation of attention problems|Correlation of behavioural problems|Correlation of autistic features|Correlation of visuospatial judgement (NF1 twins only)|Correlation of executive control (TSC twins only),False,
NCT02004054,Interest of Dynamic Measures of the Pupil in Optic Neuritis,Interest of Dynamic Measures of the Pupil in Optic Neuritis,COMPLETED,2012-12,2013-05,2013-05,2013-12-06,2013-12-06,OBSERVATIONAL,,30.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Optic Neuritis,multiple sclerosis|diameter pupil,France,Paris,,1,measure of pupil diameter,OTHER,Comparison between the PCT frequency of the eye affected by optic neuritis and a sane eye,,False,
NCT01195870,Assessment of Patient Use of a New Device: RebiSmart,Assessment of Patient Use of a New Device: RebiSmart,COMPLETED,2009-07,2010-09,2010-10,2014-02-17,2010-09-06,OBSERVATIONAL,,63.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono Limited, UK",INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Rebif|Interferon beta-1a,,,,0,,,Percentage of subjects who liked using the RebiSmart device based on a score of 6 or more on a Visual Analogue Scale (VAS) at the end of 12-week treatment period,Percentage of patients who found RebiSmart easy or very easy to use at the end of 12-week treatment period|Top three functions of the device patients found most useful; top ranked from 1 to 10,False,
NCT04881422,"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project","Sport, Rehabilitation and Nutrition in Multiple Sclerosis: An Innovative Multidisciplinary High Impact Intervention for the Lifestyle Change",UNKNOWN,2018-07-15,2021-12-31,2022-06-30,2021-05-11,2021-05-11,INTERVENTIONAL,NA,30.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,lifestyle|multiple sclerosis|nutrition|rehabilitation|motivation|adherence,Italy,Milan,,1,B-HIPE (Brief High Impact Preparatory Experience),BEHAVIORAL,FS-36 Health Related Quality of Life (HRQoL)|The Fatigue Severity Scale (FSS)|Food frequency questionnaire (FFQ),MSIS29- Multiple Sclerosis Impact Scale|MOS Sleep Scale (MOSS)|Restless Legs Scale (RLS)|Six minute walking test (6MWT)|Hospital Anxiety and Depression Scale (HADS),False,
NCT02623946,Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients,Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients,COMPLETED,2015-11,2020-12-09,2021-02,2021-07-28,2015-12-08,OBSERVATIONAL,,10.0,ACTUAL,Clinique Neuro-Outaouais,OTHER,CogState Ltd.,INDUSTRY,Multiple Sclerosis,motor evoked potentials,Canada,Gatineau,Quebec,1,,,intrapatient correlation coefficient of MEP's,"Correlation coefficient between the changes from baseline MEP results and clinical measures (EDSS, 6MW, T25FWT, 9HPT)|Correlation between the change in the conduction index and the change in clincal measures",False,
NCT02159573,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)","A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)",COMPLETED,2014-07,2015-01,2015-01,2016-06-07,2014-06-10,OBSERVATIONAL,,530.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,United States,Birmingham,Alabama,43,natalizumab|dimethyl fumarate,BIOLOGICAL|DRUG,Kaplan-Meier Estimates for the Proportion of Participants relapsed at 12 months after initiation of treatment with Tecfidera,ARR at 12 months post-initiation of treatment with Tecfidera|The percent of participants with MS-related hospitalization at 12 months post-initiation of treatment with Tecfidera|The percent of participants with relapses requiring treatment with intravenous steroids,False,
NCT02424825,Rouxbe Pilot for MS,"A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis",COMPLETED,2015-02,2015-05,2015-05,2019-04-29,2015-04-23,INTERVENTIONAL,NA,15.0,ACTUAL,Oregon Health and Science University,OTHER,Rouxbe Cooking School,UNKNOWN,Multiple Sclerosis,diet|cooking|multiple sclerosis|fatigue,United States,Portland,Oregon,1,Cooking Course,BEHAVIORAL,"Program Feasibility and Efficacy (composite of student perception, learning, and adherence by surveys)","Weight Change measured by body weight, body mass index, waist circumference|Diet Change measured by NutritionQuest Block Food Frequency Questionnaire, Opening Survey, Program Evaluation Survey|Program Evaluation through Program Evaluation Survey|Fatigue measured by Modified Fatigue Impact Scale-5 and Fatigue Severity Scale",False,
NCT03497468,Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis,Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis,UNKNOWN,2018-04,2018-06-01,2018-06,2018-04-13,2018-04-13,INTERVENTIONAL,NA,34.0,ESTIMATED,Bezmialem Vakif University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",task-oriented training|exercise training|mobility|balance|fatigue|quality of life,,,,0,Combined exercise training|Task-oriented training,OTHER|OTHER,Functional capacity,dynamic gait skills|limitation of gait|dynamic balance and fall risk|sitatic balance|dynamic balance|severity of fatigue|impact of fatigue|Quality of life,False,
NCT00037115,"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.","An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.",WITHDRAWN,2002-05,2002-12,2002-12,2018-04-12,2002-05-17,INTERVENTIONAL,PHASE4,0.0,ACTUAL,MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute,OTHER,Consultants in Neurology,INDUSTRY,Demyelinating Disorders|Multiple Sclerosis|Optic Neuritis|Myelitis|Neuritis,Demyelinating|Multiple Sclerosis|Myelitis|Neuritis|Optic Neuritis|AVONEX|methotrexate|methylprednisolone|interferon beta 1a|demyelination|central nervous system|brain|nerve|lesions|enhancement|enhancing,United States,Kansas City,Missouri,1,interferon beta 1a|methotrexate|methylprednisolone,DRUG|DRUG|DRUG,,,False,
NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis,COMPLETED,2005-01,,2005-12,2012-11-22,2005-09-21,OBSERVATIONAL,,432.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,United States,Many Locations,Alabama,9,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Description of long term course of disease,Comparison to natural history cohort,False,
NCT05437276,A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS),A Therapeutic Experience Program (TEP) Study Assessing Adherence to On-Label PoNS® Therapy for Improvement of Gait in People With Multiple Sclerosis (MS) in a Real-World Clinical Setting,COMPLETED,2022-07-01,2024-06-30,2024-12-31,2025-03-28,2022-06-29,OBSERVATIONAL,,43.0,ACTUAL,Helius Medical Inc,INDUSTRY,,,Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS),"Gait, rehabilitation, PoNS, device, therapy, adherence, outcome",United States,Atlanta,Georgia,5,PoNS®,DEVICE,Measure subjects' adherence to PoNS therapy (device + physical therapy),1) Clinical improvement and its relationship to adherence over the 14-week course of PoNS therapy by evaluating|1) Clinical improvement and its relationship to adherence over the 14-week course of PoNS therapy by evaluating|1) Clinical improvement and its relationship to adherence over the 14-week course of PoNS therapy by evaluating|Clinical improvement among subjects receiving a second course of PoNS therapy as measured by:|Clinical improvement among subjects receiving a second course of PoNS therapy as measured by:|3) Association between likelihood of second course of therapy and magnitudes of improvement with adherence during the initial therapy,False,
NCT02674217,Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells,Outpatient Hematopoietic Grafting in Patients With Multiple Sclerosis Employing Autologous Non-cryopreserved Peripheral Blood Stem Cells: A Feasibility Study,ENROLLING_BY_INVITATION,2015-05,2025-12,2025-12,2023-09-07,2016-02-04,INTERVENTIONAL,NA,1000.0,ESTIMATED,Centro de Hematología y Medicina Interna,OTHER,,,Multiple Sclerosis,,,,,0,Hematopoietic stem cell transplantation,PROCEDURE,Expanded Disability Status Scale,Overall survival,False,
NCT05058729,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) - COVID-19 Questionnaire Linkage Sub-Study,COMPLETED,2020-12-07,2021-10-08,2021-10-08,2023-04-18,2021-09-28,OBSERVATIONAL,,1507.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis (MS),,United States,Baltimore,Maryland,6,,,Number of Completed COVID-19 Questionnaires Able to be Linked to a MS PATHS Participant Identifier (ID),,False,
NCT06303024,Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis,Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis at High Risk of disEase Acitivity Through a Preventive personaLised and InnovAtive rehaBiLitation stratEgy. (RELIABLE),RECRUITING,2023-06-14,2024-03-01,2026-03-01,2024-03-12,2024-03-12,INTERVENTIONAL,NA,140.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,Careggi Hospital|Sheba Medical Center|Uppsala University,OTHER|OTHER_GOV|OTHER,"Multiple Sclerosis, Relapsing-Remitting",,Italy,Florence,,1,personalized combined physical and cognitive intervention,OTHER,Symbol Digit Modalities Test (SDMT)|California Verbal Learning Test second edition (CVLT-II)|Brief Visuo-Spatial Memory Test- Revised (BVMT-R)|Word list generation (WLG)|Stroop test|Test Intelligenza Breve (TIB)|9 hole peg test (9HPT)|The Hospital Anxiety and Depression Scale (HADS)|Beck Depression Inventory second edition|The Modified Fatigue Impact Scale (MFIS)|The Multiple Sclerosis Walking Scale (MSWS-12)|Multiple Sclerosis Impact Scale (MSIS-29-V2)|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|six minutes walking test (6MWT)|Romberg test|handgrip test|cognitive-motor interference|Timed 25-foot walk|brain MRI scan|International Physical Activity Questionnaire (IPAQ),,False,
NCT04548154,Proximal Resistance Training for People With Multiple Sclerosis,Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People With Multiple Sclerosis: A Feasibility Study,COMPLETED,2020-10-12,2022-10-31,2022-10-31,2025-04-18,2020-09-14,INTERVENTIONAL,NA,34.0,ACTUAL,"University of Colorado, Denver",OTHER,National Institute of Neurological Disorders and Stroke (NINDS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH),NIH|NIH|NIH,Multiple Sclerosis,Exercise|Hip abduction|Trunk muscles,United States,Aurora,Colorado,1,Proximal Resistance Training,OTHER,Change in 6-minute walk test,Change in average daily step count|Change in movement patterns|Change in Multiple Sclerosis Walking Scale-12|Change in Multiple Sclerosis Self-Efficacy Score|Change in Exercise Self-Efficacy Scale|Change in Exercise Stages of Change category|Change in Modified Fatigue Impact Scale,False,
NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409),COMPLETED,2015-01-07,2020-07-15,2020-07-15,2022-03-28,2014-10-02,INTERVENTIONAL,PHASE4,1062.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United States,Cullman,Alabama,131,alemtuzumab GZ402673,DRUG,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Infusion-Associated Reactions (IAR)|Number of Participants With Adverse Events of Special Interest (AESI)|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities","Annualized Relapse Rate|Proportion of Participants Who Were Relapse Free|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60|Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) Lesions Per MRI Scan|Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan|Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New T1 (and New Hypointense T1) Lesions Per MRI Scan|Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T1 Lesions at Months 12, 24, 36, 48, and 60|Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T2 Lesions at Months 12, 24, 36, 48, and 60|Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Brain Parenchymal Fraction (BPF) at Month 12, 24, 36, 48, and 60|Change From Baseline in Self-reported Quality of Life (QoL) as Assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Month 12, 24, 36, 48, and 60|Change From Baseline in Functional Assessment of Multiple Sclerosis (FAMS) Score at Month 12, 24, 36, 48, and 60|Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Score: Utility Scores at Month 12, 24, 36, 48, and 60|Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores at Month 12, 24, 36, 48, and 60|Modified Healthcare Resource Utilization Questionnaire (HRUQ): Number of Participants Who Reported Change in Employment Situation, Availing of Sick Leaves, Admissions and Stays in Hospital, Rehabilitation Centers or Nursing Homes Due to Multiple Sclerosis|Modified HRUQ: Number of Participants Who Reported Other Changes/Changes in Lifestyle Due to Multiple Sclerosis|Health Related Productivity Questionnaire (HRPQ): Number of Participants Reporting Current Employment Status (Part Time/Full Time/Not Employed) Due to Multiple Sclerosis|HRPQ: Total Scheduled Working Hours and Number of Hours Missed From Work Due to Multiple Sclerosis|HRPQ: Percentage Impact on Work Output Due to Multiple Sclerosis|HRPQ: Total Scheduled Household Chores Hours; Number of Hours Missed From Household Chores Due to Multiple Sclerosis|HRPQ: Percentage Impact on Work Output for Household Chores Due to Multiple Sclerosis|HRPQ: Duration of Disease (in Months) Since Development of Multiple Sclerosis|HRPQ: Number of Participants Who Reported Impact on Work Due to Multiple Sclerosis",True,2021-07-23
NCT03536559,Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis,"A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis",TERMINATED,2018-11-23,2022-04-27,2022-07-12,2023-04-03,2018-05-24,INTERVENTIONAL,PHASE2,73.0,ACTUAL,Clene Nanomedicine,INDUSTRY,Clene Australia Pty Ltd.,INDUSTRY,"Relapsing Remitting Multiple Sclerosis|Optic Neuropathy|Optic; Neuritis, With Demyelination",gold|nanocrystal|multifocal visual evoked potential|full field visual evoked potential|low contrast vision|low contrast letter acuity|remyelination|demyelination,United States,Dallas,Texas,7,CNM-Au8|Placebo,DRUG|DRUG,Measures of Visual Function,Other Measures of Neurological Function,False,
NCT03651362,Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis,Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis,UNKNOWN,2016-02,2019-02,2019-02,2018-08-31,2018-08-29,OBSERVATIONAL,,50.0,ESTIMATED,"University Hospital, Lille",OTHER,,,Optic Neuritis,optic neuritis|DIR|visual disability|CIS|multiple sclerosis|NMOSD,France,Lille,,1,,,Severity of retinal axonal loss around papilla after a clinical episode of optic neuritis,Severity of retinal axonal loss within macula after a clinical episode of optic neuritis|Severity of visual disability after a clinical episode of optic neuritis|Severity of microstructural architecture of optic nerve after a clinical episode of optic neuritis|Progression of optic nerve lesion length,False,
NCT04438954,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels","Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels of Multiple Sclerosis Patients in the COVID-19 Pandemic",COMPLETED,2020-05-05,2020-06-05,2020-06-18,2020-06-22,2020-06-19,OBSERVATIONAL,,30.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Multiple Sclerosis|Covid-19,Multiple Sclerosis|Covid-19 pandemic|Fatigue|Physical activity|Sleep quality|Anxiety,Turkey (Türkiye),Ankara,,1,,,Fatigue|Physical activity|Sleep quality|Anxiety,,False,
NCT06270342,The Effect of Dual Task On Upper Extremity Functions In Multiple Sclerosis Patients,The Effect of Dual Task On Upper Extremity Functions In Multiple Sclerosis Patients,COMPLETED,2023-06-01,2023-09-01,2023-12-15,2024-02-21,2024-02-21,OBSERVATIONAL,,60.0,ACTUAL,Kutahya Health Sciences University,OTHER,,,Multiple Sclerosis,Dual Task|Dual Task Effect|Multiple Sclerosis|Upper Extremity,Turkey (Türkiye),Kütahya,,1,dual task assessment,OTHER,The Minnesota Manual Dexterity Test|Dual Task Questionnaire|Edinburgh Handedness Questionnaire|Expanded Disability Status Scale|Brief International Cognitive Assessment Battery for Multiple Sclerosis|Beck Depression Scale|Fatigue Impact Scale|Multiple Sclerosis Quality of Life Questionnaire-54,,False,
NCT03512886,The Effect of Multiple-Task Training in Patients With Multiple Sclerosis,The Effect of Multiple-Task Training on Physical and Cognitive Functions in Patients With Multiple Sclerosis,COMPLETED,2018-06-18,2019-07-04,2019-07-25,2019-07-30,2018-05-01,INTERVENTIONAL,NA,39.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Multi-task training|Balance|Mobility|Cognition|Upper extremity function,Turkey (Türkiye),Ankara,,1,Multi-task training|Single task training,OTHER|OTHER,Mobility|Modified Sensory Organization Test|Upper extremity function|cognitive function,Physical Activity|Fatigue Impact|Fatigue Severity|Balance Confidence|Neuropsychological Questionnaire,False,
NCT03434873,Effect of Motor Cortex Versus Sacral Magnetic Stimulation in Multiple Sclerosis Patients With Urinary Tract Dysfunction,Effect of Motor Cortex Magnetic Stimulation Versus Sacral Magnetic Stimulation in Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients,COMPLETED,2014-10,2015-04,2015-04,2018-02-15,2018-02-15,INTERVENTIONAL,NA,40.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis|Lower Urinary Tract Symptoms,"magnetic stimulation, multiple sclerosis",,,,0,magnetic stimulation,OTHER,Change from baseline King's Health QoL questionnaire score after treatment|Change from baseline Post-void residual urine after treatment|Change from baseline Maximum Cystometric Capacity (MCC) after treatment|Change from baseline Maximum Flow Rate (Qmax) after treatment|Change from baseline Detrusor pressure at maximum flow rate (Pdet @Qmax) after treatment,,False,
NCT04540861,Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease,Managed Access Program (MAP) to Provide Access to Siponimod Treatment for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With no Satisfactory Alternative Treatment,AVAILABLE,,,,2024-10-29,2020-09-07,EXPANDED_ACCESS,,,,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,SPMS with active disease|SPMS|Secondary Progressive Multiple Sclerosis|siponimod|Mayzent,,,,0,Siponimod,DRUG,,,False,
NCT01037088,Effects of Vaporized Marijuana on Neuropathic Pain,CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain,COMPLETED,2009-12,2012-11,2012-11,2018-01-31,2009-12-21,INTERVENTIONAL,PHASE1|PHASE2,44.0,ACTUAL,"University of California, Davis",OTHER,Center for Medicinal Cannabis Research|VA Northern California Health Care System,OTHER|FED,Neuropathic Pain|Reflex Sympathetic Dystrophy|Peripheral Neuropathy|Post-herpetic Neuralgia|Spinal Cord Injury|Multiple Sclerosis,cannabis|marijuana|neuropathy|antinociception|mood|cognition|neuropathic pain,United States,Sacramento,California,1,Mild dose cannabis|Low dose cannabis|Cannabis,DRUG|DRUG|DRUG,Participants With 30% or Greater Reduction in Pain Intensity,Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis,True,2013-04-09
NCT00937677,Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study,Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.,COMPLETED,2007-11,2009-12,2010-11,2011-09-07,2009-07-13,OBSERVATIONAL,,85.0,ACTUAL,University at Buffalo,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Tysabri|VWMTR,United States,Buffalo,New York,1,Tysabri,DRUG,To define the effect of Tysabri monotherapy on a voxel-wise basis using magnetization transfer ratio dynamic mapping of the lesions and normal appearing brain tissue in patients with relapsing-remitting multiple sclerosis.,To investigate differences in the capacity for remyelination measured by MTR between patients who do or do not respond to Tysabri monotherapy.,False,
NCT04463316,GROWing Up With Rare GENEtic Syndromes,GROWing Up With Rare GENEtic Syndromes ….When Children With Complex Genetic Syndromes Reach Adult Age,RECRUITING,2018-10-01,2030-01-01,2030-01-01,2023-09-06,2020-07-09,OBSERVATIONAL,,600.0,ESTIMATED,dr. Laura C. G. de Graaff-Herder,OTHER,,,"Prader-Willi Syndrome|PWS-like Syndrome|Silver Russel Syndrome|Congenital Hypopituitarism|Klinefelter (XXY-)Syndrome|Congenital Adrenal Hyperplasia|XXXXY Syndrome|XXYY Syndrome|XXXX Syndrome (Tetra-X Syndrome)|Disorders of Sex Development|Turner Syndrome|46, XY DSD|Tuberous Sclerosis|Neurofibromatosis|Albright Hereditaire Osteodystrofie|Cornelia de Lange Syndrome|Saethre-Chotzen Syndrome|17p- Deletiesyndrome|VCF Syndrome|POLR3A Mutatie|Ohdo Syndrome|Jacobsen Syndrome / 11 q Syndrome|Myrhe Syndrome|CHARGE Syndrome|1q25-32 Deletie|Bardet Biedl Syndrome|Rett Syndrome|22q11 Deletion Syndrome|Allan-Herndon-Dudley Syndrome|Kallmann Syndrome|Rare Bone Disorders|Noonan Syndrome|Williams-Beuren Syndrome",,Netherlands,Rotterdam,South Holland,1,Retrospective file studies,DIAGNOSTIC_TEST,Presence of physical health problems|Laboratory values|Physical and psychological complaints|Medication use,,False,
NCT04212689,Virtual Reality Approach in Multiple Sclerosis,The Effectiveness of Game-Based Virtual Reality Approach in Patients With Multiple Sclerosis,UNKNOWN,2020-01-20,2021-06-01,2021-06-01,2020-09-04,2019-12-27,INTERVENTIONAL,NA,40.0,ESTIMATED,Marmara University,OTHER,,,Rehabilitation|Multiple Sclerosis,Rehabilitation|Physiotherapy and Rehabilitation|Virtual Reality|Multiple Sclerosis|Upper extremity,Turkey (Türkiye),Istanbul,,1,Game Based Virtual Reality Exercises|Conventional Physiotherapy and Rehabilitation,DEVICE|OTHER,Change in range of motion from baseline to week 4|Change in level of pain from baseline to week 4|Change in disability of the upper extremity from baseline to week 4|Change in pain threshold from baseline to week 4|Change in proprioception from baseline to week 4|Change in kinesiophobia from baseline to week 4|Satisfaction of the Treatment|Change in muscle strength from baseline to week 4|Change in disability of the fingers from baseline to week 4|Change in spasticity from baseline to week 4,,False,
NCT02269930,Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers,An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers,COMPLETED,2014-10,2014-12,2014-12,2015-02-02,2014-10-21,INTERVENTIONAL,PHASE1,30.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Evansville,Indiana,1,peginterferon beta-1a|Rebif,DRUG|DRUG,"Cumulative area under the concentration-time curve (AUC), as measured by area under the concentration-time curve from time zero to 336 hours post dose (AUC0-336h)",Maximum observed serum concentration (Cmax) of BIIB017 and Rebif|Number of participants experiencing Adverse Events (AE) and Serious Adverse Events (SAE),False,
NCT02227524,Trekking Poles to Aid Multiple Sclerosis Gait Impairment,Trekking Poles to Aid Multiple Sclerosis Gait Impairment,COMPLETED,2014-04,2019-03-07,2019-03-07,2024-04-11,2014-08-28,INTERVENTIONAL,NA,29.0,ACTUAL,Rowan University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Walking|Gait,United States,Stratford,New Jersey,1,No device|Single-point cane (SPC)|Four-point cane (FPC)|Trekking pole (TP).,OTHER|DEVICE|DEVICE|DEVICE,Composite measures of walking,,False,
NCT06133049,A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants,Zeposia (Ozanimod) Pregnancy Study: A Retrospective Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring,ACTIVE_NOT_RECRUITING,2021-03-16,2031-03-31,2031-08-31,2023-11-15,2023-11-15,OBSERVATIONAL,,2961.0,ESTIMATED,Bristol-Myers Squibb,INDUSTRY,,,Multiple Sclerosis,,United States,Eden Prairie,Minnesota,1,Ozanimod|Select DMTs other than ozanimod|No DMTs,DRUG|DRUG|DRUG,Prevalence of major congenital malformations among infants,Number of spontaneous abortions|Number of preterm births|Number of stillbirths|Number of participants with pre-eclampsia|Number of participants with eclampsia|Number of infants small for gestational age|Number of serious or opportunistic infections in liveborn infants up to one year of age|Number of infant postnatal growth deficiencies|Number of infant developmental deficiencies|Number of neonatal hospitalizations|Number of infant deaths|Number of neonatal deaths|Number of perinatal deaths,False,
NCT05447143,Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis,Examination of the Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis: A Randomized Controlled Single-Blind Trial,COMPLETED,2021-09-30,2021-11-30,2022-06-15,2022-07-20,2022-07-07,INTERVENTIONAL,NA,60.0,ACTUAL,Muğla Sıtkı Koçman University,OTHER,,,Multiple Sclerosis|Exercise Program|Telerehabilitation|Autoimmune Disorder,"MS (Multiple Sclerosis)|Exercise, Physical|Exercise Therapy|Physical Exertion",Turkey (Türkiye),Muğla,Merkez,1,Fatigue Severity Scale|Berg Balance Test|Time up and go- 25 steps walking test|Multiple Sclerosis Quality of Life|Brief International Cognitive Assessment for MS (BICAMS)|Beck Depression and Anxiety Scale,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Timed up and go with 25 steps walking test|Fatigue Severity Scale|Brief International Cognitive Assessment for MS (BICAMS)|Berg Balance Scale,Beck Depression and Anxiety Scale|Mulitple Sclerosis Quality of life- 54,False,
NCT06410326,"Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve","Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve",COMPLETED,2024-04-01,2024-04-01,2024-04-01,2024-05-13,2024-05-13,OBSERVATIONAL,,2600.0,ACTUAL,National MS Center Melsbroek,OTHER,Vrije Universiteit Brussel,OTHER,Multiple Sclerosis,,Belgium,Melsbroek,Vlaams-Brabant,1,,,EDSS|Functional tests|Cognitive tests|The EQ-Visual Analog Score (EQ-VAS),,False,
NCT05185986,Investigating the Home-based RCTs of Pilates Exercises and Cognitive Rehabilitation Exercises for Executive Functions and Anxiety in MS.,Comparison the Home-based Pilates Exercises and the Combination of Home-based Pilates Exercises With Home-based Cognitive Rehabilitation Exercises on Executive Functions and Anxiety in Multiple Sclerosis Patients.,COMPLETED,2021-12-20,2022-02-28,2022-03-07,2022-03-15,2022-01-11,INTERVENTIONAL,NA,51.0,ACTUAL,Arak University of Medical Sciences,OTHER,Pardis Specialized Wellness Institute,OTHER,Multiple Sclerosis,Multiple sclerosis|Executive Functions|Anxiety|Pilates|Cognitive Rehabilitation,Iran,Isfahan,,1,Home-Based Pilates exercise|Home-based Cognitive Rehabilitation|waiting list group,BEHAVIORAL|OTHER|OTHER,change from baseline total number of cWMI|change from baseline total time of cTOL|change from baseline score of BAI,,False,
NCT03801473,Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients,Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients,COMPLETED,2019-02-04,2020-03-01,2020-03-01,2021-05-07,2019-01-11,INTERVENTIONAL,NA,42.0,ACTUAL,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",OTHER,,,Multiple Sclerosis,rehabilitation|robot assisted gait training,Turkey (Türkiye),Istanbul,,1,robot assisted gait therapy|Conventional rehabilitation,OTHER|OTHER,Fatigue Severity Score|Fatigue Severity Score|Fatigue Severity Score|Hospital Anxiety Depression Scale-Depression Subscale (HADS-D)|Hospital Anxiety Depression Scale- Depression Subscale (HADS-D)|Hospital Anxiety Depression Scale- Depression Subscale (HADS-D)|Hospital Anxiety Depression Scale- Anxiety Subscale (HADS-A)|Hospital Anxiety Depression Scale-Anxiety Subscale (HADS-A)|Hospital Anxiety Depression Scale-Anxiety Subscale (HADS-A),Multiple Sclerosis Quality of Life-54 (MSQOL-54)-Physical Health|Multiple Sclerosis Quality of Life-54 (MSQOL-54)-Physical Health|Multiple Sclerosis Quality of Life-54 (MSQOL-54)- Physical Health|Expanded Disability Status Scale (EDSS)|Expanded Disability Status Scale (EDSS)|Expanded Disability Status Scale (EDSS)|Functional Ambulation Classification|Functional Ambulation Classification|Functional Ambulation Classification|Walking Ability|Walking Ability|Walking Ability|Berg Balance Test (BBT)|Berg Balance Test (BBT)|Berg Balance Test (BBT),True,2021-02-02
NCT06209515,Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study,Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study,ACTIVE_NOT_RECRUITING,2022-01-01,2027-12-31,2027-12-31,2024-01-31,2024-01-17,OBSERVATIONAL,,61292.0,ESTIMATED,Kuopio University Hospital,OTHER,,,Neurodegenerative Diseases|Alzheimer Disease|Frontotemporal Dementia|Lewy Body Disease|Vascular Dementia|Parkinson Disease|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Amyotrophic Lateral Sclerosis|Huntington Disease,,Finland,Kuopio,,1,,,"Criminal behaviour: Type of offence, time of offence and other disruptive behaviour|Socio-demographic data|Hospital diagnoses|Medication use|Causes of death",,False,
NCT06293079,The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis,"The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs on Gait, Functional Capacity, EMG Muscle Activation and Fatigue in Patients With Multiple Sclerosis",COMPLETED,2023-08-30,2024-02-12,2024-09-30,2024-12-20,2024-03-05,INTERVENTIONAL,NA,44.0,ACTUAL,Biruni University,OTHER,,,Multiple Sclerosis,telerehabilitation|exercise therapy|MS patients,Turkey (Türkiye),Istanbul,,1,Exercise Program,OTHER,Gait Speed|Functional Capacity,EMG muscle activation for work and rest average|EMG muscle activation for peak torque|Modified Fatigue Impact Scale,False,
NCT02365259,Phototherapy in Persons With Multiple Sclerosis,Effect of UVB Phototherapy on Serum Vitamin D in Persons With Multiple Sclerosis; a Placebo Controlled Study,UNKNOWN,2015-01,2016-02,2016-02,2015-02-18,2015-02-18,INTERVENTIONAL,PHASE1,20.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis,,United States,Urbana,Illinois,1,Phototherapy,DEVICE,Change from Baseline in Serum Vitamin D at 4 and 8 weeks,Change from Baseline in Walking Speed at 4 and 8 weeks|Change from Baseline in Cognitive Function at 4 and 8 weeks|Change from Baseline in Mood State at 4 and 8 weeks,False,
NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,"A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)",COMPLETED,2012-06-08,2015-07-13,2015-07-13,2021-01-05,2012-06-20,INTERVENTIONAL,PHASE4,881.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,United States,Cullman,Alabama,123,Fingolimod|Disease Modifying therapy,DRUG|DRUG,Participant Retention Rate Over 12 Months,Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set|Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)|Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)|Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)|Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score,True,2018-01-12
NCT06611280,Deuterium Metabolic Imaging in People with Multiple Sclerosis,Deuterium Metabolic Imaging in People with Multiple Sclerosis,RECRUITING,2024-10-01,2025-10-01,2026-05-01,2024-10-09,2024-09-24,OBSERVATIONAL,,20.0,ESTIMATED,University of Aarhus,OTHER,,,Multiple Sclerosis (MS) - Relapsing-remitting,,Denmark,Aarhus C,,1,No Interventions,OTHER,lactate to glx ratio,Six-minute walk test|25 meter walk test|Six-spot-step-test|Handgrip strength|5-sit-to-stand|Processing speed - Selective reminding test|Memory function - Symbol digit modality test|Glukose level|Lactat level|Glucose uptake|glucose to glx ratio|Clinical information on multiple sclerosis - Disease modifying treatment|Clinical information on multiple sclerosis - Time since diagnosis|Modified Fatigue Impact Scale|Clinical information on multiple sclerosis - Expanded disability status score|Multiple Sclerosis Impact Scale,False,
NCT06829680,Investigation of the Effects of Pilates Training Combined with Whole Body Vibration on Balance and Mobility in Individuals with Multiple Sclerosis,Investigation of the Effects of Pilates Training Combined with Whole Body Vibration on Balance and Mobility in Individuals with Multiple Sclerosis,COMPLETED,2023-12-28,2024-08-22,2024-09-21,2025-02-17,2025-02-17,INTERVENTIONAL,NA,34.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Balance|Multiple Sclerosis|Mobility|Pilates|Vibration,Turkey (Türkiye),Ankara,,1,Pilates|Whole Body Vibration,OTHER|OTHER,The Activities-specific Balance Confidence Scale|The Five Times Sit-to-Stand Test|The Timed Up and Go Test|The 6-Minute Walk Test|The Limits of Stability Test|The Postural Stability Test|The Modified Sensory Organization Test|The Side-bridge Test|The Biering-Sorensen Test|The Trunk Flexor Test|The Prone Bridge Test|The Sit-ups Test|The Modified Push-ups Test,The Nine-Hole Peg Test|The Fatigue Severity Scale|The Fatigue Impact Scale,False,
NCT01279655,Motor Training and White Matter in Multiple Sclerosis (MS),"The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis.",TERMINATED,2011-01,2011-12,2013-05,2012-09-12,2011-01-19,INTERVENTIONAL,NA,60.0,ACTUAL,Hasselt University,OTHER,KU Leuven|Provinciale Hogeschool Limburg,OTHER|OTHER,Multiple Sclerosis,,Belgium,Diepenbeek,Limburg,1,tDCS|Bimanual Training,DEVICE|BEHAVIORAL,Change in White Matter,Change in Quality of Life|Blood sample,False,
NCT05815108,Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome,Prevalence and Prognostic Value of Epstein Barr Virus (EBV) Infection in Patients With Radiologically Isolated Syndrome (RIS),COMPLETED,2023-03-15,2023-03-17,2023-03-17,2025-05-08,2023-04-18,OBSERVATIONAL,,156.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis|Radiologically Isolated Syndrome|Epstein-Barr Virus,,France,Nice,,1,NO INTERVENTION,OTHER,Comparaison of IgG EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay,Comparaison of IgM VCA EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay|Comparaison of IgG VCA EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay|Prevalence of EBV seropositivity in RIS patients according to their MRI activity|Prevalence of EBV seropositivity in RIS patients according to their clinical and/or MRI activity (EDA)|Assessment correlation between antibodies titers and clinical conversion|Assessment correlation between antibodies titers and clinical and/or MRI activity (EDA),False,
NCT03468868,Comparative Effectiveness Study Telerehab Versus Conventional,Comparative Effectiveness Study of an Exercise Intervention Delivered Via Telerehabilitation and Conventional Mode of Delivery,COMPLETED,2018-07-23,2023-09-12,2023-09-12,2025-01-13,2018-03-19,INTERVENTIONAL,NA,379.0,ACTUAL,"Shepherd Center, Atlanta GA",OTHER,"University of Alabama at Birmingham|University of North Carolina, Chapel Hill|University of Georgia|The Cleveland Clinic|University of Colorado, Denver|Marquette University|Accelerated Cure Project for Multiple Sclerosis|Patient-Centered Outcomes Research Institute|Tanner Foundation for Multiple Sclerosis|Massachusetts General Hospital",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,Multiple sclerosis|Exercise|Physical activity|Telerehabilitation|Comparative effectiveness study|Social cognitive theory|Health behavior change,United States,Birmingham,Alabama,9,Exercise program for people with MS,BEHAVIORAL,Timed 25 Foot Walk Test (T25FWT),Six Minute Walk Test (6MWT)|Multiple Sclerosis Walking Scale (MSWS)-12 Questionnaire|Godin Leisure-Time Physical Activity (LTPA) Questionnaire|Quality of Life in Neurological Disorders (Neuro-QOL) Survey|Multiple Sclerosis Impact Scale (MSIS)-29|Modified Fatigue Impact Scale (MFIS)|Expanded Disability Status Scale (EDSS)|Patient Determined Disease Steps (PDDS),True,2024-12-09
NCT04688710,Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis,Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis,COMPLETED,2021-04-30,2023-06-27,2023-12-31,2024-05-17,2020-12-30,INTERVENTIONAL,NA,333.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society|The University of Queensland,OTHER|OTHER,Multiple Sclerosis|Fatigue,,United States,Seattle,Washington,1,Self-Hypnosis (HYP)|Mindfulness Meditation (MM),BEHAVIORAL|BEHAVIORAL,Change in Fatigue Severity,"Change in Sleep Quality assessed via PROMIS Sleep Disturbance Short Form 4a, version 1.0|Change in Pain Interference|Change in Pain Intensity and Fatigue (current)|Change in Pain Intensity (past week)|Change in Depressive Symptoms|Change in Anxiety|Change in Physical Function|Treatment Preference|Device Use for Treatment|Change in Global Impression of Change|Change in Global Assessment of Treatment Satisfaction|Barriers and Facilitators to Treatment",False,
NCT01357980,Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",COMPLETED,2011-05,2013-03,2013-03,2022-09-27,2011-05-23,INTERVENTIONAL,PHASE2,47.0,ACTUAL,Ipsen,INDUSTRY,,,Detrusor Muscle Hyperactivity,Detrusor Muscle Overactivity,Czechia,Prague,,17,Botulinum toxin type A|Placebo,BIOLOGICAL|DRUG,Daily Incontinence Episode Frequency (IEF),Urodynamics: Maximum Cystometric Capacity|Urodynamics:Maximum Detrusor Pressure|Physician's Global Assessment Score of Treatment Response|Physician's Global Assessment Score of Treatment Response|Physician's Global Assessment Score of Treatment Response|Quality of Life (QoL) Total Summary Score|Pain Visual Analogue Scale (VAS) Score: Before Treatment Injection|Pain Visual Analogue Scale (VAS) Score: During Treatment Injection Procedure,True,2014-09-01
NCT03230903,Physical Telerehabilitation in Multiple Sclerosis,Physical Telerehabilitation in Patients With Multiple Sclerosis With Significant Mobility Impairment,COMPLETED,2016-10,2020-09,2020-09,2021-02-18,2017-07-27,INTERVENTIONAL,NA,78.0,ACTUAL,Columbia University,OTHER,United States Department of Defense,FED,Multiple Sclerosis,Multiple Sclerosis|Telerehabilitation|Physical rehabilitation,United States,New York,New York,1,Home telerehabilitation|Usual Care,OTHER|OTHER,Cardiorespiratory fitness,MS Self-efficacy scale|Exercise adherence|Center for Epidemiologic Studies Depression Scale (CES-D)|Berg Balance Scale (BBS)|2-Minute Walk Test (2MWT),False,
NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,"A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)",COMPLETED,2010-03-31,2016-08-25,2016-08-25,2018-11-09,2010-01-18,INTERVENTIONAL,PHASE2,410.0,ACTUAL,Biogen,INDUSTRY,AbbVie,INDUSTRY,Relapsing-Remitting Multiple Sclerosis,MS|Multiple Sclerosis,Czechia,Brno,,65,BIIB019 (Daclizumab)|trivalent seasonal influenza vaccine,BIOLOGICAL|BIOLOGICAL,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs|Area Under the Concentration-Time Curve Over the Dosing Interval (AUC0-t) After Dose 4 for Daclizumab",Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline|Annual Change in Volume of New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline|Number of Participants With Total Number of New Gadolinium-enhancing Lesions|Annual Change in Number of T1 Hypointense Lesions|Annual Change in Volume of New Gadolinium-Enhancing Lesions|Annual Change in Volume of T1 Hypointense Lesions|Percent Change in Total Brain Volume|Number of Participants With Antibodies to DAC HYP|Annualized Relapse Rate (ARR)|Number of Participants With Sustained Disability Progression for 12 Weeks|Number of Participants With Sustained Disability Progression for 24 Weeks|Observed Maximum Concentration (Cmax) After Dose 4 for Daclizumab|Time to Reach Maximum Concentration (Tmax) for Daclizumab After Dose 4|Observed Minimum Concentration (Cmin) for Daclizumab After Dose 4|Participant-Reported Pain Visual Analog Scale (VAS) Score|Summary of Injection Site Assessment Performed by Clinician,True,2018-11-09
NCT06495138,Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis,Daily Versus Intermittent Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis,RECRUITING,2025-04-21,2026-09,2027-03,2025-07-16,2024-07-10,INTERVENTIONAL,NA,138.0,ESTIMATED,Emory University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Treatment of multiple sclerosis|Incremental Vestibulo-ocular Reflex Adaptation|Dizziness in people with multiple sclerosis,United States,Atlanta,Georgia,1,StableEyes,DEVICE,Composite VOR gain (cVOR gain),Best Corrected Dynamic Visual Acuity (During Head Movements)|Balance Evaluation Systems Test Total Score|Gait Disorientation Test (GDT) Score|Dizziness Handicap Inventory Total Score|Activities-specific Balance Confidence Scale Average Score|Oscillopsia Visual Analog Scale Score|Disequilibrium Visual Analog Scale Score|Multiple Sclerosis Quality of Life - 54 (MSQOL-54) Total Score|Global Perception of Effect Score,False,
NCT02679885,Teriflunomide Male Transmission Study,Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners,COMPLETED,2015-10,2018-08,2018-09,2019-01-02,2016-02-10,OBSERVATIONAL,,20.0,ACTUAL,Griffin Hospital,OTHER,,,Multiple Sclerosis,,United States,Derby,Connecticut,1,,,Serum levels of teriflunomide in males and their female partners,,False,
NCT03216915,Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis,FINGORHYMS - Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis,UNKNOWN,2013-06-01,2019-12-31,2020-12-31,2019-01-08,2017-07-13,OBSERVATIONAL,,100.0,ESTIMATED,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,Multiple Sclerosis,Heart Rhythm|Fingolimod|autonomic nervous system|Effects of Medicinal Substance,Germany,Hamburg,,1,Gilenya®; Novartis Pharmaceuticals Corporation,DRUG,Recurrence of AF,,False,
NCT07115017,"This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.",Investigation of Inflammation Using [18F]FZTA,RECRUITING,2025-08,2028-12,2029-12,2025-08-11,2025-08-11,OBSERVATIONAL,,80.0,ESTIMATED,Washington University School of Medicine,OTHER,,,Multiple Sclerosis,,United States,St Louis,Missouri,1,[18F] FZTA,DRUG,"PET imaging studies of [18F]-FZTA in healthy control participants and participants with Multiple Sclerosis, and measuring the uptake of [18F]-FZTA tracer.",,False,
NCT03711968,Interoception and Sense of Movement in the Patient With Multiple Sclerosis,Interoception and Sense of Movement in the Patient With Multiple Sclerosis: Proposal of a Rehabilitation Protocol,COMPLETED,2018-09-13,2019-01-07,2019-03-20,2019-07-09,2018-10-19,INTERVENTIONAL,NA,63.0,ACTUAL,University of Roma La Sapienza,OTHER,,,Multiple Sclerosis,Interoception|Sense of movement|Posture|body scheme,Italy,Rome,,1,Rehabilitative treatment protocol,OTHER,Change in interoception,Change in posture|Change in balance 1|Change in balance 2|Change in QOL.|Change in body image 1|Change in body image 2,False,
NCT02428218,Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS),"A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis",WITHDRAWN,2016-05,2027-01,2027-01,2016-04-13,2015-04-28,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Relapsing Forms of Multiple Sclerosis,Randomized|Ages 10-17|Pediatrics|Placebo controlled|Relapse-Remitting|Multiple Sclerosis|Safety|Efficacy|BG00012,,,,0,dimethyl fumarate|Placebo,DRUG|DRUG,Time to first multiple sclerosis (MS) relapse,Number of participants that experience adverse events (AEs) and serious adverse events (SAEs)|Number of new or newly enlarging T2 Hyperintense Lesions on Brain magnetic resonance imaging (MRI) scans|Number of gadolinium-enhancing Lesions|Annualized MS relapse rate,False,
NCT03418376,Carnosine Loading and Periodized Training in MS and HC,The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.,COMPLETED,2017-02-01,2017-10-30,2017-12-30,2020-04-20,2018-02-01,INTERVENTIONAL,NA,45.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis|Exercise Therapy|Dietary Supplement,,Belgium,Diepenbeek,Limburg,1,Beta-alanine supplementation|Exercise intervention,DIETARY_SUPPLEMENT|OTHER,VO2max|Serum Lactate|Body Composition|Strength Assessment Core Musculature|Workload,,True,2020-04-20
NCT03934489,Emotion Regulation Skills Training for Individuals With MS and Their Support Partners,Reducing Depression and Anxiety in Individuals With Multiple Sclerosis (MS) and Their Support Partners: An Emotion Regulation Skills Training Intervention,COMPLETED,2020-01-07,2021-03-15,2021-03-15,2021-03-24,2019-05-02,INTERVENTIONAL,NA,40.0,ACTUAL,Johns Hopkins University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Baltimore,Maryland,1,PERSIST|Facilitated Peer Support,BEHAVIORAL|BEHAVIORAL,Change in Depression Subscale score of the Hospital Anxiety and Depression Scale (HADS-D)|Change in Anxiety Subscale score of the Hospital Anxiety and Depression Scale (HADS-A),Change in Difficulties in Emotion Regulation Scale (DERS-16) score|Change in Problem Solving Inventory (PSI) score|Change in RAND 36-Item Short Form Health Survey (SF-36) score|Change in Zarit Burden Interview (ZBI) score,False,
NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis,COMPLETED,2013-10,2015-01,2015-01,2015-03-13,2013-05-29,INTERVENTIONAL,PHASE3,70.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,Belgium,Brussels,,10,teriflunomide HMR1726|cholestyramine|charcoal,DRUG|DRUG|DRUG,Change from baseline in Lymphocyte subset parameters as measured by flow cytometry,Change from baseline in biased T cell clonal repertoire based T cell receptor (TCR) spectratyping|Change from baseline in serum cytokine as measured by multicytokine array tool|Change from baseline in Mitogen/TCR-specific T cell proliferation as measured by flow cytometry,False,
NCT04498286,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients: a Large Study in the Amsterdam MS Cohort,COMPLETED,2020-08-08,2021-10-31,2021-10-31,2023-01-04,2020-08-04,OBSERVATIONAL,,546.0,ACTUAL,Zoé van Kempen,OTHER,,,Multiple Sclerosis,,Netherlands,Amsterdam,,1,Testing of SARS-CoV-2 antibodies,DIAGNOSTIC_TEST,The correlation of COVID-19 disease course with MS immunomodulatory treatment,,False,
NCT00674141,Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment,Nasal Administration of Dexamethasone for MS Treatment,WITHDRAWN,2008-07,2008-12,2009-01,2010-06-03,2008-05-07,INTERVENTIONAL,PHASE1,10.0,ESTIMATED,Hadassah Medical Organization,OTHER,,,MS Patient With Relpasing Remitting Attacks,"Multiple Sclerosis, relapsing remitting, Dexamethasone",Israel,Jerusalem,,1,Dexamethasone soduim phosphate,DRUG,reduction in the EDSS functional system score,,False,
NCT01077466,Natalizumab Treatment of Progressive Multiple Sclerosis,Natalizumab Treatment of Progressive Multiple Sclerosis,COMPLETED,2010-03,2012-01,2012-01,2012-02-17,2010-03-01,INTERVENTIONAL,PHASE2,24.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,"Copenhagen University Hospital, Hvidovre|Biogen|University of Copenhagen|Signifikans ApS",OTHER|INDUSTRY|OTHER|OTHER,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Natalizumab|Treatment|Safety|Efficacy|Cerebrospinal fluid|Osteopontin,Denmark,Copenhagen,,1,Natalizumab,DRUG,Cerebrospinal fluid (CSF) osteopontin,Expanded disability status scale (EDSS)|Timed 25-foot Walk (T25FW)|Multiple Sclerosis Impairment Score (MSIS)|Multiple Sclerosis Functional Composite|Short Form 36 Health Survey (SF36)|CSF Neurofilament Heavy Chain|CSF Myelin Basic Protein|Atrophy|Magnetization transfer ratio (MTR)|Diffusion transfer imaging (DTI)|CSF cell count|Change in IgG-index|CSF nitrogen oxide metabolites|CSF-serum albumine concentration quotient|CSF CXCL13|Matrix metalloproteinase-9 (MMP-9)|New Gadolinium-enhancing lesions (GdEL)|Volume of lesions on T2-weighted MRI images|Number of new or enlarging lesions on T2-weighted MRI images,False,
NCT02960984,Neurorehabilitation on Upper Limb and on Fatigue in Multiple Sclerosis,Effects of Neurorehabilitation on Upper Limb Performance and on Fatigue in People With Multiple Sclerosis,UNKNOWN,2016-11,2017-12,,2016-11-11,2016-11-10,INTERVENTIONAL,NA,20.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,University of Genova,OTHER,Multiple Sclerosis,,Italy,Milan,,1,Task Oriented rehabilitation and aerobic training,OTHER,Change from Baseline in 9-hole peg test at 2 and 4 months|Change from Baseline in Heart Rate at 2 and 4 months,,False,
NCT06386133,Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care,"Chronic Fatigue in Multiple Sclerosis: Validating Clinical Performance, Economic, and Organizational Benefits of MSCopilot Boost Compared to Standard Care",NOT_YET_RECRUITING,2024-10-01,2025-07-01,2026-04-01,2024-04-26,2024-04-26,INTERVENTIONAL,NA,208.0,ESTIMATED,Ad scientiam,OTHER,Assistance Publique - Hôpitaux de Paris,OTHER,"Multiple Sclerosis|Fatigue Syndrome, Chronic",Mobile application|Digital monitoring|Fatigue management|Multiple sclerosis,,,,0,MS Boost|Standard of care,DEVICE|OTHER,To demonstrate that MSCopilot Boost is superior to standard practice in reducing the impact of fatigue on Patients with Multiple Sclerosis,To evaluate the impact of fatigue in both groups.|To compare the effect of MSCopilot Boost in reducing fatigue impact compared to standard practice (Short term and Medium term)|To compare the fatigue impact between the two groups.|To compare the effect of MSCopilot Boost in reducing perceived fatigue compared to standard practice.|Correlation of MSCopilot Boost functional test performed autonomously at home with its standard counterpart performed under supervised conditions at the hospital.|Correlation of MSCopilot Boost functional test performed autonomously at home with its standard counterparts performed under supervised conditions at the hospital.|Correlation of MSCopilot Boost functional test performed autonomously at home with its standard counterpart performed under supervised conditions at the hospital.|Correlation of MSCopilot Boost functional test performed autonomously at home with its standard counterpart performed under supervised conditions at the hospital.|Correlation of MSCopilot Boost functional test performed autonomously at home with its standard counterpart performed under supervised conditions at the hospital.|Correlation of the answers of MSCopilot Boost questionnaire performed autonomously with its standard counterpart performed under supervised conditions at the hospital|Correlation of the answers of MSCopilot Boost questionnaire performed autonomously with its standard counterpart performed under supervised conditions at the hospital|Correlation of the answers of MSCopilot Boost questionnaire performed autonomously with its standard counterpart performed under supervised conditions at the hospital|Correlation of the answers of MSCopilot Boost questionnaire performed autonomously with its standard counterpart performed under supervised conditions at the hospital|Correlation of the answers of MSCopilot Boost questionnaire performed autonomously with its standard counterpart performed under supervised conditions at the hospital|Correlation of the reproductibility of MSCopilot Boost functional test from the hospital to home.|Correlation of the reproductibility of MSCopilot Boost functional test from the hospital to home.|Correlation of the reproductibility of MSCopilot Boost functional test from the hospital to home.|Correlation of the reproductibility of MSCopilot Boost functional test from the hospital to home.|To evaluate the test-retest reliability of MSCopilot Boost functional test performed at home.|To evaluate the test-retest reliability of MSCopilot Boost functional test performed at home.|To evaluate the test-retest reliability of MSCopilot Boost functional test performed at home.|To evaluate the test-retest reliability of MSCopilot Boost functional tests performed at home.|To evaluate the test-retest reliability of MSCopilot Boost functional tests performed at home.|To assess the number of adverse events of using MSCopilot Boost.|To compare the effect of MSCopilot Boost on walking compared to standard practice: -Assessed by the functional standard test performed at the hospital -Assessed at home|To compare the proportion of patients whose symptoms improved in both groups on Fatigue impact.|To compare the proportion of patients whose symptoms improved in both groups on anxiety and depression.|To compare the proportion of patients whose symptoms improved in both groups on Depression.|To compare the proportion of patients whose symptoms improved in both groups on Fatigue.|To compare the proportion of patients whose symptoms improved in both groups on Walking.|To compare the proportion of patients whose symptoms improved in both groups on Dexterity.|To compare the proportion of patients whose symptoms improved in both groups on Cognition.|To compare the proportion of patients whose symptoms improved in both groups on the Low-contrast Vision.|To compare the effect of MSCopilot Boost on quality of life compared to standard practice.|To compare the effect of MSCopilot Boost on the mean overall physical activity compared to standard practice.|To evaluate the satisfaction and user experience of both patients and healthcare professionals regarding MSCopilot Boost.|To assess the clinical benefit of MSCopilot Boost reported by patients and healthcare professionals.|To assess the organizational impact of MSCopilot Boost as reported by healthcare professionals.|To assess user compliance with MSCopilot Boost throughout the follow-up period.,False,
NCT01768910,Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction,The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques,COMPLETED,2011-12,2015-07-17,2018-12,2019-03-18,2013-01-16,INTERVENTIONAL,NA,91.0,ACTUAL,University of Zurich,OTHER,Swiss National Science Foundation|Balgrist University Hospital,OTHER|OTHER,Neurogenic Lower Urinary Tract Dysfunction|Multiple Sclerosis|Overactive Bladder|Spinal Cord Injury,lower urinary tract|bladder|supraspinal control|neuroimaging|functional magnetic resonance imaging|diffusion tensor imaging|functional connectivity|neurogenic lower urinary tract dysfunction|overactive bladder|multiple sclerosis|spinal cord injury,Switzerland,Zurich,,2,fMRI|bladder filling|bladder cooling|additional post-treatment fMRI scan,OTHER|OTHER|OTHER|OTHER,Bold signal|Structural and functional connectivity,Side effects,False,
NCT06460324,A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab,Assessment of COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab in the United States: A Multicenter Medical Record Review Study,COMPLETED,2022-05-20,2023-07-03,2023-07-03,2024-06-14,2024-06-14,OBSERVATIONAL,,38.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Number of Ofatumumab-treated Patients with an Immune Response to FDA-authorized COVID-19 Vaccination by Vaccination Status|Number of Ofatumumab-treated Patients with an Immune Response to FDA-authorized COVID-19 Vaccination by Prior Disease Modifying Therapy (DMT),Mean Age at Index Date by Vaccination Status|Mean Age at Index Date by Prior Disease Modifying Therapy (DMT)|Gender at Index Date by Vaccination Status|Gender at Index Date by Prior DMT|Race at Index Date by Vaccination Status|Race at Index Date by Prior DMT|Number of Patients per United States Region at Index Date by Vaccination Status|Number of Patients per United States Region at Index Date by Prior DMT|Time since MS Diagnosis at Index Date by Vaccination Status|Time since MS Diagnosis at Index Date by Prior DMT|Number of Patients with Relapsing-remitting Multiple Sclerosis (MS) at Index Date by Vaccination Status|Number of Patients with Relapsing-remitting MS at Index Date by Prior DMT|Number of Patients with Secondary Progressive MS at Index Date by Vaccination Status|Number of Patients with Secondary Progressive MS at Index Date by Prior DMT|Number of Patients with Primary Progressive MS at Index Date by Vaccination Status|Number of Patients with Primary Progressive MS at Index Date by Prior DMT|Mean Number of Comorbidities Within 12 Months Preceding Index Date by Vaccination Status|Mean Number of Comorbidities Within 12 Months Preceding Index Date by Prior DMT|Number of Patients by Most Common Comorbidities (greater than 15%) Within 12 Months Preceding Index Date by Vaccination Status|Number of Patients by Most Common Comorbidities (greater than 15%) Within 12 Months Preceding Index Date by Prior DMT|Number of Patients Treated with DMTs any Time Prior to Ofatumumab Initiation by Vaccination Status|Number of Patients Treated with DMTs any Time Prior to Ofatumumab Initiation Categorized by Prior DMT,False,
NCT03336424,Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.,Prospective Randomized Controlled Trial Comparing the Non-invasive vs the Invasive Investigations in Multiple Sclerosis Patients With Urinary Disorders.,UNKNOWN,2017-10-01,2019-08,2019-10,2018-09-06,2017-11-08,INTERVENTIONAL,NA,60.0,ESTIMATED,Saint-Joseph University,OTHER,,,"Multiple Sclerosis|Urinary Bladder, Neurogenic|Urodynamics","MS|Multiple sclerosis|urinary Bladder, Neurogenic|Urodynamics|Randomized controlled trial",Lebanon,Beirut,,1,Non-invasive investigations|Invasive investigations,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,urinary symptoms|urinary quality of life,,False,
NCT05510817,Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS,"Multiparametric Clinical, Radiological, Neuropsychological, and Neurophysiological Assessment to Investigate Prognostic Factors for Disease Evolution and Treatment Response in MS: a Prospective Study.",RECRUITING,2022-06-06,2026-06-06,2026-06-06,2023-12-05,2022-08-22,INTERVENTIONAL,NA,50.0,ESTIMATED,University Hospital of Mont-Godinne,OTHER,Saint-Luc University Hospital,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",MRI|evoked potentials|cognitive function|PROMs,Belgium,Yvoir,Namur,1,Multiparametric assessment,OTHER,Predictors of disease evolution|evaluation of evolutionary patterns of cognitive status (impaired vs non impaired)/changes from baseline|baseline predictors of future cognitive impairment,"alteration in strategic white matter tracts at the early stages of RRMS, in patients with and without cognitive impairment|predictive role of mEPS in predicting future disability",False,
NCT03878810,Exergaming in Persons With Multiple Sclerosis With Restless Legs Syndrome,Effects of Video Game-based Physical Activity Training in Persons With Multiple Sclerosis With Restless Legs Syndrome,COMPLETED,2019-03-29,2021-09-15,2021-12-15,2022-06-01,2019-03-18,INTERVENTIONAL,NA,65.0,ACTUAL,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Exergaming,BEHAVIORAL,International Restless Legs Syndrome Study Group rating scale for restless legs syndrome,Timed 25-Foot Walk|12-Item Multiple sclerosis walking scale|Modified Fatigue Impact Scale|Timed Up and Go test|6-Minute Walk Test|Epworth Sleepiness Scale|Godin Leisure Time Exercise Questionnaire|Hospital Anxiety And Depression Scale - Anxiety|Hospital Anxiety And Depression Scale - Depression|Multiple Sclerosis International Quality of Life questionnaire|Multiple Sclerosis-Related Symptom Checklist,False,
NCT01910259,MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial,"A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.",COMPLETED,2014-12-18,2018-06-14,2018-07-04,2020-03-26,2013-07-29,INTERVENTIONAL,PHASE2,445.0,ACTUAL,"University College, London",OTHER,"Medical Research Council|National Institute for Health Research, United Kingdom|National Multiple Sclerosis Society|University of Edinburgh|Queen Mary University of London|Keele University|University of Sheffield|University of Leeds|University of Warwick",OTHER_GOV|OTHER_GOV|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Secondary Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis|Neuroprotective|Repurposed drugs|Brain atrophy|Percentage Brain Volume Change|Magnetic Resonance Imaging|Optical Coherence Tomography|Cerebrospinal fluid|Amiloride|Riluzole|Double blind|Placebo|Fluoxetine,United Kingdom,Edinburgh,,13,Amiloride|Riluzole|Fluoxetine|Placebo,DRUG|DRUG|DRUG|DRUG,MRI-derived Percentage Brain Volume Change (PBVC).,Multi-arm trial strategy assessment|Count of new and enlarging T2 lesions|Pseudo-atrophy|Clinical measure of neuroprotection|Health economics,False,
NCT05177952,Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis,The Chronic Effects of Low-Load Blood Flow Restriction or Standard of Care Resistance Exercise on Muscle and Neuromuscular Function in Patients With Multiple Sclerosis,COMPLETED,2022-01-01,2024-01-31,2024-05-31,2024-06-11,2022-01-05,INTERVENTIONAL,NA,20.0,ACTUAL,University of Central Florida,OTHER,AdventHealth,OTHER,Training Study|Multiple Sclerosis|Blood Flow Restriction,Blood Flow Restriction|Multiple Sclerosis|Exercise,United States,Orlando,Florida,1,Blood Flow Restriction|Standard of Care,OTHER|OTHER,Change in Functional Outcomes- 10meter|Change in Functional Outcomes- 6min walk|Change in Functional Outcomes- CST|Change in Functional Outcomes- 30CST|Change in Functional Outcomes- MFIS,Changes in Strength,False,
NCT00040482,High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis,"Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis",COMPLETED,1999-04,,2005-08,2020-01-18,2002-06-28,INTERVENTIONAL,PHASE2,10.0,,Baylor College of Medicine,OTHER,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",OTHER|OTHER,Multiple Sclerosis,,United States,Houston,Texas,1,Cyclophosphamide|ATG|MESNA|Radiation therapy,DRUG|DRUG|DRUG|PROCEDURE,,,False,
NCT04599023,Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System,Assessing the Feasibility of the Multiple Sclerosis Performance Test (MSPT) Device in Routine Clinical Practice in the Swiss Healthcare System,TERMINATED,2020-10-16,2022-08-31,2022-08-31,2023-03-10,2020-10-22,OBSERVATIONAL,,182.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,Biogen,INDUSTRY,Multiple Sclerosis|Clinically Isolated Syndrome,MS|CIS|MSFC|Contrast Sensitivity Test|Walking Speed Test|25 foot walk|Manual Dexterity Test|Processing Speed Test|self-administrating|medical device,Switzerland,Bern,,1,MSPT,DEVICE,Percentage of patients who complete all modules|Percentage of patients who complete each module|Percentage of patients who skip modules|Time to complete the MSPT|Time to complete the individual MSPT modules|Frequency of reasons for not completing test modules|Frequency distribution of demographic characteristics of patients who fail to complete specific MSPT modules,Net promoter score based on satisfaction questionnaires|Net promoter score based on patient questionnaire|Net promoter score based on treating physician and administrator questionnaire for improved monitoring of MS disease progression|Net promoter score based on satisfaction questionnaires conducted with treating physicians and the MSPT administrator to probe about experience|Change in MSPT outcomes in patient subgroups of interest at baseline and at each visit over time,False,
NCT03735823,IL-11 in the Development of Multiple Sclerosis,The Role of IL-II in the Development of Autoimmune Response in Multiple Sclerosis,UNKNOWN,2018-06-01,2023-05-31,2023-05-31,2022-06-06,2018-11-08,OBSERVATIONAL,,96.0,ESTIMATED,Thomas Jefferson University,OTHER,,,Multiple Sclerosis,IL-11 T cell migration,United States,Philadelphia,Pennsylvania,1,"No intervention, just collect blood samples and CSF samples",OTHER,Adhesion marker expression of IL-11 producing CD4 T cells in the CNS and peripheral|Cytokine receptor expression of IL-11 producing CD4 T cells in the CNS and peripheral|Chemokine receptor expression of IL-11 producing CD4 T cells in the CNS and peripheral|transcription factor expression of IL-11 producing CD4 T cells in the CNS and peripheral,,False,
NCT03931278,Sonification Embodied Associations,"Investigating Auditory Sonification (Melodic and Single Tones) and Visual Real-time Feedback as a Tool for Embodied Associations, and Its Effects on Learning and Balance in Persons With Multiple Sclerosis",COMPLETED,2018-12-18,2020-01-24,2020-01-24,2020-05-27,2019-04-30,INTERVENTIONAL,NA,62.0,ACTUAL,Hasselt University,OTHER,University Ghent|Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,OTHER|OTHER|OTHER,Multiple Sclerosis,,Belgium,Ghent,,3,learning and recall of a sequence of body movements,OTHER,accuracy|precision,Inter Step intervals|Inter Stride intervals|step duration on the tile,False,
NCT03552185,Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies,Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies,COMPLETED,2018-01-01,2018-06-15,2018-06-15,2018-08-13,2018-06-11,OBSERVATIONAL,,100.0,ACTUAL,Kasr El Aini Hospital,OTHER,,,Multiple Sclerosis,Neurogenic Dysphagia|Multiple Sclerosis,Egypt,Cairo,,1,,,screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires|screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires|Assessment of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires,,False,
NCT02117050,RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate,"RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)",TERMINATED,2014-06,2015-04,2015-04,2017-01-23,2014-04-17,INTERVENTIONAL,PHASE4,1.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Rebif ®|Tecfidera ™|treatment change,United States,Boston,Massachusetts,1,Rebif®,DRUG,Change From Baseline in Treatment Satisfaction Score Determined by the Global Satisfaction Sub-scale of the Treatment Satisfaction Questionnaire for Medication (TSQM [Version II]) at Week 24,"Change From Baseline in Patient-Determined Disease Steps Questionnaire (PDDS) Score at Week 24|Change From Baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) Score at Week 24|Change From Baseline in TSQM (Version II) - Total Score at Week 12 and Week 24|Change From Baseline in TSQM (Version II) - Medication Effectiveness, Side Effects, and Convenience Subscale Scores at Week 24|Change From Baseline in TSQM (Version II) - Global Satisfaction, Medication Effectiveness, Side Effects, and Convenience Subscale Scores at Week 12|Change From Baseline in Work Productivity and Activity Impairment- General Health (WPAI-GH) Questionnaire Score at Week 24|Change From Baseline in Number of Combined Unique Active (CUA) Lesions, New Time or Enlarging Constant 2 (T2) Lesions, and New Gadolinium Enhanced (Gd+) Time Constant 1 (T1) Lesions at Week 24|Annualized Relapse Rate (ARR)",True,2017-01-23
NCT01758224,Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation,Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis,COMPLETED,2012-09,2015-09,2015-09,2016-08-04,2013-01-01,INTERVENTIONAL,NA,4.0,ACTUAL,The Cleveland Clinic,OTHER,United States Department of Defense,FED,Multiple Sclerosis,Multiple Sclerosis|Functional Magnetic Stimulation|Pulmonary Function,United States,Cleveland,Ohio,1,Functional Magnetic Stimulation|Resistive Expiratory Muscle Training,OTHER|OTHER,Pulmonary Function Testing (PFT),,False,
NCT02201108,"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension",COMPLETED,2014-07-16,2019-10-25,2024-07-29,2025-02-06,2014-07-25,INTERVENTIONAL,PHASE3,166.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Multiple Sclerosis,,United States,Cullman,Alabama,57,Teriflunomide|Placebo,DRUG|DRUG,Time to First Confirmed Clinical Relapse,"Probability of Participants Who Were Clinical Relapse Free at Weeks 24, 48, 72, 96, 120, 144, 168 and 192|Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan|Brain Magnetic Resonance Imaging Assessment: Number of T1 Gadolinium (Gd)-Enhancing T1 Lesions Per MRI Scan|Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T2 Lesions at Weeks 24, 36, 48, 72, 96, 144 and 192|Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T1 Hypointense Lesions|Brain Magnetic Resonance Imaging Assessment: Number of New T1 Hypointense Lesions Per MRI Scan|Brain Magnetic Resonance Imaging Assessment: Percentage of Participants Free of New or Enlarged MRI T2-Lesions|Brain Magnetic Resonance Imaging Assessment: Percent Change From Baseline in Brain Volume at Weeks 24, 36, 48, 72, 96, 144 and 192|Cognitive Assessment: Change From Baseline in Total Number of Correct Substitutions Measured by Symbol Digit Modalities Test (SDMT) at Weeks 24, 48, 72, 96, 120, 144, 168 and 192|Cognitive Assessment: Change From Baseline in Number of Completed Items Measured by Symbol Digit Modalities Test at Weeks 24, 48, 72, 96, 120, 144, 168 and 192|Cognitive Assessment: Change From Baseline in Brief Visuospatial Memory Test-Revised (BVMT-R) Scores at Weeks 96 and 192|Cognitive Assessment: Change From Baseline in Trail Making Test- Part A (TMT-A) Test Scores (in Seconds) at Week 96 and 192|Cognitive Assessment: Change From Baseline in Trail Making Test B (TMT-B) Test Scores (in Seconds) at Weeks 96 and 192|Cognitive Assessment: Change From Baseline in Beery Visual-motor Integration (BVMI) Scores at Weeks 96 and 192|Cognitive Assessment: Change From Baseline in Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary Total Raw Scores at Weeks 96 and 192|Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Letter Fluency Total Correct Raw Score at Weeks 96 and 192|Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System Category Fluency Total Correct Raw Score at Weeks 96 and 192|Cognitive Assessment - Selective Reminding Test (SRT): Change From Baseline in Total Number of Words on Delayed Recall at Weeks 96 and 192|DB: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide|OL: Time to First Confirmed Clinical Relapse|OL: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide",True,2020-11-30
NCT06416176,The Effect of a Mindfulness-Based Stress Reduction Program in Patients With Multiple Sclerosis,"The Effect of a Mindfulness-Based Stress Reduction Program On Fatigue, Self-Efficacy And Stress in Patients With Multiple Sclerosis: A Randomized Controlled Trial",COMPLETED,2020-07-01,2020-10-01,2020-11-15,2024-05-16,2024-05-16,INTERVENTIONAL,NA,30.0,ACTUAL,Halic University,OTHER,,,Multiple Sclerosis|Mindfulness|Upper Motor Neuron Lesion,Mindfulness|Multiple sclerosis|Fatigue|Self-efficacy,Turkey (Türkiye),Istanbul,Eyüpsultan,1,Mindfulness-Based Stress Reduction (MBSR) Program,OTHER,Fatigue Impact Scale|Self-Efficacy Scale|Perceived Stress Scale,,False,
NCT04368403,A Study of KHK4827 in Patients With Systemic Sclerosis,"A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic Sclerosis",COMPLETED,2017-10-06,2019-01-31,2025-03-31,2025-07-11,2020-04-29,INTERVENTIONAL,PHASE1,8.0,ACTUAL,"Kyowa Kirin Co., Ltd.",INDUSTRY,,,Systemic Sclerosis,systemic sclerosis|brodalumab|KHK4827,Japan,Bunkyo-ku,Tokyo,1,KHK4827,DRUG,serum KHK4827 concentration,Change in modified Rodnan skin score (mRSS) from baseline,False,
NCT03540485,Safety and Efficacy of Melatonin in Patients with Multiple Progressive Primary Sclerosis,"Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients with Multiple Progressive Primary Sclerosis",RECRUITING,2019-11-29,2026-03,2026-12,2024-11-15,2018-05-30,INTERVENTIONAL,PHASE1|PHASE2,50.0,ESTIMATED,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,OTHER,,,"Sclerosis, Multiple|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Autoimmune Diseases",,Spain,Seville,Seville,3,Melatonin|Placebo,DRUG|OTHER,Rates of neurological impairment|Rates of disability,Number of participants with treatment-related adverse events|Cerebral atrophy|Fatigue|Quality of life using the Multiple Sclerosis International Quality of Life scale|Sleep disorders|Spasticity,False,
NCT01838174,A Trial of Neuroprotection With ACTH in Acute Optic Neuritis,A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis,TERMINATED,2013-05,2022-01-13,2022-01-13,2023-04-27,2013-04-23,INTERVENTIONAL,PHASE4,37.0,ACTUAL,"University of Colorado, Denver",OTHER,Mallinckrodt|University of Pennsylvania,INDUSTRY|OTHER,Multiple Sclerosis,Optic Neuritis,United States,Aurora,Colorado,2,ACTHAR Gel (ACTH)|IV methylprednisolone (steroids),DRUG|DRUG,Retinal Nerve Fiber Layer (RNFL) thickness,Frequency of RNFL swelling,False,
NCT01541618,A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis,A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis,COMPLETED,2012-01,2012-07,2012-07,2020-09-02,2012-03-01,OBSERVATIONAL,,15.0,ACTUAL,"MSDx, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,MS|RRMS|RR Multiple Sclerosis,United States,Tucson,Arizona,1,MSDX Complex-1 Biomarker test,OTHER,Change in MSDX Complex-1 between baseline and 6-month visit,Gadolinium MRI and MSDX Complex-1 level,False,
NCT04838990,TELEMS: Feasibility of Remote Patient Visits in MS,TELE MS RCT: A Randomized Controlled Trial to Evaluate Feasibility of Remote Patient Visits in People With Multiple Sclerosis,COMPLETED,2020-11-01,2021-09-01,2021-10-01,2022-01-21,2021-04-09,INTERVENTIONAL,NA,45.0,ACTUAL,Medical University of Vienna,OTHER,,,Multiple Sclerosis,multiple sclerosis|remote visits|telemedicine|remote patient monitoring|remote monitoring,Austria,Vienna,,1,"EDSS|Discussion of symptoms, Patient reported outcome (MSIS)",OTHER|OTHER,TMPQ,PPSM,False,
NCT05982925,Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders,Longitudinal Investigation of Cortical Demyelination and Meningeal Inflammation in Multiple Sclerosis and Related Disorders,ENROLLING_BY_INVITATION,2022-05-06,2028-07-31,2034-07-31,2025-06-18,2023-08-09,OBSERVATIONAL,,170.0,ESTIMATED,Icahn School of Medicine at Mount Sinai,OTHER,,,"Multiple Sclerosis|Neuromyelitis Optica|Demyelinating Autoimmune Diseases, CNS",,United States,New York,New York,1,,,Cortical Lesion Number,,False,
NCT05059327,"Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC","A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex",COMPLETED,2022-03-03,2025-02-06,2025-04-28,2025-06-04,2021-09-28,INTERVENTIONAL,PHASE2,61.0,ACTUAL,Noema Pharma AG,INDUSTRY,,,Tuberous Sclerosis Complex,Basimglurant|TSC|Seizures|NOE-101,United States,Los Angeles,California,27,Basimglurant with crossover to Placebo|Placebo with crossover to Basimglurant,DRUG|DRUG,Mean percentage in monthly seizure frequency during the maintenance dosing in Period 2 (Weeks 13 to 16) and Period 4 (Weeks 27-30).,"Number of patients considered treatment responders.|Longest seizure free interval (i.e., seizure free days).|Change in the severity of symptoms of TSC as measured by Caregiver Global Impression of Change (CGIC) score during maintenance dosing in Period 2 (Weeks 13 to 16) and Period 4 (Weeks 27-30) compared to Baseline.|Change in the Sheehan Disability Scale during maintenance dosing in Period 2 (Weeks 13 to 16) and Period 4 (Weeks 27-30) compared to baseline.|Safety of the study drug in children, adolescents and young adults with seizures associated with TSC.",False,
NCT03805061,Effects of Aerobic and Isokinetic Exercise in Multiple Sclerosis,Evaluation of the Effects of Aerobic and Isokinetic Exercise Program on Muscle Power Cardiovascular System and Life Quality in Multiple Sclerosis Patients,COMPLETED,2008-04-30,2008-10-30,2008-11-01,2019-01-15,2019-01-15,INTERVENTIONAL,NA,40.0,ACTUAL,Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization,OTHER,,,Multiple Sclerosis,Multiple sclerosis|aerobic|isokinetic|exercise,,,,0,'aerobic exercise'|'isokinetic exercise',OTHER|DEVICE,Muscle strenght outcomes|Quality of life outcomes|The effort capacity outcomes,,False,
NCT01199861,Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS),"A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)",COMPLETED,2010-08,2011-05,2011-05,2012-06-19,2010-09-13,INTERVENTIONAL,PHASE3,138.0,ACTUAL,Novartis,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing multiple sclerosis|MS|Immune response,Belgium,Aalst,,25,Fingolimod|Placebo|Seasonal influenza vaccine|Tetanus toxoid vaccine,DRUG|DRUG|BIOLOGICAL|BIOLOGICAL,Immune Response 3 Weeks After Seasonal Influenza Vaccination,Immune Response 6 Weeks After Seasonal Influenza Vaccination|Immune Response 3 Weeks After Tetanus Toxoid Booster|Immune Response 6 Weeks After Tetanus Toxoid Booster|Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 3 Weeks After Vaccination|Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 6 Weeks After Vaccination|Number of Participants With Adverse Events (AEs),True,2012-06-19
NCT04494256,"A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation","A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the ATXN2 Gene",TERMINATED,2020-09-28,2024-08-13,2024-08-13,2024-09-19,2020-07-31,INTERVENTIONAL,PHASE1|PHASE2,99.0,ACTUAL,Biogen,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,Phoenix,Arizona,17,BIIB105|Placebo,DRUG|DRUG,Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants with AEs and SAEs,"Part 1: Serum Concentrations of BIIB105|Part 1: CSF Concentrations of BIIB105|Part 1: Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUCinf)|Part 1: Area Under the Serum Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast)|Part 1: Maximum Observed Serum Concentration (Cmax)|Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)|Part 1: Elimination Half-Life (t1/2) in Serum|Part 1: Change From Baseline in Plasma Levels of Neurofilament Light Chain (NfL)|Integrated Parts 1 and 2: CSF Trough PK Concentration of BIIB105|Integrated Parts 1 and 2: Serum PK Concentration of BIIB105|Integrated Parts 1 and 2: Change From Baseline in Plasma Levels of NfL|Integrated Parts 1 and 2: Change From Baseline in Slow Vital Capacity (SVC)|Integrated Parts 1 and 2: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score|Integrated Parts 1 and 2: Change From Baseline in Muscle Strength, as Measured by Handheld Dynamometry (HHD)|Integrated Parts 1 and 2: Time to Death or Permanent Ventilation|Integrated Parts 1 and 2: Time to Death|Integrated Parts 1 and 2: Time to Death, Incorporating Post-Study Withdrawal or Study Completion Vital Status Data",False,
NCT02823951,"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®","Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)",COMPLETED,2016-02,2017-04,2018-02,2018-03-01,2016-07-06,OBSERVATIONAL,,479.0,ACTUAL,IMS HEALTH GmbH & Co. OHG,INDUSTRY,EMD Serono,INDUSTRY,Relapsing-remitting Multiple Sclerosis,,United States,Birmingham,Alabama,23,Rebif|Tecfidera,DRUG|DRUG,NEDA-2,"Clinical differences between the two treatment groups|Neurological differences between two treatment groups|Proportion of individuals within each treatment group who discontinued, stratified by reason",False,
NCT05344040,Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial,Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial,COMPLETED,2022-05-25,2022-12-01,2022-12-01,2022-12-05,2022-04-25,INTERVENTIONAL,EARLY_PHASE1,25.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis,Exercise|Physical Activity|Cognition|Walking|Stretching,United States,West Orange,New Jersey,1,Remotely Delivered and Supported Aerobic Walking Exercise Training|Remotely Delivered and Supported Stretching and Toning Exercise Training,BEHAVIORAL|BEHAVIORAL,Change in Cognitive Processing Speed,Change in Verbal Learning and Memory,False,
NCT02474940,MS Symptom Management Study,Enhancing the Benefits of Pain and Fatigue Treatment in MS,COMPLETED,2015-06,2016-11,2016-11,2017-12-26,2015-06-18,INTERVENTIONAL,NA,37.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Chronic Pain|Fatigue,"Multiple Sclerosis|Chronic Pain|Chronic Fatigue|Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Central Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Demyelinating Diseases",United States,Seattle,Washington,1,Intervention #1|Intervention #2|Intervention #3,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in average pain intensity pre-treatment to post-treatment|Change in average fatigue severity pre-treatment to post-treatment,,False,
NCT05277740,Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis,Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis,RECRUITING,2022-09-01,2024-07,2024-07,2023-11-09,2022-03-14,OBSERVATIONAL,,120.0,ESTIMATED,McGill University,OTHER,Innodem Neurosciences,INDUSTRY,Clinically Isolated Syndrome|Relapsing Remitting Multiple Sclerosis,multiple sclerosis|clinically isolated syndrome|eye-tracking,Canada,Montreal,Quebec,1,Eye-tracking,DEVICE,Change from Baseline in Symbol Digit Modalities Test (SDMT) score at Month 12,Change from Baseline in the Expanded Disability Status Scale (EDSS) score at Month 12|Change from Baseline in the Brief International Cognitive Assessment for MS (BICAMS) scores at Month 12|Change from Baseline in the Multiple sclerosis functional composite (MSFC) scores at Month 12,False,
NCT02664623,Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients,"Effectiveness of Personalized Nutrition Advice Delivered Via Dietary Consultations for Optimizing Dietary Calcium Intake in Patients With Multiple Sclerosis (MS) and Monitored as Outpatients: a Randomized, Single-blind, Bicentric Study",COMPLETED,2016-07-13,2020-01-06,2020-01-06,2020-01-27,2016-01-27,INTERVENTIONAL,NA,182.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,,,Multiple Sclerosis,,France,Alès,,2,Individual dietary consultations|Dietary advice sheet,PROCEDURE|PROCEDURE,Calcium intake in mg per day|Calcium intake in mg per day,QALCIMUM questionnaire (mg/day)|QALCIMUM questionnaire (mg/day)|Expanded Disability Status Scale (EDSS)|Expanded Disability Status Scale (EDSS)|Paced Auditory Serial Addition Test|Paced Auditory Serial Addition Test|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale|EQ-5D questionnaire|EQ-5D questionnaire|Mini Fatigue Impact Scale|Mini Fatigue Impact Scale|Dietary classification|25-hydroxy-vitamin D (D2 + D3) levels (nmol/L)|25-hydroxy-vitamin D (D2 + D3) plasma levels (nmol/L),False,
NCT04090996,Effects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients,Ffects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients With Low Level of Disability,UNKNOWN,2021-01-20,2022-04-20,2022-09-20,2021-02-11,2019-09-16,INTERVENTIONAL,NA,20.0,ESTIMATED,"University Hospital, Limoges",OTHER,,,Multiple Sclerosis,,France,Limoges,,1,Dual TAsk,DIAGNOSTIC_TEST,Oscillation rate,,False,
NCT04233970,Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis,Development and Evaluation of an Interactive Web-based Programme on Relapse Management for People With Multiple Sclerosis - a Randomized Controlled Trial With Mixed Methods Process Evaluation,COMPLETED,2020-02-17,2023-04-30,2023-05-05,2023-09-13,2020-01-18,INTERVENTIONAL,NA,160.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,"University of Cologne|University Medical Center Goettingen|Heinrich-Heine University, Duesseldorf|Gaia AG|Deutsche Multiple Sklerose Gesellschaft (DMSG), Bundesverband e.V.|MS-Stiftung Trier|BBK Dachverband e.V.",OTHER|OTHER|OTHER|INDUSTRY|UNKNOWN|UNKNOWN|UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing Remitting|Relapse Management|Steroids|Autonomy,Germany,Hamburg,,1,web-based intervention programme|web-based information material offered via the same platform (broca®) in addition to usual care,BEHAVIORAL|BEHAVIORAL,Assessment of change in relapse treatment (relapses not treated or treated with oral steroids).,Annual relapse rate|Relapse Risk Knowledge|Planned Behaviour in MS Scale (PBMS relapse)|Control Preference Scale relapse (CPS relapse)|Patient Activation Measure (PAM)|Impairment in the Expanded Disability Status Scale (EDSS)|United Kingdom Neurological Disability Scale (UNDS)|Hamburg Quality of life in MS Scale (HAQUAMS)|EQ-5D|Hospital Anxiety and Depression Scale (HADS)|Health Economic Evaluation,False,
NCT07002151,"Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patients","Effect of Educational Kinesiology Program on Cognition, Manual Dexterity and Bimanual Coordination in Patients With Multiple Sclerosis",COMPLETED,2024-01-10,2025-05-10,2025-05-10,2025-06-03,2025-06-03,INTERVENTIONAL,NA,36.0,ACTUAL,Cairo University,OTHER,,,Relapsing-remitting Multiple Sclerosis,RRMS|cognitive impairment|manual dexterity|bimanual coordination|educational kinesiology program,Egypt,Cairo,,1,educational kinesiology training program intervention for study group|conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups,OTHER|OTHER,cognition,manual dexterity and bimanual coordination,False,
NCT06220669,A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis,"An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis",RECRUITING,2024-03-19,2027-08,2028-08,2025-09-24,2024-01-24,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,Eli Lilly and Company,INDUSTRY,,,Multiple Sclerosis,"Relapsing remitting multiple sclerosis, Clinically isolated syndrome, Secondary progressive multiple sclerosis with disease activity.",United States,Coral Springs,Florida,50,LY3541860|Placebo,DRUG|DRUG,Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions,Cumulative Number of Total Number of T1 GdE Lesions|Cumulative Number of New and/or Enlarging T2 Lesions|Pharmacokinetics (PK): Plasma Trough Concentrations of LY3541860,False,
NCT05423769,"Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt","Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt",COMPLETED,2022-01-19,2023-11-30,2023-11-30,2024-08-23,2022-06-21,OBSERVATIONAL,,30.0,ACTUAL,Hikma Pharmaceuticals LLC,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Fingolimod|Generic Fingolimod|Nervous System|Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Cohort Study|Observational Study|Effectiveness|Safety|Disease Modifying Treatments,Egypt,Alexandria,,2,Fingolimod,DRUG,Proportion of patients with AEs and SAEs (including laboratory abnormalities).|Proportion of patients experiencing a relapse.|Time to First Relapse (TTFR)|Proportion of patients with disability progression as measured by the EDSS over time.,Proportion of patients with AEs and SAEs (including laboratory abnormalities) leading to treatment discontinuation.,False,
NCT00785083,A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma,"A Double-blind, Randomized, Placebo-controlled, Parallel, Time-lagged, Ascending, Multi-centre, Multiple-dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma",COMPLETED,2008-09,2009-02,,2016-11-18,2008-11-05,INTERVENTIONAL,PHASE2,36.0,ACTUAL,Novartis,INDUSTRY,,,Asthma,"Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume",United Kingdom,Manchester,,1,FTY720|Placebo,DRUG|DRUG,Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10|Safety of FTY720,Use of short acting beta agonists during treatment compared to pre-treatment|Pharmacokinetics of FTY720 and FTY720-P,False,
NCT01516554,Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients,"A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients",TERMINATED,2012-02,2014-01,2014-07,2014-07-08,2012-01-25,INTERVENTIONAL,PHASE2,3.0,ACTUAL,"Health Sciences Centre, Winnipeg, Manitoba",OTHER,University of Manitoba|Consortium of Multiple Sclerosis Centers|Manitoba Medical Service Foundation,OTHER|OTHER|OTHER,Multiple Sclerosis|Fatigue,Multiple Sclerosis|Fatigue,Canada,Winnipeg,Manitoba,1,Testosterone undecanoate|placebo,DRUG|DRUG,Change in fatigue (measured with Modified Fatigue Impact Scale [M-FIS]),"Change in fatigue as measured on a visual analog scale (VAS)|Quality of life as measured with the Aging Males' Symptoms (AMS) scale|Neurological status as measured with the Expanded Disability Status Scale (EDSS)|Number of participants with , type and severity of adverse events",False,
NCT03004794,Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort,,COMPLETED,2015-06,2016-08,2016-08,2016-12-29,2016-12-29,OBSERVATIONAL,,1581.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,,,,,0,medical records review,OTHER,Evoked Potentials (measure latency in m.sec)|Cerebrospinal Fluid (CSF): measure IgG index and Oligoclonal bands (OCB),,False,
NCT06113666,A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.,Digital Cognitive Behavior Therapy for Insomnia Compared With Digital Patient Education About Insomnia in People With Multiple Sclerosis in Norway,RECRUITING,2023-11-16,2025-10-30,2029-10-30,2025-02-10,2023-11-02,INTERVENTIONAL,NA,550.0,ESTIMATED,St. Olavs Hospital,OTHER,,,Multiple Sclerosis|Insomnia,Cognitive Behavioral Therapy for Insomnia|Fatigue|Cognitive performance,Norway,Trondheim,,1,Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Digital patient education about insomnia (PE),BEHAVIORAL|BEHAVIORAL,Between-group difference in insomnia severity at week 9 after randomization,Between-group difference in insomnia severity at week 33 after randomization|Between-group difference in insomnia severity at week 61 after randomization|Prospective daily sleep-wake pattern at week 9 after randomization|Prospective daily sleep-wake pattern at week 33 after randomization|Prospective daily sleep-wake pattern at week 61 after randomization|Self-reported mental health status at baseline|Self-reported mental health status at week 9 after randomization|Self-reported mental health status at week 33 after randomization|Self-reported mental health status at week 61 after randomization|Anxiety/depression at baseline|Anxiety/depression at week 9 after randomization|Anxiety/depression at week 33 after randomization|Anxiety/depression at week 61 after randomization|Fatigue at baseline|Fatigue at week 9 after randomization|Fatigue at week 33 after randomization|Fatigue at week 61 after randomization|Fatigue severity at baseline|Fatigue severity at week 9 after randomization|Fatigue severity at week 33 after randomization|Fatigue severity at week 61 after randomization|Cognitive test performance at baseline|Cognitive test performance at week 9 after randomization|Cognitive test performance at week 33 after randomization|Cognitive test performance at week 61 after randomization|Continuous recordings of daytime activity and sleep from baseline to 9 weeks after randomization|Use of health care services at baseline|Use of health care services at 61 weeks after randomization|Use of health care services at 5 years after randomization|Medication use at baseline|Medication use at 61 weeks after randomization|Medication use at 5 years after randomization|Costs of treatment offered by the public services at baseline|Costs of treatment offered by the public services 61 weeks after randomization|Costs of treatment offered by the public services 5 years after randomization|Sick leave or in receipt of disability benefits at baseline|Sick leave or in receipt of disability benefits 61 weeks after randomization|Sick leave or in receipt of disability benefits 5 years after randomization|Information about the MS disease at baseline|Information about the MS disease at week 61 after randomization|Information about the MS disease at 5 years after randomization|Excessive daytime sleepiness at baseline|Subjective cognitive disfunction at baseline|Subjective executive functions at baseline|Subjective executive functions at 9 weeks after randomization|Subjective executive functions at 33 weeks after randomization|Subjective executive functions at 61 weeks after randomization|Subjective disability status at baseline|Fatigue before and after cognitive testing at baseline|Fatigue before and after cognitive testing at 9 weeks|Fatigue before and after cognitive testing at 33 weeks|Fatigue before and after cognitive testing at 61 weeks|Perceived performance after cognitive testing at baseline|Perceived performance after cognitive testing at 9 weeks|Perceived performance after cognitive testing at 33 weeks|Perceived performance after cognitive testing at 61 weeks|Perceived exertion after cognitive testing at baseline|Perceived exertion after cognitive testing at 9 weeks|Perceived exertion after cognitive testing at 33 weeks|Perceived exertion after cognitive testing at 61 weeks|Insomnia symptoms and severity at baseline|Insomnia symptoms and severity at 9 weeks|Insomnia symptoms and severity at 33 weeks|Insomnia symptoms and severity at 61 weeks|Pain map with numeric rating scale at baseline|Frequency of alcohol use at baseline|Frequency of alcohol use at 9 weeks|Frequency of alcohol use at 33 weeks|Frequency of alcohol use at 61 weeks|Self reported quality of life at baseline|Self reported quality of life at 9 weeks|Self reported quality of life at 33 weeks|Self reported quality of life at 61 weeks after randomization|General health state at baseline|General health state at 9 weeks|General health state at 33 weeks|General health state at 61 weeks|Opinion on negative effects of the intervention at 9 weeks|Opinion on negative effects of the intervention at 61 weeks|Use of therapeutic techniques at 33 weeks|Use of therapeutic techniques at 61 weeks|Self-reported medication usage at baseline|Self-reported previous and current physical and mental disorders at baseline|Self-reported physical activity at baseline|Self-reported Body Mass Index (BMI) at baseline|Self-reported internet and media usage at baseline|Self-reported previous treatments for mental disorders at baseline|Self-reported previous treatments for insomnia at baseline|Self-reported duration of sleep problems at baseline,False,
NCT03291756,CorEvitas Multiple Sclerosis (MS) Registry,CorEvitas Multiple Sclerosis (MS) Registry,ENROLLING_BY_INVITATION,2017-08-10,2100-12,2100-12,2024-12-04,2017-09-25,OBSERVATIONAL,,1000.0,ESTIMATED,CorEvitas,NETWORK,,,Multiple Sclerosis,,United States,Waltham,Massachusetts,1,,,Number of patients with adverse events (AEs) or serious adverse events (SAEs).,"Patient reported: Patient Clinical Global Impression (PCGI) Scale|Disease burden: Relapse Information|Percentage of patients with history of comorbidities|Physician reported: Nine-Hole Peg Test (9-HPT)|Physician reported: Symbol Digit Modalities Test (SMDT)|Patient reported: Patient reported: Work productivity and Activity Impairment (WPAI)|Patient reported: Patient reported :MS Quality of Life, MSIS-29|Patient reported: MS Disability Score29",False,
NCT03933202,A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2),Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Oral or Infusion DMDs for RMS (MASTER-2),COMPLETED,2019-07-22,2024-11-11,2024-11-11,2025-04-06,2019-05-01,OBSERVATIONAL,,291.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Cladribine Tablets|Observational|Mavenclad,United States,Cullman,Alabama,66,Cladribine Tablets,DRUG,Annualized Relapse Rate (ARR) (Prospective Assessment),"Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Total Score at Month 6, 12 and 24|Change From Baseline in 36-Item Short Form Health Survey (SF-36) Total Score at Month 6, 12 and 24|Change From Baseline in Modified Fatigue Impact Scale - 5-item version (MFIS-5) Total Score at Month 6, 12 and 24|Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24|Change From Baseline in 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Total Score at Month 6, 12 and 24|Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24|Number of Participants With Adherence to Treatment as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)|Percentage of Participants with Relapse (Prospective Assessment)|Percentage of Participants With Relapse Associated With Hospitalization, Diagnosis or Reason for Hospitalization|Percentage of Participants With Relapse Associated With Glucocorticoid Use|Treatment Pattern as Evaluated by Number of Participants With Previous Treatment for Multiple Sclerosis (MS)|Percentage of Participants Who Discontinue Cladribine Tablets|Percentage of Participants With Reason for Discontinuation of Cladribine Tablets|Elapsed Time to Discontinuation After First Dose of Cladribine Tablets|Number of Doses Received by Participants as per United States Prescribing Information|Percentage of Planned Doses Received by Participants as per United States Prescribing Information|Number of Participants with Subsequent Treatment Chosen Following Discontinuation of Cladribine Tablets|Number of Participants Assessed of Concomitant Multiple Sclerosis Medications Used During Study Period|Annualized Relapse Rate (ARR) (Retrospective Assessment)|Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs) and Special Situations",False,
NCT04203017,Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis,Allogeneic Fecal Microbiota Transplantation as a Consolidation Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis,TERMINATED,2019-06-01,2023-11-29,2023-11-29,2023-12-06,2019-12-18,INTERVENTIONAL,PHASE1,20.0,ACTUAL,St. Petersburg State Pavlov Medical University,OTHER,,,Multiple Sclerosis,,Russia,Saint Petersburg,,1,allogeneic fecal microbiota,BIOLOGICAL,To evaluate effectiveness of autoHSCT in combination with FMT in patients with refractory multiple sclerosis,To evaluate overall survival after autoHSCT in combination with FMT in patients with refractory multiple sclerosis|To evaluate adverse effects after FMT in immunocompromised patients|Quality of life status 1|Quality of life status 2|Evaluation of Immune system reconstitution after autoHSCT 1|Evaluation of Immune system reconstitution after autoHSCT 2|Impact of autoHSCT on brain structure anatomy,False,
NCT01714089,Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis,A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis,WITHDRAWN,,,,2016-04-06,2012-10-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Revalesio Corporation,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing remitting multiple sclerosis|RR-MS,United States,New York,New York,1,RNS60 125 ml|RNS60 250 ml|Interferon beta 1a,DRUG|DRUG|DRUG,Change in number of GAD-enhancing lesions from baseline,"Change in number of T2 lesions from baseline|Brain volume|T2 lesion volume|Annualized Relapse Rate|Expanded Disability Status Scale (EDSS), change from baseline|Multiple Sclerosis Functional Composite, change from baseline",False,
NCT01085318,Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial,"A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group",COMPLETED,2010-06-30,2012-02-29,2012-03-31,2018-02-23,2010-03-11,INTERVENTIONAL,PHASE4,38.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,,United States,Rockland,Massachusetts,1,Rebif,DRUG,Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months,Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months,True,2013-05-03
NCT05325359,L Test in Multiple Sclerosis,Validity and Reliability of L Test in Persons With Multiple Sclerosis,UNKNOWN,2022-02-07,2022-04-18,2022-05-09,2022-04-13,2022-04-13,OBSERVATIONAL,,50.0,ESTIMATED,Firat University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Balance|L test|Validity|Gait,Turkey (Türkiye),Elâzığ,,1,L test,BEHAVIORAL,L test|Timed Get Up and Go Test,3-meter Walk Back Test|10-Meter Walk Test (10MeWT),False,
NCT07064291,Enhancing Self-Esteem in Patients With Multiple Sclerosis: A Randomised Controlled Trial of the Lexical Association Technique,Améliorer l'Estime de Soi Des Patients Atteints de sclérose en Plaques : Test d'efficacité de la Technique d'Association Lexicale,NOT_YET_RECRUITING,2025-09,2027-09,2027-09,2025-07-14,2025-07-14,INTERVENTIONAL,NA,160.0,ESTIMATED,"University Hospital, Grenoble",OTHER,"Laboratoire interuniversitaire de psychologie : personnalité, cognition et changement social - LIP-PC2S|Laboratoire de Psychologie et NeuroCognition",UNKNOWN|OTHER,Multiple Sclerosis|Quality of Life (QOL),Multiple Sclerosis|Psychological Well-Being|Lexical Association Technique|Randomized Controlled Trial|Quality of Life|Cognitive Intervention|Home-Based Therapy|Psychology|Mental Imagery|Self-esteem,France,Grenoble,Grenoble,1,The Lexical Association Technique (LAT)|Placebo of the Lexical Association Technique,OTHER|OTHER,Effect of the therapeutic technique on patients' self-esteem assessed by comparing patients score at the RSES between the experimental and active control group after the procedure.,Durability of the effects on patients' self-esteem assessed by comparing patients score at the RSES between the experimental and active control group at distance from the end of the procedure.|Effects on quality of life assessed by comparing the evolution of scores on the Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) between the experimental and active control groups at distance from the end of the procedure.|Effects of the procedure on self-efficacy assessed by comparing the evolution of patients' scores on the General Self-Efficacy Scale (GSE) between the experimental and active control groups at distance from the end of the procedure.|Effects on illness adaptation assessed by comparing the evolution of patients' scores on the Coping with Health Injuries and Problems questionnaire (CHIP) between the experimental and active control groups at distance from the end of the procedure.|Effects of the procedure on depressive symptoms assessed by comparing the evolution of patients' scores on the Center for Epidemiological Studies Depression Scale (CES-D) between the experimental and active control groups at distance from the end of the|Effects on trait anxiety assessed by comparing the evolution of patients' scores on the State-Trait Anxiety Inventory - Trait subscale (STAI-Y B) between the experimental and active control groups at distance from the end of the procedure.|Effects of the procedure on perceived stress assessed by comparing the evolution of patients' scores on the Perceived Stress Scale - 10 items (PSS-10) between the experimental and active control groups at distance from the end of the procedure.,False,
NCT04843813,Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-,Lutein and Multiple Sclerosis Experimental Study (LuMES),UNKNOWN,2021-03-26,2023-03,2023-03,2021-04-15,2021-04-14,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,"Division of Nutritional Sciences, University of Illinois at Urbana-Champaign|National Institutes of Health (NIH)",UNKNOWN|NIH,Multiple Sclerosis,Multiple Sclerosis|Cognitive Function|Lutein,United States,Urbana,Illinois,1,Lutein|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Macular Pigment Optical Density|Attentional Accuracy|Attentional Reaction Time|Attentional Resource Allocation|Attentional Processing Speed,,False,
NCT04140305,Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063),"A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)",TERMINATED,2020-01-16,2025-05-15,2025-05-15,2025-06-12,2019-10-25,INTERVENTIONAL,PHASE3,188.0,ACTUAL,Celgene,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|RPC-1063|Ozanimod|Phase 3b,United States,Birmingham,Alabama,61,RPC-1063,DRUG,Proportion of subjects with an increase in raw score of ≥ 4 points or 10% from baseline (improved),"Proportion of subjects with a decrease in raw score of ≥ 4 points or 10% from baseline (worsened)|Proportion of subjects with a raw score change from baseline who do not meet the improved or worsened definition (stable)|Proportion of subjects with an increase in raw score of ≥ 3 points from baseline|Proportion of subjects with a decrease in raw score of ≥ 3 points from baseline|Change from baseline in Symbol Digit Modalities Test (SMDT)|Percent change from baseline in thalamic, cortical grey matter, whole brain, lateral ventricular, and MOV volumes|Proportion of subjects free of gadolinium enhancing (GdE) lesions over 3 years|GdE lesion volume over 3 years|Number of unique new or enlarging hyperintense T2-weighted lesions and their volume from baseline to Year 3|Number of unique new or enlarging hypointense T1 weighted lesions and their volume from baseline to Year 3|Treatment Satisfaction Questionnaire for Medication (TSQM v1.4)|Work Productivity and Activity Impairment-Multiple Sclerosis (WPAI-MS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Hospital Anxiety and Depression Scale (HADS)|Annualized relapse rate (ARR)|Timed 25-foot Walk (T25W)|Nine-hole Peg Test (9-HPT)|Expanded Disability Status Scale (EDSS)|Adverse Events (AEs)",False,
NCT07111637,"Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis","Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis",RECRUITING,2025-06-14,2026-04-14,2026-04-14,2025-08-13,2025-08-08,INTERVENTIONAL,NA,1336.0,ESTIMATED,Queen Mary University of London,OTHER,icometrixLeuven,INDUSTRY,Multiple Sclerosis,,United Kingdom,London,,1,AI software,DEVICE,To assess the clinical usefulness of icobrain ms by evaluating the detection of disease activity (as defined by new/expanding lesions).,,False,
NCT06001424,Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients,Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients,COMPLETED,2018-06-24,2021-04-30,2021-05-29,2023-08-21,2023-08-21,INTERVENTIONAL,NA,30.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis|Ataxia,Multiple Sclerosis|ataxia|coordination|life kinetic exercises,Egypt,Giza,,1,physical therapy|life kinetic exercises,OTHER|OTHER,Lower Extremity Motor Coordination Test (LEMOCOT)|Lower Extremity Motor Coordination Test (LEMOCOT),Four Square Step Test (FSST)|Four Square Step Test (FSST),False,
NCT00202254,Multiple Sclerosis Rehabilitation Study,'Functioning and Disability' and 'Quality of Life' in an Australian Community Cohort With Multiple Sclerosis.,COMPLETED,2004-12,2005-12,2005-12,2015-06-03,2005-09-20,INTERVENTIONAL,NA,100.0,,Melbourne Health,OTHER,,,Multiple Sclerosis,Mulitple Sclerosis|MS,,,,0,Physiotherapy|Occupational therapy|Speech pathology,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,"Improvement in fatigue levels and psychological well being (depression, stress and anxiety) in MS patients. Outcome will be measured at 13 months since recruitment.",- Improvement in function and activities of daily living ie. disability- Quality of life.- Carer Burder in multiple sclerosis.- Utilisation of health services.- 13 months follow up.,False,
NCT06987994,The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MS,The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With Multiple Sclerosis,COMPLETED,2024-12-01,2025-02-18,2025-02-28,2025-05-23,2025-05-23,INTERVENTIONAL,NA,30.0,ACTUAL,Istinye University,OTHER,,,Multiple Sclerosis|Multiple Sclerosis (MS) - Relapsing-remitting|Virtual Reality,multiple sclerosis|virtual reality|fatigue|functional capacity|physical therapy,Turkey (Türkiye),Istanbul,,1,control group( physical therapy)|Experemental group,OTHER|OTHER,Fatigue Severity Score (FSS),Timed Up and Go Test (TUG),False,
NCT01216137,Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial,The Effects of Vestibular Rehabilitation on MS-related Fatigue and Upright Postural Control: a Randomized Controlled Trial,COMPLETED,2007-01,2010-07,2010-10,2013-01-29,2010-10-07,INTERVENTIONAL,NA,38.0,ACTUAL,"University of Colorado, Denver",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Fatigue|Balance|Dizziness,Multiple Sclerosis|Fatigue|Balance|Upright Postural Control|Dizziness,,,,0,Exercise: Vestibular Rehabilitation|Exercise,OTHER|OTHER,Self-reported fatigue|Upright postural control|Walking capacity,Self-reported dizziness|Self-reported depression,False,
NCT01047319,"A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis","A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis",TERMINATED,2010-05-27,2017-06-30,2017-06-30,2021-12-09,2010-01-12,INTERVENTIONAL,PHASE3,1047.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis,United States,Homewood,Alabama,144,Laquinimod,DRUG,Participants With Treatment-Emergent Adverse Events (TEAEs),Participants With Potentially Clinically Significant Abnormal Vital Signs|Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study|Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study|Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study,True,2019-01-09
NCT04388592,The Effect of Nurse Practitioner (NP-led) Care Upon Mood in People With Multiple Sclerosis,"MS Wellness Navigator: The Effect of Nurse Practitioner (NP-led) Care on Mood, Anxiety and Health Related Quality of Life in People With Multiple Sclerosis - A Randomized Trial",COMPLETED,2017-04-01,2019-04-30,2019-11-30,2024-09-19,2020-05-14,INTERVENTIONAL,NA,248.0,ACTUAL,University of Alberta,OTHER,University Hospital Foundation,OTHER,Multiple Sclerosis|Nurse's Role,multiple sclerosis|nurse's role|depression and anxiety|quality of life|patient satisfaction,Canada,Edmonton,Alberta,1,Nurse Practitioner (NP) Led Care Arm,OTHER,Difference in Change in Hospital Anxiety & Depression Scale - Depression (HADS-D) and Hospital Anxiety & Depression Scale-Anxiety (HADS-A) scores,Difference in Change in Hospital Anxiety & Depression Scale - Depression (HADS-D) and Hospital Anxiety & Depression Scale-Anxiety (HADS-A) scores|Difference in Change in Euro Quality of Life Measurement (EQ5D)|Difference in Change Modified Fatigue Impact Scale (MFIS) score|Qualitative Consultant Satisfaction Questionnaire (CSQ)|Difference in Change in Caregiver Health-Related Quality of Life in MS (CAREQOL-MS)|Number of Participant Outpatient Healthcare Interactions/Visits,False,
NCT00638833,Memantine Therapy for Multiple Sclerosis,Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis,TERMINATED,2007-09,2008-03,2008-03,2012-06-08,2008-03-19,INTERVENTIONAL,PHASE2,20.0,ACTUAL,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,H. Lundbeck A/S,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis,Spain,Pamplona,Navarre,1,Memantine|Placebo,DRUG|DRUG,to assess the efficacy of Memantine in improving memory deficit in MS patients using the SRT scale,"1. tests for attention (PASAT3, SDMT, Stroop), executive (Raven, MATTIS) and memory (10/36, SRT), quality of life (SF36), and fatigue (Krupp). 2. attention evoked potentials 3. clinical course, disability (EDSS, MSFC, MSSS).",False,
NCT06222359,Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study,Acceptability of Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study,NOT_YET_RECRUITING,2024-02,2025-02,2025-02,2024-01-24,2024-01-24,OBSERVATIONAL,,102.0,ESTIMATED,King's College London,OTHER,King's College Hospital NHS Trust,OTHER,Multiple Sclerosis|Depression|Anxiety,,,,,0,COMPASS,DEVICE,Psychological Distress (primary outcome for a future full scale trial).,Reach of screening and COMPASS MS intervention|Reach of screening and COMPASS MS intervention|Reach of screening and COMPASS MS intervention|Reach of screening and COMPASS MS intervention|Efficacy: psychological outcomes|Efficacy: psychological outcomes|Efficacy: Psycho-social outcomes|Implementation of COMPASS|Implementation of COMPASS|Implementation of COMPASS|Implementation of COMPASS|Adoption,False,
NCT02139696,Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation,Does Targeting of Sphingosine-1 Phosphate Receptors Reduce Microglial Activation in Multiple Sclerosis? A [11C]PK11195 Brain PET Study,COMPLETED,2013-09,2015-01,2016-10,2018-05-11,2014-05-15,OBSERVATIONAL,,10.0,ACTUAL,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,,1,PET and MRI,RADIATION,Change of 11C-PK11195-radioligand binding using PET,MRI metrics,False,
NCT03589105,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting","An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis",COMPLETED,2018-08-06,2021-02-15,2021-02-15,2022-01-11,2018-07-17,INTERVENTIONAL,PHASE4,423.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,France,Agen,,46,Ocrelizumab 300 mg|Ocrelizumab 600 mg,DRUG|DRUG,Percentage of participants free of disease activity,"Annualized relapse rate|Percentage of participants with stable, improved, or worsened expanded disability status scale (EDSS)|Percentage of participants with confirmed disability progression at Week 24 (CDP24)|Mean Change in EDSS|Percentage of relapse-free RMS participants|Percentage of participants with no T1 gadolinium-enhancing lesion and no new and/or enlarging T2 lesion as detected by brain MRI|Percentage of participants with no T1 gadolinium-enhancing lesion as detected by brain MRI|Percentage of participants with no new and/or enlarging T2 lesion as detected by brain MRI|Change in the score of MS symptom severity scale (SymptoMScreen)|Change in the score of Modified Fatigue Impact Scale (MFIS)|Change in the score of EuroQol 5-Dimension Questionnaire (EQ-5D-5L with Visual Analogue Scale (VAS)) for health-related quality of life|Change in the score of Work Productivity and Activity Impairment scale (WPAI:SHP)|Change in the score of Multiple Sclerosis International Quality Of Life Questionnaire (MusiQOL)|Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM-14)|Percentage of Participants with Adverse Events (AE)",False,
NCT00146159,Study Evaluating Mitoxantrone in Multiple Sclerosis,"A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis",TERMINATED,2005-03,2007-09,,2007-12-28,2005-09-05,INTERVENTIONAL,PHASE3,336.0,ESTIMATED,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,Multiple Sclerosis,Germany,Berg,,7,Mitoxantrone,DRUG,"3 clinical measures combined in a multivariate analysis: confirmed Expanded Disability Status Scale(EDSS)|deterioration, change of ambulation index, time to first relapse requiring corticoid treatment","derivations of EDSS and relapses; MRI (baseline, 2 years)",False,
NCT03209479,"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) ""Prevention of Relapse of Multiple Sclerosis""","Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) ""Prevention of Relapse of Multiple Sclerosis""",COMPLETED,2015-11-24,2024-03-31,2024-03-31,2024-06-13,2017-07-06,OBSERVATIONAL,,1332.0,ACTUAL,Teva Takeda Pharma Ltd.,INDUSTRY,,,Multiple Sclerosis,,Japan,Tokyo,,1,Glatiramer acetate,DRUG,Percentage of participants who had one or more adverse events|Annual Relapse Rate (ARR),Changes in the number of lesions from brain MRI findings|Changes in functional evaluation scores (Expanded Disability Status Scale [EDSS])|Changes in functional evaluation scores (Functional Systems [FS]),False,
NCT02490046,D-mannose for the Prevention of UTIs in Multiple Sclerosis,Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis,UNKNOWN,2015-02,2015-10,2015-11,2015-07-03,2015-07-03,INTERVENTIONAL,PHASE1,20.0,ESTIMATED,"University College, London",OTHER,UCLH,UNKNOWN,Multiple Sclerosis|Recurrent Urinary Tract Infections,D mannose|multiple sclerosis|recurrent urinary infections,United Kingdom,London,,1,D Mannose,DIETARY_SUPPLEMENT,Compliance (self-usage diary and weight of returned containers of D-mannose),Antibiotic prescription (Number of prescriptions for antibiotics required),False,
NCT00938366,Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects,"An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis",COMPLETED,2008-01,2009-01,2009-01,2016-04-14,2009-07-13,INTERVENTIONAL,PHASE1,18.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono S.A., Geneva",INDUSTRY,Multiple Sclerosis,,,,,0,Cladribine|Pantoprazole,DRUG|DRUG,Maximum Plasma Concentration (Cmax) of Cladribine|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Cladribine,"Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Cladribine|Time to Reach the Maximum Plasma Concentration (Tmax) of Cladribine|Apparent Terminal Half-life (t1/2) of Cladribine|Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of Cladribine|Percentage of Subjects With Any Treatment Emergent Adverse Events (TEAEs), Serious AEs, AEs Leading to Death, and AEs Leading to Discontinuation",True,2015-10-20
NCT05605951,Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve,The Acute Optic Neuritis Network (ACON): a Non-interventional Prospective Multicenter Study on Diagnosis and Treatment of Acute Optic Neuritis,RECRUITING,2020-08-15,2025-12-31,2025-12-31,2022-11-04,2022-11-04,OBSERVATIONAL,,200.0,ESTIMATED,"Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul",OTHER,,,Demyelinating Diseases|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder Attack|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Optic Neuritis,,United States,Aurora,Colorado,26,non-interventional study,OTHER,"to investigate whether MS-ON, AQP4-IgG+ON and MOG-IgG+ON patients treated with early high-dose corticosteroids for visual loss have better visual outcomes and QoL than those with late treatment.","Visual and structural outcomes of acute ON in patients treated with high-dose corticosteroid-therapy versus plasmapheresis as first-line treatment.|Visual and structural outcomes of acute ON in patients treated with high-dose corticosteroid-therapy versus plasmapheresis as first-line treatment.|Visual and structural outcomes of acute ON in patients treated with high-dose corticosteroid-therapy versus plasmapheresis as first-line treatment.|Visual and structural outcomes of MS-ON in patients treated with high-dose corticosteroid-therapy with oral prednisone taper vs. without taper as standard of care.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Diagnostic and prognostic value of biomarker levels (NfL, GFAP) and associations with visual pathway damage (MRI- and OCT-based) in the acute stage and during follow-up.|Characterization of MOG-IgG and AQP4-IgG levels and compartmentalisation (serum vs. CSF, using simultaneous paired samples) and associated risks for subsequent relapses in subjects with AQP4-IgG+ON and MOG-IgG+ON.|Characterization of MOG-IgG and AQP4-IgG levels and compartmentalisation (serum vs. CSF, using simultaneous paired samples) and associated risks for subsequent relapses in subjects with AQP4-IgG+ON and MOG-IgG+ON.|Characterization of MOG-IgG and AQP4-IgG levels and compartmentalisation (serum vs. CSF, using simultaneous paired samples) and associated risks for subsequent relapses in subjects with AQP4-IgG+ON and MOG-IgG+ON.|Characterization of MOG-IgG and AQP4-IgG levels and compartmentalisation (serum vs. CSF, using simultaneous paired samples) and associated risks for subsequent relapses in subjects with AQP4-IgG+ON and MOG-IgG+ON.|Diagnostic value of OCT markers (e.g. increased pRNFL) for diagnosis of MS, NMOSD, and MOGAD.|Diagnostic value of OCT markers (e.g. increased pRNFL) for diagnosis of MS, NMOSD, and MOGAD.|Prognostic value of OCT markers (e.g. increased pRNFL) for the visual outcome at 1-year follow-up.|Diagnostic value of OCT markers for a conversion from acute ON to clinically definite MS.|Diagnostic value of OCT markers for a conversion from acute ON to clinically definite MS.|Diagnostic value of OCT markers for a conversion from acute ON to clinically definite MS.|Diagnostic value of early clinical variables (i.e. visual loss and pain patterns).|Diagnostic value of early clinical variables (i.e. visual loss and pain patterns).|Diagnostic value of early clinical variables (i.e. visual loss and pain patterns).|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.|Characterization of visual function in daily routine, visual QoL scores and incidence of depression at 1-year follow-up.",False,
NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients","A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients ""TIMER"" Study",COMPLETED,2009-08,2012-07,2012-07,2017-03-21,2009-03-30,INTERVENTIONAL,PHASE4,224.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Relapsing Remitting Multiple Sclerosis (RRMS),TYSABRI naive|Relapsing-remitting multiple sclerosis (RRMS),Belgium,Liège,,15,BG00002 (natalizumab),DRUG,Change From Baseline in the Timed 100-meter Walk Test (T100T)|Change From Baseline in the Timed 25-foot Walk Test (T25FW)|Change From Baseline in Maximum Walking Distance (MWD)|Change From Baseline in Expanded Disability Status Scale (EDSS),Correlation Between the EDSS and MWD (Pearson Correlation Coefficient)|Correlation Between the EDSS and MWD (Spearman Correlation Coefficient)|Correlation Between the T100T and T25FW (Pearson Correlation Coefficient)|Correlation Between the T100T and T25FW (Spearman Correlation Coefficient)|Correlation Between the EDSS and T25FW (Pearson Correlation Coefficient)|Correlation Between the EDSS and T25FW (Spearman Correlation Coefficient)|Correlation Between the EDSS and T100T (Pearson Correlation Coefficient)|Correlation Between the EDSS and T100T (Spearman Correlation Coefficient)|Improvement in Timed 25FT Walk Speed and T100T Speed at Week 24 and 48,True,2014-11-18
NCT07108088,"Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application","Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application. Clinical Investigation: NS-BOOSST",NOT_YET_RECRUITING,2025-07-31,2026-09-15,2026-09-15,2025-08-06,2025-08-06,INTERVENTIONAL,NA,34.0,ESTIMATED,ÖSSUR France,INDUSTRY,Pôle Saint Hélier,OTHER,Stroke|Multiple Sclerosis|Cerebral Palsy|Neuromuscular Deficits,,France,Hérouville-Saint-Clair,,2,NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation|Carbon orthosis (control),DEVICE|DEVICE,Walking speed : 10m walk test,Functional Gait Assessment (FGA)|6 minute walk test|Spatio-temoral gait analysis,False,
NCT02047760,Neuroretinal Biomarkers in Neurodegenerative Diseases,"Investigation Into the Role of Neuroretinal Biomarkers in the Phenotyping of Neurodegenerative Diseases, and Potential for Tracking Progression and Monitoring Impact of Interventions, Events and Therapies.",COMPLETED,2014-03,2016-02,2016-02,2016-05-11,2014-01-28,OBSERVATIONAL,,80.0,ESTIMATED,University of Edinburgh,OTHER,,,Multiple Sclerosis,,United Kingdom,Edinburgh,,1,,,Retinal nerve fibre layer (RNFL) thickness change over time,Retinal vascular fractal dimension change over time,False,
NCT04276324,"Effects of Ten-Weeks Power Training on Neuromuscular Performance, Heart Rate Variability, Sleep Quality and Mobility in Persons With Multiple Sclerosis","Effects of Ten-Weeks Resistance Training on Neuromuscular Performance, Heart Rate Variability, Sleep Quality and Mobility in Persons With Multiple Sclerosis",COMPLETED,2020-03-10,2020-06-15,2020-10-15,2020-10-23,2020-02-19,INTERVENTIONAL,NA,36.0,ACTUAL,Universidad Católica San Antonio de Murcia,OTHER,,,Multiple Sclerosis,,Spain,Murcia,,1,Resistance training|Testing sessions,OTHER|OTHER,Maximal Voluntary Isometric Contraction of Knee Extension|Maximal Voluntary Isometric Contraction of Knee Extension|Rate of Force Development|Rate of Force Development|Central Activation Ratio|Central Activation Ratio|Spasticity|Spasticity,Walking speed|Walking speed|Static balance|Static balance|Functional capacity|Functional capacity|Heart Rate Variability|Heart Rate Variability|Sleep Quality|Sleep Quality,False,
NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,"An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis",COMPLETED,2010-01,2010-12,2010-12,2012-01-05,2009-12-14,OBSERVATIONAL,,176.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,10,"Betaseron (Interferon beta-1b, BAY86-5046)",DRUG,"Descriptive exploration of mortality, EDSS, cognition, resource use, SPMS status and employment history by length of exposure to Betaseron and stratified by the original clinical trial group assignment (1.6 MIU, 8 MIU, placebo)",,False,
NCT03817424,"A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis","A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis",COMPLETED,2018-12-13,2020-07-20,2020-07-20,2024-12-13,2019-01-25,INTERVENTIONAL,PHASE1,31.0,ACTUAL,Amgen,INDUSTRY,,,Systemic Lupus Erythematosus|Cutaneous Lupus Erythematosus|Sjogren's Syndrome|Systemic Sclerosis|Polymyositis|Dermatomyositis,,United States,Anniston,Alabama,30,VIB7734|Placebo,DRUG|DRUG,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Adverse Events of Special Interest (AESIs)|Number of Participants With Laboratory Abnormalities Reported as TEAEs|Number of Participants With Vital Sign Abnormalities Reported as TEAEs|Number of Participants With 12-Lead Electrocardiogram Abnormalities Reported as TEAEs,Maximum Observed Serum Concentration (Cmax) of VIB7734 Maximum Observed Serum Concentration (Cmax) of VIB7734|Area Under the Concentration-time Curve (AUC) of VIB7734|Systemic Clearance (CL) of VIB7734|Terminal Half-life (t1/2) of VIB7734|Number of Participants With Positive Anti-Drug Antibodies of VIB7734|Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score (Cohorts 2 and 3)|Blood Levels of pDCs,False,
NCT01945359,Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design,"A Pilot Study to Assess Disease State Stability, Efficacy, and Tolerability in a Natalizumab to Dimethyl Fumarate Crossover Design",COMPLETED,2013-09,2014-09,2015-06,2015-10-16,2013-09-18,OBSERVATIONAL,,30.0,ACTUAL,"Rocky Mountain MS Research Group, LLC",OTHER,Biogen,INDUSTRY,Relapsing Remitting Multiple Sclerosis,Relapsing Multiple Sclerosis|Dimethyl Fumarate|Natalizumab,United States,Salt Lake City,Utah,1,,,Disease Stability,Quantify disease stability,False,
NCT01450072,Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE,Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE,COMPLETED,2010-06,2011-12,2012-12,2025-06-18,2011-10-12,INTERVENTIONAL,NA,20.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,,United States,Buffalo,New York,1,Selective Venography followed by therapeutic balloon angioplasty|Control arm,DEVICE|OTHER,Percentage of Patients With Immediate and Short-term SAE,Number of Participants With More Than 75% of Normal Outflow at 1 Year Post-angioplasty,True,2025-06-18
NCT03247894,Obstetric Anesthesia and Analgesia and Multiple Sclerosis,Influence of Obstetric Anesthesia and Analgesia on the Progression of the Disease in Multiple Sclerosis Parturients: Retrospective Cohort Study,COMPLETED,2014-08-01,2017-07-31,2017-08-01,2019-05-29,2017-08-14,OBSERVATIONAL,,70.0,ACTUAL,Brno University Hospital,OTHER,Masaryk University,OTHER,Multiple Sclerosis,"Multiple sclerosis, anesthesia",Czechia,"Brno, Czechia, 62500",Czechia,1,Data search,OTHER,Multiple sclerosis decompensation/progression at 3rd month|Multiple sclerosis decompensation/progression,MS progression and the type of anesthetic method,False,
NCT05299151,Gait Analysis in Multiple Sclerosis Patients,The Effect of Vestibular Rehabilitation on the Kinetic and Kinematic Parameters of Walking in Patients With Multiple Sclerosis,COMPLETED,2022-06-01,2024-03-01,2024-05-01,2024-07-09,2022-03-28,INTERVENTIONAL,NA,22.0,ACTUAL,Istanbul Kültür University,OTHER,Istanbul University - Cerrahpasa,OTHER,Multiple Sclerosis|3D Gait Analysis|Vestibular Rehabilitation,"gait analysis, multiple sclerosis, vestibular, kinetic, kinematic",Turkey (Türkiye),Istanbul,,1,Vestibular exercises|Standard neurorehabilitation exercises,OTHER|OTHER,3D Gait Analysis System - pre assesment|3D Gait Analysis System - post assesment,One Leg Standing Test - pre assesment|One Leg Standing Test - post assessment|Dizziness Handicap Inventory - pre assessment|Dizziness Handicap Inventory - post assessment|2 Minute Walking Test - pre assessment|2 Minute Walking Test - post assessment,False,
NCT02046629,A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects",COMPLETED,2014-05,2014-07,2014-07,2014-08-21,2014-01-28,INTERVENTIONAL,PHASE1,12.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,China,Shanghai,,1,Teriflunomide HMR1726|cholestyramine,DRUG|DRUG,Pharmacokinetic parameters for teriflunomide determined from plasma concentration,"safety assessments (adverse events, laboratory data, vital sign, and ECG parameters)",False,
NCT04909502,"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis","A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients With Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101",SUSPENDED,2021-10-19,2023-12,2024-04,2022-10-21,2021-06-01,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,Emerald Health Pharmaceuticals,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis|Nervous System Diseases|Demyelinating Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Relapsing Forms of Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Relapsing Secondary Progressive Multiple Sclerosis,United States,Cullman,Alabama,4,EHP-101 25 mg OD|EHP-101 25 mg BID|EHP-101 50 mg OD|EHP-101 50 mg BID,DRUG|DRUG|DRUG|DRUG,Incidence and severity of Treatment Emergent Adverse Events,Brain lesion activity measured by MRI|Disease progression measured by MS Functional Composite (MSFC)|Disease progression measured by Expanded Disability Status Scale (EDSS)|Disease progression measured by Symbol Digit Modalities Test (SDMT)|Disability status measured by MS Functional Composite (MSFC)|Disability status measured by Expanded Disability Status Scale (EDSS)|Disability status measured by Symbol Digit Modalities Test (SDMT)|Time to first relapse|Preliminary Annualized Relapse Rate (ARR)|Percent of patients who experience a relapse|Proportion of patients who remain qualified as relapse-free|Change in blood levels of neurofilament light chain (NfL),False,
NCT03561402,Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio),Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio),COMPLETED,2016-12-01,2020-12-30,2020-12-30,2021-03-24,2018-06-19,OBSERVATIONAL,,24.0,ACTUAL,McGill University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",biomarker|teriflunomide|activity,Canada,Montreal,Quebec,1,Teriflunomide,DRUG,Biomarkers and disease activity in patients treated with Teriflunomide (Aubagio),,False,
NCT06372145,A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.,"An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis",RECRUITING,2024-04-16,2029-04-30,2029-04-30,2025-08-05,2024-04-17,INTERVENTIONAL,PHASE3,2500.0,ESTIMATED,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,,United States,Birmingham,Alabama,323,Tolebrutinib|Placebo|Teriflunomide,DRUG|DRUG|DRUG,"Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuation|Number of Participants with Potentially clinically significant abnormalities (PCSAs)",Time to onset of 6-month confirmed disability worsening (CDW for RMS) or confirmed disability progression (CDP for PPMS and NRSPMS) for participants from pivotal studies|Annualized Relapse Rate (ARR) for RMS only|Number of new and/or enlarging T2-hyperintense lesions per year|Change from baseline in total volume of T2-hyperintense lesions|ToleDYNAMIC substudy Change from baseline in biomarkers,False,
NCT02726672,Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis,Fatigue and Inspiratory Muscles Training Against Resistance in Patients With Multiple Sclerosis With Severe Disabilities,TERMINATED,2016-02,2018-05,2018-11,2018-11-23,2016-04-04,INTERVENTIONAL,NA,46.0,ACTUAL,Lille Catholic University,OTHER,,,Multiple Sclerosis,inspiratory muscles|multiple sclerosis|rehabilitation,France,Lomme,,1,respiratory rehabilitation using Powerbreathe,DEVICE,Fatigue graded according to EMIF-SEP questionnaire,Sleep disorders graded according to the Epworth Sleepiness Scale|Quality of life graded according to the SEP-59 questionnaire|Maximal inspiratory pressure graded according to the Black and Hyatt method|Maximal expiratory pressure graded according to Black and Hyatt method|Forced vital capacity (FVC) graded with a portable spirometer|Tidal volume graded with a portable spirometer|Forced expiratory volume in one second (FEV1) graded with a portable spirometer|FEV1/ FVC ratio graded with a portable spirometer|Energy consumption during repeated effort|Depression graded according to the French version of the Beck Depression Inventory Fast-Screen|Swallowing problems graded according to the DYMUS score|Level of disability graded by the EDSS (Expanded Disability Status Scale)|Collection of the drug treatments received evaluated by a questionnaire,False,
NCT03567239,Impact of Custom Assistive and Adaptive Technology in Rehabilitation,Evaluating the Impact of Custom Assistive and Adaptive Technology,COMPLETED,2018-06-25,2019-09-01,2020-02-26,2024-11-25,2018-06-25,INTERVENTIONAL,NA,5.0,ACTUAL,Madonna Rehabilitation Hospital,OTHER,,,Disability Physical|Brain Injuries|Stroke|Spinal Cord Injuries|Multiple Sclerosis|Paralysis,Rehabilitation Engineering|Adaptive Devices|Assistive Technology,United States,Lincoln,Nebraska,1,Using adaptive device.,DEVICE,The PIADS (Psychosocial Impact of Assistive Devices) Mean Score,Workload|QUEST Questionnaire Form Scores,True,2024-11-25
NCT02962414,Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment,"An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.",ACTIVE_NOT_RECRUITING,2017-06-08,2027-08-04,2027-08-13,2025-05-28,2016-11-11,INTERVENTIONAL,PHASE3,206.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex,Everolimus|Tuberous sclerosis complex|TSC|Refractory seizure|Roll over study|Long term safety|PASS,United States,Phoenix,Arizona,68,everolimus,DRUG,Occurances of adverse events and serious adverse events,Percentage of patients with clinical benefit,False,
NCT02687633,Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex,Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex,COMPLETED,2015-09,2017-08,2017-08,2018-05-02,2016-02-22,INTERVENTIONAL,NA,8.0,ACTUAL,"University of California, Los Angeles",OTHER,Boston Children's Hospital,OTHER,Tuberous Sclerosis Complex,,United States,Los Angeles,California,1,JASPER,BEHAVIORAL,"change from baseline in Joint Engagement (shared engagement in a play routine) at 2 weeks into study participation, according to the parent caregiver interaction assessment.|change from baseline in Joint Engagement (shared engagement in a play routine) at 3 months into study participation, according to the parent caregiver interaction assessment.|change from baseline in Joint Engagement (shared engagement in a play routine) at 6 months into study participation, according to the parent caregiver interaction assessment.","Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 2 weeks|Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 3 months|Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 6 months|Change from baseline in Symbolic Play (types of play and level of play) at 2 weeks, according to the Structured Play Assessment (SPA)|Change from baseline in Symbolic Play (types of play and level of play) at 3 months, according to the Structured Play Assessment (SPA)|Change from baseline in Symbolic Play (types of play and level of play) at 6 months, according to the Structured Play Assessment (SPA)|Change from baseline at 3 months in developmental quotient, as determined by the Mullen Scales of Early Learning|Change from baseline at 6 months in developmental quotient, as determined by the Mullen Scales of Early Learning|Change from baseline at 2 weeks in the amount of Parent use of social communication support strategies|Change from baseline at 3 months in the amount of Parent use of social communication support strategies|Change from baseline at 6 months in the amount of Parent use of social communication support strategies",False,
NCT00947752,Safety of New Formulation of Glatiramer Acetate,"An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection",COMPLETED,2009-07,2009-09,2009-11,2017-03-14,2009-07-28,INTERVENTIONAL,PHASE3,147.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis (RRMS)|Glatiramer Acetate (GA),,,,0,Glatiramer Acetate|Experimental Glatiramer Acetate,DRUG|DRUG,Subject-reported Pain Associated Immediately After Each Injection,Degree of Pain Within 5 Mins After Injection,True,2011-06-09
NCT00483847,TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World,TYGRIS - ROW: TYSABRI® Global Observational Program in Safety - Rest of World,COMPLETED,2006-09,2014-11,2014-11,2015-04-13,2007-06-07,OBSERVATIONAL,,4296.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,TYGRIS - Rest of World (ROW)|TYSABRI|natalizumab|Multiple Sclerosis,Germany,Mannheim,,1,,,"Number of participants with serious infections, malignancies, and other serious adverse events (SAEs)",,False,
NCT01538355,A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis,A Randomised Controlled Pilot Study to Compare the Effects of Prolonged Fasting and Ketogenic Low Glycemic Load Treatment on Health Related Quality of Life in Relapsing-remitting Multiple Sclerosis.,COMPLETED,2012-07-30,2013-02-28,2020-06-23,2021-04-08,2012-02-24,INTERVENTIONAL,NA,48.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,,,Relapsing-Remitting Multiple Sclerosis,multiple sclerosis|diet|prolonged fasting|caloric restriction|ketogenic low glycemic load treatment|health related quality of life|ketogenic diet|neurodegeneration|neuroinflammation,Germany,Berlin,,1,Prolonged Fasting|Ketogenic low glycemic load treatment|Control diet,OTHER|OTHER|OTHER,Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.,"Adherence rates, number of participants with adverse events and laboratory parameters at 6 months.",False,
NCT05175378,Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study,Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study,COMPLETED,2020-12-01,2021-02-28,2021-03-12,2022-01-03,2022-01-03,INTERVENTIONAL,NA,40.0,ACTUAL,"Iaso Maternity Hospital, Athens, Greece",OTHER,Harokopio University|G.Gennimatas General Hospital,OTHER|OTHER,Multiple Sclerosis,relapsing-remitting multiple sclerosis|Mediterranean diet|cardiovascular health,Greece,Athens,,1,Lifestyle intervention,OTHER,MedDietScore,,False,
NCT03021317,Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses,Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses,TERMINATED,2016-12-20,2020-10-07,2020-10-07,2024-05-16,2017-01-13,INTERVENTIONAL,PHASE4,5.0,ACTUAL,University of Chicago,OTHER,,,Multiple Sclerosis,,,,,0,ACTHar,DRUG,Change in T1 Lesion Relaxation Time,Change in Immune Subset Expression in CD4+FOXP3 Tregs by Flow Cytometry Post ACTHAR Intervention,True,2024-05-16
NCT06032468,ARC Intellicare for Telerehabilitation,ARC Intellicare for Telerehabilitation in Neurological Patients,COMPLETED,2023-01-09,2023-09-30,2023-12-31,2024-03-13,2023-09-13,INTERVENTIONAL,NA,90.0,ACTUAL,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,,,Parkinson Disease|Multiple Sclerosis|Stroke,,Italy,Roma,Rome,1,ARC Intellicare|Rehabilitation sheets,DEVICE|OTHER,Efficacy outcome: Six minutes walking test (6MWT)|Efficacy outcome: Borg scale|safety outcome: adverse event frequency|Usability outcome: adherence to prescription,,False,
NCT00267319,FOCUS Fatigue Outcome in Copaxone USers,Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis,COMPLETED,2003-06,2006-10,,2009-12-07,2005-12-20,INTERVENTIONAL,PHASE4,111.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,Czechia,Prague,,1,Glatiramer acetate,DRUG,fatigue impact scale,relapse rate|quality of life|depression|disability|Adverse events,False,
NCT04879628,Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis,"A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2021-06-07,2022-09-21,2027-08-23,2024-08-15,2021-05-10,INTERVENTIONAL,PHASE2,129.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,38,SAR441344 IV|placebo IV|SAR441344 SC|placebo SC|MRI contrast-enhancing preparations,DRUG|DRUG|DRUG|DRUG|DRUG,Number of new Gadolinium (Gd)-enhancing T1-hyperintense (GdE T1) lesions,Number of new or enlarging T2 lesions|Total number of GdE T1 lesions|Adverse events (AEs) and serious adverse events (SAEs)|Antidrug antibodies (ADA)|Pharmacokinetic (PK) parameters: Cmax|PK parameter: tmax|PK parameter: AUC0-tau|PK parameter: t1/2z,False,
NCT04265092,Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis,Gaitox :Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis an Observational Study on Gait Spatiotemporal Parameters,COMPLETED,2014-01,2014-03,2019-01,2020-02-11,2020-02-11,OBSERVATIONAL,,22.0,ACTUAL,Pôle Saint Hélier,OTHER,,,Multiple Sclerosis,Gait|Multiple Sclerosis|Spasticity|Toxin|Triceps surae,,,,0,Incobotulinum toxin A,DRUG,Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters|Spatiotemporal gait parameters,Six-Minute Walk Test (6MWT)|the Multiple Sclerosis Walking Scale (MSWS-12)|the Goal Attainment Scale (GAS) score with determination|The Timed Up and Go test (TUG),False,
NCT01905527,Adherence Trial With MS LifeLines ® Services,"A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)",TERMINATED,2013-07,2015-01,2015-01,2015-02-02,2013-07-23,OBSERVATIONAL,,306.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis|Relapsing-Remitting,Multiple Sclerosis|Relapsing-Remitting|Rebif|Quintiles Geographic Area Group|Standard Subgroup|Custom Subgroup|RxCrossroads Geographic Area Group,United States,Boston,Massachusetts,1,Standard Services of Group A (Group A1)|Customized Services of Group A (Group A2)|Group B,OTHER|OTHER|OTHER,"Subject-reported adherence to treatment, calculated as percent adherence ([number of actual injections / number of expected injections] * 100), for subjects in the Group A1 compared with subjects in the Group A2","Subject-reported adherence to treatment in Group A1, Group A2 and Group B at Month 12|Subject-reported adherence to treatment in Group A1, Group A2 and Group B at Months 3 and 6|Subject-reported Multiple Sclerosis Rating Scale- Revised (MSRS-R) in Group A1, Group A2 and Group B|Subject-reported Patient-determined Disease Steps Questionnaire (PDDS) in Group A1, Group A2 and Group B|Subject-reported Multiple Sclerosis Self-management Scale - Revised (MSSM-R) in Group A1, Group A2 and Group B|Subject-reported Multiple Sclerosis International Quality of Life (MusiQoL) in Group A1, Group A2 and Group B|Subject-reported Morisky Medication Adherence Scale-4 (MMAS-4) in Group A1, Group A2 and Group B|Change from Baseline in Subject-reported multiple Sclerosis Rating Scale- Revised (MSRS-R) in Group A1, Group A2 and Group B at Months 6 and 12|Change from Baseline in Subject-reported Patient-determined Disease Steps Questionnaire (PDDS) in Group A1, Group A2 and Group B at Months 6 and 12|Change from Baseline in Subject-reported Multiple Sclerosis Self-management Scale - Revised (MSSM-R) in Group A1, Group A2 and Group B at Months 6 and 12|Change from Baseline in Subject-reported Multiple Sclerosis International Quality of Life (MusiQoL) in Group A1, Group A2 and Group B at Months 6 and 12|Change from Baseline in Subject-reported score in Morisky Medication Adherence Scale-4 (MMAS-4) in Group A1, Group A2 and Group B at Months 2, 6, 9 and 12|Percentage of subjects who dropped-out of the trial along with the reasons of dropping out in Group A1, Group A2 and Group B|Percentage of subjects with more than 80 percent and 90 percent subject-reported adherence to treatment in Group A1, Group A2 and Group B|Percentage of subject demographic characteristics in Group A1, Group A2 and Group B",False,
NCT06311474,Remote Assessment and Intervention for Behavior Problems in Kids With TSC,Assessment and Treatment of Behavior Problems in TSC at Preschool Age: A Telehealth Approach,ACTIVE_NOT_RECRUITING,2022-08-01,2025-12,2026-02,2025-08-27,2024-03-15,INTERVENTIONAL,NA,100.0,ESTIMATED,"University of California, Los Angeles",OTHER,,,Tuberous Sclerosis,TAND|TSC|Behavior Problems|PCIT|TSC-Associated Neuropsychiatric Disorders,United States,Los Angeles,California,1,Parent-Child Interaction Therapy (PCIT),BEHAVIORAL,Eyberg Child Behavior Inventory (ECBI),Behavior Assessment Scale for Children-3rd Edition (BASC-3)|Vineland Adaptive Behavior Scales-3rd Edition (Vineland-3)|Parenting Stress Index-4th Edition-Short Form (PSI-4-SF)|Dyadic Parent-Child Interaction Coding System (DPICS)|Therapy Attitude Index (TAI)|Telehealth Usability Questionnaire (TUQ)|Aberrant Behavior Checklist (ABC),False,
NCT05209113,Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis,Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis,UNKNOWN,2020-09-15,2021-12-15,2022-09-15,2022-01-27,2022-01-26,INTERVENTIONAL,NA,200.0,ACTUAL,Hacettepe University,OTHER,,,Multiple Sclerosis,self management|disease modifying treatments|clinical pharmacist|treatment adherence,Turkey (Türkiye),Ankara,Sihhiye,1,Education,OTHER,Changes in the self-management scale (Multiple Sclerosis Self Management Revised) scores of patients after the implementation of the self-management module,Changes in the patient engagement (Patient Health Engagement Scale) scores of patients after the implementation of the self-management module|Changes in the perception of care (Patient Assessment of Chronic Illness Care-PACIC) scores of patients after the implementation of the self-management module,False,
NCT04141891,Advancing Understanding of Transportation Options,Decision Making Among Older Adults: the AUTO Study,COMPLETED,2019-12-12,2023-06-23,2023-12-21,2025-02-21,2019-10-28,INTERVENTIONAL,NA,529.0,ACTUAL,"University of Colorado, Denver",OTHER,National Institute on Aging (NIA),NIH,Diabetic Retinopathy|Macular Degeneration|Glaucoma|Retinitis Pigmentosa|Vision Disorders|Acute Coronary Syndrome|Implantable Defibrillator User|Congestive Heart Failure|Hypertrophic Obstructive Cardiomyopathy|Orthostatic Hypotension|Syncope|Presyncope|Narcolepsy|Dementia|Multiple Sclerosis|Parkinson Disease|Brain Injuries|Spinal Cord Injuries|Stroke|Vertigo|Dizziness|Seizures|Substance Use|Insulin Dependent Diabetes Mellitus|Arthritis|Foot--Abnormalities|Chronic Obstructive Pulmonary Disease|Obstructive Sleep Apnea|End Stage Renal Disease|Sleep Apnea|Insomnia|Restless Legs Syndrome,,United States,La Jolla,California,3,Driving Decision Aid|Older Drivers Website,BEHAVIORAL|BEHAVIORAL,Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention),Values Clarity Subscale Score at Day 0 (Post-intervention)|Older Adult Driving Safety Knowledge Scores as Assessed by True/False Questions at Day 0 (Post-intervention)|Decision Self Efficacy Score at Day 0 (Post-intervention)|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 4-item Depression Score|Change in Ottawa Decision Regret Score|Change in Life Space Score|Change in Self-reported Driving Frequency|Change in Self-reported Situational Driving Avoidance|Occurrence of Driving Cessation|Occurrence of Self-reported Crashes,True,2025-02-21
NCT02218879,Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS,Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis,TERMINATED,2014-08,2016-04,2016-04,2016-09-05,2014-08-18,OBSERVATIONAL,,7.0,ACTUAL,Yale University,OTHER,,,Multiple Sclerosis,,United States,New Haven,Connecticut,1,Tecfidera,DRUG,Change in Glutathione Concentrations In Normal Appearing Gray Matter in Brain Measured by 7T Magnetic Resonance Imaging Scan,,False,
NCT05258396,Exploring Cortical Remyelination in Children With Multiple Sclerosis,Exploring Cortical Remyelination in Children With Multiple Sclerosis,RECRUITING,2022-08-11,2025-09-11,2025-09-11,2025-09-04,2022-02-28,INTERVENTIONAL,NA,40.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Children With Multiple Sclerosis,MRI|MS,France,Le Kremlin-Bicêtre,,3,MRI without injection of contrast product,OTHER,MTR-based individual indices,indices of cortical remyelination,False,
NCT05949580,Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis,Study to Evaluate the Usability of Introducing Integrated Digital Solutions Into Clinical Practice and the Value of Their Use in the Medical Care of Patients With Multiple Sclerosis (MS),RECRUITING,2024-10-21,2026-03-15,2026-04-30,2025-08-06,2023-07-18,OBSERVATIONAL,,500.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,icometrix,INDUSTRY,Relapsing Remitting Multiple Sclerosis,icobrain|icompanion|Multiple Sclerosis|Medical device|Patient app|Digital|Care management|Magnetic resonance imaging (MRI)|Deep learning|Artificial Intelligence (AI)|Patient Reported Outcomes (PRO),United States,Golden Valley,Minnesota,3,MS Care Platform (icobrain ms and icompanion ms),DEVICE,"HCPs: Median of the System Usability Scale (SUS) Score Reported by Radiologists and Neurologists at Month 6|HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 12|HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 24|Participants: Median Score of the mHealth App Usability Questionnaire (MAUQ) [MAUQ_E (Ease of Use) MAUQ_I (Interface and Satisfaction)] at Baseline|Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 12|Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 24|Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by Semi-structured Interviews (SSIs) at Month 6|Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 12|Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 24","Change From Baseline in Time Needed for MRI Review, Assessed by SSIs of Radiologists|Change From Baseline in Time Needed for Visit Preparation, Assessed by SSIs of Neurologists|Change From Baseline in Health Literacy Assessed by the Health Literacy Questionnaire (HLQ)|Change From Baseline in Participant Autonomy Assessed by the Patient Activation Measure® 13 (PAM13)|Change From Baseline in Medication Adherence, Assessed by the Morisky Medication Adherence Scale (MMAS)|Time in Days Needed for the Successful Installation and Integration of all Components in the MS Care Management Platform|Number of HCPs at Each Study Center Registered on the MS Care Management Platform|Factors Influencing HCPs Adoption to MS Care Management Platform Measured by SSIs|Number of MRI Scans per Study Center Analyzed With icobrain ms|Level of Engagement on Platform Assessed Monthly by the Number of Logins and Time Spent on Individual Portal Pages in the HCP Portal|Factors Influencing HCPs Adherence Measured by SSIs|Number of Participants at Each Study Center That Register for the icompanion ms Patient app|Reasons for not Registering for icompanion ms Patient app as Described by the HCP Through the icompanion ms HCP Portal|Average Number of Activities in the icompanion ms Patient app per Patient per Month|Number of Participants Using the icompanion ms Patient app With at Least 2 Activities Within 2 Months, Assessed per Month|Number of Participants That Stop Using the icompanion ms Patient app (no Activity for More Than 4 Months), Assessed per Month|Reasons for not Using the icompanion ms Patient app Regularly as Described by HCP Through the icompanion ms HCP Portal",False,
NCT02670161,Quality Improvement and Practice Based Research in Neurology Using the EMR,Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record,ENROLLING_BY_INVITATION,2016-05,2026-12,2027-12,2025-08-24,2016-02-01,INTERVENTIONAL,PHASE4,3300.0,ESTIMATED,Endeavor Health,OTHER,,,Brain Tumors|Epilepsy|Migraine|Mild Cognitive Impairment|Concussion|Multiple Sclerosis|Neuropathy|Parkinson's|Restless Legs Syndrome|Stroke,,United States,Evanston,Illinois,1,"Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)",DRUG,survival free of discontinuation or alternative prevention drug (migraine trial)|survival free of disability measured by FAQ score 9+ (memory trial)|survival free of discontinuation or alternative anti epileptic drug (epilepsy trial),,False,
NCT03574961,E-Support Groups in Multiple Sclerosis,A Randomized Controlled Trial of e-Support in Persons With Multiple Sclerosis,COMPLETED,2018-05-10,2019-04-30,2019-06-30,2020-09-01,2018-07-02,INTERVENTIONAL,NA,30.0,ACTUAL,Columbia University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,depression|social isolation,United States,New York,New York,1,e-Support group|e-Journaling placebo,BEHAVIORAL|BEHAVIORAL,Percentage of enrolled participants who completed follow-up questionnaires|Change in UCLA Loneliness Scale total score (please note that the official name of the scale is the UCLA Loneliness Scale).,Change in overall depression [Patient Health Questionnaire (PHQ-9)] total score|Change in overall Functional Assessment of Multiple Sclerosis Quality of Life (FAMS QoL) score,False,
NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks","Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod",COMPLETED,2014-09-29,2020-01-24,2020-01-24,2021-02-10,2014-09-04,INTERVENTIONAL,PHASE4,6.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,"multiple sclerosis, fingolimod, adult, FTY720, inflammatory disease, demyelination, auto-inflammatory disease, relapsing-remitting MS, CFTY720D2406",Belgium,Ghent,,4,Fingolimod,DRUG,Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event,,True,2021-02-10
NCT01144351,A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis,"A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis",TERMINATED,2010-03,2012-12,,2015-12-14,2010-06-15,INTERVENTIONAL,PHASE1,32.0,ACTUAL,Elan Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,MS|SPMS|RRMS|Relapsing Forms of Secondary Progressive Multiple Sclerosis (SPMS)|or Relapsing-Remitting Multiple Sclerosis (RRMS),United States,Berkeley,California,20,ELND002|Placebo,DRUG|DRUG,To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT) and determination of the maximum tolerated dose (MTD) in patients with multiple sclerosis (MS).,"Assessment of PK and PD measures of ELND002 (including but not limited to Cmax, Tmax, T1/2, AUC)|Assessment of the cumulative number and volume of Gd-enhancing T1-weighed MRI brain lesions|Reduction in rate of clinical relapses.",False,
NCT01244139,Safety Study of BIIB033 in Subjects With Multiple Sclerosis,"A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis",COMPLETED,2010-10,2012-04,2012-04,2017-01-09,2010-11-19,INTERVENTIONAL,PHASE1,47.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,BIIB033|Multiple Sclerosis|anti-LINGO-1 antibody|Relapsing Remitting MS|remyelination|myelin repair|Multiple ascending dose|Secondary progessive MS,United States,Centennial,Colorado,1,BIIB033|Placebo,DRUG|DRUG,"Evaluate safety and tolerability profile of two IV infusions of BIIB033 in subjects with MS|Identify incidence and types of adverse events|The incidence of serious adverse events|Changes from baseline in clinical lab assessments and vital signs|Changes form baseline in other safety measures: physical and neurological examinations, brain MRIs, and ECGs",Assess the repeat-dose serum PK profile of BIIB033|Assess the repeat-dose immunogenicity of BIIB033|Measure the concentration of BIIB033 in the cerebrospinal fluid|Explore potential biomarkers of BIIB033 activity in the periphery and in the central nervous system,False,
NCT05335031,"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)","Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)",COMPLETED,2021-03-03,2025-06-30,2025-06-30,2025-09-08,2022-04-19,OBSERVATIONAL,,450.0,ACTUAL,Bristol-Myers Squibb,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing-Remitting|Ozanimod|Zeposia®,Germany,Dresden,Saxony,1,Ozanimod,DRUG,Proportion of participants persistence with therapy,"Distribution of participant demographics characteristics: Age|Distribution of participant demographics characteristics: Sex|Distribution of participant demographics characteristics: Height|Distribution of participant demographics characteristics: Body weight|Distribution of clinical characteristics: Smoking status|Distribution of clinical characteristics: Multiple Sclerosis (MS) diagnosis|Distribution of clinical characteristics: MS anamnesis/history|Distribution of clinical characteristics: Prior diseases|Distribution of clinical characteristics: Concomitant diseases|Distribution of clinical characteristics: Concomitant medication|Distribution of clinical characteristics: Prior MS medication|Distribution of clinical characteristics: Physical examination|Distribution of clinical characteristics: Reasons for switch to ozanimod|Distribution of clinical characteristics: Treatment start with ozanimod|Distribution of clinical characteristics: Discontinuation, defined as physician's documentation of a discontinuation of ozanimod treatment|Distribution of clinical characteristics: Reason for discontinuation|Distribution of clinical characteristics: Subsequent MS treatment|Distribution of clinical characteristics: Persistence with therapy|Distribution of clinical characteristics: Adherence to therapy|Treatment Satisfaction Questionnaire for Medication (TSQM v1.4)|Symbol Digit Modalities Test (SDMT)|Fatigue scale for motor and cognitive functions (FSMC)|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|United Kingdom Neurological Disability Rating Scale (UNDS)|Clinical Relapse defined as the annualized relapse rate (ARR)|Expanded disability status scale (EDSS)|Work Productivity and Activity Index-Multiple Sclerosis (WPAI-MS German v2.1)|Multiple Sclerosis Health Resource Survey (MS-HRS 3.0)|Incidence rate for Adverse Events (AEs)",False,
NCT00418145,Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks,Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA),TERMINATED,2003-09,2013-10,2013-10,2017-05-18,2007-01-04,INTERVENTIONAL,PHASE3,16.0,ACTUAL,Fred Lublin,OTHER,National Multiple Sclerosis Society|Pfizer,OTHER|INDUSTRY,Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis,United States,New Brunswick,New Jersey,10,megadose oral methylprednisolone|IV methylprednisolone,DRUG|DRUG,Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28.,Clinical Parameters of the Multiple Sclerosis Functional Composite Scale (MSFC) Between Oral and IV Steroid Therapy in Subjects With Relapsing Forms of MS.|Frequency of Relapse Over Time (up to One Year) When Subjects With Relapsing Forms of MS Are Administered One Course of Oral Methylprednisolone Compared to IV Administration.|Improvement Using Targeted Neurological Deficits (TND).,True,2017-05-18
NCT05560139,The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients,The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients,UNKNOWN,2022-12-01,2023-05-01,2023-09-01,2022-09-29,2022-09-29,INTERVENTIONAL,NA,36.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Transcranial direct current stimulation|fatigue,,,,0,a-tDCS,DEVICE,fatigue assessment scale|visual analogue scale,changes in cortical excitability parameters at post 10th session compared to baseline measurements of cortical excitability parameters,False,
NCT02489877,Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus,Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients,UNKNOWN,2015-07,2016-07,2017-07,2015-07-03,2015-07-03,OBSERVATIONAL,,84.0,ESTIMATED,Faculdade de Ciências Médicas da Santa Casa de São Paulo,OTHER,University of Sao Paulo,OTHER,Multiple Sclerosis,multiple sclerosis|HERV-W virus|Herpesviridae family,,,,0,,,Composite: Degree of disease activity,,False,
NCT05943145,Outcomes of Group Dance and Movement Training in Ambulatory MS Patients,Outcomes of Group Dance and Movement Training in Ambulatory MS Patients,COMPLETED,2023-04-24,2023-07-14,2023-11-27,2023-11-28,2023-07-13,INTERVENTIONAL,NA,6.0,ACTUAL,GroundWorks DanceTheater,OTHER,,,Multiple Sclerosis,dance|movement,United States,Cleveland,Ohio,1,Group Dance and Movement Training,OTHER,Timed Up and Go (TUG)|9 Hole Peg Test (NHPT),"Neuro-QOL Positive Affect and Well-Being - Short Form|Neuro-QOL Lower Extremity Function (Mobility) - Short Form|Neuro-QOL Upper Extremity Function (Fine Motor, ADL) - Short Form",False,
NCT02034188,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis,COMPLETED,2014-01,2016-03,2016-03,2017-08-10,2014-01-13,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,Translational Biosciences,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|umbilical cord|mesenchymal|stem cells,Panama,Panama City,,1,Umbilical cord mesenchymal stem cells,BIOLOGICAL,Number of participants with adverse events,Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)|Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale|Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT)|Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test|Number of participants with a change in mobility and leg function as measured by the 25 foot walking test|Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire|Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)|Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI),False,
NCT03174379,A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis,A Pilot Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis,COMPLETED,2017-06-05,2019-06-06,2019-06-06,2022-03-21,2017-06-02,INTERVENTIONAL,NA,13.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,Standard of Care with no acupuncture|Acupuncture,PROCEDURE|PROCEDURE,fatigue severity scale|Medical Outcomes Study Pain Effects Scale|Gait measured by 6-minute walk test|Balance measured by 25-foot walk test,,False,
NCT01667796,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls,COMPLETED,2010-11,2014-03,2014-03,2019-03-05,2012-08-17,INTERVENTIONAL,NA,57.0,ACTUAL,Johns Hopkins University,OTHER,"University of California, San Francisco|National Multiple Sclerosis Society",OTHER|OTHER,"Multiple Sclerosis, Relapsing-remitting",Multiple sclerosis|Healthy controls|Pharmacokinetics|Vitamin D,United States,San Francisco,California,2,Vitamin D3,DIETARY_SUPPLEMENT,Change in Mean Serum Level of 25-hydroxyvitamin D,Change in Percentages of T Cell Subsets (IFNγ+ and IL-17+)|Gene Expression Microarray|Change in Cytokine Levels|Change in Percentage of B Cells,True,2016-02-01
NCT04998305,TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps,"A Phase 1/2 Two-center, Double-blind, Randomized, Placebo-controlled Multi-period Crossover (N-of-1) Study to Evaluable the Feasibility, Safety, and Efficacy of TJ-68 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps",COMPLETED,2022-09-30,2024-07-26,2024-07-26,2025-05-01,2021-08-10,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,Hiroshi Mitsumoto,OTHER,"Tsumura & Co., Tokyo, Japan",UNKNOWN,Amyotrophic Lateral Sclerosis|Muscle Cramp,,United States,Scottsdale,Arizona,3,TJ-68|Placebo,DRUG|DRUG,Visual Analog Scale (MCS-VAS) Score,Overall Muscle Cramp Scale (MCS) Score|Self-reported Cramp Pain Score|ALSFRS-R Score|Clinical Global Impression of Changes (CGIC) Score|ALSAQ-5 (Quality of Life Questionnaire) Score|Goal Attainment Scale (GAS) Score,True,2025-05-01
NCT04874051,Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases,Sensor-Based Analysis And rehabiLitation of bAlance in Neurological Diseases: a multiCentric randomizEd Clinical Trial,UNKNOWN,2019-09-02,2023-12-31,2023-12-31,2023-03-22,2021-05-05,INTERVENTIONAL,NA,120.0,ESTIMATED,"IRCCS San Camillo, Venezia, Italy",OTHER,"IRCCS San Raffaele|Istituti Clinici Scientifici Maugeri SpA|IRCCS National Neurological Institute ""C. Mondino"" Foundation|I.R.C.C.S. Fondazione Santa Lucia",OTHER|OTHER|OTHER|OTHER,Stroke|Multiple Sclerosis|Parkinson Disease,Balance|Sensor-based rehabilitation|Virtual Reality,Italy,Pavia,,5,Experimental Group|Control Group,DEVICE|OTHER,Berg Balance Scale (BBS),Number of falls during the last year|Functional Ambulation Classification (FAC)|Activities specific-Balance Confidence scale (ABC)|Functional Independence Measure (FIM)|Barthel Index (BI)|National Institution of Health Stroke Scale (NIHSS)|Unified Parkinson's Disease Rating Scale (UPDRS)|Hoehn & Yahr Scale (H&Y)|Kurtzke Extended Disability Status Scale (EDSS),False,
NCT03544177,Effects of Low-intensity Interval Walking With Blood Flow Restriction on Functional Capacity in Multiple Sclerosis,Effects of Low-intensity Interval Walking With Blood Flow Restriction on Gait Speed and Functional Impairments in Patients With Severe Multiple Sclerosis: a Pilot Study,COMPLETED,2018-05-21,2019-09-30,2019-12-30,2020-02-05,2018-06-01,INTERVENTIONAL,NA,24.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,mobility|exercise therapy|blood flow restricted exercise|rehabilitation,Italy,Ferrara,,1,BFR-Walking|Conventional therapy,OTHER|OTHER,Timed 25-foot Walk test,6-Minute Walking Test|Berg Balance Scale|5-time Sit-to-Stand test|Multiple Sclerosis Impact Scale|Fatigue Severity Scale|Short Form Health Survey 36,False,
NCT04868370,Validation of a Novel Instrument Task for Assessing Upper Limb,Validation of a Novel Instrument Task for Assessing Upper Limb Sensorimotor Impairments in Persons With Chronic Neurological Disorders,COMPLETED,2021-05-05,2023-01-31,2023-01-31,2023-11-29,2021-04-30,OBSERVATIONAL,,80.0,ACTUAL,Swiss Federal Institute of Technology,OTHER,"Kliniken Valens, Rehazentrum Valens, Taminaplatz 1, 7317 Valens",UNKNOWN,Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis Subjects,Rehabilitation|Multiple Sclerosis|Sensorimotor Impairment|Assessments|Neurological Disease,Switzerland,Valens,Canton of St. Gallen,1,Assessment of the upper limb (VPIT + PPIT),OTHER,Validation of the Physical Peg Insertion Test (PPIT)|Feasibility of the Physical Peg Insertion Test (PPIT)|Reliability of the Physical Peg Insertion Test (PPIT)|Sensitivity of the Physical Peg Insertion Test (PPIT)|Validity of the Physical Peg Insertion Test (PPIT),,False,
NCT01576354,Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis,"A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters",UNKNOWN,2012-03,2017-04,2017-04,2015-12-04,2012-04-12,INTERVENTIONAL,PHASE2,70.0,ESTIMATED,University of Zurich,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|walking function|fampridine,Switzerland,Zurich,Canton of Zurich,1,Prolonged-release Fampridine|Placebo,DRUG|DRUG,Changed walking pattern on treadmill under fampridine treatment.,6 minute Walking Test|Timed 25-foot Walk test|Timed-Up-and-Go test|Berg Balance Scale|Dynamic Gait Index|LEMMT|Actimeter|12-item MS Walking Scale|Fatigue Questionnaire (WEIMuS),False,
NCT00917839,The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis,"Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.",UNKNOWN,2009-06,2010-12,2011-12,2009-06-10,2009-06-10,INTERVENTIONAL,PHASE2,88.0,ESTIMATED,Cantonal Hospital of St. Gallen,OTHER,,,Relapsing-Remitting Multiple Sclerosis,neuroprotection|multiple sclerosis|brain atrophy|mr-spectroscopy,Switzerland,Sankt Gallen,Canton of St. Gallen,1,lamotrigine,DRUG,N-Acetyl-Aspartate / creatine - quotient in normal appearing white matter by MR-spectroscopy|Safety of lamotrigine in combination with interferon beta 1a (30 mcg) once weekly intramuscular.,relapse rate|Expanded disability status score|Fatigue Severity Score|N-Acetyl-Aspartate / creatine - quotient in normal appearing white matter by MR-spectroscopy,False,
NCT06072001,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,RECRUITING,2023-11-02,2024-09-30,2024-12-31,2024-01-31,2023-10-10,INTERVENTIONAL,PHASE3,558.0,ESTIMATED,Apurano Pharmaceuticals GmbH,INDUSTRY,,,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome With Pain|Phantom Pain|Traumatic Brain Injury",Adezunap|Pain Therapy|Pain|Pain Syndrome|Chronic Pain|Chronic Pain Syndrome|Central Nervous System|CNS|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome with Pain|Phantom Pain|Traumatic Brain Injury|THC|Tetrahydrocannabinol|Delta-9-Tetrahydrocannabinol|Cannabis|Cannabinoids,Germany,Munich,Bavaria,1,Adezunap (AP707)|Placebo,DRUG|DRUG,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 26 (end of second treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)|Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 52 (end of third treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)|Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14, treatment week 26 and treatment week 52 in comparison of study arm 1 (verum) and study arm 2 (placebo)|Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5, 11, 18, 22, 30, 34, 43, 47 in comparison of study arm 1 (verum) and study arm 2 (placebo)|Responder analysis for endpoints 1), 2), 3) and 4) for treatment week 14, 26 and 52|Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14|Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14, 26, and 52|Change of Patient Global Impression of Change (PGIC) from start to week 14, 26, and 52|Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14, 26, and 52|Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14, 26, and 52|Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14, 26, and 52|Area under NRS-curve until treatment week 5, 11, 14, 18, 22, 26, 30, 34, 39, 43, 47, 52|Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14, 26, and 52|Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52",False,
NCT05604170,Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy,"A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)",ENROLLING_BY_INVITATION,2022-05-16,2027-06,2027-06,2024-05-13,2022-11-03,INTERVENTIONAL,PHASE3,132.0,ESTIMATED,Marinus Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex-Related Epilepsy|Ganaxolone|Adjunctive,United States,Little Rock,Arkansas,59,Ganaxolone,DRUG,"Number of participants with adverse events (AEs), serious adverse events (SAEs) and withdrawals and dose-reductions due to AEs|Number of participants with abnormal vital signs|Number of participants with abnormal physical, neurological and developmental examination|Number of participants with abnormal 12-lead electrocardiogram (ECG) findings|Number of participants with abnormal clinical laboratory tests|Number of participants with abnormal Columbia-Suicide Severity Rating Scale (C-SSRS)","Percent change from Baseline in 28-day seizure frequency during open label extension|Percent change from Baseline in 28-day seizure frequency during the long-term treatment|Number of participants who will be considered as Treatment Responders|Number of Participants with Clinical Global Impression of Improvement (CGI-I)|Change from Baseline in quality-of-life scale Short Form-36 (SF-36)|Change from Baseline in percentage of Seizure-Free Days during treatment, based on seizure type|Change from Baseline in Caregiver Global Impression of Change in Seizure Intensity/Duration (CGI-CSID)",False,
NCT02408367,Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study,Intensity Depended Impact of a Single Exercise Bout on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study,UNKNOWN,2015-02,2015-05,2015-05,2015-04-21,2015-04-03,OBSERVATIONAL,,20.0,ESTIMATED,Jens Bansi,OTHER,,,Multiple Sclerosis,Training|Cognition|Multiple Sclerosis,Switzerland,Valens,Canton of St. Gallen,1,Exercise|Relaxation,BEHAVIORAL|BEHAVIORAL,Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS),Cardiorespiratory parameters|Lactate,False,
NCT01381354,"Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)","Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)",COMPLETED,2010-10,2016-02,2016-05,2018-06-26,2011-06-27,INTERVENTIONAL,PHASE1,38.0,ACTUAL,University of Iowa,OTHER,"Direct MS Canada|DJO Incorporated|Pinnaclife Inc.|TZ Press, LLC",UNKNOWN|INDUSTRY|INDUSTRY|UNKNOWN,Multiple Sclerosis,"Secondary Progressive Multiple Sclerosis, primary progressive multiple sclerosis",United States,Iowa City,Iowa,1,Progressive exercise|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Modified paleolithic diet|Omega 3 fatty acids|Full Spectrum vitamin|Essential - hydroxytyrosol|Maltodextrin fiber supplement|Mineral boost (magnesium)|Niacinamide|Methyl B12|Taurine|creatine|thiamine|riboflavin|N acetylcysteine|alpha lipoic acid|L acetyl carnitine|methyl folate|coenzyme Q|meditation|self massage|learning|Coconut oil,OTHER|DEVICE|OTHER|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|DIETARY_SUPPLEMENT,Fatigue severity scale,25 foot walk|Short Form 36|Mood scales|Cognitive Scales|Medical Symptoms Questionnaire|Side effects log|MS Function|Multiple Sclerosis Spasticity Scale-88|Daily log|Vitamin log|Medical examination|Neurological examination|Exposure history form|Health questions|Menses and pregnancy risk|Medication audit|Functional diagnoses|Manual motor testing|Berg Balance|Modified Ashworth|Circumference|Peak flow|Number of falls in prior two months|Dietary compliance|Blood pressure|Waist/ Hip ratio|MS quality of life- 54|Blood Biomarkers|Change in functional and structural brain Magnetic Resonance Imaging (MRI) measures|Fatigue severity scale|Get up and go test time|Change in weight and Body mass index (BMI)|Blood safety biomarkers|9 hole peg board test|Paced auditory serial addition task (PASAT)|Veteran specific activity questionnaire|Form 38- Daily life|Urine toxicology|Stool microbial profile|Harvard food frequency questionnaire and 24 hour food recalls|Bio impedance analysis|Exercise and electrical stimulation daily log,False,
NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,"A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2007-06,2011-08,2011-08,2015-01-26,2007-03-23,INTERVENTIONAL,PHASE3,1417.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,relapsing|multiple sclerosis|oral|remitting,United States,Birmingham,Alabama,195,BG00012|Placebo|Glatiramer Acetate,DRUG|DRUG|DRUG,Annualized Relapse Rate,Number of New or Newly Enlarging T2 Hyperintense Lesions|Number of New T1 Hypointense Lesions|Proportion of Subjects Relapsed|Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS),True,2014-06-02
NCT00334100,Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness,Treadmill Training in Chronic MS: Efficacy and Cost-Effectiveness,WITHDRAWN,2006-04,2011-09,2014-12,2014-10-09,2006-06-06,INTERVENTIONAL,NA,0.0,ACTUAL,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Exercise|multiple sclerosis|treadmill,United States,Baltimore,Maryland,1,Exercise,BEHAVIORAL,"Peak VO2 Treadmill, Step activity monitors, Timed 8 meter walk",,False,
NCT06019611,Epidural Stimulation in Multiple Sclerosis,A Pilot Study to Explore the Use of Percutaneous Spinal Stimulation in Participants With Multiple Sclerosis,COMPLETED,2023-09-11,2024-02-27,2024-02-27,2025-04-27,2023-08-31,INTERVENTIONAL,NA,2.0,ACTUAL,"Kristin Zhao, PhD",OTHER,Mayo Clinic,OTHER,Multiple Sclerosis|Demyelinating Disorder|Autoimmune Diseases,,United States,Rochester,Minnesota,1,Percutaneous epidural stimulation,DEVICE,"Kinematics|Static Balance, Eyes-open.|Electromyography (EMG)|Spasticity, Knee Extensors (1)|Spasticity, Knee Extensors (2)","Overground Ambulation|Disability|Fatigue|Pain, Overall|Bladder Control|Bowel Control|Impact of Visual Impairment|Cognitive Dysfunction|Mental Health|Social Support",True,2025-04-27
NCT07181811,Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis,"Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis: Utilizing Cognitive Assessment Scales, and Patient-Reported Outcome Measures",NOT_YET_RECRUITING,2025-09-30,2028-06-01,2028-06-01,2025-09-18,2025-09-18,INTERVENTIONAL,NA,30.0,ESTIMATED,Anza Memon,FED,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,Veterans|MS|Cognitive assessment|Ocrelizumab|OCR|Modified Fatigue Impact Scale (MFIS)|Brief International Cognitive Assessment for MS (BICAMS)|multiple sclerosis,United States,Detroit,Michigan,1,Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments,OTHER,"Change in global cognitive performance|Change in fatigue impact (Modified Fatigue Impact Scale, MFIS)","Change in health-related quality of life (Multiple Sclerosis Quality of Life-54; MSQOL-54, physical and mental composite scores)|Change in patient-reported physical and mental health (Patient-Reported Outcomes Measurement Information System, 29-item profile; PROMIS-29)",False,
NCT05332951,Study of Empathy in MS,Study of Empathy in Patients With Multiple Sclerosis,COMPLETED,2022-07-04,2022-12-19,2022-12-19,2024-02-02,2022-04-18,OBSERVATIONAL,,150.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,MS|social cognition|empathy,France,Paris,,2,Interpersonal Reactivity Index,OTHER,Interpersonal Reactivity Index (IRI),alexithymia|anxiety and depression|cognitive reserve|fatigue|cognitive deficit,False,
NCT06764602,"Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis","Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis",RECRUITING,2021-07-01,2025-12-31,2025-12-31,2025-01-08,2025-01-08,OBSERVATIONAL,,80.0,ESTIMATED,IRCCS Azienda Ospedaliero-Universitaria di Bologna,OTHER,,,Tuberous Sclerosis Complex (TSC),Tuberous Sclerosis Complex|Nephropathy|Children,Italy,Bologna,,1,,,Stage of angiomyolipoma,,False,
NCT04466228,Non-invasive Transcranial Electrical Stimulation in MS,Effects of Non-invasive Transcranial Electrical Stimulation on Cognition in Patients With Multiple Sclerosis,COMPLETED,2020-10-16,2022-08-23,2022-08-23,2023-12-04,2020-07-10,INTERVENTIONAL,NA,60.0,ACTUAL,"University of California, San Francisco",OTHER,,,Multiple Sclerosis|Cognitive Impairment,,United States,San Francisco,California,1,non-invasive transcranial electrical stimulation,DEVICE,Processing Speed Change From Baseline Assessment|EVO Performance Change From Baseline Assessment,,True,2023-12-04
NCT01514370,Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a,"ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)",COMPLETED,2012-04-30,2016-03-31,2016-03-31,2019-01-22,2012-01-23,INTERVENTIONAL,PHASE2,80.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono S.P.A., Italy",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Relapsing|Interferon beta 1a|Curcumin,Italy,Naples,,1,IFN beta 1a 44 mcg TIW|Curcumin|Placebo,DRUG|DRUG|DRUG,Number of Subjects With Active (New or Enlarging) T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) at Month 12,"Percentage of Relapse-Free Subjects at Month 12 and Month 24|Annualized Relapse Rate at Month 12 and 24|Total Number of Reported Relapses at Month 3, 6, 12 and 24|Percentage of Subjects Treated With Glucocorticoids Due to Relapses During 24 Months|Percentage of Subjects Free From Expanded Disability Status Scale (EDSS) Progression at Month 12 and 24|Hazard Ratio for Time to First Sustained Expanded Disability Status Scale (EDSS) Progression|Percentage of Subjects With Active (New/Enlarging) T2 Lesions at Month 24|Percentage of Subjects With Combined Unique Active (CUA) Lesions at Month 12 and 24|Mean Number of New Gadolinium (Gd)-Enhancing Lesions at Month 12 and 24|Mean Number of New T1 (Hypointense) Lesions at Month 12 and 24|Cumulative Number of New T1 (Hypointense) Lesions|Median Change From Baseline in Whole Brain Volume at Month 12 and 24|Median Change From Baseline in Regional Brain Volume at Month 12 and 24|Flu-like Symptoms (FLS) Assessed by FLS Scale Score|Number of Subjects With Treatment Emergent Adverse Event (TEAE), Serious AE (SAE), TEAE Leading to Death and Discontinuation|Number of Subjects With Clinical Significant Abnormality in Laboratory Parameters|Number of Subjects With One Concomitant Medication From Baseline up to Month 24|Time on Treatment (Adherence to Treatment)|Number of Subjects With Premature Termination From Treatment|Hazard Ratio for Time to First Documented Relapse",True,2019-01-22
NCT04604041,Investigation of Subclinical Markers of Multiple Sclerosis,Investigation of Subclinical Markers of Multiple Sclerosis,RECRUITING,2020-11-23,2024-12,2028-12-31,2023-10-02,2020-10-27,OBSERVATIONAL,,50.0,ESTIMATED,"University of Split, School of Medicine",OTHER,University Hospital of Split,OTHER,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis,multiple sclerosis|relapsing remitting|TMS|Cytometry|ELISA|corticosteroids|immunomodulation,Croatia,Split,,1,"1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA",DIAGNOSTIC_TEST,"TMS assessment of resting motor threshold (RMT) change|TMS assessment of motor evoked potentials (MEP) changes from upper and lower extremity muscles|TMS assessment of cortical silent period (CSP) change|TMS assessment of short afferent latency inhibition (SAI) change|EMNG assessment of distal motor latency (DML) and sensory nerve action potential latency (SNAP) change|EMNG assessment of muscle action potential amplitude (CMAP) and sensory nerve action potential amplitude (SNAP) change|EMNG assessment of motor and sensory conduction velocity (CV) change|EMNG assessment of F-wave change|CD 14 expression on peripheral blood monocytes change|CD 16 expression on peripheral blood monocytes change|CD 40 expression on peripheral blood monocytes change|CD 192 expression on peripheral blood monocytes change|Change of CD 163 levels in blood serum samples|CD 4 expression on lymphocytes|CD 25 expression on lymphocytes|CTLA-4 expression on lymphocytes|FOXP3 expression on lymphocytes|Hand dominance assessment with Edinburgh Handedness Inventory test.|Cognitive assessment change applying Letter Digit Substitution Test (LDST).|Cognitive assessment change applying Montreal Cognitive Assessment (MoCA).|Psychological assessment change applying Multiple Sclerosis Impact Scale (MSIS-29).|Psychological assessment change applying Depression, Anxiety, Stress (DASS-21) scale.|Psychological assessment change applying Fatigue Severity Scale (FSS).|Psychological assessment change applying Pain rating scale.|Psychomotor assessment of hand grip change applying SAEHAN Squeeze Dynamometer.|Psychomotor assessment change of extremity muscles applying Lafayette Manual Muscle Tester Dynamometer.|Psychomotor assessment change applying Lafayette O'Conner Finger Dexterity Test.|Barthel Index for Activities of Daily Living (ADL) change.","-Detection of potential predictors (neurophysiological, neuropsychological, clinical neurological, clinical biochemical, and MRI measures) of medication treatment of relapsing-remitting MS.",False,
NCT04948554,A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002),"A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis",TERMINATED,2023-03-10,2023-10-18,2023-10-18,2023-11-24,2021-07-02,INTERVENTIONAL,PHASE1,5.0,ACTUAL,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,,,Systemic Sclerosis With and Without Interstitial Lung Disease,Diffuse Systemic Sclerosis|Scleroderma|Systemic Sclerosis|Systemic Sclerosis-associated Interstitial Lung Disease,United States,La Jolla,California,16,MK-2225|Placebo,BIOLOGICAL|BIOLOGICAL,Number of Participants with ≥1 Adverse Event (AE)|Number of Participants Discontinuing from Study Therapy Due to AE,Area Under the Concentration-Time Curve (AUC0-tau) of MK-2225|Serum Maximum Concentration (Cmax) of MK-2225|Time to peak Serum Concentration (Tmax) of MK-2225|Serum Apparent Terminal Half-Life (t1/2) of MK-2225|Accumulation ratio of AUCtau (RAUC),False,
NCT00906737,Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities,Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities,COMPLETED,2009-04,2012-04,2012-04,2014-04-09,2009-05-21,INTERVENTIONAL,NA,18.0,ACTUAL,Mount Sinai Rehabilitation Hospital,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Gait|foot-drop|Ankle-Bot|Physical Therapy|Gait Abnormalities,United States,Hartford,Connecticut,1,Ankle-bot|Conventional focused ankle therapy,DEVICE|OTHER,Gait Parameters,,False,
NCT05382195,Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis,Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis,UNKNOWN,2022-06-01,2023-02-01,2023-02-01,2022-05-19,2022-05-19,OBSERVATIONAL,,100.0,ESTIMATED,Sohag University,OTHER,,,Patients With Multiple Sclerosis,,Egypt,Sohag,,1,hospital anxiety and depression scale,OTHER,depression in patients with multiple sclerosis|anxiety in patients with multiple sclerosis,,False,
NCT03444454,Telerehabilitation in Multiple Sclerosis,The Italian Network of Telerehabilitation: Evaluation of Telerehabilitation System for Continuum of Care in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2018-02-26,2018-12-31,2024-06-30,2024-05-03,2018-02-23,INTERVENTIONAL,NA,136.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,"IRCCS Centro Neurolesi Bonino Pulejo|Fondazione Mondino|IRCCS San Camillo, Venezia, Italy|IRCCS San Raffaele Roma|Istituti Clinici Scientifici Maugeri SpA",OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,Telerehabilitation|Virtual reality|Quality of life|transcranial Direct Current Stimulation,Italy,Milan,MI,1,VRRS Khymeia|Usual care program|VRRS Khymeia plus active tDCS|VRRS Khymeia plus placebo tDCS,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in measure of quality of life,Change in balance|Change in gait|Change gross manual dexterity|Change in global cognitive status|Change cognitive status|Change in fatigue|Change in Emotional Traits|Change in Behavioral (depression)|Change in Behavioral (anxiety),False,
NCT03147105,Armergometry to Improve Mobility in MS,Armergometry to Improve Mobility in Chronic Progressive Multiple Sclerosis,UNKNOWN,2017-05-01,2018-07-01,2018-12-31,2017-05-30,2017-05-10,INTERVENTIONAL,NA,50.0,ESTIMATED,Universitätsklinikum Hamburg-Eppendorf,OTHER,Deutsche Multiple Sklerose Gesellschaft Hamburg,UNKNOWN,Multiple Sclerosis,"chronic progressive multiple sclerosis, mobility, arm ergometry, rehabilitation",Germany,Hamburg,,1,arm ergometry,BEHAVIORAL,6 minute walking test,accelerometry|verbal learning and memory|peak oxygene uptake|brain atrophy|Brain derived neurotrophic factor,False,
NCT06384729,Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis,Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis: Randomized Clinical Trial,COMPLETED,2024-04-01,2024-05-01,2024-09-01,2025-06-17,2024-04-25,INTERVENTIONAL,NA,12.0,ACTUAL,Universidad Europea de Madrid,OTHER,,,Multiple Sclerosis,,Spain,Villaviciosa de Odón,Madrid,1,EXOPULSE Mollii Ⓡ,DEVICE,referred pain|Balance|gait speed and distance,fall risk|perception of walking difficulties|perceived quality of life,False,
NCT04973501,Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis,Evaluation of the Effect of the Physiotherapy on Mobility and Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis,COMPLETED,2016-05,2018-05,2020-12,2021-07-22,2021-07-22,INTERVENTIONAL,NA,50.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Multiple Sclerosis|Rehabilitation|Musculoskeletal Complication,Developmental kinesiology|Physiotherapy|Muscle imbalance|Musculoskeletal disorders,,,,0,Manual physiotherapeutic correction (MFK) Method|Dynamic Neuromuscular Stabilization (DNS) Method,BEHAVIORAL|BEHAVIORAL,Timed Up and Go (TUG)|Berg Balance Scale (BBS)|Dynamic Gait Index (DGI)|Five times Sit to Stand test (5STS)|2-Minute Walk Test (2MWT)|Symbol Digit Modalities Test (SDMT)|Four Square Step Test (FSST),Questionnaires - The Fatigue scale for motor and cognitive functions (FSMC)|Questionnaires -Multiple Sclerosis Impact Scale (MSIS-29)|Questionnaires - Euroqol-5 dimensions-5 levels health questionnaire|Questionnaires -Multiple Sclerosis Walking Scale-12 (MSWS-12)|Questionnaires - Rivermead Mobility (RMI)|Questionnaires- Activities-specific Balance Confidence Scale (ABC),False,
NCT04860947,"Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients","Assessment of Serum Neurofilament-light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) Levels, Atrophy of the Macular Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients",ACTIVE_NOT_RECRUITING,2019-06-25,2026-06,2026-06,2024-02-26,2021-04-27,OBSERVATIONAL,,200.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,Institut de Recherches en Biothérapie,UNKNOWN,Multiple Sclerosis,GFAP|NfL,France,Nîmes,,1,Brain MRI|Spinal Cord MRI|Retinal imaging,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Change in serum Neurofilament Light Chain serum levels since baseline|Change in serum Glial Fibrillary Acidic Protein (GFAP) serum levels since baseline|Change in Ganglion Cell Complex thickness since baseline|Change in whole brain volume since baseline|Expanded Disability Status Scale|Expanded Disability Status Scale,"Whole brain volume|Whole brain volume|Whole brain volume|Whole brain volume|Whole brain volume|Whole brain volume|Whole brain volume|Whole brain volume|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Expanded Disability Status Scale|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|Gadolinium-enhanced lesions|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|T2 lesion volume,|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|Grey matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|White matter atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Thalamic atrophy|Disease modifying drugs classification|Disease modifying drugs classification|serum NfL levels|serum GFAP levels|serum NfL levels|serum GFAP levels|serum NfL levels|serum GFAP levels|serum NfL levels|serum GFAP levels|serum NfL levels|serum GFAP levels|serum NfL levels|serum GFAP levels|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Multiple Sclerosis Functional Composite|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|Time to walk 100 meters|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|2 Minute walking distance|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive Impairment|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Cognitive evaluation|Health-related quality of life|Health-related quality of life|Health-related quality of life|Health-related quality of life|Health-related quality of life|Health-related quality of life|Health-related quality of life|Health-related quality of life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Impact of MS on daily life|Fatigue|Fatigue|Fatigue|Fatigue|Fatigue|Fatigue|Fatigue|Fatigue|Visual acuity|Visual acuity|Visual acuity|Visual acuity|Visual acuity|Visual acuity|Visual acuity|Visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Low contrast visual acuity|Relapse description|Number of new lesions",False,
NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients","Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study",COMPLETED,2019-02-14,2022-07-06,2022-07-06,2024-06-20,2018-08-09,INTERVENTIONAL,PHASE3,185.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Relapsing Multiple Sclerosis|Advancing Multiple Sclerosis,Multiple sclerosis|Relapsing multiple sclerosis|Advancing multiple sclerosis|conversion|siponimod|adult|BAF312|disease modifying therapies|cognitive assessment|open-label,United States,Birmingham,Alabama,55,Siponimod,DRUG,Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment Period,Number of Participants With at Least One Adverse Event (AE)|Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9)|Change in Heart Rate From Baseline to 6 Hours After First Treatment|Number of Participants With at Least One Hospitalization During the Treatment|Patient Retention Reported as Number of Participants Who Completed the Study,True,2023-07-20
NCT03041025,Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis,"A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis",COMPLETED,2017-06-05,2020-07-07,2020-07-07,2021-05-24,2017-02-02,INTERVENTIONAL,PHASE2,35.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Scleroderma, Systemic",Systemic Sclerosis|Repeat-dose|Phase IIA|GSK2330811|Pharmacodynamics|Pharmacokinetics|Proof of mechanism study,United States,Los Angeles,California,14,GSK2330811|Placebo,DRUG|DRUG,"Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell (WBC) Count|Change From Baseline in Hematology Parameters: Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin (MCH)|Change From Baseline in Hematology Parameters: Mean Corpuscle Volume (MCV), Mean Platelet Volume (MPV)|Change From Baseline in Hematology Parameters: Red Blood Cell (RBC) Count, Reticulocyte Count|Change From Baseline in Hematology Parameter: Red Cell Distribution Width (RDW)|Change From Baseline in Reticulocyte Production Index|Change From Baseline Hematology Parameter: Reticulocytes|Number of Participants With Worst-Case Chemistry Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline|Change From Baseline in Chemistry Parameter: Total Protein|Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH)|Change From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin|Change From Baseline in Chemistry Parameters: Cholesterol, Direct High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, Triglycerides|Change From Baseline in Chemistry Parameter: Corrected Calcium, Urea|Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate|Number of Participants With Emergent Worst Case Urinalysis Results by Dipstick|Number of Participants With Vital Signs Relative to Change From Baseline by Potential Clinical Importance (PCI) Criteria|Change From Baseline in Body Temperature|Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings",Plasma Concentrations of GSK2330811|Concentration at the End of the Dosing Interval (Ctrough) of GSK2330811|Apparent Clearance (CL/F) of GSK2330811|Apparent Volume of Distribution (Vss/F) of GSK2330811|Serum Level of Total Oncostatin M (OSM)|Serum Level of Free OSM|Number of Participants With Positive Anti-GSK2330811 Antibodies,True,2021-05-24
NCT04676204,Relationship Between Oral DMT Burden and Adherence in MS,STATURE: A Prospective Observational Study of the relationShip beTween Oral DMT bURden and adhErence in People With MS,ENROLLING_BY_INVITATION,2020-09-25,2025-11-19,2026-07-11,2022-08-31,2020-12-19,OBSERVATIONAL,,323.0,ESTIMATED,Monash University,OTHER,,,"Multiple Sclerosis|Adherence, Medication",Multiple Sclerosis|Adherence|Treatment Burden|Disease Modifying Therapy|Oral|Cladribine|Dimethyl fumarate|Fingolimod|Teriflunomide|Ozanimod|Diroximel Fumarate,Australia,Melbourne,Victoria,1,Cladribine|Dimethyl fumarate|Fingolimod|Teriflunomide|Ozanimod|Diroximel fumarate,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Medication Burden|Medication Adherence (MPR)|Medication Adherence (PDC),Multiple Sclerosis Quality of Life-54 (MSQOL-54),False,
NCT04979650,Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis,Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023,COMPLETED,2021-05-22,2023-12-28,2023-12-29,2025-07-15,2021-07-28,INTERVENTIONAL,PHASE2,102.0,ACTUAL,Mazandaran University of Medical Sciences,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Magnetic Resonance Imaging|Methylprednisolone",Multiple sclerosis|Methylprednisolone Pulse therapy|Asymptomatic enhancing lesions|Chronic black hole,Iran,Sari,Mazandaran,1,Methylprednisolone succinate|Normal saline,DRUG|DRUG,Number of black hole|Expanded disability status scale,,False,
NCT06346704,Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis,Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis (NHS-MS-EGYPT),ACTIVE_NOT_RECRUITING,2024-04-25,2026-12-31,2026-12-31,2024-12-30,2024-04-04,OBSERVATIONAL,,100.0,ESTIMATED,SYSNAV,INDUSTRY,,,Multiple Sclerosis,Digital Health Technology,Egypt,Cairo,,1,Digital HealthTechnology,OTHER,Longitudinal change of 95th centile of stride velocity,"Correlation of the Syde® variables with the clinical assessments EDSS, FSS and T25FWT",False,
NCT01093326,"Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis","Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2010-05-12,2023-09-06,2023-09-06,2025-03-30,2010-03-25,INTERVENTIONAL,PHASE2,353.0,ACTUAL,Actelion,INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,71,Ponesimod 10 mg|Ponesimod 20 mg|Ponesimod 40 mg,DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) of Confirmed Relapses|Time to First Confirmed Relapse|Time to 24 Weeks Confirmed Disability Progression,,True,2024-10-01
NCT00893217,BEYOND Pilot Study,"Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS",COMPLETED,2002-11,,2003-06,2009-11-09,2009-05-05,INTERVENTIONAL,PHASE2,71.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis|Relapsing-Remitting,,United States,Los Angeles,California,14,"Betaseron (Interferon beta-1b, BAY86-5046)|Betaseron (Interferon beta-1b, BAY86-5046)",DRUG|DRUG,To evaluate the safety and tolerability of IFNB-1b 500 mcg given subcutaneously (SC) QOD compared with the standard dose of 250 mcg QOD in patients with RRMS.,,False,
NCT07128160,Cortical Inhibition in Patients With Multiple Sclerosis,"The Relationship Between Neuropsychiatric, Radiological Findings and Cortical Inhibition in Patients With Multiple Sclerosis: A Hospital-based Study",NOT_YET_RECRUITING,2025-11-01,2026-11-01,2026-12,2025-08-17,2025-08-17,OBSERVATIONAL,,50.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,multiple sclerosis,,,,0,Clinical and Demographic Assessment|Corticospinal Inhibition Assessment|Radiological Assessment,OTHER|OTHER|OTHER,Motor Evoked Potential (MEP)|Cortical Silent Period (CSP)|Interhemispheric Inhibition (IHI),Toronto Alexithymia Scale (TAS-20)|Fatigue Severity Scale (FSS),False,
NCT02805634,Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis,Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis,COMPLETED,2016-02-09,2019-01-30,2019-01-30,2019-04-17,2016-06-20,INTERVENTIONAL,NA,30.0,ACTUAL,Brugmann University Hospital,OTHER,,,Multiple Sclerosis,nine holes peg|triple stimulation|multiple sclerosis,Belgium,Brussels,,1,Nine Hole Test|Triple Stimulation Technique,OTHER|DEVICE,Amplitude of the motor evoked potentials|Amplitude ratio of the TST|Surface ratio of the TST|Nine Holes Peg test result,,False,
NCT01950234,ACTH in Progressive Forms of MS,Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel),TERMINATED,2014-04-17,2022-12-31,2022-12-31,2025-02-11,2013-09-25,INTERVENTIONAL,PHASE2,59.0,ACTUAL,University of Minnesota,OTHER,Mallinckrodt,INDUSTRY,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,,United States,Minneapolis,Minnesota,3,ACTH|Placebo,DRUG|DRUG,Proportion of Patients Exhibiting a 20% Worsening in T25FW at 36 Months,Safety and Tolerability of ACTH: Menstrual Changes [Female]|Safety and Tolerability of ACTH: DEXA Scans|Safety and Tolerability of ACTH: Bruising|Safety and Tolerability of ACTH: Swelling Ankles|Safety and Tolerability of ACTH: Hair Loss|Safety and Tolerability of ACTH: Acne|Safety and Tolerability of ACTH: Insomnia|Safety and Tolerability of ACTH: Mood Change|Safety and Tolerability of ACTH: GI Upset|Safety and Tolerability of ACTH: Fatigue|Safety and Tolerability of ACTH: Unpleasant Taste|Safety and Tolerability of ACTH: Blurred Vision|Safety and Tolerability of ACTH: Moon Facies|Safety and Tolerability of ACTH: Skin Thinning|Safety and Tolerability of ACTH: Hirsuitism|Safety and Tolerability of ACTH: Bruising|Safety and Tolerability of ACTH: Ankle Swelling|Safety and Tolerability of ACTH: Hair Loss|Safety and Tolerability of ACTH: Cataracts|Safety and Tolerability of ACTH: Myopathy|Safety and Tolerability of ACTH: Change in Hemoglobin A1c,True,2025-02-11
NCT00942214,Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment,Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study,COMPLETED,2009-06,2011-02,2011-03,2011-03-30,2009-07-20,INTERVENTIONAL,PHASE4,300.0,ACTUAL,"University Hospital, Toulouse",OTHER,,,Multiple Sclerosis,Multiple sclerosis|natalizumab|pharmacogenomics,France,Toulouse,,1,Natalizumab,DRUG,haplotypic frequency difference between responders and non-responders,,False,
NCT02807285,Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,"An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis",NO_LONGER_AVAILABLE,,,,2017-09-07,2016-06-21,EXPANDED_ACCESS,,,,"Genentech, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Phoenix,Arizona,56,Ocrelizumab,DRUG,,,False,
NCT04300543,MicroRNA-150 and microRNA-155 in Multiple Sclerosis,MicroRNA-150 and microRNA-155 as Molecular Biomarkers in Multiple Sclerosis,UNKNOWN,2020-04,2021-04,2021-10,2020-03-09,2020-03-09,OBSERVATIONAL,,140.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,MicroRNA in MS,,,,0,,,"analyse the expression of circulating miR-150 and miR-155 in serum of MS patients|Evaluate the serum levels of oligoclonal bands, neurofilaments and chitinase-3-like-1 in serum of MS patients","Investigate the correlation between the measured biomarkers and each other and their correlation with different MS phenotypes , disability status and the patients demographic data",False,
NCT01073813,Neuroprotection and Repair in Optic Neuritis,"Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)",TERMINATED,2010-02,2011-12,2013-01,2013-01-23,2010-02-23,INTERVENTIONAL,PHASE2,6.0,ACTUAL,University of Calgary,OTHER,Neuroscience Canada,UNKNOWN,Multiple Sclerosis|Optic Neuritis,Minocycline|Retinal nerve fibre layer thickness|Macular volume|Visual outcomes,,,,0,Minocycline,DRUG,Retinal nerve fibre layer,Other functional and structural optic nerve recovery measures,False,
NCT04908085,Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis,Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple,COMPLETED,2021-10-01,2022-06-30,2022-06-30,2024-04-19,2021-06-01,INTERVENTIONAL,NA,31.0,ACTUAL,Dorothy Kessler,OTHER,,,Multiple Sclerosis|Quality of Life,Coaching,Canada,Kingston,Ontario,1,Occupational Performance Coaching,BEHAVIORAL,Change in Canadian Occupational Performance Measure,Illness Intrusiveness Rating Scale|MS Impact Scale-29|Connor-Davidson Resilience Scale-10|Impact on Participation and Autonomy Questionnaire,False,
NCT07020715,A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis,"An Autologous Vitamin D3 Tolerogenic Dendritic Cell-based Therapy in Subjects With Progressive Forms of Multiple Sclerosis: a Phase IIa, Open-label, Self-controlled, Multi-center Clinical Trial",NOT_YET_RECRUITING,2025-12-01,2025-12-01,2027-10-29,2025-06-13,2025-06-13,INTERVENTIONAL,PHASE2,10.0,ESTIMATED,"University Hospital, Antwerp",OTHER,Fundació Institut Germans Trias i Pujol,OTHER,Multiple Sclerosis,Tolerogenic dendritic cells|tolDC|Phase IIa|Multiple Sclerosis|MS|Patient Safety|Efficacy,Belgium,Edegem,,2,Tolerogenic dendritic cells (tolDC),BIOLOGICAL,Efficacy (Change in EDSS score)|Safety (Occurrence and severity of adverse events will be recorded),9 Hole Peg Test (9HPT)|Symbol Digit Modalities test (SDMT)|T2 lesion volume on MRI|Total Brain Volume on MRI|Brain Atrophy on MRI|Biomarkers,False,
NCT00395317,Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS),"Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2006-12,2009-08,2010-08,2012-04-09,2006-11-02,INTERVENTIONAL,PHASE2,343.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,magnetic resonance imaging|multiple sclerosis|SB-683699,Australia,Camperdown,New South Wales,79,Placebo|Firategrast 150 mg|Firategrast 300 mg,OTHER|DRUG|DRUG,Cumulative number of new gadolinium-enhancing lesions on monthly MRI scans during the Treatment Phase,Cumulative volume of new gadolinium-enhancing lesions on monthly MRI scans|Cumulative number of persistent gadolinium-enhancing lesions on monthly MRI scans|Cumulative number of total enhancing lesions on monthly MRI scans: the sum of new and persistent gadolinium-enhancing lesions|Cumulative number of new T1 hypointense lesions on MRI scans|Cumulative number of new/newly enlarging T2 lesions on MRI scans|Relapses Occurring during the On-Treatment Phase|Change from Baseline in Expanded Disability Status Scale (EDSS) scores|Change from Baseline in Multiple Sclerosis Functional Composite (MSFC)scores,False,
NCT06232850,Wrist Position Sense in Individuals With Multiple Sclerosis,Examining the Relationship Between Wrist Position Sense and Manual Dexterity in Individuals With Multiple Sclerosis,COMPLETED,2023-11-01,2024-04-01,2024-04-01,2024-05-08,2024-01-31,OBSERVATIONAL,,24.0,ACTUAL,Pamukkale University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Manual Dexterity|Position Sense,Turkey (Türkiye),Denizli,Deni̇zli̇,1,Position sense and manual dexterity evaluate,OTHER,Wrist Position Sense Assessment,Purdue Pegboard Test (PPT),False,
NCT05467397,Feasibility of [11C]Acetate-PET in LAM and TSC,Feasibility Study of [11C]Acetate Positron Emission Tomography (PET) as an Indicator of Early Response to Rapamycin in Lymphangioleiomyomatosis (LAM) Patients,UNKNOWN,2021-08-30,2023-08-30,2023-12-31,2023-08-01,2022-07-20,INTERVENTIONAL,PHASE1|PHASE2,16.0,ESTIMATED,Brigham and Women's Hospital,OTHER,Massachusetts General Hospital,OTHER,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,,United States,Boston,Massachusetts,1,[11C]acetate,DRUG,Quantitative analysis of [11C]acetate uptake in renal angiomyolipoma and pulmonary LAM,Feasibility of [11C]acetate PET as a biomarker of mTORC1 inhibition in LAM/TSC proliferative lesions,False,
NCT03737825,Computerized Cognitive Training in MS,Computerized Cognitive Training for Patients With Cognitive Deficits Due to Multiple Sclerosis: a Pilot Study,UNKNOWN,2019-04-25,2023-12,2023-12,2022-12-05,2018-11-13,INTERVENTIONAL,NA,40.0,ESTIMATED,"University of California, San Francisco",OTHER,,,Multiple Sclerosis|Cognitive Decline,MS|Multiple Sclerosis|Cognitive remediation|Brain training|Physical Therapy,United States,San Francisco,California,2,Computerized gaming rehabilitation Program 1|Computerized gaming rehabilitation Program 2,DEVICE|DEVICE,"Change in processing speed after 4 weeks of treatment with computerized gaming rehabilitation paired with physical activity 'Program 1', vs. 'Program 2'.","Change in attention after 4 weeks of treatment with computerized gaming rehabilitation paired with physical activity 'Program 1', vs. 'Program 2'.|Change in visual working memory after 4 weeks of computerized gaming rehabilitation paired with physical activity 'Program 1', vs. 'Program 2'.|Change in multitasking performance following 4 weeks of computerized paired with physical activity 'Program 1', vs. 'Program 2'.|Change in working memory following 4 weeks of computerized paired with physical activity 'Program 1', vs. 'Program 2'.",False,
NCT03708276,My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis,Testing a New Multiple Sclerosis Specific Web-based Symptom Self-management Program: My MS Toolkit,COMPLETED,2019-02-26,2019-09-25,2019-09-25,2023-07-20,2018-10-17,INTERVENTIONAL,NA,20.0,ACTUAL,University of Michigan,OTHER,United States Department of Defense,FED,Multiple Sclerosis,Self-management|Web-based program,United States,Ann Arbor,Michigan,1,My MS Toolkit,OTHER,Acceptability of My MS Toolkit|Feasibility of My MS Toolkit,Impact of My MS Toolkit: Change in fatigue|Impact My MS Toolkit: Change in pain interference|Impact My MS Toolkit: Change in depressive symptoms|Change in self-efficacy for managing symptoms|Participant perception of change,False,
NCT01890655,Extension Study of MT-1303,"A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study",COMPLETED,2013-08,2016-03,2016-03,2016-04-11,2013-07-02,INTERVENTIONAL,PHASE2,367.0,ACTUAL,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,relapsing-remitting multiple sclerosis|RRMS,Belgium,City Name,,17,MT-1303-Low|MT-1303-Middle|MT-1303-High,DRUG|DRUG|DRUG,Safety assessments,Clinical efficacy|Magnetic Resonance Imaging (MRI),False,
NCT02064816,A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis,"Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2014-05-31,2016-04-30,2016-04-30,2018-09-20,2014-02-17,INTERVENTIONAL,PHASE4,200.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Interferon beta 1a|Rebif®",Germany,Darmstadt,,1,Rebif®|Rebif®,DRUG|DRUG,Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12,"Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8|Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12|Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12|Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12|Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12|Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12|Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12|Change From Baseline in Circulating Levels of Cytokines at Week 12|Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12|Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12|Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12|Change From Baseline in Cytokine (Adiponectin) Level at Week 12|Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12|Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12|Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12|Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation",True,2018-09-20
NCT02490943,A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS,A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis,COMPLETED,2015-06,2019-01-01,2019-04-30,2022-03-25,2015-07-07,INTERVENTIONAL,NA,28.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,Evergreen Healthcare,OTHER,MS (Multiple Sclerosis)|Erythema,peginterferon beta-1a|MS (Multiple Sclerosis)|Injection Site Reaction Erythema,United States,Kirkland,Washington,1,Warm Compress Before Injection|Cold Compress After Injection,OTHER|OTHER,"Change from Baseline ISR Erythema Index at 24 hours, 7 days, and 14 days every 6 weeks for 18 weeks.","Change from baseline in rating of Modified Local Injection Site Reaction Scale|Erythema score on the Visual Assessment Scale.|Pain score on the visual analogue scale after 10-minutes.|Pain score on the visual analogue scale Post-Injection 24 hours, 7 days, and 14 days|Level of Comfort Post-Injection Impression of Last 3 Weeks.",False,
NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,"Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses",COMPLETED,2002-01,2015-01,2015-01,2015-03-25,2005-09-28,INTERVENTIONAL,PHASE2,147.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis Relapsing Remitting|Secondary Progressive|Progressive Relapsing,Canada,Calgary,,16,teriflunomide (HMR1726),DRUG,Number of patients with adverse events,Annualized relapse rate (number of relapses per patient-year)|Change from baseline in Kurtzke Expanded Disability Status Scale (EDSS) score|Change from baseline in Multiple Sclerosis Functional Composite (MSFC) score|Burden of disease : Change from baseline in the volume of abnormal brain tissue as measured by brain Magnetic Resonance Image (MRI)|Change from baseline in Multiple Sclerosis Quality of Life Questionnaire-54 (MSQoL-54) score|Change from baseline in subject reported fatigue as assessed by the Fatigue Impact Scale (FIS),False,
NCT02403947,MEsenchymal StEm Cells for Multiple Sclerosis,Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study,TERMINATED,2015-02,2017-12,2017-12,2018-12-03,2015-03-31,INTERVENTIONAL,PHASE1|PHASE2,1.0,ACTUAL,"University Hospital, Toulouse",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Bone-marrow|Stem cells|Cell therapy,France,Toulouse,,1,Mesenchymal stem cells|Suspension media,DRUG|DRUG,"Safety of MSCs infusion, number, timeframe of occurrence and severity of Adverse Events|efficacy: number of contrast-enhancing lesions (GEL) at MRI scan","Efficacy of the experimental treatment in term of combined MRI activity|Efficacy assessed by combined unique MRI activity, volume of GEL, and volume of BH|Efficacy assessed by combined unique MRI activity, volume of GEL and volume of BH|Efficacy: Number of relapses|Efficacy: Time to sustained progression of disability",False,
NCT01414634,"Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells","Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients",COMPLETED,2010-02,2012-10,2012-10,2015-05-04,2011-08-11,INTERVENTIONAL,PHASE1|PHASE2,9.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,,,,0,ETIMS,BIOLOGICAL,Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Number of Adverse Events,,True,2015-04-08
NCT03369106,Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study,Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study,ACTIVE_NOT_RECRUITING,2018-02-06,2020-12-15,2026-02-05,2025-03-05,2017-12-11,OBSERVATIONAL,,120.0,ESTIMATED,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,,,Multiple Sclerosis,,France,Paris,,1,Composite severity score calculation,OTHER,Change of Expanded Disability Status Scale (EDSS),Change in neuropsychological scores|Change in T2 lesion volume|Grey matter volume change,False,
NCT00469378,Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis,An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast,COMPLETED,2007-07,2009-05,2010-02,2017-03-23,2007-05-04,INTERVENTIONAL,PHASE2,46.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,firategrast|lymphocytes|leukocytes|SB-683699|cerebrospinal fluid|relapsing forms of multiple sclerosis,Belgium,Brussels,,10,firategrast,DRUG,"Assessment of total leukocytes in cerebrospinal fluid (CSF)|Change from Baseline in number of total leukocytes in CSF|Assessment of total leukocytes in blood|Change from Baseline in number of total leukocytes in blood|Assessment of total lymphocytes in CSF|Change from Baseline in number of total lymphocytes in CSF|Assessment of total lymphocytes in blood|Change from Baseline in number of total lymphocytes in blood|Assessment of lymphocyte subsets in CSF (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)|Change from Baseline in number of lymphocyte subsets in CSF (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)|Assessment of lymphocyte subsets in blood (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)|Change from Baseline in number of lymphocyte subsets in blood (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)|Assessment of lymphocyte subset CD4 count in CSF|Change from Baseline in lymphocyte subset CD4 count in CSF|Assessment of lymphocyte subset CD4 count in blood|Change from Baseline in lymphocyte subset CD4 count in blood|Assessment of lymphocyte subset CD8 count in CSF|Change from Baseline in lymphocyte subset CD8 count in CSF|Assessment of lymphocyte subset CD8 count in blood|Change from Baseline in lymphocyte subset CD8 count in blood|Assessment of CD4:CD8 ratio in CSF|Change from Baseline in CD4:CD8 ratio in CSF|Assessment of CD4:CD8 ratio in blood|Change from Baseline in CD4:CD8 ratio in blood",Assessment of CD34+ cells in the blood|Change from Baseline in number of CD34+ cells in the blood|Number of participants with adverse events (AEs) and Serious adverse events (SAEs)|Cumulative number of new gadolinium-enhancing lesions at Week 24|Cumulative volume of new gadolinium-enhancing lesions at Week 24|Cumulative number of persistent gadolinium-enhancing lesions at Week 24|Cumulative total number of enhancing Lesions at Week 24|Plasma and CSF levels of firategrast|The relationship between plasma concentration of firategrast and lymphocyte count in the CSF|The relationship between plasma concentration of firategrast and lymphocyte count in the blood|The relationship between the presence of the A allele of rs887829 and bilirubin levels,False,
NCT02391064,Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS),Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) - BICAFMS Study (Brief Cognitive Assessment in French MS Patients),COMPLETED,2015-02-17,2018-02-18,2018-02-18,2018-03-08,2015-03-18,INTERVENTIONAL,NA,421.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Bayer,INDUSTRY,Multiple Sclerosis,cognition|brief computerized cognitive assessment|impairment prediction,France,Bordeaux,,15,Cognitive evaluation|Expanded Disability Status Scale (EDSS) score,BEHAVIORAL|BEHAVIORAL,Prediction by the z score BCCAMS of cognitive impairment (at least two tests MACFIMS battery <1.5 SD of control subjects,"Determine values of neuropsychological tests in healthy according to age subjects, gender and the level education|Ability of the CEVMT to detect episodic memory deficiencies in patients with multiple sclerosis, as compared to established tests of episodic memory|Correlation between alternate forms of the CEVMT and the Brief visual memory test-revised (BVMT-R)|Prediction between cognitive impairment and occupational status/leisure activities|Effect of possible confounders on results of cognitive testing, including depression, mood, anxiety and fatigue|Reproducibility of CSCT, CEVMT and the symbol-digit modalities test in clinical settings in patients with multiple sclerosis",False,
NCT03410498,The Effects of FES in a Variety of Walking Conditions in People With MS,The Orthotic Effect of Functional Electrical Stimulation to Treat Foot Drop in People With MS Under Walking Conditions Simulating Those in Daily Life,RECRUITING,2018-08-01,2024-12-29,2024-12-29,2023-11-18,2018-01-25,INTERVENTIONAL,NA,20.0,ESTIMATED,Queen Margaret University,OTHER,,,Multiple Sclerosis,,United Kingdom,Musselburgh,,1,Incremental shuttle walk test,OTHER,3D gait analysis,Stroop test/3D gait analysis,False,
NCT01624714,Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects,Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis,UNKNOWN,2012-09,2017-04,2017-09,2014-03-11,2012-06-21,INTERVENTIONAL,PHASE1,60.0,ESTIMATED,"Samuel Forrester Hunter, MD, PhD",OTHER,,,Multiple Sclerosis,Treatment Refractory,United States,Franklin,Tennessee,1,Alemtuzumab|Alemtuzumab immunotherapy,DRUG|DRUG,Change in Neurostatus Expanded Disability Status Scale|Change in MS Severity Scale,Change in annualized relapse rate|Number of treatment days with high dose corticosteroids|Rate of serious adverse events|MRI-based cerebral volumes and burden of disease (in selected subjects),False,
NCT03698149,ECoG BMI for Motor and Speech Control,A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control,RECRUITING,2018-11-09,2026-02-28,2030-08-15,2025-06-11,2018-10-05,INTERVENTIONAL,NA,3.0,ESTIMATED,Karunesh Ganguly,OTHER,National Institute on Deafness and Other Communication Disorders (NIDCD),NIH,ALS|SCI - Spinal Cord Injury|Stroke|Multiple Sclerosis|Muscular Dystrophies,,United States,San Francisco,California,1,PMT/Blackrock Combination Device,DEVICE,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|NIDCD Primary Objective 1|NIDCD Primary Objective 2,NIDCD Secondary Objective 1|NIDCD Secondary Objective 2,False,
NCT05532943,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,RECRUITING,2023-09-08,2028-10-31,2028-10-31,2025-08-07,2022-09-08,INTERVENTIONAL,PHASE1|PHASE2,41.0,ESTIMATED,"Ever Supreme Bio Technology Co., Ltd.",INDUSTRY,,,Multiple Sclerosis,,Taiwan,Taichung,Non-US,1,Allogeneic umbilical cord mesenchymal stem cells|Control group,BIOLOGICAL|BIOLOGICAL,Primary Endpoint for Phase I portion|Primary Endpoint for Phase IIa portion,Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoint for phase I portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|Efficacy endpoints for phase IIa portion|The safety endpoints are listed below for both phase I and IIa portions|The safety endpoints are listed below for both phase I and IIa portions|The safety endpoints are listed below for both phase I and IIa portions|The safety endpoints are listed below for both phase I and IIa portions|The safety endpoints are listed below for both phase I and IIa portions,False,
NCT03387267,Videofluoroscopic Swallowing Study (VFSS),A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study,TERMINATED,2017-10-24,2018-07-23,2018-07-23,2021-05-20,2018-01-02,INTERVENTIONAL,NA,452.0,ACTUAL,Société des Produits Nestlé (SPN),INDUSTRY,Cytel Inc.|Regulatory and Clinical Research Institute Inc|Nestec Ltd.,INDUSTRY|OTHER|INDUSTRY,Stroke|Parkinson Disease|Multiple Sclerosis|Oropharyngeal Dysphagia|Alzheimer Disease|Dementia,,United States,Downey,California,13,Dysphagia Detection System,DEVICE,Area Under the Receiver Operating Characteristic (ROC) Curve to Compare the DDS Predicted Swallow Safety Outcome (Binary) vs. Clinical Reference Standard VFS for THIN-Ba,AUC Under ROC Curve to Compare the DDS Predicted Swallow Safety Outcome (Binary) vs. Clinical Reference Standard VFS for MILD-Ba|AUC Under ROC Curve to Compare the DDS Predicted Swallow Safety Outcome (Binary) vs. Clinical Reference Standard VFS for MOD-Ba|The Sensitivity & Specificity for Swallow Efficiency Using THIN-Ba|The Sensitivity & Specificity for Swallow Efficiency Using MILD-Ba|The Sensitivity & Specificity for Swallow Efficiency Using MOD-Ba,True,2021-05-20
NCT00001532,Role of Genetic Factors in the Development of Lung Disease,Role of Genetic Factors in the Pathogenesis of Lung Disease,RECRUITING,1996-09-13,,,2025-08-29,1999-11-04,OBSERVATIONAL,,3500.0,ESTIMATED,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,Suburban Hospital,OTHER,Cystic Fibrosis|Pulmonary Fibrosis|Tuberous Sclerosis|Asthma|Pulmonary Sarcoidosis,Genetic Polymorphism|Nitric Oxide Synthesis|Alpha 1-Antitrypsin|Candidate Genes|Lung Pathology|Natural History|Lung Disease|Cystic Fibrosis|Asthma,United States,Bethesda,Maryland,2,,,evaluating the role of hereditary factor,"low dose radiation CT scan, and Zoom Scan",False,
NCT03938558,Art for MS - Controlled Trial,"Art for MS - Effects of a 10 Week Multimodal Dance and Art Intervention Program on Fatigue, Fatigability, and Their Related Factors - A Controlled Pilot-trial",COMPLETED,2018-08-28,2019-04-19,2019-04-19,2020-06-01,2019-05-06,INTERVENTIONAL,NA,17.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis|Fatigue,multiple sclerosis|fatigue,Belgium,Hasselt,,1,MS-Dance|MS-Art,OTHER|OTHER,motor fatigability|motor fatigability|motor fatigability|Trait motor fatigue|Trait motor fatigue|Trait motor fatigue,Coördination test with lower limbs|Coördination test with lower limbs|Coördination test with lower limbs|Perceived motor fatigability|Perceived motor fatigability|Perceived motor fatigability|Performance cognitive fatigability and cognitive capacity|Performance cognitive fatigability and cognitive capacity|Performance cognitive fatigability and cognitive capacity|Trait fatigue|Trait fatigue|Trait fatigue|MSIS-29 Questionnaire|MSIS-29 Questionnaire|MSIS-29 Questionnaire|SF-36 Questionnaire|SF-36 Questionnaire|SF-36 Questionnaire|ABC scale|ABC scale|ABC scale|MSWS-12 Questionnaire|MSWS-12 Questionnaire|MSWS-12 Questionnaire|5xSTS T25FW|5xSTS T25FW|5xSTS T25FW|T25FW test|T25FW test|T25FW test|NHPT (Nine hole peck test)|NHPT (Nine hole peck test)|NHPT (Nine hole peck test)|DGI (Dynamic gait index)|DGI (Dynamic gait index)|DGI (Dynamic gait index)|EmNSA|EmNSA|EmNSA|CMI (Cognitive motor interference)|CMI (Cognitive motor interference)|CMI (Cognitive motor interference),False,
NCT04997148,Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS),Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS),COMPLETED,2021-08-11,2023-09-14,2023-09-14,2024-12-18,2021-08-09,OBSERVATIONAL,,116.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono Limited, UK",INDUSTRY,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|Mavenclad ®|Cladribine,United Kingdom,Coventry,,8,,,Annualized Relapse Rate in the Year Prior to Treatment Initiation With Cladribine Tablets|Annualized Relapse Rate in the Year One After Treatment Initiation With Cladribine Tablets|Annualized Relapse Rate in the Year 2 After Treatment Initiation With Cladribine Tablets|Annualized Relapse Rate in the Year 3 After Treatment Initiation With Cladribine Tablets|Annualized Relapse Rate in the Year 4 After Treatment Initiation With Cladribine Tablets|Annualized Relapse Rate in the Year 5 After Treatment Initiation With Cladribine Tablets,"Relapse-Free Rate in Each Year After Initiation of Cladribine Tablet Treatment|Time From Cladribine Tablet Initiation to First Relapse|Number of Participants Who Discontinued Cladribine Tablets|Number of Participants Who Received Subsequent Disease-modifying Therapies (DMTs) After Cladribine Tablets Discontinuation/Treatment Completion|Number of Participants With Disability Progression Assessed by Expanded Disease Severity Scale (EDSS) at Treatment Initiation and Start of Treatment Year 2|Number of Participants With Disability Progression Confirmed Over 6 Months, Assessed by Expanded Disease Severity Scale (EDSS) at 2 Years After Cladribine Tablet Treatment Initiation|Number of Participants With Grade 3 Lymphopenia, Grade 4 Lymphopenia, Herpes Infections, Serious Infections, Opportunistic Infections and Malignancies",True,2024-12-18
NCT02090348,Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate,"A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)",WITHDRAWN,2015-06,2017-10,2017-10,2015-09-07,2014-03-18,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,,,,,0,dimethyl fumarate,DRUG,Mean change from baseline in MS-related fatigue as assessed by FSMC at 12 months in participants receiving DMF,"Mean change from baseline in fatigue as assessed by FSMC in participants receiving DMF|Mean change from baseline in fatigue as assessed by FSS in participants receiving DMF|Mean change from baseline in work productivity as assessed by WPAI-MS, in participants receiving DMF|Mean change from baseline in quality of life as assessed by SF-12 in participants receiving DMF|Mean change from baseline in depression as assessed by BDI-FS in participants receiving DMF|Mean change from baseline in sleepiness assessed by ESS in participants receiving DMF|Change in MS-related fatigue (FSMC) status|Correlation of fatigue with baseline demographics and disease characteristics|Proportion of participants with reduced dose or discontinuation of fatigue-related medications",False,
NCT05252585,A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML),"Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma",RECRUITING,2023-05-01,2026-12-31,2026-12-31,2025-09-05,2022-02-23,INTERVENTIONAL,PHASE4,10.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Renal Angiomyolipoma,Tuberous Sclerosis Complex|TSC|Angiomyolipoma|AML|Everolimus,Taiwan,Taichung,Taiwan ROC,4,Everolimus,DRUG,"Percentage of participants with adverse events (AEs), Serious AEs (SAEs) and AEs of special interest (AESI)",Angiomyolipoma (AML) response rate|AML progression rate|Percentage of participants with laboratory abnormalities,False,
NCT01232738,Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS),A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS),COMPLETED,2011-12,2013-05,2013-05,2018-05-18,2010-11-02,INTERVENTIONAL,PHASE2,36.0,ACTUAL,"Yunxia Wang, MD",OTHER,Western ALS Study Group,UNKNOWN,Amyotrophic Lateral Sclerosis (ALS),,United States,Phoenix,Arizona,10,rasagiline,DRUG,Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R),Difference in Time to Treatment Failure,True,2018-05-18
NCT05248438,Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis,Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis,COMPLETED,2022-05-11,2023-05-09,2023-05-09,2023-06-12,2022-02-21,OBSERVATIONAL,,192.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Merck Sharp & Dohme LLC,INDUSTRY,Multiple Sclerosis,multiple sclerosis|gynecological care|sexuality|contraception,France,Bordeaux,,1,Questionnaire,BEHAVIORAL,Gynecological scores of women from 18 to 40 years old with multiple sclerosis with a standardized questionnaire created for the study.,"Proportion of patients affected by SEP with an Impact on sexuality according to Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19).|Proportion of patients affected by SEP with an impact on life quality according to Fatigue severity Scale (FFS).|Proportion of patients affected by SEP with an impact on life quality according to EHD scores (""échelle d'humeur dépressive"" in french)|Proportion of patients affected by SEP with an impact on life quality according to Multiple Sclerosis Quality of life (MusiQol) scores",False,
NCT06677710,IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis,A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis,SUSPENDED,2026-06-30,2026-12-31,2028-12-31,2025-04-30,2024-11-07,INTERVENTIONAL,PHASE1,34.0,ESTIMATED,"Indapta Therapeutics, INC.",INDUSTRY,,,"Multiple Sclerosis|Primary Progressive Multiple Sclerosis (PPMS)|Secondary Progressive Multiple Sclerosis (SPMS)|Non-Active Secondary Progressive Multiple Sclerosis|Non-Active SPMS|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Autoimmune Diseases|Demyelinating Diseases|Immune System Diseases|Demyelinating Autoimmune Diseases, Central Nervous System (CNS)",Progressive Multiple Sclerosis|Refractory Progressive Multiple Sclerosis|IDP-023|autoimmune disease|Cellular Therapy|MS|Natural Killer Cells,United States,Stanford,California,5,IDP-023|Ocrelizumab|Interleukin-2|Cyclophosphamide|Fludarabine|Mesna,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Incidence of AEs and SAEs - (Part 1)|Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with IL-2 and Ocrelizumab (Part 1)|Change in cellular response of autoreactive immune cells to antigen (Part 2),"Change in cellular response of autoreactive immune cells to antigen (Part 1)|Incidence of AEs and SAEs - (Part 2)|PK (PK; maximum drug concentration) of IDP-023 - (Part 1/2)|PK (area under the concentration-time curve) of IDP-023 - (Part 1/2)|PK (concentration reached by the drug immediately before the next dose is administered) of IDP-023 - (Part 1/2)|Time to onset of sustained disability progression over the treatment period, deﬁned as an increase in Expanded Disability Status Scale (EDSS) - (Part 1/2)|Biologic activity of IDP-023 in the CSF over the treatment period - (Part 1/2) over the treatment period, defined as an increase in EDSS - (Part 1/2)",False,
NCT06672484,Walking Fatigability and Brain Activity in People with Multiple Sclerosis,Gait and Cortical Activity Profile of People with Multiple Sclerosis Presenting with Walking Fatigability,RECRUITING,2024-05-22,2025-04-01,2025-12-31,2024-11-06,2024-11-04,OBSERVATIONAL,,100.0,ESTIMATED,Hasselt University,OTHER,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,OTHER|OTHER,Multiple Sclerosis|Healthy,Multiple sclerosis|walking|fatigue|fatigability|gait|cortical activity|brain activity,Belgium,Diepenbeek,Limburg,3,,,"Range of Motion (hip, knee and ankle joints) during the gait cycle|Toe-Off angle|Foot Strike angle|Relative concentration of oxyhemoglobin and deoxyhemoglobin|Gait Speed|Cadence|Step Duration|Step Duration variability|Ground reaction force|Fatigability index|Perception of gait quality change (PGQC)|Distance walked index (DWI)|6-minutes walking test","Joint power during the gait cycle|Momentum|Falls Efficacy Scale International (FES-I)|Multiple Sclerosis Walking Scale (MSWS-12)|Pittsburgh Fatigability Scale (PFS)|Modified Fatigue Impact Scale (MFIS)|Brief Self-Control Scale (BSCS)|Multiple Sclerosis Spasticity Scale-88 (MSSS-88)|Brief Pain Inventory (BPI, short form)|Expanded Disability Status Scale (EDSS)|Modified Ashworth Scale (MAS)|Motricity index (MI)|Borg scale|Variability interpeak (Foot tap test)|Number of foot tap (Foot tap test)|Fatigue Scale for Motor and Cognitive Functions (FSMC)",False,
NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",COMPLETED,2002-12,2007-09,2010-01,2015-01-08,2002-12-23,INTERVENTIONAL,PHASE2,334.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,Bayer,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Active Relapsing-Remitting Multiple Sclerosis,United States,Scottsdale,Arizona,49,Interferon beta-1a|Alemtuzumab 12 mg|Alemtuzumab 24 mg,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Probability of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate,Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment|Percent Change From Baseline in T1 Cerebral Volume at Year 3|Percent Change From Baseline in MRI T2 Lesion Volume at Year 3,True,2009-08-25
NCT03216889,Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis,Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis,COMPLETED,2017-06-29,2019-08-15,2019-08-15,2019-08-28,2017-07-13,INTERVENTIONAL,NA,43.0,ACTUAL,University of Kansas Medical Center,OTHER,National Multiple Sclerosis Society,OTHER,Insomnia,Multiple Sclerosis,United States,Kansas City,Kansas,1,Cognitive Behavioral Therapy for Insomnia|Control,BEHAVIORAL|BEHAVIORAL,Insomnia Severity Index (ISI),Pittsburgh Sleep Quality Index (PSQI)|Modified Fatigue Impact Scale (MFIS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Impact Scale (MSIS),False,
NCT02898974,Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis,Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study,COMPLETED,2016-09,2017-10,2017-10,2020-02-05,2016-09-13,OBSERVATIONAL,,22.0,ACTUAL,Colorado State University,OTHER,"William R. Shaffer, M.D.",UNKNOWN,Multiple Sclerosis,,United States,Fort Collins,Colorado,1,Medical Marijuana,BEHAVIORAL,Fatigue|Muscle Strength|Postural Stability,,True,2020-02-05
NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,An Open-label Study of Excretion Balance and Pharmacokinetics Following a Single Oral Dose of [14C]-SAR442168 (Not More Than 3.7 MBq) in Healthy Male Subjects,COMPLETED,2019-11-13,2019-12-30,2019-12-30,2025-09-23,2019-11-20,INTERVENTIONAL,PHASE1,6.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United Kingdom,Nottingham,,1,SAR442168,DRUG,Percentage of radioactive dose excreted in urine and feces,Number of subjects with Adverse events|Blood/plasma radioactivity ratio|Blood/plasma radioactivity ratio|Plasma SAR442168 /radioactivity ratio|Plasma SAR442168 /radioactivity ratio,False,
NCT02212886,"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS","A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)",COMPLETED,2014-10,2017-05,2024-11-20,2024-12-03,2014-08-08,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,Mapi Pharma Ltd.,INDUSTRY,,,Multiple Sclerosis,Glatiramer acetate|Copaxone®|Multiple sclerosis|Relapsing remitting multiple sclerosis|RRMS|GA Depot|Monthly injection,Israel,Ashkelon,,3,GA Depot 80 mg|GA Depot 40 mg,DRUG|DRUG,Safety / Adverse events,Efficacy/Change in Relapse Rate|Efficacy/Changes in brain MRI|Efficacy/Changes in EDSS,False,
NCT06475183,Probiotic Chocolate Study in Multiple Sclerosis,Effects of Probiotics on Inflammatory Biomarkers in Persons With Multiple Sclerosis (MS) and in Family Members of Persons With MS,COMPLETED,2024-06-01,2024-12-09,2024-12-09,2025-03-30,2024-06-26,INTERVENTIONAL,NA,92.0,ACTUAL,Columbia University,OTHER,,,Multiple Sclerosis|Healthy Nutrition,muliple sclerosis|probiotic,United States,New York,New York,1,"Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum",DIETARY_SUPPLEMENT,peripheral blood mononuclear cell (PBMC) profile: Change in Regulatory T (Treg) cells|peripheral blood mononuclear cell (PBMC) profile: Change in T helper (TH) cells|peripheral blood mononuclear cell (PBMC) profile: Change in T helper Th17 cells|Change in serum microbial metabolites,Change in Modified Fatigue Impact Scale-5 Impact Scale|Change in Patient-Determined Disability Scale (PDDS)|Change in Bowel Control Scale|Change in Multiple Sclerosis Rating Scale- Revised (MSRS-R) Patient-Determined Disease Steps Scale,False,
NCT05865405,"A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis","Care Technology to Ascertain, Treat, and Engage the Community to Heal Depression in Patients With Multiple Sclerosis: Closing the Gaps in Depression Care for People With MS By Closing the Information Loop",RECRUITING,2023-08-01,2025-05-15,2025-05-15,2024-02-20,2023-05-18,INTERVENTIONAL,NA,100.0,ESTIMATED,"University of California, San Francisco",OTHER,United States Department of Defense,FED,Multiple Sclerosis|MS|Depression,MS|Multiple Sclerosis|Depression|Depressed,United States,San Francisco,California,1,MS CATCH,BEHAVIORAL,Mood Screening - Primary|Mood Reporting - Secondary|Comprehensive Mood Evaluation - Secondary|Treatment recommendations - Secondary|Treatment recommendation follow-through - Secondary|Adoption (uptake) - Primary|Adoption (uptake) - Secondary,Mood scores - Primary|Mood scores - Exploratory|Mood scores - Exploratory|Other self-reported outcome - Modified Fatigue Impact Scale - Exploratory|Other self-reported outcome - Pittsburgh Sleep Quality Index - Exploratory|Other self-reported outcome - Oxford-Participation and Activities Questionnaire - Exploratory|Other self-reported outcome - Impact on Participation and Autonomy - Exploratory|Engagment (Sustained use) - Secondary|Engagement (Sustained use) - Secondary|Engagement (Sustained use) - Exploratory|Engagement (Sustained use) - Exploratoy|Engagement (Sustained use) - Exploratory|Adherence - Secondary,False,
NCT02588053,Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?,"Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).",COMPLETED,2014-07,2018-12,2019-01,2019-04-17,2015-10-27,OBSERVATIONAL,,85.0,ACTUAL,"University of Colorado, Denver",OTHER,,,Multiple Sclerosis,,United States,Aurora,Colorado,1,,,Change in Brain Atrophy Rate,Change in Mean Cortical Thickness|Change in Neocortical Gray Matter Volume|Change in Subcortical Gray Matter Volume,False,
NCT05417269,IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study,A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS),ACTIVE_NOT_RECRUITING,2022-04-12,2025-05-23,2025-12-31,2024-03-08,2022-06-14,INTERVENTIONAL,PHASE1|PHASE2,150.0,ESTIMATED,Imcyse SA,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",RR-MS|Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis|Synthetic peptide,Moldova,Chisinau,,1,IMCY-0141|Placebo|Dimethyl Fumarate,DRUG|DRUG|DRUG,Ph I Primary safety endpoint (1) - Solicited injection site and systemic AEs|Ph I Primary safety endpoint (2) - Unsolicited injection site and systemic AEs|Ph I Primary safety endpoint (3) - All SAEs|Ph I Primary safety endpoint (4) - Abnormalities on different parameters|Ph II Primary efficacy endpoint - Number of CUAL,Ph I/II Secondary endpoint (1) - Relapse rate|Ph I/II Secondary endpoint (2) - Relapse-free rate|Ph I/II Secondary endpoint (3) - EDSS Score|Ph I/II Secondary endpoint (4) - Neurofilament light chains levels|Ph II Secondary endpoint (1) - Solicited injection site and systemic AEs|Ph II Secondary endpoint (2) - Unsolicited injection site and systemic AEs|Ph II Secondary endpoint (3) - All SAEs|Ph II Secondary endpoint (4) - Abnormalities on different parameters,False,
NCT05953519,Meeting an Unmet Need in Multiple Sclerosis,Meeting an Unmet Need in Multiple Sclerosis (MS): An Evaluation of the Effectiveness of a Transdiagnostic Psychological Treatment and Its Outcomes,RECRUITING,2023-04-10,2025-04-30,2026-04-30,2023-07-20,2023-07-20,INTERVENTIONAL,NA,24.0,ESTIMATED,Kessler Foundation,OTHER,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,Unified Protocol,BEHAVIORAL,Hospital Anxiety and Depression Scale (HADS) - Change in Depression|Hospital Anxiety and Depression Scale (HADS) - Change in Anxiety,Modified Fatigue Impact Scale (MFIS) - Change in Fatigue|Pittsburgh Sleep Quality Index (PQSI) - Change in Sleep|MOS Pain Effects Scale (PES) - Change in Pain|General Self-Efficacy Scale (GSES) - Change in Self-efficacy|University of Washington Self-Efficacy Scale - Change in MS specific self-efficacy|University of Washington Resilience Scale - Change in Resilience|COPE inventory - Change in Coping|Benefit Finding in Multiple Sclerosis (BFIMS) - Change in Benefit-finding|Satisfaction with Life Scale (SWLS) - Changes in Quality of Life|Flourishing Scale (FS) - Change in Quality of Life|Ryff Psychological Well-being Scales (RYFFPWB) - Changes in well-being,False,
NCT03498131,Melatonin in Patients With Multiple Sclerosis (MS).,Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS),COMPLETED,2018-05-09,2022-07-29,2023-12-11,2025-03-30,2018-04-13,INTERVENTIONAL,EARLY_PHASE1,30.0,ACTUAL,Providence Health & Services,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|MS|Melatonin|Supplement,United States,Portland,Oregon,1,3 mg Melatonin|5 mg Melatonin,DRUG|DRUG,Urine Melatonin Levels,Modified Fatigue Impact Scale (MFIS)|Serum Melatonin Level|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Pittsburgh Sleep Quality Index (PSQI)|Relapse Rate|Patient Determined Disease Steps - Performance Scale (PDDS-PS),True,2025-02-27
NCT04415372,Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis,Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis,ENROLLING_BY_INVITATION,2021-11-19,2026-04,2027-04,2025-04-22,2020-06-04,OBSERVATIONAL,,75.0,ESTIMATED,"University of Wisconsin, Madison",OTHER,National Institute for Biomedical Imaging and Bioengineering (NIBIB),NIH,Multiple Sclerosis|MS,Magnetic resonance imaging,United States,Madison,Wisconsin,1,MRI|Neuropsychological Testing,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Measurement of macromolecular proton content (MPC) by Magnetic resonance imaging,Neurocognitive performance as measured by Minimal Assessment of Cognitive Function in MS (MACFIMS) battery of neuropsychological (NP) tests|Neurocognitive performance as measured by the Montreal Cognitive Assessment (MoCA) score,False,
NCT04034277,Lee Silverman Voice Treatment Versus Standard Speech Therapy Versus Control in Hypophonia Rehabilitation in MS,Lee Silverman Voice Treatment Versus Standard Speech and Language Therapy Versus Control in Multiple Sclerosis: a Randomized Controlled Trial,UNKNOWN,2018-01-15,2019-09-30,2020-03-30,2019-07-26,2019-07-26,INTERVENTIONAL,NA,60.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,Voice Disorders|Speech and language therapy|Lee Silverman voice treatment,Italy,Milan,,1,Lee Silverman Voice Therapy|Conventional Treatment,OTHER|OTHER,Change in intensity (dB) of 3 sustained /ah/|Change in intensity measured in decibel (dB) of three functional sentences|Change in intensity in conversation measured in decibel (dB),Change in Maximum Phonation Time (MPT) of three sustained /ah/ (sec.)|Change in Vocal Handicap Index|Change in GIRBAS,False,
NCT00429442,Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis,"A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months",WITHDRAWN,2008-03,,2011-03,2014-02-20,2007-01-31,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Anna Tsakiri,OTHER,Sanofi,INDUSTRY,Relapsing Remitting Multiple Sclerosis,Simvastatin|CNS Inflammation|Copaxone,Denmark,Glostrup Municipality,Glostrup,1,Simvastatin|placebo,DRUG|DRUG,Number of new and/or enlarging lesions on T2- weighted MRI based on MRI done 12 months following baseline compared with MRI done at baseline.,Changes in the EDSS score between baseline and 12 months after baseline.|Changes in the MFSC score between baseline and 12 months after baseline.|Number of documented relapses after baseline.|Changes in immunological parameters|Regulation of immunological activation.,False,
NCT05320237,Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,Upper Limb Rehabilitation Using Immersive Virtual Reality for People With Multiple Sclerosis; a Feasibility Trial,COMPLETED,2022-06-26,2023-04-28,2023-04-28,2023-09-13,2022-04-11,INTERVENTIONAL,NA,19.0,ACTUAL,Glasgow Caledonian University,OTHER,"MS Society, UK|NHS Lanarkshire",UNKNOWN|OTHER_GOV,Multiple Sclerosis,Multiple Sclerosis|Rehabilitation|Virtual reality,United Kingdom,Glasgow,Scotland,1,Immersive Virtual Reality Intervention,OTHER,Recruitment Rates|Number of intervention sessions completed by participants|Recording the number of drop out rates from participants|Acceptance of being assigned to the control arm|Reporting adverse effects from intervention.|Rate of completion of secondary outcomes,Nine Hole Peg Test|ABLIHAND questionnaire|Hand grip strength via Jamar dynamometer|Action Research Arm Test (ARAT)|The spasticity-related quality of life tool (SQoL-6D)|USE questionnaire|Semi-structured interviews,False,
NCT02308137,Domperidone in Secondary Progressive Multiple Sclerosis (SPMS),"Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)",COMPLETED,2015-02,2020-01-03,2020-01-03,2020-02-24,2014-12-04,INTERVENTIONAL,PHASE2,64.0,ACTUAL,University of Calgary,OTHER,Alberta Innovates Health Solutions,OTHER,"Multiple Sclerosis, Secondary Progressive",,Canada,Calgary,Alberta,1,Domperidone,DRUG,Timed 25-Foot Walk (T25W),9-Hole Peg Test|Symbol Digit Modalities Test|Functional Systems and Expanded Disability Status Scale (EDSS)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life Scale 54 item version,False,
NCT06968039,Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients,This Study is Designed to Evaluate the Efficacy of Personalized Alternating Current Stimulation in the Treatment of Working Memory in Patients With Inflammatory Demyelination of the Central Nervous System,RECRUITING,2024-12-31,2027-07-01,2027-10-01,2025-05-13,2025-05-13,INTERVENTIONAL,NA,85.0,ESTIMATED,"Xuanwu Hospital, Beijing",OTHER,,,Multiple Sclerosis|Electric Stimulation,,China,Beijing,Beijing Municipality,1,Neuroelectrics StarStim 32|Neuroelectrics StarStim 32,DEVICE|DEVICE,Working Memory Training-Related Scores|SDMT (Symbol Digit Modalities Test),AVLT (Auditory Verbal Learning Test)|Digit Span Test|BVMTR (Brief Visual Memory Test-Revised)|STROOP (Stroop Color and Word Test),False,
NCT06074419,Effects of Virtual Reality on Sleep Quality and Mental Well-being,Evaluatıon of the Effect of the Use of Vırtual Realıty Technology on Sleep Qualıty and Mental Well-Beıng in Multıple Sclerosıs Patıents,COMPLETED,2024-02-01,2024-09-01,2024-11-20,2025-01-24,2023-10-10,INTERVENTIONAL,NA,42.0,ACTUAL,Ataturk University,OTHER,,,Nursing Caries,VİRTUAL REALİTY|SLEEP QUALITY|MENTAL WELL-BEING|MULTIPLE SCLEROSIS|NURSING,Turkey (Türkiye),Erzurum,Karaman,1,Occulus quest 2 virtual reality glasses,DEVICE,Pittsburgh sleep quality index score|Warwick-Edinburgh Mental Well-Being Scale score,,False,
NCT05415956,"""Outwalk MS"" - Benefits of Outdoor Walking in Multiple Sclerosis","""Outwalk MS"" - Benefits of Outdoor Walking Exercise Therapy on Walking Capacity and Well-being in Multiple Sclerosis",COMPLETED,2021-11-01,2022-07-31,2022-11-30,2023-09-01,2022-06-13,INTERVENTIONAL,NA,60.0,ACTUAL,University of Aarhus,OTHER,The Danish MS Society,UNKNOWN,Multiple Sclerosis,Exercise|Walking,Denmark,Aarhus,Jutland,1,Walking exercise therapy,BEHAVIORAL,6-minutes walk test (6MWT),6-minutes walk test (6MWT)|Timed 25-foot walk test (T25FWT)|Timed 25-foot walk test (T25FWT)|Six spot step test (SSST)|Six spot step test (SSST)|12-item multiple sclerosis walking scale (MSWS-12)|12-item multiple sclerosis walking scale (MSWS-12)|Modified fatigue impact scale (MFIS)|Modified fatigue impact scale (MFIS)|Falls-efficacy scale (FES-I)|Falls-efficacy scale (FES-I)|WHO five well-being index (WHO5)|WHO five well-being index (WHO5)|EuroQoL 5 dimensions 3 levels (EQ5D)|EuroQoL 5 dimensions 3 levels (EQ5D)|Baecke physical activity questionnaire|Baecke physical activity questionnaire|Patient-determined disease steps (PDDS)|Patient-determined disease steps (PDDS),False,
NCT05816122,MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect,MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect,ACTIVE_NOT_RECRUITING,2023-09-22,2027-05-31,2027-05-31,2025-06-13,2023-04-18,INTERVENTIONAL,NA,336.0,ACTUAL,Ad scientiam,OTHER,,,Multiple Sclerosis,,United States,San Diego,California,34,MSCopilot® Detect mobile application,DEVICE,To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on revised-MSFC scores.,"To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on EDSS.|To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening earlier than the EDSS.|To evaluate MSCopilot® Detect individual and/or composite scores ability to detect disease progression in absence of a relapsing activity (PIRA).|To evaluate MSCopilot® Detect individual scores and/or composite scores ability to detect MSFC changes over time.|To measure MSCopilot® Detect individual scores and/or composite scores association with the clinical scores.|To assess reproducibility of MSCopilot® Detect individual scores and/or composite scores between in-clinic and at-home digital tests.|To assess reliability of MSCopilot® Detect individual scores and/or composite scores at-home over time.|To evaluate Patient QoL (Multiple Sclerosis Impact Scale: MSIS-29 and Modified Fatigue Impact Scale - 5-item version: MFIS-5) and their association with MSCopilot® Detect individual and composite scores.|To evaluate the ability of MSCopilot® Detect individual scores and/or composite score to discriminate between a relapse and a momentary disability worsening (+1 point EDSS score for an initial EDSS <5,5; +0.5 point for an initial EDSS ≥5.5).|To evaluate MSCopilot® Detect Safety|To evaluate MSCopilot® Detect Adherence|To assess the satisfaction and user experience with the MSCopilot® Detect smartphone application and the MSCopilot® Detect web dashboard.|To assess the satisfaction and user experience with the MSCopilot® Detect web dashboard.|To describe the evolution of MSCopilot® Detect individual scores and/or composite scores at-home over time.",False,
NCT01567553,The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.,Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.,TERMINATED,2009-04,2014-06,2015-06,2015-10-28,2012-03-30,OBSERVATIONAL,,37.0,ACTUAL,Rennes University Hospital,OTHER,Bayer,INDUSTRY,Multiple Sclerosis (MS)|Inflammatory Disease,inflammatory disease of the central nervous system|early clinical deficit|multiple sclerosis (MS),France,Marseille,,5,USPIO MRI - Gadolinium MRI,OTHER,▪ Change in USPIO enhancing MS lesion,Comparison of primary outcome measures with clinical outcomes and role of USPIO|Relationship of USPIO (SH U 555 C) enhancing MRI lesions with other MR parameters|Change in USPIO and/or Gadolinium enhancing MS lesions (primary outcome measure),False,
NCT02352194,Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis,Observational Study of the Physical Capacity of Patients With Multiple Sclerosis and Evaluation of the Effects of Usual Rehabilitation in the Day Hospital,UNKNOWN,2014-07,2015-07,2015-10,2015-02-02,2015-02-02,OBSERVATIONAL,,60.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis (MS),"Multiple Sclerosis, Physical therapy, Physical capacity, Fatigue",France,Garches,,1,Rehabilitation,OTHER,Assessment of the strength and fatigue,"6 minutes walking test|Evaluation of aerobic capacity during an effort test|Assessment of the balance of patients|Assessment of Spasticity with the Modified Ashworth Scale (MAS),|10 meters Walk test|Timed up and go test|Time to ascend and descend stairs|Assessment of Strength with the Medical Research Council (MRC),|Assessment of Quality of Life with SEP-59 Scale|Assessment of the balance of patients",False,
NCT04544449,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis,"A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.",ACTIVE_NOT_RECRUITING,2020-10-26,2025-09-17,2027-07-21,2025-09-24,2020-09-10,INTERVENTIONAL,PHASE3,985.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Primary Progressive",,United States,Homewood,Alabama,189,Fenebrutinib|Ocrelizumab|Placebo matched to ocrelizumab|Placebo matched to fenebrutinib,DRUG|DRUG|DRUG|DRUG,Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12),"Time to Onset of Composite 24-week CDP (cCDP24)|Time to Onset of 12-week CDP (CDP12)|Time to Onset of 24-week CDP (CDP24)|Percentage Change in Total Brain Volume Assessed by Magnetic Resonance Imaging (MRI)|Change from Baseline in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis Impact Scale, 29-Item [MSIS-29] Physical Scale|Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score|Percentage of Participants with Adverse Events (AEs)|Plasma Concentrations of Fenebrutinib at Specified Timepoints|Percent Change from Screening in Blood Neurofilament Light Chain (NfL) Levels",False,
NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY,ACTIVE_NOT_RECRUITING,2018-11-12,2026-01-25,2026-01-25,2025-09-25,2018-07-20,OBSERVATIONAL,,1710.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,Austria,Amstetten,,160,Ocrelizumab,DRUG,Changes in the overall SymptoMScreen score in participants with RMS|Changes in the overall SymptoMScreen score in participants with PPMS,"Percentage of RMS Participants with Adverse Events|Percentage of PPMS participants with Adverse Events|Time to treatment discontinuation due to adverse events with ocrelizumab in participants with RMS|Time to treatment discontinuation due to adverse events with ocrelizumab in participants with PPMS|Change in the score of Multiple Sclerosis Impact Scale (MSIS-29) in RMS participants|Change in the score of Multiple Sclerosis Impact Scale (MSIS-29) in PPMS participants|Change in the score of ABILHAND - 56 scale in RMS participants|Change in the score of ABILHAND - 56 scale in PPMS participants|Change in the score of Fatigue Scale Motor and Cognitive functions (FSMC) in RMS participant|Change in the score of Fatigue Scale Motor and Cognitive functions (FSMC) in PPMS participants|Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM) in RMS participants|Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM) in PPMS participants|Change in the score of MSWS - 12 scale in RMS participants|Change in the score of MSWS - 12 scale in PPMS participants|Changes in proportion of patients employed/non-employed, number of inpatient days, hospital admissions, medication use and associated costs over the course of the study, captured by the MS-COI in RMS Participants|Changes in proportion of patients employed/non-employed, number of inpatient days, hospital admissions, medication use and associated costs over the course of the study, captured by the MS-COI in PPMS Participants|Frequency of relapses over time in RMS patients|Disease progression in participants with RMS as measured by Expanded Disability Status Scale (EDSS) over time|Disease progression in participants with PPMS as measured by Expanded Disability Status Scale (EDSS) over time",False,
NCT02059096,Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis,Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis,UNKNOWN,2014-01-05,2023-02,2023-02,2021-02-16,2014-02-11,INTERVENTIONAL,PHASE3,66.0,ESTIMATED,"University Hospital, Clermont-Ferrand",OTHER,,,Multiple Sclerosis With Central Neuropathic Pain,Multiple Sclerosis|Repetitive transcranial magnetic stimulation (rTMS)|Chronic neuropathic pain|Cortical excitability,France,Boulogne-Billancourt,,3,Repetitive Transcranial Magnetic Stimulation (rTMS),DEVICE,"Change from baseline in ""average pain"" score on the brief pain inventory","change from baseline in ""average pain"" score on the brief pain inventory|Location of MRI abnormalities|Intra-cortical excitability evaluated by motor threshold, MEP amplitude, SICI and ICF|Number of participants with adverse events as a measure of safety and tolerability|change from baseline in specific questionnaires",False,
NCT06064162,Ketamine for MS Fatigue,"A Pilot Study of Intravenous, Subanesthetic Dose of Ketamine Versus Placebo, A Crossover Design, for Multiple Sclerosis Related Fatigue",COMPLETED,2023-12-05,2025-05-05,2025-05-05,2025-06-08,2023-10-03,INTERVENTIONAL,EARLY_PHASE1,21.0,ACTUAL,Alta Bates Summit Medical Center,OTHER,,,Multiple Sclerosis,MS related Fatigue,United States,Berkeley,California,1,ketamine,DRUG,Improve Fatigue Scores,Improve Quality of Life,False,
NCT05848323,Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue,Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue,COMPLETED,2023-10-30,2024-09-25,2024-09-25,2024-12-12,2023-05-08,INTERVENTIONAL,NA,21.0,ACTUAL,University of Washington,OTHER,,,Multiple Sclerosis|Fatigue,Multiple sclerosis|Fatigue|Cognitive behavioral therapy|Relaxation training|Behavioral activation|Cognitive therapy,United States,Seattle,Washington,1,4-week Relaxation Training|4-week Behavioral Activation|4-week Cognitive Therapy,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Intervention Acceptability|Intervention Appropriateness|Intervention Feasibility,Fatigue|Participation in Social Roles and Activities|Relaxation/Serenity|Fatigue Catastrophizing|Behavioral Activation|Cognitive Behavioural Responses Questionnaire - Short Form|Global Impression of Change,False,
NCT00869726,A Study for Patients With Secondary Progressive Multiple Sclerosis,"A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis",COMPLETED,2004-12,2009-05,2009-05,2010-06-02,2009-03-26,INTERVENTIONAL,PHASE2|PHASE3,596.0,ACTUAL,Eli Lilly and Company,INDUSTRY,BioMS Technology Corp.,INDUSTRY,Secondary Progressive Multiple Sclerosis,,Canada,Toronto,Ontario,10,dirucotide|Placebo,DRUG|DRUG,Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).,degree of change in EDSS|Brain Atrophy by MRI|Activity analysis of T2 and Gadolinium enhancing lesions|Lesion burden|Degree of change in MS Functional Composite Index (MSFC)|Relapse rates|Quality of life as measured by Short Form 36 (SF-36) or MSQoL54,False,
NCT00745615,"An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease","An Active Extension of LAQ/5062 Study. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)",TERMINATED,2005-12-07,2017-07-23,2017-07-23,2019-03-27,2008-09-03,INTERVENTIONAL,PHASE2,257.0,ACTUAL,"Teva Pharmaceutical Industries, Ltd.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,Czechia,Hradec Králové,,45,Laquinimod|Placebo,DRUG|DRUG,Double-Blind Extension Period: Number of Participants With Adverse Events (AEs)|Open-label Extension Period: Number of Participants With AEs|Double-Blind Period: Number of Participants Who Prematurely Discontinued From the Study Due to Any Reason and Due to AEs|Open-Label Period: Number of Participants Who Prematurely Discontinued From the Study Due to Any Reason and Due to AEs,Double-Blind Period: Relapse Rate: Total Number of Confirmed Relapses|Double-Blind Period: Percentage of Relapse-Free Participants|Double-Blind Period: Number of Enhancing Lesions on T1-Weighted Images|Double-Blind Period: Number of New T2 Lesions|Double-Blind Period: Volume of T2 Lesions|Double-Blind Period: Number of New Hypointense T1 Lesion on Enhanced T1 Scans|Double-Blind Period: Kurtzke's Expanded Disability Status Scale (EDSS) Score,True,2019-03-27
NCT04038541,Prebiotic vs Probiotic in Multiple Sclerosis,Prebiotic and Probiotic Treatment Trial in Multiple Sclerosis,COMPLETED,2020-03-11,2023-12-30,2023-12-30,2024-05-22,2019-07-31,INTERVENTIONAL,NA,37.0,ACTUAL,Columbia University,OTHER,National Multiple Sclerosis Society|Exegi Pharma,OTHER|UNKNOWN,Multiple Sclerosis|Clinically Isolated Syndrome (CIS),Prebiotics|Probiotics|Gut microbiome|Multiple Sclerosis,United States,New York,New York,2,Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|Probiotics (Visbiome®),DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Change in Peripheral Blood Mononuclear Cells (pBMCs)|Change in Serum Neurofilament Light Concentration|Change in relative abundance of gut microbiome,Modified Fatigue Impact Scale|Bowel Control Scale|Patient Determined Disease Steps|Multiple Sclerosis Rating Scale|Patient Health Questionnaire,False,
NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,"An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2018-05-28,2026-01-15,2026-12-04,2025-06-15,2018-05-14,INTERVENTIONAL,PHASE3,927.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Progressive Multiple Sclerosis (PMS),,United States,Laguna Hills,California,125,Ocrelizumab,DRUG,Proportion of Participants with No Evidence of Progression (NEP)|Proportion of Participants with no evidence of progression and no active disease (NEPAD),"Change from Baseline in Cognitive Function, as Measured by the Symbol Digit Modalities Test (SDMT)|Change from Baseline in Cognitive Function, as Measured by Brief Visuospatial Memory Test - Revised (BVMT-R)|Mean Change from Baseline in the Expanded Disability Status Scale (EDSS) score over the course of the study|Time to Onset of First Confirmed Disability Progression (CDP) Sustained for at least 24 and 48 Weeks|Time to Onset of First >=20% Increase in Timed 25-foot Walk Test (T25FWT) Sustained for at least 24 Weeks|Time to Onset of First >=20% Increase in 9 Hole Peg Test (9HPT) Sustained For At Least 24 Weeks|Proportion of Participants with NEP|Proportion of Participants with NEPAD|Change from Baseline in Patient-Reported Outcomes (PROs)|Change from Baseline in the number of falls and near-falls|Change in Whole Brain Volume (Whole, Cerebral White Matter, Cortical Grey Matter, Deep grey matter)|Change in thalamic volumes|Change in whole and regional cerebellar volume (cervical cord grey and white matter area)|Change in cervical cord cross-sectional area (total, white matter and grey matter)|Change in number of new/enlarging T2 lesions and total T2 Lesion Volume|Change in number of T1 Gadolinium (Gd)+ Lesions and total volume|Change in number of T1 lesions|Number in total volume of T1 lesions|Change in Slowly Evolving Lesions (SEL)|Change in normalised T1 intensity/T1 Gd+ enhancement in New Focal T2 Lesions, SELs, Persistent Areas of Non-SEL T2 Lesions, and Normal-Appearing Brain Tissue|Change in Gd-enhancing late-Fluid-Attenuated Inversion-Recovery (FLAIR) Meningeal Lesions|Change in the number/ spatial distribution of lesions in the cervical spinal cord|Spectroscopic MR: Measure of the Relative Signal Amplitude of N-Acetyl Aspartate (NAA), and Choline to Creatine|Measure of phase rim lesions using a Susceptibility-Weighted Imaging [SWI]/T2 sequence|Percentage of Participants with Adverse Events (AEs)|Rates of study treatment discontinuation due to adverse events",False,
NCT03774914,LEMTRADA Pregnancy Registry in Multiple Sclerosis,International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis,TERMINATED,2015-09-01,2021-11-22,2021-11-22,2022-04-25,2018-12-13,OBSERVATIONAL,,42.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Multiple Sclerosis,,United States,New York,New York,13,Alemtuzumab (GZ402673),DRUG,Spontaneous abortions (≤20 weeks gestation),"Major congenital malformations|Minor congenital malformations|Stillbirth (any non-deliberate foetal death at >20 weeks gestation)|Full-term live birth i.e. infants born maturely (≥37 gestation weeks)|Preterm birth i.e. infants born prematurely i.e., live-born infant i.e., (pre-term <37 weeks)|Elective terminations i.e. any induced or voluntary fetal loss|Small for gestational age at birth i.e. birth size (weight, length, or head circumference) ≤10th percentile for gender and gestational age|Any other adverse pregnancy outcomes|Infant postnatal growth (up to the first year of life)|Infant development impairment (up to the first year of life)",False,
NCT05057338,"Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study","Innovative Follow-up Across Health Care Levels to Optimize Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study",UNKNOWN,2021-08-27,2021-12-31,2022-08-30,2021-09-27,2021-09-27,INTERVENTIONAL,NA,30.0,ESTIMATED,Nordlandssykehuset HF,OTHER,Nord University|Hasselt University|Helse Nord,OTHER|OTHER|INDUSTRY,Multiple Sclerosis,Multiple sclerosis|Physiotherapy|neurology|MS nurse|coordination of care|balance|walking|physical activity|employment,Norway,Bodø,,2,CoreDISTparticipation|Standard care,BEHAVIORAL|BEHAVIORAL,MS Work Difficulties Questionnaire-23|Six-Minutes Walk Test|MS Work Difficulties Questionnaire-23|Six-Minutes Walk Test|MS Work Difficulties Questionnaire-23|Six-Minutes Walk Test,Trunk Impairment Scale Norwegian Version|Mini Balance Evaluation Systems Test|Force Platform|Activity monitors outcome 1|Activity monitors outcome 2|European Quality of Life 5-Dimension-3 Level|Multiple Sclerosis Walking Scale-12|Multiple Sclerosis Impact Scale-29|Weight|Height|age|Social status|Type of multiple sclerosis|Year of diagnosis multiple sclerosis|Medications|Expanded disability status scale|Occupation|Percentage of work|Length of education|Trunk Impairment Scale Norwegian Version|Mini Balance Evaluation Systems Test|Force Platform|Activity monitors outcome 1|Activity monitors outcome 2|European Quality of Life 5-Dimension-3 Level|Multiple Sclerosis Walking Scale-12|Multiple Sclerosis Impact Scale-29|Percentage of work|Trunk Impairment Scale Norwegian Version|Mini Balance Evaluation Systems Test|Force Platform|Activity monitors outcome 1|Activity monitors outcome 2|European Quality of Life 5-Dimension-3 Level|Multiple Sclerosis Walking Scale-12|Multiple Sclerosis Impact Scale-29|Percentage of work,False,
NCT03824938,Aspirin for Exercise in Multiple Sclerosis (ASPIRE),Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS),COMPLETED,2019-04-30,2022-02-28,2022-02-28,2023-10-27,2019-01-31,INTERVENTIONAL,PHASE3,60.0,ACTUAL,Columbia University,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,exercise|aspirin|cooling|antipyretic,United States,New York,New York,1,Aspirin 650mg Oral Capsule|Acetaminophen Tablet 650mg|Placebo,DRUG|DRUG|OTHER,Time-to-exhaustion|Exercise-induced Body Temperature Change,,True,2023-10-27
NCT03342638,Maximizing Outcome of Multiple Sclerosis Transplantation,"Maximizing Outcome of Multiple Sclerosis Transplantation: ""MOST"" Trial",TERMINATED,2017-11-08,2019-07-23,2019-10-09,2021-01-11,2017-11-17,INTERVENTIONAL,PHASE3,66.0,ACTUAL,Northwestern University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Autologous Stem Cell Transplantation|Stem Cells|Hematopoietic Stem Cell Transplantation,United States,Chicago,Illinois,1,Cyclophosphamide|Mesna|rATG|Methylprednisolone|G-CSF|IVIg|Autologous Stem Cells,DRUG|DRUG|DRUG|DRUG|DRUG|BIOLOGICAL|BIOLOGICAL,Efficacy - Rate of Disease Activity,,True,2021-01-11
NCT00349193,"A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod","A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects",COMPLETED,2005-03,2006-06,2006-08,2011-04-08,2006-07-06,INTERVENTIONAL,PHASE2,306.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis,,,,0,laquinimod 0.3|laquinimod 0.6|Placebo,DRUG|DRUG|OTHER,Reduction of brain lesions in the last 4 months of the study,Relapse rate,False,
NCT03919058,Sit Less or Exercise More: Impact on Cardiometabolic Health in MS,Sit Less or Exercise More: Impact on Cardiometabolic Health in Multiple Sclerosis,COMPLETED,2019-04-13,2021-04-30,2021-04-30,2021-08-31,2019-04-18,INTERVENTIONAL,NA,28.0,ACTUAL,Hasselt University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Non-exercise physical activity|NEPA|Cardiometabolic health|Comorbidities,Belgium,Diepenbeek,Limburg,1,Baseline activity (control regime)|Increased sitting time (sit regime)|Non-exercise physical activity (sit less regime)|Structured exercise (exercise regime),OTHER|OTHER|OTHER|OTHER,Steps per day|Sitting time|Standing time|Stepping time|Concentration of glucose|Concentration of insulin|Concentration of total cholesterol|Concentration of high density lipoprotein cholesterol (HDL-cholesterol)|Concentration of low density lipoprotein cholesterol (LDL-cholesterol)|Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)|Concentration of triglyceride|Concentration of apolipoprotein A1 (apo A1)|Concentration of apolipoprotein B (apo B)|Concentration of free fatty acids (FFA)|Concentration of C-reactive protein (CRP)|Concentration of interleukin 1 (IL-1)|Concentration of interleukin 6 (IL-6)|Steps per day|Sitting time|Standing time|Stepping time|Concentration of glucose|Concentration of insulin|Concentration of total cholesterol|Concentration of high density lipoprotein cholesterol (HDL-cholesterol)|Concentration of low density lipoprotein cholesterol (LDL-cholesterol)|Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)|Concentration of triglyceride|Concentration of apolipoprotein A1 (apo A1)|Concentration of apolipoprotein B (apo B)|Concentration of free fatty acids (FFA)|Concentration of C-reactive protein (CRP)|Concentration of interleukin 1 (IL-1)|Concentration of interleukin 6 (IL-6)|Steps per day|Sitting time|Standing time|Stepping time|Concentration of glucose|Concentration of insulin|Concentration of total cholesterol|Concentration of high density lipoprotein cholesterol (HDL-cholesterol)|Concentration of low density lipoprotein cholesterol (LDL-cholesterol)|Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)|Concentration of triglyceride|Concentration of apolipoprotein A1 (apo A1)|Concentration of apolipoprotein B (apo B)|Concentration of free fatty acids (FFA)|Concentration of C-reactive protein (CRP)|Concentration of interleukin 1 (IL-1)|Concentration of interleukin 6 (IL-6)|Steps per day|Sitting time|Standing time|Stepping time|Concentration of glucose|Concentration of insulin|Concentration of total cholesterol|Concentration of high density lipoprotein cholesterol (HDL-cholesterol)|Concentration of low density lipoprotein cholesterol (LDL-cholesterol)|Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)|Concentration of triglyceride|Concentration of apolipoprotein A1 (apo A1)|Concentration of apolipoprotein B (apo B)|Concentration of free fatty acids (FFA)|Concentration of C-reactive protein (CRP)|Concentration of interleukin 1 (IL-1)|Concentration of interleukin 6 (IL-6),Blood pressure|Body weight|Blood pressure|Body weight|Blood pressure|Body weight|Blood pressure|Body weight,False,
NCT05685784,Multiple Sclerosis Prediction and Monitoring of Progression Study,Multiple Sclerosis Prediction and Monitoring of Progression Study,RECRUITING,2022-03-01,2024-09-30,2024-09-30,2024-01-08,2023-01-17,INTERVENTIONAL,NA,70.0,ESTIMATED,"University Hospital, Ghent",OTHER,University Ghent|Byteflies,OTHER|INDUSTRY,Progressive Multiple Sclerosis,wearables,Belgium,Ghent,Oost-Vlaanderen,1,Bytelfies kit - sensor dot,DEVICE,"To validate outpatient gait analysis using sensor dots, with regards to the golden standard|To validate outpatient polysomnography using sensor dots, with regards to the golden standard",Skin-device contact safety,False,
NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",TERMINATED,2008-07-28,2015-06-22,2015-06-22,2017-06-14,2008-08-11,INTERVENTIONAL,PHASE3,970.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Primary Progressive Multiple Sclerosis,"FTY720, primary progressive multiple sclerosis,PPMS",United States,Newport Beach,California,157,FTY720|Placebo,DRUG|DRUG,Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint,Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)|Percent Change From Baseline in Brain Volume at Month 36|Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.|Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.|Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36|Number of Gd-enhancing Lesions at Month 36|Percent Change in Total T2 Lesion Volume From Baseline to Month 36|Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)|Change From Baseline in PRIMUS-Activities|Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score|Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)|Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)|Blood Concentrations of Fingolimod and Fingolimod-phosphate|Change in MSFC Z-score and Subscale Scores From Baseline to Month 36,True,2017-06-14
NCT04698538,TSC Remote Assessment and Intervention,TSC Remote Assessment and Intervention,COMPLETED,2020-10-31,2024-08-31,2024-10-28,2024-10-30,2021-01-07,INTERVENTIONAL,NA,54.0,ACTUAL,"University of California, Los Angeles",OTHER,,,TSC,TSC|tuberous sclerosis complex,United States,Los Angeles,California,1,JASPER,BEHAVIORAL,Change in Caregiver-Child Interaction (CCX)-joint engagement|Change in Short Play and Communication Evaluation (SPACE)- joint engagement,Short Play and Communication Evaluation (SPACE)- Joint attention|Short Play and Communication Evaluation (SPACE)- Play,False,
NCT00280592,Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",COMPLETED,2006-01,2008-03,2008-10,2012-05-21,2006-01-23,INTERVENTIONAL,PHASE3,171.0,ACTUAL,Rennes University Hospital,OTHER,"Pierre Fabre Laboratories|Ministry of Health, France",INDUSTRY|OTHER_GOV,Multiple Sclerosis|Urinary Tract Infections|Bladder Dysfunction,Prophylaxis|Cranberry|Neurogenic bladder,France,Besançon,,10,Cranberry|Placebo,DRUG|DRUG,Time to onset of a first UTI within one year of treatment.,Rate of patients with at least one UTI during the one-year treatment|Number of UTI|Score on Qualiveen® scale|Symptomatology of urinary disorders|EDSS score|Number of multiple sclerosis attacks|Antibiotics consumption|Safety of cranberry|Patients' observance to treatment,False,
NCT00240032,A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.,"A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.",COMPLETED,2004-10,2006-06,2006-07,2011-04-11,2005-10-17,INTERVENTIONAL,PHASE4,80.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,,,,,0,glatiramer acetate injection with oral cetirizine hydrochloride|glatiramer acetate with placebo,DRUG|DRUG,Injection Site Reaction,,False,
NCT02118298,Allocentric Memory in MS and Resting State Functional MRI,Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI,COMPLETED,2014-04,2016-04,2016-04,2016-05-13,2014-04-21,OBSERVATIONAL,,120.0,ACTUAL,Yale University,OTHER,,,Multiple Sclerosis,,United States,New Haven,Connecticut,1,,,Minimal Assessment of Cognitive Function in MS (MACFIMS),,False,
NCT07118514,Effect of Resistance Training on Psychophysiological Indicators in People With Multiple Sclerosis,"Effects of a Resistance Training Program on Immunological, Psychological, and Functional Indicators in People With Multiple Sclerosis: A Randomized Clinical Trial",COMPLETED,2024-08-15,2024-12-17,2024-12-17,2025-08-19,2025-08-12,INTERVENTIONAL,NA,40.0,ACTUAL,State University of Maringá,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|BDNF|Irisin|Anxiety|Depression|Exercise|Quality of life|Fatigue,Brazil,Maringá,Paraná,1,Progressive Resistance Training|Stretching and Relaxation Activities,BEHAVIORAL|BEHAVIORAL,"Plasma levels of cortisol, brain-derived neurotrophic factor (BDNF), and irisin.",Muscle Strength (Dynamic and Isokinetic)|Functional Mobility|Isokinetic Muscle Strength (Lower Limbs)|Fatigue|Anxiety and Depression|Health-Related Quality of Life|Optimism|Perceived Barriers to Physical Activity|Physical Activity Level|Motivation for Exercise|Trait Anxiety Levels,False,
NCT00261326,Simvastatin Treatment of Patients With Acute Optic Neuritis,"Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial",UNKNOWN,2006-09,2010-01,2011-05,2011-01-10,2005-12-05,INTERVENTIONAL,PHASE3,64.0,ESTIMATED,"Glostrup University Hospital, Copenhagen",OTHER,Alpharma ApS,INDUSTRY,Optic Neuritis|Multiple Sclerosis,Simvastatin|Optic Neuritis|Multiple Sclerosis,Denmark,Glostrup Municipality,Glostrup,1,simvastatin|placebo,DRUG|DRUG,The contrast sensibility of the eye after 3 months of the treatment,Visual acuity|visual evokes potentials (VEP)|cerebral MRI|Developing MS after 6 months,False,
NCT03201692,Improving Dynamic Balance and Gait Adaptability Using Treadmill Training,Improving Dynamic Balance and Gait Adaptability Using Treadmill Training With Visual Cues in Subjects With Neurological Disorders: Design of a Pilot Study,UNKNOWN,2017-07-01,2019-04-10,2019-04-10,2017-07-27,2017-06-28,INTERVENTIONAL,NA,48.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis|Stroke|Parkinson Disease,,Italy,Milan,,1,Virtual Reality Treadmill Training|Treadmill training,DEVICE|DEVICE,Change in the Modified Dynamic Gait Index|Change in the 6 minutes walking test,Change in Activity Balance Confidence|Change in 10-meter walking test|Change in Trial Making test|Change in Raven's Matrices,False,
NCT06608121,Upper Limb Muscle Strength Models for Patients With Motor Impairment.,Study for the Development and Evaluation of Personalised Muscle Effort Generation Models for Patients With Upper Limb Motor Deficits,RECRUITING,2024-11-05,2025-11,2025-11,2025-04-09,2024-09-23,INTERVENTIONAL,NA,60.0,ESTIMATED,Pôle Saint Hélier,OTHER,,,Stroke|Multiple Sclerosis|Spinal Cord Injuries,muscle strength|modeling|upper limb|motor impairment,France,Rennes,,1,Upper limb isokinetic forces measurements,OTHER,"Description of the residuals of the effort generation models, defined as the difference between the actual effort values and the modelled values: o Average residual of the models (mean ± standard deviation) (Main Evaluation Criterion)",,False,
NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,"A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)",COMPLETED,2014-06,2016-02,2016-03,2017-04-18,2014-04-29,INTERVENTIONAL,PHASE4,214.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Gastrointestinal event,Germany,Augsburg,,19,dimethyl fumarate,DRUG,"Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)|Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)|Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS|Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS|Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS|Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS","Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12|Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category|Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category|Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events|Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events",True,2017-04-18
NCT02799199,Fingolimod Real World Experience: the French Grand-Est Cohort,Fingolimod Real World Experience: the French Grand-Est Cohort,COMPLETED,2014-09,2015-10,2015-10,2016-06-14,2016-06-14,OBSERVATIONAL,,1014.0,ACTUAL,CHU de Reims,OTHER,,,Multiple Sclerosis,,,,,0,,,the course of the disease by magnetic resonance imaging (MRI),,False,
NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)",COMPLETED,2020-10-19,2023-11-20,2024-10-21,2025-08-15,2020-07-27,INTERVENTIONAL,PHASE3,111.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,"Ofatumumab|Relapsing multiple sclerosis|MS|RMS|CIS|RRMS|SPM|ocrelizumab|MRI|CD19 B|adult,|OMB157|open-label|rituximab",United States,Birmingham,Alabama,20,Ofatumumab,DRUG,Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Using Non-responder Imputation|Percentage of Participants With no Change or a Reduction From Baseline in the Number of Gadolinium Enhancing (GdE) Lesions at Month 12 Based on Observed Data,"Number of Participants Who Continued Study Treatment From Baseline to Months 6 and 12|Change From Baseline in CD19+ B Cell Counts Obtained by FACS|Change From Baseline in CD20+ CD3+ T Cell Counts Obtained by FACS|Number of Participants With Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)|Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Scores at Baseline, Month 6 and Month 12|Number of Participants With Treatment Emergent Adverse Events (TEAEs)",True,2024-11-01
NCT06090084,Investigation of Factors Affecting Functional Capasity in Multiple Sclerosis,Investigation of the Musculoskeletal and Respiratory System Factors Affecting Functional Capasity in Multiple Sclerosis,NOT_YET_RECRUITING,2023-10,2024-09,2024-09,2023-10-23,2023-10-19,OBSERVATIONAL,,140.0,ESTIMATED,Izmir Bakircay University,OTHER,,,Multiple Sclerosis,,,,,0,Evaluation,OTHER,6 Minute Walk Test (6MWT),The Mini Balance Evaluation Systems Test (Mini BESTest)|Evaluation of Core Muscles Strength|Evaluation of Trunk Muscle Structure|5 Times Sit To Stand Test|Evaluation of Grip Force|The Arm Function in Multiple Sclerosis Questionnaire (AMSQ)|Fatigue Severity Scale|Respiratory Muscle Strength Measurement,False,
NCT01353547,Genes and Environment in Multiple Sclerosis,Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility,RECRUITING,2017-10-01,2040-10,2040-10,2025-04-24,2011-05-13,OBSERVATIONAL,,5000.0,ESTIMATED,Columbia University,OTHER,University of Pittsburgh|Brigham and Women's Hospital,OTHER|OTHER,Multiple Sclerosis,genomic analysis|online surveys|biological specimen collection,United States,Bethesda,Maryland,5,,,Total number of subjects who are diagnosed with MS,,False,
NCT02683863,Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers,An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis,COMPLETED,2015-08,2017-01-31,2017-01-31,2017-03-22,2016-02-17,INTERVENTIONAL,PHASE4,20.0,ESTIMATED,Multiple Sclerosis Center of Northeastern New York,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Latham,New York,1,BG00012 (DMF) (Tecfidera®.),DRUG,The primary objective of the study is to investigate the PK (drug level) of DMF(study drug) in CSF with SPMS.|The primary objective of the study is to investigate the PK (drug level) of DMF(study drug) in plasma in subjects with SPMS.|The primary objective of the study is to investigate the PK (drug level) of MMF(the primary metabolite of study drug) in CSF with SPMS.|The primary objective of the study is to investigate the PK (drug level) of MMF( the primary metabolite of study drug) in plasma in subjects with SPMS.|The primary objective of the study is to investigate the PK (drug level) of DMF conjugate (study drug) in CSF with SPMS.|The primary objective of the study is to investigate the PK (drug level) of DMF conjugate (study drug) in plasma in subjects with SPMS.|The primary objective of the study is to investigate the PK (drug level) of MMF (the primary metabolite of study drug) conjugate in CSF with SPMS.|The primary objective of the study is to investigate the PK (drug level) of MMF( the primary metabolite of study drug) conjugate in plasma in subjects with SPMS.,A secondary objective is to assess the effects of DMF on PD biomarkers downstream of Nrf2 in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on biomarkers of inflammation in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on biomarkers of neuroaxonal damage in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on biomarkers of oxidative stress in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on myelin lipid biomarkers in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on pharmacogenomic biomarkers in the CSF of subjects with SPMS.|A secondary objective is to assess the effects of DMF on RNA samples from CSF cellular pellet for transcriptionomics in the CSF of subjects with SPMS.,False,
NCT03516526,Towards Personalized Dosing of Natalizumab in Multiple Sclerosis,Towards Personalized Dosing of Natalizumab in Multiple Sclerosis,COMPLETED,2016-11-03,2019-06-21,2019-07-01,2019-07-12,2018-05-04,INTERVENTIONAL,PHASE4,61.0,ACTUAL,"Amsterdam UMC, location VUmc",OTHER,Prothya Biosolutions|Erasmus Medical Center|St. Antonius Hospital|OLVG|Rijnstate Hospital,INDUSTRY|OTHER|OTHER|NETWORK|OTHER,Multiple Sclerosis,natalizumab,Netherlands,Amsterdam,,5,Natalizumab,DRUG,Gadolinium enhancing T1 lesions on brain MRI,New T2 lesions on brain MRI|Relapses|EDSS|MSFC|patient perspective measured with the SF-36|patient perspective measured with the MSIS-29,False,
NCT03584672,"The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.","The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.",UNKNOWN,2018-08-05,2018-08-20,2018-08-30,2018-07-17,2018-07-12,OBSERVATIONAL,,30.0,ESTIMATED,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Static Balance Test|Balance|Reliability|Validity,,,,0,Static Balance Test|Berg Balance Scale|Timed Up an Go Test|Four Square Step Test|Functional Reach Test|One-leg Stance Test,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Static Balance Test,Berg Balance Scale|Timed Up and Go Test|Four Square Step Test|One-leg Stance Test|Functional Reach Test,False,
NCT04979845,Telerehabilitation in Multiple Sclerosis,The Effect on Telerehabilitation on Fatigue and Sleep Quality in Patients With Multiple Sclerosis,UNKNOWN,2021-07-01,2021-12-31,2021-12-31,2021-07-28,2021-07-28,INTERVENTIONAL,NA,30.0,ESTIMATED,Marmara University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Istanbul,,1,Telerehabilitation|Video exercise,OTHER|OTHER,Pittsburgh Sleep Quality Scale,,False,
NCT01074619,Study on Cognitive Disorders of Multiple Sclerosis,Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis,COMPLETED,2005-09,2011-03,2011-11,2012-09-03,2010-02-24,INTERVENTIONAL,PHASE3,90.0,ACTUAL,"University Hospital, Caen",OTHER,"Ministry of Health, France|H. Lundbeck A/S",OTHER_GOV|INDUSTRY,Multiple Sclerosis,,France,Caen,,1,Memantine|Placebo,DRUG|DRUG,Pace Auditory Serial Addition Test(P.A.S.A.T),,False,
NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,"A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab",COMPLETED,2018-03-15,2019-12-26,2020-07-29,2022-04-29,2017-08-15,INTERVENTIONAL,PHASE2,64.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,double-blind|placebo controlled|ofatumumab|relapsing multiple sclerosis|Japanese patients|MS|RMS|adult|OMB157,Japan,Tōon,Ehime,14,Ofatumumab|Matching placebo of ofatumumab,DRUG|DRUG,Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Core Part,Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Japan vs Non-Japan - Core Part|Number of New or Enlarging T2 Lesions on MRI Scans (Annualized T2 Lesion Rate) - Core Part|Annualized Relapse Rate (ARR) - Core Part|Pharmacokinetic (PK) Concentrations of Ofatumumab - Core Part|B-cell Counts - Japan vs Non-Japan - Core Part|Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Extension Part|Number of New or Enlarging T2 Lesions on MRI Scans (Annualized T2 Lesion Rate) - Extension Part|Annualized Relapse Rate (ARR) - Extension Part|Pharmacokinetic (PK) Concentrations of Ofatumumab - Extension Part|B-cell Counts - Extension Part|Participants With Confirmed Relapse - Core and Extension Parts,True,2022-02-18
NCT02601885,A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis,An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis,COMPLETED,2016-10-18,2018-04-20,2018-04-20,2018-05-17,2015-11-11,INTERVENTIONAL,PHASE1,20.0,ACTUAL,AbbVie,INDUSTRY,,,Multiple Sclerosis,Relapsing-remitting|Secondary progressive|Relapsing forms,United States,Orlando,Florida,8,ABT-555|Placebo,DRUG|OTHER,Number and percentage of participants reporting adverse events|Concentration of anti-drug antibody (ADA) titers of ABT-555|Time to Maximum observed plasma concentration (Tmax) of ABT-555|Maximum observed plasma concentration (Cmax) of ABT-555|Area under the concentration curve (AUC) of ABT-555,"Percentage of participants who experience relapse and disability progression|Lesion volume of new, newly enlarging T2 hyperintense lesions|Number of new, newly-enlarging T2 hyperintense lesions|Total number of new Gadolinium-enhancing T1 lesions",False,
NCT06925022,Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1),Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study,ACTIVE_NOT_RECRUITING,2024-12-15,2025-06-30,2025-07-30,2025-05-08,2025-04-13,INTERVENTIONAL,NA,30.0,ESTIMATED,Universidad de Almeria,OTHER,Catholic University of Murcia|Hospital Universitario Virgen de la Arrixaca,OTHER|OTHER,Multiple Sclerosis (MS) - Relapsing-remitting,"Lifestyle Interventions|Menstrual Cycle|Multiple Sclerosis|Exercise|Cognitive-behavioral intervention|Physical Activity, Psychosocial Well-being|Nutrition intervention",Spain,Murcia,Murcia,1,Strength training session during Early Follicular Phase|Strength Training Protocol during Late Follicular Phase|Strength Training during Mid-Luteal Phase,OTHER|OTHER|OTHER,Satisfaction with Physical Activity|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Visual Analogue Scale (VAS-F): Fatigue subscale|Visual Analogue Scale (VAS-F): Fatigue subscale|Visual Analogue Scale (VAS-F): Fatigue subscale|Visual Analogue Scale (VAS-F): Fatigue subscale|Visual Analogue Scale (VAS-E): Energy subscale|Visual Analogue Scale (VAS-E): Energy subscale|Visual Analogue Scale (VAS-E): Energy subscale|Visual Analogue Scale (VAS-E): Energy subscale|Visual Analogue Scale (VAS-P): Pain subscale|Visual Analogue Scale (VAS-P): Pain subscale|Visual Analogue Scale (VAS-P): Pain subscale|Visual Analogue Scale (VAS-P): Pain subscale,Muscle oxygen saturation (SMO2)|Capillary lactate concentration|Capillary lactate concentration|Heart rate variability|Thyroid Stimulating Hormone (TSH)|Interferon-gamma (IFN-γ)|Interferon-gamma (IFN-γ)|Cognitive Function|Cognitive Function|Neurofilament Light Chain (NFL)|Neurofilament Light Chain (NFL)|Physical Self-Perception (PSP)|Pain Catastrophizing Scale (PCS)|Quality of Life questionnaire (MSQOL-54)|State-Trait Anxiety (STAI)|Rate of force development|Rate of force development|Maximum Voluntary Isometric Contraction|Maximum Voluntary Isometric Contraction|Maximal neural drive|Maximal neural drive|Central activation ratio|Central activation ratio|Upper Limb Maximum Strength|Upper Limb Maximum Strength|Spasticity|Spasticity|Intrinsic muscle characteristics: Tone (F)|Intrinsic muscle characteristics: Tone (F)|Gait speed|Gait speed|Static balance with eyes open|Static balance with eyes open|Static balance with eyes closed|Static balance with eyes closed|Sit-to-stand|Sit-to-stand|Timed Up-and-Go test|Timed Up-and-Go test|Delayed onset muscle soreness|Delayed onset muscle soreness|Delayed onset muscle soreness|Delayed onset muscle soreness|Delayed onset muscle soreness|Subjective Perception of Effort (RPE)|Subjective Perception of Effort|Subjective Perception of Effort|Subjective Perception of Effort|Fatigue Visual Analog Scale (VAS-F)|Visual Analogue Scale for Fatigue (VAS-F)|Fatigue Visual Analog Scale (VAS-F)|Fatigue Visual Analog Scale (VAS-F)|Fatigue Visual Analog Scale (VAS-F)|Body Weight|Physical Activity Level assessed by the International Physical Activity Questionnaire (IPAQ)|Adherence to the Mediterranean Diet assessed by MEDAS|Adherence to the Mediterranean Diet assessed by MEDAS|The Kurtzke Disability Scale|The Kurtzke Disability Scale|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Sleep Quality Measured by Actigraph|Sleep Quality Measured by Actigraph|Sleep Quality Measured by Actigraph|Sleep Quality Measured by Actigraph|Sleep Quality Measured by Actigraph|Progesterone (PG)|Luteinizing Hormone (LH)|Follicle-Stimulating Hormone (FSH)|Estradiol (E2)|Testosterone (T)|Interleukin-6 (IL-6)|Interleukin-6 (IL-6)|Tumor Necrosis Factor-alpha (TNF-α)|Tumor Necrosis Factor-alpha (TNF-α)|Interleukin-10 (IL-10)|Interleukin-10 (IL-10)|Transforming Growth Factor Beta 1 (TGF-β1)|Transforming Growth Factor Beta 1 (TGF-β1)|Intrinsic muscle characteristics: Stiffness (S)|Intrinsic muscle characteristics: Stiffness (S)|Intrinsic muscle characteristics: Elasticity (D)|Intrinsic muscle characteristics: Elasticity (D)|Intrinsic muscle characteristics: Relaxation (R)|Intrinsic muscle characteristics: Relaxation (R)|Intrinsic muscle characteristics: Creep (C)|Intrinsic muscle characteristics: Creep (C)|Height|Body Mass Index (BMI)|Physical Activity Level assessed by Triaxial Accelerometer|Nutrient Intake assessed by 3-Day Food Diary|Nutrient Intake assessed by 3-Day Food Diary|Lean Mass (%)|Lean Mass (kg)|Bone Mineral Content (BMC)|Bone Mineral Density (BMD)|Body Water|Phase Angle|Heart rate variability|Heart rate variability|Heart rate variability|Heart rate variability|Fat Mass (kg)|Fat Mass (%),False,
NCT05334472,A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis,Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis,COMPLETED,2021-11-24,2023-02-15,2023-02-15,2024-03-25,2022-04-19,OBSERVATIONAL,,105.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|NIS|KESIMPTA|ofatumumab,United States,East Hanover,New Jersey,1,Kesimpta,OTHER,Proportion of respondents in top two rating categories for device satisfaction on use of KESIMPTA Sensoready,"Proportion of patients by US region of residence|Proportion of patients by educational level|Patients Determined Disease Steps (PDDS)|General Health|Proportion of patients by Multiple Sclerosis Phenotype|Proportion of patients with co-morbidities|Importance of healthcare provider (HCP) instructions for first injection|Level of anxiety with injections, in general|Proportion of patients performing preparation activities for injection|Proportion of participants by site of administration|Proportion of participants by individual medication as previous Disease Modifying Therapy (DMT)|Proportion of patients who are DMT naïve or experienced|Proportion of participants by reasons for starting KESIMPTA|Proportion of participants by reasons to switch from most recent therapy|Proportion of patients agreeing with the attributes of the device Usability Characteristics during self-administration|Patient Confidence|Overall device satisfaction by treatment duration|Overall device satisfaction score of the study participants by DMT experience",False,
NCT03368157,PREG-MS: New England MS Pregnancy Registry,PREG-MS: New England MS Pregnancy Prospective Cohort Study,UNKNOWN,2017-04-07,2022-07-07,2022-12-07,2021-10-15,2017-12-11,OBSERVATIONAL,,500.0,ESTIMATED,Brigham and Women's Hospital,OTHER,,,Multiple Sclerosis|Pregnancy Related,,United States,Boston,Massachusetts,1,,,The relationship between EDSS and pregnancy course,The relationship between MS treatments and pregnancy course,False,
NCT01596881,Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis,Using OCT to Capture Retinal Microvascular Changes Associated With MS,COMPLETED,2012-04,2017-02-08,2017-02-08,2018-04-12,2012-05-11,OBSERVATIONAL,,101.0,ACTUAL,Oregon Health and Science University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Blood flow|Optical Coherence Tomography|Imaging,United States,Portland,Oregon,1,,,Number of patients with MS who also have reduced blood flow in the retina and/or changes in the blood flow to the retina compared to healthy subjects,Number of patients with MS who have different blood flow response than healthy subjects to visually stimulating patterns.,False,
NCT06251830,Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?,Aumentare il Potere Diagnostico Riducendo la Durata Dell'Esame: MR Fingerprinting Soddisfa le Aspettative?,COMPLETED,2018-09-01,2023-08-31,2023-08-31,2024-02-09,2024-02-09,OBSERVATIONAL,,610.0,ACTUAL,IRCCS Fondazione Stella Maris,OTHER,"Azienda Ospedaliero, Universitaria Pisana",OTHER,Neurodevelopmental Disorders|Neurodegenerative Diseases|Brain Tumor|Multiple Sclerosis|Epilepsy,,Italy,Pisa,,2,MRI exam with Magnetic Resonance Fingerprinting,DIAGNOSTIC_TEST,MRF diagnostic power,,False,
NCT01764737,"Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS","A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis",COMPLETED,2012-12,2014-11,2014-11,2015-02-06,2013-01-10,INTERVENTIONAL,PHASE1,50.0,ACTUAL,Vaccinex Inc.,INDUSTRY,PRA Health Sciences,INDUSTRY,Multiple Sclerosis,VX15/2503|Semaphorin 4D|SEMA4D|CD100|safety|tolerability|pharmacokinetics|immunogenicity|multiple sclerosis|monoclonal antibody,United States,Cullman,Alabama,10,VX15/2503|Placebo,DRUG|DRUG,Safety/Tolerability as determined by number of patients with adverse events,Half-life of VX15/2503|Peak plasma concentration (Cmax) of VX15/2503|Area under the plasma concentration versus time curve (AUC) of VX15/2503|Number of patients who develop anti-drug antibody,False,
NCT04913012,Exercise Booster Sessions in People With Multiple Sclerosis,Sustainability of Exercise Therapy by the Use of Exercise Booster Sessions in People With Multiple Sclerosis.,COMPLETED,2021-08-01,2024-10-04,2024-10-04,2024-12-27,2021-06-03,INTERVENTIONAL,NA,150.0,ACTUAL,University of Aarhus,OTHER,Oxford Brookes University,OTHER,Multiple Sclerosis,Exercise|Rehabilitation,Denmark,Aarhus,,1,Systematic aerobic training|Systematic resistance training|Aerobic training booster sessions|Resistance training booster sessions,COMBINATION_PRODUCT|COMBINATION_PRODUCT|COMBINATION_PRODUCT|COMBINATION_PRODUCT,Change in functional capacity measured as a composite score of the six minute walk test and the 5x sit to stand test (5STS).,Change in functional capacity measured by the Six spot step test (SSST)|Change in functional capacity measured by the Multiple Sclerosis Functional Composite (MSFC),False,
NCT03737812,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis",COMPLETED,2019-02-27,2021-01-15,2021-08-30,2023-12-21,2018-11-13,INTERVENTIONAL,PHASE2,123.0,ACTUAL,AbbVie,INDUSTRY,,,Multiple Sclerosis (MS),Progressive multiple sclerosis|Elezanumab|ABT-555,United States,Phoenix,Arizona,37,elezanumab|placebo,DRUG|DRUG,Mean Overall Response Score (ORS),Disability Improvement Response Rate|Overall Response Score (ORS)|Overall Response Score (ORS)|Overall Response Score (ORS),True,2023-12-21
NCT04286828,"Position Sense, Balance, and Dual Task Performance at the Menstrual Cycle in Females With Multiple Sclerosis","An Investigation of Knee Position Sense, Balance, and Dual Task Performance in Different Phases of Menstrual Cycle in Females With Multiple Sclerosis",COMPLETED,2019-03-25,2019-10-20,2019-11-26,2020-05-27,2020-02-27,OBSERVATIONAL,,27.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Multiple Sclerosis|Neurologic Symptoms|Menstrual Cycle,Multiple Sclerosis|Proprioception|Postural balance|Task performance and analysis,Turkey (Türkiye),Ankara,Esenboğa,1,Position Sense|Balance|Dual Task Performance,OTHER|OTHER|OTHER,Knee position sense|Balance|Dual Task Performance,,False,
NCT06735053,Impact of Virtual Reality Physiotherapy on Multiple Sclerosis Patients,Experimental Study on the Impact of a Virtual Reality-Based Physiotherapy Program as a Complement to a Conventional Physiotherapy Program in Patients With Moderate to Severe Multiple Sclerosis,RECRUITING,2025-02,2025-05,2025-07,2025-02-21,2024-12-16,INTERVENTIONAL,NA,26.0,ESTIMATED,European University of Madrid,OTHER,,,Multiple Sclerosis,multiple sclerosis|virtual reality,Spain,Móstoles,Madrid,2,Virtual Reality group|Placebo virtual reality group,OTHER|OTHER,Change in fatigue impact as measured with Modified Fatigue Impact Scale (MFIS),"Change in Physical and psicological impact of Multiple Sclerosis on patients'life measured with Multiple Sclerosis Impact Scale (MSIS-29)|Change in manual dexterity and fine motor skills|Change in gross motor manual dexterity|Change in functional independence to perform activities of daily living|Change in the ability to perform instrumental activities of daily living|Change in cognitive function|Change in physical, mental and social healths aspects related to quality of life",False,
NCT01854957,MEsenchymal StEm Cells for Multiple Sclerosis,MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis,UNKNOWN,2012-07,2014-07,2014-09,2013-05-16,2013-05-16,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,Antonio Uccelli,OTHER,Azienda Ospedaliera Universitaria Integrata Verona|Ospedale San Raffaele,OTHER|OTHER,Multiple Sclerosis,Multiple sclerosis|Mesenchymal stem cells,Italy,Genova,Genova,1,Autologous Mesenchymal Stem Cells,BIOLOGICAL,Safety|efficacy,Efficacy|Efficacy|Efficacy|Efficacy|Efficacy,False,
NCT04132167,Supervised Perturbation Training Results in Changes in Balance and Falling in Patients With Multiple Sclerosis,Supervised Perturbation Training Results in Changes in Balance and Falling in Patients With Multiple Sclerosis,UNKNOWN,2018-11-20,2019-10-20,2019-12-20,2019-10-25,2019-10-18,INTERVENTIONAL,NA,15.0,ESTIMATED,Suleyman Demirel University,OTHER,,,Multiple Sclerosis,Rehabilitation|Multiple sclerosis|Tailored interventions,Turkey (Türkiye),Isparta,,1,perturbation training,PROCEDURE,dynamic balance|walking|walking|falling|fear of falling,,False,
NCT06462339,The Effect of Online Pilates on Cognitive Function and Dual-Task Performance,Investigation of the Effects of Online Pilates Training on Cognitive Functions and Dual-Task Performance in Multiple Sclerosis Patients,COMPLETED,2024-06-28,2024-09-12,2024-11-12,2025-03-18,2024-06-17,INTERVENTIONAL,NA,28.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cognitive Function|Dual-task|Pilates|Telerehabilitation,Turkey (Türkiye),Ankara,,1,Experimental: Intervention Group,BEHAVIORAL,"Mini-Mental test-Baseline|Mini-Mental test-Post intervention|Montreal Cognitive Assessment-Baseline|Montreal Cognitive Assessment-Post intervention|Trail Making Test-Baseline|Trail Making Test-Post intervention|Stroop Test-Baseline|Stroop Test-Post intervention|Functional mobility-baseline|Dual task performance in functional mobility, Cognitive additional task (arithmetic)-baseline|Dual task performance in functional mobility, Cognitive additional task (verbal)-baseline|functional mobility-post intervention|Dual task performance in functional mobility, Cognitive additional task (arithmetic)-post intervention|Dual task performance in functional mobility, Cognitive additional task (verbal)-post intervention|balance-baseline|balance, Cognitive additional task (arithmetic)-baseline|Dual task performance in balance, Cognitive additional task (verbal)-baseline|Dual task performance in balance,Cognitive additional task (arithmetic)-post intervention|balance-post intervention|Dual task performance in balance,Cognitive additional task (arithmetic) -post intervention|Dual task performance in balance,Cognitive additional task (verbal) -post intervention|gait-baseline|Dual task performance in gait, Cognitive additional task (arithmetic)-baseline|Dual task performance in gait, Cognitive additional task (verbal)-baseline|gait-post intervention|Dual task performance in gait, Cognitive additional task (arithmetic)-post intervention|Dual task performance in gait, Cognitive additional task (verbal)-post intervention",,False,
NCT02515695,Phase I BP Interferon (IFN) Beta-001,"Bioavailability, Pharmacokinetic and Pharmacodynamic Profile of Interferon Beta-1a (Bioferon®) Administered i.v. and s.c. as Single Doses to Healthy Subjects",COMPLETED,2005-05,2005-07,2005-07,2015-08-06,2015-08-05,INTERVENTIONAL,PHASE1,12.0,ACTUAL,Centre Hospitalier Universitaire Vaudois,OTHER,BioPartners GmbH,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,,,,0,Interferon beta-1a,DRUG,Composite of interferon beta-1a PK parameters|Composite of interferon beta-1a PD markers,Number of participants with adverse events (AE)/serious adverse event (SAE) as a measure of safety and tolerability|Composite of local reactions as a measure of local tolerance|Composite of clinical laboratory tests as a measure of safety and tolerability|Composite of vital signs as a measure of safety and tolerability|Sickness behavior assessment|Electrocardiogram (ECG) as a measure of safety and tolerability,False,
NCT05896995,Efficiency of Different Exercise Approaches in Individuals Providing Primary Care to MS,Investigation of the Efficiency of Different Exercise Approaches in Individuals Providing Primary Care to Multiple Sclerosis Patients,COMPLETED,2023-05-01,2023-06-15,2023-07-07,2023-07-19,2023-06-09,INTERVENTIONAL,NA,41.0,ACTUAL,Istanbul Medipol University Hospital,OTHER,,,Back Pain,back pain|multiple sclerosis,Turkey (Türkiye),Istanbul,,1,Pilates Exercise|Mckenzie Exercise,OTHER|OTHER,Oswestry Low Back Pain Disability Questionnaire|Beck Depression Scale|Bakas Caregiver Impact Scale.|Disability status assessment.|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Algometer,,False,
NCT02043964,Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion,Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears),COMPLETED,2012-10,2018-06,2018-12,2024-03-26,2014-01-23,INTERVENTIONAL,NA,165.0,ACTUAL,Lille Catholic University,OTHER,,,Clinically Isolated Syndrome|Multiple Sclerosis,Multiple Sclerosis|Clinically Isolated Syndrome|Tears|Isoelectric focusing|Oligoclonal profile,France,Bordeaux,,15,tears and cerebrospinal fluid sampling,PROCEDURE,Test of the concordance coefficient between the analysis of tears and the analysis of cerebrospinal fluid,Diagnostic performance of isoelectric focusing of tears|Concordance between visual and automatic reading of electrophoretic profiles|Calculation of sensitivity/specificity|Calculation of positive/negative predictive value|Calculation of efficiency odds ratio,False,
NCT02901106,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP,TERMINATED,2017-05-23,2017-10-17,2017-10-17,2019-01-09,2016-09-15,INTERVENTIONAL,PHASE4,11.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|Dimethyl fumarate",France,Paris,,1,Dimethyl fumarate,DRUG,Number of patients with a relapse and/or progressive worsening of disease (EDSS score),,False,
NCT02222948,Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis,"A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)",TERMINATED,2014-09,2016-04,2016-07,2016-12-21,2014-08-22,INTERVENTIONAL,PHASE2,112.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,United States,Cullman,Alabama,32,Vatelizumab|Placebo (for Vatelizumab),DRUG|DRUG,Reduction in the cumulative number of new contrast-enhancing lesions on MRI,Safety: proportion of patients experiencing adverse events|Pharmacokinetics: serum concentrations of vatelizumab,False,
NCT06735248,A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years,"A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to ≤55 Years of Age With Multiple Sclerosis",RECRUITING,2025-04-16,2029-01-08,2029-01-08,2025-06-22,2024-12-16,INTERVENTIONAL,PHASE2,180.0,ESTIMATED,"ModernaTX, Inc.",INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|mRNA-1195|MS,United States,El Paso,Texas,1,mRNA-1195|Placebo,BIOLOGICAL|BIOLOGICAL,"Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)|Number of Participants with Unsolicited Adverse Events (AEs)|Number of Participants with Medically Attended Adverse Events (MAAEs)|Number of Participants with Adverse Events of Special Interest (AESI), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation of Study Intervention and/or Study Participation","Cumulative Number of New Gadolinium (Gd)-enhancing Longitudinal Relaxation Time (T1) Hyperintense Lesions, as Measured by Magnetic Resonance Imaging (MRI) from Baseline to Month 12 and End of Study (Day 887)|Mean Number of Gd-enhancing T1 Hyperintense Lesions Per Scan, as Measured by MRI from Baseline to Month 12 and End of Study (Day 887)|Cumulative Number of New and/or Newly Enlarging Transverse Relaxation Time (T2)-weighted Hyperintense Lesions as Measured by MRI from Baseline to Month 12 and End of Study (Day 887)|Time to First New Disease Activity on Study as Defined by a Clinical Attack Indicative of Central Nervous System (CNS) Involvement at a Site Remote to the First Attack or a New and/or Newly Enlarging T2 or Gd-enhancing Lesion on MRI|Geometric Mean Titer (GMT) of B-cell Neutralizing Antibodies (nAbs) and/or Vaccine Antigen-specific Binding Antibodies (bAbs) at Days 1, 85, and 197|Geometric Mean Fold Rise (GMFR) of B-cell nAbs and/or Vaccine Antigen-specific bAbs at Days 1, 85, and 197|Change in Expanded Disability Status Scale (EDSS) Score at 3- and 6-month Intervals from Baseline to End of Study (Day 887)|Time to 6-month Confirmed Disability Progression",False,
NCT03135249,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis,Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS),COMPLETED,2018-05-01,2020-11-04,2020-11-04,2022-02-15,2017-05-01,INTERVENTIONAL,PHASE4,9.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis (MS),,United States,Dallas,Texas,2,Alemtuzumab,DRUG,Annualized Relapse Rate (ARR) From the Time of Cessation of Natalizumab Treatment.|Relapse-free Period,Number of New T2 Lesions|Number of Enlarging T2 Lesions|Number of Gadolinium (Gd)-Enhancing Lesions,True,2022-02-15
NCT05925049,A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS),An Observational Study Utilising Data From EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS,ACTIVE_NOT_RECRUITING,2023-06-30,2026-03-31,2026-03-31,2025-09-17,2023-06-29,OBSERVATIONAL,,400.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Cambridge,Massachusetts,1,Natalizumab,DRUG,Percentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs),Percentage of Participants in Natalizumab-Experienced Cohort who Switched From Natalizumab IV Infusion to SC Injection and Develop Anti-Natalizumab Antibodies (ANAs)|Percentage of Participants With SAEs by Positive (Transient or Persistent) or Negative ANA Status|Percentage of Participants With MS Relapses by Positive (Transient or Persistent) or Negative ANA Status,False,
NCT06081348,Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders,A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders,RECRUITING,2024-09-16,2026-09,2026-09,2025-07-16,2023-10-13,INTERVENTIONAL,PHASE2,130.0,ESTIMATED,Holland Bloorview Kids Rehabilitation Hospital,OTHER,"Azrieli Foundation (Funder)|Canadian Institutes of Health Research (Funder)|Ontario Brain Institute (Funder)|McMaster University|Western University|Queen's University|University of Alberta|Alberta Health services|St. Justine's Hospital|Dalhousie University|Unity Health Toronto|University of Toronto|The Hospital for Sick Children|Maternal, Infant, Child and Youth Research Network (MICYRN)",UNKNOWN|UNKNOWN|UNKNOWN|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN,"Neurodevelopmental Disorders|Autism|Autism Spectrum Disorder|Fragile X Syndrome|Tuberous Sclerosis|22Q11 Deletion Syndrome|22Q11 Deletion|ADHD|Tic Disorders|Tourette Syndrome|Tourette Syndrome in Children|Tourette Syndrome in Adolescence|ADHD - Combined Type|ADHD Predominantly Inattentive Type|ADHD, Predominantly Hyperactive - Impulsive|Anxiety|Anxiety Disorders",,Canada,Calgary,Alberta,8,Sertraline|Placebo,DRUG|OTHER,The Screen for Child Anxiety Related Emotional Disorders (SCARED) - parent version,Clinical Global Impressions - Improvement Scale - Global (CGI-I)|Adverse events|Pediatric Quality of Life Inventory (PedsQL)|Whole blood serotonin (5-HT) assessment|Clinical Global Impressions- Improvement Scale (CGI-I) focused on anxiety,False,
NCT00331747,Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate,Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate,UNKNOWN,2006-05,,,2006-07-07,2006-05-31,INTERVENTIONAL,NA,20.0,,Sheba Medical Center,OTHER_GOV,,,Multiple Sclerosis,,Israel,Tel Litwinsky,,1,Glatiramer acetate,DRUG,Computerized gait analysis: at the beginning of treatment and after 1 year,,False,
NCT02959658,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis,COMPLETED,2016-12,2019-12-21,2020-12-09,2020-12-24,2016-11-09,INTERVENTIONAL,PHASE2,54.0,ACTUAL,"Rigshospitalet, Denmark",OTHER,Biogen,INDUSTRY,Primary Progressive Multiple Sclerosis,,Denmark,Copenhagen,,1,Dimethyl fumarate|Placebo,DRUG|DRUG,Neurofilament light chain in the cerebrospinal fluid (CSF),Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk (T25FW)|Nine hole peg test (9HPT)|Symbol digit modalities test (SDMT)|CSF/Serum Immunoglobulin type G index|Cerebrospinal fluid-serum albumin quotient|soluble CD14 (sCD14)|soluble CD27 (sCD27)|BCMA|Chitinase 3-like-1|Myelin Basic protein (MBP)|Number of new or enlarged T2 lesions|Fractional anisotropy (FA) in Normal Appearing White Matter (NAWM)|Change in lesion volume|Change from screening in in magnetization transfer ratio (MTR) of T2 lesions|Thalamic volume|Percent brain volume change (PBVC),False,
NCT02193217,A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303,,COMPLETED,,2014-12,2015-01,2015-02-20,2014-07-17,INTERVENTIONAL,PHASE1,81.0,ACTUAL,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,United Kingdom,Leeds,,1,MT-1303-Low|MT-1303-High|Fingolimod|Placebo,DRUG|DRUG|DRUG|DRUG,Mean hourly heart rate,Plasma concentration of MT-1303 and its metabolite,False,
NCT00168714,Pregnancy Exposure Registry for Avonex (Interferon Beta-1a),Avonex Pregnancy Exposure Registry,COMPLETED,2004-02,2011-09,2011-09,2014-06-09,2005-09-15,OBSERVATIONAL,,329.0,ACTUAL,Biogen,INDUSTRY,,,Prenatal Exposure Delayed Effects|Multiple Sclerosis|Pregnancy,AVONEX|Pregnancy,United States,Wilmington,North Carolina,1,BG9418 (interferon beta-1a),DRUG,Record and analyze birth defects and spontaneous fetal losses|Record and analyze pregnancy outcomes,,False,
NCT03941184,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,COMPLETED,1995-01-01,2020-11-10,2020-11-10,2020-11-23,2019-05-07,OBSERVATIONAL,,114.0,ACTUAL,Mayo Clinic,OTHER,,,"SCAD|Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Polymyositis|Guillain-Barre Syndrome|Hepatitis, Autoimmune|Graves Disease|Hashimoto Thyroiditis|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Primary Biliary Cirrhosis|Psoriasis|Rheumatoid Arthritis|Systemic Sclerosis|Sjögren Syndrome|Systemic Lupus Erythematosus|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo|Raynaud",spontaneous coronary artery dissection|autoimmune|incidence,United States,Rochester,Minnesota,1,,,Odds of autoimmune disease in SCAD cases compared to controls|Incidence Rate of SCAD,SCAD recurrence,False,
NCT03696485,Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS,"A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)",WITHDRAWN,2024-02-01,2025-02-01,2025-02-01,2024-04-18,2018-10-04,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,Stem Cell Medicine Ltd.,INDUSTRY,,,Secondary Progressive Multiple Sclerosis (SPMS),"Secondary Progressive Multiple Sclerosis (SPMS), safety",Israel,Tel Aviv,,1,SCM-010,BIOLOGICAL,Adverse Events (AEs) reported during the trial,Change in MRI scans from baseline|Change from baseline in EDSS score|Time to Confirmed Disease Progression (CDP),False,
NCT04220814,Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis,Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2020-11-03,2023-10-03,2025-12-31,2025-04-04,2020-01-07,INTERVENTIONAL,NA,94.0,ACTUAL,Rennes University Hospital,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|MRI|pronostic,France,Marseille,,2,MRI|Electrophysiology,RADIATION|OTHER,association ratio between EDSS score and focal injury fraction at inclusion,Correlation between focal lesion load and changes in Expanded Disability Status Scale (EDSS)|Correlation between the severity of lesions and changes in Expanded Disability Status Scale (EDSS)|Differences in central conduction times between patients and healthy volunteers|Correlation between focal lesion load and changes in Timed 25-Foot Walk Test (T25W)|Correlation between the severity of lesions and changes in Timed 25-Foot Walk Test (T25W)|Correlation between focal lesion load and changes in Nine Hole Peg Test (9HPT)|Correlation between the severity of lesions and changes in Nine Hole Peg Test (9HPT)|Correlation between focal lesion load and changes in walking distance|Correlation between the severity of lesions and changes in walking distance|Correlation between focal lesion load and changes in 12-Item Multiple Sclerosis Walking Scale (MSWS12) score|Correlation between the severity of lesions and all limbs electrophysiology parameters|Correlation between in focal lesion load of pathways and changes in Expanded Disability Status Scale,False,
NCT00876447,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,,COMPLETED,2009-01-01,2013-06-12,2013-09-04,2019-05-01,2009-04-06,INTERVENTIONAL,PHASE3,397.0,ACTUAL,Allergan,INDUSTRY,,,Overactive Bladder,,United States,Middlebury,Connecticut,22,Botulinum Toxin Type A 300U|Botulinum Toxin Type A 200U,BIOLOGICAL|BIOLOGICAL,Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes|Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes,Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in the Incontinence Quality of Life Instrument (I-QOL) Total Summary Score|Change From Study Baseline in Volume Per Void|Change From Study Baseline in Volume Per Void|Change From Study Baseline in Volume Per Void|Change From Study Baseline in Volume Per Void|Change From Study Baseline in Volume Per Void,True,2014-06-13
NCT06325358,the EXPOSITION Study,"EXPOSITION (EXPosome, Oxidative Stress and InflammaTION) in Persons With Multiple Sclerosis Study",NOT_YET_RECRUITING,2024-04-15,2024-12-30,2024-12-30,2024-03-22,2024-03-22,OBSERVATIONAL,,200.0,ESTIMATED,University of Pavia,OTHER,"National Research Council (Consiglio Nazionale delle Ricerche)|IRCCS National Neurological Institute ""C. Mondino"" Foundation",UNKNOWN|OTHER,"Multiple Sclerosis, Relapsing-Remitting|Environmental Exposure|Lifestyle Factors",multiple sclerosis|exposome|microRNA|cytokines|microbiome|neurofilament|air pollution|urbanization|lifestyle|nutrition|physical activity|inflammation,Italy,Pavia,,1,,,microRNAs|Air quality|Nutritional assessment|Neurofilament (NfL)|Cytokines|the Body Mass Index (BMI)|Physical activity|Quality of life related to MS|Sleep Quality|Smoking habits|Dietary supplements use|Adherence to Mediterranean diet|Effect of diet on inflammation|waist and height ratio (WHtR)|Bioelectrical impedance,Microbiome and biological biomarkers of oxidative stress and inflammation,False,
NCT04252599,Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients.,Upper Airway Function and Cardiorespiratory Performance in Impair Trunk Motor Control Multiple Sclerosis Patients.,UNKNOWN,2019-11-20,2019-12-02,2020-01-24,2020-02-05,2020-02-05,OBSERVATIONAL,,60.0,ESTIMATED,Universidad de Granada,OTHER,,,Multiple Sclerosis,,Spain,Granada,,1,,,Trunk motor control|Swallowing function|Swallowing function|Ventilation function|Phonation function|The exercise capacity focussed on lower limbs|The exercise capacity focussed on upper limbs|The anaerobic threshold,Psychological status|Psychological status|The degree of neurological functioning|The impact of the multiple sclerosis disease,False,
NCT04280484,Acute Intermittent Hypoxia in Persons With Multiple Sclerosis,Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis,COMPLETED,2018-06-18,2019-10-10,2019-12-30,2020-02-24,2020-02-21,INTERVENTIONAL,NA,10.0,ACTUAL,Shirley Ryan AbilityLab,OTHER,Edward Hines Jr. VA Hospital,FED,"Multiple Sclerosis, Relapsing-Remitting",,United States,Chicago,Illinois,1,Intermittent Hypoxia|Sham Hypoxia,OTHER|OTHER,Voluntary Ankle Strength,Electromyogram activity|Symbol Digit Modalities Test,False,
NCT03656055,Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis,Study of the Link Between Retinal Atrophy and Demyelinating Inflammatory Processes on Visual Pathways in Relapsing Multiple Sclerosis in Magnetic Resonance Imaging and Optical Coherence Tomography,COMPLETED,2017-04-21,2018-01-03,2019-01-03,2022-09-21,2018-09-04,OBSERVATIONAL,,108.0,ACTUAL,"University Hospital, Lille",OTHER,,,Multiple Sclerosis,MRI|axonal loss|MS|OCT,France,Lille,,1,,,Study of asymptomatic retinal atrophy in multiple sclerosis and asymptomatic optic nerve demyelinating lesion,Evaluation of the link between asymptomatic retinal atrophy in multiple sclerosis and intensity of demyelinating process all along the optic ways (from the retina to the visual cortex)|Evaluation of the link between symptomatic retinal atrophy in multiple sclerosis and intensity of demyelinating process all along the optic ways (from the retina to the visual cortex)|Evaluation of the link between retinal atrophy and visual connectivity|Evaluation of the link between visual disability and MRI parameters measuring intensity of demyelinating process all along the optic ways (from the retina to the visual cortex),False,
NCT01444300,Dalfampridine for Imbalance in Multiple Sclerosis,Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study,COMPLETED,2011-09,2013-09,2013-09,2014-06-16,2011-09-30,INTERVENTIONAL,PHASE2,24.0,ACTUAL,Oregon Health and Science University,OTHER,Acorda Therapeutics,INDUSTRY,Multiple Sclerosis|Fatigue,multiple sclerosis|postural balance|gait|fatigue,United States,Portland,Oregon,1,Dalfampridine|Placebo,DRUG|DRUG,Change in Automatic Postural Response (APR )Latency,Change in Activities-specific Balance Confidence (ABC) Questionnaire Scores|Change in Timed 25 Foot Walking Speed,True,2014-06-16
NCT02402426,Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research,Brain Health Registry - Online Registry for Brain Research,ENROLLING_BY_INVITATION,2013-09,2030-09,2030-09,2025-01-10,2015-03-30,OBSERVATIONAL,,200000.0,ESTIMATED,"University of California, San Francisco",OTHER,,,Healthy|Neurodegenerative Disease,Brain Health|Brain Research|Alzheimer's Disease|Neurodegenerative Disease|Parkinson's Disease|Dementia|Stroke|PTSD|Multiple Sclerosis,United States,San Francisco,California,1,,,Alzheimer's Disease,Neurodegenerative Diseases,False,
NCT00273364,Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study,Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study,COMPLETED,2005-11-16,2017-01-05,2019-08-30,2020-08-12,2006-01-09,INTERVENTIONAL,PHASE2,110.0,ACTUAL,Northwestern University,OTHER,Uppsala University|Sheffield Teaching Hospitals NHS Foundation Trust|University of Sao Paulo,OTHER|OTHER|OTHER,Multiple Sclerosis,"stem cell, autoimmune disease, multiple sclerosis",United States,Chicago,Illinois,1,Hematopoietic Stem Cell Therapy|Standard treatment with a conventional drug,PROCEDURE|DRUG,Expanded Disability Status Scale (EDSS) Improvement,,True,2020-08-12
NCT02947906,Plantar Pressure Distribution in Patient With Multiple Sclerosis,Investigating the Plantar Pressure Distribution in Patient With Multiple Sclerosis,UNKNOWN,2016-10,2016-11,2016-11,2016-10-28,2016-10-28,OBSERVATIONAL,,70.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,Gait|Loading|Multiple Sclerosis|Plantar Pressure,,,,0,No intervention,OTHER,Pedobarography for assessment of foot pressure while standing and walking,,False,
NCT04485104,"Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures","An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures",TERMINATED,2021-05-19,2025-01-28,2025-01-28,2025-03-07,2020-07-24,INTERVENTIONAL,PHASE3,3.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Seizure in Participants With Tuberous Sclerosis Complex|Seizure in Participants With Dravet Syndrome|Seizure in Participants With Lennox-Gastaut Syndrome,Epilepsy|Seizures|Infantile Spasms|Tumors|Pediatric|Children|Infants|Cannabidiol oral solution|GWP42003-P|Tuberous Sclerosis Complex|TSC|Tuberous Sclerosis|Cannabidiol|Epidiolex|CBD|Seizure|Child|TSC1|TSC2|Tuberous Sclerosis 1|Tuberous Sclerosis 2|Lennox-Gastaut Syndrome|Dravet Syndrome,United States,Little Rock,Arkansas,11,GWP42003-P,DRUG,Number of Participants with Treatment-Emergent Adverse Events (TEAEs)|Mean Change From Baseline in Blood Pressure|Mean Change From Baseline in Pulse Rate|Mean Change From Baseline in Respiration Rate|Mean Change from Baseline in Body Temperature|Mean Change From Baseline in Height|Mean Change From Baseline in Body Weight|Mean Change From Baseline in Heart Rate|Mean Change From Baseline in RR Interval|Mean Change From Baseline in PR Interval|Mean Change From Baseline in QRS Duration|Mean Change From Baseline in QT Interval|Mean Change From Baseline in QTcB and QTcF|Number of Participants with a Clinically Significant Change in Laboratory Parameters|Number of Participants with Emergence of New Types of Seizures|Plasma Concentrations of GWP42003-P and its Major Metabolites|Percentage Change from Baseline in Indication-Specific Total Countable Seizures as Recorded by Caregivers|Clinician Global Impression of Change/Severity (CGIC/S) Score|Infant and Toddler Quality of Life Questionnaire Short Form 47 (ITQOL-47) Score,Number of Treatment Responders|Percentage Change from Baseline in Total Countable Seizures|Number of Participants Who Achieved Seizure-Free Status|Percentage of Participants Still Receiving GWP42003-P,False,
NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses",COMPLETED,2004-09,2010-07,2010-07,2013-01-04,2005-08-25,INTERVENTIONAL,PHASE3,1088.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting|Secondary Progressive|Progressive Relapsing,United States,Bridgewater,New Jersey,21,Teriflunomide|Placebo (for teriflunomide),DRUG|DRUG,Annualized Relapse Rate [ARR]: Poisson Regression Estimates,Time to 12-week Sustained Disability Progression: Kaplan-Meier Estimates of the Rate of Disability Progression at Timepoints|Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)|Changes From Baseline in Fatigue Impact Scale [FIS] Total Score,True,2012-11-06
NCT05957809,Structured Exercise Training in Newly Diagnosed Multiple Sclerosis,The Effects of Structured Exercise Training on Disease Course in Newly Diagnosed Multiple Sclerosis,COMPLETED,2023-07-20,2025-03-20,2025-05-20,2025-05-25,2023-07-24,INTERVENTIONAL,NA,49.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Multiple sclerosis|newly diagnosis|exercise|postural sway|cognition,Turkey (Türkiye),Istanbul,,1,Structured exercise training,OTHER,Clinical Test of Sensory Integration of Balance Test|Postural Stability Test|Balance Error Scoring System Test|Muscle strength,2 Minute Walk Test|Timed 25 Foot Walk Test|Brief International Cognitive Assessment for MS (BICAMS)|Curl-up,False,
NCT05075499,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA),UNKNOWN,2021-03-20,2021-12,2022-09,2021-10-12,2021-10-12,INTERVENTIONAL,NA,70.0,ESTIMATED,Sheba Medical Center,OTHER_GOV,Sanofi,INDUSTRY,Multiple Sclerosis,Multiple sclerosis|COVID-19|Vaccination|Teriflunomide (Aubagio)|Alemtuzumab (Lemtrada)|Immune responses|IgG|B-cells|T-cells,Israel,Ramat Gan,,1,COVID-19 vaccination,BIOLOGICAL,Percent of SARS-COV-2 antibody positive MS COVID-19 vaccinees at 1-month post 2nd COVID-19 vaccine dose.,"Percent of SARS-COV-2 antibody positive MS COVID-19 vaccinees at 3 and 6 months post 2nd COVID-19 vaccination.|SARS-COV-2 antibody titer at 1,3 and 6 months post 2nd COVID-19 vaccination.|SARS-COV-2 B-cell memory response at 1,3 and 6 months post 2nd COVID-19 vaccination.|Percent of MS COVID-19 vaccinees with SARS-COV-2 T-cell memory positive response at 1,3 and 6 months post 2nd COVID-19 vaccination.|SARS-COV-2 T-cell memory response at 1,3 and 6 months post 2nd COVID-19 vaccination.|Percent of MS COVID-19 vaccinees with positive double immune response (two responses of the possible three), or positive triple immune response (IgG, T-cell and B-cell memory positive) at 6 months post 2nd COVID-19 vaccination.|Percent of MS COVID-19 vaccinees with SARS-COV-2 B-cell memory positive response at 1,3 and 6 months post 2nd COVID-19 vaccination. Positive cut-off value will be determined as higher than 10 SFU.",False,
NCT02987621,Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?,Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?,COMPLETED,2016-11,2018-06,2018-06,2020-07-30,2016-12-09,INTERVENTIONAL,NA,14.0,ACTUAL,Colorado State University,OTHER,,,Multiple Sclerosis,,United States,Fort Collins,Colorado,1,tDCS,DEVICE,Leg Muscle Strength With and Without tDCS.|Leg Muscle Endurance With and Without tDCS.|6 Minute Walk Test,,True,2020-02-05
NCT02220933,Effect of MD1003 in Spinal Progressive Multiple Sclerosis,Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study,UNKNOWN,2013-10,2016-01,2018-01,2017-03-27,2014-08-20,INTERVENTIONAL,PHASE3,144.0,ESTIMATED,MedDay Pharmaceuticals SA,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|EDSS,France,Bordeaux,,17,MD1003 100mg capsule|Placebo,DRUG|DRUG,Proportion of patients improved on either Expanded Disability Status Scale (EDSS) or time to walk 25 feet (TW25),Multiple Sclerosis Walking Scale (MSWS)|Clinical Global Impression / Subject Global Impression (CGI / SGI)|Unidimensional Fatigue Impact Scale (U-FIS)|Multiple Sclerosis Quality of Life Scale (SEP-59)|Hole Peg Test (9-HPT),False,
NCT00001248,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI),RECRUITING,1992-07-23,,,2025-09-16,1999-11-04,OBSERVATIONAL,,3750.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|MRI (Magnetic Resonance Imaging)|Natural History,United States,Bethesda,Maryland,1,,,the rate of change in the number of new white matter lesions per participant,,False,
NCT02887781,Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France,Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France,RECRUITING,2015-08-13,2024-12-31,2024-12-31,2024-01-05,2016-09-02,OBSERVATIONAL,,150.0,ESTIMATED,"University Hospital, Brest",OTHER,,,Tuberous Sclerosis Complex,,France,Brest,,2,,,Evolution of the renal function estimated by the MDRD GFR,,False,
NCT03456206,"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","Intake of Dietary Fibre, Red and Processed Meat and Risk of Late-Onset Chronic Inflammatory Diseases: A Prospective Danish Study on the ""Diet, Cancer and Health"" Cohort",UNKNOWN,2018-11-10,2020-09-01,2023-05-01,2020-11-10,2018-03-07,OBSERVATIONAL,,57053.0,ESTIMATED,University of Southern Denmark,OTHER,Hospital of Southern Jutland|Odense Patient Data Explorative Network|University of Aarhus|Danish Cancer Society,OTHER|OTHER|OTHER|OTHER,"Autoimmune Diseases|Inflammatory Bowel Diseases|Crohn Disease (CD)|Ulcerative Colitis (UC)|Arthritis, Rheumatoid (RA)|Spondylarthropathies|Arthritis, Psoriatic (PsA)|Psoriasis (PsO)|Multiple Sclerosis (MS)",Life Style|Diet|Food|CID|Disease risk,Denmark,Odense,,1,Intake of red and processed meat and fibres|Lifestyle factors independently or combined,OTHER|OTHER,CID diagnosis,,False,
NCT02834533,Role of Virtual Reality in MS Rehabilitation,Robotic Gait Training in Multiple Sclerosis: a Randomized Clinical Trial Evaluating Virtual Reality Role,COMPLETED,2014-01,2014-08,2015-01,2016-07-18,2016-07-15,INTERVENTIONAL,NA,40.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Multiple Sclerosis Relapse,Lokomat;|robotic rehabilitation.|Multiple Sclerosis;|Virtual reality,,,,0,Lokomat,DEVICE,Berg Balance Scale,Coping Orientation to Problem Experienced,False,
NCT05103358,Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1),A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.,ACTIVE_NOT_RECRUITING,2022-02-15,2024-12-31,2025-12-31,2024-06-03,2021-11-02,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,"Aadi Bioscience, Inc.",INDUSTRY,,,"Tumor|Tumor, Solid|Metastasis|Metastatic Cancer|Cancer|Cancer Metastatic|Tumors|Neoplasms|Neoplasm Metastasis|Solid Tumor|Advanced Solid Tumor|Advanced Cancer|Malignant Solid Tumor|Malignant Solid Neoplasm|Malignant Neoplasm|Malignant Tumor|TSC|TSC1|TSC2|Metastatic Solid Tumor|Metastatic Neoplasm",TSC1 gene|TSC2 gene|Tissue agnostic|Basket|nab-sirolimus|mTOR inhibitor|nanoparticle albumin bound|mammalian target of rapamycin|mechanistic target of rapamycin|tumor profile|tuberous sclerosis complex 1|tuberous sclerosis complex 2|mTOR|sirolimus|TSC1|TSC2|ABI-009|FYARRO|Precision|Precision 1|Pathogenic alterations|Pathogenic mutations|Inactivating mutations,United States,Birmingham,Alabama,166,nab-sirolimus,DRUG,Overall response rate (ORR),Duration of response (DOR)|Disease control rate|Time to response|Progression-free survival|Overall survival|Patient-reported outcome|Incidence and severity of treatment-emergent and treatment-related adverse events (AEs),False,
NCT00629642,Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",COMPLETED,2008-03-14,2011-01-28,2011-01-28,2024-11-14,2008-03-06,INTERVENTIONAL,PHASE4,249.0,ACTUAL,Astellas Pharma Inc,INDUSTRY,,,Multiple Sclerosis|Neurogenic Bladder|Spinal Cord Diseases,Neurogenic bladder|Vesicare,Australia,Brisbane,,39,Solifenacin Succinate|Solifenacin Succinate|Oxybutynin Hydrochloride|Placebo,DRUG|DRUG|DRUG|DRUG,Change from baseline in maximum cystometric capacity,Change from baseline in bladder volume at first involuntary contraction|Change from baseline in pressure at first leak|Change from baseline in volume at first leak|Change from baseline in maximum detrusor pressure|Change from baseline in micturition or catheterization frequency|Change from baseline in incontinence episodes|Incidence and severity of adverse events,False,
NCT02325505,"Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma","Clinical Profile Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Followed at Hospital Das Clínicas, University of Sao Paulo Medical School",COMPLETED,2016-04,2021-04,2022-08,2022-08-04,2014-12-25,OBSERVATIONAL,,200.0,ACTUAL,InCor Heart Institute,OTHER,Novartis,INDUSTRY,Tuberous Sclerosis|Lymphangioleiomyomatosis|Angiomyolipoma,,Brazil,São Paulo,,3,,,Pulmonary function tests|Chest high resolution computed tomography findings|Findings on computed tomography of the brain|Abdominal computed tomography findings|Skin lesions|Respiratory symptoms Describe all respiratory symptoms in the study population)|Quality of life evaluation with the questionnaire Short-Form Health Survey - 36 (SF-36)|Urinary and abdominal complaints|Baseline dyspna index|Treatments performed (previous and current treatments performed)|Neurological complaints,Six-minute walking distance and dessaturation during six-minute walk test|Systolic pulmonary arterial pressure|Histopathological characteristics of samples obtained from skin biopsy,False,
NCT01440101,"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","Multicenter Study of BG00002 in Japanese Subjects With RRMS, Consisting of a Multiple-Dose, Open-Label Evaluation of Its Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part A) and a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Evaluation of Safety and Efficacy (Part B)",COMPLETED,2010-11,2012-08,2012-08,2014-10-21,2011-09-26,INTERVENTIONAL,PHASE2|PHASE3,106.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Japan,Chiba,,17,Natalizumab (BG00002)|Placebo,DRUG|DRUG,Part A: Number of Participants With Adverse Events (AEs)|Part B: Rate of Development of New Active Lesions Over 24 Weeks,"Part B: Cumulative Number of New Active Lesions Over 24 Weeks|Part B: Adjusted Annualized Relapse Rate Over 24 Weeks|Part B: Cumulative Number of Gd+ Lesions Over 24 Weeks|Part B: Cumulative Number Of New Or Newly Enlarging, Non-Enhancing T2-Hyperintense Lesions Over 24 Weeks|Part B: Number of Participants Who Were Relapse Free Over 24 Weeks|Part B: Change From Baseline to Weeks 12 and 24 in the Global Assessment of Well-Being As Assessed by Participants Using a Visual Analog Scale (VAS)|Part A: Concentration of Natalizumab in Serum|Part B: Concentration of Natalizumab in Serum|Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Cmax|Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: AUC(0-last) and (0-AUC∞)|Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Tmax and T1/2|Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Vd|Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: CL|Part B: Status of Serum Antibodies to Natalizumab|Part B: Number of Participants With Adverse Events (AEs)|Part A: Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC)|Part A: Summary of Lymphocyte Counts Over Time",True,2014-10-21
NCT06516458,Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis,Development of Camera Based Gait Deviation Index for Persons With Multiple Sclerosis,RECRUITING,2024-07,2025-07,2026-07,2024-07-24,2024-07-24,OBSERVATIONAL,,40.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis Relapse|Multiple Sclerosis, Relapsing-Remitting",,United States,Chicago,Illinois,1,Camera Based Kinematic Analysis,DIAGNOSTIC_TEST,Kinematics of the gait cycle,6 minute walk test,False,
NCT02907177,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),"Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)",TERMINATED,2017-03-30,2020-03-26,2020-03-26,2021-05-18,2016-09-20,INTERVENTIONAL,PHASE3,136.0,ACTUAL,Actelion,INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,119,Ponesimod|Placebo,DRUG|OTHER,Annualized Confirmed Relapse Rate (ARR),Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96|Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96|Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability,True,2021-05-18
NCT06846281,Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.,"A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib",RECRUITING,2025-07-23,2030-02-07,2032-01-08,2025-09-11,2025-02-26,INTERVENTIONAL,PHASE3,360.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,MS|RMS|Remibrutinib|LOU064|Ocrelizumab|Age|MRI|T2 lesions|NEDA-3,Australia,Melbourne,Victoria,6,Remibrutinib oral treatment|Ocrelizumab,DRUG|DRUG,Annualized rate of new or enlarging T2 lesions_Core Part,Participants with no evidence of disease activity-3 (NEDA-3)_Core Part|Number of adverse events (AEs) and serious adverse events (SAEs)_Core Part|Annualized rate of new or enlarging T2 lesions_Extension Part|Participants with no evidence of disease activity-3 (NEDA-3)_Extension Part|Number of Adverse events and serious adverse events_Extension Part,False,
NCT04061681,Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study,Efficacy of Project BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study,COMPLETED,2020-01-01,2020-11-23,2020-11-23,2020-12-11,2019-08-20,INTERVENTIONAL,NA,15.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis|Restless Legs Syndrome,Physical Activity,United States,Birmingham,Alabama,1,Behavioral Intervention (BIPAMS),BEHAVIORAL,Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale|Physical Activity Levels as measured by the Godin Leisure-Time Exercise Questionnaire|Physical Activity Levels as measured by the Godin Leisure-Time Exercise Questionnaire,Sleep Quality as measured by the Pittsburgh Sleep Quality Index|Sleep Quality as measured by the Pittsburgh Sleep Quality Index|Sleep Quality as measured by accelerometry|Sleep Quality as measured by accelerometry|Daytime Sleepiness as measured by the Epworth Sleepiness Scale|Daytime Sleepiness as measured by the Epworth Sleepiness Scale,False,
NCT03237832,A Phase 1 Study of ARN-6039,"A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects.",COMPLETED,2016-05-16,2016-10-06,2017-02,2017-08-03,2017-08-03,INTERVENTIONAL,PHASE1,60.0,ACTUAL,Arrien Pharmaceuticals,INDUSTRY,Worldwide Clinical Trials,OTHER,Multiple Sclerosis,,,,,0,ARN-6039|Placebo,DRUG|OTHER,Change in clinical tests results over time|Change in vital signs over time|Change in physical assessment over time|Change in electrocardiograms (ECGs) over time|Determine the incidence of Treatment Adverse Events (AEs) over time,Assay maximum plasma concentration (Cmax) over time|Assay the time to Cmax (tmax) over time|Assay the area under the plasma concentration time curve from zero to the last measurable concentration (AUC0-t) over time|Assay the terminal half-life (t1/2) over time|Assay the area under the plasma concentration time curve from zero to infinity (AUC0-inf) over time|Assay the apparent oral clearance (CL/F) over time,False,
NCT02391298,An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis,An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.,COMPLETED,2014-12,2016-05,2016-05,2017-04-26,2015-03-18,INTERVENTIONAL,NA,26.0,ACTUAL,Haley Duncanson,OTHER,Suffolk University,OTHER,Multiple Sclerosis,Multiple Sclerosis|stress|meditation|attention,United States,Boston,Massachusetts,1,Mindfulness Meditation,BEHAVIORAL,The Stop Signal Test (SST)|The Freiburg Visual Acuity Test (FrACT),The Functional Assessment of Multiple Sclerosis (FAMS) Quality of Life Instrument|Feedback Questionnaire|Mindful Attention Awareness Scale|Difficulties in Emotion Regulation Scale,False,
NCT00492466,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,"A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies",COMPLETED,2003-03,2006-08,2006-08,2008-01-30,2007-06-27,INTERVENTIONAL,PHASE4,14.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Multiple Sclerosis|antibody|Neutralizing antibody|Binding antibody|MxA protein,Finland,Turku,,1,Interferon-beta-1a|methylprednisolone,DRUG|DRUG,Reduction in the proportion of patients being neutralizing antibody (NAb) positive (titre>20),Change in MxA protein values|Change in binding antibody (Bab) tires|Proportion of patients with NAb positive titre <5|Change in annualised relapse rate|The number of relapse-free patients,False,
NCT06264037,The Experience in Neurorehabilitation Setting: a Qualitative Study,"""The Experiences of Care Lived by People Admitted to Neurorehabilitation: a Qualitative Exploratory Study With a Phenomenological Approach",RECRUITING,2023-03-15,2024-12-08,2025-03-15,2024-02-16,2024-02-16,OBSERVATIONAL,,40.0,ESTIMATED,"IRCCS San Camillo, Venezia, Italy",OTHER,,,Rehabilitation|Neurologic Disorder|Stroke|Parkinson Disease|Multiple Sclerosis|Neurosurgery,,Italy,Venezia,,3,semi structured interview,OTHER,narrative contents,,False,
NCT02833311,e-Mobile Tablet for People With Chronic Conditions,Examining the Usability of Computer Tablets to Promote Symptom Self-management and Engagement in Healthy Behaviors in Adults With Chronic Conditions,COMPLETED,2013-11,2016-04,2016-04,2023-05-12,2016-07-14,INTERVENTIONAL,NA,46.0,ACTUAL,Case Western Reserve University,OTHER,,,Fibromyalgia|Multiple Sclerosis|Osteoarthritis|Sjögren's Syndrome|Parkinson's Disease,Neuromusculoskeletal condition,United States,Cleveland,Ohio,1,Computer Tablet Group|Paper and Pencil Group|Contact Control Group,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Changes From Baseline in Physical Activity,Changes From Baseline in Self-Report Physical Function|Changes From Baseline in 6-minute Walking Test|Changes From Baseline in Self-Efficacy|Changes From Baseline in Weight,True,2023-05-12
NCT00001934,Zenapax to Treat Multiple Sclerosis,"Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial",COMPLETED,1999-09,2005-08,2008-09,2011-08-05,1999-11-04,INTERVENTIONAL,PHASE2,22.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Immunotherapy|MRI,United States,Bethesda,Maryland,1,Zenapax,DRUG,Change in contrast-enhancing lesions on brain MRI.,,False,
NCT06104683,A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis,"A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis",WITHDRAWN,2024-05-01,2026-01-16,2026-02-13,2024-03-27,2023-10-27,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"Loxo Oncology, Inc.",INDUSTRY,Eli Lilly and Company,INDUSTRY,Relapsing Multiple Sclerosis|Multiple Sclerosis,Relapsing Forms Multiple Sclerosis,United States,Tampa,Florida,4,Placebo|Pirtobrutinib,DRUG|DRUG,New T1 Gadolinium (Gd)-enhancing Lesions on Brain Magnetic Resonance Imaging (MRI) Per Scan|Number of New and/or Enlarging T2 Lesions,Total Number of T1 Gd-Enhancing Lesions Per Scan|Total Number of Gd-Enhancing Lesions Per Scan|Pharmacokinetics (PK): Plasma Concentration of Pirtobrutinib,False,
NCT01103583,Hydroxyurea in Primary Progressive Multiple Sclerosis,,TERMINATED,2011-07,2013-12,,2014-02-11,2010-04-14,INTERVENTIONAL,PHASE2|PHASE3,33.0,ACTUAL,S. Andrea Hospital,OTHER,,,Multiple Sclerosis,,Italy,Rome,,2,Hydroxyurea|placebo,DRUG|OTHER,the evaluation of safety and tolerability of hydroxyurea,the evaluation of efficacy of hydroxyurea in primary progressive multiple sclerosis,False,
NCT06583395,Quest to Analyze One Thousand Humans Meditating,Effects Of Meditation On The Gut Microbiome And Human Health and Disease,ENROLLING_BY_INVITATION,2021-12-05,2025-03-25,2025-03-25,2024-11-01,2024-09-04,OBSERVATIONAL,,3000.0,ESTIMATED,Tobias Moeller-Bertram,INDUSTRY,"Metamorphosis, LLC|University of California, San Diego",UNKNOWN|OTHER,"Amyotrophic Lateral Sclerosis (ALS)|Angina, Stable|Anxiety|Asthma|Atrial Fibrillation|Cancer Brain|Cancer, Breast|Cancer Colon|Cancer, Lung|Cancer, Ovarian|Cancer Prostate|Cancer Skin|Throat Cancer|Lymphoma|Cancer, Thyroid|Cancer, Other|Cerebral Palsy|Chronic Fatigue Syndrome|Cluster Headache|Chronic Obstructive Pulmonary Disease (COPD)|Chronic Kidney Diseases|Crohn Disease|Deafness|Depression|Diabetes|Eczema|Epilepsy|Fibroids|Fibromyalgia|Heart Failure|Hypertension|Hyperthyroidism|Hypothyroidism|Irritable Bowel Syndrome (IBS)|Infertility|Lyme Disease|Macular Degeneration|Migraine|Multiple Allergies|Multiple Sclerosis|Osteoarthritis|Osteoporosis|Ovarian Cysts|Parkinson Disease|Phantom Limb Pain|Psoriasis|Post Traumatic Stress Disorder (PTSD)|Rheumatoid Arthritis|Sjogrens Disease|Spinal Cord Injury|Spinal Stenosis|Stroke|Tension Headache|Tinnitus|Ulcerative Colitis",,United States,Palm Desert,California,1,Advanced multi-component meditation practice,BEHAVIORAL,"Effect of Meditation in an Advanced Retreat Setting on Heart Rate Variability in a Global Population|Effect of Meditation in an Advanced Retreat Setting on the Gut Microbiome and Metabolites in a Global Population.|Effect of Meditation in an Advanced Retreat Setting on the Multi-omic Expression of Genes, Proteins, and Metabolites in the Blood in a Global Population|Effect of Meditation in an Advanced Retreat Setting on Physical and Emotional Health outcomes in a global population.","Assess the Effect of Meditation in an Advanced Retreat Setting on Physical and Emotional Health for Multiple Disease States|Assess the Effect of Meditation in an Advanced Retreat Setting on the Gut Microbiome and Metabolites for Multiple Disease States|Assess the Effect of Meditation in an Advanced Retreat Setting on the Differential Expression of Genes, Proteins, and Metabolites in Blood for Multiple Disease States",False,
NCT05682963,Efficacy of Square- Stepping Exercises in Individuals With Multiple Sclerosis,"Effect of Square- Stepping Exercises on Mobility, Balance and Knee Joint Position Sense in Individuals With Multiple Sclerosis",COMPLETED,2022-11-29,2023-06-30,2023-12-25,2024-01-08,2023-01-12,INTERVENTIONAL,NA,34.0,ACTUAL,Pamukkale University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Mobility|Balance|Position Sense,Turkey (Türkiye),Denizli,Centre,1,Square Step Exercises Program|Home Exercise Program,OTHER|OTHER,Timed 25-Foot Walk (T25-FW) Test,Five Times Sit to Stand Test|Four Step Square Test (FSST)|Activity-Specific Balance Confidence Scale|Knee Joint Position Sense|Expanded Disability Status Scale (EDSS),False,
NCT05912595,"EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)",The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.,RECRUITING,2023-05-18,2024-03-31,2024-07-01,2024-01-18,2023-06-22,INTERVENTIONAL,NA,36.0,ESTIMATED,Sheikh Shakhbout Medical City,OTHER,,,"Sclerosis, Multiple|MS (Multiple Sclerosis)|Spastic|Spasticity, Muscle|Oxygen Consumption",,United Arab Emirates,Abu Dhabi,,1,EXOPULSE Mollii Suit Stimulation,DEVICE,Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements|Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements|Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements|Muscular Oxygenation using Near-infrared spectroscopy (NIRS) Measurements,Numerical Rating Scale for spasticity.|Multiple Sclerosis International Quality of Life Questionnaire.|Visual Analog Score for pain.|Visual Analog Score for fatigue.|Fall risk.|Walking ability.|Overall Clinical Improvement.|Blinding Questionnaire.|Weight|Height|Muscle tone.|Body Mass Index (BMI),False,
NCT06790992,Relıabılıty and Valıdıty of the Supıne-to-stand Test Wıth Multiple Sclerosis,Relıabılıty and Valıdıty of the Supıne-to-stand Test As a Measure of Functional Motor Competence In People Wıth Multiple Sclerosis,COMPLETED,2024-08-01,2024-09-01,2024-11-01,2025-01-24,2025-01-24,OBSERVATIONAL,,34.0,ACTUAL,Sanko University,OTHER,,,Multiple Sclerosis,multiple sclerosis,Turkey (Türkiye),Gaziantep,şehitkamil,1,,,Supine-to-stand Test (SST)|Muscle Strength|Nine Hole Test|Berg Balance Test|Timed Up and Go (TUG)|Six-Minute Walk Test (6MWT)|Activity-specific Balance Confidence Scale (ABC)|Multiple Sclerosis Quality of Life-54,,False,
NCT03577977,Betaferon Use in Children and Adolescents With Multiple Sclerosis,Retrospective Data Collection on Betaferon Use in Children and Adolescents With Multiple Sclerosis,COMPLETED,2008-06-01,2009-04-15,2009-04-15,2018-07-11,2018-07-05,OBSERVATIONAL,,70.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,"Multiple sclerosis (MS), Betaseron, Betaferon",Russia,Multiple Locations,,1,"Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)",DRUG,"Mean expanded disability status scale (EDSS) score at the end of trial participation|Proportion of patients having the mean EDSS score of less than or equal to 3.0 and more than or equal to 3.5 at the end of the trial|Mean frequency of complications recorded after start of betaferon therapy|Mean EDSS score on the exacerbations recorded after start of betaferon therapy|Number of adverse events described during the trial and described as possibly, likely, or undoubtedly associated with the test drug|Number of mild, moderate, or severe adverse events|Number of serious adverse events described during the trial|Number of adverse events described during the trial and classified as an flu-like syndrome|Number of adverse events described during the trial and classified as a local reaction|Number of cases of betaferon discontinuation due to adverse events",,False,
NCT04410965,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,COMPLETED,2020-05-20,2021-07-12,2021-07-12,2025-09-24,2020-06-01,INTERVENTIONAL,PHASE4,82.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,China,China,,1,TERIFLUNOMIDE,DRUG,PK exposure: Cmax|PK exposure: AUCtau,Participants with Serious Adverse Events and Adverse Events,False,
NCT05298670,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,UNKNOWN,2022-02-01,2023-02-28,2023-03-28,2023-03-20,2022-03-28,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,German University in Cairo,OTHER,,,Multiple Sclerosis,,Egypt,Cairo,,1,MetFORMIN 1000 Mg Oral Tablet|Interferon beta-1a,DRUG|DRUG,Change in IL17 in both arms as measured by ELISA.,"Percentage of Quality of Life deterioration in both arms measured by MSQOL-54.|Change in IL22 in both arms as measured by ELISA.|Malondialdehyde in both arms as measured by Colorimetric tests.|Degree of remyelination visualized by MRI, it depends on clinician's overview.|Degree of disability assessed by Expanded Disability Status Scale.",False,
NCT04148781,Fampridine-SR and Optic Neuritis Recovery,The Effect of Fampridine-SR on Visual Function in Poorly Recovered Optic Neuritis in Persons With MS,UNKNOWN,2022-03-22,2023-12,2024-01,2022-08-25,2019-11-04,INTERVENTIONAL,EARLY_PHASE1,20.0,ESTIMATED,Courtney Casserly,OTHER,,,Optic Neuritis,Multiple sclerosis|Optic Neuritis|Fampyra,Canada,London,Ontario,1,Fampridine SR,DRUG,Change in Visual Evoked Potentials|Change in Visual Acuity|Change in Contrast Sensitivity|Change in Colour Vision|Change in Visual Fields|Optical Coherence Tomography|Change in 10-Item Neuro-Ophthalmic Supplement total scores,,False,
NCT04789551,T Cell Profiling in Patients with Multiple Sclerosis,T Cell Profiling in Patients with Multiple Sclerosis,NOT_YET_RECRUITING,2025-06-01,2025-07-01,2025-12-01,2025-03-12,2021-03-09,OBSERVATIONAL,,40.0,ESTIMATED,Boston Children's Hospital,OTHER,,,Multiple Sclerosis,,United States,Boston,Massachusetts,1,Blood Sample,OTHER,T cell populations,,False,
NCT04561557,Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System,An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System,RECRUITING,2020-09-22,2027-02-22,2027-05-31,2024-10-30,2020-09-23,INTERVENTIONAL,EARLY_PHASE1,36.0,ESTIMATED,Tongji Hospital,OTHER,"Nanjing IASO Biotechnology Co., Ltd.",INDUSTRY,Autoimmune Diseases|Autoimmune Diseases of the Nervous System|Neuromyelitis Optica Spectrum Disorder|Myasthenia Gravis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Idiopathic Inflammatory Myopathies|Multiple Sclerosis|Autoimmune Encephalitis|Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)|POEMS Syndrome,Adoptive T Cell Therapy|Chimeric antigen receptor|B-cell maturation antigen (BCMA)|Autoimmune Diseases of the Nervous System,China,Wuhan,Hubei,1,CT103A cells|Cyclophosphamide and fludarabine,BIOLOGICAL|DRUG,"Types and incidence of dose-limiting toxicity (DLT) after CT103A cells infusion|Incidence and severity of AEs, including changes in vital signs, physical examination, laboratory parameters, Electrocardiograms and Echocardiograms.",PD-Soluble BCMA|PD-Pathogenic antibody|PD-Nfl（MS）|PK-VCN|PK-BCMA CAR-T cells,False,
NCT05408767,Accelerated Brain Volume Loss in People With Multiple Sclerosis,Accelerated Brain Volume Loss in People With Multiple Sclerosis: do Real-world Observations Align With Standardized Research Findings?,COMPLETED,2021-01-01,2022-01-01,2022-05-01,2022-06-09,2022-06-07,OBSERVATIONAL,,70.0,ACTUAL,National MS Center Melsbroek,OTHER,,,Retrospective Study,,Belgium,Melsbroek,Vlaams-Brabant,1,,,The primary endpoint of this study will be the difference in annualized whole brain volume percentage change between the MS and control cohort,,False,
NCT00203086,A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis,"A Multi-Centered, Two Arm, Open Label Extension Study (to Protocol NC-100) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment With Mitoxantrone (Novantrone®) Preceding Treatment With Glatiramer Acetate (Copaxone®) vs. Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis",COMPLETED,2005-10,2009-10,2009-12,2010-04-29,2005-09-20,OBSERVATIONAL,,30.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,,,,0,,,,,False,
NCT05520554,"Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TrSQ","Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TrSQ in Neurological Diseases",COMPLETED,2022-08-15,2023-06-01,2023-07-01,2023-08-03,2022-08-30,OBSERVATIONAL,,63.0,ACTUAL,Gazi University,OTHER,,,Neurological Disease,Multiple Sclerosis|Parkinson Disease|Stroke|Telerehabilitation|Satisfaction,Turkey (Türkiye),Ankara,,1,Development of the Telerehabilitation Satisfaction Questionnaire,OTHER,Telerehabilitation Satisfaction Questionnaire in patients with Neurological disease,,False,
NCT03137602,ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study,ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study,COMPLETED,2018-03-07,2019-09-30,2019-09-30,2019-10-16,2017-05-03,INTERVENTIONAL,NA,14.0,ACTUAL,The Hospital for Sick Children,OTHER,University of Alabama at Birmingham|Queen's University,OTHER|OTHER,Pediatric Multiple Sclerosis,,Canada,Toronto,Ontario,1,ATOMIC mobile app,DEVICE,Feasibility of the ATOMIC program|Utility of the ATOMIC program|Utility of the ATOMIC program|Utility of the ATOMIC program,,False,
NCT02323269,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),"A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)",TERMINATED,2015-05,2016-03,2016-03,2016-04-08,2014-12-23,OBSERVATIONAL,,24.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting|Relapsing-Remitting Multiple Sclerosis",,Canada,Edmonton,Alberta,10,dimethyl fumarate,DRUG,Annualized Relapse Rate (ARR) at month 12,Change from baseline to Month 12 in the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM-14) score|Change from baseline to Month 12 in the Short-Form 36 (SF-36) scores|Change from baseline to Month 12 in the Modified Fatigue Impact Scale (MFIS-5) scores|Change from baseline to Month 12 in the Beck Depression Inventory (BDI-7) scores|Change from baseline to Month 12 in the Work Productivity and Impairment Questionnaire: Multiple Sclerosis (WPAI-MS) scores|Change from baseline to Month 12 in the Morisky 8-item Medication Adherence Scale (MMAS-8) scores|Change from baseline to Month 12 in patient-reported Expanded Disability Status Scale (patient-reported EDSS) scores|Proportion of patients relapsing at Month 12|Proportion of patients with relapses associated with hospitalizations at Month 12|Proportion of patients with relapses associated with steroid use at Month 12,False,
NCT05661266,Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis,Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis,RECRUITING,2023-08-16,2025-04,2025-04,2023-10-18,2022-12-22,OBSERVATIONAL,,120.0,ESTIMATED,Innodem Neurosciences,INDUSTRY,,,Multiple Sclerosis,,Canada,Montreal,Quebec,1,Eye-Tracking,DEVICE,Predictive power of eye-movement biomarkers (EMBs) for MS severity in relationship to Expanded Disability Status Scale (EDSS),Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the the California Verbal Learning Test-2 (CVLT2) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC).|Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC).,False,
NCT01142466,A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone,"Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone",COMPLETED,2005-12,2009-12,2010-01,2014-02-27,2010-06-11,INTERVENTIONAL,PHASE4,30.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Gesellschaft für Therapieforschung mbH,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Multiple sclerosis|Expanded Disability Status Scale|Multiple Sclerosis, Relapsing-Remitting|Rebif|Beta-1, interferon",,,,0,Interferon beta-1a (Rebif),DRUG,Time From Baseline to First Multiple Sclerosis Relapse (in Weeks),"Number of Relapse-free Participants|Absolute Changes in the Number of T1 Lesions From Baseline to Week 24, 48, 72 and 96|Absolute Changes in the Number of T1-Gadolinium (T1-Gd) Lesions From Baseline to Week 24, 48, 72 and 96|Absolute Changes in the Number of T2 Lesions From Baseline to Week 24, 48, 72 and 96|Mean Changes in Expanded Disability Status Scale (EDSS) Score From Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)",True,2011-06-10
NCT04772495,miRNA Biomarkers in Multiple Sclerosis,The Potential Candidate miRNA Biomarkers in Multiple Sclerosis,COMPLETED,2015-05,2017-05,2017-07,2021-02-26,2021-02-26,OBSERVATIONAL,,69.0,ACTUAL,University of Gaziantep,OTHER,,,Multiple Sclerosis|miRNA|Epigenetic|Biomarker,Multiple sclerosis|miRNA biomarkers|peripheral blood molecular diagnostics,,,,0,miRNA,GENETIC,miRNA expression,,False,
NCT05028634,Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy,"A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy",COMPLETED,2021-11-11,2023-11-15,2023-11-15,2025-02-11,2021-08-31,INTERVENTIONAL,PHASE3,63.0,ACTUAL,Celgene,INDUSTRY,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Ozanimod|Relapsing-remitting multiple sclerosis,United States,Palo Alto,California,33,"Tetanus, diphtheria, and acellular pertussis vaccine|Pneumococcal polysaccharide vaccine|Seasonal influenza vaccine",BIOLOGICAL|BIOLOGICAL|BIOLOGICAL,Percentage of Participants Meeting Immune Serological Response Criteria to Tetanus Toxoid Antigen|Percentage of Participants Meeting Immune Serological Protection Criteria to Tetanus Toxoid Antigen,Percentage of Participants With Serologic Response to Pneumococcal Polysaccharide Vaccine (PPSV23)|Percentage of Participants With Serologic Protection Against Pneumococcal Polysaccharide Vaccine (PPSV23)|Number of Participants With Adverse Events|Number of Participants With Abnormalities in Blood Chemistry Parameters|Number of Participants With Abnormalities in Blood Hematology Parameters|Change From Baseline in Blood Chemistry Parameters - Sodium; Potassium; Chloride; Calcium; Magnesium; Phosphate; Blood Urea Nitrogen; Glucose|Change From Baseline in Blood Chemistry Parameters - Creatinine; Bilirubin; Direct Bilirubin|Change From Baseline in Blood Chemistry Parameters - Albumin|Change From Baseline in Blood Chemistry Parameters - Alkaline Phosphatase|Change From Baseline in Blood Chemistry Parameters - Alanine Aminotransferase; Aspartate Aminotransferase; Gamma Glutamyl Transferase|Change From Baseline in Blood Hematology Parameters - Erythrocytes|Change From Baseline in Blood Hematology Parameters - Leukocytes; Basophils; Eosinophils; Lymphocytes; Monocytes; Neutrophils; Platelets|Change From Baseline in Blood Hematology Parameters - Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Monocytes/Leukocytes; Neutrophils/Leukocytes|Change From Baseline in Blood Hematology Parameters - Hemoglobin; Erythrocytes Mean Corpuscular HGB Concentration|Change From Baseline in Blood Hematology Parameters - Erythrocytes Mean Corpuscular Volume|Change From Baseline in Blood Hematology Parameters - Erythrocytes Mean Corpuscular Hemoglobin|Change From Baseline in Blood Hematology Parameters - Hematocrit,True,2025-01-22
NCT04853654,Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis,"Investigation of the Effects of Selective Exercise Training on Muscle Architecture, Balance, Function and Fatigue in Multiple Sclerosis",COMPLETED,2018-09-15,2020-04-15,2020-06-15,2022-01-13,2021-04-21,INTERVENTIONAL,NA,33.0,ACTUAL,Sanko University,OTHER,,,Multiple Sclerosis|Exercise,multiple sclerosis|muscle architecture|Eccentric Exercise|Concentric Exercise,Turkey (Türkiye),Gaziantep,,1,exercise,OTHER,muscle architecture parameter 1|muscle architecture parameter 2|muscle architecture parameter 3|Muscle strength,walking fatigue|perceived fatigue|physical fatigue|static balance|dynamic balance|Functional activities 1|Functional activities 2|Functional activities 3,False,
NCT06231030,Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) Turkish Adaptation,"Adaptation, Validity and Reliability of ""Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS)"" in Turkish",RECRUITING,2023-11-05,2025-11-05,2025-11-05,2024-01-31,2024-01-30,OBSERVATIONAL,,120.0,ESTIMATED,Nigde Omer Halisdemir University,OTHER,Gazi University|Hacettepe University,OTHER|OTHER,Multiple Sclerosis|Self Efficacy,Multiple sclerosis|Self Efficacy|Adaptation|Validity|Reliability,Turkey (Türkiye),Niğde,Niğde Province,3,"Validity, Reliability and Adaptation",OTHER,Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS)|General Self-Efficacy Scale|Multiple Sclerosis Quality of Life-MuSiQoL|Neurologic Fatigue Inventory-Multiple Sclerosis (NYI-MS),Mini Mental State Examination (MMSE)|Expanded Disability Status Scale (EDSS)|Interview Form,False,
NCT01424163,Dexpramipexole Japanese PK Study,"A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects",COMPLETED,2011-08,2012-02,2012-02,2021-06-22,2011-08-26,INTERVENTIONAL,PHASE1,57.0,ACTUAL,Knopp Biosciences,INDUSTRY,Biogen,INDUSTRY,Amyotrophic Lateral Sclerosis,,United Kingdom,London,,1,Single dose reduced|Single dose standard|Multiple Dose|Multiple Dose,DRUG|DRUG|DRUG|DRUG,Cmax of dexpramipexole|AUC of dexpramipexole,Changes in clinical laboratory tests|ECG changes|Vital Sign changes|Adverse Event monitoring,False,
NCT03281330,Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS),Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS),COMPLETED,2017-02-01,2018-05-30,2018-06-30,2018-08-03,2017-09-13,OBSERVATIONAL,,60.0,ACTUAL,Hasselt University,OTHER,University Ghent|Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,OTHER|OTHER|OTHER,Multiple Sclerosis,,Belgium,Ghent,,3,auditory cues and music during walking,BEHAVIORAL,Spatio-temporal parameters of gait|Spatio-temporal parameters of gait|Spatio-temporal parameters of gait|Spatio-temporal parameters of gait|Parameter's of sychronisation|Parameter's of sychronisation|Parameter's of sychronisation|Parameter's of sychronisation,subjective physical /mental fatigue|subjective physical /mental fatigue|subjective physical /mental fatigue|physical /mental fatigue|motivation|motivation|motivation|motivation,False,
NCT00306592,Natalizumab Re-Initiation of Dosing,"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation",COMPLETED,2006-03,2007-12,2008-02,2017-03-21,2006-03-24,INTERVENTIONAL,PHASE3,404.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|MS,United States,Birmingham,Alabama,63,BG00002 (natalizumab),BIOLOGICAL,Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious AEs (SAEs)|Number of Participants With Hypersensitivity-related Adverse Events|Number of Participants With Antibodies to Natalizumab,,True,2010-01-26
NCT04483609,SF-QUALIVEEN Turkish Validity and Reliability Study,"SF-QUALIVEEN Turkish Cultural Adaptation, Validity and Reliability Study",COMPLETED,2020-07-30,2020-09-30,2020-10-30,2021-06-18,2020-07-23,OBSERVATIONAL,,63.0,ACTUAL,Istanbul Aydın University,OTHER,,,Multiple Sclerosis,multiple sclerosis|urological dysfunction|assessment|scale,Turkey (Türkiye),Istanbul,,1,Questionnaire administration pre test|Questionnaire administration validation and reliability,OTHER|OTHER,SF-Qualiveen score,Urogenital Distress Inventory (UDI-6),False,
NCT03200899,Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis,Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis,COMPLETED,2014-01,2018-03,2018-06,2024-07-10,2017-06-27,INTERVENTIONAL,NA,183.0,ACTUAL,University of Texas at Austin,OTHER,,,Multiple Sclerosis,cognitive rehabilitation,United States,Austin,Texas,1,MAPSS-MS|Usual Care plus computer games,BEHAVIORAL|OTHER,Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II|Use of Compensatory Cognitive Strategies|Cognitive-related Instrumental Activities of Daily Living (IADL) Among Persons With MS,Self-Efficacy|Verbal Fluency|Nonverbal Learning and Memory|Auditory Information Processing Speed and Flexibility|Psychomotor Processing Speed,True,2024-07-10
NCT04674163,Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.,NEUROKINASE : Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.,WITHDRAWN,2023-01,2023-01,2023-01,2023-01-23,2020-12-19,INTERVENTIONAL,NA,0.0,ACTUAL,Centre Hospitalier Régional d'Orléans,OTHER,Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM),UNKNOWN,"Sclerosis, Multiple|Guillain-Barre Syndrome|Inflammation",ERK5 kinase|M2 Type Pyruvate Kinase|cytokines,,,,0,Blood sample and Cerebrospinal fluid (CSF) collection.,BIOLOGICAL,Expression of genes encoding ERK5 and PKM2 kinases by RT-qPCR,Lymphocyte phenotyping|Cytokine levels|Metabolome analysis|Measure of the neurofilament light chain (NfL),False,
NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis","A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2010-08-30,2016-10-10,2016-10-10,2018-03-27,2010-08-20,INTERVENTIONAL,PHASE2,185.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,BAF312|siponimod|Multiple Sclerosis|Relapsing remitting Multiple Sclerosis|Demyelinating Autoimmune Diseases|MS|RRMS|inflammatory disease,United States,Miami,Florida,46,BAF312,DRUG,Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.|Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)|Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)|Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)|Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)|Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set),Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set)|Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set)|Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set),True,2017-12-12
NCT03362541,A Multi-Site Trial of MS INFoRm (Fatigue Management Resource),A Multi-Site Randomized Controlled Trial of MS INFoRm: An Interactive Fatigue Management Resource for Persons With Multiple Sclerosis,COMPLETED,2018-01-30,2021-06-15,2021-06-15,2022-04-20,2017-12-05,INTERVENTIONAL,NA,161.0,ACTUAL,Dr. Marcia Finlayson,OTHER,University of Alberta|University of Calgary,OTHER|OTHER,Multiple Sclerosis,multiple sclerosis|fatigue|self-management|rehabilitation,Canada,Calgary,Alberta,3,MS INFoRm|Usual Care Control Group,BEHAVIORAL|BEHAVIORAL,Change in the Modified Fatigue Impact Scale,Change in the Multiple Sclerosis Self-Efficacy Scale|Change in the Perceived Deficits Questionnaire|Change in the Center for Epidemiological Studies Depression Scale|Change in the Impact on Participation and Autonomy Questionnaire,False,
NCT03153553,"Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis","Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis",COMPLETED,2017-04-05,2019-12-31,2019-12-31,2024-01-03,2017-05-15,INTERVENTIONAL,NA,22.0,ACTUAL,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,,,Multiple Sclerosis,,United Kingdom,Sheffield,South Yorkshire,1,Ischemic Preconditioning|Sham Intervention,OTHER|OTHER,Ability to tolerate Ischaemic Preconditioning (IPC_,Perceived rate of exertion,False,
NCT01617395,Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility,Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility,COMPLETED,2012-08-15,,,2025-09-08,2012-06-12,OBSERVATIONAL,,181.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Multiple Sclerosis|Magnetic Resonance Imaging (MRI)|Natural History,United States,Bethesda,Maryland,1,,,presence or absence of lesions on T2-weighted brain MRI|GERS,"The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms;|The time lag between defined exposures|exploratory clinical, imaging, biological data in the cross sectional|development of MS-like abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical symptoms and signs.",False,
NCT01844232,"One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity","A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity",COMPLETED,2013-04,2014-12,2015-01,2022-04-25,2013-05-01,INTERVENTIONAL,PHASE3,150.0,ACTUAL,"RVL Pharmaceuticals, Inc.",INDUSTRY,Osmotica Pharmaceutical US LLC,INDUSTRY,Multiple Sclerosis|Spasticity,Multiple sclerosis|spasticity|arbaclofen,United States,Gilbert,Arizona,35,arbaclofen,DRUG,Assessment of Adverse Events,Determination of Change in Spasticity by Total Number-transformed Modified Ashworth Scale (TNmAS),False,
NCT01695434,A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months,"A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months",COMPLETED,2012-06,2013-02,2013-02,2013-03-25,2012-09-28,OBSERVATIONAL,,60.0,ACTUAL,University at Buffalo,OTHER,,,Multiple Sclerosis,multiple sclerosis|MRI|Copaxone|healthy controls|glatiramer acetate,United States,Buffalo,New York,1,MRI,OTHER,"To explore whether treatment with GA may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.","To investigate whether treatment with GA may decrease accumulation of iron in lesions, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months.",False,
NCT05433714,Figure of 8 Walk Test in Multiple Sclerosis,The Reliability and Validity of the Figure of 8 Walk Test in Multiple Sclerosis,COMPLETED,2022-08-01,2022-10-01,2022-10-06,2022-10-10,2022-06-27,OBSERVATIONAL,,50.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Multiple Sclerosis,multiple scleorsis|balance|Walking,Turkey (Türkiye),Kahramanmaraş,,1,Assesment,OTHER,The Figure of Walk Test|The Figure of Walk Test,Berg Balance scale|Timed up and go test|Timed 25-Foot Walk test|Four Square Step Test,False,
NCT01592552,A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery,A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies,COMPLETED,2011-11,2015-03,2015-03,2023-11-22,2012-05-07,OBSERVATIONAL,,20.0,ACTUAL,Sanguine Biosciences,INDUSTRY,,,Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS),Alzheimer's Disease|Multiple Sclerosis|Parkinson's Disease|Huntington's Disease|Amyotrophic Lateral Sclerosis (ALS),United States,Sherman Oaks,California,1,,,Biospecimens & Clinical Data collection from patients with neurological diseases.,,False,
NCT06392009,"Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II","A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II",RECRUITING,2024-07-10,2025-07,2026-07,2025-07-03,2024-04-30,INTERVENTIONAL,PHASE1|PHASE2,30.0,ESTIMATED,"GRIN Therapeutics, Inc.",INDUSTRY,,,Tuberous Sclerosis Complex|Focal Cortical Dysplasia,TSC|FCD|Tuberous Sclerosis Complex|Focal Cortical Dysplasia|Astroscape,Australia,South Brisbane,,20,Radiprodil,DRUG,"Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Adverse Drug Reactions (ADRs), TEAEs Leading to Discontinuation and Severity of TEAEs|Plasma concentration of radiprodil and maximum plasma concentration (Cmax)|Plasma concentration of radiprodil versus time, area under the curve (AUCt)|Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)|Pharmacokinetic plasma concentration of radiprodil: time to Cmax (Tmax)|Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)|Number of participants with abnormal laboratory tests results|Number of participants with abnormal physical and neurological examination findings|Clinically relevant changes in safety parameters: systolic blood pressure|Clinically relevant changes in safety parameters: diastolic blood pressure|Clinically relevant changes in safety parameters: pulse rate|12-Lead ECG: Mean change from Baseline to End-of-Treatment in RR interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT interval|12-Lead ECG: Mean change from Baseline to End-of-Treatment in QTcF interval",Percent change from baseline in Video-EEG seizure burden|Change from baseline in seizure frequency|Change from baseline in number of seizure-free days and longest period with no seizures|Aberrant Behavior Checklist-Community (ABC-2C)|Caregiver Global Impression of Change (CaGI-C)|Clinical Global Impression of Change [CGI-C]|Pediatric Quality of Life Inventory [PedsQL]|Caregiver Burden Inventory (CBI)|Columbia-Suicide Severity Rating Scale (C-SSRS),False,
NCT06564311,A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone),"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-08-26,2025-08,2026-02,2025-06-12,2024-08-21,INTERVENTIONAL,PHASE2,93.0,ESTIMATED,"Zenas BioPharma (USA), LLC",INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|RMS|MS|Multiple Sclerosis,United States,Cullman,Alabama,47,Obexelimab|Placebo,DRUG|DRUG,Cumulative number of new GdE T1 hyperintense lesions,"Number of T2 Lesions|Number of GdE T1 lesions|Volume of T2 lesions|Serum NfL|Incidence of Adverse Events, injection site reactions and hypersensitivity reactions",False,
NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta,TERMINATED,2011-01,2013-04,2013-04,2014-06-09,2010-12-03,INTERVENTIONAL,PHASE3,534.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis Relapse,,United States,Cullman,Alabama,185,Teriflunomide|Placebo (for teriflunomide)|Interferon-beta (IFN-beta),DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) (Poisson Regression Estimates),"Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per Scan (Poisson Regression Estimates)|Time to 12-Week Sustained Disability Progression|Brain MRI Assessment: Volume of Gd-enhancing T1-lesions Per MRI Scan|Brain MRI Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease) at Week 24|Time to Relapse: Kaplan-Meier Estimates of the Probability of no Relapse at Week 24, 48, and 72|Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 24|Change From Baseline in Short Form Generic Health Survey - 36 Items, Version 2 (SF-36v2) Summary Scores at Week 24|Resource Utilization When Relapse|Overview of Adverse Events (AEs)",True,2014-05-22
NCT04925778,Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate,"An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)",WITHDRAWN,2021-06-30,2022-08-30,2022-09-29,2021-11-18,2021-06-14,OBSERVATIONAL,,0.0,ACTUAL,Banner Life Sciences LLC,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Bafiertam|Tecfidera|dimethyl fumarate|monomethyl fumarate|gastrointestinal,,,,0,monomethyl fumarate,DRUG,Comparison of the frequency and severity of GI symptoms before and after switching to Bafiertam®.,,False,
NCT01772199,Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis,COMPLETED,2013-02,2014-09,2014-09,2016-08-16,2013-01-21,INTERVENTIONAL,PHASE2,131.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",GSK239512|remyelination|magnetic resonance imaging|Relapsing Remitting Multiple Sclerosis|Histamine 3 Receptor Antagonist|magnetization transfer ratio,Bulgaria,Sofia,,43,GSK239512|Placebo,DRUG|DRUG,Mean change in gadolinium (Gd) enhanced (GdE) lesion magnetization transfer ratio (MTR) differences (calibrated to reference scan) from before enhancement to stable recovery (>=3 months post new GdE lesion)|Mean change in Delta MTR lesion MTR differences (calibrated to reference scan) from before lesion appearance to stable recovery (>=3 months post lesion appearance),"Change from baseline in T2 lesion MTR at Week 48|Cumulative new and enlarging Gd enhancing, T2 and Combined Unique Active lesions comparing placebo to GSK239512 treated subjects|Change from baseline at Week 48 in total brain volume, white matter volume and grey matter volume comparing placebo to GSK239512 treated subjects|Cumulative number of persistent black holes and new unenhancing T1 lesion counts comparing placebo to GSK239512 treated subjects over treatment duration up to Week 48|Proportion of new GdE lesions evolving into chronic (unenhancing) T1 lesions (black holes) comparing placebo to GSK239512 treated subjects over treatment duration up to Week 48|Mean change from baseline in overall cognitive impairment and cognitive domains comparing placebo to GSK239512 treated subjects|Comparison of Relapse Rates between placebo and GSK239512 treated subjects|Comparison of Time to First Relapse between placebo and GSK239512|Comparison of the proportion of subjects Relapse Free between placebo and GSK239512 treated subjects|Proportion of subjects with sustained worsening of Expanded Disability Severity Scale (EDSS) over 3 months comparing placebo to GSK239512 treated subjects|Mean change from baseline in the EDSS functional systems and a subset of component assessments comparing placebo to GSK239512 treated subjects|Safety and tolerability as assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Safety and tolerability as assessed by percentage of subjects withdrawing due to AEs|Safety and tolerability as assessed by summary of suicide behavior and ideation risk as assessed by the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)|Safety and tolerability as assessed by summary of suicide behavior and ideation risk as assessed by Possible Suicidality Related Adverse Event (PSRAE)|Safety and tolerability as assessed by change from baseline in clinical chemistry, hematology, and urinalysis parameters|Safety and tolerability as assessed by frequency of clinical chemistry, hematology, and urinalysis parameters of potential clinical concern|Safety and tolerability as assessed by change from baseline in blood pressure|Safety and tolerability as assessed by change from baseline in heart rate|Safety and tolerability as assessed by change from baseline in Electrocardiogram (ECG) parameters|Safety and tolerability as assessed by frequency of vital signs and ECG parameters of potential clinical concern|Trough concentration of GSK239512 at Week 4, Week 24, Week 36 and Week 48|Sparse Pharmacokinetics (PK) sampling for concentration of GSK239512 at Week 8",False,
NCT02771652,"Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients",,COMPLETED,2010-02,2011-06,2011-11,2016-06-24,2016-05-13,INTERVENTIONAL,NA,126.0,ACTUAL,University of Erlangen-Nürnberg,OTHER,Caritas-Krankenhaus Bad Mergentheim,OTHER,Multiple Sclerosis,Multiple Sclerosis|Quality of Life|exercise|internet,,,,0,e-training|Control,BEHAVIORAL|OTHER,Change in Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS),Würzburg Fatigue Scale (WEIMuS)|Muscle strength lower extremities|Forced vital capacity|Aerobic capacity|Physical activity|Peak expiratory flow,False,
NCT00118547,Health Behavior Change in Chronic Disease Management,Health Behavior Change in Chronic Disease Management,COMPLETED,2005-09,2007-09,2007-09,2011-08-12,2005-07-11,INTERVENTIONAL,NA,20.0,ACTUAL,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Adherence|Medication|Multiple Sclerosis,United States,Seattle,Washington,1,In home monitoring with feedback,BEHAVIORAL,adherence,,False,
NCT00688948,Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS),A Pilot Study Looking At The Use Of Alfuzosin In The Treatment Of Bladder Dysfunction In Patients With Multiple Sclerosis,TERMINATED,2007-11,2009-11,2009-11,2011-06-27,2008-06-03,INTERVENTIONAL,PHASE2|PHASE3,20.0,ESTIMATED,Nova Scotia Health Authority,OTHER,Sanofi,INDUSTRY,Multiple Sclerosis|Bladder Dysfunction,pilot clinical trial,Canada,Halifax,Nova Scotia,1,Alfuzosin,DRUG,"The primary efficacy measures will be the ICIQ-LUTSqol questionnaire, the IPSS questionnaire, uroflow/PVR and the voiding diaries.",,False,
NCT01699555,First-in-Human Study With GNbAC1 in Healthy Volunteers,Randomized Placebo-Controlled First-in-Human Study With GNbAC1,COMPLETED,2011-07,2012-03,2012-08,2020-10-20,2012-10-03,INTERVENTIONAL,PHASE1,33.0,ACTUAL,GeNeuro Innovation SAS,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|GNbAC1|Monoclonal antibody|Multiple Sclerosis Associated Retrovirus (MSRV)|Temelimab,,,,0,GNbAC1|GNbAC1 placebo,BIOLOGICAL|BIOLOGICAL,number of reported adverse events for healthy male subjects receiving single ascending doses of GNbAC1.,pharmacokinetics (PK) characteristics following administration of single ascending doses of GNbAC1 in healthy male subjects|immunogenicity of GNbAC1,False,
NCT07029867,Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis,Efficacy and Safety of Traditional Chinese Mecicine Yishen Daluo Yin Granule for Relapsing-remitting Multiple Sclerosis: A Randomized Controlled Trial,NOT_YET_RECRUITING,2025-06-15,2026-10-31,2026-12-31,2025-06-19,2025-06-19,INTERVENTIONAL,NA,152.0,ESTIMATED,Ying Gao,OTHER,First Affiliated Hospital of Jinan University|The Second Hospital of Hebei Medical University|Chinese PLA General Hospital,OTHER|OTHER|OTHER,Relapse Remitting Multiple Sclerosis,,,,,0,Yishen Daluo Yin granuls|Placebo,DRUG|DRUG,The proportion of patients without combined unique active lesions (CUALs) in 24W compared to baseline.,"Average Relapse Time|Annual Relapse Rate|Proportion of Patients Without Relapse|Changes in Expanded Disability Status Scale (EDSS) Compared to Baseline. A score of 0 on the scale indicates the absence of clinical symptoms, while a score of 10 represents death resulting from illness.|Number of newly added gadolinium enhanced T1 lesions compared to baseline.|Number of newly added or expanded T2 lesions compared to baseline.|Changes in T2 lesion volume compared with baseline",False,
NCT01610700,An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients,"Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension",COMPLETED,2001-05,2002-07,2002-07,2023-01-12,2012-06-04,INTERVENTIONAL,PHASE3,160.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United Kingdom,Oxford,,1,GW-1000-02|Placebo,DRUG|DRUG,Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment,Change From Baseline in Spasticity Visual Analogue Scale Score at the End of 6 Weeks of Treatment|Change From Baseline in Pain Visual Analogue Scale Score at the End of 6 Weeks of Treatment|Change From Baseline in Muscle Spasm Visual Analogue Scale Score at the End of 6 Weeks of Treatment|Change From Baseline in Tremor Visual Analogue Scale Score at the End of 6 Weeks of Treatment|Change From Baseline in Bladder Problems Visual Analogue Scale Score at the End of 6 Weeks of Treatment|Subject Global Opinion of Effect on Multiple Sclerosis at the End of Treatment|Change From Baseline in Modified Ashworth Scale Score at the End of Treatment|Change From Baseline in the Mean Beck's Depression Inventory (BDI-II) Score at the End of Treatment|Change From Baseline in the Mean Fatigue Severity Scale Questionnaire Score at the End of Treatment|Change From Baseline in the Mean Rivermead Mobility Index Score at the End of Treatment|Change From Baseline in the Mean Total 28-item General Health Questionnaire Score at the End of Treatment|Change From Baseline in the Mean Nine-hole Peg Test Score at the End of Treatment|Change From Baseline in the Mean Total Bladder Control Test Score at the End of Treatment|Change From Baseline in the Mean Tremor Activities of Daily Living Scale Score at the End of Treatment|Change From Baseline in the Mean Ten-metre Mobility Score at the End of Treatment|Change From Baseline in the Mean Sleep Quality 100 mm Visual Analogue Scale Score at the End of Treatment|Change From Baseline in the Mean Sleep Amount 100 mm Visual Analogue Scale Score at the End of Treatment|Change From Baseline in the Mean Feeling Upon Wakening 100 mm Visual Analogue Scale Score at the End of Treatment|Change From Baseline in the Mean Barthel Activities for Daily Living Scale Score at the End of Treatment|Change From Baseline in the Mean Short Orientation-Memory-Concentration Test at the End of Treatment|Change From Baseline in the Mean Reading Visual Acuity Test Score at the End of Treatment|Change From Baseline in the Mean Care-Giver Strain Index Score at the End of Treatment|Change From Baseline in the Mean Guy's Neurological Disability Scale Score at the End of Treatment|Change From Baseline in the Mean Total Adult Memory and Information Processing Battery Test Score at the End of Treatment,True,2012-09-19
NCT04175834,Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab,Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions,COMPLETED,2020-02-05,2022-05-13,2022-05-13,2024-03-04,2019-11-25,INTERVENTIONAL,PHASE3,19.0,ACTUAL,Providence Health & Services,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis|Infusion Reaction,cetirizine|diphenhydramine,United States,Portland,Oregon,1,cetrizine|diphenhydramine,DRUG|DRUG,Proportion of Participants With Infusion-related Reaction (IRR) on Day 0,"Proportion of Participants With Infusion-related Reaction (IRR) on Day 14|Proportion of Participants With an Infusion-related Reaction (IRR) on Day 168|Treatment Satisfaction Questionnaire for Medication (TSQM) Score on Days 0, 14 and 168|Stanford Sleepiness Scale (SSS) Score on Days 0, 14, and 168|Visual Analog Scale for Fatigue (VAS-F) Score on Days 0, 14 and 168|Modified Fatigue Impact Scale (MFIS) Score on Day 168|Multiple Sclerosis Impact Scale (MSIS-29) Score on Day168",True,2024-03-04
NCT04145934,A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS,A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS,COMPLETED,2020-02-06,2023-01-26,2023-01-26,2023-03-23,2019-10-31,INTERVENTIONAL,NA,78.0,ACTUAL,Oregon Health and Science University,OTHER,Portland VA Medical Center,FED,Multiple Sclerosis,fall prevention|walking aid|physical therapy,United States,Portland,Oregon,1,ADSTEP,BEHAVIORAL,Change from Baseline in Self-Reported Falls at 8 months,Change from Baseline in Functional Gait Assessment / Dynamic Gait Index,False,
NCT04547400,Relationship of Position Sense With Gait and Balance in Patients With Multiple Sclerosis,Relationship of Position Sense With Gait and Balance in Patients With Multiple Sclerosis,COMPLETED,2020-10-05,2022-05-13,2022-05-13,2022-08-05,2020-09-14,OBSERVATIONAL,,40.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Gait|Balance|Sensation,Turkey (Türkiye),Ankara,,1,assessment,OTHER,Gait|Balance,Light touch-pressure sensation|Vibration sensation|Two-point discrimination|position sensation of knee joint|Knee proprioception,False,
NCT01339234,Supported Treadmill Training for Progressive Multiple Sclerosis,Body-weight Supported Treadmill Training in Primary Progressive Multiple Sclerosis: A Pilot Trial,COMPLETED,2008-04,2009-06,2009-06,2011-04-20,2011-04-20,INTERVENTIONAL,NA,6.0,ACTUAL,"Hicks, Audrey, Ph.D.",INDIV,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,treadmill exercise|rehabilitation|progressive multiple sclerosis|functional ability|quality of life|fatigue,Canada,Hamilton,Ontario,1,Body-weight supported treadmill training,OTHER,"Change from baseline in Multiple Sclerosis Functional Composite (MSFC) at 12, 24 and 36 weeks","Change from baseline in Expanded Disability Status Scale (EDSS) at 12, 24 and 36 weeks|Change from baseline in Modified Fatigue Impact Scale (MFIS) at 12, 24 and 36 weeks|Change from baseline in Multiple Sclerosis Quality of Life-54 questionnaire at 12, 24 and 36 weeks|Change from baseline in brain-derived neurotrophic factor (BDNF) at 12, 24 and 36 weeks|Change from baseline in magnetic resonance imaging (MRI) outcomes at 24 weeks",False,
NCT03049969,Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),TERMINATED,2017-02-07,2023-03-26,2023-03-26,2024-07-09,2017-02-10,INTERVENTIONAL,NA,15.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis|Neurological Disorder,Working Memory|Cognitive Training|Transcranial Magnetic Stimulation,United States,New York,New York,1,tDCS stimulation,DEVICE,Number of Participants Completing at Least 80% of the Targeted Number of Sessions.|Number of Participants With Treatment Related Adverse Events,Change in Visual Analogue Scale (VAS) for Pain Score|Change in Negative Affect Score From the Positive and Negative Affect Scale (PANAS)|Change in Positive Affect Score From the Positive and Negative Affect Scale (PANAS)|Change in Symbol Digit Modalities Test (SDMT) Score,True,2024-06-18
NCT05590533,Turkish Version of F-2-MS,Validity and Reliability of the Turkish Version of F-2-MS Scale,UNKNOWN,2022-11,2023-04,2023-05,2022-10-21,2022-10-21,OBSERVATIONAL,,180.0,ESTIMATED,Pamukkale University,OTHER,,,Cultural Adaptation|Reliability|Validity|Multiple Sclerosis|Fatigue,,,,,0,"Cultural adaptation, reliability and validity",OTHER,F-2-MS Scale,,False,
NCT04771858,Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis,MSgoesHome - Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis,COMPLETED,2021-03-09,2023-06-28,2023-06-28,2023-07-03,2021-02-25,OBSERVATIONAL,,80.0,ACTUAL,Medical Valley Digital Health Application Center GmbH,INDUSTRY,Celgene Corporation|NeuroSys GmbH|Fraunhofer Institute for Integrated Circuits IIS|Portabiles HealthCare Technologies GmbH|University of Regensburg,INDUSTRY|UNKNOWN|UNKNOWN|UNKNOWN|OTHER,Multiple Sclerosis,Gait Analysis|Home-Monitoring,Germany,Regensburg,Bavaria,1,,,Number of detected gait cycles per patient per day|Daily sensor wear time per patient|Completeness of days during 14-day field period per patient with sensor records|System Usability Scale (SUS),Difference in time of 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic|Difference in time of 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic|Difference in gait parameters during 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic|Difference in gait parameters during 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic|Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at home|Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at clinic,False,
NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,"A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis",COMPLETED,2006-07,2015-11,2015-11,2017-09-19,2006-02-08,INTERVENTIONAL,PHASE2,25.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Immune Tolerance Network (ITN),NETWORK,Relapsing-Remitting Multiple Sclerosis,"hematopoietic stem cell transplantation|HCT- autologous hematopoietic cell transplant|HDIT-high-dose immunosuppressive therapy|BEAM -Carmustine (BCNU), Etoposide (VP-16), Cytarabine (ara-C), and Melphalan",United States,Columbus,Ohio,4,"Granulocyte-colony stimulating factor (G-CSF) and prednisone|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|Autologous hematopoietic stem cell transplant",DRUG|DRUG|PROCEDURE,Event-Free Survival Probability During the 5 Years After Transplant,Event-Free Survival Probability During the 3 Years After Transplant|Survival From Treatment-Related Mortality|Overall Survival|Survival From MS-Related Mortality|Percent of Participants Who Experienced All-Cause Morbidity|Percent of Participants Who Experienced All-Cause Morbidity Within 12 Months of Post-HCT|Time to Neutrophil Engraftment|Time to Platelet Engraftment|Event-Free Survival Probability After Transplant|MS Progression-Free Survival Probability After Transplant|MRI Activity-Free Survival Probability After Transplant|MS Relapse-Free Survival Probability After Transplant|Disease-Modifying Therapy Survival Probability After Transplant|Change From Baseline in Extended Disability Status Scale (EDSS)|Change From Baseline in Number of Gadolinium-Enhanced Lesions|Number of New T2-Weighted Lesions From Baseline|Change From Baseline in T2-Weighted Lesion Volume|Change From Baseline in T1-Weighted Lesion Volume|Percent Change From Screening in Brain Volume,True,2017-04-04
NCT04230174,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,UNKNOWN,2020-02,2022-01,2022-07,2020-01-18,2020-01-18,INTERVENTIONAL,PHASE4,24.0,ESTIMATED,Massachusetts General Hospital,OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,,,,,0,11C-PBR28,DRUG,Neuroinflammation Changes under Ocrelizumab Therapy|To assess whether changes in neuroinflammation under Ocrelizumab treatment relate to changes in structural MR metrics of brain tissue damage,To explore whether changes in functional and structural imaging metrics under Ocrelizumab are associated with changes in clinical outcomes measures,False,
NCT02294058,Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS),"A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients",COMPLETED,2014-12-03,2016-12-22,2016-12-22,2020-11-25,2014-11-19,INTERVENTIONAL,PHASE3,1346.0,ACTUAL,Celgene,INDUSTRY,,,Multiple Sclerosis,MS|RMS|Multiple Sclerosis|Relapsing Multiple Sclerosis,United States,Phoenix,Arizona,224,Ozanimod|Interferon beta-1a|Placebo to ozanimod|Placebo to interferon beta-1a,DRUG|DRUG|DRUG|DRUG,Adjusted Annualized Relapse Rate (ARR) During the Treatment Period,Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 12 Months|Adjusted Mean Number of Gadolinium Enhancing (GdE) Brain MRI Lesions at Month 12|Time to Onset of Disability Progression Confirmed After 3 Months|Time to Onset of Disability Progression Confirmed After 6 Months|Percentage of Participants Who Were Gadolinium Enhancing Lesion-Free at Month 12|Percentage of Participants Who Were T2 Lesion-Free at Month 12|Percent Change From Baseline in Normalized Brain Volume at Month 12|Change From Baseline to Month 12 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test|Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores|Number of Participants With Treatment Emergent Adverse Events,True,2020-11-25
NCT03928990,Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life,Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life,UNKNOWN,2019-01-15,2021-01,2021-01,2019-04-26,2019-04-26,INTERVENTIONAL,NA,30.0,ESTIMATED,Centre Hospitalier Universitaire de Besancon,OTHER,,,Multiple Sclerosis,,France,Besançon,,1,ActiGraph accelerometer,DEVICE,Patient's feeling,,False,
NCT00726648,CDP323 Biomarker Study,"Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.",COMPLETED,2008-07,2009-03,2009-03,2011-09-12,2008-08-01,INTERVENTIONAL,PHASE1|PHASE2,71.0,ACTUAL,UCB Pharma,INDUSTRY,Biogen,INDUSTRY,Relapsing Multiple Sclerosis,CDP323|Relapsing multiple sclerosis|Blood biomarkers,United Kingdom,Tooting,London,2,CDP323|CDP323|CDP323|CDP323|Placebo,DRUG|DRUG|DRUG|DRUG|DRUG,Pharmacodynamic parameters related to leukocyte trafficking,Standard and disease-related safety variables|Class-related safety parameters,False,
NCT02313285,A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668,"An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668",COMPLETED,2015-01-12,2022-04-20,2022-04-20,2022-05-12,2014-12-10,OBSERVATIONAL,,64.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Progressive Multiple Sclerosis,,Germany,Berlin,,1,,,"Number of patients with adverse events|Safety, as assessed by clinical (physical examination), laboratory (hematology, creatinine, and urinalysis with microscopy), ECG, and vital sign events|Clinically significant changes in thyroid function tests from baseline",Time to lymphocyte repopulation|Number of patients with anti-drug antibodies|Serum concentrations of GZ402668,False,
NCT04116424,VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study,VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study,UNKNOWN,2020-01,2021-01,2021-04,2019-10-04,2019-10-04,INTERVENTIONAL,NA,46.0,ESTIMATED,"University Hospital, Caen",OTHER,,,Multiple Sclerosis,,,,,0,nurse training of the patient|neurologist accompaniement,OTHER|OTHER,number of patients who reported at least one ADR,,False,
NCT02389426,Transcranial Doppler in Multiple Sclerosis,Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis,COMPLETED,2014-12,2015-03,2015-04,2015-04-17,2015-03-17,INTERVENTIONAL,NA,30.0,ACTUAL,Universitair Ziekenhuis Brussel,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cerebral hemodynamics|Cerebral hypoperfusion|Cerebral circulation,Belgium,Jette,Vlaams-Brabant,1,TCD baseline|TCD after bosentan administration|NIRS baseline|NIRS after bosentan administration,DEVICE|DEVICE|DEVICE|DEVICE,Detection of hemodynamic differences between MS patients and Healthy controls with TCD baseline.,Hemodynamic changes in MS patients detected with TCD after administration of Bosentan|Detection of frontal lobe oxygen saturation differences between patients with multiple sclerosis and healthy controls with near-infrared spectroscopy.|Frontal lobe oxygen saturation changes in MS patients detected with NIRS after administration of Bosentan,False,
NCT04073940,Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis,Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis,UNKNOWN,2019-08-29,2021-01-15,2021-01-15,2020-01-03,2019-08-29,INTERVENTIONAL,NA,30.0,ESTIMATED,University of Illinois at Urbana-Champaign,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|ataxia|magnetic resonance imaging|structural connectivity|resting state functional connectivity|dance|wellness|balance|mobility,United States,Champaign,Illinois,1,Targeted Ballet Program,BEHAVIORAL,Structural Connectivity|Resting-State Functional Connectivity,International Cooperative Ataxia Rating Scale (ICARS)|Mini Balance Evaluation Systems Test (Mini-BESTest)|10-Meter Walk Test (10MWT)|World Health Organization Disability Assessment Schedule (WHODAS)|World Health Organization Five Well-Being Index (WHO-5).|Smoothness Index|Step-to-Stand Stabilization Task,False,
NCT06441448,potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis,potentiALS - A Multi-method Participatory Aproach to Identify Potentials in Improving Quality of Life Among Patients With Amyotrophic Lateral Sclerosis,RECRUITING,2024-01-01,2024-08-31,2024-12-31,2024-06-04,2024-06-04,OBSERVATIONAL,,54.0,ESTIMATED,University of Leipzig,OTHER,Leipzig University Medical Center,OTHER,Amyotrophic Lateral Sclerosis,participatory aproach|quality of life|psychotherapeutic program,Germany,Leipzig,Saxony,1,case focus groups,BEHAVIORAL,Response rate,Level of Quality of Life,False,
NCT01993004,Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells,Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells,COMPLETED,2013-07,2015-12,2015-12,2016-04-21,2013-11-25,OBSERVATIONAL,,24.0,ACTUAL,"Rutgers, The State University of New Jersey",OTHER,,,Multiple Sclerosis,,United States,New Brunswick,New Jersey,1,,,Relative MicroRNA expression in B cells,,False,
NCT03759249,Sleep Medical Treatment in MS Patients Suffering From Fatigue,Control Fatigue: Sleep Medical Treatment as a Novel Therapeutic Approach to an Unmet Medical Need in Multiple Sclerosis,TERMINATED,2015-12-08,2021-05-31,2021-05-31,2021-08-03,2018-11-29,INTERVENTIONAL,NA,51.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis|Fatigue,multiple sclerosis|polysomnography,Germany,Berlin,,1,Sleep medical treatment,OTHER,Modified Fatigue Impact Scale value,,False,
NCT06608797,Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community,Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community,RECRUITING,2024-09-30,2025-12-31,2025-12-31,2025-02-21,2024-09-23,INTERVENTIONAL,NA,40.0,ESTIMATED,Kessler Foundation,OTHER,,,Multiple Sclerosis,"learning, memory, cognitive training",United States,East Hanover,New Jersey,1,Learning and memory training|Sham Comparator,BEHAVIORAL|BEHAVIORAL,California Learning Verbal Test III,Ecological Memory Simulations,False,
NCT02225977,Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.,Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.,COMPLETED,2013-07-31,2016-12-31,2017-04-30,2018-08-22,2014-08-26,OBSERVATIONAL,,125.0,ACTUAL,University of Southern California,OTHER,,,Multiple Sclerosis,,United States,Los Angeles,California,1,Gilenya,DRUG,Change in ratio of M2 versus M1 monocytes and macrophages.,,False,
NCT03677440,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: A Systematically-Developed Randomized Controlled Trial,COMPLETED,2019-02-05,2023-12-31,2024-12-31,2025-06-05,2018-09-19,INTERVENTIONAL,NA,43.0,ACTUAL,Kessler Foundation,OTHER,National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH|NIH,Multiple Sclerosis|Cognitive Impairment,,United States,West Orange,New Jersey,1,Treadmill Walking Exercise Training|Stretching-and-Toning Exercise Training,BEHAVIORAL|BEHAVIORAL,Cognitive Processing Speed|Thalamocortical Resting-State Functional Connectivity Region 1|Change in Thalamocortical Resting State Functional Connectivity Region 2,3-second Paced Auditory Serial Addition Test (PASAT)|2-second Paced Auditory Serial Addition Test (PASAT)|Pattern Comparison Test|Community Integration Questionnaire|Lawton-Brody Instrumental Activities of Daily Living|Multiple Sclerosis Impact Scale-29 Physical Subscale|Timed 25-foot Walk,True,2025-06-05
NCT03756974,BX-1 in Spasticity Due to Multiple Sclerosis,"A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS)",COMPLETED,2019-02-18,2021-03-30,2021-03-30,2021-05-05,2018-11-28,INTERVENTIONAL,PHASE3,397.0,ACTUAL,Bionorica SE,INDUSTRY,,,Spasticity Due to Multiple Sclerosis,cannabinoid|dronabinol,Czechia,Choceň,,40,BX-1|Placebo,DRUG|DRUG,Responder analysis: proportion of patients showing improvement in spasticity of 18% or more in average Numerical Rating Scale for Spasticity (NRS-S) assessment at end of treatment,"Responder analysis: proportion of patients showing improvement in spasticity (change from baseline) of 30% or more in average NRS-S assessment at end of treatment (Visit 6)|Responder analysis: proportion of patients showing improvement in spasticity (change from baseline) of 50% or more in average NRS-S assessment at end of treatment (Visit 6)|Time to response: time to reach first improvement in spasticity (change from baseline) of 18% or more, based on patient's daily spasticity assessment on the NRS-S|Time to response: time to reach first improvement in spasticity (change from baseline) of 30% or more, based on patient's daily spasticity assessment on the NRS-S|Weekly mean of the patient's daily spasticity assessments on the NRS-S during Visit 0 - Visit 6|Weekly mean of the patient's daily pain assessments on the Numerical Rating Scale for Pain (NRS-P) during Visit 0 - Visit 6|Responder analysis: proportion of patients showing improvement in pain (change from baseline) of 15% or more in average NRS-P assessment at end of treatment (Visit 6)|Responder analysis: proportion of patients showing improvement in pain (change from baseline) of 30% or more in average NRS-P assessment at end of treatment (Visit 6)|Time to response: time to reach first improvement in pain (change from baseline) of 15% or more, based on patient's pain assessment on the NRS-P|Time to response: time to reach first improvement in pain (change from baseline) of 30% or more, based on patient's pain assessment on the NRS-P|Weekly mean of the patient's daily spasm frequency and severity assessments on the Penn Spasm Frequency Scale (PSFS) during Visit 0 - Visit 6|Mean change from baseline of spasm frequency and severity assessments on the PSFS at end of treatment (Visit 6)|Mean change from baseline of Timed 25-Foot Walk (T25-FW) at Visit 4 and Visit 6|Responder analysis: proportion of patients showing improvement in TF25-FW (change from baseline) of 20% or more at Visit 6|Mean change from baseline of the physical and psychological impact of multiple sclerosis assessed with the Multiple Sclerosis Impact Scale- 29 version 2 (MSIS-29 v2) at Visit 4 and Visit 6|Mean change from baseline of quality of life measured with Short-Form Health Survey of the Medical Outcomes Study Version 2 (SF-36 v2) at Visit 6|Mean change from baseline of sleep quality measured with the Numerical Rating Scale for Sleep Quality (NRS-SQ) at Visit 3 - Visit 6|Mean change from baseline of fatigue measured with the Numerical Rating Scale for Fatigue (NRS-F) at Visit 3 - Visit 6|Overall patients' status measured by Patient´s Global Impression of Change scale (PGIC) at Visit 5 and Visit 6|Overall patients' status measured by Clinical Global Impression - Improvement scale (CGI-I) at Visit 5 and Visit 6",False,
NCT03910738,TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis,TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis,RECRUITING,2019-10-29,2027-12,2027-12,2025-06-29,2019-04-10,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,"University Hospital, Strasbourg, France",OTHER,Bayer|Fédération Hospitalo-Universitaire NEUROGENYCS|Grünenthal GmbH,INDUSTRY|UNKNOWN|INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Neuroprotection|Remyelination|Relapsing Remitting Multiple sclerosis|Testosterone undecanoate|Diffusion tensor Imaging,France,Besançon,,5,Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Placebo 4 mL Solution for Injection|MRI|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|Assessment of disability,DRUG|DRUG|PROCEDURE|BEHAVIORAL|BEHAVIORAL,Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions,"Evolution of the number of T1 hypointense lesions as detected by conventional MRI|Evolution of the volume of T1 hypointense lesions as detected by conventional MRIconventional MRI|Evolution of the number of new or enlarged T2 lesions as detected by conventional MRI|Evolution of the volume of new or enlarged T2 lesions as detected by conventional MRI|Evolution of the total volume of hyper-intensity FLAIR lesion as detected by conventional MRI|Evolution of diffusion tensor imaging (NODDI) as detected by unconventional MRI|Evolution of quantitative magnetization transfer imaging (MPF) as detected by unconventional MRI|Evolution of cognitive performance as measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|Changes in quality of life as measured by the SF-36 questionnaire|Changes in quality of life related to health as measured by the EQ-5D-3L (European Quality of Life in 3 Dimensions) questionnaire.|Changes in work productivity and daily activities due to MS, as assessed by the WPAI:MS questionnaire (Work Productivity and Activity Impairment in MS).|Changes in fatigue, measured by the Multidimensional Fatigue Impact Scale (MFIS)|Changes in anxiety and depression as measured by the Hospital assessment for Anxiety and Depression Scale (HADS) questionnaire|Evolution of disability measured MS specific Expanded Disability Status scale (EDSS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",False,
NCT00618085,Motor Imagery Practice in Neurological Rehabilitation,An Integrated Motor Imagery Program in Rehabilitation - a RCT,COMPLETED,2008-02,2009-04,2009-04,2009-05-04,2008-02-18,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,Nuffield Orthopaedic Centre NHS Trust,OTHER,Oxford Brookes University,OTHER,Stroke|Brain Injury|Multiple Sclerosis,,United Kingdom,Oxford,,1,Motor imagery practice|Standard physiotherapy and occupational therapy,BEHAVIORAL|OTHER,Goal Attainment Scaling,Motor imagery questionnaire|Timed up and go|Action research arm test,False,
NCT06820125,Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation,Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation in Patients with Multiple Sclerosis,RECRUITING,2023-07-05,2023-07-05,2026-07-05,2025-02-11,2025-02-11,INTERVENTIONAL,NA,48.0,ESTIMATED,Universita di Verona,OTHER,,,Rehabilitation|Multiple Sclerosis|Cognitive Deficit|Motor Deficits,rehabilitation|multiple sclerosis|cognitive deficits|motor deficits,Italy,Verona,verona,1,Cognitive rehabilitation: CG group|Motor rehabilitation: MG group|Combined rehabilitation: CbG group,DEVICE|DEVICE|DEVICE,Symbol Digit Modalities Test|2-minute walking test,"Brief Repeatable Battery (BRB)|The Stroop Test (ST)|Trail Making Test (TMT)|The Verbal Fluency Test (VF)|The Modified Five Point Test (MFPT)|Test of Attentional Performance (TAP; version 2.3.1)|N-Back task|Time up and Go (TUG)|eight-infrared camera system (sampling frequency: 60-120 fps) with the VICON Vero 2.2 motion analysis system (Vicon Motion Analysis System Ltd),|Modified Fatigue Impact Scale (MFIS)|The Multiple Sclerosis Quality of Life-29 (MSQOL-29)|Client Satisfaction Questionnaire (CSQ-8)",False,
NCT03175133,Strength Training to Improve Gait in People With Multiple Sclerosis,Targeted Strength Training to Improve Gait in People With Multiple Sclerosis: a Feasibility Study,COMPLETED,2017-05-23,2017-11-08,2017-11-08,2018-04-13,2017-06-05,INTERVENTIONAL,NA,11.0,ACTUAL,"University of Colorado, Denver",OTHER,,,Multiple Sclerosis,rehabilitation|physical therapy,United States,Aurora,Colorado,1,Strength exercise,OTHER,Change in Muscle Strength|Change in Timed 25 Foot Walk (T25FW),Change in 6-Minute Walk Test|Change in Dynamic Gait Index|Change in Multiple Sclerosis Walking Scale-12|Change in Patient Specific Functional Scale,False,
NCT00552955,Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women,Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis,COMPLETED,2007-10-26,,2016-03-21,2019-03-06,2007-11-02,OBSERVATIONAL,,35.0,ACTUAL,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,,,Lymphangioleiomyomas|Tuberous Sclerosis|Lymphangioleiomyomatosis,Lymphangioleiomyomatosis|Abdominal Lymphangioleiomyomas|Chyle|Ascites|Tuberous Sclerosis Complex|LAM,United States,Bethesda,Maryland,1,,,,,False,
NCT00607126,Locomotor Training in Persons With Multiple Sclerosis,Robotic Locomotor Training in Persons With Multiple Sclerosis,COMPLETED,2006-07,2009-08,2009-08,2016-08-15,2008-02-05,INTERVENTIONAL,PHASE1|PHASE2,38.0,ACTUAL,"University of California, Los Angeles",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,impaired ambulation,United States,Los Angeles,California,1,Lokomat|resistive training,DEVICE|PROCEDURE,Walking Speed as Assessed by 25' Timed Walk,Distance|Fatigue|PASAT,True,2016-08-15
NCT05920018,Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis,Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA/Tonalin® FFA 80) and Probiotics (Vivomixx®/VSL#3) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis,RECRUITING,2023-10-02,2025-02,2025-02,2024-05-08,2023-06-27,INTERVENTIONAL,NA,100.0,ESTIMATED,Universität Münster,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,Germany,Heidelberg,Baden-Wurttemberg,4,Vivomixx®|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Maltose placebo|Sunflower oil placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|OTHER|OTHER,Change of volume of 'hyperintense lesions in the T2-weighted MRI images' between baseline and after 48 weeks of therapy,Change in T2 lesions at 48 weeks compared to baseline|Number of new or enlarging T2-weighted hyperintense lesions|Volume of new or enlarged 'hyperintense lesions in the T2-weighted MRI images' as well as double inversion recovery (DIR) images|Annualized relapse rate,False,
NCT05576779,Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.,Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis in the Real-World,COMPLETED,2020-12-03,2021-12-31,2021-12-31,2022-11-08,2022-10-13,OBSERVATIONAL,,2101.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,"Multiple sclerosis,|ofatumumab,|disease-modifying therapy,|COVID-19",United States,East Hanover,New Jersey,1,Ofatunumab,OTHER,Proportion of patients initiating ofatumumab based on DMT use,Age|Gender|Number of patients: Geographic region|Number of patients: State level (Geographic region)|Number of patients: Insurance type|Number of patients: Payer|Follow-up time|Number of patients: Pre-index Charlson comorbidity index (CCI)|Number of patients: Pre-index comorbidities|Number of patients with a relapse in inpatient settings|Number of patients with a relapse in outpatient settings|Number of relapses in all patients|Number of relapses in patients with at least 1 relapse|Claims-Based Disability Score|Number of pre-index Brain and Spinal MRI scans|Number of patients: Hepatitis B virus screening|Number of patients: Quantitative serum immunoglobulin screening|Number of patients: Pre-index flu shot|Number of patients: Post-index flu shot|Pre-index: Number of patients with COVID-19 diagnosis|Post-index: Number of patients with COVID-19 diagnosis|Days between COVID-19 diagnosis and initiation of ofatumumab|Pre-index: Number of patients with COVID-19 vaccination|Post-index: Number of patients with COVID-19 vaccination|Days between COVID-19 vaccination and initiation of ofatumumab|Proportion of patients with steroid use or antihistamine as pre-medication with ofatumumab first dose|Pre-index HCRU: Number of patients with an inpatient visit|Pre-index HCRU: Number of patients with an ED visit|Pre-index HCRU: Number of patients with an outpatient visit|Pre-index HCRU: Number of patients with a pharmacy claim|Post-index HCRU: Number of patients with an inpatient visit|Post-index HCRU: Number of patients with an ED visit|Post-index HCRU: Number of patients with an outpatient visit|Post-index HCRU: Number of patients with a pharmacy claim,False,
NCT02258217,Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS),Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS),COMPLETED,2014-06,2016-06-24,2016-12,2020-09-01,2014-10-07,INTERVENTIONAL,NA,30.0,ACTUAL,OhioHealth,OTHER,,,Relapsing Remitting Multiple Sclerosis,,United States,Columbus,Ohio,1,Acthar,DRUG,ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living)|ARMS (Assessing Relapses in Multiple Sclerosis) RSH Scores (Return to Previous Health)|ARMS (Assessing Relapses in Multiple Sclerosis) TCS Scores (Total Composite Scores)|ARMS (Assessing Relapses in Multiple Sclerosis) PCS Scores (Partial Composite Scores)|MSIS (Multiple Sclerosis Impact Scale) -29 Physical Score|MSIS (Multiple Sclerosis Impact Scale) - 29 Psychological Score.|EDSS (Expanded Disability Status Scale) Scores.|SAGE (Self-administered Gerocognitive Exam) Scores,GASE Scale Questionnaire (Generic Assessment of Side Effects),True,2020-09-01
NCT05658497,Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate),Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry,RECRUITING,2023-10-27,2032-07-06,2032-07-06,2025-08-01,2022-12-20,OBSERVATIONAL,,908.0,ESTIMATED,Biogen,INDUSTRY,,,Multiple Sclerosis,Pregnancy|Relapsing forms of MS,United States,Aurora,Colorado,7,Diroximel Fumarate|Avonex|Tysabri|Dimethyl Fumarate,DRUG|DRUG|BIOLOGICAL|DRUG,Number of Major Congenital Malformations (MCMs),Number of Elective or Therapeutic Terminations|Number of Spontaneous Abortions|Number of Fetal Deaths Including Still Birth|Number of Live Births|Number of Ectopic Pregnancies|Number of Molar Pregnancies|Number of Maternal Deaths|Number of Neonatal Deaths|Number of Perinatal Deaths|Number of Infant Deaths|Number of Serious or Opportunistic Infections in Liveborn Children|Number of Infants with Abnormal Postnatal Growth and Development|Number of Participants with Pregnancy Complications,False,
NCT03282760,Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients,"A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients",COMPLETED,2017-09-09,2021-05-29,2021-05-29,2021-07-12,2017-09-14,INTERVENTIONAL,PHASE1,24.0,ACTUAL,Casa Sollievo della Sofferenza IRCCS,OTHER,Associazione Revert ONLUS|Neurocenter of Southern Switzerland|Fondazione Cellule Staminali,UNKNOWN|OTHER|UNKNOWN,Secondary-progressive Multiple Sclerosis,Cell Transplantation|Neural Stem Cells,Italy,San Giovanni Rotondo,Foggia,3,Human Neural Stem Cells,BIOLOGICAL,Incidence of Treatment Emergent AE|Percentage of Mortality in treated patients,Change in Functional disability|Change in Functional disability|Activity of Cognitive function|Relapses Rate|Relapses Rate|MS Biomarkers|Alteration in Neurophysiological parameters,False,
NCT05495425,Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC,Placebo-controlled Comparative Study of NPC-12Y Gel in Patients With Skin Lesions Associated With Tuberous Sclerosis Complex,COMPLETED,2022-06-01,2024-10-30,2024-10-30,2024-11-22,2022-08-10,INTERVENTIONAL,PHASE3,43.0,ACTUAL,Nobelpharma,INDUSTRY,,,Tuberous Sclerosis Complex,Tuberous sclerosis complex|Sirolimus|Rapalimus gel|mTOR inhibitor,Japan,Toyoake,Aichi-ken,5,NPC-12Y gel|NPC-12Y placebo gel,DRUG|DRUG,Improvements in angiofibroma,"Improvements in angiofibroma, color and size|Index of Facial Angiofibromas (IFA) score",False,
NCT05981040,"Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis","A Phase 2, Proof-of-concept, Placebo Controlled, Randomized, Multi-centre, Double Blind Study of ZYIL1 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2023-11-09,2024-06-26,2024-06-26,2024-12-19,2023-08-08,INTERVENTIONAL,PHASE2,24.0,ACTUAL,Zydus Lifesciences Limited,INDUSTRY,,,Amyotrophic Lateral Sclerosis,,India,Ahmedabad,Gujarat,7,ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|Matching placebo 25 mg and Matching placebo 50 mg,DRUG|DRUG|DRUG|DRUG,Change from baseline in the ALSFRS-R total score,"Time from baseline to the occurrence of either death, or permanent assisted ventilation|Change from baseline in slow vital capacity (SVC)|Change from baseline in serum neurofilament light chain biomarker|Number of patients with treatment emergent adverse events|Number of patients with Serious adverse event (SAE)|Cmax|AUC|Tmax",False,
NCT00343590,Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study,Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study,COMPLETED,2006-06,2006-11,2006-11,2008-10-17,2006-06-23,INTERVENTIONAL,NA,,,Logan College of Chiropractic,OTHER,,,Multiple Sclerosis,,United States,Chesterfield,Missouri,2,Whole Body Vibration machine,DEVICE,NeuroCom Balance Master|SF-EMG Nerve conduction velocity test|Berg balance score,,False,
NCT00764413,Chronotherapy in Acute Multiple Sclerosis (MS) Attack,Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?,TERMINATED,2009-04,2012-07,2012-07,2014-11-24,2008-10-02,INTERVENTIONAL,NA,57.0,ACTUAL,Sykehuset Innlandet HF,OTHER,,,Multiple Sclerosis,EDSS|methylprednisolone|circadian rhythms|MSFC,Norway,Lillehammer,Oppland,1,methylprednisolone|Sodium chlorid,DRUG|DRUG,The difference in mean changes in EDSS-score between the group receiving treatment during the night opposed to during the day.,"The difference in MSFC-score in the two groups|Side effect registered by the patient|The patient's quality of life|MRI - volume and number for MS-lesions, Gd-enhancement|Fatigue|Depression",False,
NCT03455582,Cognition Evolution and MRI Markers in PPMS Patients on 2 Years,Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study,ACTIVE_NOT_RECRUITING,2018-09-24,2026-03,2026-03,2025-02-20,2018-03-06,INTERVENTIONAL,NA,66.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Roche Pharma AG,INDUSTRY,"Multiple Sclerosis, Primary Progressive",cognitive impairment|ecological assessment|brain MRI,France,Bordeaux,,3,Clinical assessment|Ecological evaluation|Neuropsychological evaluation|Psychological evaluation|MRI Evaluation,OTHER|OTHER|OTHER|OTHER|DEVICE,Change of composite z cognitive score based on individual neuropsychological scores,Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity|Change of composite z cognitive score based on individual neuropsychological scores|Changes of composite z ecological score based on individual ecological scores,False,
NCT04025554,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,COMPLETED,2019-10-25,2023-10-24,2023-10-24,2024-12-27,2019-07-19,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Chronic Active Lesions|Ultra-high-field (7T) MRI|Interleukin-1 (IL-1)|White Matter|Paramagnetic Rim,United States,Bethesda,Maryland,1,Anakinra,DRUG,Modulation of One or All Paramagnetic Rim Lesions,"Change in the 9-hole Peg Test (9HPT)|Change in the Symbol Digit Modalities Test (SDMT)|Change in the Expanded Disability Status Scale (EDSS)|Change in Paramagnetic Rim Lesion at Any Time Point|Change in Size of Paramagnetic Rim Lesions at All Time Points, Relative to Non-rim Lesions|Changes in T1 Relaxation Time Within Paramagnetic Rim Lesions at All Time Points, Relative to Non-rim Lesions",True,2024-12-27
NCT02903537,Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS),"Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)",UNKNOWN,2017-07-06,2023-12,2023-12,2023-07-07,2016-09-16,INTERVENTIONAL,PHASE1,16.0,ESTIMATED,Fundació Institut Germans Trias i Pujol,OTHER,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive",Multiple Sclerosis|Dendritic Cells|Immune Tolerance|Myelin Proteins|Tolerogenic dendritic cells,Spain,Badalona,Barcelona,2,Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Interferon-beta,DRUG|DRUG,Safety as assessed by the occurrence and severity of adverse events|Neurologic changes|Radiologic changes,Annual relapse rate (ARR)|Expanded Disability Status Scale (EDSS)|9-Hole Peg Test (9HPT)|25-Foot Walking Test (T25FW)|Symbol Digit Modalities Test (SDMT)|Radiologic preliminary efficacy|Lymphocyte proliferation to myelin peptides|Blood Immunomonitoring studies|Feasibility,False,
NCT00062972,Improving Memory in Patients With Multiple Sclerosis,Interventions to Improve Memory in Patients With Multiple Sclerosis,WITHDRAWN,1999-09,,2002-08,2017-04-25,2003-06-19,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,U.S. Department of Education,FED,Multiple Sclerosis,Multiple Sclerosis|Cognitive Dysfunction|Treatment Interventions|Verbal memory deficits,United States,Stony Brook,New York,1,donepezil|glucose,DRUG|DRUG,,,False,
NCT02611401,Efficacy of MBI for Depressive Symptoms in Patients With MS,The Efficacy of a Mindfulness Based Intervention for Depressive Symptoms in Patients With Multiple Sclerosis and Their Caregivers. A Randomized Controlled Clinical Trial.,COMPLETED,2014-05,2016-12,2017-05,2018-09-07,2015-11-20,INTERVENTIONAL,NA,88.0,ACTUAL,"University of Turin, Italy",OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,Multiple Sclerosis|Depression,multiple sclerosis|depression|mindfulness,Italy,Orbassano,Turin,1,Mindfulness|Psychoeducation,BEHAVIORAL|BEHAVIORAL,depression score,mood disorder|QoL,False,
NCT06190912,Safety of Bryostatin in Patients With MS,"A Single-Arm, Single-Site, Single-Dose Phase 1 Study Assessing the Safety of Bryostatin in the Treatment of Patients With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-06-26,2026-06-15,2026-07-15,2025-04-24,2024-01-05,INTERVENTIONAL,PHASE1,20.0,ESTIMATED,Robert Fox,OTHER,"Synaptogenix, Inc.",UNKNOWN,Multiple Sclerosis,,United States,Cleveland,Ohio,1,Bryostatin 1,DRUG,Adverse Events|Study Medication Discontinuation|CNS inflammatory effects,,False,
NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis,COMPLETED,2007-01,2012-08,2012-08,2015-04-27,2007-04-06,INTERVENTIONAL,PHASE2|PHASE3,38.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,Eli Lilly and Company,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Duloxetine|Pain,United States,Kirkland,Washington,1,Duloxetine|Placebo,DRUG|DRUG,Percent Change in Worst Pain Score,Percent Change in Average Pain Score.|Global Impression of Change,True,2015-04-06
NCT01679041,High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment,A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy,TERMINATED,2012-11,2013-11,2013-11,2013-11-25,2012-09-05,INTERVENTIONAL,PHASE2,1.0,ACTUAL,Seah Lim M.D.,INDUSTRY,,,Multiple Sclerosis,,United States,Amarillo,Texas,3,Alemtuzumab|Fludarabine|Cyclophosphamide,DRUG|DRUG|DRUG,To evaluate the toxicity of autologous HPC transplant in patients with multiple sclerosis that have failed at least two lines of disease modifier therapy,To evaluate the effectiveness of high dose chemotherapy with HPC transplant for multiple sclerosis sclerosis that has failed at least two lines of therapy,False,
NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,Feasibility of the Multiple Sclerosis Performance Test for Assessment of Functional Performance Measures in Patients With Multiple Sclerosis,TERMINATED,2019-06-17,2022-12-05,2022-12-05,2023-01-30,2019-04-24,OBSERVATIONAL,,3073.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Clinically Isolated Syndrome,United States,Berkeley,California,33,Multiple Sclerosis Performance Test (MSPT),OTHER,Percentage of Participants Completing All Modules|Percentage of Participants Completing Each Individual Module|Percentage of Participants Skipping Modules|Average Time to Complete the Multiple Sclerosis Performance Test (MSPT)|Average Time to Complete Individual MSPT Modules|Frequency of Reasons for Not Completing MSPT Modules|Frequency Distribution of Demographic Characteristics of Participants Failing to Complete Specific MSPT Modules,,False,
NCT04237675,Postoperative Relapses in MS Patients,Assessment of Risk of Postoperative Relapses in Patients With Multiple Sclerosis; an Observational Study,RECRUITING,2019-12-20,2027-12,2027-12,2020-01-23,2020-01-23,OBSERVATIONAL,,300.0,ESTIMATED,University of Athens,OTHER,,,Multiple Sclerosis Relapse|Surgery|Anesthesia,,Greece,Athens,Attica,2,surgery and anesthesia,PROCEDURE,MS relapses,,False,
NCT02428231,Tecfidera Slow-Titration Study,"A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis",TERMINATED,2015-04,2015-12,2016-01,2017-05-05,2015-04-28,INTERVENTIONAL,PHASE3,62.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Gilbert,Arizona,20,dimethyl fumarate,DRUG,Proportion of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the Gastrointestinal Symptom Rating Scale (GSRS),"Average Change From Baseline in GSRS Scores During DMF Treatment|Time to First Worsening From Baseline in GSRS Score|Time to Recovery to Baseline From Last Occurrence of Worst GSRS Score|Average Change From Baseline in GSRS Scores to the End of Weeks 4, 6, 8, 10, 12, and 14",True,2017-05-05
NCT06461741,EMG Biofeedback Training to Improve Balance in Individuals with Multiple Sclerosis,Integrated Dual-task EMG Biofeedback Balance Training to Improve Balance in Individuals Living with Multiple Sclerosis,RECRUITING,2024-10-01,2026-07,2027-07,2024-12-03,2024-06-17,INTERVENTIONAL,NA,46.0,ESTIMATED,McMaster University,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,Balance|Falls,Canada,Hamilton,Ontario,1,Integrated Dual-task EMG Biofeedback Training (EMG-BF)|Traditional Balance Exercise Training (BAL-EX),DEVICE|BEHAVIORAL,Mini-Balance Evaluation Systems Test (Mini-BESTest),Limits of Stability (LoS)|Sway in Quiet Stance (QS)|Timed 25ft Walk Test (T25WT)|Activities-specific Balance Confidence (ABC) scale|12-item Subjective Walking Scale (SWS-12)|Short-Form 36 Health Survey (SF-36)|Fall and Near-Fall Frequency,False,
NCT04231253,MUltiple Sclerosis : T Cell / B Cell Exploration,T Cell/B Cell Collaboration in Multiple Sclerosis: Exploring an Intimate Relationship,COMPLETED,2019-02-25,2021-10-31,2021-10-31,2021-12-02,2020-01-18,OBSERVATIONAL,,90.0,ACTUAL,Rennes University Hospital,OTHER,,,Multiple Sclerosis,,France,Rennes,,1,,,To compare the transcriptome profile of infiltrating TFH cells from CIS patients to non-MS patients with neurological inflammatory diseases,To compare the transcriptome profile of infiltrating TFH cells from CIS patients to healthy volunteers.|To compare the B cell differentiation helping abilities of TFH cells from MS patients to those of HV|To compare the migration abilities of TFH cells from MS patients to those of HV,False,
NCT04198181,The Effectiveness and Safety of Resective Epilepsy Surgery for TRE,Clinical Evaluation of the Effectiveness and Safety of Resective Epilepsy Surgery for Tuberous Sclerosis Complex Related Epilepsy,ACTIVE_NOT_RECRUITING,2019-12-12,2027-03-15,2027-03-15,2025-01-17,2019-12-13,OBSERVATIONAL,,200.0,ACTUAL,Beijing Children's Hospital,OTHER,"Shenzhen Children's Hospital|Tiantan Hospital, Capital Medical University|Peking University People's Hospital|Guangdong 999 Brain Hospital|Xinqiao Hospital, Amry Medical University|Shandong Provincial Hospital|West China Hospital|Henan Provincial People's Hospital|Shanghai Children's Hospital|First Medical Center, PLA General Hospital|Fourth Medical Center, PLA General Hospital|The First Affiliated Hospital of University of Science and Technology of China|Ruijin Hospital|First Affiliated Hospital Xi'an Jiaotong University|The Second Hospital of Hebei Medical University|The First Affiliated Hospital of Shanxi Medical University|Xuanwu Hospital, Beijing|The First Hospital of Jilin University|Xiangya Hospital of Central South University|Beijing Sanbo Brain Hospital|Nanjing Medical University",OTHER_GOV|UNKNOWN|OTHER|OTHER|UNKNOWN|OTHER_GOV|OTHER|OTHER|OTHER|UNKNOWN|UNKNOWN|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Tuberous Sclerosis Complex|Epilepsy,epilepsy|tuberous sclerosis complex|resective epilepsy surgery,China,Beijing,Beijing Municipality,1,Surgery,PROCEDURE,% of patients with ILAE grading,IQ|Quality of Life: QOLIE-31,False,
NCT05505383,"The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With Multiple Sclerosis","The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With Multiple Sclerosis Patients",UNKNOWN,2022-08-18,2022-11-20,2022-12-20,2022-08-24,2022-08-17,INTERVENTIONAL,NA,22.0,ESTIMATED,Saglik Bilimleri Universitesi,OTHER,Ankara University,OTHER,Multiple Sclerosis,multiple sclerosis|backward walking training|balance|gait|functional mobility,Turkey (Türkiye),Ankara,,2,Exercise training,OTHER,Berg Balance Scale [Time Frame: 10 minutes]|Four Square Step Test|Activities-specific Balance Confidence Scale|10 Meter Walk Test|Timed 25-feet Walk Test|Six Minute Walk Test|3-meter Backward Walk Test|Dynamic Gait Index|Multiple Sclerosis Walking Scale-12|Timed Up and Go Test,,False,
NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,"BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis",COMPLETED,2013-09,2014-04,2014-06,2015-07-27,2013-02-21,INTERVENTIONAL,PHASE4,278.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,Austria,Graz,Styria,77,Several diagnostic procedures,PROCEDURE,Time to First Relapse by Kaplan-Meier Estimates|Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates|Number of Subjects With Diagnosis of Multiple Sclerosis Within Eleven years after Clinically-Isolated Syndrome (CIS) According to McDonald 2001 and 2010 Criteria|Disease Course as Assessed at the Time of BENEFIT 11|Percentage of Subjects Converting to Secondary Progressive Multiple Sclerosis (SPMS)|Time to Secondary Progressive Multiple Sclerosis (SPMS) Represented by Kaplan-Meier Estimates|Expanded Disability Status Scale (EDSS) at Year 11|Number of Subjects With Confirmed and Sustained 1-point Expanded Disability Status Scale (EDSS) Progression at Year 11|Number of Subjects With Confirmed 2.5-point Expanded Disability Status Scale (EDSS) Progression at Year 11|Percentage of Subjects who Ever Reached a Disability Status Scale (DSS) 3 and 6|Disability Based Efficacy Domain: Time to Disability Status Scale (DSS) 3 by Kaplan-Meier Estimates|Disability Based Efficacy Domain: Time to Disability Status Scale (DSS) 6 by Kaplan-Meier Estimates|Multiple Sclerosis Functional Composite (MSFC) at Year 11|Multiple Sclerosis Severity Score (MSSS) at Year 11|Cognitive Function: Paced Auditory Serial Addition Test-3 (PASAT-3) at Year 11|Cognitive function: Symbol Digit Modalities Test (SDMT)|Relapse-Based Efficacy domain: Hazard Ratio for Recurrent Relapses|Relapse Based Efficacy Domain: Annualized Relapse Rate|Time to use of Ambulatory Device Represented by Kaplan-Meier Estimates|Time to Dependence of Ambulatory Device for Walking Represented by Kaplan-Meier Estimates|Number of Subjects With Wheelchair Use After 11 years,Education Status at Year 11|Living Conditions at Year 11|Employment Status at Year 11|Multiple Sclerosis Impact on Employment at Year 11|Resource Use: Hospitalization During Last 12 months|Resource Use: Visits to Other Specialists During Last 12 months|Resource Use Assessment Questionnaire: Help from Family/Regular Ambulatory Services|Resource Use Assessment Questionnaire: Additional Ambulatory Services During Relapse|Resource Use Assessment Questionnaire: Adaptions past 6 months|Patient-Reported Outcomes (PRO)-based Efficacy Domain: Center of Epidemiological Studies Depression Scale (CES-D) Total Score at Year 11|PRO-based Efficacy Domain: Fatigue Scale for Sensory and Motor Functions (FSMC)|Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Year 11|Functional Assessment of Multiple Sclerosis (FAMS) Total Score at Year 11|PRO-based Efficacy Domain: European Quality of Life - 5 Dimensions (EQ-5D) Score at Year 11|European Quality of Life - 5 Dimensions (EQ-5D) Health-related quality of life (HRQoL) Score at Year 11|Number of Subjects who Started Second Line Therapy at Year 11|Number of Subjects who Started First Disease-Modifying Treatment (DMT) other than IFNB at Year 11|Magnet-Resonance Imaging (MRI): Number of Newly Active Lesions|Magnet-Resonance Imaging (MRI): Number of Lesions on T1- and T2-Weighted Scans|Magnet-Resonance Imaging (MRI): Volume of Lesions on T1- and T2-Weighted Scans|Magnet-Resonance Imaging (MRI): Normalized Brain Volume|Optical Coherence Tomography (OCT) Parameter - Retinal Nerve Fiber Layer (RNFL)|Optical Coherence Tomography (OCT) Parameter - Total Macular Volume (TMV)|Optical Coherence Tomography (OCT) Parameter - Pupillo Macular Bundle (PMB)|Optical Coherence Tomography (OCT) Parameter - Ganglion Cell Inner Plexiform Layer|Ophthalmological examination - Optic Nerve Head|Ophthalmological examination - Slit lamp Biomicroscopy|Ophthalmological examination - Visual Acuity|Number of Subjects with Vitamin D Intake,False,
NCT02591901,Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods),Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study,COMPLETED,2018-04-06,2019-08-02,2019-09-21,2020-03-18,2015-10-30,INTERVENTIONAL,PHASE2,48.0,ACTUAL,Buckinghamshire Healthcare NHS Trust,OTHER,"National Institute for Health Research, United Kingdom|Oxford Clinical Trials Research Unit",OTHER_GOV|UNKNOWN,UTI|Neurogenic Bladder|Antibiotic Resistance,Spinal Cord Injuries|Multiple Sclerosis|Transverse Myelitis|Neurogenic Bladder Dysfunction|Feasibility Study|Urinary Tract Infection,United Kingdom,Aylesbury,Buckinghamshire,2,Uro vaxom|Placebo comparator,DRUG|OTHER,Checklist or consensus guideline which can be used to measure a symptomatic urinary tract infection and Practicality of carrying out a definitive randomised controlled clinical study,Number of participants willing to participate|Number of successfully collected urine samples via courier|Drug compliance,False,
NCT05519553,Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis,Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis: a Mixed Methods Randomized Controlled Trial Pilot Study,NOT_YET_RECRUITING,2022-11-01,2024-03-01,2026-03-01,2022-09-01,2022-08-29,INTERVENTIONAL,NA,60.0,ESTIMATED,Nantes University Hospital,OTHER,,,"Multiple Sclerosis, Relapsing-remitting",multiple sclerosis|peer support|therapeutic adherence,,,,0,Peer support,OTHER,Therapeutic adherence,Therapeutic compliance|Participants' quality of life|Emotional wellbeing|Social support,False,
NCT01704183,Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis,Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis,COMPLETED,2012-12,2014-03,2014-03,2014-05-08,2012-10-11,OBSERVATIONAL,,27.0,ACTUAL,Kuopio University Hospital,OTHER,,,Relapse-remitting Multiple Sclerosis,relapse-remitting multiple sclerosis|heart rate variability|fingolimod|cardiac autonomic regulation,Finland,Kuopio,,2,,,change in heart rate variability,,False,
NCT04952766,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,COMPLETED,2021-03-26,2022-02-06,2022-02-06,2022-06-14,2021-07-07,INTERVENTIONAL,PHASE4,196.0,ACTUAL,Centre Hospitalier Régional d'Orléans,OTHER,,,Kidney Transplant|Myeloma|Cancer|Hematologic Malignancy|Multiple Sclerosis|Hypergammaglobulinemia|Malignant Tumor|Hiv|Diabetes Type 2,SARS-CoV-2|BNT162b2 vaccine|antibody|neutralization|mucosa|immunocompromised|healthy subject,France,Orléans,,1,Biological samples,BIOLOGICAL,Protective humoral response after vaccination,Mucosal neutralization capacity against wild-type and emerging variants of concern (VOC)|Mucosal neutralization capacity against wild-type and emerging variants of concern (VOC)|Mucosal neutralization capacity against wild-type and emerging variants of concern (VOC)|Mucosal neutralization capacity against wild-type and emerging variants of concern (VOC)|Mucosal neutralization capacity against wild-type and emerging variants of concern (VOC)|Serum and nasal neutralization capacity against wild-type and emerging variants of concern (VOC)|Serum and nasal neutralization capacity against wild-type and emerging variants of concern (VOC)|Serum and nasal neutralization capacity against wild-type and emerging variants of concern (VOC)|Serum and nasal neutralization capacity against wild-type and emerging variants of concern (VOC)|Serum and nasal neutralization capacity against wild-type and emerging variants of concern (VOC)|Clinical protection after vaccination|Clinical protection after vaccination|Clinical protection after vaccination|Clinical protection after vaccination|Clinical protection after vaccination,False,
NCT01911377,Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS,The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis,TERMINATED,2013-10,2015-05,2015-08,2015-10-02,2013-07-30,INTERVENTIONAL,PHASE2,12.0,ACTUAL,University of Manitoba,OTHER,Allergan,INDUSTRY,Neuropathic Pain|Allodynia,,Canada,Winnipeg,Manitoba,1,Botulinum Toxin Type A|Normal Saline for Injection,DRUG|DRUG,Brief Pain Inventory,Neuropathic Pain Symptom Inventory|The Hospital Anxiety and Depression Scale|Daily Sleep Interference Scale|Clinician Global Impression Scale|Patient's Global Impression Scale,False,
NCT06369766,"REtinal Markers In Neuroinflammatory Diseases (""REMIND"")",Retinal Markers in Neuroinflammatory Diseases: a Prospective Observational Study,RECRUITING,2024-01-31,2028-12,2029-02,2025-05-23,2024-04-17,OBSERVATIONAL,,500.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,University of Basel,OTHER,Multiple Sclerosis|Neuroinflammatory Diseases,Retinal Markers|OCT|Disease Progression|Progression Independent of Relapse Activity (PIRA),Switzerland,Basel,,1,Optical coherence tomography (OCT)|Static retinal vessel analyzer|Dynamic retinal vessel analyzer|Laser speckle flowgraphy system|Questionnaire,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|OTHER,Occurence of Progression Independent of Relapse Activity (PIRA)|Neuroaxonal loss in the retina (as marker of neurodegeneration in the CNS)|Neuroinflammation in the retina|Fixation instability (as marker of global neuronal dysfunction in the CNS)|Structural changes of the retinal vessels (as marker of systemic microvascular health)|(For a subgroup of participants) Functional/perfusional changes of the retinal vessels,"Relative value of retinal markers for the prediction of PIRA compared to or combined with other biomarkers of neuroaxonal damage|Comparison of the examined retinal markers of Multiple Sclerosis patients with Healthy Controls and with patients with other neuroinflammatory diseases of the CNS|The relationship between neuroaxonal loss, functional deficits and vascular changes in Multiple Sclerosis",False,
NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2002-01,2005-04,2005-12,2009-06-18,2002-02-18,INTERVENTIONAL,PHASE3,1200.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|MS,United States,Birmingham,Alabama,88,Natalizumab|Placebo,DRUG|DRUG,Primary objectives of this study are to determine if natalizumab is effective in reducing the rate of clinical relapse at 1 year and in slowing the progression of disability at 2 years as measured by EDSS.,If this combination reduces MRI lesions and the overall rate of clinical relapses,False,
NCT03111394,Study of myMS in Participants With a Diagnosis of Multiple Sclerosis,"A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis",COMPLETED,2017-04-17,2021-11-25,2021-11-25,2021-11-26,2017-04-12,OBSERVATIONAL,,200.0,ACTUAL,University of Southern California,OTHER,,,Multiple Sclerosis,MS|23andMe|MRI|Genome-wide association studies,United States,Los Angeles,California,1,,,Participants willing to provide genetic and MRI data via myMS,,False,
NCT00869986,A Study for Patients With Relapsing Remitting Multiple Sclerosis,"A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis",COMPLETED,2006-11,2009-09,2009-09,2010-09-09,2009-03-26,INTERVENTIONAL,PHASE2|PHASE3,218.0,ACTUAL,Eli Lilly and Company,INDUSTRY,BioMS Technology Corp.,INDUSTRY,Relapsing Remitting Multiple Sclerosis,,Bulgaria,Sofia,,6,dirucotide|placebo,DRUG|DRUG,Annualized relapse rate,Time to confirmed worsening of disability by Expanded Disability Status Scale (EDSS)|Time to confirmed worsening of disability by Multiple Sclerosis Functional Composite (MSFC)|Proportion of patients relapse-free|Activity analysis of T2 and Gadolinium enhancing lesions,False,
NCT00883142,Functional and Physiological Responses to Lokomat Therapy (Pilot Study),Functional and Physiological Responses to Lokomat Therapy (Pilot Study),COMPLETED,2006-10,2012-08,2013-03,2013-06-11,2009-04-17,OBSERVATIONAL,,27.0,ACTUAL,US Department of Veterans Affairs,FED,,,Spinal Cord Injuries|Multiple Sclerosis|Stroke,Lokomat|Suspended walking|Body Weight Supported|Treadmill Training,United States,The Bronx,New York,1,,,"This pilot study for power calculations on future studies that will characterize the potential benefits of Lokomat rehabilitation training on cardiovascular function, body composition and endocrine/metabolic function",,False,
NCT01281189,Phase 3 Study of Dexpramipexole in ALS,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis",COMPLETED,2011-03,2012-11,2012-11,2021-06-07,2011-01-21,INTERVENTIONAL,PHASE3,942.0,ACTUAL,Knopp Biosciences,INDUSTRY,,,Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis|ALS|Motor Neurone Disease|Motor Neuron Disease|Lou Gehrig's disease,United States,Phoenix,Arizona,82,Dexpramipexole|Placebo,DRUG|DRUG,Composite Assessment of Function and Survival (CAFS) at 12 Months|Death up to 12 Months (CAFs Individual Component)|Change From Baseline in ALSFRS-R at 12 Months (CAFs Individual Component),Death or Respiratory Insufficiency (DRI) up to Month 18|Death up to 18 Months|≤50% Predicted Upright Slow Vital Capacity (SVC) or Died up to 18 Months,True,2021-06-07
NCT05195320,Reinventing Yourself With Multiple Sclerosis (MS),"Reinventing Yourself With Multiple Sclerosis (MS): An Intervention Aimed at Improving Self-Efficacy, Coping, Psychological Well-being, and Quality of Life in MS",UNKNOWN,2022-08-01,2024-09-30,2024-09-30,2022-10-14,2022-01-18,INTERVENTIONAL,NA,48.0,ESTIMATED,Kessler Foundation,OTHER,Craig Hospital|University of Minnesota,OTHER|OTHER,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,Reinvention with MS,BEHAVIORAL,Multiple Sclerosis Self-Efficacy Scale|General Self-Efficacy Scale,Health Status Questionnaire|Satisfaction with Life Scale|Ryff Psychological Well-being Scales|Participation Assessment with Recombined Tools-Objective (PART-O)|Chicago Multiscale Depression Inventory|State Trait Anxiety Scale|Connor-Davidson Resilience Scale|Benefit Finding in Multiple Sclerosis Scale|Cope Inventory,False,
NCT02308579,Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases,"Prevalence of Chronic Cerebrospinal Venous Insufficiency in Patients With Multiple Sclerosis and Other Neurological Diseases. An Ultrasound, Blinded, Case-Controlled, Centralized Reading Assessment",COMPLETED,2014-07,2015-03,2015-03,2016-02-12,2014-12-04,OBSERVATIONAL,,499.0,ACTUAL,University at Buffalo,OTHER,University of Pavia,OTHER,Clinically Isolated Syndrome (CIS)|Multiple Sclerosis (MS)|Other Neurological Disorders (OND)|Healthy (HC),,,,,0,,,Number of MS (or CIS) and HC (or OND) who have 5 VH CCSVI CDUS criteria on doppler ultrasound,,False,
NCT05938842,Study Protocol of Online DBT-Mindfulness Intervention in Multiple Sclerosis,Online DBT-Mindfulness Intervention for Symptoms in Multiple Sclerosis: Study Protocol of a Randomized Controlled Trial,UNKNOWN,2023-10,2023-12,2024-07,2023-07-11,2023-07-11,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Vic - Central University of Catalonia,OTHER,,,Multiple Sclerosis,Multiple sclerosis|online intervention|Dialectal behaviour therapy|Mindfulness,Spain,Vic,Barcelona,1,Online DBT-Mindfulness Intervention|Online psychoeducational intervention,BEHAVIORAL|BEHAVIORAL,Changes in emotion dysregulation|Changes in decentering,Changes in fatigue|Changes in depression and anxiety|Changes in stress|Changes in QoL,False,
NCT06788886,Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases,Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study),RECRUITING,2025-02-05,2027-01-18,2027-01-18,2025-07-17,2025-01-23,INTERVENTIONAL,NA,147.0,ESTIMATED,Mayo Clinic,OTHER,,,Malignant Brain Neoplasm|Malignant Solid Neoplasm|Multiple Sclerosis|Neuroendocrine Tumor|Prostate Carcinoma,,United States,Rochester,Minnesota,1,Biospecimen Collection|Exercise Intervention|Magnetic Resonance Imaging|Questionnaire Administration|Respiratory Therapy,PROCEDURE|OTHER|PROCEDURE|OTHER|PROCEDURE,Changes in respiratory function correlated with brain activity,Change in QOL - PHQ-9|Change in QOL - GAD-7|Change in QOL - Linear Analog Self Assessment|Adherence to the breathing protocol for the intention group|Change in sleep quality - PSQI|Change in sleepiness - ESS|Change in fatigue - MFIS|Change in caregiver strain - CSI|Change in resilience - BRS|Change in ability to implement health-promoting behaviors - SRAHP,False,
NCT06233370,Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis,Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2024-03-01,2025-02-28,2025-12-31,2025-08-28,2024-01-31,INTERVENTIONAL,EARLY_PHASE1,24.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis,exercise|MRI|walking,United States,West Orange,New Jersey,1,Moderate intensity walking exercise,BEHAVIORAL,Brain Function|Brain Blood Flow,,False,
NCT04121403,Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS),Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study,COMPLETED,2019-10-16,2024-08-31,2024-08-31,2024-12-16,2019-10-09,INTERVENTIONAL,PHASE3,267.0,ACTUAL,Oslo University Hospital,OTHER,University of Oslo|Sykehuset Ostfold|Sykehuset Telemark|Vestre Viken Hospital Trust|Sorlandet Hospital HF|Helse Stavanger HF|Sykehuset Innlandet HF|Sykehuset i Vestfold HF|University Hospital of North Norway|St. Olavs Hospital,OTHER|OTHER|OTHER_GOV|OTHER|OTHER_GOV|OTHER_GOV|OTHER|OTHER|OTHER|OTHER,Relapsing Multiple Sclerosis|Multiple Sclerosis,multiple sclerosis|ms|rms|rituximab|cladribine|probe,Norway,Drammen,Buskerud,11,Rituximab|Cladribine,BIOLOGICAL|DRUG,Number of new or enlarging cerebral MRI T2 lesions,T2 lesions after 48 weeks|Annual clinical relapse rate (ARR)|Relapse-free patients|Disability progression|Change in disability,False,
NCT06711354,B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment,B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy,NOT_YET_RECRUITING,2025-06,2025-12,2025-12,2024-12-02,2024-12-02,OBSERVATIONAL,,111.0,ESTIMATED,Region Stockholm,OTHER_GOV,Haukeland University Hospital,OTHER,"Multiple Sclerosis|B-Cell Deficiency|Offspring, Adult|Immunosuppression|Pregnancy Related",,,,,0,Anti-CD20 Monoclonal Antibody,DRUG,KREC and CD19 of B-cells in offspring to mothers with MS exposed to monoclonal anti-CD20 antibodies|Antibody production post vaccination in offspring to mothers with MS exposed to monoclonal anti-CD20 antibodies|Frequency and severity of infections in mothers with MS exposed to monoclonal anti-CD20 antibodies and their offspring|Blood levels of monoclonal anti-CD20 antibodies in offspring to mothers with MS exposed to monoclonal anti-CD20 antibodies before or during pregnancy|Levels of monoclonal anti-CD20 antibodies in breastmilk of breastfeeding mothers treated with monoclonal anti-CD20 antibodies in addition to measurement of anti-CD20 antibodies and evaluation of B-cells in blood from the breastfed child,,False,
NCT02753088,Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis,"International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC ""BIOCAD"", Russia) and Copaxone®-Teva (""Teva Pharmaceutical Industries Limited"", Israel) in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2013-10,2015-11,2015-11,2021-09-16,2016-04-27,INTERVENTIONAL,PHASE3,158.0,ACTUAL,Biocad,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Equivalence|BCD-063|Copaxone-Teva,,,,0,BCD-063|Copaxone-Teva|Placebo,DRUG|DRUG|DRUG,Cumulative Unique Activity lesions,Annual relapse rate|Proportion of patients without relapses|Changing in volume of hypointense T1 lesions|Changing in volume of T2 lesions|Amount of new or extended lesions in T2 regimen|Patients proportion without lesions|T1 lesions amount|Expanded Disability Status Scale dynamics|Progression on Multiple Sclerosis Functional Composite scale comparing to the baseline|Risk of relapse|Time till the first relapse|Multiple Sclerosis Functional Composite scale dynamics,False,
NCT00067327,Treatment of Multiple Sclerosis Using Over the Counter Inosine,Treatment of Multiple Sclerosis Using Over the Counter Inosine,COMPLETED,2002-02,,2005-09,2006-03-17,2003-08-19,INTERVENTIONAL,PHASE2,30.0,,National Center for Complementary and Integrative Health (NCCIH),NIH,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing remitting multiple sclerosis|Multiple sclerosis|Peroxynitrite|Uric acid|Inosine,United States,Philadelphia,Pennsylvania,1,Inosine,DRUG,,,False,
NCT02544373,CPAP to Treat Cognitive Dysfunction in MS,A Randomized Trial of Positive Airway Pressure Therapy to Treat Cognitive Dysfunction in MS Patients With Obstructive Sleep Apnea,COMPLETED,2015-11-12,2021-06-25,2021-06-25,2022-09-14,2015-09-09,INTERVENTIONAL,NA,135.0,ACTUAL,University of Michigan,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,OSA|Obstructive Sleep Apnea|Cognition|Cognitive Dysfunction|Memory|Positive Aiway Pressure|CPAP|MS,United States,Ann Arbor,Michigan,1,PAP therapy,DEVICE,"Association Between Obstructive Sleep Apnea (OSA) Severity [as Measured by Apnea Hypopnea Index (AHI) e.g., Number of Apneic Events Per Hour of Sleep] and Baseline Performance on the Minimal Assessment of Cognitive Function in MS Battery (MACFIMS)|Change From Baseline in Performance on the Minimal Assessment of Cognitive Function in MS Battery (MACFIMS)",,True,2022-09-14
NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM),COMPLETED,2013-07,2016-02,2016-10,2017-01-27,2014-03-04,OBSERVATIONAL,,40.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis|Clinical Isolated Syndrome (CIS)|Multiple Sclerosis,,Czechia,Brno,,11,interferon beta-1a,DEVICE,Change from baseline to month 4 in injection site tolerability as measured on a composite visual analogue scale (VAS) score ranging from 0-100,"Change from baseline to month 12 in injection site tolerability as measured on a composite VAS score|Change from baseline in the VAS score of systemic tolerability|The percentage of participants still on Avonex Pen|Quality of Life as assessed by the change in Short Form (SF) Health Survey, SF-36 scores|The percentage of missed injections|Change in Fatigue Scale for Motor and Cognitive functions (FSMC) score",False,
NCT00694941,"A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)","A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2008-06,2008-12,,2012-06-13,2008-06-11,INTERVENTIONAL,PHASE2,15.0,ACTUAL,Ono Pharmaceutical Co. Ltd,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS),ONO-2506PO|Amyotrophic Lateral Sclerosis|ALS,Belgium,Brussels,,25,ONO-2506PO,DRUG,Adverse Events|Death|Tracheotomy or permanent assisted ventilation,,False,
NCT02965170,Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS,Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in a Multiple Sclerosis Patient Cohort,COMPLETED,2016-10,2017-12,2018-05,2019-04-24,2016-11-16,OBSERVATIONAL,,109.0,ACTUAL,"Rocky Mountain MS Research Group, LLC",OTHER,Abreos Biosciences,OTHER,Multiple Sclerosis,,United States,Salt Lake City,Utah,1,,,Natalizumab Concentrations in Serum,,False,
NCT01712373,Ginseng in Treatment of Fatigue in Multiple Sclerosis,Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis,COMPLETED,2010-12,2011-04,2011-04,2012-10-23,2012-10-23,INTERVENTIONAL,PHASE2,60.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,,,Fatigue,Multiple sclerosis|Ginseng|Fatigue|Quality of life,Iran,Isfahan,Isfahan,1,Ginseng|Placebo,DRUG|DRUG,Fatigue,Quality Of Life,False,
NCT05229861,The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS,"The Influence of High-Intensity Interval Training Compared to Moderate Continuous Training on Cardiorespiratory Fitness, Symptom Improvement, and Disease-specific Biomarkers in Primary Progressive Multiple Sclerosis",UNKNOWN,2022-05-10,2024-02-29,2024-02-29,2022-06-14,2022-02-08,INTERVENTIONAL,NA,61.0,ESTIMATED,Klinik Valens,OTHER,"Technische Universität Dortmund, Germany",UNKNOWN,Primary Progressive Multiple Sclerosis|Exercise|Cardiorespiratory Fitness,Multiple Sclerosis|Primary Progressive Multiple Sclerosis|Exercise|High-intensity Interval Exercise|Rehabilitation|Cardiorespiratory Fitness|Cognition|Mobility limitation|Quality of Life|Fatigue|Depression|Immune signalling|Inflammation|Kynurenine pathway,Switzerland,Valens,Canton of St. Gallen,1,HIIT|MCT,BEHAVIORAL|BEHAVIORAL,"Cardiorespiratory fitness (peak oxygen consumption, VO2peak)",Peak power output (PPO)|Cognitive performance|Cognitive impairment at baseline|Walking capacity|Physical and psychological Impairment|Fatigue|Anxiety and depressive symptoms|Kynurenine pathway (KP) metabolites|Immune status (blood cells)|Immune status (pro-inflammatory cytokines),False,
NCT05811013,Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis,Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis,RECRUITING,2023-05-27,2025-05-27,2026-05-27,2024-10-16,2023-04-13,INTERVENTIONAL,NA,40.0,ESTIMATED,Neuromed IRCCS,OTHER,,,Progressive Multiple Sclerosis,Progressive Multiple Sclerosis|transcranial Static Magnetic Field Stimulation|disability progression|cortical hyperexcitability|cortical plasticity,Italy,Pozzilli,Isernia,1,Transcranial static magnetic field stimulation (tSMS)|Sham Transcranial static magnetic field stimulation (tSMS),DEVICE|DEVICE,"Functional assessment, that ""change"" is being assessed.","Neurological Assessment, that ""change"" is being assessed.|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neuropsychological and psychometric evaluation|Neurophysiological assessment|blood neurofilament light chain (NFL) levels|Magnetic Resonance Imaging (MRI)|Patients' adherence to tSMS, potential side effects and adverse events",False,
NCT03268239,Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions,Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions,COMPLETED,2017-08-02,2021-04-26,2021-04-26,2021-09-17,2017-08-31,INTERVENTIONAL,NA,180.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Magnetic Resonance Imaging|Central Nervous System|Brain|Multiple Sclerosis|Demyelinating Diseases,,France,Paris,,1,Additional MRI sequences,DEVICE,Number of gadolinium-enhanced brain lesions,,False,
NCT05885282,Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises,Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises on Postural Control in Patients with Ataxic Multiple Sclerosis,COMPLETED,2023-07-27,2024-06-01,2024-08-01,2024-10-02,2023-06-01,INTERVENTIONAL,NA,30.0,ACTUAL,Hacettepe University,OTHER,,,Multiple Sclerosis|Ataxia,Multiple Sclerosis|ataxia|spinal stabilization|local vibration|postural control,Turkey (Türkiye),Ankara,,1,paraspinal vibration|gastrosoleus muscle complex vibration|Control Exercise,DEVICE|DEVICE|OTHER,Expanded Disability Status Scale|International Cooperative Ataxia Rating Scale|Berg Balance Scale|Trunk Impairment Scale|Limits of Stability and Postural Sways|Gait Analysis|Prone Bridge Test|Lateral Bridge Test|Sorensen Test (Trunk Extensor Test)|Trunk Flexors Test,,False,
NCT05007483,Efficacy of Diet on Quality of Life in Multiple Sclerosis,Efficacy of Diet on Quality of Life in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2022-02-10,2026-09-01,2026-12-01,2025-09-12,2021-08-16,INTERVENTIONAL,NA,162.0,ACTUAL,Terry L. Wahls,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",dietary|nutrition|fatigue|quality of life,United States,Iowa City,Iowa,1,BodyBio Balance Oil|Kirunal Fish Oil|BodyBio PC|Modified Paleolithic Elimination diet|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|Usual diet with Dietary Guidelines for Americans Diet information,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH),Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Hospital Anxiety Depression Scale (HADS)|Hospital Anxiety Depression Scale (HADS)|Hospital Anxiety Depression Scale (HADS)|Hospital Anxiety Depression Scale (HADS)|Hospital Anxiety Depression Scale (HADS)|Fatigue Severity Scale score (FSS)|Fatigue Severity Scale score (FSS)|Fatigue Severity Scale score (FSS)|Fatigue Severity Scale score (FSS)|Fatigue Severity Scale score (FSS)|Brain volume as measured by non contrast magnetic resonance imaging (MRI)|Brain lesions as measured by non contrast magnetic resonance imaging (MRI)|Timed 25 foot walk test|Timed 25 foot walk test|9 Hole peg board test|9 Hole peg board test|Low contrast visual acuity|Low contrast visual acuity|Dietary History Questionnaire IIi|Dietary History Questionnaire IIi|Critical flicker fusion|Critical flicker fusion|Ocular Coherence tomography|Ocular Coherence tomography|Ocular Coherence tomography|Neurofilament light chain|Neurofilament light chain|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)|Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH),False,
NCT04030819,Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis,Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis .a Randomized Control Study in 106Persian Patients With Relapsing Remitting Multiple Sclerosis (RRMS),UNKNOWN,2018-12-20,2019-06-18,2019-12-15,2019-07-30,2019-07-24,INTERVENTIONAL,NA,106.0,ACTUAL,Paris Nanterre University,OTHER,Isfahan University of Medical Sciences,OTHER,Anxiety,anxiety|multiple sclerosis|schema therapy,France,Paris,,1,schema therapy,BEHAVIORAL,"changes Anxiety in patient with MS,Beck Anxiety Inventory (BAI)|changes in level of cortisol","changes in depression,Beck Depression Inventory (BDI)|changes quality of life.Multiple sclerosis impact scale - 29 items(MSIS29)|changes in quality of sleep.Pittsburgh Sleep Quality Index (PSQI)|changes in fatigue.Fatigue Severity Scale (FSS)",False,
NCT06933160,Promotion of Exercise Through Physical Therapy for Multiple Sclerosis: A Pilot Study,Promotion of Exercise for Multiple Sclerosis Through Physical Therapy (PromPT),RECRUITING,2025-01-28,2026-05-15,2026-07-31,2025-09-10,2025-04-18,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Michigan,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Shirley Ryan AbilityLab,NIH|OTHER,Multiple Sclerosis,multiple sclerosis|physical activity|exercise|physical therapy,United States,Ann Arbor,Michigan,1,PromPT-MS,BEHAVIORAL,Accelerometer-measured moderate-to-vigorous physical activity,Total physical activity|Fatigue|Physical Function|Exercise Self-efficacy,False,
NCT07006805,RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis,"RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis",NOT_YET_RECRUITING,2025-08,2028-09,2029-10,2025-06-05,2025-06-05,INTERVENTIONAL,PHASE1|PHASE2,12.0,ESTIMATED,Cabaletta Bio,INDUSTRY,,,Relapsing Multiple Sclerosis (RMS)|Progressive Multiple Sclerosis (PMS)|Multiple Sclerosis - Relapsing Remitting|Multiple Sclerosis|Multiple Sclerosis (Relapsing Remitting)|Multiple Sclerosis (MS) - Relapsing-remitting|Progressive Multiple Sclerosis,CABA-201|Rese-cel|autoimmune disease|anti-CD19 CAR-T therapy|cellular therapy|Multiple Sclerosis|Relapsing MS|RRMS|Progressive MS|PPMS|SPMS|Neurology|Resecabtagene autoleucel,,,,0,CABA-201,BIOLOGICAL,Primary (Part A: Dose Escalation) incidence and severity of adverse events|Primary (Part B: Dose Expansion) incidence of and severity of adverse events in order to confirm the dose(s) of CABA-201,Part A and Part B: To evaluate the incidence and severity of adverse events|Part A and Part B: To characterize the pharmacodynamics (PD)|Part A and Part B: To characterize the pharmacokinetics (PK)|Part A and Part B: To evaluate disease related biomarkers|Part A and Part B: To evaluate the effects of CABA-201 on MS disease activity as measured by Magnetic Resonance Imaging (MRI)|Part A and Part B: The effects of CABA-201 on MS disease activity as measured by EDSS|Part A and Part B: To evaluate the effect of CABA-201 on use of subsequent MS-related therapy|Part A and Part B: To evaluate the effect of CABA-201 on patient reported and health outcomes as measured by SF-36 v2,False,
NCT07108920,Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait,Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait: What About the Risk of Falls?,RECRUITING,2025-10-01,2026-08-01,2026-08-01,2025-09-22,2025-08-07,OBSERVATIONAL,,15.0,ESTIMATED,Hopital Nord Franche-Comte,OTHER,,,Botulinum Toxin Injection|Stiff Knee Gait|Fall Risk|Rectus Femoris Muscle|Botox Injection|Spasticity With Multiple Sclerosis,Botulinum toxin injection|Rectus femoris|Balance troubles|Fall risk analysis|Stiff knee gait patients.,France,Héricourt,Nord Franche-Comté,1,Functional clinical tests,OTHER,Time Up and Go test.,Assessment of Berg Balance Scale test.,False,
NCT00675883,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,COMPLETED,2008-05,2011-12,2011-12,2012-01-30,2008-05-12,OBSERVATIONAL,,1000.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Canada,London,Ontario,1,,,Compliance with therapy in the prospective arm|Persistence on therapy between prospective and retrospective arms,Patients' satisfaction with new MSA program,False,
NCT05826431,Cubii for Exercise in People With MS,"Feasibility, Acceptability, and Preliminary Efficacy of Cubii Under-desk Elliptical for Exercise in People With Multiple Sclerosis (PwMS)",COMPLETED,2023-04-19,2023-08-31,2023-12-04,2024-12-03,2023-04-24,INTERVENTIONAL,NA,21.0,ACTUAL,University of Washington,OTHER,,,"Multiple Sclerosis|Fatigue|Activity, Motor|Quality of Life",,United States,Seattle,Washington,1,Cubii elliptical,DEVICE,Average Daily Use|Change in Activity - Godin Leisure Time Exercise Questionnaire|Change in Activity - Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 - Physical Function 20a|Device Utilization,"Change in Quality of Life - Multiple Sclerosis Quality of Life-54 (MSQOL54) Quality of Life Subscale|Change in Pain Intensity - Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Short Form 3a|Change in Pain Interference - Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Scale (Short Form 8b, V1.0)|Change in Fatigue Interference - Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue-Multiple Sclerosis 8a|Change in Depression - Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Depression 8a|Change in Anxiety - Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Anxiety 8a|Change in Fatigue Intensity - Brief Fatigue Inventory (BFI)",True,2024-12-03
NCT05934188,Exploring the Gut-Brain Axis in Ageing and Neurodegeneration,Role of the Gut-microbiota on Ageing and Neurodegeneration: a Clinical and Brain Imaging Study,RECRUITING,2023-05-01,2026-04-30,2026-04-30,2023-07-06,2023-07-06,OBSERVATIONAL,,200.0,ESTIMATED,"IRCCS San Camillo, Venezia, Italy",OTHER,IRCCS Centro San Giovanni di Dio Fatebenefratelli|Università Ca' Foscari Venezia,OTHER|UNKNOWN,Healthy|Prodromal Alzheimer's Disease|Parkinson Disease|Multiple Sclerosis,MRI|Microbiota|Stool sample|Blood sample|Neuropsychological assessment|Neuroimaging|Biomarkers for brain disorders,Italy,Venice-Lido,Venice,3,Magnetic Resonance Imaging|Neuropsychological protocol|Eating habits|Microbiome analyses|Inflammatory markers|Alzheimer's Disease biomarkers,DIAGNOSTIC_TEST|BEHAVIORAL|BEHAVIORAL|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Brain structural and functional properties|Microbiome profile,Cognitive functioning|Concentration of blood inflammatory markers|Eating habits,False,
NCT07025122,Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease,Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease,ENROLLING_BY_INVITATION,2024-01-26,2027-12-31,2028-12-31,2025-06-17,2025-06-17,OBSERVATIONAL,,100.0,ESTIMATED,"University Hospital, Martin",OTHER,Comenius University,OTHER,Fatigue in Multiple Sclerosis|Multiple Sclerosis|Neurofilaments Light Chains|GFAP|HLA DRB 1501|BCL6 (rs969625)|OS9 (rs701006),"fatigue, mitochondriopathy, neurofilaments, GFAP, genetics|intergenic variant near BCL6|intronic variant in OS9",Slovakia,Martin,Slovakia,1,,,"Quantification of fatigue and comparision with sNfL, sGFAP, and mitochondrial activity","Correlation of genetic characteristics, biomarkers, fatigue tests, and mitochondrial status with the disease burden.",False,
NCT05566756,Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies,A Non-interventional Study Evaluating Kesimpta® (Ofatumumab) Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies [KAIROS],COMPLETED,2022-10-28,2025-05-28,2025-05-28,2025-08-27,2022-10-04,OBSERVATIONAL,,307.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|MS|Kesimpta|ofatumumab,Germany,Mannheim,Baden-Wurttemberg,40,Ofatumumab,OTHER,Reasons for recent therapy switch to ofatumumab,Proportion of missed ofatumumab doses|Number of patients by reasons for treatment interruptions|Number of treatment interruptions per patient|Duration of treatment interruptions per patient|Proportion of patient subgroups with and without 100% adherence depending on different characteristics|Proportion of patients permanently discontinuing ofatumumab during the study by reason for discontinuation|Proportion of patients permanently discontinuing ofatumumab during the study by planned next DMT|Change on Multiple Sclerosis Impact Scale 29 (MSIS-29) as compared to baseline in general and depending on reasons for treatment switch|Treatment Satisfaction Questionnaire for Medication (TSQM) 1.4 as compared to baseline in general and depending on reasons for treatment switch|Fatigue Scale for Motor and Cognitive Functions (FSMC) compared to baseline in general and depending on reasons for treatment switch|Percentage of patients with no clinical evidence of disease activity (NEDA)|Proportion of patients demonstrating the individual NEDA-3 components|The proportion of subjects discontinuing treatment due to insufficient effectiveness (lack of effectiveness) or tolerability/safety reasons|Number of participants with injection related AEs,False,
NCT06837675,Effect of High Tone Power Therapy on Bladder Disturbance,Effect of High Tone Power Therapy on Bladder Disturbance in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-02,2026-01,2026-03,2025-02-20,2025-02-20,INTERVENTIONAL,NA,40.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,overactive bladder,Egypt,Cairo,Cairo Governorate,1,high tone power therapy|selected physical therapy program,DEVICE|OTHER,over active bladder symptom score (OABSS)|Urodynamic study|MS bladder check tool|The international Consultation on Incontinence Questionnaire Short Form (ICIQ-UI),,False,
NCT03963375,Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis,Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis,COMPLETED,2019-10-28,2025-05-27,2025-05-27,2025-06-11,2019-05-24,INTERVENTIONAL,PHASE4,47.0,ACTUAL,Washington University School of Medicine,OTHER,EMD Serono,INDUSTRY,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",,United States,St Louis,Missouri,5,Cladribine,DRUG,Changes in the CSF levels of lymphocyte subtypes and markers of neuronal injury during treatment with cladribine tablets in patients with RMS,,False,
NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,"A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy",COMPLETED,2022-04-13,2024-04-08,2025-07-14,2025-09-04,2021-08-10,INTERVENTIONAL,PHASE4,70.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,"PPD Development, LP|Laboratory Corporation of America|Illingworth Research Group",INDUSTRY|INDUSTRY|UNKNOWN,Multiple Sclerosis|Clinically Isolated Syndrome,"ocrelizumab, OCREVUS, placental transfer, pregnancy",United States,San Francisco,California,12,Ocrelizumab,DRUG,Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN),"Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy|Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy|Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth|Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life|Serum Concentration of Ocrelizumab in the Mother|Percentage of Infants With Adverse Events|Percentage of Mothers With Adverse Events|Infant Characteristics at Birth: Body Weight|Infant Characteristics at Birth: Head Circumference|Infant Characteristics at Birth: Body Length|Percentage of Pregnancies Resulting in Live Births, Therapeutic Abortions, or Stillbirth|Mean Titers of Antibody Immune Responses to Measles, Mumps, and Rubella (MMR) Vaccination|Percentage of Infants With Positive Humoral Response to MMR Vaccination|Mean Titers of Antibody Immune Responses to Diphtheria-Tetanus-Pertussis (DTP) Vaccine|Percentage of Infants With Positive Humoral Response to DTP Vaccine|Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccine|Percentage of Infants With Positive Humoral Response to Hib Vaccine|Mean Titers of Antibody Immune Responses to Hepatitis B Vaccine (HBV)|Percentage of Infants With Positive Humoral Response to HBV|Mean Titers of Antibody Immune Responses to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)|Percentage of Infants With Positive Humoral Response to PCV-13",True,2025-05-22
NCT01057719,Climate Influence on Physiotherapy in Multiple Sclerosis,Climate Influence on Physiotherapy in Multiple Sclerosis,COMPLETED,2006-06,2008-05,2008-05,2010-01-27,2010-01-27,INTERVENTIONAL,NA,60.0,ACTUAL,Haukeland University Hospital,OTHER,"Oslo University Hospital|University Hospital, Akershus|University of Bergen",OTHER|OTHER|OTHER,Multiple Sclerosis,cross-over design|mixed model|multiple sclerosis|physical performance measures|physical therapy|the Bobath concept|warm climate|6-minute walk test,Norway,Bergen,,1,Physiotherapy,OTHER,6-minute walk test,"Timed Up&Go|10-metre timed walk|Berg Balance Scale|Trunk Impairment Scale|Borg's Rating of Perceived Exertion|Multiple Sclerosis Impact Scale (MSIS-29)|Fatigue Severity Scale|Numerical Rating Scale; gait, balance, pain|Modified Health Assessment Questionnaire|Patient Global Impression of Change",False,
NCT00223457,Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis,Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis,COMPLETED,2004-04,,2005-09,2007-01-25,2005-09-22,OBSERVATIONAL,,1040.0,,University of Texas Southwestern Medical Center,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,multiple sclerosis|compliance|adherence|disease modifying therapy|depression|hope|quality of life,United States,Dallas,Texas,1,Factors that influence compliance,BEHAVIORAL,,,False,
NCT06405451,Respiratory Muscle Training Program in Patients With Multiple Sclerosis,Pilot Experimental Study on the Impact of a Respiratory Muscle Training Program in Patients With Multiple Sclerosis,COMPLETED,2024-04-09,2024-07-01,2024-12-31,2025-06-10,2024-05-08,INTERVENTIONAL,NA,27.0,ACTUAL,Universidad Europea de Madrid,OTHER,Fundación Madrid contra la Esclerosis Múltiple (FEMM)|Sanitas,UNKNOWN|UNKNOWN,Multiple Sclerosis|Respiration Disorders,multiple sclerosis|treatment|trunk disorder|balance|respiratory function,Spain,Villaviciosa de Odón,Madrid,1,Conventional treatment|Experimental treatment,OTHER|OTHER,Pulmonary function|Respiratory muscle strength|Abdominal and diaphragmatic muscle structure|Trunk control|Balance|Gait and transfer capacity,Therapeutic adherence,False,
NCT03646929,Motor Evoked Potentials With Modified Facilitation Technique,Motor Evoked Potentials With Modified Facilitation Technique: Normative Data and Reliability in Healthy Individuals and Comparison of Sensitivity and Specificity With Standard Technique in Patients With Multiple Sclerosis,COMPLETED,2017-12-20,2019-01-15,2019-01-15,2021-05-05,2018-08-24,INTERVENTIONAL,NA,81.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,facilitation technique|multimodal evoked potentials (mmEP) in multiple sclerosis|motor evoked potential (MEP) in multiple sclerosis,Switzerland,Basel,,1,MEP using standard facilitation technique|MEP using modified facilitation technique,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Change in Test- Re-Test reliability when using modified facilitation technique (compared to standard facilitation technique) in healthy individuals|comparison of sensitivity and specificity of modified facilitation technique and standard facilitation technique in patients with multiple sclerosis,,False,
NCT00420719,Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),Multi-Center Pivotal Study of Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS),UNKNOWN,2004-10,2009-10,2009-10,2009-03-18,2007-01-11,INTERVENTIONAL,NA,100.0,ESTIMATED,Synapse Biomedical,INDUSTRY,University Hospitals Cleveland Medical Center|Johns Hopkins University|Stanford University,OTHER|OTHER|OTHER,Amyotrophic Lateral Sclerosis (ALS),ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's disease|Diaphragm for Ventilatory Assist|Diaphragm Pacing,United States,San Francisco,California,8,Intramuscular diaphragm electrodes,DEVICE,"The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months",Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.,False,
NCT02104661,Protective Role of Oxcarbazepine in Multiple Sclerosis,OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial,COMPLETED,2014-10,2018-01-31,2018-01-31,2018-04-18,2014-04-04,INTERVENTIONAL,PHASE2,30.0,ACTUAL,Queen Mary University of London,OTHER,"National Multiple Sclerosis Society|Novartis Pharmaceuticals|Barts & The London NHS Trust|University College, London|Royal Free Hospital NHS Foundation Trust|Mid and South Essex NHS Foundation Trust|St George's Healthcare NHS Trust|Barnet and Chase Farm Hospitals NHS Trust",OTHER|INDUSTRY|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,,United Kingdom,London,,1,Oxcarbazepine|Placebo,DRUG|DRUG,Relative reduction of CSF neurofilament light chain levels,Safety of Oxcarbazepine in multiple sclerosis patients|Relative reduction of CSF neurofilament levels|Change in clinical outcome measured by neurological examination.|Change in clinical outcome measured by cognitive assessment|Change in patient reported outcomes measured by questionnaires,False,
NCT02739542,Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS),"Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)",COMPLETED,2016-03-19,2021-03-31,2021-03-31,2022-05-11,2016-04-15,INTERVENTIONAL,PHASE4,87.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,Biogen,INDUSTRY,Multiple Sclerosis (MS),Radiologically Isolated Syndrome (RIS),United States,Los Angeles,California,11,Tecfidera|Placebo,DRUG|DRUG,The Time From Randomization to the First Demyelinating Event (Acute or Development of an Initial Symptom Resulting in a Progressive Clinical Course),Change in Lesion Volume on T2-weighted MRI|Number of Newly Enlarging T2 Lesions|Number of New T2 Lesions|Newly Enlarging T2 Lesions and New T2 Lesions Combined|Number of Contrast Enhancing Lesions|Change in the Number of Participants With Brain Atrophy,True,2022-05-11
NCT05110586,"Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis","The Effect of Different Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis Patients",COMPLETED,2022-05-01,2022-08-15,2022-08-30,2022-11-15,2021-11-08,INTERVENTIONAL,NA,30.0,ACTUAL,Kahramanmaras Sutcu Imam University,OTHER,,,Multiple Sclerosis,pain|functional capacity|Quality of life|electrotherapy,Turkey (Türkiye),Kahramanmaraş,,1,Electrotherapy,OTHER,The Visual Analog Scale (VAS)|Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain questionnaire,2 min walk test|Multiple Sclerosis International Quality of Life Questionnaire,False,
NCT01071694,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,WITHDRAWN,2011-01,2012-12,2012-12,2012-04-16,2010-02-19,OBSERVATIONAL,,0.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis,|Relapsing-Remitting,|Interferon beta-1b,|Quality of life",South Korea,Many Locations,,1,"Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)",DRUG,Quality of life evaluated by several validated questionnaire,Information about safety of Betaferon in routine clinical use,False,
NCT01091727,Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity,Prospective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple Sclerosis,COMPLETED,2006-10,2009-04,2009-04,2010-03-24,2010-03-24,INTERVENTIONAL,PHASE3,57.0,ACTUAL,Sunnybrook Health Sciences Centre,OTHER,ethica Clinical Research Inc.,INDUSTRY,Neurogenic Detrusor Overactivity,Neurogenic|Detrusor|Overactive|Overactivity|Bladder|Spinal|Cord|Injury,Canada,Toronto,Ontario,1,Botulinum toxin A,DRUG,Efficacy,Efficacy,False,
NCT02340754,Mindfulness-based Stress Reduction for Multiple Sclerosis,,COMPLETED,2015-05,2017-05-30,2017-05-30,2018-04-09,2015-01-19,INTERVENTIONAL,NA,67.0,ACTUAL,National University of Natural Medicine,OTHER,National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH),NIH|NIH,Multiple Sclerosis,"mindfulness|meditation|stress, psychological|quality of life|randomized controlled trial",United States,Portland,Oregon,1,Mindfulness-based Stress Reduction|MS Education Control,BEHAVIORAL|BEHAVIORAL,"Recruitment: Number of participants enrolled over a ten-month period|Adherence to Mindfulness-based Stress Reduction (MBSR): Number of Participants who are present for at least 5 of the classes, including the final class, and complete at least 70% of homework.|Adoption: Qualitative assessment of facilitators of and barriers to participation in the MBSR program.|Completion: Number of participants with complete follow-up at 12 months post-intervention.",Change from baseline in Perceived Stress Scale at 8 weeks|Change in Perceived Stress Scale from 8 weeks to 12 months|Change from baseline in Short Form-36 Mental Health Subscale to 8 weeks|Change in Short Form-36 Mental Health Subscale from 8 weeks to 12 months|Change in baseline Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Score to 8 weeks|Change in PROMIS Anxiety Score from 8 weeks to 12 months|Change in baseline PROMIS Depression Score to 8 weeks|Change in PROMIS Depression Score from 8 weeks to 12 months|Change in baseline PROMIS Fatigue Score to 8 weeks|Change in PROMIS Fatigue Score from 8 weeks to 12 months|Change in baseline PROMIS Pain Score to 8 weeks|Change in PROMIS Pain Score from 8 weeks to 12 months,False,
NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,"A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS",COMPLETED,2019-03-13,2021-03-11,2021-03-30,2023-12-04,2019-01-10,INTERVENTIONAL,PHASE2,23.0,ACTUAL,Brainstorm-Cell Therapeutics,INDUSTRY,,,"Multiple Sclerosis, Chronic Progressive",,United States,Los Angeles,California,4,NurOwn (MSC-NTF cells),BIOLOGICAL,Number of Participants With Treatment-emergent Adverse Events,"Number of Participants With 25% or Greater Improvement From Baseline in Time 25 Foot Walk (T25FW) Speed or Nine-Hole Peg Test (9-HPT)|Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in Timed 25 Foot Walk (T25FW) Speed|Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in 9-HPT|Number of Participants Who Had >5.5 in Expanded Disability Status Scale (EDSS) at Baseline, With ≥0.5 Points Improvement From Baseline to Week 28|Number of Participants With ≥10 Points Improvement From Baseline to Week 28 in Multiple Sclerosis Walking Scale (MSWS-12)|Number of Participants With ≥8 Letter Improvement From Baseline to Week 28 in LCLA Binocular 2.5% Contrast Level|Number of Participants With ≥ 3 Points Improvement From Baseline to Week 28 in Symbol Digit Modalities Test (SDMT) Score|Change in Concentration of Vascular Endothelial Growth Factor (VEGF) Neuroprotective Biomarker From Baseline in the Cerebrospinal Fluid (CSF) 16 Weeks Following First NurOwn® Treatment|Change in Concentration of Hepatocyte Growth Factor (HGF) Neuroprotective Biomarker From Baseline in the Cerebrospinal Fluid (CSF) 16 Weeks Following NurOwn® Treatment",True,2022-11-14
NCT03151941,Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study,A Feasibility Study Monitoring the Respiratory Status of Participants Receiving or Scheduled to Receive Intrathecal Baclofen (ITB),COMPLETED,2017-03-06,2017-08-31,2017-08-31,2017-10-10,2017-05-12,OBSERVATIONAL,,15.0,ACTUAL,Solent NHS Trust,OTHER_GOV,,,Intrathecal Baclofen|Multiple Sclerosis|Respiratory System|Cerebral Palsy,,United Kingdom,Portsmouth,Hampshire,1,,,Overnight home polysomnography,Sniff nasal inspiratory pressure Expiratory and inspiratory mouth pressures Cough peak flow Expanded disability status scale Epworth sleepiness scale Semi Structured interview,False,
NCT01628315,Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study,Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study,COMPLETED,2009-03,2009-03,2014-12,2016-02-12,2012-06-26,OBSERVATIONAL,,159.0,ACTUAL,University at Buffalo,OTHER,"Charles University, Czech Republic|General University Hospital, Prague",OTHER|OTHER,"Multiple Sclerosis, Relapsing-remitting",Multiple Sclerosis|ASA|MRI|Lesion activity,United States,Buffalo,New York,1,MRI,DEVICE,Lesion Activity,,False,
NCT01414725,Core Stability Training in Multiple Sclerosis,Core Stability Training in Ambulant Individuals With Multiple Sclerosis: a Multi-centre Randomised Controlled Trial.,COMPLETED,2011-08,2013-07,2013-07,2014-03-24,2011-08-11,INTERVENTIONAL,NA,100.0,ACTUAL,University of Plymouth,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Mobility|Balance|Core Stability|Physiotherapy,United Kingdom,St Austell,Cornwall,7,Standard Physiotherapy Exercises|Core Stability Training|Relaxation,OTHER|OTHER|OTHER,Change in 10 metre timed walk (10MTW),"Change in Functional Reach - forwards and lateral|Change in Visual Analogue Scale (10 point) to determine ""Difficulty in carrying a drink when walking"".|Change in Activities-specific Balance Confidence (ABC) Scale|Change in Multiple Sclerosis 12-item Walking Scale",False,
NCT05605782,"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety",ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study),ACTIVE_NOT_RECRUITING,2021-09-02,2033-07-26,2033-07-26,2025-06-26,2022-11-04,OBSERVATIONAL,,9000.0,ACTUAL,Bristol-Myers Squibb,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing-Remitting Multiple Sclerosis|Ozanimod|Serious opportunistic infections|Serious acute liver injury|Malignancy|Macular edema,United States,Bethesda,Maryland,1,,,"Incidence of major adverse cardiovascular events (MACE)|Incidence of serious opportunistic infection (SOI)|Incidence of serious acute liver injury (SALI)|Incidence of macular edema|Identified rate of malignancies identified based upon the presence of at least 1 international classification of diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code",Incidence of symptomatic bradycardia|Incidence of progressive multifocal leukoencephalopathy (PML)|Incidence of posterior reversible encephalopathy syndrome (PRES),False,
NCT02860494,Topical Everolimus in Patients With Tuberous Sclerosis Complex,"Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus.",WITHDRAWN,2020-12,2023-12,2024-12,2021-05-03,2016-08-09,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,Hospices Civils de Lyon,OTHER,,,Facial Angiofibromas,Tuberous sclerosis complex (TSC)|topical everolimus|seamless design|dose-escalation study|m-TOR inhibitor,France,Bron,,1,Everolimus|Placebo,DRUG|DRUG,Facial Angiofibroma Severity Index (FASI),FA size|Dermatologist's global assessment of efficacy|Patient or parents self-assessment|Local tolerance of the topically applied formulation using patient self-assessment|blood levels of topically applied everolimus|dryness score|scaling scores|Dermatological quality of life,False,
NCT03949296,Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis,"A Randomized, Placebo-Controlled Study of Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis",COMPLETED,2017-12-11,2019-12-16,2019-12-16,2020-02-26,2019-05-14,INTERVENTIONAL,NA,49.0,ACTUAL,Griffin Hospital,OTHER,Yale-Griffin Prevention Research Center|Yale University- Stress Center,OTHER|UNKNOWN,Insomnia Chronic|Multiple Sclerosis,,United States,Derby,Connecticut,1,Mindfulness Intervention|Sleep Hygiene,BEHAVIORAL|BEHAVIORAL,Sleep Quality,Self-Reported Sleep Quality|Self-Reported Quality of Life,False,
NCT05441488,Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis,"A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse",ACTIVE_NOT_RECRUITING,2022-06-28,2028-12,2028-12,2025-09-12,2022-07-01,INTERVENTIONAL,PHASE3,800.0,ESTIMATED,AB Science,INDUSTRY,,,Progressive Multiple Sclerosis,Primary progressive MS|Non-active secondary progressive MS|Tyrosine kinase inhibitor|PPMS|SPMS,France,Créteil,,37,Placebo|Masitinib (4.5),DRUG|DRUG,Time to confirmed progression,Time to Expanded Disability Status Scale (EDSS) score of 7.0|Overall Change in Expanded Disability Status Scale (EDSS) Score|Brain Magnetic Resonance Imaging Assessments|Multiple Sclerosis Quality of Life (MSQOL)-54,False,
NCT00463710,Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS,Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With Relapsing-remitting and Secondary-progressive Multiple Sclerosis,COMPLETED,2005-06,,2006-09,2020-12-28,2007-04-20,OBSERVATIONAL,,150.0,,State University of New York at Buffalo,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,"MTI, DWI, Avonex, MRI",United States,Buffalo,New York,1,Avonex® monotherapy (6.0 MIU administered i.m. each week),DRUG,,,False,
NCT01767779,Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC,Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC,COMPLETED,2012-09,2016-12,2018-12,2019-04-11,2013-01-14,OBSERVATIONAL,,40.0,ESTIMATED,University of Alabama at Birmingham,OTHER,"Children's Hospital Medical Center, Cincinnati|The University of Texas Health Science Center, Houston|University of California, Los Angeles|Boston Children's Hospital",OTHER|OTHER|OTHER|OTHER,Tuberous Sclerosis Complex,Epilepsy|TSC|Tuberous Sclerosis Complex|Infants|Seizures|Biomarkers|EEG,United States,Birmingham,Alabama,5,,,Identification of EEG biomarkers as predictors of developing epilepsy in infants with Tuberous Sclerosis Complex,,False,
NCT04907305,Next-Gen MS: Feed-forward PRO Data for MS Research,"Next-Gen MS: A Prospective, Cluster-randomized Study Evaluating the Impact of ""Feed-forward"" Patient Reported Outcomes Data to Clinical Teams Managing Adults Living With MS in a Learning Health System for MS Research",TERMINATED,2021-11-02,2024-02-19,2024-02-19,2024-06-06,2021-05-28,OBSERVATIONAL,,1594.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,,,Multiple Sclerosis (MS),Multiple Sclerosis|Patient Reported Outcomes|Patient Determined Disease Steps|Learning Healthcare System,United States,Birmingham,Alabama,8,,,Change From Baseline in Health-Related Quality of Life 14 Item (HR-QoL-14),Percentage of Participants with >=1-point Increase from Baseline in Patient Determined Disease Steps (PDDS) Sustained Via Consecutive Measures Over 3 Months,False,
NCT01466322,"A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.","An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers",COMPLETED,2010-12-22,2011-02-15,2011-02-15,2017-07-07,2011-11-07,INTERVENTIONAL,PHASE1,16.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Healthy volunteers|GSK2018682|Pharmacokinetics|Relapsing Remitting Multiple Sclerosis|Pharmacodynamics,Australia,Herston,Queensland,1,GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state,DRUG,To assess the pharmacokinetics of different oral formulations of GSK2018682 in healthy volunteers,To investigate the effect of food on the pharmacokinetic parameters of the CD3 tablet formulation of GSK2018682|Evaluate the effect of different oral formulations of GSK2018682 on lymphocytes in healthy volunteers|To investigate the safety and tolerability of different oral formulations of GSK2018682 in healthy volunteers (males and females of non childbearing potential),False,
NCT02587195,A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period,"A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period",COMPLETED,2015-12-18,2020-08-31,2021-08-31,2023-03-22,2015-10-27,INTERVENTIONAL,PHASE3,5.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,Multiple Sclerosis,France,Besançon,,5,Teriflunomide,DRUG,Adverse event reporting|Adverse Events That Are Related to Treatment,Conversion based on MRI|Conversion based on Clinical evaluation|Conversion based on annualized relapse rate (ARR)|volume of abnormal brain tissue on MRI|Disability progression defined as a 1.0-point increase in EDSS score|Proportion of disability-free subjects as assessed by the EDSS|Fatigue Impact Scale|Quality of life using SF-36,False,
NCT01487096,Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,COMPLETED,2001-04,2003-03,2003-03,2012-10-04,2011-12-07,INTERVENTIONAL,PHASE2,179.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,Canada,Toronto,Ontario,2,Teriflunomide|Placebo (placebo for teriflunomide),DRUG|DRUG,MRI assessment: number of unique active lesions per scan (T2/proton density and gadolinium-enhanced T1 scan analysis)|Overview of Adverse Events [AE],MRI assessment: number of T1-enhancing lesions per scan|MRI assessment: number of T2-lesions per scan|MRI assessment: Number of participants with no new lesions|MRI assessment: Change from baseline in T2 burden of disease|Number of participants with progression on Expanded Disability Status Scale [EDSS]|Number of participants with MS relapse confirmed by Scripps Neurological Rating Scale [NRS] and EDSS scores.,False,
NCT06370403,Effects of Head and Neck Cooling and Heating on Fatigue in Multiple Sclerosis and Healthy Men,"Effects of Head and Neck Cooling and Heating on Central and Peripheral Fatigue, Motor Accuracy and Blood Markers of Stress in Multiple Sclerosis and Healthy Men",COMPLETED,2014-02-04,2016-03-01,2017-01-08,2024-04-19,2024-04-17,INTERVENTIONAL,NA,40.0,ACTUAL,Lithuanian Sports University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Cooling|Heating|Fatigue|Exercise,Lithuania,Kaunas,,1,Cooling of the head and neck|Heating of the head and neck,OTHER|OTHER,Body weight (kg)|Body fat (%)|Body free fat mass (kg)|Body mass index (kg/m2)|Change in muscle temperature (°C)|Change in plasma cortisol (nmol/L) concentrations|Change in plasma dopamine (nmol/L) concentrations|Change in plasma prolactin (ng/mL) concentrations|Change in subjective rating of perceived exertion|Change in muscle activity (mV)|Change in muscle activity (Hz)|Change in voluntary torque (Nm)|Change in involuntary torque (Nm)|Change in muscle contraction and relaxation (ms)|Change in central activation ratio (percent)|Change in constant error|Change in absolute error,Height (m),False,
NCT05760651,Awareness of Osteoporosis in Multiple Sclerosis Patients,Assessing Osteoporosis Awareness and Knowledge Levels In Turkish Multiple Sclerosis Patients: An Observational Study,COMPLETED,2023-10-10,2023-12-01,2023-12-10,2024-04-26,2023-03-08,OBSERVATIONAL,,325.0,ACTUAL,Uskudar State Hospital,OTHER_GOV,,,Multiple Sclerosis|Osteoporosis|Osteoporosis Risk,,Turkey (Türkiye),Istanbul,Sancaktepe,1,Patient Participation Form|Timed up - and - go test,OTHER|DIAGNOSTIC_TEST,Revised Osteoporosis Knowledge Test Scores|Osteoporosis Awareness Scale Scores,"Correlation between the level of knowledge and awareness regarding osteoporosis with gender, education levels, and fall risks",False,
NCT01647880,MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study),Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis,TERMINATED,2013-07,2016-04,2016-04,2021-07-29,2012-07-24,INTERVENTIONAL,PHASE2|PHASE3,15.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,"NeuroCure Clinical Research Center, Charite, Berlin",OTHER,Multiple Sclerosis,,Germany,Berlin,,2,Verum arm receiving Gilenya®|Active Comparator receiving Extavia®,DRUG|DRUG,Efficacy parameters,Efficacy parameters,False,
NCT04450030,Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis,Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action,UNKNOWN,2018-08-01,2020-09-05,2020-12-31,2020-11-12,2020-06-29,OBSERVATIONAL,,204.0,ESTIMATED,University Hospital Muenster,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",immunoadsorption|intravenous methyl prednisolone,Germany,Münster,North Rhine-Westphalia,1,Methyl Prednisolonate|Immunoadsorption,DRUG|PROCEDURE,Expanded disability status scale (EDSS),"visual-evoked potentials (VEP; P100-latency)|somatosensory-evoked potentials (SEP; Medianus and Tibialis; N20-, P40-latency)|best-corrected visual acuity (bcVA)|Expanded disability status scale (EDSS)|Multiple scleroris functional compositie (MSFC)|Short form-36 questionaire (SF-36)",False,
NCT05641714,The Reliability and Validity of the L-test in Patients With Multiple Sclerosis,The Reliability and Validity of the L-test in Patients With Multiple Sclerosis,COMPLETED,2022-12-15,2023-01-16,2023-01-16,2023-02-23,2022-12-08,OBSERVATIONAL,,68.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,L test|multiple sclerosis|functional mobility|reliability|validity,Turkey (Türkiye),Ankara,,1,L test|Timed Up and Go test|10 meter walk test|Six Minute Walk Test|The timed 360° turn test,OTHER|OTHER|OTHER|OTHER|OTHER,L test|L test-second assessment,Timed Up and Go test|10 meter walk test|6 minute walk test|the timed 360° turn test,False,
NCT02598167,Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition,Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis,COMPLETED,2015-12-07,2016-02-23,2016-02-23,2017-10-25,2015-11-05,OBSERVATIONAL,,223.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Spain,Sant Joan Despí,Barcelona,18,,,Percentage of Participants with Serious Adverse Events (Severe Life-Threatening or Less Severe)|Percentage of Participants With DMT Administration Schedule Preferences|Percentage of Participants With DMT Route of Administration Preferences|DMT Efficacy Based on Annualized Relapse Rate,Participants Education Level|Participants Employment Status|Participants RRMS Disease Duration|Number of Relapses of RRMS in Last 2 Years|Duration since Last Relapse of RRMS|Participants Current DMT for RRMS|Number of Previous DMTs Taken Prior to Switch to Current DMT|Expanded Disability Status Scale (EDSS) Score|Health-Related Quality of Life Assessment Using Euro-Quality of Life 5 Dimension Questionnaire (EQ-5D) Scale Score|Participant's Role in Decision Making measured by the Shared Decision Making Questionnaire 9-item version (SDM-Q-9) Score|Cognitive performance as measured by the Medical Outcomes Study Cognitive Functioning Scale (MOS Cog-R) Score,False,
NCT05676099,TSC Biosample Repository and Natural History Database,TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database,RECRUITING,2016-01,2050-12,2050-12,2025-07-08,2023-01-09,OBSERVATIONAL,,5000.0,ESTIMATED,National Tuberous Sclerosis Association,OTHER,,,Tuberous Sclerosis|Lymphangioleiomyomatosis,,United States,Birmingham,Alabama,24,Phlebotomy|Buccal (cheek) swab|Genetic Testing|Tissue donation after routine clinical procedure,PROCEDURE|PROCEDURE|GENETIC|OTHER,"Natural History data and biosamples including blood, tissue, or other types of biological samples from individuals with TSC",,False,
NCT02040298,Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis,"A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis",COMPLETED,2014-01,2015-09,2016-04,2025-09-17,2014-01-20,INTERVENTIONAL,PHASE2,50.0,ACTUAL,"University of California, San Francisco",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,San Francisco,California,1,Clemastine|Placebo,DRUG|DRUG,Full Field Visual Evoked Potential (VEP),Tolerability of Clemastine in Multiple Sclerosis (MS) Patients|Myelin Water Fraction (MWF) and Magnetization Transfer Ratios (MTR)|Expanded Disability Status Scale (EDSS) Score,True,2021-07-15
NCT03206034,Stylistic Memory Enhancement,Stylistic Memory Enhancement,COMPLETED,2013-03-01,2015-12-31,2015-12-31,2017-07-02,2017-07-02,INTERVENTIONAL,NA,20.0,ACTUAL,Kessler Foundation,OTHER,,,Multiple Sclerosis,Memory|Cognition,,,,0,Stylistic Memory Enhancement,BEHAVIORAL,California Verbal Learning Test (CVLT-II- Total learning,Memory Functioning Questionnaire,False,
NCT06219304,Effect of High Intensity Training on Motor and Cognitive Functions,Evaluation of the Impact of Experimentally Induced Fatigability on Motor and Cognitive Functions. Effect of High Intensity Training on Motor and Cognitive Functions:a Pilot Randomized Controlled Trial,RECRUITING,2023-09-01,2025-12-31,2025-12-31,2025-07-08,2024-01-23,INTERVENTIONAL,NA,30.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,Ente Ospedaliero Ospedali Galliera|Fondazione Italiana Sclerosi Multipla,OTHER|OTHER,Multiple Sclerosis,fatigue|balance,Italy,Milan,MI,1,Multimodal functional training|Usual care,OTHER|OTHER,difference in walking velocity during the fatiguing walking test,gait asymmetry and gait regularity|Antero-posterior and medio-lateral accelerations in stabilometric tasks|Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS),False,
NCT04750733,Impact of Core Performance on Functional Parameters in Multiple Sclerosis,Impact of Core Performance on Functional Parameters in Multiple Sclerosis,COMPLETED,2021-02-20,2022-07-01,2022-07-05,2022-07-08,2021-02-11,OBSERVATIONAL,,50.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Multiple sclerosis|core stability|postural control|isokinetic strength|physical capacity|fatigue,Turkey (Türkiye),Istanbul,,1,Assessment,OTHER,Core strength|Core endurance|Postural sway|İsokinetic strength,Physical capacity|Mobility|Fatigue,False,
NCT02633033,Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse,A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse,COMPLETED,2015-11-24,2019-05-09,2019-05-09,2019-12-09,2015-12-17,OBSERVATIONAL,,160.0,ACTUAL,Mallinckrodt,INDUSTRY,Mallinckrodt ARD Inc.,UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing-Remitting|Acthar|Corticotropin|MS,United States,Homewood,Alabama,38,,,"Physical subscale score of the Multiple Sclerosis Impact Scale, v.1 (MSIS-29v1)",Physical subscale score of the MSIS-29v1 within 6 months|Psychological subscale score of the MSIS-29v1 within 6 months|Score on the Expanded Disability Status Scale/Functional System Score (EDSS/FSS)|Clinical Global Impression of Improvement Scale (CGI-I)|Total score of the MSIS-29v1 within 6 months|Number of participants with treatment response based on the MSIS-29v1 physical subscale score|Number of participants with treatment response based on the EDSS|Percent of normal work hours missed (absenteeism) due to MS exacerbation|Number of participants with impairment at work and/or reduced on-the-job effectiveness (presenteeism) due to MS exacerbation|Number of participants with overall Impairment at Work (absenteeism + presenteeism) due to MS exacerbation|Number of participants with Impairment in activities other than work due to MS exacerbation|Number of days per month an unpaid caregiver missed work due to the patient's MS|Number of MS-related off-site clinical/office visits with a specialist or a general practitioner|Number of MS-related healthcare professional visits at home|Number of MS-related emergency department visits|Number of MS-related hospitalizations|Number of MS-related MRIs|Number of days per month of MS-related paid and unpaid caregiver assistance,False,
NCT05183152,Non-invasive BCI-controlled Assistive Devices,Non-invasive Brain-computer Interfaces for Control of Assistive Devices,RECRUITING,2021-06-16,2025-12-30,2025-12-30,2025-04-02,2022-01-10,INTERVENTIONAL,NA,100.0,ESTIMATED,University of Texas at Austin,OTHER,,,Motor Disorders|Healthy|Spinal Cord Injuries|Muscular Diseases|Motor Neuron Disease|Stroke|Traumatic Brain Injury|Movement Disorders|Multiple Sclerosis,"motor deficits|able-bodied, healthy|unilateral and bilateral stroke|spinal cord injury|motor neuron diseases|muscular diseases (i.e. myopathy)|traumatic or neurological pain|movement disorders",United States,Austin,Texas,1,NMES Feedback|Visual Feedback|TESS,DEVICE|DEVICE|DEVICE,Change in the BCI command delivery performance|Change in the focality and Strength of SMR Modulation,Stability of Motor Imagery features|Separability of Motor Imagery features|Changes in motor-evoked potential amplitude|Changes in electroencephalography functional connectivity|Change in focality of fMRI activation for different imagined movements|More discriminable fMRI activations for different imagined movements,False,
NCT05826028,Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo,Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo,COMPLETED,2020-07-09,2022-04-20,2022-04-20,2023-04-24,2023-04-24,OBSERVATIONAL,,368.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Secondary Progressive Multiple Sclerosis,,Australia,Camperdown,New South Wales,2,,,Average time for siponimod onboarding,Time to siponimod onboarding in pre-specified sub-groups|Percentage of patients who adhered to the titration protocol|Time on maintenance therapy,False,
NCT06274671,Glymphatic MRI in Clinically Isolated Syndrome,"A Pilot Study to Investigate Glymphatic System Alterations in Vivo in Patients With Clinically Isolated Syndrome, Using Magnetic Resonance Imaging",RECRUITING,2024-05-01,2025-05-15,2025-05-15,2024-07-15,2024-02-23,OBSERVATIONAL,,30.0,ESTIMATED,University of Exeter,OTHER,,,Clinically Isolated Syndrome,Clinically Isolated Syndrome|Multiple Sclerosis|Glymphatic System|Neuroimaging,United Kingdom,Exeter,,2,Magnetic Resonance Imaging,OTHER,To determine that patients with CIS display alterations of the glymphatic system visible in vivo by Structural MRI|To determine that patients with CIS display alterations of the glymphatic system visible in vivo by microstructural MRI|To determine that patients with CIS display alterations of the glymphatic system visible in vivo by diffusion-weighted MRI|To determine that patients with CIS display alterations of the glymphatic system visible in vivo by perfusion-MRI|To determine that patients with CIS display alterations of the glymphatic system visible in vivo by ALS-MRI,To correlate in vivo measures of altered glymphatic system with MRI measures of structural integrity in CIS|To correlate in vivo measures of altered glymphatic system with MRI measures of disease activity in CIS|To correlate in vivo measures of altered glymphatic system with MRI measures of enlarged Wirchow-Robin spaces in CIS|To correlate in vivo measures of altered glymphatic system with MRI measures of microstructural altertions in CIS|To correlate in vivo measures of altered glymphatic system with MRI measures of brain perfusion in CIS|To correlate in vivo measures of altered glymphatic system in CIS with clinical measures of disease severity|To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of axonal injury in CIS|To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of astrocytis integrity in CIS|To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of glymphatic activity in CIS,False,
NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,"A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis",TERMINATED,2014-12-01,2015-06-04,2015-06-04,2024-06-03,2014-05-20,INTERVENTIONAL,PHASE2,2.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,,Belgium,Leuven,,2,natalizumab,DRUG,Proportion of participants with persistent anti-natalizumab antibodies,Proportion of participants with transient anti-natalizumab antibodies|Proportion of participants with post-injection adverse events (AEs)|Proportion of participants with clinical relapse|Proportion of participants with gadolinium (Gd) enhancing lesion(s) as assessed by MRI.|Proportion of Participants that experience Adverse Events and Serious Adverse Events,False,
NCT01947036,T and B Cell Responses in Autoimmune Diseases,T and B Cell Responses Across Autoimmune Diseases,TERMINATED,2014-01,2015-10,2015-10,2016-10-26,2013-09-20,OBSERVATIONAL,,68.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Autoimmunity Centers of Excellence,OTHER,"Type 1 Diabetes Mellitus|Multiple Sclerosis|Arthritis, Rheumatoid|Crohn's Disease|Psoriasis",autoimmune disease|immune-mediated disease|T and B cells immunophenotype|IL23 signaling|genetic risk variants,United States,New Haven,Connecticut,6,,,Identify shared defects in T and B cell function by disease classification,,False,
NCT05746845,Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis,RESEPTOR 5-HT7 : Interest of the 5-HT7 Serotonin Receptor as a Biomarker in Multiple Sclerosis,COMPLETED,2023-03-06,2024-07-01,2024-07-01,2024-12-13,2023-02-28,OBSERVATIONAL,,100.0,ACTUAL,Centre Hospitalier Régional d'Orléans,OTHER,,,Healthy|Multiple Sclerosis,Multiple sclerosis|Serotonin|5-HT7 receptor|Inflammation|Lymphocytes|Monocytes|Cytokines,France,Orléans,,1,Blood sample,BIOLOGICAL,5-HT7 receptor expression on circulating cells,Expression of the 5-HT7 receptor after positive selection of different cell populations from PBMC|Expression of the different isoforms of the 5-HT7 receptor on PBMC|Functional activity of the 5-HT7 receptor on PBMC: protein studies|Functional activity of the 5-HT7 receptor on PBMC: mRNA expression studies|Relationship between Multiple sclerosis treatment on inflammation and serotonin production in serum,False,
NCT01031901,Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1),Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1,COMPLETED,2009-12,2011-02,2011-06,2012-02-27,2009-12-15,INTERVENTIONAL,PHASE1,52.0,ACTUAL,"The University of Texas Health Science Center, Houston",OTHER,Society for Pediatric Dermatology,OTHER,Tuberous Sclerosis|Neurofibromatoses|Angiofibroma|Neurofibroma,Tuberous Sclerosis|Neurofibromatoses|Angiofibroma|Neurofibroma|Sirolimus,United States,Houston,Texas,1,Skincerity|Skincerity plus sirolimus/rapamycin|Skinercity plus sirolimus/rapamycin,DRUG|DRUG|DRUG,"Rapamycin level|Complete blood count|Total cholesterol|Dermatologic sensitivity at site of application (pain, erythema, edema, pruritis)",Reduction in lesion size and appearance,False,
NCT00395200,Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS),Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis,COMPLETED,2008-07,2010-12,2010-12,2011-10-25,2006-11-02,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,University of Cambridge,OTHER,Cambridge University Hospitals NHS Foundation Trust|Medical Research Council,OTHER|OTHER_GOV,Multiple Sclerosis,Multiple Sclerosis|Safety|Therapeutics|Mesenchymal Stem Cells|Multipotent Mesenchymal Stromal Cells|Optic Neuritis,United Kingdom,Cambridge,Cambridgeshire,2,MSC Treatment,PROCEDURE,Adverse events,Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score,False,
NCT01909492,Measurement of Relaxin Peptide in Multiple Sclerosis (MS),Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis,COMPLETED,2013-09-20,2023-10-05,2023-10-05,2025-06-22,2013-07-26,OBSERVATIONAL,,30.0,ACTUAL,Providence Health & Services,OTHER,"Microstein, LLC",UNKNOWN,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|MS|Relaxin,United States,Portland,Oregon,1,Blood Draw|Lumbar Puncture,PROCEDURE|PROCEDURE,Relaxin (RLX) Levels,,True,2025-06-22
NCT05129293,Improving Prospective Memory Via Telehealth,Improving Prospective Memory Via Telehealth: A Randomized Feasibility Trial,COMPLETED,2021-11-01,2023-06-05,2023-06-30,2024-10-18,2021-11-22,INTERVENTIONAL,NA,35.0,ACTUAL,Trinity Health Of New England,OTHER,,,Multiple Sclerosis,prospective memory|cognitive dysfunction|multiple sclerosis,United States,Hartford,Connecticut,1,Prospective Memory Intervention|Educational,BEHAVIORAL|BEHAVIORAL,Memory for Intentions Test Total Score Percentile|Memory for Intentions Test Time Cue Subscale Percentile,Perceived Deficits Questionnaire-Prospective Memory Subscale,True,2024-10-18
NCT04528121,Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis,Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis,COMPLETED,2020-09-15,2020-12-30,2020-12-30,2021-02-23,2020-08-27,INTERVENTIONAL,NA,52.0,ACTUAL,Lama Saad El-Din Mahmoud,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",CoDuSe|balance|step square exercises|risk of fall|Multiple Sclerosis,Egypt,Giza,El-Sheikh Zayed City Giza 1133 Egypt,1,CoDuSe balance training and step square exercises|conventional balance training,OTHER|OTHER,Biodex balance system|Short Physical Performance Battery (SPPB)|Morse Fall Scale,,False,
NCT04599595,Characteristics of INTESTINAL DYSFUNCTION in Patients With MULTIPLE SCLEROSIS,Characteristics of INTESTINAL DYSFUNCTION in Patients With MULTIPLE SCLEROSIS. Effectiveness of the TRANSANAL IRRIGATION PROCEDURE With the PERISTEEN DEVICE in the Treatment of Constipation and Disease-related Anal Incontinence,COMPLETED,2018-06-07,2020-04-10,2020-04-10,2020-10-22,2020-10-22,OBSERVATIONAL,,100.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis|Intestinal Dysfunction|Anal Incontinence|Microbiota,transanal irrigation,Italy,Ferrara,,1,Peristeen (Coloplast),DEVICE,Incidence and prevalence of intestinal dysfunction in Multiple sclerosis|Intestinal transit time in SM patients with intestinal dysfunction,"Analysis of Microbiota in MS patients with intestinal dysfunction, before and after treatment with TAI.",False,
NCT01090492,PF-00489791 For The Treatment Of Raynaud's,"A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon",COMPLETED,2010-08-04,2011-05-31,2011-05-31,2018-05-16,2010-03-22,INTERVENTIONAL,PHASE2,243.0,ACTUAL,Pfizer,INDUSTRY,,,Raynaud's Disease|Peripheral Vascular Disease,Raynaud's phenomenon|vasospasm|scleroderma|systemic sclerosis|CREST|phosphodiesterase inhibitor,United States,Redwood City,California,55,PF-00489791|PF-00489791|PF-00489791|PF-00489791|PF-00489791|PF-00489791|PF-00489791|PF-00489791,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4,"Change From Baseline in the Number of Raynaud's Attacks at Week 1, 2, 3 and 4|Change From Baseline in Mean Duration of Raynaud's Attacks at Week 4|Change From Baseline in the Mean Raynaud's Pain Score at Week 1, 2, 3 and 4|Number of Participants With Decrease From Baseline in Digital Ulcers at Day 14 and 28: Secondary Raynaud's Phenomenon Cohort|Plasma Concentration of PF-00489791 and Its Metabolites|Number of Participants With Laboratory Test Abnormalities|Number of Participants With Clinically Significant Changes in Vital Signs and Orthostatic Blood Pressure Measurements|Number of Participants With Abnormal Electrocardiogram (ECG) Values",True,2018-05-16
NCT05983939,Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE_791 and Food Effect in Normal Healthy Volunteers",COMPLETED,2023-06-26,2024-02-01,2024-02-01,2024-02-14,2023-08-09,INTERVENTIONAL,PHASE1,56.0,ACTUAL,Contineum Therapeutics,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|PIPE-791|Health volunteers,United States,San Antonio,Texas,1,PIPE-791|Placebo,DRUG|DRUG,Safety: Treatment-Emergent Adverse Events (TEAE),Safety: Cardiac repolarization using Fridericia-corrected QT interval (QTcF)|Pharmacokinetics (PK): Blood concentration levels of PIPE-791|Pharmacokinetics: Urine concentration levels of PIPE-791,False,
NCT06112639,The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders,DANCE REhabilitation Experience (DANCEREX-DTx): Protocol for a Randomized Controlled Trial on Effectiveness of Digital Therapeutics in Chronic Neurological Disabilities,RECRUITING,2024-01-31,2025-05-01,2025-10-31,2025-01-10,2023-11-01,INTERVENTIONAL,NA,192.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,IRCCS Centro San Giovanni di Dio Fatebenefratelli|University of Milano Bicocca|IRCCS Centro Neurolesi Bonino Pulejo,OTHER|OTHER|OTHER,"Sclerosis, Multiple|Neurocognitive Impairment, Mild|Neurocognitive Dysfunction",rehabilitation|multiple sclerosis|dementia|digital therapeutics|neurocognitive dysfunction|MRI|neuroinflammation|telerehabilitation,Italy,Brescia,,3,DANCEREX-DTx|Multidimensional dance-based program|Educational Program,DEVICE|DEVICE|DEVICE,Adherence to treatment,"Change in global cognitive functioning and subdomains measured by Montreal Cognitive Assessment (MoCA; Conti et al., 2015)|Change in visuoperceptual and attentional abilities measured by Trail Making Test (TMT part-A and part-B; Giovagnoli et al., 1996)|Change in visuoperceptual and attentional abilities measured by Symbol Digit Modalities Test (SDMT; Smith A., 1973; Nocentini U., 2006)|Change in executive functions, including visual attention and inhibitory control of behavior measured by Stroop Test (Caffarra et al., 2002)|Change in Verbal and semantic fluency measured by The Verbal Fluency and Semantic Tests (Carlesimo et al., 1996; Novelli et al., 1986).|Change in long term visual memory measured by Free and Cued Selective Reminding Test (FCSRT) (Frasson et al., 2011)|Change in long term verbal memory measured by 15-Words of Rey (Carlesimo et al., 1995)|Change in Static and dynamic balance measured by Mini-Best Test (Franchignoni et al., 2010)|Change in Aerobic Capacity and Gait measured by 6' Minute Walking Test (6MWT)|Changes in affect measured by Positive-Negative Affect Schedule (PANAS; Watson et al, 1988)|Changes in Activation level of Patients measured by Patient Activation Measure 13 (PAM13; Hibbard et al., 2004)|Changes in patient's self-rated health measured by EuroQol five dimensions (5D) and five levels (5L) (The EuroQol Group, 1990; Janssen et al.,2013)|Changes in patient's self-rated health status measured by Short Form Health Survey 36 (SF36; Ware, 2000)|Changes in patient's fatigue measured by Modified Fatigue Index Scale (MFIS; Kos et al., 2006)|Changes in depressive symptoms measured by Beck Depression Inventory for Primary Care (BDI-PC, Steer et al., 1999)|Changes in anxiety level measured by State-Trait Anxiety Inventory - Form Y (STAI - Y; Spielberger, 1983; Pedrabissi & Santinello, 1989)",False,
NCT06314412,Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence,Perineal Rehabilitation: Efficacy of Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence,RECRUITING,2023-02-13,2025-04,2025-07,2024-03-18,2024-03-18,INTERVENTIONAL,NA,20.0,ESTIMATED,Istituto Auxologico Italiano,OTHER,,,Multiple Sclerosis,Incontinence|Perineum|Stoller's Afferent Nerve Stimulation|Posterior tibial nerve stimulation,Italy,Milan,,1,Stoller's Afferent Nerve Stimulation (SANS),OTHER,Measure of variation of incontinence.|Measure of variation of urinary urgency,,False,
NCT02655614,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis","A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis",COMPLETED,2016-05-31,2020-03-16,2020-03-16,2020-08-06,2016-01-14,INTERVENTIONAL,PHASE1,54.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,Amyotrophic Lateral Sclerosis,,United States,San Francisco,California,10,GDC-0134|Placebo|Rabeprazole|Midazolam|Caffeine,DRUG|DRUG|DRUG|DRUG|DRUG,Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Clinically Significant Laboratory Abnormalities|Percentage of Participants With Clinically Significant Vital Signs Abnormalities|Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings,Maximum Plasma Concentration (Cmax) of GDC-0134|Time to Maximum Plasma Concentration (tmax) of GDC-0134|Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0134|Apparent Clearance (CL/F) of GDC-0134|Apparent Terminal Volume of Distribution (Vz/F) of GDC-0134|Apparent Terminal Half-Life (t1/2) of GDC-0134|PK-Dose Proportionality of GDC-0134 as Assessed With Cmax and AUC|Accumulation Ratio of GDC-0134|Dose Normalized Cmax (Cmax/Dose) of GDC-0134|Dose Normalized AUC (AUC/Dose) of GDC-0134|t1/2 of Midazolam|t1/2 of 1-Hydroxymidazolam (Metabolite of Midazolam)|t1/2 of Caffeine|t1/2 of Paraxanthine (Metabolite of Caffeine),False,
NCT01767701,Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis,A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI,COMPLETED,2013-04,2014-09,2014-09,2017-05-30,2013-01-14,INTERVENTIONAL,PHASE2,23.0,ACTUAL,Queen Mary University of London,OTHER,Merck Sharp & Dohme LLC,INDUSTRY,Relapsing Remitting Multiple Sclerosis,raltegravir|MS|RRMS|Charcot Project,United Kingdom,London,,1,Raltegravir,DRUG,The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI,The Cumulative Number of New or Enlarging T2 Weighted Lesions on Brain MRI.|Change in Score on Multiple Sclerosis Functional Composite (MSFC). This a Composite Score Based on the Measurement of Time in Seconds for the Three Separate Measurements.|Changes in Kurtzke Extended Disability Status Scale (EDSS) Score|Cumulative Number of Gd-T1 Enhancing Lesions|Percent of Subjects With Scans Free From Enhancing Lesions in Raltegravir Treated Subjects vs. Baseline,True,2017-05-30
NCT00516893,Natalizumab High Titer Immunogenicity and Safety,"A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis",COMPLETED,2006-10,2007-10,2007-12,2014-05-15,2007-08-16,INTERVENTIONAL,PHASE2,113.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Multiple Sclerosis,natalizumab|Tysabri|Multiple Sclerosis|Relapsing Forms of Multiple Sclerosis,United States,Washington D.C.,District of Columbia,13,BG00002-E (natalizumab high titer),BIOLOGICAL,"Number of Participants With Anti-Natalizumab Antibody Negative, Transient Positive, and Persistent Positive Status","Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs|Mean Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 36|Annualized Relapse Rate",True,2009-08-13
NCT00984984,Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses,Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses,UNKNOWN,2008-03,2013-06,2014-06,2012-12-05,2009-09-25,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,Rennes University Hospital,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,France,Brest,,14,methylprednisolone PO|methylprednisolone IV,DRUG|DRUG,At least 1 point-reduction on Kurtzke functional scale,,False,
NCT00681538,"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)","A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study.",COMPLETED,2008-01,2009-01,2009-01,2023-05-06,2008-05-21,INTERVENTIONAL,PHASE3,572.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Spasticity|Multiple Sclerosis,Spasticity|Multiple Sclerosis,United Kingdom,Cliftonville,Northampton,1,Sativex®|Placebo,DRUG|DRUG,The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B).,Number of Subjects Showing an Improvement of at Least 30% or 50% in Their Mean NRS Spasticity Score (Phase B) From Baseline.|Change in Spasm Frequency (Number of Spasms Per Day) From Baseline to End of Treatment (Phase B).|Change in Sleep Disruption (Daily 11-point NRS) From Baseline to End of Treatment (Phase B).|Change in Spasticity as Measured Using the Modified Ashworth Scale From Baseline to End of Treatment (Phase B).|Change in Motricity Index Score From Baseline to End of Treatment (Phase B)for Affected Limbs.|Change in Timed 10-metre Walk From Baseline to End of Treatment (Phase B).|Subject Global Impressions of Change at End of Treatment (Phase B).|Carer Global Impressions of Change at of Treatment (Phase B).|Carer Ease of Transfer Global Impressions of Change at End of Treatment (Phase B).|Physician Global Impressions of Change at End of Treatment (Phase B).|Change EuroQoL Quality of Life Questionnaire (EQ-5D)From Baseline to End of Treatment (Phase B)|Mood Assessment: Change in Beck Depression Inventory - II (BDI-II)From Baseline to End of Treatment (Phase B),True,2011-12-07
NCT04667117,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,COMPLETED,2021-01-14,2023-07-06,2023-07-06,2024-10-09,2020-12-14,INTERVENTIONAL,PHASE4,63.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,ofatumumab|multiple sclerosis,United States,Phoenix,Arizona,3,Quadrivalent influenza vaccine|Ofatumumab|iDMT,BIOLOGICAL|DRUG|DRUG,Percentage of Participants Achieving Seroprotection at Week 4 (Observed Case)|Percentage of Participants Achieving Seroprotection at Week 4 (Non-responder Imputation),"Percentage of Participants Achieving Seroconversion at Week 4 (Observed Case)|Percentage of Participants Achieving Seroconversion at Week 4 (Non-responder Imputation)|Fold Change From Baseline in Hemagglutination Inhibition Titers|Number of Participants With Adverse Events (AEs), AEs Leading to Discontinuation and Serious Adverse Events (SAEs)",True,2024-08-01
NCT04908891,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness","A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness",COMPLETED,2018-12-12,2021-08-30,2022-08-30,2024-07-12,2021-06-01,INTERVENTIONAL,NA,78.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|Ziekenhuis Oost-Limburg|National MS Center Melsbroek|Jessa Hospital,OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis|Stroke,,Belgium,Genk,,4,"Clinical Scapular protocol (ClinScaP)|the prevalence of trunk, scapula and upper limb impairments.|the interaction between trunk, scapula and upper limb impairments.",OTHER|OTHER|OTHER,The Reaching performance scale (RPS)|The Reaching performance scale (RPS)|The clinical scapular protocol|The clinical scapular protocol,"Trunk Impairment Scale|Trunk Impairment Scale|Box and Block test|Box and Block test|The Brunnström Fugl Meyer (BFM)|The Brunnström Fugl Meyer (BFM)|The Action Research Arm Test (ARAT)|The Action Research Arm Test (ARAT)|The Nine Hole Peg Test (NHPT)|The Nine Hole Peg Test (NHPT)|The Manual Ability Measure-36 (MAM-36)|The Manual Ability Measure-36 (MAM-36)|Arm Function in Multiple Sclerosis Questionnaire|Arm Function in Multiple Sclerosis Questionnaire|Active and passive range of motion of shoulder, elbow and wrist movement|Active and passive range of motion of shoulder, elbow and wrist movement|Modified Ashworth Scale|Modified Ashworth Scale|Maximal hand grip strength test (HGS)|Maximal hand grip strength HGS)|Symbol digit modalities test|Symbol digit modalities test|Modified fatigue impact scale|Modified fatigue impact scale|National Institutes of Health Stroke Scale (NIHSS)|National Institutes of Health Stroke Scale (NIHSS)|10 Meter loop test (10MWT)|10 Meter loop test (10MWT)|Modified Rankin Scale (MRS)|Modified Rankin Scale (MRS)",False,
NCT00053417,Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis,"Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis",COMPLETED,2003-02,2003-12,2003-12,2011-08-04,2003-01-30,INTERVENTIONAL,PHASE2,206.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,Walking Ability|Muscle strength|Spasticity,United States,Phoenix,Arizona,25,"Placebo|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|15 mg fampridine-SR (4-aminopyridine, 4-AP)|20 mg fampridine-SR (4-aminopyridine, 4-AP)",DRUG|DRUG|DRUG|DRUG,Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test,,True,2011-08-04
NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,"A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.",COMPLETED,2007-05,2009-06,2009-06,2012-11-06,2007-06-21,INTERVENTIONAL,PHASE2,118.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,MS|interferon-beta|adjunctive therapy|relapses,United States,Bridgewater,New Jersey,5,Teriflunomide|Placebo (for Teriflunomide)|Interferon-β,DRUG|DRUG|DRUG,Overview of Adverse Events [AE]|Overview of AE With Potential Risk of Occurrence|Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA),Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)|Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)|Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan|Annualized Relapse Rate [ARR]: Poisson Regression Estimates|Pharmacokinetic [PK]: Teriflunomide Plasma Concentration,True,2012-11-02
NCT03729713,Computerized Cognitive Rehabilitation in MS Patients,Computerized Cognitive Rehabilitation in MS Patients,UNKNOWN,2021-04-21,2023-05,2024-05,2022-11-17,2018-11-05,INTERVENTIONAL,NA,80.0,ESTIMATED,"Rutgers, The State University of New Jersey",OTHER,Horizon Blue Cross Blue Shield of New Jersey,OTHER,Multiple Sclerosis|Cognitive Impairment,,United States,New Brunswick,New Jersey,1,Computerized cognitive rehabilitation|Sham placebo,OTHER|OTHER,Cognitive Functioning,Multiple Sclerosis Self-Efficacy Scale|Work Productivity and Activity Impairment Instrument|Multiple Sclerosis Quality of Life Inventory|Hospital Anxiety and Depression Scale|Healthcare Utilization,False,
NCT00912860,Immunogenicity and Safety Study of Serum-Free Avonex,"A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis",COMPLETED,2003-01,2004-12,2005-01,2009-06-10,2009-06-03,INTERVENTIONAL,PHASE2,155.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|interferon beta-1a|avonex,,,,0,Interferon beta-1a,DRUG,To evaluate the immunogenicity of a serum-free pre-formulated solution of AVONEX®,To evaluate the safety of a serum-free pre-formulated solution of AVONEX®,False,
NCT01838824,Applying Speed of Processing Training to Individuals With Multiple Sclerosis,Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis,COMPLETED,2011-11,2020-03,2021-12,2022-03-15,2013-04-24,INTERVENTIONAL,NA,38.0,ACTUAL,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Processing Speed|Intervention|Multiple Sclerosis|Cognition,United States,West Orange,New Jersey,1,Speed of Processing Training,BEHAVIORAL,Change in scores on standardized tests of processing speed,,False,
NCT02061397,Safety of Simvastatin in LAM and TSC,The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC),COMPLETED,2014-03,2019-12-13,2019-12-13,2020-08-25,2014-02-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,University of Pennsylvania,OTHER,The LAM Foundation,OTHER,Lymphangioleiomyomatosis|Tuberous Sclerosis Complex,lymphangioleiomyomatosis (LAM)|tuberous sclerosis complex (TSC)|simvastatin|sirolimus|everolimus,United States,Philadelphia,Pennsylvania,1,Simvastatin|Sirolimus Oral Product|Everolimus Oral Product,DRUG|DRUG|DRUG,Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients,Percent Predicted FEV1,True,2020-08-25
NCT06432686,Neurophysiological Effects of Transcutaneous Electrical Nerve Stimulation in Persons With MS,Neurophysiological Effects of Transcutaneous Electrical Nerve Stimulation in Persons With MS - a Pilot Study,NOT_YET_RECRUITING,2025-10-01,2025-12-31,2025-12-31,2025-09-10,2024-05-29,INTERVENTIONAL,NA,30.0,ESTIMATED,University Medical Center Groningen,OTHER,,,"Fatigue|Walking, Difficulty|Multiple Sclerosis",,,,,0,Transcutaneous Electrical Nerve Stimulation|Movement,DEVICE|BEHAVIORAL,BOLD activation due to TENS,,False,
NCT03684369,Improving Mobility and Reducing Fatigue in People With Multiple Sclerosis by Electrical Stimulation Therapy,Improving Mobility and Reducing Fatigue in People With Multiple Sclerosis by Electrical Stimulation Therapy,WITHDRAWN,2020-07,2024-12,2025-06,2020-11-06,2018-09-25,INTERVENTIONAL,NA,0.0,ACTUAL,"University of Colorado, Boulder",OTHER,"University of Colorado, Denver|Colorado State University",OTHER|OTHER,Multiple Sclerosis,walking|balance|fatigue,,,,0,Transcutaneous electrical nerve stimulation,DEVICE,Change in Gait Speed|Change in Walking Endurance|Change in Dynamic Balance|Change in Patient Determined Disease Steps|Change in Modified Fatigue Impact Scale|Change in MS Walking Scale-12,Change in Romberg Quotient|Change Conditioned H-reflex Amplitude|Change in Proprioception Tract|Change in Muscle Synergy Number|Change in Force Steadiness|Change in Muscle Synergy TIming|Change in Discharge characteristics,False,
NCT03752307,Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses,"Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse",COMPLETED,2019-02-15,2023-07-06,2023-07-06,2024-02-06,2018-11-23,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,University of New Mexico,OTHER,,,Multiple Sclerosis,,United States,Albuquerque,New Mexico,1,Isoxsuprine Hydrochloride|Placebo|Corticosteroid,DRUG|DRUG|DRUG,Incidence of Treatment-Emergent Adverse Events in Subjects by Measuring Measuring Changes in Vital Signs,Incidence of Adverse Event Expanded Disability Status Scale (EDSS),True,2024-02-06
NCT06161376,Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis,Prospective Study Evaluating the Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis,NOT_YET_RECRUITING,2024-12,2027-12,2027-12,2024-08-27,2023-12-07,OBSERVATIONAL,,400.0,ESTIMATED,"University Hospital, Toulouse",OTHER,,,Multiple Sclerosis,,,,,0,S1P level,OTHER,S1P concentration,,False,
NCT01454791,Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate,Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial,COMPLETED,2011-01,2013-03,2013-03,2015-03-05,2011-10-19,INTERVENTIONAL,PHASE4,40.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,"Teva Neuroscience, Inc.",INDUSTRY,Multiple Sclerosis,multiple sclerosis|diclofenac|subcutaneous injection|glatiramer acetate|Copaxone,United States,Kirkland,Washington,1,diclofenac sodium topical gel|Placebo,DRUG|OTHER,"Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks|Pain Scale at 2 Weeks",Subject Global Impression at 2 Weeks,True,2015-02-13
NCT05449574,Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year,Sensory Integration Disorders in Multiple Sclerosis,COMPLETED,2022-01-20,2022-05-25,2022-06-27,2022-07-08,2022-07-08,OBSERVATIONAL,,2.0,ACTUAL,Pomeranian Medical University Szczecin,OTHER,,,Multiple Sclerosis,multiple sclerosis;|Sensory integration|relapses|the advancement of the disease,Poland,Szczecin,Unii Lubelskiej,1,Scale for the Assessment of Sensory Integration in Adults,DIAGNOSTIC_TEST,sensory integration disorders and relapses in the last year|Sensory integration disorders and the degree of disease severity|Comparing the test group with the control group,,False,
NCT02461069,Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis,"A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)",COMPLETED,2015-05-06,2018-01-24,2018-05-07,2018-10-11,2015-06-03,INTERVENTIONAL,PHASE4,67.0,ACTUAL,University Hospital Muenster,OTHER,Biogen,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",dimethyl fumarate,Germany,Bonn,,6,Dimethyl fumarate,DRUG,Expression of lymphocyte phenotypic surface markers in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis.|Expression of lymphocyte phenotypic surface markers in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects.,T cell effector functions in terms of cytokine production of CD4+ and CD8+ in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis.|T cell effector functions in terms of cytokine production of CD4+ and CD8+ in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects.|Migratory capacity of immune cells (percentage of migrated cells) in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis.|Migratory capacity of immune cells (percentage of migrated cells) in dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects.|Mitochondrial energy metabolism of T cells upon dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis.|Mitochondrial energy metabolism of T cells upon dimethyl fumarate (Tecfidera®)-treated patients with relapsing-remitting multiple sclerosis and untreated healthy subjects.,False,
NCT06261489,Cannabis (THC vs. CBD) in Multiple Sclerosis,The Differential Effects of THC vs. CBD on Cognition in Persons With MS,NOT_YET_RECRUITING,2024-03,2025-09,2025-12,2024-02-15,2024-02-15,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,University of Calgary,OTHER,Multiple Sclerosis Society of Canada,OTHER,Multiple Sclerosis,Cannabis|Cognitive Function,,,,0,THC|CBD,DRUG|DRUG,"Cognitive outcome: The Differential Effect, if any, of THC and CBD in MS Cognition will be measured by Symbol Digit Modality Test (SDMT).|NLUTD outcome: The Differential Effect, if any, of THC and CBD on Neurogenic lower urinary tract dysfunction (NLUTD) symptoms will be measured by Neurogenic Bladder Symptom Score (NBSS).",Blinding feasibility: The ability to blind the administration of THC vs CBD in PwMS will be evaluated based on participants and investigators report.,False,
NCT02280096,Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis,"Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.",COMPLETED,2014-10,2016-02,2017-02,2019-09-12,2014-10-31,INTERVENTIONAL,PHASE2,24.0,ACTUAL,"Coordinación de Investigación en Salud, Mexico",OTHER_GOV,,,Multiple Sclerosis,Cognitive function|Multiple sclerosis|4-aminopyridine|Fatigue,Mexico,Mexico City,Mexico City,1,4-aminopyridine|Placebo,DRUG|DRUG,The Brief Repeatable Battery of Rao|Integrated Program of Neuropsychological Exploration Test Barcelona|Rey-Osterrieth Complex Figure Test (ROCF)|Five Digit Test (FDT). Processing Speed|Wisconsin Card Sorting Test (WCST)|Color Trails Test (CTT)|Tower Of London (TOL). Total Moves and Total Correct Moves|Tower Of London (TOL). Execution Time and Problem-solving Time,Improved Physical Capacity|Fatigue|Walk|Number of Participants With Abnormal Studies,True,2019-09-12
NCT00423527,Levetiracetam in Central Pain in Multiple Sclerosis(MS),"Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis",COMPLETED,2007-01,2009-01,2009-01,2009-12-18,2007-01-18,INTERVENTIONAL,PHASE4,30.0,ESTIMATED,Odense University Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|central pain|levetiracetam,Denmark,Odense C,,1,levetiracetam,DRUG,Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period),Pain rated on a 0 to 10 point numeric rating scale|Pain subtypes rated on the same scale.|Brush-evoked pain|Pin-prick-evoked pain|Cold-evoked pain|Health related quality of life (SF36)|Pain related sleep disturbance|Use of escape medication|Muscle spasms as measured on 2 different scales,False,
NCT04943289,Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis,Phase IA Trial of Intrathecal Administration of Human Umbilical Cord Blood-Derived Cell Therapy (DUOC-01) in Adults With Primary Progressive Multiple Sclerosis (PPMS),ACTIVE_NOT_RECRUITING,2021-01-24,2026-02-28,2026-02-28,2025-01-28,2021-06-29,INTERVENTIONAL,PHASE1,20.0,ACTUAL,"Joanne Kurtzberg, MD",OTHER,,,Primary Progressive Multiple Sclerosis,"Multiple Sclerosis, MS",United States,Durham,North Carolina,1,DUOC-01,BIOLOGICAL,Incidence of IT administration adverse events|Incidence of adverse events attributed to the investigational product,,False,
NCT06408259,Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis,"A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",RECRUITING,2025-04-08,2031-04-11,2036-07-13,2025-08-26,2024-05-10,INTERVENTIONAL,PHASE3,194.0,ESTIMATED,Celgene,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing-Remitting|Ozanimod|Zeposia®,United States,Phoenix,Arizona,35,Ozanimod|Fingolimod|Placebo,DRUG|DRUG|OTHER,Annualized relapse rate (ARR),Proportion of participants who did not have a confirmed relapse|Number of gadolinium enhancing (GdE) T1 lesions|Number of new or newly enlarging hyperintense lesions on T2 magnetic resonance imaging (MRI) sequences|Incidence of treatment-emergent adverse events (TEAEs) over the treatment period and over the post-treatment follow-up period|Incidence of adverse event of special interests (AESIs) over the treatment period and over the post-treatment follow-up period|Adverse events (AEs) leading to discontinuation over the treatment period and over the post-treatment follow-up period|Steady state plasma concentrations of ozanimod|Steady state plasma concentrations of the primary active metabolite CC112273|Change from baseline pharmacodynamics (PD) biomarkers of absolute lymphocyte count,False,
NCT04408742,"Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis","The Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple Sclerosis",COMPLETED,2019-04-15,2019-10-20,2019-12-11,2020-06-01,2020-05-29,OBSERVATIONAL,,14.0,ACTUAL,Ankara Yildirim Beyazıt University,OTHER,,,Multiple Sclerosis|Menstrual Pain|Anxiety|Fatigue|Neurologic Symptoms,multiple Sclerosis|menstrual cycle|proprioception|postural balance|pain|fatigue|anxiety,Turkey (Türkiye),Ankara,Esenboğa,1,pain|fatigue|anxiety|position sense|balance|dual task performance,OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,pain intensity|anxiety|fatigue|position sense|balance|dual task performance,,False,
NCT06283524,Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis,Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis,NOT_YET_RECRUITING,2024-03-18,2025-10-18,2026-03-18,2024-02-28,2024-02-28,OBSERVATIONAL,,100.0,ESTIMATED,Innodem Neurosciences,INDUSTRY,,,Multiple Sclerosis,,Canada,Montreal,Quebec,1,Eye-Tracking,DEVICE,Predictive power of eye-movement biomarkers (EMBs) for MS severity in relationship to Expanded Disability Status Scale (EDSS),Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Rey Auditory Verbal Learning Test (RAVLT) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS).|Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC).|Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC).,False,
NCT00393588,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,The Use of Magnetic Resonance Imaging to Investigate Cortical Damage in Patients With Multiple Sclerosis and Correlation With Cognitive Dysfunction,COMPLETED,2006-10-26,,2011-09-29,2017-07-02,2006-10-30,OBSERVATIONAL,,50.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Brain|Cognitive Deficits|Cognitive Testing|MRI|Multiple Sclerosis|MS|Healthy Volunteer|HV,United States,Bethesda,Maryland,1,,,,,False,
NCT03501342,"Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis","Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis",COMPLETED,2018-04-09,2018-09-01,2018-09-01,2018-10-12,2018-04-18,INTERVENTIONAL,NA,39.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|virtual reality|balance|mobility|fatigue,Turkey (Türkiye),Ankara,,1,Virtual reality group|Dynamic Balance Training,OTHER|OTHER,Berg Balance Scale,Timed Up and Go Test|Modified Sensory Organization Test|One-leg standing duration|Activities-specific Balance Confidence|Fatigue Severity Scale|Fatigue Impact Scale,False,
NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,"A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis",TERMINATED,2012-08-09,2018-04-30,2018-04-30,2019-05-28,2012-07-04,INTERVENTIONAL,PHASE3,1064.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis (RRMS),,United States,Cullman,Alabama,130,fingolimod|glatiramer acetate,DRUG|DRUG,Confirmed Annualized Relapse Rate,New or Newly Enlarging T2 Lesions|Number of Participants Free of New/Newly Enlarged T2 Lesions|Change From Baseline in T2 Lesion Volume|Gd Enhancing T1 Lesion Count|Gd Enhancing T1 Lesion Volume|Percentage of Patients Free of New T1 Hypointense Lesions|Change From Baseline in TSQM Scales|Percent Brain Volume Change From Baseline,True,2019-05-28
NCT05809986,Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study,Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study,RECRUITING,2023-11-27,2026-09-15,2026-09-15,2025-01-14,2023-04-12,OBSERVATIONAL,,174.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,Relapsing Multiple Sclerosis|RMS|Ofatumumab|NIS|Portugal,Portugal,Amadora,,10,Ofatumumab,OTHER,Proportion of patients demonstrating NEDA-3,Proportion of patients demonstrating no evidence of disease activity in individual components of NEDA-3|Multiple Sclerosis Impact Scale Questionnaire (MSIS-29)|Fatigue Symptoms and Impacts Questionnaire - Relapsing Multiple Sclerosis (FSIQ-RMS)|Treatment Satisfaction Questionnaire for Multiple Sclerosis (TSQM-9)|Proportion of patients permanently discontinuing Ofatumumab during the study|Proportion of patients demonstrating NEDA-3 in the overall population.,False,
NCT06511154,"The Effect of Cognitive Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Multiple Sclerosis","The Effect of Cognitive Exercise in Addition to Physical Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Individuals With Multiple Sclerosis",RECRUITING,2024-05-13,2025-05-15,2025-06-15,2024-07-19,2024-07-19,INTERVENTIONAL,NA,32.0,ESTIMATED,Ankara Yildirim Beyazıt University,OTHER,Gulhane Training and Research Hospital,OTHER_GOV,Multiple Sclerosis,Multiple Sclerosis|Cognitive Rehabilitation|LOTCA,Turkey (Türkiye),Ankara,,1,Cognitive Rehabilitation|Core-based Upper Extremity Exercises,OTHER|OTHER,Cognitive status|Upper extremity,Coordination|Balance|Fatigue|Position Sense,False,
NCT05136222,Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease,"A Multi-centre Randomised Controlled Trial of Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease (PSG4NIVinMND; 3, Three Letter Acronyms [3TLA])",RECRUITING,2021-12-15,2026-02-28,2028-02-28,2022-06-23,2021-11-29,INTERVENTIONAL,NA,244.0,ESTIMATED,University of Melbourne,OTHER,"Austin Hospital, Melbourne Australia|Institute for Breathing and Sleep, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Macquarie University, Australia|Macquarie Health|Western Sydney Local Health District|Flinders Medical Centre|Sir Charles Gairdner Hospital|The Prince Charles Hospital|Monash University|Motor Neurone Disease Australia|FightMND|Australian Motor Neurone Disease Registry|Calvary Bethlehem|Perron Institute for Neurological and Translational Science",OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER_GOV|OTHER|OTHER_GOV|OTHER|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|OTHER,Motor Neuron Disease / Amyotrophic Lateral Sclerosis,Non-invasive ventilation|Polysomnography|Sleep study|Amyotrophic lateral sclerosis|Chronic respiratory failure,Australia,Adelaide,,13,Intervention polysomnography|Sham polysomnography,OTHER|OTHER,Adherence with NIV,Intolerance of NIV|Respiratory function|Maximal inspiratory/expiratory pressure|Sniff nasal pressure|Arousal index (during polysomnography)|Asynchrony index (during polysomnography)|Oxygen indices (during polysomnography)|Total sleep time (during polysomnography)|% rapid eye movement (REM) sleep (during polysomnography)|% slow wave sleep (SWS) (during polysomnography)|Asynchrony sub-indices (during polysomnography)|Dyspnoea Amyotrophic Lateral Sclerosis (DALS-15)|Health-related quality of life - Severe Respiratory Insufficient Questionnaire (SRI)|Health-related quality of life - Assessment of Quality of Life (8-Dimension-AQoL)|Health-related quality of life - Calgary Sleep Apnoea Quality of Life Index (SAQLI)|Functional rating - Amyotrophic Lateral Sclerosis Functional Rating Scale (Revised) (ALSFRS)|Sleep quality - Pittsburgh Sleep Quality Index (PSQI)|Daytime somnolence - Epworth Sleepiness Scale (ESS)|Daytime somnolence - Karolinska Sleepiness Scales (KSS)|Carer burden - Caregiver Burden Scale (CBS)|Cost effectiveness of the intervention|Usual clinical care practices|Usual care and the barriers and enablers to undertaking the intervention|Experience of receiving the intervention and the barriers and enablers to the PSG and NIV usage|Experience of the person they are caring for receiving the intervention and the barriers and enablers to the PSG and NIV usage,False,
NCT05073731,Telerehabilitation-based Upper Extremity Training in People With Multiple Sclerosis,"Investigation of the Effects of the Synchronized Telerehabilitation-based Upper Extremity Training Program on Hand-arm Function, Pain, Fatigue, Quality of Life, and Participation in People With Multiple Sclerosis",UNKNOWN,2021-12-15,2022-09-30,2022-10-28,2022-06-01,2021-10-11,INTERVENTIONAL,NA,30.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Telerehabilitation-based Upper Extremity Training,OTHER,Nine-Hole Peg Test,Expanded Disability Status Scale|Jamar Hand Dynamometer|Arm Function in Multiple Sclerosis Questionnaire|Preference-based Multiple Sclerosis Index|The Modified Fatigue Impact Scale - 5|Sensewear Armband|Global Perceived Effect Scale|Impact of Participation and Autonomy Questionnaire|Brief Pain Inventory-Short Form,False,
NCT02618902,"A ""negative""dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial","A ""negative""dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial",COMPLETED,2017-05-30,2022-02-03,2022-02-03,2024-12-09,2015-12-02,INTERVENTIONAL,PHASE1,9.0,ACTUAL,"University Hospital, Antwerp",OTHER,,,Multiple Sclerosis,patient safety|tolerogenic dendritic cells|tolDC,Belgium,Edegem,,1,tolerogenic dendritic cells (tolDC),BIOLOGICAL,Safety (Occurrence and severity of adverse events will be recorded)|Feasibility (Generation of GMP-grade cell product released according to QC),Expanded disability status scale (EDSS)|9 Hole Peg Test (9HPT)|25 Foot walk test (T25FW)|Symbol Digit Modalities test (SDMT)|Number of Gd-enhancing lesions on MRI|Number of new or enlarging T2 lesions on MRI,False,
NCT03404388,Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis,Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis,ENROLLING_BY_INVITATION,2020-04-01,2025-01-31,2025-03-31,2023-12-12,2018-01-19,INTERVENTIONAL,NA,150.0,ESTIMATED,Wayne State University,OTHER,,,Multiple Sclerosis,,United States,Detroit,Michigan,1,Balance Training,BEHAVIORAL,Change in Dual-Task Cost,Berg Balance Scale|Objective Balance Control,False,
NCT05179577,A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)",NOT_YET_RECRUITING,2026-01,2027-01,2027-04,2024-08-21,2022-01-05,INTERVENTIONAL,PHASE3,442.0,ESTIMATED,"RVL Pharmaceuticals, Inc.",INDUSTRY,,,Spasticity,,,,,0,Arbaclofen|Placebo,DRUG|DRUG,Change from Baseline to Maintenance Treatment Period for Total Numeric-Transformed Modified Ashworth Scale Most Affected Limb (TNmAS-MAL)|Responder Analysis of Ashworth Scale Score (AS-MAL-R) for Maintenance Treatment Period,Change from Baseline to Maintenance Treatment Period for Total Numeric-Transformed Modified Ashworth Scale Total Limbs (TNmAS-TL)|Clinician's global impression of change (CGIC) for Maintenance Treatment Period|Numeric Rating Scale of Spasticity (NRS-S) for Maintenance Treatment Period|Expanded Disability Status Scale (EDSS) for Maintenance Treatment Period,False,
NCT00203112,Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline,"A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).",COMPLETED,2004-06,2006-06,2006-07,2011-04-12,2005-09-20,INTERVENTIONAL,PHASE2,44.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapse Remitting Multiple Sclerosis,,,,,0,glatiramer acetate with minocycline|Glatiramer acetate with placebo,DRUG|DRUG,To evaluate the add-on treatment effect of oral minocycline in subjects treated with daily injection of GA as reflected by number of MRI T1 Gd-enhancing lesions in T1-weighted images.,Assessment of tolerability and safety,False,
NCT03344094,Mechanism of Action of Ocrelizumab in Multiple Sclerosis,Mechanism of Action of Ocrelizumab in Multiple Sclerosis,COMPLETED,2018-02-23,2019-04-10,2019-04-10,2025-02-21,2017-11-17,OBSERVATIONAL,,30.0,ACTUAL,University of Chicago,OTHER,,,Multiple Sclerosis|Immune System Diseases,,United States,Chicago,Illinois,1,ocrelizumab,DRUG,Number of Participants With Complete Depletion of B Cells,,True,2025-02-21
NCT03396822,Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis,Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis,COMPLETED,2018-09-24,2023-05-25,2023-05-25,2024-02-28,2018-01-11,OBSERVATIONAL,,24.0,ACTUAL,"University of Maryland, Baltimore",OTHER,"Genentech, Inc.",INDUSTRY,Multiple Sclerosis,multiple sclerosis|7T MRI|Meningeal inflammation,United States,Baltimore,Maryland,1,Gadoteridol,DRUG,Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab.,Reduction in the Proportion of Participants With Meningeal Enhancement After Treatment With Ocrelizumab Compared to Pre-treatment Baseline.,True,2024-02-05
NCT05364203,Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX),Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity,COMPLETED,2022-05-10,2024-12-02,2024-12-02,2025-09-24,2022-05-06,INTERVENTIONAL,NA,42.0,ACTUAL,"University Hospital, Clermont-Ferrand",OTHER,,,Central Neurogical Impairment,"central neurological impairment (stroke, multiple sclerosis)|virtual reality mask|spasticity|botulinum toxin injections|stress|pain",France,Clermont-Ferrand,France,1,DEEPSEN virtual reality mask,DEVICE,Heart rate variability (HRV) before injection and during the injections,Effect on the pain induced by the injection|Quality of the conditions for performing botulinum toxin injections,False,
NCT02301442,Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis,"A Randomised Controlled Trial of an Exercise Plus Behaviour Change Intervention in People With MS: the ""Step it Up"" Study Protocol",COMPLETED,2014-09,2016-02,2016-02,2016-05-13,2014-11-26,INTERVENTIONAL,NA,65.0,ACTUAL,University of Limerick,OTHER,,,Multiple Sclerosis,,Ireland,Limerick,Munster,1,Exercise + behaviour change intervention|Exercise + control education,BEHAVIORAL|BEHAVIORAL,Change in walking mobility from weeks 1 to 36,Change in lower limb functional muscle strength from weeks 1 to 36|Change in aerobic fitness from weeks 1 to 36|Change in anxiety and depression from weeks 1 to 36|Change in cognitive processing from weeks 1 to 36|Change in physical activity levels from weeks 1 to 36|Change in self-reported fatigue from weeks 1 to 36|Change in self-reported impact of MS from weeks 1 to 36,False,
NCT04792866,3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON),3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis in Patients Presenting With Acute Visual Loss and Otherwise Normal Ophthalmological Examination,COMPLETED,2018-01-01,2020-03-01,2020-08-01,2021-03-15,2021-03-11,OBSERVATIONAL,,1200.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Optic Neuritis|Multiple Sclerosis|Encephalopathy,,France,Paris,Île-de-France Region,1,Magnetic Resonance Imaging,DIAGNOSTIC_TEST,Detection of optic neuropathies using MRI,,False,
NCT04428775,A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease,"A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,2020-09-08,2021-10-01,2021-10-01,2021-11-08,2020-06-11,INTERVENTIONAL,PHASE2,12.0,ACTUAL,"AZTherapies, Inc.",INDUSTRY,,,Amyotrophic Lateral Sclerosis,ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's disease|mild ALS|moderate ALS|mild to moderate ALS,United States,La Jolla,California,6,ALZT-OP1a (cromolyn),DRUG,Plasma Biomarkers,"Changes from baseline in ALS disease progression|Time to Event Requiring Respiratory Support|Changes from baseline in pulmonary function (forced vital capacity)|Changes from baseline in pulmonary function (peak inspiratory flow rate)|Incidence of adverse event (tolerability) related to ALZT-OP1a|Number of participants with abnormal vital signs|Number of participants with abnormal physical or neurological examinations|Number of participants with abnormal electrocardiograms (ECGs)|Number of participants with treatment emergent clinically significant laboratory assessments|Changes from baseline in suicidal ideation and behavior|The number of study dropouts due to serious, unanticipated treatment emergent adverse events",False,
NCT03438357,Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI,Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI,COMPLETED,2019-01-02,2022-07-06,2022-07-06,2023-02-08,2018-02-19,OBSERVATIONAL,,200.0,ACTUAL,Centre Hospitalier Universitaire de Nīmes,OTHER,Roche Pharma AG,INDUSTRY,Multiple Sclerosis|Clinically Isolated Syndrome,,France,Nîmes,,1,Analysis of cerebral MRI with automatic segmentation software,OTHER,"Lesions detected by Pixyl.Neuro software that were missed by manual analysis of MRI images follow-up images compared to reference image (new T2 lesions, enlarging T2 lesions, new T1 gadolinium lesions)",Inter-reader reproducibility|Software versus manual analysis reproducibility for same reader|Classification of discordances,False,
NCT01417312,Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients,,COMPLETED,2011-07,2012-11,2013-01,2021-07-29,2011-08-16,INTERVENTIONAL,NA,20.0,ACTUAL,"Charite University, Berlin, Germany",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|Green tea extract|Metabolism,Germany,Berlin,,1,Capsules with 160 mg Teavigo (at least 94% EGCG)|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,"Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo",,False,
NCT06261528,Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis,A Phase I Study of Circadian Focused Light Therapy for Fatigue Reduction in Progressive Multiple Sclerosis (NO-FATIGUE),RECRUITING,2024-04-18,2025-12-01,2025-12-01,2025-07-16,2024-02-15,INTERVENTIONAL,PHASE1,20.0,ESTIMATED,University of Texas Southwestern Medical Center,OTHER,National Multiple Sclerosis Society|International Progressive Multiple Sclerosis Alliance,OTHER|UNKNOWN,Progressive Multiple Sclerosis,Fatigue|Sleepiness|Circadian,United States,Dallas,Texas,1,Light therapy,DEVICE,Treatment Emergent Adverse Events (TEAEs),,False,
NCT03706131,The Effect of Cervical Mobilization on Balance and Spasticity in Multiple Sclerosis Individuals,The Effect of Cervical Mobilization on Balance and Spasticity in Multiple Sclerosis Individuals,COMPLETED,2021-04-01,2021-04-30,2021-04-30,2021-05-10,2018-10-15,INTERVENTIONAL,NA,36.0,ACTUAL,Hacettepe University,OTHER,,,Multiple Sclerosis|Balance; Distorted,multiple sclerosis|cervical region|balance|spasticity|mobilisation,Turkey (Türkiye),Ankara,,1,cervical mobilisation,OTHER,Computerized Dynamic Posturography,Berg Balance Scale|Range of Motion|Modified Ashworth Scale,False,
NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),"A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials",ACTIVE_NOT_RECRUITING,2018-07-12,2025-09-23,2025-09-23,2025-06-27,2018-07-26,INTERVENTIONAL,PHASE3,1500.0,ESTIMATED,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,Argentina,Buenos Aires,,157,Ocrelizumab,DRUG,"Time to onset of CDP sustained for at least 24 weeks and for at least 48 weeks|Percentage of participants who have confirmed disability improvement (CDI), CDP for at least 24 weeks and for at least 48 weeks yearly and over the duration of the treatment|Percentage of participants who have improved, stable or worsened disability compared with baseline|Mean change from inclusion in parent study in EDSS score over the course of the treatment|Time to 20% increase in timed 25-foot walk test (T25FWT)","Time to first protocol-defined event of disease activity|Time to first relapse|Annualized relapse rate|Percentage of participants relapse free, yearly and over the course of the treatment|Percentage of participants with no evidence of protocol-defined disease activity (NEDA) yearly and over the duration of the treatment|Percentage of participants with no evidence of progression (NEP)|Percentage of participants with no evidence of progression sustained for at least 24 weeks and no active disease (NEPAD)|Change from baseline in cognitive performance as measured by the Symbol digit modalities test (SDMT)|Total number of T1 Gd-enhancing lesions as detected by brain MRI over time|Total number of new and/or enlarging T2 lesion as detected by brain MRI over time|Change in total T1 hypointense lesion volume over time|Total number of fluid-attenuated inversion-recovery (FLAIR) late enhancing lesions as detected by brain MRI over time|Change in brain volume (grey and white matter) as detected by brain MRI over time|Presence and evolution of leptomeningeal follicles as detected by MRI|Time to treatment discontinuation/switch|Participant reported outcomes: Employment status (Work Productivity and Activity Impairment Questionnaire [WPAI])|Participant reported outcomes: SymptoMScreen Score|Participant reported outcomes: Quality of life (QoL) (Multiple Sclerosis Impact Scale [MSIS]-29)|Percentage of Participants with Adverse Events|Total number of FLAIR late enhancing lesions as detected by brain MRI at the end of the treatment period",False,
NCT00819195,Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis,Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis,COMPLETED,2008-12,2012-09,2012-09,2013-10-08,2009-01-08,OBSERVATIONAL,,17.0,ACTUAL,"University of California, San Francisco",OTHER,"National Multiple Sclerosis Society|Teva Neuroscience, Inc.",OTHER|INDUSTRY,Multiple Sclerosis,relapsing-remitting|multiple sclerosis|Copaxone|glatiramer acetate|MS,United States,San Francisco,California,1,Glatiramer acetate,DRUG,Production of inflammatory cytokines by monocytes and naive T cells.,,False,
NCT04580381,Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort,Real World Effectiveness of Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis in a French Cohort,COMPLETED,2020-09-01,2021-10-01,2021-10-30,2022-03-09,2020-10-08,OBSERVATIONAL,,500.0,ACTUAL,"University Hospital, Caen",OTHER,Biogen,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",Natalizumab|Extended Interval Dosing,France,Bobigny,,5,Natalizumab Injection [Tysabri],DRUG,Annualized Relapse Ratio,Disability progression|NEDA-3 achievement|Radiological activity,False,
NCT06343558,Gait and Balance Impairment in Rare and Very Rare Neurological Diseases,Gait and Balance Impairment in Rare and Very Rare Neurological Diseases,RECRUITING,2023-05-30,2027-05-01,2027-05-01,2025-08-03,2024-04-02,OBSERVATIONAL,,200.0,ESTIMATED,Istituto Auxologico Italiano,OTHER,IRCCS Istituto Neurologico Carlo Besta,UNKNOWN,Multiple Sclerosis|Parkinson Disease|Peripheral Neuropathy|Rare Diseases|Healthy|Healthy Aging,Rare neurological diseases|Very rare neurological diseases|Undiagnosed neurological diseases|Upright stance|Balance|Risk of falling|Gait analysis|Posturography,Italy,Milan,Milan,2,"Questionnaires, clinical scales and instrumental tests",OTHER,Balance (Mini-BESTest)|Balance (Timed Up and Go test)|Gait speed|Gait analysis - kinematic - stride length|Gait analysis - kinematic - duration|Gait analysis - kinematic - width of the base of support|Gait analysis - kinematic - dorsal ankle angle|Gait analysis - dynamic - reaction force|Gait analysis - dynamic - ankle power|Gait analysis - dynamic - energy|Posturography - static - centre of pressure position|Posturography - static - centre of mass position|Posturography - dynamic - centre of pressure position|Posturography - dynamic - centre of mass position,,False,
NCT05575843,Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®,Neurostatus-SMARTCARE in Comparison to Standard Neurostatus- EDSS® - a Swiss Multicenter Randomized Cross-over Study,COMPLETED,2022-12-09,2023-11-17,2024-03-01,2024-07-23,2022-10-12,INTERVENTIONAL,NA,101.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,"Novartis Pharma AG, Basel, Switzerland",UNKNOWN,Multiple Sclerosis (MS),Expanded Disability Status Scale (EDSS)|Neurostatus|Neurostatus-eEDSS|Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB),Switzerland,Basel,,2,Neurostatus-SMARTCARE|Standard Neurostatus-EDSS,OTHER|OTHER,"Inter-rater reliability, i.e. the concordance rate between Neurostatus-SMARTCARE and Neurostatus-EDSS® at EDSS step level",Inter-rater reliability at subscore level between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®|Inter-rater reliability at Functional System Score (FSS) levels between Neurostatus-SMARTCARE and standard Neurostatus-EDSS®|Number of assessments rated correctly by neurologists in comparison to HCPs|Number and type of the same error occurring more than once at the individual rater level|Inter-rater reliability in capturing the number of changes in the Expanded Disability Status Scale (EDSS) through worsening and progression or improvement occurring between the first and second measurement.,False,
NCT01606215,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,Stem Cells in Rapidly Evolving Active Multiple Sclerosis,COMPLETED,2013-01,2019-08,2019-08,2025-01-14,2012-05-25,INTERVENTIONAL,PHASE1|PHASE2,21.0,ACTUAL,Imperial College London,OTHER,,,Multiple Sclerosis,multiple sclerosis|mesenchymal stem cells|bone marrow|rapidly evolving,United Kingdom,London,,1,Mesenchymal stem cells|Placebo,DRUG|DRUG,"Number of Adverse Events Assessed by CTCAE v4.0|Number of GELs Newly Appearing at Weeks 4, 12 and 24 After MSC Therapy in the First 24 Weeks of Trial","Number of Newly Appearing GELs Over Months 1, 3 and 6 Will be Compared Between Treatment Groups.|Comparison of Contrast Enhancing Lesions Between Treatment Periods Following Crossover|Combined Unique MRI Activity|Relapses|Progression of Disability",True,2025-01-14
NCT01404117,"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability",,WITHDRAWN,2012-03,2013-12,2014-01,2013-08-27,2011-07-27,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis,,,,,0,Laquinimod 0.6|Laquinimod 1.2|Glatiramer Acetate or interferon-beta+ Placebo,DRUG|DRUG|OTHER,Safety and efficacy,Tolerability,False,
NCT04221191,"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP","Study on the Dimethyl Fumarate (DMF, Tecfidera®) Persistence of Remitting-relapsing Multiple Sclerosis (RR-MS) Patients Included in the French Patient Support Program (PSP) OroSEP",COMPLETED,2019-08-19,2022-09-14,2022-09-14,2023-08-01,2020-01-09,OBSERVATIONAL,,353.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,France,Agen,,63,Dimethyl Fumarate|PSP,DRUG|OTHER,Percentage of Participants with Oral Dimethyl Fumarate (DMF) Persistence at 6 Months,Percentage of Participants with Oral Dimethyl Fumarate (DMF) Persistence at Both 1 Month and 3 Months|Percentage of Participant's with Adherence at 6 Months|Percentage of Participants by Reason of Oral Dimethyl Fumarate (DMF) Discontinuation at 3 Months and 6 Months|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Adverse Events (AEs) Related to Treatment|Percentage of Participants with Adverse Events (AEs) Leading to Treatment Discontinuation|Percentage of Participants with Adverse Events (AEs) of Interest|Participant's Anxiety at Inclusion and at 6 Months|Participant's Satisfaction Regarding Dimethyl Fumarate (DMF) Treatment at 6 Months|Participant's Satisfaction Regarding their Participation in OroSEP Patient Support Program (PSP)|Neurologists' Satisfaction Regarding their Participation in OroSEP Patient Support Program (PSP),False,
NCT05412043,"Fatigability in Persons With Multiple Sclerosis: Inputs From Cognition, Walking and Coordination",Walking-related Fatigability in Persons With Multiple Sclerosis: Psychometric Properties of Cognitive and Coordination Fatigability Assessment & Proof-of-concept of a Rehabilitation Intervention,COMPLETED,2021-09-01,2023-03-30,2024-05-30,2024-07-22,2022-06-09,INTERVENTIONAL,NA,16.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek,OTHER|OTHER,Multiple Sclerosis,Multiple sclerosis|Walking-fatigability|cognitive-fatigability|coordination-fatigability|Psychometric properties,Belgium,Overpelt,,2,"Dance therapy|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability",BEHAVIORAL|OTHER,The phase coordination index (PCI)|The phase coordination index (PCI)|The phase coordination index (PCI)|Movement Amplitude- Chair Coordination test|Movement Amplitude- Chair Coordination test|Movement Amplitude- Chair Coordination test|Movement Frequency- Chair Coordination test|Movement Frequency- Chair Coordination test|Movement Frequency- Chair Coordination test|Workload- Chair Coordination test|Workload- Chair Coordination test|Workload- Chair Coordination test|Motor fatigability during the 6 minutes condition|Motor fatigability during the 6 minutes condition|Motor fatigability during the 6 minutes condition|the paced auditory serial addition test (PASAT)|the paced auditory serial addition test (PASAT)|the paced auditory serial addition test (PASAT)|the symbol digit modality test (SDMT)|the symbol digit modality test (SDMT)|the symbol digit modality test (SDMT)|The 6 minute walking test|The 6 minute walking test|The 6 minute walking test,Spatiotemporal gait parameter- Cadence|Spatiotemporal gait parameter- Cadence|Spatiotemporal gait parameter- Cadence|Spatiotemporal gait parameter- Stride length|Spatiotemporal gait parameter- Stride length|Spatiotemporal gait parameter- Stride length|Spatiotemporal gait parameter- Gait speed|Spatiotemporal gait parameter- Gait speed|Spatiotemporal gait parameter- Gait speed|Spatiotemporal gait parameter- Double support|Spatiotemporal gait parameter- Double support|Spatiotemporal gait parameter- Double support|Short Form of the International Physical Activity Questionnaire (IPAQ-SF)|Short Form of the International Physical Activity Questionnaire (IPAQ-SF)|Short Form of the International Physical Activity Questionnaire (IPAQ-SF)|Physical activity by means of step count|Physical activity by means of step count|Physical activity by means of step count|the MFIS (modified fatigue impact scale)|the MFIS (modified fatigue impact scale)|the MFIS (modified fatigue impact scale)|The Pittsburgh Sleep Quality Index (PSQI)|The Pittsburgh Sleep Quality Index (PSQI)|The Pittsburgh Sleep Quality Index (PSQI)|Multiple Sclerosis Walking Scale-12 item (MSWS-12)|Multiple Sclerosis Walking Scale-12 item (MSWS-12)|Multiple Sclerosis Walking Scale-12 item (MSWS-12)|25-foot walk test (T25FW)|25-foot walk test (T25FW)|25-foot walk test (T25FW)|the nine-hole peg test (NHPT)|the nine-hole peg test (NHPT)|the nine-hole peg test (NHPT)|the 6-minute walking test|the 6-minute walking test|the 6-minute walking test|VAS (visual analogue scale)|VAS (visual analogue scale)|VAS (visual analogue scale),False,
NCT06966115,Optimising Access to Vocational Rehabilitation for People With Multiple Sclerosis,Optimising Access to Vocational Rehabilitation Through Multiple Sclerosis Charities: A Feasibility Randomised Controlled Trial,NOT_YET_RECRUITING,2025-06-10,2027-07-01,2027-12-01,2025-05-11,2025-05-11,INTERVENTIONAL,NA,60.0,ESTIMATED,University of Nottingham,OTHER,,,Multiple Sclerosis,Vocational Rehabilitation|multiple sclerosis|job retention,United Kingdom,Nottingham,,1,Multiple Sclerosis Vocational Rehabilitation (MSVR),BEHAVIORAL,Health-related quality of life|Work Productivity and Activity Impairment Questionnaire- Multiple Sclerosis,Goal Attaiment Scaling|Patient Health Questionnaire - 9 (PHQ-9)|Generalised Anxiety Disorder - 7 (GAD-7)|Perceived Difficulties Questionnaire|Health-related quality of life|Fatigue levels|Self-efficacy|Reasonable Adjustments,False,
NCT02408718,Assistive Device Training in Multiple Sclerosis,Assistive Device Training for Functional Mobility and Connectivity in Multiple Sclerosis,COMPLETED,2015-07,2016-09,2016-09,2016-09-21,2015-04-03,INTERVENTIONAL,NA,40.0,ACTUAL,Portland VA Medical Center,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,Mobility|walking aids|falls|gait and balance,United States,Portland,Oregon,1,Assistive Device Training,BEHAVIORAL,Change from Baseline in Functional Mobility at Completion of Training and the Following Three Months|Change from Baseline in Falls at Completion of Training and the Following Three Months|Change from Baseline in Functional Neural Connectivity (fMRI) at Completion of Training,Change from Baseline in Satisfaction with Assistive Device at Completion of Training and the Following Three Months|Change from Baseline in Balance Confidence at Completion of Training and the Following Three Months|Change from Baseline in Multiple Sclerosis Impact at Completion of Training and the Following Three Months|Change from Baseline in Physical Activity at Completion of Training and the Following Three Months,False,
NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2),"A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis",COMPLETED,2020-06-11,2024-07-16,2024-07-16,2025-07-02,2020-06-01,INTERVENTIONAL,PHASE3,899.0,ACTUAL,Sanofi,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Cullman,Alabama,186,Tolebrutinib|Teriflunomide HMR1726|Placebo to match Tolebrutinib|Placebo to match Teriflunomide,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses,"Time to Onset of 6-Month Confirmed Disability Worsening as Assessed by Expanded Disability Status Scale|Time to Onset of 3-Month Confirmed Disability Worsening as Assessed by Expanded Disability Status Scale|Mean Number of New and/or Enlarging T2-Hyperintense Lesions Per Year|Mean Number of New Gadolinium-Enhancing T1-Hyperintense Lesions Per Scan|Change From Baseline in Cognitive Function as Assessed by the Symbol Digit Modalities Test (SDMT) at EOS|Change From Baseline in Cognitive Function as Assessed by the California Verbal Learning Test Second Edition (CVLT-II) at EOS|Time to Onset of 6-Month Confirmed Disability Improvement (CDI) as Assessed by Expanded Disability Status Scale|Percent Change in Brain Volume Loss at EOS Compared to Month 6|Change From Baseline in Multiple Sclerosis Quality of Life 54 (MSQoL-54) Questionnaire Score at EOS|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), TEAEs Leading to Permanent Study Intervention Discontinuation and Adverse Events of Special Interest (AESIs)|Change From Baseline in Plasma Neurofilament Light Chain (NfL) and Serum Chitinase-3 Like Protein-1 (Chi3L1) Levels at EOS|Change From Baseline in Serum Immunoglobulin (Ig) Levels at EOS",True,2025-06-18
NCT03345940,Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis,A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl-Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers,TERMINATED,2017-04-30,2019-10-30,2019-10-30,2019-10-31,2017-11-17,INTERVENTIONAL,PHASE4,55.0,ACTUAL,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,OTHER,Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova,OTHER|OTHER,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis,Italy,Milan,,1,Fingolimod|Dimethyl Fumarate,DRUG|DRUG,effectiveness of fingolimod 0.5 mg once daily versus dimethyl-fumarate 240 mg twice daily,Annual relapse rate|Number of Gd+ MRI lesions|Brain volume loss|Prevention of sustained disability progression (EDSS worsening)|Prevention of Objective sustained disability progression|Patient-NEDA|Prevention of Cognitive decline|Evaluation of social cognition|Evaluation of quality of decision making|Preservation of Quality of life|Convenience perception|Psychiatric symptoms|Fatigue,False,
NCT06681623,A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS),"A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)",RECRUITING,2024-08-13,2027-09-30,2027-09-30,2024-11-18,2024-11-08,OBSERVATIONAL,,20.0,ESTIMATED,Neurology Center of New England P.C.,OTHER,,,"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis",,United States,Foxborough,Massachusetts,1,Ublituximab,DRUG,"Incidence of infection (including UTI and other active acute, opportunistic and/or chronic infection)|Incidence of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs)",Total number of new and/or enlarging T2 lesions on all available brain MRI scans|Functional Assessment (Expanded Disability Status Scale (EDSS))|Multiple Sclerosis Impact Scale (MSIS-29)|Absolute lymphocyte count (ALC)|Immunoglobulin levels|Functional Assessment (Timed 25-Foot Walk Test (T25-FW)),False,
NCT06385197,Improving the Effect of Multiple Sclerosis Drugs by Chronobiology,Improving the Effect of Dimethyl Fumarate and Diroximel Fumarate (DRF) for Patients With Multiple Sclerosis by Chronobiology,COMPLETED,2022-05-08,2023-06-01,2023-06-02,2024-05-06,2024-04-25,INTERVENTIONAL,NA,8.0,ACTUAL,Hadassah Medical Organization,OTHER,,,Multiple Sclerosis,,Israel,Jerusalem,,1,App randomizing dosing regimen,DEVICE,safety assessment|assessment of AE|assessment of AE,,False,
NCT04721717,AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis,AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis,RECRUITING,2020-09-01,2027-03-28,2027-03-28,2025-08-08,2021-01-25,OBSERVATIONAL,,160.0,ESTIMATED,University of Alabama at Birmingham,OTHER,,,Spinal Cord Injuries|Multiple Sclerosis|Transverse Myelitis|Amyotrophic Lateral Sclerosis,,United States,Birmingham,Alabama,1,,,The Grief and Loss Scale|Emotional Distress - Depression|Perceived Stress Scale|Impact of Events Scale|Meaning and Purpose|Self-Efficacy for Managing Chronic Conditions - Managing Emotions|Sleep Disturbance|Sleep Impact|Ability to Participate in Social Roles and Activities|Satisfaction with Social Roles and Activities|Connor-Davidson Resilience Scale,Cortisol level|Quality of Life During Serious Illness - Family Carers|Hospital Anxiety and Depression Scale (HADS)|Caregiver Burden Inventory,False,
NCT04574024,HFS (High-Fiber Supplement) in MS (Multiple Sclerosis),Effect of High-fiber Supplement in Multiple Sclerosis,COMPLETED,2022-03-21,2024-06-30,2024-07-15,2024-12-17,2020-10-05,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,"Suhayl Dhib-Jalbut, MD",OTHER,,,Multiple Sclerosis,High-fiber supplement,United States,New Brunswick,New Jersey,1,NBT-NM108,DRUG,Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients|Examine the Effect of NBT-NM108 on Anaerostipes in MS Patients.|Effect of NBT-NM108 on Fecal Lcn-2 Levels in MS Patients,,True,2024-12-17
NCT03670459,Forty Five Patients With Multiple Sclerosis Recieved Vestibular Rehabilitation and Balance Training,Cawthorne Cooksey Versus Vestibular Habituation Exercises on Trunk Kinetics and Velocity of Gait in Patients With Multiple Sclerosis,COMPLETED,2017-12-31,2018-07-21,2018-09-04,2018-09-13,2018-09-13,INTERVENTIONAL,NA,45.0,ACTUAL,October 6 University,OTHER,,,Neurologic Disorder,,Egypt,Giza,,1,Cawthorne Cooksey exercises|Vestibular habituation exercises|Balance exercises,OTHER|OTHER|OTHER,Isokinetic dynamometer,,False,
NCT01883310,Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects,"The Effects of a Task-oriented Circuit Training Combined With Cerebellar Transcranial Direct Current Stimulation on Locomotor Function, Balance and Mobility in Multiple Sclerosis Subjects",COMPLETED,2017-02-01,2017-07-01,2017-11-01,2017-11-20,2013-06-21,INTERVENTIONAL,NA,30.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis Subjects,Multiple Sclerosis|transcranial direct current stimulation|TOCT|task-oriented circuit training|locomotor function|mobility|balance,Italy,Ferrara,,1,sham tDCS + TOCT|real tDCS +TOCT,DEVICE|DEVICE,"Change from baseline on locomotor function, mobility and balance in multiple sclerosis subjects with gait speed (Timed 25-Foot Walk)",mobility (Timed Up and Go)|Balance (Dynamic Gait Index)|walking endurance (six minute walking test|fatigue (fatigue severity scale)|Short Form (36) Health Survey (SF-36),False,
NCT06634225,Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP),IMUSEP : Use of Inertial Navigation Systems to Detect and Characterize Early Locomotor Disorders in Patients With Multiple Sclerosis.,RECRUITING,2024-11-11,2025-11-11,2025-11-11,2025-09-10,2024-10-09,OBSERVATIONAL,,70.0,ESTIMATED,Lille Catholic University,OTHER,Roche Pharma AG,INDUSTRY,Multiple Sclerosis|Medical Device|Coordination and Balance Disturbances,Multiple Sclerosis|Trigno Avanti Sensor|Coordination and Balance Disturbances,France,Lomme,Hauts-de-France,2,Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95%) for validity of the Trigno® Avanti Sensor,Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95%) for repeatability|Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95% )for the whole-body angular momentum|Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95%) between the Expanded Disability Status Scale (EDSS) and the contribution and inefficiency indexes|Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95%) between the MSWS-12 (multiple sclerosis walking scale-two weeks) and the contribution and inefficiency indexes|Intra-class correlation coefficients (ICC) and their 95% confidence intervals (IC95%) between the MSWS-12 and whole-body angular momentum method (Trigno® Avanti Sensor inertial units / 3D 3D).|Differences in contribution and inefficiency indexes between groups,False,
NCT06381297,Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.,The Effect Of Medial Olivocochlear Efferents On Speech Discrimination In Noise In Multiple Sclerosis.,COMPLETED,2020-10-09,2023-03-23,2023-04-23,2024-04-24,2024-04-24,INTERVENTIONAL,NA,60.0,ACTUAL,Asuman Kucukoner,OTHER,,,Multiple Sclerosis-Relapsing-Remitting,"Multıple sclerosis,|Auditory efferent system|Contralateral supression|speech in noise discrimination",Turkey (Türkiye),Samsun,,1,Hearing test|Speech in noise discrimination test|Montreal Cognitive Assessment Scale|Symbol Number Modalities Test (SDMT),DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Pure tone Audiometry Test|Speech Audiometry|Speech Discrimination in Noise Test|Otoacoustic Emission Test|Contralateral Suppression Test,Montreal Cognitive Assessment Scale|Symbol Digit Modalities Test,False,
NCT00913510,Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,TERMINATED,2009-12,2012-05,2012-05,2021-11-11,2009-06-04,INTERVENTIONAL,NA,24.0,ACTUAL,Wellspect HealthCare,INDUSTRY,,,Bladder Dysfunction|Multiple Sclerosis,,Belgium,Esneux,,5,CIC using LoFric Primo|Anticholinergic medication,DEVICE|DRUG,Percent Change From Baseline in Frequency of Micturition Per Day at 8 Weeks.,,True,2014-01-06
NCT00919217,Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms,Exploratory Study on the Timing of MS Symptoms,RECRUITING,2008-08,2025-12,2025-12,2025-02-20,2009-06-12,OBSERVATIONAL,,80.0,ESTIMATED,University of Louisville,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|MS|Relapsing-remitting multiple sclerosis|RR-MS|Women,United States,Louisville,Kentucky,1,,,number of days with appearance or worsening of symptoms,timing of appearance or worsening of symptoms,False,
NCT07000968,"The Effect of Task-Oriented Training and Virtual Reality Training on Balance, Gait and Fatigue in Individuals With Multiple Sclerosis","The Effect of Task-Oriented Training and Virtual Reality Training on Balance, Gait and Fatigue in Individuals With Multiple Sclerosis",COMPLETED,2023-01-15,2024-06-01,2024-08-01,2025-06-03,2025-06-03,INTERVENTIONAL,NA,63.0,ACTUAL,Inonu University,OTHER,,,"Multiple Sclerosis|Balance Impairment, Gait Disorders, Fatigue|Multiple Sclerosis Bening|Multiple Sclerosis Relapsing Remitting",Task Oriented Training|Virtual Reality|Multiple Sclerosis,Turkey (Türkiye),Malatya,Central,1,Virtual Reality Training Group|Task-Oriented Training Group|Conventional Training Group,OTHER|OTHER|OTHER,Berg Balance Test,Fatigue Severity Scale,False,
NCT04586023,Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),"A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2021-03-24,2025-09-05,2027-07-09,2025-09-18,2020-10-14,INTERVENTIONAL,PHASE3,751.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Cullman,Alabama,108,Fenebrutinib|Teriflunomide|Placebo,DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),"Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12)|Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)|Time to Onset of 12-week Confirmed Disability Progression (CDP12)|Time to Onset of 24-week Confirmed Disability Progression (CDP24)|Total Number of T1 Gadolinium-enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions as Detected by Magnetic Resonance Imaging (MRI)|Percentage Change in Total Brain Volume from Week 24 as Assessed by MRI|Change in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis, 29-Item [MSIS-29] Physical Scale|Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score|Change from Baseline to Week 48 in the Concentration of Blood Neurofilament Light chain (NfL)|Percentage of Participants with Adverse Events (AEs)|Plasma Concentrations of Fenebrutinib at Specified Timepoints|Time to Onset of Composite 12-week Confirmed Progression Independent of Relapse Activity (cPIRA12)",False,
NCT05327322,Functional Outcomes From Diets in Multiple Sclerosis,The Impact of Diet Quality and Calorie Restriction on Physical Function and Patient Reported Outcomes in Multiple Sclerosis,RECRUITING,2023-03-20,2026-01-31,2026-01-31,2025-04-08,2022-04-14,INTERVENTIONAL,NA,100.0,ESTIMATED,University of Alabama at Birmingham,OTHER,Washington University School of Medicine|United States Department of Defense,OTHER|FED,Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,,United States,Birmingham,Alabama,2,Glycemic load|Calorie restriction|Behavioral support,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Multiple Sclerosis Functional Composite (MSFC)|Multiple Sclerosis Functional Composite (MSFC)|Multiple Sclerosis Functional Composite (MSFC),Brief International Cognitive Assessment for MS (BICAMS)|Brief International Cognitive Assessment for MS (BICAMS)|Brief International Cognitive Assessment for MS (BICAMS)|Patient reported outcomes: Hospital Anxiety and Depression Scale (HADS)|Patient reported outcomes: Hospital Anxiety and Depression Scale (HADS)|Patient reported outcomes: Hospital Anxiety and Depression Scale (HADS)|Patient reported outcomes: Modified Fatigue Impact Scale (MFIS)|Patient reported outcomes: Modified Fatigue Impact Scale (MFIS)|Patient reported outcomes: Modified Fatigue Impact Scale (MFIS)|Patient reported outcomes: Fatigue Severity Scale (FSS)|Patient reported outcomes: Fatigue Severity Scale (FSS)|Patient reported outcomes: Fatigue Severity Scale (FSS)|Patient reported outcomes: Visual Analog Fatigue Scale (VAFS)|Patient reported outcomes: Visual Analog Fatigue Scale (VAFS)|Patient reported outcomes: Visual Analog Fatigue Scale (VAFS)|Patient reported outcomes: Short-form McGill Pain Questionnaire Revised (SF-MPQ-2)|Patient reported outcomes: Short-form McGill Pain Questionnaire Revised (SF-MPQ-2)|Patient reported outcomes: Short-form McGill Pain Questionnaire Revised (SF-MPQ-2)|Patient reported outcomes: Pittsburg Sleep Quality Index (PSQI)|Patient reported outcomes: Pittsburg Sleep Quality Index (PSQI)|Patient reported outcomes: Pittsburg Sleep Quality Index (PSQI),False,
NCT02263339,Exercise & Brain Health in MS,Aerobic Exercise to Improve Brain Metabolism in MS,COMPLETED,2014-09,2016-04,2016-05-25,2019-06-19,2014-10-13,INTERVENTIONAL,NA,24.0,ACTUAL,Oregon Health and Science University,OTHER,,,Multiple Sclerosis,Exercise|MRI,United States,Portland,Oregon,1,Aerobic Exercise|Stretching|Aerobic Exercise- Healthy Subjects,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Comparison of correlations in changes in VO2Max at 12 weeks with changes in brain ATP production at 12 weeks between aerobic exercise group and stretching group.,Changes in Cognition at 12 weeks|Changes in fatigue at 12 weeks,False,
NCT01512329,Pacing Activity Self-management for Patients With Multiple Sclerosis,Pacing Activity Self-management for Patients With Multiple Sclerosis: Randomized Controlled Clinical Trial,COMPLETED,2011-10,2014-02,2014-10,2015-12-17,2012-01-19,INTERVENTIONAL,PHASE2,31.0,ACTUAL,Vrije Universiteit Brussel,OTHER,"University Hospital, Antwerp|Universiteit Antwerpen|Artesis University College, Antwerp",OTHER|OTHER|OTHER,Multiple Sclerosis,neurology|physiotherapy|physical therapy|occupational therapy|stress management|activity management|treatment,Belgium,Melsbroek,,1,pacing|relaxation,BEHAVIORAL|BEHAVIORAL,the change in scores obtained from the Canadian Occupational Performance Measure (COPM),the change in subscale scores on the Medical Outcomes Short Form 37 Health Status Survey (SF-36)|the change in subscale scores on the Checklist Individual Strength (CIS)|the change in autonomic activity at rest and following 3 activities of daily living,False,
NCT01051128,Continuous Intrathecal Baclofen Infusion for Chronic Spasticity,Continuous Intrathecal Baclofen Infusion for the Management of Chronic Spasticity,WITHDRAWN,2010-01,2010-06,2010-12,2015-03-06,2010-01-18,INTERVENTIONAL,PHASE3,0.0,ACTUAL,Flowonix Medical,INDUSTRY,,,Spasticity,neurological disorders|multiple sclerosis|stroke|cerebral palsy|spinal cord|brain injuries|neurodegenerative diseases,,,,0,Prometra Programmable Implantable Pump System,DEVICE,The primary endpoint is: A change in the average lower extremity spasticity score as measured by the Modified Ashworth Scale,Secondary Endpoints include: Change in overall spasm frequency as measured by the Penn Spasm Frequency Scale. Change in overall Quality of Life as measured by the SF 36 and PSQI. SAE-free survival. DRAE-free survival. Tabulation of device complications.,False,
NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,"A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)",TERMINATED,2011-09,2012-11,2012-11,2014-08-08,2011-12-26,INTERVENTIONAL,PHASE3,142.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS),Relapsing remitting multiple sclerosis|multiple sclerosis (MS)|safety|tolerability|health outcomes|fingolimod|disease control|MRI,Australia,Box Hill,Victoria,44,Fingolimod|Placebo,DRUG|DRUG,Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment,"Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment|Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment|Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)|Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group|Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion|Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period|Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment",True,2014-04-04
NCT04578041,TRPMS to Improve Mobility and Depression in Multiple Sclerosis,"An Open Label Pilot Study to Investigate the Effect of Transcranial Rotating Permanent Magnetic Stimulation (TRPMS) on Gait, Balance and Depression in People With Multiple Sclerosis (MS)",WITHDRAWN,2023-01-01,2023-03-05,2023-03-05,2023-12-28,2020-10-08,INTERVENTIONAL,NA,0.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,Transcranial Rotating Permanent Magnetic Stimulation,,,,0,TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|Aerobic Exercise Program|Computerized CT (Cognitive Training),DEVICE|OTHER|OTHER,Percent of Sessions Completed|Change in Gait Velocity|Change in PROMIS Depression Score,Change in Gait Velocity|Change in Distance Traveled During 2-Minute Walking Test|Change in the Total Time for Completing the Timed Up and Go (TUG) test|Change in Modified Fatigue Impact Scale (MFIS) Score|Change in Short Form (SF)-36 Score|Change in PROMIS Depression Score|Change in Center for Epidemiological Studies-Depression short form (CESD-10) Score|Change in Patient Health Questionnaire 9 (PHQ-9) Score|Change in Inventory of Depressive Symptomatology Self-Report (IDS-SR) Score,False,
NCT03213522,Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy,A Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy for the Treatment of Lower Urinary Tract Dysfunction in People With Multiple Sclerosis: A Pilot Study,UNKNOWN,2017-04-10,2018-04-09,2018-04-09,2017-07-11,2017-07-11,INTERVENTIONAL,NA,30.0,ESTIMATED,CentraState Medical Center,OTHER,,,Multiple Sclerosis|Bladder Dysfunction|Urinary Incontinence|Overactive Bladder,,United States,Freehold,New Jersey,1,Pelvic Floor Physical Therapy|Craniosacral Therapy,PROCEDURE|PROCEDURE,PFDI-20|PFIQ-7,MSQOL-54|Post void residual volume|Resting SEMG|Systolic BP|Systolic BP|Diastolic BP|Diastolic BP|Pulse|Pulse,False,
NCT06256575,Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis,"Treatment of Digital Ulcers in Systemic Sclerosis With Diosmin: A Randomized, Double-blind, Placebo-controlled Multi-centre Pilot Study",RECRUITING,2025-05-02,2027-07-15,2027-08-15,2025-07-10,2024-02-13,INTERVENTIONAL,NA,45.0,ESTIMATED,Primus Pharmaceuticals,INDUSTRY,KGK Science Inc.,INDUSTRY,"Scleroderma, Systemic|Digital Ulcer",SSc|Digital Ulcers|Sclerosis|Scleroderma,Canada,London,Ontario,2,Diosmin|Placebo,COMBINATION_PRODUCT|OTHER,Efficacy - Number (%) of healed baseline ulcers,Safety - number of adverse events,False,
NCT05402501,Lifestyle Intervention for Patients With Multiple Sclerosis,Lifestyle Intervention for Patients With Multiple Sclerosis,UNKNOWN,2021-04-15,2024-11,2024-11,2022-06-02,2022-06-02,OBSERVATIONAL,,900.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,"National MS Foundation, The Netherlands|Voeding Leeft",UNKNOWN|UNKNOWN,Multiple Sclerosis,Lifestyle,Netherlands,Amsterdam,North Holland,1,"Lifestyle intervention program ""Leef! met MS""",BEHAVIORAL,Multiple Sclerosis Impact Scale (MSIS-29),12-item Short Form Health Survey (SF-12)|EuroQol 5 Dimensions Questionnaire (EQ-5D)|BMI|Waist circumference|Bristol stool chart|Medical Consumption Questionnaire (iMCQ)|Hospital Anxiety and Depression Scale (HADS)|Checklist Individual Strength-20-r (CIS-20)|Multiple Sclerosis Neuropyschological Screening Questionnaire - patient version (MSNQ-P)|Medical Outcomes Study Sleep Scale (MOS-ss)|Dutch Norm for Healthy Physical Activity (In Dutch: Nederlandse Norm voor Gezond Bewegen (NNGB))|Perceived stress scale (PSS)|iMTA Productivity Cost Questionnaire (iPCQ)|Neurokeys keyboard app|MS sherpa app - Smartphone-adapted Symbol Digit Modalities Test (sSDMT)|MS sherpa app - Smartphone-adapted two-minute walking test|MS sherpa app - questionnaire,False,
NCT00940719,Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS),The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study,COMPLETED,2009-08,2010-03,2010-07,2010-08-11,2009-07-16,INTERVENTIONAL,NA,15.0,ESTIMATED,Maastricht University Medical Center,OTHER,Orbis Medical Centre,OTHER,Multiple Sclerosis,Multiple Sclerosis|Regulatory T cell function|Vitamin D|Vitamin D3|25-hydroxyvitamin D,Netherlands,Sittard,,1,vitamin D3,DIETARY_SUPPLEMENT,T cell regulation,serum 25-hydroxyvitamin D levels|calcium metabolism,False,
NCT04106830,Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE),Prospective Cohort Study of CLinical and Imaging Patterns of NeUroinflammation DisEases (CLUE),RECRUITING,2019-01-01,2025-12-31,2028-12-31,2024-12-24,2019-09-27,OBSERVATIONAL,,1000.0,ESTIMATED,Beijing Tiantan Hospital,OTHER,,,NMO Spectrum Disorder|MRI|Multiple Sclerosis|MOGAD,,China,Beijing,Beijing Municipality,1,Intravenous steroid,DRUG,The brain structural change over time between the baseline MRI and the follow-up MRIs|The spinal cord change over time between the baseline MRI and the follow-up MRIs.|The functional change over time between the baseline MRI and the follow-up MRIs.,Change from Baseline Expanded Disability Status Scale （EDSS）/ Functional Systems （FS）|Timed 25-foot Walk|Mean change in visual acuity as assessed by Sloan 2.5% low contrast visual acuity chart.,False,
NCT05757830,PURO - PUlmonary Rehabilitation With O-RAGT Platform,"Metabolic Consumption, Cardiorespiratory Effort, Cardiac Autonomic Control and Fatigability During Exoskeleton-assisted (the U&O Suite) sit-to Stand Maneuver and Walking in People With Neurological Diseases With Moderate to Severe Gait Disability.",COMPLETED,2022-12-23,2023-03-31,2023-03-31,2023-06-15,2023-03-07,INTERVENTIONAL,NA,20.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,Roessingh Research and Development|Hospital Nacional de Parapléjicos de Toledo|Lithuanian University of Health Sciences,OTHER|OTHER|OTHER,Multiple Sclerosis|Spinal Cord Injury|Stroke|Traumatic Brain Damage,,Italy,Milan,MI,4,UANGO suite exoskeleton,DEVICE,Walking meters change during 4 minute walking test,Number of repetitions change in one-minute sit to stand test|Average VO2 change during 4 minute walking test|O2 cost of walking change during 4 minute walking test|Net metabolic power change during 4 minute walking test|Physiological cost index (PCI) change during 4 minute walking test|Average heart rate change during 4 minute walking test|Heart rate increase change during 4 minute walking test|Rating of perceived exertion of lower limbs change before and after each trials|Rating of perceived exertion of breath change before and after each trials|Assessment of device usability at the end of each condition|Assessment of users satisfaction at the end of each condition|Assessment of the work load change during each trials,False,
NCT05242731,Telemonitoring and Connected Care Applied to Multiple Sclerose,"MonSter Study, Telemonitoring and Connected Care Applied to Multiple Sclerose",ACTIVE_NOT_RECRUITING,2021-04-29,2024-04-29,2025-12-31,2023-10-10,2022-02-16,INTERVENTIONAL,NA,208.0,ESTIMATED,Isala,OTHER,,,Multiple Sclerosis,,Netherlands,Groningen,Nederland,4,"MSmonitor, a self-management/education program with e-health interventions|Video calling program ""Better-close""|Researchmanager program",DEVICE|DEVICE|DEVICE,The primary endpoint is Multiple Sclerose Quality of Life (MSQuol54),Impact on participation and autonomy (IPA)|Work together on health (PIH)|Health questionnaire (Eq5D-5L)|MS Self-Efficacy Scale (MSSES)|Medical Consumption Questionnaire (iMCQ)|Productivity Costs Questionnaire (iPCQ)|Patient satisfaction questionnaire (PTO),False,
NCT01993095,FlexToBa for People With Multiple Sclerosis,Improving Functional Performance in Persons With MS Via Physical Activity DVD Intervention,COMPLETED,2013-10,2014-09,2014-09,2017-02-23,2013-11-25,INTERVENTIONAL,NA,50.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Multiple Sclerosis|Quality of Life|Functional Fitness,United States,Urbana,Illinois,1,"Home-based, DVD-delivered physical activity|Behavioral: Usual care/Wait list",BEHAVIORAL|BEHAVIORAL,Change from baseline to six-months in assessments of functional fitness of sedentary adults who have Multiple Sclerosis|Change from baseline to six-months in assessments of functional fitness of sedentary adults who have MS|Change in assessments of functional fitness assessments in sedentary adults with MS|Change from baseline to six-months in assessments of functional fitness of sedentary adults with MS|Change from baseline to six-months in assessments of functional fitness of sedentary adults who have MS|Change from baseline to six-months in assessments of functional fitness of sedentary adults with MS|Change from baseline to six-months in assessments of functional fitness of sedentary adults who have MS|Change from baseline to six-months in assessments of reported quality of life in people with MS|Change from baseline to six-months in assessments of reported quality of life in people with MS,Change from baseline to six-months in assessments of cognitive performance in sedentary adults with MS|Change from baseline to six-months in assessments of reported barriers self-efficacy in people with MS|Changes in physical activity relating to specified exercise program in sedentary adults with MS|Objective changes in physical activity in sedentary adults with MS|Self-reported changes in physical activity in sedentary adults with MS|Change from baseline to six-months in assessments of reported gait self-efficacy in sedentary adults with MS|Change from baseline to six-months in assessments of reported exercise self-efficacy in sedentary people with MS|Change from baseline to six-months in assessments of reported self-efficacy of walking in sedentary people with MS,False,
NCT01065727,Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis,"Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis",UNKNOWN,2010-02,2016-02,2019-02,2012-12-03,2010-02-09,INTERVENTIONAL,NA,250.0,ESTIMATED,Rennes University Hospital,OTHER,,,Multiple Sclerosis,Reemitting aggressive multiple sclerosis,France,Brest,,2,mitoxantrone - immunomodulator|natalizumab,OTHER|OTHER,cost effectiveness,progressive neurological disability,False,
NCT02717429,Cognitive and Emotion Regulation Training in MS,Cognitive and Emotion Regulation Training in Multiple Sclerosis,COMPLETED,2015-10,2017-05-14,2017-05-14,2018-04-17,2016-03-23,INTERVENTIONAL,NA,62.0,ACTUAL,Ohio State University,OTHER,,,Multiple Sclerosis,,United States,Columbus,Ohio,1,Mindfulness Meditation|Computerized Cognitive Training,BEHAVIORAL|BEHAVIORAL,Change in Reported Engagement After Worry and Rumination Inductions,Cognitive Performance on Brief Repeatable Battery (BRB)|Heart Rate Variability (HRV)|Daily Emotion Regulation Diary|Improvements on a Self-Report Measure of Emotion Dysregulation|Improvements on a Self-Report Measure of Depression|Improvements on a Self-Report Measures of Anxiety|Improvements on a Self-Report Measure of Perceived Stress|Improvements on a Self-Report Measure of Quality of Life,False,
NCT02764372,Telerehabilitation Upper Extremity for Neurological Disorders,Serious Games for Upper Extremity Rehabilitation for Patients With Neurological Disorders: A Pilot Study,COMPLETED,2015-07,2016-03,2016-04,2016-05-06,2016-05-06,INTERVENTIONAL,PHASE1,20.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,University of Bremen,OTHER,Multiple Sclerosis|Stroke,Arm rehabilitation|Serious games|stroke|Multiple sclerosis,,,,0,Serious games|Exergames,BEHAVIORAL|BEHAVIORAL,9 Hole peg test|Box and Block test,Short Form 12|the EQ-5D visual analogue scale (EQ-VAS),False,
NCT01834586,Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications,Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH),COMPLETED,2013-03,2015-03,2015-03,2018-04-10,2013-04-18,INTERVENTIONAL,PHASE4,30.0,ACTUAL,"Brown, Theodore R., M.D., MPH",INDIV,,,Multiple Sclerosis,,United States,Kirkland,Washington,1,Anesthetic Topical Adhesive Synera,DRUG,Pain Rating,Average Pain Rating,True,2018-03-13
NCT00292253,Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects,"A Randomized, Multicenter, Parallel Group, Open-label Study Comparing the Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing Remitting MS Patients",COMPLETED,2001-01,2002-12,2002-12,2013-08-06,2006-02-15,INTERVENTIONAL,PHASE3,1883.0,ACTUAL,EMD Serono,INDUSTRY,Merck Serono International SA,INDUSTRY,"Multiple Sclerosis, Relapsing-remitting",MS,,,,0,Rebif® via Rebiject™Mini|Rebif® via manual injections,DEVICE|DEVICE,Percentage of subjects with moderate to severe (Grade 3-5) injection site reactions based on physician assessment,Number of subjects with any injection site reactions based on physician assessment|Percentage of moderate to severe (Grade 3-5) injection site reactions reported per subject based on subject reports|Percentage of injection site reactions reported per subject based on subject reports,False,
NCT02836327,Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders,Multimodel MRI to Explore the Pathophysiology of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders,UNKNOWN,2014-09,2019-09,2021-09,2016-08-09,2016-07-19,OBSERVATIONAL,,300.0,ESTIMATED,Chinese PLA General Hospital,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders,MRI|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders|Multimodel,China,Beijing,Beijing Municipality,1,Magnetic Resonance Imaging,OTHER,Recurrence,,False,
NCT05402956,Aerobic Exercise in Persons With Multiple Sclerosis With Restless Legs Syndrome,Effect of Aerobic Exercise Training in Persons With Multiple Sclerosis With Restless Legs Syndrome,UNKNOWN,2022-05-30,2023-10,2023-12,2022-06-06,2022-06-02,INTERVENTIONAL,NA,30.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,1,Aerobic exercise,BEHAVIORAL,International Restless Legs Syndrome Study Group rating scale for restless legs syndrome,Timed 25-Foot Walk|12-Item Multiple sclerosis walking scale|Epworth Sleepiness Scale|Multiple Sclerosis International Quality of Life questionnaire|Pittsburgh Sleep Quality Index|Time Up and Go Test|Six-Minute Walk Test|Two-Minute Walk Test|Estimated VO2 Max,False,
NCT01076595,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period","Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program",COMPLETED,2010-05,2013-11,2014-07,2015-07-03,2010-02-26,OBSERVATIONAL,,73.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|BetaPlus program|Recurrent/remittent multiple sclerosis patients|Adherence to treatment regimen,France,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,The adherence to treatment (rate of patients continuing with Betaferon® regimen after 24 months),"Compliance to Betaferon according physician (rate of patients with compliance rater > 94,5%)|Adherence to treatment (rate of patients continuing with the Betaferon® regimen at 6 and 12 months)|Rate of patients with prematurely study discontinuation|Patient's autonomy with regard to the Betaferon® injections (Number of injections realized by the patient alone/total number of injections)|Tolerability of Betaferon injections (rate and number of injections)|Patient's Quality of Life (Mean total score of FAMS [Functional Assessment of Multiple Sclerosis])|Fatigue (mean total score of FSS [Fatigue Severity scale])|Progression of clinical Condition( annual rate of Relapses)|Percentage of patients with change of in EDSS (Expanded Disability Status Scale) < 1 between M0 and end of the study|Percentage of patients with change in EDSS< 1 and no relapse between M0 and M24",False,
NCT05070286,Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.,A Lifestyle Weight Management Program for Paediatric Patients With Demyelinating Conditions: Interviews and Stakeholder Meetings.,UNKNOWN,2022-01-01,2022-12-31,2022-12-31,2022-01-21,2021-10-07,OBSERVATIONAL,,45.0,ESTIMATED,Oxford Brookes University,OTHER,Great Ormond Street Hospital for Children NHS Foundation Trust|Guy's and St Thomas' NHS Foundation Trust|Oxford University Hospitals NHS Trust,OTHER|OTHER|OTHER,Multiple Sclerosis|Neuromyelitis Optica,Paediatric,United Kingdom,Oxford,Oxfordshire,1,Observational Study.,BEHAVIORAL,Lifestyle interviews: Themes and factors.,,False,
NCT03841903,Spinal Cord Analysis in Multiple Sclerosis,Structural Analysis of Spinal Cord Grey and White Matter Changes in Patients With Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC-study),COMPLETED,2017-07-01,2020-03-24,2020-03-24,2020-03-31,2019-02-15,OBSERVATIONAL,,79.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,,,Multiple Sclerosis,Spinal cord|Spinal cord atrophy|Cerebrospinal Fluid|Swiss Multiple Sclerosis Cohort,Switzerland,Basel,,1,spinal cord MRI,DIAGNOSTIC_TEST,Change in SC atrophy assessed by MRI,Change in Timed 25-foot walk test (T25-FW)|Change in Multiple Sclerosis Walking Scale-12 (MSWS-12) Questionnaire,False,
NCT01417273,Impact of Vitamin A on Multiple Sclerosis (MS),Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients,UNKNOWN,2010-02,2013-02,2013-08,2011-08-16,2011-08-16,INTERVENTIONAL,PHASE4,100.0,ESTIMATED,Tehran University of Medical Sciences,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple sclerosis|immune system|vitamin A|(MSFC)Multiple Sclerosis Functional Composite|(EDSS)Expanded Disability Status Scale|(MRI)Magnetic resonance imaging,Iran,Tehran,,1,vitamin A|Drug: placebo,DIETARY_SUPPLEMENT|DRUG,Expanded Disability Status Scale (EDSS)|Multiple Sclerosis Functional Composite (MSFC)|fatigue scores|depression score|Number of active lesion in magnetic resonance imaging (MRI) number of active lesion in brain MRI,number of disease relapses,False,
NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,"Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)",COMPLETED,2017-01-30,2020-10-26,2020-10-26,2020-11-25,2017-06-06,INTERVENTIONAL,PHASE4,80.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,Portugal,Amadora,,15,peginterferon beta-1a|interferon beta-1a|interferon beta-1b,DRUG|DRUG|DRUG,Combined Counts of Adverse Events (AEs) of Flu-Like Symptoms (FLS)|Combined Counts of AEs of Injection Site Reactions (ISRs)|Combined Counts of AEs of Injection Site Reactions (ISRs)|Combined Counts of AEs of ISR Pain (ISRP),"Change in Participant-Reported Treatment Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM-9) in Participants Treated with PLEGRIDY Versus Current SC IFN-β|Change in Participant-Reported Treatment Satisfaction Using TSQM-9 in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in Participant-Reported Outcome (PRO) Measures in EuroQol Group 5-Dimension 3-Level Version (EQ-5D-3L) Index in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Change in PRO Measures in EQ-5D-3L Index in Participants Continuously Treated with PLEGRIDY Versus Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in EQ-5D-3L Index in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in Work Productivity and Activity Impairment Questionnaire: Multiple Sclerosis V2.1 (WPAI: MS) Score in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Change in PRO Measures in WPAI: MS Score in Participants Continuously Treated with PLEGRIDY Versus Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in WPAI: MS Score in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Percentage of Participants with Changes in Clinical Status Assessed Using the Expanded Disability Status Scale (EDSS)|Change in PRO Measures in 12-Item Short Form Survey (SF-12) Score in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Change in PRO Measures in SF-12 Score in Participants Continuously Treated with PLEGRIDY Versus Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in SF-12 Score in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in Fatigue Severity Scale (FSS) Score in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Change in PRO Measures in FSS Score in Participants Continuously Treated with PLEGRIDY Versus Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in FSS Score in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in Hospital Anxiety And Depression Scale (HADS) Score in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Change in PRO Measures in HADS Score in Participants Continuously Treated with PLEGRIDY Versus Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Change in PRO Measures in HADS Score in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Participants Adherence to Study Treatment as Measured by Treatment Adherence Questionnaire|Participants Adherence to Study Treatment as Measured by Returned Injection Pens|Participants Adherence to Study Treatment as Measured by Treatment Adherence Questionnaire in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Participants Adherence to Study Treatment as Measured by Returned Injection Pens in Participants Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period|Proportion of Pain-Free Participants Immediately After Injection (Defined as 0 mm for All Full-Dose Injections on VAS of Participant-Reported Pain) at End Of the Comparator Period in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Proportion of Pain-Free Participants 30 Minutes after Injection (Defined as 0 mm for All Full-Dose Injections on VAS of Participant-Reported Pain) at End of the Comparator Period in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Average Change in Participant-Reported VAS Pain Score from Pre-Injection to 30 Minutes Post-Injection in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Average Change in Participant-Reported VAS Pain Score from Pre-Injection to Immediate Post-Injection in Participants Treated with PLEGRIDY Versus Current SC IFN-Β|Percentage of Participants with Changes in Relapse Activity|Annualized Relapse Rate (ARR) in Participants in the Overall Population|Proportion of Relapsed Participants in Overall Population|Percentage of Participants with an Adverse Event (AE), Serious AE, and Discontinuations of Study Treatment due to an AE in Participants Treated with PLEGRIDY Versus Current SC IFN-β|Percentage of Participants with an AE, Serious AE, and Discontinuation of Study Treatment due to an AE Continuously Treated with PLEGRIDY|Percentage of Participants with an AE, Serious AE, and Discontinuation of Study Treatment due to an AE Who Switched from Current SC IFN-Β Therapy to PLEGRIDY at the End of the Comparator Period",False,
NCT05470751,GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,COMPLETED,2023-02-02,2024-04-06,2024-04-06,2024-04-30,2022-07-22,OBSERVATIONAL,,72.0,ACTUAL,ConvaTec Inc.,INDUSTRY,,,Bladder Outlet Obstruction|Multiple Sclerosis|Cauda Equina Syndrome|Enlarged Prostate With Lower Urinary Tract Symptoms|Parkinson Disease|Lower Urinary Tract Symptoms|Detrusor Underactivity|Spinal Cord Injuries,neurogenic bladder|intermittent self-catherterisation|pain|bladder outflow obstruction,United States,West Orange,New Jersey,16,Intermittent self-catheterisation,DEVICE,To assess difficulty during catheterisation and quality of life using the ICDQ and ISC-Q validated questionnaires during catheterisation,To assess patient confidence regarding reduced stickiness plus related risk of urethral injury and resultant bleeding or infection|To assess compliance with the self-catheterization for the study duration,False,
NCT04711941,A ToM Training for People With Multiple Sclerosis: an Efficacy Study.,Effectiveness of a Novel Theory of Mind Training for People With Multiple Sclerosis: a Randomised Controlled Trial.,UNKNOWN,2021-02-01,2021-05,2021-09,2021-05-06,2021-01-15,INTERVENTIONAL,NA,40.0,ESTIMATED,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Multiple Sclerosis,theory of mind|rehabilitation|multiple sclerosis|neurodegenerative disease,Italy,Milan,,1,Rehabilitation training,BEHAVIORAL,Reading the Mind from the Eyes (RMET)|Strange Stories|Faux pas|False Belief Task,Toronto Alexithymia Scale (TAS-20)|Multiple Sclerosis Quality of Life 54 questionnaire (MSQOL54)|Montreal Cognitive Assessment (MoCA)|The Brief Repeatable Battery of Neuropsychological Test (BRB-NT),False,
NCT02641041,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants","A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects",COMPLETED,2016-02,2016-09,2016-09,2016-10-10,2015-12-29,INTERVENTIONAL,PHASE1,24.0,ACTUAL,Biogen,INDUSTRY,,,Central Nervous System (CNS) Demyelinating Disease|Multiple Sclerosis,Japanese|Single Ascending Dose (SAD)|Multiple Ascending Dose (MAD),United Kingdom,Leeds,West Yorkshire,1,BIIB033|Placebo,BIOLOGICAL|OTHER,Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant neurological examination abnormalities,PK parameter of BIIB033: Area under the concentration-time curve from time zero to infinity (AUCinf)|PK parameter of BIIB033: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)|PK parameter of BIIB033: AUC over a given dosing interval|PK parameter of BIIB033: Maximum observed concentration (Cmax)|PK parameter of BIIB033: Time to reach maximum observed concentration (Tmax)|PK parameter of BIIB033: Terminal elimination half-life (t1/2)|PK parameter of BIIB033: Volume of distribution at steady state (Vss)|PK parameter of BIIB033: Clearance (CL)|PK parameter of BIIB033: accumulation ratio (RAC)|Number of participants with positive serum BIIB033 antibodies,False,
NCT06263556,Effectiveness of TTNS in MS Patients With Lower Urinary Track Symptoms,Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation in Multiple Sclerosis Patients With Lower Urinary Track Symptoms: A Sham Controlled Prospective Randomized Controlled Study,RECRUITING,2024-01-17,2024-11-05,2024-12-05,2024-02-16,2024-02-16,INTERVENTIONAL,NA,64.0,ESTIMATED,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,OTHER_GOV,,,Multiple Sclerosis|Lower Urinary Tract Symptoms,Multiple Sclerosis|Lower Urinary Track Symptoms|LUTS|Posterior tibial nerve stimulation|TPTNS|TTNS,Turkey (Türkiye),Istanbul,,1,Pelvic floor exercises|Transcutaneous posterior tibial nerve stimulation|Sham stimulation,BEHAVIORAL|DEVICE|DEVICE,Incontinence Quality of Life (I-QOL),Post-void residue (PVR)|Bladder diary|International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF),False,
NCT06473753,Pelvic Floor Disorders in Multiple Sclerosis Patients,Clinical and Neurophysiological Assessment of Pelvic Floor Dysfunction in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-01,2025-10-01,2025-10-01,2024-06-25,2024-06-25,OBSERVATIONAL,,120.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,,,"Clinical assessment of bowel, bladder, and sexual dysfunction in patients with MS though applying specific related scales",Motor evoked potential using TMS with parameters gained using single pulse paradigm,False,
NCT03838770,tDCS for the Management of Multiple Sclerosis Related Fatigue,Transcranial Direct Current Stimulation (tDCS) for the Management of Multiple Sclerosis Related Fatigue,COMPLETED,2019-04-04,2021-06-30,2021-06-30,2021-12-16,2019-02-12,INTERVENTIONAL,NA,122.0,ACTUAL,NYU Langone Health,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,New York,New York,1,Active tDCS|sham tDCS,DEVICE|DEVICE,change from baseline in the self-reported Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue instrument.,,False,
NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,"A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis",COMPLETED,2015-12-06,2016-03,2021-03-01,2021-03-10,2015-10-22,INTERVENTIONAL,PHASE1,24.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Progressive Multiple Sclerosis,,Spain,Barcelona,,1,Acyclovir|Methylprednisolone|alemtuzumab GZ402673|alemtuzumab GZ402673|Paracetamol|Loratadine|Ceterizine|Dexchlorpheniramine,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration,Change from baseline in lymphocyte subsets after alemtuzumab administration|Change from baseline in total lymphocyte count after alemtuzumab administration|Change from baseline in helper/suppressor ratio after alemtuzumab administration|Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax)|Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax)|Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast)|Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC)|Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z)|Number of patients with adverse events|Number of patients with adverse events of special interest|Number of patients with injection site reactions,False,
NCT06141473,Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis,"Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis",RECRUITING,2023-12-13,2027-05-06,2027-05-06,2025-08-28,2023-11-21,INTERVENTIONAL,PHASE3,1600.0,ESTIMATED,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Birmingham,Alabama,358,Frexalimab|Teriflunomide|Placebo infusion|Placebo tablet|MRI contrast-enhancing agents|Cholestyramine|Activated charcoal,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapses,"Time to onset of composite confirmed disability worsening (cCDW)|Time to onset of cCDW, confirmed over 3 months|Time to onset of individual components of the composite, confirmed over 3-months or 6-months|Time to onset of confirmed disability improvement (CDI)|Progression independent of relapse activity defined as the time to onset of 6-month cCDW|Total number of new and/or enlarging T2 hyperintense lesions as detected by MRI|Total number of new Gd-enhancing T1hyperintense lesions per scan as detected by MRI|Percent change in brain volume loss as detected by brain MRI scans at the EOS compared to Month 6|Change in cognitive function at the EOS compared to baseline as assessed by the symbol digit modalities test (SDMT)|Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time|Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue MS-8 over time|Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs and safety scales during the study period|Number of participants with potentially clinically significant abnormality (PCSAs) in laboratory tests, ECG and vital signs during the study period|Number of participants with antidrug (ADAs) over time|Change from baseline in plasma neurofilament light chain (NfL) levels over time|Frexalimab plasma concentration over time",False,
NCT03807973,Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.,Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.,RECRUITING,2021-10-05,2028-10,2028-10,2024-11-04,2019-01-17,INTERVENTIONAL,PHASE1,120.0,ESTIMATED,University of Alabama at Birmingham,OTHER,,,Fibromyalgia|Chronic Fatigue Syndrome|Multiple Sclerosis|Healthy,,United States,Birmingham,Alabama,1,[Zr-89]Oxine-labeled leukocytes PET/MRI,DRUG,Regional brain distribution of radiolabeled white blood cells,,False,
NCT06374108,Resistance Training and Corticospinal Excitability in Multiple Sclerosis,Effects of Supervised Progressive Resistance Training on Central Nervous System Functioning (Corticospinal Excitability) and Walking Capacity in Persons With Multiple Sclerosis,RECRUITING,2024-05-01,2025-12-31,2026-05-31,2024-12-11,2024-04-18,INTERVENTIONAL,NA,54.0,ESTIMATED,University of Aarhus,OTHER,Aarhus University Hospital|University of Copenhagen,OTHER|OTHER,Multiple Sclerosis,,Denmark,Aarhus,Central Jutland,2,Progressive resistance training,BEHAVIORAL,MEP/Mmax ratio,Muscle strength|Voluntary activation I|Voluntary activation II|Force Steadiness|Rate of Force Developement|Ultrasound|Resting Motor Threshold (rMT)|Active Motor Threshold (aMT)|MEP latency (resting)|MEP latency (active)|MEP amplitude (resting)|MEP amplitude (active)|Short-interval intracortical Inhibition (SICI)|Intracortical facilitation (ICF)|Cortical Silent Period (CSP)|Central Motor Conduction Time (CMCT)|EEG-EMG coherence (0-1)|Timed 25 feet walk test (T25FWT)|6-minute walk test (6MWT)|Six spot step test (SSST)|5 sit-to-stand (5STS)|9-step stair ascend (9SSA)|Patient determined disease steps (PDDS)|Multiple Sclerosis Walking Scale (MSWS)|Modified fatigue impact scale (MFIS)|MS impact scale (MSIS)|Falls-efficacy scale - international (FES-1)|The Physical Activity Enjoyment Scale (PACES)|Brief pain inventory (BPI)|Baecke physical activity|Accelerometry,False,
NCT04117035,"A Personalised Radiosurgery Procedure for People With Trigeminal Neuralgia to Improve Pain, Quality of Life and Reduce Complications","A Personalised Radiosurgery Procedure for People With Trigeminal Neuralgia to Improve Pain, Quality of Life and Reduce Complications - a Confidence in Concept Pilot Study (PROMOTION)",UNKNOWN,2019-11-01,2022-12-31,2023-12-31,2023-06-27,2019-10-07,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Leeds,OTHER,,,Trigeminal Neuralgia|Multiple Sclerosis|Pain,multiple sclerosis|trigeminal neuralgia|Pain|Quality of life,United Kingdom,Sheffield,,1,Gamma Knife Radiosurgery (GKRS) personalised procedure|GKRS standard care,PROCEDURE|PROCEDURE,Barrow Neurological Institute (BNI) pain measure|Barrow Neurological Institute (BNI) numbness measure,Current medication and dosage|Vision complications|Motor impairment|Cognitive impairment,False,
NCT04621708,Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS,Pilot Study of the Safety and Tolerability of Left Dorsolateral Prefrontal Cortex Intermittent Theta Burst rTMS for Major Depressive Disorder in Multiple Sclerosis,UNKNOWN,2020-04-30,2024-04-30,2024-04-30,2023-03-15,2020-11-09,INTERVENTIONAL,NA,20.0,ESTIMATED,Sunnybrook Health Sciences Centre,OTHER,,,Multiple Sclerosis|Major Depressive Disorder,MS|MDD,Canada,Toronto,Ontario,1,Repetitive transcranial magnetic stimulation,DEVICE,Change in depressive symptoms,"Change in anxiety and depressive symptoms|Change in fatigue, severity and impact|Change in Neuropsychological function|Change in fatigue, severity and impact|Change in Neuropsychological function",False,
NCT00981084,Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS),The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study,COMPLETED,2009-09,2011-04,2011-04,2013-10-14,2009-09-22,INTERVENTIONAL,PHASE2|PHASE3,33.0,ACTUAL,"University of Missouri, Kansas City",OTHER,University of Kansas,OTHER,Multiple Sclerosis,,United States,Kansas City,Kansas,1,armodafinil,DRUG,Learning and Memory Measures.|CPT -Test of Information Processing Speed|Stroop|Word Generation,,True,2013-10-14
NCT02852317,Urinary Markers of Detrusor Overactivity in Spina Bifida Patients,Urinary Markers of Detrusor Overactivity in Spina Bifida Patients,COMPLETED,2015-03-16,2017-03-29,2017-07-17,2018-09-11,2016-08-02,OBSERVATIONAL,,134.0,ACTUAL,Rennes University Hospital,OTHER,,,Spina Bifida|Multiple Sclerosis|Spinal Cord Injury|Overactive Bladder,,France,Rennes,,1,,,Accuracy of urinary markers will be evaluated by area under the curve (AUC),,False,
NCT05154370,China National Registry of Neuro-Inflammatory Diseases,China National Registry of Neuro-Inflammatory Diseases: a Prospective Cohort Study,RECRUITING,2021-12-15,2026-11-01,2026-11-01,2023-07-21,2021-12-13,OBSERVATIONAL,,10000.0,ESTIMATED,Beijing Tiantan Hospital,OTHER,,,Multiple Sclerosis|NMO Spectrum Disorder|Clinically Isolated Syndrome|CNS Demyelinating Autoimmune Diseases|Acute Disseminated Encephalomyelitis|Primay Angiitis of the Central Nervous System|Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy,,China,Beijing,Beijing Municipality,1,Intravenous steroid,DRUG,Annual relapse rate (ARR) between baseline and follow-up in patients with IDD|Change in EDSS scores of patients with IDD between baseline and follow-up over time,The brain structural change over time between the baseline MRI and the follow-up MRIs|The spinal cord change over time between the baseline MRI and the follow-up MRIs.|Change of the central vein sign at 7T MRI.|Change of rim of iron at 7T MRI.|Change in High-contrast Letter Acuity (HCLA) over time at baseline and during follow-up in patients with IDD|Change in Low-contrast Letter Acuity (LCLA) over time at baseline and during follow-up in patients with IDD|Percentage Change in Spectral-domain Optical Coherence Tomography (SD-OCT) Average Retinal Nerve Fiber Layer (RNFL) Thickness at baseline and every year.|Percentage change in SD-OCT Average Retinal Ganglion Cell Layer/Inner Plexiform Retinal Layer (RGCL/IPL) every year.|Changes in cognitive function of patients with IDD at baseline and over time during follow-up|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|NF-L level in serum.|Determination of serum autoimmune antibodies,False,
NCT01763983,Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis,A Randomized Controlled Trial Testing the Additive Benefits of CBT and Exercise For Psychological Stress and Cognitive Dysfunction in MS,COMPLETED,2013-01,2016-10,2016-10,2016-10-17,2013-01-09,INTERVENTIONAL,NA,173.0,ACTUAL,Sunnybrook Health Sciences Centre,OTHER,Multiple Sclerosis Society of Canada,OTHER,"Multiple Sclerosis|Cognitive Deficits|Stress, Psychological","Multiple Sclerosis|Stress, Psychological|Psychological Stress|Emotional Stress|Cognitive Deficits|Cognitive Dysfunction",Canada,Toronto,Ontario,1,Cognitive Behavioural Therapy|Aerobic Exercise,BEHAVIORAL|BEHAVIORAL,Change from Baseline in General Health Questionnaire (GHQ-28) at 12 Weeks,Change from Baseline in the Minimal Assessment of Cognitive Function in MS at 12 Weeks,False,
NCT06939166,Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases,A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed / Refractory Neurological Autoimmune Diseases,NOT_YET_RECRUITING,2025-06,2026-04,2027-10,2025-05-28,2025-04-22,INTERVENTIONAL,EARLY_PHASE1,12.0,ESTIMATED,Tianjin Huanhu Hospital,OTHER,"Shanghai Xiniao Biotech Co., Ltd.",INDUSTRY,Neuromyelitis Optica Spectrum Disorders|Myasthenia Gravis|Multiple Sclerosis|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Autoimmune Encephalitis,Universal Allogeneic CAR T-cells,China,Tianjin,,1,UCAR T-cell,DRUG,"The number and severity of dose-limiting toxicity (DLT) events|The total number, incidence, and severity of AEs",NMOSD、MS: Expanded Disability Status Scale (EDSS) score|NMOSD、MS: Modified Rankin Scale|MG: Quantitative Myasthenia Gravis Score (QMG)|MG: Myasthenia Gravis Activities if Daily Living (MG-ADL) Score|CIDP: Inflammatory Neuropathy Cause and Treatment (INCAT) Score|AE: Change in CASE,False,
NCT01122056,Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis,Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis,COMPLETED,2010-05,2012-06-01,2012-06-01,2017-03-03,2010-05-12,INTERVENTIONAL,NA,128.0,ESTIMATED,University of British Columbia,OTHER,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|b1b-interferon|Fatigue|Exercise,Canada,Vancouver,British Columbia,1,Physical exercise training,OTHER,Multiple Sclerosis Fatigue|Quality of Life|Injection site visual analog scale (0-10),,False,
NCT06949956,Administration of Fingolimod in Greek Patients With Multiple Sclerosis.,"Administration of Fingolimod in Greek Patients With Multiple Sclerosis for the Evaluation of the Efficacy and Safety, Based on the Standard Clinical Practice.",NOT_YET_RECRUITING,2025-06-01,2027-12-31,2027-12-31,2025-05-02,2025-04-29,OBSERVATIONAL,,140.0,ESTIMATED,Elpen Pharmaceutical Co. Inc.,INDUSTRY,AHEPA University Hospital,OTHER,Relapsing Remitting Multiple Sclerosis,RRMS|ARR|EDSS|Fingolimod,,,,0,,,"Annualized Relapse Rate, ARR","Expanded Disability Status Scale, EDSS|Progression Independent of Relapse Activity, PIRA|Further calculation of Progression Independent of Relapse Activity (PIRA) taking into account clinical and imaging data (if available).|Quality of Life (QoL) of patients with multiple sclerosis.|Safety evaluation of the drug throughout the treatment period.",False,
NCT04130997,An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis,An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2019-11-18,2030-02-01,2030-02-01,2025-09-12,2019-10-18,INTERVENTIONAL,PHASE3,1100.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis (RMS),,United States,Pasadena,California,86,Ublituximab,BIOLOGICAL,Annualized Relapse Rate (ARR),,False,
NCT03140449,Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis,Study of Combination Therapy With Topical Rapamycin and Calcitriol for Cutaneous Lesions of Tuberous Sclerosis: A Double-blind Randomized Controlled Trial,COMPLETED,2013-09-05,2016-11-07,2017-04-25,2017-05-04,2017-05-04,INTERVENTIONAL,PHASE3,52.0,ACTUAL,National Taiwan University Hospital,OTHER,,,Facial Angiofibroma,Tuberous sclerosis complex|facial angiofibroma|rapamycin|calcitriol,,,,0,Rapamycin|Calcitriol|Rapamycin-calcitriol combination,DRUG|DRUG|DRUG,facial angioﬁbroma severity index (FASI),,False,
NCT05234879,The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis,The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis With Impaired Balance and Mobility,COMPLETED,2022-05-04,2024-09-29,2024-09-29,2024-10-18,2022-02-10,INTERVENTIONAL,NA,10.0,ACTUAL,Queen Margaret University,OTHER,Multiple Sclerosis Society of Great Britain,UNKNOWN,Multiple Sclerosis,,United Kingdom,Musselburgh,East Lothian,1,Frame Running,OTHER,Exercise Self Efficacy Scale|Exercise Self Efficacy Scale|Psychological Impact of Assistive Devices Scale|Psychological Impact of Assistive Devices Scale|Five times sit-to-stand test|Five times sit-to-stand test|Canadian Occupational Performance Measure|Canadian Occupational Performance Measure|Resting blood pressure|Resting blood pressure|six minute Frame Running test|six minute Frame Running test|Frame Running shuttle run/walk test|Frame Running shuttle run/walk test|weekly step count|weekly step count|Fatigue Scale for Motor and Cognitive Functions (FSMC)|Fatigue Scale for Motor and Cognitive Functions (FSMC)|Multiple Sclerosis Walking Scale|Multiple Sclerosis Walking Scale|Godin Leisure time exercise questionnaire|Godin Leisure time exercise questionnaire,number of weekly training session attended|Heart rate during the training session|Heart rate during the training session,False,
NCT03963492,Intermittent vs Continuous Walking in People With Multiple Sclerosis,Intermittent vs. Continuous Walking Training in People With Multiple Sclerosis: a Comparison of Effectiveness,SUSPENDED,2019-07-01,2023-02-28,2023-02-28,2022-05-12,2019-05-24,INTERVENTIONAL,NA,24.0,ESTIMATED,"Rutgers, The State University of New Jersey",OTHER,"Mount Sinai Rehabilitation Hospital|City University of New York, School of Public Health",OTHER|OTHER,Multiple Sclerosis,Walking|Gait|Fatigue,United States,Hartford,Connecticut,1,Walking,OTHER,Change in 6-minute Walk Test distance,Change in 12-item Multiple Sclerosis Walking Scale score|Change in Fatigue Severity Scale score|Change in Step Length|Change in Step Time|Change in Stride Velocity|Change in Cadence,False,
NCT04533971,The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis,The Effect of a Series of Systemic Cryotherapy Treatments on the Bioelectrical Activity of Muscles and the Functional State of Patients With Multiple Sclerosis,COMPLETED,2015-04-01,2019-12-20,2019-12-20,2025-06-24,2020-09-01,INTERVENTIONAL,NA,114.0,ACTUAL,Pomeranian Medical University Szczecin,OTHER,,,Multiple Sclerosis (ICD10-G35),,,,,0,Whole body cryotherapy,OTHER,Assessment of changes in the level of fatigue|Assessment of changes in walking speed|Assessment of changes in hand grip strength|Assessment of changes in the bioelectrical activity of muscles.,,False,
NCT01142492,A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®),Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®),COMPLETED,2005-01,2008-07,2008-07,2014-03-18,2010-06-11,OBSERVATIONAL,,403.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Interferon beta|Multiple Sclerosis,,,,0,Interferon beta-1a,DRUG,Subjects' compliance to treatment,,False,
NCT04767698,Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis,Addition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease Activity,TERMINATED,2021-10-01,2022-05-10,2022-05-10,2023-03-07,2021-02-23,INTERVENTIONAL,PHASE2,4.0,ACTUAL,Johns Hopkins University,OTHER,GlaxoSmithKline,INDUSTRY,Multiple Sclerosis,,United States,Baltimore,Maryland,1,Belimumab|Short-course Ocrelizumab|Continued Ocrelizumab,DRUG|DRUG|DRUG,Pneumococcal Vaccine Antibody Response|Safety as Assessed by Adverse Events,Difference Between the Two Treatment Groups in GM-CSF/IL-10 Ratio|Difference Between the Two Treatment Groups in IL-6/IL-10 Ratio|Assessment of Return of Disease Activity by Month 24|Assessment of Return of Disease Activity by Month 36|Assessment of Clinical Disease Activity by Month 24|Assessment of Clinical Disease Activity by Month 36|Proportion of Participants With a Three-month Confirmed Increase in EDSS Score|Proportion of Participants With a Three-month Confirmed Increase in EDSS Score|Proportion of Participants With a Three-month Confirmed Decrease in EDSS Score|Proportion of Participants With a Three-month Confirmed Decrease in EDSS Score|Change in Serum Neurofilament Light Chain (NfL) in pg/mL|Change in Serum Neurofilament Light Chain (NfL) in pg/mL,True,2023-03-07
NCT06552611,Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis,Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis,RECRUITING,2024-08-08,2025-07-01,2025-07-01,2024-08-14,2024-08-14,INTERVENTIONAL,PHASE1,4.0,ESTIMATED,University of Washington,OTHER,,,Multiple Sclerosis,Rehabilitation|Neuromodulation|Spinal Cord stimulation,United States,Seattle,Washington,1,Transcutaneous electrical spinal cord stimulation + therapy|Occupational Therapy,COMBINATION_PRODUCT|OTHER,Nine-Hole Peg Test|NeuroQoL Upper Extremity Function|Participant Drop-out rate,Action Research Arm Test|Box and Blocks Test|Grip force|Pinch force|Modified Ashworth Scale|Patient-reported Impact of Spasticity Measure|Modified Fatigue Impact Scale|PROMIS Pain Interference|PROMIS Pain Intensity|Bowel Control Scale|Bladder Control Scale|Global Impression of Change|Ability to Participate in Social Roles and Activities,False,
NCT00819000,Therapy Optimization in Multiple Sclerosis (MS),TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies,COMPLETED,2008-12,2012-12,2013-01,2013-01-29,2009-01-08,OBSERVATIONAL,,2878.0,ACTUAL,"Teva Neuroscience, Inc.",INDUSTRY,,,Multiple Sclerosis,Specialty Pharmacy|Therapy Management|Medication Compliance|Medication Adherence|Medication Persistence|Health Outcomes,United States,Swartz Creek,Michigan,3,"Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b",DRUG,"Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes","Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes",False,
NCT00176592,"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI","Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium",COMPLETED,2003-01,2007-01,2007-01,2021-11-16,2005-09-15,INTERVENTIONAL,PHASE4,75.0,ACTUAL,University of Medicine and Dentistry of New Jersey,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Brain|Betaseron|Copaxone|MRI,United States,Newark,New Jersey,1,Betaseron|Copaxone,DRUG|DRUG,"The Primary Outcome Measure is the Number of ""Combined Active Lesions"" (CAL) by Monthly MRI at the Conclusion of the Study.",The Number of Enhancing Lesions.|The Number of MRI Disease Free Patients.,True,2021-11-16
NCT03457753,Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis,"A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment.",WITHDRAWN,2018-03-01,2018-03-27,2018-03-27,2019-05-13,2018-03-08,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Aquestive Therapeutics,INDUSTRY,Inventiv Health|Covance,UNKNOWN|INDUSTRY,ALS,Amyotrophic Lateral Sclerosis,United States,Dallas,Texas,1,Riluzole Oral Soluble Film,DRUG,Change from baseline in NCI-CTC score at week 12,,False,
NCT00488839,IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis,"A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis",COMPLETED,2007-06,2008-05,2008-05,2019-11-06,2007-06-20,INTERVENTIONAL,PHASE3,173.0,ACTUAL,"Impax Laboratories, LLC",INDUSTRY,,,Multiple Sclerosis,Spasticity|Multiple Sclerosis,United States,Tucson,Arizona,31,IPX056 20 mg|IPX056 40 mg|Encapsulated Baclofen 20 mg|Placebo Baclofen Tablet|IPX056 10 mg|IPX056 30 mg|IPX056 35 mg|Placebo IPX056 20 mg|Placebo IPX056 40 mg,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,"Overall mean changes from predose (baseline) in total Ashworth scores of the four lower extremity muscle groups (hip adductors, knee flexors, knee extensors, and plantar flexors) of both lower limbs over 12 hours assessed hourly after dosing",Duration of effect (improvement in Ashworth Scale) for IPX056|Establishment of relationships between baclofen plasma concentration with improvement in Ashworth Scale,False,
NCT01006265,"Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis","Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2009-10-01,2011-06-01,2011-07-01,2025-03-30,2009-11-02,INTERVENTIONAL,PHASE2,464.0,ACTUAL,Actelion,INDUSTRY,,,Multiple Sclerosis,,United States,Scottsdale,Arizona,115,ACT-128800 Dose 1|Placebo|ACT-128800 Dose 2|ACT-128800 Dose 3,DRUG|DRUG|DRUG|DRUG,Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24,Annualized Confirmed Relapse Rate|Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24,True,2021-06-11
NCT03525834,Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.,"Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery",COMPLETED,2018-11-09,2020-09-25,2020-09-25,2021-09-09,2018-05-16,INTERVENTIONAL,PHASE4,40.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Renal Angiomyolipoma,TSC|tuberous sclerosis complex|AML|afinitor|everolimus|RAD001|mTOR|kidney|lymphangioleiomyomatosis|renal angiomyolipoma,China,Wuhan,Hubei,5,Everolimus,DRUG,Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks|Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks|Percentage of Participants With Severe Renal Impairment|Percentage of Participants With NCI CTCA Grade 3/4 Serum Creatinine,True,2021-09-09
NCT06755463,Acupressure in MS Patients,"The Effect of Acupressure on Beta-Endorphin, Hypocretin, Cognition, and Patient-Reported Outcome Measures in Multiple Sclerosis Patients (APEX-MS Trial): a Single-Blind, Randomized Controlled Trial",NOT_YET_RECRUITING,2025-03-18,2026-01-06,2026-01-06,2025-03-20,2025-01-01,INTERVENTIONAL,NA,82.0,ESTIMATED,Abant Izzet Baysal University,OTHER,,,Multiple Sclerosis,multiple sclerosis|pain|fatigue|cognition|quality of life|depression,,,,0,Self-acupressure education,OTHER,Beta-Endorphin levels|Hypocretin levels|Cognition,Pain measurement|Fatigue|Depression|Quality of life measurement,False,
NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,"International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg",COMPLETED,2007-05,2008-03,2008-03,2015-04-23,2007-04-12,INTERVENTIONAL,PHASE3,1420.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing multiple sclerosis|interferon beta 1b|Betaferon|Betaseron,United States,Birmingham,Alabama,184,"Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaseron, BAY86-5046)",DRUG|DRUG|DRUG,Flu-like-syndrome|Injection-site Reactions|Liver Enzyme Elevations|Hematological Abnormalities,Percentage of Patients With Neutralizing Antibody Titer to IFNB-1b of Different Cut-off Values,True,2009-08-17
NCT06919900,Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis,Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis,NOT_YET_RECRUITING,2025-04,2028-03,2028-12,2025-04-09,2025-04-09,INTERVENTIONAL,NA,64.0,ESTIMATED,Georgia State University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis (Relapsing Remitting),Falls|Fall prevention|Slips|Trips,United States,Atlanta,Georgia,1,Perturbation Training|Treadmill Walking,BEHAVIORAL|BEHAVIORAL,Perturbation Outcome (Fall or Non-Fall) on the Treadmill or Overground,Dynamic Gait Stability as defined by the Feasible Stability Region (FSR) Theory|Leg Muscle Reaction Time|Recovery Step Length|Prospective Real-Life Falls and Near Falls,False,
NCT04121065,Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS),Interventional Not Pharmacological Study to Investigate the Role of ADA in Multiple Sclerosis PatientsTreated With an Immune-Reconstitution Therapy (2-CdA),RECRUITING,2020-09-07,2024-10,2025-06,2024-03-29,2019-10-09,OBSERVATIONAL,,150.0,ESTIMATED,Neuromed IRCCS,OTHER,,,Relapsing Multiple Sclerosis,ADA|Genetic polymorphism|Relapsing Multiple Sclerosis|Immune-reconstitution therapy|2-CdA|single nucleotide polymorphisms|lymphopenia induced by 2-CdA treatment|ADA genetic variant rs244072|non-risk/risk allele T/C,Italy,Pozzilli,Isernia,1,Blood withdrawal,PROCEDURE,"1. Evaluation of lymphopenia, measured by the number of lymphocytes per cubic millimeter (mm3) and associated to ADA polymorphism","Genotyping of SNPs and gene expression for correlation analysis with disease effectiveness of Cladribine treatment|Evaluation of DCK and 5'NT genes expression|Statistical correlation of EBV genotypes with responder or non-responder conditions|Quantification of DCK and cytosolic forms of NT5 and evaluation of CD4+ enzyme activity|Genes expression|Measure of T cell extracellular acidification rate and mitochondrial respiration|Measure of metabolic profile|Blood levels of B-Cell Activating Factor (BAFF) and Proliferating-Inducing Ligand|Assessment of MFI (Mean Fluorescence Intensity) levels in NK, T and B cell subsets|Assessment of synaptic alterations induced by T-cell-released cytokines|Assessment of disease progression measuring the change in the Expanded Disability Status Scale (EDSS)/Kurtzke|Assessment of Kurtzke Functional System Score (KFS) evaluating the type and severity of neurologic impairment|Assessment of upper extremity (arm and hand) function performing the 9-Hole Peg Test (9HPT)|Assessment of of lower extremity function, performing the Timed 25-Foot Walk test (T25FW)|Assessment of attention and information processing speed, performing the Symbol Digit Modality Test (SDMT)|Evaluation of the change in Annualized Relapse Rate (ARR).|Evaluation of Disease Activity measuring the Percentage of ""No Evidence of Disease Activity"" (NEDA) .|Collection of safety and tolerability data: number of patients with treatment related adverse events classified by MedDRA",False,
NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab,"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod",COMPLETED,2020-07-14,2024-10-09,2025-03-11,2025-05-11,2020-04-20,INTERVENTIONAL,PHASE3,562.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,RMS|MS|multiple sclerosis|relapsing multiple sclerosis|OMB157|adult|secondary progressive MS|SPMS,United States,Fullerton,California,122,Ofatumumab,BIOLOGICAL,Annual Relapse Rate (ARR),Safety evaluation,False,
NCT00493298,Tysabri Observational Program,TOP: TYSABRI Observational Program,COMPLETED,2007-06-29,2023-11-01,2023-11-01,2024-04-08,2007-06-28,OBSERVATIONAL,,6620.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,disease progression|Multiple Sclerosis|disease activity|Tysabri|natalizumab|long-term safety,Argentina,Buenos Aires,,419,Tysabri,DRUG,Number of Participants with Serious Adverse Events (SAE),"Annualized Relapse Rate (ARR)|Distribution of the Total Number of Relapses|Time to First Relapse|Percentage of Participants with Relapse|Percentage of Participants with Disability Progression|Percentage of Participants that reach Expanded Disability Status Score (EDSS) Milestones Indicating Increasing Disability|Percentage of Participants whose EDSS Worsened, Stabilized or Improved and Sustained over 6 Months|Evaluation of Baseline Disease Characteristics as Prognostic Indicators for Disease Activity and Disability Progression Over Time|Evaluation of Short-Term (1 year) Disease Outcomes as Prognostic Indicators for Disease Activity and Disability Progression Over Time",False,
NCT06283563,Online Physical Activity Tracking in Patients With Multiple Sclerosis,"The Effect of Online Physical Activity Tracking on Physical Activity Level, Psychological Health, Fatigue and Quality of Life in Patients With Multiple Sclerosis",NOT_YET_RECRUITING,2024-02-28,2025-02-15,2025-02-28,2024-02-28,2024-02-28,INTERVENTIONAL,NA,10.0,ESTIMATED,Inonu University,OTHER,,,Multiple Sclerosis,physical activity|depression|life quality|Multiple sclerosis,,,,0,Physical activity tracking|No physical activity tracking,OTHER|OTHER,Smartphone pedometer|Smartphone pedometer|International Physical Activity Questionnaire - Short Form|International Physical Activity Questionnaire - Short Form,Beck Depression Inventory II|Beck Depression Inventory II|Beck Anxiety Inventory|Beck Anxiety Inventory|Fatigue Severity Scale|Fatigue Severity Scale|Multiple Sclerosis Quality of Life-54|Multiple Sclerosis Quality of Life-54,False,
NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,"Betaferon Prospective Study on Adherence, Coping and Nursing Support",COMPLETED,2008-06,2013-09,2014-10,2015-10-16,2008-11-07,OBSERVATIONAL,,1723.0,ACTUAL,Bayer,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis (RRMS),Clinically Isolated Syndrome (CIS),Argentina,Many Locations,,36,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Proportion of patients adhering to treatment,"Rate of early treatment termination|Rate of study dropout|Predictive value of BL parameters, WCQ, HADS, RODQ|WCQ (Ways of Coping Questionnaire)|HADS (Hospital Anxiety and Depression Scale)|RODQ (Risk of Dropout Questionnaire)|EDSS (Expanded Disability Status Scale)|Relapse rate",False,
NCT00010842,Natural Antioxidants in the Treatment of Multiple Sclerosis,Natural Antioxidants in the Treatment of Multiple Sclerosis,COMPLETED,1999-09,,2004-12,2006-08-18,2001-02-05,INTERVENTIONAL,PHASE1|PHASE2,,,National Center for Complementary and Integrative Health (NCCIH),NIH,,,Multiple Sclerosis,,United States,Portland,Oregon,1,Ginkgo biloba|Alpha-lipoic acid|Vitamin E/Selenium|Essential fatty acids,DRUG|DRUG|DRUG|DRUG,,,False,
NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,"A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2019-08-12,2025-01-15,2028-01-19,2025-08-26,2019-07-29,INTERVENTIONAL,PHASE3,1013.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Primary Progressive",,United States,Laguna Hills,California,159,Ocrelizumab|Placebo,DRUG|DRUG,Time to Onset of Composite 12-week Confirmed Disability Progression (CDP),"Time to 12-week CDP in 9-Hole Peg Test (9-HPT)|Time to 12-week CDP in EDSS|Time to 24-week CDP in 9-HPT|Time to 24-week CDP in EDSS|Annual Rate of Percent Change From Baseline in Total Volume of T2 Lesions on Magnetic Resonance Imaging (MRI) Scans|Annual Rate of Percent Change From 24 Week in Total Brain Volume on MRI Scans|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants With Serious Adverse Events (SAEs)|Percentage of Participants With AEs Leading to Study Treatment Withdrawal|Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab|Plasma Concentration of Ocrelizumab|Evaluation of Ocrelizumab Pharmacodynamics, as Measured by B-Cell Levels in Blood",False,
NCT00559702,Safety Study of Natalizumab to Treat Multiple Sclerosis (MS),"A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis",COMPLETED,2007-10,2011-11,2011-11,2014-09-09,2007-11-16,INTERVENTIONAL,PHASE1,76.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis,natalizumab|multiple sclerosis|Tysabri ®,United States,Phoenix,Arizona,12,natalizumab|standard of care,DRUG|OTHER,Maximum observed concentration (Cmax) of natalizumab|Time to maximum observed concentration (Tmax) of natalizumab|Area under the curve to the last measurable concentration (AUC0-last) of natalizumab|Apparent volume of distribution of natalizumab|Half-life of natalizumab|Area under the curve extrapolated to infinity (AUC0-∞) of natalizumab|Apparent Clearance of natalizumab|α4-integrin saturation,Number of Participants with adverse events|Number of participants with abnormalities in vital signs|Number of participants with changes in the physical examination|Number of participants with abnormal laboratory test results|Number of participants with natalizumab antibodies|Change from Baseline in expanded disability status scale (EDSS)|Change form Baseline in Multiple Sclerosis Functional Composite Scale (MFSC)|Change from Baseline in Symbol Digit Modalities Test (SDMT)|Change from Baseline in visual analog scale (VAS)|Change from Baseline in visual function test|Number of new or newly enlarging T2 hyperintense lesions|Number of new gadolinium-enhanced lesions|Number of new T1 hypointense lesions|Whole brain atrophy|Percent change in magnetization transfer ratio (MTR)|Diffusion tensor imaging (DTI)|Injection site pain assessment,False,
NCT05964829,Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis,"A Crossover Study Evaluating the Impact of the Cionic Neural Sleeve on Mobility, Disability, Fall Risk, and Physical Activity in Multiple Sclerosis",RECRUITING,2023-09-04,2026-06,2026-07,2025-09-24,2023-07-28,INTERVENTIONAL,NA,14.0,ESTIMATED,"Cionic, Inc.",INDUSTRY,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive",,United States,Cleveland,Ohio,1,Cionic Neural Sleeve NS-100|Walking Program,DEVICE|BEHAVIORAL,Change in Gait Speed|Change in Perceived Walking Ability|Change in MS Disability|Amount of Daily Walking/Activity Level|Duration of Daily Walking/Activity Level,,False,
NCT00766272,Lokomat Training Effects on MS Gait Abnormalities,Gait Rehabilitation for Multiple Sclerosis Using Robot-assisted Body-weight-supported Treadmill Training (Lokomat),TERMINATED,2008-06,2008-06,2008-06,2013-09-23,2008-10-03,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,US Department of Veterans Affairs,FED,,,Multiple Sclerosis,Rehabilitation|Treadmill|MS|Gait|Robot,United States,Providence,Rhode Island,1,Lokomat,DEVICE,Frequency of Falls,,False,
NCT07011875,"The Effect of Physical Activity Levels on Dysmenorrhea Severity, Menstrual Symptoms, and Functional and Emotional Status in Women Diagnosed With Multiple Sclerosis","The Effect of Physical Activity Levels on Dysmenorrhea Severity, Menstrual Symptoms, and Functional and Emotional Status in Women Diagnosed With Multiple Sclerosis",ENROLLING_BY_INVITATION,2025-06-02,2025-08,2025-09,2025-06-10,2025-06-10,OBSERVATIONAL,,60.0,ESTIMATED,Karabuk University,OTHER,,,Multiple Sclerosis|Physical Activity|Dysmenorrhea|Emotional Disorder,Multiple Sclerosis|Physical Activity Level|Dysmenorrhea Severity|Menstrual Symptom|Functional and Emotional Status,Turkey (Türkiye),Karabük,Karabük Province,1,,,Numerical Rating Scale|Functional and Emotional Impact of Dysmenorrhea|International Physical Activity Questionnaire - Short Form|Patient Determined Disease Steps|Menstrual Symptom Questionnaire,,False,
NCT04120675,Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis,The Effects of Early Harvest Extra Virgin Olive Oil on Cognition and Mental Health of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis Patients,COMPLETED,2018-11-09,2021-06-01,2021-06-06,2021-07-09,2019-10-09,INTERVENTIONAL,NA,30.0,ACTUAL,Aristotle University Of Thessaloniki,OTHER,"Greek Alzheimer's Association and Related Disorders|Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com)",OTHER|UNKNOWN,Progressive Multiple Sclerosis,extra virgin olive oil|cognition|mental health|multiple sclerosis,Greece,Thessaloniki,Macedonia,1,Early Harvest Extra Virgin Olive Oil,DIETARY_SUPPLEMENT,Greek Verbal Learning Test (GVLT)- Assessment of auditory and verbal memory|Brief Visuospatial Memory Test (BVMT)- Assessment of visual and spatial memory|Symbol Digit Modalities Test (SDMT)- Assessment of processing speed and working memory|Perceived Deficits Questionnaire (PDQ)- Measurement of subjective cognitive deficits|Frontal Assessment Battery (FAB)- Assessment of frontal deficits|Beck Depression Scale (BDI)- Measurement of depressive symptoms|Mental Health Inventory (MHI)- Measurement of emotional condition and mental health problems,,False,
NCT06372977,Kappa Index Versus Csf Oligoclonal Bands in Diagnosis of ms and Prediction of Disease Activity,Kappa Index Versus Csf Oligoclonal Bands in Diagnosis of Multiple Sclerosis and Prediction of Disease,NOT_YET_RECRUITING,2024-05,2025-12,2026-05,2024-04-18,2024-04-18,OBSERVATIONAL,,140.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,kappa index,DIAGNOSTIC_TEST,Assess the diagnostic performance of CSF k index in differentiating MS from other inflammatory and non-inflammatory neurological diseases .|Assess the diagnostic performance of CSF IgG OCBs in differentiating MS from other inflammatory and non-inflammatory neurological diseases .,Assess the role of k FLC in predicting disease activity (conversion from CIS to MS)|Assess the role of OCBs in predicting disease activity (conversion from CIS to MS),False,
NCT04198207,The Effectiveness and Safety of Vagus Nerve Stimulation for TRE,Clinical Evaluation of the Effectiveness and Safety of Vagus Nerve Stimulation for Tuberous Sclerosis Complex Related Epilepsy,COMPLETED,2019-12-10,2024-12-10,2024-12-10,2024-12-19,2019-12-13,OBSERVATIONAL,,70.0,ACTUAL,Beijing Children's Hospital,OTHER,"Beijing Tiantan Hospital|The First Hospital of Jilin University|Xuanwu Hospital, Beijing|Capital Medical University|Peking University First Hospital|China-Japan Friendship Hospital|Chinese PLA General Hospital|Fourth Medical Center of PLA General Hospital|Capital Institute of Pediatrics, China|The Second Hospital of Hebei Medical University|Xijing Hospital|First Affiliated Hospital Xi'an Jiaotong University|Children's Hospital of Fudan University|RenJi Hospital|Jining Medical University|Xiamen Humanity Hospital|Xiangya Hospital of Central South University|Wuhan Medical Care Center for Women and Children|Guangdong 999 Brain Hospital|Shenzhen Children's Hospital|Army Medical University, China|West China Hospital",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER_GOV|OTHER|OTHER,Tuberous Sclerosis Complex|Epilepsy,tuberous sclerosis complex|epilepsy|vagus nerve stimulation,China,Beijing,,1,,,% of patients with Mchugh grading,IQ|Quality of Life: QOLIE-31,False,
NCT05374811,"The Relationship of Neuropathic Pain With Incontinence, Disability and Life Quality in Multiple Sclerosis Patients","The Relationship of Neuropathic Pain With Incontinence, Functional Disability and Quality of Life in Patients With Multiple Sclerosis",COMPLETED,2022-04-15,2022-11-15,2022-11-15,2023-09-28,2022-05-16,OBSERVATIONAL,,175.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,"Multiple Sclerosis|Disabilities Multiple|Quality of Life|Incontinence, Urinary|Incontinence Bowel|Neuropathic Pain",,Turkey (Türkiye),Istanbul,,1,Neuropathic Pain,OTHER,Neuropathic pain assessed by Douleur Neuropathic-4 (DN-4) questionnaire.|Urinary and bowel incotinance assessed by the Functional Independence Measure.|Disability in multiple sclerosis assessed by the Kurtzke Expanded Disability Status Scale|Performance in activities of daily living assessed by the Barthel Index.|Health status assessed by Monitoring My Multiple Sclerosis.|The levels of anxiety and depression assessed by Hospital Anxiety and Depression Scale.|Sleep quality assessed by Pittsburgh Sleep Quality Index.,Descriptive information,False,
NCT00958009,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study","A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of a Ready-to-use, Single-use Autoinjector (SA) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc), Three Times a Week (Tiw)",COMPLETED,2009-10,2010-04,2010-06,2013-08-07,2009-08-13,INTERVENTIONAL,PHASE3,109.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,,United States,Rockland,Massachusetts,1,Rebidose®,DEVICE,Proportion of Relapsing Multiple Sclerosis (RMS) Subjects Rating the Single-use Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire,"Multiple Secondary Endpoints Were Assessed, Based on Questions From the User Trial Questionnaire Related to the Single-use Autoinjector Device Use-related Outcomes.",True,2010-12-30
NCT06864936,Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis,Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis,NOT_YET_RECRUITING,2025-06-01,2027-03-30,2027-06-30,2025-03-07,2025-03-07,INTERVENTIONAL,NA,30.0,ESTIMATED,"University of Maryland, Baltimore",OTHER,"TG Therapeutics, Inc.",INDUSTRY,Multiple Sclerosis (MS) - Relapsing-remitting,,United States,Baltimore,Maryland,1,Ublituximab|Other disease modifying therapies,DRUG|OTHER,Evaluation of the effect of ublituximab on macular hyperreflective foci (HRF) in MS.|Evaluation of the effect of ublituximab on inner limiting membrane (ILM) macrophage-like cells (MLC).,,False,
NCT01712945,Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis,Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis,TERMINATED,2012-06,2017-08,2017-10,2019-04-30,2012-10-24,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,Cambridge University Hospitals NHS Foundation Trust,OTHER,,,Multiple Sclerosis,Alemtuzumab|Palifermin|Reconstitution|Thymus,United Kingdom,Cambridge,Cambridgeshire,1,Palifermin|Alemtuzumab,DRUG|DRUG,incidence of clinical autoimmunity,Absolute numbers of naive T cells|Safety events,False,
NCT06891937,Self-Directed Positive Psychology Intervention for Newly Diagnosed Multiple Sclerosis,A Self-directed Positive Psychology Intervention for Individuals With Newly Diagnosed Multiple Sclerosis,COMPLETED,2022-07-20,2024-10-17,2024-10-17,2025-03-28,2025-03-24,INTERVENTIONAL,NA,30.0,ACTUAL,Brigham and Women's Hospital,OTHER,,,Multiple Sclerosis,Positive psychology|Positive affect,United States,Boston,Massachusetts,1,Positive psychology,BEHAVIORAL,Percentage of PP exercises completed by subjects,"Subject ratings of ease of completion of PP exercises|Subject ratings of utility of PP exercises|Changes in affect|Change in trait optimism|Changes in physical, mental and social health|Changes in resilience",False,
NCT05131828,"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy","CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy",ACTIVE_NOT_RECRUITING,2022-03-08,2025-05,2025-05,2025-04-24,2021-11-23,INTERVENTIONAL,PHASE2,70.0,ESTIMATED,Cambridge University Hospitals NHS Foundation Trust,OTHER,University of Cambridge,OTHER,Multiple Sclerosis,,United Kingdom,Cambridge,,1,Metformin and clemastine in combination|Placebo,DRUG|DRUG,the change in the P100 latency of the full-field visual evoked potential (VEP) between baseline and week 26 for each affected eye of participants,"The change in MF-VEP latency, between baseline and week 26, for those eyes with delayed latency at baseline|The change in lesional MTR, between baseline and week 26, for the lesions stratified by location|The change in lesional MTR between baseline and week 26, for the lesions stratified by tissue-specific cohort baseline lesional MTR values|Adverse events and withdrawals attributable to metformin and/or clemastine",False,
NCT01128075,Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects,"Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart™ for Self-injection of Rebif® in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS)",COMPLETED,2009-08,2014-04,2014-04,2014-07-09,2010-05-21,OBSERVATIONAL,,198.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"EMD Inc., Canada",INDUSTRY,Multiple Sclerosis|MS,RebiSmart|Rebif|Adherence|Multidose|Relapsing Multiple Sclerosis|RMS,Canada,Vancouver,,1,RebiSmart™|RebiSmart™,DEVICE|DEVICE,Treatment adherence for RMS subjects over 24 weeks of treatment when using RebiSmart™ for self-injection of Rebif® in a multi-dose cartridge.,Long-term adherence in subjects with RMS over 96 weeks of treatment using RebiSmart for self-injection of Rebif® in multi-dose cartridge.|Treatment persistence by measuring treatment discontinuations|Treatment compliance|Comparison of subject treatment adherence between categories of cognitive function|Longitudinal changes in anxiety symptoms|Qualitative assessment of subjects' experience with RebiSmart,False,
NCT03825601,PET with [18F]Flumazenil As an Index of Neurodegeneration in MS,PET with [18F]Flumazenil As an Index of Neurodegeneration in MS: Sensitivity At an Early Disease Stage and Pathophysiological Meaning,COMPLETED,2019-05-02,2024-08-26,2024-08-26,2025-03-05,2019-01-31,INTERVENTIONAL,NA,45.0,ACTUAL,"Institut National de la Santé Et de la Recherche Médicale, France",OTHER_GOV,,,Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis,"Patients,|Multiple Sclerosis,|Relapsing-Remitting",France,Paris,,1,PET with [11C]Flumazenil,DIAGNOSTIC_TEST,Concentration of benzodiazepine receptors (BZR) measured from 11C -Flumazenil binding in different groups,individual maps of neurodegeneration: changes in individual mapping of Flumazenil binding in different groups|volume of cortical lesions assessed on 7T MRI in different groups assessed in Cortical lesion volume|volume of white matter lesions segmented on 3T T2 sequences: white matter lesion load|Volume of gadolinium-enhanced white matter lesions on T1 sequence|Voxel wise assessment of Magnetization transfer ratio (MTR) to assess changes in the grey and in the white matter in different groups|functional connectivity changes in patients,False,
NCT03306875,Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis,Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis,COMPLETED,2017-11-01,2018-04-30,2018-10-20,2018-11-26,2017-10-11,INTERVENTIONAL,NA,50.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Multiple Sclerosis,multiple sclerosis|cognitive training|telerehabilitation|personality|Conscientiousness|predict,United States,Buffalo,New York,1,Cognitive Training,BEHAVIORAL,Impact of Conscientiousness on Cognitive Training Outcomes|Cognitive Training Outcomes,Moderating role of executive function|Moderating role of program adherence|Impact of baseline brain connectivity on cognitive rehabilitation outcomes,False,
NCT04144257,Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue,Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue,UNKNOWN,2020-03-12,2021-09-30,2021-09-30,2021-07-28,2019-10-30,INTERVENTIONAL,PHASE1|PHASE2,12.0,ESTIMATED,Brigham and Women's Hospital,OTHER,U.S. Army Medical Research Acquisition Activity,FED,Multiple Sclerosis,,United States,Boston,Massachusetts,1,[F-18]PBR06|[C-11]Methylreboxetine,DRUG|DRUG,Standardized Uptake Value (SUV)/Standardized Uptake Value Ratio (SUVR),Modified Fatigue Impact Scale (MFIS)|Binding Potential (BPnd)|MRI grey matter lesional load/brain atrophy|Tissue Volume of distribution (Vt)/Distribution Volume Ratios (DVR)|MRI global/regional volumetrics,False,
NCT00492765,Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis,"A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis",COMPLETED,2006-02,2010-04,2010-04,2010-10-15,2007-06-27,INTERVENTIONAL,PHASE4,380.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Combination therapy|Simvastatin|Multiple Sclerosis|Interferon-beta-1a,Denmark,Copenhagen,,1,Interferon-beta-1a|Simvastatin|Placebo,DRUG|DRUG|DRUG,The time to first documented relapse,"3Annual rate of documented relapses after randomisation|Number of new and/or enlarging lesions on T2-weighted MRI based on MRI done 12 months following randomisation compared with MRI done at time of randomisation|Proportion of patients without disease activity after randomisation (i.e. no relapses, no increase in EDSS score and no increase in enlarging or new T2 lesions).",False,
NCT03659981,Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T MRI Study,Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T Magnetic Resonance Imaging Study,ACTIVE_NOT_RECRUITING,2018-12-20,2022-05-19,2026-11-19,2024-08-06,2018-09-06,INTERVENTIONAL,NA,32.0,ACTUAL,Assistance Publique Hopitaux De Marseille,OTHER,,,Multiple Sclerosis,,France,Marseille,PACA,1,MRI 7T,OTHER,number of cortical lesions,,False,
NCT03005119,"Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms","A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms",UNKNOWN,2018-03-01,2018-12,2018-12,2017-09-28,2016-12-29,INTERVENTIONAL,PHASE2,70.0,ESTIMATED,"PhytoTech Therapeutics, Ltd.",INDUSTRY,,,Multiple Sclerosis,,Israel,"Tel Hashomer, Ramat Gan",,1,PTL201|Placebo Oral Capsule,DRUG|DRUG,Incidence of study treatment-related adverse events (AE)|Change in sNRS scores from randomization to end of placebo-controlled treatment phase,Incidence of all AEs|Percent change in walking velocity|Clinical Global Impression Improvement (CGI-I) assessment using a 7-point scale condition|Cadence (steps/min) assessment|Stride length (cm) assessment|pNRS assessment|Spasm frequency assessment|Sleep disturbance assessment|Assessment of clinical gait measures|Assessment of clinical gait measures,False,
NCT05857280,"EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)",The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP 2),RECRUITING,2023-03-21,2024-12-31,2025-04-15,2024-04-17,2023-05-12,INTERVENTIONAL,NA,36.0,ESTIMATED,Sheikh Shakhbout Medical City,OTHER,,,"Sclerosis, Multiple|MS (Multiple Sclerosis)|Spasticity, Muscle|Spastic",,United Arab Emirates,Abu Dhabi,,1,EXOPULSE Mollii Suit Stimulation,DEVICE,Balance using Berg Balance Scale (BBS)|Balance using Berg Balance Scale (BBS)|Balance using Berg Balance Scale (BBS)|Balance using Berg Balance Scale (BBS),Visual Analog Score for spasticity.|Mobility.|Visual Analog Score for pain.|Multiple Sclerosis International Quality of Life Questionnaire.|Overall Clinical improvement.|Blinding Questionnaire.|Visual Analog Score for fatigue.|Muscle tone.|Fall Risk|Weight.|Height.|Time Up and Go (TUG)|Body Mass Index (BMI),False,
NCT01730209,Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex,Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex,UNKNOWN,2012-11,2015-11,2016-11,2015-05-05,2012-11-21,INTERVENTIONAL,PHASE2|PHASE3,60.0,ESTIMATED,Erasmus Medical Center,OTHER,Utrecht University,OTHER,Tuberous Sclerosis Complex|TSC Related Cognitive Disability|TSC Related Autism|TSC Related Learning Problems,Tuberous Sclerosis Complex|TSC|Autism|Learning problems|Everolimus|RAD001|Treatment|Cognition|Intellectual disability,Netherlands,Rotterdam,,1,Everolimus|Placebo,DRUG|DRUG,Cognitive ability measured by IQ,"Autistic features|Social and communicational skills|Working memory and attention, information processing|Visual-motor integration|Child behavior|Executive functioning|Sleeping problems|Child health|Sensory related difficulties|Epilepsy",False,
NCT03316404,Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response,Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response,COMPLETED,2017-11-07,2020-02-24,2020-02-25,2024-08-06,2017-10-20,OBSERVATIONAL,,1168.0,ACTUAL,DxTerity Diagnostics,INDUSTRY,,,Multiple Sclerosis|MS,Multiple Sclerosis|MS,United States,Compton,California,1,,,Obtain blood samples and associated clinical and demographic data from participants diagnosed with Multiple Sclerosis (MS),,False,
NCT06874764,Effect of Training With Wireless Lightning Reaction Systems on Cognitive Functions in Individuals With Multiple Sclerosis,Effects of Agility and Cognitive Training With Reaction System on Cognitive Functions and Walking in Individuals With Multiple Sclerosis,NOT_YET_RECRUITING,2025-09,2025-12,2026-01,2025-08-24,2025-03-13,INTERVENTIONAL,NA,40.0,ESTIMATED,Ege University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Cognitive|Virtual reality|Agility|Training|Gait,Turkey (Türkiye),Izmir,Bornova,1,Wireless Lighting Reaction System Training(Agility plus Cognitive),OTHER,Cognitive Functions,Balance assessment|Anxiety and Depression Status|Fatigue Assessment|MS Quality of Life|Static Posture Assessment(Static Balance)|Static Posture Assessment(Visual Dependency)|Static Posture Assessment(Proprioception Disturbance)|Static Posture Assessment(Vestibular Dominant)|Gait Analysis(Step length)|Gait Analysis(Stride length)|Gait Analysis(Step time)|Gait Analysis(Step width)|Gait Analysis(Cadence)|Gait Analysis(Percentage distribution of walking phases),False,
NCT05951985,High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners,High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners: A 2-Year Longitudinal Study,COMPLETED,2023-08-15,2025-07-14,2025-08-14,2025-08-22,2023-07-19,INTERVENTIONAL,NA,100.0,ACTUAL,Arkansas Colleges of Health Education,OTHER,,,Neurologic Disorder|Parkinson Disease|Spinal Cord Injuries|Spina Bifida|Stroke|Poliomyelitis|Multiple Sclerosis|Brain Injuries,hift|exercise,United States,Fort Smith,Arkansas,1,HIFT,BEHAVIORAL,Participant Attendance at 24 months,Change in lower extremity functional strength at 24 months|hange in Parkinson's Disease Questionnaire - 39 (PDQ-39) at 24 months|Change in fast-paced gait speed at 24 months|Change in fast-paced wheelchair propulsion speed at 24 months|Change in 6 Minute Walk Test at 24 months|Change in 6 Minute Propulsion Test at 24 months|Change in Movement Disorder Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at 24 months|Change in accelerometer-measured moderate-to-vigorous physical activity at 24 months|Participant Retention at 24 months|Participant Recruitment Rates|Change in four square step test at 24 months|YMCA Bench Press Test at 24 months|30 second peak power test at 24 months|Change in self-reported exercise confidence at 24 months|Change in self-reported pain at 24 months|Change in self-reported sleep quality at 24 months|Change in self-reported social support at 24 months|Change in self-reported physical ability at 24 months|Self-reported safety with program at 24 months|Self-reported satisfaction with coach supervision at 24 months|Self-reported feelings of inclusion at 24 months|Self-reported feelings of exercise intensity at 24 months|Self-reported feelings of exercise variety at 24 months|Self-reported feelings of exercise applicability in real life at 24 months,False,
NCT06443333,"National, Multicentric Registry Study on Neuroimmunological Diseases in China","National, Multicentric Registry Study on Neuroimmunological Diseases in China",RECRUITING,2020-12-01,2024-12-30,2024-12-30,2024-06-05,2024-06-05,OBSERVATIONAL,,7000.0,ESTIMATED,"Xuanwu Hospital, Beijing",OTHER,,,Multiple Sclerosis|NMO Spectrum Disorder|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Myasthenia Gravis|Autoimmune Encephalitis|Acute Disseminated Encephalomyelitis,,China,Beijing,Beijing Municipality,1,Data collection and follow-up observation|Data collection,OTHER|OTHER,Annual recurrence rate,"Change in Expanded Disability Status Scale scores (EDSS)|Change in MRI of head, optic nerve and spinal cord|Change in serum and CSF autoimmune antibody status|Change in Activity of Daily Living Scale (ADL)|Change in the relative power spectral density|Changes in Symbol Digit Modalities Test (SDMT)|Changes in Montreal Cognitive Assessment Test (MoCA)|changes in Mini-Mental Status Exam (MMSE)",False,
NCT06668649,Polish Version Fatigue Severity Scale,Validation of Polish Language Version of Fatigue Severity Scale,RECRUITING,2024-11-04,2026-12-31,2027-03-31,2024-11-08,2024-10-31,OBSERVATIONAL,,310.0,ESTIMATED,Jakub Antczak,OTHER,"Institute of Psychiatry and Neurology, Warsaw",OTHER,"Multiple Sclerosis|Amyotrophic Lateral Sclerosis|Stroke, Ischemic",Fatigue|Multiple Sclerosis|stroke|quality of life,Poland,Krakow,Lesser Poland Voivodeship,2,Testing with Questionnaires,DIAGNOSTIC_TEST,Internal Consistency|Validity|Reliability,Impact of fatigue on quality of life - index|Impact of fatigue on quality of life - visual analogue scale|Impact of fatigue on depression|Difference in fatigue level between patients and controls,False,
NCT00662649,Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,"An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis",COMPLETED,2008-02,2011-06,2011-06,2012-07-12,2008-04-21,INTERVENTIONAL,PHASE3,920.0,ACTUAL,Novartis,INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis.|Relapse-remitting|Fingolimod,Australia,Chatswood,,103,Fingolimod 0.5 mg|Fingolimod 1.25 mg,DRUG|DRUG,Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)|Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free|Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)|Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study),Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)|Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)|Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)|Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)|Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression,True,2012-07-12
NCT02104492,Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis,Clinical Research on the Effect of a 12-week Respiratory Muscles Training Program in Persons With Relapsing-remitting Multiple Sclerosis,UNKNOWN,2014-03,2015-03,2015-03,2014-04-04,2014-04-04,INTERVENTIONAL,NA,40.0,ESTIMATED,University of Malaga,OTHER,,,Relapsing-remitting Multiple Sclerosis,multiple sclerosis|respiratory muscle strength|maximal inspiratory pressure (MIP)|maximal expiratory pressure (MEP)|respiratory muscle endurance|quality of life|qualitative research,Spain,Málaga,Málaga,1,a 12-week Respiratory Muscles Training Program (RMTP)|Active Comparator,OTHER|OTHER,Maximal inspiratory pressures (MIP) and maximal expiratory pressures (MEP),Pulmonary function test|Handgrip strength|Multiple-Sit-to-Stand Test (MSTS)|The 12 item MS Walking Scale (MSWS-12)|Timed 25 foot walk (T25FW)|Gait analysis|The 54 items Specific Questionnaire Quality of Life Multiple Sclerosis (MSQOL-54)|10 Maximum Resistance (10RM)|Perceptions Measures,False,
NCT00179478,Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis,Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10),COMPLETED,2001-02,2009-03,2009-03,2017-09-06,2005-09-16,INTERVENTIONAL,PHASE4,155.0,ACTUAL,Beth Israel Deaconess Medical Center,OTHER,Biogen,INDUSTRY,Multiple Sclerosis|Optic Neuritis|Transverse Myelitis|Acute Brainstem/Cerebellar Syndrome,Multiple sclerosis|Interferon Beta|MRI|Optic neuritis|Transverse Myelitis,United States,Derby,Connecticut,26,interferon beta 1a 30 ug IM once weekly,DRUG,Rate of Development of Clinical Definite Multiple Sclerosis (CDMS) Over 10 Years,Annualized Relapse Rate|Number of Participants With an EDSS > 3.5 at Study Completion|The Number of New or Enlarging MRI T2 Lesions at 10 Years,True,2017-09-06
NCT00468611,Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis,"A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis",TERMINATED,2007-06,2009-07,2009-09,2009-08-13,2007-05-03,INTERVENTIONAL,PHASE3,510.0,ACTUAL,BioMS Technology Corp.,INDUSTRY,,,"Multiple Sclerosis, Secondary Progressive",Secondary Progressive Multiple Sclerosis|Multiple Sclerosis,,,,0,MBP8298,DRUG,Time to progression of disease in subjects with SPMS as measured by the EDSS after 24 months of treatment,"To assess the safety of MBP8298, degree of change in the EDSS scores, effect of MBP8298 on MRI parameters, difference in relapse rates, effect on MSFC, subject's quality of life (MSQoL54) and fatigue (MFIS) after 24 months of treatment",False,
NCT06447571,Trunk Rehabilitation Compared to Core Stability in Patients With Multiple Sclerosis,"The Effect of Trunk Rehabilitation Compared to Core Stability on Balance, Gait, Falls and Community Mobility in Patients With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2023-10-01,2024-06-01,2024-12,2024-06-07,2024-06-07,INTERVENTIONAL,NA,40.0,ACTUAL,King Abdulaziz University,OTHER,,,Multiple Sclerosis|Trunk|Physical Therapy,,Saudi Arabia,Jeddah,,1,Trunk Rehabilitation|Core Stability,OTHER|OTHER,Trunk Impairment Scale (TIS),Berg Balance Scale (BBS)|Timed Up and Go (TUG)|Modified Falls Efficacy Scale (MFES)|Modified Fatigue Impact Scale (MFIS)|Reintegration to Normal Living Index (RNLI),False,
NCT04804787,Emotions in Multiple Sclerosis,Emotions Recognition in Multiple Sclerosis,UNKNOWN,2021-06-23,2024-12-23,2024-12-23,2023-06-22,2021-03-18,INTERVENTIONAL,NA,100.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Emotions recognition|Cognitive disorders,France,Lille,,1,Carrying out a tests and questionnaires battery,DIAGNOSTIC_TEST,Emotion's valence|Emotion's intensity|Emotion recognition|Certainty's degree of answers,California Verbal Learning Test (CVLT)|Brief Visuo-spatial Memory Test (BVMT)|Symbol Digit Modalities Test (SDMT)|Stroop test|Trail Making test|Verbal fluency test|Beck Depression Inventory (BDI)|State Trait Anxiety Inventory Y-A (STAI Y-A)|State Trait Anxiety Inventory Y-B (STAI Y-B)|Toronto Alexithymia Scale-20 (TAS-20)|Dot Probe Task|Change in the electrodermal response during emotion recognition test,False,
NCT00670449,An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis,"An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",COMPLETED,2008-04,2012-04,2012-04,2013-09-04,2008-05-01,INTERVENTIONAL,PHASE2,143.0,ACTUAL,Novartis,INDUSTRY,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,Multiple Sclerosis,FTY720|multiple sclerosis|MS,Japan,Chiba,,20,Fingolimod,DRUG,Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions,Percentage of Patients Free of New or Newly Enlarged T2 Weighted MRI Lesions|Aggregate Annualized Relapse Rate (ARR) Based on Confirmed Relapses|Percentage of Patients Relapse-free at the End of the Study|Percentage of Patients Free From 3-month and 6-month Confirmed Disability Progression at Their Last Expanded Disability Status Scale (EDSS) Assessment|Change From Core Study Baseline in the Expanded Disability Status Scale (EDSS) Score,True,2013-09-04
NCT03442049,Effects of Core Stability Training on Gait in Multiple Sclerosis Patients,Randomized Controlled Trial of Core Stability Training in Patients With Multiple Sclerosis: Biomechanical and Performance Based Analysis of Gait,COMPLETED,2015-01-01,2016-02-20,2016-05-01,2018-02-22,2018-02-22,INTERVENTIONAL,NA,68.0,ACTUAL,Hacettepe University,OTHER,,,"Multiple Sclerosis|Gait Disorders, Neurologic",Multiple Sclerosis|Gait|Spinal Stabilization Exercises|Plantar Pressure Distribution|Rehabilitation,,,,0,Physiotherapy - Study group|Physiotherapy - control group,OTHER|OTHER,6 Minutes Walk Test|Modified Borg Scale|Plantar Pressure Distribution|Plantar Pressure Distribution|Multiple Sclerosis Quality of Life Scale,Muscle strength with hand held dynamometer|Muscle strength with hand held dynamometer|Muscle strength with hand held dynamometer|Muscle strength with hand held dynamometer|Muscle strength with hand held dynamometer|MiniBESTest|Dynamic Gait Index,False,
NCT06280755,Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.,Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study,RECRUITING,2024-03-01,2027-04,2027-04,2025-01-21,2024-02-28,OBSERVATIONAL,,7000.0,ESTIMATED,icometrix,INDUSTRY,"Charite University, Berlin, Germany|Ruhr University of Bochum|Technische Universität Dresden|University Hospital, Lille|Casa di Cura IGEA|General University Hospital, Prague|Hoffmann-La Roche|Bristol-Myers Squibb|Imcyse SA|AB Science|Nocturne UG|Aalto University",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER|INDUSTRY|INDUSTRY|INDUSTRY|INDUSTRY|UNKNOWN|OTHER,Multiple Sclerosis|NMO Spectrum Disorder|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Radiologically Isolated Syndrome|Clinically Isolated Syndrome,Multiple Sclerosis|Prognosis|Progression|AI models|disease worsening,Czechia,Prague,Praha 2,3,,,The number of patients from each institution who have contributed data to the database.|The number of patients from each institution whose data was mapped to the common data model of the harmonised database.|The number of patients from the control arms of clinical trials who have contributed data to the database.|The data completeness of each variable in the harmonised database.,"The representativeness of the harmonised dataset for the MS patient population as evaluated by age range, gender balance, the distribution of country of residence, the distribution of race/ethnicity and the distribution of educational level|The validity of the data through an assessment of the amount of erroneous or impossible data entries for each variable.|The temporal uniformity of each institution's data over time as assessed by the number of changes to variables over time (addition of new variables or variables no longer being captured, alterations to how variables are captured).|The temporal uniformity of the harmonised dataset over time as assessed by the average time between subsequent assessments of each variable.|The presence of contextual information on standard data gathering and analysis processes of each institution|The presence of a unique and pseudonymised patient ID for all data of each patient, allowing to link such data of each patient.|The temporal uniformity of MRI data over time as assessed by the comparability of MRI scans and the average time between subsequent MRI assessments for each patient.|The percentage of MRI data sets which are compliant with the MAGNIMS-CMSC-NAIMS acquisition guidelines.|The percentage of MRI data sets for which the automated quality control process of icobrain ms did not indicate any quality issues upon analysis.|The percentage of patients with a complete disease modifying treatment history available, from the date of diagnosis to the current day.|The percentage of patients with a complete disease history available, from the date of diagnosis to the current day.|The validity and temporal uniformity for disability assessment as clinically determined by EDSS, Functional systems score, T25FWT, 9HPT and SDMT.",False,
NCT06025903,Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis,Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis,RECRUITING,2021-09-20,2024-09-30,2025-05-30,2024-03-22,2023-09-06,OBSERVATIONAL,,140.0,ESTIMATED,IRCCS San Raffaele,OTHER,Azienda Socio Sanitaria Territoriale della Valle Olona,OTHER,Multiple Sclerosis,multiple sclerosis|mitochondria,Italy,Milan,MI,2,,,sequencing of mitochondrial DNA,,False,
NCT06329414,Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis,Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis,RECRUITING,2024-01-16,2026-01,2026-01,2024-03-25,2024-03-25,OBSERVATIONAL,,12.0,ESTIMATED,University of Utah,OTHER,,,Multiple Sclerosis|Major Depressive Disorder|Treatment Resistant Depression,multiple sclerosis|depression|major depressive disorder|treatment resistant depression|transcranial magnetic stimulation|TMS,United States,Salt Lake City,Utah,1,,,"Feasibility of TMS treatment for MDD, per participant retention rates.|Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment.",Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment.|Depression remission rates will be measured using MADRS scores before and after treatment.|MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden.,False,
NCT05357638,Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body,Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body,RECRUITING,2022-05-02,2025-05-02,2025-11-02,2023-04-25,2022-05-03,INTERVENTIONAL,NA,48.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,Netherlands Brain Foundation,OTHER,Parkinson Disease|Multiple Sclerosis,,Netherlands,Amsterdam,North Holland,1,High Intensity Interval Training (HIIT)|Continuous Aerobic Training (CAT)|Movement Advice,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change in anxiety and depressive symptoms,"Change in disease severity|Change in cognitive function (i.e., ability to inhibit cognitive interference)|Change in cognitive function (i.e., mental flexibility)|Change in cognitive function (i.e., range of cognitive operations: motor speed, attention, and visuoperceptual functions)|Change in fatigue|Change in sleep quality|Change in well-being|Change in quality of life|Change in motor capacity (i.e., walking speed)|Change in motor capacity (i.e., lower extremity function, mobility, and fall risk)|Change in motor capacity (i.e., finger dexterity)|Change in activities of daily living|Change in biomarkers of neuroplasticity in blood|Change in biomarkers of neurodegeneration in blood|Change in brain morphology|Change in structural brain connectivity|Change in brain connectivity|Change in brain iron concentration in the Substantia Nigra|Change in brain neuromelanin content|Change in daily mood|Change in daily anxiety|Change in daily ability to concentrate|Change in daily fatigue|Change in daily sleep quality",False,
NCT00464958,One Year Extension Study To Protocol C2/5/TZ:MS-05,Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study,TERMINATED,2008-01,2008-12,2008-12,2009-02-19,2007-04-24,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,Teva GTC,INDUSTRY,,,Spasticity|Multiple Sclerosis,Fatigue|Spasticity|Sublingual Tizanidine|Epworth Sleepiness Scale|Fatigue Severity Scale,Israel,Tel Aviv,,1,sublingual tizanidine 12 mg,DRUG,"Clinical Efficacy- reduction in next-day spasticity (Ashworth scores)|Safety- No increase in next-day somnolence/fatigue, measured via Epworth Sleepiness Scale (ESS) and Fatigue Severity Scale (FSS) questionnaires","Additional Safety Measures: Clinical Laboratories (hematology and clinical chemistry, with special emphasis on liver function tests); Blood pressure monitoring (standard vital signs: BP and pulse at every monthly visit, + 24 hour Holter ambulatory Blood",False,
NCT04295616,Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).,The Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).,TERMINATED,2020-01-13,2020-07-20,2020-07-20,2020-08-05,2020-03-04,INTERVENTIONAL,NA,5.0,ACTUAL,National Multiple Sclerosis Center,OTHER,National MS Center Melsbroek,OTHER,Multiple Sclerosis,,Belgium,Melsbroek,,1,Intrapulmonary percussive ventilation (IPV)|Active breathing training,DEVICE|BEHAVIORAL,Change in breathing force,Change in Pulmonary Dysfunction Index (PDI)|Change in Maximum Phonation time (MFT)|Change in Voice Handicap Index (VHI-10)|Change in Vital Capacity (VC)|Change in Maximum Inspiratory Pressure (MIP)|Change in Maximum Expiratory Pressure (MEP)|Change in Visual Analogue Scale (VAS) for fatigue,False,
NCT00780455,Rehabilitation Study in MS Patients,"Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®",TERMINATED,2008-10,2009-09,2009-09,2015-05-29,2008-10-27,INTERVENTIONAL,PHASE4,4.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",KineSEP|Rehabilitation|Betaferon,France,Rennes,Brittany Region,10,"Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b, FRP about 6 weeks after randomization",DRUG|DRUG,Total Walking Area (in Covered Meters) Either After 6 Minute or at the Time of the Premature Stop of the Test.|Time of Discomfort Appearance|Distance of Discomfort Appearance|Rhythm Change During 6 Minutes Walking Test,Covered Distance Gain Between MR2 Visit and MR3 Visit|Knee Isokinetic Gain Between Baseline and 12 Weeks After MR1 Visit|Posturography Gain in Static Equilibrium Performances Between Baseline and 12 Weeks After MR1 Visit|Posturography Gain in Static Equilibrium Performances Between MR2 and MR3 Visits|Number of Participants With Fatigue Based on Participants Self Assessment Using the Fatigue Severity Scale (FSS)|Quality of Life Assessed by Use of Self-questionnaire (SEP-59),True,2013-02-26
NCT06726135,The NRC Dataset. Developing a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study,The National Rehabilitation Centre Dataset. Development of a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study,NOT_YET_RECRUITING,2025-01,2025-06,2025-06,2024-12-19,2024-12-10,OBSERVATIONAL,,50.0,ESTIMATED,ThomasCorbett,OTHER,Nottingham University Hospital NHS Trust,UNKNOWN,Pain|Traumatic Brain Injury|Major Trauma|Multiple Sclerosis|Amputees / Rehabilitation|Spinal Cord Injuries (SCI)|Functional Neurological Disorder|Intensive Care Unit (ICU) Acquired Weakness (ICU - AW)|Trauma Related Injuries,E-delphi|Delphi|Multidisciplinary|Rehabilitation|Core outcome set|Dataset|national rehabilitation centre|outcome measure instruments|inpatient,,,,0,,,To develop a Core Outcome Set (COS) for rehabilitation to be used as the foundation of the National Rehabilitation Centre Dataset.,,False,
NCT06159361,Balance Targeted Exercises for Individuals With MS,The Effect of a Targeted Exercise Program on Balance and Postural Responses in Patients With Multiple Sclerosis (MS),COMPLETED,2023-12-06,2024-09-01,2024-12-30,2025-01-31,2023-12-06,INTERVENTIONAL,NA,7.0,ACTUAL,University of Miami,OTHER,,,Multiple Sclerosis,,United States,Miami,Florida,1,Balance targeted exercises,BEHAVIORAL,Change in balance ability as measured by the BESTest|Change in reaction time|Change in movement velocity|Change in endpoint excursion percentage|Change in directional control percentage|Change in maximum excursion percentage|Change in muscle responses latency as measured by MCT|Change in postural muscles responses latency as measured by Electromyography (EMG)|Change in APA as measured by microvolts|Change in CPA as measured by microvolts,Change in balance confidence as measured by ABC|Change in quality of life as measured by the MSQoL-54,False,
NCT07058870,Unravelling The Optimisation And Consolidation Of Motor Skills In People With Multiple Sclerosis With Mild to Moderate Gait Impairment: A Feasibility Study,Unravelling The Optimisation And Consolidation Of Motor Skills In People With Multiple Sclerosis With Mild to Moderate Gait Impairment Via High Intensity Task Oriented Circuit Training: A Feasibility Study,RECRUITING,2024-10-15,2026-02-28,2026-02-28,2025-07-10,2025-07-10,INTERVENTIONAL,NA,18.0,ESTIMATED,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,high intensity training|multiple sclerosis|motor learning|mild to moderate multiple sclerosis,Italy,Ferrara,FE,1,High Intensity Task Oriented Circuit Training + Telerehabilitation,BEHAVIORAL,Change in Balance,"Change in mobility, balance, walking ability, and fall risk|Change in Dual task Cost|Change in quantitative mobility and leg function performance|Change in auditory information processing speed and flexibility|Change in Walking Speed|Change in ability to modify balance while walking in the presence of external demands|Change in dynamic balance during an activity requiring weight-shift and movement while in single-leg stance|Change in ability to transition from a supine positon to a standing position.|Change in functional lower extremity strength|Change in Walking capacity|Change in Subjective Trait Fatigue|Change in impacts of multiple sclerosis in people' lifes|Change in balance confidence|Change in perceieved impact of MS on the individual's walking ability.|Change in Walking Fatigability",False,
NCT03172741,The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis,The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis,WITHDRAWN,2017-01,2018-01,2018-01,2018-07-18,2017-06-01,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,Colorado State University,OTHER,,,Multiple Sclerosis,Cannabis,,,,0,Medical Marijuana|Placebo,DRUG|DRUG,Leg Strength|Fatigue Severity Scale|25 foot walk test|9 hole peg test|Paced Auditory Serial Addition Test|Becks Depression Inventory|Quality of Life|Pain Effect Scale.,Fat Mass|Lean Body Mass,False,
NCT06012513,Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis,Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2023-09,2025-09,2025-12,2023-08-25,2023-08-25,OBSERVATIONAL,,60.0,ESTIMATED,Assiut University,OTHER,,,Sleep Disorder,,,,,0,,,Identification of different types of sleep disorders in patients with multiple sclerosis,,False,
NCT03854123,"Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics","Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics",COMPLETED,2018-09-21,2020-09-23,2020-09-23,2022-02-03,2019-02-26,OBSERVATIONAL,,159.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Observatoire Français de la sclérose en plaques (OFSEP)|Novartis,UNKNOWN|INDUSTRY,Multiple Sclerosis,Geriatric population|EDMUS|OFSEP,France,Bordeaux,,3,,,Evaluation of MS evolution with disability progression (irreversible Disability Status Scale) in 75 to 77 years Old MS Patients from the age of 65 years-old to present time,Frequency of clinical relapses in 75 years Old or Older MS Patients from the age of 65 years-old to present time|Description of the clinical characteristics at 75 years Old|Description of the Cerebral MRI at 75 years Old|Description of the paraclinical characteristics at 75 years Old|Description of the paraclinical characteristics at 75 years Old|Socio-demographic data|Socio-demographic data|Socio-demographic data|Description of the treatments at 75 years Old|Description of the treatments at 75 years Old|Description of the treatments at 75 years Old|Measure of health-related quality of life at 75 years Old|Evaluation of cognitive functions at 75 years Old,False,
NCT04832269,Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour,"Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone (MP) During Pregnancy on Offspring Cognitive Function, Stress Sensitivity, Behaviour and Functional and Structural Brain Development",RECRUITING,2020-10-19,2023-12-31,2024-12-31,2024-03-06,2021-04-05,OBSERVATIONAL,,80.0,ESTIMATED,Jena University Hospital,OTHER,"Ruhr University of Bochum|Interdisciplinary Center of Clinical Research of the Medical Faculty Jena|Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",OTHER|UNKNOWN|INDUSTRY,Multiple Sclerosis,fetal programming|pregnancy|relapse therapy,Germany,Bochum,,2,Exposure to methylprednisolone during pregnancy,OTHER,General cognitive ability - Reynolds Intellectual Assessment Scales and Screening (RIAS),"Structural brain development - BrainAge score|Salivary cortisol decay curve|Salivary alpha-amylase|Heart rate variability|Spectral edge frequency in the EEG|External assessment sheet for attention deficit / hyperactivity disorder (FBB-ADHS, German Version)|Child Behavior Checklist (CBCL/6-18R)|Strengths and Difficulties Questionnaire (SDQ-Deu-S)|Continuous Performance Test (CPT)|Emotional excitability scale from Personality questionnaire for children between 9 and 14 years (PFK 9-14, German Version)|Movement Assessment Battery for Children - Second Edition (M-ABC-2)|Child anxiety test III (KAT-III, German version)",False,
NCT05060354,COVID-19 Vaccine Response in Treated MS Patients,Immune Response to SARS-CoV2 Vaccinations in Treated MS Patients Compared to Controls,COMPLETED,2021-06-01,2023-09-15,2023-09-28,2024-01-25,2021-09-29,OBSERVATIONAL,,159.0,ACTUAL,Brigham and Women's Hospital,OTHER,,,Multiple Sclerosis|Healthy,Multiple Sclerosis|COVID-19|mRNA vaccine,United States,Boston,Massachusetts,1,Blood draw,OTHER,Primary endpoint,Secondary endpoint 1|Secondary endpoint 2|Secondary endpoint 3|Secondary endpoint 4|Secondary endpoint 5,False,
NCT03798366,A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis,"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered GLPG1690 for 24 Weeks in Subjects With Systemic Sclerosis",COMPLETED,2019-01-14,2020-05-21,2020-06-22,2021-05-04,2019-01-09,INTERVENTIONAL,PHASE2,33.0,ACTUAL,Galapagos NV,INDUSTRY,,,Systemic Sclerosis,,United States,Los Angeles,California,18,GLPG1690|Placebo,DRUG|DRUG,Change From Baseline in mRSS at Week 4|Change From Baseline in mRSS at Week 8|Change From Baseline in mRSS at Week 16|Change From Baseline in mRSS at Week 24,Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs,True,2021-05-04
NCT00004645,"Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone",,UNKNOWN,1995-01,,,2005-06-24,2000-02-25,INTERVENTIONAL,PHASE3,22.0,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Mayo Clinic,OTHER,Acute Disseminated Encephalomyelitis|Devic's Syndrome|Marburg's Variant of Multiple Sclerosis|Balo's Concentric Sclerosis|Acute Transverse Myelitis,Balo's concentric sclerosis|Devic's syndrome|Marburg's variant of multiple sclerosis|acute disseminated encephalomyelitis|acute transverse myelitis|multiple sclerosis|neurologic and psychiatric disorders|rare disease,,,,0,Plasma exchange,PROCEDURE,,,False,
NCT05713890,Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis,An Integrated and Home-based Motor Rehabilitation Combining Virtual Reality and Action Observation Treatment in People With Multiple Sclerosis: a Clinical and Neuroimaging Study,RECRUITING,2023-04-06,2025-04,2025-07,2023-09-28,2023-02-06,INTERVENTIONAL,NA,60.0,ESTIMATED,IRCCS San Raffaele,OTHER,Istituto di Neuroscienze Consiglio Nazionale delle Ricerche,NETWORK,Multiple Sclerosis,,Italy,Milan,,1,Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|Home-based landscape observation with virtual-reality for upper limb rehabilitation,OTHER|OTHER,Change in right hand Nine-hole peg test (9HPT),Change in left hand Nine-hole peg test (9HPT)|Change in hand grip strength|Change in finger tapping frequency|Change in Medical Research Council (MRC) scale|Change in Modified Ashworth Scale (MAS)|Change in items 1-6 of the Functional Independence Measure (FIM)|Change in Expanded Disability Status Scale (EDSS)|Change in Paced Auditory Serial Addition Test (PASAT)|Change in Symbol-Digit Modalities Test (SDMT)|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Modified Fatigue Impact Scale (MFIS)|Change in Arm Function in Multiple Sclerosis Questionnaire (AMSQ)|Change in Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Change in global brain volume|Changes in regional gray matter volumes|Changes in white matter microstructural architecture|Changes in resting state functional connectivity|Changes in brain activation during an object manipulation task,False,
NCT04928313,Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran,"A Phase IV, Post-marketing, Prospective, Multicenter Study to Investigate the Safety and Effectiveness of Cinnomer® (Glatiramer-Acetate) in Multiple Sclerosis (MS) Treatment in Iran",COMPLETED,2015-04-12,2020-02-17,2020-02-17,2021-06-16,2021-06-16,OBSERVATIONAL,,368.0,ACTUAL,Cinnagen,INDUSTRY,,,Relapsing Multiple Sclerosis,Glatiramer Acetate|Multiple Sclerosis|Quality of Life|Cinnomer|Annualized Relapse Rate|Safety|Relapsing,,,,0,Glatiramer Acetate,DRUG,Safety assessment,Change from Baseline in Annualized Relapse Rate|The proportion of relapse-free patients|Change from Baseline in Expanded Disability Status Scale (EDSS)|Change in Mean Number of T2 and Gd-enhancing lesions|Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQoL) Questionnaire Scale Score at Month 14|Change From Baseline in the Beck Depression Inventory II (BDI-II) Total Score at month 14,False,
NCT04131673,MS and NMOSD in African-Americans,MS and NMOSD in African-Americans: a Prospective Data Collection Protocol Using REDCap,WITHDRAWN,2019-07-05,2023-12-31,2023-12-31,2022-11-14,2019-10-18,OBSERVATIONAL,,0.0,ACTUAL,Jagannadha R Avasarala,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica,multiple sclerosis|MS|Neuromyelitis optica spectrum disorder|NMOSD|African Americans,United States,Lexington,Kentucky,1,,,Clinical data collection and comparison,MRI analysis|Diagnostic tests collection and comparison,False,
NCT05528666,Risk Perception in Multiple Sclerosis,Risk Perception in Multiple Sclerosis,COMPLETED,2021-09-09,2021-09-17,2021-09-17,2022-11-08,2022-09-06,OBSERVATIONAL,,4361.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,"Multiple sclerosis (MS),|Disease-modifying therapies (DMTs),|High efficacy treatments (HETs),|Nonhigh efficacy treatments (Non-HETs)",United States,East Hanover,New Jersey,1,High Efficacy Therapy (HET)|Non High Efficacy Therapy (Non-HET),OTHER|OTHER,"Proportion of patients who were switched based on risk perception (infections, malignancies, others)",Number of patients with ranking of the frequency of switches due to risk perception|Proportion of patients who switched due to lack of efficacy|Proportion of patients who changed treatment group versus patients who continued in the same treatment group|Number of relapses|Expanded Disability Status Scale (EDSS)|Age|Gender|Number of patients: Employment status|Number of patients with Initial MS diagnosis|Number of patients with Current MS diagnosis|Number of patients with previous disease modifying treatment,False,
NCT03737851,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis",COMPLETED,2018-12-11,2021-08-09,2021-09-09,2023-12-22,2018-11-13,INTERVENTIONAL,PHASE2,208.0,ACTUAL,AbbVie,INDUSTRY,,,Multiple Sclerosis (MS),Relapsing multiple sclerosis|Multiple sclerosis|Elezanumab|ABT-555,United States,Birmingham,Alabama,49,elezanumab|placebo,DRUG|DRUG,Mean Overall Response Score (ORS) at Week 52,Disability Improvement Response Rate|Overall Response Score (ORS)|Overall Response Score (ORS)|Overall Response Score (ORS),True,2023-12-22
NCT03808142,PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon,PROmyBETAappGame: Ascertaining Medication Usage & Patient Reported Outcomes Via the myBETAapp and Exploring Gamification in Patients With Multiple Sclerosis Treated With Betaferon,COMPLETED,2019-02-20,2020-04-20,2020-09-02,2021-08-25,2019-01-17,OBSERVATIONAL,,79.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,Germany,Multiple Locations,,1,"myBETAapp|PEAK|Betaferon, BAY86-5046|BETACONNECT",OTHER|OTHER|DRUG|DEVICE,"Compliance percentage to therapy|Persistence percentage of therapy|Adherence percentage to therapy, assessed prospectively|Absolute number of injections missed per 3-month intervals|Relative proportion of injections missed per 3-month intervals",Compliance percentage to therapy|Persistence percentage of therapy|Adherence percentage to therapy|Absolute number of injections missed per 3-month intervals|Relative proportion of injections missed per 3-month intervals|Health-related quality of life assessed by questionnaire EQ-5D-5L|Scores of Treatment Satisfaction Questionnaire for Medication version 2 (TSQM v.II)|Response level of Satisfaction with the BETAPLUS patient support program (service questionnaire)|Response level of Satisfaction with the BETACONNECT autoinjector (service questionnaire)|Response level of Satisfaction with the myBETAapp (service questionnaire)|Feedback based on free text on supporting services or devices|Number of MS patients using the mobile-based cognitive training tool - PEAK|Proportion of MS patients using the mobile-based cognitive training tool - PEAK|Frequency of mobile-based cognitive training tool - PEAK usage (trainings/week)|Duration of mobile-based cognitive training tool - PEAK usage (days)|Cumulative time played per game of mobile-based cognitive training tool - PEAK usage (minutes),False,
NCT04798651,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,RECRUITING,2021-09-30,2026-09,2026-09,2025-02-20,2021-03-15,INTERVENTIONAL,NA,150.0,ESTIMATED,"University Hospital, Bordeaux",OTHER,University of Bordeaux,OTHER,Multiple Sclerosis|Clinically Isolated Syndrome,Autoimmune Diseases of the Nervous System|Multiple sclerosis|clinically isolated syndrome|lymphoid cells|CD4 T cells|B cells,France,Bordeaux,,1,blood sample|cerebro-spinal fluid,BIOLOGICAL|BIOLOGICAL,Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.,Quantification of disease activity scores|Quantification of disease activity scores|Number of lesions|Size of lesions|Localisation of lesions|Types of lesions|duration of the disease|age at onset and progression|number of relapses|date of relapses|Treatment,False,
NCT04595045,Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis,Effectiveness of Botulinum Toxin Type A Infiltrations in the Gait and Quality of Life in Adults With Spastic Lower Limb Paresis Secondary to Multiple Sclerosis,COMPLETED,2019-01-24,2022-07-28,2022-07-28,2022-08-09,2020-10-20,INTERVENTIONAL,PHASE3,84.0,ACTUAL,Aránzazu Vázquez Doce,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Botulinum toxin type A,Spain,Majadahonda,Madrid,2,Botulinum toxin type A infiltrations,DRUG,Effectiveness of repeated Botulinum Toxin infiltrations using objective results obtained by the clinician (Six Minutes Walking Test - 6MWT).|Effectiveness of repeated Botulinum Toxin infiltrations using results reported by the patient (Twelve item Multiple Sclerosis Walking Scale - MSWS-12).,Evaluation of spasticity using Modified Ashworth Spasticity scale (MAS scale).|Evaluation of disability using Expanded Disability Status Scale de Kurtzke (EDSS scale).|Evaluation of the quality of life after the use of botulinum toxin type A using Multiple Sclerosis Quality of Life 54 (MSQoL-54).|Assessment of medium and long-term objectives using Goal Attainment Scaling (GAS scale).|Number of adverse events.,False,
NCT01796860,Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis,The Impact of Ankle Foot Orthosis (AFO) on Gait Recovery in Select Individuals With Multiple Sclerosis (MS),TERMINATED,2012-09,2013-08,2013-08,2015-08-21,2013-02-22,INTERVENTIONAL,NA,10.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,,,Multiple Sclerosis,Gait|AFO|MS,United States,Dallas,Texas,1,AFO,OTHER,Change in Step Length From Initial Testing to End of Study,Number of Participants With Change in Muscle Activity With Surface Electromyography (EMG) of Key Lower Extremity Muscles From Baseline to Final Testing,True,2015-08-03
NCT07164924,Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility,Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility,COMPLETED,2018-01-01,2024-12-08,2024-12-08,2025-09-10,2025-09-10,OBSERVATIONAL,,800.0,ACTUAL,"University Hospital, Clermont-Ferrand",OTHER,Observatoire Français de la sclérose en plaques (OFSEP)|Roche Diagnostic Ltd.|ARSEP foundation,UNKNOWN|INDUSTRY|UNKNOWN,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders|Fertility,Fertility|Anti-Mullerian Hormone (AMH)|Multiple sclerosis (MS)|Female|Disease activity,France,Amiens,,27,blood sample to analyse AMH level on the serum,BIOLOGICAL,the evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml),Evaluation of the potential impact of previous treatments used on AMH level,False,
NCT00391079,Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS,"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis",COMPLETED,2006-09,2008-04,2008-09,2013-06-24,2006-10-23,INTERVENTIONAL,PHASE3,339.0,ACTUAL,GW Pharmaceuticals Ltd,INDUSTRY,,,Multiple Sclerosis,Central Neuropathic Pain,Canada,Calgary,Alberta,6,Sativex|Placebo,DRUG|DRUG,Change in Mean Pain Due to MS NRS Score|Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Pain Score From Baseline,Change in Pain From Baseline to End of the Treatment Using the NPS (Neuropathic Pain Scale)|Change From Baseline to End of Treatment in Break-through Analgesia Usage|Change From Baseline to End of Treatment in BPI (Brief Pain Inventory) Short Form|Change in Subject Global Impression of Change (SGIC)|Change in Sleep Disruption NRS,True,2012-07-04
NCT04133779,Observational Study on Multiple Sclerosis,Multiple Sclerosis,COMPLETED,2010-12-29,2012-05-30,2012-05-30,2019-10-21,2019-10-21,OBSERVATIONAL,,1767.0,ACTUAL,Fondazione Italiana Sclerosi Multipla,OTHER,,,Multiple Sclerosis,,,,,0,"neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|neurological evaluation, ecocolor-Doppler|medical history, vital signs, ecocolor-Doppler",PROCEDURE|PROCEDURE|PROCEDURE,The presence of CCSVI,,False,
NCT06453694,Efgartigimod for the Treatment of Acute Optic Neuritis,A Pilot Randomized Trial of Efgartigimod Alfa for the Treatment of Incident Moderate to Severe Acute Optic Neuritis,NOT_YET_RECRUITING,2024-10,2026-12,2027-07,2024-06-12,2024-06-12,INTERVENTIONAL,PHASE2,20.0,ESTIMATED,"Anastasia Vishnevetsky, MD, MPH",OTHER,argenx,INDUSTRY,Optic Neuritis,Optic neuritis|Inflammatory optic neuropathy|Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)|Neuromyelitis Optica Spectrum Disorder (NMOSD)|Multiple Sclerosis,United States,Boston,Massachusetts,2,Efgartigimod Alfa|Placebo,DRUG|DRUG,Recruitment Rate|Study Adherence Rate|Change in high contrast visual acuity for effect size and standard deviation estimation|Change in low contrast visual acuity for effect size and standard deviation estimation,Retention rate|Screen failure rate|Pre-screen failure rate|Drug adherence rate|Full improvement in visual acuity (high contrast)|Full improvement in visual acuity (low contrast)|Personal maximal improvement (high contrast)|Personal maximal improvement (low contrast)|Improvement in high contrast visual acuity at 3 months|Improvement in high contrast visual acuity at 6 months|Rescue treatment|Difference in change in low contrast visual acuity from baseline to 6 months between groups|Difference in change in low contrast visual acuity from baseline to 6 months between groups|The number and proportion of participants with low contrast visual acuity of 0|Contrast sensitivity|Color Vision|Visual fields|Vision Related Quality of Life|Efgartigimod safety measures,False,
NCT01591551,NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness,NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness,COMPLETED,2012-03,2013-08,2013-08,2014-01-29,2012-05-04,INTERVENTIONAL,PHASE4,37.0,ACTUAL,"Cornerstone Health Care, PA",OTHER,Biogen,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting",,United States,Patchogue,New York,3,Natalizumab (Tysabri),DRUG,Change in parameters of sleep as measured by polysomnography and multi-sleep latency test over 6 months of Natalizumab treatment.,"Change in neurocognition parameters over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.|Change in subjective measures of fatigue, sleepiness and mood over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.",False,
NCT05930379,A Feasibility Pilot Study on Lee Silverman Voice Treatment-Loud: a Telerehabilitation Approach,A Feasibility Pilot Study on Lee Silverman Voice Treatment (LSVT)-Loud on Voice Intensity and Voice Use in Daily Living in People With Multiple Sclerosis: a Telerehabilitation Approach,COMPLETED,2023-06-10,2024-09-01,2024-09-01,2025-09-04,2023-07-05,INTERVENTIONAL,NA,20.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,Fondazione Italiana Sclerosi Multipla,OTHER,Multiple Sclerosis,Telerehabilitation|Speech Therapy|Multiple Sclerosis|Voice Intensity|Hypophonia|Digital Health,Italy,Milan,Italy/Milan,1,LSVT-Loud delivered by telerehabilitation|LSVT-Loud in the clinic,OTHER|OTHER,Change in the vocal Intensity during 1-minute monologue dB SPL,"Change in the vocal Intensity during 1-minute monologue dB SPL|Change in sustained /a/ voice intensity (dB SPL/a/)|Change in the perception of voice as measured by the Voice Handicap Index (VHI, Jacobson et al., 1997)|hange in perceived quality of life (especially in cognition, life activities, and participation domain) as measured by the World Health Organization disability assessment schedule 2.0 (WHODAS 2.0; Federici et al., 2017)|Protocol adherence",False,
NCT00792766,Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM),Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis,COMPLETED,2008-12,2013-09,2013-09,2013-09-18,2008-11-18,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,"Children's Hospital Medical Center, Cincinnati",OTHER,Novartis,INDUSTRY,Tuberous Sclerosis|Angiolipoma,Tuberous Sclerosis Complex (TSC)|Angiolipoma|mTOR|Everolimus,United States,Cincinnati,Ohio,1,everolimus (RAD001),DRUG,RAD001 tolerance,Angiomyolipoma volume reduction,False,
NCT05809505,Feasibility and Safety of the 360-degree Turn Test Delivered Via Telehealth,Feasibility and Safety of the 360-degree Turn Test Delivered Via Telehealth,UNKNOWN,2023-05-01,2024-12-01,2025-01-01,2023-06-07,2023-04-12,INTERVENTIONAL,NA,50.0,ESTIMATED,Uskudar State Hospital,OTHER_GOV,,,Multiple Sclerosis,telehealth|multiple sclerosis|360-degree Turn Test,Turkey (Türkiye),Istanbul,Başakşehir,1,360-degree Turn Test|Expanded Disability Status Scale|Perceived Exertion,DIAGNOSTIC_TEST|OTHER|OTHER,Number of patients who safely completed the 360-degree turn test and completed the measurement in a way that could be used in clinical trials or follow-up,,False,
NCT02711566,Robot-based Rehabilitation of Upper Limb Impairment in Multiple Sclerosis,"Robot-based Assessment and Therapy in the Treatment of Upper Limb Impairment in Multiple Sclerosis: a Multi-center, Randomised Controlled Trial",COMPLETED,2010-01,2011-07,2011-12,2016-03-17,2016-03-17,INTERVENTIONAL,NA,41.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,University of Genova|Azienda Sanitaria Locale 3 Genovese,OTHER|OTHER,Multiple Sclerosis,Rehabilitation|Robot-assisted therapy,,,,0,Physioassistant: Haptic training|Physioassistant: Sensorimotor training,DEVICE|DEVICE,Change of the 9 Hole Peg Test score,Treatment change in percentage of responders at 9 Hole Peg Test score|Absolute change of exercise performance|Absolute change of task difficulty,False,
NCT04057066,Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis (Feasibility Study),Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis. A Feasibility Study.,COMPLETED,2019-02-28,2019-08-16,2019-08-16,2020-04-27,2019-08-14,INTERVENTIONAL,NA,26.0,ACTUAL,University of Erlangen-Nürnberg,OTHER,"Neurological Rehabilitation Center Quellenhof|ZTM Bad Kissingen|Medi train - Zentrum für Gesundheitssport, Sport- und Physiotherapie|proMX GmbH Nürnberg|motionNET systems Limited|Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg (AMSEL) e.V.|Klinikum Würzburg Mitte GmbH",UNKNOWN|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Multiple Sclerosis,multiple sclerosis|e-health|physical activity promotion|exercise|feasibility|online|internet based,Germany,Bad Wildbad,Baden-Wurttemberg,3,Physical activity counseling|Exercise,BEHAVIORAL|BEHAVIORAL,Acceptability of the Intervention and participants' experiences (focus groups)|Compliance with intervention protocol (completed training sessions and e-learning modules)|Acceptability of the Intervention and participants' experiences (interviews),Changes in objectively measures physical activity|Changes in subjectively measured physical activity: European Health Interview Survey-Physical Activity Questionnaire (EHIS-PAQ)|Würzburger Fatigue Inventory for MS (WEIMuS)|Allgemeine Depressionsskala (ADS-L)|Multiple Sclerosis Walking Scale-12,False,
NCT03607773,Mindfulness for Newly Diagnosed Multiple Sclerosis,Mindfulness Group Intervention for Newly Diagnosed Persons With Multiple Sclerosis: A Pilot Study,COMPLETED,2018-09-19,2020-01-20,2020-01-20,2021-03-23,2018-07-31,INTERVENTIONAL,NA,26.0,ACTUAL,Sarah Morrow,OTHER,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,Multiple Sclerosis,Multiple Sclerosis|Mindfulness,Canada,London,Ontario,1,Mindfulness Behavioural Intervention (MBI) group,BEHAVIORAL,Change in coping skills,,False,
NCT03505294,The Effect of Task-Oriented Training in Patients With Multiple Sclerosis,The Effect of Task-Oriented Training on the Physical and Cognitive Functions in Patients With Multiple Sclerosis,COMPLETED,2018-06-18,2018-11-30,2018-12-24,2019-01-30,2018-04-23,INTERVENTIONAL,NA,20.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|task-oriented training|physical performance|cognition,Turkey (Türkiye),Ankara,,1,Task-oriented training,OTHER,Gait Assessment|Walking ability|mobility|Modified Sensory Organization Test|upper extremity function|cognitive function,Balance Scale|Balance Confidence|Fatigue Severity|Fatigue Impact|Physical Activity|Neuropsychological Questionnaire,False,
NCT04932616,Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis,Use of the Functional Gait Assessment in Patients With Multiple Sclerosis: Examining Reliability Between Face-to-Face and Online Applications,UNKNOWN,2021-01-26,2021-07-01,2021-08-01,2021-06-21,2021-06-21,OBSERVATIONAL,,32.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,teleassessment|functional gait assessment|balance|walk,Turkey (Türkiye),Istanbul,Sisli,1,,,Functional Gait Assessment,Timed 25-Foot Walk Test|Timed Up and Go Test|Berg Balance Test|The Four Square Step Test|12-item Multiple Sclerosis Walking Scale,False,
NCT02472938,Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis,"Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis",WITHDRAWN,2015-07,2019-07,2020-07,2015-12-28,2015-06-16,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Biogen,INDUSTRY,GB Pharma Services & Consulting s.r.l.,INDUSTRY,Relapsing Remitting Multiple Sclerosis,Relapsing remitting Multiple Sclerosis,,,,0,dimethyl fumarate|Placebo,DRUG|OTHER,Mean number of cumulative combined unique active (CUA) lesions (registered from week 4 to 24),Mean number of CUA|Mean number of hypointense T1 lesions|New Gd+ lesions|New/enlarging T2 lesions,False,
NCT01918800,A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis,A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis,COMPLETED,2013-03-28,2015-12-30,2015-12-30,2018-07-26,2013-08-08,INTERVENTIONAL,NA,282.0,ACTUAL,VA Office of Research and Development,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,fatigue|quality of life|rehabilitation|self management|energy effectiveness,United States,Gainesville,Florida,4,Fatigue: Take control|MS: Take Control,BEHAVIORAL|BEHAVIORAL,Modified Fatigue Impact Scale,Multiple Sclerosis Self Efficacy Scale|Beck Depression Inventory II (BDI-II)|SF-36|Rapid Assessment of Physical Activity (RAPA)|Pittsburgh Sleep Quality Index (PSQI)|Timed 25 Foot Walk (T25-FW),True,2017-03-13
NCT00472992,Pregnancy Exposure Registry for Tysabri®,TYSABRI® Pregnancy Exposure Registry,COMPLETED,2007-01,2012-07,2012-07,2014-08-11,2007-05-14,OBSERVATIONAL,,376.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Crohn's Disease|Prenatal Exposure|Multiple Sclerosis|Pregnancy,Pregnancy|TYSABRI,United States,Morgantown,West Virginia,1,,,"Number of spontaneous abortions, fetal losses including stillbirths, and ectopic pregnancies|Number of elective or therapeutic pregnancy terminations|Number of Live Births|Number of Live Births with Birth Defects",,False,
NCT05403463,The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV,The Effect of Covid-19 on the Disease Course of Multiple Sclerosis,COMPLETED,2022-03-01,2022-06-01,2022-06-01,2022-06-08,2022-06-03,OBSERVATIONAL,,230.0,ACTUAL,Marie D'hooghe,OTHER,,,COVID-19,,Belgium,Melsbroek,Vlaams Brabant,1,,,The investigators hereby aim to answer the question whether COVID-19 affects the progression of clinical disability in MS,vaccination status and progression MS,False,
NCT03796247,Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event,Alexithymia Frequency and Interhemispheric Transfer in Patients With a First Demyelinating Event: Initial Phase of Multiple Sclerosis,COMPLETED,2011-05-02,2016-05,2016-05,2019-01-08,2019-01-08,OBSERVATIONAL,,57.0,ACTUAL,"University Hospital, Lille",OTHER,,,Multiple Sclerosis,cognition|alexithymia,France,Lille,,1,,,Frequency of alexithymia in the CIS population,relation between alexithymia and cognitive impairment in CIS patients and controls|relation between alexithymia and thymic disorder in CIS and controls|relation between alexithymia and thymic disorder in CIS and controls|relation between alexithymia and thymic disorder in CIS and controls|relation between alexithymia and thymic disorder in CIS and controls|to evaluate the callosal functions and inter-hemispheric transfer in CIS and controls,False,
NCT03768830,"Impact of Exercise on ""Invisible"" Symptoms and Quality of Life in Multiple Sclerosis Individuals","Impact of 8-weeks Mild Exercise Training on ""Invisible"" Symptoms and Quality of Life in Ambulatory and Non-ambulatory (EDSS From 0.0 - 8.0) Individuals With Multiple Sclerosis: a Randomized Controlled Trial",COMPLETED,2018-10-01,2019-02-05,2019-02-05,2019-04-16,2018-12-07,INTERVENTIONAL,NA,50.0,ACTUAL,University of Rijeka,OTHER,,,Multiple Sclerosis|Quality of Life|Motivation|Pain|Headache|Migraine|Anxiety Disorders|Depressive Disorder|Sleep Disorder|Insomnia|Physical Disability|Fatigue,Quality of life|Multiple Sclerosis|Pain|Headache|Anxiety Disorders|Depressive Disorder|Sleep Disorder|Fatigue,Croatia,Rijeka,,1,Exercise training,BEHAVIORAL,Change of fatigue intensity|Change of pain intensity|Change in quality of life|Change in sleeping quality - ISI|Change in sleeping quality - PSQI|Change in psychological symptoms|Change in Headache-Migraine intensity and frequency,Motivation evaluation,False,
NCT06203106,NYSCF Scientific Discovery Biobank,NYSCF Scientific Discovery Biobank,RECRUITING,2022-11-10,2045-11-10,2045-11-10,2025-03-03,2024-01-12,OBSERVATIONAL,,10000.0,ESTIMATED,New York Stem Cell Foundation Research Institute,OTHER,,,"ALS|Amyotrophic Lateral Sclerosis|Alzheimer Disease|Alzheimer Disease, Early Onset|Alzheimer Disease, Late Onset|Batten Disease|Corticobasal Degeneration|Dementia|Frontotemporal Dementia|Huntington Disease|Lewy Body Disease|Multiple Sclerosis|Multiple System Atrophy|Parkinson Disease|Parkinson's Disease and Parkinsonism|Progressive Supranuclear Palsy|INAD|Diabetes|Diabetes Mellitus|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Macular Degeneration|Ovarian Cancer|Cervical Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|PTSD|Post Traumatic Stress Disorder",ALS|Amyotrophic Lateral Sclerosis|Alzheimer Disease|Batten Disease|Corticobasal Degeneration|Dementia|Frontotemporal Dementia|Huntington Disease|Lewy Body Disease|Multiple Sclerosis|Multiple System Atrophy|Parkinson Disease|Parkinsonism|Progressive Supranuclear Palsy|INAD|Diabetes|Diabetes Type 1|Diabetes Type 2|Macular Degeneration|Women's Reproductive Cancer|Ovarian Cancer|Cervical Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|PTSD|Post Traumatic Stress Disorder,United States,New York,New York,1,Biological Sample Collection,OTHER,Biobank,,False,
NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2007-01,2011-02,2011-02,2015-01-26,2007-01-11,INTERVENTIONAL,PHASE3,1234.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,relapsing|oral|remitting|multiple sclerosis,United States,Gilbert,Arizona,159,BG00012|Placebo,DRUG|DRUG,Proportion of Subjects Relapsed,Number of New or Newly Enlarging T2 Hyperintense Lesions|Number of Gadolinium-enhancing T1-weighted Lesions|Number of Subjects With Gadolinium (Gd)-Enhancing Lesions|Annualized Relapse Rate|Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS),True,2014-06-02
NCT04131764,Diagnosis of ON With or Without MS or NMOSD,"Utility of Quantification of Afferent Pupillary Defect in Predicting Optic Nerve Disease in Retrobulbar Neuritis, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease - a Retrospective and Prospective Analysis",TERMINATED,2019-10-04,2022-09-06,2022-09-06,2022-11-14,2019-10-18,OBSERVATIONAL,,112.0,ACTUAL,Jagannadha R Avasarala,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder Attack|Neuromyelitis Optica Spectrum Disorder Relapse|Neuromyelitis Optica Spectrum Disorder Progression|Optic Neuritis,multiple sclerosis|MS|Neuromyelitis optica spectrum disorder|NMOSD|optic neuritis|pupillary response|RAPD|rapid afferent pupillary defect,United States,Lexington,Kentucky,1,"Reflex (Brightlamp Inc., Purdue University)",DIAGNOSTIC_TEST,Feasibility of device for diagnosis of ON|Comparative data assessment,,False,
NCT06195800,Biomarkers of aHSCT,Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation,RECRUITING,2023-08-09,2026-08-09,2026-08-09,2024-01-08,2024-01-08,OBSERVATIONAL,,15.0,ESTIMATED,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,Sheffield Hospitals Charity|Nottingham Trent University|University of Sheffield,UNKNOWN|OTHER|OTHER,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|aHSCT|Autologous haematopoetic stem cell transplantation,United Kingdom,Sheffield,England,1,,,"Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment.|Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment.",Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips.|Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS)|Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA)|Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC)|Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36)|Evaluate immunological disease response and the duration of response to aHSCT according to symbol digit modality test (SDMT)|Evaluate immunological disease response and the duration of response to aHSCT according to Karnofsky performance status,False,
NCT03461419,Use of Stromal Vascular Fraction in Multiple Sclerosis,Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,SUSPENDED,2019-08-01,2027-01-01,2028-12-15,2025-09-12,2018-03-12,INTERVENTIONAL,NA,100.0,ESTIMATED,Healeon Medical Inc,INDUSTRY,Global Alliance for Regenerative Medicine,OTHER,Multiple Sclerosis|Autoimmune,Multiple Sclerosis|Demyelinating Disease|Nervous System Degenerative Disease|Autoimmune Disease,United States,Stevensville,Montana,2,Microcannula Harvest Adipose Stroma|Centricyte 1000|Sterile Normal Saline IV Deployment of cSVF,PROCEDURE|DEVICE|PROCEDURE,Number of participants with adverse events [Time Frame: Outcome measures evaluated at baseline and reviewed at 6 month intervals for average time frame of 5 years],Deficits of Neurologic Functioning prior to treatment|Quality of Life|Brain Lesions,False,
NCT00127530,Study of Oral Fampridine-SR in Multiple Sclerosis,"Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis",COMPLETED,2005-05,2006-06,2006-09,2018-09-11,2005-08-08,INTERVENTIONAL,PHASE3,300.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,Walking Ability,United States,Birmingham,Alabama,34,Fampridine-SR|Placebo,DRUG|DRUG,Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk),Lower Extremity Manual Muscle Test; Ashworth Score for Spasticity,True,2011-05-06
NCT04943887,CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis,Clinical Trial of a Telehealth Group-Based Intervention to Improve Mood in Underrepresented Individuals With Multiple Sclerosis: The Connect Trial (CONNECT),COMPLETED,2021-08-01,2022-06-01,2022-06-01,2022-08-23,2021-06-29,INTERVENTIONAL,NA,52.0,ACTUAL,eSupport Health,OTHER,,,Multiple Sclerosis,Online Support Group,United States,New York,New York,1,eSupport Health Weekly Group Sessions for PwMS,BEHAVIORAL,Adherence and completion,Hospital Anxiety and Depression Scale (HADS),False,
NCT01658384,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients,Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients,COMPLETED,2011-09,2015-02,2015-03,2019-03-06,2012-08-07,OBSERVATIONAL,,63.0,ACTUAL,Clinique Neuro-Outaouais,OTHER,CogState Ltd.,INDUSTRY,Multiple Sclerosis,,Canada,Gatineau,Quebec,1,,,SDMT CogState battery,,False,
NCT03737097,Online Spaced Education to Improve Fall Prevention by Patients With Multiple Sclerosis,Impact of Online Spaced Education on Long-term Retention of Knowledge About Fall Prevention by Patients With Multiple Sclerosis,UNKNOWN,2019-02-21,2019-10-15,2019-11-15,2019-03-01,2018-11-09,INTERVENTIONAL,NA,320.0,ESTIMATED,Hospital Israelita Albert Einstein,OTHER,,,Education of Patients,Fall|Multiple Sclerosis,Brazil,São Paulo,São Paulo,1,Online Spaced Education|Brochure Education,OTHER|OTHER,Change in test scores between cohorts measured in weeks 1-24,Fall rate|Adherence to fall prevention strategies|Individuals satisfaction with the fall prevention education method|Baseline knowledge levels of patients assessed via their initial responses to the questions|Pre and post-test performances differences by age|Pre and post-test performances differences by gender|Pre and post-test performances differences by history of falls,False,
NCT01641120,Assessing Tolerability of Avonex Intramuscular Injections,Assessing Tolerability of Avonex Intramuscular Injections With a 25 Gauge Needle Versus 30 Gauge Needle,COMPLETED,2012-05,2014-02,2014-02,2016-02-01,2012-07-16,INTERVENTIONAL,NA,20.0,ACTUAL,Trinity Health Of New England,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|Intramuscular Injections|Relapsing Remitting,United States,Hartford,Connecticut,1,Avonex,DRUG,Change in Patient Visual Analog Scale Score for Pre-injection Anxiety|Visual Analog Scale Score for Post-injection Pain,Fear of Injection|Perception of Needle,True,2016-02-01
NCT04458688,Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis,"Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis: a Novel, Advanced Multimodal MRI and Optical Coherence Tomography-Angiography (OCTA) Study",RECRUITING,2021-11-20,2025-07,2030-12,2022-06-06,2020-07-07,OBSERVATIONAL,,80.0,ESTIMATED,Wayne State University,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|ocrelizumab|magnetic resonance imaging (MRI)|optical coherence tomography angiography (OCTA),United States,Detroit,Michigan,1,Observation of Ocrelizumab as Treatment in RRMS Patients,OTHER,Magnetic Resonance Imaging (MRI) with contrast|Optical Coherence Tomography Angiography (OCTA),,False,
NCT04725175,Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE-307 and Food Effect in Normal Healthy Volunteers",COMPLETED,2021-02-26,2021-09-01,2021-09-01,2021-11-03,2021-01-26,INTERVENTIONAL,PHASE1,70.0,ACTUAL,Contineum Therapeutics,INDUSTRY,,,Multiple Sclerosis,,Australia,Nedlands,Western Australia,1,PIPE-307|Placebo oral tablet,DRUG|DRUG,Safety: Treatment-Emergent Adverse Events (TEAE),Safety: Cardiac repolarization using Fridericia-corrected QT interval (QTcF)|Pharmacokinetics (PK): Blood concentration levels of PIPE-307|PK: Urine concentration levels of PIPE-307|Exploratory: Impact of PIPE-307 on Cogstate,False,
NCT04002492,Effects of a Weight Based Training Program on MS Patients,"Effects of a Weight Based Training Program on Bone Density, Cognition, and Quality of Life of Multiple Sclerosis Patients",UNKNOWN,2019-07-01,2019-11,2019-12,2019-08-15,2019-06-28,INTERVENTIONAL,NA,25.0,ESTIMATED,"Holy Name Medical Center, Inc.",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,sarcopenia|osteopenia|exercise|body weight training|bone density|demyelination|cognition,United States,Teaneck,New Jersey,1,Bodyweight training,BEHAVIORAL,Osteopenia,Depression and Quality of Life: MSIS (Multiple Sclerosis impact scale) survey/questionnaire|Cognition,False,
NCT02104011,Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers,Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial,COMPLETED,2015-05-22,2017-11-22,2017-11-22,2018-01-23,2014-04-04,INTERVENTIONAL,PHASE2,2.0,ACTUAL,"University Hospital, Bordeaux",OTHER,,,Renal Angiomyolipomas|Tuberous Sclerosis,Angiomyolipomas in tuberous sclerosis|Beta-blockers|Anti-angiogenic therapies,France,Bordeaux,,1,Propranolol,DRUG,Evolution of angiomyolipomas volume,Renal function evolution|Effect on the potential haemorraghic transformation|Improvement of the quality of life|Effect on face angiofibromas,False,
NCT03751306,Aerobic Exercise and Transcranial Low Laser Therapy in Patients With Central Nervous System Injury,Sensory-Motor and Cardiorespiratory Rehabilitation Associated With Transcranial Laser Therapy in Patients With Central Nervous System Injury,UNKNOWN,2019-01-14,2019-07-31,2020-03-05,2018-11-27,2018-11-23,INTERVENTIONAL,NA,90.0,ESTIMATED,Universidade do Vale do Paraíba,OTHER,,,"Post Stroke|Post-Traumatic Headache|Spinal Injuries|Cerebral Palsy, Spastic|Surgery|Sclerosis, Multiple|Spastic",Neurological Diseases|Cardiorespiratory Rehabilitation|Aerobic exercise|Fotobiomodulação Transcraniana,Brazil,São José dos Campos,São Paulo,1,Transcranial Photobiomodulation|Transcranial Photobiomodulation (Placebo)|Cardiorespiratory Rehabilitation,PROCEDURE|PROCEDURE|PROCEDURE,Change in Muscular electrical activity (Surface electromyograph).|Change in analysis of bipodal balance during the squat movement.|Change in analysis of the heart rate variability to study the responses of the autonomic nervous system|Change in Pulmonary function analysis (spirometry): forced vital capacity|Change in Pulmonary function analysis (spirometry): forced expiratory volume in the first second|Change in Pulmonary function analysis (spirometry): Tiffeneau Index|Change in Pulmonary function analysis (spirometry): maximum voluntary ventilation|Change in analysis of inspiratory muscle strength|Analysis of expiratory muscle strength|Change in analysis of Peak expiratory flow.|Change in analysis of the thoracic expandability (axillary level).|Change in analysis of the thoracic expandability (xiphoid level).|Change in analysis of abdominal level expandability.|Change in analysis of change in Infrared Thermography.|Change in aariation of blood lactate level.|Change in 6-Minute Walk Test (Adapted)|Change in Mini-Mental State Examination (MINI MENTAL).|Change in Short Form 36 questionnaire (SF-36),Follow-up: Evaluation Muscular electrical activity (Surface electromyograph)|Follow-up: Analysis of bipodal balance during the squat movement|Follow-up: Analysis of the heart rate variability to study the responses of the autonomic nervous system|Follow-up: Pulmonary function analysis (spirometry): forced vital capacity|Follow-up: Pulmonary function analysis (spirometry): forced expiratory volume in the first second|Follow-up: Pulmonary function analysis (spirometry):Tiffeneau Index|Follow-up: Pulmonary function analysis (spirometry): maximum voluntary ventilation|Follow-up: Analysis of inspiratory muscle strength|Follow-up: Analysis of expiratory muscle strength|Follow-up: Analysis of Peak expiratory flow.|Follow-up: Analysis of the thoracic expandability (axillary level).|Follow-up: Analysis of the thoracic expandability (xiphoid level).|Follow-up: Analysis of abdominal level expandability.|Follow-up: Analysis of change in Infrared Thermography.|Follow-up: Variation of blood lactate level.|Follow-up: Analysis 6-Minute Walk Test (Adapted)|Follow-up: Evaluation Mini-Mental State Examination (MINI MENTAL).|Follow-up: Evaluation Short Form 36 questionnaire (SF-36),False,
NCT01802489,Amiloride Clinical Trial In Optic Neuritis,A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis,COMPLETED,2013-02,2015-11,2015-11,2018-05-17,2013-03-01,INTERVENTIONAL,PHASE2,46.0,ACTUAL,University of Oxford,OTHER,Multiple Sclerosis Society of Great Britain and Northern Ireland,UNKNOWN,Optic Neuritis|Multiple Sclerosis,Optic neuritis|Multiple sclerosis|Retinal nerve fibre layer|Axonal loss|Neuroprotection|MRI|Optical coherence tomography|Amiloride|Acid Sensing Ion Channels,United Kingdom,Oxford,,1,Amiloride|Placebo,DRUG|DRUG,Scanning laser polarimetry determined retinal nerve fibre layer thickness,Optical coherence tomography determined difference in retinal nerve fibre layer thickness.|Differences between the amiloride and placebo groups in non-conventional MRI surrogate marker of white matter and grey matter injury and connectivity by 3T scanning.|Visual Function|Visual Electrophysiology|Quality of life questionnaires,False,
NCT04075968,The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS,The Effect of Cognitive Group Exercise Combined With Physical Exercise in Multiple Sclerosis Patients,COMPLETED,2018-12-01,2019-11-15,2019-12-01,2021-02-10,2019-09-03,OBSERVATIONAL,,20.0,ACTUAL,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,OTHER_GOV,,,Multiple Sclerosis,,Turkey (Türkiye),Istanbul,,1,Cognitive exercise|Home exercise,OTHER|OTHER,Neuro-psychometric Test (NPT)|Berg Balance Scale|Mini Mental State Test (MMST),Modified Ashworth Scale (MAS),False,
NCT01518660,Multiple Sclerosis and Progressive Resistance Training,"Multiple Sclerosis - Inflammatory, Neurological and Muscular Adaptations to Progressive Resistance Training",COMPLETED,2012-02,2014-01,2014-01,2014-12-02,2012-01-26,INTERVENTIONAL,NA,35.0,ACTUAL,University of Aarhus,OTHER,Aarhus University Hospital|Biogen,OTHER|INDUSTRY,Multiple Sclerosis (Relapsing Remitting),Resistance Training|Strength Training,Denmark,Aarhus C,,2,Training,BEHAVIORAL,Blood-borne biomarkers,Neuro-muscular function of knee extensors|Walking performance|Self-reported measures|Brain volume|Body Composition|Thigh muscle cross-sectional area,False,
NCT06849960,Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis,Reliabilitiy and Validity of the Two-minute Step Test in Patients With Multiple Sclerosis,ENROLLING_BY_INVITATION,2025-02-01,2025-02-15,2025-03-01,2025-02-27,2025-02-27,OBSERVATIONAL,,50.0,ESTIMATED,Sanko University,OTHER,,,Multiple Sclerosis,multiple sclerosis,Turkey (Türkiye),Şehitkamil,Gaziantep,2,,,2 min step test (2MST)|2-min walk test (2MWT)|One-leg stand test (OLSTS),,False,
NCT05349474,Metformin Treatment in Progressive Multiple Sclerosis,"A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis",COMPLETED,2022-04-26,2025-05-30,2025-05-30,2025-07-22,2022-04-27,INTERVENTIONAL,EARLY_PHASE1,23.0,ACTUAL,"University of California, Los Angeles",OTHER,,,Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Multiple sclerosis|Demyelinating disease,United States,Los Angeles,California,1,"Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Placebo oral tablet identical to metformin, up to 4 tablets a day",DRUG|DRUG,number of patients with adverse events between baseline and conclusion (month 0 and month 12)|number of patients with laboratory abnormalities between baseline and conclusion (month 0 and month 12)|number of patients with new T2 lesions on MRI from baseline to conclusion (month 0 and month 12),a reduction in localized cortical thinning on brain MRI between baseline and conclusion (month 0 and month 12)|a reduction in thalamic atrophy on brain MRI between baseline and conclusion (month 0 and month 12),False,
NCT02283918,Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery,Study to Establish Patient-Matched Population Norms for the MS-COG,COMPLETED,2014-11,2015-08,2015-08,2015-10-05,2014-11-05,OBSERVATIONAL,,467.0,ACTUAL,Biogen,INDUSTRY,,,Healthy,,United States,Thornton,Colorado,8,,,Selective Reminding Test (SRT) Score|Brief Visuospatial Memory Test-Revised (BVMT-R) Score|2- second and 3-second Paced Auditory Serial Addition Test (PASAT) Score|Symbol Digit Modalities Test (SDMT) Score,,False,
NCT01279876,Melatonin in Relapsing-Remitting Multiple Sclerosis Patients,Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients,COMPLETED,2010-10,2014-01,2014-02,2015-08-14,2011-01-19,INTERVENTIONAL,PHASE2,25.0,ACTUAL,Tehran University of Medical Sciences,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,Iran,Tehran,Tehran Province,1,Melatonin,DRUG,Number of relapses|EDSS|PASAT-3 score|proportion of brain gray matter volume to intracranial volume,MSFC score,False,
NCT06312046,Motor-cognitive Performance in People With Multiple Sclerosis,Motor-cognitive Performance in People With Multiple Sclerosis - Brain Activity and Effects of Balance Exercise,RECRUITING,2024-02-26,2025-12-31,2027-08-31,2025-07-10,2024-03-15,INTERVENTIONAL,NA,90.0,ESTIMATED,Karolinska Institutet,OTHER,Karolinska University Hospital,OTHER,Multiple Sclerosis|Postural Balance,Balance|Exercise|Multiple sclerosis,Sweden,Stockholm,Stockholm County,1,HiBalance-MS,OTHER,Mini Balance Evaluation Systems test.,"10-Meter Walk Test, maximum speed.|10-Meter Walk Test, self-selected speed.|2-Minute Walk Test, self-selected speed.|Gait speed during simultaneous dual task performance.|Stride length during dual task gait performance.|Step time during dual task gait performance.|Response errors in dual task cognitive performance|Reaction time in dual task cognitive performance|Six-Spot Step Test.|Completion time in the Trail Making Test.|Number of errors in the Trail Making Test.|Immediate and delayed recall in the Ray Auditory Verbal Learning Test.|Cognitive processing speed in the Symbol Digit Modalities Test.|Cognitive function - composite measure of three cognitive tests.|Physical activity level.|Physical activity level, self-reported.|Physical exercise habits, self-reported.|The generic Walk-12 questionnaire.|Falls Efficacy Scale - International.|Assesment of anxiety with the Hospital Anxiety and Depression Scale.|Assesment of depression with the Hospital Anxiety and Depression Scale.|Modified Fatigue Impact Scale.|Occupational Gap Questionnaire.|Acceptance of Chronic Health Condition scale.|Multiple Sclerosis Impact Scale - physical impact.|Multiple Sclerosis Impact Scale - psychological impact.|Euroqol-5 Dimensions-5 Level (EuroQoL-5D-5L).|Euroqol Visual Analogue Scale (EQ VAS).|World Health Organization Disability Assessment Schedule, version 2.0. (WHODAS 2.0)",False,
NCT02969304,Study of Utilization Patterns of Dimethyl Fumarate in Germany,Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany,COMPLETED,2016-12-30,2017-03-02,2017-03-02,2017-07-19,2016-11-21,OBSERVATIONAL,,930.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Tecfidera|Off-label|Utilization,Germany,Leipzig,Saxony,1,dimethyl fumarate,DRUG,"Proportion of dimethyl fumarate use that is prescribed ""on-label"" versus ""off-label"" in Germany",Demographic characteristics of dimethyl fumarate users|Prescription drug history of dimethyl fumarate users|Duration of therapy in participants newly initiating dimethyl fumarate treatment|Number of medical specialists prescribing dimethyl fumarate as identified according to specialty-specific billing codes at outpatient visits.|Medical history of dimethyl fumarate users|Concomitant medication use of dimethyl fumarate users,False,
NCT06770959,"Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study","Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study",NOT_YET_RECRUITING,2025-01,2026-12,2026-12,2025-01-13,2025-01-13,OBSERVATIONAL,,80.0,ESTIMATED,Assiut University,OTHER,,,MS (Multiple Sclerosis),,,,,0,,,Detection of Prevalence of git and hepatic manifestation in people with MS and its relations to MS treatment,,False,
NCT07058896,Unravelling The Optimisation And Consolidation Of Motor Skills In People With Multiple Sclerosis With Severe Gait Impairment: A Feasibility Study,Unravelling The Optimisation And Consolidation Of Motor Skills In People With Multiple Sclerosis With Severe Gait Impairment Via High Intensity Task Oriented Circuit Training: A Feasibility Study,RECRUITING,2024-10-28,2025-10-31,2025-10-31,2025-07-10,2025-07-10,INTERVENTIONAL,NA,18.0,ESTIMATED,University Hospital of Ferrara,OTHER,,,Multiple Sclerosis,multiple sclerosis|high intensity training|motor learning|circuit training|rehabilitation|balance|mobility,Italy,Ferrara,FE,1,High intensity task oriented circuit training + Telerehabilitation,BEHAVIORAL,Change in Static Balance,"Change in Walking capacity|Change in Walking speed|Change in mobility, balance, walking ability, and fall risk|Change in quantitative mobility and leg function performance|Change in auditory information processing speed and flexibility|Changes in functional lower extremity strength|Change in cardiovascular fitness|Change in Subjective Trait Fatigue|Change in impacts of multiple sclerosis in people' lifes|Change in balance confidence|Change in functional performance of the upper extremity|Change in self perceived manual ability|Change in Walking Fatigability",False,
NCT05878873,The Neural Mechanisms of Split-belt Treadmill Adaptation in People With Multiple Sclerosis,The Neural Underpinnings and the Impact of Wearable Sensory Stimulation During Split-belt Treadmill Adaptation in People With Multiple Sclerosis,COMPLETED,2023-11-28,2024-06-30,2024-06-30,2025-07-03,2023-05-26,INTERVENTIONAL,NA,51.0,ACTUAL,Colorado State University,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,split-belt treadmill|adaptation|multiple sclerosis|functional near-infrared spectroscopy|cortical activation|gait asymmetry|locomotion|sensorimotor control,United States,Fort Collins,Colorado,1,Split-belt Treadmill|Transcutaneous Electrical Nerve Stimulation (TENS),BEHAVIORAL|DEVICE,Change in Cortical Activation|Change in Adaptation Savings|Rate of Step Length Asymmetry Adaptation,,True,2025-07-03
NCT00859482,Differential Immune Effects of Natalizumab,A Phase IV Study to Investigate Differential Immune Effects of Natalizumab,COMPLETED,2006-07,2007-07,2007-07,2009-03-11,2009-03-11,OBSERVATIONAL,,27.0,ACTUAL,Cantonal Hospital of St. Gallen,OTHER,,,"Multiple Sclerosis, Relapsing Remitting",natalizumab|multiple sclerosis,,,,0,,,Function of T regulatory cells,Change in distinct immune cell lines,False,
NCT05033782,Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis,Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on the Risk of Multiple Sclerosis Clinical Relapse or Clinical Worsening,COMPLETED,2022-02-08,2025-02-08,2025-02-08,2025-04-13,2021-09-05,OBSERVATIONAL,,1209.0,ACTUAL,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,"multiple sclerosis|Lockdown|COVID-19|Air pollution|Influenza, Human|Gastroenteritis|Health Services Accessibility",France,Paris,,1,questionnaire,OTHER,Multiple Sclerosis Relapse,Neurological disability accumulation,False,
NCT02664324,MSPT Device Usability Study,The Multiple Sclerosis Performance Test (MSPT) Device for Functional Assessment of Multiple Sclerosis (MS) Patients,COMPLETED,2016-03,2016-04,2016-04,2016-05-04,2016-01-27,OBSERVATIONAL,,60.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Baltimore,Maryland,3,,,Number of study participants successfully completing all modules of the MSPT device|Percent (%) of study participants successfully completing all modules of the MSPT device,Percent (%) of study participants who select agree/strongly agree (questions 1 to 5) or disagree/ strongly disagree (questions 6-9) on appropriate questions on the MSPT Usability Survey|Percent (%) of study participants who reported being satisfied or completely satisfied with using MSPT device|Difference of manual timed versus Bluetooth timed in Walking Speed Test (WST) as assessed by Timed 25 foot walk|The percent (%) of study participants who have usability issues with Bluetooth remote due to use of an assistive device(s)|Between-site differences in percent (%) of study participants who select agree/strongly agree (questions 1 to 5) or disagree/ strongly disagree (questions 6 to 9) on appropriate questions on the MSPT Usability Survey|Between-site differences in percent (%) of study participants who select satisfied/completely satisfied on MSPT Satisfaction Survey,False,
NCT02708927,"Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis","Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis",COMPLETED,2016-03-03,2019-01-28,2019-01-28,2019-02-05,2016-03-15,INTERVENTIONAL,NA,91.0,ACTUAL,"University Hospital, Bordeaux",OTHER,FONDATION POUR L'AIDE A LA RECHERCHE SUR LA SCLEROSE EN PLAQUES,UNKNOWN,Multiple Sclerosis,social integration|cognitive impairment|emotional processing|quality of life,France,Bordeaux,,2,Clinical evaluation|Cognitive evaluation,OTHER|OTHER,Interaction between measures of emotional processing (z score) and functional measures of social interaction,"Correlation between measures of emotional processing with cognitive testing (z scores by domain) and cognitive functioning evaluated by significant other|Correlation between measures of emotional processing and quality of life measures|Impact of the cognitive impairment on the relationship of emotional processing (z score) with interpersonal relationships (family, friendship, marital) and society integration and social functioning.",False,
NCT00483652,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,"Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis",COMPLETED,2007-05,2008-02,2008-05,2016-02-04,2007-06-07,INTERVENTIONAL,PHASE3,240.0,ACTUAL,Acorda Therapeutics,INDUSTRY,,,Multiple Sclerosis,multiple sclerosis|MS|walking|leg strength|demyelination,United States,Phoenix,Arizona,40,Fampridine-SR|Placebo,DRUG|DRUG,Responders Based Upon the Timed 25-Foot Walk [T25FW],Change in Lower Extremity Manual Muscle Test [LEMMT],True,2011-04-14
NCT06451159,"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis","Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-06-20,2026-06,2027-06,2025-01-20,2024-06-11,INTERVENTIONAL,PHASE1,10.0,ESTIMATED,Bruce Cree,OTHER,Kyverna Therapeutics,INDUSTRY,Progressive Multiple Sclerosis,"multiple sclerosis|CAR-T|University of California, San Francisco (UCSF)|progressive multiple sclerosis|treatment refractory progressive multiple sclerosis",United States,San Francisco,California,1,KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 (Biological) - 1 ×10^8 cells|Chemotherapy: cyclophosphamide (CYC)|Chemotherapy: fludarabine (FLU),BIOLOGICAL|BIOLOGICAL|DRUG|DRUG,The presence of CAR-T cells in CSF following their peak expansion in peripheral blood.|The incidence and severity of adverse events and dose-limiting toxicities.,The proportion of participants in whom reduction of CSF OCB and/or normalization of CSF IgG Index are detected.,False,
NCT02896179,Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis,The Effects of an Innovative Combined Virtual Reality and Robot Assisted Gait Training on Cognitive and Walking Functions in Patients With Multiple Sclerosis: A Randomized Control Trial,UNKNOWN,2016-11,2017-11,2018-11,2016-09-26,2016-09-12,INTERVENTIONAL,NA,20.0,ESTIMATED,Universita di Verona,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Gait rehabilitation|Quality of life|Virtual reality|Cognitive deficit|Robot assisted gait training,Italy,Verona,Verona,1,Robot-assisted gait training group+VR|GEO,DEVICE|DEVICE,10 meters Walking test (10-MtWT) change in gait speed (m/sec),Berg Balance Scale|2-Minute Walking Test (meters)|Activities-specific Balance Confidence Scale|Tower of London - point|Multiple Sclerosis Quality Of Life-54|Gait Analysis - Cadence (step/min)|Gait Analysis - Stride length (cm)|Gait Analysis - Step length (cm)|Gait Analysis - distance of heel to heel (cm)|Gait Analysis - time of stance (sec)|Gait Analysis - time of swing (sec)|Gait Analysis - time of single support (sec)|Gait Analysis - time of double support (sec)|Body's Centre of Pressure length (mm)|Body's Centre of Pressure Area Path (mm2)|Sustained Attention to Response Task - Time of reaction time|Phonemic Fluency Test|Paced Auditory Serial Addition Test|Trail Making Test|Wechsler Adult Intelligence Scale,False,
NCT04011579,Pilates Training in Multiple Sclerosis,Multiple Sclerosis Fitness Intervention Training With Pilates Exercises,COMPLETED,2022-03-15,2023-10-20,2023-10-20,2024-02-22,2019-07-08,INTERVENTIONAL,NA,126.0,ACTUAL,Fondazione Italiana Sclerosi Multipla,OTHER,,,Multiple Sclerosis|Physical Activity,Physical activity|Pilates|Fitness,Italy,Genoa,,1,MSFIT,OTHER,Change in Timed Up & Go (TUG),Change in Timed 25-Foot Walk (T25FW)|Change in Ambulation Index (AI)|Change in 2-Minutes Walking Test (2WT)|Change in Technology Acceptance Model (TAM)|Change in Client Satisfaction Questionnaire-8 (CSQ-8)|Change in Telehealth Satisfaction Scale (TeSS)|Adherence to the intervention based on sessions|Adherence to the intervention based on drop-out|Change in Twelve Item MS Walking Scale (MSWS-12)|Change in Visual Analogue Scale (VAS) (0-10) for balance performance|Change in Nine-Hole Peg Test (9HPT)|Change in Modified Fatigue Impact Scale (MFIS)|Change in Brief International Cognitive Assessment for MS (BICAMS)|Change in Patient Global Impression of Change (PGIC) with a 7-points scale|Change in Multiple Sclerosis Quality of Life-54 (MSQoL54)|Change in Psychological Well-Being Scales (PWB)|Change in International Physical Activity Questionnaire (IPAQ)|Change in Minnesota Leisure-Time Physical Activity Questionnaire|Correlation between genetic polymorphisms and response to protocol,False,
NCT02726373,Comparison of Intermittent vs. Continuous Walking in MS,"The Effect of Intermittent vs. Continuous Walking Training on Walking Endurance and Fatigue in People With Multiple Sclerosis: a Randomized, Crossover Trial.",COMPLETED,2013-01,2014-12,2014-12,2016-04-04,2016-04-01,INTERVENTIONAL,NA,12.0,ACTUAL,Hunter College of City University of New York,OTHER,,,"Multiple Sclerosis, Endurance",,,,,0,type of walking,OTHER,Pre to post change in 6 Minute walk test distance,Visual Analog Scale of fatigue,False,
NCT02301260,Speed of Processing Training to Improve Cognition in Multiple Sclerosis,Speed of Processing Training to Improve Cognition in Multiple Sclerosis: A Randomized Clinical Trial,COMPLETED,2014-04,2020-02,2020-02,2020-02-20,2014-11-25,INTERVENTIONAL,NA,100.0,ACTUAL,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,Processing Speed|Intervention|Multiple Sclerosis|Cognition,United States,West Orange,New Jersey,1,Speed of Processing Training (SPT)|Placebo Control,BEHAVIORAL|BEHAVIORAL,Change in scores on standardized tests of processing speed,"Change in scores on self-report of emotional functioning, measured via questionnaire|Change in scores on self-report of everyday functioning, measured via questionnaire|Change in scores on self-report of quality of life, measured via questionnaire",False,
NCT02522962,Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study,Innovative Physiotherapy and Coordination of Care for People With Multiple Sclerosis: a Randomised Controlled Trial and a Qualitative Study,UNKNOWN,2015-09,2016-09,2019-12,2019-05-13,2015-08-14,INTERVENTIONAL,NA,80.0,ACTUAL,Nordlandssykehuset HF,OTHER,Helse Nord|University of Tromso|University Hospital of North Norway|Hasselt University|University of Memphis,INDUSTRY|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,physical therapy|group-based|core stability|balance|movement quality|somatosensory stimulation|coordination,Norway,Bodø,,1,GroupCoreSIT|Standard care,BEHAVIORAL|BEHAVIORAL,Trunk Impairment Scale modified Norwegian Version|Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version|Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version|Measure a change in the outcome: Trunk Impairment Scale modified Norwegian Version|Mini-Balance Evaluation Systems Test|Measure a change in the outcome: Mini-Balance Evaluation Systems Test|Measure a change in the outcome:Mini-Balance Evaluation Systems Test|Measure a change in the outcome: Mini-Balance Evaluation Systems Test,10-Meter Walk Test|Measure a change in the outcome: 10 Meter Walk Test|Measure a change in the outcome:10 Meter Walk Test|Measure a change in the outcome: 10 Meter Walk Test|2-Minutes Walk Test|Measure a change in the outcome: 2-Minutes Walk Test|Measure a change in the outcome:2-MinutesWalk Test|Measure a change in the outcome:2-Minutes Walk Test|Rivermead Visual Gait Assessment|Measure a change in the outcome:Rivermead Visual Gait Assessment|Measure a change in the outcome:Rivermead Visual Gait Assessment|Measure a change in the outcome:Rivermead Visual Gait Assessment|MS Walking Scale-12|Measure a change in the outcome:MS Walking Scale-12|Measure a change in the outcome:MS Walking Scale-12|Measure a change in the outcome: MS Walking Scale-12|Multiple Sclerosis Impact Scale-29|Measure a change in the outcome:Multiple Sclerosis Impact Scale-29|Measure a change in the outcome:Multiple Sclerosis Impact Scale-29|Measure a change in the outcome:Multiple Sclerosis Impact Scale-29|The Patient Global Impression of Change|Measure a change in the outcome: Patient Global Impression of Change|Measure a change in the outcome: Patient Global Impression of Change|ActiGraph activity monitor.|Measure a change in the outcome:ActiGraph activity monitor.|Measure a change in the outcome:ActiGraph activity monitor|Measure a change in the outcome:ActiGraph activity monitor|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Health Questionnaire (EQ-5D-3L)|Measure a change in the outcome:Health Questionnaire (EQ-5D-3L)|Measure a change in the outcome:Health Questionnaire (EQ-5D-3L)|Measure a change in the outcome:Health Questionnaire (EQ-5D-3L),False,
NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS),COMPLETED,2018-06-20,2021-11-12,2021-11-12,2023-09-14,2017-12-12,INTERVENTIONAL,PHASE4,485.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Mavenclad®|Cladribine|Health-related Quality of Life,Austria,Linz,,92,Mavenclad®,DRUG,Change From Baseline in Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) Physical Health Composite Summary and Mental Health Composite Summary Scores at Month 24,Treatment Global Satisfaction Determined by Treatment Satisfaction Questionnaire Medication Version 1.4 (TSQM v1.4) Scale at Month 6,True,2023-09-14
NCT00910598,Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS),"A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS",UNKNOWN,2009-09,2012-06,2012-06,2010-02-10,2009-06-01,INTERVENTIONAL,PHASE4,60.0,ESTIMATED,Amphia Hospital,OTHER,Sanofi|TEVA Pharmachemie,INDUSTRY|UNKNOWN,Multiple Sclerosis,clinically isolated syndrome|relapsing remitting multiple sclerosis|glatiramer acetate|Optical Coherence Tomography,Netherlands,Breda,,2,glatiramer acetate,DRUG,Feasibility of OCT measurement in patient with CIS with or without optic neuritis or with early RRMS in the Dutch clinical setting,"Mean change in RNFL in both eyes determined by OCT at baseline, month 3, month 6, month 9, month 12|Other ophthalmological parameters",False,
NCT05210621,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY,ACTIVE_NOT_RECRUITING,2022-03-08,2026-02-24,2029-02-24,2024-05-17,2022-01-27,INTERVENTIONAL,PHASE3,72.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,Multiple Sclerosis,,France,Amiens,,15,Ocrelizumab,DRUG,Proportion of patients with upper limb disability progression|Proportion of patients with upper limb disability progression,,False,
NCT05611047,Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis,Multicentre Randomized Blinded Controlled Study of Specific Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis Using Mixed Evaluation and Ecological Validity,TERMINATED,2023-02-21,2025-02-19,2025-02-19,2025-07-01,2022-11-09,INTERVENTIONAL,NA,20.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Celgene,INDUSTRY,Multiple Sclerosis,Autoimmune Diseases of the Nervous System|Demyelinating Autoimmune Diseases|Demyelinating Diseases|Immune System Diseases|Nervous System Diseases|Pathologic Processes|cognitive impairment|ecological assessment|telerehabilitation,France,Bordeaux,,7,Clinical assessment|Classical cognitive evaluation of several domains:|Ecological evaluation|Patent reported outcomes (PRO's)|Telerehabilitation : active procedure|Telerehabilitation : comparator procedure,OTHER|OTHER|OTHER|BEHAVIORAL|OTHER|OTHER,Improvement of two of the four reaction time z scores over the 12 weeks of training in the ecological assessment of cognitive impairment (CI) using the Urban DailyCog®.,"Change in the neuropsychological tests raw scores between baseline (W0) and after rehabilitation (W12) between the two groups|Change in the neuropsychological tests raw scores between visit W12 and visit W24 between the two groups.|Change in information processing speed (IPS), composite z scores between W0-W12 and W12-W24|Change in attention and working memory (WM) domain neuropsychological tests composite z scores and raw scores between W0-W12 and W12-W24 in subgroups of patients affected for these domains|Change in the sum of the 4 reaction time differences over the 12 weeks of training in the ecological assessment of CI using the Urban DailyCog®.|Change in the patient-reported outcomes (PROs) (depression anxiety) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.|Change in the patient-reported outcomes (PROs) (daily cognitive functioning) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.|Change in the patient-reported outcomes (PROs) (fatigue) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.|Change in the patient-reported outcomes (PROs) (Health-Related Quality of Life) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.|Change in the PROs (depression anxiety) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.|Change in the PROs (daily cognitive) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.|Change in the PROs (fatigue) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.|Change in the PROs (Health-Related Quality of Life) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.",False,
NCT06444113,Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis,"A Phase IV, Prospective, Multicenter, Open-label, Mother-milk Study to Evaluate Ofatumumab Concentration in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis Receiving Ofatumumab",RECRUITING,2024-11-25,2026-05-18,2027-02-23,2025-08-05,2024-06-05,INTERVENTIONAL,PHASE4,20.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,"Lactating women,|multiple sclerosis (MS)|ofatumumab|milk concentration|breastfed infant",United States,San Francisco,California,17,Ofatunumab,DRUG,Concentration of ofatumumab in breast milk.,Evaluate other PK parameters of ofatumumab in breast milk and plasma of lactating women with RMS who have initiated or re-initiated ofatumumab treatment post-partum|Estimation of relative infant dose of ofatumumab|Safety data collected in lactating women receiving ofatumumab and their breastfed infants|Plasma Pharmacokinetics of OMB157(Cmax)|Plasma Pharmacokinetics of OMB157(AUC)|Plasma Pharmacokinetics of OMB157 (M/P Ratio),False,
NCT04036097,Prospective Stratification of Infectious Risks in Multiple Sclerosis,Prospective Stratification of Infectious Risks in Multiple Sclerosis (InRIMS-Study),COMPLETED,2019-04-10,2022-12-31,2023-12-31,2025-04-17,2019-07-29,OBSERVATIONAL,,298.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,"Swiss Multiple Sclerosis Society|Bangerter-Rhyner Stiftung|Center for Chronic Immunodeficiency (CCI) in Freiburg, Germany",UNKNOWN|UNKNOWN|UNKNOWN,Multiple Sclerosis,secondary immunodeficiencies|disease-modifying treatments (DMT)|immunosuppressive therapy|serious infection|respiratory tract infections (RTI)|urinary tract infections|infection diary|Swiss MS Cohort (SMSC)|SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation) studies,Switzerland,Basel,,1,MS-adapted AWIS questionnaire (MS-AWIS)|infection diary (MS-AWIS diary),OTHER|OTHER,AWIS RTI score|infection diary score,Comparison of infection scores between patients receiving Disease Modifying Therapies (DMTs) and those who do not receive DMTs,False,
NCT05304520,A Study for Tysabri Participant Preference,SISTER - Subcutaneous: Non-Interventional Study for Tysabri Patient Preference - Experience From Real World,COMPLETED,2021-10-12,2024-04-30,2024-04-30,2024-05-17,2022-03-31,OBSERVATIONAL,,318.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis (RRMS),,Germany,Augsburg,,40,Natalizumab,DRUG,Number of Participants by Their Preferred Method of Natalizumab Administration at Month 6|Number of Participants by Their Preferred Method of Natalizumab Administration at Month 12,Number of Participants Positive for Anti-Natalizumab-Antibody|Percentage of Participants Persistently Positive for Anti-Natalizumab-Antibody|Annual Relapse Rate|Time to Relapse|Number of Participants With Disability Improvement and Progression who Switch to Subcutaneous Natalizumab,False,
NCT02290990,"Efficacy Study of ""Imaginative Distention"", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS","A Randomized Controlled Trial on Integrated Imaginative Distention in MS Ans Insomnia: a Self Managed Tool to Cope With Fatigue, Stress and Insomnia",COMPLETED,2014-09,2015-10,2016-12,2017-04-04,2014-11-14,INTERVENTIONAL,NA,144.0,ACTUAL,Niguarda Hospital,OTHER,,,Multiple Sclerosis,,Italy,Milan,,1,"""Imaginative Distention"" technique",BEHAVIORAL,Fatigue,Quality of life|Stress|Insomnia|Physiological parameters and Neurological evaluation|Cognitive screening,False,
NCT04056897,Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis,"International Multicenter, Randomized, Double-blind, Double-masked, Placebo-controlled Study of the Efficacy and Safety of BCD-132 Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",COMPLETED,2019-06-07,2020-07-13,2022-01-12,2025-02-21,2019-08-14,INTERVENTIONAL,PHASE2,271.0,ACTUAL,Biocad,INDUSTRY,,,Multiple Sclerosis,,Russia,Nizhny Novgorod,,1,"BCD-132, 125 mg|Teriflunomide|Placebo|BCD-132, 500 mg",BIOLOGICAL|DRUG|DRUG|BIOLOGICAL,Number of T1 Gd+ Lesions (per scan),"CUA|Proportion of Patients Without Contrast-enhancing Lesions|Number of New or Enlarging T2-weighted Lesions|Number of Patients Without New or Enlarging T2-weighted Lesions|Changes in T2-weighted Lesion Volume|Changes in Hypointense T1-weighted Lesion Volume|Whole-brain Volume Change according MRI|Annual Average Frequency of Relapses|Time to First Relapse|Number of Relapse-free Patients|Number of Patients With Sustained Disability Progression|Expanded Disability Status Scale (EDSS)|Timed 25-Foot Walk|9-Hole Peg Test (9 HPT)|Symbol Digit Modalities Test (SDMT)|36-Item Short Form Survey (SF-36)|EQ-5D Questionnaire|MSQOL-54 Questionnaire|Number of Patients Who Developed AEs That, in the Investigator's Opinion, Are Related to Treatment|The Number of Patients Who Developed SAEs That, in the Investigator's Opinion, Are Related to Treatment|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The Number of Patients, in Each Group, Who Discontinued the Study Due to AEs/SAEs|Number of patients with binding and neutralizing antibodies|Beck Depression Inventory|C-SSRS",False,
NCT00219908,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis,Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b,TERMINATED,1999-07,,2006-06,2005-12-22,2005-09-22,INTERVENTIONAL,PHASE2,124.0,,Rennes University Hospital,OTHER,"Bayer|Wyeth is now a wholly owned subsidiary of Pfizer|Farmades, Italy",INDUSTRY|INDUSTRY|UNKNOWN,Relapsing-Remitting Multiple Sclerosis,Multiple sclerosis|Mitoxantrone|Methylprednisolone|Interferon beta1b|Relapse|MRI|EDSS,France,Caen,,23,Mitoxantrone,DRUG,Time to confirmed progression of at least one EDSS point during the 3 years of the study.,"- percentage of patients with confirmed progression of at least one point EDSS (confirmed at 3 and 6 months) during the 3 years of the study,|- annual rate of relapse;|- percentage of relapse-free patients during the study period,|- quality of life,|- percentage of patients without evidence of disease activity on serial MRIs at months 9, 24 and 36 (number of contrast-enhanced lesions on the annual MRIs, change in lesion burden).",False,
NCT04113135,The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis,The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis,WITHDRAWN,2020-01-01,2020-12-31,2020-12-31,2020-10-08,2019-10-02,INTERVENTIONAL,NA,0.0,ACTUAL,Winston Salem State University,OTHER,Appalachian State University,OTHER,Multiple Sclerosis,,United States,Winston-Salem,North Carolina,1,Yoga|Control,OTHER|OTHER,Mini BESTest (Change is being assessed)|9 hole peg test (Change is being assessed)|Timed 25 ft walk (Change is being assessed)|Markus Self-Efficacy Scale (Change is being assessed)|Quality of Life Scale (Change is being assessed)|Patient Determined Disease Steps (Change is being assessed)|Modified Fatigue Impact Scale (Change is being assessed)|Pittsburgh Sleep Quality Index (Change is being assessed)|Godin Leisure-Time Physical Activity Questionnaire (Change is being assessed)|Basic Demographics and Behavioral questionnaire (Change is being assessed)|Bladder control scale,,False,
NCT03586635,Automated EDSS Score Calculation by Smartphone Application,Automated EDSS Score Calculation Using a Smartphone Application in Multiple Sclerosis Patients,COMPLETED,2018-12-13,2020-12-21,2021-09-03,2022-03-18,2018-07-13,OBSERVATIONAL,,105.0,ACTUAL,Centre Hospitalier Universitaire de Nice,OTHER,,,MS CHRONIC PROGRESSIVE,,France,Nice,,1,neurological exam,OTHER,EDSS score apllication VS paper version,,False,
NCT05811689,Trabecular Bone Score in Multiple Sclerosis,Trabecular Bone Score (TBS) as an Innovative Parameter Evaluation for Bone Disease's in Multiple Sclerosis (MS) Patients and Impact of Osteoporosis on the Quality of Life of Patients With MS,COMPLETED,2021-02-14,2021-08-20,2023-02-15,2023-04-13,2023-04-13,OBSERVATIONAL,,300.0,ACTUAL,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Multiple Sclerosis|Endocrine System Diseases|Neurologic Disorder,,Italy,Messina,,1,sm tbs group,DIAGNOSTIC_TEST,DXA scanner (Horizon© DXA System),Bone Mineral Density,False,
NCT02518776,Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS,,UNKNOWN,2010-06,2016-07,,2015-08-10,2015-08-10,INTERVENTIONAL,NA,80.0,ESTIMATED,"University Hospital, Caen",OTHER,,,Multiple Sclerosis,,France,Caen,Basse-Normandie,1,Neuropsychological tests,BEHAVIORAL,anterograde episodic memory: 3 scores of emotional ESR|retrograde episodic memory: 9 scores TEMP emotional,,False,
NCT01752660,Exercise in Severely Disabled Patients With MS,Endurance Training in Severely Disabled Patients With MS - a Feasibility Study,COMPLETED,2012-10,2013-02,2013-07,2013-07-18,2012-12-19,INTERVENTIONAL,PHASE1,12.0,ACTUAL,University of Aarhus,OTHER,"The Danish MS Society|Danish MS Hospitals, Haslev and Ry|Aarhus University Hospital",UNKNOWN|OTHER|OTHER,Multiple Sclerosis,Exercise therapy|Aerobic training|Endurance training,Denmark,Ry,Jylland,1,Endurance training|Standard care,BEHAVIORAL|BEHAVIORAL,Exercise compliance|Drop out rate,Peak oxygen consumption|Box and Block test|Sit to stand test|Handgrip test|Wheel-chair test,False,
NCT00595920,Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis,"An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00",TERMINATED,2007-11,2008-12,2008-12,2016-03-15,2008-01-16,INTERVENTIONAL,PHASE2,116.0,ACTUAL,"Opexa Therapeutics, Inc.",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting|Clinically Isolated Syndrome",Tovaxin|Autologous|T-cell vaccine (TCV),United States,Cullman,Alabama,27,Tovaxin,BIOLOGICAL,Evaluate Changes in Number of Combined Unique Active Lesions on Brain Magnetic Resonance Imaging (MRI),Evaluate Changes in Rate and Severity of Multiple Sclerosis (MS) Progression|Evaluate Changes in Annualized Relapse Rate,True,2016-03-15
NCT05754593,"Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group","Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis, Compared to a Control Group",RECRUITING,2023-12-04,2025-12,2025-12,2025-02-20,2023-03-06,INTERVENTIONAL,NA,160.0,ESTIMATED,"University Hospital, Bordeaux",OTHER,,,Multiple Sclerosis,multiple sclerosis|ovarian reserve|fertility|auto-immunity,France,Bordeaux,,1,Anti-Mullerian hormone (AMH) level|Antral follicle count (AFC)|Clinical assessment,BIOLOGICAL|OTHER|OTHER,Measure of Anti-Mullerian hormone (AMH) level by blood sample to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.,Measure of Antral follicle count (AFC) by ultrasound imaging to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.,False,
NCT02471560,Tecfidera and the Gut Microbiota,"The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events.",COMPLETED,2015-11-06,2017-06-12,2017-06-12,2021-09-05,2015-06-15,INTERVENTIONAL,PHASE4,36.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Microbiota|DMF|Gastro intestinal|MS,Norway,Drammen,,7,dimethyl fumarate|injectable MS DMT,DRUG|DRUG,Comparison of the change in gut microbiota composition in participants pre vs. post initiation of DMF treatment.,Change in gut microbiota composition between DMF treated participants that do or do not develop GI AEs as measured by an increase in the Gastrointestinal Symptom Rating Scale (GSRS) score.|Changes in gut microbiota composition in participants treated with DMF compared to participants treated with an alternative injectable multiple sclerosis (MS) disease modifying therapies (DMT)|Baseline differences in the gut microbiota composition between DMF treated participants that do or do not develop GI AEs.|Changes in the gut microbiota composition of DMF treated participants after resolution of GI AEs vs. during GI AE occurrences.,False,
NCT01466114,Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition,"A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.",UNKNOWN,2011-10,2021-12,2022-04,2019-11-06,2011-11-07,INTERVENTIONAL,PHASE2,64.0,ESTIMATED,"University of California, Los Angeles",OTHER,,,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,multiple sclerosis|MS|relapsing remitting multiple sclerosis|RRMS|secondary progressive multiple sclerosis|SPMS|primary progressive multiple sclerosis|estrogen|estriol,United States,Los Angeles,California,4,estriol|Placebo|Norethindrone|Progestin Placebo,DRUG|OTHER|DRUG|OTHER,Change from baseline in cognitive function assessed by Paced Serial Addition Test (PASAT).,"Change from baseline in cognitive function as assessed by cognitive evoked potentials, measured in milliseconds.|Change from baseline in standard MS outcome measures.|Determine safety by assessing the number of subjects with adverse events with combination treatment as compared to placebo.|Change from baseline in cognitive function as assessed by a brief battery of cognitive tests.",False,
NCT02606604,Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS,Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking Performance and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study,COMPLETED,2015-11,2017-07,2017-07,2019-09-30,2015-11-17,INTERVENTIONAL,NA,15.0,ACTUAL,Stony Brook University,OTHER,,,Multiple Sclerosis,Functional Electrical Stimulation|Cycling,United States,Stony Brook,New York,1,RT 300: Lower Extremity Cycling,DEVICE,Gait Velocity: Timed Walking|Gait Velocity: Timed Walking|Gait Velocity: Timed Walking|Gait Velocity: Timed Walking,Self-reported Fatigue Using Modified Fatigue Impact Scale|Self-reported Fatigue Using Modified Fatigue Impact Scale|Self-reported Walking Using 12 Item Multiple Sclerosis Walking Scale|Self-reported Walking Using 12 Item Multiple Sclerosis Walking Scale|Overall Self-reported Quality of Life Using Multiple Sclerosis Quality of Life- 54|Overall Self-reported Quality of Life Using Multiple Sclerosis Quality of Life- 54,True,2019-09-30
NCT04601233,Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis,Testosterone TReatment for Erectile Dysfunction in Male Multiple Sclerosis Patients With Low Testosterone (TTRED-MS Study),NOT_YET_RECRUITING,2026-06,2026-12,2026-12,2025-08-29,2020-10-23,INTERVENTIONAL,PHASE4,20.0,ESTIMATED,Tulane University,OTHER,Louisiana State University Health Sciences Center in New Orleans|Antares Pharma Inc.,OTHER|INDUSTRY,Multiple Sclerosis|Erectile Dysfunction|Testosterone Deficiency,Multiple Sclerosis|Erectile Dysfunction|Testosterone Deficiency,United States,New Orleans,Louisiana,1,XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector,DRUG,Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Androgen Deficiency in the Aging Male (ADAM score).|Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Sexual Health in Men (SHIM score).|Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Male Sexual Health Questionnaire short form (MSHQ-SF).,"Measure the change in self-reported fatigue from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Modified Fatigue Impact Scale (MFIS).|Measure the change in self-reported depression from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Beck Depression Inventory (BDI).|Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Symbol Digit Modalities Test (SDMT).|Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ).|Measure the change in self-reported overall quality of life from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Multiple Sclerosis Quality of Life Scale (MSQOL-54).|Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the American Urological Association Symptom Score (AUASS).|Measure the change in self-reported urinary incontinence after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using International Consultation on Incontinence Questionnaire short form (ICIQ-SF).|Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Urogenital Distress Inventory short form (UDI-6).|Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Incontinence Impact Questionnaire short form (IIQ-7).|Measure the change in self-reported pain from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the McGill Pain Questionnaire (MPQ).|Measure the change in Multiple Sclerosis lesions, indirectly from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the serum levels of neurofilament-light chains (NF-L).",False,
NCT06071949,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,RECRUITING,2023-11-02,2024-09-30,2024-12-31,2024-01-31,2023-10-10,INTERVENTIONAL,PHASE3,558.0,ESTIMATED,Apurano Pharmaceuticals GmbH,INDUSTRY,,,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome With Pain|Phantom Pain|Traumatic Brain Injury",Adezunap|Pain Therapy|Pain|Pain Syndrome|Chronic Pain|Chronic Pain Syndrome|Central Nervous System|CNS|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome with Pain|Phantom Pain|Traumatic Brain Injury|THC|Tetrahydrocannabinol|Delta-9-Tetrahydrocannabinol|Cannabis|Cannabinoids,Germany,Munich,Bavaria,1,Adezunap|Placebo,DRUG|DRUG,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14 in comparison of study arm 1 (verum) and study arm 2 (placebo)|Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5 and 11 in comparison of study arm 1 (verum) and study arm 2 (placebo)|Responder analysis for endpoints 1) for treatment week 14|Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14|Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14|Change of Patient Global Impression of Change (PGIC) from start to week 14|Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14|Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14|Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14|Area under NRS-curve until treatment week 5, 11 and 14|Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14|Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11 and ≤14",False,
NCT02343159,Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.,"A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.",TERMINATED,2015-02-28,2016-04-15,2016-04-15,2017-05-16,2015-01-21,INTERVENTIONAL,PHASE4,84.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Homewood,Alabama,29,dimethyl fumarate|Medication Event Monitoring System (MEMS)|Adherence counseling,DRUG|DEVICE|BEHAVIORAL,Overall Adherence Rates at Month 12: Arm 3 vs. Arm 1,Overall Adherence Rates at Month 12: Arm 2 vs. Arm 1|Overall Adherence Rates at Month 6: Arm 3 vs. Arm 1|Overall Adherence Rates at Month 6: Arm 2 vs. Arm 1|Persistence Rates at Months 6 and 12|Compliance Rates at Month 6 and 12|Multiple Sclerosis Impact Scale (MSIS-29)|Work Productivity and Activity Impairment Questionnaire (WPAI: MS Version 2.0),True,2017-05-16
NCT05376579,Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy,Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy,ACTIVE_NOT_RECRUITING,2022-06-17,2026-06-30,2026-06-30,2025-01-14,2022-05-17,OBSERVATIONAL,,134.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Active Secondary Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis|aSPMS|NIS|Italy|Mayzent|siponimod,Italy,Ancona,AN,24,siponimod,OTHER,Proportion of patients with six-month CDP during 36 months of treatment,Annualized relapse rate (ARR)|Number of new/newly enlarging T2 [neT2] and Gd+T1 lesions|Expanded Disability Status Scale scores|Expanded Disability Status Scale trend|Proportion of patients with No Evidence of Disease Activity (NEDA)-3|UK Neurological Disability Scale (UKNDS)|Fatigue Scale for Motor and Cognitive Functions (FSMC)|Hospital Anxiety and Depression Scale (HADS)|Symbol Digit Modality test (SDMT)|Clinical Global Impression (CGI)|MS activity status (MS-AS) - number of relapse|MS activity status (MS-AS) - Number of patients with presence of symptoms|T25-foot-walk|9-Hole peg test|EQ-5D: EuroQol five-dimensional|TSQM-9: Treatment Satisfaction Questionnaire for Medication|Exposure adjusted proportion of patients with adverse event (AE) or serious adverse event (SAE) per 100 subject-years|Discontinuation rates due to AE or other reasons|Proportion of patient who required FDO when starting siponimod and the reason why,False,
NCT05380362,Prospective Randomized Endovascular Therapy in Multiple Sclerosis,Prospective Randomized Endovascular Therapy in Multiple Sclerosis,COMPLETED,2010-06,2013-04,2013-04,2025-08-22,2022-05-18,INTERVENTIONAL,NA,30.0,ACTUAL,University at Buffalo,OTHER,Volcano Corporation,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis,United States,Buffalo,New York,1,Venous Angioplasty|Sham Angioplasty,OTHER|OTHER,Percentage of Patients With Immediate and Short-term SAE,,True,2025-08-22
NCT06629155,Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests,Disentangling Cognitive Functioning and Visual Scanning Deficits in Cognitive Test Results in Multiple Sclerosis (MS),NOT_YET_RECRUITING,2025-03-01,2027-02-01,2027-02-01,2024-11-06,2024-10-08,OBSERVATIONAL,,50.0,ESTIMATED,Universitair Ziekenhuis Brussel,OTHER,,,Multiple Sclerosis|Internuclear Ophthalmoplegia,Cognitive impairment|Multiple Sclerosis|Internuclear Ophthalmoplegia|SDMT,,,,0,Infrared oculography,DIAGNOSTIC_TEST,Correlation between eye movement parameters and SDMT.,Number of patients with eye movement abnormalities assessed by infrared oculography|Correlation between eye movement parameters and cognitive test scores.,False,
NCT03896217,Simvastatin in Secondary Progressive Multiple Sclerosis,"A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage",COMPLETED,2019-05-16,2022-09-13,2023-06-15,2025-07-01,2019-03-29,INTERVENTIONAL,PHASE2,40.0,ACTUAL,"University College, London",OTHER,National Multiple Sclerosis Society,OTHER,Secondary Progressive Multiple Sclerosis,Multiple sclerosis,United Kingdom,London,,1,Simvastatin,DRUG,"Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus|AOSLO Measurements of Blood Flow","MRI: ASL in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus|AOSLO Blood Flow Dynamics|MRI: Brain Atrophy|MRI: Diffusion Tensor Imaging (DTI)|MRI: Neurite Density and Orientation Dispersion Imaging|MRI: MTV|OCT-A: Retinal Nerve Fibre Layer|OCT-A: Vessel Density|Clinical Outcome: EDSS|Clinical Outcomes: MSFC: 25 Foot Timed Walk|Clinical Outcomes: MSFC: 9 Hole Peg Test|Clinical Outcomes: SDMT|Clinical Outcomes: Frontal Executive Functioning: FAB|Patient-Reported Outcomes: MSIS-29v2 Questionnaires.|Patient-Reported Outcomes: MSWT-12V2 Questionnaires.|Health Economic Outcomes: EQ5D5L",True,2025-07-01
NCT05123924,Respiratory Functions in Pediatric-Onset Multiple Sclerosis,Respiratory Functions and Fatigue in Patients With Pediatric-Onset Multiple Sclerosis: A Comparative Cross-sectional Study,UNKNOWN,2021-10-29,2022-06,2022-07,2021-11-17,2021-11-17,OBSERVATIONAL,,46.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,,,Pediatric-onset Multiple Sclerosis,Pediatric-onset multiple sclerosis|Physiotherapy|Respiratory capacity|Fatigue,Turkey (Türkiye),Istanbul,Bakırköy,1,"Evaluation of respiratory capacity, respiratory muscle strength and fatigue",OTHER,Evaluation of FEV1/FVC ratio,Evaluation of Forced Vital Capacity (FVC)|Evaluation of Forced Expiratory Volume in 1 second (FEV1)|Evaluation of Peak Expiratory Flow (PEF)|Evaluation of Respiratory Muscle Strength|Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale,False,
NCT04079088,Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS),"A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis",WITHDRAWN,2021-06-30,2024-09-18,2024-09-18,2023-06-01,2019-09-06,INTERVENTIONAL,PHASE2,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Multiple Sclerosis,,,,,0,Placebo|BIIB061|Interferon-beta1|Glatiramer acetate,DRUG|DRUG|BIOLOGICAL|DRUG,Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Disability Response Score (ODRS) at Week 48,"Change from Baseline in Normalized Magnetization Transfer Ratio (nMTR) at Week 48|Change from Baseline in Diffusion Tensor Imaging Radial Diffusivity (DTI-RD) at Week 48|Change from Baseline in Normalized T1 (nT1) Intensity at Week 48|Change from Baseline in T1 Hypointense Volume at Week 48|Percentage of Participants with 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND|Percentage of Participants with 12-week Confirmed Worsening in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND|ODRS Accounting Only for 12-week Confirmed Events of Worsening and Improvement on Respective Components over the First 48 Weeks of Treatment|ODRS using 20% Threshold for T25FW over the First 48 Weeks of Treatment|ODRS using 20% Threshold for T25FW, 9HPTD, and 9HPT-ND over the First 48 Weeks of Treatment",False,
NCT05345288,Effect of Computerized Cognitive Training in Persons With MS,Effect of Computerized Cognitive Training in Persons With MS,COMPLETED,2022-06-28,2022-10-21,2022-10-21,2023-09-29,2022-04-25,INTERVENTIONAL,NA,53.0,ACTUAL,University of Nebraska,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Omaha,Nebraska,1,BrainHQ cognitive training|BrainHQ control games,DEVICE|DEVICE,Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery,,False,
NCT04548297,Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis,Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis,COMPLETED,2020-10-05,2022-05-13,2022-05-13,2022-08-05,2020-09-14,OBSERVATIONAL,,44.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|sensation|fatigue|physical activity,Turkey (Türkiye),Ankara,,1,Assessment,OTHER,Light touch-pressure sensation|Vibration sensation|position sensation of knee joint|Knee proprioception,Fatigue Severity|attention|Physical Activity|Body Awareness,False,
NCT06843382,Teriflunomide and Fatigability in MS,The Effect of Teriflunomide on Fatigability in Individuals with Multiple Sclerosis: a Multicenter Real-World Study,NOT_YET_RECRUITING,2025-03-01,2027-01-01,2027-01-01,2025-02-25,2025-02-25,OBSERVATIONAL,,100.0,ESTIMATED,TC Erciyes University,OTHER,Karadeniz Technical University|Bursa Yüksek İhtisas Education and Research Hospital|Sakarya University,OTHER|OTHER_GOV|OTHER,Multiple Sclerosis,Multiple Sclerosis|Teriflunomide|Fatigability|Real-world study,Turkey (Türkiye),Kayseri,,1,,,Walking Fatigability Index|Cognitive Fatigability Index,Walking Performance|Radiological Outcomes|Walking Endurance|Processing Speed and Attention|Hand Coordination and Dexterity|Fatigue Severity|Treatment Satisfaction|Anxiety and Depression,False,
NCT05285904,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS),ACTIVE_NOT_RECRUITING,2022-05-12,2026-06-30,2026-06-30,2025-08-11,2022-03-18,OBSERVATIONAL,,107.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,NIS|Multiple sclerosis|MS|KOSMOS|Ofatumumab|Kesimpta,Switzerland,Baden,Canton of Aargau,13,Ofatumumab,OTHER,Proportion of patients with no evidence of disease activity (NEDA-3),Proportion of patients demonstrating NEDA-3|Proportion of patients demonstrating no evidence of disease activity in individual components of NEDA-3|Proportion of patients with previous DMT medication|Proportion of patients with clinical and MRI parameters|Proportion of Ofatumumab doses not completed|Proportion of participants with a cumulative treatment interruption of more than six months|Adherence to Ofatumumab|Proportion of patients permanently discontinuing Ofatumumab|Interdependency of adherence and clinical outcome in terms of NEDA-3|Treatment effect of Ofatumumab on the impact of multiple sclerosis as measured by MSIS-29|Treatment satisfaction with Ofatumumab as measured by TSQM-9,False,
NCT06663111,Rituximab and Ocrelizumab in Serum With Multiple Sclerosis,Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS),RECRUITING,2021-03-15,2025-12,2027-12-31,2024-10-29,2024-10-29,OBSERVATIONAL,,60.0,ESTIMATED,Haukeland University Hospital,OTHER,University of Bergen,OTHER,Relapsing Remitting Multiple Sclerosis,,Norway,Bergen,Vestland,1,Blood samples for PK|Blood samples for PK,OTHER|OTHER,Serum drug concentration measured using liquid chromatography tandem mass spectrometry (LC-MS/MS),,False,
NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,Immunological Mechanisms of Immune Ablation and Autologous Hematopoietic Stem Cell Transplantation in Secondary Progressive Multiple Sclerosis,COMPLETED,2002-05-01,2011-05-04,2011-05-04,2017-07-02,2006-06-21,INTERVENTIONAL,PHASE2,34.0,ESTIMATED,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Demyelination|Inflammation|Immunosuppression|Autoimmunity|Bone Marrow|Multiple Sclerosis,United States,Chicago,Illinois,2,Stem Cell Transplanataion,PROCEDURE,,,False,
NCT03408093,Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b,Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b,COMPLETED,2009-02-03,2010-03-30,2010-03-30,2018-06-21,2018-01-23,OBSERVATIONAL,,120.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Interferon beta-1b (INFb-1b)|Multiple Sclerosis (MS)|Relapsing-remitting MS (RRMS)|Secondary progressive MS (SPMS)|Clinically isolated syndrome (CIS),,,,0,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Self-reported adherence to INFb-1b in the previous four weeks assessed by Morisky-Green (MG) test,Demographic data|Number of patients with MS diagnosis|Age at first episode and at diagnosis|Time since last relapse|Assessment of general health status using data from a questionnaire or from their clinical history collected by the investigator team|Expanded Disability Status Scale (EDSS) to assess the degree of disability caused by MS|Number of patients with adverse events during the last month|Clinical setting characteristics like existence of MS unit|Time on INFb-1b therapy,False,
NCT03138421,Central Pain Study for ABX-1431,"A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain",COMPLETED,2017-08-01,2018-07-23,2018-07-24,2019-01-25,2017-05-03,INTERVENTIONAL,PHASE1,9.0,ACTUAL,Abide Therapeutics,INDUSTRY,,,Neuromyelitis Optica Spectrum Disorder|Transverse Myelitis|Multiple Sclerosis|Longitudinally Extensive Transverse Myelitis,,United Kingdom,Liverpool,,2,ABX-1431 HCl|Placebo,DRUG|DRUG,Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale,"Short Form Brief Pain Inventory (SF-BPI) Scores|Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)|Patient Global Impression of Change (PGIC) score|Proportion of patients achieving and maintaining >30%, >50%, reduction in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis|Actigraphically estimated parameters of sleep (WASO, TST, sleep efficiency, average overnight activity counts) and general activity measured by percentage of sedentary time, and moderate to high intensity activity|Sleep interference (NRS-11) A NRS-11 scale recording sleep interference due to transverse myelitis pain / central pain in the previous week (in which 0 = no interference and 10 = greatest possible interference)|ABX-11431 and metabolite M55 plasma PK|2-AG hydrolysis in PBMC",False,
NCT05357833,Novel Imaging Markers in SPMS,Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis,COMPLETED,2022-06-01,2023-09-01,2023-09-01,2023-09-26,2022-05-03,INTERVENTIONAL,EARLY_PHASE1,11.0,ACTUAL,University of Utah,OTHER,,,"Secondary Progressive Multiple Sclerosis|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis",Perilesional microglia|Ferumoxytol|USPIO|Utrasmall superparamagnetic iron oxide nanoparticles|Infiltrating macrophages|Activated microglia|USPIO enhancement,United States,Salt Lake City,Utah,1,Ferumoxytol infusion|Gadoteridol|MRI Brain and Cervical Spine,DRUG|DRUG|DIAGNOSTIC_TEST,Signal change on T1-weighted and 3D UTE MRI brain (and upper cervical cord) before and 96 hours (±24 hours) after ferumoxytol administration,Incidence of treatment-emergent adverse events (safety and tolerability),False,
NCT01805336,Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality,Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality,COMPLETED,2013-03-28,2020-07-09,2020-07-09,2021-03-01,2013-03-06,INTERVENTIONAL,NA,60.0,ACTUAL,"University Hospital, Caen",OTHER,,,Relapsing-Remitting Multiple Sclerosis,Relapsing-Remitting MS|cognitive impairment|virtual reality,France,Caen,Basse-Normandie,2,"Assessment of attentional functions by traditional tests|Assessment of attentional functions by virtual reality tests|Assessment of executive functions by traditional tests|Assessment of executive functions by virtual reality test|Evaluation of cognitive complaint, fatigue, anxiety and depression",OTHER|OTHER|OTHER|OTHER|OTHER,Scores for traditional tests|Scores for virtual reality tests|Correlation between traditional and virtual reality tests|Z-scores for traditional and virtual reality tests,"Score for cognitive complaint questionnaire|Scores for fatigue, anxiety and depression questionnaires",False,
NCT00203099,Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine,"A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)",COMPLETED,2004-12,2006-08,2008-06,2012-05-14,2005-09-20,INTERVENTIONAL,PHASE2,18.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapse Remitting Multiple Sclerosis,,,,,0,"Glatiramer Acetate, N-Acetylcysteine",DRUG,Change in the sum of T1 Gd-enhancing lesions as reflected by MRI,MRI parameters,False,
NCT03893344,STAT4 in Multiple Sclerosis by PCR and Flow Cytometry,Detection of STAT4 in Multiple Sclerotic Patients by Polymerase Chain Reaction and Flow Cytometry,COMPLETED,2019-09-20,2020-05-20,2020-05-22,2020-06-09,2019-03-28,OBSERVATIONAL,,104.0,ACTUAL,Assiut University,OTHER,,,Multiple Sclerosis,,Egypt,Asyut,,1,detection of STAT4 gene,DIAGNOSTIC_TEST,To determine the level of STAT4 expression in different cases of multiple sclerosis,compare the sensitivity and specificity of STAT4 levels using both PCR and flow cytometry.,False,
NCT01572207,Promoting Physical Activity Behavior in Persons With Multiple Sclerosis,Using Targeted Print-material to Promote Physical Activity Behavior in Adults With Multiple Sclerosis,COMPLETED,2011-07,2012-07,2012-07,2022-01-05,2012-04-06,INTERVENTIONAL,NA,30.0,ACTUAL,Case Western Reserve University,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,Multiple Sclerosis|Exercise|Physical activity|Quality of life,United States,Cleveland,Ohio,1,Immediate exercise|Delayed exercise,BEHAVIORAL|BEHAVIORAL,Changes From Baseline in Physical Activity Behavior,Changes From Baseline in Physical Fitness|Changes From Baseline in Quality of Life,True,2015-01-26
NCT04635709,Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis,Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis,COMPLETED,2019-02-15,2020-04-01,2020-04-01,2020-11-19,2020-11-19,INTERVENTIONAL,PHASE1,50.0,ACTUAL,Taibah University,OTHER,,,Bladder Dysfunction on Patients With Multiple Sclerosis,,Saudi Arabia,Madinah,,1,biofeedback training and interferential therapy,DEVICE,Detruser pressure between and within groups|Maximum flow rate between and within groups,,False,
NCT01896700,Methylphenidate to Improve Balance and Walking in MS,Methylphenidate to Improve Balance and Walking in MS,COMPLETED,2013-07,2016-04,2016-04,2018-04-05,2013-07-11,INTERVENTIONAL,PHASE2|PHASE3,24.0,ACTUAL,Oregon Health and Science University,OTHER,Portland VA Medical Center,FED,Multiple Sclerosis,Multiple sclerosis|postural balance|walking,United States,Portland,Oregon,1,Methylphenidate|Placebo,DRUG|DRUG,Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks,Change From Baseline in Automatic Postural Response (APR) Latency at 6 Weeks|Change From Baseline in Timed 25 Foot Walk (T25FW) at 6 Weeks|Change From Baseline in Pittsburgh Sleep Quality Assessment Questionnaire Score at 6 Weeks|Change From Baseline in Modified Fatigue Index Scale Score at 6 Weeks|Change From Baseline in Vestibular-Ocular Reflex (VOR) Gain at 6 Weeks|Change From Baseline in Vestibular Ocular Reflex (VOR) Asymmetry (Percentage Asymmetric) at 6 Weeks|Change From Baseline in Vestibular Ocular Reflex (VOR) Phase (in Degrees) at 6 Weeks,True,2018-04-05
NCT05627271,The 'Wearing Off' Effect of DMT,Understanding the 'Wearing Off' Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians,COMPLETED,2023-01-10,2023-04-20,2023-04-20,2023-06-01,2022-11-25,OBSERVATIONAL,,39.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|ocrelizumab|Ocrevus|natalizumab|Tysabri|ofatumumab|Kesimpta|NIS,Switzerland,Basel,,1,ocrelizumab|natalizumab|ofatumumab,OTHER|OTHER|OTHER,Number of participants with key symptoms associated with the wearing off effect,Severity of wearing off effect symptoms|Detailed language used to describe the experience of wearing off effect|Number of participants switching from one therapy to another due to wearing off effect|Number of participants who changed the dosing/infusion schedules due to wearing off effect|Dissimilarities of clinician' and patients' views of wearing off effect,False,
NCT05500963,Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS,Reducing Fatigue in People With Multiple Sclerosis by Treatment With Transcutaneous Electrical Nerve Stimulation,RECRUITING,2023-04-25,2027-05-31,2028-11-30,2024-12-09,2022-08-15,INTERVENTIONAL,NA,60.0,ESTIMATED,"University of Colorado, Boulder",OTHER,,,Multiple Sclerosis,,United States,Boulder,Colorado,1,Transcutaneous electrical nerve stimulation,DEVICE,Fatigue|Walking limitations|Walking endurance|Mobility,Quality of life questionnaire|Muscle strength,False,
NCT03148938,Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients,""" Digitalization of Neurofunctional Tests Via a Mobile Application, Digital Assessment Multiple Sclerosis (DAMS), for Multiple Sclerosis Patients""",COMPLETED,2017-10-02,2018-07-30,2018-08-29,2018-09-14,2017-05-11,INTERVENTIONAL,NA,222.0,ACTUAL,Ad scientiam,OTHER,,,Multiple Sclerosis,DAM|multiple sclerosis|MSFC|application|mobile,France,Dijon,,10,Digital Assessment on mobile,OTHER,Diagnostic performance of DAMS 3 test measured with digital assessment versus MSFC measured with traditional tests.,Diagnostic performance of DAMS 4 tests measured with digital assessment versus MSFC (with vision test) measured with traditional tests|Diagnostic performance of DAMS 3 tests measured with digital assessment versus MSFC revised measured with traditional tests|Diagnostic performance of DAMS 4 test measured with digital assessment versus MSFC revised with vision test measured with traditional tests|Correlation between DAMS 3 tests measured with digital assessment and MSFC measured with traditional tests|Correlation between DAMS 3 tests measured with digital assessment and MSFC revised measured with traditional tests|Correlation between DAMS 4 tests measured with digital assessment and MSFC with vision test measured with traditional tests|Correlation between DAMS 3 tests measured with digital assessment and MSFC revised with vision test measured with traditional tests|Compare scores of digital assessment versus scores of traditional tests|Compare scores of digital assessment at day 0 versus 15 days later|Safety of Mobile assessment with the collect of all the adverse events,False,
NCT01442233,Plasma Exchanges in Multiple Sclerosis (MS) Relapses,Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment,COMPLETED,2012-03-08,2017-09-21,2017-09-21,2018-01-16,2011-09-28,INTERVENTIONAL,PHASE3,38.0,ACTUAL,"University Hospital, Bordeaux",OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Acute Relapsing",multiple sclerosis|plasma exchange,France,Bordeaux,,6,plasma exchange|sham exchanges procedure,PROCEDURE|PROCEDURE,4 graded-scale of improvement based on objective scales and functional assessment after 1 month,4 graded-scale of improvement based on objective scales and functional assessment|change in functional evaluation by visual analogic scales (VAS)|change in functional scores (kurtzke FS)|change of EDSS scores,False,
NCT03653273,Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP),Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years,RECRUITING,2019-01-24,2026-07,2028-01,2023-10-24,2018-08-31,INTERVENTIONAL,PHASE3,250.0,ESTIMATED,Rennes University Hospital,OTHER,,,Multiple Sclerosis,multiple sclerosis|secondary progressive|disease modifying treatment|medico economic impact|treatment withdrawal,France,Angers,,27,DMT withdrawal|DMT continuation,OTHER|DRUG,Disability progression measured by EDSS,Time of Disability progression|Disability progression measured by composite score|Disability progression measured by SDMT|Percentage of patients with Relapse|Annualized relapse rate|Time of Relapses|Percentage of patients with brain lesion|Percentage of patients with gadolinium enhancing lesion|Change in brain volume|Percentage of patients with no evidence of disease activity|Percentage of patients who resume DMT in the treatment withdrawal group|Quality of life measured by SEP-59 score|Quality of life measured by EQ-5D score|Medico economic impact,False,
NCT03863379,Sarcopenic Obesity in Neurodisabilities,Sarcopenic Obesity in Neurodisabled People,COMPLETED,2019-05-02,2021-06-15,2022-05-15,2023-01-27,2019-03-05,OBSERVATIONAL,,150.0,ACTUAL,"Dionyssiotis, Yannis, M.D.",INDIV,University of Athens|University of Patras,OTHER|OTHER,Sarcopenic Obesity|Spinal Cord Injuries|Stroke|Multiple Sclerosis|Traumatic Brain Injury,Sarcopenia|sarcopenic obesity|stroke|sci|TBI|MS,Greece,Nea Liosia,Athens,1,whole body DXA,DIAGNOSTIC_TEST,Fat and lean mass in neurodisabled|Frequency of sarcopenic obesity,Body mass index correlation with fat mass and visceral fat,False,
NCT04057222,Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis,"Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis, a Manometric Study",COMPLETED,2019-07-26,2019-09-06,2019-09-06,2019-11-29,2019-08-15,OBSERVATIONAL,,30.0,ACTUAL,Gérard Amarenco,OTHER,,,Multiple Sclerosis|Anorectal Disorders|Bladder Dysfunction,Rectal sensory function|Multiple sclerosis|anorectal disorders|Fecal incontinence|constipation|bladder sensation,France,Paris,,1,No intervention,OTHER,Variation of volume of rectal constant sensation to need to defecate,Variation of amplitude modulation of the RAIR between strong desire to void and just after|Variation of duration modulation of the RAIR between strong desire to void and just after|Variation of external anal sphincter resting pressure between strong desire to void and just after,False,
NCT07131553,Evaluation of the Wheelchair School (Drivkraft) a Clinical Study,Utvärdering av Rullstolsskolan Drivkraft en Klinisk Studie av Ett beprövat Koncept,NOT_YET_RECRUITING,2025-10-01,2027-02-01,2027-12,2025-08-20,2025-08-20,INTERVENTIONAL,NA,80.0,ESTIMATED,Karolinska Institutet,OTHER,"Aleris Rehab Station, Stockholm",UNKNOWN,Neurological Disorders|Wheelchair Mobility|Rehabilitation,wheelchair skills|spinal cord injury|multiple sclerosis|wheelchair user,Sweden,Solna,,1,"Wheelchair school|Comparison group, conventional rehabilitation",OTHER|OTHER,Drivkraft manouevering test,Wheelchair outcome measure (WhOM)|Wheelchair Skills Test (WST)|Spinal Cord Injury Falls Concern Scale (SCI-FCS),False,
NCT00414453,Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis,Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS),TERMINATED,2007-01,2011-08,2011-08,2015-07-17,2006-12-21,INTERVENTIONAL,PHASE4,19.0,ACTUAL,University of Rochester,OTHER,Endo Pharmaceuticals,INDUSTRY,Neuropathic Pain|Chronic Pain|Multiple Sclerosis,Neuropathic pain|Chronic pain|Multiple sclerosis|Central neuropathic pain|Peripheral neuropathic pain|Opioid analgesic|Lidocaine,United States,Rochester,New York,1,Lidocaine patch 5%|Extended-release oxycodone|Placebo extended-release oxycodone pills|Placebo lidocaine patches,DRUG|DRUG|DRUG|DRUG,Mean Daily Diary Pain Ratings During Final Week of Each Treatment Period,"Tolerability (e.g., Number of Adverse Effects, Number of Drop-outs)|Safety (i.e., Number of Serious Adverse Events)|Brief Pain Inventory Interference Items|Daily Diary Sleep Interference Ratings|Beck Depression Inventory|Short-form Health Survey 36 (SF-36)|Short-Form McGill Pain Questionnaire|Patient Global Impression of Change Scale|Kurtzke Expanded Disability Status Scale",True,2015-07-17
NCT00112034,"AVONEX® Combination Trial - ""ACT""","A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.",COMPLETED,2003-06,2006-06,2007-05,2008-05-09,2005-05-30,INTERVENTIONAL,PHASE4,350.0,,Biogen,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Relapsing-Remitting|AVONEX|Combination|Methotrexate|IV Methylprednisolone|IVMP|ACT|MTX,United States,Cleveland,Ohio,1,Methotrexate|IV methylprednisolone,DRUG|DRUG,Brain MRI lesion activity measured by the combined number of T2-hyperintense lesions at Month 12 that are new or enlarged since Baseline|effectiveness of AVONEX® and IVMP plus MTX in trying to reduce lesion activity on brain MRI,"Gadolinium enhancing lesion number on brain MRI, relapse rate, MS Functional Composite change, whole brain atrophy progression",False,
NCT03232073,"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis","Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2017-07-05,2024-01-16,2024-01-16,2025-06-22,2017-07-27,INTERVENTIONAL,PHASE3,877.0,ACTUAL,Actelion,INDUSTRY,,,Multiple Sclerosis,,United States,Carlsbad,California,148,Ponesimod,DRUG,"Annualized Confirmed Relapse Rate (ARR)|Time From Core Study Randomization to First Confirmed Relapse|Time to First 12-week Confirmed Disability Accumulation (CDA)|Time to First 24-week Confirmed Disability Accumulation (CDA)|Percentage of Participants With Absence of Relapses|Change From Baseline in Expanded Disability Status Scale (EDSS)|Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study|Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study|Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)|Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI|Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI|Cumulative Number of New or Enlarging T2 Lesions Measured by MRI|Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)|Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)|Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities|Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate|Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF|Change in Heart Rate (HR) From Baseline up to End of Study Treatment|Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment|Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values|Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)|Number of Participants With AE Leading to Premature Discontinuation of Study Treatment|Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC|Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline|Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOT|Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)|Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)|Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline|Change in DL[CO] (% Predicted) From Baseline to EOT|Change in DL[CO] (% Predicted) From Baseline to EOS",,True,2025-02-21
NCT03608605,Advanced MRI Sequences in Multiple Sclerosis and Its Mimics,Role of Advanced MRI Sequences in Differentiating MS and Its Mimics,UNKNOWN,2018-09-01,2020-04-01,2020-07-01,2018-08-01,2018-08-01,OBSERVATIONAL,,70.0,ESTIMATED,Assiut University,OTHER,,,Multiple Sclerosis,,,,,0,MRI,DEVICE,role of advanced MRI sequences in establishing the diagnosis of multiple sclerosis(MS),follow up of MS patients after one year of treatment,False,
NCT03961204,Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS),Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS),COMPLETED,2019-08-15,2021-02-27,2021-05-13,2023-10-31,2019-05-23,INTERVENTIONAL,PHASE4,662.0,ACTUAL,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Multiple Sclerosis (MS),Multiple Sclerosis|Cladribine|High Disease Activity,United States,Atlanta,Georgia,99,Data Collection,OTHER,Percentage of Participants Using Wheelchair or Being Bedridden Assessed by Expanded Disability Status Scale (EDSS) Score 7.0 or Higher,"Percentage of Participants With Expanded Disability Status Scale (EDSS) Score 6.0 or Higher|Clinical and Demographic Characteristic: Age, Disease Duration|Number of Participants in Each Category of Clinical and Demographic Characteristics|Clinical Characteristic: Expanded Disability Status Scale (EDSS) Score|Clinical Characteristic: Number of Relapses|Number of Total T1-weighted (T1-W) Lesions|Number of Total T2-weighted (T2-W) Lesions|T1-weighted (T1-W) Lesion Volume|T2-weighted (T2-W) Lesion Volume|Total Brain Volume",True,2022-05-05
NCT00981643,Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy,"The Effects of Meditation on Pain, Fatigue and Physical Functioning in Patients With Multiple Sclerosis and Peripheral Neuropathy",COMPLETED,2009-02,2009-11,2010-12,2017-03-03,2009-09-22,INTERVENTIONAL,NA,40.0,ACTUAL,The Cleveland Clinic,OTHER,,,Multiple Sclerosis|Peripheral Neuropathy,Meditation|Multiple Sclerosis|Peripheral Neuropathy,United States,Cleveland,Ohio,1,Meditation instruction and practice,BEHAVIORAL,"Does meditation have a beneficial effect on pain, fatigue and physical functioning in patients with multiple sclerosis and peripheral neuropathy",Does meditation lead to improvements in the neurological evaluation with regards to weakness and sensory changes with meditation.,False,
NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",COMPLETED,2013-08,2015-12,2016-03,2017-05-03,2013-05-29,INTERVENTIONAL,PHASE2,419.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,United States,Cullman,Alabama,72,BIIB033|Placebo|Avonex,DRUG|OTHER|DRUG,Proportion of Participants Confirmed as Improvement Responders for Primary Multicomponent Endpoint,Proportion of Participants Confirmed as Worsening Responders for Primary Multicomponent Endpoint|Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) and Discontinuations Due to AEs|Pharmacokinetics: BIIB033 Plasma Concentrations up to Week 84,True,2017-05-03
NCT00239655,A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED),"A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI",TERMINATED,2004-08,2005-12,2006-01,2016-08-01,2005-10-17,INTERVENTIONAL,PHASE2,120.0,ACTUAL,Merck Sharp & Dohme LLC,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,,,,,0,MK0812,DRUG,Accrual rate of new GD-enhancing lesions as assessed by MRI,Volume and cumulative number of new persistent Gd-enhancing lesions,False,
NCT06008249,Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS),"A Multi-arm, Adaptive, Group-sequential Trial NETwork to Evaluate Drug Efficacy in Patients With Amyotrophic Lateral Sclerosis (ALS)",RECRUITING,2021-08-09,2026-06,2026-06,2025-06-11,2023-08-23,INTERVENTIONAL,PHASE3,171.0,ESTIMATED,Stichting TRICALS Foundation,OTHER,Fight MND|Research Foundation Flanders|MNDA|Thierry Latran Foundation|Ulla-Carin Lindquist Foundation|Luzon Foundation|Alan Davidson Foundation|My name'5 Doddie Foundation|Stichting ALS Nederland,UNKNOWN|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Amyotrophic Lateral Sclerosis,,Australia,Adelaide,,13,Lithium Carbonate 400 MG,DRUG,"Overall survival, defined as time to death from any cause or respiratory insufficiency (DRI; defined as tracheostomy or the use of non-invasive ventilation for ≥22 h per day for ≥10 consecutive days)","Composite endpoint evaluating daily functioning and survival based on the joint model framework of survival and longitudinal ALSFRS-R total scores|Daily functioning, defined as mean change from baseline in ALSFRS-R total score.|Respiratory function, defined as mean change from baseline in SVC (%predicted of normal according to the GLI-2012 reference standard)|Quality of life, defined as change from baseline on the EQ-5D Visual Analogue Scale (single-item scale)|Quality of life, defined as change from baseline on the EQ-5D|Neuropsychological status, defined as change from baseline on the ECAS|Neuropsychological status, defined as change from baseline on the ALS-FTD-Q.|Clinical disease stage, defined as mean time spent in each stage of the King's and ALS Milano-Torino staging systems.|Change from baseline in laboratory parameters: Urinary P75ECD (ectodomain of neurotrophin receptor p75), Neurofilament light and heavy chain, Plasma creatinine|Tolerability defined as time-to-discontinuation of assigned treatment since randomization|Safety based on the safety assessments including neurological examinations, clinical laboratory evaluations, vital signs and frequency of adverse events (AEs) or serious adverse events (SAEs).",False,
NCT00882999,A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),"Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2009-04,2011-02,2012-06,2018-11-15,2009-04-17,INTERVENTIONAL,PHASE2,245.0,ACTUAL,Eli Lilly and Company,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis,Relapsing|Remitting|Multiple Sclerosis|Multiple|Sclerosis|MS|LY2127399,United States,Phoenix,Arizona,63,LY2127399|Placebo,DRUG|DRUG,"Total Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan Averaged During Weeks 12, 16, 20, and 24","Change From Baseline in Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan|Total Number of New Gd-Enhancing T1-Weighted MRI Lesions Per Scan|Total Number of New or Newly Enlarging T2-Weighted MRI Lesions|Total Volume of T2-Weighted MRI Lesions|Expanded Disability Status Scale (EDSS)|Time to First Relapse|Percentage of Relapse-Free Participants|Annualized Relapse Rate (ARR) at Week 24 and Week 48|Multiple Sclerosis Functional Composite Scale (MSFC)|Visual Analog Scale (VAS) of Wellbeing|16-Item Quick Inventory for Depressive Symptomatology Self Report (QIDS-SR16)|Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Component Scores|Pharmacokinetics (PK): Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss)|Percentage of Participants With Anti-LY2127399 Antibodies [Anti-Drug Antibodies (ADA)]|Pharmacodynamics: Change From Baseline in Peripheral Blood B Cell Subsets (Absolute Cell Counts)",True,2018-11-15
NCT00676156,A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis,A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis,COMPLETED,2005-12,2008-02,2008-11,2012-11-06,2008-05-12,INTERVENTIONAL,PHASE1,40.0,ACTUAL,Oregon Health and Science University,OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis,multiple sclerosis|lipoic acid|LA|pharmacokinetics|immunological effects,United States,Portland,Oregon,1,oral lipoic acid (LA)|lipoic acid (LA) with fish oil and LA without fish oil|R lipoic acid,DRUG|DRUG|DRUG,To determine the pharmacokinetics of orally administered LA 1200 mg. This will assess the variability in bioavailability of LA and the feasibility of conducting a more focused PK assessment in future studies with LA.,To study salivary LA concentrations corresponding to the serum levels.,False,
NCT04655222,Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program,Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program,COMPLETED,2021-04-30,2021-10-15,2021-10-15,2023-04-18,2020-12-07,OBSERVATIONAL,,470.0,ACTUAL,Biogen,INDUSTRY,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",,Germany,Göttingen,,1,Interferon Beta Therapy,DRUG,Percentage of Participants With Live Births Without Congenital Anomalies|Percentage of Participants With Live Births With Congenital Anomalies|Percentage of Participants With Ectopic Pregnancies|Percentage of Participants With Spontaneous Abortions|Percentage of Participants With Elective Abortions|Percentage of Participants With Preterm Births|Percentage of Participants With Stillbirths,"Average Weight of the Children|Average Length of the Children|Average Head Circumference of the Children|Percentage of Abnormalities Diagnosed During Pediatric Check-ups|Percentage of Women Discontinued Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy|Time to Discontinuation of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy|Percentage of Women Starting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy|Time to Start Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy|Percentage of Women Restarting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy After Birth|Time to Restart Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Birth|Percentage of Women Starting Another Multiple Sclerosis (MS) Therapy During/After Pregnancy|Time to Start Another MS Therapy During/After Pregnancy in Relation to Birth|Percentage of Women Using Other Therapies During Pregnancy|Percentage of Multiple Sclerosis Relapses in Women with Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Before, During and After Pregnancy|Change From Baseline Expanded Disability Status Scale (EDSS) During and After Pregnancy to Expanded Disability Status Scale (EDSS) Before Pregnancy|Number of Women Breastfeeding Under Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy|Duration of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Exposed Breastfeeding|Time to First Multiple Sclerosis (MS) Relapse After Introduction of the First Supplemental Feedings in Women With Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Lactation",False,
NCT06931522,Effects of Mat and Reformer Pilates in Multiple Sclerosis,"Effects of Mat and Reformer Pilates Training on Postural Adjustments, Balance, and Walking in Patients With Multiple Sclerosis",RECRUITING,2025-06-10,2025-08-01,2025-09-01,2025-06-13,2025-04-17,INTERVENTIONAL,NA,10.0,ESTIMATED,Gazi University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|balance|Pilates|gait,Turkey (Türkiye),Ankara,,1,Mat Pilates|Reformer Pilates,OTHER|OTHER,Anticipatory postural adjustments (APA)|Neuromuscular activation|Core stability|Postural stability|Gait kinematics,Balance Confidence|Mobility|Fatigue severity|Quality of life,False,
NCT04944251,Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis,Exercise in Persons With Multiple Sclerosis,COMPLETED,2019-04-01,2019-12-01,2020-01-19,2021-06-29,2021-06-29,INTERVENTIONAL,NA,43.0,ACTUAL,Ege University,OTHER,,,Multiple Sclerosis|Exercise Intervention|Neuro-Degenerative Disease,multiple sclerosis|exercise|nerve growth factor|neurotrophin 3|cognition|quality of life,Turkey (Türkiye),Izmir,Bornova,1,Regular Exercise,BEHAVIORAL,Aerobic capacity assessment after exercise intervention|Strength assessment after exercise intervention|plasma neurotrophin values (pg/ml),,False,
NCT01141751,An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy,"A Phase IV, Observational, Open-label, Multi-center Comparison Study of the Newly Developed and Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument With the Health-related QoL (MSQOL-54) Questionnaire in Subjects With Relapsing Forms of Multiple Sclerosis (RMS*) on Rebif® Therapy",COMPLETED,2005-09,2011-06,2011-06,2014-07-14,2010-06-10,OBSERVATIONAL,,334.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting","Multiple sclerosis|Expanded Disability Status Scale|Multiple Sclerosis, Relapsing-Remitting; Rebif|Beta-1, interferon",,,,0,,,Usefulness of MusiQoL in clinical practice in comparison with the established disease specific QoL instrument MSQOL-54,Evaluation of QoL instrument scores between baseline and month 24 and the relationship to measures of disease activity (relapses) and disease severity (EDSS)|Relationship between Folstein mini-mental status examination (MMSE) and Frontal assessment battery (FAB) scores and QoL instrument scores|Relationship between depression score and QoL instrument scores|Number of relapses|Expanded Disability Status Score (EDSS) scores|Number of progressions on the EDSS score,False,
NCT03332654,Stress Urinary Incontinence in Women With Multiple Sclerosis,Prevalence and Risk Factors of Stress Urinary Incontinence in Women With Multiple Sclerosis,COMPLETED,2015-02-01,2016-01-31,2016-03-31,2017-11-06,2017-11-06,OBSERVATIONAL,,363.0,ACTUAL,Lille Catholic University,OTHER,,,"Urinary Incontinence, Stress|Multiple Sclerosis","Urinary Incontinence, Stress|Multiple Sclerosis|Lower Urinary Tract Symptoms",,,,0,Determine prevalence of stress urinary incontinence,OTHER,Stress urinary incontinence,,False,
NCT03375541,Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy,Benefits of Drug Risk Aversion Calculation to Multiple Sclerosis Drug Choice and Patient Self-efficacy,WITHDRAWN,2018-03,2019-03,2019-03,2018-05-24,2017-12-18,INTERVENTIONAL,NA,0.0,ACTUAL,Duke University,OTHER,,,Multiple Sclerosis,,,,,0,Risk Aversion Calculator,OTHER,Change from Baseline Disease Self-efficacy,Time to new medication start|Medication adherence|Change from Baseline Disease Self-efficacy at 6 months|Change from Baseline Disease Self-efficacy at 12 months,False,
NCT05172466,"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab","Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab",WITHDRAWN,2022-10-31,2022-11-11,2022-11-11,2022-11-25,2021-12-29,INTERVENTIONAL,NA,0.0,ACTUAL,Icahn School of Medicine at Mount Sinai,OTHER,,,Relapsing-remitting Multiple Sclerosis (RRMS),"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis|Mobile Applications|Natalizumab|Smartphone",United States,New York,New York,1,BeCare application,DEVICE,The Expanded Disability Status Scale (EDSS)|The Expanded Disability Status Scale (EDSS)|The Expanded Disability Status Scale (EDSS)|The Expanded Disability Status Scale (EDSS),"Application Based - Timed Up and Go (TUG)|Application Based - Timed Up and Go (TUG)|Application Based - Timed Up and Go (TUG)|Application Based - Timed Up and Go (TUG)|Application Based - Tap Task|Application Based - Tap Task|Application Based - Tap Task|Application Based - Tap Task|Application Based - Path Test|Application Based - Path Test|Application Based - Path Test|Application Based - Path Test|Application Based - Transcription test|Application Based - Transcription test|Application Based - Transcription test|Application Based - Transcription test|Application Based - Timed 25-foot walk|Application Based - Timed 25-foot walk|Application Based - Timed 25-foot walk|Application Based - Timed 25-foot walk|Application Based - Coded Message Cognitive Test|Application Based - Coded Message Cognitive Test|Application Based - Coded Message Cognitive Test|Application Based - Coded Message Cognitive Test|Application Based - Six-minute walk test|Application Based - Six-minute walk test|Application Based - Six-minute walk test|Application Based - Six-minute walk test|Application Based - Contrast sensitivity test|Application Based - Contrast sensitivity test|Application Based - Contrast sensitivity test|Application Based - Contrast sensitivity test|Application Based - Arm elevation test|Application Based - Arm elevation test|Application Based - Arm elevation test|Application Based - Arm elevation test|Application Based - Memory test|Application Based - Memory test|Application Based - Memory test|Application Based - Memory test|Application Based - Vibration test|Application Based - Vibration test|Application Based - Vibration test|Application Based - Vibration test|Application Based - The Stroop Color and Word Test (SCWT)|Application Based - The Stroop Color and Word Test (SCWT)|Application Based - The Stroop Color and Word Test (SCWT)|Application Based - The Stroop Color and Word Test (SCWT)|Application Based - Self-reported mood, quality of life, function, and participation.|Application Based - Self-reported mood, quality of life, function, and participation.|Application Based - Self-reported mood, quality of life, function, and participation.|Application Based - Self-reported mood, quality of life, function, and participation.|Clinician Based - The Nine-Hole Peg Test (9HPT)|Clinician Based - The Nine-Hole Peg Test (9HPT)|Clinician Based - The Nine-Hole Peg Test (9HPT)|Clinician Based - The Nine-Hole Peg Test (9HPT)|Clinician Based - Red Saturation test|Clinician Based - Red Saturation test|Clinician Based - Red Saturation test|Clinician Based - Red Saturation test|Clinician Global Impression of Change (CGIC)|Clinician Global Impression of Change (CGIC)|Clinician Global Impression of Change (CGIC)|Clinician Global Impression of Change (CGIC)|Patient Global Impression of Change (PGIC )|Patient Global Impression of Change (PGIC )|Patient Global Impression of Change (PGIC )|Patient Global Impression of Change (PGIC )|Patient-reported - Multiple Sclerosis - Quality of Life (MS-QOL)|Patient-reported - Multiple Sclerosis - Quality of Life (MS-QOL)|Patient-reported - Multiple Sclerosis - Quality of Life (MS-QOL)|Patient-reported - Multiple Sclerosis - Quality of Life (MS-QOL)|Patient Health Questionnaire 9-item (PHQ-9)|Patient Health Questionnaire 9-item (PHQ-9)|Patient Health Questionnaire 9-item (PHQ-9)|Patient Health Questionnaire 9-item (PHQ-9)",False,
NCT02970370,"Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt",,COMPLETED,2015-12,2016-07,,2016-11-22,2016-11-22,OBSERVATIONAL,,2752.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,,,,,0,no intervention,OTHER,portrayed phenotypes and para-clinical data of Egyptian Multiple Sclerosis Patients,,False,
NCT01049451,Pulse ACTH vs. MP for MS,"Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)",COMPLETED,2009-11,2013-06,2013-07,2017-04-19,2010-01-14,INTERVENTIONAL,PHASE1,23.0,ACTUAL,University of Southern California,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|ACTH|Steroids,United States,Los Angeles,California,1,ACTH|Methylprednisolone,DRUG|DRUG,Annualized Relapse Rate,"Multiple Sclerosis Functional Composite (MSFC), Expanded Disability Status Scale score (EDSS) and Multiple Sclerosis Quality of Life (MSQOL), peripheral blood lymphocytes measure for regulatory immune activities.",False,
NCT01703429,Complementary and Alternative Care in Multiple Sclerosis,Complementary and Alternative Medicine (CAM) in Multiple Sclerosis. A Prospective Observational Study of a CAM-using Cohort,RECRUITING,2012-06,2030-06,2030-06,2020-02-11,2012-10-10,OBSERVATIONAL,,1000.0,ESTIMATED,Bastyr University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|MS|Complementary and Alternative|CAM,United States,Kenmore,Washington,1,,,"""CAM Therapies"" survey",Modified Expanded Disability Severity Score (EDSS),False,
NCT03272503,A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS),"A Phase II Randomized, Placebo-Controlled, Double Blinded, Multi-Centre Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis",UNKNOWN,2017-10-27,2020-12-31,2020-12-31,2020-05-28,2017-09-05,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,University of Calgary,OTHER,ALS Canada|Brain Canada,UNKNOWN|OTHER,ALS|Amyotrophic Lateral Sclerosis,Pimozide,Canada,Calgary,Alberta,9,Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Placebo Oral Tablet,DRUG|DRUG,Change in ALS Functional Rating Scale-Revised (ALSFRS-R),Change in Slow Vital Capacity (SVC)|Change in Decremental responses on repetitive nerve stimulation (DRRNS)|Change in Motor Power - the MRC (Medical Research Council) Sum Score|Change in Common Terminology Criteria for Adverse Events (CTCAE) will be entered for each visit for adverse effect profile analysis|Change in ALS-Specific QOL -Revised|Change in Cramp Frequency and Severity,False,
NCT02833142,"Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes","A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers",COMPLETED,2016-07,2016-11,2016-11,2016-12-08,2016-07-14,INTERVENTIONAL,PHASE1,28.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis|Acute Optic Neuritis,Healthy Volunteer|opicinumab,United States,Madison,Wisconsin,1,BIIB033 (opicinumab),DRUG,PK parameter of BIIB033: Area under the concentration-time curve from time 0 to infinity (AUC0-inf)|PK parameter of BIIB033: Area under the concentration-time curve from time 0 to Day 85 (AUC84d)|PK parameter of BIIB033: Maximum observed concentration (Cmax),Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of participants with clinically significant laboratory parameters|Number of participants with clinically significant vital sign abnormalities|Number of participants with clinically significant electrocardiograms (ECGs) abnormalities|Number of participants with clinically significant physical examination abnormalities|PK parameter of BIIB033: Time to reach maximum observed concentration (Tmax)|PK parameter of BIIB033: Terminal elimination half-life (t1/2)|PK parameter of BIIB033: Volume of distribution at steady state (Vss)|PK parameter of BIIB033: Clearance (CL)|Number of participants with presence of anti-BIIB033 antibodies,False,
NCT01457924,Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",COMPLETED,2011-11-01,2013-08-23,2015-06-10,2018-06-06,2011-10-24,INTERVENTIONAL,PHASE2,232.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|Ofatumumab,United States,Cullman,Alabama,61,Ofatumumab 3mg|Ofatumumab 30mg|Ofatumumab 60mg|Placebo,DRUG|DRUG|DRUG|DRUG,Cumulative Number of New Gadolinium-enhancing (GdE) T1 Lesions at Week 12,Cumulative Number of New GdE T1 Lesions at Week 24|Change From Baseline in Brain Volume at Week 24 and Week 48|Cumulative Number of Persistent GdE Brain Lesions on T1-weighted MRI at Week 12|Cumulative Number of All (New Plus Persistent) GdE Brain Lesions on T1-weighted MRI at Week 12|Total Volume of New GdE Brain Lesions on T1-weighted MRI at Week 12|Total Volume of All (New and Persistent) GdE Brain Lesions on T1-weighted MRI at Week 12|Cumulative Number of New and Newly Enlarging GdE T2 Lesions at Week 12|Total Volume of New and/or Newly Enlarging T2 Lesions at Week 12|Cumulative Number of New T1 Hypointense Lesions at Week 24 and Week 48|Cumulative Volume of New T1 Hypointense Lesions at Week 24 and Week 48,True,2018-03-01
NCT07182903,Fatigue in MS: From Invisible to Measurable,Fatigue in MS: From Invisible to Measurable,NOT_YET_RECRUITING,2025-10-01,2025-12-31,2025-12-31,2025-09-19,2025-09-19,OBSERVATIONAL,,40.0,ESTIMATED,University Medical Center Groningen,OTHER,UHasselt,UNKNOWN,Multiple Sclerosis,multiple sclerosis|fatigue|cytotoxic CD4 T cells,,,,0,,,Correlation between percentage of cytotoxic CD4+ T cells and FSS score|Correlation between percentage of cytotoxic CD4+ T cells and MFIS score|Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping frequency decrease|Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping amplitude decrease,Changes in muscle activation during 6MWT|Changes in muscle activation during foot tapping task|Correlation changes in walking distance between the first and last minute of the 6MWT and CD4+ CTLs|Correlation percentage voluntary muscle activation and CD4+ CTLs,False,
NCT01698086,Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial),Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?,COMPLETED,2012-10,2018-08,2018-08,2019-01-29,2012-10-02,INTERVENTIONAL,NA,88.0,ESTIMATED,"University of Colorado, Denver",OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis|Balance|Fatigue|Eye Movement,Multiple Sclerosis|Balance|Fatigue|Eye movement,United States,Aurora,Colorado,1,Vestibular rehabilitation: balance and eye movement exercises,OTHER,Balance (Dynamic Posturography/Computerized Sensory Organization Test),Visual Stability (Dynamic Visual Acuity and Gaze Stabilization Test)|Perceived fatigue (Modified Fatigue Impact Scale),False,
NCT05286242,Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients,Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients,ACTIVE_NOT_RECRUITING,2021-02-10,2026-05-31,2026-06-30,2025-04-25,2022-03-18,OBSERVATIONAL,,400.0,ESTIMATED,Yale University,OTHER,National Institute of Allergy and Infectious Diseases (NIAID)|Robert Leet and Clara Guthrie Patterson Trust,NIH|UNKNOWN,Multiple Sclerosis|Autoimmune Blistering Disease|B-Cell Deficiency,,United States,New Haven,Connecticut,1,COVID19 vaccine,BIOLOGICAL,Change in coronavirus disease 19 (COVID19) antibody titers over time|Change in severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) specific T-cell activation over time,Skin biopsy analysis|Measurement of COVID19 antibodies in saliva|Immune analysis|Changes in patient reported outcomes: COVID history|Change in patient reported outcomes: patient reported disability steps|Change in patient reported outcomes: overall symptoms,False,
NCT00097188,A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis,"A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis",COMPLETED,2004-12,,2006-12,2014-03-04,2004-11-19,INTERVENTIONAL,PHASE2,104.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,Multiple Sclerosis,Relapsing remitting multiple sclerosis,United States,Phoenix,Arizona,31,rituximab,DRUG,"To investigate the efficacy of rituximab compared with placebo, as measured by MRI scans of the brain for the total number of lesions observed, and to evaluate the safety and tolerability of rituximab in subjects with RRMS.",To evaluate the efficacy of rituximab compared with placebo.,False,
NCT06351592,First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS),"First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations",RECRUITING,2024-08-28,2029-04-26,2029-04-26,2025-09-17,2024-04-08,INTERVENTIONAL,PHASE1,42.0,ESTIMATED,Regeneron Pharmaceuticals,INDUSTRY,,,Amyotrophic Lateral Sclerosis (ALS)|Mutation in the Superoxide Dismutase-1 (SOD1) Gene,Symptomatic|Known pathogenic mutation|Predicted pathogenic mutation,Australia,Concord,New South Wales,14,ALN-SOD|Diluent|Placebo (PB),DRUG|OTHER|DRUG,Incidence of treatment-emergent adverse event (TEAEs) in participants treated with ALN-SOD|Severity of TEAEs in participants treated with ALN-SOD,Concentration of neurofilament light chain (NfL) in plasma over time|Change in concentration of NfL in plasma over time|Concentration of SOD1 protein in cerebrospinal fluid (CSF) over time|Change in concentration of SOD1 protein in CSF over time|Concentration of NfL in CSF over time|Change in concentration of NfL in CSF over time|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over time|Concentration of ALN-SOD in plasma over time|Concentration of ALN-SOD in CSF over time|Incidence of anti-drug antibodies (ADAs) to ALN-SOD in serum over time|Titer of ADAs to ALN-SOD in serum over time,False,
NCT04028232,Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).,Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).,UNKNOWN,2019-07-10,2020-04-30,2020-12-31,2020-01-23,2019-07-22,OBSERVATIONAL,,30000.0,ESTIMATED,"University Hospital, Caen",OTHER,Ecole des Hautes Etudes en Santé Publique|Hospices Civils de Lyon,OTHER|OTHER,C10.114.375.500,Multiple Sclerosis|Epidemiology|Socio-Economic Status|Net Survival,France,Caen,Normandy,18,,,Excess mortality survival,European Deprivation Index (EDI) proxy of Socio-Economic Status|Distance to MS expert care center,False,
NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis","A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)",COMPLETED,2010-08,2012-08,2012-08,2014-02-10,2010-10-07,INTERVENTIONAL,PHASE4,1053.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,Relapsing Forms of Multiple Sclerosis|Disease Modifying Therapy|fingolimod|Patient Reported Outcomes,United States,Birmingham,Alabama,149,Fingolimod|Standard MS DMTs,DRUG|DRUG,Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6,"Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death|Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6|Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS)|Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4|Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4|Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4|Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2)|Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II)|Physician-reported Clinical Global Impression of Improvement (CGI-I)",True,2013-12-05
NCT06051019,Effect of Aerobic Training vs Balance Training on Fatigue Symptom in Multiple Sclerosis Patient (FATI-gate),Comparison Between the Effects on Fatigue of Aerobic Training Versus Balance Training in Patients With Multiple Sclerosis: a Randomised Crossover Trial.,COMPLETED,2016-02-17,2019-11-30,2019-12-30,2023-09-22,2023-09-22,INTERVENTIONAL,NA,39.0,ACTUAL,Istituto Auxologico Italiano,OTHER,,,Multiple Sclerosis,fatigue|balance|multiple sclerosis|aerobic training|balance training,,,,0,Aerobic training|Balance training,OTHER|OTHER,Modified Fatigue Impact Scale Italian version,Equiscale|Equitest® Sensory Organization Test|Gait speed,False,
NCT00841321,Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis,Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis,COMPLETED,2009-01,2010-11,2010-12,2014-06-06,2009-02-11,INTERVENTIONAL,PHASE2,120.0,ACTUAL,US Department of Veterans Affairs,FED,,,"Multiple Sclerosis|Cognitive Ability, General",Ginkgo biloba|Multiple Sclerosis|Cognition|Neuropsychological Tests|Neurobehavioral Manifestations|Quality of life|Randomized Controlled Trials|Placebos|Double-Blind Method,United States,Portland,Oregon,2,Ginkgo biloba|Placebo,DRUG|DRUG,"Primary Outcome is Performance on the Interference Condition of the Stroop, the Long Delay Free Recall Portion of the California Verbal Learning Test II, the 2 Second Paced Auditory Serial Addition Test and the Controlled Oral Word Association Test.",Secondary Outcome: Measures of Self-report as Well as Family Reports of Subject's Cognitive Deficits and Assessment of Social Integration.,True,2014-05-05
NCT04969848,Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device,"Uncontrolled, Single-center Study to Quantify Gait Disturbance in Patients With Multiple Sclerosis",COMPLETED,2021-08-18,2022-05-31,2022-05-31,2022-06-03,2021-07-21,OBSERVATIONAL,,44.0,ACTUAL,Nantes University Hospital,OTHER,,,Multiple Sclerosis,Wearable sensor|Gait,France,Nantes,Loire-Atlantique,1,Wearable sensor,OTHER,Correlation with disability,Correlation with neurological function|Correlation with gait speed|Correlation with lateralization|Correlation with disability location|Correlation with MS symptoms severity|Reliability of sensor measures|Developement of dedicated algorithm to improve signal processing from IMU.,False,
NCT00200655,Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis,Safety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled Study,COMPLETED,2004-12,,2007-11,2016-04-28,2005-09-20,INTERVENTIONAL,PHASE3,40.0,ACTUAL,Nantes University Hospital,OTHER,,,Relapsing-remitting Multiple Sclerosis,,France,Nantes,,1,Pravastatin|Placebo,DRUG|DRUG,Number of gadolinium positive lesions at month 6 in each group.,Cumulated number of gadolinium positive lesions in each group after 6 months of follow-up|Number of new T2 lesions,False,
NCT01326715,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,COMPLETED,2013-10-17,2019-09-18,2022-09-13,2022-09-16,2011-03-31,INTERVENTIONAL,PHASE1,17.0,ACTUAL,National Institute of Neurological Disorders and Stroke (NINDS),NIH,,,Multiple Sclerosis,Mangafodipir|Brain|MEMRI|Healthy Volunteer|Multiple Sclerosis,United States,Bethesda,Maryland,1,Mangafodipir (Teslascan),DRUG,The primary outcome measure is normalized T1-weighted signal intensity.,,False,
NCT07106255,Task-oriented Training Intervention for Multiple Sclerosis Patients.,Task-oriented Training Intervention for Multiple Sclerosis Patients,ENROLLING_BY_INVITATION,2024-09-01,2025-12-31,2025-12-31,2025-08-06,2025-08-06,INTERVENTIONAL,NA,58.0,ESTIMATED,Universidad de Granada,OTHER,,,Multiple Sclerosis,,Spain,Granada,Granada,1,Task-oriented training|Standar medical care and leaflet fatigue management,OTHER|OTHER,Occupational Performance,Fatigue,False,
NCT05340985,Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis,"Investigating the Effects of Hydroxyvitamin D3 Versus Vitamin D3 on Clinical, and Radiologic Progress and Th17/Tregs Balance in MS Patients: A Randomized, Clinical Trial- a Pilot Study",UNKNOWN,2022-07,2023-06,2023-12,2022-04-22,2022-04-22,INTERVENTIONAL,PHASE4,54.0,ESTIMATED,Tehran University of Medical Sciences,OTHER,Boston University,OTHER,"Multiple Sclerosis, Relapsing-Remitting|Adult ALL|Vitamin D3 Deficiency",,,,,0,25(OH)D3|vitamin D3,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Number of relapses|disability|Change in MRI parameters|changing in brain parameters of Diffusion tensor imaging (DTI)|changing in Cognition|CD4+ T cell response|Differential gene expression,needing hospitalization|changing in quality of life|effective in rapidly raising circulating levels of 25(OH)D3|changing in the circulating levels of interleukin 17 as a inflammatory marker|changing in the levels of interleukin 10 as anti- inflammatory marker|changing in the levels of Tumor Necrosis Factor alpha (TNF-a) as an inflammatory marker related the T-CD4 subsets,False,
NCT03313843,Study to Assess OCT: RNFL and GCL in MS Patients,"Prospective Cross Sectional Study To Assess The Clinical Utility of Optical Coherence Tomography to Measure Axonal Degeneration of the Optic Nerve, in a Cohort of 200 Subjects Meeting the Diagnostics Criteria of Multiple Sclerosis",COMPLETED,2018-02-09,2020-12-17,2021-04-30,2021-06-02,2017-10-18,OBSERVATIONAL,,73.0,ACTUAL,"Tampa Bay Uveitis Center, LLC",OTHER,,,Multiple Sclerosis,Optical Coherence Tomography,United States,New Port Richey,Florida,2,,,Retinal Nerve Fiber Layer measurement (RNFL: peri-papillary OCT),Ganglion Cell Layer measurement (GCL: Macular OCT),False,
NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis","A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.",COMPLETED,2009-03-30,2011-05-04,2011-05-04,2020-01-13,2009-04-10,INTERVENTIONAL,PHASE2,297.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis (MS)|Relapsing-Remitting|Demyelinating Autoimmune Diseases|Disseminated sclerosis|Encephalomyelitis disseminate|Inflammatory disease|Demyelination|Auto-inflammatory disease|Devic's disease|Balo concentric sclerosis|Schilder's diffuse sclerosis,United States,Cullman,Alabama,72,BAF312|Placebo,DRUG|DRUG,Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL),Number of Confirmed Relapses - Period 1|Proportion of Participants With Relapse-free Patients - Period 1 + 2|Proportion of Participants With Relapse-free Patients - Period 1 Only|Number of New [Gd]-Enhanced T1 Lesions Monthly - Period 1 +2 at Month 3|Number of New [Gd]-Enhanced T1 Lesions Monthly - Period 1 Only at 6 Months|Number of All New Gd-enhanced T1 Lesions - Period 1 +2 at Month 3|Number of All Gd-enhanced T1 Lesions - Period 1 Only at 6 Months|Number of Monthly New/Enlarging T2 Lesions - Period 1 +2 at 3 Months|Number of Monthly New/Enlarging T2 Lesions - Period 1 Only at 6 Months|Number of Patients Without Any New MRI Disease Activity - Period 1 +2|Number of Patients Without Any New MRI Disease Activity - Period 1 Only|Number of Monthly New Gd-enhanced T1 Lesions With High Baseline Disease Activity - Period 1 +2 at 3 Months|Number of Monthly New Gd-enhanced T1 Lesions With High Baseline Disease Activity - Period 1 Only at 6 Months|Number of CUAL - Period 1|Geometric Mean BAF312 Plasma Trough Concentrations,True,2020-01-13
NCT01040117,Sensori-motor Integration Training in Multiple Sclerosis,Effects of Sensori-motor Integration Balance Training on Balance Disturbances in Patients With Multiple Sclerosis,COMPLETED,2009-12,2011-10,2012-01,2012-03-15,2009-12-29,INTERVENTIONAL,EARLY_PHASE1,80.0,ACTUAL,Universita di Verona,OTHER,,,Relapsing-remitting Multiple Sclerosis,Equilibrium|Rehabilitation|Randomized Controlled Trial|Postural instability|Sensory-motor integration,Italy,Verona,Verona,2,Sensory-motor Integration Training|Conventional neurorehabilitation treatment,PROCEDURE|PROCEDURE,Clinical assessment procedures: - Berg Balance Scale (BBS) - Activities-specific Balance Confidence Scale (ABC) Instrumental assessment procedures: - Stabilometric assessment,Clinical evaluation - Walking evaluation - Multiple Sclerosis Quality Of Life-54 (MSQOL-54) - Fatigue Severity Scale (FSS) - Postural Transfers,False,
NCT01871818,A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients,A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis.,COMPLETED,2013-05,2017-04,2017-10,2018-10-23,2013-06-07,INTERVENTIONAL,NA,240.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Rehabilitation|Chronic evolutive disease|Physiotherapy|Resistance training|Endurance training,France,Garches,Hauts DE Seine,1,Combined program|Physiotherapy in private practice,BEHAVIORAL|BEHAVIORAL,6 Minute Walk Test,Functional tests|Aerobic capacity|Strength and fatigue of the knee flexors and extensors|Clinical assessment|Balance (Berg Balance scale) and postural control assessment|Quality of Life assessment,False,
NCT03187847,Rehabilitation in Multiple Sclerosis - Sometimes Too Much?,"Changes in Perceived Fatigue and Step Counts Before and After Rehabilitation. A Prospective, Single-center, Longitudinal Observational Study.",COMPLETED,2017-08-27,2018-03-30,2018-06-04,2018-06-12,2017-06-15,OBSERVATIONAL,,28.0,ACTUAL,Klinik Valens,OTHER,,,Multiple Sclerosis,Physical Activity|Fatigue|Rehabilitation,Switzerland,Valens,,1,Actigraph GT3X,DEVICE,Changes in Fatigue|Changes in Physical Activity/Step Counts (Actigraph GT3X),quality of life in association with changes in fatigue and physical activity|emotional status (depression) in association with changes in fatigue and physical activity,False,
NCT06179758,Remote MS Care in Antwerp,Remote MS Care in Antwerp,ACTIVE_NOT_RECRUITING,2024-05-23,2026-03,2026-03,2025-06-19,2023-12-22,INTERVENTIONAL,NA,100.0,ESTIMATED,"University Hospital, Antwerp",OTHER,Janssen-Cilag div. of Johnson&Johnson SE|icometrix|Ziekenhuis Netwerk Antwerpen (ZNA)|AZ Klina,INDUSTRY|INDUSTRY|OTHER|OTHER,Multiple Sclerosis,remote monitoring,Belgium,Edegem,Antwerpen,3,icompanion app,DEVICE,the acceptance of a digital remote monitoring solution for MS (icompanion) (adherence number)|the usability of a digital remote monitoring solution for MS (icompanion),"the correlation between MS patients' subjective health experience, disease control and disease acceptation (by using the Health Monitor) and adherence and usability|the impact of the use of the solution on the Health Monitor profile (reflecting patients' subjective health experience, disease control and disease acceptation) in a pre- versus post-intervention analysis|the impact of the use the solution on the MS patients' disease self-management, by use of the MSSM-R|the impact of the solution on the clinical visit workflow, by using visual analogue scales with custom questions about impact on workflow",False,
NCT00490789,Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM,A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis,UNKNOWN,2005-10,2009-09,2009-09,2008-04-30,2007-06-25,INTERVENTIONAL,PHASE2,14.0,ESTIMATED,Cardiff University,OTHER,University of Nottingham|St Georges Hospital Medical School|Royal Sussex County Hospital|The Tuberous Sclerosis Association|Wyeth is now a wholly owned subsidiary of Pfizer,OTHER|UNKNOWN|OTHER|OTHER|INDUSTRY,Tuberous Sclerosis|Lymphangioleiomyomatosis,tuberous sclerosis|lymphangioleiomyomatosis|sirolimus|angiomyolioma|rapamycin|mTOR,United Kingdom,Cardiff,Wales,3,sirolimus,DRUG,"longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0|toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events","respiratory function tests (FEV1, FVC, DLCO), cognitive function (memory, executive skills)",False,
NCT06894940,Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies,Rehabilitation of the Upper Limb in Progressive Multiple Sclerosis: a Clinical and MRI Study of Different Rehabilitative Protocols in Patients Treated with Anti B Monoclonal Antibodies,COMPLETED,2021-06-01,2024-11-30,2024-11-30,2025-03-25,2025-03-25,INTERVENTIONAL,PHASE2,82.0,ACTUAL,University of Pavia,OTHER,University of Genova|Consorzio per Valutazioni Biologiche e Farmacologiche|A.O.U. Città della Salute e della Scienza,OTHER|OTHER|OTHER,Multiple Sclerosis,,Italy,Pavia,Lombardy,1,Active Comparator #1|Placebo|Experimental,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,The Primary endpoint is the improvement in the distal motility of the upper limb evaluated with the Nine Hole Peg test.,"Patients will be evaluated at baseline, at the end of the treatment period and after 3 months with the the action research arm test (ARAT).",False,
NCT00146068,EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis,Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period,COMPLETED,2004-09,2007-12,2007-12,2008-03-05,2005-09-05,INTERVENTIONAL,PHASE4,30.0,,University of North Carolina,OTHER,,,Multiple Sclerosis,Clinically Isolated Syndrome,United States,Chapel Hill,North Carolina,1,Avonex/Zocor,DRUG,"The primary objective of this study is to determine whether combination therapy with IFNb-1a plus simvastatin, when compared to IFNb-1a plus placebo decreases or delays additional clinical or MRI activity.|We will use the following outcome measures:|Relapse rates, Time to first relapse,Number of new T2 lesions, Number of new Gd-enhancing lesions",,False,
NCT01013350,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies (PREMIERE),COMPLETED,2009-11-30,2018-10-25,2018-10-25,2019-11-15,2009-11-13,OBSERVATIONAL,,1161.0,ACTUAL,EMD Serono,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Cladribine|PREMIERE|Observational study,United States,Cambridge,Massachusetts,1,,,"Number of Participants With Serious Adverse Drug Reactions (SADRs)|Time to Resolution of Lymphopenia, Among Registry Participants With Persistent Lymphopenia|Number of Participants With Adverse Events (AEs) in the ""Blood and Lymphatic System Disorders"" System Organ Class (SOC) and in the ""Neoplasms Benign, Malignant, and Unspecified"" SOC",Number of Participants With Pregnancy Outcomes,True,2019-11-15
NCT01080040,To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients,Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina,COMPLETED,2008-08,2013-03,2013-03,2013-10-16,2010-03-03,OBSERVATIONAL,,150.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing Remitting","Multiple Sclerosis, Relapsing Remitting|Quality of life",Argentina,Rosario,,1,,,Assess the prevalence of spasticity in subjects with RRMS,Evaluation of the impact of spasticity on the quality of life of subjects with RRMS|Evaluation of the changes in spasticity after 24 months,False,
NCT03954717,Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program,Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program,COMPLETED,2019-05-14,2022-03-11,2022-03-11,2023-08-02,2019-05-17,OBSERVATIONAL,,111.0,ACTUAL,"Shepherd Center, Atlanta GA",OTHER,"Genzyme, a Sanofi Company|Can Do Multiple Sclerosis",INDUSTRY|UNKNOWN,Multiple Sclerosis,,United States,Atlanta,Georgia,1,Shepherd CAN DO Program,BEHAVIORAL,Change in self-efficacy for symptom management at 6 months|Change in self-efficacy for symptom management at 12 months|Change in self-efficacy for symptom management at 24 months|Change in self-efficacy for quality of life at 6 months|Change in self-efficacy for quality of life at 12 months|Change in self-efficacy for quality of life at 24 months,Change in caregiver perception of burden at 6 months|Change in caregiver perception of burden at 12 months|Change in caregiver perception of burden at 24 months,False,
NCT02614989,MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis,MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis,UNKNOWN,2016-01,2017-12,2018-12,2015-11-25,2015-11-25,INTERVENTIONAL,NA,15.0,ESTIMATED,Rambam Health Care Campus,OTHER,,,Multiple Sclerosis,Tremor|Thalamotomy,,,,0,MRI guided focused ultrasound thalamotomy,PROCEDURE,Device or procedure related adverse events reported,Tremor rating scale,False,
NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,"An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)",COMPLETED,2003-06,2008-01,2008-01,2014-05-08,2005-10-12,INTERVENTIONAL,PHASE2,63.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing multiple sclerosis|interferon beta 1b|Betaferon|Betaseron,United States,Los Angeles,California,17,"Interferon beta 1b (Betaseron, BAY86-5046)|Interferon beta 1b (Betaseron, BAY86-5046)|Interferon beta 1b (Betaseron, BAY86-5046)|Interferon beta 1b (Betaseron, BAY86-5046)",DRUG|DRUG|DRUG|DRUG,"Safety and Tolerability as Defined by the Number of Subjects With Flu-like Syndrome, Fever, Myalgia, Injection Site Reactions, Injection Site Reactions Pain, Asthenia, Headache, Liver Function Abnormalities, and Bone Marrow Function Abnormalities",Frequency (Number of Patients Per Group Defined by Cut Off Values and Per Treatment Arm) of Neutralizing Antibody (NAb) Titer to IFNB-1b,True,2009-07-03
NCT01024985,Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct,Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography.,UNKNOWN,2009-09,2010-12,2011-12,2010-06-28,2009-12-03,OBSERVATIONAL,,40.0,ESTIMATED,University of Sao Paulo,OTHER,,,Multiple Sclerosis|Neuromyelitis Optica,optic neuritis|longitudinally extensive transverse myelitis|retinal nerve fiber layer|macular thickness,Brazil,São Paulo,São Paulo,1,,,,,False,
NCT00942591,Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b,"Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.",COMPLETED,2005-05,2009-04,2009-05,2009-07-21,2009-07-21,INTERVENTIONAL,PHASE2,77.0,ACTUAL,"Insel Gruppe AG, University Hospital Bern",OTHER,PharmaPart|Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel,INDUSTRY|UNKNOWN,Multiple Sclerosis,multiple sclerosis|interferon beta|atorvastatin,Switzerland,Bern,,1,Interferon beta 1b|Atorvastatin,DRUG|DRUG,Proportion of patients with new T2 lesions on MRI.,Gd-enhancing lesion on T1-weighted images|Clinical disease progression|Time to first relapse|Cortical atrophy,False,
NCT02073474,An Observational Post-Marketing Safety Registry of Sativex®,An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex®,COMPLETED,2011-02,2015-01,2015-01,2022-12-20,2014-02-27,OBSERVATIONAL,,978.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Diabetes|Cancer|Neuropathic Pain,cannabinoids|Sativex|THC|delta-9-tetrahydrocannabinol|cannabidiol|CBD|Registry|Safety|MS,,,,0,Sativex®,DRUG,Incidence rates of adverse events.,Average daily number of sprays of Sativex® used.|Number of patients experiencing fall-related injuries requiring medical attention.|Number of patients experiencing a change in driving ability.|Number of patients experiencing suicidal thoughts or attempts.|Number of patients experiencing significant psychiatric or psychotic events other than suicidality.|Incidence of patient deaths.|Number of patients receiving worthwhile benefit from Sativex®.|Number of MS patients discontinuing anti-spasticity medications.|Number of MS patients discontinuing medications for MS symptoms other than anti-spasticity medications.,False,
NCT04121468,A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis,A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis,RECRUITING,2020-02-24,2027-03,2027-10,2025-09-23,2019-10-10,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,The Hospital for Sick Children,OTHER,Queen's University|Ontario Institute for Regenerative Medicine|Unity Health Toronto|Stem Cell Network|Multiple Sclerosis Society of Canada,OTHER|UNKNOWN|OTHER|OTHER|OTHER,Multiple Sclerosis (MS),remyelination|youth|white matter|neural precursor cells|clinical trial|metformin,Canada,Toronto,Ontario,1,Metformin|Placebo,DRUG|OTHER,"Number of patients with adverse events (safety and tolerability)|Number of patients who were approached to participate, declined participation and consented to participate (recruitment)|Proportion of patients who completed each visit within the trial (retention)|Proportion of patients who completed each of the outcome measures at the appropriate time points (adherence with outcome measures)|Number of patients enrolled in the study compared to the number of patients who were able to complete study measures (tolerability with outcome measures)",Optical Coherence Tomography (OCT) - Retinal Nerve Fiber Layer Thickness|Optical Coherence Tomography (OCT) - Ganglion Cell Inner Plexiform Layer Thickness|Optical Coherence Tomography (OCT) - Optic Nerve Head Volume|Visual Evoked Potentials (VEP) - p100,False,
NCT01978574,Intellectual Enrichment to Build Cognitive Reserve in MS,A Randomized Controlled Trial of Intellectual Enrichment to Build Cognitive Reserve in Multiple Sclerosis,COMPLETED,2013-06-01,2014-06-01,2014-06-01,2020-02-20,2013-11-07,INTERVENTIONAL,NA,9.0,ACTUAL,Kessler Foundation,OTHER,National Multiple Sclerosis Society,OTHER,Cognitive Impairment in Multiple Sclerosis,Cognitive reserve|intellectual enrichment,United States,West Orange,New Jersey,1,Intellectual Enrichment daily activities|Intellectual Enrichment documentary videos,BEHAVIORAL|BEHAVIORAL,"Change from Baseline in Hopkins Verbal Learning Test and Brief Visuospatial Memory Test, Total Learning and Delayed Recall",Change from Baseline in Beck Depression Inventory,False,
NCT03177655,Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis,Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis,COMPLETED,2012-03-01,2017-03-01,2017-03-01,2017-06-06,2017-06-06,INTERVENTIONAL,NA,20.0,ACTUAL,"University of California, San Diego",OTHER,,,Multiple Sclerosis (MS),,United States,San Diego,California,1,Guided Imagery|Journaling,OTHER|OTHER,Quality of Life (MS-QOL-54),Mood (BDI-II)|Fatigue (FSS),False,
NCT02335450,Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series,Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series,COMPLETED,2015-02-12,2015-11-12,2015-11-12,2021-06-02,2015-01-09,INTERVENTIONAL,NA,5.0,ACTUAL,Oakland University,OTHER,,,Multiple Sclerosis,exercise|motivational interviewing,United States,Rochester,Michigan,1,Motivational Interviewing|Wristband physical activity monitor,BEHAVIORAL|DEVICE,Total Steps Taken Over Course of the Study,Exercise Self-Efficacy Questionnaire|Multiple Sclerosis Self-Efficacy Scale|Multiple Sclerosis Impact Scale,True,2020-08-13
NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,"A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2015-10-27,2017-02-14,2021-09-21,2024-03-26,2015-09-10,INTERVENTIONAL,PHASE3,102.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,United States,Cullman,Alabama,22,23-PPV|13-PCV Booster|Influenza Vaccine|KLH|OCR|TT Vaccine,BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|BIOLOGICAL|DRUG|BIOLOGICAL,Percentage of Participants With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine,"Percentage of Participants With Positive Response to TT Vaccine Measured 4 Weeks After TT Vaccine|Percentage of Participants With Tetanus Antibody Titer >/=0.2 IU/mL or 2-Fold Increase in Tetanus Antibody Titers|Mean Levels of Anti-Tetanus Antibody|Mean Levels of Anti-KLH Antibody: Immunoglobulin (Ig) G|Mean Levels of Anti-KLH Antibody: Ig M|Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 23-PPV|Percentage of Participants With Positive Response Against >/=2 Pneumococcal Serotypes|Percentage of Participants With Positive Response Against >/=12 Pneumococcal Serotypes|Mean Levels of Anti-Pneumococcal Antibody|Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 13-PCV|Mean Level of Anti-Pneumococcal Antibody|Percentage of Participants With Seroprotection|Percentage of Participants With 2-Fold Increase in Strain-Specific HI Titers|Percentage of Participants With 4-Fold Increase in Strain-Specific HI Titers|Percentage of Participants With Seroconversion|Strain-Specific Geometric Mean Titer Levels|Ratio of Strain-Specific Geometric Mean Titer Levels Postvaccination to Prevaccination|Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions|MRI Parameters: Number of T2 Lesions|MRI Parameters: Categorical Number of T2 Lesions|MRI Parameters: Number of Gadolinium (Gd)-Enhancing T1 Lesions|MRI Parameters: Categorical Number of Gd-enhancing T1 Lesions|MRI Parameters: Normalized Brain Volume|MRI Parameters: Volume of T2 Lesions: White Matter Volume|MRI Parameters: Cortical Grey Matter Volume|MRI Parameters: T1 Unenhancing Lesion Volume|MRI Parameters: Total Number of Lesions|Cellular Immune Response Assessed by Flow Cytometry|Total Immunoglobulin|Percentage of Participants With Anti-Drug Antibody Formation|Percentage of Participants With Adverse Events (AEs), Serious AEs, or AEs Leading to Study Discontinuation",True,2018-06-06
NCT04288011,Validation of the BeCare Multiple Sclerosis Assessment App,Validation of the BeCare Multiple Sclerosis Assessment App,UNKNOWN,2021-02-26,2022-12-20,2023-02-20,2022-12-23,2020-02-27,OBSERVATIONAL,,30.0,ESTIMATED,BeCare Link LLC,INDUSTRY,Yale University,OTHER,Multiple Sclerosis,MS|mobile app|machine learning|EDSS|BeCare,United States,New Haven,Connecticut,1,,,Clinical EDSS score vs MLA EDSS score comparison|Clinical EDSS score vs MLA EDSS score comparison|Clinical EDSS score vs MLA EDSS score comparison,Disease Progression Measured by Change in EDSS score|Development of a novel application to measure change in MS,False,
NCT05937971,Plantar Sensitivity Training and Aerobic Exercise Training in Patients With Multiple Sclerosis (PlaSTAcET Study),"Examination of the Implications of Plantar Sensitivity Training and Aerobic Exercise Training on Balance, Functional Capacity, Gait and Proprioception in Patients With Multiple Sclerosis",RECRUITING,2023-09-01,2024-06-01,2024-08-01,2023-09-28,2023-07-10,INTERVENTIONAL,NA,30.0,ESTIMATED,Istanbul Arel University,OTHER,Istanbul University - Cerrahpasa,OTHER,Multiple Sclerosis,multiple sclerosis|plantar sensitivity|plantar sensitivity training|aerobic training|clinical trial|balance|gait|functional capacity|proprioception,Turkey (Türkiye),Istanbul,Zeytinburnu,1,plantar sensitivity training|aerobic exercise training,OTHER|OTHER,"Balance measurement (One-leg standing test(seconds))|Balance measurement (measurement of spatiotemporal parameters of balance (with baropodometry) -Bipedal 30 seconds oscillation amplitude (mm)|Balance measurement (measurement of spatiotemporal parameters of balance (with baropodometry)-Maximum oscillating amplitude (mm)|Balance measurement (measurement of spatiotemporal parameters of balance (with baropodometry)-Average oscillation rate (mm/s)|gait measurement (-timed 25-foot walk test)|gait measurement(spatiotemporal parameters of gait (with baropodometry) -stride length (mm))|gait measurement spatiotemporal parameters of gait (with baropodometry) -Bilateral maximum pressure (gr/cm2)|gait measurement spatiotemporal parameters of gait (with baropodometry) -Bilateral mean pressure (gr/cm2)|gait measurement (spatiotemporal parameters of gait (with baropodometry) -Right-left load distribution (%) (from five different points: 1st metatarsal head, 2nd-3rd metatarsal head, 4th-5th metatarsal head, heel medial, heel lateral)",functional capacity measurement|proprioception measurement (-Ankle position sensation)|proprioception measurement (-Sensation of ankle kinesthesia),False,
NCT05131971,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants","A Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3888130B in Healthy Participants Aged 18-55 Inclusive",COMPLETED,2021-11-01,2023-10-12,2023-10-12,2025-03-26,2021-11-23,INTERVENTIONAL,PHASE1,54.0,ACTUAL,GlaxoSmithKline,INDUSTRY,,,"Multiple Sclerosis|Colitis, Ulcerative",Anti-Drug Antibodies|Double-blind|GSK3888130B|Pharmacodynamics|Pharmacokinetics|Single Dose Escalation,United Kingdom,Cambridge,,1,GSK3888130B|Placebo,DRUG|DRUG,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Changes in Hematology Results|Number of Participants With Worst-case Cluster of Differentiation (CD) 4+ T Cell Counts Results by Maximum Grade Increase Post-Baseline Relative to Baseline|Number of Participants With Worst-case Creatinine Results by Maximum Grade Increase Post-Baseline Relative to Baseline|Number of Participants With Clinically Significant Changes in Clinical Chemistry Results|Number of Participants With Worst-case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline|Number of Participants With Clinically Significant Changes in Vital Sign Results|Number of Participants With Positive Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) and Varicella Zoster Virus (VZV) DNA|Number of Participants With Positive Epstein-Barr Virus (EBV) DNA|Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings,"Serum Concentrations of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|Serum Concentrations of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration|Serum Concentrations of GSK3888130B for Dose Levels 6 and 7 IV Administration|Area Under the Concentration-time Curve From Time Zero to Time t (AUC[0 to t]) of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|AUC(0 to t) for Dose Levels 3 and 5 Subcutaneous Administration|AUC(0 to t) for Dose Levels 6 and 7 Intravenous Administration|Maximum Observed Plasma Concentration (Cmax) of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|Cmax of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration|Cmax of GSK3888130B for Dose Levels 6 and 7 Intravenous Administration|Time to Cmax (Tmax) of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|Tmax of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration|Tmax of GSK3888130B for Dose Levels 6 and 7 Intravenous Administration|Half-life (t1/2) of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|t1/2 of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration|t1/2 of GSK3888130B for Dose Levels 6 and 7 Intravenous Administration|Clearance (CL) of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration|Clearance Factor (CL/F) of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration|CL of GSK3888130B for Dose Levels 6 and 7 Intravenous Administration|Number of Participants With Positive Anti-drug Antibodies Against GSK3888130B|Percent Peak Reduction From Baseline in Derived Free Interleukin 7 (IL 7) in Blood|Median Fluorescence Intensity (MdFI) of B-cell Lymphoma 2 (Bcl-2) Expression in CD4+ T Cells in Blood",True,2025-03-26
NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839,TERMINATED,2015-02,2016-04,2016-07,2016-12-21,2014-12-03,INTERVENTIONAL,PHASE2,62.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,United States,Cullman,Alabama,18,Vatelizumab,DRUG,Proportion of patients experiencing adverse events,Change in total volume of T2 lesions|Change in number of T1 hypointense lesions,False,
NCT06526364,Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland),Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland),RECRUITING,2024-12-10,2029-06,2029-06,2025-01-29,2024-07-29,OBSERVATIONAL,,100.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,Luxembourg Institute of Health|Research Center for Clinical Neuroimmunology and Neuroscience Basel,OTHER_GOV|OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",Immune-meditated Diseases|Artificial Intelligence|Personalized medicine|Treatment change|Phenotyping|Clinnova,Switzerland,Basel,,1,All participants will be asked to provide data and samples for collection and analysis.,OTHER,Set of biomarkers,Expanded Disability Status Scale (EDSS)|9-Hole Peg Test (9-HPT)|Timed 25-Foot Walk (T25FW)|Stroop Test (Victoria Version)|Symbol Digit Modalities Test (SDMT)|Trail Making Test A&B (TMT A&B)|Multiple Sclerosis Inventory of Cognition (MUSIC)|Digit span backwards (DSB)|Rey-Osterrieth Complex Figure Test (ROCF)|Verbal Learn and Memory Test (VLMT)|Near vision acuity test|Contrast vision test (Pelli-Robson low-contrast chart)|Short-form Food Frequency Questionnaire (SFFFQ)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Impact Scale (MSIS-29)|MS Symptom Tracker|Relapse reporting|Multiple Sclerosis Quality of Life-54 (MSQoL-54)|Hospital Anxiety and Depression Scale (HADS)|Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8a|PROMIS Numeric Rating Scale v1.0 - Pain Intensity 1a|PROMIS Short Form v1.1 - Pain Interference 4a|PROMIS Short Form v2.0 - Cognitive Function - Abilities 8a|PROMIS Scale v1.2 - Global Health|electronic Health Literacy Scale (eHEALS),False,
NCT02914964,Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study,Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study,COMPLETED,2016-08,2020-01-26,2025-02-26,2025-03-19,2016-09-26,INTERVENTIONAL,NA,95.0,ACTUAL,Terry L. Wahls,OTHER,National Multiple Sclerosis Society,OTHER,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Fatigue|Quality of Life|Diet,United States,Iowa City,Iowa,1,Swank Diet|Wahls Elimination Diet,BEHAVIORAL|BEHAVIORAL,Change in participant perceived fatigue severity|Change in participant perceived fatigue severity|Change in the impact of fatigue on daily life|Change in the impact of fatigue on daily life,Change in participant walk speed|Change in participant walk speed|Change in gait (walk)|Change in gait (walk)|Change in fine motor function|Change in fine motor function|Change in nutrient intake based on the recommended daily allowance (RDA)|Change in nutrient intake based on the recommended daily allowance (RDA)|Change in cognitive function|Change in cognitive function|Change in steps per day|Change in steps per day|Change in participant Quality of Life (QoL) - General Health|Change in participant Quality of Life (QoL) - General Health|Change in participant Quality of Life (QoL) - Mental Health|Change in participant Quality of Life (QoL) - Mental Health|Change in total sleep time|Change in total sleep time|Change in perceived anxiety|Change in perceived anxiety|Change in perceived depression|Change in perceived depression,False,
NCT03458767,A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology,A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology,COMPLETED,2017-10-09,2018-06-01,2018-06-01,2018-07-17,2018-03-08,INTERVENTIONAL,NA,16.0,ACTUAL,University of Texas at Austin,OTHER,,,Multiple Sclerosis,Cognitive function|Physical activity|Self-management,United States,Austin,Texas,1,Eight weekly 90-minute group educational sessions,BEHAVIORAL,Change from Baseline NIH Toolbox Picture Vocabulary Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Oral Reading Recognition at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Flanker Inhibitory Control and Attention Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Dimensional Change Card Sort Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox List Sorting Working Memory Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Oral Symbol Digit Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Pattern Comparison Processing Speed Test at 8-weeks (post-intervention)|Change from Baseline NIH Toolbox Picture Sequence Memory Test at 8-weeks (post-intervention),Change from Baseline Multiple Sclerosis Self-Management Scale (MSSM) at 8-weeks (post-intervention)|Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Medications and Treatments 4a at 8-weeks (post-intervention)|Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Symptoms 4a at 8-weeks (post-intervention)|Change from Baseline PROMIS Short Form v1.0 - Self-Efficacy for Managing Daily Activities 4a at 8-weeks (post-intervention)|Change from Baseline Neuro-Quality of Life (QoL) Short Form v2.0 - Cognitive Function at 8-weeks (post-intervention)|Change from Baseline Neuro-QoL Short Form v1.0 - Depression at 8-weeks (post-intervention)|Change from Baseline Neuro-QoL Short Form v1.0 - Fatigue at 8-weeks (post-intervention)|Change from Baseline Neuro-QoL Short Form v1.0 - Sleep Disturbance 4a at 8-weeks (post-intervention)|Change from Baseline Physical Activity - steps at 8-weeks (post-intervention)|Change from Baseline Physical Activity - activity count at 8-weeks (post-intervention)|Change from Baseline Sleep quality - sleep latency at 8-weeks (post-intervention)|Change from Baseline Sleep quality - wake after sleep onset at 8-weeks (post-intervention)|Change from Baseline Sleep quality - total sleep time at 8-weeks (post-intervention)|Change from Baseline Sleep quality - sleep efficiency at 8-weeks (post-intervention),False,
NCT05474209,"Effect of Tai Chi on Balance, Mood, Cognition, and Quality of Life in Patients With Multiple Sclerosis",The Combined Impact of a Structured Tai Chi Exercise Program on Selected Clinical Aspects and Quality of Life of Patients With Multiple Sclerosis,COMPLETED,2019-01-01,2020-01-31,2022-01-31,2022-07-26,2022-07-26,INTERVENTIONAL,NA,25.0,ACTUAL,Comenius University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Tai Chi Chuan|balance|non-pharmacological interventions|physical therapy|posturography,Slovakia,Bratislava,Slovak Republic,1,"""Tai-chi"" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes",OTHER,V0 visit- Static posturography|V1 visit- Static posturography|V2 visit- Static posturography|V3 visit- Static posturography|V4 visit- Static posturography|V0 visit- Static posturography LI|V1 visit- Static posturography LI|V2 visit- Static posturography LI|V3 visit- Static posturography LI|V4 visit- Static posturography LI|V0 visit- Static posturography TA|V1 visit- Static posturography TA|V2 visit- Static posturography TA|V3 visit- Static posturography TA|V4 visit- Static posturography TA|V0 visit- Static posturography RMS|V1 visit- Static posturography RMS|V2 visit- Static posturography RMS|V3 visit- Static posturography RMS|V4 visit- Static posturography RMS|V0 visit- Mini-BESTest|V1 visit- Mini-BESTest|V2 visit- Mini-BESTest|V3 visit- Mini-BESTest|V4 visit- Mini-BESTest,V0 visit- EDSS - Expanded disability status scale|V1 visit- EDSS - Expanded disability status scale|V2 visit- EDSS - Expanded disability status scale|V3 visit- EDSS - Expanded disability status scale|V4 visit- EDSS - Expanded disability status scale|V0 visit- T25FW - Timed 25-foot walk test|V1 visit- T25FW - Timed 25-foot walk test|V2 visit- T25FW - Timed 25-foot walk test|V3 visit- T25FW - Timed 25-foot walk test|V4 visit- T25FW - Timed 25-foot walk test|V0 visit- PASAT - Paced Auditory Serial Addition|V1 visit- PASAT - Paced Auditory Serial Addition|V2 visit- PASAT - Paced Auditory Serial Addition|V3 visit- PASAT - Paced Auditory Serial Addition|V4 visit- PASAT - Paced Auditory Serial Addition|V0 visit- SDMT - Symbol Digit Modalities Test|V1 visit- SDMT - Symbol Digit Modalities Test|V2 visit- SDMT - Symbol Digit Modalities Test|V3 visit- SDMT - Symbol Digit Modalities Test|V4 visit- SDMT - Symbol Digit Modalities Test|V0 visit- EQ-5D - European Quality of Life Questionnaire|V1 visit- EQ-5D - European Quality of Life Questionnaire|V2 visit- EQ-5D - European Quality of Life Questionnaire|V3 visit- EQ-5D - European Quality of Life Questionnaire|V4 visit- EQ-5D - European Quality of Life Questionnaire|V0 visit- FES - Falls Efficacy Scale|V1 visit- FES - Falls Efficacy Scale|V2 visit- FES - Falls Efficacy Scale|V3 visit- FES - Falls Efficacy Scale|V4 visit- FES - Falls Efficacy Scale|V0 visit- ABC - Activities-Specific Balance Confidence Scale|V1 visit- ABC - Activities-Specific Balance Confidence Scale|V2 visit- ABC - Activities-Specific Balance Confidence Scale|V3 visit- ABC - Activities-Specific Balance Confidence Scale|V4 visit- ABC - Activities-Specific Balance Confidence Scale|V0 visit- BDI-II - The Beck Depression Inventory|V1 visit- BDI-II - The Beck Depression Inventory|V2 visit- BDI-II - The Beck Depression Inventory|V3 visit- BDI-II - The Beck Depression Inventory|V4 visit- BDI-II - The Beck Depression Inventory|V0 visit- BAI - The Beck Anxiety Inventory|V1 visit- BAI - The Beck Anxiety Inventory|V2 visit- BAI - The Beck Anxiety Inventory|V3 visit- BAI - The Beck Anxiety Inventory|V4 visit- BAI - The Beck Anxiety Inventory|V0 visit- MoCA - Montreal cognitive assessment|V1 visit- MoCA - Montreal cognitive assessment|V2 visit- MoCA - Montreal cognitive assessment|V3 visit- MoCA - Montreal cognitive assessment|V4 visit- MoCA - Montreal cognitive assessment,False,
NCT07151547,Cut-Off Values for Gait and Balance in MS,Determination of Cut-Off Values for Gait Variability and Balance Scores in Patients With Multiple Sclerosis,RECRUITING,2025-08-06,2025-11-06,2026-01-06,2025-09-03,2025-09-03,OBSERVATIONAL,,60.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,cut-off|falls|gait variability|limits of stability|postural sways|multiple sclerosis,Turkey (Türkiye),Ankara,Altındağ,1,,,Limits of Stability|Postural sways|Gait variability|Fall Histories,,False,
NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,"A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)",COMPLETED,2002-08,,2003-05,2010-01-27,2008-01-23,OBSERVATIONAL,,136.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Interferon beta 1a|Avonex,United States,Los Angeles,California,11,Interferon beta-1a|Interferon beta-1a,DRUG|DRUG,,,False,
NCT04806217,Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis,Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis,UNKNOWN,2022-07-01,2024-01-01,2024-01-01,2022-01-13,2021-03-19,INTERVENTIONAL,NA,40.0,ESTIMATED,Lille Catholic University,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Theory of Mind|Nonverbal false belief task|Cognitive functions|Inhibition and inference abilities,,,,0,Theory of Mind,OTHER,"Number of correct answers to the ""unknown reality"" false belief tasks|Number of correct answers to the ""known reality"" false belief tasks",California Verbal Learning Test (CVLT)|Brief Visuo-spatial Memory Test (BVMT)|Symbol Digit Modalities Test (SDMT)|Stroop test|Trail Making test|Verbal fluency test|Verbal fluency test|Beck Depression Inventory (BDI),False,
NCT03550170,Fatigue Management Programs for People With MS,Comparing the Effectiveness of Fatigue Management Programs for People With MS,COMPLETED,2019-03-01,2023-04-28,2023-04-28,2025-02-04,2018-06-08,INTERVENTIONAL,NA,590.0,ACTUAL,Case Western Reserve University,OTHER,"Patient-Centered Outcomes Research Institute|University of Illinois at Chicago|University of Minnesota|Queen's University, Kingston, Ontario|Dalhousie University|The Cleveland Clinic",OTHER|OTHER|OTHER|OTHER|OTHER|OTHER,Multiple Sclerosis,Fatigue|Wellness|Multiple Sclerosis|Quality of life,United States,Chicago,Illinois,3,"Teleconference|Internet|1-to-1, in-person or videoconference",BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Change From Baseline in Fatigue Levels,Change From Baseline in Health-related Quality of Life: Psychological Composite,True,2024-09-23
NCT00260741,Cannabis for Spasticity in Multiple Sclerosis,Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study,TERMINATED,2003-03,,2006-01,2007-04-04,2005-12-02,INTERVENTIONAL,PHASE1|PHASE2,60.0,,Center for Medicinal Cannabis Research,OTHER,,,Multiple Sclerosis,cannabis|marijuana|Multiple Sclerosis|Spasticity,United States,Sacramento,California,1,Smoked Cannabis,DRUG,Change in an objective measurement of spasticity between the pretreatment assessment and the 4- and 8-week assessments.,"Differences between active agent and placebo in the changes in Ashworth Scale, Functional System Score, Expanded Disability Status Score, Ambulation Index, Functional Composite Score, and Quality of Life Inventory.",False,
NCT04261556,tDCS to Enhance Cognitive Training in Multiple Sclerosis,"Innovative Protocol Targeting Cognitive Dysfunction in Multiple Sclerosis: tDCS to Enhance Cognitive Training in a Randomized, Double-blind, Controlled, Exploratory Pilot Study",WITHDRAWN,2019-11-21,2023-12,2024-12,2024-01-03,2020-02-10,INTERVENTIONAL,NA,0.0,ACTUAL,University of Milano Bicocca,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",Multiple sclerosis|Relapsing remitting multiple sclerosis|Cognitive training|Cognitive rehabilitation|Cognitive remediation|Neuromodulation|Transcranial direct current stimulation,Italy,Monza,,1,Real tDCS + CCT|Sham tDCS + CCT,DEVICE|DEVICE,Change in Symbol Digit Modalities Test (SDMT)|Change in Paced Auditory Serial Addition Test (PASAT)|Change in Wisconsin Card Sorting Test (WCST)|Change in Stroop test|Change in Digit Spans,Number of sessions done by esch participants (Feasibility)|Number tDCS-related of discomfort or side effects experienced by each participants (Safety)|Changes in Brief Repeatable Battery of Neuropsychological Tests (BRBN-T)|Changes in Beck Depression Inventory (BDI)|Changes in Expanded Disability Status Scale (EDSS) measurements|Changes in Multiple Sclerosis Functional Composite (MFSC)|Changes in Modified Fatigue Impact Scale (MFIS)|Changes in Multiple Sclerosis Quality of Life (MSQOL-54)|Changes in alpha oscillations measured with Electroencephalogram (EEG) Resting State From Baseline,False,
NCT05571631,Effect of Arm Ergometer Exercise Training on Upper Extremity Function in People With Multiple Sclerosis.,Investigation of the Effect of the Combination of Arm Ergometer Exercise and Balance Training on Upper Extremity Function in People With Multiple Sclerosis,UNKNOWN,2022-10-15,2024-09-15,2024-11-15,2022-10-07,2022-10-07,INTERVENTIONAL,NA,30.0,ESTIMATED,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,multiple sclerosis|upper extremity|balance|rehabilitation,,,,0,exercise,OTHER,Nine-Hole Peg Test,Expanded Disability Status Scale|Jamar Hand Dynamometer|Arm Function in Multiple Sclerosis Questionnaire|Preference-based Multiple Sclerosis Index|Estimated VO2 Max|Modified Fatigue Impact Scale|Timed Up and Go test|Activities-Specific Balance Confidence Scale|Coin Rotation Test,False,
NCT06221631,BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis,Brain Aging - a Comparative Study in Healthy and Patients With Multiple Sclerosis as Model of a Chronic Neuroinflammatory Disorder (BrainAgeMS),RECRUITING,2024-08-27,2028-03,2028-03,2024-11-18,2024-01-24,OBSERVATIONAL,,200.0,ESTIMATED,"Insel Gruppe AG, University Hospital Bern",OTHER,Schweizerische Multiple Sklerose Gesellschaft|University of Bern,OTHER|OTHER,Multiple Sclerosis,Brain Aging|Multiple Sclerosis|Neurodegeneration|Quantitative MRI,Switzerland,Bern,,1,,,Brain Age Gap in patients with MS,Relationship of brain age gaps with disease severity|Relationship of brain age gaps with gait speed|Relationship of brain age gaps with upper extremity function|Relationship of brain age gaps with sitting-to-raise time|Relationship of brain age gaps with cognitive symptoms|Relationship of brain age gaps with depression symptoms|Relationship of brain age gaps with fatigue|Relationship of brain age gaps with quality of life,False,
NCT02287454,Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis,Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis: a Randomized Clinical Trial,COMPLETED,2013-01,2013-07,2013-07,2017-11-13,2014-11-10,INTERVENTIONAL,NA,32.0,ACTUAL,University of Deusto,OTHER,,,Multiple Sclerosis,"Multiple Sclerosis, cognitive rehabilitation, REHACOP",Spain,Bilbao,Biskai,1,cognitive remediation program: REHACOP,OTHER,Change in attention after receiving cognitive rehabilitation treatment|Change in working memory after receiving cognitive remediation treatment|Change in processing speed after receiving cognitive remediation treatment|Change in verbal memory after receiving cognitive remediation treatment|Change in verbal fluency after receiving cognitive remediation treatment|Change in executive functioning after receiving cognitive remediation treatment.,,False,
NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies",TERMINATED,2017-11-15,2021-02-12,2021-02-12,2022-04-28,2017-07-19,INTERVENTIONAL,PHASE2,263.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,Remyelination|Re-myelination|DMT|LINGO-1|Anti-LINGO-1|Opicinumab,United States,Cullman,Alabama,159,BIIB033 (opicinumab)|Placebo,DRUG|DRUG,Part 1: Overall Response Score|Part 2: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs),"Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND|Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or 3-Second Paced Auditory Serial Addition Test (PASAT-3)|Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 72 Weeks of the Study|Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and Symbol Digit Modalities Test (SDMT)|Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)|Part 2: Overall Response Score|Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND|Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or PASAT-3|Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 96 Weeks of the Study|Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and SDMT|Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)|Part 2: Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values|Part 2: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Values|Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Vital Signs Values|Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Weight Values|Part 2: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline Visit",True,2022-04-28
NCT00004816,A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis,,COMPLETED,1995-07,,,2005-06-24,2000-02-25,INTERVENTIONAL,PHASE1,25.0,,National Center for Research Resources (NCRR),NIH,Stanford University,OTHER,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,,,,0,monoclonal antibody M-T412,DRUG,,,False,
NCT00950248,Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS),Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis,COMPLETED,2009-11-01,2018-04-30,2018-08-06,2019-03-19,2009-07-31,INTERVENTIONAL,PHASE1|PHASE2,85.0,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,Primary Progressive Multiple Sclerosis,Idebenone|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy|Mitochondrial Enhancer|Multiple Sclerosis|MS|Primary Progressive Multiple Sclerosis,United States,Bethesda,Maryland,1,Idebenone|placebo,DRUG|OTHER,Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase,Change in the AUC of Individualized Rates of Enlargement of Ventricular Volume From Baseline to Treatment Phase|Disability Progression Measured by EDSS-plus|Change in Slopes of 25FW Time From Baseline to Treatment Phase|Change in Slopes of 9HPT Time From Baseline to Treatment Phase|Change in Slopes of SNRS From Baseline to Treatment Phase on|Change in Slopes of EDSS From Baseline to Treatment Phase,True,2019-03-07
NCT06541626,Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases,Sun Yat-Sen Prospective Cohort Study of Central Nervous System Idiopathic Inflammatory Demyelinating Diseases,RECRUITING,2024-01-01,2035-12-31,2035-12-31,2024-08-07,2024-08-07,OBSERVATIONAL,,450.0,ESTIMATED,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,,,"Multiple Sclerosis, MS|Neuromyelitis Optica Spectrum Disorders|Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease|Acute Disseminated Encephalomyelitis|Clinically Isolated Syndrome|Demyelinating Disorder",CNS IIDD|follow-up,China,Guangzhou,Guangdong,1,,,Relapse|Long-term neurological function,"Long-term neurological function|Sub-scores of the Expanded Disability Status Scale (EDSS)|Optical coherence tomography (OCT) of the eyes: retinal nerve fiber layer thickness, macular thickness|Changes in humoral immune markers|Changes in pathogenic antibody titers|P100 amplitude of visual evoked potentials|P100 latency of visual evoked potentials|Latency of somatosensory evoked potentials;|Latency of brainstem auditory evoked potentials;|Amplitude of somatosensory evoked potentials;|Amplitude of brainstem auditory evoked potentials;",False,
NCT05748015,Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis,Definition of Autonomic Nervous System Involvement in Patients With Relapsing-remitting and Primary Progressive Multiple Sclerosis,RECRUITING,2021-03-04,2025-09-30,2025-12-30,2025-01-30,2023-02-28,INTERVENTIONAL,NA,60.0,ESTIMATED,Istituti Clinici Scientifici Maugeri SpA,OTHER,,,Multiple Sclerosis,autonomic nervous system|sensory nervous system|rehabilitation|skin biopsy,Italy,Telese Terme,Benevento,2,"quantification of sensory and autonomic small nerve fibers by punch skin biopsy|Cardiovascular Reflexes testing|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms",DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|OTHER,Cardiovascular reflex test|Sudomotor function test,Quantification of peripheral autonomic nerve fibers|Quantification of peripheral sensory nerve fibers,False,
NCT02988401,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,COMPLETED,2017-12-01,2021-12-17,2021-12-17,2023-03-10,2016-12-09,INTERVENTIONAL,PHASE1|PHASE2,105.0,ACTUAL,Johns Hopkins University,OTHER,United States Department of Defense,FED,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive",,United States,Baltimore,Maryland,1,Insulin|Placebo (Sterile diluent),DRUG|DRUG,Change in Cognitive Function as Assessed by the Symbol Digit Modalities Test (SDMT),"Number of Participants With Adverse Events Leading to Study Discontinuation|Fingerstick Blood Glucose (Subset)|Change From Baseline in Cognitive Function as Assessed by the Controlled Oral Word Association Test (COWAT)|Change From Baseline in Cognitive Function as Assessed by the California Verbal Learning Test, Second Edition (CVLT-II)|Change From Baseline in Cognitive Function as Assessed by the Brief Visuospatial Memory Test - Revised (BVMT-R) Delayed Recall|Change in Cognitive Function as Assessed by the Rao-version of the Paced Auditory Serial Addition Test (PASAT)|Change From Baseline in Cognitive Function as Assessed by the Judgement of Line Orientation Test (JLO)|Change From Baseline in Cognitive Function as Assessed by the Delis-Kaplan Executive Function System Sorting Test",True,2023-03-10
NCT06800144,Effect of Music Therapy on Pain in People With Multiple Sclerosis,"Effect of Telerehabilitation-Based Heart Rate-Synchronized Motor Imagery Music Therapy on Pain, Autonomic Function and Psychosocial Parameters in People With Multiple Sclerosis",NOT_YET_RECRUITING,2025-10-01,2026-12-01,2027-12-01,2025-09-03,2025-01-29,INTERVENTIONAL,NA,45.0,ESTIMATED,Istanbul Bilgi University,OTHER,,,"Multiple Sclerosis, MS",Music Therapy in Multiple Sclerosis,,,,0,Heart rate synchronized motor imagery music therapy|Heart rate synchronized music therapy,BEHAVIORAL|BEHAVIORAL,Visual Analog Scale (VAS),PainDETECT|Nordic Musculoskeletal Questionnaire|Central Sensitization Questionnaire- Short Form|Modified Fatigue Impact Scale|Hospital Anxiety and Depression Scale|Preference Based MS Index|Pittsburgh Sleep Quality Index|Heart Rate Variability|Paced Auditory Serial Addition Test,False,
NCT02848898,The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients,"The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study",UNKNOWN,2016-08,2017-05,2017-07,2016-07-29,2016-07-29,INTERVENTIONAL,NA,60.0,ESTIMATED,Federico II University,OTHER,,,Multiple Sclerosis,Focal Vibrations|Neurorehabilitation|Spasticity|Multiple Sclerosis,Italy,Naples,Campania,1,Equistasi|Placebo,DEVICE|OTHER,Gait Velocity|First step length|Swing phase|Stance phase|Double support time,H/M ratio|Berg Balance Scale|Modified Fatigue Scale,False,
NCT01973491,ATX-MS-1467 in Multiple Sclerosis,"An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis",COMPLETED,2014-02-28,2016-04-30,2016-04-30,2017-07-02,2013-10-31,INTERVENTIONAL,PHASE2,37.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,ATX-MS-1467 (MSC2358825A)|Relapsing Multiple Sclerosis|Magnetic resonance imaging (MRI)|M2736,Germany,Darmstadt,,1,ATX-MS-1467,DRUG,Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans,"Total Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs)|Change From Baseline in Total Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) at Weeks 12, 16, 20, 24, 28 and 36|Change From Baseline in Total Volume of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) at Weeks 12, 16, 20, 24, 28 and 36|Total Number of New or Newly Enlarging Time Constant 2 (T2) Lesions|Change From Week 0 in Total Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) at Weeks 12, 16, 20, 24, 28 and 36|Change From Week 0 in Total Volume of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) at Weeks 12, 16, 20, 24, 28 and 36|Mean Annualized Relapse Rate|Time to First Relapse|Change From Baseline in Total Expanded Disability Status Scale (EDSS) Score at Week 20|Change From Baseline in Total Multiple Sclerosis Functional Composite (MSFC) Score at Week 20|Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation|Number of Subjects Experiencing Injection Site Reactions (ISRs)",True,2017-04-13
NCT01067521,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo","A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design",COMPLETED,2010-06-22,2012-05-08,2017-05-12,2021-12-09,2010-02-11,INTERVENTIONAL,PHASE3,1404.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,Relapsing Remitting Multiple Sclerosis|Glatiramer Acetate,United States,Birmingham,Alabama,176,Glatiramer acetate (GA)|Placebo,DRUG|DRUG,Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression|Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression,"The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression|The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression|Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period|The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression|The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression|Brain Atrophy As Defined by the Percent of Change in Brain Volume From Baseline to Months 6, 12 and 36 Estimated by a Mixed Model for Repeated Measures|Participants With Treatment-Emergent Adverse Events (TEAEs)",True,2018-10-09
NCT04760990,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,COMPLETED,2021-02-01,2023-12-15,2023-12-15,2025-04-23,2021-02-18,OBSERVATIONAL,,1181.0,ACTUAL,"University Hospital, Basel, Switzerland",OTHER,Swiss Multiple Sclerosis Registry,OTHER,Multiple Sclerosis|COVID-19 (Severe Coronavirus Disease 2019),Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|Swiss Multiple Sclerosis Cohort (SMSC),Switzerland,Aarau,,7,data collection|analysis of blood samples,OTHER|OTHER,Incidence of severe COVID-19 as defined by the WHO clinical progression scale (Score 6-9)|COVID-19 related death defined by the WHO clinical progression scale (Score 10),Proportion of patients with Anti-SARS-CoV-2 seroconversion|Change in mean titers of IgM- and IgG-antibodies against SARS-CoV-2|Change in individual titers of IgM- and IgG-antibodies against SARS-CoV-2|Proportion of total confirmed SARS-CoV-2-infections (independent of WHO clinical progression scale Score).,False,
NCT00202410,Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis,"Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study.",COMPLETED,2001-11,2007-09,2008-04,2011-05-19,2005-09-20,INTERVENTIONAL,PHASE2|PHASE3,80.0,ACTUAL,S. Andrea Hospital,OTHER,Italian Multiple Sclerosis Foundation|Istituto Superiore di Sanità,OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Tuberculosis vaccine|Therapy,Italy,Rome,Roma,1,Bacille of Calmette-Guerin|placebo,BIOLOGICAL|OTHER,number of gad-enhancing lesions in T1|number of lesions in T1 and new lesions in T2,volume of T2 lesions|volume of T1 lesions (black holes),False,
NCT00213135,A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),"A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)",COMPLETED,2005-04,2008-11,2008-11,2014-02-07,2005-09-21,INTERVENTIONAL,PHASE3,1326.0,ACTUAL,EMD Serono,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,,,,0,Cladribine 5.25 mg/kg|Cladribine 3.5 mg/kg|Placebo,DRUG|DRUG|OTHER,Annualized Qualifying Relapse Rate,"Percentage of Relapse-free Participants|Time to Disability Progression|Mean Number of Combined Unique (CU) Lesions, Active Time Constant 2 (T2) Lesions, and Active Time Constant 1 (T1) Gadolinium-Enhanced (Gd+) Lesions Per Participant Per Scan",True,2013-12-02
NCT01842191,Efficacy of Fish Oil in Multiple Sclerosis,"Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b",COMPLETED,2010-05,2011-12,2012-12,2013-05-22,2013-04-29,INTERVENTIONAL,PHASE4,50.0,ACTUAL,"Coordinación de Investigación en Salud, Mexico",OTHER_GOV,,,Relapsing- Remitting Multiple Sclerosis,R-R MS,Mexico,Guadalajara,Jalisco,1,Fish Oil|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,TNF alpha,"IL-1 beta, IL-6, Lipoperoxides, nitric oxide",False,
NCT01903291,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,"A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate",COMPLETED,2013-08,2016-02,2016-02,2016-07-25,2013-07-19,OBSERVATIONAL,,333.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,,United States,Birmingham,Alabama,62,dimethyl fumarate,DRUG,Annualized Relapse Rate,Change in 14-item Treatment Satisfaction Questionnaire for Medication (TSQM-14) scores.|Change in Short-Form 36 (SF-36) scores.|Change in Modified Fatigue Impact Scale (MFIS-5) scores.|Change in Beck Depression Inventory (BDI-7) scores.|Change in Work Productivity and Impairment Questionnaire: Multiple Sclerosis (WPAI-MS) scores.|Change in Morisky 8-item Medication Adherence Scale (MMAS-8) scores.|Change in Patient-reported Expanded Disability Status Scale (patient-reported EDSS) scores.|Proportion of patients experiencing a relapse.|Proportion of patients with relapses associated with hospitalizations.|Proportion of patients with relapses associated with steroid use.,False,
NCT03360188,Pediatric Onset Multiple Sclerosis in Egyptians,Pediatric Multiple Sclerosis in Egypt. A Multi-center Registry of 186 Patients,COMPLETED,2011-06,2015-12,2015-12,2017-12-05,2017-12-04,OBSERVATIONAL,,237.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis in Children,,,,,0,,,time to EDSS 4,,False,
NCT05046535,The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis,The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis,COMPLETED,2021-09-01,2024-02-01,2024-06-01,2024-06-14,2021-09-16,OBSERVATIONAL,,72.0,ACTUAL,University of Jordan,OTHER,,,Multiple Sclerosis,Sleep quality|Cigarette Smoking|Physical Activity|Secondhand smoke,Jordan,Amman,,1,Sleep quality and physical activity|Nicotine dependence|Nicotine and cotinine serum levels|Smoking,BEHAVIORAL|GENETIC|DIAGNOSTIC_TEST|BEHAVIORAL,Nicotine and cotinine serum levels|Sleep quality|Physical activity and cardiorespiratory fitness,Genetic predisposition to nicotine dependence and other blood tests,False,
NCT01845896,"Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis","Rehabilitation in MS: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis",COMPLETED,2013-03,2014-03,2014-03,2014-05-06,2013-05-03,INTERVENTIONAL,NA,34.0,ACTUAL,Bert Op't Eijnde,OTHER,,,Multiple Sclerosis|Healthy Controls,high intensity interval training|combined training|insulin resistance|muscle contractile properties,Belgium,Diepenbeek,,1,Training,BEHAVIORAL,insulin sensitivity (insulin profile)|muscle contractile properties,muscle strength of knee extensor/flexor|aerobic capacity|cytokine profile|Self-reported measures|body composition,False,
NCT05002062,"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients","The Influence of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in Multiple Sclerosis Patients",COMPLETED,2020-12-21,2021-05-18,2021-06-07,2022-01-18,2021-08-12,INTERVENTIONAL,NA,40.0,ACTUAL,Cairo University,OTHER,,,Multiple Sclerosis,,Egypt,Giza,Dokki,1,"""RehaCom"" computer-based cognitive training in addition to Conventional physical therapy program|Conventional physical therapy program",DEVICE|OTHER,Level of primary fatigue|Level of Attention/concentration|Figural Memory|Mental Reaction behavior|Serum levels of Tumor Necrosis Factor-alpha (TNF-alpha) and Interferon-gamma(INF-gamma),,False,
NCT00147446,Stress Management for Patients With Multiple Sclerosis,"Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes",COMPLETED,2005-05,2009-01,2009-01,2013-09-10,2005-09-07,INTERVENTIONAL,PHASE2,121.0,ACTUAL,Northwestern University,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Multiple Sclerosis,Stress|Stress Management|Behavioral Medicine|Multiple Sclerosis|Psychoneuroimmunology,United States,San Francisco,California,3,Individual Stress Management|Wait List Control,BEHAVIORAL|OTHER,No.of Gd+ Lesions From Week 8 to Week 24,No.of New or Enlarged T2 Lesions From Week 8 to Week 24,True,2013-09-10
NCT04721340,The Minnesota Manual Dexterity Test As A Measure Of Hand Function in Multiple Sclerosis,Upper Limb Assessment in Multiple Sclerosis: The Minnesota Manual Dexterity Test As A Measure Of Hand Function,COMPLETED,2021-02-02,2021-05-02,2021-05-16,2021-06-15,2021-01-22,OBSERVATIONAL,,80.0,ACTUAL,Istanbul Aydın University,OTHER,,,Multiple Sclerosis,multiple sclerosis|upper limb|manual dexterity|assessment|minnesota manual dexterity test,Turkey (Türkiye),Istanbul,Küçükçekmece,1,Test Group|Control Grup,OTHER|OTHER,Minnesota Manual Dexterity Test,9-Hole Peg Test|ABILHAND|grip strength|pinch strength|Fatigue Severity Scale,False,
NCT04097418,Aerobic Training Effects on Motor and Cognitive Performances in MS: an Exploratory Study With Structural and Functional MRI,Effects of Aerobic Training on Motor and Cognitive Performances in Patients With MS: an Exploratory Study With Structural and Functional MRI,RECRUITING,2015-06-13,2024-12-31,2024-12-31,2023-09-28,2019-09-20,INTERVENTIONAL,NA,80.0,ESTIMATED,IRCCS San Raffaele,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Aerobic Training|rehabilitation,Italy,Milan,,1,Aerobic training compared to conventional motor training,BEHAVIORAL,Longitudinal changes of brain GM volumes following aerobic training or conventional motor training|Longitudinal changes of WM microstructural abnormalities following aerobic training or conventional motor training|Resting State Functional Connectivity MRI changes following aerobic training or conventional motor training|Functional MRI changes following aerobic training or conventional motor training|Effects of aerobic training compared to conventional motor training on global clinical disability|Effects of aerobic training compared to conventional motor training on clinical disability|Effects of aerobic training compared to conventional motor training on behavioural measures|Effects of aerobic training compared to conventional motor training on spasticity|Effects of aerobic training compared to conventional motor training on walking ability|Effects of aerobic training compared to conventional motor training on person's mobility,Effects of aerobic training compared to conventional motor training on cognitive functions|Effects of aerobic training compared to conventional motor training on fatigue|Effects of aerobic training compared to conventional motor training on depression|Effects of aerobic training compared to conventional motor training on quality of life,False,
NCT04585659,Qigong for Multiple Sclerosis: A Feasibility Study,Qigong for Multiple Sclerosis: A Feasibility Study,COMPLETED,2017-02-01,2018-03-16,2018-03-16,2020-10-14,2020-10-14,INTERVENTIONAL,NA,20.0,ACTUAL,National University of Natural Medicine,OTHER,,,Multiple Sclerosis,Qigong|Pragmatic Design|Gait|Multiple Sclerosis,United States,Portland,Oregon,1,Qigong,OTHER,Feasibility Outcome 1: Number of participants recruited for the study|Feasibility Outcome 2: Number of participants retained in the study|Feasibility Outcome 3: Percent able to participate in qigong classes|Feasibility Outcome 4: Percent attendance in qigong classes,"Clinical Measure 1: Walking speed assessed by the Timed-25-Foot-Walk Test|Clinical Measure 2: Mobility, balance and walking ability assessed by the Timed-Up-and-Go Test|Clinical Measure 3: Multidirectional mobility assessed by the Four-Square-Step-Test|Clinical Measure 4: Physical and psychological well-being assessed by the Multiple Sclerosis Impact Scale (MSIS-29)|Clinical Measure 5: Impact of multiple sclerosis on walking ability assessed by the Multiple Sclerosis Walking Scale (MSWS-12)|Clinical Measure 6: Fatigue assessed by the Modified Fatigue Impact Scale Short Version (MFIS-5)|Clinical Measure 7: Health-related quality of life assessed by the Patient Reported Outcomes Measurement Information System global heath (mental and physical, v1.1)|Clinical Measure 8: Health-related quality of life assessed by the Patient Reported Outcomes Measurement Information System physical function (v1.2)|Clinical Measure 9: Health-related quality of life assessed by the Patient Reported Outcomes Measurement Information System fatigue (v1.0)|Clinical Measure 10: Health-related quality of life assessed by the Patient Reported Outcomes Measurement Information System anxiety (v1.0)|Clinical Measure 11: Health-related quality of life assessed by the Patient Reported Outcomes Measurement Information System depression (v1.0)",False,
NCT04933552,Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent,Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study,RECRUITING,2021-12-15,2032-05-31,2032-05-31,2024-05-16,2021-06-21,OBSERVATIONAL,,867.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|PASS|Post-Authorization Safety Study|Mayzent|Siponimod|Pregnancy,United States,La Jolla,California,1,Siponimod,OTHER,Prevalence of major structural defects,Number of spontaneous abortion/miscarriage|Number of stillbirth|Number of elective termination|Number of premature delivery|Number of preeclampsia / eclampsia|Pattern of 3 or more minor structural defects|Small for gestational age|Postnatal growth small for age at approximately one year of age|Developmental performance at approximately one year of age|Serious or opportunistic infections in the first year of life,False,
NCT03204747,Effect of Need to Void on Gait Speed in Multiple Sclerosis,Effect of Need to Void on Gait Speed in Multiple Sclerosis,COMPLETED,2017-02-27,2017-08-31,2017-08-31,2019-07-19,2017-07-02,OBSERVATIONAL,,71.0,ACTUAL,Pierre and Marie Curie University,OTHER,,,Multiple Sclerosis|Lower Urinary Tract Symptoms|Gait,Gait speed|multiple sclerosis|lower urinary tract symptoms|overactive bladder,France,Paris,,1,Observational study : gait speed,OTHER,Gait speed,Time for Timed up and Go|Variation of gait speed,False,
NCT06839924,Effect of Motor Cognitive Interference on Cognition and Quality of Life on Patients with Multiple Sclerosis,Effect of Motor Cognitive Interference on Cognition and Quality of Life on Multiple Sclerosis Patients,ACTIVE_NOT_RECRUITING,2024-12-10,2025-06-12,2025-08-01,2025-02-21,2025-02-21,INTERVENTIONAL,NA,44.0,ACTUAL,Cairo University,OTHER,,,"Multiple Sclerosis, MS",Multiple Sclerosis|MS|Cognition|Cognitive Motor Interference|quality of life|Qol,Egypt,Giza,Dokki,1,Cognitive Motor Interference|traditional physical therapy,BEHAVIORAL|BEHAVIORAL,Cognition (working memory and divided attention),A health-related quality of life,False,
NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis",COMPLETED,2011-08-31,2015-04-02,2022-12-31,2024-03-04,2010-11-24,INTERVENTIONAL,PHASE3,821.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Phoenix,Arizona,142,Interferon beta-1a|Ocrelizumab-matching placebo|Ocrelizumab|Interferon beta-1a-matching placebo,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks,"Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period|Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment|Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment|Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks|Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period|Number of T1 Hypointense Lesions During the Double-Blind Treatment|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96|Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96|Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96|Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96|Number of Participants With Adverse Events (AEs)|Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)|Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab",True,2017-07-18
NCT01611987,The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis,The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis,UNKNOWN,2012-09,2017-12,2018-12,2017-04-26,2012-06-05,INTERVENTIONAL,NA,240.0,ESTIMATED,McGill University,OTHER,,,Multiple Sclerosis,,Canada,Toronto,Ontario,5,MStep|General guideline approach,OTHER|OTHER,oxygen consumption,muscle strength measured with Biodex|6 Minute Walk test (6MWT)|Anaerobic leg power|Patient Determined Disease Steps (PDDS)|Change in fatigue levels|Rand 36|EQ-5D|Patient generated Index|Exercise Self-Efficacy Scale|Change in perception about exercise benefits and exercise barrier|Modified Canadian Aerobic Fitness test,False,
NCT06805318,Feasibility of a Vocational Rehabilitation Intervention for Job Retention in Workers With MS-RiaLSM Intervention Project,Development and Assessment of a Vocational Rehabilitation Intervention for Job Retention in Workers With Multiple Sclerosis (RiaLSM Intervention Project),RECRUITING,2025-01-15,2025-10-31,2025-10-31,2025-06-17,2025-02-03,INTERVENTIONAL,NA,30.0,ESTIMATED,Fondazione Italiana Sclerosi Multipla,OTHER,"Italian Multiple Sclerosis Society (AISM)Liguria, Genoa|IRCCS Santa Lucia Foundation, Rome|IRCCS San Martino Hospital, Genoa|Italian Workers' Compensation Authority (INAIL)|Department of Health Science (DiSSaL), University of Genoa, Genoa",UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,Multiple Sclerosis|Vocational Rehabilitation,Multiple Sclerosis|Vocational Rehabilitation|Occupational Rehabilitation|Return to Work|Work Maintenance|Work Placement|Vocational Guidance|Reasonable Accomodation,Italy,Rome,Lazio,2,Vocational Rehabilitation intervention for pwMS,BEHAVIORAL,Interception|Acceptance|Adherence|Lost to Follow-Up|Canadian Occupational Performance Measure (COPM)|Client Satisfaction Questionnaire (CSQ)|Global Perceived Effect (GPE) scale|Barthel Index (BI)|Hospital Anxiety Depression scale (HADS)|Modified Fatigue (MFIS-21)|Multiple Sclerosis Neuropsychological Questionnaire for patient (MSNQ-p)|WHO Disability Assessment Schedule (WHODAS),,False,
NCT03983252,Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis,Effect of Alemtuzumab on Microglial Activation Assessed Using Novel [F-18]-Based Positron Emission Tomography (PET) Ligand in Multiple Sclerosis,UNKNOWN,2019-07,2024-05-01,2024-05-01,2019-06-12,2019-06-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ESTIMATED,Brigham and Women's Hospital,OTHER,"Genzyme, a Sanofi Company",INDUSTRY,Multiple Sclerosis,,United States,Boston,Massachusetts,1,[F-18]PBR06,DRUG,PET Uptake/Standardized uptake value ratio (SUVR) change,PET Uptake/Standardized uptake value ratio (SUVR) change|T2/FLAIR lesion load change|Whole brain/deep gray matter atrophy change|Expanded Disability Status Scale (EDSS) change|Timed 25-foot walk (T25FW) change|Modified Fatigue Impact Scale (MIFS) change|Minimal Assessment of Cognitive Function in MS (MACFIMS) change,False,
NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,COMPLETED,2009-12-17,2016-04-12,2016-09-01,2017-07-12,2009-08-24,OBSERVATIONAL,,68.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|MS|Non-interventional,Austria,Many Locations,,6,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,Safety and tolerability of Betaferon in this patient population,Proportion of patients being relapse free|Time to first relapse|Annualized relapse rate|Disability progression measured by the expanded disability status scale (EDSS)|Outcome on neurological function|Fatigue assessed by Fatigue Severity Scale (FSS)|MRI measurements (if available)|MRI measurements and potential correlation with neuropsychological impairment|Laboratory outcomes,False,
NCT04148313,A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis,WITHDRAWN,2020-03-02,2030-03,2030-07,2025-06-05,2019-11-01,OBSERVATIONAL,,0.0,ACTUAL,ProgenaBiome,OTHER,,,Multiple Sclerosis|MS,,United States,Ventura,California,1,No Intervention,OTHER,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,Validation of Sequencing Methods,False,
NCT04869358,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS),COMPLETED,2021-05-27,2022-05-10,2023-06-13,2025-05-16,2021-05-03,INTERVENTIONAL,PHASE4,34.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapsing Multiple Sclerosis,COVID-19|SARS-CoV-2 mRNA vaccine|immune response|Ofatumumab|Relapsing Multiple Sclerosis|RMS|adult|MS,Germany,Berlin,,6,Ofatumumab,DRUG,Percentage of Participants Having Established SARS-CoV-2-specific T Cells After Receiving a modRNA Vaccine,Percentage of Participants Who Maintained T-cell Response After Receiving a modRNA Vaccine|Increase in Specific T-cells After Receiving an modRNA Booster Vaccine|Percentage of RMS Participants With Quantifiable Levels of SARS-CoV-2 Serum Functional Antibodies by Visits and Subcohorts (EAS)|SARS-CoV-2 Specific CD4+ Effector Memory T-cells,True,2024-12-11
NCT05170126,A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring,"ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring",RECRUITING,2022-08-08,2032-06-30,2032-06-30,2025-05-11,2021-12-27,OBSERVATIONAL,,1182.0,ESTIMATED,Bristol-Myers Squibb,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Ozanimod|Pregnancy|Outcomes|Obstetric|Infant,United States,Wilmington,North Carolina,3,,,Major congenital malformations,Minor congenital malformations|Pre-eclampsia|Eclampsia|Spontaneous abortion|Stillbirth|Elective termination|Preterm birth|Small for gestational age|Postnatal growth deficiency|Infant developmental deficiency|Perinatal death|Neonatal death|Infant death|Serious or opportunistic infant infection (SOI),False,
NCT06554340,"Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension",Targeting Vascular Mechanisms of Functional Outcomes Via Home-based Exercise Training Among Persons With Multiple Sclerosis Who Have Hypertension,RECRUITING,2025-04-15,2027-08,2027-08,2025-08-22,2024-08-15,INTERVENTIONAL,NA,80.0,ESTIMATED,"University of Massachusetts, Boston",OTHER,University of Illinois at Chicago|University of Alabama at Birmingham,OTHER|OTHER,Multiple Sclerosis|Hypertension,exercise|blood pressure|mobility|cognition,United States,Boston,Massachusetts,1,Home-based aerobic training,BEHAVIORAL,Information processing speed|Timed 25-Foot Walk,Blood pressure|Flow-mediated dilation|Forearm blood flow|Cardiorespiratory fitness,False,
NCT06676618,Effect of Multimodal Exercise Training in Patients With Multiple Sclerosis,Effect of Multimodal Exercise Training on Disease Activity and Functional Status in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2024-12-01,2026-12-01,2027-04-01,2024-11-07,2024-11-06,INTERVENTIONAL,NA,40.0,ESTIMATED,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Exercise|Physiotherapy|Degenerative diseases|Disease activity|Multimodal,Turkey (Türkiye),Istanbul,Buyukcekmece,1,Multimodal Exercise Training|Control Group,OTHER|OTHER,Multiple Sclerosis Functional Composite Test (The change between the initial value and the value after 3 months will be evaluated).|Functional Magnetic Resonance Imaging (fMRI) (The change between the initial value and the value after 3 months will be evaluated).|Brain-derived neurotrophic factor (BDNF) assessment (The change between the initial value and the value after 3 months will be evaluated).,The Expanded Disability Status Scale (EDSS) (The change between the initial value and the value after 3 months will be evaluated).|6 Minute Walk Test (6MWT) (The change between the initial value and the value after 3 months will be evaluated).|ActiGraph wGT3X-BT (The change between the initial value and the value after 3 months will be evaluated).|The Godin Leisure-Time Exercise Questionnaire (The change between the initial value and the value after 3 months will be evaluated).|Balance Assessment (The change between the initial value and the value after 3 months will be evaluated).|Fatigue Severity Scale (The change between the initial value and the value after 3 months will be evaluated).|Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) (The change between the initial value and the value after 3 months will be evaluated).,False,
NCT06721416,Comparing the Acute Effects of Different Exercise Approaches in Patients With Multiple Sclerosis,Comparing the Acute Effects and Cortical Hemodynamic Response of Different Exercise Approaches in Patients With Multiple Sclerosis: fNIRS Study,COMPLETED,2024-12-01,2025-07-30,2025-08-30,2025-09-17,2024-12-06,INTERVENTIONAL,NA,12.0,ACTUAL,Acibadem University,OTHER,,,Multiple Sclerosis,multiple sclerosis|aerobic exercise|virtual reality|fatigue|cognition,Turkey (Türkiye),Ataşehir,Istanbul,1,Traditional Aerobic Exercise|VR Based Aerobic Exercise|Conventional Exercise,OTHER|OTHER|OTHER,Energy Spent|Cortical Activity|Body Temperature|Electrodermal Activity|Cognitive Function|Cognitive Function|Cognitive Function|Physical Fatigue|Satisfaction Level satisfaction level Satisfaction Level|Late-term fatigue,,False,
NCT06355804,Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis,Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2024-04-29,2026-08-01,2026-12-01,2025-09-17,2024-04-09,INTERVENTIONAL,NA,52.0,ACTUAL,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,Physical activity|Behavior change|Behavioral intervention,United States,Chicago,Illinois,1,Physical activity condition|Waitlist condition,BEHAVIORAL|BEHAVIORAL,Physical Activity Behavior|Physical Activity Behavior|Physical Activity Level (Light physical activity)|Physical Activity Level (Moderate-to-vigorous physical activity)|Physical Activity Level (Daily step count),Health-related quality of Life|Health-related Quality of Life|Fatigue Severity|Depressive Symptoms|Anxiety,False,
NCT04856384,Effect of Variance on Error Correction During Coupling,Understanding the Effect of Variances on Precision in Predictive Coding When Walking to Music and Metronomes in Persons With Multiple Sclerosis With Progressive Subtypes.,COMPLETED,2021-02-01,2024-10-22,2024-12-31,2025-02-27,2021-04-23,INTERVENTIONAL,NA,13.0,ACTUAL,Hasselt University,OTHER,National MS Center Melsbroek|Revalidatie & MS Centrum Overpelt,OTHER|OTHER,Multiple Sclerosis|Progressive Multiple Sclerosis,,Belgium,Melsbroek,,2,synchronisation abilities,OTHER,"Motricity Index of dorsi flexors, knee extensors and hip flexors|Modified Aschowrth scale Hamstrings, Tricepts Surae, Quadricepts|Scale for the assessment and rating of ataxia|Dynamic gait index|Time up and Go test|6 minute walking test|Brief repeatable battery of Rao|Symbol digit mobility test|Stroop test 0|MS walking scale -12|Activities-specific balance confidence scale|Modified fatigue impact scale|Hospital Anxiety and Depression Scale|Dual task questionnaire|Perceptual tempo and rhythm judgements|Asynchrony|64 channel EEG measurement|Resultant Vector Length|Resultant Vector Length|Relative phase angle|Relative phase angle",Cadencce|Cadencce|Stride length|Stride length|Speed|Speed|Double Support|Double Support|Perceived cognitive and physical fatigue|Perceived cognitive and physical fatigue|Perceived motivation|Perceived motivation|Perceived walking speed|Perceived walking speed|64 channel EEG measurement (only conducted in 4 PwMS and HC)|64 channel EEG measurement (only conducted in 4 PwMS and HC),False,
NCT05019248,Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine,A Non-interventional Observation Study to Evaluate Immune Responses Following Seasonal Influenza Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Cladribine Tablets,UNKNOWN,2020-09-01,2021-12-31,2022-04-30,2021-08-24,2021-08-24,OBSERVATIONAL,,260.0,ESTIMATED,"Heinrich-Heine University, Duesseldorf",OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Vaccine Response Impaired",influenza vaccination|cladribine,Germany,Düsseldorf,North Rhine-Westphalia,1,Most recent vaccine to seasonal influenza,BIOLOGICAL,Proportion who achieve seroprotection,Fraction with 2-fold increase of HI titers|Fraction with 4-fold increase of HI titers|Seroconversion rate|Mean antibody titers|Cellular immune responses|Serum immunoglobulin subtypes|Influenza infections,False,
NCT03451955,The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS,The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging,COMPLETED,2018-01-19,2022-06-07,2022-06-16,2022-12-28,2018-03-02,INTERVENTIONAL,NA,103.0,ACTUAL,University of Copenhagen,OTHER,"Rigshospitalet, Denmark",OTHER,Optic Neuritis|Multiple Sclerosis|Clinically Isolated Syndrome,gluten|gluten free diet|blood brain barrier permeability|intestinal permeability|neuroinflammation|autoimmunity,Denmark,Copenhagen,Frederiksberg,2,Gluten-free diet,OTHER,Permeability of the blood brain barrier,Intestinal permeability|Intestinal absorption capacity|Counts of T cell subpopulations in peripheral blood and CSF|Macrophage activation in peripheral blood and CSF|Neuroinflammation|Bacterial translocation|Osteopontin as a marker of disease activity in multiple sclerosis|Enterocyte damage|Gut microbiota profiling,False,
NCT02612935,An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis,An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis,COMPLETED,2015-03,2017-02,2017-02,2017-05-25,2015-11-24,OBSERVATIONAL,,88.0,ACTUAL,"Lumos Labs, Inc.",INDUSTRY,Dignity Health,OTHER,Multiple Sclerosis (MS),,,,,0,Lumosity,DEVICE,"Performance Characteristics and Usability measures of Lumosity, as measured by Self-Report Descriptive Questionnaires","Efficacy of Lumosity in individuals with MS, as measured with the BPT|Efficacy of Lumosity in individuals with MS, as measured with the MSNQ|Efficacy of Lumosity in individuals with MS, as measured with the MOCA|Efficacy of Lumosity in individuals with MS, as measured with the MSIS-29.|Efficacy of Lumosity in individuals with MS, as measured with the BDI.|Engagement - as measured by number of unique days played and number of games played",False,
NCT02830074,Treatment of Sleep-disordered Breathing in Patients With SCI,Does Treatment of Sleep-Disordered Breathing Improve Functional Outcomes in SCI,COMPLETED,2017-05-01,2019-09-30,2020-03-30,2021-05-19,2016-07-12,INTERVENTIONAL,NA,73.0,ACTUAL,VA Office of Research and Development,FED,,,Spinal Cord Injury|Sleep-disordered Breathing|Spinal Cord Disease|Multiple Sclerosis,Sleep Apnea Syndromes|Spinal Cord Injuries|Sleep|Quality of life,United States,Detroit,Michigan,1,Best practices PAP + patient Education +ongoing Support and Training|Sleep Education,BEHAVIORAL|BEHAVIORAL,PAP Adherence|Subjective Sleep Quality Was Measured by The Pittsburgh Sleep Quality Index (PSQI),Quality of Life Was Measured by WHO-QOL BREF Questionnaire|Respiratory Function: Spirometry and Respiratory Muscle Force|Functional Status Was Measured by CHART Questionnaire.|Depressive Symptom Severity|Fatigue Symptoms|Epworth Sleepiness Scale,True,2021-04-22
NCT06239090,Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis,Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis.Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis,RECRUITING,2023-12-01,2024-06-30,2025-11-30,2024-02-02,2024-02-02,INTERVENTIONAL,NA,44.0,ESTIMATED,IRCCS Centro Neurolesi Bonino Pulejo,OTHER,,,Multiple Sclerosis|Mood Disorders|Cognitive Impairment,,Italy,Messina,,1,Rehacor-T|Sham Intervention,DEVICE|BEHAVIORAL,Neuropsychological assessment|Mood assessment,,False,
NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis",COMPLETED,2011-09-20,2015-05-12,2022-12-30,2024-03-08,2011-08-09,INTERVENTIONAL,PHASE3,835.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Phoenix,Arizona,165,Interferon beta-1a|Ocrelizumab-matching placebo|Ocrelizumab|Interferon beta-1a-matching placebo,DRUG|DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period,"Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period|Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment|Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment|Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks In Double Blind Period|Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period|Number of T1 Hypointense Lesions During the Double-Blind Treatment|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96 In Double Blind Period|Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96 In Double Blind Period|Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96 In Double Blind Period|Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96 In Double Blind Period|Number of Participants With Adverse Events (AEs)|Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC) In Double Blind Period|Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab In Double Blind Period",True,2017-07-18
NCT00645749,Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis,Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis,COMPLETED,2008-07,2015-08-13,2015-08-13,2019-02-06,2008-03-28,INTERVENTIONAL,PHASE1,17.0,ACTUAL,"University of Wisconsin, Madison",OTHER,National Multiple Sclerosis Society,OTHER,Relapsing Remitting Multiple Sclerosis,,United States,Madison,Wisconsin,1,Helminth ova,BIOLOGICAL,"MS activity, as judged by the number of new gadolinium-enhancing lesions on serial MRI scans",,False,
NCT03942952,PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.,PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.,COMPLETED,2019-10-22,2023-06-30,2023-06-30,2023-09-05,2019-05-08,OBSERVATIONAL,,49.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting|Neuromyelitis Optica|Acute Disseminated Encephalomyelitis|Transverse Myelitis",Multiple Sclerosis|NMO|anti-MOG|Acute Disseminated Encephalolmyelitis,United States,Dallas,Texas,1,,,"MRI Brain without contrast|MRI Brain without contrast|Change in Score of Delis-Kaplan Executive Function System (D-KEFS) Color|Change in Score of Word Interference Test (CWIT)|Change in Score of Symbol Digit Modalities (SDMT)- Oral Version|Change in Score of Beery-Buktencia Developmental Test of Visual-Motor Integration, Sixth Edition (VMI-6)|Change in Score of Wechsler Intelligence Scale for Children-5th edition (WISCV)|Change in Score of Wechsler Adult Intelligence Scale-Fourth edition (WAIS-IV) Digits Forward|Change in Score of WISC-V or WAIS-IV Digits Backward|Change in Score of California Verbal Learning Test- Children's Version (CVLT-C) or California Verbal Learning Test-Second Edition (CVLT-II)|Change i Score of D-KEFS Letter and Category Fluency|Change in Score of WASI-II|Change in Score of Woodcock-Johnson Tests of Achievement Letter Word identification|Change in Score of Reading Fluency|Change in Score of Calculation|Change in Score of Math Fluency|Change in Score of Word Attack|Change in Score of Grooved Pegboard|Change in Score of Trail Making Test, Part A and B|Change in Score of Conners Continuous Performance Test 3rd Edition",Change in Examination of Optical Coherence Tomography|Change in PROMIS Mobility score|Change in PROMIS Pain score|Change in PROMIS Peer relationship score|Change in PROMIS Stress score|Change in PROMIS Upper extremity movement score|Change in score of 25 foot timed walk|Change in score of 6 minute timed walk|Change in score of Hauser Ambulation Index|Change in score of Multiple Sclerosis Functional Capacity (MSFC)|Change in score of Modified Rankin Scale,False,
NCT05084638,"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.","AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.",ACTIVE_NOT_RECRUITING,2022-01-25,2025-02-04,2026-02-16,2025-04-06,2021-10-20,INTERVENTIONAL,PHASE4,180.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapse Remitting Multiple Sclerosis,early relapsing multiple sclerosis|ofatumumab|healthy control|treatment naïve|young adult population|MS-related disability|biomarker|MRI,United States,Chandler,Arizona,36,Ofatumumab,DRUG,Percentage of participants achieving NEDA-3 (No Evidence of Disease Activity-3),Number of relapses|Number of participants that were 3-month Disability Worsening-free|Number of participants with NEDA (No Evidence of Disease Activity) - Clinical|Number of participants with NEDA (No Evidence of Disease Activity) - Radiological|Change from Baseline in Gd+ lesion count|Change from Baseline in Gd+ lesion volume|Change from Baseline in new/enlarging T2 lesion count|Change from Baseline in T2 lesion volume|Change from Baseline for NeuroQOL|Change from Baseline for Patient Determined Disease Steps (PDDS)|Brain volume loss (BVL) assessment (whole brain and regional)|Number of participants with treatment emergent adverse events|Change from Baseline in new unenhancing T1 lesion number|Change from Baseline in T1 unenhancing lesion volume,False,
NCT06330324,Reproductive Options in Inherited Skin Diseases,Reproductive Options in Inherited Skin Diseases: an International Observational Cohort Study,ENROLLING_BY_INVITATION,2024-01-01,2026-09-01,2026-09-01,2025-05-18,2024-03-26,OBSERVATIONAL,,650.0,ESTIMATED,Maastricht University Medical Center,OTHER,,,Ichthyosis|Palmoplantar Keratoses|Epidermolysis Bullosa|Ectodermal Dysplasia|Basal Cell Nevus Syndrome|Birt-Hogg-Dube Syndrome|Tuberous Sclerosis|Xeroderma Pigmentosum|Cutis Laxa|Albinism,,Netherlands,Maastricht,Limburg,1,,,Assessment of clinical outcomes of reproductive options,,False,
NCT05560880,High Intensity Interval Gait Training in Multiple Sclerosis,The Effects of High Intensity Interval Gait Training vs. Moderate Intensity Continuous Gait Training in Multiple Sclerosis,UNKNOWN,2022-09-01,2023-12-31,2023-12-31,2022-10-06,2022-09-30,INTERVENTIONAL,NA,30.0,ESTIMATED,Hunter College of City University of New York,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,High Intensity Interval Gait training|Moderate Intensity Interval gait training,BEHAVIORAL|BEHAVIORAL,Change in Six minute walk test time from before to after the intervention,Change in Functional gait assessment score from before to after the intervention|Change in Hand held dynamometry values from before to after the intervention|Change in Multiple sclerosis impact scale 29 from before to afterthe intervention,False,
NCT02849782,Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.,Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances,COMPLETED,2014-02-04,2019-03-01,2019-03-01,2021-02-02,2016-07-29,INTERVENTIONAL,PHASE4,89.0,ACTUAL,Centre Hospitalier Universitaire de Besancon,OTHER,,,Multiple Sclerosis,Gait analysis|Fampridine|Fatigue|Daily activity|Cognition,France,Besançon,,1,Fampridine,DRUG,6 Minute Walk Test (6MWT),"Verbal fluencies|Verbal fluencies|Verbal fluencies|Verbal fluencies|Verbal fluencies|Symbol Digit Modalities Test|Symbol Digit Modalities Test|Symbol Digit Modalities Test|Symbol Digit Modalities Test|Symbol Digit Modalities Test|Modified Fatigue Impact Scale (mFIS)|Modified Fatigue Impact Scale (mFIS)|Modified Fatigue Impact Scale (mFIS)|Modified Fatigue Impact Scale (mFIS)|Modified Fatigue Impact Scale (mFIS)|Fatigue Severity Scale (FSS)|Fatigue Severity Scale (FSS)|Fatigue Severity Scale (FSS)|Fatigue Severity Scale (FSS)|Fatigue Severity Scale (FSS)|Multiple Sclerosis Walking Scale 12 (MSWS12)|Multiple Sclerosis Walking Scale 12 (MSWS12)|Multiple Sclerosis Walking Scale 12 (MSWS12)|Multiple Sclerosis Walking Scale 12 (MSWS12)|Multiple Sclerosis Walking Scale 12 (MSWS12)|""PERception de la Sclérose En Plaques et de ses Poussées"" (PERSEPP)|""PERception de la Sclérose En Plaques et de ses Poussées"" (PERSEPP)|""PERception de la Sclérose En Plaques et de ses Poussées"" (PERSEPP)|""PERception de la Sclérose En Plaques et de ses Poussées"" (PERSEPP)|""PERception de la Sclérose En Plaques et de ses Poussées"" (PERSEPP)|Physical activity in real life condition|Physical activity in real life condition|Timed 25 Walk Test (T25WT)|Timed 25 Walk Test (T25WT)|Timed 25 Walk Test (T25WT)|Timed 25 Walk Test (T25WT)|Timed 25 Walk Test (T25WT)|Timed Up and Go test (TUG)|Timed Up and Go test (TUG)|Timed Up and Go test (TUG)|Timed Up and Go test (TUG)|Timed Up and Go test (TUG)|6 Minute Walk Test (6MWT)|6 Minute Walk Test (6MWT)|6 Minute Walk Test (6MWT)|6 Minute Walk Test (6MWT)",False,
NCT04586010,A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),"A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2021-03-17,2026-01-27,2027-11-30,2025-08-27,2020-10-14,INTERVENTIONAL,PHASE3,746.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Relapsing Multiple Sclerosis,,United States,Birmingham,Alabama,160,Fenebrutinib|Teriflunomide|Placebo,DRUG|DRUG|DRUG,Annualized Relapse Rate (ARR),"Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12)|Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)|Time to Onset of 12-week Confirmed Disability Progression (CDP12)|Time to Onset of 24-week Confirmed Disability Progression (CDP24)|Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions as Detected by Magnetic Resonance Imaging (MRI)|Percentage Change in Total Brain Volume from Week 24 as Assessed by MRI|Change in Participant-Reported Physical Impacts of Multiple Sclerosis (MS) Measured by the Multiple Sclerosis, 29-Item [MSIS-29] Physical Scale|Time to Onset of 12-week Confirmed 4-point worsening in Symbol Digit Modality Test (SDMT) Score|Change from Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)|Percentage of Participants with Adverse Events (AEs)|Plasma Concentrations of Fenebrutinib at Specified Timepoints|Time to Onset of Composite 12-week Confirmed Progression Independent of Relapse Activity (cPIRA12)",False,
NCT00047580,Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.,"A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity",COMPLETED,2002-06,,2002-09,2015-12-14,2002-10-10,INTERVENTIONAL,PHASE3,120.0,,Elan Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Muscle Spasticity|Spinal Cord Injury|Stroke,Spasticity|spasticity secondary to Multiple Sclerosis|Spinal Cord Injury|Stroke,United States,Tucson,Arizona,16,tizanidine hydrochloride capsule,DRUG,,,False,
NCT02142946,Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study,Quantified Balance Measures During Stance and Gait: Clinical Relevance for Multiple Sclerosis Patients in Comparison to Patients With Inner Ear Balance Problems. A Longitudinal Clinical Study.,RECRUITING,2018-04-01,2025-12,2025-12,2025-04-06,2014-05-20,OBSERVATIONAL,,300.0,ESTIMATED,"University Hospital, Basel, Switzerland",OTHER,,,Balance Control,,Switzerland,Basel,,1,,,Change in balance during stance and gait,,False,
NCT03887546,Inspiratory Muscle Training in Multiple Sclerosis,Effects of a 12-week Inspiratory Muscle Training Program With Low Resistance in Patients With Multiple Sclerosis,UNKNOWN,2019-04-23,2019-07-24,2019-09-15,2019-03-25,2019-03-25,INTERVENTIONAL,NA,67.0,ESTIMATED,University of Salamanca,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Rehabilitation|Respiration|Breathing exercise|Fatigue,,,,0,Inspiratory muscle trainer|Respiratory exercise,DEVICE|PROCEDURE,Maximal inspiratory pressure (MIP)|Maximal expiratory pressure (MEP),Dyspnea|Maximum voluntary ventilation (MVV)|Forced expiratory volume in the first second (FEV1)|Peak expiratory flow (PEF)|Mean expiratory flow (FEF25-75)|Vital capacity (VC)|Tidal volume (VT)|Forced vital capacity (FVC),False,
NCT03862313,Repetitive Transorbital Alternating Current Stimulation in Acute Autoimmune Optic Neuritis,"Assessing Repetitive Transorbital Alternating Current Stimulation in Acute Autoimmune Inflammatory Optic Neuritis Using the NextWave® 1.1 System: A Prospective, Randomized, Patient-blinded, Sham-controlled Pilot Study",TERMINATED,2019-10-14,2019-12-27,2019-12-27,2021-03-30,2019-03-05,INTERVENTIONAL,NA,2.0,ACTUAL,University of Zurich,OTHER,"University Hospital, Zürich|Swiss MS Society|Data Management, Clinical Trials Center, Zurich, Switzerland",OTHER|UNKNOWN|UNKNOWN,Acute Autoimmune Inflammatory Optic Neuritis,optic neuritis|multiple sclerosis|repetitive transorbital alternating current stimulation|optical coherence tomography|low-contrast visual acuity,Switzerland,Zurich,,1,active-rtACS treatment|sham-rtACS treatment,DEVICE|DEVICE,The primary functional outcome measure will be low-contrast visual acuity [LogMAR] at 16 weeks (3 month follow-up) in ON eyes.|The primary structural outcome measure will be the mean change in macular ganglion cell and inner plexiform layer thickness [µm] of the affected ON eye at 16 weeks in comparison to baseline of the unaffected contralateral NON eye (pre-treatment).|The primary safety outcome measure will be the total number of adverse events during the entire study period,Low-contrast visual acuity [LogMAR] at 4 (post-treatment) weeks in ON eyes.|The mean change in macular ganglion cell and inner plexiform layer thickness [µm] of the affected ON eye at 4 weeks in comparison to baseline of the unaffected contralateral NON eye (pre-treatment).|High-contrast visual acuity [LogMAR] at 16 weeks (3 month follow-up) in ON eyes.|High-contrast visual acuity [LogMAR] at 4 weeks (post-treatment) in ON eyes.|Colour vision [tritan] at 16 weeks (3 month follow-up) in ON eyes.|Colour vision [tritan] at 4 weeks (post-treatment) in ON eyes.|Visual field testing [dB] at 16 weeks (3 month follow-up) in ON eyes.|Visual field testing [dB] at 4 weeks (post-treatment) in ON eyes.|Recovery of pattern-reversal visual evoked potential conduction velocity of the affected optic nerve [ms] compared to the intra-individual baseline of the unaffected optic nerve at 16 weeks (3 month follow-up).|Patient-reported vision-related quality of life assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) at 16 weeks (3 month follow-up).|Patient-reported vision-related quality of life assessed by the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) at 4 weeks (post-treatment).|The mean change in peripapillary retinal nerve fibre layer (pRNFL) thickness [µm] of the affected ON eye at 16 weeks (3 month follow-up) in comparison to baseline of the contralateral NON eye.|The mean change in peripapillary retinal nerve fibre layer (pRNFL) thickness [µm] of the affected ON eye at 4 weeks (post-treatment) in comparison to baseline of the contralateral NON eye.|The mean change in macular inner nuclear layer (INL) thickness [µm] of the affected ON eye at 16 weeks (3 month follow-up) in comparison to baseline of the contralateral NON eye.|The mean change in macular inner nuclear layer (INL) thickness [µm] of the affected ON eye at 4 (post-treatment) weeks in comparison to baseline of the contralateral NON eye.,False,
NCT03606460,A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS),"A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis",COMPLETED,2018-09-14,2019-05-31,2019-05-31,2020-06-29,2018-07-30,INTERVENTIONAL,PHASE3,141.0,ACTUAL,"Genentech, Inc.",INDUSTRY,,,Multiple Sclerosis,,United States,Aurora,Colorado,5,Ocrelizumab Dose 1|Ocrelizumab Dose 2 and Dose 3,DRUG|DRUG,Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab,Percentage of Participants With IRRs|Percentage of Participants With IRRs Treated With the 300 mg Shorter Dose of Ocrelizumab,True,2020-06-29
NCT02939079,Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients,"Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-α , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2015-04,2016-09,2016-10,2019-05-14,2016-10-19,INTERVENTIONAL,PHASE2|PHASE3,50.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,Shiraz University of Medical Sciences,OTHER,Multiple Sclerosis,Multiple Sclerosis|Fingolimod|Fish Oil,,,,0,Fingolimod|Fish Oil|Placebo (for Fish Oil),DRUG|DIETARY_SUPPLEMENT|DRUG,Serum Level of TNF-α|Serum Level of IL1b|Serum Level of IL6|Serum Level of IFN-gamma|Serum Level of TNF-α|Serum Level of TNF-α|Serum Level of IL1b|Serum Level of IL1b|Serum Level of IL6|Serum Level of IL6|Serum Level of IFN-gamma|Serum Level of IFN-gamma,,True,2019-05-14
NCT00001465,Study of the Disease Process of Lymphangioleiomyomatosis,Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM),RECRUITING,1995-12-18,,,2025-09-24,1999-11-04,OBSERVATIONAL,,2000.0,ESTIMATED,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,,,Lung Disease|Pneumothorax|Tuberous Sclerosis|Lymphangioleiomyomatosis,Smooth Muscle Proliferation|Bronchoscopy|Female|Pneumothorax|Tuberous Sclerosis|Natural History,United States,Bethesda,Maryland,1,Toshibia Aquilion One CT,DEVICE,Define the clinical course of the disease LAM andelucidate the pathogenesis of LAM at cellular and molecular levels,,False,
NCT04563832,Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit,Self-administered Hyperinsufflation Chest Mobilization Randomized Study on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit,UNKNOWN,2021-11-25,2022-10,2022-10,2022-04-12,2020-09-24,INTERVENTIONAL,NA,84.0,ESTIMATED,Assistance Publique - Hôpitaux de Paris,OTHER,,,Multiple Sclerosis,,France,Garches,Haut de Seine,1,Standardized respiratory management program|CoughAssist,OTHER|OTHER,"Effectiveness of a self-administered automated hyperinsufflation technique for 2 years, versus standard management, on respiratory infection risk within 2 years after randomization, in patients with MS.","Effect of COUGH-ASSIST on slowing the decline in respiratory function,|Functional effectiveness of COUGH-ASSIST|Tolerance and compliance with COUGH-ASSIST,|Effectiveness of COUGH-ASSIST in reducing the risk of serious respiratory infection",False,
NCT02369926,Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis,"Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS), Stage 1",UNKNOWN,2014-11,2018-06,,2017-10-12,2015-02-24,INTERVENTIONAL,PHASE2,20.0,ESTIMATED,Transparency Life Sciences,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",multiple sclerosis|telemedicine|remote monitoring|lisinopril,United States,New York,New York,1,Multiple Sclerosis Functional Composite|Mobile Multiple Sclerosis Functional Composite,PROCEDURE|PROCEDURE,Safety of mMSFC Tally|MSFC Score Comparison|Mobile Timed Walk Test Value Comparison|Mobile 9-hole Peg Test Time Comparison|Mobile Paced Auditory Serial Addition Test Score Comparison,,False,
NCT05798520,A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS),"A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis",RECRUITING,2023-07-25,2027-09-07,2027-09-07,2025-06-22,2023-04-04,INTERVENTIONAL,PHASE2,275.0,ESTIMATED,Biogen,INDUSTRY,,,Relapsing Forms of Multiple Sclerosis,Multiple Sclerosis|Diroximel fumarate|BIIB091,United States,Scottsdale,Arizona,77,BIIB091|DRF|Placebo,DRUG|DRUG|DRUG,Part 1: Number of Participants With Adverse Events (AEs)|Part 1: Number of Participants With Serious Adverse Events (SAEs)|Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions,"Part 1: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions|Part 1: Cumulative Number of New or Enlarging T2 Hyperintense Lesions|Part 1: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions|Part 1: Mean Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF), RR, PR, QRS, and QT Intervals|Part 1: Number of Participants With Change From Baseline in Heart Rate|Part 1: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Part 2: Cumulative Number of New or Enlarging T2 Hyperintense Lesions|Part 2: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions|Part 2: Number of Participants With AEs|Part 2: Number of Participants With SAEs|Part 2: Number of Participants With Change From Baseline in QTcF, RR, PR, QRS, and QT intervals|Part 2: Number of Participants With Change From Baseline in Heart Rate|Part 2: Number of Participants With ECG Abnormalities as Assessed by 12-Lead ECG Measurements",False,
NCT06782724,Psilocybin Therapy for Psychological Distress in Palliative Patients,"The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients with COPD, ALS, MS, or APD.",NOT_YET_RECRUITING,2025-03-01,2027-01-01,2028-01-01,2025-01-20,2025-01-20,INTERVENTIONAL,PHASE2,108.0,ESTIMATED,University Medical Center Groningen,OTHER,"HumanKindLabs|University of Copenhagen|CTC Clinical Trial Consultants AB|OPEN Foundation|IESE Business School|Uppsala University|The Champalimaud Centre, Lisbon, Portugal|Stockholm University|University of Groningen, The Netherlands|National Institute of Mental Health, Czech Republic|European Association for Palliative Care (EAPC)|Madopa|Bispebjerg Hospital, Copenhagen, Denmark|European Association of Neurological Associations (EFNA)|29k International AB|Lung Alliance Netherlands|European Psychiatric Association|Norrsken Mind",UNKNOWN|OTHER|INDUSTRY|UNKNOWN|UNKNOWN|OTHER|UNKNOWN|OTHER|UNKNOWN|OTHER|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN|UNKNOWN,COPD (Chronic Obstructive Pulmonary Disease)|ALS (Amyotrophic Lateral Sclerosis)|MS (Multiple Sclerosis)|Major Depressive Disorder (MDD)|Atypical Parkinson Disease,psilocybin|therapy|palliative|care|palliative care|end-of-life distress|depression|psychological distress|psypal|copd|als|ms|apd|chronic obstructive pulmonary disorder|amyotrophic lateral sclerosis|multiple sclerosis|major depressive disorder|atypical parkinson disease|existential distress,,,,0,Psilocybin therapy,DRUG,Depressive symptoms (MADRS),"Response rate|End-of-life anxiety|Anxiety and depression (symptoms)|Demoralization|Impact on Quality of life|Caregiver burden|Daily functioning in COPD|Health-related quality of life in COPD|Health-related quality of life in ALS|Functional status in ALS|Health-related quality of life in MS|Health-related quality of life in APD|Motor and non-motor symptoms in APD|Functional magnetic resonance imaging (fMRI) in APD|Incidence, severity, and frequency of (serious) adverse events following psilocybin therapy",False,
NCT04822623,Imaging Evaluation of Central Nervous Autoimmune Diseases,Computer Aided Imaging Evaluation of Central Nervous System Autoimmune Diseases,UNKNOWN,2021-05-01,2021-12-31,2022-07-01,2021-03-30,2021-03-30,OBSERVATIONAL,,300.0,ESTIMATED,Qilu Hospital of Shandong University,OTHER,,,MS (Multiple Sclerosis)|NMO Spectrum Disorder,,,,,0,MRI,DIAGNOSTIC_TEST,Results of MRI data analysis,,False,
NCT01848327,Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis,A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.,COMPLETED,2013-02,2017-12,2017-12,2018-01-25,2013-05-07,INTERVENTIONAL,NA,124.0,ACTUAL,University of Miami,OTHER,National Multiple Sclerosis Society|Cerecin,OTHER|INDUSTRY,Relapsing Remitting MS|Secondary Progressive MS|Primary Progressive MS,Cognition|Neuropsychology|Multiple Sclerosis,United States,Miami,Florida,1,Caprylic Triglyceride|Placebo,DIETARY_SUPPLEMENT|DIETARY_SUPPLEMENT,Change in Total Learning (Trials 1-5) on the California Verbal Learning Test-2nd Edition (CVLT-II) (range from 0 to 80)|Change in Symbol Digit Modalities Test (SDMT) (range from 0-110)|Number of participants reporting adverse events,Change in EDSS|Change in Beck Depression Inventory -2nd edition (BDI-II)|Change in Multiple Sclerosis Quality of Life Inventory (MSQOL-54)|Change in Modified Fatigue Impact Scale (MFIS),False,
NCT07132775,"Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain","Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain",RECRUITING,2025-07-23,2027-07,2027-07,2025-09-09,2025-08-20,INTERVENTIONAL,NA,15.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,Otto Bock Healthcare Products GmbH,INDUSTRY,Multiple Sclerosis|Fibromyalgia|Neurologic Disorder|Neuromuscular Disorders,,United States,Chicago,Illinois,1,Active full-body stimulation|Sham full-body stimulation,DEVICE|OTHER,Berg Balance Scale,Manual Muscle Test|Modified Ashworth Scale|10 Meter Walk Test|6 Minute Walk Test|Timed Up and Go|Twelve-Item Multiple Sclerosis Walking Scale|Falls Efficacy Scale|Multiple Sclerosis International Quality of Life Questionnaire|Clinical Global Impressions Scale,False,
NCT03827928,LoveYourBrain Yoga for Multiple Sclerosis,"The Acceptability, Feasibility, and Impact of a Group-based Yoga and Psychoeducation Program for Community-dwelling Adults With Multiple Sclerosis: A Randomized, Cross-over Pilot Study",COMPLETED,2019-07-01,2019-12-30,2019-12-30,2020-02-05,2019-02-04,INTERVENTIONAL,NA,15.0,ACTUAL,Dartmouth-Hitchcock Medical Center,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Fatigue|Anxiety|Depression,United States,Lebanon,New Hampshire,1,Yoga/meditation,BEHAVIORAL,Feasibility of conducting a yoga intervention study,Change in subject self-rated fatigue|Change in subject self-rated self-efficacy|Change in subject self-rated anxiety|Change in subject self-rated depression|Change in subject self-rated positive affect|Change in subject cognition/processing speed|Change in subject self-rated sleep disturbance|Change in subject self-rated pain interference|Change in subject self-rated quality of life|Change in subject self-rated cognitive function|Satisfaction rating of 6-week yoga program on a scale of 1 - 10,False,
NCT07151534,"Body Awareness, Trunk Stability, and Arm Function in MS","Investigation of the Relationship Between Body Awareness, Trunk Stabilization, and Upper Extremity Functionality in Individuals With Multiple Sclerosis",RECRUITING,2025-08-06,2026-01-06,2026-03-06,2025-09-03,2025-09-03,OBSERVATIONAL,,50.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,body awareness|upper extremity|trunk stabilization|multiple sclerosis,Turkey (Türkiye),Ankara,Altındağ,1,,,"Body Awareness Questionnaire|Body Awareness Rating Questionnaire|Upper Extremity Functionality-Grip strength|Upper Extremity Functionality-Pinch strength|Upper Extremity Functionality-Nine Hole Peg Test (9HPT)|Trunk Stabilization- Trunk Impairment Scale (TIS),|Trunk Stabilization-plank endurance test|Trunk Stabilization-side bridge test|Trunk Stabilization-Modified Biering-Sorensen|Trunk Stabilization-Trunk flexor test|Trunk Stabilization-Sit up test|Trunk Stabilization-Modifiye push up test",,False,
NCT04002934,Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis,"A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis",COMPLETED,2019-09-10,2025-05-13,2025-05-20,2025-06-08,2019-07-01,INTERVENTIONAL,PHASE2,63.0,ACTUAL,"Riley Bove, MD",OTHER,,,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",MS|RRMS|Remyelination|Repair|Multiple Sclerosis|SERM|Estrogen|BZA|Bazedoxifene|Myelin Repair|Conbriza,United States,San Francisco,California,1,Bazedoxifene Acetate,DRUG,Myelin Water Fraction (MWF) on MRI,Changes in BICAMS scores|Changes in MSFC scores|Changes in BICAMS scores|Changes in MSFC scores|Myelin Water Fraction (MWF) on MRI|Visual Evoked Potential (VEP) P100 Latency|Visual Evoked Potential (VEP) P100 Latency|Novel Digital Measures of Cognition|FitBit Activity|Serum Neurofilament Light Chain (NFL) levels|Expanded Disability Status Scale (EDSS)|Bladder Control Scale (BLCS)|Bowel Control Scale (BWCS)|Pittsburgh Sleep Quality Index (PSQI)|12-Item Multiple Sclerosis Walking Scale (MSWS-12)|Center for Epidemiological Studies Depression Scale (CESD)|Modified Fatigue Impact Score (MFIS)|36-Item Short Form Survey (SF36)|Visual Function Questionnaire (VFQ25)|Total T2 Lesion Volume|Number of New/Enlarging T2 Lesions|Levels of Brain Atrophy|Timed Up and Go (TUG) test,False,
NCT02157064,Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis,Autologous Adipose Stromal Vascular Fraction Outcomes Research Study,UNKNOWN,2014-05,2019-05,2019-05,2018-08-31,2014-06-05,OBSERVATIONAL,,221.0,ACTUAL,StemGenex,INDUSTRY,,,Multiple Sclerosis,,United States,San Diego,California,1,,,Change from Baseline in Overall Quality of Life Over the Course of a 12 Month Period as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI),Change from Baseline in Overall General Quality of Life Over the Course of a 12 Month Period as Measured by the Health Status Questionnaire (SF-36)|Change from Baseline in Fatigue Over the Course of a 12 Month Period as Measured by the Modified Fatigue Impact Scale (MFIS)|Change from Baseline in Pain and Other Sensory Symptoms Over the Course of a 12 Month Period as Measured by the MOS Pain Effects Scale (PES)|Change from Baseline in Sexual Satisfaction Over the Course of a 12 Month Period as Measured by the Sexual Satisfaction Scale (SSS)|Change from Baseline in Bladder Control Over the Course of a 12 Month Period as Measured by the Bladder Control Scale (BLCS)|Change from Baseline in Bowel Control Over the Course of a 12 Month Period as Measured by the Bowel Control Scale (BWCS)|Change from Baseline in Visual Problems Over the Course of a 12 Month Period as Measured by the Impact of Visual Impairment Scale (IVIS)|Change from Baseline in Cognitive Problems Over the Course of a 12 Month Period as Measured by the Perceived Deficits Questionnaire (PDQ)|Change from Baseline in Emotional Distress Over the Course of a 12 Month Period as Measured by the Mental Health Inventory (MHI)|Change from Baseline in Social Support Over the Course of a 12 Month Period as Measured by the Modified MOS Social Support Survey (MSSS),False,
NCT05197699,Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study,"A Multicenter, Prospective Cohort Study to Document the Immunization Status of MS Patients in Germany With Focus on Anti-SARS-CoV-2 Vaccination Response",TERMINATED,2021-07-01,2023-09-30,2023-09-30,2024-04-17,2022-01-19,OBSERVATIONAL,,160.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis (MS),SARS-Cov2 vaccination,Germany,Bamberg,,12,,,Number of Participants who Developed an Immune Response to Their Last SARS-CoV-2-Vaccination,Number of Participants who Retained an Immune Response to Their Last SARS-CoV-2-Vaccination|Change From Baseline in SARS-CoV-2 Spike Immunoglobulin A (IgA) Levels|Change From Baseline in SARS-CoV-2 Spike Immunoglobulin G (IgG) Levels|Change From Baseline in SARS-CoV-2-Nucleocapsid Protein (NCP) IgG Levels|Number of Participants who Developed an Immune Response to Their SARS-CoV-2-Vaccination|Number of Participants by Applied SARS-CoV-2 Vaccine and Vaccination Cycle|Number of Participants per Vaccination Cycle|Number of Participants with the Tolerability to the Applied Vaccine According to the Predefined Categories,False,
NCT01108887,"An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.","Assessment of Adherence, Effectiveness & Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.",COMPLETED,2009-09,2013-01,2013-01,2013-09-17,2010-04-22,OBSERVATIONAL,,912.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,"Merck Serono S.A., Geneva",INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Relapsing-Remitting|RebiSmart|Rebif|Interferon beta-1a",Netherlands,Breda,,1,,,Adherence to treatment,Effectiveness and convenience of treatment|Safety of treatment,False,
NCT03500328,Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial,"A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2018-05-02,2026-08-01,2026-08-01,2025-05-30,2018-04-18,INTERVENTIONAL,NA,900.0,ACTUAL,Johns Hopkins University,OTHER,Patient-Centered Outcomes Research Institute|National Multiple Sclerosis Society,OTHER|OTHER,"Multiple Sclerosis, Relapsing-Remitting",,United States,Birmingham,Alabama,47,"Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod",OTHER|OTHER,Time to sustained disability progression|Change in Overall Burden of MS,Patient-Determined Disease Steps (PDDS)|Multiple Sclerosis Functional Composite (MSFC) Composite Score|Timed 25 Foot Walk Test|Nine-hole Peg Test|Paced Auditory Serial Addition Test (PASAT)|Low contrast visual acuity|Patient-reported incomplete relapse recovery|Neurologic exam-based incomplete relapse recovery|Cognition using Symbol Digit Modality Test (SDMT)|Multiple Sclerosis Impact Scale (MSIS-29)|Quality of Life in Neurological Disorders (Neuro-QoL): Anxiety Subscale|Quality of Life in Neurological Disorders (Neuro-QoL): Depression Subscale|Quality of Life in Neurological Disorders (Neuro-QoL): Fatigue Subscale|Quality of Life in Neurological Disorders (Neuro-QoL): Upper Extremity Function|Quality of Life in Neurological Disorders (Neuro-QoL): Lower Extremity Function|Quality of Life in Neurological Disorders (Neuro-QoL): Cognitive Function|Quality of Life in Neurological Disorders (Neuro-QoL): Positive Affect/Well-being|Quality of Life in Neurological Disorders (Neuro-QoL): Sleep Disturbance|Quality of Life in Neurological Disorders (Neuro-QoL): Ability to Participate in Social Roles and Activities|Quality of Life in Neurological Disorders (Neuro-QoL): Satisfaction with Social Roles and Activities|Quality of Life in Neurological Disorders (Neuro-QoL): Stigma|Employment status|Marital status|Serious Adverse Events (SAEs)|Adverse event resulting in a decision to change disease-modifying therapy|Severe COVID-19 Infection,False,
NCT02568111,Brimonidine Tartrate for the Treatment of Injection Related Erythema,Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE),WITHDRAWN,2016-02,2016-08,2016-08,2016-04-25,2015-10-05,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing-Remitting Multiple Sclerosis (RRMS),erythema|PLEGRIDY|injection site reaction (ISR)|MS|RRMS,,,,0,peginterferon beta-1a|brimonidine tartrate|Vehicle Gel,DRUG|DRUG|DRUG,Change in either Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA) scale measured as at least 1-grade improvement on CEA and/or at least 1-grade improvement on PSA scale assessed by the physician and participant,Composite change in both CEA and PSA scale measured as at least 1-grade improvement on CEA and 1-grade improvement on PSA respectively|Composite change in both CEA and PSA scale measured as at least 2-grade improvement on CEA and 2-grade improvement on PSA|Participant's self-assessment of satisfaction with the overall appearance of their skin by using a Patient's Assessment of Appearance (PAA) grading scale,False,
NCT03674099,Imatinib for Multiple Sclerosis (MS) Relapses,"Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study",UNKNOWN,2018-10-01,2022-12-31,2023-07-30,2021-08-02,2018-09-17,INTERVENTIONAL,PHASE2,200.0,ESTIMATED,Tomas Olsson,OTHER,The Swedish Research Council,OTHER_GOV,Multiple Sclerosis,Multiple Sclerosis relaps|Imatinib|Methylprednisolone,Denmark,Copenhagen,,14,Imatinib Mesylate|Methylprednisolone,DRUG|DRUG,Functional system score (FSS) change in the most worsened FSS after 28 days due to the acute relapse,"Functional system score (FSS) change between baseline and week 12 in the most worsened FSS due to the acute relapse|Mean expanded disability status scale (EDSS) change between baseline and day 28|Mean change in 9-hole peg test (evaluates upper limb function) between baseline and day 28|Mean change in timed 25- walk between baseline and day 28|Mean change in symbol digital modality test (SDMT) between baseline and day 28|Mean change in Multiple Sclerosis Impact Scale (MSIS-29; MS-specific quality of life (QoL) scale) between baseline and day 28|Mean change in EQ5D (EuroQol 5 dimensions) (general QoL) between baseline and day 28.|Any difference in number of new brain MRI lesions at day 14 with regards to the baseline, comparing the two drugs|Any difference in number of new brain MRI lesions at day 28 with regards to the baseline, comparing the two drugs",False,
NCT06714487,Cognitive Stimulation in Patients With Sclerosis Multiple,JUGUEMOS - Cognitive Stimulation Through Games : a New Active Aging Approach to Enhance Users' Everyday Challenges Sclerosis Multiple,COMPLETED,2016-02,2016-09,2017-05,2024-12-03,2024-12-03,INTERVENTIONAL,NA,80.0,ACTUAL,Institut Investigacio Sanitaria Pere Virgili,OTHER,,,Multiple Sclerosis,Multiple sclerosis|play and Playthings|cognitive therapy,,,,0,cognitive stimulation through games,OTHER,"Capacity to stimulate the functions cognitive, is why cognitive stimulation through strategies and neuropsychological specific set of board games, improve cognitive performance in patients with RRMS and PMSC .","Positive social interaction generated by the group reinforcement groups treatment will lead to improved mood of its participants.|Cognitive improvement achieved after participation in a group of cognitive stimulation through strategies and neuropsychological games, improve the quality of life Patients with RRMS and SPMS .",False,
NCT01659593,Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients,Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.,UNKNOWN,2012-09,2016-09,2018-06,2016-03-08,2012-08-08,INTERVENTIONAL,NA,140.0,ESTIMATED,"Central Hospital, Nancy, France",OTHER,"University Hospital, Strasbourg, France|Centre Hospitalier Universitaire Dijon|Centre Hospitalier Universitaire de Besancon",OTHER|OTHER|OTHER,Cognitive Disorders|Multiple Sclerosis,cognitive disorders|multiple sclerosis|neuropsychology,France,Nancy,,1,procog|Placebo,OTHER|OTHER,cognitive function measured by SRT-List score,quality of life measured by MusiQol,False,
NCT02035514,Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis,COMPLETED,2013-12,2016-07,2016-07,2016-12-15,2014-01-14,INTERVENTIONAL,PHASE1|PHASE2,9.0,ACTUAL,Germans Trias i Pujol Hospital,OTHER,"Ministerio de Sanidad, Servicios Sociales e Igualdad",OTHER_GOV,Relapsing Remitting Multiple Sclerosis (RRMS),multiple sclerosis|mesenchymal stem cells|autologous transplantation|MRI efficacy|clinical safety,Spain,Badalona,Barcelona,1,Bone marrow autologous mesenchymal stem cells transplantation,BIOLOGICAL,Change from baseline in safety|Change from baseline in effectiveness by MRI,Feasibility|Change from baseline in effectiveness by MRI|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect|Change from baseline in effectiveness by MRI|Change in clinical efficacy|Change in clinical efficacy|Change in Quality of life|Change in Quality of life|Immunology|Immunology|Axonal effect,False,
NCT06298201,E-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity,Investigating of Effects of e-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity,RECRUITING,2024-04,2024-11,2025-07,2024-03-07,2024-03-07,INTERVENTIONAL,NA,300.0,ESTIMATED,University of Southern Denmark,OTHER,,,Multiple Sclerosis,multiple sclerosis|Comorbidity|physical exercise|e-Based,Denmark,Odense,,2,E-Based Physical Exercise Intervention,OTHER,"6-meters' walk test|""no evidence of disease activity"" (NEDA-3) score","Cognitive function, evaluated using the Montreal Cognitive Assessment (MoCA),|Fatigue levels, assessed using the short-form Neuro-QOL Fatigue Scale|Neurofilament Light Chain (NfL) determination",False,
NCT01816100,The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients,The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients: A Multimodal Neuroimaging Investigation,COMPLETED,2013-09-16,2015-09-01,2015-09-01,2023-09-01,2013-03-21,INTERVENTIONAL,NA,6.0,ACTUAL,University of Nebraska,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,multiple sclerosis|exercise|MEG|DTI|Brain changes,United States,Omaha,Nebraska,1,specifically design 6 month resistance training program|6 months weight resistance and balance program,OTHER|BEHAVIORAL,Determine activation differences in neural regions serving motor function,Effect of a 6 month resistance and balance program on activation in sensorimotor brain areas,False,
NCT01599234,A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis,"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.",COMPLETED,2005-03,2005-12,2005-12,2023-05-03,2012-05-15,INTERVENTIONAL,PHASE3,337.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United Kingdom,Reading,,1,Sativex|Placebo,DRUG|DRUG,Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment),Number of Subjects With a 30% or Greater Improvement in Mean Spasticity 0-10 NRS Score at the End of Treatment Compared to Baseline|Change From Baseline in the Mean Modified Ashworth Scale Score at the End of Treatment|Change From Baseline in Mean Sleep Quality 0-10 NRS During the Last 14 Days of Treatment (End of Treatment)|Incidence of Adverse Events as a Measure of Subject Safety|Change From Baseline in Mean Timed 10 Metre Walk Time at the End of Treatment|Carer Global Impression of Change at the End of Treatment|Change From Baseline in the Mean Total Barthel Activities of Daily Living Index Score at the End of Treatment|Number of Subjects With a 50% or Greater Improvement in Mean Spasticity 0-10 NRS Score at the End of Treatment Compared to Baseline,True,2012-08-16
NCT06276634,Intermittent Hypoxia in Persons With Multiple Sclerosis,Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis,RECRUITING,2024-04-30,2026-01,2027-01,2025-07-25,2024-02-26,INTERVENTIONAL,NA,21.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Northwestern University,NIH|OTHER,"Multiple Sclerosis|Multiple Sclerosis-Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive",multiple sclerosis|AIH|Hypoxia,United States,Chicago,Illinois,1,Acute Intermittent Hypoxia|Sham-Acute Intermittent Hypoxia,OTHER|OTHER,Ankle Plantarflexion Strength,Task fMRI,False,
NCT00509145,Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS),"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS",COMPLETED,2007-11-13,2010-11-08,2010-11-08,2021-11-02,2007-07-31,INTERVENTIONAL,PHASE3,1106.0,ACTUAL,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,,,Multiple Sclerosis,Relapsing|Remitting,United States,Phoenix,Arizona,144,Laquinimod|Placebo,DRUG|OTHER,Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period,Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images|Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions|Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)|Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score,True,2021-11-02
NCT05351957,Dry Needling for Treating Spasticity in Multiple Sclerosis,Dry Needling for Treating Spasticity in Multiple Sclerosis,COMPLETED,2018-02-18,2020-04-20,2020-09-22,2022-04-28,2022-04-28,INTERVENTIONAL,NA,10.0,ACTUAL,Hospital Universitario de Canarias,OTHER,,,Multiple Sclerosis,"Dry needling, multiple sclerosis, physiotherapy",Spain,San Cristóbal de La Laguna,Santa Cruz De Tenerife,1,Dry needling,PROCEDURE,Change in 9HOLD PEG TEST score|Change in 25 foot walk score|Change in Time up and go test score|Change in Expanded Disability Status Scale (EDSS) score|Change in Multiple sclerosis Quality of life-54 (MSQol54) score,,False,
NCT01535664,"An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)","An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS",COMPLETED,2012-01,2012-05,2012-06,2013-10-14,2012-02-20,OBSERVATIONAL,,20.0,ACTUAL,Acorda Therapeutics,INDUSTRY,"Prometrika, LLC|BCS Consulting, Inc.",INDUSTRY|INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|MS,United States,Oklahoma City,Oklahoma,1,Withdrawal of dalfampridine-ER 10mg,OTHER,Composite Score Overall Gait After Withdrawal and Reinitiation of Dalfampridine-ER 10mg|Composite Score Overall Balance After Withdrawal and Reinitiation of Dalfampridine-ER 10mg,Change on the Berg's Balance Scale (BBS) After Withdrawal and Reinitiation of Dalfampridine-ER 10mg|Change on the Two Minute Walk Test (2MWT) After Withdrawal and Reinitiation of Dalfampridine-ER 10mg|Change on the Timed 25 Foot Walk Test (T25FW) After Withdrawal and Reinitiation of Dalfampridine-ER 10mg,True,2013-10-14
NCT06149663,Intermediate-Size Expanded Access Protocol (EAP) for LP352,Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP),AVAILABLE,,,,2025-01-22,2023-11-29,EXPANDED_ACCESS,,,,Longboard Pharmaceuticals,INDUSTRY,,,Dravet Syndrome|Lennox Gastaut Syndrome|Developmental and Epileptic Encephalopathies,CDKL5 deficiency disorder|developmental and epileptic encephalopathy|Dravet Syndrome|epilepsy|Lennox Gastaut Syndrome|treatment resistant epilepsy|tuberous sclerosis complex,United States,Downey,California,22,LP352,DRUG,,,False,
NCT00619307,Transition to Rebif New Formulation,"A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis",COMPLETED,2007-07,2008-04,2008-04,2014-02-27,2008-02-20,INTERVENTIONAL,PHASE3,117.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Relapsing Multiple Sclerosis,,France,Paris,,2,Rebif New Formulation + prophylactic Ibuprofen|Rebif New Formulation + ibuprofen PRN,DRUG|DRUG,Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu-like Symptom Score,Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Total Score|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Satisfaction Score|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score,True,2010-07-26
NCT05974852,Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS,"Effect of Ocrelizumab on Choroid Plexus Changes in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study",ACTIVE_NOT_RECRUITING,2023-10-01,2024-02-28,2025-12-30,2025-02-25,2023-08-03,OBSERVATIONAL,,732.0,ESTIMATED,State University of New York at Buffalo,OTHER,"Genentech, Inc.",INDUSTRY,Primary Progressive Multiple Sclerosis,,United States,Buffalo,New York,1,Ocrelizumab,OTHER,T2 lesion volume,Changes in choroid plexus,False,
NCT02675413,Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS,Mechanisms of Action of Dimethyl Fumarate in Relapsing MS,WITHDRAWN,2016-04,2016-04,2016-04,2016-07-20,2016-02-05,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Washington University School of Medicine,OTHER,Biogen,INDUSTRY,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Cerebral Spinal Fluid|Dimethyl Fumarate|Tecfidera|Multiple Sclerosis|Relapsing MS|RRMS|Mechanism of Action,United States,St Louis,Missouri,2,Dimethyl Fumarate,DRUG,"Mean differences in Indicators of Oxidative stress (Nitrate, nitrite (um/L), Glutathione (uM), and F2-isoprostanes (pg/ml)) in blood and CSF at baseline and 12 months|Mean differences in markers of axonal damage to assess whether DMF protects against neurodegeneration at baseline and 12 months|Mean differences in MS-relevant cytokines, chemokines and osteopontin to examine the immunologic consequences of DMF therapy during autoimmune CNS inflammation.|Mean differences in the phenotype and activation status of adaptive and innate immune cells in the CSF and peripheral circulation at baseline and 12 months.",Correlation of Biomarkers with Imaging and Clinical Outcome Measures,False,
NCT04027114,Individualized Physiotherapy and Activity Coaching for Multiple Sclerosis,Individualized Physiotherapy and Activity Coaching for Multiple Sclerosis (IPAC-MS): A Randomised Controlled Trial,COMPLETED,2019-07-12,2021-01-15,2021-06-21,2021-11-30,2019-07-19,INTERVENTIONAL,NA,120.0,ACTUAL,University of Saskatchewan,OTHER,Saskatchewan Health Research Foundation (SHRF)|Saskatchewan Centre for Patient-Oriented Research,UNKNOWN|OTHER,Multiple Sclerosis,randomized controlled trial|multiple sclerosis|physiotherapy|behaviour change|physical activity|exercise|disability progression|walking function,Canada,Saskatoon,Saskatchewan,1,Individualized behavioural physical activity intervention,BEHAVIORAL,Godin Leisure Time Exercise Questionnaire (GLTEQ) Score,Multiple Sclerosis Impact Scale version 2 (MSIS-29 v2)|Multiple Sclerosis Self Efficacy Scale (MSSE)|Interviews and Exit surveys|Intervention Description,False,
NCT04004026,3 Meter Backwards Walk Test and Multiple Sclerosis,The Validity and Reliability of 3 Meter Backwards Walk Test in Multiple Sclerosis Patients,COMPLETED,2019-07-01,2020-04-15,2020-06-30,2021-04-14,2019-07-01,OBSERVATIONAL,,40.0,ACTUAL,Sanko University,OTHER,,,"Multiple Sclerosis|Walking, Difficulty|Balance; Distorted",Multiple Sclerosis|3-m backwards walk|Balance|Fall risk|validity|reliability,Turkey (Türkiye),Gaziantep,Şehitkamil,1,Assesment,OTHER,3 m backwards walk test,Timed up and go test|12 Items MS Walking Scale|2 min walk test|25 foot walk test|4 square step test,False,
NCT02652013,Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis,Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis,COMPLETED,2015-12,2019-12,2020-01,2020-07-27,2016-01-11,INTERVENTIONAL,NA,76.0,ACTUAL,Pôle Saint Hélier,OTHER,"Rennes University Hospital|University Hospital, Angers|Université Européenne de Bretagne",OTHER|OTHER_GOV|OTHER,Multiple Sclerosis|Social Cognition|Neuropsychology|Psychological Therory|Theory of Mind,,France,Rennes,Brittany Region,1,cognitive evaluation,OTHER,conversation test|indirect langage comprehension,,False,
NCT06653283,Application of Multiparametric Structural and Functional MRI in Unraveling the Substrates of Cognitive Impairment and Disability in Multiple Sclerosis,Application of Multiparametric Structural and Functional MRI in Unraveling the Substrates of Cognitive Impairment and Disability in Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-20,2025-10-30,2025-12-30,2024-10-22,2024-10-22,OBSERVATIONAL,,104.0,ESTIMATED,Zhuo Wang,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Cognitive Impairment,China,Lanzhou,Gansu,1,,,DTI-ALPS CPV,,False,
NCT01803867,An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis,"A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)",COMPLETED,2013-03,2014-10,2015-01,2015-02-27,2013-03-04,INTERVENTIONAL,PHASE1,72.0,ACTUAL,Acorda Therapeutics,INDUSTRY,PRA Health Sciences,INDUSTRY,Multiple Sclerosis,MS|Multiple Sclerosis,United States,Long Beach,California,17,rHIgM22,DRUG,Safety and tolerability of single ascending doses of the human monoclonal rHIgM22 in patients with MS.,Measure the pharmacokinetics (PK) of single ascending doses of rHIgM22|Measure the pharmacodynamics of single ascending doses of rHIgM22 using the Expanded Disability Status Scale (EDSS),False,
NCT02184494,Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients,"Phase 1 Study of A Double-Blind Placebo-Controlled Study of the Effect of Beta-Alanine and Whole Body Vibration on Neurologic Motoric Function, Vascular Function, and Quality of Life in Parkinson's Disease",COMPLETED,2014-08,2014-11,2014-12,2017-03-30,2014-07-09,INTERVENTIONAL,NA,34.0,ACTUAL,Florida State University,OTHER,,,Parkinson's Disease|Multiple Sclerosis,Parkinson's Disease|Multiple Sclerosis|Fatigue|Resting Energy Expenditure|Whole Body Vibration|Exercise|Blood Lactate,United States,Tallahassee,Florida,2,"pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)",DEVICE,Blood Lactate Response,Resting Energy Expenditure,True,2015-11-16
NCT03266965,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach,COMPLETED,2018-03-23,2020-08-07,2020-08-07,2020-10-08,2017-08-30,INTERVENTIONAL,PHASE1,18.0,ACTUAL,University of Miami,OTHER,United States Department of Defense,FED,Multiple Sclerosis,Fatigue|Histamine,United States,Miami,Florida,1,Carbidopa|L-Histidine,DRUG|DIETARY_SUPPLEMENT,Number of adverse events experienced by participants.,Change extent of fatigue.|Change in Quality of life.|Change of fatigue impact scale.|Change of visual pain.|Change of daytime sleepiness.|Change of hunger sensitivity.,False,
NCT05811416,A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,"Observational, Multicenter Study to Describe the Persistence in Relapsing Remitting Multiple Sclerosis Naive Patients With Low-moderate Activity Treated With Ozanimod (Zeposia®) in Clinical Practice in Spain",ACTIVE_NOT_RECRUITING,2023-06-14,2025-09-26,2025-09-26,2025-06-29,2023-04-13,OBSERVATIONAL,,200.0,ESTIMATED,Bristol-Myers Squibb,INDUSTRY,,,Relapsing-remitting Multiple Sclerosis (RRMS),Ozanimod|Zeposia|Relapsing-remitting multiple sclerosis,Spain,Barcelona,,1,,,Time from ozanimod treatment initiation to ozanimod treatment permanent discontinuation|Percentage of participants on treatment with ozanimod at 24 months,"Percentage of participants with ozanimod treatment at 3 and 12 months|Percentage of participants with ozanimod treatment discontinuation|Percentage of participants switching to treatment alternative|Annualized relapse rate at month 12 month and month 24|Proportion of participants with an increase in Symbol Digit Modalities Test (SDMT) score of ≥4 points|Proportion of participants with a decrease SDMT score of ≥4 points|Proportion of participants with a stable SDMT score|Change from baseline in SDMT score at month 3, 12 and 24|Change from baseline in Neurofilament light (NfL) levels at month 6, 12 and 24|Proportion of participants with change of ≥1.0 point from baseline in expanded disability status scale (EDSS) score at Month 3, 12 and 24|Change from baseline in EDSS score at Month 3, 12 and 24|Change from baseline in number of new or enlarging hypointense T1 lesions at month 12 and 24|Change from baseline in number of new or enlarging hypointense T2 lesions at month 12 and 24|Change from baseline in number of new or enlarging gadolinium enhancing brain lesions at month 12 and 24|Number of Participants with at least one Adverse Event (AE)|Number of Participants with AE that imply discontinuation of ozanimod|Description of sociodemographic characteristics of participants|Description of clinical characteristics of participants",False,
NCT05209815,Safety of Exposure to Natalizumab During Pregnancy,Safety of Exposure to Natalizumab During Pregnancy,COMPLETED,2022-06-20,2023-12-22,2023-12-22,2024-01-16,2022-01-27,OBSERVATIONAL,,68.0,ACTUAL,"University Hospital, Bordeaux",OTHER,Biogen,INDUSTRY,Multiple Sclerosis,Natalizumab|Safety|pregnancy,France,Besançon,,27,Questionnaire,BEHAVIORAL,Proportion of patients who presented serious adverse events (SAE) during their pregnancy,"Proportion of patients who presented pregnancy complications|Proportion of patients who presented delivery complications|Proportion of patients who presented postpartum AEs of interest|Proportion of viable children at birth|Average weight at birth|apgar score at birth|Number of child AEs of interest (haematological, infectious, malformations) at birth|Number of child AEs of interest (haematological, infectious, malformations) two years after birth",False,
NCT04855825,Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS,Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS,RECRUITING,2017-10-05,2025-12-30,2025-12-30,2024-04-02,2021-04-22,INTERVENTIONAL,NA,10.0,ESTIMATED,Kessler Foundation,OTHER,Kessler Institute for Rehabilitation,INDUSTRY,"Multiple Sclerosis|Gait Disorders, Neurologic|Motility Disorder|Cognitive Impairment",,United States,West Orange,New Jersey,1,Robotic Exoskeleton Rehabilitation|Conventional Gait Therapy,DEVICE|OTHER,Distance walked in a specific time duration|Neuropsychological measures of thinking|Brain scans,,False,
NCT01142453,An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients,Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring,COMPLETED,2005-05,2008-06,2008-06,2014-07-14,2010-06-11,OBSERVATIONAL,,231.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,Gesellschaft für Therapieforschung mbH,INDUSTRY,Relapsing-Remitting Multiple Sclerosis,Multiple sclerosis|Rebif|Interferon,,,,0,Interferon beta 1a,DRUG,"The course of the therapy, the assessment of the effectiveness, safety and compatibility were documented over the observation period",,False,
NCT01233245,BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program,BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program,COMPLETED,2004-04,2009-06,2009-06,2012-11-15,2010-11-03,OBSERVATIONAL,,1077.0,ACTUAL,Bayer,INDUSTRY,,,Relapsing Remitting MS (RRMS)|Secondary Progressive MS (SPMS),Multiple Sclerosis|Adherence|Interferon beta-1b|Coping Styles,Czechia,Many Locations,,15,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,"Identification of reasons why patients are switched from other disease modifying drugs to Betaferon due to perceived lack of efficacy, adverse events, poor compliance, and others.|Assessment of factors predictive of non-adherence to disease modifying drugs such as demographic data, course of disease, drug history, patients characteristics, history of poor compliance to prior therapy or others.","Assessment of impact of supportive elements of the BetaPlus Program like nurse support, auto-injector, website, etc on treatment adherence.|Evaluation of impact of Betaferon treatment on health related quality of life using the Functional Assessment of Multiple Sclerosis Questionnaire - FAMS.|Assessment of coping processes by applying the Ways of Coping Questionnaire.|Measurement of safety of Betaferon by assessing the number of participants with adverse events and severe adverse events. Classification by MedDRA category.",False,
NCT01811290,A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis,"A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis",UNKNOWN,2013-01,2018-07,2018-12,2018-02-01,2013-03-14,OBSERVATIONAL,,36.0,ESTIMATED,"Simnad, Virginia, M.D.",INDIV,Novartis,INDUSTRY,Multiple Sclerosis,,United States,Kirkland,Washington,1,,,Assess change in bone mass density in subjects taking Gilenya versus subjects taking alternative disease modifying therapy or no therapy.,,False,
NCT01071083,Treatment Interruption of Natalizumab,Randomized Treatment Interruption of Natalizumab,COMPLETED,2010-03,2011-11,2011-11,2013-09-19,2010-02-19,INTERVENTIONAL,PHASE2,175.0,ACTUAL,Biogen,INDUSTRY,Elan Pharmaceuticals,INDUSTRY,Relapsing Remitting Multiple Sclerosis,MS,United States,Cullman,Alabama,33,natalizumab|interferon beta 1-a|methylprednisolone|IV placebo|glatiramer acetate,DRUG|DRUG|DRUG|OTHER|DRUG,"Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.","Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.",True,2013-01-30
NCT03028675,pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress,pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress,COMPLETED,2017-05-01,2018-08-10,2018-08-10,2020-07-13,2017-01-23,OBSERVATIONAL,,4.0,ACTUAL,NYU Langone Health,OTHER,,,Multiple Sclerosis,,United States,New York,New York,1,MRI Scan,OTHER,pH measurements,,False,
NCT03166930,Evaluation of a Spasticity Management Program for People With Multiple Sclerosis,Evaluation of a Spasticity Management Program for People With Multiple Sclerosis,COMPLETED,2018-01-01,2021-07-30,2022-01-31,2022-07-18,2017-05-25,INTERVENTIONAL,NA,231.0,ACTUAL,VA Office of Research and Development,FED,Oregon Health and Science University,OTHER,Multiple Sclerosis,Muscle Spasticity|Muscle Stretching Exercises,United States,Portland,Oregon,1,Spasticity Take Control|Stretching for People with MS: An Illustrated Manual,BEHAVIORAL|BEHAVIORAL,"Impact of spasticity, measured by the Multiple Sclerosis Spasticity Scale-88","Severity of spasticity, measured by the Numeric Rating Scale for Spasticity|Fatigue, measured by the Modified Fatigue Impact Scale|Sleep quality and quantity, measured by the Pittsburge Sleep Quality Index|Impact on day-to-day life, measured by the Multiple Sclerosis Impact Scale-29|PROMIS Item Bank v1.0 - Emotional Distress - Depression-Short Form 8a|Impact on multiple sclerosis on walking, measured by the Multiple Sclerosis Walking Scale-12|Walking measured by the Timed 25 Foot Walk|Walking and turning measured by the Timed Up and Go",False,
NCT02047825,Upper Limbs Intervention in Multiple Sclerosis,Intervention Focused on Lower Limbs and Functionality in Patients With Multiple Sclerosis,COMPLETED,2014-01,2015-08,2016-02,2016-11-01,2014-01-28,INTERVENTIONAL,NA,37.0,ACTUAL,Universidad de Granada,OTHER,,,Multiple Sclerosis,Multiple sclerosis|Dexterity|Upper limbs,Spain,Granada,Spain,1,Upper limbs intervention|Usual treatment,OTHER|OTHER,Changes in manual dexterity,Changes in apraxia|Changes in grip strength|Change in fatigue|Upper limb functioning|Pinch strength|Tapping speed,False,
NCT02544750,"An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)","A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures",COMPLETED,2016-08-31,2021-06-11,2021-06-11,2022-07-14,2015-09-09,INTERVENTIONAL,PHASE3,199.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,GW Pharmaceuticals Ltd,INDUSTRY,Tuberous Sclerosis Complex|Seizures,,United States,Boston,Massachusetts,1,GWP42003-P,DRUG,"Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)|Number of Participants With Any TEAE, by Severity",Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period|Number of Participants Considered Treatment Responders During the OLE Treatment Period|Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period|Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period,True,2022-07-14
NCT06167447,Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis,"Evaluation Of The Existence Of Kinesiophobia In Patients With Multiple Sclerosis; Effect Of Kinesiophobia On Physical Activity,Functional Status, Quality Of Life and Depression",COMPLETED,2021-01-01,2021-05-01,2021-06-30,2023-12-12,2023-12-12,OBSERVATIONAL,,90.0,ACTUAL,Gazi University,OTHER,,,Multiple Sclerosis|Kinesiophobia,Multiple sclerosis|kinesiophobia|fear of movement,Turkey (Türkiye),Ankara,,1,questionnaire and examination,OTHER,Tampa Scale of Kinesiophobia,,False,
NCT04984278,Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis",TERMINATED,2021-08-16,2022-11-11,2022-11-11,2024-12-11,2021-07-30,INTERVENTIONAL,PHASE3,56.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Spasticity With Multiple Sclerosis,multiple sclerosis|MS|spasticity|velocity-dependent muscle tone|nabiximols,United States,Denver,Colorado,30,Nabiximols|Placebo,DRUG|DRUG,Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6),Change From Baseline in Lower Limb Muscle Tone-4 (LLMT-4)|Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)|Change From Baseline in Blood Pressure|Change From Baseline in Heart Rate|Change From Baseline in Clinical Laboratory Test Values|Change From Baseline in Erythrocytes|Change From Baseline in Hemoglobin|Change From Baseline in Hematocrit Ratio|Change From Baseline in Erythrocyte Mean Corpuscular Volume|Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin|Change From Baseline in Electrocardiogram Parameters|Change From Baseline in Electrocardiogram Pulse Rate|Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (CSSRS),True,2024-02-05
NCT04982991,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,"A Phase 1, Open-label, 3-treatment Period, 1-sequence, Cross-over Study of the Pharmacokinetics, Safety and Tolerability After Single Ascending Oral Doses of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants.",COMPLETED,2021-08-05,2021-10-11,2021-10-11,2022-04-25,2021-07-29,INTERVENTIONAL,PHASE1,14.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis Healthy Subjects,,United Kingdom,Harrow,"London, City of",1,RIPK1 inhibitor,DRUG,Assessment of pharmacokinetic (PK) parameter: Cmax|Assessment of pharmacokinetic (PK) parameter: AUClast|Assessment of pharmacokinetic (PK) parameter: AUC,Assessment of adverse events (AEs),False,
NCT04057898,Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,"A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis",ACTIVE_NOT_RECRUITING,2020-05-28,2025-12,2026-12,2025-09-16,2019-08-15,INTERVENTIONAL,PHASE2|PHASE3,234.0,ACTUAL,MediciNova,INDUSTRY,,,Amyotrophic Lateral Sclerosis,ALS|MN-166|ibudilast|amyotrophic lateral sclerosis,United States,Orange,California,16,MN-166|placebo,DRUG|DRUG,Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.,"Mean change from baseline of muscle strength measured by hand-held dynamometry|Mean change from baseline on quality of life assessed by ALSAQ-5 at Month 12|Mean change from baseline of functional activity measured by ALSFRS-R at Month 12|Responders, measured in percent of subjects overall, whose ALSFRS-R total score was stable or improved|Time to survival|Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Changes from Baseline in Laboratory Values",False,
NCT02587806,A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS,"An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS",UNKNOWN,2015-02,2017-02,2017-02,2015-10-28,2015-10-27,INTERVENTIONAL,PHASE1|PHASE2,69.0,ESTIMATED,Novo Cellular Medicine Institute LLP,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",RRMS,India,Pune,Maharashtra,2,Autologous Bone Marrow-Derived Mononuclear Stem Cells|Liberation therapy,BIOLOGICAL|OTHER,Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with adverse events,Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease,False,
NCT06486116,Effectiveness of Task Specific Home Exercise Program,Effectiveness of Task Specific Home Exercise Program,RECRUITING,2024-06-01,2025-12-31,2026-01-31,2024-07-03,2024-07-03,INTERVENTIONAL,NA,30.0,ESTIMATED,New York Presbyterian Brooklyn Methodist Hospital,OTHER,,,Multiple Sclerosis,,United States,Brooklyn,New York,1,Task Specific Physical Therapy Home Program,BEHAVIORAL,6 Minute Walk Test|The Functional Gait Assessment|The Mini Balance Evaluation Systems Test (MBEST),,False,
NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA,COMPLETED,2014-10,2016-04,2016-04,2016-06-09,2014-07-31,INTERVENTIONAL,PHASE4,58.0,ACTUAL,"Genzyme, a Sanofi Company",INDUSTRY,,,Relapsing-remitting Multiple Sclerosis,,Belgium,Bruges,,20,Alemtuzumab GZ402673|cetirizine|ranitidine|methylprednisolone|methylprednisolone|aciclovir|esomeprazole|ibuprofen|paracetamol,DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG|DRUG,Proportion of IARs that are graded mild according to the Common Toxicity Criteria (CTC). An IAR is any adverse event occurring during or within 24 hours of LEMTRADA infusion.|Proportion of IARs|Proportion and type of serious IARs|Proportion by type (as defined by clinical symptoms),,False,
NCT03508089,Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis,Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis,UNKNOWN,2017-08-22,2017-10-26,2018-06-30,2018-04-25,2018-04-25,INTERVENTIONAL,NA,60.0,ESTIMATED,Versailles Hospital,OTHER,,,"Sclerosis, Multiple",,France,Le Chesnay,,1,Ocular fundus on patient with Multiple Sclerosis|Ocular Fundus on voluntary person,OTHER|OTHER,To compare the wall / lumen ratio (WLR) of retinal arterioles (common marker of microangiopathies) between multiple sclerosis patients and controls using the adaptive optics technique.,"Compare between patients with multiple sclerosis and controls, retinal arteriolar gauges measured by external and internal diameter.|Correlate possible changes in arteriolar WLR with internal and external diameter, smoking, age, blood pressure, fatigue (MFIS), cognition (MDT) and disability (EDSS) scores to ambient air and normobaric oxygen.",False,
NCT00790400,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),"A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",COMPLETED,2009-04,2011-06,2015-11,2017-02-17,2008-11-13,INTERVENTIONAL,PHASE3,118.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),"Angiomyolipoma|AML|Tuberous Sclerosis Complex|TSC|mTOR|RAD001|Mammalian Target of Rapamycin|Everolimus|Afinitor|SEGA|Subependymal Giant Cell Astrocytoma|Seizures|Tuberous sclerosis complex (TSC)|Tuberous sclerosis|benign tumors of brain|kidney|heart|eyes|lungs|skinTSC1|TSC2|hamaratin|tuberin, tumor growth suppressors|gyri|tubers|Sporadic Lymphangioleiomyomatosis.|Lymphangioleiomyomatosis (LAM)|rare lung disease",United States,Birmingham,Alabama,25,Everolimus (RAD001)|Everolimus Placebo,DRUG|DRUG,Angiomyolipoma Response Rate as Per Central Radiology Review,Time to Angiomyolipoma Progression as Per Central Radiology Review|Skin Lesion Response Rate as Per Investigator (Only Patients With at Least One Skin Lesion at Baseline)|Percentage of Participants With Renal Impairment|Change From Baseline in Plasma Angiogenic Molecules - Vascular Endothelial Growth Factor (VEGF) Marker|Everolimus Trough Concentrations (Cmin)|Everolimus Blood Concentrations (C2h) at 2 Hours Post-dose|Time to Angiomyolipoma Response - Only Everolimus Patients With Angiomyolipoma Response|Duration of Angiomyolipoma Response - Only Everolimus Patients With Angiomyolipoma Response|Duration of Skin Lesion Response - Only Everolimus Patients With Best Overall Skin Lesion Response of Complete Clinical Response (CCR) or Partial Response (PR),True,2012-08-28
NCT06433752,A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS),REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE),RECRUITING,2024-07-22,2027-07-01,2027-07-01,2025-09-12,2024-05-30,OBSERVATIONAL,,500.0,ESTIMATED,"TG Therapeutics, Inc.",INDUSTRY,,,Relapsing Multiple Sclerosis|Multiple Sclerosis,,United States,Birmingham,Alabama,62,No Intervention,OTHER,Annualized Relapse Rate (ARR),Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Infusion Related Reaction (IRR) at Each Infusion,False,
NCT00014755,"Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis",,COMPLETED,1997-12,,,2005-06-24,2001-04-11,INTERVENTIONAL,PHASE1,35.0,,Fred Hutchinson Cancer Center,OTHER,,,Multiple Sclerosis,multiple sclerosis|neurologic and psychiatric disorders|rare disease,United States,Duarte,California,6,anti-thymocyte globulin|cyclophosphamide|filgrastim|prednisone|peripheral blood stem cell transplantation|irradiation,DRUG|DRUG|DRUG|DRUG|PROCEDURE|PROCEDURE,,,False,
NCT01706055,Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE),Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon®,COMPLETED,2012-09,2015-09,2016-03,2017-03-14,2012-10-15,OBSERVATIONAL,,629.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis (MS)|Interferon,Poland,Many Locations,,1,"Interferon beta-1b (Betaseron, BAY86-5046)",BIOLOGICAL,Mean severity score of Flu-Like Symptoms (FLS) recorded within the first 6 months following treatment initiation|MS patient with Flu-Like Symptoms (FLS) demographic profile|Frequency of usage of particular pharmacological and non-pharmacological practices applied by investigators to prevent or manage FLS,The impact of FLS on patients daily activities as measured by current professional/educational status|Betaferon tolerability measured as occurrence of Adverse Events (AE) and FLS over 6 months period,False,
NCT05622643,OFSEP Very High Definition Cohort,"Very High Definition Cohort: Assessment of New Prognostic Biomarkers of Disability Worsening in a Multicenter Cohort of MS Patients by Imaging, Optical Coherence Tomography and Biology",RECRUITING,2023-01-19,2026-01-01,2027-01-01,2024-02-20,2022-11-18,OBSERVATIONAL,,300.0,ESTIMATED,EDMUS Foundation,OTHER,,,Multiple Sclerosis,Prognostic factors|MS progression|MRI|OCT|NFL|GFAP,France,Lyon,,5,MRI,OTHER,Global disability progression,"Composite disability progression score|Change in the Symbol Digit Modalities Test score|Change in the American Spinal Cord Injury Association motor sub-score|Focal inflammatory activity|No evidence of disease activity 3|Between-subject, between-center and between-session coefficient of variation of measurements extracted quantitative MRI|Number of brain and spinal cord lesion detected using 3D MP2RAGE sequence and the classical OFSEP sequences at baseline and 2 year|Number of new brain and spinal cord lesion detected at 2 years using 3DMP2RAGE sequence and the classical OFSEP sequences|Number of detected brain and spinal cord lesions per patient and per expert with and without the automatic tool at baseline and 2 year",False,
NCT05832515,AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis,Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.,RECRUITING,2020-10-01,2025-10-01,2026-12-01,2024-05-07,2023-04-27,INTERVENTIONAL,PHASE1,200.0,ESTIMATED,St. Petersburg State Pavlov Medical University,OTHER,,,Multiple Sclerosis,Autoimmune Diseases|AHSCT|Fludarabine,Russia,Saint Petersburg,,1,Fludarabine Phosphate for Injection,DRUG,Multiple sclerosis progression free survival,Cumulative incidence of mortality|To evaluate adverse effects after FluCy200 conditioning regimen|Quality of life status 1|Quality of life status 2|Quality of life status 3|Quality of life status 4|Neurological status 1|Immune reconstitution|Magnetic resonance imaging response,False,
NCT04082260,Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response,Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response,UNKNOWN,2017-01,2022-01,2022-01,2019-09-20,2019-09-09,OBSERVATIONAL,,150.0,ESTIMATED,University Hospital Muenster,OTHER,,,Multiple Sclerosis,,Germany,Münster,North Rhine-Westphalia,1,Alemtuzumab Injection [Lemtrada],DRUG,"Absolute and relative change of cell-counts compared to baseline of T cell subsets in the peripheral blood (every 6 months)|Absolute and relative change of cell-counts compared to baseline of B-cell subsets in the peripheral blood (every 6 months)|Absolute and relative change of cell-counts compared to baseline of natural killer cells in the peripheral blood (every 6 months)|Absolute and relative change of cell-counts compared to baseline of antigen-presenting cells in the peripheral blood (every 6 months)|Absolute and relative change of cell-counts compared to baseline of myeloid-derived suppressor cells in the peripheral blood (every 6 months)|Change from baseline in levels of markers of autoimmunity (ANA, cANCA and pANCA) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (anti-dsDNA) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (anti-TSH-Receptor) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity(anti-TPO) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (Rheumatoid factor) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (anti-CCP) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (anti-GBM) in the serum (every 6 months):|Change from baseline in levels of markers of autoimmunity (antiplatelet antibodies) in the serum (every 6 months):",Functional characterization of T-cells and B cells in the peripheral blood (every 6 months),False,
NCT04024969,DiagnosE Using the Central veIn SIgn,DECISIve - DiagnosE Using the Central veIn SIgn. A Prospective Diagnostic Superiority Study Comparing T2* MRI and Lumbar Puncture in Patients Presenting With Possible Multiple Sclerosis,UNKNOWN,2019-11-06,2022-05,2022-11,2020-03-04,2019-07-18,OBSERVATIONAL,,115.0,ESTIMATED,Nottingham University Hospitals NHS Trust,OTHER,,,Multiple Sclerosis,Central Vein Sign|Translational Neuroimaging|Multiple Sclerosis,United Kingdom,Cardiff,,4,T2* MRI|Lumbar puncture to test for presence of unmatched oligoclonal bands,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,The sensitivity of the central vein sign (CVS) on T2* MRI scan and lumbar puncture with oligoclonal band testing at diagnosing MS at the time of the patients' first presentation.,The specificity of the central vein sign (CVS) on T2* MRI scan and lumbar puncture with oligoclonal band testing at diagnosing MS at the time of the patients' first presentation.|The sensitivity and specificity of the 'rule of six' proposed in Mistry et al. 2016.,False,
NCT05469568,Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis,Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis,RECRUITING,2022-07-15,2025-06-30,2025-08-30,2025-02-06,2022-07-21,INTERVENTIONAL,NA,50.0,ESTIMATED,Brno University Hospital,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Telerehabilitation|Circuit Training|Movement Skills|Quality of Life,Czechia,Brno,Czech Republic,1,Circuit training followed by telerehabilitation|Usual care,OTHER|OTHER,Change from Baseline Movement skills score at 12 weeks and 6 months,Change from Baseline Depression score at 12 weeks and 6 months|Change from Baseline Walking skills score at 12 weeks and 6 months|Exercise adherence|Change from Baseline Health related quality of life score at 12 weeks and 6 months,False,
NCT01450124,"Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)","Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial",COMPLETED,2011-09,2014-12,2014-12,2020-02-25,2011-10-12,INTERVENTIONAL,PHASE2,29.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,,,Relapsing Remitting Multiple Sclerosis,,Germany,Berlin,,2,Boswellic acids (BOSWELAN),DRUG,Mean number of total Gd-enhancing lesions,Number of new active lesions (new Gd-enhancing lesions +new or enlarging non-enhancing T2 lesions)|Relapse rate,False,
NCT02673827,"Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis","Effect of Progressive Muscle Relaxation as a Nursing Intervention on Sleep Quality, Depression and Stress in People With Multiple Sclerosis",COMPLETED,2014-04,2014-10,2015-07,2016-02-04,2016-02-04,INTERVENTIONAL,PHASE2,40.0,ACTUAL,Federal University of Espirito Santo,OTHER,,,Multiple Sclerosis|Depression|Sleep|Stress Psychological,,,,,0,Progressive muscle relaxation,OTHER,Stress Level,Level of depression|sleep quality,False,
NCT01524250,Optic Neuritis Recovery After Oral or IV Corticosteroids,Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial,COMPLETED,2012-03,2015-05,2015-05,2015-09-02,2012-02-01,INTERVENTIONAL,PHASE2|PHASE3,51.0,ACTUAL,London Health Sciences Centre,OTHER,The Physicians' Services Incorporated Foundation,OTHER,Optic Neuritis,Multiple Sclerosis|relapse|demyelination|treatment|corticosteroids,Canada,London,Ontario,2,corticosteroids|corticosteroids,DRUG|DRUG,P100 latency of the Visual Evoked Potential in the affected eye,High contrast visual acuity|contrast sensitivity|P100 latency of the Visual Evoked Potential in the affected eye,False,
NCT06884579,Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: the ADVICE Protocol Study (Phase 2),Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study,ACTIVE_NOT_RECRUITING,2025-04-15,2025-06-15,2025-07-30,2025-05-06,2025-03-19,INTERVENTIONAL,NA,60.0,ESTIMATED,Universidad de Almeria,OTHER,Hospital Universitario Virgen de la Arrixaca,OTHER,Multiple Sclerosis (MS) - Relapsing-remitting,Relapsing-Remitting MS|Fatigue|Cognitive Behavioral Therapy|Physical exercise|Dietary habits|Women&#39;s Health,Spain,Murcia,Murcia,1,"Strength training, nutrition, and behavioral training|Self-Guided and Unsupervised Program with General Recommendations",OTHER|OTHER,Satisfaction with Physical Activity|Satisfaction with Physical Activity|Visual Analogue Scale for Fatigue (VAS-F)|Visual Analogue Scale for Fatigue (VAS-F)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS),Inflammatory Profile|Inflammatory Profile|The hormonal profile|Cognitive Function|Cognitive Function|Neurofilament Light Chain (NFL)|Neurofilament Light Chain (NFL)|Physical Self-Perception|Physical Self-Perception|Walking Endurance|Walking Endurance|Pain Catastrophizing|Pain Catastrophizing|Quality of Life questionnaire|Quality of Life questionnaire|State-Trait Anxiety|State-Trait Anxiety|Rate of force development|Rate of force development|Maximum Voluntary Isometric Contraction|Maximum Voluntary Isometric Contraction|Maximal neural drive|Maximal neural drive|Central activation ratio|Central activation ratio|Upper Limb Maximum Strength|Upper Limb Maximum Strength|Spasticity|Spasticity|Intrinsic muscle characteristics|Intrinsic muscle characteristics|Gait speed|Gait speed|Static balance with eyes open|Static balance with eyes open|Static balance with eyes closed|Static balance with eyes closed|Sit-to-stand|Sit-to-stand|Timed Up-and-Go test|Timed Up-and-Go test|Delayed onset muscle soreness|Subjective Perception of Effort|Fatigue Visual Analog Scale (VAS-F)|Anthropometric|Anthropometric|Bioimpedance|Bioimpedance|Physical Activity Levels|Physical Activity Levels|Dietary and Nutritional Follow-up|Dietary and Nutritional Follow-up|The Kurtzke Disability Scale|The Kurtzke Disability Scale|Subjective Sleep Quality Questionnaire|Subjective Sleep Quality Questionnaire|Sleep Quality Measured by Actigraph|Sleep Quality Measured by Actigraph|Delayed onset muscle soreness|Subjective Perception of Effort|Fatigue Visual Analog Scale (VAS-F),False,
NCT04673240,CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY,"CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SPASTICITY AFTER TRAUMATIC BRAIN INJURY, SPINAL CORD INJURY OR IN MULTIPLE SCLEROSIS PATIENTS: AN OBSERVATIONAL STUDY",UNKNOWN,2019-03-29,2021-12-31,2022-06-30,2020-12-17,2020-12-17,OBSERVATIONAL,,70.0,ESTIMATED,Università degli Studi del Piemonte Orientale Amedeo Avogadro,OTHER,Ipsen|Azienda Ospedaliero Universitaria Maggiore della Carita|SIRN,INDUSTRY|OTHER|UNKNOWN,Spasticity|Brain Injuries|Spinal Cord Injuries|Multiple Sclerosis,,Italy,Novara,,1,Botulinum toxin type A injection,DRUG,Modified Ashworth Scale (MAS),Global Assessment of Efficacy scale)|active range of motion|passive range of motion|Numeric Rating Scale for pain|EQ5-D|interval of time between BoNT-A reinjections,False,
NCT05322915,Therapeutic Effects of Line Dancing in People With MS,"Therapeutic Effects of Line Dancing in People With Multiple Sclerosis: an Evaluator-blinded, Randomized Controlled Study",COMPLETED,2021-06-01,2022-01-15,2022-01-15,2022-04-12,2022-04-12,INTERVENTIONAL,NA,31.0,ACTUAL,Gazi University,OTHER,Hacettepe University|Fenerbahce University,OTHER|OTHER,Multiple Sclerosis,line dance|balance|anxiety|depression|quality of life|Multiple Sclerosis,Turkey (Türkiye),Ankara,,1,line dancing,OTHER,Berg Balance Scale,Hospital Anxiety and Depression Scale|Multiple Sclerosis Quality of Life-54,False,
NCT02326935,Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis,"Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis",TERMINATED,2014-11,2018-05-18,2018-05-18,2018-05-22,2014-12-30,INTERVENTIONAL,PHASE1,2.0,ACTUAL,American CryoStem Corporation,INDUSTRY,,,Multiple Sclerosis,"MS|Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive|Myelitis",Cayman Islands,George Town,,1,Autologous adipose derived mesenchymal cells,BIOLOGICAL,Standard Complication Questionnaire|MS Impact Scale - MSIS-29|Modified SF-36 Cell-Based Therapy Follow Up|Physical Evaluation,MS Impact Scale - MSIS-29|MS Impact Scale - MSIS-29|Modified SF-36 Cell-Based Therapy Follow Up|Standard Complication Questionnaire|Standard Complication Questionnaire|Standard Complication Questionnaire|Standard Complication Questionnaire|Standard Complication Questionnaire|Standard Complication Questionnaire|Physical Evaluation|Physical Evaluation,False,
NCT02980640,Swiss Multiple Sclerosis Registry,Swiss Multiple Sclerosis Registry,RECRUITING,2016-06,2041-06,2041-06,2025-05-15,2016-12-02,OBSERVATIONAL,,10000.0,ESTIMATED,Swiss Multiple Sclerosis Registry,OTHER,University of Zurich|Schweizerische Multiple Sklerose Gesellschaft,OTHER|OTHER,Multiple Sclerosis,Multiple Sclerosis|Treatment|Quality of Life|Symptoms,Switzerland,Zurich,Canton of Zurich,1,,,Change in Health-Related Quality of Life|Change in Self-Assessment of Health Status,Occurrence of MS Symptoms|Occurrence of Adverse Drug Effects|Occurrence of MS Relapse,False,
NCT06981013,Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis,Effects of Balance-based Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis,RECRUITING,2025-03-01,2026-12,2026-12,2025-05-20,2025-05-20,INTERVENTIONAL,NA,40.0,ESTIMATED,University of St. Augustine for Health Sciences,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|muscle activation|ankle muscles|balance vest,United States,Saint Augustine,Florida,1,balance based torso weighting,OTHER,Muscle Activation of B lateral gastrocnemius and tibialis anterior|Postural Sway as measured by center of pressure displacement,,False,
NCT04338061,Study of Evobrutinib in Participants With RMS (evolutionRMS 2),"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)",TERMINATED,2020-07-02,2023-10-02,2024-03-19,2025-03-21,2020-04-08,INTERVENTIONAL,PHASE3,1166.0,ACTUAL,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,Relapsing Multiple Sclerosis,Evobrutinib|Teriflunomide|Aubagio®|Relapsing Multiple Sclerosis,United States,Cullman,Alabama,278,Teriflunomide|Evobrutinib,DRUG|DRUG,Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR),"DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)|DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156|DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156|DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions|DBTP and DBE Period: New or Enlarging T2 Lesions Rate|DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12|DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)|DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity|DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure|DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate|DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate|DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight|DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature|DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate|DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes|DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin|DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin|DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate|DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine|DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine|DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels|DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels",True,2025-01-14
NCT02257606,Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial,Robot-assisted Training on the Upper Limb in Persons With MS: an RCT,COMPLETED,2011-07,2011-09,2011-09,2015-07-03,2014-10-06,INTERVENTIONAL,NA,17.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|Expertise Centre for digital Media|tUL|iMinds|Interreg,OTHER|UNKNOWN|UNKNOWN|INDUSTRY|OTHER,Multiple Sclerosis,,,,,0,I-TRAVLE training,OTHER,Motricity index|Fugl-Meyer|Action Research arm test|Motor Activity log|Jamar handgrip strength,,False,
NCT02795052,Neurologic Stem Cell Treatment Study,Neurologic Bone Marrow Derived Stem Cell Treatment Study,RECRUITING,2016-06,2026-07-31,2027-07-31,2025-06-06,2016-06-09,INTERVENTIONAL,NA,500.0,ESTIMATED,MD Stem Cells,INDUSTRY,,,Neurologic Disorders|Nervous System Diseases|Neurodegenerative Diseases|Neurological Disorders|Stroke|Traumatic Brain Injury|Cadasil|Chronic Traumatic Encephalopathy|Cerebral Infarction|Cerebral Ischemia|Cerebral Stroke|Cerebral Hemorrhage|Parkinson|Multi-System Degeneration|MSA - Multiple System Atrophy|Progressive Supranuclear Palsy|ALS|Amyotrophic Lateral Sclerosis|Neuropathy|Diabetic Neuropathies|Alzheimer Disease|Dementia|Frontotemporal Dementia|Lewy Body Disease|Cognitive Impairment|Lewy Body Variant of Alzheimer Disease,Neurologic Disease|Cerebral Vascular Accident|Stroke|Traumatic Brain Injury|Multiple Sclerosis|Parkinsons Disease|Neuropathy|Diabetic Neuropathy|Cerebral Ischemia|Cognitive Impairment|Dementia|Neurodegeneration,United States,Westport,Connecticut,3,Intravenous and Intranasal BMSC,PROCEDURE,Change in Neurologic Function,,False,
NCT01464749,Task-oriented Circuit Class Training in Multiple Sclerosis Subjects,,COMPLETED,2011-05,2012-05,2013-10,2014-04-10,2011-11-03,INTERVENTIONAL,NA,24.0,ACTUAL,University Hospital of Ferrara,OTHER,Università degli Studi di Ferrara,OTHER,Multiple Sclerosis,multiple sclerosis|gait rehabilitation,Italy,Ferrara,Emilia-Romagna,1,Task-oriented circuit class training|usual care,BEHAVIORAL|BEHAVIORAL,Feasibility of task-oriented circuit class therapy,gait speed|mobility|Balance|walking endurance|fatigue|Physical and psychological impact|Impact on mobility and walking,False,
NCT02661555,Aerobic Exercise and Brain Health in Multiple Sclerosis,Effects of Aerobic Exercise on Brain Health in People With Multiple Sclerosis,COMPLETED,2016-01,2018-08,2019-05,2021-06-03,2016-01-22,INTERVENTIONAL,NA,86.0,ACTUAL,University of Aarhus,OTHER,Jascha Fonden|Knud and Edith Eriksens memorial fund|University of Southern Denmark|Augustinus fund|Masku Neurological Center,OTHER|UNKNOWN|OTHER|UNKNOWN|UNKNOWN,Multiple Sclerosis|Brain Atrophy|Cognitive Impairment,,Denmark,Aarhus,Aarhus C,1,Aerobic exercise,OTHER,Percentage brain volume change,"Cognition measured by the Brief Repeatable Battery of Neuropsychological Tests|Blood samples: Cytokines and neurotrophins|VO2max|Regional volume change changes (e.g. hippocampus, thalamus)|Modified Fatigue Impact Scale|Fatigue Severity Scale|Major Depression Inventory|Short Form 36|Multiple Sclerosis Impact Scale 29|6-min walk test|Six Spot Step Test",False,
NCT02427776,A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis,"A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL)",TERMINATED,2015-01,2016-08,2016-08,2017-08-22,2015-04-28,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,Imcyse SA,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",,Belgium,Brussels,,3,Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope,BIOLOGICAL,Safety of the cell based immunotherapy (Adverse events)|Safety of the cell based immunotherapy (Vital signs)|Safety of the cell based immunotherapy (Physical examination)|Safety of the cell based immunotherapy (Laboratory parameters)|Safety of the cell based immunotherapy (MRI),MRI derived parameters|Expanded Disability Status Scale (EDSS)|Clinical relapses|Circulating MOG specific cytolytic CD4+ cells|Circulating anti-MOG antibodies,False,
NCT02848976,Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life,Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life,COMPLETED,2009-01,2010-04,2010-05,2016-07-29,2016-07-29,OBSERVATIONAL,,32.0,ACTUAL,Nantes University Hospital,OTHER,,,Multiple Sclerosis,,France,Nantes,,1,Re-training to effort (RE),OTHER,SEP-59 questionnaire in MS|Scale impact of fatigue in MS (EMIF-SEP),,False,
NCT04338646,Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis,Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis,COMPLETED,2019-07-01,2020-04-15,2020-04-30,2022-02-18,2020-04-08,OBSERVATIONAL,,150.0,ACTUAL,Gérard Amarenco,OTHER,,,Fall|Multiple Sclerosis|Lower Urinary Tract Symptoms,Fall|multiple sclerosis|lower urinary tract symptoms|overactive bladder,France,Paris,,1,Clinical tests,OTHER,Number of falls in the past 3 months,Number of falls in the past year,False,
NCT04595513,Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants,Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants,COMPLETED,2020-09-08,2022-12-15,2022-12-15,2024-05-16,2020-10-20,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,"Children's Hospital Medical Center, Cincinnati",OTHER,,,Tuberous Sclerosis Complex|Epilepsy,,United States,Cincinnati,Ohio,1,TAVT-18 (sirolimus),DRUG,Safety - Adverse Events|Efficacy - Time to Seizure Onset,Treatment Discontinuance Due to Adverse Events|Treatment Disruption Due to Adverse Events|Precision Dosing Accuracy|Age at Seizure Onset|Seizure Type|Seizure Frequency|TAND Severity Assessed by the TAND-L Checklist|Adaptive Behavior Assessed by the the VABS|Global Neurodevelopment Assessed by the Bayley Scales of Infant Development,True,2024-05-16
NCT02781142,Motor Imagery Training in Persons With Multiple Sclerosis,The Effect of Telerehabilitation Based Motor Imagery Training on Gait and Balance Performance of the Persons With Multiple Sclerosis: A Randomized Controlled Trial,COMPLETED,2016-05,2017-10,2017-11,2018-04-03,2016-05-24,INTERVENTIONAL,NA,70.0,ACTUAL,Dokuz Eylul University,OTHER,,,Multiple Sclerosis,,Turkey (Türkiye),Izmir,,2,Motor imagery training,OTHER,Dynamic Gait Index,Expanded Disability Status Scale|Kinesthetic and Visual Imagery Questionnaire (KVIQ)-10|Movement Imagery Questionnaire-Revised Second Edition (MIQ-RS)|Mental Chronometry for 2-Meter Walk Test|Mental Chronometry for 5-Meter Walk Test|Mental Chronometry for 10-Meter Walk Test|Mental Chronometry for Timed 25-Foot Walk|Mental Chronometry for Timed Up and Go Test|Mental Chronometry for Five Times Sit to Stand Test|2-Meter Walk Test|5-Meter Walk Test|10-Meter Walk Test|Timed 25-Foot Walk|2-Minute Walk Test|Twelve Item MS Walking Scale|Timed Up and Go Test|Five Times Sit to Stand Test|Curl-up Test|Activities-specific Balance Confidence Scale|Postural Stability Test by Balance System™|The Limits of Stability Test by Balance System™|Fall Risk Test by Balance System™|Modified Fatigue Impact Scale|Hospital Anxiety and Depression Scale|Multiple Sclerosis International Quality of Life Questionnaire|Symbol Digit Modalities Test|Selective Reminding Test|10/36 Spatial Recall Test,False,
NCT06672770,Effect of Functional Inspiratory Muscle Training in Patients with Multiple Sclerosis,"Investigation of the Effects of Functional Inspiratory Muscle Training on Respiratory Muscle Strength, Functional Exercise Capacity and Cognitive Function in Patients with Multiple Sclerosis",NOT_YET_RECRUITING,2024-11-01,2025-10-31,2025-12-20,2024-11-04,2024-11-04,INTERVENTIONAL,NA,63.0,ESTIMATED,Selcuk University,OTHER,,,Core Muscles|Functional Inspiratory Muscle Training|Multiple Sclerosis|Respiratory Muscles,Core muscles|Functional inspiratory muscle training|Multiple sclerosis|Respiratory muscles,Turkey (Türkiye),Konya,Selcuklu,1,Functional Inspiratory Muscle Training|Basic Inspiratory Muscle Training,OTHER|OTHER,Inspiratory Respiratory Muscle Strength|Expiratory Respiratory Muscle Strength|Respiratory Function (FEV₁)|Respiratory Function (FVC)|Respiratory Function (FEV₁/FVC)|Respiratory Function (PEF)|Respiratory Function (FEF%25-75)|Respiratory Function (VC)|Paced Auditory Serial Addition Test (PASAT)|Symbol Digit Modalities Test (SDMT)|Stroop Test|Walking|Balance|Functional Exercise Capacity|Physical Activity|Quality of Life|Core Muscles (Pelvic Bridge Test)|Core Muscles (Modified Plank Test),,False,
NCT04178005,Cladribine Tablets After Treatment With Natalizumab (CLADRINA),Cladribine Tablets After Treatment With Natalizumab (CLADRINA),ACTIVE_NOT_RECRUITING,2020-02-19,2026-08-30,2026-12,2024-12-02,2019-11-26,INTERVENTIONAL,PHASE4,40.0,ESTIMATED,University of Texas Southwestern Medical Center,OTHER,EMD Serono,INDUSTRY,Multiple Sclerosis,,United States,Overland Park,Kansas,2,Cladribine,DRUG,"Absolute and percent change of T cells, B cells, DC subset and NfL levels in blood.",Annualized Relapse Rate (ARR),False,
NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,"A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE)",COMPLETED,2012-04-16,2019-02-08,2019-02-08,2019-06-05,2011-11-28,OBSERVATIONAL,,4734.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis,,Argentina,Ciudad Autonoma de Buanos Aires,Buenos Aires,164,Fampridine,DRUG,Number of Participants with Adverse Events,Utilization patterns of Fampyra in Routine Clinical Practice|Effectiveness of risk minimization measures|Change from Baseline in Physician's Clinical Global Impression of Improvement (CGI-I) of Walking Ability Assessed Whenever the Multiple Sclerosis Participant is Seen by the Neurologist|Participants' Assessment of Physical and Psychological Impact of Multiple Sclerosis Using the Multiple Sclerosis Impact Scale-29 Items (MSIS-29),False,
NCT01994018,Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake,Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake,COMPLETED,2011-11,2014-06,2014-06,2022-04-29,2013-11-25,OBSERVATIONAL,,100.0,ACTUAL,OSF Healthcare System,OTHER,,,Multiple Sclerosis,Vitamin D|Interferon Beta|Glatiramer Acetate|Relapse rates,United States,Peoria,Illinois,1,,,• Annual relapse rates,Expanded Disability Status Scale|Multiple Sclerosis Responders|Multiple Sclerosis Non-Responders|Response to immunodulators among patients who received MS treatment with or without vitamin D|non-response to immunodulators among patients who received MS treatment with or without vitamin D|MRI (brain images),False,
NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,"A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis",TERMINATED,2013-12-20,2015-05-05,2018-09-13,2021-01-05,2014-01-16,INTERVENTIONAL,PHASE2,8.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Relapse Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis|Magnetic Resonance Imaging|VAY736|Lanalumab|monoclonal antibody|gadolinium [Gd]-enhancing lesions|B-Cell,United States,Long Beach,California,5,VAY736|Placebo,DRUG|DRUG,"Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16","Number of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16|Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16|Number of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16|T2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.|Number of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.|Proportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.|Number of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death",True,2019-10-30
NCT03271125,Intensive Multimodal Training for Persons With MS,Intensive Multimodal Training for Persons With Multiple Sclerosis: Random Controlled Trial,COMPLETED,2013-01-08,2015-05-19,,2017-09-01,2017-09-01,INTERVENTIONAL,NA,42.0,ACTUAL,Fondazione Don Carlo Gnocchi Onlus,OTHER,,,Rehabilitation|Multiple Sclerosis,Intervention|Multiple sclerosis|Treadmill|Mobility,Italy,Milan,MI,1,Treadmill|Resistance,BEHAVIORAL|BEHAVIORAL,Two minute walking test|Timed up and go test,The Frontal Assessment Battery|Ten meter walking test|The Berg Balance Scale|Dynamic Gait Index|The Short Form-12 questionnaire (SF-12),False,
NCT06384716,Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program Patients With Multiple Sclerosis,Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program on Pelvic Floor Function in Patients With Multiple Sclerosis,RECRUITING,2024-02-19,2024-07-01,2024-09-01,2024-04-25,2024-04-25,INTERVENTIONAL,NA,32.0,ESTIMATED,Universidad Europea de Madrid,OTHER,,,"Multiple Sclerosis|Pelvic Floor Disorders|Incontinence, Urinary",,Spain,Madrid,,1,rehabilitation programme based on motor control of core muscles,OTHER,Difference in the percentage of initial and final maximum activity of the pelvic floor muscles.|- Differences between the initial and final thickness of the oblique abdominis and transverse oblique muscles by ultrasound.|- Differences in the assessment of health-related quality of life before and after the intervention measured with the I-QOL questionnaire.|- Differences in the assessment of female UI before and after intervention using the I-CIQ questionnaire,- Difference in the percentage of initial and final maximum activity of the paravertebral musculature activity.|- Differences between initial and final amplitude of initial and final diaphragmatic excursion by ultrasound.|- Difference between initial and final FVC/- Differences between the initial and final peak expired volume (FEV1)|differences between peak expiratory pressure (PEM) and minimum initial and end inspiratory pressure (MIP).|balance,False,
NCT06643858,Normal Chinese Lifespan Brain Charts Initiative (NCLBCI),Establishment of Chinese Brain Charts for Individualized Diagnosis of Major Brain Diseases,RECRUITING,2023-12-01,2025-11,2026-05,2024-10-26,2024-10-16,OBSERVATIONAL,,10000.0,ESTIMATED,Beijing Tiantan Hospital,OTHER,,,Healthy|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorders|Neurodegenerative Diseases|Cerebrovascular Diseases,Brain Charts|Individualized Diagnosis,China,Beijing,Beijing Municipality,1,No intervention,OTHER,Number of Brain Imaging Scans Collected and Processed Across Multiple Centers|Accuracy and Reliability of Structural Brain Chart Models|Accuracy and Reliability of Functional Brain Chart Models|User Access and Interaction Metrics on Brain Chart Online Platform|Number of Brain Chart Products Released and Marketed,Number of Peer-Reviewed Papers Published and Patents Filed|Number of Multicenter Sites Using Brain Charts for Clinical and Research Purposes,False,
NCT06982833,Trunk Restraint in Multiple Sclerosis,Investigation of the Effect of Trunk Restraint on Upper Extremity Functionality in Individuals With Multiple Sclerosis,COMPLETED,2025-03-10,2025-04-10,2025-04-15,2025-05-21,2025-05-21,INTERVENTIONAL,NA,96.0,ACTUAL,Zonguldak Bulent Ecevit University,OTHER,,,Multiple Sclerosis|Healthy Control,,Turkey (Türkiye),Zonguldak,,2,Trunk restraint,OTHER,Expanded Disability Status Scale (EDSS)|Trunk Impairment Scale (TIS)|Nine-Hole Peg Test (9HPT),,False,
NCT01824550,Home Exercise Intervention in Persons With Multiple Sclerosis,"Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis",COMPLETED,2012-11-13,2017-09-07,2018-09-07,2019-09-26,2013-04-04,INTERVENTIONAL,NA,59.0,ACTUAL,University of Illinois at Chicago,OTHER,,,Multiple Sclerosis,,United States,Chicago,Illinois,1,home-based exercise training condition,OTHER,Subclinical atherosclerosis,Mobility disability,False,
NCT01214317,Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis,Study of Combinative Effect of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Patients With Aggressive Multiple Sclerosis,COMPLETED,2010-01,2012-01,2012-02,2020-09-16,2010-10-05,INTERVENTIONAL,NA,40.0,ACTUAL,Isfahan University of Medical Sciences,OTHER,,,Multiple Sclerosis,multiple sclerosis|mitoxantrone|plasmapheresis|induction therapy,Iran,Isfahan,,1,plasmapheresis,PROCEDURE,Expanded Disability Status Score|Change From Baseline in Mean Number of MS Plaques Found on Brain MRI,,True,2020-09-16
NCT05208840,A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,WITHDRAWN,2023-09-15,2025-01-31,2026-01-31,2024-01-23,2022-01-26,INTERVENTIONAL,PHASE4,0.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,Multiple Sclerosis,,Russia,Moskva,Moscow Oblast,2,Ocrelizumab,DRUG,The number of LMCE foci at the Month 24 visit compared to the number of LMCE foci at the Baseline visit in the LMCE-positive group,The change from the Baseline visit in LMCE foci at the Month 12 visit in the LMCE- positive group.|The change from the Baseline visit in LMCE foci at the Month 12 visit in the LMCE-negative group|The change from the Baseline visit in LMCE foci at the Month 24 visit in the LMCE-negative group|Time until 3-months composite confirmed disability progression in the LMCE-positive group and the LMCE-negative group|Time until 3-months confirmed disability progression in the LMCE-positive group and the LMCE-negative group|Time until 3-months confirmed 20% worsening in arm function (9-HPT) in the LMCE-positive group and the LMCE-negative group|Time until 3-months confirmed 20% worsening of gait function (T25FWT) in the LMCE-positive group and the LMCE-negative group|Percentage of Participants with Adverse Events,False,
NCT04806568,MS-NEUROPLAST: Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients with Multiple Sclerosis,Cognitive Decline Prognosis in Multiple Sclerosis: Effectiveness of a Computerized Cognitive Training Treatment on Cortical Reorganization,RECRUITING,2020-12-01,2025-12-31,2025-12-31,2024-11-04,2021-03-19,INTERVENTIONAL,NA,180.0,ESTIMATED,Aristotle University Of Thessaloniki,OTHER,King Fahad Medical City,OTHER_GOV,Multiple Sclerosis|Cognitive Decline,EEG|Network Efficiency|Adaptive|Plasticity|Maladaptive Reorganization|Cognitive Training,Greece,Thessaloniki,Central Macedonia,1,Cognitive Training|Monitoring of daily activity,OTHER|DEVICE,Change in current density strength of the cortical activity as measured via EEG|Change in cortical connectivity as measured via EEG|Changes in the graph theory indexes as measured via EEG,Change in audiovisual integration functionality|Change in Mini Mental Status Examination (MMSE)|Change in Clock Drawing Test (CDT)|Change in Brief Visuospatial Memory Test (BVMT)|Change in Symbol Digit Modalities Test (SDMT)|Change in Verbal Fluency: Phonemic [ Chi-Sigma-Alpha]|Change in Verbal Fluency: Semantic [Animals-Fruits-Objects]|Change in Digit Span (For-Back-Seq) _WAIS-4GR|Change in Stroop Neuropsychological Test (SNST)|Change in Greek Accentuation Test (GAT)|Change in Depression Anxiety Stress Scale (DASS-21)|Change in Multiple Sclerosis Impact Scale (MSIS-29)|Change in the Cognitive Reserve Questionnaire (CRIq)|Change in Modified Fatigue Impact Scale (MFIS)|Change in EQ-5D-5L|Change in EQ-5D-5L -EQ-VAS|Change in Beck Depression Inventory-Fast Screen (BDI-FS)|Change in Timed 25-Foot Walk (T25-FW)|Change in 3 m backwards walk test|Change in Hole Peg Test (9-HPT)|Change in Four Square Step Test (FSST)|Change in Single Leg Stance Test (SLS)|Change in the Handgrip Strength Test,False,
NCT03594487,Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis,"Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function",ACTIVE_NOT_RECRUITING,2018-11-16,2024-08-01,2024-08-01,2024-06-21,2018-07-20,INTERVENTIONAL,PHASE1,30.0,ESTIMATED,Jeffrey Gelfand,OTHER,,,Relapsing Remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing Remitting Multiple Sclerosis|Fecal Microbiota Transplantation,United States,San Francisco,California,1,FMP30 Donor Stool|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Observational Control,DRUG|PROCEDURE|OTHER,Subjects who complete the study protocol|Change in fecal microbiota|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Induction of T regulatory or Th2 cells and/or reduction of Th1 or Th17 cells|Plasma CD19+ B cell count percentages|Plasma CD20+ B cell count percentages|Plasma CD19+ B cell absolute count|Plasma CD20+ B cell absolute count|Measurement of Serum Immunoglobulin Levels|Incidence of new T2/FLAIR lesions|Measurement of T2/FLAIR lesion volume|Number of T2/FLAIR lesions|Total Gadolinium Enhancing Lesions,False,
NCT05844826,Evaluation of the Microbiome in Multiple Sclerosis,A Clinical Study To Evaluate Small Intestine Microbiome In Multiple Sclerosis (MS),TERMINATED,2023-06-26,2024-04-24,2024-04-24,2025-05-15,2023-05-06,INTERVENTIONAL,NA,40.0,ACTUAL,Nimble Science Ltd.,INDUSTRY,IGY Life Sciences,UNKNOWN,Multiple Sclerosis,,Canada,Calgary,Alberta,1,SIMBA Capsule,DEVICE,"16s microbiome sequencing and LC-MS metabolomic analysis will be performed on these samples to compare gut microbiome and metabolite profiles of healthy control and diagnosed MS patients|Comparison of blood samples from Multiple Sclerosis (MS) and healthy control participants for biomarkers of inflammation, as analysed using ELISA, protenomic methods, and commercially available assays.",,False,
NCT04158063,Cognitive-motor Interference in Persons With MS,Cognitive-motor Interference in Persons With MS: Dual Task Assessment and Training - A Multi-center Study,COMPLETED,2016-10-10,2018-07-01,2018-07-01,2019-11-13,2019-11-08,INTERVENTIONAL,NA,112.0,ACTUAL,Hasselt University,OTHER,Revalidatie & MS Centrum Overpelt|National MS Center Melsbroek|AZ Klina|Centre Hospitalier Universitaire de Liege|Masku Neurological Rehabilitation Centre|Tel Aviv University|Sheba Medical Center|AISM Rehabilitation Service of Genoa,OTHER|OTHER|OTHER|OTHER|UNKNOWN|OTHER|OTHER_GOV|UNKNOWN,Multiple Sclerosis,,Belgium,Overpelt,,1,Dual Task Training|Single Mobility Training,BEHAVIORAL|OTHER,Digit Span - Walk - Dual Task Cost (%)|Digit Span - Walk - Dual Task Cost (%)|Digit Span - Walk - Dual Task Cost (%)|Subtraction - Walk - Dual Task Cost (%)|Subtraction - Walk - Dual Task Cost (%)|Subtraction - Walk - Dual Task Cost (%)|Vigilance - Walk - Dual Task Cost (%)|Vigilance - Walk - Dual Task Cost (%)|Vigilance - Walk - Dual Task Cost (%)|Digit Span - Cup - Dual Task Cost (%)|Digit Span - Cup - Dual Task Cost (%)|Digit Span - Cup - Dual Task Cost (%)|Subtraction - Cup - Dual Task Cost (%)|Subtraction - Cup - Dual Task Cost (%)|Subtraction - Cup - Dual Task Cost (%)|Vigilance - Cup - Dual Task Cost (%)|Vigilance - Cup - Dual Task Cost (%)|Vigilance - Cup - Dual Task Cost (%)|Digit Span - Obstacles - Dual Task Cost (%)|Digit Span - Obstacles - Dual Task Cost (%)|Digit Span - Obstacles - Dual Task Cost (%)|Subtraction - Obstacles - Dual Task Cost (%)|Subtraction - Obstacles - Dual Task Cost (%)|Subtraction - Obstacles - Dual Task Cost (%)|Vigilance - Obstacles - Dual Task Cost (%)|Vigilance - Obstacles - Dual Task Cost (%)|Vigilance - Obstacles - Dual Task Cost (%)|Digit Span - Crisscross - Dual Task Cost (%)|Digit Span - Crisscross - Dual Task Cost (%)|Digit Span - Crisscross - Dual Task Cost (%)|Subtraction - Crisscross - Dual Task Cost (%)|Subtraction - Crisscross - Dual Task Cost (%)|Subtraction - Crisscross - Dual Task Cost (%)|Vigilance - Crisscross - Dual Task Cost (%)|Vigilance - Crisscross - Dual Task Cost (%)|Vigilance - Crisscross - Dual Task Cost (%),Brief Repeatable Battery of Neuropsychological Tests|Part of Brief Repeatable Battery of Neuropsychological Tests|Part of Brief Repeatable Battery of Neuropsychological Tests|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Multiple Sclerosis Impact Scale-29 (MSIS-29)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Modified Fatigue Impact Scale (MFIS)|Dual Task Questionnaire|Dual Task Questionnaire|Dual Task Questionnaire|Timed 25 Foot-walk test (T25FW)|Timed 25 Foot-walk test (T25FW)|Timed 25 Foot-walk test (T25FW)|Timed-up-and-go test (TUG)|Timed-up-and-go test (TUG)|Timed-up-and-go test (TUG)|Dynamic Gait Index (DGI)|Dynamic Gait Index (DGI)|Dynamic Gait Index (DGI)|2-minute walking test (2MWT)|2-minute walking test (2MWT)|2-minute walking test (2MWT)|Multiple sclerosis walking scale-12 (MSWS-12)|Multiple sclerosis walking scale-12 (MSWS-12)|Multiple sclerosis walking scale-12 (MSWS-12)|Falls efficacy scale (FES-I)|Falls efficacy scale (FES-I)|Falls efficacy scale (FES-I),False,
NCT02544763,"A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)","A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures",COMPLETED,2016-04-06,2019-01-22,2019-02-26,2022-09-28,2015-09-09,INTERVENTIONAL,PHASE3,224.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex|Seizures,,United States,Birmingham,Alabama,44,GWP42003-P|Placebo,DRUG|DRUG,Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration),Number of Participants Considered Treatment Responders During the Treatment Period (Maintenance and Titration)|Change From Baseline in the Caregiver Global Impression of Change (CGIC) or Participant Global Impression of Change (PGIC) Score at the Participant's Last Visit|Percent Change From Baseline in Total Seizures During the Treatment Period (Maintenance and Titration)|Number of Participants With Any Severe Treatment-emergent Adverse Event (TEAE),True,2020-09-23
NCT03000647,Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis,Assessment of the Effectiveness of Guided by a Physiotherapist Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence (UI) in Patients With Relapsing-Remitting (RR) Multiple Sclerosis,COMPLETED,2015-10,2016-10,2016-10,2019-07-11,2016-12-22,INTERVENTIONAL,NA,48.0,ACTUAL,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,OTHER,Universidad Rey Juan Carlos,OTHER,Relapsing-Remitting Multiple Sclerosis|Urinary Incontinence,Pelvic floor muscle exercise|Supervision|Physiotherapy,Spain,Villalba,Madrid,1,Pelvic floor exercises guided by a physiotherapist|Non guided pelvic floor exercises,PROCEDURE|PROCEDURE,Decrease in the number of urinary leakages from baseline,Decrease of urinary incontinence severity from baseline|Change in quality of life from baseline|Decrease in the number of urinary leakages from baseline|Lower urinary tract symptoms from baseline|Adherence,False,
NCT01918501,Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients,Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients,UNKNOWN,2013-08,2015-07,2015-07,2013-12-03,2013-08-07,INTERVENTIONAL,NA,120.0,ESTIMATED,Ziv Hospital,OTHER_GOV,,,Multiple Sclerosis,multiple sclerosis|Remyelination|Mitochondria|fatty acids,Israel,Safed,,1,Blood testing,PROCEDURE,Levels of approximately 30 fatty acids in the serum and in erythrocyte samples.,Monitor mitochondrial transmembrane potential as a marker for the mitochondria general function.,False,
NCT01080001,"A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina",Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina,COMPLETED,2008-08,2010-12,2012-11,2014-03-07,2010-03-03,OBSERVATIONAL,,71.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,"Multiple Sclerosis, Relapsing-remitting","Multiple sclerosis|Multiple sclerosis, Relapsing-remitting|Expanded Disability Status Scale|Fatigue|Hamilton Depression Inventory|Depression",Argentina,Capital Federal,Buenos Aires,1,,,Multiple Sclerosis International Quality of Life (MusiQoL) in multiple sclerosis fatigue (MSF) [Fatigue Severity Scale (FSS) >5] versus multiple sclerosis nonfatigue (MSNF) (FSS <4) subjects,Demographic characteristics|Duration of the disease|Treatment or treatment changes|Expanded Disability Status Scale (EDSS)|Hamilton Depression Inventory-17 (HDI-17)|Fatigue Severity Scale (FSS),False,
NCT06860932,A Palliative Care Model Impact on Knowledge and Attitudes,A Palliative Care Model Impact on Knowledge and Attitudes,RECRUITING,2025-02-01,2026-02-01,2026-06-30,2025-09-16,2025-03-06,INTERVENTIONAL,NA,50.0,ESTIMATED,Hunter College of City University of New York,OTHER,National Center for Advancing Translational Sciences (NCATS),NIH,"Multiple Sclerosis, MS",,United States,New York,New York,2,Palliative care video comprises the conversation and advance directives.|Palliative care written material,BEHAVIORAL|BEHAVIORAL,"Palliative care preferences (i.e., care considerations, discontinuation of care, versus continued full care) for neurological care (Aim 1).",Palliative care knowledge|Preparation for decision making|Decisional conflict|Advance care planning engagement,False,
NCT03723434,Physiology of Interregional Connectivity in the Human Brain,Physiology of Interregional Connectivity in the Human Brain,UNKNOWN,2017-05-31,2020-11,2020-11,2018-10-29,2018-10-29,INTERVENTIONAL,NA,76.0,ESTIMATED,Shirley Ryan AbilityLab,OTHER,Northwestern University,OTHER,Healthy|Stroke|Traumatic Brain Injury|Multiple Sclerosis,Human|Brain|Connectivity|Stroke|Traumatic brain injury|Multiple sclerosis|Transcranial magnetic stimulation|Paired associative stimulation|Electroencephalography|Magnetic resonance imaging,United States,Chicago,Illinois,1,Single-pulse transcranial magnetic stimulation (spTMS)|Paired associative stimulation (PAS)|Repetitive transcranial magnetic stimulation (rTMS),DEVICE|DEVICE|DEVICE,Changes in EEG effective connectivity|Changes in resting-state EEG coherence,Motor evoked potentials (MEPs)|MRI functional connectivity|MRI structural connectivity,False,
NCT05926167,Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery,VALIDATE II Study: Observational Trial Evaluating Elevated Factor VIII Related Labs in Multiple Sclerosis Relapse as a Marker for Incomplete Recovery,NOT_YET_RECRUITING,2023-09-12,2024-05,2024-12,2023-09-14,2023-07-03,OBSERVATIONAL,,9.0,ESTIMATED,Dignity Health Medical Foundation,OTHER,,,Multiple Sclerosis|Relapse,multiple sclerosis relapse biomarker|Factor VIII,,,,0,"blood tests drawn days 1, 8, 22 and 90 of the study",DIAGNOSTIC_TEST,"Correlation of Factor VIII activity, Factor VIII with MS relapse|Correlation of Factor VIII activity, Factor VIII antigen with MS relapse incomplete recovery|Correlation of additional labs with MS relapse or MS relapse incomplete recovery|Correlation of MRI findings with MS relapse and MS relapse recovery",,False,
NCT06964581,Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis,Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis: Proposal for an Integrated Cognitive Treatment in a Telematic Format,RECRUITING,2023-02-08,2025-04-22,2025-09-30,2025-05-09,2025-05-09,INTERVENTIONAL,NA,60.0,ESTIMATED,Universita di Verona,OTHER,,,Telerehabilitation|Multiple Sclerosis|Cognitive Disorders|Neurorehabilitation,telerehabilitation|multiple sclerosis|cognitive disorders,Italy,Verona,verona,1,Cognitive treatment delivered via telerehabilitation.|In-person cognitive treatment.,BEHAVIORAL|BEHAVIORAL,Paced Auditory Serial Addition Task (PASAT),"Trail Making Test Part A (TMT-A)|Trail Making Test Part B (TMT-B)|Symbol Digit Modalities Test|Modified Five Point Test (MFPT)|""Learning"" subtest of the Rivermead Behavioural Memory Test-3 (RBMT-3)|Phonemic Verbal Fluency Test|Test of Attentional Performance (TAP)|Modified Fatigue Impact Scale (MFIS)|Multiple Sclerosis Quality of Life 54 (MSQOL-54)|Depression, Anxiety, and Stress Scale (DASS)",False,
NCT00928967,"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients","Prospective Multicenter, Non-interventional Study to Evaluate the Impact of the Introduction of Interferon Beta-1 b Treatment on Daily Life Activities in Patients at High Risk of Developing Multiple Sclerosis After a First Clinical Demyelinating Event or Having Received a Confirmed Diagnosis of RRMS",COMPLETED,2007-05,2010-03,2010-11,2015-10-09,2009-06-26,OBSERVATIONAL,,67.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,Multiple Sclerosis|Quality of life,France,Many Locations,,1,"Interferon beta-1b, (Betaseron BAY86-5046)",DRUG,Evolution of the Daily Life score: Analysis of variance for repeated measurements.,"Evolution of the SF 36 score, Fatigue score, Beck's depression score: analysis of variance for repeated measurements|Correlation coefficient with quality of life scales|Kinetics of treatment discontinuation: Kaplan Meier|Rate of treatment continuation",False,
NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry,COMPLETED,2013-10-30,2022-02-10,2022-02-10,2022-06-21,2013-07-30,OBSERVATIONAL,,408.0,ACTUAL,Biogen,INDUSTRY,,,Multiple Sclerosis|Exposure During Pregnancy,,United States,Cambridge,Massachusetts,15,Dimethyl fumarate|Peginterferon beta-1a,DRUG|DRUG,Pregnancy Loss|Live Birth,,False,
NCT04448444,Brain Activity Changes Following Neuroproprioceptive Physiotherapy in Multiple Sclerosis,Brain Activity Changes Following Neuroproprioceptive Physiotherapy in Multiple Sclerosis,COMPLETED,2015-05,2017-05-15,2019-11-10,2020-06-29,2020-06-25,INTERVENTIONAL,NA,87.0,ACTUAL,"Charles University, Czech Republic",OTHER,,,Neuronal Plasticity|Multiple Sclerosis|Rehabilitation,,,,,0,Motor Program Activating Therapy|Vojta reflex locomotion,BEHAVIORAL|BEHAVIORAL,Brain activity|Brain activity,Nine Hole Peg Test - NHPT|Paced Auditory Serial Addition Test - PASAT|Berg Balance Scale - BBS|Timed 25 Foot Walk - T25FW|Timed Up and Go - TUG,False,
NCT04925557,Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis,"Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis",TERMINATED,2021-11-13,2023-06-01,2023-08-05,2025-05-13,2021-06-14,INTERVENTIONAL,PHASE2|PHASE3,8.0,ACTUAL,State University of New York at Buffalo,OTHER,,,Secondary-progressive Multiple Sclerosis,,United States,Buffalo,New York,1,Mayzent|Ocrevus,DRUG|DRUG,Change From Baseline in PET Activation at 12 Months,"Change From Baseline in PET Activation at 6,12,24 and 36 Months Between Mayzent and Active Comparator|Number of New Ultrasmall Superparamagnetic Iron Oxide Particles",True,2025-05-13
NCT03849001,Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS,Impact of Acute Leg Cycling at Different Intensities on Restless Legs Syndrome Severity in Persons With Multiple Sclerosis,WITHDRAWN,2019-09-01,2019-09-01,2019-09-01,2019-12-02,2019-02-21,INTERVENTIONAL,NA,0.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,Multiple Sclerosis|Restless Legs Syndrome,Exercise,,,,0,Exercise Conditions|Exercise Conditions|Exercise Conditions|Exercise Conditions,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT)|Restless Legs Syndrome Severity as measured by the Suggested Immobilization Test (SIT),Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS)|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS)|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS)|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS)|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS)|Restless Legs Syndrome Severity as measured by the International Restless Legs Syndrome Study Group Scale (IRLS),False,
NCT05393765,The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis,The Evaluation of the Effect of an Interactive Web-based Program That Supports Nurse-led Self-regulation in the Management of Multiple Sclerosis,COMPLETED,2022-06-13,2022-09-01,2023-06-01,2023-09-13,2022-05-26,INTERVENTIONAL,NA,76.0,ACTUAL,Selcuk University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Self-Management|Nursing|Self-Regulation,Turkey (Türkiye),Selçuklu,Konya,1,Yönetebilirim,BEHAVIORAL,Change in self-management,Fatigue Severity Scale|State-Trait Anxiety Inventory (STAI)|System Usability Scale|Program Usage Level Tracking Form,False,
NCT06020937,Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study,Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-30,2025-07-30,2026-12-30,2024-05-08,2023-09-01,OBSERVATIONAL,,200.0,ESTIMATED,University of Catania,OTHER,University of Roma La Sapienza|Hospital General Universitario Santa Lucia|Klinik und Poliklinik fur Kinderheilkunde,OTHER|OTHER|OTHER,Multiple Sclerosis,,Italy,Catania,Sicily,1,TDI|Trigeminal Test|Cognitive Evaluation by Montreal Cognitive Assessment|Anxiety and Depression questionnaire|Visual Analogue Scale Ratings|Quality of smell Questionnaire,DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST|DIAGNOSTIC_TEST,Trigeminal component,,False,
NCT01075737,An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers,Observational Study to Assess the Quality of Life of the Caregivers of Patients With Multiple Sclerosis,COMPLETED,2008-08,2011-03,2012-03,2014-02-17,2010-02-25,OBSERVATIONAL,,141.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Sclerosis|Quality of life,Argentina,Santiago del Estero,,1,,,Impact of MS on QoL of subjects diagnosed with multiple sclerosis (MS) and their caregivers,Correlation between QoL of subjects with MS and their caregivers|Predictors of QoL of caregivers,False,
NCT01604265,A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis,"A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.",COMPLETED,2002-03,2002-08,2002-08,2023-01-10,2012-05-23,INTERVENTIONAL,PHASE3,66.0,ACTUAL,Jazz Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis|Neuropathic Pain,,United Kingdom,Liverpool,,1,Placebo|Sativex,DRUG|DRUG,Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks),Change From Baseline in the Mean 0-10 Numerical Rating Scale Sleep Score at the End of Treatment (4 Weeks)|Subject Global Impression of Change at Week 4|Change From Baseline in the Mean Neuropathic Pain Scale 0-10 Numerical Rating Scale Score at the End of Treatment (Week 4)|Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment (Week 4)|Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment (Week 4)|Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment (Week 4)|Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for the 'Paced Auditory Serial Addition Task' (PASAT) at the End of Treatment (Week 4)|Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment (4 Weeks)|Change From Baseline in the Mean Total Guy's Neurological Disability Scale Score at the End of Treatment (4 Weeks)|Change From Baseline in the Mean 0-100 mm Visual Analogue Scale Score for Intoxication Levels at the End of Treatment (4 Weeks)|Change From Baseline in The Hospital Anxiety and Depression Scale Score for Depression at the End of Treatment (4 Weeks)|Change From Baseline in The Hospital Anxiety and Depression Scale Score for Anxiety at the End of Treatment (4 Weeks)|Change From Baseline in the Multiple Sclerosis Functional Composite Score at the End of Treatment (4 Weeks)|Incidence of Adverse Events as a Measure of Patient Safety.,True,2012-09-19
NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,"International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.",COMPLETED,2003-11,,2007-08,2008-12-19,2004-12-16,INTERVENTIONAL,PHASE3,2244.0,ACTUAL,Bayer,INDUSTRY,,,"Multiple Sclerosis, Relapsing-Remitting",Relapsing multiple sclerosis|interferon beta 1b|Betaferon|Betaseron,United States,Birmingham,Alabama,199,"Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|Copaxone",DRUG|DRUG|DRUG,Hazard ratio for relapses,Time to confirmed Expanded Disability Status Score (EDSS) progression|Magnetic Resonance Imaging (MRI): Change from screening in volume of hypointense lesion on enhanced T1 weighted images,False,
NCT04429789,Waking Hypnosis in the Treatment of MS-related Fatigue,Waking Hypnosis in the Treatment of MS-related Fatigue: Pilot and Feasibility Study,COMPLETED,2020-05-27,2021-03-31,2021-03-31,2021-05-03,2020-06-12,INTERVENTIONAL,NA,32.0,ACTUAL,University of Washington,OTHER,National Multiple Sclerosis Society,OTHER,Multiple Sclerosis,,United States,Seattle,Washington,1,Active-Alert Hypnosis|Traditional Hypnosis,BEHAVIORAL|BEHAVIORAL,Fatigue Self Efficacy|Fatigue Self Efficacy|Fatigue Self Efficacy|Fatigue Self Efficacy|Fatigue Severity|Fatigue Severity|Fatigue Severity|Fatigue Severity,Psychological and Physical Function|Psychological and Physical Function|Psychological and Physical Function|Psychological and Physical Function|Activity Level|Activity Level|Activity Level|Activity Level|Suggestibility|Suggestibility|Attitudes towards hypnosis|Attitudes towards hypnosis|Attitudes towards hypnosis|Attitudes towards hypnosis|Treatment Outcome Expectancy|Sleep Quality|Sleep Quality|Sleep Quality|Sleep Quality|Illness Perception|Illness Perception|Illness Perception|Illness Perception,False,
NCT03239860,Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis,"A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis",TERMINATED,2017-06-06,2018-11-14,2018-11-14,2020-10-20,2017-08-04,INTERVENTIONAL,PHASE2,220.0,ACTUAL,GeNeuro SA,INDUSTRY,Les Laboratoires Servier|Worldwide Clinical Trials|Institut de Recherches Internationales Servier,UNKNOWN|OTHER|OTHER,"Multiple Sclerosis, Relapsing-Remitting",Multiple Sclerosis|Multiple Sclerosis Relapsing-Remitting|GNbAC1|MRI|Monoclonal antibody|Multiple Sclerosis associated retrovirus MSRV|MS|RRMS|HERV-W|Temelimab,Bulgaria,Sofia,,12,GNbAC1 Monoclonal Antibody,DRUG,Long term safety of GNbAC1,Long term efficacy of GNbAC1 in terms of MRI outcomes|Long term efficacy of GNbAC1 in terms of relapse rate|Long term efficacy of GNbAC1 in terms of disability|Long term efficacy of GNbAC1 in terms of disease progression,False,
NCT01956227,Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior,Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior,COMPLETED,2013-04,2014-09,2014-09,2014-11-25,2013-10-08,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,University of Illinois at Urbana-Champaign,OTHER,,,Multiple Sclerosis|Adult Disease,,United States,Urbana,Illinois,1,Home-based exercise|Education|Exercise plus Education,BEHAVIORAL|BEHAVIORAL|BEHAVIORAL,Fall incidence,Physiological Fall Risk|Mobility|Balance,False,
NCT03969927,User-friendliness of a Portable Driving Simulator,User-friendliness of a Portable Driving Simulator to Retrain Impaired Driving Skills in Stroke Survivors and in Individuals With Parkinson's Disease and Multiple Sclerosis,RECRUITING,2019-08-28,2025-06-30,2025-06-30,2024-08-16,2019-05-31,INTERVENTIONAL,NA,30.0,ESTIMATED,University of Kansas Medical Center,OTHER,,,Parkinson Disease|Multiple Sclerosis|Stroke,Simulation|Driving Simulation,United States,Kansas City,Kansas,1,Low-Fidelity PDS|High Fidelity Fixed-Base Simulator,DEVICE|DEVICE,User-Friendliness|Simulator Sickness|Driving Performance,,False,
NCT03656627,Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease,"Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease",TERMINATED,2019-06-27,2021-03-18,2021-03-18,2023-02-15,2018-09-04,INTERVENTIONAL,PHASE1,7.0,ACTUAL,"Alliance Foundation Trials, LLC.",OTHER,Bristol-Myers Squibb,INDUSTRY,Autoimmune Diseases|Non-small Cell Lung Cancer|Rheumatoid Arthritis|Psoriasis|Giant Cell Arteritis|Polymyalgia Rheumatica|Systemic Lupus Erythematosus|Crohn Disease|Multiple Sclerosis|Ulcerative Colitis,Autoimmune Diseases|Non-small Cell Lung Cancer|Ulcerative Colitis|Multiple Sclerosis|Crohn Disease|Systemic Lupus Erythematosus|Polymyalgia Rheumatica|Giant Cell Arteritis|Psoriasis|Rheumatoid Arthritis|Nivolumab|Opdivo,United States,Chicago,Illinois,9,Nivolumab,DRUG,Dose-Limiting Toxicity (DLT),Overall Response Rate|Progression-Free Survival|Overall Survival,False,
NCT04603196,Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis,Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis,RECRUITING,2019-06-20,2026-06-20,2030-06-20,2025-05-23,2020-10-26,OBSERVATIONAL,,800.0,ESTIMATED,Beth Israel Deaconess Medical Center,OTHER,,,Multiple Sclerosis|Obstructive Sleep Apnea,,United States,Boston,Massachusetts,1,,,Home Sleep Study Data,Questionnaire data,False,
NCT04993274,Sensitivity of Motor Assessment in MS - a Prospective Cohort Study,Sensitivity of Quantitative Motor Performance Measures in Multiple Sclerosis - a Prospective Cohort Study Over Two Years Using Microsoft Kinect,UNKNOWN,2019-02-20,2022-11,2022-11,2021-08-10,2021-08-06,OBSERVATIONAL,,100.0,ACTUAL,Friedemann Paul,OTHER,Roche Pharma AG,INDUSTRY,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Chronic Progressive",multiple sclerosis|gait|balance|postural control|progression|observational|assessment|motion capture,Germany,Berlin,,1,PASS-MS,DIAGNOSTIC_TEST,change in PASS-MS kinematic parameter Short Maximum Speed Walk - Speed (SMSW-MaxS),,False,
NCT06106074,Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants,"A Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants",COMPLETED,2020-08-10,2022-05-23,2022-05-23,2023-10-30,2023-10-30,INTERVENTIONAL,PHASE1,71.0,ACTUAL,Sanofi,INDUSTRY,,,Multiple Sclerosis,,United States,Knoxville,Tennessee,1,Tolebrutinib|Placebo,DRUG|DRUG,Part 1a and Part 2: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs)|Part 1b: Total (free and bound) SAR442168 concentrations in CSF|Part 1b: Total (free and bound) SAR442168 metabolite(s) concentrations in CSF|Part 1c and Part 1d: Maximum plasma concentration observed (Cmax) ratio fed/fast of SAR442168|Part 1c and Part1d: Cmax ratio fed/fasted of SAR442168 metabolite(s)|Part 1c and Part 1d: Area under the plasma concentration versus time curve (AUC) ratio fed/fast of SAR442168|Part 1c and Part1d: AUC ratio fed/fast of SAR442168 metabolite(s),"All Parts: Cmax of SAR442168|All Parts: Cmax of SAR442168 metabolite(s)|Part 1a, Part 1b and Part 2: tmax of SAR442168|Part 1a, Part 1b and Part 2: tmax of SAR442168 metabolite(s)|Part 1a, Part 1b, Part1c and Part 1d: AUC of SAR442168|Part 1a, Part 1b, Part1c and Part 1d: AUC of SAR442168 metabolite(s)|Part 2: AUC0-tau for SAR442168|Part 2: AUC0-tau for SAR442168 metabolite(s)|Part 1b, Part1c and 1d: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs)",False,
NCT06566261,ABA-101 in Participants With Progressive Multiple Sclerosis,"A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-09-11,2026-02,2027-02,2025-07-03,2024-08-22,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,Abata Therapeutics,INDUSTRY,,,Progressive Multiple Sclerosis,Progressive Multiple Sclerosis|Cell Therapy|Multiple Sclerosis|Treg|Regulatory T Cell,United States,Baltimore,Maryland,3,ABA-101,BIOLOGICAL,Incidence of adverse events (safety and tolerability),,False,
NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis (MS),COMPLETED,2014-06,2015-12,2015-12,2017-03-23,2014-12-04,INTERVENTIONAL,PHASE4,177.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis","Multiple Sclerosis, MS, RRMS, relapsing forms of multiple sclerosis, fingolimod, FTY720, Gilenya",Canada,Ottawa,Ontario,26,Assessments arm,OTHER,Change From Baseline (BL) in Expanded Disability Status Scale (EDSS),Number of Participants With Disability Progression|Number of Participants With EDSS <4 or <6|Number of Participants Not Using a Wheelchair or Being Bedridden|Number of Participants Classified as Secondary Progressive MS (SPMS)|Percentage of Participants With First Use of an Ambulatory Device|Percentage of Participants With First Use of a Wheelchair|Change From Baseline in Multiple Sclerosis Fuctional Composite (MSFC) Component: Nine Hole Peg Test (9-HPT)|Change From Baseline in MSFC Component: Paced Auditory Serial Addition Test (PASAT) Score|Change From Baseline in MSFC Component: Timed 25-foot Walk Test Score|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Z Score|Total Volume in T2 Lesion|Change From Baseline in Total Volume of T2 Lesion|Third Ventricle Diameter|Change From Baseline in Third Ventricle Diameter|Percentage Brain Volume Change (PBVC)|Correlation Coeffcients Between FTY Treatment Duration and Disability Progression Parameters,True,2017-03-23
NCT07152145,Pilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis,Transcutaneous Electrical Spinal Stimulation (tSCS) for Improving Upper Limb Function in People With MS,NOT_YET_RECRUITING,2025-10,2026-12,2026-12,2025-09-03,2025-09-03,INTERVENTIONAL,NA,60.0,ESTIMATED,Parc de Salut Mar,OTHER,,,Multiple Sclerosis,Spinal Cord Neuromodulation|Non-invasive neuromodulation|Upper limb function|Neurorehabilitation,Spain,Barcelona,,1,Active stimulation tSCS|Sham: stimulations using a non-active electric stimulation|Occupational/Upper Limb Rehabilitation Therapy,DEVICE|DEVICE|BEHAVIORAL,Change in Upper Limb Function (9-Hole Peg Test),"Change in Hand Grip Strength (Dynamometry)|Change in Quality of Life (EQ-5D-5L)|Change in Fatigue (Modified Fatigue Impact Scale - MFIS)|Change in Manual Dexterity (Box and Block Test)|Patient-Reported Upper Limb Function (Multiple Sclerosis Impact Scale - MSIS-29, upper limb subitems)|Safety and Tolerability",False,
NCT06987851,An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD,"An Extension, Multicenter, Open-Label, Non-Comparative Clinical Study of the Efficacy and Safety of Long-Term Use of BCD-132 (JSC BIOCAD) in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD",COMPLETED,2022-03-22,2024-05-16,2024-05-16,2025-05-23,2025-05-23,INTERVENTIONAL,PHASE3,44.0,ACTUAL,Biocad,INDUSTRY,,,Multiple Sclerosis,"multiple sclerosis, relapsing multiple sclerosis, anti-CD20, DMT, divosilimab",Russia,Kirov,,15,Divozilimab,BIOLOGICAL,Annualized relapse rate,Time to first relapse|Proportion of patients without confirmed relapses|Total number of T1 Gd+ lesions (per scan)|Proportion of patients without contrast-enhancing lesions|Proportion of patients without new or enlarging T2 lesions|Number of new or enlarged T2 lesions|Number of CUA (Combined Unique Active) lesions|Changes over time in neurological deficit parameters according to the Expanded Disability Status Scale (EDSS)|Changes over time in Timed 25-Foot Walk Test|Changes over time in 9-Hole Peg Test|Changes over time in Symbol Digit Modalities Test (SDMT)|Changes over time in quality of life indicators assessed with the SF-36 questionnaire,False,
NCT06061939,Effects of Blood Flow Restriction Training on Middle-aged People With Multiple Sclerosis.,Effects of a Resistance Training Program Based on Blood Flow Restriction Training for People Over 45 Years of Age With Multiple Sclerosis on Muscle Strength and Functionality.,COMPLETED,2024-03-05,2024-03-11,2024-06-07,2025-05-30,2023-09-29,INTERVENTIONAL,NA,94.0,ACTUAL,University of Jaén,OTHER,,,"Sclerosis, Multiple",,Spain,Jaén,,1,Blood Flow Restriction training with Oclussion Cuff.,OTHER,Disability Status|Multiple Sclerosis Impact|Short Form-36 (SF-36).|Muscle strength|Gait impact|Anxiety and depression|Sleep quality|Walking speed|Physical fitness|Walking endurance|Balance and gait|Multiple Sclerosis Quality of Life-54|Executive functions|Fatigue,Symbol Digit Modalities Test (SDMT)|Stress level|MoCA (Montreal Cognitive Assessment)|Mini-Mental State Examination (MMSE)|Chair sit and reach test|Back scratch test|Isaacs Test.|Stoicism|Hand coordination,False,
NCT03839381,"Turkish Version of Mini-BESTest, Validity and Reliability for Adult Participants With Sensoriomotor Impairments",Turkish Version of Mini-BESTest- Balance Evaluation Systems Test: A Translation and Transcultural Adaptation Study Incorporating Validity and Reliability Analysis for Adult Participants With Sensoriomotor Impairments,UNKNOWN,2019-03-04,2019-11-29,2019-12-04,2019-02-15,2019-02-15,OBSERVATIONAL,,50.0,ESTIMATED,T.C. ORDU ÜNİVERSİTESİ,OTHER,,,"Parkinson Disease|Multiple Sclerosis|Trauma, Brain",mini BESTest|balance defisit|postural control|Sensoriomotor impairment,,,,0,,,Mini BESTest,,False,
NCT05005013,A Teleheath tDCS Approach to Decrease Cannabis Use,A Teleheath tDCS Approach to Decrease Cannabis Use: Towards Reducing Multiple Sclerosis Disability,COMPLETED,2022-09-13,2024-02-14,2024-05-22,2025-06-24,2021-08-13,INTERVENTIONAL,PHASE2,52.0,ACTUAL,NYU Langone Health,OTHER,National Institutes of Health (NIH),NIH,Cannabis Use Disorder|Multiple Sclerosis,,United States,New York,New York,1,Transcranial Direct Current Stimulation (tDCS)|Sham - Transcranial Direct Current Stimulation (tDCS)|Mindfulness,OTHER|OTHER|OTHER,Change in Kessler Psychological Distress Scale (K10) Score|Change in Positive and Negative Affect Schedule Score - Positive Affect (PANAS-PA)|Change in Positive and Negative Affect Schedule Score - Negative Affect (PANAS-NA)|Change in Marijuana Craving Questionnaire (MCQ-17) Score|Change in Cannabis Withdrawal Scale (CWS) Score|Change in Number of Weekly Sessions of Cannabis Use|Change in Number of Monthly Sessions of Cannabis Use,Change in Kessler Psychological Distress Scale (K10) Score|Change in Positive and Negative Affect Schedule Score - Positive Affect (PANAS-PA)|Change in Positive and Negative Affect Schedule Score - Negative Affect (PANAS-NA)|Change in Marijuana Craving Questionnaire (MCQ-17) Score|Change in Cannabis Withdrawal Scale (CWS) Score|Change in Number of Weekly Sessions of Cannabis Use|Change in Number of Monthly Sessions of Cannabis Use,True,2025-06-24
NCT03356366,MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis,Magnetic Resonance Imaging Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2017-10-02,2023-01-16,2028-12-31,2024-08-06,2017-11-29,INTERVENTIONAL,NA,70.0,ACTUAL,Assistance Publique Hopitaux De Marseille,OTHER,,,Multiple Sclerosis,,France,Marseille,,1,"MRI 3T|MRI 1,5T|MRI 7T",OTHER|OTHER|OTHER,Measurement of the Expanded Disability Status Scale (EDSS) value (score from 0 to 20) constituing the actual international reference scale to measure the level of disability caused by parkinson disease,,False,
NCT02894281,Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease,,COMPLETED,2016-06,2017-06-30,2017-06-30,2017-07-07,2016-09-09,OBSERVATIONAL,,22.0,ACTUAL,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,,,Optic Neuritis,Pupillary light reflex|Multiple sclerosis,France,Paris,,1,pupillary light reflex,DEVICE,pupillary cycle time,,False,
NCT04806620,Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research,Unhide® Project Also Known as The Unhide® Solve Together Unified Platform,RECRUITING,2023-07-05,2030-06-30,2030-12-31,2025-09-10,2021-03-19,OBSERVATIONAL,,10000.0,ESTIMATED,Brain Inflammation Collaborative,OTHER,Solve ME/CFS Initiative|Care Evolution|Columbia University,OTHER|UNKNOWN|OTHER,"Post-Acute COVID-19 Syndrome|ME/CFS|Rheumatic Arthritis|Juvenile Rheumatoid Arthritis (JRA)|Psoriatic Arthritis (PsA)|Ankylosing Spondylitis (AS)|Autoimmune Encephalitis|Bipolar Disorder (BPD)|Celiac Disease|Celiac Disease in Children|Chronic Lyme Disease|Post-treatment Lyme Disease Syndrome|Crohn's Disease|Dysautonomia|Anorexia Nervosa|Bulimia Nervosa|ARFID|Avoidant / Restrictive Food Intake Disorder|Ehlers Danlos Syndrome|Endometriosis|Fibromyalgia (FM)|Long COVID|Lupus|Major Depression|Migraines|Mast Cell Activation Syndrome|Multiple Sclerosis|Myalgic Encephalomyelitis (ME)|Myasthenia Gravis, Generalized|Myasthenia Gravis in Children|Narcolepsy|Obsessive Compulsive Disorder (OCD)|PANDAS|Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)|POTS - Postural Orthostatic Tachycardia Syndrome|General Anxiety Disorder, Social Anxiety Disorder|PTSD - Post Traumatic Stress Disorder|Psoriasis|Traumatic Brain Injury|Tourette's Syndrome|Inflammatory Bowel Disease (IBD)|Autoimmune Diseases|Neurological Diseases or Conditions|Psychiatric Disorder|Sjogren&#39;s Syndrome|Ulcerative Colitis and Crohn&#39;s Disease","Long COVID|Myalgic Encephalomyelitis|Chronic Fatigue Syndrome|Longitudinal Natural History Study|Observational|Neuroinflammatory Disease|Brain inflammation|Neuroinflammatory disorders|PANS/PANDAS|Autoimmune encephalitis|ME/CFS|Dysautonomia / POTS|Multiple sclerosis|Autoimmune disease|Inflammatory bowel disease (Crohn's, ulcerative colitis)|Celiac disease|Migraines|Mood disorders (anxiety, depression, bipolar, PTSD, OCD)|Mobile health app|Patient registry|Wearable devices|Fatigue|Post-exertional malaise|Brain Fog|Mental health",United States,Delafield,Wisconsin,1,,,Phenotypic data collection|Subtyping|Passive data collection,Demographics|Comorbitities|Quality of Life and Functional Status|Symptoms,False,
NCT07123272,Usability of the MeTime MS App,Usability of the MeTime MS Acupressure Mobile Application in Adults With MS,COMPLETED,2025-03-17,2025-05-16,2025-05-16,2025-09-12,2025-08-14,INTERVENTIONAL,NA,10.0,ACTUAL,University of Michigan,OTHER,National Center for Complementary and Integrative Health (NCCIH),NIH,Multiple Sclerosis|Pain|Fatigue Symptom,chronic pain|acupressure|digital health|fatigue|usability|feasibility,United States,Ann Arbor,Michigan,1,Self-guided smartphone application for relaxing acupressure|Self-guided smartphone application for relaxing acupressure,BEHAVIORAL|BEHAVIORAL,Participant perception of Me Time MS app usability,System Usability Scale (SUS) adapted for the MeTime MS app,False,
NCT07033975,A Specialized Diet for Multiple Sclerosis,A Flavonoid-enriched Mediterranean Diet for Multiple Sclerosis,RECRUITING,2023-04-04,2028-12,2028-12,2025-06-24,2025-06-24,INTERVENTIONAL,NA,100.0,ESTIMATED,Jerome J. A. Hendriks,OTHER,Revalidatie & MS Centrum Overpelt,OTHER,Multiple Sclerosis,,Belgium,Diepenbeek,Limburg,1,Flavonoid-enriched Mediterranean Diet,OTHER,Microbiota changes,,False,
NCT02466165,Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy,Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy,COMPLETED,2015-02,2015-08,2015-12,2017-06-20,2015-06-09,INTERVENTIONAL,NA,80.0,ACTUAL,Bert Op't Eijnde,OTHER,,,Multiple Sclerosis|Healthy Controls,cardiometabolic risk|physical exercise,Belgium,Diepenbeek,,2,Physical exercise,BEHAVIORAL,"dyslipidemia, as determined by the analysis of blood samples|hypertension / blood pressure as determined by supine blood pressure measures|body fat as determined by DEXA scan|glucose tolerance / insulin resistance as determined by oral glucose tolerance test|inflammation as determined by analysis of blood samples",muscle strength of knee extensor/flexor and elbow extensor/flexor as determined by Biodex|aerobic capacity as determined by a maximal endurance test on the bike|blood lactate concentrations during exercise as determined by a maximal endurance test on the bike|heart function,False,
NCT05081271,COVID-19 Booster Vaccination in Persons With Multiple Sclerosis,COVID-19 Booster Vaccination in Persons With Multiple Sclerosis,TERMINATED,2021-10-15,2022-05-30,2022-05-30,2022-11-21,2021-10-18,INTERVENTIONAL,EARLY_PHASE1,10.0,ACTUAL,Griffin Hospital,OTHER,Yale-Griffin Prevention Research Center|Multiple Sclerosis Treatment Center,OTHER|UNKNOWN,Multiple Sclerosis,multiple sclerosis|MS,United States,Derby,Connecticut,1,Homologous booster|Heterologous booster,BIOLOGICAL|BIOLOGICAL,Percent who test positive for COVID-19 spike protein antibodies following booster,Comparison of COVID-19 spike protein antibodies based on booster received|Comparison of COVID-19 spike protein antibodies based on disease-modifying treatment|Correlation of COVID-19 spike protein antibodies with B and T cell levels and immunoglobulins,False,
NCT02870634,Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND,A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease,COMPLETED,2016-11-16,2019-10-30,2020-01-30,2020-03-17,2016-08-17,INTERVENTIONAL,PHASE1,50.0,ESTIMATED,Collaborative Medicinal Development Pty Limited,INDUSTRY,,,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,,Australia,Sydenham,New South Wales,2,Cu(II)ATSM,DRUG,recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities,"Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)|Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score|Treatment-related change in respiratory function by seated forced vital capacity (FCV)|Treatment-related change in quality of life by ALSSQOL-R score|Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response|Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Treatment-related change in respiratory function by sniff nasal pressure (SNP) test",False,
NCT00970333,Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions,Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions,COMPLETED,2009-08,2010-10,2010-10,2012-02-08,2009-09-02,INTERVENTIONAL,PHASE1,3.0,ACTUAL,Institute for Neurodegenerative Disorders,OTHER,,,Alzheimer Disease|Parkinson Disease|Multiple Sclerosis,Alzheimer disease|Parkinson disease|Multiple Sclerosis,United States,New Haven,Connecticut,1,[18F]-FEPPA,DRUG,"The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.",,False,
NCT03368677,Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression,Targeting SPMS: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression. A [11C]PK11195 Brain PET Study,ACTIVE_NOT_RECRUITING,2017-12-01,2027-06,2027-12,2025-04-13,2017-12-11,OBSERVATIONAL,,26.0,ACTUAL,Turku University Hospital,OTHER_GOV,,,Multiple Sclerosis,,Finland,Turku,Southwest Finland,1,,,Change of 11C-PK11195-radioligand binding using PET,MRI metrics|EDSS|BICAMS,False,
NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY),COMPLETED,2018-05-28,2020-05-05,2022-02-21,2023-03-16,2017-12-06,INTERVENTIONAL,PHASE4,270.0,ACTUAL,"Merck KGaA, Darmstadt, Germany",INDUSTRY,,,Multiple Sclerosis,Multiple sclerosis|Mavenclad ®|Cladribine,Australia,Sydney,New South Wales,54,Mavenclad®,DRUG,Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 1 (Month 1-6)|Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 2 (Month 2-6)|Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 3 (Month 3-6),"Percent Change From Baseline in Counts of Immune Cell Subsets - B Cells at Month 3, 6, 12, 15, 18 and 24|Percent Change From Baseline in Counts of Immune Cell Subsets - T Cells at Month 3, 6, 12, 15, 18 and 24|Percent Change From Baseline in Counts of Immune Cell Subsets - NK Cells at Month 3, 6, 12, 15, 18 and 24",True,2021-05-27
NCT04555863,haMSter: a Novel Smartphone Communication Tool for People With MS,haMSter: a Novel Smartphone Communication Tool for People With MS,COMPLETED,2020-04-01,2021-04-01,2021-06-01,2021-10-13,2020-09-21,INTERVENTIONAL,NA,50.0,ACTUAL,Medical University of Vienna,OTHER,,,M-health|Multiple Sclerosis,m-health|multiple sclerosis|patient reported outcomes,Austria,Vienna,,1,haMSter smartphone app,DEVICE,adherence to device,Overall satisfaction with this application in telemedicine|General satisfaction with specific Features of the haMSter app,False,
NCT00324506,Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis,"A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis",COMPLETED,2006-05,2009-06,2009-06,2013-06-19,2006-05-11,INTERVENTIONAL,PHASE2,43.0,ACTUAL,University of Texas Southwestern Medical Center,OTHER,Aspreva Pharmaceuticals,INDUSTRY,Multiple Sclerosis,,United States,Farmington Hills,Michigan,3,Mycophenolate Mofetil (CellCept),DRUG,The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when compared with weekly intramuscular Avonex in relapsing multiple sclerosis. Safety will be assessed by virtue of changes in MRI,"Secondary Objectives:|Changes in exacerbation frequency, incidence of exacerbations in the treated groups, changes in level of sustained disability|, changes in quality of life measures, assessment of fatigue",False,
NCT01118130,Pharmacogenomics of Drug Safety in Multiple Sclerosis,Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment,RECRUITING,2010-06,2025-05,2025-05,2024-05-08,2010-05-06,OBSERVATIONAL,,300.0,ESTIMATED,University of British Columbia,OTHER,Canadian Institutes of Health Research (CIHR)|Canada Foundation for Innovation|Genome Canada|British Columbia Clinical Genomics Network,OTHER_GOV|OTHER|OTHER|OTHER,Multiple Sclerosis,Genetics|genomics|Multiple Sclerosis|beta-interferons,Canada,Vancouver,British Columbia,5,,,Experienced an adverse drug reaction or not?,,False,
NCT06627465,Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis,Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis,NOT_YET_RECRUITING,2024-10-15,2026-01-01,2028-01-01,2024-10-04,2024-10-04,OBSERVATIONAL,,600.0,ESTIMATED,"Amsterdam UMC, location VUmc",OTHER,,,Multiple Sclerosis,digital monitoring|mHealth|multiple sclerosis,Netherlands,Arnhem,Gelderland,3,MS Sherpa|Neurokeys,DEVICE|DEVICE,Impact of digital monitoring questionnaire: healthcare provider|Adherence to the MS Sherpa application.|Application outcomes of MS Sherpa|Impact of digital monitoring questionnaire: patient|Adherence to the Neurokeys application|Medical consumption questionnaire (iMCQ)|Productivity costs questionnaire (iPCQ)|Application outcomes of Neurokeys,,False,
NCT02767609,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging,COMPLETED,2014-05,2017-03-03,2017-03-03,2019-04-30,2016-05-10,INTERVENTIONAL,NA,1.0,ACTUAL,Loma Linda University,OTHER,,,Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor,,,,,0,Magnetic Resonance Imaging,DEVICE,Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI.,,True,2019-04-30
NCT00663663,Telephone Intervention for Pain Study (TIPS),Efficacy of Telephone-Delivered Cognitive Behavioral Therapy for Chronic Pain,COMPLETED,2009-09,2013-06,2013-06,2013-08-30,2008-04-22,INTERVENTIONAL,NA,207.0,ACTUAL,University of Washington,OTHER,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Chronic Pain|Multiple Sclerosis|Amputation|Spinal Cord Injury,,United States,Seattle,Washington,1,Telephone-Delivered Intervention 1|Telephone-Delivered Intervention 2,BEHAVIORAL|BEHAVIORAL,Average pain intensity,"Physical Functioning-Brief Pain Inventory (Cleeland & Ryan, 1994)|Patient Health Questionnaire-8 (PHQ-8) (Kroenke & Spitzer, 2002)|Pain Catastrophizing Scale (Sullivan et al., 1995)",False,
NCT05485831,"Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY","Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)",RECRUITING,2025-02-24,2026-01,2026-01,2025-09-25,2022-08-03,OBSERVATIONAL,,100.0,ESTIMATED,Jazz Pharmaceuticals,INDUSTRY,Advice Pharma Group srl,INDUSTRY,Lennox Gastaut Syndrome|Dravet Syndrome|Tuberous Sclerosis Complex,seizures|Epidyolex|cannabidiol oral solution,Italy,Bologna,,18,Epidiolex 100 mg/mL Oral Solution,DRUG,Number of Participants Remaining on Therapy from Enrollment,"Average Number of Seizure-Free Days in the Last 28 Days|Longest Duration of Seizure Free Days in the Last 28 Days|Average Maintenance Dose of Epidyolex®|Maximum Maintenance Dose of Epidyolex®|Type, Dosage, and Frequency of Concomitant Anti-Seizure Medications (ASMs)|Number of Participants Reducing Number/Dosage of Concomitant Medication Related to Epilepsy|Change from Baseline to Week 28 (V3) in the Child Behavior Check List (CBCL)|Change from Baseline to Week 52 (V5) in the Child Behavior Check List (CBCL)|Change from Baseline to Week 28 (V3) in the Visual Analog Scale (VAS) of 10 Non-seizure Related Outcomes (NSRO)|Change from Baseline to Week 52 (V5) in the VAS of 10 NSRO|Average Caregiver Global Impression of Change (CGIC) Score at Week 28 (V3)|Average CGIC Score at Week 52 (V5)|Average Caregiver Global Impression of Change in Seizure Duration (CGICSD) Score at Week 28 (V3)|Average CGICSD Score at Week 52 (V5)|Average Physician Global Impression of Change (PGIC) Score at Week 28 (V3)|Average PGIC Score at Week 52 (V5)",False,
NCT05998616,Feasibility of Remote Exercise Training for Hispanics/Latinos With MS,The Feasibility and Efficacy of a Remotely Delivered Exercise Training Intervention for the Hispanic/Latino Community With Multiple Sclerosis,ACTIVE_NOT_RECRUITING,2024-04-27,2025-06-30,2025-12-31,2025-07-24,2023-08-21,INTERVENTIONAL,NA,33.0,ACTUAL,University of Illinois at Chicago,OTHER,National Institute on Minority Health and Health Disparities (NIMHD),NIH,Multiple Sclerosis,Multiple Sclerosis|Hispanics/Latinos|Exercise Intervention|Remote Exercise Training|Feasibility Study|Randomized Controlled Trial|Health Disparities|Social Determinants of Health|Physical Function|Cognitive Function|Fatigue|Quality of Life|Telerehabilitation|Health Equity,United States,Chicago,Illinois,1,Exercise Training Program|Flexibility Program,BEHAVIORAL|BEHAVIORAL,"Process: Participant Recruitment and Retention|Resources: Communication and Monetary Requirements of the Study|Management: Data Management and Safety Reporting During the Study|Scientific: Safety, Burden and Treatment Effect of the Study",Lower Extremity Function|Visual Processing Speed|Verbal Learning and Memory|Fatigue Severity|Depressive Symptoms|Exercise Behavior|Health-related Quality of Life,False,
NCT05323734,Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy,"A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC)",COMPLETED,2022-04-01,2024-09-09,2024-10-14,2025-07-11,2022-04-12,INTERVENTIONAL,PHASE3,129.0,ACTUAL,Marinus Pharmaceuticals,INDUSTRY,,,Tuberous Sclerosis Complex,Tuberous Sclerosis Complex-Related Epilepsy|Ganaxolone|Adjunctive,United States,Little Rock,Arkansas,63,Ganaxolone|Placebo,DRUG|DRUG,Percent Change From Baseline in 28-day Seizure Frequency for Primary Seizure Type During Double Blind Period,Number of Participants Who Were Considered as Treatment Responders During Double Blind Period|Number of Responders to Clinical Global Impression of Improvement (CGI-I) Scale as Assessed by Parent/Caregiver|Number of Responders to Clinical Global Impression of Improvement (CGI-I) Scale as Assessed by Clinician,True,2025-07-11
NCT04743284,Tele-Assessment and Face-to-Face Evaluation of Balance in MS,The Agreement Between Face-to-Face and Tele-Assessment of Balance Tests in Patient With Multiple Sclerosis,COMPLETED,2021-03-05,2022-01-16,2022-03-07,2024-03-21,2021-02-08,OBSERVATIONAL,,40.0,ACTUAL,Istanbul University - Cerrahpasa,OTHER,,,Multiple Sclerosis,Tele-medicine|Neurorehabilitation|Stability|Gait|Questionnaire,Turkey (Türkiye),Istanbul,,1,,,Berg Balance Test|Dynamic Gait Index|Timed Up and Go Test,,False,
NCT04796584,Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication,Efficacy of COVID 19 SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication (SARSmRNA_MS),TERMINATED,2022-07-11,2022-10-04,2022-10-25,2023-04-03,2021-03-15,OBSERVATIONAL,,20.0,ACTUAL,Providence Health & Services,OTHER,,,Multiple Sclerosis,mRNA-based SARS-CoV-2 vaccination,United States,Portland,Oregon,1,Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus,OTHER,Titer of antibody against SARS-CoV-2 spike protein|Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein|Quantity of TNF-a secreted in response to stimulation with SARS-CoV-2 spike protein,Titer of antibody against SARS-CoV-2 spike protein|Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein|Quantity of TNF-a secreted in response to stimulation with SARS-CoV-2 spike protein|Titer of antibody against SARS-CoV-2 spike protein|Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein|Titer of antibody against SARS-CoV-2 spike protein|Quantity of TNF-a secreted in response to stimulation with SARS-CoV-2 spike protein|Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein,False,
NCT03718247,Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS,The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis,COMPLETED,2018-10-31,2021-06-21,2021-07-01,2022-05-18,2018-10-24,OBSERVATIONAL,,45.0,ACTUAL,University of Virginia,OTHER,,,Relapsing Remitting Multiple Sclerosis,Ketogenic diet,United States,Charlottesville,Virginia,1,Modified Atkins diet,OTHER,Diet Tolerability and compliance|Diet Benefits,Physical changes,False,
NCT07126730,Effects of EXOPULSE Mollii Suit on Spasticity and Functionality in Multiple Sclerosis Patients,Investigating the Effects of the EXOPULSE Mollii Suit on Spasticity and Functionality in Patients With Multiple Sclerosis,NOT_YET_RECRUITING,2025-09-01,2026-01-01,2026-02-01,2025-08-17,2025-08-17,INTERVENTIONAL,NA,30.0,ESTIMATED,Hacettepe University,OTHER,,,Multiple Sclerosis,spasticity|delete,,,,0,EXOPULSE Mollii Suit + Exercise|EXOPULSE Mollii Suit,DEVICE|DEVICE,Modified Ashworth Scale (MAS)|Berg Balance Scale (BBS)|OptoGait Gait Analysis System,EDSS (Expanded Disability Status Scale)|Visual Analog Scale (VAS) for pain and fatigue|Fatigue Severity Scale|9-Hole Peg Test|5 Times Sit to Stand Test|Timed Up and Go (TUG) Test|10 meter Walk Test|12-Item Multiple Sclerosis Walking Scale|Functional Independence Measure (FIM)|Multiple Sclerosis Quality of Life-54 (MSQOL-54),False,
NCT04942938,Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS,"A Pilot Study of Neubie, a Direct Current Electrical Stimulation Device, to Inhibit Lower Extremity Spasticity Levels and Normalize Muscle Functional Use During Transfers and Ambulation in Individuals With Multiple Sclerosis",COMPLETED,2021-06-20,2022-07-05,2022-07-05,2025-07-04,2021-06-29,INTERVENTIONAL,NA,7.0,ACTUAL,CommonSpirit Health,OTHER,NeuFit - Neurological Fitness and Education,INDUSTRY,Multiple Sclerosis,,United States,Littleton,Colorado,1,Neubie,DEVICE,Expanded Disability Status Score|Expanded Disability Status Score|12 Item MS Walking Scale|12 Item MS Walking Scale|Manual Muscle Test|Manual Muscle Test|Manual Muscle Test|Timed 25 Foot Walk Test (T25FW)|Multiple Sclerosis Impact Scale (MSIS-29)|Timed 25 Foot Walk Test (T25FW)|Timed 25 Foot Walk Test (T25FW)|Multiple Sclerosis Impact Scale (MSIS-29)|Modified Ashworth Test|Modified Ashworth Test,,True,2025-04-18
NCT04928716,Multiple Sclerosis and Voiding Symptoms: How to Assess?,Multiple Sclerosis and Voiding Symptoms: How to Assess?,COMPLETED,2019-01-01,2020-01-01,2020-01-01,2021-06-23,2021-06-16,OBSERVATIONAL,,100.0,ACTUAL,Pierre and Marie Curie University,OTHER,,,Multiple Sclerosis|Lower Urinary Tract Symptoms|Voiding Disorders,multiple sclerosis|Lower Urinary Tract Symptoms|voiding disorders|neurogenic bladder|urodynamics,France,Paris,,1,voiding phase evaluation,OTHER,Description of the voiding phase,,False,
NCT02346279,Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists,Study to Evaluate the Responsiveness and Minimal Clinical Important Difference (MCID) of the 'Multiple Sclerosis Questionnaire for Physiotherapists' (MSQPT),COMPLETED,2011-04,2013-10,2013-10,2015-01-27,2015-01-26,OBSERVATIONAL,,81.0,ACTUAL,Institut fuer Physiotherapieforschung,OTHER,Schweizer Physiotherapie Verband physioswiss|Schweizerische Multiple Sklerose Gesellschaft,UNKNOWN|OTHER,Multiple Sclerosis,Multiple Sclerosis|Rehabilitation|Questionnaire|Patient-Reported Outcome|Responsiveness|Minimal Important Clinical Difference,,,,0,"Questionnaires, EDSS, physical test",OTHER,Multiple Sclerosis Questionnaire for Physical Therapists,6 Meter Timed Walking Test|Nine Hole Peg Test|Berg Balance Scale|Hamburg Quality of Life Questionnaire in Multiple Sclerosis|Expanded Disability Status Scale|6 Minutes Walking Test,False,
NCT02446886,Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS,Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS,TERMINATED,2016-06,2020-03,2020-06,2021-01-22,2015-05-18,INTERVENTIONAL,PHASE4,15.0,ACTUAL,Weill Medical College of Cornell University,OTHER,Mallinckrodt,INDUSTRY,Multiple Sclerosis,Multiple Sclerosis|MS|RRMS|SPMS|ACTH,United States,New York,New York,1,Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®),DRUG,Change in Myelin Water Fraction (MWF) Within New Enhancing Lesions Over the Course of 12 Months,Physical Disability as Measured by EDSS|Change in T2 Lesion Volume|Cortical Volume|Whole Brain Volume|Longitudinal Assessment of MWF,True,2021-01-22
NCT01380041,Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients,Identification of Multiple Sclerosis Biomarkers in Human CSF by Means of Cytokine Array,TERMINATED,2011-06,2011-06,2013-06,2015-07-21,2011-06-27,OBSERVATIONAL,,101.0,ACTUAL,"University Hospital, Montpellier",OTHER,,,Multiple Sclerosis,Multiple sclerosisCerebrospinal fluidBiomarkerCytokineArray,France,Montpellier,,1,,,Identification of SEP markers,,False,
NCT02644083,Tecfidera and MRI for Brain Energy in MS,Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate,TERMINATED,2016-02,2018-07,2018-07,2018-08-29,2015-12-31,OBSERVATIONAL,,4.0,ACTUAL,Oregon Health and Science University,OTHER,Biogen,INDUSTRY,Multiple Sclerosis,,United States,Portland,Oregon,1,Dimethyl fumarate,DRUG,Changes in phosphocreatine (PCr) in cerebral grey matter,Changes in ATP in normal appearing white matter (NAWM),False,
NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,"A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",COMPLETED,2011-03-02,2015-07-23,2022-12-31,2024-01-10,2010-09-03,INTERVENTIONAL,PHASE3,735.0,ACTUAL,Hoffmann-La Roche,INDUSTRY,,,"Multiple Sclerosis, Primary Progressive",,United States,Phoenix,Arizona,184,Ocrelizumab|Placebo,DRUG|OTHER,Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period,Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period|Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120|Percent Change From Baseline in Total Volume of T2 Lesions at Week 120|Percent Change in Total Brain Volume From Week 24 to Week 120|Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120|Number of Participants With at Least One Adverse Event (AE),True,2017-12-26
NCT04687332,IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases,Immunoadsorption or Plasma Exchange - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases,COMPLETED,2016-06-01,2019-09-15,2019-12-01,2021-02-17,2020-12-29,INTERVENTIONAL,NA,32.0,ACTUAL,University Medical Center Mainz,OTHER,,,Neurological Autoimmune Diseases,"Plasma exchange (PE)|immunoadsorption (IA)|multiple sclerosis|neuromyelitis optica,|chronic inflammatory demyelinating polyneuropathy|acute inflammatory demyelinating polyradiculoneuropathy|autoimmune encephalitis",Germany,Mainz,Rhineland-Palatinate,1,"Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)",OTHER,"Change in descriptive characterization of Symptoms|Change in the ""Expanded Disability Status Scale"" (EDSS)",Change in concentration of Immunglobulins|Change in concentration of human cytokines,False,
NCT02411838,Calorie Restriction in Multiple Sclerosis Patients,A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients,COMPLETED,2014-02,2016-12,2017-06,2020-05-29,2015-04-08,INTERVENTIONAL,NA,17.0,ACTUAL,Washington University School of Medicine,OTHER,,,Multiple Sclerosis,Multiple sclerosis|calorie restriction|adipokines,United States,St Louis,Missouri,1,Calorie restriction,OTHER,Blood biomarkers|Blood biomarkers|Blood biomarker|Blood biomarker,"Clinical - Disability on the Expanded Disability Status Scale (EDSS)|Clinical-Ambulation, hand and cognitive functions on the Multiple Sclerosis Functional Composite (MSFC) scale|Clinical - Cognitive functions using the Symbol Digit Modality Test (SDMT).|Clinical - Quality of life on the Multiple Sclerosis Quality of Life Inventory (MSQLI).|Gut microbiome changes ( stool sample )",False,
NCT02542787,Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis,"A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis",COMPLETED,2015-08,2017-10,2017-10,2018-03-02,2015-09-07,INTERVENTIONAL,PHASE2,160.0,ESTIMATED,Canbex Therapeutics Ltd,INDUSTRY,,,Spasticity in People With Multiple Sclerosis,MS|Spasticity|VSN16R,United Kingdom,Liverpool,,4,VSN16R|Placebo,DRUG|OTHER,Numerical Rating Scale,Modified Ashworth Scale,False,
NCT04326283,"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)","A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral Sclerosis",TERMINATED,2020-04-02,2023-04-28,2023-04-28,2023-05-09,2020-03-30,INTERVENTIONAL,PHASE1|PHASE2,23.0,ACTUAL,Genuv Inc.,INDUSTRY,,,Amyotrophic Lateral Sclerosis,ALS|Lou Gehrig's disease,South Korea,Busan,,5,Trametinib (0.5 mg)|Trametinib (1 mg)|Riluzole (100 mg),DRUG|DRUG|DRUG,Safety and tolerability of SNR1611: adverse events,K-ALSFRS-R score|FVC|CSF trough concentrations of SNR1611|Plasma trough concentrations of SNR1611|Milestone,False,
NCT05615454,Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis,Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis,UNKNOWN,2023-02-28,2023-12-30,2024-03-30,2023-03-09,2022-11-14,INTERVENTIONAL,NA,50.0,ESTIMATED,Imam Abdulrahman Bin Faisal University,OTHER,,,"Erectile Dysfunction Due to Diseases Classified Elsewhere|Multiple Sclerosis, Relapsing-Remitting",BEMER|Erectile Dysfunction|Multiple Sclerosis|bio-electromagnetic energy regulation therapy,Saudi Arabia,Dammam,,2,"bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|placebo BEMER",DEVICE|DEVICE,International Index of Erectile Function - Erectile Function (IIEF-EF),"The Arizona Sexual Experience (ASEX) Scale|Modified Fatigue Impact Scale (MFIS)|The Multiple Sclerosis, Intimacy, and Sexuality Questionnaire (MSISQ-19)",False,
NCT05585541,Teleassessment in Ataxic Multiple Sclerosis,Comparison of the International Cooperative Ataxia Rating Scale (ICARS) and Scale for the Assessment and Rating of Ataxia (SARA) Scores With Face-to-Face and Tele-Assessment Methods in Ataxic Multiple Sclerosis Patients,COMPLETED,2022-10-24,2023-06-01,2023-06-30,2024-02-28,2022-10-19,OBSERVATIONAL,,30.0,ACTUAL,Hacettepe University,OTHER,,,Ataxia|Multiple Sclerosis,,Turkey (Türkiye),Ankara,,1,,,ICARS|SARA,Expanded Disability Status Scale (EDSS)|Montreal Cognitive Assessment (MoCA)|Telemedicine Satisfaction Questionnaire|Telehealth Usability Questionnaire,False,
NCT04971005,Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial,A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST),TERMINATED,2021-08-27,2022-02-04,2022-02-04,2022-03-16,2021-07-21,INTERVENTIONAL,PHASE2,1.0,ACTUAL,Universitätsklinikum Hamburg-Eppendorf,OTHER,Neovii Biotech|Clinical Trial Center North (CTC North GmbH & Co. KG),INDUSTRY|OTHER,Relapsing-Remitting Multiple Sclerosis,autologous hematopoetic stem cell transplantation|alemtzumab|ocrelizumab|randomised controlled trial|aggressive highly active multiple sclerosis|no evidence of diseae activity (NEDA),Germany,Hamburg,,2,Autologous Hematopoietic Stem Cell Transplantation|Ocrelizumab|Alemtuzumab,DRUG|DRUG|DRUG,Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity),Efficacy of treatment defined by EDSS|Efficacy of treatment defined by the annualized relapse rate|Efficacy of treatment defined by the number of new T2 lesions|Efficacy of treatment defined by the number of Gd-enhancing lesions|Efficacy of treatment defined by multiple sclerosis functional composite (MSFC) change|Efficacy of treatment defined by Hamburg quality of life scale in MS (HAQUAMS)|Efficacy of treatment defined by the Percentage Brain Volume Change (PBVC)|Efficacy of treatment defined by grey and white matter atrophy|Rate of AE / SAE including NCI grade 3 and 4 non-haematological toxicities,False,
NCT06760624,Effectiveness of Ofatumumab in Real-world Practice,Effectiveness of Ofatumumab in Real-world Practice,COMPLETED,2023-10-24,2024-01-15,2024-01-15,2025-03-25,2025-01-07,OBSERVATIONAL,,779.0,ACTUAL,Novartis Pharmaceuticals,INDUSTRY,,,Multiple Sclerosis,,United States,East Hanover,New Jersey,1,,,Annualized Relapse Rate (ARR) in the Pre-Index Period|ARR in the Post-index Period|Incidence Rate Ratio,Age|Number of Patients per Demographic Category|Mean Deyo-Charlson Comorbidity Index|Mean Number of Psychiatric Diagnostic Group (PDG) Mental Health Disorders|Number of Patients Categorized by Top Five Selected Comorbidities|Number of Patients Categorized by Top Five MS-related Symptoms and Secondary Conditions|Number of Patients Categorized by MS Disability Level|Number of Patients Categorized by DMT Used in the Pre-index Period|Pre-index Healthcare Resource Utilization (HCRU): Number of MS-related Hospitalizations per Person-year (PPY)|Pre-index HCRU: Number of Days of MS-related Hospitalization PPY|Pre-index HCRU: Number of MS-related Healthcare Visits PPY|Post-index HCRU: Number of MS-related Hospitalizations PPY|Post-index HCRU: Number of Days of MS-related Hospitalization PPY|Post-index HCRU: Number of MS-related Healthcare Visits PPY|Incidence Rate Ratio of MS-related Hospitalizations|Incidence Rate Ratio of Days of MS-related Hospitalizations|Incidence Rate Ratio of MS-related Emergency Department Visits|Incidence Rate Ratio of MS-related Outpatient Visits,False,
NCT01938495,Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS),"Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2013-08,2017-01,2017-04,2023-03-09,2013-09-10,INTERVENTIONAL,PHASE2,52.0,ACTUAL,Barrow Neurological Institute,OTHER,ALS Association|Muscular Dystrophy Association|Synapse Biomedical,OTHER|OTHER|INDUSTRY,Amyotrophic Lateral Sclerosis (ALS),ALS|DPS|Diaphragm Pacing,United States,Phoenix,Arizona,25,NeuRx® Diaphragm Pacing System™ (DPS),DEVICE,Survival,quality of life,False,
NCT06655896,Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis,"A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis",RECRUITING,2024-10-29,2028-12-15,2032-10-13,2025-07-29,2024-10-24,INTERVENTIONAL,PHASE2,86.0,ESTIMATED,Novartis Pharmaceuticals,INDUSTRY,,,"Scleroderma, Diffuse","Diffuse cutaneous systemic sclerosis (dcSSc)|Scleroderma, Diffuse|revised Composite Response Index in Systemic Sclerosis (rCRISS)|modified Rodnan skin score (mRSS)|forced vital capacity (FVC)",United States,San Francisco,California,47,rapcabtagene autoleucel|rituximab,BIOLOGICAL|BIOLOGICAL,Achievement of a treatment response as per the Revised Composite Response Index in Systemic Sclerosis 50 (rCRISS50) definition at Week 52.,Change from baseline in Forced Vital Capacity (FVC)% predicted at Week 52|Change from baseline in modified Rodnan Skin Score (mRSS) at Week 52.|Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52.|Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs),False,
NCT04154579,"Arts & Health Education to Improve Health, Resilience, and Well-Being","A Randomized Controlled Trial Utilizing the Arts to Improve Health, Resilience, and Well-Being in Individuals With Chronic Health Conditions in Underserved Neighborhoods",TERMINATED,2019-07-01,2020-06-23,2020-06-23,2022-09-09,2019-11-06,INTERVENTIONAL,NA,60.0,ACTUAL,Lisa Gallagher,OTHER,"National Endowment for the Arts, United States|Cuyahoga Arts and Culture|The Cleveland Clinic",FED|UNKNOWN|OTHER,Hypertension|Diabetes|Obesity|COPD|CHF|High Cholesterol|Asthma|Chronic Pain|Multiple Sclerosis|Depression|Anxiety|Heart Diseases|Stroke,Chronic health conditions|Arts-based program|Health education program|Health|Resilience|Well-being,United States,Euclid,Ohio,1,HeRe We Arts|HeRe We Ed,BEHAVIORAL|BEHAVIORAL,Change in Short Depression-Happiness Scale from Week 1 to Week 8|Change in Short Depression-Happiness Scale from Week 8 to Week 16|Change in Short Depression-Happiness Scale from Week 1 to Week 16|Change in Short Warwick-Edinburgh Mental Well-Being Scale from Week 1 to Week 8|Change in Short Warwick-Edinburgh Mental Well-Being Scale from Week 8 to Week 16|Change in Short Warwick-Edinburgh Mental Well-Being Scale from Week 1 to Week 16|Change in Brief Resilient Coping Scale from Week 1 to Week 8|Change in Brief Resilient Coping Scale from Week 8 to Week 16|Change in Brief Resilient Coping Scale from Week 1 to Week 16|Change in Godin-Shephard Leisure-Time Physical Activity Questionnaire from Week 1 to Week 8|Change in Godin-Shephard Leisure-Time Physical Activity Questionnaire from Week 8 to Week 16|Change in Godin-Shephard Leisure-Time Physical Activity Questionnaire from Week 1 to Week 16|Change in PROMIS Scale v1.2 - Global Health from Week 1 to Week 8|Change in PROMIS Scale v1.2 - Global Health from Week 8 to Week 16|Change in PROMIS Scale v1.2 - Global Health from Week 1 to Week 16|Change in Systolic and Diastolic Blood Pressure from Week 1 to Week 8|Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16|Change in Systolic and Diastolic Blood Pressure from Week 1 to Week 16|Change in Heart Rate from Week 1 to Week 8|Change in Heart Rate from Week 8 to Week 16|Change in Heart Rate from Week 1 to Week 16|Change in Pulse Oximetry from Week 1 to Week 8|Change in Pulse Oximetry from Week 8 to Week 16|Change in Pulse Oximetry from Week 1 to Week 16,Change in HeRe We Arts Survey from Week 1 to Week 8|Change in HeRe We Ed Survey from Week 1 to Week 8|Weekly Post-Session Survey,False,
NCT03073603,Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS),Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS),COMPLETED,2017-04-20,2021-08-31,2021-08-31,2023-08-16,2017-03-08,INTERVENTIONAL,PHASE4,259.0,ACTUAL,"University of Colorado, Denver",OTHER,Patient-Centered Outcomes Research Institute|National Multiple Sclerosis Society|University of Alabama at Birmingham,OTHER|OTHER|OTHER,Multiple Sclerosis,,United States,Los Angeles,California,19,Discontinuation of disease modifying therapy|Standard of Care,DRUG|DRUG,Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration,Number With Disability Progression Confirmed at 6 Months Using the Expanded Disability Status Scale (EDSS)|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Upper Extremity Function|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Lower Extremity Function|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Fatigue|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Sleep Disturbance|Change in Neuro-QoL (Quality of Life) Short Form Scores -- General Concerns|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Executive Function|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Communication|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Anxiety|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Depression|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Positive Affect and Well-Being|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Emotional-Behavioral Dyscontrol|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Satisfaction With Social Roles and Activities|Change in Neuro-QoL (Quality of Life) Short Form Scores -- Ability to Participate in Social Roles and Activities|Change in SymptoMScreen Composite Score (SymptoMScreen - Overall Symptom Severity).|Change in Patient-Determined Disease Steps (PDDS - Disability).|Change in Symbol Digit Modalities Test (SDMT - Cognition).|Evaluation of the Patient's Quality of Life Using the MSIS-29 Scale -- Physical Impact|Evaluation of the Patient's Quality of Life Using the MSIS-29 Scale -- Psychological Impact,True,2022-10-06
NCT03000127,Testosterone for Fatigue in Men With MS,A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis,WITHDRAWN,2018-07-01,2023-06-30,2024-01-01,2019-11-06,2016-12-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,"University of California, Los Angeles",OTHER,Washington University School of Medicine,OTHER,Multiple Sclerosis,testosterone|multiple sclerosis|fatigue,United States,Los Angeles,California,2,AndroGel 1 % Topical Gel|Placebos,DRUG|DRUG,Modified Fatigue Impact Scale (MFIS),Localized Gray Matter Atrophy|Axon Density in White Matter,False,
NCT07002034,RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses,"A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses",RECRUITING,2025-07-30,2026-11,2026-12,2025-09-12,2025-06-03,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,Reunion Neuroscience Inc,INDUSTRY,,,Adjustment Disorder,Cancer|Amyotrophic Lateral Sclerosis (ALS)|Multiple Sclerosis (MS)|Parkinson&amp;#39;s Disease (PD)|Idiopathic Pulmonary Fibrosis (IPF)|Depression|Anxiety|Psychiatric Distress,United States,Birmingham,Alabama,12,RE104 for Injection,DRUG,RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score,"RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)|RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.",False,
NCT04832399,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT),COMPLETED,2013-11-12,2023-10-02,2023-10-02,2024-02-05,2021-04-05,OBSERVATIONAL,,60.0,ACTUAL,Biogen,INDUSTRY,,,Relapsing Remitting Multiple Sclerosis,,Portugal,Amadora,,18,Natalizumab,DRUG,Overall Disease-Free Status at Month 12|Clinical Disease-Free Status at Month 12 in Comparison to the Previous Year|Annualized Relapse Rate at Month 12 in Comparison to the Previous Year,"Overall Disease-Free Status at Months 24, 36 and 48|Clinical Disease-free Status Every 6 Months|Annualized Relapse Rate (ARR)|Change From Baseline in Sustained Expanded Disability Status Scale (EDSS) Score (24-week Sustained)|MRI measures: T2, T1, T1 with Gadolinium (Gd)|Cognitive Impairment Using Symbol Digit Modalities Test (SDMT)|Change From Baseline in Ability to Work and Productivity as Assessed by Work Productivity and Activity Impairment (WPAI) Questionnaire|Quality of life (QoL) Assessed Using Fatigue Severity Scale|QoL assessed using Multiple Sclerosis Functional Composite (MSFC) Test|QoL Assessed Using Beck Depression Inventory, 2nd Edition (BDI-II)|QoL Assessed Using Multiple Sclerosis Impact Scale (MSIS-29)",False,
NCT02287948,Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects,Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects,COMPLETED,2014-09,2015-12,2016-01,2016-02-03,2014-11-11,OBSERVATIONAL,,40.0,ACTUAL,University Hospital of Ferrara,OTHER,,,Postural Balance|Multiple Sclerosis,Balance|Multiple Sclerosis|Nintendo Wii Fit,Italy,Ferrara,Ferrara,1,Nintendo Wii Fit Balance Board,DEVICE,Parameters related with postural balance and the chance to fall,"Timed ""up and go"" test (TUG)|Dynamic Gait Index (DGI)|Berg Balance Scale|Unified Balance Scale - Unified Balance Scale (UBS)",False,
NCT00544037,BENEFIT Extension Study,Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis,COMPLETED,2007-09,2011-01,2011-01,2012-03-05,2007-10-16,OBSERVATIONAL,,283.0,ACTUAL,Bayer,INDUSTRY,,,Multiple Sclerosis,,Austria,Many Locations,,18,"Interferon beta-1b (Betaseron, BAY86-5046)",DRUG,To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study,,False,
NCT06075472,The Effect of Inspiratory Muscle Training on Balance and Postural Control in Multiple Sclerosis Patients,The Effect of Inspiratory Muscle Training on Balance and Postural Control in Multiple Sclerosis Patients,COMPLETED,2023-03-06,2024-02-26,2024-06-26,2025-05-06,2023-10-10,INTERVENTIONAL,NA,29.0,ACTUAL,Marmara University,OTHER,,,Multiple Sclerosis,balance|inspiratory muscle training|postural control,Turkey (Türkiye),Istanbul,Şişli,1,Inspiratory Muscle Training|Balance Exercises,OTHER|OTHER,Mini-BesTEST|Trunk Impact Scale,Falls Efficacy Scale International|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Activities-Specific Balance Confidence Scale|Two minutes walking test|Pulmonary Function Test,False,
NCT06533930,"Evaluation of the Relationship Between Optic Nerve Diameter and Optic Nerve Sheath Diameter Measured by Transorbital Sonography With Clinical, Radiological, and Electrophysiological Parameters in Multiple Sclerosis Patients","Evaluation of the Relationship Between Optic Nerve Diameter and Optic Nerve Sheath Diameter Measured by Transorbital Sonography With Clinical, Radiological, and Electrophysiological Parameters in Multiple Sclerosis Patients",COMPLETED,2023-10-01,2024-04-01,2024-04-01,2025-08-29,2024-08-01,OBSERVATIONAL,,136.0,ACTUAL,Kutahya Health Sciences University,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Transorbital Sonography|Optic Nerve Sheath Diameter|Optic Nerve Diameter|Magnetic Resonance Imaging|Visual Evoked Potentials|Optical Coherence Tomography,Turkey (Türkiye),Kütahya,Kütahya,1,Transorbital Sonography|Orbita Magnetic Resonance Imaging|Visual Evoked Potentials|Optical Coherence Tomography,OTHER|OTHER|OTHER|OTHER,Transorbital Sonography|Orbita Magnetic Resonance Imaging,Visual Evoked Potentials|Optical Coherence Tomography|Expanded Disability Status Scale,False,
NCT06526130,Influence of Anaesthesia Type on Multiple Sclerosis Relapse,Multiple Sclerosis Comparison of Relapse Incidence After General and Neuraxial Anesthesia: a Retrospective Observational Study,COMPLETED,2012-01-01,2022-12-31,2024-05-16,2024-07-30,2024-07-29,OBSERVATIONAL,,56.0,ACTUAL,Varazdin General Hospital,OTHER,,,Multiple Sclerosis,Multiple Sclerosis|anaesthesia|relapse,,,,0,General anaesthesia|Neuraxial anaesthesia,PROCEDURE|PROCEDURE,Multiple sclerosis relapse after 1 month|Multiple sclerosis relapse after 3 months|Multiple sclerosis relapse after 6 months|Multiple sclerosis relapse after 12 months,,False,
NCT00710645,Lido Workset Study,Assessment of Spasticity in MS Patients Using a Lido Workset,COMPLETED,2003-04,2012-06,2012-07,2017-02-24,2008-07-04,OBSERVATIONAL,,31.0,ACTUAL,"University of California, Davis",OTHER,,,Multiple Sclerosis,Multiple Sclerosis|Spasticity,United States,Sacramento,California,1,Lido Workset,DEVICE,Assess measure of spasticity,,False,
NCT03551275,"Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis","A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2018-02-22,2018-10-18,2019-03-28,2021-09-08,2018-06-11,INTERVENTIONAL,PHASE1,24.0,ACTUAL,Biocad,INDUSTRY,,,Multiple Sclerosis,BCD-132|Multiple Sclerosis|anti-CD20,Russia,Moscow,,5,BCD-132,BIOLOGICAL,"The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-132|The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-132|The proportion of patients, in each group, who discontinued the study due to AEs/SAEs|The proportion of BAb- and NAb-positive patients",AUC (0-2016 hours)|AUC (0-∞)|AUEC (0-2016 hours)|AUEC (0-∞),False,
NCT06789419,Predicting Epileptogenic Tubers in Patients with Tuberous Sclerosis Complex,Predicting Epileptogenic Tubers in Patients with Tuberous Sclerosis Complex Using a Fusion Model Integrating Lesion Network Mapping and Machine Learning,COMPLETED,2016-07-01,2023-06-01,2023-06-01,2025-01-23,2025-01-23,OBSERVATIONAL,,112.0,ACTUAL,Beijing Children's Hospital,OTHER,,,Tuberous Sclerosis Complex,TSC|TSC MRI,,,,0,,,seizure freedom after surgery,,False,
NCT02260557,Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis,"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis",COMPLETED,2014-10,2015-04,2015-06,2025-02-03,2014-10-09,INTERVENTIONAL,PHASE2,74.0,ACTUAL,Actelion,INDUSTRY,,,Raynaud's Phenomenon Secondary to Systemic Sclerosis,Systemic Sclerosis|Raynaud's Phenomenon,,,,0,Selexipag|Placebo,DRUG|DRUG,Average number of Raynaud's phenomenon (RP) attacks per week during the maintenance treatment period,Number of patients with treatment-emergent adverse events|Number of patients with treatment-emergent serious adverse events,False,
NCT04972929,Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis,Effects of Chiropractic Care on Pro- and Anti-inflammatory Cytokine Levels in Multiple Sclerosis,COMPLETED,2022-12-15,2025-03-12,2025-03-12,2025-03-17,2021-07-22,INTERVENTIONAL,NA,26.0,ACTUAL,University of Alabama at Birmingham,OTHER,,,"Multiple Sclerosis, Relapsing-Remitting",chiropractic|spinal manipulation|multiple sclerosis|cytokines,United States,Birmingham,Alabama,1,Spinal Manipulation|Sham Spinal Manipulation,OTHER|OTHER,Serum inflammatory cytokine levels|Serum inflammatory cytokine levels|Serum inflammatory cytokine levels,Fatigue Severity Scale|Fatigue Severity Scale|Modified Fatigue Impact Scale|Modified Fatigue Impact Scale|Cognitive Processing Speed|Cognitive Processing Speed|Short-form McGill Pain Questionnaire|Short-form McGill Pain Questionnaire|Hospital Anxiety Depression Scale|Hospital Anxiety Depression Scale|Insomnia Severity Index|Insomnia Severity Index|Nine-Hole Peg Test|Nine-Hole Peg Test|Timed 25 foot Walk Test|Timed 25 foot Walk Test,False,
NCT05954195,Effect of High Intensity Interval Training in Patients With Multiple Sclerosis,Effect of High Intensity Interval Training in Patients With Multiple Sclerosis: Systematic Review,UNKNOWN,2023-07-20,2023-11-30,2023-12-18,2023-07-20,2023-07-20,INTERVENTIONAL,NA,86.0,ESTIMATED,Cairo University,OTHER,,,Multiple Sclerosis,Multiple sclerosis AND high intensity interval training,Egypt,Damietta,,1,high intensity interval training,OTHER,cognitive function,mental processing speed,False,
NCT06178029,Effectiveness of Acupuncture Treatment Applied in Addition to the Rehabilitation Program in Multiple Sclerosis Patients,Effectiveness of Acupuncture Treatment Applied in Addition to the Rehabilitation Program in Multiple Sclerosis Patients,COMPLETED,2023-06-18,2024-01-31,2024-04-15,2024-07-12,2023-12-20,INTERVENTIONAL,NA,40.0,ACTUAL,Ankara City Hospital Bilkent,OTHER,,,Multiple Sclerosis,Acupuncture|Gait|Fatigue,Turkey (Türkiye),Ankara,Bilkent-Cankaya,1,Acupuncture|Conventional Rehabilitation,OTHER|OTHER,Timed 25 Foot Walk Test Score,Neurogenic Bladder Symptom Scoring|Incontinence Quality of Life Questionnaire|Multiple Sclerosis Quality of Life-54 (MSQOL-54)|Fatigue Severity Scale,False,
NCT05758831,RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.,A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis,RECRUITING,2023-06-01,2030-03-31,2030-05-01,2024-04-16,2023-03-07,INTERVENTIONAL,PHASE3,386.0,ESTIMATED,Rennes University Hospital,OTHER,,,Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis,Multiple Sclerosis|Relapsing-remitting,France,Lyon,Bron,23,Perfusion of treatment Rituximab|Perfusion of treatment Ocrelizumab,DRUG|DRUG,To demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the percentage of patients without disease activity at 2 years.,"To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Annualized relapse rate|To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Time of onset of the first relapse|To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Percentage of patients without relapse|To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Percentage of patients without disability progression|MRI parameters : gadolinium (Gd) enhancing lesions|MRI parameters : gadolinium (Gd) enhancing lesions|MRI parameters : Mean Number of new T2 lesions|MRI parameters : Percentage of patients with one or more new T2 lesions|Patients quality of life : EQ-5D-5L|Patients quality of life : MusiQOL (Multiple Sclerosis International Quality of Life questionnaire)|Patients quality of life : MusiQOL|Patients experience : Musicare|Patients experience : Musicare|Medico-economic impact: cost-utility ratio, QALY|Safety: Number of each adverse event|Safety: Number of each severe adverse events",False,
NCT06915272,Effects of Sailing and Cooing in the Quality of Life of Multiple Sclerosis Individuals,Effects of Head and Neck Cooling on Environmental Symptom Management and Mood in People With Multiple Sclerosis During Sailing,COMPLETED,2023-05-06,2023-05-15,2023-05-17,2025-04-08,2025-04-08,INTERVENTIONAL,NA,45.0,ACTUAL,University of Thessaly,OTHER,,,Multiple Sclerosis (MS) - Relapsing-remitting,,Greece,Thessaloniki,,1,Head and Neck Cooling Intervention,OTHER,Change in MS-related symptoms and heat sensitivity (as measured by Environmental Symptoms Questionnaire - ESQ-IV),Change in Mood Disturbances,False,
NCT06138132,A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis,"A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",ACTIVE_NOT_RECRUITING,2024-04-10,2027-06,2027-06,2025-03-30,2023-11-18,INTERVENTIONAL,PHASE1,12.0,ESTIMATED,Stanford University,OTHER,Kyverna Therapeutics,INDUSTRY,"Multiple Sclerosis|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Secondary Progressive",KYV-101|autoimmune disease|anti-CD19 CAR-T therapy|cellular therapy,United States,Palo Alto,California,1,KYV-101 anti-CD19 CAR-T cell therapy|Standard lymphodepletion regimen,BIOLOGICAL|DRUG,Frequency of dose limiting toxicities at each dose level,Incidence of adverse events (AEs) including clinical tolerance and laboratory abnormalities|To characterize the pharmacokinetics (PK)|To characterize the pharmacodynamics (PD)|To evaluate clinical response|To evaluate clinical response|To evaluate clinical response,False,
NCT05509426,Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?,Determining Who Benefits Most From Cognitive Rehabilitation for Attention and Memory in Multiple Sclerosis: A Randomised Controlled Feasibility Trial,UNKNOWN,2022-08-15,2023-07,2023-11,2022-09-09,2022-08-22,INTERVENTIONAL,NA,36.0,ESTIMATED,University of Nottingham,OTHER,National Multiple Sclerosis Society|University of Lincoln,OTHER|OTHER,Multiple Sclerosis,,United Kingdom,Nottingham,,1,Cognitive Rehabilitation,BEHAVIORAL,"Acceptability and feasibility of conducting an online group-based cognitive rehabilitation programme.|Appropriateness of eligibility criteria, baseline and outcome measures, recording of sessions, and randomisation protocol.|Estimating sample size needed for Phase III RCT.|Completion rates of outcome measures.","Multiple Sclerosis Impact Scale-29|Everyday Memory Questionnaire-participant.|Everyday Memory Questionnaire-relative.|General Health Questionnaire-30.|Fatigue Severity Scale.|EuroQol-5 Dimensions, five-level version.|Guy's Neurological Disability Scale.|Brief Repeatable Battery of Neuropsychological Tests.|Doors and People test.|Trail Making Test.",False,
